### abstracts1728.txt
The	0	3	|O
design	4	10	|O
,	10	11	|O
synthesis	12	21	|O
,	21	22	|O
and	23	26	|O
biological	27	37	|O
evaluation	38	48	|O
of	49	51	|O
several	52	59	|O
unsaturated	60	71	|O
acyclonucleosides	72	89	|O
related	90	97	|O
to	98	100	|O
augustmycin	101	112	|O
A	113	114	|O
are	115	118	|O
described	119	128	|O
.	128	129	|O
The	130	133	|O
(	134	135	|B-IUPAC
propargyloxy	135	147	|I-IUPAC
)	147	148	|I-IUPAC
methyl	148	154	|I-IUPAC
acyclonucleoside	155	171	|I-IUPAC
analogues	172	181	|B-MODIFIER
of	182	184	|O
6	185	186	|B-IUPAC
-	186	187	|I-IUPAC
chloropurine	187	199	|I-IUPAC
,	199	200	|O
adenine	201	208	|B-IUPAC
,	208	209	|O
6	210	211	|B-IUPAC
-	211	212	|I-IUPAC
methoxypurine	212	225	|I-IUPAC
,	225	226	|O
hypoxanthine	227	239	|B-IUPAC
,	239	240	|O
6	241	242	|B-IUPAC
-	242	243	|I-IUPAC
mercaptopurine	243	257	|I-IUPAC
,	257	258	|O
and	259	262	|O
azathioprine	263	275	|B-IUPAC
have	276	280	|O
been	281	285	|O
prepared	286	294	|O
.	294	295	|O
The	296	299	|O
9	300	301	|B-IUPAC
-	301	302	|I-IUPAC
[	302	303	|I-IUPAC
(	303	304	|I-IUPAC
propargyloxy	304	316	|I-IUPAC
)	316	317	|I-IUPAC
methyl	317	323	|I-IUPAC
]	323	324	|I-IUPAC
adenine	324	331	|I-IUPAC
(	332	333	|O
5	333	334	|O
)	334	335	|O
and	336	339	|O
9	340	341	|B-IUPAC
-	341	342	|I-IUPAC
[	342	343	|I-IUPAC
(	343	344	|I-IUPAC
propargyloxy	344	356	|I-IUPAC
)	356	357	|I-IUPAC
methyl	357	363	|I-IUPAC
]	363	364	|I-IUPAC
hypoxanthine	364	376	|I-IUPAC
(	377	378	|O
12	378	380	|O
)	380	381	|O
analogues	382	391	|B-MODIFIER
were	392	396	|O
converted	397	406	|O
to	407	409	|O
the	410	413	|O
corresponding	414	427	|O
5'	428	430	|B-IUPAC
-	430	431	|I-IUPAC
tributylstannyl	431	446	|I-IUPAC
intermediates	447	460	|B-MODIFIER
(	461	462	|O
9	462	463	|O
and	464	467	|O
13	468	470	|O
)	470	471	|O
,	471	472	|O
respectively	473	485	|O
,	485	486	|O
which	487	492	|O
gave	493	497	|O
9	498	499	|B-IUPAC
-	499	500	|I-IUPAC
[	500	501	|I-IUPAC
[	501	502	|I-IUPAC
[	502	503	|I-IUPAC
(	503	504	|I-IUPAC
Z	504	505	|I-IUPAC
)	505	506	|I-IUPAC
-	506	507	|I-IUPAC
5	507	508	|I-IUPAC
-	508	509	|I-IUPAC
iodo	509	513	|I-IUPAC
-	513	514	|I-IUPAC
5	514	515	|I-IUPAC
-	515	516	|I-IUPAC
propenyl	516	524	|I-IUPAC
]	524	525	|I-IUPAC
oxy	525	528	|I-IUPAC
]	528	529	|I-IUPAC
methyl	529	535	|I-IUPAC
]	535	536	|I-IUPAC
adenine	536	543	|I-IUPAC
(	544	545	|O
10	545	547	|O
)	547	548	|O
and	549	552	|O
9	553	554	|B-IUPAC
-	554	555	|I-IUPAC
[	555	556	|I-IUPAC
[	556	557	|I-IUPAC
[	557	558	|I-IUPAC
(	558	559	|I-IUPAC
Z	559	560	|I-IUPAC
)	560	561	|I-IUPAC
-	561	562	|I-IUPAC
5	562	563	|I-IUPAC
-	563	564	|I-IUPAC
iodo	564	568	|I-IUPAC
-	568	569	|I-IUPAC
5	569	570	|I-IUPAC
-	570	571	|I-IUPAC
propenyl	571	579	|I-IUPAC
]	579	580	|I-IUPAC
oxy	580	583	|I-IUPAC
]	583	584	|I-IUPAC
methyl	584	590	|I-IUPAC
]	590	591	|I-IUPAC
hypoxanthine	591	603	|I-IUPAC
(	604	605	|O
14	605	607	|O
)	607	608	|O
,	608	609	|O
respectively	610	622	|O
,	622	623	|O
after	624	629	|O
iododestannylation	630	648	|O
.	648	649	|O
The	650	653	|O
[	654	655	|O
125I	655	659	|O
]	659	660	|O
-	660	661	|O
radiolabeled	661	673	|O
congeners	674	683	|O
of	684	686	|O
10	687	689	|O
and	690	693	|O
14	694	696	|O
were	697	701	|O
prepared	702	710	|O
as	711	713	|O
potential	714	723	|O
metabolic	724	733	|O
markers	734	741	|O
.	741	742	|O
Among	743	748	|O
the	749	752	|O
unsaturated	753	764	|O
acyclonucleosides	765	782	|O
tested	783	789	|O
,	789	790	|O
9	791	792	|B-IUPAC
-	792	793	|I-IUPAC
[	793	794	|I-IUPAC
(	794	795	|I-IUPAC
propargyloxy	795	807	|I-IUPAC
)	807	808	|I-IUPAC
methyl	808	814	|I-IUPAC
]	814	815	|I-IUPAC
-	815	816	|I-IUPAC
6	816	817	|I-IUPAC
-	817	818	|I-IUPAC
chloropurine	818	830	|I-IUPAC
(	831	832	|O
3	832	833	|O
)	833	834	|O
,	834	835	|O
9	836	837	|B-IUPAC
-	837	838	|I-IUPAC
[	838	839	|I-IUPAC
(	839	840	|I-IUPAC
propargyloxy	840	852	|I-IUPAC
)	852	853	|I-IUPAC
methyl	853	859	|I-IUPAC
]	859	860	|I-IUPAC
-	860	861	|I-IUPAC
6	861	862	|I-IUPAC
-	862	863	|I-IUPAC
mercaptopurine	863	877	|I-IUPAC
(	878	879	|O
15	879	881	|O
)	881	882	|O
,	882	883	|O
9	884	885	|B-IUPAC
-	885	886	|I-IUPAC
[	886	887	|I-IUPAC
(	887	888	|I-IUPAC
propargyloxy	888	900	|I-IUPAC
)	900	901	|I-IUPAC
methyl	901	907	|I-IUPAC
]	907	908	|I-IUPAC
azathioprine	908	920	|I-IUPAC
(	921	922	|O
17	922	924	|O
)	924	925	|O
,	925	926	|O
and	927	930	|O
angustmycin	931	942	|O
A	943	944	|O
analogue	945	953	|O
10	954	956	|O
showed	957	963	|O
inhibition	964	974	|O
of	975	977	|O
cancer	978	984	|O
cell	985	989	|O
growth	990	996	|O
,	996	997	|O
but	998	1001	|O
only	1002	1006	|O
at	1007	1009	|O
a	1010	1011	|O
minimal	1012	1019	|O
level	1020	1025	|O
,	1025	1026	|O
and	1027	1030	|O
17	1031	1033	|O
also	1034	1038	|O
showed	1039	1045	|O
14%	1046	1049	|O
cancer	1050	1056	|O
cell	1057	1061	|O
death	1062	1067	|O
in	1068	1070	|O
vitro	1071	1076	|O
.	1076	1077	|O
Compound	1078	1086	|O
10	1087	1089	|O
provided	1090	1098	|O
approximately	1099	1112	|O
50%	1113	1116	|O
protection	1117	1127	|O
against	1128	1135	|O
HIV	1136	1139	|O
at	1140	1142	|O
10	1143	1145	|O
(	1145	1146	|O
-	1146	1147	|O
4	1147	1148	|O
)	1148	1149	|O
M	1150	1151	|O
concentrations	1152	1166	|O
.	1166	1167	|O
Biodistribution	1168	1183	|O
results	1184	1191	|O
of	1192	1194	|O
[	1195	1196	|O
125I	1196	1200	|O
]	1200	1201	|O
-	1201	1202	|O
10	1202	1204	|O
in	1205	1207	|O
mice	1208	1212	|O
indicate	1213	1221	|O
that	1222	1226	|O
compound	1227	1235	|O
10	1236	1238	|O
is	1239	1241	|O
readily	1242	1249	|O
metabolized	1250	1261	|O
via	1262	1265	|O
deiodination	1266	1278	|O
in	1279	1281	|O
vivo	1282	1286	|O
,	1286	1287	|O
possibly	1288	1296	|O
by	1297	1299	|O
serving	1300	1307	|O
as	1308	1310	|O
a	1311	1312	|O
substrate	1313	1322	|O
for	1323	1326	|O
the	1327	1330	|O
enzyme	1331	1337	|O
S	1338	1339	|B-IUPAC
-	1339	1340	|I-IUPAC
adenosyl	1340	1348	|I-IUPAC
-	1348	1349	|I-IUPAC
L	1349	1350	|I-IUPAC
-	1350	1351	|I-IUPAC
homocysteine	1351	1363	|I-IUPAC
hydrolase	1364	1373	|O
.	1373	1374	|O

### abstracts931.txt
Sulfur	0	6	|O
-	6	7	|O
bridged	7	14	|O
pregnanes	15	24	|O
6,19	25	29	|B-IUPAC
-	29	30	|I-IUPAC
epithioprogesterone	30	49	|I-IUPAC
,	49	50	|O
21	51	53	|B-IUPAC
-	53	54	|I-IUPAC
hydroxy	54	61	|I-IUPAC
-	61	62	|I-IUPAC
6,19	62	66	|I-IUPAC
-	66	67	|I-IUPAC
epithioprogesterone	67	86	|I-IUPAC
,	86	87	|O
and	88	91	|O
the	92	95	|O
corresponding	96	109	|O
sulfoxides	110	120	|O
and	121	124	|O
sulfones	125	133	|O
were	134	138	|O
synthesized	139	150	|O
and	151	154	|O
tested	155	161	|O
as	162	164	|O
blockers	165	173	|O
of	174	176	|O
the	177	180	|O
immunosuppresive	181	197	|O
activity	198	206	|O
of	207	209	|O
dexamethasone	210	223	|O
in	224	226	|O
rat	227	230	|O
thymocytes	231	241	|O
.	241	242	|O
A	243	244	|O
new	245	248	|O
one	249	252	|O
-	252	253	|O
pot	253	256	|O
procedure	257	266	|O
is	267	269	|O
described	270	279	|O
for	280	283	|O
the	284	287	|O
preparation	288	299	|O
of	300	302	|O
6,19	303	307	|B-IUPAC
-	307	308	|I-IUPAC
epithioprogesterone	308	327	|I-IUPAC
and	328	331	|O
related	332	339	|O
compounds	340	349	|O
by	350	352	|O
iodocyclization	353	368	|O
of	369	371	|O
a	372	373	|O
19	374	376	|B-IUPAC
-	376	377	|I-IUPAC
sulfanylpregn	377	390	|I-IUPAC
-	390	391	|I-IUPAC
5	391	392	|I-IUPAC
-	392	393	|I-IUPAC
ene	393	396	|I-IUPAC
.	396	397	|O
Antiimmunosuppresive	398	418	|O
activity	419	427	|O
was	428	431	|O
evaluated	432	441	|O
by	442	444	|O
the	445	448	|O
ability	449	456	|O
of	457	459	|O
the	460	463	|O
different	464	473	|O
steroids	474	482	|O
to	483	485	|O
block	486	491	|O
dexamethasone	492	505	|O
-	505	506	|O
mediated	506	514	|O
apoptosis	515	524	|O
in	525	527	|O
thymocytes	528	538	|O
and	539	542	|O
dexamethasone	543	556	|O
-	556	557	|O
mediated	557	565	|O
inhibition	566	576	|O
of	577	579	|O
the	580	583	|O
NFkappa	584	591	|O
-	591	592	|O
B	592	593	|O
transcription	594	607	|O
factor	608	614	|O
activity	615	623	|O
.	623	624	|O
DNA	625	628	|O
fragmentation	629	642	|O
and	643	646	|O
annexin	647	654	|O
V	655	656	|O
-	656	657	|O
FITC	657	661	|O
positive	662	670	|O
cells	671	676	|O
were	677	681	|O
taken	682	687	|O
as	688	690	|O
parameters	691	701	|O
of	702	704	|O
apoptosis	705	714	|O
whereas	715	722	|O
NFkappa	723	730	|O
-	730	731	|O
B	731	732	|O
activity	733	741	|O
was	742	745	|O
tested	746	752	|O
by	753	755	|O
the	756	759	|O
expression	760	770	|O
of	771	773	|O
the	774	777	|O
reporter	778	786	|O
vector	787	793	|O
kappaB	794	800	|O
-	800	801	|O
luciferase	801	811	|O
by	812	814	|O
TNF	815	818	|O
-	818	819	|O
alpha	819	824	|O
in	825	827	|O
Hela	828	832	|O
cells	833	838	|O
.	838	839	|O
21	840	842	|B-IUPAC
-	842	843	|I-IUPAC
Hydroxy	843	850	|I-IUPAC
-	850	851	|I-IUPAC
6,19	851	855	|I-IUPAC
-	855	856	|I-IUPAC
epithioprogesterone	856	875	|I-IUPAC
S	876	877	|I-IUPAC
,	877	878	|I-IUPAC
S	878	879	|I-IUPAC
-	879	880	|I-IUPAC
dioxide	880	887	|I-IUPAC
had	888	891	|O
improved	892	900	|O
activity	901	909	|O
in	910	912	|O
both	913	917	|O
parameters	918	928	|O
,	928	929	|O
while	930	935	|O
21	936	938	|B-IUPAC
-	938	939	|I-IUPAC
hydroxy	939	946	|I-IUPAC
-	946	947	|I-IUPAC
6,19	947	951	|I-IUPAC
-	951	952	|I-IUPAC
epithioprogesterone	952	971	|I-IUPAC
had	972	975	|O
improved	976	984	|O
activity	985	993	|O
only	994	998	|O
in	999	1001	|O
blocking	1002	1010	|O
dexamethasone	1011	1024	|O
-	1024	1025	|O
induced	1025	1032	|O
programmed	1033	1043	|O
cell	1044	1048	|O
death	1049	1054	|O
.	1054	1055	|O

### abstracts4814.txt
A	0	1	|O
new	2	5	|O
procedure	6	15	|O
for	16	19	|O
the	20	23	|O
preparation	24	35	|O
of	36	38	|O
the	39	42	|O
antiviral	43	52	|O
and	53	56	|O
antitumor	57	66	|O
agent	67	72	|O
3	73	74	|B-IUPAC
-	74	75	|I-IUPAC
deazaguanine	75	87	|I-IUPAC
(	88	89	|O
1	89	90	|O
)	90	91	|O
and	92	95	|O
its	96	99	|O
metabolite	100	110	|O
3	111	112	|B-IUPAC
-	112	113	|I-IUPAC
deazaguanosine	113	127	|I-IUPAC
(	128	129	|O
2	129	130	|O
)	130	131	|O
has	132	135	|O
been	136	140	|O
developed	141	150	|O
by	151	153	|O
reacting	154	162	|O
methyl	163	169	|B-IUPAC
5	170	171	|I-IUPAC
(	171	172	|I-IUPAC
4	172	173	|I-IUPAC
)	173	174	|I-IUPAC
-	174	175	|I-IUPAC
(	175	176	|I-IUPAC
cyanomethyl	176	187	|I-IUPAC
)	187	188	|I-IUPAC
imidazole	189	198	|I-IUPAC
-	198	199	|I-IUPAC
4	199	200	|I-IUPAC
(	200	201	|I-IUPAC
5	201	202	|I-IUPAC
)	202	203	|I-IUPAC
-	203	204	|I-IUPAC
carboxylate	204	215	|I-IUPAC
(	216	217	|O
4	217	218	|O
)	218	219	|O
and	220	223	|O
5	224	225	|B-IUPAC
-	225	226	|I-IUPAC
(	226	227	|I-IUPAC
cyanomethyl	227	238	|I-IUPAC
)	238	239	|I-IUPAC
-	239	240	|I-IUPAC
1	240	241	|I-IUPAC
-	241	242	|I-IUPAC
(	243	244	|I-IUPAC
2,3,5	244	249	|I-IUPAC
-	249	250	|I-IUPAC
tri	250	253	|I-IUPAC
-	253	254	|I-IUPAC
O	254	255	|I-IUPAC
-	255	256	|I-IUPAC
benzoyl	256	263	|I-IUPAC
-	263	264	|I-IUPAC
beta	264	268	|I-IUPAC
-	268	269	|I-IUPAC
D	269	270	|I-IUPAC
-	270	271	|I-IUPAC
ribofuranosyl	271	284	|I-IUPAC
)	284	285	|I-IUPAC
imidazole	285	294	|I-IUPAC
-	294	295	|I-IUPAC
4	295	296	|I-IUPAC
-	296	297	|I-IUPAC
carboxylate	297	308	|I-IUPAC
(	309	310	|O
6	310	311	|O
)	311	312	|O
,	312	313	|O
respectively	314	326	|O
,	326	327	|O
with	328	332	|O
hydrazine	333	342	|O
.	342	343	|O
The	344	347	|O
3	348	349	|B-IUPAC
-	349	350	|I-IUPAC
deazaguanosine	350	364	|I-IUPAC
3'	365	367	|I-IUPAC
,	367	368	|I-IUPAC
5'	368	370	|I-IUPAC
-	370	371	|I-IUPAC
cyclic	371	377	|I-IUPAC
phosphate	378	387	|I-IUPAC
(	388	389	|O
13	389	391	|O
)	391	392	|O
was	393	396	|O
prepared	397	405	|O
from	406	410	|O
5	411	412	|B-IUPAC
-	412	413	|I-IUPAC
(	413	414	|I-IUPAC
cyanomethyl	414	425	|I-IUPAC
)	425	426	|I-IUPAC
-	426	427	|I-IUPAC
1	427	428	|I-IUPAC
-	428	429	|I-IUPAC
beta	429	433	|I-IUPAC
-	433	434	|I-IUPAC
D	434	435	|I-IUPAC
-	435	436	|I-IUPAC
ribofuranosyl	436	449	|I-IUPAC
-	449	450	|I-IUPAC
imidazole	450	459	|I-IUPAC
-	459	460	|I-IUPAC
4	460	461	|I-IUPAC
-	461	462	|I-IUPAC
carboxamide	462	473	|I-IUPAC
5'	474	476	|I-IUPAC
-	476	477	|I-IUPAC
phosphate	477	486	|I-IUPAC
.	486	487	|O
Glycosylation	488	501	|O
of	502	504	|O
the	505	508	|O
trimethylsilyl	509	523	|O
4	524	525	|O
with	526	530	|O
1	531	532	|B-IUPAC
-	532	533	|I-IUPAC
O	533	534	|I-IUPAC
-	534	535	|I-IUPAC
methyl	535	541	|I-IUPAC
-	541	542	|I-IUPAC
2	542	543	|I-IUPAC
-	543	544	|I-IUPAC
deoxy	544	549	|I-IUPAC
-	549	550	|I-IUPAC
3,5	550	553	|I-IUPAC
-	553	554	|I-IUPAC
di	554	556	|I-IUPAC
-	556	557	|I-IUPAC
O	557	558	|I-IUPAC
-	558	559	|I-IUPAC
p	559	560	|I-IUPAC
-	560	561	|I-IUPAC
toluoyl	561	568	|I-IUPAC
-	568	569	|I-IUPAC
D	569	570	|I-IUPAC
-	570	571	|I-IUPAC
ribofuranose	571	583	|I-IUPAC
in	584	586	|O
the	587	590	|O
presence	591	599	|O
of	600	602	|O
trimethylsilyl	603	617	|B-IUPAC
trifluoromethanesulfonate	618	643	|I-IUPAC
gave	644	648	|O
the	649	652	|O
corresponding	653	666	|O
N	667	668	|B-IUPAC
-	668	669	|I-IUPAC
1	669	670	|I-IUPAC
and	671	674	|O
N	675	676	|B-IUPAC
-	676	677	|I-IUPAC
3	677	678	|I-IUPAC
glycosyl	679	687	|I-IUPAC
derivatives	688	699	|B-MODIFIER
with	700	704	|O
alpha	705	710	|O
-	710	711	|O
configuration	711	724	|O
(	725	726	|O
18	726	728	|O
and	729	732	|O
20	733	735	|O
)	735	736	|O
as	737	739	|O
the	740	743	|O
major	744	749	|O
products	750	758	|O
,	758	759	|O
along	760	765	|O
with	766	770	|O
minor	771	776	|O
amounts	777	784	|O
of	785	787	|O
the	788	791	|O
beta	792	796	|O
-	796	797	|O
anomers	797	804	|O
(	805	806	|O
19	806	808	|O
and	809	812	|O
21	813	815	|O
)	815	816	|O
.	816	817	|O
However	818	825	|O
,	825	826	|O
glycosylation	827	840	|O
of	841	843	|O
the	844	847	|O
sodium	848	854	|O
salt	855	859	|O
of	860	862	|O
4	863	864	|O
with	865	869	|O
1	870	871	|B-IUPAC
-	871	872	|I-IUPAC
chloro	872	878	|I-IUPAC
-	878	879	|I-IUPAC
2	879	880	|I-IUPAC
-	880	881	|I-IUPAC
deoxy	881	886	|I-IUPAC
-	886	887	|I-IUPAC
3,5	887	890	|I-IUPAC
-	890	891	|I-IUPAC
di	891	893	|I-IUPAC
-	893	894	|I-IUPAC
O	894	895	|I-IUPAC
-	895	896	|I-IUPAC
p	896	897	|I-IUPAC
-	897	898	|I-IUPAC
toluoyl	898	905	|I-IUPAC
-	905	906	|I-IUPAC
alpha	906	911	|I-IUPAC
-	911	912	|I-IUPAC
D	912	913	|I-IUPAC
-	913	914	|I-IUPAC
erythro	914	921	|I-IUPAC
-	921	922	|I-IUPAC
pentofurano	922	933	|I-IUPAC
se	934	936	|I-IUPAC
(	937	938	|O
17	938	940	|O
)	940	941	|O
gave	942	946	|O
exclusively	947	958	|O
the	959	962	|O
beta	963	967	|O
-	967	968	|O
anomers	968	975	|O
(	976	977	|O
19	977	979	|O
and	980	983	|O
21	984	986	|O
)	986	987	|O
in	988	990	|O
good	991	995	|O
yield	996	1001	|O
.	1001	1002	|O
Base	1003	1007	|O
-	1007	1008	|O
catalyzed	1008	1017	|O
ring	1018	1022	|O
closure	1023	1030	|O
of	1031	1033	|O
these	1034	1039	|O
imidazole	1040	1049	|O
nucleosides	1050	1061	|O
gave	1062	1066	|O
2'	1067	1069	|B-IUPAC
-	1069	1070	|I-IUPAC
deoxy	1070	1075	|I-IUPAC
-	1075	1076	|I-IUPAC
3	1076	1077	|I-IUPAC
-	1077	1078	|I-IUPAC
deazaguanosine	1078	1092	|I-IUPAC
(	1093	1094	|O
29	1094	1096	|O
)	1096	1097	|O
,	1097	1098	|O
the	1099	1102	|O
alpha	1103	1108	|O
-	1108	1109	|O
anomer	1109	1115	|O
28	1116	1118	|O
,	1118	1119	|O
and	1120	1123	|O
the	1124	1127	|O
corresponding	1128	1141	|O
N	1142	1143	|O
-	1143	1144	|O
3	1144	1145	|O
positional	1146	1156	|O
isomers	1157	1164	|O
27	1165	1167	|O
and	1168	1171	|O
26	1172	1174	|O
.	1174	1175	|O
The	1176	1179	|O
site	1180	1184	|O
of	1185	1187	|O
glycosylation	1188	1201	|O
and	1202	1205	|O
the	1206	1209	|O
anomeric	1210	1218	|O
configuration	1219	1232	|O
of	1233	1235	|O
these	1236	1241	|O
nucleosides	1242	1253	|O
have	1254	1258	|O
been	1259	1263	|O
assigned	1264	1272	|O
on	1273	1275	|O
the	1276	1279	|O
basis	1280	1285	|O
of	1286	1288	|O
1'	1289	1291	|O
NMR	1292	1295	|O
and	1296	1299	|O
UV	1300	1302	|O
spectral	1303	1311	|O
characteristics	1312	1327	|O
and	1328	1331	|O
by	1332	1334	|O
single	1335	1341	|O
-	1341	1342	|O
crystal	1342	1349	|O
X	1350	1351	|O
-	1351	1352	|O
ray	1352	1355	|O
analysis	1356	1364	|O
for	1365	1368	|O
27-29	1369	1374	|O
.	1374	1375	|O
In	1376	1378	|O
a	1379	1380	|O
preliminary	1381	1392	|O
screening	1393	1402	|O
,	1402	1403	|O
several	1404	1411	|O
of	1412	1414	|O
these	1415	1420	|O
compounds	1421	1430	|O
have	1431	1435	|O
demonstrated	1436	1448	|O
significant	1449	1460	|O
broad	1461	1466	|O
-	1466	1467	|O
spectrum	1467	1475	|O
antiviral	1476	1485	|O
activity	1486	1494	|O
against	1495	1502	|O
certain	1503	1510	|O
DNA	1511	1514	|O
and	1515	1518	|O
RNA	1519	1522	|O
viruses	1523	1530	|O
in	1531	1533	|O
vitro	1534	1539	|O
,	1539	1540	|O
as	1541	1543	|O
well	1544	1548	|O
as	1549	1551	|O
moderate	1552	1560	|O
activity	1561	1569	|O
against	1570	1577	|O
L1210	1578	1583	|O
and	1584	1587	|O
P388	1588	1592	|O
leukemia	1593	1601	|O
in	1602	1604	|O
cell	1605	1609	|O
culture	1610	1617	|O
.	1617	1618	|O

### abstracts2462.txt
To	0	2	|O
synthesize	3	13	|O
potent	14	20	|O
antagonists	21	32	|O
of	33	35	|O
the	36	39	|O
mu	40	42	|O
-	42	43	|O
opioid	43	49	|O
receptor	50	58	|O
,	58	59	|O
we	60	62	|O
prepared	63	71	|O
a	72	73	|O
series	74	80	|O
of	81	83	|O
endomorphin	84	95	|O
-	95	96	|O
1	96	97	|O
and	98	101	|O
endomorphin	102	113	|O
-	113	114	|O
2	114	115	|O
analogues	116	125	|O
with	126	130	|O
3	131	132	|B-IUPAC
-	132	133	|I-IUPAC
(	133	134	|I-IUPAC
1	134	135	|I-IUPAC
-	135	136	|I-IUPAC
naphthyl	136	144	|I-IUPAC
)	144	145	|I-IUPAC
-	145	146	|I-IUPAC
d	146	147	|I-IUPAC
-	147	148	|I-IUPAC
alanine	148	155	|I-IUPAC
(	156	157	|O
d	157	158	|O
-	158	159	|O
1	159	160	|O
-	160	161	|O
Nal	161	164	|O
)	164	165	|O
or	166	168	|O
3	169	170	|B-IUPAC
-	170	171	|I-IUPAC
(	171	172	|I-IUPAC
2	172	173	|I-IUPAC
-	173	174	|I-IUPAC
naphthyl	174	182	|I-IUPAC
)	182	183	|I-IUPAC
-	183	184	|I-IUPAC
d	184	185	|I-IUPAC
-	185	186	|I-IUPAC
alanine	186	193	|I-IUPAC
(	194	195	|O
d	195	196	|O
-	196	197	|O
2	197	198	|O
-	198	199	|O
Nal	199	202	|O
)	202	203	|O
in	204	206	|O
position	207	215	|O
4	216	217	|O
.	217	218	|O
Some	219	223	|O
of	224	226	|O
these	227	232	|O
analogues	233	242	|O
displayed	243	252	|O
weak	253	257	|O
antagonist	258	268	|O
properties	269	279	|O
.	279	280	|O
We	281	283	|O
tried	284	289	|O
to	290	292	|O
strengthen	293	303	|O
these	304	309	|O
properties	310	320	|O
by	321	323	|O
introducing	324	335	|O
the	336	339	|O
structurally	340	352	|O
modified	353	361	|O
tyrosine	362	370	|O
residue	371	378	|O
2,6	379	382	|B-IUPAC
-	382	383	|I-IUPAC
dimethyltyrosine	383	399	|I-IUPAC
(	400	401	|O
Dmt	401	404	|O
)	404	405	|O
in	406	408	|O
place	409	414	|O
of	415	417	|O
Tyr1	418	422	|O
.	422	423	|O
Among	424	429	|O
the	430	433	|O
synthesized	434	445	|O
compounds	446	455	|O
,	455	456	|O
[	457	458	|O
Dmt1	458	462	|O
,	462	463	|O
d	464	465	|O
-	465	466	|O
2	466	467	|O
-	467	468	|O
Nal4	468	472	|O
]	472	473	|O
endomorphin	473	484	|O
-	484	485	|O
1	485	486	|O
,	486	487	|O
designated	488	498	|O
antanal	499	506	|O
-	506	507	|O
1	507	508	|O
,	508	509	|O
and	510	513	|O
[	514	515	|O
Dmt1	515	519	|O
,	519	520	|O
d	521	522	|O
-	522	523	|O
2	523	524	|O
-	524	525	|O
Nal4	525	529	|O
]	529	530	|O
endomorphin	530	541	|O
-	541	542	|O
2	542	543	|O
,	543	544	|O
designated	545	555	|O
antanal	556	563	|O
-	563	564	|O
2	564	565	|O
,	565	566	|O
turned	567	573	|O
out	574	577	|O
to	578	580	|O
be	581	583	|O
highly	584	590	|O
potent	591	597	|O
and	598	601	|O
selective	602	611	|O
mu	612	614	|O
-	614	615	|O
opioid	615	621	|O
receptor	622	630	|O
antagonists	631	642	|O
,	642	643	|O
as	644	646	|O
judged	647	653	|O
on	654	656	|O
the	657	660	|O
basis	661	666	|O
of	667	669	|O
two	670	673	|O
functional	674	684	|O
assays	685	691	|O
,	691	692	|O
the	693	696	|O
receptor	697	705	|O
binding	706	713	|O
assay	714	719	|O
and	720	723	|O
the	724	727	|O
hot	728	731	|O
plate	732	737	|O
test	738	742	|O
of	743	745	|O
analgesia	746	755	|O
.	755	756	|O
Interestingly	757	770	|O
,	770	771	|O
another	772	779	|O
analogue	780	788	|O
of	789	791	|O
this	792	796	|O
series	797	803	|O
,	803	804	|O
[	805	806	|O
Dmt1	806	810	|O
,	810	811	|O
d	812	813	|O
-	813	814	|O
1	814	815	|O
-	815	816	|O
Nal4	816	820	|O
]	820	821	|O
endomorphin	821	832	|O
-	832	833	|O
1	833	834	|O
,	834	835	|O
turned	836	842	|O
out	843	846	|O
to	847	849	|O
be	850	852	|O
a	853	854	|O
moderately	855	865	|O
potent	866	872	|O
mixed	873	878	|O
mu	879	881	|O
-	881	882	|O
agonist	882	889	|O
/	889	890	|O
delta	890	895	|O
-	895	896	|O
antagonist	896	906	|O
.	906	907	|O

### abstracts4829.txt
A	0	1	|O
family	2	8	|O
of	9	11	|O
analogues	12	21	|O
of	22	24	|O
des	25	28	|O
-	28	29	|O
AA	29	31	|O
(	31	32	|O
1,2,5	32	37	|O
)	37	38	|O
-	38	39	|O
[	39	40	|O
DTrp	40	44	|O
(	44	45	|O
8	45	46	|O
)	46	47	|O
/	47	48	|O
D2Nal	48	53	|O
(	53	54	|O
8	54	55	|O
)	55	56	|O
]	56	57	|O
-	57	58	|O
SRIF	58	62	|O
that	63	67	|O
contain	68	75	|O
a	76	77	|O
4	78	79	|B-IUPAC
-	79	80	|I-IUPAC
(	80	81	|I-IUPAC
N	81	82	|I-IUPAC
-	82	83	|I-IUPAC
isopropyl	83	92	|I-IUPAC
)	92	93	|I-IUPAC
-	93	94	|I-IUPAC
aminomethylphenylalanine	94	118	|I-IUPAC
(	119	120	|O
IAmp	120	124	|O
)	124	125	|O
at	126	128	|O
position	129	137	|O
9	138	139	|O
was	140	143	|O
identified	144	154	|O
that	155	159	|O
has	160	163	|O
high	164	168	|O
affinity	169	177	|O
and	178	181	|O
selectivity	182	193	|O
for	194	197	|O
human	198	203	|O
somatostatin	204	216	|O
receptor	217	225	|O
subtype	226	233	|O
1	234	235	|O
(	236	237	|O
sst1	237	241	|O
)	241	242	|O
.	242	243	|O
The	244	247	|O
binding	248	255	|O
affinities	256	266	|O
of	267	269	|O
des	270	273	|O
-	273	274	|O
AA	274	276	|O
(	276	277	|O
1,2,5	277	282	|O
)	282	283	|O
-	283	284	|O
[	284	285	|O
DTrp	285	289	|O
(	289	290	|O
8	290	291	|O
)	291	292	|O
,	292	293	|O
IAmp	293	297	|O
(	297	298	|O
9	298	299	|O
)	299	300	|O
]	300	301	|O
-	301	302	|O
SRIF	302	306	|O
(	307	308	|O
c	308	309	|O
[	309	310	|O
H	310	311	|O
-	311	312	|O
Cys	312	315	|O
-	315	316	|O
Lys	316	319	|O
-	319	320	|O
Phe	320	323	|O
-	323	324	|O
Phe	324	327	|O
-	327	328	|O
DTrp	328	332	|O
-	332	333	|O
IAmp	333	337	|O
-	337	338	|O
Thr	338	341	|O
-	341	342	|O
Phe	342	345	|O
-	345	346	|O
Thr	346	349	|O
-	349	350	|O
Ser	350	353	|O
-	353	354	|O
Cys	354	357	|O
-	357	358	|O
OH	358	360	|O
]	360	361	|O
,	361	362	|O
CH	363	365	|O
-	365	366	|O
275	366	369	|O
)	369	370	|O
(	371	372	|O
7	372	373	|O
)	373	374	|O
,	374	375	|O
des	376	379	|O
-	379	380	|O
AA	380	382	|O
(	382	383	|O
1,5	383	386	|O
)	386	387	|O
-	387	388	|O
[	388	389	|O
Tyr	389	392	|O
(	392	393	|O
2	393	394	|O
)	394	395	|O
,	395	396	|O
DTrp	396	400	|O
(	400	401	|O
8	401	402	|O
)	402	403	|O
,	403	404	|O
IAmp	404	408	|O
(	408	409	|O
9	409	410	|O
)	410	411	|O
]	411	412	|O
-	412	413	|O
SRIF	413	417	|O
(	418	419	|O
CH	419	421	|O
-	421	422	|O
288	422	425	|O
)	425	426	|O
(	427	428	|O
16	428	430	|O
)	430	431	|O
,	431	432	|O
des	433	436	|O
-	436	437	|O
AA	437	439	|O
(	439	440	|O
1,2,5	440	445	|O
)	445	446	|O
-	446	447	|O
[	447	448	|O
Tyr	448	451	|O
(	451	452	|O
7	452	453	|O
)	453	454	|O
,	454	455	|O
DTrp	455	459	|O
(	459	460	|O
8	460	461	|O
)	461	462	|O
,	462	463	|O
IAmp	463	467	|O
(	467	468	|O
9	468	469	|O
)	469	470	|O
]	470	471	|O
-	471	472	|O
SRIF	472	476	|O
(	477	478	|O
23	478	480	|O
)	480	481	|O
,	481	482	|O
and	483	486	|O
des	487	490	|O
-	490	491	|O
AA	491	493	|O
(	493	494	|O
1,2,5	494	499	|O
)	499	500	|O
-	500	501	|O
[	501	502	|O
DTrp	502	506	|O
(	506	507	|O
8	507	508	|O
)	508	509	|O
,	509	510	|O
IAmp	510	514	|O
(	514	515	|O
9	515	516	|O
)	516	517	|O
,	517	518	|O
Tyr	518	521	|O
(	521	522	|O
11	522	524	|O
)	524	525	|O
]	525	526	|O
-	526	527	|O
SRIF	527	531	|O
(	532	533	|O
25	533	535	|O
)	535	536	|O
are	537	540	|O
about	541	546	|O
(	547	548	|O
1	548	549	|O
)	549	550	|O
/	550	551	|O
(	551	552	|O
7	552	553	|O
)	553	554	|O
,	554	555	|O
(	556	557	|O
1	557	558	|O
)	558	559	|O
/	559	560	|O
(	560	561	|O
4	561	562	|O
)	562	563	|O
,	563	564	|O
(	565	566	|O
1	566	567	|O
)	567	568	|O
/	568	569	|O
(	569	570	|O
125	570	573	|O
)	573	574	|O
,	574	575	|O
and	576	579	|O
(	580	581	|O
1	581	582	|O
)	582	583	|O
/	583	584	|O
(	584	585	|O
4	585	586	|O
)	586	587	|O
that	588	592	|O
of	593	595	|O
SRIF	596	600	|O
-	600	601	|O
28	601	603	|O
(	604	605	|O
1	605	606	|O
)	606	607	|O
to	608	610	|O
sst1	611	615	|O
,	615	616	|O
respectively	617	629	|O
,	629	630	|O
about	631	636	|O
(	637	638	|O
1	638	639	|O
)	639	640	|O
/	640	641	|O
(	641	642	|O
65	642	644	|O
)	644	645	|O
,	645	646	|O
(	647	648	|O
1	648	649	|O
)	649	650	|O
/	650	651	|O
(	651	652	|O
130	652	655	|O
)	655	656	|O
,	656	657	|O
&	658	659	|O
lt	659	661	|O
;	661	662	|O
(	662	663	|O
1	663	664	|O
)	664	665	|O
/	665	666	|O
(	666	667	|O
1000	667	671	|O
)	671	672	|O
,	672	673	|O
and	674	677	|O
&	678	679	|O
lt	679	681	|O
;	681	682	|O
(	682	683	|O
1	683	684	|O
)	684	685	|O
/	685	686	|O
(	686	687	|O
150	687	690	|O
)	690	691	|O
that	692	696	|O
of	697	699	|O
1	700	701	|O
to	702	704	|O
sst3	705	709	|O
,	709	710	|O
respectively	711	723	|O
,	723	724	|O
and	725	728	|O
about	729	734	|O
or	735	737	|O
less	738	742	|O
than	743	747	|O
(	748	749	|O
1	749	750	|O
)	750	751	|O
/	751	752	|O
(	752	753	|O
1000	753	757	|O
)	757	758	|O
that	759	763	|O
of	764	766	|O
1	767	768	|O
to	769	771	|O
the	772	775	|O
other	776	781	|O
three	782	787	|O
human	788	793	|O
SRIF	794	798	|O
receptor	799	807	|O
subtypes	808	816	|O
.	816	817	|O
A	818	819	|O
substitution	820	832	|O
of	833	835	|O
DTrp	836	840	|O
(	840	841	|O
8	841	842	|O
)	842	843	|O
by	844	846	|O
D2Nal	847	852	|O
(	852	853	|O
8	853	854	|O
)	854	855	|O
in	856	858	|O
7	859	860	|O
to	861	863	|O
yield	864	869	|O
des	870	873	|O
-	873	874	|O
AA	874	876	|O
(	876	877	|O
1,2,5	877	882	|O
)	882	883	|O
-	883	884	|O
[	884	885	|O
D2Nal	885	890	|O
(	890	891	|O
8	891	892	|O
)	892	893	|O
,	893	894	|O
IAmp	894	898	|O
(	898	899	|O
9	899	900	|O
)	900	901	|O
]	901	902	|O
-	902	903	|O
SRIF	903	907	|O
(	908	909	|O
13	909	911	|O
)	911	912	|O
and	913	916	|O
in	917	919	|O
16	920	922	|O
to	923	925	|O
yield	926	931	|O
des	932	935	|O
-	935	936	|O
AA	936	938	|O
(	938	939	|O
1,5	939	942	|O
)	942	943	|O
-	943	944	|O
[	944	945	|O
Tyr	945	948	|O
(	948	949	|O
2	949	950	|O
)	950	951	|O
,	951	952	|O
D2Nal	952	957	|O
(	957	958	|O
8	958	959	|O
)	959	960	|O
,	960	961	|O
IAmp	961	965	|O
(	965	966	|O
9	966	967	|O
)	967	968	|O
]	968	969	|O
-	969	970	|O
SRIF	970	974	|O
(	975	976	|O
17	976	978	|O
)	978	979	|O
was	980	983	|O
intended	984	992	|O
to	993	995	|O
increase	996	1004	|O
chemical	1005	1013	|O
stability	1014	1023	|O
,	1023	1024	|O
selectivity	1025	1036	|O
,	1036	1037	|O
and	1038	1041	|O
affinity	1042	1050	|O
and	1051	1054	|O
resulted	1055	1063	|O
in	1064	1066	|O
two	1067	1070	|O
analogues	1071	1080	|O
that	1081	1085	|O
were	1086	1090	|O
less	1091	1095	|O
potent	1096	1102	|O
or	1103	1105	|O
equipotent	1106	1116	|O
with	1117	1121	|O
similar	1122	1129	|O
selectivity	1130	1141	|O
,	1141	1142	|O
respectively	1143	1155	|O
.	1155	1156	|O
Carbamoylation	1157	1171	|O
of	1172	1174	|O
the	1175	1178	|O
N	1179	1180	|O
-	1180	1181	|O
terminus	1181	1189	|O
as	1190	1192	|O
in	1193	1195	|O
des	1196	1199	|O
-	1199	1200	|O
AA	1200	1202	|O
(	1202	1203	|O
1,2,5	1203	1208	|O
)	1208	1209	|O
-	1209	1210	|O
[	1210	1211	|O
DTrp	1211	1215	|O
(	1215	1216	|O
8	1216	1217	|O
)	1217	1218	|O
,	1218	1219	|O
IAmp	1219	1223	|O
(	1223	1224	|O
9	1224	1225	|O
)	1225	1226	|O
,	1226	1227	|O
Tyr	1227	1230	|O
(	1230	1231	|O
11	1231	1233	|O
)	1233	1234	|O
]	1234	1235	|O
-	1235	1236	|O
Cbm	1236	1239	|O
-	1239	1240	|O
SRIF	1240	1244	|O
(	1245	1246	|O
27	1246	1248	|O
)	1248	1249	|O
increased	1250	1259	|O
affinity	1260	1268	|O
slightly	1269	1277	|O
as	1278	1280	|O
well	1281	1285	|O
as	1286	1288	|O
improved	1289	1297	|O
selectivity	1298	1309	|O
.	1309	1310	|O
Monoiodination	1311	1325	|O
of	1326	1328	|O
25	1329	1331	|O
to	1332	1334	|O
yield	1335	1340	|O
26	1341	1343	|O
and	1344	1347	|O
of	1348	1350	|O
27	1351	1353	|O
to	1354	1356	|O
yield	1357	1362	|O
28	1363	1365	|O
resulted	1366	1374	|O
in	1375	1377	|O
an	1378	1380	|O
additional	1381	1391	|O
4	1392	1393	|O
-	1393	1394	|O
fold	1394	1398	|O
increase	1399	1407	|O
in	1408	1410	|O
affinity	1411	1419	|O
at	1420	1422	|O
sst1	1423	1427	|O
.	1427	1428	|O
Desamination	1429	1441	|O
of	1442	1444	|O
the	1445	1448	|O
N	1449	1450	|O
-	1450	1451	|O
terminus	1451	1459	|O
of	1460	1462	|O
17	1463	1465	|O
to	1466	1468	|O
yield	1469	1474	|O
18	1475	1477	|O
,	1477	1478	|O
on	1479	1481	|O
the	1482	1485	|O
other	1486	1491	|O
hand	1492	1496	|O
,	1496	1497	|O
resulted	1498	1506	|O
in	1507	1509	|O
significant	1510	1521	|O
loss	1522	1526	|O
of	1527	1529	|O
affinity	1530	1538	|O
.	1538	1539	|O
Attempts	1540	1548	|O
at	1549	1551	|O
reducing	1552	1560	|O
the	1561	1564	|O
size	1565	1569	|O
of	1570	1572	|O
the	1573	1576	|O
ring	1577	1581	|O
with	1582	1586	|O
maintenance	1587	1598	|O
of	1599	1601	|O
selectivity	1602	1613	|O
failed	1614	1620	|O
in	1621	1623	|O
that	1624	1628	|O
des	1629	1632	|O
-	1632	1633	|O
AA	1633	1635	|O
(	1635	1636	|O
1,4,5,13	1636	1644	|O
)	1644	1645	|O
-	1645	1646	|O
[	1646	1647	|O
Tyr	1647	1650	|O
(	1650	1651	|O
2	1651	1652	|O
)	1652	1653	|O
,	1653	1654	|O
DTrp	1654	1658	|O
(	1658	1659	|O
8	1659	1660	|O
)	1660	1661	|O
,	1661	1662	|O
IAmp	1662	1666	|O
(	1666	1667	|O
9	1667	1668	|O
)	1668	1669	|O
]	1669	1670	|O
-	1670	1671	|O
SRIF	1671	1675	|O
(	1676	1677	|O
33	1677	1679	|O
)	1679	1680	|O
and	1681	1684	|O
des	1685	1688	|O
-	1688	1689	|O
AA	1689	1691	|O
(	1691	1692	|O
1,4,5,6,12,13	1692	1705	|O
)	1705	1706	|O
-	1706	1707	|O
[	1707	1708	|O
Tyr	1708	1711	|O
(	1711	1712	|O
2	1712	1713	|O
)	1713	1714	|O
,	1714	1715	|O
DTrp	1715	1719	|O
(	1719	1720	|O
8	1720	1721	|O
)	1721	1722	|O
,	1722	1723	|O
IAmp	1723	1727	|O
(	1727	1728	|O
9	1728	1729	|O
)	1729	1730	|O
]	1730	1731	|O
-	1731	1732	|O
SRIF	1732	1736	|O
(	1737	1738	|O
34	1738	1740	|O
)	1740	1741	|O
progressively	1742	1755	|O
lost	1756	1760	|O
affinity	1761	1769	|O
for	1770	1773	|O
all	1774	1777	|O
receptors	1778	1787	|O
.	1787	1788	|O
Both	1789	1793	|O
des	1794	1797	|O
-	1797	1798	|O
AA	1798	1800	|O
(	1800	1801	|O
1,2,5	1801	1806	|O
)	1806	1807	|O
-	1807	1808	|O
[	1808	1809	|O
DTrp	1809	1813	|O
(	1813	1814	|O
8	1814	1815	|O
)	1815	1816	|O
,	1816	1817	|O
IAmp	1817	1821	|O
(	1821	1822	|O
9	1822	1823	|O
)	1823	1824	|O
,	1824	1825	|O
Tyr	1825	1828	|O
(	1828	1829	|O
11	1829	1831	|O
)	1831	1832	|O
]	1832	1833	|O
-	1833	1834	|O
Cbm	1834	1837	|O
-	1837	1838	|O
SRIF	1838	1842	|O
(	1843	1844	|O
27	1844	1846	|O
)	1846	1847	|O
and	1848	1851	|O
des	1852	1855	|O
-	1855	1856	|O
AA	1856	1858	|O
(	1858	1859	|O
1,2,5	1859	1864	|O
)	1864	1865	|O
-	1865	1866	|O
[	1866	1867	|O
DCys	1867	1871	|O
(	1871	1872	|O
3	1872	1873	|O
)	1873	1874	|O
,	1874	1875	|O
DTrp	1875	1879	|O
(	1879	1880	|O
8	1880	1881	|O
)	1881	1882	|O
,	1882	1883	|O
IAmp	1883	1887	|O
(	1887	1888	|O
9	1888	1889	|O
)	1889	1890	|O
,	1890	1891	|O
Tyr	1891	1894	|O
(	1894	1895	|O
11	1895	1897	|O
)	1897	1898	|O
]	1898	1899	|O
-	1899	1900	|O
Cbm	1900	1903	|O
-	1903	1904	|O
SRIF	1904	1908	|O
(	1909	1910	|O
29	1910	1912	|O
)	1912	1913	|O
show	1914	1918	|O
agonistic	1919	1928	|O
activity	1929	1937	|O
in	1938	1940	|O
a	1941	1942	|O
cAMP	1943	1947	|O
assay	1948	1953	|O
;	1953	1954	|O
therefore	1955	1964	|O
,	1964	1965	|O
the	1966	1969	|O
structural	1970	1980	|O
basis	1981	1986	|O
for	1987	1990	|O
the	1991	1994	|O
agonist	1995	2002	|O
property	2003	2011	|O
of	2012	2014	|O
this	2015	2019	|O
family	2020	2026	|O
of	2027	2029	|O
analogues	2030	2039	|O
is	2040	2042	|O
not	2043	2046	|O
contingent	2047	2057	|O
upon	2058	2062	|O
the	2063	2066	|O
chirality	2067	2076	|O
of	2077	2079	|O
the	2080	2083	|O
Cys	2084	2087	|O
residue	2088	2095	|O
at	2096	2098	|O
position	2099	2107	|O
3	2108	2109	|O
as	2110	2112	|O
shown	2113	2118	|O
to	2119	2121	|O
be	2122	2124	|O
the	2125	2128	|O
case	2129	2133	|O
in	2134	2136	|O
18	2137	2139	|O
-	2139	2140	|O
membered	2140	2148	|O
ring	2149	2153	|O
SRIF	2154	2158	|O
octapeptides	2159	2171	|O
.	2171	2172	|O
None	2173	2177	|O
of	2178	2180	|O
the	2181	2184	|O
high	2185	2189	|O
affinity	2190	2198	|O
structures	2199	2209	|O
described	2210	2219	|O
here	2220	2224	|O
showed	2225	2231	|O
receptor	2232	2240	|O
antagonism	2241	2251	|O
.	2251	2252	|O
We	2253	2255	|O
have	2256	2260	|O
prepared	2261	2269	|O
the	2270	2273	|O
radiolabeled	2274	2286	|O
des	2287	2290	|O
-	2290	2291	|O
AA	2291	2293	|O
(	2293	2294	|O
1,2,5	2294	2299	|O
)	2299	2300	|O
-	2300	2301	|O
[	2301	2302	|O
DTrp	2302	2306	|O
(	2306	2307	|O
8	2307	2308	|O
)	2308	2309	|O
,	2309	2310	|O
IAmp	2310	2314	|O
(	2314	2315	|O
9	2315	2316	|O
)	2316	2317	|O
,	2317	2318	|O
(	2318	2319	|O
125	2319	2322	|O
)	2322	2323	|O
ITyr	2323	2327	|O
(	2327	2328	|O
11	2328	2330	|O
)	2330	2331	|O
]	2331	2332	|O
-	2332	2333	|O
SRIF	2333	2337	|O
(	2338	2339	|O
(	2339	2340	|O
125	2340	2343	|O
)	2343	2344	|O
I	2344	2345	|O
-	2345	2346	|O
25	2346	2348	|O
)	2348	2349	|O
and	2350	2353	|O
des	2354	2357	|O
-	2357	2358	|O
AA	2358	2360	|O
(	2360	2361	|O
1,2,5	2361	2366	|O
)	2366	2367	|O
-	2367	2368	|O
[	2368	2369	|O
DTrp	2369	2373	|O
(	2373	2374	|O
8	2374	2375	|O
)	2375	2376	|O
,	2376	2377	|O
IAmp	2377	2381	|O
(	2381	2382	|O
9	2382	2383	|O
)	2383	2384	|O
,	2384	2385	|O
(	2386	2387	|O
125	2387	2390	|O
)	2390	2391	|O
ITyr	2391	2395	|O
(	2395	2396	|O
11	2396	2398	|O
)	2398	2399	|O
]	2399	2400	|O
-	2400	2401	|O
Cbm	2401	2404	|O
-	2404	2405	|O
SRIF	2405	2409	|O
(	2410	2411	|O
(	2411	2412	|O
125	2412	2415	|O
)	2415	2416	|O
I	2416	2417	|O
-	2417	2418	|O
27	2418	2420	|O
)	2420	2421	|O
,	2421	2422	|O
used	2423	2427	|O
them	2428	2432	|O
as	2433	2435	|O
in	2436	2438	|O
vitro	2439	2444	|O
tracers	2445	2452	|O
,	2452	2453	|O
and	2454	2457	|O
found	2458	2463	|O
them	2464	2468	|O
to	2469	2471	|O
be	2472	2474	|O
superior	2475	2483	|O
to	2484	2486	|O
des	2487	2490	|O
-	2490	2491	|O
AA	2491	2493	|O
(	2493	2494	|O
1,5	2494	2497	|O
)	2497	2498	|O
-	2498	2499	|O
[	2499	2500	|O
(	2500	2501	|O
125	2501	2504	|O
)	2504	2505	|O
ITyr	2505	2509	|O
(	2509	2510	|O
2	2510	2511	|O
)	2511	2512	|O
,	2512	2513	|O
DTrp	2513	2517	|O
(	2517	2518	|O
8	2518	2519	|O
)	2519	2520	|O
,	2520	2521	|O
IAmp	2521	2525	|O
(	2525	2526	|O
9	2526	2527	|O
)	2527	2528	|O
]	2528	2529	|O
-	2529	2530	|O
SRIF	2530	2534	|O
(	2535	2536	|O
(	2536	2537	|O
125	2537	2540	|O
)	2540	2541	|O
I	2541	2542	|O
-	2542	2543	|O
16	2543	2545	|O
)	2545	2546	|O
for	2547	2550	|O
the	2551	2554	|O
detection	2555	2564	|O
of	2565	2567	|O
sst1	2568	2572	|O
tumors	2573	2579	|O
in	2580	2582	|O
receptor	2583	2591	|O
autoradiography	2592	2607	|O
studies	2608	2615	|O
.	2615	2616	|O

### abstracts2901.txt
2	0	1	|B-PARTIUPAC
-	1	2	|I-PARTIUPAC
Fluoro	2	8	|I-PARTIUPAC
-	8	9	|I-PARTIUPAC
,	9	10	|O
5	11	12	|B-PARTIUPAC
-	12	13	|I-PARTIUPAC
fluoro	13	19	|I-PARTIUPAC
-	19	20	|I-PARTIUPAC
and	21	24	|O
6	25	26	|B-IUPAC
-	26	27	|I-IUPAC
fluorodimethoxybenzaldehydes	27	55	|I-IUPAC
were	56	60	|O
prepared	61	69	|O
by	70	72	|O
photochemical	73	86	|O
decomposition	87	100	|O
of	101	103	|O
the	104	107	|O
corresponding	108	121	|O
diazonium	122	131	|O
fluoroborates	132	145	|O
.	145	146	|O
The	147	150	|O
aldehydes	151	160	|O
were	161	165	|O
converted	166	175	|O
to	176	178	|O
the	179	182	|O
cyanohydrin	183	194	|B-IUPAC
trimethylsilyl	195	209	|I-IUPAC
ethers	210	216	|I-IUPAC
,	216	217	|O
which	218	223	|O
,	223	224	|O
in	225	227	|O
turn	228	232	|O
,	232	233	|O
were	234	238	|O
reduced	239	246	|O
to	247	249	|O
the	250	253	|O
dimethoxyphenethanolamines	254	280	|B-IUPAC
.	280	281	|O
Boron	282	287	|O
tribromide	288	298	|O
demethylation	299	312	|O
afforded	313	321	|O
the	322	325	|O
racemic	326	333	|O
ring	334	338	|O
-	338	339	|O
fluorinated	339	350	|O
norepinephrines	351	366	|O
.	366	367	|O
An	368	370	|O
alternate	371	380	|O
route	381	386	|O
,	386	387	|O
using	388	393	|O
the	394	397	|O
dibenzyloxyfluoroaldehyde	398	423	|B-IUPAC
,	423	424	|O
was	425	428	|O
also	429	433	|O
used	434	438	|O
to	439	441	|O
prepare	442	449	|O
6	450	451	|B-IUPAC
-	451	452	|I-IUPAC
fluoronorepinephrine	452	472	|I-IUPAC
.	472	473	|O
The	474	477	|O
fluorine	478	486	|O
substituent	487	498	|O
markedly	499	507	|O
increases	508	517	|O
the	518	521	|O
phenolic	522	530	|O
acidities	531	540	|O
of	541	543	|O
these	544	549	|O
analogues	550	559	|O
.	559	560	|O
The	561	564	|O
biological	565	575	|O
properties	576	586	|O
conferred	587	596	|O
upon	597	601	|O
norepinephrine	602	616	|O
by	617	619	|O
the	620	623	|O
fluorine	624	632	|O
substituents	633	645	|O
in	646	648	|O
peripheral	649	659	|O
and	660	663	|O
central	664	671	|O
adrenergically	672	686	|O
responsive	687	697	|O
systems	698	705	|O
clearly	706	713	|O
demonstrate	714	725	|O
that	726	730	|O
2	731	732	|B-IUPAC
-	732	733	|I-IUPAC
fluoronorepinephrine	733	753	|I-IUPAC
is	754	756	|O
a	757	758	|O
nearly	759	765	|O
a	766	767	|O
pure	768	772	|O
beta	773	777	|O
-	777	778	|O
adrenergic	778	788	|O
agonist	789	796	|O
,	796	797	|O
while	798	803	|O
6	804	805	|B-IUPAC
-	805	806	|I-IUPAC
fluoronorepinephrine	806	826	|I-IUPAC
is	827	829	|O
an	830	832	|O
alpha	833	838	|O
-	838	839	|O
adrenergic	839	849	|O
agonist	850	857	|O
.	857	858	|O
5	859	860	|B-IUPAC
-	860	861	|I-IUPAC
Fluoronorepinephrine	861	881	|I-IUPAC
retains	882	889	|O
both	890	894	|O
beta	895	899	|O
-	899	900	|O
and	901	904	|O
alpha	905	910	|O
-	910	911	|O
adrenergic	911	921	|O
agonist	922	929	|O
properties	930	940	|O
.	940	941	|O
Receptor	942	950	|O
-	950	951	|O
binding	951	958	|O
studies	959	966	|O
with	967	971	|O
specific	972	980	|O
radiolabeled	981	993	|O
ligands	994	1001	|O
indicate	1002	1010	|O
that	1011	1015	|O
the	1016	1019	|O
specificity	1020	1031	|O
conferred	1032	1041	|O
by	1042	1044	|O
the	1045	1048	|O
site	1049	1053	|O
of	1054	1056	|O
fluorine	1057	1065	|O
substituents	1066	1078	|O
results	1079	1086	|O
from	1087	1091	|O
a	1092	1093	|O
change	1094	1100	|O
in	1101	1103	|O
the	1104	1107	|O
affinity	1108	1116	|O
of	1117	1119	|O
these	1120	1125	|O
analogues	1126	1135	|O
for	1136	1139	|O
the	1140	1143	|O
alpha	1144	1149	|O
-	1149	1150	|O
and	1151	1154	|O
beta	1155	1159	|O
-	1159	1160	|O
adrenergic	1160	1170	|O
receptors	1171	1180	|O
.	1180	1181	|O

### abstracts4817.txt
Three	0	5	|O
N	6	7	|B-IUPAC
-	7	8	|I-IUPAC
fluoroethyl	8	19	|I-IUPAC
-	19	20	|I-IUPAC
substituted	20	31	|B-MODIFIER
(	32	33	|B-IUPAC
imidazolylphenyl	33	49	|I-IUPAC
)	49	50	|I-IUPAC
formamidine	50	61	|I-IUPAC
derivatives	62	73	|B-MODIFIER
,	73	74	|O
namely	75	81	|O
,	81	82	|O
2	83	84	|B-IUPAC
-	84	85	|I-IUPAC
fluoroethyl	85	96	|I-IUPAC
(	97	98	|O
3b	98	100	|O
)	100	101	|O
,	101	102	|O
2,2	103	106	|B-IUPAC
-	106	107	|I-IUPAC
difluoroethyl	107	120	|I-IUPAC
(	121	122	|O
3c	122	124	|O
)	124	125	|O
,	125	126	|O
and	127	130	|O
2,2,2	131	136	|B-IUPAC
-	136	137	|I-IUPAC
trifluoroethyl	137	151	|I-IUPAC
(	152	153	|O
3d	153	155	|O
)	155	156	|O
,	156	157	|O
were	158	162	|O
prepared	163	171	|O
to	172	174	|O
test	175	179	|O
the	180	183	|O
effect	184	190	|O
of	191	193	|O
fluorine	194	202	|O
substitution	203	215	|O
on	216	218	|O
basicity	219	227	|O
and	228	231	|O
,	231	232	|O
then	233	237	|O
,	237	238	|O
on	239	241	|O
H2	242	244	|O
-	244	245	|O
antagonist	245	255	|O
affinity	256	264	|O
in	265	267	|O
comparison	268	278	|O
with	279	283	|O
the	284	287	|O
unsubstituted	288	301	|B-MODIFIER
N	302	303	|B-IUPAC
-	303	304	|I-IUPAC
ethyl	304	309	|I-IUPAC
derivative	310	320	|B-MODIFIER
(	321	322	|O
3a	322	324	|O
)	324	325	|O
,	325	326	|O
taken	327	332	|O
as	333	335	|O
a	336	337	|O
model	338	343	|O
of	344	346	|O
mifentidine	347	358	|O
.	358	359	|O
Imidazolylphenyl	360	376	|O
isothiocyanate	377	391	|O
(	392	393	|O
1	393	394	|O
)	394	395	|O
,	395	396	|O
obtained	397	405	|O
by	406	408	|O
reaction	409	417	|O
of	418	420	|O
4	421	422	|B-IUPAC
-	422	423	|I-IUPAC
(	423	424	|I-IUPAC
aminophenyl	424	435	|I-IUPAC
)	435	436	|I-IUPAC
imidazole	436	445	|I-IUPAC
with	446	450	|O
carbon	451	457	|O
disulfide	458	467	|O
and	468	471	|O
ethyl	472	477	|B-IUPAC
chloroformate	478	491	|I-IUPAC
,	491	492	|O
was	493	496	|O
condensed	497	506	|O
with	507	511	|O
the	512	515	|O
requisite	516	525	|O
2	526	527	|B-IUPAC
-	527	528	|I-IUPAC
fluoro	528	534	|I-IUPAC
-	534	535	|O
substituted	535	546	|B-MODIFIER
ethylamines	547	558	|B-IUPAC
to	559	561	|O
give	562	566	|O
the	567	570	|O
intermediate	571	583	|O
thioureas	584	593	|O
(	594	595	|O
2b	595	597	|O
-	597	598	|O
d	598	599	|O
)	599	600	|O
.	600	601	|O
Desulfurization	602	617	|O
of	618	620	|O
these	621	626	|O
thioureas	627	636	|O
by	637	639	|O
Raney	640	645	|O
nickel	646	652	|O
furnished	653	662	|O
the	663	666	|O
desired	667	674	|O
formamidines	675	687	|O
(	688	689	|O
3b	689	691	|O
-	691	692	|O
d	692	693	|O
)	693	694	|O
.	694	695	|O
Increasing	696	706	|O
fluorine	707	715	|O
substitution	716	728	|O
was	729	732	|O
found	733	738	|O
to	739	741	|O
decrease	742	750	|O
basicity	751	759	|O
of	760	762	|O
the	763	766	|O
formamidino	767	778	|O
group	779	784	|O
substantially	785	798	|O
(	799	800	|O
3a	800	802	|O
,	802	803	|O
pKa	804	807	|O
=	808	809	|O
8.65	810	814	|O
;	814	815	|O
3b	816	818	|O
,	818	819	|O
pKa	820	823	|O
=	824	825	|O
8.12	826	830	|O
;	830	831	|O
3c	832	834	|O
,	834	835	|O
pKa	836	839	|O
=	840	841	|O
6.60	842	846	|O
;	846	847	|O
3d	848	850	|O
,	850	851	|O
pKa	852	855	|O
=	856	857	|O
6.14	858	862	|O
)	862	863	|O
,	863	864	|O
while	865	870	|O
having	871	877	|O
a	878	879	|O
modest	880	886	|O
effect	887	893	|O
on	894	896	|O
the	897	900	|O
imidazole	901	910	|O
portion	911	918	|O
.	918	919	|O
Affinity	920	928	|O
at	929	931	|O
the	932	935	|O
H2	936	938	|O
receptors	939	948	|O
,	948	949	|O
evaluated	950	959	|O
from	960	964	|O
antagonism	965	975	|O
of	976	978	|O
histamine	979	988	|O
-	988	989	|O
stimulated	989	999	|O
chronotropic	1000	1012	|O
response	1013	1021	|O
on	1022	1024	|O
guinea	1025	1031	|O
pig	1032	1035	|O
atria	1036	1041	|O
,	1041	1042	|O
increased	1043	1052	|O
following	1053	1062	|O
fluorine	1063	1071	|O
substitution	1072	1084	|O
(	1085	1086	|O
3a	1086	1088	|O
,	1088	1089	|O
KB	1090	1092	|O
=	1093	1094	|O
177	1095	1098	|O
;	1098	1099	|O
3b	1100	1102	|O
,	1102	1103	|O
KB	1104	1106	|O
=	1107	1108	|O
61	1109	1111	|O
;	1111	1112	|O
3c	1113	1115	|O
,	1115	1116	|O
KB	1117	1119	|O
=	1120	1121	|O
21	1122	1124	|O
;	1124	1125	|O
3d	1126	1128	|O
,	1128	1129	|O
KB	1130	1132	|O
=	1133	1134	|O
7.6	1135	1138	|O
)	1138	1139	|O
.	1139	1140	|O
It	1141	1143	|O
is	1144	1146	|O
concluded	1147	1156	|O
that	1157	1161	|O
H2	1162	1164	|O
-	1164	1165	|O
receptor	1165	1173	|O
antagonist	1174	1184	|O
affinity	1185	1193	|O
in	1194	1196	|O
the	1197	1200	|O
mifentidine	1201	1212	|O
series	1213	1219	|O
is	1220	1222	|O
mostly	1223	1229	|O
dependent	1230	1239	|O
on	1240	1242	|O
the	1243	1246	|O
availability	1247	1259	|O
of	1260	1262	|O
the	1263	1266	|O
neutral	1267	1274	|O
species	1275	1282	|O
.	1282	1283	|O
These	1284	1289	|O
data	1290	1294	|O
support	1295	1302	|O
the	1303	1306	|O
hypothesis	1307	1317	|O
that	1318	1322	|O
mifentidine	1323	1334	|O
,	1334	1335	|O
like	1336	1340	|O
cimetidine	1341	1351	|O
,	1351	1352	|O
acts	1353	1357	|O
through	1358	1365	|O
the	1366	1369	|O
neutral	1370	1377	|O
species	1378	1385	|O
.	1385	1386	|O

### abstracts3118.txt
Glycosylation	0	13	|O
of	14	16	|O
ethyl	17	22	|B-IUPAC
3	23	24	|I-IUPAC
(	24	25	|I-IUPAC
5	25	26	|I-IUPAC
)	26	27	|I-IUPAC
-	27	28	|I-IUPAC
(	28	29	|I-IUPAC
bromomethyl	29	40	|I-IUPAC
)	40	41	|I-IUPAC
pyrazole	41	49	|I-IUPAC
-	49	50	|I-IUPAC
5	50	51	|I-IUPAC
(	51	52	|I-IUPAC
3	52	53	|I-IUPAC
)	53	54	|I-IUPAC
-	54	55	|I-IUPAC
carboxylate	55	66	|I-IUPAC
(	67	68	|O
3	68	69	|O
)	69	70	|O
and	71	74	|O
3	75	76	|B-IUPAC
(	76	77	|I-IUPAC
5	77	78	|I-IUPAC
)	78	79	|I-IUPAC
-	79	80	|I-IUPAC
(	80	81	|I-IUPAC
bromomethyl	81	92	|I-IUPAC
)	92	93	|I-IUPAC
pyrazole	93	101	|I-IUPAC
-	101	102	|I-IUPAC
5	102	103	|I-IUPAC
(	103	104	|I-IUPAC
3	104	105	|I-IUPAC
)	105	106	|I-IUPAC
-	106	107	|I-IUPAC
carboxamide	107	118	|I-IUPAC
(	119	120	|O
4	120	121	|O
)	121	122	|O
with	123	127	|O
poly	128	132	|O
-	132	133	|O
O	133	134	|O
-	134	135	|O
acetylated	135	145	|O
sugars	146	152	|O
via	153	156	|O
an	157	159	|O
acid	160	164	|O
-	164	165	|O
catalyzed	165	174	|O
fusion	175	181	|O
method	182	188	|O
afforded	189	197	|O
the	198	201	|O
corresponding	202	215	|O
ethyl	216	221	|B-IUPAC
3	222	223	|I-IUPAC
-	223	224	|I-IUPAC
(	224	225	|I-IUPAC
bromomethyl	225	236	|I-IUPAC
)	236	237	|I-IUPAC
pyrazole	237	245	|I-IUPAC
-	245	246	|I-IUPAC
5	246	247	|I-IUPAC
-	247	248	|I-IUPAC
carboxylate	248	259	|I-IUPAC
and	260	263	|O
3	264	265	|B-IUPAC
-	265	266	|I-IUPAC
(	266	267	|I-IUPAC
bromomethyl	267	278	|I-IUPAC
)	278	279	|I-IUPAC
pyrazole	279	287	|I-IUPAC
-	287	288	|I-IUPAC
5	288	289	|I-IUPAC
-	289	290	|I-IUPAC
carboxamide	290	301	|I-IUPAC
substituted	302	313	|B-MODIFIER
nucleosides	314	325	|I-MODIFIER
5	326	327	|I-MODIFIER
and	328	331	|O
7	332	333	|B-MODIFIER
,	333	334	|O
respectively	335	347	|O
.	347	348	|O
In	349	351	|O
some	352	356	|O
cases	357	362	|O
,	362	363	|O
the	364	367	|O
positional	368	378	|O
isomers	379	386	|O
6	387	388	|O
and	389	392	|O
8	393	394	|O
were	395	399	|O
also	400	404	|O
obtained	405	413	|O
.	413	414	|O
Treatment	415	424	|O
of	425	427	|O
5	428	429	|O
and	430	433	|O
7	434	435	|O
with	436	440	|O
methanolic	441	451	|O
ammonia	452	459	|O
gave	460	464	|O
the	465	468	|O
deprotected	469	480	|O
3	481	482	|B-IUPAC
-	482	483	|I-IUPAC
(	483	484	|I-IUPAC
aminomethyl	484	495	|I-IUPAC
)	495	496	|I-IUPAC
pyrazole	496	504	|I-IUPAC
-	504	505	|I-IUPAC
5	505	506	|I-IUPAC
-	506	507	|I-IUPAC
carboxamide	507	518	|I-IUPAC
nucleosides	519	530	|B-MODIFIER
9	531	532	|O
.	532	533	|O
Reaction	534	542	|O
of	543	545	|O
3	546	547	|O
-	547	548	|O
-	548	549	|O
5	549	550	|O
and	551	554	|O
7	555	556	|O
with	557	561	|O
bis	562	565	|B-IUPAC
(	565	566	|I-IUPAC
2	566	567	|I-IUPAC
-	567	568	|I-IUPAC
chloroethyl	568	579	|I-IUPAC
)	579	580	|I-IUPAC
amine	580	585	|I-IUPAC
led	586	589	|O
to	590	592	|O
the	593	596	|O
corresponding	597	610	|O
pyrazole	611	619	|O
nitrogen	620	628	|O
mustards	629	637	|O
10	638	640	|O
-	640	641	|O
-	641	642	|O
13	642	644	|O
.	644	645	|O
All	646	649	|O
the	650	653	|O
bromomethylpyrazole	654	673	|O
nucleosides	674	685	|O
described	686	695	|O
showed	696	702	|O
significant	703	714	|O
cytostatic	715	725	|O
activity	726	734	|O
against	735	742	|O
HeLa	743	747	|O
cell	748	752	|O
cultures	753	761	|O
.	761	762	|O

### abstracts1628.txt
2beta	0	5	|O
-	5	6	|O
(	6	7	|O
R	7	8	|O
)	8	9	|O
-	9	10	|O
Carbo	10	15	|O
-	15	16	|O
1	16	17	|O
-	17	18	|O
fluoro	18	24	|O
-	24	25	|O
2	25	26	|O
-	26	27	|O
propoxy	27	34	|O
-	34	35	|O
3beta	35	40	|O
-	40	41	|O
(	41	42	|O
4	42	43	|O
-	43	44	|O
chlorophenyl	44	56	|O
)	56	57	|O
tro	58	61	|O
pane	62	66	|O
(	67	68	|O
(	68	69	|O
R	69	70	|O
)	70	71	|O
-	71	72	|O
FIPCT	72	77	|O
,	77	78	|O
R	79	80	|O
-	80	81	|O
6	81	82	|O
)	82	83	|O
and	84	87	|O
2beta	88	93	|B-IUPAC
-	93	94	|I-IUPAC
(	94	95	|I-IUPAC
S	95	96	|I-IUPAC
)	96	97	|I-IUPAC
-	97	98	|I-IUPAC
carbo	98	103	|I-IUPAC
-	103	104	|I-IUPAC
1	104	105	|I-IUPAC
-	105	106	|I-IUPAC
fluoro	106	112	|I-IUPAC
-	112	113	|I-IUPAC
2	113	114	|I-IUPAC
-	114	115	|I-IUPAC
propoxy	115	122	|I-IUPAC
-	122	123	|I-IUPAC
3beta	123	128	|I-IUPAC
-	128	129	|I-IUPAC
(	129	130	|I-IUPAC
4	130	131	|I-IUPAC
-	131	132	|I-IUPAC
chlorophenyl	132	144	|I-IUPAC
)	144	145	|I-IUPAC
tro	146	149	|I-IUPAC
pane	150	154	|I-IUPAC
(	155	156	|O
(	156	157	|O
S	157	158	|O
)	158	159	|O
-	159	160	|O
FIPCT	160	165	|O
,	165	166	|O
S	167	168	|O
-	168	169	|O
6	169	170	|O
)	170	171	|O
were	172	176	|O
prepared	177	185	|O
and	186	189	|O
evaluated	190	199	|O
in	200	202	|O
vitro	203	208	|O
and	209	212	|O
in	213	215	|O
vivo	216	220	|O
for	221	224	|O
dopamine	225	233	|O
transporter	234	245	|O
(	246	247	|O
DAT	247	250	|O
)	250	251	|O
selectivity	252	263	|O
and	264	267	|O
specificity	268	279	|O
.	279	280	|O
High	281	285	|O
specific	286	294	|O
activity	295	303	|O
[	304	305	|O
(	305	306	|O
18	306	308	|O
)	308	309	|O
F	309	310	|O
]	310	311	|O
(	311	312	|O
R	312	313	|O
)	313	314	|O
-	314	315	|O
FIPCT	315	320	|O
and	321	324	|O
[	325	326	|O
(	326	327	|O
18	327	329	|O
)	329	330	|O
F	330	331	|O
]	331	332	|O
(	332	333	|O
S	333	334	|O
)	334	335	|O
-	335	336	|O
FIPCT	336	341	|O
were	342	346	|O
synthesized	347	358	|O
in	359	361	|O
5%	362	364	|O
radiochemical	365	378	|O
yield	379	384	|O
(	385	386	|O
decay	386	391	|O
-	391	392	|O
corrected	392	401	|O
to	402	404	|O
end	405	408	|O
of	409	411	|O
bombardment	412	423	|O
(	424	425	|O
EOB	425	428	|O
)	428	429	|O
)	429	430	|O
by	431	433	|O
preparation	434	445	|O
of	446	448	|O
the	449	452	|O
precursors	453	463	|O
2beta	464	469	|B-IUPAC
-	469	470	|I-IUPAC
carbo	470	475	|I-IUPAC
-	475	476	|I-IUPAC
R	476	477	|I-IUPAC
-	477	478	|I-IUPAC
1	478	479	|I-IUPAC
-	479	480	|I-IUPAC
mesyloxy	480	488	|I-IUPAC
-	488	489	|I-IUPAC
2	489	490	|I-IUPAC
-	490	491	|I-IUPAC
propoxy	491	498	|I-IUPAC
-	498	499	|I-IUPAC
3beta	499	504	|I-IUPAC
-	504	505	|I-IUPAC
(	505	506	|I-IUPAC
4	506	507	|I-IUPAC
-	507	508	|I-IUPAC
chlorop	508	515	|I-IUPAC
hen	516	519	|I-IUPAC
yl	520	522	|I-IUPAC
)	522	523	|I-IUPAC
tropane	523	530	|I-IUPAC
(	531	532	|O
R	532	533	|O
-	533	534	|O
12	534	536	|O
)	536	537	|O
and	538	541	|O
2beta	542	547	|B-IUPAC
-	547	548	|I-IUPAC
carbo	548	553	|I-IUPAC
-	553	554	|I-IUPAC
S	554	555	|I-IUPAC
-	555	556	|I-IUPAC
1	556	557	|I-IUPAC
-	557	558	|I-IUPAC
mesyloxy	558	566	|I-IUPAC
-	566	567	|I-IUPAC
2	567	568	|I-IUPAC
-	568	569	|I-IUPAC
propoxy	569	576	|I-IUPAC
-	576	577	|I-IUPAC
3beta	577	582	|I-IUPAC
-	582	583	|I-IUPAC
(	583	584	|I-IUPAC
4	584	585	|I-IUPAC
-	585	586	|I-IUPAC
chlorop	586	593	|I-IUPAC
hen	594	597	|I-IUPAC
yl	598	600	|I-IUPAC
)	600	601	|I-IUPAC
tropane	601	608	|I-IUPAC
(	609	610	|O
S	610	611	|O
-	611	612	|O
12	612	614	|O
)	614	615	|O
followed	616	624	|O
by	625	627	|O
treatment	628	637	|O
with	638	642	|O
no	643	645	|O
carrier	646	653	|O
-	653	654	|O
added	654	659	|O
potassium	660	669	|O
[	669	670	|O
(	670	671	|O
18	671	673	|O
)	673	674	|O
F	674	675	|O
]	675	676	|O
fluoride	676	684	|O
and	685	688	|O
kyrptofix	689	698	|O
K222	699	703	|O
in	704	706	|O
acetonitrile	707	719	|O
.	719	720	|O
Competition	721	732	|O
binding	733	740	|O
in	741	743	|O
cells	744	749	|O
stably	750	756	|O
expressing	757	767	|O
the	768	771	|O
transfected	772	783	|O
human	784	789	|O
DAT	790	793	|O
and	794	797	|O
serotonin	798	807	|O
transporter	808	819	|O
(	820	821	|O
SERT	821	825	|O
)	825	826	|O
labeled	827	834	|O
by	835	837	|O
[	838	839	|O
(	839	840	|O
3	840	841	|O
)	841	842	|O
H	842	843	|O
]	843	844	|O
WIN	844	847	|O
35428	848	853	|O
and	854	857	|O
[	858	859	|O
(	859	860	|O
3	860	861	|O
)	861	862	|O
H	862	863	|O
]	863	864	|O
citalopram	864	874	|O
,	874	875	|O
respectively	876	888	|O
,	888	889	|O
demonstrated	890	902	|O
the	903	906	|O
following	907	916	|O
order	917	922	|O
of	923	925	|O
DAT	926	929	|O
affinity	930	938	|O
(	939	940	|O
K	940	941	|O
(	941	942	|O
i	942	943	|O
)	943	944	|O
in	945	947	|O
nM	948	950	|O
)	950	951	|O
:	951	952	|O
GBR	953	956	|O
12909	957	962	|O
(	963	964	|O
0.36	964	968	|O
)	968	969	|O
&	970	971	|O
gt	971	973	|O
;	973	974	|O
CIT	975	978	|O
(	979	980	|O
0.48	980	984	|O
)	984	985	|O
&	986	987	|O
gt	987	989	|O
;	989	990	|O
(	991	992	|O
S	992	993	|O
)	993	994	|O
-	994	995	|O
FIPCT	995	1000	|O
(	1001	1002	|O
0.67	1002	1006	|O
)	1006	1007	|O
&	1008	1009	|O
gt	1009	1011	|O
;	1011	1012	|O
&	1012	1013	|O
gt	1013	1015	|O
;	1015	1016	|O
(	1017	1018	|O
R	1018	1019	|O
)	1019	1020	|O
-	1020	1021	|O
FIPCT	1021	1026	|O
(	1027	1028	|O
3.2	1028	1031	|O
)	1031	1032	|O
.	1032	1033	|O
The	1034	1037	|O
affinity	1038	1046	|O
of	1047	1049	|O
(	1050	1051	|O
S	1051	1052	|O
)	1052	1053	|O
-	1053	1054	|O
FIPCT	1054	1059	|O
and	1060	1063	|O
(	1064	1065	|O
R	1065	1066	|O
)	1066	1067	|O
-	1067	1068	|O
FIPCT	1068	1073	|O
for	1074	1077	|O
SERT	1078	1082	|O
was	1083	1086	|O
127	1087	1090	|O
-	1090	1091	|O
and	1092	1095	|O
20	1096	1098	|O
-	1098	1099	|O
fold	1099	1103	|O
lower	1104	1109	|O
,	1109	1110	|O
respectively	1111	1123	|O
,	1123	1124	|O
than	1125	1129	|O
for	1130	1133	|O
DAT	1134	1137	|O
.	1137	1138	|O
In	1139	1141	|O
vivo	1142	1146	|O
biodistribution	1147	1162	|O
studies	1163	1170	|O
were	1171	1175	|O
performed	1176	1185	|O
in	1186	1188	|O
male	1189	1193	|O
rats	1194	1198	|O
and	1199	1202	|O
demonstrated	1203	1215	|O
that	1216	1220	|O
the	1221	1224	|O
brain	1225	1230	|O
uptake	1231	1237	|O
of	1238	1240	|O
[	1241	1242	|O
(	1242	1243	|O
18	1243	1245	|O
)	1245	1246	|O
F	1246	1247	|O
]	1247	1248	|O
(	1248	1249	|O
R	1249	1250	|O
)	1250	1251	|O
-	1251	1252	|O
FIPCT	1252	1257	|O
and	1258	1261	|O
[	1262	1263	|O
(	1263	1264	|O
18	1264	1266	|O
)	1266	1267	|O
F	1267	1268	|O
]	1268	1269	|O
(	1269	1270	|O
S	1270	1271	|O
)	1271	1272	|O
-	1272	1273	|O
FIPCT	1273	1278	|O
were	1279	1283	|O
selective	1284	1293	|O
and	1294	1297	|O
specific	1298	1306	|O
for	1307	1310	|O
DAT	1311	1314	|O
rich	1315	1319	|O
regions	1320	1327	|O
(	1328	1329	|O
caudate	1329	1336	|O
and	1337	1340	|O
putamen	1341	1348	|O
)	1348	1349	|O
.	1349	1350	|O
PET	1351	1354	|O
brain	1355	1360	|O
imaging	1361	1368	|O
studies	1369	1376	|O
in	1377	1379	|O
monkeys	1380	1387	|O
demonstrated	1388	1400	|O
high	1401	1405	|O
[	1406	1407	|O
(	1407	1408	|O
18	1408	1410	|O
)	1410	1411	|O
F	1411	1412	|O
]	1412	1413	|O
(	1413	1414	|O
R	1414	1415	|O
)	1415	1416	|O
-	1416	1417	|O
FIPCT	1417	1422	|O
and	1423	1426	|O
[	1427	1428	|O
(	1428	1429	|O
18	1429	1431	|O
)	1431	1432	|O
F	1432	1433	|O
]	1433	1434	|O
(	1434	1435	|O
S	1435	1436	|O
)	1436	1437	|O
-	1437	1438	|O
FIPCT	1438	1443	|O
uptake	1444	1450	|O
in	1451	1453	|O
the	1454	1457	|O
caudate	1458	1465	|O
and	1466	1469	|O
putamen	1470	1477	|O
which	1478	1483	|O
resulted	1484	1492	|O
in	1493	1495	|O
caudate	1496	1503	|O
-	1503	1504	|O
to	1504	1506	|O
-	1506	1507	|O
cerebellum	1507	1517	|O
and	1518	1521	|O
putamen	1522	1529	|O
-	1529	1530	|O
to	1530	1532	|O
-	1532	1533	|O
cerebellum	1533	1543	|O
ratios	1544	1550	|O
of	1551	1553	|O
2.5-3.5	1554	1561	|O
at	1562	1564	|O
115	1565	1568	|O
min	1569	1572	|O
.	1572	1573	|O
[	1574	1575	|O
(	1575	1576	|O
18	1576	1578	|O
)	1578	1579	|O
F	1579	1580	|O
]	1580	1581	|O
(	1581	1582	|O
R	1582	1583	|O
)	1583	1584	|O
-	1584	1585	|O
FIPCT	1585	1590	|O
uptake	1591	1597	|O
in	1598	1600	|O
the	1601	1604	|O
caudate	1605	1612	|O
/	1612	1613	|O
putamen	1613	1620	|O
achieved	1621	1629	|O
transient	1630	1639	|O
equilibrium	1640	1651	|O
at	1652	1654	|O
75	1655	1657	|O
min	1658	1661	|O
.	1661	1662	|O
In	1663	1665	|O
an	1666	1668	|O
imaging	1669	1676	|O
experiment	1677	1687	|O
with	1688	1692	|O
[	1693	1694	|O
(	1694	1695	|O
18	1695	1697	|O
)	1697	1698	|O
F	1698	1699	|O
]	1699	1700	|O
(	1700	1701	|O
S	1701	1702	|O
)	1702	1703	|O
-	1703	1704	|O
FIPCT	1704	1709	|O
in	1710	1712	|O
a	1713	1714	|O
rhesus	1715	1721	|O
monkey	1722	1728	|O
with	1729	1733	|O
its	1734	1737	|O
left	1738	1742	|O
hemisphere	1743	1753	|O
lesioned	1754	1762	|O
with	1763	1767	|O
MPTP	1768	1772	|O
,	1772	1773	|O
radioactivity	1774	1787	|O
was	1788	1791	|O
reduced	1792	1799	|O
to	1800	1802	|O
background	1803	1813	|O
in	1814	1816	|O
the	1817	1820	|O
caudate	1821	1828	|O
and	1829	1832	|O
putamen	1833	1840	|O
of	1841	1843	|O
the	1844	1847	|O
lesioned	1848	1856	|O
hemisphere	1857	1867	|O
.	1867	1868	|O
The	1869	1872	|O
high	1873	1877	|O
specific	1878	1886	|O
activity	1887	1895	|O
one	1896	1899	|O
-	1899	1900	|O
step	1900	1904	|O
radiolabeling	1905	1918	|O
preparation	1919	1930	|O
and	1931	1934	|O
high	1935	1939	|O
specificity	1940	1951	|O
and	1952	1955	|O
selectivity	1956	1967	|O
of	1968	1970	|O
[	1971	1972	|O
(	1972	1973	|O
18	1973	1975	|O
)	1975	1976	|O
F	1976	1977	|O
]	1977	1978	|O
(	1978	1979	|O
R	1979	1980	|O
)	1980	1981	|O
-	1981	1982	|O
FIPCT	1982	1987	|O
and	1988	1991	|O
[	1992	1993	|O
(	1993	1994	|O
18	1994	1996	|O
)	1996	1997	|O
F	1997	1998	|O
]	1998	1999	|O
(	1999	2000	|O
S	2000	2001	|O
)	2001	2002	|O
-	2002	2003	|O
FIPCT	2003	2008	|O
for	2009	2012	|O
DAT	2013	2016	|O
indicate	2017	2025	|O
[	2026	2027	|O
(	2027	2028	|O
18	2028	2030	|O
)	2030	2031	|O
F	2031	2032	|O
]	2032	2033	|O
(	2033	2034	|O
R	2034	2035	|O
)	2035	2036	|O
-	2036	2037	|O
FIPCT	2037	2042	|O
and	2043	2046	|O
[	2047	2048	|O
(	2048	2049	|O
18	2049	2051	|O
)	2051	2052	|O
F	2052	2053	|O
]	2053	2054	|O
(	2054	2055	|O
S	2055	2056	|O
)	2056	2057	|O
-	2057	2058	|O
FIPCT	2058	2063	|O
are	2064	2067	|O
potential	2068	2077	|O
radioligands	2078	2090	|O
for	2091	2094	|O
mapping	2095	2102	|O
brain	2103	2108	|O
DAT	2109	2112	|O
in	2113	2115	|O
humans	2116	2122	|O
using	2123	2128	|O
PET	2129	2132	|O
.	2132	2133	|O

### abstracts4821.txt
Steric	0	6	|O
and	7	10	|O
electrostatic	11	24	|O
requirements	25	37	|O
at	38	40	|O
position	41	49	|O
6	50	51	|O
of	52	54	|O
[	55	56	|O
Nle	56	59	|O
(	59	60	|O
10	60	62	|O
)	62	63	|O
]	63	64	|O
NKA	64	67	|O
(	67	68	|O
4-10	68	72	|O
)	72	73	|O
,	73	74	|O
a	75	76	|O
full	77	81	|O
agonist	82	89	|O
of	90	92	|O
NK	93	95	|O
-	95	96	|O
2	96	97	|O
receptors	98	107	|O
,	107	108	|O
for	109	112	|O
molecular	113	122	|O
recognition	123	134	|O
by	135	137	|O
the	138	141	|O
receptor	142	150	|O
were	151	155	|O
studied	156	163	|O
.	163	164	|O
Two	165	168	|O
series	169	175	|O
of	176	178	|O
peptide	179	186	|O
analogues	187	196	|O
,	196	197	|O
(	198	199	|O
a	199	200	|O
)	200	201	|O
p	202	203	|O
-	203	204	|O
substituted	204	215	|O
analogues	216	225	|O
,	225	226	|O
[	227	228	|O
p	228	229	|O
-	229	230	|O
X	230	231	|O
-	231	232	|O
Phe	232	235	|O
(	235	236	|O
6	236	237	|O
)	237	238	|O
,	238	239	|O
Nle	240	243	|O
(	243	244	|O
10	244	246	|O
)	246	247	|O
]	247	248	|O
NKA	248	251	|O
(	251	252	|O
4-10	252	256	|O
)	256	257	|O
,	257	258	|O
where	259	264	|O
X	265	266	|O
=	267	268	|O
F	269	270	|O
,	270	271	|O
Cl	272	274	|O
,	274	275	|O
Br	276	278	|O
,	278	279	|O
I	280	281	|O
,	281	282	|O
NH	283	285	|O
(	285	286	|O
2	286	287	|O
)	287	288	|O
,	288	289	|O
NO	290	292	|O
(	292	293	|O
2	293	294	|O
)	294	295	|O
,	295	296	|O
and	297	300	|O
(	301	302	|O
b	302	303	|O
)	303	304	|O
[	305	306	|O
D	306	307	|O
-	307	308	|O
Phe	308	311	|O
(	311	312	|O
6	312	313	|O
)	313	314	|O
,	314	315	|O
Nle	315	318	|O
(	318	319	|O
10	319	321	|O
)	321	322	|O
]	322	323	|O
NKA	323	326	|O
(	326	327	|O
4-10	327	331	|O
)	331	332	|O
,	332	333	|O
[	334	335	|O
Trp	335	338	|O
(	338	339	|O
6	339	340	|O
)	340	341	|O
,	341	342	|O
Nle	342	345	|O
(	345	346	|O
10	346	348	|O
)	348	349	|O
]	349	350	|O
NKA	350	353	|O
(	353	354	|O
4-10	354	358	|O
)	358	359	|O
,	359	360	|O
and	361	364	|O
[	365	366	|O
Chex	366	370	|O
-	370	371	|O
Ala	371	374	|O
(	374	375	|O
6	375	376	|O
)	376	377	|O
,	377	378	|O
Nle	378	381	|O
(	381	382	|O
10	382	384	|O
)	384	385	|O
]	385	386	|O
NKA	386	389	|O
(	389	390	|O
4-10	390	394	|O
)	394	395	|O
,	395	396	|O
were	397	401	|O
synthesized	402	413	|O
,	413	414	|O
and	415	418	|O
their	419	424	|O
biological	425	435	|O
activity	436	444	|O
was	445	448	|O
examined	449	457	|O
.	457	458	|O
Competition	459	470	|O
binding	471	478	|O
experiments	479	490	|O
with	491	495	|O
[	496	497	|O
(	497	498	|O
3	498	499	|O
)	499	500	|O
H	500	501	|O
]	501	502	|O
NKA	502	505	|O
were	506	510	|O
performed	511	520	|O
using	521	526	|O
cloned	527	533	|O
human	534	539	|O
NK	540	542	|O
-	542	543	|O
2	543	544	|O
receptors	545	554	|O
expressed	555	564	|O
in	565	567	|O
CHO	568	571	|O
cells	572	577	|O
.	577	578	|O
Antagonistic	579	591	|O
and	592	595	|O
agonistic	596	605	|O
properties	606	616	|O
of	617	619	|O
the	620	623	|O
analogues	624	633	|O
were	634	638	|O
studied	639	646	|O
using	647	652	|O
an	653	655	|O
in	656	658	|O
vitro	659	664	|O
functional	665	675	|O
assay	676	681	|O
with	682	686	|O
hamster	687	694	|O
tracheal	695	703	|O
rings	704	709	|O
.	709	710	|O
The	711	714	|O
rank	715	719	|O
order	720	725	|O
of	726	728	|O
potency	729	736	|O
of	737	739	|O
agonists	740	748	|O
was	749	752	|O
[	753	754	|O
Nle	754	757	|O
(	757	758	|O
10	758	760	|O
)	760	761	|O
]	761	762	|O
NKA	762	765	|O
(	765	766	|O
4-10	766	770	|O
)	770	771	|O
approximately	772	785	|O
[	786	787	|O
p	787	788	|O
-	788	789	|O
F	789	790	|O
-	790	791	|O
Phe	791	794	|O
(	794	795	|O
6	795	796	|O
)	796	797	|O
,	797	798	|O
Nle	798	801	|O
(	801	802	|O
10	802	804	|O
)	804	805	|O
]	805	806	|O
NKA	806	809	|O
(	809	810	|O
4-10	810	814	|O
)	814	815	|O
&	816	817	|O
gt	817	819	|O
;	819	820	|O
[	821	822	|O
p	822	823	|O
-	823	824	|O
NH	824	826	|O
(	826	827	|O
2	827	828	|O
)	828	829	|O
-	829	830	|O
Phe	830	833	|O
(	833	834	|O
6	834	835	|O
)	835	836	|O
,	836	837	|O
Nle	837	840	|O
(	840	841	|O
10	841	843	|O
)	843	844	|O
]	844	845	|O
NKA	845	848	|O
(	848	849	|O
4-10	849	853	|O
)	853	854	|O
&	855	856	|O
gt	856	858	|O
;	858	859	|O
[	860	861	|O
p	861	862	|O
-	862	863	|O
Cl	863	865	|O
-	865	866	|O
Phe	866	869	|O
(	869	870	|O
6	870	871	|O
)	871	872	|O
,	872	873	|O
Nle	873	876	|O
(	876	877	|O
10	877	879	|O
)	879	880	|O
]	880	881	|O
NKA	881	884	|O
(	884	885	|O
4-10	885	889	|O
)	889	890	|O
&	891	892	|O
gt	892	894	|O
;	894	895	|O
[	896	897	|O
p	897	898	|O
-	898	899	|O
NO	899	901	|O
(	901	902	|O
2	902	903	|O
)	903	904	|O
-	904	905	|O
Phe	905	908	|O
(	908	909	|O
6	909	910	|O
)	910	911	|O
,	911	912	|O
Nle	912	915	|O
(	915	916	|O
10	916	918	|O
)	918	919	|O
]	919	920	|O
NKA	920	923	|O
(	923	924	|O
4-10	924	928	|O
)	928	929	|O
&	930	931	|O
gt	931	933	|O
;	933	934	|O
[	935	936	|O
Trp	936	939	|O
(	939	940	|O
6	940	941	|O
)	941	942	|O
,	942	943	|O
Nle	943	946	|O
(	946	947	|O
10	947	949	|O
)	949	950	|O
]	950	951	|O
NKA	951	954	|O
(	954	955	|O
4-10	955	959	|O
)	959	960	|O
.	960	961	|O
Size	962	966	|O
and	967	970	|O
planarity	971	980	|O
of	981	983	|O
the	984	987	|O
aromatic	988	996	|O
side	997	1001	|O
chain	1002	1007	|O
were	1008	1012	|O
crucially	1013	1022	|O
important	1023	1032	|O
for	1033	1036	|O
the	1037	1040	|O
biological	1041	1051	|O
activity	1052	1060	|O
,	1060	1061	|O
whereas	1062	1069	|O
electron	1070	1078	|O
-	1078	1079	|O
donating	1079	1087	|O
and	1088	1091	|O
electron	1092	1100	|O
-	1100	1101	|O
withdrawing	1101	1112	|O
properties	1113	1123	|O
of	1124	1126	|O
the	1127	1130	|O
para	1131	1135	|O
-	1135	1136	|O
substituent	1136	1147	|O
were	1148	1152	|O
less	1153	1157	|O
important	1158	1167	|O
.	1167	1168	|O
The	1169	1172	|O
results	1173	1180	|O
favor	1181	1186	|O
the	1187	1190	|O
hypothesis	1191	1201	|O
that	1202	1206	|O
weakly	1207	1213	|O
polar	1214	1219	|O
pi	1220	1222	|O
-	1222	1223	|O
pi	1223	1225	|O
interactions	1226	1238	|O
exist	1239	1244	|O
between	1245	1252	|O
the	1253	1256	|O
aromatic	1257	1265	|O
group	1266	1271	|O
and	1272	1275	|O
the	1276	1279	|O
receptor	1280	1288	|O
.	1288	1289	|O

### abstracts3383.txt
We	0	2	|O
have	3	7	|O
previously	8	18	|O
described	19	28	|O
(	29	30	|B-IUPAC
RS	30	32	|I-IUPAC
)	32	33	|I-IUPAC
-	33	34	|I-IUPAC
2	34	35	|I-IUPAC
-	35	36	|I-IUPAC
amino	36	41	|I-IUPAC
-	41	42	|I-IUPAC
3	42	43	|I-IUPAC
-	43	44	|I-IUPAC
(	44	45	|I-IUPAC
3	45	46	|I-IUPAC
-	46	47	|I-IUPAC
hydroxy	47	54	|I-IUPAC
-	54	55	|I-IUPAC
7,8	55	58	|I-IUPAC
-	58	59	|I-IUPAC
dihydro	59	66	|I-IUPAC
-	66	67	|I-IUPAC
6H	67	69	|I-IUPAC
-	69	70	|I-IUPAC
cyclohepta	70	80	|I-IUPAC
[	80	81	|I-IUPAC
d	81	82	|I-IUPAC
]	82	83	|I-IUPAC
isoxazol	83	91	|I-IUPAC
-	91	92	|I-IUPAC
4	92	93	|I-IUPAC
-	93	94	|I-IUPAC
yl	94	96	|I-IUPAC
)	96	97	|I-IUPAC
propionic	97	106	|I-IUPAC
acid	107	111	|I-IUPAC
(	112	113	|O
4	113	114	|O
-	114	115	|O
AHCP	115	119	|O
)	119	120	|O
as	121	123	|O
a	124	125	|O
highly	126	132	|O
effective	133	142	|O
agonist	143	150	|O
at	151	153	|O
non	154	157	|B-IUPAC
-	157	158	|I-IUPAC
N	158	159	|I-IUPAC
-	159	160	|I-IUPAC
methyl	160	166	|I-IUPAC
-	166	167	|I-IUPAC
d	167	168	|I-IUPAC
-	168	169	|I-IUPAC
aspartate	169	178	|I-IUPAC
(	179	180	|O
non	180	183	|O
-	183	184	|O
NMDA	184	188	|O
)	188	189	|O
glutamate	190	199	|O
(	200	201	|O
Glu	201	204	|O
)	204	205	|O
receptors	206	215	|O
in	216	218	|O
vivo	219	223	|O
,	223	224	|O
which	225	230	|O
is	231	233	|O
more	234	238	|O
potent	239	245	|O
than	246	250	|O
(	251	252	|B-IUPAC
RS	252	254	|I-IUPAC
)	254	255	|I-IUPAC
-	255	256	|I-IUPAC
2	256	257	|I-IUPAC
-	257	258	|I-IUPAC
amino	258	263	|I-IUPAC
-	263	264	|I-IUPAC
3	264	265	|I-IUPAC
-	265	266	|I-IUPAC
(	266	267	|I-IUPAC
3	267	268	|I-IUPAC
-	268	269	|I-IUPAC
hydroxy	269	276	|I-IUPAC
-	276	277	|I-IUPAC
5	277	278	|I-IUPAC
-	278	279	|I-IUPAC
methylisoxazol	279	293	|I-IUPAC
-	293	294	|I-IUPAC
4	294	295	|I-IUPAC
-	295	296	|I-IUPAC
yl	296	298	|I-IUPAC
)	298	299	|I-IUPAC
propionic	299	308	|I-IUPAC
acid	309	313	|I-IUPAC
(	314	315	|O
AMPA	315	319	|O
)	319	320	|O
but	321	324	|O
inactive	325	333	|O
at	334	336	|O
NMDA	337	341	|O
receptors	342	351	|O
.	351	352	|O
However	353	360	|O
,	360	361	|O
4	362	363	|O
-	363	364	|O
AHCP	364	368	|O
was	369	372	|O
found	373	378	|O
to	379	381	|O
be	382	384	|O
much	385	389	|O
weaker	390	396	|O
than	397	401	|O
AMPA	402	406	|O
as	407	409	|O
an	410	412	|O
inhibitor	413	422	|O
of	423	425	|O
[	426	427	|O
(	427	428	|O
3	428	429	|O
)	429	430	|O
H	430	431	|O
]	431	432	|O
AMPA	432	436	|O
binding	437	444	|O
and	445	448	|O
to	449	451	|O
have	452	456	|O
limited	457	464	|O
effect	465	471	|O
in	472	474	|O
a	475	476	|O
[	477	478	|O
(	478	479	|O
3	479	480	|O
)	480	481	|O
H	481	482	|O
]	482	483	|O
kainic	483	489	|O
acid	490	494	|O
binding	495	502	|O
assay	503	508	|O
using	509	514	|O
rat	515	518	|O
cortical	519	527	|O
membranes	528	537	|O
.	537	538	|O
To	539	541	|O
shed	542	546	|O
light	547	552	|O
on	553	555	|O
the	556	559	|O
mechanism	560	569	|O
(	569	570	|O
s	570	571	|O
)	571	572	|O
underlying	573	583	|O
this	584	588	|O
quite	589	594	|O
enigmatic	595	604	|O
pharmacological	605	620	|O
profile	621	628	|O
of	629	631	|O
4	632	633	|O
-	633	634	|O
AHCP	634	638	|O
,	638	639	|O
we	640	642	|O
have	643	647	|O
now	648	651	|O
developed	652	661	|O
a	662	663	|O
synthesis	664	673	|O
of	674	676	|O
(	677	678	|O
S	678	679	|O
)	679	680	|O
-	680	681	|O
4	681	682	|O
-	682	683	|O
AHCP	683	687	|O
(	688	689	|O
6	689	690	|O
)	690	691	|O
and	692	695	|O
(	696	697	|O
R	697	698	|O
)	698	699	|O
-	699	700	|O
4	700	701	|O
-	701	702	|O
AHCP	702	706	|O
(	707	708	|O
7	708	709	|O
)	709	710	|O
.	710	711	|O
At	712	714	|O
cloned	715	721	|O
metabotropic	722	734	|O
Glu	735	738	|O
receptors	739	748	|O
mGluR1alpha	749	760	|O
(	761	762	|O
group	762	767	|O
I	768	769	|O
)	769	770	|O
,	770	771	|O
mGluR2	772	778	|O
(	779	780	|O
group	780	785	|O
II	786	788	|O
)	788	789	|O
,	789	790	|O
and	791	794	|O
mGluR4a	795	802	|O
(	803	804	|O
group	804	809	|O
III	810	813	|O
)	813	814	|O
,	814	815	|O
neither	816	823	|O
6	824	825	|O
nor	826	829	|O
7	830	831	|O
showed	832	838	|O
significant	839	850	|O
agonist	851	858	|O
or	859	861	|O
antagonist	862	872	|O
effects	873	880	|O
.	880	881	|O
The	882	885	|O
stereoisomer	886	898	|O
6	899	900	|O
,	900	901	|O
but	902	905	|O
not	906	909	|O
7	910	911	|O
,	911	912	|O
activated	913	922	|O
cloned	923	929	|O
AMPA	930	934	|O
receptor	935	943	|O
subunits	944	952	|O
GluR1o	953	959	|O
,	959	960	|O
GluR3o	961	967	|O
,	967	968	|O
and	969	972	|O
GluR4o	973	979	|O
with	980	984	|O
EC	985	987	|O
(	987	988	|O
50	988	990	|O
)	990	991	|O
values	992	998	|O
in	999	1001	|O
the	1002	1005	|O
range	1006	1011	|O
4.5-15	1012	1018	|O
microM	1019	1025	|O
and	1026	1029	|O
the	1030	1033	|O
coexpressed	1034	1045	|O
kainate	1046	1053	|O
-	1053	1054	|O
preferring	1054	1064	|O
subunits	1065	1073	|O
GluR6	1074	1079	|O
+	1080	1081	|O
KA2	1082	1085	|O
(	1086	1087	|O
EC	1087	1089	|O
(	1089	1090	|O
50	1090	1092	|O
)	1092	1093	|O
=	1094	1095	|O
6.4	1096	1099	|O
microM	1100	1106	|O
)	1106	1107	|O
.	1107	1108	|O
Compound	1109	1117	|O
6	1118	1119	|O
,	1119	1120	|O
but	1121	1124	|O
not	1125	1128	|O
7	1129	1130	|O
,	1130	1131	|O
proved	1132	1138	|O
to	1139	1141	|O
be	1142	1144	|O
a	1145	1146	|O
very	1147	1151	|O
potent	1152	1158	|O
agonist	1159	1166	|O
(	1167	1168	|O
EC	1168	1170	|O
(	1170	1171	|O
50	1171	1173	|O
)	1173	1174	|O
=	1175	1176	|O
0.13	1177	1181	|O
microM	1182	1188	|O
)	1188	1189	|O
at	1190	1192	|O
the	1193	1196	|O
kainate	1197	1204	|O
-	1204	1205	|O
preferring	1205	1215	|O
GluR5	1216	1221	|O
subunit	1222	1229	|O
,	1229	1230	|O
equipotent	1231	1241	|O
with	1242	1246	|O
(	1247	1248	|B-IUPAC
S	1248	1249	|I-IUPAC
)	1249	1250	|I-IUPAC
-	1250	1251	|I-IUPAC
2	1251	1252	|I-IUPAC
-	1252	1253	|I-IUPAC
amino	1253	1258	|I-IUPAC
-	1258	1259	|I-IUPAC
3	1259	1260	|I-IUPAC
-	1260	1261	|I-IUPAC
(	1261	1262	|I-IUPAC
5	1262	1263	|I-IUPAC
-	1263	1264	|I-IUPAC
tert	1264	1268	|I-IUPAC
-	1268	1269	|I-IUPAC
butyl	1269	1274	|I-IUPAC
-	1274	1275	|I-IUPAC
3	1275	1276	|I-IUPAC
-	1276	1277	|I-IUPAC
hydroxyisothiazol	1277	1294	|I-IUPAC
-	1294	1295	|I-IUPAC
4	1295	1296	|I-IUPAC
-	1296	1297	|I-IUPAC
yl	1297	1299	|I-IUPAC
)	1299	1300	|I-IUPAC
propionic	1300	1309	|I-IUPAC
acid	1310	1314	|I-IUPAC
[	1315	1316	|O
(	1316	1317	|O
S	1317	1318	|O
)	1318	1319	|O
-	1319	1320	|O
Thio	1320	1324	|O
-	1324	1325	|O
ATPA	1325	1329	|O
,	1329	1330	|O
4	1331	1332	|O
]	1332	1333	|O
and	1334	1337	|O
almost	1338	1344	|O
4	1345	1346	|O
times	1347	1352	|O
more	1353	1357	|O
potent	1358	1364	|O
than	1365	1369	|O
(	1370	1371	|B-IUPAC
S	1371	1372	|I-IUPAC
)	1372	1373	|I-IUPAC
-	1373	1374	|I-IUPAC
2	1374	1375	|I-IUPAC
-	1375	1376	|I-IUPAC
amino	1376	1381	|I-IUPAC
-	1381	1382	|I-IUPAC
3	1382	1383	|I-IUPAC
-	1383	1384	|I-IUPAC
(	1384	1385	|I-IUPAC
5	1385	1386	|I-IUPAC
-	1386	1387	|I-IUPAC
tert	1387	1391	|I-IUPAC
-	1391	1392	|I-IUPAC
butyl	1392	1397	|I-IUPAC
-	1397	1398	|I-IUPAC
3	1398	1399	|I-IUPAC
-	1399	1400	|I-IUPAC
hydroxyisoxazol	1400	1415	|I-IUPAC
-	1415	1416	|I-IUPAC
4	1416	1417	|I-IUPAC
-	1417	1418	|I-IUPAC
yl	1418	1420	|I-IUPAC
)	1420	1421	|I-IUPAC
propionic	1421	1430	|I-IUPAC
acid	1431	1435	|I-IUPAC
[	1436	1437	|O
(	1437	1438	|O
S	1438	1439	|O
)	1439	1440	|O
-	1440	1441	|O
ATPA	1441	1445	|O
,	1445	1446	|O
3	1447	1448	|O
]	1448	1449	|O
.	1449	1450	|O
Compound	1451	1459	|O
6	1460	1461	|O
thus	1462	1466	|O
represents	1467	1477	|O
a	1478	1479	|O
new	1480	1483	|O
structural	1484	1494	|O
class	1495	1500	|O
of	1501	1503	|O
GluR5	1504	1509	|O
agonists	1510	1518	|O
.	1518	1519	|O
Molecular	1520	1529	|O
modeling	1530	1538	|O
and	1539	1542	|O
docking	1543	1550	|O
to	1551	1553	|O
a	1554	1555	|O
crystal	1556	1563	|O
structure	1564	1573	|O
of	1574	1576	|O
the	1577	1580	|O
extracellular	1581	1594	|O
binding	1595	1602	|O
domain	1603	1609	|O
of	1610	1612	|O
the	1613	1616	|O
AMPA	1617	1621	|O
subunit	1622	1629	|O
GluR2	1630	1635	|O
has	1636	1639	|O
enabled	1640	1647	|O
identification	1648	1662	|O
of	1663	1665	|O
the	1666	1669	|O
probable	1670	1678	|O
active	1679	1685	|O
conformation	1686	1698	|O
and	1699	1702	|O
binding	1703	1710	|O
mode	1711	1715	|O
of	1716	1718	|O
6	1719	1720	|O
.	1720	1721	|O
We	1722	1724	|O
are	1725	1728	|O
able	1729	1733	|O
to	1734	1736	|O
rationalize	1737	1748	|O
the	1749	1752	|O
observed	1753	1761	|O
selectivities	1762	1775	|O
by	1776	1778	|O
comparing	1779	1788	|O
the	1789	1792	|O
docking	1793	1800	|O
of	1801	1803	|O
4	1804	1805	|O
and	1806	1809	|O
6	1810	1811	|O
to	1812	1814	|O
subtype	1815	1822	|O
constructs	1823	1833	|O
,	1833	1834	|O
i.e.	1835	1839	|O
,	1839	1840	|O
a	1841	1842	|O
crystal	1843	1850	|O
structure	1851	1860	|O
of	1861	1863	|O
the	1864	1867	|O
extracellular	1868	1881	|O
binding	1882	1889	|O
domain	1890	1896	|O
of	1897	1899	|O
GluR2	1900	1905	|O
and	1906	1909	|O
a	1910	1911	|O
homology	1912	1920	|O
model	1921	1926	|O
of	1927	1929	|O
GluR5	1930	1935	|O
.	1935	1936	|O

### abstracts4121.txt
N	0	1	|O
-	1	2	|O
Methylacetazolamide	2	21	|O
was	22	25	|O
shown	26	31	|O
to	32	34	|O
be	35	37	|O
active	38	44	|O
topically	45	54	|O
in	55	57	|O
reducing	58	66	|O
intraocular	67	78	|O
pressure	79	87	|O
(	88	89	|O
IOP	89	92	|O
)	92	93	|O
to	94	96	|O
a	97	98	|O
small	99	104	|O
but	105	108	|O
statistically	109	122	|O
significant	123	134	|O
level	135	140	|O
in	141	143	|O
the	144	147	|O
normotensive	148	160	|O
rabbit	161	167	|O
eye	168	171	|O
.	171	172	|O
In	173	175	|O
vivo	176	180	|O
experiments	181	192	|O
with	193	197	|O
N	198	199	|B-IUPAC
-	199	200	|I-IUPAC
methylacetazolamide	200	219	|I-IUPAC
suggest	220	227	|O
that	228	232	|O
ocular	233	239	|O
metabolism	240	250	|O
to	251	253	|O
acetazolamide	254	267	|O
was	268	271	|O
responsible	272	283	|O
for	284	287	|O
the	288	291	|O
observed	292	300	|O
topical	301	308	|O
activity	309	317	|O
.	317	318	|O
Examination	319	330	|O
of	331	333	|O
initial	334	341	|O
rate	342	346	|O
kinetics	347	355	|O
of	356	358	|O
carbonic	359	367	|O
anhydrase	368	377	|O
catalyzed	378	387	|O
p	388	389	|B-IUPAC
-	389	390	|I-IUPAC
nitrophenyl	390	401	|I-IUPAC
acetate	402	409	|I-IUPAC
hydrolysis	410	420	|O
showed	421	427	|O
that	428	432	|O
N	433	434	|B-IUPAC
-	434	435	|I-IUPAC
methylacetazolamide	435	454	|I-IUPAC
was	455	458	|O
a	459	460	|O
competitive	461	472	|O
inhibitor	473	482	|O
,	482	483	|O
in	484	486	|O
contrast	487	495	|O
to	496	498	|O
noncompetitive	499	513	|O
inhibition	514	524	|O
seen	525	529	|O
with	530	534	|O
acetazolamide	535	548	|O
and	549	552	|O
other	553	558	|O
primary	559	566	|O
sulfonamide	567	578	|O
inhibitors	579	589	|O
.	589	590	|O
N	591	592	|B-MODIFIER
-	592	593	|I-MODIFIER
Substituted	593	604	|I-MODIFIER
and	605	608	|O
unsubstituted	609	622	|B-MODIFIER
4	623	624	|B-PARTIUPAC
-	624	625	|I-PARTIUPAC
chlorobenzene	625	638	|I-PARTIUPAC
-	638	639	|I-PARTIUPAC
and	640	643	|O
4	644	645	|B-IUPAC
-	645	646	|I-IUPAC
nitrobenzenesulfonamides	646	670	|I-IUPAC
were	671	675	|O
also	676	680	|O
synthesized	681	692	|O
,	692	693	|O
and	694	697	|O
their	698	703	|O
biochemical	704	715	|O
characteristics	716	731	|O
and	732	735	|O
in	736	738	|O
vivo	739	743	|O
ability	744	751	|O
to	752	754	|O
lower	755	760	|O
IOP	761	764	|O
when	765	769	|O
applied	770	777	|O
topically	778	787	|O
were	788	792	|O
determined	793	803	|O
.	803	804	|O
The	805	808	|O
primary	809	816	|O
sulfonamides	817	829	|O
were	830	834	|O
reversible	835	845	|O
noncompetitive	846	860	|O
inhibitors	861	871	|O
of	872	874	|O
carbonic	875	883	|O
anhydrase	884	893	|O
,	893	894	|O
with	895	899	|O
no	900	902	|O
effect	903	909	|O
on	910	912	|O
IOP	913	916	|O
after	917	922	|O
topical	923	930	|O
administration	931	945	|O
.	945	946	|O
4	947	948	|B-PARTIUPAC
-	948	949	|I-PARTIUPAC
Nitrobenzene	949	961	|I-PARTIUPAC
-	961	962	|I-PARTIUPAC
and	963	966	|O
4	967	968	|B-IUPAC
-	968	969	|I-IUPAC
chlorobenzenesulfonamides	969	994	|I-IUPAC
containing	995	1005	|O
both	1006	1010	|O
N	1011	1012	|B-IUPAC
-	1012	1013	|I-IUPAC
hydroxy	1013	1020	|I-IUPAC
and	1021	1024	|O
N	1025	1026	|B-IUPAC
-	1026	1027	|I-IUPAC
methyl	1027	1033	|I-IUPAC
substituents	1034	1046	|B-MODIFIER
were	1047	1051	|O
model	1052	1057	|O
irreversible	1058	1070	|O
inhibitors	1071	1081	|O
of	1082	1084	|O
carbonic	1085	1093	|O
anhydrase	1094	1103	|O
and	1104	1107	|O
exhibited	1108	1117	|O
a	1118	1119	|O
trend	1120	1125	|O
toward	1126	1132	|O
topical	1133	1140	|O
activity	1141	1149	|O
in	1150	1152	|O
reducing	1153	1161	|O
IOP	1162	1165	|O
in	1166	1168	|O
normotensive	1169	1181	|O
rabbit	1182	1188	|O
eyes	1189	1193	|O
.	1193	1194	|O
Therefore	1195	1204	|O
,	1204	1205	|O
this	1206	1210	|O
paper	1211	1216	|O
describes	1217	1226	|O
the	1227	1230	|O
synthesis	1231	1240	|O
and	1241	1244	|O
characterization	1245	1261	|O
of	1262	1264	|O
two	1265	1268	|O
types	1269	1274	|O
of	1275	1277	|O
carbonic	1278	1286	|O
anhydrase	1287	1296	|O
inhibitors	1297	1307	|O
;	1307	1308	|O
the	1309	1312	|O
N	1313	1314	|B-IUPAC
-	1314	1315	|I-IUPAC
methyl	1315	1321	|I-IUPAC
-	1321	1322	|O
substituted	1322	1333	|B-MODIFIER
sulfonamides	1334	1346	|B-IUPAC
are	1347	1350	|O
reversible	1351	1361	|O
competitive	1362	1373	|O
inhibitors	1374	1384	|O
of	1385	1387	|O
carbonic	1388	1396	|O
anhydrase	1397	1406	|O
,	1406	1407	|O
while	1408	1413	|O
the	1414	1417	|O
N	1418	1419	|B-IUPAC
-	1419	1420	|I-IUPAC
hydroxy	1420	1427	|I-IUPAC
-	1427	1428	|I-IUPAC
N	1428	1429	|I-IUPAC
-	1429	1430	|I-IUPAC
methyl	1430	1436	|I-IUPAC
-	1436	1437	|O
substituted	1437	1448	|B-MODIFIER
sulfonamides	1449	1461	|B-IUPAC
are	1462	1465	|O
irreversible	1466	1478	|O
inhibitors	1479	1489	|O
.	1489	1490	|O

### abstracts3095.txt
The	0	3	|O
synthesis	4	13	|O
and	14	17	|O
pharmacological	18	33	|O
profile	34	41	|O
of	42	44	|O
a	45	46	|O
series	47	53	|O
of	54	56	|O
neuroprotective	57	72	|O
adenosine	73	82	|O
agonists	83	91	|O
are	92	95	|O
described	96	105	|O
.	105	106	|O
Novel	107	112	|O
A	113	114	|O
(	114	115	|O
1	115	116	|O
)	116	117	|O
agonists	118	126	|O
with	127	131	|O
potent	132	138	|O
central	139	146	|O
nervous	147	154	|O
system	155	161	|O
effects	162	169	|O
and	170	173	|O
diminished	174	184	|O
influence	185	194	|O
on	195	197	|O
the	198	201	|O
cardiovascular	202	216	|O
system	217	223	|O
are	224	227	|O
reported	228	236	|O
and	237	240	|O
compared	241	249	|O
to	250	252	|O
selected	253	261	|O
reference	262	271	|O
adenosine	272	281	|O
agonists	282	290	|O
.	290	291	|O
The	292	295	|O
novel	296	301	|O
compounds	302	311	|O
featured	312	320	|O
are	321	324	|O
derived	325	332	|O
structurally	333	345	|O
from	346	350	|O
two	351	354	|O
key	355	358	|O
lead	359	363	|O
structures	364	374	|O
:	374	375	|O
2	376	377	|B-IUPAC
-	377	378	|I-IUPAC
chloro	378	384	|I-IUPAC
-	384	385	|I-IUPAC
N	385	386	|I-IUPAC
-	386	387	|I-IUPAC
(	387	388	|I-IUPAC
1	388	389	|I-IUPAC
-	389	390	|I-IUPAC
phenoxy	390	397	|I-IUPAC
-	397	398	|I-IUPAC
2	398	399	|I-IUPAC
-	399	400	|I-IUPAC
propyl	400	406	|I-IUPAC
)	406	407	|I-IUPAC
adenosine	407	416	|I-IUPAC
(	417	418	|O
NNC	418	421	|O
21-0041	422	429	|O
,	429	430	|O
9	431	432	|O
)	432	433	|O
and	434	437	|O
2	438	439	|B-IUPAC
-	439	440	|I-IUPAC
chloro	440	446	|I-IUPAC
-	446	447	|I-IUPAC
N	447	448	|I-IUPAC
-	448	449	|I-IUPAC
(	449	450	|I-IUPAC
1	450	451	|I-IUPAC
-	451	452	|I-IUPAC
piperidinyl	452	463	|I-IUPAC
)	463	464	|I-IUPAC
adenosine	464	473	|I-IUPAC
(	474	475	|O
NNC	475	478	|O
90-1515	479	486	|O
,	486	487	|O
4	488	489	|O
)	489	490	|O
.	490	491	|O
The	492	495	|O
agonists	496	504	|O
are	505	508	|O
characterized	509	522	|O
in	523	525	|O
terms	526	531	|O
of	532	534	|O
their	535	540	|O
in	541	543	|O
vitro	544	549	|O
profiles	550	558	|O
,	558	559	|O
both	560	564	|O
binding	565	572	|O
and	573	576	|O
functional	577	587	|O
,	587	588	|O
and	589	592	|O
in	593	595	|O
vivo	596	600	|O
activity	601	609	|O
in	610	612	|O
relevant	613	621	|O
animal	622	628	|O
models	629	635	|O
.	635	636	|O
Neuroprotective	637	652	|O
properties	653	663	|O
assessed	664	672	|O
after	673	678	|O
postischemic	679	691	|O
dosing	692	698	|O
in	699	701	|O
a	702	703	|O
Mongolian	704	713	|O
gerbil	714	720	|O
severe	721	727	|O
temporary	728	737	|O
forebrain	738	747	|O
ischemia	748	756	|O
paradigm	757	765	|O
,	765	766	|O
using	767	772	|O
hippocampal	773	784	|O
CA1	785	788	|O
damage	789	795	|O
endpoints	796	805	|O
,	805	806	|O
and	807	810	|O
the	811	814	|O
efficacy	815	823	|O
of	824	826	|O
these	827	832	|O
agonists	833	841	|O
in	842	844	|O
an	845	847	|O
A	848	849	|O
(	849	850	|O
1	850	851	|O
)	851	852	|O
functional	853	863	|O
assay	864	869	|O
show	870	874	|O
similarities	875	887	|O
to	888	890	|O
some	891	895	|O
reference	896	905	|O
adenosine	906	915	|O
agonists	916	924	|O
.	924	925	|O
However	926	933	|O
,	933	934	|O
the	935	938	|O
new	939	942	|O
compounds	943	952	|O
we	953	955	|O
describe	956	964	|O
exhibit	965	972	|O
diminished	973	983	|O
cardiovascular	984	998	|O
effects	999	1006	|O
in	1007	1009	|O
both	1010	1014	|O
anesthetized	1015	1027	|O
and	1028	1031	|O
awake	1032	1037	|O
rats	1038	1042	|O
when	1043	1047	|O
compared	1048	1056	|O
to	1057	1059	|O
reference	1060	1069	|O
A	1070	1071	|O
(	1071	1072	|O
1	1072	1073	|O
)	1073	1074	|O
agonists	1075	1083	|O
such	1084	1088	|O
as	1089	1091	|O
(	1092	1093	|B-IUPAC
R	1093	1094	|I-IUPAC
)	1094	1095	|I-IUPAC
-	1095	1096	|I-IUPAC
phenylisopropyladenosine	1096	1120	|I-IUPAC
(	1121	1122	|O
R	1122	1123	|O
-	1123	1124	|O
PIA	1124	1127	|O
,	1127	1128	|O
5	1129	1130	|O
)	1130	1131	|O
,	1131	1132	|O
N	1133	1134	|B-IUPAC
-	1134	1135	|I-IUPAC
cyclopentyladenosine	1135	1155	|I-IUPAC
(	1156	1157	|O
CPA	1157	1160	|O
,	1160	1161	|O
2	1162	1163	|O
)	1163	1164	|O
,	1164	1165	|O
4	1166	1167	|O
,	1167	1168	|O
N	1169	1170	|B-IUPAC
-	1170	1171	|I-IUPAC
[	1171	1172	|I-IUPAC
(	1172	1173	|I-IUPAC
1S	1173	1175	|I-IUPAC
,	1175	1176	|I-IUPAC
trans	1176	1181	|I-IUPAC
)	1181	1182	|I-IUPAC
-	1182	1183	|I-IUPAC
2	1183	1184	|I-IUPAC
-	1184	1185	|I-IUPAC
hydroxycyclopentyl	1185	1203	|I-IUPAC
]	1203	1204	|I-IUPAC
adenosine	1204	1213	|I-IUPAC
(	1214	1215	|O
GR	1215	1217	|O
79236	1218	1223	|O
,	1223	1224	|O
26	1225	1227	|O
)	1227	1228	|O
,	1228	1229	|O
N	1230	1231	|B-IUPAC
-	1231	1232	|I-IUPAC
cyclohexyl	1232	1242	|I-IUPAC
-	1242	1243	|I-IUPAC
2'	1243	1245	|I-IUPAC
-	1245	1246	|I-IUPAC
O	1246	1247	|I-IUPAC
-	1247	1248	|I-IUPAC
methyladenosine	1248	1263	|I-IUPAC
(	1264	1265	|O
SDZ	1265	1268	|O
WAG	1269	1272	|O
994	1273	1276	|O
,	1276	1277	|O
27	1278	1280	|O
)	1280	1281	|O
,	1281	1282	|O
and	1283	1286	|O
N	1287	1288	|B-IUPAC
-	1288	1289	|I-IUPAC
[	1289	1290	|I-IUPAC
(	1290	1291	|I-IUPAC
2	1291	1292	|I-IUPAC
-	1292	1293	|I-IUPAC
methylphenyl	1293	1305	|I-IUPAC
)	1305	1306	|I-IUPAC
methyl	1306	1312	|I-IUPAC
]	1312	1313	|I-IUPAC
adenosine	1313	1322	|I-IUPAC
(	1323	1324	|O
Metrifudil	1324	1334	|O
,	1334	1335	|O
28	1336	1338	|O
)	1338	1339	|O
.	1339	1340	|O
In	1341	1343	|O
mouse	1344	1349	|O
permanent	1350	1359	|O
middle	1360	1366	|O
cerebral	1367	1375	|O
artery	1376	1382	|O
occlusion	1383	1392	|O
focal	1393	1398	|O
ischemia	1399	1407	|O
,	1407	1408	|O
2	1409	1410	|B-IUPAC
-	1410	1411	|I-IUPAC
chloro	1411	1417	|I-IUPAC
-	1417	1418	|I-IUPAC
N	1418	1419	|I-IUPAC
-	1419	1420	|I-IUPAC
[	1420	1421	|I-IUPAC
(	1421	1422	|I-IUPAC
R	1422	1423	|I-IUPAC
)	1423	1424	|I-IUPAC
-	1424	1425	|I-IUPAC
[	1425	1426	|I-IUPAC
(	1426	1427	|I-IUPAC
2	1427	1428	|I-IUPAC
-	1428	1429	|I-IUPAC
benzothiazolyl	1429	1443	|I-IUPAC
)	1443	1444	|I-IUPAC
thio	1444	1448	|I-IUPAC
]	1448	1449	|I-IUPAC
-	1449	1450	|I-IUPAC
2	1450	1451	|I-IUPAC
-	1451	1452	|I-IUPAC
propyl	1452	1458	|I-IUPAC
]	1458	1459	|I-IUPAC
adenosine	1459	1468	|I-IUPAC
(	1469	1470	|O
NNC	1470	1473	|O
21-0136	1474	1481	|O
,	1481	1482	|O
12	1483	1485	|O
)	1485	1486	|O
exhibited	1487	1496	|O
significant	1497	1508	|O
neuroprotection	1509	1524	|O
at	1525	1527	|O
the	1528	1531	|O
remarkably	1532	1542	|O
low	1543	1546	|O
total	1547	1552	|O
intraperitoneal	1553	1568	|O
dose	1569	1573	|O
of	1574	1576	|O
0.1	1577	1580	|O
mg	1581	1583	|O
/	1583	1584	|O
kg	1584	1586	|O
,	1586	1587	|O
a	1588	1589	|O
dose	1590	1594	|O
at	1595	1597	|O
which	1598	1603	|O
no	1604	1606	|O
cardiovascular	1607	1621	|O
effects	1622	1629	|O
are	1630	1633	|O
observed	1634	1642	|O
in	1643	1645	|O
conscious	1646	1655	|O
rats	1656	1660	|O
.	1660	1661	|O
The	1662	1665	|O
novel	1666	1671	|O
agonists	1672	1680	|O
described	1681	1690	|O
inhibit	1691	1698	|O
6	1699	1700	|B-IUPAC
,	1700	1701	|I-IUPAC
7	1702	1703	|I-IUPAC
-	1703	1704	|I-IUPAC
dimethoxy	1704	1713	|I-IUPAC
-	1713	1714	|I-IUPAC
4	1714	1715	|I-IUPAC
-	1715	1716	|I-IUPAC
ethyl	1716	1721	|I-IUPAC
-	1721	1722	|I-IUPAC
beta	1722	1726	|I-IUPAC
-	1726	1727	|I-IUPAC
carboline	1727	1736	|I-IUPAC
-	1736	1737	|I-IUPAC
3	1737	1738	|I-IUPAC
-	1738	1739	|I-IUPAC
carboxylate	1739	1750	|I-IUPAC
-	1750	1751	|O
induced	1751	1758	|B-MODIFIER
seizures	1759	1767	|I-MODIFIER
,	1767	1768	|O
and	1769	1772	|O
in	1773	1775	|O
mouse	1776	1781	|O
locomotor	1782	1791	|O
activity	1792	1800	|O
higher	1801	1807	|O
doses	1808	1813	|O
are	1814	1817	|O
required	1818	1826	|O
to	1827	1829	|O
reach	1830	1835	|O
ED	1836	1838	|O
(	1838	1839	|O
50	1839	1841	|O
)	1841	1842	|O
values	1843	1849	|O
than	1850	1854	|O
for	1855	1858	|O
reference	1859	1868	|O
A	1869	1870	|O
(	1870	1871	|O
1	1871	1872	|O
)	1872	1873	|O
agonists	1874	1882	|O
.	1882	1883	|O
We	1884	1886	|O
conclude	1887	1895	|O
that	1896	1900	|O
two	1901	1904	|O
of	1905	1907	|O
the	1908	1911	|O
novel	1912	1917	|O
adenosine	1918	1927	|O
derivatives	1928	1939	|O
revealed	1940	1948	|O
herein	1949	1955	|O
,	1955	1956	|O
12	1957	1959	|B-PARTIUPAC
and	1960	1963	|O
5'	1964	1966	|B-IUPAC
-	1966	1967	|I-IUPAC
deoxy	1967	1972	|I-IUPAC
-	1972	1973	|I-IUPAC
5'	1973	1975	|I-IUPAC
-	1975	1976	|I-IUPAC
chloro	1976	1982	|I-IUPAC
-	1982	1983	|I-IUPAC
N	1983	1984	|I-IUPAC
-	1984	1985	|I-IUPAC
[	1985	1986	|I-IUPAC
4	1986	1987	|I-IUPAC
-	1987	1988	|I-IUPAC
(	1988	1989	|I-IUPAC
phenylthio	1989	1999	|I-IUPAC
)	1999	2000	|I-IUPAC
-	2000	2001	|I-IUPAC
1	2001	2002	|I-IUPAC
-	2002	2003	|I-IUPAC
piperidinyl	2003	2014	|I-IUPAC
]	2014	2015	|I-IUPAC
adenosine	2015	2024	|I-IUPAC
(	2025	2026	|O
NNC	2026	2029	|O
21-0147	2030	2037	|O
,	2037	2038	|O
13	2039	2041	|O
)	2041	2042	|O
,	2042	2043	|O
representatives	2044	2059	|O
of	2060	2062	|O
a	2063	2064	|O
new	2065	2068	|O
series	2069	2075	|O
of	2076	2078	|O
P	2079	2080	|O
(	2080	2081	|O
1	2081	2082	|O
)	2082	2083	|O
ligands	2084	2091	|O
,	2091	2092	|O
reinforce	2093	2102	|O
the	2103	2106	|O
fact	2107	2111	|O
that	2112	2116	|O
novel	2117	2122	|O
selective	2123	2132	|O
adenosine	2133	2142	|O
A	2143	2144	|O
(	2144	2145	|O
1	2145	2146	|O
)	2146	2147	|O
agonists	2148	2156	|O
have	2157	2161	|O
potential	2162	2171	|O
in	2172	2174	|O
the	2175	2178	|O
treatment	2179	2188	|O
of	2189	2191	|O
cerebral	2192	2200	|O
ischemia	2201	2209	|O
in	2210	2212	|O
humans	2213	2219	|O
.	2219	2220	|O

### abstracts1775.txt
Conversion	0	10	|O
of	11	13	|O
the	14	17	|O
8	18	19	|B-IUPAC
-	19	20	|I-IUPAC
phenolic	20	28	|I-IUPAC
1,2,3,4,5,6	29	40	|I-IUPAC
-	40	41	|I-IUPAC
hexahydro	41	50	|I-IUPAC
-	50	51	|I-IUPAC
2,6	51	54	|I-IUPAC
-	54	55	|I-IUPAC
methano	55	62	|I-IUPAC
-	62	63	|I-IUPAC
3	63	64	|I-IUPAC
-	64	65	|I-IUPAC
benzazocines	65	77	|I-IUPAC
to	78	80	|O
the	81	84	|O
corresponding	85	98	|O
8	99	100	|B-IUPAC
-	100	101	|I-IUPAC
thiophenolic	101	113	|I-IUPAC
analogues	114	123	|B-MODIFIER
was	124	127	|O
achieved	128	136	|O
by	137	139	|O
three	140	145	|O
different	146	155	|O
routes	156	162	|O
.	162	163	|O
Diazotization	164	177	|O
of	178	180	|O
8	181	182	|B-IUPAC
-	182	183	|I-IUPAC
amino	183	188	|I-IUPAC
-	188	189	|I-IUPAC
2,6	189	192	|I-IUPAC
-	192	193	|I-IUPAC
methano	193	200	|I-IUPAC
-	200	201	|I-IUPAC
3	201	202	|I-IUPAC
-	202	203	|I-IUPAC
benzazocine	203	214	|I-IUPAC
(	215	216	|O
2	216	217	|O
)	217	218	|O
followed	219	227	|O
by	228	230	|O
the	231	234	|O
reaction	235	243	|O
with	244	248	|O
CH3SNa	249	255	|O
afforded	256	264	|O
8	265	266	|B-IUPAC
-	266	267	|I-IUPAC
(	267	268	|I-IUPAC
methylthio	268	278	|I-IUPAC
)	278	279	|I-IUPAC
-	279	280	|I-IUPAC
1,2,3,4,5,6	280	291	|I-IUPAC
-	291	292	|I-IUPAC
hexahydro	292	301	|I-IUPAC
-	301	302	|I-IUPAC
2,6	302	305	|I-IUPAC
-	305	306	|I-IUPAC
methano	306	313	|I-IUPAC
-	313	314	|I-IUPAC
3	314	315	|I-IUPAC
-	315	316	|I-IUPAC
benzazocine	316	327	|I-IUPAC
(	328	329	|O
3	329	330	|O
)	330	331	|O
.	331	332	|O
Another	333	340	|O
route	341	346	|O
using	347	352	|O
Grewe	353	358	|O
cyclization	359	370	|O
was	371	374	|O
also	375	379	|O
examined	380	388	|O
for	389	392	|O
the	393	396	|O
synthesis	397	406	|O
of	407	409	|O
3	410	411	|O
.	411	412	|O
As	413	415	|O
the	416	419	|O
most	420	424	|O
effective	425	434	|O
route	435	440	|O
,	440	441	|O
Newman	442	448	|O
-	448	449	|O
Kwart	449	454	|O
rearrangement	455	468	|O
of	469	471	|O
benzazocines	472	484	|O
was	485	488	|O
selected	489	497	|O
and	498	501	|O
closely	502	509	|O
investigated	510	522	|O
.	522	523	|O
8	524	525	|B-IUPAC
-	525	526	|I-IUPAC
(	526	527	|I-IUPAC
N	527	528	|I-IUPAC
,	528	529	|I-IUPAC
N	529	530	|I-IUPAC
-	530	531	|I-IUPAC
Dimethylthiocarbamoyl	531	552	|I-IUPAC
)	552	553	|I-IUPAC
oxy	553	556	|I-IUPAC
derivatives	557	568	|B-MODIFIER
(	569	570	|O
6a	570	572	|O
-	572	573	|O
e	573	574	|O
)	574	575	|O
rearranged	576	586	|O
to	587	589	|O
8	590	591	|B-IUPAC
-	591	592	|I-IUPAC
(	592	593	|I-IUPAC
N	593	594	|I-IUPAC
,	594	595	|I-IUPAC
N	595	596	|I-IUPAC
-	596	597	|I-IUPAC
dimethylcarbamoyl	597	614	|I-IUPAC
)	614	615	|I-IUPAC
thio	615	619	|I-IUPAC
derivatives	620	631	|B-MODIFIER
(	632	633	|O
7a	633	635	|O
-	635	636	|O
e	636	637	|O
)	637	638	|O
in	639	641	|O
good	642	646	|O
yields	647	653	|O
.	653	654	|O
Reductive	655	664	|O
cleavage	665	673	|O
of	674	676	|O
7a	677	679	|O
-	679	680	|O
e	680	681	|O
and	682	685	|O
subsequent	686	696	|O
methylation	697	708	|O
or	709	711	|O
acylations	712	722	|O
gave	723	727	|O
the	728	731	|O
title	732	737	|O
compounds	738	747	|O
(	748	749	|O
3	749	750	|O
,	750	751	|O
8-24	752	756	|O
)	756	757	|O
.	757	758	|O
Although	759	767	|O
analgesic	768	777	|O
activities	778	788	|O
of	789	791	|O
sulfur	792	798	|O
-	798	799	|O
containing	799	809	|O
benzazocines	810	822	|O
decreased	823	832	|O
compared	833	841	|O
to	842	844	|O
the	845	848	|O
corresponding	849	862	|O
hydroxy	863	870	|O
compounds	871	880	|O
,	880	881	|O
the	882	885	|O
N	886	887	|B-IUPAC
-	887	888	|I-IUPAC
methyl	888	894	|I-IUPAC
derivative	895	905	|B-MODIFIER
(	906	907	|O
S	907	908	|O
-	908	909	|O
metazocine	909	919	|O
,	919	920	|O
8	921	922	|O
)	922	923	|O
showed	924	930	|O
potent	931	937	|O
analgesic	938	947	|O
activity	948	956	|O
.	956	957	|O

### abstracts3783.txt
Two	0	3	|O
alkylating	4	14	|O
glucocorticoids	15	30	|O
have	31	35	|O
been	36	40	|O
synthesized	41	52	|O
in	53	55	|O
order	56	61	|O
to	62	64	|O
test	65	69	|O
the	70	73	|O
possibility	74	85	|O
of	86	88	|O
alkylating	89	99	|O
glucocorticoid	100	114	|O
receptors	115	124	|O
.	124	125	|O
The	126	129	|O
title	130	135	|O
compounds	136	145	|O
are	146	149	|O
9alpha	150	156	|B-IUPAC
-	156	157	|I-IUPAC
fluoro	157	163	|I-IUPAC
-	163	164	|I-IUPAC
11beta	164	170	|I-IUPAC
,	170	171	|I-IUPAC
16alpha	171	178	|I-IUPAC
,	178	179	|I-IUPAC
17alpha	179	186	|I-IUPAC
,	186	187	|I-IUPAC
21	187	189	|I-IUPAC
-	189	190	|I-IUPAC
tetrahydroxypregna	190	208	|I-IUPAC
-	208	209	|I-IUPAC
1,4	209	212	|I-IUPAC
-	212	213	|I-IUPAC
diene	213	218	|I-IUPAC
-	218	219	|I-IUPAC
3,20	219	223	|I-IUPAC
-	223	224	|I-IUPAC
dione	224	229	|I-IUPAC
21	230	232	|I-IUPAC
-	232	233	|I-IUPAC
[	233	234	|I-IUPAC
bis	234	237	|I-IUPAC
(	237	238	|I-IUPAC
2	238	239	|I-IUPAC
-	239	240	|I-IUPAC
chloroethyl	240	251	|I-IUPAC
)	251	252	|I-IUPAC
carbamate	252	261	|I-IUPAC
]	261	262	|I-IUPAC
16,17	263	268	|I-IUPAC
-	268	269	|I-IUPAC
acetonide	269	278	|I-IUPAC
(	279	280	|O
I	280	281	|O
)	281	282	|O
and	283	286	|O
11beta	287	293	|B-IUPAC
,	293	294	|I-IUPAC
17alpha	294	301	|I-IUPAC
,	301	302	|I-IUPAC
21	302	304	|I-IUPAC
-	304	305	|I-IUPAC
trihydroxypregn	305	320	|I-IUPAC
-	320	321	|I-IUPAC
4	321	322	|I-IUPAC
-	322	323	|I-IUPAC
ene	323	326	|I-IUPAC
-	326	327	|I-IUPAC
3,20	327	331	|I-IUPAC
-	331	332	|I-IUPAC
dione	332	337	|I-IUPAC
21	338	340	|I-IUPAC
-	340	341	|I-IUPAC
[	341	342	|I-IUPAC
bis	342	345	|I-IUPAC
(	345	346	|I-IUPAC
2	346	347	|I-IUPAC
-	347	348	|I-IUPAC
chloroethyl	348	359	|I-IUPAC
)	359	360	|I-IUPAC
carbamate	360	369	|I-IUPAC
]	369	370	|I-IUPAC
(	371	372	|O
II	372	374	|O
)	374	375	|O
,	375	376	|O
prepared	377	385	|O
from	386	390	|O
triamcinolone	391	404	|O
acetonide	405	414	|O
and	415	418	|O
cortisol	419	427	|O
,	427	428	|O
respectively	429	441	|O
,	441	442	|O
through	443	450	|O
the	451	454	|O
reaction	455	463	|O
of	464	466	|O
the	467	470	|O
C	471	472	|O
-	472	473	|O
21	473	475	|O
hydroxyl	476	484	|B-IUPAC
group	485	490	|B-MODIFIER
with	491	495	|O
phosgene	496	504	|O
and	505	508	|O
di	509	511	|B-IUPAC
-	511	512	|I-IUPAC
2	512	513	|I-IUPAC
-	513	514	|I-IUPAC
chloroethylamine	514	530	|I-IUPAC
in	531	533	|O
the	534	537	|O
presence	538	546	|O
of	547	549	|O
triethylamine	550	563	|O
.	563	564	|O
Both	565	569	|O
compounds	570	579	|O
are	580	583	|O
biologically	584	596	|O
active	597	603	|O
as	604	606	|O
inhibitors	607	617	|O
of	618	620	|O
the	621	624	|O
growth	625	631	|O
of	632	634	|O
cultured	635	643	|O
mouse	644	649	|O
fibroblasts	650	661	|O
and	662	665	|O
are	666	669	|O
able	670	674	|O
to	675	677	|O
compete	678	685	|O
for	686	689	|O
the	690	693	|O
specific	694	702	|O
binding	703	710	|O
of	711	713	|O
radiolabeled	714	726	|O
triamcinolone	727	740	|O
acetonide	741	750	|O
to	751	753	|O
the	754	757	|O
L929	758	762	|O
cell	763	767	|O
receptor	768	776	|O
.	776	777	|O
The	778	781	|O
bis	782	785	|B-IUPAC
(	785	786	|I-IUPAC
2	786	787	|I-IUPAC
-	787	788	|I-IUPAC
chloroethyl	788	799	|I-IUPAC
)	799	800	|I-IUPAC
carbamate	800	809	|I-IUPAC
moiety	810	816	|B-MODIFIER
is	817	819	|O
capable	820	827	|O
of	828	830	|O
reacting	831	839	|O
with	840	844	|O
nucleophilic	845	857	|O
groups	858	864	|O
as	865	867	|O
evidenced	868	877	|O
by	878	880	|O
the	881	884	|O
colorimetric	885	897	|O
reaction	898	906	|O
with	907	911	|O
4	912	913	|B-IUPAC
-	913	914	|I-IUPAC
(	914	915	|I-IUPAC
p	915	916	|I-IUPAC
-	916	917	|I-IUPAC
nitrobenzyl	917	928	|I-IUPAC
)	928	929	|I-IUPAC
pyridine	929	937	|I-IUPAC
.	937	938	|O
Both	939	943	|O
the	944	947	|O
interaction	948	959	|O
with	960	964	|O
the	965	968	|O
receptor	969	977	|O
and	978	981	|O
inhibition	982	992	|O
of	993	995	|O
cell	996	1000	|O
growth	1001	1007	|O
by	1008	1010	|O
these	1011	1016	|O
two	1017	1020	|O
glucocorticoids	1021	1036	|O
are	1037	1040	|O
reversible	1041	1051	|O
.	1051	1052	|O

### abstracts3280.txt
Syntheses	0	9	|O
of	10	12	|O
the	13	16	|O
enantiomers	17	28	|O
of	29	31	|O
myo	32	35	|B-IUPAC
-	35	36	|I-IUPAC
inositol	36	44	|I-IUPAC
1,3,4	45	50	|I-IUPAC
-	50	51	|I-IUPAC
trisphosphate	51	64	|I-IUPAC
are	65	68	|O
described	69	78	|O
.	78	79	|O
1,4	80	83	|B-IUPAC
-	83	84	|I-IUPAC
Di	84	86	|I-IUPAC
-	86	87	|I-IUPAC
O	87	88	|I-IUPAC
-	88	89	|I-IUPAC
allyl	89	94	|I-IUPAC
-	94	95	|I-IUPAC
myo	95	98	|I-IUPAC
-	98	99	|I-IUPAC
inositol	99	107	|I-IUPAC
was	108	111	|O
regioselectively	112	128	|O
p	129	130	|O
-	130	131	|O
methoxybenzylated	131	148	|O
at	149	151	|O
the	152	155	|O
3	156	157	|O
-	157	158	|O
position	158	166	|O
to	167	169	|O
give	170	174	|O
1,4	175	178	|B-IUPAC
-	178	179	|I-IUPAC
di	179	181	|I-IUPAC
-	181	182	|I-IUPAC
O	182	183	|I-IUPAC
-	183	184	|I-IUPAC
allyl	184	189	|I-IUPAC
-	189	190	|I-IUPAC
3	190	191	|I-IUPAC
-	191	192	|I-IUPAC
O	192	193	|I-IUPAC
-	193	194	|I-IUPAC
(	194	195	|I-IUPAC
p	195	196	|I-IUPAC
-	196	197	|I-IUPAC
methoxybenzyl	197	210	|I-IUPAC
)	210	211	|I-IUPAC
-	211	212	|I-IUPAC
myo	212	215	|I-IUPAC
-	215	216	|I-IUPAC
inositol	216	224	|I-IUPAC
followed	225	233	|O
by	234	236	|O
benzylation	237	248	|O
of	249	251	|O
the	252	255	|O
remaining	256	265	|O
free	266	270	|O
hydroxyl	271	279	|B-IUPAC
groups	280	286	|B-MODIFIER
to	287	289	|O
give	290	294	|O
the	295	298	|O
key	299	302	|O
intermediate	303	315	|O
1,4	316	319	|B-IUPAC
-	319	320	|I-IUPAC
di	320	322	|I-IUPAC
-	322	323	|I-IUPAC
O	323	324	|I-IUPAC
-	324	325	|I-IUPAC
allyl	325	330	|I-IUPAC
-	330	331	|I-IUPAC
2,5,6	331	336	|I-IUPAC
-	336	337	|I-IUPAC
tri	337	340	|I-IUPAC
-	340	341	|I-IUPAC
O	341	342	|I-IUPAC
-	342	343	|I-IUPAC
benzyl	343	349	|I-IUPAC
-	349	350	|I-IUPAC
3	350	351	|I-IUPAC
-	351	352	|I-IUPAC
O	352	353	|I-IUPAC
-	353	354	|I-IUPAC
(	354	355	|I-IUPAC
p	355	356	|I-IUPAC
-	356	357	|I-IUPAC
methoxybenzyl	357	370	|I-IUPAC
)	370	371	|I-IUPAC
-	371	372	|I-IUPAC
myo	372	375	|I-IUPAC
-	375	376	|I-IUPAC
inositol	376	384	|I-IUPAC
.	384	385	|O
Removal	386	393	|O
of	394	396	|O
the	397	400	|O
p	401	402	|B-IUPAC
-	402	403	|I-IUPAC
methoxybenzyl	403	416	|I-IUPAC
and	417	420	|O
allyl	421	426	|B-IUPAC
groups	427	433	|B-MODIFIER
gave	434	438	|O
2,4,5	439	444	|B-IUPAC
-	444	445	|I-IUPAC
tri	445	448	|I-IUPAC
-	448	449	|I-IUPAC
O	449	450	|I-IUPAC
-	450	451	|I-IUPAC
benzyl	451	457	|I-IUPAC
-	457	458	|I-IUPAC
myo	458	461	|I-IUPAC
-	461	462	|I-IUPAC
inositol	462	470	|I-IUPAC
which	471	476	|O
was	477	480	|O
phosphitylated	481	495	|O
with	496	500	|O
bis	501	504	|B-IUPAC
(	504	505	|I-IUPAC
benzyloxy	505	514	|I-IUPAC
)	514	515	|I-IUPAC
(	515	516	|I-IUPAC
diisopropylamino	516	532	|I-IUPAC
)	532	533	|I-IUPAC
phosphine	533	542	|I-IUPAC
to	543	545	|O
give	546	550	|O
the	551	554	|O
fully	555	560	|O
protected	561	570	|O
trisphosphite	571	584	|O
triester	585	593	|O
.	593	594	|O
Oxidation	595	604	|O
using	605	610	|O
tert	611	615	|B-IUPAC
-	615	616	|I-IUPAC
butyl	616	621	|I-IUPAC
hydroperoxide	622	635	|I-IUPAC
gave	636	640	|O
2,5,6	641	646	|B-IUPAC
-	646	647	|I-IUPAC
tri	647	650	|I-IUPAC
-	650	651	|I-IUPAC
O	651	652	|I-IUPAC
-	652	653	|I-IUPAC
benzyl	653	659	|I-IUPAC
-	659	660	|I-IUPAC
1,3,4	660	665	|I-IUPAC
-	665	666	|I-IUPAC
tris	666	670	|I-IUPAC
(	670	671	|I-IUPAC
dibenzylphospho	671	686	|I-IUPAC
)	686	687	|I-IUPAC
-	687	688	|I-IUPAC
myo	688	691	|I-IUPAC
-	691	692	|I-IUPAC
inositol	692	700	|I-IUPAC
,	700	701	|O
and	702	705	|O
deprotection	706	718	|O
using	719	724	|O
sodium	725	731	|O
in	732	734	|O
liquid	735	741	|O
ammonia	742	749	|O
gave	750	754	|O
racemic	755	762	|B-MODIFIER
myo	763	766	|B-IUPAC
-	766	767	|I-IUPAC
inositol	767	775	|I-IUPAC
1,3,4	776	781	|I-IUPAC
-	781	782	|I-IUPAC
trisphosphate	782	795	|I-IUPAC
.	795	796	|O
Deprotection	797	809	|O
of	810	812	|O
the	813	816	|O
key	817	820	|O
intermediate	821	833	|O
1,4	834	837	|B-IUPAC
-	837	838	|I-IUPAC
di	838	840	|I-IUPAC
-	840	841	|I-IUPAC
O	841	842	|I-IUPAC
-	842	843	|I-IUPAC
allyl	843	848	|I-IUPAC
-	848	849	|I-IUPAC
2,5,6	849	854	|I-IUPAC
-	854	855	|I-IUPAC
tri	855	858	|I-IUPAC
-	858	859	|I-IUPAC
O	859	860	|I-IUPAC
-	860	861	|I-IUPAC
benzyl	861	867	|I-IUPAC
-	867	868	|I-IUPAC
3	868	869	|I-IUPAC
-	869	870	|I-IUPAC
O	870	871	|I-IUPAC
-	871	872	|I-IUPAC
(	872	873	|I-IUPAC
p	873	874	|I-IUPAC
-	874	875	|I-IUPAC
methoxybenzyl	875	888	|I-IUPAC
)	888	889	|I-IUPAC
-	889	890	|I-IUPAC
myo	890	893	|I-IUPAC
-	893	894	|I-IUPAC
inositol	894	902	|I-IUPAC
by	903	905	|O
isomerization	906	919	|O
of	920	922	|O
allyl	923	928	|O
groups	929	935	|O
followed	936	944	|O
by	945	947	|O
mild	948	952	|O
acid	953	957	|O
hydrolysis	958	968	|O
gave	969	973	|O
2,4,5	974	979	|B-IUPAC
-	979	980	|I-IUPAC
tri	980	983	|I-IUPAC
-	983	984	|I-IUPAC
O	984	985	|I-IUPAC
-	985	986	|I-IUPAC
benzyl	986	992	|I-IUPAC
-	992	993	|I-IUPAC
1	993	994	|I-IUPAC
-	994	995	|I-IUPAC
O	995	996	|I-IUPAC
-	996	997	|I-IUPAC
(	997	998	|I-IUPAC
p	998	999	|I-IUPAC
-	999	1000	|I-IUPAC
methoxybenzyl	1000	1013	|I-IUPAC
)	1013	1014	|I-IUPAC
-	1014	1015	|I-IUPAC
myo	1015	1018	|I-IUPAC
-	1018	1019	|I-IUPAC
inositol	1019	1027	|I-IUPAC
,	1027	1028	|O
which	1029	1034	|O
was	1035	1038	|O
converted	1039	1048	|O
to	1049	1051	|O
the	1052	1055	|O
diastereoisomeric	1056	1073	|O
(	1074	1075	|O
bis	1075	1078	|B-IUPAC
-	1078	1079	|I-IUPAC
(	1079	1080	|I-IUPAC
-	1080	1081	|I-IUPAC
)	1081	1082	|I-IUPAC
-	1082	1083	|I-IUPAC
camphanates	1083	1094	|I-IUPAC
.	1094	1095	|O
The	1096	1099	|O
diastereoisomers	1100	1116	|O
were	1117	1121	|O
separated	1122	1131	|O
by	1132	1134	|O
column	1135	1141	|O
chromatography	1142	1156	|O
and	1157	1160	|O
the	1161	1164	|O
camphanates	1165	1176	|O
and	1177	1180	|O
the	1181	1184	|O
p	1185	1186	|B-IUPAC
-	1186	1187	|I-IUPAC
methoxybenzyl	1187	1200	|I-IUPAC
group	1201	1206	|B-MODIFIER
removed	1207	1214	|O
by	1215	1217	|O
saponification	1218	1232	|O
and	1233	1236	|O
acid	1237	1241	|O
hydrolysis	1242	1252	|O
,	1252	1253	|O
respectively	1254	1266	|O
,	1266	1267	|O
for	1268	1271	|O
each	1272	1276	|O
diastereoisomer	1277	1292	|O
to	1293	1295	|O
give	1296	1300	|O
the	1301	1304	|O
enantiomers	1305	1316	|O
of	1317	1319	|O
2,4,5	1320	1325	|B-IUPAC
-	1325	1326	|I-IUPAC
tri	1326	1329	|I-IUPAC
-	1329	1330	|I-IUPAC
O	1330	1331	|I-IUPAC
-	1331	1332	|I-IUPAC
benzyl	1332	1338	|I-IUPAC
-	1338	1339	|I-IUPAC
myo	1339	1342	|I-IUPAC
-	1342	1343	|I-IUPAC
inositol	1343	1351	|I-IUPAC
.	1351	1352	|O
The	1353	1356	|O
absolute	1357	1365	|O
configurations	1366	1380	|O
of	1381	1383	|O
the	1384	1387	|O
latter	1388	1394	|O
were	1395	1399	|O
established	1400	1411	|O
by	1412	1414	|O
conversion	1415	1425	|O
of	1426	1428	|O
1L	1429	1431	|B-IUPAC
-	1431	1432	|I-IUPAC
2,5,6	1432	1437	|I-IUPAC
-	1437	1438	|I-IUPAC
tri	1438	1441	|I-IUPAC
-	1441	1442	|I-IUPAC
O	1442	1443	|I-IUPAC
-	1443	1444	|I-IUPAC
benzyl	1444	1450	|I-IUPAC
-	1450	1451	|I-IUPAC
3	1451	1452	|I-IUPAC
-	1452	1453	|I-IUPAC
O	1453	1454	|I-IUPAC
-	1454	1455	|I-IUPAC
(	1455	1456	|I-IUPAC
p	1456	1457	|I-IUPAC
-	1457	1458	|I-IUPAC
methoxybenyl	1458	1470	|I-IUPAC
)	1470	1471	|I-IUPAC
-	1471	1472	|I-IUPAC
myo	1472	1475	|I-IUPAC
-	1475	1476	|I-IUPAC
inositol	1476	1484	|I-IUPAC
to	1485	1487	|O
the	1488	1491	|O
known	1492	1497	|O
1L	1498	1500	|B-IUPAC
-	1500	1501	|I-IUPAC
1,2,4,5,6	1501	1510	|I-IUPAC
-	1510	1511	|I-IUPAC
penta	1511	1516	|I-IUPAC
-	1516	1517	|I-IUPAC
O	1517	1518	|I-IUPAC
-	1518	1519	|I-IUPAC
benzyl	1519	1525	|I-IUPAC
-	1525	1526	|I-IUPAC
myo	1526	1529	|I-IUPAC
-	1529	1530	|I-IUPAC
inositol	1530	1538	|I-IUPAC
.	1538	1539	|O
Phosphorylation	1540	1555	|O
and	1556	1559	|O
deblocking	1560	1570	|O
gave	1571	1575	|O
the	1576	1579	|O
D	1580	1581	|O
-	1581	1582	|O
and	1583	1586	|O
L	1587	1588	|O
-	1588	1589	|O
enantiomers	1589	1600	|O
of	1601	1603	|O
myo	1604	1607	|B-IUPAC
-	1607	1608	|I-IUPAC
inositol	1608	1616	|I-IUPAC
1,3,4	1617	1622	|I-IUPAC
-	1622	1623	|I-IUPAC
trisphosphate	1623	1636	|I-IUPAC
.	1636	1637	|O
Biological	1638	1648	|O
evaluation	1649	1659	|O
in	1660	1662	|O
Limulus	1663	1670	|O
photoreceptors	1671	1685	|O
showed	1686	1692	|O
that	1693	1697	|O
1L	1698	1700	|B-IUPAC
-	1700	1701	|I-IUPAC
myo	1701	1704	|I-IUPAC
-	1704	1705	|I-IUPAC
inositol	1705	1713	|I-IUPAC
1,3,4	1714	1719	|I-IUPAC
-	1719	1720	|I-IUPAC
trisphosphate	1720	1733	|I-IUPAC
was	1734	1737	|O
much	1738	1742	|O
more	1743	1747	|O
active	1748	1754	|O
than	1755	1759	|O
the	1760	1763	|O
D	1764	1765	|O
-	1765	1766	|O
enantiomer	1766	1776	|O
,	1776	1777	|O
producing	1778	1787	|O
repetitive	1788	1798	|O
bursts	1799	1805	|O
of	1806	1808	|O
depolarization	1809	1823	|O
due	1824	1827	|O
to	1828	1830	|O
mobilization	1831	1843	|O
of	1844	1846	|O
intracellular	1847	1860	|O
calcium	1861	1868	|O
.	1868	1869	|O

### abstracts512.txt
The	0	3	|O
formation	4	13	|O
of	14	16	|O
nitric	17	23	|O
oxide	24	29	|O
(	30	31	|O
NO	31	33	|O
)	33	34	|O
was	35	38	|O
followed	39	47	|O
during	48	54	|O
the	55	58	|O
oxidation	59	68	|O
of	69	71	|O
37	72	74	|O
N	75	76	|B-IUPAC
-	76	77	|I-IUPAC
hydroxyguanidines	77	94	|I-IUPAC
or	95	97	|O
related	98	105	|O
derivatives	106	117	|O
,	117	118	|O
including	119	128	|O
18	129	131	|O
new	132	135	|O
N	136	137	|B-IUPAC
-	137	138	|I-IUPAC
aryl	138	142	|I-IUPAC
N'	143	145	|I-IUPAC
-	145	146	|I-IUPAC
hydroxyguanidines	146	163	|I-IUPAC
,	163	164	|O
by	165	167	|O
recombinant	168	179	|O
inducible	180	189	|O
nitric	190	196	|O
oxide	197	202	|O
synthase	203	211	|O
(	212	213	|O
NOS	213	216	|O
II	217	219	|O
)	219	220	|O
.	220	221	|O
Several	222	229	|O
N	230	231	|B-IUPAC
-	231	232	|I-IUPAC
aryl	232	236	|I-IUPAC
N'	237	239	|I-IUPAC
-	239	240	|I-IUPAC
hydroxyguanidines	240	257	|I-IUPAC
bearing	258	265	|O
a	266	267	|O
relatively	268	278	|O
small	279	284	|O
,	284	285	|O
electron	286	294	|O
-	294	295	|O
donating	295	303	|O
para	304	308	|O
subtituent	309	319	|O
,	319	320	|O
such	321	325	|O
as	326	328	|O
H	329	330	|O
,	330	331	|O
F	332	333	|O
,	333	334	|O
Cl	335	337	|O
,	337	338	|O
CH	339	341	|O
(	341	342	|O
3	342	343	|O
)	343	344	|O
,	344	345	|O
OH	346	348	|O
,	348	349	|O
OCH	350	353	|O
(	353	354	|O
3	354	355	|O
)	355	356	|O
,	356	357	|O
and	358	361	|O
NH	362	364	|O
(	364	365	|O
2	365	366	|O
)	366	367	|O
,	367	368	|O
led	369	372	|O
to	373	375	|O
NO	376	378	|O
formation	379	388	|O
rates	389	394	|O
between	395	402	|O
8	403	404	|O
and	405	408	|O
41%	409	412	|O
of	413	415	|O
that	416	420	|O
of	421	423	|O
NO	424	426	|O
formation	427	436	|O
from	437	441	|O
the	442	445	|O
natural	446	453	|O
NOS	454	457	|O
substrate	458	467	|O
,	467	468	|O
N	469	470	|B-IUPAC
(	470	471	|I-IUPAC
omega	471	476	|I-IUPAC
)	476	477	|I-IUPAC
-	477	478	|I-IUPAC
hydroxy	478	485	|I-IUPAC
-	485	486	|I-IUPAC
L	486	487	|I-IUPAC
-	487	488	|I-IUPAC
arginine	488	496	|I-IUPAC
(	497	498	|O
NOHA	498	502	|O
)	502	503	|O
.	503	504	|O
The	505	508	|O
characteristics	509	524	|O
of	525	527	|O
these	528	533	|O
reactions	534	543	|O
were	544	548	|O
very	549	553	|O
similar	554	561	|O
to	562	564	|O
those	565	570	|O
previously	571	581	|O
reported	582	590	|O
for	591	594	|O
the	595	598	|O
oxidation	599	608	|O
of	609	611	|O
NOHA	612	616	|O
by	617	619	|O
NOS	620	623	|O
:	623	624	|O
(	624	625	|O
i	625	626	|O
)	626	627	|O
the	628	631	|O
strict	632	638	|O
requirement	639	650	|O
of	651	653	|O
NOS	654	657	|O
containing	658	668	|O
(	669	670	|B-IUPAC
6R	670	672	|I-IUPAC
)	672	673	|I-IUPAC
-	673	674	|I-IUPAC
5,6,7,8	674	681	|I-IUPAC
-	681	682	|I-IUPAC
tetrahydro	682	692	|I-IUPAC
-	692	693	|I-IUPAC
L	693	694	|I-IUPAC
-	694	695	|I-IUPAC
biopterin	695	704	|I-IUPAC
,	704	705	|O
reduced	706	713	|O
nicotinamide	714	726	|O
adenine	727	734	|O
dinucleotide	735	747	|O
phosphate	748	757	|O
,	757	758	|O
and	759	762	|O
O	763	764	|O
(	764	765	|O
2	765	766	|O
)	766	767	|O
for	768	771	|O
the	772	775	|O
oxidation	776	785	|O
to	786	788	|O
occur	789	794	|O
,	794	795	|O
(	796	797	|O
ii	797	799	|O
)	799	800	|O
the	801	804	|O
formation	805	814	|O
of	815	817	|O
NO	818	820	|O
and	821	824	|O
the	825	828	|O
corresponding	829	842	|O
urea	843	847	|O
in	848	850	|O
a	851	852	|O
1	853	854	|O
:	854	855	|O
1	855	856	|O
molar	857	862	|O
ratio	863	868	|O
,	868	869	|O
and	870	873	|O
(	874	875	|O
iii	875	878	|O
)	878	879	|O
a	880	881	|O
strong	882	888	|O
inhibitory	889	899	|O
effect	900	906	|O
of	907	909	|O
the	910	913	|O
classical	914	923	|O
NOS	924	927	|O
inhibitors	928	938	|O
such	939	943	|O
as	944	946	|O
N	947	948	|B-IUPAC
(	948	949	|I-IUPAC
omega	949	954	|I-IUPAC
)	954	955	|I-IUPAC
-	955	956	|I-IUPAC
nitro	956	961	|I-IUPAC
-	961	962	|I-IUPAC
L	962	963	|I-IUPAC
-	963	964	|I-IUPAC
arginine	964	972	|I-IUPAC
and	973	976	|O
S	977	978	|B-IUPAC
-	978	979	|I-IUPAC
ethyl	979	984	|I-IUPAC
-	984	985	|I-IUPAC
iso	985	988	|I-IUPAC
-	988	989	|I-IUPAC
thiourea	989	997	|I-IUPAC
.	997	998	|O
Structure	999	1008	|O
-	1008	1009	|O
activity	1009	1017	|O
relationship	1018	1030	|O
studies	1031	1038	|O
showed	1039	1045	|O
that	1046	1050	|O
two	1051	1054	|O
structural	1055	1065	|O
factors	1066	1073	|O
are	1074	1077	|O
crucial	1078	1085	|O
for	1086	1089	|O
NO	1090	1092	|O
formation	1093	1102	|O
from	1103	1107	|O
compounds	1108	1117	|O
containing	1118	1128	|O
a	1129	1130	|O
C	1131	1132	|O
(	1132	1133	|O
triple	1133	1139	|O
bond	1140	1144	|O
)	1144	1145	|O
NOH	1145	1148	|O
function	1149	1157	|O
.	1157	1158	|O
The	1159	1162	|O
first	1163	1168	|O
one	1169	1172	|O
is	1173	1175	|O
the	1176	1179	|O
presence	1180	1188	|O
of	1189	1191	|O
a	1192	1193	|O
monosubstituted	1194	1209	|B-MODIFIER
N	1210	1211	|B-IUPAC
-	1211	1212	|I-IUPAC
hydroxyguanidine	1212	1228	|I-IUPAC
function	1229	1237	|O
,	1237	1238	|O
since	1239	1244	|O
disubstituted	1245	1258	|B-MODIFIER
N	1259	1260	|B-IUPAC
-	1260	1261	|I-IUPAC
hydroxyguanidines	1261	1278	|I-IUPAC
,	1278	1279	|O
amidoximes	1280	1290	|O
,	1290	1291	|O
ketoximes	1292	1301	|O
,	1301	1302	|O
and	1303	1306	|O
aldoximes	1307	1316	|O
failed	1317	1323	|O
to	1324	1326	|O
produce	1327	1334	|O
NO	1335	1337	|O
.	1337	1338	|O
The	1339	1342	|O
second	1343	1349	|O
one	1350	1353	|O
is	1354	1356	|O
the	1357	1360	|O
presence	1361	1369	|O
of	1370	1372	|O
a	1373	1374	|O
N	1375	1376	|O
-	1376	1377	|O
phenyl	1377	1383	|O
ring	1384	1388	|O
bearing	1389	1396	|O
a	1397	1398	|O
relatively	1399	1409	|O
small	1410	1415	|O
,	1415	1416	|O
not	1417	1420	|O
electron	1421	1429	|O
-	1429	1430	|O
withdrawing	1430	1441	|O
para	1442	1446	|O
substituent	1447	1458	|O
that	1459	1463	|O
could	1464	1469	|O
favorably	1470	1479	|O
interact	1480	1488	|O
with	1489	1493	|O
a	1494	1495	|O
hydrophobic	1496	1507	|O
cavity	1508	1514	|O
close	1515	1520	|O
to	1521	1523	|O
the	1524	1527	|O
NOS	1528	1531	|O
catalytic	1532	1541	|O
site	1542	1546	|O
.	1546	1547	|O
The	1548	1551	|O
k	1552	1553	|O
(	1553	1554	|O
cat	1554	1557	|O
)	1557	1558	|O
value	1559	1564	|O
for	1565	1568	|O
NOS	1569	1572	|O
II	1573	1575	|O
-	1575	1576	|O
catalyzed	1576	1585	|O
oxidation	1586	1595	|O
of	1596	1598	|O
N	1599	1600	|B-IUPAC
-	1600	1601	|I-IUPAC
para	1601	1605	|I-IUPAC
-	1605	1606	|I-IUPAC
fluorophenyl	1606	1618	|I-IUPAC
N'	1619	1621	|I-IUPAC
-	1621	1622	|I-IUPAC
hydroxyguanidine	1622	1638	|I-IUPAC
was	1639	1642	|O
80%	1643	1646	|O
of	1647	1649	|O
that	1650	1654	|O
found	1655	1660	|O
for	1661	1664	|O
NOHA	1665	1669	|O
,	1669	1670	|O
and	1671	1674	|O
its	1675	1678	|O
k	1679	1680	|O
(	1680	1681	|O
cat	1681	1684	|O
)	1684	1685	|O
/	1685	1686	|O
K	1686	1687	|O
(	1687	1688	|O
m	1688	1689	|O
)	1689	1690	|O
value	1691	1696	|O
was	1697	1700	|O
only	1701	1705	|O
9	1706	1707	|O
-	1707	1708	|O
fold	1708	1712	|O
lower	1713	1718	|O
than	1719	1723	|O
that	1724	1728	|O
of	1729	1731	|O
NOHA	1732	1736	|O
.	1736	1737	|O
Interestingly	1738	1751	|O
,	1751	1752	|O
the	1753	1756	|O
K	1757	1758	|O
(	1758	1759	|O
m	1759	1760	|O
)	1760	1761	|O
value	1762	1767	|O
found	1768	1773	|O
for	1774	1777	|O
NOS	1778	1781	|O
II	1782	1784	|O
-	1784	1785	|O
catalyzed	1785	1794	|O
oxidation	1795	1804	|O
of	1805	1807	|O
N	1808	1809	|B-IUPAC
-	1809	1810	|I-IUPAC
(	1810	1811	|I-IUPAC
3	1811	1812	|I-IUPAC
-	1812	1813	|I-IUPAC
thienyl	1813	1820	|I-IUPAC
)	1820	1821	|I-IUPAC
N'	1822	1824	|I-IUPAC
-	1824	1825	|I-IUPAC
hydroxyguanidine	1825	1841	|I-IUPAC
was	1842	1845	|O
25	1846	1848	|O
microM	1849	1855	|O
,	1855	1856	|O
almost	1857	1863	|O
identical	1864	1873	|O
to	1874	1876	|O
that	1877	1881	|O
of	1882	1884	|O
NOHA	1885	1889	|O
.	1889	1890	|O
Recombinant	1891	1902	|O
NOS	1903	1906	|O
I	1907	1908	|O
and	1909	1912	|O
NOS	1913	1916	|O
III	1917	1920	|O
also	1921	1925	|O
oxidize	1926	1933	|O
several	1934	1941	|O
N	1942	1943	|B-MODIFIER
-	1943	1944	|I-MODIFIER
aryl	1944	1948	|I-MODIFIER
N'	1949	1951	|B-IUPAC
-	1951	1952	|I-IUPAC
hydroxyguanidines	1952	1969	|I-IUPAC
with	1970	1974	|O
the	1975	1978	|O
formation	1979	1988	|O
of	1989	1991	|O
NO	1992	1994	|O
,	1994	1995	|O
with	1996	2000	|O
a	2001	2002	|O
clearly	2003	2010	|O
different	2011	2020	|O
substrate	2021	2030	|O
specificity	2031	2042	|O
.	2042	2043	|O
The	2044	2047	|O
best	2048	2052	|O
substrates	2053	2063	|O
of	2064	2066	|O
the	2067	2070	|O
studied	2071	2078	|O
series	2079	2085	|O
for	2086	2089	|O
NOS	2090	2093	|O
I	2094	2095	|O
and	2096	2099	|O
NOS	2100	2103	|O
III	2104	2107	|O
were	2108	2112	|O
N	2113	2114	|B-PARTIUPAC
-	2114	2115	|I-PARTIUPAC
(	2115	2116	|I-PARTIUPAC
para	2116	2120	|I-PARTIUPAC
-	2120	2121	|I-PARTIUPAC
hydroxyphenyl	2121	2134	|I-PARTIUPAC
)	2134	2135	|I-PARTIUPAC
and	2136	2139	|O
N	2140	2141	|B-IUPAC
-	2141	2142	|I-IUPAC
(	2142	2143	|I-IUPAC
meta	2143	2147	|I-IUPAC
-	2147	2148	|I-IUPAC
aminophenyl	2148	2159	|I-IUPAC
)	2159	2160	|I-IUPAC
N'	2161	2163	|I-IUPAC
-	2163	2164	|I-IUPAC
hydroxyguanidine	2164	2180	|I-IUPAC
,	2180	2181	|O
respectively	2182	2194	|O
.	2194	2195	|O
Among	2196	2201	|O
the	2202	2205	|O
studied	2206	2213	|O
compounds	2214	2223	|O
,	2223	2224	|O
the	2225	2228	|O
para	2229	2233	|O
-	2233	2234	|O
chlorophenyl	2234	2246	|O
and	2247	2250	|O
para	2251	2255	|O
-	2255	2256	|O
methylphenyl	2256	2268	|O
derivatives	2269	2280	|O
were	2281	2285	|O
selective	2286	2295	|O
substrates	2296	2306	|O
of	2307	2309	|O
NOS	2310	2313	|O
II	2314	2316	|O
.	2316	2317	|O
These	2318	2323	|O
results	2324	2331	|O
open	2332	2336	|O
the	2337	2340	|O
way	2341	2344	|O
toward	2345	2351	|O
a	2352	2353	|O
new	2354	2357	|O
class	2358	2363	|O
of	2364	2366	|O
selective	2367	2376	|O
NO	2377	2379	|O
donors	2380	2386	|O
after	2387	2392	|O
in	2393	2395	|O
situ	2396	2400	|O
oxidation	2401	2410	|O
by	2411	2413	|O
each	2414	2418	|O
NOS	2419	2422	|O
family	2423	2429	|O
.	2429	2430	|O

### abstracts2413.txt
Several	0	7	|O
novel	8	13	|O
substituted	14	25	|B-MODIFIER
tetrahydro	26	36	|B-PARTIUPAC
-	36	37	|I-PARTIUPAC
and	38	41	|O
hexahydro	42	51	|B-IUPAC
-	51	52	|I-IUPAC
1,2	52	55	|I-IUPAC
-	55	56	|I-IUPAC
benzisothiazol	56	70	|I-IUPAC
-	70	71	|I-IUPAC
3	71	72	|I-IUPAC
-	72	73	|I-IUPAC
one	73	76	|I-IUPAC
1,1	77	80	|I-IUPAC
-	80	81	|I-IUPAC
dioxides	81	89	|I-IUPAC
and	90	93	|O
thiadiazinones	94	108	|B-IUPAC
were	109	113	|O
prepared	114	122	|O
and	123	126	|O
examined	127	135	|O
in	136	138	|O
a	139	140	|O
series	141	147	|O
of	148	150	|O
in	151	153	|O
vitro	154	159	|O
and	160	163	|O
in	164	166	|O
vivo	167	171	|O
tests	172	177	|O
to	178	180	|O
determine	181	190	|O
their	191	196	|O
pharmacological	197	212	|O
profile	213	220	|O
.	220	221	|O
Most	222	226	|O
compounds	227	236	|O
were	237	241	|O
orally	242	248	|O
active	249	255	|O
in	256	258	|O
blocking	259	267	|O
the	268	271	|O
conditioned	272	283	|O
avoidance	284	293	|O
response	294	302	|O
(	303	304	|O
CAR	304	307	|O
)	307	308	|O
but	309	312	|O
did	313	316	|O
not	317	320	|O
antagonize	321	331	|O
apomorphine	332	343	|O
-	343	344	|O
induced	344	351	|O
stereotyped	352	363	|O
behavior	364	372	|O
.	372	373	|O
Several	374	381	|O
compounds	382	391	|O
demonstrated	392	404	|O
moderate	405	413	|O
to	414	416	|O
high	417	421	|O
affinity	422	430	|O
for	431	434	|O
the	435	438	|O
5	439	440	|O
-	440	441	|O
HT1A	441	445	|O
receptor	446	454	|O
binding	455	462	|O
site	463	467	|O
,	467	468	|O
with	469	473	|O
compounds	474	483	|O
37	484	486	|O
and	487	490	|O
38	491	493	|O
containing	494	504	|O
2	505	506	|B-IUPAC
-	506	507	|I-IUPAC
pyrimidinylpiperazinyl	507	529	|I-IUPAC
and	530	533	|O
[	534	535	|B-IUPAC
3	535	536	|I-IUPAC
-	536	537	|I-IUPAC
(	537	538	|I-IUPAC
trifluoromethyl	538	553	|I-IUPAC
)	553	554	|I-IUPAC
phenyl	554	560	|I-IUPAC
]	560	561	|I-IUPAC
piperazinyl	561	572	|I-IUPAC
moieties	573	581	|B-MODIFIER
and	582	585	|O
compound	586	594	|O
47	595	597	|O
containing	598	608	|O
the	609	612	|O
2	613	614	|B-IUPAC
-	614	615	|I-IUPAC
pyrazinylpiperazinyl	615	635	|I-IUPAC
moiety	636	642	|B-MODIFIER
displaying	643	653	|O
the	654	657	|O
highest	658	665	|O
affinity	666	674	|O
(	675	676	|O
Ki	676	678	|O
values	679	685	|O
of	686	688	|O
10	689	691	|O
,	691	692	|O
4	693	694	|O
,	694	695	|O
and	696	699	|O
9	700	701	|O
nM	702	704	|O
,	704	705	|O
respectively	706	718	|O
)	718	719	|O
.	719	720	|O
Compound	721	729	|O
37	730	732	|O
,	732	733	|O
3	734	735	|B-IUPAC
-	735	736	|I-IUPAC
[	736	737	|I-IUPAC
4	737	738	|I-IUPAC
-	738	739	|I-IUPAC
[	739	740	|I-IUPAC
4	740	741	|I-IUPAC
-	741	742	|I-IUPAC
(	742	743	|I-IUPAC
2	743	744	|I-IUPAC
-	744	745	|I-IUPAC
pyrimidinyl	745	756	|I-IUPAC
)	756	757	|I-IUPAC
-	757	758	|I-IUPAC
1	758	759	|I-IUPAC
-	759	760	|I-IUPAC
piperazinyl	760	771	|I-IUPAC
]	771	772	|I-IUPAC
butyl	772	777	|I-IUPAC
]	777	778	|I-IUPAC
hexahydro	778	787	|I-IUPAC
-	787	788	|I-IUPAC
4	788	789	|I-IUPAC
,	789	790	|I-IUPAC
7	791	792	|I-IUPAC
-	792	793	|I-IUPAC
etheno	793	799	|I-IUPAC
-	799	800	|I-IUPAC
1H	800	802	|I-IUPAC
-	802	803	|I-IUPAC
cyclobut	803	811	|I-IUPAC
[	812	813	|I-IUPAC
f	813	814	|I-IUPAC
]	814	815	|I-IUPAC
-	815	816	|I-IUPAC
1,2	816	819	|I-IUPAC
-	819	820	|I-IUPAC
benzisothiazol	820	834	|I-IUPAC
-	834	835	|I-IUPAC
3	835	836	|I-IUPAC
(	836	837	|I-IUPAC
2H	837	839	|I-IUPAC
)	839	840	|I-IUPAC
-	840	841	|I-IUPAC
one	841	844	|I-IUPAC
1,1	845	848	|I-IUPAC
-	848	849	|I-IUPAC
dioxide	849	856	|I-IUPAC
,	856	857	|O
buspirone	858	867	|O
,	867	868	|O
and	869	872	|O
ipsapirone	873	883	|O
showed	884	890	|O
similarities	891	903	|O
in	904	906	|O
their	907	912	|O
neurochemical	913	926	|O
and	927	930	|O
behavioral	931	941	|O
profiles	942	950	|O
.	950	951	|O
They	952	956	|O
were	957	961	|O
similar	962	969	|O
in	970	972	|O
potency	973	980	|O
in	981	983	|O
blocking	984	992	|O
CAR	993	996	|O
with	997	1001	|O
AB50	1002	1006	|O
values	1007	1013	|O
of	1014	1016	|O
39	1017	1019	|O
,	1019	1020	|O
32	1021	1023	|O
,	1023	1024	|O
and	1025	1028	|O
42	1029	1031	|O
mg	1032	1034	|O
/	1034	1035	|O
kg	1035	1037	|O
,	1037	1038	|O
respectively	1039	1051	|O
.	1051	1052	|O
They	1053	1057	|O
also	1058	1062	|O
demonstrated	1063	1075	|O
high	1076	1080	|O
affinity	1081	1089	|O
and	1090	1093	|O
selectivity	1094	1105	|O
for	1106	1109	|O
the	1110	1113	|O
5	1114	1115	|O
-	1115	1116	|O
HT1A	1116	1120	|O
receptor	1121	1129	|O
site	1130	1134	|O
(	1135	1136	|O
Ki	1136	1138	|O
=	1139	1140	|O
10	1141	1143	|O
nM	1144	1146	|O
)	1146	1147	|O
and	1148	1151	|O
exhibited	1152	1161	|O
partial	1162	1169	|O
agonist	1170	1177	|O
/	1177	1178	|O
antagonist	1178	1188	|O
activity	1189	1197	|O
in	1198	1200	|O
the	1201	1204	|O
serotonin	1205	1214	|O
syndrome	1215	1223	|O
test	1224	1228	|O
.	1228	1229	|O
In	1230	1232	|O
addition	1233	1241	|O
,	1241	1242	|O
compound	1243	1251	|O
37	1252	1254	|O
inhibited	1255	1264	|O
apomorphine	1265	1276	|O
-	1276	1277	|O
induced	1277	1284	|O
climbing	1285	1293	|O
behavior	1294	1302	|O
much	1303	1307	|O
more	1308	1312	|O
potently	1313	1321	|O
(	1322	1323	|O
ED50	1323	1327	|O
of	1328	1330	|O
3.4	1331	1334	|O
mg	1335	1337	|O
/	1337	1338	|O
kg	1338	1340	|O
)	1340	1341	|O
than	1342	1346	|O
stereotyped	1347	1358	|O
behavior	1359	1367	|O
(	1368	1369	|O
ED50	1369	1373	|O
of	1374	1376	|O
32.2	1377	1381	|O
mg	1382	1384	|O
/	1384	1385	|O
kg	1385	1387	|O
)	1387	1388	|O
and	1389	1392	|O
will	1393	1397	|O
be	1398	1400	|O
evaluated	1401	1410	|O
further	1411	1418	|O
.	1418	1419	|O
Structure	1420	1429	|O
-	1429	1430	|O
activity	1430	1438	|O
relationships	1439	1452	|O
within	1453	1459	|O
this	1460	1464	|O
series	1465	1471	|O
of	1472	1474	|O
compounds	1475	1484	|O
are	1485	1488	|O
discussed	1489	1498	|O
.	1498	1499	|O

### abstracts2196.txt
The	0	3	|O
synthesis	4	13	|O
of	14	16	|O
various	17	24	|O
substituted	25	36	|B-MODIFIER
5	37	38	|B-IUPAC
-	38	39	|I-IUPAC
amino	39	44	|I-IUPAC
-	44	45	|I-IUPAC
2	45	46	|I-IUPAC
-	46	47	|I-IUPAC
pyridinecarboxylic	47	65	|I-IUPAC
acids	66	71	|I-IUPAC
and	72	75	|O
their	76	81	|O
derivatives	82	93	|O
is	94	96	|O
described	97	106	|O
by	107	109	|O
three	110	115	|O
general	116	123	|O
methods	124	131	|O
:	131	132	|O
(	133	134	|O
1	134	135	|O
)	135	136	|O
reductive	137	146	|O
alkylation	147	157	|O
of	158	160	|O
methyl	161	167	|B-IUPAC
5	168	169	|I-IUPAC
-	169	170	|I-IUPAC
amino	170	175	|I-IUPAC
-	175	176	|I-IUPAC
2	176	177	|I-IUPAC
-	177	178	|I-IUPAC
pyridinecarboxylates	178	198	|I-IUPAC
(	199	200	|O
2	200	201	|O
)	201	202	|O
and	203	206	|O
subsequent	207	217	|O
hydrolysis	218	228	|O
;	228	229	|O
(	230	231	|O
2	231	232	|O
)	232	233	|O
alkylation	234	244	|O
of	245	247	|O
the	248	251	|O
urethane	252	260	|O
(	261	262	|O
9	262	263	|O
)	263	264	|O
,	264	265	|O
followed	266	274	|O
by	275	277	|O
hydrolysis	278	288	|O
;	288	289	|O
and	290	293	|O
(	294	295	|O
3	295	296	|O
)	296	297	|O
selective	298	307	|O
NaBH4	308	313	|O
reduction	314	323	|O
of	324	326	|O
the	327	330	|O
appropriate	331	342	|O
amide	343	348	|O
of	349	351	|O
(	352	353	|O
2	353	354	|O
)	354	355	|O
,	355	356	|O
followed	357	365	|O
by	366	368	|O
hydrolysis	369	379	|O
.	379	380	|O
A	381	382	|O
more	383	387	|O
specific	388	396	|O
process	397	404	|O
was	405	408	|O
used	409	413	|O
for	414	417	|O
the	418	421	|O
5	422	423	|B-IUPAC
-	423	424	|I-IUPAC
(	424	425	|I-IUPAC
phenylamino	425	436	|I-IUPAC
)	436	437	|I-IUPAC
compound	438	446	|B-MODIFIER
,	446	447	|O
i.e.	448	452	|O
,	452	453	|O
nucleophilic	454	466	|O
displacement	467	479	|O
of	480	482	|O
nitrite	483	490	|O
from	491	495	|O
methyl	496	502	|B-IUPAC
5	503	504	|I-IUPAC
-	504	505	|I-IUPAC
nitro	505	510	|I-IUPAC
-	510	511	|I-IUPAC
2	511	512	|I-IUPAC
-	512	513	|I-IUPAC
pyridinecarboxylate	513	532	|I-IUPAC
by	533	535	|O
sodioformanilide	536	552	|O
and	553	556	|O
subsequent	557	567	|O
hydrolysis	568	578	|O
.	578	579	|O
Many	580	584	|O
of	585	587	|O
these	588	593	|O
2	594	595	|B-IUPAC
-	595	596	|I-IUPAC
pyridinecarboxylic	596	614	|I-IUPAC
acid	615	619	|I-IUPAC
derivatives	620	631	|B-MODIFIER
were	632	636	|O
potent	637	643	|O
antihypertensive	644	660	|O
agents	661	667	|O
in	668	670	|O
the	671	674	|O
spontaneously	675	688	|O
hypertensive	689	701	|O
rat	702	705	|O
(	706	707	|O
SHR	707	710	|O
)	710	711	|O
.	711	712	|O
Optimization	713	725	|O
of	726	728	|O
structural	729	739	|O
parameters	740	750	|O
for	751	754	|O
this	755	759	|O
activity	760	768	|O
yielded	769	776	|O
compounds	777	786	|O
54	787	789	|O
,	789	790	|O
55	791	793	|O
,	793	794	|O
34	795	797	|O
,	797	798	|O
65	799	801	|O
,	801	802	|O
and	803	806	|O
22	807	809	|O
,	809	810	|O
which	811	816	|O
were	817	821	|O
selected	822	830	|O
for	831	834	|O
further	835	842	|O
study	843	848	|O
in	849	851	|O
the	852	855	|O
renal	856	861	|O
hypertensive	862	874	|O
dog	875	878	|O
(	879	880	|O
RHD	880	883	|O
)	883	884	|O
.	884	885	|O
Based	886	891	|O
on	892	894	|O
these	895	900	|O
studies	901	908	|O
,	908	909	|O
one	910	913	|O
compound	914	922	|O
,	922	923	|O
5	924	925	|B-IUPAC
-	925	926	|I-IUPAC
[	926	927	|I-IUPAC
(	927	928	|I-IUPAC
4	928	929	|I-IUPAC
-	929	930	|I-IUPAC
fluorobenzyl	930	942	|I-IUPAC
)	942	943	|I-IUPAC
amino	943	948	|I-IUPAC
]	948	949	|I-IUPAC
-	949	950	|I-IUPAC
2	950	951	|I-IUPAC
-	951	952	|I-IUPAC
pyridinecarboxylic	952	970	|I-IUPAC
acid	971	975	|I-IUPAC
(	976	977	|O
65	977	979	|O
)	979	980	|O
,	980	981	|O
was	982	985	|O
selected	986	994	|O
for	995	998	|O
preclinical	999	1010	|O
toxicity	1011	1019	|O
evaluation	1020	1030	|O
.	1030	1031	|O
Based	1032	1037	|O
on	1038	1040	|O
the	1041	1044	|O
toxicological	1045	1058	|O
findings	1059	1067	|O
,	1067	1068	|O
it	1069	1071	|O
was	1072	1075	|O
decided	1076	1083	|O
not	1084	1087	|O
to	1088	1090	|O
pursue	1091	1097	|O
compound	1098	1106	|O
65	1107	1109	|O
clinically	1110	1120	|O
.	1120	1121	|O

### abstracts4731.txt
The	0	3	|O
synthesis	4	13	|O
and	14	17	|O
structure	18	27	|O
-	27	28	|O
activity	28	36	|O
relationships	37	50	|O
(	51	52	|O
SAR	52	55	|O
)	55	56	|O
of	57	59	|O
1	60	61	|B-IUPAC
-	61	62	|I-IUPAC
alkyl	62	67	|I-IUPAC
-	67	68	|I-IUPAC
2	68	69	|I-IUPAC
-	69	70	|I-IUPAC
phenylethylamine	70	86	|I-IUPAC
derivatives	87	98	|B-MODIFIER
5-8	99	102	|O
designed	103	111	|O
from	112	116	|O
N	117	118	|B-IUPAC
,	118	119	|I-IUPAC
N	120	121	|I-IUPAC
-	121	122	|I-IUPAC
dipropyl	122	130	|I-IUPAC
-	130	131	|I-IUPAC
2	131	132	|I-IUPAC
-	132	133	|I-IUPAC
[	133	134	|I-IUPAC
4	134	135	|I-IUPAC
-	135	136	|I-IUPAC
methoxy	136	143	|I-IUPAC
-	143	144	|I-IUPAC
3	144	145	|I-IUPAC
-	145	146	|I-IUPAC
(	146	147	|I-IUPAC
2	147	148	|I-IUPAC
-	148	149	|I-IUPAC
phenylethoxy	149	161	|I-IUPAC
)	161	162	|I-IUPAC
phenyl	162	168	|I-IUPAC
]	168	169	|I-IUPAC
ethylamine	169	179	|I-IUPAC
hydrochloride	180	193	|I-IUPAC
(	194	195	|O
1	195	196	|O
,	196	197	|O
NE	198	200	|O
-	200	201	|O
100	201	204	|O
)	204	205	|O
are	206	209	|O
presented	210	219	|O
.	219	220	|O
The	221	224	|O
SAR	225	228	|O
between	229	236	|O
compound	237	245	|O
1	246	247	|O
and	248	251	|O
1	252	253	|B-IUPAC
-	253	254	|I-IUPAC
alkyl	254	259	|I-IUPAC
-	259	260	|I-IUPAC
2	260	261	|I-IUPAC
-	261	262	|I-IUPAC
phenylethylamine	262	278	|I-IUPAC
derivatives	279	290	|B-MODIFIER
suggested	291	300	|O
that	301	305	|O
the	306	309	|O
alkyl	310	315	|O
group	316	321	|O
on	322	324	|O
the	325	328	|O
1	329	330	|O
-	330	331	|O
position	331	339	|O
carbon	340	346	|O
of	347	349	|O
2	350	351	|B-IUPAC
-	351	352	|I-IUPAC
[	352	353	|I-IUPAC
4	353	354	|I-IUPAC
-	354	355	|I-IUPAC
methoxy	355	362	|I-IUPAC
-	362	363	|I-IUPAC
3	363	364	|I-IUPAC
-	364	365	|I-IUPAC
(	365	366	|I-IUPAC
2	366	367	|I-IUPAC
-	367	368	|I-IUPAC
phenylethyl	368	379	|I-IUPAC
)	379	380	|I-IUPAC
phenyl	380	386	|I-IUPAC
]	386	387	|I-IUPAC
ethylamine	387	397	|I-IUPAC
derivatives	398	409	|B-MODIFIER
played	410	416	|O
the	417	420	|O
role	421	425	|O
of	426	428	|O
one	429	432	|O
of	433	435	|O
the	436	439	|O
propyl	440	446	|O
groups	447	453	|O
on	454	456	|O
the	457	460	|O
aminic	461	467	|O
nitrogen	468	476	|O
of	477	479	|O
compound	480	488	|O
1	489	490	|O
.	490	491	|O
(	492	493	|B-IUPAC
-	493	494	|I-IUPAC
)	494	495	|I-IUPAC
-	495	496	|I-IUPAC
N	496	497	|I-IUPAC
-	497	498	|I-IUPAC
Propyl	498	504	|I-IUPAC
-	504	505	|I-IUPAC
1	505	506	|I-IUPAC
-	506	507	|I-IUPAC
butyl	507	512	|I-IUPAC
-	512	513	|I-IUPAC
2	513	514	|I-IUPAC
-	514	515	|I-IUPAC
[	515	516	|I-IUPAC
4	516	517	|I-IUPAC
-	517	518	|I-IUPAC
methoxy	518	525	|I-IUPAC
-	525	526	|I-IUPAC
3	526	527	|I-IUPAC
-	527	528	|I-IUPAC
(	528	529	|I-IUPAC
2	529	530	|I-IUPAC
-	530	531	|I-IUPAC
phenylethoxy	531	543	|I-IUPAC
)	543	544	|I-IUPAC
phenyl	544	550	|I-IUPAC
]	550	551	|I-IUPAC
ethylam	551	558	|I-IUPAC
ine	559	562	|I-IUPAC
hydrochloride	563	576	|I-IUPAC
(	577	578	|O
(	578	579	|O
-	579	580	|O
)	580	581	|O
-	581	582	|O
6d	582	584	|O
,	584	585	|O
NE	586	588	|O
-	588	589	|O
537	589	592	|O
)	592	593	|O
and	594	597	|O
(	598	599	|B-IUPAC
-	599	600	|I-IUPAC
)	600	601	|I-IUPAC
-	601	602	|I-IUPAC
N	602	603	|I-IUPAC
-	603	604	|I-IUPAC
propyl	604	610	|I-IUPAC
-	610	611	|I-IUPAC
1	611	612	|I-IUPAC
-	612	613	|I-IUPAC
(	613	614	|I-IUPAC
3	614	615	|I-IUPAC
-	615	616	|I-IUPAC
methybutyl	616	626	|I-IUPAC
)	626	627	|I-IUPAC
-	627	628	|I-IUPAC
2	628	629	|I-IUPAC
-	629	630	|I-IUPAC
[	630	631	|I-IUPAC
4	631	632	|I-IUPAC
-	632	633	|I-IUPAC
methoxy	633	640	|I-IUPAC
-	640	641	|I-IUPAC
3	641	642	|I-IUPAC
-	642	643	|I-IUPAC
(	643	644	|I-IUPAC
2	644	645	|I-IUPAC
-	645	646	|I-IUPAC
phenylethoxy	646	658	|I-IUPAC
)	659	660	|I-IUPAC
phenyl	660	666	|I-IUPAC
]	666	667	|I-IUPAC
e	667	668	|I-IUPAC
thylamine	669	678	|I-IUPAC
hydrochloride	679	692	|I-IUPAC
(	693	694	|O
(	694	695	|O
-	695	696	|O
)	696	697	|O
-	697	698	|O
6i	698	700	|O
,	700	701	|O
NE	702	704	|O
-	704	705	|O
535	705	708	|O
)	708	709	|O
,	709	710	|O
typical	711	718	|O
compounds	719	728	|O
in	729	731	|O
this	732	736	|O
series	737	743	|O
,	743	744	|O
have	745	749	|O
potent	750	756	|O
and	757	760	|O
selective	761	770	|O
sigma	771	776	|O
(	776	777	|O
1	777	778	|O
)	778	779	|O
affinity	780	788	|O
.	788	789	|O

### abstracts1068.txt
We	0	2	|O
have	3	7	|O
previously	8	18	|O
shown	19	24	|O
that	25	29	|O
(	30	31	|B-IUPAC
S	31	32	|I-IUPAC
)	32	33	|I-IUPAC
-	33	34	|I-IUPAC
2	34	35	|I-IUPAC
-	35	36	|I-IUPAC
amino	36	41	|I-IUPAC
-	41	42	|I-IUPAC
3	42	43	|I-IUPAC
-	43	44	|I-IUPAC
(	44	45	|I-IUPAC
3	45	46	|I-IUPAC
-	46	47	|I-IUPAC
hydroxy	47	54	|I-IUPAC
-	54	55	|I-IUPAC
5	55	56	|I-IUPAC
-	56	57	|I-IUPAC
phenyl	57	63	|I-IUPAC
-	63	64	|I-IUPAC
4	64	65	|I-IUPAC
-	65	66	|I-IUPAC
isoxazolyl	66	76	|I-IUPAC
)	76	77	|I-IUPAC
propionic	77	86	|I-IUPAC
acid	87	91	|I-IUPAC
[	92	93	|O
(	93	94	|O
S	94	95	|O
)	95	96	|O
-	96	97	|O
APPA	97	101	|O
,	101	102	|O
2	103	104	|O
]	104	105	|O
is	106	108	|O
a	109	110	|O
weak	111	115	|O
agonist	116	123	|O
at	124	126	|O
(	127	128	|B-IUPAC
RS	128	130	|I-IUPAC
)	130	131	|I-IUPAC
-	131	132	|I-IUPAC
2	132	133	|I-IUPAC
-	133	134	|I-IUPAC
amino	134	139	|I-IUPAC
-	139	140	|I-IUPAC
3	140	141	|I-IUPAC
-	141	142	|I-IUPAC
(	142	143	|I-IUPAC
3	143	144	|I-IUPAC
-	144	145	|I-IUPAC
hydroxy	145	152	|I-IUPAC
-	152	153	|I-IUPAC
5	153	154	|I-IUPAC
-	154	155	|I-IUPAC
methyl	155	161	|I-IUPAC
-	161	162	|I-IUPAC
4	162	163	|I-IUPAC
-	163	164	|I-IUPAC
isoxazolyl	164	174	|I-IUPAC
)	174	175	|I-IUPAC
propionic	175	184	|I-IUPAC
acid	185	189	|I-IUPAC
(	190	191	|O
AMPA	191	195	|O
)	195	196	|O
receptors	197	206	|O
,	206	207	|O
specifically	208	220	|O
activated	221	230	|O
by	231	233	|O
(	234	235	|O
S	235	236	|O
)	236	237	|O
-	237	238	|O
AMPA	238	242	|O
(	243	244	|O
1	244	245	|O
)	245	246	|O
,	246	247	|O
whereas	248	255	|O
(	256	257	|B-IUPAC
S	257	258	|I-IUPAC
)	258	259	|I-IUPAC
-	259	260	|I-IUPAC
2	260	261	|I-IUPAC
-	261	262	|I-IUPAC
amino	262	267	|I-IUPAC
-	267	268	|I-IUPAC
3	268	269	|I-IUPAC
-	269	270	|I-IUPAC
[	270	271	|I-IUPAC
3	271	272	|I-IUPAC
-	272	273	|I-IUPAC
hydroxy	273	280	|I-IUPAC
-	280	281	|I-IUPAC
5	281	282	|I-IUPAC
-	282	283	|I-IUPAC
(	283	284	|I-IUPAC
2	284	285	|I-IUPAC
-	285	286	|I-IUPAC
pyridyl	286	293	|I-IUPAC
)	293	294	|I-IUPAC
-	294	295	|I-IUPAC
4	295	296	|I-IUPAC
-	296	297	|I-IUPAC
isoxazolyl	297	307	|I-IUPAC
]	307	308	|I-IUPAC
propionic	308	317	|I-IUPAC
acid	318	322	|I-IUPAC
[	323	324	|O
(	324	325	|O
S	325	326	|O
)	326	327	|O
-	327	328	|O
2	328	329	|O
-	329	330	|O
Py	330	332	|O
-	332	333	|O
AMPA	333	337	|O
,	337	338	|O
5	339	340	|O
]	340	341	|O
and	342	345	|O
(	346	347	|B-IUPAC
RS	347	349	|I-IUPAC
)	349	350	|I-IUPAC
-	350	351	|I-IUPAC
2	351	352	|I-IUPAC
-	352	353	|I-IUPAC
amino	353	358	|I-IUPAC
-	358	359	|I-IUPAC
3	359	360	|I-IUPAC
-	360	361	|I-IUPAC
[	361	362	|I-IUPAC
3	362	363	|I-IUPAC
-	363	364	|I-IUPAC
hydroxy	364	371	|I-IUPAC
-	371	372	|I-IUPAC
5	372	373	|I-IUPAC
-	373	374	|I-IUPAC
(	374	375	|I-IUPAC
2	375	376	|I-IUPAC
-	376	377	|I-IUPAC
thiazolyl	377	386	|I-IUPAC
)	386	387	|I-IUPAC
-	387	388	|I-IUPAC
4	388	389	|I-IUPAC
-	389	390	|I-IUPAC
isoxazolyl	390	400	|I-IUPAC
]	400	401	|I-IUPAC
propionic	401	410	|I-IUPAC
acid	411	415	|I-IUPAC
(	416	417	|O
4	417	418	|O
)	418	419	|O
are	420	423	|O
potent	424	430	|O
AMPA	431	435	|O
agonists	436	444	|O
.	444	445	|O
On	446	448	|O
the	449	452	|O
other	453	458	|O
hand	459	463	|O
,	463	464	|O
(	465	466	|O
R	466	467	|O
)	467	468	|O
-	468	469	|O
APPA	469	473	|O
(	474	475	|O
3	475	476	|O
)	476	477	|O
and	478	481	|O
(	482	483	|O
R	483	484	|O
)	484	485	|O
-	485	486	|O
2	486	487	|O
-	487	488	|O
Py	488	490	|O
-	490	491	|O
AMPA	491	495	|O
(	496	497	|O
6	497	498	|O
)	498	499	|O
have	500	504	|O
been	505	509	|O
shown	510	515	|O
to	516	518	|O
be	519	521	|O
weak	522	526	|O
AMPA	527	531	|O
antagonists	532	543	|O
.	543	544	|O
We	545	547	|O
now	548	551	|O
report	552	558	|O
the	559	562	|O
synthesis	563	572	|O
of	573	575	|O
2	576	577	|O
-	577	578	|O
Py	578	580	|O
-	580	581	|O
AMPA	581	585	|O
(	586	587	|O
7a	587	589	|O
)	589	590	|O
and	591	594	|O
the	595	598	|O
isomeric	599	607	|O
compounds	608	617	|O
3	618	619	|O
-	619	620	|O
Py	620	622	|O
-	622	623	|O
AMPA	623	627	|O
(	628	629	|O
7b	629	631	|O
)	631	632	|O
and	633	636	|O
4	637	638	|O
-	638	639	|O
Py	639	641	|O
-	641	642	|O
AMPA	642	646	|O
(	647	648	|O
7c	648	650	|O
)	650	651	|O
as	652	654	|O
well	655	659	|O
as	660	662	|O
the	663	666	|O
7a	667	669	|O
analogues	670	679	|O
,	679	680	|O
(	681	682	|B-IUPAC
RS	682	684	|I-IUPAC
)	684	685	|I-IUPAC
-	685	686	|I-IUPAC
2	686	687	|I-IUPAC
-	687	688	|I-IUPAC
amino	688	693	|I-IUPAC
-	693	694	|I-IUPAC
3	694	695	|I-IUPAC
-	695	696	|I-IUPAC
[	696	697	|I-IUPAC
3	697	698	|I-IUPAC
-	698	699	|I-IUPAC
hydroxy	699	706	|I-IUPAC
-	706	707	|I-IUPAC
5	707	708	|I-IUPAC
-	708	709	|I-IUPAC
(	709	710	|I-IUPAC
6	710	711	|I-IUPAC
-	711	712	|I-IUPAC
methyl	712	718	|I-IUPAC
-	718	719	|I-IUPAC
2	719	720	|I-IUPAC
-	720	721	|I-IUPAC
pyridyl	721	728	|I-IUPAC
)	728	729	|I-IUPAC
-	729	730	|I-IUPAC
4	730	731	|I-IUPAC
-	731	732	|I-IUPAC
isoxazolyl	732	742	|I-IUPAC
]	742	743	|I-IUPAC
p	743	744	|I-IUPAC
ropion	745	751	|I-IUPAC
ic	752	754	|I-IUPAC
acid	755	759	|I-IUPAC
(	760	761	|O
7d	761	763	|O
)	763	764	|O
and	765	768	|O
(	769	770	|B-IUPAC
RS	770	772	|I-IUPAC
)	772	773	|I-IUPAC
-	773	774	|I-IUPAC
2	774	775	|I-IUPAC
-	775	776	|I-IUPAC
amino	776	781	|I-IUPAC
-	781	782	|I-IUPAC
3	782	783	|I-IUPAC
-	783	784	|I-IUPAC
[	784	785	|I-IUPAC
3	785	786	|I-IUPAC
-	786	787	|I-IUPAC
hydroxy	787	794	|I-IUPAC
-	794	795	|I-IUPAC
5	795	796	|I-IUPAC
-	796	797	|I-IUPAC
(	797	798	|I-IUPAC
2	798	799	|I-IUPAC
-	799	800	|I-IUPAC
quinolinyl	800	810	|I-IUPAC
)	810	811	|I-IUPAC
-	811	812	|I-IUPAC
4	812	813	|I-IUPAC
-	813	814	|I-IUPAC
isoxazolyl	814	824	|I-IUPAC
]	824	825	|I-IUPAC
propionic	825	834	|I-IUPAC
acid	835	839	|I-IUPAC
(	840	841	|O
7e	841	843	|O
)	843	844	|O
.	844	845	|O
Furthermore	846	857	|O
,	857	858	|O
(	859	860	|B-IUPAC
RS	860	862	|I-IUPAC
)	862	863	|I-IUPAC
-	863	864	|I-IUPAC
2	864	865	|I-IUPAC
-	865	866	|I-IUPAC
amino	866	871	|I-IUPAC
-	871	872	|I-IUPAC
3	872	873	|I-IUPAC
-	873	874	|I-IUPAC
[	874	875	|I-IUPAC
3	875	876	|I-IUPAC
-	876	877	|I-IUPAC
hydroxy	877	884	|I-IUPAC
-	884	885	|I-IUPAC
5	885	886	|I-IUPAC
-	886	887	|I-IUPAC
(	887	888	|I-IUPAC
2	888	889	|I-IUPAC
-	889	890	|I-IUPAC
furyl	890	895	|I-IUPAC
)	895	896	|I-IUPAC
-	896	897	|I-IUPAC
4	897	898	|I-IUPAC
-	898	899	|I-IUPAC
isoxazolyl	899	909	|I-IUPAC
]	909	910	|I-IUPAC
propionic	910	919	|I-IUPAC
acid	920	924	|I-IUPAC
(	925	926	|O
2	926	927	|O
-	927	928	|O
Fu	928	930	|O
-	930	931	|O
AMPA	931	935	|O
,	935	936	|O
7f	937	939	|O
)	939	940	|O
and	941	944	|O
its	945	948	|O
5	949	950	|B-IUPAC
-	950	951	|I-IUPAC
bromo	951	956	|I-IUPAC
-	956	957	|I-IUPAC
2	957	958	|I-IUPAC
-	958	959	|I-IUPAC
furyl	959	964	|I-IUPAC
derivative	965	975	|B-MODIFIER
(	976	977	|O
7g	977	979	|O
)	979	980	|O
were	981	985	|O
synthesized	986	997	|O
,	997	998	|O
and	999	1002	|O
(	1003	1004	|O
S	1004	1005	|O
)	1005	1006	|O
-	1006	1007	|O
2	1007	1008	|O
-	1008	1009	|O
Fu	1009	1011	|O
-	1011	1012	|O
AMPA	1012	1016	|O
(	1017	1018	|O
8	1018	1019	|O
)	1019	1020	|O
and	1021	1024	|O
(	1025	1026	|O
R	1026	1027	|O
)	1027	1028	|O
-	1028	1029	|O
2	1029	1030	|O
-	1030	1031	|O
Fu	1031	1033	|O
-	1033	1034	|O
AMPA	1034	1038	|O
(	1039	1040	|O
9	1040	1041	|O
)	1041	1042	|O
were	1043	1047	|O
prepared	1048	1056	|O
by	1057	1059	|O
semipreparative	1060	1075	|O
chiral	1076	1082	|O
HPLC	1083	1087	|O
resolution	1088	1098	|O
of	1099	1101	|O
7f	1102	1104	|O
.	1104	1105	|O
HPLC	1106	1110	|O
analyses	1111	1119	|O
and	1120	1123	|O
circular	1124	1132	|O
dichroism	1133	1142	|O
spectroscopy	1143	1155	|O
indicated	1156	1165	|O
the	1166	1169	|O
absolute	1170	1178	|O
stereochemistry	1179	1194	|O
of	1195	1197	|O
8	1198	1199	|O
and	1200	1203	|O
9	1204	1205	|O
to	1206	1208	|O
be	1209	1211	|O
S	1212	1213	|O
and	1214	1217	|O
R	1218	1219	|O
,	1219	1220	|O
respectively	1221	1233	|O
.	1233	1234	|O
This	1235	1239	|O
was	1240	1243	|O
confirmed	1244	1253	|O
by	1254	1256	|O
an	1257	1259	|O
X	1260	1261	|O
-	1261	1262	|O
ray	1262	1265	|O
crystallographic	1266	1282	|O
analysis	1283	1291	|O
of	1292	1294	|O
9	1295	1296	|O
.	1296	1297	|O
HCl	1297	1300	|O
.	1300	1301	|O
In	1302	1304	|O
receptor	1305	1313	|O
binding	1314	1321	|O
(	1322	1323	|O
IC50	1323	1327	|O
values	1328	1334	|O
)	1334	1335	|O
and	1336	1339	|O
rat	1340	1343	|O
cortical	1344	1352	|O
wedge	1353	1358	|O
electrophysiological	1359	1379	|O
(	1380	1381	|O
EC50	1381	1385	|O
values	1386	1392	|O
)	1392	1393	|O
studies	1394	1401	|O
,	1401	1402	|O
7c	1403	1405	|O
(	1406	1407	|O
IC50	1407	1411	|O
=	1412	1413	|O
5.5	1414	1417	|O
+	1418	1419	|O
/	1419	1420	|O
-	1420	1421	|O
0.6	1422	1425	|O
microM	1426	1432	|O
;	1432	1433	|O
EC50	1434	1438	|O
=	1439	1440	|O
96	1441	1443	|O
+	1444	1445	|O
/	1445	1446	|O
-	1446	1447	|O
5	1448	1449	|O
microM	1450	1456	|O
)	1456	1457	|O
was	1458	1461	|O
shown	1462	1467	|O
to	1468	1470	|O
be	1471	1473	|O
markedly	1474	1482	|O
weaker	1483	1489	|O
than	1490	1494	|O
7a	1495	1497	|O
(	1498	1499	|O
IC50	1499	1503	|O
=	1504	1505	|O
0.57	1506	1510	|O
+	1511	1512	|O
/	1512	1513	|O
-	1513	1514	|O
0.16	1515	1519	|O
microM	1520	1526	|O
;	1526	1527	|O
EC50	1528	1532	|O
=	1533	1534	|O
7.4	1535	1538	|O
+	1539	1540	|O
/	1540	1541	|O
-	1541	1542	|O
0.2	1543	1546	|O
microM	1547	1553	|O
)	1553	1554	|O
as	1555	1557	|O
an	1558	1560	|O
AMPA	1561	1565	|O
agonist	1566	1573	|O
,	1573	1574	|O
whereas	1575	1582	|O
7b	1583	1585	|O
,	1585	1586	|O
d	1586	1587	|O
,	1587	1588	|O
e	1588	1589	|O
were	1590	1594	|O
inactive	1595	1603	|O
.	1603	1604	|O
The	1605	1608	|O
very	1609	1613	|O
potent	1614	1620	|O
AMPA	1621	1625	|O
agonist	1626	1633	|O
effect	1634	1640	|O
of	1641	1643	|O
7f	1644	1646	|O
(	1647	1648	|O
IC50	1648	1652	|O
=	1653	1654	|O
0.15	1655	1659	|O
+	1660	1661	|O
/	1661	1662	|O
-	1662	1663	|O
0.03	1664	1668	|O
microM	1669	1675	|O
;	1675	1676	|O
EC50	1677	1681	|O
=	1682	1683	|O
1.7	1684	1687	|O
+	1688	1689	|O
/	1689	1690	|O
-	1690	1691	|O
0	1692	1693	|O
.	1693	1694	|O
2	1695	1696	|O
microM	1697	1703	|O
)	1703	1704	|O
was	1705	1708	|O
shown	1709	1714	|O
to	1715	1717	|O
reside	1718	1724	|O
exclusively	1725	1736	|O
in	1737	1739	|O
8	1740	1741	|O
(	1742	1743	|O
IC50	1743	1747	|O
=	1748	1749	|O
0.11	1750	1754	|O
+	1755	1756	|O
/	1756	1757	|O
-	1757	1758	|O
0.01	1759	1763	|O
microM	1764	1770	|O
;	1770	1771	|O
EC50	1772	1776	|O
=	1777	1778	|O
0.71	1779	1783	|O
+	1784	1785	|O
/	1785	1786	|O
-	1786	1787	|O
0.11	1788	1792	|O
microM	1793	1799	|O
)	1799	1800	|O
,	1800	1801	|O
whereas	1802	1809	|O
9	1810	1811	|O
did	1812	1815	|O
not	1816	1819	|O
interact	1820	1828	|O
significantly	1829	1842	|O
with	1843	1847	|O
AMPA	1848	1852	|O
receptors	1853	1862	|O
,	1862	1863	|O
either	1864	1870	|O
as	1871	1873	|O
an	1874	1876	|O
agonist	1877	1884	|O
or	1885	1887	|O
as	1888	1890	|O
an	1891	1893	|O
antagonist	1894	1904	|O
.	1904	1905	|O
8	1906	1907	|O
was	1908	1911	|O
shown	1912	1917	|O
to	1918	1920	|O
be	1921	1923	|O
photochemically	1924	1939	|O
active	1940	1946	|O
and	1947	1950	|O
is	1951	1953	|O
a	1954	1955	|O
potential	1956	1965	|O
photoaffinity	1966	1979	|O
label	1980	1985	|O
for	1986	1989	|O
the	1990	1993	|O
recognition	1994	2005	|O
site	2006	2010	|O
of	2011	2013	|O
the	2014	2017	|O
AMPA	2018	2022	|O
receptors	2023	2032	|O
.	2032	2033	|O
Compound	2034	2042	|O
7g	2043	2045	|O
turned	2046	2052	|O
out	2053	2056	|O
to	2057	2059	|O
be	2060	2062	|O
a	2063	2064	|O
very	2065	2069	|O
weak	2070	2074	|O
AMPA	2075	2079	|O
receptor	2080	2088	|O
agonist	2089	2096	|O
(	2097	2098	|O
IC50	2098	2102	|O
=	2103	2104	|O
12	2105	2107	|O
+	2108	2109	|O
/	2109	2110	|O
-	2110	2111	|O
0.7	2112	2115	|O
microM	2116	2122	|O
;	2122	2123	|O
EC50	2124	2128	|O
=	2129	2130	|O
160	2131	2134	|O
+	2135	2136	|O
/	2136	2137	|O
-	2137	2138	|O
15	2139	2141	|O
microM	2142	2148	|O
)	2148	2149	|O
.	2149	2150	|O
None	2151	2155	|O
of	2156	2158	|O
these	2159	2164	|O
new	2165	2168	|O
compounds	2169	2178	|O
showed	2179	2185	|O
detectable	2186	2196	|O
effects	2197	2204	|O
at	2205	2207	|O
N	2208	2209	|B-IUPAC
-	2209	2210	|I-IUPAC
methyl	2210	2216	|I-IUPAC
-	2216	2217	|I-IUPAC
d	2217	2218	|I-IUPAC
-	2218	2219	|I-IUPAC
aspartic	2219	2227	|I-IUPAC
acid	2228	2232	|I-IUPAC
(	2233	2234	|O
NMDA	2234	2238	|O
)	2238	2239	|O
or	2240	2242	|O
kainic	2243	2249	|O
acid	2250	2254	|O
receptors	2255	2264	|O
in	2265	2267	|O
vitro	2268	2273	|O
.	2273	2274	|O
The	2275	2278	|O
present	2279	2286	|O
studies	2287	2294	|O
have	2295	2299	|O
emphasized	2300	2310	|O
that	2311	2315	|O
the	2316	2319	|O
presence	2320	2328	|O
of	2329	2331	|O
a	2332	2333	|O
heteroatom	2334	2344	|O
in	2345	2347	|O
the	2348	2351	|O
2	2352	2353	|O
-	2353	2354	|O
position	2354	2362	|O
of	2363	2365	|O
the	2366	2369	|O
heteroaryl	2370	2380	|O
5	2381	2382	|O
-	2382	2383	|O
substituent	2383	2394	|O
greatly	2395	2402	|O
facilitates	2403	2414	|O
AMPA	2415	2419	|O
receptor	2420	2428	|O
agonist	2429	2436	|O
activity	2437	2445	|O
.	2445	2446	|O

### abstracts938.txt
Biological	0	10	|O
tests	11	16	|O
indicate	17	25	|O
hexahydro	26	35	|B-IUPAC
-	35	36	|I-IUPAC
1H	36	38	|I-IUPAC
-	38	39	|I-IUPAC
indeno	39	45	|I-IUPAC
[	45	46	|I-IUPAC
1,2	46	49	|I-IUPAC
-	49	50	|I-IUPAC
b	50	51	|I-IUPAC
]	51	52	|I-IUPAC
pyridines	52	61	|I-IUPAC
to	62	64	|O
be	65	67	|O
potential	68	77	|O
human	78	83	|O
antidepressants	84	99	|O
with	100	104	|O
additional	105	115	|O
stimulating	116	127	|O
properties	128	138	|O
.	138	139	|O
Two	140	143	|O
diastereomeric	144	158	|O
series	159	165	|O
with	166	170	|O
H4a	171	174	|O
,	174	175	|O
H5	175	177	|O
-	177	178	|O
trans	178	183	|O
,	183	184	|O
H4a	184	187	|O
,	187	188	|O
H9b	188	191	|O
-	191	192	|O
cis	192	195	|O
and	196	199	|O
H4a	200	203	|O
,	203	204	|O
H5	204	206	|O
-	206	207	|O
cis	207	210	|O
,	210	211	|O
H4a	211	214	|O
,	214	215	|O
H9b	215	218	|O
-	218	219	|O
cis	219	222	|O
configurations	223	237	|O
have	238	242	|O
been	243	247	|O
tested	248	254	|O
biologically	255	267	|O
.	267	268	|O
The	269	272	|O
results	273	280	|O
revealed	281	289	|O
that	290	294	|O
the	295	298	|O
H4a	299	302	|O
,	302	303	|O
H5	303	305	|O
-	305	306	|O
cis	306	309	|O
,	309	310	|O
H4a	310	313	|O
,	313	314	|O
H9b	314	317	|O
-	317	318	|O
cis	318	321	|O
series	322	328	|O
and	329	332	|O
the	333	336	|O
ortho	337	342	|O
-	342	343	|O
substituted	343	354	|O
5	355	356	|O
-	356	357	|O
phenyl	357	363	|O
H4a	364	367	|O
,	367	368	|O
H5	368	370	|O
-	370	371	|O
trans	371	376	|O
,	376	377	|O
H4a	377	380	|O
,	380	381	|O
H9b	381	384	|O
-	384	385	|O
cis	385	388	|O
compounds	389	398	|O
lack	399	403	|O
activity	404	412	|O
.	412	413	|O
Neither	414	421	|O
the	422	425	|O
conformation	426	438	|O
with	439	443	|O
lowest	444	450	|O
potential	451	460	|O
energy	461	467	|O
nor	468	471	|O
any	472	475	|O
other	476	481	|O
electron	482	490	|O
-	490	491	|O
derived	491	498	|O
parameter	499	508	|O
correlate	509	518	|O
with	519	523	|O
these	524	529	|O
data	530	534	|O
.	534	535	|O
The	536	539	|O
only	540	544	|O
relevant	545	553	|O
difference	554	564	|O
between	565	572	|O
the	573	576	|O
active	577	583	|O
and	584	587	|O
the	588	591	|O
inactive	592	600	|O
compounds	601	610	|O
detected	611	619	|O
thus	620	624	|O
far	625	628	|O
is	629	631	|O
the	632	635	|O
rotational	636	646	|O
barrier	647	654	|O
of	655	657	|O
the	658	661	|O
phenyl	662	668	|O
in	669	671	|O
the	672	675	|O
5	676	677	|O
-	677	678	|O
position	678	686	|O
.	686	687	|O
The	688	691	|O
conclusion	692	702	|O
was	703	706	|O
reached	707	714	|O
that	715	719	|O
certain	720	727	|O
conformations	728	741	|O
,	741	742	|O
which	743	748	|O
do	749	751	|O
not	752	755	|O
resemble	756	764	|O
those	765	770	|O
of	771	773	|O
lowest	774	780	|O
potential	781	790	|O
energy	791	797	|O
,	797	798	|O
cannot	799	805	|O
be	806	808	|O
adopted	809	816	|O
by	817	819	|O
the	820	823	|O
inactive	824	832	|O
compounds	833	842	|O
.	842	843	|O
Therefore	844	853	|O
,	853	854	|O
the	855	858	|O
interaction	859	870	|O
of	871	873	|O
the	874	877	|O
drug	878	882	|O
with	883	887	|O
the	888	891	|O
binding	892	899	|O
site	900	904	|O
,	904	905	|O
responsible	906	917	|O
for	918	921	|O
its	922	925	|O
biological	926	936	|O
activity	937	945	|O
,	945	946	|O
appears	947	954	|O
to	955	957	|O
be	958	960	|O
governed	961	969	|O
by	970	972	|O
a	973	974	|O
dynamic	975	982	|O
process	983	990	|O
.	990	991	|O
This	992	996	|O
process	997	1004	|O
is	1005	1007	|O
characterized	1008	1021	|O
by	1022	1024	|O
a	1025	1026	|O
transformation	1027	1041	|O
of	1042	1044	|O
the	1045	1048	|O
conformation	1049	1061	|O
of	1062	1064	|O
lowest	1065	1071	|O
potential	1072	1081	|O
energy	1082	1088	|O
to	1089	1091	|O
one	1092	1095	|O
with	1096	1100	|O
an	1101	1103	|O
energy	1104	1110	|O
content	1111	1118	|O
above	1119	1124	|O
the	1125	1128	|O
minimum	1129	1136	|O
.	1136	1137	|O

### abstracts4904.txt
A	0	1	|O
number	2	8	|O
of	9	11	|O
4,7	12	15	|B-MODIFIER
-	15	16	|I-MODIFIER
disubstituted	16	29	|I-MODIFIER
benzopyran	30	40	|B-IUPAC
-	40	41	|I-IUPAC
2	41	42	|I-IUPAC
-	42	43	|I-IUPAC
ones	43	47	|I-IUPAC
were	48	52	|O
synthesized	53	64	|O
and	65	68	|O
evaluated	69	78	|O
for	79	82	|O
crude	83	88	|O
rat	89	92	|O
lens	93	97	|O
aldose	98	104	|O
reductase	105	114	|O
inhibitory	115	125	|O
activity	126	134	|O
.	134	135	|O
Substituents	136	148	|O
on	149	151	|O
position	152	160	|O
4	161	162	|O
included	163	171	|O
CH3	172	175	|O
,	175	176	|O
CO2H	177	181	|O
,	181	182	|O
CH2CO2H	183	190	|O
,	190	191	|O
CH	192	194	|O
=	195	196	|O
CHCO2H	197	203	|O
,	203	204	|O
and	205	208	|O
CH2CH2CO2H	209	219	|O
.	219	220	|O
The	221	224	|O
aromatic	225	233	|O
substituents	234	246	|O
included	247	255	|O
OH	256	258	|O
,	258	259	|O
OCH3	260	264	|O
,	264	265	|O
OCOCH3	266	272	|O
,	272	273	|O
CH2CH3	274	280	|O
,	280	281	|O
and	282	285	|O
Cl	286	288	|O
.	288	289	|O
Also	290	294	|O
included	295	303	|O
in	304	306	|O
the	307	310	|O
study	311	316	|O
were	317	321	|O
3	322	323	|B-PARTIUPAC
-	323	324	|I-PARTIUPAC
oxo	324	327	|I-PARTIUPAC
-	327	328	|I-PARTIUPAC
3H	328	330	|I-PARTIUPAC
-	330	331	|I-PARTIUPAC
naphtho	331	338	|I-PARTIUPAC
[	338	339	|I-PARTIUPAC
2,1	339	342	|I-PARTIUPAC
-	342	343	|I-PARTIUPAC
b	343	344	|I-PARTIUPAC
]	344	345	|I-PARTIUPAC
pyran	345	350	|I-PARTIUPAC
-	350	351	|I-PARTIUPAC
1	351	352	|I-PARTIUPAC
-	352	353	|I-PARTIUPAC
acetic	353	359	|I-PARTIUPAC
,	359	360	|O
2	361	362	|B-PARTIUPAC
-	362	363	|I-PARTIUPAC
oxo	363	366	|I-PARTIUPAC
-	366	367	|I-PARTIUPAC
2H	367	369	|I-PARTIUPAC
-	369	370	|I-PARTIUPAC
naphtho	370	377	|I-PARTIUPAC
[	377	378	|I-PARTIUPAC
1,2	378	381	|I-PARTIUPAC
-	381	382	|I-PARTIUPAC
b	382	383	|I-PARTIUPAC
]	383	384	|I-PARTIUPAC
pyran	384	389	|I-PARTIUPAC
-	389	390	|I-PARTIUPAC
4	390	391	|I-PARTIUPAC
-	391	392	|I-PARTIUPAC
acetic	392	398	|I-PARTIUPAC
,	398	399	|O
and	400	403	|O
1	404	405	|B-IUPAC
-	405	406	|I-IUPAC
naphthylacetic	406	420	|I-IUPAC
acids	421	426	|I-IUPAC
.	426	427	|O
The	428	431	|O
benzopyran	432	442	|O
and	443	446	|O
naphthopyran	447	459	|O
derivatives	460	471	|O
were	472	476	|O
prepared	477	485	|O
by	486	488	|O
the	489	492	|O
classical	493	502	|O
von	503	506	|O
Pechmann	507	515	|O
reaction	516	524	|O
.	524	525	|O
General	526	533	|O
structure	534	543	|O
-	543	544	|O
activity	544	552	|O
relationships	553	566	|O
reveal	567	573	|O
that	574	578	|O
optimal	579	586	|O
enzyme	587	593	|O
inhibitory	594	604	|O
activity	605	613	|O
is	614	616	|O
displayed	617	626	|O
by	627	629	|O
those	630	635	|O
compounds	636	645	|O
possessing	646	656	|O
the	657	660	|O
acetic	661	667	|B-IUPAC
acid	668	672	|I-IUPAC
moiety	673	679	|B-MODIFIER
.	679	680	|O
For	681	684	|O
example	685	692	|O
,	692	693	|O
the	694	697	|O
most	698	702	|O
potent	703	709	|O
derivative	710	720	|O
,	720	721	|O
3	722	723	|B-IUPAC
-	723	724	|I-IUPAC
oxo	724	727	|I-IUPAC
-	727	728	|I-IUPAC
3H	728	730	|I-IUPAC
-	730	731	|I-IUPAC
naphtho	731	738	|I-IUPAC
[	738	739	|I-IUPAC
2,1	739	742	|I-IUPAC
-	742	743	|I-IUPAC
b	743	744	|I-IUPAC
]	744	745	|I-IUPAC
pyran	745	750	|I-IUPAC
-	750	751	|I-IUPAC
1	751	752	|I-IUPAC
-	752	753	|I-IUPAC
acetic	753	759	|I-IUPAC
acid	760	764	|I-IUPAC
with	765	769	|O
an	770	772	|O
IC50	773	777	|O
of	778	780	|O
0.020	781	786	|O
microM	787	793	|O
,	793	794	|O
is	795	797	|O
as	798	800	|O
potent	801	807	|O
as	808	810	|O
sorbinil	811	819	|O
(	820	821	|O
IC50	821	825	|O
=	826	827	|O
0.017	828	833	|O
microM	834	840	|O
)	840	841	|O
in	842	844	|O
the	845	848	|O
crude	849	854	|O
rat	855	858	|O
lens	859	863	|O
aldose	864	870	|O
reductase	871	880	|O
assay	881	886	|O
.	886	887	|O

### abstracts1327.txt
Modification	0	12	|O
of	13	15	|O
the	16	19	|O
benzodiazepine	20	34	|O
(	35	36	|O
BZ	36	38	|O
)	38	39	|O
receptor	40	48	|O
binding	49	56	|O
template	57	65	|O
2	66	67	|B-IUPAC
-	67	68	|I-IUPAC
aryl	68	72	|I-IUPAC
[	72	73	|I-IUPAC
1,2,4	73	78	|I-IUPAC
]	78	79	|I-IUPAC
triazolo	79	87	|I-IUPAC
[	87	88	|I-IUPAC
1,5	88	91	|I-IUPAC
-	91	92	|I-IUPAC
c	92	93	|I-IUPAC
]	93	94	|I-IUPAC
quinazolin	94	104	|I-IUPAC
-	104	105	|I-IUPAC
5	105	106	|I-IUPAC
(	106	107	|I-IUPAC
6H	107	109	|I-IUPAC
)	109	110	|I-IUPAC
-	110	111	|I-IUPAC
one	111	114	|I-IUPAC
by	115	117	|O
replacement	118	129	|O
of	130	132	|O
the	133	136	|O
annelated	137	146	|O
benzene	147	154	|O
ring	155	159	|O
with	160	164	|O
various	165	172	|O
alicyclic	173	182	|O
and	183	186	|O
heterocyclic	187	199	|O
moieties	200	208	|O
led	209	212	|O
to	213	215	|O
novel	216	221	|O
structures	222	232	|O
with	233	237	|O
potent	238	244	|O
BZ	245	247	|O
receptor	248	256	|O
binding	257	264	|O
affinity	265	273	|O
.	273	274	|O
High	275	279	|O
affinity	280	288	|O
was	289	292	|O
found	293	298	|O
in	299	301	|O
some	302	306	|O
cycloalkyl	307	317	|B-MODIFIER
-	317	318	|I-MODIFIER
annelated	318	327	|I-MODIFIER
[	328	329	|B-IUPAC
1,2,4	329	334	|I-IUPAC
]	334	335	|I-IUPAC
triazolo	335	343	|I-IUPAC
[	343	344	|I-IUPAC
1,5	344	347	|I-IUPAC
-	347	348	|I-IUPAC
c	348	349	|I-IUPAC
]	349	350	|I-IUPAC
pyrimidin	350	359	|I-IUPAC
-	359	360	|I-IUPAC
5	360	361	|I-IUPAC
(	361	362	|I-IUPAC
6H	362	364	|I-IUPAC
)	364	365	|I-IUPAC
-	365	366	|I-IUPAC
ones	366	370	|I-IUPAC
and	371	374	|O
in	375	377	|O
some	378	382	|O
7,8,9,10	383	391	|B-IUPAC
-	391	392	|I-IUPAC
tetrahydropyrido	392	408	|I-IUPAC
[	408	409	|I-IUPAC
3,4	409	412	|I-IUPAC
-	412	413	|I-IUPAC
e	413	414	|I-IUPAC
]	414	415	|I-IUPAC
[	415	416	|I-IUPAC
1,2,4	416	421	|I-IUPAC
]	421	422	|I-IUPAC
triazolo	422	430	|I-IUPAC
[	430	431	|I-IUPAC
1,5	431	434	|I-IUPAC
-	434	435	|I-IUPAC
c	435	436	|I-IUPAC
]	436	437	|I-IUPAC
pyrimidin	437	446	|I-IUPAC
-	446	447	|I-IUPAC
5	448	449	|I-IUPAC
(	449	450	|I-IUPAC
6H	450	452	|I-IUPAC
)	452	453	|I-IUPAC
-	453	454	|I-IUPAC
ones	454	458	|I-IUPAC
,	458	459	|O
in	460	462	|O
which	463	468	|O
the	469	472	|O
degree	473	479	|O
of	480	482	|O
activity	483	491	|O
was	492	495	|O
strongly	496	504	|O
dependent	505	514	|O
on	515	517	|O
the	518	521	|O
N	522	523	|O
-	523	524	|O
substituent	524	535	|O
in	536	538	|O
the	539	542	|O
9	543	544	|O
-	544	545	|O
position	545	553	|O
.	553	554	|O
Nine	555	559	|O
compounds	560	569	|O
with	570	574	|O
BZ	575	577	|O
receptor	578	586	|O
IC50	587	591	|O
binding	592	599	|O
affinity	600	608	|O
values	609	615	|O
equal	616	621	|O
or	622	624	|O
superior	625	633	|O
to	634	636	|O
diazepam	637	645	|O
were	646	650	|O
evaluated	651	660	|O
in	661	663	|O
secondary	664	673	|O
screening	674	683	|O
.	683	684	|O
One	685	688	|O
of	689	691	|O
these	692	697	|O
,	697	698	|O
9	699	700	|B-IUPAC
-	700	701	|I-IUPAC
benzyl	701	707	|I-IUPAC
-	707	708	|I-IUPAC
2	708	709	|I-IUPAC
-	709	710	|I-IUPAC
phenyl	710	716	|I-IUPAC
-	716	717	|I-IUPAC
7,8,9,10	717	725	|I-IUPAC
-	725	726	|I-IUPAC
tetrahydropyrido	726	742	|I-IUPAC
[	742	743	|I-IUPAC
3,4	743	746	|I-IUPAC
-	746	747	|I-IUPAC
e	747	748	|I-IUPAC
]	748	749	|I-IUPAC
[	750	751	|I-IUPAC
1,2,4	751	756	|I-IUPAC
]	756	757	|I-IUPAC
triazolo	757	765	|I-IUPAC
[	765	766	|I-IUPAC
1,5	766	769	|I-IUPAC
-	769	770	|I-IUPAC
c	770	771	|I-IUPAC
]	771	772	|I-IUPAC
pyrimidin	772	781	|I-IUPAC
-	781	782	|I-IUPAC
5	782	783	|I-IUPAC
(	783	784	|I-IUPAC
6H	784	786	|I-IUPAC
)	786	787	|I-IUPAC
-	787	788	|I-IUPAC
one	788	791	|I-IUPAC
,	791	792	|O
showed	793	799	|O
good	800	804	|O
activity	805	813	|O
in	814	816	|O
rats	817	821	|O
as	822	824	|O
a	825	826	|O
potential	827	836	|O
anxiolytic	837	847	|O
agent	848	853	|O
without	854	861	|O
sedative	862	870	|O
liability	871	880	|O
.	880	881	|O
However	882	889	|O
,	889	890	|O
it	891	893	|O
increased	894	903	|O
the	904	907	|O
rotorod	908	915	|O
deficit	916	923	|O
produced	924	932	|O
by	933	935	|O
ethanol	936	943	|O
at	944	946	|O
anxiolytic	947	957	|O
doses	958	963	|O
,	963	964	|O
an	965	967	|O
indication	968	978	|O
of	979	981	|O
alcohol	982	989	|O
interaction	990	1001	|O
.	1001	1002	|O
Thus	1003	1007	|O
,	1007	1008	|O
none	1009	1013	|O
of	1014	1016	|O
the	1017	1020	|O
compounds	1021	1030	|O
showed	1031	1037	|O
an	1038	1040	|O
advantage	1041	1050	|O
over	1051	1055	|O
CGS	1056	1059	|O
9896	1060	1064	|O
(	1065	1066	|O
Yokoyama	1066	1074	|O
et	1075	1077	|O
al.	1078	1081	|O
J	1082	1083	|O
.	1083	1084	|O
Med.	1085	1089	|O
Chem.	1090	1095	|O
1982	1096	1100	|O
,	1100	1101	|O
25	1102	1104	|O
,	1104	1105	|O
337-339	1106	1113	|O
)	1113	1114	|O
,	1114	1115	|O
which	1116	1121	|O
is	1122	1124	|O
free	1125	1129	|O
of	1130	1132	|O
sedative	1133	1141	|O
and	1142	1145	|O
alcohol	1146	1153	|O
interaction	1154	1165	|O
potential	1166	1175	|O
as	1176	1178	|O
measured	1179	1187	|O
by	1188	1190	|O
the	1191	1194	|O
test	1195	1199	|O
procedures	1200	1210	|O
described	1211	1220	|O
.	1220	1221	|O

### abstracts98.txt
Appropriately	0	13	|O
substituted	14	25	|O
2,3	26	29	|B-IUPAC
-	29	30	|I-IUPAC
dihydro	30	37	|I-IUPAC
-	37	38	|I-IUPAC
7H	38	40	|I-IUPAC
-	40	41	|I-IUPAC
thiazolo	41	49	|I-IUPAC
[	49	50	|I-IUPAC
3,2	50	53	|I-IUPAC
-	53	54	|I-IUPAC
a	54	55	|I-IUPAC
]	55	56	|I-IUPAC
pyrimidin	56	65	|I-IUPAC
-	65	66	|I-IUPAC
7	66	67	|I-IUPAC
-	67	68	|I-IUPAC
ones	68	72	|I-IUPAC
9-12	73	77	|O
and	78	81	|O
18	82	84	|O
were	85	89	|O
considered	90	100	|O
as	101	103	|O
annulated	104	113	|O
analogues	114	123	|O
of	124	126	|O
HEPT	127	131	|O
(	132	133	|O
1	133	134	|B-IUPAC
-	134	135	|I-IUPAC
[	135	136	|I-IUPAC
(	136	137	|I-IUPAC
2	137	138	|I-IUPAC
-	138	139	|I-IUPAC
hydroxyethoxy	139	152	|I-IUPAC
)	152	153	|I-IUPAC
methyl	153	159	|I-IUPAC
]	159	160	|I-IUPAC
-	160	161	|I-IUPAC
6	161	162	|I-IUPAC
-	162	163	|I-IUPAC
(	163	164	|I-IUPAC
phenylthio	164	174	|I-IUPAC
)	174	175	|I-IUPAC
-	175	176	|I-IUPAC
thymine	176	183	|I-IUPAC
)	183	184	|O
,	184	185	|O
and	186	189	|O
some	190	194	|O
of	195	197	|O
these	198	203	|O
compounds	204	213	|O
were	214	218	|O
also	219	223	|O
found	224	229	|O
active	230	236	|O
against	237	244	|O
HIV	245	248	|O
-	248	249	|O
1	249	250	|O
,	250	251	|O
the	252	255	|O
most	256	260	|O
active	261	267	|O
one	268	271	|O
being	272	277	|O
2,3	278	281	|B-IUPAC
-	281	282	|I-IUPAC
dihydro	282	289	|I-IUPAC
-	289	290	|I-IUPAC
5	290	291	|I-IUPAC
-	291	292	|I-IUPAC
[	292	293	|I-IUPAC
(	293	294	|I-IUPAC
3,5	294	297	|I-IUPAC
-	297	298	|I-IUPAC
dimethylphenyl	298	312	|I-IUPAC
)	312	313	|I-IUPAC
methyl	313	319	|I-IUPAC
]	319	320	|I-IUPAC
-	320	321	|I-IUPAC
3	321	322	|I-IUPAC
-	322	323	|I-IUPAC
ethoxy	323	329	|I-IUPAC
-	329	330	|I-IUPAC
6	330	331	|I-IUPAC
-	331	332	|I-IUPAC
ethyl	332	337	|I-IUPAC
-	337	338	|I-IUPAC
7H	338	340	|I-IUPAC
-	340	341	|I-IUPAC
thiazolo	342	350	|I-IUPAC
[	350	351	|I-IUPAC
3,2	351	354	|I-IUPAC
-	354	355	|I-IUPAC
a	355	356	|I-IUPAC
]	356	357	|I-IUPAC
pyrimidin	357	366	|I-IUPAC
-	366	367	|I-IUPAC
7	367	368	|I-IUPAC
-	368	369	|I-IUPAC
one	369	372	|I-IUPAC
(	373	374	|O
10b	374	377	|O
)	377	378	|O
.	378	379	|O
S	380	381	|O
-	381	382	|O
Alkylation	382	392	|O
of	393	395	|O
5	396	397	|B-IUPAC
-	397	398	|I-IUPAC
alkyl	398	403	|I-IUPAC
-	403	404	|I-IUPAC
6	404	405	|I-IUPAC
-	405	406	|I-IUPAC
(	406	407	|I-IUPAC
arylmethyl	407	417	|I-IUPAC
)	417	418	|I-IUPAC
-	418	419	|I-IUPAC
2	419	420	|I-IUPAC
-	420	421	|I-IUPAC
thiouracils	421	432	|I-IUPAC
1-4	433	436	|O
was	437	440	|O
performed	441	450	|O
with	451	455	|O
2	456	457	|B-IUPAC
-	457	458	|I-IUPAC
bromoacetaldehyde	458	475	|I-IUPAC
acetals	476	483	|I-IUPAC
to	484	486	|O
furnish	487	494	|O
the	495	498	|O
S	499	500	|B-IUPAC
-	500	501	|I-IUPAC
[	501	502	|I-IUPAC
bis	502	505	|I-IUPAC
(	505	506	|I-IUPAC
alkoxy	506	512	|I-IUPAC
)	512	513	|I-IUPAC
ethyl	513	518	|I-IUPAC
]	518	519	|I-IUPAC
derivatives	520	531	|B-MODIFIER
5-8	532	535	|O
and	536	539	|O
with	540	544	|O
allyl	545	550	|O
bromide	551	558	|O
to	559	561	|O
furnish	562	569	|O
S	570	571	|B-IUPAC
-	571	572	|I-IUPAC
allyl	572	577	|I-IUPAC
derivatives	578	589	|B-MODIFIER
17	590	592	|O
.	592	593	|O
The	594	597	|O
target	598	604	|O
compounds	605	614	|O
9-12	615	619	|O
were	620	624	|O
obtained	625	633	|O
by	634	636	|O
an	637	639	|O
N1	640	642	|O
regioselective	643	657	|O
intramolecular	658	672	|O
cyclization	673	684	|O
reaction	685	693	|O
of	694	696	|O
silylated	697	706	|O
5-8	707	710	|O
using	711	716	|O
trimethylsilyl	717	731	|O
trifluoromethanesulfonate	732	757	|O
(	758	759	|O
TMS	759	762	|O
triflate	763	771	|O
)	771	772	|O
as	773	775	|O
the	776	779	|O
catalyst	780	788	|O
.	788	789	|O
Treatment	790	799	|O
of	800	802	|O
the	803	806	|O
S	807	808	|B-IUPAC
-	808	809	|I-IUPAC
allyl	809	814	|I-IUPAC
derivatives	815	826	|B-MODIFIER
17	827	829	|O
with	830	834	|O
bromine	835	842	|O
in	843	845	|O
dry	846	849	|O
methylene	850	859	|O
chloride	860	868	|O
afforded	869	877	|O
the	878	881	|O
3	882	883	|B-IUPAC
-	883	884	|I-IUPAC
(	884	885	|I-IUPAC
bromomethyl	885	896	|I-IUPAC
)	896	897	|I-IUPAC
derivatives	898	909	|B-MODIFIER
18	910	912	|O
.	912	913	|O

### abstracts1717.txt
A	0	1	|O
novel	2	7	|O
series	8	14	|O
of	15	17	|O
nonpeptide	18	28	|O
CCK	29	32	|O
(	32	33	|O
2	33	34	|O
)	34	35	|O
receptor	36	44	|O
antagonists	45	56	|O
has	57	60	|O
been	61	65	|O
prepared	66	74	|O
,	74	75	|O
in	76	78	|O
which	79	84	|O
2,7	85	88	|B-IUPAC
-	88	89	|I-IUPAC
dioxo	89	94	|I-IUPAC
-	94	95	|I-IUPAC
2,3,4,5,6,7	95	106	|I-IUPAC
-	106	107	|I-IUPAC
hexahydro	107	116	|I-IUPAC
-	116	117	|I-IUPAC
1H	117	119	|I-IUPAC
-	119	120	|I-IUPAC
benzo	120	125	|I-IUPAC
[	125	126	|I-IUPAC
h	126	127	|I-IUPAC
]	127	128	|I-IUPAC
[	128	129	|I-IUPAC
1	129	130	|I-IUPAC
,	130	131	|I-IUPAC
4	132	133	|I-IUPAC
]	133	134	|I-IUPAC
diazonine	134	143	|I-IUPAC
(	144	145	|O
5	145	146	|O
)	146	147	|O
was	148	151	|O
used	152	156	|O
as	157	159	|O
a	160	161	|O
chemical	162	170	|O
template	171	179	|O
.	179	180	|O
This	181	185	|O
uncommon	186	194	|O
ring	195	199	|O
system	200	206	|O
was	207	210	|O
obtained	211	219	|O
in	220	222	|O
a	223	224	|O
highly	225	231	|O
substituted	232	243	|O
form	244	248	|O
and	249	252	|O
in	253	255	|O
high	256	260	|O
yield	261	266	|O
by	267	269	|O
ozonolysis	270	280	|O
of	281	283	|O
the	284	287	|O
enamine	288	295	|O
bond	296	300	|O
of	301	303	|O
1,2,3,4	304	311	|B-IUPAC
-	311	312	|I-IUPAC
tetrahydro	312	322	|I-IUPAC
-	322	323	|I-IUPAC
9H	323	325	|I-IUPAC
-	325	326	|I-IUPAC
pyrido	326	332	|I-IUPAC
[	332	333	|I-IUPAC
3	333	334	|I-IUPAC
,	334	335	|I-IUPAC
4	336	337	|I-IUPAC
-	337	338	|I-IUPAC
b	338	339	|I-IUPAC
]	339	340	|I-IUPAC
indole	340	346	|I-IUPAC
derivatives	347	358	|B-MODIFIER
(	359	360	|O
4	360	361	|O
)	361	362	|O
,	362	363	|O
in	364	366	|O
which	367	372	|O
the	373	376	|O
configuration	377	390	|O
of	391	393	|O
the	394	397	|O
substituents	398	410	|O
was	411	414	|O
established	415	426	|O
stereoselectively	427	444	|O
via	445	448	|O
the	449	452	|O
Pictet	453	459	|O
-	459	460	|O
Spengler	460	468	|O
reaction	469	477	|O
.	477	478	|O
Further	479	486	|O
structural	487	497	|O
manipulation	498	510	|O
was	511	514	|O
guided	515	521	|O
by	522	524	|O
molecular	525	534	|O
modeling	535	543	|O
through	544	551	|O
comparison	552	562	|O
of	563	565	|O
fieldpoint	566	576	|O
-	576	577	|O
based	577	582	|O
structures	583	593	|O
of	594	596	|O
candidate	597	606	|O
compounds	607	616	|O
with	617	621	|O
a	622	623	|O
selected	624	632	|O
low	633	636	|O
-	636	637	|O
energy	637	643	|O
conformation	644	656	|O
of	657	659	|O
the	660	663	|O
representative	664	678	|O
CCK	679	682	|O
(	682	683	|O
2	683	684	|O
)	684	685	|O
receptor	686	694	|O
antagonist	695	705	|O
5	706	707	|B-IUPAC
-	707	708	|I-IUPAC
[	708	709	|I-IUPAC
[	709	710	|I-IUPAC
[	710	711	|I-IUPAC
(	711	712	|I-IUPAC
1S	712	714	|I-IUPAC
)	714	715	|I-IUPAC
-	715	716	|I-IUPAC
[	716	717	|I-IUPAC
[	717	718	|I-IUPAC
(	718	719	|I-IUPAC
3	719	720	|I-IUPAC
,	720	721	|I-IUPAC
5	722	723	|I-IUPAC
-	723	724	|I-IUPAC
dicarboxyphenyl	724	739	|I-IUPAC
)	739	740	|I-IUPAC
amino	740	745	|I-IUPAC
]	745	746	|I-IUPAC
carbonyl	746	754	|I-IUPAC
]	754	755	|I-IUPAC
-	755	756	|I-IUPAC
2	756	757	|I-IUPAC
-	757	758	|I-IUPAC
phenylethyl	758	769	|I-IUPAC
]	769	770	|I-IUPAC
amino	770	775	|I-IUPAC
]	775	776	|I-IUPAC
carbonyl	776	784	|I-IUPAC
]	784	785	|I-IUPAC
-	785	786	|I-IUPAC
6	786	787	|I-IUPAC
-	787	788	|I-IUPAC
[	789	790	|I-IUPAC
[	790	791	|I-IUPAC
(	791	792	|I-IUPAC
1	793	794	|I-IUPAC
-	794	795	|I-IUPAC
adamantylmethyl	795	810	|I-IUPAC
)	810	811	|I-IUPAC
amino	811	816	|I-IUPAC
]	816	817	|I-IUPAC
carbonyl	817	825	|I-IUPAC
]	825	826	|I-IUPAC
indole	826	832	|I-IUPAC
(	833	834	|O
JB93182	834	841	|O
(	842	843	|O
3	843	844	|O
)	844	845	|O
)	845	846	|O
.	846	847	|O
By	848	850	|O
this	851	855	|O
approach	856	864	|O
compounds	865	874	|O
such	875	879	|O
as	880	882	|O
(	883	884	|B-IUPAC
3R	884	886	|I-IUPAC
,	886	887	|I-IUPAC
5S	888	890	|I-IUPAC
)	890	891	|I-IUPAC
-	891	892	|I-IUPAC
4	892	893	|I-IUPAC
-	893	894	|I-IUPAC
acetyl	894	900	|I-IUPAC
-	900	901	|I-IUPAC
3	901	902	|I-IUPAC
-	902	903	|I-IUPAC
(	903	904	|I-IUPAC
1	904	905	|I-IUPAC
-	905	906	|I-IUPAC
adamantyl	906	915	|I-IUPAC
)	915	916	|I-IUPAC
methyl	916	922	|I-IUPAC
-	922	923	|I-IUPAC
1	923	924	|I-IUPAC
-	924	925	|I-IUPAC
(	925	926	|I-IUPAC
2	926	927	|I-IUPAC
-	927	928	|I-IUPAC
chlorobenzyl	928	940	|I-IUPAC
)	940	941	|I-IUPAC
-	941	942	|I-IUPAC
5	942	943	|I-IUPAC
-	943	944	|I-IUPAC
carboxymet	944	954	|I-IUPAC
hyl	955	958	|I-IUPAC
aminocarbonyl	959	972	|I-IUPAC
-	972	973	|I-IUPAC
2,7	973	976	|I-IUPAC
-	976	977	|I-IUPAC
dioxo	977	982	|I-IUPAC
-	982	983	|I-IUPAC
2,3,4,5,6,7	983	994	|I-IUPAC
-	994	995	|I-IUPAC
hexahydro	995	1004	|I-IUPAC
-	1004	1005	|I-IUPAC
1H	1005	1007	|I-IUPAC
-	1007	1008	|I-IUPAC
benzo	1008	1013	|I-IUPAC
[	1013	1014	|I-IUPAC
h	1014	1015	|I-IUPAC
]	1015	1016	|I-IUPAC
[	1016	1017	|I-IUPAC
1	1017	1018	|I-IUPAC
,	1018	1019	|I-IUPAC
4	1020	1021	|I-IUPAC
]	1021	1022	|I-IUPAC
diazonine	1022	1031	|I-IUPAC
(	1032	1033	|O
32	1033	1035	|O
)	1035	1036	|O
were	1037	1041	|O
prepared	1042	1050	|O
.	1050	1051	|O
Compound	1052	1060	|O
32	1061	1063	|O
behaved	1064	1071	|O
as	1072	1074	|O
a	1075	1076	|O
competitive	1077	1088	|O
CCK	1089	1092	|O
(	1092	1093	|O
2	1093	1094	|O
)	1094	1095	|O
receptor	1096	1104	|O
antagonist	1105	1115	|O
in	1116	1118	|O
vitro	1119	1124	|O
as	1125	1127	|O
judged	1128	1134	|O
by	1135	1137	|O
its	1138	1141	|O
inhibition	1142	1152	|O
of	1153	1155	|O
pentagastrin	1156	1168	|O
-	1168	1169	|O
stimulated	1169	1179	|O
acid	1180	1184	|O
secretion	1185	1194	|O
in	1195	1197	|O
an	1198	1200	|O
isolated	1201	1209	|O
,	1209	1210	|O
lumen	1211	1216	|O
-	1216	1217	|O
perfused	1217	1225	|O
,	1225	1226	|O
immature	1227	1235	|O
rat	1236	1239	|O
stomach	1240	1247	|O
assay	1248	1253	|O
(	1254	1255	|O
pK	1255	1257	|O
(	1257	1258	|O
B	1258	1259	|O
)	1259	1260	|O
=	1261	1262	|O
6.74	1263	1267	|O
+	1268	1269	|O
/	1269	1270	|O
-	1270	1271	|O
0.27	1272	1276	|O
)	1276	1277	|O
and	1278	1281	|O
by	1282	1284	|O
its	1285	1288	|O
displacement	1289	1301	|O
of	1302	1304	|O
[	1305	1306	|O
(	1306	1307	|O
125	1307	1310	|O
)	1310	1311	|O
I	1311	1312	|O
]	1312	1313	|O
CCK	1313	1316	|O
-	1316	1317	|O
8S	1317	1319	|O
from	1320	1324	|O
CCK	1325	1328	|O
(	1328	1329	|O
2	1329	1330	|O
)	1330	1331	|O
sites	1332	1337	|O
in	1338	1340	|O
mouse	1341	1346	|O
cortical	1347	1355	|O
homogenates	1356	1367	|O
(	1368	1369	|O
pK	1369	1371	|O
(	1371	1372	|O
i	1372	1373	|O
)	1373	1374	|O
=	1375	1376	|O
6.99	1377	1381	|O
+	1382	1383	|O
/	1383	1384	|O
-	1384	1385	|O
0.05	1386	1390	|O
)	1390	1391	|O
.	1391	1392	|O
Compound	1393	1401	|O
32	1402	1404	|O
was	1405	1408	|O
100	1409	1412	|O
-	1412	1413	|O
fold	1413	1417	|O
selective	1418	1427	|O
for	1428	1431	|O
CCK	1432	1435	|O
(	1435	1436	|O
2	1436	1437	|O
)	1437	1438	|O
over	1439	1443	|O
CCK	1444	1447	|O
(	1447	1448	|O
1	1448	1449	|O
)	1449	1450	|O
receptors	1451	1460	|O
based	1461	1466	|O
on	1467	1469	|O
the	1470	1473	|O
affinity	1474	1482	|O
estimate	1483	1491	|O
obtained	1492	1500	|O
in	1501	1503	|O
a	1504	1505	|O
guinea	1506	1512	|O
pig	1513	1516	|O
pancreas	1517	1525	|O
radioligand	1526	1537	|O
binding	1538	1545	|O
assay	1546	1551	|O
(	1552	1553	|O
pK	1553	1555	|O
(	1555	1556	|O
i	1556	1557	|O
)	1557	1558	|O
=	1559	1560	|O
5.0	1561	1564	|O
)	1564	1565	|O
.	1565	1566	|O

### abstracts3746.txt
A	0	1	|O
group	2	7	|O
of	8	10	|O
racemic	11	18	|B-MODIFIER
alkyl	19	24	|B-IUPAC
and	25	28	|O
2	29	30	|B-PARTIUPAC
-	30	31	|I-PARTIUPAC
phenethyl	31	40	|I-PARTIUPAC
1,4	41	44	|I-PARTIUPAC
-	44	45	|I-PARTIUPAC
dihydro	45	52	|I-PARTIUPAC
-	52	53	|I-PARTIUPAC
2,6	53	56	|I-PARTIUPAC
-	56	57	|I-PARTIUPAC
dimethyl	57	65	|I-PARTIUPAC
-	65	66	|I-PARTIUPAC
3	66	67	|I-PARTIUPAC
-	67	68	|I-PARTIUPAC
nitro	68	73	|I-PARTIUPAC
-	73	74	|I-PARTIUPAC
4	74	75	|I-PARTIUPAC
-	75	76	|I-PARTIUPAC
(	76	77	|I-PARTIUPAC
3	77	78	|B-MODIFIER
-	78	79	|I-MODIFIER
or	80	82	|O
6	83	84	|B-MODIFIER
-	84	85	|I-MODIFIER
substituted	85	96	|I-MODIFIER
-	96	97	|O
2	97	98	|B-PARTIUPAC
-	98	99	|I-PARTIUPAC
pyridyl	99	106	|I-PARTIUPAC
)	106	107	|I-PARTIUPAC
-	107	108	|I-PARTIUPAC
5	108	109	|I-PARTIUPAC
-	109	110	|I-PARTIUPAC
pyridinecarboxylates	110	130	|I-PARTIUPAC
(	131	132	|O
13a	132	135	|O
-	135	136	|O
q	136	137	|O
)	137	138	|O
was	139	142	|O
prepared	143	151	|O
using	152	157	|O
a	158	159	|O
modified	160	168	|O
Hantzsch	169	177	|O
reaction	178	186	|O
that	187	191	|O
involved	192	200	|O
the	201	204	|O
condensation	205	217	|O
of	218	220	|O
a	221	222	|O
3	223	224	|B-MODIFIER
-	224	225	|I-MODIFIER
or	226	228	|O
6	229	230	|B-MODIFIER
-	230	231	|I-MODIFIER
substituted	231	242	|I-MODIFIER
-	242	243	|O
2	243	244	|B-IUPAC
-	244	245	|I-IUPAC
pyridinecarboxaldehyde	245	267	|I-IUPAC
(	268	269	|O
7a	269	271	|O
-	271	272	|O
j	272	273	|O
)	273	274	|O
with	275	279	|O
an	280	282	|O
alkyl	283	288	|B-IUPAC
or	289	291	|O
2	292	293	|B-IUPAC
-	293	294	|I-IUPAC
phenethyl	294	303	|I-IUPAC
3	304	305	|I-IUPAC
-	305	306	|I-IUPAC
aminocrotonate	306	320	|I-IUPAC
(	321	322	|O
11a	322	325	|O
-	325	326	|O
d	326	327	|O
)	327	328	|O
and	329	332	|O
nitroacetone	333	345	|O
(	346	347	|O
12	347	349	|O
)	349	350	|O
.	350	351	|O
Nuclear	352	359	|O
Overhauser	360	370	|O
(	371	372	|O
NOE	372	375	|O
)	375	376	|O
studies	377	384	|O
indicated	385	394	|O
there	395	400	|O
is	401	403	|O
a	404	405	|O
significant	406	417	|O
rotamer	418	425	|O
fraction	426	434	|O
in	435	437	|O
solution	438	446	|O
where	447	452	|O
the	453	456	|O
pyridyl	457	464	|O
nitrogen	465	473	|O
is	474	476	|O
oriented	477	485	|O
above	486	491	|O
the	492	495	|O
1,4	496	499	|B-IUPAC
-	499	500	|I-IUPAC
dihydropyridine	500	515	|I-IUPAC
ring	516	520	|B-MODIFIER
,	520	521	|O
irrespective	522	534	|O
of	535	537	|O
whether	538	545	|O
a	546	547	|O
substituent	548	559	|O
is	560	562	|O
located	563	570	|O
at	571	573	|O
the	574	577	|O
3	578	579	|O
-	579	580	|O
or	581	583	|O
6	584	585	|O
-	585	586	|O
position	586	594	|O
.	594	595	|O
A	596	597	|O
potential	598	607	|O
H	608	609	|O
-	609	610	|O
bonding	610	617	|O
interaction	618	629	|O
between	630	637	|O
the	638	641	|O
pyridyl	642	649	|O
nitrogen	650	658	|O
free	659	663	|O
electron	664	672	|O
pair	673	677	|O
and	678	681	|O
the	682	685	|O
suitably	686	694	|O
positioned	695	705	|O
1,4	706	709	|B-IUPAC
-	709	710	|I-IUPAC
dihydropyridine	710	725	|I-IUPAC
NH	726	728	|B-MODIFIER
moiety	729	735	|I-MODIFIER
may	736	739	|O
stablize	740	748	|O
this	749	753	|O
rotamer	754	761	|O
orientation	762	773	|O
.	773	774	|O
In	775	777	|O
vitro	778	783	|O
calcium	784	791	|O
channel	792	799	|O
antagonist	800	810	|O
and	811	814	|O
agonist	815	822	|O
activities	823	833	|O
were	834	838	|O
determined	839	849	|O
using	850	855	|O
guinea	856	862	|O
pig	863	866	|O
ileum	867	872	|O
longitudinal	873	885	|O
smooth	886	892	|O
muscle	893	899	|O
(	900	901	|O
GPILSM	901	907	|O
)	907	908	|O
and	909	912	|O
guinea	913	919	|O
pig	920	923	|O
left	924	928	|O
atrium	929	935	|O
(	936	937	|O
GPLA	937	941	|O
)	941	942	|O
assays	943	949	|O
,	949	950	|O
respectively	951	963	|O
.	963	964	|O
Compounds	965	974	|O
having	975	981	|O
an	982	984	|O
i	985	986	|O
-	986	987	|O
Pr	987	989	|O
ester	990	995	|O
substituent	996	1007	|O
acted	1008	1013	|O
as	1014	1016	|O
dual	1017	1021	|O
cardioselective	1022	1037	|O
calcium	1038	1045	|O
channel	1046	1053	|O
agonists	1054	1062	|O
(	1063	1064	|O
GPLA	1064	1068	|O
)	1068	1069	|O
/	1069	1070	|O
smooth	1070	1076	|O
muscle	1077	1083	|O
-	1083	1084	|O
selective	1084	1093	|O
calcium	1094	1101	|O
channel	1102	1109	|O
antagonists	1110	1121	|O
(	1122	1123	|O
GPILSM	1123	1129	|O
)	1129	1130	|O
,	1130	1131	|O
except	1132	1138	|O
for	1139	1142	|O
the	1143	1146	|O
C	1147	1148	|O
-	1148	1149	|O
4	1149	1150	|O
3	1151	1152	|B-IUPAC
-	1152	1153	|I-IUPAC
nitro	1153	1158	|I-IUPAC
-	1158	1159	|I-IUPAC
2	1159	1160	|I-IUPAC
-	1160	1161	|I-IUPAC
pyridyl	1161	1168	|I-IUPAC
compound	1169	1177	|B-MODIFIER
which	1178	1183	|O
exhibited	1184	1193	|O
an	1194	1196	|O
antagonist	1197	1207	|O
effect	1208	1214	|O
on	1215	1217	|O
both	1218	1222	|O
GPLA	1223	1227	|O
and	1228	1231	|O
GPILSM	1232	1238	|O
.	1238	1239	|O
In	1240	1242	|O
contrast	1243	1251	|O
,	1251	1252	|O
the	1253	1256	|O
compounds	1257	1266	|O
with	1267	1271	|O
a	1272	1273	|O
phenethyl	1274	1283	|O
ester	1284	1289	|O
group	1290	1295	|O
,	1295	1296	|O
which	1297	1302	|O
exhibited	1303	1312	|O
antagonist	1313	1323	|O
activity	1324	1332	|O
(	1333	1334	|O
IC50	1334	1338	|O
=	1339	1340	|O
10	1341	1343	|O
(	1343	1344	|O
-	1344	1345	|O
5	1345	1346	|O
)	1346	1347	|O
-	1347	1348	|O
10	1348	1350	|O
(	1350	1351	|O
-	1351	1352	|O
7	1352	1353	|O
)	1353	1354	|O
M	1355	1356	|O
range	1357	1362	|O
)	1362	1363	|O
on	1364	1366	|O
GPILSM	1367	1373	|O
,	1373	1374	|O
were	1375	1379	|O
devoid	1380	1386	|O
of	1387	1389	|O
cardiac	1390	1397	|O
agonist	1398	1405	|O
activity	1406	1414	|O
on	1415	1417	|O
GPLA	1418	1422	|O
.	1422	1423	|O
Structure	1424	1433	|O
-	1433	1434	|O
activity	1434	1442	|O
relationships	1443	1456	|O
showing	1457	1464	|O
the	1465	1468	|O
effect	1469	1475	|O
of	1476	1478	|O
a	1479	1480	|O
substituent	1481	1492	|O
(	1493	1494	|O
Me	1494	1496	|O
,	1496	1497	|O
CF3	1498	1501	|O
,	1501	1502	|O
Cl	1503	1505	|O
,	1505	1506	|O
NO2	1507	1510	|O
,	1510	1511	|O
Ph	1512	1514	|O
)	1514	1515	|O
at	1516	1518	|O
the	1519	1522	|O
3	1523	1524	|O
-	1524	1525	|O
or	1526	1528	|O
6	1529	1530	|O
-	1530	1531	|O
position	1531	1539	|O
of	1540	1542	|O
a	1543	1544	|O
C	1545	1546	|O
-	1546	1547	|O
4	1547	1548	|O
2	1549	1550	|B-IUPAC
-	1550	1551	|I-IUPAC
pyridyl	1551	1558	|I-IUPAC
moiety	1559	1565	|B-MODIFIER
and	1566	1569	|O
a	1570	1571	|O
variety	1572	1579	|O
of	1580	1582	|O
ester	1583	1588	|O
substituents	1589	1601	|O
(	1602	1603	|O
Me	1603	1605	|O
,	1605	1606	|O
Et	1607	1609	|O
,	1609	1610	|O
i	1611	1612	|O
-	1612	1613	|O
Pr	1613	1615	|O
,	1615	1616	|O
PhCH2CH2	1617	1625	|O
-	1625	1626	|O
)	1626	1627	|O
upon	1628	1632	|O
calcium	1633	1640	|O
channel	1641	1648	|O
modulation	1649	1659	|O
are	1660	1663	|O
described	1664	1673	|O
.	1673	1674	|O
Compounds	1675	1684	|O
possessing	1685	1695	|O
a	1696	1697	|O
3	1698	1699	|B-MODIFIER
-	1699	1700	|I-MODIFIER
or	1701	1703	|O
6	1704	1705	|B-MODIFIER
-	1705	1706	|I-MODIFIER
substituted	1706	1717	|I-MODIFIER
-	1717	1718	|O
2	1718	1719	|B-IUPAC
-	1719	1720	|I-IUPAC
pyridyl	1720	1727	|I-IUPAC
moiety	1728	1734	|B-MODIFIER
,	1734	1735	|O
in	1736	1738	|O
conjuction	1739	1749	|O
with	1750	1754	|O
an	1755	1757	|O
i	1758	1759	|O
-	1759	1760	|O
Pr	1760	1762	|O
ester	1763	1768	|O
substituent	1769	1780	|O
,	1780	1781	|O
are	1782	1785	|O
novel	1786	1791	|O
1,4	1792	1795	|B-IUPAC
-	1795	1796	|I-IUPAC
dihydropyridine	1796	1811	|I-IUPAC
calcium	1812	1819	|O
channel	1820	1827	|O
modulators	1828	1838	|O
that	1839	1843	|O
offer	1844	1849	|O
a	1850	1851	|O
new	1852	1855	|O
drug	1856	1860	|O
design	1861	1867	|O
approach	1868	1876	|O
directed	1877	1885	|O
to	1886	1888	|O
the	1889	1892	|O
treatment	1893	1902	|O
of	1903	1905	|O
congestive	1906	1916	|O
heart	1917	1922	|O
failure	1923	1930	|O
and	1931	1934	|O
may	1935	1938	|O
also	1939	1943	|O
be	1944	1946	|O
useful	1947	1953	|O
as	1954	1956	|O
probes	1957	1963	|O
to	1964	1966	|O
study	1967	1972	|O
the	1973	1976	|O
structure	1977	1986	|O
-	1986	1987	|O
function	1987	1995	|O
relationships	1996	2009	|O
of	2010	2012	|O
calcium	2013	2020	|O
channels	2021	2029	|O
.	2029	2030	|O

### abstracts3566.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
4'	12	14	|B-MODIFIER
-	14	15	|I-MODIFIER
substituted	15	26	|I-MODIFIER
spiro	27	32	|B-IUPAC
[	32	33	|I-IUPAC
4H	33	35	|I-IUPAC
-	35	36	|I-IUPAC
3,1	36	39	|I-IUPAC
-	39	40	|I-IUPAC
benzoxazine	40	51	|I-IUPAC
-	51	52	|I-IUPAC
4,4	52	55	|I-IUPAC
'	55	56	|I-IUPAC
-	56	57	|I-IUPAC
piperidin	57	66	|I-IUPAC
]	66	67	|I-IUPAC
-	67	68	|I-IUPAC
2	68	69	|I-IUPAC
(	69	70	|I-IUPAC
1H	70	72	|I-IUPAC
)	72	73	|I-IUPAC
-	73	74	|I-IUPAC
ones	74	78	|I-IUPAC
was	79	82	|O
prepared	83	91	|O
and	92	95	|O
evaluated	96	105	|O
for	106	109	|O
antihypertensive	110	126	|O
activity	127	135	|O
in	136	138	|O
the	139	142	|O
spontaneously	143	156	|O
hypertensive	157	169	|O
rat	170	173	|O
(	174	175	|O
SHR	175	178	|O
)	178	179	|O
.	179	180	|O
The	181	184	|O
basic	185	190	|O
ring	191	195	|O
system	196	202	|O
was	203	206	|O
prepared	207	215	|O
in	216	218	|O
one	219	222	|O
step	223	227	|O
by	228	230	|O
condensation	231	243	|O
of	244	246	|O
dilithiated	247	258	|B-MODIFIER
(	259	260	|B-IUPAC
tert	260	264	|I-IUPAC
-	264	265	|I-IUPAC
butoxycarbonyl	265	279	|I-IUPAC
)	279	280	|I-IUPAC
aniline	280	287	|I-IUPAC
(	288	289	|O
3	289	290	|O
)	290	291	|O
with	292	296	|O
(	297	298	|B-IUPAC
tert	298	302	|I-IUPAC
-	302	303	|I-IUPAC
butoxycarbonyl	303	317	|I-IUPAC
)	317	318	|I-IUPAC
piperidinone	318	330	|I-IUPAC
.	330	331	|O
Deprotection	332	344	|O
afforded	345	353	|O
6	354	355	|O
,	355	356	|O
which	357	362	|O
was	363	366	|O
condensed	367	376	|O
with	377	381	|O
expoxides	382	391	|O
or	392	394	|O
alkyl	395	400	|O
halides	401	408	|O
to	409	411	|O
furnish	412	419	|O
the	420	423	|O
title	424	429	|O
compounds	430	439	|O
.	439	440	|O
The	441	444	|O
most	445	449	|O
active	450	456	|O
compound	457	465	|O
was	466	469	|O
dl	470	472	|B-IUPAC
-	472	473	|I-IUPAC
erythro	473	480	|I-IUPAC
-	480	481	|I-IUPAC
4'	481	483	|I-IUPAC
-	483	484	|I-IUPAC
[	484	485	|I-IUPAC
2	485	486	|I-IUPAC
-	486	487	|I-IUPAC
(	487	488	|I-IUPAC
1,4	488	491	|I-IUPAC
-	491	492	|I-IUPAC
benzodioxan	492	503	|I-IUPAC
-	503	504	|I-IUPAC
2	504	505	|I-IUPAC
-	505	506	|I-IUPAC
yl	506	508	|I-IUPAC
)	508	509	|I-IUPAC
-	509	510	|I-IUPAC
2	510	511	|I-IUPAC
-	511	512	|I-IUPAC
hydroxyethyl	512	524	|I-IUPAC
]	524	525	|I-IUPAC
spiro	525	530	|I-IUPAC
[	531	532	|I-IUPAC
4H	532	534	|I-IUPAC
-	534	535	|I-IUPAC
3,1	535	538	|I-IUPAC
-	538	539	|I-IUPAC
benzoxazine	539	550	|I-IUPAC
-	550	551	|I-IUPAC
4,4	551	554	|I-IUPAC
'	554	555	|I-IUPAC
-	555	556	|I-IUPAC
piperidin	556	565	|I-IUPAC
]	565	566	|I-IUPAC
-	566	567	|I-IUPAC
2	567	568	|I-IUPAC
(	568	569	|I-IUPAC
1H	569	571	|I-IUPAC
)	571	572	|I-IUPAC
-	572	573	|I-IUPAC
one	573	576	|I-IUPAC
(	577	578	|O
9	578	579	|O
)	579	580	|O
,	580	581	|O
and	582	585	|O
various	586	593	|O
modifications	594	607	|O
of	608	610	|O
this	611	615	|O
compound	616	624	|O
were	625	629	|O
made	630	634	|O
in	635	637	|O
order	638	643	|O
to	644	646	|O
elucidate	647	656	|O
the	657	660	|O
structure	661	670	|O
-	670	671	|O
activity	671	679	|O
relationships	680	693	|O
in	694	696	|O
the	697	700	|O
series	701	707	|O
.	707	708	|O
Preliminary	709	720	|O
indications	721	732	|O
are	733	736	|O
that	737	741	|O
9	742	743	|O
may	744	747	|O
act	748	751	|O
by	752	754	|O
both	755	759	|O
central	760	767	|O
and	768	771	|O
peripheral	772	782	|O
mechanisms	783	793	|O
.	793	794	|O

### abstracts1794.txt
A	0	1	|O
number	2	8	|O
of	9	11	|O
N	12	13	|B-IUPAC
,	13	14	|I-IUPAC
N	14	15	|I-IUPAC
:	15	16	|I-IUPAC
N'	16	18	|I-IUPAC
,	18	19	|I-IUPAC
N'	19	21	|I-IUPAC
:	21	22	|I-IUPAC
N	22	23	|I-IUPAC
"	23	24	|I-IUPAC
,	24	25	|I-IUPAC
N	25	26	|I-IUPAC
"	26	27	|I-IUPAC
-	27	28	|I-IUPAC
tri	28	31	|I-IUPAC
-	31	32	|I-IUPAC
1,2	32	35	|I-IUPAC
-	35	36	|I-IUPAC
ethanediylphosphoric	37	57	|I-IUPAC
triamide	58	66	|I-IUPAC
(	67	68	|O
TEPA	68	72	|O
)	72	73	|O
and	74	77	|O
N	78	79	|B-IUPAC
,	79	80	|I-IUPAC
N	80	81	|I-IUPAC
:	81	82	|I-IUPAC
N'	82	84	|I-IUPAC
,	84	85	|I-IUPAC
N'	85	87	|I-IUPAC
:	87	88	|I-IUPAC
N	88	89	|I-IUPAC
"	89	90	|I-IUPAC
,	90	91	|I-IUPAC
N	91	92	|I-IUPAC
"	92	93	|I-IUPAC
-	93	94	|I-IUPAC
tri	94	97	|I-IUPAC
-	97	98	|I-IUPAC
1,2	98	101	|I-IUPAC
-	101	102	|I-IUPAC
ethanediylphosphorothioic	103	128	|I-IUPAC
triamide	129	137	|I-IUPAC
(	138	139	|O
thio	139	143	|O
-	143	144	|O
TEPA	144	148	|O
)	148	149	|O
derivatives	150	161	|O
containing	162	172	|O
either	173	179	|O
two	180	183	|O
aziridine	184	193	|B-IUPAC
moieties	194	202	|B-MODIFIER
(	203	204	|O
1a	204	206	|O
)	206	207	|O
or	208	210	|O
two	211	214	|O
(	215	216	|B-IUPAC
2	216	217	|I-IUPAC
-	217	218	|I-IUPAC
chloroethyl	218	229	|I-IUPAC
)	229	230	|I-IUPAC
amino	230	235	|I-IUPAC
functions	236	245	|B-MODIFIER
(	246	247	|O
1b	247	249	|O
)	249	250	|O
and	251	254	|O
either	255	261	|O
a	262	263	|O
2,2,6,6	264	271	|B-IUPAC
-	271	272	|I-IUPAC
tetramethylpiperidine	272	293	|I-IUPAC
,	293	294	|O
1	295	296	|B-IUPAC
-	296	297	|I-IUPAC
oxy	297	300	|I-IUPAC
-	300	301	|I-IUPAC
2,2,6,6	301	308	|I-IUPAC
-	308	309	|I-IUPAC
tetramethylpiperidine	309	330	|I-IUPAC
or	331	333	|O
1	334	335	|B-IUPAC
-	335	336	|I-IUPAC
hydroxy	336	343	|I-IUPAC
-	343	344	|I-IUPAC
2,2,6,6	344	351	|I-IUPAC
-	351	352	|I-IUPAC
tetramethylpiperidine	352	373	|I-IUPAC
component	374	383	|B-MODIFIER
were	384	388	|O
synthesized	389	400	|O
and	401	404	|O
tested	405	411	|O
against	412	419	|O
lymphocytic	420	431	|O
leukemia	432	440	|O
P388	441	445	|O
in	446	448	|O
mice	449	453	|O
.	453	454	|O
In	455	457	|O
a	458	459	|O
structure	460	469	|O
-	469	470	|O
activity	470	478	|O
comparison	479	489	|O
it	490	492	|O
was	493	496	|O
found	497	502	|O
that	503	507	|O
at	508	510	|O
optimum	511	518	|O
dose	519	523	|O
all	524	527	|O
compounds	528	537	|O
containing	538	548	|O
the	549	552	|O
nitroxyl	553	561	|O
radical	562	569	|O
were	570	574	|O
more	575	579	|O
active	580	586	|O
than	587	591	|O
the	592	595	|O
corresponding	596	609	|O
hydroxylamine	610	623	|O
derivatives	624	635	|O
.	635	636	|O
The	637	640	|O
open	641	645	|O
-	645	646	|O
chain	646	651	|O
compounds	652	661	|O
(	662	663	|O
1b	663	665	|O
)	665	666	|O
were	667	671	|O
less	672	676	|O
active	677	683	|O
than	684	688	|O
the	689	692	|O
corresponding	693	706	|O
aziridine	707	716	|O
ring	717	721	|O
compounds	722	731	|O
(	732	733	|O
1a	733	735	|O
)	735	736	|O
.	736	737	|O
The	738	741	|O
replacement	742	753	|O
of	754	756	|O
the	757	760	|O
X	761	762	|O
=	763	764	|O
bridge	765	771	|O
in	772	774	|O
1a	775	777	|O
with	778	782	|O
the	783	786	|O
X	787	788	|O
=	789	790	|O
N	791	792	|O
(	792	793	|O
CH3	793	796	|O
)	796	797	|O
group	798	803	|O
resulted	804	812	|O
in	813	815	|O
lowering	816	824	|O
of	825	827	|O
the	828	831	|O
anticancer	832	842	|O
activity	843	851	|O
.	851	852	|O

### abstracts3878.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
esters	12	18	|O
of	19	21	|O
6beta	22	27	|B-IUPAC
-	27	28	|I-IUPAC
hydroxynortropane	28	45	|I-IUPAC
and	46	49	|O
the	50	53	|O
N	54	55	|B-IUPAC
-	55	56	|I-IUPAC
methyl	56	62	|I-IUPAC
analogue	63	71	|B-MODIFIER
6beta	72	77	|B-IUPAC
-	77	78	|I-IUPAC
tropanol	78	86	|I-IUPAC
were	87	91	|O
synthesized	92	103	|O
and	104	107	|O
screened	108	116	|O
versus	117	123	|O
binding	124	131	|O
of	132	134	|O
an	135	137	|O
antagonist	138	148	|O
(	149	150	|O
quinuclidinyl	150	163	|B-IUPAC
benzilate	164	173	|I-IUPAC
)	173	174	|O
and	175	178	|O
an	179	181	|O
agonist	182	189	|O
(	190	191	|O
oxotremorine	191	203	|O
-	203	204	|O
M	204	205	|O
)	205	206	|O
at	207	209	|O
sites	210	215	|O
on	216	218	|O
human	219	224	|O
m	225	226	|O
(	226	227	|O
1	227	228	|O
)	228	229	|O
-	229	230	|O
,	230	231	|O
m	232	233	|O
(	233	234	|O
2	234	235	|O
)	235	236	|O
-	236	237	|O
,	237	238	|O
m	239	240	|O
(	240	241	|O
3	241	242	|O
)	242	243	|O
-	243	244	|O
,	244	245	|O
and	246	249	|O
m	250	251	|O
(	251	252	|O
4	252	253	|O
)	253	254	|O
-	254	255	|O
muscarinic	255	265	|O
receptors	266	275	|O
in	276	278	|O
transfected	279	290	|O
cell	291	295	|O
membranes	296	305	|O
and	306	309	|O
on	310	312	|O
native	313	319	|O
M	320	321	|O
(	321	322	|O
1	322	323	|O
)	323	324	|O
-	324	325	|O
muscarinic	325	335	|O
receptors	336	345	|O
in	346	348	|O
rat	349	352	|O
brain	353	358	|O
membranes	359	368	|O
and	369	372	|O
native	373	379	|O
M	380	381	|O
(	381	382	|O
2	382	383	|O
)	383	384	|O
-	384	385	|O
muscarinic	385	395	|O
receptors	396	405	|O
in	406	408	|O
rat	409	412	|O
heart	413	418	|O
membranes	419	428	|O
.	428	429	|O
Most	430	434	|O
6beta	435	440	|B-IUPAC
-	440	441	|I-IUPAC
acyloxy	441	448	|I-IUPAC
(	448	449	|I-IUPAC
nor	449	452	|I-IUPAC
)	452	453	|I-IUPAC
tropanes	453	461	|I-IUPAC
had	462	465	|O
higher	466	472	|O
affinity	473	481	|O
versus	482	488	|O
oxotremorine	489	501	|O
-	501	502	|O
M	502	503	|O
binding	504	511	|O
compared	512	520	|O
to	521	523	|O
quinuclidinyl	524	537	|O
benzilate	538	547	|O
binding	548	555	|O
at	556	558	|O
transfected	559	570	|O
m	571	572	|O
(	572	573	|O
1	573	574	|O
)	574	575	|O
-	575	576	|O
and	577	580	|O
native	581	587	|O
M	588	589	|O
(	589	590	|O
1	590	591	|O
)	591	592	|O
-	592	593	|O
receptors	593	602	|O
,	602	603	|O
indicative	604	614	|O
of	615	617	|O
agonist	618	625	|O
activity	626	634	|O
.	634	635	|O
6beta	636	641	|B-IUPAC
-	641	642	|I-IUPAC
Acetoxynortropane	642	659	|I-IUPAC
had	660	663	|O
K	664	665	|O
(	665	666	|O
i	666	667	|O
)	667	668	|O
values	669	675	|O
versus	676	682	|O
oxotremorine	683	695	|O
-	695	696	|O
M	696	697	|O
binding	698	705	|O
at	706	708	|O
m	709	710	|O
(	710	711	|O
1	711	712	|O
)	712	713	|O
-	713	714	|O
,	714	715	|O
m	716	717	|O
(	717	718	|O
2	718	719	|O
)	719	720	|O
-	720	721	|O
,	721	722	|O
and	723	726	|O
m	727	728	|O
(	728	729	|O
4	729	730	|O
)	730	731	|O
-	731	732	|O
receptors	732	741	|O
ranging	742	749	|O
from	750	754	|O
4	755	756	|O
to	757	759	|O
7	760	761	|O
nM	762	764	|O
.	764	765	|O
N	766	767	|O
-	767	768	|O
Methylation	768	779	|O
reduced	780	787	|O
affinity	788	796	|O
greatly	797	804	|O
as	805	807	|O
did	808	811	|O
increasing	812	822	|O
the	823	826	|O
size	827	831	|O
of	832	834	|O
the	835	838	|O
acyl	839	843	|O
moiety	844	850	|O
.	850	851	|O
The	852	855	|O
affinity	856	864	|O
of	865	867	|O
6beta	868	873	|B-IUPAC
-	873	874	|I-IUPAC
benzoyloxynortropane	874	894	|I-IUPAC
and	895	898	|O
other	899	904	|O
analogues	905	914	|O
with	915	919	|O
larger	920	926	|O
acyl	927	931	|O
moieties	932	940	|O
was	941	944	|O
little	945	951	|O
affected	952	960	|O
by	961	963	|O
N	964	965	|O
-	965	966	|O
methylation	966	977	|O
or	978	980	|O
in	981	983	|O
some	984	988	|O
cases	989	994	|O
was	995	998	|O
increased	999	1008	|O
.	1008	1009	|O
6beta	1010	1015	|B-IUPAC
-	1015	1016	|I-IUPAC
Acyloxy	1016	1023	|I-IUPAC
(	1023	1024	|I-IUPAC
nor	1024	1027	|I-IUPAC
)	1027	1028	|I-IUPAC
tropanes	1028	1036	|I-IUPAC
and	1037	1040	|O
classical	1041	1050	|O
muscarinic	1051	1061	|O
agonists	1062	1070	|O
,	1070	1071	|O
such	1072	1076	|O
as	1077	1079	|O
muscarine	1080	1089	|O
and	1090	1093	|O
oxotremorine	1094	1106	|O
,	1106	1107	|O
had	1108	1111	|O
higher	1112	1118	|O
affinity	1119	1127	|O
versus	1128	1134	|O
oxotremorine	1135	1147	|O
-	1147	1148	|O
M	1148	1149	|O
binding	1150	1157	|O
compared	1158	1166	|O
to	1167	1169	|O
quinuclidinyl	1170	1183	|O
benzilate	1184	1193	|O
binding	1194	1201	|O
at	1202	1204	|O
native	1205	1211	|O
M	1212	1213	|O
(	1213	1214	|O
2	1214	1215	|O
)	1215	1216	|O
-	1216	1217	|O
muscarinic	1217	1227	|O
receptors	1228	1237	|O
of	1238	1240	|O
heart	1241	1246	|O
,	1246	1247	|O
but	1248	1251	|O
not	1252	1255	|O
at	1256	1258	|O
transfected	1259	1270	|O
m	1271	1272	|O
(	1272	1273	|O
2	1273	1274	|O
)	1274	1275	|O
-	1275	1276	|O
muscarinic	1276	1286	|O
receptors	1287	1296	|O
.	1296	1297	|O
Antagonist	1298	1308	|O
/	1308	1309	|O
agonist	1309	1316	|O
binding	1317	1324	|O
ratios	1325	1331	|O
were	1332	1336	|O
not	1337	1340	|O
obtained	1341	1349	|O
for	1350	1353	|O
transfected	1354	1365	|O
m	1366	1367	|O
(	1367	1368	|O
3	1368	1369	|O
)	1369	1370	|O
-	1370	1371	|O
receptors	1371	1380	|O
,	1380	1381	|O
since	1382	1387	|O
significant	1388	1399	|O
oxotremorine	1400	1412	|O
-	1412	1413	|O
M	1413	1414	|O
binding	1415	1422	|O
could	1423	1428	|O
not	1429	1432	|O
be	1433	1435	|O
detected	1436	1444	|O
.	1444	1445	|O
6beta	1446	1451	|B-IUPAC
-	1451	1452	|I-IUPAC
Acyloxy	1452	1459	|I-IUPAC
(	1459	1460	|I-IUPAC
nor	1460	1463	|I-IUPAC
)	1463	1464	|I-IUPAC
tropane	1464	1471	|I-IUPAC
,	1471	1472	|O
two	1473	1476	|O
other	1477	1482	|O
(	1483	1484	|O
nor	1484	1487	|O
)	1487	1488	|O
tropanes	1488	1496	|O
,	1496	1497	|O
and	1498	1501	|O
the	1502	1505	|O
classical	1506	1515	|O
muscarinic	1516	1526	|O
agonists	1527	1535	|O
had	1536	1539	|O
higher	1540	1546	|O
affinity	1547	1555	|O
versus	1556	1562	|O
agonist	1563	1570	|O
binding	1571	1578	|O
compared	1579	1587	|O
to	1588	1590	|O
antagonist	1591	1601	|O
binding	1602	1609	|O
for	1610	1613	|O
transfected	1614	1625	|O
m	1626	1627	|O
(	1627	1628	|O
4	1628	1629	|O
)	1629	1630	|O
-	1630	1631	|O
receptors	1631	1640	|O
.	1640	1641	|O
The	1642	1645	|O
antagonist	1646	1656	|O
/	1656	1657	|O
agonist	1657	1664	|O
binding	1665	1672	|O
ratio	1673	1678	|O
method	1679	1685	|O
is	1686	1688	|O
clearly	1689	1696	|O
not	1697	1700	|O
always	1701	1707	|O
reliable	1708	1716	|O
for	1717	1720	|O
predicting	1721	1731	|O
agonist	1732	1739	|O
activity	1740	1748	|O
at	1749	1751	|O
muscarinic	1752	1762	|O
receptors	1763	1772	|O
.	1772	1773	|O

### abstracts55.txt
New	0	3	|O
histamine	4	13	|O
derivatives	14	25	|O
characterized	26	39	|O
by	40	42	|O
a	43	44	|O
(	45	46	|O
substituted	46	57	|O
)	57	58	|O
aryl	59	63	|O
,	63	64	|O
heteroaryl	65	75	|O
,	75	76	|O
benzyl	77	83	|O
,	83	84	|O
or	85	87	|O
heteroarylmethyl	88	104	|O
substituent	105	116	|O
in	117	119	|O
the	120	123	|O
C2	124	126	|O
position	127	135	|O
of	136	138	|O
the	139	142	|O
imidazole	143	152	|O
ring	153	157	|O
have	158	162	|O
been	163	167	|O
prepared	168	176	|O
from	177	181	|O
appropriate	182	193	|O
imidates	194	202	|O
or	203	205	|O
amidines	206	214	|O
,	214	215	|O
respectively	216	228	|O
,	228	229	|O
and	230	233	|O
2	234	235	|B-IUPAC
-	235	236	|I-IUPAC
oxo	236	239	|I-IUPAC
-	239	240	|I-IUPAC
4	240	241	|I-IUPAC
-	241	242	|I-IUPAC
phthalimido	242	253	|I-IUPAC
-	253	254	|I-IUPAC
1	254	255	|I-IUPAC
-	255	256	|I-IUPAC
butyl	256	261	|I-IUPAC
acetate	262	269	|I-IUPAC
(	270	271	|O
1	271	272	|O
)	272	273	|O
.	273	274	|O
The	275	278	|O
compounds	279	288	|O
were	289	293	|O
screened	294	302	|O
as	303	305	|O
potential	306	315	|O
H1	316	318	|O
receptor	319	327	|O
agonists	328	336	|O
on	337	339	|O
the	340	343	|O
isolated	344	352	|O
guinea	353	359	|O
pig	360	363	|O
ileum	364	369	|O
.	369	370	|O
The	371	374	|O
3	375	376	|B-IUPAC
-	376	377	|I-IUPAC
halogenated	377	388	|I-IUPAC
2	389	390	|I-IUPAC
-	390	391	|I-IUPAC
phenylhistamines	391	407	|I-IUPAC
(	408	409	|O
halogen	409	416	|O
=	417	418	|O
Br	419	421	|O
(	422	423	|O
35	423	425	|O
)	425	426	|O
and	427	430	|O
I	431	432	|O
(	433	434	|O
36	434	436	|O
)	436	437	|O
)	437	438	|O
were	439	443	|O
equipotent	444	454	|O
with	455	459	|O
histamine	460	469	|O
,	469	470	|O
while	471	476	|O
2	477	478	|B-IUPAC
-	478	479	|I-IUPAC
(	479	480	|I-IUPAC
3	480	481	|I-IUPAC
-	481	482	|I-IUPAC
(	482	483	|I-IUPAC
trifluoromethyl	483	498	|I-IUPAC
)	498	499	|I-IUPAC
phenyl	499	505	|I-IUPAC
)	505	506	|I-IUPAC
histamine	506	515	|I-IUPAC
(	516	517	|O
2	517	518	|B-IUPAC
-	518	519	|I-IUPAC
[	519	520	|I-IUPAC
2	520	521	|I-IUPAC
-	521	522	|I-IUPAC
(	522	523	|I-IUPAC
3	523	524	|I-IUPAC
-	524	525	|I-IUPAC
(	525	526	|I-IUPAC
trifluoromethyl	526	541	|I-IUPAC
)	541	542	|I-IUPAC
phenyl	542	548	|I-IUPAC
)	548	549	|I-IUPAC
-	549	550	|I-IUPAC
1H	550	552	|I-IUPAC
-	552	553	|I-IUPAC
imidazol	553	561	|I-IUPAC
-	561	562	|I-IUPAC
4	562	563	|I-IUPAC
-	563	564	|I-IUPAC
yl	564	566	|I-IUPAC
]	566	567	|I-IUPAC
ethanamine	567	577	|I-IUPAC
(	578	579	|O
39	579	581	|O
)	581	582	|O
)	582	583	|O
was	584	587	|O
significantly	588	601	|O
more	602	606	|O
potent	607	613	|O
than	614	618	|O
histamine	619	628	|O
(	629	630	|O
39	630	632	|O
:	632	633	|O
pD2	634	637	|O
=	638	639	|O
6.81	640	644	|O
,	644	645	|O
relative	646	654	|O
activity	655	663	|O
=	664	665	|O
128%	666	670	|O
)	670	671	|O
.	671	672	|O
The	673	676	|O
2	677	678	|O
-	678	679	|O
substituted	679	690	|O
histamine	691	700	|O
analogues	701	710	|O
were	711	715	|O
partial	716	723	|O
H1	724	726	|O
receptor	727	735	|O
agonists	736	744	|O
on	745	747	|O
the	748	751	|O
endothelium	752	763	|O
-	763	764	|O
denuded	764	771	|O
isolated	772	780	|O
guinea	781	787	|O
pig	788	791	|O
aorta	792	797	|O
with	798	802	|O
pEC50	803	808	|O
values	809	815	|O
generally	816	825	|O
smaller	826	833	|O
than	834	838	|O
observed	839	847	|O
on	848	850	|O
the	851	854	|O
guinea	855	861	|O
pig	862	865	|O
ileum	866	871	|O
,	871	872	|O
but	873	876	|O
the	877	880	|O
rank	881	885	|O
order	886	891	|O
of	892	894	|O
potency	895	902	|O
was	903	906	|O
found	907	912	|O
to	913	915	|O
be	916	918	|O
similar	919	926	|O
.	926	927	|O
The	928	931	|O
contractile	932	943	|O
effects	944	951	|O
on	952	954	|O
guinea	955	961	|O
pig	962	965	|O
ileum	966	971	|O
and	972	975	|O
aorta	976	981	|O
,	981	982	|O
respectively	983	995	|O
,	995	996	|O
could	997	1002	|O
be	1003	1005	|O
blocked	1006	1013	|O
concentration	1014	1027	|O
-	1027	1028	|O
dependently	1028	1039	|O
by	1040	1042	|O
the	1043	1046	|O
H1	1047	1049	|O
receptor	1050	1058	|O
antagonist	1059	1069	|O
mepyramine	1070	1080	|O
,	1080	1081	|O
yielding	1082	1090	|O
KB	1091	1093	|O
values	1094	1100	|O
for	1101	1104	|O
mepyramine	1105	1115	|O
in	1116	1118	|O
the	1119	1122	|O
nanomolar	1123	1132	|O
range	1133	1138	|O
.	1138	1139	|O
In	1140	1142	|O
vitro	1143	1148	|O
compounds	1149	1158	|O
35	1159	1161	|O
and	1162	1165	|O
39	1166	1168	|O
bound	1169	1174	|O
to	1175	1177	|O
[	1178	1179	|O
3H	1179	1181	|O
]	1181	1182	|O
mepyramine	1182	1192	|O
-	1192	1193	|O
labeled	1193	1200	|O
guinea	1201	1207	|O
pig	1208	1211	|O
cerebellar	1212	1222	|O
membranes	1223	1232	|O
with	1233	1237	|O
a	1238	1239	|O
pKi	1240	1243	|O
of	1244	1246	|O
6.1	1247	1250	|O
and	1251	1254	|O
5.9	1255	1258	|O
,	1258	1259	|O
respectively	1260	1272	|O
.	1272	1273	|O
However	1274	1281	|O
,	1281	1282	|O
upon	1283	1287	|O
iv	1288	1290	|O
administration	1291	1305	|O
,	1305	1306	|O
35	1307	1309	|O
(	1310	1311	|O
3-100	1311	1316	|O
mg	1317	1319	|O
/	1319	1320	|O
kg	1320	1322	|O
)	1322	1323	|O
and	1324	1327	|O
39	1328	1330	|O
(	1331	1332	|O
3-300	1332	1337	|O
mg	1338	1340	|O
/	1340	1341	|O
kg	1341	1343	|O
)	1343	1344	|O
failed	1345	1351	|O
to	1352	1354	|O
inhibit	1355	1362	|O
the	1363	1366	|O
binding	1367	1374	|O
of	1375	1377	|O
[	1378	1379	|O
3H	1379	1381	|O
]	1381	1382	|O
mepyramine	1382	1392	|O
to	1393	1395	|O
mouse	1396	1401	|O
cerebral	1402	1410	|O
cortex	1411	1417	|O
in	1418	1420	|O
vivo	1421	1425	|O
,	1425	1426	|O
thereby	1427	1434	|O
indicating	1435	1445	|O
that	1446	1450	|O
these	1451	1456	|O
histamine	1457	1466	|O
derivatives	1467	1478	|O
are	1479	1482	|O
not	1483	1486	|O
able	1487	1491	|O
to	1492	1494	|O
penetrate	1495	1504	|O
the	1505	1508	|O
blood	1509	1514	|O
-	1514	1515	|O
brain	1515	1520	|O
barrier	1521	1528	|O
.	1528	1529	|O
In	1530	1532	|O
functional	1533	1543	|O
in	1544	1546	|O
vitro	1547	1552	|O
studies	1553	1560	|O
on	1561	1563	|O
histamine	1564	1573	|O
H2	1574	1576	|O
,	1576	1577	|O
H3	1578	1580	|O
,	1580	1581	|O
and	1582	1585	|O
other	1586	1591	|O
neurotransmitter	1592	1608	|O
receptors	1609	1618	|O
the	1619	1622	|O
selectivity	1623	1634	|O
of	1635	1637	|O
39	1638	1640	|O
was	1641	1644	|O
found	1645	1650	|O
to	1651	1653	|O
be	1654	1656	|O
2138	1657	1661	|O
(	1662	1663	|O
H1	1663	1665	|O
:	1665	1666	|O
H2	1666	1668	|O
)	1668	1669	|O
,	1669	1670	|O
&	1671	1672	|O
gt	1672	1674	|O
;	1674	1675	|O
64	1676	1678	|O
(	1679	1680	|O
H1	1680	1682	|O
:	1682	1683	|O
H3	1683	1685	|O
)	1685	1686	|O
,	1686	1687	|O
1000	1688	1692	|O
(	1693	1694	|O
H1	1694	1696	|O
:	1696	1697	|O
M3	1697	1699	|O
)	1699	1700	|O
,	1700	1701	|O
105	1702	1705	|O
(	1706	1707	|O
H1	1707	1709	|O
:	1709	1710	|O
alpha	1710	1715	|O
1	1716	1717	|O
)	1717	1718	|O
,	1718	1719	|O
708	1720	1723	|O
(	1724	1725	|O
H1	1725	1727	|O
:	1727	1728	|O
beta	1728	1732	|O
1	1733	1734	|O
)	1734	1735	|O
,	1735	1736	|O
and	1737	1740	|O
71	1741	1743	|O
(	1744	1745	|O
H1	1745	1747	|O
:	1747	1748	|O
5HT2A	1748	1753	|O
)	1753	1754	|O
.	1754	1755	|O
Thus	1756	1760	|O
compound	1761	1769	|O
39	1770	1772	|O
is	1773	1775	|O
the	1776	1779	|O
most	1780	1784	|O
potent	1785	1791	|O
and	1792	1795	|O
selective	1796	1805	|O
H1	1806	1808	|O
receptor	1809	1817	|O
agonist	1818	1825	|O
reported	1826	1834	|O
so	1835	1837	|O
far	1838	1841	|O
.	1841	1842	|O
These	1843	1848	|O
results	1849	1856	|O
make	1857	1861	|O
meta	1862	1866	|B-MODIFIER
-	1866	1867	|I-MODIFIER
substituted	1867	1878	|I-MODIFIER
2	1879	1880	|B-IUPAC
-	1880	1881	|I-IUPAC
phenylhistamines	1881	1897	|I-IUPAC
,	1897	1898	|O
especially	1899	1909	|O
2	1910	1911	|B-PARTIUPAC
-	1911	1912	|I-PARTIUPAC
(	1912	1913	|I-PARTIUPAC
3	1913	1914	|I-PARTIUPAC
-	1914	1915	|I-PARTIUPAC
(	1915	1916	|I-PARTIUPAC
trifluoromethyl	1916	1931	|I-PARTIUPAC
)	1931	1932	|I-PARTIUPAC
phenyl	1932	1938	|I-PARTIUPAC
)	1938	1939	|I-PARTIUPAC
-	1939	1940	|I-PARTIUPAC
and	1941	1944	|O
2	1945	1946	|B-IUPAC
-	1946	1947	|I-IUPAC
(	1947	1948	|I-IUPAC
3	1948	1949	|I-IUPAC
-	1949	1950	|I-IUPAC
bromophenyl	1950	1961	|I-IUPAC
)	1961	1962	|I-IUPAC
histamine	1962	1971	|I-IUPAC
(	1972	1973	|O
39	1973	1975	|O
and	1976	1979	|O
35	1980	1982	|O
,	1982	1983	|O
respectively	1984	1996	|O
)	1996	1997	|O
valuable	1998	2006	|O
experimental	2007	2019	|O
tools	2020	2025	|O
for	2026	2029	|O
the	2030	2033	|O
selective	2034	2043	|O
stimulation	2044	2055	|O
of	2056	2058	|O
histamine	2059	2068	|O
H1	2069	2071	|O
receptors	2072	2081	|O
and	2082	2085	|O
the	2086	2089	|O
study	2090	2095	|O
of	2096	2098	|O
H1	2099	2101	|O
receptor	2102	2110	|O
-	2110	2111	|O
mediated	2111	2119	|O
functions	2120	2129	|O
.	2129	2130	|O

### abstracts3015.txt
Substrate	0	9	|O
enantioselectivity	10	28	|O
in	29	31	|O
the	32	35	|O
conjugation	36	47	|O
of	48	50	|O
phenethyl	51	60	|O
halides	61	68	|O
catalyzed	69	78	|O
by	79	81	|O
the	82	85	|O
glutathione	86	97	|O
S	98	99	|O
-	99	100	|O
transferases	100	112	|O
was	113	116	|O
studied	117	124	|O
with	125	129	|O
partially	130	139	|O
purified	140	148	|O
isozymes	149	157	|O
from	158	162	|O
rat	163	166	|O
liver	167	172	|O
.	172	173	|O
All	174	177	|O
of	178	180	|O
the	181	184	|O
isozymes	185	193	|O
tested	194	200	|O
possessed	201	210	|O
measurable	211	221	|O
activity	222	230	|O
with	231	235	|O
phenethyl	236	245	|O
chloride	246	254	|O
.	254	255	|O
Tranferase	256	266	|O
A	267	268	|O
was	269	272	|O
the	273	276	|O
most	277	281	|O
active	282	288	|O
isozyme	289	296	|O
tested	297	303	|O
.	303	304	|O
Each	305	309	|O
of	310	312	|O
the	313	316	|O
isozymes	317	325	|O
demonstrated	326	338	|O
a	339	340	|O
high	341	345	|O
degree	346	352	|O
of	353	355	|O
substrate	356	365	|O
enantioselectivity	366	384	|O
,	384	385	|O
with	386	390	|O
transferase	391	402	|O
A	403	404	|O
being	405	410	|O
the	411	414	|O
most	415	419	|O
enantioselective	420	436	|O
isozyme	437	444	|O
.	444	445	|O
The	446	449	|O
enantioselectivity	450	468	|O
was	469	472	|O
determined	473	483	|O
by	484	486	|O
high	487	491	|O
-	491	492	|O
pressure	492	500	|O
liquid	501	507	|O
chromatographic	508	523	|O
analysis	524	532	|O
of	533	535	|O
the	536	539	|O
enzymatically	540	553	|O
formed	554	560	|O
diastereomeric	561	575	|O
products	576	584	|O
.	584	585	|O
The	586	589	|O
effect	590	596	|O
of	597	599	|O
limiting	600	608	|O
glutathione	609	620	|O
concentrations	621	635	|O
on	636	638	|O
the	639	642	|O
stereochemical	643	657	|O
outcome	658	665	|O
of	666	668	|O
the	669	672	|O
transferase	673	684	|O
A	685	686	|O
catalyzed	687	696	|O
conjugation	697	708	|O
of	709	711	|O
the	712	715	|O
chiral	716	722	|O
substrate	723	732	|O
,	732	733	|O
(	734	735	|B-IUPAC
S	735	736	|I-IUPAC
)	736	737	|I-IUPAC
-	737	738	|I-IUPAC
phenethyl	738	747	|I-IUPAC
chloride	748	756	|I-IUPAC
(	757	758	|O
4	758	759	|O
mM	760	762	|O
)	762	763	|O
,	763	764	|O
was	765	768	|O
investigated	769	781	|O
.	781	782	|O
The	783	786	|O
stereochemical	787	801	|O
course	802	808	|O
of	809	811	|O
the	812	815	|O
enzymatic	816	825	|O
reaction	826	834	|O
was	835	838	|O
not	839	842	|O
significantly	843	856	|O
altered	857	864	|O
at	865	867	|O
glutathione	868	879	|O
concentrations	880	894	|O
as	895	897	|O
low	898	901	|O
as	902	904	|O
25	905	907	|O
microM	908	914	|O
.	914	915	|O
The	916	919	|O
major	920	925	|O
product	926	933	|O
of	934	936	|O
conjugation	937	948	|O
had	949	952	|O
the	953	956	|O
opposite	957	965	|O
stereochemistry	966	981	|O
at	982	984	|O
the	985	988	|O
benzylic	989	997	|O
carbon	998	1004	|O
,	1004	1005	|O
indicating	1006	1016	|O
that	1017	1021	|O
the	1022	1025	|O
reaction	1026	1034	|O
proceeded	1035	1044	|O
primarily	1045	1054	|O
with	1055	1059	|O
inversion	1060	1069	|O
of	1070	1072	|O
configuration	1073	1086	|O
.	1086	1087	|O
The	1088	1091	|O
glutathione	1092	1103	|O
conjugates	1104	1114	|O
,	1114	1115	|O
S	1116	1117	|B-IUPAC
-	1117	1118	|I-IUPAC
[	1118	1119	|I-IUPAC
(	1119	1120	|I-IUPAC
R	1120	1121	|I-IUPAC
)	1121	1122	|I-IUPAC
-	1122	1123	|I-IUPAC
1	1123	1124	|I-IUPAC
-	1124	1125	|I-IUPAC
phenylethyl	1125	1136	|I-IUPAC
]	1136	1137	|I-IUPAC
glutathione	1137	1148	|I-IUPAC
,	1148	1149	|O
S	1150	1151	|B-IUPAC
-	1151	1152	|I-IUPAC
[	1152	1153	|I-IUPAC
(	1153	1154	|I-IUPAC
S	1154	1155	|I-IUPAC
)	1155	1156	|I-IUPAC
-	1156	1157	|I-IUPAC
1	1157	1158	|I-IUPAC
-	1158	1159	|I-IUPAC
phenylethyl	1159	1170	|I-IUPAC
]	1170	1171	|I-IUPAC
glutathione	1171	1182	|I-IUPAC
,	1182	1183	|O
S	1184	1185	|B-IUPAC
-	1185	1186	|I-IUPAC
benzylglutathione	1186	1203	|I-IUPAC
,	1203	1204	|O
and	1205	1208	|O
S	1209	1210	|B-IUPAC
-	1210	1211	|I-IUPAC
methylglutathione	1211	1228	|I-IUPAC
were	1229	1233	|O
studied	1234	1241	|O
as	1242	1244	|O
inhibitors	1245	1255	|O
of	1256	1258	|O
the	1259	1262	|O
transferase	1263	1274	|O
A	1275	1276	|O
catalyzed	1277	1286	|O
conjugation	1287	1298	|O
of	1299	1301	|O
1	1302	1303	|B-IUPAC
-	1303	1304	|I-IUPAC
chloro	1304	1310	|I-IUPAC
-	1310	1311	|I-IUPAC
2,4	1311	1314	|I-IUPAC
-	1314	1315	|I-IUPAC
dinitrobenzene	1315	1329	|I-IUPAC
.	1329	1330	|O
The	1331	1334	|O
order	1335	1340	|O
of	1341	1343	|O
the	1344	1347	|O
inhibitory	1348	1358	|O
potency	1359	1366	|O
was	1367	1370	|O
S	1371	1372	|B-IUPAC
-	1372	1373	|I-IUPAC
[	1373	1374	|I-IUPAC
(	1374	1375	|I-IUPAC
S	1375	1376	|I-IUPAC
)	1376	1377	|I-IUPAC
-	1377	1378	|I-IUPAC
1	1378	1379	|I-IUPAC
-	1379	1380	|I-IUPAC
phenylethyl	1380	1391	|I-IUPAC
]	1391	1392	|I-IUPAC
glutathione	1392	1403	|I-IUPAC
=	1404	1405	|O
S	1406	1407	|B-IUPAC
-	1407	1408	|I-IUPAC
benzylglutathione	1408	1425	|I-IUPAC
greater	1426	1433	|O
than	1434	1438	|O
S	1439	1440	|B-IUPAC
-	1440	1441	|I-IUPAC
[	1441	1442	|I-IUPAC
(	1442	1443	|I-IUPAC
R	1443	1444	|I-IUPAC
)	1444	1445	|I-IUPAC
-	1445	1446	|I-IUPAC
1	1446	1447	|I-IUPAC
-	1447	1448	|I-IUPAC
phenylethyl	1448	1459	|I-IUPAC
]	1459	1460	|I-IUPAC
glutathione	1460	1471	|I-IUPAC
greater	1472	1479	|O
than	1480	1484	|O
S	1485	1486	|B-IUPAC
-	1486	1487	|I-IUPAC
methylglutathione	1487	1504	|I-IUPAC
.	1504	1505	|O
This	1506	1510	|O
represented	1511	1522	|O
the	1523	1526	|O
first	1527	1532	|O
demonstration	1533	1546	|O
of	1547	1549	|O
the	1550	1553	|O
stereoselective	1554	1569	|O
product	1570	1577	|O
inhibition	1578	1588	|O
of	1589	1591	|O
the	1592	1595	|O
glutathione	1596	1607	|O
S	1608	1609	|O
-	1609	1610	|O
transferases	1610	1622	|O
.	1622	1623	|O

### abstracts261.txt
Due	0	3	|O
to	4	6	|O
the	7	10	|O
antiviral	11	20	|O
activity	21	29	|O
of	30	32	|O
certain	33	40	|O
5	41	42	|O
-	42	43	|O
substituted	43	54	|O
imidazole	55	64	|O
nucleosides	65	76	|O
related	77	84	|O
to	85	87	|O
ribavirin	88	97	|O
,	97	98	|O
5	99	100	|B-IUPAC
-	100	101	|I-IUPAC
methylimidazole	101	116	|I-IUPAC
-	116	117	|I-IUPAC
4	117	118	|I-IUPAC
-	118	119	|I-IUPAC
carboxamide	119	130	|I-IUPAC
nucleosides	131	142	|B-MODIFIER
having	143	149	|O
beta	150	154	|B-IUPAC
-	154	155	|I-IUPAC
D	155	156	|I-IUPAC
-	156	157	|I-IUPAC
ribofuranosyl	157	170	|I-IUPAC
,	170	171	|O
2	172	173	|B-PARTIUPAC
-	173	174	|I-PARTIUPAC
deoxy	174	179	|I-PARTIUPAC
-	179	180	|I-PARTIUPAC
beta	180	184	|I-PARTIUPAC
-	184	185	|I-PARTIUPAC
and	186	189	|O
-	190	191	|B-PARTIUPAC
alpha	191	196	|I-PARTIUPAC
-	196	197	|I-PARTIUPAC
D	197	198	|I-PARTIUPAC
-	198	199	|I-PARTIUPAC
ribofuranosyl	199	212	|I-PARTIUPAC
,	212	213	|O
and	214	217	|O
(	218	219	|B-IUPAC
2	219	220	|I-IUPAC
-	220	221	|I-IUPAC
hydroxyethoxy	221	234	|I-IUPAC
)	234	235	|I-IUPAC
methyl	235	241	|I-IUPAC
moieties	242	250	|B-MODIFIER
have	251	255	|O
been	256	260	|O
prepared	261	269	|O
and	270	273	|O
tested	274	280	|O
as	281	283	|O
antiviral	284	293	|O
agents	294	300	|O
.	300	301	|O
1	302	303	|B-IUPAC
-	303	304	|I-IUPAC
beta	304	308	|I-IUPAC
-	308	309	|I-IUPAC
D	309	310	|I-IUPAC
-	310	311	|I-IUPAC
Ribofuranosyl	311	324	|I-IUPAC
-	324	325	|I-IUPAC
5	325	326	|I-IUPAC
-	326	327	|I-IUPAC
methylimidazole	327	342	|I-IUPAC
-	342	343	|I-IUPAC
4	343	344	|I-IUPAC
-	344	345	|I-IUPAC
carboxamide	345	356	|I-IUPAC
was	357	360	|O
obtained	361	369	|O
by	370	372	|O
deacetylation	373	386	|O
of	387	389	|O
the	390	393	|O
corresponding	394	407	|O
tri	408	411	|B-IUPAC
-	411	412	|I-IUPAC
O	412	413	|I-IUPAC
-	413	414	|I-IUPAC
acetyl	414	420	|I-IUPAC
nucleoside	421	431	|I-IUPAC
11	432	434	|O
or	435	437	|O
by	438	440	|O
deacetylation	441	454	|O
and	455	458	|O
ammonolysis	459	470	|O
of	471	473	|O
the	474	477	|O
blocked	478	485	|O
ethyl	486	491	|B-IUPAC
5	492	493	|I-IUPAC
-	493	494	|I-IUPAC
methylimidazole	494	509	|I-IUPAC
-	509	510	|I-IUPAC
4	510	511	|I-IUPAC
-	511	512	|I-IUPAC
carboxylate	512	523	|I-IUPAC
nucleoside	524	534	|I-IUPAC
10	535	537	|O
,	537	538	|O
which	539	544	|O
was	545	548	|O
prepared	549	557	|O
from	558	562	|O
the	563	566	|O
stannic	567	574	|O
chloride	575	583	|O
catalyzed	584	593	|O
condensation	594	606	|O
of	607	609	|O
the	610	613	|O
trimethylsilyl	614	628	|B-IUPAC
derivative	629	639	|B-MODIFIER
of	640	642	|O
ethyl	643	648	|B-IUPAC
4	649	650	|I-IUPAC
(	650	651	|I-IUPAC
5	651	652	|I-IUPAC
)	652	653	|I-IUPAC
-	653	654	|I-IUPAC
methylimidazole	654	669	|I-IUPAC
-	669	670	|I-IUPAC
5	670	671	|I-IUPAC
(	671	672	|I-IUPAC
4	672	673	|I-IUPAC
)	673	674	|I-IUPAC
-	674	675	|I-IUPAC
carboxylate	675	686	|I-IUPAC
.	686	687	|O
Glycosylation	688	701	|O
of	702	704	|O
4	705	706	|B-IUPAC
(	706	707	|I-IUPAC
5	707	708	|I-IUPAC
)	708	709	|I-IUPAC
-	709	710	|I-IUPAC
methylimidazole	710	725	|I-IUPAC
-	725	726	|I-IUPAC
5	726	727	|I-IUPAC
(	727	728	|I-IUPAC
4	728	729	|I-IUPAC
)	729	730	|I-IUPAC
-	730	731	|I-IUPAC
carboxamide	731	742	|I-IUPAC
with	743	747	|O
3,5	748	751	|B-IUPAC
-	751	752	|I-IUPAC
di	752	754	|I-IUPAC
-	754	755	|I-IUPAC
O	755	756	|I-IUPAC
-	756	757	|I-IUPAC
p	757	758	|I-IUPAC
-	758	759	|I-IUPAC
toluoyl	759	766	|I-IUPAC
-	766	767	|I-IUPAC
2	767	768	|I-IUPAC
-	768	769	|I-IUPAC
deoxy	769	774	|I-IUPAC
-	774	775	|I-IUPAC
D	775	776	|I-IUPAC
-	776	777	|I-IUPAC
erythro	777	784	|I-IUPAC
-	784	785	|I-IUPAC
pentofuranosyl	785	799	|I-IUPAC
chloride	800	808	|I-IUPAC
via	809	812	|O
mercuric	813	821	|O
cyanide	822	829	|O
method	830	836	|O
provided	837	845	|O
an	846	848	|O
anomeric	849	857	|O
mixture	858	865	|O
of	866	868	|O
the	869	872	|O
blocked	873	880	|O
5	881	882	|B-IUPAC
-	882	883	|I-IUPAC
methylimidazole	883	898	|I-IUPAC
-	898	899	|I-IUPAC
4	899	900	|I-IUPAC
-	900	901	|I-IUPAC
carboxamide	901	912	|I-IUPAC
deoxynucleoside	913	928	|I-IUPAC
14	929	931	|O
along	932	937	|O
with	938	942	|O
an	943	945	|O
anomeric	946	954	|O
mixture	955	962	|O
of	963	965	|O
the	966	969	|O
4	970	971	|B-IUPAC
-	971	972	|I-IUPAC
methyl	972	978	|I-IUPAC
5	979	980	|I-IUPAC
-	980	981	|I-IUPAC
carboxamide	981	992	|I-IUPAC
isomer	993	999	|B-MODIFIER
15	1000	1002	|O
.	1002	1003	|O
Separation	1004	1014	|O
of	1015	1017	|O
compound	1018	1026	|O
14	1027	1029	|O
into	1030	1034	|O
the	1035	1038	|O
corresponding	1039	1052	|O
beta	1053	1057	|O
and	1058	1061	|O
alpha	1062	1067	|O
anomers	1068	1075	|O
was	1076	1079	|O
achieved	1080	1088	|O
by	1089	1091	|O
conversion	1092	1102	|O
to	1103	1105	|O
the	1106	1109	|O
3'	1110	1112	|B-IUPAC
,	1112	1113	|I-IUPAC
5'	1113	1115	|I-IUPAC
-	1115	1116	|I-IUPAC
di	1116	1118	|I-IUPAC
-	1118	1119	|I-IUPAC
O	1119	1120	|I-IUPAC
-	1120	1121	|I-IUPAC
acetyl	1121	1127	|I-IUPAC
derivatives	1128	1139	|B-MODIFIER
17	1140	1142	|O
and	1143	1146	|O
18	1147	1149	|O
,	1149	1150	|O
which	1151	1156	|O
after	1157	1162	|O
chromatographic	1163	1178	|O
separation	1179	1189	|O
were	1190	1194	|O
deacetylated	1195	1207	|O
to	1208	1210	|O
give	1211	1215	|O
1	1216	1217	|B-IUPAC
-	1217	1218	|I-IUPAC
(	1218	1219	|I-IUPAC
2	1219	1220	|I-IUPAC
-	1220	1221	|I-IUPAC
deoxy	1221	1226	|I-IUPAC
-	1226	1227	|I-IUPAC
beta	1227	1231	|I-IUPAC
-	1231	1232	|I-IUPAC
D	1232	1233	|I-IUPAC
-	1233	1234	|I-IUPAC
erythro	1234	1241	|I-IUPAC
-	1241	1242	|I-IUPAC
pentofuranosyl	1242	1256	|I-IUPAC
)	1256	1257	|I-IUPAC
-	1257	1258	|I-IUPAC
5	1258	1259	|I-IUPAC
-	1259	1260	|I-IUPAC
methylimidazole	1260	1275	|I-IUPAC
-	1275	1276	|I-IUPAC
4	1276	1277	|I-IUPAC
-	1277	1278	|I-IUPAC
carboxa	1278	1285	|I-IUPAC
mid	1286	1289	|I-IUPAC
e	1290	1291	|I-IUPAC
and	1292	1295	|O
its	1296	1299	|O
alpha	1300	1305	|O
anomer	1306	1312	|O
20	1313	1315	|O
.	1315	1316	|O
1	1317	1318	|B-IUPAC
-	1318	1319	|I-IUPAC
[	1319	1320	|I-IUPAC
(	1320	1321	|I-IUPAC
2	1321	1322	|I-IUPAC
-	1322	1323	|I-IUPAC
Hydroxyethoxy	1323	1336	|I-IUPAC
)	1336	1337	|I-IUPAC
methyl	1337	1343	|I-IUPAC
]	1343	1344	|I-IUPAC
-	1344	1345	|I-IUPAC
5	1345	1346	|I-IUPAC
-	1346	1347	|I-IUPAC
methylimidazole	1347	1362	|I-IUPAC
-	1362	1363	|I-IUPAC
4	1363	1364	|I-IUPAC
-	1364	1365	|I-IUPAC
carboxamide	1365	1376	|I-IUPAC
was	1377	1380	|O
prepared	1381	1389	|O
by	1390	1392	|O
alkylation	1393	1403	|O
of	1404	1406	|O
the	1407	1410	|O
imidazole	1411	1420	|O
13	1421	1423	|O
with	1424	1428	|O
(	1429	1430	|B-IUPAC
2	1430	1431	|I-IUPAC
-	1431	1432	|I-IUPAC
acetoxyethoxy	1432	1445	|I-IUPAC
)	1445	1446	|I-IUPAC
methyl	1446	1452	|I-IUPAC
bromide	1453	1460	|I-IUPAC
followed	1461	1469	|O
by	1470	1472	|O
treatment	1473	1482	|O
with	1483	1487	|O
methanolic	1488	1498	|O
ammonia	1499	1506	|O
.	1506	1507	|O
All	1508	1511	|O
these	1512	1517	|O
imidazole	1518	1527	|O
nucleosides	1528	1539	|O
were	1540	1544	|O
tested	1545	1551	|O
in	1552	1554	|O
HeLa	1555	1559	|O
cell	1560	1564	|O
cultures	1565	1573	|O
against	1574	1581	|O
type	1582	1586	|O
1	1587	1588	|O
herpes	1589	1595	|O
simplex	1596	1603	|O
and	1604	1607	|O
vesicular	1608	1617	|O
stomatitis	1618	1628	|O
viruses	1629	1636	|O
.	1636	1637	|O
The	1638	1641	|O
ribofuranosyl	1642	1655	|B-IUPAC
derivative	1656	1666	|B-MODIFIER
12	1667	1669	|O
showed	1670	1676	|O
a	1677	1678	|O
significant	1679	1690	|O
activity	1691	1699	|O
against	1700	1707	|O
type	1708	1712	|O
1	1713	1714	|O
herpes	1715	1721	|O
simplex	1722	1729	|O
virus	1730	1735	|O
.	1735	1736	|O

### abstracts3043.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
thymidylate	12	23	|O
synthetase	24	34	|O
inhibitors	35	45	|O
was	46	49	|O
synthesized	50	61	|O
,	61	62	|O
some	63	67	|O
of	68	70	|O
which	71	76	|O
were	77	81	|O
potential	82	91	|O
irreversible	92	104	|O
inhibitors	105	115	|O
.	115	116	|O
5	117	118	|B-IUPAC
-	118	119	|I-IUPAC
Formyl	119	125	|I-IUPAC
-	125	126	|I-IUPAC
2'	126	128	|I-IUPAC
-	128	129	|I-IUPAC
deoxyuridine	129	141	|I-IUPAC
(	142	143	|O
9	143	144	|O
)	144	145	|O
and	146	149	|O
its	150	153	|O
dithiolane	154	164	|B-IUPAC
derivative	165	175	|B-MODIFIER
11	176	178	|O
were	179	183	|O
prepared	184	192	|O
by	193	195	|O
condensation	196	208	|O
of	209	211	|O
the	212	215	|O
bis	216	219	|B-IUPAC
(	219	220	|I-IUPAC
trimethylsilyl	220	234	|I-IUPAC
)	234	235	|I-IUPAC
derivative	236	246	|B-MODIFIER
of	247	249	|O
5	250	251	|B-IUPAC
-	251	252	|I-IUPAC
formyluracil	252	264	|I-IUPAC
dimethyl	265	273	|I-IUPAC
acetal	274	280	|I-IUPAC
and	281	284	|O
the	285	288	|O
protected	289	298	|O
chloro	299	305	|O
sugar	306	311	|O
followed	312	320	|O
by	321	323	|O
saponification	324	338	|O
of	339	341	|O
the	342	345	|O
protective	346	356	|O
groups	357	363	|O
.	363	364	|O
5	365	366	|B-IUPAC
-	366	367	|I-IUPAC
Acetyl	367	373	|I-IUPAC
-	373	374	|I-IUPAC
2'	374	376	|I-IUPAC
-	376	377	|I-IUPAC
deoxyuridine	377	389	|I-IUPAC
(	390	391	|O
15	391	393	|O
)	393	394	|O
was	395	398	|O
prepared	399	407	|O
in	408	410	|O
the	411	414	|O
same	415	419	|O
way	420	423	|O
from	424	428	|O
5	429	430	|B-IUPAC
-	430	431	|I-IUPAC
acetyluracil	431	443	|I-IUPAC
.	443	444	|O
Treatment	445	454	|O
of	455	457	|O
the	458	461	|O
diester	462	469	|O
of	470	472	|O
5	473	474	|B-IUPAC
-	474	475	|I-IUPAC
allyl	475	480	|I-IUPAC
-	480	481	|I-IUPAC
2'	481	483	|I-IUPAC
-	483	484	|I-IUPAC
deoxyuridine	484	496	|I-IUPAC
(	497	498	|O
17	498	500	|O
or	501	503	|O
22	504	506	|O
)	506	507	|O
with	508	512	|O
m	513	514	|B-IUPAC
-	514	515	|I-IUPAC
chloroperbenzoic	515	531	|I-IUPAC
acid	532	536	|I-IUPAC
gave	537	541	|O
the	542	545	|O
corresponding	546	559	|O
epoxide	560	567	|O
.	567	568	|O
Dimethylamine	569	582	|O
removed	583	590	|O
the	591	594	|O
ester	595	600	|O
groups	601	607	|O
and	608	611	|O
opened	612	618	|O
the	619	622	|O
epoxide	623	630	|O
to	631	633	|O
give	634	638	|O
the	639	642	|O
amino	643	648	|O
alcohol	649	656	|O
24	657	659	|O
.	659	660	|O
The	661	664	|O
diester	665	672	|O
of	673	675	|O
5	676	677	|B-IUPAC
-	677	678	|I-IUPAC
chloromethyl	678	690	|I-IUPAC
-	690	691	|I-IUPAC
2'	691	693	|I-IUPAC
-	693	694	|I-IUPAC
deoxyuridine	694	706	|I-IUPAC
(	707	708	|O
27	708	710	|O
)	710	711	|O
treated	712	719	|O
with	720	724	|O
methanol	725	733	|B-IUPAC
or	734	736	|O
sodium	737	743	|O
azide	744	749	|O
gave	750	754	|O
5	755	756	|B-PARTIUPAC
-	756	757	|I-PARTIUPAC
methoxymethyl	757	770	|I-PARTIUPAC
-	770	771	|I-PARTIUPAC
(	772	773	|O
29	773	775	|O
)	775	776	|O
and	777	780	|O
5	781	782	|B-PARTIUPAC
-	782	783	|I-PARTIUPAC
azidomethyl	783	794	|I-PARTIUPAC
-	794	795	|I-PARTIUPAC
(	796	797	|O
31	797	799	|O
)	799	800	|O
2'	801	803	|B-IUPAC
-	803	804	|I-IUPAC
deoxyuridines	804	817	|I-IUPAC
.	817	818	|O
Compound	819	827	|O
27	828	830	|O
also	831	835	|O
was	836	839	|O
converted	840	849	|O
to	850	852	|O
5	853	854	|B-IUPAC
-	854	855	|I-IUPAC
iodoacetamidomethyl	855	874	|I-IUPAC
-	874	875	|I-IUPAC
2'	875	877	|I-IUPAC
-	877	878	|I-IUPAC
deoxyuridine	878	890	|I-IUPAC
by	891	893	|O
treatment	894	903	|O
with	904	908	|O
ammonia	909	916	|O
,	916	917	|O
chloroacetyl	918	930	|O
chloride	931	939	|O
,	939	940	|O
base	941	945	|O
saponification	946	960	|O
,	960	961	|O
and	962	965	|O
finally	966	973	|O
sodium	974	980	|O
iodide	981	987	|O
.	987	988	|O

### abstracts2777.txt
Reaction	0	8	|O
of	9	11	|O
5,6,7,8	12	19	|B-IUPAC
-	19	20	|I-IUPAC
tetrahydrofolic	20	35	|I-IUPAC
acid	36	40	|I-IUPAC
(	41	42	|O
THF	42	45	|O
,	45	46	|O
7	46	47	|O
)	47	48	|O
with	49	53	|O
phosgene	54	62	|O
,	62	63	|O
thiophosgene	64	76	|O
,	76	77	|O
and	78	81	|O
cyanogen	82	90	|O
bromide	91	98	|O
gave	99	103	|O
the	104	107	|O
bridged	108	115	|O
derivatives	116	127	|O
,	127	128	|O
5,10	129	133	|O
-	133	134	|O
(	134	135	|O
CO	135	137	|O
)	137	138	|O
-	138	139	|O
THF	139	142	|O
(	143	144	|O
8	144	145	|O
)	145	146	|O
,	146	147	|O
5,10	148	152	|O
-	152	153	|O
(	153	154	|O
CS	154	156	|O
)	156	157	|O
-	157	158	|O
THF	158	161	|O
(	162	163	|O
9	163	164	|O
)	164	165	|O
,	165	166	|O
and	167	170	|O
5,10	171	175	|O
-	175	176	|O
(	176	177	|O
C	177	178	|O
=	179	180	|O
NH	181	183	|O
)	183	184	|O
-	184	185	|O
THF	185	188	|O
(	189	190	|O
11	190	192	|O
)	192	193	|O
,	193	194	|O
respectively	195	207	|O
.	207	208	|O
Catalytic	209	218	|O
hydrogenation	219	232	|O
of	233	235	|O
10	236	238	|B-IUPAC
-	238	239	|I-IUPAC
(	239	240	|I-IUPAC
chloroacetyl	240	252	|I-IUPAC
)	252	253	|I-IUPAC
folic	253	258	|I-IUPAC
acid	259	263	|I-IUPAC
(	264	265	|O
2	265	266	|O
)	266	267	|O
gave	268	272	|O
5,10	273	277	|O
-	277	278	|O
(	278	279	|O
CH2CO	279	284	|O
)	284	285	|O
-	285	286	|O
THF	286	289	|O
(	290	291	|O
12	291	293	|O
)	293	294	|O
.	294	295	|O
A	296	297	|O
similar	298	305	|O
reaction	306	314	|O
with	315	319	|O
10	320	322	|B-IUPAC
-	322	323	|I-IUPAC
(	323	324	|I-IUPAC
3	324	325	|I-IUPAC
-	325	326	|I-IUPAC
chloropropionyl	326	341	|I-IUPAC
)	341	342	|I-IUPAC
folic	342	347	|I-IUPAC
acid	348	352	|I-IUPAC
(	353	354	|O
3	354	355	|O
)	355	356	|O
gave	357	361	|O
10	362	364	|O
-	364	365	|O
(	365	366	|O
ClCH2CH2CO	366	376	|O
)	376	377	|O
-	377	378	|O
THF	378	381	|O
(	382	383	|O
14	383	385	|O
)	385	386	|O
rather	387	393	|O
than	394	398	|O
5,10	399	403	|O
-	403	404	|O
(	404	405	|O
CH2CH2CO	405	413	|O
)	413	414	|O
-	414	415	|O
THF	415	418	|O
(	419	420	|O
13	420	422	|O
)	422	423	|O
.	423	424	|O
In	425	427	|O
the	428	431	|O
catalytic	432	441	|O
hydrogenation	442	455	|O
of	456	458	|O
10	459	461	|B-IUPAC
-	461	462	|I-IUPAC
ethoxalylfolic	462	476	|I-IUPAC
acid	477	481	|I-IUPAC
(	482	483	|O
5	483	484	|O
)	484	485	|O
,	485	486	|O
the	487	490	|O
initial	491	498	|O
product	499	506	|O
10	507	509	|O
-	509	510	|O
(	510	511	|O
EtO2CCO	511	518	|O
)	518	519	|O
-	519	520	|O
THF	520	523	|O
(	524	525	|O
22	525	527	|O
)	527	528	|O
rearranged	529	539	|O
readily	540	547	|O
to	548	550	|O
give	551	555	|O
5	556	557	|O
-	557	558	|O
(	558	559	|O
EtO2CCO	559	566	|O
)	566	567	|O
-	567	568	|O
THF	568	571	|O
(	572	573	|O
21	573	575	|O
)	575	576	|O
.	576	577	|O
Acylation	578	587	|O
of	588	590	|O
THF	591	594	|O
with	595	599	|O
chloroacetyl	600	612	|O
chloride	613	621	|O
gave	622	626	|O
a	627	628	|O
N5	629	631	|O
,	631	632	|O
N10	632	635	|O
-	635	636	|O
diacylated	636	646	|O
product	647	654	|O
(	655	656	|O
18	656	658	|O
or	659	661	|O
19	662	664	|O
)	664	665	|O
,	665	666	|O
which	667	672	|O
could	673	678	|O
not	679	682	|O
be	683	685	|O
converted	686	695	|O
to	696	698	|O
5,10	699	703	|O
-	703	704	|O
COCH2	704	709	|O
)	709	710	|O
-	710	711	|O
THF	711	714	|O
(	715	716	|O
17	716	718	|O
)	718	719	|O
.	719	720	|O
Reductive	721	730	|O
alkylation	731	741	|O
of	742	744	|O
THF	745	748	|O
with	749	753	|O
glyoxylic	754	763	|O
acid	764	768	|O
and	769	772	|O
5	773	774	|B-IUPAC
-	774	775	|I-IUPAC
hydroxypentanal	775	790	|I-IUPAC
,	790	791	|O
respectively	792	804	|O
,	804	805	|O
gave	806	810	|O
5	811	812	|O
-	812	813	|O
(	813	814	|O
HO2CCH2	814	821	|O
)	821	822	|O
-	822	823	|O
THF	823	826	|O
(	827	828	|O
24	828	830	|O
)	830	831	|O
and	832	835	|O
5	836	837	|O
-	837	838	|O
[	838	839	|O
HO	839	841	|O
(	841	842	|O
CH2	842	845	|O
)	845	846	|O
5	846	847	|O
]	847	848	|O
-	848	849	|O
THF	849	852	|O
(	853	854	|O
25	854	856	|O
)	856	857	|O
.	857	858	|O
Reductive	859	868	|O
dialkylation	869	881	|O
of	882	884	|O
THF	885	888	|O
with	889	893	|O
formaldehyde	894	906	|O
gave	907	911	|O
5,10	912	916	|O
-	916	917	|O
(	917	918	|O
CH3	918	921	|O
)	921	922	|O
2	922	923	|O
-	923	924	|O
THF	924	927	|O
(	928	929	|O
27	929	931	|O
)	931	932	|O
,	932	933	|O
whereas	934	941	|O
glyoxal	942	949	|O
gave	950	954	|O
5,10	955	959	|O
-	959	960	|O
CH2CH2	960	966	|O
)	966	967	|O
-	967	968	|O
THF	968	971	|O
(	972	973	|O
10	973	975	|O
)	975	976	|O
.	976	977	|O
Also	978	982	|O
,	982	983	|O
both	984	988	|O
folic	989	994	|O
acid	995	999	|O
and	1000	1003	|O
5	1004	1005	|O
-	1005	1006	|O
(	1006	1007	|O
CHO	1007	1010	|O
)	1010	1011	|O
-	1011	1012	|O
THF	1012	1015	|O
were	1016	1020	|O
reductively	1021	1032	|O
alkylated	1033	1042	|O
with	1043	1047	|O
formaldehyde	1048	1060	|O
to	1061	1063	|O
give	1064	1068	|O
10	1069	1071	|B-IUPAC
-	1071	1072	|I-IUPAC
methylfolic	1072	1083	|I-IUPAC
acid	1084	1088	|I-IUPAC
(	1089	1090	|O
6	1090	1091	|O
)	1091	1092	|O
and	1093	1096	|O
5	1097	1098	|O
-	1098	1099	|O
(	1099	1100	|O
CHO	1100	1103	|O
)	1103	1104	|O
-	1104	1105	|O
10	1105	1107	|O
-	1107	1108	|O
(	1108	1109	|O
CH3	1109	1112	|O
)	1112	1113	|O
-	1113	1114	|O
THF	1114	1117	|O
(	1118	1119	|O
28	1119	1121	|O
)	1121	1122	|O
,	1122	1123	|O
respectively	1124	1136	|O
.	1136	1137	|O
These	1138	1143	|O
compounds	1144	1153	|O
were	1154	1158	|O
tested	1159	1165	|O
as	1166	1168	|O
inhibitors	1169	1179	|O
of	1180	1182	|O
the	1183	1186	|O
enzymes	1187	1194	|O
involved	1195	1203	|O
in	1204	1206	|O
folate	1207	1213	|O
metabolism	1214	1224	|O
and	1225	1228	|O
for	1229	1232	|O
activity	1233	1241	|O
against	1242	1249	|O
lymphocytic	1250	1261	|O
leukemia	1262	1270	|O
P388	1271	1275	|O
in	1276	1278	|O
mice	1279	1283	|O
.	1283	1284	|O

### abstracts2562.txt
A	0	1	|O
broad	2	7	|O
screening	8	17	|O
of	18	20	|O
phytochemicals	21	35	|O
has	36	39	|O
demonstrated	40	52	|O
that	53	57	|O
certain	58	65	|O
flavone	66	73	|O
and	74	77	|O
flavonol	78	86	|O
derivatives	87	98	|O
have	99	103	|O
a	104	105	|O
relatively	106	116	|O
high	117	121	|O
affinity	122	130	|O
at	131	133	|O
A3	134	136	|O
adenosine	137	146	|O
receptors	147	156	|O
,	156	157	|O
with	158	162	|O
Ki	163	165	|O
values	166	172	|O
of	173	175	|O
&	176	177	|O
gt	177	179	|O
;	179	180	|O
or	181	183	|O
=	184	185	|O
1	186	187	|O
microM	188	194	|O
(	195	196	|O
Ji	196	198	|O
et	199	201	|O
al.	202	205	|O
J	206	207	|O
.	207	208	|O
Med.	209	213	|O
Chem.	214	219	|O
1996	220	224	|O
,	224	225	|O
39	226	228	|O
,	228	229	|O
781-788	230	237	|O
)	237	238	|O
.	238	239	|O
We	240	242	|O
have	243	247	|O
further	248	255	|O
modified	256	264	|O
the	265	268	|O
flavone	269	276	|O
structure	277	286	|O
to	287	289	|O
achieve	290	297	|O
a	298	299	|O
degree	300	306	|O
of	307	309	|O
selectivity	310	321	|O
for	322	325	|O
cloned	326	332	|O
human	333	338	|O
brain	339	344	|O
A3	345	347	|O
receptors	348	357	|O
,	357	358	|O
determined	359	369	|O
in	370	372	|O
competitive	373	384	|O
binding	385	392	|O
assays	393	399	|O
versus	400	406	|O
[	407	408	|O
125I	408	412	|O
]	412	413	|O
AB	413	415	|O
-	415	416	|O
MECA	416	420	|O
[	420	421	|O
N6	421	423	|B-IUPAC
-	423	424	|I-IUPAC
(	424	425	|I-IUPAC
4	425	426	|I-IUPAC
-	426	427	|I-IUPAC
amino	427	432	|I-IUPAC
-	432	433	|I-IUPAC
3	433	434	|I-IUPAC
-	434	435	|I-IUPAC
iodobenzyl	435	445	|I-IUPAC
)	445	446	|I-IUPAC
adenosine	446	455	|I-IUPAC
-	455	456	|I-IUPAC
5'	456	458	|I-IUPAC
-	458	459	|I-IUPAC
(	459	460	|I-IUPAC
N	460	461	|I-IUPAC
-	461	462	|I-IUPAC
methylur	462	470	|I-IUPAC
onamide	471	478	|I-IUPAC
)	478	479	|I-IUPAC
]	479	480	|O
.	480	481	|O
Affinity	482	490	|O
was	491	494	|O
determined	495	505	|O
in	506	508	|O
radioligand	509	520	|O
binding	521	528	|O
assays	529	535	|O
at	536	538	|O
rat	539	542	|O
brain	543	548	|O
A1	549	551	|O
and	552	555	|O
A2a	556	559	|O
receptors	560	569	|O
using	570	575	|O
[	576	577	|O
3H	577	579	|O
]	579	580	|O
-	580	581	|O
N6	581	583	|O
-	583	584	|O
PIA	584	587	|O
(	588	589	|O
[	589	590	|B-IUPAC
3H	590	592	|I-IUPAC
]	592	593	|I-IUPAC
-	593	594	|I-IUPAC
(	594	595	|I-IUPAC
R	595	596	|I-IUPAC
)	596	597	|I-IUPAC
-	597	598	|I-IUPAC
N6	598	600	|I-IUPAC
-	600	601	|I-IUPAC
phenylisopropyladenosine	601	625	|I-IUPAC
)	625	626	|O
and	627	630	|O
[	631	632	|O
3H	632	634	|O
]	634	635	|O
CGS21680	635	643	|O
[	644	645	|O
[	645	646	|B-IUPAC
3H	646	648	|I-IUPAC
]	648	649	|I-IUPAC
-	649	650	|I-IUPAC
2	650	651	|I-IUPAC
-	651	652	|I-IUPAC
[	652	653	|I-IUPAC
[	653	654	|I-IUPAC
4	654	655	|I-IUPAC
-	655	656	|I-IUPAC
(	656	657	|I-IUPAC
2	657	658	|I-IUPAC
-	658	659	|I-IUPAC
carboxyethyl	659	671	|I-IUPAC
)	671	672	|I-IUPAC
phenyl	672	678	|I-IUPAC
]	678	679	|I-IUPAC
ethylamino	679	689	|I-IUPAC
]	689	690	|I-IUPAC
-	690	691	|I-IUPAC
5'	691	693	|I-IUPAC
-	693	694	|I-IUPAC
(	694	695	|I-IUPAC
N	695	696	|I-IUPAC
-	696	697	|I-IUPAC
ethylcarbamoyl+	697	712	|I-IUPAC
+	712	713	|I-IUPAC
+	714	715	|I-IUPAC
)	715	716	|I-IUPAC
adenosine	716	725	|I-IUPAC
]	725	726	|O
,	726	727	|O
respectively	728	740	|O
.	740	741	|O
The	742	745	|O
triethyl	746	754	|O
and	755	758	|O
tripropyl	759	768	|O
ether	769	774	|O
derivatives	775	786	|O
of	787	789	|O
the	790	793	|O
flavonol	794	802	|O
galangin	803	811	|O
,	811	812	|O
4	813	814	|O
,	814	815	|O
had	816	819	|O
Ki	820	822	|O
values	823	829	|O
of	830	832	|O
0.3	833	836	|O
-	837	838	|O
0.4	839	842	|O
microM	843	849	|O
at	850	852	|O
human	853	858	|O
A3	859	861	|O
receptors	862	871	|O
.	871	872	|O
The	873	876	|O
presence	877	885	|O
of	886	888	|O
a	889	890	|O
5	891	892	|B-IUPAC
-	892	893	|I-IUPAC
hydroxyl	893	901	|I-IUPAC
group	902	907	|B-MODIFIER
increased	908	917	|O
selectivity	918	929	|O
of	930	932	|O
flavonols	933	942	|O
for	943	946	|O
human	947	952	|O
A3	953	955	|O
receptors	956	965	|O
.	965	966	|O
The	967	970	|O
2'	971	973	|B-IUPAC
,	973	974	|I-IUPAC
3,4	974	977	|I-IUPAC
'	977	978	|I-IUPAC
,	978	979	|I-IUPAC
7	979	980	|I-IUPAC
-	980	981	|I-IUPAC
tetraethyl	981	991	|I-IUPAC
ether	992	997	|I-IUPAC
derivative	998	1008	|B-MODIFIER
of	1009	1011	|O
the	1012	1015	|O
flavonol	1016	1024	|O
morin	1025	1030	|O
,	1030	1031	|O
7	1032	1033	|O
,	1033	1034	|O
displayed	1035	1044	|O
a	1045	1046	|O
Ki	1047	1049	|O
value	1050	1055	|O
of	1056	1058	|O
4.8	1059	1062	|O
microM	1063	1069	|O
at	1070	1072	|O
human	1073	1078	|O
A3	1079	1081	|O
receptors	1082	1091	|O
and	1092	1095	|O
was	1096	1099	|O
inactive	1100	1108	|O
at	1109	1111	|O
rat	1112	1115	|O
A1	1116	1118	|O
/	1118	1119	|O
A2a	1119	1122	|O
receptors	1123	1132	|O
.	1132	1133	|O
3,6	1134	1137	|B-IUPAC
-	1137	1138	|I-IUPAC
Dichloro	1138	1146	|I-IUPAC
-	1146	1147	|I-IUPAC
2'	1147	1149	|I-IUPAC
-	1149	1150	|I-IUPAC
(	1150	1151	|I-IUPAC
isopropyloxy	1151	1163	|I-IUPAC
)	1163	1164	|I-IUPAC
-	1164	1165	|I-IUPAC
4'	1165	1167	|I-IUPAC
-	1167	1168	|I-IUPAC
methylflavone	1168	1181	|I-IUPAC
,	1181	1182	|O
11e	1183	1186	|O
,	1186	1187	|O
was	1188	1191	|O
both	1192	1196	|O
potent	1197	1203	|O
and	1204	1207	|O
highly	1208	1214	|O
selective	1215	1224	|O
(	1225	1226	|O
approximately	1226	1239	|O
200	1240	1243	|O
-	1243	1244	|O
fold	1244	1248	|O
)	1248	1249	|O
for	1250	1253	|O
human	1254	1259	|O
A3	1260	1262	|O
receptors	1263	1272	|O
(	1273	1274	|O
Ki	1274	1276	|O
=	1277	1278	|O
0.56	1279	1283	|O
microM	1284	1290	|O
)	1290	1291	|O
.	1291	1292	|O
Among	1293	1298	|O
dihydroflavonol	1299	1314	|O
analogues	1315	1324	|O
,	1324	1325	|O
the	1326	1329	|O
2	1330	1331	|B-IUPAC
-	1331	1332	|I-IUPAC
styryl	1332	1338	|I-IUPAC
instead	1339	1346	|O
of	1347	1349	|O
the	1350	1353	|O
2	1354	1355	|B-IUPAC
-	1355	1356	|I-IUPAC
aryl	1356	1360	|I-IUPAC
substituent	1361	1372	|B-MODIFIER
,	1372	1373	|O
in	1374	1376	|O
15	1377	1379	|O
,	1379	1380	|O
afforded	1381	1389	|O
selectivity	1390	1401	|O
for	1402	1405	|O
human	1406	1411	|O
A3	1412	1414	|O
vs	1415	1417	|O
rat	1418	1421	|O
A1	1422	1424	|O
or	1425	1427	|O
A2A	1428	1431	|O
receptors	1432	1441	|O
.	1441	1442	|O
The	1443	1446	|O
2	1447	1448	|B-IUPAC
-	1448	1449	|I-IUPAC
styryl	1449	1455	|I-IUPAC
-	1455	1456	|I-IUPAC
6	1456	1457	|I-IUPAC
-	1457	1458	|I-IUPAC
propoxy	1458	1465	|I-IUPAC
derivative	1466	1476	|B-MODIFIER
,	1476	1477	|O
20	1478	1480	|O
,	1480	1481	|O
of	1482	1484	|O
the	1485	1488	|O
furanochromone	1489	1503	|O
visnagin	1504	1512	|O
was	1513	1516	|O
30	1517	1519	|O
-	1519	1520	|O
fold	1520	1524	|O
selective	1525	1534	|O
for	1535	1538	|O
human	1539	1544	|O
A3	1545	1547	|O
receptors	1548	1557	|O
vs	1558	1560	|O
either	1561	1567	|O
rat	1568	1571	|O
A1	1572	1574	|O
or	1575	1577	|O
A2A	1578	1581	|O
receptors	1582	1591	|O
.	1591	1592	|O
Several	1593	1600	|O
of	1601	1603	|O
the	1604	1607	|O
more	1608	1612	|O
potent	1613	1619	|O
derivatives	1620	1631	|O
effectively	1632	1643	|O
antagonized	1644	1655	|O
the	1656	1659	|O
effects	1660	1667	|O
of	1668	1670	|O
an	1671	1673	|O
agonist	1674	1681	|O
in	1682	1684	|O
a	1685	1686	|O
functional	1687	1697	|O
A3	1698	1700	|O
receptor	1701	1709	|O
assay	1710	1715	|O
,	1715	1716	|O
i.e.	1717	1721	|O
inhibition	1722	1732	|O
of	1733	1735	|O
adenylyl	1736	1744	|B-IUPAC
cyclase	1745	1752	|I-IUPAC
in	1753	1755	|O
CHO	1756	1759	|O
cells	1760	1765	|O
expressing	1766	1776	|O
cloned	1777	1783	|O
rat	1784	1787	|O
A3	1788	1790	|O
receptors	1791	1800	|O
.	1800	1801	|O
In	1802	1804	|O
conclusion	1805	1815	|O
,	1815	1816	|O
these	1817	1822	|O
series	1823	1829	|O
of	1830	1832	|O
flavonoids	1833	1843	|O
provide	1844	1851	|O
leads	1852	1857	|O
for	1858	1861	|O
the	1862	1865	|O
development	1866	1877	|O
of	1878	1880	|O
novel	1881	1886	|O
potent	1887	1893	|O
and	1894	1897	|O
subtype	1898	1905	|O
selective	1906	1915	|O
A3	1916	1918	|O
antagonists	1919	1930	|O
.	1930	1931	|O

### abstracts875.txt
A	0	1	|O
number	2	8	|O
of	9	11	|O
novel	12	17	|O
dihydropyridine	18	33	|O
derivatives	34	45	|O
based	46	51	|O
upon	52	56	|O
1	57	58	|B-IUPAC
,	58	59	|I-IUPAC
4	60	61	|I-IUPAC
-	61	62	|I-IUPAC
dihydro	62	69	|I-IUPAC
-	69	70	|I-IUPAC
3	70	71	|I-IUPAC
-	71	72	|I-IUPAC
(	72	73	|I-IUPAC
methoxycarbonyl	73	88	|I-IUPAC
)	88	89	|I-IUPAC
-	89	90	|I-IUPAC
2	90	91	|I-IUPAC
,	91	92	|I-IUPAC
6	93	94	|I-IUPAC
-	94	95	|I-IUPAC
dimethyl	95	103	|I-IUPAC
-	103	104	|I-IUPAC
4	104	105	|I-IUPAC
-	105	106	|I-IUPAC
(	106	107	|I-IUPAC
4	107	108	|I-IUPAC
-	108	109	|I-IUPAC
nitrophenyl	109	120	|I-IUPAC
)	120	121	|I-IUPAC
-	121	122	|I-IUPAC
5	122	123	|I-IUPAC
-	123	124	|I-IUPAC
(	124	125	|I-IUPAC
(	125	126	|I-IUPAC
3	126	127	|I-IUPAC
-	127	128	|I-IUPAC
(	128	129	|I-IUPAC
4	129	130	|I-IUPAC
,	130	131	|I-IUPAC
4	132	133	|I-IUPAC
-	133	134	|I-IUPAC
diphenylpiperidin	134	151	|I-IUPAC
-	151	152	|I-IUPAC
1	152	153	|I-IUPAC
-	153	154	|I-IUPAC
yl	154	156	|I-IUPAC
)	156	157	|I-IUPAC
propyl	157	163	|I-IUPAC
)	163	164	|I-IUPAC
aminocarbonyl	164	177	|I-IUPAC
)	177	178	|I-IUPAC
pyridine	178	186	|I-IUPAC
(	187	188	|O
4	188	189	|O
)	189	190	|O
have	191	195	|O
been	196	200	|O
synthesized	201	212	|O
and	213	216	|O
tested	217	223	|O
at	224	226	|O
cloned	227	233	|O
human	234	239	|O
alpha	240	245	|O
adrenoceptors	246	259	|O
as	260	262	|O
well	263	267	|O
as	268	270	|O
the	271	274	|O
rat	275	278	|O
L	279	280	|O
-	280	281	|O
type	281	285	|O
calcium	286	293	|O
channel	294	301	|O
.	301	302	|O
Within	303	309	|O
this	310	314	|O
compound	315	323	|O
series	324	330	|O
,	330	331	|O
5	332	333	|B-IUPAC
-	333	334	|I-IUPAC
(	334	335	|I-IUPAC
aminocarbonyl	335	348	|I-IUPAC
)	348	349	|I-IUPAC
-	349	350	|I-IUPAC
1,4	350	353	|I-IUPAC
-	353	354	|I-IUPAC
dihydro	354	361	|I-IUPAC
-	361	362	|I-IUPAC
2	362	363	|I-IUPAC
,	363	364	|I-IUPAC
6	365	366	|I-IUPAC
-	366	367	|I-IUPAC
dimethyl	367	375	|I-IUPAC
-	375	376	|I-IUPAC
4	376	377	|I-IUPAC
-	377	378	|I-IUPAC
(	378	379	|I-IUPAC
4	379	380	|I-IUPAC
-	380	381	|I-IUPAC
nitrophenyl	381	392	|I-IUPAC
)	392	393	|I-IUPAC
-	393	394	|I-IUPAC
3	394	395	|I-IUPAC
-	395	396	|I-IUPAC
(	396	397	|I-IUPAC
(	397	398	|I-IUPAC
3	398	399	|I-IUPAC
-	399	400	|I-IUPAC
(	400	401	|I-IUPAC
4	401	402	|I-IUPAC
,	402	403	|I-IUPAC
4	404	405	|I-IUPAC
-	405	406	|I-IUPAC
diphenylpiperidin	406	423	|I-IUPAC
-	423	424	|I-IUPAC
1	424	425	|I-IUPAC
-	425	426	|I-IUPAC
yl	426	428	|I-IUPAC
)	428	429	|I-IUPAC
propyl	429	435	|I-IUPAC
)	435	436	|I-IUPAC
aminocarbonyl	436	449	|I-IUPAC
)	449	450	|I-IUPAC
pyridine	450	458	|I-IUPAC
(	459	460	|O
19	460	462	|O
)	462	463	|O
displayed	464	473	|O
good	474	478	|O
binding	479	486	|O
affinity	487	495	|O
and	496	499	|O
selectivity	500	511	|O
for	512	515	|O
the	516	519	|O
alpha1a	520	527	|O
adrenoceptor	528	540	|O
(	541	542	|O
pKi	542	545	|O
=	546	547	|O
8.73	548	552	|O
)	552	553	|O
and	554	557	|O
potently	558	566	|O
inhibited	567	576	|O
(	577	578	|O
pA2	578	581	|O
=	582	583	|O
9.23	584	588	|O
)	588	589	|O
phenylephrine	590	603	|O
-	603	604	|O
induced	604	611	|O
contraction	612	623	|O
of	624	626	|O
the	627	630	|O
human	631	636	|O
prostate	637	645	|O
.	645	646	|O

### abstracts1462.txt
The	0	3	|O
synthesis	4	13	|O
of	14	16	|O
several	17	24	|O
analogues	25	34	|O
of	35	37	|O
(	38	39	|B-IUPAC
8R	39	41	|I-IUPAC
)	41	42	|I-IUPAC
-	42	43	|I-IUPAC
3	43	44	|I-IUPAC
-	44	45	|I-IUPAC
(	45	46	|I-IUPAC
2	46	47	|I-IUPAC
-	47	48	|I-IUPAC
deoxy	48	53	|I-IUPAC
-	53	54	|I-IUPAC
beta	54	58	|I-IUPAC
-	58	59	|I-IUPAC
D	59	60	|I-IUPAC
-	60	61	|I-IUPAC
erythro	61	68	|I-IUPAC
-	68	69	|I-IUPAC
pentofuranosyl	70	84	|I-IUPAC
)	84	85	|I-IUPAC
-	85	86	|I-IUPAC
3,6,7,8	86	93	|I-IUPAC
-	93	94	|I-IUPAC
tetrahydroimidazo	94	111	|I-IUPAC
[	111	112	|I-IUPAC
4,5	112	115	|I-IUPAC
-	115	116	|I-IUPAC
d	116	117	|I-IUPAC
]	117	118	|I-IUPAC
[	118	119	|I-IUPAC
1,3	119	122	|I-IUPAC
]	122	123	|I-IUPAC
diazepin	123	131	|I-IUPAC
-	131	132	|I-IUPAC
8	132	133	|I-IUPAC
-	133	134	|I-IUPAC
ol	134	136	|I-IUPAC
(	137	138	|O
pentostatin	138	149	|O
,	149	150	|O
1a	151	153	|O
)	153	154	|O
is	155	157	|O
described	158	167	|O
.	167	168	|O
Ring	169	173	|O
closure	174	181	|O
of	182	184	|O
2	185	186	|B-IUPAC
-	186	187	|I-IUPAC
amino	187	192	|I-IUPAC
-	192	193	|I-IUPAC
1	193	194	|I-IUPAC
-	194	195	|I-IUPAC
(	195	196	|I-IUPAC
5	196	197	|I-IUPAC
-	197	198	|I-IUPAC
amino	198	203	|I-IUPAC
-	203	204	|I-IUPAC
1H	204	206	|I-IUPAC
-	206	207	|I-IUPAC
imidazol	207	215	|I-IUPAC
-	215	216	|I-IUPAC
4	216	217	|I-IUPAC
-	217	218	|I-IUPAC
yl	218	220	|I-IUPAC
)	220	221	|I-IUPAC
ethanone	221	229	|I-IUPAC
dihydrochloride	230	245	|I-IUPAC
(	246	247	|O
3	247	248	|O
)	248	249	|O
with	250	254	|O
triethyl	255	263	|B-IUPAC
orthoacetate	264	276	|I-IUPAC
or	277	279	|O
triethyl	280	288	|B-IUPAC
orthopropionate	289	304	|I-IUPAC
gave	305	309	|O
the	310	313	|O
C	314	315	|B-MODIFIER
-	315	316	|I-MODIFIER
5	316	317	|I-MODIFIER
methyl	318	324	|B-IUPAC
and	325	328	|O
ethyl	329	334	|B-IUPAC
ketoaglycons	335	347	|I-IUPAC
,	347	348	|O
6,7	349	352	|B-IUPAC
-	352	353	|I-IUPAC
dihydro	353	360	|I-IUPAC
-	360	361	|I-IUPAC
5	361	362	|I-IUPAC
-	362	363	|I-IUPAC
methylimidazo	363	376	|I-IUPAC
[	376	377	|I-IUPAC
4,5	377	380	|I-IUPAC
-	380	381	|I-IUPAC
d	381	382	|I-IUPAC
]	382	383	|I-IUPAC
[	383	384	|I-IUPAC
1,3	384	387	|I-IUPAC
]	387	388	|I-IUPAC
diazepin	388	396	|I-IUPAC
-	396	397	|I-IUPAC
8	397	398	|I-IUPAC
(	398	399	|I-IUPAC
3H	399	401	|I-IUPAC
)	401	402	|I-IUPAC
-	402	403	|I-IUPAC
one	403	406	|I-IUPAC
(	407	408	|O
4b	408	410	|O
)	410	411	|O
and	412	415	|O
5	416	417	|B-IUPAC
-	417	418	|I-IUPAC
ethyl	418	423	|I-IUPAC
-	423	424	|I-IUPAC
6,7	424	427	|I-IUPAC
-	427	428	|I-IUPAC
dihydroimidazo	428	442	|I-IUPAC
[	442	443	|I-IUPAC
4,5	443	446	|I-IUPAC
-	446	447	|I-IUPAC
d	447	448	|I-IUPAC
]	448	449	|I-IUPAC
[	449	450	|I-IUPAC
1,3	450	453	|I-IUPAC
]	453	454	|I-IUPAC
diazepin	454	462	|I-IUPAC
-	462	463	|I-IUPAC
8	463	464	|I-IUPAC
(	464	465	|I-IUPAC
3H	465	467	|I-IUPAC
)	467	468	|I-IUPAC
-	468	469	|I-IUPAC
one	469	472	|I-IUPAC
(	473	474	|O
4c	474	476	|O
)	476	477	|O
,	477	478	|O
respectively	479	491	|O
.	491	492	|O
Stannic	493	500	|O
chloride	501	509	|O
catalyzed	510	519	|O
condensation	520	532	|O
of	533	535	|O
the	536	539	|O
pertrimethylsilyl	540	557	|O
derivatives	558	569	|O
of	570	572	|O
4b	573	575	|O
and	576	579	|O
4c	580	582	|O
with	583	587	|O
a	588	589	|O
protected	590	599	|O
glycosyl	600	608	|O
halide	609	615	|O
afforded	616	624	|O
anomeric	625	633	|O
mixtures	634	642	|O
of	643	645	|O
ketonucleosides	646	661	|O
3	662	663	|B-PARTIUPAC
-	663	664	|I-PARTIUPAC
(	664	665	|I-PARTIUPAC
2	665	666	|I-PARTIUPAC
-	666	667	|I-PARTIUPAC
deoxy	667	672	|I-PARTIUPAC
-	672	673	|I-PARTIUPAC
3,5	673	676	|I-PARTIUPAC
-	676	677	|I-PARTIUPAC
di	677	679	|I-PARTIUPAC
-	679	680	|I-PARTIUPAC
O	680	681	|I-PARTIUPAC
-	681	682	|I-PARTIUPAC
p	682	683	|I-PARTIUPAC
-	683	684	|I-PARTIUPAC
toluoyl	684	691	|I-PARTIUPAC
-	691	692	|I-PARTIUPAC
beta	692	696	|I-PARTIUPAC
-	696	697	|I-PARTIUPAC
and	698	701	|O
-	702	703	|B-PARTIUPAC
alpha	703	708	|I-PARTIUPAC
-	708	709	|I-PARTIUPAC
D	709	710	|I-PARTIUPAC
-	710	711	|I-PARTIUPAC
erythro	711	718	|I-PARTIUPAC
-	718	719	|I-PARTIUPAC
pentofuranosyl	719	733	|I-PARTIUPAC
)	733	734	|I-PARTIUPAC
-	734	735	|I-PARTIUPAC
6,7	735	738	|I-PARTIUPAC
-	738	739	|I-PARTIUPAC
dihydro	739	746	|I-PARTIUPAC
-	746	747	|I-PARTIUPAC
5	747	748	|I-PARTIUPAC
-	748	749	|I-PARTIUPAC
methylimidazo	749	762	|I-PARTIUPAC
[	762	763	|I-PARTIUPAC
4,5	763	766	|I-PARTIUPAC
-	766	767	|I-PARTIUPAC
d	767	768	|I-PARTIUPAC
]	768	769	|I-PARTIUPAC
[	770	771	|I-PARTIUPAC
1,3	771	774	|I-PARTIUPAC
]	774	775	|I-PARTIUPAC
diazepin	775	783	|I-PARTIUPAC
-	783	784	|I-PARTIUPAC
8	784	785	|I-PARTIUPAC
(	785	786	|I-PARTIUPAC
3H	786	788	|I-PARTIUPAC
)	788	789	|I-PARTIUPAC
-	789	790	|I-PARTIUPAC
one	790	793	|I-PARTIUPAC
(	794	795	|O
5b	795	797	|O
and	798	801	|O
6b	802	804	|O
)	804	805	|O
and	806	809	|O
3	810	811	|B-PARTIUPAC
-	811	812	|I-PARTIUPAC
(	812	813	|I-PARTIUPAC
2	813	814	|I-PARTIUPAC
-	814	815	|I-PARTIUPAC
deoxy	815	820	|I-PARTIUPAC
-	820	821	|I-PARTIUPAC
3,5	821	824	|I-PARTIUPAC
-	824	825	|I-PARTIUPAC
di	825	827	|I-PARTIUPAC
-	827	828	|I-PARTIUPAC
O	828	829	|I-PARTIUPAC
-	829	830	|I-PARTIUPAC
p	830	831	|I-PARTIUPAC
-	831	832	|I-PARTIUPAC
toluoyl	832	839	|I-PARTIUPAC
)	839	840	|I-PARTIUPAC
-	840	841	|I-PARTIUPAC
beta	841	845	|I-PARTIUPAC
-	845	846	|I-PARTIUPAC
and	847	850	|O
-	851	852	|B-PARTIUPAC
alpha	852	857	|I-PARTIUPAC
-	857	858	|I-PARTIUPAC
D	858	859	|I-PARTIUPAC
-	859	860	|I-PARTIUPAC
erythro	860	867	|I-PARTIUPAC
-	867	868	|I-PARTIUPAC
pentofuranosyl	868	882	|I-PARTIUPAC
)	882	883	|I-PARTIUPAC
-	883	884	|I-PARTIUPAC
5	884	885	|I-PARTIUPAC
-	885	886	|I-PARTIUPAC
ethyl	886	891	|I-PARTIUPAC
-	891	892	|I-PARTIUPAC
6,7	892	895	|I-PARTIUPAC
-	895	896	|I-PARTIUPAC
dihydroimidazo	896	910	|I-PARTIUPAC
[	910	911	|I-PARTIUPAC
4,5	911	914	|I-PARTIUPAC
-	914	915	|I-PARTIUPAC
d	915	916	|I-PARTIUPAC
]	916	917	|I-PARTIUPAC
-	917	918	|I-PARTIUPAC
[	919	920	|I-PARTIUPAC
1,3	920	923	|I-PARTIUPAC
]	923	924	|I-PARTIUPAC
diazepin	924	932	|I-PARTIUPAC
-	932	933	|I-PARTIUPAC
8	933	934	|I-PARTIUPAC
(	934	935	|I-PARTIUPAC
3H	935	937	|I-PARTIUPAC
)	937	938	|I-PARTIUPAC
-	938	939	|I-PARTIUPAC
one	939	942	|I-PARTIUPAC
(	943	944	|O
5c	944	946	|O
and	947	950	|O
6c	951	953	|O
)	953	954	|O
,	954	955	|O
respectively	956	968	|O
.	968	969	|O
Subsequent	970	980	|O
separation	981	991	|O
of	992	994	|O
the	995	998	|O
anomers	999	1006	|O
,	1006	1007	|O
followed	1008	1016	|O
by	1017	1019	|O
deprotection	1020	1032	|O
and	1033	1036	|O
reduction	1037	1046	|O
of	1047	1049	|O
5b	1050	1052	|O
,	1052	1053	|O
6b	1054	1056	|O
,	1056	1057	|O
and	1058	1061	|O
5c	1062	1064	|O
,	1064	1065	|O
afforded	1066	1074	|O
the	1075	1078	|O
respective	1079	1089	|O
8R	1090	1092	|O
and	1093	1096	|O
8S	1097	1099	|O
isomers	1100	1107	|O
.	1107	1108	|O
Stannic	1109	1116	|O
chloride	1117	1125	|O
catalyzed	1126	1135	|O
condensation	1136	1148	|O
of	1149	1151	|O
pertrimethylsilyl	1152	1169	|O
ketoaglycon	1170	1181	|O
4a	1182	1184	|O
with	1185	1189	|O
2	1190	1191	|B-IUPAC
-	1191	1192	|I-IUPAC
(	1192	1193	|I-IUPAC
chloromethoxy	1193	1206	|I-IUPAC
)	1206	1207	|I-IUPAC
-	1207	1208	|I-IUPAC
1	1208	1209	|I-IUPAC
-	1209	1210	|I-IUPAC
(	1210	1211	|I-IUPAC
p	1211	1212	|I-IUPAC
-	1212	1213	|I-IUPAC
toluoyloxy	1213	1223	|I-IUPAC
)	1223	1224	|I-IUPAC
ethane	1225	1231	|I-IUPAC
to	1232	1234	|O
give	1235	1239	|O
ketonucleoside	1240	1254	|O
6,7	1255	1258	|B-IUPAC
-	1258	1259	|I-IUPAC
dihydro	1259	1266	|I-IUPAC
-	1266	1267	|I-IUPAC
3	1267	1268	|I-IUPAC
-	1268	1269	|I-IUPAC
[	1269	1270	|I-IUPAC
[	1270	1271	|I-IUPAC
2	1271	1272	|I-IUPAC
-	1272	1273	|I-IUPAC
(	1273	1274	|I-IUPAC
p	1274	1275	|I-IUPAC
-	1275	1276	|I-IUPAC
toluoyloxy	1276	1286	|I-IUPAC
)	1286	1287	|I-IUPAC
ethoxy	1287	1293	|I-IUPAC
]	1293	1294	|I-IUPAC
methyl	1295	1301	|I-IUPAC
]	1301	1302	|I-IUPAC
imidazo	1302	1309	|I-IUPAC
[	1309	1310	|I-IUPAC
4,5	1310	1313	|I-IUPAC
-	1313	1314	|I-IUPAC
d	1314	1315	|I-IUPAC
]	1315	1316	|I-IUPAC
[	1316	1317	|I-IUPAC
1,3	1317	1320	|I-IUPAC
]	1320	1321	|I-IUPAC
diazepin	1321	1329	|I-IUPAC
-	1329	1330	|I-IUPAC
8	1330	1331	|I-IUPAC
(	1331	1332	|I-IUPAC
3H	1332	1334	|I-IUPAC
)	1334	1335	|I-IUPAC
-	1335	1336	|I-IUPAC
one	1336	1339	|I-IUPAC
(	1340	1341	|O
9a	1341	1343	|O
)	1343	1344	|O
was	1345	1348	|O
followed	1349	1357	|O
by	1358	1360	|O
deprotection	1361	1373	|O
to	1374	1376	|O
6,7	1377	1380	|B-IUPAC
-	1380	1381	|I-IUPAC
dihydro	1381	1388	|I-IUPAC
-	1388	1389	|I-IUPAC
3	1389	1390	|I-IUPAC
[	1390	1391	|I-IUPAC
(	1391	1392	|I-IUPAC
2	1392	1393	|I-IUPAC
-	1393	1394	|I-IUPAC
hydroxyethoxy	1394	1407	|I-IUPAC
)	1407	1408	|I-IUPAC
methyl	1408	1414	|I-IUPAC
]	1414	1415	|I-IUPAC
imidazo	1415	1422	|I-IUPAC
[	1422	1423	|I-IUPAC
4,5	1423	1426	|I-IUPAC
-	1426	1427	|I-IUPAC
d	1427	1428	|I-IUPAC
]	1428	1429	|I-IUPAC
[	1429	1430	|I-IUPAC
1,3	1430	1433	|I-IUPAC
]	1433	1434	|I-IUPAC
diazepin	1435	1443	|I-IUPAC
-	1443	1444	|I-IUPAC
8	1444	1445	|I-IUPAC
(	1445	1446	|I-IUPAC
3H	1446	1448	|I-IUPAC
)	1448	1449	|I-IUPAC
-	1449	1450	|I-IUPAC
one	1450	1453	|I-IUPAC
(	1454	1455	|O
9b	1455	1457	|O
)	1457	1458	|O
and	1459	1462	|O
then	1463	1467	|O
reduction	1468	1477	|O
to	1478	1480	|O
the	1481	1484	|O
racemic	1485	1492	|O
acyclic	1493	1500	|O
pentostatin	1501	1512	|O
analogue	1513	1521	|O
(	1522	1523	|B-IUPAC
+	1523	1524	|I-IUPAC
/	1524	1525	|I-IUPAC
-	1525	1526	|I-IUPAC
)	1526	1527	|I-IUPAC
-	1527	1528	|I-IUPAC
3,6,7,8	1528	1535	|I-IUPAC
-	1535	1536	|I-IUPAC
tetrahydro	1536	1546	|I-IUPAC
-	1546	1547	|I-IUPAC
3	1547	1548	|I-IUPAC
-	1548	1549	|I-IUPAC
[	1549	1550	|I-IUPAC
(	1551	1552	|I-IUPAC
2	1552	1553	|I-IUPAC
-	1553	1554	|I-IUPAC
hydroxyethoxy	1554	1567	|I-IUPAC
)	1567	1568	|I-IUPAC
methyl	1568	1574	|I-IUPAC
]	1574	1575	|I-IUPAC
imidazo	1575	1582	|I-IUPAC
[	1582	1583	|I-IUPAC
4,5	1583	1586	|I-IUPAC
-	1586	1587	|I-IUPAC
d	1587	1588	|I-IUPAC
]	1588	1589	|I-IUPAC
[	1589	1590	|I-IUPAC
1,3	1590	1593	|I-IUPAC
]	1593	1594	|I-IUPAC
diazepin	1594	1602	|I-IUPAC
-	1602	1603	|I-IUPAC
8	1603	1604	|I-IUPAC
-	1604	1605	|I-IUPAC
ol	1605	1607	|I-IUPAC
(	1608	1609	|O
2	1609	1610	|O
)	1610	1611	|O
.	1611	1612	|O
Ki	1613	1615	|O
values	1616	1622	|O
for	1623	1626	|O
the	1627	1630	|O
in	1631	1633	|O
vitro	1634	1639	|O
adenosine	1640	1649	|O
deaminase	1650	1659	|O
(	1660	1661	|O
EC	1661	1663	|O
3.5.4.4	1664	1671	|O
;	1671	1672	|O
type	1673	1677	|O
I	1678	1679	|O
;	1679	1680	|O
calf	1681	1685	|O
intestinal	1686	1696	|O
mucosa	1697	1703	|O
)	1703	1704	|O
inhibitory	1705	1715	|O
activities	1716	1726	|O
of	1727	1729	|O
1b	1730	1732	|O
,	1732	1733	|O
1c	1734	1736	|O
,	1736	1737	|O
and	1738	1741	|O
2	1742	1743	|O
were	1744	1748	|O
determined	1749	1759	|O
to	1760	1762	|O
be	1763	1765	|O
1.6	1766	1769	|O
X	1770	1771	|O
10	1772	1774	|O
(	1774	1775	|O
-	1775	1776	|O
8	1776	1777	|O
)	1777	1778	|O
,	1778	1779	|O
1.5	1780	1783	|O
X	1784	1785	|O
10	1786	1788	|O
(	1788	1789	|O
-	1789	1790	|O
6	1790	1791	|O
)	1791	1792	|O
,	1792	1793	|O
and	1794	1797	|O
9.8	1798	1801	|O
X	1802	1803	|O
10	1804	1806	|O
(	1806	1807	|O
-	1807	1808	|O
8	1808	1809	|O
)	1809	1810	|O
M	1811	1812	|O
,	1812	1813	|O
respectively	1814	1826	|O
.	1826	1827	|O
When	1828	1832	|O
compounds	1833	1842	|O
2	1843	1844	|O
and	1845	1848	|O
9b	1849	1851	|O
were	1852	1856	|O
tested	1857	1863	|O
in	1864	1866	|O
combination	1867	1878	|O
with	1879	1883	|O
vidarabine	1884	1894	|O
against	1895	1902	|O
herpes	1903	1909	|O
simplex	1910	1917	|O
virus	1918	1923	|O
,	1923	1924	|O
type	1925	1929	|O
1	1930	1931	|O
,	1931	1932	|O
in	1933	1935	|O
an	1936	1938	|O
HEp	1939	1942	|O
-	1942	1943	|O
2	1943	1944	|O
plaque	1945	1951	|O
reduction	1952	1961	|O
assay	1962	1967	|O
,	1967	1968	|O
only	1969	1973	|O
compound	1974	1982	|O
2	1983	1984	|O
was	1985	1988	|O
able	1989	1993	|O
to	1994	1996	|O
potentiate	1997	2007	|O
the	2008	2011	|O
antiviral	2012	2021	|O
activity	2022	2030	|O
of	2031	2033	|O
vidarabine	2034	2044	|O
.	2044	2045	|O

### abstracts608.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
2	12	13	|B-MODIFIER
-	13	14	|I-MODIFIER
(	14	15	|I-MODIFIER
4	15	16	|I-MODIFIER
-	16	17	|I-MODIFIER
substituted	17	28	|I-MODIFIER
-	28	29	|O
1	29	30	|B-IUPAC
-	30	31	|I-IUPAC
(	31	32	|I-IUPAC
homo	32	36	|I-IUPAC
)	36	37	|I-IUPAC
piperazinyl	37	48	|I-IUPAC
)	48	49	|I-IUPAC
benzimidazoles	49	63	|I-IUPAC
was	64	67	|O
prepared	68	76	|O
and	77	80	|O
tested	81	87	|O
for	88	91	|O
H1	92	94	|O
-	94	95	|O
antihistaminic	95	109	|O
activity	110	118	|O
in	119	121	|O
vitro	122	127	|O
and	128	131	|O
in	132	134	|O
vivo	135	139	|O
.	139	140	|O
Most	141	145	|O
of	146	148	|O
the	149	152	|O
compounds	153	162	|O
showed	163	169	|O
antihistaminic	170	184	|O
activity	185	193	|O
and	194	197	|O
some	198	202	|O
of	203	205	|O
the	206	209	|O
1	210	211	|B-MODIFIER
-	211	212	|I-MODIFIER
[	212	213	|I-MODIFIER
2	213	214	|I-MODIFIER
-	214	215	|I-MODIFIER
(	215	216	|I-MODIFIER
substituted	216	227	|I-MODIFIER
-	227	228	|I-MODIFIER
oxy	228	231	|I-MODIFIER
)	231	232	|I-MODIFIER
ethyl	232	237	|I-MODIFIER
]	237	238	|I-MODIFIER
derivatives	239	250	|B-MODIFIER
exhibited	251	260	|O
potent	261	267	|O
activity	268	276	|O
.	276	277	|O
In	278	280	|O
a	281	282	|O
structure	283	292	|O
-	292	293	|O
activity	293	301	|O
comparison	302	312	|O
it	313	315	|O
was	316	319	|O
found	320	325	|O
that	326	330	|O
the	331	334	|O
oxygen	335	341	|O
atom	342	346	|O
in	347	349	|O
the	350	353	|O
2	354	355	|B-MODIFIER
-	355	356	|I-MODIFIER
(	356	357	|I-MODIFIER
substituted	357	368	|I-MODIFIER
-	368	369	|I-MODIFIER
oxy	369	372	|I-MODIFIER
)	372	373	|I-MODIFIER
ethyl	373	378	|I-MODIFIER
group	379	384	|B-MODIFIER
at	385	387	|O
the	388	391	|O
1	392	393	|O
-	393	394	|O
position	394	402	|O
of	403	405	|O
the	406	409	|O
benzimidazole	410	423	|O
nucleus	424	431	|O
played	432	438	|O
an	439	441	|O
important	442	451	|O
role	452	456	|O
for	457	460	|O
potent	461	467	|O
antihistaminic	468	482	|O
activity	483	491	|O
,	491	492	|O
especially	493	503	|O
in	504	506	|O
vivo	507	511	|O
.	511	512	|O
One	513	516	|O
of	517	519	|O
the	520	523	|O
most	524	528	|O
potent	529	535	|O
compounds	536	545	|O
,	545	546	|O
1	547	548	|B-IUPAC
-	548	549	|I-IUPAC
(	549	550	|I-IUPAC
2	550	551	|I-IUPAC
-	551	552	|I-IUPAC
ethoxyethyl	552	563	|I-IUPAC
)	563	564	|I-IUPAC
-	564	565	|I-IUPAC
2	565	566	|I-IUPAC
-	566	567	|I-IUPAC
(	567	568	|I-IUPAC
4	568	569	|I-IUPAC
-	569	570	|I-IUPAC
methyl	570	576	|I-IUPAC
-	576	577	|I-IUPAC
1	577	578	|I-IUPAC
-	578	579	|I-IUPAC
homopiperazinyl	579	594	|I-IUPAC
)	594	595	|I-IUPAC
benzimidazole	595	608	|I-IUPAC
(	609	610	|O
69	610	612	|O
)	612	613	|O
,	613	614	|O
was	615	618	|O
39	619	621	|O
times	622	627	|O
more	628	632	|O
potent	633	639	|O
than	640	644	|O
chlorpheniramine	645	661	|O
maleate	662	669	|O
in	670	672	|O
H1	673	675	|O
-	675	676	|O
antihistaminic	676	690	|O
activity	691	699	|O
in	700	702	|O
vivo	703	707	|O
and	708	711	|O
was	712	715	|O
selected	716	724	|O
for	725	728	|O
clinical	729	737	|O
evaluation	738	748	|O
.	748	749	|O
The	750	753	|O
structure	754	763	|O
of	764	766	|O
compound	767	775	|O
69	776	778	|O
is	779	781	|O
of	782	784	|O
interest	785	793	|O
because	794	801	|O
it	802	804	|O
provides	805	813	|O
only	814	818	|O
a	819	820	|O
single	821	827	|O
aromatic	828	836	|O
unit	837	841	|O
linked	842	848	|O
through	849	856	|O
a	857	858	|O
chain	859	864	|O
to	865	867	|O
a	868	869	|O
basic	870	875	|O
nitrogen	876	884	|O
,	884	885	|O
while	886	891	|O
most	892	896	|O
H1	897	899	|O
-	899	900	|O
antihistaminic	900	914	|O
agents	915	921	|O
have	922	926	|O
structures	927	937	|O
that	938	942	|O
comprise	943	951	|O
a	952	953	|O
double	954	960	|O
-	960	961	|O
aromatic	961	969	|O
unit	970	974	|O
linked	975	981	|O
through	982	989	|O
a	990	991	|O
chain	992	997	|O
to	998	1000	|O
a	1001	1002	|O
basic	1003	1008	|O
tertiary	1009	1017	|O
amino	1018	1023	|O
group	1024	1029	|O
.	1029	1030	|O

### abstracts2914.txt
(	0	1	|O
E	1	2	|O
)	2	3	|O
-	3	4	|O
4	4	5	|O
-	5	6	|O
[	6	7	|O
4	7	8	|O
-	8	9	|O
(	9	10	|O
Methylthio	10	20	|O
)	20	21	|O
phenyl	21	27	|O
]	27	28	|O
-	28	29	|O
1	29	30	|O
-	30	31	|O
(	31	32	|O
2	32	33	|O
-	33	34	|O
piperidinyl	34	45	|O
)	45	46	|O
-	46	47	|O
3	47	48	|O
-	48	49	|O
buten	49	54	|O
-	54	55	|O
2	55	56	|O
-	56	57	|O
one	57	60	|O
hydrochloride	61	74	|O
(	75	76	|O
44	76	78	|O
,	78	79	|O
RMI	80	83	|O
14	84	86	|O
133A	87	91	|O
)	91	92	|O
was	93	96	|O
found	97	102	|O
to	103	105	|O
inhibit	106	113	|O
ADP	114	117	|O
-	117	118	|O
induced	118	125	|O
aggregation	126	137	|O
of	138	140	|O
blood	141	146	|O
platelets	147	156	|O
.	156	157	|O
It	158	160	|O
was	161	164	|O
selected	165	173	|O
from	174	178	|O
a	179	180	|O
large	181	186	|O
series	187	193	|O
of	194	196	|O
(	197	198	|B-PARTIUPAC
2	198	199	|I-PARTIUPAC
-	199	200	|I-PARTIUPAC
piperidinyl	200	211	|I-PARTIUPAC
)	211	212	|I-PARTIUPAC
-	212	213	|I-PARTIUPAC
and	214	217	|O
(	218	219	|B-IUPAC
2	219	220	|I-IUPAC
-	220	221	|I-IUPAC
pyrrolidinyl	221	233	|I-IUPAC
)	233	234	|I-IUPAC
ethanones	234	243	|I-IUPAC
synthesized	244	255	|O
by	256	258	|O
a	259	260	|O
modified	261	269	|O
Schopf	270	276	|O
reaction	277	285	|O
from	286	290	|O
enolate	291	298	|O
magnesium	299	308	|O
salts	309	314	|O
of	315	317	|O
beta	318	322	|O
-	322	323	|O
keto	323	327	|O
acids	328	333	|O
and	334	337	|O
2,3,4,5	338	345	|B-IUPAC
-	345	346	|I-IUPAC
tetrahydropyridine	346	364	|I-IUPAC
trimer	365	371	|B-MODIFIER
or	372	374	|O
3,4	375	378	|B-IUPAC
-	378	379	|I-IUPAC
dihydro	379	386	|I-IUPAC
-	386	387	|I-IUPAC
2H	387	389	|I-IUPAC
-	389	390	|I-IUPAC
pyrrole	390	397	|I-IUPAC
trimer	398	404	|B-MODIFIER
,	404	405	|O
respectively	406	418	|O
.	418	419	|O
Evaluation	420	430	|O
of	431	433	|O
the	434	437	|O
compounds	438	447	|O
was	448	451	|O
carried	452	459	|O
out	460	463	|O
in	464	466	|O
vitro	467	472	|O
on	473	475	|O
human	476	481	|O
blood	482	487	|O
platelets	488	497	|O
.	497	498	|O
Structure	499	508	|O
-	508	509	|O
activity	509	517	|O
relationships	518	531	|O
are	532	535	|O
discussed	536	545	|O
.	545	546	|O
44	547	549	|O
also	550	554	|O
inhibited	555	564	|O
platelet	565	573	|O
aggregation	574	585	|O
ex	586	588	|O
vivo	589	593	|O
in	594	596	|O
guinea	597	603	|O
pigs	604	608	|O
.	608	609	|O
Subacute	610	618	|O
toxicity	619	627	|O
evaluation	628	638	|O
in	639	641	|O
dogs	642	646	|O
and	647	650	|O
guinea	651	657	|O
pigs	658	662	|O
showed	663	669	|O
it	670	672	|O
to	673	675	|O
have	676	680	|O
an	681	683	|O
unfavorable	684	695	|O
therapeutic	696	707	|O
ratio	708	713	|O
.	713	714	|O
1	715	716	|B-IUPAC
-	716	717	|I-IUPAC
[	717	718	|I-IUPAC
4'	718	720	|I-IUPAC
-	720	721	|I-IUPAC
Chloro	721	727	|I-IUPAC
(	727	728	|I-IUPAC
1,1	728	731	|I-IUPAC
'	731	732	|I-IUPAC
-	732	733	|I-IUPAC
biphenyl	733	741	|I-IUPAC
)	741	742	|I-IUPAC
-	742	743	|I-IUPAC
4	743	744	|I-IUPAC
-	744	745	|I-IUPAC
yl	745	747	|I-IUPAC
-	747	748	|I-IUPAC
a1	748	750	|I-IUPAC
-	750	751	|I-IUPAC
2	751	752	|I-IUPAC
-	752	753	|I-IUPAC
(	753	754	|I-IUPAC
2	754	755	|I-IUPAC
-	755	756	|I-IUPAC
piperdinyl	756	766	|I-IUPAC
)	766	767	|I-IUPAC
ethanone	767	775	|I-IUPAC
hydrochloride	776	789	|I-IUPAC
(	790	791	|O
18	791	793	|O
,	793	794	|O
RMI	795	798	|O
12436A	799	805	|O
)	805	806	|O
was	807	810	|O
found	811	816	|O
to	817	819	|O
lower	820	825	|O
serum	826	831	|O
cholesterol	832	843	|O
levles	844	850	|O
in	851	853	|O
rats	854	858	|O
with	859	863	|O
concurrent	864	874	|O
accumulation	875	887	|O
of	888	890	|O
(	891	892	|B-IUPAC
3beta	892	897	|I-IUPAC
)	897	898	|I-IUPAC
-	898	899	|I-IUPAC
cholesta	899	907	|I-IUPAC
-	907	908	|I-IUPAC
5,7	908	911	|I-IUPAC
-	911	912	|I-IUPAC
dien	912	916	|I-IUPAC
-	916	917	|I-IUPAC
3	917	918	|I-IUPAC
-	918	919	|I-IUPAC
ol	919	921	|I-IUPAC
,	921	922	|O
suggesting	923	933	|O
inhibition	934	944	|O
of	945	947	|O
7	948	949	|B-IUPAC
-	949	950	|I-IUPAC
dehydrocholesterol	950	968	|I-IUPAC
delta7	969	975	|O
-	975	976	|O
reductase	976	985	|O
.	985	986	|O

### abstracts676.txt
A	0	1	|O
new	2	5	|O
class	6	11	|O
of	12	14	|O
5	15	16	|B-PARTIUPAC
-	16	17	|I-PARTIUPAC
halo	17	21	|I-PARTIUPAC
-	21	22	|I-PARTIUPAC
6	22	23	|I-PARTIUPAC
-	23	24	|I-PARTIUPAC
alkoxy	24	30	|I-PARTIUPAC
(	30	31	|O
or	31	33	|O
azido	34	39	|B-PARTIUPAC
)	39	40	|O
-	40	41	|B-PARTIUPAC
5,6	41	44	|I-PARTIUPAC
-	44	45	|I-PARTIUPAC
dihydro	45	52	|I-PARTIUPAC
-	52	53	|I-PARTIUPAC
3'	53	55	|I-PARTIUPAC
-	55	56	|I-PARTIUPAC
azido	56	61	|I-PARTIUPAC
-	61	62	|I-PARTIUPAC
3'	62	64	|I-PARTIUPAC
-	64	65	|I-PARTIUPAC
deoxythymidines	65	80	|I-PARTIUPAC
was	81	84	|O
investigated	85	97	|O
as	98	100	|O
potential	101	110	|O
anti	111	115	|O
-	115	116	|O
AIDS	116	120	|O
drugs	121	126	|O
.	126	127	|O
These	128	133	|O
5,6	134	137	|B-IUPAC
-	137	138	|I-IUPAC
dihydro	138	145	|I-IUPAC
derivatives	146	157	|B-MODIFIER
,	157	158	|O
which	159	164	|O
are	165	168	|O
also	169	173	|O
potential	174	183	|O
prodrugs	184	192	|O
to	193	195	|O
3'	196	198	|B-IUPAC
-	198	199	|I-IUPAC
azido	199	204	|I-IUPAC
-	204	205	|I-IUPAC
3'	205	207	|I-IUPAC
-	207	208	|I-IUPAC
deoxythymidine	208	222	|I-IUPAC
(	223	224	|O
AZT	224	227	|O
)	227	228	|O
,	228	229	|O
were	230	234	|O
designed	235	243	|O
in	244	246	|O
an	247	249	|O
effort	250	256	|O
to	257	259	|O
enhance	260	267	|O
the	268	271	|O
duration	272	280	|O
of	281	283	|O
action	284	290	|O
,	290	291	|O
lipophilicity	292	305	|O
,	305	306	|O
and	307	310	|O
cephalic	311	319	|O
delivery	320	328	|O
to	329	331	|O
the	332	335	|O
central	336	343	|O
nervous	344	351	|O
system	352	358	|O
.	358	359	|O
The	360	363	|O
5	364	365	|B-PARTIUPAC
-	365	366	|I-PARTIUPAC
halo	366	370	|I-PARTIUPAC
-	370	371	|I-PARTIUPAC
6	371	372	|I-PARTIUPAC
-	372	373	|I-PARTIUPAC
alkoxy	373	379	|I-PARTIUPAC
(	379	380	|O
or	380	382	|O
azido	383	388	|B-PARTIUPAC
)	388	389	|O
-	389	390	|B-PARTIUPAC
5,6	390	393	|I-PARTIUPAC
-	393	394	|I-PARTIUPAC
dihydro	394	401	|I-PARTIUPAC
-	401	402	|I-PARTIUPAC
3'	402	404	|I-PARTIUPAC
-	404	405	|I-PARTIUPAC
azido	405	410	|I-PARTIUPAC
-	410	411	|I-PARTIUPAC
3'	411	413	|I-PARTIUPAC
-	413	414	|I-PARTIUPAC
deoxythymidines	414	429	|I-PARTIUPAC
,	429	430	|O
which	431	436	|O
differ	437	443	|O
in	444	446	|O
configuration	447	460	|O
at	461	463	|O
the	464	467	|O
C	468	469	|O
-	469	470	|O
5	470	471	|O
and	472	475	|O
C	476	477	|O
-	477	478	|O
6	478	479	|O
positions	480	489	|O
,	489	490	|O
were	491	495	|O
synthesized	496	507	|O
by	508	510	|O
the	511	514	|O
regiospecific	515	528	|O
addition	529	537	|O
of	538	540	|O
XR	541	543	|O
(	544	545	|O
X	545	546	|O
=	547	548	|O
Br	549	551	|O
,	551	552	|O
Cl	553	555	|O
,	555	556	|O
I	557	558	|O
;	558	559	|O
R	560	561	|O
=	562	563	|O
alkoxy	564	570	|O
,	570	571	|O
azido	572	577	|O
)	577	578	|O
to	579	581	|O
the	582	585	|O
5,6	586	589	|O
-	589	590	|O
olefinic	590	598	|O
bond	599	603	|O
of	604	606	|O
AZT	607	610	|O
.	610	611	|O
The	612	615	|O
5	616	617	|B-IUPAC
-	617	618	|I-IUPAC
halo	618	622	|I-IUPAC
-	622	623	|I-IUPAC
6	623	624	|I-IUPAC
-	624	625	|I-IUPAC
methoxy	625	632	|I-IUPAC
-	632	633	|I-IUPAC
5,6	633	636	|I-IUPAC
-	636	637	|I-IUPAC
dihydro	637	644	|I-IUPAC
derivatives	645	656	|B-MODIFIER
of	657	659	|O
AZT	660	663	|O
are	664	667	|O
more	668	672	|O
lipophilic	673	683	|O
(	684	685	|O
P	685	686	|O
=	687	688	|O
3.3-18.8	689	697	|O
range	698	703	|O
)	703	704	|O
than	705	709	|O
the	710	713	|O
parent	714	720	|O
compound	721	729	|O
AZT	730	733	|O
(	734	735	|O
P	735	736	|O
=	737	738	|O
1.29	739	743	|O
)	743	744	|O
.	744	745	|O
These	746	751	|O
5	752	753	|B-IUPAC
-	753	754	|I-IUPAC
halo	754	758	|I-IUPAC
-	758	759	|I-IUPAC
6	759	760	|I-IUPAC
-	760	761	|I-IUPAC
methoxy	761	768	|I-IUPAC
-	768	769	|I-IUPAC
5,6	769	772	|I-IUPAC
-	772	773	|I-IUPAC
dihydro	773	780	|I-IUPAC
compounds	781	790	|B-MODIFIER
,	790	791	|O
like	792	796	|O
AZT	797	800	|O
,	800	801	|O
did	802	805	|O
not	806	809	|O
undergo	810	817	|O
glycosidic	818	828	|O
bond	829	833	|O
cleavage	834	842	|O
upon	843	847	|O
incubation	848	858	|O
with	859	863	|O
Escherichia	864	875	|O
coli	876	880	|O
thymidine	881	890	|O
phosphorylase	891	904	|O
.	904	905	|O
Regeneration	906	918	|O
of	919	921	|O
the	922	925	|O
5,6	926	929	|O
-	929	930	|O
olefinic	930	938	|O
bond	939	943	|O
to	944	946	|O
give	947	951	|O
AZT	952	955	|O
,	955	956	|O
upon	957	961	|O
incubation	962	972	|O
of	973	975	|O
the	976	979	|O
5	980	981	|B-IUPAC
-	981	982	|I-IUPAC
halo	982	986	|I-IUPAC
-	986	987	|I-IUPAC
6	987	988	|I-IUPAC
-	988	989	|I-IUPAC
methoxy	989	996	|I-IUPAC
-	996	997	|I-IUPAC
5,6	997	1000	|I-IUPAC
-	1000	1001	|I-IUPAC
dihydro	1001	1008	|I-IUPAC
compounds	1009	1018	|B-MODIFIER
with	1019	1023	|O
glutathione	1024	1035	|O
,	1035	1036	|O
mouse	1037	1042	|O
blood	1043	1048	|O
,	1048	1049	|O
or	1050	1052	|O
mouse	1053	1058	|O
liver	1059	1064	|O
homogenate	1065	1075	|O
,	1075	1076	|O
was	1077	1080	|O
dependent	1081	1090	|O
upon	1091	1095	|O
the	1096	1099	|O
nature	1100	1106	|O
of	1107	1109	|O
the	1110	1113	|O
5	1114	1115	|B-IUPAC
-	1115	1116	|I-IUPAC
halo	1116	1120	|I-IUPAC
substituent	1121	1132	|B-MODIFIER
(	1133	1134	|O
I	1134	1135	|O
&	1136	1137	|O
gt	1137	1139	|O
;	1139	1140	|O
Br	1141	1143	|O
)	1143	1144	|O
.	1144	1145	|O
No	1146	1148	|O
5,6	1149	1152	|O
-	1152	1153	|O
olefinic	1153	1161	|O
bond	1162	1166	|O
regeneration	1167	1179	|O
was	1180	1183	|O
observed	1184	1192	|O
for	1193	1196	|O
the	1197	1200	|O
5	1201	1202	|B-IUPAC
-	1202	1203	|I-IUPAC
chloro	1203	1209	|I-IUPAC
analogs	1210	1217	|B-MODIFIER
.	1217	1218	|O
The	1219	1222	|O
ability	1223	1230	|O
of	1231	1233	|O
these	1234	1239	|O
5	1240	1241	|B-PARTIUPAC
-	1241	1242	|I-PARTIUPAC
halo	1242	1246	|I-PARTIUPAC
-	1246	1247	|I-PARTIUPAC
6	1247	1248	|I-PARTIUPAC
-	1248	1249	|I-PARTIUPAC
alkoxy	1249	1255	|I-PARTIUPAC
(	1256	1257	|O
or	1257	1259	|O
azido	1260	1265	|B-PARTIUPAC
)	1265	1266	|O
-	1266	1267	|B-PARTIUPAC
5,6	1267	1270	|I-PARTIUPAC
-	1270	1271	|I-PARTIUPAC
dihydro	1271	1278	|I-PARTIUPAC
-	1278	1279	|I-PARTIUPAC
3'	1279	1281	|I-PARTIUPAC
-	1281	1282	|I-PARTIUPAC
azido	1282	1287	|I-PARTIUPAC
-	1287	1288	|I-PARTIUPAC
3'	1288	1290	|I-PARTIUPAC
-	1290	1291	|I-PARTIUPAC
deoxythymidines	1291	1306	|I-PARTIUPAC
to	1307	1309	|O
protect	1310	1317	|O
CEM	1318	1321	|O
cells	1322	1327	|O
against	1328	1335	|O
HIV	1336	1339	|O
-	1339	1340	|O
induced	1340	1347	|O
cytopathogenicity	1348	1365	|O
was	1366	1369	|O
evaluated	1370	1379	|O
.	1379	1380	|O
Structure	1381	1390	|O
-	1390	1391	|O
activity	1391	1399	|O
studies	1400	1407	|O
showed	1408	1414	|O
that	1415	1419	|O
the	1420	1423	|O
C	1424	1425	|O
-	1425	1426	|O
5	1426	1427	|O
substituent	1428	1439	|O
(	1440	1441	|O
I	1441	1442	|O
,	1442	1443	|O
Br	1444	1446	|O
,	1446	1447	|O
Cl	1448	1450	|O
)	1450	1451	|O
was	1452	1455	|O
a	1456	1457	|O
determinant	1458	1469	|O
of	1470	1472	|O
anti	1473	1477	|O
-	1477	1478	|O
HIV	1478	1481	|O
-	1481	1482	|O
1	1482	1483	|O
activity	1484	1492	|O
where	1493	1498	|O
the	1499	1502	|O
potency	1503	1510	|O
order	1511	1516	|O
was	1517	1520	|O
I	1521	1522	|O
&	1523	1524	|O
gt	1524	1526	|O
;	1526	1527	|O
or	1528	1530	|O
=	1531	1532	|O
Br	1533	1535	|O
&	1536	1537	|O
gt	1537	1539	|O
;	1539	1540	|O
Cl	1541	1543	|O
.	1543	1544	|O
In	1545	1547	|O
the	1548	1551	|O
5	1552	1553	|O
-	1553	1554	|O
bromo	1554	1559	|O
series	1560	1566	|O
of	1567	1569	|O
compounds	1570	1579	|O
,	1579	1580	|O
the	1581	1584	|O
C	1585	1586	|O
-	1586	1587	|O
6	1587	1588	|O
substituent	1589	1600	|O
was	1601	1604	|O
also	1605	1609	|O
a	1610	1611	|O
determinant	1612	1623	|O
of	1624	1626	|O
activity	1627	1635	|O
where	1636	1641	|O
6	1642	1643	|O
-	1643	1644	|O
OMe	1644	1647	|O
and	1648	1651	|O
6	1652	1653	|O
-	1653	1654	|O
OEt	1654	1657	|O
substituents	1658	1670	|O
exhibited	1671	1680	|O
a	1681	1682	|O
greater	1683	1690	|O
potency	1691	1698	|O
than	1699	1703	|O
the	1704	1707	|O
corresponding	1708	1721	|O
6	1722	1723	|O
-	1723	1724	|O
i	1724	1725	|O
-	1725	1726	|O
PrO	1726	1729	|O
,	1729	1730	|O
6	1731	1732	|B-IUPAC
-	1732	1733	|I-IUPAC
(	1733	1734	|I-IUPAC
1	1734	1735	|I-IUPAC
-	1735	1736	|I-IUPAC
octyloxy	1736	1744	|I-IUPAC
)	1744	1745	|I-IUPAC
,	1745	1746	|O
6	1747	1748	|B-IUPAC
-	1748	1749	|I-IUPAC
(	1749	1750	|I-IUPAC
1	1750	1751	|I-IUPAC
-	1751	1752	|I-IUPAC
hexadecyloxy	1752	1764	|I-IUPAC
)	1764	1765	|I-IUPAC
,	1765	1766	|O
and	1767	1770	|O
6	1771	1772	|B-IUPAC
-	1772	1773	|I-IUPAC
azido	1773	1778	|I-IUPAC
analogs	1779	1786	|B-MODIFIER
.	1786	1787	|O
All	1788	1791	|O
of	1792	1794	|O
the	1795	1798	|O
5	1799	1800	|B-IUPAC
-	1800	1801	|I-IUPAC
chloro	1801	1807	|I-IUPAC
-	1807	1808	|I-IUPAC
6	1808	1809	|I-IUPAC
-	1809	1810	|O
substituted	1810	1821	|B-MODIFIER
-	1821	1822	|O
5,6	1822	1825	|B-IUPAC
-	1825	1826	|I-IUPAC
dihydro	1826	1833	|I-IUPAC
compounds	1834	1843	|B-MODIFIER
were	1844	1848	|O
inactive	1849	1857	|O
,	1857	1858	|O
except	1859	1865	|O
for	1866	1869	|O
the	1870	1873	|O
approximately	1874	1887	|O
equipotent	1888	1898	|O
6	1899	1900	|O
-	1900	1901	|O
OMe	1901	1904	|O
and	1905	1908	|O
6	1909	1910	|B-IUPAC
-	1910	1911	|I-IUPAC
azido	1911	1916	|I-IUPAC
diastereomeric	1917	1931	|I-IUPAC
mixtures	1932	1940	|B-MODIFIER
which	1941	1946	|O
were	1947	1951	|O
2-3	1952	1955	|O
log	1956	1959	|O
units	1960	1965	|O
less	1966	1970	|O
active	1971	1977	|O
than	1978	1982	|O
the	1983	1986	|O
reference	1987	1996	|O
drug	1997	2001	|O
AZT	2002	2005	|O
.	2005	2006	|O
The	2007	2010	|O
configuration	2011	2024	|O
at	2025	2027	|O
the	2028	2031	|O
C	2032	2033	|O
-	2033	2034	|O
5	2034	2035	|O
and	2036	2039	|O
C	2040	2041	|O
-	2041	2042	|O
6	2042	2043	|O
positions	2044	2053	|O
also	2054	2058	|O
influenced	2059	2069	|O
potency	2070	2077	|O
where	2078	2083	|O
the	2084	2087	|O
activity	2088	2096	|O
of	2097	2099	|O
the	2100	2103	|O
5R	2104	2106	|O
,	2106	2107	|O
6R	2107	2109	|O
-	2109	2110	|O
diastereomer	2110	2122	|O
was	2123	2126	|O
generally	2127	2136	|O
greater	2137	2144	|O
than	2145	2149	|O
that	2150	2154	|O
of	2155	2157	|O
the	2158	2161	|O
corresponding	2162	2175	|O
5S	2176	2178	|O
,	2178	2179	|O
6S	2179	2181	|O
-	2181	2182	|O
diastereomer	2182	2194	|O
.	2194	2195	|O
(	2195	2196	|O
ABSTRACT	2196	2204	|O
TRUNCATED	2205	2214	|O
AT	2215	2217	|O
400	2218	2221	|O
WORDS	2222	2227	|O
)	2227	2228	|O

### abstracts1602.txt
The	0	3	|O
synthesis	4	13	|O
of	14	16	|O
certain	17	24	|O
heteroarotinoids	25	41	|O
has	42	45	|O
been	46	50	|O
achieved	51	59	|O
,	59	60	|O
namely	61	67	|O
the	68	71	|O
systems	72	79	|O
(	80	81	|B-IUPAC
2E	81	83	|I-IUPAC
,	83	84	|I-IUPAC
4E	84	86	|I-IUPAC
,	86	87	|I-IUPAC
6E	87	89	|I-IUPAC
)	89	90	|I-IUPAC
-	90	91	|I-IUPAC
3,7	91	94	|I-IUPAC
-	94	95	|I-IUPAC
dimethyl	95	103	|I-IUPAC
-	103	104	|I-IUPAC
7	104	105	|I-IUPAC
-	105	106	|I-IUPAC
(	106	107	|I-IUPAC
1,2,3,4	107	114	|I-IUPAC
-	114	115	|I-IUPAC
tetrahydro	115	125	|I-IUPAC
-	125	126	|I-IUPAC
4,4	126	129	|I-IUPAC
-	129	130	|I-IUPAC
dimethyl	130	138	|I-IUPAC
-	138	139	|I-IUPAC
6	139	140	|I-IUPAC
-	141	142	|I-IUPAC
thiochromanyl	142	155	|I-IUPAC
)	155	156	|I-IUPAC
-	156	157	|I-IUPAC
2,4,6	157	162	|I-IUPAC
-	162	163	|I-IUPAC
heptatrienoic	163	176	|I-IUPAC
acid	177	181	|I-IUPAC
(	182	183	|O
1a	183	185	|O
)	185	186	|O
,	186	187	|O
ethyl	188	193	|B-IUPAC
(	194	195	|I-IUPAC
2E	195	197	|I-IUPAC
,	197	198	|I-IUPAC
4E	198	200	|I-IUPAC
,	200	201	|I-IUPAC
6E	201	203	|I-IUPAC
)	203	204	|I-IUPAC
-	204	205	|I-IUPAC
3,7	205	208	|I-IUPAC
-	208	209	|I-IUPAC
dimethyl	209	217	|I-IUPAC
-	217	218	|I-IUPAC
7	218	219	|I-IUPAC
-	219	220	|I-IUPAC
(	221	222	|I-IUPAC
1,2,3,4	222	229	|I-IUPAC
-	229	230	|I-IUPAC
teterahydro	230	241	|I-IUPAC
-	241	242	|I-IUPAC
4,4	242	245	|I-IUPAC
-	245	246	|I-IUPAC
dimethyl	246	254	|I-IUPAC
-	254	255	|I-IUPAC
6	255	256	|I-IUPAC
-	256	257	|I-IUPAC
thiochromanyl	257	270	|I-IUPAC
)	270	271	|I-IUPAC
-	271	272	|I-IUPAC
2,4,6	272	277	|I-IUPAC
-	277	278	|I-IUPAC
heptatrienoate	279	293	|I-IUPAC
(	294	295	|O
1b	295	297	|O
)	297	298	|O
,	298	299	|O
(	300	301	|B-IUPAC
2E	301	303	|I-IUPAC
,	303	304	|I-IUPAC
4E	304	306	|I-IUPAC
,	306	307	|I-IUPAC
6E	307	309	|I-IUPAC
)	309	310	|I-IUPAC
-	310	311	|I-IUPAC
3,7	311	314	|I-IUPAC
-	314	315	|I-IUPAC
dimethyl	315	323	|I-IUPAC
-	323	324	|I-IUPAC
7	324	325	|I-IUPAC
-	325	326	|I-IUPAC
(	326	327	|I-IUPAC
1,2,3,4	327	334	|I-IUPAC
-	334	335	|I-IUPAC
tetrahydro	335	345	|I-IUPAC
-	345	346	|I-IUPAC
4,4	346	349	|I-IUPAC
-	349	350	|I-IUPAC
dimethyl	350	358	|I-IUPAC
-	358	359	|I-IUPAC
6	359	360	|I-IUPAC
-	361	362	|I-IUPAC
chromanyl	362	371	|I-IUPAC
)	371	372	|I-IUPAC
-	372	373	|I-IUPAC
2,4,6	373	378	|I-IUPAC
-	378	379	|I-IUPAC
heptatrienoic	379	392	|I-IUPAC
acid	393	397	|I-IUPAC
(	398	399	|O
1c	399	401	|O
)	401	402	|O
,	402	403	|O
2	404	405	|B-IUPAC
-	405	406	|I-IUPAC
phthalimidoethyl	406	422	|I-IUPAC
3,7	423	426	|I-IUPAC
-	426	427	|I-IUPAC
dimethyl	427	435	|I-IUPAC
-	435	436	|I-IUPAC
7	436	437	|I-IUPAC
-	437	438	|I-IUPAC
(	438	439	|I-IUPAC
1,2,3,4	439	446	|I-IUPAC
-	446	447	|I-IUPAC
tetrahydro	447	457	|I-IUPAC
-	457	458	|I-IUPAC
4	458	459	|I-IUPAC
4	460	461	|I-IUPAC
-	461	462	|I-IUPAC
dimethyl	462	470	|I-IUPAC
-	470	471	|I-IUPAC
6	471	472	|I-IUPAC
-	472	473	|I-IUPAC
thiochromanyl	473	486	|I-IUPAC
)	486	487	|I-IUPAC
-	487	488	|I-IUPAC
2,4,6	488	493	|I-IUPAC
-	493	494	|I-IUPAC
heptatrienoate	494	508	|I-IUPAC
(	509	510	|O
1d	510	512	|O
)	512	513	|O
,	513	514	|O
methyl	515	521	|B-IUPAC
(	522	523	|I-IUPAC
E	523	524	|I-IUPAC
)	524	525	|I-IUPAC
-	525	526	|I-IUPAC
p	526	527	|I-IUPAC
-	527	528	|I-IUPAC
[	528	529	|I-IUPAC
2	529	530	|I-IUPAC
-	530	531	|I-IUPAC
(	531	532	|I-IUPAC
4,4	532	535	|I-IUPAC
-	535	536	|I-IUPAC
dimethyl	537	545	|I-IUPAC
-	545	546	|I-IUPAC
6	546	547	|I-IUPAC
-	547	548	|I-IUPAC
chromanyl	548	557	|I-IUPAC
)	557	558	|I-IUPAC
-	558	559	|I-IUPAC
1	559	560	|I-IUPAC
-	560	561	|I-IUPAC
propenyl	561	569	|I-IUPAC
]	569	570	|I-IUPAC
benzoate	570	578	|I-IUPAC
(	579	580	|O
2a	580	582	|O
)	582	583	|O
,	583	584	|O
(	585	586	|B-IUPAC
E	586	587	|I-IUPAC
)	587	588	|I-IUPAC
-	588	589	|I-IUPAC
p	589	590	|I-IUPAC
-	590	591	|I-IUPAC
[	591	592	|I-IUPAC
2	592	593	|I-IUPAC
-	593	594	|I-IUPAC
(	594	595	|I-IUPAC
4,4	595	598	|I-IUPAC
-	598	599	|I-IUPAC
dimethyl	599	607	|I-IUPAC
-	607	608	|I-IUPAC
6	608	609	|I-IUPAC
-	609	610	|I-IUPAC
chromanyl	610	619	|I-IUPAC
)	619	620	|I-IUPAC
-	620	621	|I-IUPAC
1	621	622	|I-IUPAC
-	622	623	|I-IUPAC
propenyl	623	631	|I-IUPAC
]	631	632	|I-IUPAC
benzyl	632	638	|I-IUPAC
alcohol	639	646	|I-IUPAC
(	647	648	|O
2b	648	650	|O
)	650	651	|O
,	651	652	|O
(	653	654	|B-IUPAC
E	654	655	|I-IUPAC
)	655	656	|I-IUPAC
-	656	657	|I-IUPAC
p	657	658	|I-IUPAC
-	658	659	|I-IUPAC
[	659	660	|I-IUPAC
2	660	661	|I-IUPAC
-	661	662	|I-IUPAC
(	662	663	|I-IUPAC
4,4	663	666	|I-IUPAC
-	666	667	|I-IUPAC
dimethyl	667	675	|I-IUPAC
-	675	676	|I-IUPAC
6	676	677	|I-IUPAC
-	677	678	|I-IUPAC
chromanyl	678	687	|I-IUPAC
)	687	688	|I-IUPAC
-	688	689	|I-IUPAC
1	689	690	|I-IUPAC
-	690	691	|I-IUPAC
propenyl	691	699	|I-IUPAC
]	699	700	|I-IUPAC
benzonitrile	700	712	|I-IUPAC
(	713	714	|O
2c	714	716	|O
)	716	717	|O
,	717	718	|O
(	719	720	|B-IUPAC
E	720	721	|I-IUPAC
)	721	722	|I-IUPAC
-	722	723	|I-IUPAC
p	723	724	|I-IUPAC
-	724	725	|I-IUPAC
[	725	726	|I-IUPAC
2	726	727	|I-IUPAC
-	727	728	|I-IUPAC
(	728	729	|I-IUPAC
4,4	729	732	|I-IUPAC
-	732	733	|I-IUPAC
dimethyl	733	741	|I-IUPAC
-	741	742	|I-IUPAC
6	742	743	|I-IUPAC
-	743	744	|I-IUPAC
chromanyl	744	753	|I-IUPAC
)	753	754	|I-IUPAC
-	754	755	|I-IUPAC
1	755	756	|I-IUPAC
-	756	757	|I-IUPAC
propenyl	757	765	|I-IUPAC
]	765	766	|I-IUPAC
benzaldehyde	766	778	|I-IUPAC
(	779	780	|O
2d	780	782	|O
)	782	783	|O
,	783	784	|O
methyl	785	791	|B-IUPAC
4	792	793	|I-IUPAC
-	793	794	|I-IUPAC
[	794	795	|I-IUPAC
2	795	796	|I-IUPAC
-	796	797	|I-IUPAC
(	797	798	|I-IUPAC
2,3	798	801	|I-IUPAC
-	801	802	|I-IUPAC
dihydro	802	809	|I-IUPAC
-	809	810	|I-IUPAC
3,3	810	813	|I-IUPAC
-	813	814	|I-IUPAC
dimethyl	814	822	|I-IUPAC
-	822	823	|I-IUPAC
5	823	824	|I-IUPAC
-	824	825	|I-IUPAC
benzofuranyl	825	837	|I-IUPAC
)	837	838	|I-IUPAC
-	838	839	|I-IUPAC
1	839	840	|I-IUPAC
-	840	841	|I-IUPAC
propenyl	841	849	|I-IUPAC
]	849	850	|I-IUPAC
benzoate	851	859	|I-IUPAC
(	860	861	|O
3a	861	863	|O
)	863	864	|O
,	864	865	|O
and	866	869	|O
(	870	871	|B-IUPAC
E	871	872	|I-IUPAC
)	872	873	|I-IUPAC
-	873	874	|I-IUPAC
p	874	875	|I-IUPAC
-	875	876	|I-IUPAC
[	876	877	|I-IUPAC
2	877	878	|I-IUPAC
-	878	879	|I-IUPAC
(	879	880	|I-IUPAC
2,3	880	883	|I-IUPAC
-	883	884	|I-IUPAC
dihydro	884	891	|I-IUPAC
-	891	892	|I-IUPAC
3,3	892	895	|I-IUPAC
-	895	896	|I-IUPAC
dimethyl	896	904	|I-IUPAC
-	904	905	|I-IUPAC
5	905	906	|I-IUPAC
-	906	907	|I-IUPAC
benzofuranyl	907	919	|I-IUPAC
)	919	920	|I-IUPAC
-	920	921	|I-IUPAC
1	921	922	|I-IUPAC
-	922	923	|I-IUPAC
propenyl	924	932	|I-IUPAC
]	932	933	|I-IUPAC
benzoic	933	940	|I-IUPAC
acid	941	945	|I-IUPAC
(	946	947	|O
3b	947	949	|O
)	949	950	|O
.	950	951	|O
Characterization	952	968	|O
via	969	972	|O
elemental	973	982	|O
,	982	983	|O
IR	984	986	|O
,	986	987	|O
1H	988	990	|O
NMR	991	994	|O
,	994	995	|O
and	996	999	|O
13C	1000	1003	|O
NMR	1004	1007	|O
analyses	1008	1016	|O
was	1017	1020	|O
completed	1021	1030	|O
for	1031	1034	|O
these	1035	1040	|O
heterocycles	1041	1053	|O
.	1053	1054	|O
The	1055	1058	|O
biological	1059	1069	|O
activity	1070	1078	|O
of	1079	1081	|O
these	1082	1087	|O
heteroarotinoids	1088	1104	|O
was	1105	1108	|O
assayed	1109	1116	|O
by	1117	1119	|O
either	1120	1126	|O
the	1127	1130	|O
suppression	1131	1142	|O
of	1143	1145	|O
the	1146	1149	|O
12	1150	1152	|B-IUPAC
-	1152	1153	|I-IUPAC
O	1153	1154	|I-IUPAC
-	1154	1155	|I-IUPAC
tetradecanoylphorbol	1155	1175	|I-IUPAC
13	1176	1178	|I-IUPAC
-	1178	1179	|I-IUPAC
acetate	1179	1186	|I-IUPAC
(	1187	1188	|O
TPA	1188	1191	|O
)	1191	1192	|O
induced	1193	1200	|O
synthesis	1201	1210	|O
of	1211	1213	|O
ornithine	1214	1223	|O
decarboxylase	1224	1237	|O
(	1238	1239	|O
ODC	1239	1242	|O
)	1242	1243	|O
in	1244	1246	|O
mouse	1247	1252	|O
skin	1253	1257	|O
or	1258	1260	|O
the	1261	1264	|O
induction	1265	1274	|O
of	1275	1277	|O
differentiation	1278	1293	|O
of	1294	1296	|O
human	1297	1302	|O
(	1303	1304	|O
HL	1304	1306	|O
-	1306	1307	|O
60	1307	1309	|O
)	1309	1310	|O
promyelocytic	1311	1324	|O
cells	1325	1330	|O
.	1330	1331	|O
In	1332	1334	|O
the	1335	1338	|O
ODC	1339	1342	|O
assay	1343	1348	|O
,	1348	1349	|O
systems	1350	1357	|O
1a	1358	1360	|O
-	1360	1361	|O
c	1361	1362	|O
exhibited	1363	1372	|O
strong	1373	1379	|O
activity	1380	1388	|O
(	1389	1390	|O
within	1390	1396	|O
10%	1397	1400	|O
of	1401	1403	|O
or	1404	1406	|O
less	1407	1411	|O
than	1412	1416	|O
the	1417	1420	|O
control	1421	1428	|O
)	1428	1429	|O
whereas	1430	1437	|O
alcohols	1438	1446	|O
2b	1447	1449	|O
and	1450	1453	|O
3a	1454	1456	|O
showed	1457	1463	|O
good	1464	1468	|O
activity	1469	1477	|O
(	1478	1479	|O
within	1479	1485	|O
50%	1486	1489	|O
of	1490	1492	|O
the	1493	1496	|O
control	1497	1504	|O
)	1504	1505	|O
as	1506	1508	|O
compared	1509	1517	|O
to	1518	1520	|O
either	1521	1527	|O
13	1528	1530	|B-IUPAC
-	1530	1531	|I-IUPAC
cis	1531	1534	|I-IUPAC
-	1534	1535	|I-IUPAC
retinoic	1535	1543	|I-IUPAC
acid	1544	1548	|I-IUPAC
or	1549	1551	|O
trans	1552	1557	|B-IUPAC
-	1557	1558	|I-IUPAC
retinoic	1558	1566	|I-IUPAC
acid	1567	1571	|I-IUPAC
.	1571	1572	|O
Moderate	1573	1581	|O
activity	1582	1590	|O
was	1591	1594	|O
observed	1595	1603	|O
with	1604	1608	|O
2a	1609	1611	|O
and	1612	1615	|O
2b	1616	1618	|O
while	1619	1624	|O
1d	1625	1627	|O
and	1628	1631	|O
2c	1632	1634	|O
were	1635	1639	|O
essentially	1640	1651	|O
inactive	1652	1660	|O
.	1660	1661	|O
With	1662	1666	|O
the	1667	1670	|O
HL	1671	1673	|O
-	1673	1674	|O
60	1674	1676	|O
assay	1677	1682	|O
,	1682	1683	|O
1a	1684	1686	|O
and	1687	1690	|O
1c	1691	1693	|O
were	1694	1698	|O
approximately	1699	1712	|O
2	1713	1714	|O
-	1714	1715	|O
and	1716	1719	|O
5	1720	1721	|O
-	1721	1722	|O
fold	1722	1726	|O
less	1727	1731	|O
active	1732	1738	|O
,	1738	1739	|O
respectively	1740	1752	|O
,	1752	1753	|O
than	1754	1758	|O
trans	1759	1764	|O
-	1764	1765	|O
retinoic	1765	1773	|O
acid	1774	1778	|O
.	1778	1779	|O
In	1780	1782	|O
contrast	1783	1791	|O
,	1791	1792	|O
2a	1793	1795	|O
,	1795	1796	|O
3a	1797	1799	|O
,	1799	1800	|O
and	1801	1804	|O
3b	1805	1807	|O
induced	1808	1815	|O
differentiation	1816	1831	|O
of	1832	1834	|O
only	1835	1839	|O
a	1840	1841	|O
very	1842	1846	|O
small	1847	1852	|O
percentage	1853	1863	|O
of	1864	1866	|O
the	1867	1870	|O
cells	1871	1876	|O
.	1876	1877	|O
Acids	1878	1883	|O
1a	1884	1886	|O
and	1887	1890	|O
1c	1891	1893	|O
were	1894	1898	|O
the	1899	1902	|O
most	1903	1907	|O
active	1908	1914	|O
heteroarotinoids	1915	1931	|O
in	1932	1934	|O
the	1935	1938	|O
two	1939	1942	|O
biological	1943	1953	|O
assays	1954	1960	|O
.	1960	1961	|O
Consequently	1962	1974	|O
,	1974	1975	|O
the	1976	1979	|O
presence	1980	1988	|O
of	1989	1991	|O
the	1992	1995	|O
heteroatom	1996	2006	|O
does	2007	2011	|O
not	2012	2015	|O
eradicate	2016	2025	|O
the	2026	2029	|O
activity	2030	2038	|O
of	2039	2041	|O
the	2042	2045	|O
heteroarotinoids	2046	2062	|O
and	2063	2066	|O
thus	2067	2071	|O
they	2072	2076	|O
may	2077	2080	|O
have	2081	2085	|O
potential	2086	2095	|O
as	2096	2098	|O
chemotherapeutic	2099	2115	|O
agents	2116	2122	|O
.	2122	2123	|O

### abstracts1095.txt
A	0	1	|O
number	2	8	|O
of	9	11	|O
nucleoside	12	22	|O
analogues	23	32	|O
have	33	37	|O
been	38	42	|O
either	43	49	|O
used	50	54	|O
clinically	55	65	|O
as	66	68	|O
anticancer	69	79	|O
drugs	80	85	|O
or	86	88	|O
evaluated	89	98	|O
in	99	101	|O
clinical	102	110	|O
studies	111	118	|O
,	118	119	|O
while	120	125	|O
new	126	129	|O
nucleoside	130	140	|O
analogues	141	150	|O
continue	151	159	|O
to	160	162	|O
show	163	167	|O
promise	168	175	|O
.	175	176	|O
In	177	179	|O
this	180	184	|O
article	185	192	|O
,	192	193	|O
we	194	196	|O
report	197	203	|O
synthesis	204	213	|O
and	214	217	|O
cytotoxicity	218	230	|O
of	231	233	|O
a	234	235	|O
series	236	242	|O
of	243	245	|O
new	246	249	|O
pyrido	250	256	|B-IUPAC
[	256	257	|I-IUPAC
2	257	258	|I-IUPAC
,	258	259	|I-IUPAC
3	260	261	|I-IUPAC
-	261	262	|I-IUPAC
d	262	263	|I-IUPAC
]	263	264	|I-IUPAC
pyrimidine	264	274	|I-IUPAC
nucleosides	275	286	|B-MODIFIER
.	286	287	|O
2	288	289	|B-IUPAC
-	289	290	|I-IUPAC
Amino	290	295	|I-IUPAC
-	295	296	|I-IUPAC
3	296	297	|I-IUPAC
-	297	298	|I-IUPAC
cyano	298	303	|I-IUPAC
-	303	304	|I-IUPAC
4	304	305	|I-IUPAC
-	305	306	|I-IUPAC
methoxypyridine	306	321	|I-IUPAC
was	322	325	|O
converted	326	335	|O
,	335	336	|O
in	337	339	|O
two	340	343	|O
steps	344	349	|O
,	349	350	|O
to	351	353	|O
4	354	355	|B-IUPAC
-	355	356	|I-IUPAC
amino	356	361	|I-IUPAC
-	361	362	|I-IUPAC
5	362	363	|I-IUPAC
-	363	364	|I-IUPAC
oxopyrido	364	373	|I-IUPAC
[	373	374	|I-IUPAC
2,3	374	377	|I-IUPAC
-	377	378	|I-IUPAC
d	378	379	|I-IUPAC
]	379	380	|I-IUPAC
pyrimidine	380	390	|I-IUPAC
.	390	391	|O
A	392	393	|O
variety	394	401	|O
of	402	404	|O
1	405	406	|O
-	406	407	|O
O	407	408	|O
-	408	409	|O
acetylated	409	419	|O
pentose	420	427	|O
sugar	428	433	|O
derivatives	434	445	|O
were	446	450	|O
condensed	451	460	|O
with	461	465	|O
silylated	466	475	|O
4	476	477	|B-IUPAC
-	477	478	|I-IUPAC
amino	478	483	|I-IUPAC
-	483	484	|I-IUPAC
5	484	485	|I-IUPAC
-	485	486	|I-IUPAC
oxopyrido	486	495	|I-IUPAC
[	495	496	|I-IUPAC
2,3	496	499	|I-IUPAC
-	499	500	|I-IUPAC
d	500	501	|I-IUPAC
]	501	502	|I-IUPAC
pyrimidine	502	512	|I-IUPAC
,	512	513	|O
followed	514	522	|O
by	523	525	|O
protection	526	536	|O
,	536	537	|O
to	538	540	|O
afford	541	547	|O
a	548	549	|O
series	550	556	|O
of	557	559	|O
4	560	561	|B-IUPAC
-	561	562	|I-IUPAC
amino	562	567	|I-IUPAC
-	567	568	|I-IUPAC
5	568	569	|I-IUPAC
-	569	570	|I-IUPAC
oxopyrido	570	579	|I-IUPAC
[	579	580	|I-IUPAC
2	580	581	|I-IUPAC
,	581	582	|I-IUPAC
3	583	584	|I-IUPAC
-	584	585	|I-IUPAC
d	585	586	|I-IUPAC
]	586	587	|I-IUPAC
pyrimidine	587	597	|I-IUPAC
nucleosides	598	609	|B-MODIFIER
.	609	610	|O
Further	611	618	|O
derivatizations	619	634	|O
provided	635	643	|O
an	644	646	|O
additional	647	657	|O
group	658	663	|O
of	664	666	|O
pyrido	667	673	|B-IUPAC
[	673	674	|I-IUPAC
2,3	674	677	|I-IUPAC
-	677	678	|I-IUPAC
d	678	679	|I-IUPAC
]	679	680	|I-IUPAC
pyrimidine	680	690	|I-IUPAC
nucleosides	691	702	|B-MODIFIER
.	702	703	|O
These	704	709	|O
nucleosides	710	721	|O
were	722	726	|O
evaluated	727	736	|O
for	737	740	|O
in	741	743	|O
vitro	744	749	|O
cytotoxicity	750	762	|O
to	763	765	|O
human	766	771	|O
prostate	772	780	|O
cancer	781	787	|O
(	788	789	|O
HTB	789	792	|O
-	792	793	|O
81	793	795	|O
)	795	796	|O
and	797	800	|O
mouse	801	806	|O
melanoma	807	815	|O
(	816	817	|O
B16	817	820	|O
)	820	821	|O
cells	822	827	|O
as	828	830	|O
well	831	835	|O
as	836	838	|O
normal	839	845	|O
human	846	851	|O
fibroblasts	852	863	|O
(	864	865	|O
NHF	865	868	|O
)	868	869	|O
.	869	870	|O
A	871	872	|O
number	873	879	|O
of	880	882	|O
compounds	883	892	|O
(	893	894	|O
1a	894	896	|O
,	896	897	|O
b	897	898	|O
,	898	899	|O
2a	900	902	|O
-	902	903	|O
c	903	904	|O
,	904	905	|O
f	905	906	|O
,	906	907	|O
3f	908	910	|O
+	910	911	|O
4d	911	913	|O
)	913	914	|O
showed	915	921	|O
significant	922	933	|O
cytotoxicity	934	946	|O
to	947	949	|O
cancer	950	956	|O
cells	957	962	|O
,	962	963	|O
with	964	968	|O
4	969	970	|B-IUPAC
-	970	971	|I-IUPAC
amino	971	976	|I-IUPAC
-	976	977	|I-IUPAC
5	977	978	|I-IUPAC
-	978	979	|I-IUPAC
oxo	979	982	|I-IUPAC
-	982	983	|I-IUPAC
8	983	984	|I-IUPAC
-	984	985	|I-IUPAC
(	985	986	|I-IUPAC
beta	986	990	|I-IUPAC
-	990	991	|I-IUPAC
D	991	992	|I-IUPAC
-	992	993	|I-IUPAC
ribofuranosyl	993	1006	|I-IUPAC
)	1006	1007	|I-IUPAC
pyrido	1007	1013	|I-IUPAC
[	1013	1014	|I-IUPAC
2,3	1014	1017	|I-IUPAC
-	1017	1018	|I-IUPAC
d	1018	1019	|I-IUPAC
]	1019	1020	|I-IUPAC
pyrimidine	1020	1030	|I-IUPAC
(	1031	1032	|O
1b	1032	1034	|O
)	1034	1035	|O
being	1036	1041	|O
the	1042	1045	|O
most	1046	1050	|O
potent	1051	1057	|O
proliferation	1058	1071	|O
inhibitor	1072	1081	|O
(	1082	1083	|O
EC	1083	1085	|O
(	1085	1086	|O
50	1086	1088	|O
)	1088	1089	|O
:	1089	1090	|O
0.06-0.08	1091	1100	|O
microM	1101	1107	|O
)	1107	1108	|O
to	1109	1111	|O
all	1112	1115	|O
types	1116	1121	|O
of	1122	1124	|O
cells	1125	1130	|O
tested	1131	1137	|O
.	1137	1138	|O
However	1139	1146	|O
,	1146	1147	|O
a	1148	1149	|O
selective	1150	1159	|O
inhibition	1160	1170	|O
to	1171	1173	|O
the	1174	1177	|O
cancer	1178	1184	|O
cells	1185	1190	|O
was	1191	1194	|O
observed	1195	1203	|O
for	1204	1207	|O
4	1208	1209	|B-IUPAC
-	1209	1210	|I-IUPAC
amino	1210	1215	|I-IUPAC
-	1215	1216	|I-IUPAC
5	1216	1217	|I-IUPAC
-	1217	1218	|I-IUPAC
oxo	1218	1221	|I-IUPAC
-	1221	1222	|I-IUPAC
8	1222	1223	|I-IUPAC
-	1223	1224	|I-IUPAC
(	1224	1225	|I-IUPAC
beta	1225	1229	|I-IUPAC
-	1229	1230	|I-IUPAC
D	1230	1231	|I-IUPAC
-	1231	1232	|I-IUPAC
xylofuranosyl	1232	1245	|I-IUPAC
)	1245	1246	|I-IUPAC
pyrido	1246	1252	|I-IUPAC
[	1252	1253	|I-IUPAC
2,3	1253	1256	|I-IUPAC
-	1256	1257	|I-IUPAC
d	1257	1258	|I-IUPAC
]	1258	1259	|I-IUPAC
pyrimidine	1259	1269	|I-IUPAC
(	1270	1271	|O
2b	1271	1273	|O
)	1273	1274	|O
,	1274	1275	|O
which	1276	1281	|O
is	1282	1284	|O
a	1285	1286	|O
potent	1287	1293	|O
inhibitor	1294	1303	|O
of	1304	1306	|O
HTB	1307	1310	|O
-	1310	1311	|O
81	1311	1313	|O
(	1314	1315	|O
EC	1315	1317	|O
(	1317	1318	|O
50	1318	1320	|O
)	1320	1321	|O
:	1321	1322	|O
0.73	1323	1327	|O
microM	1328	1334	|O
)	1334	1335	|O
and	1336	1339	|O
has	1340	1343	|O
a	1344	1345	|O
favorable	1346	1355	|O
in	1356	1358	|O
vitro	1359	1364	|O
selectivity	1365	1376	|O
index	1377	1382	|O
(	1383	1384	|O
28	1384	1386	|O
)	1386	1387	|O
.	1387	1388	|O

### abstracts2401.txt
Two	0	3	|O
series	4	10	|O
of	11	13	|O
compounds	14	23	|O
that	24	28	|O
are	29	32	|O
structurally	33	45	|O
related	46	53	|O
to	54	56	|O
benzomorphans	57	70	|O
,	70	71	|O
derived	72	79	|O
by	80	82	|O
structural	83	93	|O
modification	94	106	|O
of	107	109	|O
arylpiperazines	110	125	|O
with	126	130	|O
high	131	135	|O
5	136	137	|O
-	137	138	|O
HT1A	138	142	|O
affinity	143	151	|O
and	152	155	|O
moderate	156	164	|O
sigma	165	170	|O
affinity	171	179	|O
,	179	180	|O
were	181	185	|O
prepared	186	194	|O
in	195	197	|O
order	198	203	|O
to	204	206	|O
increase	207	215	|O
sigma	216	221	|O
affinity	222	230	|O
and	231	234	|O
selectivity	235	246	|O
.	246	247	|O
All	248	251	|O
new	252	255	|O
compounds	256	265	|O
are	266	269	|O
N	270	271	|B-MODIFIER
-	271	272	|I-MODIFIER
substituted	272	283	|I-MODIFIER
-	283	284	|O
omega	284	289	|B-PARTIUPAC
-	289	290	|I-PARTIUPAC
(	290	291	|I-PARTIUPAC
1,2,3,4	291	298	|I-PARTIUPAC
-	298	299	|I-PARTIUPAC
tetrahydronaphthalen	299	319	|I-PARTIUPAC
-	319	320	|I-PARTIUPAC
1	320	321	|I-PARTIUPAC
-	321	322	|I-PARTIUPAC
yl	322	324	|I-PARTIUPAC
)	324	325	|I-PARTIUPAC
-	325	326	|I-PARTIUPAC
or	327	329	|O
-	330	331	|B-PARTIUPAC
omega	331	336	|I-PARTIUPAC
-	336	337	|I-PARTIUPAC
(	337	338	|I-PARTIUPAC
1,2	338	341	|I-PARTIUPAC
-	341	342	|I-PARTIUPAC
dihydronaphthalen	342	359	|I-PARTIUPAC
-	359	360	|I-PARTIUPAC
4	360	361	|I-PARTIUPAC
-	361	362	|I-PARTIUPAC
yl	362	364	|I-PARTIUPAC
)	364	365	|I-PARTIUPAC
-	365	366	|I-PARTIUPAC
n	366	367	|I-PARTIUPAC
-	367	368	|I-PARTIUPAC
alkylamines	368	379	|I-PARTIUPAC
with	380	384	|O
,	384	385	|O
in	386	388	|O
some	389	393	|O
cases	394	399	|O
,	399	400	|O
a	401	402	|O
methoxy	403	410	|B-IUPAC
group	411	416	|B-MODIFIER
on	417	419	|O
the	420	423	|O
tetralin	424	432	|O
moiety	433	439	|O
.	439	440	|O
They	441	445	|O
were	446	450	|O
tested	451	457	|O
in	458	460	|O
radioligand	461	472	|O
binding	473	480	|O
assays	481	487	|O
on	488	490	|O
sigma	491	496	|O
(	497	498	|O
[	498	499	|O
3H	499	501	|O
]	501	502	|O
DTG	502	505	|O
and	506	509	|O
[	510	511	|O
3H	511	513	|O
]	513	514	|O
-	514	515	|O
(	515	516	|O
+	516	517	|O
)	517	518	|O
-	518	519	|O
pentazocine	519	530	|O
)	530	531	|O
,	531	532	|O
D	533	534	|O
-	534	535	|O
2	535	536	|O
dopaminergic	537	549	|O
,	549	550	|O
5	551	552	|O
-	552	553	|O
HT1A	553	557	|O
and	558	561	|O
5	562	563	|O
-	563	564	|O
HT2	564	567	|O
serotonergic	568	580	|O
,	580	581	|O
and	582	585	|O
PCP	586	589	|O
(	590	591	|O
phencyclidine	591	604	|O
)	604	605	|O
receptors	606	615	|O
.	615	616	|O
A	617	618	|O
first	619	624	|O
set	625	628	|O
of	629	631	|O
compounds	632	641	|O
bearing	642	649	|O
a	650	651	|O
4	652	653	|B-MODIFIER
-	653	654	|I-MODIFIER
(	654	655	|I-MODIFIER
1	655	656	|I-MODIFIER
-	656	657	|I-MODIFIER
substituted	657	668	|I-MODIFIER
)	668	669	|I-MODIFIER
piperazine	669	679	|O
moiety	680	686	|B-MODIFIER
as	687	689	|O
terminal	690	698	|O
fragment	699	707	|O
on	708	710	|O
the	711	714	|O
alkyl	715	720	|B-IUPAC
chain	721	726	|B-MODIFIER
showed	727	733	|O
moderate	734	742	|O
to	743	745	|O
high	746	750	|O
sigma	751	756	|O
affinity	757	765	|O
(	766	767	|O
Ki	767	769	|O
=	770	771	|O
5.3-139	772	779	|O
nM	780	782	|O
)	782	783	|O
,	783	784	|O
the	785	788	|O
most	789	793	|O
active	794	800	|O
and	801	804	|O
selective	805	814	|O
being	815	820	|O
1	821	822	|B-IUPAC
-	822	823	|I-IUPAC
cyclohexyl	823	833	|I-IUPAC
-	833	834	|I-IUPAC
4	834	835	|I-IUPAC
-	835	836	|I-IUPAC
[	836	837	|I-IUPAC
3	837	838	|I-IUPAC
-	838	839	|I-IUPAC
(	839	840	|I-IUPAC
5	840	841	|I-IUPAC
-	841	842	|I-IUPAC
methoxy	842	849	|I-IUPAC
-	849	850	|I-IUPAC
1,2,3,4	850	857	|I-IUPAC
-	857	858	|I-IUPAC
tetrahydronaphthalen	858	878	|I-IUPAC
-	878	879	|I-IUPAC
1	879	880	|I-IUPAC
-	880	881	|I-IUPAC
yl	881	883	|I-IUPAC
)	883	884	|I-IUPAC
-	884	885	|I-IUPAC
n	885	886	|I-IUPAC
-	886	887	|I-IUPAC
propyl	888	894	|I-IUPAC
]	895	896	|I-IUPAC
piperazine	896	906	|I-IUPAC
(	907	908	|O
14	908	910	|O
)	910	911	|O
,	911	912	|O
with	913	917	|O
probable	918	926	|O
pronounced	927	937	|O
sigma	938	943	|O
2	944	945	|O
affinity	946	954	|O
(	955	956	|O
Ki	956	958	|O
=	959	960	|O
5.3	961	964	|O
nM	965	967	|O
on	968	970	|O
[	971	972	|O
3H	972	974	|O
]	974	975	|O
DTG	975	978	|O
and	979	982	|O
Ki	983	985	|O
=	986	987	|O
71	988	990	|O
nM	991	993	|O
on	994	996	|O
[	997	998	|O
3H	998	1000	|O
]	1000	1001	|O
-	1001	1002	|O
(	1002	1003	|O
+	1003	1004	|O
)	1004	1005	|O
-	1005	1006	|O
pentazocine	1006	1017	|O
)	1017	1018	|O
.	1018	1019	|O
Moreover	1020	1028	|O
,	1028	1029	|O
compound	1030	1038	|O
13	1039	1041	|O
,	1041	1042	|O
a	1043	1044	|O
1	1045	1046	|B-IUPAC
-	1046	1047	|I-IUPAC
benzylpiperazine	1047	1063	|I-IUPAC
analogue	1064	1072	|B-MODIFIER
of	1073	1075	|O
14	1076	1078	|O
,	1078	1079	|O
preserved	1080	1089	|O
a	1090	1091	|O
dual	1092	1096	|O
high	1097	1101	|O
5	1102	1103	|O
-	1103	1104	|O
HT1A	1104	1108	|O
and	1109	1112	|O
sigma	1113	1118	|O
affinity	1119	1127	|O
(	1128	1129	|O
Ki	1129	1131	|O
=	1132	1133	|O
3.6	1134	1137	|O
nM	1138	1140	|O
on	1141	1143	|O
[	1144	1145	|O
3H	1145	1147	|O
]	1147	1148	|O
-	1148	1149	|O
5	1149	1150	|O
-	1150	1151	|O
HT	1151	1153	|O
and	1154	1157	|O
Ki	1158	1160	|O
=	1161	1162	|O
7.0	1163	1166	|O
nM	1167	1169	|O
on	1170	1172	|O
[	1173	1174	|O
3H	1174	1176	|O
]	1176	1177	|O
DTG	1177	1180	|O
)	1180	1181	|O
.	1181	1182	|O
The	1183	1186	|O
second	1187	1193	|O
set	1194	1197	|O
of	1198	1200	|O
compounds	1201	1210	|O
includes	1211	1219	|O
some	1220	1224	|O
N	1225	1226	|B-IUPAC
-	1226	1227	|I-IUPAC
phenylalkyl	1227	1238	|I-IUPAC
derivatives	1239	1250	|B-MODIFIER
of	1251	1253	|O
3	1254	1255	|B-IUPAC
-	1255	1256	|I-IUPAC
(	1256	1257	|I-IUPAC
5	1257	1258	|I-IUPAC
-	1258	1259	|I-IUPAC
methoxy	1259	1266	|I-IUPAC
-	1266	1267	|I-IUPAC
1,2,3,4	1267	1274	|I-IUPAC
-	1274	1275	|I-IUPAC
tetrahydronaphthalen	1275	1295	|I-IUPAC
-	1295	1296	|I-IUPAC
1	1296	1297	|I-IUPAC
-	1297	1298	|I-IUPAC
yl	1298	1300	|I-IUPAC
)	1300	1301	|I-IUPAC
-	1301	1302	|I-IUPAC
n	1303	1304	|I-IUPAC
-	1304	1305	|I-IUPAC
propylamine	1305	1316	|I-IUPAC
that	1317	1321	|O
can	1322	1325	|O
be	1326	1328	|O
considered	1329	1339	|O
to	1340	1342	|O
be	1343	1345	|O
open	1346	1350	|O
-	1350	1351	|O
chain	1351	1356	|O
derivatives	1357	1368	|O
of	1369	1371	|O
4	1372	1373	|B-MODIFIER
-	1373	1374	|I-MODIFIER
substituted	1374	1385	|I-MODIFIER
-	1385	1386	|O
1	1386	1387	|B-IUPAC
-	1387	1388	|I-IUPAC
arylpiperazines	1388	1403	|I-IUPAC
.	1403	1404	|O
Among	1405	1410	|O
these	1411	1416	|O
compounds	1417	1426	|O
that	1427	1431	|O
had	1432	1435	|O
a	1436	1437	|O
lower	1438	1443	|O
activity	1444	1452	|O
toward	1453	1459	|O
sigma	1460	1465	|O
binding	1466	1473	|O
sites	1474	1479	|O
,	1479	1480	|O
a	1481	1482	|O
high	1483	1487	|O
5	1488	1489	|O
-	1489	1490	|O
HT1A	1490	1494	|O
affinity	1495	1503	|O
was	1504	1507	|O
found	1508	1513	|O
for	1514	1517	|O
the	1518	1521	|O
N	1522	1523	|B-IUPAC
-	1523	1524	|I-IUPAC
(	1524	1525	|I-IUPAC
3	1525	1526	|I-IUPAC
-	1526	1527	|I-IUPAC
phenylpropyl	1527	1539	|I-IUPAC
)	1539	1540	|I-IUPAC
derivative	1541	1551	|B-MODIFIER
21	1552	1554	|O
(	1555	1556	|O
Ki	1556	1558	|O
=	1559	1560	|O
4.4	1561	1564	|O
nM	1565	1567	|O
)	1567	1568	|O
which	1569	1574	|O
demonstrated	1575	1587	|O
very	1588	1592	|O
good	1593	1597	|O
selectivity	1598	1609	|O
.	1609	1610	|O

### abstracts4033.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
complexes	12	21	|O
of	22	24	|O
the	25	28	|O
general	29	36	|O
formula	37	44	|O
trans	45	50	|O
-	50	51	|O
[	51	52	|O
PtCl2	52	57	|O
(	57	58	|O
Am	58	60	|O
)	60	61	|O
(	61	62	|O
pip	62	65	|O
-	65	66	|O
pip	66	69	|O
)	69	70	|O
]	70	71	|O
x	72	73	|O
HCl	74	77	|O
where	78	83	|O
pip	84	87	|O
-	87	88	|O
pip	88	91	|O
is	92	94	|O
4	95	96	|B-IUPAC
-	96	97	|I-IUPAC
piperidinopiperidine	97	117	|I-IUPAC
and	118	121	|O
Am	122	124	|O
is	125	127	|O
NH3	128	131	|O
,	131	132	|O
methylamine	133	144	|O
(	145	146	|O
MA	146	148	|O
)	148	149	|O
,	149	150	|O
dimethylamine	151	164	|B-IUPAC
(	165	166	|O
DMA	166	169	|O
)	169	170	|O
,	170	171	|O
n	172	173	|B-IUPAC
-	173	174	|I-IUPAC
propylamine	174	185	|I-IUPAC
(	186	187	|O
NPA	187	190	|O
)	190	191	|O
,	191	192	|O
isopropylamine	193	207	|O
(	208	209	|O
IPA	209	212	|O
)	212	213	|O
,	213	214	|O
n	215	216	|B-IUPAC
-	216	217	|I-IUPAC
butylamine	217	227	|I-IUPAC
(	228	229	|O
NBA	229	232	|O
)	232	233	|O
,	233	234	|O
or	235	237	|O
cyclohexylamine	238	253	|B-IUPAC
(	254	255	|O
CHA	255	258	|O
)	258	259	|O
were	260	264	|O
prepared	265	273	|O
and	274	277	|O
characterized	278	291	|O
,	291	292	|O
and	293	296	|O
their	297	302	|O
cytotoxic	303	312	|O
properties	313	323	|O
against	324	331	|O
ovarian	332	339	|O
and	340	343	|O
colon	344	349	|O
cancer	350	356	|O
cells	357	362	|O
were	363	367	|O
evaluated	368	377	|O
.	377	378	|O
The	379	382	|O
trans	383	388	|O
-	388	389	|O
[	389	390	|O
PtCl2	390	395	|O
(	395	396	|O
NH3	396	399	|O
)	399	400	|O
(	400	401	|O
pip	401	404	|O
-	404	405	|O
pip	405	408	|O
)	408	409	|O
]	409	410	|O
x	411	412	|O
HCl	413	416	|O
was	417	420	|O
significantly	421	434	|O
more	435	439	|O
potent	440	446	|O
than	447	451	|O
cisplatin	452	461	|O
in	462	464	|O
all	465	468	|O
the	469	472	|O
cisplatin	473	482	|O
-	482	483	|O
resistant	483	492	|O
ovarian	493	500	|O
cancer	501	507	|O
cell	508	512	|O
lines	513	518	|O
and	519	522	|O
was	523	526	|O
nearly	527	533	|O
as	534	536	|O
cytotoxic	537	546	|O
as	547	549	|O
cisplatin	550	559	|O
against	560	567	|O
colon	568	573	|O
cancer	574	580	|O
cells	581	586	|O
.	586	587	|O
In	588	590	|O
vivo	591	595	|O
studies	596	603	|O
in	604	606	|O
mice	607	611	|O
showed	612	618	|O
that	619	623	|O
the	624	627	|O
pip	628	631	|O
-	631	632	|O
pip	632	635	|O
complexes	636	645	|O
are	646	649	|O
significantly	650	663	|O
less	664	668	|O
toxic	669	674	|O
than	675	679	|O
cisplatin	680	689	|O
.	689	690	|O
Cisplatin	691	700	|O
was	701	704	|O
more	705	709	|O
efficacious	710	721	|O
than	722	726	|O
both	727	731	|O
trans	732	737	|O
-	737	738	|O
[	738	739	|O
PtCl2	739	744	|O
(	744	745	|O
NH3	745	748	|O
)	748	749	|O
(	749	750	|O
pip	750	753	|O
-	753	754	|O
pip	754	757	|O
)	757	758	|O
]	758	759	|O
x	760	761	|O
HCl	762	765	|O
and	766	769	|O
trans	770	775	|O
-	775	776	|O
[	776	777	|O
PtCl2	777	782	|O
(	782	783	|O
NBA	783	786	|O
)	786	787	|O
(	787	788	|O
pip	788	791	|O
-	791	792	|O
pip	792	795	|O
)	795	796	|O
]	796	797	|O
x	798	799	|O
HCl	800	803	|O
in	804	806	|O
the	807	810	|O
A2780	811	816	|O
and	817	820	|O
A2780cisR	821	830	|O
tumor	831	836	|O
xenograft	837	846	|O
models	847	853	|O
,	853	854	|O
consistent	855	865	|O
with	866	870	|O
its	871	874	|O
lower	875	880	|O
IC50	881	885	|O
values	886	892	|O
in	893	895	|O
A2780	896	901	|O
cells	902	907	|O
but	908	911	|O
contrary	912	920	|O
to	921	923	|O
the	924	927	|O
higher	928	934	|O
IC50	935	939	|O
values	940	946	|O
in	947	949	|O
A2780cisR	950	959	|O
cells	960	965	|O
.	965	966	|O
In	967	969	|O
the	970	973	|O
colon	974	979	|O
cancer	980	986	|O
cell	987	991	|O
studies	992	999	|O
,	999	1000	|O
trans	1001	1006	|O
-	1006	1007	|O
[	1007	1008	|O
PtCl2	1008	1013	|O
(	1013	1014	|O
NH3	1014	1017	|O
)	1017	1018	|O
(	1018	1019	|O
pip	1019	1022	|O
-	1022	1023	|O
pip	1023	1026	|O
)	1026	1027	|O
]	1027	1028	|O
x	1029	1030	|O
HCl	1031	1034	|O
was	1035	1038	|O
slightly	1039	1047	|O
less	1048	1052	|O
potent	1053	1059	|O
than	1060	1064	|O
cisplatin	1065	1074	|O
in	1075	1077	|O
the	1078	1081	|O
in	1082	1084	|O
vitro	1085	1090	|O
studies	1091	1098	|O
but	1099	1102	|O
had	1103	1106	|O
efficacy	1107	1115	|O
comparable	1116	1126	|O
to	1127	1129	|O
that	1130	1134	|O
of	1135	1137	|O
cisplatin	1138	1147	|O
in	1148	1150	|O
the	1151	1154	|O
in	1155	1157	|O
vivo	1158	1162	|O
xenograft	1163	1172	|O
model	1173	1178	|O
.	1178	1179	|O

### abstracts4794.txt
Palladium	0	9	|O
(	9	10	|O
0	10	11	|O
)	11	12	|O
-	12	13	|O
mediated	13	21	|O
Suzuki	22	28	|O
-	28	29	|O
Miyaura	29	36	|O
and	37	40	|O
Heck	41	45	|O
transformations	46	61	|O
have	62	66	|O
been	67	71	|O
exploited	72	81	|O
to	82	84	|O
provide	85	92	|O
examples	93	101	|O
of	102	104	|O
8	105	106	|B-IUPAC
-	106	107	|I-IUPAC
methylquino	107	118	|I-IUPAC
[	118	119	|I-IUPAC
4,3,2	119	124	|I-IUPAC
-	124	125	|I-IUPAC
kl	125	127	|I-IUPAC
]	127	128	|I-IUPAC
acridines	128	137	|I-IUPAC
and	138	141	|O
8,13	142	146	|B-IUPAC
-	146	147	|I-IUPAC
dimethylquino	147	160	|I-IUPAC
[	160	161	|I-IUPAC
4,3,2	161	166	|I-IUPAC
-	166	167	|I-IUPAC
kl	167	169	|I-IUPAC
]	169	170	|I-IUPAC
acridinium	170	180	|I-IUPAC
iodides	181	188	|I-IUPAC
bearing	189	196	|O
bulky	197	202	|O
saturated	203	212	|O
(	213	214	|B-IUPAC
3	214	215	|I-IUPAC
-	215	216	|I-IUPAC
acetoxy	216	223	|I-IUPAC
)	223	224	|I-IUPAC
propyl	224	230	|I-IUPAC
or	231	233	|O
(	234	235	|B-IUPAC
E	235	236	|I-IUPAC
)	236	237	|I-IUPAC
-	237	238	|I-IUPAC
3	238	239	|I-IUPAC
-	239	240	|I-IUPAC
(	240	241	|I-IUPAC
morpholin	241	250	|I-IUPAC
-	250	251	|I-IUPAC
4	251	252	|I-IUPAC
-	252	253	|I-IUPAC
yl	253	255	|I-IUPAC
)	255	256	|I-IUPAC
-	256	257	|I-IUPAC
3	257	258	|I-IUPAC
-	258	259	|I-IUPAC
oxopropenyl	259	270	|I-IUPAC
substituents	271	283	|B-MODIFIER
variously	284	293	|O
in	294	296	|O
the	297	300	|O
3	301	302	|O
-	302	303	|O
,	303	304	|O
6	305	306	|O
-	306	307	|O
,	307	308	|O
or	309	311	|O
10	312	314	|O
-	314	315	|O
positions	315	324	|O
of	325	327	|O
the	328	331	|O
pentacyclic	332	343	|O
nucleus	344	351	|O
.	351	352	|O
The	353	356	|O
pharmacological	357	372	|O
/	372	373	|O
pharmaceutical	373	387	|O
properties	388	398	|O
of	399	401	|O
four	402	406	|O
compounds	407	416	|O
(	417	418	|O
4	418	419	|O
,	419	420	|O
RHPS4	421	426	|O
)	426	427	|O
,	427	428	|O
(	429	430	|O
5	430	431	|O
,	431	432	|O
IH383	433	438	|O
)	438	439	|O
,	439	440	|O
(	441	442	|O
6	442	443	|O
,	443	444	|O
RHPS16	445	451	|O
)	451	452	|O
,	452	453	|O
and	454	457	|O
(	458	459	|O
17	459	461	|O
,	461	462	|O
RHPS19	463	469	|O
)	469	470	|O
were	471	475	|O
measured	476	484	|O
to	485	487	|O
assess	488	494	|O
their	495	500	|O
clinical	501	509	|O
potential	510	519	|O
as	520	522	|O
DNA	523	526	|O
G	527	528	|O
-	528	529	|O
quadruplex	529	539	|O
-	539	540	|O
stabilizing	540	551	|O
/	551	552	|O
telomerase	552	562	|O
inhibitory	563	573	|O
agents	574	580	|O
.	580	581	|O
The	582	585	|O
following	586	595	|O
properties	596	606	|O
were	607	611	|O
measured	612	620	|O
:	620	621	|O
stability	622	631	|O
in	632	634	|O
tissue	635	641	|O
culture	642	649	|O
media	650	655	|O
in	656	658	|O
the	659	662	|O
presence	663	671	|O
of	672	674	|O
A549	675	679	|O
lung	680	684	|O
and	685	688	|O
MCF	689	692	|O
-	692	693	|O
7	693	694	|O
breast	695	701	|O
tumor	702	707	|O
cells	708	713	|O
,	713	714	|O
metabolic	715	724	|O
stability	725	734	|O
when	735	739	|O
incubated	740	749	|O
with	750	754	|O
rat	755	758	|O
liver	759	764	|O
microsomes	765	775	|O
,	775	776	|O
and	777	780	|O
rate	781	785	|O
of	786	788	|O
uptake	789	795	|O
and	796	799	|O
subcellular	800	811	|O
location	812	820	|O
in	821	823	|O
A549	824	828	|O
and	829	832	|O
MCF	833	836	|O
-	836	837	|O
7	837	838	|O
cells	839	844	|O
.	844	845	|O
Compound	846	854	|O
17	855	857	|O
was	858	861	|O
unstable	862	870	|O
in	871	873	|O
tissue	874	880	|O
culture	881	888	|O
media	889	894	|O
,	894	895	|O
failed	896	902	|O
to	903	905	|O
achieve	906	913	|O
nuclear	914	921	|O
access	922	928	|O
,	928	929	|O
and	930	933	|O
was	934	937	|O
excluded	938	946	|O
from	947	951	|O
further	952	959	|O
consideration	960	973	|O
.	973	974	|O
Of	975	977	|O
the	978	981	|O
other	982	987	|O
agents	988	994	|O
,	994	995	|O
4	996	997	|O
exhibited	998	1007	|O
the	1008	1011	|O
most	1012	1016	|O
favorable	1017	1026	|O
pharmaceutical	1027	1041	|O
profile	1042	1049	|O
:	1049	1050	|O
the	1051	1054	|O
agent	1055	1060	|O
has	1061	1064	|O
appropriate	1065	1076	|O
stability	1077	1086	|O
in	1087	1089	|O
the	1090	1093	|O
presence	1094	1102	|O
of	1103	1105	|O
tumor	1106	1111	|O
cells	1112	1117	|O
and	1118	1121	|O
rat	1122	1125	|O
liver	1126	1131	|O
microsomes	1132	1142	|O
and	1143	1146	|O
achieves	1147	1155	|O
rapid	1156	1161	|O
ingress	1162	1169	|O
into	1170	1174	|O
cell	1175	1179	|O
nuclei	1180	1186	|O
where	1187	1192	|O
the	1193	1196	|O
putative	1197	1205	|O
molecular	1206	1215	|O
target	1216	1222	|O
is	1223	1225	|O
located	1226	1233	|O
.	1233	1234	|O

### abstracts3098.txt
N	0	1	|O
-	1	2	|O
(	2	3	|O
2	3	4	|O
-	4	5	|O
Naphthyl	5	13	|O
)	13	14	|O
glycine	14	21	|O
hydrazide	22	31	|O
analogues	32	41	|B-MODIFIER
were	42	46	|O
synthesized	47	58	|O
and	59	62	|O
tested	63	69	|O
for	70	73	|O
possible	74	82	|O
in	83	85	|O
vitro	86	91	|O
antitubercular	92	106	|O
activity	107	115	|O
.	115	116	|O
N	117	118	|B-IUPAC
-	118	119	|I-IUPAC
(	119	120	|I-IUPAC
2	120	121	|I-IUPAC
-	121	122	|I-IUPAC
Naphthyl	122	130	|I-IUPAC
)	130	131	|I-IUPAC
alanine	131	138	|I-IUPAC
hydrazide	139	148	|I-IUPAC
(	149	150	|O
3	150	151	|O
)	151	152	|O
,	152	153	|O
N	154	155	|B-IUPAC
-	155	156	|I-IUPAC
methyl	156	162	|I-IUPAC
-	162	163	|I-IUPAC
N	163	164	|I-IUPAC
-	164	165	|I-IUPAC
(	165	166	|I-IUPAC
2	166	167	|I-IUPAC
-	167	168	|I-IUPAC
naphthyl	168	176	|I-IUPAC
)	176	177	|I-IUPAC
glycine	177	184	|I-IUPAC
hydrazide	185	194	|I-IUPAC
(	195	196	|O
5	196	197	|O
)	197	198	|O
,	198	199	|O
N	200	201	|B-IUPAC
-	201	202	|I-IUPAC
(	202	203	|I-IUPAC
6	203	204	|I-IUPAC
-	204	205	|I-IUPAC
methoxy	205	212	|I-IUPAC
-	212	213	|I-IUPAC
2	213	214	|I-IUPAC
-	214	215	|I-IUPAC
naphthyl	215	223	|I-IUPAC
)	223	224	|I-IUPAC
glycine	224	231	|I-IUPAC
hydrazide	232	241	|I-IUPAC
(	242	243	|O
7	243	244	|O
)	244	245	|O
,	245	246	|O
and	247	250	|O
3	251	252	|B-IUPAC
-	252	253	|I-IUPAC
(	253	254	|I-IUPAC
2	254	255	|I-IUPAC
-	255	256	|I-IUPAC
naphthylamino	256	269	|I-IUPAC
)	269	270	|I-IUPAC
butyric	270	277	|I-IUPAC
acid	278	282	|I-IUPAC
hydrazide	283	292	|I-IUPAC
(	293	294	|O
23	294	296	|O
)	296	297	|O
showed	298	304	|O
potent	305	311	|O
inhibitory	312	322	|O
action	323	329	|O
against	330	337	|O
Mycobacterium	338	351	|O
tuberculosis	352	364	|O
H37Rv	365	370	|O
in	371	373	|O
Youman	374	380	|O
's	380	382	|O
medium	383	389	|O
at	390	392	|O
concentrations	393	407	|O
ranging	408	415	|O
from	416	420	|O
0.5	421	424	|O
to	425	427	|O
10.0	428	432	|O
micrograms	433	443	|O
/	443	444	|O
mL	444	446	|O
.	446	447	|O
These	448	453	|O
compounds	454	463	|O
showed	464	470	|O
significant	471	482	|O
inhibitory	483	493	|O
action	494	500	|O
against	501	508	|O
isonicotinic	509	521	|O
acid	522	526	|O
hydrazide	527	536	|O
and	537	540	|O
streptomycin	541	553	|O
-	553	554	|O
resistant	554	563	|O
strains	564	571	|O
of	572	574	|O
M	575	576	|O
.	576	577	|O
tuberculosis	578	590	|O
.	590	591	|O
N	592	593	|B-IUPAC
-	593	594	|I-IUPAC
(	594	595	|I-IUPAC
6	595	596	|I-IUPAC
-	596	597	|I-IUPAC
Quinolyl	597	605	|I-IUPAC
)	605	606	|I-IUPAC
glycine	606	613	|I-IUPAC
hydrazide	614	623	|I-IUPAC
(	624	625	|O
18	625	627	|O
)	627	628	|O
and	629	632	|O
3	633	634	|B-IUPAC
-	634	635	|I-IUPAC
(	635	636	|I-IUPAC
2	636	637	|I-IUPAC
-	637	638	|I-IUPAC
quinolylamino	638	651	|I-IUPAC
)	651	652	|I-IUPAC
butyric	652	659	|I-IUPAC
acid	660	664	|I-IUPAC
hydrazide	665	674	|I-IUPAC
(	675	676	|O
24	676	678	|O
)	678	679	|O
,	679	680	|O
which	681	686	|O
are	687	690	|O
bioisosteres	691	703	|O
of	704	706	|O
compounds	707	716	|O
1	717	718	|O
and	719	722	|O
23	723	725	|O
,	725	726	|O
showed	727	733	|O
loss	734	738	|O
of	739	741	|O
antitubercular	742	756	|O
activity	757	765	|O
at	766	768	|O
low	769	772	|O
concentrations	773	787	|O
.	787	788	|O

### abstracts3210.txt
The	0	3	|O
pyrimidine	4	14	|O
acyclonucleoside	15	31	|O
5	32	33	|B-IUPAC
-	33	34	|I-IUPAC
fluoro	34	40	|I-IUPAC
-	40	41	|I-IUPAC
1	41	42	|I-IUPAC
-	42	43	|I-IUPAC
[	43	44	|I-IUPAC
(	44	45	|I-IUPAC
2	45	46	|I-IUPAC
-	46	47	|I-IUPAC
hydroxyethoxy	47	60	|I-IUPAC
)	60	61	|I-IUPAC
methyl	61	67	|I-IUPAC
]	67	68	|I-IUPAC
uracil	68	74	|I-IUPAC
(	75	76	|O
3	76	77	|O
)	77	78	|O
was	79	82	|O
synthesized	83	94	|O
as	95	97	|O
part	98	102	|O
of	103	105	|O
a	106	107	|O
program	108	115	|O
aimed	116	121	|O
at	122	124	|O
the	125	128	|O
development	129	140	|O
of	141	143	|O
new	144	147	|O
5	148	149	|B-IUPAC
-	149	150	|I-IUPAC
fluorouracil	150	162	|I-IUPAC
derivatives	163	174	|B-MODIFIER
with	175	179	|O
fewer	180	185	|O
side	186	190	|O
effects	191	198	|O
and	199	202	|O
a	203	204	|O
broader	205	212	|O
margin	213	219	|O
of	220	222	|O
safety	223	229	|O
.	229	230	|O
Condensation	231	243	|O
of	244	246	|O
5	247	248	|B-IUPAC
-	248	249	|I-IUPAC
fluoro	249	255	|I-IUPAC
-	255	256	|I-IUPAC
2,4	256	259	|I-IUPAC
-	259	260	|I-IUPAC
bis	260	263	|I-IUPAC
[	263	264	|I-IUPAC
(	264	265	|I-IUPAC
trimethylsilyl	265	279	|I-IUPAC
)	279	280	|I-IUPAC
oxy	280	283	|I-IUPAC
]	283	284	|I-IUPAC
pyrimidine	284	294	|I-IUPAC
with	295	299	|O
2	300	301	|B-IUPAC
-	301	302	|I-IUPAC
acetoxyethyl	302	314	|I-IUPAC
acetoxymethyl	315	328	|I-IUPAC
ether	329	334	|I-IUPAC
(	335	336	|O
6	336	337	|O
)	337	338	|O
in	339	341	|O
the	342	345	|O
presence	346	354	|O
of	355	357	|O
SnCl4	358	363	|O
afforded	364	372	|O
the	373	376	|O
acetate	377	384	|O
ester	385	390	|O
7	391	392	|O
,	392	393	|O
which	394	399	|O
on	400	402	|O
deprotection	403	415	|O
with	416	420	|O
NaOMe	421	426	|O
gave	427	431	|O
3	432	433	|O
in	434	436	|O
50-60%	437	443	|O
overall	444	451	|O
yield	452	457	|O
.	457	458	|O
The	459	462	|O
5	463	464	|B-IUPAC
-	464	465	|I-IUPAC
bromo	465	470	|I-IUPAC
and	471	474	|O
5	475	476	|B-IUPAC
-	476	477	|I-IUPAC
iodo	477	481	|I-IUPAC
analogues	482	491	|B-MODIFIER
10	492	494	|O
and	495	498	|O
11	499	501	|O
,	501	502	|O
respectively	503	515	|O
,	515	516	|O
were	517	521	|O
obtained	522	530	|O
similarly	531	540	|O
.	540	541	|O
Reaction	542	550	|O
of	551	553	|O
5	554	555	|B-IUPAC
-	555	556	|I-IUPAC
fluoro	556	562	|I-IUPAC
-	562	563	|I-IUPAC
4	563	564	|I-IUPAC
-	564	565	|I-IUPAC
(	565	566	|I-IUPAC
methylthio	566	576	|I-IUPAC
)	576	577	|I-IUPAC
-	577	578	|I-IUPAC
2	578	579	|I-IUPAC
-	579	580	|I-IUPAC
[	580	581	|I-IUPAC
(	581	582	|I-IUPAC
trimethylsilyl	582	596	|I-IUPAC
)	596	597	|I-IUPAC
oxy	597	600	|I-IUPAC
]	600	601	|I-IUPAC
pyrimidine	601	611	|I-IUPAC
with	612	616	|O
2	617	618	|B-IUPAC
-	618	619	|I-IUPAC
acetoxyethyl	619	631	|I-IUPAC
acetoxymethyl	632	645	|I-IUPAC
ether	646	651	|I-IUPAC
and	652	655	|O
SnCl4	656	661	|O
,	661	662	|O
followed	663	671	|O
by	672	674	|O
ammonolysis	675	686	|O
,	686	687	|O
yielded	688	695	|O
5	696	697	|B-IUPAC
-	697	698	|I-IUPAC
fluoro	698	704	|I-IUPAC
-	704	705	|I-IUPAC
1	705	706	|I-IUPAC
-	706	707	|I-IUPAC
[	707	708	|I-IUPAC
(	708	709	|I-IUPAC
2	709	710	|I-IUPAC
-	710	711	|I-IUPAC
hydroxyethoxy	711	724	|I-IUPAC
)	724	725	|I-IUPAC
methyl	725	731	|I-IUPAC
]	731	732	|I-IUPAC
cytosine	732	740	|I-IUPAC
(	741	742	|O
12	742	744	|O
)	744	745	|O
.	745	746	|O
Deamination	747	758	|O
of	759	761	|O
12	762	764	|O
with	765	769	|O
nitrous	770	777	|O
acid	778	782	|O
produced	783	791	|O
3	792	793	|O
,	793	794	|O
thereby	795	802	|O
confirming	803	813	|O
that	814	818	|O
alkylation	819	829	|O
of	830	832	|O
5	833	834	|B-IUPAC
-	834	835	|I-IUPAC
fluoro	835	841	|I-IUPAC
-	841	842	|I-IUPAC
2,4	842	845	|I-IUPAC
-	845	846	|I-IUPAC
bis	846	849	|I-IUPAC
[	849	850	|I-IUPAC
(	850	851	|I-IUPAC
trimethylsilyl	851	865	|I-IUPAC
)	865	866	|I-IUPAC
oxy	866	869	|I-IUPAC
]	869	870	|I-IUPAC
pyrimidine	870	880	|I-IUPAC
had	881	884	|O
occurred	885	893	|O
at	894	896	|O
N1	897	899	|O
.	899	900	|O
The	901	904	|O
ID50	905	909	|O
of	910	912	|O
3	913	914	|O
against	915	922	|O
L1210	923	928	|O
mouse	929	934	|O
leukemia	935	943	|O
cells	944	949	|O
in	950	952	|O
culture	953	960	|O
was	961	964	|O
1.7	965	968	|O
x	969	970	|O
10	971	973	|O
(	973	974	|O
-	974	975	|O
5	975	976	|O
)	976	977	|O
M	978	979	|O
,	979	980	|O
as	981	983	|O
compared	984	992	|O
with	993	997	|O
1	998	999	|O
x	1000	1001	|O
10	1002	1004	|O
(	1004	1005	|O
-	1005	1006	|O
6	1006	1007	|O
)	1007	1008	|O
M	1009	1010	|O
for	1011	1014	|O
FU	1015	1017	|O
.	1017	1018	|O
The	1019	1022	|O
5	1023	1024	|B-IUPAC
-	1024	1025	|I-IUPAC
fluorocytosine	1025	1039	|I-IUPAC
analogue	1040	1048	|B-MODIFIER
12	1049	1051	|O
was	1052	1055	|O
inactive	1056	1064	|O
at	1065	1067	|O
up	1068	1070	|O
to	1071	1073	|O
1	1074	1075	|O
x	1076	1077	|O
10	1078	1080	|O
(	1080	1081	|O
-	1081	1082	|O
4	1082	1083	|O
)	1083	1084	|O
M	1085	1086	|O
,	1086	1087	|O
and	1088	1091	|O
the	1092	1095	|O
other	1096	1101	|O
halogenated	1102	1113	|O
derivatives	1114	1125	|O
10	1126	1128	|O
and	1129	1132	|O
11	1133	1135	|O
had	1136	1139	|O
no	1140	1142	|O
effect	1143	1149	|O
even	1150	1154	|O
at	1155	1157	|O
1	1158	1159	|O
x	1160	1161	|O
10	1162	1164	|O
(	1164	1165	|O
-	1165	1166	|O
3	1166	1167	|O
)	1167	1168	|O
M	1169	1170	|O
.	1170	1171	|O
When	1172	1176	|O
3	1177	1178	|O
was	1179	1182	|O
given	1183	1188	|O
ip	1189	1191	|O
in	1192	1194	|O
water	1195	1200	|O
to	1201	1203	|O
P388	1204	1208	|O
leukemic	1209	1217	|O
mice	1218	1222	|O
at	1223	1225	|O
400	1226	1229	|O
mg	1230	1232	|O
/	1232	1233	|O
kg	1233	1235	|O
(	1236	1237	|O
b	1237	1238	|O
.	1238	1239	|O
i	1239	1240	|O
.	1240	1241	|O
d	1241	1242	|O
.	1242	1243	|O
x	1244	1245	|O
4	1246	1247	|O
)	1247	1248	|O
or	1249	1251	|O
240	1252	1255	|O
mg	1256	1258	|O
/	1258	1259	|O
kg	1259	1261	|O
(	1262	1263	|O
q	1263	1264	|O
.	1264	1265	|O
d	1265	1266	|O
.	1266	1267	|O
1-9	1268	1271	|O
)	1271	1272	|O
,	1272	1273	|O
a	1274	1275	|O
75%	1276	1279	|O
increase	1280	1288	|O
in	1289	1291	|O
survival	1292	1300	|O
was	1301	1304	|O
observed	1305	1313	|O
relative	1314	1322	|O
to	1323	1325	|O
untreated	1326	1335	|O
controls	1336	1344	|O
,	1344	1345	|O
and	1346	1349	|O
there	1350	1355	|O
was	1356	1359	|O
no	1360	1362	|O
evidence	1363	1371	|O
of	1372	1374	|O
any	1375	1378	|O
host	1379	1383	|O
toxicity	1384	1392	|O
.	1392	1393	|O

### abstracts1574.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
21	12	14	|O
1,3	15	18	|B-IUPAC
-	18	19	|I-IUPAC
dialkylpyrazolo	19	34	|I-IUPAC
[	34	35	|I-IUPAC
4,3	35	38	|I-IUPAC
-	38	39	|I-IUPAC
d	39	40	|I-IUPAC
]	40	41	|I-IUPAC
pyrimidin	41	50	|I-IUPAC
-	50	51	|I-IUPAC
7	51	52	|I-IUPAC
-	52	53	|I-IUPAC
ones	53	57	|I-IUPAC
substituted	58	69	|O
in	70	72	|O
the	73	76	|O
5	77	78	|O
-	78	79	|O
position	79	87	|O
with	88	92	|O
various	93	100	|O
phenyl	101	107	|B-IUPAC
substituents	108	120	|B-MODIFIER
has	121	124	|O
been	125	129	|O
synthesized	130	141	|O
and	142	145	|O
found	146	151	|O
to	152	154	|O
have	155	159	|O
affinity	160	168	|O
for	169	172	|O
the	173	176	|O
adenosine	177	186	|O
A1	187	189	|O
receptor	190	198	|O
.	198	199	|O
The	200	203	|O
potency	204	211	|O
pattern	212	219	|O
due	220	223	|O
to	224	226	|O
substituents	227	239	|O
of	240	242	|O
the	243	246	|O
phenyl	247	253	|B-IUPAC
ring	254	258	|B-MODIFIER
was	259	262	|O
found	263	268	|O
to	269	271	|O
parallel	272	280	|O
that	281	285	|O
found	286	291	|O
in	292	294	|O
a	295	296	|O
previously	297	307	|O
reported	308	316	|O
1,3	317	320	|B-IUPAC
-	320	321	|I-IUPAC
dialkyl	321	328	|I-IUPAC
-	328	329	|I-IUPAC
8	329	330	|I-IUPAC
-	330	331	|I-IUPAC
phenylxanthine	331	345	|I-IUPAC
series	346	352	|B-MODIFIER
.	352	353	|O
A	354	355	|O
quantitative	356	368	|O
structure	369	378	|O
-	378	379	|O
activity	379	387	|O
relationship	388	400	|O
was	401	404	|O
developed	405	414	|O
between	415	422	|O
these	423	428	|O
two	429	432	|O
series	433	439	|O
that	440	444	|O
correctly	445	454	|O
predicted	455	464	|O
the	465	468	|O
potencies	469	478	|O
of	479	481	|O
six	482	485	|O
additional	486	496	|O
5	497	498	|B-MODIFIER
-	498	499	|I-MODIFIER
substituted	499	510	|I-MODIFIER
pyrazolo	511	519	|B-IUPAC
[	519	520	|I-IUPAC
4,3	520	523	|I-IUPAC
-	523	524	|I-IUPAC
d	524	525	|I-IUPAC
]	525	526	|I-IUPAC
pyrimidines	526	537	|I-IUPAC
that	538	542	|O
were	543	547	|O
synthesized	548	559	|O
during	560	566	|O
the	567	570	|O
course	571	577	|O
of	578	580	|O
the	581	584	|O
analysis	585	593	|O
.	593	594	|O
With	595	599	|O
use	600	603	|O
of	604	606	|O
the	607	610	|O
correlation	611	622	|O
as	623	625	|O
a	626	627	|O
guide	628	633	|O
,	633	634	|O
one	635	638	|O
additional	639	649	|O
5	650	651	|B-IUPAC
-	651	652	|I-IUPAC
phenylpyrazolo	652	666	|I-IUPAC
[	666	667	|I-IUPAC
4,3	667	670	|I-IUPAC
-	670	671	|I-IUPAC
d	671	672	|I-IUPAC
]	672	673	|I-IUPAC
pyrimidine	673	683	|I-IUPAC
containing	684	694	|O
a	695	696	|O
4	697	698	|B-IUPAC
-	698	699	|I-IUPAC
[	699	700	|I-IUPAC
[	700	701	|I-IUPAC
(	701	702	|I-IUPAC
dimethylamino	702	715	|I-IUPAC
)	715	716	|I-IUPAC
ethyl	716	721	|I-IUPAC
]	721	722	|I-IUPAC
amino	722	727	|I-IUPAC
]	727	728	|I-IUPAC
sulfonyl	728	736	|I-IUPAC
substituent	737	748	|B-MODIFIER
to	749	751	|O
improve	752	759	|O
aqueous	760	767	|O
solubility	768	778	|O
was	779	782	|O
prepared	783	791	|O
.	791	792	|O
On	793	795	|O
the	796	799	|O
basis	800	805	|O
of	806	808	|O
the	809	812	|O
high	813	817	|O
correlation	818	829	|O
between	830	837	|O
adenosine	838	847	|O
binding	848	855	|O
affinities	856	866	|O
of	867	869	|O
analogously	870	881	|O
substituted	882	893	|O
xanthines	894	903	|O
and	904	907	|O
pyrazolo	908	916	|B-IUPAC
-	916	917	|I-IUPAC
[	917	918	|I-IUPAC
4,3	918	921	|I-IUPAC
-	921	922	|I-IUPAC
d	922	923	|I-IUPAC
]	923	924	|I-IUPAC
pyrimidines	924	935	|I-IUPAC
and	936	939	|O
the	940	943	|O
close	944	949	|O
superposition	950	963	|O
of	964	966	|O
the	967	970	|O
heterocyclic	971	983	|O
rings	984	989	|O
and	990	993	|O
substituents	994	1006	|O
that	1007	1011	|O
is	1012	1014	|O
apparent	1015	1023	|O
from	1024	1028	|O
molecular	1029	1038	|O
models	1039	1045	|O
of	1046	1048	|O
these	1049	1054	|O
two	1055	1058	|O
series	1059	1065	|O
,	1065	1066	|O
it	1067	1069	|O
is	1070	1072	|O
hypothesized	1073	1085	|O
they	1086	1090	|O
fit	1091	1094	|O
the	1095	1098	|O
receptor	1099	1107	|O
in	1108	1110	|O
an	1111	1113	|O
analogous	1114	1123	|O
fashion	1124	1131	|O
.	1131	1132	|O

### abstracts2041.txt
The	0	3	|O
previously	4	14	|O
reported	15	23	|O
diphenyl	24	32	|B-IUPAC
1	33	34	|I-IUPAC
-	34	35	|I-IUPAC
(	35	36	|I-IUPAC
S	36	37	|I-IUPAC
)	37	38	|I-IUPAC
-	38	39	|I-IUPAC
prolylpyrrolidine	39	56	|I-IUPAC
-	56	57	|I-IUPAC
2	57	58	|I-IUPAC
(	58	59	|I-IUPAC
R	59	60	|I-IUPAC
,	60	61	|I-IUPAC
S	62	63	|I-IUPAC
)	63	64	|I-IUPAC
-	64	65	|I-IUPAC
phosphonate	65	76	|I-IUPAC
(	77	78	|O
5	78	79	|O
)	79	80	|O
was	81	84	|O
used	85	89	|O
as	90	92	|O
a	93	94	|O
lead	95	99	|O
compound	100	108	|O
for	109	112	|O
the	113	116	|O
development	117	128	|O
of	129	131	|O
potent	132	138	|O
and	139	142	|O
irreversible	143	155	|O
inhibitors	156	166	|O
of	167	169	|O
dipeptidyl	170	180	|B-IUPAC
peptidase	181	190	|I-IUPAC
IV	191	193	|I-IUPAC
(	194	195	|O
DPP	195	198	|O
IV	199	201	|O
,	201	202	|O
EC	203	205	|O
3.4.14.5	206	214	|O
)	214	215	|O
.	215	216	|O
The	217	220	|O
synthesis	221	230	|O
of	231	233	|O
a	234	235	|O
series	236	242	|O
of	243	245	|O
diaryl	246	252	|B-IUPAC
1	253	254	|I-IUPAC
-	254	255	|I-IUPAC
(	255	256	|I-IUPAC
S	256	257	|I-IUPAC
)	257	258	|I-IUPAC
-	258	259	|I-IUPAC
prolylpyrrolidine	259	276	|I-IUPAC
-	276	277	|I-IUPAC
2	277	278	|I-IUPAC
(	278	279	|I-IUPAC
R	279	280	|I-IUPAC
,	280	281	|I-IUPAC
S	281	282	|I-IUPAC
)	282	283	|I-IUPAC
-	283	284	|I-IUPAC
phosphonates	284	296	|I-IUPAC
with	297	301	|O
different	302	311	|O
substituents	312	324	|O
on	325	327	|O
the	328	331	|O
aryl	332	336	|O
rings	337	342	|O
(	343	344	|O
hydroxyl	344	352	|B-IUPAC
,	352	353	|O
methoxy	354	361	|B-IUPAC
,	361	362	|O
acylamino	363	372	|B-IUPAC
,	372	373	|O
sulfonylamino	374	387	|B-IUPAC
,	387	388	|O
ureyl	389	394	|B-IUPAC
,	394	395	|O
methoxycarbonyl	396	411	|B-IUPAC
,	411	412	|O
and	413	416	|O
alkylaminocarbonyl	417	435	|B-IUPAC
)	435	436	|O
started	437	444	|O
from	445	449	|O
the	450	453	|O
corresponding	454	467	|O
phosphites	468	478	|O
.	478	479	|O
A	480	481	|O
good	482	486	|O
correlation	487	498	|O
was	499	502	|O
found	503	508	|O
between	509	516	|O
the	517	520	|O
electronic	521	531	|O
properties	532	542	|O
of	543	545	|O
the	546	549	|O
substituent	550	561	|O
and	562	565	|O
the	566	569	|O
inhibitory	570	580	|O
activity	581	589	|O
and	590	593	|O
stability	594	603	|O
.	603	604	|O
The	605	608	|O
most	609	613	|O
striking	614	622	|O
divergence	623	633	|O
of	634	636	|O
this	637	641	|O
correlation	642	653	|O
was	654	657	|O
the	658	661	|O
high	662	666	|O
potency	667	674	|O
combined	675	683	|O
with	684	688	|O
a	689	690	|O
high	691	695	|O
stability	696	705	|O
of	706	708	|O
the	709	712	|O
4	713	714	|B-IUPAC
-	714	715	|I-IUPAC
acetylamino	715	726	|I-IUPAC
-	726	727	|O
substituted	727	738	|B-MODIFIER
derivative	739	749	|I-MODIFIER
11e	750	753	|O
.	753	754	|O
This	755	759	|O
compound	760	768	|O
shows	769	774	|O
low	775	778	|O
cytotoxicity	779	791	|O
in	792	794	|O
human	795	800	|O
peripheral	801	811	|O
blood	812	817	|O
mononuclear	818	829	|O
cells	830	835	|O
and	836	839	|O
also	840	844	|O
has	845	848	|O
favorable	849	858	|O
properties	859	869	|O
in	870	872	|O
vivo	873	877	|O
.	877	878	|O
Therefore	879	888	|O
bis	889	892	|B-IUPAC
(	892	893	|I-IUPAC
4	893	894	|I-IUPAC
-	894	895	|I-IUPAC
acetamidophenyl	895	910	|I-IUPAC
)	910	911	|I-IUPAC
1	912	913	|I-IUPAC
-	913	914	|I-IUPAC
(	914	915	|I-IUPAC
S	915	916	|I-IUPAC
)	916	917	|I-IUPAC
-	917	918	|I-IUPAC
prolylpyrrolidine	918	935	|I-IUPAC
-	935	936	|I-IUPAC
2	936	937	|I-IUPAC
(	937	938	|I-IUPAC
R	938	939	|I-IUPAC
,	939	940	|I-IUPAC
S	940	941	|I-IUPAC
)	941	942	|I-IUPAC
-	942	943	|I-IUPAC
phosphonate	943	954	|I-IUPAC
(	955	956	|O
11e	956	959	|O
)	959	960	|O
is	961	963	|O
considered	964	974	|O
as	975	977	|O
a	978	979	|O
major	980	985	|O
improvement	986	997	|O
and	998	1001	|O
will	1002	1006	|O
be	1007	1009	|O
a	1010	1011	|O
highly	1012	1018	|O
valuable	1019	1027	|O
DPP	1028	1031	|O
IV	1032	1034	|O
inhibitor	1035	1044	|O
for	1045	1048	|O
further	1049	1056	|O
studies	1057	1064	|O
on	1065	1067	|O
the	1068	1071	|O
biological	1072	1082	|O
function	1083	1091	|O
of	1092	1094	|O
the	1095	1098	|O
enzyme	1099	1105	|O
and	1106	1109	|O
the	1110	1113	|O
therapeutic	1114	1125	|O
value	1126	1131	|O
of	1132	1134	|O
its	1135	1138	|O
inhibition	1139	1149	|O
.	1149	1150	|O

### abstracts4159.txt
A	0	1	|O
number	2	8	|O
of	9	11	|O
nitrogen	12	20	|O
analogues	21	30	|O
of	31	33	|O
9	34	35	|B-IUPAC
-	35	36	|I-IUPAC
[	36	37	|I-IUPAC
(	37	38	|I-IUPAC
2	38	39	|I-IUPAC
-	39	40	|I-IUPAC
hydroxyethoxy	40	53	|I-IUPAC
)	53	54	|I-IUPAC
methyl	54	60	|I-IUPAC
]	60	61	|I-IUPAC
guanine	61	68	|I-IUPAC
[	69	70	|O
acylovir	70	78	|O
,	78	79	|O
Zovirax	80	87	|O
]	87	88	|O
containing	89	99	|O
amine	100	105	|O
functions	106	115	|O
in	116	118	|O
the	119	122	|O
side	123	127	|O
chain	128	133	|O
were	134	138	|O
synthesized	139	150	|O
and	151	154	|O
tested	155	161	|O
for	162	165	|O
antiviral	166	175	|O
activity	176	184	|O
.	184	185	|O
These	186	191	|O
purine	192	198	|O
acyclic	199	206	|O
nucleosides	207	218	|O
were	219	223	|O
prepared	224	232	|O
by	233	235	|O
reaction	236	244	|O
of	245	247	|O
tris	248	252	|B-PARTIUPAC
(	252	253	|I-PARTIUPAC
trimethylsilyl	253	267	|I-PARTIUPAC
)	267	268	|I-PARTIUPAC
guanine	268	275	|I-PARTIUPAC
or	276	278	|O
2,6	279	282	|B-IUPAC
-	282	283	|I-IUPAC
diaminopurine	283	296	|I-IUPAC
sodium	297	303	|I-IUPAC
salt	304	308	|I-IUPAC
with	309	313	|O
the	314	317	|O
chloromethyl	318	330	|O
ethers	331	337	|O
prepared	338	346	|O
from	347	351	|O
N	352	353	|B-IUPAC
-	353	354	|I-IUPAC
(	354	355	|I-IUPAC
2	355	356	|I-IUPAC
-	356	357	|I-IUPAC
hydroxyethyl	357	369	|I-IUPAC
)	369	370	|I-IUPAC
phthalimide	370	381	|I-IUPAC
,	381	382	|O
N	383	384	|B-IUPAC
-	384	385	|I-IUPAC
[	385	386	|I-IUPAC
2	386	387	|I-IUPAC
-	387	388	|I-IUPAC
(	388	389	|I-IUPAC
2	389	390	|I-IUPAC
-	390	391	|I-IUPAC
hydroxyethoxy	391	404	|I-IUPAC
)	404	405	|I-IUPAC
ethyl	405	410	|I-IUPAC
]	410	411	|I-IUPAC
phthalimide	411	422	|I-IUPAC
,	422	423	|O
or	424	426	|O
N	427	428	|B-IUPAC
-	428	429	|I-IUPAC
(	429	430	|I-IUPAC
2	430	431	|I-IUPAC
-	431	432	|I-IUPAC
hydroxyethyl	432	444	|I-IUPAC
)	444	445	|I-IUPAC
oxazolidin	445	455	|I-IUPAC
-	455	456	|I-IUPAC
2	456	457	|I-IUPAC
-	457	458	|I-IUPAC
one	458	461	|I-IUPAC
to	462	464	|O
give	465	469	|O
the	470	473	|O
N	474	475	|O
-	475	476	|O
blocked	476	483	|O
intermediates	484	497	|O
5-8	498	501	|O
.	501	502	|O
Deprotection	503	515	|O
with	516	520	|O
hydrazine	521	530	|O
or	531	533	|O
by	534	536	|O
alkaline	537	545	|O
hydrolysis	546	556	|O
gave	557	561	|O
9	562	563	|B-IUPAC
-	563	564	|I-IUPAC
[	564	565	|I-IUPAC
(	565	566	|I-IUPAC
2	566	567	|I-IUPAC
-	567	568	|I-IUPAC
aminoethoxy	568	579	|I-IUPAC
)	579	580	|I-IUPAC
methyl	580	586	|I-IUPAC
]	586	587	|I-IUPAC
guanine	587	594	|I-IUPAC
(	595	596	|O
9	596	597	|O
)	597	598	|O
,	598	599	|O
9	600	601	|B-IUPAC
-	601	602	|I-IUPAC
[	602	603	|I-IUPAC
(	603	604	|I-IUPAC
2	604	605	|I-IUPAC
-	605	606	|I-IUPAC
aminoethoxy	606	617	|I-IUPAC
)	617	618	|I-IUPAC
methyl	618	624	|I-IUPAC
]	624	625	|I-IUPAC
-	625	626	|I-IUPAC
2,6	626	629	|I-IUPAC
-	629	630	|I-IUPAC
diaminopurine	630	643	|I-IUPAC
(	644	645	|O
10	645	647	|O
)	647	648	|O
,	648	649	|O
9	650	651	|B-IUPAC
-	651	652	|I-IUPAC
[	652	653	|I-IUPAC
2	653	654	|I-IUPAC
(	654	655	|I-IUPAC
2	655	656	|I-IUPAC
-	656	657	|I-IUPAC
aminoethoxy	657	668	|I-IUPAC
]	668	669	|I-IUPAC
ethoxymethyl	669	681	|I-IUPAC
]	681	682	|I-IUPAC
guanine	682	689	|I-IUPAC
(	690	691	|O
11	691	693	|O
)	693	694	|O
,	694	695	|O
and	696	699	|O
9	700	701	|B-IUPAC
-	701	702	|I-IUPAC
[	702	703	|I-IUPAC
[	703	704	|I-IUPAC
2	704	705	|I-IUPAC
-	705	706	|I-IUPAC
[	706	707	|I-IUPAC
(	707	708	|I-IUPAC
2	708	709	|I-IUPAC
-	709	710	|I-IUPAC
hydroxyethyl	710	722	|I-IUPAC
)	722	723	|I-IUPAC
amino	723	728	|I-IUPAC
]	728	729	|I-IUPAC
ethoxy	729	735	|I-IUPAC
]	735	736	|I-IUPAC
methyl	736	742	|I-IUPAC
]	742	743	|I-IUPAC
guanine	743	750	|I-IUPAC
(	751	752	|O
12	752	754	|O
)	754	755	|O
.	755	756	|O
When	757	761	|O
tested	762	768	|O
against	769	776	|O
herpes	777	783	|O
simplex	784	791	|O
virus	792	797	|O
type	798	802	|O
1	803	804	|O
,	804	805	|O
only	806	810	|O
9	811	812	|O
was	813	816	|O
active	817	823	|O
with	824	828	|O
an	829	831	|O
IC50	832	836	|O
=	837	838	|O
8	839	840	|O
microM	841	847	|O
.	847	848	|O
Little	849	855	|O
or	856	858	|O
no	859	861	|O
activity	862	870	|O
was	871	874	|O
observed	875	883	|O
against	884	891	|O
a	892	893	|O
range	894	899	|O
of	900	902	|O
other	903	908	|O
DNA	909	912	|O
and	913	916	|O
RNA	917	920	|O
viruses	921	928	|O
.	928	929	|O

### abstracts4813.txt
Seven	0	5	|O
1,2	6	9	|B-IUPAC
-	9	10	|I-IUPAC
dihydroxy	10	19	|I-IUPAC
-	19	20	|I-IUPAC
1,2	20	23	|I-IUPAC
-	23	24	|I-IUPAC
dihydroacronycine	24	41	|I-IUPAC
and	42	45	|O
1,2	46	49	|B-IUPAC
-	49	50	|I-IUPAC
dihydroxy	50	59	|I-IUPAC
-	59	60	|I-IUPAC
1,2	60	63	|I-IUPAC
-	63	64	|I-IUPAC
dihydro	64	71	|I-IUPAC
-	71	72	|I-IUPAC
6	72	73	|I-IUPAC
-	73	74	|I-IUPAC
demethoxyacronycine	74	93	|I-IUPAC
esters	94	100	|I-IUPAC
and	101	104	|O
diesters	105	113	|O
were	114	118	|O
synthesized	119	130	|O
via	131	134	|O
osmic	135	140	|O
oxidation	141	150	|O
of	151	153	|O
acronycine	154	164	|O
or	165	167	|O
6	168	169	|B-IUPAC
-	169	170	|I-IUPAC
demethoxyacronycine	170	189	|I-IUPAC
followed	190	198	|O
by	199	201	|O
acylation	202	211	|O
.	211	212	|O
The	213	216	|O
6	217	218	|B-IUPAC
-	218	219	|I-IUPAC
demethoxyacronycine	219	238	|I-IUPAC
derivatives	239	250	|B-MODIFIER
were	251	255	|O
found	256	261	|O
to	262	264	|O
be	265	267	|O
inactive	268	276	|O
,	276	277	|O
whereas	278	285	|O
in	286	288	|O
contrast	289	297	|O
,	297	298	|O
all	299	302	|O
of	303	305	|O
the	306	309	|O
acronycine	310	320	|O
derivatives	321	332	|O
were	333	337	|O
more	338	342	|O
potent	343	349	|O
than	350	354	|O
acronycine	355	365	|O
itself	366	372	|O
when	373	377	|O
tested	378	384	|O
against	385	392	|O
L1210	393	398	|O
cells	399	404	|O
in	405	407	|O
vitro	408	413	|O
.	413	414	|O
Four	415	419	|O
selected	420	428	|O
acronycine	429	439	|O
derivatives	440	451	|O
(	452	453	|O
17,19	453	458	|O
,	458	459	|O
21	460	462	|O
,	462	463	|O
and	464	467	|O
22	468	470	|O
)	470	471	|O
were	472	476	|O
evaluated	477	486	|O
in	487	489	|O
vivo	490	494	|O
against	495	502	|O
murine	503	509	|O
P388	510	514	|O
leukemia	515	523	|O
and	524	527	|O
colon	528	533	|O
38	534	536	|O
adenocarcinoma	537	551	|O
implanted	552	561	|O
in	562	564	|O
mice	565	569	|O
.	569	570	|O
All	571	574	|O
compounds	575	584	|O
were	585	589	|O
markedly	590	598	|O
active	599	605	|O
against	606	613	|O
P388	614	618	|O
at	619	621	|O
doses	622	627	|O
4-16	628	632	|O
-	632	633	|O
fold	633	637	|O
lower	638	643	|O
than	644	648	|O
acronycine	649	659	|O
itself	660	666	|O
.	666	667	|O
Against	668	675	|O
the	676	679	|O
colon	680	685	|O
38	686	688	|O
adenocarcinoma	689	703	|O
,	703	704	|O
the	705	708	|O
three	709	714	|O
compounds	715	724	|O
17	725	727	|O
,	727	728	|O
21	729	731	|O
,	731	732	|O
and	733	736	|O
22	737	739	|O
were	740	744	|O
highly	745	751	|O
efficient	752	761	|O
.	761	762	|O
1,2	763	766	|B-IUPAC
-	766	767	|I-IUPAC
Diacetoxy	767	776	|I-IUPAC
-	776	777	|I-IUPAC
1,2	777	780	|I-IUPAC
-	780	781	|I-IUPAC
dihydroacronycine	781	798	|I-IUPAC
(	799	800	|O
17	800	802	|O
)	802	803	|O
was	804	807	|O
the	808	811	|O
most	812	816	|O
active	817	823	|O
,	823	824	|O
all	825	828	|O
the	829	832	|O
treated	833	840	|O
mice	841	845	|O
being	846	851	|O
tumor	852	857	|O
-	857	858	|O
free	858	862	|O
on	863	865	|O
day	866	869	|O
23	870	872	|O
.	872	873	|O

### abstracts432.txt
3,4	0	3	|O
-	3	4	|O
Dihydro	4	11	|O
-	11	12	|O
2	12	13	|O
(	13	14	|O
1H	14	16	|O
)	16	17	|O
-	17	18	|O
quinolones	18	28	|O
,	28	29	|O
evolved	30	37	|O
from	38	42	|O
2	43	44	|B-IUPAC
-	44	45	|I-IUPAC
carboxy	45	52	|I-IUPAC
-	52	53	|I-IUPAC
1,2,3,4	53	60	|I-IUPAC
,	60	61	|I-IUPAC
-	61	62	|I-IUPAC
tetrahydroquinolines	63	83	|I-IUPAC
and	84	87	|O
3	88	89	|B-IUPAC
-	89	90	|I-IUPAC
carboxy	90	97	|I-IUPAC
-	97	98	|I-IUPAC
4	98	99	|I-IUPAC
-	99	100	|I-IUPAC
hydroxy	100	107	|I-IUPAC
-	107	108	|I-IUPAC
2	108	109	|I-IUPAC
(	109	110	|I-IUPAC
1H	110	112	|I-IUPAC
)	112	113	|I-IUPAC
-	113	114	|I-IUPAC
quinolones	114	124	|I-IUPAC
,	124	125	|O
have	126	130	|O
been	131	135	|O
synthesized	136	147	|O
and	148	151	|O
evaluated	152	161	|O
in	162	164	|O
vitro	165	170	|O
for	171	174	|O
antagonist	175	185	|O
activity	186	194	|O
at	195	197	|O
the	198	201	|O
glycine	202	209	|O
site	210	214	|O
on	215	217	|O
the	218	221	|O
NMDA	222	226	|O
receptor	227	235	|O
and	236	239	|O
for	240	243	|O
AMPA	244	248	|O
[	249	250	|O
(	250	251	|B-IUPAC
RS	251	253	|I-IUPAC
)	253	254	|I-IUPAC
-	254	255	|I-IUPAC
alpha	255	260	|I-IUPAC
-	260	261	|I-IUPAC
amino	261	266	|I-IUPAC
-	266	267	|I-IUPAC
3	267	268	|I-IUPAC
-	268	269	|I-IUPAC
hydroxy	270	277	|I-IUPAC
-	277	278	|I-IUPAC
5	278	279	|I-IUPAC
-	279	280	|I-IUPAC
methyl	280	286	|I-IUPAC
-	286	287	|I-IUPAC
4	287	288	|I-IUPAC
-	288	289	|I-IUPAC
isoxazolepropionic	289	307	|I-IUPAC
acid	308	312	|I-IUPAC
]	312	313	|O
antagonist	314	324	|O
activity	325	333	|O
.	333	334	|O
Generally	335	344	|O
poor	345	349	|O
potency	350	357	|O
at	358	360	|O
the	361	364	|O
glycine	365	372	|O
site	373	377	|O
is	378	380	|O
observed	381	389	|O
when	390	394	|O
a	395	396	|O
variety	397	404	|O
of	405	407	|O
electron	408	416	|O
-	416	417	|O
withdrawing	417	428	|O
substituents	429	441	|O
are	442	445	|O
attached	446	454	|O
to	455	457	|O
the	458	461	|O
3	462	463	|O
-	463	464	|O
position	464	472	|O
of	473	475	|O
3,4	476	479	|B-IUPAC
-	479	480	|I-IUPAC
dihydro	480	487	|I-IUPAC
-	487	488	|I-IUPAC
2	488	489	|I-IUPAC
(	489	490	|I-IUPAC
1H	490	492	|I-IUPAC
)	492	493	|I-IUPAC
-	493	494	|I-IUPAC
quinolones	494	504	|I-IUPAC
.	504	505	|O
The	506	509	|O
analogues	510	519	|O
5-9	520	523	|O
(	524	525	|O
IC50	525	529	|O
values	530	536	|O
&	537	538	|O
gt	538	540	|O
;	540	541	|O
100	542	545	|O
microM	546	552	|O
,	552	553	|O
Table	554	559	|O
I	560	561	|O
)	561	562	|O
exist	563	568	|O
largely	569	576	|O
in	577	579	|O
the	580	583	|O
3,4	584	587	|O
-	587	588	|O
dipseudoaxial	588	601	|O
conformation	602	614	|O
(	615	616	|O
as	616	618	|O
evidenced	619	628	|O
by	629	631	|O
1H	632	634	|O
NMR	635	638	|O
spectra	639	646	|O
)	646	647	|O
,	647	648	|O
whereas	649	656	|O
the	657	660	|O
3	661	662	|O
-	662	663	|O
cyano	663	668	|O
derivative	669	679	|O
(	680	681	|O
10	681	683	|O
,	683	684	|O
IC50	685	689	|O
=	690	691	|O
12.0	692	696	|O
microM	697	703	|O
)	703	704	|O
has	705	708	|O
a	709	710	|O
relatively	711	721	|O
high	722	726	|O
population	727	737	|O
of	738	740	|O
the	741	744	|O
3	745	746	|O
-	746	747	|O
pseudoequatorial	747	763	|O
conformer	764	773	|O
.	773	774	|O
The	775	778	|O
3	779	780	|O
-	780	781	|O
nitro	781	786	|O
analogue	787	795	|O
(	796	797	|O
4	797	798	|O
,	798	799	|O
IC50	800	804	|O
=	805	806	|O
1.32	807	811	|O
microM	812	818	|O
)	818	819	|O
has	820	823	|O
a	824	825	|O
pKa	826	829	|O
approximately	830	843	|O
5	844	845	|O
and	846	849	|O
thus	850	854	|O
exists	855	861	|O
at	862	864	|O
physiological	865	878	|O
pH	879	881	|O
as	882	884	|O
an	885	887	|O
anion	888	893	|O
with	894	898	|O
the	899	902	|O
nitro	903	908	|O
group	909	914	|O
planar	915	921	|O
to	922	924	|O
the	925	928	|O
quinolone	929	938	|O
ring	939	943	|O
.	943	944	|O
The	945	948	|O
general	949	956	|O
requirement	957	968	|O
of	969	971	|O
acidity	972	979	|O
for	980	983	|O
high	984	988	|O
affinity	989	997	|O
binding	998	1005	|O
at	1006	1008	|O
the	1009	1012	|O
glycine	1013	1020	|O
/	1020	1021	|O
NMDA	1021	1025	|O
site	1026	1030	|O
is	1031	1033	|O
supported	1034	1043	|O
with	1044	1048	|O
the	1049	1052	|O
good	1053	1057	|O
activity	1058	1066	|O
of	1067	1069	|O
the	1070	1073	|O
other	1074	1079	|O
3	1080	1081	|B-PARTIUPAC
-	1081	1082	|I-PARTIUPAC
nitro	1082	1087	|I-PARTIUPAC
derivatives	1088	1099	|B-MODIFIER
(	1100	1101	|O
13-21	1101	1106	|O
)	1106	1107	|O
,	1107	1108	|O
all	1109	1112	|O
of	1113	1115	|O
which	1116	1121	|O
are	1122	1125	|O
deprotonated	1126	1138	|O
at	1139	1141	|O
physiological	1142	1155	|O
pH	1156	1158	|O
.	1158	1159	|O
The	1160	1163	|O
3	1164	1165	|B-IUPAC
-	1165	1166	|I-IUPAC
nitro	1166	1171	|I-IUPAC
-	1171	1172	|I-IUPAC
3,4	1172	1175	|I-IUPAC
-	1175	1176	|I-IUPAC
dihydro	1176	1183	|I-IUPAC
-	1183	1184	|I-IUPAC
2	1184	1185	|I-IUPAC
(	1185	1186	|I-IUPAC
1H	1186	1188	|I-IUPAC
)	1188	1189	|I-IUPAC
-	1189	1190	|I-IUPAC
quinolones	1190	1200	|I-IUPAC
and	1201	1204	|O
2	1205	1206	|B-IUPAC
-	1206	1207	|I-IUPAC
carboxy	1207	1214	|I-IUPAC
-	1214	1215	|I-IUPAC
1,2,3,4	1215	1222	|I-IUPAC
-	1222	1223	|I-IUPAC
tetrahydroquinolines	1223	1243	|I-IUPAC
show	1244	1248	|O
quite	1249	1254	|O
different	1255	1264	|O
structure	1265	1274	|O
-	1274	1275	|O
activity	1275	1283	|O
relationships	1284	1297	|O
at	1298	1300	|O
the	1301	1304	|O
4	1305	1306	|O
-	1306	1307	|O
position	1307	1315	|O
.	1315	1316	|O
The	1317	1320	|O
unselective	1321	1332	|O
excitatory	1333	1343	|O
amino	1344	1349	|O
acid	1350	1354	|O
activity	1355	1363	|O
of	1364	1366	|O
21	1367	1369	|O
is	1370	1372	|O
comparable	1373	1383	|O
with	1384	1388	|O
6,7	1389	1392	|B-IUPAC
-	1392	1393	|I-IUPAC
dichloro	1393	1401	|I-IUPAC
-	1401	1402	|I-IUPAC
quinoxaline	1402	1413	|I-IUPAC
-	1413	1414	|I-IUPAC
2,3	1414	1417	|I-IUPAC
-	1417	1418	|I-IUPAC
dione	1418	1423	|I-IUPAC
and	1424	1427	|O
6,7	1428	1431	|B-IUPAC
-	1431	1432	|I-IUPAC
dichloroquinoxalic	1432	1450	|I-IUPAC
acid	1451	1455	|I-IUPAC
and	1456	1459	|O
this	1460	1464	|O
suggests	1465	1473	|O
similarities	1474	1486	|O
in	1487	1489	|O
their	1490	1495	|O
modes	1496	1501	|O
of	1502	1504	|O
binding	1505	1512	|O
to	1513	1515	|O
excitatory	1516	1526	|O
amino	1527	1532	|O
acid	1533	1537	|O
receptors	1538	1547	|O
.	1547	1548	|O
The	1549	1552	|O
broad	1553	1558	|O
spectrum	1559	1567	|O
excitatory	1568	1578	|O
amino	1579	1584	|O
acid	1585	1589	|O
antagonist	1590	1600	|O
activity	1601	1609	|O
of	1610	1612	|O
the	1613	1616	|O
4	1617	1618	|O
-	1618	1619	|O
unsubstituted	1619	1632	|O
analogue	1633	1641	|O
21	1642	1644	|O
(	1645	1646	|O
KbNMDA	1646	1652	|O
=	1653	1654	|O
6.7	1655	1658	|O
microM	1659	1665	|O
,	1665	1666	|O
KbAMPA	1667	1673	|O
=	1674	1675	|O
9.2	1676	1679	|O
microM	1680	1686	|O
)	1686	1687	|O
and	1688	1691	|O
the	1692	1695	|O
glycine	1696	1703	|O
/	1703	1704	|O
NMDA	1704	1708	|O
selectivity	1709	1720	|O
of	1721	1723	|O
the	1724	1727	|O
other	1728	1733	|O
3	1734	1735	|B-IUPAC
-	1735	1736	|I-IUPAC
nitro	1736	1741	|I-IUPAC
derivatives	1742	1753	|B-MODIFIER
allows	1754	1760	|O
the	1761	1764	|O
proposal	1765	1773	|O
of	1774	1776	|O
a	1777	1778	|O
model	1779	1784	|O
for	1785	1788	|O
AMPA	1789	1793	|O
receptor	1794	1802	|O
binding	1803	1810	|O
which	1811	1816	|O
differs	1817	1824	|O
from	1825	1829	|O
the	1830	1833	|O
glycine	1834	1841	|O
binding	1842	1849	|O
pharmacophore	1850	1863	|O
in	1864	1866	|O
that	1867	1871	|O
there	1872	1877	|O
is	1878	1880	|O
bulk	1881	1885	|O
intolerance	1886	1897	|O
adjacent	1898	1906	|O
to	1907	1909	|O
the	1910	1913	|O
4	1914	1915	|O
-	1915	1916	|O
position	1916	1924	|O
.	1924	1925	|O
Compound	1926	1934	|O
21	1935	1937	|O
(	1938	1939	|O
L	1939	1940	|O
-	1940	1941	|O
698,544	1941	1948	|O
)	1948	1949	|O
is	1950	1952	|O
active	1953	1959	|O
(	1960	1961	|O
ED50	1961	1965	|O
=	1966	1967	|O
13.2	1968	1972	|O
mg	1973	1975	|O
/	1975	1976	|O
kg	1976	1978	|O
)	1978	1979	|O
in	1980	1982	|O
the	1983	1986	|O
DBA	1987	1990	|O
/	1990	1991	|O
2	1991	1992	|O
mouse	1993	1998	|O
anticonvulsant	1999	2013	|O
model	2014	2019	|O
and	2020	2023	|O
is	2024	2026	|O
the	2027	2030	|O
most	2031	2035	|O
potent	2036	2042	|O
combined	2043	2051	|O
glycine	2052	2059	|O
/	2059	2060	|O
NMDA	2060	2064	|O
-	2064	2065	|O
AMPA	2065	2069	|O
antagonist	2070	2080	|O
yet	2081	2084	|O
reported	2085	2093	|O
,	2093	2094	|O
in	2095	2097	|O
vivo	2098	2102	|O
,	2102	2103	|O
and	2104	2107	|O
may	2108	2111	|O
prove	2112	2117	|O
to	2118	2120	|O
be	2121	2123	|O
a	2124	2125	|O
useful	2126	2132	|O
pharmacological	2133	2148	|O
tool	2149	2153	|O
.	2153	2154	|O

### abstracts543.txt
Antagonists	0	11	|O
at	12	14	|O
the	15	18	|O
1A	19	21	|O
/	21	22	|O
2B	22	24	|O
subtype	25	32	|O
of	33	35	|O
the	36	39	|O
NMDA	40	44	|O
receptor	45	53	|O
(	54	55	|O
NR1A	55	59	|O
/	59	60	|O
2B	60	62	|O
)	62	63	|O
are	64	67	|O
typically	68	77	|O
small	78	83	|O
molecules	84	93	|O
that	94	98	|O
consist	99	106	|O
of	107	109	|O
a	110	111	|O
4	112	113	|B-PARTIUPAC
-	113	114	|I-PARTIUPAC
benzyl	114	120	|I-PARTIUPAC
-	120	121	|I-PARTIUPAC
or	122	124	|O
a	125	126	|O
4	127	128	|B-IUPAC
-	128	129	|I-IUPAC
phenylpiperidine	129	145	|I-IUPAC
with	146	150	|O
an	151	153	|O
omega	154	159	|B-IUPAC
-	159	160	|I-IUPAC
phenylalkyl	160	171	|I-IUPAC
substituent	172	183	|B-MODIFIER
on	184	186	|O
the	187	190	|O
heterocyclic	191	203	|O
nitrogen	204	212	|O
.	212	213	|O
Many	214	218	|O
of	219	221	|O
these	222	227	|O
antagonists	228	239	|O
,	239	240	|O
for	241	244	|O
example	245	252	|O
ifenprodil	253	263	|O
(	264	265	|O
1	265	266	|O
)	266	267	|O
,	267	268	|O
incorporate	269	280	|O
a	281	282	|O
4	283	284	|B-IUPAC
-	284	285	|I-IUPAC
hydroxy	285	292	|I-IUPAC
substituent	293	304	|B-MODIFIER
on	305	307	|O
the	308	311	|O
omega	312	317	|O
-	317	318	|O
phenyl	318	324	|O
group	325	330	|O
.	330	331	|O
In	332	334	|O
this	335	339	|O
study	340	345	|O
,	345	346	|O
the	347	350	|O
position	351	359	|O
of	360	362	|O
this	363	367	|O
4	368	369	|B-IUPAC
-	369	370	|I-IUPAC
hydroxy	370	377	|I-IUPAC
substituent	378	389	|B-MODIFIER
was	390	393	|O
transferred	394	405	|O
from	406	410	|O
the	411	414	|O
omega	415	420	|O
-	420	421	|O
phenyl	421	427	|O
group	428	433	|O
to	434	436	|O
the	437	440	|O
benzyl	441	447	|O
or	448	450	|O
phenyl	451	457	|O
group	458	463	|O
located	464	471	|O
on	472	474	|O
the	475	478	|O
4	479	480	|O
-	480	481	|O
position	481	489	|O
of	490	492	|O
the	493	496	|O
piperidine	497	507	|O
ring	508	512	|O
.	512	513	|O
Analogues	514	523	|O
incorporating	524	537	|O
pyrrolidine	538	549	|O
in	550	552	|O
lieu	553	557	|O
of	558	560	|O
piperidine	561	571	|O
were	572	576	|O
also	577	581	|O
prepared	582	590	|O
.	590	591	|O
Electrical	592	602	|O
recordings	603	613	|O
using	614	619	|O
cloned	620	626	|O
receptors	627	636	|O
expressed	637	646	|O
in	647	649	|O
Xenopus	650	657	|O
oocytes	658	665	|O
show	666	670	|O
that	671	675	|O
high	676	680	|O
-	680	681	|O
potency	681	688	|O
antagonists	689	700	|O
at	701	703	|O
the	704	707	|O
NR1A	708	712	|O
/	712	713	|O
2B	713	715	|O
subtype	716	723	|O
are	724	727	|O
obtained	728	736	|O
employing	737	746	|O
N	747	748	|B-IUPAC
-	748	749	|I-IUPAC
(	749	750	|I-IUPAC
omega	750	755	|I-IUPAC
-	755	756	|I-IUPAC
phenylalkyl	756	767	|I-IUPAC
)	767	768	|I-IUPAC
-	768	769	|O
substituted	769	780	|B-MODIFIER
4	781	782	|B-IUPAC
-	782	783	|I-IUPAC
(	783	784	|I-IUPAC
4	784	785	|I-IUPAC
-	785	786	|I-IUPAC
hydroxyphenyl	786	799	|I-IUPAC
)	799	800	|I-IUPAC
piperidine	800	810	|I-IUPAC
,	810	811	|O
4	812	813	|B-IUPAC
-	813	814	|I-IUPAC
(	814	815	|I-IUPAC
4	815	816	|I-IUPAC
-	816	817	|I-IUPAC
hydroxybenzyl	817	830	|I-IUPAC
)	830	831	|I-IUPAC
piperidine	831	841	|I-IUPAC
,	841	842	|O
and	843	846	|O
(	847	848	|B-IUPAC
+	848	849	|I-IUPAC
/	849	850	|I-IUPAC
-	850	851	|I-IUPAC
)	851	852	|I-IUPAC
-	852	853	|I-IUPAC
3	853	854	|I-IUPAC
-	854	855	|I-IUPAC
(	855	856	|I-IUPAC
4	856	857	|I-IUPAC
-	857	858	|I-IUPAC
hydroxyphenyl	858	871	|I-IUPAC
)	871	872	|I-IUPAC
pyrrolidine	872	883	|I-IUPAC
as	884	886	|O
exemplified	887	898	|O
by	899	901	|O
21	902	904	|O
(	905	906	|O
IC	906	908	|O
(	908	909	|O
50	909	911	|O
)	911	912	|O
=	913	914	|O
0.022	915	920	|O
microM	921	927	|O
)	927	928	|O
,	928	929	|O
33	930	932	|O
(	933	934	|O
IC	934	936	|O
(	936	937	|O
50	937	939	|O
)	939	940	|O
=	941	942	|O
0.059	943	948	|O
microM	949	955	|O
)	955	956	|O
,	956	957	|O
and	958	961	|O
40	962	964	|O
(	965	966	|O
IC	966	968	|O
(	968	969	|O
50	969	971	|O
)	971	972	|O
=	973	974	|O
0.017	975	980	|O
microM	981	987	|O
)	987	988	|O
,	988	989	|O
respectively	990	1002	|O
.	1002	1003	|O
These	1004	1009	|O
high	1010	1014	|O
-	1014	1015	|O
potency	1015	1022	|O
antagonists	1023	1034	|O
are	1035	1038	|O
&	1039	1040	|O
gt	1040	1042	|O
;	1042	1043	|O
1000	1043	1047	|O
times	1048	1053	|O
more	1054	1058	|O
potent	1059	1065	|O
at	1066	1068	|O
the	1069	1072	|O
NR1A	1073	1077	|O
/	1077	1078	|O
2B	1078	1080	|O
subtype	1081	1088	|O
than	1089	1093	|O
at	1094	1096	|O
either	1097	1103	|O
the	1104	1107	|O
NR1A	1108	1112	|O
/	1112	1113	|O
2A	1113	1115	|O
or	1116	1118	|O
NR1A	1119	1123	|O
/	1123	1124	|O
2C	1124	1126	|O
subtypes	1127	1135	|O
.	1135	1136	|O
The	1137	1140	|O
binding	1141	1148	|O
affinities	1149	1159	|O
of	1160	1162	|O
21	1163	1165	|O
at	1166	1168	|O
alpha	1169	1174	|O
(	1174	1175	|O
1	1175	1176	|O
)	1176	1177	|O
-	1177	1178	|O
adrenergic	1178	1188	|O
receptors	1189	1198	|O
(	1199	1200	|O
[	1200	1201	|B-IUPAC
(	1201	1202	|I-IUPAC
3	1202	1203	|I-IUPAC
)	1203	1204	|I-IUPAC
H	1204	1205	|I-IUPAC
]	1205	1206	|I-IUPAC
prazosin	1206	1214	|I-IUPAC
,	1214	1215	|O
IC	1216	1218	|O
(	1218	1219	|O
50	1219	1221	|O
)	1221	1222	|O
=	1223	1224	|O
0.54	1225	1229	|O
microM	1230	1236	|O
)	1236	1237	|O
and	1238	1241	|O
dopamine	1242	1250	|O
D2	1251	1253	|O
receptors	1254	1263	|O
(	1264	1265	|O
[	1265	1266	|B-IUPAC
(	1266	1267	|I-IUPAC
3	1267	1268	|I-IUPAC
)	1268	1269	|I-IUPAC
H	1269	1270	|I-IUPAC
]	1270	1271	|I-IUPAC
raclopride	1271	1281	|I-IUPAC
,	1281	1282	|O
IC	1283	1285	|O
(	1285	1286	|O
50	1286	1288	|O
)	1288	1289	|O
=	1290	1291	|O
1.2	1292	1295	|O
microM	1296	1302	|O
)	1302	1303	|O
are	1304	1307	|O
reduced	1308	1315	|O
by	1316	1318	|O
incorporating	1319	1332	|O
a	1333	1334	|O
hydroxy	1335	1342	|O
group	1343	1348	|O
onto	1349	1353	|O
the	1354	1357	|O
4	1358	1359	|O
-	1359	1360	|O
position	1360	1368	|O
of	1369	1371	|O
the	1372	1375	|O
piperidine	1376	1386	|O
ring	1387	1391	|O
and	1392	1395	|O
the	1396	1399	|O
beta	1400	1404	|O
-	1404	1405	|O
carbon	1405	1411	|O
of	1412	1414	|O
the	1415	1418	|O
N	1419	1420	|O
-	1420	1421	|O
alkyl	1421	1426	|O
spacer	1427	1433	|O
to	1434	1436	|O
give	1437	1441	|O
(	1442	1443	|O
+	1443	1444	|O
/	1444	1445	|O
-	1445	1446	|O
)	1446	1447	|O
-	1447	1448	|O
27	1448	1450	|O
:	1450	1451	|O
IC	1452	1454	|O
(	1454	1455	|O
50	1455	1457	|O
)	1457	1458	|O
NR1A	1459	1463	|O
/	1463	1464	|O
2B	1464	1466	|O
,	1466	1467	|O
0.026	1468	1473	|O
;	1473	1474	|O
alpha	1475	1480	|O
(	1480	1481	|O
1	1481	1482	|O
)	1482	1483	|O
,	1483	1484	|O
14	1485	1487	|O
;	1487	1488	|O
D2	1489	1491	|O
,	1491	1492	|O
105	1493	1496	|O
microM	1497	1503	|O
.	1503	1504	|O
The	1505	1508	|O
high	1509	1513	|O
-	1513	1514	|O
potency	1514	1521	|O
phenolic	1522	1530	|O
antagonist	1531	1541	|O
21	1542	1544	|O
and	1545	1548	|O
its	1549	1552	|O
low	1553	1556	|O
-	1556	1557	|O
potency	1557	1564	|O
O	1565	1566	|O
-	1566	1567	|O
methylated	1567	1577	|O
analogue	1578	1586	|O
18	1587	1589	|O
are	1590	1593	|O
both	1594	1598	|O
potent	1599	1605	|O
anticonvulsants	1606	1621	|O
in	1622	1624	|O
a	1625	1626	|O
mouse	1627	1632	|O
maximal	1633	1640	|O
electroshock	1641	1653	|O
-	1653	1654	|O
induced	1654	1661	|O
seizure	1662	1669	|O
(	1670	1671	|O
MES	1671	1674	|O
)	1674	1675	|O
study	1676	1681	|O
(	1682	1683	|O
ED	1683	1685	|O
(	1685	1686	|O
50	1686	1688	|O
)	1688	1689	|O
(	1690	1691	|O
iv	1691	1693	|O
)	1693	1694	|O
=	1695	1696	|O
0.23	1697	1701	|O
and	1702	1705	|O
0.56	1706	1710	|O
mg	1711	1713	|O
/	1713	1714	|O
kg	1714	1716	|O
,	1716	1717	|O
respectively	1718	1730	|O
)	1730	1731	|O
.	1731	1732	|O
These	1733	1738	|O
data	1739	1743	|O
indicate	1744	1752	|O
that	1753	1757	|O
such	1758	1762	|O
compounds	1763	1772	|O
penetrate	1773	1782	|O
the	1783	1786	|O
blood	1787	1792	|O
-	1792	1793	|O
brain	1793	1798	|O
barrier	1799	1806	|O
but	1807	1810	|O
their	1811	1816	|O
MES	1817	1820	|O
activity	1821	1829	|O
may	1830	1833	|O
not	1834	1837	|O
be	1838	1840	|O
related	1841	1848	|O
to	1849	1851	|O
NMDA	1852	1856	|O
receptor	1857	1865	|O
antagonism	1866	1876	|O
.	1876	1877	|O

### abstracts3337.txt
8	0	1	|O
-	1	2	|O
Carbamoyl	2	11	|O
-	11	12	|O
3	12	13	|O
-	13	14	|O
methylimidazo	14	27	|O
[	27	28	|O
5,1	28	31	|O
-	31	32	|O
d	32	33	|O
]	33	34	|O
-	34	35	|O
1,2,3,5	35	42	|O
-	42	43	|O
tetrazin	43	51	|O
-	51	52	|O
4	52	53	|O
(	53	54	|O
3H	54	56	|O
)	56	57	|O
-	57	58	|O
one	58	61	|O
(	62	63	|O
temozolomide	63	75	|O
,	75	76	|O
1	77	78	|O
)	78	79	|O
is	80	82	|O
an	83	85	|O
anticancer	86	96	|O
prodrug	97	104	|O
.	104	105	|O
As	106	108	|O
part	109	113	|O
of	114	116	|O
investigations	117	131	|O
to	132	134	|O
probe	135	140	|O
its	141	144	|O
postulated	145	155	|O
mode	156	160	|O
of	161	163	|O
action	164	170	|O
using	171	176	|O
PET	177	180	|O
we	181	183	|O
have	184	188	|O
developed	189	198	|O
two	199	202	|O
rapid	203	208	|O
radiosynthetic	209	223	|O
routes	224	230	|O
for	231	234	|O
the	235	238	|O
preparation	239	250	|O
of	251	253	|O
temozolomide	254	266	|O
labeled	267	274	|O
with	275	279	|O
the	280	283	|O
short	284	289	|O
-	289	290	|O
lived	290	295	|O
positron	296	304	|O
emitter	305	312	|O
,	312	313	|O
carbon	314	320	|O
-	320	321	|O
11	321	323	|O
(	324	325	|O
t	325	326	|O
(	326	327	|O
1/2	327	330	|O
)	330	331	|O
=	332	333	|O
20.4	334	338	|O
min	339	342	|O
)	342	343	|O
.	343	344	|O
Reaction	345	353	|O
of	354	356	|O
5	357	358	|B-IUPAC
-	358	359	|I-IUPAC
diazoimidazole	359	373	|I-IUPAC
-	373	374	|I-IUPAC
4	374	375	|I-IUPAC
-	375	376	|I-IUPAC
carboxamide	376	387	|I-IUPAC
(	388	389	|O
7	389	390	|O
)	390	391	|O
with	392	396	|O
the	397	400	|O
novel	401	406	|O
labeling	407	415	|O
agent	416	421	|O
[	422	423	|B-IUPAC
(	423	424	|I-IUPAC
11	424	426	|I-IUPAC
)	426	427	|I-IUPAC
C	427	428	|I-IUPAC
-	428	429	|I-IUPAC
methyl	429	435	|I-IUPAC
]	435	436	|I-IUPAC
methyl	436	442	|I-IUPAC
isocyanate	443	453	|I-IUPAC
(	454	455	|O
8	455	456	|O
)	456	457	|O
gave	458	462	|O
[	463	464	|B-IUPAC
3	464	465	|I-IUPAC
-	465	466	|I-IUPAC
N	466	467	|I-IUPAC
-	467	468	|I-IUPAC
(	468	469	|I-IUPAC
11	469	471	|I-IUPAC
)	471	472	|I-IUPAC
C	472	473	|I-IUPAC
-	473	474	|I-IUPAC
methyl	474	480	|I-IUPAC
]	480	481	|I-IUPAC
temozolomide	481	493	|I-IUPAC
(	494	495	|O
9	495	496	|O
)	496	497	|O
in	498	500	|O
14-20%	501	507	|O
radiochemical	508	521	|O
yield	522	527	|O
from	528	532	|O
[	533	534	|B-IUPAC
(	534	535	|I-IUPAC
11	535	537	|I-IUPAC
)	537	538	|I-IUPAC
C	538	539	|I-IUPAC
-	539	540	|I-IUPAC
methyl	540	546	|I-IUPAC
]	546	547	|I-IUPAC
methyl	547	553	|I-IUPAC
isocyanate	554	564	|I-IUPAC
(	565	566	|O
8	566	567	|O
)	567	568	|O
(	569	570	|O
decay	570	575	|O
corrected	576	585	|O
)	585	586	|O
.	586	587	|O
The	588	591	|O
position	592	600	|O
of	601	603	|O
radiolabeling	604	617	|O
in	618	620	|O
the	621	624	|O
3	625	626	|B-IUPAC
-	626	627	|I-IUPAC
N	627	628	|I-IUPAC
-	628	629	|I-IUPAC
methyl	629	635	|I-IUPAC
group	636	641	|B-MODIFIER
was	642	645	|O
confirmed	646	655	|O
by	656	658	|O
[	659	660	|O
(	660	661	|O
11/13	661	666	|O
)	666	667	|O
C	667	668	|O
]	668	669	|O
colabeling	669	679	|O
and	680	683	|O
subsequent	684	694	|O
carbon	695	701	|O
-	701	702	|O
13	702	704	|O
NMR	705	708	|O
spectroscopy	709	721	|O
.	721	722	|O
Similarly	723	732	|O
,	732	733	|O
the	734	737	|O
reaction	738	746	|O
of	747	749	|O
5	750	751	|B-IUPAC
-	751	752	|I-IUPAC
diazoimidazole	752	766	|I-IUPAC
-	766	767	|I-IUPAC
4	767	768	|I-IUPAC
-	768	769	|I-IUPAC
carboxamide	769	780	|I-IUPAC
(	781	782	|O
7	782	783	|O
)	783	784	|O
with	785	789	|O
[	790	791	|B-IUPAC
(	791	792	|I-IUPAC
11	792	794	|I-IUPAC
)	794	795	|I-IUPAC
C	795	796	|I-IUPAC
-	796	797	|I-IUPAC
carbonyl	797	805	|I-IUPAC
]	805	806	|I-IUPAC
methyl	806	812	|I-IUPAC
isocyanate	813	823	|I-IUPAC
(	824	825	|O
10	825	827	|O
)	827	828	|O
gave	829	833	|O
[	834	835	|B-IUPAC
4	835	836	|I-IUPAC
-	836	837	|I-IUPAC
(	837	838	|I-IUPAC
11	838	840	|I-IUPAC
)	840	841	|I-IUPAC
C	841	842	|I-IUPAC
-	842	843	|I-IUPAC
carbonyl	843	851	|I-IUPAC
]	851	852	|I-IUPAC
temozolomide	852	864	|I-IUPAC
(	865	866	|O
11	866	868	|O
)	868	869	|O
in	870	872	|O
10-15%	873	879	|O
radiochemical	880	893	|O
yield	894	899	|O
from	900	904	|O
[	905	906	|B-IUPAC
(	906	907	|I-IUPAC
11	907	909	|I-IUPAC
)	909	910	|I-IUPAC
C	910	911	|I-IUPAC
-	911	912	|I-IUPAC
carbonyl	912	920	|I-IUPAC
]	920	921	|I-IUPAC
methyl	921	927	|I-IUPAC
isocyanate	928	938	|I-IUPAC
(	939	940	|O
10	940	942	|O
)	942	943	|O
(	944	945	|O
decay	945	950	|O
corrected	951	960	|O
)	960	961	|O
.	961	962	|O
Apyrogenic	963	973	|O
samples	974	981	|O
of	982	984	|O
[	985	986	|B-IUPAC
3	986	987	|I-IUPAC
-	987	988	|I-IUPAC
N	988	989	|I-IUPAC
-	989	990	|I-IUPAC
(	990	991	|I-IUPAC
11	991	993	|I-IUPAC
)	993	994	|I-IUPAC
C	994	995	|I-IUPAC
-	995	996	|I-IUPAC
methyl	996	1002	|I-IUPAC
]	1002	1003	|I-IUPAC
temozolomide	1003	1015	|I-IUPAC
(	1016	1017	|O
9	1017	1018	|O
)	1018	1019	|O
and	1020	1023	|O
[	1024	1025	|B-IUPAC
4	1025	1026	|I-IUPAC
-	1026	1027	|I-IUPAC
(	1027	1028	|I-IUPAC
11	1028	1030	|I-IUPAC
)	1030	1031	|I-IUPAC
C	1031	1032	|I-IUPAC
-	1032	1033	|I-IUPAC
carbonyl	1033	1041	|I-IUPAC
]	1041	1042	|I-IUPAC
temozolomide	1042	1054	|I-IUPAC
(	1055	1056	|O
11	1056	1058	|O
)	1058	1059	|O
,	1059	1060	|O
with	1061	1065	|O
good	1066	1070	|O
chemical	1071	1079	|O
and	1080	1083	|O
radiochemical	1084	1097	|O
purities	1098	1106	|O
,	1106	1107	|O
have	1108	1112	|O
been	1113	1117	|O
prepared	1118	1126	|O
and	1127	1130	|O
used	1131	1135	|O
in	1136	1138	|O
human	1139	1144	|O
PET	1145	1148	|O
studies	1149	1156	|O
.	1156	1157	|O

### abstracts672.txt
Alkoxymethyl	0	12	|O
,	12	13	|O
acyloxymethyl	14	27	|O
,	27	28	|O
and	29	32	|O
mixed	33	38	|O
alkylalkoxymethyl	39	56	|O
or	57	59	|O
alkylacyloxymethyl	60	78	|O
derivatives	79	90	|O
of	91	93	|O
5	94	95	|B-IUPAC
-	95	96	|I-IUPAC
ethyl	96	101	|I-IUPAC
-	101	102	|I-IUPAC
5	102	103	|I-IUPAC
-	103	104	|I-IUPAC
phenylhydantoin	104	119	|I-IUPAC
exhibit	120	127	|O
anticonvulsant	128	142	|O
activity	143	151	|O
.	151	152	|O
Also	153	157	|O
effective	158	167	|O
are	168	171	|O
bis	172	175	|O
(	175	176	|O
alkoxymethyl	176	188	|O
)	188	189	|O
and	190	193	|O
mixed	194	199	|O
alkylalkoxymethyl	200	217	|O
derivatives	218	229	|O
of	230	232	|O
5,5	233	236	|B-IUPAC
-	236	237	|I-IUPAC
diphenylhydantoin	237	254	|I-IUPAC
.	254	255	|O
Of	256	258	|O
particular	259	269	|O
interest	270	278	|O
are	279	282	|O
1,3	283	286	|B-IUPAC
-	286	287	|I-IUPAC
bis	287	290	|I-IUPAC
(	290	291	|I-IUPAC
methoxymethyl	291	304	|I-IUPAC
)	304	305	|I-IUPAC
-	305	306	|I-IUPAC
5,5	306	309	|I-IUPAC
-	309	310	|I-IUPAC
diphenylhydantoin	310	327	|I-IUPAC
and	328	331	|O
3	332	333	|B-IUPAC
-	333	334	|I-IUPAC
acetoxymethyl	334	347	|I-IUPAC
-	347	348	|I-IUPAC
5	348	349	|I-IUPAC
-	349	350	|I-IUPAC
ethyl	350	355	|I-IUPAC
-	355	356	|I-IUPAC
5	356	357	|I-IUPAC
-	357	358	|I-IUPAC
phenylhydantoin	358	373	|I-IUPAC
,	373	374	|O
which	375	380	|O
show	381	385	|O
good	386	390	|O
activity	391	399	|O
against	400	407	|O
maximal	408	415	|O
electroshock	416	428	|O
seizures	429	437	|O
,	437	438	|O
and	439	442	|O
3	443	444	|B-IUPAC
-	444	445	|I-IUPAC
methoxymethyl	445	458	|I-IUPAC
-	458	459	|I-IUPAC
5	459	460	|I-IUPAC
-	460	461	|I-IUPAC
ethyl	461	466	|I-IUPAC
-	466	467	|I-IUPAC
5	467	468	|I-IUPAC
-	468	469	|I-IUPAC
phenylhydantoin	469	484	|I-IUPAC
,	484	485	|O
which	486	491	|O
is	492	494	|O
effective	495	504	|O
against	505	512	|O
both	513	517	|O
maximal	518	525	|O
electroshock	526	538	|O
and	539	542	|O
pentylenetetrazole	543	561	|B-IUPAC
.	561	562	|O
None	563	567	|O
of	568	570	|O
the	571	574	|O
above	575	580	|O
compounds	581	590	|O
show	591	595	|O
greater	596	603	|O
activity	604	612	|O
against	613	620	|O
maximal	621	628	|O
electroshock	629	641	|O
seizures	642	650	|O
than	651	655	|O
the	656	659	|O
parent	660	666	|O
compounds	667	676	|O
,	676	677	|O
however	678	685	|O
.	685	686	|O

### abstracts3991.txt
By	0	2	|O
a	3	4	|O
variety	5	12	|O
of	13	15	|O
synthetic	16	25	|O
routes	26	32	|O
,	32	33	|O
we	34	36	|O
have	37	41	|O
synthesized	42	53	|O
a	54	55	|O
series	56	62	|O
of	63	65	|O
3,4,5	66	71	|B-MODIFIER
-	71	72	|I-MODIFIER
trisubstituted	72	86	|I-MODIFIER
4H	87	89	|B-IUPAC
-	89	90	|I-IUPAC
1,2,4	90	95	|I-IUPAC
-	95	96	|I-IUPAC
triazoles	96	105	|I-IUPAC
and	106	109	|O
a	110	111	|O
related	112	119	|O
series	120	126	|O
of	127	129	|O
3H	130	132	|B-IUPAC
-	132	133	|I-IUPAC
imidazo	133	140	|I-IUPAC
[	140	141	|I-IUPAC
1,2	141	144	|I-IUPAC
-	144	145	|I-IUPAC
b	145	146	|I-IUPAC
]	146	147	|I-IUPAC
[	147	148	|I-IUPAC
1,2,4	148	153	|I-IUPAC
]	153	154	|I-IUPAC
triazoles	154	163	|I-IUPAC
and	164	167	|O
evaluated	168	177	|O
them	178	182	|O
in	183	185	|O
vitro	186	191	|O
and	192	195	|O
in	196	198	|O
vivo	199	203	|O
as	204	206	|O
angiotensin	207	218	|O
II	219	221	|O
(	222	223	|O
AII	223	226	|O
)	226	227	|O
antagonists	228	239	|O
.	239	240	|O
Principal	241	250	|O
efforts	251	258	|O
focused	259	266	|O
on	267	269	|O
triazoles	270	279	|O
bearing	280	287	|O
an	288	290	|O
n	291	292	|O
-	292	293	|O
alkyl	293	298	|O
substitutent	299	311	|O
at	312	314	|O
C3	315	317	|O
and	318	321	|O
a	322	323	|O
4	324	325	|B-IUPAC
-	325	326	|I-IUPAC
[	326	327	|I-IUPAC
(	327	328	|I-IUPAC
2	328	329	|I-IUPAC
-	329	330	|I-IUPAC
carboxybenzoyl	330	344	|I-IUPAC
)	344	345	|I-IUPAC
amino	345	350	|I-IUPAC
]	350	351	|I-IUPAC
benzyl	351	357	|I-IUPAC
,	357	358	|I-IUPAC
(	359	360	|I-IUPAC
2'	360	362	|I-IUPAC
-	362	363	|I-IUPAC
carboxybiphenyl	363	378	|I-IUPAC
-	378	379	|I-IUPAC
4	379	380	|I-IUPAC
-	380	381	|I-IUPAC
yl	381	383	|I-IUPAC
)	383	384	|I-IUPAC
methyl	384	390	|I-IUPAC
,	390	391	|O
or	392	394	|O
[	395	396	|B-IUPAC
2'	396	398	|I-IUPAC
-	398	399	|I-IUPAC
(	399	400	|I-IUPAC
1H	400	402	|I-IUPAC
-	402	403	|I-IUPAC
tetrazol	403	411	|I-IUPAC
-	411	412	|I-IUPAC
5	412	413	|I-IUPAC
-	413	414	|I-IUPAC
yl	414	416	|I-IUPAC
)	416	417	|I-IUPAC
biphenyl	417	425	|I-IUPAC
-	425	426	|I-IUPAC
4	426	427	|I-IUPAC
-	427	428	|I-IUPAC
yl	428	430	|I-IUPAC
]	430	431	|I-IUPAC
methyl	431	437	|I-IUPAC
side	438	442	|B-MODIFIER
chain	443	448	|I-MODIFIER
at	449	451	|O
N4	452	454	|O
.	454	455	|O
Among	456	461	|O
numerous	462	470	|O
variations	471	481	|O
at	482	484	|O
C5	485	487	|O
,	487	488	|O
benzylthio	489	499	|O
groups	500	506	|O
gave	507	511	|O
the	512	515	|O
best	516	520	|O
potency	521	528	|O
.	528	529	|O
Particularly	530	542	|O
noteworthy	543	553	|O
was	554	557	|O
3	558	559	|B-IUPAC
-	559	560	|I-IUPAC
n	560	561	|I-IUPAC
-	561	562	|I-IUPAC
butyl	562	567	|I-IUPAC
-	567	568	|I-IUPAC
5	568	569	|I-IUPAC
-	569	570	|I-IUPAC
[	570	571	|I-IUPAC
(	571	572	|I-IUPAC
2	572	573	|I-IUPAC
-	573	574	|I-IUPAC
carboxybenzyl	574	587	|I-IUPAC
)	587	588	|I-IUPAC
thio	588	592	|I-IUPAC
]	592	593	|I-IUPAC
-	593	594	|I-IUPAC
4	594	595	|I-IUPAC
-	595	596	|I-IUPAC
[	596	597	|I-IUPAC
[	597	598	|I-IUPAC
2'	598	600	|I-IUPAC
-	600	601	|I-IUPAC
(	601	602	|I-IUPAC
1H	602	604	|I-IUPAC
-	604	605	|I-IUPAC
tetrazol	605	613	|I-IUPAC
-	613	614	|I-IUPAC
5	614	615	|I-IUPAC
-	615	616	|I-IUPAC
yl	616	618	|I-IUPAC
)	619	620	|I-IUPAC
biphenyl	620	628	|I-IUPAC
-	628	629	|I-IUPAC
4	629	630	|I-IUPAC
-	631	632	|I-IUPAC
yl	633	635	|I-IUPAC
]	635	636	|I-IUPAC
methyl	636	642	|I-IUPAC
]	642	643	|I-IUPAC
-	643	644	|I-IUPAC
4H	644	646	|I-IUPAC
-	646	647	|I-IUPAC
1,2,4	647	652	|I-IUPAC
-	652	653	|I-IUPAC
triazole	653	661	|I-IUPAC
(	662	663	|O
71	663	665	|O
,	665	666	|O
IC50	667	671	|O
1.4	672	675	|O
nM	676	678	|O
)	678	679	|O
,	679	680	|O
which	681	686	|O
blocked	687	694	|O
the	695	698	|O
AII	699	702	|O
pressor	703	710	|O
response	711	719	|O
in	720	722	|O
conscious	723	732	|O
rats	733	737	|O
at	738	740	|O
0.3	741	744	|O
mg	745	747	|O
/	747	748	|O
kg	748	750	|O
iv	751	753	|O
with	754	758	|O
a	759	760	|O
duration	761	769	|O
of	770	772	|O
action	773	779	|O
of	780	782	|O
approximately	783	796	|O
6	797	798	|O
h	799	800	|O
,	800	801	|O
similar	802	809	|O
to	810	812	|O
that	813	817	|O
of	818	820	|O
DuP	821	824	|O
753	825	828	|O
.	828	829	|O
Although	830	838	|O
71	839	841	|O
was	842	845	|O
active	846	852	|O
orally	853	859	|O
only	860	864	|O
at	865	867	|O
a	868	869	|O
10	870	872	|O
-	872	873	|O
fold	873	877	|O
higher	878	884	|O
dose	885	889	|O
level	890	895	|O
,	895	896	|O
good	897	901	|O
oral	902	906	|O
bioavailability	907	922	|O
was	923	926	|O
demonstrated	927	939	|O
for	940	943	|O
a	944	945	|O
monoacidic	946	956	|O
analogue	957	965	|O
62	966	968	|O
.	968	969	|O
Most	970	974	|O
potent	975	981	|O
among	982	987	|O
the	988	991	|O
bicyclic	992	1000	|O
derivatives	1001	1012	|O
was	1013	1016	|O
2	1017	1018	|B-IUPAC
-	1018	1019	|I-IUPAC
n	1019	1020	|I-IUPAC
-	1020	1021	|I-IUPAC
butyl	1021	1026	|I-IUPAC
-	1026	1027	|I-IUPAC
5,6	1027	1030	|I-IUPAC
-	1030	1031	|I-IUPAC
dimethyl	1031	1039	|I-IUPAC
-	1039	1040	|I-IUPAC
3	1040	1041	|I-IUPAC
-	1041	1042	|I-IUPAC
[	1042	1043	|I-IUPAC
[	1043	1044	|I-IUPAC
2'	1044	1046	|I-IUPAC
-	1046	1047	|I-IUPAC
(	1047	1048	|I-IUPAC
1H	1048	1050	|I-IUPAC
-	1050	1051	|I-IUPAC
tetrazol	1051	1059	|I-IUPAC
-	1059	1060	|I-IUPAC
5	1060	1061	|I-IUPAC
-	1061	1062	|I-IUPAC
yl	1062	1064	|I-IUPAC
)	1064	1065	|I-IUPAC
biphenyl	1065	1073	|I-IUPAC
-	1073	1074	|I-IUPAC
4	1074	1075	|I-IUPAC
-	1075	1076	|I-IUPAC
yl	1076	1078	|I-IUPAC
]	1078	1079	|I-IUPAC
meth	1079	1083	|I-IUPAC
yl	1084	1086	|I-IUPAC
]	1086	1087	|I-IUPAC
-	1087	1088	|I-IUPAC
3H	1089	1091	|I-IUPAC
-	1091	1092	|I-IUPAC
imidazo	1092	1099	|I-IUPAC
[	1099	1100	|I-IUPAC
1,2	1100	1103	|I-IUPAC
-	1103	1104	|I-IUPAC
b	1104	1105	|I-IUPAC
]	1105	1106	|I-IUPAC
[	1106	1107	|I-IUPAC
1,2,4	1107	1112	|I-IUPAC
]	1112	1113	|I-IUPAC
triazole	1113	1121	|I-IUPAC
(	1122	1123	|O
93	1123	1125	|O
,	1125	1126	|O
IC50	1127	1131	|O
7.8	1132	1135	|O
nM	1136	1138	|O
)	1138	1139	|O
.	1139	1140	|O
The	1141	1144	|O
effects	1145	1152	|O
of	1153	1155	|O
hydrophobic	1156	1167	|O
,	1167	1168	|O
hydrogen	1169	1177	|O
-	1177	1178	|O
bonding	1178	1185	|O
,	1185	1186	|O
and	1187	1190	|O
ionic	1191	1196	|O
interactions	1197	1209	|O
with	1210	1214	|O
the	1215	1218	|O
AT1	1219	1222	|O
receptor	1223	1231	|O
are	1232	1235	|O
considered	1236	1246	|O
.	1246	1247	|O

### abstracts3053.txt
A	0	1	|O
still	2	7	|O
unknown	8	15	|O
tricyclic	16	25	|O
heterocyclic	26	38	|O
system	39	45	|O
(	46	47	|O
5	47	48	|O
)	48	49	|O
was	50	53	|O
synthesized	54	65	|O
from	66	70	|O
6	71	72	|B-IUPAC
-	72	73	|I-IUPAC
hydroxy	73	80	|I-IUPAC
-	80	81	|I-IUPAC
2	81	82	|I-IUPAC
-	82	83	|I-IUPAC
methylpyridazin	83	98	|I-IUPAC
-	98	99	|I-IUPAC
3	99	100	|I-IUPAC
-	100	101	|I-IUPAC
one	101	104	|I-IUPAC
and	105	108	|O
its	109	112	|O
structure	113	122	|O
identified	123	133	|O
as	134	136	|O
2,8	137	140	|B-IUPAC
-	140	141	|I-IUPAC
dichloro	141	149	|I-IUPAC
-	149	150	|I-IUPAC
6	150	151	|I-IUPAC
-	151	152	|I-IUPAC
methylpyrrolo	152	165	|I-IUPAC
[	165	166	|I-IUPAC
1,2	166	169	|I-IUPAC
-	169	170	|I-IUPAC
b	170	171	|I-IUPAC
:	171	172	|I-IUPAC
3,4	172	175	|I-IUPAC
-	175	176	|I-IUPAC
d'	176	178	|I-IUPAC
]	178	179	|I-IUPAC
dipyridazin	179	190	|I-IUPAC
-	190	191	|I-IUPAC
5	191	192	|I-IUPAC
(	192	193	|I-IUPAC
6H	193	195	|I-IUPAC
)	195	196	|I-IUPAC
-	196	197	|I-IUPAC
one	198	201	|I-IUPAC
by	202	204	|O
spectroscopic	205	218	|O
investigations	219	233	|O
.	233	234	|O
Selective	235	244	|O
condensation	245	257	|O
of	258	260	|O
5	261	262	|O
with	263	267	|O
2	268	269	|B-PARTIUPAC
-	269	270	|I-PARTIUPAC
[	270	271	|I-PARTIUPAC
4	271	272	|I-PARTIUPAC
-	272	273	|I-PARTIUPAC
(	273	274	|I-PARTIUPAC
2	274	275	|I-PARTIUPAC
-	275	276	|I-PARTIUPAC
substituted	276	287	|B-MODIFIER
-	287	288	|O
phenyl	288	294	|B-IUPAC
)	294	295	|I-IUPAC
piperazin	295	304	|I-IUPAC
-	304	305	|I-IUPAC
1	305	306	|I-IUPAC
-	306	307	|I-IUPAC
yl	307	309	|I-IUPAC
]	309	310	|I-IUPAC
ethylamine	310	320	|I-IUPAC
gave	321	325	|O
the	326	329	|O
2	330	331	|B-IUPAC
-	331	332	|I-IUPAC
arylpiperazinylethylamino	332	357	|I-IUPAC
-	357	358	|I-IUPAC
8	358	359	|I-IUPAC
-	359	360	|I-IUPAC
chloro	360	366	|I-IUPAC
derivatives	367	378	|B-MODIFIER
6a	379	381	|O
-	381	382	|O
c	382	383	|O
,	383	384	|O
which	385	390	|O
were	391	395	|O
investigated	396	408	|O
in	409	411	|O
binding	412	419	|O
studies	420	427	|O
toward	428	434	|O
the	435	438	|O
three	439	444	|O
alpha1	445	451	|O
-	451	452	|O
adrenergic	452	462	|O
and	463	466	|O
5	467	468	|O
-	468	469	|O
HT1A	469	473	|O
-	473	474	|O
serotonergic	474	486	|O
receptor	487	495	|O
subtypes	496	504	|O
.	504	505	|O
They	506	510	|O
displayed	511	520	|O
high	521	525	|O
potency	526	533	|O
on	534	536	|O
all	537	540	|O
the	541	544	|O
assays	545	551	|O
and	552	555	|O
some	556	560	|O
selectivity	561	572	|O
for	573	576	|O
alpha1a	577	584	|O
and	585	588	|O
alpha1d	589	596	|O
subtypes	597	605	|O
.	605	606	|O

### abstracts28.txt
Five	0	4	|O
1	5	6	|B-IUPAC
-	6	7	|I-IUPAC
beta	7	11	|I-IUPAC
-	11	12	|I-IUPAC
D	12	13	|I-IUPAC
-	13	14	|I-IUPAC
arabinofuranosylcytosine	14	38	|I-IUPAC
conjugates	39	49	|B-MODIFIER
and	50	53	|O
two	54	57	|O
cytidine	58	66	|O
conjugates	67	77	|O
of	78	80	|O
thioether	81	90	|O
lipids	91	97	|O
(	98	99	|O
1	99	100	|B-IUPAC
-	100	101	|I-IUPAC
S	101	102	|I-IUPAC
-	102	103	|I-IUPAC
alkylthioglycerols	103	121	|I-IUPAC
)	121	122	|O
linked	123	129	|O
by	130	132	|O
a	133	134	|O
pyrophosphate	135	148	|O
diester	149	156	|O
bond	157	161	|O
have	162	166	|O
been	167	171	|O
prepared	172	180	|O
and	181	184	|O
their	185	190	|O
antitumor	191	200	|O
activity	201	209	|O
against	210	217	|O
an	218	220	|O
ara	221	224	|O
-	224	225	|O
C2	225	227	|O
sensitive	228	237	|O
(	238	239	|O
L1210/0	239	246	|O
)	246	247	|O
and	248	251	|O
two	252	255	|O
ara	256	259	|O
-	259	260	|O
C	260	261	|O
resistant	262	271	|O
L1210	272	277	|O
lymphoid	278	286	|O
leukemia	287	295	|O
sublines	296	304	|O
in	305	307	|O
mice	308	312	|O
were	313	317	|O
evaluated	318	327	|O
.	327	328	|O
These	329	334	|O
prodrugs	335	343	|O
of	344	346	|O
ara	347	350	|O
-	350	351	|O
C	351	352	|O
include	353	360	|O
ara	361	364	|B-IUPAC
-	364	365	|I-IUPAC
CDP	365	368	|I-IUPAC
-	368	369	|I-IUPAC
rac	369	372	|I-IUPAC
-	372	373	|I-IUPAC
1	373	374	|I-IUPAC
-	374	375	|I-IUPAC
S	375	376	|I-IUPAC
-	376	377	|I-IUPAC
hexadecyl	377	386	|I-IUPAC
-	386	387	|I-IUPAC
2	387	388	|I-IUPAC
-	388	389	|I-IUPAC
O	389	390	|I-IUPAC
-	390	391	|I-IUPAC
palmitoyl	391	400	|I-IUPAC
-	400	401	|I-IUPAC
1	401	402	|I-IUPAC
-	402	403	|I-IUPAC
thioglycerol	403	415	|I-IUPAC
(	416	417	|O
8a	417	419	|O
)	419	420	|O
,	420	421	|O
ara	422	425	|B-IUPAC
-	425	426	|I-IUPAC
CDP	426	429	|I-IUPAC
-	429	430	|I-IUPAC
rac	430	433	|I-IUPAC
-	433	434	|I-IUPAC
1	434	435	|I-IUPAC
-	435	436	|I-IUPAC
S	436	437	|I-IUPAC
-	437	438	|I-IUPAC
octadecyl	438	447	|I-IUPAC
-	447	448	|I-IUPAC
2	448	449	|I-IUPAC
-	449	450	|I-IUPAC
O	450	451	|I-IUPAC
-	451	452	|I-IUPAC
palmitoylthioglycerol	452	473	|I-IUPAC
(	474	475	|O
8b	475	477	|O
)	477	478	|O
,	478	479	|O
and	480	483	|O
ara	484	487	|B-IUPAC
-	487	488	|I-IUPAC
CDP	488	491	|I-IUPAC
-	491	492	|I-IUPAC
rac	492	495	|I-IUPAC
-	495	496	|I-IUPAC
1	496	497	|I-IUPAC
-	497	498	|I-IUPAC
S	498	499	|I-IUPAC
-	499	500	|I-IUPAC
octadecyl	500	509	|I-IUPAC
-	509	510	|I-IUPAC
2	510	511	|I-IUPAC
-	511	512	|I-IUPAC
O	512	513	|I-IUPAC
-	513	514	|I-IUPAC
methyl	514	520	|I-IUPAC
(	520	521	|O
or	521	523	|O
-	524	525	|B-PARTIUPAC
ethyl	525	530	|I-PARTIUPAC
,	530	531	|O
-	532	533	|B-PARTIUPAC
hexadecyl	533	542	|I-PARTIUPAC
)	542	543	|O
thioglycerols	543	556	|B-PARTIUPAC
(	557	558	|O
8c	558	560	|O
-	560	561	|O
e	561	562	|O
)	562	563	|O
.	563	564	|O
The	565	568	|O
cytidine	569	577	|O
conjugates	578	588	|O
include	589	596	|O
CDP	597	600	|B-IUPAC
-	600	601	|I-IUPAC
rac	601	604	|I-IUPAC
-	604	605	|I-IUPAC
1	605	606	|I-IUPAC
-	606	607	|I-IUPAC
S	607	608	|I-IUPAC
-	608	609	|I-IUPAC
octadecyl	609	618	|I-IUPAC
-	618	619	|I-IUPAC
2	619	620	|I-IUPAC
-	620	621	|I-IUPAC
O	621	622	|I-IUPAC
-	622	623	|I-IUPAC
palmitoyl	623	632	|I-IUPAC
(	632	633	|O
or	633	635	|O
-	636	637	|B-PARTIUPAC
methyl	637	643	|I-PARTIUPAC
)	643	644	|O
-	644	645	|B-PARTIUPAC
1	646	647	|I-PARTIUPAC
-	647	648	|I-PARTIUPAC
thioglycerols	648	661	|I-PARTIUPAC
(	662	663	|O
9a	663	665	|O
and	666	669	|O
9b	670	672	|O
)	672	673	|O
.	673	674	|O
Sonicated	675	684	|O
solutions	685	694	|O
of	695	697	|O
the	698	701	|O
conjugates	702	712	|O
existed	713	720	|O
in	721	723	|O
the	724	727	|O
form	728	732	|O
of	733	735	|O
micellar	736	744	|O
disks	745	750	|O
(	751	752	|O
size	752	756	|O
0.01-0.04	757	766	|O
microns	767	774	|O
)	774	775	|O
.	775	776	|O
Single	777	783	|O
doses	784	789	|O
(	790	791	|O
200-400	791	798	|O
mg	799	801	|O
/	801	802	|O
kg	802	804	|O
)	804	805	|O
of	806	808	|O
8a	809	811	|O
and	812	815	|O
8b	816	818	|O
produced	819	827	|O
significant	828	839	|O
increase	840	848	|O
in	849	851	|O
life	852	856	|O
span	857	861	|O
(	862	863	|O
257-371%	863	871	|O
)	871	872	|O
in	873	875	|O
mice	876	880	|O
bearing	881	888	|O
ip	889	891	|O
implanted	892	901	|O
L1210/0	902	909	|O
leukemia	910	918	|O
.	918	919	|O
In	920	922	|O
contrast	923	931	|O
,	931	932	|O
conjugates	933	943	|O
8c	944	946	|O
-	946	947	|O
e	947	948	|O
were	949	953	|O
less	954	958	|O
effective	959	968	|O
(	969	970	|O
ILS	970	973	|O
19-75%	974	980	|O
)	980	981	|O
and	982	985	|O
cytidine	986	994	|O
conjugates	995	1005	|O
(	1006	1007	|O
9a	1007	1009	|O
and	1010	1013	|O
9b	1014	1016	|O
)	1016	1017	|O
were	1018	1022	|O
ineffective	1023	1034	|O
.	1034	1035	|O
Even	1036	1040	|O
though	1041	1047	|O
8a	1048	1050	|O
and	1051	1054	|O
8b	1055	1057	|O
were	1058	1062	|O
found	1063	1068	|O
to	1069	1071	|O
be	1072	1074	|O
curative	1075	1083	|O
in	1084	1086	|O
a	1087	1088	|O
high	1089	1093	|O
percentage	1094	1104	|O
of	1105	1107	|O
mice	1108	1112	|O
bearing	1113	1120	|O
ip	1121	1123	|O
implanted	1124	1133	|O
partially	1134	1143	|O
ara	1144	1147	|O
-	1147	1148	|O
C	1148	1149	|O
resistant	1150	1159	|O
L1210	1160	1165	|O
subline	1166	1173	|O
[	1174	1175	|O
L1210	1175	1180	|O
/	1180	1181	|O
ara	1181	1184	|O
-	1184	1185	|O
C	1185	1186	|O
(	1186	1187	|O
I	1187	1188	|O
)	1188	1189	|O
]	1189	1190	|O
,	1190	1191	|O
they	1192	1196	|O
were	1197	1201	|O
completely	1202	1212	|O
ineffective	1213	1224	|O
against	1225	1232	|O
deoxycytidine	1233	1246	|O
kinase	1247	1253	|O
deficient	1254	1263	|O
ara	1264	1267	|O
-	1267	1268	|O
C	1268	1269	|O
resistant	1270	1279	|O
L1210	1280	1285	|O
subline	1286	1293	|O
[	1294	1295	|O
L1210	1295	1300	|O
/	1300	1301	|O
ara	1301	1304	|O
-	1304	1305	|O
C	1305	1306	|O
(	1306	1307	|O
II	1307	1309	|O
)	1309	1310	|O
]	1310	1311	|O
.	1311	1312	|O
However	1313	1320	|O
,	1320	1321	|O
the	1322	1325	|O
present	1326	1333	|O
results	1334	1341	|O
,	1341	1342	|O
together	1343	1351	|O
with	1352	1356	|O
the	1357	1360	|O
previous	1361	1369	|O
,	1369	1370	|O
demonstrate	1371	1382	|O
that	1383	1387	|O
8a	1388	1390	|O
and	1391	1394	|O
8b	1395	1397	|O
are	1398	1401	|O
promising	1402	1411	|O
new	1412	1415	|O
prodrugs	1416	1424	|O
of	1425	1427	|O
ara	1428	1431	|O
-	1431	1432	|O
C	1432	1433	|O
with	1434	1438	|O
improved	1439	1447	|O
efficacy	1448	1456	|O
.	1456	1457	|O

### abstracts416.txt
Pyrazolo	0	8	|O
[	8	9	|O
3,4	9	12	|O
-	12	13	|O
d	13	14	|O
]	14	15	|O
pyrimidines	15	26	|O
are	27	30	|O
pyrazolo	31	39	|O
analogues	40	49	|O
of	50	52	|O
purines	53	60	|O
.	60	61	|O
They	62	66	|O
have	67	71	|O
been	72	76	|O
shown	77	82	|O
to	83	85	|O
be	86	88	|O
a	89	90	|O
general	91	98	|O
class	99	104	|O
of	105	107	|O
compounds	108	117	|O
which	118	123	|O
exhibit	124	131	|O
A1	132	134	|O
adenosine	135	144	|O
receptor	145	153	|O
affinity	154	162	|O
.	162	163	|O
Two	164	167	|O
series	168	174	|O
of	175	177	|O
pyrazolo	178	186	|B-IUPAC
[	186	187	|I-IUPAC
3,4	187	190	|I-IUPAC
-	190	191	|I-IUPAC
d	191	192	|I-IUPAC
]	192	193	|I-IUPAC
pyrimidine	193	203	|I-IUPAC
analogues	204	213	|B-MODIFIER
of	214	216	|O
1	217	218	|B-IUPAC
-	218	219	|I-IUPAC
methylisoguanosine	219	237	|I-IUPAC
have	238	242	|O
been	243	247	|O
synthesized	248	259	|O
.	259	260	|O
The	261	264	|O
first	265	270	|O
involved	271	279	|O
substitution	280	292	|O
of	293	295	|O
the	296	299	|O
N1	300	302	|O
-	302	303	|O
position	303	311	|O
while	312	317	|O
the	318	321	|O
second	322	328	|O
involved	329	337	|O
substitution	338	350	|O
of	351	353	|O
the	354	357	|O
N5	358	360	|O
-	360	361	|O
position	361	369	|O
.	369	370	|O
Both	371	375	|O
alkyl	376	381	|O
and	382	385	|O
aryl	386	390	|O
substituents	391	403	|O
were	404	408	|O
examined	409	417	|O
.	417	418	|O
All	419	422	|O
compounds	423	432	|O
were	433	437	|O
tested	438	444	|O
for	445	448	|O
A1	449	451	|O
adenosine	452	461	|O
receptor	462	470	|O
affinity	471	479	|O
by	480	482	|O
using	483	488	|O
a	489	490	|O
(	491	492	|B-IUPAC
R	492	493	|I-IUPAC
)	493	494	|I-IUPAC
-	494	495	|I-IUPAC
[	495	496	|I-IUPAC
3H	496	498	|I-IUPAC
]	498	499	|I-IUPAC
-	499	500	|I-IUPAC
N6	500	502	|I-IUPAC
-	502	503	|I-IUPAC
(	503	504	|I-IUPAC
phenylisopropyl	504	519	|I-IUPAC
)	519	520	|I-IUPAC
adenosine	520	529	|I-IUPAC
binding	530	537	|O
assay	538	543	|O
.	543	544	|O
The	545	548	|O
3	549	550	|O
-	550	551	|O
chlorophenyl	551	563	|O
group	564	569	|O
showed	570	576	|O
the	577	580	|O
greatest	581	589	|O
activity	590	598	|O
in	599	601	|O
the	602	605	|O
N1	606	608	|O
-	608	609	|O
position	609	617	|O
and	618	621	|O
the	622	625	|O
butyl	626	631	|O
group	632	637	|O
produced	638	646	|O
the	647	650	|O
greatest	651	659	|O
activity	660	668	|O
in	669	671	|O
the	672	675	|O
N5	676	678	|O
-	678	679	|O
position	679	687	|O
.	687	688	|O
Combination	689	700	|O
of	701	703	|O
the	704	707	|O
best	708	712	|O
substituent	713	724	|O
in	725	727	|O
each	728	732	|O
of	733	735	|O
these	736	741	|O
positions	742	751	|O
enhanced	752	760	|O
the	761	764	|O
overall	765	772	|O
activity	773	781	|O
.	781	782	|O
The	783	786	|O
most	787	791	|O
potent	792	798	|O
compound	799	807	|O
was	808	811	|O
4	812	813	|B-IUPAC
-	813	814	|I-IUPAC
amino	814	819	|I-IUPAC
-	819	820	|I-IUPAC
5	820	821	|I-IUPAC
-	821	822	|I-IUPAC
N	822	823	|I-IUPAC
-	823	824	|I-IUPAC
butyl	824	829	|I-IUPAC
-	829	830	|I-IUPAC
1	830	831	|I-IUPAC
-	831	832	|I-IUPAC
(	832	833	|I-IUPAC
3	833	834	|I-IUPAC
-	834	835	|I-IUPAC
chlorophenyl	835	847	|I-IUPAC
)	847	848	|I-IUPAC
-	848	849	|I-IUPAC
1H	849	851	|I-IUPAC
-	851	852	|I-IUPAC
pyrazolo	852	860	|I-IUPAC
[	860	861	|I-IUPAC
3,4	861	864	|I-IUPAC
-	864	865	|I-IUPAC
d	865	866	|I-IUPAC
]	866	867	|I-IUPAC
pyrimidin	867	876	|I-IUPAC
-	876	877	|I-IUPAC
6	877	878	|I-IUPAC
(	878	879	|I-IUPAC
5H	879	881	|I-IUPAC
)	881	882	|I-IUPAC
-	882	883	|I-IUPAC
one	884	887	|I-IUPAC
with	888	892	|O
an	893	895	|O
IC50	896	900	|O
of	901	903	|O
6.4	904	907	|O
x	908	909	|O
10	910	912	|O
(	912	913	|O
-	913	914	|O
6	914	915	|O
)	915	916	|O
M	917	918	|O
.	918	919	|O
Selectivity	920	931	|O
at	932	934	|O
the	935	938	|O
receptor	939	947	|O
subclasses	948	958	|O
was	959	962	|O
examined	963	971	|O
by	972	974	|O
performing	975	985	|O
an	986	988	|O
A2	989	991	|O
adenosine	992	1001	|O
receptor	1002	1010	|O
affinity	1011	1019	|O
assay	1020	1025	|O
with	1026	1030	|O
[	1031	1032	|O
3H	1032	1034	|O
]	1034	1035	|O
CGS	1035	1038	|O
21680	1039	1044	|O
.	1044	1045	|O
This	1046	1050	|O
series	1051	1057	|O
of	1058	1060	|O
compounds	1061	1070	|O
were	1071	1075	|O
slightly	1076	1084	|O
less	1085	1089	|O
potent	1090	1096	|O
at	1097	1099	|O
A2	1100	1102	|O
receptors	1103	1112	|O
.	1112	1113	|O
4	1114	1115	|B-IUPAC
-	1115	1116	|I-IUPAC
Amino	1116	1121	|I-IUPAC
-	1121	1122	|I-IUPAC
5	1122	1123	|I-IUPAC
-	1123	1124	|I-IUPAC
N	1124	1125	|I-IUPAC
-	1125	1126	|I-IUPAC
butyl	1126	1131	|I-IUPAC
-	1131	1132	|I-IUPAC
1	1132	1133	|I-IUPAC
-	1133	1134	|I-IUPAC
(	1134	1135	|I-IUPAC
3	1135	1136	|I-IUPAC
-	1136	1137	|I-IUPAC
chlorophenyl	1137	1149	|I-IUPAC
-	1149	1150	|I-IUPAC
1H	1150	1152	|I-IUPAC
-	1152	1153	|I-IUPAC
pyrazolo	1153	1161	|I-IUPAC
[	1161	1162	|I-IUPAC
3,4	1162	1165	|I-IUPAC
-	1165	1166	|I-IUPAC
d	1166	1167	|I-IUPAC
]	1167	1168	|I-IUPAC
pyrimidin	1168	1177	|I-IUPAC
-	1177	1178	|I-IUPAC
6	1178	1179	|I-IUPAC
(	1179	1180	|I-IUPAC
5H	1180	1182	|I-IUPAC
)	1182	1183	|I-IUPAC
-	1183	1184	|I-IUPAC
one	1184	1187	|I-IUPAC
was	1188	1191	|O
the	1192	1195	|O
most	1196	1200	|O
potent	1201	1207	|O
compound	1208	1216	|O
with	1217	1221	|O
an	1222	1224	|O
IC50	1225	1229	|O
of	1230	1232	|O
19.2	1233	1237	|O
x	1238	1239	|O
10	1240	1242	|O
(	1242	1243	|O
-	1243	1244	|O
6	1244	1245	|O
)	1245	1246	|O
M	1247	1248	|O
.	1248	1249	|O

### abstracts1905.txt
Several	0	7	|O
new	8	11	|O
analogues	12	21	|O
of	22	24	|O
L	25	26	|B-IUPAC
-	26	27	|I-IUPAC
fucose	27	33	|I-IUPAC
modified	34	42	|O
in	43	45	|O
the	46	49	|O
2	50	51	|O
position	52	60	|O
and	61	64	|O
the	65	68	|O
5	69	70	|B-IUPAC
-	70	71	|I-IUPAC
methyl	71	77	|I-IUPAC
group	78	83	|B-MODIFIER
have	84	88	|O
been	89	93	|O
synthesized	94	105	|O
as	106	108	|O
potential	109	118	|O
plasma	119	125	|O
-	125	126	|O
membrane	126	134	|O
glycoconjugate	135	149	|O
inhibitors	150	160	|O
or	161	163	|O
modifiers	164	173	|O
,	173	174	|O
and	175	178	|O
their	179	184	|O
biological	185	195	|O
effects	196	203	|O
have	204	208	|O
been	209	213	|O
studied	214	221	|O
.	221	222	|O
2	223	224	|B-PARTIUPAC
-	224	225	|I-PARTIUPAC
Chloro	225	231	|I-PARTIUPAC
-	231	232	|I-PARTIUPAC
,	232	233	|O
2	234	235	|B-PARTIUPAC
-	235	236	|I-PARTIUPAC
bromo	236	241	|I-PARTIUPAC
-	241	242	|I-PARTIUPAC
,	242	243	|O
and	244	247	|O
2	248	249	|B-IUPAC
-	249	250	|I-IUPAC
iodo	250	254	|I-IUPAC
-	254	255	|I-IUPAC
2	255	256	|I-IUPAC
-	256	257	|I-IUPAC
deoxy	257	262	|I-IUPAC
-	262	263	|I-IUPAC
L	263	264	|I-IUPAC
-	264	265	|I-IUPAC
fucose	265	271	|I-IUPAC
(	272	273	|O
9a	273	275	|O
,	275	276	|O
9b	277	279	|O
,	279	280	|O
and	281	284	|O
13	285	287	|O
,	287	288	|O
respectively	289	301	|O
)	301	302	|O
have	303	307	|O
been	308	312	|O
prepared	313	321	|O
by	322	324	|O
addition	325	333	|O
of	334	336	|O
the	337	340	|O
appropriate	341	352	|O
halogen	353	360	|O
to	361	363	|O
3,4	364	367	|B-IUPAC
-	367	368	|I-IUPAC
di	368	370	|I-IUPAC
-	370	371	|I-IUPAC
O	371	372	|I-IUPAC
-	372	373	|I-IUPAC
acetyl	373	379	|I-IUPAC
-	379	380	|I-IUPAC
L	380	381	|I-IUPAC
-	381	382	|I-IUPAC
fucal	382	387	|I-IUPAC
,	387	388	|O
followed	389	397	|O
by	398	400	|O
hydrolysis	401	411	|O
of	412	414	|O
the	415	418	|O
anomeric	419	427	|O
halogen	428	435	|O
and	436	439	|O
the	440	443	|O
acetyl	444	450	|O
groups	451	457	|O
.	457	458	|O
A	459	460	|O
series	461	467	|O
of	468	470	|O
four	471	475	|O
halogenated	476	487	|O
5	488	489	|B-IUPAC
-	489	490	|I-IUPAC
methyl	490	496	|I-IUPAC
analogues	497	506	|B-MODIFIER
of	507	509	|O
L	510	511	|B-IUPAC
-	511	512	|I-IUPAC
fucose	512	518	|I-IUPAC
(	519	520	|O
4	520	521	|O
,	521	522	|O
X	523	524	|O
=	525	526	|O
F	527	528	|O
,	528	529	|O
Cl	530	532	|O
,	532	533	|O
Br	534	536	|O
,	536	537	|O
and	538	541	|O
I	542	543	|O
)	543	544	|O
have	545	549	|O
been	550	554	|O
obtained	555	563	|O
starting	564	572	|O
from	573	577	|O
1,2	578	581	|B-IUPAC
:	581	582	|I-IUPAC
3,4	582	585	|I-IUPAC
-	585	586	|I-IUPAC
di	586	588	|I-IUPAC
-	588	589	|I-IUPAC
O	589	590	|I-IUPAC
-	590	591	|I-IUPAC
isopropylidene	591	605	|I-IUPAC
-	605	606	|I-IUPAC
L	606	607	|I-IUPAC
-	607	608	|I-IUPAC
galactose	608	617	|I-IUPAC
.	617	618	|O
The	619	622	|O
synthesis	623	632	|O
of	633	635	|O
this	636	640	|O
latter	641	647	|O
compound	648	656	|O
has	657	660	|O
been	661	665	|O
improved	666	674	|O
.	674	675	|O
A	676	677	|O
corresponding	678	691	|O
series	692	698	|O
of	699	701	|O
6	702	703	|B-IUPAC
-	703	704	|I-IUPAC
deoxy	704	709	|I-IUPAC
-	709	710	|I-IUPAC
6	710	711	|I-IUPAC
-	711	712	|I-IUPAC
halo	712	716	|I-IUPAC
-	716	717	|I-IUPAC
D	717	718	|I-IUPAC
-	718	719	|I-IUPAC
galactose	719	728	|I-IUPAC
analogues	729	738	|B-MODIFIER
,	738	739	|O
which	740	745	|O
are	746	749	|O
enantiomers	750	761	|O
of	762	764	|O
the	765	768	|O
5	769	770	|B-IUPAC
-	770	771	|I-IUPAC
(	771	772	|I-IUPAC
halomethyl	772	782	|I-IUPAC
)	782	783	|I-IUPAC
-	783	784	|I-IUPAC
L	784	785	|I-IUPAC
-	785	786	|I-IUPAC
fucose	786	792	|I-IUPAC
analogues	793	802	|B-MODIFIER
,	802	803	|O
has	804	807	|O
also	808	812	|O
been	813	817	|O
synthesized	818	829	|O
.	829	830	|O
Analogues	831	840	|O
4b	841	843	|O
,	843	844	|O
4c	845	847	|O
,	847	848	|O
and	849	852	|O
9b	853	855	|O
at	856	858	|O
1	859	860	|O
x	861	862	|O
10	863	865	|O
(	865	866	|O
-	866	867	|O
3	867	868	|O
)	868	869	|O
M	870	871	|O
specifically	872	884	|O
inhibited	885	894	|O
the	895	898	|O
incorporation	899	912	|O
of	913	915	|O
L	916	917	|B-IUPAC
-	917	918	|I-IUPAC
[	918	919	|I-IUPAC
3H	919	921	|I-IUPAC
]	921	922	|I-IUPAC
fucose	922	928	|I-IUPAC
into	929	933	|O
macromolecular	934	948	|O
components	949	959	|O
of	960	962	|O
SW613	963	968	|O
human	969	974	|O
mammary	975	982	|O
tumor	983	988	|O
cells	989	994	|O
.	994	995	|O
Analogue	996	1004	|O
13	1005	1007	|O
inhibited	1008	1017	|O
the	1018	1021	|O
growth	1022	1028	|O
of	1029	1031	|O
L1210	1032	1037	|O
murine	1038	1044	|O
leukemic	1045	1053	|O
cells	1054	1059	|O
with	1060	1064	|O
an	1065	1067	|O
IC50	1068	1072	|O
of	1073	1075	|O
6	1076	1077	|O
x	1078	1079	|O
10	1080	1082	|O
(	1082	1083	|O
5	1083	1084	|O
)	1084	1085	|O
M	1086	1087	|O
in	1088	1090	|O
culture	1091	1098	|O
.	1098	1099	|O
6	1100	1101	|B-IUPAC
-	1101	1102	|I-IUPAC
Deoxy	1102	1107	|I-IUPAC
-	1107	1108	|I-IUPAC
6	1108	1109	|I-IUPAC
-	1109	1110	|I-IUPAC
fluoro	1110	1116	|I-IUPAC
-	1116	1117	|I-IUPAC
D	1117	1118	|I-IUPAC
-	1118	1119	|I-IUPAC
galactose	1119	1128	|I-IUPAC
and	1129	1132	|O
its	1133	1136	|O
enantiomer	1137	1147	|O
4a	1148	1150	|O
were	1151	1155	|O
found	1156	1161	|O
to	1162	1164	|O
be	1165	1167	|O
effective	1168	1177	|O
inhibitors	1178	1188	|O
of	1189	1191	|O
D	1192	1193	|B-IUPAC
-	1193	1194	|I-IUPAC
[	1194	1195	|I-IUPAC
3H	1195	1197	|I-IUPAC
]	1197	1198	|I-IUPAC
galactose	1198	1207	|I-IUPAC
and	1208	1211	|O
L	1212	1213	|B-IUPAC
-	1213	1214	|I-IUPAC
[	1214	1215	|I-IUPAC
3H	1215	1217	|I-IUPAC
]	1217	1218	|I-IUPAC
fucose	1218	1224	|I-IUPAC
incorporation	1225	1238	|O
,	1238	1239	|O
respectively	1240	1252	|O
,	1252	1253	|O
into	1254	1258	|O
macromolecular	1259	1273	|O
components	1274	1284	|O
of	1285	1287	|O
human	1288	1293	|O
mammary	1294	1301	|O
tumor	1302	1307	|O
cells	1308	1313	|O
.	1313	1314	|O
The	1315	1318	|O
effectiveness	1319	1332	|O
of	1333	1335	|O
inhibition	1336	1346	|O
was	1347	1350	|O
reduced	1351	1358	|O
with	1359	1363	|O
an	1364	1366	|O
increase	1367	1375	|O
in	1376	1378	|O
size	1379	1383	|O
of	1384	1386	|O
the	1387	1390	|O
halogen	1391	1398	|O
atom	1399	1403	|O
.	1403	1404	|O
Analogue	1405	1413	|O
4a	1414	1416	|O
and	1417	1420	|O
its	1421	1424	|O
enantiomer	1425	1435	|O
have	1436	1440	|O
been	1441	1445	|O
tritiated	1446	1455	|O
at	1456	1458	|O
C	1459	1460	|O
-	1460	1461	|O
1	1461	1462	|O
and	1463	1466	|O
both	1467	1471	|O
were	1472	1476	|O
found	1477	1482	|O
to	1483	1485	|O
be	1486	1488	|O
activated	1489	1498	|O
to	1499	1501	|O
a	1502	1503	|O
nucleotide	1504	1514	|O
sugar	1515	1520	|O
,	1520	1521	|O
which	1522	1527	|O
was	1528	1531	|O
followed	1532	1540	|O
by	1541	1543	|O
incorporation	1544	1557	|O
into	1558	1562	|O
the	1563	1566	|O
macromolecular	1567	1581	|O
fraction	1582	1590	|O
of	1591	1593	|O
SW613	1594	1599	|O
human	1600	1605	|O
mammary	1606	1613	|O
tumor	1614	1619	|O
cells	1620	1625	|O
in	1626	1628	|O
vitro	1629	1634	|O
.	1634	1635	|O

### abstracts2040.txt
The	0	3	|O
transition	4	14	|O
metal	15	20	|O
complexes	21	30	|O
[	31	32	|B-IUPAC
eta	32	35	|I-IUPAC
(	35	36	|I-IUPAC
6	36	37	|I-IUPAC
)	37	38	|I-IUPAC
-	38	39	|I-IUPAC
(	40	41	|I-IUPAC
2beta	41	46	|I-IUPAC
-	46	47	|I-IUPAC
carbomethoxy	47	59	|I-IUPAC
-	59	60	|I-IUPAC
3beta	60	65	|I-IUPAC
-	65	66	|I-IUPAC
phenyltropane	66	79	|I-IUPAC
)	79	80	|I-IUPAC
]	80	81	|I-IUPAC
tricarbonylchromium	81	100	|I-IUPAC
(	101	102	|O
3	102	103	|O
)	103	104	|O
and	105	108	|O
[	109	110	|B-IUPAC
eta	110	113	|I-IUPAC
(	113	114	|I-IUPAC
6	114	115	|I-IUPAC
)	115	116	|I-IUPAC
-	116	117	|I-IUPAC
(	117	118	|I-IUPAC
2beta	118	123	|I-IUPAC
-	123	124	|I-IUPAC
carbomethoxy	124	136	|I-IUPAC
-	136	137	|I-IUPAC
3beta	137	142	|I-IUPAC
-	142	143	|I-IUPAC
phenyltropane	143	156	|I-IUPAC
)	156	157	|I-IUPAC
]	157	158	|I-IUPAC
[	159	160	|I-IUPAC
eta	160	163	|I-IUPAC
(	163	164	|I-IUPAC
5	164	165	|I-IUPAC
)	165	166	|I-IUPAC
-	166	167	|I-IUPAC
(	167	168	|I-IUPAC
pentamethylcyclopentadienyl	168	195	|I-IUPAC
)	195	196	|I-IUPAC
]	196	197	|I-IUPAC
ruthenium	197	206	|I-IUPAC
(	206	207	|I-IUPAC
II	207	209	|I-IUPAC
)	209	210	|I-IUPAC
triflate	210	218	|I-IUPAC
(	219	220	|O
4	220	221	|O
)	221	222	|O
were	223	227	|O
synthesized	228	239	|O
from	240	244	|O
2beta	245	250	|B-IUPAC
-	250	251	|I-IUPAC
carbomethoxy	251	263	|I-IUPAC
-	263	264	|I-IUPAC
3beta	264	269	|I-IUPAC
-	269	270	|I-IUPAC
phenyltropane	270	283	|I-IUPAC
(	284	285	|O
2	285	286	|O
,	286	287	|O
WIN	288	291	|O
35,065	292	298	|O
)	298	299	|O
to	300	302	|O
further	303	310	|O
elucidate	311	320	|O
the	321	324	|O
influence	325	334	|O
of	335	337	|O
substituents	338	350	|O
on	351	353	|O
the	354	357	|O
3beta	358	363	|O
-	363	364	|O
aryl	364	368	|O
on	369	371	|O
the	372	375	|O
affinity	376	384	|O
of	385	387	|O
the	388	391	|O
ligand	392	398	|O
for	399	402	|O
cocaine	403	410	|O
-	410	411	|O
binding	411	418	|O
sites	419	424	|O
at	425	427	|O
the	428	431	|O
dopamine	432	440	|O
transporter	441	452	|O
.	452	453	|O
The	454	457	|O
compounds	458	467	|O
were	468	472	|O
tested	473	479	|O
for	480	483	|O
their	484	489	|O
ability	490	497	|O
to	498	500	|O
displace	501	509	|O
bound	510	515	|O
[	516	517	|O
(	517	518	|O
3	518	519	|O
)	519	520	|O
H	520	521	|O
]	521	522	|O
WIN	522	525	|O
35,428	526	532	|O
(	533	534	|O
5	534	535	|O
)	535	536	|O
from	537	541	|O
rat	542	545	|O
caudate	546	553	|O
putamen	554	561	|O
tissue	562	568	|O
and	569	572	|O
for	573	576	|O
their	577	582	|O
ability	583	590	|O
to	591	593	|O
inhibit	594	601	|O
[	602	603	|O
(	603	604	|O
3	604	605	|O
)	605	606	|O
H	606	607	|O
]	607	608	|O
dopamine	608	616	|O
uptake	617	623	|O
.	623	624	|O
The	625	628	|O
binding	629	636	|O
affinity	637	645	|O
for	646	649	|O
3	650	651	|O
was	652	655	|O
2	656	657	|O
-	657	658	|O
fold	658	662	|O
greater	663	670	|O
than	671	675	|O
those	676	681	|O
observed	682	690	|O
for	691	694	|O
cocaine	695	702	|O
(	703	704	|O
1	704	705	|O
)	705	706	|O
and	707	710	|O
2	711	712	|O
,	712	713	|O
while	714	719	|O
the	720	723	|O
binding	724	731	|O
affinity	732	740	|O
for	741	744	|O
4	745	746	|O
was	747	750	|O
found	751	756	|O
to	757	759	|O
be	760	762	|O
100	763	766	|O
-	766	767	|O
fold	767	771	|O
less	772	776	|O
than	777	781	|O
those	782	787	|O
of	788	790	|O
1	791	792	|O
and	793	796	|O
2	797	798	|O
.	798	799	|O
In	800	802	|O
addition	803	811	|O
,	811	812	|O
3	813	814	|O
was	815	818	|O
equipotent	819	829	|O
with	830	834	|O
1	835	836	|O
and	837	840	|O
2	841	842	|O
in	843	845	|O
[	846	847	|O
(	847	848	|O
3	848	849	|O
)	849	850	|O
H	850	851	|O
]	851	852	|O
dopamine	852	860	|O
uptake	861	867	|O
inhibition	868	878	|O
studies	879	886	|O
,	886	887	|O
while	888	893	|O
4	894	895	|O
was	896	899	|O
10	900	902	|O
-	902	903	|O
fold	903	907	|O
less	908	912	|O
potent	913	919	|O
.	919	920	|O
The	921	924	|O
potencies	925	934	|O
of	935	937	|O
the	938	941	|O
complexes	942	951	|O
3	952	953	|O
and	954	957	|O
4	958	959	|O
correlated	960	970	|O
well	971	975	|O
with	976	980	|O
the	981	984	|O
structure	985	994	|O
-	994	995	|O
activity	995	1003	|O
relationships	1004	1017	|O
of	1018	1020	|O
other	1021	1026	|O
2beta	1027	1032	|B-IUPAC
-	1032	1033	|I-IUPAC
carbomethoxy	1033	1045	|I-IUPAC
-	1045	1046	|I-IUPAC
3beta	1046	1051	|I-IUPAC
-	1051	1052	|I-IUPAC
aryltropane	1052	1063	|I-IUPAC
derivatives	1064	1075	|B-MODIFIER
.	1075	1076	|O
These	1077	1082	|O
data	1083	1087	|O
further	1088	1095	|O
support	1096	1103	|O
a	1104	1105	|O
pharmacophore	1106	1119	|O
model	1120	1125	|O
in	1126	1128	|O
which	1129	1134	|O
the	1135	1138	|O
region	1139	1145	|O
occupied	1146	1154	|O
by	1155	1157	|O
the	1158	1161	|O
aryl	1162	1166	|O
ring	1167	1171	|O
is	1172	1174	|O
a	1175	1176	|O
lipophilic	1177	1187	|O
pocket	1188	1194	|O
with	1195	1199	|O
electropositive	1200	1215	|O
character	1216	1225	|O
.	1225	1226	|O

### abstracts4894.txt
A	0	1	|O
variety	2	9	|O
of	10	12	|O
mesoionic	13	22	|O
xanthines	23	32	|O
including	33	42	|O
mesoionic	43	52	|B-MODIFIER
thiazolo	53	61	|B-IUPAC
[	61	62	|I-IUPAC
3,2	62	65	|I-IUPAC
-	65	66	|I-IUPAC
alpha	66	71	|I-IUPAC
]	71	72	|I-IUPAC
pyrimidines	72	83	|I-IUPAC
,	83	84	|O
benzothiazolopyrimidines	85	109	|B-IUPAC
,	109	110	|O
and	111	114	|O
1,3,4	115	120	|B-IUPAC
-	120	121	|I-IUPAC
thiadiazolo	121	132	|I-IUPAC
[	132	133	|I-IUPAC
3,2	133	136	|I-IUPAC
-	136	137	|I-IUPAC
alpha	137	142	|I-IUPAC
]	142	143	|I-IUPAC
pyrimidines	143	154	|I-IUPAC
were	155	159	|O
antagonists	160	171	|O
of	172	174	|O
A1	175	177	|O
-	177	178	|O
adenosine	178	187	|O
receptors	188	197	|O
(	198	199	|O
inhibition	199	209	|O
of	210	212	|O
binding	213	220	|O
of	221	223	|O
[	224	225	|B-IUPAC
3H	225	227	|I-IUPAC
]	227	228	|I-IUPAC
-	228	229	|I-IUPAC
cyclohexyladenosine	229	248	|I-IUPAC
)	248	249	|O
and	250	253	|O
A2	254	256	|O
-	256	257	|O
adenosine	257	266	|O
receptors	267	276	|O
(	277	278	|O
inhibition	278	288	|O
of	289	291	|O
2	292	293	|B-IUPAC
-	293	294	|I-IUPAC
chloroadenosine	294	309	|I-IUPAC
-	309	310	|O
elicited	310	318	|O
accumulations	319	332	|O
of	333	335	|O
cyclic	336	342	|O
AMP	343	346	|O
)	346	347	|O
in	348	350	|O
brain	351	356	|O
tissue	357	363	|O
.	363	364	|O
Most	365	369	|O
of	370	372	|O
the	373	376	|O
compounds	377	386	|O
were	387	391	|O
less	392	396	|O
potent	397	403	|O
than	404	408	|O
theophylline	409	421	|O
and	422	425	|O
none	426	430	|O
were	431	435	|O
remarkably	436	446	|O
selective	447	456	|O
for	457	460	|O
A1	461	463	|O
-	463	464	|O
or	465	467	|O
A2	468	470	|O
-	470	471	|O
adenosine	471	480	|O
receptors	481	490	|O
.	490	491	|O
However	492	499	|O
,	499	500	|O
members	501	508	|O
of	509	511	|O
the	512	515	|O
thiadiazolopyrimidine	516	537	|B-IUPAC
class	538	543	|O
of	544	546	|O
mesoionics	547	557	|O
exhibited	558	567	|O
very	568	572	|O
low	573	576	|O
or	577	579	|O
no	580	582	|O
activity	583	591	|O
as	592	594	|O
antagonists	595	606	|O
of	607	609	|O
A2	610	612	|O
-	612	613	|O
adenosine	613	622	|O
receptors	623	632	|O
while	633	638	|O
exhibiting	639	649	|O
activity	650	658	|O
only	659	663	|O
2-4	664	667	|O
-	667	668	|O
fold	668	672	|O
lower	673	678	|O
than	679	683	|O
that	684	688	|O
of	689	691	|O
theophylline	692	704	|O
at	705	707	|O
A1	708	710	|O
-	710	711	|O
adenosine	711	720	|O
receptors	721	730	|O
.	730	731	|O
Unlike	732	738	|O
the	739	742	|O
case	743	747	|O
for	748	751	|O
theophylline	752	764	|O
,	764	765	|O
the	766	769	|O
presence	770	778	|O
of	779	781	|O
a	782	783	|O
phenyl	784	790	|O
substituent	791	802	|O
in	803	805	|O
the	806	809	|O
five	810	814	|O
-	814	815	|O
membered	815	823	|O
ring	824	828	|O
did	829	832	|O
not	833	836	|O
enhance	837	844	|O
the	845	848	|O
potency	849	856	|O
of	857	859	|O
a	860	861	|O
mesoionic	862	871	|O
thiadiazolopyrimidine	872	893	|O
.	893	894	|O
The	895	898	|O
nature	899	905	|O
of	906	908	|O
the	909	912	|O
substituents	913	925	|O
on	926	928	|O
the	929	932	|O
mesoionic	933	942	|O
ring	943	947	|O
did	948	951	|O
not	952	955	|O
appear	956	962	|O
to	963	965	|O
have	966	970	|O
marked	971	977	|O
effects	978	985	|O
on	986	988	|O
potency	989	996	|O
unlike	997	1003	|O
the	1004	1007	|O
marked	1008	1014	|O
effect	1015	1021	|O
of	1022	1024	|O
the	1025	1028	|O
nature	1029	1035	|O
of	1036	1038	|O
1,3	1039	1042	|O
-	1042	1043	|O
substituents	1043	1055	|O
on	1056	1058	|O
activity	1059	1067	|O
of	1068	1070	|O
nonmesoionic	1071	1083	|O
xanthines	1084	1093	|O
.	1093	1094	|O
The	1095	1098	|O
benzothiazolo	1099	1112	|B-IUPAC
[	1112	1113	|I-IUPAC
3,2	1113	1116	|I-IUPAC
-	1116	1117	|I-IUPAC
alpha	1117	1122	|I-IUPAC
]	1122	1123	|I-IUPAC
pyrimidines	1123	1134	|I-IUPAC
were	1135	1139	|O
the	1140	1143	|O
most	1144	1148	|O
potent	1149	1155	|O
antagonists	1156	1167	|O
,	1167	1168	|O
being	1169	1174	|O
nearly	1175	1181	|O
as	1182	1184	|O
potent	1185	1191	|O
as	1192	1194	|O
theophylline	1195	1207	|O
at	1208	1210	|O
A1	1211	1213	|O
-	1213	1214	|O
adenosine	1214	1223	|O
receptors	1224	1233	|O
and	1234	1237	|O
somewhat	1238	1246	|O
more	1247	1251	|O
potent	1252	1258	|O
than	1259	1263	|O
theophylline	1264	1276	|O
at	1277	1279	|O
A2	1280	1282	|O
-	1282	1283	|O
adenosine	1283	1292	|O
receptors	1293	1302	|O
.	1302	1303	|O

### abstracts2487.txt
The	0	3	|O
conformational	4	18	|O
characteristics	19	34	|O
of	35	37	|O
two	38	41	|O
series	42	48	|O
of	49	51	|O
5	52	53	|B-IUPAC
-	53	54	|I-IUPAC
hydroxytryptamine	54	71	|I-IUPAC
(	72	73	|O
5	73	74	|O
-	74	75	|O
HT	75	77	|O
)	77	78	|O
receptor	79	87	|O
agonists	88	96	|O
,	96	97	|O
monophenolic	98	110	|B-IUPAC
N	111	112	|I-IUPAC
,	112	113	|I-IUPAC
N	113	114	|I-IUPAC
-	114	115	|I-IUPAC
dialkylated	115	126	|B-MODIFIER
2	127	128	|B-IUPAC
-	128	129	|I-IUPAC
aminotetralins	129	143	|I-IUPAC
and	144	147	|O
trans	148	153	|B-IUPAC
-	153	154	|I-IUPAC
2	154	155	|I-IUPAC
-	155	156	|I-IUPAC
phenylcyclopropylamines	156	179	|I-IUPAC
,	179	180	|O
have	181	185	|O
been	186	190	|O
studied	191	198	|O
by	199	201	|O
a	202	203	|O
combination	204	215	|O
of	216	218	|O
experimental	219	231	|O
(	232	233	|O
NMR	233	236	|O
spectroscopy	237	249	|O
)	249	250	|O
and	251	254	|O
theoretical	255	266	|O
(	267	268	|O
molecular	268	277	|O
mechanics	278	287	|O
and	288	291	|O
MNDO	292	296	|O
calculations	297	309	|O
)	309	310	|O
methods	311	318	|O
.	318	319	|O
In	320	322	|O
addition	323	331	|O
,	331	332	|O
molecular	333	342	|O
electrostatic	343	356	|O
potentials	357	367	|O
have	368	372	|O
been	373	377	|O
calculated	378	388	|O
for	389	392	|O
selected	393	401	|O
conformations	402	415	|O
and	416	419	|O
the	420	423	|O
absolute	424	432	|O
configuration	433	446	|O
of	447	449	|O
the	450	453	|O
potent	454	460	|O
5	461	462	|O
-	462	463	|O
HT	463	465	|O
-	465	466	|O
receptor	466	474	|O
agonist	475	482	|O
(	483	484	|B-IUPAC
+	484	485	|I-IUPAC
)	485	486	|I-IUPAC
-	486	487	|I-IUPAC
cis	487	490	|I-IUPAC
-	490	491	|I-IUPAC
8	491	492	|I-IUPAC
-	492	493	|I-IUPAC
hydroxy	493	500	|I-IUPAC
-	500	501	|I-IUPAC
1	501	502	|I-IUPAC
-	502	503	|I-IUPAC
methyl	503	509	|I-IUPAC
-	509	510	|I-IUPAC
2	510	511	|I-IUPAC
-	511	512	|I-IUPAC
(	512	513	|I-IUPAC
di	513	515	|I-IUPAC
-	515	516	|I-IUPAC
n	516	517	|I-IUPAC
-	517	518	|I-IUPAC
propylamino	518	529	|I-IUPAC
)	529	530	|I-IUPAC
tetralin	530	538	|I-IUPAC
has	539	542	|O
been	543	547	|O
determined	548	558	|O
,	558	559	|O
by	560	562	|O
X	563	564	|O
-	564	565	|O
ray	565	568	|O
crystallography	569	584	|O
of	585	587	|O
the	588	591	|O
synthetic	592	601	|O
precursor	602	611	|O
,	611	612	|O
to	613	615	|O
be	616	618	|O
1S	619	621	|O
,	621	622	|O
2R	622	624	|O
.	624	625	|O
Results	626	633	|O
obtained	634	642	|O
are	643	646	|O
discussed	647	656	|O
in	657	659	|O
terms	660	665	|O
of	666	668	|O
conformational	669	683	|O
,	683	684	|O
steric	685	691	|O
,	691	692	|O
and	693	696	|O
electronic	697	707	|O
requirements	708	720	|O
for	721	724	|O
5	725	726	|O
-	726	727	|O
HT	727	729	|O
-	729	730	|O
receptor	730	738	|O
activation	739	749	|O
.	749	750	|O
It	751	753	|O
is	754	756	|O
suggested	757	766	|O
that	767	771	|O
different	772	781	|O
conformations	782	795	|O
of	796	798	|O
the	799	802	|O
5	803	804	|O
-	804	805	|O
HT	805	807	|O
-	807	808	|O
receptor	808	816	|O
agonists	817	825	|O
(	826	827	|B-IUPAC
1R	827	829	|I-IUPAC
,	829	830	|I-IUPAC
2S	830	832	|I-IUPAC
)	832	833	|I-IUPAC
-	833	834	|I-IUPAC
2	834	835	|I-IUPAC
-	835	836	|I-IUPAC
(	836	837	|I-IUPAC
2	837	838	|I-IUPAC
-	838	839	|I-IUPAC
hydroxyphenyl	839	852	|I-IUPAC
)	852	853	|I-IUPAC
-	853	854	|I-IUPAC
N	854	855	|I-IUPAC
,	855	856	|I-IUPAC
N	856	857	|I-IUPAC
-	857	858	|I-IUPAC
di	858	860	|I-IUPAC
-	860	861	|I-IUPAC
n	861	862	|I-IUPAC
-	862	863	|I-IUPAC
propylcyclopropylamine	863	885	|I-IUPAC
[	886	887	|O
(	887	888	|O
1R	888	890	|O
,	890	891	|O
2S	891	893	|O
)	893	894	|O
-	894	895	|O
4	895	896	|O
]	896	897	|O
and	898	901	|O
its	902	905	|O
3	906	907	|B-IUPAC
-	907	908	|I-IUPAC
hydroxy	908	915	|I-IUPAC
isomer	916	922	|B-MODIFIER
(	923	924	|O
1R	924	926	|O
,	926	927	|O
2S	927	929	|O
)	929	930	|O
-	930	931	|O
5	931	932	|O
are	933	936	|O
able	937	941	|O
to	942	944	|O
activate	945	953	|O
5	954	955	|O
-	955	956	|O
HT	956	958	|O
receptors	959	968	|O
.	968	969	|O
The	970	973	|O
strongly	974	982	|O
increased	983	992	|O
stereoselectivity	993	1010	|O
of	1011	1013	|O
2	1014	1015	|O
,	1015	1016	|O
4	1017	1018	|O
,	1018	1019	|O
and	1020	1023	|O
5	1024	1025	|O
as	1026	1028	|O
compared	1029	1037	|O
to	1038	1040	|O
that	1041	1045	|O
of	1046	1048	|O
8	1049	1050	|B-IUPAC
-	1050	1051	|I-IUPAC
hydroxy	1051	1058	|I-IUPAC
-	1058	1059	|I-IUPAC
2	1059	1060	|I-IUPAC
-	1060	1061	|I-IUPAC
(	1061	1062	|I-IUPAC
di	1062	1064	|I-IUPAC
-	1064	1065	|I-IUPAC
n	1065	1066	|I-IUPAC
-	1066	1067	|I-IUPAC
propylamino	1067	1078	|I-IUPAC
)	1078	1079	|I-IUPAC
tetralin	1079	1087	|I-IUPAC
(	1088	1089	|O
8	1089	1090	|O
-	1090	1091	|O
OH	1091	1093	|O
-	1093	1094	|O
DPAT	1094	1098	|O
;	1098	1099	|O
1	1100	1101	|O
)	1101	1102	|O
is	1103	1105	|O
rationalized	1106	1118	|O
on	1119	1121	|O
the	1122	1125	|O
basis	1126	1131	|O
of	1132	1134	|O
steric	1135	1141	|O
factors	1142	1149	|O
.	1149	1150	|O
Conformational	1151	1165	|O
factors	1166	1173	|O
appear	1174	1180	|O
to	1181	1183	|O
be	1184	1186	|O
responsible	1187	1198	|O
for	1199	1202	|O
the	1203	1206	|O
inability	1207	1216	|O
of	1217	1219	|O
the	1220	1223	|O
trans	1224	1229	|O
-	1229	1230	|O
C1	1230	1232	|O
-	1232	1233	|O
methyl	1233	1239	|O
-	1239	1240	|O
substituted	1240	1251	|O
derivative	1252	1262	|O
of	1263	1265	|O
1	1266	1267	|O
to	1268	1270	|O
activate	1271	1279	|O
5	1280	1281	|O
-	1281	1282	|O
HT	1282	1284	|O
receptors	1285	1294	|O
.	1294	1295	|O

### abstracts2580.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
osteotropic	12	23	|O
(	24	25	|O
bone	25	29	|O
-	29	30	|O
seeking	30	37	|O
)	37	38	|O
[	39	40	|B-IUPAC
(	40	41	|I-IUPAC
bis	41	44	|I-IUPAC
(	44	45	|I-IUPAC
phosphonomethyl	45	60	|I-IUPAC
)	60	61	|I-IUPAC
amino	61	66	|I-IUPAC
-	66	67	|I-IUPAC
kappaN	67	73	|I-IUPAC
)	73	74	|I-IUPAC
acetato	74	81	|I-IUPAC
-	81	82	|I-IUPAC
kappaO	82	88	|I-IUPAC
(	88	89	|I-IUPAC
2	89	90	|I-IUPAC
-	90	91	|I-IUPAC
)	91	92	|I-IUPAC
]	92	93	|I-IUPAC
platinum	93	101	|I-IUPAC
(	101	102	|I-IUPAC
II	102	104	|I-IUPAC
)	104	105	|I-IUPAC
complexes	106	115	|B-MODIFIER
attached	116	124	|O
to	125	127	|O
diammine	128	136	|B-IUPAC
,	136	137	|O
ethane	138	144	|B-IUPAC
-	144	145	|I-IUPAC
1,2	145	148	|I-IUPAC
-	148	149	|I-IUPAC
diamine	149	156	|I-IUPAC
,	156	157	|O
cis	158	161	|B-IUPAC
-	161	162	|I-IUPAC
R	162	163	|I-IUPAC
,	163	164	|I-IUPAC
S	164	165	|I-IUPAC
-	165	166	|I-IUPAC
cyclohexane	166	177	|I-IUPAC
-	177	178	|I-IUPAC
1,2	178	181	|I-IUPAC
-	181	182	|I-IUPAC
diamine	182	189	|I-IUPAC
,	189	190	|O
trans	191	196	|B-IUPAC
-	196	197	|I-IUPAC
S	197	198	|I-IUPAC
,	198	199	|I-IUPAC
S	199	200	|I-IUPAC
-	200	201	|I-IUPAC
cyclohexane	201	212	|I-IUPAC
-	212	213	|I-IUPAC
1,2	213	216	|I-IUPAC
-	216	217	|I-IUPAC
diamine	217	224	|I-IUPAC
,	224	225	|O
or	226	228	|O
trans	229	234	|B-IUPAC
-	234	235	|I-IUPAC
R	235	236	|I-IUPAC
,	236	237	|I-IUPAC
R	237	238	|I-IUPAC
-	238	239	|I-IUPAC
cyclohexane	239	250	|I-IUPAC
-	250	251	|I-IUPAC
1,2	251	254	|I-IUPAC
-	254	255	|I-IUPAC
diamine	255	262	|I-IUPAC
has	263	266	|O
been	267	271	|O
synthesized	272	283	|O
in	284	286	|O
accord	287	293	|O
with	294	298	|O
the	299	302	|O
concept	303	310	|O
of	311	313	|O
drug	314	318	|O
targeting	319	328	|O
and	329	332	|O
characterized	333	346	|O
by	347	349	|O
elemental	350	359	|O
analysis	360	368	|O
,	368	369	|O
(	370	371	|O
1	371	372	|O
)	372	373	|O
H	373	374	|O
,	374	375	|O
(	376	377	|O
13	377	379	|O
)	379	380	|O
C	380	381	|O
,	381	382	|O
and	383	386	|O
(	387	388	|O
31	388	390	|O
)	390	391	|O
P	391	392	|O
NMR	393	396	|O
spectroscopy	397	409	|O
.	409	410	|O
The	411	414	|O
in	415	417	|O
vitro	418	423	|O
antitumor	424	433	|O
activity	434	442	|O
in	443	445	|O
ovarian	446	453	|O
cancer	454	460	|O
cells	461	466	|O
(	467	468	|O
CH1	468	471	|O
)	471	472	|O
has	473	476	|O
been	477	481	|O
determined	482	492	|O
by	493	495	|O
means	496	501	|O
of	502	504	|O
the	505	508	|O
MTT	509	512	|O
assay	513	518	|O
.	518	519	|O
In	520	522	|O
this	523	527	|O
cisplatin	528	537	|O
-	537	538	|O
sensitive	538	547	|O
cell	548	552	|O
line	553	557	|O
the	558	561	|O
complexes	562	571	|O
containing	572	582	|O
cyclohexane	583	594	|B-IUPAC
-	594	595	|I-IUPAC
1,2	595	598	|I-IUPAC
-	598	599	|I-IUPAC
diamine	599	606	|I-IUPAC
(	607	608	|O
chxn	608	612	|O
)	612	613	|O
displayed	614	623	|O
a	624	625	|O
high	626	630	|O
activity	631	639	|O
in	640	642	|O
comparison	643	653	|O
to	654	656	|O
the	657	660	|O
diammine	661	669	|B-IUPAC
and	670	673	|O
ethane	674	680	|B-IUPAC
-	680	681	|I-IUPAC
1,2	681	684	|I-IUPAC
-	684	685	|I-IUPAC
diamine	685	692	|I-IUPAC
counterparts	693	705	|O
.	705	706	|O
In	707	709	|O
agreement	710	719	|O
with	720	724	|O
structure	725	734	|O
-	734	735	|O
activity	735	743	|O
relationships	744	757	|O
of	758	760	|O
other	761	766	|O
chxn	767	771	|O
-	771	772	|O
containing	772	782	|O
platinum	783	791	|O
(	791	792	|O
II	792	794	|O
)	794	795	|O
complexes	796	805	|O
both	806	810	|O
[	811	812	|B-IUPAC
(	812	813	|I-IUPAC
bis	813	816	|I-IUPAC
(	816	817	|I-IUPAC
phosphonomethyl	817	832	|I-IUPAC
)	832	833	|I-IUPAC
amino	833	838	|I-IUPAC
-	838	839	|I-IUPAC
kappaN	839	845	|I-IUPAC
)	845	846	|I-IUPAC
acetato	846	853	|I-IUPAC
-	853	854	|I-IUPAC
kappaO	854	860	|I-IUPAC
(	860	861	|I-IUPAC
2	861	862	|I-IUPAC
-	862	863	|I-IUPAC
)	863	864	|I-IUPAC
]	864	865	|I-IUPAC
(	865	866	|I-IUPAC
trans	866	871	|I-IUPAC
-	871	872	|I-IUPAC
cyclohexane	872	883	|I-IUPAC
-	883	884	|I-IUPAC
1,2	884	887	|I-IUPAC
-	887	888	|I-IUPAC
diamine	888	895	|I-IUPAC
)	895	896	|I-IUPAC
platinum	896	904	|I-IUPAC
(	904	905	|I-IUPAC
II	905	907	|I-IUPAC
)	907	908	|I-IUPAC
complexes	909	918	|B-MODIFIER
show	919	923	|O
superior	924	932	|O
potency	933	940	|O
than	941	945	|O
the	946	949	|O
corresponding	950	963	|O
cis	964	967	|O
-	967	968	|O
congener	968	976	|O
whereas	977	984	|O
the	985	988	|O
trans	989	994	|O
-	994	995	|O
R	995	996	|O
,	996	997	|O
R	997	998	|O
isomer	999	1005	|O
displays	1006	1014	|O
the	1015	1018	|O
highest	1019	1026	|O
activity	1027	1035	|O
.	1035	1036	|O
Within	1037	1043	|O
the	1044	1047	|O
series	1048	1054	|O
of	1055	1057	|O
complexes	1058	1067	|O
under	1068	1073	|O
investigation	1074	1087	|O
,	1087	1088	|O
potency	1089	1096	|O
decreases	1097	1106	|O
depending	1107	1116	|O
on	1117	1119	|O
the	1120	1123	|O
coordinated	1124	1135	|O
amine	1136	1141	|O
ligand	1142	1148	|O
in	1149	1151	|O
the	1152	1155	|O
following	1156	1165	|O
order	1166	1171	|O
:	1171	1172	|O
trans	1173	1178	|O
-	1178	1179	|O
R	1179	1180	|O
,	1180	1181	|O
R	1181	1182	|O
-	1182	1183	|O
chxn	1183	1187	|O
&	1188	1189	|O
gt	1189	1191	|O
;	1191	1192	|O
trans	1193	1198	|O
-	1198	1199	|O
S	1199	1200	|O
,	1200	1201	|O
S	1201	1202	|O
-	1202	1203	|O
chxn	1203	1207	|O
&	1208	1209	|O
gt	1209	1211	|O
;	1211	1212	|O
NH	1213	1215	|O
(	1215	1216	|O
3	1216	1217	|O
)	1217	1218	|O
&	1219	1220	|O
gt	1220	1222	|O
;	1222	1223	|O
or	1224	1226	|O
=	1227	1228	|O
cis	1229	1232	|O
-	1232	1233	|O
R	1233	1234	|O
,	1234	1235	|O
S	1235	1236	|O
-	1236	1237	|O
chxn	1237	1241	|O
&	1242	1243	|O
gt	1243	1245	|O
;	1245	1246	|O
en	1247	1249	|O
.	1249	1250	|O

### abstracts3597.txt
Rotationally	0	12	|O
restricted	13	23	|O
analogues	24	33	|O
of	34	36	|O
5	37	38	|B-IUPAC
-	38	39	|I-IUPAC
deazapteroyl	39	51	|I-IUPAC
-	51	52	|I-IUPAC
L	52	53	|I-IUPAC
-	53	54	|I-IUPAC
glutamate	54	63	|I-IUPAC
and	64	67	|O
(	68	69	|B-IUPAC
6R	69	71	|I-IUPAC
,	71	72	|I-IUPAC
6S	72	74	|I-IUPAC
)	74	75	|I-IUPAC
-	75	76	|I-IUPAC
5	76	77	|I-IUPAC
-	77	78	|I-IUPAC
deaza	78	83	|I-IUPAC
-	83	84	|I-IUPAC
5,6,7,8	84	91	|I-IUPAC
-	91	92	|I-IUPAC
tetrahydropteroyl	92	109	|I-IUPAC
-	109	110	|I-IUPAC
L	110	111	|I-IUPAC
-	111	112	|I-IUPAC
glutamate	112	121	|I-IUPAC
with	122	126	|O
a	127	128	|O
one	129	132	|O
-	132	133	|O
carbon	133	139	|O
bridge	140	146	|O
between	147	154	|O
the	155	158	|O
amide	159	164	|O
nitrogen	165	173	|O
and	174	177	|O
the	178	181	|O
6'	182	184	|O
-	184	185	|O
position	185	193	|O
of	194	196	|O
the	197	200	|O
p	201	202	|B-IUPAC
-	202	203	|I-IUPAC
aminobenzoyl	203	215	|I-IUPAC
moiety	216	222	|B-MODIFIER
were	223	227	|O
synthesized	228	239	|O
and	240	243	|O
tested	244	250	|O
as	251	253	|O
substrates	254	264	|O
for	265	268	|O
folylpolyglutamate	269	287	|O
synthetase	288	298	|O
(	299	300	|O
FPGS	300	304	|O
)	304	305	|O
,	305	306	|O
a	307	308	|O
key	309	312	|O
enzyme	313	319	|O
in	320	322	|O
folate	323	329	|O
metabolism	330	340	|O
and	341	344	|O
an	345	347	|O
important	348	357	|O
determinant	358	369	|O
of	370	372	|O
the	373	376	|O
therapeutic	377	388	|O
potency	389	396	|O
and	397	400	|O
selectivity	401	412	|O
of	413	415	|O
classical	416	425	|O
antifolates	426	437	|O
.	437	438	|O
The	439	442	|O
corresponding	443	456	|O
bridged	457	464	|O
analogues	465	474	|O
of	475	477	|O
5	478	479	|B-IUPAC
-	479	480	|I-IUPAC
deazapteroyl	480	492	|I-IUPAC
-	492	493	|I-IUPAC
L	493	494	|I-IUPAC
-	494	495	|I-IUPAC
ornithine	495	504	|I-IUPAC
and	505	508	|O
(	509	510	|B-IUPAC
6R	510	512	|I-IUPAC
,	512	513	|I-IUPAC
6S	513	515	|I-IUPAC
)	515	516	|I-IUPAC
-	516	517	|I-IUPAC
5	517	518	|I-IUPAC
-	518	519	|I-IUPAC
deaza	519	524	|I-IUPAC
-	524	525	|I-IUPAC
5,6,7	525	530	|I-IUPAC
,	530	531	|I-IUPAC
8	532	533	|I-IUPAC
-	533	534	|I-IUPAC
tetrahydropteroyl	534	551	|I-IUPAC
-	551	552	|I-IUPAC
L	552	553	|I-IUPAC
-	553	554	|I-IUPAC
ornithine	554	563	|I-IUPAC
were	564	568	|O
also	569	573	|O
synthesized	574	585	|O
as	586	588	|O
potential	589	598	|O
inhibitors	599	609	|O
.	609	610	|O
Condensation	611	623	|O
of	624	626	|O
diethyl	627	634	|B-IUPAC
L	635	636	|I-IUPAC
-	636	637	|I-IUPAC
glutamate	637	646	|I-IUPAC
with	647	651	|O
methyl	652	658	|B-IUPAC
2	659	660	|I-IUPAC
-	660	661	|I-IUPAC
bromomethyl	661	672	|I-IUPAC
-	672	673	|I-IUPAC
4	673	674	|I-IUPAC
-	674	675	|I-IUPAC
nitrobenzoate	675	688	|I-IUPAC
followed	689	697	|O
by	698	700	|O
catalytic	701	710	|O
reduction	711	720	|O
of	721	723	|O
the	724	727	|O
nitro	728	733	|O
group	734	739	|O
,	739	740	|O
reductive	741	750	|O
coupling	751	759	|O
with	760	764	|O
2	765	766	|B-IUPAC
-	766	767	|I-IUPAC
acetamido	767	776	|I-IUPAC
-	776	777	|I-IUPAC
6	777	778	|I-IUPAC
-	778	779	|I-IUPAC
formylpyrido	779	791	|I-IUPAC
[	791	792	|I-IUPAC
2	792	793	|I-IUPAC
,	793	794	|I-IUPAC
3	795	796	|I-IUPAC
-	796	797	|I-IUPAC
d	797	798	|I-IUPAC
]	798	799	|I-IUPAC
pyrimidin	799	808	|I-IUPAC
-	808	809	|I-IUPAC
4	809	810	|I-IUPAC
(	810	811	|I-IUPAC
3H	811	813	|I-IUPAC
)	813	814	|I-IUPAC
-	814	815	|I-IUPAC
one	815	818	|I-IUPAC
in	819	821	|O
the	822	825	|O
presence	826	834	|O
of	835	837	|O
dimethylaminoborane	838	857	|O
,	857	858	|O
and	859	862	|O
acidolysis	863	873	|O
with	874	878	|O
HBr	879	882	|O
/	882	883	|O
AcOH	883	887	|O
yielded	888	895	|O
2	896	897	|B-IUPAC
-	897	898	|I-IUPAC
L	898	899	|I-IUPAC
-	899	900	|I-IUPAC
[	900	901	|I-IUPAC
5	901	902	|I-IUPAC
-	902	903	|I-IUPAC
[	903	904	|I-IUPAC
N	904	905	|I-IUPAC
-	905	906	|I-IUPAC
(	906	907	|I-IUPAC
2	907	908	|I-IUPAC
-	908	909	|I-IUPAC
acetamido	909	918	|I-IUPAC
-	918	919	|I-IUPAC
4	919	920	|I-IUPAC
(	920	921	|I-IUPAC
3H	921	923	|I-IUPAC
)	923	924	|I-IUPAC
-	924	925	|I-IUPAC
oxopyrido	925	934	|I-IUPAC
[	934	935	|I-IUPAC
2	935	936	|I-IUPAC
,	936	937	|I-IUPAC
3	938	939	|I-IUPAC
-	939	940	|I-IUPAC
d	940	941	|I-IUPAC
]	941	942	|I-IUPAC
pyrimidin	942	951	|I-IUPAC
-	951	952	|I-IUPAC
6	952	953	|I-IUPAC
-	953	954	|I-IUPAC
yl	954	956	|I-IUPAC
)	956	957	|I-IUPAC
methylamino	957	968	|I-IUPAC
]	968	969	|I-IUPAC
-	969	970	|I-IUPAC
2	970	971	|I-IUPAC
,	971	972	|I-IUPAC
3	973	974	|I-IUPAC
-	974	975	|I-IUPAC
dihydro	975	982	|I-IUPAC
-	982	983	|I-IUPAC
1	983	984	|I-IUPAC
-	984	985	|I-IUPAC
oxo	985	988	|I-IUPAC
-	988	989	|I-IUPAC
2	989	990	|I-IUPAC
(	990	991	|I-IUPAC
1H	991	993	|I-IUPAC
)	993	994	|I-IUPAC
-	994	995	|I-IUPAC
isoindolyl	995	1005	|I-IUPAC
]	1005	1006	|I-IUPAC
glutaric	1006	1014	|I-IUPAC
acid	1015	1019	|I-IUPAC
(	1020	1021	|O
1	1021	1022	|O
)	1022	1023	|O
.	1023	1024	|O
When	1025	1029	|O
acidolysis	1030	1040	|O
was	1041	1044	|O
preceded	1045	1053	|O
by	1054	1056	|O
catalytic	1057	1066	|O
hydrogenation	1067	1080	|O
,	1080	1081	|O
the	1082	1085	|O
final	1086	1091	|O
product	1092	1099	|O
was	1100	1103	|O
the	1104	1107	|O
corresponding	1108	1121	|O
(	1122	1123	|O
6R	1123	1125	|O
,	1125	1126	|O
6S	1126	1128	|O
)	1128	1129	|O
-	1129	1130	|O
tetrahydro	1130	1140	|O
derivative	1141	1151	|O
2	1152	1153	|O
.	1153	1154	|O
A	1155	1156	|O
similar	1157	1164	|O
sequence	1165	1173	|O
starting	1174	1182	|O
from	1183	1187	|O
methyl	1188	1194	|B-IUPAC
N	1195	1196	|I-IUPAC
(	1196	1197	|I-IUPAC
delta	1197	1202	|I-IUPAC
)	1202	1203	|I-IUPAC
-	1203	1204	|I-IUPAC
benzyloxycarbonyl	1204	1221	|I-IUPAC
-	1221	1222	|I-IUPAC
L	1222	1223	|I-IUPAC
-	1223	1224	|I-IUPAC
ornithine	1224	1233	|I-IUPAC
led	1234	1237	|O
to	1238	1240	|O
2	1241	1242	|B-IUPAC
-	1242	1243	|I-IUPAC
L	1243	1244	|I-IUPAC
-	1244	1245	|I-IUPAC
[	1245	1246	|I-IUPAC
5	1246	1247	|I-IUPAC
-	1247	1248	|I-IUPAC
[	1248	1249	|I-IUPAC
N	1249	1250	|I-IUPAC
-	1250	1251	|I-IUPAC
(	1251	1252	|I-IUPAC
2	1252	1253	|I-IUPAC
-	1253	1254	|I-IUPAC
amino	1254	1259	|I-IUPAC
-	1259	1260	|I-IUPAC
4	1260	1261	|I-IUPAC
(	1261	1262	|I-IUPAC
3H	1262	1264	|I-IUPAC
)	1264	1265	|I-IUPAC
-	1265	1266	|I-IUPAC
oxopyrido	1266	1275	|I-IUPAC
[	1275	1276	|I-IUPAC
2	1276	1277	|I-IUPAC
,	1277	1278	|I-IUPAC
3	1279	1280	|I-IUPAC
-	1280	1281	|I-IUPAC
d	1281	1282	|I-IUPAC
]	1282	1283	|I-IUPAC
pyrimidin	1283	1292	|I-IUPAC
-	1292	1293	|I-IUPAC
6	1293	1294	|I-IUPAC
-	1294	1295	|I-IUPAC
yl	1295	1297	|I-IUPAC
)	1297	1298	|I-IUPAC
methylamino	1298	1309	|I-IUPAC
]	1309	1310	|I-IUPAC
-	1310	1311	|I-IUPAC
2	1311	1312	|I-IUPAC
,	1312	1313	|I-IUPAC
3	1314	1315	|I-IUPAC
-	1315	1316	|I-IUPAC
dihydro	1316	1323	|I-IUPAC
-	1323	1324	|I-IUPAC
1	1324	1325	|I-IUPAC
-	1325	1326	|I-IUPAC
oxo	1326	1329	|I-IUPAC
-	1329	1330	|I-IUPAC
2	1330	1331	|I-IUPAC
(	1331	1332	|I-IUPAC
1H	1332	1334	|I-IUPAC
)	1334	1335	|I-IUPAC
-	1335	1336	|I-IUPAC
isoindolyl	1336	1346	|I-IUPAC
]	1346	1347	|I-IUPAC
-	1347	1348	|I-IUPAC
5	1348	1349	|I-IUPAC
-	1349	1350	|I-IUPAC
aminopentanoic	1350	1364	|I-IUPAC
acid	1365	1369	|I-IUPAC
(	1370	1371	|O
3	1371	1372	|O
)	1372	1373	|O
and	1374	1377	|O
the	1378	1381	|O
(	1382	1383	|B-IUPAC
6R	1383	1385	|I-IUPAC
,	1385	1386	|I-IUPAC
6S	1386	1388	|I-IUPAC
)	1388	1389	|I-IUPAC
-	1389	1390	|I-IUPAC
tetrahydro	1390	1400	|I-IUPAC
derivative	1401	1411	|B-MODIFIER
4	1412	1413	|O
.	1413	1414	|O
Compounds	1415	1424	|O
3	1425	1426	|O
and	1427	1430	|O
4	1431	1432	|O
were	1433	1437	|O
powerful	1438	1446	|O
inhibitors	1447	1457	|O
of	1458	1460	|O
recombinant	1461	1472	|O
human	1473	1478	|O
FPGS	1479	1483	|O
,	1483	1484	|O
whereas	1485	1492	|O
1	1493	1494	|O
and	1495	1498	|O
2	1499	1500	|O
were	1501	1505	|O
exceptionally	1506	1519	|O
efficient	1520	1529	|O
FPGS	1530	1534	|O
substrates	1535	1545	|O
,	1545	1546	|O
with	1547	1551	|O
the	1552	1555	|O
reduced	1556	1563	|O
compound	1564	1572	|O
2	1573	1574	|O
giving	1575	1581	|O
a	1582	1583	|O
K	1584	1585	|O
(	1585	1586	|O
m	1586	1587	|O
)	1587	1588	|O
(	1589	1590	|O
0.018	1590	1595	|O
microM	1596	1602	|O
)	1602	1603	|O
lower	1604	1609	|O
than	1610	1614	|O
that	1615	1619	|O
of	1620	1622	|O
any	1623	1626	|O
other	1627	1632	|O
substrate	1633	1642	|O
identified	1643	1653	|O
to	1654	1656	|O
date	1657	1661	|O
.	1661	1662	|O
(	1663	1664	|B-IUPAC
6R	1664	1666	|I-IUPAC
,	1666	1667	|I-IUPAC
6S	1667	1669	|I-IUPAC
)	1669	1670	|I-IUPAC
-	1670	1671	|I-IUPAC
5	1671	1672	|I-IUPAC
-	1672	1673	|I-IUPAC
Deazatetrahydrofolate	1673	1694	|I-IUPAC
,	1694	1695	|O
in	1696	1698	|O
which	1699	1704	|O
the	1705	1708	|O
side	1709	1713	|O
chain	1714	1719	|O
is	1720	1722	|O
free	1723	1727	|O
to	1728	1730	|O
rotate	1731	1737	|O
,	1737	1738	|O
was	1739	1742	|O
rapidly	1743	1750	|O
converted	1751	1760	|O
to	1761	1763	|O
long	1764	1768	|O
-	1768	1769	|O
chain	1769	1774	|O
polyglutamates	1775	1789	|O
.	1789	1790	|O
In	1791	1793	|O
contrast	1794	1802	|O
,	1802	1803	|O
the	1804	1807	|O
reaction	1808	1816	|O
of	1817	1819	|O
1	1820	1821	|O
and	1822	1825	|O
2	1826	1827	|O
was	1828	1831	|O
limited	1832	1839	|O
to	1840	1842	|O
the	1843	1846	|O
addition	1847	1855	|O
of	1856	1858	|O
a	1859	1860	|O
single	1861	1867	|O
molecule	1868	1876	|O
of	1877	1879	|O
glutamic	1880	1888	|O
acid	1889	1893	|O
.	1893	1894	|O
Hence	1895	1900	|O
rotational	1901	1911	|O
restriction	1912	1923	|O
of	1924	1926	|O
the	1927	1930	|O
side	1931	1935	|O
chain	1936	1941	|O
did	1942	1945	|O
not	1946	1949	|O
interfere	1950	1959	|O
with	1960	1964	|O
the	1965	1968	|O
initial	1969	1976	|O
FPGS	1977	1981	|O
-	1981	1982	|O
catalyzed	1982	1991	|O
reaction	1992	2000	|O
and	2001	2004	|O
indeed	2005	2011	|O
seemed	2012	2018	|O
to	2019	2021	|O
facilitate	2022	2032	|O
it	2033	2035	|O
,	2035	2036	|O
but	2037	2040	|O
the	2041	2044	|O
ensuing	2045	2052	|O
gamma	2053	2058	|O
-	2058	2059	|O
glutamyl	2059	2067	|O
adduct	2068	2074	|O
was	2075	2078	|O
no	2079	2081	|O
longer	2082	2088	|O
an	2089	2091	|O
efficient	2092	2101	|O
substrate	2102	2111	|O
for	2112	2115	|O
the	2116	2119	|O
enzyme	2120	2126	|O
.	2126	2127	|O

### abstracts1708.txt
[	0	1	|B-IUPAC
1	1	2	|I-IUPAC
]	2	3	|I-IUPAC
Benzothieno	3	14	|I-IUPAC
[	14	15	|I-IUPAC
2,3	15	18	|I-IUPAC
-	18	19	|I-IUPAC
c	19	20	|I-IUPAC
]	20	21	|I-IUPAC
pyridines	21	30	|I-IUPAC
(	31	32	|O
10a	32	35	|O
-	35	36	|O
c	36	37	|O
,	37	38	|O
11	39	41	|O
,	41	42	|O
12a	43	46	|O
-	46	47	|O
t	47	48	|O
,	48	49	|O
and	50	53	|O
13a	54	57	|O
,	57	58	|O
b	58	59	|O
)	59	60	|O
and	61	64	|O
1,2,3,4	65	72	|B-IUPAC
-	72	73	|I-IUPAC
tetrahydro	73	83	|I-IUPAC
[	83	84	|I-IUPAC
1	84	85	|I-IUPAC
]	85	86	|I-IUPAC
benzothieno	86	97	|I-IUPAC
[	97	98	|I-IUPAC
2,3	98	101	|I-IUPAC
-	101	102	|I-IUPAC
c	102	103	|I-IUPAC
]	103	104	|I-IUPAC
pyridines	104	113	|I-IUPAC
(	114	115	|O
3a	115	117	|O
-	117	118	|O
c	118	119	|O
,	119	120	|O
7	121	122	|O
,	122	123	|O
8a	124	126	|O
-	126	127	|O
c	127	128	|O
,	128	129	|O
and	130	133	|O
9	134	135	|O
)	135	136	|O
were	137	141	|O
synthesized	142	153	|O
.	153	154	|O
The	155	158	|O
compounds	159	168	|O
are	169	172	|O
bioisosteres	173	185	|O
of	186	188	|O
beta	189	193	|O
-	193	194	|O
carbolines	194	204	|O
and	205	208	|O
1,2,3,4	209	216	|B-IUPAC
-	216	217	|I-IUPAC
tetrahydro	217	227	|I-IUPAC
-	227	228	|I-IUPAC
beta	228	232	|I-IUPAC
-	232	233	|I-IUPAC
carbolines	233	243	|I-IUPAC
where	244	249	|O
the	250	253	|O
indole	254	260	|O
nitrogen	261	269	|O
is	270	272	|O
replaced	273	281	|O
by	282	284	|O
sulfur	285	291	|O
.	291	292	|O
Their	293	298	|O
pharmacological	299	314	|O
activity	315	323	|O
was	324	327	|O
evaluated	328	337	|O
in	338	340	|O
a	341	342	|O
water	343	348	|O
lick	349	353	|O
conflict	354	362	|O
test	363	367	|O
in	368	370	|O
rats	371	375	|O
and	376	379	|O
a	380	381	|O
passive	382	389	|O
avoidance	390	399	|O
test	400	404	|O
in	405	407	|O
mice	408	412	|O
.	412	413	|O
In	414	416	|O
the	417	420	|O
1,2,3,4	421	428	|B-IUPAC
-	428	429	|I-IUPAC
tetrahydro	429	439	|I-IUPAC
[	439	440	|I-IUPAC
1	440	441	|I-IUPAC
]	441	442	|I-IUPAC
benzothieno	442	453	|I-IUPAC
[	453	454	|I-IUPAC
2,3	454	457	|I-IUPAC
-	457	458	|I-IUPAC
c	458	459	|I-IUPAC
]	459	460	|I-IUPAC
pyridine	460	468	|I-IUPAC
series	469	475	|B-MODIFIER
,	475	476	|O
the	477	480	|O
presence	481	489	|O
of	490	492	|O
ethyl	493	498	|O
ester	499	504	|O
(	505	506	|O
3b	506	508	|O
)	508	509	|O
or	510	512	|O
cyclohexyl	513	523	|O
carboxamide	524	535	|O
(	536	537	|O
7	537	538	|O
)	538	539	|O
groups	540	546	|O
at	547	549	|O
C	550	551	|O
-	551	552	|O
3	552	553	|O
conferred	554	563	|O
good	564	568	|O
anticonflict	569	581	|O
activity	582	590	|O
and	591	594	|O
lessening	595	604	|O
of	605	607	|O
memory	608	614	|O
impairment	615	625	|O
,	625	626	|O
while	627	632	|O
N	633	634	|O
-	634	635	|O
acylation	635	644	|O
of	645	647	|O
3b	648	650	|O
abolished	651	660	|O
activity	661	669	|O
.	669	670	|O
In	671	673	|O
the	674	677	|O
[	678	679	|B-IUPAC
1	679	680	|I-IUPAC
]	680	681	|I-IUPAC
benzothieno	681	692	|I-IUPAC
(	692	693	|I-IUPAC
2,3	693	696	|I-IUPAC
-	696	697	|I-IUPAC
c	697	698	|I-IUPAC
]	698	699	|I-IUPAC
pyridine	699	707	|I-IUPAC
series	708	714	|B-MODIFIER
,	714	715	|O
the	716	719	|O
aminoethyl	720	730	|B-IUPAC
carboxamide	731	742	|I-IUPAC
(	743	744	|O
12a	744	747	|O
)	747	748	|O
group	749	754	|B-MODIFIER
at	755	757	|O
C	758	759	|O
-	759	760	|O
3	760	761	|O
also	762	766	|O
conferred	767	776	|O
activity	777	785	|O
,	785	786	|O
but	787	790	|O
other	791	796	|O
amides	797	803	|O
studied	804	811	|O
were	812	816	|O
not	817	820	|O
active	821	827	|O
.	827	828	|O
The	829	832	|O
most	833	837	|O
potent	838	844	|O
compounds	845	854	|O
(	855	856	|O
3b	856	858	|O
,	858	859	|O
7	860	861	|O
,	861	862	|O
and	863	866	|O
12a	867	870	|O
)	870	871	|O
were	872	876	|O
also	877	881	|O
administered	882	894	|O
orally	895	901	|O
and	902	905	|O
had	906	909	|O
potent	910	916	|O
anticonflict	917	929	|O
and	930	933	|O
antiscopolamine	934	949	|O
amnesia	950	957	|O
-	957	958	|O
reversal	958	966	|O
activity	967	975	|O
.	975	976	|O
These	977	982	|O
compounds	983	992	|O
did	993	996	|O
not	997	1000	|O
bind	1001	1005	|O
to	1006	1008	|O
the	1009	1012	|O
BZP	1013	1016	|O
receptor	1017	1025	|O
in	1026	1028	|O
spite	1029	1034	|O
of	1035	1037	|O
having	1038	1044	|O
structures	1045	1055	|O
similar	1056	1063	|O
to	1064	1066	|O
those	1067	1072	|O
of	1073	1075	|O
beta	1076	1080	|O
-	1080	1081	|O
carbolines	1081	1091	|O
.	1091	1092	|O
Compound	1093	1101	|O
7	1102	1103	|O
bound	1104	1109	|O
strongly	1110	1118	|O
to	1119	1121	|O
5	1122	1123	|O
-	1123	1124	|O
HT1A	1124	1128	|O
receptors	1129	1138	|O
and	1139	1142	|O
would	1143	1148	|O
be	1149	1151	|O
expected	1152	1160	|O
to	1161	1163	|O
be	1164	1166	|O
a	1167	1168	|O
novel	1169	1174	|O
anxiolytic	1175	1185	|O
.	1185	1186	|O

### abstracts1609.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
new	12	15	|O
dipeptidyl	16	26	|O
alpha	27	32	|O
-	32	33	|O
keto	33	37	|O
amides	38	44	|O
of	45	47	|O
the	48	51	|O
general	52	59	|O
structure	60	69	|O
R1	70	72	|O
-	72	73	|O
L	73	74	|O
-	74	75	|O
Leu	75	78	|O
-	78	79	|O
D	79	80	|O
,	80	81	|O
L	81	82	|O
-	82	83	|O
AA	83	85	|O
-	85	86	|O
CONH	86	90	|O
-	90	91	|O
R2	91	93	|O
were	94	98	|O
synthesized	99	110	|O
and	111	114	|O
evaluated	115	124	|O
as	125	127	|O
inhibitors	128	138	|O
for	139	142	|O
the	143	146	|O
cysteine	147	155	|O
proteases	156	165	|O
calpain	166	173	|O
I	174	175	|O
,	175	176	|O
calpain	177	184	|O
II	185	187	|O
,	187	188	|O
and	189	192	|O
cathepsin	193	202	|O
B	203	204	|O
.	204	205	|O
They	206	210	|O
combine	211	218	|O
10	219	221	|O
different	222	231	|O
N	232	233	|O
-	233	234	|O
protecting	234	244	|O
groups	245	251	|O
(	252	253	|O
R1	253	255	|O
)	255	256	|O
,	256	257	|O
3	258	259	|O
amino	260	265	|O
acids	266	271	|O
residues	272	280	|O
in	281	283	|O
P1	284	286	|O
(	287	288	|O
AA	288	290	|O
)	290	291	|O
,	291	292	|O
and	293	296	|O
44	297	299	|O
distinct	300	308	|O
substituents	309	321	|O
on	322	324	|O
the	325	328	|O
alpha	329	334	|O
-	334	335	|O
keto	335	339	|O
amide	340	345	|O
nitrogen	346	354	|O
(	355	356	|O
R2	356	358	|O
)	358	359	|O
.	359	360	|O
In	361	363	|O
general	364	371	|O
,	371	372	|O
calpain	373	380	|O
II	381	383	|O
was	384	387	|O
more	388	392	|O
sensitive	393	402	|O
to	403	405	|O
these	406	411	|O
inhibitors	412	422	|O
than	423	427	|O
calpain	428	435	|O
I	436	437	|O
,	437	438	|O
with	439	443	|O
a	444	445	|O
large	446	451	|O
number	452	458	|O
of	459	461	|O
inhibitors	462	472	|O
displaying	473	483	|O
dissociation	484	496	|O
constants	497	506	|O
(	507	508	|O
Ki	508	510	|O
)	510	511	|O
in	512	514	|O
the	515	518	|O
10-100	519	525	|O
nM	526	528	|O
range	529	534	|O
.	534	535	|O
Calpain	536	543	|O
I	544	545	|O
was	546	549	|O
also	550	554	|O
effectively	555	566	|O
inhibited	567	576	|O
,	576	577	|O
but	578	581	|O
very	582	586	|O
low	587	590	|O
Ki	591	593	|O
values	594	600	|O
were	601	605	|O
observed	606	614	|O
with	615	619	|O
a	620	621	|O
smaller	622	629	|O
number	630	636	|O
of	637	639	|O
inhibitors	640	650	|O
than	651	655	|O
with	656	660	|O
calpain	661	668	|O
II	669	671	|O
.	671	672	|O
Cathepsin	673	682	|O
B	683	684	|O
was	685	688	|O
weakly	689	695	|O
inhibited	696	705	|O
by	706	708	|O
most	709	713	|O
compounds	714	723	|O
in	724	726	|O
this	727	731	|O
study	732	737	|O
.	737	738	|O
The	739	742	|O
best	743	747	|O
inhibitors	748	758	|O
for	759	762	|O
calpain	763	770	|O
II	771	773	|O
were	774	778	|O
Z	779	780	|O
-	780	781	|O
Leu	781	784	|O
-	784	785	|O
Abu	785	788	|O
-	788	789	|O
CONH	789	793	|O
-	793	794	|O
CH2	794	797	|O
-	797	798	|O
CHOH	798	802	|O
-	802	803	|O
C6H5	803	807	|O
(	808	809	|O
Ki	809	811	|O
=	812	813	|O
15	814	816	|O
nM	817	819	|O
)	819	820	|O
,	820	821	|O
Z	822	823	|O
-	823	824	|O
Leu	824	827	|O
-	827	828	|O
Abu	828	831	|O
-	831	832	|O
CONH	832	836	|O
-	836	837	|O
CH2	837	840	|O
-	840	841	|O
2	841	842	|O
-	842	843	|O
pyridyl	843	850	|O
(	851	852	|O
Ki	852	854	|O
=	855	856	|O
17	857	859	|O
nM	860	862	|O
)	862	863	|O
,	863	864	|O
and	865	868	|O
Z	869	870	|O
-	870	871	|O
Leu	871	874	|O
-	874	875	|O
Abu	875	878	|O
-	878	879	|O
CONH	879	883	|O
-	883	884	|O
CH2	884	887	|O
-	887	888	|O
C6H3	888	892	|O
(	892	893	|O
3,5	893	896	|O
(	896	897	|O
OMe	897	900	|O
)	900	901	|O
2	901	902	|O
)	902	903	|O
(	904	905	|O
Ki	905	907	|O
=	908	909	|O
22	910	912	|O
nM	913	915	|O
)	915	916	|O
.	916	917	|O
The	918	921	|O
best	922	926	|O
calpain	927	934	|O
I	935	936	|O
inhibitor	937	946	|O
in	947	949	|O
this	950	954	|O
study	955	960	|O
was	961	964	|O
Z	965	966	|O
-	966	967	|O
Leu	967	970	|O
-	970	971	|O
Nva	971	974	|O
-	974	975	|O
CONH	975	979	|O
-	979	980	|O
CH2	980	983	|O
-	983	984	|O
2	984	985	|O
-	985	986	|O
pyridyl	986	993	|O
(	994	995	|O
Ki	995	997	|O
=	998	999	|O
19	1000	1002	|O
nM	1003	1005	|O
)	1005	1006	|O
.	1006	1007	|O
The	1008	1011	|O
peptide	1012	1019	|O
alpha	1020	1025	|O
-	1025	1026	|O
keto	1026	1030	|O
amide	1031	1036	|O
Z	1037	1038	|O
-	1038	1039	|O
Leu	1039	1042	|O
-	1042	1043	|O
Abu	1043	1046	|O
-	1046	1047	|O
CONH	1047	1051	|O
-	1051	1052	|O
(	1052	1053	|O
CH2	1053	1056	|O
)	1056	1057	|O
2-3	1057	1060	|O
-	1060	1061	|O
indolyl	1061	1068	|O
was	1069	1072	|O
the	1073	1076	|O
best	1077	1081	|O
inhibitor	1082	1091	|O
for	1092	1095	|O
cathepsin	1096	1105	|O
B	1106	1107	|O
(	1108	1109	|O
Ki	1109	1111	|O
=	1112	1113	|O
31	1114	1116	|O
nM	1117	1119	|O
)	1119	1120	|O
.	1120	1121	|O
Some	1122	1126	|O
compounds	1127	1136	|O
acted	1137	1142	|O
as	1143	1145	|O
specific	1146	1154	|O
calpain	1155	1162	|O
inhibitors	1163	1173	|O
,	1173	1174	|O
with	1175	1179	|O
comparable	1180	1190	|O
activity	1191	1199	|O
on	1200	1202	|O
both	1203	1207	|O
calpains	1208	1216	|O
I	1217	1218	|O
and	1219	1222	|O
II	1223	1225	|O
and	1226	1229	|O
a	1230	1231	|O
lack	1232	1236	|O
of	1237	1239	|O
activity	1240	1248	|O
on	1249	1251	|O
cathepsin	1252	1261	|O
B	1262	1263	|O
(	1264	1265	|O
e.g.	1265	1269	|O
,	1269	1270	|O
40	1271	1273	|O
,	1273	1274	|O
42	1275	1277	|O
,	1277	1278	|O
48	1279	1281	|O
,	1281	1282	|O
70	1283	1285	|O
)	1285	1286	|O
.	1286	1287	|O
Others	1288	1294	|O
were	1295	1299	|O
specific	1300	1308	|O
inhibitors	1309	1319	|O
for	1320	1323	|O
calpain	1324	1331	|O
I	1332	1333	|O
(	1334	1335	|O
e.g.	1335	1339	|O
,	1339	1340	|O
73	1341	1343	|O
)	1343	1344	|O
or	1345	1347	|O
calpain	1348	1355	|O
II	1356	1358	|O
(	1359	1360	|O
e.g.	1360	1364	|O
,	1364	1365	|O
18	1366	1368	|O
,	1368	1369	|O
19	1370	1372	|O
,	1372	1373	|O
33	1374	1376	|O
,	1376	1377	|O
35	1378	1380	|O
,	1380	1381	|O
56	1382	1384	|O
)	1384	1385	|O
.	1385	1386	|O
Such	1387	1391	|O
inhibitors	1392	1402	|O
may	1403	1406	|O
be	1407	1409	|O
useful	1410	1416	|O
in	1417	1419	|O
elucidating	1420	1431	|O
the	1432	1435	|O
physiological	1436	1449	|O
and	1450	1453	|O
pathological	1454	1466	|O
events	1467	1473	|O
involving	1474	1483	|O
these	1484	1489	|O
proteases	1490	1499	|O
and	1500	1503	|O
may	1504	1507	|O
become	1508	1514	|O
possible	1515	1523	|O
therapeutic	1524	1535	|O
agents	1536	1542	|O
.	1542	1543	|O

### abstracts2335.txt
Lipophilic	0	10	|O
methotrexate	11	23	|O
(	24	25	|O
MTX	25	28	|O
)	28	29	|O
and	30	33	|O
3'	34	36	|B-IUPAC
,	36	37	|I-IUPAC
5'	37	39	|I-IUPAC
-	39	40	|I-IUPAC
dichloromethotrexate	40	60	|I-IUPAC
(	61	62	|O
DCM	62	65	|O
)	65	66	|O
diesters	67	75	|B-MODIFIER
were	76	80	|O
prepared	81	89	|O
by	90	92	|O
HCl	93	96	|O
-	96	97	|O
catalyzed	97	106	|O
esterification	107	121	|O
or	122	124	|O
by	125	127	|O
neutral	128	135	|O
esterification	136	150	|O
using	151	156	|O
cesium	157	163	|O
carbonate	164	173	|O
and	174	177	|O
an	178	180	|O
alkyl	181	186	|O
or	187	189	|O
aralkyl	190	197	|O
halide	198	204	|O
in	205	207	|O
Me2SO	208	213	|O
.	213	214	|O
The	215	218	|O
products	219	227	|O
were	228	232	|O
tested	233	239	|O
for	240	243	|O
in	244	246	|O
vivo	247	251	|O
antitumor	252	261	|O
activity	262	270	|O
against	271	278	|O
L1210	279	284	|O
leukemia	285	293	|O
in	294	296	|O
mice	297	301	|O
to	302	304	|O
test	305	309	|O
whether	310	317	|O
all	318	321	|O
MTX	322	325	|O
and	326	329	|O
DCM	330	333	|O
diesters	334	342	|O
are	343	346	|O
therapeutically	347	362	|O
equivalent	363	373	|O
in	374	376	|O
this	377	381	|O
species	382	389	|O
.	389	390	|O
Contrary	391	399	|O
to	400	402	|O
what	403	407	|O
has	408	411	|O
been	412	416	|O
found	417	422	|O
with	423	427	|O
simple	428	434	|O
primary	435	442	|O
dialkyl	443	450	|O
esters	451	457	|O
,	457	458	|O
ortho	459	464	|O
-	464	465	|O
substituted	465	476	|O
dibenzyl	477	485	|O
esters	486	492	|O
of	493	495	|O
MTX	496	499	|O
produce	500	507	|O
longer	508	514	|O
survival	515	523	|O
on	524	526	|O
a	527	528	|O
q3dX3	529	534	|O
schedule	535	543	|O
than	544	548	|O
does	549	553	|O
MTX	554	557	|O
itself	558	564	|O
and	565	568	|O
show	569	573	|O
a	574	575	|O
dose	576	580	|O
-	580	581	|O
sparing	581	588	|O
effect	589	595	|O
comparable	596	606	|O
to	607	609	|O
that	610	614	|O
of	615	617	|O
MTX	618	621	|O
at	622	624	|O
shorter	625	632	|O
treatment	633	642	|O
intervals	643	652	|O
.	652	653	|O
Thus	654	658	|O
,	658	659	|O
MTX	660	663	|O
bis	664	667	|B-IUPAC
(	667	668	|I-IUPAC
6	668	669	|I-IUPAC
-	669	670	|I-IUPAC
chloropiperonyl	670	685	|I-IUPAC
)	685	686	|I-IUPAC
ester	687	692	|I-IUPAC
at	693	695	|O
an	696	698	|O
MTX	699	702	|O
-	702	703	|O
equivalent	703	713	|O
dose	714	718	|O
of	719	721	|O
5.5	722	725	|O
mg	726	728	|O
/	728	729	|O
kg	729	731	|O
gave	732	736	|O
a	737	738	|O
+	739	740	|O
88%	740	743	|O
increase	744	752	|O
in	753	755	|O
median	756	762	|O
life	763	767	|O
span	768	772	|O
(	773	774	|O
ILS	774	777	|O
)	777	778	|O
,	778	779	|O
whereas	780	787	|O
for	788	791	|O
MTX	792	795	|O
a	796	797	|O
+	798	799	|O
88%	799	802	|O
ILS	803	806	|O
required	807	815	|O
30	816	818	|O
mg	819	821	|O
/	821	822	|O
kg	822	824	|O
.	824	825	|O
When	826	830	|O
the	831	834	|O
MTX	835	838	|O
-	838	839	|O
equivalent	839	849	|O
dose	850	854	|O
of	855	857	|O
MTX	858	861	|O
bis	862	865	|B-IUPAC
(	865	866	|I-IUPAC
6	866	867	|I-IUPAC
-	867	868	|I-IUPAC
chloropiperonyl	868	883	|I-IUPAC
)	883	884	|I-IUPAC
ester	885	890	|I-IUPAC
was	891	894	|O
increased	895	904	|O
to	905	907	|O
40	908	910	|O
mg	911	913	|O
/	913	914	|O
kg	914	916	|O
,	916	917	|O
a	918	919	|O
+	920	921	|O
167%	921	925	|O
ILS	926	929	|O
was	930	933	|O
observed	934	942	|O
,	942	943	|O
as	944	946	|O
compared	947	955	|O
with	956	960	|O
a	961	962	|O
+	963	964	|O
100%	964	968	|O
ILS	969	972	|O
with	973	977	|O
60	978	980	|O
mg	981	983	|O
/	983	984	|O
kg	984	986	|O
of	987	989	|O
the	990	993	|O
parent	994	1000	|O
drug	1001	1005	|O
.	1005	1006	|O
High	1007	1011	|O
activity	1012	1020	|O
(	1021	1022	|O
greater	1022	1029	|O
than	1030	1034	|O
100%	1035	1039	|O
ILS	1040	1043	|O
)	1043	1044	|O
was	1045	1048	|O
likewise	1049	1057	|O
shown	1058	1063	|O
by	1064	1066	|O
the	1067	1070	|O
bis	1071	1074	|B-PARTIUPAC
(	1074	1075	|I-PARTIUPAC
2,5	1075	1078	|I-PARTIUPAC
-	1078	1079	|I-PARTIUPAC
dimethylbenzyl	1079	1093	|I-PARTIUPAC
)	1093	1094	|I-PARTIUPAC
,	1094	1095	|O
bis	1096	1099	|B-PARTIUPAC
(	1099	1100	|I-PARTIUPAC
2,6	1100	1103	|I-PARTIUPAC
-	1103	1104	|I-PARTIUPAC
dichlorobenzyl	1104	1118	|I-PARTIUPAC
)	1118	1119	|I-PARTIUPAC
,	1119	1120	|O
and	1121	1124	|O
di	1125	1127	|B-IUPAC
-	1127	1128	|I-IUPAC
3	1128	1129	|I-IUPAC
-	1129	1130	|I-IUPAC
picolyl	1130	1137	|I-IUPAC
esters	1138	1144	|I-IUPAC
of	1145	1147	|O
MTX	1148	1151	|O
and	1152	1155	|O
by	1156	1158	|O
the	1159	1162	|O
bis	1163	1166	|B-IUPAC
(	1166	1167	|I-IUPAC
1	1167	1168	|I-IUPAC
-	1168	1169	|I-IUPAC
methylbutyl	1169	1180	|I-IUPAC
)	1180	1181	|I-IUPAC
ester	1182	1187	|I-IUPAC
of	1188	1190	|O
DCM	1191	1194	|O
.	1194	1195	|O
The	1196	1199	|O
results	1200	1207	|O
of	1208	1210	|O
this	1211	1215	|O
study	1216	1221	|O
indicate	1222	1230	|O
that	1231	1235	|O
MTX	1236	1239	|O
and	1240	1243	|O
DCM	1244	1247	|O
esters	1248	1254	|O
are	1255	1258	|O
not	1259	1262	|O
therapeutically	1263	1278	|O
equivalent	1279	1289	|O
in	1290	1292	|O
mice	1293	1297	|O
,	1297	1298	|O
despite	1299	1306	|O
the	1307	1310	|O
high	1311	1315	|O
serum	1316	1321	|O
esterase	1322	1330	|O
activity	1331	1339	|O
in	1340	1342	|O
this	1343	1347	|O
species	1348	1355	|O
,	1355	1356	|O
and	1357	1360	|O
that	1361	1365	|O
an	1366	1368	|O
up	1369	1371	|O
to	1372	1374	|O
10	1375	1377	|O
-	1377	1378	|O
fold	1378	1382	|O
reduction	1383	1392	|O
in	1393	1395	|O
total	1396	1401	|O
administered	1402	1414	|O
dose	1415	1419	|O
on	1420	1422	|O
the	1423	1426	|O
q3dX3	1427	1432	|O
schedule	1433	1441	|O
is	1442	1444	|O
feasible	1445	1453	|O
by	1454	1456	|O
this	1457	1461	|O
approach	1462	1470	|O
.	1470	1471	|O

### abstracts3304.txt
The	0	3	|O
higher	4	10	|O
toxicity	11	19	|O
of	20	22	|O
neonicotinoid	23	36	|O
insecticides	37	49	|O
such	50	54	|O
as	55	57	|O
N	58	59	|B-IUPAC
-	59	60	|I-IUPAC
(	60	61	|I-IUPAC
6	61	62	|I-IUPAC
-	62	63	|I-IUPAC
chloropyridin	63	76	|I-IUPAC
-	76	77	|I-IUPAC
3	77	78	|I-IUPAC
-	78	79	|I-IUPAC
ylmethyl	79	87	|I-IUPAC
)	87	88	|I-IUPAC
-	88	89	|I-IUPAC
2	89	90	|I-IUPAC
-	90	91	|I-IUPAC
nitroiminoimidazolidine	91	114	|I-IUPAC
(	115	116	|O
imidacloprid	116	128	|O
)	128	129	|O
to	130	132	|O
insects	133	140	|O
than	141	145	|O
mammals	146	153	|O
is	154	156	|O
due	157	160	|O
in	161	163	|O
large	164	169	|O
part	170	174	|O
to	175	177	|O
target	178	184	|O
site	185	189	|O
specificity	190	201	|O
at	202	204	|O
the	205	208	|O
corresponding	209	222	|O
nicotinic	223	232	|O
acetylcholine	233	246	|O
receptors	247	256	|O
(	257	258	|O
nAChRs	258	264	|O
)	264	265	|O
.	265	266	|O
We	267	269	|O
propose	270	277	|O
that	278	282	|O
neonicotinoids	283	297	|O
with	298	302	|O
a	303	304	|O
protonated	305	315	|O
N	316	317	|O
-	317	318	|O
unsubstituted	318	331	|O
imine	332	337	|O
or	338	340	|O
equivalent	341	351	|O
substituent	352	363	|O
recognize	364	373	|O
the	374	377	|O
anionic	378	385	|O
subsite	386	393	|O
of	394	396	|O
the	397	400	|O
mammalian	401	410	|O
alpha4beta2	411	422	|O
nAChR	423	428	|O
whereas	429	436	|O
the	437	440	|O
negatively	441	451	|O
charged	452	459	|O
(	460	461	|O
delta	461	466	|O
(	466	467	|O
-	467	468	|O
)	468	469	|O
)	469	470	|O
tip	471	474	|O
of	475	477	|O
the	478	481	|O
neonicotinoid	482	495	|O
insecticides	496	508	|O
interacts	509	518	|O
with	519	523	|O
a	524	525	|O
putative	526	534	|O
cationic	535	543	|O
subsite	544	551	|O
of	552	554	|O
the	555	558	|O
insect	559	565	|O
nAChR	566	571	|O
.	571	572	|O
This	573	577	|O
hypothesis	578	588	|O
can	589	592	|O
be	593	595	|O
tested	596	602	|O
by	603	605	|O
using	606	611	|O
two	612	615	|O
photoaffinity	616	629	|O
probes	630	636	|O
that	637	641	|O
differ	642	648	|O
only	649	653	|O
in	654	656	|O
the	657	660	|O
N	661	662	|O
-	662	663	|O
unsubstituted	663	676	|O
imine	677	682	|O
vs	683	685	|O
negatively	686	696	|O
charged	697	704	|O
(	705	706	|O
delta	706	711	|O
(	711	712	|O
-	712	713	|O
)	713	714	|O
)	714	715	|O
tip	716	719	|O
.	719	720	|O
Synthesis	721	730	|O
methodology	731	742	|O
was	743	746	|O
developed	747	756	|O
for	757	760	|O
compounds	761	770	|O
combining	771	780	|O
three	781	786	|O
moieties	787	795	|O
:	795	796	|O
pyridin	797	804	|B-IUPAC
-	804	805	|I-IUPAC
3	805	806	|I-IUPAC
-	806	807	|I-IUPAC
ylmethyl	807	815	|I-IUPAC
or	816	818	|O
6	819	820	|B-IUPAC
-	820	821	|I-IUPAC
chloropyridin	821	834	|I-IUPAC
-	834	835	|I-IUPAC
3	835	836	|I-IUPAC
-	836	837	|I-IUPAC
ylmethyl	837	845	|I-IUPAC
and	846	849	|O
their	850	855	|O
4	856	857	|B-PARTIUPAC
-	857	858	|I-PARTIUPAC
and	859	862	|O
5	863	864	|B-IUPAC
-	864	865	|I-IUPAC
azido	865	870	|I-IUPAC
analogues	871	880	|B-MODIFIER
;	880	881	|O
imidazolidine	882	895	|B-IUPAC
,	895	896	|O
4	897	898	|B-IUPAC
-	898	899	|I-IUPAC
imidazoline	899	910	|I-IUPAC
or	911	913	|O
4	914	915	|B-IUPAC
-	915	916	|I-IUPAC
thiazoline	916	926	|I-IUPAC
;	926	927	|O
and	928	931	|O
N	932	933	|B-MODIFIER
-	933	934	|I-MODIFIER
unsubstituted	934	947	|I-MODIFIER
imine	948	953	|B-IUPAC
,	953	954	|O
nitroimine	955	965	|O
,	965	966	|O
cyanoimine	967	977	|O
,	977	978	|O
or	979	981	|O
nitromethylene	982	996	|O
.	996	997	|O
Structure	998	1007	|O
-	1007	1008	|O
activity	1008	1016	|O
studies	1017	1024	|O
compared	1025	1033	|O
displacement	1034	1046	|O
of	1047	1049	|O
[	1050	1051	|O
(	1051	1052	|O
3	1052	1053	|O
)	1053	1054	|O
H	1054	1055	|O
]	1055	1056	|O
nicotine	1056	1064	|O
binding	1065	1072	|O
in	1073	1075	|O
mammalian	1076	1085	|O
alpha4beta2	1086	1097	|O
nAChR	1098	1103	|O
and	1104	1107	|O
[	1108	1109	|O
(	1109	1110	|O
3	1110	1111	|O
)	1111	1112	|O
H	1112	1113	|O
]	1113	1114	|O
imidacloprid	1114	1126	|O
binding	1127	1134	|O
in	1135	1137	|O
Drosophila	1138	1148	|O
nAChR	1149	1154	|O
.	1154	1155	|O
Preferred	1156	1165	|O
compounds	1166	1175	|O
are	1176	1179	|O
N	1180	1181	|B-IUPAC
-	1181	1182	|I-IUPAC
(	1182	1183	|I-IUPAC
5	1183	1184	|I-IUPAC
-	1184	1185	|I-IUPAC
azido	1185	1190	|I-IUPAC
-	1190	1191	|I-IUPAC
6	1191	1192	|I-IUPAC
-	1192	1193	|I-IUPAC
chloropyridin	1193	1206	|I-IUPAC
-	1206	1207	|I-IUPAC
3	1207	1208	|I-IUPAC
-	1208	1209	|I-IUPAC
ylmethyl	1209	1217	|I-IUPAC
)	1217	1218	|I-IUPAC
with	1219	1223	|O
2	1224	1225	|B-IUPAC
-	1225	1226	|I-IUPAC
iminothiazoline	1226	1241	|I-IUPAC
for	1242	1245	|O
alpha4beta2	1246	1257	|O
(	1258	1259	|O
K	1259	1260	|O
(	1260	1261	|O
i	1261	1262	|O
)	1262	1263	|O
=	1264	1265	|O
0.47	1266	1270	|O
nM	1271	1273	|O
)	1273	1274	|O
and	1275	1278	|O
with	1279	1283	|O
2	1284	1285	|B-IUPAC
-	1285	1286	|I-IUPAC
nitroiminothiazoline	1286	1306	|I-IUPAC
or	1307	1309	|O
2	1310	1311	|B-IUPAC
-	1311	1312	|I-IUPAC
nitromethyleneimidazolidine	1312	1339	|I-IUPAC
for	1340	1343	|O
Drosophila	1344	1354	|O
(	1355	1356	|O
K	1356	1357	|O
(	1357	1358	|O
i	1358	1359	|O
)	1359	1360	|O
=	1361	1362	|O
0.72-3.9	1363	1371	|O
nM	1372	1374	|O
)	1374	1375	|O
.	1375	1376	|O

### abstracts3134.txt
Improved	0	8	|O
rationally	9	19	|O
designed	20	28	|O
lead	29	33	|O
drug	34	38	|O
structures	39	49	|O
against	50	57	|O
African	58	65	|O
trypanosomiasis	66	81	|O
,	81	82	|O
Chagas	83	89	|O
disease	90	97	|O
,	97	98	|O
and	99	102	|O
leishmaniasis	103	116	|O
were	117	121	|O
obtained	122	130	|O
against	131	138	|O
trypanothione	139	152	|O
reductase	153	162	|O
from	163	167	|O
Trypanosoma	168	179	|O
cruzi	180	185	|O
.	185	186	|O
Substituted	187	198	|B-MODIFIER
-	198	199	|I-MODIFIER
benzyl	199	205	|I-MODIFIER
[	206	207	|B-IUPAC
3	207	208	|I-IUPAC
-	208	209	|I-IUPAC
(	209	210	|I-IUPAC
2	210	211	|I-IUPAC
-	211	212	|I-IUPAC
chloro	212	218	|I-IUPAC
-	218	219	|I-IUPAC
4a	219	221	|I-IUPAC
,	221	222	|I-IUPAC
10a	223	226	|I-IUPAC
-	226	227	|I-IUPAC
dihydrophenothiazin	227	246	|I-IUPAC
-	246	247	|I-IUPAC
10	247	249	|I-IUPAC
-	249	250	|I-IUPAC
yl	250	252	|I-IUPAC
)	252	253	|I-IUPAC
propyl	253	259	|I-IUPAC
]	259	260	|I-IUPAC
dimethylammonium	260	276	|I-IUPAC
salts	277	282	|I-IUPAC
,	282	283	|O
synthesized	284	295	|O
by	296	298	|O
Menschutkin	299	310	|O
quaternization	311	325	|O
of	326	328	|O
the	329	332	|O
tertiary	333	341	|O
alkylamine	342	352	|O
omega	353	358	|O
-	358	359	|O
nitrogen	359	367	|O
atom	368	372	|O
of	373	375	|O
chlorpromazine	376	390	|O
,	390	391	|O
were	392	396	|O
linear	397	403	|O
,	403	404	|O
competitive	405	416	|O
inhibitors	417	427	|O
of	428	430	|O
recombinant	431	442	|O
trypanothione	443	456	|O
reductase	457	466	|O
from	467	471	|O
T	472	473	|O
.	473	474	|O
cruzi	475	480	|O
,	480	481	|O
with	482	486	|O
either	487	493	|O
trypanothione	494	507	|O
disulfide	508	517	|O
or	518	520	|O
N	521	522	|B-IUPAC
-	522	523	|I-IUPAC
benzyloxycarbonyl	523	540	|I-IUPAC
-	540	541	|I-IUPAC
L	541	542	|I-IUPAC
-	542	543	|I-IUPAC
cysteinylglycyl	543	558	|I-IUPAC
3	559	560	|I-IUPAC
-	560	561	|I-IUPAC
dimethylaminopropylamide	561	585	|I-IUPAC
disulfide	586	595	|I-IUPAC
as	596	598	|O
substrate	599	608	|O
.	608	609	|O
The	610	613	|O
permanent	614	623	|O
positive	624	632	|O
charge	633	639	|O
on	640	642	|O
the	643	646	|O
distal	647	653	|O
nitrogen	654	662	|O
atom	663	667	|O
of	668	670	|O
the	671	674	|O
tricyclic	675	684	|O
side	685	689	|O
chain	690	695	|O
contribution	696	708	|O
to	709	711	|O
binding	712	719	|O
was	720	723	|O
estimated	724	733	|O
as	734	736	|O
&	737	738	|O
gt	738	740	|O
;	740	741	|O
/	741	742	|O
=	742	743	|O
5.6	743	746	|O
kcal	747	751	|O
.	751	752	|O
mol	752	755	|O
(	755	756	|O
-	756	757	|O
1	757	758	|O
)	758	759	|O
by	760	762	|O
comparison	763	773	|O
with	774	778	|O
the	779	782	|O
analogue	783	791	|O
with	792	796	|O
the	797	800	|O
cationic	801	809	|O
nitrogen	810	818	|O
atom	819	823	|O
of	824	826	|O
the	827	830	|O
quaternary	831	841	|O
replaced	842	850	|O
by	851	853	|O
an	854	856	|O
ether	857	862	|O
oxygen	863	869	|O
atom	870	874	|O
.	874	875	|O
A	876	877	|O
further	878	885	|O
major	886	891	|O
contribution	892	904	|O
to	905	907	|O
improving	908	917	|O
K	918	919	|O
(	919	920	|O
i	920	921	|O
)	921	922	|O
values	923	929	|O
and	930	933	|O
inhibition	934	944	|O
strength	945	953	|O
was	954	957	|O
the	958	961	|O
hydrophobic	962	973	|O
natures	974	981	|O
and	982	985	|O
structures	986	996	|O
of	997	999	|O
the	1000	1003	|O
N	1004	1005	|B-IUPAC
-	1005	1006	|I-IUPAC
benzyl	1006	1012	|I-IUPAC
substituents	1013	1025	|B-MODIFIER
.	1025	1026	|O
The	1027	1030	|O
strongest	1031	1040	|O
inhibitor	1041	1050	|O
,	1050	1051	|O
the	1052	1055	|O
[	1056	1057	|B-IUPAC
3	1057	1058	|I-IUPAC
-	1058	1059	|I-IUPAC
(	1059	1060	|I-IUPAC
2	1060	1061	|I-IUPAC
-	1061	1062	|I-IUPAC
chloro	1062	1068	|I-IUPAC
-	1068	1069	|I-IUPAC
4a	1069	1071	|I-IUPAC
,	1071	1072	|I-IUPAC
10a	1072	1075	|I-IUPAC
-	1075	1076	|I-IUPAC
dihydrophenothiazin	1076	1095	|I-IUPAC
-	1095	1096	|I-IUPAC
10	1096	1098	|I-IUPAC
-	1098	1099	|I-IUPAC
yl	1099	1101	|I-IUPAC
)	1101	1102	|I-IUPAC
propyl	1102	1108	|I-IUPAC
]	1108	1109	|I-IUPAC
(	1109	1110	|I-IUPAC
3	1110	1111	|I-IUPAC
,	1111	1112	|I-IUPAC
4	1113	1114	|I-IUPAC
-	1114	1115	|I-IUPAC
dichlorobenzyl	1115	1129	|I-IUPAC
)	1129	1130	|I-IUPAC
dimethylammonium	1130	1146	|I-IUPAC
derivative	1147	1157	|B-MODIFIER
(	1158	1159	|O
K	1159	1160	|O
(	1160	1161	|O
i	1161	1162	|O
)	1162	1163	|O
0.12	1164	1168	|O
microM	1169	1175	|O
)	1175	1176	|O
,	1176	1177	|O
was	1178	1181	|O
approximately	1182	1195	|O
2	1196	1197	|O
orders	1198	1204	|O
of	1205	1207	|O
magnitude	1208	1217	|O
more	1218	1222	|O
inhibitory	1223	1233	|O
than	1234	1238	|O
the	1239	1242	|O
parent	1243	1249	|O
chlorpromazine	1250	1264	|O
.	1264	1265	|O
Several	1266	1273	|O
of	1274	1276	|O
these	1277	1282	|O
quaternary	1283	1293	|O
phenothiazines	1294	1308	|O
completely	1309	1319	|O
inhibited	1320	1329	|O
T	1330	1331	|O
.	1331	1332	|O
brucei	1333	1339	|O
parasite	1340	1348	|O
growth	1349	1355	|O
in	1356	1358	|O
vitro	1359	1364	|O
at	1365	1367	|O
&	1368	1369	|O
lt	1369	1371	|O
;	1371	1372	|O
1	1372	1373	|O
microM	1374	1380	|O
.	1380	1381	|O
Antiparasite	1382	1394	|O
activity	1395	1403	|O
was	1404	1407	|O
not	1408	1411	|O
solely	1412	1418	|O
determined	1419	1429	|O
by	1430	1432	|O
inhibition	1433	1443	|O
strength	1444	1452	|O
against	1453	1460	|O
trypanothione	1461	1474	|O
reductase	1475	1484	|O
,	1484	1485	|O
there	1486	1491	|O
being	1492	1497	|O
a	1498	1499	|O
strong	1500	1506	|O
contribution	1507	1519	|O
from	1520	1524	|O
hydrophobicity	1525	1539	|O
(	1540	1541	|O
for	1541	1544	|O
example	1545	1552	|O
,	1552	1553	|O
benzhydryl	1554	1564	|B-IUPAC
-	1564	1565	|O
quaternized	1565	1576	|B-MODIFIER
chlorpromazime	1577	1591	|B-IUPAC
had	1592	1595	|O
ED	1596	1598	|O
(	1598	1599	|O
50	1599	1601	|O
)	1601	1602	|O
&	1603	1604	|O
lt	1604	1606	|O
;	1606	1607	|O
1	1608	1609	|O
microM	1610	1616	|O
)	1616	1617	|O
.	1617	1618	|O
Although	1619	1627	|O
active	1628	1634	|O
against	1635	1642	|O
Leishmania	1643	1653	|O
donovani	1654	1662	|O
,	1662	1663	|O
none	1664	1668	|O
of	1669	1671	|O
the	1672	1675	|O
analogues	1676	1685	|O
showed	1686	1692	|O
major	1693	1698	|O
improvement	1699	1710	|O
in	1711	1713	|O
this	1714	1718	|O
activity	1719	1727	|O
relative	1728	1736	|O
to	1737	1739	|O
chlorpromazine	1740	1754	|O
or	1755	1757	|O
other	1758	1763	|O
nonquaternized	1764	1778	|O
phenothiazines	1779	1793	|O
.	1793	1794	|O
The	1795	1798	|O
p	1799	1800	|B-IUPAC
-	1800	1801	|I-IUPAC
tert	1801	1805	|I-IUPAC
-	1805	1806	|I-IUPAC
butylbenzyl	1806	1817	|I-IUPAC
-	1817	1818	|O
quaternized	1818	1829	|B-MODIFIER
analogue	1830	1838	|I-MODIFIER
very	1839	1843	|O
strongly	1844	1852	|O
inhibited	1853	1862	|O
(	1863	1864	|O
ED	1864	1866	|O
(	1866	1867	|O
50	1867	1869	|O
)	1869	1870	|O
&	1871	1872	|O
lt	1872	1874	|O
;	1874	1875	|O
1	1876	1877	|O
microM	1878	1884	|O
)	1884	1885	|O
growth	1886	1892	|O
of	1893	1895	|O
the	1896	1899	|O
amastigote	1900	1910	|O
stage	1911	1916	|O
of	1917	1919	|O
T	1920	1921	|O
.	1921	1922	|O
cruzi	1923	1928	|O
.	1928	1929	|O

### abstracts4332.txt
After	0	5	|O
our	6	9	|O
discovery	10	19	|O
that	20	24	|O
H	25	26	|O
-	26	27	|O
c	27	28	|O
[	28	29	|O
Cys	29	32	|O
-	32	33	|O
Phe	33	36	|O
-	36	37	|O
Phe	37	40	|O
-	40	41	|O
DNal	41	45	|O
-	45	46	|O
Lys	46	49	|O
-	49	50	|O
Thr	50	53	|O
-	53	54	|O
Phe	54	57	|O
-	57	58	|O
Cys	58	61	|O
]	61	62	|O
-	62	63	|O
OH	63	65	|O
(	66	67	|O
ODN	67	70	|O
-	70	71	|O
8	71	72	|O
)	72	73	|O
had	74	77	|O
high	78	82	|O
affinity	83	91	|O
and	92	95	|O
marginal	96	104	|O
selectivity	105	116	|O
for	117	120	|O
human	121	126	|O
sst	127	130	|O
(	130	131	|O
3	131	132	|O
)	132	133	|O
(	134	135	|O
part	135	139	|O
2	140	141	|O
of	142	144	|O
this	145	149	|O
series	150	156	|O
:	156	157	|O
Erchegyi	158	166	|O
et	167	169	|O
al.	170	173	|O
J	174	175	|O
.	175	176	|O
Med.	177	181	|O
Chem.	182	187	|O
,	187	188	|O
preceding	189	198	|O
paper	199	204	|O
in	205	207	|O
this	208	212	|O
issue	213	218	|O
)	218	219	|O
(	219	220	|O
11	220	222	|O
)	222	223	|O
and	224	227	|O
that	228	232	|O
H	233	234	|O
-	234	235	|O
c	235	236	|O
[	236	237	|O
Cys	237	240	|O
-	240	241	|O
Phe	241	244	|O
-	244	245	|O
Phe	245	248	|O
-	248	249	|O
DTrp	249	253	|O
-	253	254	|O
Lys	254	257	|O
-	257	258	|O
Thr	258	261	|O
-	261	262	|O
Phe	262	265	|O
-	265	266	|O
Cys	266	269	|O
]	269	270	|O
-	270	271	|O
OH	271	273	|O
(	274	275	|O
ODT	275	278	|O
-	278	279	|O
8	279	280	|O
,	280	281	|O
3	282	283	|O
)	283	284	|O
had	285	288	|O
high	289	293	|O
affinity	294	302	|O
and	303	306	|O
marginal	307	315	|O
selectivity	316	327	|O
for	328	331	|O
human	332	337	|O
sst	338	341	|O
(	341	342	|O
4	342	343	|O
)	343	344	|O
,	344	345	|O
that	346	350	|O
H	351	352	|O
-	352	353	|O
c	353	354	|O
[	354	355	|O
Cys	355	358	|O
-	358	359	|O
Phe	359	362	|O
-	362	363	|O
Tyr	363	366	|O
-	366	367	|O
D	367	368	|O
-	368	369	|O
threo	369	374	|O
-	374	375	|O
beta	375	379	|O
-	379	380	|O
Me2Nal	380	386	|O
-	386	387	|O
Lys	387	390	|O
-	390	391	|O
Thr	391	394	|O
-	394	395	|O
Phe	395	398	|O
-	398	399	|O
Cys	399	402	|O
]	402	403	|O
-	403	404	|O
OH	404	406	|O
had	407	410	|O
high	411	415	|O
affinity	416	424	|O
for	425	428	|O
all	429	432	|O
sst	433	436	|O
's	436	438	|O
except	439	445	|O
for	446	449	|O
sst	450	453	|O
(	453	454	|O
1	454	455	|O
)	455	456	|O
,	456	457	|O
and	458	461	|O
that	462	466	|O
H	467	468	|O
-	468	469	|O
c	469	470	|O
[	470	471	|O
Cys	471	474	|O
-	474	475	|O
Phe	475	478	|O
-	478	479	|O
Tyr	479	482	|O
-	482	483	|O
L	483	484	|O
-	484	485	|O
threo	485	490	|O
-	490	491	|O
beta	491	495	|O
-	495	496	|O
Me2Nal	496	502	|O
-	502	503	|O
Lys	503	506	|O
-	506	507	|O
Thr	507	510	|O
-	510	511	|O
Phe	511	514	|O
-	514	515	|O
Cys	515	518	|O
]	518	519	|O
-	519	520	|O
OH	520	522	|O
had	523	526	|O
high	527	531	|O
affinity	532	540	|O
for	541	544	|O
sst	545	548	|O
(	548	549	|O
4	549	550	|O
)	550	551	|O
(	552	553	|O
IC	553	555	|O
(	555	556	|O
50	556	558	|O
)	558	559	|O
=	560	561	|O
2.1	562	565	|O
nM	566	568	|O
)	568	569	|O
,	569	570	|O
with	571	575	|O
more	576	580	|O
than	581	585	|O
50	586	588	|O
-	588	589	|O
fold	589	593	|O
selectivity	594	605	|O
toward	606	612	|O
the	613	616	|O
other	617	622	|O
receptors	623	632	|O
(	633	634	|O
parts	634	639	|O
1	640	641	|O
and	642	645	|O
2	646	647	|O
of	648	650	|O
this	651	655	|O
series	656	662	|O
:	662	663	|O
Rivier	664	670	|O
et	671	673	|O
al.	674	677	|O
and	678	681	|O
Erchegyi	682	690	|O
et	691	693	|O
al.	694	697	|O
J	698	699	|O
.	699	700	|O
Med.	701	705	|O
Chem.	706	711	|O
,	711	712	|O
preceding	713	722	|O
papers	723	729	|O
in	730	732	|O
this	733	737	|O
issue	738	743	|O
)	743	744	|O
,	744	745	|O
we	746	748	|O
found	749	754	|O
H	755	756	|O
-	756	757	|O
c	757	758	|O
[	758	759	|O
Cys	759	762	|O
-	762	763	|O
Phe	763	766	|O
-	766	767	|O
Phe	767	770	|O
-	770	771	|O
Trp	771	774	|O
-	774	775	|O
Lys	775	778	|O
-	778	779	|O
Thr	779	782	|O
-	782	783	|O
Phe	783	786	|O
-	786	787	|O
Cys	787	790	|O
]	790	791	|O
-	791	792	|O
OH	792	794	|O
(	795	796	|O
OLT	796	799	|O
-	799	800	|O
8	800	801	|O
,	801	802	|O
2	803	804	|O
)	804	805	|O
,	805	806	|O
H	807	808	|O
-	808	809	|O
c	809	810	|O
[	810	811	|O
Cys	811	814	|O
-	814	815	|O
Phe	815	818	|O
-	818	819	|O
Phe	819	822	|O
-	822	823	|O
L	823	824	|O
-	824	825	|O
threo	825	830	|O
-	830	831	|O
beta	831	835	|O
-	835	836	|O
MeTrp	836	841	|O
-	841	842	|O
Lys	842	845	|O
-	845	846	|O
Thr	846	849	|O
-	849	850	|O
Phe	850	853	|O
-	853	854	|O
Cys	854	857	|O
]	857	858	|O
-	858	859	|O
OH	859	861	|O
(	862	863	|O
4	863	864	|O
)	864	865	|O
and	866	869	|O
H	870	871	|O
-	871	872	|O
c	872	873	|O
[	873	874	|O
Cys	874	877	|O
-	877	878	|O
Phe	878	881	|O
-	881	882	|O
Phe	882	885	|O
-	885	886	|O
D	886	887	|O
-	887	888	|O
threo	888	893	|O
-	893	894	|O
beta	894	898	|O
-	898	899	|O
MeTrp	899	904	|O
-	904	905	|O
Lys	905	908	|O
-	908	909	|O
Thr	909	912	|O
-	912	913	|O
Phe	913	916	|O
-	916	917	|O
Cys	917	920	|O
]	920	921	|O
-	921	922	|O
OH	922	924	|O
(	925	926	|O
5	926	927	|O
)	927	928	|O
to	929	931	|O
have	932	936	|O
very	937	941	|O
high	942	946	|O
affinity	947	955	|O
for	956	959	|O
sst	960	963	|O
(	963	964	|O
4	964	965	|O
)	965	966	|O
(	967	968	|O
IC	968	970	|O
(	970	971	|O
50	971	973	|O
)	973	974	|O
=	975	976	|O
0.7	977	980	|O
,	980	981	|O
1.8	982	985	|O
,	985	986	|O
and	987	990	|O
4.0	991	994	|O
nM	995	997	|O
,	997	998	|O
respectively	999	1011	|O
)	1011	1012	|O
and	1013	1016	|O
5	1017	1018	|O
-	1018	1019	|O
to	1020	1022	|O
10	1023	1025	|O
-	1025	1026	|O
fold	1026	1030	|O
selectivity	1031	1042	|O
versus	1043	1049	|O
the	1050	1053	|O
other	1054	1059	|O
sst	1060	1063	|O
's	1063	1065	|O
.	1065	1066	|O
From	1067	1071	|O
earlier	1072	1079	|O
work	1080	1084	|O
,	1084	1085	|O
we	1086	1088	|O
concluded	1089	1098	|O
that	1099	1103	|O
an	1104	1106	|O
l	1107	1108	|O
-	1108	1109	|O
amino	1109	1114	|O
acid	1115	1119	|O
at	1120	1122	|O
position	1123	1131	|O
8	1132	1133	|O
and	1134	1137	|O
a	1138	1139	|O
tyrosine	1140	1148	|B-IUPAC
or	1149	1151	|O
4	1152	1153	|B-IUPAC
-	1153	1154	|I-IUPAC
aminophenylalanine	1154	1172	|I-IUPAC
substitution	1173	1185	|B-MODIFIER
at	1186	1188	|O
position	1189	1197	|O
7	1198	1199	|O
may	1200	1203	|O
lead	1204	1208	|O
to	1209	1211	|O
high	1212	1216	|O
sst	1217	1220	|O
(	1220	1221	|O
4	1221	1222	|O
)	1222	1223	|O
selectivity	1224	1235	|O
.	1235	1236	|O
In	1237	1239	|O
fact	1240	1244	|O
,	1244	1245	|O
[	1246	1247	|O
Tyr	1247	1250	|O
(	1250	1251	|O
7	1251	1252	|O
)	1252	1253	|O
]	1253	1254	|O
-	1254	1255	|O
2	1255	1256	|O
(	1257	1258	|O
6	1258	1259	|O
)	1259	1260	|O
and	1261	1264	|O
[	1265	1266	|O
Tyr	1266	1269	|O
(	1269	1270	|O
7	1270	1271	|O
)	1271	1272	|O
]	1272	1273	|O
-	1273	1274	|O
3	1274	1275	|O
(	1276	1277	|O
7	1277	1278	|O
)	1278	1279	|O
show	1280	1284	|O
ca.	1285	1288	|O
5	1289	1290	|O
-	1290	1291	|O
fold	1291	1295	|O
selectivity	1296	1307	|O
for	1308	1311	|O
sst	1312	1315	|O
(	1315	1316	|O
4	1316	1317	|O
)	1317	1318	|O
,	1318	1319	|O
and	1320	1323	|O
[	1324	1325	|O
Aph	1325	1328	|O
(	1328	1329	|O
7	1329	1330	|O
)	1330	1331	|O
]	1331	1332	|O
-	1332	1333	|O
2	1333	1334	|O
(	1335	1336	|O
8	1336	1337	|O
)	1337	1338	|O
and	1339	1342	|O
[	1343	1344	|O
Aph	1344	1347	|O
(	1347	1348	|O
7	1348	1349	|O
)	1349	1350	|O
]	1350	1351	|O
-	1351	1352	|O
3	1352	1353	|O
(	1354	1355	|O
9	1355	1356	|O
)	1356	1357	|O
have	1358	1362	|O
high	1363	1367	|O
sst	1368	1371	|O
(	1371	1372	|O
4	1372	1373	|O
)	1373	1374	|O
affinity	1375	1383	|O
(	1384	1385	|O
IC	1385	1387	|O
(	1387	1388	|O
50	1388	1390	|O
)	1390	1391	|O
=	1392	1393	|O
1.2	1394	1397	|O
and	1398	1401	|O
0.88	1402	1406	|O
nM	1407	1409	|O
,	1409	1410	|O
respectively	1411	1423	|O
)	1423	1424	|O
and	1425	1428	|O
selectivity	1429	1440	|O
,	1440	1441	|O
suggesting	1442	1452	|O
that	1453	1457	|O
indeed	1458	1464	|O
an	1465	1467	|O
l	1468	1469	|O
-	1469	1470	|O
residue	1470	1477	|O
at	1478	1480	|O
position	1481	1489	|O
8	1490	1491	|O
will	1492	1496	|O
direct	1497	1503	|O
selectivity	1504	1515	|O
toward	1516	1522	|O
sst	1523	1526	|O
(	1526	1527	|O
4	1527	1528	|O
)	1528	1529	|O
.	1529	1530	|O
Unexpectedly	1531	1543	|O
,	1543	1544	|O
[	1545	1546	|O
Ala	1546	1549	|O
(	1549	1550	|O
7	1550	1551	|O
)	1551	1552	|O
]	1552	1553	|O
-	1553	1554	|O
2	1554	1555	|O
(	1556	1557	|O
10	1557	1559	|O
)	1559	1560	|O
and	1561	1564	|O
[	1565	1566	|O
Ala	1566	1569	|O
(	1569	1570	|O
7	1570	1571	|O
)	1571	1572	|O
]	1572	1573	|O
-	1573	1574	|O
3	1574	1575	|O
(	1576	1577	|O
11	1577	1579	|O
)	1579	1580	|O
have	1581	1585	|O
very	1586	1590	|O
high	1591	1595	|O
sst	1596	1599	|O
(	1599	1600	|O
4	1600	1601	|O
)	1601	1602	|O
affinity	1603	1611	|O
(	1612	1613	|O
IC	1613	1615	|O
(	1615	1616	|O
50	1616	1618	|O
)	1618	1619	|O
=	1620	1621	|O
0.84	1622	1626	|O
and	1627	1630	|O
0.98	1631	1635	|O
nM	1636	1638	|O
,	1638	1639	|O
respectively	1640	1652	|O
)	1652	1653	|O
and	1654	1657	|O
selectivity	1658	1669	|O
(	1670	1671	|O
&	1671	1672	|O
gt	1672	1674	|O
;	1674	1675	|O
600	1675	1678	|O
-	1678	1679	|O
and	1680	1683	|O
200	1684	1687	|O
-	1687	1688	|O
fold	1688	1692	|O
,	1692	1693	|O
respectively	1694	1706	|O
)	1706	1707	|O
.	1707	1708	|O
The	1709	1712	|O
combination	1713	1724	|O
of	1725	1727	|O
Tyr	1728	1731	|O
(	1731	1732	|O
2	1732	1733	|O
)	1733	1734	|O
and	1735	1738	|O
dTrp	1739	1743	|O
(	1743	1744	|O
8	1744	1745	|O
)	1745	1746	|O
in	1747	1749	|O
analogues	1750	1759	|O
14	1760	1762	|O
and	1763	1766	|O
22	1767	1769	|O
did	1770	1773	|O
not	1774	1777	|O
affect	1778	1784	|O
the	1785	1788	|O
affinity	1789	1797	|O
of	1798	1800	|O
the	1801	1804	|O
analogues	1805	1814	|O
for	1815	1818	|O
sst	1819	1822	|O
(	1822	1823	|O
4	1823	1824	|O
)	1824	1825	|O
(	1826	1827	|O
IC	1827	1829	|O
(	1829	1830	|O
50	1830	1832	|O
)	1832	1833	|O
=	1834	1835	|O
1.2	1836	1839	|O
and	1840	1843	|O
1.1	1844	1847	|O
nM	1848	1850	|O
,	1850	1851	|O
respectively	1852	1864	|O
)	1864	1865	|O
but	1866	1869	|O
resulted	1870	1878	|O
in	1879	1881	|O
loss	1882	1886	|O
of	1887	1889	|O
selectivity	1890	1901	|O
,	1901	1902	|O
whereas	1903	1910	|O
the	1911	1914	|O
combination	1915	1926	|O
of	1927	1929	|O
Tyr	1930	1933	|O
(	1933	1934	|O
2	1934	1935	|O
)	1935	1936	|O
and	1937	1940	|O
LTrp	1941	1945	|O
(	1945	1946	|O
8	1946	1947	|O
)	1947	1948	|O
in	1949	1951	|O
H	1952	1953	|O
-	1953	1954	|O
Tyr	1954	1957	|O
-	1957	1958	|O
c	1958	1959	|O
[	1959	1960	|O
Cys	1960	1963	|O
-	1963	1964	|O
Phe	1964	1967	|O
-	1967	1968	|O
Aph	1968	1971	|O
-	1971	1972	|O
Trp	1972	1975	|O
-	1975	1976	|O
Lys	1976	1979	|O
-	1979	1980	|O
Thr	1980	1983	|O
-	1983	1984	|O
Phe	1984	1987	|O
-	1987	1988	|O
Cys	1988	1991	|O
]	1991	1992	|O
-	1992	1993	|O
OH	1993	1995	|O
(	1996	1997	|O
13	1997	1999	|O
)	1999	2000	|O
and	2001	2004	|O
H	2005	2006	|O
-	2006	2007	|O
Tyr	2007	2010	|O
-	2010	2011	|O
c	2011	2012	|O
[	2012	2013	|O
Cys	2013	2016	|O
-	2016	2017	|O
Phe	2017	2020	|O
-	2020	2021	|O
Ala	2021	2024	|O
-	2024	2025	|O
Trp	2025	2028	|O
-	2028	2029	|O
Lys	2029	2032	|O
-	2032	2033	|O
Thr	2033	2036	|O
-	2036	2037	|O
Phe	2037	2040	|O
-	2040	2041	|O
Cys	2041	2044	|O
]	2044	2045	|O
-	2045	2046	|O
OH	2046	2048	|O
(	2048	2049	|O
19	2049	2051	|O
)	2051	2052	|O
retained	2053	2061	|O
high	2062	2066	|O
affinity	2067	2075	|O
(	2076	2077	|O
IC	2077	2079	|O
(	2079	2080	|O
50	2080	2082	|O
)	2082	2083	|O
=	2084	2085	|O
1.9	2086	2089	|O
and	2090	2093	|O
1.98	2094	2098	|O
nM	2099	2101	|O
,	2101	2102	|O
respectively	2103	2115	|O
)	2115	2116	|O
and	2117	2120	|O
sst	2121	2124	|O
(	2124	2125	|O
4	2125	2126	|O
)	2126	2127	|O
selectivity	2128	2139	|O
(	2140	2141	|O
&	2141	2142	|O
gt	2142	2144	|O
;	2144	2145	|O
50	2145	2147	|O
and	2148	2151	|O
&	2152	2153	|O
gt	2153	2155	|O
;	2155	2156	|O
250	2156	2159	|O
,	2159	2160	|O
respectively	2161	2173	|O
)	2173	2174	|O
.	2174	2175	|O
Interestingly	2176	2189	|O
,	2189	2190	|O
the	2191	2194	|O
same	2195	2199	|O
substitutions	2200	2213	|O
at	2214	2216	|O
positions	2217	2226	|O
2	2227	2228	|O
and	2229	2232	|O
7	2233	2234	|O
,	2234	2235	|O
with	2236	2240	|O
l	2241	2242	|O
-	2242	2243	|O
threo	2243	2248	|O
-	2248	2249	|O
beta	2249	2253	|O
-	2253	2254	|O
MeTrp	2254	2259	|O
at	2260	2262	|O
position	2263	2271	|O
8	2272	2273	|O
,	2273	2274	|O
yielded	2275	2282	|O
a	2283	2284	|O
much	2285	2289	|O
less	2290	2294	|O
selective	2295	2304	|O
analogue	2305	2313	|O
(	2314	2315	|O
20	2315	2317	|O
)	2317	2318	|O
.	2318	2319	|O
Carbamoylation	2320	2334	|O
of	2335	2337	|O
the	2338	2341	|O
N	2342	2343	|O
-	2343	2344	|O
terminus	2344	2352	|O
of	2353	2355	|O
most	2356	2360	|O
of	2361	2363	|O
these	2364	2369	|O
analogues	2370	2379	|O
resulted	2380	2388	|O
in	2389	2391	|O
slightly	2392	2400	|O
improved	2401	2409	|O
affinity	2410	2418	|O
,	2418	2419	|O
selectivity	2420	2431	|O
,	2431	2432	|O
or	2433	2435	|O
both	2436	2440	|O
.	2440	2441	|O
Other	2442	2447	|O
amino	2448	2453	|O
acid	2454	2458	|O
substitutions	2459	2472	|O
in	2473	2475	|O
this	2476	2480	|O
series	2481	2487	|O
,	2487	2488	|O
such	2489	2493	|O
as	2494	2496	|O
those	2497	2502	|O
with	2503	2507	|O
Amp	2508	2511	|O
(	2512	2513	|O
25	2513	2515	|O
,	2515	2516	|O
26	2517	2519	|O
)	2519	2520	|O
,	2520	2521	|O
Orn	2522	2525	|O
(	2526	2527	|O
27	2527	2529	|O
)	2529	2530	|O
,	2530	2531	|O
or	2532	2534	|O
IAmp	2535	2539	|O
(	2540	2541	|O
29	2541	2543	|O
)	2543	2544	|O
at	2545	2547	|O
position	2548	2556	|O
7	2557	2558	|O
,	2558	2559	|O
were	2560	2564	|O
also	2565	2569	|O
tolerated	2570	2579	|O
but	2580	2583	|O
with	2584	2588	|O
a	2589	2590	|O
2	2591	2592	|O
-	2592	2593	|O
to	2594	2596	|O
3	2597	2598	|O
-	2598	2599	|O
fold	2599	2603	|O
loss	2604	2608	|O
of	2609	2611	|O
affinity	2612	2620	|O
and	2621	2624	|O
concomitant	2625	2636	|O
loss	2637	2641	|O
of	2642	2644	|O
selectivity	2645	2656	|O
.	2656	2657	|O
Analogous	2658	2667	|O
peptides	2668	2676	|O
with	2677	2681	|O
a	2682	2683	|O
tyrosine	2684	2692	|O
at	2693	2695	|O
position	2696	2704	|O
11	2705	2707	|O
(	2708	2709	|O
31-36	2709	2714	|O
)	2714	2715	|O
were	2716	2720	|O
less	2721	2725	|O
selective	2726	2735	|O
than	2736	2740	|O
the	2741	2744	|O
corresponding	2745	2758	|O
peptides	2759	2767	|O
with	2768	2772	|O
a	2773	2774	|O
tyrosine	2775	2783	|O
at	2784	2786	|O
position	2787	2795	|O
2	2796	2797	|O
.	2797	2798	|O
Several	2799	2806	|O
analogues	2807	2816	|O
in	2817	2819	|O
this	2820	2824	|O
series	2825	2831	|O
compared	2832	2840	|O
favorably	2841	2850	|O
with	2851	2855	|O
the	2856	2859	|O
non	2860	2863	|O
-	2863	2864	|O
peptide	2864	2871	|O
L	2872	2873	|O
-	2873	2874	|O
803,087	2874	2881	|O
(	2882	2883	|O
37	2883	2885	|O
)	2885	2886	|O
in	2887	2889	|O
terms	2890	2895	|O
of	2896	2898	|O
affinity	2899	2907	|O
and	2908	2911	|O
selectivity	2912	2923	|O
.	2923	2924	|O
Analogues	2925	2934	|O
8	2935	2936	|O
,	2936	2937	|O
10	2938	2940	|O
,	2940	2941	|O
and	2942	2945	|O
21	2946	2948	|O
potently	2949	2957	|O
inhibited	2958	2967	|O
the	2968	2971	|O
forskolin	2972	2981	|O
-	2981	2982	|O
stimulated	2982	2992	|O
cAMP	2993	2997	|O
production	2998	3008	|O
in	3009	3011	|O
sst	3012	3015	|O
(	3015	3016	|O
4	3016	3017	|O
)	3017	3018	|O
-	3018	3019	|O
transfected	3019	3030	|O
cells	3031	3036	|O
,	3036	3037	|O
therefore	3038	3047	|O
acting	3048	3054	|O
as	3055	3057	|O
full	3058	3062	|O
agonists	3063	3071	|O
.	3071	3072	|O
Cold	3073	3077	|O
monoiodination	3078	3092	|O
of	3093	3095	|O
19	3096	3098	|O
yielded	3099	3106	|O
21	3107	3109	|O
,	3109	3110	|O
with	3111	3115	|O
retention	3116	3125	|O
of	3126	3128	|O
high	3129	3133	|O
sst	3134	3137	|O
(	3137	3138	|O
4	3138	3139	|O
)	3139	3140	|O
selectivity	3141	3152	|O
and	3153	3156	|O
affinity	3157	3165	|O
(	3166	3167	|O
IC	3167	3169	|O
(	3169	3170	|O
50	3170	3172	|O
)	3172	3173	|O
=	3174	3175	|O
3.5	3176	3179	|O
nM	3180	3182	|O
)	3182	3183	|O
.	3183	3184	|O
(	3185	3186	|O
125	3186	3189	|O
)	3189	3190	|O
Iodinated	3190	3199	|O
19	3200	3202	|O
selectively	3203	3214	|O
binds	3215	3220	|O
to	3221	3223	|O
sst	3224	3227	|O
(	3227	3228	|O
4	3228	3229	|O
)	3229	3230	|O
-	3230	3231	|O
transfected	3231	3242	|O
cells	3243	3248	|O
but	3249	3252	|O
not	3253	3256	|O
to	3257	3259	|O
sst	3260	3263	|O
(	3263	3264	|O
1-3	3264	3267	|O
)	3267	3268	|O
-	3268	3269	|O
or	3270	3272	|O
sst	3273	3276	|O
(	3276	3277	|O
5	3277	3278	|O
)	3278	3279	|O
-	3279	3280	|O
transfected	3280	3291	|O
cells	3292	3297	|O
.	3297	3298	|O
Binding	3299	3306	|O
in	3307	3309	|O
sst	3310	3313	|O
(	3313	3314	|O
4	3314	3315	|O
)	3315	3316	|O
-	3316	3317	|O
transfected	3317	3328	|O
cells	3329	3334	|O
was	3335	3338	|O
completely	3339	3349	|O
displaced	3350	3359	|O
by	3360	3362	|O
SRIF	3363	3367	|O
-	3367	3368	|O
28	3368	3370	|O
or	3371	3373	|O
the	3374	3377	|O
sst	3378	3381	|O
(	3381	3382	|O
4	3382	3383	|O
)	3383	3384	|O
-	3384	3385	|O
selective	3385	3394	|O
L	3395	3396	|O
-	3396	3397	|O
803,087	3397	3404	|O
.	3404	3405	|O

### abstracts591.txt
Nineteen	0	8	|O
previously	9	19	|O
undescribed	20	31	|O
2,4	32	35	|B-IUPAC
-	35	36	|I-IUPAC
diamino	36	43	|I-IUPAC
-	43	44	|I-IUPAC
6	44	45	|I-IUPAC
-	45	46	|I-IUPAC
(	46	47	|I-IUPAC
arylmethyl	47	57	|I-IUPAC
)	57	58	|I-IUPAC
-	58	59	|I-IUPAC
5,6,7	59	64	|I-IUPAC
,	64	65	|I-IUPAC
8	66	67	|I-IUPAC
-	67	68	|I-IUPAC
tetrahydroquinazolines	68	90	|I-IUPAC
(	91	92	|O
5a	92	94	|O
-	94	95	|O
m	95	96	|O
,	96	97	|O
10-12	98	103	|O
)	103	104	|O
were	105	109	|O
synthesized	110	121	|O
as	122	124	|O
part	125	129	|O
of	130	132	|O
a	133	134	|O
larger	135	141	|O
effort	142	148	|O
to	149	151	|O
assess	152	158	|O
the	159	162	|O
therapeutic	163	174	|O
potential	175	184	|O
of	185	187	|O
lipophilic	188	198	|O
dihydrofolate	199	212	|O
reductase	213	222	|O
(	223	224	|O
DHFR	224	228	|O
)	228	229	|O
inhibitors	230	240	|O
against	241	248	|O
opportunistic	249	262	|O
infections	263	273	|O
of	274	276	|O
AIDS	277	281	|O
.	281	282	|O
Condensation	283	295	|O
of	296	298	|O
appropriately	299	312	|O
substituted	313	324	|O
(	325	326	|O
arylmethyl	326	336	|O
)	336	337	|O
triphenylphosphoranes	337	358	|O
with	359	363	|O
4	364	365	|B-IUPAC
,	365	366	|I-IUPAC
4	367	368	|I-IUPAC
-	368	369	|I-IUPAC
ethylenedioxycyclohexanone	369	395	|I-IUPAC
,	395	396	|O
followed	397	405	|O
by	406	408	|O
hydrogenation	409	422	|O
(	423	424	|O
H2	424	426	|O
/	426	427	|O
Pd	427	429	|O
-	429	430	|O
C	430	431	|O
)	431	432	|O
and	433	436	|O
acidolysis	437	447	|O
,	447	448	|O
yielded	449	456	|O
the	457	460	|O
corresponding	461	474	|O
4	475	476	|B-IUPAC
-	476	477	|I-IUPAC
(	477	478	|I-IUPAC
arylmethyl	478	488	|I-IUPAC
)	488	489	|I-IUPAC
cyclohexanones	489	503	|I-IUPAC
,	503	504	|O
which	505	510	|O
were	511	515	|O
then	516	520	|O
condensed	521	530	|O
with	531	535	|O
cyanoguanidine	536	550	|O
to	551	553	|O
form	554	558	|O
the	559	562	|O
tetrahydroquinazolines	563	585	|O
.	585	586	|O
Three	587	592	|O
simple	593	599	|O
2	600	601	|B-IUPAC
,	601	602	|I-IUPAC
4	603	604	|I-IUPAC
-	604	605	|I-IUPAC
diamino	605	612	|I-IUPAC
-	612	613	|I-IUPAC
6	613	614	|I-IUPAC
-	614	615	|I-IUPAC
alkyl	615	620	|I-IUPAC
-	620	621	|I-IUPAC
5,6,7,8	621	628	|I-IUPAC
-	628	629	|I-IUPAC
tetrahydroquinazoline	629	650	|I-IUPAC
model	651	656	|B-MODIFIER
compounds	657	666	|I-MODIFIER
(	667	668	|O
9a	668	670	|O
-	670	671	|O
c	671	672	|O
)	672	673	|O
were	674	678	|O
also	679	683	|O
prepared	684	692	|O
in	693	695	|O
one	696	699	|O
step	700	704	|O
from	705	709	|O
commercially	710	722	|O
available	723	732	|O
4	733	734	|B-IUPAC
-	734	735	|I-IUPAC
alkylcyclohexanones	735	754	|I-IUPAC
by	755	757	|O
this	758	762	|O
method	763	769	|O
.	769	770	|O
Enzyme	771	777	|O
inhibition	778	788	|O
assays	789	795	|O
against	796	803	|O
rat	804	807	|O
liver	808	813	|O
DHFR	814	818	|O
,	818	819	|O
Pneumocystis	820	832	|O
carinii	833	840	|O
DHFR	841	845	|O
,	845	846	|O
and	847	850	|O
the	851	854	|O
bifunctional	855	867	|O
DHFR	868	872	|O
-	872	873	|O
TS	873	875	|O
enzyme	876	882	|O
from	883	887	|O
Toxoplasma	888	898	|O
gondii	899	905	|O
were	906	910	|O
carried	911	918	|O
out	919	922	|O
,	922	923	|O
and	924	927	|O
the	928	931	|O
selectivity	932	943	|O
ratios	944	950	|O
IC50	951	955	|O
(	955	956	|O
rat	956	959	|O
)	959	960	|O
/	960	961	|O
IC50	961	965	|O
(	965	966	|O
P	966	967	|O
.	967	968	|O
carinii	969	976	|O
)	976	977	|O
and	978	981	|O
IC50	982	986	|O
(	986	987	|O
rat	987	990	|O
)	990	991	|O
/	991	992	|O
IC50	992	996	|O
(	996	997	|O
T	997	998	|O
.	998	999	|O
gondii	1000	1006	|O
)	1006	1007	|O
were	1008	1012	|O
compared	1013	1021	|O
.	1021	1022	|O
The	1023	1026	|O
three	1027	1032	|O
most	1033	1037	|O
potent	1038	1044	|O
inhibitors	1045	1055	|O
of	1056	1058	|O
P	1059	1060	|O
.	1060	1061	|O
carinii	1062	1069	|O
DHFR	1070	1074	|O
were	1075	1079	|O
the	1080	1083	|O
2,5	1084	1087	|B-IUPAC
-	1087	1088	|I-IUPAC
dimethoxybenzyl	1088	1103	|I-IUPAC
(	1104	1105	|O
5j	1105	1107	|O
)	1107	1108	|O
,	1108	1109	|O
3	1110	1111	|B-IUPAC
,	1111	1112	|I-IUPAC
4	1113	1114	|I-IUPAC
-	1114	1115	|I-IUPAC
dimethoxybenzyl	1115	1130	|I-IUPAC
(	1131	1132	|O
5k	1132	1134	|O
)	1134	1135	|O
,	1135	1136	|O
and	1137	1140	|O
3,4,5	1141	1146	|B-IUPAC
-	1146	1147	|I-IUPAC
trimethoxybenzyl	1147	1163	|I-IUPAC
(	1164	1165	|O
5l	1165	1167	|O
)	1167	1168	|O
analogues	1169	1178	|B-MODIFIER
,	1178	1179	|O
with	1180	1184	|O
IC50	1185	1189	|O
values	1190	1196	|O
of	1197	1199	|O
0.057	1200	1205	|O
,	1205	1206	|O
0.10	1207	1211	|O
,	1211	1212	|O
and	1213	1216	|O
0.091	1217	1222	|O
microM	1223	1229	|O
,	1229	1230	|O
respectively	1231	1243	|O
.	1243	1244	|O
The	1245	1248	|O
remaining	1249	1258	|O
compounds	1259	1268	|O
generally	1269	1278	|O
had	1279	1282	|O
IC50	1283	1287	|O
values	1288	1294	|O
in	1295	1297	|O
the	1298	1301	|O
0.1-1.0	1302	1309	|O
microM	1310	1316	|O
range	1317	1322	|O
.	1322	1323	|O
However	1324	1331	|O
all	1332	1335	|O
the	1336	1339	|O
compounds	1340	1349	|O
were	1350	1354	|O
more	1355	1359	|O
potent	1360	1366	|O
against	1367	1374	|O
the	1375	1378	|O
rat	1379	1382	|O
liver	1383	1388	|O
enzyme	1389	1395	|O
than	1396	1400	|O
the	1401	1404	|O
P	1405	1406	|O
.	1406	1407	|O
carinii	1408	1415	|O
enzyme	1416	1422	|O
and	1423	1426	|O
thus	1427	1431	|O
were	1432	1436	|O
nonselective	1437	1449	|O
.	1449	1450	|O
The	1451	1454	|O
T	1455	1456	|O
.	1456	1457	|O
gondii	1458	1464	|O
enzyme	1465	1471	|O
was	1472	1475	|O
always	1476	1482	|O
more	1483	1487	|O
sensitive	1488	1497	|O
than	1498	1502	|O
the	1503	1506	|O
P	1507	1508	|O
.	1508	1509	|O
carinii	1510	1517	|O
enzyme	1518	1524	|O
,	1524	1525	|O
with	1526	1530	|O
most	1531	1535	|O
of	1536	1538	|O
the	1539	1542	|O
analogues	1543	1552	|O
giving	1553	1559	|O
IC50	1560	1564	|O
values	1565	1571	|O
of	1572	1574	|O
0.01-0.1	1575	1583	|O
microM	1584	1590	|O
.	1590	1591	|O
Moderate	1592	1600	|O
5-10	1601	1605	|O
-	1605	1606	|O
fold	1606	1610	|O
selectivity	1611	1622	|O
for	1623	1626	|O
T	1627	1628	|O
.	1628	1629	|O
gondii	1630	1636	|O
versus	1637	1643	|O
rat	1644	1647	|O
liver	1648	1653	|O
DHFR	1654	1658	|O
was	1659	1662	|O
observed	1663	1671	|O
with	1672	1676	|O
five	1677	1681	|O
compounds	1682	1691	|O
,	1691	1692	|O
the	1693	1696	|O
best	1697	1701	|O
combination	1702	1713	|O
of	1714	1716	|O
potency	1717	1724	|O
and	1725	1728	|O
selectivity	1729	1740	|O
being	1741	1746	|O
achieved	1747	1755	|O
with	1756	1760	|O
the	1761	1764	|O
2	1765	1766	|B-IUPAC
-	1766	1767	|I-IUPAC
methoxybenzyl	1767	1780	|I-IUPAC
analogue	1781	1789	|B-MODIFIER
5d	1790	1792	|O
,	1792	1793	|O
which	1794	1799	|O
had	1800	1803	|O
an	1804	1806	|O
IC50	1807	1811	|O
of	1812	1814	|O
0.014	1815	1820	|O
microM	1821	1827	|O
and	1828	1831	|O
a	1832	1833	|O
selectivity	1834	1845	|O
ratio	1846	1851	|O
of	1852	1854	|O
8.6	1855	1858	|O
.	1858	1859	|O
One	1860	1863	|O
compound	1864	1872	|O
(	1873	1874	|O
5l	1874	1876	|O
)	1876	1877	|O
was	1878	1881	|O
tested	1882	1888	|O
for	1889	1892	|O
antiproliferative	1893	1910	|O
activity	1911	1919	|O
against	1920	1927	|O
P	1928	1929	|O
.	1929	1930	|O
carinii	1931	1938	|O
trophozoites	1939	1951	|O
in	1952	1954	|O
culture	1955	1962	|O
at	1963	1965	|O
a	1966	1967	|O
concentration	1968	1981	|O
of	1982	1984	|O
10	1985	1987	|O
microgram	1988	1997	|O
/	1997	1998	|O
mL	1998	2000	|O
and	2001	2004	|O
was	2005	2008	|O
found	2009	2014	|O
to	2015	2017	|O
completely	2018	2028	|O
suppress	2029	2037	|O
growth	2038	2044	|O
over	2045	2049	|O
7	2050	2051	|O
days	2052	2056	|O
.	2056	2057	|O
The	2058	2061	|O
suppressive	2062	2073	|O
effect	2074	2080	|O
of	2081	2083	|O
5l	2084	2086	|O
was	2087	2090	|O
the	2091	2094	|O
same	2095	2099	|O
as	2100	2102	|O
that	2103	2107	|O
of	2108	2110	|O
trimethoprim	2111	2123	|O
(	2124	2125	|O
10	2125	2127	|O
microgram	2128	2137	|O
/	2137	2138	|O
mL	2138	2140	|O
)	2140	2141	|O
+	2142	2143	|O
sulfamethoxazole	2144	2160	|O
(	2161	2162	|O
250	2162	2165	|O
microgram	2166	2175	|O
/	2175	2176	|O
mL	2176	2178	|O
)	2178	2179	|O
,	2179	2180	|O
a	2181	2182	|O
standard	2183	2191	|O
clinical	2192	2200	|O
combination	2201	2212	|O
for	2213	2216	|O
the	2217	2220	|O
treatment	2221	2230	|O
of	2231	2233	|O
P	2234	2235	|O
.	2235	2236	|O
carinii	2237	2244	|O
pneumonia	2245	2254	|O
in	2255	2257	|O
AIDS	2258	2262	|O
patients	2263	2271	|O
.	2271	2272	|O
Four	2273	2277	|O
compounds	2278	2287	|O
(	2288	2289	|O
5a	2289	2291	|O
,	2291	2292	|O
h	2292	2293	|O
,	2293	2294	|O
k	2294	2295	|O
,	2295	2296	|O
l	2296	2297	|O
)	2297	2298	|O
were	2299	2303	|O
tested	2304	2310	|O
against	2311	2318	|O
T	2319	2320	|O
.	2320	2321	|O
gondii	2322	2328	|O
tachyzoites	2329	2340	|O
in	2341	2343	|O
culture	2344	2351	|O
and	2352	2355	|O
were	2356	2360	|O
found	2361	2366	|O
to	2367	2369	|O
have	2370	2374	|O
a	2375	2376	|O
potency	2377	2384	|O
(	2385	2386	|O
IC50	2386	2390	|O
=	2391	2392	|O
0.1-0.5	2393	2400	|O
microM	2401	2407	|O
)	2407	2408	|O
similar	2409	2416	|O
to	2417	2419	|O
that	2420	2424	|O
of	2425	2427	|O
pyrimethamine	2428	2441	|O
(	2442	2443	|O
IC50	2443	2447	|O
=	2448	2449	|O
0.69	2450	2454	|O
microM	2455	2461	|O
)	2461	2462	|O
,	2462	2463	|O
a	2464	2465	|O
standard	2466	2474	|O
clinical	2475	2483	|O
agent	2484	2489	|O
for	2490	2493	|O
the	2494	2497	|O
treatment	2498	2507	|O
of	2508	2510	|O
cerebral	2511	2519	|O
toxoplasmosis	2520	2533	|O
in	2534	2536	|O
AIDS	2537	2541	|O
patients	2542	2550	|O
.	2550	2551	|O
Compound	2552	2560	|O
5h	2561	2563	|O
was	2564	2567	|O
also	2568	2572	|O
active	2573	2579	|O
against	2580	2587	|O
T	2588	2589	|O
.	2589	2590	|O
gondii	2591	2597	|O
infection	2598	2607	|O
in	2608	2610	|O
mice	2611	2615	|O
when	2616	2620	|O
given	2621	2626	|O
qdx8	2627	2631	|O
by	2632	2634	|O
peritoneal	2635	2645	|O
injection	2646	2655	|O
at	2656	2658	|O
doses	2659	2664	|O
ranging	2665	2672	|O
from	2673	2677	|O
62.5	2678	2682	|O
(	2683	2684	|O
initial	2684	2691	|O
dose	2692	2696	|O
)	2696	2697	|O
to	2698	2700	|O
25	2701	2703	|O
mg	2704	2706	|O
/	2706	2707	|O
kg	2707	2709	|O
.	2709	2710	|O
Survival	2711	2719	|O
was	2720	2723	|O
prolonged	2724	2733	|O
to	2734	2736	|O
the	2737	2740	|O
same	2741	2745	|O
degree	2746	2752	|O
as	2753	2755	|O
with	2756	2760	|O
25	2761	2763	|O
mg	2764	2766	|O
/	2766	2767	|O
kg	2767	2769	|O
clindamycin	2770	2781	|O
,	2781	2782	|O
another	2783	2790	|O
widely	2791	2797	|O
used	2798	2802	|O
drug	2803	2807	|O
against	2808	2815	|O
toxoplasmosis	2816	2829	|O
.	2829	2830	|O
Three	2831	2836	|O
compounds	2837	2846	|O
(	2847	2848	|O
5j	2848	2850	|O
-	2850	2851	|O
l	2851	2852	|O
)	2852	2853	|O
were	2854	2858	|O
tested	2859	2865	|O
for	2866	2869	|O
antiproliferative	2870	2887	|O
activity	2888	2896	|O
against	2897	2904	|O
human	2905	2910	|O
tumor	2911	2916	|O
cells	2917	2922	|O
in	2923	2925	|O
culture	2926	2933	|O
.	2933	2934	|O
Among	2935	2940	|O
the	2941	2944	|O
25	2945	2947	|O
cell	2948	2952	|O
lines	2953	2958	|O
in	2959	2961	|O
the	2962	2965	|O
National	2966	2974	|O
Cancer	2975	2981	|O
Institute	2982	2991	|O
panel	2992	2997	|O
for	2998	3001	|O
which	3002	3007	|O
data	3008	3012	|O
were	3013	3017	|O
confirmed	3018	3027	|O
in	3028	3030	|O
two	3031	3034	|O
independent	3035	3046	|O
experiments	3047	3058	|O
,	3058	3059	|O
the	3060	3063	|O
IC50	3064	3068	|O
for	3069	3072	|O
at	3073	3075	|O
least	3076	3081	|O
two	3082	3085	|O
of	3086	3088	|O
these	3089	3094	|O
compounds	3095	3104	|O
was	3105	3108	|O
&	3109	3110	|O
lt	3110	3112	|O
;	3112	3113	|O
10	3113	3115	|O
microM	3116	3122	|O
against	3123	3130	|O
17	3131	3133	|O
cell	3134	3138	|O
lines	3139	3144	|O
(	3145	3146	|O
68%	3146	3149	|O
)	3149	3150	|O
and	3151	3154	|O
in	3155	3157	|O
the	3158	3161	|O
0	3162	3163	|O
.	3163	3164	|O
1-1	3165	3168	|O
microM	3169	3175	|O
range	3176	3181	|O
against	3182	3189	|O
13	3190	3192	|O
cell	3193	3197	|O
lines	3198	3203	|O
(	3204	3205	|O
52%	3205	3208	|O
)	3208	3209	|O
.	3209	3210	|O
One	3211	3214	|O
compound	3215	3223	|O
(	3224	3225	|O
5j	3225	3227	|O
)	3227	3228	|O
had	3229	3232	|O
an	3233	3235	|O
IC50	3236	3240	|O
of	3241	3243	|O
&	3244	3245	|O
lt	3245	3247	|O
;	3247	3248	|O
0.01	3248	3252	|O
microM	3253	3259	|O
against	3260	3267	|O
four	3268	3272	|O
of	3273	3275	|O
the	3276	3279	|O
cell	3280	3284	|O
lines	3285	3290	|O
.	3290	3291	|O
The	3292	3295	|O
activity	3296	3304	|O
profiles	3305	3313	|O
of	3314	3316	|O
5k	3317	3319	|O
,	3319	3320	|O
l	3320	3321	|O
were	3322	3326	|O
generally	3327	3336	|O
similar	3337	3344	|O
to	3345	3347	|O
that	3348	3352	|O
of	3353	3355	|O
5j	3356	3358	|O
except	3359	3365	|O
that	3366	3370	|O
there	3371	3376	|O
were	3377	3381	|O
no	3382	3384	|O
cells	3385	3390	|O
against	3391	3398	|O
which	3399	3404	|O
the	3405	3408	|O
IC50	3409	3413	|O
was	3414	3417	|O
&	3418	3419	|O
lt	3419	3421	|O
;	3421	3422	|O
0.01	3422	3426	|O
microM	3427	3433	|O
.	3433	3434	|O

### abstracts3535.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
novel	12	17	|O
(	18	19	|B-IUPAC
1,3	19	22	|I-IUPAC
-	22	23	|I-IUPAC
dialkyl	23	30	|I-IUPAC
-	30	31	|I-IUPAC
5	31	32	|I-IUPAC
-	32	33	|I-IUPAC
amino	33	38	|I-IUPAC
-	38	39	|I-IUPAC
1H	39	41	|I-IUPAC
-	41	42	|I-IUPAC
pyrazol	42	49	|I-IUPAC
-	49	50	|I-IUPAC
4	50	51	|I-IUPAC
-	51	52	|I-IUPAC
yl	52	54	|I-IUPAC
)	54	55	|I-IUPAC
arylmethanones	55	69	|I-IUPAC
was	70	73	|O
synthesized	74	85	|O
.	85	86	|O
Pharmacological	87	102	|O
evaluation	103	113	|O
of	114	116	|O
these	117	122	|O
compounds	123	132	|O
demonstrated	133	145	|O
central	146	153	|O
nervous	154	161	|O
system	162	168	|O
depressant	169	179	|O
activity	180	188	|O
,	188	189	|O
potential	190	199	|O
anticonvulsant	200	214	|O
properties	215	225	|O
,	225	226	|O
and	227	230	|O
a	231	232	|O
low	233	236	|O
order	237	242	|O
of	243	245	|O
acute	246	251	|O
toxicity	252	260	|O
.	260	261	|O
In	262	264	|O
addition	265	273	|O
,	273	274	|O
selected	275	283	|O
compounds	284	293	|O
showed	294	300	|O
potential	301	310	|O
antipsychotic	311	324	|O
effects	325	332	|O
.	332	333	|O
This	334	338	|O
report	339	345	|O
focuses	346	353	|O
on	354	356	|O
the	357	360	|O
synthesis	361	370	|O
and	371	374	|O
structure	375	384	|O
-	384	385	|O
activity	385	393	|O
relationships	394	407	|O
of	408	410	|O
these	411	416	|O
compounds	417	426	|O
.	426	427	|O
(	428	429	|B-IUPAC
5	429	430	|I-IUPAC
-	430	431	|I-IUPAC
Amino	431	436	|I-IUPAC
-	436	437	|I-IUPAC
1	437	438	|I-IUPAC
-	438	439	|I-IUPAC
ethyl	439	444	|I-IUPAC
-	444	445	|I-IUPAC
3	445	446	|I-IUPAC
-	446	447	|I-IUPAC
methyl	447	453	|I-IUPAC
-	453	454	|I-IUPAC
1H	454	456	|I-IUPAC
-	456	457	|I-IUPAC
pyrazol	457	464	|I-IUPAC
-	464	465	|I-IUPAC
4	465	466	|I-IUPAC
-	466	467	|I-IUPAC
yl	467	469	|I-IUPAC
)	469	470	|I-IUPAC
(	470	471	|I-IUPAC
2	471	472	|I-IUPAC
-	472	473	|I-IUPAC
chlorophenyl	473	485	|I-IUPAC
)	485	486	|I-IUPAC
methanone	487	496	|I-IUPAC
(	497	498	|O
21	498	500	|O
)	500	501	|O
was	502	505	|O
the	506	509	|O
most	510	514	|O
active	515	521	|O
compound	522	530	|O
against	531	538	|O
pentylenetetrazole	539	557	|O
-	557	558	|O
induced	558	565	|O
convulsions	566	577	|O
.	577	578	|O
(	579	580	|B-IUPAC
5	580	581	|I-IUPAC
-	581	582	|I-IUPAC
Amino	582	587	|I-IUPAC
-	587	588	|I-IUPAC
1,3	588	591	|I-IUPAC
-	591	592	|I-IUPAC
dimethyl	592	600	|I-IUPAC
-	600	601	|I-IUPAC
1H	601	603	|I-IUPAC
-	603	604	|I-IUPAC
pyrazol	604	611	|I-IUPAC
-	611	612	|I-IUPAC
4	612	613	|I-IUPAC
-	613	614	|I-IUPAC
yl	614	616	|I-IUPAC
)	616	617	|I-IUPAC
(	617	618	|I-IUPAC
3	618	619	|I-IUPAC
-	619	620	|I-IUPAC
chlorophenyl	620	632	|I-IUPAC
)	632	633	|I-IUPAC
methanone	633	642	|I-IUPAC
(	643	644	|O
4	644	645	|O
)	645	646	|O
also	647	651	|O
has	652	655	|O
a	656	657	|O
favorable	658	667	|O
anticonvulsant	668	682	|O
depression	683	693	|O
ratio	694	699	|O
.	699	700	|O
(	701	702	|B-IUPAC
5	702	703	|I-IUPAC
-	703	704	|I-IUPAC
Amino	704	709	|I-IUPAC
-	709	710	|I-IUPAC
1,3	710	713	|I-IUPAC
-	713	714	|I-IUPAC
dimethyl	714	722	|I-IUPAC
-	722	723	|I-IUPAC
1H	723	725	|I-IUPAC
-	725	726	|I-IUPAC
pyrazol	726	733	|I-IUPAC
-	733	734	|I-IUPAC
4	734	735	|I-IUPAC
-	735	736	|I-IUPAC
yl	736	738	|I-IUPAC
)	738	739	|I-IUPAC
(	739	740	|I-IUPAC
3	740	741	|I-IUPAC
-	741	742	|I-IUPAC
trifluoromethylphenyl	742	763	|I-IUPAC
)	763	764	|I-IUPAC
methan	764	770	|I-IUPAC
one	771	774	|I-IUPAC
(	775	776	|O
8	776	777	|O
)	777	778	|O
,	778	779	|O
(	780	781	|B-IUPAC
5	781	782	|I-IUPAC
-	782	783	|I-IUPAC
amino	783	788	|I-IUPAC
-	788	789	|I-IUPAC
1,3	789	792	|I-IUPAC
-	792	793	|I-IUPAC
dimethyl	793	801	|I-IUPAC
-	801	802	|I-IUPAC
1H	802	804	|I-IUPAC
-	804	805	|I-IUPAC
pyrazol	805	812	|I-IUPAC
-	812	813	|I-IUPAC
4	813	814	|I-IUPAC
-	814	815	|I-IUPAC
yl	815	817	|I-IUPAC
)	817	818	|I-IUPAC
(	818	819	|I-IUPAC
3	819	820	|I-IUPAC
-	820	821	|I-IUPAC
thienyl	821	828	|I-IUPAC
)	828	829	|I-IUPAC
methanone	829	838	|I-IUPAC
(	839	840	|O
13	840	842	|O
)	842	843	|O
,	843	844	|O
and	845	848	|O
(	849	850	|B-IUPAC
5	850	851	|I-IUPAC
-	851	852	|I-IUPAC
amino	852	857	|I-IUPAC
-	857	858	|I-IUPAC
3	858	859	|I-IUPAC
-	859	860	|I-IUPAC
ethyl	860	865	|I-IUPAC
-	865	866	|I-IUPAC
1	866	867	|I-IUPAC
-	867	868	|I-IUPAC
methyl	868	874	|I-IUPAC
-	874	875	|I-IUPAC
1H	875	877	|I-IUPAC
-	877	878	|I-IUPAC
pyrazol	878	885	|I-IUPAC
-	885	886	|I-IUPAC
4	886	887	|I-IUPAC
-	887	888	|I-IUPAC
yl	888	890	|I-IUPAC
)	890	891	|I-IUPAC
phenylmethanone	891	906	|I-IUPAC
(	907	908	|O
14	908	910	|O
)	910	911	|O
are	912	915	|O
very	916	920	|O
potent	921	927	|O
depressants	928	939	|O
.	939	940	|O
(	941	942	|B-IUPAC
5	942	943	|I-IUPAC
-	943	944	|I-IUPAC
Amino	944	949	|I-IUPAC
-	949	950	|I-IUPAC
1,3	950	953	|I-IUPAC
-	953	954	|I-IUPAC
dimethyl	954	962	|I-IUPAC
-	962	963	|I-IUPAC
1H	963	965	|I-IUPAC
-	965	966	|I-IUPAC
pyrazol	966	973	|I-IUPAC
-	973	974	|I-IUPAC
4	974	975	|I-IUPAC
-	975	976	|I-IUPAC
yl	976	978	|I-IUPAC
)	978	979	|I-IUPAC
(	979	980	|I-IUPAC
2	980	981	|I-IUPAC
-	981	982	|I-IUPAC
thienyl	982	989	|I-IUPAC
)	989	990	|I-IUPAC
methanone	990	999	|I-IUPAC
(	1000	1001	|O
12	1001	1003	|O
)	1003	1004	|O
possessed	1005	1014	|O
marked	1015	1021	|O
central	1022	1029	|O
depressant	1030	1040	|O
activity	1041	1049	|O
without	1050	1057	|O
anticonvulsant	1058	1072	|O
activity	1073	1081	|O
and	1082	1085	|O
without	1086	1093	|O
impairment	1094	1104	|O
of	1105	1107	|O
motor	1108	1113	|O
functioning	1114	1125	|O
.	1125	1126	|O
(	1127	1128	|B-IUPAC
5	1128	1129	|I-IUPAC
-	1129	1130	|I-IUPAC
Amino	1130	1135	|I-IUPAC
-	1135	1136	|I-IUPAC
1,3	1136	1139	|I-IUPAC
-	1139	1140	|I-IUPAC
dimethyl	1140	1148	|I-IUPAC
-	1148	1149	|I-IUPAC
1H	1149	1151	|I-IUPAC
-	1151	1152	|I-IUPAC
pyrazol	1152	1159	|I-IUPAC
-	1159	1160	|I-IUPAC
4	1160	1161	|I-IUPAC
-	1161	1162	|I-IUPAC
yl	1162	1164	|I-IUPAC
)	1164	1165	|I-IUPAC
(	1166	1167	|I-IUPAC
2	1167	1168	|I-IUPAC
-	1168	1169	|I-IUPAC
fluorophenyl	1169	1181	|I-IUPAC
)	1181	1182	|I-IUPAC
methanone	1182	1191	|I-IUPAC
(	1192	1193	|O
2	1193	1194	|O
)	1194	1195	|O
has	1196	1199	|O
a	1200	1201	|O
behavioral	1202	1212	|O
profile	1213	1220	|O
suggestive	1221	1231	|O
of	1232	1234	|O
antipsychotic	1235	1248	|O
activity	1249	1257	|O
and	1258	1261	|O
gave	1262	1266	|O
a	1267	1268	|O
positive	1269	1277	|O
Ames	1278	1282	|O
test	1283	1287	|O
result	1288	1294	|O
.	1294	1295	|O

### abstracts4463.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
2,4	12	15	|B-PARTIUPAC
-	15	16	|I-PARTIUPAC
diamino	16	23	|I-PARTIUPAC
-	23	24	|I-PARTIUPAC
6	24	25	|I-PARTIUPAC
-	25	26	|I-PARTIUPAC
[	26	27	|I-PARTIUPAC
(	27	28	|I-PARTIUPAC
aralkyl	28	35	|I-PARTIUPAC
and	36	39	|O
alicyclic	40	49	|B-PARTIUPAC
)	49	50	|I-PARTIUPAC
thio	50	54	|I-PARTIUPAC
-	54	55	|I-PARTIUPAC
,	55	56	|O
sulfinyl	57	65	|B-PARTIUPAC
-	65	66	|I-PARTIUPAC
,	66	67	|O
and	68	71	|O
sulfonyl	72	80	|B-PARTIUPAC
]	80	81	|I-PARTIUPAC
quinazolines	81	93	|I-PARTIUPAC
was	94	97	|O
prepared	98	106	|O
via	107	110	|O
condensation	111	123	|O
of	124	126	|O
5	127	128	|B-IUPAC
-	128	129	|I-IUPAC
chloro	129	135	|I-IUPAC
-	135	136	|I-IUPAC
2	136	137	|I-IUPAC
-	137	138	|I-IUPAC
nitrobenzonitrile	138	155	|I-IUPAC
or	156	158	|O
5,6	159	162	|B-IUPAC
-	162	163	|I-IUPAC
dichloro	163	171	|I-IUPAC
-	171	172	|I-IUPAC
2	172	173	|I-IUPAC
-	173	174	|I-IUPAC
nitrobenzonitrile	174	191	|I-IUPAC
with	192	196	|O
the	197	200	|O
appropriate	201	212	|O
aralkyl	213	220	|O
or	221	223	|O
alicyclic	224	233	|O
thiopseudourea	234	248	|O
,	248	249	|O
reduction	250	259	|O
of	260	262	|O
the	263	266	|O
resulting	267	276	|O
2	277	278	|B-IUPAC
-	278	279	|I-IUPAC
nitro	279	284	|I-IUPAC
-	284	285	|I-IUPAC
5	285	286	|I-IUPAC
-	286	287	|I-IUPAC
[	287	288	|I-IUPAC
(	288	289	|I-IUPAC
aralkyl	289	296	|I-IUPAC
or	297	299	|I-IUPAC
alicyclic	300	309	|I-IUPAC
)	309	310	|I-IUPAC
thio	310	314	|I-IUPAC
]	314	315	|I-IUPAC
benzonitrile	315	327	|I-IUPAC
with	328	332	|O
stannous	333	341	|O
chloride	342	350	|O
to	351	353	|O
the	354	357	|O
amine	358	363	|O
,	363	364	|O
and	365	368	|O
cyclization	369	380	|O
with	381	385	|O
chloroformamidine	386	403	|B-IUPAC
hydrochloride	404	417	|I-IUPAC
.	417	418	|O
Oxidation	419	428	|O
was	429	432	|O
effected	433	441	|O
with	442	446	|O
hydrogen	447	455	|O
peroxide	456	464	|O
or	465	467	|O
the	468	471	|O
bromine	472	479	|O
complex	480	487	|O
of	488	490	|O
1,4	491	494	|B-IUPAC
-	494	495	|I-IUPAC
diazabicyclo	495	507	|I-IUPAC
[	507	508	|I-IUPAC
2.2.2	508	513	|I-IUPAC
]	513	514	|I-IUPAC
octane	514	520	|I-IUPAC
.	520	521	|O
These	522	527	|O
analogues	528	537	|O
when	538	542	|O
examined	543	551	|O
for	552	555	|O
suppressive	556	567	|O
activity	568	576	|O
against	577	584	|O
drug	585	589	|O
-	589	590	|O
sensitive	590	599	|O
lines	600	605	|O
of	606	608	|O
Plasmodium	609	619	|O
berghei	620	627	|O
in	628	630	|O
mice	631	635	|O
were	636	640	|O
not	641	644	|O
as	645	647	|O
active	648	654	|O
as	655	657	|O
2,4	658	661	|B-IUPAC
-	661	662	|I-IUPAC
diamino	662	669	|I-IUPAC
-	669	670	|I-IUPAC
6	670	671	|I-IUPAC
-	671	672	|I-IUPAC
[	672	673	|I-IUPAC
3,4	673	676	|I-IUPAC
-	676	677	|I-IUPAC
dichlorobenzyl	677	691	|I-IUPAC
)	691	692	|I-IUPAC
amino	692	697	|I-IUPAC
]	697	698	|I-IUPAC
quinazoline	698	709	|I-IUPAC
(	710	711	|O
Ia	711	713	|O
)	713	714	|O
.	714	715	|O

### abstracts1950.txt
We	0	2	|O
describe	3	11	|O
the	12	15	|O
synthesis	16	25	|O
and	26	29	|O
some	30	34	|O
pharmacological	35	50	|O
properties	51	61	|O
of	62	64	|O
16	65	67	|O
new	68	71	|O
in	72	74	|O
vivo	75	79	|O
antagonists	80	91	|O
of	92	94	|O
oxytocin	95	103	|O
.	103	104	|O
These	105	110	|O
are	111	114	|O
based	115	120	|O
on	121	123	|O
modifications	124	137	|O
of	138	140	|O
three	141	146	|O
peptides	147	155	|O
:	155	156	|O
A	157	158	|O
,	158	159	|O
B	160	161	|O
,	161	162	|O
and	163	166	|O
C	167	168	|O
.	168	169	|O
A	170	171	|O
is	172	174	|O
our	175	178	|O
previously	179	189	|O
reported	190	198	|O
potent	199	205	|O
and	206	209	|O
selective	210	219	|O
antagonist	220	230	|O
of	231	233	|O
the	234	237	|O
vasopressor	238	249	|O
(	250	251	|O
V1	251	253	|O
receptor	254	262	|O
)	262	263	|O
responses	264	273	|O
to	274	276	|O
arginine	277	285	|O
-	285	286	|O
vasopressin	286	297	|O
(	298	299	|O
AVP	299	302	|O
)	302	303	|O
/	303	304	|O
weak	304	308	|O
oxytocin	309	317	|O
antagonist	318	328	|O
,	328	329	|O
[	330	331	|B-IUPAC
1	331	332	|I-IUPAC
-	332	333	|I-IUPAC
(	333	334	|I-IUPAC
beta	334	338	|I-IUPAC
-	338	339	|I-IUPAC
mercapto	339	347	|I-IUPAC
-	347	348	|I-IUPAC
beta	348	352	|I-IUPAC
,	352	353	|I-IUPAC
beta	353	357	|I-IUPAC
-	357	358	|I-IUPAC
pentamethylenepropionic	358	381	|I-IUPAC
acid	382	386	|I-IUPAC
)	386	387	|I-IUPAC
,	387	388	|I-IUPAC
2	389	390	|I-IUPAC
-	390	391	|I-IUPAC
O	391	392	|I-IUPAC
-	392	393	|I-IUPAC
methyltyrosine	393	407	|I-IUPAC
]	407	408	|I-IUPAC
arginine	408	416	|I-IUPAC
-	416	417	|I-IUPAC
vasopressin	417	428	|I-IUPAC
(	429	430	|O
d	430	431	|O
(	431	432	|O
CH2	432	435	|O
)	435	436	|O
5	436	437	|O
[	437	438	|O
Tyr	438	441	|O
(	441	442	|O
Me	442	444	|O
)	444	445	|O
2	445	446	|O
]	446	447	|O
AVP	447	450	|O
.	450	451	|O
B	452	453	|O
reported	454	462	|O
here	463	467	|O
,	467	468	|O
the	469	472	|O
Ile3	473	477	|O
analogue	478	486	|O
of	487	489	|O
A	490	491	|O
,	491	492	|O
is	493	495	|O
d	496	497	|O
(	497	498	|O
CH2	498	501	|O
)	501	502	|O
5	502	503	|O
[	503	504	|O
Tyr	504	507	|O
(	507	508	|O
Me	508	510	|O
)	510	511	|O
2	511	512	|O
]	512	513	|O
AVT	513	516	|O
(	517	518	|O
5	518	519	|O
below	520	525	|O
)	525	526	|O
and	527	530	|O
C	531	532	|O
is	533	535	|O
our	536	539	|O
previously	540	550	|O
reported	551	559	|O
potent	560	566	|O
nonselective	567	579	|O
oxytocin	580	588	|O
antagonist	589	599	|O
/	599	600	|O
AVP	600	603	|O
V1	604	606	|O
antagonist	607	617	|O
,	617	618	|O
[	619	620	|B-IUPAC
1	620	621	|I-IUPAC
-	621	622	|I-IUPAC
(	622	623	|I-IUPAC
beta	623	627	|I-IUPAC
-	627	628	|I-IUPAC
mercapto	628	636	|I-IUPAC
-	636	637	|I-IUPAC
beta	637	641	|I-IUPAC
,	641	642	|I-IUPAC
beta	642	646	|I-IUPAC
-	646	647	|I-IUPAC
pentamethylenepropionic	647	670	|I-IUPAC
acid	671	675	|I-IUPAC
)	675	676	|I-IUPAC
,	676	677	|I-IUPAC
2	677	678	|I-IUPAC
-	678	679	|I-IUPAC
O	679	680	|I-IUPAC
-	680	681	|I-IUPAC
methyltyrosine	682	696	|I-IUPAC
,	696	697	|I-IUPAC
8	697	698	|I-IUPAC
-	698	699	|I-IUPAC
ornithine	699	708	|I-IUPAC
]	708	709	|I-IUPAC
vasotocin	709	718	|I-IUPAC
(	719	720	|O
d	720	721	|O
(	721	722	|O
CH2	722	725	|O
)	725	726	|O
5	726	727	|O
[	727	728	|O
Tyr	728	731	|O
(	731	732	|O
Me	732	734	|O
)	734	735	|O
2	735	736	|O
]	736	737	|O
OVT	737	740	|O
)	740	741	|O
.	741	742	|O
The	743	746	|O
following	747	756	|O
substitutions	757	770	|O
and	771	774	|O
deletions	775	784	|O
,	784	785	|O
alone	786	791	|O
or	792	794	|O
in	795	797	|O
combination	798	809	|O
,	809	810	|O
were	811	815	|O
employed	816	824	|O
in	825	827	|O
A	828	829	|O
,	829	830	|O
B	831	832	|O
,	832	833	|O
and	834	837	|O
C	838	839	|O
:	839	840	|O
1	841	842	|B-IUPAC
-	842	843	|I-IUPAC
deaminopenicillamine	843	863	|I-IUPAC
(	864	865	|O
dP	865	867	|O
)	867	868	|O
;	868	869	|O
D	870	871	|O
-	871	872	|O
Tyr	872	875	|O
(	875	876	|O
Alk	876	879	|O
)	879	880	|O
2	880	881	|O
(	882	883	|O
where	883	888	|O
Alk	889	892	|O
=	893	894	|O
Me	895	897	|O
or	898	900	|O
Et	901	903	|O
)	903	904	|O
,	904	905	|O
D	906	907	|O
-	907	908	|O
Phe2	908	912	|O
;	912	913	|O
Val4	914	918	|O
,	918	919	|O
Thr4	920	924	|O
;	924	925	|O
delta	926	931	|O
3	932	933	|O
-	933	934	|O
Pro7	934	938	|O
;	938	939	|O
Lys8	940	944	|O
,	944	945	|O
Cit8	946	950	|O
;	950	951	|O
desGly9	952	959	|O
,	959	960	|O
desGly	961	967	|O
-	967	968	|O
NH2	968	971	|O
(	971	972	|O
9	972	973	|O
)	973	974	|O
,	974	975	|O
Ala	976	979	|O
-	979	980	|O
NH2	980	983	|O
(	983	984	|O
9	984	985	|O
)	985	986	|O
;	986	987	|O
Leu	988	991	|O
-	991	992	|O
NH2	992	995	|O
(	995	996	|O
9	996	997	|O
)	997	998	|O
;	998	999	|O
Arg	1000	1003	|O
-	1003	1004	|O
NH2	1004	1007	|O
(	1007	1008	|O
9	1008	1009	|O
)	1009	1010	|O
.	1010	1011	|O
The	1012	1015	|O
16	1016	1018	|O
new	1019	1022	|O
analogues	1023	1032	|O
are	1033	1036	|O
(	1037	1038	|O
1	1038	1039	|O
)	1039	1040	|O
d	1041	1042	|O
(	1042	1043	|O
CH2	1043	1046	|O
)	1046	1047	|O
5	1047	1048	|O
[	1048	1049	|O
D	1049	1050	|O
-	1050	1051	|O
Tyr	1051	1054	|O
(	1054	1055	|O
Me	1055	1057	|O
)	1057	1058	|O
2	1058	1059	|O
]	1059	1060	|O
AVP	1060	1063	|O
,	1063	1064	|O
(	1065	1066	|O
2	1066	1067	|O
)	1067	1068	|O
d	1069	1070	|O
(	1070	1071	|O
CH2	1071	1074	|O
)	1074	1075	|O
5	1075	1076	|O
[	1076	1077	|O
D	1077	1078	|O
-	1078	1079	|O
Tyr	1079	1082	|O
(	1082	1083	|O
Me	1083	1085	|O
)	1085	1086	|O
2	1086	1087	|O
,	1087	1088	|O
Val4	1089	1093	|O
,	1093	1094	|O
delta	1094	1099	|O
3	1100	1101	|O
-	1101	1102	|O
Pro7	1102	1106	|O
]	1106	1107	|O
AVP	1107	1110	|O
,	1110	1111	|O
(	1112	1113	|O
3	1113	1114	|O
)	1114	1115	|O
d	1116	1117	|O
(	1117	1118	|O
CH2	1118	1121	|O
)	1121	1122	|O
5	1122	1123	|O
[	1123	1124	|O
D	1124	1125	|O
-	1125	1126	|O
Tyr	1126	1129	|O
-	1129	1130	|O
(	1130	1131	|O
Et	1131	1133	|O
)	1133	1134	|O
2	1134	1135	|O
,	1135	1136	|O
Val4	1137	1141	|O
,	1141	1142	|O
Lys8	1142	1146	|O
]	1146	1147	|O
VP	1147	1149	|O
,	1149	1150	|O
(	1151	1152	|O
4	1152	1153	|O
)	1153	1154	|O
d	1155	1156	|O
(	1156	1157	|O
CH2	1157	1160	|O
)	1160	1161	|O
5	1161	1162	|O
[	1162	1163	|O
D	1163	1164	|O
-	1164	1165	|O
Tyr	1165	1168	|O
(	1168	1169	|O
Et	1169	1171	|O
)	1171	1172	|O
2	1172	1173	|O
,	1173	1174	|O
Val4	1174	1178	|O
,	1178	1179	|O
Cit8	1179	1183	|O
]	1183	1184	|O
VP	1184	1186	|O
,	1186	1187	|O
(	1188	1189	|O
5	1189	1190	|O
)	1190	1191	|O
d	1192	1193	|O
(	1193	1194	|O
CH2	1194	1197	|O
)	1197	1198	|O
5	1198	1199	|O
[	1199	1200	|O
Tyr	1200	1203	|O
(	1203	1204	|O
Me	1204	1206	|O
)	1206	1207	|O
2	1207	1208	|O
]	1208	1209	|O
AVT	1209	1212	|O
,	1212	1213	|O
(	1214	1215	|O
6	1215	1216	|O
)	1216	1217	|O
d	1218	1219	|O
(	1219	1220	|O
CH2	1220	1223	|O
)	1223	1224	|O
5	1224	1225	|O
[	1225	1226	|O
Tyr	1226	1229	|O
(	1229	1230	|O
Me	1230	1232	|O
)	1232	1233	|O
2	1233	1234	|O
,	1234	1235	|O
Lys8	1235	1239	|O
]	1239	1240	|O
VT	1240	1242	|O
,	1242	1243	|O
(	1244	1245	|O
7	1245	1246	|O
)	1246	1247	|O
dP	1248	1250	|O
[	1250	1251	|O
Tyr	1251	1254	|O
(	1254	1255	|O
Me	1255	1257	|O
)	1257	1258	|O
2	1258	1259	|O
]	1259	1260	|O
AVT	1260	1263	|O
,	1263	1264	|O
(	1265	1266	|O
8	1266	1267	|O
)	1267	1268	|O
dP	1269	1271	|O
[	1271	1272	|O
Tyr	1272	1275	|O
(	1275	1276	|O
Me	1276	1278	|O
)	1278	1279	|O
2	1279	1280	|O
,	1280	1281	|O
Val4	1281	1285	|O
]	1285	1286	|O
AVT	1286	1289	|O
,	1289	1290	|O
(	1291	1292	|O
9	1292	1293	|O
)	1293	1294	|O
d	1295	1296	|O
(	1296	1297	|O
CH2	1297	1300	|O
)	1300	1301	|O
5	1301	1302	|O
[	1302	1303	|O
D	1303	1304	|O
-	1304	1305	|O
Tyr	1305	1308	|O
(	1308	1309	|O
Me	1309	1311	|O
)	1311	1312	|O
2	1312	1313	|O
,	1313	1314	|O
Val4	1315	1319	|O
]	1319	1320	|O
AVT	1320	1323	|O
,	1323	1324	|O
(	1325	1326	|O
10	1326	1328	|O
)	1328	1329	|O
d	1330	1331	|O
(	1331	1332	|O
CH2	1332	1335	|O
)	1335	1336	|O
5	1336	1337	|O
[	1337	1338	|O
D	1338	1339	|O
-	1339	1340	|O
Phe2	1340	1344	|O
,	1344	1345	|O
Val4	1345	1349	|O
]	1349	1350	|O
AVT	1350	1353	|O
,	1353	1354	|O
(	1355	1356	|O
11	1356	1358	|O
)	1358	1359	|O
d	1360	1361	|O
(	1361	1362	|O
CH2	1362	1365	|O
)	1365	1366	|O
5	1366	1367	|O
[	1367	1368	|O
Tyr	1368	1371	|O
(	1371	1372	|O
Me	1372	1374	|O
)	1374	1375	|O
2	1375	1376	|O
,	1376	1377	|O
Thr4	1377	1381	|O
]	1381	1382	|O
OVT	1382	1385	|O
,	1385	1386	|O
(	1387	1388	|O
12	1388	1390	|O
)	1390	1391	|O
d	1392	1393	|O
(	1393	1394	|O
CH2	1394	1397	|O
)	1397	1398	|O
5	1398	1399	|O
[	1399	1400	|O
Tyr	1400	1403	|O
(	1403	1404	|O
Me	1404	1406	|O
)	1406	1407	|O
2	1407	1408	|O
,	1408	1409	|O
Thr4	1409	1413	|O
,	1413	1414	|O
Ala	1414	1417	|O
-	1417	1418	|O
NH2	1418	1421	|O
(	1421	1422	|O
9	1422	1423	|O
)	1423	1424	|O
]	1424	1425	|O
OVT	1425	1428	|O
,	1428	1429	|O
(	1430	1431	|O
13	1431	1433	|O
)	1433	1434	|O
d	1435	1436	|O
(	1436	1437	|O
CH2	1437	1440	|O
)	1440	1441	|O
5	1441	1442	|O
[	1442	1443	|O
Tyr	1443	1446	|O
(	1446	1447	|O
Me	1447	1449	|O
)	1449	1450	|O
2	1450	1451	|O
,	1451	1452	|O
Thr4	1452	1456	|O
,	1456	1457	|O
Leu	1457	1460	|O
-	1460	1461	|O
NH2	1461	1464	|O
(	1464	1465	|O
9	1465	1466	|O
)	1466	1467	|O
]	1467	1468	|O
OVT	1468	1471	|O
,	1471	1472	|O
(	1473	1474	|O
14	1474	1476	|O
)	1476	1477	|O
d	1478	1479	|O
(	1479	1480	|O
CH2	1480	1483	|O
)	1483	1484	|O
5	1484	1485	|O
[	1485	1486	|O
Tyr	1486	1489	|O
(	1489	1490	|O
Me	1490	1492	|O
)	1492	1493	|O
2	1493	1494	|O
,	1494	1495	|O
Thr4	1495	1499	|O
,	1499	1500	|O
Arg	1500	1503	|O
-	1503	1504	|O
NH2	1504	1507	|O
(	1507	1508	|O
9	1508	1509	|O
)	1509	1510	|O
]	1510	1511	|O
OVT	1511	1514	|O
,	1514	1515	|O
(	1516	1517	|O
15	1517	1519	|O
)	1519	1520	|O
desGly	1521	1527	|O
-	1527	1528	|O
NH2	1528	1531	|O
(	1531	1532	|O
9	1532	1533	|O
)	1533	1534	|O
,	1534	1535	|O
d	1535	1536	|O
(	1536	1537	|O
CH2	1537	1540	|O
)	1540	1541	|O
5	1541	1542	|O
[	1542	1543	|O
Tyr	1543	1546	|O
(	1546	1547	|O
Me	1547	1549	|O
)	1549	1550	|O
2	1550	1551	|O
,	1551	1552	|O
Thr4	1552	1556	|O
]	1556	1557	|O
OVT	1557	1560	|O
,	1560	1561	|O
(	1562	1563	|O
16	1563	1565	|O
)	1565	1566	|O
desGly9	1567	1574	|O
,	1574	1575	|O
d	1575	1576	|O
(	1576	1577	|O
CH2	1577	1580	|O
)	1580	1581	|O
5	1581	1582	|O
[	1582	1583	|O
Tyr	1583	1586	|O
(	1586	1587	|O
Me	1587	1589	|O
)	1589	1590	|O
2	1590	1591	|O
,	1591	1592	|O
Thr4	1592	1596	|O
]	1596	1597	|O
OVT	1597	1600	|O
.	1600	1601	|O
1-4	1602	1605	|O
are	1606	1609	|O
analogues	1610	1619	|O
of	1620	1622	|O
A	1623	1624	|O
,	1624	1625	|O
5-10	1626	1630	|O
are	1631	1634	|O
analogues	1635	1644	|O
of	1645	1647	|O
B	1648	1649	|O
,	1649	1650	|O
and	1651	1654	|O
11-16	1655	1660	|O
are	1661	1664	|O
analogues	1665	1674	|O
of	1675	1677	|O
C	1678	1679	|O
.	1679	1680	|O
Their	1681	1686	|O
protected	1687	1696	|O
precursors	1697	1707	|O
were	1708	1712	|O
synthesized	1713	1724	|O
either	1725	1731	|O
entirely	1732	1740	|O
by	1741	1743	|O
the	1744	1747	|O
solid	1748	1753	|O
-	1753	1754	|O
phase	1754	1759	|O
method	1760	1766	|O
or	1767	1769	|O
by	1770	1772	|O
a	1773	1774	|O
combination	1775	1786	|O
of	1787	1789	|O
solid	1790	1795	|O
-	1795	1796	|O
phase	1796	1801	|O
and	1802	1805	|O
solution	1806	1814	|O
methods	1815	1822	|O
(	1823	1824	|O
1	1824	1825	|O
+	1826	1827	|O
8	1828	1829	|O
or	1830	1832	|O
8	1833	1834	|O
+	1835	1836	|O
1	1837	1838	|O
couplings	1839	1848	|O
)	1848	1849	|O
.	1849	1850	|O
All	1851	1854	|O
analogues	1855	1864	|O
were	1865	1869	|O
tested	1870	1876	|O
in	1877	1879	|O
rats	1880	1884	|O
for	1885	1888	|O
agonistic	1889	1898	|O
and	1899	1902	|O
antagonistic	1903	1915	|O
activities	1916	1926	|O
in	1927	1929	|O
oxytocic	1930	1938	|O
(	1939	1940	|O
in	1940	1942	|O
vitro	1943	1948	|O
,	1948	1949	|O
without	1950	1957	|O
and	1958	1961	|O
with	1962	1966	|O
Mg2+	1967	1971	|O
,	1971	1972	|O
and	1973	1976	|O
in	1977	1979	|O
vivo	1980	1984	|O
)	1984	1985	|O
assays	1986	1992	|O
as	1993	1995	|O
well	1996	2000	|O
as	2001	2003	|O
by	2004	2006	|O
antidiuretic	2007	2019	|O
and	2020	2023	|O
vasopressor	2024	2035	|O
assays	2036	2042	|O
.	2042	2043	|O
All	2044	2047	|O
analogues	2048	2057	|O
exhibit	2058	2065	|O
potent	2066	2072	|O
oxytocic	2073	2081	|O
antagonism	2082	2092	|O
in	2093	2095	|O
vitro	2096	2101	|O
and	2102	2105	|O
in	2106	2108	|O
vivo	2109	2113	|O
.	2113	2114	|O
With	2115	2119	|O
an	2120	2122	|O
in	2123	2125	|O
vitro	2126	2131	|O
pA2	2132	2135	|O
(	2136	2137	|O
in	2137	2139	|O
the	2140	2143	|O
absence	2144	2151	|O
of	2152	2154	|O
Mg2+	2155	2159	|O
)	2159	2160	|O
=	2161	2162	|O
9.12	2163	2167	|O
+	2168	2169	|O
/	2169	2170	|O
-	2170	2171	|O
0.09	2172	2176	|O
,	2176	2177	|O
dP	2178	2180	|O
[	2180	2181	|O
Tyr	2181	2184	|O
(	2184	2185	|O
Me	2185	2187	|O
)	2187	2188	|O
2	2188	2189	|O
]	2189	2190	|O
AVT	2190	2193	|O
is	2194	2196	|O
(	2197	2198	|O
7	2198	2199	|O
)	2199	2200	|O
one	2201	2204	|O
of	2205	2207	|O
the	2208	2211	|O
most	2212	2216	|O
potent	2217	2223	|O
in	2224	2226	|O
vitro	2227	2232	|O
oxytocin	2233	2241	|O
antagonists	2242	2253	|O
reported	2254	2262	|O
to	2263	2265	|O
date	2266	2270	|O
.	2270	2271	|O
Fifteen	2272	2279	|O
of	2280	2282	|O
these	2283	2288	|O
analogues	2289	2298	|O
(	2299	2300	|O
all	2300	2303	|O
but	2304	2307	|O
6	2308	2309	|O
)	2309	2310	|O
appear	2311	2317	|O
as	2318	2320	|O
potent	2321	2327	|O
or	2328	2330	|O
more	2331	2335	|O
potent	2336	2342	|O
in	2343	2345	|O
vivo	2346	2350	|O
oxytocin	2351	2359	|O
antagonists	2360	2371	|O
than	2372	2376	|O
C	2377	2378	|O
(	2379	2380	|O
pA2	2380	2383	|O
=	2384	2385	|O
7.37	2386	2390	|O
+	2391	2392	|O
/	2392	2393	|O
-	2393	2394	|O
0.17	2395	2399	|O
)	2399	2400	|O
.	2400	2401	|O
Analogues	2402	2411	|O
1-9	2412	2415	|O
and	2416	2419	|O
14	2420	2422	|O
are	2423	2426	|O
potent	2427	2433	|O
AVP	2434	2437	|O
V1	2438	2440	|O
antagonists	2441	2452	|O
.	2452	2453	|O
Their	2454	2459	|O
anti	2460	2464	|O
-	2464	2465	|O
V1	2465	2467	|O
pA2	2468	2471	|O
values	2472	2478	|O
range	2479	2484	|O
from	2485	2489	|O
7.92	2490	2494	|O
to	2495	2497	|O
8.45	2498	2502	|O
.	2502	2503	|O
They	2504	2508	|O
are	2509	2512	|O
thus	2513	2517	|O
nonselective	2518	2530	|O
oxytocin	2531	2539	|O
antagonists	2540	2551	|O
.	2551	2552	|O
(	2552	2553	|O
ABSTRACT	2553	2561	|O
TRUNCATED	2562	2571	|O
AT	2572	2574	|O
400	2575	2578	|O
WORDS	2579	2584	|O
)	2584	2585	|O

### abstracts1784.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
6	12	13	|B-MODIFIER
-	13	14	|I-MODIFIER
substituted	14	25	|I-MODIFIER
decahydroisoquinoline	26	47	|B-IUPAC
-	47	48	|I-IUPAC
3	48	49	|I-IUPAC
-	49	50	|I-IUPAC
carboxylic	50	60	|I-IUPAC
acids	61	66	|I-IUPAC
were	67	71	|O
prepared	72	80	|O
as	81	83	|O
excitatory	84	94	|O
amino	95	100	|O
acid	101	105	|O
(	106	107	|O
EAA	107	110	|O
)	110	111	|O
receptor	112	120	|O
antagonists	121	132	|O
.	132	133	|O
These	134	139	|O
compounds	140	149	|O
are	150	153	|O
antagonists	154	165	|O
at	166	168	|O
the	169	172	|O
N	173	174	|B-IUPAC
-	174	175	|I-IUPAC
methyl	175	181	|I-IUPAC
-	181	182	|I-IUPAC
D	182	183	|I-IUPAC
-	183	184	|I-IUPAC
aspartate	184	193	|I-IUPAC
(	194	195	|O
NMDA	195	199	|O
)	199	200	|O
and	201	204	|O
2	205	206	|B-IUPAC
-	206	207	|I-IUPAC
amino	207	212	|I-IUPAC
-	212	213	|I-IUPAC
3	213	214	|I-IUPAC
-	214	215	|I-IUPAC
(	215	216	|I-IUPAC
5	216	217	|I-IUPAC
-	217	218	|I-IUPAC
methyl	218	224	|I-IUPAC
-	224	225	|I-IUPAC
3	225	226	|I-IUPAC
-	226	227	|I-IUPAC
hydroxyisoxazol	227	242	|I-IUPAC
-	242	243	|I-IUPAC
4	243	244	|I-IUPAC
-	244	245	|I-IUPAC
yl	245	247	|I-IUPAC
)	247	248	|I-IUPAC
propanoic	249	258	|I-IUPAC
acid	259	263	|I-IUPAC
(	264	265	|O
AMPA	265	269	|O
)	269	270	|O
subclasses	271	281	|O
of	282	284	|O
ligand	285	291	|O
gated	292	297	|O
ion	298	301	|O
channel	302	309	|O
(	310	311	|O
ionotropic	311	321	|O
)	321	322	|O
EAA	323	326	|O
receptors	327	336	|O
.	336	337	|O
(	338	339	|B-IUPAC
3S	339	341	|I-IUPAC
,	341	342	|I-IUPAC
4aR	342	345	|I-IUPAC
,	345	346	|I-IUPAC
6R	347	349	|I-IUPAC
,	349	350	|I-IUPAC
8aR	350	353	|I-IUPAC
)	353	354	|I-IUPAC
-	354	355	|I-IUPAC
6	355	356	|I-IUPAC
-	356	357	|I-IUPAC
(	357	358	|I-IUPAC
2	358	359	|I-IUPAC
-	359	360	|I-IUPAC
(	360	361	|I-IUPAC
1H	361	363	|I-IUPAC
-	363	364	|I-IUPAC
tetrazol	364	372	|I-IUPAC
-	372	373	|I-IUPAC
5	373	374	|I-IUPAC
-	374	375	|I-IUPAC
yl	375	377	|I-IUPAC
)	377	378	|I-IUPAC
ethyl	378	383	|I-IUPAC
)	383	384	|I-IUPAC
-	384	385	|I-IUPAC
1,2,3,4,4	386	395	|I-IUPAC
a	395	396	|I-IUPAC
,	396	397	|I-IUPAC
5,6,7,8,8	397	406	|I-IUPAC
a	406	407	|I-IUPAC
-	407	408	|I-IUPAC
decahydroisoquinoline	408	429	|I-IUPAC
-	429	430	|I-IUPAC
3	430	431	|I-IUPAC
-	431	432	|I-IUPAC
carboxylic	432	442	|I-IUPAC
acid	443	447	|I-IUPAC
(	448	449	|O
9	449	450	|O
)	450	451	|O
is	452	454	|O
a	455	456	|O
potent	457	463	|O
,	463	464	|O
selective	465	474	|O
and	475	478	|O
systemically	479	491	|O
active	492	498	|O
AMPA	499	503	|O
antagonist	504	514	|O
.	514	515	|O
Other	516	521	|O
analogs	522	529	|O
from	530	534	|O
this	535	539	|O
series	540	546	|O
,	546	547	|O
including	548	557	|O
(	558	559	|B-IUPAC
3S	559	561	|I-IUPAC
,	561	562	|I-IUPAC
4aR	562	565	|I-IUPAC
,	565	566	|I-IUPAC
6S	566	568	|I-IUPAC
,	568	569	|I-IUPAC
8aR	569	572	|I-IUPAC
)	572	573	|I-IUPAC
-	573	574	|I-IUPAC
6	574	575	|I-IUPAC
-	575	576	|I-IUPAC
(	576	577	|I-IUPAC
(	577	578	|I-IUPAC
1H	578	580	|I-IUPAC
-	580	581	|I-IUPAC
tetrazol	581	589	|I-IUPAC
-	589	590	|I-IUPAC
5	590	591	|I-IUPAC
-	591	592	|I-IUPAC
yl	592	594	|I-IUPAC
)	594	595	|I-IUPAC
methyl	595	601	|I-IUPAC
)	601	602	|I-IUPAC
-	602	603	|I-IUPAC
1,2,3,4,4	604	613	|I-IUPAC
a	613	614	|I-IUPAC
,	614	615	|I-IUPAC
5,6,7,8,8	615	624	|I-IUPAC
a	624	625	|I-IUPAC
-	625	626	|I-IUPAC
decahydroisoquinoline	626	647	|I-IUPAC
-	647	648	|I-IUPAC
3	648	649	|I-IUPAC
-	649	650	|I-IUPAC
carboxylic	650	660	|I-IUPAC
acid	661	665	|I-IUPAC
(	666	667	|O
32	667	669	|O
)	669	670	|O
and	671	674	|O
(	675	676	|B-IUPAC
3S	676	678	|I-IUPAC
,	678	679	|I-IUPAC
4aR	679	682	|I-IUPAC
,	682	683	|I-IUPAC
6S	683	685	|I-IUPAC
,	685	686	|I-IUPAC
8aR	686	689	|I-IUPAC
)	689	690	|I-IUPAC
-	690	691	|I-IUPAC
6	691	692	|I-IUPAC
-	692	693	|I-IUPAC
(	694	695	|I-IUPAC
phosphonomethyl	695	710	|I-IUPAC
)	710	711	|I-IUPAC
-	711	712	|I-IUPAC
1,2,3,4,4	712	721	|I-IUPAC
a	721	722	|I-IUPAC
,	722	723	|I-IUPAC
5,6,7,8,8	723	732	|I-IUPAC
a	732	733	|I-IUPAC
-	733	734	|I-IUPAC
decahydroisoquinoline	734	755	|I-IUPAC
-	755	756	|I-IUPAC
3	756	757	|I-IUPAC
-	757	758	|I-IUPAC
ca	758	760	|I-IUPAC
rboxylic	761	769	|I-IUPAC
acid	770	774	|I-IUPAC
(	775	776	|O
61	776	778	|O
)	778	779	|O
are	780	783	|O
potent	784	790	|O
,	790	791	|O
selective	792	801	|O
,	801	802	|O
and	803	806	|O
systemically	807	819	|O
active	820	826	|O
NMDA	827	831	|O
antagonists	832	843	|O
.	843	844	|O
This	845	849	|O
and	850	853	|O
the	854	857	|O
subsequent	858	868	|O
publication	869	880	|O
look	881	885	|O
at	886	888	|O
the	889	892	|O
AMPA	893	897	|O
antagonist	898	908	|O
aspects	909	916	|O
of	917	919	|O
this	920	924	|O
SAR	925	928	|O
.	928	929	|O
Herein	930	936	|O
we	937	939	|O
report	940	946	|O
the	947	950	|O
effects	951	958	|O
of	959	961	|O
varying	962	969	|O
stereochemistry	970	985	|O
around	986	992	|O
the	993	996	|O
hydroisoquinoline	997	1014	|O
ring	1015	1019	|O
;	1019	1020	|O
of	1021	1023	|O
tetrahydro	1024	1034	|O
-	1034	1035	|O
versus	1035	1041	|O
decahydroisoquinoline	1042	1063	|O
;	1063	1064	|O
of	1065	1067	|O
having	1068	1074	|O
the	1075	1078	|O
carboxylic	1079	1089	|O
acid	1090	1094	|O
at	1095	1097	|O
C	1098	1099	|O
-	1099	1100	|O
1	1100	1101	|O
versus	1102	1108	|O
C	1109	1110	|O
-	1110	1111	|O
3	1111	1112	|O
;	1112	1113	|O
of	1114	1116	|O
varying	1117	1124	|O
the	1125	1128	|O
length	1129	1135	|O
of	1136	1138	|O
the	1139	1142	|O
carbon	1143	1149	|O
chain	1150	1155	|O
connecting	1156	1166	|O
a	1167	1168	|O
tetrazole	1169	1178	|O
to	1179	1181	|O
the	1182	1185	|O
bicyclic	1186	1194	|O
nucleus	1195	1202	|O
;	1202	1203	|O
and	1204	1207	|O
of	1208	1210	|O
holding	1211	1218	|O
the	1219	1222	|O
connecting	1223	1233	|O
chain	1234	1239	|O
constant	1240	1248	|O
at	1249	1251	|O
two	1252	1255	|O
atoms	1256	1261	|O
,	1261	1262	|O
the	1263	1266	|O
effect	1267	1273	|O
of	1274	1276	|O
heteroatom	1277	1287	|O
substitution	1288	1300	|O
in	1301	1303	|O
the	1304	1307	|O
position	1308	1316	|O
adjacent	1317	1325	|O
to	1326	1328	|O
the	1329	1332	|O
bicyclic	1333	1341	|O
nucleus	1342	1349	|O
and	1350	1353	|O
substitution	1354	1366	|O
with	1367	1371	|O
methyl	1372	1378	|O
or	1379	1381	|O
phenyl	1382	1388	|O
on	1389	1391	|O
the	1392	1395	|O
chain	1396	1401	|O
.	1401	1402	|O
Compounds	1403	1412	|O
were	1413	1417	|O
evaluated	1418	1427	|O
on	1428	1430	|O
rat	1431	1434	|O
cortical	1435	1443	|O
tissue	1444	1450	|O
for	1451	1454	|O
their	1455	1460	|O
ability	1461	1468	|O
to	1469	1471	|O
inhibit	1472	1479	|O
the	1480	1483	|O
binding	1484	1491	|O
of	1492	1494	|O
radioligands	1495	1507	|O
selective	1508	1517	|O
for	1518	1521	|O
AMPA	1522	1526	|O
(	1527	1528	|O
[	1528	1529	|O
3H	1529	1531	|O
]	1531	1532	|O
AMPA	1532	1536	|O
)	1536	1537	|O
,	1537	1538	|O
NMDA	1539	1543	|O
(	1544	1545	|O
[	1545	1546	|O
3H	1546	1548	|O
]	1548	1549	|O
CGS	1549	1552	|O
19755	1553	1558	|O
)	1558	1559	|O
,	1559	1560	|O
and	1561	1564	|O
kainic	1565	1571	|O
acid	1572	1576	|O
(	1577	1578	|O
[	1578	1579	|O
3H	1579	1581	|O
]	1581	1582	|O
-	1582	1583	|O
kainic	1583	1589	|O
acid	1590	1594	|O
)	1594	1595	|O
receptors	1596	1605	|O
and	1606	1609	|O
for	1610	1613	|O
their	1614	1619	|O
ability	1620	1627	|O
to	1628	1630	|O
inhibit	1631	1638	|O
depolarizations	1639	1654	|O
induced	1655	1662	|O
by	1663	1665	|O
AMPA	1666	1670	|O
(	1671	1672	|O
40	1672	1674	|O
microM	1675	1681	|O
)	1681	1682	|O
,	1682	1683	|O
NMDA	1684	1688	|O
(	1689	1690	|O
40	1690	1692	|O
microM	1693	1699	|O
)	1699	1700	|O
,	1700	1701	|O
and	1702	1705	|O
kainic	1706	1712	|O
acid	1713	1717	|O
(	1718	1719	|O
10	1719	1721	|O
microM	1722	1728	|O
)	1728	1729	|O
.	1729	1730	|O
Our	1731	1734	|O
findings	1735	1743	|O
revealed	1744	1752	|O
that	1753	1757	|O
the	1758	1761	|O
optimal	1762	1769	|O
stereochemical	1770	1784	|O
array	1785	1790	|O
was	1791	1794	|O
the	1795	1798	|O
same	1799	1803	|O
for	1804	1807	|O
both	1808	1812	|O
NMDA	1813	1817	|O
(	1818	1819	|O
32	1819	1821	|O
and	1822	1825	|O
61	1826	1828	|O
)	1828	1829	|O
and	1830	1833	|O
AMPA	1834	1838	|O
(	1839	1840	|O
9	1840	1841	|O
)	1841	1842	|O
antagonists	1843	1854	|O
identified	1855	1865	|O
in	1866	1868	|O
this	1869	1873	|O
series	1874	1880	|O
and	1881	1884	|O
that	1885	1889	|O
the	1890	1893	|O
tetrahydroisoquinoline	1894	1916	|O
(	1917	1918	|O
25	1918	1920	|O
)	1920	1921	|O
and	1922	1925	|O
the	1926	1929	|O
C	1930	1931	|B-MODIFIER
-	1931	1932	|I-MODIFIER
1	1932	1933	|I-MODIFIER
carboxy	1934	1941	|B-IUPAC
(	1942	1943	|O
30	1943	1945	|O
)	1945	1946	|O
analogs	1947	1954	|B-MODIFIER
of	1955	1957	|O
9	1958	1959	|O
are	1960	1963	|O
inactive	1964	1972	|O
.	1972	1973	|O
With	1974	1978	|O
a	1979	1980	|O
tetrazole	1981	1990	|O
in	1991	1993	|O
the	1994	1997	|O
distal	1998	2004	|O
acid	2005	2009	|O
position	2010	2018	|O
,	2018	2019	|O
an	2020	2022	|O
ethylene	2023	2031	|O
spacer	2032	2038	|O
(	2039	2040	|O
9	2040	2041	|O
)	2041	2042	|O
is	2043	2045	|O
optimal	2046	2053	|O
;	2053	2054	|O
substitution	2055	2067	|O
with	2068	2072	|O
oxygen	2073	2079	|O
or	2080	2082	|O
nitrogen	2083	2091	|O
on	2092	2094	|O
the	2095	2098	|O
chain	2099	2104	|O
in	2105	2107	|O
the	2108	2111	|O
position	2112	2120	|O
adjacent	2121	2129	|O
to	2130	2132	|O
the	2133	2136	|O
bicyclic	2137	2145	|O
nucleus	2146	2153	|O
significantly	2154	2167	|O
reduced	2168	2175	|O
activity	2176	2184	|O
,	2184	2185	|O
while	2186	2191	|O
substitution	2192	2204	|O
with	2205	2209	|O
a	2210	2211	|O
methyl	2212	2218	|O
or	2219	2221	|O
phenyl	2222	2228	|O
group	2229	2234	|O
on	2235	2237	|O
the	2238	2241	|O
chain	2242	2247	|O
was	2248	2251	|O
well	2252	2256	|O
tolerated	2257	2266	|O
.	2266	2267	|O

### abstracts2322.txt
As	0	2	|O
part	3	7	|O
of	8	10	|O
a	11	12	|O
program	13	20	|O
in	21	23	|O
which	24	29	|O
we	30	32	|O
are	33	36	|O
attempting	37	47	|O
(	48	49	|O
a	49	50	|O
)	50	51	|O
to	52	54	|O
delineate	55	64	|O
the	65	68	|O
structural	69	79	|O
features	80	88	|O
at	89	91	|O
positions	92	101	|O
1-9	102	105	|O
in	106	108	|O
our	109	112	|O
previously	113	123	|O
reported	124	132	|O
antidiuretic	133	145	|O
antagonists	146	157	|O
required	158	166	|O
for	167	170	|O
antidiuretic	171	183	|O
antagonism	184	194	|O
and	195	198	|O
(	199	200	|O
b	200	201	|O
)	201	202	|O
to	203	205	|O
obtain	206	212	|O
analogues	213	222	|O
with	223	227	|O
enhanced	228	236	|O
antiantidiuretic	237	253	|O
potency	254	261	|O
and	262	265	|O
/	265	266	|O
or	266	268	|O
selectivity	269	280	|O
,	280	281	|O
we	282	284	|O
have	285	289	|O
synthesized	290	301	|O
14	302	304	|O
new	305	308	|O
analogues	309	318	|O
of	319	321	|O
the	322	325	|O
antidiuretic	326	338	|O
antagonist	339	349	|O
[	350	351	|B-IUPAC
1	351	352	|I-IUPAC
-	352	353	|I-IUPAC
(	353	354	|I-IUPAC
beta	354	358	|I-IUPAC
-	358	359	|I-IUPAC
mercapto	359	367	|I-IUPAC
-	367	368	|I-IUPAC
beta	368	372	|I-IUPAC
,	372	373	|I-IUPAC
beta	373	377	|I-IUPAC
-	377	378	|I-IUPAC
cyclopentamethylenepropionic	378	406	|I-IUPAC
acid	407	411	|I-IUPAC
)	411	412	|I-IUPAC
,	412	413	|I-IUPAC
2	413	414	|I-IUPAC
-	414	415	|I-IUPAC
D	415	416	|I-IUPAC
-	416	417	|I-IUPAC
phenylalanine	417	430	|I-IUPAC
,	430	431	|I-IUPAC
4	431	432	|I-IUPAC
-	432	433	|I-IUPAC
valine	433	439	|I-IUPAC
]	439	440	|I-IUPAC
arginine	440	448	|I-IUPAC
-	448	449	|I-IUPAC
vasopressin	449	460	|I-IUPAC
[	461	462	|O
d	462	463	|O
-	463	464	|O
(	464	465	|O
CH2	465	468	|O
)	468	469	|O
5	469	470	|O
-	470	471	|O
D	471	472	|O
-	472	473	|O
Phe2VAVP	473	481	|O
)	481	482	|O
,	482	483	|O
in	484	486	|O
which	487	492	|O
the	493	496	|O
valine	497	503	|O
residue	504	511	|O
at	512	514	|O
position	515	523	|O
4	524	525	|O
was	526	529	|O
replaced	530	538	|O
by	539	541	|O
the	542	545	|O
following	546	555	|O
L	556	557	|B-IUPAC
-	557	558	|I-IUPAC
amino	558	563	|I-IUPAC
acids	564	569	|I-IUPAC
and	570	573	|O
glycine	574	581	|B-PARTIUPAC
:	581	582	|O
Ile	583	586	|O
,	586	587	|O
Abu	588	591	|O
,	591	592	|O
Thr	593	596	|O
,	596	597	|O
Ala	598	601	|O
,	601	602	|O
Gln	603	606	|O
,	606	607	|O
Lys	608	611	|O
,	611	612	|O
Cha	613	616	|O
,	616	617	|O
Nle	618	621	|O
,	621	622	|O
Nva	623	626	|O
,	626	627	|O
Phe	628	631	|O
,	631	632	|O
Leu	633	636	|O
,	636	637	|O
Gly	638	641	|O
,	641	642	|O
Tyr	643	646	|O
,	646	647	|O
and	648	651	|O
Pro	652	655	|O
.	655	656	|O
These	657	662	|O
analogues	663	672	|O
are	673	676	|O
1	677	678	|O
,	678	679	|O
d	680	681	|O
-	681	682	|O
(	682	683	|O
CH2	683	686	|O
)	686	687	|O
5	687	688	|O
-	688	689	|O
D	689	690	|O
-	690	691	|O
Phe2	691	695	|O
,	695	696	|O
Ile4AVP	696	703	|O
;	703	704	|O
2	705	706	|O
,	706	707	|O
d	708	709	|O
(	709	710	|O
CH2	710	713	|O
)	713	714	|O
5	714	715	|O
-	715	716	|O
D	716	717	|O
-	717	718	|O
Phe2	718	722	|O
,	722	723	|O
Abu4AVP	723	730	|O
;	730	731	|O
3	732	733	|O
,	733	734	|O
d	735	736	|O
(	736	737	|O
CH2	737	740	|O
)	740	741	|O
5	741	742	|O
-	742	743	|O
D	743	744	|O
-	744	745	|O
Phe2	745	749	|O
,	749	750	|O
Thr4AVP	750	757	|O
;	757	758	|O
4	759	760	|O
,	760	761	|O
d	762	763	|O
(	763	764	|O
CH2	764	767	|O
)	767	768	|O
5	768	769	|O
-	769	770	|O
D	770	771	|O
-	771	772	|O
Phe2	772	776	|O
,	776	777	|O
Ala4AVP	777	784	|O
;	784	785	|O
5	785	786	|O
,	786	787	|O
d	788	789	|O
(	789	790	|O
CH2	790	793	|O
)	793	794	|O
5	794	795	|O
-	795	796	|O
D	796	797	|O
-	797	798	|O
Phe2AVP	798	805	|O
;	805	806	|O
6	807	808	|O
,	808	809	|O
d	810	811	|O
(	811	812	|O
CH2	812	815	|O
)	815	816	|O
5	816	817	|O
-	817	818	|O
D	818	819	|O
-	819	820	|O
Phe2	820	824	|O
,	824	825	|O
Lys4AVP	825	832	|O
;	832	833	|O
7	834	835	|O
,	835	836	|O
d	837	838	|O
(	838	839	|O
CH2	839	842	|O
)	842	843	|O
5	843	844	|O
-	844	845	|O
D	845	846	|O
-	846	847	|O
Phe2	847	851	|O
,	851	852	|O
Cha4AVP	852	859	|O
;	859	860	|O
8	861	862	|O
,	862	863	|O
d	864	865	|O
(	865	866	|O
CH2	866	869	|O
)	869	870	|O
5	870	871	|O
-	871	872	|O
D	872	873	|O
-	873	874	|O
Phe2	874	878	|O
,	878	879	|O
Nle4AVP	879	886	|O
;	886	887	|O
9	888	889	|O
,	889	890	|O
d	891	892	|O
(	892	893	|O
CH2	893	896	|O
)	896	897	|O
5	897	898	|O
-	898	899	|O
D	899	900	|O
-	900	901	|O
Phe2	901	905	|O
,	905	906	|O
Nva4AVP	906	913	|O
;	913	914	|O
10	915	917	|O
,	917	918	|O
d	919	920	|O
(	920	921	|O
CH2	921	924	|O
)	924	925	|O
5	925	926	|O
-	926	927	|O
D	927	928	|O
-	928	929	|O
Phe2	929	933	|O
,	933	934	|O
Phe4AVP	934	941	|O
;	941	942	|O
11	943	945	|O
,	945	946	|O
d	947	948	|O
(	948	949	|O
CH2	949	952	|O
)	952	953	|O
5	953	954	|O
-	954	955	|O
D	955	956	|O
-	956	957	|O
Phe2	957	961	|O
,	961	962	|O
Leu4AVP	962	969	|O
;	969	970	|O
12	971	973	|O
,	973	974	|O
d	975	976	|O
(	976	977	|O
CH2	977	980	|O
)	980	981	|O
5	981	982	|O
-	982	983	|O
D	983	984	|O
-	984	985	|O
Phe2	985	989	|O
,	989	990	|O
Gly4AVP	990	997	|O
;	997	998	|O
13	999	1001	|O
,	1001	1002	|O
d	1003	1004	|O
(	1004	1005	|O
CH2	1005	1008	|O
)	1008	1009	|O
5	1009	1010	|O
-	1010	1011	|O
D	1011	1012	|O
-	1012	1013	|O
Phe2	1013	1017	|O
,	1017	1018	|O
Tyr4AVP	1018	1025	|O
;	1025	1026	|O
14	1027	1029	|O
,	1029	1030	|O
d	1031	1032	|O
(	1032	1033	|O
CH2	1033	1036	|O
)	1036	1037	|O
5	1037	1038	|O
-	1038	1039	|O
D	1039	1040	|O
-	1040	1041	|O
Phe2	1041	1045	|O
,	1045	1046	|O
Pro4AVP	1046	1053	|O
.	1053	1054	|O
The	1055	1058	|O
protected	1059	1068	|O
intermediates	1069	1082	|O
required	1083	1091	|O
for	1092	1095	|O
the	1096	1099	|O
synthesis	1100	1109	|O
of	1110	1112	|O
all	1113	1116	|O
of	1117	1119	|O
these	1120	1125	|O
peptides	1126	1134	|O
were	1135	1139	|O
prepared	1140	1148	|O
by	1149	1151	|O
the	1152	1155	|O
solid	1156	1161	|O
-	1161	1162	|O
phase	1162	1167	|O
method	1168	1174	|O
and	1175	1178	|O
cleaved	1179	1186	|O
from	1187	1191	|O
the	1192	1195	|O
resin	1196	1201	|O
by	1202	1204	|O
ammonolysis	1205	1216	|O
.	1216	1217	|O
Following	1218	1227	|O
deblocking	1228	1238	|O
with	1239	1243	|O
Na	1244	1246	|O
in	1247	1249	|O
NH3	1250	1253	|O
and	1254	1257	|O
oxidizing	1258	1267	|O
with	1268	1272	|O
K3	1273	1275	|O
[	1275	1276	|O
Fe	1276	1278	|O
(	1278	1279	|O
CN	1279	1281	|O
)	1281	1282	|O
6	1282	1283	|O
]	1283	1284	|O
,	1284	1285	|O
each	1286	1290	|O
peptide	1291	1298	|O
was	1299	1302	|O
purified	1303	1311	|O
on	1312	1314	|O
Sephadex	1315	1323	|O
G	1324	1325	|O
-	1325	1326	|O
15	1326	1328	|O
in	1329	1331	|O
a	1332	1333	|O
two	1334	1337	|O
-	1337	1338	|O
step	1338	1342	|O
procedure	1343	1352	|O
using	1353	1358	|O
50%	1359	1362	|O
HOAc	1363	1367	|O
and	1368	1371	|O
0.2	1372	1375	|O
M	1376	1377	|O
HOAc	1378	1382	|O
as	1383	1385	|O
eluants	1386	1393	|O
.	1393	1394	|O
Analogues	1395	1404	|O
1-14	1405	1409	|O
were	1410	1414	|O
tested	1415	1421	|O
for	1422	1425	|O
agonistic	1426	1435	|O
and	1436	1439	|O
antagonistic	1440	1452	|O
activities	1453	1463	|O
by	1464	1466	|O
antidiuretic	1467	1479	|O
,	1479	1480	|O
vasopressor	1481	1492	|O
,	1492	1493	|O
and	1494	1497	|O
oxytocic	1498	1506	|O
assays	1507	1513	|O
in	1514	1516	|O
rats	1517	1521	|O
.	1521	1522	|O
Analogues	1523	1532	|O
1	1533	1534	|O
,	1534	1535	|O
2	1536	1537	|O
,	1537	1538	|O
and	1539	1542	|O
4-6	1543	1546	|O
exhibit	1547	1554	|O
no	1555	1557	|O
detectable	1558	1568	|O
antidiuretic	1569	1581	|O
agonistic	1582	1591	|O
activity	1592	1600	|O
.	1600	1601	|O
All	1602	1605	|O
analogues	1606	1615	|O
,	1615	1616	|O
with	1617	1621	|O
the	1622	1625	|O
exception	1626	1635	|O
of	1636	1638	|O
the	1639	1642	|O
Pro4	1643	1647	|O
-	1647	1648	|O
containing	1648	1658	|O
analogue	1659	1667	|O
,	1667	1668	|O
are	1669	1672	|O
antidiuretic	1673	1685	|O
antagonists	1686	1697	|O
.	1697	1698	|O
Their	1699	1704	|O
antiantidiuretic	1705	1721	|O
pA2	1722	1725	|O
values	1726	1732	|O
are	1733	1736	|O
as	1737	1739	|O
follows	1740	1747	|O
:	1747	1748	|O
1	1749	1750	|O
,	1750	1751	|O
8.24	1752	1756	|O
+	1757	1758	|O
/	1758	1759	|O
-	1759	1760	|O
0.08	1761	1765	|O
;	1765	1766	|O
2	1767	1768	|O
,	1768	1769	|O
7.96	1770	1774	|O
+	1775	1776	|O
/	1776	1777	|O
-	1777	1778	|O
0.07	1779	1783	|O
;	1783	1784	|O
3	1785	1786	|O
,	1786	1787	|O
7.62	1788	1792	|O
+	1793	1794	|O
/	1794	1795	|O
-	1795	1796	|O
0.09	1797	1801	|O
;	1801	1802	|O
4	1803	1804	|O
,	1804	1805	|O
7.52	1806	1810	|O
+	1811	1812	|O
/	1812	1813	|O
-	1813	1814	|O
0.03	1815	1819	|O
;	1819	1820	|O
5	1821	1822	|O
,	1822	1823	|O
7.21	1824	1828	|O
+	1829	1830	|O
/	1830	1831	|O
-	1831	1832	|O
0.07	1833	1837	|O
;	1837	1838	|O
6	1839	1840	|O
,	1840	1841	|O
7.22	1842	1846	|O
+	1847	1848	|O
/	1848	1849	|O
-	1849	1850	|O
0.12	1851	1855	|O
;	1855	1856	|O
7	1857	1858	|O
,	1858	1859	|O
7.19	1860	1864	|O
+	1865	1866	|O
/	1866	1867	|O
-	1867	1868	|O
0.08	1869	1873	|O
;	1873	1874	|O
8	1875	1876	|O
,	1876	1877	|O
7.12	1878	1882	|O
+	1883	1884	|O
/	1884	1885	|O
-	1885	1886	|O
0.09	1887	1891	|O
;	1891	1892	|O
9	1893	1894	|O
,	1894	1895	|O
6.99	1896	1900	|O
+	1901	1902	|O
/	1902	1903	|O
-	1903	1904	|O
0.06	1905	1909	|O
;	1909	1910	|O
10	1911	1913	|O
,	1913	1914	|O
6.07	1915	1919	|O
+	1920	1921	|O
/	1921	1922	|O
-	1922	1923	|O
0.11	1924	1928	|O
;	1928	1929	|O
11	1930	1932	|O
,	1932	1933	|O
6.07	1934	1938	|O
+	1939	1940	|O
/	1940	1941	|O
-	1941	1942	|O
0.11	1943	1947	|O
;	1947	1948	|O
12	1949	1951	|O
,	1951	1952	|O
5.85	1953	1957	|O
+	1958	1959	|O
/	1959	1960	|O
-	1960	1961	|O
0.05	1962	1966	|O
;	1966	1967	|O
13	1968	1970	|O
,	1970	1971	|O
approximately	1972	1985	|O
5.57	1986	1990	|O
;	1990	1991	|O
14	1992	1994	|O
,	1994	1995	|O
a	1996	1997	|O
weak	1998	2002	|O
agonist	2003	2010	|O
(	2011	2012	|O
0.004	2012	2017	|O
U	2018	2019	|O
/	2019	2020	|O
mg	2020	2022	|O
)	2022	2023	|O
.	2023	2024	|O
Analogues	2025	2034	|O
1-14	2035	2039	|O
also	2040	2044	|O
antagonize	2045	2055	|O
the	2056	2059	|O
vascular	2060	2068	|O
responses	2069	2078	|O
to	2079	2081	|O
arginine	2082	2090	|O
-	2090	2091	|O
vasopressin	2091	2102	|O
(	2103	2104	|O
AVP	2104	2107	|O
)	2107	2108	|O
and	2109	2112	|O
the	2113	2116	|O
in	2117	2119	|O
vitro	2120	2125	|O
oxytocic	2126	2134	|O
responses	2135	2144	|O
to	2145	2147	|O
oxytocin	2148	2156	|O
.	2156	2157	|O
Analogues	2158	2167	|O
1	2168	2169	|O
,	2169	2170	|O
2	2171	2172	|O
,	2172	2173	|O
3	2174	2175	|O
,	2175	2176	|O
and	2177	2180	|O
5	2181	2182	|O
have	2183	2187	|O
also	2188	2192	|O
been	2193	2197	|O
shown	2198	2203	|O
to	2204	2206	|O
antagonize	2207	2217	|O
the	2218	2221	|O
in	2222	2224	|O
vivo	2225	2229	|O
oxytocic	2230	2238	|O
responses	2239	2248	|O
to	2249	2251	|O
oxytocin	2252	2260	|O
.	2260	2261	|O
Five	2262	2266	|O
of	2267	2269	|O
these	2270	2275	|O
analogues	2276	2285	|O
(	2286	2287	|O
1	2287	2288	|O
,	2288	2289	|O
2	2290	2291	|O
,	2291	2292	|O
3	2293	2294	|O
,	2294	2295	|O
6	2296	2297	|O
,	2297	2298	|O
and	2299	2302	|O
7	2303	2304	|O
)	2304	2305	|O
exhibit	2306	2313	|O
enhanced	2314	2322	|O
antiantidiuretic	2323	2339	|O
/	2339	2340	|O
antivasopressor	2340	2355	|O
selectivity	2356	2367	|O
.	2367	2368	|O
d	2369	2370	|O
(	2370	2371	|O
CH2	2371	2374	|O
)	2374	2375	|O
5	2375	2376	|O
-	2376	2377	|O
D	2377	2378	|O
-	2378	2379	|O
Phe2	2379	2383	|O
,	2383	2384	|O
Lys4AVP	2384	2391	|O
and	2392	2395	|O
other	2396	2401	|O
position	2402	2410	|O
-	2410	2411	|O
4	2411	2412	|O
analogues	2413	2422	|O
with	2423	2427	|O
side	2428	2432	|O
-	2432	2433	|O
chain	2433	2438	|O
functional	2439	2449	|O
groups	2450	2456	|O
may	2457	2460	|O
be	2461	2463	|O
useful	2464	2470	|O
covalent	2471	2479	|O
ligands	2480	2487	|O
with	2488	2492	|O
which	2493	2498	|O
to	2499	2501	|O
probe	2502	2507	|O
the	2508	2511	|O
structural	2512	2522	|O
characteristics	2523	2538	|O
of	2539	2541	|O
AVP	2542	2545	|O
renal	2546	2551	|O
and	2552	2555	|O
vascular	2556	2564	|O
receptors	2565	2574	|O
.	2574	2575	|O
With	2576	2580	|O
an	2581	2583	|O
antiantidiuretic	2584	2600	|O
"	2601	2602	|O
effective	2602	2611	|O
dose	2612	2616	|O
"	2616	2617	|O
of	2618	2620	|O
0.46	2621	2625	|O
+	2626	2627	|O
/	2627	2628	|O
-	2628	2629	|O
0.07	2630	2634	|O
nmol	2635	2639	|O
/	2639	2640	|O
kg	2640	2642	|O
and	2643	2646	|O
a	2647	2648	|O
pA2	2649	2652	|O
value	2653	2658	|O
of	2659	2661	|O
8.24	2662	2666	|O
+	2667	2668	|O
/	2668	2669	|O
-	2669	2670	|O
0.08	2671	2675	|O
,	2675	2676	|O
d	2677	2678	|O
(	2678	2679	|O
CH2	2679	2682	|O
)	2682	2683	|O
5	2683	2684	|O
-	2684	2685	|O
D	2685	2686	|O
-	2686	2687	|O
Phe2	2687	2691	|O
,	2691	2692	|O
Ile4AVP	2692	2699	|O
(	2700	2701	|O
1	2701	2702	|O
)	2702	2703	|O
appears	2704	2711	|O
to	2712	2714	|O
be	2715	2717	|O
the	2718	2721	|O
most	2722	2726	|O
potent	2727	2733	|O
antidiuretic	2734	2746	|O
antagonist	2747	2757	|O
reported	2758	2766	|O
to	2767	2769	|O
date	2770	2774	|O
.	2774	2775	|O
(	2775	2776	|O
ABSTRACT	2776	2784	|O
TRUNCATED	2785	2794	|O
AT	2795	2797	|O
400	2798	2801	|O
WORDS	2802	2807	|O
)	2807	2808	|O

### abstracts999.txt
The	0	3	|O
synthesis	4	13	|O
and	14	17	|O
alpha	18	23	|O
2	24	25	|O
-	25	26	|O
adrenergic	26	36	|O
activity	37	45	|O
of	46	48	|O
a	49	50	|O
series	51	57	|O
of	58	60	|O
indolin	61	68	|B-PARTIUPAC
-	68	69	|I-PARTIUPAC
2	69	70	|I-PARTIUPAC
-	70	71	|I-PARTIUPAC
yl	71	73	|I-PARTIUPAC
and	74	77	|O
tetrahydroquinolin	78	96	|B-IUPAC
-	96	97	|I-IUPAC
2	97	98	|I-IUPAC
-	98	99	|I-IUPAC
yl	99	101	|I-IUPAC
imidazolines	102	114	|I-IUPAC
are	115	118	|O
described	119	128	|O
.	128	129	|O
The	130	133	|O
indolin	134	141	|B-IUPAC
-	141	142	|I-IUPAC
2	142	143	|I-IUPAC
-	143	144	|I-IUPAC
yl	144	146	|I-IUPAC
imidazoline	147	158	|I-IUPAC
4b	159	161	|O
was	162	165	|O
found	166	171	|O
to	172	174	|O
possess	175	182	|O
potent	183	189	|O
alpha	190	195	|O
2	196	197	|O
-	197	198	|O
adrenergic	198	208	|O
agonist	209	216	|O
and	217	220	|O
antagonist	221	231	|O
activity	232	240	|O
.	240	241	|O
The	242	245	|O
modification	246	258	|O
of	259	261	|O
the	262	265	|O
substituents	266	278	|O
on	279	281	|O
the	282	285	|O
indoline	286	294	|O
ring	295	299	|O
of	300	302	|O
4b	303	305	|O
has	306	309	|O
led	310	313	|O
to	314	316	|O
the	317	320	|O
separation	321	331	|O
of	332	334	|O
these	335	340	|O
activities	341	351	|O
.	351	352	|O
Substitution	353	365	|O
on	366	368	|O
the	369	372	|O
aromatic	373	381	|O
ring	382	386	|O
of	387	389	|O
4b	390	392	|O
with	393	397	|O
halogen	398	405	|O
or	406	408	|O
increasing	409	419	|O
the	420	423	|O
size	424	428	|O
of	429	431	|O
the	432	435	|O
N	436	437	|B-IUPAC
-	437	438	|I-IUPAC
alkyl	438	443	|I-IUPAC
substituent	444	455	|B-MODIFIER
of	456	458	|O
4b	459	461	|O
gave	462	466	|O
alpha	467	472	|O
2	473	474	|O
-	474	475	|O
adrenergic	475	485	|O
antagonists	486	497	|O
without	498	505	|O
agonist	506	513	|O
activity	514	522	|O
.	522	523	|O
The	524	527	|O
N	528	529	|B-IUPAC
-	529	530	|I-IUPAC
allylindoline	530	543	|I-IUPAC
4d	544	546	|O
is	547	549	|O
more	550	554	|O
potent	555	561	|O
than	562	566	|O
idazoxan	567	575	|O
in	576	578	|O
vitro	579	584	|O
and	585	588	|O
is	589	591	|O
equipotent	592	602	|O
in	603	605	|O
vivo	606	610	|O
,	610	611	|O
but	612	615	|O
is	616	618	|O
less	619	623	|O
receptor	624	632	|O
selective	633	642	|O
(	643	644	|O
alpha	644	649	|O
2	650	651	|O
vs.	652	655	|O
alpha	656	661	|O
1	662	663	|O
)	663	664	|O
than	665	669	|O
idazoxan	670	678	|O
.	678	679	|O
The	680	683	|O
cis	684	687	|B-IUPAC
-	687	688	|I-IUPAC
1,3	688	691	|I-IUPAC
-	691	692	|I-IUPAC
dimethylindolin	692	707	|I-IUPAC
-	707	708	|I-IUPAC
2	708	709	|I-IUPAC
-	709	710	|I-IUPAC
yl	710	712	|I-IUPAC
imidazoline	713	724	|I-IUPAC
6a	725	727	|O
is	728	730	|O
an	731	733	|O
alpha	734	739	|O
2	740	741	|O
-	741	742	|O
adrenergic	742	752	|O
agonist	753	760	|O
equal	761	766	|O
in	767	769	|O
potency	770	777	|O
to	778	780	|O
clonidine	781	790	|O
in	791	793	|O
vitro	794	799	|O
,	799	800	|O
while	801	806	|O
the	807	810	|O
trans	811	816	|B-IUPAC
-	816	817	|I-IUPAC
1,3	817	820	|I-IUPAC
-	820	821	|I-IUPAC
dimethylindolin	821	836	|I-IUPAC
-	836	837	|I-IUPAC
2	837	838	|I-IUPAC
-	838	839	|I-IUPAC
yl	839	841	|I-IUPAC
imidazoline	842	853	|I-IUPAC
6b	854	856	|O
is	857	859	|O
a	860	861	|O
moderately	862	872	|O
potent	873	879	|O
alpha	880	885	|O
2	886	887	|O
-	887	888	|O
adrenergic	888	898	|O
antagonist	899	909	|O
.	909	910	|O

### abstracts562.txt
2	0	1	|O
-	1	2	|O
Amino	2	7	|O
-	7	8	|O
3	8	9	|O
-	9	10	|O
aroylthiophenes	10	25	|O
are	26	29	|O
agonist	30	37	|O
allosteric	38	48	|O
enhancers	49	58	|O
(	59	60	|O
AE	60	62	|O
)	62	63	|O
at	64	66	|O
the	67	70	|O
A	71	72	|O
(	72	73	|O
1	73	74	|O
)	74	75	|O
adenosine	76	85	|O
receptor	86	94	|O
(	95	96	|O
A	96	97	|O
(	97	98	|O
1	98	99	|O
)	99	100	|O
AR	100	102	|O
)	102	103	|O
.	103	104	|O
Here	105	109	|O
we	110	112	|O
report	113	119	|O
the	120	123	|O
syntheses	124	133	|O
of	134	136	|O
three	137	142	|O
kinds	143	148	|O
of	149	151	|O
novel	152	157	|O
2	158	159	|B-IUPAC
-	159	160	|I-IUPAC
aminothiophenes	160	175	|I-IUPAC
and	176	179	|O
assays	180	186	|O
of	187	189	|O
their	190	195	|O
AE	196	198	|O
activity	199	207	|O
at	208	210	|O
the	211	214	|O
human	215	220	|O
A	221	222	|O
(	222	223	|O
1	223	224	|O
)	224	225	|O
AR	225	227	|O
(	228	229	|O
hA	229	231	|O
(	231	232	|O
1	232	233	|O
)	233	234	|O
AR	234	236	|O
)	236	237	|O
,	237	238	|O
namely	239	245	|O
,	245	246	|O
(	247	248	|O
1	248	249	|O
)	249	250	|O
2	251	252	|B-IUPAC
-	252	253	|I-IUPAC
amino	253	258	|I-IUPAC
-	258	259	|I-IUPAC
4,5	259	262	|I-IUPAC
-	262	263	|I-IUPAC
diphenylthiophene	263	280	|I-IUPAC
-	280	281	|I-IUPAC
3	281	282	|I-IUPAC
-	282	283	|I-IUPAC
carboxylates	283	295	|I-IUPAC
,	295	296	|O
3a	297	299	|O
-	299	300	|O
h	300	301	|O
,	301	302	|O
(	303	304	|O
2	304	305	|O
)	305	306	|O
2	307	308	|B-IUPAC
-	308	309	|I-IUPAC
amino	309	314	|I-IUPAC
-	314	315	|I-IUPAC
3	315	316	|I-IUPAC
-	316	317	|I-IUPAC
benzoyl	317	324	|I-IUPAC
-	324	325	|I-IUPAC
4,5	325	328	|I-IUPAC
-	328	329	|I-IUPAC
diphenylthiophenes	329	347	|I-IUPAC
,	347	348	|O
7a	349	351	|O
-	351	352	|O
p	352	353	|O
,	353	354	|O
and	355	358	|O
(	359	360	|O
3	360	361	|O
)	361	362	|O
2	363	364	|B-IUPAC
-	364	365	|I-IUPAC
amino	365	370	|I-IUPAC
-	370	371	|I-IUPAC
5	371	372	|I-IUPAC
-	372	373	|I-IUPAC
bromo	373	378	|I-IUPAC
-	378	379	|I-IUPAC
3	379	380	|I-IUPAC
-	380	381	|I-IUPAC
benzoyl	381	388	|I-IUPAC
-	388	389	|I-IUPAC
4	389	390	|I-IUPAC
-	390	391	|I-IUPAC
phenylthiophenes	391	407	|I-IUPAC
,	407	408	|O
10a	409	412	|O
-	412	413	|O
h	413	414	|O
.	414	415	|O
An	416	418	|O
in	419	421	|O
vitro	422	427	|O
assay	428	433	|O
employing	434	443	|O
the	444	447	|O
A	448	449	|O
(	449	450	|O
1	450	451	|O
)	451	452	|O
AR	452	454	|O
agonist	455	462	|O
[	463	464	|O
(	464	465	|O
125	465	468	|O
)	468	469	|O
I	469	470	|O
]	470	471	|O
ABA	471	474	|O
and	475	478	|O
membranes	479	488	|O
from	489	493	|O
CHO	494	497	|O
-	497	498	|O
K1	498	500	|O
cells	501	506	|O
stably	507	513	|O
expressing	514	524	|O
the	525	528	|O
hA	529	531	|O
(	531	532	|O
1	532	533	|O
)	533	534	|O
AR	534	536	|O
measured	537	545	|O
an	546	548	|O
index	549	554	|O
of	555	557	|O
AE	558	560	|O
activity	561	569	|O
,	569	570	|O
the	571	574	|O
ability	575	582	|O
of	583	585	|O
a	586	587	|O
candidate	588	597	|O
AE	598	600	|O
to	601	603	|O
stabilize	604	613	|O
the	614	617	|O
agonist	618	625	|O
-	625	626	|O
A	626	627	|O
(	627	628	|O
1	628	629	|O
)	629	630	|O
AR	630	632	|O
-	632	633	|O
G	633	634	|O
protein	635	642	|O
ternary	643	650	|O
complex	651	658	|O
,	658	659	|O
scored	660	666	|O
as	667	669	|O
the	670	673	|O
percentage	674	684	|O
of	685	687	|O
ternary	688	695	|O
complex	696	703	|O
remaining	704	713	|O
after	714	719	|O
10	720	722	|O
min	723	726	|O
of	727	729	|O
dissociation	730	742	|O
initiated	743	752	|O
by	753	755	|O
CPX	756	759	|O
and	760	763	|O
GTPgammaS	764	773	|O
.	773	774	|O
The	775	778	|O
AE	779	781	|O
activity	782	790	|O
score	791	796	|O
of	797	799	|O
2	800	801	|B-IUPAC
-	801	802	|I-IUPAC
amino	802	807	|I-IUPAC
-	807	808	|I-IUPAC
4,5	808	811	|I-IUPAC
-	811	812	|I-IUPAC
dimethyl	812	820	|I-IUPAC
-	820	821	|I-IUPAC
3	821	822	|I-IUPAC
-	822	823	|I-IUPAC
(	823	824	|I-IUPAC
3	824	825	|I-IUPAC
-	825	826	|I-IUPAC
trifluoromethylbenzoyl	826	848	|I-IUPAC
)	848	849	|I-IUPAC
thiophene	849	858	|I-IUPAC
(	859	860	|O
PD	860	862	|O
81,723	863	869	|O
)	869	870	|O
,	870	871	|O
which	872	877	|O
was	878	881	|O
19%	882	885	|O
,	885	886	|O
served	887	893	|O
as	894	896	|O
a	897	898	|O
standard	899	907	|O
for	908	911	|O
comparison	912	922	|O
.	922	923	|O
Two	924	927	|O
3	928	929	|B-IUPAC
-	929	930	|I-IUPAC
carboxythiophene	930	946	|I-IUPAC
3	947	948	|I-IUPAC
-	948	949	|I-IUPAC
trifluoromethylbenzyl	949	970	|I-IUPAC
esters	971	977	|I-IUPAC
,	977	978	|O
3d	979	981	|O
(	982	983	|O
49%	983	986	|O
)	986	987	|O
and	988	991	|O
3f	992	994	|O
(	995	996	|O
63%	996	999	|O
)	999	1000	|O
,	1000	1001	|O
had	1002	1005	|O
substantial	1006	1017	|O
AE	1018	1020	|O
activity	1021	1029	|O
.	1029	1030	|O
The	1031	1034	|O
3	1035	1036	|B-IUPAC
-	1036	1037	|I-IUPAC
(	1037	1038	|I-IUPAC
1	1038	1039	|I-IUPAC
-	1039	1040	|I-IUPAC
naphthoyl	1040	1049	|I-IUPAC
)	1049	1050	|I-IUPAC
substituent	1051	1062	|B-MODIFIER
of	1063	1065	|O
7e	1066	1068	|O
(	1069	1070	|O
52%	1070	1073	|O
)	1073	1074	|O
also	1075	1079	|O
supported	1080	1089	|O
AE	1090	1092	|O
activity	1093	1101	|O
.	1101	1102	|O
Compounds	1103	1112	|O
in	1113	1115	|O
series	1116	1122	|O
3	1123	1124	|O
tended	1125	1131	|O
to	1132	1134	|O
be	1135	1137	|O
more	1138	1142	|O
potent	1143	1149	|O
,	1149	1150	|O
10a	1151	1154	|O
and	1155	1158	|O
10c	1159	1162	|O
having	1163	1169	|O
scores	1170	1176	|O
of	1177	1179	|O
91	1180	1182	|O
and	1183	1186	|O
80%	1187	1190	|O
,	1190	1191	|O
respectively	1192	1204	|O
.	1204	1205	|O
The	1206	1209	|O
activity	1210	1218	|O
of	1219	1221	|O
2	1222	1223	|B-IUPAC
-	1223	1224	|I-IUPAC
amino	1224	1229	|I-IUPAC
-	1229	1230	|I-IUPAC
5	1230	1231	|I-IUPAC
-	1231	1232	|I-IUPAC
bromo	1232	1237	|I-IUPAC
-	1237	1238	|I-IUPAC
3	1238	1239	|I-IUPAC
-	1239	1240	|I-IUPAC
ethoxycarbonyl	1240	1254	|I-IUPAC
-	1254	1255	|I-IUPAC
4	1255	1256	|I-IUPAC
-	1256	1257	|I-IUPAC
(	1257	1258	|I-IUPAC
3	1258	1259	|I-IUPAC
-	1259	1260	|I-IUPAC
nitrophenyl	1260	1271	|I-IUPAC
)	1271	1272	|I-IUPAC
thiophene	1272	1281	|I-IUPAC
,	1281	1282	|O
10h	1283	1286	|O
(	1287	1288	|O
26%	1288	1291	|O
)	1291	1292	|O
,	1292	1293	|O
is	1294	1296	|O
an	1297	1299	|O
exception	1300	1309	|O
to	1310	1312	|O
the	1313	1316	|O
rule	1317	1321	|O
that	1322	1326	|O
a	1327	1328	|O
3	1329	1330	|B-IUPAC
-	1330	1331	|I-IUPAC
ethoxycarbonyl	1331	1345	|I-IUPAC
substituent	1346	1357	|B-MODIFIER
cannot	1358	1364	|O
support	1365	1372	|O
AE	1373	1375	|O
activity	1376	1384	|O
.	1384	1385	|O

### abstracts3065.txt
The	0	3	|O
novel	4	9	|O
acidic	10	16	|O
amino	17	22	|O
acids	23	28	|O
6a	29	31	|O
-	31	32	|O
c	32	33	|O
,	33	34	|O
7	35	36	|O
,	36	37	|O
and	38	41	|O
8	42	43	|O
have	44	48	|O
been	49	53	|O
synthesized	54	65	|O
via	66	69	|O
1,3	70	73	|O
-	73	74	|O
dipolar	74	81	|O
cycloadditions	82	96	|O
,	96	97	|O
using	98	103	|O
nitrile	104	111	|O
oxides	112	118	|O
and	119	122	|O
alkynes	123	130	|O
.	130	131	|O
The	132	135	|O
prepared	136	144	|O
compounds	145	154	|O
are	155	158	|O
heterocyclic	159	171	|O
analogues	172	181	|O
of	182	184	|O
glutamic	185	193	|O
acid	194	198	|O
with	199	203	|O
differing	204	213	|O
chain	214	219	|O
lengths	220	227	|O
.	227	228	|O
One	229	232	|O
of	233	235	|O
these	236	241	|O
compounds	242	251	|O
,	251	252	|O
(	253	254	|B-IUPAC
RS	254	256	|I-IUPAC
)	256	257	|I-IUPAC
-	257	258	|I-IUPAC
2	258	259	|I-IUPAC
-	259	260	|I-IUPAC
amino	260	265	|I-IUPAC
-	265	266	|I-IUPAC
3	266	267	|I-IUPAC
-	267	268	|I-IUPAC
(	268	269	|I-IUPAC
3	269	270	|I-IUPAC
-	270	271	|I-IUPAC
carboxy	271	278	|I-IUPAC
-	278	279	|I-IUPAC
5	279	280	|I-IUPAC
-	280	281	|I-IUPAC
methyl	281	287	|I-IUPAC
-	287	288	|I-IUPAC
4	288	289	|I-IUPAC
-	289	290	|I-IUPAC
isoxazolyl	291	301	|I-IUPAC
)	301	302	|I-IUPAC
propionic	302	311	|I-IUPAC
acid	312	316	|I-IUPAC
(	317	318	|O
ACPA	318	322	|O
,	322	323	|O
8	324	325	|O
)	325	326	|O
,	326	327	|O
was	328	331	|O
shown	332	337	|O
in	338	340	|O
[	341	342	|O
3H	342	344	|O
]	344	345	|O
AMPA	345	349	|O
binding	350	357	|O
studies	358	365	|O
to	366	368	|O
be	369	371	|O
more	372	376	|O
active	377	383	|O
than	384	388	|O
AMPA	389	393	|O
itself	394	400	|O
(	401	402	|O
IC50	402	406	|O
=	407	408	|O
20	409	411	|O
nM	412	414	|O
compared	415	423	|O
to	424	426	|O
IC50	427	431	|O
=	432	433	|O
79	434	436	|O
nM	437	439	|O
for	440	443	|O
AMPA	444	448	|O
)	448	449	|O
.	449	450	|O
No	451	453	|O
affinity	454	462	|O
for	463	466	|O
NMDA	467	471	|O
receptors	472	481	|O
(	482	483	|O
NMDA	483	487	|O
-	487	488	|O
sensitive	488	497	|O
[	498	499	|O
3H	499	501	|O
]	501	502	|O
glutamic	502	510	|O
acid	511	515	|O
binding	516	523	|O
)	523	524	|O
was	525	528	|O
found	529	534	|O
,	534	535	|O
and	536	539	|O
only	540	544	|O
weak	545	549	|O
affinity	550	558	|O
in	559	561	|O
[	562	563	|O
3H	563	565	|O
]	565	566	|O
kainic	566	572	|O
acid	573	577	|O
binding	578	585	|O
(	586	587	|O
IC50	587	591	|O
=	592	593	|O
6.3	594	597	|O
microM	598	604	|O
)	604	605	|O
was	606	609	|O
detected	610	618	|O
.	618	619	|O
The	620	623	|O
excitatory	624	634	|O
activity	635	643	|O
in	644	646	|O
rat	647	650	|O
cortical	651	659	|O
wedge	660	665	|O
also	666	670	|O
showed	671	677	|O
that	678	682	|O
ACPA	683	687	|O
was	688	691	|O
more	692	696	|O
potent	697	703	|O
than	704	708	|O
AMPA	709	713	|O
(	714	715	|O
EC50	715	719	|O
=	720	721	|O
1.0	722	725	|O
microM	726	732	|O
compared	733	741	|O
to	742	744	|O
EC50	745	749	|O
=	750	751	|O
3.5	752	755	|O
microM	756	762	|O
for	763	766	|O
AMPA	767	771	|O
)	771	772	|O
.	772	773	|O
The	774	777	|O
depolarizing	778	790	|O
effect	791	797	|O
of	798	800	|O
ACPA	801	805	|O
could	806	811	|O
be	812	814	|O
fully	815	820	|O
antagonized	821	832	|O
by	833	835	|O
the	836	839	|O
selective	840	849	|O
non	850	853	|O
-	853	854	|O
NMDA	854	858	|O
antagonist	859	869	|O
6	870	871	|B-IUPAC
-	871	872	|I-IUPAC
cyano	872	877	|I-IUPAC
-	877	878	|I-IUPAC
7	878	879	|I-IUPAC
-	879	880	|I-IUPAC
nitro	880	885	|I-IUPAC
-	885	886	|I-IUPAC
quinoxazoline	886	899	|I-IUPAC
-	899	900	|I-IUPAC
2,3	900	903	|I-IUPAC
-	903	904	|I-IUPAC
dione	904	909	|I-IUPAC
(	910	911	|O
CNQX	911	915	|O
)	915	916	|O
,	916	917	|O
but	918	921	|O
was	922	925	|O
unaffected	926	936	|O
by	937	939	|O
the	940	943	|O
selective	944	953	|O
NMDA	954	958	|O
antagonist	959	969	|O
D	970	971	|B-IUPAC
-	971	972	|I-IUPAC
2	972	973	|I-IUPAC
-	973	974	|I-IUPAC
amino	974	979	|I-IUPAC
-	979	980	|I-IUPAC
5	980	981	|I-IUPAC
-	981	982	|I-IUPAC
phosphonovaleric	982	998	|I-IUPAC
acid	999	1003	|I-IUPAC
(	1004	1005	|O
AP5	1005	1008	|O
)	1008	1009	|O
.	1009	1010	|O

### abstracts609.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
C11	12	15	|B-MODIFIER
-	15	16	|I-MODIFIER
substituted	16	27	|I-MODIFIER
(	28	29	|B-IUPAC
R	29	30	|I-IUPAC
)	30	31	|I-IUPAC
-	31	32	|I-IUPAC
aporphines	32	42	|I-IUPAC
and	43	46	|O
C11	47	50	|B-MODIFIER
-	50	51	|I-MODIFIER
oxygenated	51	61	|I-MODIFIER
(	62	63	|B-IUPAC
R	63	64	|I-IUPAC
)	64	65	|I-IUPAC
-	65	66	|I-IUPAC
noraporphines	66	79	|I-IUPAC
has	80	83	|O
been	84	88	|O
synthesized	89	100	|O
and	101	104	|O
evaluated	105	114	|O
for	115	118	|O
central	119	126	|O
serotonergic	127	139	|O
and	140	143	|O
dopaminergic	144	156	|O
effects	157	164	|O
in	165	167	|O
vitro	168	173	|O
and	174	177	|O
in	178	180	|O
vivo	181	185	|O
.	185	186	|O
The	187	190	|O
various	191	198	|O
C11	199	202	|O
-	202	203	|O
substituents	203	215	|O
were	216	220	|O
introduced	221	231	|O
using	232	237	|O
efficient	238	247	|O
nickel	248	254	|O
-	254	255	|O
and	256	259	|O
palladium	260	269	|O
-	269	270	|O
catalyzed	270	279	|O
reactions	280	289	|O
of	290	292	|O
the	293	296	|O
corresponding	297	310	|O
triflate	311	319	|O
(	320	321	|B-IUPAC
R	321	322	|I-IUPAC
)	322	323	|I-IUPAC
-	323	324	|I-IUPAC
11	324	326	|I-IUPAC
-	326	327	|I-IUPAC
[	327	328	|I-IUPAC
[	328	329	|I-IUPAC
(	329	330	|I-IUPAC
trifluoromethyl	330	345	|I-IUPAC
)	345	346	|I-IUPAC
sulfonyl	346	354	|I-IUPAC
]	354	355	|I-IUPAC
oxy	355	358	|I-IUPAC
]	358	359	|I-IUPAC
aporphine	359	368	|I-IUPAC
(	369	370	|O
6	370	371	|O
)	371	372	|O
.	372	373	|O
Several	374	381	|O
compounds	382	391	|O
display	392	399	|O
high	400	404	|O
affinity	405	413	|O
to	414	416	|O
serotonin	417	426	|O
5	427	428	|O
-	428	429	|O
HT1A	429	433	|O
receptors	434	443	|O
in	444	446	|O
spite	447	452	|O
of	453	455	|O
major	456	461	|O
differences	462	473	|O
in	474	476	|O
steric	477	483	|O
bulk	484	488	|O
and	489	492	|O
electronic	493	503	|O
properties	504	514	|O
of	515	517	|O
the	518	521	|O
various	522	529	|O
C11	530	533	|O
-	533	534	|O
substituents	534	546	|O
.	546	547	|O
A	548	549	|O
change	550	556	|O
of	557	559	|O
the	560	563	|O
N	564	565	|B-IUPAC
-	565	566	|I-IUPAC
methyl	566	572	|I-IUPAC
group	573	578	|B-MODIFIER
of	579	581	|O
the	582	585	|O
nonselective	586	598	|O
3	599	600	|O
to	601	603	|O
H	604	605	|O
[	606	607	|O
23	607	609	|O
,	609	610	|O
(	611	612	|B-IUPAC
R	612	613	|I-IUPAC
)	613	614	|I-IUPAC
-	614	615	|I-IUPAC
11	615	617	|I-IUPAC
-	617	618	|I-IUPAC
hydroxynoraporphine	618	637	|I-IUPAC
]	637	638	|O
or	639	641	|O
propyl	642	648	|O
[	649	650	|O
2	650	651	|O
,	651	652	|O
(	653	654	|B-IUPAC
R	654	655	|I-IUPAC
)	655	656	|I-IUPAC
-	656	657	|I-IUPAC
11	657	659	|I-IUPAC
-	659	660	|I-IUPAC
hydroxy	660	667	|I-IUPAC
-	667	668	|I-IUPAC
N	668	669	|I-IUPAC
-	669	670	|I-IUPAC
propylnoraporphine	670	688	|I-IUPAC
]	688	689	|O
increases	690	699	|O
the	700	703	|O
selectivity	704	715	|O
for	716	719	|O
5	720	721	|O
-	721	722	|O
HT1A	722	726	|O
receptors	727	736	|O
(	737	738	|O
100	738	741	|O
-	741	742	|O
fold	742	746	|O
)	746	747	|O
and	748	751	|O
dopamine	752	760	|O
D2A	761	764	|O
receptors	765	774	|O
(	775	776	|O
3	776	777	|O
-	777	778	|O
fold	778	782	|O
)	782	783	|O
,	783	784	|O
respectively	785	797	|O
.	797	798	|O
Compounds	799	808	|O
3	809	810	|O
and	811	814	|O
23	815	817	|O
have	818	822	|O
similar	823	830	|O
affinities	831	841	|O
to	842	844	|O
5	845	846	|O
-	846	847	|O
HT1A	847	851	|O
receptors	852	861	|O
,	861	862	|O
whereas	863	870	|O
the	871	874	|O
propyl	875	881	|B-IUPAC
substituent	882	893	|B-MODIFIER
of	894	896	|O
2	897	898	|O
not	899	902	|O
only	903	907	|O
enhances	908	916	|O
the	917	920	|O
selectivity	921	932	|O
for	933	936	|O
D2A	937	940	|O
receptors	941	950	|O
but	951	954	|O
also	955	959	|O
increases	960	969	|O
the	970	973	|O
D2A	974	977	|O
affinity	978	986	|O
.	986	987	|O
Modeling	988	996	|O
of	997	999	|O
ligand	1000	1006	|O
-	1006	1007	|O
receptor	1007	1015	|O
binding	1016	1023	|O
site	1024	1028	|O
interactions	1029	1041	|O
yielded	1042	1049	|O
an	1050	1052	|O
interaction	1053	1064	|O
site	1065	1069	|O
model	1070	1075	|O
for	1076	1079	|O
the	1080	1083	|O
5	1084	1085	|O
-	1085	1086	|O
HT1A	1086	1090	|O
receptor	1091	1099	|O
that	1100	1104	|O
describes	1105	1114	|O
a	1115	1116	|O
gradual	1117	1124	|O
change	1125	1131	|O
in	1132	1134	|O
binding	1135	1142	|O
mode	1143	1147	|O
for	1148	1151	|O
C11	1152	1155	|B-PARTIUPAC
-	1155	1156	|I-PARTIUPAC
hydroxy	1156	1163	|I-PARTIUPAC
,	1163	1164	|O
-	1165	1166	|B-PARTIUPAC
methoxy	1166	1173	|I-PARTIUPAC
-	1173	1174	|I-PARTIUPAC
,	1174	1175	|O
and	1176	1179	|O
-	1180	1181	|B-PARTIUPAC
phenyl	1181	1187	|I-PARTIUPAC
-	1187	1188	|O
substituted	1188	1199	|B-MODIFIER
derivatives	1200	1211	|I-MODIFIER
.	1211	1212	|O
Hydrogen	1213	1221	|O
bonding	1222	1229	|O
is	1230	1232	|O
hereby	1233	1239	|O
gradually	1240	1249	|O
replaced	1250	1258	|O
by	1259	1261	|O
van	1262	1265	|O
der	1266	1269	|O
Waals	1270	1275	|O
interactions	1276	1288	|O
involving	1289	1298	|O
a	1299	1300	|O
relatively	1301	1311	|O
large	1312	1317	|O
lipophilic	1318	1328	|O
pocket	1329	1335	|O
.	1335	1336	|O
The	1337	1340	|O
derived	1341	1348	|O
D2A	1349	1352	|O
receptor	1353	1361	|O
model	1362	1367	|O
can	1368	1371	|O
accommodate	1372	1383	|O
both	1384	1388	|O
the	1389	1392	|O
N	1393	1394	|B-IUPAC
-	1394	1395	|I-IUPAC
propyl	1395	1401	|I-IUPAC
substituent	1402	1413	|B-MODIFIER
of	1414	1416	|O
2	1417	1418	|O
and	1419	1422	|O
the	1423	1426	|O
C11	1427	1430	|B-IUPAC
-	1430	1431	|I-IUPAC
ethyl	1431	1436	|I-IUPAC
substituent	1437	1448	|B-MODIFIER
of	1449	1451	|O
11	1452	1454	|O
[	1455	1456	|O
(	1456	1457	|B-IUPAC
R	1457	1458	|I-IUPAC
)	1458	1459	|I-IUPAC
-	1459	1460	|I-IUPAC
11	1460	1462	|I-IUPAC
-	1462	1463	|I-IUPAC
ethylaporphine	1463	1477	|I-IUPAC
]	1477	1478	|O
.	1478	1479	|O

### abstracts952.txt
Methotrexate	0	12	|O
poly	13	17	|O
(	17	18	|O
gamma	18	23	|O
-	23	24	|O
L	24	25	|O
-	25	26	|O
glutamate	26	35	|O
)	35	36	|O
s	36	37	|O
bearing	38	45	|O
two	46	49	|O
and	50	53	|O
three	54	59	|O
glutamate	60	69	|O
units	70	75	|O
above	76	81	|O
that	82	86	|O
present	87	94	|O
in	95	97	|O
methotrexate	98	110	|O
have	111	115	|O
been	116	120	|O
synthesized	121	132	|O
by	133	135	|O
extension	136	145	|O
of	146	148	|O
a	149	150	|O
previously	151	161	|O
described	162	171	|O
route	172	177	|O
used	178	182	|O
to	183	185	|O
synthesize	186	196	|O
the	197	200	|O
lower	201	206	|O
conjugate	207	216	|O
bearing	217	224	|O
one	225	228	|O
added	229	234	|O
glutamate	235	244	|O
unit	245	249	|O
.	249	250	|O
Key	251	254	|O
steps	255	260	|O
in	261	263	|O
the	264	267	|O
sequence	268	276	|O
are	277	280	|O
the	281	284	|O
peptide	285	292	|O
coupling	293	301	|O
of	302	304	|O
N	305	306	|B-IUPAC
-	306	307	|I-IUPAC
[	307	308	|I-IUPAC
4	308	309	|I-IUPAC
-	309	310	|I-IUPAC
[	310	311	|I-IUPAC
[	311	312	|I-IUPAC
(	312	313	|I-IUPAC
benzyloxy	313	322	|I-IUPAC
)	322	323	|I-IUPAC
carbonyl	323	331	|I-IUPAC
]	331	332	|I-IUPAC
-	332	333	|I-IUPAC
methylamino	333	344	|I-IUPAC
]	344	345	|I-IUPAC
benzoyl	345	352	|I-IUPAC
]	352	353	|I-IUPAC
-	353	354	|I-IUPAC
L	354	355	|I-IUPAC
-	355	356	|I-IUPAC
glutamic	356	364	|I-IUPAC
acid	365	369	|I-IUPAC
alpha	370	375	|I-IUPAC
-	375	376	|I-IUPAC
benzyl	376	382	|I-IUPAC
ester	383	388	|I-IUPAC
(	389	390	|O
5	390	391	|O
)	391	392	|O
with	393	397	|O
oligo	398	403	|B-IUPAC
(	403	404	|I-IUPAC
gamma	404	409	|I-IUPAC
-	409	410	|I-IUPAC
L	410	411	|I-IUPAC
-	411	412	|I-IUPAC
glutamate	412	421	|I-IUPAC
)	421	422	|I-IUPAC
benzyl	423	429	|I-IUPAC
esters	430	436	|I-IUPAC
,	436	437	|O
removal	438	445	|O
of	446	448	|O
blocking	449	457	|O
groups	458	464	|O
by	465	467	|O
catalytic	468	477	|O
hydrogenolysis	478	492	|O
,	492	493	|O
and	494	497	|O
introduction	498	510	|O
of	511	513	|O
the	514	517	|O
(	518	519	|B-IUPAC
2,4	519	522	|I-IUPAC
-	522	523	|I-IUPAC
diamino	523	530	|I-IUPAC
-	530	531	|I-IUPAC
6	531	532	|I-IUPAC
-	532	533	|I-IUPAC
pteridinyl	533	543	|I-IUPAC
)	543	544	|I-IUPAC
methyl	544	550	|I-IUPAC
grouping	551	559	|B-MODIFIER
by	560	562	|O
alkylation	563	573	|O
with	574	578	|O
6	579	580	|B-IUPAC
-	580	581	|I-IUPAC
(	581	582	|I-IUPAC
bromomethyl	582	593	|I-IUPAC
)	593	594	|I-IUPAC
-	594	595	|I-IUPAC
2,4	595	598	|I-IUPAC
-	598	599	|I-IUPAC
pteridinediamine	599	615	|I-IUPAC
hydrobromide	616	628	|I-IUPAC
.	628	629	|O
Elaboration	630	641	|O
of	642	644	|O
the	645	648	|O
required	649	657	|O
oligo	658	663	|B-IUPAC
(	663	664	|I-IUPAC
gamma	664	669	|I-IUPAC
-	669	670	|I-IUPAC
L	670	671	|I-IUPAC
-	671	672	|I-IUPAC
glutamate	672	681	|I-IUPAC
)	681	682	|I-IUPAC
chain	683	688	|O
was	689	692	|O
achieved	693	701	|O
one	702	705	|O
unit	706	710	|O
at	711	713	|O
a	714	715	|O
time	716	720	|O
,	720	721	|O
beginning	722	731	|O
with	732	736	|O
the	737	740	|O
coupling	741	749	|O
of	750	752	|O
L	753	754	|B-IUPAC
-	754	755	|I-IUPAC
glutamic	755	763	|I-IUPAC
acid	764	768	|I-IUPAC
dibenzyl	769	777	|I-IUPAC
ester	778	783	|I-IUPAC
with	784	788	|O
[	789	790	|B-IUPAC
(	790	791	|I-IUPAC
tert	791	795	|I-IUPAC
-	795	796	|I-IUPAC
butyloxy	796	804	|I-IUPAC
)	804	805	|I-IUPAC
carbonyl	805	813	|I-IUPAC
]	813	814	|I-IUPAC
-	814	815	|I-IUPAC
L	815	816	|I-IUPAC
-	816	817	|I-IUPAC
glutamic	817	825	|I-IUPAC
acid	826	830	|I-IUPAC
alpha	831	836	|I-IUPAC
-	836	837	|I-IUPAC
benzyl	837	843	|I-IUPAC
ester	844	849	|I-IUPAC
(	850	851	|O
7	851	852	|O
)	852	853	|O
,	853	854	|O
followed	855	863	|O
by	864	866	|O
selective	867	876	|O
removal	877	884	|O
of	885	887	|O
the	888	891	|O
tert	892	896	|O
-	896	897	|O
butyloxycarbonyl	897	913	|O
grouping	914	922	|O
and	923	926	|O
another	927	934	|O
coupling	935	943	|O
step	944	948	|O
with	949	953	|O
5	954	955	|O
or	956	958	|O
7	959	960	|O
as	961	963	|O
required	964	972	|O
.	972	973	|O
Diphenylphosphoryl	974	992	|O
azide	993	998	|O
was	999	1002	|O
used	1003	1007	|O
as	1008	1010	|O
the	1011	1014	|O
coupling	1015	1023	|O
reagent	1024	1031	|O
in	1032	1034	|O
each	1035	1039	|O
conversion	1040	1050	|O
producing	1051	1060	|O
a	1061	1062	|O
peptide	1063	1070	|O
linkage	1071	1078	|O
.	1078	1079	|O

### abstracts1165.txt
The	0	3	|O
[	4	5	|B-IUPAC
1,2,4	5	10	|I-IUPAC
]	10	11	|I-IUPAC
triazolo	11	19	|I-IUPAC
[	19	20	|I-IUPAC
1,5	20	23	|I-IUPAC
-	23	24	|I-IUPAC
a	24	25	|I-IUPAC
]	25	26	|I-IUPAC
triazine	26	34	|I-IUPAC
derivative	35	45	|B-MODIFIER
3	46	47	|O
,	47	48	|O
more	49	53	|O
commonly	54	62	|O
known	63	68	|O
in	69	71	|O
the	72	75	|O
field	76	81	|O
of	82	84	|O
adenosine	85	94	|O
research	95	103	|O
as	104	106	|O
ZM	107	109	|O
-	109	110	|O
241385	110	116	|O
,	116	117	|O
has	118	121	|O
previously	122	132	|O
been	133	137	|O
demonstrated	138	150	|O
to	151	153	|O
be	154	156	|O
a	157	158	|O
potent	159	165	|O
and	166	169	|O
selective	170	179	|O
adenosine	180	189	|O
A2a	190	193	|O
receptor	194	202	|O
antagonist	203	213	|O
,	213	214	|O
although	215	223	|O
with	224	228	|O
limited	229	236	|O
oral	237	241	|O
bioavailability	242	257	|O
.	257	258	|O
This	259	263	|O
[	264	265	|B-IUPAC
1,2,4	265	270	|I-IUPAC
]	270	271	|I-IUPAC
triazolo	271	279	|I-IUPAC
[	279	280	|I-IUPAC
1,5	280	283	|I-IUPAC
-	283	284	|I-IUPAC
a	284	285	|I-IUPAC
]	285	286	|I-IUPAC
triazine	286	294	|I-IUPAC
core	295	299	|B-MODIFIER
structure	300	309	|I-MODIFIER
has	310	313	|O
now	314	317	|O
been	318	322	|O
improved	323	331	|O
by	332	334	|O
incorporating	335	348	|O
various	349	356	|O
piperazine	357	367	|O
derivatives	368	379	|O
.	379	380	|O
With	381	385	|O
some	386	390	|O
preliminary	391	402	|O
optimization	403	415	|O
,	415	416	|O
the	417	420	|O
A2a	421	424	|O
binding	425	432	|O
affinity	433	441	|O
of	442	444	|O
some	445	449	|O
of	450	452	|O
the	453	456	|O
best	457	461	|O
piperazine	462	472	|O
derivatives	473	484	|O
is	485	487	|O
almost	488	494	|O
as	495	497	|O
good	498	502	|O
as	503	505	|O
that	506	510	|O
of	511	513	|O
compound	514	522	|O
3	523	524	|O
.	524	525	|O
The	526	529	|O
selectivity	530	541	|O
level	542	547	|O
over	548	552	|O
the	553	556	|O
adenosine	557	566	|O
A1	567	569	|O
receptor	570	578	|O
subtype	579	586	|O
for	587	590	|O
some	591	595	|O
of	596	598	|O
the	599	602	|O
more	603	607	|O
active	608	614	|O
analogues	615	624	|O
is	625	627	|O
also	628	632	|O
fairly	633	639	|O
high	640	644	|O
,	644	645	|O
&	646	647	|O
gt	647	649	|O
;	649	650	|O
400	651	654	|O
-	654	655	|O
fold	655	659	|O
in	660	662	|O
some	663	667	|O
cases	668	673	|O
.	673	674	|O
Many	675	679	|O
compounds	680	689	|O
within	690	696	|O
this	697	701	|O
piperazine	702	712	|O
series	713	719	|O
of	720	722	|O
[	723	724	|B-IUPAC
1,2,4	724	729	|I-IUPAC
]	729	730	|I-IUPAC
triazolo	730	738	|I-IUPAC
[	738	739	|I-IUPAC
1,5	739	742	|I-IUPAC
-	742	743	|I-IUPAC
a	743	744	|I-IUPAC
]	744	745	|I-IUPAC
triazine	745	753	|I-IUPAC
have	754	758	|O
now	759	762	|O
been	763	767	|O
shown	768	773	|O
to	774	776	|O
have	777	781	|O
good	782	786	|O
oral	787	791	|O
bioavailability	792	807	|O
in	808	810	|O
the	811	814	|O
rat	815	818	|O
,	818	819	|O
with	820	824	|O
some	825	829	|O
as	830	832	|O
high	833	837	|O
as	838	840	|O
89%	841	844	|O
(	845	846	|O
compound	846	854	|O
35	855	857	|O
)	857	858	|O
.	858	859	|O
More	860	864	|O
significantly	865	878	|O
,	878	879	|O
some	880	884	|O
piperazines	885	896	|O
derivatives	897	908	|O
of	909	911	|O
[	912	913	|B-IUPAC
1,2,4	913	918	|I-IUPAC
]	918	919	|I-IUPAC
triazolo	919	927	|I-IUPAC
[	927	928	|I-IUPAC
1,5	928	931	|I-IUPAC
-	931	932	|I-IUPAC
a	932	933	|I-IUPAC
]	933	934	|I-IUPAC
triazine	934	942	|I-IUPAC
also	943	947	|O
possessed	948	957	|O
good	958	962	|O
oral	963	967	|O
efficacy	968	976	|O
in	977	979	|O
rodent	980	986	|O
models	987	993	|O
of	994	996	|O
Parkinson	997	1006	|O
's	1006	1008	|O
disease	1009	1016	|O
.	1016	1017	|O
For	1018	1021	|O
instance	1022	1030	|O
,	1030	1031	|O
compound	1032	1040	|O
34	1041	1043	|O
was	1044	1047	|O
orally	1048	1054	|O
active	1055	1061	|O
in	1062	1064	|O
the	1065	1068	|O
rat	1069	1072	|O
catalepsy	1073	1082	|O
model	1083	1088	|O
at	1089	1091	|O
3	1092	1093	|O
mg	1094	1096	|O
/	1096	1097	|O
kg	1097	1099	|O
.	1099	1100	|O
In	1101	1103	|O
the	1104	1107	|O
6	1108	1109	|B-IUPAC
-	1109	1110	|I-IUPAC
hydroxydopamine	1110	1125	|I-IUPAC
-	1125	1126	|O
lesioned	1126	1134	|O
rat	1135	1138	|O
model	1139	1144	|O
,	1144	1145	|O
this	1146	1150	|O
compound	1151	1159	|O
was	1160	1163	|O
also	1164	1168	|O
quite	1169	1174	|O
effective	1175	1184	|O
,	1184	1185	|O
with	1186	1190	|O
a	1191	1192	|O
minimum	1193	1200	|O
effective	1201	1210	|O
dose	1211	1215	|O
of	1216	1218	|O
3	1219	1220	|O
mg	1221	1223	|O
/	1223	1224	|O
kg	1224	1226	|O
po	1227	1229	|O
.	1229	1230	|O

### abstracts570.txt
The	0	3	|O
racemate	4	12	|O
and	13	16	|O
the	17	20	|O
enantiomers	21	32	|B-MODIFIER
of	33	35	|O
1	36	37	|B-IUPAC
-	37	38	|I-IUPAC
(	38	39	|I-IUPAC
3	39	40	|I-IUPAC
-	40	41	|I-IUPAC
methoxy	41	48	|I-IUPAC
-	48	49	|I-IUPAC
4	49	50	|I-IUPAC
-	50	51	|I-IUPAC
methyphenyl	51	62	|I-IUPAC
)	62	63	|I-IUPAC
-	63	64	|I-IUPAC
2	64	65	|I-IUPAC
-	65	66	|I-IUPAC
aminopropane	67	79	|I-IUPAC
(	80	81	|O
6	81	82	|O
)	82	83	|O
and	84	87	|O
racemic	88	95	|B-MODIFIER
5	96	97	|B-IUPAC
-	97	98	|I-IUPAC
methoxy	98	105	|I-IUPAC
-	105	106	|I-IUPAC
6	106	107	|I-IUPAC
-	107	108	|I-IUPAC
methyl	108	114	|I-IUPAC
-	114	115	|I-IUPAC
2	115	116	|I-IUPAC
-	116	117	|I-IUPAC
aminoindan	117	127	|I-IUPAC
(	128	129	|O
11	129	131	|O
)	131	132	|O
were	133	137	|O
tested	138	144	|O
for	145	148	|O
stimulus	149	157	|O
generalization	158	172	|O
in	173	175	|O
the	176	179	|O
two	180	183	|O
-	183	184	|O
lever	184	189	|O
drug	190	194	|O
-	194	195	|O
discrimination	195	209	|O
paradigm	210	218	|O
.	218	219	|O
Both	220	224	|O
6	225	226	|O
and	227	230	|O
11	231	233	|O
were	234	238	|O
found	239	244	|O
to	245	247	|O
substitute	248	258	|O
with	259	263	|O
high	264	268	|O
potency	269	276	|O
in	277	279	|O
3,4	280	283	|B-IUPAC
-	283	284	|I-IUPAC
(	284	285	|I-IUPAC
methylenedioxy	285	299	|I-IUPAC
)	299	300	|I-IUPAC
methamphetamine	300	315	|I-IUPAC
(	316	317	|O
1	317	318	|O
)	318	319	|O
and	320	323	|O
(	324	325	|B-IUPAC
S	325	326	|I-IUPAC
)	326	327	|I-IUPAC
-	327	328	|I-IUPAC
1	328	329	|I-IUPAC
-	329	330	|I-IUPAC
(	330	331	|I-IUPAC
1,3	331	334	|I-IUPAC
-	334	335	|I-IUPAC
benzodioxol	335	346	|I-IUPAC
-	346	347	|I-IUPAC
5	347	348	|I-IUPAC
-	348	349	|I-IUPAC
yl	349	351	|I-IUPAC
)	351	352	|I-IUPAC
-	352	353	|I-IUPAC
2	353	354	|I-IUPAC
-	354	355	|I-IUPAC
(	355	356	|I-IUPAC
methylamino	356	367	|I-IUPAC
)	367	368	|I-IUPAC
butane	368	374	|I-IUPAC
(	375	376	|O
2	376	377	|O
)	377	378	|O
trained	379	386	|O
rats	387	391	|O
.	391	392	|O
In	393	395	|O
the	396	399	|O
latter	400	406	|O
assay	407	412	|O
,	412	413	|O
both	414	418	|O
enantiomers	419	430	|O
of	431	433	|O
6	434	435	|O
had	436	439	|O
identical	440	449	|O
potencies	450	459	|O
,	459	460	|O
but	461	464	|O
their	465	470	|O
dose	471	475	|O
-	475	476	|O
response	476	484	|O
curves	485	491	|O
were	492	496	|O
not	497	500	|O
parallel	501	509	|O
.	509	510	|O
Racemic	511	518	|O
6	519	520	|O
,	520	521	|O
but	522	525	|O
not	526	529	|O
11	530	532	|O
,	532	533	|O
partially	534	543	|O
substituted	544	555	|O
for	556	559	|O
LSD	560	563	|O
.	563	564	|O
Racemic	565	572	|O
6	573	574	|O
and	575	578	|O
11	579	581	|O
did	582	585	|O
not	586	589	|O
substitute	590	600	|O
in	601	603	|O
(	604	605	|O
S	605	606	|O
)	606	607	|O
-	607	608	|O
amphetamine	608	619	|O
-	619	620	|O
trained	620	627	|O
rats	628	632	|O
.	632	633	|O
All	634	637	|O
of	638	640	|O
the	641	644	|O
test	645	649	|O
compounds	650	659	|O
were	660	664	|O
potent	665	671	|O
inhibitors	672	682	|O
of	683	685	|O
[	686	687	|O
3H	687	689	|O
]	689	690	|O
-	690	691	|O
5	691	692	|O
-	692	693	|O
HT	693	695	|O
uptake	696	702	|O
into	703	707	|O
synaptosomes	708	720	|O
in	721	723	|O
vitro	724	729	|O
,	729	730	|O
with	731	735	|O
the	736	739	|O
S	740	741	|O
enantiomer	742	752	|O
of	753	755	|O
6	756	757	|O
being	758	763	|O
most	764	768	|O
active	769	775	|O
.	775	776	|O
Rat	777	780	|O
brain	781	786	|O
monoamine	787	796	|O
levels	797	803	|O
were	804	808	|O
unaltered	809	818	|O
1	819	820	|O
week	821	825	|O
following	826	835	|O
a	836	837	|O
single	838	844	|O
high	845	849	|O
dose	850	854	|O
(	855	856	|O
10	856	858	|O
or	859	861	|O
20	862	864	|O
mg	865	867	|O
/	867	868	|O
kg	868	870	|O
,	870	871	|O
sc	872	874	|O
)	874	875	|O
of	876	878	|O
6	879	880	|O
or	881	883	|O
11	884	886	|O
,	886	887	|O
or	888	890	|O
two	891	894	|O
weeks	895	900	|O
following	901	910	|O
a	911	912	|O
subacute	913	921	|O
dosing	922	928	|O
regimen	929	936	|O
(	937	938	|O
20	938	940	|O
mg	941	943	|O
/	943	944	|O
kg	944	946	|O
,	946	947	|O
sc	948	950	|O
,	950	951	|O
twice	952	957	|O
a	958	959	|O
day	960	963	|O
for	964	967	|O
4	968	969	|O
days	970	974	|O
)	974	975	|O
.	975	976	|O
In	977	979	|O
addition	980	988	|O
,	988	989	|O
radioligand	990	1001	|O
-	1001	1002	|O
binding	1002	1009	|O
parameters	1010	1020	|O
in	1021	1023	|O
rat	1024	1027	|O
brain	1028	1033	|O
homogenate	1034	1044	|O
with	1045	1049	|O
the	1050	1053	|O
5	1054	1055	|O
-	1055	1056	|O
HT	1056	1058	|O
uptake	1059	1065	|O
inhibitor	1066	1075	|O
[	1076	1077	|O
3H	1077	1079	|O
]	1079	1080	|O
paroxetine	1080	1090	|O
were	1091	1095	|O
unchanged	1096	1105	|O
after	1106	1111	|O
subacute	1112	1120	|O
dosing	1121	1127	|O
with	1128	1132	|O
either	1133	1139	|O
racemic	1140	1147	|O
6	1148	1149	|O
or	1150	1152	|O
11	1153	1155	|O
.	1155	1156	|O
The	1157	1160	|O
results	1161	1168	|O
indicate	1169	1177	|O
that	1178	1182	|O
compounds	1183	1192	|O
6	1193	1194	|O
and	1195	1198	|O
11	1199	1201	|O
have	1202	1206	|O
animal	1207	1213	|O
behavioral	1214	1224	|O
pharmacology	1225	1237	|O
similar	1238	1245	|O
to	1246	1248	|O
the	1249	1252	|O
methylenedioxy	1253	1267	|O
compounds	1268	1277	|O
1	1278	1279	|O
and	1280	1283	|O
2	1284	1285	|O
,	1285	1286	|O
but	1287	1290	|O
that	1291	1295	|O
they	1296	1300	|O
do	1301	1303	|O
not	1304	1307	|O
induce	1308	1314	|O
the	1315	1318	|O
serotonin	1319	1328	|O
neurotoxicity	1329	1342	|O
that	1343	1347	|O
has	1348	1351	|O
been	1352	1356	|O
observed	1357	1365	|O
for	1366	1369	|O
the	1370	1373	|O
latter	1374	1380	|O
two	1381	1384	|O
drugs	1385	1390	|O
.	1390	1391	|O

### abstracts960.txt
The	0	3	|O
development	4	15	|O
of	16	18	|O
a	19	20	|O
prostaglandin	21	34	|O
PGF2	35	39	|O
alpha	40	45	|O
photoaffinity	46	59	|O
probe	60	65	|O
led	66	69	|O
to	70	72	|O
the	73	76	|O
synthesis	77	86	|O
and	87	90	|O
biological	91	101	|O
evaluation	102	112	|O
of	113	115	|O
azide	116	121	|B-MODIFIER
-	121	122	|I-MODIFIER
substituted	122	133	|I-MODIFIER
17	134	136	|B-IUPAC
-	136	137	|I-IUPAC
phenyl	137	143	|I-IUPAC
-	143	144	|I-IUPAC
18,19,20	144	152	|I-IUPAC
-	152	153	|I-IUPAC
trinorprostaglandin	153	172	|I-IUPAC
F2	173	175	|I-IUPAC
alpha	176	181	|I-IUPAC
and	182	185	|O
16	186	188	|B-IUPAC
-	188	189	|I-IUPAC
phenoxy	189	196	|I-IUPAC
-	196	197	|I-IUPAC
17,18,19,20	197	208	|I-IUPAC
-	208	209	|I-IUPAC
tetranorprostaglandin	209	230	|I-IUPAC
F2	231	233	|I-IUPAC
alpha	234	239	|I-IUPAC
derivatives	240	251	|O
.	251	252	|O
Two	253	256	|O
approaches	257	267	|O
for	268	271	|O
the	272	275	|O
preparation	276	287	|O
of	288	290	|O
iodinated	291	300	|O
versions	301	309	|O
of	310	312	|O
these	313	318	|O
prostaglandins	319	333	|O
were	334	338	|O
evaluated	339	348	|O
:	348	349	|O
(	350	351	|O
1	351	352	|O
)	352	353	|O
iodination	354	364	|O
of	365	367	|O
a	368	369	|O
phenyl	370	376	|O
azide	377	382	|O
bearing	383	390	|O
an	391	393	|O
activating	394	404	|O
hydroxyl	405	413	|O
group	414	419	|O
and	420	423	|O
(	424	425	|O
2	425	426	|O
)	426	427	|O
iodination	428	438	|O
of	439	441	|O
an	442	444	|O
aniline	445	452	|O
precursor	453	462	|O
to	463	465	|O
the	466	469	|O
phenyl	470	476	|O
azide	477	482	|O
group	483	488	|O
and	489	492	|O
subsequent	493	503	|O
conversion	504	514	|O
of	515	517	|O
the	518	521	|O
aniline	522	529	|O
to	530	532	|O
the	533	536	|O
phenyl	537	543	|O
azide	544	549	|O
.	549	550	|O
In	551	553	|O
the	554	557	|O
first	558	563	|O
approach	564	572	|O
,	572	573	|O
17	574	576	|B-IUPAC
-	576	577	|I-IUPAC
(	577	578	|I-IUPAC
4	578	579	|I-IUPAC
-	579	580	|I-IUPAC
azido	580	585	|I-IUPAC
-	585	586	|I-IUPAC
2	586	587	|I-IUPAC
-	587	588	|I-IUPAC
hydroxyphenyl	588	601	|I-IUPAC
)	601	602	|I-IUPAC
-	602	603	|I-IUPAC
18,19,20	603	611	|I-IUPAC
-	611	612	|I-IUPAC
trinorprostaglandin	612	631	|I-IUPAC
F2	632	634	|I-IUPAC
alpha	635	640	|I-IUPAC
,	640	641	|O
16	642	644	|B-IUPAC
-	644	645	|I-IUPAC
(	645	646	|I-IUPAC
5	646	647	|I-IUPAC
-	647	648	|I-IUPAC
azido	648	653	|I-IUPAC
-	653	654	|I-IUPAC
3	654	655	|I-IUPAC
-	655	656	|I-IUPAC
hydroxyphenoxy	656	670	|I-IUPAC
)	670	671	|I-IUPAC
-	671	672	|I-IUPAC
17,18,19,20	672	683	|I-IUPAC
-	683	684	|I-IUPAC
tetranorprostaglandin	684	705	|I-IUPAC
F2	706	708	|I-IUPAC
alpha	709	714	|I-IUPAC
,	714	715	|O
and	716	719	|O
16	720	722	|B-IUPAC
-	722	723	|I-IUPAC
(	723	724	|I-IUPAC
4	724	725	|I-IUPAC
-	725	726	|I-IUPAC
azido	726	731	|I-IUPAC
-	731	732	|I-IUPAC
2	732	733	|I-IUPAC
-	733	734	|I-IUPAC
hydroxyphenoxy	734	748	|I-IUPAC
)	748	749	|I-IUPAC
-	749	750	|I-IUPAC
17,18,19,20	750	761	|I-IUPAC
-	761	762	|I-IUPAC
tetranorprostaglandin	762	783	|I-IUPAC
F2	784	786	|I-IUPAC
alpha	787	792	|I-IUPAC
were	793	797	|O
prepared	798	806	|O
by	807	809	|O
using	810	815	|O
the	816	819	|O
Corey	820	825	|O
synthesis	826	835	|O
,	835	836	|O
but	837	840	|O
were	841	845	|O
biologically	846	858	|O
inactive	859	867	|O
presumably	868	878	|O
as	879	881	|O
a	882	883	|O
result	884	890	|O
of	891	893	|O
the	894	897	|O
hydrophilic	898	909	|O
phenolic	910	918	|O
hydroxyl	919	927	|O
group	928	933	|O
.	933	934	|O
In	935	937	|O
the	938	941	|O
second	942	948	|O
approach	949	957	|O
,	957	958	|O
the	959	962	|O
iodination	963	973	|O
of	974	976	|O
a	977	978	|O
17	979	981	|B-IUPAC
-	981	982	|I-IUPAC
(	982	983	|I-IUPAC
4	983	984	|I-IUPAC
-	984	985	|I-IUPAC
aminophenyl	985	996	|I-IUPAC
)	996	997	|I-IUPAC
-	997	998	|I-IUPAC
18,19,20	998	1006	|I-IUPAC
-	1006	1007	|I-IUPAC
trinorprostaglandin	1007	1026	|I-IUPAC
F2	1027	1029	|I-IUPAC
alpha	1030	1035	|I-IUPAC
derivative	1036	1046	|B-MODIFIER
delivered	1047	1056	|O
17	1057	1059	|B-IUPAC
-	1059	1060	|I-IUPAC
(	1060	1061	|I-IUPAC
4	1061	1062	|I-IUPAC
-	1062	1063	|I-IUPAC
azido	1063	1068	|I-IUPAC
-	1068	1069	|I-IUPAC
3	1069	1070	|I-IUPAC
-	1070	1071	|I-IUPAC
iodophenyl	1071	1081	|I-IUPAC
)	1081	1082	|I-IUPAC
-	1082	1083	|I-IUPAC
18,19,20	1083	1091	|I-IUPAC
-	1091	1092	|I-IUPAC
trinorprostaglandin	1092	1111	|I-IUPAC
F2	1112	1114	|I-IUPAC
alpha	1115	1120	|I-IUPAC
,	1120	1121	|O
which	1122	1127	|O
exhibited	1128	1137	|O
competitive	1138	1149	|O
binding	1150	1157	|O
with	1158	1162	|O
natural	1163	1170	|O
[	1171	1172	|O
3H	1172	1174	|O
]	1174	1175	|O
PGF2	1175	1179	|O
alpha	1180	1185	|O
to	1186	1188	|O
ovine	1189	1194	|O
luteal	1195	1201	|O
cells	1202	1207	|O
and	1208	1211	|O
to	1212	1214	|O
plasma	1215	1221	|O
membranes	1222	1231	|O
of	1232	1234	|O
bovine	1235	1241	|O
corpora	1242	1249	|O
lutea	1250	1255	|O
.	1255	1256	|O
[	1257	1258	|B-IUPAC
125I	1258	1262	|I-IUPAC
]	1262	1263	|I-IUPAC
-	1263	1264	|I-IUPAC
17	1264	1266	|I-IUPAC
-	1266	1267	|I-IUPAC
(	1267	1268	|I-IUPAC
4	1268	1269	|I-IUPAC
-	1269	1270	|I-IUPAC
Azido	1270	1275	|I-IUPAC
-	1275	1276	|I-IUPAC
3	1276	1277	|I-IUPAC
-	1277	1278	|I-IUPAC
iodophenyl	1278	1288	|I-IUPAC
)	1288	1289	|I-IUPAC
-	1289	1290	|I-IUPAC
18,19,20	1290	1298	|I-IUPAC
-	1298	1299	|I-IUPAC
trinorprostaglandin	1299	1318	|I-IUPAC
F2	1319	1321	|I-IUPAC
alpha	1322	1327	|I-IUPAC
was	1328	1331	|O
utilized	1332	1340	|O
in	1341	1343	|O
a	1344	1345	|O
preliminary	1346	1357	|O
photoaffinity	1358	1371	|O
cross	1372	1377	|O
-	1377	1378	|O
linking	1378	1385	|O
experiment	1386	1396	|O
.	1396	1397	|O

### abstracts4211.txt
We	0	2	|O
have	3	7	|O
synthesized	8	19	|O
five	20	24	|O
fluorinated	25	36	|O
derivatives	37	48	|O
of	49	51	|O
WAY	52	55	|O
100635	56	62	|O
,	62	63	|O
N	64	65	|B-IUPAC
-	65	66	|I-IUPAC
{	66	67	|I-IUPAC
2	67	68	|I-IUPAC
-	68	69	|I-IUPAC
[	69	70	|I-IUPAC
4	70	71	|I-IUPAC
-	71	72	|I-IUPAC
(	72	73	|I-IUPAC
2	73	74	|I-IUPAC
-	74	75	|I-IUPAC
methoxyphenyl	75	88	|I-IUPAC
)	88	89	|I-IUPAC
piperazino	89	99	|I-IUPAC
]	99	100	|I-IUPAC
ethyl	100	105	|I-IUPAC
}	105	106	|I-IUPAC
-	106	107	|I-IUPAC
N	107	108	|I-IUPAC
-	108	109	|I-IUPAC
(	109	110	|I-IUPAC
2	110	111	|I-IUPAC
-	111	112	|I-IUPAC
pyridyl	112	119	|I-IUPAC
)	119	120	|I-IUPAC
cyclohe	120	127	|I-IUPAC
xaneca	128	134	|I-IUPAC
rboxamide	135	144	|I-IUPAC
(	145	146	|O
4a	146	148	|O
)	148	149	|O
,	149	150	|O
using	151	156	|O
various	157	164	|O
acids	165	170	|O
in	171	173	|O
place	174	179	|O
of	180	182	|O
the	183	186	|O
cyclohexanecarboxylic	187	208	|B-IUPAC
acid	209	213	|I-IUPAC
(	214	215	|O
CHCA	215	219	|O
,	219	220	|O
2a	221	223	|O
)	223	224	|O
in	225	227	|O
the	228	231	|O
reaction	232	240	|O
scheme	241	247	|O
.	247	248	|O
The	249	252	|O
five	253	257	|O
acids	258	263	|O
are	264	267	|O
4	268	269	|B-IUPAC
-	269	270	|I-IUPAC
fluorobenzoic	270	283	|I-IUPAC
acid	284	288	|I-IUPAC
(	289	290	|O
FB	290	292	|O
,	292	293	|O
2b	294	296	|O
)	296	297	|O
,	297	298	|O
4	299	300	|B-IUPAC
-	300	301	|I-IUPAC
fluoro	301	307	|I-IUPAC
-	307	308	|I-IUPAC
3	308	309	|I-IUPAC
-	309	310	|I-IUPAC
methylbenzoic	310	323	|I-IUPAC
acid	324	328	|I-IUPAC
(	329	330	|O
MeFB	330	334	|O
,	334	335	|O
2c	336	338	|O
)	338	339	|O
,	339	340	|O
trans	341	346	|B-IUPAC
-	346	347	|I-IUPAC
4	347	348	|I-IUPAC
-	348	349	|I-IUPAC
fluorocyclohexanecarboxylic	349	376	|I-IUPAC
acid	377	381	|I-IUPAC
(	382	383	|O
FC	383	385	|O
,	385	386	|O
2d	387	389	|O
)	389	390	|O
,	390	391	|O
4	392	393	|B-IUPAC
-	393	394	|I-IUPAC
(	394	395	|I-IUPAC
fluoromethyl	395	407	|I-IUPAC
)	407	408	|I-IUPAC
benzoic	408	415	|I-IUPAC
acid	416	420	|I-IUPAC
(	421	422	|O
FMeB	422	426	|O
,	426	427	|O
2e	428	430	|O
)	430	431	|O
,	431	432	|O
and	433	436	|O
3	437	438	|B-IUPAC
-	438	439	|I-IUPAC
nitro	439	444	|I-IUPAC
-	444	445	|I-IUPAC
4	445	446	|I-IUPAC
-	446	447	|I-IUPAC
(	447	448	|I-IUPAC
fluoromethyl	448	460	|I-IUPAC
)	460	461	|I-IUPAC
benzoic	461	468	|I-IUPAC
acid	469	473	|I-IUPAC
(	474	475	|O
NFMeB	475	480	|O
,	480	481	|O
2f	482	484	|O
)	484	485	|O
(	486	487	|O
see	487	490	|O
Scheme	491	497	|O
1	498	499	|O
)	499	500	|O
.	500	501	|O
These	502	507	|O
compounds	508	517	|O
were	518	522	|O
radiolabeled	523	535	|O
with	536	540	|O
fluorine	541	549	|O
-	549	550	|O
18	550	552	|O
,	552	553	|O
and	554	557	|O
their	558	563	|O
biological	564	574	|O
properties	575	585	|O
were	586	590	|O
evaluated	591	600	|O
in	601	603	|O
rats	604	608	|O
and	609	612	|O
compared	613	621	|O
with	622	626	|O
those	627	632	|O
of	633	635	|O
[	636	637	|O
11C	637	640	|O
]	640	641	|O
carbonyl	641	649	|O
WAY	650	653	|O
100635	654	660	|O
(	661	662	|O
[	662	663	|O
carbonyl	663	671	|O
-	671	672	|O
11C	672	675	|O
]	675	676	|O
4a	676	678	|O
)	678	679	|O
.	679	680	|O
[	681	682	|O
Carbonyl	682	690	|O
-	690	691	|O
11C	691	694	|O
]	694	695	|O
4a	695	697	|O
cleared	698	705	|O
the	706	709	|O
brain	710	715	|O
with	716	720	|O
a	721	722	|O
biological	723	733	|O
half	734	738	|O
-	738	739	|O
life	739	743	|O
averaging	744	753	|O
41	754	756	|O
min	757	760	|O
.	760	761	|O
The	762	765	|O
metabolite	766	776	|O
-	776	777	|O
corrected	777	786	|O
blood	787	792	|O
radioactivity	793	806	|O
had	807	810	|O
a	811	812	|O
half	813	817	|O
-	817	818	|O
life	818	822	|O
of	823	825	|O
29	826	828	|O
min	829	832	|O
.	832	833	|O
[	834	835	|O
18F	835	838	|O
]	838	839	|O
FCWAY	839	844	|O
(	845	846	|O
[	846	847	|O
18F	847	850	|O
]	850	851	|O
4d	851	853	|O
)	853	854	|O
gave	855	859	|O
half	860	864	|O
-	864	865	|O
lives	865	870	|O
and	871	874	|O
intercepts	875	885	|O
comparable	886	896	|O
to	897	899	|O
[	900	901	|O
carbonyl	901	909	|O
-	909	910	|O
11C	910	913	|O
]	913	914	|O
4a	914	916	|O
in	917	919	|O
the	920	923	|O
brain	924	929	|O
,	929	930	|O
but	931	934	|O
the	935	938	|O
blood	939	944	|O
clearance	945	954	|O
was	955	958	|O
faster	959	965	|O
.	965	966	|O
[	967	968	|O
18F	968	971	|O
]	971	972	|O
FBWAY	972	977	|O
(	978	979	|O
[	979	980	|O
18F	980	983	|O
]	983	984	|O
4b	984	986	|O
)	986	987	|O
showed	988	994	|O
an	995	997	|O
early	998	1003	|O
rapid	1004	1009	|O
net	1010	1013	|O
efflux	1014	1020	|O
from	1021	1025	|O
the	1026	1029	|O
whole	1030	1035	|O
brain	1036	1041	|O
,	1041	1042	|O
clearing	1043	1051	|O
with	1052	1056	|O
a	1057	1058	|O
biological	1059	1069	|O
half	1070	1074	|O
-	1074	1075	|O
life	1075	1079	|O
of	1080	1082	|O
35	1083	1085	|O
min	1086	1089	|O
.	1089	1090	|O
The	1091	1094	|O
metabolite	1095	1105	|O
-	1105	1106	|O
corrected	1106	1115	|O
blood	1116	1121	|O
half	1122	1126	|O
-	1126	1127	|O
life	1127	1131	|O
was	1132	1135	|O
41	1136	1138	|O
min	1139	1142	|O
.	1142	1143	|O
The	1144	1147	|O
comparable	1148	1158	|O
whole	1159	1164	|O
brain	1165	1170	|O
and	1171	1174	|O
blood	1175	1180	|O
half	1181	1185	|O
-	1185	1186	|O
lives	1186	1191	|O
for	1192	1195	|O
Me	1196	1198	|O
[	1198	1199	|O
18F	1199	1202	|O
]	1202	1203	|O
FBWAY	1203	1208	|O
(	1209	1210	|O
[	1210	1211	|O
18F	1211	1214	|O
]	1214	1215	|O
4c	1215	1217	|O
)	1217	1218	|O
were	1219	1223	|O
16	1224	1226	|O
and	1227	1230	|O
18	1231	1233	|O
min	1234	1237	|O
,	1237	1238	|O
respectively	1239	1251	|O
.	1251	1252	|O
For	1253	1256	|O
each	1257	1261	|O
compound	1262	1270	|O
,	1270	1271	|O
the	1272	1275	|O
corresponding	1276	1289	|O
carboxylic	1290	1300	|O
acid	1301	1305	|O
was	1306	1309	|O
identified	1310	1320	|O
as	1321	1323	|O
a	1324	1325	|O
major	1326	1331	|O
metabolite	1332	1342	|O
in	1343	1345	|O
blood	1346	1351	|O
.	1351	1352	|O
Fluoride	1353	1361	|O
was	1362	1365	|O
also	1366	1370	|O
found	1371	1376	|O
after	1377	1382	|O
injection	1383	1392	|O
of	1393	1395	|O
[	1396	1397	|O
18F	1397	1400	|O
]	1400	1401	|O
4d	1401	1403	|O
.	1403	1404	|O
However	1405	1412	|O
,	1412	1413	|O
for	1414	1417	|O
all	1418	1421	|O
compounds	1422	1431	|O
there	1432	1437	|O
was	1438	1441	|O
a	1442	1443	|O
good	1444	1448	|O
correlation	1449	1460	|O
(	1461	1462	|O
R	1462	1463	|O
&	1464	1465	|O
gt	1465	1467	|O
;	1467	1468	|O
0.97	1469	1473	|O
)	1473	1474	|O
between	1475	1482	|O
the	1483	1486	|O
differential	1487	1499	|O
uptake	1500	1506	|O
ratio	1507	1512	|O
(	1513	1514	|O
DUR	1514	1517	|O
,	1517	1518	|O
(	1519	1520	|O
%	1520	1521	|O
ID	1521	1523	|O
/	1523	1524	|O
g	1524	1525	|O
)	1525	1526	|O
x	1527	1528	|O
body	1529	1533	|O
weight	1534	1540	|O
(	1541	1542	|O
g	1542	1543	|O
)	1543	1544	|O
/	1544	1545	|O
100	1545	1548	|O
)	1548	1549	|O
in	1550	1552	|O
individual	1553	1563	|O
rat	1564	1567	|O
brain	1568	1573	|O
regions	1574	1581	|O
at	1582	1584	|O
30	1585	1587	|O
min	1588	1591	|O
after	1592	1597	|O
injection	1598	1607	|O
and	1608	1611	|O
the	1612	1615	|O
concentration	1616	1629	|O
of	1630	1632	|O
receptors	1633	1642	|O
as	1643	1645	|O
determined	1646	1656	|O
by	1657	1659	|O
in	1660	1662	|O
vitro	1663	1668	|O
quantitative	1669	1681	|O
autoradiography	1682	1697	|O
in	1698	1700	|O
rat	1701	1704	|O
.	1704	1705	|O
Specific	1706	1714	|O
binding	1715	1722	|O
ratios	1723	1729	|O
[	1730	1731	|O
region	1731	1737	|O
of	1738	1740	|O
interest	1741	1749	|O
(	1750	1751	|O
ROI	1751	1754	|O
)	1754	1755	|O
/	1755	1756	|O
cerebellum	1756	1766	|O
-	1766	1767	|O
1	1767	1768	|O
]	1768	1769	|O
in	1770	1772	|O
control	1773	1780	|O
studies	1781	1788	|O
for	1789	1792	|O
cortex	1793	1799	|O
(	1800	1801	|O
Ctx	1801	1804	|O
)	1804	1805	|O
and	1806	1809	|O
hippocampus	1810	1821	|O
(	1822	1823	|O
H	1823	1824	|O
)	1824	1825	|O
were	1826	1830	|O
higher	1831	1837	|O
for	1838	1841	|O
[	1842	1843	|O
carbonyl	1843	1851	|O
-	1851	1852	|O
11C	1852	1855	|O
]	1855	1856	|O
4a	1856	1858	|O
and	1859	1862	|O
[	1863	1864	|O
18F	1864	1867	|O
]	1867	1868	|O
4d	1868	1870	|O
compared	1871	1879	|O
to	1880	1882	|O
[	1883	1884	|O
18F	1884	1887	|O
]	1887	1888	|O
4b	1888	1890	|O
and	1891	1894	|O
[	1895	1896	|O
18F	1896	1899	|O
]	1899	1900	|O
4c	1900	1902	|O
.	1902	1903	|O
[	1904	1905	|O
18F	1905	1908	|O
]	1908	1909	|O
4d	1909	1911	|O
has	1912	1915	|O
similar	1916	1923	|O
pharmacokinetic	1924	1939	|O
properties	1940	1950	|O
and	1951	1954	|O
comparable	1955	1965	|O
specific	1966	1974	|O
binding	1975	1982	|O
ratios	1983	1989	|O
to	1990	1992	|O
[	1993	1994	|O
carbonyl	1994	2002	|O
-	2002	2003	|O
11C	2003	2006	|O
]	2006	2007	|O
4a	2007	2009	|O
.	2009	2010	|O
Fifty	2011	2016	|O
nanomoles	2017	2026	|O
of	2027	2029	|O
4a	2030	2032	|O
blocked	2033	2040	|O
only	2041	2045	|O
30%	2046	2049	|O
of	2050	2052	|O
the	2053	2056	|O
specific	2057	2065	|O
binding	2066	2073	|O
of	2074	2076	|O
[	2077	2078	|O
18F	2078	2081	|O
]	2081	2082	|O
4d	2082	2084	|O
,	2084	2085	|O
while	2086	2091	|O
complete	2092	2100	|O
blockade	2101	2109	|O
was	2110	2113	|O
obtained	2114	2122	|O
from	2123	2127	|O
co	2128	2130	|O
-	2130	2131	|O
injection	2131	2140	|O
of	2141	2143	|O
200	2144	2147	|O
nmol	2148	2152	|O
of	2153	2155	|O
4a	2156	2158	|O
(	2159	2160	|O
H	2160	2161	|O
/	2161	2162	|O
Cb	2162	2164	|O
-	2164	2165	|O
1	2165	2166	|O
from	2167	2171	|O
17.2	2172	2176	|O
to	2177	2179	|O
0.6	2180	2183	|O
)	2183	2184	|O
.	2184	2185	|O
[	2186	2187	|O
18F	2187	2190	|O
]	2190	2191	|O
4b	2191	2193	|O
and	2194	2197	|O
[	2198	2199	|O
18F	2199	2202	|O
]	2202	2203	|O
4c	2203	2205	|O
showed	2206	2212	|O
lower	2213	2218	|O
specific	2219	2227	|O
binding	2228	2235	|O
ratios	2236	2242	|O
than	2243	2247	|O
[	2248	2249	|O
carbonyl	2249	2257	|O
-	2257	2258	|O
11C	2258	2261	|O
]	2261	2262	|O
4a	2262	2264	|O
and	2265	2268	|O
[	2269	2270	|O
18F	2270	2273	|O
]	2273	2274	|O
4d	2274	2276	|O
.	2276	2277	|O
[	2278	2279	|O
18F	2279	2282	|O
]	2282	2283	|O
4c	2283	2285	|O
was	2286	2289	|O
superior	2290	2298	|O
to	2299	2301	|O
[	2302	2303	|O
18F	2303	2306	|O
]	2306	2307	|O
4b	2307	2309	|O
since	2310	2315	|O
its	2316	2319	|O
specific	2320	2328	|O
binding	2329	2336	|O
was	2337	2340	|O
more	2341	2345	|O
readily	2346	2353	|O
blocked	2354	2361	|O
by	2362	2364	|O
4a	2365	2367	|O
.	2367	2368	|O
These	2369	2374	|O
studies	2375	2382	|O
suggest	2383	2390	|O
that	2391	2395	|O
[	2396	2397	|O
18F	2397	2400	|O
]	2400	2401	|O
4c	2401	2403	|O
should	2404	2410	|O
be	2411	2413	|O
a	2414	2415	|O
useful	2416	2422	|O
compound	2423	2431	|O
to	2432	2434	|O
assess	2435	2441	|O
dynamic	2442	2449	|O
changes	2450	2457	|O
in	2458	2460	|O
serotonin	2461	2470	|O
levels	2471	2477	|O
while	2478	2483	|O
[	2484	2485	|O
18F	2485	2488	|O
]	2488	2489	|O
4d	2489	2491	|O
,	2491	2492	|O
with	2493	2497	|O
its	2498	2501	|O
high	2502	2506	|O
contrast	2507	2515	|O
and	2516	2519	|O
F	2520	2521	|O
-	2521	2522	|O
18	2522	2524	|O
label	2525	2530	|O
,	2530	2531	|O
should	2532	2538	|O
provide	2539	2546	|O
better	2547	2553	|O
statistics	2554	2564	|O
and	2565	2568	|O
quantification	2569	2583	|O
for	2584	2587	|O
static	2588	2594	|O
measurement	2595	2606	|O
of	2607	2609	|O
5	2610	2611	|O
-	2611	2612	|O
HT1A	2612	2616	|O
receptor	2617	2625	|O
distribution	2626	2638	|O
.	2638	2639	|O

### abstracts4336.txt
A	0	1	|O
conformationally	2	18	|O
defined	19	26	|O
retinoic	27	35	|O
acid	36	40	|O
analog	41	47	|O
(	48	49	|O
1	49	50	|O
)	50	51	|O
which	52	57	|O
contains	58	66	|O
a	67	68	|O
dimethylene	69	80	|O
bridge	81	87	|O
to	88	90	|O
maintain	91	99	|O
the	100	103	|O
6	104	105	|O
-	105	106	|O
s	106	107	|O
-	107	108	|O
trans	108	113	|O
orientation	114	125	|O
for	126	129	|O
two	130	133	|O
terminal	134	142	|O
double	143	149	|O
bonds	150	155	|O
in	156	158	|O
the	159	162	|O
polyene	163	170	|O
chain	171	176	|O
was	177	180	|O
synthesized	181	192	|O
.	192	193	|O
A	194	195	|O
Reformatsky	196	207	|O
reaction	208	216	|O
was	217	220	|O
utilized	221	229	|O
to	230	232	|O
extend	233	239	|O
the	240	243	|O
polyene	244	251	|O
chain	252	257	|O
of	258	260	|O
the	261	264	|O
starting	265	273	|O
enone	274	279	|O
,	279	280	|O
which	281	286	|O
provided	287	295	|O
exclusively	296	307	|O
the	308	311	|O
9Z	312	314	|O
-	314	315	|O
configuration	315	328	|O
for	329	332	|O
the	333	336	|O
intermediate	337	349	|O
aldehyde	350	358	|O
.	358	359	|O
A	360	361	|O
Horners	362	369	|O
-	369	370	|O
Emmons	370	376	|O
condensation	377	389	|O
with	390	394	|O
this	395	399	|O
aldehyde	400	408	|O
then	409	413	|O
produced	414	422	|O
retinoic	423	431	|O
acid	432	436	|O
analogs	437	444	|O
with	445	449	|O
both	450	454	|O
9Z	455	457	|O
-	457	458	|O
and	459	462	|O
9Z	463	465	|O
,	465	466	|O
13Z	466	469	|O
-	469	470	|O
configurations	470	484	|O
.	484	485	|O
An	486	488	|O
I2	489	491	|O
-	491	492	|O
catalyzed	492	501	|O
isomerization	502	515	|O
of	516	518	|O
the	519	522	|O
intermediate	523	535	|O
9Z	536	538	|B-IUPAC
-	538	539	|I-IUPAC
aldehyde	539	547	|I-IUPAC
yielded	548	555	|O
the	556	559	|O
all	560	563	|B-IUPAC
-	563	564	|I-IUPAC
E	564	565	|I-IUPAC
-	565	566	|I-IUPAC
aldehyde	566	574	|I-IUPAC
,	574	575	|O
which	576	581	|O
was	582	585	|O
olefinated	586	596	|O
as	597	599	|O
above	600	605	|O
to	606	608	|O
yield	609	614	|O
the	615	618	|O
(	619	620	|B-PARTIUPAC
all	620	623	|I-PARTIUPAC
-	623	624	|I-PARTIUPAC
E	624	625	|I-PARTIUPAC
)	625	626	|I-PARTIUPAC
-	626	627	|I-PARTIUPAC
and	628	631	|O
(	632	633	|B-IUPAC
13Z	633	636	|I-IUPAC
)	636	637	|I-IUPAC
-	637	638	|I-IUPAC
retinoic	638	646	|I-IUPAC
acid	647	651	|I-IUPAC
analogs	652	659	|B-MODIFIER
of	660	662	|O
1	663	664	|O
.	664	665	|O
Each	666	670	|O
configurational	671	686	|O
isomer	687	693	|O
of	694	696	|O
1	697	698	|O
was	699	702	|O
evaluated	703	712	|O
for	713	716	|O
its	717	720	|O
ability	721	728	|O
to	729	731	|O
inhibit	732	739	|O
the	740	743	|O
binding	744	751	|O
of	752	754	|O
retinoic	755	763	|O
acid	764	768	|O
to	769	771	|O
CRABP	772	777	|O
(	778	779	|O
chick	779	784	|O
skin	785	789	|O
)	789	790	|O
and	791	794	|O
to	795	797	|O
inhibit	798	805	|O
the	806	809	|O
chemical	810	818	|O
induction	819	828	|O
of	829	831	|O
ornithine	832	841	|O
decarboxylase	842	855	|O
in	856	858	|O
mouse	859	864	|O
skin	865	869	|O
.	869	870	|O
In	871	873	|O
each	874	878	|O
assay	879	884	|O
(	885	886	|O
all	886	889	|O
-	889	890	|O
E	890	891	|O
)	891	892	|O
-	892	893	|O
1	893	894	|O
was	895	898	|O
the	899	902	|O
most	903	907	|O
active	908	914	|O
isomer	915	921	|O
,	921	922	|O
and	923	926	|O
this	927	931	|O
activity	932	940	|O
was	941	944	|O
comparable	945	955	|O
to	956	958	|O
or	959	961	|O
better	962	968	|O
than	969	973	|O
that	974	978	|O
for	979	982	|O
(	983	984	|B-IUPAC
all	984	987	|I-IUPAC
-	987	988	|I-IUPAC
E	988	989	|I-IUPAC
)	989	990	|I-IUPAC
-	990	991	|I-IUPAC
retinoic	991	999	|I-IUPAC
acid	1000	1004	|I-IUPAC
.	1004	1005	|O
(	1006	1007	|O
all	1007	1010	|O
-	1010	1011	|O
E	1011	1012	|O
)	1012	1013	|O
-	1013	1014	|O
1	1014	1015	|O
and	1016	1019	|O
(	1020	1021	|O
13Z	1021	1024	|O
)	1024	1025	|O
-	1025	1026	|O
1	1026	1027	|O
were	1028	1032	|O
both	1033	1037	|O
shown	1038	1043	|O
to	1044	1046	|O
be	1047	1049	|O
equally	1050	1057	|O
effective	1058	1067	|O
as	1068	1070	|O
(	1071	1072	|B-IUPAC
13Z	1072	1075	|I-IUPAC
)	1075	1076	|I-IUPAC
-	1076	1077	|I-IUPAC
retinoic	1077	1085	|I-IUPAC
acid	1086	1090	|I-IUPAC
in	1091	1093	|O
suppressing	1094	1105	|O
the	1106	1109	|O
proliferation	1110	1123	|O
of	1124	1126	|O
human	1127	1132	|O
sebaceous	1133	1142	|O
cells	1143	1148	|O
in	1149	1151	|O
vitro	1152	1157	|O
.	1157	1158	|O
(	1159	1160	|O
all	1160	1163	|O
-	1163	1164	|O
E	1164	1165	|O
)	1165	1166	|O
-	1166	1167	|O
1	1167	1168	|O
was	1169	1172	|O
further	1173	1180	|O
evaluated	1181	1190	|O
for	1191	1194	|O
its	1195	1198	|O
ability	1199	1206	|O
to	1207	1209	|O
prevent	1210	1217	|O
the	1218	1221	|O
induction	1222	1231	|O
of	1232	1234	|O
mouse	1235	1240	|O
skin	1241	1245	|O
papillomas	1246	1256	|O
and	1257	1260	|O
to	1261	1263	|O
induce	1264	1270	|O
signs	1271	1276	|O
of	1277	1279	|O
vitamin	1280	1287	|O
A	1288	1289	|O
toxicity	1290	1298	|O
in	1299	1301	|O
mice	1302	1306	|O
.	1306	1307	|O
The	1308	1311	|O
cancer	1312	1318	|O
chemopreventive	1319	1334	|O
activity	1335	1343	|O
of	1344	1346	|O
(	1347	1348	|O
all	1348	1351	|O
-	1351	1352	|O
E	1352	1353	|O
)	1353	1354	|O
-	1354	1355	|O
1	1355	1356	|O
was	1357	1360	|O
comparable	1361	1371	|O
to	1372	1374	|O
that	1375	1379	|O
of	1380	1382	|O
(	1383	1384	|B-IUPAC
all	1384	1387	|I-IUPAC
-	1387	1388	|I-IUPAC
E	1388	1389	|I-IUPAC
)	1389	1390	|I-IUPAC
-	1390	1391	|I-IUPAC
retinoic	1391	1399	|I-IUPAC
acid	1400	1404	|I-IUPAC
,	1404	1405	|O
and	1406	1409	|O
the	1410	1413	|O
toxicity	1414	1422	|O
was	1423	1426	|O
comparable	1427	1437	|O
to	1438	1440	|O
or	1441	1443	|O
slightly	1444	1452	|O
better	1453	1459	|O
than	1460	1464	|O
that	1465	1469	|O
of	1470	1472	|O
the	1473	1476	|O
natural	1477	1484	|O
vitamin	1485	1492	|O
.	1492	1493	|O

### abstracts2730.txt
A	0	1	|O
number	2	8	|O
of	9	11	|O
3,4	12	15	|B-MODIFIER
-	15	16	|I-MODIFIER
disubstituted	16	29	|I-MODIFIER
pyrazolo	30	38	|B-IUPAC
[	38	39	|I-IUPAC
3,4	39	42	|I-IUPAC
-	42	43	|I-IUPAC
d	43	44	|I-IUPAC
]	44	45	|I-IUPAC
pyrimidine	45	55	|I-IUPAC
ribonucleosides	56	71	|B-MODIFIER
were	72	76	|O
synthesized	77	88	|O
and	89	92	|O
tested	93	99	|O
for	100	103	|O
their	104	109	|O
biological	110	120	|O
activity	121	129	|O
.	129	130	|O
Glycosylation	131	144	|O
of	145	147	|O
persilylated	148	160	|O
as	161	163	|O
well	164	168	|O
as	169	171	|O
nonsilylated	172	184	|O
3	185	186	|B-IUPAC
-	186	187	|I-IUPAC
bromoallopurinol	187	203	|I-IUPAC
with	204	208	|O
1	209	210	|B-IUPAC
-	210	211	|I-IUPAC
O	211	212	|I-IUPAC
-	212	213	|I-IUPAC
acetyl	213	219	|I-IUPAC
-	219	220	|I-IUPAC
2,3,5	220	225	|I-IUPAC
-	225	226	|I-IUPAC
tri	226	229	|I-IUPAC
-	229	230	|I-IUPAC
O	230	231	|I-IUPAC
-	231	232	|I-IUPAC
benzoyl	232	239	|I-IUPAC
-	239	240	|I-IUPAC
D	240	241	|I-IUPAC
-	241	242	|I-IUPAC
ribofuranose	242	254	|I-IUPAC
(	255	256	|O
4	256	257	|O
)	257	258	|O
provided	259	267	|O
the	268	271	|O
key	272	275	|O
intermediate	276	288	|O
3	289	290	|B-IUPAC
-	290	291	|I-IUPAC
bromo	291	296	|I-IUPAC
-	296	297	|I-IUPAC
1	297	298	|I-IUPAC
-	298	299	|I-IUPAC
(	299	300	|I-IUPAC
2,3,5	300	305	|I-IUPAC
-	305	306	|I-IUPAC
tri	306	309	|I-IUPAC
-	309	310	|I-IUPAC
O	310	311	|I-IUPAC
-	311	312	|I-IUPAC
benzoyl	312	319	|I-IUPAC
-	319	320	|I-IUPAC
beta	320	324	|I-IUPAC
-	324	325	|I-IUPAC
D	325	326	|I-IUPAC
-	326	327	|I-IUPAC
ribofuranosyl	327	340	|I-IUPAC
)	340	341	|I-IUPAC
-	341	342	|I-IUPAC
pyrazolo	342	350	|I-IUPAC
[	350	351	|I-IUPAC
3,4	351	354	|I-IUPAC
-	354	355	|I-IUPAC
d	355	356	|I-IUPAC
]	356	357	|I-IUPAC
pyrimidin	358	367	|I-IUPAC
-	367	368	|I-IUPAC
4	368	369	|I-IUPAC
(	369	370	|I-IUPAC
5H	370	372	|I-IUPAC
)	372	373	|I-IUPAC
-	373	374	|I-IUPAC
one	374	377	|I-IUPAC
(	378	379	|O
5a	379	381	|O
)	381	382	|O
.	382	383	|O
Similar	384	391	|O
glycosylations	392	406	|O
of	407	409	|O
3	410	411	|B-IUPAC
-	411	412	|I-IUPAC
cyanoallopurinol	412	428	|I-IUPAC
and	429	432	|O
3	433	434	|B-IUPAC
-	434	435	|I-IUPAC
(	435	436	|I-IUPAC
methylthio	436	446	|I-IUPAC
)	446	447	|I-IUPAC
allopurinol	447	458	|I-IUPAC
furnished	459	468	|O
the	469	472	|O
corresponding	473	486	|O
protected	487	496	|O
N	497	498	|B-IUPAC
-	498	499	|I-IUPAC
1	499	500	|I-IUPAC
glycosyl	501	509	|I-IUPAC
derivatives	510	521	|B-MODIFIER
(	522	523	|O
5b	523	525	|O
and	526	529	|O
5c	530	532	|O
)	532	533	|O
.	533	534	|O
Debenzoylation	535	549	|O
of	550	552	|O
these	553	558	|O
nucleosides	559	570	|O
(	571	572	|O
5a	572	574	|O
-	574	575	|O
c	575	576	|O
)	576	577	|O
gave	578	582	|O
the	583	586	|O
corresponding	587	600	|O
3	601	602	|B-PARTIUPAC
-	602	603	|I-PARTIUPAC
bromo	603	608	|I-PARTIUPAC
-	608	609	|I-PARTIUPAC
,	609	610	|O
3	611	612	|B-PARTIUPAC
-	612	613	|I-PARTIUPAC
cyano	613	618	|I-PARTIUPAC
-	618	619	|I-PARTIUPAC
,	619	620	|O
and	621	624	|O
3	625	626	|B-IUPAC
-	626	627	|I-IUPAC
(	627	628	|I-IUPAC
methylthio	628	638	|I-IUPAC
)	638	639	|I-IUPAC
allopurinol	639	650	|I-IUPAC
nucleosides	651	662	|B-MODIFIER
(	663	664	|O
6a	664	666	|O
-	666	667	|O
c	667	668	|O
)	668	669	|O
.	669	670	|O
The	671	674	|O
site	675	679	|O
of	680	682	|O
glycosylation	683	696	|O
and	697	700	|O
anomeric	701	709	|O
configuration	710	723	|O
of	724	726	|O
6a	727	729	|O
and	730	733	|O
6c	734	736	|O
were	737	741	|O
assigned	742	750	|O
on	751	753	|O
the	754	757	|O
basis	758	763	|O
of	764	766	|O
spectral	767	775	|O
studies	776	783	|O
as	784	786	|O
well	787	791	|O
as	792	794	|O
conversion	795	805	|O
to	806	808	|O
allopurinol	809	820	|O
ribonucleoside	821	835	|O
,	835	836	|O
whereas	837	844	|O
the	845	848	|O
structural	849	859	|O
assignment	860	870	|O
of	871	873	|O
6b	874	876	|O
was	877	880	|O
made	881	885	|O
by	886	888	|O
single	889	895	|O
-	895	896	|O
crystal	896	903	|O
X	904	905	|O
-	905	906	|O
ray	906	909	|O
analysis	910	918	|O
.	918	919	|O
Conventional	920	932	|O
functional	933	943	|O
group	944	949	|O
transformation	950	964	|O
of	965	967	|O
5a	968	970	|O
and	971	974	|O
5b	975	977	|O
provided	978	986	|O
a	987	988	|O
number	989	995	|O
of	996	998	|O
novel	999	1004	|O
3	1005	1006	|O
-	1006	1007	|O
substituted	1007	1018	|O
allopurinol	1019	1030	|O
nucleosides	1031	1042	|O
,	1042	1043	|O
which	1044	1049	|O
included	1050	1058	|O
10a	1059	1062	|O
and	1063	1066	|O
18a	1067	1070	|O
-	1070	1071	|O
d	1071	1072	|O
.	1072	1073	|O
Glycosylation	1074	1087	|O
of	1088	1090	|O
4	1091	1092	|B-IUPAC
-	1092	1093	|I-IUPAC
amino	1093	1098	|I-IUPAC
-	1098	1099	|I-IUPAC
3	1099	1100	|I-IUPAC
-	1100	1101	|I-IUPAC
bromopyrazolo	1101	1114	|I-IUPAC
[	1114	1115	|I-IUPAC
3,4	1115	1118	|I-IUPAC
-	1118	1119	|I-IUPAC
d	1119	1120	|I-IUPAC
]	1120	1121	|I-IUPAC
pyrimidine	1121	1131	|I-IUPAC
(	1132	1133	|O
14	1133	1135	|O
)	1135	1136	|O
with	1137	1141	|O
4	1142	1143	|O
and	1144	1147	|O
subsequent	1148	1158	|O
debenzoylation	1159	1173	|O
gave	1174	1178	|O
3	1179	1180	|B-IUPAC
-	1180	1181	|I-IUPAC
bromo	1181	1186	|I-IUPAC
-	1186	1187	|I-IUPAC
4	1187	1188	|I-IUPAC
-	1188	1189	|I-IUPAC
aminopyrazolo	1189	1202	|I-IUPAC
[	1202	1203	|I-IUPAC
3,4	1203	1206	|I-IUPAC
-	1206	1207	|I-IUPAC
d	1207	1208	|I-IUPAC
]	1208	1209	|I-IUPAC
pyrimidine	1209	1219	|I-IUPAC
ribonucleoside	1220	1234	|B-MODIFIER
(	1235	1236	|O
13a	1236	1239	|O
)	1239	1240	|O
from	1241	1245	|O
which	1246	1251	|O
3,4	1252	1255	|B-IUPAC
-	1255	1256	|I-IUPAC
diamino	1256	1263	|I-IUPAC
-	1263	1264	|I-IUPAC
1	1264	1265	|I-IUPAC
-	1265	1266	|I-IUPAC
beta	1266	1270	|I-IUPAC
-	1270	1271	|I-IUPAC
D	1271	1272	|I-IUPAC
-	1272	1273	|I-IUPAC
ribofuranosylpyrazolo	1273	1294	|I-IUPAC
[	1294	1295	|I-IUPAC
3,4	1295	1298	|I-IUPAC
-	1298	1299	|I-IUPAC
d	1299	1300	|I-IUPAC
]	1300	1301	|I-IUPAC
pyrimidine	1301	1311	|I-IUPAC
(	1312	1313	|O
13b	1313	1316	|O
)	1316	1317	|O
was	1318	1321	|O
obtained	1322	1330	|O
by	1331	1333	|O
amination	1334	1343	|O
.	1343	1344	|O
Thiation	1345	1353	|O
of	1354	1356	|O
5b	1357	1359	|O
,	1359	1360	|O
followed	1361	1369	|O
by	1370	1372	|O
deblocking	1373	1383	|O
,	1383	1384	|O
gave	1385	1389	|O
3	1390	1391	|B-IUPAC
-	1391	1392	|I-IUPAC
cyanothiopurinol	1392	1408	|I-IUPAC
ribonucleoside	1409	1423	|B-MODIFIER
(	1424	1425	|O
20	1425	1427	|O
)	1427	1428	|O
.	1428	1429	|O
All	1430	1433	|O
of	1434	1436	|O
these	1437	1442	|O
compounds	1443	1452	|O
were	1453	1457	|O
tested	1458	1464	|O
in	1465	1467	|O
vitro	1468	1473	|O
against	1474	1481	|O
certain	1482	1489	|O
viruses	1490	1497	|O
,	1497	1498	|O
tumor	1499	1504	|O
cells	1505	1510	|O
,	1510	1511	|O
and	1512	1515	|O
the	1516	1519	|O
parasite	1520	1528	|O
Leishmania	1529	1539	|O
tropica	1540	1547	|O
.	1547	1548	|O
Among	1549	1554	|O
the	1555	1558	|O
3	1559	1560	|O
-	1560	1561	|O
substituted	1561	1572	|O
allopurinol	1573	1584	|O
nucleosides	1585	1596	|O
,	1596	1597	|O
18b	1598	1601	|O
and	1602	1605	|O
18c	1606	1609	|O
showed	1610	1616	|O
significant	1617	1628	|O
activity	1629	1637	|O
against	1638	1645	|O
Para	1646	1650	|O
3	1651	1652	|O
virus	1653	1658	|O
and	1659	1662	|O
were	1663	1667	|O
found	1668	1673	|O
to	1674	1676	|O
be	1677	1679	|O
potent	1680	1686	|O
inhibitors	1687	1697	|O
of	1698	1700	|O
growth	1701	1707	|O
of	1708	1710	|O
L1210	1711	1716	|O
and	1717	1720	|O
P388	1721	1725	|O
leukemia	1726	1734	|O
.	1734	1735	|O
Compound	1736	1744	|O
20	1745	1747	|O
exhibited	1748	1757	|O
the	1758	1761	|O
most	1762	1766	|O
significant	1767	1778	|O
broad	1779	1784	|O
-	1784	1785	|O
spectrum	1785	1793	|O
in	1794	1796	|O
vitro	1797	1802	|O
antiviral	1803	1812	|O
and	1813	1816	|O
antitumor	1817	1826	|O
activity	1827	1835	|O
.	1835	1836	|O
3	1837	1838	|B-IUPAC
-	1838	1839	|I-IUPAC
Bromoallopurinol	1839	1855	|I-IUPAC
ribonucleoside	1856	1870	|B-MODIFIER
(	1871	1872	|O
6a	1872	1874	|O
)	1874	1875	|O
was	1876	1879	|O
found	1880	1885	|O
to	1886	1888	|O
be	1889	1891	|O
more	1892	1896	|O
active	1897	1903	|O
than	1904	1908	|O
allopurinol	1909	1920	|O
ribonucleoside	1921	1935	|O
against	1936	1943	|O
Leishmania	1944	1954	|O
tropica	1955	1962	|O
within	1963	1969	|O
human	1970	1975	|O
macrophages	1976	1987	|O
in	1988	1990	|O
vitro	1991	1996	|O
.	1996	1997	|O

### abstracts2174.txt
The	0	3	|O
synthesis	4	13	|O
of	14	16	|O
10	17	19	|B-IUPAC
-	19	20	|I-IUPAC
alkyl	20	25	|I-IUPAC
analogues	26	35	|B-MODIFIER
of	36	38	|O
the	39	42	|O
potent	43	49	|O
antitumor	50	59	|O
agent	60	65	|O
8,10	66	70	|B-IUPAC
-	70	71	|I-IUPAC
dideazaminopterin	71	88	|I-IUPAC
is	89	91	|O
described	92	101	|O
.	101	102	|O
Alkylation	103	113	|O
of	114	116	|O
appropriate	117	128	|O
alpha	129	134	|O
-	134	135	|O
alkyl	135	140	|O
homoterephthalate	141	158	|O
esters	159	165	|O
with	166	170	|O
2,4	171	174	|B-IUPAC
-	174	175	|I-IUPAC
diamino	175	182	|I-IUPAC
-	182	183	|I-IUPAC
6	183	184	|I-IUPAC
-	184	185	|I-IUPAC
(	185	186	|I-IUPAC
bromomethyl	186	197	|I-IUPAC
)	197	198	|I-IUPAC
-	198	199	|I-IUPAC
8	199	200	|I-IUPAC
-	200	201	|I-IUPAC
deazapteridine	201	215	|I-IUPAC
afforded	216	224	|O
10	225	227	|B-IUPAC
-	227	228	|I-IUPAC
alkyl	228	233	|I-IUPAC
-	233	234	|I-IUPAC
10	234	236	|I-IUPAC
-	236	237	|I-IUPAC
carboxy	237	244	|I-IUPAC
-	244	245	|I-IUPAC
4	245	246	|I-IUPAC
-	246	247	|I-IUPAC
amino	247	252	|I-IUPAC
-	252	253	|I-IUPAC
4	253	254	|I-IUPAC
-	254	255	|I-IUPAC
deoxy	255	260	|I-IUPAC
-	260	261	|I-IUPAC
8,10	261	265	|I-IUPAC
-	265	266	|I-IUPAC
dideazapteroic	266	280	|I-IUPAC
acid	281	285	|I-IUPAC
diesters	286	294	|I-IUPAC
.	294	295	|O
Ester	296	301	|O
cleavage	302	310	|O
and	311	314	|O
decarboxylation	315	330	|O
at	331	333	|O
C	334	335	|O
-	335	336	|O
10	336	338	|O
were	339	343	|O
accomplished	344	356	|O
by	357	359	|O
heating	360	367	|O
with	368	372	|O
sodium	373	379	|O
cyanide	380	387	|O
in	388	390	|O
Me2SO	391	396	|O
at	397	399	|O
170-180	400	407	|O
degrees	408	415	|O
C	416	417	|O
to	418	420	|O
afford	421	427	|O
the	428	431	|O
2,4	432	435	|B-IUPAC
-	435	436	|I-IUPAC
diamino	436	443	|I-IUPAC
-	443	444	|I-IUPAC
10	444	446	|I-IUPAC
-	446	447	|I-IUPAC
alkyl	447	452	|I-IUPAC
-	452	453	|I-IUPAC
8,10	453	457	|I-IUPAC
-	457	458	|I-IUPAC
dideazapteroic	458	472	|I-IUPAC
acids	473	478	|I-IUPAC
.	478	479	|O
The	480	483	|O
acids	484	489	|O
were	490	494	|O
coupled	495	502	|O
with	503	507	|O
diethyl	508	515	|O
glutamate	516	525	|O
,	525	526	|O
followed	527	535	|O
by	536	538	|O
saponification	539	553	|O
,	553	554	|O
to	555	557	|O
give	558	562	|O
the	563	566	|O
10	567	569	|B-IUPAC
-	569	570	|I-IUPAC
alkyl	570	575	|I-IUPAC
-	575	576	|I-IUPAC
8,10	576	580	|I-IUPAC
-	580	581	|I-IUPAC
dideazaminopterins	581	599	|I-IUPAC
.	599	600	|O
The	601	604	|O
compounds	605	614	|O
were	615	619	|O
potent	620	626	|O
inhibitors	627	637	|O
of	638	640	|O
growth	641	647	|O
in	648	650	|O
folate	651	657	|O
-	657	658	|O
dependent	658	667	|O
bacteria	668	676	|O
,	676	677	|O
Streptococcus	678	691	|O
faecium	692	699	|O
and	700	703	|O
Lactobacillus	704	717	|O
casei	718	723	|O
.	723	724	|O
The	725	728	|O
10	729	731	|B-IUPAC
-	731	732	|I-IUPAC
methyl	732	738	|I-IUPAC
and	739	742	|O
10	743	745	|B-IUPAC
-	745	746	|I-IUPAC
ethyl	746	751	|I-IUPAC
analogues	752	761	|B-MODIFIER
gave	762	766	|O
the	767	770	|O
highest	771	778	|O
percent	779	786	|O
increases	787	796	|O
in	797	799	|O
life	800	804	|O
span	805	809	|O
for	810	813	|O
mice	814	818	|O
infected	819	827	|O
with	828	832	|O
L1210	833	838	|O
leukemia	839	847	|O
with	848	852	|O
ILS	853	856	|O
values	857	863	|O
of	864	866	|O
+	867	868	|O
203	868	871	|O
and	872	875	|O
+	876	877	|O
235%	877	881	|O
,	881	882	|O
respectively	883	895	|O
.	895	896	|O

### abstracts2455.txt
Of	0	2	|O
a	3	4	|O
series	5	11	|O
of	12	14	|O
58	15	17	|O
aliphatic	18	27	|O
nucleoside	28	38	|O
analogues	39	48	|O
,	48	49	|O
(	50	51	|B-IUPAC
S	51	52	|I-IUPAC
)	52	53	|I-IUPAC
-	53	54	|I-IUPAC
9	54	55	|I-IUPAC
-	55	56	|I-IUPAC
(	56	57	|I-IUPAC
2,3	57	60	|I-IUPAC
-	60	61	|I-IUPAC
dihydroxypropyl	61	76	|I-IUPAC
)	76	77	|I-IUPAC
adenine	77	84	|I-IUPAC
[	85	86	|O
(	86	87	|O
S	87	88	|O
)	88	89	|O
-	89	90	|O
DHPA	90	94	|O
]	94	95	|O
proved	96	102	|O
to	103	105	|O
be	106	108	|O
the	109	112	|O
most	113	117	|O
active	118	124	|O
congener	125	133	|O
,	133	134	|O
when	135	139	|O
assayed	140	147	|O
for	148	151	|O
antiviral	152	161	|O
activity	162	170	|O
in	171	173	|O
primary	174	181	|O
rabbit	182	188	|O
kidney	189	195	|O
cell	196	200	|O
cultures	201	209	|O
challenged	210	220	|O
with	221	225	|O
either	226	232	|O
vaccinia	233	241	|O
or	242	244	|O
vesicular	245	254	|O
stomatitis	255	265	|O
virus	266	271	|O
.	271	272	|O
Whereas	273	280	|O
most	281	285	|O
analogues	286	295	|O
derived	296	303	|O
from	304	308	|O
substituted	309	320	|O
purine	321	327	|O
and	328	331	|O
pyrimidine	332	342	|O
bases	343	348	|O
and	349	352	|O
bearing	353	360	|O
various	361	368	|O
hydroxy	369	376	|B-MODIFIER
-	376	377	|I-MODIFIER
or	378	380	|O
amino	381	386	|B-MODIFIER
-	386	387	|I-MODIFIER
substituted	387	398	|I-MODIFIER
alkyl	399	404	|B-IUPAC
chains	405	411	|B-MODIFIER
did	412	415	|O
not	416	419	|O
show	420	424	|O
evidence	425	433	|O
of	434	436	|O
antiviral	437	446	|O
activity	447	455	|O
at	456	458	|O
a	459	460	|O
concentration	461	474	|O
of	475	477	|O
2	478	479	|O
mM	480	482	|O
,	482	483	|O
(	484	485	|O
S	485	486	|O
)	486	487	|O
-	487	488	|O
DHPA	488	492	|O
inhibited	493	502	|O
both	503	507	|O
vaccinia	508	516	|O
and	517	520	|O
vesicular	521	530	|O
stomatitis	531	541	|O
virus	542	547	|O
replication	548	559	|O
at	560	562	|O
0.05-0.1	563	571	|O
mM	572	574	|O
.	574	575	|O
For	576	579	|O
9	580	581	|B-IUPAC
-	581	582	|I-IUPAC
[	582	583	|I-IUPAC
(	583	584	|I-IUPAC
RS	584	586	|I-IUPAC
)	586	587	|I-IUPAC
-	587	588	|I-IUPAC
2,3	588	591	|I-IUPAC
-	591	592	|I-IUPAC
diazidopropyl	592	605	|I-IUPAC
]	605	606	|I-IUPAC
adenine	606	613	|I-IUPAC
and	614	617	|O
some	618	622	|O
di	623	625	|B-MODIFIER
-	625	626	|I-MODIFIER
and	627	630	|O
trihydroxybutyl	631	646	|B-MODIFIER
analogues	647	656	|I-MODIFIER
of	657	659	|O
DHPA	660	664	|O
,	664	665	|O
viz	666	669	|O
.	669	670	|O
,	670	671	|O
9	672	673	|B-IUPAC
-	673	674	|I-IUPAC
[	674	675	|I-IUPAC
(	675	676	|I-IUPAC
2RS	676	679	|I-IUPAC
,	679	680	|I-IUPAC
3SR	680	683	|I-IUPAC
)	683	684	|I-IUPAC
-	684	685	|I-IUPAC
2,3	685	688	|I-IUPAC
-	688	689	|I-IUPAC
dihydroxybutylladenine	689	711	|I-IUPAC
,	711	712	|O
9	713	714	|B-PARTIUPAC
-	714	715	|I-PARTIUPAC
[	715	716	|I-PARTIUPAC
(	716	717	|I-PARTIUPAC
RS	717	719	|I-PARTIUPAC
)	719	720	|I-PARTIUPAC
-	720	721	|I-PARTIUPAC
or	722	724	|O
9	725	726	|B-IUPAC
-	726	727	|I-IUPAC
[	727	728	|I-IUPAC
(	728	729	|I-IUPAC
S	729	730	|I-IUPAC
)	730	731	|I-IUPAC
-	731	732	|I-IUPAC
3,4	732	735	|I-IUPAC
-	735	736	|I-IUPAC
dihydroxybutyl	736	750	|I-IUPAC
]	750	751	|I-IUPAC
adenine	751	758	|I-IUPAC
,	758	759	|O
9	760	761	|B-IUPAC
-	761	762	|I-IUPAC
[	762	763	|I-IUPAC
(	763	764	|I-IUPAC
2S	764	766	|I-IUPAC
,	766	767	|I-IUPAC
3R	767	769	|I-IUPAC
)	769	770	|I-IUPAC
-	770	771	|I-IUPAC
2,3,4	771	776	|I-IUPAC
-	776	777	|I-IUPAC
trihydroxybutyl	777	792	|I-IUPAC
]	792	793	|I-IUPAC
adenine	793	800	|I-IUPAC
,	800	801	|O
and	802	805	|O
3	806	807	|B-IUPAC
-	807	808	|I-IUPAC
(	808	809	|I-IUPAC
adenin	809	815	|I-IUPAC
-	815	816	|I-IUPAC
9	816	817	|I-IUPAC
-	817	818	|I-IUPAC
yl	818	820	|I-IUPAC
)	820	821	|I-IUPAC
-	821	822	|I-IUPAC
(	822	823	|I-IUPAC
RS	823	825	|I-IUPAC
)	825	826	|I-IUPAC
-	826	827	|I-IUPAC
alanine	827	834	|I-IUPAC
,	834	835	|O
an	836	838	|O
antiviral	839	848	|O
effect	849	855	|O
was	856	859	|O
noted	860	865	|O
at	866	868	|O
a	869	870	|O
concentration	871	884	|O
of	885	887	|O
0.5-1	888	893	|O
mM	894	896	|O
.	896	897	|O

### abstracts991.txt
Several	0	7	|O
N	8	9	|O
(	9	10	|O
1	10	11	|O
)	11	12	|O
-	12	13	|O
substituted	13	24	|O
polyamines	25	35	|O
containing	36	46	|O
various	47	54	|O
spacer	55	61	|O
units	62	67	|O
between	68	75	|O
nitrogen	76	84	|O
centers	85	92	|O
were	93	97	|O
synthesized	98	109	|O
as	110	112	|O
their	113	118	|O
respective	119	129	|O
HCl	130	133	|O
salts	134	139	|O
.	139	140	|O
The	141	144	|O
N	145	146	|O
(	146	147	|O
1	147	148	|O
)	148	149	|O
-	149	150	|O
substituents	150	162	|O
included	163	171	|O
benzyl	172	178	|B-IUPAC
,	178	179	|O
naphthalen	180	190	|B-IUPAC
-	190	191	|I-IUPAC
1	191	192	|I-IUPAC
-	192	193	|I-IUPAC
ylmethyl	193	201	|I-IUPAC
,	201	202	|O
anthracen	203	212	|B-IUPAC
-	212	213	|I-IUPAC
9	213	214	|I-IUPAC
-	214	215	|I-IUPAC
ylmethyl	215	223	|I-IUPAC
,	223	224	|O
and	225	228	|O
pyren	229	234	|B-IUPAC
-	234	235	|I-IUPAC
1	235	236	|I-IUPAC
-	236	237	|I-IUPAC
ylmethyl	237	245	|I-IUPAC
.	245	246	|O
The	247	250	|O
polyamine	251	260	|O
spacer	261	267	|O
units	268	273	|O
ranged	274	280	|O
from	281	285	|O
generic	286	293	|O
(	294	295	|O
4,4	295	298	|B-IUPAC
-	298	299	|I-IUPAC
triamine	299	307	|I-IUPAC
,	307	308	|O
4,3	309	312	|B-IUPAC
-	312	313	|I-IUPAC
triamine	313	321	|I-IUPAC
,	321	322	|O
and	323	326	|O
diaminooctane	327	340	|O
)	340	341	|O
spacers	342	349	|O
to	350	352	|O
more	353	357	|O
exotic	358	364	|O
[	365	366	|O
2	366	367	|B-IUPAC
-	367	368	|I-IUPAC
(	368	369	|I-IUPAC
ethoxy	369	375	|I-IUPAC
)	375	376	|I-IUPAC
ethanoxy	376	384	|I-IUPAC
-	384	385	|I-IUPAC
containing	385	395	|B-MODIFIER
diamine	396	403	|B-IUPAC
,	403	404	|O
hydroxylated	405	417	|B-MODIFIER
4,3	418	421	|B-IUPAC
-	421	422	|I-IUPAC
triamine	422	430	|I-IUPAC
,	430	431	|O
and	432	435	|O
cyclohexylene	436	449	|O
-	449	450	|O
containing	450	460	|O
triamine	461	469	|O
]	469	470	|O
spacers	471	478	|O
.	478	479	|O
Two	480	483	|O
control	484	491	|O
compounds	492	501	|O
were	502	506	|O
also	507	511	|O
evaluated	512	521	|O
:	521	522	|O
N	523	524	|B-IUPAC
-	524	525	|I-IUPAC
(	525	526	|I-IUPAC
anthracen	526	535	|I-IUPAC
-	535	536	|I-IUPAC
9	536	537	|I-IUPAC
-	537	538	|I-IUPAC
ylmethyl	538	546	|I-IUPAC
)	546	547	|I-IUPAC
-	547	548	|I-IUPAC
butylamine	548	558	|I-IUPAC
and	559	562	|O
N	563	564	|B-IUPAC
-	564	565	|I-IUPAC
(	565	566	|I-IUPAC
anthracen	566	575	|I-IUPAC
-	575	576	|I-IUPAC
9	576	577	|I-IUPAC
-	577	578	|I-IUPAC
ylmethyl	578	586	|I-IUPAC
)	586	587	|I-IUPAC
-	587	588	|I-IUPAC
butanediamine	588	601	|I-IUPAC
.	601	602	|O
Biological	603	613	|O
activities	614	624	|O
in	625	627	|O
L1210	628	633	|O
(	634	635	|O
murine	635	641	|O
leukemia	642	650	|O
)	650	651	|O
,	651	652	|O
alpha	653	658	|B-IUPAC
-	658	659	|I-IUPAC
difluoromethylornithine	659	682	|I-IUPAC
(	683	684	|O
DFMO	684	688	|O
)	688	689	|O
-	689	690	|O
treated	690	697	|O
L1210	698	703	|O
,	703	704	|O
and	705	708	|O
Chinese	709	716	|O
hamster	717	724	|O
ovary	725	730	|O
(	731	732	|O
CHO	732	735	|O
)	735	736	|O
and	737	740	|O
its	741	744	|O
polyamine	745	754	|O
transport	755	764	|O
-	764	765	|O
deficient	765	774	|O
mutant	775	781	|O
(	782	783	|O
CHO	783	786	|O
-	786	787	|O
MG	787	789	|O
)	789	790	|O
cell	791	795	|O
lines	796	801	|O
were	802	806	|O
investigated	807	819	|O
via	820	823	|O
IC	824	826	|O
(	826	827	|O
50	827	829	|O
)	829	830	|O
cytotoxicity	831	843	|O
determinations	844	858	|O
.	858	859	|O
K	860	861	|O
(	861	862	|O
i	862	863	|O
)	863	864	|O
values	865	871	|O
for	872	875	|O
spermidine	876	886	|O
uptake	887	893	|O
were	894	898	|O
also	899	903	|O
determined	904	914	|O
in	915	917	|O
L1210	918	923	|O
cells	924	929	|O
.	929	930	|O
Of	931	933	|O
the	934	937	|O
series	938	944	|O
studied	945	952	|O
,	952	953	|O
the	954	957	|O
N	958	959	|B-IUPAC
(	959	960	|I-IUPAC
1	960	961	|I-IUPAC
)	961	962	|I-IUPAC
-	962	963	|I-IUPAC
benzyl	963	969	|I-IUPAC
-	969	970	|I-IUPAC
4,4	970	973	|I-IUPAC
-	973	974	|I-IUPAC
triamine	974	982	|I-IUPAC
system	983	989	|B-MODIFIER
6	990	991	|O
had	992	995	|O
significantly	996	1009	|O
higher	1010	1016	|O
IC	1017	1019	|O
(	1019	1020	|O
50	1020	1022	|O
)	1022	1023	|O
values	1024	1030	|O
(	1031	1032	|O
lower	1032	1037	|O
cytotoxicity	1038	1050	|O
)	1050	1051	|O
in	1052	1054	|O
the	1055	1058	|O
L1210	1059	1064	|O
,	1064	1065	|O
CHO	1066	1069	|O
,	1069	1070	|O
and	1071	1074	|O
CHO	1075	1078	|O
-	1078	1079	|O
MG	1079	1081	|O
cell	1082	1086	|O
lines	1087	1092	|O
.	1092	1093	|O
A	1094	1095	|O
cellular	1096	1104	|O
debenzylation	1105	1118	|O
process	1119	1126	|O
was	1127	1130	|O
observed	1131	1139	|O
in	1140	1142	|O
L1210	1143	1148	|O
cells	1149	1154	|O
with	1155	1159	|O
6	1160	1161	|O
and	1162	1165	|O
generated	1166	1175	|O
"	1176	1177	|O
free	1177	1181	|O
"	1181	1182	|O
homospermidine	1183	1197	|O
.	1197	1198	|O
The	1199	1202	|O
size	1203	1207	|O
of	1208	1210	|O
the	1211	1214	|O
N	1215	1216	|B-IUPAC
(	1216	1217	|I-IUPAC
1	1217	1218	|I-IUPAC
)	1218	1219	|I-IUPAC
-	1219	1220	|I-IUPAC
arylmethyl	1220	1230	|I-IUPAC
substituent	1231	1242	|B-MODIFIER
had	1243	1246	|O
direct	1247	1253	|O
bearing	1254	1261	|O
on	1262	1264	|O
the	1265	1268	|O
observed	1269	1277	|O
cytotoxicity	1278	1290	|O
in	1291	1293	|O
CHO	1294	1297	|O
-	1297	1298	|O
MG	1298	1300	|O
cells	1301	1306	|O
.	1306	1307	|O
The	1308	1311	|O
N	1312	1313	|B-PARTIUPAC
(	1313	1314	|I-PARTIUPAC
1	1314	1315	|I-PARTIUPAC
)	1315	1316	|I-PARTIUPAC
-	1316	1317	|I-PARTIUPAC
naphthalenylmethyl	1317	1335	|I-PARTIUPAC
,	1335	1336	|O
N	1337	1338	|B-PARTIUPAC
(	1338	1339	|I-PARTIUPAC
1	1339	1340	|I-PARTIUPAC
)	1340	1341	|I-PARTIUPAC
-	1341	1342	|I-PARTIUPAC
anthracenylmethyl	1342	1359	|I-PARTIUPAC
,	1359	1360	|O
and	1361	1364	|O
N	1365	1366	|B-IUPAC
(	1366	1367	|I-IUPAC
1	1367	1368	|I-IUPAC
)	1368	1369	|I-IUPAC
-	1369	1370	|I-IUPAC
pyrenylmethyl	1370	1383	|I-IUPAC
4,4	1384	1387	|I-IUPAC
-	1387	1388	|I-IUPAC
triamines	1388	1397	|I-IUPAC
had	1398	1401	|O
similar	1402	1409	|O
toxicity	1410	1418	|O
(	1419	1420	|O
IC	1420	1422	|O
(	1422	1423	|O
50	1423	1425	|O
)	1425	1426	|O
s	1426	1427	|O
:	1427	1428	|O
approximately	1429	1442	|O
0.5	1443	1446	|O
microM	1447	1453	|O
)	1453	1454	|O
in	1455	1457	|O
CHO	1458	1461	|O
cells	1462	1467	|O
,	1467	1468	|O
which	1469	1474	|O
have	1475	1479	|O
an	1480	1482	|O
active	1483	1489	|O
polyamine	1490	1499	|O
transporter	1500	1511	|O
(	1512	1513	|O
PAT	1513	1516	|O
)	1516	1517	|O
.	1517	1518	|O
However	1519	1526	|O
,	1526	1527	|O
this	1528	1532	|O
series	1533	1539	|O
had	1540	1543	|O
IC	1544	1546	|O
(	1546	1547	|O
50	1547	1549	|O
)	1549	1550	|O
values	1551	1557	|O
of	1558	1560	|O
&	1561	1562	|O
gt	1562	1564	|O
;	1564	1565	|O
100	1565	1568	|O
microM	1569	1575	|O
,	1575	1576	|O
66.7	1577	1581	|O
microM	1582	1588	|O
,	1588	1589	|O
and	1590	1593	|O
15.5	1594	1598	|O
microM	1599	1605	|O
,	1605	1606	|O
respectively	1607	1619	|O
,	1619	1620	|O
in	1621	1623	|O
CHO	1624	1627	|O
-	1627	1628	|O
MG	1628	1630	|O
cells	1631	1636	|O
,	1636	1637	|O
which	1638	1643	|O
are	1644	1647	|O
PAT	1648	1651	|O
-	1651	1652	|O
deficient	1652	1661	|O
.	1661	1662	|O
The	1663	1666	|O
observed	1667	1675	|O
lower	1676	1681	|O
cytotoxicity	1682	1694	|O
in	1695	1697	|O
the	1698	1701	|O
PAT	1702	1705	|O
-	1705	1706	|O
deficient	1706	1715	|O
CHO	1716	1719	|O
-	1719	1720	|O
MG	1720	1722	|O
cell	1723	1727	|O
line	1728	1732	|O
supported	1733	1742	|O
the	1743	1746	|O
premise	1747	1754	|O
that	1755	1759	|O
the	1760	1763	|O
conjugates	1764	1774	|O
use	1775	1778	|O
PAT	1779	1782	|O
for	1783	1786	|O
cellular	1787	1795	|O
entry	1796	1801	|O
.	1801	1802	|O
In	1803	1805	|O
general	1806	1813	|O
,	1813	1814	|O
moderate	1815	1823	|O
affinities	1824	1834	|O
for	1835	1838	|O
the	1839	1842	|O
polyamine	1843	1852	|O
transporter	1853	1864	|O
were	1865	1869	|O
observed	1870	1878	|O
for	1879	1882	|O
the	1883	1886	|O
N	1887	1888	|B-IUPAC
-	1888	1889	|I-IUPAC
arylmethyl	1889	1899	|I-IUPAC
4,4	1900	1903	|I-IUPAC
-	1903	1904	|I-IUPAC
triamine	1904	1912	|I-IUPAC
series	1913	1919	|B-MODIFIER
with	1920	1924	|O
their	1925	1930	|O
L1210	1931	1936	|O
K	1937	1938	|O
(	1938	1939	|O
i	1939	1940	|O
)	1940	1941	|O
values	1942	1948	|O
all	1949	1952	|O
near	1953	1957	|O
3	1958	1959	|O
microM	1960	1966	|O
.	1966	1967	|O
In	1968	1970	|O
summary	1971	1978	|O
,	1978	1979	|O
the	1980	1983	|O
4,4	1984	1987	|B-IUPAC
-	1987	1988	|I-IUPAC
triamine	1988	1996	|I-IUPAC
motif	1997	2002	|B-MODIFIER
was	2003	2006	|O
shown	2007	2012	|O
to	2013	2015	|O
facilitate	2016	2026	|O
entry	2027	2032	|O
of	2033	2035	|O
polyamine	2036	2045	|O
conjugates	2046	2056	|O
into	2057	2061	|O
cells	2062	2067	|O
containing	2068	2078	|O
active	2079	2085	|O
polyamine	2086	2095	|O
transporters	2096	2108	|O
.	2108	2109	|O

### abstracts2383.txt
The	0	3	|O
utility	4	11	|O
of	12	14	|O
polyamines	15	25	|O
as	26	28	|O
vectors	29	36	|O
for	37	40	|O
the	41	44	|O
intracellular	45	58	|O
transport	59	68	|O
of	69	71	|O
iron	72	76	|O
chelators	77	86	|O
is	87	89	|O
further	90	97	|O
described	98	107	|O
.	107	108	|O
Consistent	109	119	|O
with	120	124	|O
earlier	125	132	|O
results	133	140	|O
with	141	145	|O
polyamine	146	155	|O
analogues	156	165	|O
,	165	166	|O
these	167	172	|O
studies	173	180	|O
underscore	181	191	|O
the	192	195	|O
importance	196	206	|O
of	207	209	|O
charge	210	216	|O
in	217	219	|O
the	220	223	|O
design	224	230	|O
of	231	233	|O
polyamine	234	243	|O
-	243	244	|O
vectored	244	252	|O
chelators	253	262	|O
.	262	263	|O
Four	264	268	|O
polyamine	269	278	|O
conjugates	279	289	|O
are	290	293	|O
synthesized	294	305	|O
,	305	306	|O
two	307	310	|O
of	311	313	|O
terephthalic	314	326	|O
acid	327	331	|O
[	332	333	|O
N	333	334	|B-IUPAC
(	334	335	|I-IUPAC
1	335	336	|I-IUPAC
)	336	337	|I-IUPAC
-	337	338	|I-IUPAC
(	338	339	|I-IUPAC
4	339	340	|I-IUPAC
-	340	341	|I-IUPAC
carboxy	341	348	|I-IUPAC
)	348	349	|I-IUPAC
benzoylspermine	349	364	|I-IUPAC
(	365	366	|O
7	366	367	|O
)	367	368	|O
and	369	372	|O
its	373	376	|O
methyl	377	383	|O
ester	384	389	|O
(	390	391	|O
6	391	392	|O
)	392	393	|O
]	393	394	|O
and	395	398	|O
two	399	402	|O
of	403	405	|O
(	406	407	|B-IUPAC
S	407	408	|I-IUPAC
)	408	409	|I-IUPAC
-	409	410	|I-IUPAC
2	410	411	|I-IUPAC
-	411	412	|I-IUPAC
(	412	413	|I-IUPAC
2,4	413	416	|I-IUPAC
-	416	417	|I-IUPAC
dihydroxyphenyl	417	432	|I-IUPAC
)	432	433	|I-IUPAC
-	433	434	|I-IUPAC
4,5	434	437	|I-IUPAC
-	437	438	|I-IUPAC
dihydro	438	445	|I-IUPAC
-	445	446	|I-IUPAC
4	446	447	|I-IUPAC
-	447	448	|I-IUPAC
methyl	448	454	|I-IUPAC
-	454	455	|I-IUPAC
4	455	456	|I-IUPAC
-	456	457	|I-IUPAC
thiazolecarboxylic	457	475	|I-IUPAC
acid	476	480	|I-IUPAC
[	481	482	|O
(	482	483	|O
S	483	484	|O
)	484	485	|O
-	485	486	|O
4'	486	488	|O
-	488	489	|O
(	489	490	|O
HO	490	492	|O
)	492	493	|O
-	493	494	|O
DADFT	494	499	|O
]	499	500	|O
[	501	502	|O
(	502	503	|B-IUPAC
S	503	504	|I-IUPAC
)	504	505	|I-IUPAC
-	505	506	|I-IUPAC
4,5	506	509	|I-IUPAC
-	509	510	|I-IUPAC
dihydro	510	517	|I-IUPAC
-	517	518	|I-IUPAC
2	518	519	|I-IUPAC
-	519	520	|I-IUPAC
[	520	521	|I-IUPAC
2	521	522	|I-IUPAC
-	522	523	|I-IUPAC
hydroxy	523	530	|I-IUPAC
-	530	531	|I-IUPAC
4	531	532	|I-IUPAC
-	532	533	|I-IUPAC
(	533	534	|I-IUPAC
12	534	536	|I-IUPAC
-	536	537	|I-IUPAC
amino	537	542	|I-IUPAC
-	542	543	|I-IUPAC
5,9	543	546	|I-IUPAC
-	546	547	|I-IUPAC
diazadodecyl	547	559	|I-IUPAC
-	559	560	|I-IUPAC
oxy	560	563	|I-IUPAC
)	563	564	|I-IUPAC
phenyl	564	570	|I-IUPAC
]	570	571	|I-IUPAC
-	571	572	|I-IUPAC
4	572	573	|I-IUPAC
-	573	574	|I-IUPAC
methyl	574	580	|I-IUPAC
-	580	581	|I-IUPAC
4	581	582	|I-IUPAC
-	582	583	|I-IUPAC
thiazolecarboxylic	583	601	|I-IUPAC
acid	602	606	|I-IUPAC
(	607	608	|O
10	608	610	|O
)	610	611	|O
and	612	615	|O
its	616	619	|O
ethyl	620	625	|O
ester	626	631	|O
(	632	633	|O
9	633	634	|O
)	634	635	|O
]	635	636	|O
.	636	637	|O
These	638	643	|O
four	644	648	|O
molecules	649	658	|O
were	659	663	|O
evaluated	664	673	|O
in	674	676	|O
murine	677	683	|O
leukemia	684	692	|O
L1210	693	698	|O
cells	699	704	|O
for	705	708	|O
their	709	714	|O
impact	715	721	|O
on	722	724	|O
cell	725	729	|O
proliferation	730	743	|O
(	744	745	|O
48	745	747	|O
-	747	748	|O
and	749	752	|O
96	753	755	|O
-	755	756	|O
h	756	757	|O
IC	758	760	|O
(	760	761	|O
50	761	763	|O
)	763	764	|O
values	765	771	|O
)	771	772	|O
,	772	773	|O
their	774	779	|O
ability	780	787	|O
to	788	790	|O
compete	791	798	|O
with	799	803	|O
spermidine	804	814	|O
for	815	818	|O
the	819	822	|O
polyamine	823	832	|O
transport	833	842	|O
apparatus	843	852	|O
(	853	854	|O
K	854	855	|O
(	855	856	|O
i	856	857	|O
)	857	858	|O
)	858	859	|O
,	859	860	|O
and	861	864	|O
their	865	870	|O
intracellular	871	884	|O
accumulation	885	897	|O
.	897	898	|O
The	899	902	|O
data	903	907	|O
revealed	908	916	|O
that	917	921	|O
when	922	926	|O
neutral	927	934	|O
molecules	935	944	|O
(	945	946	|O
cargo	946	951	|O
fragments	952	961	|O
)	961	962	|O
were	963	967	|O
fixed	968	973	|O
to	974	976	|O
the	977	980	|O
polyamine	981	990	|O
vector	991	997	|O
,	997	998	|O
the	999	1002	|O
conjugates	1003	1013	|O
competed	1014	1022	|O
well	1023	1027	|O
with	1028	1032	|O
spermidine	1033	1043	|O
for	1044	1047	|O
transport	1048	1057	|O
and	1058	1061	|O
were	1062	1066	|O
accumulated	1067	1078	|O
intracellularly	1079	1094	|O
to	1095	1097	|O
millimolar	1098	1108	|O
levels	1109	1115	|O
.	1115	1116	|O
However	1117	1124	|O
,	1124	1125	|O
this	1126	1130	|O
was	1131	1134	|O
not	1135	1138	|O
the	1139	1142	|O
case	1143	1147	|O
when	1148	1152	|O
the	1153	1156	|O
cargo	1157	1162	|O
fragments	1163	1172	|O
were	1173	1177	|O
negatively	1178	1188	|O
charged	1189	1196	|O
.	1196	1197	|O
Metabolic	1198	1207	|O
studies	1208	1215	|O
of	1216	1218	|O
the	1219	1222	|O
polyamine	1223	1232	|O
-	1232	1233	|O
vectored	1233	1241	|O
(	1242	1243	|O
S	1243	1244	|O
)	1244	1245	|O
-	1245	1246	|O
4'	1246	1248	|O
-	1248	1249	|O
(	1249	1250	|O
HO	1250	1252	|O
)	1252	1253	|O
-	1253	1254	|O
DADFTs	1254	1260	|O
in	1261	1263	|O
rodents	1264	1271	|O
indicated	1272	1281	|O
that	1282	1286	|O
not	1287	1290	|O
only	1291	1295	|O
did	1296	1299	|O
the	1300	1303	|O
expected	1304	1312	|O
deaminopropylation	1313	1331	|O
step	1332	1336	|O
occur	1337	1342	|O
,	1342	1343	|O
but	1344	1347	|O
also	1348	1352	|O
a	1353	1354	|O
surprisingly	1355	1367	|O
high	1368	1372	|O
level	1373	1378	|O
of	1379	1381	|O
oxidative	1382	1391	|O
deamination	1392	1403	|O
at	1404	1406	|O
the	1407	1410	|O
terminal	1411	1419	|O
primary	1420	1427	|O
nitrogens	1428	1437	|O
took	1438	1442	|O
place	1443	1448	|O
.	1448	1449	|O
Finally	1450	1457	|O
,	1457	1458	|O
the	1459	1462	|O
iron	1463	1467	|O
-	1467	1468	|O
clearing	1468	1476	|O
efficiency	1477	1487	|O
of	1488	1490	|O
the	1491	1494	|O
(	1495	1496	|O
S	1496	1497	|O
)	1497	1498	|O
-	1498	1499	|O
4'	1499	1501	|O
-	1501	1502	|O
(	1502	1503	|O
HO	1503	1505	|O
)	1505	1506	|O
-	1506	1507	|O
DADFT	1507	1512	|O
conjugates	1513	1523	|O
was	1524	1527	|O
determined	1528	1538	|O
in	1539	1541	|O
a	1542	1543	|O
bile	1544	1548	|O
-	1548	1549	|O
duct	1549	1553	|O
-	1553	1554	|O
cannulated	1554	1564	|O
rodent	1565	1571	|O
model	1572	1577	|O
.	1577	1578	|O
Attaching	1579	1588	|O
the	1589	1592	|O
ligand	1593	1599	|O
to	1600	1602	|O
a	1603	1604	|O
polyamine	1605	1614	|O
vector	1615	1621	|O
had	1622	1625	|O
a	1626	1627	|O
profound	1628	1636	|O
effect	1637	1643	|O
on	1644	1646	|O
increasing	1647	1657	|O
the	1658	1661	|O
iron	1662	1666	|O
-	1666	1667	|O
clearing	1667	1675	|O
efficiency	1676	1686	|O
of	1687	1689	|O
this	1690	1694	|O
chelator	1695	1703	|O
relative	1704	1712	|O
to	1713	1715	|O
its	1716	1719	|O
parent	1720	1726	|O
drug	1727	1731	|O
.	1731	1732	|O

### abstracts1016.txt
This	0	4	|O
publication	5	16	|O
describes	17	26	|O
the	27	30	|O
synthesis	31	40	|O
and	41	44	|O
optimization	45	57	|O
of	58	60	|O
a	61	62	|O
novel	63	68	|O
series	69	75	|O
of	76	78	|O
stilbene	79	87	|O
endothelin	88	98	|O
antagonists	99	110	|O
.	110	111	|O
Analysis	112	120	|O
of	121	123	|O
the	124	127	|O
SAR	128	131	|O
established	132	143	|O
for	144	147	|O
previous	148	156	|O
papers	157	163	|O
in	164	166	|O
this	167	171	|O
series	172	178	|O
prompted	179	187	|O
the	188	191	|O
design	192	198	|O
and	199	202	|O
synthesis	203	212	|O
of	213	215	|O
(	216	217	|B-IUPAC
Z	217	218	|I-IUPAC
)	218	219	|I-IUPAC
-	219	220	|I-IUPAC
4	220	221	|I-IUPAC
-	221	222	|I-IUPAC
phenyl	222	228	|I-IUPAC
-	228	229	|I-IUPAC
5	229	230	|I-IUPAC
-	230	231	|I-IUPAC
(	231	232	|I-IUPAC
3	232	233	|I-IUPAC
-	233	234	|I-IUPAC
benzyloxyphenyl	234	249	|I-IUPAC
)	249	250	|I-IUPAC
pent	250	254	|I-IUPAC
-	254	255	|I-IUPAC
4	255	256	|I-IUPAC
-	256	257	|I-IUPAC
enoic	257	262	|I-IUPAC
acid	263	267	|I-IUPAC
3	268	269	|O
which	270	275	|O
was	276	279	|O
found	280	285	|O
to	286	288	|O
be	289	291	|O
a	292	293	|O
moderately	294	304	|O
active	305	311	|O
inhibitor	312	321	|O
of	322	324	|O
the	325	328	|O
binding	329	336	|O
of	337	339	|O
[	340	341	|O
125I	341	345	|O
]	345	346	|O
ET	346	348	|O
-	348	349	|O
1	349	350	|O
to	351	353	|O
ETA	354	357	|O
receptors	358	367	|O
with	368	372	|O
an	373	375	|O
IC50	376	380	|O
of	381	383	|O
6	384	385	|O
microM	386	392	|O
.	392	393	|O
More	394	398	|O
interestingly	399	412	|O
,	412	413	|O
the	414	417	|O
intermediate	418	430	|O
compound	431	439	|O
(	440	441	|B-IUPAC
E	441	442	|I-IUPAC
)	442	443	|I-IUPAC
-	443	444	|I-IUPAC
2	444	445	|I-IUPAC
-	445	446	|I-IUPAC
phenyl	446	452	|I-IUPAC
-	452	453	|I-IUPAC
3	453	454	|I-IUPAC
-	454	455	|I-IUPAC
(	455	456	|I-IUPAC
3	456	457	|I-IUPAC
-	457	458	|I-IUPAC
benzyloxyphenyl	458	473	|I-IUPAC
)	473	474	|I-IUPAC
propenoic	474	483	|I-IUPAC
acid	484	488	|I-IUPAC
5	489	490	|O
was	491	494	|O
equiactive	495	505	|O
with	506	510	|O
3	511	512	|O
.	512	513	|O
Optimization	514	526	|O
of	527	529	|O
5	530	531	|O
resulted	532	540	|O
in	541	543	|O
the	544	547	|O
preparation	548	559	|O
of	560	562	|O
(	563	564	|B-IUPAC
E	564	565	|I-IUPAC
)	565	566	|I-IUPAC
-	566	567	|I-IUPAC
2	567	568	|I-IUPAC
-	568	569	|I-IUPAC
phenyl	569	575	|I-IUPAC
-	575	576	|I-IUPAC
3	576	577	|I-IUPAC
-	577	578	|I-IUPAC
(	578	579	|I-IUPAC
2	579	580	|I-IUPAC
-	580	581	|I-IUPAC
cyano	581	586	|I-IUPAC
-	586	587	|I-IUPAC
5	587	588	|I-IUPAC
-	588	589	|I-IUPAC
(	589	590	|I-IUPAC
thien	590	595	|I-IUPAC
-	595	596	|I-IUPAC
3	596	597	|I-IUPAC
-	597	598	|I-IUPAC
ylmethoxy	598	607	|I-IUPAC
)	607	608	|I-IUPAC
)	608	609	|I-IUPAC
phenylprope	609	620	|I-IUPAC
noic	621	625	|I-IUPAC
acid	626	630	|I-IUPAC
18	631	633	|O
(	634	635	|O
RPR111723	635	644	|O
)	644	645	|O
which	646	651	|O
had	652	655	|O
an	656	658	|O
IC50	659	663	|O
in	664	666	|O
the	667	670	|O
binding	671	678	|O
assay	679	684	|O
of	685	687	|O
80	688	690	|O
nM	691	693	|O
on	694	696	|O
the	697	700	|O
ETA	701	704	|O
receptor	705	713	|O
and	714	717	|O
a	718	719	|O
pKB	720	723	|O
of	724	726	|O
6.5	727	730	|O
in	731	733	|O
the	734	737	|O
functional	738	748	|O
assay	749	754	|O
,	754	755	|O
measured	756	764	|O
on	765	767	|O
rat	768	771	|O
aortic	772	778	|O
strips	779	785	|O
.	785	786	|O
Reduction	787	796	|O
of	797	799	|O
the	800	803	|O
acid	804	808	|O
group	809	814	|O
of	815	817	|O
5	818	819	|O
gave	820	824	|O
the	825	828	|O
first	829	834	|O
nonacidic	835	844	|O
ETA	845	848	|O
antagonist	849	859	|O
in	860	862	|O
our	863	866	|O
series	867	873	|O
,	873	874	|O
(	875	876	|B-IUPAC
E	876	877	|I-IUPAC
)	877	878	|I-IUPAC
-	878	879	|I-IUPAC
2	879	880	|I-IUPAC
-	880	881	|I-IUPAC
phenyl	881	887	|I-IUPAC
-	887	888	|I-IUPAC
3	888	889	|I-IUPAC
-	889	890	|I-IUPAC
(	890	891	|I-IUPAC
3	891	892	|I-IUPAC
-	892	893	|I-IUPAC
benzyloxyphenoxy	893	909	|I-IUPAC
)	909	910	|I-IUPAC
prop2	910	915	|I-IUPAC
-	915	916	|I-IUPAC
enol	916	920	|I-IUPAC
6	921	922	|O
with	923	927	|O
an	928	930	|O
IC50	931	935	|O
of	936	938	|O
20	939	941	|O
microM	942	948	|O
.	948	949	|O
Optimization	950	962	|O
of	963	965	|O
6	966	967	|O
resulted	968	976	|O
in	977	979	|O
the	980	983	|O
preparation	984	995	|O
of	996	998	|O
2	999	1000	|B-IUPAC
-	1000	1001	|I-IUPAC
(	1001	1002	|I-IUPAC
2	1002	1003	|I-IUPAC
-	1003	1004	|I-IUPAC
methylphenyl	1004	1016	|I-IUPAC
)	1016	1017	|I-IUPAC
-	1017	1018	|I-IUPAC
3	1018	1019	|I-IUPAC
-	1019	1020	|I-IUPAC
(	1020	1021	|I-IUPAC
2	1021	1022	|I-IUPAC
-	1022	1023	|I-IUPAC
cyano	1023	1028	|I-IUPAC
-	1028	1029	|I-IUPAC
5	1029	1030	|I-IUPAC
-	1030	1031	|I-IUPAC
(	1031	1032	|I-IUPAC
thien	1032	1037	|I-IUPAC
-	1037	1038	|I-IUPAC
3	1038	1039	|I-IUPAC
-	1039	1040	|I-IUPAC
ylmethyl	1040	1048	|I-IUPAC
)	1048	1049	|I-IUPAC
phenyl	1049	1055	|I-IUPAC
)	1055	1056	|I-IUPAC
pro	1056	1059	|I-IUPAC
p	1060	1061	|I-IUPAC
-	1061	1062	|I-IUPAC
2	1062	1063	|I-IUPAC
-	1063	1064	|I-IUPAC
enol	1064	1068	|I-IUPAC
33	1069	1071	|O
with	1072	1076	|O
an	1077	1079	|O
IC50	1080	1084	|O
of	1085	1087	|O
300	1088	1091	|O
nM	1092	1094	|O
on	1095	1097	|O
the	1098	1101	|O
ETA	1102	1105	|O
receptor	1106	1114	|O
.	1114	1115	|O

### abstracts1652.txt
Several	0	7	|O
potentially	8	19	|O
bis	20	23	|O
(	23	24	|O
alkylating	24	34	|O
)	34	35	|O
bis	36	39	|O
(	39	40	|O
quinones	40	48	|O
)	48	49	|O
(	50	51	|O
3-5	51	54	|O
)	54	55	|O
and	56	59	|O
1,4	60	63	|B-PARTIUPAC
-	63	64	|I-PARTIUPAC
and	65	68	|O
1,3	69	72	|B-IUPAC
-	72	73	|I-IUPAC
bis	73	76	|I-IUPAC
(	76	77	|I-IUPAC
alkylating	77	87	|I-IUPAC
)	87	88	|I-IUPAC
monoquinones	89	101	|I-IUPAC
(	102	103	|O
6-13	103	107	|O
)	107	108	|O
belonging	109	118	|O
to	119	121	|O
general	122	129	|O
structure	130	139	|O
2,2	140	143	|B-PARTIUPAC
'	143	144	|I-PARTIUPAC
-	144	145	|I-PARTIUPAC
ethylenebis	145	156	|I-PARTIUPAC
[	156	157	|I-PARTIUPAC
5	157	158	|I-PARTIUPAC
-	158	159	|I-PARTIUPAC
[	159	160	|I-PARTIUPAC
(	160	161	|O
leaving	161	168	|O
group	169	174	|O
)	174	175	|O
methyl	175	181	|B-PARTIUPAC
]	181	182	|I-PARTIUPAC
-	182	183	|I-PARTIUPAC
1,4	183	186	|I-PARTIUPAC
-	186	187	|I-PARTIUPAC
benzoquinone	187	199	|I-PARTIUPAC
]	199	200	|I-PARTIUPAC
(	201	202	|O
3-5	202	205	|O
)	205	206	|O
and	207	210	|O
2,5	211	214	|B-PARTIUPAC
-	214	215	|I-PARTIUPAC
and	216	219	|O
2,6	220	223	|B-PARTIUPAC
-	223	224	|I-PARTIUPAC
bis	224	227	|I-PARTIUPAC
[	227	228	|I-PARTIUPAC
(	228	229	|O
leaving	229	236	|O
group	237	242	|O
)	242	243	|O
methyl	243	249	|B-PARTIUPAC
]	249	250	|I-PARTIUPAC
-	250	251	|I-PARTIUPAC
1,4	251	254	|I-PARTIUPAC
-	254	255	|I-PARTIUPAC
benzoquinone	255	267	|I-PARTIUPAC
water	268	273	|O
-	273	274	|O
soluble	274	281	|O
and	282	285	|O
-	286	287	|O
insoluble	287	296	|O
classes	297	304	|O
were	305	309	|O
prepared	310	318	|O
by	319	321	|O
oxidative	322	331	|O
demethylation	332	345	|O
of	346	348	|O
the	349	352	|O
corresponding	353	366	|O
tetramethoxydiphenylethanes	367	394	|O
(	395	396	|O
17-19	396	401	|O
)	401	402	|O
and	403	406	|O
dimethoxybenzenes	407	424	|O
(	425	426	|O
24	426	428	|O
,	428	429	|O
27	430	432	|O
,	432	433	|O
36-39	434	439	|O
)	439	440	|O
,	440	441	|O
respectively	442	454	|O
.	454	455	|O
Methods	456	463	|O
employed	464	472	|O
for	473	476	|O
the	477	480	|O
preparation	481	492	|O
of	493	495	|O
tetramethoxydiphenylethane	496	522	|B-IUPAC
intermediates	523	536	|O
involved	537	545	|O
(	546	547	|O
1	547	548	|O
)	548	549	|O
arylmethyl	550	560	|O
bromide	561	568	|O
coupling	569	577	|O
and	578	581	|O
(	582	583	|O
2	583	584	|O
)	584	585	|O
catalytic	586	595	|O
hydrogenation	596	609	|O
of	610	612	|O
stilbene	613	621	|O
intermediates	622	635	|O
derived	636	643	|O
via	644	647	|O
Wittig	648	654	|O
reaction	655	663	|O
of	664	666	|O
(	667	668	|O
arylmethyl	668	678	|O
)	678	679	|O
phosphonium	679	690	|O
salts	691	696	|O
with	697	701	|O
aryl	702	706	|O
aldehydes	707	716	|O
.	716	717	|O
However	718	725	|O
,	725	726	|O
in	727	729	|O
biological	730	740	|O
investigations	741	755	|O
using	756	761	|O
a	762	763	|O
subcutaneous	764	776	|O
B16	777	780	|O
(	781	782	|O
hypoxic	782	789	|O
)	789	790	|O
melanoma	791	799	|O
tumor	800	805	|O
in	806	808	|O
BDF1	809	813	|O
hybrid	814	820	|O
mice	821	825	|O
with	826	830	|O
cyclophosphamide	831	847	|O
as	848	850	|O
positive	851	859	|O
control	860	867	|O
the	868	871	|O
most	872	876	|O
interesting	877	888	|O
series	889	895	|O
of	896	898	|O
structurally	899	911	|O
related	912	919	|O
analogues	920	929	|O
were	930	934	|O
the	935	938	|O
potentially	939	950	|O
monoalkylating	951	965	|O
monoquinones	966	978	|O
of	979	981	|O
the	982	985	|O
2	986	987	|B-PARTIUPAC
-	987	988	|I-PARTIUPAC
[	988	989	|I-PARTIUPAC
(	989	990	|O
leaving	990	997	|O
group	998	1003	|O
)	1003	1004	|O
methyl	1004	1010	|B-PARTIUPAC
]	1010	1011	|I-PARTIUPAC
-	1011	1012	|I-PARTIUPAC
1,4	1012	1015	|I-PARTIUPAC
-	1015	1016	|I-PARTIUPAC
benzoquinone	1016	1028	|I-PARTIUPAC
type	1029	1033	|B-MODIFIER
(	1034	1035	|O
i.e.	1035	1039	|O
,	1039	1040	|O
14	1041	1043	|O
and	1044	1047	|O
15	1048	1050	|O
)	1050	1051	|O
having	1052	1058	|O
water	1059	1064	|O
-	1064	1065	|O
insoluble	1065	1074	|O
(	1075	1076	|O
acetoxy	1076	1083	|O
)	1083	1084	|O
and	1085	1088	|O
water	1089	1094	|O
-	1094	1095	|O
solubilizing	1095	1107	|O
(	1108	1109	|O
succinate	1109	1118	|O
)	1118	1119	|O
groups	1120	1126	|O
.	1126	1127	|O
Serial	1128	1134	|O
measurements	1135	1147	|O
of	1148	1150	|O
tumor	1151	1156	|O
size	1157	1161	|O
,	1161	1162	|O
and	1163	1166	|O
evaluation	1167	1177	|O
of	1178	1180	|O
increased	1181	1190	|O
life	1191	1195	|O
span	1196	1200	|O
,	1200	1201	|O
in	1202	1204	|O
response	1205	1213	|O
to	1214	1216	|O
drug	1217	1221	|O
treatment	1222	1231	|O
also	1232	1236	|O
revealed	1237	1245	|O
potentially	1246	1257	|O
1,4	1258	1261	|B-PARTIUPAC
-	1261	1262	|I-PARTIUPAC
bis	1262	1265	|I-PARTIUPAC
(	1265	1266	|O
alkylating	1266	1276	|O
)	1276	1277	|O
(	1278	1279	|B-PARTIUPAC
bromomethyl	1279	1290	|I-PARTIUPAC
)	1290	1291	|I-PARTIUPAC
-	1291	1292	|I-PARTIUPAC
1,4	1292	1295	|I-PARTIUPAC
-	1295	1296	|I-PARTIUPAC
quinone	1296	1303	|I-PARTIUPAC
7	1304	1305	|O
and	1306	1309	|O
1,3	1310	1313	|B-PARTIUPAC
-	1313	1314	|I-PARTIUPAC
bis	1314	1317	|I-PARTIUPAC
(	1317	1318	|O
alkylating	1318	1328	|O
)	1328	1329	|O
(	1330	1331	|B-PARTIUPAC
hydroxymethyl	1331	1344	|I-PARTIUPAC
)	1344	1345	|I-PARTIUPAC
-	1345	1346	|I-PARTIUPAC
1,4	1346	1349	|I-PARTIUPAC
-	1349	1350	|I-PARTIUPAC
quinone	1350	1357	|I-PARTIUPAC
10	1358	1360	|O
to	1361	1363	|O
have	1364	1368	|O
variable	1369	1377	|O
activity	1378	1386	|O
,	1386	1387	|O
but	1388	1391	|O
none	1392	1396	|O
of	1397	1399	|O
the	1400	1403	|O
potentially	1404	1415	|O
bis	1416	1419	|O
(	1419	1420	|O
alkylating	1420	1430	|O
)	1430	1431	|O
bis	1432	1435	|O
(	1435	1436	|O
quinones	1436	1444	|O
)	1444	1445	|O
showed	1446	1452	|O
antitumor	1453	1462	|O
properties	1463	1473	|O
in	1474	1476	|O
this	1477	1481	|O
model	1482	1487	|O
.	1487	1488	|O

### abstracts1984.txt
The	0	3	|O
homologous	4	14	|O
series	15	21	|O
of	22	24	|O
acidic	25	31	|O
amino	32	37	|O
acids	38	43	|O
,	43	44	|O
ranging	45	52	|O
from	53	57	|O
aspartic	58	66	|O
acid	67	71	|O
(	72	73	|O
1	73	74	|O
)	74	75	|O
to	76	78	|O
2	79	80	|B-IUPAC
-	80	81	|I-IUPAC
aminosuberic	81	93	|I-IUPAC
acid	94	98	|I-IUPAC
(	99	100	|O
5	100	101	|O
)	101	102	|O
,	102	103	|O
and	104	107	|O
the	108	111	|O
corresponding	112	125	|O
series	126	132	|O
of	133	135	|O
3	136	137	|B-IUPAC
-	137	138	|I-IUPAC
isoxazolol	138	148	|I-IUPAC
bioisosteres	149	161	|B-MODIFIER
of	162	164	|O
these	165	170	|O
amino	171	176	|O
acids	177	182	|O
,	182	183	|O
ranging	184	191	|O
from	192	196	|O
(	197	198	|B-IUPAC
RS	198	200	|I-IUPAC
)	200	201	|I-IUPAC
-	201	202	|I-IUPAC
2	202	203	|I-IUPAC
-	203	204	|I-IUPAC
amino	204	209	|I-IUPAC
-	209	210	|I-IUPAC
2	210	211	|I-IUPAC
-	211	212	|I-IUPAC
(	212	213	|I-IUPAC
3	213	214	|I-IUPAC
-	214	215	|I-IUPAC
hydroxy	215	222	|I-IUPAC
-	222	223	|I-IUPAC
5	223	224	|I-IUPAC
-	224	225	|I-IUPAC
methylisoxazol	225	239	|I-IUPAC
-	239	240	|I-IUPAC
4	240	241	|I-IUPAC
-	241	242	|I-IUPAC
yl	242	244	|I-IUPAC
)	244	245	|I-IUPAC
acetic	245	251	|I-IUPAC
acid	252	256	|I-IUPAC
(	257	258	|O
AMAA	258	262	|O
,	262	263	|O
6	264	265	|O
)	265	266	|O
to	267	269	|O
(	270	271	|B-IUPAC
RS	271	273	|I-IUPAC
)	273	274	|I-IUPAC
-	274	275	|I-IUPAC
2	275	276	|I-IUPAC
-	276	277	|I-IUPAC
amino	277	282	|I-IUPAC
-	282	283	|I-IUPAC
6	283	284	|I-IUPAC
-	284	285	|I-IUPAC
(	285	286	|I-IUPAC
3	286	287	|I-IUPAC
-	287	288	|I-IUPAC
hydroxy	288	295	|I-IUPAC
-	295	296	|I-IUPAC
5	296	297	|I-IUPAC
-	297	298	|I-IUPAC
methylisoxazol	298	312	|I-IUPAC
-	312	313	|I-IUPAC
4	313	314	|I-IUPAC
-	314	315	|I-IUPAC
yl	315	317	|I-IUPAC
)	317	318	|I-IUPAC
hexanoic	318	326	|I-IUPAC
acid	327	331	|I-IUPAC
(	332	333	|O
10	333	335	|O
)	335	336	|O
,	336	337	|O
were	338	342	|O
tested	343	349	|O
as	350	352	|O
ligands	353	360	|O
for	361	364	|O
metabotropic	365	377	|O
excitatory	378	388	|O
amino	389	394	|O
acid	395	399	|O
receptors	400	409	|O
(	410	411	|O
mGlu1	411	416	|O
alpha	417	422	|O
,	422	423	|O
mGlu2	424	429	|O
,	429	430	|O
mGlu4a	431	437	|O
,	437	438	|O
and	439	442	|O
mGlu6	443	448	|O
)	448	449	|O
.	449	450	|O
Whereas	451	458	|O
AMAA	459	463	|O
(	464	465	|O
6	465	466	|O
)	466	467	|O
and	468	471	|O
(	472	473	|B-IUPAC
RS	473	475	|I-IUPAC
)	475	476	|I-IUPAC
-	476	477	|I-IUPAC
2	477	478	|I-IUPAC
-	478	479	|I-IUPAC
amino	479	484	|I-IUPAC
-	484	485	|I-IUPAC
3	485	486	|I-IUPAC
-	486	487	|I-IUPAC
(	487	488	|I-IUPAC
3	488	489	|I-IUPAC
-	489	490	|I-IUPAC
hydroxy	490	497	|I-IUPAC
-	497	498	|I-IUPAC
5	498	499	|I-IUPAC
-	499	500	|I-IUPAC
methylisoxazol	500	514	|I-IUPAC
-	514	515	|I-IUPAC
4	515	516	|I-IUPAC
-	516	517	|I-IUPAC
yl	517	519	|I-IUPAC
)	519	520	|I-IUPAC
propinoic	520	529	|I-IUPAC
acid	530	534	|I-IUPAC
(	535	536	|O
AMPA	536	540	|O
,	540	541	|O
7	542	543	|O
)	543	544	|O
are	545	548	|O
potent	549	555	|O
and	556	559	|O
highly	560	566	|O
selective	567	576	|O
agonists	577	585	|O
at	586	588	|O
N	589	590	|B-IUPAC
-	590	591	|I-IUPAC
methyl	591	597	|I-IUPAC
-	597	598	|I-IUPAC
D	598	599	|I-IUPAC
-	599	600	|I-IUPAC
aspartic	600	608	|I-IUPAC
acid	609	613	|I-IUPAC
(	614	615	|O
NMDA	615	619	|O
)	619	620	|O
and	621	624	|O
AMPA	625	629	|O
receptors	630	639	|O
,	639	640	|O
respectively	641	653	|O
,	653	654	|O
the	655	658	|O
higher	659	665	|O
homologue	666	675	|O
of	676	678	|O
AMPA	679	683	|O
(	684	685	|O
7	685	686	|O
)	686	687	|O
,	687	688	|O
(	689	690	|B-IUPAC
RS	690	692	|I-IUPAC
)	692	693	|I-IUPAC
-	693	694	|I-IUPAC
2	694	695	|I-IUPAC
-	695	696	|I-IUPAC
amino	696	701	|I-IUPAC
-	701	702	|I-IUPAC
4	702	703	|I-IUPAC
-	703	704	|I-IUPAC
(	704	705	|I-IUPAC
3	705	706	|I-IUPAC
-	706	707	|I-IUPAC
hydroxy	707	714	|I-IUPAC
-	714	715	|I-IUPAC
5	715	716	|I-IUPAC
-	716	717	|I-IUPAC
methylisoxazol	717	731	|I-IUPAC
-	731	732	|I-IUPAC
4	732	733	|I-IUPAC
-	733	734	|I-IUPAC
yl	734	736	|I-IUPAC
)	736	737	|I-IUPAC
butyric	737	744	|I-IUPAC
acid	745	749	|I-IUPAC
(	750	751	|O
homo	751	755	|O
-	755	756	|O
AMPA	756	760	|O
,	760	761	|O
8	762	763	|O
)	763	764	|O
,	764	765	|O
is	766	768	|O
inactive	769	777	|O
at	778	780	|O
ionotropic	781	791	|O
excitatory	792	802	|O
amino	803	808	|O
acid	809	813	|O
receptors	814	823	|O
.	823	824	|O
Homo	825	829	|O
-	829	830	|O
AMPA	830	834	|O
(	835	836	|O
8	836	837	|O
)	837	838	|O
,	838	839	|O
which	840	845	|O
is	846	848	|O
a	849	850	|O
3	851	852	|B-IUPAC
-	852	853	|I-IUPAC
isoxazolol	853	863	|I-IUPAC
bioisostere	864	875	|B-MODIFIER
of	876	878	|O
2	879	880	|B-IUPAC
-	880	881	|I-IUPAC
aminoadipic	881	892	|I-IUPAC
acid	893	897	|I-IUPAC
(	898	899	|O
3	899	900	|O
)	900	901	|O
,	901	902	|O
was	903	906	|O
,	906	907	|O
however	908	915	|O
,	915	916	|O
shown	917	922	|O
to	923	925	|O
be	926	928	|O
a	929	930	|O
specific	931	939	|O
and	940	943	|O
rather	944	950	|O
potent	951	957	|O
agonist	958	965	|O
at	966	968	|O
mGlu6	969	974	|O
,	974	975	|O
approximately	976	989	|O
4	990	991	|O
times	992	997	|O
weaker	998	1004	|O
than	1005	1009	|O
the	1010	1013	|O
nonselective	1014	1026	|O
excitatory	1027	1037	|O
amino	1038	1043	|O
acid	1044	1048	|O
receptor	1049	1057	|O
agonist	1058	1065	|O
(	1066	1067	|B-IUPAC
S	1067	1068	|I-IUPAC
)	1068	1069	|I-IUPAC
-	1069	1070	|I-IUPAC
glutamic	1070	1078	|I-IUPAC
acid	1079	1083	|I-IUPAC
.	1083	1084	|O
2	1085	1086	|B-IUPAC
-	1086	1087	|I-IUPAC
Aminoadipic	1087	1098	|I-IUPAC
acid	1099	1103	|I-IUPAC
(	1104	1105	|O
3	1105	1106	|O
)	1106	1107	|O
,	1107	1108	|O
which	1109	1114	|O
shows	1115	1120	|O
a	1121	1122	|O
complex	1123	1130	|O
excitatory	1131	1141	|O
amino	1142	1147	|O
acid	1148	1152	|O
synaptic	1153	1161	|O
pharmacology	1162	1174	|O
,	1174	1175	|O
was	1176	1179	|O
an	1180	1182	|O
agonist	1183	1190	|O
at	1191	1193	|O
mGlu6	1194	1199	|O
as	1200	1202	|O
well	1203	1207	|O
as	1208	1210	|O
mGlu2	1211	1216	|O
.	1216	1217	|O
AMPA	1218	1222	|O
(	1223	1224	|O
7	1224	1225	|O
)	1225	1226	|O
and	1227	1230	|O
the	1231	1234	|O
higher	1235	1241	|O
homologue	1242	1251	|O
of	1252	1254	|O
homo	1255	1259	|O
-	1259	1260	|O
AMPA	1260	1264	|O
(	1265	1266	|O
8	1266	1267	|O
)	1267	1268	|O
,	1268	1269	|O
(	1270	1271	|B-IUPAC
RS	1271	1273	|I-IUPAC
)	1273	1274	|I-IUPAC
-	1274	1275	|I-IUPAC
2	1275	1276	|I-IUPAC
-	1276	1277	|I-IUPAC
amino	1277	1282	|I-IUPAC
-	1282	1283	|I-IUPAC
5	1283	1284	|I-IUPAC
-	1284	1285	|I-IUPAC
(	1285	1286	|I-IUPAC
3	1286	1287	|I-IUPAC
-	1287	1288	|I-IUPAC
hydroxy	1288	1295	|I-IUPAC
-	1295	1296	|I-IUPAC
5	1296	1297	|I-IUPAC
-	1297	1298	|I-IUPAC
methylisoxazol	1298	1312	|I-IUPAC
-	1312	1313	|I-IUPAC
4	1313	1314	|I-IUPAC
-	1314	1315	|I-IUPAC
yl	1315	1317	|I-IUPAC
)	1317	1318	|I-IUPAC
pentanoic	1318	1327	|I-IUPAC
acid	1328	1332	|I-IUPAC
(	1333	1334	|O
9	1334	1335	|O
)	1335	1336	|O
,	1336	1337	|O
showed	1338	1344	|O
relatively	1345	1355	|O
weak	1356	1360	|O
agonist	1361	1368	|O
effects	1369	1376	|O
at	1377	1379	|O
mGlu6	1380	1385	|O
.	1385	1386	|O
It	1387	1389	|O
is	1390	1392	|O
concluded	1393	1402	|O
that	1403	1407	|O
homo	1408	1412	|O
-	1412	1413	|O
AMPA	1413	1417	|O
(	1418	1419	|O
8	1419	1420	|O
)	1420	1421	|O
is	1422	1424	|O
likely	1425	1431	|O
to	1432	1434	|O
be	1435	1437	|O
a	1438	1439	|O
useful	1440	1446	|O
tool	1447	1451	|O
for	1452	1455	|O
studies	1456	1463	|O
of	1464	1466	|O
the	1467	1470	|O
pharmacology	1471	1483	|O
and	1484	1487	|O
physiological	1488	1501	|O
role	1502	1506	|O
of	1507	1509	|O
mGlu6	1510	1515	|O
.	1515	1516	|O
We	1517	1519	|O
describe	1520	1528	|O
a	1529	1530	|O
new	1531	1534	|O
versatile	1535	1544	|O
synthesis	1545	1554	|O
of	1555	1557	|O
this	1558	1562	|O
homologue	1563	1572	|O
of	1573	1575	|O
AMPA	1576	1580	|O
and	1581	1584	|O
the	1585	1588	|O
synthesis	1589	1598	|O
of	1599	1601	|O
compound	1602	1610	|O
10	1611	1613	|O
.	1613	1614	|O

### abstracts2210.txt
A	0	1	|O
novel	2	7	|O
series	8	14	|O
of	15	17	|O
(	18	19	|B-IUPAC
2R	19	21	|I-IUPAC
)	21	22	|I-IUPAC
-	22	23	|I-IUPAC
2	23	24	|I-IUPAC
-	24	25	|I-IUPAC
[	25	26	|I-IUPAC
(	26	27	|I-IUPAC
1R	27	29	|I-IUPAC
)	29	30	|I-IUPAC
-	30	31	|I-IUPAC
3	31	32	|I-IUPAC
,	32	33	|I-IUPAC
3	34	35	|I-IUPAC
-	35	36	|I-IUPAC
difluorocyclopentyl	36	55	|I-IUPAC
]	55	56	|I-IUPAC
-	56	57	|I-IUPAC
2	57	58	|I-IUPAC
-	58	59	|I-IUPAC
hydroxy	59	66	|I-IUPAC
-	66	67	|I-IUPAC
2	67	68	|I-IUPAC
-	68	69	|I-IUPAC
phenylacetamides	69	85	|I-IUPAC
was	86	89	|O
designed	90	98	|O
and	99	102	|O
synthesized	103	114	|O
based	115	120	|O
on	121	123	|O
the	124	127	|O
structure	128	137	|O
and	138	141	|O
biological	142	152	|O
profiles	153	161	|O
of	162	164	|O
an	165	167	|O
active	168	174	|O
metabolite	175	185	|O
2	186	187	|O
of	188	190	|O
our	191	194	|O
prototype	195	204	|O
muscarinic	205	215	|O
M	216	217	|O
(	217	218	|O
3	218	219	|O
)	219	220	|O
receptor	221	229	|O
selective	230	239	|O
antagonist	240	250	|O
1	251	252	|O
,	252	253	|O
to	254	256	|O
develop	257	264	|O
a	265	266	|O
potent	267	273	|O
,	273	274	|O
long	275	279	|O
-	279	280	|O
acting	280	286	|O
,	286	287	|O
orally	288	294	|O
active	295	301	|O
M	302	303	|O
(	303	304	|O
3	304	305	|O
)	305	306	|O
antagonist	307	317	|O
for	318	321	|O
the	322	325	|O
treatment	326	335	|O
of	336	338	|O
urinary	339	346	|O
tract	347	352	|O
disorders	353	362	|O
,	362	363	|O
irritable	364	373	|O
bowel	374	379	|O
syndrome	380	388	|O
,	388	389	|O
and	390	393	|O
respiratory	394	405	|O
disorders	406	415	|O
.	415	416	|O
Investigation	417	430	|O
of	431	433	|O
(	434	435	|B-IUPAC
2R	435	437	|I-IUPAC
)	437	438	|I-IUPAC
-	438	439	|I-IUPAC
2	439	440	|I-IUPAC
-	440	441	|I-IUPAC
[	441	442	|I-IUPAC
(	442	443	|I-IUPAC
1R	443	445	|I-IUPAC
)	445	446	|I-IUPAC
-	446	447	|I-IUPAC
3	447	448	|I-IUPAC
,	448	449	|I-IUPAC
3	450	451	|I-IUPAC
-	451	452	|I-IUPAC
difluorocyclopentyl	452	471	|I-IUPAC
]	471	472	|I-IUPAC
-	472	473	|I-IUPAC
2	473	474	|I-IUPAC
-	474	475	|I-IUPAC
hydroxy	475	482	|I-IUPAC
-	482	483	|I-IUPAC
2	483	484	|I-IUPAC
-	484	485	|I-IUPAC
phenylacetamides	485	501	|I-IUPAC
containing	502	512	|O
a	513	514	|O
phenyl	515	521	|B-IUPAC
or	522	524	|O
heterocyclic	525	537	|B-IUPAC
ring	538	542	|B-MODIFIER
as	543	545	|O
the	546	549	|O
piperidinyl	550	561	|B-IUPAC
side	562	566	|B-MODIFIER
chain	567	572	|I-MODIFIER
in	573	575	|O
place	576	581	|O
of	582	584	|O
the	585	588	|O
4	589	590	|B-IUPAC
-	590	591	|I-IUPAC
methyl	591	597	|I-IUPAC
-	597	598	|I-IUPAC
3	598	599	|I-IUPAC
-	599	600	|I-IUPAC
pentenyl	600	608	|I-IUPAC
moiety	609	615	|B-MODIFIER
of	616	618	|O
15a	619	622	|O
revealed	623	631	|O
that	632	636	|O
this	637	641	|O
acid	642	646	|O
moiety	647	653	|O
was	654	657	|O
a	658	659	|O
versatile	660	669	|O
template	670	678	|O
for	679	682	|O
improving	683	692	|O
the	693	696	|O
selectivity	697	708	|O
for	709	712	|O
M	713	714	|O
(	714	715	|O
3	715	716	|O
)	716	717	|O
over	718	722	|O
M	723	724	|O
(	724	725	|O
2	725	726	|O
)	726	727	|O
receptors	728	737	|O
in	738	740	|O
comparison	741	751	|O
with	752	756	|O
the	757	760	|O
corresponding	761	774	|O
cyclopentylphenylacetic	775	798	|O
acid	799	803	|O
group	804	809	|O
.	809	810	|O
However	811	818	|O
,	818	819	|O
since	820	825	|O
the	826	829	|O
in	830	832	|O
vitro	833	838	|O
metabolic	839	848	|O
stability	849	858	|O
of	859	861	|O
these	862	867	|O
analogues	868	877	|O
was	878	881	|O
insufficient	882	894	|O
compared	895	903	|O
with	904	908	|O
that	909	913	|O
of	914	916	|O
2	917	918	|O
,	918	919	|O
further	920	927	|O
derivatization	928	942	|O
was	943	946	|O
performed	947	956	|O
by	957	959	|O
introducing	960	971	|O
an	972	974	|O
appropriate	975	986	|O
hydrophilic	987	998	|O
group	999	1004	|O
into	1005	1009	|O
the	1010	1013	|O
phenyl	1014	1020	|B-IUPAC
or	1021	1023	|O
2	1024	1025	|B-IUPAC
-	1025	1026	|I-IUPAC
pyridyl	1026	1033	|I-IUPAC
ring	1034	1038	|B-MODIFIER
.	1038	1039	|O
Thus	1040	1044	|O
,	1044	1045	|O
the	1046	1049	|O
1	1050	1051	|B-IUPAC
-	1051	1052	|I-IUPAC
(	1052	1053	|I-IUPAC
6	1053	1054	|I-IUPAC
-	1054	1055	|I-IUPAC
aminopyridin	1055	1067	|I-IUPAC
-	1067	1068	|I-IUPAC
2	1068	1069	|I-IUPAC
-	1069	1070	|I-IUPAC
ylmethyl	1070	1078	|I-IUPAC
)	1078	1079	|I-IUPAC
piperidine	1079	1089	|I-IUPAC
analogue	1090	1098	|B-MODIFIER
15y	1099	1102	|O
exhibiting	1103	1113	|O
190	1114	1117	|O
-	1117	1118	|O
fold	1118	1122	|O
selectivity	1123	1134	|O
for	1135	1138	|O
M	1139	1140	|O
(	1140	1141	|O
3	1141	1142	|O
)	1142	1143	|O
receptors	1144	1153	|O
(	1154	1155	|O
K	1155	1156	|O
(	1156	1157	|O
i	1157	1158	|O
)	1158	1159	|O
=	1160	1161	|O
2.8	1162	1165	|O
nM	1166	1168	|O
)	1168	1169	|O
over	1170	1174	|O
M	1175	1176	|O
(	1176	1177	|O
2	1177	1178	|O
)	1178	1179	|O
receptors	1180	1189	|O
(	1190	1191	|O
K	1191	1192	|O
(	1192	1193	|O
i	1193	1194	|O
)	1194	1195	|O
=	1196	1197	|O
530	1198	1201	|O
nM	1202	1204	|O
)	1204	1205	|O
in	1206	1208	|O
a	1209	1210	|O
human	1211	1216	|O
binding	1217	1224	|O
assay	1225	1230	|O
and	1231	1234	|O
good	1235	1239	|O
in	1240	1242	|O
vitro	1243	1248	|O
metabolic	1249	1258	|O
stability	1259	1268	|O
in	1269	1271	|O
dog	1272	1275	|O
and	1276	1279	|O
human	1280	1285	|O
hepatic	1286	1293	|O
microsomes	1294	1304	|O
was	1305	1308	|O
identified	1309	1319	|O
.	1319	1320	|O
This	1321	1325	|O
compound	1326	1334	|O
has	1335	1338	|O
excellent	1339	1348	|O
oral	1349	1353	|O
activity	1354	1362	|O
at	1363	1365	|O
4	1366	1367	|O
h	1368	1369	|O
after	1370	1375	|O
oral	1376	1380	|O
dosing	1381	1387	|O
(	1388	1389	|O
1	1389	1390	|O
mg	1391	1393	|O
/	1393	1394	|O
kg	1394	1396	|O
)	1396	1397	|O
,	1397	1398	|O
inhibiting	1399	1409	|O
methacholine	1410	1422	|O
-	1422	1423	|O
induced	1423	1430	|O
bronchoconstriction	1431	1450	|O
in	1451	1453	|O
dogs	1454	1458	|O
,	1458	1459	|O
and	1460	1463	|O
may	1464	1467	|O
be	1468	1470	|O
useful	1471	1477	|O
in	1478	1480	|O
clinical	1481	1489	|O
situations	1490	1500	|O
in	1501	1503	|O
which	1504	1509	|O
M	1510	1511	|O
(	1511	1512	|O
3	1512	1513	|O
)	1513	1514	|O
over	1515	1519	|O
M	1520	1521	|O
(	1521	1522	|O
2	1522	1523	|O
)	1523	1524	|O
selectivity	1525	1536	|O
is	1537	1539	|O
desirable	1540	1549	|O
.	1549	1550	|O

### abstracts174.txt
3	0	1	|B-IUPAC
-	1	2	|I-IUPAC
Methoxy	2	9	|I-IUPAC
-	9	10	|I-IUPAC
4,5,6,7	10	17	|I-IUPAC
-	17	18	|I-IUPAC
tetrahydro	18	28	|I-IUPAC
-	28	29	|I-IUPAC
1,2	29	32	|I-IUPAC
-	32	33	|I-IUPAC
benzisoxazol	33	45	|I-IUPAC
-	45	46	|I-IUPAC
4	46	47	|I-IUPAC
-	47	48	|I-IUPAC
one	48	51	|I-IUPAC
(	52	53	|O
20a	53	56	|O
)	56	57	|O
,	57	58	|O
or	59	61	|O
the	62	65	|O
corresponding	66	79	|O
3	80	81	|B-IUPAC
-	81	82	|I-IUPAC
ethoxy	82	88	|I-IUPAC
analogue	89	97	|B-MODIFIER
(	98	99	|O
20b	99	102	|O
)	102	103	|O
,	103	104	|O
and	105	108	|O
3	109	110	|B-IUPAC
-	110	111	|I-IUPAC
chloro	111	117	|I-IUPAC
-	117	118	|I-IUPAC
4,5,6	118	123	|I-IUPAC
,	123	124	|I-IUPAC
7	125	126	|I-IUPAC
-	126	127	|I-IUPAC
tetrahydro	127	137	|I-IUPAC
-	137	138	|I-IUPAC
1,2	138	141	|I-IUPAC
-	141	142	|I-IUPAC
benzisothiazol	142	156	|I-IUPAC
-	156	157	|I-IUPAC
4	157	158	|I-IUPAC
-	158	159	|I-IUPAC
one	159	162	|I-IUPAC
(	163	164	|O
51	164	166	|O
)	166	167	|O
were	168	172	|O
synthesized	173	184	|O
by	185	187	|O
regioselective	188	202	|O
chromic	203	210	|O
acid	211	215	|O
oxidation	216	225	|O
of	226	228	|O
the	229	232	|O
respective	233	243	|O
bicyclic	244	252	|O
tetrahydrobenzenes	253	271	|O
19a	272	275	|O
,	275	276	|O
b	276	277	|O
and	278	281	|O
50	282	284	|O
,	284	285	|O
and	286	289	|O
they	290	294	|O
were	295	299	|O
used	300	304	|O
as	305	307	|O
key	308	311	|O
intermediates	312	325	|O
for	326	329	|O
the	330	333	|O
syntheses	334	343	|O
of	344	346	|O
the	347	350	|O
target	351	357	|O
zwitterionic	358	370	|O
3	371	372	|B-IUPAC
-	372	373	|I-IUPAC
isoxazolols	373	384	|I-IUPAC
8-15	385	389	|O
and	390	393	|O
3	394	395	|B-IUPAC
-	395	396	|I-IUPAC
isothiazolols	396	409	|I-IUPAC
16	410	412	|O
and	413	416	|O
17	417	419	|O
,	419	420	|O
respectively	421	433	|O
.	433	434	|O
These	435	440	|O
reaction	441	449	|O
sequences	450	459	|O
involved	460	468	|O
different	469	478	|O
reductive	479	488	|O
processes	489	498	|O
.	498	499	|O
Whereas	500	507	|O
(	508	509	|B-IUPAC
RS	509	511	|I-IUPAC
)	511	512	|I-IUPAC
-	512	513	|I-IUPAC
4	513	514	|I-IUPAC
-	514	515	|I-IUPAC
amino	515	520	|I-IUPAC
-	520	521	|I-IUPAC
3	521	522	|I-IUPAC
-	522	523	|I-IUPAC
hydroxy	523	530	|I-IUPAC
-	530	531	|I-IUPAC
4,5,6,7	531	538	|I-IUPAC
-	538	539	|I-IUPAC
tetrahydro	539	549	|I-IUPAC
-	549	550	|I-IUPAC
1,2	550	553	|I-IUPAC
-	553	554	|I-IUPAC
benzisoxazole	554	567	|I-IUPAC
(	568	569	|O
8	569	570	|O
,	570	571	|O
exo	572	575	|O
-	575	576	|O
THPO	576	580	|O
)	580	581	|O
was	582	585	|O
synthesized	586	597	|O
via	598	601	|O
aluminum	602	610	|O
amalgam	611	618	|O
reduction	619	628	|O
of	629	631	|O
oxime	632	637	|O
22a	638	641	|O
or	642	644	|O
22b	645	648	|O
,	648	649	|O
compounds	650	659	|O
9	660	661	|O
,	661	662	|O
11-13	663	668	|O
,	668	669	|O
and	670	673	|O
15-17	674	679	|O
were	680	684	|O
obtained	685	693	|O
via	694	697	|O
reductive	698	707	|O
aminations	708	718	|O
.	718	719	|O
Compound	720	728	|O
10	729	731	|O
was	732	735	|O
synthesized	736	747	|O
via	748	751	|O
N	752	753	|O
-	753	754	|O
ethylation	754	764	|O
of	765	767	|O
the	768	771	|O
N	772	773	|O
-	773	774	|O
Boc	774	777	|O
-	777	778	|O
protected	778	787	|O
primary	788	795	|O
amine	796	801	|O
25	802	804	|O
.	804	805	|O
The	806	809	|O
enantiomers	810	821	|O
of	822	824	|O
8	825	826	|O
were	827	831	|O
obtained	832	840	|O
in	841	843	|O
high	844	848	|O
enantiomeric	849	861	|O
purities	862	870	|O
(	871	872	|O
ee	872	874	|O
&	875	876	|O
gt	876	878	|O
;	878	879	|O
/	879	880	|O
=	880	881	|O
99.1%	882	887	|O
)	887	888	|O
via	889	892	|O
the	893	896	|O
diastereomeric	897	911	|O
amides	912	918	|O
32	919	921	|O
and	922	925	|O
33	926	928	|O
,	928	929	|O
synthesized	930	941	|O
from	942	946	|O
the	947	950	|O
primary	951	958	|O
amine	959	964	|O
23b	965	968	|O
and	969	972	|O
(	973	974	|B-IUPAC
R	974	975	|I-IUPAC
)	975	976	|I-IUPAC
-	976	977	|I-IUPAC
alpha	977	982	|I-IUPAC
-	982	983	|I-IUPAC
methoxyphenylacetyl	983	1002	|I-IUPAC
chloride	1003	1011	|I-IUPAC
and	1012	1015	|O
subsequent	1016	1026	|O
separation	1027	1037	|O
by	1038	1040	|O
preparative	1041	1052	|O
HPLC	1053	1057	|O
.	1057	1058	|O
The	1059	1062	|O
enantiomers	1063	1074	|O
of	1075	1077	|O
9	1078	1079	|O
were	1080	1084	|O
prepared	1085	1093	|O
analogously	1094	1105	|O
from	1106	1110	|O
the	1111	1114	|O
secondary	1115	1124	|O
amine	1125	1130	|O
27	1131	1133	|O
.	1133	1134	|O
On	1135	1137	|O
the	1138	1141	|O
basis	1142	1147	|O
of	1148	1150	|O
X	1151	1152	|O
-	1152	1153	|O
ray	1153	1156	|O
crystallographic	1157	1173	|O
analyses	1174	1182	|O
,	1182	1183	|O
the	1184	1187	|O
configuration	1188	1201	|O
of	1202	1204	|O
oxime	1205	1210	|O
22a	1211	1214	|O
was	1215	1218	|O
shown	1219	1224	|O
to	1225	1227	|O
be	1228	1230	|O
E	1231	1232	|O
and	1233	1236	|O
the	1237	1240	|O
absolute	1241	1249	|O
configurations	1250	1264	|O
of	1265	1267	|O
(	1268	1269	|O
-	1269	1270	|O
)	1270	1271	|O
-	1271	1272	|O
8	1272	1273	|O
x	1274	1275	|O
HCl	1276	1279	|O
and	1280	1283	|O
(	1284	1285	|O
+	1285	1286	|O
)	1286	1287	|O
-	1287	1288	|O
9	1288	1289	|O
x	1290	1291	|O
HBr	1292	1295	|O
were	1296	1300	|O
established	1301	1312	|O
to	1313	1315	|O
be	1316	1318	|O
R	1319	1320	|O
.	1320	1321	|O
The	1322	1325	|O
effects	1326	1333	|O
of	1334	1336	|O
the	1337	1340	|O
target	1341	1347	|O
compounds	1348	1357	|O
on	1358	1360	|O
GABA	1361	1365	|O
uptake	1366	1372	|O
mechanisms	1373	1383	|O
in	1384	1386	|O
vitro	1387	1392	|O
were	1393	1397	|O
measured	1398	1406	|O
using	1407	1412	|O
a	1413	1414	|O
rat	1415	1418	|O
brain	1419	1424	|O
synaptosomal	1425	1437	|O
preparation	1438	1449	|O
and	1450	1453	|O
primary	1454	1461	|O
cultures	1462	1470	|O
of	1471	1473	|O
mouse	1474	1479	|O
cortical	1480	1488	|O
neurons	1489	1496	|O
and	1497	1500	|O
glia	1501	1505	|O
cells	1506	1511	|O
(	1512	1513	|O
astrocytes	1513	1523	|O
)	1523	1524	|O
.	1524	1525	|O
Whereas	1526	1533	|O
the	1534	1537	|O
classical	1538	1547	|O
GABA	1548	1552	|O
uptake	1553	1559	|O
inhibitor	1560	1569	|O
,	1569	1570	|O
(	1571	1572	|B-IUPAC
R	1572	1573	|I-IUPAC
)	1573	1574	|I-IUPAC
-	1574	1575	|I-IUPAC
nipecotic	1575	1584	|I-IUPAC
acid	1585	1589	|I-IUPAC
(	1590	1591	|O
2	1591	1592	|O
)	1592	1593	|O
,	1593	1594	|O
nonselectively	1595	1609	|O
inhibits	1610	1618	|O
neuronal	1619	1627	|O
(	1628	1629	|O
IC	1629	1631	|O
(	1631	1632	|O
50	1632	1634	|O
)	1634	1635	|O
=	1636	1637	|O
12	1638	1640	|O
microM	1641	1647	|O
)	1647	1648	|O
and	1649	1652	|O
glial	1653	1658	|O
(	1659	1660	|O
IC	1660	1662	|O
(	1662	1663	|O
50	1663	1665	|O
)	1665	1666	|O
=	1667	1668	|O
16	1669	1671	|O
microM	1672	1678	|O
)	1678	1679	|O
GABA	1680	1684	|O
uptake	1685	1691	|O
and	1692	1695	|O
4,5,6,7	1696	1703	|B-IUPAC
-	1703	1704	|I-IUPAC
tetrahydroisoxazolo	1704	1723	|I-IUPAC
	1723	1724	|I-IUPAC
	1724	1725	|I-IUPAC
4,5	1725	1728	|I-IUPAC
-	1728	1729	|I-IUPAC
cpyridin	1729	1737	|I-IUPAC
-	1737	1738	|I-IUPAC
3	1738	1739	|I-IUPAC
-	1739	1740	|I-IUPAC
ol	1740	1742	|I-IUPAC
(	1743	1744	|O
1	1744	1745	|O
,	1745	1746	|O
THPO	1747	1751	|O
)	1751	1752	|O
shows	1753	1758	|O
some	1759	1763	|O
selectivity	1764	1775	|O
for	1776	1779	|O
glial	1780	1785	|O
(	1786	1787	|O
IC	1787	1789	|O
(	1789	1790	|O
50	1790	1792	|O
)	1792	1793	|O
=	1794	1795	|O
268	1796	1799	|O
microM	1800	1806	|O
)	1806	1807	|O
versus	1808	1814	|O
neuronal	1815	1823	|O
(	1824	1825	|O
IC	1825	1827	|O
(	1827	1828	|O
50	1828	1830	|O
)	1830	1831	|O
=	1832	1833	|O
530	1834	1837	|O
microM	1838	1844	|O
)	1844	1845	|O
GABA	1846	1850	|O
uptake	1851	1857	|O
,	1857	1858	|O
exo	1859	1862	|O
-	1862	1863	|O
THPO	1863	1867	|O
(	1868	1869	|O
8	1869	1870	|O
)	1870	1871	|O
was	1872	1875	|O
shown	1876	1881	|O
to	1882	1884	|O
be	1885	1887	|O
more	1888	1892	|O
potent	1893	1899	|O
as	1900	1902	|O
an	1903	1905	|O
inhibitor	1906	1915	|O
of	1916	1918	|O
glial	1919	1924	|O
(	1925	1926	|O
IC	1926	1928	|O
(	1928	1929	|O
50	1929	1931	|O
)	1931	1932	|O
=	1933	1934	|O
200	1935	1938	|O
microM	1939	1945	|O
)	1945	1946	|O
rather	1947	1953	|O
than	1954	1958	|O
neuronal	1959	1967	|O
(	1968	1969	|O
IC	1969	1971	|O
(	1971	1972	|O
50	1972	1974	|O
)	1974	1975	|O
=	1976	1977	|O
900	1978	1981	|O
microM	1982	1988	|O
)	1988	1989	|O
GABA	1990	1994	|O
uptake	1995	2001	|O
.	2001	2002	|O
This	2003	2007	|O
selectivity	2008	2019	|O
was	2020	2023	|O
more	2024	2028	|O
pronounced	2029	2039	|O
for	2040	2043	|O
9	2044	2045	|O
,	2045	2046	|O
which	2047	2052	|O
showed	2053	2059	|O
IC	2060	2062	|O
(	2062	2063	|O
50	2063	2065	|O
)	2065	2066	|O
values	2067	2073	|O
of	2074	2076	|O
40	2077	2079	|O
and	2080	2083	|O
500	2084	2087	|O
microM	2088	2094	|O
as	2095	2097	|O
an	2098	2100	|O
inhibitor	2101	2110	|O
of	2111	2113	|O
glial	2114	2119	|O
and	2120	2123	|O
neuronal	2124	2132	|O
GABA	2133	2137	|O
uptake	2138	2144	|O
,	2144	2145	|O
respectively	2146	2158	|O
.	2158	2159	|O
These	2160	2165	|O
effects	2166	2173	|O
of	2174	2176	|O
8	2177	2178	|O
and	2179	2182	|O
9	2183	2184	|O
proved	2185	2191	|O
to	2192	2194	|O
be	2195	2197	|O
enantioselective	2198	2214	|O
,	2214	2215	|O
(	2216	2217	|O
R	2217	2218	|O
)	2218	2219	|O
-	2219	2220	|O
(	2220	2221	|O
-	2221	2222	|O
)	2222	2223	|O
-	2223	2224	|O
8	2224	2225	|O
and	2226	2229	|O
(	2230	2231	|O
R	2231	2232	|O
)	2232	2233	|O
-	2233	2234	|O
(	2234	2235	|O
+	2235	2236	|O
)	2236	2237	|O
-	2237	2238	|O
9	2238	2239	|O
being	2240	2245	|O
the	2246	2249	|O
active	2250	2256	|O
inhibitors	2257	2267	|O
of	2268	2270	|O
both	2271	2275	|O
uptake	2276	2282	|O
systems	2283	2290	|O
.	2290	2291	|O
The	2292	2295	|O
selectivity	2296	2307	|O
of	2308	2310	|O
9	2311	2312	|O
as	2313	2315	|O
a	2316	2317	|O
glial	2318	2323	|O
GABA	2324	2328	|O
uptake	2329	2335	|O
inhibitor	2336	2345	|O
was	2346	2349	|O
largely	2350	2357	|O
lost	2358	2362	|O
by	2363	2365	|O
replacing	2366	2375	|O
the	2376	2379	|O
N	2380	2381	|B-IUPAC
-	2381	2382	|I-IUPAC
methyl	2382	2388	|I-IUPAC
group	2389	2394	|B-MODIFIER
of	2395	2397	|O
9	2398	2399	|O
by	2400	2402	|O
an	2403	2405	|O
ethyl	2406	2411	|B-IUPAC
group	2412	2417	|B-MODIFIER
,	2417	2418	|O
compound	2419	2427	|O
10	2428	2430	|O
being	2431	2436	|O
an	2437	2439	|O
almost	2440	2446	|O
equipotent	2447	2457	|O
inhibitor	2458	2467	|O
of	2468	2470	|O
glial	2471	2476	|O
(	2477	2478	|O
IC	2478	2480	|O
(	2480	2481	|O
50	2481	2483	|O
)	2483	2484	|O
=	2485	2486	|O
280	2487	2490	|O
microM	2491	2497	|O
)	2497	2498	|O
and	2499	2502	|O
neuronal	2503	2511	|O
(	2512	2513	|O
IC	2513	2515	|O
(	2515	2516	|O
50	2516	2518	|O
)	2518	2519	|O
=	2520	2521	|O
400	2522	2525	|O
microM	2526	2532	|O
)	2532	2533	|O
GABA	2534	2538	|O
uptake	2539	2545	|O
.	2545	2546	|O
The	2547	2550	|O
remaining	2551	2560	|O
target	2561	2567	|O
compounds	2568	2577	|O
,	2577	2578	|O
11-17	2579	2584	|O
,	2584	2585	|O
were	2586	2590	|O
very	2591	2595	|O
weak	2596	2600	|O
or	2601	2603	|O
inactive	2604	2612	|O
as	2613	2615	|O
inhibitors	2616	2626	|O
of	2627	2629	|O
both	2630	2634	|O
uptake	2635	2641	|O
systems	2642	2649	|O
.	2649	2650	|O
Compounds	2651	2660	|O
9-13	2661	2665	|O
and	2666	2669	|O
15	2670	2672	|O
were	2673	2677	|O
shown	2678	2683	|O
to	2684	2686	|O
be	2687	2689	|O
essentially	2690	2701	|O
inactive	2702	2710	|O
against	2711	2718	|O
isoniazide	2719	2729	|O
-	2729	2730	|O
induced	2730	2737	|O
convulsions	2738	2749	|O
in	2750	2752	|O
mice	2753	2757	|O
after	2758	2763	|O
subcutaneous	2764	2776	|O
administration	2777	2791	|O
.	2791	2792	|O
The	2793	2796	|O
isomeric	2797	2805	|B-MODIFIER
pivaloyloxymethyl	2806	2823	|B-IUPAC
derivatives	2824	2835	|B-MODIFIER
of	2836	2838	|O
9	2839	2840	|O
,	2840	2841	|O
compounds	2842	2851	|O
43	2852	2854	|O
and	2855	2858	|O
44	2859	2861	|O
,	2861	2862	|O
were	2863	2867	|O
synthesized	2868	2879	|O
and	2880	2883	|O
tested	2884	2890	|O
as	2891	2893	|O
potential	2894	2903	|O
prodrugs	2904	2912	|O
in	2913	2915	|O
the	2916	2919	|O
isoniazide	2920	2930	|O
animal	2931	2937	|O
model	2938	2943	|O
.	2943	2944	|O
Both	2945	2949	|O
43	2950	2952	|O
(	2953	2954	|O
ED	2954	2956	|O
(	2956	2957	|O
50	2957	2959	|O
)	2959	2960	|O
=	2961	2962	|O
150	2963	2966	|O
micromol	2967	2975	|O
/	2975	2976	|O
kg	2976	2978	|O
)	2978	2979	|O
and	2980	2983	|O
44	2984	2986	|O
(	2987	2988	|O
ED	2988	2990	|O
(	2990	2991	|O
50	2991	2993	|O
)	2993	2994	|O
=	2995	2996	|O
220	2997	3000	|O
micromol	3001	3009	|O
/	3009	3010	|O
kg	3010	3012	|O
)	3012	3013	|O
showed	3014	3020	|O
anticonvulsant	3021	3035	|O
effects	3036	3043	|O
,	3043	3044	|O
and	3045	3048	|O
this	3049	3053	|O
effect	3054	3060	|O
of	3061	3063	|O
43	3064	3066	|O
was	3067	3070	|O
shown	3071	3076	|O
to	3077	3079	|O
reside	3080	3086	|O
in	3087	3089	|O
the	3090	3093	|O
(	3094	3095	|O
R	3095	3096	|O
)	3096	3097	|O
-	3097	3098	|O
(	3098	3099	|O
+	3099	3100	|O
)	3100	3101	|O
-	3101	3102	|O
enantiomer	3102	3112	|O
,	3112	3113	|O
45	3114	3116	|O
(	3117	3118	|O
ED	3118	3120	|O
(	3120	3121	|O
50	3121	3123	|O
)	3123	3124	|O
=	3125	3126	|O
44	3127	3129	|O
micromol	3130	3138	|O
/	3138	3139	|O
kg	3139	3141	|O
)	3141	3142	|O
.	3142	3143	|O
Compound	3144	3152	|O
9	3153	3154	|O
also	3155	3159	|O
showed	3160	3166	|O
anticonvulsant	3167	3181	|O
activity	3182	3190	|O
when	3191	3195	|O
administered	3196	3208	|O
intracerebroventricularly	3209	3234	|O
(	3235	3236	|O
ED	3236	3238	|O
(	3238	3239	|O
50	3239	3241	|O
)	3241	3242	|O
=	3243	3244	|O
59	3245	3247	|O
nmol	3248	3252	|O
)	3252	3253	|O
.	3253	3254	|O

### abstracts905.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
substituted	12	23	|O
racemic	24	31	|O
naphthofurans	32	45	|O
were	46	50	|O
synthesized	51	62	|O
as	63	65	|O
"	66	67	|O
hybrid	67	73	|O
"	73	74	|O
molecules	75	84	|O
of	85	87	|O
the	88	91	|O
two	92	95	|O
major	96	101	|O
prototypical	102	114	|O
hallucinogenic	115	129	|O
drug	130	134	|O
classes	135	142	|O
,	142	143	|O
the	144	147	|O
phenethylamines	148	163	|O
and	164	167	|O
the	168	171	|O
tryptamines	172	183	|O
/	183	184	|O
ergolines	184	193	|O
.	193	194	|O
Although	195	203	|O
it	204	206	|O
was	207	210	|O
hypothesized	211	223	|O
that	224	228	|O
these	229	234	|O
new	235	238	|O
agents	239	245	|O
might	246	251	|O
possess	252	259	|O
high	260	264	|O
affinity	265	273	|O
for	274	277	|O
the	278	281	|O
serotonin	282	291	|O
5	292	293	|O
-	293	294	|O
HT2A	294	298	|O
/	298	299	|O
2C	299	301	|O
receptor	302	310	|O
subtypes	311	319	|O
,	319	320	|O
unexpected	321	331	|O
affinity	332	340	|O
for	341	344	|O
muscarinic	345	355	|O
receptors	356	365	|O
was	366	369	|O
observed	370	378	|O
.	378	379	|O
The	380	383	|O
compounds	384	393	|O
initially	394	403	|O
synthesized	404	415	|O
for	416	419	|O
this	420	424	|O
study	425	430	|O
were	431	435	|O
(	436	437	|B-PARTIUPAC
+	437	438	|I-PARTIUPAC
/	438	439	|I-PARTIUPAC
-	439	440	|I-PARTIUPAC
)	440	441	|I-PARTIUPAC
-	441	442	|I-PARTIUPAC
anti	442	446	|I-PARTIUPAC
-	446	447	|I-PARTIUPAC
and	448	451	|O
syn	452	455	|B-IUPAC
-	455	456	|I-IUPAC
4	456	457	|I-IUPAC
-	457	458	|I-IUPAC
amino	458	463	|I-IUPAC
-	463	464	|I-IUPAC
6	464	465	|I-IUPAC
-	465	466	|I-IUPAC
methoxy	466	473	|I-IUPAC
-	473	474	|I-IUPAC
2a	474	476	|I-IUPAC
,	476	477	|I-IUPAC
3,4,5	477	482	|I-IUPAC
-	482	483	|I-IUPAC
tetrahydro	483	493	|I-IUPAC
-	493	494	|I-IUPAC
2H	494	496	|I-IUPAC
-	496	497	|I-IUPAC
naphtho	497	504	|I-IUPAC
[	504	505	|I-IUPAC
1,8	505	508	|I-IUPAC
-	508	509	|I-IUPAC
bc	509	511	|I-IUPAC
]	511	512	|I-IUPAC
furan	512	517	|I-IUPAC
(	518	519	|O
4a	519	521	|O
,	521	522	|O
b	522	523	|O
)	523	524	|O
,	524	525	|O
respectively	526	538	|O
,	538	539	|O
and	540	543	|O
their	544	549	|O
8	550	551	|O
-	551	552	|O
bromo	552	557	|O
derivatives	558	569	|O
4c	570	572	|O
,	572	573	|O
d	573	574	|O
,	574	575	|O
respectively	576	588	|O
.	588	589	|O
The	590	593	|O
brominated	594	604	|O
primary	605	612	|O
amines	613	619	|O
4c	620	622	|O
,	622	623	|O
d	623	624	|O
were	625	629	|O
assayed	630	637	|O
initially	638	647	|O
for	648	651	|O
activity	652	660	|O
in	661	663	|O
the	664	667	|O
two	668	671	|O
-	671	672	|O
lever	672	677	|O
drug	678	682	|O
discrimination	683	697	|O
(	698	699	|O
DD	699	701	|O
)	701	702	|O
paradigm	703	711	|O
in	712	714	|O
rats	715	719	|O
trained	720	727	|O
to	728	730	|O
discriminate	731	743	|O
saline	744	750	|O
from	751	755	|O
LSD	756	759	|O
tartrate	760	768	|O
(	769	770	|O
0	770	771	|O
.	771	772	|O
08	773	775	|O
mg	776	778	|O
/	778	779	|O
kg	779	781	|O
)	781	782	|O
.	782	783	|O
Also	784	788	|O
,	788	789	|O
4c	790	792	|O
,	792	793	|O
d	793	794	|O
were	795	799	|O
evaluated	800	809	|O
for	810	813	|O
their	814	819	|O
ability	820	827	|O
to	828	830	|O
compete	831	838	|O
against	839	846	|O
agonist	847	854	|O
and	855	858	|O
antagonist	859	869	|O
radioligands	870	882	|O
at	883	885	|O
cloned	886	892	|O
human	893	898	|O
5	899	900	|O
-	900	901	|O
HT2A	901	905	|O
,	905	906	|O
5	907	908	|O
-	908	909	|O
HT2B	909	913	|O
,	913	914	|O
and	915	918	|O
5	919	920	|O
-	920	921	|O
HT2C	921	925	|O
receptors	926	935	|O
.	935	936	|O
After	937	942	|O
the	943	946	|O
syn	947	950	|O
diastereomers	951	964	|O
were	965	969	|O
found	970	975	|O
to	976	978	|O
have	979	983	|O
the	984	987	|O
highest	988	995	|O
activity	996	1004	|O
in	1005	1007	|O
these	1008	1013	|O
preliminary	1014	1025	|O
assays	1026	1032	|O
,	1032	1033	|O
the	1034	1037	|O
N	1038	1039	|O
-	1039	1040	|O
alkylated	1040	1049	|O
analogues	1050	1059	|O
syn	1060	1063	|B-IUPAC
-	1063	1064	|I-IUPAC
N	1064	1065	|I-IUPAC
,	1065	1066	|I-IUPAC
N	1066	1067	|I-IUPAC
-	1067	1068	|I-IUPAC
dimethyl	1068	1076	|I-IUPAC
-	1076	1077	|I-IUPAC
4	1077	1078	|I-IUPAC
-	1078	1079	|I-IUPAC
amino	1079	1084	|I-IUPAC
-	1084	1085	|I-IUPAC
6	1085	1086	|I-IUPAC
-	1086	1087	|I-IUPAC
methoxy	1087	1094	|I-IUPAC
-	1094	1095	|I-IUPAC
2a	1095	1097	|I-IUPAC
,	1097	1098	|I-IUPAC
3,4	1098	1101	|I-IUPAC
,	1101	1102	|I-IUPAC
5	1103	1104	|I-IUPAC
-	1104	1105	|I-IUPAC
tetrahydro	1105	1115	|I-IUPAC
-	1115	1116	|I-IUPAC
2H	1116	1118	|I-IUPAC
-	1118	1119	|I-IUPAC
naphtho	1119	1126	|I-IUPAC
[	1126	1127	|I-IUPAC
1,8	1127	1130	|I-IUPAC
-	1130	1131	|I-IUPAC
bc	1131	1133	|I-IUPAC
]	1133	1134	|I-IUPAC
furan	1134	1139	|I-IUPAC
(	1140	1141	|O
4e	1141	1143	|O
)	1143	1144	|O
and	1145	1148	|O
syn	1149	1152	|B-IUPAC
-	1152	1153	|I-IUPAC
N	1153	1154	|I-IUPAC
,	1154	1155	|I-IUPAC
N	1156	1157	|I-IUPAC
-	1157	1158	|I-IUPAC
dipropyl	1158	1166	|I-IUPAC
-	1166	1167	|I-IUPAC
4	1167	1168	|I-IUPAC
-	1168	1169	|I-IUPAC
amino	1169	1174	|I-IUPAC
-	1174	1175	|I-IUPAC
6	1175	1176	|I-IUPAC
-	1176	1177	|I-IUPAC
methoxy	1177	1184	|I-IUPAC
-	1184	1185	|I-IUPAC
2a	1185	1187	|I-IUPAC
,	1187	1188	|I-IUPAC
3,4,5	1188	1193	|I-IUPAC
-	1193	1194	|I-IUPAC
tetrahydro	1194	1204	|I-IUPAC
-	1204	1205	|I-IUPAC
2H	1205	1207	|I-IUPAC
-	1207	1208	|I-IUPAC
naphtho	1208	1215	|I-IUPAC
[	1215	1216	|I-IUPAC
1	1216	1217	|I-IUPAC
,	1217	1218	|I-IUPAC
8	1219	1220	|I-IUPAC
-	1220	1221	|I-IUPAC
bc	1221	1223	|I-IUPAC
]	1223	1224	|I-IUPAC
furan	1224	1229	|I-IUPAC
(	1230	1231	|O
4f	1231	1233	|O
)	1233	1234	|O
were	1235	1239	|O
prepared	1240	1248	|O
and	1249	1252	|O
assayed	1253	1260	|O
for	1261	1264	|O
their	1265	1270	|O
affinities	1271	1281	|O
at	1282	1284	|O
[	1285	1286	|O
3H	1286	1288	|O
]	1288	1289	|O
ketanserin	1289	1299	|O
-	1299	1300	|O
labeled	1300	1307	|O
5	1308	1309	|O
-	1309	1310	|O
HT2A	1310	1314	|O
and	1315	1318	|O
[	1319	1320	|O
3H	1320	1322	|O
]	1322	1323	|O
-	1323	1324	|O
8	1324	1325	|O
-	1325	1326	|O
OH	1326	1328	|O
-	1328	1329	|O
DPAT	1329	1333	|O
-	1333	1334	|O
labeled	1334	1341	|O
5	1342	1343	|O
-	1343	1344	|O
HT1A	1344	1348	|O
sites	1349	1354	|O
.	1354	1355	|O
All	1356	1359	|O
of	1360	1362	|O
the	1363	1366	|O
molecules	1367	1376	|O
tested	1377	1383	|O
had	1384	1387	|O
relatively	1388	1398	|O
low	1399	1402	|O
affinity	1403	1411	|O
for	1412	1415	|O
serotonin	1416	1425	|O
receptors	1426	1435	|O
,	1435	1436	|O
yet	1437	1440	|O
a	1441	1442	|O
preliminary	1443	1454	|O
screen	1455	1461	|O
indicated	1462	1471	|O
that	1472	1476	|O
compound	1477	1485	|O
4d	1486	1488	|O
had	1489	1492	|O
affinity	1493	1501	|O
for	1502	1505	|O
muscarinic	1506	1516	|O
receptors	1517	1526	|O
.	1526	1527	|O
Thus	1528	1532	|O
,	1532	1533	|O
4b	1534	1536	|O
,	1536	1537	|O
d	1537	1538	|O
,	1538	1539	|O
e	1539	1540	|O
were	1541	1545	|O
evaluated	1546	1555	|O
for	1556	1559	|O
their	1560	1565	|O
affinity	1566	1574	|O
at	1575	1577	|O
muscarinic	1578	1588	|O
M1	1589	1591	|O
-	1591	1592	|O
M5	1592	1594	|O
receptors	1595	1604	|O
and	1605	1608	|O
also	1609	1613	|O
assessed	1614	1622	|O
for	1623	1626	|O
their	1627	1632	|O
functional	1633	1643	|O
characteristics	1644	1659	|O
at	1660	1662	|O
the	1663	1666	|O
M1	1667	1669	|O
and	1670	1673	|O
M2	1674	1676	|O
isoforms	1677	1685	|O
.	1685	1686	|O
Compound	1687	1695	|O
4d	1696	1698	|O
had	1699	1702	|O
affinities	1703	1713	|O
of	1714	1716	|O
12-33	1717	1722	|O
nM	1723	1725	|O
at	1726	1728	|O
all	1729	1732	|O
of	1733	1735	|O
the	1736	1739	|O
muscarinic	1740	1750	|O
sites	1751	1756	|O
,	1756	1757	|O
with	1758	1762	|O
4b	1763	1765	|O
,	1765	1766	|O
e	1766	1767	|O
having	1768	1774	|O
much	1775	1779	|O
lower	1780	1785	|O
affinity	1786	1794	|O
.	1794	1795	|O
All	1796	1799	|O
three	1800	1805	|O
compounds	1806	1815	|O
fully	1816	1821	|O
antagonized	1822	1833	|O
the	1834	1837	|O
effects	1838	1845	|O
of	1846	1848	|O
carbachol	1849	1858	|O
at	1859	1861	|O
the	1862	1865	|O
M1	1866	1868	|O
receptor	1869	1877	|O
,	1877	1878	|O
while	1879	1884	|O
only	1885	1889	|O
4d	1890	1892	|O
completely	1893	1903	|O
antagonized	1904	1915	|O
carbachol	1916	1925	|O
at	1926	1928	|O
the	1929	1932	|O
M2	1933	1935	|O
receptor	1936	1944	|O
.	1944	1945	|O
The	1946	1949	|O
fact	1950	1954	|O
that	1955	1959	|O
the	1960	1963	|O
naphthofurans	1964	1977	|O
lack	1978	1982	|O
LSD	1983	1986	|O
-	1986	1987	|O
like	1987	1991	|O
activity	1992	2000	|O
suggests	2001	2009	|O
that	2010	2014	|O
they	2015	2019	|O
do	2020	2022	|O
not	2023	2026	|O
bind	2027	2031	|O
to	2032	2034	|O
the	2035	2038	|O
serotonin	2039	2048	|O
receptor	2049	2057	|O
in	2058	2060	|O
a	2061	2062	|O
way	2063	2066	|O
such	2067	2071	|O
that	2072	2076	|O
the	2077	2080	|O
tricyclic	2081	2090	|O
naphthofuran	2091	2103	|O
nucleus	2104	2111	|O
is	2112	2114	|O
bioisosteric	2115	2127	|O
with	2128	2132	|O
,	2132	2133	|O
and	2134	2137	|O
directly	2138	2146	|O
superimposable	2147	2161	|O
upon	2162	2166	|O
,	2166	2167	|O
the	2168	2171	|O
A	2172	2173	|O
,	2173	2174	|O
B	2175	2176	|O
,	2176	2177	|O
and	2178	2181	|O
C	2182	2183	|O
rings	2184	2189	|O
of	2190	2192	|O
LSD	2193	2196	|O
.	2196	2197	|O
This	2198	2202	|O
also	2203	2207	|O
implies	2208	2215	|O
,	2215	2216	|O
therefore	2217	2226	|O
,	2226	2227	|O
that	2228	2232	|O
the	2233	2236	|O
hallucinogenic	2237	2251	|O
phenethylamines	2252	2267	|O
cannot	2268	2274	|O
be	2275	2277	|O
directly	2278	2286	|O
superimposed	2287	2299	|O
on	2300	2302	|O
LSD	2303	2306	|O
in	2307	2309	|O
a	2310	2311	|O
common	2312	2318	|O
binding	2319	2326	|O
orientation	2327	2338	|O
for	2339	2342	|O
these	2343	2348	|O
two	2349	2352	|O
chemical	2353	2361	|O
classes	2362	2369	|O
,	2369	2370	|O
contrary	2371	2379	|O
to	2380	2382	|O
previous	2383	2391	|O
hypotheses	2392	2402	|O
.	2402	2403	|O

### abstracts329.txt
A	0	1	|O
Langendorff	2	13	|O
guinea	14	20	|O
pig	21	24	|O
heart	25	30	|O
preparation	31	42	|O
served	43	49	|O
for	50	53	|O
the	54	57	|O
assay	58	63	|O
of	64	66	|O
agonist	67	74	|O
potency	75	82	|O
of	83	85	|O
a	86	87	|O
series	88	94	|O
of	95	97	|O
26	98	100	|O
2	101	102	|B-IUPAC
-	102	103	|I-IUPAC
aralkoxyadenosines	103	121	|I-IUPAC
at	122	124	|O
the	125	128	|O
A1	129	131	|O
and	132	135	|O
A2	136	138	|O
receptors	139	148	|O
of	149	151	|O
,	151	152	|O
respectively	153	165	|O
,	165	166	|O
the	167	170	|O
atrioventricular	171	187	|O
node	188	192	|O
(	193	194	|O
conduction	194	204	|O
block	205	210	|O
)	210	211	|O
and	212	215	|O
coronary	216	224	|O
arteries	225	233	|O
(	234	235	|O
vasodilation	235	247	|O
)	247	248	|O
.	248	249	|O
All	250	253	|O
of	254	256	|O
the	257	260	|O
analogues	261	270	|O
are	271	274	|O
weak	275	279	|O
agonists	280	288	|O
at	289	291	|O
the	292	295	|O
A1	296	298	|O
receptor	299	307	|O
,	307	308	|O
requiring	309	318	|O
concentrations	319	333	|O
greater	334	341	|O
than	342	346	|O
9	347	348	|O
microM	349	355	|O
to	356	358	|O
cause	359	364	|O
second	365	371	|O
degree	372	378	|O
heart	379	384	|O
block	385	390	|O
.	390	391	|O
At	392	394	|O
the	395	398	|O
A2	399	401	|O
receptor	402	410	|O
2	411	412	|B-IUPAC
-	412	413	|I-IUPAC
phenethoxyadenosine	413	432	|I-IUPAC
is	433	435	|O
the	436	439	|O
most	440	444	|O
potent	445	451	|O
of	452	454	|O
the	455	458	|O
2	459	460	|B-IUPAC
-	460	461	|I-IUPAC
phenylalkyladenosines	461	482	|I-IUPAC
.	482	483	|O
The	484	487	|O
activity	488	496	|O
of	497	499	|O
ring	500	504	|O
-	504	505	|O
substituted	505	516	|O
(	517	518	|O
F	518	519	|O
,	519	520	|O
Cl	521	523	|O
,	523	524	|O
CH3	525	528	|O
,	528	529	|O
and	530	533	|O
OCH3	534	538	|O
)	538	539	|O
2	540	541	|B-IUPAC
-	541	542	|I-IUPAC
phenethoxyadenosines	542	562	|I-IUPAC
increases	563	572	|O
ortho	573	578	|O
less	579	583	|O
than	584	588	|O
meta	589	593	|O
less	594	598	|O
than	599	603	|O
para	604	608	|O
.	608	609	|O
The	610	613	|O
EC50s	614	619	|O
of	620	622	|O
coronary	623	631	|O
vasoactivity	632	644	|O
of	645	647	|O
several	648	655	|O
para	656	660	|O
-	660	661	|O
substituted	661	672	|O
analogues	673	682	|O
are	683	686	|O
in	687	689	|O
the	690	693	|O
subnanomolar	694	706	|O
range	707	712	|O
.	712	713	|O
The	714	717	|O
most	718	722	|O
potent	723	729	|O
analogue	730	738	|O
,	738	739	|O
2	740	741	|B-IUPAC
-	741	742	|I-IUPAC
[	742	743	|I-IUPAC
2	743	744	|I-IUPAC
-	744	745	|I-IUPAC
(	745	746	|I-IUPAC
4	746	747	|I-IUPAC
-	747	748	|I-IUPAC
methylphenyl	748	760	|I-IUPAC
)	760	761	|I-IUPAC
ethoxy	761	767	|I-IUPAC
]	767	768	|I-IUPAC
adenosine	768	777	|I-IUPAC
19	778	780	|O
,	780	781	|O
has	782	785	|O
an	786	788	|O
EC50	789	793	|O
for	794	797	|O
coronary	798	806	|O
vasodilation	807	819	|O
of	820	822	|O
190	823	826	|O
pM	827	829	|O
and	830	833	|O
an	834	836	|O
A1	837	839	|O
/	839	840	|O
A2	840	842	|O
selectivity	843	854	|O
ratio	855	860	|O
of	861	863	|O
44,000	864	870	|O
.	870	871	|O
Aryl	872	876	|O
groups	877	883	|O
such	884	888	|O
as	889	891	|O
thienyl	892	899	|O
,	899	900	|O
indoloyl	901	909	|O
,	909	910	|O
or	911	913	|O
naphthyl	914	922	|O
also	923	927	|O
support	928	935	|O
A2	936	938	|O
agonist	939	946	|O
activity	947	955	|O
.	955	956	|O
Although	957	965	|O
2	966	967	|B-IUPAC
-	967	968	|I-IUPAC
oxoadenosine	968	980	|I-IUPAC
is	981	983	|O
3	984	985	|O
times	986	991	|O
more	992	996	|O
vasoactive	997	1007	|O
than	1008	1012	|O
2	1013	1014	|B-IUPAC
-	1014	1015	|I-IUPAC
aminoadenosine	1015	1029	|I-IUPAC
,	1029	1030	|O
the	1031	1034	|O
activities	1035	1045	|O
of	1046	1048	|O
the	1049	1052	|O
phenyl	1053	1059	|B-IUPAC
derivatives	1060	1071	|B-MODIFIER
are	1072	1075	|O
markedly	1076	1084	|O
different	1085	1094	|O
;	1094	1095	|O
2	1096	1097	|B-IUPAC
-	1097	1098	|I-IUPAC
phenoxyadenosine	1098	1114	|I-IUPAC
is	1115	1117	|O
23	1118	1120	|O
times	1121	1126	|O
weaker	1127	1133	|O
than	1134	1138	|O
2	1139	1140	|B-IUPAC
-	1140	1141	|I-IUPAC
(	1141	1142	|I-IUPAC
phenylamino	1142	1153	|I-IUPAC
)	1153	1154	|I-IUPAC
adenosine	1154	1163	|I-IUPAC
(	1164	1165	|O
CV	1165	1167	|O
-	1167	1168	|O
1808	1168	1172	|O
)	1172	1173	|O
.	1173	1174	|O

### abstracts1305.txt
In	0	2	|O
an	3	5	|O
attempt	6	13	|O
to	14	16	|O
increase	17	25	|O
the	26	29	|O
combined	30	38	|O
toxicity	39	47	|O
of	48	50	|O
the	51	54	|O
metabolic	55	64	|O
end	65	68	|O
-	68	69	|O
products	69	77	|O
[	78	79	|O
acrolein	79	87	|O
(	88	89	|O
4	89	90	|O
)	90	91	|O
and	92	95	|O
phosphoramide	96	109	|O
mustard	110	117	|O
(	118	119	|O
3	119	120	|O
)	120	121	|O
]	121	122	|O
from	123	127	|O
cyclophosphamide	128	144	|O
(	145	146	|O
1	146	147	|O
)	147	148	|O
,	148	149	|O
the	150	153	|O
analog	154	160	|B-MODIFIER
2	161	162	|B-IUPAC
-	162	163	|I-IUPAC
[	163	164	|I-IUPAC
bis	164	167	|I-IUPAC
(	167	168	|I-IUPAC
2	168	169	|I-IUPAC
-	169	170	|I-IUPAC
chloroethyl	170	181	|I-IUPAC
)	181	182	|I-IUPAC
amino	182	187	|I-IUPAC
]	187	188	|I-IUPAC
tetrahydro	188	198	|I-IUPAC
-	198	199	|I-IUPAC
6	199	200	|I-IUPAC
-	200	201	|I-IUPAC
trifluoromethyl	201	216	|I-IUPAC
-	216	217	|I-IUPAC
2H	217	219	|I-IUPAC
-	219	220	|I-IUPAC
1,3,2	220	225	|I-IUPAC
-	225	226	|I-IUPAC
oxazaphosphorine	226	242	|I-IUPAC
2	243	244	|I-IUPAC
-	244	245	|I-IUPAC
oxide	245	250	|I-IUPAC
(	251	252	|O
2	252	253	|O
,	253	254	|O
6	255	256	|B-IUPAC
-	256	257	|I-IUPAC
trifluoromethylcyclophosphamide	257	288	|I-IUPAC
)	288	289	|O
was	290	293	|O
synthesized	294	305	|O
and	306	309	|O
its	310	313	|O
metabolism	314	324	|O
and	325	328	|O
antitumor	329	338	|O
activity	339	347	|O
studied	348	355	|O
.	355	356	|O
Following	357	366	|O
metabolism	367	377	|O
of	378	380	|O
2	381	382	|O
by	383	385	|O
rat	386	389	|O
liver	390	395	|O
microsomes	396	406	|O
the	407	410	|O
predicted	411	420	|O
formation	421	430	|O
of	431	433	|O
4,4,4	434	439	|B-IUPAC
-	439	440	|I-IUPAC
trifluorocrotonaldehyde	440	463	|I-IUPAC
(	464	465	|O
5	465	466	|O
)	466	467	|O
was	468	471	|O
confirmed	472	481	|O
by	482	484	|O
isolation	485	494	|O
and	495	498	|O
identification	499	513	|O
,	513	514	|O
by	515	517	|O
mass	518	522	|O
spectrometry	523	535	|O
,	535	536	|O
of	537	539	|O
its	540	543	|O
dinitrophenylhydrazone	544	566	|O
.	566	567	|O
The	568	571	|O
therapeutic	572	583	|O
indices	584	591	|O
(	592	593	|O
LD50	593	597	|O
-	597	598	|O
/	598	599	|O
ID90	599	603	|O
)	603	604	|O
for	605	608	|O
2	609	610	|O
against	611	618	|O
the	619	622	|O
ADJ	623	626	|O
/	626	627	|O
PC6	627	630	|O
mouse	631	636	|O
tumor	637	642	|O
and	643	646	|O
the	647	650	|O
Walker	651	657	|O
256	658	661	|O
tumor	662	667	|O
in	668	670	|O
the	671	674	|O
rat	675	678	|O
were	679	683	|O
28.6	684	688	|O
and	689	692	|O
7.7	693	696	|O
,	696	697	|O
respectively	698	710	|O
,	710	711	|O
and	712	715	|O
were	716	720	|O
lower	721	726	|O
than	727	731	|O
the	732	735	|O
corresponding	736	749	|O
values	750	756	|O
for	757	760	|O
1	761	762	|O
(	763	764	|O
91.8	764	768	|O
and	769	772	|O
33.2	773	777	|O
,	777	778	|O
respectively	779	791	|O
)	791	792	|O
although	793	801	|O
the	802	805	|O
toxicities	806	816	|O
toward	817	823	|O
Walker	824	830	|O
cells	831	836	|O
in	837	839	|O
a	840	841	|O
bioassay	842	850	|O
system	851	857	|O
of	858	860	|O
1	861	862	|O
and	863	866	|O
2	867	868	|O
following	869	878	|O
microsomal	879	889	|O
metabolism	890	900	|O
were	901	905	|O
similar	906	913	|O
.	913	914	|O
In	915	917	|O
order	918	923	|O
to	924	926	|O
study	927	932	|O
the	933	936	|O
toxicities	937	947	|O
of	948	950	|O
4	951	952	|O
and	953	956	|O
5	957	958	|O
released	959	967	|O
under	968	973	|O
drug	974	978	|O
metabolizing	979	991	|O
conditions	992	1002	|O
independently	1003	1016	|O
of	1017	1019	|O
the	1020	1023	|O
production	1024	1034	|O
of	1035	1037	|O
a	1038	1039	|O
toxic	1040	1045	|O
mustard	1046	1053	|O
the	1054	1057	|O
analogs	1058	1065	|B-MODIFIER
18	1066	1068	|O
[	1069	1070	|O
2	1070	1071	|B-IUPAC
-	1071	1072	|I-IUPAC
(	1072	1073	|I-IUPAC
diethylamino	1073	1085	|I-IUPAC
)	1085	1086	|I-IUPAC
tetrahydro	1086	1096	|I-IUPAC
-	1096	1097	|I-IUPAC
2H	1097	1099	|I-IUPAC
-	1099	1100	|I-IUPAC
1,3,2	1100	1105	|I-IUPAC
-	1105	1106	|I-IUPAC
oxazaphosphorine	1106	1122	|I-IUPAC
2	1123	1124	|I-IUPAC
-	1124	1125	|I-IUPAC
oxide	1125	1130	|I-IUPAC
]	1130	1131	|O
and	1132	1135	|O
6	1136	1137	|O
[	1138	1139	|O
2	1139	1140	|B-IUPAC
-	1140	1141	|I-IUPAC
(	1141	1142	|I-IUPAC
diethylamino	1142	1154	|I-IUPAC
)	1154	1155	|I-IUPAC
tetrahydro	1155	1165	|I-IUPAC
-	1165	1166	|I-IUPAC
6	1166	1167	|I-IUPAC
-	1167	1168	|I-IUPAC
trifluoromethyl	1168	1183	|I-IUPAC
-	1183	1184	|I-IUPAC
2H	1184	1186	|I-IUPAC
-	1186	1187	|I-IUPAC
1,3,2	1187	1192	|I-IUPAC
-	1192	1193	|I-IUPAC
oxazaphosphorine	1193	1209	|I-IUPAC
2	1210	1211	|I-IUPAC
-	1211	1212	|I-IUPAC
oxide	1212	1217	|I-IUPAC
]	1217	1218	|O
were	1219	1223	|O
also	1224	1228	|O
synthesized	1229	1240	|O
.	1240	1241	|O
The	1242	1245	|O
release	1246	1253	|O
of	1254	1256	|O
5	1257	1258	|O
from	1259	1263	|O
6	1264	1265	|O
following	1266	1275	|O
metabolism	1276	1286	|O
was	1287	1290	|O
confirmed	1291	1300	|O
and	1301	1304	|O
shown	1305	1310	|O
by	1311	1313	|O
use	1314	1317	|O
of	1318	1320	|O
the	1321	1324	|O
bioassay	1325	1333	|O
system	1334	1340	|O
to	1341	1343	|O
be	1344	1346	|O
an	1347	1349	|O
event	1350	1355	|O
of	1356	1358	|O
similar	1359	1366	|O
toxicity	1367	1375	|O
to	1376	1378	|O
release	1379	1386	|O
of	1387	1389	|O
4	1390	1391	|O
from	1392	1396	|O
18	1397	1399	|O
;	1399	1400	|O
in	1401	1403	|O
vivo	1404	1408	|O
,	1408	1409	|O
however	1410	1417	|O
,	1417	1418	|O
6	1419	1420	|O
(	1421	1422	|O
LD50	1422	1426	|O
330	1427	1430	|O
mg	1431	1433	|O
/	1433	1434	|O
kg	1434	1436	|O
)	1436	1437	|O
was	1438	1441	|O
more	1442	1446	|O
toxic	1447	1452	|O
to	1453	1455	|O
mice	1456	1460	|O
than	1461	1465	|O
18	1466	1468	|O
(	1469	1470	|O
LD50	1470	1474	|O
greater	1475	1482	|O
than	1483	1487	|O
500	1488	1491	|O
mg	1492	1494	|O
/	1494	1495	|O
kg	1495	1497	|O
)	1497	1498	|O
.	1498	1499	|O

### abstracts4571.txt
There	0	5	|O
is	6	8	|O
reported	9	17	|O
the	18	21	|O
first	22	27	|O
four	28	32	|O
members	33	40	|O
of	41	43	|O
heteroarotinoids	44	60	|O
,	60	61	|O
the	62	65	|O
names	66	71	|O
of	72	74	|O
which	75	80	|O
are	81	84	|O
ethyl	85	90	|B-IUPAC
(	91	92	|I-IUPAC
E	92	93	|I-IUPAC
)	93	94	|I-IUPAC
-	94	95	|I-IUPAC
p	95	96	|I-IUPAC
-	96	97	|I-IUPAC
[	97	98	|I-IUPAC
2	98	99	|I-IUPAC
-	99	100	|I-IUPAC
(	100	101	|I-IUPAC
4,4	101	104	|I-IUPAC
-	104	105	|I-IUPAC
dimethylthiochroman	105	124	|I-IUPAC
-	124	125	|I-IUPAC
6	125	126	|I-IUPAC
-	126	127	|I-IUPAC
yl	127	129	|I-IUPAC
)	129	130	|I-IUPAC
propenyl	130	138	|I-IUPAC
]	138	139	|I-IUPAC
benzoate	139	147	|I-IUPAC
(	148	149	|O
1b	149	151	|O
)	151	152	|O
,	152	153	|O
ethyl	154	159	|B-IUPAC
(	160	161	|I-IUPAC
E	161	162	|I-IUPAC
)	162	163	|I-IUPAC
-	163	164	|I-IUPAC
p	164	165	|I-IUPAC
-	165	166	|I-IUPAC
[	166	167	|I-IUPAC
2	167	168	|I-IUPAC
-	168	169	|I-IUPAC
(	169	170	|I-IUPAC
4,4	170	173	|I-IUPAC
-	173	174	|I-IUPAC
dimethylchroman	174	189	|I-IUPAC
-	189	190	|I-IUPAC
6	190	191	|I-IUPAC
-	191	192	|I-IUPAC
yl	192	194	|I-IUPAC
)	194	195	|I-IUPAC
propenyl	195	203	|I-IUPAC
]	203	204	|I-IUPAC
benzoate	204	212	|I-IUPAC
(	213	214	|O
1c	214	216	|O
)	216	217	|O
,	217	218	|O
ethyl	219	224	|B-IUPAC
(	225	226	|I-IUPAC
E	226	227	|I-IUPAC
)	227	228	|I-IUPAC
-	228	229	|I-IUPAC
p	229	230	|I-IUPAC
-	230	231	|I-IUPAC
[	231	232	|I-IUPAC
2	232	233	|I-IUPAC
-	233	234	|I-IUPAC
(	234	235	|I-IUPAC
4,4	235	238	|I-IUPAC
-	238	239	|I-IUPAC
dimethyl	239	247	|I-IUPAC
-	247	248	|I-IUPAC
1	248	249	|I-IUPAC
-	249	250	|I-IUPAC
oxothiochroman	250	264	|I-IUPAC
-	264	265	|I-IUPAC
6	265	266	|I-IUPAC
-	266	267	|I-IUPAC
yl	267	269	|I-IUPAC
)	269	270	|I-IUPAC
propenyl	270	278	|I-IUPAC
]	278	279	|I-IUPAC
benzoate	279	287	|I-IUPAC
(	288	289	|O
1d	289	291	|O
)	291	292	|O
,	292	293	|O
and	294	297	|O
(	298	299	|B-IUPAC
E	299	300	|I-IUPAC
)	300	301	|I-IUPAC
-	301	302	|I-IUPAC
p	302	303	|I-IUPAC
-	303	304	|I-IUPAC
[	304	305	|I-IUPAC
2	305	306	|I-IUPAC
-	306	307	|I-IUPAC
(	307	308	|I-IUPAC
4,4	308	311	|I-IUPAC
-	311	312	|I-IUPAC
dimethylchroman	312	327	|I-IUPAC
-	327	328	|I-IUPAC
6	328	329	|I-IUPAC
-	329	330	|I-IUPAC
yl	330	332	|I-IUPAC
)	332	333	|I-IUPAC
propenyl	333	341	|I-IUPAC
]	341	342	|I-IUPAC
benzoic	342	349	|I-IUPAC
acid	350	354	|I-IUPAC
(	355	356	|O
1e	356	358	|O
)	358	359	|O
.	359	360	|O
IR	361	363	|O
,	363	364	|O
1H	365	367	|O
NMR	368	371	|O
and	372	375	|O
13C	376	379	|O
NMR	380	383	|O
data	384	388	|O
have	389	393	|O
been	394	398	|O
recorded	399	407	|O
for	408	411	|O
each	412	416	|O
compound	417	425	|O
and	426	429	|O
support	430	437	|O
the	438	441	|O
structural	442	452	|O
assignments	453	464	|O
.	464	465	|O
To	466	468	|O
provide	469	476	|O
a	477	478	|O
firm	479	483	|O
basis	484	489	|O
for	490	493	|O
comparison	494	504	|O
purposes	505	513	|O
of	514	516	|O
future	517	523	|O
analogues	524	533	|O
,	533	534	|O
an	535	537	|O
X	538	539	|O
-	539	540	|O
ray	540	543	|O
analysis	544	552	|O
was	553	556	|O
performed	557	566	|O
on	567	569	|O
a	570	571	|O
single	572	578	|O
crystal	579	586	|O
of	587	589	|O
ethyl	590	595	|B-IUPAC
(	596	597	|I-IUPAC
E	597	598	|I-IUPAC
)	598	599	|I-IUPAC
-	599	600	|I-IUPAC
p	600	601	|I-IUPAC
-	601	602	|I-IUPAC
[	602	603	|I-IUPAC
2	603	604	|I-IUPAC
-	604	605	|I-IUPAC
(	605	606	|I-IUPAC
4,4	606	609	|I-IUPAC
-	609	610	|I-IUPAC
dimethylthiochroman	610	629	|I-IUPAC
-	629	630	|I-IUPAC
6	630	631	|I-IUPAC
-	631	632	|I-IUPAC
yl	632	634	|I-IUPAC
)	634	635	|I-IUPAC
propenyl	635	643	|I-IUPAC
]	643	644	|I-IUPAC
benzoate	644	652	|I-IUPAC
(	653	654	|O
1b	654	656	|O
)	656	657	|O
and	658	661	|O
a	662	663	|O
precursor	664	673	|O
4,4	674	677	|B-IUPAC
-	677	678	|I-IUPAC
dimethylthiochroman	678	697	|I-IUPAC
-	697	698	|I-IUPAC
6	698	699	|I-IUPAC
-	699	700	|I-IUPAC
yl	700	702	|I-IUPAC
methyl	703	709	|I-IUPAC
ketone	710	716	|I-IUPAC
1,1	717	720	|I-IUPAC
-	720	721	|I-IUPAC
dioxide	721	728	|I-IUPAC
(	729	730	|O
18	730	732	|O
)	732	733	|O
.	733	734	|O
These	735	740	|O
data	741	745	|O
for	746	749	|O
the	750	753	|O
heteroarotinoid	754	769	|O
1b	770	772	|O
revealed	773	781	|O
that	782	786	|O
the	787	790	|O
two	791	794	|O
aryl	795	799	|O
ring	800	804	|O
systems	805	812	|O
were	813	817	|O
nearly	818	824	|O
perpendicular	825	838	|O
in	839	841	|O
each	842	846	|O
of	847	849	|O
the	850	853	|O
two	854	857	|O
molecules	858	867	|O
present	868	875	|O
in	876	878	|O
the	879	882	|O
unit	883	887	|O
cell	888	892	|O
(	893	894	|O
86.37	894	899	|O
degrees	900	907	|O
and	908	911	|O
84.17	912	917	|O
degrees	918	925	|O
,	925	926	|O
respectively	927	939	|O
)	939	940	|O
.	940	941	|O
The	942	945	|O
space	946	951	|O
group	952	957	|O
for	958	961	|O
both	962	966	|O
molecules	967	976	|O
was	977	980	|O
P1	981	983	|O
in	984	986	|O
triclinic	987	996	|O
systems	997	1004	|O
.	1004	1005	|O
Unit	1006	1010	|O
cell	1011	1015	|O
dimensions	1016	1026	|O
(	1027	1028	|O
at	1028	1030	|O
15	1031	1033	|O
degrees	1034	1041	|O
C	1042	1043	|O
)	1043	1044	|O
are	1045	1048	|O
as	1049	1051	|O
follows	1052	1059	|O
:	1059	1060	|O
for	1061	1064	|O
1b	1065	1067	|O
,	1067	1068	|O
a	1069	1070	|O
=	1071	1072	|O
20.568	1073	1079	|O
(	1080	1081	|O
6	1081	1082	|O
)	1082	1083	|O
A	1084	1085	|O
,	1085	1086	|O
b	1087	1088	|O
=	1089	1090	|O
14.760	1091	1097	|O
(	1098	1099	|O
3	1099	1100	|O
)	1100	1101	|O
A	1102	1103	|O
,	1103	1104	|O
c	1105	1106	|O
=	1107	1108	|O
7.679	1109	1114	|O
(	1115	1116	|O
2	1116	1117	|O
)	1117	1118	|O
A	1119	1120	|O
,	1120	1121	|O
alpha	1122	1127	|O
=	1128	1129	|O
113.33	1130	1136	|O
(	1137	1138	|O
2	1138	1139	|O
)	1139	1140	|O
degrees	1141	1148	|O
,	1148	1149	|O
beta	1150	1154	|O
=	1155	1156	|O
79.45	1157	1162	|O
(	1163	1164	|O
2	1164	1165	|O
)	1165	1166	|O
degrees	1167	1174	|O
,	1174	1175	|O
gamma	1176	1181	|O
=	1182	1183	|O
79.98	1184	1189	|O
(	1190	1191	|O
2	1191	1192	|O
)	1192	1193	|O
degrees	1194	1201	|O
,	1201	1202	|O
Z	1203	1204	|O
=	1205	1206	|O
4	1207	1208	|O
;	1208	1209	|O
for	1210	1213	|O
18	1214	1216	|O
,	1216	1217	|O
a	1218	1219	|O
=	1220	1221	|O
9.292	1222	1227	|O
(	1228	1229	|O
5	1229	1230	|O
)	1230	1231	|O
A	1232	1233	|O
,	1233	1234	|O
b	1235	1236	|O
=	1237	1238	|O
9.291	1239	1244	|O
(	1245	1246	|O
5	1246	1247	|O
)	1247	1248	|O
A	1249	1250	|O
,	1250	1251	|O
c	1252	1253	|O
=	1254	1255	|O
7.951	1256	1261	|O
(	1262	1263	|O
3	1263	1264	|O
)	1264	1265	|O
A	1266	1267	|O
,	1267	1268	|O
alpha	1269	1274	|O
=	1275	1276	|O
102.16	1277	1283	|O
(	1284	1285	|O
3	1285	1286	|O
)	1286	1287	|O
degrees	1288	1295	|O
,	1295	1296	|O
beta	1297	1301	|O
=	1302	1303	|O
77.49	1304	1309	|O
(	1310	1311	|O
3	1311	1312	|O
)	1312	1313	|O
degrees	1314	1321	|O
,	1321	1322	|O
gamma	1323	1328	|O
=	1329	1330	|O
79.60	1331	1336	|O
(	1337	1338	|O
4	1338	1339	|O
)	1339	1340	|O
degrees	1341	1348	|O
,	1348	1349	|O
Z	1350	1351	|O
=	1352	1353	|O
2	1354	1355	|O
.	1355	1356	|O
The	1357	1360	|O
sulfur	1361	1367	|O
-	1367	1368	|O
containing	1368	1378	|O
ring	1379	1383	|O
is	1384	1386	|O
in	1387	1389	|O
a	1390	1391	|O
distorted	1392	1401	|O
half	1402	1406	|O
-	1406	1407	|O
chair	1407	1412	|O
in	1413	1415	|O
1b	1416	1418	|O
and	1419	1422	|O
the	1423	1426	|O
methyl	1427	1433	|O
carbon	1434	1440	|O
C	1441	1442	|O
(	1442	1443	|O
12	1443	1445	|O
)	1445	1446	|O
is	1447	1449	|O
shown	1450	1455	|O
to	1456	1458	|O
be	1459	1461	|O
trans	1462	1467	|O
to	1468	1470	|O
H	1471	1472	|O
(	1472	1473	|O
13	1473	1475	|O
)	1475	1476	|O
at	1477	1479	|O
the	1480	1483	|O
C	1484	1485	|O
(	1485	1486	|O
11	1486	1488	|O
)	1488	1489	|O
-	1489	1490	|O
C	1490	1491	|O
(	1491	1492	|O
13	1492	1494	|O
)	1494	1495	|O
bond	1496	1500	|O
.	1500	1501	|O
The	1502	1505	|O
biological	1506	1516	|O
activity	1517	1525	|O
of	1526	1528	|O
these	1529	1534	|O
arotinoids	1535	1545	|O
was	1546	1549	|O
determined	1550	1560	|O
in	1561	1563	|O
the	1564	1567	|O
tracheal	1568	1576	|O
organ	1577	1582	|O
culture	1583	1590	|O
assay	1591	1596	|O
and	1597	1600	|O
compared	1601	1609	|O
with	1610	1614	|O
trans	1615	1620	|O
-	1620	1621	|O
retinoic	1621	1629	|O
acid	1630	1634	|O
for	1635	1638	|O
ability	1639	1646	|O
to	1647	1649	|O
reverse	1650	1657	|O
keratinization	1658	1672	|O
in	1673	1675	|O
vitamin	1676	1683	|O
A	1684	1685	|O
deficient	1686	1695	|O
hamsters	1696	1704	|O
.	1704	1705	|O
The	1706	1709	|O
ester	1710	1715	|O
1b	1716	1718	|O
displayed	1719	1728	|O
activity	1729	1737	|O
about	1738	1743	|O
one	1744	1747	|O
-	1747	1748	|O
half	1748	1752	|O
log	1753	1756	|O
unit	1757	1761	|O
less	1762	1766	|O
than	1767	1771	|O
that	1772	1776	|O
of	1777	1779	|O
the	1780	1783	|O
reference	1784	1793	|O
while	1794	1799	|O
1c	1800	1802	|O
and	1803	1806	|O
1e	1807	1809	|O
had	1810	1813	|O
activity	1814	1822	|O
nearly	1823	1829	|O
one	1830	1833	|O
log	1834	1837	|O
until	1838	1843	|O
less	1844	1848	|O
than	1849	1853	|O
trans	1854	1859	|O
-	1859	1860	|O
retinoic	1860	1868	|O
acid	1869	1873	|O
.	1873	1874	|O
The	1875	1878	|O
sulfoxide	1879	1888	|O
was	1889	1892	|O
the	1893	1896	|O
least	1897	1902	|O
active	1903	1909	|O
of	1910	1912	|O
the	1913	1916	|O
heteroretinoids	1917	1932	|O
.	1932	1933	|O

### abstracts653.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
new	12	15	|O
5	16	17	|B-IUPAC
-	17	18	|I-IUPAC
(	18	19	|I-IUPAC
1	19	20	|I-IUPAC
-	20	21	|I-IUPAC
hydroxy	21	28	|I-IUPAC
-	28	29	|I-IUPAC
2	29	30	|I-IUPAC
-	30	31	|I-IUPAC
iodoethyl	31	40	|I-IUPAC
)	40	41	|I-IUPAC
-	41	42	|I-IUPAC
2'	42	44	|I-IUPAC
-	44	45	|I-IUPAC
deoxyuridine	45	57	|I-IUPAC
and	58	61	|O
uridine	62	69	|B-IUPAC
compounds	70	79	|B-MODIFIER
(	80	81	|O
11	81	83	|O
,	83	84	|O
16	85	87	|O
)	87	88	|O
was	89	92	|O
synthesized	93	104	|O
by	105	107	|O
the	108	111	|O
regiospecific	112	125	|O
addition	126	134	|O
of	135	137	|O
HOI	138	141	|O
to	142	144	|O
the	145	148	|O
vinyl	149	154	|O
substituent	155	166	|O
of	167	169	|O
5	170	171	|B-IUPAC
-	171	172	|I-IUPAC
vinyl	172	177	|I-IUPAC
-	177	178	|I-IUPAC
2'	178	180	|I-IUPAC
-	180	181	|I-IUPAC
deoxyuridine	181	193	|I-IUPAC
(	194	195	|O
10a	195	198	|O
)	198	199	|O
,	199	200	|O
5	201	202	|B-IUPAC
-	202	203	|I-IUPAC
vinyl	203	208	|I-IUPAC
-	208	209	|I-IUPAC
2'	209	211	|I-IUPAC
-	211	212	|I-IUPAC
fluoro	212	218	|I-IUPAC
-	218	219	|I-IUPAC
2'	219	221	|I-IUPAC
-	221	222	|I-IUPAC
deoxyuridine	222	234	|I-IUPAC
(	235	236	|O
10b	236	239	|O
)	239	240	|O
,	240	241	|O
5	242	243	|B-IUPAC
-	243	244	|I-IUPAC
vinyluridine	244	256	|I-IUPAC
(	257	258	|O
10c	258	261	|O
)	261	262	|O
,	262	263	|O
and	264	267	|O
(	268	269	|B-IUPAC
E	269	270	|I-IUPAC
)	270	271	|I-IUPAC
-	271	272	|I-IUPAC
5	272	273	|I-IUPAC
-	273	274	|I-IUPAC
(	274	275	|I-IUPAC
2	275	276	|I-IUPAC
-	276	277	|I-IUPAC
iodovinyl	277	286	|I-IUPAC
)	286	287	|I-IUPAC
-	287	288	|I-IUPAC
2'	288	290	|I-IUPAC
-	290	291	|I-IUPAC
deoxyuridine	291	303	|I-IUPAC
(	304	305	|O
4b	305	307	|O
)	307	308	|O
.	308	309	|O
Treatment	310	319	|O
of	320	322	|O
the	323	326	|O
iodohydrins	327	338	|O
11a	339	342	|O
-	342	343	|O
c	343	344	|O
with	345	349	|O
methanolic	350	360	|O
sulfuric	361	369	|O
acid	370	374	|O
afforded	375	383	|O
the	384	387	|O
corresponding	388	401	|O
5	402	403	|B-IUPAC
-	403	404	|I-IUPAC
(	404	405	|I-IUPAC
1	405	406	|I-IUPAC
-	406	407	|I-IUPAC
methoxy	407	414	|I-IUPAC
-	414	415	|I-IUPAC
2	415	416	|I-IUPAC
-	416	417	|I-IUPAC
iodoethyl	417	426	|I-IUPAC
)	426	427	|I-IUPAC
derivatives	428	439	|B-MODIFIER
(	440	441	|O
12a	441	444	|O
-	444	445	|O
c	445	446	|O
)	446	447	|O
.	447	448	|O
In	449	451	|O
contrast	452	460	|O
,	460	461	|O
reaction	462	470	|O
of	471	473	|O
5	474	475	|B-IUPAC
-	475	476	|I-IUPAC
(	476	477	|I-IUPAC
1	477	478	|I-IUPAC
-	478	479	|I-IUPAC
hydroxy	479	486	|I-IUPAC
-	486	487	|I-IUPAC
2	487	488	|I-IUPAC
-	488	489	|I-IUPAC
iodoethyl	489	498	|I-IUPAC
)	498	499	|I-IUPAC
-	499	500	|I-IUPAC
2'	500	502	|I-IUPAC
-	502	503	|I-IUPAC
deoxyuridine	503	515	|I-IUPAC
(	516	517	|O
11a	517	520	|O
)	520	521	|O
with	522	526	|O
sodium	527	533	|O
carbonate	534	543	|O
in	544	546	|O
methanol	547	555	|O
afforded	556	564	|O
a	565	566	|O
mixture	567	574	|O
of	575	577	|O
5	578	579	|B-IUPAC
-	579	580	|I-IUPAC
(	580	581	|I-IUPAC
1	581	582	|I-IUPAC
-	582	583	|I-IUPAC
hydroxy	583	590	|I-IUPAC
-	590	591	|I-IUPAC
2	591	592	|I-IUPAC
-	592	593	|I-IUPAC
methoxyethyl	593	605	|I-IUPAC
)	605	606	|I-IUPAC
-	606	607	|I-IUPAC
2'	607	609	|I-IUPAC
-	609	610	|I-IUPAC
deoxyuridine	610	622	|I-IUPAC
(	623	624	|O
13	624	626	|O
)	626	627	|O
and	628	631	|O
2,3	632	635	|B-IUPAC
-	635	636	|I-IUPAC
dihydro	636	643	|I-IUPAC
-	643	644	|I-IUPAC
3	644	645	|I-IUPAC
-	645	646	|I-IUPAC
hydroxy	646	653	|I-IUPAC
-	653	654	|I-IUPAC
5	654	655	|I-IUPAC
-	655	656	|I-IUPAC
(	656	657	|I-IUPAC
2'	657	659	|I-IUPAC
-	659	660	|I-IUPAC
deoxy	660	665	|I-IUPAC
-	665	666	|I-IUPAC
beta	666	670	|I-IUPAC
-	670	671	|I-IUPAC
D	671	672	|I-IUPAC
-	672	673	|I-IUPAC
ribofuranosyl	673	686	|I-IUPAC
)	686	687	|I-IUPAC
-	687	688	|I-IUPAC
furano	689	695	|I-IUPAC
[	695	696	|I-IUPAC
2,3	696	699	|I-IUPAC
-	699	700	|I-IUPAC
d	700	701	|I-IUPAC
]	701	702	|I-IUPAC
pyrimidin	702	711	|I-IUPAC
-	711	712	|I-IUPAC
6	712	713	|I-IUPAC
(	713	714	|I-IUPAC
5H	714	716	|I-IUPAC
)	716	717	|I-IUPAC
-	717	718	|I-IUPAC
one	718	721	|I-IUPAC
(	722	723	|O
14	723	725	|O
)	725	726	|O
.	726	727	|O
The	728	731	|O
most	732	736	|O
active	737	743	|O
compound	744	752	|O
,	752	753	|O
5	754	755	|B-IUPAC
-	755	756	|I-IUPAC
(	756	757	|I-IUPAC
1	757	758	|I-IUPAC
-	758	759	|I-IUPAC
methoxy	759	766	|I-IUPAC
-	766	767	|I-IUPAC
2	767	768	|I-IUPAC
-	768	769	|I-IUPAC
iodoethyl	769	778	|I-IUPAC
)	778	779	|I-IUPAC
-	779	780	|I-IUPAC
2'	780	782	|I-IUPAC
-	782	783	|I-IUPAC
deoxyuridine	783	795	|I-IUPAC
(	796	797	|O
12a	797	800	|O
,	800	801	|O
ID50	802	806	|O
=	807	808	|O
0.1	809	812	|O
micrograms	813	823	|O
/	823	824	|O
mL	824	826	|O
)	826	827	|O
,	827	828	|O
which	829	834	|O
exhibited	835	844	|O
antiviral	845	854	|O
activity	855	863	|O
(	864	865	|O
HSV	865	868	|O
-	868	869	|O
1	869	870	|O
)	870	871	|O
100	872	875	|O
-	875	876	|O
fold	876	880	|O
higher	881	887	|O
than	888	892	|O
that	893	897	|O
of	898	900	|O
the	901	904	|O
5	905	906	|B-IUPAC
-	906	907	|I-IUPAC
(	907	908	|I-IUPAC
1	908	909	|I-IUPAC
-	909	910	|I-IUPAC
hydroxy	910	917	|I-IUPAC
-	917	918	|I-IUPAC
2	918	919	|I-IUPAC
-	919	920	|I-IUPAC
iodoethyl	920	929	|I-IUPAC
)	929	930	|I-IUPAC
analogue	931	939	|B-MODIFIER
(	940	941	|O
11a	941	944	|O
)	944	945	|O
,	945	946	|O
was	947	950	|O
less	951	955	|O
active	956	962	|O
than	963	967	|O
IVDU	968	972	|O
or	973	975	|O
acyclovir	976	985	|O
(	986	987	|O
ID50	987	991	|O
=	992	993	|O
0.01-0.1	994	1002	|O
micrograms	1003	1013	|O
/	1013	1014	|O
mL	1014	1016	|O
range	1017	1022	|O
)	1022	1023	|O
.	1023	1024	|O
The	1025	1028	|O
C	1029	1030	|O
-	1030	1031	|O
5	1031	1032	|O
substituent	1033	1044	|O
in	1045	1047	|O
the	1048	1051	|O
2'	1052	1054	|B-IUPAC
-	1054	1055	|I-IUPAC
deoxyuridine	1055	1067	|I-IUPAC
series	1068	1074	|B-MODIFIER
was	1075	1078	|O
a	1079	1080	|O
determinant	1081	1092	|O
of	1093	1095	|O
cytotoxic	1096	1105	|O
activity	1106	1114	|O
,	1114	1115	|O
as	1116	1118	|O
determined	1119	1129	|O
in	1130	1132	|O
the	1133	1136	|O
in	1137	1139	|O
vitro	1140	1145	|O
L1210	1146	1151	|O
screen	1152	1158	|O
,	1158	1159	|O
where	1160	1165	|O
the	1166	1169	|O
relative	1170	1178	|O
activity	1179	1187	|O
order	1188	1193	|O
was	1194	1197	|O
CH	1198	1200	|O
(	1200	1201	|O
OH	1201	1203	|O
)	1203	1204	|O
CHI2	1204	1208	|O
(	1209	1210	|O
16	1210	1212	|O
)	1212	1213	|O
greater	1214	1221	|O
than	1222	1226	|O
CH	1227	1229	|O
(	1229	1230	|O
OMe	1230	1233	|O
)	1233	1234	|O
CH2I	1234	1238	|O
(	1239	1240	|O
12a	1240	1243	|O
)	1243	1244	|O
greater	1245	1252	|O
than	1253	1257	|O
CH	1258	1260	|O
(	1260	1261	|O
OH	1261	1263	|O
)	1263	1264	|O
CH2I	1264	1268	|O
(	1269	1270	|O
11a	1270	1273	|O
)	1273	1274	|O
congruent	1275	1284	|O
to	1285	1287	|O
CH	1288	1290	|O
(	1290	1291	|O
OH	1291	1293	|O
)	1293	1294	|O
CH2OMe	1294	1300	|O
(	1301	1302	|O
13	1302	1304	|O
)	1304	1305	|O
.	1305	1306	|O
The	1307	1310	|O
2'	1311	1313	|O
-	1313	1314	|O
substituent	1314	1325	|O
was	1326	1329	|O
also	1330	1334	|O
a	1335	1336	|O
determinant	1337	1348	|O
of	1349	1351	|O
cytotoxic	1352	1361	|O
activity	1362	1370	|O
in	1371	1373	|O
the	1374	1377	|O
5	1378	1379	|B-IUPAC
-	1379	1380	|I-IUPAC
(	1380	1381	|I-IUPAC
1	1381	1382	|I-IUPAC
-	1382	1383	|I-IUPAC
hydroxy	1383	1390	|I-IUPAC
-	1390	1391	|I-IUPAC
2	1391	1392	|I-IUPAC
-	1392	1393	|I-IUPAC
iodoethyl	1393	1402	|I-IUPAC
)	1402	1403	|I-IUPAC
(	1404	1405	|O
11a	1405	1408	|O
-	1408	1409	|O
c	1409	1410	|O
)	1410	1411	|O
and	1412	1415	|O
5	1416	1417	|B-IUPAC
-	1417	1418	|I-IUPAC
(	1418	1419	|I-IUPAC
1	1419	1420	|I-IUPAC
-	1420	1421	|I-IUPAC
methoxy	1421	1428	|I-IUPAC
-	1428	1429	|I-IUPAC
2	1429	1430	|I-IUPAC
-	1430	1431	|I-IUPAC
iodoethyl	1431	1440	|I-IUPAC
)	1440	1441	|I-IUPAC
series	1442	1448	|B-MODIFIER
of	1449	1451	|O
compounds	1452	1461	|O
,	1461	1462	|O
where	1463	1468	|O
the	1469	1472	|O
relative	1473	1481	|O
activity	1482	1490	|O
profile	1491	1498	|O
was	1499	1502	|O
2'	1503	1505	|B-IUPAC
-	1505	1506	|I-IUPAC
deoxyuridine	1506	1518	|I-IUPAC
greater	1519	1526	|O
than	1527	1531	|O
2'	1532	1534	|B-IUPAC
-	1534	1535	|I-IUPAC
fluoro	1535	1541	|I-IUPAC
-	1541	1542	|I-IUPAC
2'	1542	1544	|I-IUPAC
-	1544	1545	|I-IUPAC
deoxyuridine	1545	1557	|I-IUPAC
greater	1558	1565	|O
than	1566	1570	|O
uridine	1571	1578	|B-IUPAC
(	1579	1580	|O
11a	1580	1583	|O
greater	1584	1591	|O
than	1592	1596	|O
11b	1597	1600	|O
greater	1601	1608	|O
than	1609	1613	|O
or	1614	1616	|O
equal	1617	1622	|O
to	1623	1625	|O
11c	1626	1629	|O
;	1629	1630	|O
12a	1631	1634	|O
greater	1635	1642	|O
than	1643	1647	|O
12b	1648	1651	|O
greater	1652	1659	|O
than	1660	1664	|O
12c	1665	1668	|O
)	1668	1669	|O
.	1669	1670	|O
The	1671	1674	|O
most	1675	1679	|O
active	1680	1686	|O
cytotoxic	1687	1696	|O
agent	1697	1702	|O
(	1703	1704	|O
16	1704	1706	|O
)	1706	1707	|O
,	1707	1708	|O
possessing	1709	1719	|O
a	1720	1721	|O
5	1722	1723	|B-IUPAC
-	1723	1724	|I-IUPAC
(	1724	1725	|I-IUPAC
1	1725	1726	|I-IUPAC
-	1726	1727	|I-IUPAC
hydroxy	1727	1734	|I-IUPAC
-	1734	1735	|I-IUPAC
2,2	1735	1738	|I-IUPAC
-	1738	1739	|I-IUPAC
diiodoethyl	1739	1750	|I-IUPAC
)	1750	1751	|I-IUPAC
substituent	1752	1763	|B-MODIFIER
(	1764	1765	|O
ED50	1765	1769	|O
=	1770	1771	|O
0.77	1772	1776	|O
micrograms	1777	1787	|O
/	1787	1788	|O
mL	1788	1790	|O
)	1790	1791	|O
,	1791	1792	|O
exhibited	1793	1802	|O
an	1803	1805	|O
activity	1806	1814	|O
approaching	1815	1826	|O
that	1827	1831	|O
of	1832	1834	|O
melphalan	1835	1844	|O
(	1845	1846	|O
ED50	1846	1850	|O
=	1851	1852	|O
0.15	1853	1857	|O
micrograms	1858	1868	|O
/	1868	1869	|O
mL	1869	1871	|O
)	1871	1872	|O
.	1872	1873	|O
All	1874	1877	|O
compounds	1878	1887	|O
tested	1888	1894	|O
,	1894	1895	|O
except	1896	1902	|O
for	1903	1906	|O
13	1907	1909	|O
and	1910	1913	|O
14	1914	1916	|O
,	1916	1917	|O
exhibited	1918	1927	|O
high	1928	1932	|O
affinity	1933	1941	|O
(	1942	1943	|O
Ki	1943	1945	|O
=	1946	1947	|O
0.035-0.22	1948	1958	|O
mM	1959	1961	|O
range	1962	1967	|O
relative	1968	1976	|O
to	1977	1979	|O
deoxyuridine	1980	1992	|O
,	1992	1993	|O
Ki	1994	1996	|O
=	1997	1998	|O
0.125	1999	2004	|O
)	2004	2005	|O
for	2006	2009	|O
the	2010	2013	|O
murine	2014	2020	|O
NBMPR	2021	2026	|O
-	2026	2027	|O
sensitive	2027	2036	|O
erythrocyte	2037	2048	|O
nucleoside	2049	2059	|O
transport	2060	2069	|O
system	2070	2076	|O
,	2076	2077	|O
suggesting	2078	2088	|O
that	2089	2093	|O
these	2094	2099	|O
iodohydrins	2100	2111	|O
are	2112	2115	|O
good	2116	2120	|O
permeants	2121	2130	|O
of	2131	2133	|O
cell	2134	2138	|O
membranes	2139	2148	|O
.	2148	2149	|O

### abstracts717.txt
A	0	1	|O
number	2	8	|O
of	9	11	|O
derivatives	12	23	|O
structurally	24	36	|O
related	37	44	|O
to	45	47	|O
cirazoline	48	58	|O
(	59	60	|O
1	60	61	|O
)	61	62	|O
were	63	67	|O
synthesized	68	79	|O
and	80	83	|O
studied	84	91	|O
with	92	96	|O
the	97	100	|O
purpose	101	108	|O
of	109	111	|O
modulating	112	122	|O
alpha2	123	129	|O
-	129	130	|O
adrenoreceptors	130	145	|O
selectivity	146	157	|O
versus	158	164	|O
both	165	169	|O
alpha1	170	176	|O
-	176	177	|O
adrenoreceptors	177	192	|O
and	193	196	|O
I2	197	199	|O
imidazoline	200	211	|O
binding	212	219	|O
sites	220	225	|O
.	225	226	|O
The	227	230	|O
most	231	235	|O
potent	236	242	|O
alpha2	243	249	|O
-	249	250	|O
agonist	250	257	|O
was	258	261	|O
2	262	263	|B-IUPAC
-	263	264	|I-IUPAC
[	264	265	|I-IUPAC
1	265	266	|I-IUPAC
-	266	267	|I-IUPAC
(	267	268	|I-IUPAC
biphenyl	268	276	|I-IUPAC
-	276	277	|I-IUPAC
2	277	278	|I-IUPAC
-	278	279	|I-IUPAC
yloxy	279	284	|I-IUPAC
)	284	285	|I-IUPAC
ethyl	285	290	|I-IUPAC
]	290	291	|I-IUPAC
-	291	292	|I-IUPAC
4,5	292	295	|I-IUPAC
-	295	296	|I-IUPAC
dihydro	296	303	|I-IUPAC
-	303	304	|I-IUPAC
1H	304	306	|I-IUPAC
-	306	307	|I-IUPAC
imidazole	307	316	|I-IUPAC
(	317	318	|O
7	318	319	|O
)	319	320	|O
,	320	321	|O
whose	322	327	|O
key	328	331	|O
pharmacophoric	332	346	|O
features	347	355	|O
closely	356	363	|O
matched	364	371	|O
those	372	377	|O
found	378	383	|O
in	384	386	|O
the	387	390	|O
alpha2	391	397	|O
-	397	398	|O
agonist	398	405	|O
2	406	407	|B-IUPAC
-	407	408	|I-IUPAC
(	408	409	|I-IUPAC
3	409	410	|I-IUPAC
-	410	411	|I-IUPAC
exo	411	414	|I-IUPAC
-	414	415	|I-IUPAC
(	415	416	|I-IUPAC
3	416	417	|I-IUPAC
-	417	418	|I-IUPAC
phenylprop	418	428	|I-IUPAC
-	428	429	|I-IUPAC
1	429	430	|I-IUPAC
-	430	431	|I-IUPAC
yl	431	433	|I-IUPAC
)	433	434	|I-IUPAC
-	434	435	|I-IUPAC
2	435	436	|I-IUPAC
-	436	437	|I-IUPAC
exo	437	440	|I-IUPAC
-	440	441	|I-IUPAC
norbornyl	441	450	|I-IUPAC
)	450	451	|I-IUPAC
amino	451	456	|I-IUPAC
-	456	457	|I-IUPAC
2	457	458	|I-IUPAC
-	458	459	|I-IUPAC
oxazoline	459	468	|I-IUPAC
(	469	470	|O
15	470	472	|O
)	472	473	|O
.	473	474	|O
(	475	476	|O
S	476	477	|O
)	477	478	|O
-	478	479	|O
(	479	480	|O
-	480	481	|O
)	481	482	|O
-	482	483	|O
7	483	484	|O
was	485	488	|O
the	489	492	|O
most	493	497	|O
potent	498	504	|O
of	505	507	|O
the	508	511	|O
two	512	515	|O
enantiomers	516	527	|O
,	527	528	|O
confirming	529	539	|O
the	540	543	|O
stereospecificity	544	561	|O
of	562	564	|O
the	565	568	|O
interaction	569	580	|O
with	581	585	|O
alpha2	586	592	|O
-	592	593	|O
adrenoreceptors	593	608	|O
.	608	609	|O
This	610	614	|O
eutomer	615	622	|O
was	623	626	|O
tested	627	633	|O
on	634	636	|O
two	637	640	|O
algesiometric	641	654	|O
paradigms	655	664	|O
and	665	668	|O
,	668	669	|O
because	670	677	|O
of	678	680	|O
the	681	684	|O
interaction	685	696	|O
with	697	701	|O
alpha2	702	708	|O
-	708	709	|O
adrenoreceptors	709	724	|O
,	724	725	|O
showed	726	732	|O
a	733	734	|O
potent	735	741	|O
and	742	745	|O
long	746	750	|O
-	750	751	|O
lasting	751	758	|O
antinociceptive	759	774	|O
activity	775	783	|O
,	783	784	|O
since	785	790	|O
it	791	793	|O
was	794	797	|O
abolished	798	807	|O
by	808	810	|O
the	811	814	|O
selective	815	824	|O
alpha2	825	831	|O
-	831	832	|O
antagonist	832	842	|O
RX821002	843	851	|O
.	851	852	|O

### abstracts3981.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
substituted	12	23	|B-MODIFIER
1,4	24	27	|B-IUPAC
-	27	28	|I-IUPAC
dihydronaphthoquinones	28	50	|I-IUPAC
,	50	51	|O
hydroindoloquinones	52	71	|O
,	71	72	|O
benzofuran	73	83	|B-IUPAC
-	83	84	|I-IUPAC
4,7	84	87	|I-IUPAC
-	87	88	|I-IUPAC
dihydroquinones	88	103	|I-IUPAC
,	103	104	|O
and	105	108	|O
benzothiophene	109	123	|B-IUPAC
-	123	124	|I-IUPAC
4,7	124	127	|I-IUPAC
-	127	128	|I-IUPAC
dihydroquinones	128	143	|I-IUPAC
were	144	148	|O
synthesized	149	160	|O
and	161	164	|O
evaluated	165	174	|O
for	175	178	|O
inhibitory	179	189	|O
activity	190	198	|O
against	199	206	|O
5	207	208	|O
-	208	209	|O
lipoxygenase	209	221	|O
.	221	222	|O
These	223	228	|O
compounds	229	238	|O
were	239	243	|O
found	244	249	|O
to	250	252	|O
be	253	255	|O
active	256	262	|O
in	263	265	|O
vitro	266	271	|O
for	272	275	|O
LTC4	276	280	|O
/	280	281	|O
D4	281	283	|O
inhibition	284	294	|O
with	295	299	|O
the	300	303	|O
potencies	304	313	|O
(	314	315	|O
IC50	315	319	|O
's	319	321	|O
)	321	322	|O
ranging	323	330	|O
from	331	335	|O
0.2	336	339	|O
to	340	342	|O
85	343	345	|O
microM	346	352	|O
.	352	353	|O
Active	354	360	|O
1,4	361	364	|B-IUPAC
-	364	365	|I-IUPAC
dihydronaphthoquinone	365	386	|I-IUPAC
acetates	387	395	|I-IUPAC
(	396	397	|O
IC50	397	401	|O
less	402	406	|O
than	407	411	|O
20	412	414	|O
microM	415	421	|O
)	421	422	|O
were	423	427	|O
evaluated	428	437	|O
in	438	440	|O
an	441	443	|O
ex	444	446	|O
vivo	447	451	|O
LTB4	452	456	|O
inhibition	457	467	|O
assay	468	473	|O
.	473	474	|O
The	475	478	|O
acetates	479	487	|O
of	488	490	|O
1,4	491	494	|B-IUPAC
-	494	495	|I-IUPAC
dihydronaphthoquinones	495	517	|I-IUPAC
containing	518	528	|O
the	529	532	|O
alkyl	533	538	|O
substituent	539	550	|O
(	550	551	|O
s	551	552	|O
)	552	553	|O
(	554	555	|O
2	555	556	|B-IUPAC
-	556	557	|I-IUPAC
n	557	558	|I-IUPAC
-	558	559	|I-IUPAC
butyl	559	564	|I-IUPAC
,	564	565	|O
11	566	568	|O
,	568	569	|O
and	570	573	|O
2,3	574	577	|B-IUPAC
-	577	578	|I-IUPAC
diethyl	578	585	|I-IUPAC
,	585	586	|O
15	587	589	|O
)	589	590	|O
exhibited	591	600	|O
the	601	604	|O
best	605	609	|O
activity	610	618	|O
in	619	621	|O
LTC4	622	626	|O
/	626	627	|O
D4	627	629	|O
inhibition	630	640	|O
(	641	642	|O
IC50	642	646	|O
=	647	648	|O
0.2-0.4	649	656	|O
microM	657	663	|O
,	663	664	|O
in	665	667	|O
vitro	668	673	|O
)	673	674	|O
as	675	677	|O
well	678	682	|O
as	683	685	|O
in	686	688	|O
LTB4	689	693	|O
inhibition	694	704	|O
(	705	706	|O
60-75%	706	712	|O
inhibition	713	723	|O
)	723	724	|O
.	724	725	|O

### abstracts584.txt
In	0	2	|O
the	3	6	|O
present	7	14	|O
investigation	15	28	|O
,	28	29	|O
the	30	33	|O
last	34	38	|O
two	39	42	|O
possible	43	51	|O
modes	52	57	|O
of	58	60	|O
generating	61	71	|O
conformationally	72	88	|O
semirigid	89	98	|O
diacylglycerol	99	113	|O
(	114	115	|O
DAG	115	118	|O
)	118	119	|O
analogues	120	129	|O
embedded	130	138	|O
into	139	143	|O
five	144	148	|O
-	148	149	|O
membered	149	157	|O
ring	158	162	|O
lactones	163	171	|O
as	172	174	|O
templates	175	184	|O
III	185	188	|O
and	189	192	|O
IV	193	195	|O
are	196	199	|O
investigated	200	212	|O
.	212	213	|O
The	214	217	|O
first	218	223	|O
two	224	227	|O
templates	228	237	|O
studied	238	245	|O
in	246	248	|O
previous	249	257	|O
investigations	258	272	|O
corresponded	273	285	|O
to	286	288	|O
2	289	290	|B-IUPAC
-	290	291	|I-IUPAC
deoxyribonolactone	291	309	|I-IUPAC
(	310	311	|O
template	311	319	|O
I	320	321	|O
)	321	322	|O
and	323	326	|O
4,4	327	330	|B-MODIFIER
-	330	331	|I-MODIFIER
disubstituted	331	344	|I-MODIFIER
gamma	345	350	|B-IUPAC
-	350	351	|I-IUPAC
butyrolactone	351	364	|I-IUPAC
(	365	366	|O
template	366	374	|O
II	375	377	|O
)	377	378	|O
,	378	379	|O
with	380	384	|O
the	385	388	|O
latter	389	395	|O
producing	396	405	|O
potent	406	412	|O
protein	413	420	|O
kinase	421	427	|O
C	428	429	|O
(	430	431	|O
PK	431	433	|O
-	433	434	|O
C	434	435	|O
)	435	436	|O
ligands	437	444	|O
with	445	449	|O
low	450	453	|O
nanomolar	454	463	|O
binding	464	471	|O
affinities	472	482	|O
.	482	483	|O
The	484	487	|O
templates	488	497	|O
reported	498	506	|O
in	507	509	|O
this	510	514	|O
work	515	519	|O
correspond	520	530	|O
to	531	533	|O
2,3	534	537	|B-PARTIUPAC
-	537	538	|I-PARTIUPAC
dideoxy	538	545	|I-PARTIUPAC
-	545	546	|I-PARTIUPAC
L	546	547	|I-PARTIUPAC
-	547	548	|I-PARTIUPAC
erythro	548	555	|I-PARTIUPAC
-	555	556	|I-PARTIUPAC
or	557	559	|O
-	560	561	|B-PARTIUPAC
threo	561	566	|I-PARTIUPAC
-	566	567	|I-PARTIUPAC
hexono	567	573	|I-PARTIUPAC
-	573	574	|I-PARTIUPAC
1,4	574	577	|I-PARTIUPAC
-	577	578	|I-PARTIUPAC
lactone	578	585	|I-PARTIUPAC
(	586	587	|O
template	587	595	|O
III	596	599	|O
)	599	600	|O
and	601	604	|O
2	605	606	|B-IUPAC
-	606	607	|I-IUPAC
deoxyapiolactone	607	623	|I-IUPAC
(	624	625	|O
template	625	633	|O
IV	634	636	|O
)	636	637	|O
.	637	638	|O
Compounds	639	648	|O
constructed	649	660	|O
with	661	665	|O
the	666	669	|O
dideoxy	670	677	|B-PARTIUPAC
-	677	678	|I-PARTIUPAC
L	678	679	|I-PARTIUPAC
-	679	680	|I-PARTIUPAC
erythro	680	687	|I-PARTIUPAC
-	687	688	|I-PARTIUPAC
or	689	691	|O
-	692	693	|B-PARTIUPAC
threo	693	698	|I-PARTIUPAC
-	698	699	|I-PARTIUPAC
hexono	699	705	|I-PARTIUPAC
-	705	706	|I-PARTIUPAC
1,4	706	709	|I-PARTIUPAC
-	709	710	|I-PARTIUPAC
lactone	710	717	|I-PARTIUPAC
template	718	726	|O
were	727	731	|O
synthesized	732	743	|O
stereospecifically	744	762	|O
from	763	767	|O
tri	768	771	|B-IUPAC
-	771	772	|I-IUPAC
O	772	773	|I-IUPAC
-	773	774	|I-IUPAC
acetyl	774	780	|I-IUPAC
-	780	781	|I-IUPAC
L	781	782	|I-IUPAC
-	782	783	|I-IUPAC
glucal	783	789	|I-IUPAC
and	790	793	|O
L	794	795	|B-IUPAC
-	795	796	|I-IUPAC
galactono	796	805	|I-IUPAC
-	805	806	|I-IUPAC
1,4	806	809	|I-IUPAC
-	809	810	|I-IUPAC
lactone	810	817	|I-IUPAC
,	817	818	|O
respectively	819	831	|O
.	831	832	|O
Compounds	833	842	|O
constructed	843	854	|O
with	855	859	|O
the	860	863	|O
2	864	865	|B-IUPAC
-	865	866	|I-IUPAC
deoxyapiolactone	866	882	|I-IUPAC
template	883	891	|O
were	892	896	|O
synthesized	897	908	|O
stereoselectively	909	926	|O
from	927	931	|O
di	932	934	|B-IUPAC
-	934	935	|I-IUPAC
O	935	936	|I-IUPAC
-	936	937	|I-IUPAC
isopropylidene	937	951	|I-IUPAC
-	951	952	|I-IUPAC
alpha	952	957	|I-IUPAC
-	957	958	|I-IUPAC
D	958	959	|I-IUPAC
-	959	960	|I-IUPAC
apiose	960	966	|I-IUPAC
.	966	967	|O
Inhibition	968	978	|O
of	979	981	|O
the	982	985	|O
binding	986	993	|O
of	994	996	|O
[	997	998	|B-IUPAC
3H	998	1000	|I-IUPAC
]	1000	1001	|I-IUPAC
phorbol	1001	1008	|I-IUPAC
-	1008	1009	|I-IUPAC
12,13	1009	1014	|I-IUPAC
-	1014	1015	|I-IUPAC
dibutyrate	1015	1025	|I-IUPAC
to	1026	1028	|O
PK	1029	1031	|O
-	1031	1032	|O
C	1032	1033	|O
alpha	1034	1039	|O
showed	1040	1046	|O
that	1047	1051	|O
only	1052	1056	|O
the	1057	1060	|O
threo	1061	1066	|O
-	1066	1067	|O
isomer	1067	1073	|O
,	1073	1074	|O
5	1075	1076	|B-IUPAC
-	1076	1077	|I-IUPAC
O	1077	1078	|I-IUPAC
-	1078	1079	|I-IUPAC
tetradecanoyl	1079	1092	|I-IUPAC
-	1092	1093	|I-IUPAC
2,3	1093	1096	|I-IUPAC
-	1096	1097	|I-IUPAC
dideoxy	1097	1104	|I-IUPAC
-	1104	1105	|I-IUPAC
L	1105	1106	|I-IUPAC
-	1106	1107	|I-IUPAC
threo	1107	1112	|I-IUPAC
-	1112	1113	|I-IUPAC
hexono	1113	1119	|I-IUPAC
-	1119	1120	|I-IUPAC
1,4	1120	1123	|I-IUPAC
-	1123	1124	|I-IUPAC
lactone	1124	1131	|I-IUPAC
(	1132	1133	|O
2	1133	1134	|O
)	1134	1135	|O
was	1136	1139	|O
a	1140	1141	|O
good	1142	1146	|O
PK	1147	1149	|O
-	1149	1150	|O
C	1150	1151	|O
ligand	1152	1158	|O
(	1159	1160	|O
Ki	1160	1162	|O
=	1163	1164	|O
1	1165	1166	|O
microM	1167	1173	|O
)	1173	1174	|O
.	1174	1175	|O
The	1176	1179	|O
rest	1180	1184	|O
of	1185	1187	|O
the	1188	1191	|O
ligands	1192	1199	|O
had	1200	1203	|O
poorer	1204	1210	|O
affinities	1211	1221	|O
with	1222	1226	|O
Ki	1227	1229	|O
values	1230	1236	|O
between	1237	1244	|O
10	1245	1247	|O
and	1248	1251	|O
28	1252	1254	|O
microM	1255	1261	|O
.	1261	1262	|O
With	1263	1267	|O
these	1268	1273	|O
results	1274	1281	|O
,	1281	1282	|O
the	1283	1286	|O
order	1287	1292	|O
of	1293	1295	|O
importance	1296	1306	|O
of	1307	1309	|O
five	1310	1314	|O
-	1314	1315	|O
membered	1315	1323	|O
ring	1324	1328	|O
lactones	1329	1337	|O
as	1338	1340	|O
competent	1341	1350	|O
templates	1351	1360	|O
for	1361	1364	|O
the	1365	1368	|O
construction	1369	1381	|O
of	1382	1384	|O
semirigid	1385	1394	|O
DAG	1395	1398	|O
surrogates	1399	1409	|O
with	1410	1414	|O
effective	1415	1424	|O
PK	1425	1427	|O
-	1427	1428	|O
C	1428	1429	|O
binding	1430	1437	|O
affinity	1438	1446	|O
can	1447	1450	|O
be	1451	1453	|O
established	1454	1465	|O
as	1466	1468	|O
II	1469	1471	|O
&	1472	1473	|O
gt	1473	1475	|O
;	1475	1476	|O
&	1476	1477	|O
gt	1477	1479	|O
;	1479	1480	|O
I	1481	1482	|O
approximately	1483	1496	|O
III	1497	1500	|O
&	1501	1502	|O
gt	1502	1504	|O
;	1504	1505	|O
IV	1506	1508	|O
.	1508	1509	|O

### abstracts3092.txt
Structure	0	9	|O
-	9	10	|O
activity	10	18	|O
relationships	19	32	|O
have	33	37	|O
been	38	42	|O
investigated	43	55	|O
for	56	59	|O
inhibition	60	70	|O
of	71	73	|O
DNA	74	77	|O
-	77	78	|O
dependent	78	87	|O
protein	88	95	|O
kinase	96	102	|O
(	103	104	|O
DNA	104	107	|O
-	107	108	|O
PK	108	110	|O
)	110	111	|O
and	112	115	|O
ATM	116	119	|O
kinase	120	126	|O
by	127	129	|O
a	130	131	|O
series	132	138	|O
of	139	141	|O
pyran	142	147	|B-IUPAC
-	147	148	|I-IUPAC
2	148	149	|I-IUPAC
-	149	150	|I-IUPAC
ones	150	154	|I-IUPAC
,	154	155	|O
pyran	156	161	|B-IUPAC
-	161	162	|I-IUPAC
4	162	163	|I-IUPAC
-	163	164	|I-IUPAC
ones	164	168	|I-IUPAC
,	168	169	|O
thiopyran	170	179	|B-IUPAC
-	179	180	|I-IUPAC
4	180	181	|I-IUPAC
-	181	182	|I-IUPAC
ones	182	186	|I-IUPAC
,	186	187	|O
and	188	191	|O
pyridin	192	199	|B-IUPAC
-	199	200	|I-IUPAC
4	200	201	|I-IUPAC
-	201	202	|I-IUPAC
ones	202	206	|I-IUPAC
.	206	207	|O
A	208	209	|O
wide	210	214	|O
range	215	220	|O
of	221	223	|O
IC50	224	228	|O
values	229	235	|O
were	236	240	|O
observed	241	249	|O
for	250	253	|O
pyranones	254	263	|O
and	264	267	|O
thiopyranones	268	281	|O
substituted	282	293	|O
at	294	296	|O
the	297	300	|O
6	301	302	|O
-	302	303	|O
position	303	311	|O
,	311	312	|O
with	313	317	|O
the	318	321	|O
3	322	323	|O
-	323	324	|O
and	325	328	|O
5	329	330	|O
-	330	331	|O
positions	331	340	|O
proving	341	348	|O
intolerant	349	359	|O
to	360	362	|O
substitution	363	375	|O
.	375	376	|O
Related	377	384	|O
pyran	385	390	|B-IUPAC
-	390	391	|I-IUPAC
2	391	392	|I-IUPAC
-	392	393	|I-IUPAC
ones	393	397	|I-IUPAC
,	397	398	|O
pyran	399	404	|B-IUPAC
-	404	405	|I-IUPAC
4	405	406	|I-IUPAC
-	406	407	|I-IUPAC
ones	407	411	|I-IUPAC
,	411	412	|O
and	413	416	|O
thiopyran	417	426	|B-IUPAC
-	426	427	|I-IUPAC
4	427	428	|I-IUPAC
-	428	429	|I-IUPAC
ones	429	433	|I-IUPAC
showed	434	440	|O
similar	441	448	|O
IC50	449	453	|O
values	454	460	|O
against	461	468	|O
DNA	469	472	|O
-	472	473	|O
PK	473	475	|O
,	475	476	|O
whereas	477	484	|O
the	485	488	|O
pyridin	489	496	|B-IUPAC
-	496	497	|I-IUPAC
4	497	498	|I-IUPAC
-	498	499	|I-IUPAC
one	499	502	|I-IUPAC
system	503	509	|B-MODIFIER
proved	510	516	|O
,	516	517	|O
in	518	520	|O
general	521	528	|O
,	528	529	|O
ineffective	530	541	|O
at	542	544	|O
inhibiting	545	555	|O
DNA	556	559	|O
-	559	560	|O
PK	560	562	|O
.	562	563	|O
Extended	564	572	|O
libraries	573	582	|O
exploring	583	592	|O
the	593	596	|O
6	597	598	|O
-	598	599	|O
position	599	607	|O
of	608	610	|O
2	611	612	|B-IUPAC
-	612	613	|I-IUPAC
morpholino	613	623	|I-IUPAC
-	623	624	|I-IUPAC
pyran	624	629	|I-IUPAC
-	629	630	|I-IUPAC
4	630	631	|I-IUPAC
-	631	632	|I-IUPAC
ones	632	636	|I-IUPAC
and	637	640	|O
2	641	642	|B-IUPAC
-	642	643	|I-IUPAC
morpholino	643	653	|I-IUPAC
-	653	654	|I-IUPAC
thiopyrano	654	664	|I-IUPAC
-	664	665	|I-IUPAC
4	665	666	|I-IUPAC
-	666	667	|I-IUPAC
ones	667	671	|I-IUPAC
identified	672	682	|O
the	683	686	|O
first	687	692	|O
highly	693	699	|O
potent	700	706	|O
and	707	710	|O
selective	711	720	|O
ATM	721	724	|O
inhibitor	725	734	|O
2	735	736	|B-IUPAC
-	736	737	|I-IUPAC
morpholin	737	746	|I-IUPAC
-	746	747	|I-IUPAC
4	747	748	|I-IUPAC
-	748	749	|I-IUPAC
yl	749	751	|I-IUPAC
-	751	752	|I-IUPAC
6	752	753	|I-IUPAC
-	753	754	|I-IUPAC
thianthren	754	764	|I-IUPAC
-	764	765	|I-IUPAC
1	765	766	|I-IUPAC
-	766	767	|I-IUPAC
yl	767	769	|I-IUPAC
-	769	770	|I-IUPAC
pyran	770	775	|I-IUPAC
-	775	776	|I-IUPAC
4	776	777	|I-IUPAC
-	777	778	|I-IUPAC
one	778	781	|I-IUPAC
(	782	783	|O
151C	783	787	|O
;	787	788	|O
ATM	789	792	|O
;	792	793	|O
IC50	794	798	|O
=	799	800	|O
13	801	803	|O
nM	804	806	|O
)	806	807	|O
and	808	811	|O
revealed	812	820	|O
constrained	821	832	|O
SARs	833	837	|O
for	838	841	|O
ATM	842	845	|O
inhibition	846	856	|O
compared	857	865	|O
with	866	870	|O
DNA	871	874	|O
-	874	875	|O
PK	875	877	|O
.	877	878	|O
One	879	882	|O
of	883	885	|O
the	886	889	|O
most	890	894	|O
potent	895	901	|O
DNA	902	905	|O
-	905	906	|O
PK	906	908	|O
inhibitors	909	919	|O
identified	920	930	|O
,	930	931	|O
2	932	933	|B-IUPAC
-	933	934	|I-IUPAC
(	934	935	|I-IUPAC
4	935	936	|I-IUPAC
-	936	937	|I-IUPAC
methoxyphenyl	937	950	|I-IUPAC
)	950	951	|I-IUPAC
-	951	952	|I-IUPAC
6	952	953	|I-IUPAC
-	953	954	|I-IUPAC
(	954	955	|I-IUPAC
morpholin	955	964	|I-IUPAC
-	964	965	|I-IUPAC
4	965	966	|I-IUPAC
-	966	967	|I-IUPAC
yl	967	969	|I-IUPAC
)	969	970	|I-IUPAC
pyran	970	975	|I-IUPAC
-	975	976	|I-IUPAC
4	976	977	|I-IUPAC
-	977	978	|I-IUPAC
one	978	981	|I-IUPAC
(	982	983	|O
16	983	985	|O
;	985	986	|O
DNA	987	990	|O
-	990	991	|O
PK	991	993	|O
;	993	994	|O
IC50	995	999	|O
=	1000	1001	|O
220	1002	1005	|O
nM	1006	1008	|O
)	1008	1009	|O
effectively	1010	1021	|O
sensitized	1022	1032	|O
HeLa	1033	1037	|O
cells	1038	1043	|O
to	1044	1046	|O
the	1047	1050	|O
topoisomerase	1051	1064	|O
II	1065	1067	|O
inhibitor	1068	1077	|O
etoposide	1078	1087	|O
in	1088	1090	|O
vitro	1091	1096	|O
.	1096	1097	|O

### abstracts1035.txt
Radiolabeled	0	12	|O
m	13	14	|B-IUPAC
-	14	15	|I-IUPAC
iodobenzylguanidine	15	34	|I-IUPAC
(	35	36	|O
MIBG	36	40	|O
)	40	41	|O
is	42	44	|O
a	45	46	|O
tumor	47	52	|O
-	52	53	|O
seeking	53	60	|O
radioactive	61	72	|O
drug	73	77	|O
used	78	82	|O
in	83	85	|O
the	86	89	|O
diagnosis	90	99	|O
and	100	103	|O
treatment	104	113	|O
of	114	116	|O
pheochromocytomas	117	134	|O
and	135	138	|O
neuroblastomas	139	153	|O
.	153	154	|O
It	155	157	|O
is	158	160	|O
transported	161	172	|O
into	173	177	|O
the	178	181	|O
tumor	182	187	|O
cells	188	193	|O
by	194	196	|O
the	197	200	|O
neuronal	201	209	|O
norepinephrine	210	224	|O
(	225	226	|O
NE	226	228	|O
)	228	229	|O
transporter	230	241	|O
(	242	243	|O
NET	243	246	|O
)	246	247	|O
which	248	253	|O
is	254	256	|O
expressed	257	266	|O
in	267	269	|O
almost	270	276	|O
all	277	280	|O
neuroblastoma	281	294	|O
cells	295	300	|O
.	300	301	|O
Here	302	306	|O
,	306	307	|O
we	308	310	|O
describe	311	319	|O
the	320	323	|O
synthesis	324	333	|O
and	334	337	|O
some	338	342	|O
pharmacological	343	358	|O
properties	359	369	|O
of	370	372	|O
a	373	374	|O
series	375	381	|O
of	382	384	|O
fluorescent	385	396	|O
compounds	397	406	|O
structurally	407	419	|O
related	420	427	|O
to	428	430	|O
the	431	434	|O
NET	435	438	|O
substrate	439	448	|O
,	448	449	|O
MIBG	450	454	|O
,	454	455	|O
or	456	458	|O
to	459	461	|O
the	462	465	|O
NET	466	469	|O
inhibitors	470	480	|O
,	480	481	|O
(	482	483	|B-IUPAC
-	483	484	|I-IUPAC
)	484	485	|I-IUPAC
-	485	486	|I-IUPAC
(	486	487	|I-IUPAC
2R	487	489	|I-IUPAC
,	489	490	|I-IUPAC
3S	490	492	|I-IUPAC
)	492	493	|I-IUPAC
-	493	494	|I-IUPAC
cocaine	494	501	|I-IUPAC
and	502	505	|O
nisoxetine	506	516	|O
.	516	517	|O
Three	518	523	|O
of	524	526	|O
10	527	529	|O
synthesized	530	541	|O
fluorescent	542	553	|O
compounds	554	563	|O
,	563	564	|O
1	565	566	|B-IUPAC
-	566	567	|I-IUPAC
(	567	568	|I-IUPAC
1	568	569	|I-IUPAC
-	569	570	|I-IUPAC
naphthylmethyl	570	584	|I-IUPAC
)	584	585	|I-IUPAC
guanidinium	585	596	|I-IUPAC
sulfate	597	604	|I-IUPAC
(	605	606	|O
1	606	607	|O
)	607	608	|O
,	608	609	|O
1	610	611	|B-IUPAC
-	611	612	|I-IUPAC
[	612	613	|I-IUPAC
2	613	614	|I-IUPAC
-	614	615	|I-IUPAC
(	615	616	|I-IUPAC
dibenz	616	622	|I-IUPAC
[	622	623	|I-IUPAC
b	623	624	|I-IUPAC
,	624	625	|I-IUPAC
f	626	627	|I-IUPAC
]	627	628	|I-IUPAC
azepin	628	634	|I-IUPAC
-	634	635	|I-IUPAC
5	635	636	|I-IUPAC
-	636	637	|I-IUPAC
yl	637	639	|I-IUPAC
)	639	640	|I-IUPAC
ethyl	640	645	|I-IUPAC
]	645	646	|I-IUPAC
guanidinium	646	657	|I-IUPAC
sulfate	658	665	|I-IUPAC
(	666	667	|O
2	667	668	|O
)	668	669	|O
,	669	670	|O
and	671	674	|O
(	675	676	|B-IUPAC
2R	676	678	|I-IUPAC
,	678	679	|I-IUPAC
3S	680	682	|I-IUPAC
)	682	683	|I-IUPAC
-	683	684	|I-IUPAC
2beta	684	689	|I-IUPAC
-	689	690	|I-IUPAC
ethoxycarbonyl	690	704	|I-IUPAC
-	704	705	|I-IUPAC
3beta	705	710	|I-IUPAC
-	710	711	|I-IUPAC
tropanyl	711	719	|I-IUPAC
5	720	721	|I-IUPAC
-	721	722	|I-IUPAC
(	722	723	|I-IUPAC
dimethylamino	723	736	|I-IUPAC
)	736	737	|I-IUPAC
naphthalene	737	748	|I-IUPAC
-	748	749	|I-IUPAC
1	749	750	|I-IUPAC
-	750	751	|I-IUPAC
sulfonate	751	760	|I-IUPAC
(	761	762	|O
6	762	763	|O
)	763	764	|O
,	764	765	|O
exhibited	766	775	|O
high	776	780	|O
affinity	781	789	|O
(	790	791	|O
IC	791	793	|O
(	793	794	|O
50	794	796	|O
)	796	797	|O
about	798	803	|O
50	804	806	|O
nM	807	809	|O
)	809	810	|O
for	811	814	|O
the	815	818	|O
NET	819	822	|O
.	822	823	|O
The	824	827	|O
nisoxetine	828	838	|O
derivatives	839	850	|O
8	851	852	|O
(	853	854	|O
rac	854	857	|B-IUPAC
-	857	858	|I-IUPAC
N	858	859	|I-IUPAC
-	859	860	|I-IUPAC
[	860	861	|I-IUPAC
(	861	862	|I-IUPAC
3	862	863	|I-IUPAC
-	863	864	|I-IUPAC
methylamino	864	875	|I-IUPAC
-	875	876	|I-IUPAC
1	876	877	|I-IUPAC
-	877	878	|I-IUPAC
phenyl	878	884	|I-IUPAC
)	884	885	|I-IUPAC
propyl	885	891	|I-IUPAC
]	891	892	|I-IUPAC
-	892	893	|I-IUPAC
5	893	894	|I-IUPAC
-	894	895	|I-IUPAC
(	895	896	|I-IUPAC
dimethylamino	896	909	|I-IUPAC
)	909	910	|I-IUPAC
-	910	911	|I-IUPAC
1	911	912	|I-IUPAC
-	912	913	|I-IUPAC
naphthale	913	922	|I-IUPAC
nesulfonamide	923	936	|I-IUPAC
)	936	937	|O
and	938	941	|O
9	942	943	|O
(	944	945	|O
rac	945	948	|B-IUPAC
-	948	949	|I-IUPAC
4	949	950	|I-IUPAC
-	950	951	|I-IUPAC
[	951	952	|I-IUPAC
(	952	953	|I-IUPAC
3	953	954	|I-IUPAC
-	954	955	|I-IUPAC
methylamino	955	966	|I-IUPAC
-	966	967	|I-IUPAC
1	967	968	|I-IUPAC
-	968	969	|I-IUPAC
phenyl	969	975	|I-IUPAC
)	975	976	|I-IUPAC
propyl	976	982	|I-IUPAC
]	982	983	|I-IUPAC
amino	983	988	|I-IUPAC
-	988	989	|I-IUPAC
7	989	990	|I-IUPAC
-	990	991	|I-IUPAC
nitro	991	996	|I-IUPAC
-	996	997	|I-IUPAC
2,1	997	1000	|I-IUPAC
,	1000	1001	|I-IUPAC
3	1002	1003	|I-IUPAC
-	1003	1004	|I-IUPAC
benzoxadiazole	1004	1018	|I-IUPAC
)	1018	1019	|O
and	1020	1023	|O
especially	1024	1034	|O
the	1035	1038	|O
guanidine	1039	1048	|O
derivative	1049	1059	|O
4	1060	1061	|O
(	1062	1063	|O
1	1063	1064	|B-IUPAC
-	1064	1065	|I-IUPAC
[	1065	1066	|I-IUPAC
4	1066	1067	|I-IUPAC
-	1067	1068	|I-IUPAC
(	1068	1069	|I-IUPAC
4	1069	1070	|I-IUPAC
-	1070	1071	|I-IUPAC
phenyl	1071	1077	|I-IUPAC
-	1077	1078	|I-IUPAC
1,3	1078	1081	|I-IUPAC
-	1081	1082	|I-IUPAC
butadienyl	1082	1092	|I-IUPAC
)	1092	1093	|I-IUPAC
benzyl	1093	1099	|I-IUPAC
]	1099	1100	|I-IUPAC
guanidinium	1100	1111	|I-IUPAC
sulfate	1112	1119	|I-IUPAC
)	1119	1120	|O
which	1121	1126	|O
are	1127	1130	|O
characterized	1131	1144	|O
by	1145	1147	|O
intermediate	1148	1160	|O
affinity	1161	1169	|O
for	1170	1173	|O
the	1174	1177	|O
NET	1178	1181	|O
(	1182	1183	|O
IC	1183	1185	|O
(	1185	1186	|O
50	1186	1188	|O
)	1188	1189	|O
370-850	1190	1197	|O
nM	1198	1200	|O
)	1200	1201	|O
caused	1202	1208	|O
significant	1209	1220	|O
and	1221	1224	|O
nisoxetine	1225	1235	|O
-	1235	1236	|O
sensitive	1236	1245	|O
cell	1246	1250	|O
fluorescence	1251	1263	|O
.	1263	1264	|O
At	1265	1267	|O
least	1268	1273	|O
the	1274	1277	|O
guanidine	1278	1287	|O
derivative	1288	1298	|O
4	1299	1300	|O
might	1301	1306	|O
represent	1307	1316	|O
a	1317	1318	|O
potentially	1319	1330	|O
useful	1331	1337	|O
agent	1338	1343	|O
for	1344	1347	|O
imaging	1348	1355	|O
of	1356	1358	|O
neuroblastoma	1359	1372	|O
cells	1373	1378	|O
.	1378	1379	|O

### abstracts2478.txt
Selective	0	9	|O
protection	10	20	|O
of	21	23	|O
(	24	25	|B-IUPAC
9R	25	27	|I-IUPAC
)	27	28	|I-IUPAC
-	28	29	|I-IUPAC
9	29	30	|I-IUPAC
-	30	31	|I-IUPAC
amino	31	36	|I-IUPAC
-	36	37	|I-IUPAC
9	37	38	|I-IUPAC
-	38	39	|I-IUPAC
deoxoerythromycin	39	56	|I-IUPAC
A	57	58	|I-IUPAC
allowed	59	66	|O
for	67	70	|O
elimination	71	82	|O
of	83	85	|O
the	86	89	|O
12	90	92	|B-PARTIUPAC
-	92	93	|I-PARTIUPAC
hydroxyl	93	101	|I-PARTIUPAC
group	102	107	|B-MODIFIER
to	108	110	|O
afford	111	117	|O
a	118	119	|O
versatile	120	129	|O
12,21	130	135	|O
-	135	136	|O
olefin	136	142	|O
intermediate	143	155	|O
.	155	156	|O
Further	157	164	|O
modifications	165	178	|O
of	179	181	|O
the	182	185	|O
intermediate	186	198	|O
led	199	202	|O
to	203	205	|O
the	206	209	|O
syntheses	210	219	|O
of	220	222	|O
(	223	224	|B-IUPAC
9R	224	226	|I-IUPAC
)	226	227	|I-IUPAC
-	227	228	|I-IUPAC
9	228	229	|I-IUPAC
-	229	230	|I-IUPAC
deoxo	230	235	|I-IUPAC
-	235	236	|I-IUPAC
9	236	237	|I-IUPAC
-	237	238	|I-IUPAC
(	238	239	|I-IUPAC
N	239	240	|I-IUPAC
,	240	241	|I-IUPAC
N	241	242	|I-IUPAC
-	242	243	|I-IUPAC
dimethylamino	243	256	|I-IUPAC
)	256	257	|I-IUPAC
-	257	258	|I-IUPAC
12,21	258	263	|I-IUPAC
-	263	264	|I-IUPAC
epoxyerythromycin	264	281	|I-IUPAC
B	282	283	|I-IUPAC
,	283	284	|O
(	285	286	|B-IUPAC
9R	286	288	|I-IUPAC
)	288	289	|I-IUPAC
-	289	290	|I-IUPAC
9	290	291	|I-IUPAC
-	291	292	|I-IUPAC
deoxo	292	297	|I-IUPAC
-	297	298	|I-IUPAC
9	298	299	|I-IUPAC
-	299	300	|I-IUPAC
(	300	301	|I-IUPAC
N	301	302	|I-IUPAC
,	302	303	|I-IUPAC
N	303	304	|I-IUPAC
-	304	305	|I-IUPAC
dimethylamino	305	318	|I-IUPAC
)	318	319	|I-IUPAC
-	319	320	|I-IUPAC
21	320	322	|I-IUPAC
-	322	323	|I-IUPAC
hydroxyerythromycin	323	342	|I-IUPAC
A	343	344	|I-IUPAC
,	344	345	|O
and	346	349	|O
(	350	351	|B-IUPAC
9R	351	353	|I-IUPAC
)	353	354	|I-IUPAC
-	354	355	|I-IUPAC
9	355	356	|I-IUPAC
-	356	357	|I-IUPAC
deoxo	357	362	|I-IUPAC
-	362	363	|I-IUPAC
9	363	364	|I-IUPAC
-	364	365	|I-IUPAC
(	365	366	|I-IUPAC
N	366	367	|I-IUPAC
,	367	368	|I-IUPAC
N	368	369	|I-IUPAC
-	369	370	|I-IUPAC
dimethylamino	370	383	|I-IUPAC
)	383	384	|I-IUPAC
-	384	385	|I-IUPAC
21	385	387	|I-IUPAC
-	387	388	|I-IUPAC
hydroxyerythromycin	388	407	|I-IUPAC
B	408	409	|I-IUPAC
.	409	410	|O
All	411	414	|O
three	415	420	|O
compounds	421	430	|O
retained	431	439	|O
antibacterial	440	453	|O
activity	454	462	|O
against	463	470	|O
several	471	478	|O
organisms	479	488	|O
normally	489	497	|O
susceptible	498	509	|O
to	510	512	|O
(	513	514	|B-IUPAC
9R	514	516	|I-IUPAC
)	516	517	|I-IUPAC
-	517	518	|I-IUPAC
9	518	519	|I-IUPAC
-	519	520	|I-IUPAC
deoxo	520	525	|I-IUPAC
-	525	526	|I-IUPAC
9	526	527	|I-IUPAC
-	527	528	|I-IUPAC
(	528	529	|I-IUPAC
N	529	530	|I-IUPAC
,	530	531	|I-IUPAC
N	531	532	|I-IUPAC
-	532	533	|I-IUPAC
dimethylamino	533	546	|I-IUPAC
)	546	547	|I-IUPAC
erythromycin	547	559	|I-IUPAC
A	560	561	|I-IUPAC
.	561	562	|O
However	563	570	|O
,	570	571	|O
the	572	575	|O
21	576	578	|O
-	578	579	|O
hydroxylated	579	591	|O
erythromycin	592	604	|O
A	605	606	|O
analogue	607	615	|O
was	616	619	|O
weaker	620	626	|O
in	627	629	|O
potency	630	637	|O
than	638	642	|O
the	643	646	|O
corresponding	647	660	|O
erythromycin	661	673	|O
B	674	675	|O
congener	676	684	|O
and	685	688	|O
much	689	693	|O
weaker	694	700	|O
than	701	705	|O
the	706	709	|O
epoxy	710	715	|O
derivative	716	726	|O
.	726	727	|O
This	728	732	|O
suggests	733	741	|O
that	742	746	|O
while	747	752	|O
substitution	753	765	|O
of	766	768	|O
a	769	770	|O
polar	771	776	|O
functionality	777	790	|O
at	791	793	|O
C	794	795	|O
-	795	796	|O
21	796	798	|O
does	799	803	|O
not	804	807	|O
abolish	808	815	|O
antibacterial	816	829	|O
activity	830	838	|O
,	838	839	|O
introduction	840	852	|O
of	853	855	|O
vicinal	856	863	|O
polar	864	869	|O
groups	870	876	|O
at	877	879	|O
both	880	884	|O
C	885	886	|O
-	886	887	|O
12	887	889	|O
and	890	893	|O
C	894	895	|O
-	895	896	|O
21	896	898	|O
may	899	902	|O
lead	903	907	|O
to	908	910	|O
reduction	911	920	|O
in	921	923	|O
potency	924	931	|O
.	931	932	|O
Nevertheless	933	945	|O
,	945	946	|O
these	947	952	|O
21	953	955	|O
-	955	956	|O
functionalized	956	970	|O
derivatives	971	982	|O
of	983	985	|O
(	986	987	|B-IUPAC
9R	987	989	|I-IUPAC
)	989	990	|I-IUPAC
-	990	991	|I-IUPAC
erythromycylamine	991	1008	|I-IUPAC
provide	1009	1016	|O
an	1017	1019	|O
entry	1020	1025	|O
into	1026	1030	|O
novel	1031	1036	|O
analogues	1037	1046	|O
of	1047	1049	|O
the	1050	1053	|O
important	1054	1063	|O
macrolide	1064	1073	|O
antibiotic	1074	1084	|O
erythromycin	1085	1097	|O
.	1097	1098	|O

### abstracts1216.txt
The	0	3	|O
syntheses	4	13	|O
of	14	16	|O
(	17	18	|B-IUPAC
3RS	18	21	|I-IUPAC
,	21	22	|I-IUPAC
4RS	22	25	|I-IUPAC
)	25	26	|I-IUPAC
-	26	27	|I-IUPAC
4	27	28	|I-IUPAC
-	28	29	|I-IUPAC
hydroxypiperidine	29	46	|I-IUPAC
-	46	47	|I-IUPAC
3	47	48	|I-IUPAC
-	48	49	|I-IUPAC
carboxylic	49	59	|I-IUPAC
acid	60	64	|I-IUPAC
(	65	66	|O
4	66	67	|O
)	67	68	|O
,	68	69	|O
(	70	71	|B-IUPAC
3RS	71	74	|I-IUPAC
,	74	75	|I-IUPAC
5SR	75	78	|I-IUPAC
)	78	79	|I-IUPAC
-	79	80	|I-IUPAC
5	80	81	|I-IUPAC
-	81	82	|I-IUPAC
hydroxypiperidine	82	99	|I-IUPAC
-	99	100	|I-IUPAC
3	100	101	|I-IUPAC
-	101	102	|I-IUPAC
carboxylic	102	112	|I-IUPAC
acid	113	117	|I-IUPAC
(	118	119	|O
20	119	121	|O
)	121	122	|O
,	122	123	|O
(	124	125	|B-IUPAC
3RS	125	128	|I-IUPAC
,	128	129	|I-IUPAC
4SR	129	132	|I-IUPAC
)	132	133	|I-IUPAC
-	133	134	|I-IUPAC
4	134	135	|I-IUPAC
-	135	136	|I-IUPAC
acetamidopiperidine	136	155	|I-IUPAC
-	155	156	|I-IUPAC
3	156	157	|I-IUPAC
-	157	158	|I-IUPAC
carboxylic	158	168	|I-IUPAC
acid	169	173	|I-IUPAC
(	174	175	|O
10	175	177	|O
)	177	178	|O
,	178	179	|O
and	180	183	|O
(	184	185	|B-IUPAC
3RS	185	188	|I-IUPAC
,	188	189	|I-IUPAC
5SR	189	192	|I-IUPAC
)	192	193	|I-IUPAC
-	193	194	|I-IUPAC
5	194	195	|I-IUPAC
-	195	196	|I-IUPAC
acetamidopiperidine	196	215	|I-IUPAC
-	215	216	|I-IUPAC
3	216	217	|I-IUPAC
-	217	218	|I-IUPAC
carboxylic	218	228	|I-IUPAC
acid	229	233	|I-IUPAC
(	234	235	|O
18	235	237	|O
)	237	238	|O
,	238	239	|O
related	240	247	|O
to	248	250	|O
the	251	254	|O
specific	255	263	|O
gamma	264	269	|B-IUPAC
-	269	270	|I-IUPAC
aminobutyric	270	282	|I-IUPAC
acid	283	287	|I-IUPAC
(	288	289	|O
GABA	289	293	|O
)	293	294	|O
uptake	295	301	|O
inhibitors	302	312	|O
(	313	314	|B-IUPAC
RS	314	316	|I-IUPAC
)	316	317	|I-IUPAC
-	317	318	|I-IUPAC
piperidine	318	328	|I-IUPAC
-	328	329	|I-IUPAC
3	329	330	|I-IUPAC
-	330	331	|I-IUPAC
carboxylic	331	341	|I-IUPAC
acid	342	346	|I-IUPAC
(	347	348	|O
nipecotic	348	357	|O
acid	358	362	|O
)	362	363	|O
and	364	367	|O
(	368	369	|B-IUPAC
3RS	369	372	|I-IUPAC
,	372	373	|I-IUPAC
4SR	373	376	|I-IUPAC
)	376	377	|I-IUPAC
-	377	378	|I-IUPAC
4	378	379	|I-IUPAC
-	379	380	|I-IUPAC
hydroxypiperidine	380	397	|I-IUPAC
-	397	398	|I-IUPAC
3	398	399	|I-IUPAC
-	399	400	|I-IUPAC
carboxylic	400	410	|I-IUPAC
acid	411	415	|I-IUPAC
(	416	417	|O
21	417	419	|O
)	419	420	|O
,	420	421	|O
are	422	425	|O
described	426	435	|O
.	435	436	|O
Furthermore	437	448	|O
,	448	449	|O
(	450	451	|B-IUPAC
3RS	451	454	|I-IUPAC
,	454	455	|I-IUPAC
4SR	455	458	|I-IUPAC
)	458	459	|I-IUPAC
-	459	460	|I-IUPAC
3	460	461	|I-IUPAC
-	461	462	|I-IUPAC
hydroxypiperidine	462	479	|I-IUPAC
-	479	480	|I-IUPAC
4	480	481	|I-IUPAC
-	481	482	|I-IUPAC
carboxylic	482	492	|I-IUPAC
acid	493	497	|I-IUPAC
(	498	499	|O
14	499	501	|O
)	501	502	|O
,	502	503	|O
related	504	511	|O
to	512	514	|O
the	515	518	|O
specific	519	527	|O
GABA	528	532	|O
agonist	533	540	|O
piperidine	541	551	|B-IUPAC
-	551	552	|I-IUPAC
4	552	553	|I-IUPAC
-	553	554	|I-IUPAC
carboxylic	554	564	|I-IUPAC
acid	565	569	|I-IUPAC
(	570	571	|O
isonipecotic	571	583	|O
acid	584	588	|O
)	588	589	|O
,	589	590	|O
has	591	594	|O
been	595	599	|O
synthesized	600	611	|O
.	611	612	|O
The	613	616	|O
structures	617	627	|O
of	628	630	|O
4	631	632	|O
,	632	633	|O
10	634	636	|O
,	636	637	|O
14	638	640	|O
,	640	641	|O
18	642	644	|O
,	644	645	|O
and	646	649	|O
20	650	652	|O
have	653	657	|O
been	658	662	|O
established	663	674	|O
by	675	677	|O
270	678	681	|O
-	681	682	|O
MHz	682	685	|O
1H	686	688	|O
NMR	689	692	|O
spectroscopic	693	706	|O
analyses	707	715	|O
.	715	716	|O
The	717	720	|O
affinity	721	729	|O
of	730	732	|O
the	733	736	|O
compounds	737	746	|O
for	747	750	|O
the	751	754	|O
GABA	755	759	|O
receptors	760	769	|O
and	770	773	|O
for	774	777	|O
the	778	781	|O
neuronal	782	790	|O
(	791	792	|O
synaptosomal	792	804	|O
)	804	805	|O
GABA	806	810	|O
uptake	811	817	|O
system	818	824	|O
in	825	827	|O
vitro	828	833	|O
has	834	837	|O
been	838	842	|O
measured	843	851	|O
.	851	852	|O
Compound	853	861	|O
14	862	864	|O
interacts	865	874	|O
selectively	875	886	|O
with	887	891	|O
the	892	895	|O
GABA	896	900	|O
receptors	901	910	|O
but	911	914	|O
less	915	919	|O
effectively	920	931	|O
than	932	936	|O
isonipecotic	937	949	|O
acid	950	954	|O
and	955	958	|O
the	959	962	|O
cis	963	966	|O
-	966	967	|O
isomer	967	973	|O
22	974	976	|O
.	976	977	|O
Compounds	978	987	|O
4	988	989	|O
,	989	990	|O
18	991	993	|O
,	993	994	|O
and	995	998	|O
20	999	1001	|O
are	1002	1005	|O
inhibitors	1006	1016	|O
of	1017	1019	|O
the	1020	1023	|O
GABA	1024	1028	|O
uptake	1029	1035	|O
system	1036	1042	|O
,	1042	1043	|O
although	1044	1052	|O
much	1053	1057	|O
weaker	1058	1064	|O
than	1065	1069	|O
nipecotic	1070	1079	|O
acid	1080	1084	|O
and	1085	1088	|O
(	1089	1090	|B-IUPAC
3RS	1090	1093	|I-IUPAC
,	1093	1094	|I-IUPAC
4SR	1094	1097	|I-IUPAC
)	1097	1098	|I-IUPAC
-	1098	1099	|I-IUPAC
4	1099	1100	|I-IUPAC
-	1100	1101	|I-IUPAC
hydroxypiperidine	1101	1118	|I-IUPAC
-	1118	1119	|I-IUPAC
3	1119	1120	|I-IUPAC
-	1120	1121	|I-IUPAC
carboxylic	1121	1131	|I-IUPAC
acid	1132	1136	|I-IUPAC
(	1137	1138	|O
21	1138	1140	|O
)	1140	1141	|O
.	1141	1142	|O
Compound	1143	1151	|O
10	1152	1154	|O
is	1155	1157	|O
inactive	1158	1166	|O
in	1167	1169	|O
both	1170	1174	|O
test	1175	1179	|O
systems	1180	1187	|O
.	1187	1188	|O

### abstracts1280.txt
This	0	4	|O
study	5	10	|O
emphasizes	11	21	|O
the	22	25	|O
importance	26	36	|O
of	37	39	|O
the	40	43	|O
metabolic	44	53	|O
conversion	54	64	|O
of	65	67	|O
the	68	71	|O
enantiomers	72	83	|O
of	84	86	|O
3	87	88	|B-IUPAC
-	88	89	|I-IUPAC
(	89	90	|I-IUPAC
3	90	91	|I-IUPAC
-	91	92	|I-IUPAC
hydroxyphenyl	92	105	|I-IUPAC
)	105	106	|I-IUPAC
-	106	107	|I-IUPAC
N	107	108	|I-IUPAC
-	108	109	|I-IUPAC
n	109	110	|I-IUPAC
-	110	111	|I-IUPAC
propylpiperidine	111	127	|I-IUPAC
(	128	129	|O
3	129	130	|O
-	130	131	|O
PPP	131	134	|O
)	134	135	|O
into	136	140	|O
their	141	146	|O
catechol	147	155	|O
analogues	156	165	|O
,	165	166	|O
the	167	170	|O
enantiomers	171	182	|O
of	183	185	|O
3	186	187	|B-IUPAC
-	187	188	|I-IUPAC
(	188	189	|I-IUPAC
3,4	189	192	|I-IUPAC
-	192	193	|I-IUPAC
dihydroxyphenyl	193	208	|I-IUPAC
)	208	209	|I-IUPAC
-	209	210	|I-IUPAC
N	210	211	|I-IUPAC
-	211	212	|I-IUPAC
n	212	213	|I-IUPAC
-	213	214	|I-IUPAC
propylpiperidine	214	230	|I-IUPAC
.	230	231	|O
These	232	237	|O
isomers	238	245	|O
are	246	249	|O
both	250	254	|O
shown	255	260	|O
to	261	263	|O
be	264	266	|O
excellent	267	276	|O
substrates	277	287	|O
for	288	291	|O
COMT	292	296	|O
,	296	297	|O
with	298	302	|O
a	303	304	|O
slight	305	311	|O
preference	312	322	|O
for	323	326	|O
the	327	330	|O
S	331	332	|O
-	332	333	|O
(	333	334	|O
-	334	335	|O
)	335	336	|O
enantiomer	337	347	|O
.	347	348	|O
Assessment	349	359	|O
of	360	362	|O
the	363	366	|O
dopaminergic	367	379	|O
activity	380	388	|O
of	389	391	|O
these	392	397	|O
catechols	398	407	|O
and	408	411	|O
the	412	415	|O
results	416	423	|O
from	424	428	|O
the	429	432	|O
determination	433	446	|O
of	447	449	|O
brain	450	455	|O
levels	456	462	|O
of	463	465	|O
the	466	469	|O
enantiomers	470	481	|O
of	482	484	|O
3	485	486	|O
-	486	487	|O
PPP	487	490	|O
and	491	494	|O
their	495	500	|O
metabolites	501	512	|O
indicate	513	521	|O
that	522	526	|O
the	527	530	|O
metabolites	531	542	|O
probably	543	551	|O
do	552	554	|O
not	555	558	|O
alter	559	564	|O
the	565	568	|O
pharmacological	569	584	|O
profiles	585	593	|O
established	594	605	|O
for	606	609	|O
(	610	611	|O
R	611	612	|O
)	612	613	|O
-	613	614	|O
(	614	615	|O
+	615	616	|O
)	616	617	|O
-	617	618	|O
and	619	622	|O
(	623	624	|O
S	624	625	|O
)	625	626	|O
-	626	627	|O
(	627	628	|O
-	628	629	|O
)	629	630	|O
-	630	631	|O
3	631	632	|O
-	632	633	|O
PPP	633	636	|O
.	636	637	|O
The	638	641	|O
conversion	642	652	|O
of	653	655	|O
the	656	659	|O
monophenols	660	671	|O
into	672	676	|O
catecholic	677	687	|O
metabolites	688	699	|O
is	700	702	|O
only	703	707	|O
1-5%	708	712	|O
,	712	713	|O
and	714	717	|O
the	718	721	|O
further	722	729	|O
conversion	730	740	|O
of	741	743	|O
these	744	749	|O
catecholic	750	760	|O
metabolites	761	772	|O
into	773	777	|O
methoxylated	778	790	|O
analogues	791	800	|O
is	801	803	|O
very	804	808	|O
rapid	809	814	|O
.	814	815	|O
However	816	823	|O
,	823	824	|O
the	825	828	|O
very	829	833	|O
interesting	834	845	|O
observation	846	857	|O
was	858	861	|O
made	862	866	|O
that	867	871	|O
,	871	872	|O
when	873	877	|O
inhibiting	878	888	|O
COMT	889	893	|O
by	894	896	|O
means	897	902	|O
of	903	905	|O
tropolone	906	915	|O
and	916	919	|O
subsequently	920	932	|O
treating	933	941	|O
the	942	945	|O
rats	946	950	|O
with	951	955	|O
high	956	960	|O
doses	961	966	|O
of	967	969	|O
(	970	971	|O
S	971	972	|O
)	972	973	|O
-	973	974	|O
(	974	975	|O
-	975	976	|O
)	976	977	|O
-	977	978	|O
3	978	979	|O
-	979	980	|O
PPP	980	983	|O
(	984	985	|O
ip	985	987	|O
)	987	988	|O
,	988	989	|O
postsynaptic	990	1002	|O
dopaminergic	1003	1015	|O
activity	1016	1024	|O
was	1025	1028	|O
elicited	1029	1037	|O
.	1037	1038	|O
This	1039	1043	|O
has	1044	1047	|O
never	1048	1053	|O
been	1054	1058	|O
seen	1059	1063	|O
for	1064	1067	|O
(	1068	1069	|O
S	1069	1070	|O
)	1070	1071	|O
-	1071	1072	|O
(	1072	1073	|O
-	1073	1074	|O
)	1074	1075	|O
-	1075	1076	|O
3	1076	1077	|O
-	1077	1078	|O
PPP	1078	1081	|O
without	1082	1089	|O
tropolone	1090	1099	|O
pretreatment	1100	1112	|O
and	1113	1116	|O
might	1117	1122	|O
indicate	1123	1131	|O
that	1132	1136	|O
,	1136	1137	|O
in	1138	1140	|O
this	1141	1145	|O
special	1146	1153	|O
case	1154	1158	|O
,	1158	1159	|O
the	1160	1163	|O
catecholic	1164	1174	|O
metabolite	1175	1185	|O
affects	1186	1193	|O
the	1194	1197	|O
in	1198	1200	|O
vivo	1201	1205	|O
pharmacological	1206	1221	|O
profile	1222	1229	|O
of	1230	1232	|O
(	1233	1234	|O
S	1234	1235	|O
)	1235	1236	|O
-	1236	1237	|O
(	1237	1238	|O
-	1238	1239	|O
)	1239	1240	|O
-	1240	1241	|O
3	1241	1242	|O
-	1242	1243	|O
PPP	1243	1246	|O
.	1246	1247	|O

### abstracts758.txt
The	0	3	|O
synthesis	4	13	|O
of	14	16	|O
a	17	18	|O
range	19	24	|O
of	25	27	|O
3	28	29	|B-IUPAC
-	29	30	|I-IUPAC
hydroxy	30	37	|I-IUPAC
-	37	38	|I-IUPAC
4	38	39	|I-IUPAC
(	39	40	|I-IUPAC
1H	40	42	|I-IUPAC
)	42	43	|I-IUPAC
-	43	44	|I-IUPAC
pyridinones	44	55	|I-IUPAC
with	56	60	|O
potential	61	70	|O
for	71	74	|O
the	75	78	|O
chelation	79	88	|O
of	89	91	|O
iron	92	96	|O
(	96	97	|O
III	97	100	|O
)	100	101	|O
is	102	104	|O
described	105	114	|O
.	114	115	|O
The	116	119	|O
pKa	120	123	|O
values	124	130	|O
of	131	133	|O
respective	134	144	|O
ligands	145	152	|O
and	153	156	|O
the	157	160	|O
stability	161	170	|O
constants	171	180	|O
of	181	183	|O
their	184	189	|O
iron	190	194	|O
(	194	195	|O
III	195	198	|O
)	198	199	|O
complexes	200	209	|O
are	210	213	|O
presented	214	223	|O
.	223	224	|O
The	225	228	|O
distribution	229	241	|O
coefficient	242	253	|O
values	254	260	|O
of	261	263	|O
a	264	265	|O
range	266	271	|O
of	272	274	|O
48	275	277	|O
hydroxypyridinones	278	296	|O
and	297	300	|O
their	301	306	|O
corresponding	307	320	|O
iron	321	325	|O
(	325	326	|O
III	326	329	|O
)	329	330	|O
complexes	331	340	|O
between	341	348	|O
1	349	350	|O
-	350	351	|O
octanol	351	358	|O
and	359	362	|O
MOPS	363	367	|O
buffer	368	374	|O
(	375	376	|O
pH	376	378	|O
7.4	379	382	|O
)	382	383	|O
are	384	387	|O
reported	388	396	|O
.	396	397	|O
The	398	401	|O
range	402	407	|O
of	408	410	|O
log	411	414	|O
Dcomplex	415	423	|O
values	424	430	|O
covers	431	437	|O
7	438	439	|O
orders	440	446	|O
of	447	449	|O
magnitude	450	459	|O
.	459	460	|O
The	461	464	|O
results	465	472	|O
suggest	473	480	|O
the	481	484	|O
existence	485	494	|O
of	495	497	|O
a	498	499	|O
biphasic	500	508	|O
relationship	509	521	|O
between	522	529	|O
the	530	533	|O
distribution	534	546	|O
coefficient	547	558	|O
values	559	565	|O
of	566	568	|O
the	569	572	|O
chelator	573	581	|O
and	582	585	|O
the	586	589	|O
corresponding	590	603	|O
iron	604	608	|O
(	608	609	|O
III	609	612	|O
)	612	613	|O
complexes	614	623	|O
.	623	624	|O
For	625	628	|O
ligands	629	636	|O
with	637	641	|O
a	642	643	|O
log	644	647	|O
Dligand	648	655	|O
=	656	657	|O
-	658	659	|O
1	659	660	|O
,	660	661	|O
a	662	663	|O
linear	664	670	|O
relationship	671	683	|O
exists	684	690	|O
with	691	695	|O
a	696	697	|O
value	698	703	|O
of	704	706	|O
the	707	710	|O
slope	711	716	|O
2.53	717	721	|O
,	721	722	|O
whereas	723	730	|O
with	731	735	|O
ligands	736	743	|O
with	744	748	|O
a	749	750	|O
log	751	754	|O
Dligand	755	762	|O
&	763	764	|O
lt	764	766	|O
;	766	767	|O
-	768	769	|O
1	769	770	|O
,	770	771	|O
a	772	773	|O
linear	774	780	|O
relationship	781	793	|O
exists	794	800	|O
with	801	805	|O
a	806	807	|O
slope	808	813	|O
of	814	816	|O
0.49	817	821	|O
.	821	822	|O
The	823	826	|O
reduced	827	834	|O
slope	835	840	|O
for	841	844	|O
the	845	848	|O
more	849	853	|O
hydrophilic	854	865	|O
molecules	866	875	|O
of	876	878	|O
the	879	882	|O
series	883	889	|O
offers	890	896	|O
some	897	901	|O
advantage	902	911	|O
for	912	915	|O
this	916	920	|O
type	921	925	|O
of	926	928	|O
hydroxypyridinone	929	946	|O
as	947	949	|O
the	950	953	|O
distribution	954	966	|O
coefficients	967	979	|O
for	980	983	|O
such	984	988	|O
complexes	989	998	|O
do	999	1001	|O
not	1002	1005	|O
change	1006	1012	|O
so	1013	1015	|O
rapidly	1016	1023	|O
with	1024	1028	|O
increasing	1029	1039	|O
ligand	1040	1046	|O
hydrophilicity	1047	1061	|O
.	1061	1062	|O
The	1063	1066	|O
ability	1067	1074	|O
of	1075	1077	|O
selected	1078	1086	|O
3	1087	1088	|B-IUPAC
-	1088	1089	|I-IUPAC
hydroxypyridinones	1089	1107	|I-IUPAC
to	1108	1110	|O
facilitate	1111	1121	|O
the	1122	1125	|O
excretion	1126	1135	|O
of	1136	1138	|O
iron	1139	1143	|O
in	1144	1146	|O
bile	1147	1151	|O
was	1152	1155	|O
investigated	1156	1168	|O
in	1169	1171	|O
non	1172	1175	|O
-	1175	1176	|O
iron	1176	1180	|O
-	1180	1181	|O
overloaded	1181	1191	|O
,	1191	1192	|O
bile	1193	1197	|O
duct	1198	1202	|O
-	1202	1203	|O
cannulated	1203	1213	|O
rats	1214	1218	|O
and	1219	1222	|O
in	1223	1225	|O
a	1226	1227	|O
[	1228	1229	|O
59Fe	1229	1233	|O
]	1233	1234	|O
ferritin	1234	1242	|O
-	1242	1243	|O
loaded	1243	1249	|O
rat	1250	1253	|O
model	1254	1259	|O
.	1259	1260	|O
Both	1261	1265	|O
systems	1266	1273	|O
compare	1274	1281	|O
the	1282	1285	|O
ability	1286	1293	|O
of	1294	1296	|O
chelators	1297	1306	|O
to	1307	1309	|O
remove	1310	1316	|O
iron	1317	1321	|O
from	1322	1326	|O
the	1327	1330	|O
liver	1331	1336	|O
,	1336	1337	|O
the	1338	1341	|O
prime	1342	1347	|O
target	1348	1354	|O
organ	1355	1360	|O
in	1361	1363	|O
thalassemia	1364	1375	|O
.	1375	1376	|O
The	1377	1380	|O
N	1381	1382	|B-IUPAC
-	1382	1383	|I-IUPAC
(	1383	1384	|I-IUPAC
hydroxyalkyl	1384	1396	|I-IUPAC
)	1396	1397	|I-IUPAC
-	1397	1398	|I-IUPAC
3	1398	1399	|I-IUPAC
-	1399	1400	|I-IUPAC
hydroxypyridin	1400	1414	|I-IUPAC
-	1414	1415	|I-IUPAC
4	1415	1416	|I-IUPAC
-	1416	1417	|I-IUPAC
ones	1417	1421	|I-IUPAC
are	1422	1425	|O
demonstrated	1426	1438	|O
to	1439	1441	|O
be	1442	1444	|O
orally	1445	1451	|O
active	1452	1458	|O
under	1459	1464	|O
the	1465	1468	|O
in	1469	1471	|O
vivo	1472	1476	|O
conditions	1477	1487	|O
adopted	1488	1495	|O
.	1495	1496	|O
Thus	1497	1501	|O
both	1502	1506	|O
1	1507	1508	|B-PARTIUPAC
-	1508	1509	|I-PARTIUPAC
(	1509	1510	|I-PARTIUPAC
hydroxyalkyl	1510	1522	|I-PARTIUPAC
)	1522	1523	|I-PARTIUPAC
-	1523	1524	|I-PARTIUPAC
and	1525	1528	|O
1	1529	1530	|B-IUPAC
-	1530	1531	|I-IUPAC
(	1531	1532	|I-IUPAC
carboxyalkyl	1532	1544	|I-IUPAC
)	1544	1545	|I-IUPAC
pyridinones	1545	1556	|I-IUPAC
are	1557	1560	|O
able	1561	1565	|O
to	1566	1568	|O
remove	1569	1575	|O
iron	1576	1580	|O
from	1581	1585	|O
the	1586	1589	|O
liver	1590	1595	|O
.	1595	1596	|O
Although	1597	1605	|O
1	1606	1607	|B-IUPAC
-	1607	1608	|I-IUPAC
(	1608	1609	|I-IUPAC
carboxyalkyl	1609	1621	|I-IUPAC
)	1621	1622	|I-IUPAC
hydroxypyridinones	1622	1640	|I-IUPAC
are	1641	1644	|O
active	1645	1651	|O
,	1651	1652	|O
they	1653	1657	|O
do	1658	1660	|O
not	1661	1664	|O
demonstrate	1665	1676	|O
any	1677	1680	|O
clear	1681	1686	|O
advantage	1687	1696	|O
over	1697	1701	|O
Deferiprone	1702	1713	|O
(	1714	1715	|O
1,2	1715	1718	|B-IUPAC
-	1718	1719	|I-IUPAC
dimethyl	1719	1727	|I-IUPAC
-	1727	1728	|I-IUPAC
3	1728	1729	|I-IUPAC
-	1729	1730	|I-IUPAC
hydroxypyridin	1730	1744	|I-IUPAC
-	1744	1745	|I-IUPAC
4	1745	1746	|I-IUPAC
-	1746	1747	|I-IUPAC
one	1747	1750	|I-IUPAC
)	1750	1751	|O
.	1751	1752	|O
Indeed	1753	1759	|O
1	1760	1761	|B-IUPAC
-	1761	1762	|I-IUPAC
(	1762	1763	|I-IUPAC
hydroxyalkyl	1763	1775	|I-IUPAC
)	1775	1776	|I-IUPAC
hydroxypyridinones	1776	1794	|I-IUPAC
which	1795	1800	|O
are	1801	1804	|O
known	1805	1810	|O
to	1811	1813	|O
be	1814	1816	|O
rapidly	1817	1824	|O
converted	1825	1834	|O
to	1835	1837	|O
1	1838	1839	|B-IUPAC
-	1839	1840	|I-IUPAC
(	1840	1841	|I-IUPAC
carboxyalkyl	1841	1853	|I-IUPAC
)	1853	1854	|I-IUPAC
hydroxypyridinones	1854	1872	|I-IUPAC
are	1873	1876	|O
also	1877	1881	|O
marginally	1882	1892	|O
superior	1893	1901	|O
to	1902	1904	|O
Deferiprone	1905	1916	|O
.	1916	1917	|O
In	1918	1920	|O
contrast	1921	1929	|O
,	1929	1930	|O
2	1931	1932	|B-IUPAC
-	1932	1933	|I-IUPAC
ethyl	1933	1938	|I-IUPAC
-	1938	1939	|I-IUPAC
1	1939	1940	|I-IUPAC
-	1940	1941	|I-IUPAC
(	1941	1942	|I-IUPAC
2'	1942	1944	|I-IUPAC
-	1944	1945	|I-IUPAC
hydroxyethyl	1945	1957	|I-IUPAC
)	1957	1958	|I-IUPAC
-	1958	1959	|I-IUPAC
3	1959	1960	|I-IUPAC
-	1960	1961	|I-IUPAC
hydroxypyridin	1961	1975	|I-IUPAC
-	1975	1976	|I-IUPAC
4	1976	1977	|I-IUPAC
-	1977	1978	|I-IUPAC
one	1978	1981	|I-IUPAC
,	1981	1982	|O
which	1983	1988	|O
is	1989	1991	|O
not	1992	1995	|O
metabolized	1996	2007	|O
to	2008	2010	|O
the	2011	2014	|O
corresponding	2015	2028	|O
(	2029	2030	|O
carboxyalkyl	2030	2042	|O
)	2042	2043	|O
hydroxypyridinone	2043	2060	|O
,	2060	2061	|O
was	2062	2065	|O
found	2066	2071	|O
to	2072	2074	|O
be	2075	2077	|O
superior	2078	2086	|O
to	2087	2089	|O
Deferiprone	2090	2101	|O
and	2102	2105	|O
therefore	2106	2115	|O
deserves	2116	2124	|O
further	2125	2132	|O
consideration	2133	2146	|O
as	2147	2149	|O
an	2150	2152	|O
orally	2153	2159	|O
active	2160	2166	|O
iron	2167	2171	|O
chelator	2172	2180	|O
with	2181	2185	|O
potential	2186	2195	|O
for	2196	2199	|O
the	2200	2203	|O
treatment	2204	2213	|O
of	2214	2216	|O
iron	2217	2221	|O
overload	2222	2230	|O
associated	2231	2241	|O
with	2242	2246	|O
transfusion	2247	2258	|O
-	2258	2259	|O
dependent	2259	2268	|O
thalassemia	2269	2280	|O
.	2280	2281	|O

### abstracts2030.txt
Degarelix	0	9	|O
(	10	11	|O
FE200486	11	19	|O
,	19	20	|O
Ac	21	23	|O
-	23	24	|O
d	24	25	|O
-	25	26	|O
2Nal	26	30	|O
(	30	31	|O
1	31	32	|O
)	32	33	|O
-	33	34	|O
d	34	35	|O
-	35	36	|O
4Cpa	36	40	|O
(	40	41	|O
2	41	42	|O
)	42	43	|O
-	43	44	|O
d	44	45	|O
-	45	46	|O
3Pal	46	50	|O
(	50	51	|O
3	51	52	|O
)	52	53	|O
-	53	54	|O
Ser	54	57	|O
(	57	58	|O
4	58	59	|O
)	59	60	|O
-	60	61	|O
4Aph	61	65	|O
(	65	66	|O
l	66	67	|O
-	67	68	|O
Hor	68	71	|O
)	71	72	|O
(	72	73	|O
5	73	74	|O
)	74	75	|O
-	75	76	|O
d	76	77	|O
-	77	78	|O
4Aph	78	82	|O
(	82	83	|O
Cbm	83	86	|O
)	86	87	|O
(	87	88	|O
6	88	89	|O
)	89	90	|O
-	90	91	|O
Leu	91	94	|O
(	94	95	|O
7	95	96	|O
)	96	97	|O
-	97	98	|O
ILys	98	102	|O
(	102	103	|O
8	103	104	|O
)	104	105	|O
-	105	106	|O
Pro	106	109	|O
(	109	110	|O
9	110	111	|O
)	111	112	|O
-	112	113	|O
d	113	114	|O
-	114	115	|O
Ala	115	118	|O
(	118	119	|O
10	119	121	|O
)	121	122	|O
-	122	123	|O
NH	123	125	|O
(	125	126	|O
2	126	127	|O
)	127	128	|O
)	128	129	|O
is	130	132	|O
a	133	134	|O
potent	135	141	|O
and	142	145	|O
very	146	150	|O
long	151	155	|O
acting	156	162	|O
antagonist	163	173	|O
of	174	176	|O
gonadotropin	177	189	|O
-	189	190	|O
releasing	190	199	|O
hormone	200	207	|O
(	208	209	|O
GnRH	209	213	|O
)	213	214	|O
after	215	220	|O
subcutaneous	221	233	|O
administration	234	248	|O
in	249	251	|O
mammals	252	259	|O
including	260	269	|O
humans	270	276	|O
.	276	277	|O
Analogues	278	287	|O
of	288	290	|O
degarelix	291	300	|O
were	301	305	|O
synthesized	306	317	|O
,	317	318	|O
characterized	319	332	|O
,	332	333	|O
and	334	337	|O
screened	338	346	|O
for	347	350	|O
the	351	354	|O
antagonism	355	365	|O
of	366	368	|O
GnRH	369	373	|O
-	373	374	|O
induced	374	381	|O
response	382	390	|O
in	391	393	|O
a	394	395	|O
reporter	396	404	|O
gene	405	409	|O
assay	410	415	|O
in	416	418	|O
HEK	419	422	|O
-	422	423	|O
293	423	426	|O
cells	427	432	|O
expressing	433	443	|O
the	444	447	|O
human	448	453	|O
GnRH	454	458	|O
receptor	459	467	|O
.	467	468	|O
The	469	472	|O
duration	473	481	|O
of	482	484	|O
action	485	491	|O
was	492	495	|O
also	496	500	|O
determined	501	511	|O
in	512	514	|O
the	515	518	|O
castrated	519	528	|O
male	529	533	|O
rat	534	537	|O
assay	538	543	|O
to	544	546	|O
measure	547	554	|O
the	555	558	|O
extent	559	565	|O
(	566	567	|O
efficacy	567	575	|O
and	576	579	|O
duration	580	588	|O
of	589	591	|O
action	592	598	|O
)	598	599	|O
of	600	602	|O
inhibition	603	613	|O
of	614	616	|O
luteinizing	617	628	|O
hormone	629	636	|O
(	637	638	|O
LH	638	640	|O
)	640	641	|O
release	642	649	|O
.	649	650	|O
Structurally	651	663	|O
,	663	664	|O
this	665	669	|O
series	670	676	|O
of	677	679	|O
analogues	680	689	|O
has	690	693	|O
novel	694	699	|O
substitutions	700	713	|O
at	714	716	|O
positions	717	726	|O
3	727	728	|O
,	728	729	|O
7	730	731	|O
,	731	732	|O
and	733	736	|O
8	737	738	|O
and	739	742	|O
N	743	744	|O
(	744	745	|O
alpha	745	750	|O
)	750	751	|O
-	751	752	|O
methylation	752	763	|O
at	764	766	|O
positions	767	776	|O
6	777	778	|O
,	778	779	|O
7	780	781	|O
,	781	782	|O
and	783	786	|O
8	787	788	|O
in	789	791	|O
the	792	795	|O
structure	796	805	|O
of	806	808	|O
degarelix	809	818	|O
.	818	819	|O
These	820	825	|O
substitutions	826	839	|O
were	840	844	|O
designed	845	853	|O
to	854	856	|O
probe	857	862	|O
the	863	866	|O
spatial	867	874	|O
limitations	875	886	|O
of	887	889	|O
the	890	893	|O
receptor	894	902	|O
's	902	904	|O
cavity	905	911	|O
and	912	915	|O
to	916	918	|O
map	919	922	|O
the	923	926	|O
steric	927	933	|O
and	934	937	|O
ionic	938	943	|O
boundaries	944	954	|O
.	954	955	|O
Some	956	960	|O
functional	961	971	|O
groups	972	978	|O
were	979	983	|O
introduced	984	994	|O
that	995	999	|O
were	1000	1004	|O
hypothesized	1005	1017	|O
to	1018	1020	|O
influence	1021	1030	|O
the	1031	1034	|O
phamacokinetic	1035	1049	|O
properties	1050	1060	|O
of	1061	1063	|O
the	1064	1067	|O
analogues	1068	1077	|O
such	1078	1082	|O
as	1083	1085	|O
bioavailability	1086	1101	|O
,	1101	1102	|O
solubility	1103	1113	|O
,	1113	1114	|O
intra	1115	1120	|O
-	1120	1121	|O
or	1122	1124	|O
intermolecular	1125	1139	|O
hydrogen	1140	1148	|O
bond	1149	1153	|O
forming	1154	1161	|O
capacity	1162	1170	|O
,	1170	1171	|O
and	1172	1175	|O
ability	1176	1183	|O
to	1184	1186	|O
bind	1187	1191	|O
carrier	1192	1199	|O
proteins	1200	1208	|O
.	1208	1209	|O
Substitutions	1210	1223	|O
at	1224	1226	|O
positions	1227	1236	|O
3	1237	1238	|O
(	1239	1240	|O
[	1240	1241	|B-IUPAC
N	1241	1242	|I-IUPAC
(	1242	1243	|I-IUPAC
beta	1243	1247	|I-IUPAC
)	1247	1248	|I-IUPAC
-	1248	1249	|I-IUPAC
(	1249	1250	|I-IUPAC
2	1250	1251	|I-IUPAC
-	1251	1252	|I-IUPAC
pyridyl	1252	1259	|I-IUPAC
-	1259	1260	|I-IUPAC
methyl	1260	1266	|I-IUPAC
)	1266	1267	|I-IUPAC
d	1267	1268	|I-IUPAC
-	1268	1269	|I-IUPAC
Dap	1269	1272	|I-IUPAC
(	1272	1273	|I-IUPAC
3	1273	1274	|I-IUPAC
)	1274	1275	|I-IUPAC
]	1275	1276	|I-IUPAC
degarelix	1276	1285	|I-IUPAC
,	1285	1286	|O
IC	1287	1289	|O
(	1289	1290	|O
50	1290	1292	|O
)	1292	1293	|O
=	1294	1295	|O
2.71	1296	1300	|O
nM	1301	1303	|O
)	1303	1304	|O
(	1305	1306	|O
5	1306	1307	|O
)	1307	1308	|O
,	1308	1309	|O
7	1310	1311	|O
(	1312	1313	|O
[	1313	1314	|B-IUPAC
Pra	1314	1317	|I-IUPAC
(	1317	1318	|I-IUPAC
7	1318	1319	|I-IUPAC
)	1319	1320	|I-IUPAC
]	1320	1321	|I-IUPAC
degarelix	1321	1330	|I-IUPAC
,	1330	1331	|O
IC	1332	1334	|O
(	1334	1335	|O
50	1335	1337	|O
)	1337	1338	|O
=	1339	1340	|O
2.11	1341	1345	|O
nM	1346	1348	|O
)	1348	1349	|O
(	1350	1351	|O
16	1351	1353	|O
)	1353	1354	|O
,	1354	1355	|O
and	1356	1359	|O
8	1360	1361	|O
(	1362	1363	|O
[	1363	1364	|B-IUPAC
N	1364	1365	|I-IUPAC
(	1365	1366	|I-IUPAC
delta	1366	1371	|I-IUPAC
)	1371	1372	|I-IUPAC
-	1372	1373	|I-IUPAC
(	1373	1374	|I-IUPAC
IGly	1374	1378	|I-IUPAC
)	1378	1379	|I-IUPAC
Orn	1379	1382	|I-IUPAC
(	1382	1383	|I-IUPAC
8	1383	1384	|I-IUPAC
)	1384	1385	|I-IUPAC
]	1385	1386	|I-IUPAC
degarelix	1386	1395	|I-IUPAC
,	1395	1396	|O
IC	1397	1399	|O
(	1399	1400	|O
50	1400	1402	|O
)	1402	1403	|O
=	1404	1405	|O
1.38	1406	1410	|O
nM	1411	1413	|O
)	1413	1414	|O
(	1415	1416	|O
20	1416	1418	|O
)	1418	1419	|O
and	1420	1423	|O
N	1424	1425	|O
-	1425	1426	|O
methylation	1426	1437	|O
(	1438	1439	|O
[	1439	1440	|B-IUPAC
N	1440	1441	|I-IUPAC
(	1441	1442	|I-IUPAC
alpha	1442	1447	|I-IUPAC
)	1447	1448	|I-IUPAC
-	1448	1449	|I-IUPAC
methyl	1449	1455	|I-IUPAC
-	1455	1456	|I-IUPAC
Leu	1456	1459	|I-IUPAC
(	1459	1460	|I-IUPAC
7	1460	1461	|I-IUPAC
)	1461	1462	|I-IUPAC
]	1462	1463	|I-IUPAC
degarelix	1463	1472	|I-IUPAC
,	1472	1473	|O
IC	1474	1476	|O
(	1476	1477	|O
50	1477	1479	|O
)	1479	1480	|O
=	1481	1482	|O
1.47	1483	1487	|O
nM	1488	1490	|O
)	1490	1491	|O
(	1492	1493	|O
32	1493	1495	|O
)	1495	1496	|O
yielded	1497	1504	|O
analogues	1505	1514	|O
that	1515	1519	|O
were	1520	1524	|O
equipotent	1525	1535	|O
to	1536	1538	|O
degarelix	1539	1548	|O
(	1549	1550	|O
2	1550	1551	|O
)	1551	1552	|O
in	1553	1555	|O
vitro	1556	1561	|O
(	1562	1563	|O
IC	1563	1565	|O
(	1565	1566	|O
50	1566	1568	|O
)	1568	1569	|O
=	1570	1571	|O
1.64	1572	1576	|O
nM	1577	1579	|O
)	1579	1580	|O
but	1581	1584	|O
shorter	1585	1592	|O
acting	1593	1599	|O
in	1600	1602	|O
vivo	1603	1607	|O
.	1607	1608	|O
Out	1609	1612	|O
of	1613	1615	|O
the	1616	1619	|O
33	1620	1622	|O
novel	1623	1628	|O
analogues	1629	1638	|O
tested	1639	1645	|O
for	1646	1649	|O
the	1650	1653	|O
duration	1654	1662	|O
of	1663	1665	|O
action	1666	1672	|O
in	1673	1675	|O
this	1676	1680	|O
series	1681	1687	|O
,	1687	1688	|O
two	1689	1692	|O
analogues	1693	1702	|O
(	1703	1704	|O
[	1704	1705	|B-IUPAC
N	1705	1706	|I-IUPAC
(	1706	1707	|I-IUPAC
epsilon	1707	1714	|I-IUPAC
)	1714	1715	|I-IUPAC
-	1715	1716	|I-IUPAC
cyclohexyl	1716	1726	|I-IUPAC
-	1726	1727	|I-IUPAC
Lys	1727	1730	|I-IUPAC
(	1730	1731	|I-IUPAC
8	1731	1732	|I-IUPAC
)	1732	1733	|I-IUPAC
]	1733	1734	|I-IUPAC
degarelix	1734	1743	|I-IUPAC
,	1743	1744	|O
IC	1745	1747	|O
(	1747	1748	|O
50	1748	1750	|O
)	1750	1751	|O
=	1752	1753	|O
1.50	1754	1758	|O
nM	1759	1761	|O
)	1761	1762	|O
(	1763	1764	|O
23	1764	1766	|O
)	1766	1767	|O
and	1768	1771	|O
(	1772	1773	|O
[	1773	1774	|B-IUPAC
N	1774	1775	|I-IUPAC
(	1775	1776	|I-IUPAC
beta	1776	1780	|I-IUPAC
)	1780	1781	|I-IUPAC
-	1781	1782	|I-IUPAC
(	1782	1783	|I-IUPAC
IbetaAla	1783	1791	|I-IUPAC
)	1791	1792	|I-IUPAC
Dap	1792	1795	|I-IUPAC
(	1795	1796	|I-IUPAC
8	1796	1797	|I-IUPAC
)	1797	1798	|I-IUPAC
]	1798	1799	|I-IUPAC
degarelix	1799	1808	|I-IUPAC
,	1808	1809	|O
IC	1810	1812	|O
(	1812	1813	|O
50	1813	1815	|O
)	1815	1816	|O
=	1817	1818	|O
1.98	1819	1823	|O
nM	1824	1826	|O
)	1826	1827	|O
(	1828	1829	|O
26	1829	1831	|O
)	1831	1832	|O
had	1833	1836	|O
antagonist	1837	1847	|O
potencies	1848	1857	|O
and	1858	1861	|O
duration	1862	1870	|O
of	1871	1873	|O
action	1874	1880	|O
similar	1881	1888	|O
to	1889	1891	|O
that	1892	1896	|O
of	1897	1899	|O
azaline	1900	1907	|O
B	1908	1909	|O
{	1910	1911	|O
inhibited	1911	1920	|O
LH	1921	1923	|O
(	1924	1925	|O
&	1925	1926	|O
gt	1926	1928	|O
;	1928	1929	|O
80%	1929	1932	|O
)	1932	1933	|O
release	1934	1941	|O
for	1942	1945	|O
&	1946	1947	|O
gt	1947	1949	|O
;	1949	1950	|O
72	1950	1952	|O
h	1953	1954	|O
after	1955	1960	|O
sc	1961	1963	|O
injection	1964	1973	|O
to	1974	1976	|O
castrated	1977	1986	|O
male	1987	1991	|O
rats	1992	1996	|O
at	1997	1999	|O
a	2000	2001	|O
standard	2002	2010	|O
dose	2011	2015	|O
of	2016	2018	|O
50	2019	2021	|O
mug	2022	2025	|O
/	2025	2026	|O
rat	2026	2029	|O
in	2030	2032	|O
5%	2033	2035	|O
mannitol	2036	2044	|O
}	2044	2045	|O
.	2045	2046	|O
Under	2047	2052	|O
similar	2053	2060	|O
conditions	2061	2071	|O
analogues	2072	2081	|O
(	2082	2083	|O
[	2083	2084	|B-IUPAC
N	2084	2085	|I-IUPAC
(	2085	2086	|I-IUPAC
gamma	2086	2091	|I-IUPAC
)	2091	2092	|I-IUPAC
-	2092	2093	|I-IUPAC
(	2093	2094	|I-IUPAC
IGly	2094	2098	|I-IUPAC
)	2098	2099	|I-IUPAC
Dab	2099	2102	|I-IUPAC
(	2102	2103	|I-IUPAC
8	2103	2104	|I-IUPAC
)	2104	2105	|I-IUPAC
]	2105	2106	|I-IUPAC
degarelix	2106	2115	|I-IUPAC
,	2115	2116	|O
IC	2117	2119	|O
(	2119	2120	|O
50	2120	2122	|O
)	2122	2123	|O
=	2124	2125	|O
1.56	2126	2130	|O
nM	2131	2133	|O
)	2133	2134	|O
(	2135	2136	|O
21	2136	2138	|O
)	2138	2139	|O
and	2140	2143	|O
(	2144	2145	|O
[	2145	2146	|O
IOrn	2146	2150	|O
(	2150	2151	|O
8	2151	2152	|O
)	2152	2153	|O
]	2153	2154	|O
degarelix	2154	2163	|O
,	2163	2164	|O
IC	2165	2167	|O
(	2167	2168	|O
50	2168	2170	|O
)	2170	2171	|O
=	2172	2173	|O
1.72	2174	2178	|O
nM	2179	2181	|O
)	2181	2182	|O
(	2183	2184	|O
18	2184	2186	|O
)	2186	2187	|O
had	2188	2191	|O
a	2192	2193	|O
longer	2194	2200	|O
duration	2201	2209	|O
of	2210	2212	|O
action	2213	2219	|O
{	2220	2221	|O
inhibited	2221	2230	|O
LH	2231	2233	|O
(	2234	2235	|O
&	2235	2236	|O
gt	2236	2238	|O
;	2238	2239	|O
96	2239	2241	|O
h	2242	2243	|O
)	2243	2244	|O
release	2245	2252	|O
}	2252	2253	|O
than	2254	2258	|O
azaline	2259	2266	|O
B	2267	2268	|O
;	2268	2269	|O
however	2270	2277	|O
they	2278	2282	|O
were	2283	2287	|O
shorter	2288	2295	|O
acting	2296	2302	|O
than	2303	2307	|O
degarelix	2308	2317	|O
.	2317	2318	|O
Hydrophilicity	2319	2333	|O
of	2334	2336	|O
these	2337	2342	|O
analogues	2343	2352	|O
,	2352	2353	|O
a	2354	2355	|O
potential	2356	2365	|O
measure	2366	2373	|O
of	2374	2376	|O
their	2377	2382	|O
ability	2383	2390	|O
to	2391	2393	|O
be	2394	2396	|O
formulated	2397	2407	|O
for	2408	2411	|O
sustained	2412	2421	|O
release	2422	2429	|O
,	2429	2430	|O
was	2431	2434	|O
determined	2435	2445	|O
using	2446	2451	|O
RP	2452	2454	|O
-	2454	2455	|O
HPLC	2455	2459	|O
at	2460	2462	|O
neutral	2463	2470	|O
pH	2471	2473	|O
yielding	2474	2482	|O
analogues	2483	2492	|O
with	2493	2497	|O
shorter	2498	2505	|O
as	2506	2508	|O
well	2509	2513	|O
as	2514	2516	|O
longer	2517	2523	|O
retention	2524	2533	|O
times	2534	2539	|O
.	2539	2540	|O
No	2541	2543	|O
correlation	2544	2555	|O
was	2556	2559	|O
found	2560	2565	|O
between	2566	2573	|O
retention	2574	2583	|O
times	2584	2589	|O
and	2590	2593	|O
antagonist	2594	2604	|O
potency	2605	2612	|O
or	2613	2615	|O
duration	2616	2624	|O
of	2625	2627	|O
action	2628	2634	|O
.	2634	2635	|O

### abstracts2285.txt
At	0	2	|O
physiological	3	16	|O
pH	17	19	|O
,	19	20	|O
the	21	24	|O
spatial	25	32	|O
arrangement	33	44	|O
of	45	47	|O
the	48	51	|O
three	52	57	|O
charges	58	65	|O
of	66	68	|O
DL	69	71	|B-IUPAC
-	71	72	|I-IUPAC
tetrazol	72	80	|I-IUPAC
-	80	81	|I-IUPAC
5	81	82	|I-IUPAC
-	82	83	|I-IUPAC
ylglycine	83	92	|I-IUPAC
(	93	94	|O
5	94	95	|O
)	95	96	|O
could	97	102	|O
be	103	105	|O
viewed	106	112	|O
as	113	115	|O
similar	116	123	|O
to	124	126	|O
those	127	132	|O
found	133	138	|O
in	139	141	|O
certain	142	149	|O
conformations	150	163	|O
of	164	166	|O
the	167	170	|O
two	171	174	|O
excitatory	175	185	|O
amino	186	191	|O
acids	192	197	|O
(	198	199	|O
EAAs	199	203	|O
)	203	204	|O
-	204	205	|O
-	205	206	|O
aspartic	206	214	|O
and	215	218	|O
glutamic	219	227	|O
acids	228	233	|O
.	233	234	|O
Given	235	240	|O
significant	241	252	|O
binding	253	260	|O
to	261	263	|O
one	264	267	|O
or	268	270	|O
more	271	275	|O
EAA	276	279	|O
receptors	280	289	|O
,	289	290	|O
5	291	292	|O
would	293	298	|O
offer	299	304	|O
unique	305	311	|O
modeling	312	320	|O
and	321	324	|O
perhaps	325	332	|O
biological	333	343	|O
opportunities	344	357	|O
.	357	358	|O
We	359	361	|O
have	362	366	|O
previously	367	377	|O
shown	378	383	|O
it	384	386	|O
to	387	389	|O
be	390	392	|O
the	393	396	|O
most	397	401	|O
potent	402	408	|O
NMDA	409	413	|O
agonist	414	421	|O
known	422	427	|O
,	427	428	|O
with	429	433	|O
a	434	435	|O
unique	436	442	|O
and	443	446	|O
marked	447	453	|O
in	454	456	|O
vitro	457	462	|O
neutrotoxicity	463	477	|O
at	478	480	|O
depolarizing	481	493	|O
concentrations	494	508	|O
.	508	509	|O
Now	510	513	|O
we	514	516	|O
report	517	523	|O
the	524	527	|O
details	528	535	|O
required	536	544	|O
for	545	548	|O
its	549	552	|O
synthesis	553	562	|O
,	562	563	|O
together	564	572	|O
with	573	577	|O
its	578	581	|O
potency	582	589	|O
and	590	593	|O
efficacy	594	602	|O
in	603	605	|O
two	606	609	|O
assays	610	616	|O
of	617	619	|O
functional	620	630	|O
activation	631	641	|O
of	642	644	|O
the	645	648	|O
NMDA	649	653	|O
receptor	654	662	|O
,	662	663	|O
namely	664	670	|O
agonist	671	678	|O
-	678	679	|O
influenced	679	689	|O
[	690	691	|O
3H	691	693	|O
]	693	694	|O
MK801	694	699	|O
binding	700	707	|O
and	708	711	|O
agonist	712	719	|O
-	719	720	|O
induced	720	727	|O
release	728	735	|O
of	736	738	|O
the	739	742	|O
neurotransmitter	743	759	|O
[	760	761	|O
3H	761	763	|O
]	763	764	|O
-	764	765	|O
norepinephrine	765	779	|O
from	780	784	|O
brain	785	790	|O
slices	791	797	|O
.	797	798	|O
In	799	801	|O
both	802	806	|O
these	807	812	|O
assays	813	819	|O
DL	820	822	|B-IUPAC
-	822	823	|I-IUPAC
tetrazol	823	831	|I-IUPAC
-	831	832	|I-IUPAC
5	832	833	|I-IUPAC
-	833	834	|I-IUPAC
ylglycine	834	843	|I-IUPAC
proved	844	850	|O
to	851	853	|O
be	854	856	|O
more	857	861	|O
potent	862	868	|O
and	869	872	|O
efficacious	873	884	|O
than	885	889	|O
NMDA	890	894	|O
and	895	898	|O
cis	899	902	|O
-	902	903	|O
methanoglutamate	903	919	|O
.	919	920	|O
It	921	923	|O
was	924	927	|O
more	928	932	|O
potent	933	939	|O
than	940	944	|O
,	944	945	|O
and	946	949	|O
equally	950	957	|O
efficacious	958	969	|O
to	970	972	|O
,	972	973	|O
L	974	975	|O
-	975	976	|O
glutamate	976	985	|O
in	986	988	|O
[	989	990	|O
3H	990	992	|O
]	992	993	|O
MK801	993	998	|O
binding	999	1006	|O
.	1006	1007	|O
The	1008	1011	|O
structural	1012	1022	|O
features	1023	1031	|O
of	1032	1034	|O
5	1035	1036	|O
may	1037	1040	|O
well	1041	1045	|O
reflect	1046	1053	|O
optimal	1054	1061	|O
agonist	1062	1069	|O
interaction	1070	1081	|O
at	1082	1084	|O
the	1085	1088	|O
NMDA	1089	1093	|O
receptor	1094	1102	|O
site	1103	1107	|O
.	1107	1108	|O
(	1109	1110	|O
We	1110	1112	|O
considered	1113	1123	|O
the	1124	1127	|O
possibility	1128	1139	|O
that	1140	1144	|O
some	1145	1149	|O
decarboxylation	1150	1165	|O
of	1166	1168	|O
DL	1169	1171	|B-IUPAC
-	1171	1172	|I-IUPAC
tetrazol	1172	1180	|I-IUPAC
-	1180	1181	|I-IUPAC
5	1181	1182	|I-IUPAC
-	1182	1183	|I-IUPAC
ylglycine	1183	1192	|I-IUPAC
may	1193	1196	|O
have	1197	1201	|O
occurred	1202	1210	|O
during	1211	1217	|O
testing	1218	1225	|O
.	1225	1226	|O
This	1227	1231	|O
would	1232	1237	|O
give	1238	1242	|O
5	1243	1244	|B-IUPAC
-	1244	1245	|I-IUPAC
(	1245	1246	|I-IUPAC
aminomethyl	1246	1257	|I-IUPAC
)	1257	1258	|I-IUPAC
tetrazole	1258	1267	|I-IUPAC
(	1268	1269	|O
13	1269	1271	|O
)	1271	1272	|O
,	1272	1273	|O
the	1274	1277	|O
tetrazole	1278	1287	|O
acid	1288	1292	|O
analog	1293	1299	|O
of	1300	1302	|O
glycine	1303	1310	|O
;	1310	1311	|O
and	1312	1315	|O
glycine	1316	1323	|O
is	1324	1326	|O
involved	1327	1335	|O
in	1336	1338	|O
NMDA	1339	1343	|O
receptor	1344	1352	|O
activation	1353	1363	|O
.	1363	1364	|O
Compound	1365	1373	|O
13	1374	1376	|O
does	1377	1381	|O
not	1382	1385	|O
affect	1386	1392	|O
[	1393	1394	|O
3H	1394	1396	|O
]	1396	1397	|O
glycine	1397	1404	|O
binding	1405	1412	|O
at	1413	1415	|O
the	1416	1419	|O
strychnine	1420	1430	|O
-	1430	1431	|O
insensitive	1431	1442	|O
glycine	1443	1450	|O
binding	1451	1458	|O
site	1459	1463	|O
,	1463	1464	|O
and	1465	1468	|O
[	1469	1470	|O
3H	1470	1472	|O
]	1472	1473	|O
MK801	1473	1478	|O
binding	1479	1486	|O
studies	1487	1494	|O
showed	1495	1501	|O
that	1502	1506	|O
the	1507	1510	|O
(	1511	1512	|B-IUPAC
aminomethyl	1512	1523	|I-IUPAC
)	1523	1524	|I-IUPAC
-	1524	1525	|I-IUPAC
tetrazole	1525	1534	|I-IUPAC
,	1534	1535	|O
even	1536	1540	|O
if	1541	1543	|O
is	1544	1546	|O
formed	1547	1553	|O
,	1553	1554	|O
would	1555	1560	|O
probably	1561	1569	|O
have	1570	1574	|O
no	1575	1577	|O
effect	1578	1584	|O
on	1585	1587	|O
the	1588	1591	|O
activity	1592	1600	|O
of	1601	1603	|O
tetrazol	1604	1612	|B-IUPAC
-	1612	1613	|I-IUPAC
5	1613	1614	|I-IUPAC
-	1614	1615	|I-IUPAC
ylglycine	1615	1624	|I-IUPAC
at	1625	1627	|O
the	1628	1631	|O
NMDA	1632	1636	|O
receptor	1637	1645	|O
.	1645	1646	|O

### abstracts3111.txt
The	0	3	|O
thermal	4	11	|O
Fischer	12	19	|O
indolization	20	32	|O
of	33	35	|O
hydrazones	36	46	|O
resulting	47	56	|O
from	57	61	|O
4	62	63	|B-IUPAC
-	63	64	|I-IUPAC
hydrazino	64	73	|I-IUPAC
-	73	74	|I-IUPAC
5	74	75	|I-IUPAC
-	75	76	|I-IUPAC
methyl	76	82	|I-IUPAC
-	82	83	|I-IUPAC
1H	83	85	|I-IUPAC
-	85	86	|I-IUPAC
pyridin	86	93	|I-IUPAC
-	93	94	|I-IUPAC
2	94	95	|I-IUPAC
-	95	96	|I-IUPAC
one	96	99	|I-IUPAC
and	100	103	|O
various	104	111	|O
beta	112	116	|B-PARTIUPAC
-	116	117	|I-PARTIUPAC
and	118	121	|O
alpha	122	127	|B-IUPAC
-	127	128	|I-IUPAC
tetralones	128	138	|I-IUPAC
led	139	142	|O
to	143	145	|O
4	146	147	|B-IUPAC
-	147	148	|I-IUPAC
methyl	148	154	|I-IUPAC
-	154	155	|I-IUPAC
6,7	155	158	|I-IUPAC
-	158	159	|I-IUPAC
dihydro	159	166	|I-IUPAC
-	166	167	|I-IUPAC
2H	167	169	|I-IUPAC
,	169	170	|I-IUPAC
5H	170	172	|I-IUPAC
-	172	173	|I-IUPAC
pyrido	173	179	|I-IUPAC
[	179	180	|I-IUPAC
4,3	180	183	|I-IUPAC
-	183	184	|I-IUPAC
b	185	186	|I-IUPAC
]	186	187	|I-IUPAC
benzo	187	192	|I-IUPAC
[	192	193	|I-IUPAC
e	193	194	|I-IUPAC
]	194	195	|I-IUPAC
indol	195	200	|I-IUPAC
-	200	201	|I-IUPAC
1	201	202	|I-IUPAC
-	202	203	|I-IUPAC
ones	203	207	|I-IUPAC
and	208	211	|O
4	212	213	|B-IUPAC
-	213	214	|I-IUPAC
methyl	214	220	|I-IUPAC
-	220	221	|I-IUPAC
11	221	223	|I-IUPAC
-	223	224	|I-IUPAC
dihydro	224	231	|I-IUPAC
-	231	232	|I-IUPAC
2H	232	234	|I-IUPAC
,	234	235	|I-IUPAC
5H	235	237	|I-IUPAC
-	237	238	|I-IUPAC
pyrido	238	244	|I-IUPAC
[	244	245	|I-IUPAC
4,3	245	248	|I-IUPAC
-	248	249	|I-IUPAC
b	250	251	|I-IUPAC
]	251	252	|I-IUPAC
benzo	252	257	|I-IUPAC
[	257	258	|I-IUPAC
g	258	259	|I-IUPAC
]	259	260	|I-IUPAC
indol	260	265	|I-IUPAC
-	265	266	|I-IUPAC
1	266	267	|I-IUPAC
-	267	268	|I-IUPAC
ones	268	272	|I-IUPAC
,	272	273	|O
respectively	274	286	|O
.	286	287	|O
After	288	293	|O
aromatization	294	307	|O
,	307	308	|O
these	309	314	|O
compounds	315	324	|O
were	325	329	|O
transformed	330	341	|O
by	342	344	|O
phosphorus	345	355	|O
oxychloride	356	367	|O
,	367	368	|O
giving	369	375	|O
1	376	377	|B-PARTIUPAC
-	377	378	|I-PARTIUPAC
chloro	378	384	|I-PARTIUPAC
-	384	385	|I-PARTIUPAC
4	385	386	|I-PARTIUPAC
-	386	387	|I-PARTIUPAC
methyl	387	393	|I-PARTIUPAC
-	393	394	|I-PARTIUPAC
5H	394	396	|I-PARTIUPAC
-	396	397	|I-PARTIUPAC
pyrido	397	403	|I-PARTIUPAC
[	403	404	|I-PARTIUPAC
4,3	404	407	|I-PARTIUPAC
-	407	408	|I-PARTIUPAC
b	409	410	|I-PARTIUPAC
]	410	411	|I-PARTIUPAC
benzo	411	416	|I-PARTIUPAC
[	416	417	|I-PARTIUPAC
e	417	418	|I-PARTIUPAC
]	418	419	|I-PARTIUPAC
-	419	420	|I-PARTIUPAC
and	421	424	|O
-	425	426	|B-PARTIUPAC
benzo	426	431	|I-PARTIUPAC
[	431	432	|I-PARTIUPAC
g	432	433	|I-PARTIUPAC
]	433	434	|I-PARTIUPAC
indoles	434	441	|I-PARTIUPAC
which	442	447	|O
were	448	452	|O
substituted	453	464	|O
by	465	467	|O
[	468	469	|B-IUPAC
(	469	470	|I-IUPAC
dialkylamino	470	482	|I-IUPAC
)	482	483	|I-IUPAC
alkyl	483	488	|I-IUPAC
]	488	489	|I-IUPAC
amines	489	495	|I-IUPAC
.	495	496	|O
The	497	500	|O
resulting	501	510	|O
1	511	512	|B-PARTIUPAC
-	512	513	|I-PARTIUPAC
[	513	514	|I-PARTIUPAC
[	514	515	|I-PARTIUPAC
(	515	516	|I-PARTIUPAC
dialkylamino	516	528	|I-PARTIUPAC
)	528	529	|I-PARTIUPAC
alkyl	529	534	|I-PARTIUPAC
]	534	535	|I-PARTIUPAC
amino	535	540	|I-PARTIUPAC
]	540	541	|I-PARTIUPAC
-	541	542	|I-PARTIUPAC
4	542	543	|I-PARTIUPAC
-	543	544	|I-PARTIUPAC
methyl	544	550	|I-PARTIUPAC
-	550	551	|I-PARTIUPAC
5H	551	553	|I-PARTIUPAC
-	553	554	|I-PARTIUPAC
pyrido	554	560	|I-PARTIUPAC
-	560	561	|I-PARTIUPAC
[	562	563	|I-PARTIUPAC
4,3	563	566	|I-PARTIUPAC
-	566	567	|I-PARTIUPAC
b	567	568	|I-PARTIUPAC
]	568	569	|I-PARTIUPAC
benzo	569	574	|I-PARTIUPAC
[	574	575	|I-PARTIUPAC
e	575	576	|I-PARTIUPAC
]	576	577	|I-PARTIUPAC
-	577	578	|I-PARTIUPAC
and	579	582	|O
-	583	584	|B-PARTIUPAC
benzo	584	589	|I-PARTIUPAC
[	589	590	|I-PARTIUPAC
g	590	591	|I-PARTIUPAC
]	591	592	|I-PARTIUPAC
indoles	592	599	|I-PARTIUPAC
,	599	600	|O
as	601	603	|O
well	604	608	|O
as	609	611	|O
hydroxy	612	619	|O
derivatives	620	631	|O
obtained	632	640	|O
by	641	643	|O
demethylation	644	657	|O
of	658	660	|O
methoxylated	661	673	|O
compounds	674	683	|O
with	684	688	|O
hydrobromic	689	700	|O
acid	701	705	|O
,	705	706	|O
were	707	711	|O
tested	712	718	|O
for	719	722	|O
antitumor	723	732	|O
activity	733	741	|O
in	742	744	|O
vitro	745	750	|O
(	751	752	|O
leukemic	752	760	|O
and	761	764	|O
solid	765	770	|O
tumor	771	776	|O
cells	777	782	|O
)	782	783	|O
and	784	787	|O
in	788	790	|O
vivo	791	795	|O
on	796	798	|O
various	799	806	|O
experimental	807	819	|O
tumor	820	825	|O
models	826	832	|O
using	833	838	|O
the	839	842	|O
standard	843	851	|O
NCI	852	855	|O
protocols	856	865	|O
.	865	866	|O
1	867	868	|B-IUPAC
-	868	869	|I-IUPAC
[	869	870	|I-IUPAC
[	870	871	|I-IUPAC
3	871	872	|I-IUPAC
-	872	873	|I-IUPAC
(	873	874	|I-IUPAC
Dialkylamino	874	886	|I-IUPAC
)	886	887	|I-IUPAC
propyl	887	893	|I-IUPAC
]	893	894	|I-IUPAC
-	894	895	|I-IUPAC
amino	895	900	|I-IUPAC
]	900	901	|I-IUPAC
-	901	902	|I-IUPAC
4	902	903	|I-IUPAC
-	903	904	|I-IUPAC
methyl	904	910	|I-IUPAC
-	910	911	|I-IUPAC
9	911	912	|I-IUPAC
-	912	913	|I-IUPAC
hydroxy	913	920	|I-IUPAC
-	920	921	|I-IUPAC
5H	921	923	|I-IUPAC
-	923	924	|I-IUPAC
pyrido	924	930	|I-IUPAC
[	930	931	|I-IUPAC
4,3	931	934	|I-IUPAC
-	934	935	|I-IUPAC
b	936	937	|I-IUPAC
]	937	938	|I-IUPAC
benzo	938	943	|I-IUPAC
[	943	944	|I-IUPAC
e	944	945	|I-IUPAC
]	945	946	|I-IUPAC
indoles	946	953	|I-IUPAC
appeared	954	962	|O
as	963	965	|O
a	966	967	|O
promising	968	977	|O
new	978	981	|O
class	982	987	|O
of	988	990	|O
antineoplastic	991	1005	|O
agents	1006	1012	|O
.	1012	1013	|O

### abstracts4637.txt
The	0	3	|O
determination	4	17	|O
of	18	20	|O
the	21	24	|O
structure	25	34	|O
and	35	38	|O
function	39	47	|O
of	48	50	|O
the	51	54	|O
sigma	55	60	|O
receptor	61	69	|O
subtypes	70	78	|O
and	79	82	|O
their	83	88	|O
physiological	89	102	|O
role	103	107	|O
(	107	108	|O
s	108	109	|O
)	109	110	|O
has	111	114	|O
been	115	119	|O
impeded	120	127	|O
by	128	130	|O
the	131	134	|O
unavailability	135	149	|O
of	150	152	|O
selective	153	162	|O
ligands	163	170	|O
.	170	171	|O
We	172	174	|O
have	175	179	|O
developed	180	189	|O
a	190	191	|O
new	192	195	|O
class	196	201	|O
of	202	204	|O
sigma	205	210	|O
subtype	211	218	|O
selective	219	228	|O
receptor	229	237	|O
ligands	238	245	|O
that	246	250	|O
are	251	254	|O
(	255	256	|B-IUPAC
E	256	257	|I-IUPAC
)	257	258	|I-IUPAC
-	258	259	|I-IUPAC
8	259	260	|I-IUPAC
-	260	261	|I-IUPAC
benzylidene	261	272	|I-IUPAC
derivatives	273	284	|B-MODIFIER
of	285	287	|O
the	288	291	|O
synthetic	292	301	|O
opioid	302	308	|O
(	309	310	|B-PARTIUPAC
+	310	311	|I-PARTIUPAC
/	311	312	|I-PARTIUPAC
-	312	313	|I-PARTIUPAC
)	313	314	|I-PARTIUPAC
-	314	315	|I-PARTIUPAC
,	315	316	|O
(	317	318	|B-PARTIUPAC
+	318	319	|I-PARTIUPAC
)	319	320	|I-PARTIUPAC
-	320	321	|I-PARTIUPAC
,	321	322	|O
and	323	326	|O
(	327	328	|B-IUPAC
-	328	329	|I-IUPAC
)	329	330	|I-IUPAC
-	330	331	|I-IUPAC
2	331	332	|I-IUPAC
-	332	333	|I-IUPAC
methyl	333	339	|I-IUPAC
-	339	340	|I-IUPAC
5	340	341	|I-IUPAC
-	341	342	|I-IUPAC
(	342	343	|I-IUPAC
3	343	344	|I-IUPAC
-	344	345	|I-IUPAC
hydroxyphenyl	345	358	|I-IUPAC
)	358	359	|I-IUPAC
morphan	359	366	|I-IUPAC
-	366	367	|I-IUPAC
7	367	368	|I-IUPAC
-	368	369	|I-IUPAC
one	369	372	|I-IUPAC
(	373	374	|O
1	374	375	|O
)	375	376	|O
.	376	377	|O
The	378	381	|O
derivatives	382	393	|O
can	394	397	|O
be	398	400	|O
prepared	401	409	|O
by	410	412	|O
reaction	413	421	|O
of	422	424	|O
1	425	426	|O
,	426	427	|O
(	428	429	|O
+	429	430	|O
)	430	431	|O
-	431	432	|O
1	432	433	|O
,	433	434	|O
and	435	438	|O
(	439	440	|O
-	440	441	|O
)	441	442	|O
-	442	443	|O
1	443	444	|O
with	445	449	|O
the	450	453	|O
appropriate	454	465	|O
benzaldehyde	466	478	|O
under	479	484	|O
Claisen	485	492	|O
-	492	493	|O
Schmidt	493	500	|O
conditions	501	511	|O
.	511	512	|O
Incorporation	513	526	|O
of	527	529	|O
substituted	530	541	|B-MODIFIER
(	542	543	|B-IUPAC
E	543	544	|I-IUPAC
)	544	545	|I-IUPAC
-	545	546	|I-IUPAC
8	546	547	|I-IUPAC
-	547	548	|I-IUPAC
benzylidene	548	559	|I-IUPAC
moieties	560	568	|B-MODIFIER
onto	569	573	|O
the	574	577	|O
7	578	579	|O
-	579	580	|O
keto	580	584	|O
precursor	585	594	|O
of	595	597	|O
(	598	599	|B-IUPAC
+	599	600	|I-IUPAC
)	600	601	|I-IUPAC
-	601	602	|I-IUPAC
2	602	603	|I-IUPAC
-	603	604	|I-IUPAC
methyl	604	610	|I-IUPAC
-	610	611	|I-IUPAC
5	611	612	|I-IUPAC
-	612	613	|I-IUPAC
(	613	614	|I-IUPAC
3	614	615	|I-IUPAC
-	615	616	|I-IUPAC
hydroxyphenyl	616	629	|I-IUPAC
)	629	630	|I-IUPAC
morphan	630	637	|I-IUPAC
,	637	638	|O
(	639	640	|O
+	640	641	|O
)	641	642	|O
-	642	643	|O
1	643	644	|O
,	644	645	|O
produces	646	654	|O
compounds	655	664	|O
(	665	666	|O
-	666	667	|O
)	667	668	|O
-	668	669	|O
2	669	670	|O
through	671	678	|O
(	679	680	|O
-	680	681	|O
)	681	682	|O
-	682	683	|O
7	683	684	|O
(	685	686	|O
5.8-32.0	686	694	|O
nM	695	697	|O
,	697	698	|O
sigma	699	704	|O
1	705	706	|O
)	706	707	|O
,	707	708	|O
which	709	714	|O
have	715	719	|O
between	720	727	|O
a	728	729	|O
25	730	732	|O
-	732	733	|O
and	734	737	|O
131	738	741	|O
-	741	742	|O
fold	742	746	|O
increase	747	755	|O
in	756	758	|O
affinity	759	767	|O
for	768	771	|O
the	772	775	|O
sigma	776	781	|O
1	782	783	|O
receptor	784	792	|O
subtype	793	800	|O
relative	801	809	|O
to	810	812	|O
the	813	816	|O
keto	817	821	|O
precursor	822	831	|O
(	832	833	|O
+	833	834	|O
)	834	835	|O
-	835	836	|O
1	836	837	|O
(	838	839	|O
Ki	839	841	|O
=	842	843	|O
762	844	847	|O
nM	848	850	|O
,	850	851	|O
sigma	852	857	|O
1	858	859	|O
)	859	860	|O
.	860	861	|O
Compound	862	870	|O
(	871	872	|O
-	872	873	|O
)	873	874	|O
-	874	875	|O
2	875	876	|O
is	877	879	|O
the	880	883	|O
most	884	888	|O
selective	889	898	|O
of	899	901	|O
this	902	906	|O
group	907	912	|O
(	913	914	|O
16	914	916	|O
-	916	917	|O
fold	917	921	|O
)	921	922	|O
for	923	926	|O
the	927	930	|O
sigma	931	936	|O
1	937	938	|O
subtype	939	946	|O
versus	947	953	|O
sigma	954	959	|O
2	960	961	|O
.	961	962	|O
Substitution	963	975	|O
of	976	978	|O
an	979	981	|O
(	982	983	|B-IUPAC
E	983	984	|I-IUPAC
)	984	985	|I-IUPAC
-	985	986	|I-IUPAC
8	986	987	|I-IUPAC
-	987	988	|I-IUPAC
benzylidene	988	999	|I-IUPAC
moiety	1000	1006	|B-MODIFIER
onto	1007	1011	|O
the	1012	1015	|O
7	1016	1017	|B-MODIFIER
-	1017	1018	|I-MODIFIER
keto	1018	1022	|I-MODIFIER
precursor	1023	1032	|I-MODIFIER
of	1033	1035	|O
(	1036	1037	|B-IUPAC
-	1037	1038	|I-IUPAC
)	1038	1039	|I-IUPAC
-	1039	1040	|I-IUPAC
2	1040	1041	|I-IUPAC
-	1041	1042	|I-IUPAC
methyl	1042	1048	|I-IUPAC
-	1048	1049	|I-IUPAC
5	1049	1050	|I-IUPAC
-	1050	1051	|I-IUPAC
(	1051	1052	|I-IUPAC
3	1052	1053	|I-IUPAC
-	1053	1054	|I-IUPAC
hydroxyphenyl	1054	1067	|I-IUPAC
)	1067	1068	|I-IUPAC
morphan	1068	1075	|I-IUPAC
,	1075	1076	|O
(	1077	1078	|O
-	1078	1079	|O
)	1079	1080	|O
-	1080	1081	|O
1	1081	1082	|O
,	1082	1083	|O
produces	1084	1092	|O
compounds	1093	1102	|O
(	1103	1104	|O
+	1104	1105	|O
)	1105	1106	|O
-	1106	1107	|O
2	1107	1108	|O
-	1108	1109	|O
(	1109	1110	|O
+	1110	1111	|O
)	1111	1112	|O
-	1112	1113	|O
9	1113	1114	|O
(	1115	1116	|O
6.4-52.6	1116	1124	|O
nM	1125	1127	|O
,	1127	1128	|O
sigma	1129	1134	|O
2	1135	1136	|O
)	1136	1137	|O
,	1137	1138	|O
which	1139	1144	|O
have	1145	1149	|O
at	1150	1152	|O
least	1153	1158	|O
a	1159	1160	|O
475-3906	1161	1169	|O
-	1169	1170	|O
fold	1170	1174	|O
increase	1175	1183	|O
in	1184	1186	|O
affinity	1187	1195	|O
for	1196	1199	|O
the	1200	1203	|O
sigma	1204	1209	|O
2	1210	1211	|O
receptor	1212	1220	|O
subtype	1221	1228	|O
relative	1229	1237	|O
to	1238	1240	|O
the	1241	1244	|O
keto	1245	1249	|O
precursor	1250	1259	|O
(	1260	1261	|O
-	1261	1262	|O
)	1262	1263	|O
-	1263	1264	|O
1	1264	1265	|O
(	1266	1267	|O
Ki	1267	1269	|O
=	1270	1271	|O
25	1272	1274	|O
x	1275	1276	|O
10	1277	1279	|O
(	1279	1280	|O
3	1280	1281	|O
)	1281	1282	|O
nM	1283	1285	|O
)	1285	1286	|O
.	1286	1287	|O
This	1288	1292	|O
enhancement	1293	1304	|O
of	1305	1307	|O
sigma	1308	1313	|O
2	1314	1315	|O
receptor	1316	1324	|O
affinity	1325	1333	|O
is	1334	1336	|O
accompanied	1337	1348	|O
by	1349	1351	|O
substantial	1352	1363	|O
selectivity	1364	1375	|O
of	1376	1378	|O
all	1379	1382	|O
of	1383	1385	|O
these	1386	1391	|O
dextrorotatory	1392	1406	|O
products	1407	1415	|O
for	1416	1419	|O
the	1420	1423	|O
sigma	1424	1429	|O
2	1430	1431	|O
relative	1432	1440	|O
to	1441	1443	|O
the	1444	1447	|O
sigma	1448	1453	|O
1	1454	1455	|O
subtype	1456	1463	|O
(	1464	1465	|O
32-238	1465	1471	|O
-	1471	1472	|O
fold	1472	1476	|O
)	1476	1477	|O
,	1477	1478	|O
and	1479	1482	|O
thus	1483	1487	|O
,	1487	1488	|O
they	1489	1493	|O
are	1494	1497	|O
among	1498	1503	|O
the	1504	1507	|O
most	1508	1512	|O
sigma	1513	1518	|O
2	1519	1520	|O
selective	1521	1530	|O
compounds	1531	1540	|O
currently	1541	1550	|O
known	1551	1556	|O
.	1556	1557	|O
Furthermore	1558	1569	|O
,	1569	1570	|O
the	1571	1574	|O
sigma	1575	1580	|O
1	1581	1582	|O
subtype	1583	1590	|O
is	1591	1593	|O
highly	1594	1600	|O
enantioselective	1601	1617	|O
for	1618	1621	|O
the	1622	1625	|O
levorotatory	1626	1638	|O
isomers	1639	1646	|O
,	1646	1647	|O
(	1648	1649	|O
-	1649	1650	|O
)	1650	1651	|O
-	1651	1652	|O
2	1652	1653	|O
-	1653	1654	|O
(	1654	1655	|O
-	1655	1656	|O
)	1656	1657	|O
-	1657	1658	|O
7	1658	1659	|O
(	1660	1661	|O
41-1034	1661	1668	|O
-	1668	1669	|O
fold	1669	1673	|O
)	1673	1674	|O
,	1674	1675	|O
whereas	1676	1683	|O
the	1684	1687	|O
sigma	1688	1693	|O
2	1694	1695	|O
subtype	1696	1703	|O
is	1704	1706	|O
only	1707	1711	|O
somewhat	1712	1720	|O
enantioselective	1721	1737	|O
for	1738	1741	|O
the	1742	1745	|O
dextrorotatory	1746	1760	|O
isomers	1761	1768	|O
,	1768	1769	|O
(	1770	1771	|O
+	1771	1772	|O
)	1772	1773	|O
-	1773	1774	|O
2	1774	1775	|O
-	1775	1776	|O
(	1776	1777	|O
+	1777	1778	|O
)	1778	1779	|O
-	1779	1780	|O
7	1780	1781	|O
(	1782	1783	|O
2.6-9.3	1783	1790	|O
-	1790	1791	|O
fold	1791	1795	|O
)	1795	1796	|O
.	1796	1797	|O
All	1798	1801	|O
of	1802	1804	|O
these	1805	1810	|O
derivatives	1811	1822	|O
retain	1823	1829	|O
substantial	1830	1841	|O
affinity	1842	1850	|O
for	1851	1854	|O
the	1855	1858	|O
mu	1859	1861	|O
opioid	1862	1868	|O
receptor	1869	1877	|O
.	1877	1878	|O
Despite	1879	1886	|O
the	1887	1890	|O
high	1891	1895	|O
affinity	1896	1904	|O
of	1905	1907	|O
the	1908	1911	|O
dextrorotatory	1912	1926	|O
derivatives	1927	1938	|O
for	1939	1942	|O
the	1943	1946	|O
mu	1947	1949	|O
opioid	1950	1956	|O
receptor	1957	1965	|O
,	1965	1966	|O
the	1967	1970	|O
high	1971	1975	|O
affinity	1976	1984	|O
and	1985	1988	|O
selectivity	1989	2000	|O
for	2001	2004	|O
sigma	2005	2010	|O
2	2011	2012	|O
over	2013	2017	|O
sigma	2018	2023	|O
1	2024	2025	|O
sites	2026	2031	|O
will	2032	2036	|O
surely	2037	2043	|O
prove	2044	2049	|O
beneficial	2050	2060	|O
as	2061	2063	|O
tools	2064	2069	|O
for	2070	2073	|O
the	2074	2077	|O
delineation	2078	2089	|O
of	2090	2092	|O
the	2093	2096	|O
function	2097	2105	|O
and	2106	2109	|O
physiological	2110	2123	|O
role	2124	2128	|O
of	2129	2131	|O
sigma	2132	2137	|O
2	2138	2139	|O
receptors	2140	2149	|O
.	2149	2150	|O

### abstracts3430.txt
Some	0	4	|O
novel	5	10	|O
6	11	12	|B-IUPAC
-	12	13	|I-IUPAC
fluoro	13	19	|I-IUPAC
-	19	20	|I-IUPAC
7	20	21	|I-IUPAC
-	21	22	|O
substituted	22	33	|B-MODIFIER
-	33	34	|O
1,4	34	37	|B-IUPAC
-	37	38	|I-IUPAC
dihydro	38	45	|I-IUPAC
-	45	46	|I-IUPAC
4	46	47	|I-IUPAC
-	47	48	|I-IUPAC
oxoquinoline	48	60	|I-IUPAC
-	60	61	|I-IUPAC
3	61	62	|I-IUPAC
-	62	63	|I-IUPAC
carboxylic	63	73	|I-IUPAC
acids	74	79	|I-IUPAC
have	80	84	|O
been	85	89	|O
prepared	90	98	|O
.	98	99	|O
At	100	102	|O
the	103	106	|O
N	107	108	|O
-	108	109	|O
1	109	110	|O
position	111	119	|O
"	120	121	|O
standard	121	129	|O
"	129	130	|O
substitution	131	143	|O
was	144	147	|O
employed	148	156	|O
with	157	161	|O
the	162	165	|O
ethyl	166	171	|B-IUPAC
,	171	172	|O
cyclopropyl	173	184	|B-IUPAC
,	184	185	|O
and	186	189	|O
p	190	191	|B-IUPAC
-	191	192	|I-IUPAC
fluorophenyl	192	204	|I-IUPAC
groups	205	211	|B-MODIFIER
being	212	217	|O
used	218	222	|O
.	222	223	|O
At	224	226	|O
C	227	228	|O
-	228	229	|O
7	229	230	|O
the	231	234	|O
introduction	235	247	|O
of	248	250	|O
some	251	255	|O
novel	256	261	|O
piperazines	262	273	|O
was	274	277	|O
made	278	282	|O
.	282	283	|O
Most	284	288	|O
notably	289	296	|O
,	296	297	|O
2	298	299	|B-IUPAC
-	299	300	|I-IUPAC
(	300	301	|I-IUPAC
fluoromethyl	301	313	|I-IUPAC
)	313	314	|I-IUPAC
piperazine	314	324	|I-IUPAC
(	325	326	|O
10	326	328	|O
)	328	329	|O
and	330	333	|O
hexahydro	334	343	|B-IUPAC
-	343	344	|I-IUPAC
6	344	345	|I-IUPAC
-	345	346	|I-IUPAC
fluoro	346	352	|I-IUPAC
-	352	353	|I-IUPAC
1H	353	355	|I-IUPAC
-	355	356	|I-IUPAC
1,4	356	359	|I-IUPAC
-	359	360	|I-IUPAC
diazepine	360	369	|I-IUPAC
(	370	371	|O
16	371	373	|O
,	373	374	|O
fluorohomopiperazine	375	395	|O
)	395	396	|O
at	397	399	|O
the	400	403	|O
quinolone	404	413	|O
C	414	415	|O
-	415	416	|O
7	416	417	|O
position	418	426	|O
produced	427	435	|O
products	436	444	|O
with	445	449	|O
similar	450	457	|O
in	458	460	|O
vitro	461	466	|O
antibacterial	467	480	|O
activity	481	489	|O
as	490	492	|O
the	493	496	|O
ciprofloxacin	497	510	|O
reference	511	520	|O
.	520	521	|O
The	522	525	|O
in	526	528	|O
vivo	529	533	|O
efficacy	534	542	|O
of	543	545	|O
1	546	547	|B-IUPAC
-	547	548	|I-IUPAC
cyclopropyl	548	559	|I-IUPAC
-	559	560	|I-IUPAC
6	560	561	|I-IUPAC
-	561	562	|I-IUPAC
fluoro	562	568	|I-IUPAC
-	568	569	|I-IUPAC
7	569	570	|I-IUPAC
-	570	571	|I-IUPAC
[	571	572	|I-IUPAC
3	572	573	|I-IUPAC
-	573	574	|I-IUPAC
(	574	575	|I-IUPAC
fluoromethyl	575	587	|I-IUPAC
)	587	588	|I-IUPAC
piperazinyl	588	599	|I-IUPAC
]	599	600	|I-IUPAC
-	600	601	|I-IUPAC
1,4	601	604	|I-IUPAC
-	604	605	|I-IUPAC
dihydro	605	612	|I-IUPAC
-	612	613	|I-IUPAC
4	613	614	|I-IUPAC
-	614	615	|I-IUPAC
oxoquinoline	616	628	|I-IUPAC
-	628	629	|I-IUPAC
3	629	630	|I-IUPAC
-	630	631	|I-IUPAC
carboxylic	631	641	|I-IUPAC
acid	642	646	|I-IUPAC
(	647	648	|O
20	648	650	|O
)	650	651	|O
was	652	655	|O
excellent	656	665	|O
with	666	670	|O
better	671	677	|O
oral	678	682	|O
absorption	683	693	|O
than	694	698	|O
ciprofloxacin	699	712	|O
(	713	714	|O
2	714	715	|O
)	715	716	|O
.	716	717	|O

### abstracts3745.txt
In	0	2	|O
a	3	4	|O
continuing	5	15	|O
effort	16	22	|O
to	23	25	|O
design	26	32	|O
small	33	38	|O
-	38	39	|O
molecule	39	47	|O
inhibitors	48	58	|O
of	59	61	|O
dihydrofolate	62	75	|O
reductase	76	85	|O
(	86	87	|O
DHFR	87	91	|O
)	91	92	|O
that	93	97	|O
combine	98	105	|O
the	106	109	|O
enzyme	110	116	|O
-	116	117	|O
binding	117	124	|O
selectivity	125	136	|O
of	137	139	|O
2,4	140	143	|B-IUPAC
-	143	144	|I-IUPAC
diamino	144	151	|I-IUPAC
-	151	152	|I-IUPAC
5	152	153	|I-IUPAC
-	153	154	|I-IUPAC
(	154	155	|I-IUPAC
3'	155	157	|I-IUPAC
,	157	158	|I-IUPAC
4'	158	160	|I-IUPAC
,	160	161	|I-IUPAC
5'	161	163	|I-IUPAC
-	163	164	|I-IUPAC
trimethoxybenzyl	164	180	|I-IUPAC
)	180	181	|I-IUPAC
pyrimidine	181	191	|I-IUPAC
(	192	193	|O
trimethoprim	193	205	|O
,	205	206	|O
TMP	207	210	|O
)	210	211	|O
with	212	216	|O
the	217	220	|O
potency	221	228	|O
of	229	231	|O
2,4	232	235	|B-IUPAC
-	235	236	|I-IUPAC
diamino	236	243	|I-IUPAC
-	243	244	|I-IUPAC
5	244	245	|I-IUPAC
-	245	246	|I-IUPAC
methyl	246	252	|I-IUPAC
-	252	253	|I-IUPAC
6	253	254	|I-IUPAC
-	254	255	|I-IUPAC
(	255	256	|I-IUPAC
2'	256	258	|I-IUPAC
,	258	259	|I-IUPAC
5'	259	261	|I-IUPAC
-	261	262	|I-IUPAC
dimethoxybenzyl	262	277	|I-IUPAC
)	277	278	|I-IUPAC
pyrido	278	284	|I-IUPAC
[	284	285	|I-IUPAC
2,3	285	288	|I-IUPAC
-	288	289	|I-IUPAC
d	289	290	|I-IUPAC
]	290	291	|I-IUPAC
pyrimidine	291	301	|I-IUPAC
(	302	303	|O
piritrexim	303	313	|O
,	313	314	|O
PTX	315	318	|O
)	318	319	|O
,	319	320	|O
seven	321	326	|O
previously	327	337	|O
undescribed	338	349	|O
2,4	350	353	|B-PARTIUPAC
-	353	354	|I-PARTIUPAC
diamino	354	361	|I-PARTIUPAC
-	361	362	|I-PARTIUPAC
5	362	363	|I-PARTIUPAC
-	363	364	|I-PARTIUPAC
[	364	365	|I-PARTIUPAC
2'	365	367	|I-PARTIUPAC
-	367	368	|I-PARTIUPAC
methoxy	368	375	|I-PARTIUPAC
-	375	376	|I-PARTIUPAC
5'	376	378	|I-PARTIUPAC
-	378	379	|I-PARTIUPAC
(	379	380	|O
substituted	380	391	|B-MODIFIER
benzyl	392	398	|B-PARTIUPAC
)	398	399	|O
]	399	400	|B-PARTIUPAC
pyrimidines	400	411	|I-PARTIUPAC
were	412	416	|O
synthesized	417	428	|O
in	429	431	|O
which	432	437	|O
the	438	441	|O
substituent	442	453	|O
at	454	456	|O
the	457	460	|O
5'	461	463	|O
-	463	464	|O
position	464	472	|O
was	473	476	|O
a	477	478	|O
carboxyphenyl	479	492	|B-IUPAC
group	493	498	|B-MODIFIER
linked	499	505	|O
to	506	508	|O
the	509	512	|O
benzyl	513	519	|B-IUPAC
moiety	520	526	|B-MODIFIER
by	527	529	|O
a	530	531	|O
bridge	532	538	|O
of	539	541	|O
two	542	545	|O
or	546	548	|O
four	549	553	|O
atoms	554	559	|O
in	560	562	|O
length	563	569	|O
.	569	570	|O
The	571	574	|O
new	575	578	|O
analogues	579	588	|O
were	589	593	|O
all	594	597	|O
obtained	598	606	|O
from	607	611	|O
2,4	612	615	|B-IUPAC
-	615	616	|I-IUPAC
diamino	616	623	|I-IUPAC
-	623	624	|I-IUPAC
5	624	625	|I-IUPAC
-	625	626	|I-IUPAC
(	626	627	|I-IUPAC
5'	627	629	|I-IUPAC
-	629	630	|I-IUPAC
iodo	630	634	|I-IUPAC
-	634	635	|I-IUPAC
2'	635	637	|I-IUPAC
-	637	638	|I-IUPAC
methoxybenzyl	638	651	|I-IUPAC
)	651	652	|I-IUPAC
pyrimidine	652	662	|I-IUPAC
via	663	666	|O
a	667	668	|O
Sonogashira	669	680	|O
reaction	681	689	|O
,	689	690	|O
followed	691	699	|O
,	699	700	|O
where	701	706	|O
appropriate	707	718	|O
,	718	719	|O
by	720	722	|O
catalytic	723	732	|O
hydrogenation	733	746	|O
.	746	747	|O
The	748	751	|O
new	752	755	|O
analogues	756	765	|O
were	766	770	|O
tested	771	777	|O
as	778	780	|O
inhibitors	781	791	|O
of	792	794	|O
DHFR	795	799	|O
from	800	804	|O
Pneumocystis	805	817	|O
carinii	818	825	|O
(	826	827	|O
Pc	827	829	|O
)	829	830	|O
,	830	831	|O
Toxoplasma	832	842	|O
gondii	843	849	|O
(	850	851	|O
Tg	851	853	|O
)	853	854	|O
,	854	855	|O
and	856	859	|O
Mycobacterium	860	873	|O
avium	874	879	|O
(	880	881	|O
Ma	881	883	|O
)	883	884	|O
,	884	885	|O
three	886	891	|O
life	892	896	|O
-	896	897	|O
threatening	897	908	|O
pathogens	909	918	|O
often	919	924	|O
found	925	930	|O
in	931	933	|O
AIDS	934	938	|O
patients	939	947	|O
and	948	951	|O
individuals	952	963	|O
whose	964	969	|O
immune	970	976	|O
system	977	983	|O
is	984	986	|O
impaired	987	995	|O
as	996	998	|O
a	999	1000	|O
result	1001	1007	|O
of	1008	1010	|O
treatment	1011	1020	|O
with	1021	1025	|O
immunosuppressive	1026	1043	|O
chemotherapy	1044	1056	|O
or	1057	1059	|O
radiation	1060	1069	|O
.	1069	1070	|O
The	1071	1074	|O
selectivity	1075	1086	|O
index	1087	1092	|O
(	1093	1094	|O
SI	1094	1096	|O
)	1096	1097	|O
of	1098	1100	|O
each	1101	1105	|O
compound	1106	1114	|O
was	1115	1118	|O
obtained	1119	1127	|O
by	1128	1130	|O
dividing	1131	1139	|O
its	1140	1143	|O
50%	1144	1147	|O
inhibitory	1148	1158	|O
concentration	1159	1172	|O
(	1173	1174	|O
IC	1174	1176	|O
(	1176	1177	|O
50	1177	1179	|O
)	1179	1180	|O
)	1180	1181	|O
against	1182	1189	|O
Pc	1190	1192	|O
,	1192	1193	|O
Tg	1194	1196	|O
,	1196	1197	|O
or	1198	1200	|O
Ma	1201	1203	|O
DHFR	1204	1208	|O
by	1209	1211	|O
its	1212	1215	|O
IC	1216	1218	|O
(	1218	1219	|O
50	1219	1221	|O
)	1221	1222	|O
against	1223	1230	|O
rat	1231	1234	|O
DHFR	1235	1239	|O
.	1239	1240	|O
2,4	1241	1244	|B-IUPAC
-	1244	1245	|I-IUPAC
Diamino	1245	1252	|I-IUPAC
-	1252	1253	|I-IUPAC
[	1253	1254	|I-IUPAC
2'	1254	1256	|I-IUPAC
-	1256	1257	|I-IUPAC
methoxy	1257	1264	|I-IUPAC
-	1264	1265	|I-IUPAC
5'	1265	1267	|I-IUPAC
-	1267	1268	|I-IUPAC
(	1268	1269	|I-IUPAC
3	1269	1270	|I-IUPAC
-	1270	1271	|I-IUPAC
carboxyphenyl	1271	1284	|I-IUPAC
)	1284	1285	|I-IUPAC
ethynylbenzyl	1285	1298	|I-IUPAC
]	1298	1299	|I-IUPAC
pyrimidine	1299	1309	|I-IUPAC
(	1310	1311	|O
28	1311	1313	|O
)	1313	1314	|O
,	1314	1315	|O
with	1316	1320	|O
an	1321	1323	|O
IC	1324	1326	|O
(	1326	1327	|O
50	1327	1329	|O
)	1329	1330	|O
of	1331	1333	|O
23	1334	1336	|O
nM	1337	1339	|O
and	1340	1343	|O
an	1344	1346	|O
SI	1347	1349	|O
of	1350	1352	|O
28	1353	1355	|O
in	1356	1358	|O
the	1359	1362	|O
Pc	1363	1365	|O
DHFR	1366	1370	|O
assay	1371	1376	|O
,	1376	1377	|O
had	1378	1381	|O
about	1382	1387	|O
the	1388	1391	|O
same	1392	1396	|O
potency	1397	1404	|O
as	1405	1407	|O
PTX	1408	1411	|O
and	1412	1415	|O
was	1416	1419	|O
520	1420	1423	|O
times	1424	1429	|O
more	1430	1434	|O
potent	1435	1441	|O
than	1442	1446	|O
TMP	1447	1450	|O
.	1450	1451	|O
As	1452	1454	|O
an	1455	1457	|O
inhibitor	1458	1467	|O
of	1468	1470	|O
Tg	1471	1473	|O
DHFR	1474	1478	|O
,	1478	1479	|O
28	1480	1482	|O
had	1483	1486	|O
an	1487	1489	|O
IC	1490	1492	|O
(	1492	1493	|O
50	1493	1495	|O
)	1495	1496	|O
of	1497	1499	|O
5.5	1500	1503	|O
nM	1504	1506	|O
(	1507	1508	|O
510	1508	1511	|O
-	1511	1512	|O
fold	1512	1516	|O
lower	1517	1522	|O
than	1523	1527	|O
that	1528	1532	|O
of	1533	1535	|O
TMP	1536	1539	|O
and	1540	1543	|O
similar	1544	1551	|O
to	1552	1554	|O
that	1555	1559	|O
of	1560	1562	|O
PTX	1563	1566	|O
)	1566	1567	|O
and	1568	1571	|O
an	1572	1574	|O
SI	1575	1577	|O
value	1578	1583	|O
of	1584	1586	|O
120	1587	1590	|O
(	1591	1592	|O
2	1592	1593	|O
-	1593	1594	|O
fold	1594	1598	|O
better	1599	1605	|O
than	1606	1610	|O
TMP	1611	1614	|O
and	1615	1618	|O
vastly	1619	1625	|O
superior	1626	1634	|O
to	1635	1637	|O
PTX	1638	1641	|O
)	1641	1642	|O
.	1642	1643	|O
Against	1644	1651	|O
Ma	1652	1654	|O
DHFR	1655	1659	|O
,	1659	1660	|O
28	1661	1663	|O
had	1664	1667	|O
IC	1668	1670	|O
(	1670	1671	|O
50	1671	1673	|O
)	1673	1674	|O
and	1675	1678	|O
SI	1679	1681	|O
values	1682	1688	|O
of	1689	1691	|O
1.5	1692	1695	|O
nM	1696	1698	|O
and	1699	1702	|O
430	1703	1706	|O
,	1706	1707	|O
respectively	1708	1720	|O
,	1720	1721	|O
compared	1722	1730	|O
with	1731	1735	|O
300	1736	1739	|O
nM	1740	1742	|O
and	1743	1746	|O
610	1747	1750	|O
for	1751	1754	|O
TMP	1755	1758	|O
.	1758	1759	|O
Although	1760	1768	|O
it	1769	1771	|O
had	1772	1775	|O
2.5	1776	1779	|O
-	1779	1780	|O
fold	1780	1784	|O
lower	1785	1790	|O
potency	1791	1798	|O
than	1799	1803	|O
28	1804	1806	|O
against	1807	1814	|O
Ma	1815	1817	|O
DHFR	1818	1822	|O
(	1823	1824	|O
IC	1824	1826	|O
(	1826	1827	|O
50	1827	1829	|O
)	1829	1830	|O
=	1831	1832	|O
3.7	1833	1836	|O
nM	1837	1839	|O
)	1839	1840	|O
and	1841	1844	|O
was	1845	1848	|O
substantially	1849	1862	|O
weaker	1863	1869	|O
against	1870	1877	|O
Pc	1878	1880	|O
and	1881	1884	|O
Tg	1885	1887	|O
DHFR	1888	1892	|O
,	1892	1893	|O
2,4	1894	1897	|B-IUPAC
-	1897	1898	|I-IUPAC
diamino	1898	1905	|I-IUPAC
-	1905	1906	|I-IUPAC
[	1906	1907	|I-IUPAC
2'	1907	1909	|I-IUPAC
-	1909	1910	|I-IUPAC
methoxy	1910	1917	|I-IUPAC
-	1917	1918	|I-IUPAC
5'	1918	1920	|I-IUPAC
-	1920	1921	|I-IUPAC
(	1921	1922	|I-IUPAC
4	1922	1923	|I-IUPAC
-	1923	1924	|I-IUPAC
carboxyphenyl	1924	1937	|I-IUPAC
)	1937	1938	|I-IUPAC
ethynylbenzyl	1938	1951	|I-IUPAC
]	1951	1952	|I-IUPAC
pyrimidine	1952	1962	|I-IUPAC
(	1963	1964	|O
29	1964	1966	|O
)	1966	1967	|O
,	1967	1968	|O
with	1969	1973	|O
the	1974	1977	|O
carboxy	1978	1985	|B-IUPAC
group	1986	1991	|B-MODIFIER
at	1992	1994	|O
the	1995	1998	|O
para	1999	2003	|O
rather	2004	2010	|O
than	2011	2015	|O
the	2016	2019	|O
meta	2020	2024	|O
position	2025	2033	|O
,	2033	2034	|O
displayed	2035	2044	|O
2200	2045	2049	|O
-	2049	2050	|O
fold	2050	2054	|O
selectivity	2055	2066	|O
against	2067	2074	|O
the	2075	2078	|O
Ma	2079	2081	|O
enzyme	2082	2088	|O
and	2089	2092	|O
was	2093	2096	|O
the	2097	2100	|O
most	2101	2105	|O
selective	2106	2115	|O
2,4	2116	2119	|B-IUPAC
-	2119	2120	|I-IUPAC
diamino	2120	2127	|I-IUPAC
-	2127	2128	|I-IUPAC
5	2128	2129	|I-IUPAC
-	2129	2130	|I-IUPAC
(	2130	2131	|O
5'	2131	2133	|B-MODIFIER
-	2133	2134	|O
substituted	2134	2145	|I-MODIFIER
benzyl	2146	2152	|B-PARTIUPAC
)	2152	2153	|O
pyrimidine	2153	2163	|B-PARTIUPAC
inhibitor	2164	2173	|O
of	2174	2176	|O
this	2177	2181	|O
enzyme	2182	2188	|O
we	2189	2191	|O
have	2192	2196	|O
encountered	2197	2208	|O
to	2209	2211	|O
date	2212	2216	|O
.	2216	2217	|O
Additional	2218	2228	|O
bioassay	2229	2237	|O
data	2238	2242	|O
for	2243	2246	|O
these	2247	2252	|O
compounds	2253	2262	|O
are	2263	2266	|O
also	2267	2271	|O
reported	2272	2280	|O
.	2280	2281	|O

### abstracts2126.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
2	12	13	|B-IUPAC
-	13	14	|I-IUPAC
(	14	15	|I-IUPAC
diethylamino	15	27	|I-IUPAC
)	27	28	|I-IUPAC
thieno1	28	35	|I-IUPAC
,	35	36	|I-IUPAC
3	36	37	|I-IUPAC
	37	38	|I-IUPAC
	38	39	|I-IUPAC
xazin	39	44	|I-IUPAC
-	44	45	|I-IUPAC
4	45	46	|I-IUPAC
-	46	47	|I-IUPAC
ones	47	51	|I-IUPAC
was	52	55	|O
synthesized	56	67	|O
and	68	71	|O
evaluated	72	81	|O
in	82	84	|O
vitro	85	90	|O
for	91	94	|O
inhibitory	95	105	|O
activity	106	114	|O
toward	115	121	|O
human	122	127	|O
leukocyte	128	137	|O
elastase	138	146	|O
(	147	148	|O
HLE	148	151	|O
)	151	152	|O
.	152	153	|O
The	154	157	|O
Gewald	158	164	|O
thiophene	165	174	|O
synthesis	175	184	|O
was	185	188	|O
utilized	189	197	|O
to	198	200	|O
obtain	201	207	|O
several	208	215	|O
ethyl	216	221	|B-IUPAC
2	222	223	|I-IUPAC
-	223	224	|I-IUPAC
aminothiophene	224	238	|I-IUPAC
-	238	239	|I-IUPAC
3	239	240	|I-IUPAC
-	240	241	|I-IUPAC
carboxylates	241	253	|I-IUPAC
.	253	254	|O
These	255	260	|O
precursors	261	271	|O
were	272	276	|O
subjected	277	286	|O
to	287	289	|O
a	290	291	|O
five	292	296	|O
-	296	297	|O
step	297	301	|O
route	302	307	|O
to	308	310	|O
obtain	311	317	|O
thieno2	318	325	|B-IUPAC
,	325	326	|I-IUPAC
3	326	327	|I-IUPAC
-	327	328	|I-IUPAC
d1	328	330	|I-IUPAC
,	330	331	|I-IUPAC
3	331	332	|I-IUPAC
	332	333	|I-IUPAC
	333	334	|I-IUPAC
xazin	334	339	|I-IUPAC
-	339	340	|I-IUPAC
4	340	341	|I-IUPAC
-	341	342	|I-IUPAC
ones	342	346	|I-IUPAC
bearing	347	354	|O
various	355	362	|O
substituents	363	375	|O
at	376	378	|O
positions	379	388	|O
5	389	390	|O
and	391	394	|O
6	395	396	|O
.	396	397	|O
Both	398	402	|O
thieno2	403	410	|B-IUPAC
,	410	411	|I-IUPAC
3	411	412	|I-IUPAC
-	412	413	|I-IUPAC
d	413	414	|I-IUPAC
and	415	418	|O
thieno3	419	426	|B-IUPAC
,	426	427	|I-IUPAC
2	427	428	|I-IUPAC
-	428	429	|I-IUPAC
d	429	430	|I-IUPAC
fused	431	436	|O
oxazin	437	443	|B-IUPAC
-	443	444	|I-IUPAC
4	444	445	|I-IUPAC
-	445	446	|I-IUPAC
ones	446	450	|I-IUPAC
possess	451	458	|O
extraordinary	459	472	|O
chemical	473	481	|O
stability	482	491	|O
,	491	492	|O
which	493	498	|O
was	499	502	|O
expressed	503	512	|O
as	513	515	|O
rate	516	520	|O
constants	521	530	|O
of	531	533	|O
the	534	537	|O
alkaline	538	546	|O
hydrolysis	547	557	|O
.	557	558	|O
The	559	562	|O
kinetic	563	570	|O
parameters	571	581	|O
of	582	584	|O
the	585	588	|O
HLE	589	592	|O
inhibition	593	603	|O
were	604	608	|O
determined	609	619	|O
.	619	620	|O
The	621	624	|O
most	625	629	|O
potent	630	636	|O
compound	637	645	|O
,	645	646	|O
2	647	648	|B-IUPAC
-	648	649	|I-IUPAC
(	649	650	|I-IUPAC
diethylamino	650	662	|I-IUPAC
)	662	663	|I-IUPAC
-	663	664	|I-IUPAC
4H	664	666	|I-IUPAC
-	666	667	|I-IUPAC
1benzothieno2	667	680	|I-IUPAC
,	680	681	|I-IUPAC
3	681	682	|I-IUPAC
-	682	683	|I-IUPAC
d1	683	685	|I-IUPAC
,	685	686	|I-IUPAC
3	686	687	|I-IUPAC
	687	688	|I-IUPAC
	688	689	|I-IUPAC
xazin	689	694	|I-IUPAC
-	694	695	|I-IUPAC
4	695	696	|I-IUPAC
-	696	697	|I-IUPAC
one	697	700	|I-IUPAC
,	700	701	|O
exhibited	702	711	|O
a	712	713	|O
K	714	715	|O
(	715	716	|O
i	716	717	|O
)	717	718	|O
value	719	724	|O
of	725	727	|O
5.8	728	731	|O
nM	732	734	|O
.	734	735	|O
2	736	737	|B-IUPAC
-	737	738	|I-IUPAC
(	738	739	|I-IUPAC
Diethylamino	739	751	|I-IUPAC
)	751	752	|I-IUPAC
thieno1	752	759	|I-IUPAC
,	759	760	|I-IUPAC
3	761	762	|I-IUPAC
	762	763	|I-IUPAC
	763	764	|I-IUPAC
xazin	764	769	|I-IUPAC
-	769	770	|I-IUPAC
4	770	771	|I-IUPAC
-	771	772	|I-IUPAC
ones	772	776	|I-IUPAC
act	777	780	|O
as	781	783	|O
acyl	784	788	|O
-	788	789	|O
enzyme	789	795	|O
inhibitors	796	806	|O
of	807	809	|O
HLE	810	813	|O
,	813	814	|O
similar	815	822	|O
to	823	825	|O
the	826	829	|O
inhibition	830	840	|O
of	841	843	|O
serine	844	850	|O
proteases	851	860	|O
by	861	863	|O
4H	864	866	|B-IUPAC
-	866	867	|I-IUPAC
3,1	867	870	|I-IUPAC
-	870	871	|I-IUPAC
benzoxazin	871	881	|I-IUPAC
-	881	882	|I-IUPAC
4	882	883	|I-IUPAC
-	883	884	|I-IUPAC
ones	884	888	|I-IUPAC
.	888	889	|O
The	890	893	|O
isosteric	894	903	|O
benzene	904	911	|O
-	911	912	|O
thiophene	912	921	|O
replacement	922	933	|O
accounts	934	942	|O
for	943	946	|O
an	947	949	|O
enhanced	950	958	|O
stability	959	968	|O
of	969	971	|O
the	972	975	|O
acyl	976	980	|O
-	980	981	|O
enzyme	981	987	|O
intermediates	988	1001	|O
.	1001	1002	|O

### abstracts2031.txt
In	0	2	|O
order	3	8	|O
to	9	11	|O
develop	12	19	|O
tracers	20	27	|O
with	28	32	|O
higher	33	39	|O
specific	40	48	|O
activity	49	57	|O
to	58	60	|O
supplant	61	69	|O
the	70	73	|O
currently	74	83	|O
used	84	88	|O
[	89	90	|O
3H	90	92	|O
]	92	93	|O
-	93	94	|O
8	94	95	|O
-	95	96	|O
OH	96	98	|O
-	98	99	|O
DPAT	99	103	|O
[	104	105	|O
8	105	106	|B-IUPAC
-	106	107	|I-IUPAC
hydroxy	107	114	|I-IUPAC
-	114	115	|I-IUPAC
2	115	116	|I-IUPAC
-	116	117	|I-IUPAC
(	117	118	|I-IUPAC
N	118	119	|I-IUPAC
,	119	120	|I-IUPAC
N	120	121	|I-IUPAC
-	121	122	|I-IUPAC
di	122	124	|I-IUPAC
-	124	125	|I-IUPAC
n	125	126	|I-IUPAC
-	126	127	|I-IUPAC
propylamino	127	138	|I-IUPAC
)	138	139	|I-IUPAC
tetralin	139	147	|I-IUPAC
]	147	148	|O
for	149	152	|O
in	153	155	|O
vitro	156	161	|O
and	162	165	|O
in	166	168	|O
vivo	169	173	|O
evaluation	174	184	|O
of	185	187	|O
5	188	189	|O
-	189	190	|O
HT1A	190	194	|O
receptors	195	204	|O
,	204	205	|O
a	206	207	|O
new	208	211	|O
radioiodinated	212	226	|O
ligand	227	233	|O
was	234	237	|O
prepared	238	246	|O
.	246	247	|O
(	248	249	|B-IUPAC
R	249	250	|I-IUPAC
,	250	251	|I-IUPAC
S	251	252	|I-IUPAC
)	252	253	|I-IUPAC
-	253	254	|I-IUPAC
trans	254	259	|I-IUPAC
-	259	260	|I-IUPAC
8	260	261	|I-IUPAC
-	261	262	|I-IUPAC
Hydroxy	263	270	|I-IUPAC
-	270	271	|I-IUPAC
2	271	272	|I-IUPAC
-	272	273	|I-IUPAC
[	273	274	|I-IUPAC
N	274	275	|I-IUPAC
-	275	276	|I-IUPAC
n	276	277	|I-IUPAC
-	277	278	|I-IUPAC
propyl	278	284	|I-IUPAC
-	284	285	|I-IUPAC
N	285	286	|I-IUPAC
-	286	287	|I-IUPAC
(	287	288	|I-IUPAC
3'	288	290	|I-IUPAC
-	290	291	|I-IUPAC
iodo	291	295	|I-IUPAC
-	295	296	|I-IUPAC
2'	296	298	|I-IUPAC
-	298	299	|I-IUPAC
propenyl	299	307	|I-IUPAC
)	307	308	|I-IUPAC
amino	308	313	|I-IUPAC
]	313	314	|I-IUPAC
tetralin	314	322	|I-IUPAC
(	323	324	|O
trans	324	329	|O
-	329	330	|O
8	330	331	|O
-	331	332	|O
OH	332	334	|O
-	334	335	|O
PIPAT	335	340	|O
)	340	341	|O
,	341	342	|O
8	343	344	|O
,	344	345	|O
was	346	349	|O
synthesized	350	361	|O
by	362	364	|O
a	365	366	|O
10	367	369	|O
-	369	370	|O
step	370	374	|O
reaction	375	383	|O
.	383	384	|O
Binding	385	392	|O
studies	393	400	|O
with	401	405	|O
rat	406	409	|O
hippocampal	410	421	|O
membrane	422	430	|O
homogenates	431	442	|O
showed	443	449	|O
that	450	454	|O
8	455	456	|O
exhibited	457	466	|O
a	467	468	|O
Ki	469	471	|O
value	472	477	|O
of	478	480	|O
0.92	481	485	|O
nM	486	488	|O
against	489	496	|O
(	497	498	|O
R	498	499	|O
,	499	500	|O
S	500	501	|O
)	501	502	|O
-	502	503	|O
[	503	504	|O
3H	504	506	|O
]	506	507	|O
-	507	508	|O
8	508	509	|O
-	509	510	|O
OH	510	512	|O
-	512	513	|O
DPAT	513	517	|O
.	517	518	|O
Radiolabeled	519	531	|O
[	532	533	|O
125I	533	537	|O
]	537	538	|O
-	538	539	|O
8	539	540	|O
was	541	544	|O
prepared	545	553	|O
from	554	558	|O
the	559	562	|O
corresponding	563	576	|O
tri	577	580	|B-IUPAC
-	580	581	|I-IUPAC
n	581	582	|I-IUPAC
-	582	583	|I-IUPAC
butyltin	583	591	|I-IUPAC
precursor	592	601	|O
via	602	605	|O
an	606	608	|O
oxidative	609	618	|O
iododestannylation	619	637	|O
reaction	638	646	|O
with	647	651	|O
sodium	652	658	|O
[	659	660	|O
125I	660	664	|O
]	664	665	|O
iodide	665	671	|O
.	671	672	|O
Binding	673	680	|O
studies	681	688	|O
in	689	691	|O
the	692	695	|O
hippocampal	696	707	|O
homogenates	708	719	|O
revealed	720	728	|O
that	729	733	|O
[	734	735	|O
125I	735	739	|O
]	739	740	|O
-	740	741	|O
8	741	742	|O
bound	743	748	|O
to	749	751	|O
a	752	753	|O
single	754	760	|O
high	761	765	|O
-	765	766	|O
affinity	766	774	|O
site	775	779	|O
(	780	781	|O
Kd	781	783	|O
=	784	785	|O
0.38	786	790	|O
+	791	792	|O
/	792	793	|O
-	793	794	|O
0.03	795	799	|O
nM	800	802	|O
,	802	803	|O
Bmax	803	807	|O
=	808	809	|O
310	810	813	|O
+	814	815	|O
/	815	816	|O
-	816	817	|O
20	818	820	|O
fmol	821	825	|O
/	825	826	|O
mg	826	828	|O
of	829	831	|O
protein	832	839	|O
)	839	840	|O
.	840	841	|O
Competition	842	853	|O
binding	854	861	|O
experiments	862	873	|O
clearly	874	881	|O
indicated	882	891	|O
that	892	896	|O
the	897	900	|O
new	901	904	|O
ligand	905	911	|O
displayed	912	921	|O
the	922	925	|O
expected	926	934	|O
5	935	936	|O
-	936	937	|O
HT1A	937	941	|O
receptor	942	950	|O
binding	951	958	|O
profile	959	966	|O
.	966	967	|O
The	968	971	|O
rank	972	976	|O
order	977	982	|O
of	983	985	|O
potency	986	993	|O
was	994	997	|O
(	998	999	|O
R	999	1000	|O
,	1000	1001	|O
S	1001	1002	|O
)	1002	1003	|O
-	1003	1004	|O
trans	1004	1009	|O
-	1009	1010	|O
8	1010	1011	|O
-	1011	1012	|O
OH	1012	1014	|O
-	1014	1015	|O
PIPAT	1015	1020	|O
&	1021	1022	|O
gt	1022	1024	|O
;	1024	1025	|O
(	1026	1027	|O
R	1027	1028	|O
,	1028	1029	|O
S	1029	1030	|O
)	1030	1031	|O
-	1031	1032	|O
8	1033	1034	|O
-	1034	1035	|O
OH	1035	1037	|O
-	1037	1038	|O
DPAT	1038	1042	|O
&	1043	1044	|O
gt	1044	1046	|O
;	1046	1047	|O
WB4101	1048	1054	|O
&	1055	1056	|O
gt	1056	1058	|O
;	1058	1059	|O
5	1060	1061	|O
-	1061	1062	|O
HT	1062	1064	|O
&	1065	1066	|O
gt	1066	1068	|O
;	1068	1069	|O
(	1070	1071	|O
R	1071	1072	|O
,	1072	1073	|O
S	1073	1074	|O
)	1074	1075	|O
-	1075	1076	|O
trans	1076	1081	|O
-	1081	1082	|O
7	1082	1083	|O
-	1083	1084	|O
OH	1084	1086	|O
-	1086	1087	|O
PIPAT	1087	1092	|O
&	1093	1094	|O
gt	1094	1096	|O
;	1096	1097	|O
(	1098	1099	|O
R	1099	1100	|O
,	1100	1101	|O
S	1101	1102	|O
)	1102	1103	|O
-	1103	1104	|O
7	1104	1105	|O
-	1105	1106	|O
OH	1106	1108	|O
-	1108	1109	|O
DPAT	1109	1113	|O
&	1114	1115	|O
gt	1115	1117	|O
;	1117	1118	|O
(	1119	1120	|B-IUPAC
R	1120	1121	|I-IUPAC
,	1121	1122	|I-IUPAC
S	1122	1123	|I-IUPAC
)	1123	1124	|I-IUPAC
-	1124	1125	|I-IUPAC
propranolol	1125	1136	|I-IUPAC
&	1137	1138	|O
gt	1138	1140	|O
;	1140	1141	|O
spiperone	1142	1151	|O
&	1152	1153	|O
gt	1153	1155	|O
;	1155	1156	|O
&	1156	1157	|O
gt	1157	1159	|O
;	1159	1160	|O
ketanserin	1161	1171	|O
&	1172	1173	|O
gt	1173	1175	|O
;	1175	1176	|O
&	1176	1177	|O
gt	1177	1179	|O
;	1179	1180	|O
dopamine	1181	1189	|O
&	1190	1191	|O
gt	1191	1193	|O
;	1193	1194	|O
atropine	1195	1203	|O
.	1203	1204	|O
This	1205	1209	|O
new	1210	1213	|O
ligand	1214	1220	|O
offers	1221	1227	|O
several	1228	1235	|O
unique	1236	1242	|O
advantages	1243	1253	|O
,	1253	1254	|O
including	1255	1264	|O
high	1265	1269	|O
specific	1270	1278	|O
activity	1279	1287	|O
,	1287	1288	|O
high	1289	1293	|O
binding	1294	1301	|O
affinity	1302	1310	|O
,	1310	1311	|O
and	1312	1315	|O
low	1316	1319	|O
nonspecific	1320	1331	|O
binding	1332	1339	|O
,	1339	1340	|O
all	1341	1344	|O
of	1345	1347	|O
which	1348	1353	|O
make	1354	1358	|O
it	1359	1361	|O
an	1362	1364	|O
excellent	1365	1374	|O
probe	1375	1380	|O
for	1381	1384	|O
the	1385	1388	|O
investigation	1389	1402	|O
and	1403	1406	|O
characterization	1407	1423	|O
of	1424	1426	|O
5	1427	1428	|O
-	1428	1429	|O
HT1A	1429	1433	|O
receptors	1434	1443	|O
.	1443	1444	|O

### abstracts506.txt
Two	0	3	|O
2,3	4	7	|B-IUPAC
-	7	8	|I-IUPAC
dihydrobenzofuran	8	25	|I-IUPAC
analogues	26	35	|B-MODIFIER
of	36	38	|O
hallucinogenic	39	53	|O
amphetamines	54	66	|O
were	67	71	|O
prepared	72	80	|O
and	81	84	|O
evaluated	85	94	|O
for	95	98	|O
activity	99	107	|O
in	108	110	|O
the	111	114	|O
two	115	118	|O
-	118	119	|O
lever	119	124	|O
drug	125	129	|O
-	129	130	|O
discrimination	130	144	|O
paradigm	145	153	|O
in	154	156	|O
rats	157	161	|O
trained	162	169	|O
to	170	172	|O
discriminate	173	185	|O
saline	186	192	|O
from	193	197	|O
LSD	198	201	|O
tartrate	202	210	|O
(	211	212	|O
0.08	212	216	|O
mg	217	219	|O
/	219	220	|O
kg	220	222	|O
)	222	223	|O
and	224	227	|O
for	228	231	|O
the	232	235	|O
ability	236	243	|O
to	244	246	|O
displace	247	255	|O
[	256	257	|O
125I	257	261	|O
]	261	262	|O
-	262	263	|O
(	263	264	|O
R	264	265	|O
)	265	266	|O
-	266	267	|O
DOI	267	270	|O
[	271	272	|B-IUPAC
(	272	273	|I-IUPAC
125I	274	278	|I-IUPAC
]	278	279	|I-IUPAC
-	279	280	|I-IUPAC
(	280	281	|I-IUPAC
R	281	282	|I-IUPAC
)	282	283	|I-IUPAC
-	283	284	|I-IUPAC
1	284	285	|I-IUPAC
-	285	286	|I-IUPAC
(	286	287	|I-IUPAC
2,5	287	290	|I-IUPAC
-	290	291	|I-IUPAC
dimethoxy	291	300	|I-IUPAC
-	300	301	|I-IUPAC
4	301	302	|I-IUPAC
-	302	303	|I-IUPAC
iodophenyl	303	313	|I-IUPAC
)	313	314	|I-IUPAC
-	314	315	|I-IUPAC
2	315	316	|I-IUPAC
-	316	317	|I-IUPAC
aminopropane	317	329	|I-IUPAC
)	329	330	|I-IUPAC
from	331	335	|O
rat	336	339	|O
cortical	340	348	|O
homogenate	349	359	|O
5	360	361	|O
-	361	362	|O
HT2	362	365	|O
receptors	366	375	|O
.	375	376	|O
The	377	380	|O
compounds	381	390	|O
,	390	391	|O
1	392	393	|B-IUPAC
-	393	394	|I-IUPAC
(	394	395	|I-IUPAC
5	395	396	|I-IUPAC
-	396	397	|I-IUPAC
methoxy	397	404	|I-IUPAC
-	404	405	|I-IUPAC
2,3	405	408	|I-IUPAC
-	408	409	|I-IUPAC
dihydrobenzofuran	409	426	|I-IUPAC
-	426	427	|I-IUPAC
4	427	428	|I-IUPAC
-	428	429	|I-IUPAC
yl	429	431	|I-IUPAC
)	431	432	|I-IUPAC
-	432	433	|I-IUPAC
2	433	434	|I-IUPAC
-	434	435	|I-IUPAC
aminopropane	435	447	|I-IUPAC
(	448	449	|O
6a	449	451	|O
)	451	452	|O
and	453	456	|O
its	457	460	|O
7	461	462	|O
-	462	463	|O
brominated	463	473	|O
analogue	474	482	|O
6b	483	485	|O
,	485	486	|O
possessed	487	496	|O
activity	497	505	|O
comparable	506	516	|O
to	517	519	|O
their	520	525	|O
conformationally	526	542	|O
flexible	543	551	|O
counterparts	552	564	|O
1	565	566	|B-IUPAC
-	566	567	|I-IUPAC
(	567	568	|I-IUPAC
2,5	568	571	|I-IUPAC
-	571	572	|I-IUPAC
dimethoxyphenyl	572	587	|I-IUPAC
)	587	588	|I-IUPAC
-	588	589	|I-IUPAC
2	589	590	|I-IUPAC
-	590	591	|I-IUPAC
aminopropane	591	603	|I-IUPAC
(	604	605	|O
3	605	606	|O
)	606	607	|O
and	608	611	|O
its	612	615	|O
4	616	617	|O
-	617	618	|O
bromo	618	623	|O
derivative	624	634	|O
DOB	635	638	|O
(	639	640	|O
5	640	641	|O
)	641	642	|O
,	642	643	|O
respectively	644	656	|O
.	656	657	|O
The	658	661	|O
results	662	669	|O
suggest	670	677	|O
that	678	682	|O
the	683	686	|O
dihydrofuran	687	699	|O
ring	700	704	|O
in	705	707	|O
6a	708	710	|O
and	711	714	|O
6b	715	717	|O
models	718	724	|O
the	725	728	|O
active	729	735	|O
conformation	736	748	|O
of	749	751	|O
the	752	755	|O
5	756	757	|B-IUPAC
-	757	758	|I-IUPAC
methoxy	758	765	|I-IUPAC
groups	766	772	|B-MODIFIER
in	773	775	|O
3	776	777	|O
and	778	781	|O
5	782	783	|O
.	783	784	|O
Free	785	789	|O
energy	790	796	|O
of	797	799	|O
binding	800	807	|O
,	807	808	|O
derived	809	816	|O
from	817	821	|O
radioligand	822	833	|O
displacement	834	846	|O
KA	847	849	|O
values	850	856	|O
,	856	857	|O
indicated	858	867	|O
that	868	872	|O
addition	873	881	|O
of	882	884	|O
the	885	888	|O
bromine	889	896	|O
in	897	899	|O
either	900	906	|O
series	907	913	|O
contributes	914	925	|O
2.4-3.2	926	933	|O
kcal	934	938	|O
/	938	939	|O
mol	939	942	|O
of	943	945	|O
binding	946	953	|O
energy	954	960	|O
.	960	961	|O
On	962	964	|O
the	965	968	|O
basis	969	974	|O
of	975	977	|O
surface	978	985	|O
area	986	990	|O
of	991	993	|O
the	994	997	|O
bromine	998	1005	|O
atom	1006	1010	|O
,	1010	1011	|O
this	1012	1016	|O
value	1017	1022	|O
is	1023	1025	|O
2-3	1026	1029	|O
times	1030	1035	|O
higher	1036	1042	|O
than	1043	1047	|O
would	1048	1053	|O
be	1054	1056	|O
expected	1057	1065	|O
on	1066	1068	|O
the	1069	1072	|O
basis	1073	1078	|O
of	1079	1081	|O
hydrophobic	1082	1093	|O
binding	1094	1101	|O
.	1101	1102	|O
Thus	1103	1107	|O
,	1107	1108	|O
hydrophobicity	1109	1123	|O
of	1124	1126	|O
the	1127	1130	|O
para	1131	1135	|O
substituent	1136	1147	|O
alone	1148	1153	|O
cannot	1154	1160	|O
account	1161	1168	|O
for	1169	1172	|O
the	1173	1176	|O
dramatic	1177	1185	|O
enhancement	1186	1197	|O
of	1198	1200	|O
hallucinogenic	1201	1215	|O
activity	1216	1224	|O
.	1224	1225	|O
Although	1226	1234	|O
this	1235	1239	|O
substituent	1240	1251	|O
may	1252	1255	|O
play	1256	1260	|O
a	1261	1262	|O
minor	1263	1268	|O
role	1269	1273	|O
in	1274	1276	|O
orienting	1277	1286	|O
the	1287	1290	|O
conformation	1291	1303	|O
of	1304	1306	|O
the	1307	1310	|O
5	1311	1312	|O
-	1312	1313	|O
methoxy	1313	1320	|O
group	1321	1326	|O
in	1327	1329	|O
derivatives	1330	1341	|O
such	1342	1346	|O
as	1347	1349	|O
4	1350	1351	|O
and	1352	1355	|O
5	1356	1357	|O
,	1357	1358	|O
there	1359	1364	|O
appears	1365	1372	|O
to	1373	1375	|O
be	1376	1378	|O
some	1379	1383	|O
other	1384	1389	|O
,	1389	1390	|O
as	1391	1393	|O
yet	1394	1397	|O
unknown	1398	1405	|O
,	1405	1406	|O
critical	1407	1415	|O
receptor	1416	1424	|O
interaction	1425	1436	|O
.	1436	1437	|O

### abstracts1307.txt
N	0	1	|O
,	1	2	|O
O	2	3	|O
-	3	4	|O
Dicarbethoxy	4	16	|O
-	16	17	|O
4	17	18	|O
-	18	19	|O
chlorobenzenesulfohydroxamate	19	48	|O
(	49	50	|O
1c	50	52	|O
)	52	53	|O
and	54	57	|O
O	58	59	|B-IUPAC
-	59	60	|I-IUPAC
carbethoxy	60	70	|I-IUPAC
-	70	71	|I-IUPAC
N	71	72	|I-IUPAC
-	72	73	|I-IUPAC
hydroxysaccharin	73	89	|I-IUPAC
(	90	91	|O
6	91	92	|O
)	92	93	|O
,	93	94	|O
both	95	99	|O
potential	100	109	|O
carbethoxylating	110	126	|O
agents	127	133	|O
,	133	134	|O
inhibited	135	144	|O
yeast	145	150	|O
aldehyde	151	159	|O
dehydrogenase	160	173	|O
(	174	175	|O
AlDH	175	179	|O
)	179	180	|O
with	181	185	|O
IC50	186	190	|O
's	190	192	|O
of	193	195	|O
24	196	198	|O
and	199	202	|O
56	203	205	|O
microM	206	212	|O
,	212	213	|O
respectively	214	226	|O
.	226	227	|O
The	228	231	|O
esterase	232	240	|O
activity	241	249	|O
of	250	252	|O
the	253	256	|O
enzyme	257	263	|O
was	264	267	|O
commensurably	268	281	|O
inhibited	282	291	|O
.	291	292	|O
AlDH	293	297	|O
activity	298	306	|O
was	307	310	|O
only	311	315	|O
partially	316	325	|O
restored	326	334	|O
on	335	337	|O
incubation	338	348	|O
with	349	353	|O
mercaptoethanol	354	369	|O
(	370	371	|O
20	371	373	|O
mM	374	376	|O
)	376	377	|O
for	378	381	|O
1	382	383	|O
h	384	385	|O
.	385	386	|O
On	387	389	|O
incubation	390	400	|O
with	401	405	|O
rat	406	409	|O
plasma	410	416	|O
,	416	417	|O
1c	418	420	|O
liberated	421	430	|O
nitroxyl	431	439	|B-IUPAC
,	439	440	|O
a	441	442	|O
potent	443	449	|O
inhibitor	450	459	|O
of	460	462	|O
AlDH	463	467	|O
.	467	468	|O
Under	469	474	|O
the	475	478	|O
same	479	483	|O
conditions	484	494	|O
,	494	495	|O
nitroxyl	496	504	|B-IUPAC
generation	505	515	|O
from	516	520	|O
6	521	522	|O
was	523	526	|O
minimal	527	534	|O
,	534	535	|O
a	536	537	|O
result	538	544	|O
compatible	545	555	|O
with	556	560	|O
a	561	562	|O
previous	563	571	|O
observation	572	583	|O
that	584	588	|O
nitroxyl	589	597	|O
generation	598	608	|O
from	609	613	|O
N	614	615	|B-IUPAC
-	615	616	|I-IUPAC
hydroxysaccharin	616	632	|I-IUPAC
(	633	634	|O
7	634	635	|O
)	635	636	|O
,	636	637	|O
the	638	641	|O
product	642	649	|O
of	650	652	|O
the	653	656	|O
hydrolysis	657	667	|O
of	668	670	|O
the	671	674	|O
carbethoxy	675	685	|B-IUPAC
group	686	691	|B-MODIFIER
of	692	694	|O
6	695	696	|O
,	696	697	|O
was	698	701	|O
minimal	702	709	|O
at	710	712	|O
physiological	713	726	|O
pH	727	729	|O
.	729	730	|O
Since	731	736	|O
chemical	737	745	|O
carbethoxylating	746	762	|O
agents	763	769	|O
represented	770	781	|O
by	782	784	|O
the	785	788	|O
O	789	790	|B-MODIFIER
-	790	791	|I-MODIFIER
carbethoxylated	791	806	|I-MODIFIER
N	807	808	|B-IUPAC
-	808	809	|I-IUPAC
hydroxyphthalimide	809	827	|I-IUPAC
,	827	828	|O
1	829	830	|B-IUPAC
-	830	831	|I-IUPAC
hydroxybenzotriazole	831	851	|I-IUPAC
,	851	852	|O
and	853	856	|O
N	857	858	|B-IUPAC
-	858	859	|I-IUPAC
hydroxysuccinimide	859	877	|I-IUPAC
(	878	879	|O
8	879	880	|O
,	880	881	|O
9	882	883	|O
,	883	884	|O
and	885	888	|O
10	889	891	|O
,	891	892	|O
respectively	893	905	|O
)	905	906	|O
likewise	907	915	|O
inhibited	916	925	|O
yeast	926	931	|O
AlDH	932	936	|O
,	936	937	|O
albeit	938	944	|O
with	945	949	|O
IC50	950	954	|O
's	954	956	|O
1	957	958	|O
order	959	964	|O
of	965	967	|O
magnitude	968	977	|O
higher	978	984	|O
,	984	985	|O
we	986	988	|O
postulate	989	998	|O
that	999	1003	|O
1c	1004	1006	|O
and	1007	1010	|O
6	1011	1012	|O
act	1013	1016	|O
as	1017	1019	|O
irreversible	1020	1032	|O
inhibitors	1033	1043	|O
of	1044	1046	|O
AlDH	1047	1051	|O
by	1052	1054	|O
carbethoxylating	1055	1071	|O
the	1072	1075	|O
active	1076	1082	|O
site	1083	1087	|O
of	1088	1090	|O
the	1091	1094	|O
enzyme	1095	1101	|O
.	1101	1102	|O

### abstracts989.txt
The	0	3	|O
synthesis	4	13	|O
of	14	16	|O
aminoaceto	17	27	|B-IUPAC
-	27	28	|I-IUPAC
2'	28	30	|I-IUPAC
,	30	31	|I-IUPAC
6'	31	33	|I-IUPAC
-	33	34	|I-IUPAC
xylidides	34	43	|I-IUPAC
substituted	44	55	|B-MODIFIER
on	56	58	|O
the	59	62	|O
amide	63	68	|O
nitrogen	69	77	|O
with	78	82	|O
2	83	84	|B-IUPAC
-	84	85	|I-IUPAC
(	85	86	|I-IUPAC
diethylamino	86	98	|I-IUPAC
)	98	99	|I-IUPAC
ethyl	99	104	|I-IUPAC
,	104	105	|O
2	106	107	|B-IUPAC
-	107	108	|I-IUPAC
aminoethyl	108	118	|I-IUPAC
,	118	119	|O
2	120	121	|B-IUPAC
-	121	122	|I-IUPAC
hydroxyethyl	122	134	|I-IUPAC
,	134	135	|O
and	136	139	|O
2	140	141	|B-IUPAC
-	141	142	|I-IUPAC
ethoxyethyl	142	153	|I-IUPAC
groups	154	160	|B-MODIFIER
is	161	163	|O
described	164	173	|O
.	173	174	|O
The	175	178	|O
2	179	180	|B-IUPAC
-	180	181	|I-IUPAC
aminoethyl	181	191	|I-IUPAC
derivatives	192	203	|B-MODIFIER
were	204	208	|O
prepared	209	217	|O
by	218	220	|O
treatment	221	230	|O
of	231	233	|O
N	234	235	|B-IUPAC
-	235	236	|I-IUPAC
(	236	237	|I-IUPAC
2	237	238	|I-IUPAC
-	238	239	|I-IUPAC
phthalimidoethyl	239	255	|I-IUPAC
)	255	256	|I-IUPAC
-	256	257	|I-IUPAC
2'	257	259	|I-IUPAC
,	259	260	|I-IUPAC
6'	260	262	|I-IUPAC
-	262	263	|I-IUPAC
xylidine	263	271	|I-IUPAC
with	272	276	|O
chloroacetyl	277	289	|O
chloride	290	298	|O
,	298	299	|O
followed	300	308	|O
by	309	311	|O
treatment	312	321	|O
with	322	326	|O
either	327	333	|O
potassium	334	343	|O
phthalmide	344	354	|O
or	355	357	|O
diethylamine	358	370	|O
.	370	371	|O
Hydrazinolysis	372	386	|O
of	387	389	|O
the	390	393	|O
phthalimides	394	406	|O
liberated	407	416	|O
the	417	420	|O
free	421	425	|O
amines	426	432	|O
.	432	433	|O
The	434	437	|O
remaining	438	447	|O
target	448	454	|O
compounds	455	464	|O
were	465	469	|O
produced	470	478	|O
by	479	481	|O
alkylation	482	492	|O
of	493	495	|O
lidocaine	496	505	|O
or	506	508	|O
of	509	511	|O
2	512	513	|B-IUPAC
-	513	514	|I-IUPAC
phthalimidoaceto	514	530	|I-IUPAC
-	530	531	|I-IUPAC
2'	531	533	|I-IUPAC
,	533	534	|I-IUPAC
6'	534	536	|I-IUPAC
-	536	537	|I-IUPAC
xylidide	537	545	|I-IUPAC
with	546	550	|O
the	551	554	|O
appropriate	555	566	|O
halide	567	573	|O
and	574	577	|O
sodium	578	584	|O
hydride	585	592	|O
,	592	593	|O
followed	594	602	|O
by	603	605	|O
hydrazinolysis	606	620	|O
where	621	626	|O
necessary	627	636	|O
.	636	637	|O
All	638	641	|O
target	642	648	|O
compounds	649	658	|O
were	659	663	|O
evaluated	664	673	|O
for	674	677	|O
antiarrhythmic	678	692	|O
efficacy	693	701	|O
against	702	709	|O
chloroform	710	720	|O
-	720	721	|O
induced	721	728	|O
ventricular	729	740	|O
tachycardia	741	752	|O
,	752	753	|O
as	754	756	|O
well	757	761	|O
as	762	764	|O
for	765	768	|O
acute	769	774	|O
CNS	775	778	|O
toxicity	779	787	|O
in	788	790	|O
mice	791	795	|O
.	795	796	|O
Most	797	801	|O
of	802	804	|O
the	805	808	|O
target	809	815	|O
compounds	816	825	|O
were	826	830	|O
more	831	835	|O
potent	836	842	|O
than	843	847	|O
the	848	851	|O
corresponding	852	865	|O
secondary	866	875	|O
amides	876	882	|O
and	883	886	|O
had	887	890	|O
improved	891	899	|O
therapeutic	900	911	|O
margins	912	919	|O
toward	920	926	|O
CNS	927	930	|O
toxicity	931	939	|O
.	939	940	|O
The	941	944	|O
diamines	945	953	|O
N	954	955	|B-IUPAC
-	955	956	|I-IUPAC
(	956	957	|I-IUPAC
2	957	958	|I-IUPAC
-	958	959	|I-IUPAC
aminoethyl	959	969	|I-IUPAC
)	969	970	|I-IUPAC
-	970	971	|I-IUPAC
2	971	972	|I-IUPAC
-	972	973	|I-IUPAC
aminoaceto	973	983	|I-IUPAC
-	983	984	|I-IUPAC
2'	984	986	|I-IUPAC
,	986	987	|I-IUPAC
6'	987	989	|I-IUPAC
-	989	990	|I-IUPAC
xylidide	990	998	|I-IUPAC
(	999	1000	|O
13	1000	1002	|O
)	1002	1003	|O
and	1004	1007	|O
N	1008	1009	|B-IUPAC
-	1009	1010	|I-IUPAC
(	1010	1011	|I-IUPAC
2	1011	1012	|I-IUPAC
-	1012	1013	|I-IUPAC
aminoethyl	1013	1023	|I-IUPAC
)	1023	1024	|I-IUPAC
-	1024	1025	|I-IUPAC
-	1025	1026	|I-IUPAC
2	1026	1027	|I-IUPAC
-	1027	1028	|I-IUPAC
(	1028	1029	|I-IUPAC
diethylamino	1029	1041	|I-IUPAC
)	1041	1042	|I-IUPAC
aceto	1042	1047	|I-IUPAC
-	1047	1048	|I-IUPAC
2'	1048	1050	|I-IUPAC
,	1050	1051	|I-IUPAC
6'	1051	1053	|I-IUPAC
-	1053	1054	|I-IUPAC
xylidide	1054	1062	|I-IUPAC
(	1063	1064	|O
29	1064	1066	|O
)	1066	1067	|O
are	1068	1071	|O
especially	1072	1082	|O
promising	1083	1092	|O
in	1093	1095	|O
this	1096	1100	|O
respect	1101	1108	|O
.	1108	1109	|O
Several	1110	1117	|O
compounds	1118	1127	|O
were	1128	1132	|O
tested	1133	1139	|O
as	1140	1142	|O
spinal	1143	1149	|O
anesthetics	1150	1161	|O
.	1161	1162	|O

### abstracts390.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
analogues	12	21	|O
of	22	24	|O
the	25	28	|O
analgesic	29	38	|O
dipeptide	39	48	|O
derivative	49	59	|O
H	60	61	|O
-	61	62	|O
Lys	62	65	|O
-	65	66	|O
Trp	66	69	|O
(	69	70	|O
NPS	70	73	|O
)	73	74	|O
-	74	75	|O
OMe	75	78	|O
has	79	82	|O
been	83	87	|O
designed	88	96	|O
to	97	99	|O
determine	100	109	|O
the	110	113	|O
influence	114	123	|O
of	124	126	|O
the	127	130	|O
(	131	132	|B-IUPAC
2	132	133	|I-IUPAC
-	133	134	|I-IUPAC
nitrophenyl	134	145	|I-IUPAC
)	145	146	|I-IUPAC
sulfenyl	146	154	|I-IUPAC
(	155	156	|O
NPS	156	159	|O
)	159	160	|O
moiety	161	167	|B-MODIFIER
on	168	170	|O
the	171	174	|O
activity	175	183	|O
.	183	184	|O
The	185	188	|O
syntheses	189	198	|O
and	199	202	|O
antinociceptive	203	218	|O
effects	219	226	|O
of	227	229	|O
these	230	235	|O
analogues	236	245	|O
of	246	248	|O
general	249	256	|O
formula	257	264	|O
H	265	266	|O
-	266	267	|O
Lys	267	270	|O
-	270	271	|O
Trp	271	274	|O
(	274	275	|O
R	275	276	|O
)	276	277	|O
-	277	278	|O
OMe	278	281	|O
[	282	283	|O
R	283	284	|O
=	285	286	|O
phenylsulfenyl	287	301	|B-IUPAC
(	302	303	|O
PS	303	305	|O
)	305	306	|O
(	307	308	|O
9	308	309	|O
)	309	310	|O
;	310	311	|O
R	312	313	|O
=	314	315	|O
(	316	317	|B-IUPAC
2	317	318	|I-IUPAC
-	318	319	|I-IUPAC
carbomethyoxyphenyl	319	338	|I-IUPAC
)	338	339	|I-IUPAC
sulfenyl	339	347	|I-IUPAC
(	348	349	|O
CmPS	349	353	|O
)	353	354	|O
(	355	356	|O
10	356	358	|O
)	358	359	|O
;	359	360	|O
R	361	362	|O
=	363	364	|O
(	365	366	|B-IUPAC
4	366	367	|I-IUPAC
-	367	368	|I-IUPAC
nitrophenyl	368	379	|I-IUPAC
)	379	380	|I-IUPAC
sulfenyl	380	388	|I-IUPAC
(	389	390	|O
pNPS	390	394	|O
)	394	395	|O
(	396	397	|O
11	397	399	|O
)	399	400	|O
;	400	401	|O
R	402	403	|O
=	404	405	|O
(	406	407	|B-IUPAC
2,4	407	410	|I-IUPAC
-	410	411	|I-IUPAC
dinitrophenyl	411	424	|I-IUPAC
)	424	425	|I-IUPAC
sulfenyl	425	433	|I-IUPAC
(	434	435	|O
DNPS	435	439	|O
)	439	440	|O
(	441	442	|O
12	442	444	|O
)	444	445	|O
;	445	446	|O
R	447	448	|O
=	449	450	|O
[	451	452	|B-IUPAC
2	452	453	|I-IUPAC
-	453	454	|I-IUPAC
(	454	455	|I-IUPAC
acetylamino	455	466	|I-IUPAC
)	466	467	|I-IUPAC
-	467	468	|I-IUPAC
2	468	469	|I-IUPAC
-	469	470	|I-IUPAC
carbomethoxyethyl	470	487	|I-IUPAC
]	487	488	|I-IUPAC
sulfenyl	488	496	|I-IUPAC
(	497	498	|O
AacCmES	498	505	|O
)	505	506	|O
(	507	508	|O
13	508	510	|O
)	510	511	|O
;	511	512	|O
R	513	514	|O
=	515	516	|O
[	517	518	|B-IUPAC
2	518	519	|I-IUPAC
-	519	520	|I-IUPAC
(	520	521	|I-IUPAC
acetylamino	521	532	|I-IUPAC
)	532	533	|I-IUPAC
phenyl	533	539	|I-IUPAC
]	539	540	|I-IUPAC
sulfenyl	540	548	|I-IUPAC
(	549	550	|O
AacPS	550	555	|O
)	555	556	|O
(	557	558	|O
17	558	560	|O
)	560	561	|O
;	561	562	|O
R	563	564	|O
=	565	566	|O
tert	567	571	|B-IUPAC
-	571	572	|I-IUPAC
butylsulfenyl	572	585	|I-IUPAC
(	586	587	|O
t	587	588	|O
-	588	589	|O
BuS	589	592	|O
)	592	593	|O
(	594	595	|O
23	595	597	|O
)	597	598	|O
;	598	599	|O
R	600	601	|O
=	602	603	|O
(	604	605	|B-IUPAC
2	605	606	|I-IUPAC
-	606	607	|I-IUPAC
carbomethoxyethyl	607	624	|I-IUPAC
)	624	625	|I-IUPAC
sulfenyl	625	633	|I-IUPAC
(	634	635	|O
CmES	635	639	|O
)	639	640	|O
(	641	642	|O
24	642	644	|O
)	644	645	|O
]	645	646	|O
are	647	650	|O
described	651	660	|O
.	660	661	|O
Reaction	662	670	|O
of	671	673	|O
Z	674	675	|O
-	675	676	|O
Lys	676	679	|O
(	679	680	|O
Z	680	681	|O
)	681	682	|O
-	682	683	|O
Trp	683	686	|O
-	686	687	|O
OMe	687	690	|O
(	691	692	|O
3	692	693	|O
)	693	694	|O
with	695	699	|O
PS	700	702	|O
-	702	703	|O
,	703	704	|O
CmPS	705	709	|O
-	709	710	|O
,	710	711	|O
pNPS	712	716	|O
-	716	717	|O
,	717	718	|O
DNPS	719	723	|O
-	723	724	|O
,	724	725	|O
and	726	729	|O
AacCmES	730	737	|O
-	737	738	|O
Cl	738	740	|O
afforded	741	749	|O
the	750	753	|O
corresponding	754	767	|O
2	768	769	|B-IUPAC
-	769	770	|I-IUPAC
(	770	771	|I-IUPAC
sulfenyl	771	779	|I-IUPAC
)	779	780	|I-IUPAC
tryptophan	780	790	|I-IUPAC
derivatives	791	802	|B-MODIFIER
,	802	803	|O
which	804	809	|O
on	810	812	|O
treatment	813	822	|O
with	823	827	|O
boron	828	833	|B-IUPAC
-	833	834	|I-IUPAC
tris	834	838	|I-IUPAC
(	838	839	|I-IUPAC
trifluoroacetate	839	855	|I-IUPAC
)	855	856	|I-IUPAC
/	856	857	|O
trifluoroacetic	857	872	|O
acid	873	877	|O
or	878	880	|O
trimethylsilyl	881	895	|O
iodide	896	902	|O
in	903	905	|O
acetonitrile	906	918	|O
(	919	920	|O
Me3SiI	920	926	|O
/	926	927	|O
CH3CN	927	932	|O
)	932	933	|O
provided	934	942	|O
9-13	943	947	|O
,	947	948	|O
respectively	949	961	|O
.	961	962	|O
Sulfenylation	963	976	|O
of	977	979	|O
3	980	981	|O
with	982	986	|O
NPS	987	990	|O
-	990	991	|O
Cl	991	993	|O
gave	994	998	|O
Z	999	1000	|O
-	1000	1001	|O
Lys	1001	1004	|O
(	1004	1005	|O
Z	1005	1006	|O
)	1006	1007	|O
-	1007	1008	|O
Trp	1008	1011	|O
(	1011	1012	|O
NPS	1012	1015	|O
)	1015	1016	|O
-	1016	1017	|O
OMe	1017	1020	|O
,	1020	1021	|O
which	1022	1027	|O
,	1027	1028	|O
on	1029	1031	|O
catalytic	1032	1041	|O
hydrogenation	1042	1055	|O
of	1056	1058	|O
the	1059	1062	|O
nitro	1063	1068	|O
group	1069	1074	|O
using	1075	1080	|O
10%	1081	1084	|O
Pd	1085	1087	|O
/	1087	1088	|O
C	1088	1089	|O
followed	1090	1098	|O
by	1099	1101	|O
acetylation	1102	1113	|O
of	1114	1116	|O
the	1117	1120	|O
resulting	1121	1130	|O
amino	1131	1136	|O
function	1137	1145	|O
and	1146	1149	|O
removal	1150	1157	|O
of	1158	1160	|O
the	1161	1164	|O
protecting	1165	1175	|O
Z	1176	1177	|O
groups	1178	1184	|O
,	1184	1185	|O
gave	1186	1190	|O
17	1191	1193	|O
.	1193	1194	|O
Condensation	1195	1207	|O
of	1208	1210	|O
2	1211	1212	|B-PARTIUPAC
-	1212	1213	|I-PARTIUPAC
(	1213	1214	|I-PARTIUPAC
tert	1214	1218	|I-PARTIUPAC
-	1218	1219	|I-PARTIUPAC
butylsulfenyl	1219	1232	|I-PARTIUPAC
)	1232	1233	|I-PARTIUPAC
-	1233	1234	|I-PARTIUPAC
and	1235	1238	|O
2	1239	1240	|B-IUPAC
-	1240	1241	|I-IUPAC
[	1241	1242	|I-IUPAC
(	1242	1243	|I-IUPAC
2	1243	1244	|I-IUPAC
-	1244	1245	|I-IUPAC
carbomethoxyethyl	1245	1262	|I-IUPAC
)	1262	1263	|I-IUPAC
sulfenyl	1263	1271	|I-IUPAC
]	1271	1272	|I-IUPAC
tryptophan	1272	1282	|I-IUPAC
methyl	1283	1289	|I-IUPAC
ester	1290	1295	|I-IUPAC
,	1295	1296	|O
obtained	1297	1305	|O
by	1306	1308	|O
reaction	1309	1317	|O
of	1318	1320	|O
methyl	1321	1327	|B-IUPAC
3a	1328	1330	|I-IUPAC
-	1330	1331	|I-IUPAC
hydroxy	1331	1338	|I-IUPAC
-	1338	1339	|I-IUPAC
1,2,3,3	1339	1346	|I-IUPAC
a	1346	1347	|I-IUPAC
,	1347	1348	|I-IUPAC
8,8	1348	1351	|I-IUPAC
a	1351	1352	|I-IUPAC
-	1352	1353	|I-IUPAC
hexahydropyrrolo	1353	1369	|I-IUPAC
[	1369	1370	|I-IUPAC
2,3	1370	1373	|I-IUPAC
-	1373	1374	|I-IUPAC
b	1374	1375	|I-IUPAC
]	1375	1376	|I-IUPAC
indole	1376	1382	|I-IUPAC
-	1382	1383	|I-IUPAC
2	1383	1384	|I-IUPAC
-	1384	1385	|I-IUPAC
carboxyla	1385	1394	|I-IUPAC
te	1395	1397	|I-IUPAC
with	1398	1402	|O
the	1403	1406	|O
corresponding	1407	1420	|O
thiol	1421	1426	|O
,	1426	1427	|O
with	1428	1432	|O
Z	1433	1434	|O
-	1434	1435	|O
Lys	1435	1438	|O
(	1438	1439	|O
Z	1439	1440	|O
)	1440	1441	|O
-	1441	1442	|O
OSu	1442	1445	|O
afforded	1446	1454	|O
Z	1455	1456	|O
-	1456	1457	|O
Lys	1457	1460	|O
(	1460	1461	|O
Z	1461	1462	|O
)	1462	1463	|O
-	1463	1464	|O
Trp	1464	1467	|O
(	1467	1468	|O
t	1468	1469	|O
-	1469	1470	|O
BuS	1470	1473	|O
)	1473	1474	|O
-	1474	1475	|O
OMe	1475	1478	|O
and	1479	1482	|O
Z	1483	1484	|O
-	1484	1485	|O
Lys	1485	1488	|O
(	1488	1489	|O
Z	1489	1490	|O
)	1490	1491	|O
-	1491	1492	|O
Trp	1492	1495	|O
(	1495	1496	|O
CmES	1496	1500	|O
)	1500	1501	|O
-	1501	1502	|O
OMe	1502	1505	|O
,	1505	1506	|O
which	1507	1512	|O
on	1513	1515	|O
treatment	1516	1525	|O
with	1526	1530	|O
Me3SiI	1531	1537	|O
/	1537	1538	|O
CH3CN	1538	1543	|O
provided	1544	1552	|O
23	1553	1555	|O
and	1556	1559	|O
24	1560	1562	|O
,	1562	1563	|O
respectively	1564	1576	|O
.	1576	1577	|O
Intracerebroventricular	1578	1601	|O
administration	1602	1616	|O
of	1617	1619	|O
10	1620	1622	|O
elicited	1623	1631	|O
a	1632	1633	|O
naloxone	1634	1642	|O
-	1642	1643	|O
reversible	1643	1653	|O
antinociceptive	1654	1669	|O
effect	1670	1676	|O
in	1677	1679	|O
mice	1680	1684	|O
similar	1685	1692	|O
to	1693	1695	|O
that	1696	1700	|O
of	1701	1703	|O
H	1704	1705	|O
-	1705	1706	|O
Lys	1706	1709	|O
-	1709	1710	|O
Trp	1710	1713	|O
(	1713	1714	|O
NPS	1714	1717	|O
)	1717	1718	|O
-	1718	1719	|O
OMe	1719	1722	|O
.	1722	1723	|O
No	1724	1726	|O
analgesia	1727	1736	|O
was	1737	1740	|O
however	1741	1748	|O
found	1749	1754	|O
with	1755	1759	|O
the	1760	1763	|O
phenylsulfenyl	1764	1778	|O
or	1779	1781	|O
acyclic	1782	1789	|O
sulfenyl	1790	1798	|O
substituted	1799	1810	|O
dipeptides	1811	1821	|O
9	1822	1823	|O
,	1823	1824	|O
11	1825	1827	|O
,	1827	1828	|O
and	1829	1832	|O
17	1833	1835	|O
or	1836	1838	|O
13	1839	1841	|O
,	1841	1842	|O
23	1843	1845	|O
,	1845	1846	|O
and	1847	1850	|O
24	1851	1853	|O
.	1853	1854	|O
The	1855	1858	|O
Trp	1859	1862	|O
(	1862	1863	|O
DNPS	1863	1867	|O
)	1867	1868	|O
-	1868	1869	|O
containing	1869	1879	|O
analogue	1880	1888	|O
was	1889	1892	|O
neurotoxic	1893	1903	|O
.	1903	1904	|O
Structure	1905	1914	|O
-	1914	1915	|O
activity	1915	1923	|O
studies	1924	1931	|O
indicate	1932	1940	|O
that	1941	1945	|O
the	1946	1949	|O
role	1950	1954	|O
of	1955	1957	|O
the	1958	1961	|O
NPS	1962	1965	|O
and	1966	1969	|O
CmPS	1970	1974	|O
moieties	1975	1983	|O
could	1984	1989	|O
be	1990	1992	|O
related	1993	2000	|O
to	2001	2003	|O
the	2004	2007	|O
adoption	2008	2016	|O
of	2017	2019	|O
a	2020	2021	|O
preferential	2022	2034	|O
active	2035	2041	|O
conformation	2042	2054	|O
.	2054	2055	|O

### abstracts666.txt
Adenosine	0	9	|O
5'	10	12	|O
-	12	13	|O
triphosphate	13	25	|O
(	26	27	|O
ATP	27	30	|O
)	30	31	|O
derivatives	32	43	|B-MODIFIER
of	44	46	|O
the	47	50	|O
types	51	56	|O
N6	57	59	|O
-	59	60	|O
R	60	61	|O
-	61	62	|O
ATP	62	65	|O
[	66	67	|O
R	67	68	|O
=	69	70	|O
(	71	72	|O
CH2	72	75	|O
)	75	76	|O
nNHCOCH2I	76	85	|O
,	85	86	|O
(	87	88	|O
CH2	88	91	|O
)	91	92	|O
nNHCO	92	97	|O
-	97	98	|O
(	98	99	|O
CH2	99	102	|O
)	102	103	|O
mNHCOCH2I	103	112	|O
,	112	113	|O
or	114	116	|O
(	117	118	|O
CH2	118	121	|O
)	121	122	|O
nCON	122	126	|O
(	126	127	|O
Me	127	129	|O
)	129	130	|O
(	130	131	|O
CH2	131	134	|O
)	134	135	|O
mN	135	137	|O
(	137	138	|O
Me	138	140	|O
)	140	141	|O
CO	141	143	|O
(	143	144	|O
CH2	144	147	|O
)	147	148	|O
nNHCOCH2I	148	157	|O
]	157	158	|O
,	158	159	|O
N6	160	162	|O
-	162	163	|O
Me	163	165	|O
-	165	166	|O
N6	166	168	|O
-	168	169	|O
R	169	170	|O
-	170	171	|O
ATP	171	174	|O
[	175	176	|O
R	176	177	|O
=	178	179	|O
(	180	181	|O
CH2	181	184	|O
)	184	185	|O
nN	185	187	|O
-	187	188	|O
(	188	189	|O
Me	189	191	|O
)	191	192	|O
CO	192	194	|O
(	194	195	|O
CH2	195	198	|O
)	198	199	|O
mNHCOCH2I	199	208	|O
]	208	209	|O
,	209	210	|O
and	211	214	|O
8	215	216	|O
-	216	217	|O
R	217	218	|O
-	218	219	|O
ATP	219	222	|O
[	223	224	|O
R	224	225	|O
=	226	227	|O
NM	228	230	|O
(	230	231	|O
CH2	231	234	|O
)	234	235	|O
nNHCOCH2I	235	244	|O
]	244	245	|O
with	246	250	|O
5	251	252	|O
-	252	253	|O
-	253	254	|O
19	254	256	|O
spacer	257	263	|O
atoms	264	269	|O
between	270	277	|O
N6	278	280	|O
or	281	283	|O
C	284	285	|O
-	285	286	|O
8	286	287	|O
and	288	291	|O
iodine	292	298	|O
have	299	303	|O
been	304	308	|O
evaluated	309	318	|O
as	319	321	|O
potential	322	331	|O
exo	332	335	|O
-	335	336	|O
ATP	336	339	|O
-	339	340	|O
site	340	344	|O
-	344	345	|O
directed	345	353	|O
reagents	354	362	|O
for	363	366	|O
phosphokinases	367	381	|O
.	381	382	|O
Substrate	383	392	|O
and	393	396	|O
inhibitor	397	406	|O
properties	407	417	|O
indicated	418	427	|O
that	428	432	|O
the	433	436	|O
compounds	437	446	|O
possessed	447	456	|O
affinity	457	465	|O
for	466	469	|O
the	470	473	|O
ATP	474	477	|O
sites	478	483	|O
of	484	486	|O
the	487	490	|O
muscle	491	497	|O
(	498	499	|O
M	499	500	|O
)	500	501	|O
,	501	502	|O
kidney	503	509	|O
(	510	511	|O
K	511	512	|O
)	512	513	|O
,	513	514	|O
and	515	518	|O
liver	519	524	|O
(	525	526	|O
L	526	527	|O
)	527	528	|O
isozymes	529	537	|O
of	538	540	|O
rat	541	544	|O
pyruvate	545	553	|O
kinase	554	560	|O
(	561	562	|O
PK	562	564	|O
)	564	565	|O
,	565	566	|O
of	567	569	|O
E	570	571	|O
.	571	572	|O
coli	573	577	|O
thymidine	578	587	|O
kinase	588	594	|O
(	595	596	|O
TK	596	598	|O
)	598	599	|O
,	599	600	|O
and	601	604	|O
of	605	607	|O
yeast	608	613	|O
hexokinase	614	624	|O
(	625	626	|O
HK	626	628	|O
)	628	629	|O
and	630	633	|O
rat	634	637	|O
KH	638	640	|O
I	641	642	|O
,	642	643	|O
II	644	646	|O
,	646	647	|O
and	648	651	|O
III	652	655	|O
isozymes	656	664	|O
.	664	665	|O
Tests	666	671	|O
for	672	675	|O
time	676	680	|O
-	680	681	|O
dependent	681	690	|O
loss	691	695	|O
of	696	698	|O
enzyme	699	705	|O
activity	706	714	|O
(	715	716	|O
inactivation	716	728	|O
)	728	729	|O
were	730	734	|O
performed	735	744	|O
under	745	750	|O
conditions	751	761	|O
in	762	764	|O
which	765	770	|O
a	771	772	|O
large	773	778	|O
proportion	779	789	|O
of	790	792	|O
each	793	797	|O
phosphokinase	798	811	|O
was	812	815	|O
present	816	823	|O
as	824	826	|O
an	827	829	|O
enzyme	830	836	|O
-	836	837	|O
inhibitor	837	846	|O
complex	847	854	|O
.	854	855	|O
No	856	858	|O
ATP	859	862	|O
-	862	863	|O
site	863	867	|O
-	867	868	|O
directed	868	876	|O
inactivations	877	890	|O
resulted	891	899	|O
when	900	904	|O
the	905	908	|O
M	909	910	|O
,	910	911	|O
L	912	913	|O
,	913	914	|O
or	915	917	|O
K	918	919	|O
isozymes	920	928	|O
of	929	931	|O
PK	932	934	|O
were	935	939	|O
exposed	940	947	|O
for	948	951	|O
8	952	953	|O
h	954	955	|O
,	955	956	|O
22	957	959	|O
degrees	960	967	|O
C	968	969	|O
,	969	970	|O
to	971	973	|O
5	974	975	|O
mM	976	978	|O
levels	979	985	|O
of	986	988	|O
18	989	991	|O
ATP	992	995	|O
derivatives	996	1007	|O
or	1008	1010	|O
6	1011	1012	|O
analogous	1013	1022	|O
ADP	1023	1026	|O
derivatives	1027	1038	|O
or	1039	1041	|O
when	1042	1046	|O
yeast	1047	1052	|O
HK	1053	1055	|O
or	1056	1058	|O
rat	1059	1062	|O
KH	1063	1065	|O
I	1066	1067	|O
,	1067	1068	|O
II	1069	1071	|O
,	1071	1072	|O
or	1073	1075	|O
III	1076	1079	|O
was	1080	1083	|O
exposed	1084	1091	|O
for	1092	1095	|O
6	1096	1097	|O
h	1098	1099	|O
,	1099	1100	|O
22	1101	1103	|O
degrees	1104	1111	|O
C	1112	1113	|O
,	1113	1114	|O
to	1115	1117	|O
5	1118	1119	|O
mM	1120	1122	|O
levels	1123	1129	|O
of	1130	1132	|O
28	1133	1135	|O
ATP	1136	1139	|O
derivatives	1140	1151	|O
.	1151	1152	|O
Escherichia	1153	1164	|O
coli	1165	1169	|O
TK	1170	1172	|O
was	1173	1176	|O
inactivated	1177	1188	|O
by	1189	1191	|O
6	1192	1193	|O
of	1194	1196	|O
25	1197	1199	|O
ATP	1200	1203	|O
derivatives	1204	1215	|O
tested	1216	1222	|O
at	1223	1225	|O
10	1226	1228	|O
mM	1229	1231	|O
,	1231	1232	|O
6	1233	1234	|O
h	1235	1236	|O
,	1236	1237	|O
0	1238	1239	|O
degrees	1240	1247	|O
C	1248	1249	|O
;	1249	1250	|O
inactivation	1251	1263	|O
was	1264	1267	|O
slowed	1268	1274	|O
by	1275	1277	|O
MgATP	1278	1283	|O
in	1284	1286	|O
the	1287	1290	|O
case	1291	1295	|O
of	1296	1298	|O
N6	1299	1301	|O
-	1301	1302	|O
CH3	1302	1305	|O
-	1305	1306	|O
N6	1306	1308	|O
-	1308	1309	|O
R	1309	1310	|O
-	1310	1311	|O
ATP	1311	1314	|O
[	1315	1316	|O
R	1316	1317	|O
=	1318	1319	|O
(	1320	1321	|O
CH2	1321	1324	|O
)	1324	1325	|O
4N	1325	1327	|O
(	1327	1328	|O
CH3	1328	1331	|O
)	1331	1332	|O
CO	1332	1334	|O
(	1334	1335	|O
CH2	1335	1338	|O
)	1338	1339	|O
5NHCOCH2I	1339	1348	|O
]	1348	1349	|O
.	1349	1350	|O
Only	1351	1355	|O
1%	1356	1358	|O
of	1359	1361	|O
298	1362	1365	|O
enzyme	1366	1372	|O
-	1372	1373	|O
inhibitor	1373	1382	|O
combinations	1383	1395	|O
exhibited	1396	1405	|O
ATP	1406	1409	|O
-	1409	1410	|O
site	1410	1414	|O
-	1414	1415	|O
directed	1415	1423	|O
inactivation	1424	1436	|O
,	1436	1437	|O
signifying	1438	1448	|O
that	1449	1453	|O
few	1454	1457	|O
suitably	1458	1466	|O
positioned	1467	1477	|O
and	1478	1481	|O
sufficiently	1482	1494	|O
reactive	1495	1503	|O
nucleophilic	1504	1516	|O
groups	1517	1523	|O
were	1524	1528	|O
present	1529	1536	|O
near	1537	1541	|O
the	1542	1545	|O
enzymic	1546	1553	|O
ATP	1554	1557	|O
sites	1558	1563	|O
.	1563	1564	|O
Studies	1565	1572	|O
have	1573	1577	|O
now	1578	1581	|O
shown	1582	1587	|O
that	1588	1592	|O
exo	1593	1596	|O
-	1596	1597	|O
active	1597	1603	|O
-	1603	1604	|O
site	1604	1608	|O
-	1608	1609	|O
directed	1609	1617	|O
reagents	1618	1626	|O
can	1627	1630	|O
act	1631	1634	|O
as	1635	1637	|O
isozyme	1638	1645	|O
-	1645	1646	|O
or	1647	1649	|O
species	1650	1657	|O
-	1657	1658	|O
selective	1658	1667	|O
enzyme	1668	1674	|O
inhibitors	1675	1685	|O
.	1685	1686	|O
The	1687	1690	|O
present	1691	1698	|O
survey	1699	1705	|O
indicates	1706	1715	|O
that	1716	1720	|O
in	1721	1723	|O
many	1724	1728	|O
cases	1729	1734	|O
such	1735	1739	|O
reagents	1740	1748	|O
may	1749	1752	|O
be	1753	1755	|O
difficult	1756	1765	|O
of	1766	1768	|O
access	1769	1775	|O
when	1776	1780	|O
data	1781	1785	|O
are	1786	1789	|O
not	1790	1793	|O
available	1794	1803	|O
regarding	1804	1813	|O
structural	1814	1824	|O
or	1825	1827	|O
physicochemical	1828	1843	|O
features	1844	1852	|O
of	1853	1855	|O
the	1856	1859	|O
target	1860	1866	|O
enzyme	1867	1873	|O
adjacent	1874	1882	|O
to	1883	1885	|O
its	1886	1889	|O
catalytic	1890	1899	|O
site	1900	1904	|O
.	1904	1905	|O

### abstracts2519.txt
The	0	3	|O
synthesis	4	13	|O
of	14	16	|O
2'	17	19	|B-IUPAC
-	19	20	|I-IUPAC
fluoro	20	26	|I-IUPAC
-	26	27	|I-IUPAC
10	27	29	|I-IUPAC
-	29	30	|I-IUPAC
propargyl	30	39	|I-IUPAC
-	39	40	|I-IUPAC
5,8	40	43	|I-IUPAC
-	43	44	|I-IUPAC
dideazafolic	44	56	|I-IUPAC
acid	57	61	|I-IUPAC
and	62	65	|O
its	66	69	|O
2	70	71	|B-IUPAC
-	71	72	|I-IUPAC
desamino	72	80	|I-IUPAC
,	80	81	|O
2	82	83	|B-IUPAC
-	83	84	|I-IUPAC
desamino	84	92	|I-IUPAC
-	92	93	|I-IUPAC
2	93	94	|I-IUPAC
-	94	95	|I-IUPAC
hydroxymethyl	95	108	|I-IUPAC
,	108	109	|O
and	110	113	|O
2	114	115	|B-IUPAC
-	115	116	|I-IUPAC
desamino	116	124	|I-IUPAC
-	124	125	|I-IUPAC
2	125	126	|I-IUPAC
-	126	127	|I-IUPAC
methoxy	127	134	|I-IUPAC
analogues	135	144	|B-MODIFIER
is	145	147	|O
described	148	157	|O
.	157	158	|O
In	159	161	|O
general	162	169	|O
the	170	173	|O
synthetic	174	183	|O
route	184	189	|O
involved	190	198	|O
the	199	202	|O
coupling	203	211	|O
of	212	214	|O
diethyl	215	222	|B-IUPAC
N	223	224	|I-IUPAC
-	224	225	|I-IUPAC
[	225	226	|I-IUPAC
2	226	227	|I-IUPAC
-	227	228	|I-IUPAC
fluoro	228	234	|I-IUPAC
-	234	235	|I-IUPAC
4	235	236	|I-IUPAC
-	236	237	|I-IUPAC
(	237	238	|I-IUPAC
prop	238	242	|I-IUPAC
-	242	243	|I-IUPAC
2	243	244	|I-IUPAC
-	244	245	|I-IUPAC
ynylamino	245	254	|I-IUPAC
)	254	255	|I-IUPAC
benzoyl	255	262	|I-IUPAC
]	262	263	|I-IUPAC
-	263	264	|I-IUPAC
L	264	265	|I-IUPAC
-	265	266	|I-IUPAC
glutamate	266	275	|I-IUPAC
with	276	280	|O
the	281	284	|O
appropriate	285	296	|O
6	297	298	|B-IUPAC
-	298	299	|I-IUPAC
(	299	300	|I-IUPAC
bromomethyl	300	311	|I-IUPAC
)	311	312	|I-IUPAC
quinazoline	312	323	|I-IUPAC
followed	324	332	|O
by	333	335	|O
deprotection	336	348	|O
with	349	353	|O
mild	354	358	|O
alkali	359	365	|O
.	365	366	|O
These	367	372	|O
four	373	377	|O
compounds	378	387	|O
together	388	396	|O
with	397	401	|O
the	402	405	|O
2	406	407	|B-IUPAC
-	407	408	|I-IUPAC
desamino	408	416	|I-IUPAC
-	416	417	|I-IUPAC
2	417	418	|I-IUPAC
-	418	419	|I-IUPAC
methyl	419	425	|I-IUPAC
analogue	426	434	|B-MODIFIER
were	435	439	|O
tested	440	446	|O
for	447	450	|O
their	451	456	|O
activity	457	465	|O
against	466	473	|O
L1210	474	479	|O
thymidylate	480	491	|O
synthase	492	500	|O
(	501	502	|O
TS	502	504	|O
)	504	505	|O
.	505	506	|O
They	507	511	|O
were	512	516	|O
also	517	521	|O
examined	522	530	|O
for	531	534	|O
their	535	540	|O
inhibition	541	551	|O
of	552	554	|O
the	555	558	|O
growth	559	565	|O
of	566	568	|O
the	569	572	|O
L1210	573	578	|O
cell	579	583	|O
line	584	588	|O
and	589	592	|O
of	593	595	|O
two	596	599	|O
mutant	600	606	|O
L1210	607	612	|O
cell	613	617	|O
lines	618	623	|O
,	623	624	|O
the	625	628	|O
L1210	629	634	|O
:	634	635	|O
R7A	635	638	|O
that	639	643	|O
overproduces	644	656	|O
dihydrofolate	657	670	|O
reductase	671	680	|O
(	681	682	|O
DHFR	682	686	|O
)	686	687	|O
and	688	691	|O
the	692	695	|O
L1210	696	701	|O
:	701	702	|O
1565	702	706	|O
that	707	711	|O
has	712	715	|O
impaired	716	724	|O
uptake	725	731	|O
of	732	734	|O
reduced	735	742	|O
folates	743	750	|O
.	750	751	|O
Compared	752	760	|O
with	761	765	|O
their	766	771	|O
non	772	775	|O
-	775	776	|O
fluorinated	776	787	|O
parent	788	794	|O
compounds	795	804	|O
,	804	805	|O
the	806	809	|O
2'	810	812	|B-IUPAC
-	812	813	|I-IUPAC
fluoro	813	819	|I-IUPAC
analogues	820	829	|B-MODIFIER
were	830	834	|O
all	835	838	|O
approximately	839	852	|O
2	853	854	|O
-	854	855	|O
fold	855	859	|O
more	860	864	|O
potent	865	871	|O
as	872	874	|O
TS	875	877	|O
inhibitors	878	888	|O
.	888	889	|O
Similarly	890	899	|O
,	899	900	|O
they	901	905	|O
also	906	910	|O
showed	911	917	|O
improved	918	926	|O
inhibition	927	937	|O
of	938	940	|O
L1210	941	946	|O
cell	947	951	|O
growth	952	958	|O
(	959	960	|O
1.5-5	960	965	|O
-	965	966	|O
fold	966	970	|O
)	970	971	|O
,	971	972	|O
and	973	976	|O
this	977	981	|O
activity	982	990	|O
was	991	994	|O
prevented	995	1004	|O
by	1005	1007	|O
co	1008	1010	|O
-	1010	1011	|O
incubation	1011	1021	|O
with	1022	1026	|O
thymidine	1027	1036	|O
.	1036	1037	|O
All	1038	1041	|O
had	1042	1045	|O
retained	1046	1054	|O
or	1055	1057	|O
improved	1058	1066	|O
activity	1067	1075	|O
against	1076	1083	|O
both	1084	1088	|O
the	1089	1092	|O
L1210	1093	1098	|O
:	1098	1099	|O
R7A	1099	1102	|O
and	1103	1106	|O
L1210	1107	1112	|O
:	1112	1113	|O
1565	1113	1117	|O
cell	1118	1122	|O
lines	1123	1128	|O
.	1128	1129	|O

### abstracts1297.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
8	12	13	|O
-	13	14	|O
(	14	15	|O
trifluoromethyl	15	30	|O
)	30	31	|O
-	31	32	|O
substituted	32	43	|O
quinolones	44	54	|O
has	55	58	|O
been	59	63	|O
prepared	64	72	|O
and	73	76	|O
evaluated	77	86	|O
for	87	90	|O
in	91	93	|O
vitro	94	99	|O
and	100	103	|O
in	104	106	|O
vivo	107	111	|O
antibacterial	112	125	|O
activity	126	134	|O
,	134	135	|O
and	136	139	|O
phototolerance	140	154	|O
in	155	157	|O
a	158	159	|O
mouse	160	165	|O
phototolerance	166	180	|O
assay	181	186	|O
.	186	187	|O
These	188	193	|O
analogues	194	203	|O
were	204	208	|O
compared	209	217	|O
to	218	220	|O
the	221	224	|O
corresponding	225	238	|O
series	239	245	|O
of	246	248	|O
6,8	249	252	|B-PARTIUPAC
-	252	253	|I-PARTIUPAC
difluoro	253	261	|I-PARTIUPAC
-	261	262	|I-PARTIUPAC
and	263	266	|O
6	267	268	|B-IUPAC
-	268	269	|I-IUPAC
fluoro	269	275	|I-IUPAC
-	275	276	|I-IUPAC
8H	276	278	|I-IUPAC
-	278	279	|I-IUPAC
quinolones	279	289	|I-IUPAC
(	290	291	|O
ciprofloxacin	291	304	|O
type	305	309	|O
)	309	310	|O
.	310	311	|O
Although	312	320	|O
their	321	326	|O
in	327	329	|O
vitro	330	335	|O
antibacterial	336	349	|O
activities	350	360	|O
are	361	364	|O
less	365	369	|O
than	370	374	|O
the	375	378	|O
6,8	379	382	|B-IUPAC
-	382	383	|I-IUPAC
difluoro	383	391	|I-IUPAC
analogues	392	401	|B-MODIFIER
,	401	402	|O
the	403	406	|O
8	407	408	|B-IUPAC
-	408	409	|I-IUPAC
(	409	410	|I-IUPAC
trifluoromethyl	410	425	|I-IUPAC
)	425	426	|I-IUPAC
quinolones	426	436	|I-IUPAC
are	437	440	|O
generally	441	450	|O
equivalent	451	461	|O
to	462	464	|O
their	465	470	|O
8H	471	473	|O
analogues	474	483	|O
.	483	484	|O
In	485	487	|O
vivo	488	492	|O
,	492	493	|O
they	494	498	|O
are	499	502	|O
comparable	503	513	|O
to	514	516	|O
the	517	520	|O
6,8	521	524	|B-IUPAC
-	524	525	|I-IUPAC
difluoro	525	533	|I-IUPAC
series	534	540	|B-MODIFIER
and	541	544	|O
show	545	549	|O
up	550	552	|O
to	553	555	|O
10	556	558	|O
-	558	559	|O
fold	559	563	|O
improvement	564	575	|O
in	576	578	|O
efficacy	579	587	|O
when	588	592	|O
compared	593	601	|O
to	602	604	|O
their	605	610	|O
ciprofloxacin	611	624	|O
counterparts	625	637	|O
vs	638	640	|O
Streptococcus	641	654	|O
pyogenes	655	663	|O
and	664	667	|O
Streptococcus	668	681	|O
pneumonia	682	691	|O
.	691	692	|O
In	693	695	|O
the	696	699	|O
phototolerance	700	714	|O
model	715	720	|O
,	720	721	|O
the	722	725	|O
8	726	727	|B-IUPAC
-	727	728	|I-IUPAC
(	728	729	|I-IUPAC
trifluoromethyl	729	744	|I-IUPAC
)	744	745	|I-IUPAC
quinolones	745	755	|I-IUPAC
are	756	759	|O
comparable	760	770	|O
to	771	773	|O
the	774	777	|O
8H	778	780	|B-IUPAC
-	780	781	|I-IUPAC
quinolones	781	791	|I-IUPAC
.	791	792	|O
Both	793	797	|O
of	798	800	|O
these	801	806	|O
series	807	813	|O
display	814	821	|O
much	822	826	|O
higher	827	833	|O
no	834	836	|O
effect	837	843	|O
doses	844	849	|O
(	850	851	|O
greater	851	858	|O
tolerance	859	868	|O
)	868	869	|O
than	870	874	|O
the	875	878	|O
corresponding	879	892	|O
6,8	893	896	|B-IUPAC
-	896	897	|I-IUPAC
difluoroquinolones	897	915	|I-IUPAC
.	915	916	|O

### abstracts1810.txt
The	0	3	|O
syntheses	4	13	|O
and	14	17	|O
anthelmintic	18	30	|O
activities	31	41	|O
of	42	44	|O
31	45	47	|O
3	48	49	|B-PARTIUPAC
-	49	50	|I-PARTIUPAC
and	51	54	|O
5	55	56	|B-IUPAC
-	56	57	|I-IUPAC
(	57	58	|I-IUPAC
isothiocyanatophenyl	58	78	|I-IUPAC
)	78	79	|I-IUPAC
-	79	80	|I-IUPAC
1,2,4	80	85	|I-IUPAC
-	85	86	|I-IUPAC
oxadiazoles	86	97	|I-IUPAC
are	98	101	|O
reported	102	110	|O
.	110	111	|O
In	112	114	|O
the	115	118	|O
primary	119	126	|O
anthelmintic	127	139	|O
screen	140	146	|O
,	146	147	|O
3	148	149	|B-IUPAC
-	149	150	|I-IUPAC
(	150	151	|I-IUPAC
4	151	152	|I-IUPAC
-	152	153	|I-IUPAC
isothiocyanatophenyl	153	173	|I-IUPAC
)	173	174	|I-IUPAC
-	174	175	|I-IUPAC
1,2,4	175	180	|I-IUPAC
-	180	181	|I-IUPAC
oxadiazole	181	191	|I-IUPAC
(	192	193	|O
39	193	195	|O
)	195	196	|O
showed	197	203	|O
100%	204	208	|O
nematocidal	209	220	|O
activity	221	229	|O
and	230	233	|O
3	234	235	|B-IUPAC
-	235	236	|I-IUPAC
(	236	237	|I-IUPAC
2	237	238	|I-IUPAC
-	238	239	|I-IUPAC
furanyl	239	246	|I-IUPAC
)	246	247	|I-IUPAC
-	247	248	|I-IUPAC
5	248	249	|I-IUPAC
-	249	250	|I-IUPAC
(	250	251	|I-IUPAC
4	251	252	|I-IUPAC
-	252	253	|I-IUPAC
isothiocyanatophenyl	253	273	|I-IUPAC
)	273	274	|I-IUPAC
-	274	275	|I-IUPAC
1,2,4	275	280	|I-IUPAC
-	280	281	|I-IUPAC
oxadiazole	281	291	|I-IUPAC
(	292	293	|O
63	293	295	|O
)	295	296	|O
,	296	297	|O
3	298	299	|B-IUPAC
-	299	300	|I-IUPAC
(	300	301	|I-IUPAC
2	301	302	|I-IUPAC
-	302	303	|I-IUPAC
furanyl	303	310	|I-IUPAC
)	310	311	|I-IUPAC
-	311	312	|I-IUPAC
5	312	313	|I-IUPAC
-	313	314	|I-IUPAC
(	314	315	|I-IUPAC
2	315	316	|I-IUPAC
-	316	317	|I-IUPAC
chloro	317	323	|I-IUPAC
-	323	324	|I-IUPAC
4	324	325	|I-IUPAC
-	325	326	|I-IUPAC
isothiocyanatophenyl	326	346	|I-IUPAC
)	346	347	|I-IUPAC
-	347	348	|I-IUPAC
1,2,4	348	353	|I-IUPAC
-	353	354	|I-IUPAC
oxadiazole	354	364	|I-IUPAC
(	365	366	|O
64	366	368	|O
)	368	369	|O
,	369	370	|O
and	371	374	|O
3	375	376	|B-IUPAC
-	376	377	|I-IUPAC
(	377	378	|I-IUPAC
2	378	379	|I-IUPAC
-	379	380	|I-IUPAC
furanyl	380	387	|I-IUPAC
)	387	388	|I-IUPAC
-	388	389	|I-IUPAC
5	389	390	|I-IUPAC
-	390	391	|I-IUPAC
(	391	392	|I-IUPAC
4	392	393	|I-IUPAC
-	393	394	|I-IUPAC
chloro	394	400	|I-IUPAC
-	400	401	|I-IUPAC
3	401	402	|I-IUPAC
-	402	403	|I-IUPAC
isothiocyanatophenyl	403	423	|I-IUPAC
)	423	424	|I-IUPAC
-	424	425	|I-IUPAC
1,2,4	425	430	|I-IUPAC
-	430	431	|I-IUPAC
oxadiazole	431	441	|I-IUPAC
(	442	443	|O
66	443	445	|O
)	445	446	|O
showed	447	453	|O
100%	454	458	|O
taeniacidal	459	470	|O
activity	471	479	|O
when	480	484	|O
administered	485	497	|O
orally	498	504	|O
to	505	507	|O
mice	508	512	|O
.	512	513	|O
The	514	517	|O
two	518	521	|O
most	522	526	|O
active	527	533	|O
members	534	541	|O
of	542	544	|O
this	545	549	|O
series	550	556	|O
,	556	557	|O
39	558	560	|O
and	561	564	|O
63	565	567	|O
,	567	568	|O
were	569	573	|O
active	574	580	|O
against	581	588	|O
the	589	592	|O
gastrointestinal	593	609	|O
nematodes	610	619	|O
of	620	622	|O
sheep	623	628	|O
at	629	631	|O
100	632	635	|O
mg	636	638	|O
/	638	639	|O
kg	639	641	|O
.	641	642	|O
In	643	645	|O
addition	646	654	|O
,	654	655	|O
39	656	658	|O
was	659	662	|O
also	663	667	|O
found	668	673	|O
to	674	676	|O
be	677	679	|O
active	680	686	|O
against	687	694	|O
hookworms	695	704	|O
in	705	707	|O
dogs	708	712	|O
at	713	715	|O
a	716	717	|O
single	718	724	|O
,	724	725	|O
oral	726	730	|O
dose	731	735	|O
of	736	738	|O
200	739	742	|O
mg	743	745	|O
/	745	746	|O
kg	746	748	|O
.	748	749	|O

### abstracts4034.txt
A	0	1	|O
novel	2	7	|O
class	8	13	|O
of	14	16	|O
5	17	18	|O
-	18	19	|O
substituted	19	30	|O
acyclic	31	38	|O
pyrimidine	39	49	|O
nucleosides	50	61	|O
,	61	62	|O
1	63	64	|B-IUPAC
-	64	65	|I-IUPAC
[	65	66	|I-IUPAC
(	66	67	|I-IUPAC
2	67	68	|I-IUPAC
-	68	69	|I-IUPAC
hydroxyethoxy	69	82	|I-IUPAC
)	82	83	|I-IUPAC
methyl	83	89	|I-IUPAC
]	89	90	|I-IUPAC
-	90	91	|I-IUPAC
5	91	92	|I-IUPAC
-	92	93	|I-IUPAC
(	93	94	|I-IUPAC
1	94	95	|I-IUPAC
-	95	96	|I-IUPAC
azidovinyl	96	106	|I-IUPAC
)	106	107	|I-IUPAC
uracil	107	113	|I-IUPAC
(	114	115	|O
9a	115	117	|O
)	117	118	|O
,	118	119	|O
1	120	121	|B-IUPAC
-	121	122	|I-IUPAC
[	122	123	|I-IUPAC
(	123	124	|I-IUPAC
2	124	125	|I-IUPAC
-	125	126	|I-IUPAC
hydroxy	126	133	|I-IUPAC
-	133	134	|I-IUPAC
1	134	135	|I-IUPAC
-	135	136	|I-IUPAC
(	136	137	|I-IUPAC
hydroxymethyl	137	150	|I-IUPAC
)	150	151	|I-IUPAC
ethoxy	151	157	|I-IUPAC
)	157	158	|I-IUPAC
methyl	158	164	|I-IUPAC
]	164	165	|I-IUPAC
-	165	166	|I-IUPAC
5	166	167	|I-IUPAC
-	167	168	|I-IUPAC
(	168	169	|I-IUPAC
1	169	170	|I-IUPAC
-	170	171	|I-IUPAC
azidovinyl	171	181	|I-IUPAC
)	181	182	|I-IUPAC
uracil	182	188	|I-IUPAC
(	189	190	|O
9b	190	192	|O
)	192	193	|O
,	193	194	|O
and	195	198	|O
1	199	200	|B-IUPAC
-	200	201	|I-IUPAC
[	201	202	|I-IUPAC
4	202	203	|I-IUPAC
-	203	204	|I-IUPAC
hydroxy	204	211	|I-IUPAC
-	211	212	|I-IUPAC
3	212	213	|I-IUPAC
-	213	214	|I-IUPAC
(	214	215	|I-IUPAC
hydroxymethyl	215	228	|I-IUPAC
)	228	229	|I-IUPAC
-	229	230	|I-IUPAC
1	230	231	|I-IUPAC
-	231	232	|I-IUPAC
butyl	232	237	|I-IUPAC
]	237	238	|I-IUPAC
-	238	239	|I-IUPAC
5	239	240	|I-IUPAC
-	240	241	|I-IUPAC
(	241	242	|I-IUPAC
1	242	243	|I-IUPAC
-	243	244	|I-IUPAC
azidovinyl	244	254	|I-IUPAC
)	254	255	|I-IUPAC
uracil	255	261	|I-IUPAC
(	262	263	|O
9c	263	265	|O
)	265	266	|O
,	266	267	|O
were	268	272	|O
synthesized	273	284	|O
by	285	287	|O
regiospecific	288	301	|O
addition	302	310	|O
of	311	313	|O
bromine	314	321	|O
azide	322	327	|O
to	328	330	|O
the	331	334	|O
5	335	336	|B-IUPAC
-	336	337	|I-IUPAC
vinyl	337	342	|I-IUPAC
substituent	343	354	|B-MODIFIER
of	355	357	|O
the	358	361	|O
respective	362	372	|O
5	373	374	|B-IUPAC
-	374	375	|I-IUPAC
vinyluracils	375	387	|I-IUPAC
(	388	389	|O
2a	389	391	|O
-	391	392	|O
c	392	393	|O
)	393	394	|O
followed	395	403	|O
by	404	406	|O
treatment	407	416	|O
of	417	419	|O
the	420	423	|O
obtained	424	432	|O
5	433	434	|B-IUPAC
-	434	435	|I-IUPAC
(	435	436	|I-IUPAC
1	436	437	|I-IUPAC
-	437	438	|I-IUPAC
azido	438	443	|I-IUPAC
-	443	444	|I-IUPAC
2	444	445	|I-IUPAC
-	445	446	|I-IUPAC
bromoethyl	446	456	|I-IUPAC
)	456	457	|I-IUPAC
compounds	458	467	|B-MODIFIER
(	468	469	|O
3a	469	471	|O
-	471	472	|O
c	472	473	|O
)	473	474	|O
with	475	479	|O
t	480	481	|O
-	481	482	|O
BuOK	482	486	|O
,	486	487	|O
to	488	490	|O
affect	491	497	|O
the	498	501	|O
base	502	506	|O
-	506	507	|O
catalyzed	507	516	|O
elimination	517	528	|O
of	529	531	|O
HBr	532	535	|O
.	535	536	|O
Thermal	537	544	|O
decomposition	545	558	|O
of	559	561	|O
9b	562	564	|O
and	565	568	|O
9c	569	571	|O
at	572	574	|O
110	575	578	|O
degrees	579	586	|O
C	587	588	|O
in	589	591	|O
dioxane	592	599	|O
yielded	600	607	|O
corresponding	608	621	|O
5	622	623	|B-IUPAC
-	623	624	|I-IUPAC
[	624	625	|I-IUPAC
2	625	626	|I-IUPAC
-	626	627	|I-IUPAC
(	627	628	|I-IUPAC
1	628	629	|I-IUPAC
-	629	630	|I-IUPAC
azirinyl	630	638	|I-IUPAC
)	638	639	|I-IUPAC
]	639	640	|I-IUPAC
uracil	640	646	|I-IUPAC
analogues	647	656	|B-MODIFIER
(	657	658	|O
10b	658	661	|O
,	661	662	|O
c	662	663	|O
)	663	664	|O
.	664	665	|O
The	666	669	|O
5	670	671	|B-IUPAC
-	671	672	|I-IUPAC
(	672	673	|I-IUPAC
1	673	674	|I-IUPAC
-	674	675	|I-IUPAC
azidovinyl	675	685	|I-IUPAC
)	685	686	|I-IUPAC
uracil	686	692	|I-IUPAC
derivatives	693	704	|B-MODIFIER
9a	705	707	|O
-	707	708	|O
c	708	709	|O
were	710	714	|O
found	715	720	|O
to	721	723	|O
exhibit	724	731	|O
potent	732	738	|O
and	739	742	|O
selective	743	752	|O
in	753	755	|O
vitro	756	761	|O
anti	762	766	|O
-	766	767	|O
HBV	767	770	|O
activity	771	779	|O
against	780	787	|O
duck	788	792	|O
hepatitis	793	802	|O
B	803	804	|O
virus	805	810	|O
(	811	812	|O
DHBV	812	816	|O
)	816	817	|O
infected	818	826	|O
primary	827	834	|O
duck	835	839	|O
hepatocytes	840	851	|O
at	852	854	|O
low	855	858	|O
concentrations	859	873	|O
(	874	875	|O
EC	875	877	|O
(	877	878	|O
50	878	880	|O
)	880	881	|O
=	882	883	|O
0.01-0.1	884	892	|O
microg	893	899	|O
/	899	900	|O
mL	900	902	|O
range	903	908	|O
)	908	909	|O
.	909	910	|O
The	911	914	|O
most	915	919	|O
active	920	926	|O
anti	927	931	|O
-	931	932	|O
DHBV	932	936	|O
agent	937	942	|O
(	943	944	|O
9c	944	946	|O
)	946	947	|O
,	947	948	|O
possessing	949	959	|O
a	960	961	|O
[	962	963	|B-IUPAC
4	963	964	|I-IUPAC
-	964	965	|I-IUPAC
hydroxy	965	972	|I-IUPAC
-	972	973	|I-IUPAC
3	973	974	|I-IUPAC
-	974	975	|I-IUPAC
(	975	976	|I-IUPAC
hydroxymethyl	976	989	|I-IUPAC
)	989	990	|I-IUPAC
-	990	991	|I-IUPAC
1	991	992	|I-IUPAC
-	992	993	|I-IUPAC
butyl	993	998	|I-IUPAC
]	998	999	|I-IUPAC
substituent	1000	1011	|B-MODIFIER
at	1012	1014	|O
N	1015	1016	|O
-	1016	1017	|O
1	1017	1018	|O
,	1018	1019	|O
exhibited	1020	1029	|O
an	1030	1032	|O
activity	1033	1041	|O
(	1042	1043	|O
EC	1043	1045	|O
(	1045	1046	|O
50	1046	1048	|O
)	1048	1049	|O
of	1050	1052	|O
0.01-0.05	1053	1062	|O
microg	1063	1069	|O
/	1069	1070	|O
mL	1070	1072	|O
)	1072	1073	|O
comparable	1074	1084	|O
to	1085	1087	|O
that	1088	1092	|O
of	1093	1095	|O
reference	1096	1105	|O
compound	1106	1114	|O
(	1115	1116	|B-IUPAC
-	1116	1117	|I-IUPAC
)	1117	1118	|I-IUPAC
-	1118	1119	|I-IUPAC
beta	1119	1123	|I-IUPAC
-	1123	1124	|I-IUPAC
L	1124	1125	|I-IUPAC
-	1125	1126	|I-IUPAC
2'	1126	1128	|I-IUPAC
,	1128	1129	|I-IUPAC
3'	1129	1131	|I-IUPAC
-	1131	1132	|I-IUPAC
dideoxy	1132	1139	|I-IUPAC
-	1139	1140	|I-IUPAC
3'	1140	1142	|I-IUPAC
-	1142	1143	|I-IUPAC
thiacytidine	1143	1155	|I-IUPAC
(	1156	1157	|O
3	1157	1158	|O
-	1158	1159	|O
TC	1159	1161	|O
)	1161	1162	|O
(	1163	1164	|O
EC	1164	1166	|O
(	1166	1167	|O
50	1167	1169	|O
)	1169	1170	|O
=	1171	1172	|O
0.01-0.05	1173	1182	|O
microg	1183	1189	|O
/	1189	1190	|O
mL	1190	1192	|O
)	1192	1193	|O
.	1193	1194	|O
In	1195	1197	|O
contrast	1198	1206	|O
,	1206	1207	|O
related	1208	1215	|O
5	1216	1217	|B-IUPAC
-	1217	1218	|I-IUPAC
[	1218	1219	|I-IUPAC
2	1219	1220	|I-IUPAC
-	1220	1221	|I-IUPAC
(	1221	1222	|I-IUPAC
1	1222	1223	|I-IUPAC
-	1223	1224	|I-IUPAC
azirinyl	1224	1232	|I-IUPAC
)	1232	1233	|I-IUPAC
]	1233	1234	|I-IUPAC
uracil	1234	1240	|I-IUPAC
analogues	1241	1250	|B-MODIFIER
(	1251	1252	|O
10b	1252	1255	|O
,	1255	1256	|O
c	1256	1257	|O
)	1257	1258	|O
were	1259	1263	|O
devoid	1264	1270	|O
of	1271	1273	|O
anti	1274	1278	|O
-	1278	1279	|O
DHBV	1279	1283	|O
activity	1284	1292	|O
,	1292	1293	|O
indicating	1294	1304	|O
that	1305	1309	|O
an	1310	1312	|O
acyclic	1313	1320	|O
side	1321	1325	|O
chain	1326	1331	|O
at	1332	1334	|O
C	1335	1336	|O
-	1336	1337	|O
5	1337	1338	|O
position	1339	1347	|O
of	1348	1350	|O
the	1351	1354	|O
pyrimidine	1355	1365	|O
ring	1366	1370	|O
is	1371	1373	|O
essential	1374	1383	|O
for	1384	1387	|O
anti	1388	1392	|O
-	1392	1393	|O
HBV	1393	1396	|O
activity	1397	1405	|O
.	1405	1406	|O
The	1407	1410	|O
pyrimidine	1411	1421	|O
nucleosides	1422	1433	|O
(	1434	1435	|O
9a	1435	1437	|O
-	1437	1438	|O
c	1438	1439	|O
,	1439	1440	|O
10b	1441	1444	|O
,	1444	1445	|O
c	1445	1446	|O
)	1446	1447	|O
exhibited	1448	1457	|O
no	1458	1460	|O
cytotoxic	1461	1470	|O
activity	1471	1479	|O
against	1480	1487	|O
a	1488	1489	|O
panel	1490	1495	|O
of	1496	1498	|O
60	1499	1501	|O
human	1502	1507	|O
cancer	1508	1514	|O
cell	1515	1519	|O
lines	1520	1525	|O
.	1525	1526	|O
All	1527	1530	|O
of	1531	1533	|O
the	1534	1537	|O
compounds	1538	1547	|O
investigated	1548	1560	|O
did	1561	1564	|O
not	1565	1568	|O
show	1569	1573	|O
any	1574	1577	|O
detectable	1578	1588	|O
toxicity	1589	1597	|O
to	1598	1600	|O
several	1601	1608	|O
stationary	1609	1619	|O
and	1620	1623	|O
proliferating	1624	1637	|O
host	1638	1642	|O
cell	1643	1647	|O
lines	1648	1653	|O
or	1654	1656	|O
to	1657	1659	|O
mitogen	1660	1667	|O
stimulated	1668	1678	|O
proliferating	1679	1692	|O
human	1693	1698	|O
T	1699	1700	|O
lymphocytes	1701	1712	|O
,	1712	1713	|O
up	1714	1716	|O
to	1717	1719	|O
the	1720	1723	|O
highest	1724	1731	|O
concentration	1732	1745	|O
tested	1746	1752	|O
.	1752	1753	|O

### abstracts2195.txt
The	0	3	|O
isomeric	4	12	|O
4	13	14	|B-PARTIUPAC
-	14	15	|I-PARTIUPAC
(	15	16	|I-PARTIUPAC
3	16	17	|I-PARTIUPAC
-	17	18	|I-PARTIUPAC
chloro	18	24	|I-PARTIUPAC
-	24	25	|I-PARTIUPAC
4	25	26	|I-PARTIUPAC
-	26	27	|I-PARTIUPAC
hydroxyphenyl	27	40	|I-PARTIUPAC
)	40	41	|I-PARTIUPAC
-	41	42	|I-PARTIUPAC
and	43	46	|O
4	47	48	|B-IUPAC
-	48	49	|I-IUPAC
(	49	50	|I-IUPAC
4	50	51	|I-IUPAC
-	51	52	|I-IUPAC
chloro	52	58	|I-IUPAC
-	58	59	|I-IUPAC
3	59	60	|I-IUPAC
-	60	61	|I-IUPAC
hydroxyphenyl	61	74	|I-IUPAC
)	74	75	|I-IUPAC
-	75	76	|I-IUPAC
1,2,3,4	76	83	|I-IUPAC
-	83	84	|I-IUPAC
tetrahydroisoquinolines	84	107	|I-IUPAC
,	107	108	|O
the	109	112	|O
N	113	114	|B-IUPAC
-	114	115	|I-IUPAC
methyl	115	121	|I-IUPAC
derivative	122	132	|B-MODIFIER
of	133	135	|O
the	136	139	|O
4	140	141	|B-IUPAC
-	141	142	|I-IUPAC
(	142	143	|I-IUPAC
4	143	144	|I-IUPAC
-	144	145	|I-IUPAC
chloro	145	151	|I-IUPAC
-	151	152	|I-IUPAC
3	152	153	|I-IUPAC
-	153	154	|I-IUPAC
hydroxyphenyl	154	167	|I-IUPAC
)	167	168	|I-IUPAC
isomer	169	175	|B-MODIFIER
,	175	176	|O
and	177	180	|O
4	181	182	|B-IUPAC
-	182	183	|I-IUPAC
(	183	184	|I-IUPAC
3	184	185	|I-IUPAC
-	185	186	|I-IUPAC
hydroxyphenyl	186	199	|I-IUPAC
)	199	200	|I-IUPAC
-	200	201	|I-IUPAC
1,2,3,4	201	208	|I-IUPAC
-	208	209	|I-IUPAC
tetrahydroisoquinoline	209	231	|I-IUPAC
were	232	236	|O
synthesized	237	248	|O
and	249	252	|O
evaluated	253	262	|O
for	263	266	|O
dopamine	267	275	|O
D	276	277	|O
-	277	278	|O
1	278	279	|O
antagonist	280	290	|O
activity	291	299	|O
.	299	300	|O
The	301	304	|O
4	305	306	|B-IUPAC
-	306	307	|I-IUPAC
(	307	308	|I-IUPAC
3	308	309	|I-IUPAC
-	309	310	|I-IUPAC
chloro	310	316	|I-IUPAC
-	316	317	|I-IUPAC
4	317	318	|I-IUPAC
-	318	319	|I-IUPAC
hydroxyphenyl	319	332	|I-IUPAC
)	332	333	|I-IUPAC
and	334	337	|O
the	338	341	|O
4	342	343	|B-IUPAC
-	343	344	|I-IUPAC
(	344	345	|I-IUPAC
3	345	346	|I-IUPAC
-	346	347	|I-IUPAC
hydroxyphenyl	347	360	|I-IUPAC
)	360	361	|I-IUPAC
isomer	362	368	|B-MODIFIER
possessed	369	378	|O
similar	379	386	|O
potencies	387	396	|O
as	397	399	|O
D	400	401	|O
-	401	402	|O
1	402	403	|O
antagonists	404	415	|O
.	415	416	|O
Introduction	417	429	|O
of	430	432	|O
the	433	436	|O
N	437	438	|B-IUPAC
-	438	439	|I-IUPAC
methyl	439	445	|I-IUPAC
group	446	451	|B-MODIFIER
enhanced	452	460	|O
potency	461	468	|O
about	469	474	|O
twofold	475	482	|O
.	482	483	|O
The	484	487	|O
"	488	489	|O
pharmacophore	489	502	|O
"	502	503	|O
for	504	507	|O
selective	508	517	|O
dopamine	518	526	|O
D	527	528	|O
-	528	529	|O
1	529	530	|O
antagonist	531	541	|O
activity	542	550	|O
appears	551	558	|O
to	559	561	|O
be	562	564	|O
a	565	566	|O
tertiary	567	575	|O
2	576	577	|B-IUPAC
-	577	578	|I-IUPAC
(	578	579	|I-IUPAC
3	579	580	|I-IUPAC
-	580	581	|I-IUPAC
hydroxyphenyl	581	594	|I-IUPAC
)	594	595	|I-IUPAC
-	595	596	|I-IUPAC
2	596	597	|I-IUPAC
-	597	598	|I-IUPAC
phenethylamine	598	612	|I-IUPAC
.	612	613	|O

### abstracts4230.txt
Spiro	0	5	|O
[	5	6	|O
isobenzofuran	6	19	|O
-	19	20	|O
1	20	21	|O
(	21	22	|O
3H	22	24	|O
)	24	25	|O
,	25	26	|O
4'	26	28	|O
-	28	29	|O
piperidines	29	40	|O
]	40	41	|O
and	42	45	|O
the	46	49	|O
corresponding	50	63	|O
benzofuran	64	74	|O
and	75	78	|O
benzopyran	79	89	|O
derivatives	90	101	|O
have	102	106	|O
been	107	111	|O
synthesized	112	123	|O
and	124	127	|O
evaluated	128	137	|O
as	138	140	|O
sigma	141	146	|O
ligands	147	154	|O
.	154	155	|O
The	156	159	|O
compounds	160	169	|O
are	170	173	|O
related	174	181	|O
to	182	184	|O
Lu	185	187	|O
28-179	188	194	|O
(	195	196	|O
1'	196	198	|B-IUPAC
-	198	199	|I-IUPAC
[	199	200	|I-IUPAC
4	200	201	|I-IUPAC
-	201	202	|I-IUPAC
[	202	203	|I-IUPAC
1	203	204	|I-IUPAC
-	204	205	|I-IUPAC
(	205	206	|I-IUPAC
4	206	207	|I-IUPAC
-	207	208	|I-IUPAC
fluorophenyl	208	220	|I-IUPAC
)	220	221	|I-IUPAC
-	221	222	|I-IUPAC
1H	222	224	|I-IUPAC
-	224	225	|I-IUPAC
indol	225	230	|I-IUPAC
-	230	231	|I-IUPAC
3	231	232	|I-IUPAC
-	232	233	|I-IUPAC
yl	233	235	|I-IUPAC
]	235	236	|I-IUPAC
-	236	237	|I-IUPAC
1	237	238	|I-IUPAC
-	238	239	|I-IUPAC
butyl	240	245	|I-IUPAC
]	245	246	|I-IUPAC
spiro	246	251	|I-IUPAC
[	251	252	|I-IUPAC
isobenzofuran	252	265	|I-IUPAC
-	265	266	|I-IUPAC
1	266	267	|I-IUPAC
(	267	268	|I-IUPAC
3H	268	270	|I-IUPAC
)	270	271	|I-IUPAC
,	271	272	|I-IUPAC
4'	272	274	|I-IUPAC
-	274	275	|I-IUPAC
piperidine	275	285	|I-IUPAC
]	285	286	|I-IUPAC
)	286	287	|O
that	288	292	|O
has	293	296	|O
been	297	301	|O
demonstrated	302	314	|O
to	315	317	|O
be	318	320	|O
a	321	322	|O
selective	323	332	|O
sigma	333	338	|O
2	339	340	|O
ligand	341	347	|O
with	348	352	|O
affinity	353	361	|O
in	362	364	|O
the	365	368	|O
subnanomolar	369	381	|O
range	382	387	|O
.	387	388	|O
The	389	392	|O
object	393	399	|O
of	400	402	|O
the	403	406	|O
study	407	412	|O
was	413	416	|O
to	417	419	|O
determine	420	429	|O
the	430	433	|O
structural	434	444	|O
factors	445	452	|O
governing	453	462	|O
sigma	463	468	|O
1	469	470	|O
/	470	471	|O
sigma	471	476	|O
2	477	478	|O
affinity	479	487	|O
and	488	491	|O
selectivity	492	503	|O
within	504	510	|O
this	511	515	|O
class	516	521	|O
of	522	524	|O
compounds	525	534	|O
.	534	535	|O
The	536	539	|O
N	540	541	|O
-	541	542	|O
substituent	542	553	|O
in	554	556	|O
spiro	557	562	|B-IUPAC
[	562	563	|I-IUPAC
isobenzofuran	563	576	|I-IUPAC
-	576	577	|I-IUPAC
1	577	578	|I-IUPAC
(	578	579	|I-IUPAC
3H	579	581	|I-IUPAC
)	581	582	|I-IUPAC
,	582	583	|I-IUPAC
4'	583	585	|I-IUPAC
-	585	586	|I-IUPAC
piperidines	586	597	|I-IUPAC
]	597	598	|I-IUPAC
is	599	601	|O
highly	602	608	|O
important	609	618	|O
,	618	619	|O
both	620	624	|O
for	625	628	|O
affinity	629	637	|O
and	638	641	|O
selectivity	642	653	|O
.	653	654	|O
Spiropiperidines	655	671	|O
with	672	676	|O
no	677	679	|O
or	680	682	|O
small	683	688	|O
N	689	690	|O
-	690	691	|O
substituents	691	703	|O
(	704	705	|O
H	705	706	|O
,	706	707	|O
Me	708	710	|O
,	710	711	|O
Et	712	714	|O
)	714	715	|O
exert	716	721	|O
very	722	726	|O
low	727	730	|O
affinity	731	739	|O
for	740	743	|O
both	744	748	|O
sigma	749	754	|O
1	755	756	|O
and	757	760	|O
sigma	761	766	|O
2	767	768	|O
binding	769	776	|O
sites	777	782	|O
(	783	784	|O
IC50	784	788	|O
(	788	789	|O
sigma	789	794	|O
1	795	796	|O
,	796	797	|O
sigma	798	803	|O
2	804	805	|O
)	805	806	|O
&	807	808	|O
gt	808	810	|O
;	810	811	|O
100	812	815	|O
nM	816	818	|O
)	818	819	|O
,	819	820	|O
whereas	821	828	|O
medium	829	835	|O
-	835	836	|O
sized	836	841	|O
substituents	842	854	|O
(	855	856	|O
e.g.	856	860	|O
,	860	861	|O
Pr	862	864	|O
,	864	865	|O
Bu	866	868	|O
,	868	869	|O
Ph	870	872	|O
(	872	873	|O
CH2	873	876	|O
)	876	877	|O
2	877	878	|O
)	878	879	|O
result	880	886	|O
in	887	889	|O
potent	890	896	|O
,	896	897	|O
but	898	901	|O
unselective	902	913	|O
compounds	914	923	|O
(	924	925	|O
IC50	925	929	|O
(	929	930	|O
sigma	930	935	|O
1	936	937	|O
,	937	938	|O
sigma	939	944	|O
2	945	946	|O
)	946	947	|O
=	948	949	|O
2-5	950	953	|O
nM	954	956	|O
)	956	957	|O
.	957	958	|O
Increasing	959	969	|O
the	970	973	|O
chain	974	979	|O
length	980	986	|O
and	987	990	|O
the	991	994	|O
lipophilicity	995	1008	|O
of	1009	1011	|O
the	1012	1015	|O
N	1016	1017	|O
-	1017	1018	|O
substituent	1018	1029	|O
result	1030	1036	|O
in	1037	1039	|O
compounds	1040	1049	|O
in	1050	1052	|O
which	1053	1058	|O
high	1059	1063	|O
affinity	1064	1072	|O
for	1073	1076	|O
sigma	1077	1082	|O
2	1083	1084	|O
binding	1085	1092	|O
sites	1093	1098	|O
is	1099	1101	|O
retained	1102	1110	|O
and	1111	1114	|O
with	1115	1119	|O
selectivity	1120	1131	|O
for	1132	1135	|O
sigma	1136	1141	|O
2	1142	1143	|O
vs	1144	1146	|O
sigma	1147	1152	|O
1	1153	1154	|O
binding	1155	1162	|O
sites	1163	1168	|O
(	1169	1170	|O
e.g.	1170	1174	|O
,	1174	1175	|O
4	1176	1177	|B-IUPAC
-	1177	1178	|I-IUPAC
cyclohexyl	1178	1188	|I-IUPAC
-	1188	1189	|I-IUPAC
1	1189	1190	|I-IUPAC
-	1190	1191	|I-IUPAC
butyl	1191	1196	|I-IUPAC
:	1196	1197	|O
IC50	1198	1202	|O
-	1202	1203	|O
(	1203	1204	|O
sigma	1204	1209	|O
1	1210	1211	|O
)	1211	1212	|O
=	1213	1214	|O
1.5	1215	1218	|O
nM	1219	1221	|O
,	1221	1222	|O
IC50	1223	1227	|O
(	1227	1228	|O
sigma	1228	1233	|O
2	1234	1235	|O
)	1235	1236	|O
=	1237	1238	|O
0.07	1239	1243	|O
nM	1244	1246	|O
)	1246	1247	|O
.	1247	1248	|O
Introduction	1249	1261	|O
of	1262	1264	|O
substituents	1265	1277	|O
in	1278	1280	|O
the	1281	1284	|O
benzene	1285	1292	|O
ring	1293	1297	|O
of	1298	1300	|O
the	1301	1304	|O
spiro	1305	1310	|B-IUPAC
[	1310	1311	|I-IUPAC
isobenzofuran	1311	1324	|I-IUPAC
-	1324	1325	|I-IUPAC
1	1325	1326	|I-IUPAC
(	1326	1327	|I-IUPAC
3H	1327	1329	|I-IUPAC
)	1329	1330	|I-IUPAC
,	1330	1331	|I-IUPAC
4'	1331	1333	|I-IUPAC
-	1333	1334	|I-IUPAC
piperidine	1334	1344	|I-IUPAC
]	1344	1345	|I-IUPAC
ring	1346	1350	|O
system	1351	1357	|O
of	1358	1360	|O
Lu	1361	1363	|O
28-179	1364	1370	|O
mainly	1371	1377	|O
affects	1378	1385	|O
affinity	1386	1394	|O
for	1395	1398	|O
sigma	1399	1404	|O
1	1405	1406	|O
binding	1407	1414	|O
sites	1415	1420	|O
.	1420	1421	|O
Compounds	1422	1431	|O
with	1432	1436	|O
substituents	1437	1449	|O
(	1450	1451	|O
F	1451	1452	|O
,	1452	1453	|O
CF3	1454	1457	|O
)	1457	1458	|O
in	1459	1461	|O
the	1462	1465	|O
4	1466	1467	|O
-	1467	1468	|O
or	1469	1471	|O
7	1472	1473	|O
-	1473	1474	|O
position	1474	1482	|O
of	1483	1485	|O
the	1486	1489	|O
isobenzofuran	1490	1503	|O
display	1504	1511	|O
high	1512	1516	|O
affinity	1517	1525	|O
for	1526	1529	|O
sigma	1530	1535	|O
2	1536	1537	|O
binding	1538	1545	|O
sites	1546	1551	|O
(	1552	1553	|O
IC50	1553	1557	|O
(	1557	1558	|O
sigma	1558	1563	|O
2	1564	1565	|O
)	1565	1566	|O
=	1567	1568	|O
0.5-2	1569	1574	|O
nM	1575	1577	|O
)	1577	1578	|O
and	1579	1582	|O
very	1583	1587	|O
low	1588	1591	|O
affinity	1592	1600	|O
for	1601	1604	|O
sigma	1605	1610	|O
1	1611	1612	|O
binding	1613	1620	|O
sites	1621	1626	|O
(	1627	1628	|O
IC50	1628	1632	|O
(	1632	1633	|O
sigma	1633	1638	|O
1	1639	1640	|O
)	1640	1641	|O
&	1642	1643	|O
gt	1643	1645	|O
;	1645	1646	|O
100	1647	1650	|O
nM	1651	1653	|O
)	1653	1654	|O
.	1654	1655	|O
Compounds	1656	1665	|O
with	1666	1670	|O
substituents	1671	1683	|O
(	1684	1685	|O
F	1685	1686	|O
,	1686	1687	|O
CF3	1688	1691	|O
,	1691	1692	|O
Me	1693	1695	|O
)	1695	1696	|O
in	1697	1699	|O
the	1700	1703	|O
5	1704	1705	|O
-	1705	1706	|O
or	1707	1709	|O
6	1710	1711	|O
-	1711	1712	|O
position	1712	1720	|O
of	1721	1723	|O
the	1724	1727	|O
isobenzofuran	1728	1741	|O
exert	1742	1747	|O
increased	1748	1757	|O
affinity	1758	1766	|O
for	1767	1770	|O
sigma	1771	1776	|O
1	1777	1778	|O
binding	1779	1786	|O
sites	1787	1792	|O
(	1793	1794	|O
IC50	1794	1798	|O
(	1798	1799	|O
sigma	1799	1804	|O
1	1805	1806	|O
)	1806	1807	|O
=	1808	1809	|O
5-30	1810	1814	|O
nM	1815	1817	|O
,	1817	1818	|O
IC50	1819	1823	|O
(	1823	1824	|O
sigma	1824	1829	|O
2	1830	1831	|O
)	1831	1832	|O
=	1833	1834	|O
0.3-7	1835	1840	|O
nM	1841	1843	|O
)	1843	1844	|O
,	1844	1845	|O
thus	1846	1850	|O
rendering	1851	1860	|O
unselective	1861	1872	|O
compounds	1873	1882	|O
.	1882	1883	|O
Exchanging	1884	1894	|O
the	1895	1898	|O
isobenzofuran	1899	1912	|O
moiety	1913	1919	|O
of	1920	1922	|O
Lu	1923	1925	|O
28-179	1926	1932	|O
with	1933	1937	|O
thioisobenzofuran	1938	1955	|O
,	1955	1956	|O
benzofuran	1957	1967	|O
,	1967	1968	|O
or	1969	1971	|O
benzopyran	1972	1982	|O
also	1983	1987	|O
has	1988	1991	|O
a	1992	1993	|O
pronounced	1994	2004	|O
effect	2005	2011	|O
on	2012	2014	|O
both	2015	2019	|O
affinity	2020	2028	|O
and	2029	2032	|O
selectivity	2033	2044	|O
for	2045	2048	|O
sigma	2049	2054	|O
binding	2055	2062	|O
sites	2063	2068	|O
.	2068	2069	|O
The	2070	2073	|O
position	2074	2082	|O
of	2083	2085	|O
the	2086	2089	|O
oxygen	2090	2096	|O
atom	2097	2101	|O
and	2102	2105	|O
the	2106	2109	|O
position	2110	2118	|O
of	2119	2121	|O
the	2122	2125	|O
spiroconnection	2126	2141	|O
with	2142	2146	|O
the	2147	2150	|O
4	2151	2152	|O
-	2152	2153	|O
position	2153	2161	|O
of	2162	2164	|O
the	2165	2168	|O
piperidine	2169	2179	|O
ring	2180	2184	|O
were	2185	2189	|O
varied	2190	2196	|O
,	2196	2197	|O
and	2198	2201	|O
only	2202	2206	|O
compounds	2207	2216	|O
in	2217	2219	|O
which	2220	2225	|O
both	2226	2230	|O
the	2231	2234	|O
benzene	2235	2242	|O
ring	2243	2247	|O
and	2248	2251	|O
the	2252	2255	|O
heteroatom	2256	2266	|O
are	2267	2270	|O
attached	2271	2279	|O
directly	2280	2288	|O
to	2289	2291	|O
the	2292	2295	|O
piperidine	2296	2306	|O
ring	2307	2311	|O
retain	2312	2318	|O
high	2319	2323	|O
affinity	2324	2332	|O
and	2333	2336	|O
selectivity	2337	2348	|O
for	2349	2352	|O
sigma	2353	2358	|O
2	2359	2360	|O
binding	2361	2368	|O
sites	2369	2374	|O
(	2375	2376	|O
e.g.	2376	2380	|O
,	2380	2381	|O
3,4	2382	2385	|B-IUPAC
-	2385	2386	|I-IUPAC
dihydro	2386	2393	|I-IUPAC
-	2393	2394	|I-IUPAC
1'	2394	2396	|I-IUPAC
-	2396	2397	|I-IUPAC
[	2397	2398	|I-IUPAC
4	2398	2399	|I-IUPAC
-	2399	2400	|I-IUPAC
[	2400	2401	|I-IUPAC
1	2401	2402	|I-IUPAC
-	2402	2403	|I-IUPAC
(	2403	2404	|I-IUPAC
4	2404	2405	|I-IUPAC
-	2405	2406	|I-IUPAC
fluorophenyl	2406	2418	|I-IUPAC
)	2418	2419	|I-IUPAC
-	2419	2420	|I-IUPAC
1H	2420	2422	|I-IUPAC
-	2422	2423	|I-IUPAC
indol	2423	2428	|I-IUPAC
-	2428	2429	|I-IUPAC
3	2429	2430	|I-IUPAC
-	2430	2431	|I-IUPAC
yl	2431	2433	|I-IUPAC
]	2433	2434	|I-IUPAC
-	2434	2435	|I-IUPAC
1	2435	2436	|I-IUPAC
-	2436	2437	|I-IUPAC
butyl	2438	2443	|I-IUPAC
]	2443	2444	|I-IUPAC
spiro	2444	2449	|I-IUPAC
[	2449	2450	|I-IUPAC
1H	2450	2452	|I-IUPAC
-	2452	2453	|I-IUPAC
2	2453	2454	|I-IUPAC
-	2454	2455	|I-IUPAC
benzopyran	2455	2465	|I-IUPAC
-	2465	2466	|I-IUPAC
1,4	2466	2469	|I-IUPAC
'	2469	2470	|I-IUPAC
-	2470	2471	|I-IUPAC
piperidine	2471	2481	|I-IUPAC
]	2481	2482	|I-IUPAC
:	2482	2483	|O
IC50	2484	2488	|O
(	2488	2489	|O
sigma	2489	2494	|O
1	2495	2496	|O
)	2496	2497	|O
=	2498	2499	|O
53	2500	2502	|O
nM	2503	2505	|O
,	2505	2506	|O
IC50	2507	2511	|O
(	2511	2512	|O
sigma	2512	2517	|O
2	2518	2519	|O
)	2519	2520	|O
=	2521	2522	|O
0.9	2523	2526	|O
nM	2527	2529	|O
)	2529	2530	|O
.	2530	2531	|O
(	2531	2532	|O
ABSTRACT	2532	2540	|O
TRUNCATED	2541	2550	|O
AT	2551	2553	|O
400	2554	2557	|O
WORDS	2558	2563	|O
)	2563	2564	|O

### abstracts4600.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
22	12	14	|B-IUPAC
-	14	15	|I-IUPAC
hydroxycholesterol	15	33	|I-IUPAC
derivatives	34	45	|B-MODIFIER
with	46	50	|O
a	51	52	|O
modified	53	61	|O
side	62	66	|O
chain	67	72	|O
terminus	73	81	|O
was	82	85	|O
prepared	86	94	|O
.	94	95	|O
These	96	101	|O
agents	102	108	|O
were	109	113	|O
evaluated	114	123	|O
in	124	126	|O
vitro	127	132	|O
and	133	136	|O
in	137	139	|O
vivo	140	144	|O
for	145	148	|O
their	149	154	|O
ability	155	162	|O
to	163	165	|O
suppress	166	174	|O
HMG	175	178	|O
CoA	179	182	|O
reductase	183	192	|O
,	192	193	|O
the	194	197	|O
rate	198	202	|O
-	202	203	|O
limiting	203	211	|O
enzyme	212	218	|O
of	219	221	|O
cholesterol	222	233	|O
biosynthesis	234	246	|O
.	246	247	|O
In	248	250	|O
tissue	251	257	|O
culture	258	265	|O
assays	266	272	|O
,	272	273	|O
22	274	276	|B-IUPAC
-	276	277	|I-IUPAC
hydroxycholesterol	277	295	|I-IUPAC
as	296	298	|O
well	299	303	|O
as	304	306	|O
the	307	310	|O
side	311	315	|O
chain	316	321	|O
modified	322	330	|O
analogues	331	340	|O
were	341	345	|O
potent	346	352	|O
inhibitors	353	363	|O
of	364	366	|O
HMG	367	370	|O
CoA	371	374	|O
reductase	375	384	|O
.	384	385	|O
However	386	393	|O
,	393	394	|O
only	395	399	|O
those	400	405	|O
sterols	406	413	|O
with	414	418	|O
a	419	420	|O
modified	421	429	|O
side	430	434	|O
chain	435	440	|O
terminus	441	449	|O
were	450	454	|O
effective	455	464	|O
suppressors	465	476	|O
of	477	479	|O
liver	480	485	|O
reductase	486	495	|O
when	496	500	|O
administered	501	513	|O
ig	514	516	|O
to	517	519	|O
rats	520	524	|O
.	524	525	|O
22	526	528	|B-IUPAC
-	528	529	|I-IUPAC
Hydroxy	529	536	|I-IUPAC
-	536	537	|I-IUPAC
25	537	539	|I-IUPAC
-	539	540	|I-IUPAC
methylcholesterol	540	557	|I-IUPAC
(	558	559	|O
4a	559	561	|O
)	561	562	|O
and	563	566	|O
25	567	569	|B-IUPAC
-	569	570	|I-IUPAC
fluoro	570	576	|I-IUPAC
-	576	577	|I-IUPAC
22	577	579	|I-IUPAC
-	579	580	|I-IUPAC
hydroxycholesterol	580	598	|I-IUPAC
(	599	600	|O
15a	600	603	|O
)	603	604	|O
significantly	605	618	|O
lowered	619	626	|O
serum	627	632	|O
cholesterol	633	644	|O
levels	645	651	|O
when	652	656	|O
administered	657	669	|O
ig	670	672	|O
to	673	675	|O
primates	676	684	|O
;	684	685	|O
25	686	688	|B-IUPAC
-	688	689	|I-IUPAC
chloro	689	695	|I-IUPAC
-	695	696	|I-IUPAC
22	696	698	|I-IUPAC
-	698	699	|I-IUPAC
hydroxycholesterol	699	717	|I-IUPAC
(	718	719	|O
15b	719	722	|O
)	722	723	|O
and	724	727	|O
the	728	731	|O
analogue	732	740	|O
with	741	745	|O
a	746	747	|O
cyclopropyl	748	759	|B-IUPAC
terminus	760	768	|B-MODIFIER
,	768	769	|O
20b	770	773	|O
,	773	774	|O
were	775	779	|O
ineffective	780	791	|O
.	791	792	|O
The	793	796	|O
cholesterol	797	808	|O
-	808	809	|O
lowering	809	817	|O
sterols	818	825	|O
did	826	829	|O
not	830	833	|O
significantly	834	847	|O
alter	848	853	|O
lipoprotein	854	865	|O
levels	866	872	|O
;	872	873	|O
however	874	881	|O
,	881	882	|O
the	883	886	|O
two	887	890	|O
compounds	891	900	|O
have	901	905	|O
been	906	910	|O
shown	911	916	|O
to	917	919	|O
inhibit	920	927	|O
acyl	928	932	|O
-	932	933	|O
coenzyme	933	941	|O
A	942	943	|O
:	943	944	|O
cholesterol	944	955	|O
acyl	956	960	|O
-	960	961	|O
transferase	961	972	|O
(	973	974	|O
ACAT	974	978	|O
)	978	979	|O
in	980	982	|O
tissue	983	989	|O
culture	990	997	|O
studies	998	1005	|O
.	1005	1006	|O

### abstracts3761.txt
Hypoxic	0	7	|O
cells	8	13	|O
are	14	17	|O
an	18	20	|O
important	21	30	|O
target	31	37	|O
for	38	41	|O
antitumor	42	51	|O
therapy	52	59	|O
because	60	67	|O
tumors	68	74	|O
are	75	78	|O
typically	79	88	|O
characterized	89	102	|O
by	103	105	|O
such	106	110	|O
cells	111	116	|O
.	116	117	|O
Virtually	118	127	|O
all	128	131	|O
tumors	132	138	|O
which	139	144	|O
are	145	148	|O
present	149	156	|O
as	157	159	|O
solid	160	165	|O
masses	166	172	|O
contain	173	180	|O
hypoxic	181	188	|O
cells	189	194	|O
,	194	195	|O
while	196	201	|O
normal	202	208	|O
cells	209	214	|O
generally	215	224	|O
have	225	229	|O
an	230	232	|O
adequate	233	241	|O
supply	242	248	|O
of	249	251	|O
oxygen	252	258	|O
.	258	259	|O
Accordingly	260	271	|O
,	271	272	|O
antitumor	273	282	|O
agents	283	289	|O
can	290	293	|O
be	294	296	|O
made	297	301	|O
selective	302	311	|O
for	312	315	|O
tumors	316	322	|O
by	323	325	|O
virtue	326	332	|O
of	333	335	|O
high	336	340	|O
activity	341	349	|O
under	350	355	|O
hypoxic	356	363	|O
conditions	364	374	|O
.	374	375	|O
The	376	379	|O
initial	380	387	|O
purpose	388	395	|O
of	396	398	|O
this	399	403	|O
work	404	408	|O
was	409	412	|O
to	413	415	|O
determine	416	425	|O
the	426	429	|O
influence	430	439	|O
of	440	442	|O
different	443	452	|O
groups	453	459	|O
in	460	462	|O
position	463	471	|O
3	472	473	|O
.	473	474	|O
Thus	475	479	|O
,	479	480	|O
the	481	484	|O
synthesis	485	494	|O
of	495	497	|O
some	498	502	|O
3	503	504	|O
-	504	505	|O
NH	505	507	|O
-	507	508	|O
substituted	508	519	|O
derivatives	520	531	|O
(	532	533	|O
2a	533	535	|O
,	535	536	|O
3a	537	539	|O
,	539	540	|O
4a	541	543	|O
)	543	544	|O
starting	545	553	|O
from	554	558	|O
3	559	560	|B-IUPAC
-	560	561	|I-IUPAC
amino	561	566	|I-IUPAC
-	566	567	|I-IUPAC
2	567	568	|I-IUPAC
-	568	569	|I-IUPAC
quinoxalinecarbonitrile	569	592	|I-IUPAC
1,4	593	596	|I-IUPAC
-	596	597	|I-IUPAC
di	597	599	|I-IUPAC
-	599	600	|I-IUPAC
N	600	601	|I-IUPAC
-	601	602	|I-IUPAC
oxide	602	607	|I-IUPAC
(	608	609	|O
1a	609	611	|O
)	611	612	|O
is	613	615	|O
described	616	625	|O
.	625	626	|O
Reductive	627	636	|O
deamination	637	648	|O
of	649	651	|O
compounds	652	661	|O
1a	662	664	|O
-	664	665	|O
k	665	666	|O
provides	667	675	|O
the	676	679	|O
2	680	681	|B-IUPAC
-	681	682	|I-IUPAC
quinoxalinecarbonitriles	682	706	|I-IUPAC
5a	707	709	|O
-	709	710	|O
k	710	711	|O
,	711	712	|O
which	713	718	|O
are	719	722	|O
more	723	727	|O
potent	728	734	|O
,	734	735	|O
while	736	741	|O
selectivity	742	753	|O
is	754	756	|O
maintained	757	767	|O
or	768	770	|O
increased	771	780	|O
in	781	783	|O
some	784	788	|O
derivatives	789	800	|O
.	800	801	|O
The	802	805	|O
compound	806	814	|O
7	815	816	|B-IUPAC
-	816	817	|I-IUPAC
(	817	818	|I-IUPAC
4	818	819	|I-IUPAC
-	819	820	|I-IUPAC
nitrophenyl	820	831	|I-IUPAC
)	831	832	|I-IUPAC
-	832	833	|I-IUPAC
2	833	834	|I-IUPAC
-	834	835	|I-IUPAC
quinoxalinecarbonitrile	835	858	|I-IUPAC
1,4	859	862	|I-IUPAC
-	862	863	|I-IUPAC
di	863	865	|I-IUPAC
-	865	866	|I-IUPAC
N	866	867	|I-IUPAC
-	867	868	|I-IUPAC
oxide	868	873	|I-IUPAC
(	874	875	|O
5k	875	877	|O
)	877	878	|O
is	879	881	|O
150	882	885	|O
-	885	886	|O
fold	886	890	|O
more	891	895	|O
potent	896	902	|O
than	903	907	|O
tirapazamine	908	920	|O
(	921	922	|O
3	922	923	|B-IUPAC
-	923	924	|I-IUPAC
amino	924	929	|I-IUPAC
-	929	930	|I-IUPAC
1,2,4	930	935	|I-IUPAC
-	935	936	|I-IUPAC
benzotriazine	937	950	|I-IUPAC
1,4	951	954	|I-IUPAC
-	954	955	|I-IUPAC
di	955	957	|I-IUPAC
-	957	958	|I-IUPAC
N	958	959	|I-IUPAC
-	959	960	|I-IUPAC
oxide	960	965	|I-IUPAC
)	965	966	|O
,	966	967	|O
which	968	973	|O
has	974	977	|O
been	978	982	|O
used	983	987	|O
as	988	990	|O
a	991	992	|O
standard	993	1001	|O
.	1001	1002	|O
Three	1003	1008	|O
derivatives	1009	1020	|O
(	1021	1022	|O
5g	1022	1024	|O
,	1024	1025	|O
i	1025	1026	|O
,	1026	1027	|O
k	1027	1028	|O
)	1028	1029	|O
show	1030	1034	|O
a	1035	1036	|O
hypoxic	1037	1044	|O
cytotoxicity	1045	1057	|O
ratio	1058	1063	|O
(	1064	1065	|O
HCR	1065	1068	|O
)	1068	1069	|O
&	1070	1071	|O
gt	1071	1073	|O
;	1073	1074	|O
or	1075	1077	|O
=	1078	1079	|O
200	1080	1083	|O
,	1083	1084	|O
better	1085	1091	|O
than	1092	1096	|O
that	1097	1101	|O
of	1102	1104	|O
tirapazamine	1105	1117	|O
(	1118	1119	|O
HCR	1119	1122	|O
=	1123	1124	|O
75	1125	1127	|O
)	1127	1128	|O
in	1129	1131	|O
V79	1132	1135	|O
cells	1136	1141	|O
.	1141	1142	|O
Replacement	1143	1154	|O
of	1155	1157	|O
the	1158	1161	|O
3	1162	1163	|B-IUPAC
-	1163	1164	|I-IUPAC
amino	1164	1169	|I-IUPAC
group	1170	1175	|B-MODIFIER
by	1176	1178	|O
chlorine	1179	1187	|O
affords	1188	1195	|O
the	1196	1199	|O
potent	1200	1206	|O
but	1207	1210	|O
nonselective	1211	1223	|O
3	1224	1225	|B-IUPAC
-	1225	1226	|I-IUPAC
chloro	1226	1232	|I-IUPAC
derivatives	1233	1244	|B-MODIFIER
6a	1245	1247	|O
-	1247	1248	|O
k	1248	1249	|O
showing	1250	1257	|O
similar	1258	1265	|O
toxicities	1266	1276	|O
under	1277	1282	|O
both	1283	1287	|O
aerobic	1288	1295	|O
and	1296	1299	|O
hypoxic	1300	1307	|O
conditions	1308	1318	|O
.	1318	1319	|O
These	1320	1325	|O
compounds	1326	1335	|O
were	1336	1340	|O
used	1341	1345	|O
as	1346	1348	|O
intermediates	1349	1362	|O
for	1363	1366	|O
the	1367	1370	|O
synthesis	1371	1380	|O
of	1381	1383	|O
a	1384	1385	|O
new	1386	1389	|O
series	1390	1396	|O
of	1397	1399	|O
water	1400	1405	|O
-	1405	1406	|O
soluble	1406	1413	|O
compounds	1414	1423	|O
derived	1424	1431	|O
from	1432	1436	|O
3	1437	1438	|B-IUPAC
-	1438	1439	|I-IUPAC
[	1439	1440	|I-IUPAC
[	1440	1441	|I-IUPAC
(	1441	1442	|I-IUPAC
N	1442	1443	|I-IUPAC
,	1443	1444	|I-IUPAC
N	1444	1445	|I-IUPAC
-	1445	1446	|I-IUPAC
dialkylamino	1447	1459	|I-IUPAC
)	1459	1460	|I-IUPAC
alkyl	1460	1465	|I-IUPAC
[	1465	1466	|I-IUPAC
amino	1466	1471	|I-IUPAC
]	1471	1472	|I-IUPAC
-	1472	1473	|I-IUPAC
2	1473	1474	|I-IUPAC
-	1474	1475	|I-IUPAC
quinoxalinecarbonitrile	1475	1498	|I-IUPAC
1,4	1499	1502	|I-IUPAC
-	1502	1503	|I-IUPAC
di	1503	1505	|I-IUPAC
-	1505	1506	|I-IUPAC
N	1506	1507	|I-IUPAC
-	1507	1508	|I-IUPAC
oxides	1508	1514	|I-IUPAC
10a	1515	1518	|O
-	1518	1519	|O
i	1519	1520	|O
and	1521	1524	|O
11a	1525	1528	|O
-	1528	1529	|O
i	1529	1530	|O
.	1530	1531	|O
The	1532	1535	|O
7	1536	1537	|B-IUPAC
-	1537	1538	|I-IUPAC
chloro	1538	1544	|I-IUPAC
and	1545	1548	|O
the	1549	1552	|O
7	1553	1554	|B-IUPAC
-	1554	1555	|I-IUPAC
trifluoromethyl	1555	1570	|I-IUPAC
derivatives	1571	1582	|B-MODIFIER
10b	1583	1586	|O
,	1586	1587	|O
f	1587	1588	|O
have	1589	1593	|O
demonstrated	1594	1606	|O
high	1607	1611	|O
potency	1612	1619	|O
(	1620	1621	|O
0.4	1621	1624	|O
and	1625	1628	|O
0.3	1629	1632	|O
microM	1633	1639	|O
)	1639	1640	|O
and	1641	1644	|O
excellent	1645	1654	|O
selectivity	1655	1666	|O
(	1667	1668	|O
HCR	1668	1671	|O
=	1672	1673	|O
250	1674	1677	|O
and	1678	1681	|O
340	1682	1685	|O
)	1685	1686	|O
.	1686	1687	|O
Several	1688	1695	|O
7	1696	1697	|B-IUPAC
-	1697	1698	|I-IUPAC
chloro	1698	1704	|I-IUPAC
analogues	1705	1714	|B-MODIFIER
,	1714	1715	|O
12b	1716	1719	|O
,	1719	1720	|O
13b	1721	1724	|O
.1	1724	1726	|O
,	1726	1727	|O
b	1727	1728	|O
.2	1728	1730	|O
,	1730	1731	|O
and	1732	1735	|O
14b	1736	1739	|O
,	1739	1740	|O
and	1741	1744	|O
the	1745	1748	|O
dimer	1749	1754	|O
16b	1755	1758	|O
have	1759	1763	|O
been	1764	1768	|O
prepared	1769	1777	|O
and	1778	1781	|O
evaluated	1782	1791	|O
in	1792	1794	|O
order	1795	1800	|O
to	1801	1803	|O
determine	1804	1813	|O
the	1814	1817	|O
optimum	1818	1825	|O
lateral	1826	1833	|O
chain	1834	1839	|O
in	1840	1842	|O
position	1843	1851	|O
3	1852	1853	|O
,	1853	1854	|O
which	1855	1860	|O
appears	1861	1868	|O
to	1869	1871	|O
be	1872	1874	|O
the	1875	1878	|O
[	1879	1880	|B-IUPAC
(	1880	1881	|I-IUPAC
N	1881	1882	|I-IUPAC
,	1882	1883	|I-IUPAC
N	1883	1884	|I-IUPAC
-	1884	1885	|I-IUPAC
dimethylamino	1885	1898	|I-IUPAC
)	1898	1899	|I-IUPAC
propyl	1899	1905	|I-IUPAC
]	1905	1906	|I-IUPAC
amino	1906	1911	|I-IUPAC
moiety	1912	1918	|B-MODIFIER
.	1918	1919	|O

### abstracts838.txt
Condensation	0	12	|O
of	13	15	|O
14	16	18	|B-IUPAC
-	18	19	|I-IUPAC
bromodaunorubicin	19	36	|I-IUPAC
with	37	41	|O
thiols	42	48	|O
in	49	51	|O
methanol	52	60	|O
,	60	61	|O
in	62	64	|O
the	65	68	|O
presence	69	77	|O
of	78	80	|O
potassium	81	90	|O
carbonate	91	100	|O
,	100	101	|O
resulted	102	110	|O
in	111	113	|O
the	114	117	|O
formation	118	127	|O
of	128	130	|O
14	131	133	|O
-	133	134	|O
thia	134	138	|O
analogues	139	148	|O
of	149	151	|O
the	152	155	|O
antitumor	156	165	|O
antibiotic	166	176	|O
adriamycin	177	187	|O
.	187	188	|O
However	189	196	|O
,	196	197	|O
similar	198	205	|O
condensation	206	218	|O
of	219	221	|O
N	222	223	|B-IUPAC
-	223	224	|I-IUPAC
(	224	225	|I-IUPAC
trifluoroacetyl	225	240	|I-IUPAC
)	240	241	|I-IUPAC
-	241	242	|I-IUPAC
14	242	244	|I-IUPAC
-	244	245	|I-IUPAC
iododaunorubicin	245	261	|I-IUPAC
with	262	266	|O
thiols	267	273	|O
invariably	274	284	|O
led	285	288	|O
to	289	291	|O
a	292	293	|O
redox	294	299	|O
reaction	300	308	|O
,	308	309	|O
with	310	314	|O
the	315	318	|O
formation	319	328	|O
of	329	331	|O
N	332	333	|B-IUPAC
-	333	334	|I-IUPAC
(	334	335	|I-IUPAC
trifluoroacetyl	335	350	|I-IUPAC
)	350	351	|I-IUPAC
daunorubicin	351	363	|I-IUPAC
and	364	367	|O
disulfides	368	378	|O
.	378	379	|O
Accordingly	380	391	|O
,	391	392	|O
N	393	394	|B-IUPAC
-	394	395	|I-IUPAC
(	395	396	|I-IUPAC
trifluoroacetyl	396	411	|I-IUPAC
)	411	412	|I-IUPAC
-	412	413	|I-IUPAC
14	413	415	|I-IUPAC
-	415	416	|I-IUPAC
bromodaunorubicin	416	433	|I-IUPAC
was	434	437	|O
used	438	442	|O
for	443	446	|O
reaction	447	455	|O
with	456	460	|O
thiols	461	467	|O
to	468	470	|O
yield	471	476	|O
thia	477	481	|O
analogues	482	491	|O
of	492	494	|O
the	495	498	|O
clinically	499	509	|O
active	510	516	|O
but	517	520	|O
non	521	524	|O
-	524	525	|O
DNA	525	528	|O
-	528	529	|O
binding	529	536	|O
adriamycin	537	547	|O
analogue	548	556	|O
N	557	558	|B-IUPAC
-	558	559	|I-IUPAC
(	559	560	|I-IUPAC
trifluoroacetyl	560	575	|I-IUPAC
)	575	576	|I-IUPAC
adriamycin	576	586	|I-IUPAC
14	587	589	|I-IUPAC
-	589	590	|I-IUPAC
valerate	590	598	|I-IUPAC
(	599	600	|O
AD	600	602	|O
32	603	605	|O
)	605	606	|O
.	606	607	|O
Reaction	608	616	|O
of	617	619	|O
14	620	622	|B-IUPAC
-	622	623	|I-IUPAC
bromoadunorubicin	623	640	|I-IUPAC
with	641	645	|O
alpha	646	651	|O
,	651	652	|O
omega	653	658	|O
-	658	659	|O
alkanedithiols	659	673	|O
gave	674	678	|O
bis	679	682	|O
(	682	683	|O
thiaadriamycin	683	697	|O
)	697	698	|O
analogues	699	708	|O
as	709	711	|O
potential	712	721	|O
difunctional	722	734	|O
intercalating	735	748	|O
agents	749	755	|O
.	755	756	|O
The	757	760	|O
aforementioned	761	775	|O
products	776	784	|O
,	784	785	|O
plus	786	790	|O
two	791	794	|O
related	795	802	|O
phenylselena	803	815	|O
derivatives	816	827	|O
,	827	828	|O
were	829	833	|O
examined	834	842	|O
for	843	846	|O
in	847	849	|O
vitro	850	855	|O
growth	856	862	|O
inhibition	863	873	|O
,	873	874	|O
in	875	877	|O
vivo	878	882	|O
antitumor	883	892	|O
activity	893	901	|O
,	901	902	|O
and	903	906	|O
,	906	907	|O
where	908	913	|O
appropriate	914	925	|O
,	925	926	|O
DNA	927	930	|O
binding	931	938	|O
.	938	939	|O
A	940	941	|O
number	942	948	|O
of	949	951	|O
agents	952	958	|O
,	958	959	|O
most	960	964	|O
notably	965	972	|O
14	973	975	|B-IUPAC
-	975	976	|I-IUPAC
(	976	977	|I-IUPAC
carbethoxymethyl	977	993	|I-IUPAC
)	993	994	|I-IUPAC
-	994	995	|I-IUPAC
14	995	997	|I-IUPAC
-	997	998	|I-IUPAC
thiaadriamycin	998	1012	|I-IUPAC
and	1013	1016	|O
N	1017	1018	|B-IUPAC
-	1018	1019	|I-IUPAC
(	1019	1020	|I-IUPAC
trifluoroacetyl	1020	1035	|I-IUPAC
)	1035	1036	|I-IUPAC
-	1036	1037	|I-IUPAC
14	1037	1039	|I-IUPAC
-	1039	1040	|I-IUPAC
phenyl	1040	1046	|I-IUPAC
-	1046	1047	|I-IUPAC
14	1047	1049	|I-IUPAC
-	1049	1050	|I-IUPAC
selenaadriamycin	1050	1066	|I-IUPAC
,	1066	1067	|O
were	1068	1072	|O
active	1073	1079	|O
against	1080	1087	|O
murine	1088	1094	|O
L1210	1095	1100	|O
leukemia	1101	1109	|O
in	1110	1112	|O
vivo	1113	1117	|O
.	1117	1118	|O
Several	1119	1126	|O
of	1127	1129	|O
the	1130	1133	|O
amino	1134	1139	|O
glycoside	1140	1149	|O
unsubstituted	1150	1163	|O
14	1164	1166	|B-IUPAC
-	1166	1167	|I-IUPAC
thiaadriamycin	1167	1181	|I-IUPAC
analogues	1182	1191	|B-MODIFIER
exhibited	1192	1201	|O
DNA	1202	1205	|O
-	1205	1206	|O
binding	1206	1213	|O
properties	1214	1224	|O
equivalent	1225	1235	|O
to	1236	1238	|O
those	1239	1244	|O
of	1245	1247	|O
adriamycin	1248	1258	|O
.	1258	1259	|O

### abstracts4139.txt
Three	0	5	|O
electrophilic	6	19	|O
amide	20	25	|O
analogues	26	35	|O
of	36	38	|O
(	39	40	|B-IUPAC
S	40	41	|I-IUPAC
)	41	42	|I-IUPAC
-	42	43	|I-IUPAC
2,3	43	46	|I-IUPAC
-	46	47	|I-IUPAC
diaminopropionic	47	63	|I-IUPAC
acid	64	68	|I-IUPAC
(	69	70	|O
1	70	71	|O
,	71	72	|O
DAP	73	76	|O
)	76	77	|O
have	78	82	|O
been	83	87	|O
prepared	88	96	|O
as	97	99	|O
potential	100	109	|O
inhibitors	110	120	|O
of	121	123	|O
L	124	125	|O
-	125	126	|O
asparagine	126	136	|O
synthetase	137	147	|O
(	148	149	|O
ASase	149	154	|O
,	154	155	|O
from	156	160	|O
Novikoff	161	169	|O
hepatoma	170	178	|O
,	178	179	|O
EC	180	182	|O
6.3.5.4	183	190	|O
)	190	191	|O
.	191	192	|O
DAP	193	196	|O
was	197	200	|O
selectively	201	212	|O
blocked	213	220	|O
by	221	223	|O
the	224	227	|O
carbobenzoxy	228	240	|O
(	241	242	|O
Cbz	242	245	|O
)	245	246	|O
group	247	252	|O
to	253	255	|O
give	256	260	|O
3	261	262	|O
-	262	263	|O
N	263	264	|O
-	264	265	|O
Cbz	265	268	|O
-	268	269	|O
DAP	269	272	|O
(	273	274	|O
2a	274	276	|O
)	276	277	|O
.	277	278	|O
Esterification	279	293	|O
of	294	296	|O
2a	297	299	|O
with	300	304	|O
isobutylene	305	316	|O
afforded	317	325	|O
tert	326	330	|B-IUPAC
-	330	331	|I-IUPAC
butyl	331	336	|I-IUPAC
3	337	338	|I-IUPAC
-	338	339	|I-IUPAC
N	339	340	|I-IUPAC
-	340	341	|I-IUPAC
carbobenzoxy	341	353	|I-IUPAC
-	353	354	|I-IUPAC
(	354	355	|I-IUPAC
S	355	356	|I-IUPAC
)	356	357	|I-IUPAC
-	357	358	|I-IUPAC
2,3	358	361	|I-IUPAC
-	361	362	|I-IUPAC
diaminopropionate	362	379	|I-IUPAC
(	380	381	|O
3a	381	383	|O
)	383	384	|O
,	384	385	|O
which	386	391	|O
was	392	395	|O
then	396	400	|O
blocked	401	408	|O
at	409	411	|O
the	412	415	|O
2	416	417	|O
position	418	426	|O
with	427	431	|O
the	432	435	|O
tert	436	440	|B-IUPAC
-	440	441	|I-IUPAC
butoxycarbonyl	441	455	|I-IUPAC
(	456	457	|O
Boc	457	460	|O
)	460	461	|O
group	462	467	|B-MODIFIER
to	468	470	|O
give	471	475	|O
tert	476	480	|B-IUPAC
-	480	481	|I-IUPAC
butyl	481	486	|I-IUPAC
2	487	488	|I-IUPAC
-	488	489	|I-IUPAC
[	489	490	|I-IUPAC
(	490	491	|I-IUPAC
S	491	492	|I-IUPAC
)	492	493	|I-IUPAC
-	493	494	|I-IUPAC
(	494	495	|I-IUPAC
tert	495	499	|I-IUPAC
-	499	500	|I-IUPAC
butoxycarbonyl	500	514	|I-IUPAC
)	514	515	|I-IUPAC
amino	515	520	|I-IUPAC
]	520	521	|I-IUPAC
-	521	522	|I-IUPAC
3	522	523	|I-IUPAC
-	523	524	|I-IUPAC
[	524	525	|I-IUPAC
(	525	526	|I-IUPAC
carbobenzoxy	526	538	|I-IUPAC
)	538	539	|I-IUPAC
amino	539	544	|I-IUPAC
]	544	545	|I-IUPAC
propionate	545	555	|I-IUPAC
(	556	557	|O
4	557	558	|O
)	558	559	|O
.	559	560	|O
Selective	561	570	|O
cleavage	571	579	|O
of	580	582	|O
the	583	586	|O
Cbz	587	590	|O
group	591	596	|O
by	597	599	|O
H2	600	602	|O
/	602	603	|O
Pd	603	605	|O
gave	606	610	|O
the	611	614	|O
key	615	618	|O
intermediate	619	631	|O
tert	632	636	|B-IUPAC
-	636	637	|I-IUPAC
butyl	637	642	|I-IUPAC
2	643	644	|I-IUPAC
-	644	645	|I-IUPAC
N	645	646	|I-IUPAC
-	646	647	|I-IUPAC
(	647	648	|I-IUPAC
tert	648	652	|I-IUPAC
-	652	653	|I-IUPAC
butoxycarbonyl	653	667	|I-IUPAC
)	667	668	|I-IUPAC
-	668	669	|I-IUPAC
(	669	670	|I-IUPAC
S	670	671	|I-IUPAC
)	671	672	|I-IUPAC
-	672	673	|I-IUPAC
2,3	673	676	|I-IUPAC
-	676	677	|I-IUPAC
diaminopropionate	677	694	|I-IUPAC
(	695	696	|O
5	696	697	|O
)	697	698	|O
,	698	699	|O
which	700	705	|O
was	706	709	|O
acylated	710	718	|O
,	718	719	|O
via	720	723	|O
the	724	727	|O
N	728	729	|B-IUPAC
-	729	730	|I-IUPAC
hydroxysuccinimide	730	748	|I-IUPAC
esters	749	755	|I-IUPAC
,	755	756	|O
with	757	761	|O
bromoacetic	762	773	|B-IUPAC
acid	774	778	|I-IUPAC
,	778	779	|O
dichloroacetic	780	794	|O
acid	795	799	|O
,	799	800	|O
and	801	804	|O
fumaric	805	812	|B-IUPAC
acid	813	817	|I-IUPAC
monoethyl	818	827	|I-IUPAC
ester	828	833	|I-IUPAC
to	834	836	|O
give	837	841	|O
tert	842	846	|B-IUPAC
-	846	847	|I-IUPAC
butyl	847	852	|I-IUPAC
2	853	854	|I-IUPAC
-	854	855	|I-IUPAC
[	855	856	|I-IUPAC
(	856	857	|I-IUPAC
S	857	858	|I-IUPAC
)	858	859	|I-IUPAC
-	859	860	|I-IUPAC
(	860	861	|I-IUPAC
tert	861	865	|I-IUPAC
-	865	866	|I-IUPAC
butoxycarbonyl	866	880	|I-IUPAC
)	880	881	|I-IUPAC
-	881	882	|I-IUPAC
amino	882	887	|I-IUPAC
]	887	888	|I-IUPAC
-	888	889	|I-IUPAC
3	889	890	|I-IUPAC
-	890	891	|I-IUPAC
(	891	892	|I-IUPAC
2	892	893	|I-IUPAC
-	893	894	|I-IUPAC
bromoacetamido	894	908	|I-IUPAC
)	908	909	|I-IUPAC
propionate	909	919	|I-IUPAC
(	920	921	|O
6a	921	923	|O
)	923	924	|O
,	924	925	|O
tert	926	930	|B-IUPAC
-	930	931	|I-IUPAC
butyl	931	936	|I-IUPAC
2	937	938	|I-IUPAC
-	938	939	|I-IUPAC
[	939	940	|I-IUPAC
(	940	941	|I-IUPAC
S	941	942	|I-IUPAC
)	942	943	|I-IUPAC
-	943	944	|I-IUPAC
(	944	945	|I-IUPAC
tert	945	949	|I-IUPAC
-	949	950	|I-IUPAC
butoxycarbonyl	950	964	|I-IUPAC
)	964	965	|I-IUPAC
amino	965	970	|I-IUPAC
]	970	971	|I-IUPAC
-	971	972	|I-IUPAC
3	972	973	|I-IUPAC
-	973	974	|I-IUPAC
(	974	975	|I-IUPAC
2,2	975	978	|I-IUPAC
-	978	979	|I-IUPAC
dichloroacetamido	979	996	|I-IUPAC
)	996	997	|I-IUPAC
propionate	997	1007	|I-IUPAC
(	1008	1009	|O
6b	1009	1011	|O
)	1011	1012	|O
,	1012	1013	|O
and	1014	1017	|O
tert	1018	1022	|B-IUPAC
-	1022	1023	|I-IUPAC
butyl	1023	1028	|I-IUPAC
2	1029	1030	|I-IUPAC
-	1030	1031	|I-IUPAC
[	1031	1032	|I-IUPAC
(	1032	1033	|I-IUPAC
S	1033	1034	|I-IUPAC
)	1034	1035	|I-IUPAC
-	1035	1036	|I-IUPAC
(	1036	1037	|I-IUPAC
tert	1037	1041	|I-IUPAC
-	1041	1042	|I-IUPAC
butoxycarbonyl	1042	1056	|I-IUPAC
)	1056	1057	|I-IUPAC
amino	1057	1062	|I-IUPAC
]	1062	1063	|I-IUPAC
-	1063	1064	|I-IUPAC
3	1064	1065	|I-IUPAC
-	1065	1066	|I-IUPAC
(	1066	1067	|I-IUPAC
ethoxycarbonyl	1067	1081	|I-IUPAC
)	1081	1082	|I-IUPAC
acrylamido	1082	1092	|I-IUPAC
]	1092	1093	|I-IUPAC
-	1093	1094	|I-IUPAC
propionate	1094	1104	|I-IUPAC
(	1105	1106	|O
6c	1106	1108	|O
)	1108	1109	|O
,	1109	1110	|O
respectively	1111	1123	|O
.	1123	1124	|O
Deblocking	1125	1135	|O
of	1136	1138	|O
6a	1139	1141	|O
-	1141	1142	|O
c	1142	1143	|O
gave	1144	1148	|O
the	1149	1152	|O
corresponding	1153	1166	|O
amino	1167	1172	|B-IUPAC
acids	1173	1178	|I-IUPAC
(	1179	1180	|B-IUPAC
S	1180	1181	|I-IUPAC
)	1181	1182	|I-IUPAC
-	1182	1183	|I-IUPAC
2	1183	1184	|I-IUPAC
-	1184	1185	|I-IUPAC
amino	1185	1190	|I-IUPAC
-	1190	1191	|I-IUPAC
3	1191	1192	|I-IUPAC
-	1192	1193	|I-IUPAC
(	1193	1194	|I-IUPAC
2	1194	1195	|I-IUPAC
-	1195	1196	|I-IUPAC
bromoacetamido	1196	1210	|I-IUPAC
)	1210	1211	|I-IUPAC
propionic	1211	1220	|I-IUPAC
acid	1221	1225	|I-IUPAC
hydrobromide	1226	1238	|I-IUPAC
(	1239	1240	|O
7a	1240	1242	|O
)	1242	1243	|O
,	1243	1244	|O
(	1245	1246	|B-IUPAC
S	1246	1247	|I-IUPAC
)	1247	1248	|I-IUPAC
-	1248	1249	|I-IUPAC
2	1249	1250	|I-IUPAC
-	1250	1251	|I-IUPAC
amino	1251	1256	|I-IUPAC
-	1256	1257	|I-IUPAC
3	1257	1258	|I-IUPAC
-	1258	1259	|I-IUPAC
(	1259	1260	|I-IUPAC
2,2	1260	1263	|I-IUPAC
-	1263	1264	|I-IUPAC
dichloroacetamido	1264	1281	|I-IUPAC
)	1281	1282	|I-IUPAC
propionic	1282	1291	|I-IUPAC
acid	1292	1296	|I-IUPAC
(	1297	1298	|O
7b	1298	1300	|O
)	1300	1301	|O
,	1301	1302	|O
and	1303	1306	|O
ethyl	1307	1312	|B-IUPAC
N	1313	1314	|I-IUPAC
-	1314	1315	|I-IUPAC
[	1315	1316	|I-IUPAC
(	1316	1317	|I-IUPAC
S	1317	1318	|I-IUPAC
)	1318	1319	|I-IUPAC
-	1319	1320	|I-IUPAC
2	1320	1321	|I-IUPAC
-	1321	1322	|I-IUPAC
amino	1322	1327	|I-IUPAC
-	1327	1328	|I-IUPAC
2	1328	1329	|I-IUPAC
-	1329	1330	|I-IUPAC
carboxyethyl	1330	1342	|I-IUPAC
]	1342	1343	|I-IUPAC
fumarate	1343	1351	|I-IUPAC
(	1352	1353	|O
7c	1353	1355	|O
)	1355	1356	|O
.	1356	1357	|O
By	1358	1360	|O
a	1361	1362	|O
slightly	1363	1371	|O
different	1372	1381	|O
procedure	1382	1391	|O
,	1391	1392	|O
5	1393	1394	|O
was	1395	1398	|O
converted	1399	1408	|O
in	1409	1411	|O
two	1412	1415	|O
steps	1416	1421	|O
to	1422	1424	|O
(	1425	1426	|B-IUPAC
S	1426	1427	|I-IUPAC
)	1427	1428	|I-IUPAC
-	1428	1429	|I-IUPAC
2	1429	1430	|I-IUPAC
-	1430	1431	|I-IUPAC
amino	1431	1436	|I-IUPAC
-	1436	1437	|I-IUPAC
3	1437	1438	|I-IUPAC
-	1438	1439	|I-IUPAC
acetamidopropionic	1439	1457	|I-IUPAC
acid	1458	1462	|I-IUPAC
hydrobromide	1463	1475	|I-IUPAC
(	1476	1477	|O
7d	1477	1479	|O
)	1479	1480	|O
.	1480	1481	|O
The	1482	1485	|O
inhibition	1486	1496	|O
of	1497	1499	|O
ASase	1500	1505	|O
by	1506	1508	|O
7a	1509	1511	|O
-	1511	1512	|O
c	1512	1513	|O
at	1514	1516	|O
1	1517	1518	|O
mM	1519	1521	|O
was	1522	1525	|O
93	1526	1528	|O
,	1528	1529	|O
19	1530	1532	|O
,	1532	1533	|O
and	1534	1537	|O
37%	1538	1541	|O
,	1541	1542	|O
respectively	1543	1555	|O
,	1555	1556	|O
while	1557	1562	|O
7d	1563	1565	|O
was	1566	1569	|O
without	1570	1577	|O
inhibition	1578	1588	|O
at	1589	1591	|O
2	1592	1593	|O
mM	1594	1596	|O
.	1596	1597	|O
Compounds	1598	1607	|O
7a	1608	1610	|O
-	1610	1611	|O
c	1611	1612	|O
failed	1613	1619	|O
to	1620	1622	|O
increase	1623	1631	|O
the	1632	1635	|O
life	1636	1640	|O
span	1641	1645	|O
of	1646	1648	|O
mice	1649	1653	|O
infected	1654	1662	|O
with	1663	1667	|O
B16	1668	1671	|O
melanoma	1672	1680	|O
.	1680	1681	|O

### abstracts1310.txt
4	0	1	|O
-	1	2	|O
(	2	3	|O
Dimethylamino	3	16	|O
)	16	17	|O
-	17	18	|O
and	19	22	|O
4	23	24	|B-IUPAC
-	24	25	|I-IUPAC
(	25	26	|I-IUPAC
methylamino	26	37	|I-IUPAC
)	37	38	|I-IUPAC
-	38	39	|I-IUPAC
3'	39	41	|I-IUPAC
-	41	42	|I-IUPAC
arylspiro	42	51	|I-IUPAC
[	51	52	|I-IUPAC
cyclohexane	52	63	|I-IUPAC
-	63	64	|I-IUPAC
1,1	64	67	|I-IUPAC
'	67	68	|I-IUPAC
(	68	69	|I-IUPAC
3'	69	71	|I-IUPAC
H	71	72	|I-IUPAC
)	72	73	|I-IUPAC
-	73	74	|I-IUPAC
isobenzofuran	74	87	|I-IUPAC
]	87	88	|I-IUPAC
derivatives	89	100	|B-MODIFIER
were	101	105	|O
prepared	106	114	|O
as	115	117	|O
analogues	118	127	|O
of	128	130	|O
previously	131	141	|O
reported	142	150	|O
3	151	152	|B-IUPAC
-	152	153	|I-IUPAC
arylspiro	153	162	|I-IUPAC
[	162	163	|I-IUPAC
isobenzofuran	163	176	|I-IUPAC
-	176	177	|I-IUPAC
1	177	178	|I-IUPAC
(	178	179	|I-IUPAC
3H	179	181	|I-IUPAC
)	181	182	|I-IUPAC
,	182	183	|I-IUPAC
4'	183	185	|I-IUPAC
-	185	186	|I-IUPAC
piperidines	186	197	|I-IUPAC
]	197	198	|I-IUPAC
.	198	199	|O
Metalation	200	210	|O
of	211	213	|O
benzanilide	214	225	|O
with	226	230	|O
n	231	232	|B-IUPAC
-	232	233	|I-IUPAC
butyllithium	233	245	|I-IUPAC
,	245	246	|O
addition	247	255	|O
of	256	258	|O
4	259	260	|B-IUPAC
-	260	261	|I-IUPAC
(	261	262	|I-IUPAC
dimethylamino	262	275	|I-IUPAC
)	275	276	|I-IUPAC
cyclohexanone	276	289	|I-IUPAC
,	289	290	|O
and	291	294	|O
acidification	295	308	|O
afforded	309	317	|O
a	318	319	|O
mixture	320	327	|O
of	328	330	|O
cis	331	334	|B-PARTIUPAC
-	334	335	|I-PARTIUPAC
and	336	339	|O
trans	340	345	|B-IUPAC
-	345	346	|I-IUPAC
4	346	347	|I-IUPAC
-	347	348	|I-IUPAC
(	348	349	|I-IUPAC
dimethylamino	349	362	|I-IUPAC
)	362	363	|I-IUPAC
spiro	363	368	|I-IUPAC
[	368	369	|I-IUPAC
cyclohexane	369	380	|I-IUPAC
-	380	381	|I-IUPAC
1,1	381	384	|I-IUPAC
'	384	385	|I-IUPAC
(	385	386	|I-IUPAC
3'	386	388	|I-IUPAC
H	388	389	|I-IUPAC
)	389	390	|I-IUPAC
-	390	391	|I-IUPAC
isobenzofuran	391	404	|I-IUPAC
]	404	405	|I-IUPAC
-	405	406	|I-IUPAC
3'	406	408	|I-IUPAC
-	408	409	|I-IUPAC
ones	409	413	|I-IUPAC
(	414	415	|O
1a	415	417	|O
,	417	418	|O
b	418	419	|O
)	419	420	|O
,	420	421	|O
which	422	427	|O
were	428	432	|O
separated	433	442	|O
by	443	445	|O
fractional	446	456	|O
crystallization	457	472	|O
.	472	473	|O
Addition	474	482	|O
of	483	485	|O
aryllithium	486	497	|O
or	498	500	|O
aryl	501	505	|O
Grignard	506	514	|O
reagents	515	523	|O
to	524	526	|O
1a	527	529	|O
,	529	530	|O
b	530	531	|O
and	532	535	|O
formic	536	542	|O
acid	543	547	|O
reduction	548	557	|O
afforded	558	566	|O
cis	567	570	|B-PARTIUPAC
-	570	571	|I-PARTIUPAC
and	572	575	|O
trans	576	581	|B-IUPAC
-	581	582	|I-IUPAC
4	582	583	|I-IUPAC
-	583	584	|I-IUPAC
(	584	585	|I-IUPAC
dimethylamino	585	598	|I-IUPAC
)	598	599	|I-IUPAC
-	599	600	|I-IUPAC
3'	600	602	|I-IUPAC
-	602	603	|I-IUPAC
arylspiro	603	612	|I-IUPAC
[	612	613	|I-IUPAC
cyclohexane	613	624	|I-IUPAC
-	624	625	|I-IUPAC
1,1	625	628	|I-IUPAC
'	628	629	|I-IUPAC
(	629	630	|I-IUPAC
3'	630	632	|I-IUPAC
H	632	633	|I-IUPAC
)	633	634	|I-IUPAC
-	634	635	|I-IUPAC
isobenzofurans	635	649	|I-IUPAC
]	649	650	|I-IUPAC
3a	651	653	|O
-	653	654	|O
f	654	655	|O
,	655	656	|O
which	657	662	|O
were	663	667	|O
converted	668	677	|O
to	678	680	|O
secondary	681	690	|O
amine	691	696	|O
analogues	697	706	|O
5a	707	709	|O
-	709	710	|O
e	710	711	|O
.	711	712	|O
Tentative	713	722	|O
stereochemical	723	737	|O
assignments	738	749	|O
are	750	753	|O
based	754	759	|O
on	760	762	|O
chemical	763	771	|O
arguments	772	781	|O
and	782	785	|O
are	786	789	|O
supported	790	799	|O
by	800	802	|O
13C	803	806	|O
NMR	807	810	|O
chemical	811	819	|O
shift	820	825	|O
data	826	830	|O
.	830	831	|O
Marked	832	838	|O
inhibition	839	849	|O
of	850	852	|O
tetrabenazine	853	866	|O
-	866	867	|O
induced	867	874	|O
ptosis	875	881	|O
is	882	884	|O
a	885	886	|O
property	887	895	|O
of	896	898	|O
most	899	903	|O
antidepressants	904	919	|O
,	919	920	|O
and	921	924	|O
significant	925	936	|O
antitetrabenazine	937	954	|O
activity	955	963	|O
is	964	966	|O
observed	967	975	|O
for	976	979	|O
several	980	987	|O
of	988	990	|O
these	991	996	|O
compounds	997	1006	|O
.	1006	1007	|O
Optimal	1008	1015	|O
antitetrabenazine	1016	1033	|O
activity	1034	1042	|O
is	1043	1045	|O
associated	1046	1056	|O
with	1057	1061	|O
the	1062	1065	|O
cis	1066	1069	|B-PARTIUPAC
-	1069	1070	|I-PARTIUPAC
3'	1070	1072	|I-PARTIUPAC
-	1072	1073	|I-PARTIUPAC
phenyl	1073	1079	|I-PARTIUPAC
series	1080	1086	|B-MODIFIER
,	1086	1087	|O
and	1088	1091	|O
the	1092	1095	|O
cis	1096	1099	|O
secondary	1100	1109	|O
amine	1110	1115	|O
5a	1116	1118	|O
is	1119	1121	|O
approximately	1122	1135	|O
twice	1136	1141	|O
as	1142	1144	|O
potent	1145	1151	|O
as	1152	1154	|O
the	1155	1158	|O
cis	1159	1162	|O
tertiary	1163	1171	|O
amine	1172	1177	|O
3a	1178	1180	|O
.	1180	1181	|O
The	1182	1185	|O
various	1186	1193	|O
compounds	1194	1203	|O
are	1204	1207	|O
relatively	1208	1218	|O
weak	1219	1223	|O
with	1224	1228	|O
respect	1229	1236	|O
to	1237	1239	|O
potentiation	1240	1252	|O
of	1253	1255	|O
L	1256	1257	|B-IUPAC
-	1257	1258	|I-IUPAC
5	1258	1259	|I-IUPAC
-	1259	1260	|I-IUPAC
hydroxytryptophan	1260	1277	|I-IUPAC
-	1277	1278	|O
induced	1278	1285	|O
seizures	1286	1294	|O
.	1294	1295	|O

### abstracts2986.txt
Several	0	7	|O
series	8	14	|O
of	15	17	|O
N6	18	20	|O
-	20	21	|O
or	22	24	|O
8	25	26	|O
-	26	27	|O
substituted	27	38	|O
derivatives	39	50	|O
of	51	53	|O
adenosine	54	63	|B-IUPAC
5'	64	66	|I-IUPAC
-	66	67	|I-IUPAC
triphosphate	67	79	|I-IUPAC
(	80	81	|O
ATP	81	84	|O
)	84	85	|O
were	86	90	|O
synthesized	91	102	|O
.	102	103	|O
N6	104	106	|B-IUPAC
-	106	107	|I-IUPAC
(	107	108	|I-IUPAC
omega	108	113	|I-IUPAC
-	113	114	|I-IUPAC
Aminoalkyl	114	124	|I-IUPAC
)	124	125	|I-IUPAC
derivatives	126	137	|B-MODIFIER
of	138	140	|O
adenosine	141	150	|B-IUPAC
5'	151	153	|I-IUPAC
-	153	154	|I-IUPAC
monophosphate	154	167	|I-IUPAC
(	168	169	|O
AMP	169	172	|O
)	172	173	|O
were	174	178	|O
converted	179	188	|O
into	189	193	|O
their	194	199	|O
omega	200	205	|B-IUPAC
-	205	206	|I-IUPAC
N	206	207	|I-IUPAC
-	207	208	|I-IUPAC
carbobenzyloxy	208	222	|I-IUPAC
derivatives	223	234	|B-MODIFIER
,	234	235	|O
and	236	239	|O
these	240	245	|O
were	246	250	|O
converted	251	260	|O
,	260	261	|O
via	262	265	|O
the	266	269	|O
2'	270	272	|B-IUPAC
,	272	273	|I-IUPAC
3'	273	275	|I-IUPAC
-	275	276	|I-IUPAC
O	276	277	|I-IUPAC
-	277	278	|I-IUPAC
carbonyl	278	286	|I-IUPAC
derivatives	287	298	|B-MODIFIER
of	299	301	|O
their	302	307	|O
5'	308	310	|B-IUPAC
-	310	311	|I-IUPAC
phosphorimidazolidates	311	333	|I-IUPAC
,	333	334	|O
into	335	339	|O
the	340	343	|O
corresponding	344	357	|O
ATP	358	361	|O
derivatives	362	373	|O
.	373	374	|O
Hydrogenolytic	375	389	|O
removal	390	397	|O
of	398	400	|O
the	401	404	|O
carbobenzyloxy	405	419	|O
groups	420	426	|O
,	426	427	|O
followed	428	436	|O
by	437	439	|O
iodoacetylation	440	455	|O
of	456	458	|O
the	459	462	|O
omega	463	468	|O
-	468	469	|O
amino	469	474	|O
groups	475	481	|O
with	482	486	|O
N	487	488	|B-IUPAC
-	488	489	|I-IUPAC
(	489	490	|I-IUPAC
iodoacetoxy	490	501	|I-IUPAC
)	501	502	|I-IUPAC
succinimide	502	513	|I-IUPAC
,	513	514	|O
gave	515	519	|O
N6	520	522	|O
-	522	523	|O
R	523	524	|O
-	524	525	|O
ATP	525	528	|O
,	528	529	|O
where	530	535	|O
R	536	537	|O
=	538	539	|O
(	540	541	|O
CH2	541	544	|O
)	544	545	|O
nNHCOCH2I	545	554	|O
(	555	556	|O
n	556	557	|O
=	558	559	|O
2	560	561	|O
-	561	562	|O
-	562	563	|O
8	563	564	|O
)	564	565	|O
or	566	568	|O
(	569	570	|O
CH2	570	573	|O
)	573	574	|O
nCON	574	578	|O
)	578	579	|O
CH3	579	582	|O
)	582	583	|O
(	583	584	|O
CH2	584	587	|O
)	587	588	|O
mN	588	590	|O
(	590	591	|O
CH3	591	594	|O
)	594	595	|O
CO	595	597	|O
(	597	598	|O
CH2	598	601	|O
)	601	602	|O
nNHCOCH2I	602	611	|O
(	612	613	|O
n	613	614	|O
=	615	616	|O
m	617	618	|O
=	619	620	|O
3	621	622	|O
;	622	623	|O
n	624	625	|O
=	626	627	|O
3	628	629	|O
,	629	630	|O
m	631	632	|O
=	633	634	|O
4	635	636	|O
;	636	637	|O
n	638	639	|O
=	640	641	|O
4	642	643	|O
,	643	644	|O
m	645	646	|O
=	647	648	|O
3	649	650	|O
;	650	651	|O
n	652	653	|O
=	654	655	|O
m	656	657	|O
=	658	659	|O
4	660	661	|O
)	661	662	|O
.	662	663	|O
Condensation	664	676	|O
of	677	679	|O
N6	680	682	|B-IUPAC
-	682	683	|I-IUPAC
(	683	684	|I-IUPAC
omega	684	689	|I-IUPAC
-	689	690	|I-IUPAC
aminoalkyl	690	700	|I-IUPAC
)	700	701	|I-IUPAC
derivatives	702	713	|B-MODIFIER
of	714	716	|O
AMP	717	720	|O
with	721	725	|O
N	726	727	|B-IUPAC
-	727	728	|I-IUPAC
hydroxysuccinimide	728	746	|I-IUPAC
esters	747	753	|I-IUPAC
of	754	756	|O
omega	757	762	|B-IUPAC
-	762	763	|I-IUPAC
[	763	764	|I-IUPAC
N	764	765	|I-IUPAC
-	765	766	|I-IUPAC
(	766	767	|I-IUPAC
carbobenzyloxy	767	781	|I-IUPAC
)	781	782	|I-IUPAC
amino	782	787	|I-IUPAC
]	787	788	|I-IUPAC
carboxylic	789	799	|I-IUPAC
acids	800	805	|I-IUPAC
gave	806	810	|O
N6	811	813	|O
-	813	814	|O
(	814	815	|O
CH2	815	818	|O
)	818	819	|O
nNHCO	819	824	|O
(	824	825	|O
CH2	825	828	|O
)	828	829	|O
mNH	829	832	|O
-	832	833	|O
Cbz	833	836	|O
derivatives	837	848	|O
of	849	851	|O
AMP	852	855	|O
which	856	861	|O
,	861	862	|O
upon	863	867	|O
conversion	868	878	|O
to	879	881	|O
the	882	885	|O
corresponding	886	899	|O
derivatives	900	911	|O
of	912	914	|O
ATP	915	918	|O
,	918	919	|O
followed	920	928	|O
by	929	931	|O
removal	932	939	|O
of	940	942	|O
the	943	946	|O
carbobenzyloxy	947	961	|B-IUPAC
group	962	967	|B-MODIFIER
and	968	971	|O
iodoacetylation	972	987	|O
,	987	988	|O
as	989	991	|O
described	992	1001	|O
above	1002	1007	|O
,	1007	1008	|O
gave	1009	1013	|O
N6	1014	1016	|O
-	1016	1017	|O
(	1017	1018	|O
CH2	1018	1021	|O
)	1021	1022	|O
nNHCO	1022	1027	|O
(	1027	1028	|O
CH2	1028	1031	|O
)	1031	1032	|O
mNHCOCH2I	1032	1041	|O
-	1041	1042	|O
ATP	1042	1045	|O
derivatives	1046	1057	|O
(	1058	1059	|O
n	1059	1060	|O
=	1061	1062	|O
3	1063	1064	|O
,	1064	1065	|O
m	1066	1067	|O
=	1068	1069	|O
5	1070	1071	|O
or	1072	1074	|O
6	1075	1076	|O
;	1076	1077	|O
n	1078	1079	|O
=	1080	1081	|O
4	1082	1083	|O
,	1083	1084	|O
m	1085	1086	|O
=	1087	1088	|O
5	1089	1090	|O
;	1090	1091	|O
n	1092	1093	|O
=	1094	1095	|O
6	1096	1097	|O
,	1097	1098	|O
m	1099	1100	|O
=	1101	1102	|O
1	1103	1104	|O
-	1104	1105	|O
-	1105	1106	|O
6	1106	1107	|O
)	1107	1108	|O
.	1108	1109	|O
The	1110	1113	|O
same	1114	1118	|O
sequence	1119	1127	|O
of	1128	1130	|O
reactions	1131	1140	|O
starting	1141	1149	|O
with	1150	1154	|O
N6	1155	1157	|B-IUPAC
-	1157	1158	|I-IUPAC
[	1158	1159	|I-IUPAC
omega	1159	1164	|I-IUPAC
-	1164	1165	|I-IUPAC
(	1165	1166	|I-IUPAC
methylamino	1166	1177	|I-IUPAC
)	1177	1178	|I-IUPAC
alkyl	1178	1183	|I-IUPAC
]	1183	1184	|I-IUPAC
derivatives	1185	1196	|B-MODIFIER
of	1197	1199	|O
N6	1200	1202	|O
-	1202	1203	|O
CH3	1203	1206	|O
-	1206	1207	|O
AMP	1207	1210	|O
gave	1211	1215	|O
N6	1216	1218	|O
-	1218	1219	|O
CH3	1219	1222	|O
,	1222	1223	|O
N6	1224	1226	|O
-	1226	1227	|O
(	1227	1228	|O
CH2	1228	1231	|O
)	1231	1232	|O
nH	1232	1234	|O
(	1234	1235	|O
CH3	1235	1238	|O
)	1238	1239	|O
CO	1239	1241	|O
(	1241	1242	|O
CH2	1242	1245	|O
)	1245	1246	|O
mNHCOCH2I	1246	1255	|O
derivatives	1256	1267	|O
of	1268	1270	|O
ATP	1271	1274	|O
(	1275	1276	|O
n	1276	1277	|O
=	1278	1279	|O
4	1280	1281	|O
,	1281	1282	|O
m	1283	1284	|O
=	1285	1286	|O
3	1287	1288	|O
,	1288	1289	|O
5	1290	1291	|O
or	1292	1294	|O
6	1295	1296	|O
;	1296	1297	|O
n	1298	1299	|O
=	1300	1301	|O
6	1302	1303	|O
,	1303	1304	|O
m	1305	1306	|O
=	1307	1308	|O
5	1309	1310	|O
or	1311	1313	|O
6	1314	1315	|O
)	1315	1316	|O
.	1316	1317	|O
Reaction	1318	1326	|O
of	1327	1329	|O
alpha	1330	1335	|O
,	1335	1336	|O
omega	1337	1342	|O
-	1342	1343	|O
diaminoalkanes	1343	1357	|O
with	1358	1362	|O
8	1363	1364	|O
-	1364	1365	|O
Br	1365	1367	|O
-	1367	1368	|O
ATP	1368	1371	|O
gave	1372	1376	|O
8	1377	1378	|O
-	1378	1379	|O
NH	1379	1381	|O
(	1381	1382	|O
CH2	1382	1385	|O
)	1385	1386	|O
nNH2	1386	1390	|O
derivatives	1391	1402	|O
of	1403	1405	|O
ATP	1406	1409	|O
,	1409	1410	|O
which	1411	1416	|O
upon	1417	1421	|O
iodoacetylation	1422	1437	|O
gave	1438	1442	|O
8	1443	1444	|O
-	1444	1445	|O
NH	1445	1447	|O
(	1447	1448	|O
CH2	1448	1451	|O
)	1451	1452	|O
nNHCOCH2I	1452	1461	|O
derivatives	1462	1473	|O
of	1474	1476	|O
ATP	1477	1480	|O
(	1481	1482	|O
n	1482	1483	|O
=	1484	1485	|O
2	1486	1487	|O
,	1487	1488	|O
4	1489	1490	|O
,	1490	1491	|O
6	1492	1493	|O
,	1493	1494	|O
or	1495	1497	|O
8	1498	1499	|O
)	1499	1500	|O
.	1500	1501	|O
Substrate	1502	1511	|O
and	1512	1515	|O
inhibitor	1516	1525	|O
properties	1526	1536	|O
indicated	1537	1546	|O
that	1547	1551	|O
the	1552	1555	|O
ATP	1556	1559	|O
derivatives	1560	1571	|O
are	1572	1575	|O
potential	1576	1585	|O
exco	1586	1590	|O
-	1590	1591	|O
ATP	1591	1594	|O
-	1594	1595	|O
site	1595	1599	|O
-	1599	1600	|O
directed	1600	1608	|O
inactivators	1609	1621	|O
of	1622	1624	|O
hexokinases	1625	1636	|O
,	1636	1637	|O
adenylate	1638	1647	|O
kinases	1648	1655	|O
,	1655	1656	|O
and	1657	1660	|O
pyruvate	1661	1669	|O
kinases	1670	1677	|O
.	1677	1678	|O

### abstracts2011.txt
Several	0	7	|O
7	8	9	|B-IUPAC
-	9	10	|I-IUPAC
hydroxypyrazolo	10	25	|I-IUPAC
[	25	26	|I-IUPAC
1,5	26	29	|I-IUPAC
-	29	30	|I-IUPAC
a	30	31	|I-IUPAC
]	31	32	|I-IUPAC
pyrimidines	32	43	|I-IUPAC
(	44	45	|O
1-21	45	49	|O
)	49	50	|O
,	50	51	|O
7	52	53	|B-IUPAC
-	53	54	|I-IUPAC
mercaptopyrazolo	54	70	|I-IUPAC
[	70	71	|I-IUPAC
1,5	71	74	|I-IUPAC
-	74	75	|I-IUPAC
a	75	76	|I-IUPAC
]	76	77	|I-IUPAC
pyrimidines	77	88	|I-IUPAC
(	89	90	|O
37-49	90	95	|O
)	95	96	|O
,	96	97	|O
and	98	101	|O
4	102	103	|B-IUPAC
-	103	104	|I-IUPAC
alkylpyrazolo	104	117	|I-IUPAC
[	117	118	|I-IUPAC
1,5	118	121	|I-IUPAC
-	121	122	|I-IUPAC
a	122	123	|I-IUPAC
]	123	124	|I-IUPAC
pyrimidin	124	133	|I-IUPAC
-	133	134	|I-IUPAC
7	134	135	|I-IUPAC
-	135	136	|I-IUPAC
ones	136	140	|I-IUPAC
(	141	142	|O
50-55	142	147	|O
)	147	148	|O
and	149	152	|O
the	153	156	|O
corresponding	157	170	|O
4	171	172	|B-IUPAC
-	172	173	|I-IUPAC
alkylpyrazolo	173	186	|I-IUPAC
[	186	187	|I-IUPAC
1,5	187	190	|I-IUPAC
-	190	191	|I-IUPAC
a	191	192	|I-IUPAC
]	192	193	|I-IUPAC
pyrimidine	193	203	|I-IUPAC
-	203	204	|I-IUPAC
7	204	205	|I-IUPAC
-	205	206	|I-IUPAC
thiones	206	213	|I-IUPAC
(	214	215	|O
56-60	215	220	|O
)	220	221	|O
were	222	226	|O
synthesized	227	238	|O
and	239	242	|O
tested	243	249	|O
for	250	253	|O
antischistosomal	254	270	|O
activity	271	279	|O
against	280	287	|O
Schistosoma	288	299	|O
mansoni	300	307	|O
.	307	308	|O
Of	309	311	|O
the	312	315	|O
compounds	316	325	|O
examined	326	334	|O
,	334	335	|O
the	336	339	|O
greatest	340	348	|O
degree	349	355	|O
of	356	358	|O
activity	359	367	|O
in	368	370	|O
vitro	371	376	|O
was	377	380	|O
found	381	386	|O
with	387	391	|O
the	392	395	|O
7	396	397	|B-IUPAC
-	397	398	|I-IUPAC
mercaptopyrazolo	398	414	|I-IUPAC
[	414	415	|I-IUPAC
1,5	415	418	|I-IUPAC
-	418	419	|I-IUPAC
a	419	420	|I-IUPAC
]	420	421	|I-IUPAC
pyrimidines	421	432	|I-IUPAC
.	432	433	|O
In	434	436	|O
particular	437	447	|O
,	447	448	|O
compounds	449	458	|O
37	459	461	|O
and	462	465	|O
47	466	468	|O
proved	469	475	|O
lethal	476	482	|O
at	483	485	|O
100	486	489	|O
micrograms	490	500	|O
/	500	501	|O
mL	501	503	|O
after	504	509	|O
an	510	512	|O
exposure	513	521	|O
of	522	524	|O
only	525	529	|O
1	530	531	|O
h	532	533	|O
.	533	534	|O
The	535	538	|O
7	539	540	|B-IUPAC
-	540	541	|I-IUPAC
hydroxypyrazolo	541	556	|I-IUPAC
[	556	557	|I-IUPAC
1,5	557	560	|I-IUPAC
-	560	561	|I-IUPAC
a	561	562	|I-IUPAC
]	562	563	|I-IUPAC
-	563	564	|I-IUPAC
pyrimidines	564	575	|I-IUPAC
were	576	580	|O
not	581	584	|O
as	585	587	|O
active	588	594	|O
.	594	595	|O
None	596	600	|O
of	601	603	|O
the	604	607	|O
compounds	608	617	|O
exhibiting	618	628	|O
in	629	631	|O
vitro	632	637	|O
activity	638	646	|O
were	647	651	|O
active	652	658	|O
against	659	666	|O
S	667	668	|O
.	668	669	|O
mansoni	670	677	|O
in	678	680	|O
vivo	681	685	|O
.	685	686	|O

### abstracts4373.txt
The	0	3	|O
metabolic	4	13	|O
fate	14	18	|O
of	19	21	|O
tolazamide	22	32	|O
,	32	33	|O
1	34	35	|B-IUPAC
-	35	36	|I-IUPAC
(	36	37	|I-IUPAC
hexahydroazepin	37	52	|I-IUPAC
-	52	53	|I-IUPAC
1	53	54	|I-IUPAC
-	54	55	|I-IUPAC
yl	55	57	|I-IUPAC
)	57	58	|I-IUPAC
-	58	59	|I-IUPAC
3	59	60	|I-IUPAC
-	60	61	|I-IUPAC
p	61	62	|I-IUPAC
-	62	63	|I-IUPAC
tolylsulfonylurea	63	80	|I-IUPAC
(	81	82	|O
1	82	83	|O
)	83	84	|O
,	84	85	|O
was	86	89	|O
studied	90	97	|O
in	98	100	|O
man	101	104	|O
and	105	108	|O
in	109	111	|O
the	112	115	|O
rat	116	119	|O
using	120	125	|O
tritium	126	133	|O
-	133	134	|O
labeled	134	141	|O
1	142	143	|O
.	143	144	|O
The	145	148	|O
metabolites	149	160	|O
were	161	165	|O
isolated	166	174	|O
in	175	177	|O
crystalline	178	189	|O
form	190	194	|O
from	195	199	|O
urine	200	205	|O
for	206	209	|O
structure	210	219	|O
determination	220	233	|O
.	233	234	|O
The	235	238	|O
crystal	239	246	|O
structure	247	256	|O
and	257	260	|O
final	261	266	|O
molecular	267	276	|O
structure	277	286	|O
of	287	289	|O
one	290	293	|O
of	294	296	|O
these	297	302	|O
,	302	303	|O
1	304	305	|B-IUPAC
-	305	306	|I-IUPAC
(	306	307	|I-IUPAC
4	307	308	|I-IUPAC
-	308	309	|I-IUPAC
hydroxyhexahydroazepin	309	331	|I-IUPAC
-	331	332	|I-IUPAC
1	332	333	|I-IUPAC
-	333	334	|I-IUPAC
yl	334	336	|I-IUPAC
)	336	337	|I-IUPAC
-	337	338	|I-IUPAC
3	338	339	|I-IUPAC
-	339	340	|I-IUPAC
p	340	341	|I-IUPAC
-	341	342	|I-IUPAC
tolylsulfonylurea	342	359	|I-IUPAC
(	360	361	|O
5	361	362	|O
)	362	363	|O
,	363	364	|O
were	365	369	|O
determined	370	380	|O
using	381	386	|O
single	387	393	|O
-	393	394	|O
crystal	394	401	|O
X	402	403	|O
-	403	404	|O
ray	404	407	|O
techniques	408	418	|O
.	418	419	|O
Following	420	429	|O
oral	430	434	|O
administration	435	449	|O
of	450	452	|O
tritiated	453	462	|O
tolazamide	463	473	|O
to	474	476	|O
male	477	481	|O
humans	482	488	|O
,	488	489	|O
85%	490	493	|O
of	494	496	|O
the	497	500	|O
radioactivity	501	514	|O
was	515	518	|O
excreted	519	527	|O
in	528	530	|O
urine	531	536	|O
during	537	543	|O
a	544	545	|O
5	546	547	|O
-	547	548	|O
day	548	551	|O
period	552	558	|O
.	558	559	|O
In	560	562	|O
addition	563	571	|O
to	572	574	|O
being	575	580	|O
excreted	581	589	|O
in	590	592	|O
urine	593	598	|O
unchanged	599	608	|O
,	608	609	|O
tolazamide	610	620	|O
was	621	624	|O
metabolized	625	636	|O
to	637	639	|O
1	640	641	|B-IUPAC
-	641	642	|I-IUPAC
(	642	643	|I-IUPAC
hexahydroazepin	643	658	|I-IUPAC
-	658	659	|I-IUPAC
1	659	660	|I-IUPAC
-	660	661	|I-IUPAC
yl	661	663	|I-IUPAC
)	663	664	|I-IUPAC
-	664	665	|I-IUPAC
3	665	666	|I-IUPAC
-	666	667	|I-IUPAC
p	667	668	|I-IUPAC
-	668	669	|I-IUPAC
(	669	670	|I-IUPAC
carboxyphenyl	670	683	|I-IUPAC
)	683	684	|I-IUPAC
sulfonylurea	684	696	|I-IUPAC
(	697	698	|O
2	698	699	|O
)	699	700	|O
,	700	701	|O
p	702	703	|B-IUPAC
-	703	704	|I-IUPAC
toluenesulfonamide	704	722	|I-IUPAC
(	723	724	|O
3	724	725	|O
)	725	726	|O
,	726	727	|O
1	728	729	|B-IUPAC
-	729	730	|I-IUPAC
(	730	731	|I-IUPAC
hexahydroazepin	731	746	|I-IUPAC
-	746	747	|I-IUPAC
1	747	748	|I-IUPAC
-	748	749	|I-IUPAC
yl	749	751	|I-IUPAC
)	751	752	|I-IUPAC
-	752	753	|I-IUPAC
3	753	754	|I-IUPAC
-	754	755	|I-IUPAC
p	755	756	|I-IUPAC
-	756	757	|I-IUPAC
(	757	758	|I-IUPAC
hydroxymethylphenyl	758	777	|I-IUPAC
)	777	778	|I-IUPAC
sulfonylurea	778	790	|I-IUPAC
(	791	792	|O
4	792	793	|O
)	793	794	|O
,	794	795	|O
1	796	797	|B-IUPAC
-	797	798	|I-IUPAC
(	798	799	|I-IUPAC
4	799	800	|I-IUPAC
-	800	801	|I-IUPAC
hydroxyhexahydroazepin	801	823	|I-IUPAC
-	823	824	|I-IUPAC
1	824	825	|I-IUPAC
-	825	826	|I-IUPAC
yl	826	828	|I-IUPAC
)	828	829	|I-IUPAC
-	829	830	|I-IUPAC
3	830	831	|I-IUPAC
-	831	832	|I-IUPAC
p	832	833	|I-IUPAC
-	833	834	|I-IUPAC
tolylsulfonylurea	834	851	|I-IUPAC
(	852	853	|O
5	853	854	|O
)	854	855	|O
and	856	859	|O
a	860	861	|O
labile	862	868	|O
,	868	869	|O
unidentified	870	882	|O
metabolite	883	893	|O
6	894	895	|O
by	896	898	|O
man	899	902	|O
.	902	903	|O
The	904	907	|O
relative	908	916	|O
amounts	917	924	|O
of	925	927	|O
these	928	933	|O
materials	934	943	|O
excreted	944	952	|O
in	953	955	|O
0-24	956	960	|O
-	960	961	|O
h	961	962	|O
urine	963	968	|O
collections	969	980	|O
from	981	985	|O
eight	986	991	|O
subjects	992	1000	|O
averaged	1001	1009	|O
7	1010	1011	|O
,	1011	1012	|O
17	1013	1015	|O
,	1015	1016	|O
26	1017	1019	|O
,	1019	1020	|O
10	1021	1023	|O
,	1023	1024	|O
25	1025	1027	|O
,	1027	1028	|O
and	1029	1032	|O
15%	1033	1036	|O
for	1037	1040	|O
1-6	1041	1044	|O
,	1044	1045	|O
respectively	1046	1058	|O
.	1058	1059	|O
In	1060	1062	|O
the	1063	1066	|O
female	1067	1073	|O
rat	1074	1077	|O
,	1077	1078	|O
79%	1079	1082	|O
of	1083	1085	|O
an	1086	1088	|O
orally	1089	1095	|O
administered	1096	1108	|O
dose	1109	1113	|O
of	1114	1116	|O
tritiated	1117	1126	|O
tolazamide	1127	1137	|O
was	1138	1141	|O
excreted	1142	1150	|O
in	1151	1153	|O
urine	1154	1159	|O
during	1160	1166	|O
a	1167	1168	|O
5	1169	1170	|O
-	1170	1171	|O
day	1171	1174	|O
period	1175	1181	|O
as	1182	1184	|O
1-4	1185	1188	|O
.	1188	1189	|O
The	1190	1193	|O
relative	1194	1202	|O
amounts	1203	1210	|O
of	1211	1213	|O
these	1214	1219	|O
materials	1220	1229	|O
excreted	1230	1238	|O
during	1239	1245	|O
the	1246	1249	|O
24	1250	1252	|O
-	1252	1253	|O
h	1253	1254	|O
period	1255	1261	|O
following	1262	1271	|O
administration	1272	1286	|O
of	1287	1289	|O
tolazamide	1290	1300	|O
were	1301	1305	|O
10	1306	1308	|O
,	1308	1309	|O
5	1310	1311	|O
,	1311	1312	|O
5	1313	1314	|O
,	1314	1315	|O
and	1316	1319	|O
80%	1320	1323	|O
for	1324	1327	|O
1-4	1328	1331	|O
,	1331	1332	|O
respectively	1333	1345	|O
.	1345	1346	|O

### abstracts2333.txt
Incubation	0	10	|O
of	11	13	|O
5	14	15	|B-IUPAC
-	15	16	|I-IUPAC
hydroxytryptamine	16	33	|I-IUPAC
(	34	35	|O
1	35	36	|O
)	36	37	|O
with	38	42	|O
L	43	44	|O
-	44	45	|O
cysteine	45	53	|O
and	54	57	|O
pig	58	61	|O
or	62	64	|O
bovine	65	71	|O
brain	72	77	|O
microsomes	78	88	|O
and	89	92	|O
an	93	95	|O
NADPH	96	101	|O
-	101	102	|O
generating	102	112	|O
system	113	119	|O
or	120	122	|O
with	123	127	|O
synaptosomes	128	140	|O
results	141	148	|O
in	149	151	|O
the	152	155	|O
rapid	156	161	|O
formation	162	171	|O
of	172	174	|O
the	175	178	|O
(	179	180	|B-MODIFIER
2R	180	182	|I-MODIFIER
,	182	183	|I-MODIFIER
4R	183	185	|I-MODIFIER
)	185	186	|I-MODIFIER
-	186	187	|I-MODIFIER
and	188	191	|O
(	192	193	|B-MODIFIER
2S	193	195	|I-MODIFIER
,	195	196	|I-MODIFIER
4R	196	198	|I-MODIFIER
)	198	199	|I-MODIFIER
-	199	200	|I-MODIFIER
epimers	200	207	|I-MODIFIER
of	208	210	|O
2	211	212	|B-IUPAC
-	212	213	|I-IUPAC
[	213	214	|I-IUPAC
(	214	215	|I-IUPAC
5	215	216	|I-IUPAC
-	216	217	|I-IUPAC
hydroxy	217	224	|I-IUPAC
-	224	225	|I-IUPAC
1H	225	227	|I-IUPAC
-	227	228	|I-IUPAC
indol	228	233	|I-IUPAC
-	233	234	|I-IUPAC
3	234	235	|I-IUPAC
-	235	236	|I-IUPAC
yl	236	238	|I-IUPAC
)	238	239	|I-IUPAC
methyl	239	245	|I-IUPAC
]	245	246	|I-IUPAC
thiazolidine	246	258	|I-IUPAC
.	258	259	|O
Incubation	260	270	|O
of	271	273	|O
1	274	275	|O
and	276	279	|O
glutathione	280	291	|O
under	292	297	|O
the	298	301	|O
same	302	306	|O
experimental	307	319	|O
conditions	320	330	|O
yields	331	337	|O
the	338	341	|O
(	342	343	|B-MODIFIER
2R	343	345	|I-MODIFIER
,	345	346	|I-MODIFIER
4R	346	348	|I-MODIFIER
)	348	349	|I-MODIFIER
-	349	350	|I-MODIFIER
and	351	354	|O
(	355	356	|B-MODIFIER
2S	356	358	|I-MODIFIER
,	358	359	|I-MODIFIER
4R	359	361	|I-MODIFIER
)	361	362	|I-MODIFIER
-	362	363	|I-MODIFIER
epimers	363	370	|I-MODIFIER
of	371	373	|O
alpha	374	379	|B-IUPAC
-	379	380	|I-IUPAC
amino	380	385	|I-IUPAC
-	385	386	|I-IUPAC
4	386	387	|I-IUPAC
-	387	388	|I-IUPAC
[	388	389	|I-IUPAC
[	389	390	|I-IUPAC
(	390	391	|I-IUPAC
carboxymethyl	391	404	|I-IUPAC
)	404	405	|I-IUPAC
amino	405	410	|I-IUPAC
]	410	411	|I-IUPAC
carbonyl	411	419	|I-IUPAC
]	419	420	|I-IUPAC
-	420	421	|I-IUPAC
2	421	422	|I-IUPAC
-	422	423	|I-IUPAC
[	423	424	|I-IUPAC
(	424	425	|I-IUPAC
5	425	426	|I-IUPAC
-	426	427	|I-IUPAC
hydroxy	427	434	|I-IUPAC
-	434	435	|I-IUPAC
1H	435	437	|I-IUPAC
-	437	438	|I-IUPAC
indol	439	444	|I-IUPAC
-	444	445	|I-IUPAC
3	445	446	|I-IUPAC
-	446	447	|I-IUPAC
yl	447	449	|I-IUPAC
)	449	450	|I-IUPAC
methyl	450	456	|I-IUPAC
]	456	457	|I-IUPAC
-	457	458	|I-IUPAC
delta	458	463	|I-IUPAC
-	463	464	|I-IUPAC
oxo	464	467	|I-IUPAC
-	467	468	|I-IUPAC
3	468	469	|I-IUPAC
-	469	470	|I-IUPAC
thiazolidinepentanoic	470	491	|I-IUPAC
acid	492	496	|I-IUPAC
.	496	497	|O
These	498	503	|O
various	504	511	|O
thiazolidine	512	524	|O
derivatives	525	536	|O
are	537	540	|O
formed	541	547	|O
by	548	550	|O
nucleophilic	551	563	|O
addition	564	572	|O
of	573	575	|O
the	576	579	|O
thiol	580	585	|O
residues	586	594	|O
of	595	597	|O
cysteine	598	606	|O
or	607	609	|O
glutathione	610	621	|O
to	622	624	|O
the	625	628	|O
aldehyde	629	637	|B-IUPAC
group	638	643	|B-MODIFIER
of	644	646	|O
5	647	648	|B-IUPAC
-	648	649	|I-IUPAC
hydroxyindole	649	662	|I-IUPAC
-	662	663	|I-IUPAC
3	663	664	|I-IUPAC
-	664	665	|I-IUPAC
acetaldehyde	665	677	|I-IUPAC
(	678	679	|O
2	679	680	|O
)	680	681	|O
,	681	682	|O
the	683	686	|O
primary	687	694	|O
product	695	702	|O
of	703	705	|O
the	706	709	|O
monoamine	710	719	|O
oxidase	720	727	|O
-	727	728	|O
mediated	728	736	|O
oxidative	737	746	|O
deamination	747	758	|O
of	759	761	|O
1	762	763	|O
.	763	764	|O
The	765	768	|O
facile	769	775	|O
reaction	776	784	|O
of	785	787	|O
cysteine	788	796	|O
and	797	800	|O
glutathione	801	812	|O
with	813	817	|O
2	818	819	|O
might	820	825	|O
represent	826	835	|O
a	836	837	|O
mechanism	838	847	|O
designed	848	856	|O
to	857	859	|O
scavenge	860	868	|O
the	869	872	|O
biogenic	873	881	|O
aldehyde	882	890	|O
and	891	894	|O
therefore	895	904	|O
to	905	907	|O
prevent	908	915	|O
its	916	919	|O
alkylation	920	930	|O
of	931	933	|O
key	934	937	|O
intraneuronal	938	951	|O
protein	952	959	|O
nucleophiles	960	972	|O
.	972	973	|O

### abstracts2805.txt
We	0	2	|O
have	3	7	|O
found	8	13	|O
that	14	18	|O
alpha	19	24	|B-IUPAC
-	24	25	|I-IUPAC
aryl	25	29	|I-IUPAC
-	29	30	|O
substituted	30	41	|B-MODIFIER
halo	42	46	|B-IUPAC
enol	47	51	|I-IUPAC
lactones	52	60	|I-IUPAC
(	61	62	|O
I	62	63	|O
and	64	67	|O
II	68	70	|O
)	70	71	|O
are	72	75	|O
effective	76	85	|O
mechanism	86	95	|O
-	95	96	|O
based	96	101	|O
inactivators	102	114	|O
for	115	118	|O
chymotrypsin	119	131	|O
.	131	132	|O
In	133	135	|O
this	136	140	|O
study	141	146	|O
,	146	147	|O
we	148	150	|O
have	151	155	|O
investigated	156	168	|O
,	168	169	|O
for	170	173	|O
comparative	174	185	|O
purposes	186	194	|O
,	194	195	|O
halo	196	200	|B-IUPAC
enol	201	205	|I-IUPAC
lactones	206	214	|I-IUPAC
with	215	219	|O
aryl	220	224	|O
functions	225	234	|O
situated	235	243	|O
beta	244	248	|O
and	249	252	|O
gamma	253	258	|O
to	259	261	|O
the	262	265	|O
lactone	266	273	|O
carbonyl	274	282	|O
group	283	288	|O
.	288	289	|O
We	290	292	|O
synthesized	293	304	|O
4	305	306	|B-IUPAC
-	306	307	|I-IUPAC
phenyl	307	313	|I-IUPAC
-	313	314	|I-IUPAC
5	314	315	|I-IUPAC
(	315	316	|I-IUPAC
E	316	317	|I-IUPAC
)	317	318	|I-IUPAC
-	318	319	|I-IUPAC
(	319	320	|I-IUPAC
iodomethylidene	320	335	|I-IUPAC
)	335	336	|I-IUPAC
tetrahydro	336	346	|I-IUPAC
-	346	347	|I-IUPAC
2	347	348	|I-IUPAC
-	348	349	|I-IUPAC
furanone	349	357	|I-IUPAC
(	358	359	|O
1	359	360	|O
)	360	361	|O
,	361	362	|O
4	363	364	|B-IUPAC
-	364	365	|I-IUPAC
phenyl	365	371	|I-IUPAC
-	371	372	|I-IUPAC
5	372	373	|I-IUPAC
(	373	374	|I-IUPAC
E	374	375	|I-IUPAC
)	375	376	|I-IUPAC
-	376	377	|I-IUPAC
(	377	378	|I-IUPAC
iodomethylidene	378	393	|I-IUPAC
)	393	394	|I-IUPAC
dihydro	394	401	|I-IUPAC
-	401	402	|I-IUPAC
2	402	403	|I-IUPAC
-	403	404	|I-IUPAC
furanone	404	412	|I-IUPAC
(	413	414	|O
2	414	415	|O
)	415	416	|O
,	416	417	|O
4	418	419	|B-IUPAC
-	419	420	|I-IUPAC
phenyl	420	426	|I-IUPAC
-	426	427	|I-IUPAC
6	427	428	|I-IUPAC
(	428	429	|I-IUPAC
E	429	430	|I-IUPAC
)	430	431	|I-IUPAC
-	431	432	|I-IUPAC
(	432	433	|I-IUPAC
iodomethylidene	433	448	|I-IUPAC
)	448	449	|I-IUPAC
tetrahydro	449	459	|I-IUPAC
-	459	460	|I-IUPAC
2	460	461	|I-IUPAC
-	461	462	|I-IUPAC
pyranone	462	470	|I-IUPAC
(	471	472	|O
3	472	473	|O
)	473	474	|O
,	474	475	|O
and	476	479	|O
5	480	481	|B-IUPAC
-	481	482	|I-IUPAC
phenyl	482	488	|I-IUPAC
-	488	489	|I-IUPAC
6	489	490	|I-IUPAC
(	490	491	|I-IUPAC
E	491	492	|I-IUPAC
)	492	493	|I-IUPAC
-	493	494	|I-IUPAC
(	494	495	|I-IUPAC
iodomethylidene	495	510	|I-IUPAC
)	510	511	|I-IUPAC
tetrahydro	511	521	|I-IUPAC
-	521	522	|I-IUPAC
2	522	523	|I-IUPAC
-	523	524	|I-IUPAC
pyranone	524	532	|I-IUPAC
(	533	534	|O
4	534	535	|O
)	535	536	|O
,	536	537	|O
using	538	543	|O
a	544	545	|O
halolactonization	546	563	|O
reaction	564	572	|O
to	573	575	|O
convert	576	583	|O
the	584	587	|O
appropriate	588	599	|O
phenyl	600	606	|O
-	606	607	|O
substituted	607	618	|O
acetylenic	619	629	|O
acid	630	634	|O
precursor	635	644	|O
into	645	649	|O
the	650	653	|O
corresponding	654	667	|O
5	668	669	|B-IUPAC
(	669	670	|I-IUPAC
E	670	671	|I-IUPAC
)	671	672	|I-IUPAC
-	672	673	|I-IUPAC
(	673	674	|I-IUPAC
halomethylidene	674	689	|I-IUPAC
)	689	690	|I-IUPAC
furanone	690	698	|I-IUPAC
and	699	702	|O
6	703	704	|B-IUPAC
(	704	705	|I-IUPAC
E	705	706	|I-IUPAC
)	706	707	|I-IUPAC
-	707	708	|I-IUPAC
(	708	709	|I-IUPAC
halomethylidene	709	724	|I-IUPAC
)	724	725	|I-IUPAC
pyranone	725	733	|I-IUPAC
system	734	740	|B-MODIFIER
.	740	741	|O
The	742	745	|O
4	746	747	|B-IUPAC
-	747	748	|I-IUPAC
phenylfuranone	748	762	|I-IUPAC
(	763	764	|O
1	764	765	|O
and	766	769	|O
2	770	771	|O
)	771	772	|O
and	773	776	|O
the	777	780	|O
5	781	782	|B-IUPAC
-	782	783	|I-IUPAC
phenylpyranone	783	797	|I-IUPAC
(	798	799	|O
4	799	800	|O
)	800	801	|O
proved	802	808	|O
to	809	811	|O
be	812	814	|O
only	815	819	|O
reversible	820	830	|O
,	830	831	|O
competitive	832	843	|O
inhibitors	844	854	|O
.	854	855	|O
By	856	858	|O
contrast	859	867	|O
,	867	868	|O
the	869	872	|O
4	873	874	|B-IUPAC
-	874	875	|I-IUPAC
phenyltetrahydropyranone	875	899	|I-IUPAC
(	900	901	|O
3	901	902	|O
)	902	903	|O
inactivated	904	915	|O
alpha	916	921	|O
-	921	922	|O
chymotrypsin	922	934	|O
in	935	937	|O
a	938	939	|O
time	940	944	|O
-	944	945	|O
dependent	945	954	|O
manner	955	961	|O
.	961	962	|O
This	963	967	|O
inactivation	968	980	|O
was	981	984	|O
very	985	989	|O
rapid	990	995	|O
but	996	999	|O
reversible	1000	1010	|O
,	1010	1011	|O
with	1012	1016	|O
regeneration	1017	1029	|O
of	1030	1032	|O
enzyme	1033	1039	|O
activity	1040	1048	|O
being	1049	1054	|O
spontaneous	1055	1066	|O
and	1067	1070	|O
hydrazine	1071	1080	|O
-	1080	1081	|O
accelerated	1081	1092	|O
,	1092	1093	|O
suggestive	1094	1104	|O
of	1105	1107	|O
the	1108	1111	|O
intermediacy	1112	1124	|O
of	1125	1127	|O
a	1128	1129	|O
stable	1130	1136	|O
acyl	1137	1141	|O
enzyme	1142	1148	|O
.	1148	1149	|O
Kinetic	1150	1157	|O
comparison	1158	1168	|O
of	1169	1171	|O
the	1172	1175	|O
iodomethylene	1176	1189	|O
lactone	1190	1197	|O
3	1198	1199	|O
with	1200	1204	|O
the	1205	1208	|O
corresponding	1209	1222	|O
protio	1223	1229	|O
lactone	1230	1237	|O
25	1238	1240	|O
indicates	1241	1250	|O
that	1251	1255	|O
the	1256	1259	|O
iodine	1260	1266	|O
accelerates	1267	1278	|O
the	1279	1282	|O
rate	1283	1287	|O
of	1288	1290	|O
chymotrypsin	1291	1303	|O
acylation	1304	1313	|O
but	1314	1317	|O
produces	1318	1326	|O
an	1327	1329	|O
acyl	1330	1334	|O
enzyme	1335	1341	|O
that	1342	1346	|O
is	1347	1349	|O
more	1350	1354	|O
hydrolytically	1355	1369	|O
labile	1370	1376	|O
than	1377	1381	|O
that	1382	1386	|O
formed	1387	1393	|O
from	1394	1398	|O
lactone	1399	1406	|O
25	1407	1409	|O
.	1409	1410	|O
From	1411	1415	|O
the	1416	1419	|O
results	1420	1427	|O
of	1428	1430	|O
this	1431	1435	|O
study	1436	1441	|O
,	1441	1442	|O
we	1443	1445	|O
conclude	1446	1454	|O
that	1455	1459	|O
a	1460	1461	|O
phenyl	1462	1468	|O
group	1469	1474	|O
situated	1475	1483	|O
at	1484	1486	|O
C	1487	1488	|O
-	1488	1489	|O
3	1489	1490	|O
(	1491	1492	|O
alpha	1492	1497	|O
to	1498	1500	|O
the	1501	1504	|O
lactone	1505	1512	|O
carbonyl	1513	1521	|O
group	1522	1527	|O
)	1527	1528	|O
in	1529	1531	|O
both	1532	1536	|O
the	1537	1540	|O
5	1541	1542	|B-IUPAC
(	1542	1543	|I-IUPAC
E	1543	1544	|I-IUPAC
)	1544	1545	|I-IUPAC
-	1545	1546	|I-IUPAC
(	1546	1547	|I-IUPAC
iodomethylidene	1547	1562	|I-IUPAC
)	1562	1563	|I-IUPAC
tetrahydro	1563	1573	|I-IUPAC
-	1573	1574	|I-IUPAC
2	1574	1575	|I-IUPAC
-	1575	1576	|I-IUPAC
furanone	1576	1584	|I-IUPAC
(	1585	1586	|O
I	1586	1587	|O
)	1587	1588	|O
and	1589	1592	|O
6	1593	1594	|B-IUPAC
(	1594	1595	|I-IUPAC
E	1595	1596	|I-IUPAC
)	1596	1597	|I-IUPAC
-	1597	1598	|I-IUPAC
(	1598	1599	|I-IUPAC
iodomethylidene	1599	1614	|I-IUPAC
)	1614	1615	|I-IUPAC
tetrahydro	1615	1625	|I-IUPAC
-	1625	1626	|I-IUPAC
2	1626	1627	|I-IUPAC
-	1627	1628	|I-IUPAC
pyranone	1628	1636	|I-IUPAC
(	1637	1638	|O
II	1638	1640	|O
)	1640	1641	|O
series	1642	1648	|O
is	1649	1651	|O
essential	1652	1661	|O
for	1662	1665	|O
their	1666	1671	|O
activity	1672	1680	|O
as	1681	1683	|O
mechanism	1684	1693	|O
-	1693	1694	|O
based	1694	1699	|O
irreversible	1700	1712	|O
inactivators	1713	1725	|O
of	1726	1728	|O
chymotrypsin	1729	1741	|O
.	1741	1742	|O
The	1743	1746	|O
corresponding	1747	1760	|O
beta	1761	1765	|O
-	1765	1766	|O
aryl	1766	1770	|O
-	1770	1771	|O
substituted	1771	1782	|O
lactones	1783	1791	|O
,	1791	1792	|O
by	1793	1795	|O
contrast	1796	1804	|O
,	1804	1805	|O
are	1806	1809	|O
potent	1810	1816	|O
acylating	1817	1826	|O
agents	1827	1833	|O
that	1834	1838	|O
lead	1839	1843	|O
to	1844	1846	|O
acyl	1847	1851	|O
enzymes	1852	1859	|O
of	1860	1862	|O
high	1863	1867	|O
stability	1868	1877	|O
.	1877	1878	|O

### abstracts3837.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
5	12	13	|B-IUPAC
-	13	14	|I-IUPAC
(	14	15	|I-IUPAC
naphthalenylsulfonyl	15	35	|I-IUPAC
)	35	36	|I-IUPAC
-	36	37	|I-IUPAC
2,4	37	40	|I-IUPAC
-	40	41	|I-IUPAC
thiazolidinediones	41	59	|I-IUPAC
were	60	64	|O
synthesized	65	76	|O
and	77	80	|O
evaluated	81	90	|O
for	91	94	|O
antihyperglycemic	95	112	|O
activity	113	121	|O
in	122	124	|O
an	125	127	|O
insulin	128	135	|O
-	135	136	|O
resistant	136	145	|O
,	145	146	|O
genetically	147	158	|O
diabetic	159	167	|O
db	168	170	|O
/	170	171	|O
db	171	173	|O
mouse	174	179	|O
model	180	185	|O
of	186	188	|O
non	189	192	|O
-	192	193	|O
insulin	193	200	|O
-	200	201	|O
dependent	201	210	|O
diabetes	211	219	|O
mellitus	220	228	|O
(	229	230	|O
NIDDM	230	235	|O
)	235	236	|O
.	236	237	|O
The	238	241	|O
sulfones	242	250	|O
could	251	256	|O
be	257	259	|O
synthesized	260	271	|O
by	272	274	|O
a	275	276	|O
novel	277	282	|O
,	282	283	|O
selective	284	293	|O
C	294	295	|O
-	295	296	|O
5	296	297	|O
sulfonylation	298	311	|O
of	312	314	|O
dilithio	315	323	|B-IUPAC
-	323	324	|I-IUPAC
2,4	324	327	|I-IUPAC
-	327	328	|I-IUPAC
thiazolidinedione	328	345	|I-IUPAC
with	346	350	|O
appropriate	351	362	|O
sulfonyl	363	371	|O
chlorides	372	381	|O
.	381	382	|O
Within	383	389	|O
this	390	394	|O
series	395	401	|O
,	401	402	|O
naphthalene	403	414	|O
was	415	418	|O
found	419	424	|O
to	425	427	|O
be	428	430	|O
superior	431	439	|O
to	440	442	|O
other	443	448	|O
groups	449	455	|O
for	456	459	|O
eliciting	460	469	|O
antihyperglycemic	470	487	|O
activity	488	496	|O
,	496	497	|O
including	498	507	|O
the	508	511	|O
p	512	513	|B-IUPAC
-	513	514	|I-IUPAC
alkoxyphenyl	514	526	|I-IUPAC
group	527	532	|B-MODIFIER
found	533	538	|O
in	539	541	|O
ciglitazone	542	553	|O
,	553	554	|O
a	555	556	|O
prototypical	557	569	|O
agent	570	575	|O
for	576	579	|O
this	580	584	|O
activity	585	593	|O
.	593	594	|O
Attachment	595	605	|O
of	606	608	|O
the	609	612	|O
5	613	614	|B-IUPAC
-	614	615	|I-IUPAC
sulfonyl	615	623	|I-IUPAC
-	623	624	|I-IUPAC
2,4	624	627	|I-IUPAC
-	627	628	|I-IUPAC
thiazolidinedione	628	645	|I-IUPAC
moiety	646	652	|B-MODIFIER
to	653	655	|O
the	656	659	|O
2	660	661	|O
-	661	662	|O
naphthalene	662	673	|O
position	674	682	|O
led	683	686	|O
to	687	689	|O
optimum	690	697	|O
activity	698	706	|O
.	706	707	|O
Other	708	713	|O
linkers	714	721	|O
between	722	729	|O
the	730	733	|O
naphthalene	734	745	|O
and	746	749	|O
2,4	750	753	|B-IUPAC
-	753	754	|I-IUPAC
thiazolidinedione	754	771	|I-IUPAC
rings	772	777	|B-MODIFIER
,	777	778	|O
such	779	783	|O
as	784	786	|O
thio	787	791	|O
,	791	792	|O
methylene	793	802	|O
,	802	803	|O
oxy	804	807	|O
,	807	808	|O
and	809	812	|O
sulfinyl	813	821	|O
led	822	825	|O
to	826	828	|O
decreased	829	838	|O
antihyperglycemic	839	856	|O
activity	857	865	|O
.	865	866	|O
The	867	870	|O
best	871	875	|O
analogue	876	884	|O
,	884	885	|O
5	886	887	|B-IUPAC
-	887	888	|I-IUPAC
(	888	889	|I-IUPAC
2	889	890	|I-IUPAC
-	890	891	|I-IUPAC
naphthalenylsulfonyl	891	911	|I-IUPAC
)	911	912	|I-IUPAC
-	912	913	|I-IUPAC
2,4	913	916	|I-IUPAC
-	916	917	|I-IUPAC
thiazolidinedione	917	934	|I-IUPAC
(	935	936	|O
AY	936	938	|O
-	938	939	|O
31,637	939	945	|O
)	945	946	|O
was	947	950	|O
equipotent	951	961	|O
to	962	964	|O
ciglitazone	965	976	|O
in	977	979	|O
two	980	983	|O
animal	984	990	|O
models	991	997	|O
of	998	1000	|O
NIDDM	1001	1006	|O
.	1006	1007	|O

### abstracts3163.txt
The	0	3	|O
reduction	4	13	|O
of	14	16	|O
acetylcholinesterase	17	37	|O
(	38	39	|O
AChE	39	43	|O
)	43	44	|O
activity	45	53	|O
in	54	56	|O
the	57	60	|O
brain	61	66	|O
has	67	70	|O
been	71	75	|O
measured	76	84	|O
in	85	87	|O
dementia	88	96	|O
disorders	97	106	|O
such	107	111	|O
as	112	114	|O
Alzheimer	115	124	|O
's	124	126	|O
disease	127	134	|O
and	135	138	|O
dementia	139	147	|O
with	148	152	|O
Lewy	153	157	|O
bodies	158	164	|O
using	165	170	|O
(	171	172	|O
11	172	174	|O
)	174	175	|O
C	175	176	|O
-	176	177	|O
labeled	177	184	|O
acetylcholine	185	198	|O
analogues	199	208	|O
,	208	209	|O
N	210	211	|B-IUPAC
-	211	212	|I-IUPAC
[	212	213	|I-IUPAC
(	213	214	|I-IUPAC
11	214	216	|I-IUPAC
)	216	217	|I-IUPAC
C	217	218	|I-IUPAC
]	218	219	|I-IUPAC
methylpiperidin	219	234	|I-IUPAC
-	234	235	|I-IUPAC
4	235	236	|I-IUPAC
-	236	237	|I-IUPAC
yl	237	239	|I-IUPAC
acetate	240	247	|I-IUPAC
and	248	251	|O
propionate	252	262	|O
,	262	263	|O
and	264	267	|O
positron	268	276	|O
emission	277	285	|O
tomography	286	296	|O
(	297	298	|O
PET	298	301	|O
)	301	302	|O
.	302	303	|O
Our	304	307	|O
aim	308	311	|O
was	312	315	|O
to	316	318	|O
develop	319	326	|O
an	327	329	|O
(	330	331	|O
18	331	333	|O
)	333	334	|O
F	334	335	|O
-	335	336	|O
labeled	336	343	|O
acetylcholine	344	357	|O
analogue	358	366	|O
useful	367	373	|O
for	374	377	|O
brain	378	383	|O
AChE	384	388	|O
mapping	389	396	|O
with	397	401	|O
PET	402	405	|O
,	405	406	|O
since	407	412	|O
(	413	414	|O
18	414	416	|O
)	416	417	|O
F	417	418	|O
,	418	419	|O
with	420	424	|O
a	425	426	|O
longer	427	433	|O
half	434	438	|O
-	438	439	|O
life	439	443	|O
,	443	444	|O
has	445	448	|O
advantages	449	459	|O
over	460	464	|O
(	465	466	|O
11	466	468	|O
)	468	469	|O
C	469	470	|O
.	470	471	|O
In	472	474	|O
a	475	476	|O
preliminary	477	488	|O
study	489	494	|O
,	494	495	|O
a	496	497	|O
series	498	504	|O
of	505	507	|O
N	508	509	|B-PARTIUPAC
-	509	510	|I-PARTIUPAC
[	510	511	|I-PARTIUPAC
(	511	512	|I-PARTIUPAC
14	512	514	|I-PARTIUPAC
)	514	515	|I-PARTIUPAC
C	515	516	|I-PARTIUPAC
]	516	517	|I-PARTIUPAC
ethylpiperidin	517	531	|I-PARTIUPAC
-	531	532	|I-PARTIUPAC
3	532	533	|I-PARTIUPAC
-	533	534	|I-PARTIUPAC
yl	534	536	|I-PARTIUPAC
or	537	539	|O
-	540	541	|B-PARTIUPAC
4	541	542	|I-PARTIUPAC
-	542	543	|I-PARTIUPAC
ylmethanol	543	553	|I-PARTIUPAC
esters	554	560	|I-PARTIUPAC
(	561	562	|O
acetyl	562	568	|O
and	569	572	|O
propionyl	573	582	|O
esters	583	589	|O
)	589	590	|O
were	591	595	|O
newly	596	601	|O
designed	602	610	|O
and	611	614	|O
evaluated	615	624	|O
in	625	627	|O
vitro	628	633	|O
regarding	634	643	|O
the	644	647	|O
reactivity	648	658	|O
with	659	663	|O
and	664	667	|O
specificity	668	679	|O
to	680	682	|O
AChE	683	687	|O
using	688	693	|O
purified	694	702	|O
human	703	708	|O
enzymes	709	716	|O
,	716	717	|O
leading	718	725	|O
to	726	728	|O
a	729	730	|O
novel	731	736	|O
(	737	738	|O
18	738	740	|O
)	740	741	|O
F	741	742	|O
-	742	743	|O
labeled	743	750	|O
acetylcholine	751	764	|O
analogue	765	773	|O
,	773	774	|O
N	775	776	|B-IUPAC
-	776	777	|I-IUPAC
[	777	778	|I-IUPAC
(	778	779	|I-IUPAC
18	779	781	|I-IUPAC
)	781	782	|I-IUPAC
F	782	783	|I-IUPAC
]	783	784	|I-IUPAC
fluoroethylpiperidin	784	804	|I-IUPAC
-	804	805	|I-IUPAC
4	805	806	|I-IUPAC
-	806	807	|I-IUPAC
ylmethyl	807	815	|I-IUPAC
acetate	816	823	|I-IUPAC
.	823	824	|O
In	825	827	|O
rat	828	831	|O
experiments	832	843	|O
,	843	844	|O
the	845	848	|O
(	849	850	|O
18	850	852	|O
)	852	853	|O
F	853	854	|O
-	854	855	|O
labeled	855	862	|O
candidate	863	872	|O
showed	873	879	|O
desirable	880	889	|O
properties	890	900	|O
for	901	904	|O
PET	905	908	|O
AChE	909	913	|O
measurement	914	925	|O
:	925	926	|O
high	927	931	|O
brain	932	937	|O
uptake	938	944	|O
of	945	947	|O
the	948	951	|O
authentic	952	961	|O
ester	962	967	|O
,	967	968	|O
high	969	973	|O
AChE	974	978	|O
specificity	979	990	|O
,	990	991	|O
a	992	993	|O
moderate	994	1002	|O
hydrolysis	1003	1013	|O
rate	1014	1018	|O
,	1018	1019	|O
and	1020	1023	|O
low	1024	1027	|O
membrane	1028	1036	|O
permeability	1037	1049	|O
(	1050	1051	|O
metabolic	1051	1060	|O
trapping	1061	1069	|O
)	1069	1070	|O
of	1071	1073	|O
the	1074	1077	|O
metabolite	1078	1088	|O
.	1088	1089	|O

### abstracts2924.txt
A	0	1	|O
potent	2	8	|O
and	9	12	|O
orally	13	19	|O
active	20	26	|O
NK1	27	30	|O
antagonist	31	41	|O
,	41	42	|O
trans	43	48	|B-IUPAC
-	48	49	|I-IUPAC
N	49	50	|I-IUPAC
-	50	51	|I-IUPAC
[	51	52	|I-IUPAC
3	52	53	|I-IUPAC
,	53	54	|I-IUPAC
5	55	56	|I-IUPAC
-	56	57	|I-IUPAC
bis	57	60	|I-IUPAC
(	60	61	|I-IUPAC
trifluoromethyl	61	76	|I-IUPAC
)	76	77	|I-IUPAC
benzyl	77	83	|I-IUPAC
]	83	84	|I-IUPAC
-	84	85	|I-IUPAC
7,8	85	88	|I-IUPAC
-	88	89	|I-IUPAC
dihydro	89	96	|I-IUPAC
-	96	97	|I-IUPAC
N	97	98	|I-IUPAC
,	98	99	|I-IUPAC
7	100	101	|I-IUPAC
-	101	102	|I-IUPAC
dimethyl	102	110	|I-IUPAC
-	110	111	|I-IUPAC
5	111	112	|I-IUPAC
-	112	113	|I-IUPAC
(	113	114	|I-IUPAC
4	114	115	|I-IUPAC
-	115	116	|I-IUPAC
methylphenyl	116	128	|I-IUPAC
)	128	129	|I-IUPAC
-	129	130	|I-IUPAC
8	130	131	|I-IUPAC
-	131	132	|I-IUPAC
oxo	132	135	|I-IUPAC
-	135	136	|I-IUPAC
1,7	136	139	|I-IUPAC
-	139	140	|I-IUPAC
naphthyridine	140	153	|I-IUPAC
-	153	154	|I-IUPAC
6	154	155	|I-IUPAC
-	155	156	|I-IUPAC
carboxamide	156	167	|I-IUPAC
(	168	169	|O
1t	169	171	|O
)	171	172	|O
,	172	173	|O
was	174	177	|O
shown	178	183	|O
to	184	186	|O
exist	187	192	|O
as	193	195	|O
a	196	197	|O
mixture	198	205	|O
of	206	208	|O
separable	209	218	|O
and	219	222	|O
stable	223	229	|O
(	230	231	|O
R	231	232	|O
)	232	233	|O
-	233	234	|O
and	235	238	|O
(	239	240	|O
S	240	241	|O
)	241	242	|O
-	242	243	|O
atropisomers	243	255	|O
(	256	257	|O
1t	257	259	|O
-	259	260	|O
A	260	261	|O
and	262	265	|O
1t	266	268	|O
-	268	269	|O
B	269	270	|O
)	270	271	|O
originating	272	283	|O
from	284	288	|O
the	289	292	|O
restricted	293	303	|O
rotation	304	312	|O
around	313	319	|O
the	320	323	|O
-	324	325	|O
C	325	326	|O
(	326	327	|O
6	327	328	|O
)	328	329	|O
-	329	330	|O
C	330	331	|O
(	331	332	|O
=	332	333	|O
O	333	334	|O
)	334	335	|O
-	335	336	|O
bond	337	341	|O
;	341	342	|O
the	343	346	|O
antagonistic	347	359	|O
activities	360	370	|O
of	371	373	|O
1t	374	376	|O
-	376	377	|O
A	377	378	|O
were	379	383	|O
ca.	384	387	|O
6-13	388	392	|O
-	392	393	|O
fold	393	397	|O
higher	398	404	|O
than	405	409	|O
those	410	415	|O
of	416	418	|O
1t	419	421	|O
-	421	422	|O
B	422	423	|O
.	423	424	|O
Analogues	425	434	|O
of	435	437	|O
1t	438	440	|O
(	441	442	|O
3	442	443	|O
)	443	444	|O
,	444	445	|O
which	446	451	|O
have	452	456	|O
(	457	458	|B-PARTIUPAC
S	458	459	|I-PARTIUPAC
)	459	460	|I-PARTIUPAC
-	460	461	|I-PARTIUPAC
and	462	465	|O
(	466	467	|B-IUPAC
R	467	468	|I-IUPAC
)	468	469	|I-IUPAC
-	469	470	|I-IUPAC
methyl	470	476	|I-IUPAC
groups	477	483	|B-MODIFIER
at	484	486	|O
the	487	490	|O
benzylic	491	499	|O
methylene	500	509	|O
portion	510	517	|O
of	518	520	|O
1t	521	523	|O
,	523	524	|O
were	525	529	|O
prepared	530	538	|O
and	539	542	|O
separated	543	552	|O
into	553	557	|O
the	558	561	|O
diastereomeric	562	576	|O
atropisomers	577	589	|O
,	589	590	|O
3a	591	593	|O
-	593	594	|O
A	594	595	|O
,	595	596	|O
3a	597	599	|O
-	599	600	|O
B	600	601	|O
and	602	605	|O
3b	606	608	|O
-	608	609	|O
A	609	610	|O
,	610	611	|O
3b	612	614	|O
-	614	615	|O
B	615	616	|O
,	616	617	|O
in	618	620	|O
enantiomerically	621	637	|O
pure	638	642	|O
forms	643	648	|O
.	648	649	|O
Among	650	655	|O
the	656	659	|O
four	660	664	|O
isomers	665	672	|O
of	673	675	|O
3	676	677	|O
,	677	678	|O
the	679	682	|O
(	683	684	|O
aR	684	686	|O
,	686	687	|O
S	688	689	|O
)	689	690	|O
-	690	691	|O
enantiomer	691	701	|O
(	702	703	|O
3a	703	705	|O
-	705	706	|O
A	706	707	|O
)	707	708	|O
exhibited	709	718	|O
the	719	722	|O
most	723	727	|O
potent	728	734	|O
antagonistic	735	747	|O
activities	748	758	|O
with	759	763	|O
an	764	766	|O
IC50	767	771	|O
value	772	777	|O
of	778	780	|O
0.80	781	785	|O
nM	786	788	|O
(	789	790	|O
in	790	792	|O
vitro	793	798	|O
inhibition	799	809	|O
of	810	812	|O
[	813	814	|O
125I	814	818	|O
]	818	819	|O
BH	819	821	|O
-	821	822	|O
SP	822	824	|O
binding	825	832	|O
in	833	835	|O
human	836	841	|O
IM	842	844	|O
-	844	845	|O
9	845	846	|O
cells	847	852	|O
)	852	853	|O
and	854	857	|O
ED50	858	862	|O
values	863	869	|O
of	870	872	|O
9.3	873	876	|O
micrograms	877	887	|O
/	887	888	|O
kg	888	890	|O
(	891	892	|O
iv	892	894	|O
)	894	895	|O
and	896	899	|O
67.7	900	904	|O
micrograms	905	915	|O
/	915	916	|O
kg	916	918	|O
(	919	920	|O
po	920	922	|O
)	922	923	|O
(	924	925	|O
in	925	927	|O
vivo	928	932	|O
inhibition	933	943	|O
of	944	946	|O
capsaicin	947	956	|O
-	956	957	|O
induced	957	964	|O
plasma	965	971	|O
extravasation	972	985	|O
in	986	988	|O
guinea	989	995	|O
pig	996	999	|O
trachea	1000	1007	|O
)	1007	1008	|O
,	1008	1009	|O
while	1010	1015	|O
the	1016	1019	|O
activity	1020	1028	|O
of	1029	1031	|O
the	1032	1035	|O
(	1036	1037	|O
aS	1037	1039	|O
,	1039	1040	|O
R	1040	1041	|O
)	1041	1042	|O
-	1042	1043	|O
enantiomer	1043	1053	|O
(	1054	1055	|O
3b	1055	1057	|O
-	1057	1058	|O
B	1058	1059	|O
)	1059	1060	|O
was	1061	1064	|O
the	1065	1068	|O
weakest	1069	1076	|O
with	1077	1081	|O
an	1082	1084	|O
IC50	1085	1089	|O
value	1090	1095	|O
of	1096	1098	|O
620	1099	1102	|O
nM	1103	1105	|O
.	1105	1106	|O
The	1107	1110	|O
structure	1111	1120	|O
-	1120	1121	|O
activity	1121	1129	|O
relationships	1130	1143	|O
in	1144	1146	|O
this	1147	1151	|O
series	1152	1158	|O
of	1159	1161	|O
antagonists	1162	1173	|O
indicate	1174	1182	|O
that	1183	1187	|O
the	1188	1191	|O
(	1192	1193	|O
R	1193	1194	|O
)	1194	1195	|O
-	1195	1196	|O
configuration	1196	1209	|O
at	1210	1212	|O
the	1213	1216	|O
axial	1217	1222	|O
bond	1223	1227	|O
and	1228	1231	|O
the	1232	1235	|O
stacking	1236	1244	|O
(	1245	1246	|O
or	1246	1248	|O
stacking	1249	1257	|O
-	1257	1258	|O
like	1258	1262	|O
)	1262	1263	|O
conformation	1264	1276	|O
between	1277	1284	|O
the	1285	1288	|O
two	1289	1292	|O
phenyl	1293	1299	|B-IUPAC
rings	1300	1305	|B-MODIFIER
as	1306	1308	|O
shown	1309	1314	|O
in	1315	1317	|O
1t	1318	1320	|O
-	1320	1321	|O
A	1321	1322	|O
and	1323	1326	|O
3a	1327	1329	|O
-	1329	1330	|O
A	1330	1331	|O
are	1332	1335	|O
essential	1336	1345	|O
for	1346	1349	|O
high	1350	1354	|O
-	1354	1355	|O
affinity	1355	1363	|O
binding	1364	1371	|O
and	1372	1375	|O
suggest	1376	1383	|O
that	1384	1388	|O
the	1389	1392	|O
amide	1393	1398	|B-IUPAC
moiety	1399	1405	|B-MODIFIER
functions	1406	1415	|O
as	1416	1418	|O
a	1419	1420	|O
hydrogen	1421	1429	|O
bond	1430	1434	|O
acceptor	1435	1443	|O
in	1444	1446	|O
the	1447	1450	|O
interaction	1451	1462	|O
with	1463	1467	|O
the	1468	1471	|O
receptor	1472	1480	|O
.	1480	1481	|O

### abstracts507.txt
Nonclassical	0	12	|O
antifolates	13	24	|O
,	24	25	|O
2,4	26	29	|B-IUPAC
-	29	30	|I-IUPAC
diamino	30	37	|I-IUPAC
-	37	38	|I-IUPAC
5	38	39	|I-IUPAC
-	39	40	|I-IUPAC
substituted	40	51	|I-IUPAC
-	51	52	|I-IUPAC
furo	52	56	|I-IUPAC
[	56	57	|I-IUPAC
2	57	58	|I-IUPAC
,	58	59	|I-IUPAC
3	60	61	|I-IUPAC
-	61	62	|I-IUPAC
d	62	63	|I-IUPAC
]	63	64	|I-IUPAC
pyrimidines	64	75	|I-IUPAC
3-12	76	80	|O
with	81	85	|O
bridge	86	92	|O
region	93	99	|O
variations	100	110	|O
of	111	113	|O
C8	114	116	|O
-	116	117	|O
S9	117	119	|O
,	119	120	|O
C8	121	123	|O
-	123	124	|O
N9	124	126	|O
,	126	127	|O
and	128	131	|O
C8	132	134	|O
-	134	135	|O
O9	135	137	|O
and	138	141	|O
1	142	143	|B-IUPAC
-	143	144	|I-IUPAC
naphthyl	144	152	|I-IUPAC
,	152	153	|O
2	154	155	|B-IUPAC
-	155	156	|I-IUPAC
naphthyl	156	164	|I-IUPAC
,	164	165	|O
2	166	167	|B-IUPAC
-	167	168	|I-IUPAC
phenoxyphenyl	168	181	|I-IUPAC
,	181	182	|O
4	183	184	|B-IUPAC
-	184	185	|I-IUPAC
phenoxyphenyl	185	198	|I-IUPAC
,	198	199	|O
and	200	203	|O
2	204	205	|B-IUPAC
-	205	206	|I-IUPAC
biphenyl	206	214	|I-IUPAC
side	215	219	|B-MODIFIER
chains	220	226	|I-MODIFIER
were	227	231	|O
synthesized	232	243	|O
as	244	246	|O
phenyl	247	253	|O
ring	254	258	|O
appended	259	267	|O
analogues	268	277	|O
of	278	280	|O
previously	281	291	|O
reported	292	300	|O
2	301	302	|B-IUPAC
,	302	303	|I-IUPAC
4	304	305	|I-IUPAC
-	305	306	|I-IUPAC
diamino	306	313	|I-IUPAC
-	313	314	|I-IUPAC
5	314	315	|I-IUPAC
-	315	316	|I-IUPAC
(	316	317	|I-IUPAC
anilinomethyl	317	330	|I-IUPAC
)	330	331	|I-IUPAC
furo	331	335	|I-IUPAC
[	335	336	|I-IUPAC
2,3	336	339	|I-IUPAC
-	339	340	|I-IUPAC
d	340	341	|I-IUPAC
]	341	342	|I-IUPAC
pyrimidines	342	353	|I-IUPAC
.	353	354	|O
The	355	358	|O
phenyl	359	365	|O
ring	366	370	|O
appended	371	379	|O
analogues	380	389	|O
were	390	394	|O
designed	395	403	|O
to	404	406	|O
specifically	407	419	|O
interact	420	428	|O
with	429	433	|O
Phe69	434	439	|O
of	440	442	|O
dihydrofolate	443	456	|O
reductase	457	466	|O
(	467	468	|O
DHFR	468	472	|O
)	472	473	|O
from	474	478	|O
Pneumocystis	479	491	|O
carinii	492	499	|O
(	500	501	|O
pc	501	503	|O
)	503	504	|O
to	505	507	|O
afford	508	514	|O
selective	515	524	|O
inhibitors	525	535	|O
of	536	538	|O
pcDHFR	539	545	|O
.	545	546	|O
Additional	547	557	|O
substituted	558	569	|O
phenyl	570	576	|O
side	577	581	|O
chains	582	588	|O
which	589	594	|O
include	595	602	|O
2,5	603	606	|B-IUPAC
-	606	607	|I-IUPAC
dichloro	607	615	|I-IUPAC
,	615	616	|O
3,4	617	620	|B-IUPAC
-	620	621	|I-IUPAC
dichloro	621	629	|I-IUPAC
,	629	630	|O
3,4,5	631	636	|B-IUPAC
-	636	637	|I-IUPAC
trichloro	637	646	|I-IUPAC
,	646	647	|O
3	648	649	|B-IUPAC
-	649	650	|I-IUPAC
methoxy	650	657	|I-IUPAC
,	657	658	|O
and	659	662	|O
2,5	663	666	|B-IUPAC
-	666	667	|I-IUPAC
dimethoxy	667	676	|I-IUPAC
analogues	677	686	|B-MODIFIER
13-17	687	692	|O
were	693	697	|O
also	698	702	|O
synthesized	703	714	|O
.	714	715	|O
The	716	719	|O
compounds	720	729	|O
were	730	734	|O
prepared	735	743	|O
by	744	746	|O
nucleophilic	747	759	|O
displacement	760	772	|O
of	773	775	|O
2,4	776	779	|B-IUPAC
-	779	780	|I-IUPAC
diamino	780	787	|I-IUPAC
-	787	788	|I-IUPAC
5	788	789	|I-IUPAC
-	789	790	|I-IUPAC
(	790	791	|I-IUPAC
chloromethyl	791	803	|I-IUPAC
)	803	804	|I-IUPAC
furo	804	808	|I-IUPAC
[	808	809	|I-IUPAC
2,3	809	812	|I-IUPAC
-	812	813	|I-IUPAC
d	813	814	|I-IUPAC
]	814	815	|I-IUPAC
pyrimidine	815	825	|I-IUPAC
(	825	826	|O
2	826	827	|O
)	827	828	|O
with	829	833	|O
the	834	837	|O
appropriate	838	849	|O
thiol	850	855	|O
,	855	856	|O
amine	857	862	|O
,	862	863	|O
or	864	866	|O
naphthol	867	875	|O
.	875	876	|O
Compound	877	885	|O
2	886	887	|O
was	888	891	|O
obtained	892	900	|O
from	901	905	|O
2,4	906	909	|B-IUPAC
-	909	910	|I-IUPAC
diamino	910	917	|I-IUPAC
-	917	918	|I-IUPAC
6	918	919	|I-IUPAC
-	919	920	|I-IUPAC
hydroxypyrimidine	920	937	|I-IUPAC
and	938	941	|O
1	942	943	|B-IUPAC
,	943	944	|I-IUPAC
3	945	946	|I-IUPAC
-	946	947	|I-IUPAC
dichloroacetone	947	962	|I-IUPAC
.	962	963	|O
The	964	967	|O
compounds	968	977	|O
were	978	982	|O
evaluated	983	992	|O
as	993	995	|O
inhibitors	996	1006	|O
against	1007	1014	|O
DHFR	1015	1019	|O
from	1020	1024	|O
P	1025	1026	|O
.	1026	1027	|O
carinii	1028	1035	|O
,	1035	1036	|O
Toxoplasma	1037	1047	|O
gondii	1048	1054	|O
,	1054	1055	|O
and	1056	1059	|O
rat	1060	1063	|O
liver	1064	1069	|O
.	1069	1070	|O
Two	1071	1074	|O
analogues	1075	1084	|O
,	1084	1085	|O
2,4	1086	1089	|B-IUPAC
-	1089	1090	|I-IUPAC
diamino	1090	1097	|I-IUPAC
-	1097	1098	|I-IUPAC
5	1098	1099	|I-IUPAC
-	1099	1100	|I-IUPAC
[	1100	1101	|I-IUPAC
(	1101	1102	|I-IUPAC
2'	1102	1104	|I-IUPAC
-	1104	1105	|I-IUPAC
naphthylthio	1105	1117	|I-IUPAC
)	1117	1118	|I-IUPAC
methyl	1118	1124	|I-IUPAC
]	1124	1125	|I-IUPAC
furo	1125	1129	|I-IUPAC
[	1129	1130	|I-IUPAC
2	1130	1131	|I-IUPAC
,	1131	1132	|I-IUPAC
3	1133	1134	|I-IUPAC
-	1134	1135	|I-IUPAC
d	1135	1136	|I-IUPAC
]	1136	1137	|I-IUPAC
pyrimidine	1137	1147	|I-IUPAC
(	1148	1149	|O
5	1149	1150	|O
)	1150	1151	|O
and	1152	1155	|O
2,4	1156	1159	|B-IUPAC
-	1159	1160	|I-IUPAC
diamino	1160	1167	|I-IUPAC
-	1167	1168	|I-IUPAC
5	1168	1169	|I-IUPAC
-	1169	1170	|I-IUPAC
[	1170	1171	|I-IUPAC
(	1171	1172	|I-IUPAC
2'	1172	1174	|I-IUPAC
-	1174	1175	|I-IUPAC
phenylanilino	1175	1188	|I-IUPAC
)	1188	1189	|I-IUPAC
methyl	1189	1195	|I-IUPAC
]	1195	1196	|I-IUPAC
furo	1196	1200	|I-IUPAC
[	1200	1201	|I-IUPAC
2,3	1201	1204	|I-IUPAC
-	1204	1205	|I-IUPAC
d	1205	1206	|I-IUPAC
]	1206	1207	|I-IUPAC
pyrimidine	1207	1217	|I-IUPAC
(	1218	1219	|O
11	1219	1221	|O
)	1221	1222	|O
showed	1223	1229	|O
significant	1230	1241	|O
selectivity	1242	1253	|O
and	1254	1257	|O
potency	1258	1265	|O
for	1266	1269	|O
pcDHFR	1270	1276	|O
compared	1277	1285	|O
to	1286	1288	|O
trimethoprim	1289	1301	|O
.	1301	1302	|O
The	1303	1306	|O
X	1307	1308	|O
-	1308	1309	|O
ray	1309	1312	|O
crystal	1313	1320	|O
structure	1321	1330	|O
of	1331	1333	|O
5	1334	1335	|O
with	1336	1340	|O
pcDHFR	1341	1347	|O
was	1348	1351	|O
also	1352	1356	|O
carried	1357	1364	|O
out	1365	1368	|O
,	1368	1369	|O
which	1370	1375	|O
corroborated	1376	1388	|O
the	1389	1392	|O
design	1393	1399	|O
rationale	1400	1409	|O
and	1410	1413	|O
indicated	1414	1423	|O
a	1424	1425	|O
hydrophobic	1426	1437	|O
interaction	1438	1449	|O
of	1450	1452	|O
the	1453	1456	|O
naphthalene	1457	1468	|O
ring	1469	1473	|O
of	1474	1476	|O
5	1477	1478	|O
and	1479	1482	|O
Phe69	1483	1488	|O
of	1489	1491	|O
pcDHFR	1492	1498	|O
which	1499	1504	|O
is	1505	1507	|O
responsible	1508	1519	|O
,	1519	1520	|O
in	1521	1523	|O
part	1524	1528	|O
,	1528	1529	|O
for	1530	1533	|O
the	1534	1537	|O
more	1538	1542	|O
than	1543	1547	|O
18	1548	1550	|O
-	1550	1551	|O
fold	1551	1555	|O
selectivity	1556	1567	|O
of	1568	1570	|O
5	1571	1572	|O
for	1573	1576	|O
pcDHFR	1577	1583	|O
as	1584	1586	|O
compared	1587	1595	|O
with	1596	1600	|O
rat	1601	1604	|O
liver	1605	1610	|O
DHFR	1611	1615	|O
.	1615	1616	|O

### abstracts680.txt
New	0	3	|O
compounds	4	13	|O
of	14	16	|O
the	17	20	|O
nitroimidazole	21	35	|O
series	36	42	|O
have	43	47	|O
been	48	52	|O
synthesized	53	64	|O
as	65	67	|O
radiosensitizers	68	84	|O
which	85	90	|O
selectively	91	102	|O
sensitize	103	112	|O
hypoxic	113	120	|O
cells	121	126	|O
to	127	129	|O
the	130	133	|O
lethal	134	140	|O
effect	141	147	|O
of	148	150	|O
radiation	151	160	|O
.	160	161	|O
The	162	165	|O
reaction	166	174	|O
of	175	177	|O
2,4	178	181	|B-IUPAC
(	181	182	|I-IUPAC
5	182	183	|I-IUPAC
)	183	184	|I-IUPAC
-	184	185	|I-IUPAC
dinitroimidazole	185	201	|I-IUPAC
(	202	203	|O
2	203	204	|O
)	204	205	|O
with	206	210	|O
chloroethanol	211	224	|O
or	225	227	|O
hydrochloric	228	240	|O
acid	241	245	|O
yielded	246	253	|O
4	254	255	|B-IUPAC
(	255	256	|I-IUPAC
5	256	257	|I-IUPAC
)	257	258	|I-IUPAC
-	258	259	|I-IUPAC
nitro	259	264	|I-IUPAC
-	264	265	|I-IUPAC
5	265	266	|I-IUPAC
(	266	267	|I-IUPAC
4	267	268	|I-IUPAC
)	268	269	|I-IUPAC
-	269	270	|I-IUPAC
chloroimidazole	270	285	|I-IUPAC
(	286	287	|O
3	287	288	|O
)	288	289	|O
,	289	290	|O
which	291	296	|O
upon	297	301	|O
reaction	302	310	|O
with	311	315	|O
ethylene	316	324	|O
oxide	325	330	|O
yielded	331	338	|O
the	339	342	|O
4	343	344	|B-IUPAC
-	344	345	|I-IUPAC
nitro	345	350	|I-IUPAC
-	350	351	|I-IUPAC
5	351	352	|I-IUPAC
-	352	353	|I-IUPAC
chloroimidazole	353	368	|I-IUPAC
-	368	369	|I-IUPAC
1	369	370	|I-IUPAC
-	370	371	|I-IUPAC
ethanol	371	378	|I-IUPAC
(	379	380	|O
6	380	381	|O
)	381	382	|O
.	382	383	|O
Reaction	384	392	|O
of	393	395	|O
2	396	397	|O
with	398	402	|O
ethylene	403	411	|O
oxide	412	417	|O
resulted	418	426	|O
in	427	429	|O
a	430	431	|O
mixture	432	439	|O
of	440	442	|O
two	443	446	|O
compounds	447	456	|O
,	456	457	|O
the	458	461	|O
2,4	462	465	|B-IUPAC
-	465	466	|I-IUPAC
dinitroimidazole	466	482	|I-IUPAC
-	482	483	|I-IUPAC
1	483	484	|I-IUPAC
-	484	485	|I-IUPAC
ethanol	485	492	|I-IUPAC
(	493	494	|O
4	494	495	|O
)	495	496	|O
and	497	500	|O
2,3	501	504	|B-IUPAC
-	504	505	|I-IUPAC
dihydro	505	512	|I-IUPAC
-	512	513	|I-IUPAC
5	513	514	|I-IUPAC
-	514	515	|I-IUPAC
nitroimidazo	515	527	|I-IUPAC
[	527	528	|I-IUPAC
2,1	528	531	|I-IUPAC
-	531	532	|I-IUPAC
b	532	533	|I-IUPAC
]	533	534	|I-IUPAC
oxazole	534	541	|I-IUPAC
(	542	543	|O
5	543	544	|O
)	544	545	|O
.	545	546	|O
The	547	550	|O
structure	551	560	|O
of	561	563	|O
the	564	567	|O
new	568	571	|O
heterocyclic	572	584	|O
compound	585	593	|O
5	594	595	|O
was	596	599	|O
confirmed	600	609	|O
by	610	612	|O
1H	613	615	|O
NMR	616	619	|O
,	619	620	|O
mass	621	625	|O
spectrum	626	634	|O
,	634	635	|O
and	636	639	|O
X	640	641	|O
-	641	642	|O
ray	642	645	|O
crystallography	646	661	|O
.	661	662	|O
These	663	668	|O
agents	669	675	|O
were	676	680	|O
tested	681	687	|O
for	688	691	|O
their	692	697	|O
ability	698	705	|O
to	706	708	|O
sensitize	709	718	|O
hypoxic	719	726	|O
Escherichia	727	738	|O
coli	739	743	|O
cells	744	749	|O
to	750	752	|O
killing	753	760	|O
by	761	763	|O
ionizing	764	772	|O
radiation	773	782	|O
.	782	783	|O
Compound	784	792	|O
4	793	794	|O
was	795	798	|O
found	799	804	|O
to	805	807	|O
be	808	810	|O
the	811	814	|O
most	815	819	|O
active	820	826	|O
agent	827	832	|O
of	833	835	|O
this	836	840	|O
series	841	847	|O
of	848	850	|O
compounds	851	860	|O
.	860	861	|O

### abstracts557.txt
The	0	3	|O
synthesis	4	13	|O
of	14	16	|O
6	17	18	|B-MODIFIER
-	18	19	|I-MODIFIER
substituted	19	30	|I-MODIFIER
5	31	32	|B-IUPAC
-	32	33	|I-IUPAC
(	33	34	|I-IUPAC
thienylvinyl	34	46	|I-IUPAC
)	46	47	|I-IUPAC
imidazo	47	54	|I-IUPAC
[	54	55	|I-IUPAC
2,1	55	58	|I-IUPAC
-	58	59	|I-IUPAC
b	59	60	|I-IUPAC
]	60	61	|I-IUPAC
thiazoles	61	70	|I-IUPAC
and	71	74	|O
6	75	76	|B-IUPAC
-	76	77	|I-IUPAC
thienylimidazo	77	91	|I-IUPAC
[	91	92	|I-IUPAC
2,1	92	95	|I-IUPAC
-	95	96	|I-IUPAC
b	96	97	|I-IUPAC
]	97	98	|I-IUPAC
thiazoles	98	107	|I-IUPAC
is	108	110	|O
reported	111	119	|O
.	119	120	|O
These	121	126	|O
compounds	127	136	|O
were	137	141	|O
tested	142	148	|O
as	149	151	|O
specific	152	160	|O
inhibitors	161	171	|O
of	172	174	|O
the	175	178	|O
NADH	179	183	|O
:	183	184	|O
ubiquinone	185	195	|O
(	196	197	|O
UBQ	197	200	|O
)	200	201	|O
reductase	202	211	|O
activity	212	220	|O
of	221	223	|O
NADH	224	228	|O
dehydrogenase	229	242	|O
in	243	245	|O
mitochondrial	246	259	|O
membranes	260	269	|O
.	269	270	|O
The	271	274	|O
6	275	276	|B-IUPAC
-	276	277	|I-IUPAC
thienylimidazo	277	291	|I-IUPAC
[	291	292	|I-IUPAC
2,1	292	295	|I-IUPAC
-	295	296	|I-IUPAC
b	296	297	|I-IUPAC
]	297	298	|I-IUPAC
thiazoles	298	307	|I-IUPAC
were	308	312	|O
more	313	317	|O
potent	318	324	|O
in	325	327	|O
mammalian	328	337	|O
than	338	342	|O
in	343	345	|O
nematode	346	354	|O
mitochondria	355	367	|O
and	368	371	|O
had	372	375	|O
an	376	378	|O
average	379	386	|O
titer	387	392	|O
of	393	395	|O
0.11	396	400	|O
mM	401	403	|O
for	404	407	|O
2	408	409	|B-IUPAC
-	409	410	|I-IUPAC
methyl	410	416	|I-IUPAC
-	416	417	|I-IUPAC
6	417	418	|I-IUPAC
-	418	419	|I-IUPAC
(	419	420	|I-IUPAC
2	420	421	|I-IUPAC
-	421	422	|I-IUPAC
thienyl	422	429	|I-IUPAC
)	429	430	|I-IUPAC
imidazo	430	437	|I-IUPAC
[	437	438	|I-IUPAC
2,1	438	441	|I-IUPAC
-	441	442	|I-IUPAC
b	442	443	|I-IUPAC
]	443	444	|I-IUPAC
thiazole	444	452	|I-IUPAC
(	453	454	|O
10	454	456	|O
)	456	457	|O
.	457	458	|O
This	459	463	|O
compound	464	472	|O
is	473	475	|O
noncompetitive	476	490	|O
with	491	495	|O
the	496	499	|O
ubiquinone	500	510	|O
substrate	511	520	|O
and	521	524	|O
interacts	525	534	|O
with	535	539	|O
a	540	541	|O
site	542	546	|O
which	547	552	|O
is	553	555	|O
mutually	556	564	|O
exclusive	565	574	|O
with	575	579	|O
that	580	584	|O
of	585	587	|O
rotenone	588	596	|O
but	597	600	|O
nonexclusive	601	613	|O
with	614	618	|O
that	619	623	|O
of	624	626	|O
piericidin	627	637	|O
and	638	641	|O
several	642	649	|O
other	650	655	|O
inhibitors	656	666	|O
of	667	669	|O
NADH	670	674	|O
dehydrogenase	675	688	|O
.	688	689	|O
In	690	692	|O
the	693	696	|O
series	697	703	|O
of	704	706	|O
5	707	708	|B-IUPAC
-	708	709	|I-IUPAC
(	709	710	|I-IUPAC
thienylvinyl	710	722	|I-IUPAC
)	722	723	|I-IUPAC
imidazothiazoles	723	739	|I-IUPAC
,	739	740	|O
the	741	744	|O
hydrobromide	745	757	|B-MODIFIER
of	758	760	|O
(	761	762	|B-IUPAC
E	762	763	|I-IUPAC
)	763	764	|I-IUPAC
-	764	765	|I-IUPAC
6	765	766	|I-IUPAC
-	766	767	|I-IUPAC
chloro	767	773	|I-IUPAC
-	773	774	|I-IUPAC
5	774	775	|I-IUPAC
-	775	776	|I-IUPAC
(	776	777	|I-IUPAC
2	777	778	|I-IUPAC
-	778	779	|I-IUPAC
thienylvinyl	779	791	|I-IUPAC
)	791	792	|I-IUPAC
imidazo	792	799	|I-IUPAC
[	799	800	|I-IUPAC
2,1	800	803	|I-IUPAC
-	803	804	|I-IUPAC
b	804	805	|I-IUPAC
]	805	806	|I-IUPAC
thiazole	806	814	|I-IUPAC
(	815	816	|O
E	816	817	|O
-	817	818	|O
5	818	819	|O
.	819	820	|O
HBr	820	823	|O
)	823	824	|O
was	825	828	|O
found	829	834	|O
to	835	837	|O
be	838	840	|O
more	841	845	|O
potent	846	852	|O
as	853	855	|O
an	856	858	|O
inhibitor	859	868	|O
of	869	871	|O
the	872	875	|O
NADH	876	880	|O
:	880	881	|O
UBQ	881	884	|O
activity	885	893	|O
(	894	895	|O
IC50	895	899	|O
=	900	901	|O
15-17	902	907	|O
microM	908	914	|O
)	914	915	|O
than	916	920	|O
the	921	924	|O
6	925	926	|B-IUPAC
-	926	927	|I-IUPAC
thienylimidazoles	927	944	|I-IUPAC
such	945	949	|O
as	950	952	|O
10	953	955	|O
.	955	956	|O
The	957	960	|O
inhibitory	961	971	|O
action	972	978	|O
of	979	981	|O
E	982	983	|O
-	983	984	|O
5	984	985	|O
.	985	986	|O
HBr	986	989	|O
and	990	993	|O
its	994	997	|O
analogs	998	1005	|O
is	1006	1008	|O
different	1009	1018	|O
from	1019	1023	|O
that	1024	1028	|O
of	1029	1031	|O
compound	1032	1040	|O
10	1041	1043	|O
as	1044	1046	|O
indicated	1047	1056	|O
by	1057	1059	|O
the	1060	1063	|O
mutual	1064	1070	|O
exclusivity	1071	1082	|O
with	1083	1087	|O
other	1088	1093	|O
inhibitors	1094	1104	|O
and	1105	1108	|O
the	1109	1112	|O
relative	1113	1121	|O
inhibition	1122	1132	|O
of	1133	1135	|O
the	1136	1139	|O
activity	1140	1148	|O
with	1149	1153	|O
various	1154	1161	|O
electron	1162	1170	|O
acceptors	1171	1180	|O
.	1180	1181	|O

### abstracts1770.txt
The	0	3	|O
transformation	4	18	|O
of	19	21	|O
milrinone	22	31	|O
to	32	34	|O
1,3	35	38	|B-IUPAC
-	38	39	|I-IUPAC
dihydro	39	46	|I-IUPAC
-	46	47	|I-IUPAC
5	47	48	|I-IUPAC
-	48	49	|I-IUPAC
methyl	49	55	|I-IUPAC
-	55	56	|I-IUPAC
6	56	57	|I-IUPAC
-	57	58	|I-IUPAC
(	58	59	|I-IUPAC
4	59	60	|I-IUPAC
-	60	61	|I-IUPAC
pyridinyl	61	70	|I-IUPAC
)	70	71	|I-IUPAC
-	71	72	|I-IUPAC
2H	72	74	|I-IUPAC
-	74	75	|I-IUPAC
imidazo	75	82	|I-IUPAC
[	82	83	|I-IUPAC
4,5	83	86	|I-IUPAC
-	86	87	|I-IUPAC
b	87	88	|I-IUPAC
]	88	89	|I-IUPAC
pyridin	89	96	|I-IUPAC
-	96	97	|I-IUPAC
2	97	98	|I-IUPAC
-	98	99	|I-IUPAC
one	99	102	|I-IUPAC
(	103	104	|O
13a	104	107	|O
)	107	108	|O
,	108	109	|O
5	110	111	|B-IUPAC
-	111	112	|I-IUPAC
methyl	112	118	|I-IUPAC
-	118	119	|I-IUPAC
6	119	120	|I-IUPAC
-	120	121	|I-IUPAC
(	121	122	|I-IUPAC
4	122	123	|I-IUPAC
-	123	124	|I-IUPAC
pyridinyl	124	133	|I-IUPAC
)	133	134	|I-IUPAC
thiazolo	134	142	|I-IUPAC
[	142	143	|I-IUPAC
4,5	143	146	|I-IUPAC
-	146	147	|I-IUPAC
b	147	148	|I-IUPAC
]	148	149	|I-IUPAC
pyridin	149	156	|I-IUPAC
-	156	157	|I-IUPAC
2	157	158	|I-IUPAC
(	158	159	|I-IUPAC
3H	159	161	|I-IUPAC
)	161	162	|I-IUPAC
-	162	163	|I-IUPAC
one	163	166	|I-IUPAC
(	167	168	|O
51	168	170	|O
)	170	171	|O
,	171	172	|O
and	173	176	|O
7	177	178	|B-IUPAC
-	178	179	|I-IUPAC
methyl	179	185	|I-IUPAC
-	185	186	|I-IUPAC
6	186	187	|I-IUPAC
-	187	188	|I-IUPAC
(	188	189	|I-IUPAC
4	189	190	|I-IUPAC
-	190	191	|I-IUPAC
pyridinyl	191	200	|I-IUPAC
)	200	201	|I-IUPAC
-	201	202	|I-IUPAC
1,8	202	205	|I-IUPAC
-	205	206	|I-IUPAC
naphthyridin	206	218	|I-IUPAC
-	218	219	|I-IUPAC
2	219	220	|I-IUPAC
(	220	221	|I-IUPAC
1H	221	223	|I-IUPAC
)	223	224	|I-IUPAC
-	224	225	|I-IUPAC
one	225	228	|I-IUPAC
(	229	230	|O
22	230	232	|O
)	232	233	|O
resulted	234	242	|O
in	243	245	|O
very	246	250	|O
potent	251	257	|O
cAMP	258	262	|O
PDE	263	266	|O
III	267	270	|O
inhibitors	271	281	|O
with	282	286	|O
in	287	289	|O
vitro	290	295	|O
activity	296	304	|O
in	305	307	|O
the	308	311	|O
nanomolar	312	321	|O
range	322	327	|O
.	327	328	|O
1,3	329	332	|B-IUPAC
-	332	333	|I-IUPAC
Dihydro	333	340	|I-IUPAC
-	340	341	|I-IUPAC
2H	341	343	|I-IUPAC
-	343	344	|I-IUPAC
imidazo	344	351	|I-IUPAC
[	351	352	|I-IUPAC
4,5	352	355	|I-IUPAC
-	355	356	|I-IUPAC
b	356	357	|I-IUPAC
]	357	358	|I-IUPAC
pyridin	358	365	|I-IUPAC
-	365	366	|I-IUPAC
2	366	367	|I-IUPAC
-	367	368	|I-IUPAC
ones	368	372	|I-IUPAC
13	373	375	|O
were	376	380	|O
prepared	381	389	|O
from	390	394	|O
2	395	396	|B-IUPAC
-	396	397	|I-IUPAC
aminopyridine	397	410	|I-IUPAC
-	410	411	|I-IUPAC
3	411	412	|I-IUPAC
-	412	413	|I-IUPAC
carboxylic	413	423	|I-IUPAC
acids	424	429	|I-IUPAC
(	430	431	|O
7	431	432	|O
,	432	433	|O
10	434	436	|O
)	436	437	|O
via	438	441	|O
Curtius	442	449	|O
rearrangement	450	463	|O
.	463	464	|O
1,8	465	468	|B-IUPAC
-	468	469	|I-IUPAC
Naphthyridin	469	481	|I-IUPAC
-	481	482	|I-IUPAC
2	482	483	|I-IUPAC
(	483	484	|I-IUPAC
1H	484	486	|I-IUPAC
)	486	487	|I-IUPAC
-	487	488	|I-IUPAC
one	488	491	|I-IUPAC
22	492	494	|O
and	495	498	|O
the	499	502	|O
corresponding	503	516	|O
3,4	517	520	|B-IUPAC
-	520	521	|I-IUPAC
dihydro	521	528	|I-IUPAC
derivative	529	539	|B-MODIFIER
28	540	542	|O
were	543	547	|O
prepared	548	556	|O
from	557	561	|O
5	562	563	|B-IUPAC
-	563	564	|I-IUPAC
bromo	564	569	|I-IUPAC
-	569	570	|I-IUPAC
2	570	571	|I-IUPAC
-	571	572	|I-IUPAC
methyl	572	578	|I-IUPAC
[	578	579	|I-IUPAC
3,4	579	582	|I-IUPAC
'	582	583	|I-IUPAC
-	583	584	|I-IUPAC
bipyridin	584	593	|I-IUPAC
]	593	594	|I-IUPAC
-	594	595	|I-IUPAC
6	595	596	|I-IUPAC
-	596	597	|I-IUPAC
amine	597	602	|I-IUPAC
(	603	604	|O
21	604	606	|O
)	606	607	|O
and	608	611	|O
5	612	613	|B-IUPAC
-	613	614	|I-IUPAC
bromo	614	619	|I-IUPAC
-	619	620	|I-IUPAC
2	620	621	|I-IUPAC
-	621	622	|I-IUPAC
methyl	622	628	|I-IUPAC
[	628	629	|I-IUPAC
3,4	629	632	|I-IUPAC
-	632	633	|I-IUPAC
bipyridin	633	642	|I-IUPAC
]	642	643	|I-IUPAC
-	643	644	|I-IUPAC
6	644	645	|I-IUPAC
(	645	646	|I-IUPAC
1H	646	648	|I-IUPAC
)	648	649	|I-IUPAC
-	649	650	|I-IUPAC
one	650	653	|I-IUPAC
(	654	655	|O
24	655	657	|O
)	657	658	|O
,	658	659	|O
respectively	660	672	|O
,	672	673	|O
via	674	677	|O
Heck	678	682	|O
reaction	683	691	|O
.	691	692	|O
Thiazolo	693	701	|B-IUPAC
[	701	702	|I-IUPAC
4,5	702	705	|I-IUPAC
-	705	706	|I-IUPAC
b	706	707	|I-IUPAC
]	707	708	|I-IUPAC
pyridin	708	715	|I-IUPAC
-	715	716	|I-IUPAC
2	716	717	|I-IUPAC
(	717	718	|I-IUPAC
3H	718	720	|I-IUPAC
)	720	721	|I-IUPAC
-	721	722	|I-IUPAC
ones	722	726	|I-IUPAC
35	727	729	|O
were	730	734	|O
prepared	735	743	|O
from	744	748	|O
6	749	750	|B-IUPAC
-	750	751	|I-IUPAC
bromo	751	756	|I-IUPAC
[	756	757	|I-IUPAC
3,4	757	760	|I-IUPAC
'	760	761	|I-IUPAC
-	761	762	|I-IUPAC
bipyridin	762	771	|I-IUPAC
]	771	772	|I-IUPAC
-	772	773	|I-IUPAC
6	773	774	|I-IUPAC
-	774	775	|I-IUPAC
amines	775	781	|I-IUPAC
30	782	784	|O
and	785	788	|O
32	789	791	|O
via	792	795	|O
a	796	797	|O
four	798	802	|O
-	802	803	|O
step	803	807	|O
sequence	808	816	|O
.	816	817	|O
Treatment	818	827	|O
of	828	830	|O
6	831	832	|B-IUPAC
-	832	833	|I-IUPAC
amino	833	838	|I-IUPAC
-	838	839	|I-IUPAC
2	839	840	|I-IUPAC
-	840	841	|I-IUPAC
methyl	841	847	|I-IUPAC
[	847	848	|I-IUPAC
3,4	848	851	|I-IUPAC
'	851	852	|I-IUPAC
-	852	853	|I-IUPAC
bipyridine	853	863	|I-IUPAC
]	863	864	|I-IUPAC
-	864	865	|I-IUPAC
5	865	866	|I-IUPAC
-	866	867	|I-IUPAC
thiol	867	872	|I-IUPAC
(	873	874	|O
59	874	876	|O
)	876	877	|O
with	878	882	|O
ethyl	883	888	|B-IUPAC
bromoacetate	889	901	|B-IUPAC
and	902	905	|O
ethyl	906	911	|B-IUPAC
bromodifluoroacetate	912	932	|B-IUPAC
gave	933	937	|O
pyridothiazinones	938	955	|O
60	956	958	|O
and	959	962	|O
61	963	965	|O
,	965	966	|O
respectively	967	979	|O
.	979	980	|O

### abstracts2276.txt
Several	0	7	|O
3beta	8	13	|B-PARTIUPAC
-	13	14	|I-PARTIUPAC
(	14	15	|O
substituted	15	26	|B-MODIFIER
phenyl	27	33	|B-PARTIUPAC
)	33	34	|O
-	34	35	|B-PARTIUPAC
2beta	35	40	|I-PARTIUPAC
-	40	41	|I-PARTIUPAC
(	41	42	|I-PARTIUPAC
3	42	43	|B-MODIFIER
-	43	44	|I-MODIFIER
substituted	44	55	|I-MODIFIER
isoxazol	56	64	|B-PARTIUPAC
-	64	65	|I-PARTIUPAC
5	65	66	|I-PARTIUPAC
-	66	67	|I-PARTIUPAC
yl	67	69	|I-PARTIUPAC
)	69	70	|I-PARTIUPAC
tropanes	70	78	|I-PARTIUPAC
(	79	80	|O
3a	80	82	|O
-	82	83	|O
t	83	84	|O
)	84	85	|O
were	86	90	|O
evaluated	91	100	|O
for	101	104	|O
their	105	110	|O
ability	111	118	|O
to	119	121	|O
inhibit	122	129	|O
radioligand	130	141	|O
binding	142	149	|O
at	150	152	|O
the	153	156	|O
DAT	157	160	|O
,	160	161	|O
5	162	163	|O
-	163	164	|O
HTT	164	167	|O
,	167	168	|O
and	169	172	|O
NET	173	176	|O
as	177	179	|O
well	180	184	|O
as	185	187	|O
in	188	190	|O
gross	191	196	|O
observation	197	208	|O
and	209	212	|O
locomotor	213	222	|O
activity	223	231	|O
in	232	234	|O
mice	235	239	|O
and	240	243	|O
in	244	246	|O
rats	247	251	|O
trained	252	259	|O
to	260	262	|O
discriminate	263	275	|O
cocaine	276	283	|O
.	283	284	|O
All	285	288	|O
compounds	289	298	|O
showed	299	305	|O
high	306	310	|O
affinity	311	319	|O
for	320	323	|O
the	324	327	|O
DAT	328	331	|O
.	331	332	|O
The	333	336	|O
IC	337	339	|O
(	339	340	|O
50	340	342	|O
)	342	343	|O
values	344	350	|O
ranged	351	357	|O
from	358	362	|O
0.5	363	366	|O
to	367	369	|O
26	370	372	|O
nM	373	375	|O
.	375	376	|O
With	377	381	|O
the	382	385	|O
exception	386	395	|O
of	396	398	|O
3e	399	401	|O
and	402	405	|O
3f	406	408	|O
,	408	409	|O
which	410	415	|O
have	416	420	|O
no	421	423	|O
substituent	424	435	|O
on	436	438	|O
the	439	442	|O
2beta	443	448	|B-IUPAC
-	448	449	|I-IUPAC
(	449	450	|I-IUPAC
1,2	450	453	|I-IUPAC
-	453	454	|I-IUPAC
isoxazole	454	463	|I-IUPAC
)	463	464	|I-IUPAC
ring	465	469	|B-MODIFIER
,	469	470	|O
all	471	474	|O
compounds	475	484	|O
were	485	489	|O
selective	490	499	|O
for	500	503	|O
the	504	507	|O
DAT	508	511	|O
relative	512	520	|O
to	521	523	|O
the	524	527	|O
5	528	529	|O
-	529	530	|O
HTT	530	533	|O
and	534	537	|O
NET	538	541	|O
.	541	542	|O
No	543	545	|O
compound	546	554	|O
showed	555	561	|O
death	562	567	|O
when	568	572	|O
dosed	573	578	|O
at	579	581	|O
100	582	585	|O
mg	586	588	|O
/	588	589	|O
kg	589	591	|O
;	591	592	|O
however	593	600	|O
,	600	601	|O
most	602	606	|O
compounds	607	616	|O
did	617	620	|O
show	621	625	|O
signs	626	631	|O
typical	632	639	|O
of	640	642	|O
dopamine	643	651	|O
activity	652	660	|O
.	660	661	|O
The	662	665	|O
ED	666	668	|O
(	668	669	|O
50	669	671	|O
)	671	672	|O
values	673	679	|O
for	680	683	|O
2beta	684	689	|B-IUPAC
-	689	690	|I-IUPAC
(	690	691	|I-IUPAC
1,2	691	694	|I-IUPAC
-	694	695	|I-IUPAC
isoxazoles	695	705	|I-IUPAC
)	705	706	|I-IUPAC
that	707	711	|O
caused	712	718	|O
locomotor	719	728	|O
stimulation	729	740	|O
ranged	741	747	|O
from	748	752	|O
0.2	753	756	|O
to	757	759	|O
12.8	760	764	|O
mg	765	767	|O
/	767	768	|O
kg	768	770	|O
.	770	771	|O
Most	772	776	|O
compounds	777	786	|O
showed	787	793	|O
slower	794	800	|O
on	801	803	|O
-	803	804	|O
set	804	807	|O
and	808	811	|O
longer	812	818	|O
duration	819	827	|O
of	828	830	|O
action	831	837	|O
relative	838	846	|O
to	847	849	|O
cocaine	850	857	|O
.	857	858	|O
Surprisingly	859	871	|O
,	871	872	|O
3beta	873	878	|B-IUPAC
-	878	879	|I-IUPAC
(	879	880	|I-IUPAC
4	880	881	|I-IUPAC
-	881	882	|I-IUPAC
methylphenyl	882	894	|I-IUPAC
)	894	895	|I-IUPAC
-	895	896	|I-IUPAC
2beta	896	901	|I-IUPAC
-	901	902	|I-IUPAC
[	902	903	|I-IUPAC
3	903	904	|I-IUPAC
-	904	905	|I-IUPAC
(	905	906	|I-IUPAC
4'	906	908	|I-IUPAC
-	908	909	|I-IUPAC
chlorophenyl	909	921	|I-IUPAC
)	921	922	|I-IUPAC
isoxazol	922	930	|I-IUPAC
-	930	931	|I-IUPAC
5	931	932	|I-IUPAC
-	932	933	|I-IUPAC
yl	933	935	|I-IUPAC
]	935	936	|I-IUPAC
tropane	936	943	|I-IUPAC
(	944	945	|O
3p	945	947	|O
)	947	948	|O
and	949	952	|O
3beta	953	958	|B-IUPAC
-	958	959	|I-IUPAC
(	959	960	|I-IUPAC
4	960	961	|I-IUPAC
-	961	962	|I-IUPAC
methylphenyl	962	974	|I-IUPAC
)	974	975	|I-IUPAC
-	975	976	|I-IUPAC
2beta	976	981	|I-IUPAC
-	981	982	|I-IUPAC
[	982	983	|I-IUPAC
3	983	984	|I-IUPAC
-	984	985	|I-IUPAC
(	985	986	|I-IUPAC
4'	986	988	|I-IUPAC
-	988	989	|I-IUPAC
methylphenyl	989	1001	|I-IUPAC
)	1001	1002	|I-IUPAC
isoxazol	1002	1010	|I-IUPAC
-	1010	1011	|I-IUPAC
5	1011	1012	|I-IUPAC
-	1012	1013	|I-IUPAC
yl	1013	1015	|I-IUPAC
]	1015	1016	|I-IUPAC
tropane	1016	1023	|I-IUPAC
(	1024	1025	|O
3r	1025	1027	|O
)	1027	1028	|O
did	1029	1032	|O
not	1033	1036	|O
produce	1037	1044	|O
significant	1045	1056	|O
increases	1057	1066	|O
in	1067	1069	|O
locomotor	1070	1079	|O
activity	1080	1088	|O
.	1088	1089	|O
In	1090	1092	|O
the	1093	1096	|O
cocaine	1097	1104	|O
discrimination	1105	1119	|O
test	1120	1124	|O
,	1124	1125	|O
all	1126	1129	|O
analogues	1130	1139	|O
showed	1140	1146	|O
full	1147	1151	|O
or	1152	1154	|O
at	1155	1157	|O
least	1158	1163	|O
50%	1164	1167	|O
generalization	1168	1182	|O
with	1183	1187	|O
the	1188	1191	|O
exception	1192	1201	|O
of	1202	1204	|O
3p	1205	1207	|O
,	1207	1208	|O
which	1209	1214	|O
did	1215	1218	|O
not	1219	1222	|O
show	1223	1227	|O
generalization	1228	1242	|O
.	1242	1243	|O
Importantly	1244	1255	|O
,	1255	1256	|O
both	1257	1261	|O
the	1262	1265	|O
locomotor	1266	1275	|O
activity	1276	1284	|O
and	1285	1288	|O
the	1289	1292	|O
cocaine	1293	1300	|O
discrimination	1301	1315	|O
ED	1316	1318	|O
(	1318	1319	|O
50	1319	1321	|O
)	1321	1322	|O
values	1322	1328	|O
were	1329	1333	|O
correlated	1334	1344	|O
with	1345	1349	|O
the	1350	1353	|O
DAT	1354	1357	|O
binding	1358	1365	|O
but	1366	1369	|O
not	1370	1373	|O
5	1374	1375	|O
-	1375	1376	|O
HTT	1376	1379	|O
and	1380	1383	|O
NET	1384	1387	|O
binding	1388	1395	|O
.	1395	1396	|O
This	1397	1401	|O
provides	1402	1410	|O
further	1411	1418	|O
support	1419	1426	|O
for	1427	1430	|O
the	1431	1434	|O
dopamine	1435	1443	|O
hypothesis	1444	1454	|O
of	1455	1457	|O
cocaine	1458	1465	|O
abuse	1466	1471	|O
.	1471	1472	|O
High	1473	1477	|O
DAT	1478	1481	|O
affinity	1482	1490	|O
and	1491	1494	|O
selectivity	1495	1506	|O
,	1506	1507	|O
increased	1508	1517	|O
locomotor	1518	1527	|O
activity	1528	1536	|O
with	1537	1541	|O
slow	1542	1546	|O
onset	1547	1552	|O
and	1553	1556	|O
long	1557	1561	|O
duration	1562	1570	|O
of	1571	1573	|O
action	1574	1580	|O
,	1580	1581	|O
and	1582	1585	|O
generalization	1586	1600	|O
to	1601	1603	|O
cocaine	1604	1611	|O
shown	1612	1617	|O
by	1618	1620	|O
the	1621	1624	|O
3beta	1625	1630	|B-PARTIUPAC
-	1630	1631	|I-PARTIUPAC
(	1631	1632	|O
substituted	1632	1643	|B-MODIFIER
phenyl	1644	1650	|B-PARTIUPAC
)	1650	1651	|O
-	1651	1652	|I-PARTIUPAC
2beta	1652	1657	|I-PARTIUPAC
-	1657	1658	|I-PARTIUPAC
(	1658	1659	|I-PARTIUPAC
3	1659	1660	|B-MODIFIER
-	1660	1661	|I-MODIFIER
substituted	1661	1672	|I-MODIFIER
isoxazol	1673	1681	|B-IUPAC
-	1681	1682	|I-IUPAC
5	1682	1683	|I-IUPAC
-	1683	1684	|I-IUPAC
yl	1684	1686	|I-IUPAC
)	1686	1687	|I-IUPAC
tropanes	1687	1695	|I-IUPAC
are	1696	1699	|O
properties	1700	1710	|O
thought	1711	1718	|O
necessary	1719	1728	|O
for	1729	1732	|O
a	1733	1734	|O
pharmacotherapy	1735	1750	|O
for	1751	1754	|O
treating	1755	1763	|O
cocaine	1764	1771	|O
abuse	1772	1777	|O
.	1777	1778	|O

### abstracts2449.txt
Tomaymycin	0	10	|O
is	11	13	|O
a	14	15	|O
member	16	22	|O
of	23	25	|O
the	26	29	|O
pyrrolo	30	37	|B-IUPAC
[	37	38	|I-IUPAC
1,4	38	41	|I-IUPAC
]	41	42	|I-IUPAC
benzodiazepine	42	56	|I-IUPAC
antitumor	57	66	|O
-	66	67	|O
antibiotic	67	77	|O
group	78	83	|O
that	84	88	|O
binds	89	94	|O
covalently	95	105	|O
to	106	108	|O
the	109	112	|O
exocyclic	113	122	|B-MODIFIER
2	123	124	|B-IUPAC
-	124	125	|I-IUPAC
amino	125	130	|I-IUPAC
group	131	136	|B-MODIFIER
of	137	139	|O
guanine	140	147	|O
in	148	150	|O
DNA	151	154	|O
.	154	155	|O
Previous	156	164	|O
correlation	165	176	|O
of	177	179	|O
fluorescence	180	192	|O
and	193	196	|O
NMR	197	200	|O
data	201	205	|O
suggested	206	215	|O
that	216	220	|O
the	221	224	|O
11R	225	228	|O
,	228	229	|O
11aS	229	233	|O
and	234	237	|O
the	238	241	|O
11S	242	245	|O
,	245	246	|O
11aS	246	250	|O
diastereomers	251	264	|O
of	265	267	|O
tomaymycin	268	278	|O
could	279	284	|O
bind	285	289	|O
to	290	292	|O
DNA	293	296	|O
in	297	299	|O
two	300	303	|O
orientations	304	316	|O
relative	317	325	|O
to	326	328	|O
the	329	332	|O
covalently	333	343	|O
modified	344	352	|O
guanine	353	360	|O
(	361	362	|O
Barkley	362	369	|O
,	369	370	|O
M	371	372	|O
.	372	373	|O
D	374	375	|O
.	375	376	|O
;	376	377	|O
Cheatham	378	386	|O
,	386	387	|O
S	388	389	|O
.	389	390	|O
;	390	391	|O
Thurston	392	400	|O
,	400	401	|O
D	402	403	|O
.	403	404	|O
E	405	406	|O
.	406	407	|O
;	407	408	|O
Hurley	409	415	|O
,	415	416	|O
L	417	418	|O
.	418	419	|O
H	420	421	|O
.	421	422	|O
Biochemistry	423	435	|O
1986	436	440	|O
,	440	441	|O
25	442	444	|O
,	444	445	|O
3021-3031	446	455	|O
)	455	456	|O
.	456	457	|O
We	458	460	|O
now	461	464	|O
report	465	471	|O
on	472	474	|O
fluorescence	475	487	|O
,	487	488	|O
one	489	492	|O
-	492	493	|O
and	494	497	|O
two	498	501	|O
-	501	502	|O
dimensional	502	513	|O
proton	514	520	|O
NMR	521	524	|O
,	524	525	|O
and	526	529	|O
molecular	530	539	|O
modeling	540	548	|O
studies	549	556	|O
of	557	559	|O
the	560	563	|O
tomaymycin	564	574	|O
-	574	575	|O
d	575	576	|O
(	576	577	|O
ATGCAT	577	583	|O
)	583	584	|O
2	584	585	|O
adduct	586	592	|O
,	592	593	|O
which	594	599	|O
corroborate	600	611	|O
these	612	617	|O
earlier	618	625	|O
observations	626	638	|O
.	638	639	|O
Fluorescence	640	652	|O
measurements	653	665	|O
show	666	670	|O
that	671	675	|O
there	676	681	|O
are	682	685	|O
two	686	689	|O
species	690	697	|O
of	698	700	|O
tomaymycin	701	711	|O
bound	712	717	|O
to	718	720	|O
d	721	722	|O
(	722	723	|O
ATGCAT	723	729	|O
)	729	730	|O
2	730	731	|O
,	731	732	|O
which	733	738	|O
are	739	742	|O
tentatively	743	754	|O
identified	755	765	|O
as	766	768	|O
the	769	772	|O
11R	773	776	|O
,	776	777	|O
11aS	777	781	|O
and	782	785	|O
11S	786	789	|O
,	789	790	|O
11aS	790	794	|O
diastereomers	795	808	|O
.	808	809	|O
Two	810	813	|O
distinct	814	822	|O
sets	823	827	|O
of	828	830	|O
signals	831	838	|O
for	839	842	|O
the	843	846	|O
tomaymycin	847	857	|O
molecule	858	866	|O
are	867	870	|O
present	871	878	|O
in	879	881	|O
the	882	885	|O
proton	886	892	|O
NMR	893	896	|O
spectrum	897	905	|O
of	906	908	|O
the	909	912	|O
tomaymycin	913	923	|O
-	923	924	|O
d	924	925	|O
(	925	926	|O
ATGCAT	926	932	|O
)	932	933	|O
2	933	934	|O
duplex	935	941	|O
adduct	942	948	|O
.	948	949	|O
Two	950	953	|O
-	953	954	|O
dimensional	954	965	|O
correlation	966	977	|O
spectroscopy	978	990	|O
(	991	992	|O
2D	992	994	|O
-	994	995	|O
COSY	995	999	|O
)	999	1000	|O
studies	1001	1008	|O
also	1009	1013	|O
show	1014	1018	|O
connectivities	1019	1033	|O
for	1034	1037	|O
four	1038	1042	|O
cytosine	1043	1051	|O
H5	1052	1054	|O
-	1054	1055	|O
H6	1055	1057	|O
and	1058	1061	|O
eight	1062	1067	|O
thymine	1068	1075	|O
methyl	1076	1082	|O
-	1082	1083	|O
H6	1083	1085	|O
protons	1086	1093	|O
and	1094	1097	|O
thus	1098	1102	|O
clearly	1103	1110	|O
establish	1111	1120	|O
the	1121	1124	|O
presence	1125	1133	|O
of	1134	1136	|O
two	1137	1140	|O
distinct	1141	1149	|O
species	1150	1157	|O
of	1158	1160	|O
tomaymycin	1161	1171	|O
-	1171	1172	|O
d	1172	1173	|O
(	1173	1174	|O
ATGCAT	1174	1180	|O
)	1180	1181	|O
2	1181	1182	|O
adducts	1183	1190	|O
in	1191	1193	|O
solution	1194	1202	|O
.	1202	1203	|O
A	1204	1205	|O
single	1206	1212	|O
scalar	1213	1219	|O
11-11	1220	1225	|O
a	1225	1226	|O
1H	1227	1229	|O
NMR	1230	1233	|O
coupling	1234	1242	|O
in	1243	1245	|O
the	1246	1249	|O
2D	1250	1252	|O
-	1252	1253	|O
COSY	1253	1257	|O
spectrum	1258	1266	|O
is	1267	1269	|O
indicative	1270	1280	|O
of	1281	1283	|O
an	1284	1286	|O
adduct	1287	1293	|O
species	1294	1301	|O
that	1302	1306	|O
has	1307	1310	|O
an	1311	1313	|O
S	1314	1315	|O
configuration	1316	1329	|O
at	1330	1332	|O
the	1333	1336	|O
C	1337	1338	|O
-	1338	1339	|O
11	1339	1341	|O
position	1342	1350	|O
.	1350	1351	|O
Two	1352	1355	|O
-	1355	1356	|O
dimensional	1356	1367	|O
nuclear	1368	1375	|O
Overhauser	1376	1386	|O
effect	1387	1393	|O
(	1394	1395	|O
NOESY	1395	1400	|O
)	1400	1401	|O
spectra	1402	1409	|O
of	1410	1412	|O
the	1413	1416	|O
tomaymycin	1417	1427	|O
-	1427	1428	|O
d	1428	1429	|O
(	1429	1430	|O
ATGCAT	1430	1436	|O
)	1436	1437	|O
2	1437	1438	|O
duplex	1439	1445	|O
adduct	1446	1452	|O
show	1453	1457	|O
that	1458	1462	|O
the	1463	1466	|O
adducts	1467	1474	|O
are	1475	1478	|O
relatively	1479	1489	|O
nondistortive	1490	1503	|O
.	1503	1504	|O
In	1505	1507	|O
a	1508	1509	|O
NOESY	1510	1515	|O
experiment	1516	1526	|O
,	1526	1527	|O
cross	1528	1533	|O
-	1533	1534	|O
peaks	1534	1539	|O
were	1540	1544	|O
identified	1545	1555	|O
between	1556	1563	|O
both	1564	1568	|O
the	1569	1572	|O
aromatic	1573	1581	|O
H9	1582	1584	|O
proton	1585	1591	|O
and	1592	1595	|O
the	1596	1599	|O
ethylidine	1600	1610	|O
methyl	1611	1617	|O
protons	1618	1625	|O
of	1626	1628	|O
tomaymycin	1629	1639	|O
and	1640	1643	|O
two	1644	1647	|O
different	1648	1657	|O
adenine	1658	1665	|O
H2	1666	1668	|O
protons	1669	1676	|O
of	1677	1679	|O
d	1680	1681	|O
(	1681	1682	|O
ATGCAT	1682	1688	|O
)	1688	1689	|O
2	1689	1690	|O
.	1690	1691	|O
Molecular	1692	1701	|O
mechanics	1702	1711	|O
calculations	1712	1724	|O
with	1725	1729	|O
AMBER	1730	1735	|O
show	1736	1740	|O
that	1741	1745	|O
the	1746	1749	|O
two	1750	1753	|O
species	1754	1761	|O
with	1762	1766	|O
the	1767	1770	|O
thermodynamically	1771	1788	|O
most	1789	1793	|O
favorable	1794	1803	|O
binding	1804	1811	|O
energies	1812	1820	|O
are	1821	1824	|O
the	1825	1828	|O
11R	1829	1832	|O
,	1832	1833	|O
11aS	1833	1837	|O
and	1838	1841	|O
11S	1842	1845	|O
,	1845	1846	|O
11aS	1846	1850	|O
isomers	1851	1858	|O
with	1859	1863	|O
their	1864	1869	|O
aromatic	1870	1878	|O
rings	1879	1884	|O
to	1885	1887	|O
the	1888	1891	|O
5'	1892	1894	|O
and	1895	1898	|O
3'	1899	1901	|O
sides	1902	1907	|O
of	1908	1910	|O
the	1911	1914	|O
covalently	1915	1925	|O
bound	1926	1931	|O
guanine	1932	1939	|O
,	1939	1940	|O
respectively	1941	1953	|O
.	1953	1954	|O
The	1955	1958	|O
NOEs	1959	1963	|O
observed	1964	1972	|O
between	1973	1980	|O
tomaymycin	1981	1991	|O
protons	1992	1999	|O
and	2000	2003	|O
adenine	2004	2011	|O
H2	2012	2014	|O
protons	2015	2022	|O
are	2023	2026	|O
in	2027	2029	|O
accord	2030	2036	|O
with	2037	2041	|O
molecular	2042	2051	|O
modeling	2052	2060	|O
studies	2061	2068	|O
.	2068	2069	|O
Taken	2070	2075	|O
together	2076	2084	|O
,	2084	2085	|O
these	2086	2091	|O
results	2092	2099	|O
strongly	2100	2108	|O
suggest	2109	2116	|O
that	2117	2121	|O
the	2122	2125	|O
two	2126	2129	|O
forms	2130	2135	|O
of	2136	2138	|O
tomaymycin	2139	2149	|O
bound	2150	2155	|O
to	2156	2158	|O
d	2159	2160	|O
(	2160	2161	|O
ATGCAT	2161	2167	|O
)	2167	2168	|O
2	2168	2169	|O
are	2170	2173	|O
the	2174	2177	|O
11S	2178	2181	|O
,	2181	2182	|O
11aS	2182	2186	|O
and	2187	2190	|O
11R	2191	2194	|O
,	2194	2195	|O
11aS	2195	2199	|O
species	2200	2207	|O
,	2207	2208	|O
oriented	2209	2217	|O
with	2218	2222	|O
their	2223	2228	|O
aromatic	2229	2237	|O
rings	2238	2243	|O
to	2244	2246	|O
the	2247	2250	|O
3'	2251	2253	|O
and	2254	2257	|O
5'	2258	2260	|O
sides	2261	2266	|O
,	2266	2267	|O
respectively	2268	2280	|O
,	2280	2281	|O
of	2282	2284	|O
the	2285	2288	|O
covalently	2289	2299	|O
modified	2300	2308	|O
guanines	2309	2317	|O
.	2317	2318	|O

### abstracts729.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
28	12	14	|O
4	15	16	|B-MODIFIER
-	16	17	|I-MODIFIER
substituted	17	28	|I-MODIFIER
and	29	32	|O
4,5	33	36	|B-MODIFIER
-	36	37	|I-MODIFIER
disubstituted	37	50	|I-MODIFIER
2	51	52	|B-IUPAC
-	52	53	|I-IUPAC
pyridylimidazoles	53	70	|I-IUPAC
was	71	74	|O
synthesized	75	86	|O
and	87	90	|O
evaluated	91	100	|O
in	101	103	|O
vitro	104	109	|O
for	110	113	|O
inhibition	114	124	|O
of	125	127	|O
xanthine	128	136	|O
oxidase	137	144	|O
.	144	145	|O
Included	146	154	|O
within	155	161	|O
this	162	166	|O
group	167	172	|O
are	173	176	|O
examples	177	185	|O
of	186	188	|O
2	189	190	|B-IUPAC
-	190	191	|I-IUPAC
pyridylimidazopyridines	191	214	|I-IUPAC
and	215	218	|O
halo	219	223	|B-MODIFIER
-	223	224	|I-MODIFIER
substituted	224	235	|I-MODIFIER
2	236	237	|B-IUPAC
-	237	238	|I-IUPAC
pyridylbenzimidazoles	238	259	|I-IUPAC
.	259	260	|O
Five	261	265	|O
compounds	266	275	|O
exhibited	276	285	|O
inhibitory	286	296	|O
activity	297	305	|O
in	306	308	|O
the	309	312	|O
same	313	317	|O
range	318	323	|O
as	324	326	|O
the	327	330	|O
standards	331	340	|O
,	340	341	|O
4	342	343	|B-IUPAC
-	343	344	|I-IUPAC
hydroxypyrazolo	344	359	|I-IUPAC
[	359	360	|I-IUPAC
3,4	360	363	|I-IUPAC
-	363	364	|I-IUPAC
d	364	365	|I-IUPAC
]	365	366	|I-IUPAC
pyrimidine	366	376	|I-IUPAC
and	377	380	|O
2	381	382	|B-IUPAC
-	382	383	|I-IUPAC
(	383	384	|I-IUPAC
4	384	385	|I-IUPAC
-	385	386	|I-IUPAC
pyridyl	386	393	|I-IUPAC
)	393	394	|I-IUPAC
-	394	395	|I-IUPAC
4	395	396	|I-IUPAC
-	396	397	|I-IUPAC
trifluoromethylimidazole	397	421	|I-IUPAC
(	422	423	|O
22	423	425	|O
)	425	426	|O
.	426	427	|O
Two	428	431	|O
examples	432	440	|O
,	440	441	|O
2	442	443	|B-IUPAC
-	443	444	|I-IUPAC
(	444	445	|I-IUPAC
4	445	446	|I-IUPAC
-	446	447	|I-IUPAC
pyridyl	447	454	|I-IUPAC
)	454	455	|I-IUPAC
-	455	456	|I-IUPAC
4,5	456	459	|I-IUPAC
-	459	460	|I-IUPAC
dicyanoimidazole	460	476	|I-IUPAC
(	477	478	|O
16	478	480	|O
)	480	481	|O
and	482	485	|O
2	486	487	|B-IUPAC
-	487	488	|I-IUPAC
(	488	489	|I-IUPAC
4	489	490	|I-IUPAC
-	490	491	|I-IUPAC
pyridyl	491	498	|I-IUPAC
)	498	499	|I-IUPAC
-	499	500	|I-IUPAC
4	500	501	|I-IUPAC
-	501	502	|I-IUPAC
nitroimidazole	502	516	|I-IUPAC
(	517	518	|O
3	518	519	|O
)	519	520	|O
,	520	521	|O
were	522	526	|O
at	527	529	|O
least	530	535	|O
an	536	538	|O
order	539	544	|O
of	545	547	|O
magnitude	548	557	|O
more	558	562	|O
active	563	569	|O
than	570	574	|O
the	575	578	|O
standards	579	588	|O
and	589	592	|O
therefore	593	602	|O
rank	603	607	|O
among	608	613	|O
the	614	617	|O
most	618	622	|O
potent	623	629	|O
known	630	635	|O
inhibitors	636	646	|O
of	647	649	|O
the	650	653	|O
enzyme	654	660	|O
.	660	661	|O

### abstracts3112.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
N2	12	14	|B-PARTIUPAC
(	14	15	|O
and	15	18	|O
N4	19	21	|B-PARTIUPAC
)	21	22	|O
-	22	23	|B-PARTIUPAC
aryl	23	27	|B-PARTIUPAC
-	27	28	|B-PARTIUPAC
N4	28	30	|B-PARTIUPAC
(	30	31	|O
and	31	34	|O
N2	35	37	|B-PARTIUPAC
)	37	38	|O
-	38	39	|B-PARTIUPAC
[	39	40	|I-PARTIUPAC
(	40	41	|I-PARTIUPAC
dialkylamino	41	53	|I-PARTIUPAC
)	53	54	|I-PARTIUPAC
alkyl	54	59	|I-PARTIUPAC
]	59	60	|I-PARTIUPAC
-	60	61	|I-PARTIUPAC
2,4	61	64	|I-PARTIUPAC
-	64	65	|I-PARTIUPAC
quinazolinediamines	65	84	|I-PARTIUPAC
has	85	88	|O
been	89	93	|O
synthesized	94	105	|O
for	106	109	|O
antimalarial	110	122	|O
evaluation	123	133	|O
.	133	134	|O
Condensation	135	147	|O
of	148	150	|O
the	151	154	|O
appropriate	155	166	|O
2,4	167	170	|B-IUPAC
-	170	171	|I-IUPAC
dichloroquinazoline	171	190	|I-IUPAC
(	191	192	|O
IV	192	194	|O
)	194	195	|O
with	196	200	|O
the	201	204	|O
requisite	205	214	|O
N	215	216	|B-IUPAC
,	216	217	|I-IUPAC
N	217	218	|I-IUPAC
-	218	219	|I-IUPAC
dialkylalkylenediamine	219	241	|I-IUPAC
afforded	242	250	|O
a	251	252	|O
series	253	259	|O
of	260	262	|O
2	263	264	|B-IUPAC
-	264	265	|I-IUPAC
chloro	265	271	|I-IUPAC
-	271	272	|I-IUPAC
N	272	273	|I-IUPAC
-	273	274	|I-IUPAC
[	274	275	|I-IUPAC
(	275	276	|I-IUPAC
dialkylamino	276	288	|I-IUPAC
)	288	289	|I-IUPAC
alkyl	289	294	|I-IUPAC
]	294	295	|I-IUPAC
-	295	296	|I-IUPAC
4	296	297	|I-IUPAC
-	297	298	|I-IUPAC
quinazolinamines	298	314	|I-IUPAC
(	315	316	|O
V	316	317	|O
)	317	318	|O
which	319	324	|O
were	325	329	|O
condensed	330	339	|O
with	340	344	|O
the	345	348	|O
appropriate	349	360	|O
arylamine	361	370	|O
to	371	373	|O
provide	374	381	|O
the	382	385	|O
corresponding	386	399	|O
N2	400	402	|B-IUPAC
-	402	403	|I-IUPAC
aryl	403	407	|I-IUPAC
-	407	408	|I-IUPAC
N4	408	410	|I-IUPAC
-	410	411	|I-IUPAC
[	411	412	|I-IUPAC
(	412	413	|I-IUPAC
dialkylamino	413	425	|I-IUPAC
)	425	426	|I-IUPAC
alkyl	426	431	|I-IUPAC
]	431	432	|I-IUPAC
-	432	433	|I-IUPAC
2,4	433	436	|I-IUPAC
-	436	437	|I-IUPAC
quinazolinediamines	437	456	|I-IUPAC
(	457	458	|O
VI	458	460	|O
)	460	461	|O
.	461	462	|O
Hydrolysis	463	473	|O
of	474	476	|O
2,4	477	480	|B-IUPAC
-	480	481	|I-IUPAC
dichloroquinazoline	481	500	|I-IUPAC
to	501	503	|O
2	504	505	|B-IUPAC
-	505	506	|I-IUPAC
chloro	506	512	|I-IUPAC
-	512	513	|I-IUPAC
4	513	514	|I-IUPAC
-	514	515	|I-IUPAC
quinazolinol	515	527	|I-IUPAC
was	528	531	|O
followed	532	540	|O
by	541	543	|O
condensation	544	556	|O
with	557	561	|O
the	562	565	|O
appropriate	566	577	|O
N	578	579	|B-IUPAC
,	579	580	|I-IUPAC
N	580	581	|I-IUPAC
-	581	582	|I-IUPAC
dialkylalkylenediamine	582	604	|I-IUPAC
to	605	607	|O
give	608	612	|O
an	613	615	|O
array	616	621	|O
of	622	624	|O
2	625	626	|B-IUPAC
-	626	627	|I-IUPAC
[	627	628	|I-IUPAC
[	628	629	|I-IUPAC
(	629	630	|I-IUPAC
dialkylamino	630	642	|I-IUPAC
)	642	643	|I-IUPAC
alkyl	643	648	|I-IUPAC
]	648	649	|I-IUPAC
amino	649	654	|I-IUPAC
]	654	655	|I-IUPAC
-	655	656	|I-IUPAC
4	656	657	|I-IUPAC
-	657	658	|I-IUPAC
quinazolinols	658	671	|I-IUPAC
(	672	673	|O
IXa	673	676	|O
)	676	677	|O
.	677	678	|O
Chlorination	679	691	|O
with	692	696	|O
phosphorus	697	707	|O
oxychloride	708	719	|O
and	720	723	|O
condensation	724	736	|O
with	737	741	|O
a	742	743	|O
requisite	744	753	|O
arylamine	754	763	|O
provided	764	772	|O
the	773	776	|O
N2	777	779	|B-IUPAC
-	779	780	|I-IUPAC
[	780	781	|I-IUPAC
(	781	782	|I-IUPAC
dialkylamino	782	794	|I-IUPAC
)	794	795	|I-IUPAC
alkyl	795	800	|I-IUPAC
]	800	801	|I-IUPAC
-	801	802	|I-IUPAC
N4	802	804	|I-IUPAC
-	804	805	|I-IUPAC
phenyl	805	811	|I-IUPAC
-	811	812	|I-IUPAC
2,4	812	815	|I-IUPAC
-	815	816	|I-IUPAC
quinazolinediamines	816	835	|I-IUPAC
(	836	837	|O
X	837	838	|O
)	838	839	|O
.	839	840	|O
Antimalarial	841	853	|O
activity	854	862	|O
was	863	866	|O
general	867	874	|O
among	875	880	|O
the	881	884	|O
N2	885	887	|B-IUPAC
-	887	888	|I-IUPAC
aryl	888	892	|I-IUPAC
-	892	893	|I-IUPAC
N4	893	895	|I-IUPAC
-	895	896	|I-IUPAC
[	896	897	|I-IUPAC
(	897	898	|I-IUPAC
dialkylamino	898	910	|I-IUPAC
)	910	911	|I-IUPAC
alkyl	911	916	|I-IUPAC
]	916	917	|I-IUPAC
-	917	918	|I-IUPAC
2,4	918	921	|I-IUPAC
-	921	922	|I-IUPAC
quinazolinediamines	922	941	|I-IUPAC
(	942	943	|O
VI	943	945	|O
)	945	946	|O
,	946	947	|O
while	948	953	|O
the	954	957	|O
reverse	958	965	|O
isomers	966	973	|O
were	974	978	|O
of	979	981	|O
lower	982	987	|O
activity	988	996	|O
.	996	997	|O
Phototoxic	998	1008	|O
liability	1009	1018	|O
precluded	1019	1028	|O
clinical	1029	1037	|O
evaluation	1038	1048	|O
of	1049	1051	|O
a	1052	1053	|O
member	1054	1060	|O
of	1061	1063	|O
the	1064	1067	|O
series	1068	1074	|O
.	1074	1075	|O

### abstracts3440.txt
Careful	0	7	|O
analysis	8	16	|O
of	17	19	|O
the	20	23	|O
NMR	24	27	|O
structures	28	38	|O
of	39	41	|O
cyclo	42	47	|O
(	47	48	|O
4-10	48	52	|O
)	52	53	|O
[	53	54	|O
Ac	54	56	|O
-	56	57	|O
Delta	57	62	|O
(	62	63	|O
3	63	64	|O
)	64	65	|O
Pro	65	68	|O
(	68	69	|O
1	69	70	|O
)	70	71	|O
,	71	72	|O
DFpa	72	76	|O
(	76	77	|O
2	77	78	|O
)	78	79	|O
,	79	80	|O
DTrp	80	84	|O
(	84	85	|O
3	85	86	|O
)	86	87	|O
,	87	88	|O
Asp	88	91	|O
(	91	92	|O
4	92	93	|O
)	93	94	|O
,	94	95	|O
DNal	95	99	|O
(	100	101	|O
6	101	102	|O
)	102	103	|O
,	103	104	|O
Dpr	105	108	|O
(	108	109	|O
10	109	111	|O
)	111	112	|O
]	112	113	|O
GnRH	113	117	|O
,	117	118	|O
dicyclo	119	126	|O
(	126	127	|O
4-10/5-8	127	135	|O
)	135	136	|O
[	136	137	|O
Ac	137	139	|O
-	139	140	|O
DNal	140	144	|O
(	144	145	|O
1	145	146	|O
)	146	147	|O
,	147	148	|O
DCpa	148	152	|O
(	152	153	|O
2	153	154	|O
)	154	155	|O
,	155	156	|O
DTrp	156	160	|O
(	160	161	|O
3	161	162	|O
)	162	163	|O
,	163	164	|O
Asp	165	168	|O
(	168	169	|O
4	169	170	|O
)	170	171	|O
,	171	172	|O
Glu	173	176	|O
(	176	177	|O
5	177	178	|O
)	178	179	|O
,	179	180	|O
DArg	180	184	|O
(	184	185	|O
6	185	186	|O
)	186	187	|O
,	187	188	|O
Lys	188	191	|O
(	191	192	|O
8	192	193	|O
)	193	194	|O
,	194	195	|O
Dpr	195	198	|O
(	198	199	|O
10	199	201	|O
)	201	202	|O
]	202	203	|O
GnRH	203	207	|O
,	207	208	|O
and	209	212	|O
dicyclo	213	220	|O
(	220	221	|O
4-10/5	221	227	|O
,	227	228	|O
5'	229	231	|O
-	231	232	|O
8	232	233	|O
)	233	234	|O
[	234	235	|O
Ac	235	237	|O
-	237	238	|O
DNal	238	242	|O
(	242	243	|O
1	243	244	|O
)	244	245	|O
,	245	246	|O
DCpa	246	250	|O
(	250	251	|O
2	251	252	|O
)	252	253	|O
,	253	254	|O
DPal	254	258	|O
(	258	259	|O
3	259	260	|O
)	260	261	|O
,	261	262	|O
Asp	262	265	|O
(	265	266	|O
4	266	267	|O
)	267	268	|O
,	268	269	|O
Glu	270	273	|O
(	273	274	|O
5	274	275	|O
)	275	276	|O
(	276	277	|O
Gly	277	280	|O
)	280	281	|O
,	281	282	|O
DArg	282	286	|O
(	286	287	|O
6	287	288	|O
)	288	289	|O
,	289	290	|O
Dbu	290	293	|O
(	293	294	|O
8	294	295	|O
)	295	296	|O
,	296	297	|O
Dpr	298	301	|O
(	301	302	|O
10	302	304	|O
)	304	305	|O
]	305	306	|O
GnRH	306	310	|O
showed	311	317	|O
that	318	322	|O
,	322	323	|O
in	324	326	|O
the	327	330	|O
N	331	332	|O
-	332	333	|O
terminal	333	341	|O
tripeptide	342	352	|O
,	352	353	|O
a	354	355	|O
type	356	360	|O
II	361	363	|O
beta	364	368	|O
-	368	369	|O
turn	369	373	|O
around	374	380	|O
residues	381	389	|O
1	390	391	|O
and	392	395	|O
2	396	397	|O
was	398	401	|O
probable	402	410	|O
along	411	416	|O
with	417	421	|O
a	422	423	|O
gamma	424	429	|O
-	429	430	|O
turn	430	434	|O
around	435	441	|O
DTrp	442	446	|O
(	446	447	|O
3	447	448	|O
)	448	449	|O
/	449	450	|O
DPal	450	454	|O
(	454	455	|O
3	455	456	|O
)	456	457	|O
.	457	458	|O
This	459	463	|O
suggested	464	473	|O
the	474	477	|O
possibility	478	489	|O
of	490	492	|O
constraining	493	505	|O
the	506	509	|O
N	510	511	|O
-	511	512	|O
terminus	512	520	|O
by	521	523	|O
the	524	527	|O
introduction	528	540	|O
of	541	543	|O
a	544	545	|O
cyclo	546	551	|O
(	551	552	|O
1-3	552	555	|O
)	555	556	|O
scaffold	557	565	|O
.	565	566	|O
Optimization	567	579	|O
of	580	582	|O
ring	583	587	|O
size	588	592	|O
and	593	596	|O
composition	597	608	|O
led	609	612	|O
to	613	615	|O
the	616	619	|O
discovery	620	629	|O
of	630	632	|O
cyclo	633	638	|O
(	638	639	|O
1-3	639	642	|O
)	642	643	|O
[	643	644	|O
Ac	644	646	|O
-	646	647	|O
DAsp	647	651	|O
(	651	652	|O
1	652	653	|O
)	653	654	|O
,	654	655	|O
DCpa	655	659	|O
(	659	660	|O
2	660	661	|O
)	661	662	|O
,	662	663	|O
DLys	663	667	|O
(	667	668	|O
3	668	669	|O
)	669	670	|O
,	670	671	|O
DNal	671	675	|O
(	675	676	|O
6	676	677	|O
)	677	678	|O
,	678	679	|O
DAla	680	684	|O
(	684	685	|O
10	685	687	|O
)	687	688	|O
]	688	689	|O
GnRH	689	693	|O
(	694	695	|O
5	695	696	|O
,	696	697	|O
K	698	699	|O
(	699	700	|O
i	700	701	|O
)	701	702	|O
=	703	704	|O
0.82	705	709	|O
nM	710	712	|O
)	712	713	|O
,	713	714	|O
cyclo	715	720	|O
(	720	721	|O
1,1	721	724	|O
'	724	725	|O
-	725	726	|O
3	726	727	|O
)	727	728	|O
[	728	729	|O
Ac	729	731	|O
-	731	732	|O
DAsp	732	736	|O
(	736	737	|O
1	737	738	|O
)	738	739	|O
(	739	740	|O
Gly	740	743	|O
)	743	744	|O
,	744	745	|O
DCpa	746	750	|O
(	750	751	|O
2	751	752	|O
)	752	753	|O
,	753	754	|O
DOrn	754	758	|O
(	758	759	|O
3	759	760	|O
)	760	761	|O
,	761	762	|O
DNal	762	766	|O
(	766	767	|O
6	767	768	|O
)	768	769	|O
,	769	770	|O
DAla	770	774	|O
(	774	775	|O
10	775	777	|O
)	777	778	|O
]	778	779	|O
GnRH	779	783	|O
(	784	785	|O
13	785	787	|O
,	787	788	|O
K	789	790	|O
(	790	791	|O
i	791	792	|O
)	792	793	|O
=	794	795	|O
0.34	796	800	|O
nM	801	803	|O
)	803	804	|O
,	804	805	|O
cyclo	806	811	|O
(	811	812	|O
1	812	813	|O
,	813	814	|O
1'	815	817	|O
-	817	818	|O
3	818	819	|O
)	819	820	|O
[	820	821	|O
Ac	821	823	|O
-	823	824	|O
DAsp	824	828	|O
(	828	829	|O
1	829	830	|O
)	830	831	|O
(	831	832	|O
Gly	832	835	|O
)	835	836	|O
,	836	837	|O
DCpa	837	841	|O
(	841	842	|O
2	842	843	|O
)	843	844	|O
,	844	845	|O
DLys	845	849	|O
(	849	850	|O
3	850	851	|O
)	851	852	|O
,	852	853	|O
DNal	853	857	|O
(	857	858	|O
6	858	859	|O
)	859	860	|O
,	860	861	|O
DA	861	863	|O
la	864	866	|O
(	866	867	|O
10	867	869	|O
)	869	870	|O
]	870	871	|O
GnRH	871	875	|O
(	876	877	|O
20	877	879	|O
,	879	880	|O
K	881	882	|O
(	882	883	|O
i	883	884	|O
)	884	885	|O
=	886	887	|O
0.14	888	892	|O
nM	893	895	|O
)	895	896	|O
,	896	897	|O
and	898	901	|O
cyclo	902	907	|O
(	907	908	|O
1,1	908	911	|O
'	911	912	|O
-	912	913	|O
3	913	914	|O
)	914	915	|O
[	915	916	|O
Ac	916	918	|O
-	918	919	|O
DAsp	919	923	|O
(	923	924	|O
1	924	925	|O
)	925	926	|O
(	926	927	|O
betaAla	927	934	|O
)	934	935	|O
,	935	936	|O
DCpa	937	941	|O
(	941	942	|O
2	942	943	|O
)	943	944	|O
,	944	945	|O
DOrn	946	950	|O
(	950	951	|O
3	951	952	|O
)	952	953	|O
,	953	954	|O
DNal	954	958	|O
(	958	959	|O
6	959	960	|O
)	960	961	|O
,	961	962	|O
DAla	962	966	|O
(	966	967	|O
10	967	969	|O
)	969	970	|O
]	970	971	|O
GnRH	971	975	|O
(	976	977	|O
21	977	979	|O
,	979	980	|O
K	981	982	|O
(	982	983	|O
i	983	984	|O
)	984	985	|O
=	986	987	|O
0.17	988	992	|O
nM	993	995	|O
)	995	996	|O
,	996	997	|O
which	998	1003	|O
inhibited	1004	1013	|O
ovulation	1014	1023	|O
significantly	1024	1037	|O
at	1038	1040	|O
doses	1041	1046	|O
equal	1047	1052	|O
to	1053	1055	|O
or	1056	1058	|O
lower	1059	1064	|O
than	1065	1069	|O
25	1070	1072	|O
microgram	1073	1082	|O
/	1082	1083	|O
rat	1083	1086	|O
.	1086	1087	|O
These	1088	1093	|O
results	1094	1101	|O
were	1102	1106	|O
particularly	1107	1119	|O
unexpected	1120	1130	|O
in	1131	1133	|O
view	1134	1138	|O
of	1139	1141	|O
the	1142	1145	|O
critical	1146	1154	|O
role	1155	1159	|O
(	1159	1160	|O
s	1160	1161	|O
)	1161	1162	|O
originally	1163	1173	|O
ascribed	1174	1182	|O
to	1183	1185	|O
the	1186	1189	|O
side	1190	1194	|O
chains	1195	1201	|O
of	1202	1204	|O
residues	1205	1213	|O
1	1214	1215	|O
and	1216	1219	|O
3	1220	1221	|O
.	1221	1222	|O
(	1222	1223	|O
1	1223	1224	|O
)	1224	1225	|O
Other	1226	1231	|O
closely	1232	1239	|O
related	1240	1247	|O
analogues	1248	1257	|O
,	1257	1258	|O
such	1259	1263	|O
as	1264	1266	|O
those	1267	1272	|O
where	1273	1278	|O
the	1279	1282	|O
[	1283	1284	|O
DAsp	1284	1288	|O
(	1288	1289	|O
1	1289	1290	|O
)	1290	1291	|O
(	1291	1292	|O
betaAla	1292	1299	|O
)	1299	1300	|O
,	1300	1301	|O
DOrn	1302	1306	|O
(	1306	1307	|O
3	1307	1308	|O
)	1308	1309	|O
]	1309	1310	|O
cycle	1311	1316	|O
of	1317	1319	|O
21	1320	1322	|O
was	1323	1326	|O
changed	1327	1334	|O
to	1335	1337	|O
[	1338	1339	|O
DOrn	1339	1343	|O
(	1343	1344	|O
1	1344	1345	|O
)	1345	1346	|O
(	1346	1347	|O
betaAla	1347	1354	|O
)	1354	1355	|O
,	1355	1356	|O
DAsp	1357	1361	|O
(	1361	1362	|O
3	1362	1363	|O
)	1363	1364	|O
]	1364	1365	|O
of	1366	1368	|O
cyclo	1369	1374	|O
(	1374	1375	|O
1,1	1375	1378	|O
'	1378	1379	|O
-	1379	1380	|O
3	1380	1381	|O
)	1381	1382	|O
[	1382	1383	|O
Ac	1383	1385	|O
-	1385	1386	|O
DOrn	1386	1390	|O
(	1390	1391	|O
1	1391	1392	|O
)	1392	1393	|O
(	1393	1394	|O
betaAla	1394	1401	|O
)	1401	1402	|O
,	1402	1403	|O
DCpa	1404	1408	|O
(	1408	1409	|O
2	1409	1410	|O
)	1410	1411	|O
,	1411	1412	|O
DAsp	1412	1416	|O
(	1416	1417	|O
3	1417	1418	|O
)	1418	1419	|O
,	1419	1420	|O
DNal	1420	1424	|O
(	1424	1425	|O
6	1425	1426	|O
)	1426	1427	|O
,	1427	1428	|O
DAla	1428	1432	|O
(	1432	1433	|O
10	1433	1435	|O
)	1435	1436	|O
]	1436	1437	|O
GnRH	1437	1441	|O
(	1442	1443	|O
22	1443	1445	|O
,	1445	1446	|O
K	1447	1448	|O
(	1448	1449	|O
i	1449	1450	|O
)	1450	1451	|O
=	1452	1453	|O
2.2	1454	1457	|O
nM	1458	1460	|O
)	1460	1461	|O
or	1462	1464	|O
where	1465	1470	|O
the	1471	1474	|O
size	1475	1479	|O
of	1480	1482	|O
the	1483	1486	|O
cycle	1487	1492	|O
was	1493	1496	|O
conserved	1497	1506	|O
and	1507	1510	|O
[	1511	1512	|O
DAsp	1512	1516	|O
(	1516	1517	|O
1	1517	1518	|O
)	1518	1519	|O
(	1519	1520	|O
betaAla	1520	1527	|O
)	1527	1528	|O
,	1528	1529	|O
DOrn	1530	1534	|O
(	1534	1535	|O
3	1535	1536	|O
)	1536	1537	|O
]	1537	1538	|O
was	1539	1542	|O
replaced	1543	1551	|O
by	1552	1554	|O
[	1555	1556	|O
DGlu	1556	1560	|O
(	1560	1561	|O
1	1561	1562	|O
)	1562	1563	|O
(	1563	1564	|O
Gly	1564	1567	|O
)	1567	1568	|O
,	1568	1569	|O
DOrn	1570	1574	|O
(	1574	1575	|O
3	1575	1576	|O
)	1576	1577	|O
]	1577	1578	|O
as	1579	1581	|O
in	1582	1584	|O
cyclo	1585	1590	|O
(	1590	1591	|O
1	1591	1592	|O
,	1592	1593	|O
1'	1594	1596	|O
-	1596	1597	|O
3	1597	1598	|O
)	1598	1599	|O
[	1599	1600	|O
Ac	1600	1602	|O
-	1602	1603	|O
DGlu	1603	1607	|O
(	1607	1608	|O
1	1608	1609	|O
)	1609	1610	|O
(	1610	1611	|O
Gly	1611	1614	|O
)	1614	1615	|O
,	1615	1616	|O
DCpa	1616	1620	|O
(	1620	1621	|O
2	1621	1622	|O
)	1622	1623	|O
,	1623	1624	|O
DOrn	1624	1628	|O
(	1628	1629	|O
3	1629	1630	|O
)	1630	1631	|O
,	1631	1632	|O
DNal	1632	1636	|O
(	1636	1637	|O
6	1637	1638	|O
)	1638	1639	|O
,	1639	1640	|O
DA	1640	1642	|O
la	1643	1645	|O
(	1645	1646	|O
10	1646	1648	|O
)	1648	1649	|O
]	1649	1650	|O
GnRH	1650	1654	|O
(	1655	1656	|O
23	1656	1658	|O
,	1658	1659	|O
K	1660	1661	|O
(	1661	1662	|O
i	1662	1663	|O
)	1663	1664	|O
=	1665	1666	|O
4.2	1667	1670	|O
nM	1671	1673	|O
)	1673	1674	|O
,	1674	1675	|O
were	1676	1680	|O
approximately	1681	1694	|O
100	1695	1698	|O
and	1699	1702	|O
25	1703	1705	|O
times	1706	1711	|O
less	1712	1716	|O
potent	1717	1723	|O
in	1724	1726	|O
vivo	1727	1731	|O
,	1731	1732	|O
respectively	1733	1745	|O
.	1745	1746	|O
Analogues	1747	1756	|O
with	1757	1761	|O
ring	1762	1766	|O
sizes	1767	1772	|O
of	1773	1775	|O
18	1776	1778	|O
	1779	1780	|O
	1780	1781	|O
cyclo	1781	1786	|O
(	1786	1787	|O
1	1787	1788	|O
,	1788	1789	|O
1'	1790	1792	|O
-	1792	1793	|O
3	1793	1794	|O
)	1794	1795	|O
[	1795	1796	|O
Ac	1796	1798	|O
-	1798	1799	|O
DGlu	1799	1803	|O
(	1803	1804	|O
1	1804	1805	|O
)	1805	1806	|O
(	1806	1807	|O
Gly	1807	1810	|O
)	1810	1811	|O
,	1811	1812	|O
DCpa	1812	1816	|O
(	1816	1817	|O
2	1817	1818	|O
)	1818	1819	|O
,	1819	1820	|O
DLys	1820	1824	|O
(	1824	1825	|O
3	1825	1826	|O
)	1826	1827	|O
,	1827	1828	|O
DNal	1828	1832	|O
(	1832	1833	|O
6	1833	1834	|O
)	1834	1835	|O
,	1835	1836	|O
DA	1836	1838	|O
la	1839	1841	|O
(	1841	1842	|O
10	1842	1844	|O
)	1844	1845	|O
]	1845	1846	|O
GnRH	1846	1850	|O
(	1851	1852	|O
24	1852	1854	|O
)	1854	1855	|O
	1855	1856	|O
	1856	1857	|O
and	1858	1861	|O
19	1862	1864	|O
	1865	1866	|O
	1866	1867	|O
cyclo	1867	1872	|O
(	1872	1873	|O
1,1	1873	1876	|O
'	1876	1877	|O
-	1877	1878	|O
3	1878	1879	|O
)	1879	1880	|O
[	1880	1881	|O
Ac	1881	1883	|O
-	1883	1884	|O
DGlu	1884	1888	|O
(	1888	1889	|O
1	1889	1890	|O
)	1890	1891	|O
(	1891	1892	|O
betaAla	1892	1899	|O
)	1899	1900	|O
,	1900	1901	|O
DCpa	1901	1905	|O
(	1905	1906	|O
2	1906	1907	|O
)	1907	1908	|O
,	1908	1909	|O
DLys	1909	1913	|O
(	1913	1914	|O
3	1915	1916	|O
)	1916	1917	|O
,	1917	1918	|O
DNal	1918	1922	|O
(	1922	1923	|O
6	1923	1924	|O
)	1924	1925	|O
,	1925	1926	|O
DAla	1927	1931	|O
(	1931	1932	|O
10	1932	1934	|O
)	1934	1935	|O
]	1935	1936	|O
GnRH	1936	1940	|O
(	1941	1942	|O
25	1942	1944	|O
)	1944	1945	|O
	1945	1946	|O
	1946	1947	|O
atoms	1948	1953	|O
were	1954	1958	|O
also	1959	1963	|O
less	1964	1968	|O
potent	1969	1975	|O
than	1976	1980	|O
21	1981	1983	|O
with	1984	1988	|O
slightly	1989	1997	|O
higher	1998	2004	|O
K	2005	2006	|O
(	2006	2007	|O
i	2007	2008	|O
)	2008	2009	|O
values	2010	2016	|O
(	2017	2018	|O
1.5	2018	2021	|O
and	2022	2025	|O
2.2	2026	2029	|O
nM	2030	2032	|O
,	2032	2033	|O
respectively	2034	2046	|O
)	2046	2047	|O
.	2047	2048	|O
These	2049	2054	|O
results	2055	2062	|O
suggested	2063	2072	|O
that	2073	2077	|O
the	2078	2081	|O
N	2082	2083	|O
-	2083	2084	|O
terminal	2084	2092	|O
tripeptide	2093	2103	|O
was	2104	2107	|O
likely	2108	2114	|O
to	2115	2117	|O
assume	2118	2124	|O
a	2125	2126	|O
folded	2127	2133	|O
conformation	2134	2146	|O
favoring	2147	2155	|O
the	2156	2159	|O
close	2160	2165	|O
proximity	2166	2175	|O
of	2176	2178	|O
the	2179	2182	|O
side	2183	2187	|O
chains	2188	2194	|O
of	2195	2197	|O
residues	2198	2206	|O
1	2207	2208	|O
and	2209	2212	|O
3	2213	2214	|O
.	2214	2215	|O
The	2216	2219	|O
dicyclic	2220	2228	|O
analogue	2229	2237	|O
dicyclo	2238	2245	|O
(	2245	2246	|O
1-3/4-10	2246	2254	|O
)	2254	2255	|O
[	2255	2256	|O
Ac	2256	2258	|O
-	2258	2259	|O
DAsp	2259	2263	|O
(	2263	2264	|O
1	2264	2265	|O
)	2265	2266	|O
,	2266	2267	|O
DCpa	2267	2271	|O
(	2271	2272	|O
2	2272	2273	|O
)	2273	2274	|O
,	2274	2275	|O
DLys	2275	2279	|O
(	2279	2280	|O
3	2280	2281	|O
)	2281	2282	|O
,	2282	2283	|O
Asp	2283	2286	|O
(	2287	2288	|O
4	2288	2289	|O
)	2289	2290	|O
,	2290	2291	|O
DNal	2291	2295	|O
(	2295	2296	|O
6	2296	2297	|O
)	2297	2298	|O
,	2298	2299	|O
Dpr	2300	2303	|O
(	2303	2304	|O
10	2304	2306	|O
)	2306	2307	|O
]	2307	2308	|O
GnRH	2308	2312	|O
(	2313	2314	|O
26	2314	2316	|O
)	2316	2317	|O
was	2318	2321	|O
fully	2322	2327	|O
active	2328	2334	|O
at	2335	2337	|O
500	2338	2341	|O
microgram	2342	2351	|O
,	2351	2352	|O
with	2353	2357	|O
a	2358	2359	|O
K	2360	2361	|O
(	2361	2362	|O
i	2362	2363	|O
)	2363	2364	|O
value	2365	2370	|O
of	2371	2373	|O
1	2374	2375	|O
nM	2376	2378	|O
.	2378	2379	|O
The	2380	2383	|O
in	2384	2386	|O
vivo	2387	2391	|O
potency	2392	2399	|O
of	2400	2402	|O
26	2403	2405	|O
was	2406	2409	|O
at	2410	2412	|O
least	2413	2418	|O
10	2419	2421	|O
-	2421	2422	|O
fold	2422	2426	|O
less	2427	2431	|O
than	2432	2436	|O
that	2437	2441	|O
of	2442	2444	|O
monocyclic	2445	2455	|O
cyclo	2456	2461	|O
(	2461	2462	|O
1-3	2462	2465	|O
)	2465	2466	|O
[	2466	2467	|O
Ac	2467	2469	|O
-	2469	2470	|O
DAsp	2470	2474	|O
(	2474	2475	|O
1	2475	2476	|O
)	2476	2477	|O
,	2477	2478	|O
DCpa	2478	2482	|O
(	2482	2483	|O
2	2483	2484	|O
)	2484	2485	|O
,	2485	2486	|O
DLys	2486	2490	|O
(	2490	2491	|O
3	2491	2492	|O
)	2492	2493	|O
,	2493	2494	|O
DNal	2494	2498	|O
(	2498	2499	|O
6	2499	2500	|O
)	2500	2501	|O
,	2501	2502	|O
DAla	2503	2507	|O
(	2507	2508	|O
10	2508	2510	|O
)	2510	2511	|O
]	2511	2512	|O
GnRH	2512	2516	|O
(	2517	2518	|O
5	2518	2519	|O
)	2519	2520	|O
;	2520	2521	|O
this	2522	2526	|O
suggested	2527	2536	|O
the	2537	2540	|O
existence	2541	2550	|O
of	2551	2553	|O
unfavorable	2554	2565	|O
interactions	2566	2578	|O
between	2579	2586	|O
the	2587	2590	|O
now	2591	2594	|O
optimized	2595	2604	|O
and	2605	2608	|O
constrained	2609	2620	|O
(	2621	2622	|O
1-3	2622	2625	|O
)	2625	2626	|O
and	2627	2630	|O
(	2631	2632	|O
4-10	2632	2636	|O
)	2636	2637	|O
cyclic	2638	2644	|O
moieties	2645	2653	|O
that	2654	2658	|O
must	2659	2663	|O
interact	2664	2672	|O
as	2673	2675	|O
originally	2676	2686	|O
hypothesized	2687	2699	|O
.	2699	2700	|O
Tricyclo	2701	2709	|O
(	2709	2710	|O
1-3/4-10/5-8	2710	2722	|O
)	2722	2723	|O
[	2723	2724	|O
Ac	2724	2726	|O
-	2726	2727	|O
DGlu	2727	2731	|O
(	2731	2732	|O
1	2732	2733	|O
)	2733	2734	|O
,	2734	2735	|O
DCpa	2735	2739	|O
(	2739	2740	|O
2	2740	2741	|O
)	2741	2742	|O
,	2742	2743	|O
DLys	2744	2748	|O
(	2748	2749	|O
3	2749	2750	|O
)	2750	2751	|O
,	2751	2752	|O
Asp	2752	2755	|O
(	2755	2756	|O
4	2756	2757	|O
)	2757	2758	|O
,	2758	2759	|O
Glu	2759	2762	|O
(	2762	2763	|O
5	2763	2764	|O
)	2764	2765	|O
,	2765	2766	|O
DNal	2767	2771	|O
(	2771	2772	|O
6	2772	2773	|O
)	2773	2774	|O
,	2774	2775	|O
Lys	2775	2778	|O
(	2778	2779	|O
8	2779	2780	|O
)	2780	2781	|O
,	2781	2782	|O
Dpr	2782	2785	|O
(	2785	2786	|O
10	2786	2788	|O
)	2788	2789	|O
]	2789	2790	|O
GnRH	2791	2795	|O
(	2796	2797	|O
27	2797	2799	|O
)	2799	2800	|O
was	2801	2804	|O
inactive	2805	2813	|O
at	2814	2816	|O
500	2817	2820	|O
microgram	2821	2830	|O
/	2830	2831	|O
rat	2831	2834	|O
with	2835	2839	|O
a	2840	2841	|O
corresponding	2842	2855	|O
low	2856	2859	|O
affinity	2860	2868	|O
(	2869	2870	|O
K	2870	2871	|O
(	2871	2872	|O
i	2872	2873	|O
)	2873	2874	|O
=	2875	2876	|O
4.6	2877	2880	|O
nM	2881	2883	|O
)	2883	2884	|O
when	2885	2889	|O
compared	2890	2898	|O
to	2899	2901	|O
those	2902	2907	|O
of	2908	2910	|O
the	2911	2914	|O
most	2915	2919	|O
potent	2920	2926	|O
analogues	2927	2936	|O
(	2937	2938	|O
K	2938	2939	|O
(	2939	2940	|O
i	2940	2941	|O
)	2941	2942	|O
&	2943	2944	|O
lt	2944	2946	|O
;	2946	2947	|O
0.5	2948	2951	|O
nM	2952	2954	|O
)	2954	2955	|O
.	2955	2956	|O

### abstracts3448.txt
Molecular	0	9	|O
interactions	10	22	|O
between	23	30	|O
RGD	31	34	|O
peptides	35	43	|O
and	44	47	|O
integrins	48	57	|O
are	58	61	|O
known	62	67	|O
to	68	70	|O
mediate	71	78	|O
many	79	83	|O
biological	84	94	|O
and	95	98	|O
pathological	99	111	|O
processes	112	121	|O
.	121	122	|O
This	123	127	|O
has	128	131	|O
led	132	135	|O
to	136	138	|O
an	139	141	|O
increased	142	151	|O
interest	152	160	|O
in	161	163	|O
the	164	167	|O
development	168	179	|O
of	180	182	|O
RGD	183	186	|O
compounds	187	196	|O
with	197	201	|O
high	202	206	|O
affinity	207	215	|O
and	216	219	|O
improved	220	228	|O
selectivity	229	240	|O
for	241	244	|O
integrin	245	253	|O
receptors	254	263	|O
.	263	264	|O
In	265	267	|O
this	268	272	|O
study	273	278	|O
,	278	279	|O
we	280	282	|O
synthesized	283	294	|O
and	295	298	|O
evaluated	299	308	|O
a	309	310	|O
series	311	317	|O
of	318	320	|O
multimeric	321	331	|O
RGD	332	335	|O
compounds	336	345	|O
constructed	346	357	|O
on	358	360	|O
a	361	362	|O
dicarboxylic	363	375	|O
acid	376	380	|O
-	380	381	|O
containing	381	391	|O
near	392	396	|O
-	396	397	|O
infrared	397	405	|O
(	406	407	|O
NIR	407	410	|O
)	410	411	|O
fluorescent	412	423	|O
dye	424	427	|O
(	428	429	|O
cypate	429	435	|O
)	435	436	|O
for	437	440	|O
tumor	441	446	|O
targeting	447	456	|O
.	456	457	|O
An	458	460	|O
array	461	466	|O
of	467	469	|O
NIR	470	473	|O
fluorescent	474	485	|O
RGD	486	489	|O
compounds	490	499	|O
was	500	503	|O
prepared	504	512	|O
efficiently	513	524	|O
,	524	525	|O
including	526	535	|O
one	536	539	|O
RGD	540	543	|O
monomer	544	551	|O
(	552	553	|O
cypate	553	559	|O
-	559	560	|O
(	560	561	|O
RGD	561	564	|O
)	564	565	|O
(	565	566	|O
2	566	567	|O
)	567	568	|O
-	568	569	|O
NH	569	571	|O
(	571	572	|O
2	572	573	|O
)	573	574	|O
)	574	575	|O
,	575	576	|O
two	577	580	|O
RGD	581	584	|O
dimers	585	591	|O
(	592	593	|O
cypate	593	599	|O
-	599	600	|O
(	600	601	|O
RGD	601	604	|O
)	604	605	|O
(	605	606	|O
2	606	607	|O
)	607	608	|O
-	608	609	|O
NH	609	611	|O
(	611	612	|O
2	612	613	|O
)	613	614	|O
and	615	618	|O
cypate	619	625	|O
-	625	626	|O
(	626	627	|O
RGD	627	630	|O
-	630	631	|O
NH	631	633	|O
(	633	634	|O
2	634	635	|O
)	635	636	|O
)	636	637	|O
(	637	638	|O
2	638	639	|O
)	639	640	|O
)	640	641	|O
,	641	642	|O
one	643	646	|O
trimer	647	653	|O
(	654	655	|O
cypate	655	661	|O
-	661	662	|O
(	662	663	|O
RGD	663	666	|O
)	666	667	|O
(	667	668	|O
3	668	669	|O
)	669	670	|O
-	670	671	|O
NH	671	673	|O
(	673	674	|O
2	674	675	|O
)	675	676	|O
)	676	677	|O
,	677	678	|O
two	679	682	|O
tetramers	683	692	|O
(	693	694	|O
cypate	694	700	|O
-	700	701	|O
(	701	702	|O
RGD	702	705	|O
)	705	706	|O
(	706	707	|O
4	707	708	|O
)	708	709	|O
-	709	710	|O
NH	710	712	|O
(	712	713	|O
2	713	714	|O
)	714	715	|O
and	716	719	|O
cypate	720	726	|O
-	726	727	|O
[	727	728	|O
(	728	729	|O
RGD	729	732	|O
)	732	733	|O
(	733	734	|O
2	734	735	|O
)	735	736	|O
-	736	737	|O
NH	737	739	|O
(	739	740	|O
2	740	741	|O
)	741	742	|O
]	742	743	|O
(	743	744	|O
2	744	745	|O
)	745	746	|O
)	746	747	|O
,	747	748	|O
one	749	752	|O
hexamer	753	760	|O
(	761	762	|O
cypate	762	768	|O
-	768	769	|O
[	769	770	|O
(	770	771	|O
RGD	771	774	|O
)	774	775	|O
(	775	776	|O
3	776	777	|O
)	777	778	|O
-	778	779	|O
NH	779	781	|O
(	781	782	|O
2	782	783	|O
)	783	784	|O
]	784	785	|O
(	785	786	|O
2	786	787	|O
)	787	788	|O
)	788	789	|O
,	789	790	|O
and	791	794	|O
one	795	798	|O
octamer	799	806	|O
(	807	808	|O
cypate	808	814	|O
-	814	815	|O
[	815	816	|O
(	816	817	|O
RGD	817	820	|O
)	820	821	|O
(	821	822	|O
4	822	823	|O
)	823	824	|O
-	824	825	|O
NH	825	827	|O
(	827	828	|O
2	828	829	|O
)	829	830	|O
]	830	831	|O
(	831	832	|O
2	832	833	|O
)	833	834	|O
)	834	835	|O
.	835	836	|O
The	837	840	|O
binding	841	848	|O
affinity	849	857	|O
of	858	860	|O
the	861	864	|O
multimeric	865	875	|O
RGD	876	879	|O
compounds	880	889	|O
for	890	893	|O
alpha	894	899	|O
(	899	900	|O
v	900	901	|O
)	901	902	|O
beta	902	906	|O
(	906	907	|O
3	907	908	|O
)	908	909	|O
integrin	910	918	|O
receptor	919	927	|O
(	928	929	|O
ABIR	929	933	|O
)	933	934	|O
showed	935	941	|O
a	942	943	|O
remarkable	944	954	|O
increase	955	963	|O
relative	964	972	|O
to	973	975	|O
the	976	979	|O
monomer	980	987	|O
cypate	988	994	|O
-	994	995	|O
RGD	995	998	|O
-	998	999	|O
NH	999	1001	|O
(	1001	1002	|O
2	1002	1003	|O
)	1003	1004	|O
.	1004	1005	|O
Generally	1006	1015	|O
,	1015	1016	|O
the	1017	1020	|O
divalent	1021	1029	|O
linear	1030	1036	|O
arrays	1037	1043	|O
of	1044	1046	|O
the	1047	1050	|O
multimeric	1051	1061	|O
RGD	1062	1065	|O
units	1066	1071	|O
bound	1072	1077	|O
the	1078	1081	|O
ABIR	1082	1086	|O
with	1087	1091	|O
slightly	1092	1100	|O
higher	1101	1107	|O
affinity	1108	1116	|O
than	1117	1121	|O
their	1122	1127	|O
monovalent	1128	1138	|O
analogues	1139	1148	|O
.	1148	1149	|O
These	1150	1155	|O
results	1156	1163	|O
suggest	1164	1171	|O
that	1172	1176	|O
the	1177	1180	|O
receptor	1181	1189	|O
binding	1190	1197	|O
affinity	1198	1206	|O
was	1207	1210	|O
not	1211	1214	|O
only	1215	1219	|O
dependent	1220	1229	|O
on	1230	1232	|O
the	1233	1236	|O
number	1237	1243	|O
of	1244	1246	|O
RGD	1247	1250	|O
moieties	1251	1259	|O
but	1260	1263	|O
also	1264	1268	|O
on	1269	1271	|O
the	1272	1275	|O
spatial	1276	1283	|O
alignments	1284	1294	|O
of	1295	1297	|O
the	1298	1301	|O
pendant	1302	1309	|O
peptides	1310	1318	|O
.	1318	1319	|O
Internalization	1320	1335	|O
of	1336	1338	|O
the	1339	1342	|O
compounds	1343	1352	|O
by	1353	1355	|O
ABIR	1356	1360	|O
-	1360	1361	|O
positive	1361	1369	|O
tumor	1370	1375	|O
cells	1376	1381	|O
(	1382	1383	|O
A549	1383	1387	|O
)	1387	1388	|O
was	1389	1392	|O
monitored	1393	1402	|O
by	1403	1405	|O
NIR	1406	1409	|O
fluorescence	1410	1422	|O
microscopy	1423	1433	|O
.	1433	1434	|O
The	1435	1438	|O
data	1439	1443	|O
showed	1444	1450	|O
that	1451	1455	|O
endocytosis	1456	1467	|O
of	1468	1470	|O
the	1471	1474	|O
octameric	1475	1484	|O
RGD	1485	1488	|O
derivative	1489	1499	|O
was	1500	1503	|O
significantly	1504	1517	|O
higher	1518	1524	|O
by	1525	1527	|O
comparison	1528	1538	|O
to	1539	1541	|O
other	1542	1547	|O
compounds	1548	1557	|O
in	1558	1560	|O
this	1561	1565	|O
study	1566	1571	|O
.	1571	1572	|O
In	1573	1575	|O
vivo	1576	1580	|O
noninvasive	1581	1592	|O
optical	1593	1600	|O
imaging	1601	1608	|O
and	1609	1612	|O
biodistribution	1613	1628	|O
data	1629	1633	|O
showed	1634	1640	|O
that	1641	1645	|O
the	1646	1649	|O
compounds	1650	1659	|O
were	1660	1664	|O
retained	1665	1673	|O
in	1674	1676	|O
A549	1677	1681	|O
tumor	1682	1687	|O
tissue	1688	1694	|O
.	1694	1695	|O
These	1696	1701	|O
results	1702	1709	|O
clearly	1710	1717	|O
demonstrated	1718	1730	|O
that	1731	1735	|O
an	1736	1738	|O
array	1739	1744	|O
of	1745	1747	|O
simple	1748	1754	|O
RGD	1755	1758	|O
tripeptides	1759	1770	|O
on	1771	1773	|O
a	1774	1775	|O
NIR	1776	1779	|O
fluorescent	1780	1791	|O
dye	1792	1795	|O
core	1796	1800	|O
can	1801	1804	|O
be	1805	1807	|O
recognized	1808	1818	|O
by	1819	1821	|O
ABIR	1822	1826	|O
.	1826	1827	|O
Optimization	1828	1840	|O
of	1841	1843	|O
the	1844	1847	|O
spatial	1848	1855	|O
alignment	1856	1865	|O
of	1866	1868	|O
the	1869	1872	|O
RGD	1873	1876	|O
moieties	1877	1885	|O
through	1886	1893	|O
careful	1894	1901	|O
molecular	1902	1911	|O
design	1912	1918	|O
and	1919	1922	|O
library	1923	1930	|O
construction	1931	1943	|O
could	1944	1949	|O
induce	1950	1956	|O
multivalent	1957	1968	|O
ligand	1969	1975	|O
-	1975	1976	|O
receptor	1976	1984	|O
interactions	1985	1997	|O
useful	1998	2004	|O
for	2005	2008	|O
in	2009	2011	|O
vivo	2012	2016	|O
tumor	2017	2022	|O
imaging	2023	2030	|O
and	2031	2034	|O
tumor	2035	2040	|O
-	2040	2041	|O
targeted	2041	2049	|O
therapy	2050	2057	|O
.	2057	2058	|O

### abstracts4408.txt
Syntheses	0	9	|O
of	10	12	|O
(	13	14	|B-IUPAC
R	14	15	|I-IUPAC
)	15	16	|I-IUPAC
-	16	17	|I-IUPAC
(	17	18	|I-IUPAC
-	18	19	|I-IUPAC
)	19	20	|I-IUPAC
-	20	21	|I-IUPAC
2	21	22	|I-IUPAC
-	22	23	|I-IUPAC
methoxyapomorphine	23	41	|I-IUPAC
(	42	43	|O
R	43	44	|O
-	44	45	|O
8	45	46	|O
)	46	47	|O
,	47	48	|O
its	49	52	|O
antipode	53	61	|O
S	62	63	|O
-	63	64	|O
8	64	65	|O
,	65	66	|O
and	67	70	|O
its	71	74	|O
(	75	76	|B-PARTIUPAC
R	76	77	|I-PARTIUPAC
)	77	78	|I-PARTIUPAC
-	78	79	|I-PARTIUPAC
(	79	80	|I-PARTIUPAC
-	80	81	|I-PARTIUPAC
)	81	82	|I-PARTIUPAC
-	82	83	|I-PARTIUPAC
N	83	84	|I-PARTIUPAC
-	84	85	|I-PARTIUPAC
n	85	86	|I-PARTIUPAC
-	86	87	|I-PARTIUPAC
propyl	87	93	|I-PARTIUPAC
R	94	95	|O
-	95	96	|O
9	96	97	|O
derivatives	98	109	|B-MODIFIER
are	110	113	|O
described	114	123	|O
.	123	124	|O
The	125	128	|O
dopaminergic	129	141	|O
receptor	142	150	|O
affinities	151	161	|O
of	162	164	|O
these	165	170	|O
compounds	171	180	|O
and	181	184	|O
their	185	190	|O
2	191	192	|B-MODIFIER
-	192	193	|I-MODIFIER
unsubstituted	193	206	|I-MODIFIER
counterparts	207	219	|I-MODIFIER
(	220	221	|B-IUPAC
R	221	222	|I-IUPAC
)	222	223	|I-IUPAC
-	223	224	|I-IUPAC
(	224	225	|I-IUPAC
-	225	226	|I-IUPAC
)	226	227	|I-IUPAC
-	227	228	|I-IUPAC
apomorphine	228	239	|I-IUPAC
(	240	241	|O
R	241	242	|O
(	242	243	|O
-	243	244	|O
)	244	245	|O
-	245	246	|O
APO	246	249	|O
,	249	250	|O
R	251	252	|O
-	252	253	|O
1	253	254	|O
)	254	255	|O
,	255	256	|O
(	257	258	|B-IUPAC
S	258	259	|I-IUPAC
)	259	260	|I-IUPAC
-	260	261	|I-IUPAC
(	261	262	|I-IUPAC
+	262	263	|I-IUPAC
)	263	264	|I-IUPAC
-	264	265	|I-IUPAC
apomorphine	265	276	|I-IUPAC
(	277	278	|O
S	278	279	|O
(	279	280	|O
+	280	281	|O
)	281	282	|O
-	282	283	|O
APO	283	286	|O
,	286	287	|O
S	288	289	|O
-	289	290	|O
1	290	291	|O
)	291	292	|O
,	292	293	|O
and	294	297	|O
(	298	299	|B-IUPAC
R	299	300	|I-IUPAC
)	300	301	|I-IUPAC
-	301	302	|I-IUPAC
(	302	303	|I-IUPAC
-	303	304	|I-IUPAC
)	304	305	|I-IUPAC
-	305	306	|I-IUPAC
N	306	307	|I-IUPAC
-	307	308	|I-IUPAC
n	308	309	|I-IUPAC
-	309	310	|I-IUPAC
propylnorapomorphine	310	330	|I-IUPAC
(	331	332	|O
R	332	333	|O
(	333	334	|O
-	334	335	|O
)	335	336	|O
-	336	337	|O
NPA	337	340	|O
,	340	341	|O
R	342	343	|O
-	343	344	|O
2	344	345	|O
)	345	346	|O
,	346	347	|O
as	348	350	|O
well	351	355	|O
as	356	358	|O
those	359	364	|O
of	365	367	|O
(	368	369	|B-IUPAC
R	369	370	|I-IUPAC
)	370	371	|I-IUPAC
-	371	372	|I-IUPAC
(	372	373	|I-IUPAC
-	373	374	|I-IUPAC
)	374	375	|I-IUPAC
-	375	376	|I-IUPAC
2	376	377	|I-IUPAC
-	377	378	|I-IUPAC
chloroapomorphine	378	395	|I-IUPAC
(	396	397	|O
R	397	398	|O
(	398	399	|O
-	399	400	|O
)	400	401	|O
-	401	402	|O
2	402	403	|O
-	403	404	|O
Cl	404	406	|O
-	406	407	|O
APO	407	410	|O
,	410	411	|O
R	412	413	|O
-	413	414	|O
6	414	415	|O
)	415	416	|O
,	416	417	|O
(	418	419	|B-IUPAC
R	419	420	|I-IUPAC
)	420	421	|I-IUPAC
-	421	422	|I-IUPAC
(	422	423	|I-IUPAC
-	423	424	|I-IUPAC
)	424	425	|I-IUPAC
-	425	426	|I-IUPAC
2	426	427	|I-IUPAC
-	427	428	|I-IUPAC
bromoapomorphine	428	444	|I-IUPAC
(	445	446	|O
R	446	447	|O
(	447	448	|O
-	448	449	|O
)	449	450	|O
-	450	451	|O
2	451	452	|O
-	452	453	|O
Br	453	455	|O
-	455	456	|O
APO	456	459	|O
,	459	460	|O
R	461	462	|O
-	462	463	|O
6	463	464	|O
)	464	465	|O
,	465	466	|O
were	467	471	|O
determined	472	482	|O
with	483	487	|O
tissue	488	494	|O
membrane	495	503	|O
preparations	504	516	|O
of	517	519	|O
corpus	520	526	|O
striatum	527	535	|O
from	536	540	|O
rat	541	544	|O
brain	545	550	|O
.	550	551	|O
Contribution	552	564	|O
of	565	567	|O
both	568	572	|O
an	573	575	|O
N	576	577	|B-PARTIUPAC
-	577	578	|I-PARTIUPAC
n	578	579	|I-PARTIUPAC
-	579	580	|I-PARTIUPAC
propyl	580	586	|I-PARTIUPAC
and	587	590	|O
a	591	592	|O
2	593	594	|B-PARTIUPAC
-	594	595	|I-PARTIUPAC
hydroxy	595	602	|I-PARTIUPAC
in	603	605	|O
(	606	607	|B-IUPAC
R	607	608	|I-IUPAC
)	608	609	|I-IUPAC
-	609	610	|I-IUPAC
(	610	611	|I-IUPAC
-	611	612	|I-IUPAC
)	612	613	|I-IUPAC
-	613	614	|I-IUPAC
2	614	615	|I-IUPAC
-	615	616	|I-IUPAC
hydroxy	616	623	|I-IUPAC
-	623	624	|I-IUPAC
N	624	625	|I-IUPAC
-	625	626	|I-IUPAC
n	626	627	|I-IUPAC
-	627	628	|I-IUPAC
propylnorapomorphine	628	648	|I-IUPAC
(	649	650	|O
R	650	651	|O
(	651	652	|O
-	652	653	|O
)	653	654	|O
-	654	655	|O
2	655	656	|O
-	656	657	|O
OH	657	659	|O
-	659	660	|O
NPA	660	663	|O
,	663	664	|O
R	665	666	|O
-	666	667	|O
7	667	668	|O
)	668	669	|O
or	670	672	|O
a	673	674	|O
methoxy	675	682	|O
group	683	688	|O
in	689	691	|O
(	692	693	|B-IUPAC
R	693	694	|I-IUPAC
)	694	695	|I-IUPAC
-	695	696	|I-IUPAC
(	696	697	|I-IUPAC
-	697	698	|I-IUPAC
)	698	699	|I-IUPAC
-	699	700	|I-IUPAC
2	700	701	|I-IUPAC
-	701	702	|I-IUPAC
methoxy	702	709	|I-IUPAC
-	709	710	|I-IUPAC
N	710	711	|I-IUPAC
-	711	712	|I-IUPAC
n	712	713	|I-IUPAC
-	713	714	|I-IUPAC
propylnorapomorphine	714	734	|I-IUPAC
(	735	736	|O
R	736	737	|O
(	737	738	|O
-	738	739	|O
)	739	740	|O
-	740	741	|O
2	741	742	|O
-	742	743	|O
OCH3	743	747	|O
-	747	748	|O
NPA	748	751	|O
,	751	752	|O
R	753	754	|O
-	754	755	|O
9	755	756	|O
)	756	757	|O
produced	758	766	|O
the	767	770	|O
highest	771	778	|O
D2	779	781	|O
affinity	782	790	|O
(	791	792	|O
0.053	792	797	|O
and	798	801	|O
0.17	802	806	|O
nM	807	809	|O
)	809	810	|O
and	811	814	|O
D2	815	817	|O
over	818	822	|O
D1	823	825	|O
selectivity	826	837	|O
(	838	839	|O
17,300	839	845	|O
and	846	849	|O
10,500	850	856	|O
times	857	862	|O
)	862	863	|O
of	864	866	|O
the	867	870	|O
compounds	871	880	|O
evaluated	881	890	|O
.	890	891	|O
The	892	895	|O
structure	896	905	|O
-	905	906	|O
affinity	906	914	|O
relationships	915	928	|O
of	929	931	|O
these	932	937	|O
2	938	939	|O
-	939	940	|O
substituted	940	951	|O
aporphines	952	962	|O
suggest	963	970	|O
that	971	975	|O
secondary	976	985	|O
binding	986	993	|O
sites	994	999	|O
of	1000	1002	|O
D2	1003	1005	|O
receptors	1006	1015	|O
interact	1016	1024	|O
with	1025	1029	|O
2	1030	1031	|O
-	1031	1032	|O
substituents	1032	1044	|O
on	1045	1047	|O
the	1048	1051	|O
A	1052	1053	|O
ring	1054	1058	|O
of	1059	1061	|O
aporphines	1062	1072	|O
through	1073	1080	|O
H	1081	1082	|O
-	1082	1083	|O
bonding	1083	1090	|O
.	1090	1091	|O

### abstracts1993.txt
On	0	2	|O
the	3	6	|O
basis	7	12	|O
of	13	15	|O
our	16	19	|O
previous	20	28	|O
observation	29	40	|O
that	41	45	|O
N1	46	48	|B-IUPAC
-	48	49	|I-IUPAC
alkyl	49	54	|I-IUPAC
substituted	55	66	|B-MODIFIER
chlorpropamide	67	81	|B-IUPAC
derivatives	82	93	|B-MODIFIER
when	94	98	|O
administered	99	111	|O
to	112	114	|O
rats	115	119	|O
nonenzymatically	120	136	|O
eliminated	137	147	|O
n	148	149	|B-IUPAC
-	149	150	|I-IUPAC
propyl	150	156	|I-IUPAC
isocyanate	157	167	|I-IUPAC
,	167	168	|O
a	169	170	|O
known	171	176	|O
inhibitor	177	186	|O
of	187	189	|O
aldehyde	190	198	|O
dehydrogenase	199	212	|O
(	213	214	|O
AlDH	214	218	|O
)	218	219	|O
,	219	220	|O
we	221	223	|O
have	224	228	|O
synthesized	229	240	|O
other	241	246	|O
latentiated	247	258	|O
n	259	260	|B-IUPAC
-	260	261	|I-IUPAC
propyl	261	267	|I-IUPAC
isocyanates	268	279	|I-IUPAC
as	280	282	|O
in	283	285	|O
vivo	286	290	|O
inhibitors	291	301	|O
of	302	304	|O
AlDH	305	309	|O
.	309	310	|O
N1	311	313	|B-IUPAC
-	313	314	|I-IUPAC
Allylchlorpropamide	314	333	|I-IUPAC
3	334	335	|O
was	336	339	|O
,	339	340	|O
as	341	343	|O
expected	344	352	|O
,	352	353	|O
a	354	355	|O
potent	356	362	|O
inhibitor	363	372	|O
of	373	375	|O
hepatic	376	383	|O
AlDH	384	388	|O
in	389	391	|O
rats	392	396	|O
,	396	397	|O
as	398	400	|O
indicated	401	410	|O
by	411	413	|O
the	414	417	|O
4	418	419	|O
-	419	420	|O
fold	420	424	|O
increase	425	433	|O
in	434	436	|O
the	437	440	|O
levels	441	447	|O
of	448	450	|O
ethanol	451	458	|O
-	458	459	|O
derived	459	466	|O
blood	467	472	|O
acetaldehyde	473	485	|O
relative	486	494	|O
to	495	497	|O
that	498	502	|O
elicited	503	511	|O
by	512	514	|O
chlorpropamide	515	529	|O
itself	530	536	|O
.	536	537	|O
Closely	538	545	|O
following	546	555	|O
in	556	558	|O
activity	559	567	|O
in	568	570	|O
decreasing	571	581	|O
order	582	587	|O
were	588	592	|O
N3	593	595	|B-IUPAC
-	595	596	|I-IUPAC
(	596	597	|I-IUPAC
n	597	598	|I-IUPAC
-	598	599	|I-IUPAC
propylcarbamoyl	599	614	|I-IUPAC
)	614	615	|I-IUPAC
uracil	615	621	|I-IUPAC
(	622	623	|O
7	623	624	|O
)	624	625	|O
,	625	626	|O
N	626	627	|B-IUPAC
-	627	628	|I-IUPAC
(	628	629	|I-IUPAC
n	629	630	|I-IUPAC
-	630	631	|I-IUPAC
propylcarbamoyl	631	646	|I-IUPAC
)	646	647	|I-IUPAC
saccharin	647	656	|I-IUPAC
(	657	658	|O
6	658	659	|O
)	659	660	|O
,	660	661	|O
and	662	665	|O
the	666	669	|O
S	670	671	|B-IUPAC
-	671	672	|I-IUPAC
(	672	673	|I-IUPAC
n	673	674	|I-IUPAC
-	674	675	|I-IUPAC
propylcarbamoyl	675	690	|I-IUPAC
)	690	691	|I-IUPAC
derivative	692	702	|B-MODIFIER
(	703	704	|O
9	704	705	|O
)	705	706	|O
of	707	709	|O
benzyl	710	716	|B-IUPAC
mercaptan	717	726	|I-IUPAC
.	726	727	|O
However	728	735	|O
,	735	736	|O
two	737	740	|O
hydantoin	741	750	|O
derivatives	751	762	|O
,	762	763	|O
5	764	765	|O
and	766	769	|O
8	770	771	|O
,	771	772	|O
were	773	777	|O
totally	778	785	|O
inactive	786	794	|O
in	795	797	|O
inhibiting	798	808	|O
AlDH	809	813	|O
in	814	816	|O
vivo	817	821	|O
.	821	822	|O
A	823	824	|O
prodrug	825	832	|O
of	833	835	|O
N1	836	838	|B-IUPAC
-	838	839	|I-IUPAC
ethylchlorpropamide	839	858	|I-IUPAC
,	858	859	|O
viz	860	863	|O
.	863	864	|O
,	864	865	|O
its	866	869	|O
N3	870	872	|B-IUPAC
-	872	873	|I-IUPAC
trifluoroacetyl	873	888	|I-IUPAC
derivative	889	899	|B-MODIFIER
(	900	901	|O
4b	901	903	|O
)	903	904	|O
,	904	905	|O
was	906	909	|O
a	910	911	|O
good	912	916	|O
in	917	919	|O
vivo	920	924	|O
inhibitor	925	934	|O
of	935	937	|O
AlDH	938	942	|O
,	942	943	|O
mimicking	944	953	|O
the	954	957	|O
activity	958	966	|O
of	967	969	|O
the	970	973	|O
parent	974	980	|O
N1	981	983	|B-IUPAC
-	983	984	|I-IUPAC
ethylchlorpropamide	984	1003	|I-IUPAC
.	1003	1004	|O
These	1005	1010	|O
results	1011	1018	|O
suggest	1019	1026	|O
that	1027	1031	|O
latent	1032	1038	|O
alkyl	1039	1044	|B-IUPAC
isocyanates	1045	1056	|I-IUPAC
are	1057	1060	|O
inhibitors	1061	1071	|O
of	1072	1074	|O
AlDH	1075	1079	|O
,	1079	1080	|O
giving	1081	1087	|O
further	1088	1095	|O
support	1096	1103	|O
to	1104	1106	|O
the	1107	1110	|O
hypothesis	1111	1121	|O
that	1122	1126	|O
the	1127	1130	|O
inhibition	1131	1141	|O
of	1142	1144	|O
AlDH	1145	1149	|O
in	1150	1152	|O
vivo	1153	1157	|O
by	1158	1160	|O
the	1161	1164	|O
hypoglycemic	1165	1177	|O
agent	1178	1183	|O
chlorpropamide	1184	1198	|O
may	1199	1202	|O
be	1203	1205	|O
due	1206	1209	|O
to	1210	1212	|O
the	1213	1216	|O
release	1217	1224	|O
of	1225	1227	|O
n	1228	1229	|B-IUPAC
-	1229	1230	|I-IUPAC
propyl	1230	1236	|I-IUPAC
isocyanate	1237	1247	|I-IUPAC
following	1248	1257	|O
metabolic	1258	1267	|O
bioactivation	1268	1281	|O
.	1281	1282	|O

### abstracts3754.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
polyamines	12	22	|O
based	23	28	|O
on	29	31	|O
the	32	35	|O
high	36	40	|O
affinity	41	49	|O
sigma	50	55	|O
receptor	56	64	|O
ligand	65	71	|O
N	72	73	|B-IUPAC
-	73	74	|I-IUPAC
[	74	75	|I-IUPAC
2	75	76	|I-IUPAC
-	76	77	|I-IUPAC
(	77	78	|I-IUPAC
3,4	78	81	|I-IUPAC
-	81	82	|I-IUPAC
dichlorophenyl	82	96	|I-IUPAC
)	96	97	|I-IUPAC
-	97	98	|I-IUPAC
ethyl	98	103	|I-IUPAC
]	103	104	|I-IUPAC
-	104	105	|I-IUPAC
N	105	106	|I-IUPAC
-	106	107	|I-IUPAC
methyl	107	113	|I-IUPAC
-	113	114	|I-IUPAC
2	114	115	|I-IUPAC
-	115	116	|I-IUPAC
(	116	117	|I-IUPAC
1	117	118	|I-IUPAC
-	118	119	|I-IUPAC
pyrrolidinyl	119	131	|I-IUPAC
)	131	132	|I-IUPAC
ethylamine	132	142	|I-IUPAC
(	143	144	|O
3	144	145	|O
)	145	146	|O
were	147	151	|O
developed	152	161	|O
and	162	165	|O
evaluated	166	175	|O
for	176	179	|O
their	180	185	|O
binding	186	193	|O
characteristics	194	209	|O
at	210	212	|O
sigma	213	218	|O
-	218	219	|O
1	219	220	|O
and	221	224	|O
sigma	225	230	|O
-	230	231	|O
2	231	232	|O
receptor	233	241	|O
subtypes	242	250	|O
.	250	251	|O
The	252	255	|O
data	256	260	|O
indicated	261	270	|O
that	271	275	|O
a	276	277	|O
considerable	278	290	|O
degree	291	297	|O
of	298	300	|O
structural	301	311	|O
variation	312	321	|O
is	322	324	|O
possible	325	333	|O
while	334	339	|O
still	340	345	|O
retaining	346	355	|O
nanomolar	356	365	|O
affinity	366	374	|O
at	375	377	|O
sigma	378	383	|O
receptors	384	393	|O
.	393	394	|O
As	395	397	|O
the	398	401	|O
structure	402	411	|O
of	412	414	|O
the	415	418	|O
polyamines	419	429	|O
was	430	433	|O
varied	434	440	|O
,	440	441	|O
their	442	447	|O
binding	448	455	|O
at	456	458	|O
sigma	459	464	|O
-	464	465	|O
1	465	466	|O
and	467	470	|O
sigma	471	476	|O
-	476	477	|O
2	477	478	|O
subtypes	479	487	|O
showed	488	494	|O
quite	495	500	|O
different	501	510	|O
and	511	514	|O
in	515	517	|O
some	518	522	|O
cases	523	528	|O
opposite	529	537	|O
trends	538	544	|O
,	544	545	|O
supporting	546	556	|O
the	557	560	|O
belief	561	567	|O
that	568	572	|O
these	573	578	|O
are	579	582	|O
pharmacologically	583	600	|O
distinct	601	609	|O
entities	610	618	|O
.	618	619	|O
Polyamines	620	630	|O
containing	631	641	|O
two	642	645	|O
nitrogen	646	654	|O
atoms	655	660	|O
showed	661	667	|O
optimal	668	675	|O
binding	676	683	|O
at	684	686	|O
both	687	691	|O
sigma	692	697	|O
-	697	698	|O
1	698	699	|O
and	700	703	|O
sigma	704	709	|O
-	709	710	|O
2	710	711	|O
receptor	712	720	|O
subtypes	721	729	|O
.	729	730	|O
Although	731	739	|O
additional	740	750	|O
nitrogen	751	759	|O
atoms	760	765	|O
resulted	766	774	|O
in	775	777	|O
decreased	778	787	|O
affinity	788	796	|O
at	797	799	|O
sigma	800	805	|O
-	805	806	|O
1	806	807	|O
and	808	811	|O
sigma	812	817	|O
-	817	818	|O
2	818	819	|O
subtypes	820	828	|O
,	828	829	|O
an	830	832	|O
increase	833	841	|O
in	842	844	|O
selectivity	845	856	|O
for	857	860	|O
sigma	861	866	|O
-	866	867	|O
2	867	868	|O
subtypes	869	877	|O
was	878	881	|O
evident	882	889	|O
;	889	890	|O
the	891	894	|O
parent	895	901	|O
3	902	903	|O
showed	904	910	|O
greater	911	918	|O
selectivity	919	930	|O
for	931	934	|O
sigma	935	940	|O
-	940	941	|O
1	941	942	|O
subtypes	943	951	|O
.	951	952	|O
Internitrogen	953	966	|O
spacings	967	975	|O
had	976	979	|O
a	980	981	|O
large	982	987	|O
effect	988	994	|O
on	995	997	|O
binding	998	1005	|O
affinity	1006	1014	|O
and	1015	1018	|O
subtype	1019	1026	|O
selectivity	1027	1038	|O
.	1038	1039	|O
For	1040	1043	|O
example	1044	1051	|O
,	1051	1052	|O
the	1053	1056	|O
difference	1057	1067	|O
between	1068	1075	|O
N	1076	1077	|B-IUPAC
-	1077	1078	|I-IUPAC
[	1078	1079	|I-IUPAC
3	1079	1080	|I-IUPAC
-	1080	1081	|I-IUPAC
(	1081	1082	|I-IUPAC
1	1082	1083	|I-IUPAC
-	1083	1084	|I-IUPAC
pyrrolidinyl	1084	1096	|I-IUPAC
)	1096	1097	|I-IUPAC
propyl	1097	1103	|I-IUPAC
]	1103	1104	|I-IUPAC
-	1104	1105	|I-IUPAC
N'	1105	1107	|I-IUPAC
-	1107	1108	|I-IUPAC
(	1108	1109	|I-IUPAC
3,4	1109	1112	|I-IUPAC
-	1112	1113	|I-IUPAC
dichlorobenzyl	1113	1127	|I-IUPAC
)	1127	1128	|I-IUPAC
-	1128	1129	|I-IUPAC
N	1129	1130	|I-IUPAC
,	1130	1131	|I-IUPAC
N'	1131	1133	|I-IUPAC
-	1133	1134	|I-IUPAC
dimethylethylenediamine	1135	1158	|I-IUPAC
(	1159	1160	|O
8	1160	1161	|O
)	1161	1162	|O
[	1163	1164	|O
K	1164	1165	|O
(	1165	1166	|O
i	1166	1167	|O
)	1167	1168	|O
=	1169	1170	|O
29.9	1171	1175	|O
nM	1176	1178	|O
at	1179	1181	|O
sigma	1182	1187	|O
-	1187	1188	|O
1	1188	1189	|O
receptor	1190	1198	|O
and	1199	1202	|O
18.3	1203	1207	|O
nM	1208	1210	|O
at	1211	1213	|O
sigma	1214	1219	|O
-	1219	1220	|O
2	1220	1221	|O
receptor	1222	1230	|O
]	1230	1231	|O
to	1232	1234	|O
N	1235	1236	|B-IUPAC
-	1236	1237	|I-IUPAC
[	1237	1238	|I-IUPAC
3	1238	1239	|I-IUPAC
-	1239	1240	|I-IUPAC
(	1240	1241	|I-IUPAC
1	1241	1242	|I-IUPAC
-	1242	1243	|I-IUPAC
pyrrolidinyl	1243	1255	|I-IUPAC
)	1255	1256	|I-IUPAC
propyl	1256	1262	|I-IUPAC
]	1262	1263	|I-IUPAC
-	1263	1264	|I-IUPAC
N'	1264	1266	|I-IUPAC
-	1266	1267	|I-IUPAC
(	1267	1268	|I-IUPAC
3,4	1268	1271	|I-IUPAC
-	1271	1272	|I-IUPAC
dichlorobenzyl	1272	1286	|I-IUPAC
)	1286	1287	|I-IUPAC
-	1287	1288	|I-IUPAC
N	1289	1290	|I-IUPAC
,	1290	1291	|I-IUPAC
N'	1291	1293	|I-IUPAC
-	1293	1294	|I-IUPAC
dimethylethylenediamine	1294	1317	|I-IUPAC
(	1318	1319	|O
10	1319	1321	|O
)	1321	1322	|O
[	1323	1324	|O
K	1324	1325	|O
(	1325	1326	|O
i	1326	1327	|O
)	1327	1328	|O
=	1329	1330	|O
1.49	1331	1335	|O
nM	1336	1338	|O
at	1339	1341	|O
sigma	1342	1347	|O
-	1347	1348	|O
1	1348	1349	|O
receptor	1350	1358	|O
and	1359	1362	|O
12.1	1363	1367	|O
nM	1368	1370	|O
at	1371	1373	|O
sigma	1374	1379	|O
-	1379	1380	|O
2	1380	1381	|O
receptor	1382	1390	|O
]	1390	1391	|O
illustrates	1392	1403	|O
the	1404	1407	|O
importance	1408	1418	|O
of	1419	1421	|O
internitrogen	1422	1435	|O
spacing	1436	1443	|O
.	1443	1444	|O
Triamines	1445	1454	|O
11	1455	1457	|O
and	1458	1461	|O
13	1462	1464	|O
[	1465	1466	|O
Ki	1466	1468	|O
(	1468	1469	|O
sigma	1469	1474	|O
-	1474	1475	|O
2	1475	1476	|O
)	1476	1477	|O
/	1477	1478	|O
K	1478	1479	|O
(	1479	1480	|O
i	1480	1481	|O
)	1481	1482	|O
(	1482	1483	|O
sigma	1483	1488	|O
-	1488	1489	|O
1	1489	1490	|O
)	1490	1491	|O
=	1492	1493	|O
0.19	1494	1498	|O
and	1499	1502	|O
0.10	1503	1507	|O
,	1507	1508	|O
respectively	1509	1521	|O
]	1521	1522	|O
containing	1523	1533	|O
the	1534	1537	|O
N	1538	1539	|O
-	1539	1540	|O
N	1540	1541	|O
-	1541	1542	|O
N	1542	1543	|O
-	1543	1544	|O
Ar	1544	1546	|O
spacings	1547	1555	|O
3-3-2	1556	1561	|O
and	1562	1565	|O
4-4-2	1566	1571	|O
,	1571	1572	|O
proved	1573	1579	|O
to	1580	1582	|O
be	1583	1585	|O
the	1586	1589	|O
most	1590	1594	|O
sigma	1595	1600	|O
-	1600	1601	|O
2	1601	1602	|O
subtype	1603	1610	|O
selective	1611	1620	|O
of	1621	1623	|O
the	1624	1627	|O
15	1628	1630	|O
polyamines	1631	1641	|O
examined	1642	1650	|O
in	1651	1653	|O
this	1654	1658	|O
study	1659	1664	|O
.	1664	1665	|O
The	1666	1669	|O
N	1670	1671	|O
-	1671	1672	|O
N	1672	1673	|O
-	1673	1674	|O
N	1674	1675	|O
spacings	1676	1684	|O
appear	1685	1691	|O
to	1692	1694	|O
be	1695	1697	|O
an	1698	1700	|O
important	1701	1710	|O
factor	1711	1717	|O
in	1718	1720	|O
their	1721	1726	|O
sigma	1727	1732	|O
-	1732	1733	|O
2	1733	1734	|O
subtype	1735	1742	|O
selectivity	1743	1754	|O
.	1754	1755	|O
These	1756	1761	|O
compounds	1762	1771	|O
will	1772	1776	|O
serve	1777	1782	|O
as	1783	1785	|O
templates	1786	1795	|O
in	1796	1798	|O
the	1799	1802	|O
design	1803	1809	|O
of	1810	1812	|O
still	1813	1818	|O
further	1819	1826	|O
sigma	1827	1832	|O
-	1832	1833	|O
2	1833	1834	|O
subtype	1835	1842	|O
selective	1843	1852	|O
ligands	1853	1860	|O
.	1860	1861	|O
The	1862	1865	|O
pyrrolidine	1866	1877	|O
ring	1878	1882	|O
(	1883	1884	|O
present	1884	1891	|O
in	1892	1894	|O
most	1895	1899	|O
of	1900	1902	|O
the	1903	1906	|O
polyamines	1907	1917	|O
tested	1918	1924	|O
in	1925	1927	|O
this	1928	1932	|O
series	1933	1939	|O
)	1939	1940	|O
proved	1941	1947	|O
to	1948	1950	|O
be	1951	1953	|O
an	1954	1956	|O
important	1957	1966	|O
recognition	1967	1978	|O
site	1979	1983	|O
for	1984	1987	|O
sigma	1988	1993	|O
receptor	1994	2002	|O
binding	2003	2010	|O
activity	2011	2019	|O
.	2019	2020	|O
Furthermore	2021	2032	|O
,	2032	2033	|O
alkyl	2034	2039	|O
substitution	2040	2052	|O
also	2053	2057	|O
appears	2058	2065	|O
to	2066	2068	|O
be	2069	2071	|O
important	2072	2081	|O
since	2082	2087	|O
the	2088	2091	|O
stripped	2092	2100	|O
down	2101	2105	|O
polyamines	2106	2116	|O
N	2117	2118	|B-IUPAC
-	2118	2119	|I-IUPAC
[	2119	2120	|I-IUPAC
2	2120	2121	|I-IUPAC
-	2121	2122	|I-IUPAC
(	2122	2123	|I-IUPAC
3,4	2123	2126	|I-IUPAC
-	2126	2127	|I-IUPAC
dichlorophenyl	2127	2141	|I-IUPAC
)	2141	2142	|I-IUPAC
ethyl	2142	2147	|I-IUPAC
]	2147	2148	|I-IUPAC
ethylenediamine	2148	2163	|I-IUPAC
(	2164	2165	|O
15	2165	2167	|O
)	2167	2168	|O
and	2169	2172	|O
N1	2173	2175	|B-IUPAC
-	2175	2176	|I-IUPAC
[	2176	2177	|I-IUPAC
2	2177	2178	|I-IUPAC
-	2178	2179	|I-IUPAC
(	2179	2180	|I-IUPAC
3,4	2180	2183	|I-IUPAC
-	2183	2184	|I-IUPAC
dichlorophenyl	2184	2198	|I-IUPAC
)	2198	2199	|I-IUPAC
ethyl	2199	2204	|I-IUPAC
]	2204	2205	|I-IUPAC
diethylenetriamine	2205	2223	|I-IUPAC
(	2224	2225	|O
16	2225	2227	|O
)	2227	2228	|O
exhibited	2229	2238	|O
relatively	2239	2249	|O
low	2250	2253	|O
binding	2254	2261	|O
affinity	2262	2270	|O
.	2270	2271	|O

### abstracts4326.txt
Substituted	0	11	|O
indole	12	18	|B-IUPAC
-	18	19	|I-IUPAC
5	19	20	|I-IUPAC
-	20	21	|I-IUPAC
carboxamides	21	33	|I-IUPAC
and	34	37	|O
indole	38	44	|B-IUPAC
-	44	45	|I-IUPAC
6	45	46	|I-IUPAC
-	46	47	|I-IUPAC
carboxamides	47	59	|I-IUPAC
have	60	64	|O
been	65	69	|O
found	70	75	|O
to	76	78	|O
be	79	81	|O
potent	82	88	|O
and	89	92	|O
selective	93	102	|O
antagonists	103	114	|O
of	115	117	|O
the	118	121	|O
peptidoleukotrienes	122	141	|O
.	141	142	|O
Initial	143	150	|O
derivatives	151	162	|O
of	163	165	|O
these	166	171	|O
series	172	178	|O
(	179	180	|O
4	180	181	|B-IUPAC
-	181	182	|I-IUPAC
[	182	183	|I-IUPAC
[	183	184	|I-IUPAC
5	184	185	|I-IUPAC
-	185	186	|I-IUPAC
[	186	187	|I-IUPAC
(	187	188	|I-IUPAC
cyclopentylmethyl	188	205	|I-IUPAC
)	205	206	|I-IUPAC
carbamoyl	206	215	|I-IUPAC
]	215	216	|I-IUPAC
-	216	217	|I-IUPAC
1	217	218	|I-IUPAC
-	218	219	|I-IUPAC
methylindol	219	230	|I-IUPAC
-	230	231	|I-IUPAC
3	231	232	|I-IUPAC
-	232	233	|I-IUPAC
yl	233	235	|I-IUPAC
]	235	236	|I-IUPAC
methyl	237	243	|I-IUPAC
]	243	244	|I-IUPAC
-	244	245	|I-IUPAC
3	245	246	|I-IUPAC
-	246	247	|I-IUPAC
methoxy	247	254	|I-IUPAC
-	254	255	|I-IUPAC
N	255	256	|I-IUPAC
-	256	257	|I-IUPAC
[	257	258	|I-IUPAC
(	258	259	|I-IUPAC
2	259	260	|I-IUPAC
-	260	261	|I-IUPAC
methylphenyl	261	273	|I-IUPAC
)	273	274	|I-IUPAC
sulfonyl	274	282	|I-IUPAC
]	282	283	|I-IUPAC
benzamide	283	292	|I-IUPAC
(	293	294	|O
5a	294	296	|O
)	296	297	|O
and	298	301	|O
4	302	303	|B-IUPAC
-	303	304	|I-IUPAC
[	304	305	|I-IUPAC
[	305	306	|I-IUPAC
6	306	307	|I-IUPAC
-	307	308	|I-IUPAC
[	308	309	|I-IUPAC
(	309	310	|I-IUPAC
cyclopentylmethyl	310	327	|I-IUPAC
)	327	328	|I-IUPAC
carbamoyl	328	337	|I-IUPAC
]	337	338	|I-IUPAC
-	338	339	|I-IUPAC
3	339	340	|I-IUPAC
-	340	341	|I-IUPAC
methylindol	341	352	|I-IUPAC
-	352	353	|I-IUPAC
1	353	354	|I-IUPAC
-	354	355	|I-IUPAC
yl	355	357	|I-IUPAC
]	357	358	|I-IUPAC
methyl	359	365	|I-IUPAC
]	365	366	|I-IUPAC
-	366	367	|I-IUPAC
3	367	368	|I-IUPAC
-	368	369	|I-IUPAC
methoxy	369	376	|I-IUPAC
-	376	377	|I-IUPAC
N	377	378	|I-IUPAC
-	378	379	|I-IUPAC
[	379	380	|I-IUPAC
(	380	381	|I-IUPAC
2	381	382	|I-IUPAC
-	382	383	|I-IUPAC
methylphenyl	383	395	|I-IUPAC
)	395	396	|I-IUPAC
sulfonyl	396	404	|I-IUPAC
]	404	405	|I-IUPAC
benzamide	405	414	|I-IUPAC
(	415	416	|O
6a	416	418	|O
)	418	419	|O
,	419	420	|O
respectively	421	433	|O
)	433	434	|O
,	434	435	|O
when	436	440	|O
compared	441	449	|O
to	450	452	|O
the	453	456	|O
corresponding	457	470	|O
indole	471	477	|O
amides	478	484	|O
(	485	486	|O
e.g.	486	490	|O
28	491	493	|O
and	494	497	|O
29	498	500	|O
)	500	501	|O
,	501	502	|O
were	503	507	|O
found	508	513	|O
to	514	516	|O
be	517	519	|O
approximately	520	533	|O
10	534	536	|O
-	536	537	|O
fold	537	541	|O
less	542	546	|O
potent	547	553	|O
in	554	556	|O
vitro	557	562	|O
and	563	566	|O
substantially	567	580	|O
less	581	585	|O
active	586	592	|O
when	593	597	|O
administered	598	610	|O
orally	611	617	|O
to	618	620	|O
guinea	621	627	|O
pigs	628	632	|O
.	632	633	|O
Efforts	634	641	|O
to	642	644	|O
improve	645	652	|O
the	653	656	|O
potency	657	664	|O
of	665	667	|O
the	668	671	|O
title	672	677	|O
series	678	684	|O
by	685	687	|O
variation	688	697	|O
of	698	700	|O
the	701	704	|O
amide	705	710	|O
,	710	711	|O
indole	712	718	|O
,	718	719	|O
or	720	722	|O
sulfonamide	723	734	|O
substituents	735	747	|O
led	748	751	|O
to	752	754	|O
compounds	755	764	|O
of	765	767	|O
comparable	768	778	|O
in	779	781	|O
vitro	782	787	|O
potency	788	795	|O
to	796	798	|O
ICI	799	802	|O
204,219	803	810	|O
,	810	811	|O
but	812	815	|O
of	816	818	|O
somewhat	819	827	|O
lower	828	833	|O
oral	834	838	|O
activity	839	847	|O
.	847	848	|O
A	849	850	|O
trend	851	856	|O
which	857	862	|O
suggested	863	872	|O
that	873	877	|O
more	878	882	|O
lipophilic	883	893	|O
transposed	894	904	|O
amides	905	911	|O
were	912	916	|O
needed	917	923	|O
to	924	926	|O
increase	927	935	|O
oral	936	940	|O
activity	941	949	|O
was	950	953	|O
exploited	954	963	|O
with	964	968	|O
some	969	973	|O
success	974	981	|O
and	982	985	|O
has	986	989	|O
led	990	993	|O
to	994	996	|O
the	997	1000	|O
discovery	1001	1010	|O
of	1011	1013	|O
5q	1014	1016	|O
(	1017	1018	|O
4	1018	1019	|B-IUPAC
-	1019	1020	|I-IUPAC
[	1020	1021	|I-IUPAC
[	1021	1022	|I-IUPAC
5	1022	1023	|I-IUPAC
-	1023	1024	|I-IUPAC
[	1024	1025	|I-IUPAC
(	1025	1026	|I-IUPAC
2	1026	1027	|I-IUPAC
-	1027	1028	|I-IUPAC
ethylbutyl	1028	1038	|I-IUPAC
)	1038	1039	|I-IUPAC
-	1039	1040	|I-IUPAC
carbamoyl	1040	1049	|I-IUPAC
]	1049	1050	|I-IUPAC
-	1050	1051	|I-IUPAC
1	1051	1052	|I-IUPAC
-	1052	1053	|I-IUPAC
ethylindol	1053	1063	|I-IUPAC
-	1063	1064	|I-IUPAC
3	1064	1065	|I-IUPAC
-	1065	1066	|I-IUPAC
yl	1066	1068	|I-IUPAC
]	1068	1069	|I-IUPAC
methyl	1069	1075	|I-IUPAC
]	1075	1076	|I-IUPAC
-	1076	1077	|I-IUPAC
3	1078	1079	|I-IUPAC
-	1079	1080	|I-IUPAC
methoxy	1081	1088	|I-IUPAC
-	1088	1089	|I-IUPAC
N	1089	1090	|I-IUPAC
-	1090	1091	|I-IUPAC
[	1091	1092	|I-IUPAC
(	1092	1093	|I-IUPAC
2	1093	1094	|I-IUPAC
-	1094	1095	|I-IUPAC
methylphenyl	1095	1107	|I-IUPAC
)	1107	1108	|I-IUPAC
sulfonyl	1108	1116	|I-IUPAC
]	1116	1117	|I-IUPAC
benzamide	1117	1126	|I-IUPAC
)	1126	1127	|O
,	1127	1128	|O
a	1129	1130	|O
transposed	1131	1141	|O
amide	1142	1147	|O
with	1148	1152	|O
subnanomolar	1153	1165	|O
affinity	1166	1174	|O
for	1175	1178	|O
the	1179	1182	|O
leukotriene	1183	1194	|O
receptor	1195	1203	|O
and	1204	1207	|O
an	1208	1210	|O
oral	1211	1215	|O
ED50	1216	1220	|O
of	1221	1223	|O
5	1224	1225	|O
mg	1226	1228	|O
/	1228	1229	|O
kg	1229	1231	|O
in	1232	1234	|O
a	1235	1236	|O
model	1237	1242	|O
of	1243	1245	|O
asthma	1246	1252	|O
in	1253	1255	|O
guinea	1256	1262	|O
pigs	1263	1267	|O
.	1267	1268	|O
In	1269	1271	|O
this	1272	1276	|O
model	1277	1282	|O
,	1282	1283	|O
ICI	1284	1287	|O
204,219	1288	1295	|O
was	1296	1299	|O
active	1300	1306	|O
at	1307	1309	|O
0.4	1310	1313	|O
mg	1314	1316	|O
/	1316	1317	|O
kg	1317	1319	|O
.	1319	1320	|O
The	1321	1324	|O
absolute	1325	1333	|O
bioavailability	1334	1349	|O
of	1350	1352	|O
5q	1353	1355	|O
has	1356	1359	|O
been	1360	1364	|O
found	1365	1370	|O
to	1371	1373	|O
be	1374	1376	|O
28%	1377	1380	|O
in	1381	1383	|O
the	1384	1387	|O
rat	1388	1391	|O
,	1391	1392	|O
as	1393	1395	|O
compared	1396	1404	|O
to	1405	1407	|O
68%	1408	1411	|O
for	1412	1415	|O
ICI	1416	1419	|O
204,219	1420	1427	|O
,	1427	1428	|O
with	1429	1433	|O
significant	1434	1445	|O
levels	1446	1452	|O
of	1453	1455	|O
5q	1456	1458	|O
observed	1459	1467	|O
in	1468	1470	|O
the	1471	1474	|O
blood	1475	1480	|O
of	1481	1483	|O
rats	1484	1488	|O
up	1489	1491	|O
to	1492	1494	|O
24	1495	1497	|O
h	1498	1499	|O
postdose	1500	1508	|O
.	1508	1509	|O

### abstracts4775.txt
Variable	0	8	|O
-	8	9	|O
temperature	9	20	|O
proton	21	27	|O
nuclear	28	35	|O
magnetic	36	44	|O
resonance	45	54	|O
studies	55	62	|O
have	63	67	|O
shown	68	73	|O
that	74	78	|O
5	79	80	|B-IUPAC
-	80	81	|I-IUPAC
(	81	82	|I-IUPAC
2	82	83	|I-IUPAC
-	83	84	|I-IUPAC
propylidene	84	95	|I-IUPAC
)	95	96	|I-IUPAC
-	96	97	|I-IUPAC
10	97	99	|I-IUPAC
-	99	100	|I-IUPAC
(	100	101	|I-IUPAC
4	101	102	|I-IUPAC
-	102	103	|I-IUPAC
methylpiperazino	103	119	|I-IUPAC
)	119	120	|I-IUPAC
-	120	121	|I-IUPAC
5H	121	123	|I-IUPAC
-	123	124	|I-IUPAC
dibenzo	124	131	|I-IUPAC
[	131	132	|I-IUPAC
a	132	133	|I-IUPAC
,	133	134	|I-IUPAC
d	134	135	|I-IUPAC
]	135	136	|I-IUPAC
cycloheptene	137	149	|I-IUPAC
,	149	150	|O
a	151	152	|O
5,11	153	157	|B-IUPAC
-	157	158	|I-IUPAC
dicarbo	158	165	|I-IUPAC
analogue	166	174	|B-MODIFIER
of	175	177	|O
the	178	181	|O
atypical	182	190	|O
neuroleptic	191	202	|O
agent	203	208	|O
clozapine	209	218	|B-IUPAC
[	219	220	|I-IUPAC
8	220	221	|I-IUPAC
-	221	222	|I-IUPAC
chloro	222	228	|I-IUPAC
-	228	229	|I-IUPAC
11	229	231	|I-IUPAC
-	231	232	|I-IUPAC
(	232	233	|I-IUPAC
4	233	234	|I-IUPAC
-	234	235	|I-IUPAC
methylpiperazino	235	251	|I-IUPAC
)	251	252	|I-IUPAC
-	252	253	|I-IUPAC
5H	253	255	|I-IUPAC
-	255	256	|I-IUPAC
dibenzo	256	263	|I-IUPAC
[	263	264	|I-IUPAC
b	264	265	|I-IUPAC
,	265	266	|I-IUPAC
e	266	267	|I-IUPAC
]	267	268	|I-IUPAC
[	268	269	|I-IUPAC
1,4	269	272	|I-IUPAC
]	272	273	|I-IUPAC
diazepine	273	282	|I-IUPAC
]	282	283	|I-IUPAC
,	283	284	|O
exists	285	291	|O
as	292	294	|O
thermally	295	304	|O
stable	305	311	|O
configurational	312	327	|O
isomers	328	335	|O
.	335	336	|O
The	337	340	|O
presence	341	349	|O
of	350	352	|O
the	353	356	|O
2	357	358	|B-IUPAC
-	358	359	|I-IUPAC
propylidene	359	370	|I-IUPAC
group	371	376	|B-MODIFIER
at	377	379	|O
C	380	381	|O
-	381	382	|O
5	382	383	|O
on	384	386	|O
the	387	390	|O
5H	391	393	|B-IUPAC
-	393	394	|I-IUPAC
dibenzo	394	401	|I-IUPAC
[	401	402	|I-IUPAC
a	402	403	|I-IUPAC
,	403	404	|I-IUPAC
d	404	405	|I-IUPAC
]	405	406	|I-IUPAC
cycloheptene	406	418	|I-IUPAC
moiety	419	425	|B-MODIFIER
did	426	429	|O
not	430	433	|O
interfere	434	443	|O
greatly	444	451	|O
,	451	452	|O
as	453	455	|O
compared	456	464	|O
to	465	467	|O
clozapine	468	477	|O
,	477	478	|O
with	479	483	|O
the	484	487	|O
in	488	490	|O
vitro	491	496	|O
affinity	497	505	|O
of	506	508	|O
this	509	513	|O
5,11	514	518	|B-IUPAC
-	518	519	|I-IUPAC
dicarbo	519	526	|I-IUPAC
analogue	527	535	|B-MODIFIER
of	536	538	|O
clozapine	539	548	|O
for	549	552	|O
muscarinic	553	563	|O
and	564	567	|O
dopamine	568	576	|O
D	577	578	|O
-	578	579	|O
1	579	580	|O
and	581	584	|O
D	585	586	|O
-	586	587	|O
2	587	588	|O
binding	589	596	|O
sites	597	602	|O
in	603	605	|O
rat	606	609	|O
brain	610	615	|O
.	615	616	|O
Since	617	622	|O
the	623	626	|O
presence	627	635	|O
and	636	639	|O
position	640	648	|O
of	649	651	|O
a	652	653	|O
chloro	654	660	|O
substituent	661	672	|O
on	673	675	|O
the	676	679	|O
5H	680	682	|B-IUPAC
-	682	683	|I-IUPAC
dibenzo	683	690	|I-IUPAC
[	690	691	|I-IUPAC
b	691	692	|I-IUPAC
,	692	693	|I-IUPAC
e	693	694	|I-IUPAC
]	694	695	|I-IUPAC
[	695	696	|I-IUPAC
1,4	696	699	|I-IUPAC
]	699	700	|I-IUPAC
diazepine	700	709	|I-IUPAC
moiety	710	716	|B-MODIFIER
have	717	721	|O
a	722	723	|O
marked	724	730	|O
influence	731	740	|O
on	741	743	|O
the	744	747	|O
respective	748	758	|O
binding	759	766	|O
affinities	767	777	|O
of	778	780	|O
1,4	781	784	|B-IUPAC
-	784	785	|I-IUPAC
diazepines	785	795	|I-IUPAC
related	796	803	|O
to	804	806	|O
clozapine	807	816	|O
,	816	817	|O
chloro	818	824	|B-MODIFIER
-	824	825	|I-MODIFIER
substituted	825	836	|I-MODIFIER
5,11	837	841	|B-IUPAC
-	841	842	|I-IUPAC
dicarbo	842	849	|I-IUPAC
analogues	850	859	|B-MODIFIER
of	860	862	|O
clozapine	863	872	|O
were	873	877	|O
prepared	878	886	|O
in	887	889	|O
order	890	895	|O
to	896	898	|O
further	899	906	|O
examine	907	914	|O
structure	915	924	|O
-	924	925	|O
activity	925	933	|O
relationships	934	947	|O
.	947	948	|O
Evaluation	949	959	|O
of	960	962	|O
these	963	968	|O
analogues	969	978	|O
for	979	982	|O
binding	983	990	|O
to	991	993	|O
muscarinic	994	1004	|O
and	1005	1008	|O
dopamine	1009	1017	|O
binding	1018	1025	|O
sites	1026	1031	|O
in	1032	1034	|O
comparison	1035	1045	|O
with	1046	1050	|O
clozapine	1051	1060	|O
and	1061	1064	|O
other	1065	1070	|O
5H	1071	1073	|B-IUPAC
-	1073	1074	|I-IUPAC
dibenzo	1074	1081	|I-IUPAC
[	1081	1082	|I-IUPAC
b	1082	1083	|I-IUPAC
,	1083	1084	|I-IUPAC
e	1084	1085	|I-IUPAC
]	1085	1086	|I-IUPAC
[	1086	1087	|I-IUPAC
1,4	1087	1090	|I-IUPAC
]	1090	1091	|I-IUPAC
diazepine	1091	1100	|I-IUPAC
analogues	1101	1110	|B-MODIFIER
of	1111	1113	|O
clozapine	1114	1123	|O
shows	1124	1129	|O
that	1130	1134	|O
the	1135	1138	|O
dopamine	1139	1147	|O
D	1148	1149	|O
-	1149	1150	|O
1	1150	1151	|O
and	1152	1155	|O
D	1156	1157	|O
-	1157	1158	|O
2	1158	1159	|O
receptor	1160	1168	|O
affinities	1169	1179	|O
of	1180	1182	|O
both	1183	1187	|O
the	1188	1191	|O
5	1192	1193	|B-IUPAC
-	1193	1194	|I-IUPAC
(	1194	1195	|I-IUPAC
2	1195	1196	|I-IUPAC
-	1196	1197	|I-IUPAC
propylidene	1197	1208	|I-IUPAC
)	1208	1209	|I-IUPAC
-	1209	1210	|I-IUPAC
5,11	1210	1214	|I-IUPAC
-	1214	1215	|I-IUPAC
dicarbo	1215	1222	|I-IUPAC
analogue	1223	1231	|B-MODIFIER
and	1232	1235	|O
its	1236	1239	|O
corresponding	1240	1253	|O
distal	1254	1260	|O
-	1260	1261	|O
chloro	1261	1267	|O
derivative	1268	1278	|O
,	1278	1279	|O
2	1280	1281	|B-IUPAC
-	1281	1282	|I-IUPAC
chloro	1282	1288	|I-IUPAC
-	1288	1289	|I-IUPAC
5	1289	1290	|I-IUPAC
-	1290	1291	|I-IUPAC
(	1291	1292	|I-IUPAC
2	1292	1293	|I-IUPAC
-	1293	1294	|I-IUPAC
propylidene	1294	1305	|I-IUPAC
)	1305	1306	|I-IUPAC
-	1306	1307	|I-IUPAC
10	1307	1309	|I-IUPAC
-	1309	1310	|I-IUPAC
(	1310	1311	|I-IUPAC
4	1311	1312	|I-IUPAC
-	1312	1313	|I-IUPAC
methylpiperazino	1313	1329	|I-IUPAC
)	1329	1330	|I-IUPAC
-	1330	1331	|I-IUPAC
5H	1331	1333	|I-IUPAC
-	1333	1334	|I-IUPAC
dibenzo	1335	1342	|I-IUPAC
[	1342	1343	|I-IUPAC
a	1343	1344	|I-IUPAC
,	1344	1345	|I-IUPAC
d	1345	1346	|I-IUPAC
]	1346	1347	|I-IUPAC
cycloheptene	1347	1359	|I-IUPAC
,	1359	1360	|O
are	1361	1364	|O
retained	1365	1373	|O
.	1373	1374	|O
Because	1375	1382	|O
of	1383	1385	|O
the	1386	1389	|O
susceptibility	1390	1404	|O
to	1405	1407	|O
acid	1408	1412	|O
-	1412	1413	|O
catalyzed	1413	1422	|O
hydrolysis	1423	1433	|O
of	1434	1436	|O
these	1437	1442	|O
tertiary	1443	1451	|O
enamines	1452	1460	|O
,	1460	1461	|O
however	1462	1469	|O
,	1469	1470	|O
these	1471	1476	|O
compounds	1477	1486	|O
serve	1487	1492	|O
only	1493	1497	|O
as	1498	1500	|O
model	1501	1506	|O
compounds	1507	1516	|O
for	1517	1520	|O
their	1521	1526	|O
structure	1527	1536	|O
-	1536	1537	|O
activity	1537	1545	|O
evaluation	1546	1556	|O
.	1556	1557	|O
Since	1558	1563	|O
the	1564	1567	|O
proximal	1568	1576	|O
nitrogen	1577	1585	|O
atom	1586	1590	|O
of	1591	1593	|O
the	1594	1597	|O
piperazine	1598	1608	|O
ring	1609	1613	|O
is	1614	1616	|O
redundant	1617	1626	|O
for	1627	1630	|O
biological	1631	1641	|O
activity	1642	1650	|O
,	1650	1651	|O
5	1652	1653	|B-IUPAC
-	1653	1654	|I-IUPAC
(	1654	1655	|I-IUPAC
2	1655	1656	|I-IUPAC
-	1656	1657	|I-IUPAC
propylidene	1657	1668	|I-IUPAC
)	1668	1669	|I-IUPAC
-	1669	1670	|I-IUPAC
10	1670	1672	|I-IUPAC
-	1672	1673	|I-IUPAC
(	1673	1674	|I-IUPAC
1	1674	1675	|I-IUPAC
-	1675	1676	|I-IUPAC
methyl	1676	1682	|I-IUPAC
-	1682	1683	|I-IUPAC
4	1683	1684	|I-IUPAC
-	1684	1685	|I-IUPAC
pyridyl	1685	1692	|I-IUPAC
)	1692	1693	|I-IUPAC
-	1693	1694	|I-IUPAC
5H	1694	1696	|I-IUPAC
-	1696	1697	|I-IUPAC
dibenzo	1697	1704	|I-IUPAC
[	1704	1705	|I-IUPAC
a	1705	1706	|I-IUPAC
,	1706	1707	|I-IUPAC
d	1707	1708	|I-IUPAC
]	1708	1709	|I-IUPAC
cycloh	1709	1715	|I-IUPAC
eptene	1716	1722	|I-IUPAC
and	1723	1726	|O
its	1727	1730	|O
2	1731	1732	|B-IUPAC
-	1732	1733	|I-IUPAC
chloro	1733	1739	|I-IUPAC
derivative	1740	1750	|B-MODIFIER
are	1751	1754	|O
excellent	1755	1764	|O
candidates	1765	1775	|O
for	1776	1779	|O
resolution	1780	1790	|O
into	1791	1795	|O
enantiomers	1796	1807	|O
as	1808	1810	|O
a	1811	1812	|O
means	1813	1818	|O
to	1819	1821	|O
separate	1822	1830	|O
antimuscarinic	1831	1845	|O
and	1846	1849	|O
antidopaminergic	1850	1866	|O
activity	1867	1875	|O
,	1875	1876	|O
respectively	1877	1889	|O
,	1889	1890	|O
associated	1891	1901	|O
with	1902	1906	|O
only	1907	1911	|O
a	1912	1913	|O
single	1914	1920	|O
stereoisomer	1921	1933	|O
.	1933	1934	|O

### abstracts3667.txt
The	0	3	|O
9	4	5	|B-IUPAC
-	5	6	|I-IUPAC
aza	6	9	|I-IUPAC
analogue	10	18	|B-MODIFIER
of	19	21	|O
N	22	23	|B-IUPAC
-	23	24	|I-IUPAC
(	24	25	|I-IUPAC
trifluoroacetyl	25	40	|I-IUPAC
)	40	41	|I-IUPAC
-	41	42	|I-IUPAC
4	42	43	|I-IUPAC
-	43	44	|I-IUPAC
demethoxydaunomycin	44	63	|I-IUPAC
has	64	67	|O
been	68	72	|O
synthesized	73	84	|O
from	85	89	|O
2,5	90	93	|B-IUPAC
-	93	94	|I-IUPAC
dimethoxybenzaldehyde	94	115	|I-IUPAC
.	115	116	|O
Pomeranz	117	125	|O
-	125	126	|O
Fritsch	126	133	|O
condensation	134	146	|O
followed	147	155	|O
by	156	158	|O
borohydride	159	170	|O
reduction	171	180	|O
and	181	184	|O
acid	185	189	|O
-	189	190	|O
catalyzed	190	199	|O
cyclization	200	211	|O
led	212	215	|O
smoothly	216	224	|O
to	225	227	|O
4	228	229	|B-IUPAC
-	229	230	|I-IUPAC
hydroxy	230	237	|I-IUPAC
-	237	238	|I-IUPAC
5,8	238	241	|I-IUPAC
-	241	242	|I-IUPAC
dimethoxy	242	251	|I-IUPAC
-	251	252	|I-IUPAC
1,2,3,4	252	259	|I-IUPAC
-	259	260	|I-IUPAC
tetrahydroisoquinoline	260	282	|I-IUPAC
.	282	283	|O
Selective	284	293	|O
N	294	295	|O
-	295	296	|O
acetylation	296	307	|O
and	308	311	|O
subsequent	312	322	|O
Friedel	323	330	|O
-	330	331	|O
Crafts	331	337	|O
acylation	338	347	|O
with	348	352	|O
phthalic	353	361	|O
anhydride	362	371	|O
produced	372	380	|O
2	381	382	|B-IUPAC
-	382	383	|I-IUPAC
acetyl	383	389	|I-IUPAC
-	389	390	|I-IUPAC
5,12	390	394	|I-IUPAC
-	394	395	|I-IUPAC
dihydroxy	395	404	|I-IUPAC
-	404	405	|I-IUPAC
1,2	405	408	|I-IUPAC
-	408	409	|I-IUPAC
dihydro	409	416	|I-IUPAC
-	416	417	|I-IUPAC
2	417	418	|I-IUPAC
-	418	419	|I-IUPAC
azanaphthacene	419	433	|I-IUPAC
-	433	434	|I-IUPAC
6,11	434	438	|I-IUPAC
-	438	439	|I-IUPAC
dione	439	444	|I-IUPAC
,	444	445	|O
which	446	451	|O
was	452	455	|O
protected	456	465	|O
as	466	468	|O
its	469	472	|O
dimethyl	473	481	|O
ether	482	487	|O
and	488	491	|O
epoxidized	492	502	|O
to	503	505	|O
an	506	508	|O
acylated	509	517	|O
aza	518	521	|O
Brigl	522	527	|O
's	527	529	|O
anhydride	530	539	|O
.	539	540	|O
This	541	545	|O
was	546	549	|O
converted	550	559	|O
to	560	562	|O
(	563	564	|B-IUPAC
+	564	565	|I-IUPAC
/	565	566	|I-IUPAC
-	566	567	|I-IUPAC
)	567	568	|I-IUPAC
-	568	569	|I-IUPAC
2	569	570	|I-IUPAC
-	570	571	|I-IUPAC
acetyl	571	577	|I-IUPAC
-	577	578	|I-IUPAC
4	578	579	|I-IUPAC
-	579	580	|I-IUPAC
hydroxy	580	587	|I-IUPAC
-	587	588	|I-IUPAC
5,12	588	592	|I-IUPAC
-	592	593	|I-IUPAC
dimethoxy	593	602	|I-IUPAC
-	602	603	|I-IUPAC
1,2,3,4	603	610	|I-IUPAC
-	610	611	|I-IUPAC
tetrahydro	611	621	|I-IUPAC
-	621	622	|I-IUPAC
2	622	623	|I-IUPAC
-	623	624	|I-IUPAC
azanaphthacene	625	639	|I-IUPAC
-	639	640	|I-IUPAC
6,11	640	644	|I-IUPAC
-	644	645	|I-IUPAC
dione	645	650	|I-IUPAC
by	651	653	|O
dehydration	654	665	|O
to	666	668	|O
the	669	672	|O
4	673	674	|B-IUPAC
-	674	675	|I-IUPAC
keto	675	679	|I-IUPAC
analogue	680	688	|B-MODIFIER
followed	689	697	|O
by	698	700	|O
cyanoborohydride	701	717	|O
reduction	718	727	|O
either	728	734	|O
stepwise	735	743	|O
or	744	746	|O
in	747	749	|O
situ	750	754	|O
.	754	755	|O
The	756	759	|O
protecting	760	770	|O
groups	771	777	|O
were	778	782	|O
removed	783	790	|O
with	791	795	|O
boron	796	801	|O
trichloride	802	813	|O
and	814	817	|O
the	818	821	|O
resulting	822	831	|O
aglycone	832	840	|O
glycosidated	841	853	|O
with	854	858	|O
optically	859	868	|O
active	869	875	|O
N	876	877	|B-IUPAC
,	877	878	|I-IUPAC
O	878	879	|I-IUPAC
-	879	880	|I-IUPAC
bis	880	883	|I-IUPAC
(	883	884	|I-IUPAC
trifluoroacetyl	884	899	|I-IUPAC
)	899	900	|I-IUPAC
daunosamine	900	911	|I-IUPAC
bromide	912	919	|I-IUPAC
and	920	923	|O
silver	924	930	|O
trifluoromethanesulfonate	931	956	|O
.	956	957	|O
The	958	961	|O
resulting	962	971	|O
diastereoisomers	972	988	|O
were	989	993	|O
separated	994	1003	|O
by	1004	1006	|O
column	1007	1013	|O
chromatography	1014	1028	|O
and	1029	1032	|O
their	1033	1038	|O
structures	1039	1049	|O
established	1050	1061	|O
by	1062	1064	|O
CD	1065	1067	|O
and	1068	1071	|O
NMR	1072	1075	|O
spectroscopy	1076	1088	|O
.	1088	1089	|O
Unexpectedly	1090	1102	|O
it	1103	1105	|O
was	1106	1109	|O
not	1110	1113	|O
possible	1114	1122	|O
to	1123	1125	|O
remove	1126	1132	|O
the	1133	1136	|O
N	1137	1138	|B-IUPAC
-	1138	1139	|I-IUPAC
trifluoroacetyl	1139	1154	|I-IUPAC
blocking	1155	1163	|B-MODIFIER
group	1164	1169	|I-MODIFIER
without	1170	1177	|O
aromatization	1178	1191	|O
to	1192	1194	|O
the	1195	1198	|O
azanaphthaquinone	1199	1216	|O
.	1216	1217	|O
Both	1218	1222	|O
(	1223	1224	|B-PARTIUPAC
R	1224	1225	|I-PARTIUPAC
)	1225	1226	|I-PARTIUPAC
-	1226	1227	|I-PARTIUPAC
and	1228	1231	|O
(	1232	1233	|B-IUPAC
S	1233	1234	|I-IUPAC
)	1234	1235	|I-IUPAC
-	1235	1236	|I-IUPAC
acetyl	1236	1242	|I-IUPAC
-	1242	1243	|I-IUPAC
4	1243	1244	|I-IUPAC
-	1244	1245	|I-IUPAC
O	1245	1246	|I-IUPAC
-	1246	1247	|I-IUPAC
[	1247	1248	|I-IUPAC
N	1248	1249	|I-IUPAC
-	1249	1250	|I-IUPAC
(	1250	1251	|I-IUPAC
trifluoroacetyl	1251	1266	|I-IUPAC
)	1266	1267	|I-IUPAC
daunosaminyl	1267	1279	|I-IUPAC
]	1279	1280	|I-IUPAC
-	1280	1281	|I-IUPAC
5,12	1281	1285	|I-IUPAC
-	1285	1286	|I-IUPAC
dihydroxy	1286	1295	|I-IUPAC
-	1295	1296	|I-IUPAC
2	1296	1297	|I-IUPAC
-	1297	1298	|I-IUPAC
azanaphthacene	1299	1313	|I-IUPAC
-	1313	1314	|I-IUPAC
6,11	1314	1318	|I-IUPAC
-	1318	1319	|I-IUPAC
dione	1319	1324	|I-IUPAC
were	1325	1329	|O
inactive	1330	1338	|O
ip	1339	1341	|O
in	1342	1344	|O
mice	1345	1349	|O
carrying	1350	1358	|O
the	1359	1362	|O
P388	1363	1367	|O
tumor	1368	1373	|O
.	1373	1374	|O
Drugs	1375	1380	|O
were	1381	1385	|O
given	1386	1391	|O
at	1392	1394	|O
various	1395	1402	|O
concentrations	1403	1417	|O
on	1418	1420	|O
days	1421	1425	|O
0	1426	1427	|O
,	1427	1428	|O
5	1429	1430	|O
,	1430	1431	|O
and	1432	1435	|O
9	1436	1437	|O
.	1437	1438	|O

### abstracts3223.txt
Novel	0	5	|O
N	6	7	|B-IUPAC
-	7	8	|I-IUPAC
(	8	9	|I-IUPAC
4	9	10	|I-IUPAC
-	10	11	|I-IUPAC
oxochroman	11	21	|I-IUPAC
-	21	22	|I-IUPAC
8	22	23	|I-IUPAC
-	23	24	|I-IUPAC
yl	24	26	|I-IUPAC
)	26	27	|I-IUPAC
amide	27	32	|I-IUPAC
derivatives	33	44	|B-MODIFIER
1	45	46	|O
were	47	51	|O
synthesized	52	63	|O
and	64	67	|O
tested	68	74	|O
for	75	78	|O
their	79	84	|O
ability	85	92	|O
to	93	95	|O
inhibit	96	103	|O
rabbit	104	110	|O
small	111	116	|O
intestinal	117	127	|O
ACAT	128	132	|O
(	133	134	|O
acyl	134	138	|O
-	138	139	|O
CoA	139	142	|O
:	142	143	|O
cholesterol	143	154	|O
acyltransferase	155	170	|O
)	170	171	|O
in	172	174	|O
vitro	175	180	|O
and	181	184	|O
to	185	187	|O
lower	188	193	|O
serum	194	199	|O
total	200	205	|O
cholesterol	206	217	|O
in	218	220	|O
cholesterol	221	232	|O
-	232	233	|O
fed	233	236	|O
rats	237	241	|O
in	242	244	|O
vivo	245	249	|O
.	249	250	|O
Among	251	256	|O
the	257	260	|O
synthesized	261	272	|O
compounds	273	282	|O
,	282	283	|O
N	284	285	|B-IUPAC
-	285	286	|I-IUPAC
(	286	287	|I-IUPAC
7	287	288	|I-IUPAC
-	288	289	|I-IUPAC
alkoxy	289	295	|I-IUPAC
-	295	296	|I-IUPAC
4	296	297	|I-IUPAC
-	297	298	|I-IUPAC
oxochroman	298	308	|I-IUPAC
-	308	309	|I-IUPAC
8	309	310	|I-IUPAC
-	310	311	|I-IUPAC
yl	311	313	|I-IUPAC
)	313	314	|I-IUPAC
amide	314	319	|I-IUPAC
derivatives	320	331	|B-MODIFIER
showed	332	338	|O
potent	339	345	|O
ACAT	346	350	|O
inhibitory	351	361	|O
activity	362	370	|O
both	371	375	|O
in	376	378	|O
vitro	379	384	|O
and	385	388	|O
in	389	391	|O
vivo	392	396	|O
.	396	397	|O
The	398	401	|O
structure	402	411	|O
-	411	412	|O
activity	412	420	|O
relationships	421	434	|O
of	435	437	|O
these	438	443	|O
N	444	445	|B-IUPAC
-	445	446	|I-IUPAC
(	446	447	|I-IUPAC
4	447	448	|I-IUPAC
-	448	449	|I-IUPAC
oxochroman	449	459	|I-IUPAC
-	459	460	|I-IUPAC
8	460	461	|I-IUPAC
-	461	462	|I-IUPAC
yl	462	464	|I-IUPAC
)	464	465	|I-IUPAC
amides	465	471	|I-IUPAC
and	472	475	|O
related	476	483	|O
compounds	484	493	|O
are	494	497	|O
discussed	498	507	|O
on	508	510	|O
the	511	514	|O
basis	515	520	|O
of	521	523	|O
these	524	529	|O
two	530	533	|O
assays	534	540	|O
.	540	541	|O
The	542	545	|O
carbonyl	546	554	|B-IUPAC
group	555	560	|B-MODIFIER
at	561	563	|O
position	564	572	|O
4	573	574	|O
of	575	577	|O
the	578	581	|O
4	582	583	|B-IUPAC
-	583	584	|I-IUPAC
chromanone	584	594	|I-IUPAC
was	595	598	|O
essential	599	608	|O
for	609	612	|O
potent	613	619	|O
ACAT	620	624	|O
inhibitory	625	635	|O
activity	636	644	|O
.	644	645	|O
N	646	647	|B-IUPAC
-	647	648	|I-IUPAC
(	648	649	|I-IUPAC
Chromon	649	656	|I-IUPAC
-	656	657	|I-IUPAC
8	657	658	|I-IUPAC
-	658	659	|I-IUPAC
yl	659	661	|I-IUPAC
)	661	662	|I-IUPAC
derivatives	663	674	|B-MODIFIER
were	675	679	|O
less	680	684	|O
potent	685	691	|O
than	692	696	|O
N	697	698	|B-IUPAC
-	698	699	|I-IUPAC
(	699	700	|I-IUPAC
4	700	701	|I-IUPAC
-	701	702	|I-IUPAC
oxochroman	702	712	|I-IUPAC
-	712	713	|I-IUPAC
8	713	714	|I-IUPAC
-	714	715	|I-IUPAC
yl	715	717	|I-IUPAC
)	717	718	|I-IUPAC
derivatives	719	730	|B-MODIFIER
.	730	731	|O
An	732	734	|O
alkoxy	735	741	|O
group	742	747	|O
at	748	750	|O
position	751	759	|O
7	760	761	|O
of	762	764	|O
the	765	768	|O
4	769	770	|B-IUPAC
-	770	771	|I-IUPAC
chromanone	771	781	|I-IUPAC
moiety	782	788	|B-MODIFIER
was	789	792	|O
important	793	802	|O
for	803	806	|O
potent	807	813	|O
ACAT	814	818	|O
inhibitory	819	829	|O
activity	830	838	|O
.	838	839	|O
In	840	842	|O
the	843	846	|O
N	847	848	|B-IUPAC
-	848	849	|I-IUPAC
(	849	850	|I-IUPAC
7	850	851	|I-IUPAC
-	851	852	|I-IUPAC
alkoxy	852	858	|I-IUPAC
-	858	859	|I-IUPAC
4	859	860	|I-IUPAC
-	860	861	|I-IUPAC
oxochroman	861	871	|I-IUPAC
-	871	872	|I-IUPAC
8	872	873	|I-IUPAC
-	873	874	|I-IUPAC
yl	874	876	|I-IUPAC
)	876	877	|I-IUPAC
amide	877	882	|I-IUPAC
derivatives	883	894	|B-MODIFIER
,	894	895	|O
another	896	903	|O
necessary	904	913	|O
factor	914	920	|O
to	921	923	|O
elicit	924	930	|O
the	931	934	|O
potent	935	941	|O
ACAT	942	946	|O
inhibitory	947	957	|O
activity	958	966	|O
was	967	970	|O
lipophilicity	971	984	|O
of	985	987	|O
the	988	991	|O
molecules	992	1001	|O
.	1001	1002	|O
The	1003	1006	|O
highly	1007	1013	|O
lipophilic	1014	1024	|O
acid	1025	1029	|O
amides	1030	1036	|O
N	1037	1038	|B-IUPAC
-	1038	1039	|I-IUPAC
(	1039	1040	|I-IUPAC
7	1040	1041	|I-IUPAC
-	1041	1042	|I-IUPAC
methoxy	1042	1049	|I-IUPAC
-	1049	1050	|I-IUPAC
4	1050	1051	|I-IUPAC
-	1051	1052	|I-IUPAC
oxochroman	1052	1062	|I-IUPAC
-	1062	1063	|I-IUPAC
8	1063	1064	|I-IUPAC
-	1064	1065	|I-IUPAC
yl	1065	1067	|I-IUPAC
)	1067	1068	|I-IUPAC
-	1068	1069	|I-IUPAC
2,2	1069	1072	|I-IUPAC
-	1072	1073	|I-IUPAC
dimethyldodecanamide	1073	1093	|I-IUPAC
(	1094	1095	|O
35	1095	1097	|O
)	1097	1098	|O
and	1099	1102	|O
4	1103	1104	|B-IUPAC
-	1104	1105	|I-IUPAC
[	1105	1106	|I-IUPAC
[	1106	1107	|I-IUPAC
6	1107	1108	|I-IUPAC
-	1108	1109	|I-IUPAC
(	1109	1110	|I-IUPAC
4	1110	1111	|I-IUPAC
-	1111	1112	|I-IUPAC
chlorophenoxy	1112	1125	|I-IUPAC
)	1125	1126	|I-IUPAC
hexyl	1126	1131	|I-IUPAC
]	1131	1132	|I-IUPAC
oxy	1132	1135	|I-IUPAC
]	1135	1136	|I-IUPAC
-	1136	1137	|I-IUPAC
N	1137	1138	|I-IUPAC
-	1138	1139	|I-IUPAC
(	1139	1140	|I-IUPAC
7	1140	1141	|I-IUPAC
-	1141	1142	|I-IUPAC
methoxy	1142	1149	|I-IUPAC
-	1149	1150	|I-IUPAC
4	1150	1151	|I-IUPAC
-	1151	1152	|I-IUPAC
oxochroman	1152	1162	|I-IUPAC
-	1162	1163	|I-IUPAC
8	1163	1164	|I-IUPAC
-	1164	1165	|I-IUPAC
yl	1166	1168	|I-IUPAC
)	1168	1169	|I-IUPAC
benzamide	1169	1178	|I-IUPAC
(	1179	1180	|O
63	1180	1182	|O
)	1182	1183	|O
showed	1184	1190	|O
potent	1191	1197	|O
activity	1198	1206	|O
.	1206	1207	|O
Introduction	1208	1220	|O
of	1221	1223	|O
a	1224	1225	|O
highly	1226	1232	|O
lipophilic	1233	1243	|O
alkoxy	1244	1250	|O
group	1251	1256	|O
at	1257	1259	|O
position	1260	1268	|O
7	1269	1270	|O
of	1271	1273	|O
the	1274	1277	|O
4	1278	1279	|B-IUPAC
-	1279	1280	|I-IUPAC
chromanone	1280	1290	|I-IUPAC
moiety	1291	1297	|B-MODIFIER
instead	1298	1305	|O
of	1306	1308	|O
methoxy	1309	1316	|O
group	1317	1322	|O
also	1323	1327	|O
resulted	1328	1336	|O
in	1337	1339	|O
potent	1340	1346	|O
activity	1347	1355	|O
.	1355	1356	|O
In	1357	1359	|O
this	1360	1364	|O
case	1365	1369	|O
,	1369	1370	|O
highest	1371	1378	|O
inhibitory	1379	1389	|O
activity	1390	1398	|O
was	1399	1402	|O
obtained	1403	1411	|O
by	1412	1414	|O
N	1415	1416	|B-IUPAC
-	1416	1417	|I-IUPAC
[	1417	1418	|I-IUPAC
7	1418	1419	|I-IUPAC
-	1419	1420	|I-IUPAC
(	1420	1421	|I-IUPAC
decyloxy	1421	1429	|I-IUPAC
)	1429	1430	|I-IUPAC
-	1430	1431	|I-IUPAC
4	1431	1432	|I-IUPAC
-	1432	1433	|I-IUPAC
oxochroman	1433	1443	|I-IUPAC
-	1443	1444	|I-IUPAC
8	1444	1445	|I-IUPAC
-	1445	1446	|I-IUPAC
yl	1446	1448	|I-IUPAC
]	1448	1449	|I-IUPAC
-	1449	1450	|I-IUPAC
2,2	1450	1453	|I-IUPAC
-	1453	1454	|I-IUPAC
dimethylpropanamid	1454	1472	|I-IUPAC
e	1473	1474	|I-IUPAC
(	1475	1476	|O
65	1476	1478	|O
)	1478	1479	|O
.	1479	1480	|O
The	1481	1484	|O
most	1485	1489	|O
potent	1490	1496	|O
compound	1497	1505	|O
,	1505	1506	|O
N	1507	1508	|B-IUPAC
-	1508	1509	|I-IUPAC
(	1509	1510	|I-IUPAC
7	1510	1511	|I-IUPAC
-	1511	1512	|I-IUPAC
methoxy	1512	1519	|I-IUPAC
-	1519	1520	|I-IUPAC
4	1520	1521	|I-IUPAC
-	1521	1522	|I-IUPAC
oxochroman	1522	1532	|I-IUPAC
-	1532	1533	|I-IUPAC
8	1533	1534	|I-IUPAC
-	1534	1535	|I-IUPAC
yl	1535	1537	|I-IUPAC
)	1537	1538	|I-IUPAC
-	1538	1539	|I-IUPAC
2,2	1539	1542	|I-IUPAC
-	1542	1543	|I-IUPAC
dimethyldodecanamide	1543	1563	|I-IUPAC
(	1564	1565	|O
35	1565	1567	|O
,	1567	1568	|O
TEI	1569	1572	|O
-	1572	1573	|O
6522	1573	1577	|O
)	1577	1578	|O
,	1578	1579	|O
showed	1580	1586	|O
significant	1587	1598	|O
ACAT	1599	1603	|O
inhibitory	1604	1614	|O
activity	1615	1623	|O
(	1624	1625	|O
rabbit	1625	1631	|O
small	1632	1637	|O
intestine	1638	1647	|O
IC50	1648	1652	|O
=	1653	1654	|O
13	1655	1657	|O
nM	1658	1660	|O
,	1660	1661	|O
rabbit	1662	1668	|O
liver	1669	1674	|O
IC50	1675	1679	|O
=	1680	1681	|O
16	1682	1684	|O
nM	1685	1687	|O
)	1687	1688	|O
,	1688	1689	|O
foam	1690	1694	|O
cell	1695	1699	|O
formation	1700	1709	|O
inhibitory	1710	1720	|O
activity	1721	1729	|O
(	1730	1731	|O
rat	1731	1734	|O
peritoneal	1735	1745	|O
macrophage	1746	1756	|O
IC50	1757	1761	|O
=	1762	1763	|O
160	1764	1767	|O
nM	1768	1770	|O
)	1770	1771	|O
,	1771	1772	|O
and	1773	1776	|O
extremely	1777	1786	|O
potent	1787	1793	|O
serum	1794	1799	|O
cholesterol	1800	1811	|O
-	1811	1812	|O
lowering	1812	1820	|O
activity	1821	1829	|O
in	1830	1832	|O
cholesterol	1833	1844	|O
-	1844	1845	|O
fed	1845	1848	|O
rats	1849	1853	|O
(	1854	1855	|O
61%	1855	1858	|O
at	1859	1861	|O
a	1862	1863	|O
dose	1864	1868	|O
of	1869	1871	|O
0.1	1872	1875	|O
mg	1876	1878	|O
/	1878	1879	|O
kg	1879	1881	|O
/	1881	1882	|O
day	1882	1885	|O
po	1886	1888	|O
)	1888	1889	|O
.	1889	1890	|O

### abstracts2741.txt
An	0	2	|O
enantiospecific	3	18	|O
method	19	25	|O
was	26	29	|O
developed	30	39	|O
for	40	43	|O
the	44	47	|O
synthesis	48	57	|O
of	58	60	|O
3	61	62	|B-PARTIUPAC
-	62	63	|I-PARTIUPAC
fluoromethyl	63	75	|I-PARTIUPAC
-	75	76	|I-PARTIUPAC
,	76	77	|O
3	78	79	|B-PARTIUPAC
-	79	80	|I-PARTIUPAC
hydroxymethyl	80	93	|I-PARTIUPAC
-	93	94	|I-PARTIUPAC
,	94	95	|O
and	96	99	|O
3	100	101	|B-IUPAC
-	101	102	|I-IUPAC
chloromethyl	102	114	|I-IUPAC
-	114	115	|I-IUPAC
7	115	116	|I-IUPAC
-	116	117	|O
substituted	117	128	|B-MODIFIER
-	128	129	|O
1,2,3,4	129	136	|B-IUPAC
-	136	137	|I-IUPAC
tetrahydroisoquinolines	137	160	|I-IUPAC
(	161	162	|O
THIQs	162	167	|O
)	167	168	|O
from	169	173	|O
phenylalanine	174	187	|O
.	187	188	|O
Biochemical	189	200	|O
evaluation	201	211	|O
of	212	214	|O
the	215	218	|O
enantiomers	219	230	|O
of	231	233	|O
these	234	239	|O
compounds	240	249	|O
at	250	252	|O
both	253	257	|O
PNMT	258	262	|O
and	263	266	|O
the	267	270	|O
alpha	271	276	|O
(	276	277	|O
2	277	278	|O
)	278	279	|O
-	279	280	|O
adrenoceptor	280	292	|O
indicates	293	302	|O
that	303	307	|O
both	308	312	|O
sites	313	318	|O
display	319	326	|O
similar	327	334	|O
stereoselectivity	335	352	|O
.	352	353	|O
Overall	354	361	|O
the	362	365	|O
R	366	367	|O
-	367	368	|O
enantiomer	368	378	|O
was	379	382	|O
usually	383	390	|O
the	391	394	|O
more	395	399	|O
potent	400	406	|O
enantiomer	407	417	|O
at	418	420	|O
both	421	425	|O
PNMT	426	430	|O
and	431	434	|O
the	435	438	|O
alpha	439	444	|O
(	444	445	|O
2	445	446	|O
)	446	447	|O
-	447	448	|O
adrenoceptor	448	460	|O
for	461	464	|O
these	465	470	|O
3	471	472	|B-PARTIUPAC
-	472	473	|I-PARTIUPAC
fluoromethyl	473	485	|I-PARTIUPAC
-	485	486	|I-PARTIUPAC
,	486	487	|O
3	488	489	|B-PARTIUPAC
-	489	490	|I-PARTIUPAC
hydroxymethyl	490	503	|I-PARTIUPAC
-	503	504	|I-PARTIUPAC
,	504	505	|O
and	506	509	|O
3	510	511	|B-IUPAC
-	511	512	|I-IUPAC
chloromethyl	512	524	|I-IUPAC
-	524	525	|I-IUPAC
THIQs	525	530	|I-IUPAC
.	530	531	|O
The	532	535	|O
one	536	539	|O
exception	540	549	|O
is	550	552	|O
3	553	554	|B-IUPAC
-	554	555	|I-IUPAC
hydroxymethyl	555	568	|I-IUPAC
-	568	569	|I-IUPAC
7	569	570	|I-IUPAC
-	570	571	|I-IUPAC
nitro	571	576	|I-IUPAC
-	576	577	|I-IUPAC
THIQ	577	581	|I-IUPAC
(	582	583	|O
9	583	584	|O
)	584	585	|O
,	585	586	|O
which	587	592	|O
was	593	596	|O
found	597	602	|O
to	603	605	|O
display	606	613	|O
the	614	617	|O
opposite	618	626	|O
stereoselectivity	627	644	|O
at	645	647	|O
the	648	651	|O
alpha	652	657	|O
(	657	658	|O
2	658	659	|O
)	659	660	|O
-	660	661	|O
adrenoceptor	661	673	|O
.	673	674	|O
A	675	676	|O
comparison	677	687	|O
of	688	690	|O
the	691	694	|O
PNMT	695	699	|O
inhibitory	700	710	|O
potency	711	718	|O
of	719	721	|O
the	722	725	|O
enantiomers	726	737	|O
of	738	740	|O
these	741	746	|O
3	747	748	|B-PARTIUPAC
-	748	749	|I-PARTIUPAC
fluoromethyl	749	761	|I-PARTIUPAC
-	761	762	|I-PARTIUPAC
,	762	763	|O
3	764	765	|B-PARTIUPAC
-	765	766	|I-PARTIUPAC
hydroxymethyl	766	779	|I-PARTIUPAC
-	779	780	|I-PARTIUPAC
,	780	781	|O
and	782	785	|O
3	786	787	|B-IUPAC
-	787	788	|I-IUPAC
chloromethyl	788	800	|I-IUPAC
-	800	801	|I-IUPAC
THIQs	801	806	|I-IUPAC
indicates	807	816	|O
that	817	821	|O
all	822	825	|O
of	826	828	|O
the	829	832	|O
3	833	834	|O
-	834	835	|O
substituted	835	846	|O
-	846	847	|O
THIQs	847	852	|O
displayed	853	862	|O
similar	863	870	|O
inhibitory	871	881	|O
potency	882	889	|O
for	890	893	|O
PNMT	894	898	|O
.	898	899	|O
However	900	907	|O
,	907	908	|O
the	909	912	|O
nature	913	919	|O
of	920	922	|O
the	923	926	|O
3	927	928	|O
-	928	929	|O
substituent	929	940	|O
was	941	944	|O
found	945	950	|O
to	951	953	|O
have	954	958	|O
a	959	960	|O
major	961	966	|O
effect	967	973	|O
on	974	976	|O
the	977	980	|O
alpha	981	986	|O
(	986	987	|O
2	987	988	|O
)	988	989	|O
-	989	990	|O
adrenoceptor	990	1002	|O
affinity	1003	1011	|O
of	1012	1014	|O
these	1015	1020	|O
compounds	1021	1030	|O
with	1031	1035	|O
the	1036	1039	|O
3	1040	1041	|B-PARTIUPAC
-	1041	1042	|I-PARTIUPAC
hydroxymethyl	1042	1055	|I-PARTIUPAC
-	1055	1056	|I-PARTIUPAC
and	1057	1060	|O
3	1061	1062	|B-IUPAC
-	1062	1063	|I-IUPAC
fluoromethyl	1063	1075	|I-IUPAC
-	1075	1076	|I-IUPAC
THIQs	1076	1081	|I-IUPAC
having	1082	1088	|O
the	1089	1092	|O
highest	1093	1100	|O
affinity	1101	1109	|O
and	1110	1113	|O
THIQs	1114	1119	|O
containing	1120	1130	|O
the	1131	1134	|O
3	1135	1136	|B-PARTIUPAC
-	1136	1137	|I-PARTIUPAC
chloromethyl	1137	1149	|I-PARTIUPAC
moiety	1150	1156	|B-MODIFIER
the	1157	1160	|O
least	1161	1166	|O
.	1166	1167	|O
Compounds	1168	1177	|O
R	1178	1179	|B-IUPAC
-	1179	1180	|I-IUPAC
3	1180	1181	|I-IUPAC
-	1181	1182	|I-IUPAC
fluoromethyl	1182	1194	|I-IUPAC
-	1194	1195	|I-IUPAC
7	1195	1196	|I-IUPAC
-	1196	1197	|I-IUPAC
cyano	1197	1202	|I-IUPAC
-	1202	1203	|I-IUPAC
THIQ	1203	1207	|I-IUPAC
(	1208	1209	|O
R	1209	1210	|O
-	1210	1211	|O
12	1211	1213	|O
)	1213	1214	|O
and	1215	1218	|O
R	1219	1220	|B-IUPAC
-	1220	1221	|I-IUPAC
3	1221	1222	|I-IUPAC
-	1222	1223	|I-IUPAC
fluoromethyl	1223	1235	|I-IUPAC
-	1235	1236	|I-IUPAC
7	1236	1237	|I-IUPAC
-	1237	1238	|I-IUPAC
N	1238	1239	|I-IUPAC
-	1239	1240	|I-IUPAC
(	1240	1241	|I-IUPAC
4	1241	1242	|I-IUPAC
-	1242	1243	|I-IUPAC
chlorophenyl	1243	1255	|I-IUPAC
)	1255	1256	|I-IUPAC
aminosulfonyl	1256	1269	|I-IUPAC
-	1269	1270	|I-IUPAC
THIQ	1270	1274	|I-IUPAC
(	1275	1276	|O
R	1276	1277	|O
-	1277	1278	|O
13	1278	1280	|O
)	1280	1281	|O
and	1282	1285	|O
both	1286	1290	|O
enantiomers	1291	1302	|O
of	1303	1305	|O
3	1306	1307	|B-IUPAC
-	1307	1308	|I-IUPAC
chloromethyl	1308	1320	|I-IUPAC
-	1320	1321	|I-IUPAC
7	1321	1322	|I-IUPAC
-	1322	1323	|I-IUPAC
nitro	1323	1328	|I-IUPAC
-	1328	1329	|I-IUPAC
THIQ	1329	1333	|I-IUPAC
(	1334	1335	|O
R	1335	1336	|O
-	1336	1337	|O
and	1338	1341	|O
S	1342	1343	|O
-	1343	1344	|O
30	1344	1346	|O
)	1346	1347	|O
are	1348	1351	|O
the	1352	1355	|O
most	1356	1360	|O
selective	1361	1370	|O
inhibitors	1371	1381	|O
in	1382	1384	|O
this	1385	1389	|O
study	1390	1395	|O
and	1396	1399	|O
display	1400	1407	|O
selectivities	1408	1421	|O
(	1422	1423	|O
alpha	1423	1428	|O
(	1428	1429	|O
2	1429	1430	|O
)	1430	1431	|O
-	1431	1432	|O
adrenoceptor	1432	1444	|O
K	1445	1446	|O
(	1446	1447	|O
i	1447	1448	|O
)	1448	1449	|O
/	1449	1450	|O
PNMT	1450	1454	|O
K	1455	1456	|O
(	1456	1457	|O
i	1457	1458	|O
)	1458	1459	|O
)	1459	1460	|O
greater	1461	1468	|O
than	1469	1473	|O
200	1474	1477	|O
.	1477	1478	|O
These	1479	1484	|O
compounds	1485	1494	|O
give	1495	1499	|O
important	1500	1509	|O
insight	1510	1517	|O
into	1518	1522	|O
the	1523	1526	|O
steric	1527	1533	|O
and	1534	1537	|O
stereochemical	1538	1552	|O
preferences	1553	1564	|O
of	1565	1567	|O
both	1568	1572	|O
PNMT	1573	1577	|O
and	1578	1581	|O
the	1582	1585	|O
alpha	1586	1591	|O
(	1591	1592	|O
2	1592	1593	|O
)	1593	1594	|O
-	1594	1595	|O
adrenoceptor	1595	1607	|O
,	1607	1608	|O
which	1609	1614	|O
should	1615	1621	|O
assist	1622	1628	|O
in	1629	1631	|O
the	1632	1635	|O
development	1636	1647	|O
of	1648	1650	|O
new	1651	1654	|O
PNMT	1655	1659	|O
inhibitors	1660	1670	|O
.	1670	1671	|O

### abstracts4293.txt
We	0	2	|O
have	3	7	|O
previously	8	18	|O
shown	19	24	|O
that	25	29	|O
the	30	33	|O
2	34	35	|B-IUPAC
-	35	36	|I-IUPAC
amino	36	41	|I-IUPAC
-	41	42	|I-IUPAC
3	42	43	|I-IUPAC
-	43	44	|I-IUPAC
(	44	45	|I-IUPAC
3	45	46	|I-IUPAC
-	46	47	|I-IUPAC
hydroxy	47	54	|I-IUPAC
-	54	55	|I-IUPAC
5	55	56	|I-IUPAC
-	56	57	|I-IUPAC
methyl	57	63	|I-IUPAC
-	63	64	|I-IUPAC
4	64	65	|I-IUPAC
-	65	66	|I-IUPAC
isoxazolyl	66	76	|I-IUPAC
)	76	77	|I-IUPAC
propionic	77	86	|I-IUPAC
acid	87	91	|I-IUPAC
(	92	93	|O
AMPA	93	97	|O
)	97	98	|O
receptor	99	107	|O
agonist	108	115	|O
,	115	116	|O
2	117	118	|B-IUPAC
-	118	119	|I-IUPAC
amino	119	124	|I-IUPAC
-	124	125	|I-IUPAC
3	125	126	|I-IUPAC
-	126	127	|I-IUPAC
(	127	128	|I-IUPAC
3	128	129	|I-IUPAC
-	129	130	|I-IUPAC
carboxy	130	137	|I-IUPAC
-	137	138	|I-IUPAC
5	138	139	|I-IUPAC
-	139	140	|I-IUPAC
methyl	140	146	|I-IUPAC
-	146	147	|I-IUPAC
4	147	148	|I-IUPAC
-	148	149	|I-IUPAC
isoxazolyl	149	159	|I-IUPAC
)	159	160	|I-IUPAC
propionic	160	169	|I-IUPAC
acid	170	174	|I-IUPAC
(	175	176	|O
ACPA	176	180	|O
,	180	181	|O
2	182	183	|O
)	183	184	|O
,	184	185	|O
binds	186	191	|O
to	192	194	|O
AMPA	195	199	|O
receptors	200	209	|O
in	210	212	|O
a	213	214	|O
manner	215	221	|O
different	222	231	|O
from	232	236	|O
that	237	241	|O
of	242	244	|O
AMPA	245	249	|O
(	250	251	|O
1	251	252	|O
)	252	253	|O
itself	254	260	|O
and	261	264	|O
that	265	269	|O
2	270	271	|O
,	271	272	|O
in	273	275	|O
contrast	276	284	|O
to	285	287	|O
1	288	289	|O
,	289	290	|O
also	291	295	|O
binds	296	301	|O
to	302	304	|O
kainic	305	311	|O
acid	312	316	|O
receptor	317	325	|O
sites	326	331	|O
.	331	332	|O
To	333	335	|O
elucidate	336	345	|O
the	346	349	|O
structural	350	360	|O
requirements	361	373	|O
for	374	377	|O
selective	378	387	|O
activation	388	398	|O
of	399	401	|O
the	402	405	|O
site	406	410	|O
/	410	411	|O
conformation	411	423	|O
of	424	426	|O
AMPA	427	431	|O
receptors	432	441	|O
recognized	442	452	|O
by	453	455	|O
2	456	457	|O
,	457	458	|O
a	459	460	|O
number	461	467	|O
of	468	470	|O
isosteric	471	480	|O
analogues	481	490	|O
of	491	493	|O
2	494	495	|O
have	496	500	|O
now	501	504	|O
been	505	509	|O
synthesized	510	521	|O
and	522	525	|O
pharmacologically	526	543	|O
characterized	544	557	|O
.	557	558	|O
The	559	562	|O
compound	563	571	|O
2	572	573	|B-IUPAC
-	573	574	|I-IUPAC
amino	574	579	|I-IUPAC
-	579	580	|I-IUPAC
3	580	581	|I-IUPAC
-	581	582	|I-IUPAC
(	582	583	|I-IUPAC
5	583	584	|I-IUPAC
-	584	585	|I-IUPAC
carboxy	585	592	|I-IUPAC
-	592	593	|I-IUPAC
3	593	594	|I-IUPAC
-	594	595	|I-IUPAC
methoxy	595	602	|I-IUPAC
-	602	603	|I-IUPAC
4	603	604	|I-IUPAC
-	604	605	|I-IUPAC
isoxazolyl	605	615	|I-IUPAC
)	615	616	|I-IUPAC
propionic	616	625	|I-IUPAC
acid	626	630	|I-IUPAC
(	631	632	|O
3a	632	634	|O
)	634	635	|O
(	636	637	|O
IC	637	639	|O
(	639	640	|O
50	640	642	|O
)	642	643	|O
=	644	645	|O
0.11	646	650	|O
microM	651	657	|O
;	657	658	|O
EC	659	661	|O
(	661	662	|O
50	662	664	|O
)	664	665	|O
=	666	667	|O
1.2	668	671	|O
microM	672	678	|O
)	678	679	|O
,	679	680	|O
which	681	686	|O
is	687	689	|O
a	690	691	|O
regioisostere	692	705	|O
of	706	708	|O
2	709	710	|O
with	711	715	|O
a	716	717	|O
methoxy	718	725	|O
group	726	731	|O
substituted	732	743	|O
for	744	747	|O
the	748	751	|O
methyl	752	758	|B-IUPAC
group	759	764	|B-MODIFIER
,	764	765	|O
was	766	769	|O
approximately	770	783	|O
equipotent	784	794	|O
with	795	799	|O
2	800	801	|O
(	802	803	|O
IC	803	805	|O
(	805	806	|O
50	806	808	|O
)	808	809	|O
=	810	811	|O
0.020	812	817	|O
microM	818	824	|O
;	824	825	|O
EC	826	828	|O
(	828	829	|O
50	829	831	|O
)	831	832	|O
=	833	834	|O
1.0	835	838	|O
microM	839	845	|O
)	845	846	|O
as	847	849	|O
an	850	852	|O
inhibitor	853	862	|O
of	863	865	|O
[	866	867	|O
(	867	868	|O
3	868	869	|O
)	869	870	|O
H	870	871	|O
]	871	872	|O
AMPA	872	876	|O
binding	877	884	|O
and	885	888	|O
as	889	891	|O
an	892	894	|O
AMPA	895	899	|O
agonist	900	907	|O
,	907	908	|O
respectively	909	921	|O
,	921	922	|O
whereas	923	930	|O
the	931	934	|O
corresponding	935	948	|O
3	949	950	|O
-	950	951	|O
ethoxy	951	957	|O
analogue	958	966	|O
3b	967	969	|O
(	970	971	|O
IC	971	973	|O
(	973	974	|O
50	974	976	|O
)	976	977	|O
=	978	979	|O
1.0	980	983	|O
microM	984	990	|O
;	990	991	|O
EC	992	994	|O
(	994	995	|O
50	995	997	|O
)	997	998	|O
=	999	1000	|O
4.8	1001	1004	|O
microM	1005	1011	|O
)	1011	1012	|O
was	1013	1016	|O
slightly	1017	1025	|O
weaker	1026	1032	|O
.	1032	1033	|O
The	1034	1037	|O
analogues	1038	1047	|O
3c	1048	1050	|O
-	1050	1051	|O
e	1051	1052	|O
,	1052	1053	|O
containing	1054	1064	|O
C3	1065	1067	|O
alkoxy	1068	1074	|O
groups	1075	1081	|O
,	1081	1082	|O
were	1083	1087	|O
an	1088	1090	|O
order	1091	1096	|O
of	1097	1099	|O
magnitude	1100	1109	|O
weaker	1110	1116	|O
than	1117	1121	|O
3b	1122	1124	|O
,	1124	1125	|O
whereas	1126	1133	|O
the	1134	1137	|O
additional	1138	1148	|O
steric	1149	1155	|O
bulk	1156	1160	|O
of	1161	1163	|O
the	1164	1167	|O
alkoxy	1168	1174	|O
groups	1175	1181	|O
of	1182	1184	|O
3f	1185	1187	|O
-	1187	1188	|O
i	1188	1189	|O
or	1190	1192	|O
the	1193	1196	|O
presence	1197	1205	|O
of	1206	1208	|O
an	1209	1211	|O
acidic	1212	1218	|O
hydroxyl	1219	1227	|O
group	1228	1233	|O
at	1234	1236	|O
the	1237	1240	|O
3	1241	1242	|O
-	1242	1243	|O
position	1243	1251	|O
of	1252	1254	|O
the	1255	1258	|O
isoxazole	1259	1268	|O
ring	1269	1273	|O
of	1274	1276	|O
3j	1277	1279	|O
prevented	1280	1289	|O
interaction	1290	1301	|O
with	1302	1306	|O
AMPA	1307	1311	|O
receptor	1312	1320	|O
sites	1321	1326	|O
.	1326	1327	|O
The	1328	1331	|O
2	1332	1333	|B-IUPAC
-	1333	1334	|I-IUPAC
amino	1334	1339	|I-IUPAC
-	1339	1340	|I-IUPAC
3	1340	1341	|I-IUPAC
-	1341	1342	|I-IUPAC
(	1342	1343	|I-IUPAC
2	1343	1344	|I-IUPAC
-	1344	1345	|I-IUPAC
alkyl	1345	1350	|I-IUPAC
-	1350	1351	|I-IUPAC
5	1351	1352	|I-IUPAC
-	1352	1353	|I-IUPAC
carboxy	1353	1360	|I-IUPAC
-	1360	1361	|I-IUPAC
3	1361	1362	|I-IUPAC
-	1362	1363	|I-IUPAC
oxo	1363	1366	|I-IUPAC
-	1366	1367	|I-IUPAC
4	1367	1368	|I-IUPAC
-	1368	1369	|I-IUPAC
isoxazolyl	1369	1379	|I-IUPAC
)	1379	1380	|I-IUPAC
propionic	1380	1389	|I-IUPAC
acids	1390	1395	|I-IUPAC
4a	1396	1398	|O
,	1398	1399	|O
b	1399	1400	|O
,	1400	1401	|O
i	1402	1403	|O
,	1403	1404	|O
which	1405	1410	|O
are	1411	1414	|O
regioisosteric	1415	1429	|O
analogues	1430	1439	|O
of	1440	1442	|O
3a	1443	1445	|O
,	1445	1446	|O
b	1446	1447	|O
,	1447	1448	|O
i	1448	1449	|O
,	1449	1450	|O
showed	1451	1457	|O
negligible	1458	1468	|O
interaction	1469	1480	|O
with	1481	1485	|O
AMPA	1486	1490	|O
recognition	1491	1502	|O
sites	1503	1508	|O
.	1508	1509	|O
Similarly	1510	1519	|O
,	1519	1520	|O
replacement	1521	1532	|O
of	1533	1535	|O
the	1536	1539	|O
carboxyl	1540	1548	|B-IUPAC
group	1549	1554	|B-MODIFIER
of	1555	1557	|O
3b	1558	1560	|O
by	1561	1563	|O
isosteric	1564	1573	|O
tetrazolyl	1574	1584	|B-IUPAC
or	1585	1587	|O
1,2,4	1588	1593	|B-IUPAC
-	1593	1594	|I-IUPAC
triazolyl	1594	1603	|I-IUPAC
groups	1604	1610	|B-MODIFIER
to	1611	1613	|O
give	1614	1618	|O
5	1619	1620	|O
and	1621	1624	|O
6	1625	1626	|O
,	1626	1627	|O
respectively	1628	1640	|O
,	1640	1641	|O
or	1642	1644	|O
conversion	1645	1655	|O
of	1656	1658	|O
3b	1659	1661	|O
into	1662	1666	|O
analogue	1667	1675	|O
7	1676	1677	|O
,	1677	1678	|O
in	1679	1681	|O
which	1682	1687	|O
the	1688	1691	|O
diaminosquaric	1692	1706	|O
acid	1707	1711	|O
group	1712	1717	|O
has	1718	1721	|O
been	1722	1726	|O
bioisosterically	1727	1743	|O
substituted	1744	1755	|O
for	1756	1759	|O
the	1760	1763	|O
alpha	1764	1769	|B-IUPAC
-	1769	1770	|I-IUPAC
aminocarboxylic	1770	1785	|I-IUPAC
acid	1786	1790	|I-IUPAC
unit	1791	1795	|O
,	1795	1796	|O
provided	1797	1805	|O
compounds	1806	1815	|O
completely	1816	1826	|O
devoid	1827	1833	|O
of	1834	1836	|O
effect	1837	1843	|O
at	1844	1846	|O
AMPA	1847	1851	|O
receptors	1852	1861	|O
.	1861	1862	|O
In	1863	1865	|O
contrast	1866	1874	|O
to	1875	1877	|O
the	1878	1881	|O
parent	1882	1888	|O
compound	1889	1897	|O
ACPA	1898	1902	|O
(	1903	1904	|O
2	1904	1905	|O
)	1905	1906	|O
(	1907	1908	|O
IC	1908	1910	|O
(	1910	1911	|O
50	1911	1913	|O
)	1913	1914	|O
=	1915	1916	|O
6.3	1917	1920	|O
microM	1921	1927	|O
)	1927	1928	|O
,	1928	1929	|O
none	1930	1934	|O
of	1935	1937	|O
the	1938	1941	|O
analogues	1942	1951	|O
described	1952	1961	|O
showed	1962	1968	|O
detectable	1969	1979	|O
inhibitory	1980	1990	|O
effect	1991	1997	|O
on	1998	2000	|O
[	2001	2002	|B-IUPAC
(	2002	2003	|I-IUPAC
3	2003	2004	|I-IUPAC
)	2004	2005	|I-IUPAC
H	2005	2006	|I-IUPAC
]	2006	2007	|I-IUPAC
kainic	2007	2013	|I-IUPAC
acid	2014	2018	|I-IUPAC
receptor	2019	2027	|O
binding	2028	2035	|O
.	2035	2036	|O

### abstracts2913.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
4	12	13	|B-IUPAC
(	13	14	|I-IUPAC
5	14	15	|I-IUPAC
)	15	16	|I-IUPAC
-	16	17	|I-IUPAC
iodo	17	21	|I-IUPAC
-	21	22	|I-IUPAC
5	22	23	|I-IUPAC
(	23	24	|I-IUPAC
4	24	25	|I-IUPAC
)	25	26	|I-IUPAC
-	26	27	|I-IUPAC
nitro	27	32	|I-IUPAC
-	32	33	|I-IUPAC
1	33	34	|I-IUPAC
-	34	35	|O
substituted	35	46	|B-MODIFIER
-	46	47	|O
imidazoles	47	57	|B-IUPAC
has	58	61	|O
been	62	66	|O
synthesized	67	78	|O
and	79	82	|O
tested	83	89	|O
for	90	93	|O
their	94	99	|O
ability	100	107	|O
to	108	110	|O
selectively	111	122	|O
radiosensitize	123	137	|O
hypoxic	138	145	|O
Chinese	146	153	|O
hamster	154	161	|O
cells	162	167	|O
(	168	169	|O
V	169	170	|O
-	170	171	|O
79	171	173	|O
)	173	174	|O
to	175	177	|O
the	178	181	|O
lethal	182	188	|O
effect	189	195	|O
of	196	198	|O
radiation	199	208	|O
.	208	209	|O
The	210	213	|O
reaction	214	222	|O
of	223	225	|O
4	226	227	|B-IUPAC
(	227	228	|I-IUPAC
5	228	229	|I-IUPAC
)	229	230	|I-IUPAC
-	230	231	|I-IUPAC
iodo	231	235	|I-IUPAC
-	235	236	|I-IUPAC
5	236	237	|I-IUPAC
-	237	238	|I-IUPAC
(	238	239	|I-IUPAC
4	239	240	|I-IUPAC
)	240	241	|I-IUPAC
-	241	242	|I-IUPAC
nitroimidazole	242	256	|I-IUPAC
with	257	261	|O
1,2	262	265	|B-IUPAC
-	265	266	|I-IUPAC
epoxy	266	271	|I-IUPAC
-	271	272	|I-IUPAC
3	272	273	|I-IUPAC
-	273	274	|I-IUPAC
methoxypropane	274	288	|I-IUPAC
and	289	292	|O
ethyl	293	298	|B-IUPAC
alpha	299	304	|I-IUPAC
-	304	305	|I-IUPAC
chloroacetate	305	318	|I-IUPAC
produced	319	327	|O
two	328	331	|O
isomeric	332	340	|O
products	341	349	|O
in	350	352	|O
each	353	357	|O
case	358	362	|O
,	362	363	|O
which	364	369	|O
were	370	374	|O
identified	375	385	|O
by	386	388	|O
their	389	394	|O
NMR	395	398	|O
spectra	399	406	|O
.	406	407	|O
The	408	411	|O
ethyl	412	417	|O
esters	418	424	|O
were	425	429	|O
further	430	437	|O
reacted	438	445	|O
with	446	450	|O
3	451	452	|B-IUPAC
-	452	453	|I-IUPAC
picolylamine	453	465	|I-IUPAC
to	466	468	|O
produce	469	476	|O
corresponding	477	490	|O
amides	491	497	|O
.	497	498	|O
The	499	502	|O
5	503	504	|B-IUPAC
-	504	505	|I-IUPAC
iodo	505	509	|I-IUPAC
-	509	510	|I-IUPAC
4	510	511	|I-IUPAC
-	511	512	|I-IUPAC
nitroimidazole	512	526	|I-IUPAC
-	526	527	|I-IUPAC
1	527	528	|I-IUPAC
-	528	529	|I-IUPAC
N	529	530	|I-IUPAC
-	530	531	|I-IUPAC
(	531	532	|I-IUPAC
3	532	533	|I-IUPAC
-	533	534	|I-IUPAC
picolyl	534	541	|I-IUPAC
)	541	542	|I-IUPAC
acetamide	542	551	|I-IUPAC
on	552	554	|O
further	555	562	|O
reaction	563	571	|O
with	572	576	|O
m	577	578	|B-IUPAC
-	578	579	|I-IUPAC
chloroperbenzoic	579	595	|I-IUPAC
acid	596	600	|I-IUPAC
produced	601	609	|O
the	610	613	|O
corresponding	614	627	|O
N	628	629	|O
-	629	630	|O
oxide	630	635	|O
.	635	636	|O
These	637	642	|O
compounds	643	652	|O
were	653	657	|O
generally	658	667	|O
more	668	672	|O
toxic	673	678	|O
to	679	681	|O
V	682	683	|O
-	683	684	|O
79	684	686	|O
cells	687	692	|O
than	693	697	|O
the	698	701	|O
2	702	703	|B-IUPAC
-	703	704	|I-IUPAC
nitroimidazole	704	718	|I-IUPAC
derivatives	719	730	|B-MODIFIER
and	731	734	|O
were	735	739	|O
found	740	745	|O
to	746	748	|O
be	749	751	|O
more	752	756	|O
effective	757	766	|O
radiosensitizers	767	783	|O
in	784	786	|O
vitro	787	792	|O
.	792	793	|O
The	794	797	|O
5	798	799	|B-IUPAC
-	799	800	|I-IUPAC
iodo	800	804	|I-IUPAC
-	804	805	|I-IUPAC
4	805	806	|I-IUPAC
-	806	807	|I-IUPAC
nitroimidazole	807	821	|I-IUPAC
derivatives	822	833	|B-MODIFIER
were	834	838	|O
more	839	843	|O
efficient	844	853	|O
as	854	856	|O
sensitizers	857	868	|O
than	869	873	|O
the	874	877	|O
4	878	879	|B-IUPAC
-	879	880	|I-IUPAC
iodo	880	884	|I-IUPAC
-	884	885	|I-IUPAC
5	885	886	|I-IUPAC
-	886	887	|I-IUPAC
nitroimidazole	887	901	|I-IUPAC
derivatives	902	913	|B-MODIFIER
,	913	914	|O
and	915	918	|O
the	919	922	|O
sensitizing	923	934	|O
efficiency	935	945	|O
of	946	948	|O
this	949	953	|O
class	954	959	|O
of	960	962	|O
agents	963	969	|O
was	970	973	|O
found	974	979	|O
to	980	982	|O
have	983	987	|O
significant	988	999	|O
correlation	1000	1011	|O
with	1012	1016	|O
their	1017	1022	|O
partition	1023	1032	|O
coefficients	1033	1045	|O
.	1045	1046	|O

### abstracts464.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
PGE2	12	16	|O
,	16	17	|O
16,16	18	23	|B-IUPAC
-	23	24	|I-IUPAC
dimethyl	24	32	|I-IUPAC
-	32	33	|I-IUPAC
PGE2	33	37	|I-IUPAC
,	37	38	|O
and	39	42	|O
PGF2	43	47	|O
alpha	48	53	|O
analogues	54	63	|O
modified	64	72	|O
at	73	75	|O
the	76	79	|O
carboxyl	80	88	|O
terminus	89	97	|O
with	98	102	|O
tetrazole	103	112	|O
,	112	113	|O
amide	114	119	|O
,	119	120	|O
acylurea	121	129	|O
,	129	130	|O
imide	131	136	|O
,	136	137	|O
and	138	141	|O
sulfonimide	142	153	|O
functionalities	154	169	|O
was	170	173	|O
evaluated	174	183	|O
for	184	187	|O
uterine	188	195	|O
stimulant	196	205	|O
,	205	206	|O
bronchodilator	207	221	|O
,	221	222	|O
hypotensive	223	234	|O
,	234	235	|O
gastric	236	243	|O
antisecretory	244	257	|O
,	257	258	|O
and	259	262	|O
diarrheal	263	272	|O
activity	273	281	|O
.	281	282	|O
These	283	288	|O
compounds	289	298	|O
were	299	303	|O
prepared	304	312	|O
by	313	315	|O
modification	316	328	|O
of	329	331	|O
the	332	335	|O
Corey	336	341	|O
prostaglandin	342	355	|O
synthesis	356	365	|O
utilizing	366	375	|O
as	376	378	|O
a	379	380	|O
key	381	384	|O
step	385	389	|O
condensation	390	402	|O
of	403	405	|O
known	406	411	|O
hemiacetals	412	423	|O
with	424	428	|O
the	429	432	|O
ylide	433	438	|O
derived	439	446	|O
from	447	451	|O
the	452	455	|O
requisite	456	465	|O
substituted	466	477	|O
phosphonium	478	489	|O
salts	490	495	|O
.	495	496	|O
Structure	497	506	|O
-	506	507	|O
-	507	508	|O
activity	508	516	|O
relationships	517	530	|O
suggest	531	538	|O
that	539	543	|O
a	544	545	|O
proton	546	552	|O
at	553	555	|O
the	556	559	|O
C	560	561	|O
-	561	562	|O
1	562	563	|O
position	564	572	|O
appears	573	580	|O
necessary	581	590	|O
for	591	594	|O
agonist	595	602	|O
activity	603	611	|O
and	612	615	|O
the	616	619	|O
acidity	620	627	|O
of	628	630	|O
this	631	635	|O
proton	636	642	|O
has	643	646	|O
a	647	648	|O
relatively	649	659	|O
greater	660	667	|O
influence	668	677	|O
on	678	680	|O
activity	681	689	|O
than	690	694	|O
pendant	695	702	|O
steric	703	709	|O
bulk	710	714	|O
.	714	715	|O
Noteworthy	716	726	|O
are	727	730	|O
the	731	734	|O
tissue	735	741	|O
-	741	742	|O
selective	742	751	|O
bronchodilator	752	766	|O
activity	767	775	|O
of	776	778	|O
N	779	780	|B-IUPAC
-	780	781	|I-IUPAC
acetyl	781	787	|I-IUPAC
-	787	788	|I-IUPAC
PGE2	788	792	|I-IUPAC
-	792	793	|I-IUPAC
carboxamide	793	804	|I-IUPAC
and	805	808	|O
the	809	812	|O
selectivity	813	824	|O
for	825	828	|O
uterine	829	836	|O
tissue	837	843	|O
of	844	846	|O
N	847	848	|B-IUPAC
-	848	849	|I-IUPAC
methanesulfonyl	849	864	|I-IUPAC
-	864	865	|I-IUPAC
PGE2	865	869	|I-IUPAC
-	869	870	|I-IUPAC
carboxamide	870	881	|I-IUPAC
,	881	882	|O
2	883	884	|B-IUPAC
-	884	885	|I-IUPAC
decarboxy	885	894	|I-IUPAC
-	894	895	|I-IUPAC
2	895	896	|I-IUPAC
-	896	897	|I-IUPAC
(	897	898	|I-IUPAC
tetrazol	898	906	|I-IUPAC
-	906	907	|I-IUPAC
5	907	908	|I-IUPAC
-	908	909	|I-IUPAC
yl	909	911	|I-IUPAC
)	911	912	|I-IUPAC
-	912	913	|I-IUPAC
16,16	913	918	|I-IUPAC
-	918	919	|I-IUPAC
dimethyl	919	927	|I-IUPAC
-	927	928	|I-IUPAC
PGE2	928	932	|I-IUPAC
,	932	933	|O
N	934	935	|B-IUPAC
-	935	936	|I-IUPAC
acetyl	936	942	|I-IUPAC
-	942	943	|I-IUPAC
16,16	943	948	|I-IUPAC
-	948	949	|I-IUPAC
dimethyl	949	957	|I-IUPAC
-	957	958	|I-IUPAC
PGE2	958	962	|I-IUPAC
-	962	963	|I-IUPAC
carboxamide	963	974	|I-IUPAC
,	974	975	|O
and	976	979	|O
N	980	981	|B-IUPAC
-	981	982	|I-IUPAC
methanesulfonyl	982	997	|I-IUPAC
-	997	998	|I-IUPAC
16,16	998	1003	|I-IUPAC
-	1003	1004	|I-IUPAC
dimethyl	1004	1012	|I-IUPAC
-	1012	1013	|I-IUPAC
PGE2	1013	1017	|I-IUPAC
-	1017	1018	|I-IUPAC
carboxamide	1018	1029	|I-IUPAC
.	1029	1030	|O

### abstracts1031.txt
The	0	3	|O
retinoic	4	12	|O
acid	13	17	|O
receptors	18	27	|O
(	28	29	|O
RARs	29	33	|O
)	33	34	|O
transduce	35	44	|O
retinoid	45	53	|O
dependant	54	63	|O
gene	64	68	|O
regulation	69	79	|O
,	79	80	|O
and	81	84	|O
many	85	89	|O
biological	90	100	|O
effects	101	108	|O
of	109	111	|O
retinoids	112	121	|O
are	122	125	|O
mediated	126	134	|O
through	135	142	|O
binding	143	150	|O
and	151	154	|O
activation	155	165	|O
of	166	168	|O
three	169	174	|O
closely	175	182	|O
related	183	190	|O
receptor	191	199	|O
subtypes	200	208	|O
(	209	210	|O
RAR	210	213	|O
alpha	214	219	|O
,	219	220	|O
RAR	221	224	|O
beta	225	229	|O
,	229	230	|O
and	231	234	|O
RAR	235	238	|O
gamma	239	244	|O
)	244	245	|O
.	245	246	|O
In	247	249	|O
order	250	255	|O
to	256	258	|O
investigate	259	270	|O
the	271	274	|O
role	275	279	|O
of	280	282	|O
receptor	283	291	|O
subtypes	292	300	|O
,	300	301	|O
we	302	304	|O
have	305	309	|O
carried	310	317	|O
out	318	321	|O
a	322	323	|O
chemical	324	332	|O
synthesis	333	342	|O
program	343	350	|O
to	351	353	|O
seek	354	358	|O
selective	359	368	|O
retinoids	369	378	|O
for	379	382	|O
these	383	388	|O
receptors	389	398	|O
.	398	399	|O
We	400	402	|O
measured	403	411	|O
receptor	412	420	|O
binding	421	428	|O
affinity	429	437	|O
using	438	443	|O
recombinant	444	455	|O
RAR	456	459	|O
alpha	460	465	|O
,	465	466	|O
-	467	468	|O
beta	468	472	|O
,	472	473	|O
and	474	477	|O
-	478	479	|O
gamma	479	484	|O
proteins	485	493	|O
and	494	497	|O
assessed	498	506	|O
cellular	507	515	|O
differentiating	516	531	|O
activity	532	540	|O
in	541	543	|O
F9	544	546	|O
murine	547	553	|O
teratocarcinoma	554	569	|O
cells	570	575	|O
(	576	577	|O
F9	577	579	|O
cells	580	585	|O
)	585	586	|O
.	586	587	|O
This	588	592	|O
research	593	601	|O
has	602	605	|O
identified	606	616	|O
the	617	620	|O
4	621	622	|B-MODIFIER
-	622	623	|I-MODIFIER
substituted	623	634	|I-MODIFIER
-	634	635	|O
3	635	636	|B-IUPAC
-	636	637	|I-IUPAC
(	637	638	|I-IUPAC
1	638	639	|I-IUPAC
-	639	640	|I-IUPAC
adamantyl	640	649	|I-IUPAC
)	649	650	|I-IUPAC
phenyl	650	656	|I-IUPAC
moiety	657	663	|B-MODIFIER
as	664	666	|O
a	667	668	|O
new	669	672	|O
pharmacophore	673	686	|O
which	687	692	|O
can	693	696	|O
replace	697	704	|O
the	705	708	|O
beta	709	713	|B-IUPAC
-	713	714	|I-IUPAC
cyclogeranylidene	714	731	|I-IUPAC
ring	732	736	|B-MODIFIER
of	737	739	|O
the	740	743	|O
naturally	744	753	|O
occurring	754	763	|O
all	764	767	|B-IUPAC
-	767	768	|I-IUPAC
trans	768	773	|I-IUPAC
-	773	774	|I-IUPAC
retinoic	774	782	|I-IUPAC
acid	783	787	|I-IUPAC
.	787	788	|O
Two	789	792	|O
chemical	793	801	|O
series	802	808	|O
derived	809	816	|O
from	817	821	|O
the	822	825	|O
general	826	833	|O
structures	834	844	|O
6	845	846	|B-IUPAC
-	846	847	|I-IUPAC
(	847	848	|I-IUPAC
3	848	849	|I-IUPAC
-	849	850	|I-IUPAC
tertioalkylphenyl	850	867	|I-IUPAC
)	867	868	|I-IUPAC
-	868	869	|I-IUPAC
2	869	870	|I-IUPAC
-	870	871	|I-IUPAC
naphthoic	871	880	|I-IUPAC
acid	881	885	|I-IUPAC
(	886	887	|O
series	887	893	|O
I	894	895	|O
)	895	896	|O
and	897	900	|O
4	901	902	|B-IUPAC
-	902	903	|I-IUPAC
[	903	904	|I-IUPAC
(	904	905	|I-IUPAC
E	905	906	|I-IUPAC
)	906	907	|I-IUPAC
-	907	908	|I-IUPAC
2	908	909	|I-IUPAC
-	909	910	|I-IUPAC
(	910	911	|I-IUPAC
3	911	912	|I-IUPAC
-	912	913	|I-IUPAC
tertioalkylphenyl	913	930	|I-IUPAC
)	930	931	|I-IUPAC
propenyl	931	939	|I-IUPAC
]	939	940	|I-IUPAC
benzoic	940	947	|I-IUPAC
acid	948	952	|I-IUPAC
(	953	954	|O
series	954	960	|O
II	961	963	|O
)	963	964	|O
were	965	969	|O
developed	970	979	|O
.	979	980	|O
In	981	983	|O
particular	984	994	|O
,	994	995	|O
we	996	998	|O
have	999	1003	|O
obtained	1004	1012	|O
the	1013	1016	|O
RAR	1017	1020	|O
gamma	1021	1026	|O
selective	1027	1036	|O
derivatives	1037	1048	|O
6	1049	1050	|B-IUPAC
-	1050	1051	|I-IUPAC
[	1051	1052	|I-IUPAC
3	1052	1053	|I-IUPAC
-	1053	1054	|I-IUPAC
(	1054	1055	|I-IUPAC
1	1055	1056	|I-IUPAC
-	1056	1057	|I-IUPAC
adamantyl	1057	1066	|I-IUPAC
)	1066	1067	|I-IUPAC
-	1067	1068	|I-IUPAC
4	1068	1069	|I-IUPAC
-	1069	1070	|I-IUPAC
hydroxyphenyl	1070	1083	|I-IUPAC
]	1083	1084	|I-IUPAC
-	1084	1085	|I-IUPAC
2	1085	1086	|I-IUPAC
-	1086	1087	|I-IUPAC
naphthoic	1087	1096	|I-IUPAC
acid	1097	1101	|I-IUPAC
(	1102	1103	|O
7	1103	1104	|O
)	1104	1105	|O
[	1106	1107	|O
Ki	1107	1109	|O
(	1109	1110	|O
RAR	1110	1113	|O
alpha	1114	1119	|O
)	1119	1120	|O
=	1121	1122	|O
6500	1123	1127	|O
nM	1128	1130	|O
,	1130	1131	|O
Ki	1132	1134	|O
(	1134	1135	|O
RAR	1135	1138	|O
beta	1139	1143	|O
)	1143	1144	|O
=	1145	1146	|O
2480	1147	1151	|O
nM	1152	1154	|O
,	1154	1155	|O
Ki	1156	1158	|O
(	1158	1159	|O
RAR	1159	1162	|O
gamma	1163	1168	|O
)	1168	1169	|O
=	1170	1171	|O
77	1172	1174	|O
nM	1175	1177	|O
]	1177	1178	|O
and	1179	1182	|O
4	1183	1184	|B-IUPAC
-	1184	1185	|I-IUPAC
[	1185	1186	|I-IUPAC
(	1186	1187	|I-IUPAC
E	1187	1188	|I-IUPAC
)	1188	1189	|I-IUPAC
-	1189	1190	|I-IUPAC
2	1190	1191	|I-IUPAC
-	1191	1192	|I-IUPAC
[	1192	1193	|I-IUPAC
3	1193	1194	|I-IUPAC
-	1194	1195	|I-IUPAC
(	1195	1196	|I-IUPAC
1	1196	1197	|I-IUPAC
-	1197	1198	|I-IUPAC
adamantyl	1198	1207	|I-IUPAC
)	1207	1208	|I-IUPAC
-	1208	1209	|I-IUPAC
4	1209	1210	|I-IUPAC
-	1210	1211	|I-IUPAC
hydroxyphenyl	1211	1224	|I-IUPAC
]	1224	1225	|I-IUPAC
propenyl	1225	1233	|I-IUPAC
]	1233	1234	|I-IUPAC
benzoic	1234	1241	|I-IUPAC
acid	1242	1246	|I-IUPAC
(	1247	1248	|O
19	1248	1250	|O
)	1250	1251	|O
[	1252	1253	|O
Ki	1253	1255	|O
(	1255	1256	|O
RAR	1256	1259	|O
alpha	1260	1265	|O
)	1265	1266	|O
=	1267	1268	|O
1,144	1269	1274	|O
nM	1275	1277	|O
,	1277	1278	|O
Ki	1279	1281	|O
(	1281	1282	|O
RAR	1282	1285	|O
beta	1286	1290	|O
)	1290	1291	|O
=	1292	1293	|O
1245	1294	1298	|O
nM	1299	1301	|O
,	1301	1302	|O
Ki	1303	1305	|O
(	1305	1306	|O
RAR	1306	1309	|O
gamma	1310	1315	|O
)	1315	1316	|O
=	1317	1318	|O
53	1319	1321	|O
nM	1322	1324	|O
]	1324	1325	|O
.	1325	1326	|O
In	1327	1329	|O
series	1330	1336	|O
I	1337	1338	|O
,	1338	1339	|O
the	1340	1343	|O
presence	1344	1352	|O
of	1353	1355	|O
a	1356	1357	|O
phenol	1358	1364	|B-PARTIUPAC
group	1365	1370	|B-MODIFIER
,	1370	1371	|O
irrespective	1372	1384	|O
of	1385	1387	|O
the	1388	1391	|O
nature	1392	1398	|O
of	1399	1401	|O
tertioalkyl	1402	1413	|B-PARTIUPAC
group	1414	1419	|B-MODIFIER
,	1419	1420	|O
imparted	1421	1429	|O
at	1430	1432	|O
least	1433	1438	|O
partial	1439	1446	|O
RAR	1447	1450	|O
gamma	1451	1456	|O
selectivity	1457	1468	|O
,	1468	1469	|O
whereas	1470	1477	|O
in	1478	1480	|O
series	1481	1487	|O
II	1488	1490	|O
,	1490	1491	|O
the	1492	1495	|O
presence	1496	1504	|O
of	1505	1507	|O
both	1508	1512	|O
adamantyl	1513	1522	|B-PARTIUPAC
and	1523	1526	|O
phenol	1527	1533	|B-PARTIUPAC
groups	1534	1540	|B-MODIFIER
is	1541	1543	|O
needed	1544	1550	|O
to	1551	1553	|O
confer	1554	1560	|O
RAR	1561	1564	|O
gamma	1565	1570	|O
selectivity	1571	1582	|O
.	1582	1583	|O
The	1584	1587	|O
RAR	1588	1591	|O
gamma	1592	1597	|O
selective	1598	1607	|O
ligands	1608	1615	|O
induce	1616	1622	|O
differentiation	1623	1638	|O
in	1639	1641	|O
F9	1642	1644	|O
cells	1645	1650	|O
(	1651	1652	|O
7	1652	1653	|O
,	1653	1654	|O
AC50	1655	1659	|O
=	1660	1661	|O
33	1662	1664	|O
nM	1665	1667	|O
;	1667	1668	|O
19	1669	1671	|O
,	1671	1672	|O
AC50	1673	1677	|O
=	1678	1679	|O
66	1680	1682	|O
nM	1683	1685	|O
)	1685	1686	|O
.	1686	1687	|O
From	1688	1692	|O
series	1693	1699	|O
I	1700	1701	|O
,	1701	1702	|O
a	1703	1704	|O
mixed	1705	1710	|O
RAR	1711	1714	|O
beta	1715	1719	|O
-	1719	1720	|O
gamma	1720	1725	|O
agonist	1726	1733	|O
with	1734	1738	|O
potent	1739	1745	|O
cellular	1746	1754	|O
differentiating	1755	1770	|O
activity	1771	1779	|O
was	1780	1783	|O
selected	1784	1792	|O
for	1793	1796	|O
development	1797	1808	|O
as	1809	1811	|O
a	1812	1813	|O
topical	1814	1821	|O
antiacne	1822	1830	|O
agent	1831	1836	|O
,	1836	1837	|O
6	1838	1839	|B-IUPAC
-	1839	1840	|I-IUPAC
[	1840	1841	|I-IUPAC
3	1841	1842	|I-IUPAC
-	1842	1843	|I-IUPAC
(	1843	1844	|I-IUPAC
1	1844	1845	|I-IUPAC
-	1845	1846	|I-IUPAC
adamantyl	1846	1855	|I-IUPAC
)	1855	1856	|I-IUPAC
-	1856	1857	|I-IUPAC
4	1857	1858	|I-IUPAC
-	1858	1859	|I-IUPAC
methoxyphenyl	1859	1872	|I-IUPAC
]	1872	1873	|I-IUPAC
-	1873	1874	|I-IUPAC
2	1874	1875	|I-IUPAC
-	1875	1876	|I-IUPAC
naphthoic	1876	1885	|I-IUPAC
acid	1886	1890	|I-IUPAC
(	1891	1892	|O
5	1892	1893	|O
,	1893	1894	|O
CD	1895	1897	|O
271	1898	1901	|O
)	1901	1902	|O
[	1903	1904	|O
Ki	1904	1906	|O
(	1906	1907	|O
RAR	1907	1910	|O
alpha	1911	1916	|O
)	1916	1917	|O
=	1918	1919	|O
1100	1920	1924	|O
nM	1925	1927	|O
,	1927	1928	|O
Ki	1929	1931	|O
-	1931	1932	|O
(	1932	1933	|O
RAR	1933	1936	|O
beta	1937	1941	|O
)	1941	1942	|O
=	1943	1944	|O
34	1945	1947	|O
nM	1948	1950	|O
,	1950	1951	|O
Ki	1952	1954	|O
(	1954	1955	|O
RAR	1955	1958	|O
gamma	1959	1964	|O
)	1964	1965	|O
=	1966	1967	|O
130	1968	1971	|O
nM	1972	1974	|O
,	1974	1975	|O
AC50	1976	1980	|O
(	1980	1981	|O
F9	1981	1983	|O
)	1983	1984	|O
=	1985	1986	|O
37	1987	1989	|O
nM	1990	1992	|O
]	1992	1993	|O
.	1993	1994	|O
Finally	1995	2002	|O
,	2002	2003	|O
from	2004	2008	|O
series	2009	2015	|O
II	2016	2018	|O
,	2018	2019	|O
we	2020	2022	|O
have	2023	2027	|O
obtained	2028	2036	|O
a	2037	2038	|O
weak	2039	2043	|O
antagonist	2044	2054	|O
in	2055	2057	|O
the	2058	2061	|O
F9	2062	2064	|O
cellular	2065	2073	|O
differentiation	2074	2089	|O
assay	2090	2095	|O
,	2095	2096	|O
4	2097	2098	|B-IUPAC
-	2098	2099	|I-IUPAC
[	2099	2100	|I-IUPAC
(	2100	2101	|I-IUPAC
E	2101	2102	|I-IUPAC
)	2102	2103	|I-IUPAC
-	2103	2104	|I-IUPAC
2	2104	2105	|I-IUPAC
-	2105	2106	|I-IUPAC
(	2106	2107	|I-IUPAC
3	2107	2108	|I-IUPAC
-	2108	2109	|I-IUPAC
tert	2109	2113	|I-IUPAC
-	2113	2114	|I-IUPAC
butyl	2114	2119	|I-IUPAC
-	2119	2120	|I-IUPAC
4	2120	2121	|I-IUPAC
-	2121	2122	|I-IUPAC
hydroxyphenyl	2122	2135	|I-IUPAC
)	2135	2136	|I-IUPAC
propenyl	2136	2144	|I-IUPAC
]	2144	2145	|I-IUPAC
benzoic	2145	2152	|I-IUPAC
acid	2153	2157	|I-IUPAC
(	2158	2159	|O
15	2159	2161	|O
,	2161	2162	|O
IC50	2163	2167	|O
=	2168	2169	|O
700	2170	2173	|O
nM	2174	2176	|O
)	2176	2177	|O
.	2177	2178	|O

### abstracts3670.txt
In	0	2	|O
an	3	5	|O
attempt	6	13	|O
to	14	16	|O
determine	17	26	|O
some	27	31	|O
of	32	34	|O
the	35	38	|O
structural	39	49	|O
features	50	58	|O
in	59	61	|O
position	62	70	|O
1	71	72	|O
that	73	77	|O
account	78	85	|O
for	86	89	|O
antivasopressor	90	105	|O
activity	106	114	|O
,	114	115	|O
eight	116	121	|O
new	122	125	|O
1	126	127	|O
-	127	128	|O
(	128	129	|O
beta	129	133	|O
,	133	134	|O
beta	135	139	|O
-	139	140	|O
dialkyl	140	147	|O
-	147	148	|O
substituted	148	159	|O
)	159	160	|O
analogues	161	170	|O
of	171	173	|O
1	174	175	|B-IUPAC
-	175	176	|I-IUPAC
(	176	177	|I-IUPAC
3	177	178	|I-IUPAC
-	178	179	|I-IUPAC
mercaptopropanoic	179	196	|I-IUPAC
acid	197	201	|I-IUPAC
)	201	202	|I-IUPAC
-	202	203	|I-IUPAC
8	203	204	|I-IUPAC
-	204	205	|I-IUPAC
arginine	205	213	|I-IUPAC
-	213	214	|I-IUPAC
vasopressin	214	225	|I-IUPAC
and	226	229	|O
1	230	231	|B-IUPAC
-	231	232	|I-IUPAC
(	232	233	|I-IUPAC
3	233	234	|I-IUPAC
-	234	235	|I-IUPAC
mercaptopropanoic	235	252	|I-IUPAC
acid	253	257	|I-IUPAC
)	257	258	|I-IUPAC
-	258	259	|I-IUPAC
2	259	260	|I-IUPAC
-	260	261	|I-IUPAC
O	261	262	|I-IUPAC
-	262	263	|I-IUPAC
methyltyrosine	263	277	|I-IUPAC
-	277	278	|I-IUPAC
8	278	279	|I-IUPAC
-	279	280	|I-IUPAC
arginine	280	288	|I-IUPAC
-	288	289	|I-IUPAC
vasopressin	289	300	|I-IUPAC
have	301	305	|O
been	306	310	|O
designed	311	319	|O
and	320	323	|O
synthesized	324	335	|O
.	335	336	|O
The	337	340	|O
protected	341	350	|O
precursors	351	361	|O
required	362	370	|O
for	371	374	|O
these	375	380	|O
peptides	381	389	|O
were	390	394	|O
obtained	395	403	|O
by	404	406	|O
a	407	408	|O
combination	409	420	|O
of	421	423	|O
solid	424	429	|O
-	429	430	|O
phase	430	435	|O
and	436	439	|O
solutions	440	449	|O
methods	450	457	|O
.	457	458	|O
Some	459	463	|O
of	464	466	|O
the	467	470	|O
reported	471	479	|O
analogues	480	489	|O
,	489	490	|O
namely	491	497	|O
1	498	499	|B-IUPAC
-	499	500	|I-IUPAC
(	500	501	|I-IUPAC
1	501	502	|I-IUPAC
-	502	503	|I-IUPAC
mercapto	503	511	|I-IUPAC
-	511	512	|I-IUPAC
4	512	513	|I-IUPAC
-	513	514	|I-IUPAC
methylcyclohexaneacetic	514	537	|I-IUPAC
acid	538	542	|I-IUPAC
)	542	543	|I-IUPAC
-	543	544	|I-IUPAC
8	544	545	|I-IUPAC
-	545	546	|I-IUPAC
arginine	546	554	|I-IUPAC
-	554	555	|I-IUPAC
vasopressin	555	566	|I-IUPAC
,	566	567	|O
1	568	569	|B-IUPAC
-	569	570	|I-IUPAC
(	570	571	|I-IUPAC
1	571	572	|I-IUPAC
-	572	573	|I-IUPAC
mercapto	573	581	|I-IUPAC
-	581	582	|I-IUPAC
4	582	583	|I-IUPAC
-	583	584	|I-IUPAC
methylcyclohexaneacetic	584	607	|I-IUPAC
acid	608	612	|I-IUPAC
)	612	613	|I-IUPAC
-	613	614	|I-IUPAC
2	614	615	|I-IUPAC
-	615	616	|I-IUPAC
O	616	617	|I-IUPAC
-	617	618	|I-IUPAC
methyltryosine	618	632	|I-IUPAC
-	632	633	|I-IUPAC
8	633	634	|I-IUPAC
-	634	635	|I-IUPAC
arginine	635	643	|I-IUPAC
-	643	644	|I-IUPAC
vasopressin	644	655	|I-IUPAC
,	655	656	|O
1	657	658	|B-IUPAC
-	658	659	|I-IUPAC
(	659	660	|I-IUPAC
4	660	661	|I-IUPAC
-	661	662	|I-IUPAC
tert	662	666	|I-IUPAC
-	666	667	|I-IUPAC
butyl	667	672	|I-IUPAC
-	672	673	|I-IUPAC
1	673	674	|I-IUPAC
-	674	675	|I-IUPAC
mercaptocyclohexaneacetic	675	700	|I-IUPAC
acid	701	705	|I-IUPAC
)	705	706	|I-IUPAC
-	706	707	|I-IUPAC
2	707	708	|I-IUPAC
-	708	709	|I-IUPAC
O	709	710	|I-IUPAC
-	710	711	|I-IUPAC
methyltyrosine	711	725	|I-IUPAC
-	725	726	|I-IUPAC
8	726	727	|I-IUPAC
-	727	728	|I-IUPAC
arginine	728	736	|I-IUPAC
-	736	737	|I-IUPAC
vasopressin	738	749	|I-IUPAC
,	749	750	|O
1	751	752	|B-IUPAC
-	752	753	|I-IUPAC
(	753	754	|I-IUPAC
1	754	755	|I-IUPAC
-	755	756	|I-IUPAC
mercapto	756	764	|I-IUPAC
-	764	765	|I-IUPAC
4	765	766	|I-IUPAC
-	766	767	|I-IUPAC
phenylcyclohexaneacetic	767	790	|I-IUPAC
acid	791	795	|I-IUPAC
)	795	796	|I-IUPAC
-	796	797	|I-IUPAC
8	797	798	|I-IUPAC
-	798	799	|I-IUPAC
arginine	799	807	|I-IUPAC
-	807	808	|I-IUPAC
vasopressin	808	819	|I-IUPAC
and	820	823	|O
1	824	825	|B-IUPAC
-	825	826	|I-IUPAC
(	826	827	|I-IUPAC
1	827	828	|I-IUPAC
-	828	829	|I-IUPAC
mercapto	829	837	|I-IUPAC
-	837	838	|I-IUPAC
4	838	839	|I-IUPAC
-	839	840	|I-IUPAC
phenylcyclohexaneacetic	840	863	|I-IUPAC
acid	864	868	|I-IUPAC
)	868	869	|I-IUPAC
-	869	870	|I-IUPAC
2	870	871	|I-IUPAC
-	871	872	|I-IUPAC
O	872	873	|I-IUPAC
-	873	874	|I-IUPAC
methyltyrosine	874	888	|I-IUPAC
-	888	889	|I-IUPAC
8	889	890	|I-IUPAC
-	890	891	|I-IUPAC
arginine	891	899	|I-IUPAC
-	899	900	|I-IUPAC
vasopressin	901	912	|I-IUPAC
,	912	913	|O
are	914	917	|O
among	918	923	|O
the	924	927	|O
most	928	932	|O
potent	933	939	|O
and	940	943	|O
selective	944	953	|O
antagonists	954	965	|O
of	966	968	|O
the	969	972	|O
vasopressor	973	984	|O
response	985	993	|O
to	994	996	|O
arginine	997	1005	|O
-	1005	1006	|O
vasopressin	1006	1017	|O
reported	1018	1026	|O
to	1027	1029	|O
date	1030	1034	|O
.	1034	1035	|O

### abstracts2430.txt
Glycosylated	0	12	|O
antitumor	13	22	|O
ether	23	28	|O
lipids	29	35	|O
(	36	37	|O
GAELs	37	42	|O
)	42	43	|O
,	43	44	|O
analogs	45	52	|O
of	53	55	|O
1	56	57	|B-IUPAC
-	57	58	|I-IUPAC
O	58	59	|I-IUPAC
-	59	60	|I-IUPAC
octadecyl	60	69	|I-IUPAC
-	69	70	|I-IUPAC
2	70	71	|I-IUPAC
-	71	72	|I-IUPAC
O	72	73	|I-IUPAC
-	73	74	|I-IUPAC
methyl	74	80	|I-IUPAC
-	80	81	|I-IUPAC
sn	81	83	|I-IUPAC
-	83	84	|I-IUPAC
glycero	84	91	|I-IUPAC
-	91	92	|I-IUPAC
3	92	93	|I-IUPAC
-	93	94	|I-IUPAC
phosphocholine	94	108	|I-IUPAC
(	109	110	|O
1	110	111	|O
,	111	112	|O
ET	113	115	|O
-	115	116	|O
18	116	118	|O
-	118	119	|O
OCH3	119	123	|O
,	123	124	|O
edelfosine	125	135	|O
)	135	136	|O
,	136	137	|O
were	138	142	|O
synthesized	143	154	|O
in	155	157	|O
good	158	162	|O
overall	163	170	|O
yields	171	177	|O
by	178	180	|O
glycosylation	181	194	|O
of	195	197	|O
1	198	199	|B-IUPAC
-	199	200	|I-IUPAC
O	200	201	|I-IUPAC
-	201	202	|I-IUPAC
alkyl	202	207	|I-IUPAC
-	207	208	|I-IUPAC
2	208	209	|I-IUPAC
-	209	210	|I-IUPAC
O	210	211	|I-IUPAC
-	211	212	|I-IUPAC
methyl	212	218	|I-IUPAC
-	218	219	|I-IUPAC
sn	219	221	|I-IUPAC
-	221	222	|I-IUPAC
glycerol	222	230	|I-IUPAC
and	231	234	|O
tested	235	241	|O
for	242	245	|O
in	246	248	|O
vitro	249	254	|O
antineoplastic	255	269	|O
activity	270	278	|O
against	279	286	|O
a	287	288	|O
variety	289	296	|O
of	297	299	|O
murine	300	306	|O
and	307	310	|O
human	311	316	|O
tumor	317	322	|O
cell	323	327	|O
lines	328	333	|O
.	333	334	|O
Stereospecific	335	349	|O
glycosylation	350	363	|O
was	364	367	|O
achieved	368	376	|O
by	377	379	|O
the	380	383	|O
use	384	387	|O
of	388	390	|O
2	391	392	|B-PARTIUPAC
-	392	393	|I-PARTIUPAC
O	393	394	|I-PARTIUPAC
-	394	395	|I-PARTIUPAC
acetyl	395	401	|I-PARTIUPAC
-	401	402	|I-PARTIUPAC
3,4,6	402	407	|I-PARTIUPAC
-	407	408	|I-PARTIUPAC
tri	408	411	|I-PARTIUPAC
-	411	412	|I-PARTIUPAC
O	412	413	|I-PARTIUPAC
-	413	414	|I-PARTIUPAC
benzylglucopyranosyl	414	434	|I-PARTIUPAC
and	435	438	|O
-	439	440	|B-PARTIUPAC
mannopyranosyl	440	454	|I-PARTIUPAC
trichloroacetimidates	455	476	|I-PARTIUPAC
as	477	479	|O
donors	480	486	|O
,	486	487	|O
with	488	492	|O
trimethylsilyl	493	507	|B-IUPAC
trifluoromethanesulfonate	508	533	|I-IUPAC
as	534	536	|O
catalyst	537	545	|O
in	546	548	|O
the	549	552	|O
presence	553	561	|O
of	562	564	|O
molecular	565	574	|O
sieves	575	581	|O
at	582	584	|O
-	585	586	|O
78	586	588	|O
degrees	589	596	|O
C	597	598	|O
.	598	599	|O
The	600	603	|O
GAELs	604	609	|O
differ	610	616	|O
from	617	621	|O
1	622	623	|O
in	624	626	|O
having	627	633	|O
the	634	637	|O
sn	638	640	|B-IUPAC
-	640	641	|I-IUPAC
3	641	642	|I-IUPAC
-	642	643	|I-IUPAC
phosphocholine	643	657	|I-IUPAC
residue	658	665	|O
replaced	666	674	|O
by	675	677	|O
one	678	681	|O
of	682	684	|O
the	685	688	|O
following	689	698	|O
monosaccharide	699	713	|O
residues	714	722	|O
:	722	723	|O
beta	724	728	|B-PARTIUPAC
-	728	729	|I-PARTIUPAC
and	730	733	|O
alpha	734	739	|B-IUPAC
-	739	740	|I-IUPAC
2	740	741	|I-IUPAC
-	741	742	|I-IUPAC
deoxy	742	747	|I-IUPAC
-	747	748	|I-IUPAC
D	748	749	|I-IUPAC
-	749	750	|I-IUPAC
arabino	750	757	|I-IUPAC
-	757	758	|I-IUPAC
hexopyranosyl	758	771	|I-IUPAC
,	771	772	|O
alpha	773	778	|B-IUPAC
-	778	779	|I-IUPAC
D	779	780	|I-IUPAC
-	780	781	|I-IUPAC
mannopyranosyl	781	795	|I-IUPAC
,	795	796	|O
2	797	798	|B-IUPAC
-	798	799	|I-IUPAC
O	799	800	|I-IUPAC
-	800	801	|I-IUPAC
methyl	801	807	|I-IUPAC
-	807	808	|I-IUPAC
beta	808	812	|I-IUPAC
-	812	813	|I-IUPAC
D	813	814	|I-IUPAC
-	814	815	|I-IUPAC
glucopyranosyl	815	829	|I-IUPAC
,	829	830	|O
and	831	834	|O
2	835	836	|B-IUPAC
-	836	837	|I-IUPAC
O	837	838	|I-IUPAC
-	838	839	|I-IUPAC
methyl	839	845	|I-IUPAC
-	845	846	|I-IUPAC
alpha	846	851	|I-IUPAC
-	851	852	|I-IUPAC
D	852	853	|I-IUPAC
-	853	854	|I-IUPAC
mannopyranosyl	854	868	|I-IUPAC
.	868	869	|O
1	870	871	|B-IUPAC
-	871	872	|I-IUPAC
O	872	873	|I-IUPAC
-	873	874	|I-IUPAC
Hexadecyl	874	883	|I-IUPAC
-	883	884	|I-IUPAC
2	884	885	|I-IUPAC
-	885	886	|I-IUPAC
O	886	887	|I-IUPAC
-	887	888	|I-IUPAC
methyl	888	894	|I-IUPAC
-	894	895	|I-IUPAC
3	895	896	|I-IUPAC
-	896	897	|I-IUPAC
O	897	898	|I-IUPAC
-	898	899	|I-IUPAC
(	899	900	|I-IUPAC
2'	900	902	|I-IUPAC
-	902	903	|I-IUPAC
deoxy	903	908	|I-IUPAC
-	908	909	|I-IUPAC
beta	909	913	|I-IUPAC
-	913	914	|I-IUPAC
D	914	915	|I-IUPAC
-	915	916	|I-IUPAC
arabino	916	923	|I-IUPAC
-	923	924	|I-IUPAC
hexopyranosyl	924	937	|I-IUPAC
)	937	938	|I-IUPAC
-	938	939	|I-IUPAC
sn	940	942	|I-IUPAC
-	942	943	|I-IUPAC
glycerol	943	951	|I-IUPAC
(	952	953	|O
2	953	954	|O
)	954	955	|O
was	956	959	|O
more	960	964	|O
effective	965	974	|O
than	975	979	|O
1	980	981	|O
in	982	984	|O
inhibiting	985	995	|O
the	996	999	|O
growth	1000	1006	|O
of	1007	1009	|O
MCF	1010	1013	|O
-	1013	1014	|O
7	1014	1015	|O
(	1016	1017	|O
human	1017	1022	|O
breast	1023	1029	|O
cancer	1030	1036	|O
)	1036	1037	|O
and	1038	1041	|O
its	1042	1045	|O
adriamycin	1046	1056	|O
-	1056	1057	|O
resistant	1057	1066	|O
form	1067	1071	|O
MCF	1072	1075	|O
-	1075	1076	|O
7	1076	1077	|O
/	1077	1078	|O
adriamycin	1078	1088	|O
,	1088	1089	|O
and	1090	1093	|O
murine	1094	1100	|O
Lewis	1101	1106	|O
lung	1107	1111	|O
cancer	1112	1118	|O
cells	1119	1124	|O
.	1124	1125	|O
2	1126	1127	|B-IUPAC
-	1127	1128	|I-IUPAC
Deoxy	1128	1133	|I-IUPAC
-	1133	1134	|I-IUPAC
beta	1134	1138	|I-IUPAC
-	1138	1139	|I-IUPAC
D	1139	1140	|I-IUPAC
-	1140	1141	|I-IUPAC
arabino	1141	1148	|I-IUPAC
-	1148	1149	|I-IUPAC
hexopyranoside	1149	1163	|I-IUPAC
2	1164	1165	|O
was	1166	1169	|O
also	1170	1174	|O
an	1175	1177	|O
effective	1178	1187	|O
growth	1188	1194	|O
inhibitor	1195	1204	|O
of	1205	1207	|O
two	1208	1211	|O
drug	1212	1216	|O
-	1216	1217	|O
resistant	1217	1226	|O
leukemic	1227	1235	|O
cell	1236	1240	|O
lines	1241	1246	|O
,	1246	1247	|O
P388	1248	1252	|O
/	1252	1253	|O
Adr	1253	1256	|O
and	1257	1260	|O
L1210	1261	1266	|O
/	1266	1267	|O
vmdr	1267	1271	|O
.	1271	1272	|O

### abstracts3007.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
sulfonyl	12	20	|B-IUPAC
-	20	21	|I-IUPAC
N	21	22	|I-IUPAC
-	22	23	|I-IUPAC
hydroxyguanidine	23	39	|I-IUPAC
derivatives	40	51	|B-MODIFIER
was	52	55	|O
designed	56	64	|O
and	65	68	|O
synthesized	69	80	|O
for	81	84	|O
cytotoxic	85	94	|O
evaluation	95	105	|O
as	106	108	|O
potential	109	118	|O
anticancer	119	129	|O
agents	130	136	|O
on	137	139	|O
the	140	143	|O
basis	144	149	|O
of	150	152	|O
the	153	156	|O
lead	157	161	|O
compound	162	170	|O
LY	171	173	|O
-	173	174	|O
181984	174	180	|O
.	180	181	|O
Replacement	182	193	|O
of	194	196	|O
the	197	200	|O
ureido	201	207	|O
moiety	208	214	|O
of	215	217	|O
the	218	221	|O
lead	222	226	|O
compound	227	235	|O
with	236	240	|O
hydroxyguanidine	241	257	|O
provided	258	266	|O
a	267	268	|O
stable	269	275	|O
cytotoxic	276	285	|O
agent	286	291	|O
.	291	292	|O
The	293	296	|O
conformation	297	309	|O
of	310	312	|O
sulfonyl	313	321	|B-IUPAC
-	321	322	|I-IUPAC
N	322	323	|I-IUPAC
-	323	324	|I-IUPAC
hydroxyguanidine	324	340	|I-IUPAC
derivatives	341	352	|B-MODIFIER
,	352	353	|O
such	354	358	|O
as	359	361	|O
N	362	363	|B-IUPAC
-	363	364	|I-IUPAC
(	364	365	|I-IUPAC
4	365	366	|I-IUPAC
-	366	367	|I-IUPAC
chlorophenyl	367	379	|I-IUPAC
)	379	380	|I-IUPAC
-	380	381	|I-IUPAC
N'	381	383	|I-IUPAC
-	383	384	|I-IUPAC
[	384	385	|I-IUPAC
(	385	386	|I-IUPAC
benzo	386	391	|I-IUPAC
[	391	392	|I-IUPAC
2,1,3	392	397	|I-IUPAC
]	397	398	|I-IUPAC
thiadiazol	398	408	|I-IUPAC
-	408	409	|I-IUPAC
4	409	410	|I-IUPAC
-	410	411	|I-IUPAC
yl	411	413	|I-IUPAC
)	413	414	|I-IUPAC
sulfonyl	414	422	|I-IUPAC
]	422	423	|I-IUPAC
-	423	424	|I-IUPAC
N	424	425	|I-IUPAC
"	425	426	|I-IUPAC
-	426	427	|I-IUPAC
hydroxyguanidine	428	444	|I-IUPAC
(	445	446	|O
4g	446	448	|O
)	448	449	|O
,	449	450	|O
investigated	451	463	|O
utilizing	464	473	|O
HMBC	474	478	|O
NMR	479	482	|O
,	482	483	|O
theoretical	484	495	|O
calculations	496	508	|O
,	508	509	|O
and	510	513	|O
X	514	515	|O
-	515	516	|O
ray	516	519	|O
crystallography	520	535	|O
,	535	536	|O
indicated	537	546	|O
stacking	547	555	|O
of	556	558	|O
the	559	562	|O
two	563	566	|O
aromatic	567	575	|O
rings	576	581	|O
.	581	582	|O
The	583	586	|O
derivatives	587	598	|O
were	599	603	|O
evaluated	604	613	|O
for	614	617	|O
in	618	620	|O
vitro	621	626	|O
cytoxicity	627	637	|O
against	638	645	|O
five	646	650	|O
human	651	656	|O
tumor	657	662	|O
cell	663	667	|O
lines	668	673	|O
,	673	674	|O
including	675	684	|O
HepG2	685	690	|O
,	690	691	|O
TSGH	692	696	|O
8302	697	701	|O
,	701	702	|O
COLO	703	707	|O
205	708	711	|O
,	711	712	|O
KB	713	715	|O
,	715	716	|O
and	717	720	|O
MOLT	721	725	|O
-	725	726	|O
4	726	727	|O
.	727	728	|O
The	729	732	|O
cytotoxic	733	742	|O
activities	743	753	|O
of	754	756	|O
the	757	760	|O
derived	761	768	|O
compounds	769	778	|O
against	779	786	|O
the	787	790	|O
human	791	796	|O
tumor	797	802	|O
cell	803	807	|O
lines	808	813	|O
were	814	818	|O
equal	819	824	|O
to	825	827	|O
or	828	830	|O
greater	831	838	|O
than	839	843	|O
that	844	848	|O
of	849	851	|O
the	852	855	|O
lead	856	860	|O
compound	861	869	|O
.	869	870	|O
N	871	872	|B-IUPAC
-	872	873	|I-IUPAC
(	873	874	|I-IUPAC
4	874	875	|I-IUPAC
-	875	876	|I-IUPAC
Chlorophenyl	876	888	|I-IUPAC
)	888	889	|I-IUPAC
-	889	890	|I-IUPAC
N'	890	892	|I-IUPAC
-	892	893	|I-IUPAC
[	893	894	|I-IUPAC
[	894	895	|I-IUPAC
3,5	895	898	|I-IUPAC
-	898	899	|I-IUPAC
dichloro	899	907	|I-IUPAC
-	907	908	|I-IUPAC
4	908	909	|I-IUPAC
-	909	910	|I-IUPAC
(	910	911	|I-IUPAC
4	911	912	|I-IUPAC
-	912	913	|I-IUPAC
nitrophenoxy	913	925	|I-IUPAC
)	925	926	|I-IUPAC
phenyl	926	932	|I-IUPAC
]	932	933	|I-IUPAC
sulfonyl	933	941	|I-IUPAC
]	941	942	|I-IUPAC
-	942	943	|I-IUPAC
N	944	945	|I-IUPAC
"	945	946	|I-IUPAC
-	946	947	|I-IUPAC
hydroxyguanidine	948	964	|I-IUPAC
(	965	966	|O
4n	966	968	|O
)	968	969	|O
and	970	973	|O
N	974	975	|B-IUPAC
-	975	976	|I-IUPAC
(	976	977	|I-IUPAC
4	977	978	|I-IUPAC
-	978	979	|I-IUPAC
chlorophenyl	979	991	|I-IUPAC
)	991	992	|I-IUPAC
-	992	993	|I-IUPAC
N'	993	995	|I-IUPAC
-	995	996	|I-IUPAC
[	996	997	|I-IUPAC
[	997	998	|I-IUPAC
3,5	998	1001	|I-IUPAC
-	1001	1002	|I-IUPAC
dichloro	1002	1010	|I-IUPAC
-	1010	1011	|I-IUPAC
4	1011	1012	|I-IUPAC
-	1012	1013	|I-IUPAC
(	1013	1014	|I-IUPAC
2	1014	1015	|I-IUPAC
-	1015	1016	|I-IUPAC
chloro	1016	1022	|I-IUPAC
-	1022	1023	|I-IUPAC
4	1023	1024	|I-IUPAC
-	1024	1025	|I-IUPAC
nitrophenoxy	1025	1037	|I-IUPAC
)	1037	1038	|I-IUPAC
phenyl	1038	1044	|I-IUPAC
]	1044	1045	|I-IUPAC
sulfonyl	1046	1054	|I-IUPAC
]	1054	1055	|I-IUPAC
-	1055	1056	|I-IUPAC
N	1056	1057	|I-IUPAC
"	1057	1058	|I-IUPAC
-	1058	1059	|I-IUPAC
hydroxyguanidine	1059	1075	|I-IUPAC
(	1076	1077	|O
4o	1077	1079	|O
)	1079	1080	|O
exhibited	1081	1090	|O
the	1091	1094	|O
greatest	1095	1103	|O
growth	1104	1110	|O
inhibition	1111	1121	|O
of	1122	1124	|O
solid	1125	1130	|O
tumor	1131	1136	|O
cell	1137	1141	|O
lines	1142	1147	|O
.	1147	1148	|O
Compound	1149	1157	|O
4o	1158	1160	|O
was	1161	1164	|O
found	1165	1170	|O
to	1171	1173	|O
possess	1174	1181	|O
antitumor	1182	1191	|O
activity	1192	1200	|O
against	1201	1208	|O
murine	1209	1215	|O
K1735	1216	1221	|O
/	1221	1222	|O
M2	1222	1224	|O
melanoma	1225	1233	|O
xenografts	1234	1244	|O
.	1244	1245	|O

### abstracts3422.txt
A	0	1	|O
study	2	7	|O
of	8	10	|O
ring	11	15	|O
-	15	16	|O
expanded	16	24	|O
analogues	25	34	|O
of	35	37	|O
the	38	41	|O
4	42	43	|B-IUPAC
-	43	44	|I-IUPAC
(	44	45	|I-IUPAC
propananilido	45	58	|I-IUPAC
)	58	59	|I-IUPAC
piperidine	59	69	|I-IUPAC
analgesics	70	80	|O
has	81	84	|O
been	85	89	|O
undertaken	90	100	|O
in	101	103	|O
order	104	109	|O
to	110	112	|O
evaluate	113	121	|O
the	122	125	|O
influence	126	135	|O
of	136	138	|O
this	139	143	|O
structural	144	154	|O
modification	155	167	|O
on	168	170	|O
both	171	175	|O
analgesic	176	185	|O
activity	186	194	|O
and	195	198	|O
physical	199	207	|O
-	207	208	|O
dependence	208	218	|O
capacity	219	227	|O
.	227	228	|O
Thus	229	233	|O
,	233	234	|O
a	235	236	|O
series	237	243	|O
of	244	246	|O
1	247	248	|B-MODIFIER
-	248	249	|I-MODIFIER
substituted	249	260	|I-MODIFIER
4	261	262	|B-IUPAC
-	262	263	|I-IUPAC
(	263	264	|I-IUPAC
propananilido	264	277	|I-IUPAC
)	277	278	|I-IUPAC
perhydroazepine	278	293	|I-IUPAC
derivatives	294	305	|B-MODIFIER
was	306	309	|O
synthesized	310	321	|O
and	322	325	|O
pharmacologically	326	343	|O
evaluated	344	353	|O
in	354	356	|O
mice	357	361	|O
for	362	365	|O
analgesic	366	375	|O
activity	376	384	|O
and	385	388	|O
physical	389	397	|O
-	397	398	|O
dependence	398	408	|O
capacity	409	417	|O
.	417	418	|O
The	419	422	|O
results	423	430	|O
of	431	433	|O
this	434	438	|O
study	439	444	|O
indicate	445	453	|O
that	454	458	|O
the	459	462	|O
ring	463	467	|O
-	467	468	|O
expanded	468	476	|O
analogues	477	486	|O
of	487	489	|O
the	490	493	|O
4	494	495	|B-IUPAC
-	495	496	|I-IUPAC
(	496	497	|I-IUPAC
propananilido	497	510	|I-IUPAC
)	510	511	|I-IUPAC
piperidines	511	522	|I-IUPAC
retain	523	529	|O
a	530	531	|O
relatively	532	542	|O
high	543	547	|O
degree	548	554	|O
of	555	557	|O
analgesic	558	567	|O
potency	568	575	|O
,	575	576	|O
except	577	583	|O
in	584	586	|O
the	587	590	|O
case	591	595	|O
of	596	598	|O
the	599	602	|O
1	603	604	|B-IUPAC
-	604	605	|I-IUPAC
phenylethylated	605	620	|I-IUPAC
analogue	621	629	|B-MODIFIER
which	630	635	|O
is	636	638	|O
approximately	639	652	|O
150	653	656	|O
-	656	657	|O
fold	657	661	|O
less	662	666	|O
potent	667	673	|O
than	674	678	|O
the	679	682	|O
correspondingly	683	698	|O
1	699	700	|O
-	700	701	|O
substituted	701	712	|O
piperidine	713	723	|O
analgesic	724	733	|O
.	733	734	|O
Evaluation	735	745	|O
of	746	748	|O
physical	749	757	|O
-	757	758	|O
dependence	758	768	|O
capacity	769	777	|O
of	778	780	|O
the	781	784	|O
most	785	789	|O
potent	790	796	|O
1	797	798	|B-MODIFIER
-	798	799	|I-MODIFIER
substituted	799	810	|I-MODIFIER
4	811	812	|B-IUPAC
-	812	813	|I-IUPAC
(	813	814	|I-IUPAC
propananilido	814	827	|I-IUPAC
)	827	828	|I-IUPAC
perhydroazepines	828	844	|I-IUPAC
reveals	845	852	|O
no	853	855	|O
significant	856	867	|O
difference	868	878	|O
for	879	882	|O
these	883	888	|O
compounds	889	898	|O
as	899	901	|O
compared	902	910	|O
with	911	915	|O
morphine	916	924	|O
.	924	925	|O
The	926	929	|O
4	930	931	|B-IUPAC
-	931	932	|I-IUPAC
(	932	933	|I-IUPAC
propananilido	933	946	|I-IUPAC
)	946	947	|I-IUPAC
perhydroazepines	947	963	|I-IUPAC
having	964	970	|O
1	971	972	|O
-	972	973	|O
substitutents	973	986	|O
in	987	989	|O
common	990	996	|O
with	997	1001	|O
known	1002	1007	|O
opiate	1008	1014	|O
antagonists	1015	1026	|O
failed	1027	1033	|O
to	1034	1036	|O
exhibit	1037	1044	|O
antagonism	1045	1055	|O
of	1056	1058	|O
morphine	1059	1067	|O
analgesia	1068	1077	|O
.	1077	1078	|O

### abstracts2769.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
compounds	12	21	|O
related	22	29	|O
to	30	32	|O
ethyl	33	38	|B-IUPAC
4	39	40	|I-IUPAC
-	40	41	|I-IUPAC
benzyloxybenzoate	41	58	|I-IUPAC
was	59	62	|O
synthesized	63	74	|O
and	75	78	|O
evaluated	79	88	|O
for	89	92	|O
potential	93	102	|O
hypolipidemic	103	116	|O
activity	117	125	|O
in	126	128	|O
rats	129	133	|O
.	133	134	|O
Structure	135	144	|O
-	144	145	|O
-	145	146	|O
activity	146	154	|O
relationships	155	168	|O
are	169	172	|O
discussed	173	182	|O
in	183	185	|O
terms	186	191	|O
of	192	194	|O
cholesterol	195	206	|O
-	206	207	|O
lowering	207	215	|O
activity	216	224	|O
together	225	233	|O
with	234	238	|O
effects	239	246	|O
on	247	249	|O
weight	250	256	|O
gain	257	261	|O
and	262	265	|O
liver	266	271	|O
lipids	272	278	|O
.	278	279	|O
A	280	281	|O
number	282	288	|O
of	289	291	|O
the	292	295	|O
compounds	296	305	|O
inhibited	306	315	|O
cholesterol	316	327	|O
and	328	331	|O
free	332	336	|O
fatty	337	342	|O
acid	343	347	|O
biosynthesis	348	360	|O
from	361	365	|O
[	366	367	|O
1-14	367	371	|O
C	371	372	|O
]	372	373	|O
acetate	373	380	|O
in	381	383	|O
rat	384	387	|O
liver	388	393	|O
slices	394	400	|O
in	401	403	|O
vitro	404	409	|O
.	409	410	|O
Ethyl	411	416	|O
4	417	418	|B-IUPAC
-	418	419	|I-IUPAC
benzyloxybenzoate	419	436	|I-IUPAC
,	436	437	|O
ethyl	438	443	|B-IUPAC
-	443	444	|I-IUPAC
4	444	445	|I-IUPAC
-	445	446	|I-IUPAC
benzyloxybenzoic	446	462	|I-IUPAC
acid	463	467	|I-IUPAC
,	467	468	|O
ethyl	469	474	|B-IUPAC
4	475	476	|I-IUPAC
-	476	477	|I-IUPAC
p	477	478	|I-IUPAC
-	478	479	|I-IUPAC
bromobenzyloxybenzoates	479	502	|I-IUPAC
,	502	503	|O
and	504	507	|O
4	508	509	|B-IUPAC
-	509	510	|I-IUPAC
o	510	511	|I-IUPAC
-	511	512	|I-IUPAC
methoxybenzyloxyphenyl	512	534	|I-IUPAC
acetate	535	542	|I-IUPAC
exhibited	543	552	|O
the	553	556	|O
most	557	561	|O
favorable	562	571	|O
spectrum	572	580	|O
of	581	583	|O
activity	584	592	|O
.	592	593	|O

### abstracts2171.txt
In	0	2	|O
this	3	7	|O
paper	8	13	|O
we	14	16	|O
describe	17	25	|O
the	26	29	|O
synthesis	30	39	|O
of	40	42	|O
a	43	44	|O
series	45	51	|O
of	52	54	|O
novel	55	60	|O
2	61	62	|B-IUPAC
-	62	63	|I-IUPAC
[	63	64	|I-IUPAC
(	64	65	|I-IUPAC
4	65	66	|I-IUPAC
-	66	67	|I-IUPAC
alkylsemicarbazono	67	85	|I-IUPAC
)	85	86	|I-IUPAC
-	86	87	|I-IUPAC
(	87	88	|I-IUPAC
4	88	89	|I-IUPAC
-	89	90	|I-IUPAC
aminophenyl	90	101	|I-IUPAC
)	101	102	|I-IUPAC
-	102	103	|I-IUPAC
methyl	103	109	|I-IUPAC
]	109	110	|I-IUPAC
-	110	111	|I-IUPAC
4,5	111	114	|I-IUPAC
-	114	115	|I-IUPAC
methylenedioxyphenylacetic	115	141	|I-IUPAC
acid	142	146	|I-IUPAC
alkyl	147	152	|I-IUPAC
esters	153	159	|I-IUPAC
(	160	161	|O
10-19	161	166	|O
)	166	167	|O
carrying	168	176	|O
an	177	179	|O
alkylsemicarbazono	180	198	|O
moiety	199	205	|O
at	206	208	|O
a	209	210	|O
benzylic	211	219	|O
site	220	224	|O
.	224	225	|O
The	226	229	|O
influence	230	239	|O
of	240	242	|O
this	243	247	|O
group	248	253	|O
on	254	256	|O
the	257	260	|O
biological	261	271	|O
activity	272	280	|O
was	281	284	|O
evaluated	285	294	|O
by	295	297	|O
testing	298	305	|O
the	306	309	|O
corresponding	310	323	|O
derivatives	324	335	|O
20-22	336	341	|O
in	342	344	|O
which	345	350	|O
the	351	354	|O
4	355	356	|B-PARTIUPAC
-	356	357	|I-PARTIUPAC
alkylsemicarbazono	357	375	|I-PARTIUPAC
moiety	376	382	|B-MODIFIER
was	383	386	|O
removed	387	394	|O
(	395	396	|O
compound	396	404	|O
20	405	407	|O
)	407	408	|O
or	409	411	|O
its	412	415	|O
alkylureido	416	427	|O
portion	428	435	|O
shifted	436	443	|O
at	444	446	|O
position	447	455	|O
1	456	457	|O
(	458	459	|O
compounds	459	468	|O
21-22	469	474	|O
)	474	475	|O
.	475	476	|O
Furthermore	477	488	|O
,	488	489	|O
the	490	493	|O
involvement	494	505	|O
of	506	508	|O
the	509	512	|O
4	513	514	|B-PARTIUPAC
-	514	515	|I-PARTIUPAC
aminobenzyl	515	526	|I-PARTIUPAC
moiety	527	533	|B-MODIFIER
in	534	536	|O
the	537	540	|O
anticonvulsant	541	555	|O
activity	556	564	|O
was	565	568	|O
evaluated	569	578	|O
by	579	581	|O
testing	582	589	|O
derivative	590	600	|O
23	601	603	|O
.	603	604	|O
The	605	608	|O
anticonvulsant	609	623	|O
activity	624	632	|O
of	633	635	|O
all	636	639	|O
compounds	640	649	|O
was	650	653	|O
assayed	654	661	|O
against	662	669	|O
audiogenic	670	680	|O
seizures	681	689	|O
induced	690	697	|O
in	698	700	|O
DBA	701	704	|O
/	704	705	|O
2	705	706	|O
mice	707	711	|O
.	711	712	|O
Within	713	719	|O
this	720	724	|O
series	725	731	|O
of	732	734	|O
derivatives	735	746	|O
,	746	747	|O
2	748	749	|B-IUPAC
-	749	750	|I-IUPAC
[	750	751	|I-IUPAC
(	751	752	|I-IUPAC
4	752	753	|I-IUPAC
-	753	754	|I-IUPAC
aminophenyl	754	765	|I-IUPAC
)	765	766	|I-IUPAC
-	766	767	|I-IUPAC
(	767	768	|I-IUPAC
4	768	769	|I-IUPAC
-	769	770	|I-IUPAC
methylsemicarbazono	770	789	|I-IUPAC
)	789	790	|I-IUPAC
-	790	791	|I-IUPAC
methyl	791	797	|I-IUPAC
]	797	798	|I-IUPAC
-	798	799	|I-IUPAC
4,5	799	802	|I-IUPAC
-	802	803	|I-IUPAC
methylenedioxyphenylacetic	803	829	|I-IUPAC
acid	830	834	|I-IUPAC
methyl	835	841	|I-IUPAC
ester	842	847	|I-IUPAC
(	848	849	|O
10	849	851	|O
)	851	852	|O
proved	853	859	|O
to	860	862	|O
be	863	865	|O
the	866	869	|O
most	870	874	|O
active	875	881	|O
compound	882	890	|O
.	890	891	|O
It	892	894	|O
displayed	895	904	|O
a	905	906	|O
potency	907	914	|O
5	915	916	|O
-	916	917	|O
fold	917	921	|O
higher	922	928	|O
than	929	933	|O
that	934	938	|O
shown	939	944	|O
by	945	947	|O
1	948	949	|B-IUPAC
-	949	950	|I-IUPAC
(	950	951	|I-IUPAC
4	951	952	|I-IUPAC
-	952	953	|I-IUPAC
aminophenyl	953	964	|I-IUPAC
)	964	965	|I-IUPAC
-	965	966	|I-IUPAC
4	966	967	|I-IUPAC
-	967	968	|I-IUPAC
methyl	968	974	|I-IUPAC
-	974	975	|I-IUPAC
7,8	975	978	|I-IUPAC
-	978	979	|I-IUPAC
methylenedioxy	979	993	|I-IUPAC
-	993	994	|I-IUPAC
5H	994	996	|I-IUPAC
-	996	997	|I-IUPAC
2,3	997	1000	|I-IUPAC
-	1000	1001	|I-IUPAC
benzodiazepine	1001	1015	|I-IUPAC
(	1016	1017	|O
1	1017	1018	|O
,	1018	1019	|O
GYKI	1020	1024	|O
52466	1025	1030	|O
)	1030	1031	|O
,	1031	1032	|O
a	1033	1034	|O
well	1035	1039	|O
-	1039	1040	|O
known	1040	1045	|O
noncompetitive	1046	1060	|O
2	1061	1062	|B-IUPAC
-	1062	1063	|I-IUPAC
amino	1063	1068	|I-IUPAC
-	1068	1069	|I-IUPAC
3	1069	1070	|I-IUPAC
-	1070	1071	|I-IUPAC
(	1071	1072	|I-IUPAC
3	1072	1073	|I-IUPAC
-	1073	1074	|I-IUPAC
hydroxy	1074	1081	|I-IUPAC
-	1081	1082	|I-IUPAC
5	1082	1083	|I-IUPAC
-	1083	1084	|I-IUPAC
methylisoxazol	1084	1098	|I-IUPAC
-	1098	1099	|I-IUPAC
4	1099	1100	|I-IUPAC
-	1100	1101	|I-IUPAC
yl	1101	1103	|I-IUPAC
)	1103	1104	|I-IUPAC
propionic	1104	1113	|I-IUPAC
acid	1114	1118	|I-IUPAC
(	1119	1120	|O
AMPA	1120	1124	|O
)	1124	1125	|O
receptor	1126	1134	|O
antagonist	1135	1145	|O
.	1145	1146	|O
Compound	1147	1155	|O
10	1156	1158	|O
was	1159	1162	|O
also	1163	1167	|O
effective	1168	1177	|O
in	1178	1180	|O
suppressing	1181	1192	|O
seizures	1193	1201	|O
induced	1202	1209	|O
in	1210	1212	|O
Swiss	1213	1218	|O
mice	1219	1223	|O
by	1224	1226	|O
maximal	1227	1234	|O
electroshock	1235	1247	|O
(	1248	1249	|O
MES	1249	1252	|O
)	1252	1253	|O
or	1254	1256	|O
pentylenetetrazole	1257	1275	|O
(	1276	1277	|O
PTZ	1277	1280	|O
)	1280	1281	|O
.	1281	1282	|O
Furthermore	1283	1294	|O
,	1294	1295	|O
it	1296	1298	|O
antagonized	1299	1310	|O
in	1311	1313	|O
vivo	1314	1318	|O
seizures	1319	1327	|O
induced	1328	1335	|O
by	1336	1338	|O
icv	1339	1342	|O
administration	1343	1357	|O
of	1358	1360	|O
AMPA	1361	1365	|O
or	1366	1368	|O
kainate	1369	1376	|O
(	1377	1378	|O
KA	1378	1380	|O
)	1380	1381	|O
.	1381	1382	|O
Using	1383	1388	|O
the	1389	1392	|O
patch	1393	1398	|O
-	1398	1399	|O
clamp	1399	1404	|O
technique	1405	1414	|O
in	1415	1417	|O
primary	1418	1425	|O
cultures	1426	1434	|O
of	1435	1437	|O
granule	1438	1445	|O
neurons	1446	1453	|O
we	1454	1456	|O
tested	1457	1463	|O
compounds	1464	1473	|O
10	1474	1476	|O
and	1477	1480	|O
21	1481	1483	|O
for	1484	1487	|O
their	1488	1493	|O
ability	1494	1501	|O
to	1502	1504	|O
modulate	1505	1513	|O
currents	1514	1522	|O
evoked	1523	1529	|O
by	1530	1532	|O
KA	1533	1535	|O
and	1536	1539	|O
2	1540	1541	|B-IUPAC
-	1541	1542	|I-IUPAC
amino	1542	1547	|I-IUPAC
-	1547	1548	|I-IUPAC
3	1548	1549	|I-IUPAC
-	1549	1550	|I-IUPAC
(	1550	1551	|I-IUPAC
3	1551	1552	|I-IUPAC
-	1552	1553	|I-IUPAC
hydroxy	1553	1560	|I-IUPAC
-	1560	1561	|I-IUPAC
5	1561	1562	|I-IUPAC
-	1562	1563	|I-IUPAC
tert	1563	1567	|I-IUPAC
-	1567	1568	|I-IUPAC
butylisoxazol	1568	1581	|I-IUPAC
-	1581	1582	|I-IUPAC
4	1582	1583	|I-IUPAC
-	1583	1584	|I-IUPAC
yl	1584	1586	|I-IUPAC
)	1586	1587	|I-IUPAC
propionic	1587	1596	|I-IUPAC
acid	1597	1601	|I-IUPAC
(	1602	1603	|O
ATPA	1603	1607	|O
)	1607	1608	|O
.	1608	1609	|O
These	1610	1615	|O
two	1616	1619	|O
derivatives	1620	1631	|O
reduced	1632	1639	|O
KA	1640	1642	|O
and	1643	1646	|O
ATPA	1647	1651	|O
currents	1652	1660	|O
to	1661	1663	|O
a	1664	1665	|O
larger	1666	1672	|O
extent	1673	1679	|O
than	1680	1684	|O
that	1685	1689	|O
shown	1690	1695	|O
by	1696	1698	|O
reference	1699	1708	|O
compound	1709	1717	|O
1	1718	1719	|O
.	1719	1720	|O
Compounds	1721	1730	|O
10	1731	1733	|O
and	1734	1737	|O
21	1738	1740	|O
were	1741	1745	|O
also	1746	1750	|O
able	1751	1755	|O
to	1756	1758	|O
reduce	1759	1765	|O
neuronal	1766	1774	|O
cell	1775	1779	|O
death	1780	1785	|O
induced	1786	1793	|O
by	1794	1796	|O
the	1797	1800	|O
application	1801	1812	|O
of	1813	1815	|O
KA	1816	1818	|O
(	1819	1820	|O
100	1820	1823	|O
microM	1824	1830	|O
)	1830	1831	|O
.	1831	1832	|O

### abstracts2784.txt
Novel	0	5	|O
3	6	7	|O
-	7	8	|O
substituted	8	19	|O
analogues	20	29	|O
of	30	32	|O
4	33	34	|B-IUPAC
-	34	35	|I-IUPAC
amino	35	40	|I-IUPAC
-	40	41	|I-IUPAC
1	41	42	|I-IUPAC
-	42	43	|I-IUPAC
beta	43	47	|I-IUPAC
-	47	48	|I-IUPAC
D	48	49	|I-IUPAC
-	49	50	|I-IUPAC
ribofuranosyl	50	63	|I-IUPAC
-	63	64	|I-IUPAC
2	64	65	|I-IUPAC
(	65	66	|I-IUPAC
1H	66	68	|I-IUPAC
)	68	69	|I-IUPAC
-	69	70	|I-IUPAC
pyridinone	70	80	|I-IUPAC
(	81	82	|O
3	82	83	|B-IUPAC
-	83	84	|I-IUPAC
deazacytidine	84	97	|I-IUPAC
,	97	98	|O
3	99	100	|O
)	100	101	|O
and	102	105	|O
4	106	107	|B-IUPAC
-	107	108	|I-IUPAC
hydroxy	108	115	|I-IUPAC
-	115	116	|I-IUPAC
1	116	117	|I-IUPAC
-	117	118	|I-IUPAC
beta	118	122	|I-IUPAC
-	122	123	|I-IUPAC
D	123	124	|I-IUPAC
-	124	125	|I-IUPAC
ribofuranosyl	125	138	|I-IUPAC
-	138	139	|I-IUPAC
2	139	140	|I-IUPAC
(	140	141	|I-IUPAC
1H	141	143	|I-IUPAC
)	143	144	|I-IUPAC
-	144	145	|I-IUPAC
pyridinone	145	155	|I-IUPAC
(	156	157	|O
3	157	158	|B-IUPAC
-	158	159	|I-IUPAC
deazauridine	159	171	|I-IUPAC
,	171	172	|O
4	173	174	|O
)	174	175	|O
have	176	180	|O
been	181	185	|O
synthesized	186	197	|O
and	198	201	|O
tested	202	208	|O
for	209	212	|O
antitumor	213	222	|O
and	223	226	|O
antiviral	227	236	|O
activity	237	245	|O
.	245	246	|O
Thus	247	251	|O
the	252	255	|O
3	256	257	|B-PARTIUPAC
-	257	258	|I-PARTIUPAC
chloro	258	264	|I-PARTIUPAC
(	265	266	|O
9a	266	268	|O
)	268	269	|O
,	269	270	|O
3	271	272	|B-PARTIUPAC
-	272	273	|I-PARTIUPAC
bromo	273	278	|I-PARTIUPAC
(	279	280	|O
9b	280	282	|O
)	282	283	|O
,	283	284	|O
and	285	288	|O
3	289	290	|B-PARTIUPAC
-	290	291	|I-PARTIUPAC
nitro	291	296	|I-PARTIUPAC
(	297	298	|O
9c	298	300	|O
)	300	301	|O
analogues	302	311	|B-MODIFIER
of	312	314	|O
3	315	316	|O
and	317	320	|O
the	321	324	|O
3	325	326	|B-PARTIUPAC
-	326	327	|I-PARTIUPAC
chloro	327	333	|I-PARTIUPAC
(	334	335	|O
9d	335	337	|O
)	337	338	|O
,	338	339	|O
3	340	341	|B-PARTIUPAC
-	341	342	|I-PARTIUPAC
bromo	342	347	|I-PARTIUPAC
(	348	349	|O
9e	349	351	|O
)	351	352	|O
,	352	353	|O
and	354	357	|O
3	358	359	|B-PARTIUPAC
-	359	360	|I-PARTIUPAC
nitro	360	365	|I-PARTIUPAC
(	366	367	|O
9f	367	369	|O
)	369	370	|O
analogues	371	380	|B-MODIFIER
of	381	383	|O
4	384	385	|O
were	386	390	|O
prepared	391	399	|O
by	400	402	|O
standard	403	411	|O
glycosylating	412	425	|O
procedures	426	436	|O
.	436	437	|O
Novel	438	443	|O
requisite	444	453	|O
heterocycles	454	466	|B-MODIFIER
4	467	468	|B-IUPAC
-	468	469	|I-IUPAC
amino	469	474	|I-IUPAC
-	474	475	|I-IUPAC
3	475	476	|I-IUPAC
-	476	477	|I-IUPAC
chloro	477	483	|I-IUPAC
-	483	484	|I-IUPAC
2	484	485	|I-IUPAC
(	485	486	|I-IUPAC
1H	486	488	|I-IUPAC
)	488	489	|I-IUPAC
-	489	490	|I-IUPAC
pyridinone	490	500	|I-IUPAC
(	501	502	|O
7a	502	504	|O
)	504	505	|O
and	506	509	|O
4	510	511	|B-IUPAC
-	511	512	|I-IUPAC
amino	512	517	|I-IUPAC
-	517	518	|I-IUPAC
3	518	519	|I-IUPAC
-	519	520	|I-IUPAC
bromo	520	525	|I-IUPAC
-	525	526	|I-IUPAC
2	526	527	|I-IUPAC
(	527	528	|I-IUPAC
1H	528	530	|I-IUPAC
)	530	531	|I-IUPAC
-	531	532	|I-IUPAC
pyridinone	532	542	|I-IUPAC
(	543	544	|O
7b	544	546	|O
)	546	547	|O
were	548	552	|O
prepared	553	561	|O
by	562	564	|O
halogenating	565	577	|O
4	578	579	|B-IUPAC
-	579	580	|I-IUPAC
amino	580	585	|I-IUPAC
-	585	586	|I-IUPAC
2	586	587	|I-IUPAC
(	587	588	|I-IUPAC
1H	588	590	|I-IUPAC
)	590	591	|I-IUPAC
-	591	592	|I-IUPAC
pyridinone	592	602	|I-IUPAC
(	603	604	|O
5	604	605	|O
)	605	606	|O
.	606	607	|O
Requisite	608	617	|O
heterocycles	618	630	|O
4	631	632	|B-IUPAC
-	632	633	|I-IUPAC
amino	633	638	|I-IUPAC
-	638	639	|I-IUPAC
3	639	640	|I-IUPAC
-	640	641	|I-IUPAC
nitro	641	646	|I-IUPAC
-	646	647	|I-IUPAC
2	647	648	|I-IUPAC
(	648	649	|I-IUPAC
1H	649	651	|I-IUPAC
)	651	652	|I-IUPAC
-	652	653	|I-IUPAC
pyridinone	653	663	|I-IUPAC
(	664	665	|O
7c	665	667	|O
)	667	668	|O
,	668	669	|O
3	670	671	|B-IUPAC
-	671	672	|I-IUPAC
chloro	672	678	|I-IUPAC
-	678	679	|I-IUPAC
4	679	680	|I-IUPAC
-	680	681	|I-IUPAC
hydroxy	681	688	|I-IUPAC
-	688	689	|I-IUPAC
2	689	690	|I-IUPAC
(	690	691	|I-IUPAC
1H	691	693	|I-IUPAC
)	693	694	|I-IUPAC
-	694	695	|I-IUPAC
pyridinone	695	705	|I-IUPAC
(	706	707	|O
7d	707	709	|O
)	709	710	|O
,	710	711	|O
3	712	713	|B-IUPAC
-	713	714	|I-IUPAC
bromo	714	719	|I-IUPAC
-	719	720	|I-IUPAC
4	720	721	|I-IUPAC
-	721	722	|I-IUPAC
hydroxy	722	729	|I-IUPAC
-	729	730	|I-IUPAC
2	730	731	|I-IUPAC
(	731	732	|I-IUPAC
1H	732	734	|I-IUPAC
)	734	735	|I-IUPAC
-	735	736	|I-IUPAC
pyridinone	736	746	|I-IUPAC
(	747	748	|O
7e	748	750	|O
)	750	751	|O
,	751	752	|O
and	753	756	|O
4	757	758	|B-IUPAC
-	758	759	|I-IUPAC
hydroxy	759	766	|I-IUPAC
-	766	767	|I-IUPAC
3	767	768	|I-IUPAC
-	768	769	|I-IUPAC
nitro	769	774	|I-IUPAC
-	774	775	|I-IUPAC
2	775	776	|I-IUPAC
(	776	777	|I-IUPAC
1H	777	779	|I-IUPAC
)	779	780	|I-IUPAC
-	780	781	|I-IUPAC
pyridinone	781	791	|I-IUPAC
(	792	793	|O
7f	793	795	|O
)	795	796	|O
were	797	801	|O
synthesized	802	813	|O
by	814	816	|O
known	817	822	|O
procedures	823	833	|O
from	834	838	|O
4	839	840	|B-IUPAC
-	840	841	|I-IUPAC
hydroxy	841	848	|I-IUPAC
-	848	849	|I-IUPAC
2	849	850	|I-IUPAC
(	850	851	|I-IUPAC
1H	851	853	|I-IUPAC
)	853	854	|I-IUPAC
-	854	855	|I-IUPAC
pyridinone	855	865	|I-IUPAC
(	866	867	|O
6	867	868	|O
)	868	869	|O
.	869	870	|O
Structure	871	880	|O
proof	881	886	|O
of	887	889	|O
target	890	896	|O
nucleosides	897	908	|O
was	909	912	|O
provided	913	921	|O
by	922	924	|O
independent	925	936	|O
synthesis	937	946	|O
,	946	947	|O
1H	948	950	|O
NMR	951	954	|O
,	954	955	|O
and	956	959	|O
UV	960	962	|O
.	962	963	|O
Compounds	964	973	|O
9a	974	976	|O
-	976	977	|O
f	977	978	|O
were	979	983	|O
devoid	984	990	|O
of	991	993	|O
activity	994	1002	|O
against	1003	1010	|O
intraperitoneally	1011	1028	|O
implanted	1029	1038	|O
L1210	1039	1044	|O
leukemia	1045	1053	|O
in	1054	1056	|O
mice	1057	1061	|O
.	1061	1062	|O
Compound	1063	1071	|O
9f	1072	1074	|O
displayed	1075	1084	|O
significant	1085	1096	|O
activity	1097	1105	|O
against	1106	1113	|O
rhinovirus	1114	1124	|O
type	1125	1129	|O
34	1130	1132	|O
grown	1133	1138	|O
in	1139	1141	|O
WISH	1142	1146	|O
cells	1147	1152	|O
.	1152	1153	|O
4	1154	1155	|B-IUPAC
-	1155	1156	|I-IUPAC
Amino	1156	1161	|I-IUPAC
-	1161	1162	|I-IUPAC
3	1162	1163	|I-IUPAC
-	1163	1164	|I-IUPAC
fluoro	1164	1170	|I-IUPAC
-	1170	1171	|I-IUPAC
1	1171	1172	|I-IUPAC
-	1172	1173	|I-IUPAC
beta	1173	1177	|I-IUPAC
-	1177	1178	|I-IUPAC
D	1178	1179	|I-IUPAC
-	1179	1180	|I-IUPAC
ribofuranosyl	1180	1193	|I-IUPAC
-	1193	1194	|I-IUPAC
2	1194	1195	|I-IUPAC
(	1195	1196	|I-IUPAC
1H	1196	1198	|I-IUPAC
)	1198	1199	|I-IUPAC
-	1199	1200	|I-IUPAC
pyridinone	1200	1210	|I-IUPAC
(	1211	1212	|O
1	1212	1213	|O
)	1213	1214	|O
displayed	1215	1224	|O
good	1225	1229	|O
activity	1230	1238	|O
against	1239	1246	|O
intraperitoneally	1247	1264	|O
implanted	1265	1274	|O
P388	1275	1279	|O
leukemia	1280	1288	|O
in	1289	1291	|O
mice	1292	1296	|O
,	1296	1297	|O
but	1298	1301	|O
it	1302	1304	|O
was	1305	1308	|O
devoid	1309	1315	|O
of	1316	1318	|O
activity	1319	1327	|O
against	1328	1335	|O
M5076	1336	1341	|O
sarcoma	1342	1349	|O
,	1349	1350	|O
amelanotic	1351	1361	|O
(	1362	1363	|O
LOX	1363	1366	|O
)	1366	1367	|O
melanoma	1368	1376	|O
xenograft	1377	1386	|O
,	1386	1387	|O
and	1388	1391	|O
subrenal	1392	1400	|O
capsule	1401	1408	|O
human	1409	1414	|O
mammary	1415	1422	|O
carcinoma	1423	1432	|O
MX	1433	1435	|O
-	1435	1436	|O
1	1436	1437	|O
xenograft	1438	1447	|O
in	1448	1450	|O
mice	1451	1455	|O
.	1455	1456	|O
Compound	1457	1465	|O
1	1466	1467	|O
also	1468	1472	|O
displayed	1473	1482	|O
significant	1483	1494	|O
activity	1495	1503	|O
against	1504	1511	|O
rhinovirus	1512	1522	|O
type	1523	1527	|O
34	1528	1530	|O
.	1530	1531	|O

### abstracts3052.txt
The	0	3	|O
in	4	6	|O
vitro	7	12	|O
screening	13	22	|O
for	23	26	|O
trypanocidal	27	39	|O
activity	40	48	|O
against	49	56	|O
Trypanosoma	57	68	|O
brucei	69	75	|O
rhodesiense	76	87	|O
of	88	90	|O
an	91	93	|O
in	94	96	|O
-	96	97	|O
house	97	102	|O
library	103	110	|O
of	111	113	|O
62	114	116	|O
compounds	117	126	|O
[	127	128	|O
i.e.	128	132	|O
alkane	133	139	|O
,	139	140	|O
diphenyl	141	149	|O
,	149	150	|O
and	151	154	|O
azaalkane	155	164	|O
bisguanidines	165	178	|O
and	179	182	|O
bis	183	186	|B-IUPAC
(	186	187	|I-IUPAC
2	187	188	|I-IUPAC
-	188	189	|I-IUPAC
aminoimidazolines	189	206	|I-IUPAC
)	206	207	|I-IUPAC
]	207	208	|O
,	208	209	|O
which	210	215	|O
were	216	220	|O
chosen	221	227	|O
for	228	231	|O
their	232	237	|O
structural	238	248	|O
similarity	249	259	|O
to	260	262	|O
the	263	266	|O
trypanocidal	267	279	|O
agents	280	286	|O
synthalin	287	296	|O
(	297	298	|O
1,10	298	302	|B-IUPAC
-	302	303	|I-IUPAC
decanediguanidine	303	320	|I-IUPAC
)	320	321	|O
and	322	325	|O
4,4	326	329	|B-IUPAC
'	329	330	|I-IUPAC
-	330	331	|I-IUPAC
diguanidinodiphenylmethane	331	357	|I-IUPAC
and	358	361	|O
the	362	365	|O
polyamine	366	375	|B-IUPAC
N	376	377	|I-IUPAC
(	377	378	|I-IUPAC
1	378	379	|I-IUPAC
)	379	380	|I-IUPAC
-	380	381	|I-IUPAC
(	381	382	|I-IUPAC
3	382	383	|I-IUPAC
-	383	384	|I-IUPAC
amino	384	389	|I-IUPAC
-	389	390	|I-IUPAC
propyl	390	396	|I-IUPAC
)	396	397	|I-IUPAC
propane	397	404	|I-IUPAC
-	404	405	|I-IUPAC
1,3	405	408	|I-IUPAC
-	408	409	|I-IUPAC
diamine	409	416	|I-IUPAC
,	416	417	|O
respectively	418	430	|O
,	430	431	|O
is	432	434	|O
reported	435	443	|O
.	443	444	|O
The	445	448	|O
original	449	457	|O
synthetic	458	467	|O
procedure	468	477	|O
for	478	481	|O
the	482	485	|O
preparation	486	497	|O
of	498	500	|O
21	501	503	|O
of	504	506	|O
these	507	512	|O
compounds	513	522	|O
is	523	525	|O
also	526	530	|O
reported	531	539	|O
.	539	540	|O
Most	541	545	|O
compounds	546	555	|O
displayed	556	565	|O
low	566	569	|O
micromolar	570	580	|O
antitrypanosomal	581	597	|O
activity	598	606	|O
,	606	607	|O
with	608	612	|O
five	613	617	|O
of	618	620	|O
them	621	625	|O
presenting	626	636	|O
a	637	638	|O
nanomolar	639	648	|O
inhibitory	649	659	|O
action	660	666	|O
on	667	669	|O
the	670	673	|O
parasite	674	682	|O
:	682	683	|O
1,9	684	687	|B-IUPAC
-	687	688	|I-IUPAC
nonanediguanidine	688	705	|I-IUPAC
(	706	707	|O
1c	707	709	|O
)	709	710	|O
,	710	711	|O
1,12	712	716	|B-IUPAC
-	716	717	|I-IUPAC
dodecanediguanidine	717	736	|I-IUPAC
(	737	738	|O
1d	738	740	|O
)	740	741	|O
,	741	742	|O
4,4	743	746	|B-IUPAC
'	746	747	|I-IUPAC
-	747	748	|I-IUPAC
bis	748	751	|I-IUPAC
[	751	752	|I-IUPAC
1,3	752	755	|I-IUPAC
-	755	756	|I-IUPAC
bis	756	759	|I-IUPAC
(	759	760	|I-IUPAC
tert	760	764	|I-IUPAC
-	764	765	|I-IUPAC
butoxycarbonyl	765	779	|I-IUPAC
)	779	780	|I-IUPAC
-	780	781	|I-IUPAC
2	781	782	|I-IUPAC
-	782	783	|I-IUPAC
imidazolidinylimino	783	802	|I-IUPAC
]	802	803	|I-IUPAC
diphenylamine	803	816	|I-IUPAC
(	817	818	|O
28a	818	821	|O
)	821	822	|O
,	822	823	|O
4,4	824	827	|B-IUPAC
'	827	828	|I-IUPAC
-	828	829	|I-IUPAC
bis	829	832	|I-IUPAC
(	832	833	|I-IUPAC
4,5	833	836	|I-IUPAC
-	836	837	|I-IUPAC
dihydro	837	844	|I-IUPAC
-	844	845	|I-IUPAC
1H	845	847	|I-IUPAC
-	847	848	|I-IUPAC
2	848	849	|I-IUPAC
-	849	850	|I-IUPAC
imidazolylamino	850	865	|I-IUPAC
)	865	866	|I-IUPAC
diphenylamine	866	879	|I-IUPAC
(	880	881	|O
28b	881	884	|O
)	884	885	|O
,	885	886	|O
and	887	890	|O
4,4	891	894	|B-IUPAC
'	894	895	|I-IUPAC
-	895	896	|I-IUPAC
diguanidinodiphenylamine	896	920	|I-IUPAC
(	921	922	|O
32b	922	925	|O
)	925	926	|O
.	926	927	|O
Those	928	933	|O
molecules	934	943	|O
that	944	948	|O
showed	949	955	|O
an	956	958	|O
excellent	959	968	|O
in	969	971	|O
vitro	972	977	|O
activity	978	986	|O
as	987	989	|O
well	990	994	|O
as	995	997	|O
high	998	1002	|O
selectivity	1003	1014	|O
for	1015	1018	|O
the	1019	1022	|O
parasite	1023	1031	|O
[	1032	1033	|O
e.g.	1033	1037	|O
1c	1038	1040	|O
(	1041	1042	|O
IC	1042	1044	|O
(	1044	1045	|O
50	1045	1047	|O
)	1047	1048	|O
=	1049	1050	|O
49	1051	1053	|O
nM	1054	1056	|O
;	1056	1057	|O
SI	1058	1060	|O
&	1061	1062	|O
gt	1062	1064	|O
;	1064	1065	|O
5294	1066	1070	|O
)	1070	1071	|O
,	1071	1072	|O
28b	1073	1076	|O
(	1077	1078	|O
IC	1078	1080	|O
(	1080	1081	|O
50	1081	1083	|O
)	1083	1084	|O
=	1085	1086	|O
69	1087	1089	|O
nM	1090	1092	|O
;	1092	1093	|O
SI	1094	1096	|O
=	1097	1098	|O
3072	1099	1103	|O
)	1103	1104	|O
,	1104	1105	|O
32b	1106	1109	|O
(	1110	1111	|O
IC	1111	1113	|O
(	1113	1114	|O
50	1114	1116	|O
)	1116	1117	|O
=	1118	1119	|O
22	1120	1122	|O
nM	1123	1125	|O
;	1125	1126	|O
SI	1127	1129	|O
=	1130	1131	|O
29.5	1132	1136	|O
)	1136	1137	|O
,	1137	1138	|O
41b	1139	1142	|O
(	1143	1144	|O
IC	1144	1146	|O
(	1146	1147	|O
50	1147	1149	|O
)	1149	1150	|O
=	1151	1152	|O
118	1153	1156	|O
nM	1157	1159	|O
;	1159	1160	|O
SI	1161	1163	|O
=	1164	1165	|O
881	1166	1169	|O
)	1169	1170	|O
]	1170	1171	|O
represent	1172	1181	|O
new	1182	1185	|O
antitrypanosomal	1186	1202	|O
lead	1203	1207	|O
compounds	1208	1217	|O
.	1217	1218	|O

### abstracts4382.txt
In	0	2	|O
earlier	3	10	|O
reports	11	18	|O
we	19	21	|O
identified	22	32	|O
specific	33	41	|O
point	42	47	|O
substitutions	48	61	|O
(	62	63	|O
DPhe12	63	69	|O
,	69	70	|O
Nle21	70	75	|O
,	75	76	|O
38	76	78	|O
)	78	79	|O
,	79	80	|O
cyclization	81	92	|O
strategies	93	103	|O
[	104	105	|O
in	105	107	|O
particular	108	118	|O
,	118	119	|O
introduction	120	132	|O
of	133	135	|O
lactam	136	142	|O
rings	143	148	|O
such	149	153	|O
as	154	156	|O
that	157	161	|O
of	162	164	|O
cyclo	165	170	|O
(	170	171	|O
Glu30	171	176	|O
,	176	177	|O
Lys33	177	182	|O
)	182	183	|O
]	183	184	|O
,	184	185	|O
and	186	189	|O
deletions	190	199	|O
(	200	201	|O
residues	201	209	|O
1-7	210	213	|O
)	213	214	|O
in	215	217	|O
the	218	221	|O
CRF	222	225	|O
molecule	226	234	|O
that	235	239	|O
led	240	243	|O
to	244	246	|O
agonists	247	255	|O
.	255	256	|O
We	257	259	|O
also	260	264	|O
noted	265	270	|O
that	271	275	|O
further	276	283	|O
deletions	284	293	|O
(	294	295	|O
residues	295	303	|O
8-14	304	308	|O
)	308	309	|O
produced	310	318	|O
antagonists	319	330	|O
such	331	335	|O
as	336	338	|O
astressin	339	348	|O
	349	350	|O
	350	351	|O
cyclo	351	356	|O
(	356	357	|O
30-33	357	362	|O
)	362	363	|O
[	363	364	|O
DPhe12	364	370	|O
,	370	371	|O
Nle21	371	376	|O
,	376	377	|O
38	377	379	|O
,	379	380	|O
Glu30	381	386	|O
,	386	387	|O
Lys33	388	393	|O
]	393	394	|O
hCRF	394	398	|O
(	398	399	|O
12-41	399	404	|O
)	404	405	|O
	405	406	|O
	406	407	|O
(	408	409	|O
1	409	410	|O
)	410	411	|O
.	411	412	|O
We	413	415	|O
hypothesized	416	428	|O
that	429	433	|O
the	434	437	|O
lactam	438	444	|O
ring	445	449	|O
promoted	450	458	|O
conformational	459	473	|O
stability	474	483	|O
to	484	486	|O
yield	487	492	|O
analogues	493	502	|O
with	503	507	|O
increased	508	517	|O
potency	518	525	|O
both	526	530	|O
in	531	533	|O
vitro	534	539	|O
and	540	543	|O
in	544	546	|O
vivo	547	551	|O
as	552	554	|O
compared	555	563	|O
to	564	566	|O
that	567	571	|O
of	572	574	|O
their	575	580	|O
linear	581	587	|O
counterparts	588	600	|O
.	600	601	|O
Additionally	602	614	|O
,	614	615	|O
we	616	618	|O
reported	619	627	|O
that	628	632	|O
cyclo	633	638	|O
(	638	639	|O
30-33	639	644	|O
)	644	645	|O
[	645	646	|O
DPhe12	646	652	|O
,	652	653	|O
Nle21	653	658	|O
,	658	659	|O
38	659	661	|O
,	661	662	|O
Glu30	663	668	|O
,	668	669	|O
DHis32	669	675	|O
,	675	676	|O
Lys33	676	681	|O
]	681	682	|O
hCRF	682	686	|O
(	686	687	|O
12-41	687	692	|O
)	692	693	|O
(	694	695	|O
3	695	696	|O
)	696	697	|O
and	698	701	|O
dicyclo	702	709	|O
(	709	710	|O
26-36,30-33	710	721	|O
)	721	722	|O
[	722	723	|O
Ac	723	725	|O
-	725	726	|O
Asp9	726	730	|O
,	730	731	|O
DPhe12	731	737	|O
,	737	738	|O
Nle21	738	743	|O
,	743	744	|O
38	744	746	|O
,	746	747	|O
Cys26	748	753	|O
,	753	754	|O
Glu30	755	760	|O
,	760	761	|O
Lys33	761	766	|O
,	766	767	|O
Cys36	768	773	|O
]	773	774	|O
hCRF	774	778	|O
(	778	779	|O
9-41	779	783	|O
)	783	784	|O
were	785	789	|O
ca.	790	793	|O
twice	794	799	|O
and	800	803	|O
1/100	804	809	|O
as	810	812	|O
potent	813	819	|O
as	820	822	|O
astressin	823	832	|O
,	832	833	|O
respectively	834	846	|O
,	846	847	|O
suggesting	848	858	|O
a	859	860	|O
putative	861	869	|O
turn	870	874	|O
that	875	879	|O
encompasses	880	891	|O
residues	892	900	|O
30-33	901	906	|O
(	907	908	|O
previous	908	916	|O
paper	917	922	|O
:	922	923	|O
Koerber	924	931	|O
et	932	934	|O
al.	935	938	|O
J	939	940	|O
.	940	941	|O
Med.	942	946	|O
Chem.	947	952	|O
1998	953	957	|O
,	957	958	|O
41	959	961	|O
)	961	962	|O
.	962	963	|O
To	964	966	|O
increase	967	975	|O
the	976	979	|O
potency	980	987	|O
of	988	990	|O
1	991	992	|O
and	993	996	|O
/	996	997	|O
or	997	999	|O
3	1000	1001	|O
in	1002	1004	|O
vivo	1005	1009	|O
,	1009	1010	|O
we	1011	1013	|O
extended	1014	1022	|O
their	1023	1028	|O
chain	1029	1034	|O
length	1035	1041	|O
by	1042	1044	|O
one	1045	1048	|O
(	1049	1050	|O
5-8	1050	1053	|O
)	1053	1054	|O
,	1054	1055	|O
two	1056	1059	|O
(	1060	1061	|O
9	1061	1062	|O
,	1062	1063	|O
10	1064	1066	|O
)	1066	1067	|O
,	1067	1068	|O
and	1069	1072	|O
three	1073	1078	|O
(	1079	1080	|O
11	1080	1082	|O
,	1082	1083	|O
12	1084	1086	|O
)	1086	1087	|O
residues	1088	1096	|O
at	1097	1099	|O
the	1100	1103	|O
N	1104	1105	|O
-	1105	1106	|O
terminus	1106	1114	|O
and	1115	1118	|O
acetylated	1119	1129	|O
(	1130	1131	|O
6	1131	1132	|O
,	1132	1133	|O
8	1134	1135	|O
,	1135	1136	|O
10	1137	1139	|O
,	1139	1140	|O
12	1141	1143	|O
)	1143	1144	|O
.	1144	1145	|O
Of	1146	1148	|O
the	1149	1152	|O
compounds	1153	1162	|O
tested	1163	1169	|O
for	1170	1173	|O
duration	1174	1182	|O
of	1183	1185	|O
action	1186	1192	|O
(	1193	1194	|O
1	1194	1195	|O
,	1195	1196	|O
3-6	1197	1200	|O
,	1200	1201	|O
8	1202	1203	|O
)	1203	1204	|O
,	1204	1205	|O
we	1206	1208	|O
found	1209	1214	|O
6	1215	1216	|O
and	1217	1220	|O
8	1221	1222	|O
to	1223	1225	|O
be	1226	1228	|O
slightly	1229	1237	|O
longer	1238	1244	|O
-	1244	1245	|O
acting	1245	1251	|O
than	1252	1256	|O
astressin	1257	1266	|O
or	1267	1269	|O
[	1270	1271	|O
DHis32	1271	1277	|O
]	1277	1278	|O
astressin	1278	1287	|O
,	1287	1288	|O
while	1289	1294	|O
their	1295	1300	|O
potencies	1301	1310	|O
in	1311	1313	|O
vitro	1314	1319	|O
were	1320	1324	|O
not	1325	1328	|O
significantly	1329	1342	|O
different	1343	1352	|O
from	1353	1357	|O
that	1358	1362	|O
of	1363	1365	|O
3	1366	1367	|O
.	1367	1368	|O
Additionally	1369	1381	|O
,	1381	1382	|O
we	1383	1385	|O
introduced	1386	1396	|O
CalphaMe	1397	1405	|O
-	1405	1406	|O
leucine	1406	1413	|O
residues	1414	1422	|O
in	1423	1425	|O
lieu	1426	1430	|O
of	1431	1433	|O
leucine	1434	1441	|O
at	1442	1444	|O
positions	1445	1454	|O
14	1455	1457	|O
,	1457	1458	|O
15	1459	1461	|O
,	1461	1462	|O
19	1463	1465	|O
,	1465	1466	|O
27	1467	1469	|O
,	1469	1470	|O
and	1471	1474	|O
37	1475	1477	|O
in	1478	1480	|O
[	1481	1482	|O
DHis32	1482	1488	|O
]	1488	1489	|O
astressin	1489	1498	|O
.	1498	1499	|O
The	1500	1503	|O
analogue	1504	1512	|O
[	1513	1514	|O
CalphaMe	1514	1522	|O
-	1522	1523	|O
Leu27	1523	1528	|O
,	1528	1529	|O
DHis32	1529	1535	|O
]	1535	1536	|O
astressin	1536	1545	|O
(	1546	1547	|O
16	1547	1549	|O
)	1549	1550	|O
was	1551	1554	|O
more	1555	1559	|O
potent	1560	1566	|O
(	1567	1568	|O
although	1568	1576	|O
not	1577	1580	|O
statistically	1581	1594	|O
in	1595	1597	|O
all	1598	1601	|O
cases	1602	1607	|O
)	1607	1608	|O
than	1609	1613	|O
the	1614	1617	|O
other	1618	1623	|O
four	1624	1628	|O
analogues	1629	1638	|O
in	1639	1641	|O
vitro	1642	1647	|O
.	1647	1648	|O
While	1649	1654	|O
acetylation	1655	1666	|O
of	1667	1669	|O
the	1670	1673	|O
N	1674	1675	|O
-	1675	1676	|O
terminus	1676	1684	|O
of	1685	1687	|O
16	1688	1690	|O
(	1691	1692	|O
i.e.	1692	1696	|O
,	1696	1697	|O
18	1698	1700	|O
)	1700	1701	|O
or	1702	1704	|O
of	1705	1707	|O
[	1708	1709	|O
CalphaMe	1709	1717	|O
-	1717	1718	|O
Leu27	1718	1723	|O
]	1723	1724	|O
astressin	1724	1733	|O
(	1734	1735	|O
i.e.	1735	1739	|O
,	1739	1740	|O
19	1741	1743	|O
)	1743	1744	|O
did	1745	1748	|O
not	1749	1752	|O
have	1753	1757	|O
a	1758	1759	|O
significant	1760	1771	|O
effect	1772	1778	|O
on	1779	1781	|O
in	1782	1784	|O
vitro	1785	1790	|O
potency	1791	1798	|O
,	1798	1799	|O
elongation	1800	1810	|O
of	1811	1813	|O
the	1814	1817	|O
N	1818	1819	|O
-	1819	1820	|O
terminus	1820	1828	|O
by	1829	1831	|O
one	1832	1835	|O
or	1836	1838	|O
three	1839	1844	|O
residues	1845	1853	|O
in	1854	1856	|O
addition	1857	1865	|O
to	1866	1868	|O
acetylation	1869	1880	|O
resulted	1881	1889	|O
in	1890	1892	|O
cyclo	1893	1898	|O
(	1898	1899	|O
30-33	1899	1904	|O
)	1904	1905	|O
[	1905	1906	|O
DPhe12	1906	1912	|O
,	1912	1913	|O
Nle21	1913	1918	|O
,	1918	1919	|O
CalphaMe	1919	1927	|O
-	1927	1928	|O
Leu27	1928	1933	|O
,	1933	1934	|O
Glu3	1934	1938	|O
0	1939	1940	|O
,	1940	1941	|O
DHis32	1941	1947	|O
,	1947	1948	|O
Lys33	1948	1953	|O
,	1953	1954	|O
Nle38	1955	1960	|O
]	1960	1961	|O
Ac	1961	1963	|O
-	1963	1964	|O
hCRF	1964	1968	|O
(	1968	1969	|O
11-41	1969	1974	|O
)	1974	1975	|O
(	1976	1977	|O
21	1977	1979	|O
)	1979	1980	|O
,	1980	1981	|O
cyclo	1982	1987	|O
(	1987	1988	|O
30-33	1988	1993	|O
)	1993	1994	|O
[	1994	1995	|O
DPhe12	1995	2001	|O
,	2001	2002	|O
Nle21	2002	2007	|O
,	2007	2008	|O
CalphaMe	2008	2016	|O
-	2016	2017	|O
Leu27	2017	2022	|O
,	2022	2023	|O
Glu30	2024	2029	|O
,	2029	2030	|O
Lys33	2030	2035	|O
,	2035	2036	|O
Nle38	2036	2041	|O
]	2041	2042	|O
Ac	2042	2044	|O
-	2044	2045	|O
hCRF	2045	2049	|O
(	2049	2050	|O
9-41	2050	2054	|O
)	2054	2055	|O
(	2056	2057	|O
22	2057	2059	|O
)	2059	2060	|O
,	2060	2061	|O
and	2062	2065	|O
cyclo	2066	2071	|O
(	2071	2072	|O
30-33	2072	2077	|O
)	2077	2078	|O
[	2078	2079	|O
DPhe12	2079	2085	|O
,	2085	2086	|O
Nle21	2087	2092	|O
,	2092	2093	|O
CalphaMe	2094	2102	|O
-	2102	2103	|O
Leu27	2103	2108	|O
,	2108	2109	|O
Glu30	2109	2114	|O
,	2114	2115	|O
DHis32	2115	2121	|O
,	2121	2122	|O
Lys33	2122	2127	|O
,	2127	2128	|O
Nle38	2128	2133	|O
]	2134	2135	|O
Ac	2135	2137	|O
-	2137	2138	|O
hCRF	2138	2142	|O
(	2142	2143	|O
9-41	2143	2147	|O
)	2147	2148	|O
(	2149	2150	|O
23	2150	2152	|O
)	2152	2153	|O
that	2154	2158	|O
were	2159	2163	|O
longer	2164	2170	|O
-	2170	2171	|O
acting	2171	2177	|O
than	2178	2182	|O
6	2183	2184	|O
and	2185	2188	|O
8	2189	2190	|O
(	2191	2192	|O
ca.	2192	2195	|O
2	2196	2197	|O
h	2198	2199	|O
inhibition	2200	2210	|O
of	2211	2213	|O
ACTH	2214	2218	|O
secretion	2219	2228	|O
at	2229	2231	|O
25	2232	2234	|O
micrograms	2235	2245	|O
/	2245	2246	|O
adrenalectomized	2246	2262	|O
rat	2263	2266	|O
)	2266	2267	|O
.	2267	2268	|O
Analogues	2269	2278	|O
22	2279	2281	|O
and	2282	2285	|O
23	2286	2288	|O
were	2289	2293	|O
also	2294	2298	|O
more	2299	2303	|O
potent	2304	2310	|O
than	2311	2315	|O
astressin	2316	2325	|O
at	2326	2328	|O
reversing	2329	2338	|O
intracisternal	2339	2353	|O
CRF	2354	2357	|O
-	2357	2358	|O
and	2359	2362	|O
abdominal	2363	2372	|O
surgery	2373	2380	|O
-	2380	2381	|O
induced	2381	2388	|O
delay	2389	2394	|O
of	2395	2397	|O
gastric	2398	2405	|O
emptying	2406	2414	|O
in	2415	2417	|O
conscious	2418	2427	|O
rats	2428	2432	|O
.	2432	2433	|O

### abstracts2121.txt
A	0	1	|O
new	2	5	|O
means	6	11	|O
of	12	14	|O
accessing	15	24	|O
N	25	26	|B-IUPAC
(	26	27	|I-IUPAC
1	27	28	|I-IUPAC
)	28	29	|I-IUPAC
-	29	30	|I-IUPAC
cyclopropylmethyl	30	47	|I-IUPAC
-	47	48	|I-IUPAC
N	48	49	|I-IUPAC
(	49	50	|I-IUPAC
11	50	52	|I-IUPAC
)	52	53	|I-IUPAC
-	53	54	|I-IUPAC
ethylnorspermine	54	70	|I-IUPAC
(	71	72	|O
CPMENSPM	72	80	|O
)	80	81	|O
and	82	85	|O
the	86	89	|O
first	90	95	|O
synthesis	96	105	|O
of	106	108	|O
(	109	110	|B-IUPAC
2R	110	112	|I-IUPAC
,	112	113	|I-IUPAC
10S	113	116	|I-IUPAC
)	116	117	|I-IUPAC
-	117	118	|I-IUPAC
N	118	119	|I-IUPAC
(	119	120	|I-IUPAC
1	120	121	|I-IUPAC
)	121	122	|I-IUPAC
-	122	123	|I-IUPAC
cyclopropylmethyl	123	140	|I-IUPAC
-	140	141	|I-IUPAC
2,10	141	145	|I-IUPAC
-	145	146	|I-IUPAC
dihydroxy	146	155	|I-IUPAC
-	155	156	|I-IUPAC
N	156	157	|I-IUPAC
(	157	158	|I-IUPAC
11	158	160	|I-IUPAC
)	160	161	|I-IUPAC
-	161	162	|I-IUPAC
ethylnorspermine	162	178	|I-IUPAC
[	179	180	|O
(	180	181	|O
2R	181	183	|O
,	183	184	|O
10S	184	187	|O
)	187	188	|O
-	188	189	|O
(	189	190	|O
HO	190	192	|O
)	192	193	|O
(	193	194	|O
2	194	195	|O
)	195	196	|O
CPMENSPM	196	204	|O
]	204	205	|O
are	206	209	|O
described	210	219	|O
.	219	220	|O
Both	221	225	|O
of	226	228	|O
these	229	234	|O
polyamine	235	244	|O
analogues	245	254	|O
are	255	258	|O
shown	259	264	|O
to	265	267	|O
be	268	270	|O
more	271	275	|O
active	276	282	|O
against	283	290	|O
L1210	291	296	|O
murine	297	303	|O
leukemia	304	312	|O
cell	313	317	|O
growth	318	324	|O
than	325	329	|O
either	330	336	|O
N	337	338	|B-IUPAC
(	338	339	|I-IUPAC
1	339	340	|I-IUPAC
)	340	341	|I-IUPAC
,	341	342	|I-IUPAC
N	342	343	|I-IUPAC
(	343	344	|I-IUPAC
11	344	346	|I-IUPAC
)	346	347	|I-IUPAC
-	347	348	|I-IUPAC
diethylnorspermine	348	366	|I-IUPAC
(	367	368	|O
DENSPM	368	374	|O
)	374	375	|O
or	376	378	|O
(	379	380	|B-IUPAC
2R	380	382	|I-IUPAC
,	382	383	|I-IUPAC
10R	383	386	|I-IUPAC
)	386	387	|I-IUPAC
-	387	388	|I-IUPAC
N	388	389	|I-IUPAC
(	389	390	|I-IUPAC
1	390	391	|I-IUPAC
)	391	392	|I-IUPAC
,	392	393	|I-IUPAC
N	393	394	|I-IUPAC
(	394	395	|I-IUPAC
11	395	397	|I-IUPAC
)	397	398	|I-IUPAC
-	398	399	|I-IUPAC
diethyl	399	406	|I-IUPAC
-	406	407	|I-IUPAC
2,10	407	411	|I-IUPAC
-	411	412	|I-IUPAC
dihydroxynorspermine	412	432	|I-IUPAC
[	433	434	|O
(	434	435	|O
2R	435	437	|O
,	437	438	|O
10R	438	441	|O
)	441	442	|O
-	442	443	|O
(	443	444	|O
HO	444	446	|O
)	446	447	|O
(	447	448	|O
2	448	449	|O
)	449	450	|O
DENSPM	450	456	|O
]	456	457	|O
after	458	463	|O
96	464	466	|O
h	467	468	|O
of	469	471	|O
treatment	472	481	|O
;	481	482	|O
the	483	486	|O
activity	487	495	|O
was	496	499	|O
comparable	500	510	|O
to	511	513	|O
that	514	518	|O
of	519	521	|O
(	522	523	|B-IUPAC
2S	523	525	|I-IUPAC
,	525	526	|I-IUPAC
10S	526	529	|I-IUPAC
)	529	530	|I-IUPAC
-	530	531	|I-IUPAC
N	531	532	|I-IUPAC
(	532	533	|I-IUPAC
1	533	534	|I-IUPAC
)	534	535	|I-IUPAC
,	535	536	|I-IUPAC
N	536	537	|I-IUPAC
(	537	538	|I-IUPAC
11	538	540	|I-IUPAC
)	540	541	|I-IUPAC
-	541	542	|I-IUPAC
diethyl	542	549	|I-IUPAC
-	549	550	|I-IUPAC
2,10	550	554	|I-IUPAC
-	554	555	|I-IUPAC
dihydroxynorspermine	555	575	|I-IUPAC
[	576	577	|O
(	577	578	|O
2S	578	580	|O
,	580	581	|O
10S	581	584	|O
)	584	585	|O
-	585	586	|O
(	586	587	|O
HO	587	589	|O
)	589	590	|O
(	590	591	|O
2	591	592	|O
)	592	593	|O
DENSPM	593	599	|O
]	599	600	|O
at	601	603	|O
96	604	606	|O
h	607	608	|O
.	608	609	|O
Both	610	614	|O
cyclopropyl	615	626	|B-PARTIUPAC
compounds	627	636	|B-MODIFIER
reduced	637	644	|O
putrescine	645	655	|O
and	656	659	|O
spermidine	660	670	|O
pools	671	676	|O
,	676	677	|O
but	678	681	|O
less	682	686	|O
effectively	687	698	|O
than	699	703	|O
did	704	707	|O
DENSPM	708	714	|O
and	715	718	|O
its	719	722	|O
derivatives	723	734	|O
.	734	735	|O
Only	736	740	|O
CPMENSPM	741	749	|O
,	749	750	|O
and	751	754	|O
not	755	758	|O
(	759	760	|O
2R	760	762	|O
,	762	763	|O
10S	763	766	|O
)	766	767	|O
-	767	768	|O
(	768	769	|O
HO	769	771	|O
)	771	772	|O
(	772	773	|O
2	773	774	|O
)	774	775	|O
CPMENSPM	775	783	|O
,	783	784	|O
lowered	785	792	|O
spermine	793	801	|O
pools	802	807	|O
.	807	808	|O
As	809	811	|O
with	812	816	|O
DENSPM	817	823	|O
and	824	827	|O
(	828	829	|O
2R	829	831	|O
,	831	832	|O
10R	832	835	|O
)	835	836	|O
-	836	837	|O
(	837	838	|O
HO	838	840	|O
)	840	841	|O
(	841	842	|O
2	842	843	|O
)	843	844	|O
DENSPM	844	850	|O
,	850	851	|O
both	852	856	|O
cyclopropyl	857	868	|B-PARTIUPAC
analogues	869	878	|B-MODIFIER
diminished	879	889	|O
ornithine	890	899	|O
decarboxylase	900	913	|O
and	914	917	|O
S	918	919	|B-IUPAC
-	919	920	|I-IUPAC
adenosylmethionine	920	938	|I-IUPAC
decarboxylase	939	952	|O
activity	953	961	|O
.	961	962	|O
Unlike	963	969	|O
the	970	973	|O
hydroxylated	974	986	|O
DENSPM	987	993	|O
compounds	994	1003	|O
,	1003	1004	|O
both	1005	1009	|O
cyclopropyl	1010	1021	|O
norspermines	1022	1034	|O
substantially	1035	1048	|O
upregulated	1049	1060	|O
spermidine	1061	1071	|O
/	1071	1072	|O
spermine	1072	1080	|O
N	1081	1082	|O
(	1082	1083	|O
1	1083	1084	|O
)	1084	1085	|O
-	1085	1086	|O
acetyltransferase	1086	1103	|O
.	1103	1104	|O
The	1105	1108	|O
most	1109	1113	|O
interesting	1114	1125	|O
effect	1126	1132	|O
of	1133	1135	|O
hydroxylating	1136	1149	|O
CPMENSPM	1150	1158	|O
is	1159	1161	|O
the	1162	1165	|O
profound	1166	1174	|O
reduction	1175	1184	|O
in	1185	1187	|O
toxicity	1188	1196	|O
compared	1197	1205	|O
with	1206	1210	|O
that	1211	1215	|O
of	1216	1218	|O
the	1219	1222	|O
parent	1223	1229	|O
drug	1230	1234	|O
.	1234	1235	|O
The	1236	1239	|O
same	1240	1244	|O
phenomenon	1245	1255	|O
had	1256	1259	|O
been	1260	1264	|O
observed	1265	1273	|O
for	1274	1277	|O
the	1278	1281	|O
DENSPM	1282	1288	|O
/	1288	1289	|O
(	1289	1290	|O
2R	1290	1292	|O
,	1292	1293	|O
10R	1293	1296	|O
)	1296	1297	|O
-	1297	1298	|O
(	1298	1299	|O
HO	1299	1301	|O
)	1301	1302	|O
(	1302	1303	|O
2	1303	1304	|O
)	1304	1305	|O
DENSPM	1305	1311	|O
pair	1312	1316	|O
.	1316	1317	|O
Thus	1318	1322	|O
,	1322	1323	|O
hydroxylation	1324	1337	|O
of	1338	1340	|O
norspermine	1341	1352	|O
analogues	1353	1362	|O
appears	1363	1370	|O
to	1371	1373	|O
be	1374	1376	|O
a	1377	1378	|O
way	1379	1382	|O
to	1383	1385	|O
maintain	1386	1394	|O
the	1395	1398	|O
compounds	1399	1408	|O
'	1408	1409	|O
antiproliferative	1410	1427	|O
activity	1428	1436	|O
while	1437	1442	|O
reducing	1443	1451	|O
their	1452	1457	|O
toxicity	1458	1466	|O
.	1466	1467	|O

### abstracts2358.txt
Three	0	5	|O
series	6	12	|O
of	13	15	|O
benzamides	16	26	|O
of	27	29	|O
N	30	31	|B-MODIFIER
,	31	32	|I-MODIFIER
N	32	33	|I-MODIFIER
-	33	34	|I-MODIFIER
disubstituted	34	47	|I-MODIFIER
ethylenediamines	48	64	|B-IUPAC
(	65	66	|O
linear	66	72	|B-MODIFIER
alkane	73	79	|B-IUPAC
-	79	80	|I-IUPAC
1,2	80	83	|I-IUPAC
-	83	84	|I-IUPAC
diamines	84	92	|I-IUPAC
)	92	93	|O
,	93	94	|O
1	95	96	|B-MODIFIER
-	96	97	|I-MODIFIER
substituted	97	108	|I-MODIFIER
2	109	110	|B-IUPAC
-	110	111	|I-IUPAC
(	111	112	|I-IUPAC
aminomethyl	112	123	|I-IUPAC
)	123	124	|I-IUPAC
pyrrolidines	124	136	|I-IUPAC
,	136	137	|O
and	138	141	|O
1	142	143	|B-MODIFIER
-	143	144	|I-MODIFIER
substituted	144	155	|I-MODIFIER
3	156	157	|B-IUPAC
-	157	158	|I-IUPAC
aminopyrrolidines	158	175	|I-IUPAC
(	176	177	|O
cyclic	177	183	|B-MODIFIER
alkane	184	190	|B-IUPAC
-	190	191	|I-IUPAC
1,2	191	194	|I-IUPAC
-	194	195	|I-IUPAC
diamines	195	203	|I-IUPAC
)	203	204	|O
were	205	209	|O
designed	210	218	|O
and	219	222	|O
synthesized	223	234	|O
as	235	237	|O
potential	238	247	|O
neuroleptics	248	260	|O
.	260	261	|O
All	262	265	|O
target	266	272	|O
compounds	273	282	|O
were	283	287	|O
evaluated	288	297	|O
for	298	301	|O
their	302	307	|O
inhibitory	308	318	|O
effects	319	326	|O
on	327	329	|O
apomorphine	330	341	|O
-	341	342	|O
induced	342	349	|O
stereotyped	350	361	|O
behavior	362	370	|O
in	371	373	|O
rats	374	378	|O
,	378	379	|O
and	380	383	|O
a	384	385	|O
good	386	390	|O
correlation	391	402	|O
between	403	410	|O
structure	411	420	|O
and	421	424	|O
activity	425	433	|O
was	434	437	|O
found	438	443	|O
throughout	444	454	|O
the	455	458	|O
series	459	465	|O
.	465	466	|O
In	467	469	|O
the	470	473	|O
linear	474	480	|O
series	481	487	|O
(	488	489	|O
analogues	489	498	|O
of	499	501	|O
metoclopramide	502	516	|O
)	516	517	|O
,	517	518	|O
introduction	519	531	|O
of	532	534	|O
a	535	536	|O
benzyl	537	543	|B-IUPAC
group	544	549	|B-MODIFIER
on	550	552	|O
the	553	556	|O
terminal	557	565	|O
nitrogen	566	574	|O
,	574	575	|O
rather	576	582	|O
than	583	587	|O
an	588	590	|O
ethyl	591	596	|B-IUPAC
group	597	602	|B-MODIFIER
,	602	603	|O
and	604	607	|O
a	608	609	|O
methyl	610	616	|B-IUPAC
group	617	622	|B-MODIFIER
on	623	625	|O
the	626	629	|O
p	630	631	|B-IUPAC
-	631	632	|I-IUPAC
amino	632	637	|I-IUPAC
group	638	643	|B-MODIFIER
of	644	646	|O
metoclopramide	647	661	|O
both	662	666	|O
enhanced	667	675	|O
the	676	679	|O
activity	680	688	|O
.	688	689	|O
The	690	693	|O
resulting	694	703	|O
N	704	705	|B-IUPAC
-	705	706	|I-IUPAC
[	706	707	|I-IUPAC
2	707	708	|I-IUPAC
-	708	709	|I-IUPAC
(	709	710	|I-IUPAC
N	710	711	|I-IUPAC
-	711	712	|I-IUPAC
benzyl	712	718	|I-IUPAC
-	718	719	|I-IUPAC
N	719	720	|I-IUPAC
-	720	721	|I-IUPAC
methylamino	721	732	|I-IUPAC
)	732	733	|I-IUPAC
ethyl	733	738	|I-IUPAC
]	738	739	|I-IUPAC
-	739	740	|I-IUPAC
5	740	741	|I-IUPAC
-	741	742	|I-IUPAC
chloro	742	748	|I-IUPAC
-	748	749	|I-IUPAC
2	749	750	|I-IUPAC
-	750	751	|I-IUPAC
methoxy	751	758	|I-IUPAC
-	758	759	|I-IUPAC
4	759	760	|I-IUPAC
-	760	761	|I-IUPAC
(	761	762	|I-IUPAC
methylamino	762	773	|I-IUPAC
)	773	774	|I-IUPAC
benzamide	775	784	|I-IUPAC
(	784	785	|O
23	785	787	|O
)	787	788	|O
was	789	792	|O
about	793	798	|O
15	799	801	|O
times	802	807	|O
more	808	812	|O
active	813	819	|O
than	820	824	|O
metoclopramide	825	839	|O
.	839	840	|O
In	841	843	|O
the	844	847	|O
cyclic	848	854	|O
series	855	861	|O
,	861	862	|O
particularly	863	875	|O
among	876	881	|O
the	882	885	|O
benzamides	886	896	|O
of	897	899	|O
1	900	901	|B-IUPAC
-	901	902	|I-IUPAC
benzyl	902	908	|I-IUPAC
-	908	909	|I-IUPAC
3	909	910	|I-IUPAC
-	910	911	|I-IUPAC
aminopyrrolidine	911	927	|I-IUPAC
,	927	928	|O
most	929	933	|O
of	934	936	|O
the	937	940	|O
compounds	941	950	|O
tested	951	957	|O
were	958	962	|O
more	963	967	|O
active	968	974	|O
than	975	979	|O
the	980	983	|O
corresponding	984	997	|O
linear	998	1004	|O
benzamides	1005	1015	|O
.	1015	1016	|O
cis	1017	1020	|B-IUPAC
-	1020	1021	|I-IUPAC
N	1021	1022	|I-IUPAC
-	1022	1023	|I-IUPAC
(	1023	1024	|I-IUPAC
1	1024	1025	|I-IUPAC
-	1025	1026	|I-IUPAC
Benzyl	1026	1032	|I-IUPAC
-	1032	1033	|I-IUPAC
2	1033	1034	|I-IUPAC
-	1034	1035	|I-IUPAC
methylpyrrolidin	1035	1051	|I-IUPAC
-	1051	1052	|I-IUPAC
3	1052	1053	|I-IUPAC
-	1053	1054	|I-IUPAC
yl	1054	1056	|I-IUPAC
)	1056	1057	|I-IUPAC
-	1057	1058	|I-IUPAC
5	1058	1059	|I-IUPAC
-	1059	1060	|I-IUPAC
chloro	1060	1066	|I-IUPAC
-	1066	1067	|I-IUPAC
2	1067	1068	|I-IUPAC
-	1068	1069	|I-IUPAC
methoxy	1069	1076	|I-IUPAC
-	1076	1077	|I-IUPAC
4	1077	1078	|I-IUPAC
-	1078	1079	|I-IUPAC
(	1079	1080	|I-IUPAC
methylamino	1080	1091	|I-IUPAC
)	1091	1092	|I-IUPAC
benzamide	1093	1102	|I-IUPAC
(	1103	1104	|O
YM	1104	1106	|O
-	1106	1107	|O
09151-2	1107	1114	|O
,	1114	1115	|O
55	1116	1118	|O
)	1118	1119	|O
was	1120	1123	|O
the	1124	1127	|O
most	1128	1132	|O
active	1133	1139	|O
among	1140	1145	|O
all	1146	1149	|O
of	1150	1152	|O
the	1153	1156	|O
compounds	1157	1166	|O
tested	1167	1173	|O
,	1173	1174	|O
being	1175	1180	|O
13	1181	1183	|O
and	1184	1187	|O
408	1188	1191	|O
times	1192	1197	|O
more	1198	1202	|O
potent	1203	1209	|O
than	1210	1214	|O
haloperidol	1215	1226	|O
and	1227	1230	|O
metoclopramide	1231	1245	|O
,	1245	1246	|O
respectively	1247	1259	|O
.	1259	1260	|O
Moreover	1261	1269	|O
,	1269	1270	|O
compound	1271	1279	|O
55	1280	1282	|O
exhibited	1283	1292	|O
a	1293	1294	|O
fairly	1295	1301	|O
high	1302	1306	|O
ratio	1307	1312	|O
of	1313	1315	|O
antistereotypic	1316	1331	|O
activity	1332	1340	|O
to	1341	1343	|O
cataleptogenicity	1344	1361	|O
compared	1362	1370	|O
with	1371	1375	|O
haloperidol	1376	1387	|O
and	1388	1391	|O
metoclopramide	1392	1406	|O
.	1406	1407	|O
It	1408	1410	|O
is	1411	1413	|O
expected	1414	1422	|O
that	1423	1427	|O
compound	1428	1436	|O
55	1437	1439	|O
may	1440	1443	|O
be	1444	1446	|O
used	1447	1451	|O
as	1452	1454	|O
a	1455	1456	|O
potent	1457	1463	|O
drug	1464	1468	|O
with	1469	1473	|O
few	1474	1477	|O
side	1478	1482	|O
effects	1483	1490	|O
in	1491	1493	|O
the	1494	1497	|O
treatment	1498	1507	|O
of	1508	1510	|O
psychosis	1511	1520	|O
.	1520	1521	|O

### abstracts5.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
monoamidic	12	22	|B-MODIFIER
derivatives	23	34	|I-MODIFIER
of	35	37	|I-MODIFIER
cis	38	41	|B-PARTIUPAC
-	41	42	|I-PARTIUPAC
and	43	46	|O
trans	47	52	|B-PARTIUPAC
-	52	53	|I-PARTIUPAC
1,2	53	56	|I-PARTIUPAC
-	56	57	|I-PARTIUPAC
cyclohexanedicarboxylic	57	80	|I-PARTIUPAC
and	81	84	|O
1,2	85	88	|B-IUPAC
-	88	89	|I-IUPAC
cyclopentanedicarboxylic	89	113	|I-IUPAC
acids	114	119	|I-IUPAC
bearing	120	127	|O
either	128	134	|O
a	135	136	|O
carboxylic	137	147	|O
,	147	148	|O
sulfhydrylic	149	161	|O
,	161	162	|O
or	163	165	|O
hydroxamic	166	176	|O
group	177	182	|O
in	183	185	|O
the	186	189	|O
side	190	194	|O
chain	195	200	|O
were	201	205	|O
synthesized	206	217	|O
and	218	221	|O
evaluated	222	231	|O
in	232	234	|O
vitro	235	240	|O
for	241	244	|O
their	245	250	|O
inhibitory	251	261	|O
activity	262	270	|O
against	271	278	|O
angiotensin	279	290	|O
converting	291	301	|O
enzyme	302	308	|O
.	308	309	|O
The	310	313	|O
compounds	314	323	|O
were	324	328	|O
designed	329	337	|O
as	338	340	|O
potential	341	350	|O
ACE	351	354	|O
inhibitors	355	365	|O
of	366	368	|O
novel	369	374	|O
structure	375	384	|O
,	384	385	|O
assuming	386	394	|O
that	395	399	|O
a	400	401	|O
monoamidic	402	412	|O
residue	413	420	|O
of	421	423	|O
an	424	426	|O
1,2	427	430	|B-IUPAC
-	430	431	|I-IUPAC
cyclomethylenedicarboxylic	431	457	|I-IUPAC
acid	458	462	|I-IUPAC
could	463	468	|O
be	469	471	|O
an	472	474	|O
alternative	475	486	|O
structure	487	496	|O
to	497	499	|O
the	500	503	|O
acylproline	504	515	|O
moiety	516	522	|O
,	522	523	|O
the	524	527	|O
carboxyl	528	536	|O
-	536	537	|O
terminal	537	545	|O
portion	546	553	|O
common	554	560	|O
to	561	563	|O
various	564	571	|O
ACE	572	575	|O
inhibitors	576	586	|O
.	586	587	|O
The	588	591	|O
most	592	596	|O
active	597	603	|O
compounds	604	613	|O
were	614	618	|O
found	619	624	|O
in	625	627	|O
the	628	631	|O
hydroxamic	632	642	|O
derivatives	643	654	|O
of	655	657	|O
cyclohexane	658	669	|O
series	670	676	|O
;	676	677	|O
within	678	684	|O
this	685	689	|O
series	690	696	|O
of	697	699	|O
derivatives	700	711	|O
a	712	713	|O
marked	714	720	|O
increase	721	729	|O
of	730	732	|O
potency	733	740	|O
was	741	744	|O
caused	745	751	|O
by	752	754	|O
alkylation	755	765	|O
of	766	768	|O
the	769	772	|O
amidic	773	779	|O
nitrogen	780	788	|O
with	789	793	|O
a	794	795	|O
methyl	796	802	|B-IUPAC
or	803	805	|O
ethyl	806	811	|B-IUPAC
group	812	817	|B-MODIFIER
.	817	818	|O
Therefore	819	828	|O
enantiomers	829	840	|O
of	841	843	|O
the	844	847	|O
selected	848	856	|O
hydroxamic	857	867	|O
derivatives	868	879	|O
of	880	882	|O
cis	883	886	|B-PARTIUPAC
-	886	887	|I-PARTIUPAC
and	888	891	|O
trans	892	897	|B-IUPAC
-	897	898	|I-IUPAC
1,2	898	901	|I-IUPAC
-	901	902	|I-IUPAC
cyclohexanedicarboxylic	902	925	|I-IUPAC
acid	926	930	|I-IUPAC
were	931	935	|O
prepared	936	944	|O
by	945	947	|O
two	948	951	|O
different	952	961	|O
chiral	962	968	|O
synthetic	969	978	|O
routes	979	985	|O
and	986	989	|O
evaluated	990	999	|O
in	1000	1002	|O
vitro	1003	1008	|O
for	1009	1012	|O
their	1013	1018	|O
ACE	1019	1022	|O
inhibitor	1023	1032	|O
potencies	1033	1042	|O
.	1042	1043	|O
The	1044	1047	|O
active	1048	1054	|O
enantiomers	1055	1066	|O
both	1067	1071	|O
of	1072	1074	|O
the	1075	1078	|O
cis	1079	1082	|O
series	1083	1089	|O
(	1090	1091	|O
21a	1091	1094	|O
,	1094	1095	|O
21c	1096	1099	|O
)	1099	1100	|O
and	1101	1104	|O
trans	1105	1110	|O
series	1111	1117	|O
(	1118	1119	|O
16b	1119	1122	|O
,	1122	1123	|O
16d	1124	1127	|O
)	1127	1128	|O
were	1129	1133	|O
found	1134	1139	|O
to	1140	1142	|O
have	1143	1147	|O
all	1148	1151	|O
R	1152	1153	|O
configuration	1154	1167	|O
at	1168	1170	|O
the	1171	1174	|O
C	1175	1176	|O
-	1176	1177	|O
2	1177	1178	|O
and	1179	1182	|O
R	1183	1184	|O
or	1185	1187	|O
S	1188	1189	|O
configuration	1190	1203	|O
at	1204	1206	|O
the	1207	1210	|O
C	1211	1212	|O
-	1212	1213	|O
1	1213	1214	|O
,	1214	1215	|O
while	1216	1221	|O
in	1222	1224	|O
the	1225	1228	|O
classical	1229	1238	|O
ACE	1239	1242	|O
inhibitors	1243	1253	|O
S	1254	1255	|O
configuration	1256	1269	|O
at	1270	1272	|O
the	1273	1276	|O
terminal	1277	1285	|O
carboxylate	1286	1297	|O
(	1298	1299	|O
corresponding	1299	1312	|O
to	1313	1315	|O
the	1316	1319	|O
C	1320	1321	|O
-	1321	1322	|O
1	1322	1323	|O
of	1324	1326	|O
our	1327	1330	|O
compounds	1331	1340	|O
)	1340	1341	|O
is	1342	1344	|O
strictly	1345	1353	|O
required	1354	1362	|O
for	1363	1366	|O
activity	1367	1375	|O
.	1375	1376	|O
The	1377	1380	|O
most	1381	1385	|O
potent	1386	1392	|O
compound	1393	1401	|O
of	1402	1404	|O
the	1405	1408	|O
series	1409	1415	|O
was	1416	1419	|O
(	1420	1421	|B-IUPAC
1S	1421	1423	|I-IUPAC
,	1423	1424	|I-IUPAC
2R	1424	1426	|I-IUPAC
)	1426	1427	|I-IUPAC
-	1427	1428	|I-IUPAC
cis	1428	1431	|I-IUPAC
-	1431	1432	|I-IUPAC
2	1432	1433	|I-IUPAC
[	1433	1434	|I-IUPAC
[	1434	1435	|I-IUPAC
[	1435	1436	|I-IUPAC
2	1436	1437	|I-IUPAC
-	1437	1438	|I-IUPAC
(	1438	1439	|I-IUPAC
hydroxyamino	1439	1451	|I-IUPAC
)	1451	1452	|I-IUPAC
-	1452	1453	|I-IUPAC
2	1453	1454	|I-IUPAC
-	1454	1455	|I-IUPAC
oxoethyl	1455	1463	|I-IUPAC
]	1463	1464	|I-IUPAC
methylamino	1464	1475	|I-IUPAC
]	1475	1476	|I-IUPAC
carbonyl	1476	1484	|I-IUPAC
]	1484	1485	|I-IUPAC
cyclohexanecarboxylic	1486	1507	|I-IUPAC
acid	1508	1512	|I-IUPAC
(	1513	1514	|O
21a	1514	1517	|O
)	1517	1518	|O
with	1519	1523	|O
an	1524	1526	|O
IC50	1527	1531	|O
value	1532	1537	|O
of	1538	1540	|O
7.0	1541	1544	|O
nM	1545	1547	|O
compared	1548	1556	|O
with	1557	1561	|O
the	1562	1565	|O
value	1566	1571	|O
of	1572	1574	|O
3.0	1575	1578	|O
nM	1579	1581	|O
for	1582	1585	|O
captopril	1586	1595	|O
.	1595	1596	|O
Further	1597	1604	|O
21a	1605	1608	|O
was	1609	1612	|O
shown	1613	1618	|O
to	1619	1621	|O
be	1622	1624	|O
highly	1625	1631	|O
selective	1632	1641	|O
and	1642	1645	|O
competitive	1646	1657	|O
ACE	1658	1661	|O
inhibitor	1662	1671	|O
.	1671	1672	|O
These	1673	1678	|O
results	1679	1686	|O
indicate	1687	1695	|O
that	1696	1700	|O
this	1701	1705	|O
non	1706	1709	|O
-	1709	1710	|O
amino	1710	1715	|O
acid	1716	1720	|O
structure	1721	1730	|O
of	1731	1733	|O
inhibitors	1734	1744	|O
meets	1745	1750	|O
the	1751	1754	|O
ACE	1755	1758	|O
active	1759	1765	|O
site	1766	1770	|O
requirements	1771	1783	|O
for	1784	1787	|O
the	1788	1791	|O
binding	1792	1799	|O
.	1799	1800	|O
The	1801	1804	|O
binding	1805	1812	|O
compatibility	1813	1826	|O
of	1827	1829	|O
the	1830	1833	|O
most	1834	1838	|O
active	1839	1845	|O
compounds	1846	1855	|O
with	1856	1860	|O
a	1861	1862	|O
model	1863	1868	|O
of	1869	1871	|O
ACE	1872	1875	|O
active	1876	1882	|O
site	1883	1887	|O
was	1888	1891	|O
evaluated	1892	1901	|O
by	1902	1904	|O
molecular	1905	1914	|O
modeling	1915	1923	|O
techniques	1924	1934	|O
.	1934	1935	|O

### abstracts580.txt
The	0	3	|O
nigrostriatal	4	17	|O
toxin	18	23	|O
1	24	25	|B-IUPAC
-	25	26	|I-IUPAC
methyl	26	32	|I-IUPAC
-	32	33	|I-IUPAC
4	33	34	|I-IUPAC
-	34	35	|I-IUPAC
phenyl	35	41	|I-IUPAC
-	41	42	|I-IUPAC
1,2,3,6	42	49	|I-IUPAC
-	49	50	|I-IUPAC
tetrahydropyridine	50	68	|I-IUPAC
(	69	70	|O
MPTP	70	74	|O
)	74	75	|O
is	76	78	|O
biotransformed	79	93	|O
by	94	96	|O
brain	97	102	|O
monoamine	103	112	|O
oxidase	113	120	|O
(	121	122	|O
MAO	122	125	|O
)	125	126	|O
to	127	129	|O
an	130	132	|O
unstable	133	141	|O
dihydropyridinium	142	159	|O
intermediate	160	172	|O
that	173	177	|O
reacts	178	184	|O
with	185	189	|O
cyanide	190	197	|O
ion	198	201	|O
to	202	204	|O
form	205	209	|O
an	210	212	|O
alpha	213	218	|B-IUPAC
-	218	219	|I-IUPAC
cyano	219	224	|I-IUPAC
-	224	225	|I-IUPAC
tetrahydropyridine	225	243	|I-IUPAC
adduct	244	250	|O
and	251	254	|O
,	254	255	|O
in	256	258	|O
the	259	262	|O
absence	263	270	|O
of	271	273	|O
cyanide	274	281	|O
ion	282	285	|O
,	285	286	|O
undergoes	287	296	|O
disproportionation	297	315	|O
to	316	318	|O
the	319	322	|O
1	323	324	|B-IUPAC
-	324	325	|I-IUPAC
methyl	325	331	|I-IUPAC
-	331	332	|I-IUPAC
4	332	333	|I-IUPAC
-	333	334	|I-IUPAC
phenylpyridinium	334	350	|I-IUPAC
species	351	358	|O
MPP+	359	363	|O
and	364	367	|O
MPTP	368	372	|O
.	372	373	|O
Comparison	374	384	|O
of	385	387	|O
the	388	391	|O
HPLC	392	396	|O
retention	397	406	|O
times	407	412	|O
,	412	413	|O
diode	414	419	|O
array	420	425	|O
UV	426	428	|O
,	428	429	|O
and	430	433	|O
chemical	434	442	|O
ion	443	446	|O
mass	447	451	|O
spectral	452	460	|O
characteristics	461	476	|O
of	477	479	|O
these	480	485	|O
products	486	494	|O
with	495	499	|O
those	500	505	|O
of	506	508	|O
synthetic	509	518	|O
standards	519	528	|O
led	529	532	|O
us	533	535	|O
to	536	538	|O
propose	539	546	|O
the	547	550	|O
1	551	552	|B-IUPAC
-	552	553	|I-IUPAC
methyl	553	559	|I-IUPAC
-	559	560	|I-IUPAC
4	560	561	|I-IUPAC
-	561	562	|I-IUPAC
phenyl	562	568	|I-IUPAC
-	568	569	|I-IUPAC
2,3	569	572	|I-IUPAC
-	572	573	|I-IUPAC
dihydropyridinium	573	590	|I-IUPAC
species	591	598	|O
2,3	599	602	|O
-	602	603	|O
MPDP+	603	608	|O
and	609	612	|O
6	613	614	|B-IUPAC
-	614	615	|I-IUPAC
cyano	615	620	|I-IUPAC
-	620	621	|I-IUPAC
1	621	622	|I-IUPAC
-	622	623	|I-IUPAC
methyl	623	629	|I-IUPAC
-	629	630	|I-IUPAC
4	630	631	|I-IUPAC
-	631	632	|I-IUPAC
phenyl	632	638	|I-IUPAC
-	638	639	|I-IUPAC
1,2,3,6	639	646	|I-IUPAC
-	646	647	|I-IUPAC
tetrahydropyridine	647	665	|I-IUPAC
as	666	668	|O
tentative	669	678	|O
structure	679	688	|O
assignments	689	700	|O
for	701	704	|O
the	705	708	|O
dihydropyridinium	709	726	|O
metabolite	727	737	|O
and	738	741	|O
the	742	745	|O
cyano	746	751	|O
adduct	752	758	|O
,	758	759	|O
respectively	760	772	|O
.	772	773	|O
Results	774	781	|O
presented	782	791	|O
in	792	794	|O
this	795	799	|O
paper	800	805	|O
confirm	806	813	|O
the	814	817	|O
first	818	823	|O
assignment	824	834	|O
and	835	838	|O
establish	839	848	|O
that	849	853	|O
,	853	854	|O
although	855	863	|O
the	864	867	|O
proposed	868	876	|O
6	877	878	|O
-	878	879	|O
cyano	879	884	|O
adduct	885	891	|O
is	892	894	|O
initially	895	904	|O
formed	905	911	|O
,	911	912	|O
the	913	916	|O
product	917	924	|O
that	925	929	|O
was	930	933	|O
isolated	934	942	|O
from	943	947	|O
the	948	951	|O
mitochondrial	952	965	|O
incubation	966	976	|O
mixtures	977	985	|O
of	986	988	|O
MPTP	989	993	|O
and	994	997	|O
sodium	998	1004	|O
cyanide	1005	1012	|O
actually	1013	1021	|O
is	1022	1024	|O
the	1025	1028	|O
isomeric	1029	1037	|O
2	1038	1039	|B-IUPAC
-	1039	1040	|I-IUPAC
cyano	1040	1045	|I-IUPAC
-	1045	1046	|I-IUPAC
1	1046	1047	|I-IUPAC
-	1047	1048	|I-IUPAC
methyl	1048	1054	|I-IUPAC
-	1054	1055	|I-IUPAC
4	1055	1056	|I-IUPAC
-	1056	1057	|I-IUPAC
phenyl	1057	1063	|I-IUPAC
-	1063	1064	|I-IUPAC
1,2,3,6	1064	1071	|I-IUPAC
-	1072	1073	|I-IUPAC
tetrahydropyridine	1073	1091	|I-IUPAC
.	1091	1092	|O
On	1093	1095	|O
the	1096	1099	|O
basis	1100	1105	|O
of	1106	1108	|O
the	1109	1112	|O
selective	1113	1122	|O
incorporation	1123	1136	|O
of	1137	1139	|O
deuterium	1140	1149	|O
into	1150	1154	|O
these	1155	1160	|O
products	1161	1169	|O
,	1169	1170	|O
we	1171	1173	|O
provide	1174	1181	|O
rational	1182	1190	|O
mechanistic	1191	1202	|O
interpretations	1203	1218	|O
of	1219	1221	|O
the	1222	1225	|O
disproportionation	1226	1244	|O
reaction	1245	1253	|O
and	1254	1257	|O
the	1258	1261	|O
rearrangement	1262	1275	|O
of	1276	1278	|O
the	1279	1282	|O
cyano	1283	1288	|O
adducts	1289	1296	|O
.	1296	1297	|O
These	1298	1303	|O
results	1304	1311	|O
establish	1312	1321	|O
that	1322	1326	|O
the	1327	1330	|O
MAO	1331	1334	|O
-	1334	1335	|O
catalyzed	1335	1344	|O
bioactivation	1345	1358	|O
of	1359	1361	|O
MPTP	1362	1366	|O
leads	1367	1372	|O
to	1373	1375	|O
the	1376	1379	|O
formation	1380	1389	|O
of	1390	1392	|O
a	1393	1394	|O
variety	1395	1402	|O
of	1403	1405	|O
reactive	1406	1414	|O
molecules	1415	1424	|O
that	1425	1429	|O
are	1430	1433	|O
potentially	1434	1445	|O
cytotoxic	1446	1455	|O
to	1456	1458	|O
nigrostriatal	1459	1472	|O
cells	1473	1478	|O
.	1478	1479	|O

### abstracts3346.txt
A	0	1	|O
novel	2	7	|O
class	8	13	|O
of	14	16	|O
tricyclic	17	26	|O
tropane	27	34	|O
analogues	35	44	|O
has	45	48	|O
been	49	53	|O
synthesized	54	65	|O
by	66	68	|O
making	69	75	|O
use	76	79	|O
of	80	82	|O
radical	83	90	|O
cyclization	91	102	|O
technology	103	113	|O
in	114	116	|O
combination	117	128	|O
with	129	133	|O
the	134	137	|O
Stille	138	144	|O
coupling	145	153	|O
reaction	154	162	|O
.	162	163	|O
As	164	166	|O
hybrids	167	174	|O
between	175	182	|O
tropanes	183	191	|O
and	192	195	|O
quinuclidines	196	209	|O
,	209	210	|O
these	211	216	|O
tropaquinuclidines	217	235	|O
represent	236	245	|O
a	246	247	|O
significant	248	259	|O
structural	260	270	|O
departure	271	280	|O
from	281	285	|O
many	286	290	|O
of	291	293	|O
the	294	297	|O
other	298	303	|O
classes	304	311	|O
of	312	314	|O
tropane	315	322	|O
ligands	323	330	|O
synthesized	331	342	|O
to	343	345	|O
date	346	350	|O
.	350	351	|O
This	352	356	|O
structure	357	366	|O
class	367	372	|O
is	373	375	|O
characterized	376	389	|O
by	390	392	|O
the	393	396	|O
boat	397	401	|O
conformation	402	414	|O
of	415	417	|O
the	418	421	|O
tropane	422	429	|O
ring	430	434	|O
and	435	438	|O
the	439	442	|O
orientation	443	454	|O
of	455	457	|O
the	458	461	|O
additional	462	472	|O
bridge	473	479	|O
(	480	481	|O
and	481	484	|O
therefore	485	494	|O
of	495	497	|O
the	498	501	|O
nitrogen	502	510	|O
lone	511	515	|O
pair	516	520	|O
)	520	521	|O
together	522	530	|O
with	531	535	|O
the	536	539	|O
unusual	540	547	|O
placement	548	557	|O
of	558	560	|O
the	561	564	|O
aromatic	565	573	|O
moiety	574	580	|O
.	580	581	|O
All	582	585	|O
compounds	586	595	|O
were	596	600	|O
tested	601	607	|O
for	608	611	|O
their	612	617	|O
ability	618	625	|O
to	626	628	|O
inhibit	629	636	|O
monoamine	637	646	|O
reuptake	647	655	|O
under	656	661	|O
identical	662	671	|O
conditions	672	682	|O
.	682	683	|O
The	684	687	|O
ability	688	695	|O
to	696	698	|O
inhibit	699	706	|O
reuptake	707	715	|O
of	716	718	|O
dopamine	719	727	|O
in	728	730	|O
comparison	731	741	|O
to	742	744	|O
cocaine	745	752	|O
is	753	755	|O
generally	756	765	|O
decreased	766	775	|O
in	776	778	|O
this	779	783	|O
series	784	790	|O
but	791	794	|O
for	795	798	|O
one	799	802	|O
compound	803	811	|O
.	811	812	|O
(	813	814	|B-IUPAC
1S	814	816	|I-IUPAC
,	816	817	|I-IUPAC
3R	817	819	|I-IUPAC
,	819	820	|I-IUPAC
6S	821	823	|I-IUPAC
)	823	824	|I-IUPAC
-	824	825	|I-IUPAC
(	825	826	|I-IUPAC
Z	826	827	|I-IUPAC
)	827	828	|I-IUPAC
-	828	829	|I-IUPAC
9	829	830	|I-IUPAC
-	830	831	|I-IUPAC
(	831	832	|I-IUPAC
thienylmethylene	832	848	|I-IUPAC
)	848	849	|I-IUPAC
-	849	850	|I-IUPAC
7	850	851	|I-IUPAC
-	851	852	|I-IUPAC
azatricyclo	852	863	|I-IUPAC
[	863	864	|I-IUPAC
4.3.1.0	864	871	|I-IUPAC
(	871	872	|I-IUPAC
3	872	873	|I-IUPAC
,	873	874	|I-IUPAC
7	875	876	|I-IUPAC
)	876	877	|I-IUPAC
]	877	878	|I-IUPAC
decane	878	884	|I-IUPAC
-	884	885	|I-IUPAC
2beta	885	890	|I-IUPAC
-	890	891	|I-IUPAC
carboxylic	891	901	|I-IUPAC
acid	902	906	|I-IUPAC
methyl	907	913	|I-IUPAC
ester	914	919	|I-IUPAC
(	920	921	|O
5h	921	923	|O
)	923	924	|O
exhibits	925	933	|O
reasonable	934	944	|O
activity	945	953	|O
at	954	956	|O
the	957	960	|O
dopamine	961	969	|O
transporter	970	981	|O
(	982	983	|O
DAT	983	986	|O
)	986	987	|O
(	988	989	|O
K	989	990	|O
(	990	991	|O
i	991	992	|O
)	992	993	|O
=	994	995	|O
268	996	999	|O
nM	1000	1002	|O
)	1002	1003	|O
and	1004	1007	|O
good	1008	1012	|O
activity	1013	1021	|O
at	1022	1024	|O
the	1025	1028	|O
norepinephrine	1029	1043	|O
transporter	1044	1055	|O
(	1056	1057	|O
NET	1057	1060	|O
)	1060	1061	|O
(	1062	1063	|O
K	1063	1064	|O
(	1064	1065	|O
i	1065	1066	|O
)	1066	1067	|O
=	1068	1069	|O
26	1070	1072	|O
nM	1073	1075	|O
)	1075	1076	|O
.	1076	1077	|O
The	1078	1081	|O
potency	1082	1089	|O
and	1090	1093	|O
selectivity	1094	1105	|O
shown	1106	1111	|O
by	1112	1114	|O
some	1115	1119	|O
of	1120	1122	|O
these	1123	1128	|O
ligands	1129	1136	|O
for	1137	1140	|O
the	1141	1144	|O
NET	1145	1148	|O
,	1148	1149	|O
serotonine	1150	1160	|O
transporter	1161	1172	|O
(	1173	1174	|O
SERT	1174	1178	|O
)	1178	1179	|O
,	1179	1180	|O
or	1181	1183	|O
NET	1184	1187	|O
/	1187	1188	|O
SERT	1188	1192	|O
is	1193	1195	|O
striking	1196	1204	|O
,	1204	1205	|O
particularly	1206	1218	|O
in	1219	1221	|O
view	1222	1226	|O
of	1227	1229	|O
the	1230	1233	|O
displacement	1234	1246	|O
of	1247	1249	|O
the	1250	1253	|O
aromatic	1254	1262	|O
ring	1263	1267	|O
in	1268	1270	|O
this	1271	1275	|O
series	1276	1282	|O
from	1283	1287	|O
its	1288	1291	|O
usual	1292	1297	|O
position	1298	1306	|O
at	1307	1309	|O
C	1310	1311	|O
-	1311	1312	|O
3	1312	1313	|O
in	1314	1316	|O
the	1317	1320	|O
WIN	1321	1324	|O
analogues	1325	1334	|O
.	1334	1335	|O
Thus	1336	1340	|O
,	1340	1341	|O
(	1342	1343	|B-IUPAC
1S	1343	1345	|I-IUPAC
,	1345	1346	|I-IUPAC
3R	1346	1348	|I-IUPAC
,	1348	1349	|I-IUPAC
6S	1349	1351	|I-IUPAC
)	1351	1352	|I-IUPAC
-	1352	1353	|I-IUPAC
(	1353	1354	|I-IUPAC
Z	1354	1355	|I-IUPAC
)	1355	1356	|I-IUPAC
-	1356	1357	|I-IUPAC
9	1357	1358	|I-IUPAC
-	1358	1359	|I-IUPAC
(	1359	1360	|I-IUPAC
4	1360	1361	|I-IUPAC
-	1361	1362	|I-IUPAC
biphenylylmethylene	1362	1381	|I-IUPAC
)	1381	1382	|I-IUPAC
-	1382	1383	|I-IUPAC
7	1383	1384	|I-IUPAC
-	1384	1385	|I-IUPAC
azatricyclo	1385	1396	|I-IUPAC
[	1396	1397	|I-IUPAC
4.3.1	1397	1402	|I-IUPAC
.	1403	1404	|I-IUPAC
0	1405	1406	|I-IUPAC
(	1406	1407	|I-IUPAC
3,7	1407	1410	|I-IUPAC
)	1410	1411	|I-IUPAC
]	1411	1412	|I-IUPAC
decane	1412	1418	|I-IUPAC
-	1418	1419	|I-IUPAC
2beta	1419	1424	|I-IUPAC
-	1424	1425	|I-IUPAC
carboxylic	1425	1435	|I-IUPAC
acid	1436	1440	|I-IUPAC
methyl	1441	1447	|I-IUPAC
ester	1448	1453	|I-IUPAC
(	1454	1455	|O
5a	1455	1457	|O
)	1457	1458	|O
is	1459	1461	|O
a	1462	1463	|O
selective	1464	1473	|O
inhibitor	1474	1483	|O
of	1484	1486	|O
norepinephrine	1487	1501	|O
reuptake	1502	1510	|O
(	1511	1512	|O
K	1512	1513	|O
(	1513	1514	|O
i	1514	1515	|O
)	1515	1516	|O
=	1517	1518	|O
12	1519	1521	|O
nM	1522	1524	|O
)	1524	1525	|O
.	1525	1526	|O
Its	1527	1530	|O
p	1531	1532	|O
-	1532	1533	|O
methoxy	1533	1540	|O
analogue	1541	1549	|O
5c	1550	1552	|O
is	1553	1555	|O
a	1556	1557	|O
mixed	1558	1563	|O
inhibitor	1564	1573	|O
of	1574	1576	|O
norepinephrine	1577	1591	|O
and	1592	1595	|O
serotonin	1596	1605	|O
reuptake	1606	1614	|O
(	1615	1616	|O
K	1616	1617	|O
(	1617	1618	|O
i	1618	1619	|O
)	1619	1620	|O
=	1621	1622	|O
187	1623	1626	|O
nM	1627	1629	|O
at	1630	1632	|O
the	1633	1636	|O
NET	1637	1640	|O
and	1641	1644	|O
56	1645	1647	|O
nM	1648	1650	|O
at	1651	1653	|O
the	1654	1657	|O
SERT	1658	1662	|O
)	1662	1663	|O
.	1663	1664	|O
The	1665	1668	|O
most	1669	1673	|O
active	1674	1680	|O
and	1681	1684	|O
selective	1685	1694	|O
compound	1695	1703	|O
we	1704	1706	|O
found	1707	1712	|O
in	1713	1715	|O
the	1716	1719	|O
present	1720	1727	|O
series	1728	1734	|O
is	1735	1737	|O
compound	1738	1746	|O
8b	1747	1749	|O
[	1750	1751	|O
(	1751	1752	|B-IUPAC
1S	1752	1754	|I-IUPAC
,	1754	1755	|I-IUPAC
3R	1755	1757	|I-IUPAC
,	1757	1758	|I-IUPAC
6S	1758	1760	|I-IUPAC
)	1760	1761	|I-IUPAC
-	1761	1762	|I-IUPAC
2	1762	1763	|I-IUPAC
-	1763	1764	|I-IUPAC
(	1764	1765	|I-IUPAC
acetoxymethyl	1765	1778	|I-IUPAC
)	1778	1779	|I-IUPAC
-	1779	1780	|I-IUPAC
(	1780	1781	|I-IUPAC
Z	1781	1782	|I-IUPAC
)	1782	1783	|I-IUPAC
-	1783	1784	|I-IUPAC
9	1784	1785	|I-IUPAC
-	1785	1786	|I-IUPAC
(	1786	1787	|I-IUPAC
3	1787	1788	|I-IUPAC
,	1788	1789	|I-IUPAC
4	1790	1791	|I-IUPAC
-	1791	1792	|I-IUPAC
dichlorophenylmethylene	1792	1815	|I-IUPAC
)	1815	1816	|I-IUPAC
-	1816	1817	|I-IUPAC
7	1817	1818	|I-IUPAC
-	1818	1819	|I-IUPAC
azatricyclo	1819	1830	|I-IUPAC
[	1830	1831	|I-IUPAC
4.3.1.0	1831	1838	|I-IUPAC
(	1838	1839	|I-IUPAC
3,7	1839	1842	|I-IUPAC
)	1842	1843	|I-IUPAC
]	1843	1844	|I-IUPAC
decane	1844	1850	|I-IUPAC
]	1851	1852	|O
.	1852	1853	|O
This	1854	1858	|O
compound	1859	1867	|O
is	1868	1870	|O
a	1871	1872	|O
potent	1873	1879	|O
(	1880	1881	|O
K	1881	1882	|O
(	1882	1883	|O
i	1883	1884	|O
)	1884	1885	|O
=	1886	1887	|O
1.6	1888	1891	|O
nM	1892	1894	|O
)	1894	1895	|O
and	1896	1899	|O
selective	1900	1909	|O
inhibitor	1910	1919	|O
of	1920	1922	|O
serotonin	1923	1932	|O
reuptake	1933	1941	|O
into	1942	1946	|O
rat	1947	1950	|O
midbrain	1951	1959	|O
synaptosomes	1960	1972	|O
.	1972	1973	|O
Its	1974	1977	|O
selectivity	1978	1989	|O
is	1990	1992	|O
about	1993	1998	|O
400	1999	2002	|O
-	2002	2003	|O
fold	2003	2007	|O
over	2008	2012	|O
the	2013	2016	|O
NET	2017	2020	|O
and	2021	2024	|O
about	2025	2030	|O
1000	2031	2035	|O
-	2035	2036	|O
fold	2036	2040	|O
over	2041	2045	|O
the	2046	2049	|O
DAT	2050	2053	|O
.	2053	2054	|O
The	2055	2058	|O
results	2059	2066	|O
of	2067	2069	|O
this	2070	2074	|O
study	2075	2080	|O
further	2081	2088	|O
demonstrate	2089	2100	|O
the	2101	2104	|O
possibility	2105	2116	|O
of	2117	2119	|O
tuning	2120	2126	|O
the	2127	2130	|O
selectivity	2131	2142	|O
of	2143	2145	|O
tropane	2146	2153	|O
analogues	2154	2163	|O
toward	2164	2170	|O
the	2171	2174	|O
SERT	2175	2179	|O
or	2180	2182	|O
NET	2183	2186	|O
binding	2187	2194	|O
site	2195	2199	|O
.	2199	2200	|O
The	2201	2204	|O
ligands	2205	2212	|O
disclosed	2213	2222	|O
herein	2223	2229	|O
provide	2230	2237	|O
additional	2238	2248	|O
pharmacological	2249	2264	|O
tools	2265	2270	|O
of	2271	2273	|O
use	2274	2277	|O
in	2278	2280	|O
attempting	2281	2291	|O
to	2292	2294	|O
correlate	2295	2304	|O
structure	2305	2314	|O
and	2315	2318	|O
transporter	2319	2330	|O
selectivity	2331	2342	|O
with	2343	2347	|O
in	2348	2350	|O
vivo	2351	2355	|O
studies	2356	2363	|O
of	2364	2366	|O
behavioral	2367	2377	|O
outcomes	2378	2386	|O
.	2386	2387	|O

### abstracts2083.txt
Recently	0	8	|O
,	8	9	|O
we	10	12	|O
reported	13	21	|O
the	22	25	|O
first	26	31	|O
human	32	37	|O
study	38	43	|O
of	44	46	|O
[	47	48	|O
99mTc	48	53	|O
]	53	54	|O
TRODAT	54	60	|O
-	60	61	|O
1	61	62	|O
,	62	63	|O
technetium	64	74	|O
,	74	75	|O
2	76	77	|B-PARTIUPAC
-	77	78	|I-PARTIUPAC
[	78	79	|I-PARTIUPAC
[	79	80	|I-PARTIUPAC
2	80	81	|I-PARTIUPAC
-	81	82	|I-PARTIUPAC
[	82	83	|I-PARTIUPAC
[	83	84	|I-PARTIUPAC
[	84	85	|I-PARTIUPAC
3	85	86	|I-PARTIUPAC
-	86	87	|I-PARTIUPAC
(	87	88	|I-PARTIUPAC
4	88	89	|I-PARTIUPAC
-	89	90	|I-PARTIUPAC
chlorophenyl	90	102	|I-PARTIUPAC
)	102	103	|I-PARTIUPAC
-	103	104	|I-PARTIUPAC
8	104	105	|I-PARTIUPAC
-	105	106	|I-PARTIUPAC
methyl	106	112	|I-PARTIUPAC
-	112	113	|I-PARTIUPAC
8	113	114	|I-PARTIUPAC
-	114	115	|I-PARTIUPAC
azabicyclo	115	125	|I-PARTIUPAC
[	125	126	|O
3.2.1	126	131	|O
]	131	132	|O
oct	132	135	|B-PARTIUPAC
-	135	136	|I-PARTIUPAC
2	136	137	|I-PARTIUPAC
-	137	138	|I-PARTIUPAC
yl	139	141	|I-PARTIUPAC
]	141	142	|I-PARTIUPAC
methyl	142	148	|I-PARTIUPAC
]	148	149	|I-PARTIUPAC
(	149	150	|I-PARTIUPAC
2	150	151	|I-PARTIUPAC
-	151	152	|I-PARTIUPAC
mercaptoethyl	152	165	|I-PARTIUPAC
)	165	166	|I-PARTIUPAC
amino	166	171	|I-PARTIUPAC
]	171	172	|I-PARTIUPAC
ethyl	172	177	|I-PARTIUPAC
]	177	178	|I-PARTIUPAC
amino	178	183	|I-PARTIUPAC
]	183	184	|I-PARTIUPAC
-	184	185	|I-PARTIUPAC
ethanethiolato	185	199	|I-PARTIUPAC
(	199	200	|I-PARTIUPAC
3	200	201	|I-PARTIUPAC
-	201	202	|I-PARTIUPAC
)	202	203	|I-PARTIUPAC
-	203	204	|I-PARTIUPAC
o	204	205	|I-PARTIUPAC
xo	206	208	|I-PARTIUPAC
-	208	209	|I-PARTIUPAC
[	210	211	|I-PARTIUPAC
1R	211	213	|I-PARTIUPAC
-	213	214	|I-PARTIUPAC
(	214	215	|I-PARTIUPAC
exo	215	218	|I-PARTIUPAC
-	218	219	|I-PARTIUPAC
exo	219	222	|I-PARTIUPAC
)	222	223	|I-PARTIUPAC
]	223	224	|I-PARTIUPAC
-	224	225	|I-PARTIUPAC
,	225	226	|O
as	227	229	|O
an	230	232	|O
imaging	233	240	|O
agent	241	246	|O
of	247	249	|O
central	250	257	|O
nervous	258	265	|O
system	266	272	|O
(	273	274	|O
CNS	274	277	|O
)	277	278	|O
dopamine	279	287	|O
transporters	288	300	|O
.	300	301	|O
Due	302	305	|O
to	306	308	|O
the	309	312	|O
existence	313	322	|O
of	323	325	|O
several	326	333	|O
chiral	334	340	|O
centers	341	348	|O
on	349	351	|O
this	352	356	|O
molecule	357	365	|O
,	365	366	|O
upon	367	371	|O
the	372	375	|O
formation	376	385	|O
of	386	388	|O
[	389	390	|O
99mTc	390	395	|O
]	395	396	|O
TRODAT	396	402	|O
-	402	403	|O
1	403	404	|O
complex	405	412	|O
(	413	414	|O
2	414	415	|O
)	415	416	|O
several	417	424	|O
diastereomers	425	438	|O
could	439	444	|O
be	445	447	|O
created	448	455	|O
.	455	456	|O
Two	457	460	|O
major	461	466	|O
diastereomers	467	480	|O
of	481	483	|O
[	484	485	|O
99mTc	485	490	|O
]	490	491	|O
TRODAT	491	497	|O
-	497	498	|O
1	498	499	|O
(	500	501	|O
2	501	502	|O
)	502	503	|O
,	503	504	|O
designated	505	515	|O
as	516	518	|O
peak	519	523	|O
A	524	525	|O
(	526	527	|O
2A	527	529	|O
)	529	530	|O
and	531	534	|O
peak	535	539	|O
B	540	541	|O
(	542	543	|O
2B	543	545	|O
)	545	546	|O
,	546	547	|O
were	548	552	|O
separated	553	562	|O
by	563	565	|O
HPLC	566	570	|O
.	570	571	|O
Biodistribution	572	587	|O
of	588	590	|O
the	591	594	|O
purified	595	603	|O
diastereomers	604	617	|O
2A	618	620	|O
,	620	621	|O
B	621	622	|O
was	623	626	|O
evaluated	627	636	|O
in	637	639	|O
rats	640	644	|O
.	644	645	|O
It	646	648	|O
appears	649	656	|O
that	657	661	|O
2A	662	664	|O
displayed	665	674	|O
a	675	676	|O
higher	677	683	|O
lipophilicity	684	697	|O
than	698	702	|O
2B	703	705	|O
(	706	707	|O
PC	707	709	|O
=	710	711	|O
305	712	715	|O
and	716	719	|O
229	720	723	|O
,	723	724	|O
respectively	725	737	|O
)	737	738	|O
,	738	739	|O
and	740	743	|O
a	744	745	|O
similar	746	753	|O
trend	754	759	|O
was	760	763	|O
observed	764	772	|O
for	773	776	|O
the	777	780	|O
initial	781	788	|O
brain	789	794	|O
uptake	795	801	|O
at	802	804	|O
2	805	806	|O
min	807	810	|O
postinjection	811	824	|O
(	825	826	|O
0.50%	826	831	|O
and	832	835	|O
0.28%	836	841	|O
dose	842	846	|O
/	846	847	|O
organ	847	852	|O
for	853	856	|O
2A	857	859	|O
,	859	860	|O
B	860	861	|O
,	861	862	|O
respectively	863	875	|O
)	875	876	|O
.	876	877	|O
At	878	880	|O
60	881	883	|O
min	884	887	|O
post	888	892	|O
-	892	893	|O
iv	893	895	|O
-	895	896	|O
injection	896	905	|O
,	905	906	|O
the	907	910	|O
specific	911	919	|O
uptakes	920	927	|O
,	927	928	|O
as	929	931	|O
measured	932	940	|O
by	941	943	|O
[	944	945	|O
striatum	945	953	|O
-	954	955	|O
cerebellum	956	966	|O
]	966	967	|O
/	967	968	|O
cerebellum	968	978	|O
(	979	980	|O
[	980	981	|O
ST	981	983	|O
-	983	984	|O
CB	984	986	|O
]	986	987	|O
/	987	988	|O
CB	988	990	|O
)	990	991	|O
ratio	992	997	|O
,	997	998	|O
were	999	1003	|O
1.72	1004	1008	|O
and	1009	1012	|O
2.79	1013	1017	|O
for	1018	1021	|O
2A	1022	1024	|O
,	1024	1025	|O
B	1025	1026	|O
,	1026	1027	|O
respectively	1028	1040	|O
.	1040	1041	|O
The	1042	1045	|O
higher	1046	1052	|O
[	1053	1054	|O
ST	1054	1056	|O
-	1056	1057	|O
CB	1057	1059	|O
]	1059	1060	|O
/	1060	1061	|O
CB	1061	1063	|O
ratio	1064	1069	|O
observed	1070	1078	|O
for	1079	1082	|O
2B	1083	1085	|O
was	1086	1089	|O
corroborated	1090	1102	|O
by	1103	1105	|O
the	1106	1109	|O
results	1110	1117	|O
of	1118	1120	|O
an	1121	1123	|O
in	1124	1126	|O
vitro	1127	1132	|O
binding	1133	1140	|O
assay	1141	1146	|O
.	1146	1147	|O
Higher	1148	1154	|O
binding	1155	1162	|O
affinity	1163	1171	|O
for	1172	1175	|O
dopamine	1176	1184	|O
transporters	1185	1197	|O
was	1198	1201	|O
observed	1202	1210	|O
for	1211	1214	|O
3B	1215	1217	|O
(	1218	1219	|O
Ki	1219	1221	|O
=	1222	1223	|O
13.87	1224	1229	|O
and	1230	1233	|O
8.42	1234	1238	|O
nM	1239	1241	|O
for	1242	1245	|O
the	1246	1249	|O
analogous	1250	1259	|O
rhenium	1260	1267	|O
complexes	1268	1277	|O
3A	1278	1280	|O
,	1280	1281	|O
B	1281	1282	|O
,	1282	1283	|O
respectively	1284	1296	|O
)	1296	1297	|O
.	1297	1298	|O
The	1299	1302	|O
structure	1303	1312	|O
of	1313	1315	|O
the	1316	1319	|O
[	1320	1321	|O
99mTc	1321	1326	|O
]	1326	1327	|O
TRODAT	1327	1333	|O
-	1333	1334	|O
1	1334	1335	|O
complexes	1336	1345	|O
was	1346	1349	|O
deduced	1350	1357	|O
using	1358	1363	|O
nonradioactive	1364	1378	|O
rhenium	1379	1386	|O
as	1387	1389	|O
a	1390	1391	|O
surrogate	1392	1401	|O
for	1402	1405	|O
radioactive	1406	1417	|O
technetium	1418	1428	|O
complex	1429	1436	|O
.	1436	1437	|O
Reacting	1438	1446	|O
free	1447	1451	|O
TRODAT	1452	1458	|O
-	1458	1459	|O
1	1459	1460	|O
ligand	1461	1467	|O
with	1468	1472	|O
[	1473	1474	|O
Bu4N	1474	1478	|O
]	1478	1479	|O
[	1479	1480	|O
ReOCl4	1480	1486	|O
]	1486	1487	|O
yielded	1488	1495	|O
two	1496	1499	|O
major	1500	1505	|O
complexes	1506	1515	|O
:	1515	1516	|O
Re	1517	1519	|O
-	1519	1520	|O
TRODAT	1520	1526	|O
-	1526	1527	|O
1A	1527	1529	|O
(	1530	1531	|O
3A	1531	1533	|O
)	1533	1534	|O
and	1535	1538	|O
Re	1539	1541	|O
-	1541	1542	|O
TRODAT	1542	1548	|O
-	1548	1549	|O
1B	1549	1551	|O
(	1552	1553	|O
3B	1553	1555	|O
)	1555	1556	|O
(	1557	1558	|O
corresponding	1558	1571	|O
with	1572	1576	|O
peaks	1577	1582	|O
A	1583	1584	|O
and	1585	1588	|O
B	1589	1590	|O
of	1591	1593	|O
[	1594	1595	|O
99mTc	1595	1600	|O
]	1600	1601	|O
TRODAT	1601	1607	|O
-	1607	1608	|O
1	1608	1609	|O
,	1609	1610	|O
respectively	1611	1623	|O
)	1623	1624	|O
,	1624	1625	|O
whose	1626	1631	|O
structures	1632	1642	|O
were	1643	1647	|O
determined	1648	1658	|O
by	1659	1661	|O
X	1662	1663	|O
-	1663	1664	|O
ray	1664	1667	|O
analysis	1668	1676	|O
.	1676	1677	|O
The	1678	1681	|O
X	1682	1683	|O
-	1683	1684	|O
ray	1684	1687	|O
structures	1688	1698	|O
show	1699	1703	|O
that	1704	1708	|O
both	1709	1713	|O
complexes	1714	1723	|O
have	1724	1728	|O
a	1729	1730	|O
pseudo	1731	1737	|O
-	1737	1738	|O
square	1738	1744	|O
-	1744	1745	|O
pyramidal	1745	1754	|O
structure	1755	1764	|O
of	1765	1767	|O
[	1768	1769	|O
RevO	1769	1773	|O
]	1773	1774	|O
3+	1774	1776	|O
N2S2	1776	1780	|O
core	1781	1785	|O
with	1786	1790	|O
oxygen	1791	1797	|O
occupying	1798	1807	|O
the	1808	1811	|O
apical	1812	1818	|O
position	1819	1827	|O
and	1828	1831	|O
the	1832	1835	|O
N	1836	1837	|O
-	1837	1838	|O
alkyl	1838	1843	|O
substitution	1844	1856	|O
in	1857	1859	|O
syn	1860	1863	|O
-	1863	1864	|O
configuration	1864	1877	|O
to	1878	1880	|O
the	1881	1884	|O
oxo	1885	1888	|O
-	1888	1889	|O
rhenium	1889	1896	|O
bond	1897	1901	|O
.	1901	1902	|O
In	1903	1905	|O
conclusion	1906	1916	|O
,	1916	1917	|O
TRODAT	1918	1924	|O
-	1924	1925	|O
1	1925	1926	|O
formed	1927	1933	|O
at	1934	1936	|O
least	1937	1942	|O
two	1943	1946	|O
diastereomers	1947	1960	|O
after	1961	1966	|O
complexing	1967	1977	|O
with	1978	1982	|O
a	1983	1984	|O
metal	1985	1990	|O
(	1990	1991	|O
V	1991	1992	|O
)	1992	1993	|O
-	1993	1994	|O
oxo	1994	1997	|O
(	1998	1999	|O
M	1999	2000	|O
=	2001	2002	|O
99mTc	2003	2008	|O
,	2008	2009	|O
Re	2010	2012	|O
)	2012	2013	|O
center	2014	2020	|O
core	2021	2025	|O
.	2025	2026	|O
The	2027	2030	|O
two	2031	2034	|O
isomers	2035	2042	|O
display	2043	2050	|O
different	2051	2060	|O
binding	2061	2068	|O
affinities	2069	2079	|O
toward	2080	2086	|O
dopamine	2087	2095	|O
transporters	2096	2108	|O
and	2109	2112	|O
distinct	2113	2121	|O
properties	2122	2132	|O
of	2133	2135	|O
localization	2136	2148	|O
in	2149	2151	|O
the	2152	2155	|O
striatum	2156	2164	|O
area	2165	2169	|O
of	2170	2172	|O
the	2173	2176	|O
brain	2177	2182	|O
where	2183	2188	|O
the	2189	2192	|O
transporters	2193	2205	|O
are	2206	2209	|O
located	2210	2217	|O
.	2217	2218	|O

### abstracts143.txt
The	0	3	|O
novel	4	9	|O
calcium	10	17	|O
antagonists	18	29	|O
3	30	31	|B-MODIFIER
-	31	32	|I-MODIFIER
N	32	33	|I-MODIFIER
-	33	34	|I-MODIFIER
substituted	34	45	|I-MODIFIER
-	45	46	|O
3,4	46	49	|B-IUPAC
-	49	50	|I-IUPAC
dihydropyrimidines	50	68	|I-IUPAC
1	69	70	|O
and	71	74	|O
9	75	76	|O
and	77	80	|O
3	81	82	|B-MODIFIER
-	82	83	|I-MODIFIER
N	83	84	|I-MODIFIER
-	84	85	|I-MODIFIER
substituted	85	96	|I-MODIFIER
-	96	97	|O
dihydro	97	104	|B-IUPAC
-	104	105	|I-IUPAC
pyrimidin	105	114	|I-IUPAC
-	114	115	|I-IUPAC
2	115	116	|I-IUPAC
(	116	117	|I-IUPAC
1H	117	119	|I-IUPAC
)	119	120	|I-IUPAC
-	120	121	|I-IUPAC
ones	121	125	|I-IUPAC
8	126	127	|O
were	128	132	|O
regioselectively	133	149	|O
synthesized	150	161	|O
in	162	164	|O
good	165	169	|O
yields	170	176	|O
.	176	177	|O
Compounds	178	187	|O
1	188	189	|O
[	190	191	|O
especially	191	201	|O
1s	202	204	|O
[	205	206	|O
R1	206	208	|O
=	209	210	|O
(	211	212	|B-PARTIUPAC
CH2	212	215	|I-PARTIUPAC
)	215	216	|I-PARTIUPAC
2N	216	218	|I-PARTIUPAC
(	218	219	|I-PARTIUPAC
benzyl	219	225	|I-PARTIUPAC
)	225	226	|I-PARTIUPAC
(	226	227	|I-PARTIUPAC
2	227	228	|I-PARTIUPAC
-	228	229	|I-PARTIUPAC
naphthylmethyl	229	243	|I-PARTIUPAC
)	243	244	|O
,	244	245	|O
R2	246	248	|O
=	249	250	|O
i	251	252	|O
-	252	253	|O
Pr	253	255	|O
,	255	256	|O
X	257	258	|O
=	259	260	|O
0	261	262	|O
-	262	263	|O
NO2	263	266	|O
]	266	267	|O
and	268	271	|O
1t	272	274	|O
[	275	276	|O
R1	276	278	|O
=	279	280	|O
(	281	282	|B-PARTIUPAC
CH2	282	285	|I-PARTIUPAC
)	285	286	|I-PARTIUPAC
2N	286	288	|I-PARTIUPAC
(	288	289	|I-PARTIUPAC
benzyl	289	295	|I-PARTIUPAC
)	295	296	|I-PARTIUPAC
(	296	297	|I-PARTIUPAC
3,4	297	300	|I-PARTIUPAC
-	300	301	|I-PARTIUPAC
dichlorobenzyl	301	315	|I-PARTIUPAC
)	315	316	|O
,	316	317	|O
R2	318	320	|O
=	321	322	|O
i	323	324	|O
-	324	325	|O
Pr	325	327	|O
,	327	328	|O
X	329	330	|O
=	331	332	|O
0	333	334	|O
-	334	335	|O
NO2	335	338	|O
]	338	339	|O
]	339	340	|O
exhibited	341	350	|O
not	351	354	|O
only	355	359	|O
more	360	364	|O
potent	365	371	|O
and	372	375	|O
longer	376	382	|O
lasting	383	390	|O
vasodilative	391	403	|O
action	404	410	|O
but	411	414	|O
also	415	419	|O
a	420	421	|O
hypotensive	422	433	|O
activity	434	442	|O
with	443	447	|O
slow	448	452	|O
onset	453	458	|O
as	459	461	|O
compared	462	470	|O
with	471	475	|O
dihydropyridines	476	492	|O
.	492	493	|O
Moreover	494	502	|O
,	502	503	|O
some	504	508	|O
dihydropyrimidines	509	527	|O
[	528	529	|O
1q	529	531	|O
[	532	533	|O
R1	533	535	|O
=	536	537	|O
(	538	539	|B-PARTIUPAC
CH2	539	542	|I-PARTIUPAC
)	542	543	|I-PARTIUPAC
2N	543	545	|I-PARTIUPAC
(	545	546	|I-PARTIUPAC
benzyl	546	552	|I-PARTIUPAC
)	552	553	|I-PARTIUPAC
(	553	554	|I-PARTIUPAC
3	554	555	|I-PARTIUPAC
-	555	556	|I-PARTIUPAC
phenylpropyl	556	568	|I-PARTIUPAC
)	568	569	|O
,	569	570	|O
R2	571	573	|O
=	574	575	|O
CH2	576	579	|B-IUPAC
(	579	580	|I-IUPAC
cyclopropyl	580	591	|I-IUPAC
)	591	592	|I-IUPAC
,	592	593	|O
X	594	595	|O
=	596	597	|O
0	598	599	|O
-	599	600	|O
NO2	600	603	|O
]	603	604	|O
,	604	605	|O
1s	606	608	|O
,	608	609	|O
and	610	613	|O
1t	614	616	|O
]	616	617	|O
were	618	622	|O
weaker	623	629	|O
in	630	632	|O
blocking	633	641	|O
atrioventricular	642	658	|O
conduction	659	669	|O
in	670	672	|O
anesthetized	673	685	|O
open	686	690	|O
-	690	691	|O
chest	691	696	|O
dogs	697	701	|O
and	702	705	|O
less	706	710	|O
toxic	711	716	|O
than	717	721	|O
the	722	725	|O
dihydropyridines	726	742	|O
.	742	743	|O

### abstracts3190.txt
A	0	1	|O
new	2	5	|O
series	6	12	|O
of	13	15	|O
thyrotropin	16	27	|O
-	27	28	|O
releasing	28	37	|O
hormone	38	45	|O
(	46	47	|O
TRH	47	50	|O
)	50	51	|O
analogues	52	61	|O
,	61	62	|O
obtained	63	71	|O
by	72	74	|O
further	75	82	|O
modifications	83	96	|O
of	97	99	|O
our	100	103	|O
most	104	108	|O
potent	109	115	|O
central	116	123	|O
nervous	124	131	|O
system	132	138	|O
(	139	140	|O
CNS	140	143	|O
)	143	144	|O
stimulating	145	156	|O
neutral	157	164	|O
tripeptides	165	176	|O
at	177	179	|O
both	180	184	|O
termini	185	192	|O
,	192	193	|O
were	194	198	|O
synthesized	199	210	|O
by	211	213	|O
the	214	217	|O
pentafluorophenyl	218	235	|O
ester	236	241	|O
method	242	248	|O
and	249	252	|O
tested	253	259	|O
for	260	263	|O
CNS	264	267	|O
and	268	271	|O
thyrotropin	272	283	|O
(	284	285	|O
TSH	285	288	|O
)	288	289	|O
releasing	290	299	|O
activity	300	308	|O
.	308	309	|O
Replacement	310	321	|O
of	322	324	|O
pyroglutamic	325	337	|O
acid	338	342	|O
by	343	345	|O
pyro	346	350	|B-IUPAC
-	350	351	|I-IUPAC
2	351	352	|I-IUPAC
-	352	353	|I-IUPAC
aminoadipic	353	364	|I-IUPAC
acid	365	369	|I-IUPAC
,	369	370	|O
2	371	372	|B-IUPAC
-	372	373	|I-IUPAC
oxoimidazolidine	373	389	|I-IUPAC
-	389	390	|I-IUPAC
4	390	391	|I-IUPAC
-	391	392	|I-IUPAC
carboxylic	392	402	|I-IUPAC
acid	403	407	|I-IUPAC
or	408	410	|O
gamma	411	416	|B-IUPAC
-	416	417	|I-IUPAC
butyrolactone	417	430	|I-IUPAC
-	430	431	|I-IUPAC
gamma	431	436	|I-IUPAC
-	436	437	|I-IUPAC
carboxylic	437	447	|I-IUPAC
acid	448	452	|I-IUPAC
and	453	456	|O
that	457	461	|O
of	462	464	|O
proline	465	472	|O
by	473	475	|O
pipecolic	476	485	|O
acid	486	490	|O
,	490	491	|O
thiazolidine	492	504	|B-IUPAC
-	504	505	|I-IUPAC
4	505	506	|I-IUPAC
-	506	507	|I-IUPAC
carboxylic	507	517	|I-IUPAC
acid	518	522	|I-IUPAC
,	522	523	|O
or	524	526	|O
homoproline	527	538	|O
in	539	541	|O
[	542	543	|O
Leu2	543	547	|O
]	547	548	|O
-	548	549	|O
and	550	553	|O
[	554	555	|O
Nva2	555	559	|O
]	559	560	|O
TRH	560	563	|O
led	564	567	|O
to	568	570	|O
tripeptides	571	582	|O
structurally	583	595	|O
widely	596	602	|O
different	603	612	|O
from	613	617	|O
TRH	618	621	|O
.	621	622	|O
In	623	625	|O
spite	626	631	|O
of	632	634	|O
this	635	639	|O
fact	640	644	|O
,	644	645	|O
7	646	647	|O
of	648	650	|O
the	651	654	|O
17	655	657	|O
analogues	658	667	|O
(	668	669	|O
1	669	670	|O
,	670	671	|O
2	672	673	|O
,	673	674	|O
8-10	675	679	|O
,	679	680	|O
16	681	683	|O
,	683	684	|O
and	685	688	|O
17	689	691	|O
)	691	692	|O
have	693	697	|O
stronger	698	706	|O
anticataleptic	707	721	|O
effect	722	728	|O
than	729	733	|O
TRH	734	737	|O
,	737	738	|O
with	739	743	|O
negligible	744	754	|O
or	755	757	|O
no	758	760	|O
hormonal	761	769	|O
potency	770	777	|O
.	777	778	|O
The	779	782	|O
highest	783	790	|O
CNS	791	794	|O
activity	795	803	|O
was	804	807	|O
achieved	808	816	|O
when	817	821	|O
pyroglutamic	822	834	|O
acid	835	839	|O
was	840	843	|O
replaced	844	852	|O
by	853	855	|O
pyro	856	860	|B-IUPAC
-	860	861	|I-IUPAC
2	861	862	|I-IUPAC
-	862	863	|I-IUPAC
aminoadipic	863	874	|I-IUPAC
acid	875	879	|I-IUPAC
at	880	882	|O
the	883	886	|O
N	887	888	|O
-	888	889	|O
terminus	889	897	|O
[	898	899	|O
pAad	899	903	|O
-	903	904	|O
Leu	904	907	|O
-	907	908	|O
Pro	908	911	|O
-	911	912	|O
NH2	912	915	|O
,	915	916	|O
1	917	918	|O
(	919	920	|O
RGH	920	923	|O
2202	924	928	|O
)	928	929	|O
,	929	930	|O
and	931	934	|O
pAad	935	939	|O
-	939	940	|O
Nva	940	943	|O
-	943	944	|O
Pro	944	947	|O
-	947	948	|O
NH2	948	951	|O
,	951	952	|O
2	952	953	|O
]	953	954	|O
.	954	955	|O
A	956	957	|O
novel	958	963	|O
synthesis	964	973	|O
of	974	976	|O
L	977	978	|B-IUPAC
-	978	979	|I-IUPAC
2	979	980	|I-IUPAC
-	980	981	|I-IUPAC
aminoadipic	981	992	|I-IUPAC
acid	993	997	|I-IUPAC
suitable	998	1006	|O
for	1007	1010	|O
large	1011	1016	|O
-	1016	1017	|O
scale	1017	1022	|O
preparation	1023	1034	|O
is	1035	1037	|O
also	1038	1042	|O
described	1043	1052	|O
.	1052	1053	|O

### abstracts2561.txt
Novel	0	5	|O
arylpiperazines	6	21	|O
were	22	26	|O
identified	27	37	|O
as	38	40	|O
alpha	41	46	|O
1	47	48	|O
-	48	49	|O
adrenoceptor	49	61	|O
(	62	63	|O
AR	63	65	|O
)	65	66	|O
subtype	67	74	|O
-	74	75	|O
selective	75	84	|O
antagonists	85	96	|O
by	97	99	|O
functional	100	110	|O
in	111	113	|O
vitro	114	119	|O
screening	120	129	|O
.	129	130	|O
3	131	132	|B-PARTIUPAC
-	132	133	|I-PARTIUPAC
[	133	134	|I-PARTIUPAC
4	134	135	|I-PARTIUPAC
-	135	136	|I-PARTIUPAC
(	136	137	|O
ortho	137	142	|B-IUPAC
-	142	143	|O
Substituted	143	154	|B-MODIFIER
phenyl	155	161	|B-IUPAC
)	161	162	|O
piperazin	162	171	|B-PARTIUPAC
-	171	172	|I-PARTIUPAC
1	172	173	|I-PARTIUPAC
-	173	174	|I-PARTIUPAC
yl	174	176	|I-PARTIUPAC
]	176	177	|I-PARTIUPAC
propylamines	177	189	|I-PARTIUPAC
were	190	194	|O
derivatized	195	206	|O
with	207	211	|O
N	212	213	|B-IUPAC
,	213	214	|I-IUPAC
N	214	215	|I-IUPAC
-	215	216	|I-IUPAC
dimethyl	216	224	|I-IUPAC
anthranilamides	225	240	|I-IUPAC
,	240	241	|O
nicotinamides	242	255	|O
,	255	256	|O
as	257	259	|O
well	260	264	|O
as	265	267	|O
carboxamides	268	280	|O
of	281	283	|O
quinoline	284	293	|O
,	293	294	|O
1,8	295	298	|B-IUPAC
-	298	299	|I-IUPAC
naphthyridine	299	312	|I-IUPAC
,	312	313	|O
pyrazolo	314	322	|B-IUPAC
[	322	323	|I-IUPAC
3,4	323	326	|I-IUPAC
-	326	327	|I-IUPAC
b	327	328	|I-IUPAC
]	328	329	|I-IUPAC
pyridine	329	337	|I-IUPAC
,	337	338	|O
isoxazolo	339	348	|B-IUPAC
[	348	349	|I-IUPAC
3,4	349	352	|I-IUPAC
-	352	353	|I-IUPAC
b	353	354	|I-IUPAC
]	354	355	|I-IUPAC
pyridine	355	363	|I-IUPAC
,	363	364	|O
imidazo	365	372	|B-IUPAC
[	372	373	|I-IUPAC
4,5	373	376	|I-IUPAC
-	376	377	|I-IUPAC
b	377	378	|I-IUPAC
]	378	379	|I-IUPAC
pyridine	379	387	|I-IUPAC
,	387	388	|O
and	389	392	|O
pyrazolo	393	401	|B-IUPAC
[	401	402	|I-IUPAC
1,5	402	405	|I-IUPAC
-	405	406	|I-IUPAC
a	406	407	|I-IUPAC
]	407	408	|I-IUPAC
pyrimidines	408	419	|I-IUPAC
.	419	420	|O
Strips	421	427	|O
of	428	430	|O
rabbit	431	437	|O
bladder	438	445	|O
neck	446	450	|O
were	451	455	|O
employed	456	464	|O
as	465	467	|O
a	468	469	|O
predictive	470	480	|O
assay	481	486	|O
for	487	490	|O
antagonism	491	501	|O
in	502	504	|O
the	505	508	|O
human	509	514	|O
lower	515	520	|O
tract	521	526	|O
.	526	527	|O
Rings	528	533	|O
of	534	536	|O
rat	537	540	|O
aorta	541	546	|O
were	547	551	|O
used	552	556	|O
as	557	559	|O
a	560	561	|O
"	562	563	|O
negative	563	571	|O
screen	572	578	|O
"	578	579	|O
for	580	583	|O
the	584	587	|O
test	588	592	|O
antagonists	593	604	|O
.	604	605	|O
Binding	606	613	|O
to	614	616	|O
alpha	617	622	|O
1	623	624	|O
-	624	625	|O
ARs	625	628	|O
was	629	632	|O
relatively	633	643	|O
sensitive	644	653	|O
to	654	656	|O
size	657	661	|O
and	662	665	|O
electronic	666	676	|O
features	677	685	|O
of	686	688	|O
the	689	692	|O
arylpiperazine	693	707	|B-IUPAC
portion	708	715	|O
of	716	718	|O
the	719	722	|O
antagonists	723	734	|O
and	735	738	|O
permissive	739	749	|O
to	750	752	|O
these	753	758	|O
features	759	767	|O
on	768	770	|O
the	771	774	|O
heteroaryl	775	785	|O
carboxamide	786	797	|O
side	798	802	|O
.	802	803	|O
These	804	809	|O
structure	810	819	|O
-	819	820	|O
affinity	820	828	|O
findings	829	837	|O
were	838	842	|O
exploited	843	852	|O
to	853	855	|O
produce	856	863	|O
nicotinamides	864	877	|O
(	878	879	|O
e.g.	879	883	|O
13ii	884	888	|O
and	889	892	|O
25x	893	896	|O
)	896	897	|O
and	898	901	|O
pyrazolo	902	910	|B-IUPAC
[	910	911	|I-IUPAC
3,4	911	914	|I-IUPAC
-	914	915	|I-IUPAC
b	915	916	|I-IUPAC
]	916	917	|I-IUPAC
pyridines	917	926	|I-IUPAC
(	927	928	|O
e.g.	928	932	|O
37f	933	936	|O
and	937	940	|O
37y	941	944	|O
)	944	945	|O
ligands	946	953	|O
with	954	958	|O
nanomolar	959	968	|O
affinity	969	977	|O
at	978	980	|O
the	981	984	|O
alpha	985	990	|O
1	991	992	|O
-	992	993	|O
AR	993	995	|O
subtype	996	1003	|O
prevalent	1004	1013	|O
in	1014	1016	|O
the	1017	1020	|O
human	1021	1026	|O
lower	1027	1032	|O
urinary	1033	1040	|O
tract	1041	1046	|O
(	1046	1047	|O
pA2	1047	1050	|O
values	1051	1057	|O
:	1057	1058	|O
8.8	1059	1062	|O
,	1062	1063	|O
10.7	1064	1068	|O
,	1068	1069	|O
9.3	1070	1073	|O
,	1073	1074	|O
and	1075	1078	|O
9.9	1079	1082	|O
,	1082	1083	|O
respectively	1084	1096	|O
)	1096	1097	|O
and	1098	1101	|O
displaying	1102	1112	|O
2-3	1113	1116	|O
orders	1117	1123	|O
of	1124	1126	|O
magnitude	1127	1136	|O
selectivity	1137	1148	|O
over	1149	1153	|O
the	1154	1157	|O
alpha	1158	1163	|O
1D	1164	1166	|O
-	1166	1167	|O
AR	1167	1169	|O
.	1169	1170	|O

### abstracts1822.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
N	12	13	|B-PARTIUPAC
-	13	14	|I-PARTIUPAC
[	14	15	|I-PARTIUPAC
4	15	16	|I-PARTIUPAC
-	16	17	|I-PARTIUPAC
(	17	18	|I-PARTIUPAC
3	18	19	|I-PARTIUPAC
-	19	20	|I-PARTIUPAC
pyridinyl	20	29	|I-PARTIUPAC
)	29	30	|I-PARTIUPAC
butyl	30	35	|I-PARTIUPAC
]	35	36	|I-PARTIUPAC
-	36	37	|I-PARTIUPAC
5,5	37	40	|I-PARTIUPAC
-	40	41	|O
disubstituted	41	54	|B-MODIFIER
-	54	55	|O
pentadienamides	55	70	|B-PARTIUPAC
was	71	74	|O
prepared	75	83	|O
and	84	87	|O
evaluated	88	97	|O
for	98	101	|O
PAF	102	105	|O
-	105	106	|O
antagonist	106	116	|O
activity	117	125	|O
.	125	126	|O
Compounds	127	136	|O
were	137	141	|O
assayed	142	149	|O
in	150	152	|O
vitro	153	158	|O
in	159	161	|O
a	162	163	|O
PAF	164	167	|O
-	167	168	|O
binding	168	175	|O
assay	176	181	|O
employing	182	191	|O
washed	192	198	|O
,	198	199	|O
whole	200	205	|O
dog	206	209	|O
platelets	210	219	|O
as	220	222	|O
the	223	226	|O
receptor	227	235	|O
source	236	242	|O
and	243	246	|O
in	247	249	|O
vivo	250	254	|O
after	255	260	|O
intravenous	261	272	|O
or	273	275	|O
oral	276	280	|O
administration	281	295	|O
for	296	299	|O
their	300	305	|O
ability	306	313	|O
to	314	316	|O
prevent	317	324	|O
PAF	325	328	|O
-	328	329	|O
induced	329	336	|O
bronchoconstriction	337	356	|O
in	357	359	|O
guinea	360	366	|O
pigs	367	371	|O
.	371	372	|O
Criteria	373	381	|O
required	382	390	|O
for	391	394	|O
good	395	399	|O
oral	400	404	|O
activity	405	413	|O
in	414	416	|O
the	417	420	|O
latter	421	427	|O
model	428	433	|O
include	434	441	|O
an	442	444	|O
(	445	446	|B-IUPAC
E	446	447	|I-IUPAC
,	447	448	|I-IUPAC
-	448	449	|I-IUPAC
E	449	450	|I-IUPAC
)	450	451	|I-IUPAC
-	451	452	|I-IUPAC
5	452	453	|I-IUPAC
-	453	454	|I-IUPAC
phenyl	454	460	|I-IUPAC
-	460	461	|I-IUPAC
2,4	461	464	|I-IUPAC
-	464	465	|I-IUPAC
pentadienamide	465	479	|I-IUPAC
,	479	480	|O
a	481	482	|O
second	483	489	|O
phenyl	490	496	|B-PARTIUPAC
or	497	499	|O
a	500	501	|O
four	502	506	|O
-	506	507	|O
or	508	510	|O
five	511	515	|O
-	515	516	|O
carbon	516	522	|O
alkyl	523	528	|B-PARTIUPAC
moiety	529	535	|B-MODIFIER
in	536	538	|O
the	539	542	|O
5	543	544	|O
-	544	545	|O
position	545	553	|O
of	554	556	|O
the	557	560	|O
diene	561	566	|O
,	566	567	|O
and	568	571	|O
an	572	574	|O
(	575	576	|B-IUPAC
R	576	577	|I-IUPAC
)	577	578	|I-IUPAC
-	578	579	|I-IUPAC
[	579	580	|I-IUPAC
1	580	581	|I-IUPAC
-	581	582	|I-IUPAC
alkyl	582	587	|I-IUPAC
-	587	588	|I-IUPAC
4	588	589	|I-IUPAC
-	589	590	|I-IUPAC
(	590	591	|I-IUPAC
3	591	592	|I-IUPAC
-	592	593	|I-IUPAC
pyridinyl	593	602	|I-IUPAC
)	602	603	|I-IUPAC
butyl	603	608	|I-IUPAC
]	608	609	|I-IUPAC
substituent	610	621	|B-MODIFIER
on	622	624	|O
the	625	628	|O
carboxamide	629	640	|O
nitrogen	641	649	|O
atom	650	654	|O
.	654	655	|O
The	656	659	|O
alkyl	660	665	|B-PARTIUPAC
substituent	666	677	|B-MODIFIER
on	678	680	|O
this	681	685	|O
side	686	690	|O
chain	691	696	|O
can	697	700	|O
be	701	703	|O
methyl	704	710	|B-PARTIUPAC
,	710	711	|O
ethyl	712	717	|B-PARTIUPAC
,	717	718	|O
or	719	721	|O
cyclopropyl	722	733	|B-PARTIUPAC
.	733	734	|O
Two	735	738	|O
members	739	746	|O
of	747	749	|O
this	750	754	|O
series	755	761	|O
,	761	762	|O
[	763	764	|B-IUPAC
R	764	765	|I-IUPAC
-	765	766	|I-IUPAC
(	766	767	|I-IUPAC
E	767	768	|I-IUPAC
)	768	769	|I-IUPAC
]	769	770	|I-IUPAC
-	770	771	|I-IUPAC
5,5	771	774	|I-IUPAC
-	774	775	|I-IUPAC
bis	775	778	|I-IUPAC
(	778	779	|I-IUPAC
4	779	780	|I-IUPAC
-	780	781	|I-IUPAC
methoxy	781	788	|I-IUPAC
-	788	789	|I-IUPAC
phenyl	789	795	|I-IUPAC
)	795	796	|I-IUPAC
-	796	797	|I-IUPAC
N	797	798	|I-IUPAC
-	798	799	|I-IUPAC
[	800	801	|I-IUPAC
1	801	802	|I-IUPAC
-	802	803	|I-IUPAC
methyl	803	809	|I-IUPAC
-	809	810	|I-IUPAC
4	810	811	|I-IUPAC
-	811	812	|I-IUPAC
(	812	813	|I-IUPAC
3	813	814	|I-IUPAC
-	814	815	|I-IUPAC
pyridinyl	815	824	|I-IUPAC
)	824	825	|I-IUPAC
butyl	825	830	|I-IUPAC
]	830	831	|I-IUPAC
-	831	832	|I-IUPAC
2,4	833	836	|I-IUPAC
-	836	837	|I-IUPAC
pentadienamide	837	851	|I-IUPAC
(	852	853	|O
31	853	855	|O
)	855	856	|O
and	857	860	|O
[	861	862	|B-IUPAC
R	862	863	|I-IUPAC
-	863	864	|I-IUPAC
(	864	865	|I-IUPAC
E	865	866	|I-IUPAC
,	866	867	|I-IUPAC
E	867	868	|I-IUPAC
)	868	869	|I-IUPAC
]	869	870	|I-IUPAC
-	870	871	|I-IUPAC
5	871	872	|I-IUPAC
-	872	873	|I-IUPAC
(	873	874	|I-IUPAC
4	874	875	|I-IUPAC
-	875	876	|I-IUPAC
methoxyphenyl	876	889	|I-IUPAC
)	889	890	|I-IUPAC
-	890	891	|I-IUPAC
N	891	892	|I-IUPAC
-	892	893	|I-IUPAC
[	893	894	|I-IUPAC
1	894	895	|I-IUPAC
-	895	896	|I-IUPAC
methyl	896	902	|I-IUPAC
-	902	903	|I-IUPAC
4	903	904	|I-IUPAC
-	904	905	|I-IUPAC
(	906	907	|I-IUPAC
3	907	908	|I-IUPAC
-	908	909	|I-IUPAC
pyridinyl	909	918	|I-IUPAC
)	918	919	|I-IUPAC
butyl	919	924	|I-IUPAC
]	924	925	|I-IUPAC
-	925	926	|I-IUPAC
2,4	926	929	|I-IUPAC
-	929	930	|I-IUPAC
decadienamide	930	943	|I-IUPAC
(	944	945	|O
58	945	947	|O
)	947	948	|O
,	948	949	|O
were	950	954	|O
selected	955	963	|O
for	964	967	|O
further	968	975	|O
pharmacological	976	991	|O
evaluation	992	1002	|O
.	1002	1003	|O
Both	1004	1008	|O
were	1009	1013	|O
found	1014	1019	|O
to	1020	1022	|O
be	1023	1025	|O
substantially	1026	1039	|O
longer	1040	1046	|O
acting	1047	1053	|O
after	1054	1059	|O
oral	1060	1064	|O
administration	1065	1079	|O
than	1080	1084	|O
the	1085	1088	|O
corresponding	1089	1102	|O
S	1103	1104	|O
enantiomers	1105	1116	|O
in	1117	1119	|O
the	1120	1123	|O
guinea	1124	1130	|O
pig	1131	1134	|O
bronchoconstriction	1135	1154	|O
assay	1155	1160	|O
.	1160	1161	|O
A	1162	1163	|O
second	1164	1170	|O
in	1171	1173	|O
vivo	1174	1178	|O
model	1179	1184	|O
used	1185	1189	|O
to	1190	1192	|O
evaluate	1193	1201	|O
PAF	1202	1205	|O
antagonists	1206	1217	|O
determines	1218	1228	|O
the	1229	1232	|O
ability	1233	1240	|O
of	1241	1243	|O
test	1244	1248	|O
compounds	1249	1258	|O
to	1259	1261	|O
decrease	1262	1270	|O
the	1271	1274	|O
area	1275	1279	|O
of	1280	1282	|O
skin	1283	1287	|O
wheals	1288	1294	|O
induced	1295	1302	|O
by	1303	1305	|O
an	1306	1308	|O
intradermal	1309	1320	|O
injection	1321	1330	|O
of	1331	1333	|O
PAF	1334	1337	|O
.	1337	1338	|O
In	1339	1341	|O
this	1342	1346	|O
model	1347	1352	|O
,	1352	1353	|O
using	1354	1359	|O
both	1360	1364	|O
rats	1365	1369	|O
and	1370	1373	|O
guinea	1374	1380	|O
pigs	1381	1385	|O
,	1385	1386	|O
compounds	1387	1396	|O
31	1397	1399	|O
and	1400	1403	|O
58	1404	1406	|O
were	1407	1411	|O
found	1412	1417	|O
to	1418	1420	|O
be	1421	1423	|O
as	1424	1426	|O
active	1427	1433	|O
as	1434	1436	|O
the	1437	1440	|O
reference	1441	1450	|O
PAF	1451	1454	|O
antagonist	1455	1465	|O
3	1466	1467	|B-IUPAC
-	1467	1468	|I-IUPAC
[	1468	1469	|I-IUPAC
4	1469	1470	|I-IUPAC
-	1470	1471	|I-IUPAC
(	1471	1472	|I-IUPAC
2	1472	1473	|I-IUPAC
-	1473	1474	|I-IUPAC
chlorophenyl	1474	1486	|I-IUPAC
)	1486	1487	|I-IUPAC
-	1487	1488	|I-IUPAC
9	1488	1489	|I-IUPAC
-	1489	1490	|I-IUPAC
methyl	1490	1496	|I-IUPAC
-	1496	1497	|I-IUPAC
6H	1497	1499	|I-IUPAC
-	1499	1500	|I-IUPAC
1	1501	1502	|I-IUPAC
-	1502	1503	|I-IUPAC
(	1503	1504	|I-IUPAC
4	1504	1505	|I-IUPAC
-	1505	1506	|I-IUPAC
morpholinyl	1506	1517	|I-IUPAC
)	1517	1518	|I-IUPAC
-	1518	1519	|I-IUPAC
1	1519	1520	|I-IUPAC
-	1520	1521	|I-IUPAC
propanone	1521	1530	|I-IUPAC
(	1531	1532	|O
45	1532	1534	|O
)	1534	1535	|O
.	1535	1536	|O

### abstracts1575.txt
Convenient	0	10	|O
procedures	11	21	|O
are	22	25	|O
described	26	35	|O
for	36	39	|O
the	40	43	|O
synthesis	44	53	|O
of	54	56	|O
5	57	58	|B-MODIFIER
-	58	59	|I-MODIFIER
substituted	59	70	|I-MODIFIER
N	71	72	|B-IUPAC
(	72	73	|I-IUPAC
4	73	74	|I-IUPAC
)	74	75	|I-IUPAC
-	75	76	|I-IUPAC
hydroxy	76	83	|I-IUPAC
-	83	84	|I-IUPAC
2'	84	86	|I-IUPAC
-	86	87	|I-IUPAC
deoxycytidines	87	101	|I-IUPAC
5a	102	104	|O
,	104	105	|O
b	105	106	|O
,	106	107	|O
d	107	108	|O
-	108	109	|O
h	109	110	|O
via	111	114	|O
transformation	115	129	|O
of	130	132	|O
the	133	136	|O
respective	137	147	|O
5	148	149	|B-MODIFIER
-	149	150	|I-MODIFIER
substituted	150	161	|I-MODIFIER
3'	162	164	|B-IUPAC
,	164	165	|I-IUPAC
5'	166	168	|I-IUPAC
-	168	169	|I-IUPAC
di	169	171	|I-IUPAC
-	171	172	|I-IUPAC
O	172	173	|I-IUPAC
-	173	174	|I-IUPAC
acetyl	174	180	|I-IUPAC
-	180	181	|I-IUPAC
2'	181	183	|I-IUPAC
-	183	184	|I-IUPAC
deoxyuridines	184	197	|I-IUPAC
1a	198	200	|O
-	200	201	|O
c	201	202	|O
,	202	203	|O
e	203	204	|O
-	204	205	|O
h	205	206	|O
.	206	207	|O
These	208	213	|O
procedures	214	224	|O
involved	225	233	|O
site	234	238	|O
-	238	239	|O
specific	239	247	|O
triazolation	248	260	|O
or	261	263	|O
N	264	265	|O
-	265	266	|O
methylimidazolation	266	285	|O
at	286	288	|O
position	289	297	|O
C	298	299	|O
(	299	300	|O
4	300	301	|O
)	301	302	|O
,	302	303	|O
followed	304	312	|O
by	313	315	|O
hydroxylamination	316	333	|O
and	334	337	|O
deblocking	338	348	|O
with	349	353	|O
MeOH	354	358	|O
-	358	359	|O
NH	359	361	|O
(	361	362	|O
3	362	363	|O
)	363	364	|O
.	364	365	|O
Nucleosides	366	377	|O
5a	378	380	|O
,	380	381	|O
b	381	382	|O
,	382	383	|O
d	383	384	|O
-	384	385	|O
h	385	386	|O
were	387	391	|O
selectively	392	403	|O
converted	404	413	|O
to	414	416	|O
the	417	420	|O
corresponding	421	434	|O
5'	435	437	|O
-	437	438	|O
monophosphates	438	452	|O
6a	453	455	|O
,	455	456	|O
b	456	457	|O
,	457	458	|O
d	458	459	|O
-	459	460	|O
h	460	461	|O
with	462	466	|O
the	467	470	|O
aid	471	474	|O
of	475	477	|O
the	478	481	|O
wheat	482	487	|O
shoot	488	493	|O
phosphotransferase	494	512	|O
system	513	519	|O
.	519	520	|O
Conformation	521	533	|O
of	534	536	|O
each	537	541	|O
nucleoside	542	552	|O
in	553	555	|O
D	556	557	|O
(	557	558	|O
2	558	559	|O
)	559	560	|O
O	560	561	|O
solution	562	570	|O
,	570	571	|O
deduced	572	579	|O
from	580	584	|O
(	585	586	|O
1	586	587	|O
)	587	588	|O
H	588	589	|O
NMR	590	593	|O
spectra	594	601	|O
and	602	605	|O
confirmed	606	615	|O
by	616	618	|O
molecular	619	628	|O
mechanics	629	638	|O
calculations	639	651	|O
,	651	652	|O
showed	653	659	|O
the	660	663	|O
pentose	664	671	|O
ring	672	676	|O
to	677	679	|O
exist	680	685	|O
predominantly	686	699	|O
in	700	702	|O
the	703	706	|O
conformation	707	719	|O
S	720	721	|O
(	722	723	|O
C	723	724	|O
-	724	725	|O
2'	725	727	|O
-	727	728	|O
endo	728	732	|O
)	732	733	|O
and	734	737	|O
the	738	741	|O
N	742	743	|O
(	743	744	|O
4	744	745	|O
)	745	746	|O
-	746	747	|O
OH	747	749	|O
group	750	755	|O
as	756	758	|O
the	759	762	|O
cis	763	766	|O
rotamer	767	774	|O
.	774	775	|O
Cell	776	780	|O
growth	781	787	|O
inhibition	788	798	|O
was	799	802	|O
studied	803	810	|O
with	811	815	|O
two	816	819	|O
L5178Y	820	826	|O
murine	827	833	|O
leukemia	834	842	|O
cell	843	847	|O
lines	848	853	|O
,	853	854	|O
parental	855	863	|O
and	864	867	|O
5	868	869	|B-IUPAC
-	869	870	|I-IUPAC
fluoro	870	876	|I-IUPAC
-	876	877	|I-IUPAC
2'	877	879	|I-IUPAC
-	879	880	|I-IUPAC
deoxyuridine	880	892	|I-IUPAC
(	893	894	|O
FdUrd	894	899	|O
)	899	900	|O
-	900	901	|O
resistant	901	910	|O
,	910	911	|O
the	912	915	|O
latter	916	922	|O
70	923	925	|O
-	925	926	|O
fold	926	930	|O
less	931	935	|O
sensitive	936	945	|O
toward	946	952	|O
FdUrd	953	958	|O
than	959	963	|O
the	964	967	|O
former	968	974	|O
.	974	975	|O
With	976	980	|O
FdUrd	981	986	|O
-	986	987	|O
resistant	987	996	|O
L5178Y	997	1003	|O
cells	1004	1009	|O
,	1009	1010	|O
5	1011	1012	|B-IUPAC
-	1012	1013	|I-IUPAC
fluoro	1013	1019	|I-IUPAC
-	1019	1020	|I-IUPAC
N	1020	1021	|I-IUPAC
(	1021	1022	|I-IUPAC
4	1022	1023	|I-IUPAC
)	1023	1024	|I-IUPAC
-	1024	1025	|I-IUPAC
hydroxy	1025	1032	|I-IUPAC
-	1032	1033	|I-IUPAC
2'	1033	1035	|I-IUPAC
-	1035	1036	|I-IUPAC
deoxycytidine	1036	1049	|I-IUPAC
(	1050	1051	|O
5e	1051	1053	|O
)	1053	1054	|O
caused	1055	1061	|O
almost	1062	1068	|O
3	1069	1070	|O
-	1070	1071	|O
fold	1071	1075	|O
stronger	1076	1084	|O
growth	1085	1091	|O
inhibition	1092	1102	|O
than	1103	1107	|O
FdUrd	1108	1113	|O
;	1113	1114	|O
5e	1115	1117	|O
was	1118	1121	|O
only	1122	1126	|O
some	1127	1131	|O
3	1132	1133	|O
-	1133	1134	|O
fold	1134	1138	|O
weaker	1139	1145	|O
growth	1146	1152	|O
inhibitor	1153	1162	|O
of	1163	1165	|O
the	1166	1169	|O
resistant	1170	1179	|O
cells	1180	1185	|O
than	1186	1190	|O
of	1191	1193	|O
the	1194	1197	|O
parental	1198	1206	|O
cells	1207	1212	|O
.	1212	1213	|O
Thymidylate	1214	1225	|O
synthase	1226	1234	|O
inhibition	1235	1245	|O
was	1246	1249	|O
studied	1250	1257	|O
with	1258	1262	|O
two	1263	1266	|O
forms	1267	1272	|O
of	1273	1275	|O
the	1276	1279	|O
enzyme	1280	1286	|O
differing	1287	1296	|O
in	1297	1299	|O
sensitivities	1300	1313	|O
toward	1314	1320	|O
5	1321	1322	|B-IUPAC
-	1322	1323	|I-IUPAC
fluoro	1323	1329	|I-IUPAC
-	1329	1330	|I-IUPAC
2'	1330	1332	|I-IUPAC
-	1332	1333	|I-IUPAC
deoxyuridine	1333	1345	|I-IUPAC
5'	1346	1348	|I-IUPAC
-	1348	1349	|I-IUPAC
monophosphate	1349	1362	|I-IUPAC
(	1363	1364	|O
FdUMP	1364	1369	|O
)	1369	1370	|O
,	1370	1371	|O
isolated	1372	1380	|O
from	1381	1385	|O
parental	1386	1394	|O
and	1395	1398	|O
FdUrd	1399	1404	|O
-	1404	1405	|O
resistant	1405	1414	|O
L1210	1415	1420	|O
cell	1421	1425	|O
lines	1426	1431	|O
.	1431	1432	|O
All	1433	1436	|O
N	1437	1438	|O
(	1438	1439	|O
4	1439	1440	|O
)	1440	1441	|O
-	1441	1442	|O
hydroxy	1442	1449	|O
-	1449	1450	|O
dCMP	1450	1454	|O
(	1455	1456	|O
6a	1456	1458	|O
,	1458	1459	|O
b	1459	1460	|O
,	1460	1461	|O
d	1461	1462	|O
-	1462	1463	|O
h	1463	1464	|O
)	1464	1465	|O
and	1466	1469	|O
dUMP	1470	1474	|O
analogues	1475	1484	|O
studied	1485	1492	|O
were	1493	1497	|O
competitive	1498	1509	|O
vs	1510	1512	|O
dUMP	1513	1517	|O
inhibitors	1518	1528	|O
of	1529	1531	|O
the	1532	1535	|O
enzyme	1536	1542	|O
.	1542	1543	|O
Analogues	1544	1553	|O
6b	1554	1556	|O
,	1556	1557	|O
d	1557	1558	|O
-	1558	1559	|O
h	1559	1560	|O
and	1561	1564	|O
5	1565	1566	|O
-	1566	1567	|O
hydroxymethyl	1567	1580	|O
-	1580	1581	|O
dUMP	1581	1585	|O
,	1585	1586	|O
similar	1587	1594	|O
to	1595	1597	|O
N	1598	1599	|O
(	1599	1600	|O
4	1600	1601	|O
)	1601	1602	|O
-	1602	1603	|O
hydroxy	1603	1610	|O
-	1610	1611	|O
dCMP	1611	1615	|O
(	1616	1617	|O
6a	1617	1619	|O
)	1619	1620	|O
and	1621	1624	|O
FdUMP	1625	1630	|O
,	1630	1631	|O
were	1632	1636	|O
also	1637	1641	|O
N	1642	1643	|O
(	1643	1644	|O
5	1644	1645	|O
)	1645	1646	|O
,	1646	1647	|O
N	1648	1649	|B-IUPAC
(	1649	1650	|I-IUPAC
10	1650	1652	|I-IUPAC
)	1652	1653	|I-IUPAC
-	1653	1654	|I-IUPAC
methylenetetrahydrofolate	1654	1679	|I-IUPAC
-	1679	1680	|O
dependent	1680	1689	|O
,	1689	1690	|O
hence	1691	1696	|O
mechanism	1697	1706	|O
-	1706	1707	|O
based	1707	1712	|O
,	1712	1713	|O
slow	1714	1718	|O
-	1718	1719	|O
binding	1719	1726	|O
inhibitors	1727	1737	|O
.	1737	1738	|O
5	1739	1740	|O
-	1740	1741	|O
Chloro	1741	1747	|O
-	1747	1748	|O
dUMP	1748	1752	|O
,	1752	1753	|O
5	1754	1755	|O
-	1755	1756	|O
bromo	1756	1761	|O
-	1761	1762	|O
dUMP	1762	1766	|O
,	1766	1767	|O
and	1768	1771	|O
5	1772	1773	|O
-	1773	1774	|O
iodo	1774	1778	|O
-	1778	1779	|O
dUMP	1779	1783	|O
,	1783	1784	|O
similar	1785	1792	|O
to	1793	1795	|O
dTMP	1796	1800	|O
,	1800	1801	|O
did	1802	1805	|O
not	1806	1809	|O
cause	1810	1815	|O
a	1816	1817	|O
time	1818	1822	|O
-	1822	1823	|O
dependent	1823	1832	|O
inactivation	1833	1845	|O
of	1846	1848	|O
the	1849	1852	|O
enzyme	1853	1859	|O
.	1859	1860	|O
Instead	1861	1868	|O
,	1868	1869	|O
they	1870	1874	|O
behaved	1875	1882	|O
as	1883	1885	|O
classic	1886	1893	|O
inhibitors	1894	1904	|O
of	1905	1907	|O
tritium	1908	1915	|O
release	1916	1923	|O
from	1924	1928	|O
[	1929	1930	|O
5	1930	1931	|O
-	1931	1932	|O
(	1932	1933	|O
3	1933	1934	|O
)	1934	1935	|O
H	1935	1936	|O
]	1936	1937	|O
dUMP	1937	1941	|O
.	1941	1942	|O
5	1943	1944	|O
-	1944	1945	|O
Bromo	1945	1950	|O
-	1950	1951	|O
dUMP	1951	1955	|O
and	1956	1959	|O
5	1960	1961	|O
-	1961	1962	|O
iodo	1962	1966	|O
-	1966	1967	|O
dUMP	1967	1971	|O
showed	1972	1978	|O
substrate	1979	1988	|O
activity	1989	1997	|O
independent	1998	2009	|O
of	2010	2012	|O
N	2013	2014	|B-IUPAC
(	2014	2015	|I-IUPAC
5	2015	2016	|I-IUPAC
)	2016	2017	|I-IUPAC
,	2017	2018	|I-IUPAC
N	2019	2020	|I-IUPAC
(	2020	2021	|I-IUPAC
10	2021	2023	|I-IUPAC
)	2023	2024	|I-IUPAC
-	2024	2025	|I-IUPAC
methylenetetrahydrofolate	2025	2050	|I-IUPAC
in	2051	2053	|O
the	2054	2057	|O
thymidylate	2058	2069	|O
synthase	2070	2078	|O
-	2078	2079	|O
catalyzed	2079	2088	|O
dehalogenation	2089	2103	|O
reaction	2104	2112	|O
.	2112	2113	|O
The	2114	2117	|O
=	2118	2119	|O
N	2119	2120	|O
-	2120	2121	|O
OH	2121	2123	|O
substituent	2124	2135	|O
of	2136	2138	|O
the	2139	2142	|O
pyrimidine	2143	2153	|O
C	2154	2155	|O
(	2155	2156	|O
4	2156	2157	|O
)	2157	2158	|O
prevented	2159	2168	|O
the	2169	2172	|O
enzyme	2173	2179	|O
-	2179	2180	|O
catalyzed	2180	2189	|O
release	2190	2197	|O
from	2198	2202	|O
the	2203	2206	|O
C	2207	2208	|O
(	2208	2209	|O
5	2209	2210	|O
)	2210	2211	|O
of	2212	2214	|O
Br	2215	2217	|O
(	2217	2218	|O
-	2218	2219	|O
)	2219	2220	|O
and	2221	2224	|O
I	2225	2226	|O
(	2226	2227	|O
-	2227	2228	|O
)	2228	2229	|O
(	2230	2231	|O
the	2231	2234	|O
same	2235	2239	|O
shown	2240	2245	|O
previously	2246	2256	|O
for	2257	2260	|O
H	2261	2262	|O
(	2262	2263	|O
+	2263	2264	|O
)	2264	2265	|O
)	2265	2266	|O
.	2266	2267	|O
While	2268	2273	|O
FdUMP	2274	2279	|O
and	2280	2283	|O
6a	2284	2286	|O
showed	2287	2293	|O
a	2294	2295	|O
higher	2296	2302	|O
affinity	2303	2311	|O
and	2312	2315	|O
greater	2316	2323	|O
inactivation	2324	2336	|O
power	2337	2342	|O
with	2343	2347	|O
the	2348	2351	|O
parental	2352	2360	|O
cell	2361	2365	|O
than	2366	2370	|O
FdUrd	2371	2376	|O
-	2376	2377	|O
resistant	2377	2386	|O
cell	2387	2391	|O
enzyme	2392	2398	|O
,	2398	2399	|O
an	2400	2402	|O
opposite	2403	2411	|O
relationship	2412	2424	|O
could	2425	2430	|O
be	2431	2433	|O
seen	2434	2438	|O
with	2439	2443	|O
5	2444	2445	|O
-	2445	2446	|O
hydroxymethyl	2446	2459	|O
-	2459	2460	|O
dUMP	2460	2464	|O
.	2464	2465	|O

### abstracts480.txt
The	0	3	|O
palladium	4	13	|O
-	13	14	|O
catalyzed	14	23	|O
coupling	24	32	|O
of	33	35	|O
3	36	37	|B-PARTIUPAC
-	37	38	|I-PARTIUPAC
and	39	42	|O
4	43	44	|B-IUPAC
-	44	45	|I-IUPAC
(	45	46	|I-IUPAC
trialkylstannyl	46	61	|I-IUPAC
)	61	62	|I-IUPAC
pyridines	62	71	|I-IUPAC
with	72	76	|O
7	77	78	|B-IUPAC
-	78	79	|I-IUPAC
bromo	79	84	|I-IUPAC
or	85	87	|O
7	88	89	|B-IUPAC
-	89	90	|I-IUPAC
chloro	90	96	|I-IUPAC
1	97	98	|B-MODIFIER
-	98	99	|I-MODIFIER
substituted	99	110	|I-MODIFIER
1,4	111	114	|B-IUPAC
-	114	115	|I-IUPAC
dihydro	115	122	|I-IUPAC
-	122	123	|I-IUPAC
4	123	124	|I-IUPAC
-	124	125	|I-IUPAC
oxo	125	128	|I-IUPAC
-	128	129	|I-IUPAC
3	129	130	|I-IUPAC
-	130	131	|I-IUPAC
quinolinecarboxylates	131	152	|I-IUPAC
has	153	156	|O
provided	157	165	|O
access	166	172	|O
to	173	175	|O
the	176	179	|O
corresponding	180	193	|O
1	194	195	|B-MODIFIER
-	195	196	|I-MODIFIER
substituted	196	207	|I-MODIFIER
1,4	208	211	|B-IUPAC
-	211	212	|I-IUPAC
dihydro	212	219	|I-IUPAC
-	219	220	|I-IUPAC
4	220	221	|I-IUPAC
-	221	222	|I-IUPAC
oxo	222	225	|I-IUPAC
-	225	226	|I-IUPAC
7	226	227	|I-IUPAC
-	227	228	|I-IUPAC
pyridinyl	228	237	|I-IUPAC
-	237	238	|I-IUPAC
3	238	239	|I-IUPAC
-	239	240	|I-IUPAC
quinolinecarboxylic	240	259	|I-IUPAC
acids	260	265	|I-IUPAC
.	265	266	|O
The	267	270	|O
antibacterial	271	284	|O
activity	285	293	|O
of	294	296	|O
these	297	302	|O
derivatives	303	314	|O
was	315	318	|O
studied	319	326	|O
with	327	331	|O
the	332	335	|O
finding	336	343	|O
that	344	348	|O
the	349	352	|O
optimal	353	360	|O
1	361	362	|O
-	362	363	|O
and	364	367	|O
7	368	369	|O
-	369	370	|O
position	370	378	|O
substituents	379	391	|O
for	392	395	|O
Gram	396	400	|O
positive	401	409	|O
activity	410	418	|O
are	419	422	|O
cyclopropyl	423	434	|O
and	435	438	|O
4	439	440	|B-PARTIUPAC
-	440	441	|I-PARTIUPAC
(	441	442	|I-PARTIUPAC
2,6	442	445	|I-PARTIUPAC
-	445	446	|I-PARTIUPAC
dimethylpyridinyl	446	463	|I-PARTIUPAC
)	463	464	|I-PARTIUPAC
,	464	465	|O
respectively	466	478	|O
.	478	479	|O
We	480	482	|O
find	483	487	|O
that	488	492	|O
for	493	496	|O
the	497	500	|O
fluorine	501	509	|O
-	509	510	|O
substituted	510	521	|O
derivatives	522	533	|O
studied	534	541	|O
,	541	542	|O
the	543	546	|O
position	547	555	|O
of	556	558	|O
the	559	562	|O
fluorine	563	571	|O
on	572	574	|O
the	575	578	|O
quinolone	579	588	|O
nucleus	589	596	|O
or	597	599	|O
the	600	603	|O
number	604	610	|O
of	611	613	|O
fluorine	614	622	|O
atoms	623	628	|O
does	629	633	|O
not	634	637	|O
seem	638	642	|O
to	643	645	|O
be	646	648	|O
important	649	658	|O
for	659	662	|O
good	663	667	|O
Gram	668	672	|O
positive	673	681	|O
activity	682	690	|O
.	690	691	|O
For	692	695	|O
1	696	697	|B-PARTIUPAC
-	697	698	|I-PARTIUPAC
cyclopropyl	698	709	|I-PARTIUPAC
7	710	711	|I-PARTIUPAC
-	711	712	|I-PARTIUPAC
(	712	713	|I-PARTIUPAC
2,6	713	716	|I-PARTIUPAC
-	716	717	|I-PARTIUPAC
dimethyl	717	725	|I-PARTIUPAC
-	725	726	|I-PARTIUPAC
4	726	727	|I-PARTIUPAC
-	727	728	|I-PARTIUPAC
pyridinyl	728	737	|I-PARTIUPAC
)	737	738	|I-PARTIUPAC
derivatives	739	750	|B-MODIFIER
,	750	751	|O
the	752	755	|O
6	756	757	|B-PARTIUPAC
-	757	758	|I-PARTIUPAC
fluoro	758	764	|I-PARTIUPAC
4a	765	767	|O
,	767	768	|O
8	769	770	|B-PARTIUPAC
-	770	771	|I-PARTIUPAC
fluoro	771	777	|I-PARTIUPAC
10d	778	781	|O
,	781	782	|O
6,8	783	786	|B-PARTIUPAC
-	786	787	|I-PARTIUPAC
difluoro	787	795	|I-PARTIUPAC
10b	796	799	|O
,	799	800	|O
and	801	804	|O
5,6,8	805	810	|B-PARTIUPAC
-	810	811	|I-PARTIUPAC
trifluoro	811	820	|I-PARTIUPAC
8	821	822	|O
,	822	823	|O
all	824	827	|O
provided	828	836	|O
equal	837	842	|O
antibacterial	843	856	|O
activity	857	865	|O
against	866	873	|O
Staphylococcus	874	888	|O
aureus	889	895	|O
ATCC	896	900	|O
29213	901	906	|O
.	906	907	|O
There	908	913	|O
is	914	916	|O
also	917	921	|O
a	922	923	|O
correlation	924	935	|O
between	936	943	|O
the	944	947	|O
substitution	948	960	|O
on	961	963	|O
the	964	967	|O
7	968	969	|B-PARTIUPAC
-	969	970	|I-PARTIUPAC
(	970	971	|I-PARTIUPAC
4	971	972	|I-PARTIUPAC
-	972	973	|I-PARTIUPAC
pyridinyl	973	982	|I-PARTIUPAC
)	982	983	|I-PARTIUPAC
group	984	989	|B-MODIFIER
and	990	993	|O
the	994	997	|O
Gram	998	1002	|O
positive	1003	1011	|O
activity	1012	1020	|O
,	1020	1021	|O
particularly	1022	1034	|O
for	1035	1038	|O
S	1039	1040	|O
.	1040	1041	|O
aureus	1042	1048	|O
,	1048	1049	|O
clearly	1050	1057	|O
indicating	1058	1068	|O
that	1069	1073	|O
the	1074	1077	|O
2,6	1078	1081	|B-PARTIUPAC
-	1081	1082	|I-PARTIUPAC
dimethylpyridinyl	1082	1099	|I-PARTIUPAC
group	1100	1105	|B-MODIFIER
is	1106	1108	|O
optimal	1109	1116	|O
.	1116	1117	|O
The	1118	1121	|O
MIC50	1122	1127	|O
value	1128	1133	|O
for	1134	1137	|O
the	1138	1141	|O
most	1142	1146	|O
potent	1147	1153	|O
agents	1154	1160	|O
in	1161	1163	|O
this	1164	1168	|O
study	1169	1174	|O
against	1175	1182	|O
S	1183	1184	|O
.	1184	1185	|O
aureus	1186	1192	|O
ATCC	1193	1197	|O
29213	1198	1203	|O
is	1204	1206	|O
0.008	1207	1212	|O
microgram	1213	1222	|O
/	1222	1223	|O
mL	1223	1225	|O
.	1225	1226	|O
By	1227	1229	|O
comparison	1230	1240	|O
,	1240	1241	|O
ciprofloxacin	1242	1255	|O
and	1256	1259	|O
aminopyrrolidine	1260	1276	|O
28	1277	1279	|O
gave	1280	1284	|O
values	1285	1291	|O
of	1292	1294	|O
0.25	1295	1299	|O
and	1300	1303	|O
0.015	1304	1309	|O
microgram	1310	1319	|O
/	1319	1320	|O
mL	1320	1322	|O
,	1322	1323	|O
respectively	1324	1336	|O
,	1336	1337	|O
against	1338	1345	|O
this	1346	1350	|O
organism	1351	1359	|O
.	1359	1360	|O

### abstracts994.txt
In	0	2	|O
an	3	5	|O
effort	6	12	|O
to	13	15	|O
develop	16	23	|O
selective	24	33	|O
inhibitors	34	44	|O
of	45	47	|O
vesicular	48	57	|O
acetylcholine	58	71	|O
storage	72	79	|O
,	79	80	|O
we	81	83	|O
have	84	88	|O
synthesized	89	100	|O
a	101	102	|O
series	103	109	|O
of	110	112	|O
semirigid	113	122	|O
vesamicol	123	132	|O
receptor	133	141	|O
ligands	142	149	|O
based	150	155	|O
on	156	158	|O
the	159	162	|O
structure	163	172	|O
of	173	175	|O
2	176	177	|B-IUPAC
-	177	178	|I-IUPAC
(	178	179	|I-IUPAC
4	179	180	|I-IUPAC
-	180	181	|I-IUPAC
phenylpiperidino	181	197	|I-IUPAC
)	197	198	|I-IUPAC
-	198	199	|I-IUPAC
cyclohexanol	199	211	|I-IUPAC
(	212	213	|O
vesamicol	213	222	|O
,	222	223	|O
AH5183	224	230	|O
,	230	231	|O
1	232	233	|O
)	233	234	|O
.	234	235	|O
In	236	238	|O
these	239	244	|O
compounds	245	254	|O
,	254	255	|O
the	256	259	|O
planes	260	266	|O
of	267	269	|O
the	270	273	|O
phenyl	274	280	|O
and	281	284	|O
piperidyl	285	294	|O
moieties	295	303	|O
of	304	306	|O
the	307	310	|O
parent	311	317	|O
ligand	318	324	|O
1	325	326	|O
are	327	330	|O
held	331	335	|O
at	336	338	|O
right	339	344	|O
angles	345	351	|O
by	352	354	|O
vinyl	355	360	|O
,	360	361	|O
ethylene	362	370	|O
,	370	371	|O
and	372	375	|O
propylene	376	385	|O
bridges	386	393	|O
to	394	396	|O
form	397	401	|O
N	402	403	|B-MODIFIER
-	403	404	|I-MODIFIER
substituted	404	415	|I-MODIFIER
derivatives	416	427	|B-MODIFIER
of	428	430	|O
spiro	431	436	|B-IUPAC
[	436	437	|I-IUPAC
indene	437	443	|I-IUPAC
-	443	444	|I-IUPAC
1,4	444	447	|I-IUPAC
'	447	448	|I-IUPAC
-	448	449	|I-IUPAC
piperidine	449	459	|I-IUPAC
]	459	460	|I-IUPAC
,	460	461	|O
2,3	462	465	|B-IUPAC
-	465	466	|I-IUPAC
dihydrospiro	466	478	|I-IUPAC
[	478	479	|I-IUPAC
indene	479	485	|I-IUPAC
-	485	486	|I-IUPAC
1,4	486	489	|I-IUPAC
'	489	490	|I-IUPAC
-	490	491	|I-IUPAC
piperidine	491	501	|I-IUPAC
]	501	502	|I-IUPAC
,	502	503	|O
and	504	507	|O
3,4	508	511	|B-IUPAC
-	511	512	|I-IUPAC
dihydrospiro	512	524	|I-IUPAC
[	524	525	|I-IUPAC
naphthalene	525	536	|I-IUPAC
-	536	537	|I-IUPAC
1	537	538	|I-IUPAC
(	538	539	|I-IUPAC
2H	539	541	|I-IUPAC
)	541	542	|I-IUPAC
,	542	543	|I-IUPAC
4'	543	545	|I-IUPAC
-	545	546	|I-IUPAC
piperidine	546	556	|I-IUPAC
]	556	557	|I-IUPAC
,	557	558	|O
respectively	559	571	|O
.	571	572	|O
Preliminary	573	584	|O
evaluation	585	595	|O
of	596	598	|O
these	599	604	|O
compounds	605	614	|O
in	615	617	|O
electric	618	626	|O
organ	627	632	|O
synaptic	633	641	|O
vesicles	642	650	|O
revealed	651	659	|O
several	660	667	|O
potent	668	674	|O
vesamicol	675	684	|O
receptor	685	693	|O
ligands	694	701	|O
,	701	702	|O
such	703	707	|O
as	708	710	|O
1'	711	713	|B-IUPAC
-	713	714	|I-IUPAC
(	714	715	|I-IUPAC
2	715	716	|I-IUPAC
-	716	717	|I-IUPAC
hydroxy	717	724	|I-IUPAC
-	724	725	|I-IUPAC
1,2,3,4	725	732	|I-IUPAC
-	732	733	|I-IUPAC
tetrahydronaphth	733	749	|I-IUPAC
-	749	750	|I-IUPAC
3	750	751	|I-IUPAC
-	751	752	|I-IUPAC
yl	752	754	|I-IUPAC
)	754	755	|I-IUPAC
spiro	755	760	|I-IUPAC
[	760	761	|I-IUPAC
1H	761	763	|I-IUPAC
-	763	764	|I-IUPAC
indene	764	770	|I-IUPAC
-	770	771	|I-IUPAC
1,4	771	774	|I-IUPAC
'	774	775	|I-IUPAC
-	775	776	|I-IUPAC
p	776	777	|I-IUPAC
iperidine	778	787	|I-IUPAC
(	788	789	|O
11b	789	792	|O
)	792	793	|O
and	794	797	|O
1'	798	800	|B-IUPAC
-	800	801	|I-IUPAC
(	801	802	|I-IUPAC
2	802	803	|I-IUPAC
-	803	804	|I-IUPAC
hydroxy	804	811	|I-IUPAC
-	811	812	|I-IUPAC
1,2,3,4	812	819	|I-IUPAC
-	819	820	|I-IUPAC
tetrahydronaphth	820	836	|I-IUPAC
-	836	837	|I-IUPAC
3	837	838	|I-IUPAC
-	838	839	|I-IUPAC
yl	839	841	|I-IUPAC
)	841	842	|I-IUPAC
spiro	842	847	|I-IUPAC
[	847	848	|I-IUPAC
2	848	849	|I-IUPAC
-	849	850	|I-IUPAC
bromo	850	855	|I-IUPAC
-	855	856	|I-IUPAC
1H	856	858	|I-IUPAC
-	858	859	|I-IUPAC
in	859	861	|I-IUPAC
den	862	865	|I-IUPAC
e	866	867	|I-IUPAC
-	867	868	|I-IUPAC
1,4	869	872	|I-IUPAC
'	872	873	|I-IUPAC
-	873	874	|I-IUPAC
piperidine	874	884	|I-IUPAC
]	884	885	|I-IUPAC
(	886	887	|O
14	887	889	|O
)	889	890	|O
,	890	891	|O
which	892	897	|O
display	898	905	|O
subnanomolar	906	918	|O
affinity	919	927	|O
for	928	931	|O
this	932	936	|O
receptor	937	945	|O
.	945	946	|O
In	947	949	|O
general	950	957	|O
,	957	958	|O
the	959	962	|O
vinyl	963	968	|O
and	969	972	|O
ethylene	973	981	|O
bridges	982	989	|O
yielded	990	997	|O
the	998	1001	|O
most	1002	1006	|O
potent	1007	1013	|O
analogs	1014	1021	|O
while	1022	1027	|O
the	1028	1031	|O
propylene	1032	1041	|O
-	1041	1042	|O
bridged	1042	1049	|O
analogs	1050	1057	|O
were	1058	1062	|O
among	1063	1068	|O
the	1069	1072	|O
least	1073	1078	|O
potent	1079	1085	|O
compounds	1086	1095	|O
.	1095	1096	|O
The	1097	1100	|O
increased	1101	1110	|O
rigidity	1111	1119	|O
of	1120	1122	|O
these	1123	1128	|O
spiro	1129	1134	|O
-	1134	1135	|O
fused	1135	1140	|O
compounds	1141	1150	|O
,	1150	1151	|O
relative	1152	1160	|O
to	1161	1163	|O
the	1164	1167	|O
corresponding	1168	1181	|O
simple	1182	1188	|O
4	1189	1190	|B-IUPAC
-	1190	1191	|I-IUPAC
phenylpiperidine	1191	1207	|I-IUPAC
derivatives	1208	1219	|B-MODIFIER
of	1220	1222	|O
vesamicol	1223	1232	|O
,	1232	1233	|O
is	1234	1236	|O
expected	1237	1245	|O
to	1246	1248	|O
confer	1249	1255	|O
greater	1256	1263	|O
selectivity	1264	1275	|O
for	1276	1279	|O
the	1280	1283	|O
vesamicol	1284	1293	|O
receptor	1294	1302	|O
.	1302	1303	|O

### abstracts3413.txt
Analogues	0	9	|O
of	10	12	|O
methotrexate	13	25	|O
(	26	27	|O
MTX	27	30	|O
)	30	31	|O
and	32	35	|O
aminopterin	36	47	|O
(	48	49	|O
AMT	49	52	|O
)	52	53	|O
modified	54	62	|O
at	63	65	|O
the	66	69	|O
gamma	70	75	|O
-	75	76	|O
position	76	84	|O
of	85	87	|O
the	88	91	|O
glutamate	92	101	|O
side	102	106	|O
chain	107	112	|O
were	113	117	|O
synthesized	118	129	|O
and	130	133	|O
evaluated	134	143	|O
as	144	146	|O
dihydrofolate	147	160	|O
reductase	161	170	|O
(	171	172	|O
DHFR	172	176	|O
)	176	177	|O
inhibitors	178	188	|O
and	189	192	|O
tumor	193	198	|O
cell	199	203	|O
growth	204	210	|O
inhibitors	211	221	|O
.	221	222	|O
Condesations	223	235	|O
of	236	238	|O
4	239	240	|B-IUPAC
-	240	241	|I-IUPAC
amino	241	246	|I-IUPAC
-	246	247	|I-IUPAC
4	247	248	|I-IUPAC
-	248	249	|I-IUPAC
deoxy	249	254	|I-IUPAC
-	254	255	|I-IUPAC
N10	255	258	|I-IUPAC
-	258	259	|I-IUPAC
methylpteroic	259	272	|I-IUPAC
acid	273	277	|I-IUPAC
(	278	279	|O
mAPA	279	283	|O
)	283	284	|O
with	285	289	|O
dimethyl	290	298	|B-IUPAC
DL	299	301	|I-IUPAC
-	301	302	|I-IUPAC
4	302	303	|I-IUPAC
-	303	304	|I-IUPAC
methyleneglutamate	304	322	|I-IUPAC
in	323	325	|O
the	326	329	|O
presence	330	338	|O
of	339	341	|O
diethyl	342	349	|O
phosphorocyanidate	350	368	|O
(	369	370	|O
DEPC	370	374	|O
)	374	375	|O
followed	376	384	|O
by	385	387	|O
alkaline	388	396	|O
hydrolysis	397	407	|O
yielded	408	415	|O
N	416	417	|B-IUPAC
-	417	418	|I-IUPAC
(	418	419	|I-IUPAC
4	419	420	|I-IUPAC
-	420	421	|I-IUPAC
amino	421	426	|I-IUPAC
-	426	427	|I-IUPAC
4	427	428	|I-IUPAC
-	428	429	|I-IUPAC
deoxy	429	434	|I-IUPAC
-	434	435	|I-IUPAC
N10	435	438	|I-IUPAC
-	438	439	|I-IUPAC
methylpteroyl	439	452	|I-IUPAC
)	452	453	|I-IUPAC
-	453	454	|I-IUPAC
DL	454	456	|I-IUPAC
-	456	457	|I-IUPAC
4	457	458	|I-IUPAC
-	458	459	|I-IUPAC
methyleneglutamic	459	476	|I-IUPAC
acid	477	481	|I-IUPAC
(	482	483	|O
gamma	483	488	|O
-	488	489	|O
methyleneMTX	489	501	|O
)	501	502	|O
.	502	503	|O
Condensation	504	516	|O
of	517	519	|O
4	520	521	|B-IUPAC
-	521	522	|I-IUPAC
amino	522	527	|I-IUPAC
-	527	528	|I-IUPAC
4	528	529	|I-IUPAC
-	529	530	|I-IUPAC
deoxy	530	535	|I-IUPAC
-	535	536	|I-IUPAC
N10	536	539	|I-IUPAC
-	539	540	|I-IUPAC
formylpteroic	540	553	|I-IUPAC
acid	554	558	|I-IUPAC
(	559	560	|O
fAPA	560	564	|O
)	564	565	|O
with	566	570	|O
dimethyl	571	579	|B-IUPAC
-	579	580	|I-IUPAC
DL	580	582	|I-IUPAC
-	582	583	|I-IUPAC
4	583	584	|I-IUPAC
-	584	585	|I-IUPAC
methyleneglutamate	585	603	|I-IUPAC
by	604	606	|O
the	607	610	|O
mixed	611	616	|O
carboxylic	617	627	|O
-	627	628	|O
carbonic	628	636	|O
anhydride	637	646	|O
method	647	653	|O
yielded	654	661	|O
N	662	663	|B-IUPAC
-	663	664	|I-IUPAC
4	664	665	|I-IUPAC
-	665	666	|I-IUPAC
amino	666	671	|I-IUPAC
-	671	672	|I-IUPAC
4	672	673	|I-IUPAC
-	673	674	|I-IUPAC
deoxypteroyl	674	686	|I-IUPAC
)	686	687	|I-IUPAC
-	687	688	|I-IUPAC
DL	688	690	|I-IUPAC
-	690	691	|I-IUPAC
4	691	692	|I-IUPAC
-	692	693	|I-IUPAC
methyleneglutamic	693	710	|I-IUPAC
acid	711	715	|I-IUPAC
(	716	717	|O
gamma	717	722	|O
-	722	723	|O
methyleneAMT	723	735	|O
)	735	736	|O
.	736	737	|O
Also	738	742	|O
prepared	743	751	|O
via	752	755	|O
DEPC	756	760	|O
coupling	761	769	|O
was	770	773	|O
a	774	775	|O
mixture	776	783	|O
of	784	786	|O
the	787	790	|O
four	791	795	|O
possible	796	804	|O
diastereomers	805	818	|O
of	819	821	|O
N	822	823	|B-IUPAC
-	823	824	|I-IUPAC
(	824	825	|I-IUPAC
4	825	826	|I-IUPAC
-	826	827	|I-IUPAC
amino	827	832	|I-IUPAC
-	832	833	|I-IUPAC
4	833	834	|I-IUPAC
-	834	835	|I-IUPAC
deoxy	835	840	|I-IUPAC
-	840	841	|I-IUPAC
N10	841	844	|I-IUPAC
-	844	845	|I-IUPAC
methylpteroyl	845	858	|I-IUPAC
)	858	859	|I-IUPAC
-	859	860	|I-IUPAC
4	860	861	|I-IUPAC
-	861	862	|I-IUPAC
cyanoglutamic	862	875	|I-IUPAC
acid	876	880	|I-IUPAC
(	881	882	|O
gamma	882	887	|O
-	887	888	|O
cyanoMTX	888	896	|O
)	896	897	|O
.	897	898	|O
The	899	902	|O
requisite	903	912	|O
intermediate	913	925	|O
gamma	926	931	|B-IUPAC
-	931	932	|I-IUPAC
tert	932	936	|I-IUPAC
-	936	937	|I-IUPAC
butyl	937	942	|I-IUPAC
alpha	943	948	|I-IUPAC
-	948	949	|I-IUPAC
methyl	949	955	|I-IUPAC
4	956	957	|I-IUPAC
-	957	958	|I-IUPAC
cyanoglutamate	958	972	|I-IUPAC
,	972	973	|O
as	974	976	|O
a	977	978	|O
DL	979	981	|O
-	981	982	|O
threo	982	987	|O
/	987	988	|O
DL	988	990	|O
-	990	991	|O
erythro	991	998	|O
mixture	999	1006	|O
,	1006	1007	|O
was	1008	1011	|O
prepared	1012	1020	|O
from	1021	1025	|O
methyl	1026	1032	|B-IUPAC
N	1033	1034	|I-IUPAC
alpha	1035	1040	|I-IUPAC
-	1040	1041	|I-IUPAC
Boc	1041	1044	|I-IUPAC
-	1044	1045	|I-IUPAC
O	1045	1046	|I-IUPAC
-	1046	1047	|I-IUPAC
tosyl	1047	1052	|I-IUPAC
-	1052	1053	|I-IUPAC
L	1053	1054	|I-IUPAC
-	1054	1055	|I-IUPAC
serinate	1055	1063	|I-IUPAC
by	1064	1066	|O
reaction	1067	1075	|O
with	1076	1080	|O
sodium	1081	1087	|B-IUPAC
tert	1088	1092	|I-IUPAC
-	1092	1093	|I-IUPAC
butyl	1093	1098	|I-IUPAC
cyanoacetate	1099	1111	|I-IUPAC
followed	1112	1120	|O
by	1121	1123	|O
mild	1124	1128	|O
trifluoroacetic	1129	1144	|O
treatment	1145	1154	|O
to	1155	1157	|O
selectively	1158	1169	|O
remove	1170	1176	|O
the	1177	1180	|O
Boc	1181	1184	|O
group	1185	1190	|O
.	1190	1191	|O
The	1192	1195	|O
gamma	1196	1201	|B-PARTIUPAC
-	1201	1202	|I-PARTIUPAC
methylene	1202	1211	|I-PARTIUPAC
derivatives	1212	1223	|B-MODIFIER
of	1224	1226	|O
MTX	1227	1230	|O
and	1231	1234	|O
AMT	1235	1238	|O
are	1239	1242	|O
attractive	1243	1253	|O
because	1254	1261	|O
of	1262	1264	|O
their	1265	1270	|O
potential	1271	1280	|O
to	1281	1283	|O
act	1284	1287	|O
as	1288	1290	|O
Michael	1291	1298	|O
acceptors	1299	1308	|O
within	1309	1315	|O
the	1316	1319	|O
DHFR	1320	1324	|O
active	1325	1331	|O
site	1332	1336	|O
.	1336	1337	|O
gamma	1338	1343	|O
-	1343	1344	|O
CyanoMTX	1344	1352	|O
may	1353	1356	|O
be	1357	1359	|O
viewed	1360	1366	|O
as	1367	1369	|O
a	1370	1371	|O
congener	1372	1380	|O
of	1381	1383	|O
the	1384	1387	|O
nonpolyglutamated	1388	1405	|O
MTX	1406	1409	|O
analogue	1410	1418	|O
gamma	1419	1424	|O
-	1424	1425	|O
fluoroMTX	1425	1434	|O
.	1434	1435	|O
In	1436	1438	|O
vitro	1439	1444	|O
bioassay	1445	1453	|O
data	1454	1458	|O
for	1459	1462	|O
the	1463	1466	|O
gamma	1467	1472	|B-IUPAC
-	1472	1473	|I-IUPAC
methylene	1473	1482	|I-IUPAC
and	1483	1486	|O
gamma	1487	1492	|B-IUPAC
-	1492	1493	|I-IUPAC
cyano	1493	1498	|I-IUPAC
compounds	1499	1508	|B-MODIFIER
support	1509	1516	|O
the	1517	1520	|O
idea	1521	1525	|O
that	1526	1530	|O
the	1531	1534	|O
active	1535	1541	|O
site	1542	1546	|O
of	1547	1549	|O
DHFR	1550	1554	|O
,	1554	1555	|O
already	1556	1563	|O
known	1564	1569	|O
for	1570	1573	|O
its	1574	1577	|O
ability	1578	1585	|O
to	1586	1588	|O
tolerate	1589	1597	|O
modification	1598	1610	|O
of	1611	1613	|O
the	1614	1617	|O
gamma	1618	1623	|B-IUPAC
-	1623	1624	|I-IUPAC
carboxyl	1624	1632	|I-IUPAC
group	1633	1638	|B-MODIFIER
of	1639	1641	|O
MTX	1642	1645	|O
and	1646	1649	|O
AMT	1650	1653	|O
,	1653	1654	|O
can	1655	1658	|O
likewise	1659	1667	|O
accommodate	1668	1679	|O
substitution	1680	1692	|O
on	1693	1695	|O
the	1696	1699	|O
gamma	1700	1705	|O
-	1705	1706	|O
carbon	1706	1712	|O
itself	1713	1719	|O
.	1719	1720	|O

### abstracts244.txt
Analogues	0	9	|O
of	10	12	|O
the	13	16	|O
2'	17	19	|B-IUPAC
,	19	20	|I-IUPAC
6'	20	22	|I-IUPAC
-	22	23	|I-IUPAC
dimethyl	23	31	|I-IUPAC
-	31	32	|I-IUPAC
L	32	33	|I-IUPAC
-	33	34	|I-IUPAC
tyrosine	34	42	|I-IUPAC
(	43	44	|I-IUPAC
Dmt	44	47	|I-IUPAC
)	47	48	|I-IUPAC
-	48	49	|I-IUPAC
1,2,3,4	49	56	|I-IUPAC
-	56	57	|I-IUPAC
tetrahydroisoquinoline	57	79	|I-IUPAC
-	79	80	|I-IUPAC
3	80	81	|I-IUPAC
-	81	82	|I-IUPAC
carboxylic	82	92	|I-IUPAC
acid	93	97	|I-IUPAC
(	98	99	|O
Tic	99	102	|O
)	102	103	|O
pharmacophore	104	117	|O
were	118	122	|O
prepared	123	131	|O
to	132	134	|O
test	135	139	|O
the	140	143	|O
hypothesis	144	154	|O
that	155	159	|O
a	160	161	|O
"	162	163	|O
spacer	163	169	|O
"	169	170	|O
and	171	174	|O
a	175	176	|O
third	177	182	|O
aromatic	183	191	|O
center	192	198	|O
in	199	201	|O
opioid	202	208	|O
peptides	209	217	|O
are	218	221	|O
required	222	230	|O
to	231	233	|O
convert	234	241	|O
a	242	243	|O
delta	244	249	|O
-	249	250	|O
antagonist	250	260	|O
into	261	265	|O
ligands	266	273	|O
with	274	278	|O
delta	279	284	|O
-	284	285	|O
agonist	285	292	|O
or	293	295	|O
with	296	300	|O
mixed	301	306	|O
delta	307	312	|O
-	312	313	|O
antagonist	313	323	|O
/	323	324	|O
mu	324	326	|O
-	326	327	|O
agonist	327	334	|O
properties	335	345	|O
.	345	346	|O
Potent	347	353	|O
delta	354	359	|O
-	359	360	|O
agonists	360	368	|O
and	369	372	|O
bifunctional	373	385	|O
compounds	386	395	|O
with	396	400	|O
high	401	405	|O
delta	406	411	|O
-	411	412	|O
and	413	416	|O
mu	417	419	|O
-	419	420	|O
opioid	420	426	|O
receptor	427	435	|O
affinities	436	446	|O
were	447	451	|O
obtained	452	460	|O
by	461	463	|O
varying	464	471	|O
the	472	475	|O
spacer	476	482	|O
length	483	489	|O
[	490	491	|O
none	491	495	|O
,	495	496	|O
NH	497	499	|O
-	499	500	|O
CH	500	502	|O
(	502	503	|O
2	503	504	|O
)	504	505	|O
,	505	506	|O
NH	507	509	|O
-	509	510	|O
CH	510	512	|O
(	512	513	|O
2	513	514	|O
)	514	515	|O
-	515	516	|O
CH	516	518	|O
(	518	519	|O
2	519	520	|O
)	520	521	|O
,	521	522	|O
Gly	523	526	|O
-	526	527	|O
NH	527	529	|O
-	529	530	|O
CH	530	532	|O
(	532	533	|O
2	533	534	|O
)	534	535	|O
]	535	536	|O
and	537	540	|O
C	541	542	|O
-	542	543	|O
terminal	543	551	|O
aromatic	552	560	|O
nucleus	561	568	|O
[	569	570	|O
1H	570	572	|B-PARTIUPAC
-	572	573	|I-PARTIUPAC
benzimidazole	573	586	|I-PARTIUPAC
-	586	587	|I-PARTIUPAC
2	587	588	|I-PARTIUPAC
-	588	589	|I-PARTIUPAC
yl	589	591	|I-PARTIUPAC
,	591	592	|O
phenyl	593	599	|B-PARTIUPAC
(	600	601	|O
Ph	601	603	|O
)	603	604	|O
and	605	608	|O
benzyl	609	615	|B-IUPAC
groups	616	622	|B-MODIFIER
]	622	623	|O
.	623	624	|O
C	625	626	|O
-	626	627	|O
terminal	627	635	|O
modification	636	648	|O
primarily	649	658	|O
affected	659	667	|O
mu	668	670	|O
-	670	671	|O
opioid	671	677	|O
receptor	678	686	|O
affinities	687	697	|O
,	697	698	|O
which	699	704	|O
increased	705	714	|O
maximally	715	724	|O
1700	725	729	|O
-	729	730	|O
fold	730	734	|O
relative	735	743	|O
to	744	746	|O
the	747	750	|O
prototype	751	760	|O
delta	761	766	|O
-	766	767	|O
antagonist	767	777	|O
H	778	779	|O
-	779	780	|O
Dmt	780	783	|O
-	783	784	|O
Tic	784	787	|O
-	787	788	|O
NH	788	790	|O
(	790	791	|O
2	791	792	|O
)	792	793	|O
and	794	797	|O
differentially	798	812	|O
modified	813	821	|O
bioactivity	822	833	|O
.	833	834	|O
In	835	837	|O
the	838	841	|O
absence	842	849	|O
of	850	852	|O
a	853	854	|O
spacer	855	861	|O
(	862	863	|O
1	863	864	|O
)	864	865	|O
,	865	866	|O
the	867	870	|O
analogue	871	879	|O
exhibited	880	889	|O
dual	890	894	|O
delta	895	900	|O
-	900	901	|O
agonism	901	908	|O
(	909	910	|O
pEC	910	913	|O
(	913	914	|O
50	914	916	|O
)	916	917	|O
,	917	918	|O
7.28	919	923	|O
)	923	924	|O
and	925	928	|O
delta	929	934	|O
-	934	935	|O
antagonism	935	945	|O
(	946	947	|O
pA	947	949	|O
(	949	950	|O
2	950	951	|O
)	951	952	|O
,	952	953	|O
7.90	954	958	|O
)	958	959	|O
.	959	960	|O
H	961	962	|O
-	962	963	|O
Dmt	963	966	|O
-	966	967	|O
Tic	967	970	|O
-	970	971	|O
NH	971	973	|O
-	973	974	|O
CH	974	976	|O
(	976	977	|O
2	977	978	|O
)	978	979	|O
-	979	980	|O
1H	980	982	|O
-	982	983	|O
benzimidazole	983	996	|O
-	996	997	|O
2	997	998	|O
-	998	999	|O
yl	999	1001	|O
(	1002	1003	|O
Bid	1003	1006	|O
)	1006	1007	|O
(	1008	1009	|O
2	1009	1010	|O
)	1010	1011	|O
became	1012	1018	|O
a	1019	1020	|O
highly	1021	1027	|O
potent	1028	1034	|O
delta	1035	1040	|O
-	1040	1041	|O
agonist	1041	1048	|O
(	1049	1050	|O
pEC	1050	1053	|O
(	1053	1054	|O
50	1054	1056	|O
)	1056	1057	|O
,	1057	1058	|O
9.90	1059	1063	|O
)	1063	1064	|O
,	1064	1065	|O
slightly	1066	1074	|O
greater	1075	1082	|O
than	1083	1087	|O
deltorphin	1088	1098	|O
C	1099	1100	|O
(	1101	1102	|O
pEC	1102	1105	|O
(	1105	1106	|O
50	1106	1108	|O
)	1108	1109	|O
,	1109	1110	|O
9.56	1111	1115	|O
)	1115	1116	|O
,	1116	1117	|O
with	1118	1122	|O
mu	1123	1125	|O
-	1125	1126	|O
agonism	1126	1133	|O
(	1134	1135	|O
pE	1135	1137	|O
(	1137	1138	|O
50	1138	1140	|O
)	1140	1141	|O
,	1141	1142	|O
7.57	1143	1147	|O
)	1147	1148	|O
,	1148	1149	|O
while	1150	1155	|O
H	1156	1157	|O
-	1157	1158	|O
Dmt	1158	1161	|O
-	1161	1162	|O
Tic	1162	1165	|O
-	1165	1166	|O
Gly	1166	1169	|O
-	1169	1170	|O
NH	1170	1172	|O
-	1172	1173	|O
CH	1173	1175	|O
(	1175	1176	|O
2	1176	1177	|O
)	1177	1178	|O
-	1178	1179	|O
Bid	1179	1182	|O
(	1183	1184	|O
4	1184	1185	|O
)	1185	1186	|O
retained	1187	1195	|O
potent	1196	1202	|O
delta	1203	1208	|O
-	1208	1209	|O
antagonism	1209	1219	|O
(	1220	1221	|O
pA	1221	1223	|O
(	1223	1224	|O
2	1224	1225	|O
)	1225	1226	|O
,	1226	1227	|O
9.0	1228	1231	|O
)	1231	1232	|O
but	1233	1236	|O
with	1237	1241	|O
an	1242	1244	|O
order	1245	1250	|O
of	1251	1253	|O
magnitude	1254	1263	|O
less	1264	1268	|O
mu	1269	1271	|O
-	1271	1272	|O
agonism	1272	1279	|O
.	1279	1280	|O
Similarly	1281	1290	|O
,	1290	1291	|O
H	1292	1293	|O
-	1293	1294	|O
Dmt	1294	1297	|O
-	1297	1298	|O
Tic	1298	1301	|O
-	1301	1302	|O
Gly	1302	1305	|O
-	1305	1306	|O
NH	1306	1308	|O
-	1308	1309	|O
Ph	1309	1311	|O
(	1312	1313	|O
5	1313	1314	|O
)	1314	1315	|O
had	1316	1319	|O
nearly	1320	1326	|O
equivalent	1327	1337	|O
high	1338	1342	|O
delta	1343	1348	|O
-	1348	1349	|O
agonism	1349	1356	|O
(	1357	1358	|O
pEC	1358	1361	|O
(	1361	1362	|O
50	1362	1364	|O
)	1364	1365	|O
,	1365	1366	|O
8.52	1367	1371	|O
)	1371	1372	|O
and	1373	1376	|O
mu	1377	1379	|O
-	1379	1380	|O
agonism	1380	1387	|O
(	1388	1389	|O
pEC	1389	1392	|O
(	1392	1393	|O
50	1393	1395	|O
)	1395	1396	|O
,	1396	1397	|O
8.59	1398	1402	|O
)	1402	1403	|O
,	1403	1404	|O
while	1405	1410	|O
H	1411	1412	|O
-	1412	1413	|O
Dmt	1413	1416	|O
-	1416	1417	|O
Tic	1417	1420	|O
-	1420	1421	|O
Gly	1421	1424	|O
-	1424	1425	|O
NH	1425	1427	|O
-	1427	1428	|O
CH	1428	1430	|O
(	1430	1431	|O
2	1431	1432	|O
)	1432	1433	|O
-	1433	1434	|O
Ph	1434	1436	|O
(	1437	1438	|O
6	1438	1439	|O
)	1439	1440	|O
whose	1441	1446	|O
spacer	1447	1453	|O
was	1454	1457	|O
longer	1458	1464	|O
by	1465	1467	|O
a	1468	1469	|O
single	1470	1476	|O
methylene	1477	1486	|O
group	1487	1492	|O
exhibited	1493	1502	|O
potent	1503	1509	|O
delta	1510	1515	|O
-	1515	1516	|O
antagonism	1516	1526	|O
(	1527	1528	|O
pA	1528	1530	|O
(	1530	1531	|O
2	1531	1532	|O
)	1532	1533	|O
,	1533	1534	|O
9.25	1535	1539	|O
)	1539	1540	|O
and	1541	1544	|O
very	1545	1549	|O
high	1550	1554	|O
mu	1555	1557	|O
-	1557	1558	|O
agonism	1558	1565	|O
(	1566	1567	|O
pEC	1567	1570	|O
(	1570	1571	|O
50	1571	1573	|O
)	1573	1574	|O
,	1574	1575	|O
8.57	1576	1580	|O
)	1580	1581	|O
.	1581	1582	|O
These	1583	1588	|O
data	1589	1593	|O
confirm	1594	1601	|O
that	1602	1606	|O
the	1607	1610	|O
distance	1611	1619	|O
between	1620	1627	|O
the	1628	1631	|O
Dmt	1632	1635	|O
-	1635	1636	|O
Tic	1636	1639	|O
pharmacophore	1640	1653	|O
and	1654	1657	|O
a	1658	1659	|O
third	1660	1665	|O
aromatic	1666	1674	|O
nucleus	1675	1682	|O
is	1683	1685	|O
an	1686	1688	|O
important	1689	1698	|O
criterion	1699	1708	|O
in	1709	1711	|O
converting	1712	1722	|O
Dmt	1723	1726	|O
-	1726	1727	|O
Tic	1727	1730	|O
from	1731	1735	|O
a	1736	1737	|O
highly	1738	1744	|O
potent	1745	1751	|O
delta	1752	1757	|O
-	1757	1758	|O
antagonist	1758	1768	|O
into	1769	1773	|O
a	1774	1775	|O
potent	1776	1782	|O
delta	1783	1788	|O
-	1788	1789	|O
agonist	1789	1796	|O
or	1797	1799	|O
into	1800	1804	|O
ligands	1805	1812	|O
with	1813	1817	|O
mixed	1818	1823	|O
delta	1824	1829	|O
-	1829	1830	|O
and	1831	1834	|O
mu	1835	1837	|O
-	1837	1838	|O
opioid	1838	1844	|O
properties	1845	1855	|O
.	1855	1856	|O

### abstracts1164.txt
Ring	0	4	|O
closure	5	12	|O
of	13	15	|O
ethyl	16	21	|B-IUPAC
3	22	23	|I-IUPAC
-	23	24	|I-IUPAC
aminopyrazole	24	37	|I-IUPAC
-	37	38	|I-IUPAC
4	38	39	|I-IUPAC
-	39	40	|I-IUPAC
carboxylate	40	51	|I-IUPAC
with	52	56	|O
sulfamoyl	57	66	|O
chloride	67	75	|O
gave	76	80	|O
1,7	81	84	|B-IUPAC
-	84	85	|I-IUPAC
dihydropyrazolo	85	100	|I-IUPAC
[	100	101	|I-IUPAC
3,4	101	104	|I-IUPAC
-	104	105	|I-IUPAC
c	105	106	|I-IUPAC
]	106	107	|I-IUPAC
[	107	108	|I-IUPAC
1,2,6	108	113	|I-IUPAC
]	113	114	|I-IUPAC
thiadiazine	114	125	|I-IUPAC
-	125	126	|I-IUPAC
4	126	127	|I-IUPAC
(	127	128	|I-IUPAC
3H	128	130	|I-IUPAC
)	130	131	|I-IUPAC
-	131	132	|I-IUPAC
one	132	135	|I-IUPAC
2,2	136	139	|I-IUPAC
-	139	140	|I-IUPAC
dioxide	140	147	|I-IUPAC
.	147	148	|O
The	149	152	|O
corresponding	153	166	|O
4	167	168	|B-IUPAC
-	168	169	|I-IUPAC
amino	169	174	|I-IUPAC
analogue	175	183	|B-MODIFIER
of	184	186	|O
this	187	191	|O
new	192	195	|O
heterocyclic	196	208	|O
ring	209	213	|O
system	214	220	|O
was	221	224	|O
similarly	225	234	|O
prepared	235	243	|O
from	244	248	|O
3	249	250	|B-IUPAC
-	250	251	|I-IUPAC
aminopyrazole	251	264	|I-IUPAC
-	264	265	|I-IUPAC
4	265	266	|I-IUPAC
-	266	267	|I-IUPAC
carbonitrile	267	279	|I-IUPAC
.	279	280	|O
Treatment	281	290	|O
of	291	293	|O
4,5,6	294	299	|B-IUPAC
-	299	300	|I-IUPAC
triamino	300	308	|I-IUPAC
-	308	309	|I-IUPAC
2H	309	311	|I-IUPAC
-	311	312	|I-IUPAC
1,2,6	312	317	|I-IUPAC
-	317	318	|I-IUPAC
thiadiazine	318	329	|I-IUPAC
1,1	330	333	|I-IUPAC
-	333	334	|I-IUPAC
dioxide	334	341	|I-IUPAC
with	342	346	|O
N	347	348	|B-IUPAC
-	348	349	|I-IUPAC
thionylaniline	349	363	|I-IUPAC
gave	364	368	|O
a	369	370	|O
derivative	371	381	|O
of	382	384	|O
another	385	392	|O
new	393	396	|O
ring	397	401	|O
system	402	408	|O
,	408	409	|O
7	410	411	|B-IUPAC
-	411	412	|I-IUPAC
amino	412	417	|I-IUPAC
-	417	418	|I-IUPAC
4H	418	420	|I-IUPAC
-	420	421	|I-IUPAC
[	421	422	|I-IUPAC
1,2,5	422	427	|I-IUPAC
]	427	428	|I-IUPAC
thiadiazolo	428	439	|I-IUPAC
[	439	440	|I-IUPAC
3,4	440	443	|I-IUPAC
-	443	444	|I-IUPAC
c	444	445	|I-IUPAC
]	445	446	|I-IUPAC
[	446	447	|I-IUPAC
1,2,6	447	452	|I-IUPAC
]	452	453	|I-IUPAC
thiadiazine	453	464	|I-IUPAC
5,5	465	468	|I-IUPAC
-	468	469	|I-IUPAC
dioxide	469	476	|I-IUPAC
.	476	477	|O
These	478	483	|O
compounds	484	493	|O
and	494	497	|O
the	498	501	|O
corresponding	502	515	|O
4	516	517	|B-IUPAC
-	517	518	|I-IUPAC
amino	518	523	|I-IUPAC
-	523	524	|O
and	525	528	|O
4	529	530	|B-IUPAC
-	530	531	|I-IUPAC
hydroxyimidazol	531	546	|I-IUPAC
[	546	547	|I-IUPAC
4,5	547	550	|I-IUPAC
-	550	551	|I-IUPAC
c	551	552	|I-IUPAC
]	552	553	|I-IUPAC
[	553	554	|I-IUPAC
1,2,6	554	559	|I-IUPAC
]	559	560	|I-IUPAC
thiadiazine	560	571	|I-IUPAC
2,2	572	575	|I-IUPAC
-	575	576	|I-IUPAC
dioxides	576	584	|I-IUPAC
were	585	589	|O
examined	590	598	|O
as	599	601	|O
potential	602	611	|O
transition	612	622	|O
-	622	623	|O
state	623	628	|O
analogue	629	637	|O
inhibitors	638	648	|O
of	649	651	|O
xanthine	652	660	|O
oxidase	661	668	|O
and	669	672	|O
guanine	673	680	|O
aminohydrolase	681	695	|O
.	695	696	|O
Two	697	700	|O
of	701	703	|O
the	704	707	|O
compounds	708	717	|O
possessed	718	727	|O
Ki	728	730	|O
values	731	737	|O
of	738	740	|O
about	741	746	|O
2x	747	749	|O
10	750	752	|O
(	752	753	|O
-	753	754	|O
4	754	755	|O
)	755	756	|O
M	757	758	|O
with	759	763	|O
guanine	764	771	|O
aminohydrolase	772	786	|O
,	786	787	|O
but	788	791	|O
no	792	794	|O
inhibition	795	805	|O
of	806	808	|O
xanthine	809	817	|O
oxidase	818	825	|O
was	826	829	|O
observed	830	838	|O
by	839	841	|O
any	842	845	|O
at	846	848	|O
5	849	850	|O
x	851	852	|O
10	853	855	|O
(	855	856	|O
-	856	857	|O
4	857	858	|O
)	858	859	|O
M	860	861	|O
.	861	862	|O

### abstracts3478.txt
[	0	1	|O
3	1	2	|O
-	2	3	|O
(	3	4	|O
1,4	4	7	|O
-	7	8	|O
Cyclohexadienyl	8	23	|O
)	23	24	|O
-	24	25	|O
L	25	26	|O
-	26	27	|O
alanine	27	34	|O
,	34	35	|O
8	35	36	|O
-	36	37	|O
lysine	37	43	|O
]	43	44	|O
vasopressin	44	55	|O
,	55	56	|O
otherwise	57	66	|O
known	67	72	|O
as	73	75	|O
[	76	77	|B-IUPAC
3	77	78	|I-IUPAC
-	78	79	|I-IUPAC
(	79	80	|I-IUPAC
2,5	80	83	|I-IUPAC
-	83	84	|I-IUPAC
dihydrophenylalanine	84	104	|I-IUPAC
)	104	105	|I-IUPAC
,	105	106	|I-IUPAC
8	106	107	|I-IUPAC
-	107	108	|I-IUPAC
lysine	108	114	|I-IUPAC
]	114	115	|I-IUPAC
vasopressin	115	126	|I-IUPAC
or	127	129	|O
[	130	131	|O
DiHPhe3	131	138	|O
]	138	139	|O
lysine	139	145	|O
-	145	146	|O
vasopressin	146	157	|O
,	157	158	|O
has	159	162	|O
been	163	167	|O
synthesized	168	179	|O
in	180	182	|O
an	183	185	|O
attempt	186	193	|O
to	194	196	|O
utilize	197	204	|O
2,5	205	208	|B-IUPAC
-	208	209	|I-IUPAC
dihydrophenylalanine	209	229	|I-IUPAC
(	230	231	|O
DiHPhe	231	237	|O
)	237	238	|O
to	239	241	|O
evaluate	242	250	|O
the	251	254	|O
contribution	255	267	|O
of	268	270	|O
aromaticity	271	282	|O
in	283	285	|O
position	286	294	|O
3	295	296	|O
to	297	299	|O
biological	300	310	|O
activity	311	319	|O
.	319	320	|O
The	321	324	|O
analogue	325	333	|O
has	334	337	|O
the	338	341	|O
same	342	346	|O
primary	347	354	|O
structure	355	364	|O
as	365	367	|O
lysine	368	374	|O
-	374	375	|O
vasopressin	375	386	|O
,	386	387	|O
except	388	394	|O
that	395	399	|O
two	400	403	|O
additional	404	414	|O
hydrogen	415	423	|O
atoms	424	429	|O
are	430	433	|O
present	434	441	|O
on	442	444	|O
the	445	448	|O
ring	449	453	|O
moiety	454	460	|O
of	461	463	|O
the	464	467	|O
phenylalanine	468	481	|O
residue	482	489	|O
in	490	492	|O
position	493	501	|O
3	502	503	|O
.	503	504	|O
The	505	508	|O
key	509	512	|O
intermediate	513	525	|O
was	526	529	|O
the	530	533	|O
protected	534	543	|O
nonapeptide	544	555	|O
N	556	557	|B-IUPAC
-	557	558	|I-IUPAC
carbobenzoxy	558	570	|I-IUPAC
-	570	571	|I-IUPAC
S	571	572	|I-IUPAC
-	572	573	|I-IUPAC
benzyl	573	579	|I-IUPAC
-	579	580	|I-IUPAC
L	580	581	|I-IUPAC
-	581	582	|I-IUPAC
cysteinyl	582	591	|I-IUPAC
-	591	592	|I-IUPAC
L	592	593	|I-IUPAC
-	593	594	|I-IUPAC
tyrosyldihydrophenyl	594	614	|I-IUPAC
-	614	615	|I-IUPAC
L	615	616	|I-IUPAC
-	616	617	|I-IUPAC
alanyl	617	623	|I-IUPAC
-	623	624	|I-IUPAC
L	624	625	|I-IUPAC
-	625	626	|I-IUPAC
glutaminyl	626	636	|I-IUPAC
-	636	637	|I-IUPAC
L	637	638	|I-IUPAC
-	638	639	|I-IUPAC
asparaginyl	639	650	|I-IUPAC
-	650	651	|I-IUPAC
S	651	652	|I-IUPAC
-	652	653	|I-IUPAC
benzyl	653	659	|I-IUPAC
-	659	660	|I-IUPAC
L	660	661	|I-IUPAC
-	661	662	|I-IUPAC
cysteinyl	662	671	|I-IUPAC
-	671	672	|I-IUPAC
L	672	673	|I-IUPAC
-	673	674	|I-IUPAC
prolyl	674	680	|I-IUPAC
-	680	681	|I-IUPAC
N	681	682	|I-IUPAC
epsilon	683	690	|I-IUPAC
-	690	691	|I-IUPAC
tosyl	691	696	|I-IUPAC
-	696	697	|I-IUPAC
L	697	698	|I-IUPAC
-	698	699	|I-IUPAC
lysylglycinamide	699	715	|I-IUPAC
that	716	720	|O
was	721	724	|O
synthesized	725	736	|O
stepwise	737	745	|O
by	746	748	|O
the	749	752	|O
solid	753	758	|O
-	758	759	|O
phase	759	764	|O
technique	765	774	|O
.	774	775	|O
Deprotection	776	788	|O
with	789	793	|O
sodium	794	800	|O
in	801	803	|O
liquid	804	810	|O
ammonia	811	818	|O
was	819	822	|O
followed	823	831	|O
by	832	834	|O
sulfhydryl	835	845	|O
oxidation	846	855	|O
with	856	860	|O
I2	861	863	|O
to	864	866	|O
give	867	871	|O
the	872	875	|O
hormone	876	883	|O
analogue	884	892	|O
.	892	893	|O
[	894	895	|O
DiHPhe3	895	902	|O
]	902	903	|O
lysine	903	909	|O
-	909	910	|O
vasopressin	910	921	|O
exhibited	922	931	|O
125	932	935	|O
-	935	936	|O
-	936	937	|O
130	937	940	|O
units	941	946	|O
/	946	947	|O
mg	947	949	|O
of	950	952	|O
antidiuretic	953	965	|O
,	965	966	|O
129	967	970	|O
-	970	971	|O
-	971	972	|O
132	972	975	|O
units	976	981	|O
/	981	982	|O
mg	982	984	|O
of	985	987	|O
rat	988	991	|O
pressor	992	999	|O
,	999	1000	|O
and	1001	1004	|O
6	1005	1006	|O
units	1007	1012	|O
/	1012	1013	|O
mg	1013	1015	|O
of	1016	1018	|O
rat	1019	1022	|O
uterus	1023	1029	|O
contracting	1030	1041	|O
activity	1042	1050	|O
.	1050	1051	|O
To	1052	1054	|O
confirm	1055	1062	|O
the	1063	1066	|O
presence	1067	1075	|O
of	1076	1078	|O
DiHPhe	1079	1085	|O
in	1086	1088	|O
the	1089	1092	|O
analogue	1093	1101	|O
,	1101	1102	|O
an	1103	1105	|O
enzymatic	1106	1115	|O
procedure	1116	1125	|O
employing	1126	1135	|O
Aspergillus	1136	1147	|O
oryzae	1148	1154	|O
was	1155	1158	|O
developed	1159	1168	|O
that	1169	1173	|O
liberates	1174	1183	|O
in	1184	1186	|O
high	1187	1191	|O
yield	1192	1197	|O
the	1198	1201	|O
amino	1202	1207	|O
acid	1208	1212	|O
residue	1213	1220	|O
in	1221	1223	|O
position	1224	1232	|O
3	1233	1234	|O
of	1235	1237	|O
the	1238	1241	|O
posterior	1242	1251	|O
pituitary	1252	1261	|O
hormone	1262	1269	|O
structure	1270	1279	|O
.	1279	1280	|O
This	1281	1285	|O
study	1286	1291	|O
should	1292	1298	|O
be	1299	1301	|O
applicable	1302	1312	|O
to	1313	1315	|O
other	1316	1321	|O
biologically	1322	1334	|O
active	1335	1341	|O
peptides	1342	1350	|O
.	1350	1351	|O

### abstracts2828.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
N	12	13	|B-IUPAC
(	13	14	|I-IUPAC
6	14	15	|I-IUPAC
)	15	16	|I-IUPAC
-	16	17	|I-IUPAC
alkyl	17	22	|I-IUPAC
-	22	23	|I-IUPAC
2	23	24	|I-IUPAC
-	24	25	|I-IUPAC
alkynyl	25	32	|I-IUPAC
derivatives	33	44	|B-MODIFIER
of	45	47	|O
adenosine	48	57	|O
(	58	59	|O
Ado	59	62	|O
)	62	63	|O
have	64	68	|O
been	69	73	|O
synthesized	74	85	|O
and	86	89	|O
evaluated	90	99	|O
for	100	103	|O
their	104	109	|O
affinity	110	118	|O
at	119	121	|O
human	122	127	|O
A	128	129	|O
(	129	130	|O
1	130	131	|O
)	131	132	|O
,	132	133	|O
A	134	135	|O
(	135	136	|O
2A	136	138	|O
)	138	139	|O
,	139	140	|O
and	141	144	|O
A	145	146	|O
(	146	147	|O
3	147	148	|O
)	148	149	|O
receptors	150	159	|O
and	160	163	|O
for	164	167	|O
their	168	173	|O
potency	174	181	|O
at	182	184	|O
A	185	186	|O
(	186	187	|O
2B	187	189	|O
)	189	190	|O
adenosine	191	200	|O
receptor	201	209	|O
subtypes	210	218	|O
.	218	219	|O
The	220	223	|O
corresponding	224	237	|O
2	238	239	|B-IUPAC
-	239	240	|I-IUPAC
(	240	241	|I-IUPAC
1	241	242	|I-IUPAC
-	242	243	|I-IUPAC
alkynyl	243	250	|I-IUPAC
)	250	251	|I-IUPAC
derivatives	252	263	|B-MODIFIER
of	264	266	|O
5'	267	269	|B-IUPAC
-	269	270	|I-IUPAC
N	270	271	|I-IUPAC
-	271	272	|I-IUPAC
ethylcarboxamidoadenosine	272	297	|I-IUPAC
(	298	299	|O
NECA	299	303	|O
)	303	304	|O
and	305	308	|O
Ado	309	312	|O
are	313	316	|O
used	317	321	|O
as	322	324	|O
reference	325	334	|O
compounds	335	344	|O
.	344	345	|O
Binding	346	353	|O
studies	354	361	|O
demonstrated	362	374	|O
that	375	379	|O
the	380	383	|O
activities	384	394	|O
of	395	397	|O
2	398	399	|O
-	399	400	|O
alkynylAdos	400	411	|O
were	412	416	|O
slightly	417	425	|O
increased	426	435	|O
for	436	439	|O
the	440	443	|O
adenosine	444	453	|O
A	454	455	|O
(	455	456	|O
1	456	457	|O
)	457	458	|O
receptor	459	467	|O
and	468	471	|O
slightly	472	480	|O
decreased	481	490	|O
for	491	494	|O
both	495	499	|O
A	500	501	|O
(	501	502	|O
3	502	503	|O
)	503	504	|O
and	505	508	|O
A	509	510	|O
(	510	511	|O
2B	511	513	|O
)	513	514	|O
subtypes	515	523	|O
compared	524	532	|O
to	533	535	|O
those	536	541	|O
of	542	544	|O
their	545	550	|O
corresponding	551	564	|O
NECA	565	569	|O
derivatives	570	581	|O
,	581	582	|O
whereas	583	590	|O
the	591	594	|O
A	595	596	|O
(	596	597	|O
2A	597	599	|O
)	599	600	|O
receptor	601	609	|O
affinities	610	620	|O
of	621	623	|O
the	624	627	|O
two	628	631	|O
series	632	638	|O
of	639	641	|O
nucleosides	642	653	|O
were	654	658	|O
similar	659	666	|O
.	666	667	|O
The	668	671	|O
presence	672	680	|O
of	681	683	|O
a	684	685	|O
methyl	686	692	|B-IUPAC
group	693	698	|B-MODIFIER
on	699	701	|O
N	702	703	|O
(	703	704	|O
6	704	705	|O
)	705	706	|O
of	707	709	|O
the	710	713	|O
2	714	715	|B-IUPAC
-	715	716	|I-IUPAC
alkynyladenosines	716	733	|I-IUPAC
,	733	734	|O
inducing	735	743	|O
an	744	746	|O
increase	747	755	|O
in	756	758	|O
affinity	759	767	|O
at	768	770	|O
the	771	774	|O
human	775	780	|O
A	781	782	|O
(	782	783	|O
3	783	784	|O
)	784	785	|O
receptor	786	794	|O
and	795	798	|O
a	799	800	|O
decrease	801	809	|O
at	810	812	|O
the	813	816	|O
other	817	822	|O
subtypes	823	831	|O
,	831	832	|O
resulted	833	841	|O
in	842	844	|O
an	845	847	|O
increase	848	856	|O
in	857	859	|O
A	860	861	|O
(	861	862	|O
3	862	863	|O
)	863	864	|O
selectivity	865	876	|O
.	876	877	|O
In	878	880	|O
particular	881	891	|O
,	891	892	|O
2	893	894	|B-IUPAC
-	894	895	|I-IUPAC
phenylethynyl	895	908	|I-IUPAC
-	908	909	|I-IUPAC
N	909	910	|I-IUPAC
(	910	911	|I-IUPAC
6	911	912	|I-IUPAC
)	912	913	|I-IUPAC
-	913	914	|I-IUPAC
methyl	914	920	|I-IUPAC
Ado	920	923	|O
(	924	925	|O
8b	925	927	|O
)	927	928	|O
showed	929	935	|O
an	936	938	|O
A	939	940	|O
(	940	941	|O
3	941	942	|O
)	942	943	|O
affinity	944	952	|O
in	953	955	|O
the	956	959	|O
low	960	963	|O
nanomolar	964	973	|O
range	974	979	|O
(	980	981	|O
K	981	982	|O
(	982	983	|O
i	983	984	|O
)	984	985	|O
(	985	986	|O
A	986	987	|O
(	987	988	|O
3	988	989	|O
)	989	990	|O
)	990	991	|O
=	992	993	|O
3.4	994	997	|O
nM	998	1000	|O
)	1000	1001	|O
,	1001	1002	|O
with	1003	1007	|O
a	1008	1009	|O
A	1010	1011	|O
(	1011	1012	|O
1	1012	1013	|O
)	1013	1014	|O
/	1014	1015	|O
A	1015	1016	|O
(	1016	1017	|O
3	1017	1018	|O
)	1018	1019	|O
and	1020	1023	|O
A	1024	1025	|O
(	1025	1026	|O
2A	1026	1028	|O
)	1028	1029	|O
/	1029	1030	|O
A	1030	1031	|O
(	1031	1032	|O
3	1032	1033	|O
)	1033	1034	|O
selectivity	1035	1046	|O
of	1047	1049	|O
about	1050	1055	|O
500	1056	1059	|O
and	1060	1063	|O
2500	1064	1068	|O
,	1068	1069	|O
respectively	1070	1082	|O
.	1082	1083	|O
These	1084	1089	|O
findings	1090	1098	|O
motivated	1099	1108	|O
us	1109	1111	|O
to	1112	1114	|O
search	1115	1121	|O
for	1122	1125	|O
the	1126	1129	|O
preparation	1130	1141	|O
of	1142	1144	|O
new	1145	1148	|O
selective	1149	1158	|O
radioligands	1159	1171	|O
for	1172	1175	|O
the	1176	1179	|O
A	1180	1181	|O
(	1181	1182	|O
3	1182	1183	|O
)	1183	1184	|O
subtype	1185	1192	|O
;	1192	1193	|O
hence	1194	1199	|O
,	1199	1200	|O
a	1201	1202	|O
procedure	1203	1212	|O
to	1213	1215	|O
introduce	1216	1225	|O
a	1226	1227	|O
tritiated	1228	1237	|O
alkylamino	1238	1248	|O
group	1249	1254	|O
in	1255	1257	|O
these	1258	1263	|O
molecules	1264	1273	|O
was	1274	1277	|O
carried	1278	1285	|O
out	1286	1289	|O
.	1289	1290	|O
As	1291	1293	|O
far	1294	1297	|O
as	1298	1300	|O
the	1301	1304	|O
potency	1305	1312	|O
at	1313	1315	|O
the	1316	1319	|O
A	1320	1321	|O
(	1321	1322	|O
2B	1322	1324	|O
)	1324	1325	|O
receptor	1326	1334	|O
,	1334	1335	|O
the	1336	1339	|O
type	1340	1344	|O
of	1345	1347	|O
2	1348	1349	|O
-	1349	1350	|O
alkynyl	1350	1357	|O
chain	1358	1363	|O
and	1364	1367	|O
the	1368	1371	|O
presence	1372	1380	|O
of	1381	1383	|O
the	1384	1387	|O
ethylcarboxamido	1388	1404	|O
group	1405	1410	|O
on	1411	1413	|O
the	1414	1417	|O
sugar	1418	1423	|O
seem	1424	1428	|O
to	1429	1431	|O
be	1432	1434	|O
very	1435	1439	|O
important	1440	1449	|O
;	1449	1450	|O
in	1451	1453	|O
fact	1454	1458	|O
,	1458	1459	|O
the	1460	1463	|O
(	1464	1465	|B-IUPAC
S	1465	1466	|I-IUPAC
)	1466	1467	|I-IUPAC
-	1467	1468	|I-IUPAC
2	1468	1469	|I-IUPAC
-	1469	1470	|I-IUPAC
phenylhydroxypropynyl	1470	1491	|I-IUPAC
NECA	1491	1495	|O
[	1496	1497	|O
(	1497	1498	|O
S	1498	1499	|O
)	1499	1500	|O
-	1500	1501	|O
PHPNECA	1501	1508	|O
,	1508	1509	|O
1e	1510	1512	|O
,	1512	1513	|O
EC	1514	1516	|O
(	1516	1517	|O
50	1517	1519	|O
)	1519	1520	|O
(	1520	1521	|O
A	1521	1522	|O
(	1522	1523	|O
2B	1523	1525	|O
)	1525	1526	|O
)	1526	1527	|O
=	1528	1529	|O
0.22	1530	1534	|O
microM	1535	1541	|O
]	1541	1542	|O
proved	1543	1549	|O
to	1550	1552	|O
be	1553	1555	|O
one	1556	1559	|O
of	1560	1562	|O
the	1563	1566	|O
most	1567	1571	|O
potent	1572	1578	|O
A	1579	1580	|O
(	1580	1581	|O
2B	1581	1583	|O
)	1583	1584	|O
agonist	1585	1592	|O
reported	1593	1601	|O
so	1602	1604	|O
far	1605	1608	|O
.	1608	1609	|O
On	1610	1612	|O
the	1613	1616	|O
other	1617	1622	|O
hand	1623	1627	|O
,	1627	1628	|O
the	1629	1632	|O
(	1633	1634	|B-IUPAC
S	1634	1635	|I-IUPAC
)	1635	1636	|I-IUPAC
-	1636	1637	|I-IUPAC
2	1637	1638	|I-IUPAC
-	1638	1639	|I-IUPAC
phenylhydroxypropynyl	1639	1660	|I-IUPAC
-	1660	1661	|I-IUPAC
N	1661	1662	|I-IUPAC
(	1662	1663	|I-IUPAC
6	1663	1664	|I-IUPAC
)	1664	1665	|I-IUPAC
-	1665	1666	|I-IUPAC
ethyl	1666	1671	|I-IUPAC
Ado	1671	1674	|O
(	1675	1676	|O
9e	1676	1678	|O
,	1678	1679	|O
EC	1680	1682	|O
(	1682	1683	|O
50	1683	1685	|O
)	1685	1686	|O
(	1686	1687	|O
A	1687	1688	|O
(	1688	1689	|O
2B	1689	1691	|O
)	1691	1692	|O
)	1692	1693	|O
=	1694	1695	|O
0.73	1696	1700	|O
microM	1701	1707	|O
)	1707	1708	|O
showed	1709	1715	|O
a	1716	1717	|O
significantly	1718	1731	|O
increase	1732	1740	|O
of	1741	1743	|O
potency	1744	1751	|O
at	1752	1754	|O
the	1755	1758	|O
A	1759	1760	|O
(	1760	1761	|O
2B	1761	1763	|O
)	1763	1764	|O
subtype	1765	1772	|O
in	1773	1775	|O
comparison	1776	1786	|O
with	1787	1791	|O
the	1792	1795	|O
N	1796	1797	|B-IUPAC
(	1797	1798	|I-IUPAC
6	1798	1799	|I-IUPAC
)	1799	1800	|I-IUPAC
-	1800	1801	|I-IUPAC
methyl	1801	1807	|I-IUPAC
,	1807	1808	|O
N	1809	1810	|B-IUPAC
(	1810	1811	|I-IUPAC
6	1811	1812	|I-IUPAC
)	1812	1813	|I-IUPAC
-	1813	1814	|I-IUPAC
isopropyl	1814	1823	|I-IUPAC
,	1823	1824	|O
and	1825	1828	|O
the	1829	1832	|O
unsubstituted	1833	1846	|O
adenosine	1847	1856	|O
derivatives	1857	1868	|O
,	1868	1869	|O
although	1870	1878	|O
it	1879	1881	|O
resulted	1882	1890	|O
in	1891	1893	|O
being	1894	1899	|O
less	1900	1904	|O
potent	1905	1911	|O
than	1912	1916	|O
(	1917	1918	|O
S	1918	1919	|O
)	1919	1920	|O
-	1920	1921	|O
PHPNECA	1921	1928	|O
(	1929	1930	|O
1e	1930	1932	|O
,	1932	1933	|O
EC	1934	1936	|O
(	1936	1937	|O
50	1937	1939	|O
)	1939	1940	|O
(	1940	1941	|O
A	1941	1942	|O
(	1942	1943	|O
2B	1943	1945	|O
)	1945	1946	|O
)	1946	1947	|O
=	1948	1949	|O
0.22	1950	1954	|O
microM	1955	1961	|O
)	1961	1962	|O
.	1962	1963	|O
These	1964	1969	|O
observations	1970	1982	|O
suggest	1983	1990	|O
that	1991	1995	|O
the	1996	1999	|O
introduction	2000	2012	|O
of	2013	2015	|O
an	2016	2018	|O
ethyl	2019	2024	|O
group	2025	2030	|O
in	2031	2033	|O
the	2034	2037	|O
N	2038	2039	|O
(	2039	2040	|O
6	2040	2041	|O
)	2041	2042	|O
-	2042	2043	|O
position	2043	2051	|O
and	2052	2055	|O
an	2056	2058	|O
ethylcarboxamido	2059	2075	|O
substituent	2076	2087	|O
in	2088	2090	|O
the	2091	2094	|O
4'	2095	2097	|O
-	2097	2098	|O
position	2098	2106	|O
of	2107	2109	|O
(	2110	2111	|B-IUPAC
S	2111	2112	|I-IUPAC
)	2112	2113	|I-IUPAC
-	2113	2114	|I-IUPAC
2	2114	2115	|I-IUPAC
-	2115	2116	|I-IUPAC
phenylhydroxypropynyladenosine	2116	2146	|I-IUPAC
could	2147	2152	|O
lead	2153	2157	|O
to	2158	2160	|O
a	2161	2162	|O
compound	2163	2171	|O
endowed	2172	2179	|O
with	2180	2184	|O
high	2185	2189	|O
potency	2190	2197	|O
at	2198	2200	|O
the	2201	2204	|O
A	2205	2206	|O
(	2206	2207	|O
2B	2207	2209	|O
)	2209	2210	|O
receptor	2211	2219	|O
.	2219	2220	|O

### abstracts1062.txt
Derivatives	0	11	|O
of	12	14	|O
the	15	18	|O
nonselective	19	31	|O
excitatory	32	42	|O
amino	43	48	|O
acid	49	53	|O
antagonist	54	64	|O
kynurenic	65	74	|O
acid	75	79	|O
(	80	81	|O
4	81	82	|B-IUPAC
-	82	83	|I-IUPAC
oxo	83	86	|I-IUPAC
-	86	87	|I-IUPAC
1,4	87	90	|I-IUPAC
-	90	91	|I-IUPAC
dihydroquinoline	91	107	|I-IUPAC
-	107	108	|I-IUPAC
2	108	109	|I-IUPAC
-	109	110	|I-IUPAC
carboxylic	110	120	|I-IUPAC
acid	121	125	|I-IUPAC
,	125	126	|O
1	127	128	|O
)	128	129	|O
have	130	134	|O
been	135	139	|O
synthesized	140	151	|O
and	152	155	|O
evaluated	156	165	|O
for	166	169	|O
in	170	172	|O
vitro	173	178	|O
antagonist	179	189	|O
activity	190	198	|O
at	199	201	|O
the	202	205	|O
excitatory	206	216	|O
amino	217	222	|O
acid	223	227	|O
receptors	228	237	|O
sensitive	238	247	|O
to	248	250	|O
N	251	252	|B-IUPAC
-	252	253	|I-IUPAC
methyl	253	259	|I-IUPAC
-	259	260	|I-IUPAC
D	260	261	|I-IUPAC
-	261	262	|I-IUPAC
aspartic	262	270	|I-IUPAC
acid	271	275	|I-IUPAC
(	276	277	|O
NMDA	277	281	|O
)	281	282	|O
,	282	283	|O
quisqualic	284	294	|O
acid	295	299	|O
(	300	301	|O
QUIS	301	305	|O
or	306	308	|O
AMPA	309	313	|O
)	313	314	|O
,	314	315	|O
and	316	319	|O
kainic	320	326	|O
acid	327	331	|O
(	332	333	|O
KA	333	335	|O
)	335	336	|O
.	336	337	|O
Introduction	338	350	|O
of	351	353	|O
substituents	354	366	|O
at	367	369	|O
the	370	373	|O
5	374	375	|O
-	375	376	|O
,	376	377	|O
7	378	379	|O
-	379	380	|O
,	380	381	|O
and	382	385	|O
5,7	386	389	|O
-	389	390	|O
positions	390	399	|O
resulted	400	408	|O
in	409	411	|O
analogues	412	421	|O
having	422	428	|O
selective	429	438	|O
NMDA	439	443	|O
antagonist	444	454	|O
action	455	461	|O
,	461	462	|O
as	463	465	|O
a	466	467	|O
result	468	474	|O
of	475	477	|O
blockade	478	486	|O
of	487	489	|O
the	490	493	|O
glycine	494	501	|O
modulatory	502	512	|O
(	513	514	|O
or	514	516	|O
coagonist	517	526	|O
)	526	527	|O
site	528	532	|O
on	533	535	|O
the	536	539	|O
NMDA	540	544	|O
receptor	545	553	|O
.	553	554	|O
Regression	555	565	|O
analysis	566	574	|O
suggested	575	584	|O
a	585	586	|O
requirement	587	598	|O
for	599	602	|O
optimally	603	612	|O
sized	613	618	|O
,	618	619	|O
hydrophobic	620	631	|O
5	632	633	|O
-	633	634	|O
and	635	638	|O
7	639	640	|O
-	640	641	|O
substituents	641	653	|O
,	653	654	|O
with	655	659	|O
bulk	660	664	|O
tolerance	665	674	|O
being	675	680	|O
greater	681	688	|O
at	689	691	|O
the	692	695	|O
5	696	697	|O
-	697	698	|O
position	698	706	|O
.	706	707	|O
Optimization	708	720	|O
led	721	724	|O
to	725	727	|O
the	728	731	|O
5	732	733	|B-IUPAC
-	733	734	|I-IUPAC
iodo	734	738	|I-IUPAC
-	738	739	|I-IUPAC
7	739	740	|I-IUPAC
-	740	741	|I-IUPAC
chloro	741	747	|I-IUPAC
derivative	748	758	|B-MODIFIER
(	759	760	|O
53	760	762	|O
)	762	763	|O
,	763	764	|O
which	765	770	|O
is	771	773	|O
the	774	777	|O
most	778	782	|O
potent	783	789	|O
and	790	793	|O
selective	794	803	|O
glycine	804	811	|O
/	811	812	|O
NMDA	812	816	|O
antagonist	817	827	|O
to	828	830	|O
date	831	835	|O
(	836	837	|O
IC50	837	841	|O
vs	842	844	|O
[	845	846	|O
3H	846	848	|O
]	848	849	|O
glycine	849	856	|O
binding	857	864	|O
,	864	865	|O
32	866	868	|O
nM	869	871	|O
;	871	872	|O
IC50	873	877	|O
's	877	879	|O
for	880	883	|O
other	884	889	|O
excitatory	890	900	|O
amino	901	906	|O
acid	907	911	|O
receptor	912	920	|O
sites	921	926	|O
,	926	927	|O
greater	928	935	|O
than	936	940	|O
100	941	944	|O
microM	945	951	|O
)	951	952	|O
.	952	953	|O
Substitution	954	966	|O
of	967	969	|O
1	970	971	|O
at	972	974	|O
the	975	978	|O
6	979	980	|O
-	980	981	|O
position	981	989	|O
resulted	990	998	|O
in	999	1001	|O
compounds	1002	1011	|O
having	1012	1018	|O
selective	1019	1028	|O
non	1029	1032	|O
-	1032	1033	|O
NMDA	1033	1037	|O
antagonism	1038	1048	|O
and	1049	1052	|O
8	1053	1054	|O
-	1054	1055	|O
substituted	1055	1066	|O
compounds	1067	1076	|O
were	1077	1081	|O
inactive	1082	1090	|O
at	1091	1093	|O
all	1094	1097	|O
receptors	1098	1107	|O
.	1107	1108	|O
The	1109	1112	|O
retention	1113	1122	|O
of	1123	1125	|O
glycine	1126	1133	|O
/	1133	1134	|O
NMDA	1134	1138	|O
antagonist	1139	1149	|O
activity	1150	1158	|O
in	1159	1161	|O
heterocyclic	1162	1174	|O
ring	1175	1179	|O
modified	1180	1188	|O
analogues	1189	1198	|O
,	1198	1199	|O
such	1200	1204	|O
as	1205	1207	|O
the	1208	1211	|O
oxanilide	1212	1221	|O
69	1222	1224	|O
and	1225	1228	|O
the	1229	1232	|O
2	1233	1234	|B-IUPAC
-	1234	1235	|I-IUPAC
carboxybenzimidazole	1235	1255	|I-IUPAC
70	1256	1258	|O
,	1258	1259	|O
suggests	1260	1268	|O
that	1269	1273	|O
the	1274	1277	|O
4	1278	1279	|B-IUPAC
-	1279	1280	|I-IUPAC
oxo	1280	1283	|I-IUPAC
tautomer	1284	1292	|B-MODIFIER
of	1293	1295	|O
1	1296	1297	|O
and	1298	1301	|O
its	1302	1305	|O
derivatives	1306	1317	|O
is	1318	1320	|O
required	1321	1329	|O
for	1330	1333	|O
activity	1334	1342	|O
.	1342	1343	|O
Structurally	1344	1356	|O
related	1357	1364	|O
quinoxaline	1365	1376	|B-IUPAC
-	1376	1377	|I-IUPAC
2,3	1377	1380	|I-IUPAC
-	1380	1381	|I-IUPAC
diones	1381	1387	|I-IUPAC
are	1388	1391	|O
also	1392	1396	|O
glycine	1397	1404	|O
/	1404	1405	|O
NMDA	1405	1409	|O
antagonists	1410	1421	|O
,	1421	1422	|O
but	1423	1426	|O
are	1427	1430	|O
not	1431	1434	|O
selective	1435	1444	|O
and	1445	1448	|O
are	1449	1452	|O
less	1453	1457	|O
potent	1458	1464	|O
than	1465	1469	|O
the	1470	1473	|O
1	1474	1475	|O
derivatives	1476	1487	|O
,	1487	1488	|O
and	1489	1492	|O
additionally	1493	1505	|O
show	1506	1510	|O
different	1511	1520	|O
structure	1521	1530	|O
-	1530	1531	|O
activity	1531	1539	|O
requirements	1540	1552	|O
for	1553	1556	|O
aromatic	1557	1565	|O
ring	1566	1570	|O
substitution	1571	1583	|O
.	1583	1584	|O
On	1585	1587	|O
the	1588	1591	|O
basis	1592	1597	|O
of	1598	1600	|O
these	1601	1606	|O
results	1607	1614	|O
,	1614	1615	|O
a	1616	1617	|O
model	1618	1623	|O
accounting	1624	1634	|O
for	1635	1638	|O
glycine	1639	1646	|O
receptor	1647	1655	|O
binding	1656	1663	|O
of	1664	1666	|O
the	1667	1670	|O
1	1671	1672	|O
derived	1673	1680	|O
antagonists	1681	1692	|O
is	1693	1695	|O
proposed	1696	1704	|O
,	1704	1705	|O
comprising	1706	1716	|O
(	1717	1718	|O
a	1718	1719	|O
)	1719	1720	|O
size	1721	1725	|O
-	1725	1726	|O
limited	1726	1733	|O
,	1733	1734	|O
hydrophobic	1735	1746	|O
binding	1747	1754	|O
of	1755	1757	|O
the	1758	1761	|O
benzene	1762	1769	|O
ring	1770	1774	|O
,	1774	1775	|O
(	1776	1777	|O
b	1777	1778	|O
)	1778	1779	|O
hydrogen	1780	1788	|O
-	1788	1789	|O
bond	1789	1793	|O
acceptance	1794	1804	|O
by	1805	1807	|O
the	1808	1811	|O
4	1812	1813	|B-IUPAC
-	1813	1814	|I-IUPAC
oxo	1814	1817	|I-IUPAC
group	1818	1823	|B-MODIFIER
,	1823	1824	|O
(	1825	1826	|O
c	1826	1827	|O
)	1827	1828	|O
hydrogen	1829	1837	|O
-	1837	1838	|O
bond	1838	1842	|O
donation	1843	1851	|O
by	1852	1854	|O
the	1855	1858	|O
1	1859	1860	|B-IUPAC
-	1860	1861	|I-IUPAC
amino	1861	1866	|I-IUPAC
group	1867	1872	|B-MODIFIER
,	1872	1873	|O
and	1874	1877	|O
(	1878	1879	|O
d	1879	1880	|O
)	1880	1881	|O
a	1882	1883	|O
Coulombic	1884	1893	|O
attraction	1894	1904	|O
of	1905	1907	|O
the	1908	1911	|O
2	1912	1913	|B-IUPAC
-	1913	1914	|I-IUPAC
carboxylate	1914	1925	|I-IUPAC
.	1925	1926	|O
The	1927	1930	|O
model	1931	1936	|O
can	1937	1940	|O
also	1941	1945	|O
account	1946	1953	|O
for	1954	1957	|O
the	1958	1961	|O
binding	1962	1969	|O
of	1970	1972	|O
quinoxaline	1973	1984	|B-IUPAC
-	1984	1985	|I-IUPAC
2,3	1985	1988	|I-IUPAC
-	1988	1989	|I-IUPAC
diones	1989	1995	|I-IUPAC
,	1995	1996	|O
quinoxalic	1997	2007	|B-IUPAC
acids	2008	2013	|I-IUPAC
,	2013	2014	|O
and	2015	2018	|O
2	2019	2020	|B-IUPAC
-	2020	2021	|I-IUPAC
carboxybenzimidazoles	2021	2042	|I-IUPAC
.	2042	2043	|O

### abstracts2526.txt
To	0	2	|O
enhance	3	10	|O
the	11	14	|O
intrinsic	15	24	|O
potency	25	32	|O
of	33	35	|O
dihydropyrimidine	36	53	|O
calcium	54	61	|O
channel	62	69	|O
blockers	70	78	|O
,	78	79	|O
we	80	82	|O
have	83	87	|O
modified	88	96	|O
the	97	100	|O
structure	101	110	|O
of	111	113	|O
previously	114	124	|O
described	125	134	|O
2	135	136	|B-IUPAC
-	136	137	|I-IUPAC
heteroalkyl	137	148	|I-IUPAC
-	148	149	|I-IUPAC
1,4	149	152	|I-IUPAC
-	152	153	|I-IUPAC
dihydropyrimidines	153	171	|I-IUPAC
2	172	173	|O
to	174	176	|O
3	177	178	|B-MODIFIER
-	178	179	|I-MODIFIER
substituted	179	190	|I-MODIFIER
1,4	191	194	|B-IUPAC
-	194	195	|I-IUPAC
dihydropyrimidines	195	213	|I-IUPAC
3	214	215	|O
.	215	216	|O
Structure	217	226	|O
-	226	227	|O
activity	227	235	|O
studies	236	243	|O
using	244	249	|O
potassium	250	259	|O
-	259	260	|O
depolarized	260	271	|O
rabbit	272	278	|O
aorta	279	284	|O
show	285	289	|O
that	290	294	|O
ortho	295	300	|B-IUPAC
,	300	301	|O
meta	302	306	|B-MODIFIER
-	306	307	|I-MODIFIER
disubstituted	307	320	|I-MODIFIER
aryl	321	325	|B-IUPAC
derivatives	326	337	|B-MODIFIER
are	338	341	|O
more	342	346	|O
potent	347	353	|O
than	354	358	|O
either	359	365	|O
ortho	366	371	|O
-	371	372	|O
or	373	375	|O
meta	376	380	|O
-	380	381	|O
monosubstituted	381	396	|O
compounds	397	406	|O
.	406	407	|O
While	408	413	|O
vasorelaxant	414	426	|O
activity	427	435	|O
was	436	439	|O
critically	440	450	|O
dependent	451	460	|O
on	461	463	|O
the	464	467	|O
size	468	472	|O
of	473	475	|O
the	476	479	|O
C5	480	482	|O
ester	483	488	|B-IUPAC
group	489	494	|B-MODIFIER
,	494	495	|O
isopropyl	496	505	|O
ester	506	511	|O
being	512	517	|O
the	518	521	|O
best	522	526	|O
,	526	527	|O
a	528	529	|O
variety	530	537	|O
of	538	540	|O
substituents	541	553	|B-MODIFIER
(	554	555	|O
carbamate	555	564	|B-IUPAC
,	564	565	|O
acyl	566	570	|B-IUPAC
,	570	571	|O
sulfonyl	572	580	|B-IUPAC
,	580	581	|O
alkyl	582	587	|B-IUPAC
)	587	588	|O
were	589	593	|O
tolerated	594	603	|O
at	604	606	|O
N3	607	609	|O
.	609	610	|O
Our	611	614	|O
results	615	622	|O
show	623	627	|O
dihydropyrimidines	628	646	|B-IUPAC
3	647	648	|O
are	649	652	|O
significantly	653	666	|O
more	667	671	|O
potent	672	678	|O
than	679	683	|O
corresponding	684	697	|O
2	698	699	|B-IUPAC
-	699	700	|I-IUPAC
heteroalkyl	700	711	|I-IUPAC
-	711	712	|I-IUPAC
1,4	712	715	|I-IUPAC
-	715	716	|I-IUPAC
dihydropyrimidines	716	734	|I-IUPAC
2	735	736	|O
and	737	740	|O
only	741	745	|O
slightly	746	754	|O
less	755	759	|O
potent	760	766	|O
than	767	771	|O
similarly	772	781	|O
substituted	782	793	|B-MODIFIER
2	794	795	|B-IUPAC
-	795	796	|I-IUPAC
heteroalkyl	796	807	|I-IUPAC
-	807	808	|I-IUPAC
1,4	808	811	|I-IUPAC
-	811	812	|I-IUPAC
dihydropyridines	812	828	|I-IUPAC
4	829	830	|O
and	831	834	|O
5	835	836	|O
.	836	837	|O
Whereas	838	845	|O
dihydropyridine	846	861	|O
enantiomers	862	873	|O
usually	874	881	|O
show	882	886	|O
10-15	887	892	|O
-	892	893	|O
fold	893	897	|O
difference	898	908	|O
in	909	911	|O
activity	912	920	|O
,	920	921	|O
the	922	925	|O
enantiomers	926	937	|O
of	938	940	|O
dihydropyrimidine	941	958	|O
3j	959	961	|O
show	962	966	|O
more	967	971	|O
than	972	976	|O
a	977	978	|O
1000	979	983	|O
-	983	984	|O
fold	984	988	|O
difference	989	999	|O
in	1000	1002	|O
activity	1003	1011	|O
.	1011	1012	|O
These	1013	1018	|O
results	1019	1026	|O
strengthen	1027	1037	|O
the	1038	1041	|O
requirement	1042	1053	|O
of	1054	1056	|O
an	1057	1059	|O
enamino	1060	1067	|O
ester	1068	1073	|O
for	1074	1077	|O
binding	1078	1085	|O
to	1086	1088	|O
the	1089	1092	|O
dihydropyridine	1093	1108	|O
receptor	1109	1117	|O
and	1118	1121	|O
indicate	1122	1130	|O
a	1131	1132	|O
nonspecific	1133	1144	|O
role	1145	1149	|O
for	1150	1153	|O
the	1154	1157	|O
N3	1158	1160	|O
-	1160	1161	|O
substituent	1161	1172	|O
.	1172	1173	|O

### abstracts800.txt
A	0	1	|O
number	2	8	|O
of	9	11	|O
N9	12	14	|O
-	14	15	|O
alkyl	15	20	|O
-	20	21	|O
substituted	21	32	|O
purines	33	40	|O
and	41	44	|O
purine	45	51	|O
ribonucleosides	52	67	|O
have	68	72	|O
been	73	77	|O
synthesized	78	89	|O
as	90	92	|O
congeners	93	102	|O
of	103	105	|O
sulfinosine	106	117	|O
and	118	121	|O
evaluated	122	131	|O
for	132	135	|O
their	136	141	|O
antileukemic	142	154	|O
activity	155	163	|O
in	164	166	|O
mice	167	171	|O
.	171	172	|O
NaH	173	176	|O
-	176	177	|O
mediated	177	185	|O
alkylation	186	196	|O
of	197	199	|O
6	200	201	|B-IUPAC
-	201	202	|I-IUPAC
chloropurine	202	214	|I-IUPAC
(	215	216	|O
4	216	217	|O
)	217	218	|O
and	219	222	|O
2	223	224	|B-IUPAC
-	224	225	|I-IUPAC
amino	225	230	|I-IUPAC
-	230	231	|I-IUPAC
6	231	232	|I-IUPAC
-	232	233	|I-IUPAC
chloropurine	233	245	|I-IUPAC
(	246	247	|O
5	247	248	|O
)	248	249	|O
with	250	254	|O
certain	255	262	|O
alkyl	263	268	|O
bromides	269	277	|O
gave	278	282	|O
N7	283	285	|O
-	285	286	|O
and	287	290	|O
N9	291	293	|O
-	293	294	|O
alkylated	294	303	|O
derivatives	304	315	|O
(	316	317	|O
7a	317	319	|O
-	319	320	|O
d	320	321	|O
and	322	325	|O
6a	326	328	|O
-	328	329	|O
d	329	330	|O
)	330	331	|O
,	331	332	|O
the	333	336	|O
N9	337	339	|O
-	339	340	|O
isomer	340	346	|O
being	347	352	|O
the	353	356	|O
major	357	362	|O
product	363	370	|O
.	370	371	|O
Treatment	372	381	|O
of	382	384	|O
6a	385	387	|O
-	387	388	|O
d	388	389	|O
and	390	393	|O
7a	394	396	|O
-	396	397	|O
d	397	398	|O
with	399	403	|O
thiourea	404	412	|O
furnished	413	422	|O
the	423	426	|O
corresponding	427	440	|O
6	441	442	|B-IUPAC
-	442	443	|I-IUPAC
thio	443	447	|I-IUPAC
derivatives	448	459	|B-MODIFIER
(	460	461	|O
9a	461	463	|O
-	463	464	|O
d	464	465	|O
and	466	469	|O
8a	470	472	|O
-	472	473	|O
d	473	474	|O
)	474	475	|O
.	475	476	|O
Amination	477	486	|O
of	487	489	|O
9a	490	492	|O
-	492	493	|O
e	493	494	|O
with	495	499	|O
aqueous	500	507	|O
chloramine	508	518	|O
solution	519	527	|O
afforded	528	536	|O
the	537	540	|O
corresponding	541	554	|O
purine	555	561	|B-IUPAC
-	561	562	|I-IUPAC
6	562	563	|I-IUPAC
-	563	564	|I-IUPAC
sulfenamides	564	576	|I-IUPAC
(	577	578	|O
10	578	580	|O
-	580	581	|O
a	581	582	|O
-	582	583	|O
e	583	584	|O
)	584	585	|O
,	585	586	|O
which	587	592	|O
on	593	595	|O
controlled	596	606	|O
oxidation	607	616	|O
with	617	621	|O
3	622	623	|B-IUPAC
-	623	624	|I-IUPAC
chloroperoxbenzoic	624	642	|I-IUPAC
acid	643	647	|I-IUPAC
(	648	649	|O
MCPBA	649	654	|O
)	654	655	|O
gave	656	660	|O
the	661	664	|O
respective	665	675	|O
(	676	677	|B-IUPAC
R	677	678	|I-IUPAC
,	678	679	|I-IUPAC
S	679	680	|I-IUPAC
)	680	681	|I-IUPAC
-	681	682	|I-IUPAC
9	682	683	|I-IUPAC
-	683	684	|I-IUPAC
alkylpurine	684	695	|I-IUPAC
-	695	696	|I-IUPAC
6	696	697	|I-IUPAC
-	697	698	|I-IUPAC
sulfinamides	698	710	|I-IUPAC
(	711	712	|O
11a	712	715	|O
-	715	716	|O
e	716	717	|O
)	717	718	|O
.	718	719	|O
A	720	721	|O
similar	722	729	|O
oxidation	730	739	|O
of	740	742	|O
2	743	744	|B-IUPAC
-	744	745	|I-IUPAC
amino	745	750	|I-IUPAC
-	750	751	|I-IUPAC
6	751	752	|I-IUPAC
-	752	753	|I-IUPAC
(	753	754	|I-IUPAC
methyl	754	760	|I-IUPAC
/	760	761	|I-IUPAC
benzylthio	761	771	|I-IUPAC
)	771	772	|I-IUPAC
-	772	773	|I-IUPAC
9	773	774	|I-IUPAC
-	774	775	|I-IUPAC
beta	775	779	|I-IUPAC
-	779	780	|I-IUPAC
D	780	781	|I-IUPAC
-	781	782	|I-IUPAC
ribofuranosylpurine	782	801	|I-IUPAC
(	802	803	|O
12a	803	806	|O
and	807	810	|O
12b	811	814	|O
)	814	815	|O
and	816	819	|O
2	820	821	|B-IUPAC
-	821	822	|I-IUPAC
amino	822	827	|I-IUPAC
-	827	828	|I-IUPAC
9	828	829	|I-IUPAC
-	829	830	|I-IUPAC
(	830	831	|I-IUPAC
2	831	832	|I-IUPAC
-	832	833	|I-IUPAC
deoxy	833	838	|I-IUPAC
-	838	839	|I-IUPAC
beta	839	843	|I-IUPAC
-	843	844	|I-IUPAC
D	844	845	|I-IUPAC
-	845	846	|I-IUPAC
erythro	846	853	|I-IUPAC
-	853	854	|I-IUPAC
pentofuranosyl	854	868	|I-IUPAC
)	868	869	|I-IUPAC
-	869	870	|I-IUPAC
6	870	871	|I-IUPAC
-	871	872	|I-IUPAC
(	873	874	|I-IUPAC
methylthio	874	884	|I-IUPAC
)	884	885	|I-IUPAC
-	885	886	|I-IUPAC
purine	886	892	|I-IUPAC
(	893	894	|O
12c	894	897	|O
)	897	898	|O
with	899	903	|O
MCPBA	904	909	|O
gave	910	914	|O
the	915	918	|O
corresponding	919	932	|O
sulfoxides	933	943	|O
(	944	945	|O
13a	945	948	|O
-	948	949	|O
c	949	950	|O
)	950	951	|O
,	951	952	|O
which	953	958	|O
on	959	961	|O
further	962	969	|O
oxidation	970	979	|O
furnished	980	989	|O
the	990	993	|O
respective	994	1004	|O
sulfones	1005	1013	|O
(	1014	1015	|O
14a	1015	1018	|O
-	1018	1019	|O
c	1019	1020	|O
)	1020	1021	|O
.	1021	1022	|O
Of	1023	1025	|O
the	1026	1029	|O
20	1030	1032	|O
compounds	1033	1042	|O
evaluated	1043	1052	|O
,	1052	1053	|O
six	1054	1057	|O
exhibited	1058	1067	|O
biologically	1068	1080	|O
significant	1081	1092	|O
anti	1093	1097	|O
-	1097	1098	|O
L1210	1098	1103	|O
activity	1104	1112	|O
in	1113	1115	|O
BD2F1	1116	1121	|O
mice	1122	1126	|O
and	1127	1130	|O
reduced	1131	1138	|O
body	1139	1143	|O
burdens	1144	1151	|O
of	1152	1154	|O
viable	1155	1161	|O
L1210	1162	1167	|O
cells	1168	1173	|O
more	1174	1178	|O
than	1179	1183	|O
90-97%	1184	1190	|O
by	1191	1193	|O
single	1194	1200	|O
treatment	1201	1210	|O
.	1210	1211	|O
Although	1212	1220	|O
compounds	1221	1230	|O
9b	1231	1233	|O
and	1234	1237	|O
9c	1238	1240	|O
at	1241	1243	|O
44	1244	1246	|O
mg	1247	1249	|O
and	1250	1253	|O
40	1254	1256	|O
mg	1257	1259	|O
/	1259	1260	|O
kg	1260	1262	|O
per	1263	1266	|O
day	1267	1270	|O
x	1271	1272	|O
1	1273	1274	|O
showed	1275	1281	|O
a	1282	1283	|O
T	1284	1285	|O
/	1285	1286	|O
C	1286	1287	|O
of	1288	1290	|O
147	1291	1294	|O
and	1295	1298	|O
149	1299	1302	|O
,	1302	1303	|O
respectively	1304	1316	|O
,	1316	1317	|O
this	1318	1322	|O
group	1323	1328	|O
of	1329	1331	|O
compounds	1332	1341	|O
was	1342	1345	|O
found	1346	1351	|O
to	1352	1354	|O
be	1355	1357	|O
less	1358	1362	|O
effective	1363	1372	|O
than	1373	1377	|O
some	1378	1382	|O
of	1383	1385	|O
the	1386	1389	|O
sulfur	1390	1396	|O
-	1396	1397	|O
containing	1397	1407	|O
drugs	1408	1413	|O
that	1414	1418	|O
we	1419	1421	|O
previously	1422	1432	|O
described	1433	1442	|O
(	1443	1444	|O
e.g.	1444	1448	|O
sulfenosine	1449	1460	|O
and	1461	1464	|O
sulfinosine	1465	1476	|O
)	1476	1477	|O
.	1477	1478	|O

### abstracts1931.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
6	12	13	|B-MODIFIER
-	13	14	|I-MODIFIER
substituted	14	25	|I-MODIFIER
4	26	27	|B-IUPAC
-	27	28	|I-IUPAC
anilinopyrimido	28	43	|I-IUPAC
[	43	44	|I-IUPAC
5,4	44	47	|I-IUPAC
-	47	48	|I-IUPAC
d	48	49	|I-IUPAC
]	49	50	|I-IUPAC
pyrimidines	50	61	|I-IUPAC
has	62	65	|O
been	66	70	|O
prepared	71	79	|O
and	80	83	|O
shown	84	89	|O
to	90	92	|O
be	93	95	|O
potent	96	102	|O
inhibitors	103	113	|O
of	114	116	|O
the	117	120	|O
tyrosine	121	129	|O
kinase	130	136	|O
activity	137	145	|O
of	146	148	|O
the	149	152	|O
epidermal	153	162	|O
growth	163	169	|O
factor	170	176	|O
receptor	177	185	|O
(	186	187	|O
EGFR	187	191	|O
)	191	192	|O
.	192	193	|O
These	194	199	|O
compounds	200	209	|O
are	210	213	|O
structurally	214	226	|O
related	227	234	|O
to	235	237	|O
the	238	241	|O
pyrido	242	248	|B-PARTIUPAC
[	248	249	|I-PARTIUPAC
3,2	249	252	|I-PARTIUPAC
-	252	253	|I-PARTIUPAC
d	253	254	|I-PARTIUPAC
]	254	255	|I-PARTIUPAC
-	255	256	|I-PARTIUPAC
and	257	260	|O
pyrido	261	267	|B-IUPAC
[	267	268	|I-IUPAC
3,4	268	271	|I-IUPAC
-	271	272	|I-IUPAC
d	272	273	|I-IUPAC
]	273	274	|I-IUPAC
-	274	275	|I-IUPAC
pyrimidines	275	286	|I-IUPAC
previously	287	297	|O
shown	298	303	|O
to	304	306	|O
be	307	309	|O
EGFR	310	314	|O
inhibitors	315	325	|O
.	325	326	|O
Their	327	332	|O
structure	333	342	|O
-	342	343	|O
activity	343	351	|O
relationships	352	365	|O
(	366	367	|O
SAR	367	370	|O
)	370	371	|O
for	372	375	|O
inhibition	376	386	|O
of	387	389	|O
the	390	393	|O
isolated	394	402	|O
enzyme	403	409	|O
more	410	414	|O
closely	415	422	|O
resemble	423	431	|O
those	432	437	|O
of	438	440	|O
the	441	444	|O
[	445	446	|O
3,2	446	449	|O
-	449	450	|O
d	450	451	|O
]	451	452	|O
than	453	457	|O
the	458	461	|O
[	462	463	|B-IUPAC
3,4	463	466	|I-IUPAC
-	466	467	|I-IUPAC
d	467	468	|I-IUPAC
]	468	469	|I-IUPAC
pyridopyrimidine	470	486	|I-IUPAC
isomers	487	494	|O
.	494	495	|O
This	496	500	|O
suggests	501	509	|O
the	510	513	|O
requirement	514	525	|O
of	526	528	|O
an	529	531	|O
aza	532	535	|O
atom	536	540	|O
in	541	543	|O
the	544	547	|O
7	548	549	|O
-	549	550	|O
but	551	554	|O
not	555	558	|O
the	559	562	|O
5	563	564	|O
-	564	565	|O
position	565	573	|O
(	574	575	|O
i.e.	575	579	|O
,	579	580	|O
a	581	582	|O
carbon	583	589	|O
atom	590	594	|O
in	595	597	|O
the	598	601	|O
5	602	603	|O
-	603	604	|O
position	604	612	|O
)	612	613	|O
for	614	617	|O
the	618	621	|O
enhanced	622	630	|O
potency	631	638	|O
shown	639	644	|O
by	645	647	|O
6	648	649	|O
-	649	650	|O
N	650	651	|O
-	651	652	|O
methylated	652	662	|O
derivatives	663	674	|O
in	675	677	|O
each	678	682	|O
series	683	689	|O
.	689	690	|O
X	691	692	|O
-	692	693	|O
ray	693	696	|O
crystal	697	704	|O
structures	705	715	|O
were	716	720	|O
determined	721	731	|O
for	732	735	|O
the	736	739	|O
three	740	745	|O
NHMe	746	750	|O
derivatives	751	762	|O
2	763	764	|O
,	764	765	|O
3	766	767	|O
,	767	768	|O
and	769	772	|O
5c	773	775	|O
in	776	778	|O
the	779	782	|O
pyrido	783	789	|B-PARTIUPAC
[	789	790	|I-PARTIUPAC
9,2	790	793	|I-PARTIUPAC
-	793	794	|I-PARTIUPAC
d	794	795	|I-PARTIUPAC
]	795	796	|I-PARTIUPAC
-	796	797	|I-PARTIUPAC
,	797	798	|I-PARTIUPAC
pyrido	799	805	|I-PARTIUPAC
[	805	806	|I-PARTIUPAC
3,4	806	809	|I-PARTIUPAC
-	809	810	|I-PARTIUPAC
d	810	811	|I-PARTIUPAC
]	811	812	|I-PARTIUPAC
-	812	813	|I-PARTIUPAC
,	813	814	|O
and	815	818	|O
pyrimido	819	827	|B-IUPAC
[	827	828	|I-IUPAC
5,4	828	831	|I-IUPAC
-	831	832	|I-IUPAC
d	832	833	|I-IUPAC
]	833	834	|I-IUPAC
-	834	835	|I-IUPAC
pyrimidine	835	845	|I-IUPAC
series	846	852	|B-MODIFIER
,	852	853	|O
respectively	854	866	|O
.	866	867	|O
These	868	873	|O
show	874	878	|O
that	879	883	|O
a	884	885	|O
carbon	886	892	|O
rather	893	899	|O
than	900	904	|O
a	905	906	|O
nitrogen	907	915	|O
atom	916	920	|O
at	921	923	|O
the	924	927	|O
5	928	929	|O
-	929	930	|O
position	930	938	|O
leads	939	944	|O
to	945	947	|O
significant	948	959	|O
conformational	960	974	|O
changes	975	982	|O
in	983	985	|O
the	986	989	|O
molecule	990	998	|O
(	999	1000	|O
a	1000	1001	|O
longer	1002	1008	|O
C5a	1009	1012	|O
-	1012	1013	|O
C4	1013	1015	|O
bond	1016	1020	|O
and	1021	1024	|O
a	1025	1026	|O
30	1027	1029	|O
degrees	1030	1037	|O
out	1038	1041	|O
-	1041	1042	|O
of	1042	1044	|O
-	1044	1045	|O
plane	1045	1050	|O
rotation	1051	1059	|O
of	1060	1062	|O
the	1063	1066	|O
phenyl	1067	1073	|O
group	1074	1079	|O
)	1079	1080	|O
,	1080	1081	|O
due	1082	1085	|O
to	1086	1088	|O
the	1089	1092	|O
requirement	1093	1104	|O
to	1105	1107	|O
relieve	1108	1115	|O
nonbonding	1116	1126	|O
interactions	1127	1139	|O
between	1140	1147	|O
the	1148	1151	|O
C5	1152	1154	|O
and	1155	1158	|O
N9	1159	1161	|O
protons	1162	1169	|O
.	1169	1170	|O
Pyrimido	1171	1179	|B-IUPAC
[	1179	1180	|I-IUPAC
5,4	1180	1183	|I-IUPAC
-	1183	1184	|I-IUPAC
d	1184	1185	|I-IUPAC
]	1185	1186	|I-IUPAC
pyrimidine	1186	1196	|I-IUPAC
analogues	1197	1206	|B-MODIFIER
bearing	1207	1214	|O
bulky	1215	1220	|O
,	1220	1221	|O
weakly	1222	1228	|O
basic	1229	1234	|O
solubilizing	1235	1247	|O
side	1248	1252	|O
chains	1253	1259	|O
linked	1260	1266	|O
to	1267	1269	|O
the	1270	1273	|O
6	1274	1275	|O
-	1275	1276	|O
position	1276	1284	|O
through	1285	1292	|O
a	1293	1294	|O
secondary	1295	1304	|O
amine	1305	1310	|O
generally	1311	1320	|O
retained	1321	1329	|O
potency	1330	1337	|O
both	1338	1342	|O
against	1343	1350	|O
the	1351	1354	|O
isolated	1355	1363	|O
enzyme	1364	1370	|O
and	1371	1374	|O
for	1375	1378	|O
inhibition	1379	1389	|O
of	1390	1392	|O
autophosphorylation	1393	1412	|O
of	1413	1415	|O
EGFR	1416	1420	|O
in	1421	1423	|O
intact	1424	1430	|O
A431	1431	1435	|O
cells	1436	1441	|O
.	1441	1442	|O
This	1443	1447	|O
agrees	1448	1454	|O
with	1455	1459	|O
a	1460	1461	|O
recent	1462	1468	|O
binding	1469	1476	|O
model	1477	1482	|O
that	1483	1487	|O
suggests	1488	1496	|O
this	1497	1501	|O
general	1502	1509	|O
class	1510	1515	|O
of	1516	1518	|O
compounds	1519	1528	|O
binds	1529	1534	|O
to	1535	1537	|O
EGFR	1538	1542	|O
with	1543	1547	|O
the	1548	1551	|O
6	1552	1553	|O
-	1553	1554	|O
position	1554	1562	|O
located	1563	1570	|O
in	1571	1573	|O
an	1574	1576	|O
area	1577	1581	|O
of	1582	1584	|O
comparative	1585	1596	|O
bulk	1597	1601	|O
tolerance	1602	1611	|O
at	1612	1614	|O
the	1615	1618	|O
entrance	1619	1627	|O
to	1628	1630	|O
the	1631	1634	|O
ATP	1635	1638	|O
-	1638	1639	|O
binding	1639	1646	|O
pocket	1647	1653	|O
.	1653	1654	|O
While	1655	1660	|O
these	1661	1666	|O
solubilized	1667	1678	|O
pyrimido	1679	1687	|B-IUPAC
[	1687	1688	|I-IUPAC
5,4	1688	1691	|I-IUPAC
-	1691	1692	|I-IUPAC
d	1692	1693	|I-IUPAC
]	1693	1694	|I-IUPAC
pyrimidine	1694	1704	|I-IUPAC
analogues	1705	1714	|B-MODIFIER
were	1715	1719	|O
less	1720	1724	|O
potent	1725	1731	|O
than	1732	1736	|O
the	1737	1740	|O
NHMe	1741	1745	|O
derivative	1746	1756	|O
5c	1757	1759	|O
in	1760	1762	|O
the	1763	1766	|O
isolated	1767	1775	|O
enzyme	1776	1782	|O
assay	1783	1788	|O
,	1788	1789	|O
some	1790	1794	|O
were	1795	1799	|O
considerably	1800	1812	|O
superior	1813	1821	|O
to	1822	1824	|O
5c	1825	1827	|O
(	1828	1829	|O
and	1829	1832	|O
among	1833	1838	|O
the	1839	1842	|O
most	1843	1847	|O
potent	1848	1854	|O
ever	1855	1859	|O
reported	1860	1868	|O
)	1868	1869	|O
as	1870	1872	|O
inhibitors	1873	1883	|O
of	1884	1886	|O
EGFR	1887	1891	|O
autophosphorylation	1892	1911	|O
in	1912	1914	|O
cellular	1915	1923	|O
assays	1924	1930	|O
.	1930	1931	|O

### abstracts2689.txt
The	0	3	|O
sodium	4	10	|O
salt	11	15	|O
of	16	18	|O
4	19	20	|B-IUPAC
-	20	21	|I-IUPAC
amino	21	26	|I-IUPAC
-	26	27	|I-IUPAC
3	27	28	|I-IUPAC
-	28	29	|I-IUPAC
cyanopyrazolo	29	42	|I-IUPAC
[	42	43	|I-IUPAC
3,4	43	46	|I-IUPAC
-	46	47	|I-IUPAC
d	47	48	|I-IUPAC
]	48	49	|I-IUPAC
pyrimidine	49	59	|I-IUPAC
(	60	61	|O
1	61	62	|O
)	62	63	|O
was	64	67	|O
condensed	68	77	|O
with	78	82	|O
(	83	84	|B-IUPAC
2	84	85	|I-IUPAC
-	85	86	|I-IUPAC
acetoxyethoxy	86	99	|I-IUPAC
)	99	100	|I-IUPAC
methyl	100	106	|I-IUPAC
bromide	107	114	|I-IUPAC
(	115	116	|O
2	116	117	|O
)	117	118	|O
to	119	121	|O
provide	122	129	|O
the	130	133	|O
corresponding	134	147	|O
protected	148	157	|O
acyclic	158	165	|O
nucleoside	166	176	|O
,	176	177	|O
4	178	179	|B-IUPAC
-	179	180	|I-IUPAC
amino	180	185	|I-IUPAC
-	185	186	|I-IUPAC
3	186	187	|I-IUPAC
-	187	188	|I-IUPAC
cyano	188	193	|I-IUPAC
-	193	194	|I-IUPAC
1	194	195	|I-IUPAC
-	195	196	|I-IUPAC
[	196	197	|I-IUPAC
(	197	198	|I-IUPAC
2	198	199	|I-IUPAC
-	199	200	|I-IUPAC
acetoxyethoxy	200	213	|I-IUPAC
)	213	214	|I-IUPAC
methyl	214	220	|I-IUPAC
]	220	221	|I-IUPAC
-	221	222	|I-IUPAC
pyrazolo	222	230	|I-IUPAC
[	230	231	|I-IUPAC
3,4	231	234	|I-IUPAC
-	234	235	|I-IUPAC
d	235	236	|I-IUPAC
]	236	237	|I-IUPAC
pyrimid	237	244	|I-IUPAC
ine	245	248	|I-IUPAC
(	249	250	|O
3	250	251	|O
)	251	252	|O
.	252	253	|O
Treatment	254	263	|O
of	264	266	|O
3	267	268	|O
with	269	273	|O
sodium	274	280	|O
methoxide	281	290	|O
in	291	293	|O
methanol	294	302	|O
provided	303	311	|O
a	312	313	|O
good	314	318	|O
yield	319	324	|O
of	325	327	|O
methyl	328	334	|B-IUPAC
4	335	336	|I-IUPAC
-	336	337	|I-IUPAC
amino	337	342	|I-IUPAC
-	342	343	|I-IUPAC
1	343	344	|I-IUPAC
-	344	345	|I-IUPAC
[	345	346	|I-IUPAC
(	346	347	|I-IUPAC
2	347	348	|I-IUPAC
-	348	349	|I-IUPAC
hydroxyethoxy	349	362	|I-IUPAC
)	362	363	|I-IUPAC
methyl	363	369	|I-IUPAC
]	369	370	|I-IUPAC
pyrazolo	370	378	|I-IUPAC
[	378	379	|I-IUPAC
3,4	379	382	|I-IUPAC
-	382	383	|I-IUPAC
d	383	384	|I-IUPAC
]	384	385	|I-IUPAC
pyrimidine	385	395	|I-IUPAC
-	395	396	|I-IUPAC
3	396	397	|I-IUPAC
-	397	398	|I-IUPAC
formimidate	399	410	|I-IUPAC
(	411	412	|O
4	412	413	|O
)	413	414	|O
.	414	415	|O
Treatment	416	425	|O
of	426	428	|O
the	429	432	|O
imidate	433	440	|O
(	441	442	|O
4	442	443	|O
)	443	444	|O
with	445	449	|O
sodium	450	456	|O
hydrogen	457	465	|O
sulfide	466	473	|O
gave	474	478	|O
the	479	482	|O
thiocarboxamide	483	498	|B-IUPAC
derivative	499	509	|B-MODIFIER
5	510	511	|O
.	511	512	|O
Aqueous	513	520	|O
base	521	525	|O
transformed	526	537	|O
4	538	539	|O
into	540	544	|O
4	545	546	|B-IUPAC
-	546	547	|I-IUPAC
amino	547	552	|I-IUPAC
-	552	553	|I-IUPAC
1	553	554	|I-IUPAC
-	554	555	|I-IUPAC
[	555	556	|I-IUPAC
(	556	557	|I-IUPAC
2	557	558	|I-IUPAC
-	558	559	|I-IUPAC
hydroxyethoxy	559	572	|I-IUPAC
)	572	573	|I-IUPAC
methyl	573	579	|I-IUPAC
]	579	580	|I-IUPAC
pyrazolo	580	588	|I-IUPAC
[	588	589	|I-IUPAC
3,4	589	592	|I-IUPAC
-	592	593	|I-IUPAC
d	593	594	|I-IUPAC
]	594	595	|I-IUPAC
pyrimidine	595	605	|I-IUPAC
-	605	606	|I-IUPAC
3	606	607	|I-IUPAC
-	607	608	|I-IUPAC
carboxamide	609	620	|I-IUPAC
(	621	622	|O
6	622	623	|O
)	623	624	|O
in	625	627	|O
good	628	632	|O
yield	633	638	|O
.	638	639	|O
Treatment	640	649	|O
of	650	652	|O
5	653	654	|O
with	655	659	|O
mercuric	660	668	|O
chloride	669	677	|O
furnished	678	687	|O
the	688	691	|O
toyocamycin	692	703	|O
analogue	704	712	|O
7	713	714	|O
.	714	715	|O
Evaluation	716	726	|O
of	727	729	|O
compounds	730	739	|O
1	740	741	|O
,	741	742	|O
3-7	743	746	|O
revealed	747	755	|O
that	756	760	|O
only	761	765	|O
the	766	769	|O
heterocycle	770	781	|O
(	782	783	|O
1	783	784	|O
)	784	785	|O
and	786	789	|O
the	790	793	|O
thiocarboxamide	794	809	|O
acyclic	810	817	|O
nucleoside	818	828	|O
(	829	830	|O
5	830	831	|O
)	831	832	|O
were	833	837	|O
active	838	844	|O
.	844	845	|O
Compound	846	854	|O
5	855	856	|O
was	857	860	|O
the	861	864	|O
more	865	869	|O
potent	870	876	|O
with	877	881	|O
activity	882	890	|O
against	891	898	|O
human	899	904	|O
cytomegalovirus	905	920	|O
and	921	924	|O
herpes	925	931	|O
simplex	932	939	|O
virus	940	945	|O
type	946	950	|O
1	951	952	|O
.	952	953	|O

### abstracts2585.txt
[	0	1	|O
1	1	2	|O
-	2	3	|O
N	3	4	|O
-	4	5	|O
Methylisoasparagine	5	24	|O
,	24	25	|O
8	25	26	|O
-	26	27	|O
isoleucine	27	37	|O
]	37	38	|O
-	38	39	|O
(	40	41	|O
I	41	42	|O
)	42	43	|O
,	43	44	|O
[	45	46	|B-PARTIUPAC
1	46	47	|I-PARTIUPAC
-	47	48	|I-PARTIUPAC
sarcosine	48	57	|I-PARTIUPAC
,	57	58	|I-PARTIUPAC
4	58	59	|I-PARTIUPAC
-	59	60	|I-PARTIUPAC
N	60	61	|I-PARTIUPAC
-	61	62	|I-PARTIUPAC
methyltyrosine	62	76	|I-PARTIUPAC
,	76	77	|I-PARTIUPAC
8	77	78	|I-PARTIUPAC
-	78	79	|I-PARTIUPAC
isoleucine	79	89	|I-PARTIUPAC
]	89	90	|I-PARTIUPAC
-	90	91	|I-PARTIUPAC
(	92	93	|O
II	93	95	|O
)	95	96	|O
,	96	97	|O
[	98	99	|B-PARTIUPAC
1	99	100	|I-PARTIUPAC
-	100	101	|I-PARTIUPAC
sarcosine	101	110	|I-PARTIUPAC
,	110	111	|I-PARTIUPAC
5	111	112	|I-PARTIUPAC
-	112	113	|I-PARTIUPAC
N	113	114	|I-PARTIUPAC
-	114	115	|I-PARTIUPAC
methylisoleucine	115	131	|I-PARTIUPAC
,	131	132	|I-PARTIUPAC
8	132	133	|I-PARTIUPAC
-	133	134	|I-PARTIUPAC
isoleucine	134	144	|I-PARTIUPAC
]	144	145	|I-PARTIUPAC
-	145	146	|I-PARTIUPAC
(	147	148	|O
III	148	151	|O
)	151	152	|O
,	152	153	|O
[	154	155	|B-PARTIUPAC
1	155	156	|I-PARTIUPAC
-	156	157	|I-PARTIUPAC
sarcosine	157	166	|I-PARTIUPAC
,	166	167	|I-PARTIUPAC
8	167	168	|I-PARTIUPAC
-	168	169	|I-PARTIUPAC
N	169	170	|I-PARTIUPAC
-	170	171	|I-PARTIUPAC
methylisoleucine	171	187	|I-PARTIUPAC
]	187	188	|I-PARTIUPAC
-	188	189	|I-PARTIUPAC
(	190	191	|O
IV	191	193	|O
)	193	194	|O
,	194	195	|O
[	196	197	|B-PARTIUPAC
1	197	198	|I-PARTIUPAC
-	198	199	|I-PARTIUPAC
sarcosine8k	199	210	|I-PARTIUPAC
-	210	211	|I-PARTIUPAC
N	211	212	|I-PARTIUPAC
-	212	213	|I-PARTIUPAC
methylisoleucine	213	229	|I-PARTIUPAC
,	229	230	|I-PARTIUPAC
8	230	231	|I-PARTIUPAC
-	231	232	|I-PARTIUPAC
N	232	233	|I-PARTIUPAC
-	233	234	|I-PARTIUPAC
methylisoleucine	234	250	|I-PARTIUPAC
]	250	251	|I-PARTIUPAC
-	251	252	|I-PARTIUPAC
(	253	254	|O
V	254	255	|O
)	255	256	|O
,	256	257	|O
[	258	259	|B-PARTIUPAC
1	259	260	|I-PARTIUPAC
-	260	261	|I-PARTIUPAC
sarcosine	261	270	|I-PARTIUPAC
,	270	271	|I-PARTIUPAC
8	271	272	|I-PARTIUPAC
-	272	273	|I-PARTIUPAC
O	273	274	|I-PARTIUPAC
-	274	275	|I-PARTIUPAC
methylthreonine	275	290	|I-PARTIUPAC
]	290	291	|I-PARTIUPAC
-	291	292	|I-PARTIUPAC
(	293	294	|O
VI	294	296	|O
)	296	297	|O
,	297	298	|O
[	299	300	|B-PARTIUPAC
1	300	301	|I-PARTIUPAC
-	301	302	|I-PARTIUPAC
sarcosine	302	311	|I-PARTIUPAC
,	311	312	|I-PARTIUPAC
8	312	313	|I-PARTIUPAC
-	313	314	|I-PARTIUPAC
methionine	314	324	|I-PARTIUPAC
]	324	325	|I-PARTIUPAC
-	325	326	|I-PARTIUPAC
(	327	328	|O
VII	328	331	|O
)	331	332	|O
,	332	333	|O
and	334	337	|O
[	338	339	|B-IUPAC
1	339	340	|I-IUPAC
-	340	341	|I-IUPAC
sarcosine	341	350	|I-IUPAC
,	350	351	|I-IUPAC
8	351	352	|I-IUPAC
-	352	353	|I-IUPAC
serine	353	359	|I-IUPAC
]	359	360	|I-IUPAC
angiotensin	360	371	|I-IUPAC
II	372	374	|I-IUPAC
(	375	376	|O
VIII	376	380	|O
)	380	381	|O
,	381	382	|O
synthesized	383	394	|O
by	395	397	|O
Merrifield	398	408	|O
's	408	410	|O
solid	411	416	|O
-	416	417	|O
phase	417	422	|O
procedure	423	432	|O
,	432	433	|O
possess	434	441	|O
respectively	442	454	|O
0.8	455	458	|O
,	458	459	|O
0.3	460	463	|O
,	463	464	|O
0.5	465	468	|O
,	468	469	|O
1.0	470	473	|O
,	473	474	|O
0.0	475	478	|O
,	478	479	|O
0.5	480	483	|O
,	483	484	|O
3.7	485	488	|O
,	488	489	|O
and	490	493	|O
0.7%	494	498	|O
pressor	499	506	|O
activity	507	515	|O
of	516	518	|O
angiotensin	519	530	|O
II	531	533	|O
(	534	535	|O
vagotomized	535	546	|O
,	546	547	|O
ganglion	548	556	|O
-	556	557	|O
blocked	557	564	|O
rats	565	569	|O
)	569	570	|O
.	570	571	|O
They	572	576	|O
caused	577	583	|O
an	584	586	|O
initial	587	594	|O
rise	595	599	|O
in	600	602	|O
blood	603	608	|O
pressure	609	617	|O
(	618	619	|O
30	619	621	|O
min	622	625	|O
of	626	628	|O
infusion	629	637	|O
,	637	638	|O
250	639	642	|O
ng	643	645	|O
/	645	646	|O
kg	646	648	|O
/	648	649	|O
min	649	652	|O
in	653	655	|O
vagotomized	656	667	|O
,	667	668	|O
ganglion	669	677	|O
-	677	678	|O
blocked	678	685	|O
rats	686	690	|O
)	690	691	|O
of	692	694	|O
16.57	695	700	|O
,	700	701	|O
9.80	702	706	|O
,	706	707	|O
22.80	708	713	|O
,	713	714	|O
32.00	715	720	|O
,	720	721	|O
7.00	722	726	|O
,	726	727	|O
15.06	728	733	|O
,	733	734	|O
32.50	735	740	|O
,	740	741	|O
and	742	745	|O
11.42	746	751	|O
mmHg	752	756	|O
and	757	760	|O
showed	761	767	|O
secretory	768	777	|O
activity	778	786	|O
(	787	788	|O
isolated	788	796	|O
cat	797	800	|O
adrenal	801	808	|O
medulla	809	816	|O
)	816	817	|O
of	818	820	|O
1.0	821	824	|O
,	824	825	|O
0.1	826	829	|O
,	829	830	|O
0.01	831	835	|O
,	835	836	|O
0.1	837	840	|O
,	840	841	|O
less	842	846	|O
than	847	851	|O
0.01	852	856	|O
,	856	857	|O
0.1	858	861	|O
,	861	862	|O
less	863	867	|O
than	868	872	|O
0.01	873	877	|O
,	877	878	|O
and	879	882	|O
0.05%	883	888	|O
of	889	891	|O
angiotensin	892	903	|O
II	904	906	|O
.	906	907	|O
On	908	910	|O
isolated	911	919	|O
organs	920	926	|O
pA2	927	930	|O
values	931	937	|O
(	938	939	|O
rabbit	939	945	|O
aortic	946	952	|O
strips	953	959	|O
)	959	960	|O
of	961	963	|O
8.74	964	968	|O
,	968	969	|O
7.44	970	974	|O
,	974	975	|O
7.64	976	980	|O
,	980	981	|O
7.85	982	986	|O
,	986	987	|O
7.89	988	992	|O
,	992	993	|O
8.76	994	998	|O
,	998	999	|O
8.63	1000	1004	|O
,	1004	1005	|O
and	1006	1009	|O
8.08	1010	1014	|O
,	1014	1015	|O
and	1016	1019	|O
pA2	1020	1023	|O
values	1024	1030	|O
(	1031	1032	|O
cat	1032	1035	|O
adrenal	1036	1043	|O
medulla	1044	1051	|O
of	1052	1054	|O
8.16	1055	1059	|O
,	1059	1060	|O
9.16	1061	1065	|O
,	1065	1066	|O
9.31	1067	1071	|O
,	1071	1072	|O
8.00	1073	1077	|O
,	1077	1078	|O
8.00	1079	1083	|O
,	1083	1084	|O
7.00	1085	1089	|O
,	1089	1090	|O
9.16	1091	1095	|O
,	1095	1096	|O
and	1097	1100	|O
9.33	1101	1105	|O
were	1106	1110	|O
obtained	1111	1119	|O
.	1119	1120	|O
Dose	1121	1125	|O
ratios	1126	1132	|O
(	1133	1134	|O
ratio	1134	1139	|O
of	1140	1142	|O
ED20	1143	1147	|O
of	1148	1150	|O
angiotensin	1151	1162	|O
II	1163	1165	|O
during	1166	1172	|O
infusion	1173	1181	|O
of	1182	1184	|O
the	1185	1188	|O
antagonist	1189	1199	|O
and	1200	1203	|O
before	1204	1210	|O
infusion	1211	1219	|O
of	1220	1222	|O
the	1223	1226	|O
antagonist	1227	1237	|O
)	1237	1238	|O
in	1239	1241	|O
vagotomized	1242	1253	|O
,	1253	1254	|O
ganglion	1255	1263	|O
-	1263	1264	|O
blocked	1264	1271	|O
rats	1272	1276	|O
,	1276	1277	|O
infused	1278	1285	|O
at	1286	1288	|O
250	1289	1292	|O
ng	1293	1295	|O
/	1295	1296	|O
kg	1296	1298	|O
/	1298	1299	|O
min	1299	1302	|O
,	1302	1303	|O
were	1304	1308	|O
33.43	1309	1314	|O
,	1314	1315	|O
2.14	1316	1320	|O
,	1320	1321	|O
3.26	1322	1326	|O
,	1326	1327	|O
2.99	1328	1332	|O
,	1332	1333	|O
0.62	1334	1338	|O
,	1338	1339	|O
62.52	1340	1345	|O
,	1345	1346	|O
incalculable	1347	1359	|O
,	1359	1360	|O
and	1361	1364	|O
11.15	1365	1370	|O
,	1370	1371	|O
respectively	1372	1384	|O
.	1384	1385	|O
The	1386	1389	|O
results	1390	1397	|O
obtained	1398	1406	|O
suggest	1407	1414	|O
that	1415	1419	|O
(	1420	1421	|O
a	1421	1422	|O
)	1422	1423	|O
analogs	1424	1431	|O
I	1432	1433	|O
and	1434	1437	|O
VI	1438	1440	|O
are	1441	1444	|O
potent	1445	1451	|O
antagonists	1452	1463	|O
of	1464	1466	|O
the	1467	1470	|O
pressor	1471	1478	|O
response	1479	1487	|O
of	1488	1490	|O
angiotensin	1491	1502	|O
II	1503	1505	|O
in	1506	1508	|O
normal	1509	1515	|O
rat	1516	1519	|O
,	1519	1520	|O
VI	1521	1523	|O
being	1524	1529	|O
the	1530	1533	|O
most	1534	1538	|O
potent	1539	1545	|O
antagonist	1546	1556	|O
thus	1557	1561	|O
far	1562	1565	|O
synthesized	1566	1577	|O
;	1577	1578	|O
(	1579	1580	|O
b	1580	1581	|O
)	1581	1582	|O
replacement	1583	1594	|O
of	1595	1597	|O
position	1598	1606	|O
4	1607	1608	|O
(	1609	1610	|O
Tyr	1610	1613	|O
)	1613	1614	|O
with	1615	1619	|O
MeTyr	1620	1625	|O
or	1626	1628	|O
position	1629	1637	|O
5	1638	1639	|O
and	1640	1643	|O
/	1643	1644	|O
or	1644	1646	|O
8	1647	1648	|O
(	1649	1650	|O
Ile	1650	1653	|O
)	1653	1654	|O
with	1655	1659	|O
Melle	1660	1665	|O
in	1666	1668	|O
[	1669	1670	|B-IUPAC
1	1670	1671	|I-IUPAC
-	1671	1672	|I-IUPAC
sarcosine	1672	1681	|I-IUPAC
,	1681	1682	|I-IUPAC
8	1682	1683	|I-IUPAC
-	1683	1684	|I-IUPAC
isoleucine	1684	1694	|I-IUPAC
]	1694	1695	|I-IUPAC
angiotensin	1695	1706	|I-IUPAC
II	1707	1709	|I-IUPAC
reduced	1710	1717	|O
the	1718	1721	|O
antagonist	1722	1732	|O
activity	1733	1741	|O
of	1742	1744	|O
this	1745	1749	|O
peptide	1750	1757	|O
(	1758	1759	|O
rabbit	1759	1765	|O
aortic	1766	1772	|O
strips	1773	1779	|O
and	1780	1783	|O
rats	1784	1788	|O
)	1788	1789	|O
,	1789	1790	|O
indicating	1791	1801	|O
that	1802	1806	|O
steric	1807	1813	|O
hindrance	1814	1823	|O
imposed	1824	1831	|O
due	1832	1835	|O
to	1836	1838	|O
N	1839	1840	|O
-	1840	1841	|O
methylation	1841	1852	|O
in	1853	1855	|O
positions	1856	1865	|O
4	1866	1867	|O
,	1867	1868	|O
5	1869	1870	|O
,	1870	1871	|O
or	1872	1874	|O
8	1875	1876	|O
was	1877	1880	|O
not	1881	1884	|O
favorable	1885	1894	|O
in	1895	1897	|O
eliminating	1898	1909	|O
the	1910	1913	|O
initial	1914	1921	|O
pressor	1922	1929	|O
activity	1930	1938	|O
or	1939	1941	|O
prolonging	1942	1952	|O
the	1953	1956	|O
duration	1957	1965	|O
of	1966	1968	|O
action	1969	1975	|O
of	1976	1978	|O
[	1979	1980	|O
Sar1	1980	1984	|O
,	1984	1985	|O
Ile8	1986	1990	|O
]	1990	1991	|O
angiotensin	1991	2002	|O
II	2003	2005	|O
without	2006	2013	|O
reducing	2014	2022	|O
its	2023	2026	|O
antagonistic	2027	2039	|O
properties	2040	2050	|O
;	2050	2051	|O
(	2052	2053	|O
c	2053	2054	|O
)	2054	2055	|O
except	2056	2062	|O
II	2063	2065	|O
,	2065	2066	|O
none	2067	2071	|O
of	2072	2074	|O
the	2075	2078	|O
analogs	2079	2086	|O
showed	2087	2093	|O
any	2094	2097	|O
enhanced	2098	2106	|O
duration	2107	2115	|O
of	2116	2118	|O
action	2119	2125	|O
,	2125	2126	|O
suggesting	2127	2137	|O
that	2138	2142	|O
N	2143	2144	|O
-	2144	2145	|O
methylation	2145	2156	|O
in	2157	2159	|O
positions	2160	2169	|O
5	2170	2171	|O
or	2172	2174	|O
8	2175	2176	|O
did	2177	2180	|O
not	2181	2184	|O
afford	2185	2191	|O
protection	2192	2202	|O
against	2203	2210	|O
proteolytic	2211	2222	|O
enzymes	2223	2230	|O
;	2230	2231	|O
and	2232	2235	|O
(	2236	2237	|O
d	2237	2238	|O
)	2238	2239	|O
perfusion	2240	2249	|O
studies	2250	2257	|O
in	2258	2260	|O
cat	2261	2264	|O
adrenals	2265	2273	|O
indicated	2274	2283	|O
that	2284	2288	|O
all	2289	2292	|O
of	2293	2295	|O
these	2296	2301	|O
analogs	2302	2309	|O
are	2310	2313	|O
only	2314	2318	|O
very	2319	2323	|O
weak	2324	2328	|O
secretagogues	2329	2342	|O
.	2342	2343	|O
With	2344	2348	|O
the	2349	2352	|O
exception	2353	2362	|O
of	2363	2365	|O
[	2366	2367	|O
Sar1	2367	2371	|O
,	2371	2372	|O
Thr	2372	2375	|O
(	2375	2376	|O
ObetaMe	2376	2383	|O
)	2383	2384	|O
8	2384	2385	|O
]	2385	2386	|O
angiotensin	2386	2397	|O
II	2398	2400	|O
,	2400	2401	|O
which	2402	2407	|O
gave	2408	2412	|O
lower	2413	2418	|O
antagonistic	2419	2431	|O
properties	2432	2442	|O
,	2442	2443	|O
all	2444	2447	|O
other	2448	2453	|O
analogs	2454	2461	|O
had	2462	2465	|O
either	2466	2472	|O
similar	2473	2480	|O
antagonistic	2481	2493	|O
properties	2494	2504	|O
or	2505	2507	|O
were	2508	2512	|O
better	2513	2519	|O
antagonists	2520	2531	|O
in	2532	2534	|O
adrenal	2535	2542	|O
medulla	2543	2550	|O
than	2551	2555	|O
in	2556	2558	|O
smooth	2559	2565	|O
muscle	2566	2572	|O
.	2572	2573	|O

### abstracts1998.txt
Treatment	0	9	|O
of	10	12	|O
7,12	13	17	|B-IUPAC
-	17	18	|I-IUPAC
benz	18	22	|I-IUPAC
[	22	23	|I-IUPAC
a	23	24	|I-IUPAC
]	24	25	|I-IUPAC
anthraquinone	25	38	|I-IUPAC
(	39	40	|O
2	40	41	|O
)	41	42	|O
with	43	47	|O
methylmagnesium	48	63	|O
iodide	64	70	|O
or	71	73	|O
methyllithium	74	87	|O
yields	88	94	|O
mixtures	95	103	|O
of	104	106	|O
cis	107	110	|B-PARTIUPAC
-	110	111	|I-PARTIUPAC
and	112	115	|O
trans	116	121	|B-IUPAC
-	121	122	|I-IUPAC
7,12	122	126	|I-IUPAC
-	126	127	|I-IUPAC
dihydro	127	134	|I-IUPAC
-	134	135	|I-IUPAC
7,12	135	139	|I-IUPAC
-	139	140	|I-IUPAC
dihydroxy	140	149	|I-IUPAC
-	149	150	|I-IUPAC
7,12	150	154	|I-IUPAC
-	154	155	|I-IUPAC
dimethylbenz	155	167	|I-IUPAC
[	167	168	|I-IUPAC
a	168	169	|I-IUPAC
]	169	170	|I-IUPAC
anthracenes	170	181	|I-IUPAC
(	182	183	|O
3a	183	185	|O
,	185	186	|O
b	186	187	|O
)	187	188	|O
,	188	189	|O
in	190	192	|O
which	193	198	|O
the	199	202	|O
ratio	203	208	|O
of	209	211	|O
cis	212	215	|O
to	216	218	|O
trans	219	224	|O
lies	225	229	|O
in	230	232	|O
the	233	236	|O
3	237	238	|O
-	238	239	|O
-	239	240	|O
4	240	241	|O
:	241	242	|O
1	242	243	|O
region	244	250	|O
.	250	251	|O
Each	252	256	|O
isomer	257	263	|O
afforded	264	272	|O
high	273	277	|O
yields	278	284	|O
of	285	287	|O
7	288	289	|B-IUPAC
-	289	290	|I-IUPAC
chloromethyl	290	302	|I-IUPAC
-	302	303	|I-IUPAC
12	303	305	|I-IUPAC
-	305	306	|I-IUPAC
methylbenz	306	316	|I-IUPAC
[	316	317	|I-IUPAC
a	317	318	|I-IUPAC
]	318	319	|I-IUPAC
anthracene	319	329	|I-IUPAC
(	330	331	|O
5	331	332	|O
)	332	333	|O
on	334	336	|O
treatment	337	346	|O
with	347	351	|O
hydrogen	352	360	|O
chloride	361	369	|O
in	370	372	|O
ethyl	373	378	|O
acetate	379	386	|O
.	386	387	|O
Similarly	388	397	|O
,	397	398	|O
5	399	400	|B-IUPAC
-	400	401	|I-IUPAC
fluoro	401	407	|I-IUPAC
-	407	408	|I-IUPAC
7,12	408	412	|I-IUPAC
-	412	413	|I-IUPAC
benz	413	417	|I-IUPAC
[	417	418	|I-IUPAC
a	418	419	|I-IUPAC
]	419	420	|I-IUPAC
anthraquinone	420	433	|I-IUPAC
(	434	435	|O
8	435	436	|O
)	436	437	|O
afforded	438	446	|O
a	447	448	|O
mixture	449	456	|O
of	457	459	|O
cis	460	463	|B-PARTIUPAC
-	463	464	|I-PARTIUPAC
and	465	468	|O
trans	469	474	|B-IUPAC
-	474	475	|I-IUPAC
5	475	476	|I-IUPAC
-	476	477	|I-IUPAC
fluoro	477	483	|I-IUPAC
-	483	484	|I-IUPAC
7,12	484	488	|I-IUPAC
-	488	489	|I-IUPAC
dihydro	489	496	|I-IUPAC
-	496	497	|I-IUPAC
7,12	497	501	|I-IUPAC
-	501	502	|I-IUPAC
dihydroxy	502	511	|I-IUPAC
-	511	512	|I-IUPAC
7,12	512	516	|I-IUPAC
-	516	517	|I-IUPAC
dimethylbenz	517	529	|I-IUPAC
[	529	530	|I-IUPAC
a	530	531	|I-IUPAC
]	531	532	|I-IUPAC
anthracenes	532	543	|I-IUPAC
(	544	545	|O
9	545	546	|O
)	546	547	|O
which	548	553	|O
yielded	554	561	|O
7	562	563	|B-IUPAC
-	563	564	|I-IUPAC
chloromethyl	564	576	|I-IUPAC
-	576	577	|I-IUPAC
5	577	578	|I-IUPAC
-	578	579	|I-IUPAC
fluoro	579	585	|I-IUPAC
-	585	586	|I-IUPAC
12	586	588	|I-IUPAC
-	588	589	|I-IUPAC
methylbenz	589	599	|I-IUPAC
[	599	600	|I-IUPAC
a	600	601	|I-IUPAC
]	601	602	|I-IUPAC
anthracene	602	612	|I-IUPAC
(	613	614	|O
10	614	616	|O
)	616	617	|O
on	618	620	|O
treatment	621	630	|O
with	631	635	|O
HCl	636	639	|O
.	639	640	|O
The	641	644	|O
chloromethyl	645	657	|O
compounds	658	667	|O
,	667	668	|O
5	669	670	|O
and	671	674	|O
10	675	677	|O
,	677	678	|O
yielded	679	686	|O
7	687	688	|B-IUPAC
-	688	689	|I-IUPAC
acetoxymethyl	689	702	|I-IUPAC
-	702	703	|I-IUPAC
12	703	705	|I-IUPAC
-	705	706	|I-IUPAC
methylbenz	706	716	|I-IUPAC
[	716	717	|I-IUPAC
a	717	718	|I-IUPAC
]	718	719	|I-IUPAC
anthracene	719	729	|I-IUPAC
(	730	731	|O
6	731	732	|O
)	732	733	|O
and	734	737	|O
7	738	739	|B-IUPAC
-	739	740	|I-IUPAC
acetoxymethyl	740	753	|I-IUPAC
-	753	754	|I-IUPAC
5	754	755	|I-IUPAC
-	755	756	|I-IUPAC
fluoro	756	762	|I-IUPAC
-	762	763	|I-IUPAC
12	763	765	|I-IUPAC
-	765	766	|I-IUPAC
methylbenz	766	776	|I-IUPAC
[	776	777	|I-IUPAC
a	777	778	|I-IUPAC
]	778	779	|I-IUPAC
anthracene	779	789	|I-IUPAC
(	790	791	|O
11	791	793	|O
)	793	794	|O
on	795	797	|O
treatment	798	807	|O
with	808	812	|O
acetate	813	820	|O
ion	821	824	|O
.	824	825	|O
Hydrolysis	826	836	|O
of	837	839	|O
6	840	841	|O
and	842	845	|O
11	846	848	|O
yielded	849	856	|O
7	857	858	|B-IUPAC
-	858	859	|I-IUPAC
hydroxymethyl	859	872	|I-IUPAC
-	872	873	|I-IUPAC
12	873	875	|I-IUPAC
-	875	876	|I-IUPAC
methylbenz	876	886	|I-IUPAC
[	886	887	|I-IUPAC
a	887	888	|I-IUPAC
]	888	889	|I-IUPAC
anthracene	889	899	|I-IUPAC
(	900	901	|O
7	901	902	|O
)	902	903	|O
and	904	907	|O
5	908	909	|B-IUPAC
-	909	910	|I-IUPAC
fluoro	910	916	|I-IUPAC
-	916	917	|I-IUPAC
7	917	918	|I-IUPAC
-	918	919	|I-IUPAC
hydroxymethyl	919	932	|I-IUPAC
-	932	933	|I-IUPAC
12	933	935	|I-IUPAC
-	935	936	|I-IUPAC
methylbenz	936	946	|I-IUPAC
[	946	947	|I-IUPAC
a	947	948	|I-IUPAC
]	948	949	|I-IUPAC
anthracene	949	959	|I-IUPAC
(	960	961	|O
12	961	963	|O
)	963	964	|O
,	964	965	|O
respectively	966	978	|O
.	978	979	|O
Since	980	985	|O
neither	986	993	|O
11	994	996	|O
nor	997	1000	|O
12	1001	1003	|O
is	1004	1006	|O
appreciably	1007	1018	|O
carcinogenic	1019	1031	|O
,	1031	1032	|O
the	1033	1036	|O
carcinogenic	1037	1049	|O
metabolism	1050	1060	|O
of	1061	1063	|O
7,12	1064	1068	|B-IUPAC
-	1068	1069	|I-IUPAC
dimethylbenz	1069	1081	|I-IUPAC
[	1081	1082	|I-IUPAC
a	1082	1083	|I-IUPAC
]	1083	1084	|I-IUPAC
anthracene	1084	1094	|I-IUPAC
(	1095	1096	|O
DMBA	1096	1100	|O
)	1100	1101	|O
probably	1102	1110	|O
does	1111	1115	|O
not	1116	1119	|O
involve	1120	1127	|O
attack	1128	1134	|O
at	1135	1137	|O
the	1138	1141	|O
7	1142	1143	|B-IUPAC
-	1143	1144	|I-IUPAC
methyl	1144	1150	|I-IUPAC
group	1151	1156	|B-MODIFIER
.	1156	1157	|O

### abstracts3081.txt
The	0	3	|O
synthesis	4	13	|O
and	14	17	|O
in	18	20	|O
vitro	21	26	|O
sigma	27	32	|O
receptor	33	41	|O
activity	42	50	|O
of	51	53	|O
the	54	57	|O
two	58	61	|O
diastereomers	62	75	|O
of	76	78	|O
U50	79	82	|O
,	82	83	|O
488	83	86	|O
[	87	88	|O
(	88	89	|O
+	89	90	|O
/	90	91	|O
-	91	92	|O
)	92	93	|O
-	93	94	|O
2	94	95	|O
]	95	96	|O
,	96	97	|O
namely	98	104	|O
,	104	105	|O
(	105	106	|B-IUPAC
1R	107	109	|I-IUPAC
,	109	110	|I-IUPAC
2S	110	112	|I-IUPAC
)	112	113	|I-IUPAC
-	113	114	|I-IUPAC
(	114	115	|I-IUPAC
+	115	116	|I-IUPAC
)	116	117	|I-IUPAC
-	117	118	|I-IUPAC
cis	119	122	|I-IUPAC
-	122	123	|I-IUPAC
3,4	123	126	|I-IUPAC
-	126	127	|I-IUPAC
dichloro	127	135	|I-IUPAC
-	135	136	|I-IUPAC
N	136	137	|I-IUPAC
-	137	138	|I-IUPAC
methyl	138	144	|I-IUPAC
-	144	145	|I-IUPAC
N	145	146	|I-IUPAC
-	146	147	|I-IUPAC
[	147	148	|I-IUPAC
2	148	149	|I-IUPAC
-	149	150	|I-IUPAC
(	150	151	|I-IUPAC
1	151	152	|I-IUPAC
-	152	153	|I-IUPAC
pyrrolidinyl	153	165	|I-IUPAC
)	165	166	|I-IUPAC
cyclohexyl	166	176	|I-IUPAC
]	176	177	|I-IUPAC
benzeneacet	177	188	|I-IUPAC
ami	189	192	|I-IUPAC
de	193	195	|I-IUPAC
[	196	197	|B-PARTIUPAC
(	197	198	|I-PARTIUPAC
+	198	199	|I-PARTIUPAC
)	199	200	|I-PARTIUPAC
-	200	201	|I-PARTIUPAC
1	201	202	|I-PARTIUPAC
]	202	203	|I-PARTIUPAC
and	204	207	|O
(	208	209	|B-IUPAC
1S	209	211	|I-IUPAC
,	211	212	|I-IUPAC
2R	212	214	|I-IUPAC
)	214	215	|I-IUPAC
-	215	216	|I-IUPAC
(	216	217	|I-IUPAC
-	217	218	|I-IUPAC
)	218	219	|I-IUPAC
-	219	220	|I-IUPAC
cis	220	223	|I-IUPAC
-	223	224	|I-IUPAC
3,4	224	227	|I-IUPAC
-	227	228	|I-IUPAC
dichloro	228	236	|I-IUPAC
-	236	237	|I-IUPAC
N	238	239	|I-IUPAC
-	239	240	|I-IUPAC
methyl	240	246	|I-IUPAC
-	246	247	|I-IUPAC
N	247	248	|I-IUPAC
-	248	249	|I-IUPAC
[	249	250	|I-IUPAC
2	250	251	|I-IUPAC
-	251	252	|I-IUPAC
(	252	253	|I-IUPAC
1	253	254	|I-IUPAC
-	254	255	|I-IUPAC
pyrrolidinyl	255	267	|I-IUPAC
)	267	268	|I-IUPAC
cyclohexyl	268	278	|I-IUPAC
]	278	279	|I-IUPAC
benzeneacetamide	279	295	|I-IUPAC
[	296	297	|O
(	297	298	|O
-	298	299	|O
)	299	300	|O
-	300	301	|O
1	301	302	|O
]	302	303	|O
,	303	304	|O
are	305	308	|O
described	309	318	|O
.	318	319	|O
(	320	321	|O
+	321	322	|O
)	322	323	|O
-	323	324	|O
1	324	325	|O
and	326	329	|O
(	330	331	|O
-	331	332	|O
)	332	333	|O
-	333	334	|O
1	334	335	|O
were	336	340	|O
synthesized	341	352	|O
from	353	357	|O
(	358	359	|B-IUPAC
+	359	360	|I-IUPAC
/	360	361	|I-IUPAC
-	361	362	|I-IUPAC
)	362	363	|I-IUPAC
-	363	364	|I-IUPAC
trans	364	369	|I-IUPAC
-	369	370	|I-IUPAC
N	370	371	|I-IUPAC
-	371	372	|I-IUPAC
methyl	372	378	|I-IUPAC
-	378	379	|I-IUPAC
2	379	380	|I-IUPAC
-	380	381	|I-IUPAC
aminocyclohexanol	381	398	|I-IUPAC
[	399	400	|O
(	400	401	|O
+	401	402	|O
/	402	403	|O
-	403	404	|O
)	404	405	|O
-	405	406	|O
3	406	407	|O
]	407	408	|O
.	408	409	|O
Pyridinium	410	420	|O
chlorochromate	421	435	|O
(	436	437	|O
PCC	437	440	|O
)	440	441	|O
oxidation	442	451	|O
of	452	454	|O
the	455	458	|O
N	459	460	|O
-	460	461	|O
t	461	462	|O
-	462	463	|O
Boc	463	466	|O
-	466	467	|O
protected	467	476	|O
derivative	477	487	|O
of	488	490	|O
(	491	492	|O
+	492	493	|O
/	493	494	|O
-	494	495	|O
)	495	496	|O
-	496	497	|O
3	497	498	|O
afforded	499	507	|O
(	508	509	|B-IUPAC
+	509	510	|I-IUPAC
/	510	511	|I-IUPAC
-	511	512	|I-IUPAC
)	512	513	|I-IUPAC
-	513	514	|I-IUPAC
2	514	515	|I-IUPAC
-	515	516	|I-IUPAC
[	516	517	|I-IUPAC
N	517	518	|I-IUPAC
-	518	519	|I-IUPAC
[	520	521	|I-IUPAC
(	521	522	|I-IUPAC
tert	522	526	|I-IUPAC
-	526	527	|I-IUPAC
butyloxy	527	535	|I-IUPAC
)	535	536	|I-IUPAC
carbonyl	536	544	|I-IUPAC
]	544	545	|I-IUPAC
-	545	546	|I-IUPAC
N	546	547	|I-IUPAC
-	547	548	|I-IUPAC
methylamino	548	559	|I-IUPAC
]	559	560	|I-IUPAC
cyclohexanone	560	573	|I-IUPAC
[	574	575	|O
(	575	576	|O
+	576	577	|O
/	577	578	|O
-	578	579	|O
)	579	580	|O
-	580	581	|O
5	581	582	|O
]	582	583	|O
.	583	584	|O
The	585	588	|O
sequence	589	597	|O
of	598	600	|O
enamine	601	608	|O
formation	609	618	|O
with	619	623	|O
pyrrolidine	624	635	|O
,	635	636	|O
catalytic	637	646	|O
reduction	647	656	|O
,	656	657	|O
N	658	659	|O
-	659	660	|O
deprotection	660	672	|O
,	672	673	|O
and	674	677	|O
optical	678	685	|O
resolution	686	696	|O
afforded	697	705	|O
(	706	707	|B-IUPAC
1R	707	709	|I-IUPAC
,	709	710	|I-IUPAC
2S	710	712	|I-IUPAC
)	712	713	|I-IUPAC
-	713	714	|I-IUPAC
(	714	715	|I-IUPAC
-	715	716	|I-IUPAC
)	716	717	|I-IUPAC
-	717	718	|I-IUPAC
cis	718	721	|I-IUPAC
-	721	722	|I-IUPAC
2	722	723	|I-IUPAC
-	723	724	|I-IUPAC
pyrrolidinyl	724	736	|I-IUPAC
-	736	737	|I-IUPAC
N	737	738	|I-IUPAC
-	738	739	|I-IUPAC
methylcyclohexylamine	739	760	|I-IUPAC
[	761	762	|O
(	762	763	|O
-	763	764	|O
)	764	765	|O
-	765	766	|O
10	766	768	|O
]	768	769	|O
and	770	773	|O
(	774	775	|B-IUPAC
1S	775	777	|I-IUPAC
,	777	778	|I-IUPAC
2R	778	780	|I-IUPAC
)	780	781	|I-IUPAC
-	781	782	|I-IUPAC
(	782	783	|I-IUPAC
+	783	784	|I-IUPAC
)	784	785	|I-IUPAC
-	785	786	|I-IUPAC
cis	786	789	|I-IUPAC
-	789	790	|I-IUPAC
2	790	791	|I-IUPAC
-	791	792	|I-IUPAC
pyrrolidinyl	792	804	|I-IUPAC
-	804	805	|I-IUPAC
N	805	806	|I-IUPAC
-	806	807	|I-IUPAC
methylcyclohexylamine	807	828	|I-IUPAC
[	829	830	|O
(	830	831	|O
+	831	832	|O
)	832	833	|O
-	833	834	|O
10	834	836	|O
]	836	837	|O
.	837	838	|O
The	839	842	|O
optical	843	850	|O
purity	851	857	|O
(	858	859	|O
greater	859	866	|O
than	867	871	|O
99.5%	872	877	|O
)	877	878	|O
of	879	881	|O
(	882	883	|O
-	883	884	|O
)	884	885	|O
-	885	886	|O
10	886	888	|O
and	889	892	|O
(	893	894	|O
+	894	895	|O
)	895	896	|O
-	896	897	|O
10	897	899	|O
was	900	903	|O
determined	904	914	|O
by	915	917	|O
HPLC	918	922	|O
analysis	923	931	|O
of	932	934	|O
the	935	938	|O
diastereomeric	939	953	|O
ureas	954	959	|O
formed	960	966	|O
by	967	969	|O
reaction	970	978	|O
with	979	983	|O
optically	984	993	|O
pure	994	998	|O
(	999	1000	|B-IUPAC
R	1000	1001	|I-IUPAC
)	1001	1002	|I-IUPAC
-	1002	1003	|I-IUPAC
alpha	1003	1008	|I-IUPAC
-	1008	1009	|I-IUPAC
methylbenzyl	1009	1021	|I-IUPAC
isocyanate	1022	1032	|I-IUPAC
.	1032	1033	|O
The	1034	1037	|O
absolute	1038	1046	|O
configuration	1047	1060	|O
of	1061	1063	|O
(	1064	1065	|O
-	1065	1066	|O
)	1066	1067	|O
-	1067	1068	|O
10	1068	1070	|O
and	1071	1074	|O
(	1075	1076	|O
+	1076	1077	|O
)	1077	1078	|O
-	1078	1079	|O
10	1079	1081	|O
was	1082	1085	|O
determined	1086	1096	|O
by	1097	1099	|O
single	1100	1106	|O
-	1106	1107	|O
crystal	1107	1114	|O
X	1115	1116	|O
-	1116	1117	|O
ray	1117	1120	|O
diffractometry	1121	1135	|O
of	1136	1138	|O
the	1139	1142	|O
bis	1143	1146	|B-IUPAC
-	1146	1147	|I-IUPAC
(	1147	1148	|I-IUPAC
R	1148	1149	|I-IUPAC
)	1149	1150	|I-IUPAC
-	1150	1151	|I-IUPAC
mandelate	1151	1160	|I-IUPAC
salt	1161	1165	|B-MODIFIER
.	1165	1166	|O
Condensation	1167	1179	|O
of	1180	1182	|O
optically	1183	1192	|O
pure	1193	1197	|O
(	1198	1199	|O
-	1199	1200	|O
)	1200	1201	|O
-	1201	1202	|O
10	1202	1204	|O
and	1205	1208	|O
(	1209	1210	|O
+	1210	1211	|O
)	1211	1212	|O
-	1212	1213	|O
10	1213	1215	|O
with	1216	1220	|O
3,4	1221	1224	|B-IUPAC
-	1224	1225	|I-IUPAC
dichlorophenylacetic	1225	1245	|I-IUPAC
acid	1246	1250	|I-IUPAC
furnished	1251	1260	|O
(	1261	1262	|O
+	1262	1263	|O
)	1263	1264	|O
-	1264	1265	|O
1	1265	1266	|O
and	1267	1270	|O
(	1271	1272	|O
-	1272	1273	|O
)	1273	1274	|O
-	1274	1275	|O
1	1275	1276	|O
,	1276	1277	|O
respectively	1278	1290	|O
.	1290	1291	|O
Compounds	1292	1301	|O
(	1302	1303	|O
+	1303	1304	|O
)	1304	1305	|O
-	1305	1306	|O
1	1306	1307	|O
,	1307	1308	|O
(	1309	1310	|O
-	1310	1311	|O
)	1311	1312	|O
-	1312	1313	|O
1	1313	1314	|O
,	1314	1315	|O
(	1316	1317	|O
-	1317	1318	|O
)	1318	1319	|O
-	1319	1320	|O
2	1320	1321	|O
,	1321	1322	|O
and	1323	1326	|O
(	1327	1328	|O
+	1328	1329	|O
)	1329	1330	|O
-	1330	1331	|O
2	1331	1332	|O
were	1333	1337	|O
compared	1338	1346	|O
for	1347	1350	|O
their	1351	1356	|O
binding	1357	1364	|O
affinities	1365	1375	|O
at	1376	1378	|O
kappa	1379	1384	|O
opioid	1385	1391	|O
,	1391	1392	|O
sigma	1393	1398	|O
,	1398	1399	|O
D2	1400	1402	|B-IUPAC
-	1402	1403	|I-IUPAC
dopamine	1403	1411	|I-IUPAC
,	1411	1412	|O
and	1413	1416	|O
phencyclidine	1417	1430	|O
(	1431	1432	|O
PCP	1432	1435	|O
)	1435	1436	|O
receptors	1437	1446	|O
in	1447	1449	|O
competitive	1450	1461	|O
binding	1462	1469	|O
assays	1470	1476	|O
using	1477	1482	|O
[	1483	1484	|O
3H	1484	1486	|O
]	1486	1487	|O
bremazocine	1487	1498	|O
(	1499	1500	|O
[	1500	1501	|O
3H	1501	1503	|O
]	1503	1504	|O
BREM	1504	1508	|O
)	1508	1509	|O
or	1510	1512	|O
[	1513	1514	|O
3H	1514	1516	|O
]	1516	1517	|O
U69	1517	1520	|O
,	1520	1521	|O
593	1521	1524	|O
,	1524	1525	|O
[	1526	1527	|B-IUPAC
3H	1527	1529	|I-IUPAC
]	1529	1530	|I-IUPAC
-	1530	1531	|I-IUPAC
(	1531	1532	|I-IUPAC
+	1532	1533	|I-IUPAC
)	1533	1534	|I-IUPAC
-	1534	1535	|I-IUPAC
3	1535	1536	|I-IUPAC
-	1536	1537	|I-IUPAC
(	1537	1538	|I-IUPAC
3	1538	1539	|I-IUPAC
-	1539	1540	|I-IUPAC
hydroxyphenyl	1540	1553	|I-IUPAC
)	1553	1554	|I-IUPAC
-	1554	1555	|I-IUPAC
N	1555	1556	|I-IUPAC
-	1556	1557	|I-IUPAC
(	1557	1558	|I-IUPAC
1	1558	1559	|I-IUPAC
-	1559	1560	|I-IUPAC
propyl	1560	1566	|I-IUPAC
)	1566	1567	|I-IUPAC
piperidine	1567	1577	|I-IUPAC
[	1578	1579	|O
[	1579	1580	|O
3H	1580	1582	|O
]	1582	1583	|O
-	1583	1584	|O
(	1584	1585	|O
+	1585	1586	|O
)	1586	1587	|O
-	1587	1588	|O
3	1588	1589	|O
-	1589	1590	|O
PPP	1590	1593	|O
]	1593	1594	|O
,	1594	1595	|O
or	1596	1598	|O
[	1599	1600	|B-IUPAC
3H	1600	1602	|I-IUPAC
]	1602	1603	|I-IUPAC
-	1603	1604	|I-IUPAC
1,3	1604	1607	|I-IUPAC
-	1607	1608	|I-IUPAC
di	1608	1610	|I-IUPAC
(	1610	1611	|I-IUPAC
o	1611	1612	|I-IUPAC
-	1612	1613	|I-IUPAC
tolyl	1613	1618	|I-IUPAC
)	1618	1619	|I-IUPAC
guanidine	1619	1628	|I-IUPAC
(	1629	1630	|O
[	1630	1631	|O
3H	1631	1633	|O
]	1633	1634	|O
DTG	1634	1637	|O
)	1637	1638	|O
,	1638	1639	|O
[	1640	1641	|B-IUPAC
3H	1641	1643	|I-IUPAC
]	1643	1644	|I-IUPAC
-	1644	1645	|I-IUPAC
(	1645	1646	|I-IUPAC
-	1646	1647	|I-IUPAC
)	1647	1648	|I-IUPAC
-	1648	1649	|I-IUPAC
sulpiride	1649	1658	|I-IUPAC
[	1659	1660	|O
[	1660	1661	|O
3H	1661	1663	|O
]	1663	1664	|O
-	1664	1665	|O
(	1665	1666	|O
-	1666	1667	|O
)	1667	1668	|O
SULP	1668	1672	|O
]	1672	1673	|O
,	1673	1674	|O
and	1675	1678	|O
[	1679	1680	|B-IUPAC
3H	1680	1682	|I-IUPAC
]	1682	1683	|I-IUPAC
-	1683	1684	|I-IUPAC
1	1684	1685	|I-IUPAC
-	1685	1686	|I-IUPAC
[	1687	1688	|I-IUPAC
1	1688	1689	|I-IUPAC
-	1689	1690	|I-IUPAC
(	1690	1691	|I-IUPAC
2	1691	1692	|I-IUPAC
-	1692	1693	|I-IUPAC
thienyl	1693	1700	|I-IUPAC
)	1700	1701	|I-IUPAC
cyclohexyl	1701	1711	|I-IUPAC
]	1711	1712	|I-IUPAC
piperidine	1712	1722	|I-IUPAC
(	1723	1724	|O
[	1724	1725	|O
3H	1725	1727	|O
]	1727	1728	|O
TCP	1728	1731	|O
)	1731	1732	|O
,	1732	1733	|O
respectively	1734	1746	|O
.	1746	1747	|O
In	1748	1750	|O
the	1751	1754	|O
systems	1755	1762	|O
examined	1763	1771	|O
,	1771	1772	|O
(	1773	1774	|O
-	1774	1775	|O
)	1775	1776	|O
-	1776	1777	|O
2	1777	1778	|O
exhibited	1779	1788	|O
the	1789	1792	|O
highest	1793	1800	|O
affinity	1801	1809	|O
for	1810	1813	|O
kappa	1814	1819	|O
receptors	1820	1829	|O
,	1829	1830	|O
with	1831	1835	|O
a	1836	1837	|O
Ki	1838	1840	|O
of	1841	1843	|O
44	1844	1846	|O
+	1847	1848	|O
/	1848	1849	|O
-	1849	1850	|O
8	1851	1852	|O
nM	1853	1855	|O
.	1855	1856	|O
However	1857	1864	|O
,	1864	1865	|O
(	1866	1867	|O
-	1867	1868	|O
)	1868	1869	|O
-	1869	1870	|O
2	1870	1871	|O
also	1872	1876	|O
showed	1877	1883	|O
moderate	1884	1892	|O
affinity	1893	1901	|O
for	1902	1905	|O
sigma	1906	1911	|O
receptors	1912	1921	|O
,	1921	1922	|O
with	1923	1927	|O
a	1928	1929	|O
Ki	1930	1932	|O
of	1933	1935	|O
594	1936	1939	|O
+	1940	1941	|O
/	1941	1942	|O
-	1942	1943	|O
3	1944	1945	|O
nM	1946	1948	|O
[	1949	1950	|O
[	1950	1951	|O
3H	1951	1953	|O
]	1953	1954	|O
-	1954	1955	|O
(	1955	1956	|O
+	1956	1957	|O
)	1957	1958	|O
-	1958	1959	|O
3	1959	1960	|O
-	1960	1961	|O
PPP	1961	1964	|O
]	1964	1965	|O
.	1965	1966	|O
The	1967	1970	|O
(	1971	1972	|O
1R	1972	1974	|O
,	1974	1975	|O
2R	1975	1977	|O
)	1977	1978	|O
-	1978	1979	|O
(	1979	1980	|O
+	1980	1981	|O
)	1981	1982	|O
-	1982	1983	|O
enantiomer	1983	1993	|O
,	1993	1994	|O
(	1995	1996	|O
+	1996	1997	|O
)	1997	1998	|O
-	1998	1999	|O
2	1999	2000	|O
,	2000	2001	|O
had	2002	2005	|O
low	2006	2009	|O
affinity	2010	2018	|O
for	2019	2022	|O
both	2023	2027	|O
kappa	2028	2033	|O
and	2034	2037	|O
sigma	2038	2043	|O
receptors	2044	2053	|O
,	2053	2054	|O
exhibiting	2055	2065	|O
Ki	2066	2068	|O
values	2069	2075	|O
of	2076	2078	|O
1298	2079	2083	|O
+	2084	2085	|O
/	2085	2086	|O
-	2086	2087	|O
49	2088	2090	|O
nM	2091	2093	|O
at	2094	2096	|O
kappa	2097	2102	|O
(	2103	2104	|O
[	2104	2105	|O
3H	2105	2107	|O
]	2107	2108	|O
BREM	2108	2112	|O
)	2112	2113	|O
and	2114	2117	|O
1270	2118	2122	|O
+	2123	2124	|O
/	2124	2125	|O
-	2125	2126	|O
168	2127	2130	|O
nM	2131	2133	|O
at	2134	2136	|O
sigma	2137	2142	|O
[	2143	2144	|O
[	2144	2145	|O
3H	2145	2147	|O
]	2147	2148	|O
-	2148	2149	|O
(	2149	2150	|O
+	2150	2151	|O
)	2151	2152	|O
-	2152	2153	|O
3	2153	2154	|O
-	2154	2155	|O
PPP	2155	2158	|O
]	2158	2159	|O
.	2159	2160	|O
In	2161	2163	|O
contrast	2164	2172	|O
,	2172	2173	|O
the	2174	2177	|O
chiral	2178	2184	|O
cis	2185	2188	|O
compounds	2189	2198	|O
(	2199	2200	|O
+	2200	2201	|O
)	2201	2202	|O
-	2202	2203	|O
1	2203	2204	|O
and	2205	2208	|O
(	2209	2210	|O
-	2210	2211	|O
)	2211	2212	|O
-	2212	2213	|O
1	2213	2214	|O
showed	2215	2221	|O
high	2222	2226	|O
affinity	2227	2235	|O
for	2236	2239	|O
sigma	2240	2245	|O
receptors	2246	2255	|O
and	2256	2259	|O
negligible	2260	2270	|O
affinity	2271	2279	|O
for	2280	2283	|O
kappa	2284	2289	|O
opioid	2290	2296	|O
receptors	2297	2306	|O
in	2307	2309	|O
the	2310	2313	|O
[	2314	2315	|O
3H	2315	2317	|O
]	2317	2318	|O
BREM	2318	2322	|O
assay	2323	2328	|O
.	2328	2329	|O
Compound	2330	2338	|O
(	2339	2340	|O
-	2340	2341	|O
)	2341	2342	|O
-	2342	2343	|O
1	2343	2344	|O
exhibited	2345	2354	|O
a	2355	2356	|O
Ki	2357	2359	|O
of	2360	2362	|O
81	2363	2365	|O
+	2366	2367	|O
/	2367	2368	|O
-	2368	2369	|O
13	2370	2372	|O
nM	2373	2375	|O
at	2376	2378	|O
sigma	2379	2384	|O
receptors	2385	2394	|O
[	2395	2396	|O
[	2396	2397	|O
3H	2397	2399	|O
]	2399	2400	|O
-	2400	2401	|O
(	2401	2402	|O
+	2402	2403	|O
)	2403	2404	|O
-	2404	2405	|O
3	2405	2406	|O
-	2406	2407	|O
PPP	2407	2410	|O
]	2410	2411	|O
and	2412	2415	|O
250	2416	2419	|O
+	2420	2421	|O
/	2421	2422	|O
-	2422	2423	|O
8	2424	2425	|O
nM	2426	2428	|O
(	2429	2430	|O
[	2430	2431	|O
3H	2431	2433	|O
]	2433	2434	|O
DTG	2434	2437	|O
)	2437	2438	|O
.	2438	2439	|O
(	2439	2440	|O
ABSTRACT	2440	2448	|O
TRUNCATED	2449	2458	|O
AT	2459	2461	|O
400	2462	2465	|O
WORDS	2466	2471	|O
)	2471	2472	|O

### abstracts642.txt
Previously	0	10	|O
,	10	11	|O
(	12	13	|B-IUPAC
R	13	14	|I-IUPAC
)	14	15	|I-IUPAC
-	15	16	|I-IUPAC
quinuclidinyl	16	29	|I-IUPAC
(	30	31	|I-IUPAC
R	31	32	|I-IUPAC
)	32	33	|I-IUPAC
-	33	34	|I-IUPAC
4	34	35	|I-IUPAC
-	35	36	|I-IUPAC
iodobenzilate	36	49	|I-IUPAC
(	50	51	|O
(	51	52	|O
R	52	53	|O
,	53	54	|O
R	54	55	|O
)	55	56	|O
-	56	57	|O
IQNB	57	61	|O
)	61	62	|O
,	62	63	|O
a	64	65	|O
muscarinic	66	76	|O
receptor	77	85	|O
antagonist	86	96	|O
,	96	97	|O
has	98	101	|O
been	102	106	|O
labeled	107	114	|O
with	115	119	|O
123I	120	124	|O
and	125	128	|O
125I	129	133	|O
for	134	137	|O
use	138	141	|O
in	142	144	|O
in	145	147	|O
vitro	148	153	|O
and	154	157	|O
in	158	160	|O
vivo	161	165	|O
studies	166	173	|O
in	174	176	|O
animals	177	184	|O
and	185	188	|O
humans	189	195	|O
.	195	196	|O
We	197	199	|O
have	200	204	|O
prepared	205	213	|O
fluoroalkyl	214	225	|O
analogs	226	233	|O
of	234	236	|O
QNB	237	240	|O
,	240	241	|O
which	242	247	|O
are	248	251	|O
amenable	252	260	|O
to	261	263	|O
labeling	264	272	|O
with	273	277	|O
18F	278	281	|O
,	281	282	|O
for	283	286	|O
potential	287	296	|O
imaging	297	304	|O
applications	305	317	|O
with	318	322	|O
positron	323	331	|O
emission	332	340	|O
tomography	341	351	|O
.	351	352	|O
The	353	356	|O
enantiomers	357	368	|O
of	369	371	|O
(	372	373	|O
fluoroalkyl	373	384	|O
)	384	385	|O
benzilic	385	393	|O
acids	394	399	|O
were	400	404	|O
prepared	405	413	|O
via	414	417	|O
an	418	420	|O
enantioselective	421	437	|O
Grignard	438	446	|O
addition	447	455	|O
reaction	456	464	|O
.	464	465	|O
Subsequent	466	476	|O
coupling	477	485	|O
of	486	488	|O
the	489	492	|O
enantiomeric	493	505	|B-MODIFIER
(	506	507	|B-IUPAC
fluoroalkyl	507	518	|I-IUPAC
)	518	519	|I-IUPAC
benzilic	519	527	|I-IUPAC
acid	528	532	|I-IUPAC
with	533	537	|O
a	538	539	|O
selected	540	548	|O
enantiomer	549	559	|O
of	560	562	|O
quinuclidinol	563	576	|O
provides	577	585	|O
fluorinated	586	597	|O
analogs	598	605	|O
of	606	608	|O
QNB	609	612	|O
with	613	617	|O
known	618	623	|O
stereochemistry	624	639	|O
at	640	642	|O
each	643	647	|O
of	648	650	|O
the	651	654	|O
stereogenic	655	666	|O
centers	667	674	|O
.	674	675	|O
These	676	681	|O
compounds	682	691	|O
exhibit	692	699	|O
different	700	709	|O
affinities	710	720	|O
for	721	724	|O
the	725	728	|O
muscarinic	729	739	|O
receptor	740	748	|O
tissue	749	755	|O
subtypes	756	764	|O
in	765	767	|O
vitro	768	773	|O
.	773	774	|O
(	775	776	|B-IUPAC
R	776	777	|I-IUPAC
,	777	778	|I-IUPAC
R	778	779	|I-IUPAC
)	779	780	|I-IUPAC
-	780	781	|I-IUPAC
4	781	782	|I-IUPAC
-	782	783	|I-IUPAC
(	783	784	|I-IUPAC
Fluoromethyl	784	796	|I-IUPAC
)	796	797	|I-IUPAC
-	797	798	|I-IUPAC
QNB	798	801	|I-IUPAC
,	801	802	|O
and	803	806	|O
(	807	808	|O
R	808	809	|O
,	809	810	|O
R	810	811	|O
)	811	812	|O
-	812	813	|O
IQNB	813	817	|O
,	817	818	|O
and	819	822	|O
(	823	824	|B-IUPAC
R	824	825	|I-IUPAC
,	825	826	|I-IUPAC
R	826	827	|I-IUPAC
)	827	828	|I-IUPAC
-	828	829	|I-IUPAC
4	829	830	|I-IUPAC
-	830	831	|I-IUPAC
(	831	832	|I-IUPAC
fluoroethyl	832	843	|I-IUPAC
)	843	844	|I-IUPAC
-	844	845	|I-IUPAC
QNB	845	848	|I-IUPAC
exhibit	849	856	|O
selectivity	857	868	|O
for	869	872	|O
the	873	876	|O
M1	877	879	|O
subtype	880	887	|O
,	887	888	|O
and	889	892	|O
(	893	894	|B-IUPAC
R	894	895	|I-IUPAC
,	895	896	|I-IUPAC
S	896	897	|I-IUPAC
)	897	898	|I-IUPAC
-	898	899	|I-IUPAC
4	899	900	|I-IUPAC
-	900	901	|I-IUPAC
(	901	902	|I-IUPAC
fluoromethyl	902	914	|I-IUPAC
)	914	915	|I-IUPAC
-	915	916	|I-IUPAC
QNB	916	919	|I-IUPAC
exhibits	920	928	|O
selectivity	929	940	|O
for	941	944	|O
the	945	948	|O
M2	949	951	|O
subtype	952	959	|O
.	959	960	|O

### abstracts4642.txt
Hypoxic	0	7	|O
cells	8	13	|O
of	14	16	|O
solid	17	22	|O
tumors	23	29	|O
are	30	33	|O
an	34	36	|O
obstacle	37	45	|O
to	46	48	|O
effective	49	58	|O
cancer	59	65	|O
therapy	66	73	|O
.	73	74	|O
Since	75	80	|O
hypoxic	81	88	|O
cells	89	94	|O
remote	95	101	|O
from	102	106	|O
the	107	110	|O
tumor	111	116	|O
blood	117	122	|O
supply	123	129	|O
may	130	133	|O
have	134	138	|O
a	139	140	|O
greater	141	148	|O
capacity	149	157	|O
for	158	161	|O
reductive	162	171	|O
reactions	172	181	|O
than	182	186	|O
well	187	191	|O
-	191	192	|O
oxygenated	192	202	|O
cells	203	208	|O
,	208	209	|O
we	210	212	|O
have	213	217	|O
prepared	218	226	|O
a	227	228	|O
series	229	235	|O
of	236	238	|O
anthraquinone	239	252	|O
prodrugs	253	261	|O
which	262	267	|O
may	268	271	|O
be	272	274	|O
capable	275	282	|O
of	283	285	|O
generating	286	296	|O
a	297	298	|O
reactive	299	307	|O
quinonemethide	308	322	|O
species	323	330	|O
following	331	340	|O
enzymatic	341	350	|O
reduction	351	360	|O
to	361	363	|O
the	364	367	|O
hydroquinone	368	380	|O
and	381	384	|O
loss	385	389	|O
of	390	392	|O
the	393	396	|O
substituent	397	408	|O
on	409	411	|O
the	412	415	|O
methylene	416	425	|O
group	426	431	|O
in	432	434	|O
the	435	438	|O
2	439	440	|O
position	441	449	|O
.	449	450	|O
The	451	454	|O
synthesized	455	466	|O
2	467	468	|B-IUPAC
-	468	469	|I-IUPAC
methyl	469	475	|I-IUPAC
-	475	476	|O
substituted	476	487	|B-MODIFIER
anthraquinone	488	501	|B-IUPAC
derivatives	502	513	|B-MODIFIER
have	514	518	|O
first	519	524	|O
half	525	529	|O
-	529	530	|O
wave	530	534	|O
reduction	535	544	|O
potentials	545	555	|O
of	556	558	|O
-	559	560	|O
0.52	560	564	|O
to	565	567	|O
-	568	569	|O
0.56	569	573	|O
V	574	575	|O
at	576	578	|O
pH	579	581	|O
7.0	582	585	|O
,	585	586	|O
which	587	592	|O
are	593	596	|O
the	597	600	|O
lowest	601	607	|O
oxidation	608	617	|O
-	617	618	|O
reduction	618	627	|O
potentials	628	638	|O
of	639	641	|O
quinone	642	649	|O
bioreductive	650	662	|O
alkylating	663	673	|O
agents	674	680	|O
synthesized	681	692	|O
by	693	695	|O
this	696	700	|O
laboratory	701	711	|O
to	712	714	|O
date	715	719	|O
.	719	720	|O
Tests	721	726	|O
of	727	729	|O
the	730	733	|O
cytotoxicity	734	746	|O
of	747	749	|O
these	750	755	|O
agents	756	762	|O
to	763	765	|O
oxygenated	766	776	|O
and	777	780	|O
chronically	781	792	|O
hypoxic	793	800	|O
EMT6	801	805	|O
tumor	806	811	|O
cells	812	817	|O
in	818	820	|O
culture	821	828	|O
demonstrated	829	841	|O
that	842	846	|O
2	847	848	|B-IUPAC
-	848	849	|I-IUPAC
(	849	850	|I-IUPAC
hydroxymethyl	850	863	|I-IUPAC
)	863	864	|I-IUPAC
anthraquinone	864	877	|I-IUPAC
,	877	878	|O
2	879	880	|B-IUPAC
-	880	881	|I-IUPAC
[	881	882	|I-IUPAC
(	882	883	|I-IUPAC
N	883	884	|I-IUPAC
-	884	885	|I-IUPAC
methylcarbamyl	885	899	|I-IUPAC
)	899	900	|I-IUPAC
-	900	901	|I-IUPAC
methyl	901	907	|I-IUPAC
]	907	908	|I-IUPAC
anthraquinone	908	921	|I-IUPAC
,	921	922	|O
2	923	924	|B-IUPAC
-	924	925	|I-IUPAC
[	925	926	|I-IUPAC
[	926	927	|I-IUPAC
(	927	928	|I-IUPAC
p	928	929	|I-IUPAC
-	929	930	|I-IUPAC
toluenesulfonyl	930	945	|I-IUPAC
)	945	946	|I-IUPAC
oxy	946	949	|I-IUPAC
]	949	950	|I-IUPAC
methyl	950	956	|I-IUPAC
]	956	957	|I-IUPAC
anthraquinone	957	970	|I-IUPAC
,	970	971	|O
and	972	975	|O
2	976	977	|B-IUPAC
-	977	978	|I-IUPAC
(	978	979	|I-IUPAC
methoxymethyl	979	992	|I-IUPAC
)	992	993	|I-IUPAC
anthraquinone	993	1006	|I-IUPAC
were	1007	1011	|O
significantly	1012	1025	|O
more	1026	1030	|O
toxic	1031	1036	|O
to	1037	1039	|O
hypoxic	1040	1047	|O
cells	1048	1053	|O
than	1054	1058	|O
to	1059	1061	|O
their	1062	1067	|O
normally	1068	1076	|O
aerated	1077	1084	|O
counterparts	1085	1097	|O
.	1097	1098	|O
The	1099	1102	|O
findings	1103	1111	|O
demonstrate	1112	1123	|O
differences	1124	1135	|O
between	1136	1143	|O
various	1144	1151	|O
leaving	1152	1159	|O
groups	1160	1166	|O
in	1167	1169	|O
the	1170	1173	|O
2	1174	1175	|O
position	1176	1184	|O
for	1185	1188	|O
the	1189	1192	|O
expression	1193	1203	|O
of	1204	1206	|O
differential	1207	1219	|O
cytotoxicity	1220	1232	|O
.	1232	1233	|O

### abstracts3005.txt
Fourteen	0	8	|O
125I	9	13	|O
-	13	14	|O
labeled	14	21	|O
aralkylguanidines	22	39	|O
were	40	44	|O
synthesized	45	56	|O
and	57	60	|O
evaluated	61	70	|O
as	71	73	|O
potential	74	83	|O
imaging	84	91	|O
agents	92	98	|O
for	99	102	|O
the	103	106	|O
adrenal	107	114	|O
medullae	115	123	|O
and	124	127	|O
tumors	128	134	|O
of	135	137	|O
adrenomedullary	138	153	|O
origin	154	160	|O
.	160	161	|O
These	162	167	|O
guanidines	168	178	|O
are	179	182	|O
radiotracer	183	194	|O
analogues	195	204	|O
of	205	207	|O
guanethidine	208	220	|O
,	220	221	|O
an	222	224	|O
antihypertensive	225	241	|O
agent	242	247	|O
thought	248	255	|O
to	256	258	|O
mediate	259	266	|O
neuron	267	273	|O
blockade	274	282	|O
by	283	285	|O
uptake	286	292	|O
into	293	297	|O
adrenergic	298	308	|O
nerves	309	315	|O
.	315	316	|O
Dog	317	320	|O
adrenal	321	328	|O
medullae	329	337	|O
were	338	342	|O
used	343	347	|O
as	348	350	|O
a	351	352	|O
model	353	358	|O
to	359	361	|O
test	362	366	|O
radiotracer	367	378	|O
affinity	379	387	|O
for	388	391	|O
catecholamine	392	405	|O
storage	406	413	|O
tissue	414	420	|O
.	420	421	|O
Tissue	422	428	|O
distribution	429	441	|O
studies	442	449	|O
revealed	450	458	|O
that	459	463	|O
a	464	465	|O
number	466	472	|O
of	473	475	|O
radioiodinated	476	490	|O
guanidines	491	501	|O
showed	502	508	|O
pronounced	509	519	|O
localization	520	532	|O
in	533	535	|O
the	536	539	|O
adrenal	540	547	|O
medullae	548	556	|O
following	557	566	|O
intravenous	567	578	|O
injection	579	588	|O
,	588	589	|O
in	590	592	|O
certain	593	600	|O
cases	601	606	|O
exceeding	607	616	|O
that	617	621	|O
of	622	624	|O
either	625	631	|O
(	632	633	|B-IUPAC
-	633	634	|I-IUPAC
)	634	635	|I-IUPAC
-	635	636	|I-IUPAC
[	636	637	|I-IUPAC
3H	637	639	|I-IUPAC
]	639	640	|I-IUPAC
norepinephrine	640	654	|I-IUPAC
or	655	657	|O
[	658	659	|B-IUPAC
14C	659	662	|I-IUPAC
]	662	663	|I-IUPAC
guanethidine	663	675	|I-IUPAC
.	675	676	|O
(	677	678	|B-IUPAC
m	678	679	|I-IUPAC
-	679	680	|I-IUPAC
[	680	681	|I-IUPAC
125I	681	685	|I-IUPAC
]	685	686	|I-IUPAC
Iodobenzyl	686	696	|I-IUPAC
)	696	697	|I-IUPAC
guanidine	697	706	|I-IUPAC
(	707	708	|O
m	708	709	|O
-	709	710	|O
IBG	710	713	|O
,	713	714	|O
2b	715	717	|O
)	717	718	|O
gave	719	723	|O
the	724	727	|O
best	728	732	|O
combination	733	744	|O
of	745	747	|O
high	748	752	|O
concentration	753	766	|O
and	767	770	|O
selectivity	771	782	|O
.	782	783	|O
The	784	787	|O
low	788	791	|O
adrenomedullary	792	807	|O
affinity	808	816	|O
observed	817	825	|O
with	826	830	|O
[	831	832	|B-IUPAC
14C	832	835	|I-IUPAC
]	835	836	|I-IUPAC
guanidine	836	845	|I-IUPAC
and	846	849	|O
m	850	851	|B-IUPAC
-	851	852	|I-IUPAC
[	852	853	|I-IUPAC
125I	853	857	|I-IUPAC
]	857	858	|I-IUPAC
iodobenzylamine	858	873	|I-IUPAC
demonstrates	874	886	|O
the	887	890	|O
uniqueness	891	901	|O
of	902	904	|O
the	905	908	|O
aralkylguanidine	909	925	|O
structure	926	935	|O
.	935	936	|O
Preliminary	937	948	|O
evidence	949	957	|O
suggests	958	966	|O
that	967	971	|O
2b	972	974	|O
is	975	977	|O
a	978	979	|O
storage	980	987	|O
analogue	988	996	|O
of	997	999	|O
norepinephrine	1000	1014	|O
.	1014	1015	|O
[	1016	1017	|O
125I	1017	1021	|O
]	1021	1022	|O
2a	1022	1024	|O
is	1025	1027	|O
now	1028	1031	|O
being	1032	1037	|O
used	1038	1042	|O
clinically	1043	1053	|O
in	1054	1056	|O
imaging	1057	1064	|O
and	1065	1068	|O
radiotherapy	1069	1081	|O
of	1082	1084	|O
catecholamine	1085	1098	|O
tumors	1099	1105	|O
,	1105	1106	|O
such	1107	1111	|O
as	1112	1114	|O
pheochromocytoma	1115	1131	|O
.	1131	1132	|O

### abstracts626.txt
The	0	3	|O
1,2	4	7	|B-IUPAC
-	7	8	|I-IUPAC
dihydropyrido	8	21	|I-IUPAC
[	21	22	|I-IUPAC
3,4	22	25	|I-IUPAC
-	25	26	|I-IUPAC
b	26	27	|I-IUPAC
]	27	28	|I-IUPAC
pyrazines	28	37	|I-IUPAC
(	38	39	|O
1	39	40	|O
)	40	41	|O
are	42	45	|O
mitotic	46	53	|O
inhibitors	54	64	|O
with	65	69	|O
significant	70	81	|O
antitumor	82	91	|O
activity	92	100	|O
in	101	103	|O
mice	104	108	|O
.	108	109	|O
Also	110	114	|O
,	114	115	|O
the	116	119	|O
active	120	126	|O
imidazo	127	134	|B-IUPAC
[	134	135	|I-IUPAC
4,5	135	138	|I-IUPAC
-	138	139	|I-IUPAC
b	139	140	|I-IUPAC
]	140	141	|I-IUPAC
pyridine	141	149	|I-IUPAC
3	150	151	|O
was	152	155	|O
shown	156	161	|O
to	162	164	|O
cause	165	170	|O
the	171	174	|O
accumulation	175	187	|O
of	188	190	|O
cells	191	196	|O
at	197	199	|O
mitosis	200	207	|O
.	207	208	|O
Routes	209	215	|O
were	216	220	|O
developed	221	230	|O
for	231	234	|O
the	235	238	|O
synthesis	239	248	|O
of	249	251	|O
congeners	252	261	|O
of	262	264	|O
3	265	266	|O
by	267	269	|O
cyclization	270	281	|O
of	282	284	|O
4	285	286	|B-PARTIUPAC
-	286	287	|I-PARTIUPAC
(	287	288	|O
substituted	288	299	|B-MODIFIER
amino	300	305	|B-IUPAC
)	305	306	|O
-	306	307	|B-PARTIUPAC
5,6	307	310	|I-PARTIUPAC
-	310	311	|I-PARTIUPAC
diaminopyridines	311	327	|I-PARTIUPAC
with	328	332	|O
ethyl	333	338	|O
orthoformate	339	351	|O
.	351	352	|O
Oxidative	353	362	|O
cyclization	363	374	|O
of	375	377	|O
either	378	384	|O
4,5	385	388	|B-PARTIUPAC
-	388	389	|I-PARTIUPAC
or	390	392	|O
5,6	393	396	|B-IUPAC
-	396	397	|I-IUPAC
diaminopyridines	397	413	|I-IUPAC
with	414	418	|O
aryl	419	423	|O
aldehydes	424	433	|O
produced	434	442	|O
the	443	446	|O
[	447	448	|O
4,5	448	451	|O
-	451	452	|O
c	452	453	|O
]	453	454	|O
and	455	458	|O
[	459	460	|O
4,5	460	463	|O
-	463	464	|O
b	464	465	|O
]	465	466	|O
imidazopyridine	467	482	|O
ring	483	487	|O
systems	488	495	|O
,	495	496	|O
respectively	497	509	|O
.	509	510	|O
The	511	514	|O
latter	515	521	|O
reaction	522	530	|O
with	531	535	|O
6	536	537	|B-PARTIUPAC
-	537	538	|I-PARTIUPAC
(	538	539	|O
substituted	539	550	|B-MODIFIER
amino	551	556	|B-IUPAC
)	556	557	|O
-	557	558	|B-PARTIUPAC
4,5	558	561	|I-PARTIUPAC
-	561	562	|I-PARTIUPAC
diaminopyridines	562	578	|I-PARTIUPAC
gave	579	583	|O
imidazo	584	591	|B-IUPAC
[	591	592	|I-IUPAC
4,5	592	595	|I-IUPAC
-	595	596	|I-IUPAC
c	596	597	|I-IUPAC
]	597	598	|I-IUPAC
pyridine	598	606	|I-IUPAC
ring	607	611	|B-MODIFIER
analogues	612	621	|I-MODIFIER
of	622	624	|O
1	625	626	|O
.	626	627	|O
Biological	628	638	|O
studies	639	646	|O
indicated	647	656	|O
that	657	661	|O
the	662	665	|O
target	666	672	|O
compounds	673	682	|O
were	683	687	|O
less	688	692	|O
active	693	699	|O
than	700	704	|O
1	705	706	|O
and	707	710	|O
3	711	712	|O
.	712	713	|O

### abstracts2872.txt
The	0	3	|O
design	4	10	|O
,	10	11	|O
synthesis	12	21	|O
,	21	22	|O
and	23	26	|O
pharmacological	27	42	|O
properties	43	53	|O
of	54	56	|O
a	57	58	|O
novel	59	64	|O
type	65	69	|O
of	70	72	|O
4	73	74	|B-IUPAC
-	74	75	|I-IUPAC
(	75	76	|I-IUPAC
1,2,5,6	76	83	|I-IUPAC
-	83	84	|I-IUPAC
tetrahydro	84	94	|I-IUPAC
-	94	95	|I-IUPAC
1	95	96	|I-IUPAC
-	96	97	|I-IUPAC
alkyl	97	102	|I-IUPAC
-	102	103	|I-IUPAC
3	103	104	|I-IUPAC
-	104	105	|I-IUPAC
pyridinyl	105	114	|I-IUPAC
)	114	115	|I-IUPAC
-	115	116	|I-IUPAC
2	116	117	|I-IUPAC
-	117	118	|I-IUPAC
thiazolamine	118	130	|I-IUPAC
with	131	135	|O
dopaminergic	136	148	|O
properties	149	159	|O
are	160	163	|O
described	164	173	|O
.	173	174	|O
In	175	177	|O
particular	178	188	|O
,	188	189	|O
4	190	191	|B-IUPAC
-	191	192	|I-IUPAC
(	192	193	|I-IUPAC
1,2,5,6	193	200	|I-IUPAC
-	200	201	|I-IUPAC
tetrahydro	201	211	|I-IUPAC
-	211	212	|I-IUPAC
1	212	213	|I-IUPAC
-	213	214	|I-IUPAC
propyl	214	220	|I-IUPAC
-	220	221	|I-IUPAC
3	221	222	|I-IUPAC
-	222	223	|I-IUPAC
pyridinyl	223	232	|I-IUPAC
)	232	233	|I-IUPAC
-	233	234	|I-IUPAC
2	234	235	|I-IUPAC
-	235	236	|I-IUPAC
thiazolamine	236	248	|I-IUPAC
(	249	250	|O
4c	250	252	|O
,	252	253	|O
PD	254	256	|O
118440	257	263	|O
)	263	264	|O
and	265	268	|O
its	269	272	|O
allyl	273	278	|B-IUPAC
analogue	279	287	|B-MODIFIER
(	288	289	|O
4i	289	291	|O
,	291	292	|O
PD	293	295	|O
120697	296	302	|O
)	302	303	|O
have	304	308	|O
been	309	313	|O
identified	314	324	|O
as	325	327	|O
orally	328	334	|O
active	335	341	|O
dopamine	342	350	|O
(	351	352	|O
DA	352	354	|O
)	354	355	|O
agonists	356	364	|O
with	365	369	|O
pronounced	370	380	|O
central	381	388	|O
nervous	389	396	|O
system	397	403	|O
effects	404	411	|O
in	412	414	|O
tests	415	420	|O
that	421	425	|O
include	426	433	|O
[	434	435	|B-IUPAC
3H	435	437	|I-IUPAC
]	437	438	|I-IUPAC
-	438	439	|I-IUPAC
haloperidol	439	450	|I-IUPAC
and	451	454	|O
[	455	456	|B-IUPAC
3H	456	458	|I-IUPAC
]	458	459	|I-IUPAC
-	459	460	|I-IUPAC
N	460	461	|I-IUPAC
-	461	462	|I-IUPAC
propylnorapomorphine	462	482	|I-IUPAC
binding	483	490	|O
,	490	491	|O
inhibition	492	502	|O
of	503	505	|O
striatal	506	514	|O
DA	515	517	|O
synthesis	518	527	|O
,	527	528	|O
inhibition	529	539	|O
of	540	542	|O
DA	543	545	|O
neuronal	546	554	|O
firing	555	561	|O
,	561	562	|O
inhibition	563	573	|O
of	574	576	|O
spontaneous	577	588	|O
locomotor	589	598	|O
activity	599	607	|O
,	607	608	|O
and	609	612	|O
reversal	613	621	|O
of	622	624	|O
reserpine	625	634	|O
-	634	635	|O
induced	635	642	|O
depression	643	653	|O
in	654	656	|O
rats	657	661	|O
.	661	662	|O
The	663	666	|O
DA	667	669	|O
autoreceptor	670	682	|O
selectivity	683	694	|O
of	695	697	|O
these	698	703	|O
heterocyclic	704	716	|O
analogues	717	726	|O
of	727	729	|O
3	730	731	|B-IUPAC
-	731	732	|I-IUPAC
(	732	733	|I-IUPAC
1	733	734	|I-IUPAC
-	734	735	|I-IUPAC
propyl	735	741	|I-IUPAC
-	741	742	|I-IUPAC
3	742	743	|I-IUPAC
-	743	744	|I-IUPAC
piperidinyl	744	755	|I-IUPAC
)	755	756	|I-IUPAC
phenol	756	762	|I-IUPAC
(	763	764	|O
3	764	765	|O
-	765	766	|O
PPP	766	769	|O
)	769	770	|O
was	771	774	|O
also	775	779	|O
evaluated	780	789	|O
.	789	790	|O
In	791	793	|O
this	794	798	|O
series	799	805	|O
,	805	806	|O
DA	807	809	|O
agonist	810	817	|O
activity	818	826	|O
was	827	830	|O
found	831	836	|O
to	837	839	|O
be	840	842	|O
highly	843	849	|O
dependent	850	859	|O
on	860	862	|O
the	863	866	|O
size	867	871	|O
of	872	874	|O
the	875	878	|O
N	879	880	|B-IUPAC
-	880	881	|I-IUPAC
alkyl	881	886	|I-IUPAC
substituent	887	898	|B-MODIFIER
,	898	899	|O
the	900	903	|O
saturation	904	914	|O
level	915	920	|O
of	921	923	|O
the	924	927	|O
six	928	931	|O
-	931	932	|O
membered	932	940	|O
ring	941	945	|O
,	945	946	|O
and	947	950	|O
the	951	954	|O
mode	955	959	|O
of	960	962	|O
attachment	963	973	|O
of	974	976	|O
the	977	980	|O
2	981	982	|B-IUPAC
-	982	983	|I-IUPAC
aminothiazole	983	996	|I-IUPAC
ring	997	1001	|B-MODIFIER
.	1001	1002	|O

### abstracts218.txt
Diarylguanidines	0	16	|O
,	16	17	|O
acting	18	24	|O
as	25	27	|O
NMDA	28	32	|O
receptor	33	41	|O
ion	42	45	|O
channel	46	53	|O
site	54	58	|O
ligands	59	66	|O
,	66	67	|O
represent	68	77	|O
a	78	79	|O
new	80	83	|O
class	84	89	|O
of	90	92	|O
potential	93	102	|O
neuroprotective	103	118	|O
drugs	119	124	|O
.	124	125	|O
Several	126	133	|O
diarylguanidines	134	150	|O
structurally	151	163	|O
related	164	171	|O
to	172	174	|O
N	175	176	|B-IUPAC
,	176	177	|I-IUPAC
N'	177	179	|I-IUPAC
-	179	180	|I-IUPAC
di	180	182	|I-IUPAC
-	182	183	|I-IUPAC
o	183	184	|I-IUPAC
-	184	185	|I-IUPAC
tolylguanidine	185	199	|I-IUPAC
(	200	201	|O
DTG	201	204	|O
)	204	205	|O
,	205	206	|O
a	207	208	|O
known	209	214	|O
selective	215	224	|O
sigma	225	230	|O
receptor	231	239	|O
ligand	240	246	|O
,	246	247	|O
were	248	252	|O
synthesized	253	264	|O
and	265	268	|O
evaluated	269	278	|O
in	279	281	|O
in	282	284	|O
vitro	285	290	|O
radioligand	291	302	|O
displacement	303	315	|O
assays	316	322	|O
,	322	323	|O
with	324	328	|O
rat	329	332	|O
or	333	335	|O
guinea	336	342	|O
pig	343	346	|O
brain	347	352	|O
membrane	353	361	|O
homogenates	362	373	|O
,	373	374	|O
using	375	380	|O
the	381	384	|O
NMDA	385	389	|O
receptor	390	398	|O
ion	399	402	|O
channel	403	410	|O
site	411	415	|O
specific	416	424	|O
radioligand	425	436	|O
[	437	438	|B-IUPAC
3H	438	440	|I-IUPAC
]	440	441	|I-IUPAC
-	441	442	|I-IUPAC
(	442	443	|I-IUPAC
+	443	444	|I-IUPAC
)	444	445	|I-IUPAC
-	445	446	|I-IUPAC
5	446	447	|I-IUPAC
(	447	448	|I-IUPAC
S	448	449	|I-IUPAC
)	449	450	|I-IUPAC
-	450	451	|I-IUPAC
methyl	451	457	|I-IUPAC
-	457	458	|I-IUPAC
10	458	460	|I-IUPAC
(	460	461	|I-IUPAC
R	461	462	|I-IUPAC
)	462	463	|I-IUPAC
,	463	464	|I-IUPAC
11	464	466	|I-IUPAC
-	466	467	|I-IUPAC
dihydro	467	474	|I-IUPAC
-	474	475	|I-IUPAC
5H	475	477	|I-IUPAC
-	477	478	|I-IUPAC
dibenzo	478	485	|I-IUPAC
[	485	486	|I-IUPAC
a	486	487	|I-IUPAC
,	487	488	|I-IUPAC
d	488	489	|I-IUPAC
]	489	490	|I-IUPAC
cyclohepten	490	501	|I-IUPAC
-	501	502	|I-IUPAC
5	502	503	|I-IUPAC
,	504	505	|I-IUPAC
10	505	507	|I-IUPAC
-	507	508	|I-IUPAC
imine	509	514	|I-IUPAC
(	515	516	|O
MK	516	518	|O
-	518	519	|O
801	519	522	|O
,	522	523	|O
3	524	525	|O
)	525	526	|O
,	526	527	|O
and	528	531	|O
the	532	535	|O
sigma	536	541	|O
receptor	542	550	|O
-	550	551	|O
specific	551	559	|O
radioligand	560	571	|O
[	572	573	|B-IUPAC
3H	573	575	|I-IUPAC
]	575	576	|I-IUPAC
-	576	577	|I-IUPAC
di	577	579	|I-IUPAC
-	579	580	|I-IUPAC
o	580	581	|I-IUPAC
-	581	582	|I-IUPAC
tolylguanidine	582	596	|I-IUPAC
(	597	598	|O
DTG	598	601	|O
,	601	602	|O
5	603	604	|O
)	604	605	|O
.	605	606	|O
This	607	611	|O
paper	612	617	|O
presents	618	626	|O
the	627	630	|O
structure	631	640	|O
-	640	641	|O
activity	641	649	|O
relationships	650	663	|O
leading	664	671	|O
to	672	674	|O
novel	675	680	|O
tri	681	684	|B-MODIFIER
-	684	685	|I-MODIFIER
and	686	689	|O
tetrasubstituted	690	706	|B-MODIFIER
guanidines	707	717	|B-IUPAC
,	717	718	|O
which	719	724	|O
exhibit	725	732	|O
high	733	737	|O
selectivity	738	749	|O
for	750	753	|O
NMDA	754	758	|O
receptor	759	767	|O
ion	768	771	|O
channel	772	779	|O
sites	780	785	|O
and	786	789	|O
weak	790	794	|O
or	795	797	|O
negligible	798	808	|O
affinity	809	817	|O
for	818	821	|O
sigma	822	827	|O
receptors	828	837	|O
.	837	838	|O
The	839	842	|O
in	843	845	|O
vitro	846	851	|O
binding	852	859	|O
results	860	867	|O
from	868	872	|O
symmetrically	873	886	|O
substituted	887	898	|O
diphenylguanidines	899	917	|O
indicated	918	927	|O
that	928	932	|O
compounds	933	942	|O
having	943	949	|O
ortho	950	955	|O
or	956	958	|O
meta	959	963	|O
substituents	964	976	|O
(	977	978	|O
with	978	982	|O
respect	983	990	|O
to	991	993	|O
the	994	997	|O
position	998	1006	|O
of	1007	1009	|O
the	1010	1013	|O
guanidine	1014	1023	|O
nitrogen	1024	1032	|O
)	1032	1033	|O
on	1034	1036	|O
the	1037	1040	|O
phenyl	1041	1047	|O
rings	1048	1053	|O
showed	1054	1060	|O
greater	1061	1068	|O
affinity	1069	1077	|O
for	1078	1081	|O
the	1082	1085	|O
NMDA	1086	1090	|O
receptor	1091	1099	|O
ion	1100	1103	|O
channel	1104	1111	|O
site	1112	1116	|O
compared	1117	1125	|O
with	1126	1130	|O
para	1131	1135	|O
-	1135	1136	|O
substituted	1136	1147	|O
derivatives	1148	1159	|O
.	1159	1160	|O
Among	1161	1166	|O
the	1167	1170	|O
group	1171	1176	|O
of	1177	1179	|O
ring	1180	1184	|O
substituents	1185	1197	|O
studied	1198	1205	|O
for	1206	1209	|O
symmetrical	1210	1221	|O
diarylguanidines	1222	1238	|O
,	1238	1239	|O
an	1240	1242	|O
isopropyl	1243	1252	|B-IUPAC
group	1253	1258	|B-MODIFIER
was	1259	1262	|O
preferred	1263	1272	|O
at	1273	1275	|O
the	1276	1279	|O
ortho	1280	1285	|O
position	1286	1294	|O
and	1295	1298	|O
an	1299	1301	|O
ethyl	1302	1307	|O
group	1308	1313	|O
was	1314	1317	|O
preferred	1318	1327	|O
at	1328	1330	|O
the	1331	1334	|O
meta	1335	1339	|O
position	1340	1348	|O
.	1348	1349	|O
Several	1350	1357	|O
unsymmetrical	1358	1371	|O
guanidines	1372	1382	|O
containing	1383	1393	|O
a	1394	1395	|O
naphthalene	1396	1407	|O
ring	1408	1412	|O
on	1413	1415	|O
one	1416	1419	|O
nitrogen	1420	1428	|O
atom	1429	1433	|O
and	1434	1437	|O
an	1438	1440	|O
ortho	1441	1446	|O
-	1446	1447	|O
or	1448	1450	|O
a	1451	1452	|O
meta	1453	1457	|O
-	1457	1458	|O
substituted	1458	1469	|O
phenyl	1470	1476	|O
ring	1477	1481	|O
on	1482	1484	|O
the	1485	1488	|O
second	1489	1495	|O
nitrogen	1496	1504	|O
atom	1505	1509	|O
,	1509	1510	|O
e.g.	1511	1515	|O
,	1515	1516	|O
N	1517	1518	|B-IUPAC
-	1518	1519	|I-IUPAC
1	1519	1520	|I-IUPAC
-	1520	1521	|I-IUPAC
naphthyl	1521	1529	|I-IUPAC
-	1529	1530	|I-IUPAC
N'	1530	1532	|I-IUPAC
-	1532	1533	|I-IUPAC
(	1533	1534	|I-IUPAC
3	1534	1535	|I-IUPAC
-	1535	1536	|I-IUPAC
ethylphenyl	1536	1547	|I-IUPAC
)	1547	1548	|I-IUPAC
guanidine	1548	1557	|I-IUPAC
(	1558	1559	|O
36	1559	1561	|O
)	1561	1562	|O
,	1562	1563	|O
showed	1564	1570	|O
a	1571	1572	|O
3-5	1573	1576	|O
-	1576	1577	|O
fold	1577	1581	|O
increase	1582	1590	|O
in	1591	1593	|O
affinity	1594	1602	|O
for	1603	1606	|O
the	1607	1610	|O
NMDA	1611	1615	|O
receptor	1616	1624	|O
ion	1625	1628	|O
channel	1629	1636	|O
site	1637	1641	|O
and	1642	1645	|O
no	1646	1648	|O
change	1649	1655	|O
in	1656	1658	|O
sigma	1659	1664	|O
receptor	1665	1673	|O
affinity	1674	1682	|O
compared	1683	1691	|O
to	1692	1694	|O
the	1695	1698	|O
respective	1699	1709	|O
symmetrical	1710	1721	|O
counterparts	1722	1734	|O
.	1734	1735	|O
Additional	1736	1746	|O
small	1747	1752	|O
substituents	1753	1765	|O
on	1766	1768	|O
the	1769	1772	|O
guanidine	1773	1782	|O
nitrogen	1783	1791	|O
atoms	1792	1797	|O
bearing	1798	1805	|O
the	1806	1809	|O
aryl	1810	1814	|O
rings	1815	1820	|O
resulted	1821	1829	|O
in	1830	1832	|O
tri	1833	1836	|O
-	1836	1837	|O
and	1838	1841	|O
tetrasubstituted	1842	1858	|O
guanidine	1859	1868	|O
derivatives	1869	1880	|O
which	1881	1886	|O
retained	1887	1895	|O
affinity	1896	1904	|O
for	1905	1908	|O
NMDA	1909	1913	|O
receptor	1914	1922	|O
ion	1923	1926	|O
channel	1927	1934	|O
sites	1935	1940	|O
but	1941	1944	|O
exhibited	1945	1954	|O
a	1955	1956	|O
significant	1957	1968	|O
reduction	1969	1978	|O
in	1979	1981	|O
their	1982	1987	|O
affinities	1988	1998	|O
for	1999	2002	|O
sigma	2003	2008	|O
receptors	2009	2018	|O
.	2018	2019	|O
For	2020	2023	|O
example	2024	2031	|O
,	2031	2032	|O
N	2033	2034	|B-IUPAC
-	2034	2035	|I-IUPAC
1	2035	2036	|I-IUPAC
-	2036	2037	|I-IUPAC
naphthyl	2037	2045	|I-IUPAC
-	2045	2046	|I-IUPAC
N'	2046	2048	|I-IUPAC
-	2048	2049	|I-IUPAC
(	2049	2050	|I-IUPAC
3	2050	2051	|I-IUPAC
-	2051	2052	|I-IUPAC
ethylphenyl	2052	2063	|I-IUPAC
)	2063	2064	|I-IUPAC
-	2064	2065	|I-IUPAC
N'	2065	2067	|I-IUPAC
-	2067	2068	|I-IUPAC
methylguanidine	2068	2083	|I-IUPAC
(	2084	2085	|O
40	2085	2087	|O
)	2087	2088	|O
showed	2089	2095	|O
high	2096	2100	|O
affinity	2101	2109	|O
for	2110	2113	|O
the	2114	2117	|O
NMDA	2118	2122	|O
receptor	2123	2131	|O
ion	2132	2135	|O
channel	2136	2143	|O
site	2144	2148	|O
(	2149	2150	|O
IC50	2150	2154	|O
=	2155	2156	|O
36	2157	2159	|O
nM	2160	2162	|O
vs	2163	2165	|O
[	2166	2167	|O
3H	2167	2169	|O
]	2169	2170	|O
-	2170	2171	|O
3	2171	2172	|O
)	2172	2173	|O
and	2174	2177	|O
low	2178	2181	|O
affinity	2182	2190	|O
for	2191	2194	|O
sigma	2195	2200	|O
receptors	2201	2210	|O
(	2211	2212	|O
IC50	2212	2216	|O
=	2217	2218	|O
2540	2219	2223	|O
nM	2224	2226	|O
vs	2227	2229	|O
[	2230	2231	|O
3H	2231	2233	|O
]	2233	2234	|O
-	2234	2235	|O
5	2235	2236	|O
)	2236	2237	|O
.	2237	2238	|O
Selectivity	2239	2250	|O
for	2251	2254	|O
the	2255	2258	|O
NMDA	2259	2263	|O
receptor	2264	2272	|O
ion	2273	2276	|O
channel	2277	2284	|O
sites	2285	2290	|O
over	2291	2295	|O
sigma	2296	2301	|O
receptors	2302	2311	|O
appears	2312	2319	|O
to	2320	2322	|O
be	2323	2325	|O
dependent	2326	2335	|O
upon	2336	2340	|O
the	2341	2344	|O
structure	2345	2354	|O
of	2355	2357	|O
the	2358	2361	|O
additional	2362	2372	|O
substituents	2373	2385	|O
on	2386	2388	|O
the	2389	2392	|O
guanidine	2393	2402	|O
nitrogen	2403	2411	|O
atoms	2412	2417	|O
bearing	2418	2425	|O
the	2426	2429	|O
aryl	2430	2434	|O
groups	2435	2441	|O
.	2441	2442	|O
Methyl	2443	2449	|O
and	2450	2453	|O
ethyl	2454	2459	|O
substituents	2460	2472	|O
are	2473	2476	|O
most	2477	2481	|O
preferred	2482	2491	|O
in	2492	2494	|O
the	2495	2498	|O
tri	2499	2502	|O
-	2502	2503	|O
and	2504	2507	|O
tetrasubstituted	2508	2524	|O
diarylguanidines	2525	2541	|O
.	2541	2542	|O
The	2543	2546	|O
trisubstituted	2547	2561	|O
guanidine	2562	2571	|O
,	2571	2572	|O
N	2573	2574	|B-IUPAC
-	2574	2575	|I-IUPAC
1	2575	2576	|I-IUPAC
-	2576	2577	|I-IUPAC
naphthyl	2577	2585	|I-IUPAC
-	2585	2586	|I-IUPAC
N'	2586	2588	|I-IUPAC
-	2588	2589	|I-IUPAC
(	2589	2590	|I-IUPAC
3	2590	2591	|I-IUPAC
-	2591	2592	|I-IUPAC
ethylphenyl	2592	2603	|I-IUPAC
)	2603	2604	|I-IUPAC
-	2604	2605	|I-IUPAC
N'	2605	2607	|I-IUPAC
-	2607	2608	|I-IUPAC
methylguanidine	2608	2623	|I-IUPAC
(	2624	2625	|O
40	2625	2627	|O
)	2627	2628	|O
and	2629	2632	|O
its	2633	2636	|O
close	2637	2642	|O
analogues	2643	2652	|O
showed	2653	2659	|O
good	2660	2664	|O
in	2665	2667	|O
vivo	2668	2672	|O
neuroprotection	2673	2688	|O
and	2689	2692	|O
are	2693	2696	|O
potential	2697	2706	|O
neuroprotective	2707	2722	|O
drug	2723	2727	|O
candidates	2728	2738	|O
for	2739	2742	|O
the	2743	2746	|O
treatment	2747	2756	|O
of	2757	2759	|O
stroke	2760	2766	|O
and	2767	2770	|O
other	2771	2776	|O
neurodegenerative	2777	2794	|O
disorders	2795	2804	|O
.	2804	2805	|O

### abstracts1518.txt
Syntheses	0	9	|O
of	10	12	|O
several	13	20	|O
carbamate	21	30	|O
analogues	31	40	|O
of	41	43	|O
2	44	45	|B-IUPAC
,	45	46	|I-IUPAC
5	47	48	|I-IUPAC
-	48	49	|I-IUPAC
bis	49	52	|I-IUPAC
(	52	53	|I-IUPAC
4	53	54	|I-IUPAC
-	54	55	|I-IUPAC
amidinophenyl	55	68	|I-IUPAC
)	68	69	|I-IUPAC
furan	69	74	|I-IUPAC
(	75	76	|O
1	76	77	|O
)	77	78	|O
under	79	84	|O
mild	85	89	|O
conditions	90	100	|O
and	101	104	|O
their	105	110	|O
evaluation	111	121	|O
as	122	124	|O
prodrugs	125	133	|O
against	134	141	|O
Pneumocystis	142	154	|O
carinii	155	162	|O
pneumonia	163	172	|O
(	173	174	|O
PCP	174	177	|O
)	177	178	|O
in	179	181	|O
an	182	184	|O
immunosuppressed	185	201	|O
rat	202	205	|O
model	206	211	|O
are	212	215	|O
described	216	225	|O
.	225	226	|O
Thus	227	231	|O
,	231	232	|O
nine	233	237	|O
new	238	241	|O
bis	242	245	|O
-	245	246	|O
carbamates	246	256	|O
:	256	257	|O
methoxycarbonyl	258	273	|B-IUPAC
(	274	275	|O
2	275	276	|O
)	276	277	|O
,	277	278	|O
2,2,2	279	284	|B-IUPAC
-	284	285	|I-IUPAC
trichloroethoxycarbonyl	285	308	|I-IUPAC
(	309	310	|O
3	310	311	|O
)	311	312	|O
,	312	313	|O
ethylthiocarbonyl	314	331	|B-IUPAC
(	332	333	|O
4	333	334	|O
)	334	335	|O
,	335	336	|O
benzyloxycarbonyl	337	354	|B-IUPAC
(	355	356	|O
5	356	357	|O
)	357	358	|O
,	358	359	|O
(	360	361	|B-IUPAC
4	361	362	|I-IUPAC
-	362	363	|I-IUPAC
methyl	363	369	|I-IUPAC
-	369	370	|I-IUPAC
2	370	371	|I-IUPAC
-	371	372	|I-IUPAC
oxo	372	375	|I-IUPAC
-	375	376	|I-IUPAC
1	376	377	|I-IUPAC
,	377	378	|I-IUPAC
3	379	380	|I-IUPAC
-	380	381	|I-IUPAC
dioxol	381	387	|I-IUPAC
-	387	388	|I-IUPAC
4	388	389	|I-IUPAC
-	389	390	|I-IUPAC
en	390	392	|I-IUPAC
-	392	393	|I-IUPAC
5	393	394	|I-IUPAC
-	394	395	|I-IUPAC
yl	395	397	|I-IUPAC
)	397	398	|I-IUPAC
methoxycarbonyl	398	413	|I-IUPAC
(	414	415	|O
6	415	416	|O
)	416	417	|O
,	417	418	|O
phenoxycarbonyl	419	434	|B-IUPAC
(	435	436	|O
7	436	437	|O
)	437	438	|O
,	438	439	|O
4	440	441	|B-IUPAC
-	441	442	|I-IUPAC
fluorophenoxycarbonyl	442	463	|I-IUPAC
(	464	465	|O
8	465	466	|O
)	466	467	|O
,	467	468	|O
4	469	470	|B-IUPAC
-	470	471	|I-IUPAC
methoxyphenoxycarbonyl	471	493	|I-IUPAC
(	494	495	|O
9	495	496	|O
)	496	497	|O
,	497	498	|O
and	499	502	|O
(	503	504	|B-IUPAC
1	504	505	|I-IUPAC
-	505	506	|I-IUPAC
acetoxy	506	513	|I-IUPAC
)	513	514	|I-IUPAC
ethoxycarbonyl	514	528	|I-IUPAC
(	529	530	|O
10	530	532	|O
)	532	533	|O
and	534	537	|O
a	538	539	|O
bis	540	543	|B-IUPAC
-	543	544	|I-IUPAC
carbonate	544	553	|I-IUPAC
ethoxycarbonyloxy	554	571	|I-IUPAC
(	572	573	|O
11	573	575	|O
)	575	576	|O
of	577	579	|O
the	580	583	|O
bis	584	587	|O
-	587	588	|O
amidine	588	595	|O
1	596	597	|O
have	598	602	|O
been	603	607	|O
synthesized	608	619	|O
and	620	623	|O
evaluated	624	633	|O
.	633	634	|O
The	635	638	|O
in	639	641	|O
vivo	642	646	|O
results	647	654	|O
show	655	659	|O
that	660	664	|O
the	665	668	|O
4	669	670	|B-IUPAC
-	670	671	|I-IUPAC
fluorophenyl	671	683	|I-IUPAC
carbamate	684	693	|I-IUPAC
8	694	695	|O
and	696	699	|O
the	700	703	|O
4	704	705	|B-IUPAC
-	705	706	|I-IUPAC
methoxyphenyl	706	719	|I-IUPAC
carbamate	720	729	|I-IUPAC
9	730	731	|O
in	732	734	|O
this	735	739	|O
series	740	746	|O
had	747	750	|O
the	751	754	|O
best	755	759	|O
anti	760	764	|O
-	764	765	|O
PCP	765	768	|O
activity	769	777	|O
by	778	780	|O
both	781	785	|O
intravenous	786	797	|O
and	798	801	|O
oral	802	806	|O
administration	807	821	|O
at	822	824	|O
a	825	826	|O
dosage	827	833	|O
level	834	839	|O
of	840	842	|O
22	843	845	|O
mol	846	849	|O
and	850	853	|O
33	854	856	|O
micromol	857	865	|O
/	865	866	|O
kg	866	868	|O
/	868	869	|O
day	869	872	|O
,	872	873	|O
respectively	874	886	|O
.	886	887	|O
Compounds	888	897	|O
3-7	898	901	|O
were	902	906	|O
also	907	911	|O
more	912	916	|O
active	917	923	|O
than	924	928	|O
the	929	932	|O
parent	933	939	|O
drug	940	944	|O
(	945	946	|O
1	946	947	|O
)	947	948	|O
on	949	951	|O
oral	952	956	|O
administration	957	971	|O
.	971	972	|O
The	973	976	|O
acute	977	982	|O
toxicity	983	991	|O
usually	992	999	|O
exhibited	1000	1009	|O
by	1010	1012	|O
the	1013	1016	|O
parent	1017	1023	|O
amidine	1024	1031	|O
1	1032	1033	|O
at	1034	1036	|O
a	1037	1038	|O
dosage	1039	1045	|O
level	1046	1051	|O
of	1052	1054	|O
22	1055	1057	|O
micromol	1058	1066	|O
/	1066	1067	|O
kg	1067	1069	|O
/	1069	1070	|O
day	1070	1073	|O
on	1074	1076	|O
intravenous	1077	1088	|O
administration	1089	1103	|O
has	1104	1107	|O
been	1108	1112	|O
significantly	1113	1126	|O
reduced	1127	1134	|O
by	1135	1137	|O
the	1138	1141	|O
prodrug	1142	1149	|O
modifications	1150	1163	|O
,	1163	1164	|O
with	1165	1169	|O
the	1170	1173	|O
exception	1174	1183	|O
of	1184	1186	|O
compound	1187	1195	|O
10	1196	1198	|O
which	1199	1204	|O
exhibited	1205	1214	|O
some	1215	1219	|O
toxicity	1220	1228	|O
.	1228	1229	|O
This	1230	1234	|O
report	1235	1241	|O
also	1242	1246	|O
describes	1247	1256	|O
the	1257	1260	|O
synthesis	1261	1270	|O
of	1271	1273	|O
several	1274	1281	|O
aryl	1282	1286	|O
-	1286	1287	|O
alkyl	1287	1292	|O
and	1293	1296	|O
aryl	1297	1301	|O
-	1301	1302	|O
aryl	1302	1306	|O
carbonates	1307	1317	|O
(	1318	1319	|O
12-14	1319	1324	|O
,	1324	1325	|O
16-23	1326	1331	|O
)	1331	1332	|O
as	1333	1335	|O
efficient	1336	1345	|O
reagents	1346	1354	|O
for	1355	1358	|O
the	1359	1362	|O
preparation	1363	1374	|O
of	1375	1377	|O
carbamate	1378	1387	|O
derivatives	1388	1399	|O
from	1400	1404	|O
bis	1405	1408	|O
-	1408	1409	|O
arylamidines	1409	1421	|O
.	1421	1422	|O

### abstracts4120.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
1	12	13	|B-IUPAC
-	13	14	|I-IUPAC
phenyl	14	20	|I-IUPAC
-	20	21	|I-IUPAC
3	21	22	|I-IUPAC
-	22	23	|I-IUPAC
amino	23	28	|I-IUPAC
-	28	29	|I-IUPAC
1,2,3,4	29	36	|I-IUPAC
-	36	37	|I-IUPAC
tetrahydronaphthalenes	37	59	|I-IUPAC
(	60	61	|O
1	61	62	|B-IUPAC
-	62	63	|I-IUPAC
phenyl	63	69	|I-IUPAC
-	69	70	|I-IUPAC
3	70	71	|I-IUPAC
-	71	72	|I-IUPAC
aminotetralins	72	86	|I-IUPAC
,	86	87	|O
PATs	88	92	|O
)	92	93	|O
previously	94	104	|O
was	105	108	|O
found	109	114	|O
to	115	117	|O
modulate	118	126	|O
tyrosine	127	135	|O
hydroxylase	136	147	|O
activity	148	156	|O
and	157	160	|O
dopamine	161	169	|O
synthesis	170	179	|O
in	180	182	|O
rodent	183	189	|O
forebrain	190	199	|O
through	200	207	|O
interaction	208	219	|O
with	220	224	|O
a	225	226	|O
binding	227	234	|O
site	235	239	|O
labeled	240	247	|O
by	248	250	|O
[	251	252	|O
(	252	253	|O
3	253	254	|O
)	254	255	|O
H	255	256	|O
]	256	257	|O
-	257	258	|O
(	258	259	|O
-	259	260	|O
)	260	261	|O
-	261	262	|O
(	262	263	|O
1R	263	265	|O
,	265	266	|O
3S	266	268	|O
)	268	269	|O
-	269	270	|O
trans	270	275	|O
-	275	276	|O
H	276	277	|O
(	277	278	|O
2	278	279	|O
)	279	280	|O
-	280	281	|O
PAT	281	284	|O
.	284	285	|O
Recently	286	294	|O
,	294	295	|O
we	296	298	|O
have	299	303	|O
discovered	304	314	|O
that	315	319	|O
PATs	320	324	|O
also	325	329	|O
bind	330	334	|O
with	335	339	|O
high	340	344	|O
affinity	345	353	|O
to	354	356	|O
the	357	360	|O
[	361	362	|O
(	362	363	|O
3	363	364	|O
)	364	365	|O
H	365	366	|O
]	366	367	|O
mepyramine	367	377	|O
-	377	378	|O
labeled	378	385	|O
H	386	387	|O
(	387	388	|O
1	388	389	|O
)	389	390	|O
receptor	391	399	|O
in	400	402	|O
rat	403	406	|O
and	407	410	|O
guinea	411	417	|O
pig	418	421	|O
brain	422	427	|O
.	427	428	|O
Here	429	433	|O
,	433	434	|O
we	435	437	|O
report	438	444	|O
the	445	448	|O
synthesis	449	458	|O
and	459	462	|O
biological	463	473	|O
evaluation	474	484	|O
of	485	487	|O
additional	488	498	|O
PAT	499	502	|O
analogues	503	512	|O
in	513	515	|O
order	516	521	|O
to	522	524	|O
identify	525	533	|O
differences	534	545	|O
in	546	548	|O
binding	549	556	|O
at	557	559	|O
these	560	565	|O
two	566	569	|O
sites	570	575	|O
.	575	576	|O
Further	577	584	|O
molecular	585	594	|O
modifications	595	608	|O
involve	609	616	|O
the	617	620	|O
pendant	621	628	|O
phenyl	629	635	|O
ring	636	640	|O
as	641	643	|O
well	644	648	|O
as	649	651	|O
quaternary	652	662	|O
amine	663	668	|O
compounds	669	678	|O
.	678	679	|O
Comparison	680	690	|O
of	691	693	|O
about	694	699	|O
38	700	702	|O
PAT	703	706	|O
analogues	707	716	|O
,	716	717	|O
10	718	720	|O
structurally	721	733	|O
diverse	734	741	|O
H	742	743	|O
(	743	744	|O
1	744	745	|O
)	745	746	|O
ligands	747	754	|O
,	754	755	|O
and	756	759	|O
several	760	767	|O
other	768	773	|O
CNS	774	777	|O
-	777	778	|O
active	778	784	|O
compounds	785	794	|O
revealed	795	803	|O
no	804	806	|O
significant	807	818	|O
differences	819	830	|O
in	831	833	|O
affinity	834	842	|O
at	843	845	|O
[	846	847	|O
(	847	848	|O
3	848	849	|O
)	849	850	|O
H	850	851	|O
]	851	852	|O
-	852	853	|O
(	853	854	|O
-	854	855	|O
)	855	856	|O
-	856	857	|O
trans	857	862	|O
-	862	863	|O
H	863	864	|O
(	864	865	|O
2	865	866	|O
)	866	867	|O
-	867	868	|O
PAT	868	871	|O
sites	872	877	|O
versus	878	884	|O
[	885	886	|O
(	886	887	|O
3	887	888	|O
)	888	889	|O
H	889	890	|O
]	890	891	|O
mepyramine	891	901	|O
-	901	902	|O
labeled	902	909	|O
H	910	911	|O
(	911	912	|O
1	912	913	|O
)	913	914	|O
receptors	915	924	|O
.	924	925	|O
These	926	931	|O
results	932	939	|O
,	939	940	|O
together	941	949	|O
with	950	954	|O
previous	955	963	|O
autoradiographic	964	980	|O
brain	981	986	|O
receptor	987	995	|O
-	995	996	|O
mapping	996	1003	|O
studies	1004	1011	|O
that	1012	1016	|O
indicate	1017	1025	|O
similar	1026	1033	|O
distribution	1034	1046	|O
of	1047	1049	|O
[	1050	1051	|O
(	1051	1052	|O
3	1052	1053	|O
)	1053	1054	|O
H	1054	1055	|O
]	1055	1056	|O
-	1056	1057	|O
(	1057	1058	|O
-	1058	1059	|O
)	1059	1060	|O
-	1060	1061	|O
trans	1061	1066	|O
-	1066	1067	|O
H	1067	1068	|O
(	1068	1069	|O
2	1069	1070	|O
)	1070	1071	|O
-	1071	1072	|O
PAT	1072	1075	|O
sites	1076	1081	|O
and	1082	1085	|O
[	1086	1087	|O
(	1087	1088	|O
3	1088	1089	|O
)	1089	1090	|O
H	1090	1091	|O
]	1091	1092	|O
mepyramine	1092	1102	|O
-	1102	1103	|O
labeled	1103	1110	|O
H	1111	1112	|O
(	1112	1113	|O
1	1113	1114	|O
)	1114	1115	|O
receptors	1116	1125	|O
,	1125	1126	|O
suggest	1127	1134	|O
that	1135	1139	|O
both	1140	1144	|O
radioligands	1145	1157	|O
label	1158	1163	|O
the	1164	1167	|O
same	1168	1172	|O
histamine	1173	1182	|O
H	1183	1184	|O
(	1184	1185	|O
1	1185	1186	|O
)	1186	1187	|O
receptors	1188	1197	|O
in	1198	1200	|O
rodent	1201	1207	|O
brain	1208	1213	|O
.	1213	1214	|O
We	1215	1217	|O
also	1218	1222	|O
report	1223	1229	|O
a	1230	1231	|O
revision	1232	1240	|O
of	1241	1243	|O
our	1244	1247	|O
previous	1248	1256	|O
comparative	1257	1268	|O
molecular	1269	1278	|O
field	1279	1284	|O
analysis	1285	1293	|O
(	1294	1295	|O
CoMFA	1295	1300	|O
)	1300	1301	|O
study	1302	1307	|O
of	1308	1310	|O
the	1311	1314	|O
PAT	1315	1318	|O
ligands	1319	1326	|O
that	1327	1331	|O
yields	1332	1338	|O
a	1339	1340	|O
highly	1341	1347	|O
predictive	1348	1358	|O
model	1359	1364	|O
for	1365	1368	|O
66	1369	1371	|O
compounds	1372	1381	|O
with	1382	1386	|O
a	1387	1388	|O
cross	1389	1394	|O
-	1394	1395	|O
validated	1395	1404	|O
R	1405	1406	|O
(	1406	1407	|O
2	1407	1408	|O
)	1408	1409	|O
(	1410	1411	|O
q	1411	1412	|O
(	1412	1413	|O
2	1413	1414	|O
)	1414	1415	|O
)	1415	1416	|O
value	1417	1422	|O
of	1423	1425	|O
0.67	1426	1430	|O
.	1430	1431	|O
This	1432	1436	|O
model	1437	1442	|O
will	1443	1447	|O
be	1448	1450	|O
useful	1451	1457	|O
for	1458	1461	|O
the	1462	1465	|O
prediction	1466	1476	|O
of	1477	1479	|O
high	1480	1484	|O
-	1484	1485	|O
affinity	1485	1493	|O
ligands	1494	1501	|O
at	1502	1504	|O
radiolabeled	1505	1517	|O
H	1518	1519	|O
(	1519	1520	|O
1	1520	1521	|O
)	1521	1522	|O
receptors	1523	1532	|O
in	1533	1535	|O
mammalian	1536	1545	|O
brain	1546	1551	|O
.	1551	1552	|O

### abstracts3090.txt
A	0	1	|O
new	2	5	|O
class	6	11	|O
of	12	14	|O
histamine	15	24	|O
analogues	25	34	|O
characterized	35	48	|O
by	49	51	|O
a	52	53	|O
3	54	55	|B-IUPAC
,	55	56	|I-IUPAC
3	57	58	|I-IUPAC
-	58	59	|I-IUPAC
diphenylpropyl	59	73	|I-IUPAC
substituent	74	85	|B-MODIFIER
at	86	88	|O
the	89	92	|O
2	93	94	|O
-	94	95	|O
position	95	103	|O
of	104	106	|O
the	107	110	|O
imidazole	111	120	|O
nucleus	121	128	|O
has	129	132	|O
been	133	137	|O
prepared	138	146	|O
outgoing	147	155	|O
from	156	160	|O
4,4	161	164	|B-IUPAC
-	164	165	|I-IUPAC
diphenylbutyronitrile	165	186	|I-IUPAC
(	187	188	|O
4b	188	190	|O
)	190	191	|O
via	192	195	|O
cyclization	196	207	|O
of	208	210	|O
the	211	214	|O
corresponding	215	228	|O
methyl	229	235	|O
imidate	236	243	|O
5b	244	246	|O
with	247	251	|O
2	252	253	|B-IUPAC
-	253	254	|I-IUPAC
oxo	254	257	|I-IUPAC
-	257	258	|I-IUPAC
4	258	259	|I-IUPAC
-	259	260	|I-IUPAC
phthalimido	260	271	|I-IUPAC
-	271	272	|I-IUPAC
1	272	273	|I-IUPAC
-	273	274	|I-IUPAC
butyl	274	279	|I-IUPAC
acetate	280	287	|I-IUPAC
or	288	290	|O
2	291	292	|B-IUPAC
-	292	293	|I-IUPAC
oxo	293	296	|I-IUPAC
-	296	297	|I-IUPAC
1,4	297	300	|I-IUPAC
-	300	301	|I-IUPAC
butandiol	301	310	|I-IUPAC
in	311	313	|O
liquid	314	320	|O
ammonia	321	328	|O
,	328	329	|O
followed	330	338	|O
by	339	341	|O
standard	342	350	|O
reactions	351	360	|O
.	360	361	|O
The	362	365	|O
title	366	371	|O
compounds	372	381	|O
displayed	382	391	|O
partial	392	399	|O
agonism	400	407	|O
on	408	410	|O
contractile	411	422	|O
H	423	424	|O
(	424	425	|O
1	425	426	|O
)	426	427	|O
receptors	428	437	|O
of	438	440	|O
the	441	444	|O
guinea	445	451	|O
-	451	452	|O
pig	452	455	|O
ileum	456	461	|O
and	462	465	|O
endothelium	466	477	|O
-	477	478	|O
denuded	478	485	|O
aorta	486	491	|O
,	491	492	|O
respectively	493	505	|O
,	505	506	|O
except	507	513	|O
10	514	516	|O
(	517	518	|O
histaprodifen	518	531	|O
;	531	532	|O
2	533	534	|B-IUPAC
-	534	535	|I-IUPAC
[	535	536	|I-IUPAC
2	536	537	|I-IUPAC
-	537	538	|I-IUPAC
(	538	539	|I-IUPAC
3	539	540	|I-IUPAC
,	540	541	|I-IUPAC
3	542	543	|I-IUPAC
-	543	544	|I-IUPAC
diphenylpropyl	544	558	|I-IUPAC
)	558	559	|I-IUPAC
-	559	560	|I-IUPAC
1H	560	562	|I-IUPAC
-	562	563	|I-IUPAC
imidazol	563	571	|I-IUPAC
-	571	572	|I-IUPAC
4	572	573	|I-IUPAC
-	573	574	|I-IUPAC
yl	574	576	|I-IUPAC
]	576	577	|I-IUPAC
ethanamine	577	587	|I-IUPAC
)	587	588	|O
which	589	594	|O
was	595	598	|O
a	599	600	|O
full	601	605	|O
agonist	606	613	|O
in	614	616	|O
the	617	620	|O
ileum	621	626	|O
assay	627	632	|O
.	632	633	|O
While	634	639	|O
10	640	642	|O
was	643	646	|O
equipotent	647	657	|O
with	658	662	|O
histamine	663	672	|O
(	673	674	|O
1	674	675	|O
)	675	676	|O
,	676	677	|O
methylhistaprodifen	678	697	|O
(	698	699	|O
13	699	701	|O
)	701	702	|O
and	703	706	|O
dimethylhistaprodifen	707	728	|O
(	729	730	|O
14	730	732	|O
)	732	733	|O
exceeded	734	742	|O
the	743	746	|O
functional	747	757	|O
potency	758	765	|O
of	766	768	|O
1	769	770	|O
by	771	773	|O
a	774	775	|O
factor	776	782	|O
of	783	785	|O
3-5	786	789	|O
(	790	791	|O
13	791	793	|O
)	793	794	|O
and	795	798	|O
2-3	799	802	|O
(	803	804	|O
14	804	806	|O
)	806	807	|O
.	807	808	|O
Compounds	809	818	|O
10	819	821	|O
and	822	825	|O
13-17	826	831	|O
relaxed	832	839	|O
precontracted	840	853	|O
rat	854	857	|O
aortic	858	864	|O
rings	865	870	|O
(	871	872	|O
intact	872	878	|O
endothelium	879	890	|O
)	890	891	|O
with	892	896	|O
relative	897	905	|O
potencies	906	915	|O
of	916	918	|O
3.3	919	922	|O
-	922	923	|O
up	924	926	|O
to	927	929	|O
28	930	932	|O
-	932	933	|O
fold	933	937	|O
(	938	939	|O
compared	939	947	|O
with	948	952	|O
1	953	954	|O
)	954	955	|O
,	955	956	|O
displaying	957	967	|O
partial	968	975	|O
agonism	976	983	|O
as	984	986	|O
well	987	991	|O
.	991	992	|O
Agonist	993	1000	|O
effects	1001	1008	|O
were	1009	1013	|O
sensitive	1014	1023	|O
to	1024	1026	|O
blockade	1027	1035	|O
by	1036	1038	|O
the	1039	1042	|O
selective	1043	1052	|O
H	1053	1054	|O
(	1054	1055	|O
1	1055	1056	|O
)	1056	1057	|O
-	1057	1058	|O
receptor	1058	1066	|O
antagonist	1067	1077	|O
mepyramine	1078	1088	|O
(	1089	1090	|O
pA	1090	1092	|O
(	1092	1093	|O
2	1093	1094	|O
)	1094	1095	|O
approximately	1096	1109	|O
9	1110	1111	|O
(	1112	1113	|O
guinea	1113	1119	|O
-	1119	1120	|O
pig	1120	1123	|O
)	1123	1124	|O
and	1125	1128	|O
pA	1129	1131	|O
(	1131	1132	|O
2	1132	1133	|O
)	1133	1134	|O
approximately	1135	1148	|O
8	1149	1150	|O
(	1151	1152	|O
rat	1152	1155	|O
aorta	1156	1161	|O
)	1161	1162	|O
)	1162	1163	|O
.	1163	1164	|O
The	1165	1168	|O
affinity	1169	1177	|O
of	1178	1180	|O
10	1181	1183	|O
and	1184	1187	|O
13-17	1188	1193	|O
for	1194	1197	|O
guinea	1198	1204	|O
-	1204	1205	|O
pig	1205	1208	|O
H	1209	1210	|O
(	1210	1211	|O
1	1211	1212	|O
)	1212	1213	|O
receptors	1214	1223	|O
increased	1224	1233	|O
20	1234	1236	|O
-	1236	1237	|O
to	1238	1240	|O
100	1241	1244	|O
-	1244	1245	|O
fold	1245	1249	|O
compared	1250	1258	|O
with	1259	1263	|O
1	1264	1265	|O
.	1265	1266	|O
Two	1267	1270	|O
lower	1271	1276	|O
homologues	1277	1287	|O
of	1288	1290	|O
10	1291	1293	|O
were	1294	1298	|O
weak	1299	1303	|O
partial	1304	1311	|O
H	1312	1313	|O
(	1313	1314	|O
1	1314	1315	|O
)	1315	1316	|O
-	1316	1317	|O
receptor	1317	1325	|O
agonists	1326	1334	|O
while	1335	1340	|O
two	1341	1344	|O
higher	1345	1351	|O
homologues	1352	1362	|O
of	1363	1365	|O
10	1366	1368	|O
were	1369	1373	|O
silent	1374	1380	|O
antagonists	1381	1392	|O
endowed	1393	1400	|O
with	1401	1405	|O
micromolar	1406	1416	|O
affinity	1417	1425	|O
for	1426	1429	|O
rat	1430	1433	|O
and	1434	1437	|O
guinea	1438	1444	|O
-	1444	1445	|O
pig	1445	1448	|O
H	1449	1450	|O
(	1450	1451	|O
1	1451	1452	|O
)	1452	1453	|O
receptors	1454	1463	|O
.	1463	1464	|O
In	1465	1467	|O
functional	1468	1478	|O
selectivity	1479	1490	|O
experiments	1491	1502	|O
,	1502	1503	|O
10	1504	1506	|O
,	1506	1507	|O
13	1508	1510	|O
,	1510	1511	|O
and	1512	1515	|O
14	1516	1518	|O
did	1519	1522	|O
not	1523	1526	|O
stimulate	1527	1536	|O
H	1537	1538	|O
(	1538	1539	|O
2	1539	1540	|O
)	1540	1541	|O
,	1541	1542	|O
H	1543	1544	|O
(	1544	1545	|O
3	1545	1546	|O
)	1546	1547	|O
,	1547	1548	|O
and	1549	1552	|O
several	1553	1560	|O
other	1561	1566	|O
neurotransmitter	1567	1583	|O
receptors	1584	1593	|O
.	1593	1594	|O
They	1595	1599	|O
displayed	1600	1609	|O
only	1610	1614	|O
low	1615	1618	|O
to	1619	1621	|O
moderate	1622	1630	|O
affinity	1631	1639	|O
for	1640	1643	|O
these	1644	1649	|O
sites	1650	1655	|O
(	1656	1657	|O
pA	1657	1659	|O
(	1659	1660	|O
2	1660	1661	|O
)	1661	1662	|O
&	1663	1664	|O
lt	1664	1666	|O
;	1666	1667	|O
6	1668	1669	|O
)	1669	1670	|O
.	1670	1671	|O
For	1672	1675	|O
a	1676	1677	|O
better	1678	1684	|O
understanding	1685	1698	|O
of	1699	1701	|O
structure	1702	1711	|O
-	1711	1712	|O
activity	1712	1720	|O
relationships	1721	1734	|O
,	1734	1735	|O
the	1736	1739	|O
interaction	1740	1751	|O
of	1752	1754	|O
1	1755	1756	|O
and	1757	1760	|O
10	1761	1763	|O
,	1763	1764	|O
13	1765	1767	|O
and	1768	1771	|O
14	1772	1774	|O
within	1775	1781	|O
the	1782	1785	|O
transmembrane	1786	1799	|O
(	1800	1801	|O
TM	1801	1803	|O
)	1803	1804	|O
domains	1805	1812	|O
of	1813	1815	|O
the	1816	1819	|O
human	1820	1825	|O
histamine	1826	1835	|O
H	1836	1837	|O
(	1837	1838	|O
1	1838	1839	|O
)	1839	1840	|O
receptor	1841	1849	|O
were	1850	1854	|O
studied	1855	1862	|O
using	1863	1868	|O
molecular	1869	1878	|O
dynamics	1879	1887	|O
simulations	1888	1899	|O
.	1899	1900	|O
Remarkable	1901	1911	|O
differences	1912	1923	|O
were	1924	1928	|O
found	1929	1934	|O
between	1935	1942	|O
the	1943	1946	|O
binding	1947	1954	|O
modes	1955	1960	|O
of	1961	1963	|O
10	1964	1966	|O
,	1966	1967	|O
13	1968	1970	|O
,	1970	1971	|O
and	1972	1975	|O
14	1976	1978	|O
and	1979	1982	|O
that	1983	1987	|O
of	1988	1990	|O
1	1991	1992	|O
.	1992	1993	|O
The	1994	1997	|O
imidazole	1998	2007	|O
ring	2008	2012	|O
of	2013	2015	|O
10	2016	2018	|O
,	2018	2019	|O
13	2020	2022	|O
,	2022	2023	|O
and	2024	2027	|O
14	2028	2030	|O
was	2031	2034	|O
placed	2035	2041	|O
'	2042	2043	|O
upside	2043	2049	|O
down	2050	2054	|O
'	2054	2055	|O
compared	2056	2064	|O
with	2065	2069	|O
1	2070	2071	|O
,	2071	2072	|O
making	2073	2079	|O
the	2080	2083	|O
interaction	2084	2095	|O
of	2096	2098	|O
the	2099	2102	|O
N	2103	2104	|O
(	2104	2105	|O
pi	2105	2107	|O
)	2107	2108	|O
-	2108	2109	|O
atom	2109	2113	|O
with	2114	2118	|O
Tyr431	2119	2125	|O
possible	2126	2134	|O
.	2134	2135	|O
This	2136	2140	|O
new	2141	2144	|O
orientation	2145	2156	|O
was	2157	2160	|O
mainly	2161	2167	|O
caused	2168	2174	|O
by	2175	2177	|O
the	2178	2181	|O
space	2182	2187	|O
filling	2188	2195	|O
substitution	2196	2208	|O
at	2209	2211	|O
the	2212	2215	|O
2	2216	2217	|O
-	2217	2218	|O
position	2218	2226	|O
of	2227	2229	|O
the	2230	2233	|O
imidazole	2234	2243	|O
ring	2244	2248	|O
and	2249	2252	|O
influenced	2253	2263	|O
the	2264	2267	|O
location	2268	2276	|O
of	2277	2279	|O
the	2280	2283	|O
protonated	2284	2294	|O
N	2295	2296	|O
(	2296	2297	|O
alpha	2297	2302	|O
)	2302	2303	|O
-	2303	2304	|O
atom	2304	2308	|O
which	2309	2314	|O
was	2315	2318	|O
positioned	2319	2329	|O
more	2330	2334	|O
between	2335	2342	|O
TM	2343	2345	|O
III	2346	2349	|O
and	2350	2353	|O
TM	2354	2356	|O
VI	2357	2359	|O
.	2359	2360	|O
This	2361	2365	|O
orientation	2366	2377	|O
can	2378	2381	|O
explain	2382	2389	|O
both	2390	2394	|O
the	2395	2398	|O
increased	2399	2408	|O
relative	2409	2417	|O
potency	2418	2425	|O
and	2426	2429	|O
the	2430	2433	|O
maximum	2434	2441	|O
effect	2442	2448	|O
of	2449	2451	|O
10	2452	2454	|O
,	2454	2455	|O
13	2456	2458	|O
,	2458	2459	|O
and	2460	2463	|O
14	2464	2466	|O
compared	2467	2475	|O
with	2476	2480	|O
1	2481	2482	|O
.	2482	2483	|O
Compound	2484	2492	|O
13	2493	2495	|O
(	2496	2497	|O
methylhistaprodifen	2497	2516	|O
;	2516	2517	|O
N	2518	2519	|B-IUPAC
(	2519	2520	|I-IUPAC
alpha	2520	2525	|I-IUPAC
)	2525	2526	|I-IUPAC
-	2526	2527	|I-IUPAC
methyl	2527	2533	|I-IUPAC
-	2533	2534	|I-IUPAC
2	2534	2535	|I-IUPAC
-	2535	2536	|I-IUPAC
[	2536	2537	|I-IUPAC
2	2537	2538	|I-IUPAC
-	2538	2539	|I-IUPAC
(	2539	2540	|I-IUPAC
3	2540	2541	|I-IUPAC
,	2541	2542	|I-IUPAC
3	2543	2544	|I-IUPAC
-	2544	2545	|I-IUPAC
diphenylpropyl	2545	2559	|I-IUPAC
)	2559	2560	|I-IUPAC
-	2560	2561	|I-IUPAC
1H	2561	2563	|I-IUPAC
-	2563	2564	|I-IUPAC
imidazol	2564	2572	|I-IUPAC
-	2572	2573	|I-IUPAC
4	2573	2574	|I-IUPAC
-	2574	2575	|I-IUPAC
yl	2575	2577	|I-IUPAC
]	2577	2578	|I-IUPAC
ethanamine	2578	2588	|I-IUPAC
)	2588	2589	|O
is	2590	2592	|O
the	2593	2596	|O
most	2597	2601	|O
potent	2602	2608	|O
histamine	2609	2618	|O
H	2619	2620	|O
(	2620	2621	|O
1	2621	2622	|O
)	2622	2623	|O
-	2623	2624	|O
receptor	2624	2632	|O
agonist	2633	2640	|O
reported	2641	2649	|O
so	2650	2652	|O
far	2653	2656	|O
in	2657	2659	|O
the	2660	2663	|O
literature	2664	2674	|O
and	2675	2678	|O
may	2679	2682	|O
become	2683	2689	|O
a	2690	2691	|O
valuable	2692	2700	|O
tool	2701	2705	|O
for	2706	2709	|O
the	2710	2713	|O
study	2714	2719	|O
of	2720	2722	|O
physiological	2723	2736	|O
and	2737	2740	|O
pathophysiological	2741	2759	|O
H	2760	2761	|O
(	2761	2762	|O
1	2762	2763	|O
)	2763	2764	|O
-	2764	2765	|O
receptor	2765	2773	|O
-	2773	2774	|O
mediated	2774	2782	|O
effects	2783	2790	|O
.	2790	2791	|O

### abstracts2034.txt
The	0	3	|O
ability	4	11	|O
of	12	14	|O
conjugates	15	25	|O
of	26	28	|O
peptides	29	37	|O
and	38	41	|O
5	42	43	|B-IUPAC
-	43	44	|I-IUPAC
fluorocytosine	44	58	|I-IUPAC
or	59	61	|O
5	62	63	|B-IUPAC
-	63	64	|I-IUPAC
fluoroorotic	64	76	|I-IUPAC
acid	77	81	|I-IUPAC
to	82	84	|O
enter	85	90	|O
Candida	91	98	|O
albicans	99	107	|O
was	108	111	|O
investigated	112	124	|O
.	124	125	|O
A	126	127	|O
number	128	134	|O
of	135	137	|O
conjugates	138	148	|O
of	149	151	|O
5	152	153	|B-IUPAC
-	153	154	|I-IUPAC
fluoroorotic	154	166	|I-IUPAC
acid	167	171	|I-IUPAC
and	172	175	|O
peptides	176	184	|O
were	185	189	|O
synthesized	190	201	|O
using	202	207	|O
1	208	209	|B-IUPAC
-	209	210	|I-IUPAC
(	210	211	|I-IUPAC
ethoxy	211	217	|I-IUPAC
-	217	218	|I-IUPAC
carbonyl	218	226	|I-IUPAC
)	226	227	|I-IUPAC
-	227	228	|I-IUPAC
2	228	229	|I-IUPAC
-	229	230	|I-IUPAC
ethoxy	230	236	|I-IUPAC
-	236	237	|I-IUPAC
1,2	237	240	|I-IUPAC
-	240	241	|I-IUPAC
dihydroquinoline	241	257	|I-IUPAC
as	258	260	|O
the	261	264	|O
coupling	265	273	|O
agent	274	279	|O
.	279	280	|O
Orotyl	281	287	|B-IUPAC
-	287	288	|I-IUPAC
L	288	289	|I-IUPAC
-	289	290	|I-IUPAC
leucyl	290	296	|I-IUPAC
-	296	297	|I-IUPAC
L	297	298	|I-IUPAC
-	298	299	|I-IUPAC
leucine	299	306	|I-IUPAC
,	306	307	|O
5	308	309	|B-IUPAC
-	309	310	|I-IUPAC
fluoro	310	316	|I-IUPAC
-	316	317	|I-IUPAC
4	317	318	|I-IUPAC
-	318	319	|I-IUPAC
(	319	320	|I-IUPAC
N	320	321	|I-IUPAC
-	321	322	|I-IUPAC
succinamoyl	322	333	|I-IUPAC
-	333	334	|I-IUPAC
L	334	335	|I-IUPAC
-	335	336	|I-IUPAC
alanyl	336	342	|I-IUPAC
-	342	343	|I-IUPAC
L	343	344	|I-IUPAC
-	344	345	|I-IUPAC
leucine	345	352	|I-IUPAC
)	352	353	|I-IUPAC
-	353	354	|I-IUPAC
2	354	355	|I-IUPAC
(	355	356	|I-IUPAC
1H	356	358	|I-IUPAC
)	358	359	|I-IUPAC
-	359	360	|I-IUPAC
pyrimidinone	360	372	|I-IUPAC
[	373	374	|O
a	374	375	|O
5	376	377	|B-IUPAC
-	377	378	|I-IUPAC
fluorocytosine	378	392	|I-IUPAC
derivative	393	403	|B-MODIFIER
]	403	404	|O
,	404	405	|O
and	406	409	|O
5	410	411	|B-IUPAC
-	411	412	|I-IUPAC
fluoroorotyl	412	424	|I-IUPAC
-	424	425	|I-IUPAC
L	425	426	|I-IUPAC
-	426	427	|I-IUPAC
leucyl	427	433	|I-IUPAC
-	433	434	|I-IUPAC
L	434	435	|I-IUPAC
-	435	436	|I-IUPAC
leucine	436	443	|I-IUPAC
all	444	447	|O
inhibited	448	457	|O
the	458	461	|O
uptake	462	468	|O
of	469	471	|O
trimethionine	472	485	|O
into	486	490	|O
C	491	492	|O
.	492	493	|O
albicans	494	502	|O
WD	503	505	|O
18-4	506	510	|O
.	510	511	|O
Inhibition	512	522	|O
by	523	525	|O
5	526	527	|B-IUPAC
-	527	528	|I-IUPAC
fluoroorotyl	528	540	|I-IUPAC
-	540	541	|I-IUPAC
L	541	542	|I-IUPAC
-	542	543	|I-IUPAC
leucyl	543	549	|I-IUPAC
-	549	550	|I-IUPAC
L	550	551	|I-IUPAC
-	551	552	|I-IUPAC
leucine	552	559	|I-IUPAC
was	560	563	|O
competitive	564	575	|O
as	576	578	|O
judged	579	585	|O
using	586	591	|O
double	592	598	|O
-	598	599	|O
reciprocal	599	609	|O
plots	610	615	|O
.	615	616	|O
Evaluation	617	627	|O
of	628	630	|O
minimum	631	638	|O
inhibitory	639	649	|O
concentrations	650	664	|O
of	665	667	|O
peptide	668	675	|B-IUPAC
-	675	676	|I-IUPAC
5	676	677	|I-IUPAC
-	677	678	|I-IUPAC
fluorocytosine	678	692	|I-IUPAC
conjugates	693	703	|B-MODIFIER
suggest	704	711	|O
that	712	716	|O
these	717	722	|O
conjugates	723	733	|O
enter	734	739	|O
C	740	741	|O
.	741	742	|O
albicans	743	751	|O
in	752	754	|O
the	755	758	|O
intact	759	765	|O
form	766	770	|O
.	770	771	|O
These	772	777	|O
results	778	785	|O
provide	786	793	|O
the	794	797	|O
first	798	803	|O
experimental	804	816	|O
evidence	817	825	|O
that	826	830	|O
peptides	831	839	|O
can	840	843	|O
carry	844	849	|O
pyrimidines	850	861	|O
into	862	866	|O
a	867	868	|O
eukaryote	869	878	|O
.	878	879	|O

### abstracts972.txt
In	0	2	|O
a	3	4	|O
previous	5	13	|O
study	14	19	|O
,	19	20	|O
we	21	23	|O
described	24	33	|O
affinity	34	42	|O
labeling	43	51	|O
of	52	54	|O
the	55	58	|O
lamb	59	63	|O
uterine	64	71	|O
estrogen	72	80	|O
receptor	81	89	|O
by	90	92	|O
17	93	95	|B-IUPAC
alpha	96	101	|I-IUPAC
-	101	102	|I-IUPAC
[	102	103	|I-IUPAC
(	103	104	|I-IUPAC
bromoacetoxy	104	116	|I-IUPAC
)	116	117	|I-IUPAC
alkyl	117	122	|I-IUPAC
/	122	123	|I-IUPAC
alkynyl	123	130	|I-IUPAC
]	130	131	|I-IUPAC
estradiols	131	141	|I-IUPAC
.	141	142	|O
However	143	150	|O
,	150	151	|O
the	152	155	|O
intrinsic	156	165	|O
receptor	166	174	|O
-	174	175	|O
alkylating	175	185	|O
activities	186	196	|O
of	197	199	|O
these	200	205	|O
compounds	206	215	|O
were	216	220	|O
probably	221	229	|O
very	230	234	|O
hampered	235	243	|O
by	244	246	|O
their	247	252	|O
poor	253	257	|O
hydrolytic	258	268	|O
stability	269	278	|O
in	279	281	|O
estrogen	282	290	|O
receptor	291	299	|O
-	299	300	|O
containing	300	310	|O
tissue	311	317	|O
extracts	318	326	|O
.	326	327	|O
Therefore	328	337	|O
,	337	338	|O
(	339	340	|O
i	340	341	|O
)	341	342	|O
to	343	345	|O
develop	346	353	|O
affinity	354	362	|O
labels	363	369	|O
of	370	372	|O
the	373	376	|O
receptor	377	385	|O
not	386	389	|O
susceptible	390	401	|O
to	402	404	|O
hydrolysis	405	415	|O
and	416	419	|O
(	420	421	|O
ii	421	423	|O
)	423	424	|O
to	425	427	|O
specify	428	435	|O
the	436	439	|O
structural	440	450	|O
requirements	451	463	|O
for	464	467	|O
17	468	470	|O
alpha	471	476	|O
-	476	477	|O
electrophilic	477	490	|O
estradiol	491	500	|O
derivatives	501	512	|O
to	513	515	|O
be	516	518	|O
potent	519	525	|O
affinity	526	534	|O
labels	535	541	|O
of	542	544	|O
the	545	548	|O
receptor	549	557	|O
,	557	558	|O
we	559	561	|O
prepared	562	570	|O
four	571	575	|O
17	576	578	|B-IUPAC
alpha	579	584	|I-IUPAC
-	584	585	|I-IUPAC
[	585	586	|I-IUPAC
(	586	587	|I-IUPAC
haloacetamido	587	600	|I-IUPAC
)	600	601	|I-IUPAC
alkyl	601	606	|I-IUPAC
]	606	607	|I-IUPAC
estradiols	607	617	|I-IUPAC
.	617	618	|O
Three	619	624	|O
were	625	629	|O
bromoacetamides	630	645	|O
differing	646	655	|O
at	656	658	|O
the	659	662	|O
alkyl	663	668	|O
substituent	669	680	|O
(	681	682	|O
methyl	682	688	|O
,	688	689	|O
ethyl	690	695	|O
,	695	696	|O
or	697	699	|O
propyl	700	706	|O
)	706	707	|O
,	707	708	|O
and	709	712	|O
the	713	716	|O
last	717	721	|O
was	722	725	|O
an	726	728	|O
[	729	730	|B-IUPAC
(	730	731	|I-IUPAC
iodoacetamido	731	744	|I-IUPAC
)	744	745	|I-IUPAC
propyl	745	751	|I-IUPAC
]	751	752	|I-IUPAC
estradiol	752	761	|I-IUPAC
prepared	762	770	|O
under	771	776	|O
both	777	781	|O
nonradioactive	782	796	|O
and	797	800	|O
3H	801	803	|O
-	803	804	|O
labeled	804	811	|O
forms	812	817	|O
.	817	818	|O
Although	819	827	|O
their	828	833	|O
affinities	834	844	|O
for	845	848	|O
the	849	852	|O
estrogen	853	861	|O
receptor	862	870	|O
were	871	875	|O
very	876	880	|O
low	881	884	|O
(	885	886	|O
from	886	890	|O
0.008%	891	897	|O
to	898	900	|O
0.02%	901	906	|O
that	907	911	|O
of	912	914	|O
estradiol	915	924	|O
)	924	925	|O
,	925	926	|O
they	927	931	|O
appeared	932	940	|O
to	941	943	|O
be	944	946	|O
efficient	947	956	|O
affinity	957	965	|O
labels	966	972	|O
of	973	975	|O
the	976	979	|O
receptor	980	988	|O
due	989	992	|O
to	993	995	|O
their	996	1001	|O
irreversible	1002	1014	|O
inhibition	1015	1025	|O
of	1026	1028	|O
[	1029	1030	|B-IUPAC
3H	1030	1032	|I-IUPAC
]	1032	1033	|I-IUPAC
estradiol	1033	1042	|I-IUPAC
specific	1043	1051	|O
binding	1052	1059	|O
in	1060	1062	|O
lamb	1063	1067	|O
uterine	1068	1075	|O
cytosol	1076	1083	|O
.	1083	1084	|O
The	1085	1088	|O
effect	1089	1095	|O
of	1096	1098	|O
the	1099	1102	|O
compounds	1103	1112	|O
was	1113	1116	|O
time	1117	1121	|O
-	1121	1122	|O
,	1122	1123	|O
pH	1124	1126	|O
-	1126	1127	|O
,	1127	1128	|O
and	1129	1132	|O
concentration	1133	1146	|O
-	1146	1147	|O
dependent	1147	1156	|O
,	1156	1157	|O
with	1158	1162	|O
&	1163	1164	|O
gt	1164	1166	|O
;	1166	1167	|O
50%	1168	1171	|O
and	1172	1175	|O
&	1176	1177	|O
gt	1177	1179	|O
;	1179	1180	|O
80%	1181	1184	|O
estrogen	1185	1193	|O
-	1193	1194	|O
binding	1194	1201	|O
sites	1202	1207	|O
inactivated	1208	1219	|O
at	1220	1222	|O
0	1223	1224	|O
degrees	1225	1232	|O
C	1233	1234	|O
and	1235	1238	|O
pH	1239	1241	|O
8.5	1242	1245	|O
,	1245	1246	|O
for	1247	1250	|O
the	1251	1254	|O
less	1255	1259	|O
active	1260	1266	|O
and	1267	1270	|O
more	1271	1275	|O
active	1276	1282	|O
compounds	1283	1292	|O
,	1292	1293	|O
respectively	1294	1306	|O
;	1306	1307	|O
the	1308	1311	|O
corresponding	1312	1325	|O
IC50	1326	1330	|O
values	1331	1337	|O
varied	1338	1344	|O
from	1345	1349	|O
approximately	1350	1363	|O
20	1364	1366	|O
nM	1367	1369	|O
to	1370	1372	|O
approximately	1373	1386	|O
10	1387	1389	|O
microM	1390	1396	|O
.	1396	1397	|O
The	1398	1401	|O
order	1402	1407	|O
of	1408	1410	|O
efficiency	1411	1421	|O
was	1422	1425	|O
[	1426	1427	|B-IUPAC
(	1427	1428	|I-IUPAC
bromoacetamido	1428	1442	|I-IUPAC
)	1442	1443	|I-IUPAC
methyl	1443	1449	|I-IUPAC
]	1449	1450	|I-IUPAC
estradiol	1450	1459	|I-IUPAC
&	1460	1461	|O
lt	1461	1463	|O
;	1463	1464	|O
[	1465	1466	|B-IUPAC
(	1466	1467	|I-IUPAC
bromoacetamido	1467	1481	|I-IUPAC
)	1481	1482	|I-IUPAC
ethyl	1482	1487	|I-IUPAC
]	1487	1488	|I-IUPAC
estradiol	1488	1497	|I-IUPAC
&	1498	1499	|O
lt	1499	1501	|O
;	1501	1502	|O
&	1502	1503	|O
lt	1503	1505	|O
;	1505	1506	|O
[	1507	1508	|B-IUPAC
(	1508	1509	|I-IUPAC
bromoacetamido	1509	1523	|I-IUPAC
)	1523	1524	|I-IUPAC
propyl	1524	1530	|I-IUPAC
]	1530	1531	|I-IUPAC
estradiol	1531	1540	|I-IUPAC
&	1541	1542	|O
lt	1542	1544	|O
;	1544	1545	|O
[	1546	1547	|B-IUPAC
(	1547	1548	|I-IUPAC
iodoacetamido	1548	1561	|I-IUPAC
)	1561	1562	|I-IUPAC
propyl	1562	1568	|I-IUPAC
]	1568	1569	|I-IUPAC
estradiol	1569	1578	|I-IUPAC
.	1578	1579	|O
Affinity	1580	1588	|O
labeling	1589	1597	|O
was	1598	1601	|O
directly	1602	1610	|O
demonstrated	1611	1623	|O
by	1624	1626	|O
ethanol	1627	1634	|O
-	1634	1635	|O
resistant	1635	1644	|O
binding	1645	1652	|O
of	1653	1655	|O
[	1656	1657	|B-IUPAC
3H	1657	1659	|I-IUPAC
]	1659	1660	|I-IUPAC
[	1660	1661	|I-IUPAC
(	1661	1662	|I-IUPAC
iodoacetamido	1662	1675	|I-IUPAC
)	1675	1676	|I-IUPAC
propyl	1676	1682	|I-IUPAC
]	1682	1683	|I-IUPAC
estradiol	1683	1692	|I-IUPAC
to	1693	1695	|O
the	1696	1699	|O
receptor	1700	1708	|O
.	1708	1709	|O
The	1710	1713	|O
irreversible	1714	1726	|O
inactivation	1727	1739	|O
of	1740	1742	|O
the	1743	1746	|O
hormone	1747	1754	|O
-	1754	1755	|O
binding	1755	1762	|O
site	1763	1767	|O
by	1768	1770	|O
the	1771	1774	|O
four	1775	1779	|O
haloacetamides	1780	1794	|O
was	1795	1798	|O
prevented	1799	1808	|O
by	1809	1811	|O
treatment	1812	1821	|O
of	1822	1824	|O
the	1825	1828	|O
cytosol	1829	1836	|O
with	1837	1841	|O
the	1842	1845	|O
thiol	1846	1851	|O
-	1851	1852	|O
specific	1852	1860	|O
reagent	1861	1868	|O
methyl	1869	1875	|O
methanethiosulfonate	1876	1896	|O
,	1896	1897	|O
suggesting	1898	1908	|O
that	1909	1913	|O
the	1914	1917	|O
target	1918	1924	|O
of	1925	1927	|O
these	1928	1933	|O
compounds	1934	1943	|O
was	1944	1947	|O
probably	1948	1956	|O
the	1957	1960	|O
-	1961	1962	|O
SH	1962	1964	|O
of	1965	1967	|O
cysteines	1968	1977	|O
.	1977	1978	|O
Negative	1979	1987	|O
results	1988	1995	|O
obtained	1996	2004	|O
with	2005	2009	|O
other	2010	2015	|O
17	2016	2018	|O
alpha	2019	2024	|O
-	2024	2025	|O
electrophilic	2025	2038	|O
estradiol	2039	2048	|O
derivatives	2049	2060	|O
suggested	2061	2070	|O
that	2071	2075	|O
affinity	2076	2084	|O
labeling	2085	2093	|O
of	2094	2096	|O
the	2097	2100	|O
receptor	2101	2109	|O
by	2110	2112	|O
such	2113	2117	|O
derivatives	2118	2129	|O
required	2130	2138	|O
a	2139	2140	|O
minimal	2141	2148	|O
distance	2149	2157	|O
,	2157	2158	|O
including	2159	2168	|O
at	2169	2171	|O
least	2172	2177	|O
four	2178	2182	|O
C	2183	2184	|O
-	2184	2185	|O
C	2185	2186	|O
or	2187	2189	|O
C	2190	2191	|O
-	2191	2192	|O
N	2192	2193	|O
bonds	2194	2199	|O
,	2199	2200	|O
between	2201	2208	|O
the	2209	2212	|O
steroid	2213	2220	|O
and	2221	2224	|O
the	2225	2228	|O
electrophilic	2229	2242	|O
carbon	2243	2249	|O
.	2249	2250	|O
We	2251	2253	|O
therefore	2254	2263	|O
concluded	2264	2273	|O
that	2274	2278	|O
target	2279	2285	|O
cysteines	2286	2295	|O
in	2296	2298	|O
the	2299	2302	|O
hormone	2303	2310	|O
-	2310	2311	|O
binding	2311	2318	|O
site	2319	2323	|O
were	2324	2328	|O
not	2329	2332	|O
in	2333	2335	|O
direct	2336	2342	|O
contact	2343	2350	|O
with	2351	2355	|O
the	2356	2359	|O
steroid	2360	2367	|O
but	2368	2371	|O
probably	2372	2380	|O
in	2381	2383	|O
the	2384	2387	|O
immediate	2388	2397	|O
neighborhood	2398	2410	|O
of	2411	2413	|O
the	2414	2417	|O
D	2418	2419	|O
ring	2420	2424	|O
of	2425	2427	|O
the	2428	2431	|O
bound	2432	2437	|O
steroid	2438	2445	|O
.	2445	2446	|O

### abstracts678.txt
Ten	0	3	|O
heretofore	4	14	|O
undescribed	15	26	|O
2,4	27	30	|B-IUPAC
-	30	31	|I-IUPAC
diamino	31	38	|I-IUPAC
-	38	39	|I-IUPAC
5	39	40	|I-IUPAC
-	40	41	|I-IUPAC
chloroquinazoline	41	58	|I-IUPAC
analogues	59	68	|B-MODIFIER
of	69	71	|O
trimetrexate	72	84	|O
(	85	86	|O
TMQ	86	89	|O
)	89	90	|O
and	91	94	|O
piritrexim	95	105	|O
(	106	107	|O
PTX	107	110	|O
)	110	111	|O
were	112	116	|O
synthesized	117	128	|O
and	129	132	|O
tested	133	139	|O
as	140	142	|O
inhibitors	143	153	|O
of	154	156	|O
dihydrofolate	157	170	|O
reductase	171	180	|O
(	181	182	|O
DHFR	182	186	|O
)	186	187	|O
from	188	192	|O
rat	193	196	|O
liver	197	202	|O
,	202	203	|O
Pneumocystis	204	216	|O
carinii	217	224	|O
,	224	225	|O
and	226	229	|O
Toxoplasma	230	240	|O
gondii	241	247	|O
.	247	248	|O
The	249	252	|O
most	253	257	|O
active	258	264	|O
quinazolines	265	277	|O
against	278	285	|O
both	286	290	|O
the	291	294	|O
P	295	296	|O
.	296	297	|O
carinii	298	305	|O
and	306	309	|O
the	310	313	|O
T	314	315	|O
.	315	316	|O
gondii	317	323	|O
enzyme	324	330	|O
were	331	335	|O
those	336	341	|O
with	342	346	|O
an	347	349	|O
ArCH2	350	355	|O
-	355	356	|O
NH	356	358	|O
or	359	361	|O
ArNHCH2	362	369	|O
side	370	374	|O
chain	375	380	|O
.	380	381	|O
Among	382	387	|O
ArNH	388	392	|O
(	392	393	|O
CH2	393	396	|O
)	396	397	|O
n	397	398	|O
compounds	399	408	|O
with	409	413	|O
n	414	415	|O
=	416	417	|O
1-3	418	421	|O
and	422	425	|O
either	426	432	|O
2'	433	435	|B-IUPAC
,	435	436	|I-IUPAC
5'	436	438	|I-IUPAC
-	438	439	|I-IUPAC
dimethoxyphenyl	439	454	|I-IUPAC
or	455	457	|O
3'	458	460	|B-IUPAC
,	460	461	|I-IUPAC
4'	461	463	|I-IUPAC
,	463	464	|I-IUPAC
5'	464	466	|I-IUPAC
-	466	467	|I-IUPAC
trimethoxyphenyl	467	483	|I-IUPAC
as	484	486	|O
the	487	490	|O
Ar	491	493	|O
moiety	494	500	|O
,	500	501	|O
activity	502	510	|O
decreased	511	520	|O
in	521	523	|O
the	524	527	|O
order	528	533	|O
n	534	535	|O
=	536	537	|O
1	538	539	|O
&	540	541	|O
gt	541	543	|O
;	543	544	|O
n	545	546	|O
=	547	548	|O
2	549	550	|O
&	551	552	|O
gt	552	554	|O
;	554	555	|O
n	556	557	|O
=	558	559	|O
3	560	561	|O
.	561	562	|O
The	563	566	|O
best	567	571	|O
inhibitor	572	581	|O
of	582	584	|O
P	585	586	|O
.	586	587	|O
carinii	588	595	|O
DHFR	596	600	|O
,	600	601	|O
2,4	602	605	|B-IUPAC
-	605	606	|I-IUPAC
diamino	606	613	|I-IUPAC
-	613	614	|I-IUPAC
5	614	615	|I-IUPAC
-	615	616	|I-IUPAC
chloro	616	622	|I-IUPAC
-	622	623	|I-IUPAC
6	623	624	|I-IUPAC
-	624	625	|I-IUPAC
[	625	626	|I-IUPAC
(	626	627	|I-IUPAC
N	627	628	|I-IUPAC
-	628	629	|I-IUPAC
methyl	629	635	|I-IUPAC
-	635	636	|I-IUPAC
3'	636	638	|I-IUPAC
,	638	639	|I-IUPAC
4'	639	641	|I-IUPAC
,	641	642	|I-IUPAC
5'	642	644	|I-IUPAC
-	644	645	|I-IUPAC
trimethoxyanilino	645	662	|I-IUPAC
)	662	663	|I-IUPAC
methy	663	668	|I-IUPAC
l	669	670	|I-IUPAC
]	670	671	|I-IUPAC
quinazoline	672	683	|I-IUPAC
(	684	685	|O
10	685	687	|O
)	687	688	|O
had	689	692	|O
an	693	695	|O
IC50	696	700	|O
of	701	703	|O
0.012	704	709	|O
microM	710	716	|O
and	717	720	|O
was	721	724	|O
slightly	725	733	|O
more	734	738	|O
potent	739	745	|O
than	746	750	|O
TMQ	751	754	|O
and	755	758	|O
PTX	759	762	|O
.	762	763	|O
Compound	764	772	|O
10	773	775	|O
was	776	779	|O
also	780	784	|O
the	785	788	|O
best	789	793	|O
inhibitor	794	803	|O
of	804	806	|O
T	807	808	|O
.	808	809	|O
gondii	810	816	|O
DHFR	817	821	|O
,	821	822	|O
with	823	827	|O
an	828	830	|O
IC50	831	835	|O
of	836	838	|O
0.0064	839	845	|O
microM	846	852	|O
corresponding	853	866	|O
again	867	872	|O
to	873	875	|O
a	876	877	|O
minor	878	883	|O
increase	884	892	|O
in	893	895	|O
activity	896	904	|O
over	905	909	|O
TMQ	910	913	|O
and	914	917	|O
PTX	918	921	|O
.	921	922	|O
However	923	930	|O
,	930	931	|O
as	932	934	|O
with	935	939	|O
these	940	945	|O
standard	946	954	|O
agents	955	961	|O
,	961	962	|O
10	963	965	|O
showed	966	972	|O
no	973	975	|O
appreciable	976	987	|O
selectivity	988	999	|O
for	1000	1003	|O
either	1004	1010	|O
the	1011	1014	|O
P	1015	1016	|O
.	1016	1017	|O
carinii	1018	1025	|O
or	1026	1028	|O
T	1029	1030	|O
.	1030	1031	|O
gondii	1032	1038	|O
enzyme	1039	1045	|O
relative	1046	1054	|O
to	1055	1057	|O
the	1058	1061	|O
rat	1062	1065	|O
liver	1066	1071	|O
enzyme	1072	1078	|O
.	1078	1079	|O
The	1080	1083	|O
highest	1084	1091	|O
selectivity	1092	1103	|O
achieved	1104	1112	|O
in	1113	1115	|O
this	1116	1120	|O
limited	1121	1128	|O
series	1129	1135	|O
was	1136	1139	|O
with	1140	1144	|O
2,4	1145	1148	|B-IUPAC
-	1148	1149	|I-IUPAC
diamino	1149	1156	|I-IUPAC
-	1156	1157	|I-IUPAC
5	1157	1158	|I-IUPAC
-	1158	1159	|I-IUPAC
chloro	1159	1165	|I-IUPAC
-	1165	1166	|I-IUPAC
6	1166	1167	|I-IUPAC
-	1167	1168	|I-IUPAC
[	1168	1169	|I-IUPAC
N	1169	1170	|I-IUPAC
-	1170	1171	|I-IUPAC
(	1171	1172	|I-IUPAC
3'	1172	1174	|I-IUPAC
,	1174	1175	|I-IUPAC
4'	1175	1177	|I-IUPAC
,	1177	1178	|I-IUPAC
5'	1178	1180	|I-IUPAC
-	1180	1181	|I-IUPAC
trimethoxybenzyl	1181	1197	|I-IUPAC
)	1197	1198	|I-IUPAC
-	1198	1199	|I-IUPAC
N	1199	1200	|I-IUPAC
-	1200	1201	|I-IUPAC
methylamino	1201	1212	|I-IUPAC
]	1212	1213	|I-IUPAC
quinazoline	1214	1225	|I-IUPAC
(	1226	1227	|O
17	1227	1229	|O
)	1229	1230	|O
against	1231	1238	|O
T	1239	1240	|O
.	1240	1241	|O
gondii	1242	1248	|O
DHFR	1249	1253	|O
.	1253	1254	|O
While	1255	1260	|O
17	1261	1263	|O
(	1264	1265	|O
IC50	1265	1269	|O
=	1270	1271	|O
0.016	1272	1277	|O
microM	1278	1284	|O
)	1284	1285	|O
was	1286	1289	|O
somewhat	1290	1298	|O
less	1299	1303	|O
potent	1304	1310	|O
than	1311	1315	|O
10	1316	1318	|O
,	1318	1319	|O
its	1320	1323	|O
selectivity	1324	1335	|O
,	1335	1336	|O
as	1337	1339	|O
defined	1340	1347	|O
by	1348	1350	|O
the	1351	1354	|O
ratio	1355	1360	|O
IC50	1361	1365	|O
(	1365	1366	|O
rat	1366	1369	|O
liver	1370	1375	|O
)	1375	1376	|O
/	1376	1377	|O
IC50	1377	1381	|O
(	1381	1382	|O
T	1382	1383	|O
.	1383	1384	|O
gondii	1385	1391	|O
)	1391	1392	|O
was	1393	1396	|O
ca.	1397	1400	|O
30	1401	1403	|O
-	1403	1404	|O
fold	1404	1408	|O
higher	1409	1415	|O
than	1416	1420	|O
that	1421	1425	|O
of	1426	1428	|O
TMQ	1429	1432	|O
or	1433	1435	|O
PTX	1436	1439	|O
.	1439	1440	|O
Two	1441	1444	|O
compounds	1445	1454	|O
,	1454	1455	|O
2,4	1456	1459	|B-IUPAC
-	1459	1460	|I-IUPAC
diamino	1460	1467	|I-IUPAC
-	1467	1468	|I-IUPAC
5	1468	1469	|I-IUPAC
-	1469	1470	|I-IUPAC
chloro	1470	1476	|I-IUPAC
-	1476	1477	|I-IUPAC
6	1477	1478	|I-IUPAC
-	1478	1479	|I-IUPAC
[	1479	1480	|I-IUPAC
(	1480	1481	|I-IUPAC
3'	1481	1483	|I-IUPAC
,	1483	1484	|I-IUPAC
4'	1484	1486	|I-IUPAC
,	1486	1487	|I-IUPAC
5'	1487	1489	|I-IUPAC
-	1489	1490	|I-IUPAC
trimethoxyanilino	1490	1507	|I-IUPAC
)	1507	1508	|I-IUPAC
methyl	1508	1514	|I-IUPAC
]	1514	1515	|I-IUPAC
quinazoline	1516	1527	|I-IUPAC
(	1528	1529	|O
9	1529	1530	|O
)	1530	1531	|O
and	1532	1535	|O
2,4	1536	1539	|B-IUPAC
-	1539	1540	|I-IUPAC
diamino	1540	1547	|I-IUPAC
-	1547	1548	|I-IUPAC
5	1548	1549	|I-IUPAC
-	1549	1550	|I-IUPAC
chloro	1550	1556	|I-IUPAC
-	1556	1557	|I-IUPAC
6	1557	1558	|I-IUPAC
-	1558	1559	|I-IUPAC
[	1559	1560	|I-IUPAC
N	1560	1561	|I-IUPAC
-	1561	1562	|I-IUPAC
(	1562	1563	|I-IUPAC
3'	1563	1565	|I-IUPAC
,	1565	1566	|I-IUPAC
4'	1566	1568	|I-IUPAC
,	1568	1569	|I-IUPAC
5'	1569	1571	|I-IUPAC
-	1571	1572	|I-IUPAC
trimethoxybenzyl	1572	1588	|I-IUPAC
)	1588	1589	|I-IUPAC
amino	1590	1595	|I-IUPAC
]	1595	1596	|I-IUPAC
quinazoline	1596	1607	|I-IUPAC
(	1608	1609	|O
15	1609	1611	|O
)	1611	1612	|O
,	1612	1613	|O
were	1614	1618	|O
also	1619	1623	|O
tested	1624	1630	|O
against	1631	1638	|O
human	1639	1644	|O
DHFR	1645	1649	|O
and	1650	1653	|O
were	1654	1658	|O
found	1659	1664	|O
to	1665	1667	|O
have	1668	1672	|O
an	1673	1675	|O
IC50	1676	1680	|O
/	1680	1681	|O
[	1681	1682	|O
E	1682	1683	|O
]	1683	1684	|O
of	1685	1687	|O
0.5	1688	1691	|O
,	1691	1692	|O
indicating	1693	1703	|O
that	1704	1708	|O
their	1709	1714	|O
binding	1715	1722	|O
was	1723	1726	|O
near	1727	1731	|O
-	1731	1732	|O
stoichiometric	1732	1746	|O
.	1746	1747	|O

### abstracts2161.txt
A	0	1	|O
number	2	8	|O
of	9	11	|O
5	12	13	|B-IUPAC
-	13	14	|I-IUPAC
heteroaromatic	14	28	|I-IUPAC
-	28	29	|O
substituted	29	40	|B-MODIFIER
2'	41	43	|B-IUPAC
-	43	44	|I-IUPAC
deoxyuridines	44	57	|I-IUPAC
were	58	62	|O
synthesized	63	74	|O
from	75	79	|O
5	80	81	|B-IUPAC
-	81	82	|I-IUPAC
iodo	82	86	|I-IUPAC
-	86	87	|I-IUPAC
2'	87	89	|I-IUPAC
-	89	90	|I-IUPAC
deoxyuridine	90	102	|I-IUPAC
using	103	108	|O
tetraorganotin	109	123	|O
reagents	124	132	|O
and	133	136	|O
palladium	137	146	|O
complexes	147	156	|O
as	157	159	|O
catalyst	160	168	|O
.	168	169	|O
The	170	173	|O
palladium	174	183	|O
-	183	184	|O
catalyzed	184	193	|O
cross	194	199	|O
-	199	200	|O
coupling	200	208	|O
reaction	209	217	|O
between	218	225	|O
5	226	227	|B-IUPAC
-	227	228	|I-IUPAC
iodo	228	232	|I-IUPAC
-	232	233	|I-IUPAC
2'	233	235	|I-IUPAC
-	235	236	|I-IUPAC
deoxyuridine	236	248	|I-IUPAC
and	249	252	|O
stannylated	253	264	|O
heteroaromatics	265	280	|O
was	281	284	|O
optimized	285	294	|O
for	295	298	|O
the	299	302	|O
synthesis	303	312	|O
of	313	315	|O
the	316	319	|O
5	320	321	|B-IUPAC
-	321	322	|I-IUPAC
thien	322	327	|I-IUPAC
-	327	328	|I-IUPAC
3	328	329	|I-IUPAC
-	329	330	|I-IUPAC
yl	330	332	|I-IUPAC
-	332	333	|I-IUPAC
2'	333	335	|I-IUPAC
-	335	336	|I-IUPAC
deoxyuridine	336	348	|I-IUPAC
and	349	352	|O
5	353	354	|B-IUPAC
-	354	355	|I-IUPAC
furan	355	360	|I-IUPAC
-	360	361	|I-IUPAC
3	361	362	|I-IUPAC
-	362	363	|I-IUPAC
yl	363	365	|I-IUPAC
-	365	366	|I-IUPAC
2'	366	368	|I-IUPAC
-	368	369	|I-IUPAC
deoxyuridine	369	381	|I-IUPAC
.	381	382	|O
5	383	384	|B-IUPAC
-	384	385	|I-IUPAC
(	385	386	|I-IUPAC
5	386	387	|I-IUPAC
-	387	388	|I-IUPAC
Iodothien	388	397	|I-IUPAC
-	397	398	|I-IUPAC
2	398	399	|I-IUPAC
-	399	400	|I-IUPAC
yl	400	402	|I-IUPAC
)	402	403	|I-IUPAC
-	403	404	|I-IUPAC
2'	404	406	|I-IUPAC
-	406	407	|I-IUPAC
deoxyuridine	407	419	|I-IUPAC
was	420	423	|O
used	424	428	|O
as	429	431	|O
starting	432	440	|O
material	441	449	|O
for	450	453	|O
the	454	457	|O
synthesis	458	467	|O
of	468	470	|O
5	471	472	|B-IUPAC
-	472	473	|I-IUPAC
(	473	474	|I-IUPAC
5	474	475	|I-IUPAC
-	475	476	|I-IUPAC
methylthien	476	487	|I-IUPAC
-	487	488	|I-IUPAC
2	488	489	|I-IUPAC
-	489	490	|I-IUPAC
yl	490	492	|I-IUPAC
)	492	493	|I-IUPAC
-	493	494	|I-IUPAC
2'	494	496	|I-IUPAC
-	496	497	|I-IUPAC
deoxyuridine	497	509	|I-IUPAC
,	509	510	|O
5	511	512	|B-IUPAC
-	512	513	|I-IUPAC
(	513	514	|I-IUPAC
5	514	515	|I-IUPAC
-	515	516	|I-IUPAC
vinylthien	516	526	|I-IUPAC
-	526	527	|I-IUPAC
2	527	528	|I-IUPAC
-	528	529	|I-IUPAC
yl	529	531	|I-IUPAC
)	531	532	|I-IUPAC
-	532	533	|I-IUPAC
2'	533	535	|I-IUPAC
-	535	536	|I-IUPAC
deoxyuridine	536	548	|I-IUPAC
,	548	549	|O
and	550	553	|O
5	554	555	|B-IUPAC
-	555	556	|I-IUPAC
(	556	557	|I-IUPAC
5	557	558	|I-IUPAC
-	558	559	|I-IUPAC
ethynylthien	559	571	|I-IUPAC
-	571	572	|I-IUPAC
2	572	573	|I-IUPAC
-	573	574	|I-IUPAC
yl	574	576	|I-IUPAC
)	576	577	|I-IUPAC
-	577	578	|I-IUPAC
2'	578	580	|I-IUPAC
-	580	581	|I-IUPAC
deoxyuridine	582	594	|I-IUPAC
.	594	595	|O
5	596	597	|B-IUPAC
-	597	598	|I-IUPAC
(	598	599	|I-IUPAC
5	599	600	|I-IUPAC
-	600	601	|I-IUPAC
Nitrothien	601	611	|I-IUPAC
-	611	612	|I-IUPAC
2	612	613	|I-IUPAC
-	613	614	|I-IUPAC
yl	614	616	|I-IUPAC
)	616	617	|I-IUPAC
-	617	618	|I-IUPAC
2'	618	620	|I-IUPAC
-	620	621	|I-IUPAC
deoxyuridine	621	633	|I-IUPAC
was	634	637	|O
synthesized	638	649	|O
using	650	655	|O
ceric	656	661	|O
ammonium	662	670	|O
nitrate	671	678	|O
as	679	681	|O
reagent	682	689	|O
.	689	690	|O
5	691	692	|B-IUPAC
-	692	693	|I-IUPAC
(	693	694	|I-IUPAC
Isoxazol	694	702	|I-IUPAC
-	702	703	|I-IUPAC
5	703	704	|I-IUPAC
-	704	705	|I-IUPAC
yl	705	707	|I-IUPAC
)	707	708	|I-IUPAC
-	708	709	|I-IUPAC
2'	709	711	|I-IUPAC
-	711	712	|I-IUPAC
deoxyuridine	712	724	|I-IUPAC
was	725	728	|O
synthesized	729	740	|O
from	741	745	|O
5	746	747	|B-IUPAC
-	747	748	|I-IUPAC
(	748	749	|I-IUPAC
3	749	750	|I-IUPAC
-	750	751	|I-IUPAC
oxopropyn	751	760	|I-IUPAC
-	760	761	|I-IUPAC
1	761	762	|I-IUPAC
-	762	763	|I-IUPAC
yl	763	765	|I-IUPAC
)	765	766	|I-IUPAC
-	766	767	|I-IUPAC
2'	767	769	|I-IUPAC
-	769	770	|I-IUPAC
deoxyuridine	770	782	|I-IUPAC
.	782	783	|O
Finally	784	791	|O
,	791	792	|O
5	793	794	|B-IUPAC
-	794	795	|I-IUPAC
(	795	796	|I-IUPAC
5	796	797	|I-IUPAC
-	797	798	|I-IUPAC
chlorothien	798	809	|I-IUPAC
-	809	810	|I-IUPAC
2	810	811	|I-IUPAC
-	811	812	|I-IUPAC
yl	812	814	|I-IUPAC
)	814	815	|I-IUPAC
-	815	816	|I-IUPAC
beta	816	820	|I-IUPAC
-	820	821	|I-IUPAC
D	821	822	|I-IUPAC
-	822	823	|I-IUPAC
arabinofuranosyluracil	823	845	|I-IUPAC
and	846	849	|O
5	850	851	|B-IUPAC
-	851	852	|I-IUPAC
(	852	853	|I-IUPAC
5	853	854	|I-IUPAC
-	854	855	|I-IUPAC
bromothien	855	865	|I-IUPAC
-	865	866	|I-IUPAC
2	866	867	|I-IUPAC
-	867	868	|I-IUPAC
yl	868	870	|I-IUPAC
)	870	871	|I-IUPAC
-	871	872	|I-IUPAC
beta	872	876	|I-IUPAC
-	876	877	|I-IUPAC
D	877	878	|I-IUPAC
-	878	879	|I-IUPAC
arabinofuranosyluracil	879	901	|I-IUPAC
were	902	906	|O
obtained	907	915	|O
by	916	918	|O
halogenation	919	931	|O
of	932	934	|O
5	935	936	|B-IUPAC
-	936	937	|I-IUPAC
thien	937	942	|I-IUPAC
-	942	943	|I-IUPAC
2	943	944	|I-IUPAC
-	944	945	|I-IUPAC
yl	945	947	|I-IUPAC
-	947	948	|I-IUPAC
beta	948	952	|I-IUPAC
-	952	953	|I-IUPAC
D	953	954	|I-IUPAC
-	954	955	|I-IUPAC
arabinofuranosyluracil	955	977	|I-IUPAC
.	977	978	|O
Introduction	979	991	|O
of	992	994	|O
an	995	997	|O
alkyl	998	1003	|O
substituent	1004	1015	|O
in	1016	1018	|O
the	1019	1022	|O
5	1023	1024	|O
-	1024	1025	|O
position	1025	1033	|O
of	1034	1036	|O
the	1037	1040	|O
thienyl	1041	1048	|O
group	1049	1054	|O
of	1055	1057	|O
5	1058	1059	|B-IUPAC
-	1059	1060	|I-IUPAC
thien	1060	1065	|I-IUPAC
-	1065	1066	|I-IUPAC
2	1066	1067	|I-IUPAC
-	1067	1068	|I-IUPAC
yl	1068	1070	|I-IUPAC
-	1070	1071	|I-IUPAC
2'	1071	1073	|I-IUPAC
-	1073	1074	|I-IUPAC
deoxyuridine	1074	1086	|I-IUPAC
or	1087	1089	|O
substitution	1090	1102	|O
of	1103	1105	|O
the	1106	1109	|O
2	1110	1111	|B-IUPAC
-	1111	1112	|I-IUPAC
deoxyribofuranose	1112	1129	|I-IUPAC
ring	1130	1134	|B-MODIFIER
by	1135	1137	|O
an	1138	1140	|O
arabinofuranose	1141	1156	|O
moiety	1157	1163	|O
gave	1164	1168	|O
decreased	1169	1178	|O
activity	1179	1187	|O
against	1188	1195	|O
HSV	1196	1199	|O
-	1199	1200	|O
1	1200	1201	|O
and	1202	1205	|O
VZV	1206	1209	|O
replication	1210	1221	|O
when	1222	1226	|O
compared	1227	1235	|O
with	1236	1240	|O
the	1241	1244	|O
5	1245	1246	|B-IUPAC
"	1246	1247	|I-IUPAC
-	1247	1248	|I-IUPAC
halogenated	1248	1259	|I-IUPAC
-	1259	1260	|I-IUPAC
5	1260	1261	|I-IUPAC
-	1261	1262	|I-IUPAC
thien	1262	1267	|I-IUPAC
-	1267	1268	|I-IUPAC
2	1268	1269	|I-IUPAC
-	1269	1270	|I-IUPAC
yl	1270	1272	|I-IUPAC
-	1272	1273	|I-IUPAC
2'	1273	1275	|I-IUPAC
-	1275	1276	|I-IUPAC
deoxyuridines	1276	1289	|I-IUPAC
.	1289	1290	|O
5	1291	1292	|B-IUPAC
-	1292	1293	|I-IUPAC
(	1293	1294	|I-IUPAC
5	1294	1295	|I-IUPAC
-	1295	1296	|I-IUPAC
Bromothien	1296	1306	|I-IUPAC
-	1306	1307	|I-IUPAC
2	1307	1308	|I-IUPAC
-	1308	1309	|I-IUPAC
yl	1309	1311	|I-IUPAC
)	1311	1312	|I-IUPAC
-	1312	1313	|I-IUPAC
2'	1313	1315	|I-IUPAC
-	1315	1316	|I-IUPAC
deoxyuridine	1316	1328	|I-IUPAC
caused	1329	1335	|O
prompt	1336	1342	|O
healing	1343	1350	|O
of	1351	1353	|O
HSV	1354	1357	|O
-	1357	1358	|O
1	1358	1359	|O
keratitis	1360	1369	|O
when	1370	1374	|O
administered	1375	1387	|O
as	1388	1390	|O
eye	1391	1394	|O
drops	1395	1400	|O
(	1401	1402	|O
0.2%	1402	1406	|O
)	1406	1407	|O
to	1408	1410	|O
rabbits	1411	1418	|O
.	1418	1419	|O

### abstracts3546.txt
(	0	1	|O
3S	1	3	|O
,	3	4	|O
4R	4	6	|O
)	6	7	|O
-	7	8	|O
4	8	9	|O
-	9	10	|O
(	10	11	|O
4	11	12	|O
-	12	13	|O
Fluorophenyl	13	25	|O
)	25	26	|O
-	26	27	|O
3	27	28	|O
-	28	29	|O
[	29	30	|O
[	30	31	|O
3,4	31	34	|O
-	34	35	|O
(	35	36	|O
methylenedioxy	36	50	|O
)	50	51	|O
phenoxy	51	58	|O
]	58	59	|O
methyl	59	65	|O
]	65	66	|O
piperidine	67	77	|O
[	78	79	|O
(	79	80	|O
3S	80	82	|O
,	82	83	|O
9R	83	85	|O
)	85	86	|O
-	86	87	|O
3	87	88	|O
,	88	89	|O
paroxetine	90	100	|O
]	100	101	|O
is	102	104	|O
a	105	106	|O
selective	107	116	|O
serotonin	117	126	|O
reuptake	127	135	|O
inhibitor	136	145	|O
(	146	147	|O
SSRI	147	151	|O
)	151	152	|O
used	153	157	|O
as	158	160	|O
an	161	163	|O
antidepressant	164	178	|O
in	179	181	|O
humans	182	188	|O
.	188	189	|O
In	190	192	|O
previous	193	201	|O
studies	202	209	|O
,	209	210	|O
we	211	213	|O
reported	214	222	|O
that	223	227	|O
certain	228	235	|O
(	236	237	|B-PARTIUPAC
1R	237	239	|I-PARTIUPAC
)	239	240	|I-PARTIUPAC
-	240	241	|I-PARTIUPAC
3	241	242	|I-PARTIUPAC
beta	243	247	|I-PARTIUPAC
-	247	248	|I-PARTIUPAC
(	248	249	|O
substituted	249	260	|B-MODIFIER
phenyl	261	267	|B-IUPAC
)	267	268	|O
nortropane	268	278	|B-PARTIUPAC
-	278	279	|I-PARTIUPAC
2	279	280	|I-PARTIUPAC
beta	281	285	|I-PARTIUPAC
-	285	286	|I-PARTIUPAC
carboxylic	286	296	|I-PARTIUPAC
acid	297	301	|I-PARTIUPAC
methyl	302	308	|I-PARTIUPAC
esters	309	315	|I-PARTIUPAC
(	316	317	|O
2a	317	319	|O
)	319	320	|O
exhibited	321	330	|O
high	331	335	|O
affinity	336	344	|O
and	345	348	|O
reasonable	349	359	|O
selectivity	360	371	|O
for	372	375	|O
the	376	379	|O
serotonin	380	389	|O
transporter	390	401	|O
(	402	403	|O
5	403	404	|O
-	404	405	|O
HTT	405	408	|O
)	408	409	|O
.	409	410	|O
The	411	414	|O
major	415	420	|O
structural	421	431	|O
differences	432	443	|O
between	444	451	|O
2a	452	454	|O
and	455	458	|O
(	459	460	|O
3S	460	462	|O
,	462	463	|O
4R	463	465	|O
)	465	466	|O
-	466	467	|O
3	467	468	|O
are	469	472	|O
that	473	477	|O
2a	478	480	|O
possesses	481	490	|O
a	491	492	|O
different	493	502	|O
absolute	503	511	|O
stereochemistry	512	527	|O
and	528	531	|O
has	532	535	|O
an	536	538	|O
ethylene	539	547	|O
bridge	548	554	|O
not	555	558	|O
present	559	566	|O
in	567	569	|O
3	570	571	|O
.	571	572	|O
In	573	575	|O
addition	576	584	|O
,	584	585	|O
2a	586	588	|O
possesses	589	598	|O
a	599	600	|O
carbomethoxy	601	613	|O
substituent	614	625	|O
adjacent	626	634	|O
to	635	637	|O
the	638	641	|O
aryl	642	646	|O
ring	647	651	|O
,	651	652	|O
whereas	653	660	|O
(	661	662	|O
3S	662	664	|O
,	664	665	|O
4R	665	667	|O
)	667	668	|O
-	668	669	|O
3	669	670	|O
contains	671	679	|O
a	680	681	|O
[	682	683	|B-IUPAC
3,4	683	686	|I-IUPAC
-	686	687	|I-IUPAC
(	687	688	|I-IUPAC
methylenedioxy	688	702	|I-IUPAC
)	702	703	|I-IUPAC
phenoxy	703	710	|I-IUPAC
]	710	711	|I-IUPAC
methyl	711	717	|I-IUPAC
group	718	723	|B-MODIFIER
.	723	724	|O
In	725	727	|O
this	728	732	|O
study	733	738	|O
,	738	739	|O
we	740	742	|O
present	743	750	|O
the	751	754	|O
synthesis	755	764	|O
and	765	768	|O
biological	769	779	|O
evaluations	780	791	|O
of	792	794	|O
six	795	798	|O
of	799	801	|O
the	802	805	|O
possible	806	814	|O
eight	815	820	|O
isomers	821	828	|O
of	829	831	|O
3	832	833	|B-IUPAC
-	833	834	|I-IUPAC
(	834	835	|I-IUPAC
4	835	836	|I-IUPAC
-	836	837	|I-IUPAC
fluorophenyl	837	849	|I-IUPAC
)	849	850	|I-IUPAC
-	850	851	|I-IUPAC
2	851	852	|I-IUPAC
-	852	853	|I-IUPAC
[	853	854	|I-IUPAC
[	854	855	|I-IUPAC
3,4	855	858	|I-IUPAC
-	858	859	|I-IUPAC
(	859	860	|I-IUPAC
methylenedioxy	860	874	|I-IUPAC
)	874	875	|I-IUPAC
phenoxy	875	882	|I-IUPAC
]	882	883	|I-IUPAC
methyl	883	889	|I-IUPAC
]	889	890	|I-IUPAC
nortropane	890	900	|I-IUPAC
+	900	901	|O
+	902	903	|O
+	903	904	|O
(	905	906	|O
4	906	907	|O
)	907	908	|O
.	908	909	|O
The	910	913	|O
data	914	918	|O
for	919	922	|O
inhibition	923	933	|O
of	934	936	|O
[	937	938	|O
3H	938	940	|O
]	940	941	|O
paroxetine	941	951	|O
binding	952	959	|O
show	960	964	|O
that	965	969	|O
(	970	971	|O
1R	971	973	|O
)	973	974	|O
-	974	975	|O
2	975	976	|O
beta	977	981	|O
,	981	982	|O
3	983	984	|O
alpha	985	990	|O
-	990	991	|O
4c	991	993	|O
,	993	994	|O
which	995	1000	|O
has	1001	1004	|O
the	1005	1008	|O
same	1009	1013	|O
stereochemistry	1014	1029	|O
as	1030	1032	|O
paroxetine	1033	1043	|O
,	1043	1044	|O
has	1045	1048	|O
the	1049	1052	|O
highest	1053	1060	|O
affinity	1061	1069	|O
at	1070	1072	|O
the	1073	1076	|O
5	1077	1078	|O
-	1078	1079	|O
HTT	1079	1082	|O
.	1082	1083	|O
Strikingly	1084	1094	|O
,	1094	1095	|O
the	1096	1099	|O
most	1100	1104	|O
potent	1105	1111	|O
compounds	1112	1121	|O
for	1122	1125	|O
inhibition	1126	1136	|O
of	1137	1139	|O
[	1140	1141	|O
3H	1141	1143	|O
]	1143	1144	|O
WIN	1144	1147	|O
-	1147	1148	|O
35,428	1148	1154	|O
binding	1155	1162	|O
were	1163	1167	|O
not	1168	1171	|O
the	1172	1175	|O
(	1176	1177	|O
1R	1177	1179	|O
)	1179	1180	|O
-	1180	1181	|O
2	1181	1182	|O
beta	1183	1187	|O
,	1187	1188	|O
3	1189	1190	|O
beta	1191	1195	|O
-	1195	1196	|O
isomers	1196	1203	|O
but	1204	1207	|O
rather	1208	1214	|O
(	1215	1216	|O
1R	1216	1218	|O
)	1218	1219	|O
-	1219	1220	|O
2	1220	1221	|O
beta	1222	1226	|O
,	1226	1227	|O
3	1228	1229	|O
alpha	1230	1235	|O
-	1235	1236	|O
4c	1236	1238	|O
and	1239	1242	|O
(	1243	1244	|O
1S	1244	1246	|O
)	1246	1247	|O
-	1247	1248	|O
2	1248	1249	|O
beta	1250	1254	|O
,	1254	1255	|O
3	1256	1257	|O
alpha	1258	1263	|O
-	1263	1264	|O
4f	1264	1266	|O
.	1266	1267	|O
Conformational	1268	1282	|O
analyses	1283	1291	|O
show	1292	1296	|O
that	1297	1301	|O
these	1302	1307	|O
isomers	1308	1315	|O
exist	1316	1321	|O
in	1322	1324	|O
a	1325	1326	|O
flattened	1327	1336	|O
boat	1337	1341	|O
conformation	1342	1354	|O
with	1355	1359	|O
pseudoequatorial	1360	1376	|O
substituents	1377	1389	|O
.	1389	1390	|O
Thus	1391	1395	|O
,	1395	1396	|O
the	1397	1400	|O
binding	1401	1408	|O
data	1409	1413	|O
show	1414	1418	|O
that	1419	1423	|O
this	1424	1428	|O
conformation	1429	1441	|O
is	1442	1444	|O
recognized	1445	1455	|O
by	1456	1458	|O
the	1459	1462	|O
DAT	1463	1466	|O
-	1466	1467	|O
associated	1467	1477	|O
binding	1478	1485	|O
site	1486	1490	|O
and	1491	1494	|O
also	1495	1499	|O
suggest	1500	1507	|O
that	1508	1512	|O
this	1513	1517	|O
conformation	1518	1530	|O
of	1531	1533	|O
paroxetine	1534	1544	|O
is	1545	1547	|O
recognized	1548	1558	|O
by	1559	1561	|O
the	1562	1565	|O
5	1566	1567	|O
-	1567	1568	|O
HTT	1568	1571	|O
-	1571	1572	|O
associated	1572	1582	|O
binding	1583	1590	|O
site	1591	1595	|O
.	1595	1596	|O

### abstracts715.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
1	12	13	|B-IUPAC
-	13	14	|I-IUPAC
[	14	15	|I-IUPAC
(	15	16	|I-IUPAC
4	16	17	|I-IUPAC
-	17	18	|I-IUPAC
hydroxyphenethyl	18	34	|I-IUPAC
)	34	35	|I-IUPAC
amino	35	40	|I-IUPAC
]	40	41	|I-IUPAC
-	41	42	|I-IUPAC
3	42	43	|I-IUPAC
-	43	44	|I-IUPAC
(	44	45	|I-IUPAC
aryloxy	45	52	|I-IUPAC
)	52	53	|I-IUPAC
propan	53	59	|I-IUPAC
-	59	60	|I-IUPAC
2	60	61	|I-IUPAC
-	61	62	|I-IUPAC
ols	62	65	|I-IUPAC
was	66	69	|O
synthesized	70	81	|O
together	82	90	|O
with	91	95	|O
several	96	103	|O
1	104	105	|B-IUPAC
-	105	106	|I-IUPAC
[	106	107	|I-IUPAC
(	107	108	|I-IUPAC
3,4	108	111	|I-IUPAC
-	111	112	|I-IUPAC
dimethoxyphenethyl	112	130	|I-IUPAC
)	130	131	|I-IUPAC
amino	131	136	|I-IUPAC
]	136	137	|I-IUPAC
-	137	138	|I-IUPAC
3	138	139	|I-IUPAC
-	139	140	|I-IUPAC
(	140	141	|I-IUPAC
aryloxy	141	148	|I-IUPAC
)	148	149	|I-IUPAC
propan	149	155	|I-IUPAC
-	155	156	|I-IUPAC
2	156	157	|I-IUPAC
-	157	158	|I-IUPAC
ols	158	161	|I-IUPAC
.	161	162	|O
Their	163	168	|O
affinity	169	177	|O
to	178	180	|O
beta	181	185	|O
1	186	187	|O
-	187	188	|O
and	189	192	|O
beta	193	197	|O
-	197	198	|O
2	198	199	|O
-	199	200	|O
adrenoceptors	200	213	|O
was	214	217	|O
determined	218	228	|O
and	229	232	|O
compared	233	241	|O
with	242	246	|O
the	247	250	|O
affinity	251	259	|O
of	260	262	|O
known	263	268	|O
beta	269	273	|O
-	273	274	|O
blockers	274	282	|O
.	282	283	|O
We	284	286	|O
were	287	291	|O
able	292	296	|O
to	297	299	|O
confirm	300	307	|O
the	308	311	|O
substantial	312	323	|O
cardioselectivity	324	341	|O
of	342	344	|O
1	345	346	|B-PARTIUPAC
-	346	347	|I-PARTIUPAC
(	347	348	|I-PARTIUPAC
3,4	348	351	|I-PARTIUPAC
-	351	352	|I-PARTIUPAC
dimethoxyphenethyl	352	370	|I-PARTIUPAC
)	370	371	|I-PARTIUPAC
-	371	372	|I-PARTIUPAC
3	372	373	|I-PARTIUPAC
-	373	374	|I-PARTIUPAC
[	374	375	|I-PARTIUPAC
(	375	376	|I-PARTIUPAC
4	376	377	|B-MODIFIER
-	377	378	|I-MODIFIER
substituted	378	389	|I-MODIFIER
aryl	390	394	|B-IUPAC
)	394	395	|B-PARTIUPAC
oxy	395	398	|I-PARTIUPAC
]	398	399	|I-PARTIUPAC
propan	399	405	|I-PARTIUPAC
-	405	406	|I-PARTIUPAC
2	406	407	|I-PARTIUPAC
-	407	408	|I-PARTIUPAC
ols	408	411	|I-PARTIUPAC
when	412	416	|O
compared	417	425	|O
to	426	428	|O
those	429	434	|O
with	435	439	|O
a	440	441	|O
1	442	443	|B-IUPAC
-	443	444	|I-IUPAC
(	444	445	|I-IUPAC
4	445	446	|I-IUPAC
-	446	447	|I-IUPAC
hydroxyphenethyl	447	463	|I-IUPAC
)	463	464	|I-IUPAC
group	465	470	|B-MODIFIER
.	470	471	|O
An	472	474	|O
increase	475	483	|O
in	484	486	|O
the	487	490	|O
size	491	495	|O
of	496	498	|O
the	499	502	|O
4	503	504	|O
substitutent	505	517	|O
of	518	520	|O
the	521	524	|O
3	525	526	|O
-	526	527	|O
(	527	528	|O
aryloxy	528	535	|O
)	535	536	|O
moiety	537	543	|O
to	544	546	|O
caproamido	547	557	|O
leads	558	563	|O
to	564	566	|O
a	567	568	|O
substantially	569	582	|O
higher	583	589	|O
affinity	590	598	|O
for	599	602	|O
the	603	606	|O
beta	607	611	|O
1	612	613	|O
-	613	614	|O
-	614	615	|O
adrenoceptor	615	627	|O
of	628	630	|O
rat	631	634	|O
ventricular	635	646	|O
muscle	647	653	|O
in	654	656	|O
the	657	660	|O
presence	661	669	|O
of	670	672	|O
the	673	676	|O
3,4	677	680	|B-IUPAC
-	680	681	|I-IUPAC
dimethoxyphenethyl	681	699	|I-IUPAC
than	700	704	|O
in	705	707	|O
the	708	711	|O
presence	712	720	|O
of	721	723	|O
the	724	727	|O
4	728	729	|B-IUPAC
-	729	730	|I-IUPAC
hydroxyphenethyl	730	746	|I-IUPAC
or	747	749	|O
isopropyl	750	759	|O
group	760	765	|O
;	765	766	|O
this	767	771	|O
combination	772	783	|O
also	784	788	|O
gave	789	793	|O
the	794	797	|O
highest	798	805	|O
cardioselectivity	806	823	|O
.	823	824	|O

### abstracts4526.txt
A	0	1	|O
number	2	8	|O
of	9	11	|O
1	12	13	|B-IUPAC
-	13	14	|I-IUPAC
hydroxyazole	14	26	|I-IUPAC
derivatives	27	38	|B-MODIFIER
were	39	43	|O
synthesized	44	55	|O
as	56	58	|O
bioisosteres	59	71	|O
of	72	74	|O
(	75	76	|B-IUPAC
S	76	77	|I-IUPAC
)	77	78	|I-IUPAC
-	78	79	|I-IUPAC
glutamic	79	87	|I-IUPAC
acid	88	92	|I-IUPAC
(	93	94	|O
Glu	94	97	|O
)	97	98	|O
and	99	102	|O
as	103	105	|O
analogues	106	115	|O
of	116	118	|O
the	119	122	|O
AMPA	123	127	|O
receptor	128	136	|O
agonist	137	144	|O
(	145	146	|B-IUPAC
R	146	147	|I-IUPAC
,	147	148	|I-IUPAC
S	148	149	|I-IUPAC
)	149	150	|I-IUPAC
-	150	151	|I-IUPAC
2	151	152	|I-IUPAC
-	152	153	|I-IUPAC
amino	153	158	|I-IUPAC
-	158	159	|I-IUPAC
3	159	160	|I-IUPAC
-	160	161	|I-IUPAC
(	161	162	|I-IUPAC
3	162	163	|I-IUPAC
-	163	164	|I-IUPAC
hydroxy	164	171	|I-IUPAC
-	171	172	|I-IUPAC
5	172	173	|I-IUPAC
-	173	174	|I-IUPAC
methyl	174	180	|I-IUPAC
-	180	181	|I-IUPAC
4	181	182	|I-IUPAC
-	182	183	|I-IUPAC
isoxazolyl	183	193	|I-IUPAC
)	193	194	|I-IUPAC
propionic	194	203	|I-IUPAC
acid	204	208	|I-IUPAC
(	209	210	|O
AMPA	210	214	|O
,	214	215	|O
3b	216	218	|O
)	218	219	|O
.	219	220	|O
All	221	224	|O
compounds	225	234	|O
were	235	239	|O
subjected	240	249	|O
to	250	252	|O
in	253	255	|O
vitro	256	261	|O
pharmacological	262	277	|O
studies	278	285	|O
,	285	286	|O
including	287	296	|O
a	297	298	|O
series	299	305	|O
of	306	308	|O
Glu	309	312	|O
receptor	313	321	|O
binding	322	329	|O
assays	330	336	|O
,	336	337	|O
uptake	338	344	|O
studies	345	352	|O
on	353	355	|O
native	356	362	|O
as	363	365	|O
well	366	370	|O
as	371	373	|O
cloned	374	380	|O
Glu	381	384	|O
uptake	385	391	|O
systems	392	399	|O
,	399	400	|O
and	401	404	|O
the	405	408	|O
electrophysiological	409	429	|O
rat	430	433	|O
cortical	434	442	|O
slice	443	448	|O
model	449	454	|O
.	454	455	|O
Compounds	456	465	|O
7a	466	468	|O
,	468	469	|O
b	469	470	|O
,	470	471	|O
analogues	472	481	|O
of	482	484	|O
AMPA	485	489	|O
bearing	490	497	|O
a	498	499	|O
1	500	501	|B-IUPAC
-	501	502	|I-IUPAC
hydroxy	502	509	|I-IUPAC
-	509	510	|I-IUPAC
5	510	511	|I-IUPAC
-	511	512	|I-IUPAC
pyrazolyl	512	521	|I-IUPAC
moiety	522	528	|B-MODIFIER
as	529	531	|O
the	532	535	|O
distal	536	542	|O
carboxylic	543	553	|O
functionality	554	567	|O
,	567	568	|O
showed	569	575	|O
only	576	580	|O
moderate	581	589	|O
affinity	590	598	|O
for	599	602	|O
[	603	604	|O
3H	604	606	|O
]	606	607	|O
AMPA	607	611	|O
receptor	612	620	|O
binding	621	628	|O
sites	629	634	|O
(	635	636	|O
IC	636	638	|O
(	638	639	|O
50	639	641	|O
)	641	642	|O
=	643	644	|O
2.7	645	648	|O
+	649	650	|O
/	650	651	|O
-	651	652	|O
0.4	653	656	|O
microM	657	663	|O
and	664	667	|O
IC	668	670	|O
(	670	671	|O
50	671	673	|O
)	673	674	|O
=	675	676	|O
2.6	677	680	|O
+	681	682	|O
/	682	683	|O
-	683	684	|O
0.6	685	688	|O
microM	689	695	|O
,	695	696	|O
respectively	697	709	|O
)	709	710	|O
,	710	711	|O
correlating	712	723	|O
with	724	728	|O
electrophysiological	729	749	|O
data	750	754	|O
from	755	759	|O
the	760	763	|O
rat	764	767	|O
cortical	768	776	|O
wedge	777	782	|O
model	783	788	|O
(	789	790	|O
EC	790	792	|O
(	792	793	|O
50	793	795	|O
)	795	796	|O
=	797	798	|O
280	799	802	|O
+	803	804	|O
/	804	805	|O
-	805	806	|O
48	807	809	|O
microM	810	816	|O
and	817	820	|O
EC	821	823	|O
(	823	824	|O
50	824	826	|O
)	826	827	|O
=	828	829	|O
586	830	833	|O
+	834	835	|O
/	835	836	|O
-	836	837	|O
41	838	840	|O
microM	841	847	|O
,	847	848	|O
respectively	849	861	|O
)	861	862	|O
.	862	863	|O
1	864	865	|B-IUPAC
-	865	866	|I-IUPAC
Hydroxy	866	873	|I-IUPAC
-	873	874	|I-IUPAC
1,2,3	874	879	|I-IUPAC
-	879	880	|I-IUPAC
triazol	880	887	|I-IUPAC
-	887	888	|I-IUPAC
5	888	889	|I-IUPAC
-	889	890	|I-IUPAC
yl	890	892	|I-IUPAC
analogues	893	902	|B-MODIFIER
of	903	905	|O
AMPA	906	910	|O
,	910	911	|O
compounds	912	921	|O
8a	922	924	|O
,	924	925	|O
b	925	926	|O
,	926	927	|O
showed	928	934	|O
high	935	939	|O
affinity	940	948	|O
for	949	952	|O
[	953	954	|O
3H	954	956	|O
]	956	957	|O
AMPA	957	961	|O
receptor	962	970	|O
binding	971	978	|O
sites	979	984	|O
(	985	986	|O
IC	986	988	|O
(	988	989	|O
50	989	991	|O
)	991	992	|O
=	993	994	|O
0.15	995	999	|O
+	1000	1001	|O
/	1001	1002	|O
-	1002	1003	|O
0.03	1004	1008	|O
microM	1009	1015	|O
and	1016	1019	|O
IC	1020	1022	|O
(	1022	1023	|O
50	1023	1025	|O
)	1025	1026	|O
=	1027	1028	|O
0.13	1029	1033	|O
+	1034	1035	|O
/	1035	1036	|O
-	1036	1037	|O
0.02	1038	1042	|O
microM	1043	1049	|O
,	1049	1050	|O
respectively	1051	1063	|O
)	1063	1064	|O
.	1064	1065	|O
Electrophysiological	1066	1086	|O
data	1087	1091	|O
showed	1092	1098	|O
that	1099	1103	|O
compound	1104	1112	|O
8a	1113	1115	|O
was	1116	1119	|O
devoid	1120	1126	|O
of	1127	1129	|O
activity	1130	1138	|O
in	1139	1141	|O
the	1142	1145	|O
rat	1146	1149	|O
cortical	1150	1158	|O
wedge	1159	1164	|O
model	1165	1170	|O
(	1171	1172	|O
EC	1172	1174	|O
(	1174	1175	|O
50	1175	1177	|O
)	1177	1178	|O
&	1179	1180	|O
gt	1180	1182	|O
;	1182	1183	|O
1000	1184	1188	|O
microM	1189	1195	|O
)	1195	1196	|O
,	1196	1197	|O
whereas	1198	1205	|O
the	1206	1209	|O
corresponding	1210	1223	|O
4	1224	1225	|B-IUPAC
-	1225	1226	|I-IUPAC
methyl	1226	1232	|I-IUPAC
analogue	1233	1241	|B-MODIFIER
8b	1242	1244	|O
was	1245	1248	|O
a	1249	1250	|O
potent	1251	1257	|O
AMPA	1258	1262	|O
receptor	1263	1271	|O
agonist	1272	1279	|O
(	1280	1281	|O
EC	1281	1283	|O
(	1283	1284	|O
50	1284	1286	|O
)	1286	1287	|O
=	1288	1289	|O
15	1290	1292	|O
+	1293	1294	|O
/	1294	1295	|O
-	1295	1296	|O
2	1297	1298	|O
microM	1299	1305	|O
)	1305	1306	|O
.	1306	1307	|O
In	1308	1310	|O
accordance	1311	1321	|O
with	1322	1326	|O
this	1327	1331	|O
disparity	1332	1341	|O
,	1341	1342	|O
compound	1343	1351	|O
8a	1352	1354	|O
was	1355	1358	|O
found	1359	1364	|O
to	1365	1367	|O
inhibit	1368	1375	|O
synaptosomal	1376	1388	|O
[	1389	1390	|O
3H	1390	1392	|O
]	1392	1393	|O
D	1393	1394	|O
-	1394	1395	|O
aspartic	1395	1403	|O
acid	1404	1408	|O
uptake	1409	1415	|O
(	1416	1417	|O
IC	1417	1419	|O
(	1419	1420	|O
50	1420	1422	|O
)	1422	1423	|O
=	1424	1425	|O
93	1426	1428	|O
+	1429	1430	|O
/	1430	1431	|O
-	1431	1432	|O
25	1433	1435	|O
microM	1436	1442	|O
)	1442	1443	|O
,	1443	1444	|O
as	1445	1447	|O
well	1448	1452	|O
as	1453	1455	|O
excitatory	1456	1466	|O
amino	1467	1472	|O
acid	1473	1477	|O
transporters	1478	1490	|O
(	1491	1492	|O
EAATs	1492	1497	|O
)	1497	1498	|O
EAAT1	1499	1504	|O
(	1505	1506	|O
IC	1506	1508	|O
(	1508	1509	|O
50	1509	1511	|O
)	1511	1512	|O
=	1513	1514	|O
100	1515	1518	|O
+	1519	1520	|O
/	1520	1521	|O
-	1521	1522	|O
30	1523	1525	|O
microM	1526	1532	|O
)	1532	1533	|O
and	1534	1537	|O
EAAT2	1538	1543	|O
(	1544	1545	|O
IC	1545	1547	|O
(	1547	1548	|O
50	1548	1550	|O
)	1550	1551	|O
=	1552	1553	|O
300	1554	1557	|O
+	1558	1559	|O
/	1559	1560	|O
-	1560	1561	|O
80	1562	1564	|O
microM	1565	1571	|O
)	1571	1572	|O
.	1572	1573	|O
By	1574	1576	|O
contrast	1577	1585	|O
,	1585	1586	|O
compound	1587	1595	|O
8b	1596	1598	|O
showed	1599	1605	|O
no	1606	1608	|O
appreciable	1609	1620	|O
affinity	1621	1629	|O
for	1630	1633	|O
Glu	1634	1637	|O
uptake	1638	1644	|O
sites	1645	1650	|O
,	1650	1651	|O
neither	1652	1659	|O
synaptosomal	1660	1672	|O
nor	1673	1676	|O
cloned	1677	1683	|O
.	1683	1684	|O
Compounds	1685	1694	|O
9a	1695	1697	|O
-	1697	1698	|O
c	1698	1699	|O
and	1700	1703	|O
10a	1704	1707	|O
,	1707	1708	|O
b	1708	1709	|O
,	1709	1710	|O
possessing	1711	1721	|O
1	1722	1723	|B-IUPAC
-	1723	1724	|I-IUPAC
hydroxyimidazole	1724	1740	|I-IUPAC
as	1741	1743	|O
the	1744	1747	|O
terminal	1748	1756	|O
acidic	1757	1763	|O
function	1764	1772	|O
,	1772	1773	|O
were	1774	1778	|O
devoid	1779	1785	|O
of	1786	1788	|O
activity	1789	1797	|O
in	1798	1800	|O
all	1801	1804	|O
of	1805	1807	|O
the	1808	1811	|O
systems	1812	1819	|O
tested	1820	1826	|O
.	1826	1827	|O
Protolytic	1828	1838	|O
properties	1839	1849	|O
of	1850	1852	|O
compounds	1853	1862	|O
7a	1863	1865	|O
,	1865	1866	|O
b	1866	1867	|O
,	1867	1868	|O
8b	1869	1871	|O
,	1871	1872	|O
and	1873	1876	|O
9b	1877	1879	|O
were	1880	1884	|O
determined	1885	1895	|O
by	1896	1898	|O
titration	1899	1908	|O
,	1908	1909	|O
and	1910	1913	|O
a	1914	1915	|O
correlation	1916	1927	|O
between	1928	1935	|O
the	1936	1939	|O
pK	1940	1942	|O
(	1942	1943	|O
a	1943	1944	|O
)	1944	1945	|O
values	1946	1952	|O
and	1953	1956	|O
the	1957	1960	|O
activity	1961	1969	|O
at	1970	1972	|O
AMPA	1973	1977	|O
receptors	1978	1987	|O
was	1988	1991	|O
apparent	1992	2000	|O
.	2000	2001	|O
Optimized	2002	2011	|O
structures	2012	2022	|O
of	2023	2025	|O
all	2026	2029	|O
the	2030	2033	|O
synthesized	2034	2045	|O
ligands	2046	2053	|O
were	2054	2058	|O
fitted	2059	2065	|O
to	2066	2068	|O
the	2069	2072	|O
known	2073	2078	|O
crystal	2079	2086	|O
structure	2087	2096	|O
of	2097	2099	|O
an	2100	2102	|O
AMPA	2103	2107	|O
-	2107	2108	|O
GluR2	2108	2113	|O
construct	2114	2123	|O
.	2123	2124	|O
Where	2125	2130	|O
substantial	2131	2142	|O
reduction	2143	2152	|O
or	2153	2155	|O
abolition	2156	2165	|O
of	2166	2168	|O
affinity	2169	2177	|O
at	2178	2180	|O
AMPA	2181	2185	|O
receptors	2186	2195	|O
was	2196	2199	|O
observed	2200	2208	|O
,	2208	2209	|O
this	2210	2214	|O
could	2215	2220	|O
be	2221	2223	|O
rationalized	2224	2236	|O
on	2237	2239	|O
the	2240	2243	|O
basis	2244	2249	|O
of	2250	2252	|O
the	2253	2256	|O
ability	2257	2264	|O
of	2265	2267	|O
the	2268	2271	|O
ligand	2272	2278	|O
to	2279	2281	|O
fit	2282	2285	|O
the	2286	2289	|O
construct	2290	2299	|O
.	2299	2300	|O
The	2301	2304	|O
results	2305	2312	|O
presented	2313	2322	|O
in	2323	2325	|O
this	2326	2330	|O
article	2331	2338	|O
point	2339	2344	|O
to	2345	2347	|O
the	2348	2351	|O
utility	2352	2359	|O
of	2360	2362	|O
1	2363	2364	|B-IUPAC
-	2364	2365	|I-IUPAC
hydroxypyrazole	2365	2380	|I-IUPAC
and	2381	2384	|O
1,2,3	2385	2390	|B-IUPAC
-	2390	2391	|I-IUPAC
hydroxytriazole	2391	2406	|I-IUPAC
as	2407	2409	|O
bioisosteres	2410	2422	|O
of	2423	2425	|O
carboxylic	2426	2436	|O
acids	2437	2442	|O
at	2443	2445	|O
Glu	2446	2449	|O
receptors	2450	2459	|O
and	2460	2463	|O
transporters	2464	2476	|O
.	2476	2477	|O
None	2478	2482	|O
of	2483	2485	|O
the	2486	2489	|O
compounds	2490	2499	|O
showed	2500	2506	|O
significant	2507	2518	|O
activity	2519	2527	|O
at	2528	2530	|O
metabotropic	2531	2543	|O
Glu	2544	2547	|O
receptors	2548	2557	|O
.	2557	2558	|O

### abstracts2378.txt
Methyl	0	6	|B-IUPAC
4	7	8	|I-IUPAC
-	8	9	|I-IUPAC
(	9	10	|I-IUPAC
isothiocyanatomethyl	10	30	|I-IUPAC
)	30	31	|I-IUPAC
thiazole	31	39	|I-IUPAC
-	39	40	|I-IUPAC
2	40	41	|I-IUPAC
-	41	42	|I-IUPAC
carbamate	42	51	|I-IUPAC
and	52	55	|O
methyl	56	62	|B-IUPAC
4	63	64	|I-IUPAC
-	64	65	|I-IUPAC
(	65	66	|I-IUPAC
isothiocyanatomethyl	66	86	|I-IUPAC
)	86	87	|I-IUPAC
selenazole	87	97	|I-IUPAC
-	97	98	|I-IUPAC
2	98	99	|I-IUPAC
-	99	100	|I-IUPAC
carbamate	100	109	|I-IUPAC
have	110	114	|O
been	115	119	|O
prepared	120	128	|O
via	129	132	|O
chemical	133	141	|O
transformations	142	157	|O
involving	158	167	|O
2	168	169	|B-IUPAC
-	169	170	|I-IUPAC
amino	170	175	|I-IUPAC
-	175	176	|I-IUPAC
4	176	177	|I-IUPAC
-	177	178	|I-IUPAC
(	178	179	|I-IUPAC
chloromethyl	179	191	|I-IUPAC
)	191	192	|I-IUPAC
thiazole	192	200	|I-IUPAC
(	201	202	|O
1	202	203	|O
)	203	204	|O
and	205	208	|O
2	209	210	|B-IUPAC
-	210	211	|I-IUPAC
amino	211	216	|I-IUPAC
-	216	217	|I-IUPAC
4	217	218	|I-IUPAC
-	218	219	|I-IUPAC
(	219	220	|I-IUPAC
chloromethyl	220	232	|I-IUPAC
)	232	233	|I-IUPAC
selenazole	233	243	|I-IUPAC
(	244	245	|O
2	245	246	|O
)	246	247	|O
,	247	248	|O
respectively	249	261	|O
,	261	262	|O
as	263	265	|O
starting	266	274	|O
materials	275	284	|O
.	284	285	|O
The	286	289	|O
homoanalog	290	300	|O
,	300	301	|O
methyl	302	308	|B-IUPAC
4	309	310	|I-IUPAC
-	310	311	|I-IUPAC
(	311	312	|I-IUPAC
2	312	313	|I-IUPAC
-	313	314	|I-IUPAC
isothiocyanatoethyl	314	333	|I-IUPAC
)	333	334	|I-IUPAC
thiazole	334	342	|I-IUPAC
-	342	343	|I-IUPAC
2	343	344	|I-IUPAC
-	344	345	|I-IUPAC
carbamate	345	354	|I-IUPAC
,	354	355	|O
was	356	359	|O
prepared	360	368	|O
from	369	373	|O
(	374	375	|B-IUPAC
2	375	376	|I-IUPAC
-	376	377	|I-IUPAC
aminothiazol	377	389	|I-IUPAC
-	389	390	|I-IUPAC
4	390	391	|I-IUPAC
-	391	392	|I-IUPAC
yl	392	394	|I-IUPAC
)	394	395	|I-IUPAC
acetic	395	401	|I-IUPAC
acid	402	406	|I-IUPAC
.	406	407	|O
All	408	411	|O
compounds	412	421	|O
prepared	422	430	|O
were	431	435	|O
evaluated	436	445	|O
for	446	449	|O
their	450	455	|O
ability	456	463	|O
to	464	466	|O
inhibit	467	474	|O
leukemia	475	483	|O
L1210	484	489	|O
cell	490	494	|O
proliferation	495	508	|O
.	508	509	|O
Methyl	510	516	|B-IUPAC
4	517	518	|I-IUPAC
-	518	519	|I-IUPAC
(	519	520	|I-IUPAC
isothiocyanatomethyl	520	540	|I-IUPAC
)	540	541	|I-IUPAC
thiazole	541	549	|I-IUPAC
-	549	550	|I-IUPAC
2	550	551	|I-IUPAC
-	551	552	|I-IUPAC
carbamate	552	561	|I-IUPAC
(	562	563	|O
7	563	564	|O
)	564	565	|O
was	566	569	|O
the	570	573	|O
most	574	578	|O
active	579	585	|O
compound	586	594	|O
in	595	597	|O
this	598	602	|O
screen	603	609	|O
,	609	610	|O
inhibiting	611	621	|O
the	622	625	|O
growth	626	632	|O
of	633	635	|O
L1210	636	641	|O
leukemic	642	650	|O
cells	651	656	|O
with	657	661	|O
an	662	664	|O
IC50	665	669	|O
=	670	671	|O
3.2	672	675	|O
microM	676	682	|O
.	682	683	|O
Mitotic	684	691	|O
blocking	692	700	|O
appears	701	708	|O
to	709	711	|O
be	712	714	|O
its	715	718	|O
primary	719	726	|O
mechanism	727	736	|O
of	737	739	|O
cytotoxic	740	749	|O
activity	750	758	|O
.	758	759	|O
Compound	760	768	|O
7	769	770	|O
also	771	775	|O
was	776	779	|O
the	780	783	|O
only	784	788	|O
compound	789	797	|O
which	798	803	|O
demonstrated	804	816	|O
significant	817	828	|O
in	829	831	|O
vivo	832	836	|O
antifilarial	837	849	|O
activity	850	858	|O
against	859	866	|O
the	867	870	|O
adult	871	876	|O
worms	877	882	|O
of	883	885	|O
Acanthocheilonema	886	903	|O
viteae	904	910	|O
in	911	913	|O
experimentally	914	928	|O
infected	929	937	|O
jirds	938	943	|O
.	943	944	|O
This	945	949	|O
compound	950	958	|O
was	959	962	|O
inactive	963	971	|O
against	972	979	|O
Brugia	980	986	|O
pahangi	987	994	|O
at	995	997	|O
a	998	999	|O
dosage	1000	1006	|O
of	1007	1009	|O
100	1010	1013	|O
mg	1014	1016	|O
/	1016	1017	|O
kg	1017	1019	|O
x	1020	1021	|O
5	1022	1023	|O
days	1024	1028	|O
.	1028	1029	|O

### abstracts2903.txt
From	0	4	|O
salicyclic	5	15	|O
acid	16	20	|O
,	20	21	|O
the	22	25	|O
two	26	29	|O
enantiomers	30	41	|O
of	42	44	|O
N	45	46	|B-IUPAC
-	46	47	|I-IUPAC
[	47	48	|I-IUPAC
(	48	49	|I-IUPAC
1	49	50	|I-IUPAC
-	50	51	|I-IUPAC
ethyl	51	56	|I-IUPAC
-	56	57	|I-IUPAC
2	57	58	|I-IUPAC
-	58	59	|I-IUPAC
pyrrolidinyl	59	71	|I-IUPAC
)	71	72	|I-IUPAC
methyl	72	78	|I-IUPAC
]	78	79	|I-IUPAC
-	79	80	|I-IUPAC
5	80	81	|I-IUPAC
-	81	82	|I-IUPAC
iodo	82	86	|I-IUPAC
-	86	87	|I-IUPAC
2	87	88	|I-IUPAC
-	88	89	|I-IUPAC
methoxybenzamide	89	105	|I-IUPAC
(	106	107	|O
6b	107	109	|O
)	109	110	|O
were	111	115	|O
prepared	116	124	|O
in	125	127	|O
a	128	129	|O
five	130	134	|O
-	134	135	|O
step	135	139	|O
synthesis	140	149	|O
.	149	150	|O
With	151	155	|O
use	156	159	|O
of	160	162	|O
Heindel	163	170	|O
's	170	172	|O
triazene	173	181	|O
method	182	188	|O
for	189	192	|O
introduction	193	205	|O
of	206	208	|O
the	209	212	|O
radionuclide	213	225	|O
,	225	226	|O
the	227	230	|O
iodine	231	237	|O
-	237	238	|O
125	238	241	|O
-	241	242	|O
labeled	242	249	|O
substituted	250	261	|O
benzamide	262	271	|O
was	272	275	|O
obtained	276	284	|O
with	285	289	|O
a	290	291	|O
calculated	292	302	|O
specific	303	311	|O
activity	312	320	|O
of	321	323	|O
136	324	327	|O
Ci	328	330	|O
/	330	331	|O
mmol	331	335	|O
and	336	339	|O
14%	340	343	|O
radiochemical	344	357	|O
yield	358	363	|O
.	363	364	|O
For	365	368	|O
the	369	372	|O
preparation	373	384	|O
of	385	387	|O
the	388	391	|O
iodine	392	398	|O
-	398	399	|O
125	399	402	|O
-	402	403	|O
labeled	403	410	|O
benzamide	411	420	|O
with	421	425	|O
higher	426	432	|O
specific	433	441	|O
activity	442	450	|O
,	450	451	|O
this	452	456	|O
method	457	463	|O
was	464	467	|O
unsuccessful	468	480	|O
and	481	484	|O
utilization	485	496	|O
of	497	499	|O
the	500	503	|O
corresponding	504	517	|O
tri	518	521	|B-IUPAC
-	521	522	|I-IUPAC
n	522	523	|I-IUPAC
-	523	524	|I-IUPAC
butyltin	524	532	|I-IUPAC
derivative	533	543	|B-MODIFIER
was	544	547	|O
required	548	556	|O
.	556	557	|O
Treatment	558	567	|O
of	568	570	|O
the	571	574	|O
latter	575	581	|O
in	582	584	|O
dilute	585	591	|O
hydrochloric	592	604	|O
acid	605	609	|O
with	610	614	|O
sodium	615	621	|O
iodide	622	628	|O
-	628	629	|O
125	629	632	|O
and	633	636	|O
chloramine	637	647	|O
-	647	648	|O
T	648	649	|O
gave	650	654	|O
[	655	656	|O
125I	656	660	|O
]	660	661	|O
(	661	662	|O
S	662	663	|O
)	663	664	|O
-	664	665	|O
6b	665	667	|O
in	668	670	|O
56%	671	674	|O
radiochemical	675	688	|O
yield	689	694	|O
and	695	698	|O
at	699	701	|O
least	702	707	|O
97%	708	711	|O
radiochemical	712	725	|O
purity	726	732	|O
.	732	733	|O
The	734	737	|O
displacement	738	750	|O
of	751	753	|O
[	754	755	|B-PARTIUPAC
125I	755	759	|I-PARTIUPAC
]	759	760	|I-PARTIUPAC
(	760	761	|I-PARTIUPAC
S	761	762	|I-PARTIUPAC
)	762	763	|I-PARTIUPAC
-	763	764	|I-PARTIUPAC
6b	764	766	|O
and	767	770	|O
[	771	772	|B-IUPAC
3H	772	774	|I-IUPAC
]	774	775	|I-IUPAC
(	775	776	|I-IUPAC
S	776	777	|I-IUPAC
)	777	778	|I-IUPAC
-	778	779	|I-IUPAC
sulpiride	779	788	|I-IUPAC
from	789	793	|O
their	794	799	|O
respective	800	810	|O
binding	811	818	|O
sites	819	824	|O
in	825	827	|O
striatal	828	836	|O
rat	837	840	|O
brain	841	846	|O
homogenates	847	858	|O
using	859	864	|O
various	865	872	|O
neuroleptic	873	884	|O
agents	885	891	|O
showed	892	898	|O
that	899	903	|O
(	904	905	|O
S	905	906	|O
)	906	907	|O
-	907	908	|O
6b	908	910	|O
has	911	914	|O
the	915	918	|O
same	919	923	|O
binding	924	931	|O
profile	932	939	|O
but	940	943	|O
more	944	948	|O
potent	949	955	|O
binding	956	963	|O
for	964	967	|O
dopamine	968	976	|O
D	977	978	|O
-	978	979	|O
2	979	980	|O
receptors	981	990	|O
than	991	995	|O
has	996	999	|O
sulpiride	1000	1009	|O
.	1009	1010	|O
These	1011	1016	|O
experiments	1017	1028	|O
also	1029	1033	|O
indicate	1034	1042	|O
that	1043	1047	|O
the	1048	1051	|O
S	1052	1053	|O
enantiomer	1054	1064	|O
of	1065	1067	|O
6b	1068	1070	|O
is	1071	1073	|O
a	1074	1075	|O
specific	1076	1084	|O
ligand	1085	1091	|O
(	1092	1093	|O
KD	1093	1095	|O
=	1096	1097	|O
1.2	1098	1101	|O
nM	1102	1104	|O
)	1104	1105	|O
for	1106	1109	|O
the	1110	1113	|O
D	1114	1115	|O
-	1115	1116	|O
2	1116	1117	|O
receptor	1118	1126	|O
.	1126	1127	|O
Further	1128	1135	|O
,	1135	1136	|O
the	1137	1140	|O
octanol	1141	1148	|O
-	1148	1149	|O
water	1149	1154	|O
partition	1155	1164	|O
coefficient	1165	1176	|O
of	1177	1179	|O
(	1180	1181	|O
S	1181	1182	|O
)	1182	1183	|O
-	1183	1184	|O
6b	1184	1186	|O
as	1187	1189	|O
determined	1190	1200	|O
by	1201	1203	|O
reverse	1204	1211	|O
-	1211	1212	|O
phase	1212	1217	|O
high	1218	1222	|O
-	1222	1223	|O
performance	1223	1234	|O
liquid	1235	1241	|O
chromatography	1242	1256	|O
was	1257	1260	|O
found	1261	1266	|O
to	1267	1269	|O
be	1270	1272	|O
40	1273	1275	|O
times	1276	1281	|O
greater	1282	1289	|O
than	1290	1294	|O
that	1295	1299	|O
for	1300	1303	|O
sulpiride	1304	1313	|O
.	1313	1314	|O
Thus	1315	1319	|O
(	1320	1321	|O
S	1321	1322	|O
)	1322	1323	|O
-	1323	1324	|O
6b	1324	1326	|O
has	1327	1330	|O
a	1331	1332	|O
lipophilicity	1333	1346	|O
that	1347	1351	|O
will	1352	1356	|O
allow	1357	1362	|O
a	1363	1364	|O
relatively	1365	1375	|O
higher	1376	1382	|O
uptake	1383	1389	|O
into	1390	1394	|O
the	1395	1398	|O
brain	1399	1404	|O
compared	1405	1413	|O
to	1414	1416	|O
sulpiride	1417	1426	|O
.	1426	1427	|O
In	1428	1430	|O
vivo	1431	1435	|O
experiments	1436	1447	|O
with	1448	1452	|O
rats	1453	1457	|O
show	1458	1462	|O
that	1463	1467	|O
[	1468	1469	|O
125I	1469	1473	|O
]	1473	1474	|O
(	1474	1475	|O
S	1475	1476	|O
)	1476	1477	|O
-	1477	1478	|O
6b	1478	1480	|O
penetrates	1481	1491	|O
readily	1492	1499	|O
into	1500	1504	|O
the	1505	1508	|O
brain	1509	1514	|O
and	1515	1518	|O
is	1519	1521	|O
preferentially	1522	1536	|O
localized	1537	1546	|O
in	1547	1549	|O
the	1550	1553	|O
striatum	1554	1562	|O
as	1563	1565	|O
compared	1566	1574	|O
to	1575	1577	|O
the	1578	1581	|O
cerebellum	1582	1592	|O
,	1592	1593	|O
the	1594	1597	|O
ratio	1598	1603	|O
of	1604	1606	|O
uptake	1607	1613	|O
being	1614	1619	|O
7.2	1620	1623	|O
to	1624	1626	|O
1	1627	1628	|O
,	1628	1629	|O
60	1630	1632	|O
min	1633	1636	|O
after	1637	1642	|O
injection	1643	1652	|O
.	1652	1653	|O
These	1654	1659	|O
observations	1660	1672	|O
of	1673	1675	|O
good	1676	1680	|O
brain	1681	1686	|O
penetration	1687	1698	|O
and	1699	1702	|O
high	1703	1707	|O
affinity	1708	1716	|O
and	1717	1720	|O
selectivity	1721	1732	|O
for	1733	1736	|O
D	1737	1738	|O
-	1738	1739	|O
2	1739	1740	|O
receptors	1741	1750	|O
indicate	1751	1759	|O
that	1760	1764	|O
the	1765	1768	|O
corresponding	1769	1782	|O
iodine	1783	1789	|O
-	1789	1790	|O
123	1790	1793	|O
-	1793	1794	|O
labeled	1794	1801	|O
benzamide	1802	1811	|O
may	1812	1815	|O
be	1816	1818	|O
a	1819	1820	|O
useful	1821	1827	|O
ligand	1828	1834	|O
for	1835	1838	|O
the	1839	1842	|O
noninvasive	1843	1854	|O
visualization	1855	1868	|O
study	1869	1874	|O
of	1875	1877	|O
dopamine	1878	1886	|O
D	1887	1888	|O
-	1888	1889	|O
2	1889	1890	|O
receptor	1891	1899	|O
sites	1900	1905	|O
in	1906	1908	|O
vivo	1909	1913	|O
by	1914	1916	|O
single	1917	1923	|O
photon	1924	1930	|O
emission	1931	1939	|O
computed	1940	1948	|O
tomography	1949	1959	|O
.	1959	1960	|O

### abstracts2868.txt
The	0	3	|O
inhibitions	4	15	|O
of	16	18	|O
cytochrome	19	29	|O
P	30	31	|O
-	31	32	|O
450	32	35	|O
dependent	36	45	|O
monooxygenase	46	59	|O
activity	60	68	|O
in	69	71	|O
microsomes	72	82	|O
from	83	87	|O
rat	88	91	|O
liver	92	97	|O
by	98	100	|O
1	101	102	|B-IUPAC
-	102	103	|I-IUPAC
phenylpyrrole	103	116	|I-IUPAC
,	116	117	|O
1	118	119	|B-IUPAC
-	119	120	|I-IUPAC
(	120	121	|I-IUPAC
2	121	122	|I-IUPAC
-	122	123	|I-IUPAC
isopropylphenyl	123	138	|I-IUPAC
)	138	139	|I-IUPAC
pyrrole	139	146	|I-IUPAC
,	146	147	|O
4	148	149	|B-IUPAC
(	149	150	|I-IUPAC
5	150	151	|I-IUPAC
)	151	152	|I-IUPAC
-	152	153	|I-IUPAC
phenylimidazole	153	168	|I-IUPAC
,	168	169	|O
and	170	173	|O
1	174	175	|B-IUPAC
-	175	176	|I-IUPAC
(	176	177	|I-IUPAC
2	177	178	|I-IUPAC
-	178	179	|I-IUPAC
isopropylphenyl	179	194	|I-IUPAC
)	194	195	|I-IUPAC
imidazole	195	204	|I-IUPAC
have	205	209	|O
been	210	214	|O
compared	215	223	|O
.	223	224	|O
The	225	228	|O
results	229	236	|O
establish	237	246	|O
that	247	251	|O
the	252	255	|O
presence	256	264	|O
of	265	267	|O
an	268	270	|O
imidazole	271	280	|O
N	281	282	|O
-	282	283	|O
3	283	284	|O
nitrogen	285	293	|O
substituent	294	305	|O
is	306	308	|O
not	309	312	|O
required	313	321	|O
to	322	324	|O
inhibit	325	332	|O
the	333	336	|O
monooxygenase	337	350	|O
activity	351	359	|O
measured	360	368	|O
by	369	371	|O
the	372	375	|O
deethylation	376	388	|O
of	389	391	|O
7	392	393	|B-IUPAC
-	393	394	|I-IUPAC
ethoxycoumarin	394	408	|I-IUPAC
.	408	409	|O
The	410	413	|O
presence	414	422	|O
of	423	425	|O
an	426	428	|O
appropriately	429	442	|O
situated	443	451	|O
N	452	453	|O
-	453	454	|O
3	454	455	|O
atom	456	460	|O
,	460	461	|O
however	462	469	|O
,	469	470	|O
as	471	473	|O
in	474	476	|O
1	477	478	|B-IUPAC
-	478	479	|I-IUPAC
(	479	480	|I-IUPAC
2	480	481	|I-IUPAC
-	481	482	|I-IUPAC
isopropylphenyl	482	497	|I-IUPAC
)	497	498	|I-IUPAC
imidazole	498	507	|I-IUPAC
,	507	508	|O
significantly	509	522	|O
decreases	523	532	|O
both	533	537	|O
the	538	541	|O
Ki	542	544	|O
and	545	548	|O
alphaKi	549	556	|O
of	557	559	|O
these	560	565	|O
mixed	566	571	|O
type	572	576	|O
inhibitors	577	587	|O
.	587	588	|O
The	589	592	|O
induction	593	602	|O
of	603	605	|O
7	606	607	|B-IUPAC
-	607	608	|I-IUPAC
ethoxycoumarin	608	622	|I-IUPAC
deethylase	623	633	|O
activity	634	642	|O
in	643	645	|O
the	646	649	|O
microsomal	650	660	|O
fraction	661	669	|O
from	670	674	|O
rat	675	678	|O
liver	679	684	|O
by	685	687	|O
alpha	688	693	|B-IUPAC
-	693	694	|I-IUPAC
naphthoflavone	694	708	|I-IUPAC
,	708	709	|O
beta	710	714	|B-IUPAC
-	714	715	|I-IUPAC
naphthoflavone	715	729	|I-IUPAC
,	729	730	|O
and	731	734	|O
3	735	736	|B-IUPAC
-	736	737	|I-IUPAC
methylcholanthrene	737	755	|I-IUPAC
and	756	759	|O
the	760	763	|O
inhibition	764	774	|O
of	775	777	|O
these	778	783	|O
activities	784	794	|O
by	795	797	|O
flavone	798	805	|O
and	806	809	|O
alpha	810	815	|B-PARTIUPAC
-	815	816	|I-PARTIUPAC
,	816	817	|O
beta	818	822	|B-PARTIUPAC
,	822	823	|O
and	824	827	|O
gamma	828	833	|B-IUPAC
-	833	834	|I-IUPAC
naphthoflavone	834	848	|I-IUPAC
have	849	853	|O
also	854	858	|O
been	859	863	|O
examined	864	872	|O
.	872	873	|O
The	874	877	|O
results	878	885	|O
establish	886	895	|O
that	896	900	|O
alpha	901	906	|B-IUPAC
-	906	907	|I-IUPAC
naphthoflavone	907	921	|I-IUPAC
is	922	924	|O
the	925	928	|O
most	929	933	|O
effective	934	943	|O
in	944	946	|O
vitro	947	952	|O
inhibitor	953	962	|O
.	962	963	|O
The	964	967	|O
results	968	975	|O
also	976	980	|O
indicate	981	989	|O
that	990	994	|O
the	995	998	|O
microsomal	999	1009	|O
monooxygenase	1010	1023	|O
activities	1024	1034	|O
induced	1035	1042	|O
in	1043	1045	|O
rat	1046	1049	|O
liver	1050	1055	|O
by	1056	1058	|O
alpha	1059	1064	|B-IUPAC
-	1064	1065	|I-IUPAC
naphthoflavone	1065	1079	|I-IUPAC
,	1079	1080	|O
beta	1081	1085	|B-IUPAC
-	1085	1086	|I-IUPAC
naphthoflavone	1086	1100	|I-IUPAC
,	1100	1101	|O
and	1102	1105	|O
3	1106	1107	|B-IUPAC
-	1107	1108	|I-IUPAC
methylcholanthrene	1108	1126	|I-IUPAC
are	1127	1130	|O
not	1131	1134	|O
equivalent	1135	1145	|O
.	1145	1146	|O
Based	1147	1152	|O
upon	1153	1157	|O
the	1158	1161	|O
observed	1162	1170	|O
results	1171	1178	|O
,	1178	1179	|O
it	1180	1182	|O
is	1183	1185	|O
concluded	1186	1195	|O
that	1196	1200	|O
differential	1201	1213	|O
effects	1214	1221	|O
of	1222	1224	|O
alpha	1225	1230	|B-PARTIUPAC
-	1230	1231	|I-PARTIUPAC
and	1232	1235	|O
beta	1236	1240	|B-IUPAC
-	1240	1241	|I-IUPAC
naphthoflavone	1241	1255	|I-IUPAC
on	1256	1258	|O
aryl	1259	1263	|O
hydrocarbon	1264	1275	|O
skin	1276	1280	|O
tumorigenesis	1281	1294	|O
may	1295	1298	|O
be	1299	1301	|O
the	1302	1305	|O
result	1306	1312	|O
of	1313	1315	|O
differential	1316	1328	|O
enzyme	1329	1335	|O
induction	1336	1345	|O
rather	1346	1352	|O
than	1353	1357	|O
the	1358	1361	|O
result	1362	1368	|O
of	1369	1371	|O
differential	1372	1384	|O
enzyme	1385	1391	|O
inhibition	1392	1402	|O
.	1402	1403	|O

### abstracts3439.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
4	12	13	|B-IUPAC
-	13	14	|I-IUPAC
(	14	15	|I-IUPAC
1H	15	17	|I-IUPAC
-	17	18	|I-IUPAC
indol	18	23	|I-IUPAC
-	23	24	|I-IUPAC
3	24	25	|I-IUPAC
-	25	26	|I-IUPAC
yl	26	28	|I-IUPAC
)	28	29	|I-IUPAC
-	29	30	|I-IUPAC
1	30	31	|I-IUPAC
-	31	32	|I-IUPAC
butyl	32	37	|I-IUPAC
-	37	38	|O
substituted	38	49	|B-MODIFIER
4	50	51	|B-IUPAC
-	51	52	|I-IUPAC
phenylpiperidines	52	69	|I-IUPAC
,	69	70	|O
4	71	72	|B-IUPAC
-	72	73	|I-IUPAC
phenyl	73	79	|I-IUPAC
-	79	80	|I-IUPAC
1,2,3,6	80	87	|I-IUPAC
-	87	88	|I-IUPAC
tetrahydropyridines	88	107	|I-IUPAC
,	107	108	|O
and	109	112	|O
4	113	114	|B-IUPAC
-	114	115	|I-IUPAC
phenylpiperazines	115	132	|I-IUPAC
was	133	136	|O
synthesized	137	148	|O
.	148	149	|O
The	150	153	|O
phenyl	154	160	|B-IUPAC
group	161	166	|B-MODIFIER
was	167	170	|O
optionally	171	181	|O
substituted	182	193	|O
with	194	198	|O
4	199	200	|B-IUPAC
-	200	201	|I-IUPAC
fluoro	201	207	|I-IUPAC
or	208	210	|O
2	211	212	|B-IUPAC
-	212	213	|I-IUPAC
methoxy	213	220	|I-IUPAC
substituents	221	233	|B-MODIFIER
.	233	234	|O
High	235	239	|O
affinity	240	248	|O
for	249	252	|O
both	253	257	|O
sigma	258	263	|O
1	264	265	|O
and	266	269	|O
sigma	270	275	|O
2	276	277	|O
binding	278	285	|O
sites	286	291	|O
was	292	295	|O
achieved	296	304	|O
with	305	309	|O
these	310	315	|O
compounds	316	325	|O
.	325	326	|O
Additionally	327	339	|O
,	339	340	|O
these	341	346	|O
compounds	347	356	|O
had	357	360	|O
relatively	361	371	|O
high	372	376	|O
affinity	377	385	|O
for	386	389	|O
serotonin	390	399	|O
5	400	401	|O
-	401	402	|O
HT1A	402	406	|O
and	407	410	|O
5	411	412	|O
-	412	413	|O
HT2A	413	417	|O
,	417	418	|O
dopamine	419	427	|O
D2	428	430	|O
,	430	431	|O
and	432	435	|O
adrenergic	436	446	|O
alpha	447	452	|O
1	453	454	|O
receptors	455	464	|O
.	464	465	|O
Introduction	466	478	|O
of	479	481	|O
a	482	483	|O
4	484	485	|B-IUPAC
-	485	486	|I-IUPAC
fluorophenyl	486	498	|I-IUPAC
substituent	499	510	|B-MODIFIER
at	511	513	|O
the	514	517	|O
indole	518	524	|O
nitrogen	525	533	|O
atom	534	538	|O
rendered	539	547	|O
very	548	552	|O
selective	553	562	|O
sigma	563	568	|O
2	569	570	|O
ligands	571	578	|O
with	579	583	|O
subnanomolar	584	596	|O
affinity	597	605	|O
for	606	609	|O
the	610	613	|O
sigma	614	619	|O
2	620	621	|O
binding	622	629	|O
site	630	634	|O
.	634	635	|O
The	636	639	|O
prototype	640	649	|O
of	650	652	|O
such	653	657	|O
a	658	659	|O
compound	660	668	|O
was	669	672	|O
1	673	674	|B-IUPAC
-	674	675	|I-IUPAC
(	675	676	|I-IUPAC
4	676	677	|I-IUPAC
-	677	678	|I-IUPAC
fluorophenyl	678	690	|I-IUPAC
)	690	691	|I-IUPAC
-	691	692	|I-IUPAC
3	692	693	|I-IUPAC
-	693	694	|I-IUPAC
[	694	695	|I-IUPAC
4	695	696	|I-IUPAC
-	696	697	|I-IUPAC
[	697	698	|I-IUPAC
4	698	699	|I-IUPAC
-	699	700	|I-IUPAC
(	700	701	|I-IUPAC
4	701	702	|I-IUPAC
-	702	703	|I-IUPAC
fluorophenyl	703	715	|I-IUPAC
)	715	716	|I-IUPAC
-	716	717	|I-IUPAC
1	717	718	|I-IUPAC
-	718	719	|I-IUPAC
piperidinyl	719	730	|I-IUPAC
]	730	731	|I-IUPAC
-	731	732	|I-IUPAC
1	732	733	|I-IUPAC
-	733	734	|I-IUPAC
butyl	734	739	|I-IUPAC
]	739	740	|I-IUPAC
-	740	741	|I-IUPAC
1H	741	743	|I-IUPAC
-	743	744	|I-IUPAC
indole	745	751	|I-IUPAC
,	751	752	|O
11a	753	756	|O
(	757	758	|O
code	758	762	|O
no	763	765	|O
.	765	766	|O
Lu	767	769	|O
29-253	770	776	|O
)	776	777	|O
.	777	778	|O
This	779	783	|O
compound	784	792	|O
had	793	796	|O
the	797	800	|O
following	801	810	|O
binding	811	818	|O
affinities	819	829	|O
:	829	830	|O
IC50	831	835	|O
(	836	837	|O
sigma	837	842	|O
1	843	844	|O
)	844	845	|O
=	846	847	|O
16	848	850	|O
nM	851	853	|O
,	853	854	|O
IC50	855	859	|O
(	860	861	|O
sigma	861	866	|O
2	867	868	|O
)	868	869	|O
=	870	871	|O
0.27	872	876	|O
nM	877	879	|O
,	879	880	|O
IC50	881	885	|O
(	886	887	|O
5	887	888	|O
-	888	889	|O
HT1A	889	893	|O
)	893	894	|O
=	895	896	|O
22,000	897	903	|O
nM	904	906	|O
,	906	907	|O
IC50	908	912	|O
(	913	914	|O
5	914	915	|O
-	915	916	|O
HT2A	916	920	|O
)	920	921	|O
=	922	923	|O
270	924	927	|O
nM	928	930	|O
,	930	931	|O
IC50	932	936	|O
(	937	938	|O
D2	938	940	|O
)	940	941	|O
=	942	943	|O
4200	944	948	|O
nM	949	951	|O
,	951	952	|O
IC50	953	957	|O
(	958	959	|O
alpha	959	964	|O
1	965	966	|O
)	966	967	|O
=	968	969	|O
220	970	973	|O
nM	974	976	|O
.	976	977	|O
Spiro	978	983	|O
-	983	984	|O
joining	984	991	|O
of	992	994	|O
the	995	998	|O
phenyl	999	1005	|B-IUPAC
and	1006	1009	|O
the	1010	1013	|O
piperidine	1014	1024	|B-IUPAC
rings	1025	1030	|B-MODIFIER
into	1031	1035	|O
a	1036	1037	|O
spiro	1038	1043	|B-IUPAC
[	1043	1044	|I-IUPAC
isobenzofuran	1044	1057	|I-IUPAC
-	1057	1058	|I-IUPAC
1	1058	1059	|I-IUPAC
(	1059	1060	|I-IUPAC
3H	1060	1062	|I-IUPAC
)	1062	1063	|I-IUPAC
,	1063	1064	|I-IUPAC
4'	1064	1066	|I-IUPAC
-	1066	1067	|I-IUPAC
piperdine	1067	1076	|I-IUPAC
]	1076	1077	|I-IUPAC
ring	1078	1082	|B-MODIFIER
system	1083	1089	|I-MODIFIER
resulted	1090	1098	|O
in	1099	1101	|O
even	1102	1106	|O
more	1107	1111	|O
selective	1112	1121	|O
compounds	1122	1131	|O
.	1131	1132	|O
Variations	1133	1143	|O
of	1144	1146	|O
the	1147	1150	|O
1	1151	1152	|O
-	1152	1153	|O
substituent	1153	1164	|O
at	1165	1167	|O
the	1168	1171	|O
indole	1172	1178	|O
and	1179	1182	|O
of	1183	1185	|O
the	1186	1189	|O
chain	1190	1195	|O
length	1196	1202	|O
of	1203	1205	|O
the	1206	1209	|O
alkylene	1210	1218	|O
spacer	1219	1225	|O
group	1226	1231	|O
were	1232	1236	|O
studied	1237	1244	|O
.	1244	1245	|O
The	1246	1249	|O
optimal	1250	1257	|O
compound	1258	1266	|O
was	1267	1270	|O
the	1271	1274	|O
spiro	1275	1280	|O
analogue	1281	1289	|O
of	1290	1292	|O
compound	1293	1301	|O
11a	1302	1305	|O
.	1305	1306	|O
This	1307	1311	|O
compound	1312	1320	|O
is	1321	1323	|O
1'	1324	1326	|B-IUPAC
-	1326	1327	|I-IUPAC
[	1327	1328	|I-IUPAC
4	1328	1329	|I-IUPAC
-	1329	1330	|I-IUPAC
[	1330	1331	|I-IUPAC
1	1331	1332	|I-IUPAC
-	1332	1333	|I-IUPAC
(	1333	1334	|I-IUPAC
4	1334	1335	|I-IUPAC
-	1335	1336	|I-IUPAC
fluorophenyl	1336	1348	|I-IUPAC
)	1348	1349	|I-IUPAC
-	1349	1350	|I-IUPAC
1H	1350	1352	|I-IUPAC
-	1352	1353	|I-IUPAC
indol	1353	1358	|I-IUPAC
-	1358	1359	|I-IUPAC
3	1359	1360	|I-IUPAC
-	1360	1361	|I-IUPAC
yl	1361	1363	|I-IUPAC
]	1363	1364	|I-IUPAC
-	1364	1365	|I-IUPAC
1	1365	1366	|I-IUPAC
-	1366	1367	|I-IUPAC
butyl	1367	1372	|I-IUPAC
]	1372	1373	|I-IUPAC
spiro	1373	1378	|I-IUPAC
[	1378	1379	|I-IUPAC
isobenzofuran	1379	1392	|I-IUPAC
-	1392	1393	|I-IUPAC
1	1394	1395	|I-IUPAC
(	1395	1396	|I-IUPAC
3H	1396	1398	|I-IUPAC
)	1398	1399	|I-IUPAC
,	1399	1400	|I-IUPAC
4'	1400	1402	|I-IUPAC
-	1402	1403	|I-IUPAC
piperidine	1403	1413	|I-IUPAC
]	1413	1414	|I-IUPAC
,	1414	1415	|O
14f	1416	1419	|O
(	1420	1421	|O
code	1421	1425	|O
no	1426	1428	|O
.	1428	1429	|O
Lu	1430	1432	|O
28-179	1433	1439	|O
)	1439	1440	|O
,	1440	1441	|O
with	1442	1446	|O
the	1447	1450	|O
binding	1451	1458	|O
affinities	1459	1469	|O
:	1469	1470	|O
IC50	1471	1475	|O
(	1476	1477	|O
sigma	1477	1482	|O
1	1483	1484	|O
)	1484	1485	|O
=	1486	1487	|O
17	1488	1490	|O
nM	1491	1493	|O
,	1493	1494	|O
IC50	1495	1499	|O
(	1500	1501	|O
sigma	1501	1506	|O
2	1507	1508	|O
)	1508	1509	|O
=	1510	1511	|O
0.12	1512	1516	|O
nM	1517	1519	|O
,	1519	1520	|O
IC50	1521	1525	|O
(	1526	1527	|O
5	1527	1528	|O
-	1528	1529	|O
HT1A	1529	1533	|O
)	1533	1534	|O
=	1535	1536	|O
21,000	1537	1543	|O
nM	1544	1546	|O
,	1546	1547	|O
IC50	1548	1552	|O
(	1553	1554	|O
5	1554	1555	|O
-	1555	1556	|O
HT2A	1556	1560	|O
)	1560	1561	|O
=	1562	1563	|O
2000	1564	1568	|O
nM	1569	1571	|O
,	1571	1572	|O
IC50	1573	1577	|O
(	1578	1579	|O
D2	1579	1581	|O
)	1581	1582	|O
=	1583	1584	|O
800	1585	1588	|O
nM	1589	1591	|O
,	1591	1592	|O
IC50	1593	1597	|O
(	1598	1599	|O
alpha	1599	1604	|O
1	1605	1606	|O
)	1606	1607	|O
=	1608	1609	|O
330	1610	1613	|O
nM	1614	1616	|O
.	1616	1617	|O
However	1618	1625	|O
,	1625	1626	|O
the	1627	1630	|O
most	1631	1635	|O
selective	1636	1645	|O
sigma	1646	1651	|O
2	1652	1653	|O
versus	1654	1660	|O
sigma	1661	1666	|O
1	1667	1668	|O
ligand	1669	1675	|O
was	1676	1679	|O
the	1680	1683	|O
tropane	1684	1691	|O
derivative	1692	1702	|O
1	1703	1704	|B-IUPAC
-	1704	1705	|I-IUPAC
(	1705	1706	|I-IUPAC
4	1706	1707	|I-IUPAC
-	1707	1708	|I-IUPAC
fluorophenyl	1708	1720	|I-IUPAC
)	1720	1721	|I-IUPAC
-	1721	1722	|I-IUPAC
3	1722	1723	|I-IUPAC
-	1723	1724	|I-IUPAC
[	1724	1725	|I-IUPAC
4	1725	1726	|I-IUPAC
-	1726	1727	|I-IUPAC
[	1727	1728	|I-IUPAC
3	1728	1729	|I-IUPAC
-	1729	1730	|I-IUPAC
(	1730	1731	|I-IUPAC
4	1731	1732	|I-IUPAC
-	1732	1733	|I-IUPAC
fluorophenyl	1733	1745	|I-IUPAC
)	1745	1746	|I-IUPAC
-	1746	1747	|I-IUPAC
8	1747	1748	|I-IUPAC
-	1748	1749	|I-IUPAC
azabicyclo	1749	1759	|I-IUPAC
[	1759	1760	|I-IUPAC
3.2.1	1760	1765	|I-IUPAC
]	1765	1766	|I-IUPAC
oct	1766	1769	|I-IUPAC
-	1769	1770	|I-IUPAC
2	1770	1771	|I-IUPAC
-	1771	1772	|I-IUPAC
en	1773	1775	|I-IUPAC
-	1775	1776	|I-IUPAC
8	1776	1777	|I-IUPAC
-	1777	1778	|I-IUPAC
yl	1778	1780	|I-IUPAC
]	1780	1781	|I-IUPAC
-	1781	1782	|I-IUPAC
1	1782	1783	|I-IUPAC
-	1783	1784	|I-IUPAC
butyl	1784	1789	|I-IUPAC
]	1789	1790	|I-IUPAC
-	1790	1791	|I-IUPAC
1H	1791	1793	|I-IUPAC
-	1793	1794	|I-IUPAC
indole	1794	1800	|I-IUPAC
,	1800	1801	|O
15a	1802	1805	|O
.	1805	1806	|O
This	1807	1811	|O
compound	1812	1820	|O
had	1821	1824	|O
the	1825	1828	|O
following	1829	1838	|O
binding	1839	1846	|O
affinities	1847	1857	|O
:	1857	1858	|O
IC50	1859	1863	|O
(	1864	1865	|O
sigma	1865	1870	|O
1	1871	1872	|O
)	1872	1873	|O
=	1874	1875	|O
1200	1876	1880	|O
nM	1881	1883	|O
,	1883	1884	|O
IC50	1885	1889	|O
(	1890	1891	|O
sigma	1891	1896	|O
2	1897	1898	|O
)	1898	1899	|O
=	1900	1901	|O
2.5	1902	1905	|O
nM	1906	1908	|O
.	1908	1909	|O
Potent	1910	1916	|O
anxiolytic	1917	1927	|O
activity	1928	1936	|O
in	1937	1939	|O
the	1940	1943	|O
black	1944	1949	|O
/	1949	1950	|O
white	1950	1955	|O
box	1956	1959	|O
exploration	1960	1971	|O
test	1972	1976	|O
in	1977	1979	|O
rats	1980	1984	|O
was	1985	1988	|O
found	1989	1994	|O
with	1995	1999	|O
the	2000	2003	|O
two	2004	2007	|O
most	2008	2012	|O
prominent	2013	2022	|O
sigma	2023	2028	|O
2	2029	2030	|O
ligands	2031	2038	|O
Lu	2039	2041	|O
29-253	2042	2048	|O
and	2049	2052	|O
Lu	2053	2055	|O
28-179	2056	2062	|O
.	2062	2063	|O
Good	2064	2068	|O
penetration	2069	2080	|O
into	2081	2085	|O
the	2086	2089	|O
CNS	2090	2093	|O
was	2094	2097	|O
documented	2098	2108	|O
both	2109	2113	|O
after	2114	2119	|O
subcutaneous	2120	2132	|O
and	2133	2136	|O
peroral	2137	2144	|O
administration	2145	2159	|O
of	2160	2162	|O
Lu	2163	2165	|O
28-179	2166	2172	|O
by	2173	2175	|O
ex	2176	2178	|O
vivo	2179	2183	|O
binding	2184	2191	|O
studies	2192	2199	|O
.	2199	2200	|O
Long	2201	2205	|O
duration	2206	2214	|O
of	2215	2217	|O
action	2218	2224	|O
was	2225	2228	|O
demonstrated	2229	2241	|O
both	2242	2246	|O
in	2247	2249	|O
ex	2250	2252	|O
vivo	2253	2257	|O
binding	2258	2265	|O
(	2266	2267	|O
T1/2	2267	2271	|O
approximately	2272	2285	|O
20	2286	2288	|O
h	2289	2290	|O
)	2290	2291	|O
and	2292	2295	|O
in	2296	2298	|O
the	2299	2302	|O
black	2303	2308	|O
/	2308	2309	|O
white	2309	2314	|O
box	2315	2318	|O
exploration	2319	2330	|O
test	2331	2335	|O
.	2335	2336	|O

### abstracts2119.txt
2beta	0	5	|B-IUPAC
-	5	6	|I-IUPAC
Carbomethoxy	6	18	|I-IUPAC
-	18	19	|I-IUPAC
3beta	19	24	|I-IUPAC
-	24	25	|I-IUPAC
(	25	26	|I-IUPAC
4'	26	28	|I-IUPAC
-	28	29	|I-IUPAC
(	29	30	|I-IUPAC
(	30	31	|I-IUPAC
Z	31	32	|I-IUPAC
)	32	33	|I-IUPAC
-	33	34	|I-IUPAC
2	34	35	|I-IUPAC
-	35	36	|I-IUPAC
iodoethenyl	36	47	|I-IUPAC
)	47	48	|I-IUPAC
phenyl	48	54	|I-IUPAC
)	54	55	|I-IUPAC
nortropane	55	65	|I-IUPAC
(	66	67	|O
ZIENT	67	72	|O
)	72	73	|O
(	74	75	|O
6	75	76	|O
)	76	77	|O
and	78	81	|O
2beta	82	87	|B-IUPAC
-	87	88	|I-IUPAC
carbomethoxy	88	100	|I-IUPAC
-	100	101	|I-IUPAC
3beta	101	106	|I-IUPAC
-	106	107	|I-IUPAC
(	107	108	|I-IUPAC
4'	108	110	|I-IUPAC
-	110	111	|I-IUPAC
(	111	112	|I-IUPAC
(	112	113	|I-IUPAC
E	113	114	|I-IUPAC
)	114	115	|I-IUPAC
-	115	116	|I-IUPAC
2	116	117	|I-IUPAC
-	117	118	|I-IUPAC
iodoethenyl	118	129	|I-IUPAC
)	129	130	|I-IUPAC
phenyl	130	136	|I-IUPAC
)	136	137	|I-IUPAC
nortropane	137	147	|I-IUPAC
(	148	149	|O
EIENT	149	154	|O
)	154	155	|O
(	156	157	|O
10	157	159	|O
)	159	160	|O
were	161	165	|O
prepared	166	174	|O
and	175	178	|O
evaluated	179	188	|O
in	189	191	|O
vitro	192	197	|O
and	198	201	|O
in	202	204	|O
vivo	205	209	|O
for	210	213	|O
serotonin	214	223	|O
transporter	224	235	|O
(	236	237	|O
SERT	237	241	|O
)	241	242	|O
selectivity	243	254	|O
and	255	258	|O
specificity	259	270	|O
.	270	271	|O
High	272	276	|O
specific	277	285	|O
activity	286	294	|O
[	295	296	|O
(	296	297	|O
123	297	300	|O
)	300	301	|O
I	301	302	|O
]	302	303	|O
ZIENT	303	308	|O
and	309	312	|O
[	313	314	|O
(	314	315	|O
123	315	318	|O
)	318	319	|O
I	319	320	|O
]	320	321	|O
EIENT	321	326	|O
were	327	331	|O
synthesized	332	343	|O
in	344	346	|O
45%	347	350	|O
(	351	352	|O
n	352	353	|O
=	354	355	|O
5	356	357	|O
)	357	358	|O
and	359	362	|O
42%	363	366	|O
(	367	368	|O
n	368	369	|O
=	370	371	|O
4	372	373	|O
)	373	374	|O
radiochemical	375	388	|O
yield	389	394	|O
(	395	396	|O
decay	396	401	|O
-	401	402	|O
corrected	402	411	|O
to	412	414	|O
end	415	418	|O
of	419	421	|O
bombardment	422	433	|O
(	434	435	|O
EOB	435	438	|O
)	438	439	|O
)	439	440	|O
,	440	441	|O
respectively	442	454	|O
,	454	455	|O
by	456	458	|O
preparation	459	470	|O
of	471	473	|O
the	474	477	|O
precursor	478	487	|O
carbomethoxy	488	500	|B-IUPAC
-	500	501	|I-IUPAC
3beta	501	506	|I-IUPAC
-	506	507	|I-IUPAC
(	507	508	|I-IUPAC
4'	508	510	|I-IUPAC
-	510	511	|I-IUPAC
(	511	512	|I-IUPAC
(	512	513	|I-IUPAC
Z	513	514	|I-IUPAC
)	514	515	|I-IUPAC
-	515	516	|I-IUPAC
2	516	517	|I-IUPAC
-	517	518	|I-IUPAC
trimethylstannylethenyl	518	541	|I-IUPAC
)	541	542	|I-IUPAC
phenyl	542	548	|I-IUPAC
)	548	549	|I-IUPAC
nortropane	549	559	|I-IUPAC
(	560	561	|O
7	561	562	|O
)	562	563	|O
and	564	567	|O
2beta	568	573	|B-IUPAC
-	573	574	|I-IUPAC
carbomethoxy	574	586	|I-IUPAC
-	586	587	|I-IUPAC
3beta	587	592	|I-IUPAC
-	592	593	|I-IUPAC
(	593	594	|I-IUPAC
4'	594	596	|I-IUPAC
-	596	597	|I-IUPAC
(	597	598	|I-IUPAC
(	598	599	|I-IUPAC
E	599	600	|I-IUPAC
)	600	601	|I-IUPAC
-	601	602	|I-IUPAC
2	602	603	|I-IUPAC
-	603	604	|I-IUPAC
tributylstannylethenyl	604	626	|I-IUPAC
)	626	627	|I-IUPAC
phenyl	627	633	|I-IUPAC
)	633	634	|I-IUPAC
nortropane	634	644	|I-IUPAC
(	645	646	|O
9	646	647	|O
)	647	648	|O
,	648	649	|O
respectively	650	662	|O
,	662	663	|O
followed	664	672	|O
by	673	675	|O
treatment	676	685	|O
with	686	690	|O
no	691	693	|O
carrier	694	701	|O
-	701	702	|O
added	702	707	|O
sodium	708	714	|O
[	715	716	|O
(	716	717	|O
123	717	720	|O
)	720	721	|O
I	721	722	|O
]	722	723	|O
iodide	723	729	|O
and	730	733	|O
hydrogen	734	742	|O
peroxide	743	751	|O
in	752	754	|O
ethanolic	755	764	|O
HCl	765	768	|O
.	768	769	|O
Competition	770	781	|O
binding	782	789	|O
in	790	792	|O
cells	793	798	|O
stably	799	805	|O
expressing	806	816	|O
the	817	820	|O
transfected	821	832	|O
human	833	838	|O
SERT	839	843	|O
,	843	844	|O
dopamine	845	853	|O
transporter	854	865	|O
(	866	867	|O
DAT	867	870	|O
)	870	871	|O
,	871	872	|O
and	873	876	|O
norepinephrine	877	891	|O
transporter	892	903	|O
(	904	905	|O
NET	905	908	|O
)	908	909	|O
using	910	915	|O
[	916	917	|O
(	917	918	|O
3	918	919	|O
)	919	920	|O
H	920	921	|O
]	921	922	|O
citalopram	922	932	|O
,	932	933	|O
[	934	935	|O
(	935	936	|O
3	936	937	|O
)	937	938	|O
H	938	939	|O
]	939	940	|O
WIN	940	943	|O
35,428	944	950	|O
,	950	951	|O
and	952	955	|O
[	956	957	|O
(	957	958	|O
3	958	959	|O
)	959	960	|O
H	960	961	|O
]	961	962	|O
nisoxetine	962	972	|O
,	972	973	|O
respectively	974	986	|O
,	986	987	|O
demonstrated	988	1000	|O
the	1001	1004	|O
following	1005	1014	|O
order	1015	1020	|O
of	1021	1023	|O
SERT	1024	1028	|O
affinity	1029	1037	|O
(	1038	1039	|O
K	1039	1040	|O
(	1040	1041	|O
i	1041	1042	|O
)	1042	1043	|O
in	1044	1046	|O
nM	1047	1049	|O
)	1049	1050	|O
:	1050	1051	|O
ZIENT	1052	1057	|O
(	1058	1059	|O
0.05	1059	1063	|O
)	1063	1064	|O
&	1065	1066	|O
gt	1066	1068	|O
;	1068	1069	|O
nor	1070	1073	|O
-	1073	1074	|O
CIT	1074	1077	|O
(	1078	1079	|O
0.12	1079	1083	|O
)	1083	1084	|O
&	1085	1086	|O
gt	1086	1088	|O
;	1088	1089	|O
&	1089	1090	|O
gt	1090	1092	|O
;	1092	1093	|O
EIENT	1094	1099	|O
(	1100	1101	|O
1.15	1101	1105	|O
)	1105	1106	|O
&	1107	1108	|O
gt	1108	1110	|O
;	1110	1111	|O
fluvoxamine	1112	1123	|O
(	1124	1125	|O
1.46	1125	1129	|O
)	1129	1130	|O
.	1130	1131	|O
The	1132	1135	|O
affinity	1136	1144	|O
of	1145	1147	|O
ZIENT	1148	1153	|O
and	1154	1157	|O
EIENT	1158	1163	|O
for	1164	1167	|O
DAT	1168	1171	|O
was	1172	1175	|O
69	1176	1178	|O
and	1179	1182	|O
1.6	1183	1186	|O
-	1186	1187	|O
fold	1187	1191	|O
lower	1192	1197	|O
,	1197	1198	|O
respectively	1199	1211	|O
,	1211	1212	|O
than	1213	1217	|O
for	1218	1221	|O
SERT	1222	1226	|O
.	1226	1227	|O
In	1228	1230	|O
vivo	1231	1235	|O
biodistribution	1236	1251	|O
and	1252	1255	|O
blocking	1256	1264	|O
studies	1265	1272	|O
were	1273	1277	|O
performed	1278	1287	|O
in	1288	1290	|O
male	1291	1295	|O
rats	1296	1300	|O
and	1301	1304	|O
demonstrated	1305	1317	|O
that	1318	1322	|O
the	1323	1326	|O
brain	1327	1332	|O
uptake	1333	1339	|O
of	1340	1342	|O
[	1343	1344	|O
(	1344	1345	|O
123	1345	1348	|O
)	1348	1349	|O
I	1349	1350	|O
]	1350	1351	|O
ZIENT	1351	1356	|O
was	1357	1360	|O
selective	1361	1370	|O
and	1371	1374	|O
specific	1375	1383	|O
for	1384	1387	|O
SERT	1388	1392	|O
-	1392	1393	|O
rich	1393	1397	|O
regions	1398	1405	|O
(	1406	1407	|O
hypothalamus	1407	1419	|O
,	1419	1420	|O
striatum	1421	1429	|O
,	1429	1430	|O
pons	1431	1435	|O
,	1435	1436	|O
and	1437	1440	|O
prefrontal	1441	1451	|O
cortex	1452	1458	|O
)	1458	1459	|O
.	1459	1460	|O
SPECT	1461	1466	|O
brain	1467	1472	|O
imaging	1473	1480	|O
studies	1481	1488	|O
in	1489	1491	|O
monkeys	1492	1499	|O
demonstrated	1500	1512	|O
high	1513	1517	|O
[	1518	1519	|O
(	1519	1520	|O
123	1520	1523	|O
)	1523	1524	|O
I	1524	1525	|O
]	1525	1526	|O
ZIENT	1526	1531	|O
uptake	1532	1538	|O
in	1539	1541	|O
the	1542	1545	|O
diencephalon	1546	1558	|O
,	1558	1559	|O
which	1560	1565	|O
resulted	1566	1574	|O
in	1575	1577	|O
diencephalon	1578	1590	|O
-	1590	1591	|O
to	1591	1593	|O
-	1593	1594	|O
cerebellum	1594	1604	|O
ratios	1605	1611	|O
of	1612	1614	|O
2.12	1615	1619	|O
at	1620	1622	|O
190	1623	1626	|O
min	1627	1630	|O
.	1630	1631	|O
[	1632	1633	|O
(	1633	1634	|O
123	1634	1637	|O
)	1637	1638	|O
I	1638	1639	|O
]	1639	1640	|O
ZIENT	1640	1645	|O
uptake	1646	1652	|O
in	1653	1655	|O
the	1656	1659	|O
diencephalon	1660	1672	|O
achieved	1673	1681	|O
transient	1682	1691	|O
equilibrium	1692	1703	|O
at	1704	1706	|O
157	1707	1710	|O
min	1711	1714	|O
.	1714	1715	|O
In	1716	1718	|O
a	1719	1720	|O
displacement	1721	1733	|O
experiment	1734	1744	|O
of	1745	1747	|O
[	1748	1749	|O
(	1749	1750	|O
123	1750	1753	|O
)	1753	1754	|O
I	1754	1755	|O
]	1755	1756	|O
ZIENT	1756	1761	|O
in	1762	1764	|O
a	1765	1766	|O
cynomolgus	1767	1777	|O
monkey	1778	1784	|O
,	1784	1785	|O
radioactivity	1786	1799	|O
was	1800	1803	|O
reduced	1804	1811	|O
by	1812	1814	|O
39%	1815	1818	|O
in	1819	1821	|O
the	1822	1825	|O
diencephalon	1826	1838	|O
at	1839	1841	|O
101	1842	1845	|O
min	1846	1849	|O
following	1850	1859	|O
injection	1860	1869	|O
of	1870	1872	|O
citalopram	1873	1883	|O
.	1883	1884	|O
The	1885	1888	|O
high	1889	1893	|O
specific	1894	1902	|O
activity	1903	1911	|O
one	1912	1915	|O
-	1915	1916	|O
step	1916	1920	|O
radiolabeling	1921	1934	|O
preparation	1935	1946	|O
and	1947	1950	|O
high	1951	1955	|O
selectivity	1956	1967	|O
of	1968	1970	|O
[	1971	1972	|O
(	1972	1973	|O
123	1973	1976	|O
)	1976	1977	|O
I	1977	1978	|O
]	1978	1979	|O
ZIENT	1979	1984	|O
for	1985	1988	|O
SERT	1989	1993	|O
support	1994	2001	|O
its	2002	2005	|O
candidacy	2006	2015	|O
as	2016	2018	|O
a	2019	2020	|O
radioligand	2021	2032	|O
for	2033	2036	|O
mapping	2037	2044	|O
brain	2045	2050	|O
SERT	2051	2055	|O
sites	2056	2061	|O
.	2061	2062	|O

### abstracts4778.txt
Several	0	7	|O
series	8	14	|O
of	15	17	|O
2,4	18	21	|B-IUPAC
-	21	22	|I-IUPAC
dihydro	22	29	|I-IUPAC
-	29	30	|I-IUPAC
2,4,5	30	35	|I-IUPAC
-	35	36	|O
trisubstituted	36	50	|B-MODIFIER
-	50	51	|O
3H	51	53	|B-IUPAC
-	53	54	|I-IUPAC
1,2,4	54	59	|I-IUPAC
-	59	60	|I-IUPAC
triazol	60	67	|I-IUPAC
-	67	68	|I-IUPAC
3	68	69	|I-IUPAC
-	69	70	|I-IUPAC
ones	70	74	|I-IUPAC
with	75	79	|O
acidic	80	86	|O
sulfonamide	87	98	|O
replacements	99	111	|O
of	112	114	|O
tetrazole	115	124	|O
at	125	127	|O
the	128	131	|O
2'	132	134	|O
-	134	135	|O
position	135	143	|O
of	144	146	|O
the	147	150	|O
biphenyl	151	159	|B-IUPAC
-	159	160	|I-IUPAC
4	160	161	|I-IUPAC
-	161	162	|I-IUPAC
ylmethyl	162	170	|I-IUPAC
side	171	175	|B-MODIFIER
chain	176	181	|I-MODIFIER
at	182	184	|O
N4	185	187	|O
were	188	192	|O
prepared	193	201	|O
and	202	205	|O
tested	206	212	|O
as	213	215	|O
angiotensin	216	227	|O
II	228	230	|O
(	231	232	|O
AII	232	235	|O
)	235	236	|O
antagonists	237	248	|O
.	248	249	|O
Preferred	250	259	|O
substituents	260	272	|O
on	273	275	|O
the	276	279	|O
triazolinone	280	292	|O
ring	293	297	|O
were	298	302	|O
n	303	304	|B-IUPAC
-	304	305	|I-IUPAC
butyl	305	310	|I-IUPAC
at	311	313	|O
C5	314	316	|O
and	317	320	|O
2	321	322	|B-IUPAC
-	322	323	|I-IUPAC
(	323	324	|I-IUPAC
trifluoromethyl	324	339	|I-IUPAC
)	339	340	|I-IUPAC
phenyl	340	346	|I-IUPAC
at	347	349	|O
N2	350	352	|O
.	352	353	|O
Subnanomolar	354	366	|O
IC50	367	371	|O
values	372	378	|O
at	379	381	|O
the	382	385	|O
AT1	386	389	|O
receptor	390	398	|O
subtype	399	406	|O
were	407	411	|O
observed	412	420	|O
for	421	424	|O
a	425	426	|O
variety	427	434	|O
of	435	437	|O
acylsulfonamides	438	454	|O
,	454	455	|O
including	456	465	|O
aroyl	466	471	|O
,	471	472	|O
heteroaroyl	473	484	|O
,	484	485	|O
and	486	489	|O
cycloalkylcarbonyl	490	508	|B-IUPAC
derivatives	509	520	|B-MODIFIER
.	520	521	|O
Certain	522	529	|O
other	530	535	|O
acidic	536	542	|O
sulfonamides	543	555	|O
,	555	556	|O
such	557	561	|O
as	562	564	|O
sulfonylcarbamates	565	583	|O
and	584	587	|O
disulfimides	588	600	|O
also	601	605	|O
displayed	606	615	|O
high	616	620	|O
affinity	621	629	|O
for	630	633	|O
the	634	637	|O
AT1	638	641	|O
receptor	642	650	|O
.	650	651	|O
In	652	654	|O
addition	655	663	|O
,	663	664	|O
AT2	665	668	|O
binding	669	676	|O
for	677	680	|O
some	681	685	|O
of	686	688	|O
these	689	694	|O
compounds	695	704	|O
was	705	708	|O
increased	709	718	|O
by	719	721	|O
as	722	724	|O
much	725	729	|O
as	730	732	|O
1000	733	737	|O
-	737	738	|O
fold	738	742	|O
over	743	747	|O
the	748	751	|O
corresponding	752	765	|O
tetrazole	766	775	|O
(	776	777	|O
e.g.	777	781	|O
,	781	782	|O
AT2	783	786	|O
IC50	787	791	|O
17	792	794	|O
nM	795	797	|O
for	798	801	|O
the	802	805	|O
tert	806	810	|B-IUPAC
-	810	811	|I-IUPAC
butyl	811	816	|I-IUPAC
sulfonylcarbamate	817	834	|I-IUPAC
92	835	837	|O
)	837	838	|O
.	838	839	|O
When	840	844	|O
evaluated	845	854	|O
for	855	858	|O
inhibition	859	869	|O
of	870	872	|O
the	873	876	|O
AII	877	880	|O
pressor	881	888	|O
response	889	897	|O
,	897	898	|O
the	899	902	|O
benchmark	903	912	|O
benzoylsulfonamide	913	931	|O
9	932	933	|O
(	934	935	|O
L	935	936	|O
-	936	937	|O
159,913	937	944	|O
)	944	945	|O
was	946	949	|O
efficacious	950	961	|O
in	962	964	|O
several	965	972	|O
species	973	980	|O
and	981	984	|O
was	985	988	|O
superior	989	997	|O
to	998	1000	|O
losartan	1001	1009	|O
(	1010	1011	|O
1a	1011	1013	|O
)	1013	1014	|O
in	1015	1017	|O
conscious	1018	1027	|O
rhesus	1028	1034	|O
monkeys	1035	1042	|O
.	1042	1043	|O
Several	1044	1051	|O
subsequent	1052	1062	|O
analogues	1063	1072	|O
,	1072	1073	|O
including	1074	1083	|O
the	1084	1087	|O
2	1088	1089	|B-IUPAC
-	1089	1090	|I-IUPAC
chlorobenzoyl	1090	1103	|I-IUPAC
(	1104	1105	|O
18	1105	1107	|O
)	1107	1108	|O
,	1108	1109	|O
(	1110	1111	|B-IUPAC
3	1111	1112	|I-IUPAC
-	1112	1113	|I-IUPAC
chlorothiophene	1113	1128	|I-IUPAC
-	1128	1129	|I-IUPAC
2	1129	1130	|I-IUPAC
-	1130	1131	|I-IUPAC
yl	1131	1133	|I-IUPAC
)	1133	1134	|I-IUPAC
carbonyl	1134	1142	|I-IUPAC
(	1143	1144	|O
51	1144	1146	|O
)	1146	1147	|O
,	1147	1148	|O
(	1149	1150	|B-IUPAC
(	1150	1151	|I-IUPAC
S	1151	1152	|I-IUPAC
)	1152	1153	|I-IUPAC
-	1153	1154	|I-IUPAC
2,2	1154	1157	|I-IUPAC
-	1157	1158	|I-IUPAC
dimethylcyclopropyl	1158	1177	|I-IUPAC
)	1177	1178	|I-IUPAC
carbonyl	1178	1186	|I-IUPAC
(	1187	1188	|O
80	1188	1190	|O
)	1190	1191	|O
,	1191	1192	|O
and	1193	1196	|O
tert	1197	1201	|B-IUPAC
-	1201	1202	|I-IUPAC
butoxycarbonyl	1202	1216	|I-IUPAC
(	1217	1218	|O
92	1218	1220	|O
)	1220	1221	|O
derivatives	1222	1233	|B-MODIFIER
,	1233	1234	|O
were	1235	1239	|O
highly	1240	1246	|O
effective	1247	1256	|O
in	1257	1259	|O
rats	1260	1264	|O
,	1264	1265	|O
surpassing	1266	1276	|O
9	1277	1278	|O
and	1279	1282	|O
losartan	1283	1291	|O
in	1292	1294	|O
duration	1295	1303	|O
of	1304	1306	|O
action	1307	1313	|O
and	1314	1317	|O
/	1317	1318	|O
or	1318	1320	|O
potency	1321	1328	|O
.	1328	1329	|O
Compound	1330	1338	|O
18	1339	1341	|O
(	1342	1343	|O
L	1343	1344	|O
-	1344	1345	|O
162,223	1345	1352	|O
)	1352	1353	|O
displayed	1354	1363	|O
very	1364	1368	|O
prolonged	1369	1378	|O
AII	1379	1382	|O
antagonism	1383	1393	|O
in	1394	1396	|O
the	1397	1400	|O
rat	1401	1404	|O
model	1405	1410	|O
(	1411	1412	|O
&	1412	1413	|O
gt	1413	1415	|O
;	1415	1416	|O
24	1417	1419	|O
h	1420	1421	|O
at	1422	1424	|O
1	1425	1426	|O
mg	1427	1429	|O
/	1429	1430	|O
kg	1430	1432	|O
iv	1433	1435	|O
)	1435	1436	|O
.	1436	1437	|O
At	1438	1440	|O
1	1441	1442	|O
mg	1443	1445	|O
/	1445	1446	|O
kg	1446	1448	|O
po	1449	1451	|O
in	1452	1454	|O
rats	1455	1459	|O
,	1459	1460	|O
18	1461	1463	|O
and	1464	1467	|O
92	1468	1470	|O
(	1471	1472	|O
L	1472	1473	|O
-	1473	1474	|O
162,234	1474	1481	|O
)	1481	1482	|O
produced	1483	1491	|O
85-87%	1492	1498	|O
peak	1499	1503	|O
inhibition	1504	1514	|O
of	1515	1517	|O
the	1518	1521	|O
AII	1522	1525	|O
pressor	1526	1533	|O
response	1534	1542	|O
with	1543	1547	|O
duration	1548	1556	|O
exceeding	1557	1566	|O
6	1567	1568	|O
h	1569	1570	|O
.	1570	1571	|O
The	1572	1575	|O
identification	1576	1590	|O
of	1591	1593	|O
triazolinone	1594	1606	|O
-	1606	1607	|O
based	1607	1612	|O
sulfonamide	1613	1624	|O
derivatives	1625	1636	|O
combining	1637	1646	|O
high	1647	1651	|O
AT1	1652	1655	|O
affinity	1656	1664	|O
,	1664	1665	|O
considerably	1666	1678	|O
enhanced	1679	1687	|O
AT2	1688	1691	|O
potency	1692	1699	|O
,	1699	1700	|O
and	1701	1704	|O
favorable	1705	1714	|O
in	1715	1717	|O
vivo	1718	1722	|O
properties	1723	1733	|O
provides	1734	1742	|O
insights	1743	1751	|O
relevant	1752	1760	|O
to	1761	1763	|O
the	1764	1767	|O
design	1768	1774	|O
of	1775	1777	|O
dual	1778	1782	|O
AT1	1783	1786	|O
/	1786	1787	|O
AT2	1787	1790	|O
receptor	1791	1799	|O
antagonists	1800	1811	|O
.	1811	1812	|O

### abstracts567.txt
A	0	1	|O
series	2	8	|B-MODIFIER
of	9	11	|O
3	12	13	|B-IUPAC
-	13	14	|I-IUPAC
(	14	15	|I-IUPAC
4	15	16	|I-IUPAC
-	16	17	|I-IUPAC
fluorophenyl	17	29	|I-IUPAC
)	29	30	|I-IUPAC
-	30	31	|I-IUPAC
1H	31	33	|I-IUPAC
-	33	34	|I-IUPAC
indoles	34	41	|I-IUPAC
substituted	42	53	|B-MODIFIER
in	54	56	|I-MODIFIER
the	57	60	|I-MODIFIER
1	61	62	|I-MODIFIER
-	62	63	|I-MODIFIER
position	63	71	|I-MODIFIER
with	72	76	|O
4	77	78	|B-IUPAC
-	78	79	|I-IUPAC
piperidinyl	79	90	|I-IUPAC
,	90	91	|O
1,2,3,6	92	99	|B-IUPAC
-	99	100	|I-IUPAC
tetrahydro	100	110	|I-IUPAC
-	110	111	|I-IUPAC
4	111	112	|I-IUPAC
-	112	113	|I-IUPAC
pyridinyl	113	122	|I-IUPAC
,	122	123	|O
and	124	127	|O
4	128	129	|B-IUPAC
-	129	130	|I-IUPAC
piperazinyl	130	141	|I-IUPAC
was	142	145	|O
synthesized	146	157	|O
.	157	158	|O
By	159	161	|O
variation	162	171	|O
of	172	174	|O
the	175	178	|O
substituents	179	191	|O
in	192	194	|O
the	195	198	|O
benzene	199	206	|O
part	207	211	|O
of	212	214	|O
the	215	218	|O
indole	219	225	|O
nucleus	226	233	|O
in	234	236	|O
1	237	238	|B-IUPAC
-	238	239	|I-IUPAC
[	239	240	|I-IUPAC
2	240	241	|I-IUPAC
-	241	242	|I-IUPAC
[	242	243	|I-IUPAC
4	243	244	|I-IUPAC
-	244	245	|I-IUPAC
[	245	246	|I-IUPAC
3-4	246	249	|I-IUPAC
-	249	250	|I-IUPAC
fluorophenyl	250	262	|I-IUPAC
)	262	263	|I-IUPAC
-	263	264	|I-IUPAC
1H	264	266	|I-IUPAC
-	266	267	|I-IUPAC
indol	267	272	|I-IUPAC
-	272	273	|I-IUPAC
1	273	274	|I-IUPAC
-	274	275	|I-IUPAC
yl	275	277	|I-IUPAC
]	277	278	|I-IUPAC
-	278	279	|I-IUPAC
1	279	280	|I-IUPAC
-	280	281	|I-IUPAC
piperidinyl	281	292	|I-IUPAC
]	292	293	|I-IUPAC
-	293	294	|I-IUPAC
ethyl	294	299	|I-IUPAC
]	299	300	|I-IUPAC
-	300	301	|I-IUPAC
2	301	302	|I-IUPAC
-	302	303	|I-IUPAC
imidazolidinones	304	320	|I-IUPAC
,	320	321	|O
the	322	325	|O
highest	326	333	|O
5	334	335	|O
-	335	336	|O
HT2	336	339	|O
receptor	340	348	|O
affinity	349	357	|O
and	358	361	|O
selectivity	362	373	|O
with	374	378	|O
respect	379	386	|O
to	387	389	|O
dopamine	390	398	|O
D2	399	401	|O
receptors	402	411	|O
and	412	415	|O
alpha	416	421	|O
1	422	423	|O
adrenoceptors	424	437	|O
were	438	442	|O
obtained	443	451	|O
by	452	454	|O
5	455	456	|B-IUPAC
-	456	457	|I-IUPAC
methyl	457	463	|I-IUPAC
substitution	464	476	|B-MODIFIER
.	476	477	|O
Different	478	487	|O
substituents	488	500	|O
were	501	505	|O
introduced	506	516	|O
in	517	519	|O
the	520	523	|O
1	524	525	|O
-	525	526	|O
position	526	534	|O
of	535	537	|O
the	538	541	|O
piperidine	542	552	|O
ring	553	557	|O
in	558	560	|O
the	561	564	|O
5	565	566	|B-IUPAC
-	566	567	|I-IUPAC
methyl	567	573	|I-IUPAC
-	573	574	|O
substituted	574	585	|B-MODIFIER
derivative	586	596	|I-MODIFIER
.	596	597	|O
Thus	598	602	|O
replacement	603	614	|O
of	615	617	|O
the	618	621	|O
2	622	623	|B-IUPAC
-	623	624	|I-IUPAC
(	624	625	|I-IUPAC
2	625	626	|I-IUPAC
-	626	627	|I-IUPAC
imidazolidinon	627	641	|I-IUPAC
-	641	642	|I-IUPAC
1	642	643	|I-IUPAC
-	643	644	|I-IUPAC
yl	644	646	|I-IUPAC
)	646	647	|I-IUPAC
ethyl	647	652	|I-IUPAC
side	653	657	|B-MODIFIER
chain	658	663	|I-MODIFIER
with	664	668	|O
a	669	670	|O
2	671	672	|B-IUPAC
-	672	673	|I-IUPAC
(	673	674	|I-IUPAC
1,3	674	677	|I-IUPAC
-	677	678	|I-IUPAC
dimethyl	678	686	|I-IUPAC
-	686	687	|I-IUPAC
1	687	688	|I-IUPAC
-	688	689	|I-IUPAC
ureido	689	695	|I-IUPAC
)	695	696	|I-IUPAC
ethyl	696	701	|I-IUPAC
or	702	704	|O
methyl	705	711	|B-IUPAC
substituent	712	723	|B-MODIFIER
resulted	724	732	|O
in	733	735	|O
unchanged	736	745	|O
affinity	746	754	|O
and	755	758	|O
selectivity	759	770	|O
for	771	774	|O
5	775	776	|O
-	776	777	|O
HT2	777	780	|O
receptors	781	790	|O
.	790	791	|O
Replacement	792	803	|O
with	804	808	|O
a	809	810	|O
2	811	812	|B-IUPAC
-	812	813	|I-IUPAC
[	813	814	|I-IUPAC
3	814	815	|I-IUPAC
-	815	816	|I-IUPAC
(	816	817	|I-IUPAC
2	817	818	|I-IUPAC
-	818	819	|I-IUPAC
propyl	819	825	|I-IUPAC
)	825	826	|I-IUPAC
-	826	827	|I-IUPAC
2	827	828	|I-IUPAC
-	828	829	|I-IUPAC
imidazolidinon	829	843	|I-IUPAC
-	843	844	|I-IUPAC
1	844	845	|I-IUPAC
-	845	846	|I-IUPAC
yl	846	848	|I-IUPAC
]	848	849	|I-IUPAC
ethyl	849	854	|I-IUPAC
side	855	859	|B-MODIFIER
chain	860	865	|I-MODIFIER
reduced	866	873	|O
binding	874	881	|O
to	882	884	|O
alpha	885	890	|O
1	891	892	|O
adrenoceptors	893	906	|O
with	907	911	|O
a	912	913	|O
factor	914	920	|O
of	921	923	|O
four	924	928	|O
,	928	929	|O
while	930	935	|O
affinities	936	946	|O
for	947	950	|O
5	951	952	|O
-	952	953	|O
HT2	953	956	|O
and	957	960	|O
D2	961	963	|O
receptors	964	973	|O
were	974	978	|O
retained	979	987	|O
,	987	988	|O
compared	989	997	|O
to	998	1000	|O
the	1001	1004	|O
3	1005	1006	|B-MODIFIER
-	1006	1007	|I-MODIFIER
unsubstituted	1007	1020	|I-MODIFIER
imidazolidinone	1021	1036	|B-IUPAC
.	1036	1037	|O
Indoles	1038	1045	|O
substituted	1046	1057	|B-MODIFIER
in	1058	1060	|O
the	1061	1064	|O
1	1065	1066	|O
-	1066	1067	|O
position	1067	1075	|O
with	1076	1080	|O
4	1081	1082	|B-IUPAC
-	1082	1083	|I-IUPAC
piperazinyl	1083	1094	|I-IUPAC
had	1095	1098	|O
generally	1099	1108	|O
weaker	1109	1115	|O
affinity	1116	1124	|O
for	1125	1128	|O
both	1129	1133	|O
5	1134	1135	|O
-	1135	1136	|O
HT2	1136	1139	|O
and	1140	1143	|O
D2	1144	1146	|O
receptors	1147	1156	|O
compared	1157	1165	|O
to	1166	1168	|O
corresponding	1169	1182	|O
4	1183	1184	|B-PARTIUPAC
-	1184	1185	|I-PARTIUPAC
piperidinyl	1185	1196	|I-PARTIUPAC
-	1196	1197	|I-PARTIUPAC
and	1198	1201	|O
1,2,3,6	1202	1209	|B-IUPAC
-	1209	1210	|I-IUPAC
tetrahydro	1210	1220	|I-IUPAC
-	1220	1221	|I-IUPAC
4	1221	1222	|I-IUPAC
-	1222	1223	|I-IUPAC
pyridinyl	1223	1232	|I-IUPAC
-	1232	1233	|O
substituted	1233	1244	|B-MODIFIER
indoles	1245	1252	|B-IUPAC
.	1252	1253	|O
Introduction	1254	1266	|O
of	1267	1269	|O
a	1270	1271	|O
methyl	1272	1278	|B-IUPAC
group	1279	1284	|B-MODIFIER
in	1285	1287	|O
the	1288	1291	|O
2	1292	1293	|O
-	1293	1294	|O
position	1294	1302	|O
of	1303	1305	|O
the	1306	1309	|O
5	1310	1311	|B-IUPAC
-	1311	1312	|I-IUPAC
methyl	1312	1318	|I-IUPAC
-	1318	1319	|O
substituted	1319	1330	|B-MODIFIER
indole	1331	1337	|O
resulted	1338	1346	|O
in	1347	1349	|O
further	1350	1357	|O
increase	1358	1366	|O
of	1367	1369	|O
selectivity	1370	1381	|O
for	1382	1385	|O
the	1386	1389	|O
5	1390	1391	|O
-	1391	1392	|O
HT2	1392	1395	|O
receptor	1396	1404	|O
.	1404	1405	|O
Compounds	1406	1415	|O
with	1416	1420	|O
potent	1421	1427	|O
receptor	1428	1436	|O
binding	1437	1444	|O
also	1445	1449	|O
potently	1450	1458	|O
inhibited	1459	1468	|O
the	1469	1472	|O
quipazine	1473	1482	|O
-	1482	1483	|O
induced	1483	1490	|O
head	1491	1495	|O
twitch	1496	1502	|O
syndrome	1503	1511	|O
in	1512	1514	|O
rats	1515	1519	|O
.	1519	1520	|O
The	1521	1524	|O
compounds	1525	1534	|O
were	1535	1539	|O
equally	1540	1547	|O
active	1548	1554	|O
after	1555	1560	|O
oral	1561	1565	|O
and	1566	1569	|O
subcutaneous	1570	1582	|O
administration	1583	1597	|O
and	1598	1601	|O
showed	1602	1608	|O
a	1609	1610	|O
long	1611	1615	|O
duration	1616	1624	|O
of	1625	1627	|O
action	1628	1634	|O
(	1635	1636	|O
&	1636	1637	|O
gt	1637	1639	|O
;	1639	1640	|O
24	1641	1643	|O
h	1644	1645	|O
)	1645	1646	|O
.	1646	1647	|O
In	1648	1650	|O
general	1651	1658	|O
,	1658	1659	|O
the	1660	1663	|O
derivatives	1664	1675	|O
were	1676	1680	|O
found	1681	1686	|O
to	1687	1689	|O
be	1690	1692	|O
considerably	1693	1705	|O
more	1706	1710	|O
potent	1711	1717	|O
at	1718	1720	|O
24	1721	1723	|O
h	1724	1725	|O
than	1726	1730	|O
at	1731	1733	|O
2	1734	1735	|O
h	1736	1737	|O
after	1738	1743	|O
the	1744	1747	|O
administration	1748	1762	|O
.	1762	1763	|O
The	1764	1767	|O
compounds	1768	1777	|O
within	1778	1784	|O
this	1785	1789	|O
series	1790	1796	|O
were	1797	1801	|O
prepared	1802	1810	|O
as	1811	1813	|O
analogues	1814	1823	|O
of	1824	1826	|O
the	1827	1830	|O
previously	1831	1841	|O
described	1842	1851	|O
1	1852	1853	|B-IUPAC
-	1853	1854	|I-IUPAC
(	1854	1855	|I-IUPAC
4	1855	1856	|I-IUPAC
-	1856	1857	|I-IUPAC
fluorophenyl	1857	1869	|I-IUPAC
)	1869	1870	|I-IUPAC
-	1870	1871	|I-IUPAC
3	1871	1872	|I-IUPAC
-	1872	1873	|I-IUPAC
(	1873	1874	|I-IUPAC
4	1874	1875	|I-IUPAC
-	1875	1876	|I-IUPAC
piperidyl	1876	1885	|I-IUPAC
)	1885	1886	|I-IUPAC
-	1886	1887	|I-IUPAC
1H	1887	1889	|I-IUPAC
-	1889	1890	|I-IUPAC
indoles	1890	1897	|I-IUPAC
by	1898	1900	|O
interchange	1901	1912	|O
of	1913	1915	|O
the	1916	1919	|O
C	1920	1921	|O
-	1921	1922	|O
3	1922	1923	|O
carbon	1924	1930	|O
atom	1931	1935	|O
and	1936	1939	|O
the	1940	1943	|O
nitrogen	1944	1952	|O
atom	1953	1957	|O
in	1958	1960	|O
the	1961	1964	|O
indole	1965	1971	|O
nucleus	1972	1979	|O
.	1979	1980	|O
The	1981	1984	|O
pharmacological	1985	2000	|O
results	2001	2008	|O
indicate	2009	2017	|O
that	2018	2022	|O
this	2023	2027	|O
isosteric	2028	2037	|O
replacement	2038	2049	|O
results	2050	2057	|O
in	2058	2060	|O
higher	2061	2067	|O
selectivity	2068	2079	|O
for	2080	2083	|O
5	2084	2085	|O
-	2085	2086	|O
HT2	2086	2089	|O
receptors	2090	2099	|O
compared	2100	2108	|O
to	2109	2111	|O
the	2112	2115	|O
former	2116	2122	|O
series	2123	2129	|O
.	2129	2130	|O
The	2131	2134	|O
1	2135	2136	|B-IUPAC
-	2136	2137	|I-IUPAC
[	2137	2138	|I-IUPAC
2	2138	2139	|I-IUPAC
-	2139	2140	|I-IUPAC
[	2140	2141	|I-IUPAC
4	2141	2142	|I-IUPAC
-	2142	2143	|I-IUPAC
[	2143	2144	|I-IUPAC
2,5	2144	2147	|I-IUPAC
-	2147	2148	|I-IUPAC
dimethyl	2148	2156	|I-IUPAC
-	2156	2157	|I-IUPAC
3	2157	2158	|I-IUPAC
-	2158	2159	|I-IUPAC
(	2159	2160	|I-IUPAC
4	2160	2161	|I-IUPAC
-	2161	2162	|I-IUPAC
fluorophenyl	2162	2174	|I-IUPAC
)	2174	2175	|I-IUPAC
-	2175	2176	|I-IUPAC
1H	2176	2178	|I-IUPAC
-	2178	2179	|I-IUPAC
indol	2179	2184	|I-IUPAC
-	2184	2185	|I-IUPAC
1	2185	2186	|I-IUPAC
-	2186	2187	|I-IUPAC
yl	2187	2189	|I-IUPAC
]	2189	2190	|I-IUPAC
-	2190	2191	|I-IUPAC
1	2191	2192	|I-IUPAC
-	2192	2193	|I-IUPAC
piperidinyl	2194	2205	|I-IUPAC
]	2205	2206	|I-IUPAC
ethyl	2206	2211	|I-IUPAC
]	2211	2212	|I-IUPAC
-	2212	2213	|I-IUPAC
2	2213	2214	|I-IUPAC
-	2214	2215	|I-IUPAC
imidazolidinone	2215	2230	|I-IUPAC
has	2231	2234	|O
high	2235	2239	|O
affinity	2240	2248	|O
for	2249	2252	|O
5	2253	2254	|O
-	2254	2255	|O
HT2	2255	2258	|O
receptors	2259	2268	|O
(	2269	2270	|O
IC50	2270	2274	|O
=	2275	2276	|O
3.4	2277	2280	|O
nM	2281	2283	|O
)	2283	2284	|O
and	2285	2288	|O
extremely	2289	2298	|O
low	2299	2302	|O
affinity	2303	2311	|O
for	2312	2315	|O
both	2316	2320	|O
dopamine	2321	2329	|O
D2	2330	2332	|O
receptors	2333	2342	|O
(	2343	2344	|O
IC50	2344	2348	|O
=	2349	2350	|O
6900	2351	2355	|O
nM	2356	2358	|O
)	2358	2359	|O
and	2360	2363	|O
alpha	2364	2369	|O
1	2370	2371	|O
adrenoceptors	2372	2385	|O
(	2386	2387	|O
IC50	2387	2391	|O
=	2392	2393	|O
2300	2394	2398	|O
nM	2399	2401	|O
)	2401	2402	|O
.	2402	2403	|O

### abstracts675.txt
The	0	3	|O
dopaminergic	4	16	|O
receptor	17	25	|O
profile	26	33	|O
of	34	36	|O
a	37	38	|O
series	39	45	|O
of	46	48	|O
trans	49	54	|B-IUPAC
-	54	55	|I-IUPAC
1	55	56	|I-IUPAC
-	56	57	|I-IUPAC
[	57	58	|I-IUPAC
(	58	59	|I-IUPAC
2	59	60	|I-IUPAC
-	60	61	|I-IUPAC
phenylcyclopropyl	61	78	|I-IUPAC
)	78	79	|I-IUPAC
methyl	79	85	|I-IUPAC
]	85	86	|I-IUPAC
-	86	87	|I-IUPAC
4	87	88	|I-IUPAC
-	88	89	|I-IUPAC
arylpiperazines	89	104	|I-IUPAC
was	105	108	|O
examined	109	117	|O
.	117	118	|O
Aromatic	119	127	|O
substitution	128	140	|O
patterns	141	149	|O
were	150	154	|O
varied	155	161	|O
with	162	166	|O
the	167	170	|O
goal	171	175	|O
of	176	178	|O
identifying	179	190	|O
a	191	192	|O
compound	193	201	|O
having	202	208	|O
affinities	209	219	|O
for	220	223	|O
the	224	227	|O
D	228	229	|O
(	229	230	|O
2	230	231	|O
)	231	232	|O
and	233	236	|O
D	237	238	|O
(	238	239	|O
4	239	240	|O
)	240	241	|O
receptors	242	251	|O
in	252	254	|O
a	255	256	|O
ratio	257	262	|O
similar	263	270	|O
to	271	273	|O
that	274	278	|O
observed	279	287	|O
for	288	291	|O
the	292	295	|O
atypical	296	304	|O
neuroleptic	305	316	|O
clozapine	317	326	|O
.	326	327	|O
The	328	331	|O
compounds	332	341	|O
(	342	343	|B-IUPAC
1S	343	345	|I-IUPAC
,	345	346	|I-IUPAC
2S	347	349	|I-IUPAC
)	349	350	|I-IUPAC
-	350	351	|I-IUPAC
trans	351	356	|I-IUPAC
-	356	357	|I-IUPAC
1	357	358	|I-IUPAC
-	358	359	|I-IUPAC
[	359	360	|I-IUPAC
(	360	361	|I-IUPAC
2	361	362	|I-IUPAC
-	362	363	|I-IUPAC
phenylcyclopropyl	363	380	|I-IUPAC
)	380	381	|I-IUPAC
methyl	381	387	|I-IUPAC
]	387	388	|I-IUPAC
-	388	389	|I-IUPAC
4	389	390	|I-IUPAC
-	390	391	|I-IUPAC
(	391	392	|I-IUPAC
2	392	393	|I-IUPAC
,	393	394	|I-IUPAC
4	395	396	|I-IUPAC
-	396	397	|I-IUPAC
dichlorophenyl	397	411	|I-IUPAC
)	411	412	|I-IUPAC
piperazine	412	422	|I-IUPAC
(	423	424	|O
5m	424	426	|O
)	426	427	|O
and	428	431	|O
(	432	433	|B-IUPAC
1S	433	435	|I-IUPAC
,	435	436	|I-IUPAC
2S	437	439	|I-IUPAC
)	439	440	|I-IUPAC
-	440	441	|I-IUPAC
trans	441	446	|I-IUPAC
-	446	447	|I-IUPAC
1	447	448	|I-IUPAC
-	448	449	|I-IUPAC
[	449	450	|I-IUPAC
(	450	451	|I-IUPAC
2	451	452	|I-IUPAC
-	452	453	|I-IUPAC
phenylcyclopropyl	453	470	|I-IUPAC
)	470	471	|I-IUPAC
methyl	471	477	|I-IUPAC
]	477	478	|I-IUPAC
-	478	479	|I-IUPAC
4	479	480	|I-IUPAC
-	480	481	|I-IUPAC
(	481	482	|I-IUPAC
2	482	483	|I-IUPAC
,	483	484	|I-IUPAC
4	485	486	|I-IUPAC
-	486	487	|I-IUPAC
dimethylphenyl	487	501	|I-IUPAC
)	501	502	|I-IUPAC
piperazine	502	512	|I-IUPAC
(	513	514	|O
5t	514	516	|O
)	516	517	|O
were	518	522	|O
selected	523	531	|O
for	532	535	|O
functional	536	546	|O
antagonists	547	558	|O
at	559	561	|O
D	562	563	|O
(	563	564	|O
2	564	565	|O
)	565	566	|O
and	567	570	|O
D	571	572	|O
(	572	573	|O
4	573	574	|O
)	574	575	|O
receptors	576	585	|O
and	586	589	|O
had	590	593	|O
a	594	595	|O
D	596	597	|O
(	597	598	|O
2	598	599	|O
)	599	600	|O
/	600	601	|O
D	601	602	|O
(	602	603	|O
4	603	604	|O
)	604	605	|O
ratio	606	611	|O
approximating	612	625	|O
that	626	630	|O
of	631	633	|O
clozapine	634	643	|O
;	643	644	|O
they	645	649	|O
proved	650	656	|O
inactive	657	665	|O
in	666	668	|O
behavioral	669	679	|O
tests	680	685	|O
of	686	688	|O
antipsychotic	689	702	|O
activity	703	711	|O
.	711	712	|O

### abstracts1665.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
eight	12	17	|O
previously	18	28	|O
undescribed	29	40	|O
2,4	41	44	|B-IUPAC
-	44	45	|I-IUPAC
diaminothieno	45	58	|I-IUPAC
[	58	59	|I-IUPAC
2,3	59	62	|I-IUPAC
-	62	63	|I-IUPAC
d	63	64	|I-IUPAC
]	64	65	|I-IUPAC
pyrimidine	65	75	|I-IUPAC
analogues	76	85	|B-MODIFIER
of	86	88	|O
the	89	92	|O
potent	93	99	|O
dihydrofolate	100	113	|O
reductase	114	123	|O
(	124	125	|O
DHFR	125	129	|O
)	129	130	|O
inhibitors	131	141	|O
trimetrexate	142	154	|O
(	155	156	|O
TMQ	156	159	|O
)	159	160	|O
and	161	164	|O
piritrexim	165	175	|O
(	176	177	|O
PTX	177	180	|O
)	180	181	|O
were	182	186	|O
synthesized	187	198	|O
as	199	201	|O
potential	202	211	|O
drugs	212	217	|O
against	218	225	|O
Pneumocystis	226	238	|O
carinii	239	246	|O
and	247	250	|O
Toxoplasma	251	261	|O
gondii	262	268	|O
,	268	269	|O
which	270	275	|O
are	276	279	|O
major	280	285	|O
causes	286	292	|O
of	293	295	|O
severe	296	302	|O
opportunistic	303	316	|O
infections	317	327	|O
in	328	330	|O
AIDS	331	335	|O
patients	336	344	|O
.	344	345	|O
2,4	346	349	|B-IUPAC
-	349	350	|I-IUPAC
Diamino	350	357	|I-IUPAC
-	357	358	|I-IUPAC
5	358	359	|I-IUPAC
-	359	360	|I-IUPAC
methyl	360	366	|I-IUPAC
-	366	367	|I-IUPAC
6	367	368	|I-IUPAC
-	368	369	|I-IUPAC
(	369	370	|I-IUPAC
aryl	370	374	|I-IUPAC
/	374	375	|I-IUPAC
aralkyl	375	382	|I-IUPAC
)	382	383	|I-IUPAC
thieno	383	389	|I-IUPAC
[	389	390	|I-IUPAC
2,3	390	393	|I-IUPAC
-	393	394	|I-IUPAC
d	394	395	|I-IUPAC
]	395	396	|I-IUPAC
pyrimidines	396	407	|I-IUPAC
with	408	412	|O
3,4,5	413	418	|B-IUPAC
-	418	419	|I-IUPAC
trimethoxy	419	429	|I-IUPAC
or	430	432	|O
2,5	433	436	|B-IUPAC
-	436	437	|I-IUPAC
dimethoxy	437	446	|I-IUPAC
substitution	447	459	|B-MODIFIER
in	460	462	|O
the	463	466	|O
aryl	467	471	|O
/	471	472	|O
aralkyl	472	479	|O
moiety	480	486	|O
and	487	490	|O
2,4	491	494	|B-IUPAC
-	494	495	|I-IUPAC
diamino	495	502	|I-IUPAC
-	502	503	|I-IUPAC
5	503	504	|I-IUPAC
-	504	505	|I-IUPAC
(	505	506	|I-IUPAC
aryl	506	510	|I-IUPAC
/	510	511	|I-IUPAC
aralkyl	511	518	|I-IUPAC
)	518	519	|I-IUPAC
thieno	519	525	|I-IUPAC
[	525	526	|I-IUPAC
2,3	526	529	|I-IUPAC
-	529	530	|I-IUPAC
d	530	531	|I-IUPAC
]	531	532	|I-IUPAC
pyrimidines	532	543	|I-IUPAC
with	544	548	|O
2,5	549	552	|B-IUPAC
-	552	553	|I-IUPAC
dimethoxy	553	562	|I-IUPAC
substitution	563	575	|B-MODIFIER
in	576	578	|O
the	579	582	|O
aryl	583	587	|O
/	587	588	|O
aralkyl	588	595	|O
moiety	596	602	|O
were	603	607	|O
obtained	608	616	|O
by	617	619	|O
reaction	620	628	|O
of	629	631	|O
the	632	635	|O
corresponding	636	649	|O
2	650	651	|B-IUPAC
-	651	652	|I-IUPAC
amino	652	657	|I-IUPAC
-	657	658	|I-IUPAC
3	658	659	|I-IUPAC
-	659	660	|I-IUPAC
cyanothiophenes	660	675	|I-IUPAC
with	676	680	|O
chloroformamidine	681	698	|O
hydrochloride	699	712	|O
.	712	713	|O
The	714	717	|O
aryl	718	722	|O
group	723	728	|O
in	729	731	|O
the	732	735	|O
5,6	736	739	|O
-	739	740	|O
disubstituted	740	753	|O
analogues	754	763	|O
was	764	767	|O
either	768	774	|O
attached	775	783	|O
directly	784	792	|O
to	793	795	|O
the	796	799	|O
hetero	800	806	|O
ring	807	811	|O
or	812	814	|O
was	815	818	|O
separated	819	828	|O
from	829	833	|O
it	834	836	|O
by	837	839	|O
one	840	843	|O
or	844	846	|O
two	847	850	|O
carbons	851	858	|O
,	858	859	|O
whereas	860	867	|O
the	868	871	|O
aryl	872	876	|O
group	877	882	|O
in	883	885	|O
the	886	889	|O
5	890	891	|O
-	891	892	|O
monosubstituted	892	907	|O
analogues	908	917	|O
was	918	921	|O
separated	922	931	|O
from	932	936	|O
the	937	940	|O
hetero	941	947	|O
ring	948	952	|O
by	953	955	|O
two	956	959	|O
or	960	962	|O
three	963	968	|O
carbons	969	976	|O
.	976	977	|O
2	978	979	|B-IUPAC
-	979	980	|I-IUPAC
Amino	980	985	|I-IUPAC
-	985	986	|I-IUPAC
3	986	987	|I-IUPAC
-	987	988	|I-IUPAC
cyano	988	993	|I-IUPAC
-	993	994	|I-IUPAC
5	994	995	|I-IUPAC
-	995	996	|I-IUPAC
methyl	996	1002	|I-IUPAC
-	1002	1003	|I-IUPAC
6	1003	1004	|I-IUPAC
-	1004	1005	|I-IUPAC
(	1005	1006	|I-IUPAC
aryl	1006	1010	|I-IUPAC
/	1010	1011	|I-IUPAC
alkyl	1011	1016	|I-IUPAC
)	1016	1017	|I-IUPAC
thiophene	1017	1026	|I-IUPAC
intermediates	1027	1040	|O
for	1041	1044	|O
the	1045	1048	|O
preparation	1049	1060	|O
of	1061	1063	|O
the	1064	1067	|O
5,6	1068	1071	|O
-	1071	1072	|O
disubstituted	1072	1085	|O
analogues	1086	1095	|O
were	1096	1100	|O
prepared	1101	1109	|O
from	1110	1114	|O
omega	1115	1120	|B-IUPAC
-	1120	1121	|I-IUPAC
aryl	1121	1125	|I-IUPAC
-	1125	1126	|I-IUPAC
2	1126	1127	|I-IUPAC
-	1127	1128	|I-IUPAC
alkylidene	1128	1138	|I-IUPAC
-	1138	1139	|I-IUPAC
malononitriles	1139	1153	|I-IUPAC
and	1154	1157	|O
sulfur	1158	1164	|O
in	1165	1167	|O
the	1168	1171	|O
presence	1172	1180	|O
of	1181	1183	|O
a	1184	1185	|O
secondary	1186	1195	|O
amine	1196	1201	|O
,	1201	1202	|O
and	1203	1206	|O
2	1207	1208	|B-IUPAC
-	1208	1209	|I-IUPAC
amino	1209	1214	|I-IUPAC
-	1214	1215	|I-IUPAC
3	1215	1216	|I-IUPAC
-	1216	1217	|I-IUPAC
cyano	1217	1222	|I-IUPAC
-	1222	1223	|I-IUPAC
4	1223	1224	|I-IUPAC
-	1224	1225	|I-IUPAC
(	1225	1226	|I-IUPAC
aryl	1226	1230	|I-IUPAC
/	1230	1231	|I-IUPAC
aralkyl	1231	1238	|I-IUPAC
)	1238	1239	|I-IUPAC
thiophene	1239	1248	|I-IUPAC
intermediates	1249	1262	|B-MODIFIER
for	1263	1266	|O
the	1267	1270	|O
preparation	1271	1282	|O
of	1283	1285	|O
the	1286	1289	|O
5	1290	1291	|O
-	1291	1292	|O
monosubstituted	1292	1307	|O
analogues	1308	1317	|O
were	1318	1322	|O
obtained	1323	1331	|O
from	1332	1336	|O
omega	1337	1342	|B-IUPAC
-	1342	1343	|I-IUPAC
aryl	1343	1347	|I-IUPAC
-	1347	1348	|I-IUPAC
1	1348	1349	|I-IUPAC
-	1349	1350	|I-IUPAC
chloro	1350	1356	|I-IUPAC
-	1356	1357	|I-IUPAC
2	1357	1358	|I-IUPAC
-	1358	1359	|I-IUPAC
alkylidenemalononitriles	1359	1383	|I-IUPAC
and	1384	1387	|O
sodium	1388	1394	|O
hydrosulfide	1395	1407	|O
.	1407	1408	|O
Synthetic	1409	1418	|O
routes	1419	1425	|O
to	1426	1428	|O
the	1429	1432	|O
heretofore	1433	1443	|O
unknown	1444	1451	|O
ylidenemalononitriles	1452	1473	|O
,	1473	1474	|O
and	1475	1478	|O
the	1479	1482	|O
ketone	1483	1489	|O
precursors	1490	1500	|O
thereof	1501	1508	|O
,	1508	1509	|O
were	1510	1514	|O
developed	1515	1524	|O
.	1524	1525	|O
The	1526	1529	|O
final	1530	1535	|O
products	1536	1544	|O
were	1545	1549	|O
tested	1550	1556	|O
in	1557	1559	|O
vitro	1560	1565	|O
as	1566	1568	|O
inhibitors	1569	1579	|O
of	1580	1582	|O
DHFR	1583	1587	|O
from	1588	1592	|O
Pneumocystis	1593	1605	|O
carinii	1606	1613	|O
,	1613	1614	|O
Toxoplasma	1615	1625	|O
gondii	1626	1632	|O
,	1632	1633	|O
rat	1634	1637	|O
liver	1638	1643	|O
,	1643	1644	|O
beef	1645	1649	|O
liver	1650	1655	|O
,	1655	1656	|O
and	1657	1660	|O
Lactobacillus	1661	1674	|O
casei	1675	1680	|O
.	1680	1681	|O
A	1682	1683	|O
selected	1684	1692	|O
number	1693	1699	|O
of	1700	1702	|O
previously	1703	1713	|O
known	1714	1719	|O
2,4	1720	1723	|B-IUPAC
-	1723	1724	|I-IUPAC
diaminothieno	1724	1737	|I-IUPAC
[	1737	1738	|I-IUPAC
2,3	1738	1741	|I-IUPAC
-	1741	1742	|I-IUPAC
d	1742	1743	|I-IUPAC
]	1743	1744	|I-IUPAC
pyrimidines	1744	1755	|I-IUPAC
lacking	1756	1763	|O
the	1764	1767	|O
3,4,5	1768	1773	|B-IUPAC
-	1773	1774	|I-IUPAC
trimethoxyphenyl	1774	1790	|I-IUPAC
and	1791	1794	|O
2,5	1795	1798	|B-IUPAC
-	1798	1799	|I-IUPAC
dimethoxyphenyl	1799	1814	|I-IUPAC
substitution	1815	1827	|B-MODIFIER
pattern	1828	1835	|I-MODIFIER
of	1836	1838	|O
TMQ	1839	1842	|O
and	1843	1846	|O
PTX	1847	1850	|O
,	1850	1851	|O
respectively	1852	1864	|O
,	1864	1865	|O
were	1866	1870	|O
also	1871	1875	|O
tested	1876	1882	|O
for	1883	1886	|O
comparison	1887	1897	|O
.	1897	1898	|O
None	1899	1903	|O
of	1904	1906	|O
the	1907	1910	|O
compounds	1911	1920	|O
was	1921	1924	|O
as	1925	1927	|O
potent	1928	1934	|O
as	1935	1937	|O
TMQ	1938	1941	|O
or	1942	1944	|O
PTX	1945	1948	|O
,	1948	1949	|O
and	1950	1953	|O
while	1954	1959	|O
some	1960	1964	|O
of	1965	1967	|O
them	1968	1972	|O
showed	1973	1979	|O
some	1980	1984	|O
selectivity	1985	1996	|O
in	1997	1999	|O
their	2000	2005	|O
binding	2006	2013	|O
to	2014	2016	|O
Pneumocystis	2017	2029	|O
carinii	2030	2037	|O
and	2038	2041	|O
Toxoplasma	2042	2052	|O
gondii	2053	2059	|O
versus	2060	2066	|O
rat	2067	2070	|O
liver	2071	2076	|O
DHFR	2077	2081	|O
,	2081	2082	|O
this	2083	2087	|O
effect	2088	2094	|O
was	2095	2098	|O
not	2099	2102	|O
deemed	2103	2109	|O
large	2110	2115	|O
enough	2116	2122	|O
to	2123	2125	|O
warrant	2126	2133	|O
further	2134	2141	|O
preclinical	2142	2153	|O
evaluation	2154	2164	|O
.	2164	2165	|O

### abstracts4577.txt
Extensive	0	9	|O
evidence	10	18	|O
gathered	19	27	|O
from	28	32	|O
structure	33	42	|O
-	42	43	|O
activity	43	51	|O
relationship	52	64	|O
analysis	65	73	|O
has	74	77	|O
identified	78	88	|O
and	89	92	|O
confirmed	93	102	|O
specific	103	111	|O
positions	112	121	|O
in	122	124	|O
the	125	128	|O
glucagon	129	137	|O
sequence	138	146	|O
that	147	151	|O
are	152	155	|O
important	156	165	|O
either	166	172	|O
for	173	176	|O
binding	177	184	|O
to	185	187	|O
its	188	191	|O
receptor	192	200	|O
or	201	203	|O
for	204	207	|O
signal	208	214	|O
transduction	215	227	|O
.	227	228	|O
Fifteen	229	236	|O
glucagon	237	245	|O
analogues	246	255	|O
have	256	260	|O
been	261	265	|O
designed	266	274	|O
and	275	278	|O
synthesized	279	290	|O
by	291	293	|O
incorporating	294	307	|O
structural	308	318	|O
changes	319	326	|O
in	327	329	|O
the	330	333	|O
N	334	335	|O
-	335	336	|O
terminal	336	344	|O
region	345	351	|O
of	352	354	|O
glucagon	355	363	|O
,	363	364	|O
in	365	367	|O
particular	368	378	|O
histidine	379	388	|O
-	388	389	|O
1	389	390	|O
,	390	391	|O
phenylalanine	392	405	|O
-	405	406	|O
6	406	407	|O
,	407	408	|O
and	409	412	|O
aspartic	413	421	|O
acid	422	426	|O
-	426	427	|O
9	427	428	|O
.	428	429	|O
This	430	434	|O
investigation	435	448	|O
was	449	452	|O
conducted	453	462	|O
to	463	465	|O
study	466	471	|O
the	472	475	|O
role	476	480	|O
of	481	483	|O
phenylalanine	484	497	|O
at	498	500	|O
position	501	509	|O
6	510	511	|O
on	512	514	|O
the	515	518	|O
glucagon	519	527	|O
mechanism	528	537	|O
of	538	540	|O
action	541	547	|O
.	547	548	|O
These	549	554	|O
glucagon	555	563	|O
analogues	564	573	|O
have	574	578	|O
been	579	583	|O
made	584	588	|O
by	589	591	|O
either	592	598	|O
deleting	599	607	|O
or	608	610	|O
substituting	611	623	|O
hydrophobic	624	635	|O
groups	636	642	|O
,	642	643	|O
hydrophilic	644	655	|O
groups	656	662	|O
,	662	663	|O
aromatic	664	672	|O
amino	673	678	|O
acids	679	684	|O
,	684	685	|O
or	686	688	|O
a	689	690	|O
D	691	692	|O
-	692	693	|O
phenylalanine	693	706	|O
residue	707	714	|O
at	715	717	|O
this	718	722	|O
position	723	731	|O
.	731	732	|O
The	733	736	|O
structures	737	747	|O
of	748	750	|O
the	751	754	|O
new	755	758	|O
analogues	759	768	|O
are	769	772	|O
as	773	775	|O
follows	776	783	|O
:	783	784	|O
[	785	786	|O
des	786	789	|O
-	789	790	|O
His1	790	794	|O
,	794	795	|O
des	796	799	|O
-	799	800	|O
Phe6	800	804	|O
,	804	805	|O
Glu9	806	810	|O
]	810	811	|O
glucagon	811	819	|O
-	819	820	|O
NH2	820	823	|O
(	824	825	|O
1	825	826	|O
)	826	827	|O
;	827	828	|O
[	829	830	|O
des	830	833	|O
-	833	834	|O
His1	834	838	|O
,	838	839	|O
Ala6	839	843	|O
,	843	844	|O
Glu9	844	848	|O
]	848	849	|O
glucagon	849	857	|O
-	857	858	|O
NH2	858	861	|O
(	862	863	|O
2	863	864	|O
)	864	865	|O
;	865	866	|O
[	867	868	|O
des	868	871	|O
-	871	872	|O
His1	872	876	|O
,	876	877	|O
Tyr6	877	881	|O
,	881	882	|O
Glu9	882	886	|O
]	886	887	|O
glucagon	887	895	|O
-	895	896	|O
NH2	896	899	|O
(	900	901	|O
3	901	902	|O
)	902	903	|O
;	903	904	|O
[	905	906	|O
des	906	909	|O
-	909	910	|O
His1	910	914	|O
,	914	915	|O
Trp6	915	919	|O
,	919	920	|O
Glu9	920	924	|O
]	924	925	|O
-	925	926	|O
glucagon	926	934	|O
-	934	935	|O
NH2	935	938	|O
(	939	940	|O
4	940	941	|O
)	941	942	|O
;	942	943	|O
[	944	945	|O
des	945	948	|O
-	948	949	|O
His1	949	953	|O
,	953	954	|O
D	954	955	|O
-	955	956	|O
Phe6	956	960	|O
,	960	961	|O
Glu9	961	965	|O
]	965	966	|O
glucagon	966	974	|O
-	974	975	|O
NH2	975	978	|O
(	979	980	|O
5	980	981	|O
)	981	982	|O
;	982	983	|O
[	984	985	|O
des	985	988	|O
-	988	989	|O
His1	989	993	|O
,	993	994	|O
Nle6	994	998	|O
,	998	999	|O
Glu9	999	1003	|O
]	1003	1004	|O
glucagon	1004	1012	|O
-	1012	1013	|O
NH2	1013	1016	|O
(	1017	1018	|O
6	1018	1019	|O
)	1019	1020	|O
;	1020	1021	|O
[	1022	1023	|O
des	1023	1026	|O
-	1026	1027	|O
His1	1027	1031	|O
,	1031	1032	|O
Asp6	1032	1036	|O
,	1036	1037	|O
Glu9	1037	1041	|O
]	1041	1042	|O
glucagon	1042	1050	|O
-	1050	1051	|O
NH2	1051	1054	|O
(	1055	1056	|O
7	1056	1057	|O
)	1057	1058	|O
;	1058	1059	|O
[	1060	1061	|O
des	1061	1064	|O
-	1064	1065	|O
His1	1065	1069	|O
,	1069	1070	|O
des	1070	1073	|O
-	1073	1074	|O
Gly4	1074	1078	|O
,	1078	1079	|O
Glu9	1079	1083	|O
]	1083	1084	|O
glucagon	1084	1092	|O
-	1092	1093	|O
NH2	1093	1096	|O
(	1097	1098	|O
8	1098	1099	|O
)	1099	1100	|O
;	1100	1101	|O
[	1102	1103	|O
desPhe6	1103	1110	|O
,	1110	1111	|O
-	1111	1112	|O
Glu9	1112	1116	|O
]	1116	1117	|O
glucagon	1117	1125	|O
-	1125	1126	|O
NH2	1126	1129	|O
(	1130	1131	|O
9	1131	1132	|O
)	1132	1133	|O
;	1133	1134	|O
[	1135	1136	|O
des	1136	1139	|O
-	1139	1140	|O
Phe6	1140	1144	|O
]	1144	1145	|O
glucagon	1145	1153	|O
-	1153	1154	|O
NH2	1154	1157	|O
(	1158	1159	|O
10	1159	1161	|O
)	1161	1162	|O
;	1162	1163	|O
[	1164	1165	|O
des	1165	1168	|O
-	1168	1169	|O
His1	1169	1173	|O
,	1173	1174	|O
des	1175	1178	|O
-	1178	1179	|O
Phe6	1179	1183	|O
]	1183	1184	|O
glucagon	1184	1192	|O
-	1192	1193	|O
NH2	1193	1196	|O
(	1197	1198	|O
11	1198	1200	|O
)	1200	1201	|O
;	1201	1202	|O
[	1203	1204	|O
des	1204	1207	|O
-	1207	1208	|O
His1	1208	1212	|O
,	1212	1213	|O
des	1214	1217	|O
-	1217	1218	|O
Phe6	1218	1222	|O
,	1222	1223	|O
Glu9	1223	1227	|O
]	1227	1228	|O
glucagon	1228	1236	|O
(	1237	1238	|O
12	1238	1240	|O
)	1240	1241	|O
;	1241	1242	|O
[	1243	1244	|O
des	1244	1247	|O
-	1247	1248	|O
Phe6	1248	1252	|O
,	1252	1253	|O
Glu9	1253	1257	|O
]	1257	1258	|O
glucagon	1258	1266	|O
(	1267	1268	|O
13	1268	1270	|O
)	1270	1271	|O
;	1271	1272	|O
[	1273	1274	|O
des	1274	1277	|O
-	1277	1278	|O
Phe6	1278	1282	|O
]	1282	1283	|O
glucagon	1283	1291	|O
(	1292	1293	|O
14	1293	1295	|O
)	1295	1296	|O
;	1296	1297	|O
and	1298	1301	|O
[	1302	1303	|O
des	1303	1306	|O
-	1306	1307	|O
His1	1307	1311	|O
,	1311	1312	|O
des	1313	1316	|O
-	1316	1317	|O
Phe6	1317	1321	|O
]	1321	1322	|O
glucagon	1322	1330	|O
(	1331	1332	|O
15	1332	1334	|O
)	1334	1335	|O
.	1335	1336	|O
The	1337	1340	|O
receptor	1341	1349	|O
binding	1350	1357	|O
potencies	1358	1367	|O
IC50	1368	1372	|O
values	1373	1379	|O
are	1380	1383	|O
48	1384	1386	|O
(	1387	1388	|O
1	1388	1389	|O
)	1389	1390	|O
,	1390	1391	|O
126	1392	1395	|O
(	1396	1397	|O
2	1397	1398	|O
)	1398	1399	|O
,	1399	1400	|O
40	1401	1403	|O
(	1404	1405	|O
3	1405	1406	|O
)	1406	1407	|O
,	1407	1408	|O
19	1409	1411	|O
(	1412	1413	|O
4	1413	1414	|O
)	1414	1415	|O
,	1415	1416	|O
100	1417	1420	|O
(	1421	1422	|O
5	1422	1423	|O
)	1423	1424	|O
,	1424	1425	|O
48	1426	1428	|O
(	1429	1430	|O
6	1430	1431	|O
)	1431	1432	|O
,	1432	1433	|O
2000	1434	1438	|O
(	1439	1440	|O
7	1440	1441	|O
)	1441	1442	|O
,	1442	1443	|O
52	1444	1446	|O
(	1447	1448	|O
8	1448	1449	|O
)	1449	1450	|O
,	1450	1451	|O
113	1452	1455	|O
(	1456	1457	|O
9	1457	1458	|O
)	1458	1459	|O
,	1459	1460	|O
512	1461	1464	|O
(	1465	1466	|O
10	1466	1468	|O
)	1468	1469	|O
,	1469	1470	|O
128	1471	1474	|O
(	1475	1476	|O
11	1476	1478	|O
)	1478	1479	|O
,	1479	1480	|O
1000	1481	1485	|O
(	1486	1487	|O
12	1487	1489	|O
)	1489	1490	|O
,	1490	1491	|O
2000	1492	1496	|O
(	1497	1498	|O
13	1498	1500	|O
)	1500	1501	|O
,	1501	1502	|O
500	1503	1506	|O
(	1507	1508	|O
14	1508	1510	|O
)	1510	1511	|O
,	1511	1512	|O
and	1513	1516	|O
200	1517	1520	|O
nM	1521	1523	|O
(	1524	1525	|O
15	1525	1527	|O
)	1527	1528	|O
.	1528	1529	|O
All	1530	1533	|O
analogues	1534	1543	|O
were	1544	1548	|O
found	1549	1554	|O
to	1555	1557	|O
be	1558	1560	|O
antagonists	1561	1572	|O
unable	1573	1579	|O
to	1580	1582	|O
activate	1583	1591	|O
the	1592	1595	|O
adenylate	1596	1605	|O
cyclase	1606	1613	|O
system	1614	1620	|O
even	1621	1625	|O
at	1626	1628	|O
concentrations	1629	1643	|O
as	1644	1646	|O
high	1647	1651	|O
as	1652	1654	|O
10	1655	1657	|O
(	1657	1658	|O
-	1658	1659	|O
5	1659	1660	|O
)	1660	1661	|O
M	1662	1663	|O
except	1664	1670	|O
for	1671	1674	|O
analogues	1675	1684	|O
6	1685	1686	|O
and	1687	1690	|O
8	1691	1692	|O
,	1692	1693	|O
which	1694	1699	|O
were	1700	1704	|O
found	1705	1710	|O
to	1711	1713	|O
be	1714	1716	|O
weak	1717	1721	|O
partial	1722	1729	|O
agonists	1730	1738	|O
/	1738	1739	|O
partial	1739	1746	|O
antagonists	1747	1758	|O
with	1759	1763	|O
maximum	1764	1771	|O
stimulation	1772	1783	|O
between	1784	1791	|O
6-12%	1792	1797	|O
.	1797	1798	|O
In	1799	1801	|O
competitive	1802	1813	|O
inhibition	1814	1824	|O
experiments	1825	1836	|O
,	1836	1837	|O
all	1838	1841	|O
the	1842	1845	|O
analogues	1846	1855	|O
caused	1856	1862	|O
a	1863	1864	|O
right	1865	1870	|O
shift	1871	1876	|O
of	1877	1879	|O
the	1880	1883	|O
glucagon	1884	1892	|O
-	1892	1893	|O
stimulated	1893	1903	|O
adenylate	1904	1913	|O
cyclase	1914	1921	|O
dose	1922	1926	|O
-	1926	1927	|O
response	1927	1935	|O
curve	1936	1941	|O
.	1941	1942	|O
The	1943	1946	|O
pA2	1947	1950	|O
values	1951	1957	|O
were	1958	1962	|O
8.20	1963	1967	|O
(	1968	1969	|O
1	1969	1970	|O
)	1970	1971	|O
,	1971	1972	|O
6.40	1973	1977	|O
(	1978	1979	|O
2	1979	1980	|O
)	1980	1981	|O
,	1981	1982	|O
6.20	1983	1987	|O
(	1988	1989	|O
3	1989	1990	|O
)	1990	1991	|O
,	1991	1992	|O
6.25	1993	1997	|O
(	1998	1999	|O
4	1999	2000	|O
)	2000	2001	|O
,	2001	2002	|O
6.30	2003	2007	|O
(	2008	2009	|O
5	2009	2010	|O
)	2010	2011	|O
,	2011	2012	|O
6.30	2013	2017	|O
(	2018	2019	|O
7	2019	2020	|O
)	2020	2021	|O
,	2021	2022	|O
6.05	2023	2027	|O
(	2028	2029	|O
8	2029	2030	|O
)	2030	2031	|O
,	2031	2032	|O
6.20	2033	2037	|O
(	2038	2039	|O
9	2039	2040	|O
)	2040	2041	|O
,	2041	2042	|O
6.30	2043	2047	|O
(	2048	2049	|O
10	2049	2051	|O
)	2051	2052	|O
,	2052	2053	|O
6.25	2054	2058	|O
(	2059	2060	|O
11	2060	2062	|O
)	2062	2063	|O
,	2063	2064	|O
6.10	2065	2069	|O
(	2070	2071	|O
12	2071	2073	|O
)	2073	2074	|O
,	2074	2075	|O
6.20	2076	2080	|O
(	2081	2082	|O
13	2082	2084	|O
)	2084	2085	|O
,	2085	2086	|O
6.20	2087	2091	|O
(	2092	2093	|O
14	2093	2095	|O
)	2095	2096	|O
,	2096	2097	|O
and	2098	2101	|O
6.35	2102	2106	|O
(	2107	2108	|O
15	2108	2110	|O
)	2110	2111	|O
.	2111	2112	|O

### abstracts1287.txt
A	0	1	|O
convenient	2	12	|O
synthesis	13	22	|O
of	23	25	|O
8	26	27	|O
-	27	28	|O
azapurine	28	37	|O
ribonucleosides	38	53	|O
substituted	54	65	|O
at	66	68	|O
the	69	72	|O
6	73	74	|O
position	75	83	|O
with	84	88	|O
thio	89	93	|B-IUPAC
,	93	94	|O
alkylthio	95	104	|B-IUPAC
,	104	105	|O
alkoxy	106	112	|B-IUPAC
,	112	113	|O
amino	114	119	|B-IUPAC
,	119	120	|O
and	121	124	|O
alkylamino	125	135	|B-IUPAC
groups	136	142	|B-MODIFIER
is	143	145	|O
described	146	155	|O
.	155	156	|O
The	157	160	|O
reaction	161	169	|O
of	170	172	|O
6	173	174	|B-IUPAC
-	174	175	|I-IUPAC
(	175	176	|I-IUPAC
methylthio	176	186	|I-IUPAC
)	186	187	|I-IUPAC
-	187	188	|I-IUPAC
8	188	189	|I-IUPAC
-	189	190	|I-IUPAC
azapurine	190	199	|I-IUPAC
(	200	201	|O
1	201	202	|O
)	202	203	|O
with	204	208	|O
2,3,5	209	214	|B-IUPAC
-	214	215	|I-IUPAC
tri	215	218	|I-IUPAC
-	218	219	|I-IUPAC
O	219	220	|I-IUPAC
-	220	221	|I-IUPAC
acetyl	221	227	|I-IUPAC
-	227	228	|I-IUPAC
D	228	229	|I-IUPAC
-	229	230	|I-IUPAC
ribofuranosyl	230	243	|I-IUPAC
chloride	244	252	|I-IUPAC
in	253	255	|O
the	256	259	|O
presence	260	268	|O
of	269	271	|O
Linde	272	277	|O
AW	278	280	|O
-	280	281	|O
500	281	284	|O
molecular	285	294	|O
sieve	295	300	|O
gave	301	305	|O
a	306	307	|O
2	308	309	|O
:	309	310	|O
1	310	311	|O
mixture	312	319	|O
of	320	322	|O
2	323	324	|O
and	325	328	|O
3	329	330	|O
,	330	331	|O
respectively	332	344	|O
.	344	345	|O
This	346	350	|O
mixture	351	358	|O
was	359	362	|O
rearranged	363	373	|O
by	374	376	|O
heating	377	384	|O
with	385	389	|O
molecular	390	399	|O
sieve	400	405	|O
in	406	408	|O
refluxing	409	418	|O
toluene	419	426	|O
to	427	429	|O
give	430	434	|O
a	435	436	|O
6	437	438	|O
:	438	439	|O
1	439	440	|O
mixture	441	448	|O
of	449	451	|O
2	452	453	|O
and	454	457	|O
3	458	459	|O
.	459	460	|O
Treatment	461	470	|O
of	471	473	|O
2	474	475	|O
or	476	478	|O
3	479	480	|O
with	481	485	|O
the	486	489	|O
appropriate	490	501	|O
nucleophiles	502	514	|O
at	515	517	|O
room	518	522	|O
temperature	523	534	|O
gave	535	539	|O
6	540	541	|B-MODIFIER
-	541	542	|I-MODIFIER
substituted	542	553	|I-MODIFIER
8	554	555	|B-IUPAC
-	555	556	|I-IUPAC
azapurine	556	565	|I-IUPAC
ribonucleosides	566	581	|I-IUPAC
(	582	583	|O
7	583	584	|B-MODIFIER
-	584	585	|I-MODIFIER
substituted	585	596	|I-MODIFIER
2	597	598	|B-PARTIUPAC
-	598	599	|I-PARTIUPAC
or	600	602	|O
3	603	604	|B-IUPAC
-	604	605	|I-IUPAC
beta	605	609	|I-IUPAC
-	609	610	|I-IUPAC
D	610	611	|I-IUPAC
-	611	612	|I-IUPAC
ribofuranosyl	612	625	|I-IUPAC
-	625	626	|I-IUPAC
3H	626	628	|I-IUPAC
-	628	629	|I-IUPAC
1,2,3	629	634	|I-IUPAC
-	634	635	|I-IUPAC
triazolo	635	643	|I-IUPAC
[	643	644	|I-IUPAC
4,5	644	647	|I-IUPAC
-	647	648	|I-IUPAC
d	648	649	|I-IUPAC
]	649	650	|I-IUPAC
pyrimidines	650	661	|I-IUPAC
)	661	662	|O
4-13	663	667	|O
.	667	668	|O
The	669	672	|O
thione	673	679	|O
11	680	682	|O
rearranges	683	693	|O
to	694	696	|O
N	697	698	|B-IUPAC
-	698	699	|I-IUPAC
beta	699	703	|I-IUPAC
-	703	704	|I-IUPAC
D	704	705	|I-IUPAC
-	705	706	|I-IUPAC
ribofuranosyl	706	719	|I-IUPAC
[	719	720	|I-IUPAC
1,2,3	720	725	|I-IUPAC
]	725	726	|I-IUPAC
thiadiazolo	726	737	|I-IUPAC
[	737	738	|I-IUPAC
5,4	738	741	|I-IUPAC
-	741	742	|I-IUPAC
d	742	743	|I-IUPAC
]	743	744	|I-IUPAC
pyrimidin	744	753	|I-IUPAC
-	753	754	|I-IUPAC
7	754	755	|I-IUPAC
-	755	756	|I-IUPAC
amine	756	761	|I-IUPAC
(	762	763	|O
14	763	765	|O
)	765	766	|O
in	767	769	|O
the	770	773	|O
solid	774	779	|O
state	780	785	|O
or	786	788	|O
in	789	791	|O
solution	792	800	|O
.	800	801	|O
All	802	805	|O
of	806	808	|O
these	809	814	|O
compounds	815	824	|O
were	825	829	|O
cytotoxic	830	839	|O
to	840	842	|O
H	843	844	|O
.	844	845	|O
Ep	845	847	|O
.	847	848	|O
No	849	851	|O
.	851	852	|O
2	853	854	|O
cells	855	860	|O
in	861	863	|O
culture	864	871	|O
except	872	878	|O
the	879	882	|O
parent	883	889	|O
base	890	894	|O
,	894	895	|O
8	896	897	|B-IUPAC
-	897	898	|I-IUPAC
aza	898	901	|I-IUPAC
-	901	902	|I-IUPAC
6	902	903	|I-IUPAC
-	903	904	|I-IUPAC
(	904	905	|I-IUPAC
methylthio	905	915	|I-IUPAC
)	915	916	|I-IUPAC
purine	916	922	|I-IUPAC
(	923	924	|O
1	924	925	|O
)	925	926	|O
and	927	930	|O
the	931	934	|O
8	935	936	|O
-	936	937	|O
isomers	937	944	|O
(	945	946	|O
3,12	946	950	|O
,	950	951	|O
and	952	955	|O
13	956	958	|O
)	958	959	|O
.	959	960	|O
Three	961	966	|O
of	967	969	|O
these	970	975	|O
compounds	976	985	|O
-	985	986	|O
8azaadenosine	986	999	|B-IUPAC
(	1000	1001	|O
4	1001	1002	|O
)	1002	1003	|O
,	1003	1004	|O
8	1005	1006	|B-IUPAC
-	1006	1007	|I-IUPAC
aza	1007	1010	|I-IUPAC
-	1010	1011	|I-IUPAC
6	1011	1012	|I-IUPAC
-	1012	1013	|I-IUPAC
(	1013	1014	|I-IUPAC
methylthio	1014	1024	|I-IUPAC
)	1024	1025	|I-IUPAC
purine	1025	1031	|I-IUPAC
ribonucleoside	1032	1046	|I-IUPAC
(	1047	1048	|O
5	1048	1049	|O
)	1049	1050	|O
,	1050	1051	|O
and	1052	1055	|O
8	1056	1057	|B-IUPAC
-	1057	1058	|I-IUPAC
aza	1058	1061	|I-IUPAC
-	1061	1062	|I-IUPAC
6	1062	1063	|I-IUPAC
-	1063	1064	|I-IUPAC
(	1064	1065	|I-IUPAC
methoxy	1065	1072	|I-IUPAC
)	1072	1073	|I-IUPAC
purine	1073	1079	|I-IUPAC
ribonucleoside	1080	1094	|I-IUPAC
(	1095	1096	|O
7	1096	1097	|O
)	1097	1098	|O
-	1098	1099	|O
showed	1099	1105	|O
borderline	1106	1116	|O
activity	1117	1125	|O
in	1126	1128	|O
the	1129	1132	|O
leukemia	1133	1141	|O
L1210	1142	1147	|O
system	1148	1154	|O
.	1154	1155	|O
The	1156	1159	|O
thiadiazolopyrimidine	1160	1181	|O
(	1182	1183	|O
14	1183	1185	|O
)	1185	1186	|O
showed	1187	1193	|O
activity	1194	1202	|O
at	1203	1205	|O
three	1206	1211	|O
dose	1212	1216	|O
levels	1217	1223	|O
.	1223	1224	|O

### abstracts1013.txt
The	0	3	|O
synthesis	4	13	|O
and	14	17	|O
pharmacological	18	33	|O
properties	34	44	|O
of	45	47	|O
several	48	55	|O
racemic	56	63	|B-MODIFIER
6,7,8,9	64	71	|B-IUPAC
-	71	72	|I-IUPAC
tetrahydro	72	82	|I-IUPAC
-	82	83	|I-IUPAC
3	83	84	|I-IUPAC
-	84	85	|I-IUPAC
hydroxy	85	92	|I-IUPAC
-	92	93	|I-IUPAC
1H	93	95	|I-IUPAC
-	95	96	|I-IUPAC
1	96	97	|I-IUPAC
-	97	98	|I-IUPAC
benzazepine	98	109	|I-IUPAC
-	109	110	|I-IUPAC
2,5	110	113	|I-IUPAC
-	113	114	|I-IUPAC
diones	114	120	|I-IUPAC
(	121	122	|O
THHBADs	122	129	|O
)	129	130	|O
are	131	134	|O
described	135	144	|O
.	144	145	|O
Synthesis	146	155	|O
was	156	159	|O
accomplished	160	172	|O
via	173	176	|O
a	177	178	|O
Schmidt	179	186	|O
reaction	187	195	|O
with	196	200	|O
5,6,7,8	201	208	|B-IUPAC
-	208	209	|I-IUPAC
tetrahydro	209	219	|I-IUPAC
-	219	220	|I-IUPAC
2	220	221	|I-IUPAC
-	221	222	|I-IUPAC
methoxynaphthalene	222	240	|I-IUPAC
-	240	241	|I-IUPAC
1,4	241	244	|I-IUPAC
-	244	245	|I-IUPAC
diones	245	251	|I-IUPAC
(	252	253	|O
THMNDs	253	259	|O
)	259	260	|O
followed	261	269	|O
by	270	272	|O
demethylation	273	286	|O
.	286	287	|O
THMNDs	288	294	|O
were	295	299	|O
prepared	300	308	|O
via	309	312	|O
a	313	314	|O
Diels	315	320	|O
-	320	321	|O
Alder	321	326	|O
reaction	327	335	|O
with	336	340	|O
2	341	342	|B-IUPAC
-	342	343	|I-IUPAC
methoxybenzoquinone	343	362	|I-IUPAC
(	363	364	|O
5	364	365	|O
)	365	366	|O
or	367	369	|O
2	370	371	|B-IUPAC
-	371	372	|I-IUPAC
bromo	372	377	|I-IUPAC
-	377	378	|I-IUPAC
5	378	379	|I-IUPAC
-	379	380	|I-IUPAC
methoxybenzoquinone	380	399	|I-IUPAC
(	400	401	|O
14	401	403	|O
)	403	404	|O
and	405	408	|O
substituted	409	420	|B-MODIFIER
1,3	421	424	|B-IUPAC
-	424	425	|I-IUPAC
butadienes	425	435	|I-IUPAC
.	435	436	|O
The	437	440	|O
pharmacology	441	453	|O
of	454	456	|O
THHBADs	457	464	|O
was	465	468	|O
characterized	469	482	|O
by	483	485	|O
electrical	486	496	|O
recordings	497	507	|O
in	508	510	|O
Xenopus	511	518	|O
oocytes	519	526	|O
expressing	527	537	|O
rat	538	541	|O
brain	542	547	|O
NMDA	548	552	|O
and	553	556	|O
AMPA	557	561	|O
receptors	562	571	|O
.	571	572	|O
THHBADs	573	580	|O
are	581	584	|O
antagonists	585	596	|O
of	597	599	|O
NMDA	600	604	|O
and	605	608	|O
AMPA	609	613	|O
receptors	614	623	|O
with	624	628	|O
functional	629	639	|O
potency	640	647	|O
being	648	653	|O
dependent	654	663	|O
upon	664	668	|O
the	669	672	|O
substitution	673	685	|O
pattern	686	693	|O
on	694	696	|O
the	697	700	|O
tetrahydrobenzene	701	718	|O
moiety	719	725	|O
.	725	726	|O
The	727	730	|O
7,8	731	734	|B-IUPAC
-	734	735	|I-IUPAC
dichloro	735	743	|I-IUPAC
-	743	744	|I-IUPAC
6	744	745	|I-IUPAC
-	745	746	|I-IUPAC
methyl	746	752	|I-IUPAC
(	753	754	|O
18a	754	757	|O
)	757	758	|O
and	759	762	|O
7,8	763	766	|B-IUPAC
-	766	767	|I-IUPAC
dichloro	767	775	|I-IUPAC
-	775	776	|I-IUPAC
6	776	777	|I-IUPAC
-	777	778	|I-IUPAC
ethyl	778	783	|I-IUPAC
(	784	785	|O
18b	785	788	|O
)	788	789	|O
analogs	790	797	|B-MODIFIER
are	798	801	|O
the	802	805	|O
most	806	810	|O
potent	811	817	|O
THHBADs	818	825	|O
prepared	826	834	|O
and	835	838	|O
have	839	843	|O
apparent	844	852	|O
antagonist	853	863	|O
dissociation	864	876	|O
constants	877	886	|O
(	887	888	|O
Kb	888	890	|O
values	891	897	|O
)	897	898	|O
of	899	901	|O
0.0041	902	908	|O
and	909	912	|O
0.0028	913	919	|O
microM	920	926	|O
,	926	927	|O
respectively	928	940	|O
,	940	941	|O
for	942	945	|O
NMDA	946	950	|O
receptors	951	960	|O
and	961	964	|O
0.51	965	969	|O
and	970	973	|O
0.72	974	978	|O
microM	979	985	|O
,	985	986	|O
respectively	987	999	|O
,	999	1000	|O
for	1001	1004	|O
AMPA	1005	1009	|O
receptors	1010	1019	|O
.	1019	1020	|O

### abstracts2361.txt
Several	0	7	|O
N	8	9	|B-IUPAC
(	9	10	|I-IUPAC
1	10	11	|I-IUPAC
)	11	12	|I-IUPAC
-	12	13	|I-IUPAC
arylalkylpolyamines	13	32	|I-IUPAC
containing	33	43	|O
various	44	51	|O
aromatic	52	60	|O
ring	61	65	|O
systems	66	73	|O
were	74	78	|O
synthesized	79	90	|O
as	91	93	|O
their	94	99	|O
respective	100	110	|O
HCl	111	114	|O
salts	115	120	|O
.	120	121	|O
The	122	125	|O
N	126	127	|O
(	127	128	|O
1	128	129	|O
)	129	130	|O
-	130	131	|O
substituents	131	143	|O
evaluated	144	153	|O
ranged	154	160	|O
in	161	163	|O
size	164	168	|O
from	169	173	|O
N	174	175	|B-IUPAC
(	175	176	|I-IUPAC
1	176	177	|I-IUPAC
)	177	178	|I-IUPAC
-	178	179	|I-IUPAC
benzyl	179	185	|I-IUPAC
,	185	186	|O
N	187	188	|B-IUPAC
(	188	189	|I-IUPAC
1	189	190	|I-IUPAC
)	190	191	|I-IUPAC
-	191	192	|I-IUPAC
naphthalen	192	202	|I-IUPAC
-	202	203	|I-IUPAC
1	203	204	|I-IUPAC
-	204	205	|I-IUPAC
ylmethyl	205	213	|I-IUPAC
,	213	214	|O
N	215	216	|B-IUPAC
(	216	217	|I-IUPAC
1	217	218	|I-IUPAC
)	218	219	|I-IUPAC
-	219	220	|I-IUPAC
2	220	221	|I-IUPAC
-	221	222	|I-IUPAC
(	222	223	|I-IUPAC
naphthalen	223	233	|I-IUPAC
-	233	234	|I-IUPAC
1	234	235	|I-IUPAC
-	235	236	|I-IUPAC
yl	236	238	|I-IUPAC
)	238	239	|I-IUPAC
ethyl	239	244	|I-IUPAC
,	244	245	|O
N	246	247	|B-IUPAC
(	247	248	|I-IUPAC
1	248	249	|I-IUPAC
)	249	250	|I-IUPAC
-	250	251	|I-IUPAC
3	251	252	|I-IUPAC
-	252	253	|I-IUPAC
(	253	254	|I-IUPAC
naphthalen	254	264	|I-IUPAC
-	264	265	|I-IUPAC
1	265	266	|I-IUPAC
-	266	267	|I-IUPAC
yl	267	269	|I-IUPAC
)	269	270	|I-IUPAC
propyl	270	276	|I-IUPAC
,	276	277	|O
N	278	279	|B-IUPAC
(	279	280	|I-IUPAC
1	280	281	|I-IUPAC
)	281	282	|I-IUPAC
-	282	283	|I-IUPAC
anthracen	283	292	|I-IUPAC
-	292	293	|I-IUPAC
9	293	294	|I-IUPAC
-	294	295	|I-IUPAC
ylmethyl	295	303	|I-IUPAC
,	303	304	|O
N	305	306	|B-IUPAC
(	306	307	|I-IUPAC
1	307	308	|I-IUPAC
)	308	309	|I-IUPAC
-	309	310	|I-IUPAC
2	310	311	|I-IUPAC
-	311	312	|I-IUPAC
(	312	313	|I-IUPAC
anthracen	313	322	|I-IUPAC
-	322	323	|I-IUPAC
9	323	324	|I-IUPAC
-	324	325	|I-IUPAC
yl	325	327	|I-IUPAC
)	327	328	|I-IUPAC
ethyl	328	333	|I-IUPAC
,	333	334	|O
N	335	336	|B-IUPAC
(	336	337	|I-IUPAC
1	337	338	|I-IUPAC
)	338	339	|I-IUPAC
-	339	340	|I-IUPAC
3	340	341	|I-IUPAC
-	341	342	|I-IUPAC
(	342	343	|I-IUPAC
anthracen	343	352	|I-IUPAC
-	352	353	|I-IUPAC
9	353	354	|I-IUPAC
-	354	355	|I-IUPAC
yl	355	357	|I-IUPAC
)	357	358	|I-IUPAC
propyl	358	364	|I-IUPAC
,	364	365	|O
and	366	369	|O
pyren	370	375	|B-IUPAC
-	375	376	|I-IUPAC
1	376	377	|I-IUPAC
-	377	378	|I-IUPAC
ylmethyl	378	386	|I-IUPAC
.	386	387	|O
The	388	391	|O
polyamine	392	401	|O
architecture	402	414	|O
was	415	418	|O
also	419	423	|O
altered	424	431	|O
and	432	435	|O
ranged	436	442	|O
from	443	447	|O
diamine	448	455	|O
to	456	458	|O
triamine	459	467	|O
and	468	471	|O
tetraamine	472	482	|O
systems	483	490	|O
.	490	491	|O
Biological	492	502	|O
activities	503	513	|O
in	514	516	|O
L1210	517	522	|O
(	523	524	|O
murine	524	530	|O
leukemia	531	539	|O
)	539	540	|O
,	540	541	|O
Chinese	542	549	|O
hamster	550	557	|O
ovary	558	563	|O
(	564	565	|O
CHO	565	568	|O
)	568	569	|O
,	569	570	|O
and	571	574	|O
CHO	575	578	|O
's	578	580	|O
polyamine	581	590	|O
transport	591	600	|O
-	600	601	|O
deficient	601	610	|O
mutant	611	617	|O
(	618	619	|O
CHO	619	622	|O
-	622	623	|O
MG	623	625	|O
)	625	626	|O
cell	627	631	|O
lines	632	637	|O
were	638	642	|O
investigated	643	655	|O
via	656	659	|O
IC	660	662	|O
(	662	663	|O
50	663	665	|O
)	665	666	|O
cytotoxicity	667	679	|O
determinations	680	694	|O
.	694	695	|O
K	696	697	|O
(	697	698	|O
i	698	699	|O
)	699	700	|O
values	701	707	|O
for	708	711	|O
spermidine	712	722	|O
uptake	723	729	|O
were	730	734	|O
also	735	739	|O
determined	740	750	|O
in	751	753	|O
L1210	754	759	|O
cells	760	765	|O
.	765	766	|O
The	767	770	|O
size	771	775	|O
of	776	778	|O
the	779	782	|O
N	783	784	|B-IUPAC
(	784	785	|I-IUPAC
1	785	786	|I-IUPAC
)	786	787	|I-IUPAC
-	787	788	|I-IUPAC
arylalkyl	788	797	|I-IUPAC
substituent	798	809	|B-MODIFIER
as	810	812	|O
well	813	817	|O
as	818	820	|O
the	821	824	|O
polyamine	825	834	|O
sequence	835	843	|O
used	844	848	|O
had	849	852	|O
direct	853	859	|O
bearing	860	867	|O
on	868	870	|O
the	871	874	|O
observed	875	883	|O
cytotoxicity	884	896	|O
profiles	897	905	|O
.	905	906	|O
N	907	908	|O
(	908	909	|O
1	909	910	|O
)	910	911	|O
-	911	912	|O
Tethers	912	919	|O
longer	920	926	|O
than	927	931	|O
ethylene	932	940	|O
showed	941	947	|O
dramatic	948	956	|O
loss	957	961	|O
of	962	964	|O
selectivity	965	976	|O
for	977	980	|O
the	981	984	|O
polyamine	985	994	|O
transporter	995	1006	|O
(	1007	1008	|O
PAT	1008	1011	|O
)	1011	1012	|O
as	1013	1015	|O
shown	1016	1021	|O
in	1022	1024	|O
a	1025	1026	|O
CHO	1027	1030	|O
/	1030	1031	|O
CHO	1031	1034	|O
-	1034	1035	|O
MG	1035	1037	|O
cytotoxicity	1038	1050	|O
screen	1051	1057	|O
.	1057	1058	|O
In	1059	1061	|O
summary	1062	1069	|O
,	1069	1070	|O
there	1071	1076	|O
are	1077	1080	|O
clear	1081	1086	|O
limits	1087	1093	|O
to	1094	1096	|O
the	1097	1100	|O
size	1101	1105	|O
of	1106	1108	|O
N	1109	1110	|O
(	1110	1111	|O
1	1111	1112	|O
)	1112	1113	|O
-	1113	1114	|O
substituents	1114	1126	|O
,	1126	1127	|O
which	1128	1133	|O
can	1134	1137	|O
be	1138	1140	|O
accommodated	1141	1153	|O
by	1154	1156	|O
the	1157	1160	|O
polyamine	1161	1170	|O
transporter	1171	1182	|O
.	1182	1183	|O
A	1184	1185	|O
direct	1186	1192	|O
correlation	1193	1204	|O
was	1205	1208	|O
observed	1209	1217	|O
between	1218	1225	|O
polyamine	1226	1235	|O
-	1235	1236	|O
conjugate	1236	1245	|O
uptake	1246	1252	|O
and	1253	1256	|O
cytotoxicity	1257	1269	|O
.	1269	1270	|O
In	1271	1273	|O
this	1274	1278	|O
regard	1279	1285	|O
,	1285	1286	|O
a	1287	1288	|O
cytotoxicity	1289	1301	|O
model	1302	1307	|O
was	1308	1311	|O
proposed	1312	1320	|O
,	1320	1321	|O
which	1322	1327	|O
describes	1328	1337	|O
a	1338	1339	|O
hydrophobic	1340	1351	|O
pocket	1352	1358	|O
of	1359	1361	|O
set	1362	1365	|O
dimensions	1366	1376	|O
adjacent	1377	1385	|O
to	1386	1388	|O
the	1389	1392	|O
putative	1393	1401	|O
PAT	1402	1405	|O
polyamine	1406	1415	|O
-	1415	1416	|O
binding	1416	1423	|O
site	1424	1428	|O
.	1428	1429	|O

### abstracts36.txt
A	0	1	|O
variety	2	9	|O
of	10	12	|O
amine	13	18	|O
complexes	19	28	|O
with	29	33	|O
1	34	35	|B-IUPAC
-	35	36	|I-IUPAC
boraadamatane	36	49	|I-IUPAC
were	50	54	|O
synthesized	55	66	|O
and	67	70	|O
subsequently	71	83	|O
evaluated	84	93	|O
for	94	97	|O
an	98	100	|O
antiproliferative	101	118	|O
effect	119	125	|O
on	126	128	|O
CD81	129	133	|O
-	133	134	|O
enriched	134	142	|O
cell	143	147	|O
lines	148	153	|O
to	154	156	|O
provide	157	164	|O
evidence	165	173	|O
for	174	177	|O
binding	178	185	|O
and	186	189	|O
activation	190	200	|O
of	201	203	|O
CD81	204	208	|O
.	208	209	|O
CD81	210	214	|O
is	215	217	|O
a	218	219	|O
member	220	226	|O
of	227	229	|O
the	230	233	|O
tetraspanin	234	245	|O
family	246	252	|O
of	253	255	|O
membrane	256	264	|O
proteins	265	273	|O
found	274	279	|O
in	280	282	|O
all	283	286	|O
cell	287	291	|O
lineages	292	300	|O
in	301	303	|O
the	304	307	|O
liver	308	313	|O
.	313	314	|O
CD81	315	319	|O
signals	320	327	|O
for	328	331	|O
antiproliferation	332	349	|O
when	350	354	|O
bound	355	360	|O
by	361	363	|O
antibodies	364	374	|O
.	374	375	|O
It	376	378	|O
is	379	381	|O
known	382	387	|O
that	388	392	|O
the	393	396	|O
HCV	397	400	|O
-	400	401	|O
E2	401	403	|O
envelope	404	412	|O
glycoprotein	413	425	|O
binds	426	431	|O
to	432	434	|O
the	435	438	|O
CD81	439	443	|O
protein	444	451	|O
.	451	452	|O
While	453	458	|O
it	459	461	|O
is	462	464	|O
unclear	465	472	|O
whether	473	480	|O
virus	481	486	|O
entry	487	492	|O
into	493	497	|O
host	498	502	|O
cells	503	508	|O
is	509	511	|O
directly	512	520	|O
linked	521	527	|O
to	528	530	|O
virus	531	536	|O
attachment	537	547	|O
via	548	551	|O
CD81	552	556	|O
for	557	560	|O
HCV	561	564	|O
,	564	565	|O
this	566	570	|O
step	571	575	|O
in	576	578	|O
the	579	582	|O
viral	583	588	|O
life	589	593	|O
cycle	594	599	|O
has	600	603	|O
recently	604	612	|O
proven	613	619	|O
to	620	622	|O
be	623	625	|O
an	626	628	|O
effective	629	638	|O
point	639	644	|O
of	645	647	|O
attack	648	654	|O
for	655	658	|O
other	659	664	|O
viruses	665	672	|O
including	673	682	|O
HIV	683	686	|O
and	687	690	|O
rhinoviruses	691	703	|O
.	703	704	|O
The	705	708	|O
aim	709	712	|O
of	713	715	|O
the	716	719	|O
current	720	727	|O
study	728	733	|O
concerns	734	742	|O
the	743	746	|O
synthesis	747	756	|O
of	757	759	|O
amantidine	760	770	|O
analogues	771	780	|O
by	781	783	|O
appending	784	793	|O
primary	794	801	|O
amines	802	808	|O
to	809	811	|O
1	812	813	|B-IUPAC
-	813	814	|I-IUPAC
boraadamantane	814	828	|I-IUPAC
to	829	831	|O
evaluate	832	840	|O
such	841	845	|O
compounds	846	855	|O
for	856	859	|O
CD81	860	864	|O
-	864	865	|O
dependent	865	874	|O
antiproliferation	875	892	|O
of	893	895	|O
CD81	896	900	|O
-	900	901	|O
enriched	901	909	|O
cell	910	914	|O
lines	915	920	|O
(	921	922	|O
astrocyte	922	931	|O
)	931	932	|O
vs	933	935	|O
CD81	936	940	|O
-	940	941	|O
deficient	941	950	|O
cell	951	955	|O
lines	956	961	|O
(	962	963	|O
C6	963	965	|O
glioma	966	972	|O
)	972	973	|O
.	973	974	|O
If	975	977	|O
the	978	981	|O
antiproliferative	982	999	|O
effect	1000	1006	|O
of	1007	1009	|O
these	1010	1015	|O
amantidine	1016	1026	|O
analogues	1027	1036	|O
proves	1037	1043	|O
to	1044	1046	|O
be	1047	1049	|O
an	1050	1052	|O
effect	1053	1059	|O
of	1060	1062	|O
binding	1063	1070	|O
and	1071	1074	|O
activating	1075	1085	|O
CD81	1086	1090	|O
,	1090	1091	|O
then	1092	1096	|O
these	1097	1102	|O
compounds	1103	1112	|O
may	1113	1116	|O
have	1117	1121	|O
the	1122	1125	|O
potential	1126	1135	|O
to	1136	1138	|O
prevent	1139	1146	|O
or	1147	1149	|O
treat	1150	1155	|O
HCV	1156	1159	|O
infections	1160	1170	|O
.	1170	1171	|O
Each	1172	1176	|O
compound	1177	1185	|O
's	1185	1187	|O
potential	1188	1197	|O
for	1198	1201	|O
preventive	1202	1212	|O
and	1213	1216	|O
therapeutic	1217	1228	|O
activity	1229	1237	|O
stems	1238	1243	|O
from	1244	1248	|O
the	1249	1252	|O
compound	1253	1261	|O
's	1261	1263	|O
potential	1264	1273	|O
to	1274	1276	|O
block	1277	1282	|O
viral	1283	1288	|O
attachment	1289	1299	|O
,	1299	1300	|O
virus	1301	1306	|O
-	1306	1307	|O
cell	1307	1311	|O
fusion	1312	1318	|O
,	1318	1319	|O
or	1320	1322	|O
virus	1323	1328	|O
entry	1329	1334	|O
into	1335	1339	|O
host	1340	1344	|O
cells	1345	1350	|O
or	1351	1353	|O
to	1354	1356	|O
counter	1357	1364	|O
potential	1365	1374	|O
mechanisms	1375	1385	|O
of	1386	1388	|O
HCV	1389	1392	|O
immune	1393	1399	|O
evasion	1400	1407	|O
.	1407	1408	|O
Out	1409	1412	|O
of	1413	1415	|O
a	1416	1417	|O
library	1418	1425	|O
of	1426	1428	|O
over	1429	1433	|O
500	1434	1437	|O
compounds	1438	1447	|O
,	1447	1448	|O
including	1449	1458	|O
randomly	1459	1467	|O
selected	1468	1476	|O
small	1477	1482	|O
molecules	1483	1492	|O
and	1493	1496	|O
rationally	1497	1507	|O
designed	1508	1516	|O
small	1517	1522	|O
molecules	1523	1532	|O
,	1532	1533	|O
only	1534	1538	|O
the	1539	1542	|O
1	1543	1544	|B-IUPAC
-	1544	1545	|I-IUPAC
boraadamantaneamine	1545	1564	|I-IUPAC
compounds	1565	1574	|B-MODIFIER
and	1575	1578	|O
structurally	1579	1591	|O
similar	1592	1599	|O
analogues	1600	1609	|O
display	1610	1617	|O
a	1618	1619	|O
significant	1620	1631	|O
antiproliferative	1632	1649	|O
effect	1650	1656	|O
on	1657	1659	|O
the	1660	1663	|O
CD81	1664	1668	|O
-	1668	1669	|O
enriched	1669	1677	|O
astrocytes	1678	1688	|O
relative	1689	1697	|O
to	1698	1700	|O
the	1701	1704	|O
CD81	1705	1709	|O
-	1709	1710	|O
deficient	1710	1719	|O
cell	1720	1724	|O
lines	1725	1730	|O
.	1730	1731	|O
In	1732	1734	|O
fact	1735	1739	|O
,	1739	1740	|O
1	1741	1742	|B-IUPAC
-	1742	1743	|I-IUPAC
boraadamantane	1743	1757	|I-IUPAC
.	1757	1758	|I-IUPAC
l	1758	1759	|I-IUPAC
-	1759	1760	|I-IUPAC
phenylalanine	1760	1773	|I-IUPAC
methyl	1774	1780	|I-IUPAC
ester	1781	1786	|I-IUPAC
complex	1787	1794	|B-MODIFIER
(	1795	1796	|O
5	1796	1797	|O
)	1797	1798	|O
,	1798	1799	|O
1	1800	1801	|B-IUPAC
-	1801	1802	|I-IUPAC
boraadamantane	1802	1816	|I-IUPAC
.	1816	1817	|I-IUPAC
ethanolamine	1817	1829	|I-IUPAC
complex	1830	1837	|B-MODIFIER
(	1838	1839	|O
8	1839	1840	|O
)	1840	1841	|O
,	1841	1842	|O
and	1843	1846	|O
(	1847	1848	|B-IUPAC
S	1848	1849	|I-IUPAC
)	1849	1850	|I-IUPAC
-	1850	1851	|I-IUPAC
2	1851	1852	|I-IUPAC
-	1852	1853	|I-IUPAC
[	1853	1854	|I-IUPAC
(	1854	1855	|I-IUPAC
adamantane	1855	1865	|I-IUPAC
-	1865	1866	|I-IUPAC
1	1866	1867	|I-IUPAC
-	1867	1868	|I-IUPAC
carbonyl	1868	1876	|I-IUPAC
)	1876	1877	|I-IUPAC
amino	1877	1882	|I-IUPAC
]	1882	1883	|I-IUPAC
-	1883	1884	|I-IUPAC
3	1884	1885	|I-IUPAC
-	1885	1886	|I-IUPAC
phenylpropionic	1886	1901	|I-IUPAC
acid	1902	1906	|I-IUPAC
(	1907	1908	|O
15	1908	1910	|O
)	1910	1911	|O
show	1912	1916	|O
a	1917	1918	|O
dose	1919	1923	|O
-	1923	1924	|O
dependent	1924	1933	|O
,	1933	1934	|O
astrocyte	1935	1944	|O
-	1944	1945	|O
selective	1945	1954	|O
antiproliferative	1955	1972	|O
activity	1973	1981	|O
in	1982	1984	|O
the	1985	1988	|O
concentration	1989	2002	|O
range	2003	2008	|O
0.1-10	2009	2015	|O
microM	2016	2022	|O
.	2022	2023	|O
This	2024	2028	|O
is	2029	2031	|O
consistent	2032	2042	|O
with	2043	2047	|O
the	2048	2051	|O
binding	2052	2059	|O
and	2060	2063	|O
activation	2064	2074	|O
of	2075	2077	|O
CD81	2078	2082	|O
and	2083	2086	|O
represents	2087	2097	|O
a	2098	2099	|O
2	2100	2101	|O
-	2101	2102	|O
fold	2102	2106	|O
improvement	2107	2118	|O
compared	2119	2127	|O
to	2128	2130	|O
the	2131	2134	|O
clinically	2135	2145	|O
prescribed	2146	2156	|O
anti	2157	2161	|O
-	2161	2162	|O
HCV	2162	2165	|O
agent	2166	2171	|O
,	2171	2172	|O
amantidine	2173	2183	|O
,	2183	2184	|O
in	2185	2187	|O
the	2188	2191	|O
same	2192	2196	|O
concentration	2197	2210	|O
range	2211	2216	|O
.	2216	2217	|O
Consequently	2218	2230	|O
,	2230	2231	|O
the	2232	2235	|O
1	2236	2237	|B-IUPAC
-	2237	2238	|I-IUPAC
boraadamantaneamine	2238	2257	|I-IUPAC
derivatives	2258	2269	|B-MODIFIER
present	2270	2277	|O
a	2278	2279	|O
promising	2280	2289	|O
lead	2290	2294	|O
in	2295	2297	|O
the	2298	2301	|O
development	2302	2313	|O
of	2314	2316	|O
small	2317	2322	|O
molecules	2323	2332	|O
with	2333	2337	|O
potential	2338	2347	|O
to	2348	2350	|O
bind	2351	2355	|O
to	2356	2358	|O
CD81	2359	2363	|O
and	2364	2367	|O
treat	2368	2373	|O
HCV	2374	2377	|O
infections	2378	2388	|O
.	2388	2389	|O

### abstracts2315.txt
A	0	1	|O
broad	2	7	|O
structure	8	17	|O
-	17	18	|O
activity	18	26	|O
program	27	34	|O
was	35	38	|O
undertaken	39	49	|O
in	50	52	|O
search	53	59	|O
of	60	62	|O
effective	63	72	|O
surrogates	73	83	|O
for	84	87	|O
the	88	91	|O
key	92	95	|O
benzothiazole	96	109	|O
side	110	114	|O
chain	115	120	|O
of	121	123	|O
the	124	127	|O
potent	128	134	|O
aldose	135	141	|O
reductase	142	151	|O
inhibitor	152	161	|O
,	161	162	|O
zopolrestat	163	174	|O
(	175	176	|O
1	176	177	|O
)	177	178	|O
.	178	179	|O
A	180	181	|O
structure	182	191	|O
-	191	192	|O
driven	192	198	|O
approach	199	207	|O
was	208	211	|O
pursued	212	219	|O
,	219	220	|O
which	221	226	|O
spanned	227	234	|O
exploration	235	246	|O
of	247	249	|O
three	250	255	|O
areas	256	261	|O
:	261	262	|O
(	263	264	|O
1	264	265	|O
)	265	266	|O
5/6	267	270	|O
fused	271	276	|O
heterocycles	277	289	|O
such	290	294	|O
as	295	297	|O
benzoxazole	298	309	|O
,	309	310	|O
benzothiophene	311	325	|O
,	325	326	|O
benzofuran	327	337	|O
,	337	338	|O
and	339	342	|O
imidazopyridine	343	358	|O
;	358	359	|O
(	360	361	|O
2	361	362	|O
)	362	363	|O
5	364	365	|O
-	365	366	|O
membered	366	374	|O
heterocycles	375	387	|O
,	387	388	|O
including	389	398	|O
oxadiazole	399	409	|O
,	409	410	|O
oxazole	411	418	|O
,	418	419	|O
thiazole	420	428	|O
,	428	429	|O
and	430	433	|O
thiadiazole	434	445	|O
,	445	446	|O
with	447	451	|O
pendant	452	459	|O
aryl	460	464	|O
groups	465	471	|O
,	471	472	|O
and	473	476	|O
(	477	478	|O
3	478	479	|O
)	479	480	|O
thioanilide	481	492	|O
as	493	495	|O
a	496	497	|O
formal	498	504	|O
equivalent	505	515	|O
of	516	518	|O
benzothiazole	519	532	|O
.	532	533	|O
Several	534	541	|O
benzoxazole	542	553	|B-IUPAC
-	553	554	|O
and	555	558	|O
1,2,4	559	564	|B-IUPAC
-	564	565	|I-IUPAC
oxadiazole	565	575	|I-IUPAC
-	575	576	|O
derived	576	583	|O
analogues	584	593	|B-MODIFIER
were	594	598	|O
found	599	604	|O
to	605	607	|O
be	608	610	|O
potent	611	617	|O
inhibitors	618	628	|O
of	629	631	|O
aldose	632	638	|O
reductase	639	648	|O
from	649	653	|O
human	654	659	|O
placenta	660	668	|O
and	669	672	|O
were	673	677	|O
orally	678	684	|O
active	685	691	|O
in	692	694	|O
preventing	695	705	|O
sorbitol	706	714	|O
accumulation	715	727	|O
in	728	730	|O
rat	731	734	|O
sciatic	735	742	|O
nerve	743	748	|O
,	748	749	|O
in	750	752	|O
an	753	755	|O
acute	756	761	|O
test	762	766	|O
of	767	769	|O
diabetic	770	778	|O
complications	779	792	|O
.	792	793	|O
3,4	794	797	|B-IUPAC
-	797	798	|I-IUPAC
Dihydro	798	805	|I-IUPAC
-	805	806	|I-IUPAC
4	806	807	|I-IUPAC
-	807	808	|I-IUPAC
oxo	808	811	|I-IUPAC
-	811	812	|I-IUPAC
3	812	813	|I-IUPAC
-	813	814	|I-IUPAC
[	814	815	|I-IUPAC
(	815	816	|I-IUPAC
5,7	816	819	|I-IUPAC
-	819	820	|I-IUPAC
difluoro	820	828	|I-IUPAC
-	828	829	|I-IUPAC
2	829	830	|I-IUPAC
-	830	831	|I-IUPAC
benzoxazolyl	831	843	|I-IUPAC
)	843	844	|I-IUPAC
methyl	844	850	|I-IUPAC
]	850	851	|I-IUPAC
-	851	852	|I-IUPAC
1	852	853	|I-IUPAC
-	853	854	|I-IUPAC
phthalazineacetic	855	872	|I-IUPAC
acid	873	877	|I-IUPAC
(	878	879	|O
124	879	882	|O
)	882	883	|O
was	884	887	|O
the	888	891	|O
best	892	896	|O
of	897	899	|O
the	900	903	|O
benzoxazole	904	915	|O
series	916	922	|O
(	923	924	|O
IC50	924	928	|O
=	929	930	|O
3.2	931	934	|O
x	935	936	|O
10	937	939	|O
(	939	940	|O
-	940	941	|O
9	941	942	|O
)	942	943	|O
M	944	945	|O
)	945	946	|O
;	946	947	|O
it	948	950	|O
suppressed	951	961	|O
accumulation	962	974	|O
of	975	977	|O
sorbitol	978	986	|O
in	987	989	|O
rat	990	993	|O
sciatic	994	1001	|O
nerve	1002	1007	|O
by	1008	1010	|O
78%	1011	1014	|O
at	1015	1017	|O
an	1018	1020	|O
oral	1021	1025	|O
dose	1026	1030	|O
of	1031	1033	|O
10	1034	1036	|O
mg	1037	1039	|O
/	1039	1040	|O
kg	1040	1042	|O
.	1042	1043	|O
Compound	1044	1052	|O
139	1053	1056	|O
,	1056	1057	|O
3,4	1058	1061	|B-IUPAC
-	1061	1062	|I-IUPAC
dihydro	1062	1069	|I-IUPAC
-	1069	1070	|I-IUPAC
4	1070	1071	|I-IUPAC
-	1071	1072	|I-IUPAC
oxo	1072	1075	|I-IUPAC
-	1075	1076	|I-IUPAC
3	1076	1077	|I-IUPAC
-	1077	1078	|I-IUPAC
[	1078	1079	|I-IUPAC
[	1079	1080	|I-IUPAC
(	1080	1081	|I-IUPAC
2	1081	1082	|I-IUPAC
-	1082	1083	|I-IUPAC
fluorophenyl	1083	1095	|I-IUPAC
)	1095	1096	|I-IUPAC
-	1096	1097	|I-IUPAC
1,2,4	1097	1102	|I-IUPAC
-	1102	1103	|I-IUPAC
oxadiazol	1104	1113	|I-IUPAC
-	1113	1114	|I-IUPAC
5	1114	1115	|I-IUPAC
-	1115	1116	|I-IUPAC
yl	1116	1118	|I-IUPAC
]	1118	1119	|I-IUPAC
methyl	1119	1125	|I-IUPAC
]	1125	1126	|I-IUPAC
-	1126	1127	|I-IUPAC
1	1127	1128	|I-IUPAC
-	1128	1129	|I-IUPAC
phthalazineacetic	1129	1146	|I-IUPAC
acid	1147	1151	|I-IUPAC
,	1151	1152	|O
with	1153	1157	|O
IC50	1158	1162	|O
less	1163	1167	|O
than	1168	1172	|O
1.0	1173	1176	|O
x	1177	1178	|O
10	1179	1181	|O
(	1181	1182	|O
-	1182	1183	|O
8	1183	1184	|O
)	1184	1185	|O
M	1186	1187	|O
,	1187	1188	|O
caused	1189	1195	|O
a	1196	1197	|O
69%	1198	1201	|O
reduction	1202	1211	|O
in	1212	1214	|O
sorbitol	1215	1223	|O
accumulation	1224	1236	|O
in	1237	1239	|O
rat	1240	1243	|O
sciatic	1244	1251	|O
nerve	1252	1257	|O
at	1258	1260	|O
an	1261	1263	|O
oral	1264	1268	|O
dose	1269	1273	|O
of	1274	1276	|O
25	1277	1279	|O
mg	1280	1282	|O
/	1282	1283	|O
kg	1283	1285	|O
.	1285	1286	|O
The	1287	1290	|O
thioanilide	1291	1302	|O
side	1303	1307	|O
chain	1308	1313	|O
featured	1314	1322	|O
in	1323	1325	|O
3	1326	1327	|B-IUPAC
-	1327	1328	|I-IUPAC
[	1328	1329	|I-IUPAC
2	1329	1330	|I-IUPAC
-	1330	1331	|I-IUPAC
[	1331	1332	|I-IUPAC
[	1332	1333	|I-IUPAC
3	1333	1334	|I-IUPAC
-	1334	1335	|I-IUPAC
(	1335	1336	|I-IUPAC
trifluoromethyl	1336	1351	|I-IUPAC
)	1351	1352	|I-IUPAC
phenyl	1352	1358	|I-IUPAC
]	1358	1359	|I-IUPAC
amino	1359	1364	|I-IUPAC
]	1364	1365	|I-IUPAC
-	1365	1366	|I-IUPAC
2	1366	1367	|I-IUPAC
-	1367	1368	|I-IUPAC
thioxoethyl	1368	1379	|I-IUPAC
]	1379	1380	|I-IUPAC
-	1380	1381	|I-IUPAC
3,4	1381	1384	|I-IUPAC
-	1384	1385	|I-IUPAC
dihydro	1385	1392	|I-IUPAC
-	1393	1394	|I-IUPAC
4	1395	1396	|I-IUPAC
-	1396	1397	|I-IUPAC
oxo	1397	1400	|I-IUPAC
-	1400	1401	|I-IUPAC
1	1401	1402	|I-IUPAC
-	1402	1403	|I-IUPAC
phthalazineacetic	1403	1420	|I-IUPAC
acid	1421	1425	|I-IUPAC
(	1426	1427	|O
195	1427	1430	|O
)	1430	1431	|O
proved	1432	1438	|O
to	1439	1441	|O
be	1442	1444	|O
an	1445	1447	|O
effective	1448	1457	|O
surrogate	1458	1467	|O
for	1468	1471	|O
benzothiazole	1472	1485	|O
.	1485	1486	|O
Compound	1487	1495	|O
195	1496	1499	|O
was	1500	1503	|O
highly	1504	1510	|O
potent	1511	1517	|O
in	1518	1520	|O
vitro	1521	1526	|O
(	1527	1528	|O
IC50	1528	1532	|O
=	1533	1534	|O
5.2	1535	1538	|O
x	1539	1540	|O
10	1541	1543	|O
(	1543	1544	|O
-	1544	1545	|O
8	1545	1546	|O
)	1546	1547	|O
M	1548	1549	|O
)	1549	1550	|O
but	1551	1554	|O
did	1555	1558	|O
not	1559	1562	|O
show	1563	1567	|O
oral	1568	1572	|O
activity	1573	1581	|O
when	1582	1586	|O
tested	1587	1593	|O
at	1594	1596	|O
100	1597	1600	|O
mg	1601	1603	|O
/	1603	1604	|O
kg	1604	1606	|O
.	1606	1607	|O
Additional	1608	1618	|O
structure	1619	1628	|O
-	1628	1629	|O
activity	1629	1637	|O
relationships	1638	1651	|O
encompassing	1652	1664	|O
a	1665	1666	|O
variety	1667	1674	|O
of	1675	1677	|O
heterocyclic	1678	1690	|O
side	1691	1695	|O
chains	1696	1702	|O
are	1703	1706	|O
discussed	1707	1716	|O
.	1716	1717	|O

### abstracts3755.txt
9,11	0	4	|O
-	4	5	|O
Secoestradiol	5	18	|O
(	19	20	|O
9	20	21	|O
)	21	22	|O
and	23	26	|O
11	27	29	|B-IUPAC
-	29	30	|I-IUPAC
hydroxy	30	37	|I-IUPAC
-	37	38	|I-IUPAC
9,11	38	42	|I-IUPAC
-	42	43	|I-IUPAC
secoestradiol	43	56	|I-IUPAC
(	57	58	|O
12	58	60	|O
)	60	61	|O
have	62	66	|O
been	67	71	|O
synthesized	72	83	|O
starting	84	92	|O
from	93	97	|O
17	98	100	|B-IUPAC
-	100	101	|I-IUPAC
acetoxyestradiol	101	117	|I-IUPAC
3	118	119	|I-IUPAC
-	119	120	|I-IUPAC
methyl	120	126	|I-IUPAC
ether	127	132	|I-IUPAC
(	133	134	|O
1	134	135	|O
)	135	136	|O
and	137	140	|O
found	141	146	|O
to	147	149	|O
possess	150	157	|O
significant	158	169	|O
antifertility	170	183	|O
activity	184	192	|O
in	193	195	|O
rats	196	200	|O
.	200	201	|O
3	203	204	|B-IUPAC
-	204	205	|I-IUPAC
Methoxy	205	212	|I-IUPAC
-	212	213	|I-IUPAC
9,11	213	217	|I-IUPAC
-	217	218	|I-IUPAC
seco	218	222	|I-IUPAC
-	222	223	|I-IUPAC
9	223	224	|I-IUPAC
-	224	225	|I-IUPAC
oxo	225	228	|I-IUPAC
-	228	229	|I-IUPAC
17beta	229	235	|I-IUPAC
-	235	236	|I-IUPAC
acetoxyestra	236	248	|I-IUPAC
-	248	249	|I-IUPAC
1,3,5	249	254	|I-IUPAC
(	254	255	|I-IUPAC
10	255	257	|I-IUPAC
)	257	258	|I-IUPAC
-	258	259	|I-IUPAC
trien	259	264	|I-IUPAC
-	264	265	|I-IUPAC
11	265	267	|I-IUPAC
-	267	268	|I-IUPAC
oic	268	271	|I-IUPAC
acid	272	276	|I-IUPAC
(	277	278	|O
2	278	279	|O
)	279	280	|O
,	280	281	|O
prepared	282	290	|O
by	291	293	|O
CrO3	294	298	|O
oxidation	299	308	|O
of	309	311	|O
1	312	313	|O
,	313	314	|O
on	315	317	|O
hydrogenolysis	318	332	|O
gave	333	337	|O
methyl	338	344	|B-IUPAC
17beta	345	351	|I-IUPAC
-	351	352	|I-IUPAC
hydroxy	352	359	|I-IUPAC
-	359	360	|I-IUPAC
3	360	361	|I-IUPAC
-	361	362	|I-IUPAC
methoxy	362	369	|I-IUPAC
-	369	370	|I-IUPAC
9,11	370	374	|I-IUPAC
-	374	375	|I-IUPAC
secoestra	375	384	|I-IUPAC
-	384	385	|I-IUPAC
1,3,5	385	390	|I-IUPAC
(	390	391	|I-IUPAC
10	391	393	|I-IUPAC
)	393	394	|I-IUPAC
-	394	395	|I-IUPAC
triene	395	401	|I-IUPAC
-	401	402	|I-IUPAC
11	402	404	|I-IUPAC
-	404	405	|I-IUPAC
carboxylate	405	416	|I-IUPAC
(	417	418	|O
3	418	419	|O
)	419	420	|O
.	420	421	|O
The	423	426	|O
17	427	429	|O
-	429	430	|O
O	430	431	|O
-	431	432	|O
THP	432	435	|O
derivative	436	446	|O
of	447	449	|O
3	450	451	|O
was	452	455	|O
treated	456	463	|O
with	464	468	|O
LiAlH4	469	475	|O
to	476	478	|O
give	479	483	|O
17beta	484	490	|B-IUPAC
-	490	491	|I-IUPAC
(	491	492	|I-IUPAC
O	492	493	|I-IUPAC
-	493	494	|I-IUPAC
tetrahydropyranyl	494	511	|I-IUPAC
)	511	512	|I-IUPAC
-	512	513	|I-IUPAC
3	513	514	|I-IUPAC
-	514	515	|I-IUPAC
methoxy	515	522	|I-IUPAC
-	522	523	|I-IUPAC
11	523	525	|I-IUPAC
-	525	526	|I-IUPAC
hydroxy	526	533	|I-IUPAC
-	533	534	|I-IUPAC
9,11	534	538	|I-IUPAC
-	538	539	|I-IUPAC
secoestra	539	548	|I-IUPAC
-	548	549	|I-IUPAC
1,3,5	549	554	|I-IUPAC
(	554	555	|I-IUPAC
10	555	557	|I-IUPAC
)	557	558	|I-IUPAC
-	558	559	|I-IUPAC
triene	559	565	|I-IUPAC
(	566	567	|O
5	567	568	|O
)	568	569	|O
.	569	570	|O
The	572	575	|O
11	576	578	|B-IUPAC
-	578	579	|I-IUPAC
O	579	580	|I-IUPAC
-	580	581	|I-IUPAC
mesylate	581	589	|I-IUPAC
of	590	592	|O
5	593	594	|O
on	595	597	|O
LiAlH4	598	604	|O
reduction	605	614	|O
followed	615	623	|O
by	624	626	|O
mild	627	631	|O
acid	632	636	|O
treatment	637	646	|O
and	647	650	|O
demethylation	651	664	|O
under	665	670	|O
alkaline	671	679	|O
conditions	680	690	|O
gave	691	695	|O
9	696	697	|O
.	697	698	|O
LiAlH4	699	705	|O
reduction	706	715	|O
of	716	718	|O
3	719	720	|O
gave	721	725	|O
9,11	726	730	|B-IUPAC
-	730	731	|I-IUPAC
seco	731	735	|I-IUPAC
-	735	736	|I-IUPAC
11	736	738	|I-IUPAC
-	738	739	|I-IUPAC
hydroxyestradiol	739	755	|I-IUPAC
3	756	757	|I-IUPAC
-	757	758	|I-IUPAC
methyl	758	764	|I-IUPAC
ether	765	770	|I-IUPAC
(	771	772	|O
11	772	774	|O
)	774	775	|O
which	776	781	|O
on	782	784	|O
demethylation	785	798	|O
gave	799	803	|O
9,11	804	808	|B-IUPAC
-	808	809	|I-IUPAC
seco	809	813	|I-IUPAC
-	813	814	|I-IUPAC
11	814	816	|I-IUPAC
-	816	817	|I-IUPAC
hydroxyestradiol	817	833	|I-IUPAC
(	834	835	|O
12	835	837	|O
)	837	838	|O
.	838	839	|O

### abstracts475.txt
Previously	0	10	|O
we	11	13	|O
have	14	18	|O
reported	19	27	|O
the	28	31	|O
discovery	32	41	|O
of	42	44	|O
ABT	45	48	|O
-	48	49	|O
627	49	52	|O
(	53	54	|O
1	54	55	|O
,	55	56	|O
A	57	58	|O
-	58	59	|O
147627	59	65	|O
,	65	66	|O
active	67	73	|O
enantiomer	74	84	|O
of	85	87	|O
A	88	89	|O
-	89	90	|O
127722	90	96	|O
)	96	97	|O
,	97	98	|O
a	99	100	|O
2,4	101	104	|B-IUPAC
-	104	105	|I-IUPAC
diaryl	105	111	|I-IUPAC
substituted	112	123	|B-MODIFIER
pyrrolidine	124	135	|B-IUPAC
-	135	136	|I-IUPAC
3	136	137	|I-IUPAC
-	137	138	|I-IUPAC
carboxylic	138	148	|I-IUPAC
acid	149	153	|I-IUPAC
based	154	159	|O
endothelin	160	170	|O
receptor	171	179	|O
-	179	180	|O
A	180	181	|O
antagonist	182	192	|O
.	192	193	|O
This	194	198	|O
compound	199	207	|O
binds	208	213	|O
to	214	216	|O
the	217	220	|O
ETA	221	224	|O
receptor	225	233	|O
with	234	238	|O
an	239	241	|O
affinity	242	250	|O
(	251	252	|O
Ki	252	254	|O
)	254	255	|O
of	256	258	|O
0	259	260	|O
.	260	261	|O
034	262	265	|O
nM	266	268	|O
and	269	272	|O
with	273	277	|O
a	278	279	|O
2000	280	284	|O
-	284	285	|O
fold	285	289	|O
selectivity	290	301	|O
for	302	305	|O
the	306	309	|O
ETA	310	313	|O
receptor	314	322	|O
versus	323	329	|O
the	330	333	|O
ETB	334	337	|O
receptor	338	346	|O
.	346	347	|O
We	348	350	|O
have	351	355	|O
expanded	356	364	|O
our	365	368	|O
structure	369	378	|O
-	378	379	|O
activity	379	387	|O
studies	388	395	|O
in	396	398	|O
this	399	403	|O
series	404	410	|O
,	410	411	|O
in	412	414	|O
an	415	417	|O
attempt	418	425	|O
to	426	428	|O
further	429	436	|O
increase	437	445	|O
the	446	449	|O
ETA	450	453	|O
selectivity	454	465	|O
.	465	466	|O
When	467	471	|O
the	472	475	|O
p	476	477	|O
-	477	478	|O
anisyl	478	484	|O
group	485	490	|O
of	491	493	|O
1	494	495	|O
was	496	499	|O
replaced	500	508	|O
by	509	511	|O
an	512	514	|O
n	515	516	|O
-	516	517	|O
pentyl	517	523	|O
group	524	529	|O
,	529	530	|O
the	531	534	|O
resultant	535	544	|O
antagonist	545	555	|O
3	556	557	|O
exhibited	558	567	|O
substantially	568	581	|O
increased	582	591	|O
ETB	592	595	|O
/	595	596	|O
ETA	596	599	|O
activity	600	608	|O
ratio	609	614	|O
,	614	615	|O
but	616	619	|O
a	620	621	|O
decreased	622	631	|O
ETA	632	635	|O
affinity	636	644	|O
.	644	645	|O
Structure	646	655	|O
-	655	656	|O
activity	656	664	|O
studies	665	672	|O
revealed	673	681	|O
that	682	686	|O
substitution	687	699	|O
and	700	703	|O
geometry	704	712	|O
of	713	715	|O
this	716	720	|O
alkyl	721	726	|O
group	727	732	|O
,	732	733	|O
and	734	737	|O
substitution	738	750	|O
on	751	753	|O
the	754	757	|O
benzodioxolyl	758	771	|O
ring	772	776	|O
,	776	777	|O
are	778	781	|O
important	782	791	|O
in	792	794	|O
optimizing	795	805	|O
this	806	810	|O
series	811	817	|O
of	818	820	|O
highly	821	827	|O
ETA	828	831	|O
selective	832	841	|O
antagonists	842	853	|O
.	853	854	|O
In	855	857	|O
particular	858	868	|O
,	868	869	|O
the	870	873	|O
combination	874	885	|O
of	886	888	|O
a	889	890	|O
(	891	892	|B-IUPAC
E	892	893	|I-IUPAC
)	893	894	|I-IUPAC
-	894	895	|I-IUPAC
2,2	895	898	|I-IUPAC
-	898	899	|I-IUPAC
dimethyl	899	907	|I-IUPAC
-	907	908	|I-IUPAC
3	908	909	|I-IUPAC
-	909	910	|I-IUPAC
pentenyl	910	918	|I-IUPAC
group	919	924	|B-MODIFIER
and	925	928	|O
a	929	930	|O
7	931	932	|B-IUPAC
-	932	933	|I-IUPAC
methoxy	933	940	|I-IUPAC
-	940	941	|I-IUPAC
1,3	941	944	|I-IUPAC
-	944	945	|I-IUPAC
benzodioxol	945	956	|I-IUPAC
-	956	957	|I-IUPAC
5	957	958	|I-IUPAC
-	958	959	|I-IUPAC
yl	959	961	|I-IUPAC
group	962	967	|B-MODIFIER
provided	968	976	|O
hydrophobic	977	988	|O
compound	989	997	|O
10b	998	1001	|O
with	1002	1006	|O
subnanomolar	1007	1019	|O
affinity	1020	1028	|O
for	1029	1032	|O
human	1033	1038	|O
ETA	1039	1042	|O
receptor	1043	1051	|O
subtype	1052	1059	|O
and	1060	1063	|O
with	1064	1068	|O
an	1069	1071	|O
ETB	1072	1075	|O
/	1075	1076	|O
ETA	1076	1079	|O
activity	1080	1088	|O
ratio	1089	1094	|O
of	1095	1097	|O
over	1098	1102	|O
130000	1103	1109	|O
.	1109	1110	|O
Meanwhile	1111	1120	|O
,	1120	1121	|O
synthetic	1122	1131	|O
efforts	1132	1139	|O
en	1140	1142	|O
route	1143	1148	|O
to	1149	1151	|O
olefinic	1152	1160	|O
compounds	1161	1170	|O
led	1171	1174	|O
to	1175	1177	|O
the	1178	1181	|O
discovery	1182	1191	|O
that	1192	1196	|O
2	1197	1198	|B-IUPAC
-	1198	1199	|I-IUPAC
pyridylethyl	1199	1211	|I-IUPAC
(	1212	1213	|O
9o	1213	1215	|O
)	1215	1216	|O
and	1217	1220	|O
2	1221	1222	|B-IUPAC
-	1222	1223	|I-IUPAC
(	1223	1224	|I-IUPAC
2	1224	1225	|I-IUPAC
-	1225	1226	|I-IUPAC
oxopyrrolidinyl	1226	1241	|I-IUPAC
)	1241	1242	|I-IUPAC
ethyl	1242	1247	|I-IUPAC
(	1248	1249	|O
9u	1249	1251	|O
)	1251	1252	|O
replacement	1253	1264	|B-MODIFIER
of	1265	1267	|O
the	1268	1271	|O
p	1272	1273	|O
-	1273	1274	|O
anisyl	1274	1280	|O
group	1281	1286	|O
of	1287	1289	|O
1yielded	1290	1298	|O
very	1299	1303	|O
hydrophilic	1304	1315	|O
ETA	1316	1319	|O
antagonists	1320	1331	|O
with	1332	1336	|O
potency	1337	1344	|O
and	1345	1348	|O
selectivity	1349	1360	|O
equal	1361	1366	|O
to	1367	1369	|O
those	1370	1375	|O
of	1376	1378	|O
10b	1379	1382	|O
.	1382	1383	|O
On	1384	1386	|O
the	1387	1390	|O
basis	1391	1396	|O
of	1397	1399	|O
overall	1400	1407	|O
superior	1408	1416	|O
affinity	1417	1425	|O
,	1425	1426	|O
high	1427	1431	|O
selectivity	1432	1443	|O
for	1444	1447	|O
the	1448	1451	|O
ETA	1452	1455	|O
receptor	1456	1464	|O
(	1465	1466	|O
Ki	1466	1468	|O
,	1468	1469	|O
0.46	1470	1474	|O
nM	1475	1477	|O
for	1478	1481	|O
ETA	1482	1485	|O
and	1486	1489	|O
13000	1490	1495	|O
nM	1496	1498	|O
for	1499	1502	|O
ETB	1503	1506	|O
)	1506	1507	|O
,	1507	1508	|O
and	1509	1512	|O
good	1513	1517	|O
oral	1518	1522	|O
bioavailability	1523	1538	|O
(	1539	1540	|O
48%	1540	1543	|O
in	1544	1546	|O
rats	1547	1551	|O
)	1551	1552	|O
,	1552	1553	|O
A	1554	1555	|O
-	1555	1556	|O
216546	1556	1562	|O
(	1563	1564	|O
10a	1564	1567	|O
)	1567	1568	|O
was	1569	1572	|O
selected	1573	1581	|O
as	1582	1584	|O
a	1585	1586	|O
potential	1587	1596	|O
clinical	1597	1605	|O
backup	1606	1612	|O
for	1613	1616	|O
1	1617	1618	|O
.	1618	1619	|O

### abstracts3415.txt
The	0	3	|O
stereochemical	4	18	|O
diversity	19	28	|O
-	28	29	|O
oriented	29	37	|O
conformational	38	52	|O
restriction	53	64	|O
strategy	65	73	|O
can	74	77	|O
be	78	80	|O
an	81	83	|O
efficient	84	93	|O
method	94	100	|O
for	101	104	|O
developing	105	115	|O
specific	116	124	|O
ligands	125	132	|O
for	133	136	|O
drug	137	141	|O
target	142	148	|O
proteins	149	157	|O
,	157	158	|O
especially	159	169	|O
in	170	172	|O
cases	173	178	|O
where	179	184	|O
neither	185	192	|O
the	193	196	|O
bioactive	197	206	|O
conformation	207	219	|O
nor	220	223	|O
the	224	227	|O
pharmacophore	228	241	|O
is	242	244	|O
known	245	250	|O
.	250	251	|O
To	252	254	|O
develop	255	262	|O
potent	263	269	|O
H3	270	272	|O
and	273	276	|O
H4	277	279	|O
receptor	280	288	|O
antagonists	289	300	|O
,	300	301	|O
a	302	303	|O
series	304	310	|O
of	311	313	|O
conformationally	314	330	|O
restricted	331	341	|O
analogues	342	351	|O
of	352	354	|O
histamine	355	364	|O
with	365	369	|O
a	370	371	|O
chiral	372	378	|B-MODIFIER
cis	379	382	|B-PARTIUPAC
-	382	383	|I-PARTIUPAC
or	384	386	|O
trans	387	392	|B-IUPAC
-	392	393	|I-IUPAC
cyclopropane	393	405	|I-IUPAC
structure	406	415	|B-MODIFIER
were	416	420	|O
designed	421	429	|O
on	430	432	|O
the	433	436	|O
basis	437	442	|O
of	443	445	|O
this	446	450	|O
strategy	451	459	|O
.	459	460	|O
These	461	466	|O
target	467	473	|O
compounds	474	483	|O
with	484	488	|O
stereochemical	489	503	|O
diversity	504	513	|O
were	514	518	|O
synthesized	519	530	|O
from	531	535	|O
the	536	539	|O
versatile	540	549	|O
chiral	550	556	|O
cyclopropane	557	569	|O
units	570	575	|O
(	576	577	|B-PARTIUPAC
1S	577	579	|I-PARTIUPAC
,	579	580	|I-PARTIUPAC
2R	580	582	|I-PARTIUPAC
)	582	583	|I-PARTIUPAC
-	583	584	|I-PARTIUPAC
and	585	588	|O
(	589	590	|B-IUPAC
1R	590	592	|I-IUPAC
,	592	593	|I-IUPAC
2R	593	595	|I-IUPAC
)	595	596	|I-IUPAC
-	596	597	|I-IUPAC
2	597	598	|I-IUPAC
-	598	599	|I-IUPAC
(	599	600	|I-IUPAC
tert	600	604	|I-IUPAC
-	604	605	|I-IUPAC
butyldiphenylsilyloxy	605	626	|I-IUPAC
)	626	627	|I-IUPAC
methyl	627	633	|I-IUPAC
-	633	634	|I-IUPAC
1	634	635	|I-IUPAC
-	635	636	|I-IUPAC
formylcyclopropane	636	654	|I-IUPAC
(	655	656	|O
6	656	657	|O
and	658	661	|O
7	662	663	|O
,	663	664	|O
respectively	665	677	|O
)	677	678	|O
or	679	681	|O
their	682	687	|O
enantiomers	688	699	|O
ent	700	703	|O
-	703	704	|O
6	704	705	|O
and	706	709	|O
ent	710	713	|O
-	713	714	|O
7	714	715	|O
.	715	716	|O
Pharmacological	717	732	|O
profiles	733	741	|O
of	742	744	|O
these	745	750	|O
conformationally	751	767	|O
restricted	768	778	|O
analogues	779	788	|O
were	789	793	|O
shown	794	799	|O
to	800	802	|O
be	803	805	|O
different	806	815	|O
depending	816	825	|O
on	826	828	|O
the	829	832	|O
cyclopropane	833	845	|O
backbones	846	855	|O
.	855	856	|O
Among	857	862	|O
the	863	866	|O
analogues	867	876	|B-MODIFIER
,	876	877	|O
(	878	879	|B-IUPAC
1R	879	881	|I-IUPAC
,	881	882	|I-IUPAC
2S	882	884	|I-IUPAC
)	884	885	|I-IUPAC
-	885	886	|I-IUPAC
2	886	887	|I-IUPAC
-	887	888	|I-IUPAC
[	888	889	|I-IUPAC
2	889	890	|I-IUPAC
-	890	891	|I-IUPAC
(	891	892	|I-IUPAC
4	892	893	|I-IUPAC
-	893	894	|I-IUPAC
chlorobenzylamino	894	911	|I-IUPAC
)	911	912	|I-IUPAC
ethyl	912	917	|I-IUPAC
]	917	918	|I-IUPAC
-	918	919	|I-IUPAC
1	919	920	|I-IUPAC
-	920	921	|I-IUPAC
(	921	922	|I-IUPAC
1H	922	924	|I-IUPAC
-	924	925	|I-IUPAC
imidazol	925	933	|I-IUPAC
-	933	934	|I-IUPAC
4	934	935	|I-IUPAC
-	935	936	|I-IUPAC
yl	936	938	|I-IUPAC
)	938	939	|I-IUPAC
cyclopropane	939	951	|I-IUPAC
(	952	953	|O
11a	953	956	|O
)	956	957	|O
with	958	962	|O
the	963	966	|O
(	967	968	|B-IUPAC
1R	968	970	|I-IUPAC
)	970	971	|I-IUPAC
-	971	972	|I-IUPAC
trans	972	977	|I-IUPAC
-	977	978	|I-IUPAC
cyclopropane	978	990	|I-IUPAC
structure	991	1000	|B-MODIFIER
has	1001	1004	|O
remarkable	1005	1015	|O
antagonistic	1016	1028	|O
activity	1029	1037	|O
to	1038	1040	|O
both	1041	1045	|O
the	1046	1049	|O
H3	1050	1052	|O
(	1053	1054	|O
Ki	1054	1056	|O
=	1057	1058	|O
8.4	1059	1062	|O
nM	1063	1065	|O
)	1065	1066	|O
and	1067	1070	|O
H4	1071	1073	|O
(	1074	1075	|O
Ki	1075	1077	|O
=	1078	1079	|O
7.6	1080	1083	|O
nM	1084	1086	|O
)	1086	1087	|O
receptors	1088	1097	|O
.	1097	1098	|O
The	1099	1102	|O
enantiomer	1103	1113	|O
of	1114	1116	|O
11a	1117	1120	|O
,	1120	1121	|O
i.e.	1122	1126	|O
,	1126	1127	|O
ent	1128	1131	|O
-	1131	1132	|O
11a	1132	1135	|O
,	1135	1136	|O
with	1137	1141	|O
the	1142	1145	|O
(	1146	1147	|B-IUPAC
1S	1147	1149	|I-IUPAC
)	1149	1150	|I-IUPAC
-	1150	1151	|I-IUPAC
trans	1151	1156	|I-IUPAC
-	1156	1157	|I-IUPAC
cyclopropane	1157	1169	|I-IUPAC
structure	1170	1179	|B-MODIFIER
turned	1180	1186	|O
out	1187	1190	|O
to	1191	1193	|O
be	1194	1196	|O
a	1197	1198	|O
highly	1199	1205	|O
potent	1206	1212	|O
and	1213	1216	|O
selective	1217	1226	|O
H3	1227	1229	|O
receptor	1230	1238	|O
antagonist	1239	1249	|O
with	1250	1254	|O
a	1255	1256	|O
Ki	1257	1259	|O
of	1260	1262	|O
3.6	1263	1266	|O
nM	1267	1269	|O
.	1269	1270	|O
Conversely	1271	1281	|O
,	1281	1282	|O
(	1283	1284	|B-IUPAC
1R	1284	1286	|I-IUPAC
,	1286	1287	|I-IUPAC
2R	1287	1289	|I-IUPAC
)	1289	1290	|I-IUPAC
-	1290	1291	|I-IUPAC
2	1291	1292	|I-IUPAC
-	1292	1293	|I-IUPAC
[	1293	1294	|I-IUPAC
(	1294	1295	|I-IUPAC
4	1295	1296	|I-IUPAC
-	1296	1297	|I-IUPAC
chlorobenzylamino	1297	1314	|I-IUPAC
)	1314	1315	|I-IUPAC
methyl	1315	1321	|I-IUPAC
]	1321	1322	|I-IUPAC
-	1322	1323	|I-IUPAC
1	1323	1324	|I-IUPAC
-	1324	1325	|I-IUPAC
(	1325	1326	|I-IUPAC
1H	1326	1328	|I-IUPAC
-	1328	1329	|I-IUPAC
imidazol	1329	1337	|I-IUPAC
-	1337	1338	|I-IUPAC
4	1338	1339	|I-IUPAC
-	1339	1340	|I-IUPAC
yl	1340	1342	|I-IUPAC
)	1342	1343	|I-IUPAC
cyclopropane	1343	1355	|I-IUPAC
(	1356	1357	|O
10a	1357	1360	|O
)	1360	1361	|O
with	1362	1366	|O
the	1367	1370	|O
(	1371	1372	|O
1R	1372	1374	|O
)	1374	1375	|O
-	1375	1376	|O
trans	1376	1381	|O
structure	1382	1391	|O
was	1392	1395	|O
selective	1396	1405	|O
for	1406	1409	|O
the	1410	1413	|O
H4	1414	1416	|O
receptor	1417	1425	|O
(	1426	1427	|O
Ki	1427	1429	|O
=	1430	1431	|O
118	1432	1435	|O
nM	1436	1438	|O
)	1438	1439	|O
compared	1440	1448	|O
to	1449	1451	|O
the	1452	1455	|O
H3	1456	1458	|O
receptor	1459	1467	|O
(	1468	1469	|O
Ki	1469	1471	|O
&	1472	1473	|O
gt	1473	1475	|O
;	1475	1476	|O
10	1477	1479	|O
(	1479	1480	|O
3	1480	1481	|O
)	1481	1482	|O
nM	1483	1485	|O
)	1485	1486	|O
.	1486	1487	|O
Thus	1488	1492	|O
,	1492	1493	|O
a	1494	1495	|O
variety	1496	1503	|O
of	1504	1506	|O
compounds	1507	1516	|O
with	1517	1521	|O
different	1522	1531	|O
pharmacological	1532	1547	|O
profiles	1548	1556	|O
have	1557	1561	|O
been	1562	1566	|O
developed	1567	1576	|O
.	1576	1577	|O
These	1578	1583	|O
results	1584	1591	|O
show	1592	1596	|O
that	1597	1601	|O
when	1602	1606	|O
the	1607	1610	|O
structure	1611	1620	|O
of	1621	1623	|O
the	1624	1627	|O
target	1628	1634	|O
protein	1635	1642	|O
is	1643	1645	|O
unknown	1646	1653	|O
,	1653	1654	|O
the	1655	1658	|O
stereochemical	1659	1673	|O
diversity	1674	1683	|O
-	1683	1684	|O
oriented	1684	1692	|O
approach	1693	1701	|O
can	1702	1705	|O
be	1706	1708	|O
a	1709	1710	|O
powerful	1711	1719	|O
strategy	1720	1728	|O
in	1729	1731	|O
medicinal	1732	1741	|O
chemical	1742	1750	|O
studies	1751	1758	|O
.	1758	1759	|O

### abstracts4800.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
dioxolane	12	21	|O
analogues	22	31	|B-MODIFIER
based	32	37	|O
on	38	40	|O
dexoxadrol	41	51	|O
(	52	53	|O
(	53	54	|B-IUPAC
4S	54	56	|I-IUPAC
,	56	57	|I-IUPAC
6S	57	59	|I-IUPAC
)	59	60	|I-IUPAC
-	60	61	|I-IUPAC
2,2	61	64	|I-IUPAC
-	64	65	|I-IUPAC
diphenyl	65	73	|I-IUPAC
-	73	74	|I-IUPAC
4	74	75	|I-IUPAC
-	75	76	|I-IUPAC
(	76	77	|I-IUPAC
2	77	78	|I-IUPAC
-	78	79	|I-IUPAC
piperidyl	79	88	|I-IUPAC
)	88	89	|I-IUPAC
-	89	90	|I-IUPAC
1,3	90	93	|I-IUPAC
-	93	94	|I-IUPAC
dioxolane	94	103	|I-IUPAC
)	103	104	|O
and	105	108	|O
etoxadrol	109	118	|O
(	119	120	|O
(	120	121	|B-IUPAC
2S	121	123	|I-IUPAC
,	123	124	|I-IUPAC
4S	124	126	|I-IUPAC
,	126	127	|I-IUPAC
6S	127	129	|I-IUPAC
)	129	130	|I-IUPAC
-	130	131	|I-IUPAC
2	131	132	|I-IUPAC
-	132	133	|I-IUPAC
ethyl	133	138	|I-IUPAC
-	138	139	|I-IUPAC
2	139	140	|I-IUPAC
-	140	141	|I-IUPAC
phenyl	141	147	|I-IUPAC
-	147	148	|I-IUPAC
4	148	149	|I-IUPAC
-	149	150	|I-IUPAC
(	150	151	|I-IUPAC
2	151	152	|I-IUPAC
-	152	153	|I-IUPAC
piperidyl	153	162	|I-IUPAC
)	162	163	|I-IUPAC
-	163	164	|I-IUPAC
1,3	164	167	|I-IUPAC
-	167	168	|I-IUPAC
dioxolane	168	177	|I-IUPAC
)	177	178	|O
were	179	183	|O
prepared	184	192	|O
and	193	196	|O
tested	197	203	|O
for	204	207	|O
their	208	213	|O
ability	214	221	|O
to	222	224	|O
displace	225	233	|O
[	234	235	|O
3H	235	237	|O
]	237	238	|O
TCP	238	241	|O
(	242	243	|O
1	243	244	|B-IUPAC
-	244	245	|I-IUPAC
[	245	246	|I-IUPAC
1	246	247	|I-IUPAC
-	247	248	|I-IUPAC
(	248	249	|I-IUPAC
2	249	250	|I-IUPAC
-	250	251	|I-IUPAC
thienyl	251	258	|I-IUPAC
)	258	259	|I-IUPAC
cyclohexyl	259	269	|I-IUPAC
]	269	270	|I-IUPAC
piperidine	270	280	|I-IUPAC
)	280	281	|O
from	282	286	|O
PCP	287	290	|O
(	291	292	|O
1	292	293	|B-IUPAC
-	293	294	|I-IUPAC
(	294	295	|I-IUPAC
1	295	296	|I-IUPAC
-	296	297	|I-IUPAC
phenylcyclohexyl	297	313	|I-IUPAC
)	313	314	|I-IUPAC
piperidine	314	324	|I-IUPAC
)	324	325	|O
binding	326	333	|O
sites	334	339	|O
in	340	342	|O
rat	343	346	|O
brain	347	352	|O
tissue	353	359	|O
homogenates	360	371	|O
.	371	372	|O
Qualitative	373	384	|O
structure	385	394	|O
-	394	395	|O
activity	395	403	|O
relationships	404	417	|O
within	418	424	|O
this	425	429	|O
series	430	436	|O
were	437	441	|O
explored	442	450	|O
through	451	458	|O
modifications	459	472	|O
of	473	475	|O
the	476	479	|O
three	480	485	|O
major	486	491	|O
structural	492	502	|O
units	503	508	|O
of	509	511	|O
dexoxadrol	512	522	|O
,	522	523	|O
the	524	527	|O
piperidine	528	538	|O
,	538	539	|O
1,3	540	543	|B-IUPAC
-	543	544	|I-IUPAC
dioxolane	544	553	|I-IUPAC
,	553	554	|O
and	555	558	|O
aromatic	559	567	|O
rings	568	573	|O
of	574	576	|O
the	577	580	|O
molecule	581	589	|O
.	589	590	|O
N	591	592	|O
-	592	593	|O
Alkyl	593	598	|O
derivatives	599	610	|O
of	611	613	|O
dexoxadrol	614	624	|O
were	625	629	|O
found	630	635	|O
to	636	638	|O
be	639	641	|O
inactive	642	650	|O
,	650	651	|O
as	652	654	|O
were	655	659	|O
those	660	665	|O
analogues	666	675	|O
where	676	681	|O
the	682	685	|O
dioxolane	686	695	|O
ring	696	700	|O
was	701	704	|O
modified	705	713	|O
.	713	714	|O
Phenyl	715	721	|O
-	721	722	|O
substituted	722	733	|O
etoxadrol	734	743	|O
analogues	744	753	|O
were	754	758	|O
compared	759	767	|O
to	768	770	|O
similarly	771	780	|O
substituted	781	792	|O
PCP	793	796	|O
analogues	797	806	|O
and	807	810	|O
distinct	811	819	|O
differences	820	831	|O
were	832	836	|O
found	837	842	|O
in	843	845	|O
their	846	851	|O
structure	852	861	|O
-	861	862	|O
activity	862	870	|O
relationships	871	884	|O
suggesting	885	895	|O
that	896	900	|O
the	901	904	|O
aromatic	905	913	|O
rings	914	919	|O
in	920	922	|O
these	923	928	|O
two	929	932	|O
drug	933	937	|O
classes	938	945	|O
interact	946	954	|O
differently	955	966	|O
with	967	971	|O
the	972	975	|O
PCP	976	979	|O
binding	980	987	|O
sites	988	993	|O
.	993	994	|O
The	995	998	|O
replacement	999	1010	|O
of	1011	1013	|O
the	1014	1017	|O
phenyl	1018	1024	|O
ring	1025	1029	|O
in	1030	1032	|O
etoxadrol	1033	1042	|O
by	1043	1045	|O
either	1046	1052	|O
a	1053	1054	|O
2	1055	1056	|O
-	1056	1057	|O
or	1058	1060	|O
3	1061	1062	|O
-	1062	1063	|O
thienyl	1063	1070	|O
ring	1071	1075	|O
led	1076	1079	|O
to	1080	1082	|O
compounds	1083	1092	|O
with	1093	1097	|O
affinity	1098	1106	|O
comparable	1107	1117	|O
to	1118	1120	|O
etoxadrol	1121	1130	|O
,	1130	1131	|O
and	1132	1135	|O
the	1136	1139	|O
replacement	1140	1151	|O
of	1152	1154	|O
the	1155	1158	|O
ethyl	1159	1164	|O
moiety	1165	1171	|O
on	1172	1174	|O
etoxadrol	1175	1184	|O
's	1184	1186	|O
dioxolane	1187	1196	|O
ring	1197	1201	|O
with	1202	1206	|O
propyl	1207	1213	|O
(	1214	1215	|O
7	1215	1216	|O
)	1216	1217	|O
or	1218	1220	|O
isopropyl	1221	1230	|O
(	1231	1232	|O
8	1232	1233	|O
)	1233	1234	|O
led	1235	1238	|O
to	1239	1241	|O
compounds	1242	1251	|O
which	1252	1257	|O
were	1258	1262	|O
more	1263	1267	|O
potent	1268	1274	|O
than	1275	1279	|O
etoxadrol	1280	1289	|O
or	1290	1292	|O
PCP	1293	1296	|O
.	1296	1297	|O
The	1298	1301	|O
most	1302	1306	|O
potent	1307	1313	|O
compound	1314	1322	|O
was	1323	1326	|O
(	1327	1328	|B-IUPAC
2S	1328	1330	|I-IUPAC
,	1330	1331	|I-IUPAC
4S	1331	1333	|I-IUPAC
,	1333	1334	|I-IUPAC
6S	1334	1336	|I-IUPAC
)	1336	1337	|I-IUPAC
-	1337	1338	|I-IUPAC
2	1338	1339	|I-IUPAC
-	1339	1340	|I-IUPAC
ethyl	1340	1345	|I-IUPAC
-	1345	1346	|I-IUPAC
2	1347	1348	|I-IUPAC
-	1348	1349	|I-IUPAC
(	1349	1350	|I-IUPAC
1	1350	1351	|I-IUPAC
-	1351	1352	|I-IUPAC
chlorophenyl	1352	1364	|I-IUPAC
)	1364	1365	|I-IUPAC
-	1365	1366	|I-IUPAC
4	1366	1367	|I-IUPAC
-	1367	1368	|I-IUPAC
(	1368	1369	|I-IUPAC
2	1369	1370	|I-IUPAC
-	1370	1371	|I-IUPAC
piperidyl	1371	1380	|I-IUPAC
)	1380	1381	|I-IUPAC
-	1381	1382	|I-IUPAC
1,3	1382	1385	|I-IUPAC
-	1385	1386	|I-IUPAC
dioxolane	1386	1395	|I-IUPAC
(	1396	1397	|O
11	1397	1399	|O
)	1399	1400	|O
,	1400	1401	|O
where	1402	1407	|O
a	1408	1409	|O
chlorine	1410	1418	|O
moiety	1419	1425	|O
was	1426	1429	|O
placed	1430	1436	|O
in	1437	1439	|O
the	1440	1443	|O
ortho	1444	1449	|O
position	1450	1458	|O
in	1459	1461	|O
the	1462	1465	|O
aromatic	1466	1474	|O
ring	1475	1479	|O
of	1480	1482	|O
etoxadrol	1483	1492	|O
.	1492	1493	|O
Its	1494	1497	|O
potency	1498	1505	|O
was	1506	1509	|O
comparable	1510	1520	|O
with	1521	1525	|O
TCP	1526	1529	|O
in	1530	1532	|O
vitro	1533	1538	|O
.	1538	1539	|O

### abstracts2644.txt
A	0	1	|O
new	2	5	|O
metabolic	6	15	|O
pathway	16	23	|O
of	24	26	|O
terminal	27	35	|O
hydroxylation	36	49	|O
(	50	51	|O
omega	51	56	|O
-	56	57	|O
hydroxylation	57	70	|O
)	70	71	|O
of	72	74	|O
the	75	78	|O
N	79	80	|B-IUPAC
-	80	81	|I-IUPAC
isopropyl	81	90	|I-IUPAC
group	91	96	|B-MODIFIER
of	97	99	|O
propranolol	100	111	|O
(	112	113	|O
1	113	114	|O
)	114	115	|O
was	116	119	|O
established	120	131	|O
.	131	132	|O
Selected	133	141	|O
ion	142	145	|O
-	145	146	|O
monitoring	146	156	|O
GC	157	159	|O
-	159	160	|O
MS	160	162	|O
analysis	163	171	|O
,	171	172	|O
based	173	178	|O
on	179	181	|O
use	182	185	|O
of	186	188	|O
the	189	192	|O
synthesized	193	204	|O
mixture	205	212	|O
of	213	215	|O
diastereoisomers	216	232	|O
of	233	235	|O
1	236	237	|B-IUPAC
-	237	238	|I-IUPAC
(	238	239	|I-IUPAC
1	239	240	|I-IUPAC
-	240	241	|I-IUPAC
hydroxy	241	248	|I-IUPAC
-	248	249	|I-IUPAC
2	249	250	|I-IUPAC
-	250	251	|I-IUPAC
propylamino	251	262	|I-IUPAC
)	262	263	|I-IUPAC
-	263	264	|I-IUPAC
3	264	265	|I-IUPAC
-	265	266	|I-IUPAC
(	266	267	|I-IUPAC
1	267	268	|I-IUPAC
-	268	269	|I-IUPAC
naphthoxy	269	278	|I-IUPAC
)	278	279	|I-IUPAC
-	279	280	|I-IUPAC
2	280	281	|I-IUPAC
-	281	282	|I-IUPAC
propanol	282	290	|I-IUPAC
(	291	292	|O
2	292	293	|O
)	293	294	|O
as	295	297	|O
a	298	299	|O
standard	300	308	|O
,	308	309	|O
established	310	321	|O
formation	322	331	|O
of	332	334	|O
both	335	339	|O
diastereoisomers	340	356	|O
of	357	359	|O
2	360	361	|O
as	362	364	|O
metabolites	365	376	|O
of	377	379	|O
1	380	381	|O
.	381	382	|O
These	383	388	|O
diastereoisomers	389	405	|O
were	406	410	|O
formed	411	417	|O
in	418	420	|O
unequal	421	428	|O
amounts	429	436	|O
when	437	441	|O
1	442	443	|O
,	443	444	|O
its	445	448	|O
hexadeuterated	449	463	|O
analogue	464	472	|O
8	473	474	|O
or	475	477	|O
heptadeuterated	478	493	|O
analogue	494	502	|O
9	503	504	|O
,	504	505	|O
were	506	510	|O
incubated	511	520	|O
in	521	523	|O
the	524	527	|O
presence	528	536	|O
of	537	539	|O
the	540	543	|O
rat	544	547	|O
liver	548	553	|O
microsomal	554	564	|O
fraction	565	573	|O
.	573	574	|O
Authentic	575	584	|O
(	585	586	|O
2R	586	588	|O
,	588	589	|O
2	589	590	|O
"	590	591	|O
S	591	592	|O
)	592	593	|O
-	593	594	|O
2	594	595	|O
,	595	596	|O
obtained	597	605	|O
from	606	610	|O
the	611	614	|O
amide	615	620	|O
formed	621	627	|O
from	628	632	|O
(	633	634	|B-IUPAC
2S	634	636	|I-IUPAC
)	636	637	|I-IUPAC
-	637	638	|I-IUPAC
3	638	639	|I-IUPAC
-	639	640	|I-IUPAC
(	640	641	|I-IUPAC
1	641	642	|I-IUPAC
-	642	643	|I-IUPAC
naphthoxy	643	652	|I-IUPAC
)	652	653	|I-IUPAC
-	653	654	|I-IUPAC
2	654	655	|I-IUPAC
-	655	656	|I-IUPAC
hydroxypropionic	656	672	|I-IUPAC
acid	673	677	|I-IUPAC
[	678	679	|O
(	679	680	|O
2S	680	682	|O
)	682	683	|O
-	683	684	|O
5	684	685	|O
]	685	686	|O
and	687	690	|O
(	691	692	|B-IUPAC
2S	692	694	|I-IUPAC
)	694	695	|I-IUPAC
-	695	696	|I-IUPAC
alaninol	696	704	|I-IUPAC
by	705	707	|O
diborane	708	716	|O
reduction	717	726	|O
,	726	727	|O
facilitated	728	739	|O
examination	740	751	|O
of	752	754	|O
stereochemical	755	769	|O
aspects	770	777	|O
of	778	780	|O
this	781	785	|O
process	786	793	|O
.	793	794	|O
From	795	799	|O
incubations	800	811	|O
of	812	814	|O
the	815	818	|O
enantiomers	819	830	|O
of	831	833	|O
1	834	835	|O
and	836	839	|O
pseudoracemic	840	853	|O
propranolol	854	865	|O
[	866	867	|O
equimolar	867	876	|O
(	877	878	|B-IUPAC
2R	878	880	|I-IUPAC
)	880	881	|I-IUPAC
-	881	882	|I-IUPAC
propranolol	882	893	|I-IUPAC
-	893	894	|I-IUPAC
3,3	894	897	|I-IUPAC
-	897	898	|I-IUPAC
d2	898	900	|I-IUPAC
and	901	904	|O
(	905	906	|B-IUPAC
2S	906	908	|I-IUPAC
)	908	909	|I-IUPAC
-	909	910	|I-IUPAC
propranolol	910	921	|I-IUPAC
-	921	922	|I-IUPAC
d0	922	924	|I-IUPAC
]	924	925	|O
in	926	928	|O
the	929	932	|O
presence	933	941	|O
of	942	944	|O
the	945	948	|O
rat	949	952	|O
liver	953	958	|O
microsomal	959	969	|O
fraction	970	978	|O
,	978	979	|O
we	980	982	|O
established	983	994	|O
that	995	999	|O
the	1000	1003	|O
diastereomeric	1004	1018	|O
products	1019	1027	|O
were	1028	1032	|O
formed	1033	1039	|O
in	1040	1042	|O
the	1043	1046	|O
order	1047	1052	|O
(	1053	1054	|O
2S	1054	1056	|O
,	1056	1057	|O
2	1057	1058	|O
"	1058	1059	|O
S	1059	1060	|O
)	1060	1061	|O
-	1061	1062	|O
2	1062	1063	|O
approximately	1064	1077	|O
equal	1078	1083	|O
to	1084	1086	|O
(	1087	1088	|O
2S	1088	1090	|O
,	1090	1091	|O
2	1091	1092	|O
"	1092	1093	|O
R	1093	1094	|O
)	1094	1095	|O
-	1095	1096	|O
2	1096	1097	|O
greater	1098	1105	|O
than	1106	1110	|O
(	1111	1112	|O
2R	1112	1114	|O
,	1114	1115	|O
2	1115	1116	|O
"	1116	1117	|O
R	1117	1118	|O
)	1118	1119	|O
-	1119	1120	|O
2	1120	1121	|O
greater	1122	1129	|O
than	1130	1134	|O
(	1135	1136	|O
2R	1136	1138	|O
,	1138	1139	|O
2	1139	1140	|O
"	1140	1141	|O
S	1141	1142	|O
)	1142	1143	|O
-	1143	1144	|O
2	1144	1145	|O
.	1145	1146	|O
(	1147	1148	|O
2S	1148	1150	|O
)	1150	1151	|O
-	1151	1152	|O
1	1152	1153	|O
,	1153	1154	|O
which	1155	1160	|O
was	1161	1164	|O
metabolized	1165	1176	|O
to	1177	1179	|O
2	1180	1181	|O
to	1182	1184	|O
a	1185	1186	|O
greater	1187	1194	|O
extent	1195	1201	|O
than	1202	1206	|O
(	1207	1208	|O
2R	1208	1210	|O
)	1210	1211	|O
-	1211	1212	|O
1	1212	1213	|O
,	1213	1214	|O
showed	1215	1221	|O
no	1222	1224	|O
stereoselectivity	1225	1242	|O
,	1242	1243	|O
affording	1244	1253	|O
about	1254	1259	|O
equal	1260	1265	|O
amounts	1266	1273	|O
of	1274	1276	|O
(	1277	1278	|O
2S	1278	1280	|O
,	1280	1281	|O
2	1281	1282	|O
"	1282	1283	|O
S	1283	1284	|O
)	1284	1285	|O
-	1285	1286	|O
2	1286	1287	|O
and	1288	1291	|O
(	1292	1293	|O
2S	1293	1295	|O
,	1295	1296	|O
2	1296	1297	|O
"	1297	1298	|O
R	1298	1299	|O
)	1299	1300	|O
-	1300	1301	|O
2	1301	1302	|O
.	1302	1303	|O
(	1304	1305	|O
2R	1305	1307	|O
)	1307	1308	|O
-	1308	1309	|O
1	1309	1310	|O
,	1310	1311	|O
which	1312	1317	|O
was	1318	1321	|O
metabolized	1322	1333	|O
to	1334	1336	|O
2	1337	1338	|O
to	1339	1341	|O
a	1342	1343	|O
lesser	1344	1350	|O
extent	1351	1357	|O
,	1357	1358	|O
afforded	1359	1367	|O
considerably	1368	1380	|O
more	1381	1385	|O
(	1386	1387	|O
2R	1387	1389	|O
,	1389	1390	|O
2	1390	1391	|O
"	1391	1392	|O
R	1392	1393	|O
)	1393	1394	|O
-	1394	1395	|O
2	1395	1396	|O
than	1397	1401	|O
(	1402	1403	|O
2R	1403	1405	|O
,	1405	1406	|O
2	1406	1407	|O
"	1407	1408	|O
S	1408	1409	|O
)	1409	1410	|O
-	1410	1411	|O
2	1411	1412	|O
.	1412	1413	|O
omega	1414	1419	|O
-	1419	1420	|O
Hydroxylation	1420	1433	|O
was	1434	1437	|O
a	1438	1439	|O
minor	1440	1445	|O
metabolic	1446	1455	|O
pathway	1456	1463	|O
in	1464	1466	|O
the	1467	1470	|O
microsomal	1471	1481	|O
incubation	1482	1492	|O
.	1492	1493	|O
About	1494	1499	|O
2000X	1500	1505	|O
less	1506	1510	|O
2	1511	1512	|O
than	1513	1517	|O
1	1518	1519	|B-IUPAC
-	1519	1520	|I-IUPAC
amino	1520	1525	|I-IUPAC
-	1525	1526	|I-IUPAC
3	1526	1527	|I-IUPAC
-	1527	1528	|I-IUPAC
(	1528	1529	|I-IUPAC
1	1529	1530	|I-IUPAC
-	1530	1531	|I-IUPAC
naphthoxy	1531	1540	|I-IUPAC
)	1540	1541	|I-IUPAC
-	1541	1542	|I-IUPAC
2	1542	1543	|I-IUPAC
-	1543	1544	|I-IUPAC
propanol	1544	1552	|I-IUPAC
(	1553	1554	|O
3	1554	1555	|O
)	1555	1556	|O
,	1556	1557	|O
the	1558	1561	|O
product	1562	1569	|O
of	1570	1572	|O
N	1573	1574	|O
-	1574	1575	|O
dealkylation	1575	1587	|O
of	1588	1590	|O
1	1591	1592	|O
,	1592	1593	|O
was	1594	1597	|O
formed	1598	1604	|O
.	1604	1605	|O

### abstracts21.txt
A	0	1	|O
detailed	2	10	|O
structure	11	20	|O
-	20	21	|O
activity	21	29	|O
analysis	30	38	|O
was	39	42	|O
carried	43	50	|O
out	51	54	|O
using	55	60	|O
eight	61	66	|O
1	67	68	|B-IUPAC
-	68	69	|I-IUPAC
alkyl	69	74	|I-IUPAC
(	74	75	|I-IUPAC
aralkyl	75	82	|I-IUPAC
)	82	83	|I-IUPAC
nipecotamides	83	96	|I-IUPAC
(	97	98	|O
type	98	102	|O
5	103	104	|O
)	104	105	|O
,	105	106	|O
33	107	109	|O
bis	110	113	|B-IUPAC
-	113	114	|I-IUPAC
nipecotamidoalkanes	114	133	|I-IUPAC
and	134	137	|O
aralkanes	138	147	|B-IUPAC
(	148	149	|O
type	149	153	|O
6	154	155	|O
)	155	156	|O
,	156	157	|O
and	158	161	|O
7	162	163	|O
N	164	165	|B-IUPAC
,	165	166	|I-IUPAC
N'	166	168	|I-IUPAC
-	168	169	|I-IUPAC
bis	169	172	|I-IUPAC
(	172	173	|I-IUPAC
nipecotoyl	173	183	|I-IUPAC
)	183	184	|I-IUPAC
-	184	185	|I-IUPAC
piperazines	185	196	|I-IUPAC
(	197	198	|O
type	198	202	|O
7	203	204	|O
)	204	205	|O
as	206	208	|O
inhibitors	209	219	|O
of	220	222	|O
human	223	228	|O
platelet	229	237	|O
aggregation	238	249	|O
.	249	250	|O
Steric	251	257	|O
factors	258	265	|O
played	266	272	|O
an	273	275	|O
important	276	285	|O
role	286	290	|O
in	291	293	|O
determining	294	305	|O
the	306	309	|O
activity	310	318	|O
of	319	321	|O
type	322	326	|O
5	327	328	|O
compounds	329	338	|O
possessing	339	349	|O
an	350	352	|O
an	353	355	|O
appropriate	356	367	|O
degree	368	374	|O
of	375	377	|O
hydrophobic	378	389	|O
character	390	399	|O
.	399	400	|O
Types	401	406	|O
6	407	408	|O
and	409	412	|O
7	413	414	|O
compounds	415	424	|O
were	425	429	|O
more	430	434	|O
potent	435	441	|O
than	442	446	|O
the	447	450	|O
corresponding	451	464	|O
type	465	469	|O
5	470	471	|O
molecules	472	481	|O
.	481	482	|O
Hydrophobic	483	494	|O
character	495	504	|O
appeared	505	513	|O
to	514	516	|O
influence	517	526	|O
the	527	530	|O
activity	531	539	|O
of	540	542	|O
type	543	547	|O
6	548	549	|O
compounds	550	559	|O
.	559	560	|O
A	561	562	|O
3	563	564	|O
-	564	565	|O
substituent	565	576	|O
on	577	579	|O
the	580	583	|O
piperidine	584	594	|O
ring	595	599	|O
was	600	603	|O
necessary	604	613	|O
for	614	617	|O
antiplatelet	618	630	|O
activity	631	639	|O
;	639	640	|O
the	641	644	|O
substituent	645	656	|O
should	657	663	|O
be	664	666	|O
preferably	667	677	|O
an	678	680	|O
amide	681	686	|O
with	687	691	|O
its	692	695	|O
C	696	697	|O
attached	698	706	|O
directly	707	715	|O
to	716	718	|O
the	719	722	|O
ring	723	727	|O
.	727	728	|O
3,5	729	732	|O
-	732	733	|O
Disubstitution	733	747	|O
and	748	751	|O
2	752	753	|O
-	753	754	|O
substitution	754	766	|O
led	767	770	|O
to	771	773	|O
a	774	775	|O
decline	776	783	|O
in	784	786	|O
activity	787	795	|O
.	795	796	|O
Optimal	797	804	|O
activity	805	813	|O
was	814	817	|O
attained	818	826	|O
when	827	831	|O
the	832	835	|O
two	836	839	|O
nipecotoyl	840	850	|O
ring	851	855	|O
N	856	857	|O
atoms	858	863	|O
were	864	868	|O
connected	869	878	|O
by	879	881	|O
an	882	884	|O
aralkyl	885	892	|B-IUPAC
group	893	898	|B-MODIFIER
,	898	899	|O
and	900	903	|O
separated	904	913	|O
by	914	916	|O
approximately	917	930	|O
7	931	932	|O
A	933	934	|O
.	934	935	|O
It	936	938	|O
is	939	941	|O
suggested	942	951	|O
that	952	956	|O
van	957	960	|O
der	961	964	|O
Waals	965	970	|O
forces	971	977	|O
and	978	981	|O
pi	982	984	|O
interactions	985	997	|O
may	998	1001	|O
govern	1002	1008	|O
the	1009	1012	|O
inhibitor	1013	1022	|O
-	1022	1023	|O
platelet	1023	1031	|O
interaction	1032	1043	|O
.	1043	1044	|O
The	1045	1048	|O
most	1049	1053	|O
potent	1054	1060	|O
type	1061	1065	|O
6	1066	1067	|O
inhibitor	1068	1077	|O
was	1078	1081	|O
alpha	1082	1087	|B-IUPAC
,	1087	1088	|I-IUPAC
alpha	1088	1093	|I-IUPAC
'	1093	1094	|I-IUPAC
-	1094	1095	|I-IUPAC
bis	1095	1098	|I-IUPAC
[	1098	1099	|I-IUPAC
3	1099	1100	|I-IUPAC
-	1100	1101	|I-IUPAC
(	1101	1102	|I-IUPAC
N	1102	1103	|I-IUPAC
-	1103	1104	|I-IUPAC
ethyl	1104	1109	|I-IUPAC
-	1109	1110	|I-IUPAC
N	1110	1111	|I-IUPAC
-	1111	1112	|I-IUPAC
butylcarbamoyl	1112	1126	|I-IUPAC
)	1126	1127	|I-IUPAC
piperidino	1127	1137	|I-IUPAC
]	1137	1138	|I-IUPAC
-	1138	1139	|I-IUPAC
p	1139	1140	|I-IUPAC
-	1140	1141	|I-IUPAC
xylene	1141	1147	|I-IUPAC
(	1148	1149	|O
6i	1149	1151	|O
)	1151	1152	|O
.	1152	1153	|O
The	1154	1157	|O
most	1158	1162	|O
potent	1163	1169	|O
type	1170	1174	|O
5	1175	1176	|O
compound	1177	1185	|O
was	1186	1189	|O
1	1190	1191	|B-IUPAC
-	1191	1192	|I-IUPAC
decyl	1192	1197	|I-IUPAC
-	1197	1198	|I-IUPAC
3	1198	1199	|I-IUPAC
-	1199	1200	|I-IUPAC
(	1200	1201	|I-IUPAC
N	1201	1202	|I-IUPAC
,	1202	1203	|I-IUPAC
N	1203	1204	|I-IUPAC
-	1204	1205	|I-IUPAC
diethylcarbamoyl	1205	1221	|I-IUPAC
)	1221	1222	|I-IUPAC
piperidine	1222	1232	|I-IUPAC
(	1233	1234	|O
5a	1234	1236	|O
)	1236	1237	|O
.	1237	1238	|O
Any	1239	1242	|O
substitution	1243	1255	|O
on	1256	1258	|O
the	1259	1262	|O
piperazine	1263	1273	|O
ring	1274	1278	|O
of	1279	1281	|O
type	1282	1286	|O
7	1287	1288	|O
compounds	1289	1298	|O
led	1299	1302	|O
to	1303	1305	|O
a	1306	1307	|O
decline	1308	1315	|O
in	1316	1318	|O
activity	1319	1327	|O
,	1327	1328	|O
the	1329	1332	|O
most	1333	1337	|O
active	1338	1344	|O
analog	1345	1351	|B-MODIFIER
being	1352	1357	|O
N	1358	1359	|B-IUPAC
,	1359	1360	|I-IUPAC
N'	1360	1362	|I-IUPAC
-	1362	1363	|I-IUPAC
bis	1363	1366	|I-IUPAC
(	1366	1367	|I-IUPAC
1	1367	1368	|I-IUPAC
-	1368	1369	|I-IUPAC
decylnipecotoyl	1369	1384	|I-IUPAC
)	1384	1385	|I-IUPAC
piperazine	1385	1395	|I-IUPAC
(	1396	1397	|O
7a	1397	1399	|O
)	1399	1400	|O
.	1400	1401	|O
It	1402	1404	|O
is	1405	1407	|O
suggested	1408	1417	|O
that	1418	1422	|O
nipecotamides	1423	1436	|O
interact	1437	1445	|O
with	1446	1450	|O
anionic	1451	1458	|O
platelet	1459	1467	|O
sites	1468	1473	|O
located	1474	1481	|O
7	1482	1483	|O
A	1484	1485	|O
from	1486	1490	|O
each	1491	1495	|O
other	1496	1501	|O
and	1502	1505	|O
connected	1506	1515	|O
by	1516	1518	|O
a	1519	1520	|O
hydrophobic	1521	1532	|O
well	1533	1537	|O
.	1537	1538	|O

### abstracts4506.txt
Synthesis	0	9	|O
of	10	12	|O
various	13	20	|O
substituted	21	32	|B-MODIFIER
5	33	34	|B-IUPAC
-	34	35	|I-IUPAC
thio	35	39	|I-IUPAC
-	39	40	|I-IUPAC
2	40	41	|I-IUPAC
-	41	42	|I-IUPAC
pyridinecarboxylic	42	60	|I-IUPAC
acids	61	66	|I-IUPAC
and	67	70	|O
their	71	76	|O
derivatives	77	88	|O
is	89	91	|O
described	92	101	|O
by	102	104	|O
three	105	110	|O
methods	111	118	|O
,	118	119	|O
i.e.	120	124	|O
,	124	125	|O
displacement	126	138	|O
of	139	141	|O
nitrite	142	149	|O
from	150	154	|O
methyl	155	161	|B-IUPAC
5	162	163	|I-IUPAC
-	163	164	|I-IUPAC
nitro	164	169	|I-IUPAC
-	169	170	|I-IUPAC
2	170	171	|I-IUPAC
-	171	172	|I-IUPAC
pyridinecarboxylate	172	191	|I-IUPAC
(	192	193	|O
10	193	195	|O
)	195	196	|O
by	197	199	|O
a	200	201	|O
thiol	202	207	|O
anion	208	213	|O
,	213	214	|O
alkylation	215	225	|O
of	226	228	|O
methyl	229	235	|B-IUPAC
5	236	237	|I-IUPAC
-	237	238	|I-IUPAC
thio	238	242	|I-IUPAC
-	242	243	|I-IUPAC
2	243	244	|I-IUPAC
-	244	245	|I-IUPAC
pyridinecarboxylate	245	264	|I-IUPAC
derived	265	272	|O
from	273	277	|O
reaction	278	286	|O
of	287	289	|O
the	290	293	|O
diazotized	294	304	|B-MODIFIER
methyl	305	311	|B-IUPAC
-	311	312	|I-IUPAC
5	312	313	|I-IUPAC
-	313	314	|I-IUPAC
amino	314	319	|I-IUPAC
-	319	320	|I-IUPAC
2	320	321	|I-IUPAC
-	321	322	|I-IUPAC
pyridinecarboxylate	322	341	|I-IUPAC
(	342	343	|O
5	343	344	|O
)	344	345	|O
with	346	350	|O
thiocyanate	351	362	|O
followed	363	371	|O
by	372	374	|O
borohydride	375	386	|O
reduction	387	396	|O
of	397	399	|O
the	400	403	|O
product	404	411	|O
,	411	412	|O
and	413	416	|O
alkylation	417	427	|O
of	428	430	|O
5	431	432	|B-IUPAC
-	432	433	|I-IUPAC
thio	433	437	|I-IUPAC
-	437	438	|I-IUPAC
2	438	439	|I-IUPAC
-	439	440	|I-IUPAC
pyridinecarbonitrile	440	460	|I-IUPAC
followed	461	469	|O
by	470	472	|O
hydrolysis	473	483	|O
.	483	484	|O
5	485	486	|B-IUPAC
-	486	487	|I-IUPAC
Thio	487	491	|I-IUPAC
-	491	492	|I-IUPAC
2	492	493	|I-IUPAC
-	493	494	|I-IUPAC
pyridinecarbonitrile	494	514	|I-IUPAC
was	515	518	|O
obtained	519	527	|O
from	528	532	|O
butyl	533	538	|B-IUPAC
6	539	540	|I-IUPAC
-	540	541	|I-IUPAC
methyl	541	547	|I-IUPAC
-	547	548	|I-IUPAC
3	548	549	|I-IUPAC
-	549	550	|I-IUPAC
pyridyl	550	557	|I-IUPAC
sulfoxide	558	567	|I-IUPAC
(	568	569	|O
2	569	570	|O
)	570	571	|O
by	572	574	|O
nitrosation	575	586	|O
and	587	590	|O
dehydration	591	602	|O
of	603	605	|O
the	606	609	|O
oxime	610	615	|O
.	615	616	|O
Many	617	621	|O
of	622	624	|O
these	625	630	|O
5	631	632	|B-IUPAC
-	632	633	|I-IUPAC
thio	633	637	|I-IUPAC
-	637	638	|I-IUPAC
2	638	639	|I-IUPAC
-	639	640	|I-IUPAC
pyridinecarboxylic	640	658	|I-IUPAC
acid	659	663	|I-IUPAC
derivatives	664	675	|B-MODIFIER
were	676	680	|O
orally	681	687	|O
active	688	694	|O
antihypertensive	695	711	|O
agents	712	718	|O
in	719	721	|O
the	722	725	|O
spontaneously	726	739	|O
hypertensive	740	752	|O
rat	753	756	|O
.	756	757	|O
Optimization	758	770	|O
of	771	773	|O
the	774	777	|O
structural	778	788	|O
parameters	789	799	|O
for	800	803	|O
this	804	808	|O
activity	809	817	|O
yiedled	818	825	|O
5	826	827	|B-IUPAC
-	827	828	|I-IUPAC
[	828	829	|I-IUPAC
m	829	830	|I-IUPAC
-	830	831	|I-IUPAC
trifluorobenzyl	831	846	|I-IUPAC
)	846	847	|I-IUPAC
thio	848	852	|I-IUPAC
]	852	853	|I-IUPAC
-	853	854	|I-IUPAC
2	854	855	|I-IUPAC
-	855	856	|I-IUPAC
pyridinecarboxylic	856	874	|I-IUPAC
acid	875	879	|I-IUPAC
(	880	881	|O
41	881	883	|O
)	883	884	|O
and	885	888	|O
its	889	892	|O
sulfoxide	893	902	|O
,	902	903	|O
42	904	906	|O
.	906	907	|O
Further	908	915	|O
biological	916	926	|O
studies	927	934	|O
with	935	939	|O
these	940	945	|O
compounds	946	955	|O
are	956	959	|O
described	960	969	|O
.	969	970	|O

### abstracts514.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
gallium	12	19	|O
(	19	20	|O
III	20	23	|O
)	23	24	|O
and	25	28	|O
iron	29	33	|O
(	33	34	|O
III	34	37	|O
)	37	38	|O
complexes	39	48	|O
with	49	53	|O
five	54	58	|O
different	59	68	|O
4N	69	71	|B-MODIFIER
-	71	72	|I-MODIFIER
substituted	72	83	|I-MODIFIER
alpha	84	89	|B-IUPAC
-	89	90	|I-IUPAC
N	90	91	|I-IUPAC
-	91	92	|I-IUPAC
heterocyclic	92	104	|I-IUPAC
thiosemicarbazones	105	123	|I-IUPAC
,	123	124	|O
viz	125	128	|O
.	128	129	|O
,	129	130	|O
2	131	132	|B-IUPAC
-	132	133	|I-IUPAC
acetylpyridine	133	147	|I-IUPAC
N	148	149	|I-IUPAC
,	149	150	|I-IUPAC
N	150	151	|I-IUPAC
-	151	152	|I-IUPAC
dimethylthiosemicarbazone	152	177	|I-IUPAC
(	178	179	|O
1	179	180	|O
)	180	181	|O
,	181	182	|O
2	183	184	|B-IUPAC
-	184	185	|I-IUPAC
acetylpyridine	185	199	|I-IUPAC
N	200	201	|I-IUPAC
-	201	202	|I-IUPAC
pyrrolidinylthiosemicarbazone	202	231	|I-IUPAC
(	232	233	|O
2	233	234	|O
)	234	235	|O
,	235	236	|O
acetylpyrazine	237	251	|B-IUPAC
N	252	253	|I-IUPAC
,	253	254	|I-IUPAC
N	254	255	|I-IUPAC
-	255	256	|I-IUPAC
dimethylthiosemicarbazone	256	281	|I-IUPAC
(	282	283	|O
3	283	284	|O
)	284	285	|O
,	285	286	|O
acetylpyrazine	287	301	|B-IUPAC
N	302	303	|I-IUPAC
-	303	304	|I-IUPAC
pyrrolidinylthiosemicarbazone	304	333	|I-IUPAC
(	334	335	|O
4	335	336	|O
)	336	337	|O
,	337	338	|O
and	339	342	|O
acetylpyrazine	343	357	|B-IUPAC
N	358	359	|I-IUPAC
-	359	360	|I-IUPAC
piperidinylthiosemicarbazone	360	388	|I-IUPAC
(	389	390	|O
5	390	391	|O
)	391	392	|O
,	392	393	|O
with	394	398	|O
the	399	402	|O
general	403	410	|O
formula	411	418	|O
[	419	420	|O
GaLCl2	420	426	|O
]	426	427	|O
(	428	429	|O
HL	429	431	|O
=	432	433	|O
1	434	435	|O
and	436	439	|O
2	440	441	|O
)	441	442	|O
and	443	446	|O
[	447	448	|O
ML2	448	451	|O
]	451	452	|O
[	452	453	|O
Y	453	454	|O
]	454	455	|O
(	456	457	|O
M	457	458	|O
=	459	460	|O
Ga	461	463	|O
,	463	464	|O
HL	465	467	|O
=	468	469	|O
1-5	470	473	|O
,	473	474	|O
Y	475	476	|O
=	477	478	|O
PF6	479	482	|O
;	482	483	|O
M	484	485	|O
=	486	487	|O
Fe	488	490	|O
,	490	491	|O
HL	492	494	|O
=	495	496	|O
1-5	497	500	|O
,	500	501	|O
Y	502	503	|O
=	504	505	|O
FeCl4	506	511	|O
and	512	515	|O
PF6	516	519	|O
)	519	520	|O
were	521	525	|O
synthesized	526	537	|O
and	538	541	|O
characterized	542	555	|O
by	556	558	|O
elemental	559	568	|O
analysis	569	577	|O
,	577	578	|O
a	579	580	|O
number	581	587	|O
of	588	590	|O
spectroscopic	591	604	|O
methods	605	612	|O
(	613	614	|O
NMR	614	617	|O
,	617	618	|O
IR	619	621	|O
,	621	622	|O
UV	623	625	|O
-	625	626	|O
vis	626	629	|O
)	629	630	|O
,	630	631	|O
mass	632	636	|O
spectrometry	637	649	|O
,	649	650	|O
and	651	654	|O
X	655	656	|O
-	656	657	|O
ray	657	660	|O
crystallography	661	676	|O
.	676	677	|O
The	678	681	|O
in	682	684	|O
vitro	685	690	|O
antitumor	691	700	|O
potency	701	708	|O
was	709	712	|O
studied	713	720	|O
in	721	723	|O
two	724	727	|O
human	728	733	|O
cancer	734	740	|O
cell	741	745	|O
lines	746	751	|O
(	752	753	|O
41M	753	756	|O
and	757	760	|O
SK	761	763	|O
-	763	764	|O
BR	764	766	|O
-	766	767	|O
3	767	768	|O
)	768	769	|O
.	769	770	|O
The	771	774	|O
central	775	782	|O
metal	783	788	|O
ions	789	793	|O
exert	794	799	|O
pronounced	800	810	|O
effects	811	818	|O
in	819	821	|O
a	822	823	|O
divergent	824	833	|O
manner	834	840	|O
:	840	841	|O
gallium	842	849	|O
(	849	850	|O
III	850	853	|O
)	853	854	|O
enhances	855	863	|O
,	863	864	|O
whereas	865	872	|O
iron	873	877	|O
(	877	878	|O
III	878	881	|O
)	881	882	|O
weakens	883	890	|O
the	891	894	|O
cytotoxicity	895	907	|O
of	908	910	|O
the	911	914	|O
ligands	915	922	|O
.	922	923	|O
The	924	927	|O
capacity	928	936	|O
of	937	939	|O
ligand	940	946	|O
1	947	948	|O
and	949	952	|O
its	953	956	|O
Ga	957	959	|O
(	959	960	|O
III	960	963	|O
)	963	964	|O
and	965	968	|O
Fe	969	971	|O
(	971	972	|O
III	972	975	|O
)	975	976	|O
complexes	977	986	|O
to	987	989	|O
destroy	990	997	|O
the	998	1001	|O
tyrosyl	1002	1009	|O
radical	1010	1017	|O
of	1018	1020	|O
the	1021	1024	|O
presumed	1025	1033	|O
target	1034	1040	|O
ribonucleotide	1041	1055	|O
reductase	1056	1065	|O
is	1066	1068	|O
reported	1069	1077	|O
.	1077	1078	|O

### abstracts3693.txt
The	0	3	|O
synthesis	4	13	|O
of	14	16	|O
11	17	19	|B-IUPAC
-	19	20	|I-IUPAC
thiohomofolic	20	33	|I-IUPAC
acid	34	38	|I-IUPAC
(	39	40	|O
2	40	41	|O
)	41	42	|O
has	43	46	|O
been	47	51	|O
accomplished	52	64	|O
by	65	67	|O
an	68	70	|O
unambiguous	71	82	|O
procedure	83	92	|O
.	92	93	|O
Reaction	94	102	|O
of	103	105	|O
1	106	107	|B-IUPAC
-	107	108	|I-IUPAC
chloro	108	114	|I-IUPAC
-	114	115	|I-IUPAC
4	115	116	|I-IUPAC
-	116	117	|I-IUPAC
[	117	118	|I-IUPAC
p	118	119	|I-IUPAC
-	119	120	|I-IUPAC
(	120	121	|I-IUPAC
carbomethoxy	121	133	|I-IUPAC
)	133	134	|I-IUPAC
thiophenoxy	134	145	|I-IUPAC
]	145	146	|I-IUPAC
-	146	147	|I-IUPAC
2	147	148	|I-IUPAC
-	148	149	|I-IUPAC
butanone	149	157	|I-IUPAC
(	158	159	|O
10	159	161	|O
)	161	162	|O
with	163	167	|O
hydroxylamine	168	181	|O
under	182	187	|O
carefully	188	197	|O
controlled	198	208	|O
conditions	209	219	|O
gave	220	224	|O
the	225	228	|O
corresponding	229	242	|O
oxime	243	248	|O
33	249	251	|O
.	251	252	|O
Conversion	253	263	|O
of	264	266	|O
this	267	271	|O
oxime	272	277	|O
to	278	280	|O
1	281	282	|B-IUPAC
-	282	283	|I-IUPAC
phthalimido	283	294	|I-IUPAC
-	294	295	|I-IUPAC
4	295	296	|I-IUPAC
-	296	297	|I-IUPAC
[	297	298	|I-IUPAC
p	298	299	|I-IUPAC
-	299	300	|I-IUPAC
(	300	301	|I-IUPAC
carbomethoxy	301	313	|I-IUPAC
)	313	314	|I-IUPAC
thiophenoxy	314	325	|I-IUPAC
]	325	326	|I-IUPAC
-	326	327	|I-IUPAC
2	327	328	|I-IUPAC
-	328	329	|I-IUPAC
butanone	329	337	|I-IUPAC
oxime	338	343	|I-IUPAC
(	344	345	|O
4	345	346	|O
)	346	347	|O
was	348	351	|O
carried	352	359	|O
out	360	363	|O
by	364	366	|O
its	367	370	|O
reaction	371	379	|O
with	380	384	|O
potassium	385	394	|O
phthalimide	395	406	|O
using	407	412	|O
crown	413	418	|O
18	419	421	|O
ether	422	427	|O
as	428	430	|O
a	431	432	|O
catalyst	433	441	|O
.	441	442	|O
Hydrazinolysis	443	457	|O
of	458	460	|O
compound	461	469	|O
4	470	471	|O
gave	472	476	|O
1	477	478	|B-IUPAC
-	478	479	|I-IUPAC
amino	479	484	|I-IUPAC
-	484	485	|I-IUPAC
4	485	486	|I-IUPAC
-	486	487	|I-IUPAC
[	487	488	|I-IUPAC
p	488	489	|I-IUPAC
-	489	490	|I-IUPAC
(	490	491	|I-IUPAC
carbomethoxy	491	503	|I-IUPAC
)	503	504	|I-IUPAC
thiophenoxy	504	515	|I-IUPAC
]	515	516	|I-IUPAC
-	516	517	|I-IUPAC
2	517	518	|I-IUPAC
-	518	519	|I-IUPAC
butanone	519	527	|I-IUPAC
oxime	528	533	|I-IUPAC
(	534	535	|O
5	535	536	|O
)	536	537	|O
,	537	538	|O
which	539	544	|O
was	545	548	|O
used	549	553	|O
for	554	557	|O
the	558	561	|O
construction	562	574	|O
of	575	577	|O
the	578	581	|O
title	582	587	|O
compound	588	596	|O
2	597	598	|O
by	599	601	|O
modification	602	614	|O
of	615	617	|O
the	618	621	|O
Boon	622	626	|O
and	627	630	|O
Leigh	631	636	|O
procedure	637	646	|O
.	646	647	|O
An	648	650	|O
alternate	651	660	|O
synthesis	661	670	|O
utilizing	671	680	|O
1	681	682	|B-IUPAC
-	682	683	|I-IUPAC
hydroxy	683	690	|I-IUPAC
-	690	691	|I-IUPAC
4	691	692	|I-IUPAC
-	692	693	|I-IUPAC
[	693	694	|I-IUPAC
p	694	695	|I-IUPAC
-	695	696	|I-IUPAC
(	696	697	|I-IUPAC
carbomethoxy	697	709	|I-IUPAC
)	709	710	|I-IUPAC
thiophenoxy	710	721	|I-IUPAC
]	721	722	|I-IUPAC
-	722	723	|I-IUPAC
2	723	724	|I-IUPAC
-	724	725	|I-IUPAC
butanone	725	733	|I-IUPAC
(	734	735	|O
11	735	737	|O
)	737	738	|O
and	739	742	|O
4	743	744	|B-IUPAC
-	744	745	|I-IUPAC
hydroxy	745	752	|I-IUPAC
-	752	753	|I-IUPAC
2,5,6	753	758	|I-IUPAC
-	758	759	|I-IUPAC
triaminopyrimidine	759	777	|I-IUPAC
has	778	781	|O
also	782	786	|O
been	787	791	|O
carried	792	799	|O
out	800	803	|O
.	803	804	|O
Compound	805	813	|O
2	814	815	|O
did	816	819	|O
not	820	823	|O
exhibit	824	831	|O
any	832	835	|O
antifolate	836	846	|O
activity	847	855	|O
against	856	863	|O
Lactobacillus	864	877	|O
casei	878	883	|O
or	884	886	|O
Streptococcus	887	900	|O
faecium	901	908	|O
.	908	909	|O
The	910	913	|O
dithionite	914	924	|O
reduction	925	934	|O
product	935	942	|O
,	942	943	|O
7,8	944	947	|B-IUPAC
-	947	948	|I-IUPAC
dihydro	948	955	|I-IUPAC
-	955	956	|I-IUPAC
11	956	958	|I-IUPAC
-	958	959	|I-IUPAC
thiohomofolic	959	972	|I-IUPAC
acid	973	977	|I-IUPAC
,	977	978	|O
was	979	982	|O
able	983	987	|O
to	988	990	|O
function	991	999	|O
as	1000	1002	|O
a	1003	1004	|O
substrate	1005	1014	|O
of	1015	1017	|O
L	1018	1019	|O
.	1019	1020	|O
casei	1021	1026	|O
dihydrofolate	1027	1040	|O
reductase	1041	1050	|O
.	1050	1051	|O
The	1052	1055	|O
catalytic	1056	1065	|O
reduction	1066	1075	|O
product	1076	1083	|O
of	1084	1086	|O
2	1087	1088	|O
,	1088	1089	|O
consisting	1090	1100	|O
of	1101	1103	|O
a	1104	1105	|O
mixture	1106	1113	|O
of	1114	1116	|O
diastereomers	1117	1130	|O
,	1130	1131	|O
exhibited	1132	1141	|O
powerful	1142	1150	|O
antifolate	1151	1161	|O
activity	1162	1170	|O
against	1171	1178	|O
both	1179	1183	|O
these	1184	1189	|O
organisms	1190	1199	|O
.	1199	1200	|O

### abstracts4921.txt
Preference	0	10	|O
for	11	14	|O
the	15	18	|O
Northern	19	27	|O
(	28	29	|O
N	29	30	|O
)	30	31	|O
ring	32	36	|O
conformation	37	49	|O
of	50	52	|O
the	53	56	|O
ribose	57	63	|O
moiety	64	70	|O
of	71	73	|O
nucleotide	74	84	|O
5'	85	87	|O
-	87	88	|O
triphosphate	88	100	|O
agonists	101	109	|O
at	110	112	|O
P2Y	113	116	|O
(	116	117	|O
1	117	118	|O
)	118	119	|O
,	119	120	|O
P2Y	121	124	|O
(	124	125	|O
2	125	126	|O
)	126	127	|O
,	127	128	|O
P2Y	129	132	|O
(	132	133	|O
4	133	134	|O
)	134	135	|O
,	135	136	|O
and	137	140	|O
P2Y	141	144	|O
(	144	145	|O
11	145	147	|O
)	147	148	|O
receptors	149	158	|O
,	158	159	|O
but	160	163	|O
not	164	167	|O
P2Y	168	171	|O
(	171	172	|O
6	172	173	|O
)	173	174	|O
receptors	175	184	|O
,	184	185	|O
was	186	189	|O
established	190	201	|O
using	202	207	|O
a	208	209	|O
ring	210	214	|O
-	214	215	|O
constrained	215	226	|O
methanocarba	227	239	|O
(	240	241	|O
a	241	242	|O
3.1.0	243	248	|O
-	248	249	|O
bicyclohexane	249	262	|O
)	262	263	|O
ring	264	268	|O
as	269	271	|O
a	272	273	|O
ribose	274	280	|O
substitute	281	291	|O
(	292	293	|O
Kim	293	296	|O
et	297	299	|O
al.	300	303	|O
J	304	305	|O
.	305	306	|O
Med.	307	311	|O
Chem.	312	317	|O
2002	318	322	|O
,	322	323	|O
45	324	326	|O
,	326	327	|O
208-218	328	335	|O
.	335	336	|O
)	336	337	|O
.	337	338	|O
We	339	341	|O
have	342	346	|O
now	347	350	|O
combined	351	359	|O
the	360	363	|O
ring	364	368	|O
-	368	369	|O
constrained	369	380	|O
(	381	382	|O
N	382	383	|O
)	383	384	|O
-	384	385	|O
methanocarba	385	397	|O
modification	398	410	|O
of	411	413	|O
adenine	414	421	|O
nucleotides	422	433	|O
with	434	438	|O
other	439	444	|O
functionalities	445	460	|O
known	461	466	|O
to	467	469	|O
enhance	470	477	|O
potency	478	485	|O
at	486	488	|O
P2	489	491	|O
receptors	492	501	|O
.	501	502	|O
The	503	506	|O
potency	507	514	|O
of	515	517	|O
the	518	521	|O
newly	522	527	|O
synthesized	528	539	|O
analogues	540	549	|O
was	550	553	|O
determined	554	564	|O
in	565	567	|O
the	568	571	|O
stimulation	572	583	|O
of	584	586	|O
phospholipase	587	600	|O
C	601	602	|O
through	603	610	|O
activation	611	621	|O
of	622	624	|O
turkey	625	631	|O
erythrocyte	632	643	|O
P2Y	644	647	|O
(	647	648	|O
1	648	649	|O
)	649	650	|O
or	651	653	|O
human	654	659	|O
P2Y	660	663	|O
(	663	664	|O
1	664	665	|O
)	665	666	|O
and	667	670	|O
P2Y	671	674	|O
(	674	675	|O
2	675	676	|O
)	676	677	|O
receptors	678	687	|O
stably	688	694	|O
expressed	695	704	|O
in	705	707	|O
astrocytoma	708	719	|O
cells	720	725	|O
.	725	726	|O
An	727	729	|O
(	730	731	|B-IUPAC
N	731	732	|I-IUPAC
)	732	733	|I-IUPAC
-	733	734	|I-IUPAC
methanocarba	734	746	|I-IUPAC
-	746	747	|I-IUPAC
2	747	748	|I-IUPAC
-	748	749	|I-IUPAC
methylthio	749	759	|I-IUPAC
-	759	760	|I-IUPAC
ADP	760	763	|I-IUPAC
analogue	764	772	|B-MODIFIER
displayed	773	782	|O
an	783	785	|O
EC	786	788	|O
(	788	789	|O
50	789	791	|O
)	791	792	|O
at	793	795	|O
the	796	799	|O
hP2Y	800	804	|O
(	804	805	|O
1	805	806	|O
)	806	807	|O
receptor	808	816	|O
of	817	819	|O
0.40	820	824	|O
nM	825	827	|O
and	828	831	|O
was	832	835	|O
55	836	838	|O
-	838	839	|O
fold	839	843	|O
more	844	848	|O
potent	849	855	|O
than	856	860	|O
the	861	864	|O
corresponding	865	878	|O
triphosphate	879	891	|O
and	892	895	|O
16	896	898	|O
-	898	899	|O
fold	899	903	|O
more	904	908	|O
potent	909	915	|O
than	916	920	|O
the	921	924	|O
riboside	925	933	|O
5'	934	936	|B-IUPAC
-	936	937	|I-IUPAC
diphosphate	937	948	|I-IUPAC
.	948	949	|O
2	950	951	|B-IUPAC
-	951	952	|I-IUPAC
Cl	952	954	|I-IUPAC
-	954	955	|I-IUPAC
(	955	956	|I-IUPAC
N	956	957	|I-IUPAC
)	957	958	|I-IUPAC
-	958	959	|I-IUPAC
methanocarba	959	971	|I-IUPAC
-	971	972	|I-IUPAC
ATP	972	975	|I-IUPAC
and	976	979	|O
its	980	983	|O
N	984	985	|O
(	985	986	|O
6	986	987	|O
)	987	988	|O
-	988	989	|O
Me	989	991	|O
analogue	992	1000	|O
were	1001	1005	|O
also	1006	1010	|O
highly	1011	1017	|O
selective	1018	1027	|O
,	1027	1028	|O
full	1029	1033	|O
agonists	1034	1042	|O
at	1043	1045	|O
P2Y	1046	1049	|O
(	1049	1050	|O
1	1050	1051	|O
)	1051	1052	|O
receptors	1053	1062	|O
.	1062	1063	|O
The	1064	1067	|O
(	1068	1069	|B-IUPAC
N	1069	1070	|I-IUPAC
)	1070	1071	|I-IUPAC
-	1071	1072	|I-IUPAC
methanocarba	1072	1084	|I-IUPAC
-	1084	1085	|I-IUPAC
2	1085	1086	|I-IUPAC
-	1086	1087	|I-IUPAC
methylthio	1087	1097	|I-IUPAC
and	1098	1101	|O
2	1102	1103	|B-IUPAC
-	1103	1104	|I-IUPAC
chloromonophosphate	1104	1123	|I-IUPAC
analogues	1124	1133	|B-MODIFIER
were	1134	1138	|O
full	1139	1143	|O
agonists	1144	1152	|O
exhibiting	1153	1163	|O
micromolar	1164	1174	|O
potency	1175	1182	|O
at	1183	1185	|O
P2Y	1186	1189	|O
(	1189	1190	|O
1	1190	1191	|O
)	1191	1192	|O
receptors	1193	1202	|O
,	1202	1203	|O
while	1204	1209	|O
the	1210	1213	|O
corresponding	1214	1227	|O
ribosides	1228	1237	|O
were	1238	1242	|O
inactive	1243	1251	|O
.	1251	1252	|O
Although	1253	1261	|O
beta	1262	1266	|B-IUPAC
,	1266	1267	|I-IUPAC
gamma	1267	1272	|I-IUPAC
-	1272	1273	|I-IUPAC
methylene	1273	1282	|I-IUPAC
-	1282	1283	|I-IUPAC
ATP	1283	1286	|I-IUPAC
was	1287	1290	|O
inactive	1291	1299	|O
at	1300	1302	|O
P2Y	1303	1306	|O
receptors	1307	1316	|O
,	1316	1317	|O
beta	1318	1322	|B-IUPAC
,	1322	1323	|I-IUPAC
gamma	1323	1328	|I-IUPAC
-	1328	1329	|I-IUPAC
methylene	1329	1338	|I-IUPAC
-	1338	1339	|I-IUPAC
(	1339	1340	|I-IUPAC
N	1340	1341	|I-IUPAC
)	1341	1342	|I-IUPAC
-	1342	1343	|I-IUPAC
methanocarba	1343	1355	|I-IUPAC
-	1355	1356	|I-IUPAC
ATP	1356	1359	|I-IUPAC
was	1360	1363	|O
a	1364	1365	|O
potent	1366	1372	|O
hP2Y	1373	1377	|O
(	1377	1378	|O
1	1378	1379	|O
)	1379	1380	|O
receptor	1381	1389	|O
agonist	1390	1397	|O
with	1398	1402	|O
an	1403	1405	|O
EC	1406	1408	|O
(	1408	1409	|O
50	1409	1411	|O
)	1411	1412	|O
of	1413	1415	|O
160	1416	1419	|O
nM	1420	1422	|O
and	1423	1426	|O
was	1427	1430	|O
selective	1431	1440	|O
versus	1441	1447	|O
hP2Y	1448	1452	|O
(	1452	1453	|O
2	1453	1454	|O
)	1454	1455	|O
and	1456	1459	|O
hP2Y	1460	1464	|O
(	1464	1465	|O
4	1465	1466	|O
)	1466	1467	|O
receptors	1468	1477	|O
.	1477	1478	|O
The	1479	1482	|O
rates	1483	1488	|O
of	1489	1491	|O
hydrolysis	1492	1502	|O
of	1503	1505	|O
Northern	1506	1514	|O
(	1515	1516	|O
N	1516	1517	|O
)	1517	1518	|O
and	1519	1522	|O
Southern	1523	1531	|O
(	1532	1533	|O
S	1533	1534	|O
)	1534	1535	|O
methanocarba	1536	1548	|O
analogues	1549	1558	|O
of	1559	1561	|O
AMP	1562	1565	|O
by	1566	1568	|O
rat	1569	1572	|O
5'	1573	1575	|O
-	1575	1576	|O
ectonucleotidase	1576	1592	|O
were	1593	1597	|O
negligible	1598	1608	|O
.	1608	1609	|O
The	1610	1613	|O
rates	1614	1619	|O
of	1620	1622	|O
hydrolysis	1623	1633	|O
of	1634	1636	|O
the	1637	1640	|O
corresponding	1641	1654	|O
triphosphates	1655	1668	|O
by	1669	1671	|O
recombinant	1672	1683	|O
rat	1684	1687	|O
NTPDase1	1688	1696	|O
and	1697	1700	|O
2	1701	1702	|O
were	1703	1707	|O
studied	1708	1715	|O
.	1715	1716	|O
Both	1717	1721	|O
isomers	1722	1729	|O
were	1730	1734	|O
hydrolyzed	1735	1745	|O
by	1746	1748	|O
NTPDase	1749	1756	|O
1	1757	1758	|O
at	1759	1761	|O
about	1762	1767	|O
half	1768	1772	|O
the	1773	1776	|O
rate	1777	1781	|O
of	1782	1784	|O
ATP	1785	1788	|O
hydrolysis	1789	1799	|O
.	1799	1800	|O
The	1801	1804	|O
(	1805	1806	|O
N	1806	1807	|O
)	1807	1808	|O
isomer	1809	1815	|O
was	1816	1819	|O
hardly	1820	1826	|O
hydrolyzed	1827	1837	|O
by	1838	1840	|O
NTPDase	1841	1848	|O
2	1849	1850	|O
,	1850	1851	|O
while	1852	1857	|O
the	1858	1861	|O
(	1862	1863	|O
S	1863	1864	|O
)	1864	1865	|O
isomer	1866	1872	|O
was	1873	1876	|O
hydrolyzed	1877	1887	|O
at	1888	1890	|O
one	1891	1894	|O
-	1894	1895	|O
third	1895	1900	|O
of	1901	1903	|O
the	1904	1907	|O
rate	1908	1912	|O
of	1913	1915	|O
ATP	1916	1919	|O
hydrolysis	1920	1930	|O
.	1930	1931	|O
This	1932	1936	|O
suggests	1937	1945	|O
that	1946	1950	|O
new	1951	1954	|O
,	1954	1955	|O
more	1956	1960	|O
stable	1961	1967	|O
and	1968	1971	|O
selective	1972	1981	|O
nucleotide	1982	1992	|O
agonists	1993	2001	|O
may	2002	2005	|O
be	2006	2008	|O
designed	2009	2017	|O
on	2018	2020	|O
the	2021	2024	|O
basis	2025	2030	|O
of	2031	2033	|O
the	2034	2037	|O
(	2038	2039	|O
N	2039	2040	|O
)	2040	2041	|O
-	2041	2042	|O
conformation	2042	2054	|O
,	2054	2055	|O
which	2056	2061	|O
greatly	2062	2069	|O
enhanced	2070	2078	|O
potency	2079	2086	|O
at	2087	2089	|O
P2Y	2090	2093	|O
(	2093	2094	|O
1	2094	2095	|O
)	2095	2096	|O
receptors	2097	2106	|O
.	2106	2107	|O

### abstracts4618.txt
The	0	3	|O
conformationally	4	20	|O
restricted	21	31	|O
,	31	32	|O
cyclic	33	39	|O
disulfide	40	49	|O
-	49	50	|O
containing	50	60	|O
delta	61	66	|O
opioid	67	73	|O
receptor	74	82	|O
selective	83	92	|O
enkephalin	93	103	|O
analogue	104	112	|O
[	113	114	|O
D	114	115	|O
-	115	116	|O
Pen2	116	120	|O
,	120	121	|O
D	121	122	|O
-	122	123	|O
Pen5	123	127	|O
]	127	128	|O
enkephalin	128	138	|O
(	139	140	|O
1	140	141	|O
,	141	142	|O
DPDPE	143	148	|O
)	148	149	|O
was	150	153	|O
systematically	154	168	|O
modified	169	177	|O
topographically	178	193	|O
by	194	196	|O
addition	197	205	|O
of	206	208	|O
a	209	210	|O
methyl	211	217	|B-IUPAC
group	218	223	|B-MODIFIER
at	224	226	|O
either	227	233	|O
the	234	237	|O
pro	238	241	|O
-	241	242	|O
S	242	243	|O
or	244	246	|O
pro	247	250	|O
-	250	251	|O
R	251	252	|O
position	253	261	|O
of	262	264	|O
the	265	268	|O
beta	269	273	|O
carbon	274	280	|O
of	281	283	|O
an	284	286	|O
L	287	288	|O
-	288	289	|O
Phe4	289	293	|O
or	294	296	|O
D	297	298	|O
-	298	299	|O
Phe4	299	303	|O
residue	304	311	|O
to	312	314	|O
give	315	319	|O
[	320	321	|O
(	321	322	|O
2S	322	324	|O
,	324	325	|O
3S	325	327	|O
)	327	328	|O
-	328	329	|O
beta	329	333	|O
-	333	334	|O
MePhe4	334	340	|O
]	340	341	|O
DPDPE	341	346	|O
(	347	348	|O
2	348	349	|O
)	349	350	|O
,	350	351	|O
[	352	353	|O
(	353	354	|O
2R	354	356	|O
,	356	357	|O
3R	357	359	|O
)	359	360	|O
-	360	361	|O
beta	361	365	|O
-	365	366	|O
MePhe4	366	372	|O
]	372	373	|O
DPDPE	373	378	|O
(	379	380	|O
3	380	381	|O
)	381	382	|O
,	382	383	|O
[	384	385	|O
(	385	386	|O
2S	386	388	|O
,	388	389	|O
3R	389	391	|O
)	391	392	|O
-	392	393	|O
beta	393	397	|O
-	397	398	|O
MePhe4	398	404	|O
]	404	405	|O
DPDPE	405	410	|O
(	411	412	|O
4	412	413	|O
)	413	414	|O
,	414	415	|O
and	416	419	|O
[	420	421	|O
(	421	422	|O
2R	422	424	|O
,	424	425	|O
3S	425	427	|O
)	427	428	|O
-	428	429	|O
beta	429	433	|O
-	433	434	|O
MePhe4	434	440	|O
]	440	441	|O
DPDPE	441	446	|O
(	447	448	|O
5	448	449	|O
)	449	450	|O
.	450	451	|O
The	452	455	|O
four	456	460	|O
corresponding	461	474	|O
isomers	475	482	|O
were	483	487	|O
prepared	488	496	|O
in	497	499	|O
which	500	505	|O
the	506	509	|O
beta	510	514	|B-IUPAC
-	514	515	|I-IUPAC
methylphenylalanine	515	534	|I-IUPAC
residue	535	542	|B-MODIFIER
was	543	546	|O
p	547	548	|O
-	548	549	|O
nitro	549	554	|O
substituted	555	566	|O
,	566	567	|O
that	568	572	|O
is	573	575	|O
with	576	580	|O
a	581	582	|O
beta	583	587	|B-IUPAC
-	587	588	|I-IUPAC
methyl	588	594	|I-IUPAC
-	594	595	|I-IUPAC
p	595	596	|I-IUPAC
-	596	597	|I-IUPAC
nitrophenylalanine	597	615	|I-IUPAC
(	616	617	|O
beta	617	621	|O
-	621	622	|O
Me	622	624	|O
-	624	625	|O
p	625	626	|O
-	626	627	|O
NO2Phe	627	633	|O
)	633	634	|O
residue	635	642	|O
,	642	643	|O
to	644	646	|O
give	647	651	|O
[	652	653	|O
(	653	654	|O
2S	654	656	|O
,	656	657	|O
3S	657	659	|O
)	659	660	|O
-	660	661	|O
beta	661	665	|O
-	665	666	|O
Me	666	668	|O
-	668	669	|O
p	669	670	|O
-	670	671	|O
NO2Phe4	671	678	|O
]	678	679	|O
DPDPE	679	684	|O
(	685	686	|O
6	686	687	|O
)	687	688	|O
,	688	689	|O
[	690	691	|O
(	691	692	|O
2R	692	694	|O
,	694	695	|O
3R	695	697	|O
)	697	698	|O
-	698	699	|O
beta	699	703	|O
-	703	704	|O
Me	704	706	|O
-	706	707	|O
p	707	708	|O
-	708	709	|O
NO2Phe4	709	716	|O
]	716	717	|O
DPDPE	717	722	|O
(	723	724	|O
7	724	725	|O
)	725	726	|O
,	726	727	|O
[	728	729	|O
(	729	730	|O
2S	730	732	|O
,	732	733	|O
3R	733	735	|O
)	735	736	|O
-	736	737	|O
beta	737	741	|O
-	741	742	|O
Me	742	744	|O
-	744	745	|O
p	745	746	|O
-	746	747	|O
NO2Phe4	747	754	|O
]	754	755	|O
DPDPE	756	761	|O
(	762	763	|O
8	763	764	|O
)	764	765	|O
,	765	766	|O
and	767	770	|O
[	771	772	|O
(	772	773	|O
2R	773	775	|O
,	775	776	|O
3S	776	778	|O
)	778	779	|O
-	779	780	|O
beta	780	784	|O
-	784	785	|O
Me	785	787	|O
-	787	788	|O
p	788	789	|O
-	789	790	|O
NO2Phe4	790	797	|O
]	797	798	|O
DPDPE	798	803	|O
(	804	805	|O
9	805	806	|O
)	806	807	|O
,	807	808	|O
respectively	809	821	|O
.	821	822	|O
The	823	826	|O
potency	827	834	|O
and	835	838	|O
selectivity	839	850	|O
(	851	852	|O
delta	852	857	|O
vs	858	860	|O
mu	861	863	|O
opioid	864	870	|O
receptor	871	879	|O
)	879	880	|O
were	881	885	|O
evaluated	886	895	|O
by	896	898	|O
radioreceptor	899	912	|O
binding	913	920	|O
assays	921	927	|O
in	928	930	|O
the	931	934	|O
rat	935	938	|O
brain	939	944	|O
using	945	950	|O
[	951	952	|O
3H	952	954	|O
]	954	955	|O
CTOP	955	959	|O
(	960	961	|O
mu	961	963	|O
ligand	964	970	|O
)	970	971	|O
and	972	975	|O
[	976	977	|O
3H	977	979	|O
]	979	980	|O
DPDPE	980	985	|O
(	986	987	|O
delta	987	992	|O
ligand	993	999	|O
)	999	1000	|O
and	1001	1004	|O
by	1005	1007	|O
bioassay	1008	1016	|O
with	1017	1021	|O
mouse	1022	1027	|O
vas	1028	1031	|O
deferens	1032	1040	|O
(	1041	1042	|O
MVD	1042	1045	|O
,	1045	1046	|O
delta	1047	1052	|O
receptor	1053	1061	|O
assay	1062	1067	|O
)	1067	1068	|O
and	1069	1072	|O
guinea	1073	1079	|O
pig	1080	1083	|O
ileum	1084	1089	|O
(	1090	1091	|O
GPI	1091	1094	|O
,	1094	1095	|O
mu	1096	1098	|O
receptor	1099	1107	|O
assay	1108	1113	|O
)	1113	1114	|O
.	1114	1115	|O
The	1116	1119	|O
eight	1120	1125	|O
analogues	1126	1135	|O
of	1136	1138	|O
DPDPE	1139	1144	|O
showed	1145	1151	|O
highly	1152	1158	|O
variable	1159	1167	|O
binding	1168	1175	|O
and	1176	1179	|O
bioassay	1180	1188	|O
activities	1189	1199	|O
particularly	1200	1212	|O
at	1213	1215	|O
the	1216	1219	|O
delta	1220	1225	|O
opioid	1226	1232	|O
receptor	1233	1241	|O
(	1242	1243	|O
4	1243	1244	|O
orders	1245	1251	|O
of	1252	1254	|O
magnitude	1255	1264	|O
)	1264	1265	|O
,	1265	1266	|O
but	1267	1270	|O
also	1271	1275	|O
at	1276	1278	|O
the	1279	1282	|O
mu	1283	1285	|O
opioid	1286	1292	|O
receptor	1293	1301	|O
,	1301	1302	|O
which	1303	1308	|O
led	1309	1312	|O
to	1313	1315	|O
large	1316	1321	|O
differences	1322	1333	|O
(	1334	1335	|O
3	1335	1336	|O
orders	1337	1343	|O
of	1344	1346	|O
magnitude	1347	1356	|O
)	1356	1357	|O
in	1358	1360	|O
receptor	1361	1369	|O
selectivity	1370	1381	|O
.	1381	1382	|O
For	1383	1386	|O
example	1387	1394	|O
,	1394	1395	|O
[	1396	1397	|O
(	1397	1398	|O
2S	1398	1400	|O
,	1400	1401	|O
3S	1401	1403	|O
)	1403	1404	|O
-	1404	1405	|O
beta	1405	1409	|O
-	1409	1410	|O
MePhe4	1410	1416	|O
]	1416	1417	|O
DPDPE	1417	1422	|O
(	1423	1424	|O
2	1424	1425	|O
)	1425	1426	|O
is	1427	1429	|O
1800	1430	1434	|O
-	1434	1435	|O
fold	1435	1439	|O
selective	1440	1449	|O
in	1450	1452	|O
binding	1453	1460	|O
to	1461	1463	|O
the	1464	1467	|O
delta	1468	1473	|O
vs	1474	1476	|O
mu	1477	1479	|O
receptor	1480	1488	|O
,	1488	1489	|O
making	1490	1496	|O
it	1497	1499	|O
one	1500	1503	|O
of	1504	1506	|O
the	1507	1510	|O
most	1511	1515	|O
selective	1516	1525	|O
delta	1526	1531	|O
opioid	1532	1538	|O
receptor	1539	1547	|O
ligands	1548	1555	|O
in	1556	1558	|O
the	1559	1562	|O
enkephalin	1563	1573	|O
series	1574	1580	|O
as	1581	1583	|O
assessed	1584	1592	|O
by	1593	1595	|O
the	1596	1599	|O
rat	1600	1603	|O
brain	1604	1609	|O
binding	1610	1617	|O
assay	1618	1623	|O
,	1623	1624	|O
whereas	1625	1632	|O
the	1633	1636	|O
corresponding	1637	1650	|O
(	1651	1652	|O
2R	1652	1654	|O
,	1654	1655	|O
3R	1655	1657	|O
)	1657	1658	|O
-	1658	1659	|O
beta	1659	1663	|O
-	1663	1664	|O
Me	1664	1666	|O
-	1666	1667	|O
p	1667	1668	|O
-	1668	1669	|O
NO2Phe	1669	1675	|O
-	1675	1676	|O
containing	1676	1686	|O
analogue	1687	1695	|O
9	1696	1697	|O
is	1698	1700	|O
only	1701	1705	|O
4.5	1706	1709	|O
-	1709	1710	|O
fold	1710	1714	|O
selective	1715	1724	|O
(	1725	1726	|O
nonselective	1726	1738	|O
)	1738	1739	|O
in	1740	1742	|O
this	1743	1747	|O
same	1748	1752	|O
assay	1753	1758	|O
.	1758	1759	|O
On	1760	1762	|O
the	1763	1766	|O
other	1767	1772	|O
hand	1773	1777	|O
,	1777	1778	|O
in	1779	1781	|O
the	1782	1785	|O
bioassay	1786	1794	|O
systems	1795	1802	|O
,	1802	1803	|O
[	1804	1805	|O
(	1805	1806	|O
2S	1806	1808	|O
,	1808	1809	|O
3S	1809	1811	|O
)	1811	1812	|O
-	1812	1813	|O
beta	1813	1817	|O
-	1817	1818	|O
Me	1818	1820	|O
-	1820	1821	|O
p	1821	1822	|O
-	1822	1823	|O
NO2Phe4	1823	1830	|O
]	1830	1831	|O
DPDPE	1831	1836	|O
(	1837	1838	|O
5	1838	1839	|O
)	1839	1840	|O
is	1841	1843	|O
more	1844	1848	|O
potent	1849	1855	|O
than	1856	1860	|O
DPDPE	1861	1866	|O
and	1867	1870	|O
8800	1871	1875	|O
-	1875	1876	|O
fold	1876	1880	|O
selective	1881	1890	|O
for	1891	1894	|O
the	1895	1898	|O
MVD	1899	1902	|O
(	1903	1904	|O
delta	1904	1909	|O
receptor	1910	1918	|O
)	1918	1919	|O
vs	1920	1922	|O
the	1923	1926	|O
GPI	1927	1930	|O
(	1931	1932	|O
mu	1932	1934	|O
receptor	1935	1943	|O
)	1943	1944	|O
,	1944	1945	|O
making	1946	1952	|O
it	1953	1955	|O
the	1956	1959	|O
most	1960	1964	|O
highly	1965	1971	|O
selective	1972	1981	|O
ligand	1982	1988	|O
in	1989	1991	|O
this	1992	1996	|O
series	1997	2003	|O
for	2004	2007	|O
the	2008	2011	|O
delta	2012	2017	|O
opioid	2018	2024	|O
receptor	2025	2033	|O
on	2034	2036	|O
the	2037	2040	|O
basis	2041	2046	|O
of	2047	2049	|O
these	2050	2055	|O
bioassays	2056	2065	|O
.	2065	2066	|O
In	2067	2069	|O
these	2070	2075	|O
assay	2076	2081	|O
systems	2082	2089	|O
,	2089	2090	|O
the	2091	2094	|O
(	2095	2096	|O
2R	2096	2098	|O
,	2098	2099	|O
3S	2099	2101	|O
)	2101	2102	|O
-	2102	2103	|O
beta	2103	2107	|O
-	2107	2108	|O
MePhe4	2108	2114	|O
-	2114	2115	|O
containing	2115	2125	|O
analogue	2126	2134	|O
5	2135	2136	|O
had	2137	2140	|O
very	2141	2145	|O
weak	2146	2150	|O
potency	2151	2158	|O
and	2159	2162	|O
virtually	2163	2172	|O
no	2173	2175	|O
receptor	2176	2184	|O
selectivity	2185	2196	|O
(	2197	2198	|O
4.4	2198	2201	|O
-	2201	2202	|O
fold	2202	2206	|O
)	2206	2207	|O
.	2207	2208	|O
These	2209	2214	|O
results	2215	2222	|O
demonstrate	2223	2234	|O
that	2235	2239	|O
topographical	2240	2253	|O
modification	2254	2266	|O
alone	2267	2272	|O
in	2273	2275	|O
a	2276	2277	|O
conformationally	2278	2294	|O
restricted	2295	2305	|O
peptide	2306	2313	|O
ligand	2314	2320	|O
can	2321	2324	|O
significantly	2325	2338	|O
modulate	2339	2347	|O
both	2348	2352	|O
potency	2353	2360	|O
and	2361	2364	|O
receptor	2365	2373	|O
selectivity	2374	2385	|O
of	2386	2388	|O
peptide	2389	2396	|O
ligands	2397	2404	|O
that	2405	2409	|O
have	2410	2414	|O
multiple	2415	2423	|O
sites	2424	2429	|O
of	2430	2432	|O
biological	2433	2443	|O
activity	2444	2452	|O
and	2453	2456	|O
suggest	2457	2464	|O
that	2465	2469	|O
this	2470	2474	|O
approach	2475	2483	|O
may	2484	2487	|O
have	2488	2492	|O
general	2493	2500	|O
application	2501	2512	|O
to	2513	2515	|O
peptide	2516	2523	|O
ligand	2524	2530	|O
design	2531	2537	|O
.	2537	2538	|O

### abstracts865.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
2	12	13	|B-MODIFIER
-	13	14	|I-MODIFIER
substituted	14	25	|I-MODIFIER
-	25	26	|O
1	26	27	|B-IUPAC
-	27	28	|I-IUPAC
[	28	29	|I-IUPAC
(	29	30	|I-IUPAC
biphenyl	30	38	|I-IUPAC
-	38	39	|I-IUPAC
4	39	40	|I-IUPAC
-	40	41	|I-IUPAC
yl	41	43	|I-IUPAC
)	43	44	|I-IUPAC
methyl	44	50	|I-IUPAC
]	50	51	|I-IUPAC
-	51	52	|I-IUPAC
1H	52	54	|I-IUPAC
-	54	55	|I-IUPAC
benzimidazole	55	68	|I-IUPAC
-	68	69	|I-IUPAC
7	69	70	|I-IUPAC
-	70	71	|I-IUPAC
carboxylic	72	82	|I-IUPAC
acids	83	88	|I-IUPAC
was	89	92	|O
prepared	93	101	|O
from	102	106	|O
the	107	110	|O
key	111	114	|O
intermediate	115	127	|O
3	128	129	|B-IUPAC
-	129	130	|I-IUPAC
amino	130	135	|I-IUPAC
-	135	136	|I-IUPAC
2	136	137	|I-IUPAC
-	137	138	|I-IUPAC
[	138	139	|I-IUPAC
[	139	140	|I-IUPAC
(	140	141	|I-IUPAC
biphenyl	141	149	|I-IUPAC
-	149	150	|I-IUPAC
4	150	151	|I-IUPAC
-	151	152	|I-IUPAC
yl	153	155	|I-IUPAC
)	155	156	|I-IUPAC
methyl	156	162	|I-IUPAC
]	162	163	|I-IUPAC
amino	163	168	|I-IUPAC
]	168	169	|I-IUPAC
benzoate	169	177	|I-IUPAC
(	178	179	|O
6a	179	181	|O
-	181	182	|O
c	182	183	|O
)	183	184	|O
in	185	187	|O
order	188	193	|O
to	194	196	|O
clarify	197	204	|O
the	205	208	|O
structure	209	218	|O
-	218	219	|O
activity	219	227	|O
relationships	228	241	|O
of	242	244	|O
various	245	252	|O
analogues	253	262	|O
of	263	265	|O
2	266	267	|B-IUPAC
-	267	268	|I-IUPAC
butyl	268	273	|I-IUPAC
-	273	274	|I-IUPAC
1	274	275	|I-IUPAC
-	275	276	|I-IUPAC
[	276	277	|I-IUPAC
[	277	278	|I-IUPAC
2'	278	280	|I-IUPAC
-	280	281	|I-IUPAC
(	281	282	|I-IUPAC
1H	282	284	|I-IUPAC
-	284	285	|I-IUPAC
tetrazol	285	293	|I-IUPAC
-	293	294	|I-IUPAC
5	294	295	|I-IUPAC
-	295	296	|I-IUPAC
yl	296	298	|I-IUPAC
)	298	299	|I-IUPAC
biphenyl	299	307	|I-IUPAC
-	307	308	|I-IUPAC
4	308	309	|I-IUPAC
-	309	310	|I-IUPAC
yl	310	312	|I-IUPAC
]	312	313	|I-IUPAC
methyl	313	319	|I-IUPAC
]	319	320	|I-IUPAC
-	320	321	|I-IUPAC
1H	321	323	|I-IUPAC
-	323	324	|I-IUPAC
ben	324	327	|I-IUPAC
zimidazole	328	338	|I-IUPAC
-	338	339	|I-IUPAC
7	340	341	|I-IUPAC
-	341	342	|I-IUPAC
carboxylic	342	352	|I-IUPAC
acid	353	357	|I-IUPAC
(	358	359	|O
CV	359	361	|O
-	361	362	|O
11194	362	367	|O
)	367	368	|O
,	368	369	|O
a	370	371	|O
potent	372	378	|O
and	379	382	|O
long	383	387	|O
acting	388	394	|O
angiotensin	395	406	|O
II	407	409	|O
(	410	411	|O
AII	411	414	|O
)	414	415	|O
receptor	416	424	|O
antagonist	425	435	|O
.	435	436	|O
The	437	440	|O
AII	441	444	|O
antagonistic	445	457	|O
activity	458	466	|O
of	467	469	|O
the	470	473	|O
benzimidazoles	474	488	|O
was	489	492	|O
investigated	493	505	|O
by	506	508	|O
in	509	511	|O
vitro	512	517	|O
assays	518	524	|O
,	524	525	|O
which	526	531	|O
included	532	540	|O
an	541	543	|O
AII	544	547	|O
receptor	548	556	|O
binding	557	564	|O
assay	565	570	|O
and	571	574	|O
AII	575	578	|O
-	578	579	|O
induced	579	586	|O
vasocontraction	587	602	|O
assay	603	608	|O
,	608	609	|O
as	610	612	|O
well	613	617	|O
as	618	620	|O
by	621	623	|O
in	624	626	|O
vivo	627	631	|O
assays	632	638	|O
such	639	643	|O
as	644	646	|O
an	647	649	|O
AII	650	653	|O
-	653	654	|O
induced	654	661	|O
pressor	662	669	|O
response	670	678	|O
in	679	681	|O
rats	682	686	|O
.	686	687	|O
Most	688	692	|O
of	693	695	|O
the	696	699	|O
benzimidazoles	700	714	|O
showed	715	721	|O
high	722	726	|O
affinity	727	735	|O
for	736	739	|O
the	740	743	|O
AII	744	747	|O
receptor	748	756	|O
(	757	758	|O
IC50	758	762	|O
value	763	768	|O
,	768	769	|O
10	770	772	|O
(	772	773	|O
-	773	774	|O
6	774	775	|O
)	775	776	|O
-	776	777	|O
10	777	779	|O
(	779	780	|O
-	780	781	|O
7	781	782	|O
)	782	783	|O
M	784	785	|O
)	785	786	|O
and	787	790	|O
inhibited	791	800	|O
the	801	804	|O
AII	805	808	|O
-	808	809	|O
induced	809	816	|O
pressor	817	824	|O
response	825	833	|O
at	834	836	|O
1	837	838	|O
or	839	841	|O
3	842	843	|O
mg	844	846	|O
/	846	847	|O
kg	847	849	|O
po	850	852	|O
,	852	853	|O
and	854	857	|O
the	858	861	|O
effects	862	869	|O
were	870	874	|O
more	875	879	|O
potent	880	886	|O
than	887	891	|O
those	892	897	|O
of	898	900	|O
CV	901	903	|O
-	903	904	|O
11194	904	909	|O
and	910	913	|O
DuP	914	917	|O
753	918	921	|O
.	921	922	|O
The	923	926	|O
structure	927	936	|O
-	936	937	|O
activity	937	945	|O
relationship	946	958	|O
studies	959	966	|O
on	967	969	|O
the	970	973	|O
binding	974	981	|O
affinity	982	990	|O
and	991	994	|O
the	995	998	|O
inhibition	999	1009	|O
of	1010	1012	|O
AII	1013	1016	|O
-	1016	1017	|O
induced	1017	1024	|O
pressor	1025	1032	|O
response	1033	1041	|O
suggested	1042	1051	|O
that	1052	1056	|O
straight	1057	1065	|O
chains	1066	1072	|O
of	1073	1075	|O
a	1076	1077	|O
certain	1078	1085	|O
length	1086	1092	|O
(	1093	1094	|O
e.g.	1094	1098	|O
,	1098	1099	|O
ethoxy	1100	1106	|O
groups	1107	1113	|O
,	1113	1114	|O
ethyl	1115	1120	|O
groups	1121	1127	|O
)	1127	1128	|O
were	1129	1133	|O
the	1134	1137	|O
best	1138	1142	|O
as	1143	1145	|O
substituents	1146	1158	|O
at	1159	1161	|O
the	1162	1165	|O
2	1166	1167	|O
-	1167	1168	|O
position	1168	1176	|O
and	1177	1180	|O
that	1181	1185	|O
their	1186	1191	|O
steric	1192	1198	|O
factors	1199	1206	|O
,	1206	1207	|O
lipophilicity	1208	1221	|O
,	1221	1222	|O
and	1223	1226	|O
electronic	1227	1237	|O
effects	1238	1245	|O
affected	1246	1254	|O
the	1255	1258	|O
potency	1259	1266	|O
of	1267	1269	|O
the	1270	1273	|O
AII	1274	1277	|O
antagonistic	1278	1290	|O
action	1291	1297	|O
.	1297	1298	|O
Both	1299	1303	|O
a	1304	1305	|O
carboxyl	1306	1314	|O
group	1315	1320	|O
at	1321	1323	|O
the	1324	1327	|O
7	1328	1329	|O
-	1329	1330	|O
position	1330	1338	|O
and	1339	1342	|O
a	1343	1344	|O
tetrazole	1345	1354	|O
ring	1355	1359	|O
at	1360	1362	|O
the	1363	1366	|O
2'	1367	1369	|O
-	1369	1370	|O
position	1370	1378	|O
were	1379	1383	|O
particularly	1384	1396	|O
important	1397	1406	|O
for	1407	1410	|O
potent	1411	1417	|O
and	1418	1421	|O
orally	1422	1428	|O
active	1429	1435	|O
AII	1436	1439	|O
antagonistic	1440	1452	|O
activity	1453	1461	|O
and	1462	1465	|O
a	1466	1467	|O
long	1468	1472	|O
-	1472	1473	|O
acting	1473	1479	|O
hypotensive	1480	1491	|O
effect	1492	1498	|O
.	1498	1499	|O
The	1500	1503	|O
representative	1504	1518	|O
compound	1519	1527	|O
,	1527	1528	|O
2	1529	1530	|B-IUPAC
-	1530	1531	|I-IUPAC
ethoxy	1531	1537	|I-IUPAC
-	1537	1538	|I-IUPAC
1	1538	1539	|I-IUPAC
-	1539	1540	|I-IUPAC
[	1540	1541	|I-IUPAC
[	1541	1542	|I-IUPAC
2'	1542	1544	|I-IUPAC
-	1544	1545	|I-IUPAC
(	1545	1546	|I-IUPAC
1H	1546	1548	|I-IUPAC
-	1548	1549	|I-IUPAC
tetrazol	1549	1557	|I-IUPAC
-	1557	1558	|I-IUPAC
5	1558	1559	|I-IUPAC
-	1559	1560	|I-IUPAC
yl	1560	1562	|I-IUPAC
)	1562	1563	|I-IUPAC
biphenyl	1563	1571	|I-IUPAC
-	1571	1572	|I-IUPAC
4	1572	1573	|I-IUPAC
-	1573	1574	|I-IUPAC
yl	1574	1576	|I-IUPAC
]	1576	1577	|I-IUPAC
methyl	1577	1583	|I-IUPAC
]	1583	1584	|I-IUPAC
-	1584	1585	|I-IUPAC
1H	1585	1587	|I-IUPAC
-	1587	1588	|I-IUPAC
benzimidazole	1589	1602	|I-IUPAC
-	1602	1603	|I-IUPAC
7	1603	1604	|I-IUPAC
-	1604	1605	|I-IUPAC
carboxylic	1605	1615	|I-IUPAC
acid	1616	1620	|I-IUPAC
(	1621	1622	|O
26b	1622	1625	|O
,	1625	1626	|O
CV	1627	1629	|O
-	1629	1630	|O
11974	1630	1635	|O
)	1635	1636	|O
,	1636	1637	|O
inhibited	1638	1647	|O
the	1648	1651	|O
specific	1652	1660	|O
binding	1661	1668	|O
of	1669	1671	|O
[	1672	1673	|O
125I	1673	1677	|O
]	1677	1678	|O
AII	1678	1681	|O
to	1682	1684	|O
bovine	1685	1691	|O
adrenal	1692	1699	|O
cortical	1700	1708	|O
membrane	1709	1717	|O
with	1718	1722	|O
an	1723	1725	|O
IC50	1726	1730	|O
value	1731	1736	|O
of	1737	1739	|O
1.1	1740	1743	|O
x	1744	1745	|O
10	1746	1748	|O
(	1748	1749	|O
-	1749	1750	|O
7	1750	1751	|O
)	1751	1752	|O
M	1753	1754	|O
.	1754	1755	|O
The	1756	1759	|O
AII	1760	1763	|O
-	1763	1764	|O
induced	1764	1771	|O
contraction	1772	1783	|O
of	1784	1786	|O
rabbit	1787	1793	|O
aortic	1794	1800	|O
strips	1801	1807	|O
was	1808	1811	|O
antagonized	1812	1823	|O
by	1824	1826	|O
CV	1827	1829	|O
-	1829	1830	|O
11974	1830	1835	|O
(	1836	1837	|O
IC50	1837	1841	|O
value	1842	1847	|O
,	1847	1848	|O
3.0	1849	1852	|O
x	1853	1854	|O
10	1855	1857	|O
(	1857	1858	|O
-	1858	1859	|O
10	1859	1861	|O
)	1861	1862	|O
M	1863	1864	|O
)	1864	1865	|O
.	1865	1866	|O
Oral	1867	1871	|O
administration	1872	1886	|O
of	1887	1889	|O
CV	1890	1892	|O
-	1892	1893	|O
11974	1893	1898	|O
to	1899	1901	|O
conscious	1902	1911	|O
normotensive	1912	1924	|O
rats	1925	1929	|O
at	1930	1932	|O
1	1933	1934	|O
mg	1935	1937	|O
/	1937	1938	|O
kg	1938	1940	|O
resulted	1941	1949	|O
in	1950	1952	|O
long	1953	1957	|O
-	1957	1958	|O
lasting	1958	1965	|O
inhibition	1966	1976	|O
of	1977	1979	|O
the	1980	1983	|O
AII	1984	1987	|O
-	1987	1988	|O
induced	1988	1995	|O
pressor	1996	2003	|O
response	2004	2012	|O
.	2012	2013	|O
CV	2014	2016	|O
-	2016	2017	|O
11974	2017	2022	|O
at	2023	2025	|O
0.1-1	2026	2031	|O
mg	2032	2034	|O
/	2034	2035	|O
kg	2035	2037	|O
iv	2038	2040	|O
reduced	2041	2048	|O
blood	2049	2054	|O
pressure	2055	2063	|O
dose	2064	2068	|O
-	2068	2069	|O
dependently	2069	2080	|O
in	2081	2083	|O
spontaneously	2084	2097	|O
hypertensive	2098	2110	|O
rats	2111	2115	|O
.	2115	2116	|O

### abstracts3384.txt
3	0	1	|O
-	1	2	|O
Deoxy	2	7	|O
-	7	8	|O
2,5	8	11	|O
-	11	12	|O
di	12	14	|O
-	14	15	|O
O	15	16	|O
-	16	17	|O
p	17	18	|O
-	18	19	|O
nitrobenzoyl	19	31	|O
-	31	32	|O
alpha	32	37	|O
-	37	38	|O
D	38	39	|O
-	39	40	|O
threo	40	45	|O
-	45	46	|O
entofuranosyl	46	59	|O
bromide	60	67	|O
(	68	69	|O
1	69	70	|O
)	70	71	|O
reacted	72	79	|O
with	80	84	|O
mercuric	85	93	|O
cyanide	94	101	|O
to	102	104	|O
give	105	109	|O
2,5	110	113	|B-IUPAC
-	113	114	|I-IUPAC
anhydro	114	121	|I-IUPAC
-	121	122	|I-IUPAC
4	122	123	|I-IUPAC
-	123	124	|I-IUPAC
deoxy	124	129	|I-IUPAC
-	129	130	|I-IUPAC
D	130	131	|I-IUPAC
-	131	132	|I-IUPAC
lyxo	132	136	|I-IUPAC
-	136	137	|I-IUPAC
hexononitrile	137	150	|I-IUPAC
(	151	152	|O
2	152	153	|O
)	153	154	|O
which	155	160	|O
upon	161	165	|O
acid	166	170	|O
hydrolysis	171	181	|O
of	182	184	|O
the	185	188	|O
CN	189	191	|O
group	192	197	|O
gave	198	202	|O
acid	203	207	|O
3	208	209	|O
.	209	210	|O
Saponification	211	225	|O
of	226	228	|O
the	229	232	|O
protecting	233	243	|O
groups	244	250	|O
gave	251	255	|O
2,5	256	259	|B-IUPAC
-	259	260	|I-IUPAC
anhydro	260	267	|I-IUPAC
-	267	268	|I-IUPAC
4	268	269	|I-IUPAC
-	269	270	|I-IUPAC
deoxy	270	275	|I-IUPAC
-	275	276	|I-IUPAC
D	276	277	|I-IUPAC
-	277	278	|I-IUPAC
lyxo	278	282	|I-IUPAC
-	282	283	|I-IUPAC
hexonic	283	290	|I-IUPAC
acid	291	295	|I-IUPAC
(	296	297	|O
4	297	298	|O
)	298	299	|O
which	300	305	|O
reacted	306	313	|O
with	314	318	|O
4,5,6	319	324	|B-IUPAC
-	324	325	|I-IUPAC
triaminopyrimidine	325	343	|I-IUPAC
forming	344	351	|O
an	352	354	|O
amide	355	360	|O
(	361	362	|O
5	362	363	|O
)	363	364	|O
that	365	369	|O
was	370	373	|O
pyrolized	374	383	|O
to	384	386	|O
give	387	391	|O
8	392	393	|B-IUPAC
-	393	394	|I-IUPAC
(	394	395	|I-IUPAC
3'	395	397	|I-IUPAC
-	397	398	|I-IUPAC
deoxy	398	403	|I-IUPAC
-	403	404	|I-IUPAC
alpha	404	409	|I-IUPAC
-	409	410	|I-IUPAC
D	410	411	|I-IUPAC
-	411	412	|I-IUPAC
threo	412	417	|I-IUPAC
-	417	418	|I-IUPAC
pentofuranosyl	418	432	|I-IUPAC
)	432	433	|I-IUPAC
adenine	434	441	|I-IUPAC
(	442	443	|O
6	443	444	|O
)	444	445	|O
.	445	446	|O
Reaction	447	455	|O
of	456	458	|O
bromide	459	466	|O
1	467	468	|O
with	469	473	|O
6	474	475	|B-IUPAC
-	475	476	|I-IUPAC
(	476	477	|I-IUPAC
benzamido	477	486	|I-IUPAC
)	486	487	|I-IUPAC
chloromercuriopurine	488	508	|I-IUPAC
followed	509	517	|O
by	518	520	|O
saponification	521	535	|O
yielded	536	543	|O
9	544	545	|B-IUPAC
-	545	546	|I-IUPAC
(	546	547	|I-IUPAC
3'	547	549	|I-IUPAC
-	549	550	|I-IUPAC
deoxy	550	555	|I-IUPAC
-	555	556	|I-IUPAC
alpha	556	561	|I-IUPAC
-	561	562	|I-IUPAC
D	562	563	|I-IUPAC
-	563	564	|I-IUPAC
threo	564	569	|I-IUPAC
-	569	570	|I-IUPAC
pentofuranosyl	570	584	|I-IUPAC
)	584	585	|I-IUPAC
adenine	585	592	|I-IUPAC
(	592	593	|O
8	593	594	|O
)	594	595	|O
.	595	596	|O
8	597	598	|B-IUPAC
-	598	599	|I-IUPAC
(	599	600	|I-IUPAC
beta	600	604	|I-IUPAC
-	604	605	|I-IUPAC
D	605	606	|I-IUPAC
-	606	607	|I-IUPAC
Ribofuranosyl	607	620	|I-IUPAC
)	620	621	|I-IUPAC
adenine	621	628	|I-IUPAC
,	628	629	|O
8	630	631	|B-IUPAC
-	631	632	|I-IUPAC
(	632	633	|I-IUPAC
beta	633	637	|I-IUPAC
-	637	638	|I-IUPAC
D	638	639	|I-IUPAC
-	639	640	|I-IUPAC
arabinofuranosyl	640	656	|I-IUPAC
)	656	657	|I-IUPAC
adenine	657	664	|I-IUPAC
,	664	665	|O
and	666	669	|O
8	670	671	|B-IUPAC
-	671	672	|I-IUPAC
(	672	673	|I-IUPAC
3'	673	675	|I-IUPAC
-	675	676	|I-IUPAC
deoxy	676	681	|I-IUPAC
-	681	682	|I-IUPAC
beta	682	686	|I-IUPAC
-	686	687	|I-IUPAC
D	687	688	|I-IUPAC
-	688	689	|I-IUPAC
erythro	689	696	|I-IUPAC
-	696	697	|I-IUPAC
pentofuranosyl	697	711	|I-IUPAC
)	711	712	|I-IUPAC
adenine	712	719	|I-IUPAC
,	719	720	|O
as	721	723	|O
well	724	728	|O
as	729	731	|O
compound	732	740	|O
6	741	742	|O
,	742	743	|O
showed	744	750	|O
no	751	753	|O
antimalarial	754	766	|O
activity	767	775	|O
.	775	776	|O

### abstracts1673.txt
The	0	3	|O
effect	4	10	|O
of	11	13	|O
substitution	14	26	|O
in	27	29	|O
the	30	33	|O
acyclic	34	41	|O
structure	42	51	|O
of	52	54	|O
1	55	56	|B-IUPAC
-	56	57	|I-IUPAC
[	57	58	|I-IUPAC
(	58	59	|I-IUPAC
2	59	60	|I-IUPAC
-	60	61	|I-IUPAC
hydroxyethoxy	61	74	|I-IUPAC
)	74	75	|I-IUPAC
methyl	75	81	|I-IUPAC
]	81	82	|I-IUPAC
-	82	83	|I-IUPAC
6	83	84	|I-IUPAC
-	84	85	|I-IUPAC
(	85	86	|I-IUPAC
phenylthio	86	96	|I-IUPAC
)	96	97	|I-IUPAC
-	97	98	|I-IUPAC
thymine	98	105	|I-IUPAC
(	106	107	|O
HEPT	107	111	|O
)	111	112	|O
on	113	115	|O
anti	116	120	|O
-	120	121	|O
HIV	121	124	|O
-	124	125	|O
1	125	126	|O
activity	127	135	|O
was	136	139	|O
investigated	140	152	|O
by	153	155	|O
synthesizing	156	168	|O
a	169	170	|O
series	171	177	|O
of	178	180	|O
deoxy	181	186	|B-IUPAC
analogs	187	194	|B-MODIFIER
and	195	198	|O
related	199	206	|O
compounds	207	216	|O
.	216	217	|O
Preparation	218	229	|O
of	230	232	|O
1	233	234	|B-IUPAC
-	234	235	|I-IUPAC
[	235	236	|I-IUPAC
(	236	237	|I-IUPAC
2	237	238	|I-IUPAC
-	238	239	|I-IUPAC
alkyloxyethoxy	239	253	|I-IUPAC
)	253	254	|I-IUPAC
methyl	254	260	|I-IUPAC
]	260	261	|I-IUPAC
-	261	262	|I-IUPAC
6	262	263	|I-IUPAC
-	263	264	|I-IUPAC
(	265	266	|I-IUPAC
phenylthio	266	276	|I-IUPAC
)	276	277	|I-IUPAC
thymine	277	284	|I-IUPAC
(	285	286	|O
2-4	286	289	|O
)	289	290	|O
derivatives	291	302	|B-MODIFIER
was	303	306	|O
carried	307	314	|O
out	315	318	|O
based	319	324	|O
on	325	327	|O
alkylation	328	338	|O
of	339	341	|O
HEPT	342	346	|O
with	347	351	|O
primary	352	359	|O
alkyl	360	365	|O
halides	366	373	|O
.	373	374	|O
Preparation	375	386	|O
of	387	389	|O
the	390	393	|O
1	394	395	|B-IUPAC
-	395	396	|I-IUPAC
[	396	397	|I-IUPAC
(	397	398	|I-IUPAC
alkyloxy	398	406	|I-IUPAC
)	406	407	|I-IUPAC
methyl	407	413	|I-IUPAC
]	413	414	|I-IUPAC
-	414	415	|I-IUPAC
6	415	416	|I-IUPAC
-	416	417	|I-IUPAC
(	417	418	|I-IUPAC
phenylthio	418	428	|I-IUPAC
)	428	429	|I-IUPAC
thymine	429	436	|I-IUPAC
(	437	438	|O
26-31	438	443	|O
)	443	444	|O
and	445	448	|O
1	449	450	|B-IUPAC
-	450	451	|I-IUPAC
[	451	452	|I-IUPAC
(	452	453	|I-IUPAC
alkyloxy	453	461	|I-IUPAC
)	461	462	|I-IUPAC
methyl	462	468	|I-IUPAC
]	468	469	|I-IUPAC
-	469	470	|I-IUPAC
6	470	471	|I-IUPAC
-	471	472	|I-IUPAC
(	472	473	|I-IUPAC
arylthio	473	481	|I-IUPAC
)	481	482	|I-IUPAC
-	482	483	|I-IUPAC
2	483	484	|I-IUPAC
-	484	485	|I-IUPAC
thiouracil	485	495	|I-IUPAC
(	496	497	|O
32-45	497	502	|O
)	502	503	|O
derivatives	504	515	|B-MODIFIER
was	516	519	|O
carried	520	527	|O
out	528	531	|O
on	532	534	|O
the	535	538	|O
basis	539	544	|O
of	545	547	|O
LDA	548	551	|O
lithiation	552	562	|O
of	563	565	|O
1	566	567	|B-IUPAC
-	567	568	|I-IUPAC
[	568	569	|I-IUPAC
(	569	570	|I-IUPAC
alkyloxy	570	578	|I-IUPAC
)	578	579	|I-IUPAC
-	579	580	|I-IUPAC
methyl	580	586	|I-IUPAC
]	586	587	|I-IUPAC
thymine	587	594	|I-IUPAC
(	595	596	|O
9-14	596	600	|O
)	600	601	|O
and	602	605	|O
1	606	607	|B-IUPAC
-	607	608	|I-IUPAC
[	608	609	|I-IUPAC
(	609	610	|I-IUPAC
alkyloxy	610	618	|I-IUPAC
)	618	619	|I-IUPAC
methyl	619	625	|I-IUPAC
]	625	626	|I-IUPAC
-	626	627	|I-IUPAC
2	627	628	|I-IUPAC
-	628	629	|I-IUPAC
thiouracil	629	639	|I-IUPAC
(	640	641	|O
15-25	641	646	|O
)	646	647	|O
followed	648	656	|O
by	657	659	|O
reaction	660	668	|O
with	669	673	|O
diaryl	674	680	|O
disulfides	681	691	|O
.	691	692	|O
The	693	696	|O
oxidative	697	706	|O
hydrolysis	707	717	|O
of	718	720	|O
the	721	724	|O
2	725	726	|B-IUPAC
-	726	727	|I-IUPAC
thiouracil	727	737	|I-IUPAC
derivatives	738	749	|B-MODIFIER
gave	750	754	|O
1	755	756	|B-IUPAC
-	756	757	|I-IUPAC
[	757	758	|I-IUPAC
(	758	759	|I-IUPAC
alkyloxy	759	767	|I-IUPAC
)	767	768	|I-IUPAC
methyl	768	774	|I-IUPAC
]	774	775	|I-IUPAC
-	775	776	|I-IUPAC
6	776	777	|I-IUPAC
-	777	778	|I-IUPAC
(	778	779	|I-IUPAC
arylthio	779	787	|I-IUPAC
)	787	788	|I-IUPAC
uracil	788	794	|I-IUPAC
derivatives	795	806	|B-MODIFIER
(	807	808	|O
46-57	808	813	|O
)	813	814	|O
.	814	815	|O
1	816	817	|B-IUPAC
-	817	818	|I-IUPAC
Alkyl	818	823	|I-IUPAC
-	823	824	|I-IUPAC
6	824	825	|I-IUPAC
-	825	826	|I-IUPAC
(	826	827	|I-IUPAC
phenylthio	827	837	|I-IUPAC
)	837	838	|I-IUPAC
thymine	838	845	|I-IUPAC
(	846	847	|O
59-61	847	852	|O
)	852	853	|O
derivatives	854	865	|B-MODIFIER
were	866	870	|O
prepared	871	879	|O
on	880	882	|O
the	883	886	|O
basis	887	892	|O
of	893	895	|O
alkylation	896	906	|O
of	907	909	|O
6	910	911	|B-IUPAC
-	911	912	|I-IUPAC
(	912	913	|I-IUPAC
phenylthio	913	923	|I-IUPAC
)	923	924	|I-IUPAC
thymine	924	931	|I-IUPAC
(	932	933	|O
58	933	935	|O
)	935	936	|O
.	936	937	|O
Methylation	938	949	|O
of	950	952	|O
the	953	956	|O
hydroxyl	957	965	|B-IUPAC
group	966	971	|B-MODIFIER
of	972	974	|O
HEPT	975	979	|O
did	980	983	|O
not	984	987	|O
affect	988	994	|O
the	995	998	|O
anti	999	1003	|O
-	1003	1004	|O
HIV	1004	1007	|O
-	1007	1008	|O
1	1008	1009	|O
activity	1010	1018	|O
of	1019	1021	|O
HEPT	1022	1026	|O
.	1026	1027	|O
Substitution	1028	1040	|O
of	1041	1043	|O
the	1044	1047	|O
1	1048	1049	|B-IUPAC
-	1049	1050	|I-IUPAC
(	1050	1051	|I-IUPAC
2	1051	1052	|I-IUPAC
-	1052	1053	|I-IUPAC
hydroxyethoxy	1053	1066	|I-IUPAC
)	1066	1067	|I-IUPAC
methyl	1067	1073	|I-IUPAC
group	1074	1079	|B-MODIFIER
by	1080	1082	|O
ethyl	1083	1088	|B-IUPAC
,	1088	1089	|O
butyl	1090	1095	|B-IUPAC
,	1095	1096	|O
methoxymethyl	1097	1110	|B-IUPAC
,	1110	1111	|O
(	1112	1113	|B-IUPAC
propyloxy	1113	1122	|I-IUPAC
)	1122	1123	|I-IUPAC
methyl	1123	1129	|I-IUPAC
,	1129	1130	|O
and	1131	1134	|O
(	1135	1136	|B-IUPAC
butyloxy	1136	1144	|I-IUPAC
)	1144	1145	|I-IUPAC
-	1145	1146	|I-IUPAC
methyl	1146	1152	|I-IUPAC
groups	1153	1159	|B-MODIFIER
somewhat	1160	1168	|O
improved	1169	1177	|O
the	1178	1181	|O
original	1182	1190	|O
anti	1191	1195	|O
-	1195	1196	|O
HIV	1196	1199	|O
-	1199	1200	|O
1	1200	1201	|O
activity	1202	1210	|O
of	1211	1213	|O
HEPT	1214	1218	|O
.	1218	1219	|O
Substitution	1220	1232	|O
with	1233	1237	|O
ethoxymethyl	1238	1250	|B-IUPAC
and	1251	1254	|O
(	1255	1256	|B-IUPAC
benzyloxy	1256	1265	|I-IUPAC
)	1265	1266	|I-IUPAC
methyl	1266	1272	|I-IUPAC
groups	1273	1279	|B-MODIFIER
further	1280	1287	|O
potentiated	1288	1299	|O
the	1300	1303	|O
activity	1304	1312	|O
[	1313	1314	|O
EC50	1314	1318	|O
:	1318	1319	|O
1	1320	1321	|B-IUPAC
-	1321	1322	|I-IUPAC
(	1322	1323	|I-IUPAC
ethoxy	1323	1329	|I-IUPAC
-	1329	1330	|I-IUPAC
methyl	1330	1336	|I-IUPAC
)	1336	1337	|I-IUPAC
-	1337	1338	|I-IUPAC
6	1338	1339	|I-IUPAC
-	1339	1340	|I-IUPAC
(	1340	1341	|I-IUPAC
phenylthio	1341	1351	|I-IUPAC
)	1351	1352	|I-IUPAC
thymine	1352	1359	|I-IUPAC
(	1360	1361	|O
27	1361	1363	|O
)	1363	1364	|O
,	1364	1365	|O
0.33	1366	1370	|O
microM	1371	1377	|O
;	1377	1378	|O
1	1379	1380	|B-IUPAC
-	1380	1381	|I-IUPAC
[	1381	1382	|I-IUPAC
(	1382	1383	|I-IUPAC
benzyloxy	1383	1392	|I-IUPAC
)	1392	1393	|I-IUPAC
methyl	1393	1399	|I-IUPAC
]	1399	1400	|I-IUPAC
-	1400	1401	|I-IUPAC
6	1401	1402	|I-IUPAC
-	1402	1403	|I-IUPAC
(	1403	1404	|I-IUPAC
phenylthio	1404	1414	|I-IUPAC
)	1414	1415	|I-IUPAC
thymine	1415	1422	|I-IUPAC
(	1423	1424	|O
31	1424	1426	|O
)	1426	1427	|O
,	1427	1428	|O
0.088	1429	1434	|O
microM	1435	1441	|O
]	1441	1442	|O
.	1442	1443	|O
When	1444	1448	|O
the	1449	1452	|O
5	1453	1454	|B-IUPAC
-	1454	1455	|I-IUPAC
methyl	1455	1461	|I-IUPAC
group	1462	1467	|B-MODIFIER
of	1468	1470	|O
27	1471	1473	|O
and	1474	1477	|O
31	1478	1480	|O
was	1481	1484	|O
replaced	1485	1493	|O
by	1494	1496	|O
an	1497	1499	|O
ethyl	1500	1505	|B-IUPAC
or	1506	1508	|O
an	1509	1511	|O
isopropyl	1512	1521	|B-IUPAC
group	1522	1527	|B-MODIFIER
,	1527	1528	|O
the	1529	1532	|O
anti	1533	1537	|O
-	1537	1538	|O
HIV	1538	1541	|O
-	1541	1542	|O
1	1542	1543	|O
activity	1544	1552	|O
was	1553	1556	|O
improved	1557	1565	|O
remarkably	1566	1576	|O
[	1577	1578	|O
EC50	1578	1582	|O
:	1582	1583	|O
5	1584	1585	|B-IUPAC
-	1585	1586	|I-IUPAC
ethyl	1586	1591	|I-IUPAC
-	1591	1592	|I-IUPAC
1	1592	1593	|I-IUPAC
-	1593	1594	|I-IUPAC
(	1594	1595	|I-IUPAC
ethoxymethyl	1595	1607	|I-IUPAC
)	1607	1608	|I-IUPAC
-	1608	1609	|I-IUPAC
6	1609	1610	|I-IUPAC
-	1610	1611	|I-IUPAC
(	1611	1612	|I-IUPAC
phenylthio	1612	1622	|I-IUPAC
)	1622	1623	|I-IUPAC
-	1623	1624	|I-IUPAC
uracil	1624	1630	|I-IUPAC
(	1631	1632	|O
46	1632	1634	|O
)	1634	1635	|O
,	1635	1636	|O
0.019	1637	1642	|O
microM	1643	1649	|O
;	1649	1650	|O
5	1651	1652	|B-IUPAC
-	1652	1653	|I-IUPAC
ethyl	1653	1658	|I-IUPAC
-	1658	1659	|I-IUPAC
1	1659	1660	|I-IUPAC
-	1660	1661	|I-IUPAC
[	1661	1662	|I-IUPAC
(	1662	1663	|I-IUPAC
benzyloxy	1663	1672	|I-IUPAC
)	1672	1673	|I-IUPAC
methyl	1673	1679	|I-IUPAC
]	1679	1680	|I-IUPAC
-	1680	1681	|I-IUPAC
6	1681	1682	|I-IUPAC
-	1682	1683	|I-IUPAC
(	1683	1684	|I-IUPAC
phenylthio	1684	1694	|I-IUPAC
)	1694	1695	|I-IUPAC
uracil	1695	1701	|I-IUPAC
(	1702	1703	|O
52	1703	1705	|O
)	1705	1706	|O
,	1706	1707	|O
0.0059	1708	1714	|O
microM	1715	1721	|O
;	1721	1722	|O
5	1723	1724	|B-IUPAC
-	1724	1725	|I-IUPAC
isopropyl	1725	1734	|I-IUPAC
-	1734	1735	|I-IUPAC
1	1735	1736	|I-IUPAC
-	1736	1737	|I-IUPAC
(	1737	1738	|I-IUPAC
ethoxymethyl	1738	1750	|I-IUPAC
)	1750	1751	|I-IUPAC
-	1751	1752	|I-IUPAC
6	1752	1753	|I-IUPAC
-	1753	1754	|I-IUPAC
(	1754	1755	|I-IUPAC
phenylthio	1755	1765	|I-IUPAC
)	1765	1766	|I-IUPAC
uracil	1766	1772	|I-IUPAC
(	1773	1774	|O
55	1774	1776	|O
)	1776	1777	|O
,	1777	1778	|O
0.012	1779	1784	|O
microM	1785	1791	|O
;	1791	1792	|O
5	1793	1794	|B-IUPAC
-	1794	1795	|I-IUPAC
isopropyl	1795	1804	|I-IUPAC
-	1804	1805	|I-IUPAC
1	1805	1806	|I-IUPAC
-	1806	1807	|I-IUPAC
[	1807	1808	|I-IUPAC
(	1808	1809	|I-IUPAC
benzyloxy	1809	1818	|I-IUPAC
)	1818	1819	|I-IUPAC
methyl	1819	1825	|I-IUPAC
]	1825	1826	|I-IUPAC
-	1826	1827	|I-IUPAC
6	1827	1828	|I-IUPAC
-	1828	1829	|I-IUPAC
(	1829	1830	|I-IUPAC
phenylthio	1830	1840	|I-IUPAC
)	1840	1841	|I-IUPAC
uracil	1841	1847	|I-IUPAC
(	1848	1849	|O
56	1849	1851	|O
)	1851	1852	|O
,	1852	1853	|O
0.0027	1854	1860	|O
microM	1861	1867	|O
]	1867	1868	|O
.	1868	1869	|O
Introduction	1870	1882	|O
of	1883	1885	|O
two	1886	1889	|O
m	1890	1891	|B-IUPAC
-	1891	1892	|I-IUPAC
methyl	1892	1898	|I-IUPAC
groups	1899	1905	|B-MODIFIER
into	1906	1910	|O
the	1911	1914	|O
phenylthio	1915	1925	|B-IUPAC
ring	1926	1930	|B-MODIFIER
also	1931	1935	|O
potentiated	1936	1947	|O
the	1948	1951	|O
activity	1952	1960	|O
.	1960	1961	|O

### abstracts791.txt
alpha	0	5	|O
-	5	6	|O
Fluoromethyl	6	18	|O
amino	19	24	|O
acids	25	30	|O
are	31	34	|O
enzyme	35	41	|O
-	41	42	|O
activated	42	51	|O
irreversible	52	64	|O
inhibitors	65	75	|O
of	76	78	|O
amino	79	84	|O
acid	85	89	|O
decarboxylases	90	104	|O
.	104	105	|O
Aromatic	106	114	|O
L	115	116	|O
-	116	117	|O
amino	117	122	|O
acid	123	127	|O
decarboxylase	128	141	|O
(	142	143	|O
AADC	143	147	|O
)	147	148	|O
is	149	151	|O
the	152	155	|O
enzyme	156	162	|O
responsible	163	174	|O
for	175	178	|O
the	179	182	|O
final	183	188	|O
step	189	193	|O
in	194	196	|O
the	197	200	|O
biosynthesis	201	213	|O
of	214	216	|O
both	217	221	|O
dopamine	222	230	|O
and	231	234	|O
serotonin	235	244	|O
via	245	248	|O
decarboxylation	249	264	|O
of	265	267	|O
L	268	269	|B-IUPAC
-	269	270	|I-IUPAC
dopa	270	274	|I-IUPAC
and	275	278	|O
5	279	280	|B-IUPAC
-	280	281	|I-IUPAC
hydroxy	281	288	|I-IUPAC
-	288	289	|I-IUPAC
L	289	290	|I-IUPAC
-	290	291	|I-IUPAC
tryptophan	291	301	|I-IUPAC
,	301	302	|O
respectively	303	315	|O
.	315	316	|O
Our	317	320	|O
goal	321	325	|O
is	326	328	|O
to	329	331	|O
utilize	332	339	|O
antagonists	340	351	|O
of	352	354	|O
the	355	358	|O
serotonin	359	368	|O
-	368	369	|O
producing	369	378	|O
enzymes	379	386	|O
(	387	388	|O
tryptophan	388	398	|O
hydroxylase	399	410	|O
and	411	414	|O
AADC	415	419	|O
)	419	420	|O
as	421	423	|O
the	424	427	|O
basis	428	433	|O
for	434	437	|O
a	438	439	|O
chemotherapeutic	440	456	|O
approach	457	465	|O
to	466	468	|O
the	469	472	|O
treatment	473	482	|O
of	483	485	|O
carcinoid	486	495	|O
tumors	496	502	|O
,	502	503	|O
a	504	505	|O
rare	506	510	|O
tumor	511	516	|O
type	517	521	|O
characterized	522	535	|O
by	536	538	|O
the	539	542	|O
overproduction	543	557	|O
of	558	560	|O
serotonin	561	570	|O
.	570	571	|O
We	572	574	|O
report	575	581	|O
here	582	586	|O
an	587	589	|O
enantiospecific	590	605	|O
synthesis	606	615	|O
of	616	618	|O
alpha	619	624	|B-IUPAC
(	624	625	|I-IUPAC
S	625	626	|I-IUPAC
)	626	627	|I-IUPAC
-	627	628	|I-IUPAC
(	628	629	|I-IUPAC
fluoromethyl	629	641	|I-IUPAC
)	641	642	|I-IUPAC
tryptophan	642	652	|I-IUPAC
[	653	654	|O
(	654	655	|O
S	655	656	|O
)	656	657	|O
-	657	658	|O
11a	658	661	|O
]	661	662	|O
and	663	666	|O
alpha	667	672	|B-IUPAC
(	672	673	|I-IUPAC
S	673	674	|I-IUPAC
)	674	675	|I-IUPAC
-	675	676	|I-IUPAC
(	676	677	|I-IUPAC
fluoromethyl	677	689	|I-IUPAC
)	689	690	|I-IUPAC
-	690	691	|I-IUPAC
5	691	692	|I-IUPAC
-	692	693	|I-IUPAC
hydroxytryptophan	693	710	|I-IUPAC
[	711	712	|O
(	712	713	|O
S	713	714	|O
)	714	715	|O
-	715	716	|O
11b	716	719	|O
]	719	720	|O
,	720	721	|O
as	722	724	|O
well	725	729	|O
as	730	732	|O
the	733	736	|O
(	737	738	|O
R	738	739	|O
)	739	740	|O
-	740	741	|O
enantiomers	741	752	|O
,	752	753	|O
based	754	759	|O
upon	760	764	|O
recent	765	771	|O
methodology	772	783	|O
involving	784	793	|O
the	794	797	|O
face	798	802	|O
-	802	803	|O
selective	803	812	|O
alkylation	813	823	|O
of	824	826	|O
cyclic	827	833	|O
tryptophan	834	844	|O
tautomers	845	854	|O
.	854	855	|O
Our	856	859	|O
synthetic	860	869	|O
route	870	875	|O
provided	876	884	|O
both	885	889	|O
enantiomers	890	901	|O
of	902	904	|O
11a	905	908	|O
and	909	912	|O
11b	913	916	|O
with	917	921	|O
greater	922	929	|O
than	930	934	|O
97%	935	938	|O
enantiomeric	939	951	|O
purity	952	958	|O
based	959	964	|O
upon	965	969	|O
evaluation	970	980	|O
of	981	983	|O
the	984	987	|O
NMR	988	991	|O
spectra	992	999	|O
of	1000	1002	|O
their	1003	1008	|O
Mosher	1009	1015	|O
's	1015	1017	|O
acid	1018	1022	|O
derivatives	1023	1034	|O
.	1034	1035	|O
(	1036	1037	|O
S	1037	1038	|O
)	1038	1039	|O
-	1039	1040	|O
11a	1040	1043	|O
was	1044	1047	|O
evaluated	1048	1057	|O
as	1058	1060	|O
a	1061	1062	|O
substrate	1063	1072	|O
for	1073	1076	|O
P815	1077	1081	|O
tryptophan	1082	1092	|O
hydroxylase	1093	1104	|O
and	1105	1108	|O
determined	1109	1119	|O
to	1120	1122	|O
have	1123	1127	|O
an	1128	1130	|O
apparent	1131	1139	|O
Km	1140	1142	|O
of	1143	1145	|O
4.31	1146	1150	|O
+	1151	1152	|O
/	1152	1153	|O
-	1153	1154	|O
1.07	1155	1159	|O
mM	1160	1162	|O
,	1162	1163	|O
essentially	1164	1175	|O
half	1176	1180	|O
the	1181	1184	|O
value	1185	1190	|O
previously	1191	1201	|O
reported	1202	1210	|O
for	1211	1214	|O
the	1215	1218	|O
racemic	1219	1226	|O
mixture	1227	1234	|O
of	1235	1237	|O
11a	1238	1241	|O
with	1242	1246	|O
rat	1247	1250	|O
brain	1251	1256	|O
stem	1257	1261	|O
tryptophan	1262	1272	|O
hydroxylase	1273	1284	|O
.	1284	1285	|O
(	1286	1287	|O
R	1287	1288	|O
)	1288	1289	|O
-	1289	1290	|O
11a	1290	1293	|O
was	1294	1297	|O
not	1298	1301	|O
a	1302	1303	|O
substrate	1304	1313	|O
for	1314	1317	|O
P815	1318	1322	|O
tryptophan	1323	1333	|O
hydroxylase	1334	1345	|O
.	1345	1346	|O
(	1347	1348	|O
S	1348	1349	|O
)	1349	1350	|O
-	1350	1351	|O
11b	1351	1354	|O
was	1355	1358	|O
evaluated	1359	1368	|O
as	1369	1371	|O
an	1372	1374	|O
enzyme	1375	1381	|O
-	1381	1382	|O
activated	1382	1391	|O
irreversible	1392	1404	|O
inhibitor	1405	1414	|O
of	1415	1417	|O
murine	1418	1424	|O
liver	1425	1430	|O
AADC	1431	1435	|O
and	1436	1439	|O
determined	1440	1450	|O
to	1451	1453	|O
have	1454	1458	|O
a	1459	1460	|O
KI	1461	1463	|O
of	1464	1466	|O
24.3	1467	1471	|O
+	1472	1473	|O
/	1473	1474	|O
-	1474	1475	|O
3.01	1476	1480	|O
microM	1481	1487	|O
and	1488	1491	|O
a	1492	1493	|O
k2	1494	1496	|O
of	1497	1499	|O
2.26	1500	1504	|O
+	1505	1506	|O
/	1506	1507	|O
-	1507	1508	|O
0.44	1509	1513	|O
min	1514	1517	|O
-	1517	1518	|O
1	1518	1519	|O
.	1519	1520	|O
(	1521	1522	|O
R	1522	1523	|O
)	1523	1524	|O
-	1524	1525	|O
11b	1525	1528	|O
was	1529	1532	|O
not	1533	1536	|O
an	1537	1539	|O
inhibitor	1540	1549	|O
of	1550	1552	|O
murine	1553	1559	|O
liver	1560	1565	|O
AADC	1566	1570	|O
.	1570	1571	|O

### abstracts3967.txt
Dextromethorphan	0	16	|O
(	17	18	|O
1	18	19	|O
,	19	20	|O
(	20	21	|B-IUPAC
+	21	22	|I-IUPAC
)	22	23	|I-IUPAC
-	23	24	|I-IUPAC
3	24	25	|I-IUPAC
-	25	26	|I-IUPAC
methoxy	26	33	|I-IUPAC
-	33	34	|I-IUPAC
17	34	36	|I-IUPAC
-	36	37	|I-IUPAC
methylmorphinan	37	52	|I-IUPAC
)	52	53	|O
demonstrates	54	66	|O
anticonvulsant	67	81	|O
activity	82	90	|O
in	91	93	|O
a	94	95	|O
variety	96	103	|O
of	104	106	|O
in	107	109	|O
vitro	110	115	|O
and	116	119	|O
in	120	122	|O
vivo	123	127	|O
models	128	134	|O
of	135	137	|O
convulsive	138	148	|O
action	149	155	|O
.	155	156	|O
It	157	159	|O
is	160	162	|O
well	163	167	|O
known	168	173	|O
that	174	178	|O
1	179	180	|O
is	181	183	|O
metabolized	184	195	|O
to	196	198	|O
its	199	202	|O
phenolic	203	211	|O
derivative	212	222	|O
dextrorphan	223	234	|O
(	235	236	|O
2	236	237	|O
)	237	238	|O
and	239	242	|O
this	243	247	|O
metabolite	248	258	|O
is	259	261	|O
also	262	266	|O
a	267	268	|O
potent	269	275	|O
anticonvulsant	276	290	|O
.	290	291	|O
A	292	293	|O
series	294	300	|O
of	301	303	|O
(	304	305	|B-MODIFIER
+	305	306	|I-MODIFIER
)	306	307	|I-MODIFIER
-	307	308	|I-MODIFIER
3	308	309	|I-MODIFIER
-	309	310	|I-MODIFIER
substituted	310	321	|I-MODIFIER
-	321	322	|O
17	322	324	|B-IUPAC
-	324	325	|I-IUPAC
methylmorphinans	325	341	|I-IUPAC
,	341	342	|O
which	343	348	|O
are	349	352	|O
structurally	353	365	|O
similar	366	373	|O
to	374	376	|O
1	377	378	|O
but	379	382	|O
are	383	386	|O
either	387	393	|O
not	394	397	|O
expected	398	406	|O
to	407	409	|O
be	410	412	|O
metabolized	413	424	|O
to	425	427	|O
2	428	429	|O
or	430	432	|O
might	433	438	|O
do	439	441	|O
so	442	444	|O
at	445	447	|O
a	448	449	|O
reduced	450	457	|O
rate	458	462	|O
,	462	463	|O
as	464	466	|O
compared	467	475	|O
to	476	478	|O
1	479	480	|O
,	480	481	|O
were	482	486	|O
prepared	487	495	|O
.	495	496	|O
Three	497	502	|O
analogs	503	510	|O
,	510	511	|O
5	512	513	|O
(	514	515	|O
(	515	516	|B-IUPAC
+	516	517	|I-IUPAC
)	517	518	|I-IUPAC
-	518	519	|I-IUPAC
3	519	520	|I-IUPAC
-	520	521	|I-IUPAC
amino	521	526	|I-IUPAC
-	526	527	|I-IUPAC
17	527	529	|I-IUPAC
-	529	530	|I-IUPAC
methylmorphinan	530	545	|I-IUPAC
)	545	546	|O
,	546	547	|O
14	548	550	|O
(	551	552	|O
(	552	553	|B-IUPAC
+	553	554	|I-IUPAC
)	554	555	|I-IUPAC
-	555	556	|I-IUPAC
3	556	557	|I-IUPAC
-	557	558	|I-IUPAC
ethoxy	558	564	|I-IUPAC
-	564	565	|I-IUPAC
17	565	567	|I-IUPAC
-	567	568	|I-IUPAC
methylmorphinan	568	583	|I-IUPAC
)	583	584	|O
,	584	585	|O
and	586	589	|O
15	590	592	|O
(	593	594	|O
(	594	595	|B-IUPAC
+	595	596	|I-IUPAC
)	596	597	|I-IUPAC
-	597	598	|I-IUPAC
3	598	599	|I-IUPAC
-	599	600	|I-IUPAC
(	600	601	|I-IUPAC
2	601	602	|I-IUPAC
-	602	603	|I-IUPAC
propoxy	603	610	|I-IUPAC
)	610	611	|I-IUPAC
-	611	612	|I-IUPAC
17	612	614	|I-IUPAC
-	614	615	|I-IUPAC
methylmorphinan	615	630	|I-IUPAC
)	630	631	|O
were	632	636	|O
found	637	642	|O
to	643	645	|O
possess	646	653	|O
potent	654	660	|O
anticonvulsant	661	675	|O
activity	676	684	|O
with	685	689	|O
full	690	694	|O
efficacy	695	703	|O
(	704	705	|O
ED50	705	709	|O
25	710	712	|O
,	712	713	|O
5.6	714	717	|O
,	717	718	|O
and	719	722	|O
3.9	723	726	|O
mg	727	729	|O
/	729	730	|O
kg	730	732	|O
,	732	733	|O
sc	734	736	|O
,	736	737	|O
respectively	738	750	|O
)	750	751	|O
in	752	754	|O
the	755	758	|O
rat	759	762	|O
supramaximal	763	775	|O
electroshock	776	788	|O
(	789	790	|O
MES	790	793	|O
)	793	794	|O
test	795	799	|O
.	799	800	|O
Binding	801	808	|O
potencies	809	818	|O
of	819	821	|O
these	822	827	|O
compounds	828	837	|O
to	838	840	|O
receptor	841	849	|O
sites	850	855	|O
labeled	856	863	|O
with	864	868	|O
[	869	870	|O
3H	870	872	|O
]	872	873	|O
dextromethorphan	873	889	|O
(	890	891	|O
[	891	892	|O
3H	892	894	|O
]	894	895	|O
1	895	896	|O
)	896	897	|O
,	897	898	|O
in	899	901	|O
rat	902	905	|O
brain	906	911	|O
and	912	915	|O
guinea	916	922	|O
pig	923	926	|O
brain	927	932	|O
subcellular	933	944	|O
fractions	945	954	|O
,	954	955	|O
and	956	959	|O
[	960	961	|O
3H	961	963	|O
]	963	964	|O
thienylcyclohexylpiperidine	964	991	|O
(	992	993	|O
TCP	993	996	|O
)	996	997	|O
and	998	1001	|O
[	1002	1003	|O
3H	1003	1005	|O
]	1005	1006	|O
glycine	1006	1013	|O
in	1014	1016	|O
rat	1017	1020	|O
brain	1021	1026	|O
,	1026	1027	|O
were	1028	1032	|O
determined	1033	1043	|O
.	1043	1044	|O
Most	1045	1049	|O
of	1050	1052	|O
the	1053	1056	|O
analogs	1057	1064	|O
displaced	1065	1074	|O
[	1075	1076	|O
3H	1076	1078	|O
]	1078	1079	|O
1	1079	1080	|O
from	1081	1085	|O
its	1086	1089	|O
binding	1090	1097	|O
sites	1098	1103	|O
,	1103	1104	|O
with	1105	1109	|O
compounds	1110	1119	|O
14	1120	1122	|O
(	1123	1124	|O
IC50	1124	1128	|O
0.42	1129	1133	|O
microM	1134	1140	|O
)	1140	1141	|O
and	1142	1145	|O
15	1146	1148	|O
(	1149	1150	|O
IC50	1150	1154	|O
0.88	1155	1159	|O
microM	1160	1166	|O
)	1166	1167	|O
having	1168	1174	|O
equivalent	1175	1185	|O
potencies	1186	1195	|O
to	1196	1198	|O
1	1199	1200	|O
(	1201	1202	|O
IC50	1202	1206	|O
0.59	1207	1211	|O
microM	1212	1218	|O
)	1218	1219	|O
,	1219	1220	|O
in	1221	1223	|O
rat	1224	1227	|O
brain	1228	1233	|O
,	1233	1234	|O
and	1235	1238	|O
no	1239	1241	|O
appreciable	1242	1253	|O
activity	1254	1262	|O
at	1263	1265	|O
the	1266	1269	|O
[	1270	1271	|O
3H	1271	1273	|O
]	1273	1274	|O
TCP	1274	1277	|O
or	1278	1280	|O
[	1281	1282	|O
3H	1282	1284	|O
]	1284	1285	|O
glycine	1285	1292	|O
-	1292	1293	|O
labeled	1293	1300	|O
sites	1301	1306	|O
.	1306	1307	|O
Compound	1308	1316	|O
5	1317	1318	|O
did	1319	1322	|O
not	1323	1326	|O
bind	1327	1331	|O
with	1332	1336	|O
appreciable	1337	1348	|O
activity	1349	1357	|O
to	1358	1360	|O
the	1361	1364	|O
[	1365	1366	|O
3H	1366	1368	|O
]	1368	1369	|O
1	1369	1370	|O
site	1371	1375	|O
,	1375	1376	|O
in	1377	1379	|O
rat	1380	1383	|O
brain	1384	1389	|O
,	1389	1390	|O
but	1391	1394	|O
did	1395	1398	|O
bind	1399	1403	|O
to	1404	1406	|O
the	1407	1410	|O
[	1411	1412	|O
3H	1412	1414	|O
]	1414	1415	|O
TCP	1415	1418	|O
site	1419	1423	|O
with	1424	1428	|O
lower	1429	1434	|O
potency	1435	1442	|O
than	1443	1447	|O
the	1448	1451	|O
parent	1452	1458	|O
1	1459	1460	|O
(	1461	1462	|O
IC50	1462	1466	|O
7.8	1467	1470	|O
and	1471	1474	|O
2.0	1475	1478	|O
microM	1479	1485	|O
,	1485	1486	|O
respectively	1487	1499	|O
)	1499	1500	|O
.	1500	1501	|O
The	1502	1505	|O
mechanism	1506	1515	|O
of	1516	1518	|O
anticonvulsant	1519	1533	|O
action	1534	1540	|O
of	1541	1543	|O
these	1544	1549	|O
agents	1550	1556	|O
is	1557	1559	|O
not	1560	1563	|O
clear	1564	1569	|O
although	1570	1578	|O
it	1579	1581	|O
appears	1582	1589	|O
that	1590	1594	|O
interaction	1595	1606	|O
at	1607	1609	|O
the	1610	1613	|O
[	1614	1615	|O
3H	1615	1617	|O
]	1617	1618	|O
1	1618	1619	|O
sites	1620	1625	|O
may	1626	1629	|O
be	1630	1632	|O
involved	1633	1641	|O
.	1641	1642	|O

### abstracts3317.txt
Clinical	0	8	|O
studies	9	16	|O
concerning	17	27	|O
the	28	31	|O
role	32	36	|O
of	37	39	|O
poly	40	44	|O
(	44	45	|O
ADP	45	48	|O
-	48	49	|O
ribose	49	55	|O
)	55	56	|O
polymerase	57	67	|O
(	68	69	|O
PARP	69	73	|O
)	73	74	|O
in	75	77	|O
the	78	81	|O
repair	82	88	|O
of	89	91	|O
drug	92	96	|O
-	96	97	|O
and	98	101	|O
radiation	102	111	|O
-	111	112	|O
induced	112	119	|O
DNA	120	123	|O
damage	124	130	|O
have	131	135	|O
been	136	140	|O
impeded	141	148	|O
by	149	151	|O
the	152	155	|O
poor	156	160	|O
solubility	161	171	|O
,	171	172	|O
lack	173	177	|O
of	178	180	|O
potency	181	188	|O
,	188	189	|O
and	190	193	|O
limited	194	201	|O
specificity	202	213	|O
of	214	216	|O
currently	217	226	|O
available	227	236	|O
inhibitors	237	247	|O
.	247	248	|O
A	249	250	|O
series	251	257	|O
of	258	260	|O
2	261	262	|B-IUPAC
-	262	263	|I-IUPAC
alkyl	263	268	|I-IUPAC
-	268	269	|O
and	270	273	|O
2	274	275	|B-IUPAC
-	275	276	|I-IUPAC
aryl	276	280	|I-IUPAC
-	280	281	|O
substituted	281	292	|B-MODIFIER
8	293	294	|B-PARTIUPAC
-	294	295	|I-PARTIUPAC
hydroxy	295	302	|I-PARTIUPAC
-	302	303	|I-PARTIUPAC
,	303	304	|O
8	305	306	|B-PARTIUPAC
-	306	307	|I-PARTIUPAC
methoxy	307	314	|I-PARTIUPAC
-	314	315	|I-PARTIUPAC
,	315	316	|O
and	317	320	|O
8	321	322	|B-IUPAC
-	322	323	|I-IUPAC
methylquinazolin	323	339	|I-IUPAC
-	339	340	|I-IUPAC
4	340	341	|I-IUPAC
(	341	342	|I-IUPAC
3H	342	344	|I-IUPAC
)	344	345	|I-IUPAC
-	345	346	|I-IUPAC
ones	346	350	|I-IUPAC
has	351	354	|O
been	355	359	|O
synthesized	360	371	|O
and	372	375	|O
evaluated	376	385	|O
for	386	389	|O
PARP	390	394	|O
inhibitory	395	405	|O
activity	406	414	|O
in	415	417	|O
permeabilized	418	431	|O
L1210	432	437	|O
murine	438	444	|O
leukemia	445	453	|O
cells	454	459	|O
.	459	460	|O
8	461	462	|B-PARTIUPAC
-	462	463	|I-PARTIUPAC
Methoxy	463	470	|I-PARTIUPAC
-	470	471	|I-PARTIUPAC
and	472	475	|O
8	476	477	|B-IUPAC
-	477	478	|I-IUPAC
methylquinazolinones	478	498	|I-IUPAC
(	499	500	|O
14-34	500	505	|O
)	505	506	|O
were	507	511	|O
readily	512	519	|O
prepared	520	528	|O
by	529	531	|O
acylation	532	541	|O
of	542	544	|O
3	545	546	|O
-	546	547	|O
substituted	547	558	|O
anthranilamides	559	574	|O
with	575	579	|O
the	580	583	|O
appropriate	584	595	|O
acid	596	600	|O
chloride	601	609	|O
,	609	610	|O
followed	611	619	|O
by	620	622	|O
base	623	627	|O
-	627	628	|O
catalyzed	628	637	|O
cyclization	638	649	|O
.	649	650	|O
The	651	654	|O
requisite	655	664	|O
8	665	666	|B-IUPAC
-	666	667	|I-IUPAC
hydroxyquinazolinones	667	688	|I-IUPAC
(	689	690	|O
6	690	691	|O
,	691	692	|O
35-39	693	698	|O
)	698	699	|O
were	700	704	|O
synthesized	705	716	|O
by	717	719	|O
demethylation	720	733	|O
of	734	736	|O
the	737	740	|O
corresponding	741	754	|O
8	755	756	|B-IUPAC
-	756	757	|I-IUPAC
methoxyquinazolinones	757	778	|I-IUPAC
with	779	783	|O
BBr3	784	788	|O
.	788	789	|O
N	790	791	|O
-	791	792	|O
Methylation	792	803	|O
of	804	806	|O
8	807	808	|B-IUPAC
-	808	809	|I-IUPAC
methoxy	809	816	|I-IUPAC
-	816	817	|I-IUPAC
2	817	818	|I-IUPAC
-	818	819	|I-IUPAC
methylquinazolinone	819	838	|I-IUPAC
(	839	840	|O
15	840	842	|O
)	842	843	|O
with	844	848	|O
MeI	849	852	|O
,	852	853	|O
followed	854	862	|O
by	863	865	|O
O	866	867	|O
-	867	868	|O
demethylation	868	881	|O
by	882	884	|O
BBr3	885	889	|O
,	889	890	|O
afforded	891	899	|O
the	900	903	|O
control	904	911	|O
N3	912	914	|B-IUPAC
-	914	915	|I-IUPAC
methylquinazolinones	915	935	|I-IUPAC
42	936	938	|O
and	939	942	|O
43	943	945	|O
,	945	946	|O
respectively	947	959	|O
.	959	960	|O
In	961	963	|O
general	964	971	|O
,	971	972	|O
an	973	975	|O
8	976	977	|B-IUPAC
-	977	978	|I-IUPAC
hydroxy	978	985	|I-IUPAC
or	986	988	|O
8	989	990	|B-IUPAC
-	990	991	|I-IUPAC
methyl	991	997	|I-IUPAC
substituent	998	1009	|B-MODIFIER
enhanced	1010	1018	|O
inhibitory	1019	1029	|O
activity	1030	1038	|O
in	1039	1041	|O
comparison	1042	1052	|O
with	1053	1057	|O
an	1058	1060	|O
8	1061	1062	|B-IUPAC
-	1062	1063	|I-IUPAC
methoxy	1063	1070	|I-IUPAC
group	1071	1076	|B-MODIFIER
.	1076	1077	|O
2	1078	1079	|B-IUPAC
-	1079	1080	|I-IUPAC
Phenylquinazolinones	1080	1100	|I-IUPAC
were	1101	1105	|O
marginally	1106	1116	|O
less	1117	1121	|O
potent	1122	1128	|O
than	1129	1133	|O
the	1134	1137	|O
corresponding	1138	1151	|O
2	1152	1153	|B-IUPAC
-	1153	1154	|I-IUPAC
methylquinazolinones	1154	1174	|I-IUPAC
,	1174	1175	|O
but	1176	1179	|O
the	1180	1183	|O
introduction	1184	1196	|O
of	1197	1199	|O
an	1200	1202	|O
electron	1203	1211	|O
-	1211	1212	|O
withdrawing	1212	1223	|O
or	1224	1226	|O
electron	1227	1235	|O
-	1235	1236	|O
donating	1236	1244	|O
4'	1245	1247	|O
-	1247	1248	|O
substituent	1248	1259	|O
on	1260	1262	|O
the	1263	1266	|O
2	1267	1268	|B-IUPAC
-	1268	1269	|I-IUPAC
aryl	1269	1273	|I-IUPAC
ring	1274	1278	|B-MODIFIER
invariably	1279	1289	|O
increased	1290	1299	|O
potency	1300	1307	|O
.	1307	1308	|O
This	1309	1313	|O
was	1314	1317	|O
particularly	1318	1330	|O
evident	1331	1338	|O
in	1339	1341	|O
the	1342	1345	|O
8	1346	1347	|B-IUPAC
-	1347	1348	|I-IUPAC
methylquinazolinone	1348	1367	|I-IUPAC
series	1368	1374	|B-MODIFIER
(	1375	1376	|O
IC50	1376	1380	|O
values	1381	1387	|O
0.13-0.27	1388	1397	|O
microM	1398	1404	|O
)	1404	1405	|O
,	1405	1406	|O
which	1407	1412	|O
are	1413	1416	|O
among	1417	1422	|O
the	1423	1426	|O
most	1427	1431	|O
potent	1432	1438	|O
PARP	1439	1443	|O
inhibitors	1444	1454	|O
reported	1455	1463	|O
to	1464	1466	|O
date	1467	1471	|O
.	1471	1472	|O
N3	1473	1475	|B-IUPAC
-	1475	1476	|I-IUPAC
Methylquinazolinones	1476	1496	|I-IUPAC
42	1497	1499	|O
and	1500	1503	|O
43	1504	1506	|O
were	1507	1511	|O
essentially	1512	1523	|O
devoid	1524	1530	|O
of	1531	1533	|O
activity	1534	1542	|O
(	1543	1544	|O
IC50	1544	1548	|O
values	1549	1555	|O
&	1556	1557	|O
gt	1557	1559	|O
;	1559	1560	|O
100	1561	1564	|O
microM	1565	1571	|O
)	1571	1572	|O
.	1572	1573	|O
In	1574	1576	|O
studies	1577	1584	|O
with	1585	1589	|O
L1210	1590	1595	|O
cells	1596	1601	|O
in	1602	1604	|O
vitro	1605	1610	|O
,	1610	1611	|O
a	1612	1613	|O
concentration	1614	1627	|O
of	1628	1630	|O
200	1631	1634	|O
microM	1635	1641	|O
8	1642	1643	|B-IUPAC
-	1643	1644	|I-IUPAC
hydroxy	1644	1651	|I-IUPAC
-	1651	1652	|I-IUPAC
2	1652	1653	|I-IUPAC
-	1653	1654	|I-IUPAC
methylquinazolinone	1654	1673	|I-IUPAC
(	1674	1675	|O
6	1675	1676	|O
,	1676	1677	|O
NU1025	1678	1684	|O
)	1684	1685	|O
(	1686	1687	|O
IC50	1687	1691	|O
value	1692	1697	|O
0.40	1698	1702	|O
microM	1703	1709	|O
)	1709	1710	|O
potentiated	1711	1722	|O
the	1723	1726	|O
cytotoxicity	1727	1739	|O
of	1740	1742	|O
the	1743	1746	|O
monomethylating	1747	1762	|O
agent	1763	1768	|O
5	1769	1770	|B-IUPAC
-	1770	1771	|I-IUPAC
(	1771	1772	|I-IUPAC
3	1772	1773	|I-IUPAC
-	1773	1774	|I-IUPAC
methyltriazen	1774	1787	|I-IUPAC
-	1787	1788	|I-IUPAC
1	1788	1789	|I-IUPAC
-	1789	1790	|I-IUPAC
yl	1790	1792	|I-IUPAC
)	1792	1793	|I-IUPAC
imidazole	1793	1802	|I-IUPAC
-	1802	1803	|I-IUPAC
4	1803	1804	|I-IUPAC
-	1804	1805	|I-IUPAC
carboxamide	1805	1816	|I-IUPAC
and	1817	1820	|O
gamma	1821	1826	|O
-	1826	1827	|O
radiation	1827	1836	|O
3.5	1837	1840	|O
-	1840	1841	|O
and	1842	1845	|O
1.4	1846	1849	|O
-	1849	1850	|O
fold	1850	1854	|O
,	1854	1855	|O
respectively	1856	1868	|O
,	1868	1869	|O
at	1870	1872	|O
the	1873	1876	|O
10%	1877	1880	|O
survival	1881	1889	|O
level	1890	1895	|O
.	1895	1896	|O

### abstracts1247.txt
A	0	1	|O
number	2	8	|O
of	9	11	|O
nucleoside	12	22	|O
and	23	26	|O
nucleotide	27	37	|O
derivatives	38	49	|O
of	50	52	|O
4	53	54	|B-IUPAC
-	54	55	|I-IUPAC
hydroxy	55	62	|I-IUPAC
-	62	63	|I-IUPAC
3	63	64	|I-IUPAC
-	64	65	|I-IUPAC
beta	65	69	|I-IUPAC
-	69	70	|I-IUPAC
D	70	71	|I-IUPAC
-	71	72	|I-IUPAC
ribofuranosylpyrazole	72	93	|I-IUPAC
-	93	94	|I-IUPAC
5	94	95	|I-IUPAC
-	95	96	|I-IUPAC
carboxamide	96	107	|I-IUPAC
(	108	109	|O
pyrazofurin	109	120	|O
,	120	121	|O
1	122	123	|O
)	123	124	|O
were	125	129	|O
prepared	130	138	|O
and	139	142	|O
tested	143	149	|O
for	150	153	|O
their	154	159	|O
antiviral	160	169	|O
and	170	173	|O
cytostatic	174	184	|O
activity	185	193	|O
in	194	196	|O
cell	197	201	|O
culture	202	209	|O
.	209	210	|O
Treatment	211	220	|O
of	221	223	|O
1	224	225	|O
with	226	230	|O
benzyl	231	237	|B-IUPAC
bromide	238	245	|I-IUPAC
gave	246	250	|O
4	251	252	|B-IUPAC
-	252	253	|I-IUPAC
O	253	254	|I-IUPAC
-	254	255	|I-IUPAC
benzylpyrazofurin	255	272	|I-IUPAC
(	273	274	|O
4	274	275	|O
)	275	276	|O
.	276	277	|O
Methylation	278	289	|O
of	290	292	|O
4	293	294	|O
with	295	299	|O
CH2N2	300	305	|O
and	306	309	|O
subsequent	310	320	|O
removal	321	328	|O
of	329	331	|O
the	332	335	|O
benzyl	336	342	|B-IUPAC
group	343	348	|B-MODIFIER
by	349	351	|O
catalytic	352	361	|O
hydrogenation	362	375	|O
provided	376	384	|O
1	385	386	|B-IUPAC
-	386	387	|I-IUPAC
methylpyrazofurin	387	404	|I-IUPAC
(	405	406	|O
8	406	407	|O
)	407	408	|O
.	408	409	|O
Direct	410	416	|O
methylation	417	428	|O
of	429	431	|O
1	432	433	|O
with	434	438	|O
CH3I	439	443	|O
furnished	444	453	|O
4	454	455	|B-IUPAC
-	455	456	|I-IUPAC
O	456	457	|I-IUPAC
-	457	458	|I-IUPAC
methylpyrazofurin	458	475	|I-IUPAC
(	476	477	|O
6	477	478	|O
)	478	479	|O
.	479	480	|O
Dehydration	481	492	|O
of	493	495	|O
the	496	499	|O
pentaacetylpyrazofurin	500	522	|O
(	523	524	|O
9	524	525	|O
)	525	526	|O
with	527	531	|O
phosgene	532	540	|O
furnished	541	550	|O
4	551	552	|B-IUPAC
-	552	553	|I-IUPAC
acetoxy	553	560	|I-IUPAC
-	560	561	|I-IUPAC
3	561	562	|I-IUPAC
-	562	563	|I-IUPAC
(	563	564	|I-IUPAC
2,3,5	564	569	|I-IUPAC
-	569	570	|I-IUPAC
tri	570	573	|I-IUPAC
-	573	574	|I-IUPAC
O	574	575	|I-IUPAC
-	575	576	|I-IUPAC
acetyl	576	582	|I-IUPAC
-	582	583	|I-IUPAC
beta	583	587	|I-IUPAC
-	587	588	|I-IUPAC
D	588	589	|I-IUPAC
-	589	590	|I-IUPAC
ribofuranosyl	590	603	|I-IUPAC
)	603	604	|I-IUPAC
-	604	605	|I-IUPAC
1	605	606	|I-IUPAC
-	606	607	|I-IUPAC
acetylpyrazol	607	620	|I-IUPAC
e	621	622	|I-IUPAC
-	622	623	|I-IUPAC
5	623	624	|I-IUPAC
-	624	625	|I-IUPAC
carbonitrile	625	637	|I-IUPAC
(	638	639	|O
10	639	641	|O
)	641	642	|O
.	642	643	|O
A	644	645	|O
similar	646	653	|O
dehydration	654	665	|O
of	666	668	|O
the	669	672	|O
precursor	673	682	|O
tetraacetyl	683	694	|B-IUPAC
derivative	695	705	|B-MODIFIER
of	706	708	|O
4	709	710	|O
gave	711	715	|O
the	716	719	|O
corresponding	720	733	|O
carbonitrile	734	746	|O
,	746	747	|O
which	748	753	|O
on	754	756	|O
deprotection	757	769	|O
and	770	773	|O
subsequent	774	784	|O
treatment	785	794	|O
with	795	799	|O
hydroxylamine	800	813	|O
furnished	814	823	|O
4	824	825	|B-IUPAC
-	825	826	|I-IUPAC
(	827	828	|I-IUPAC
benzyloxy	828	837	|I-IUPAC
)	837	838	|I-IUPAC
-	838	839	|I-IUPAC
3	839	840	|I-IUPAC
-	840	841	|I-IUPAC
beta	841	845	|I-IUPAC
-	845	846	|I-IUPAC
D	846	847	|I-IUPAC
-	847	848	|I-IUPAC
ribofuranosylpyrazole	848	869	|I-IUPAC
-	869	870	|I-IUPAC
5	870	871	|I-IUPAC
-	871	872	|I-IUPAC
carboxamidoxime	872	887	|I-IUPAC
(	888	889	|O
13	889	891	|O
)	891	892	|O
.	892	893	|O
Treatment	894	903	|O
of	904	906	|O
the	907	910	|O
tetraacetyl	911	922	|B-IUPAC
derivative	923	933	|B-MODIFIER
of	934	936	|O
4	937	938	|O
with	939	943	|O
Lawesson	944	952	|O
's	952	954	|O
reagent	955	962	|O
and	963	966	|O
subsequent	967	977	|O
deacetylation	978	991	|O
furnished	992	1001	|O
a	1002	1003	|O
mixture	1004	1011	|O
of	1012	1014	|O
4	1015	1016	|B-IUPAC
-	1016	1017	|I-IUPAC
(	1018	1019	|I-IUPAC
benzyloxy	1019	1028	|I-IUPAC
)	1028	1029	|I-IUPAC
-	1029	1030	|I-IUPAC
3	1030	1031	|I-IUPAC
-	1031	1032	|I-IUPAC
beta	1032	1036	|I-IUPAC
-	1036	1037	|I-IUPAC
D	1037	1038	|I-IUPAC
-	1038	1039	|I-IUPAC
ribofuranosylpyrazole	1039	1060	|I-IUPAC
-	1060	1061	|I-IUPAC
5	1061	1062	|I-IUPAC
-	1062	1063	|I-IUPAC
thiocarboxamide	1063	1078	|I-IUPAC
(	1079	1080	|O
15	1080	1082	|O
)	1082	1083	|O
and	1084	1087	|O
the	1088	1091	|O
corresponding	1092	1105	|O
nitrile	1106	1113	|B-IUPAC
derivative	1114	1124	|B-MODIFIER
(	1125	1126	|O
16	1126	1128	|O
)	1128	1129	|O
.	1129	1130	|O
Phosphorylation	1131	1146	|O
of	1147	1149	|O
unprotected	1150	1161	|O
4	1162	1163	|O
with	1164	1168	|O
POCl3	1169	1174	|O
and	1175	1178	|O
subsequent	1179	1189	|O
debenzylation	1190	1203	|O
of	1204	1206	|O
the	1207	1210	|O
intermediate	1211	1223	|O
17	1224	1226	|O
gave	1227	1231	|O
pyrazofurin	1232	1243	|B-IUPAC
5'	1244	1246	|I-IUPAC
-	1246	1247	|I-IUPAC
phosphate	1247	1256	|I-IUPAC
(	1257	1258	|O
18	1258	1260	|O
)	1260	1261	|O
,	1261	1262	|O
which	1263	1268	|O
provided	1269	1277	|O
the	1278	1281	|O
first	1282	1287	|O
chemical	1288	1296	|O
synthesis	1297	1306	|O
of	1307	1309	|O
18	1310	1312	|O
.	1312	1313	|O
Similar	1314	1321	|O
phosphorylation	1322	1337	|O
of	1338	1340	|O
4	1341	1342	|O
with	1343	1347	|O
POCl3	1348	1353	|O
and	1354	1357	|O
quenching	1358	1367	|O
the	1368	1371	|O
reaction	1372	1380	|O
mixture	1381	1388	|O
with	1389	1393	|O
either	1394	1400	|O
EtOH	1401	1405	|O
or	1406	1408	|O
MeOH	1409	1413	|O
,	1413	1414	|O
followed	1415	1423	|O
by	1424	1426	|O
debenzylation	1427	1440	|O
,	1440	1441	|O
furnished	1442	1451	|O
the	1452	1455	|O
5'	1456	1458	|B-IUPAC
-	1458	1459	|I-IUPAC
O	1459	1460	|I-IUPAC
-	1460	1461	|I-IUPAC
(	1461	1462	|I-IUPAC
ethyl	1462	1467	|I-IUPAC
phosphate	1468	1477	|I-IUPAC
)	1477	1478	|I-IUPAC
(	1479	1480	|O
19b	1480	1483	|O
)	1483	1484	|O
and	1485	1488	|O
5'	1489	1491	|B-IUPAC
-	1491	1492	|I-IUPAC
O	1492	1493	|I-IUPAC
-	1493	1494	|I-IUPAC
(	1494	1495	|I-IUPAC
dimethyl	1495	1503	|I-IUPAC
phosphate	1504	1513	|I-IUPAC
)	1513	1514	|I-IUPAC
(	1515	1516	|O
20b	1516	1519	|O
)	1519	1520	|O
derivatives	1521	1532	|O
of	1533	1535	|O
pyrazofurin	1536	1547	|O
.	1547	1548	|O
DCC	1549	1552	|O
-	1552	1553	|O
mediated	1553	1561	|O
cyclization	1562	1573	|O
of	1574	1576	|O
17	1577	1579	|O
,	1579	1580	|O
followed	1581	1589	|O
by	1590	1592	|O
debenzylation	1593	1606	|O
,	1606	1607	|O
gave	1608	1612	|O
pyrazofurin	1613	1624	|O
3'	1625	1627	|B-IUPAC
,	1627	1628	|I-IUPAC
5'	1628	1630	|I-IUPAC
-	1630	1631	|I-IUPAC
(	1631	1632	|I-IUPAC
cyclic	1632	1638	|I-IUPAC
)	1638	1639	|I-IUPAC
phosphate	1639	1648	|I-IUPAC
(	1649	1650	|O
21b	1650	1653	|O
)	1653	1654	|O
.	1654	1655	|O
The	1656	1659	|O
NAD	1660	1663	|O
analogue	1664	1672	|O
23b	1673	1676	|O
was	1677	1680	|O
also	1681	1685	|O
prepared	1686	1694	|O
by	1695	1697	|O
the	1698	1701	|O
treatment	1702	1711	|O
of	1712	1714	|O
17	1715	1717	|O
with	1718	1722	|O
an	1723	1725	|O
activated	1726	1735	|O
form	1736	1740	|O
of	1741	1743	|O
AMP	1744	1747	|O
in	1748	1750	|O
the	1751	1754	|O
presence	1755	1763	|O
of	1764	1766	|O
AgNO3	1767	1772	|O
.	1772	1773	|O
The	1774	1777	|O
structural	1778	1788	|O
assignment	1789	1799	|O
of	1800	1802	|O
7,8	1803	1806	|O
,	1806	1807	|O
and	1808	1811	|O
20a	1812	1815	|O
were	1816	1820	|O
made	1821	1825	|O
by	1826	1828	|O
single	1829	1835	|O
-	1835	1836	|O
crystal	1836	1843	|O
X	1844	1845	|O
-	1845	1846	|O
ray	1846	1849	|O
analysis	1850	1858	|O
,	1858	1859	|O
and	1860	1863	|O
along	1864	1869	|O
with	1870	1874	|O
pyrazofurin	1875	1886	|O
,	1886	1887	|O
their	1888	1893	|O
intramolecular	1894	1908	|O
hydrogen	1909	1917	|O
bond	1918	1922	|O
characteristics	1923	1938	|O
have	1939	1943	|O
been	1944	1948	|O
studied	1949	1956	|O
.	1956	1957	|O
All	1958	1961	|O
of	1962	1964	|O
these	1965	1970	|O
compounds	1971	1980	|O
were	1981	1985	|O
tested	1986	1992	|O
in	1993	1995	|O
Vero	1996	2000	|O
cell	2001	2005	|O
cultures	2006	2014	|O
against	2015	2022	|O
a	2023	2024	|O
spectrum	2025	2033	|O
of	2034	2036	|O
viruses	2037	2044	|O
.	2044	2045	|O
Compounds	2046	2055	|O
18	2056	2058	|O
and	2059	2062	|O
23b	2063	2066	|O
were	2067	2071	|O
active	2072	2078	|O
at	2079	2081	|O
concentrations	2082	2096	|O
very	2097	2101	|O
similar	2102	2109	|O
to	2110	2112	|O
pyrazofurin	2113	2124	|O
but	2125	2128	|O
are	2129	2132	|O
less	2133	2137	|O
toxic	2138	2143	|O
to	2144	2146	|O
the	2147	2150	|O
cells	2151	2156	|O
than	2157	2161	|O
pyrazofurin	2162	2173	|O
.	2173	2174	|O
Compounds	2175	2184	|O
19b	2185	2188	|O
,	2188	2189	|O
20b	2190	2193	|O
,	2193	2194	|O
and	2195	2198	|O
the	2199	2202	|O
3'	2203	2205	|B-IUPAC
,	2205	2206	|I-IUPAC
5'	2206	2208	|I-IUPAC
-	2208	2209	|I-IUPAC
(	2209	2210	|I-IUPAC
cyclic	2210	2216	|I-IUPAC
)	2216	2217	|I-IUPAC
phosphate	2217	2226	|I-IUPAC
21b	2227	2230	|O
are	2231	2234	|O
less	2235	2239	|O
active	2240	2246	|O
than	2247	2251	|O
1	2252	2253	|O
.	2253	2254	|O
Compounds	2255	2264	|O
18	2265	2267	|O
,	2267	2268	|O
19b	2269	2272	|O
,	2272	2273	|O
20b	2274	2277	|O
,	2277	2278	|O
and	2279	2282	|O
23b	2283	2286	|O
also	2287	2291	|O
exhibited	2292	2301	|O
significant	2302	2313	|O
inhibitory	2314	2324	|O
effects	2325	2332	|O
on	2333	2335	|O
the	2336	2339	|O
growth	2340	2346	|O
of	2347	2349	|O
L1210	2350	2355	|O
and	2356	2359	|O
P388	2360	2364	|O
leukemias	2365	2374	|O
and	2375	2378	|O
Lewis	2379	2384	|O
lung	2385	2389	|O
carcinoma	2390	2399	|O
cells	2400	2405	|O
in	2406	2408	|O
vitro	2409	2414	|O
,	2414	2415	|O
whereas	2416	2423	|O
B16	2424	2427	|O
melanoma	2428	2436	|O
cells	2437	2442	|O
were	2443	2447	|O
less	2448	2452	|O
sensitive	2453	2462	|O
to	2463	2465	|O
growth	2466	2472	|O
inhibition	2473	2483	|O
by	2484	2486	|O
these	2487	2492	|O
compounds	2493	2502	|O
.	2502	2503	|O
Pyrazofurin	2504	2515	|O
derivatives	2516	2527	|O
modified	2528	2536	|O
at	2537	2539	|O
the	2540	2543	|O
1	2544	2545	|O
-	2545	2546	|O
,	2546	2547	|O
4	2548	2549	|O
-	2549	2550	|O
,	2550	2551	|O
or	2552	2554	|O
5	2555	2556	|O
-	2556	2557	|O
position	2557	2565	|O
showed	2566	2572	|O
neither	2573	2580	|O
antiviral	2581	2590	|O
nor	2591	2594	|O
cytostatic	2595	2605	|O
activity	2606	2614	|O
in	2615	2617	|O
cell	2618	2622	|O
culture	2623	2630	|O
.	2630	2631	|O

### abstracts1835.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
7	12	13	|B-PARTIUPAC
-	13	14	|I-PARTIUPAC
(	14	15	|I-PARTIUPAC
2,3	15	18	|B-MODIFIER
-	18	19	|I-MODIFIER
disubstituted	19	32	|I-MODIFIER
-	32	33	|O
1	33	34	|B-IUPAC
-	34	35	|I-IUPAC
azetidinyl	35	45	|I-IUPAC
)	45	46	|B-PARTIUPAC
-	46	47	|I-PARTIUPAC
1,4	47	50	|I-PARTIUPAC
-	50	51	|I-PARTIUPAC
dihydro	51	58	|I-PARTIUPAC
-	58	59	|I-PARTIUPAC
6	59	60	|I-PARTIUPAC
-	60	61	|I-PARTIUPAC
fluoro	61	67	|I-PARTIUPAC
-	67	68	|I-PARTIUPAC
4	68	69	|I-PARTIUPAC
-	69	70	|I-PARTIUPAC
oxoquinoline	71	83	|I-PARTIUPAC
-	83	84	|I-PARTIUPAC
and	85	88	|O
-	89	90	|B-PARTIUPAC
1,8	90	93	|I-PARTIUPAC
-	93	94	|I-PARTIUPAC
naphthyridine	94	107	|I-PARTIUPAC
-	107	108	|I-PARTIUPAC
3	108	109	|I-PARTIUPAC
-	109	110	|I-PARTIUPAC
carboxylic	110	120	|I-PARTIUPAC
acids	121	126	|I-PARTIUPAC
,	126	127	|O
with	128	132	|O
varied	133	139	|O
substituents	140	152	|O
at	153	155	|O
the	156	159	|O
1	160	161	|O
-	161	162	|O
,	162	163	|O
5	164	165	|O
-	165	166	|O
,	166	167	|O
and	168	171	|O
8	172	173	|O
-	173	174	|O
positions	174	183	|O
,	183	184	|O
was	185	188	|O
prepared	189	197	|O
to	198	200	|O
study	201	206	|O
the	207	210	|O
effects	211	218	|O
on	219	221	|O
potency	222	229	|O
and	230	233	|O
physicochemical	234	249	|O
properties	250	260	|O
of	261	263	|O
the	264	267	|O
substituent	268	279	|O
at	280	282	|O
position	283	291	|O
2	292	293	|O
of	294	296	|O
the	297	300	|O
azetidine	301	310	|O
moiety	311	317	|O
.	317	318	|O
The	319	322	|O
activity	323	331	|O
of	332	334	|O
the	335	338	|O
title	339	344	|O
compounds	345	354	|O
was	355	358	|O
determined	359	369	|O
in	370	372	|O
vitro	373	378	|O
against	379	386	|O
Gram	387	391	|O
-	391	392	|O
positive	392	400	|O
and	401	404	|O
Gram	405	409	|O
-	409	410	|O
negative	410	418	|O
bacteria	419	427	|O
,	427	428	|O
and	429	432	|O
the	433	436	|O
in	437	439	|O
vivo	440	444	|O
efficacy	445	453	|O
of	454	456	|O
selected	457	465	|O
derivatives	466	477	|O
was	478	481	|O
determined	482	492	|O
using	493	498	|O
a	499	500	|O
mouse	501	506	|O
infection	507	516	|O
model	517	522	|O
.	522	523	|O
The	524	527	|O
X	528	529	|O
-	529	530	|O
ray	530	533	|O
crystal	534	541	|O
structures	542	552	|O
of	553	555	|O
6b	556	558	|O
,	558	559	|O
6c	560	562	|O
,	562	563	|O
and	564	567	|O
6d	568	570	|O
were	571	575	|O
found	576	581	|O
to	582	584	|O
be	585	587	|O
in	588	590	|O
reasonable	591	601	|O
agreement	602	611	|O
with	612	616	|O
the	617	620	|O
corresponding	621	634	|O
AM1	635	638	|O
calculated	639	649	|O
geometries	650	660	|O
.	660	661	|O
Correlations	662	674	|O
between	675	682	|O
antibacterial	683	696	|O
potency	697	704	|O
of	705	707	|O
all	708	711	|O
the	712	715	|O
synthesized	716	727	|O
7	728	729	|B-IUPAC
-	729	730	|I-IUPAC
azetidinylquinolones	730	750	|I-IUPAC
and	751	754	|O
naphthyridines	755	769	|O
and	770	773	|O
their	774	779	|O
calculated	780	790	|O
electronic	791	801	|O
properties	802	812	|O
and	813	816	|O
experimental	817	829	|O
capacity	830	838	|O
factors	839	846	|O
were	847	851	|O
established	852	863	|O
.	863	864	|O
Antibacterial	865	878	|O
efficacy	879	887	|O
and	888	891	|O
pharmacokinetic	892	907	|O
and	908	911	|O
physicochemical	912	927	|O
properties	928	938	|O
of	939	941	|O
selected	942	950	|O
derivatives	951	962	|O
were	963	967	|O
compared	968	976	|O
to	977	979	|O
the	980	983	|O
relevant	984	992	|O
7	993	994	|B-IUPAC
-	994	995	|I-IUPAC
(	995	996	|I-IUPAC
3	996	997	|I-IUPAC
-	997	998	|I-IUPAC
amino	998	1003	|I-IUPAC
-	1003	1004	|I-IUPAC
1	1004	1005	|I-IUPAC
-	1005	1006	|I-IUPAC
azetidinyl	1006	1016	|I-IUPAC
)	1016	1017	|I-IUPAC
and	1018	1021	|O
7	1022	1023	|B-IUPAC
-	1023	1024	|I-IUPAC
(	1024	1025	|I-IUPAC
3	1025	1026	|I-IUPAC
-	1026	1027	|I-IUPAC
amino	1027	1032	|I-IUPAC
-	1032	1033	|I-IUPAC
3	1033	1034	|I-IUPAC
-	1034	1035	|I-IUPAC
methyl	1035	1041	|I-IUPAC
-	1041	1042	|I-IUPAC
1	1042	1043	|I-IUPAC
-	1043	1044	|I-IUPAC
azetidinyl	1044	1054	|I-IUPAC
)	1054	1055	|I-IUPAC
analogues	1056	1065	|B-MODIFIER
(	1066	1067	|O
for	1067	1070	|O
Part	1071	1075	|O
1	1076	1077	|O
,	1077	1078	|O
see	1079	1082	|O
:	1082	1083	|O
J	1084	1085	|O
.	1085	1086	|O
Med.	1087	1091	|O
Chem.	1092	1097	|O
1993	1098	1102	|O
,	1102	1103	|O
36	1104	1106	|O
,	1106	1107	|O
801-810	1108	1115	|O
)	1115	1116	|O
.	1116	1117	|O
A	1118	1119	|O
combination	1120	1131	|O
of	1132	1134	|O
a	1135	1136	|O
cyclopropyl	1137	1148	|O
or	1149	1151	|O
a	1152	1153	|O
substituted	1154	1165	|O
phenyl	1166	1172	|B-IUPAC
group	1173	1178	|B-MODIFIER
at	1179	1181	|O
N	1182	1183	|O
-	1183	1184	|O
1	1184	1185	|O
and	1186	1189	|O
a	1190	1191	|O
trans	1192	1197	|B-IUPAC
-	1197	1198	|I-IUPAC
3	1198	1199	|I-IUPAC
-	1199	1200	|I-IUPAC
amino	1200	1205	|I-IUPAC
-	1205	1206	|I-IUPAC
2	1206	1207	|I-IUPAC
-	1207	1208	|I-IUPAC
methyl	1208	1214	|I-IUPAC
-	1214	1215	|I-IUPAC
1	1215	1216	|I-IUPAC
-	1216	1217	|I-IUPAC
azetidinyl	1217	1227	|I-IUPAC
group	1228	1233	|B-MODIFIER
at	1234	1236	|O
C	1237	1238	|O
-	1238	1239	|O
7	1239	1240	|O
conferred	1241	1250	|O
the	1251	1254	|O
best	1255	1259	|O
overall	1260	1267	|O
antibacterial	1268	1281	|O
,	1281	1282	|O
pharmacokinetic	1283	1298	|O
,	1298	1299	|O
and	1300	1303	|O
physicochemical	1304	1319	|O
properties	1320	1330	|O
to	1331	1333	|O
the	1334	1337	|O
azetidinylquinolones	1338	1358	|O
studied	1359	1366	|O
.	1366	1367	|O

### abstracts3051.txt
Synthetic	0	9	|O
procedures	10	20	|O
for	21	24	|O
the	25	28	|O
preparation	29	40	|O
of	41	43	|O
various	44	51	|O
3	52	53	|B-MODIFIER
-	53	54	|I-MODIFIER
unsubstituted	54	67	|I-MODIFIER
xanthines	68	77	|B-IUPAC
,	77	78	|O
including	79	88	|O
paraxanthine	89	101	|O
analogs	102	109	|O
(	110	111	|O
1,7	111	114	|B-MODIFIER
-	114	115	|I-MODIFIER
disubstituted	115	128	|I-MODIFIER
xanthines	129	138	|B-IUPAC
)	138	139	|O
and	140	143	|O
1,8	144	147	|B-MODIFIER
-	147	148	|I-MODIFIER
disubstituted	148	161	|I-MODIFIER
xanthines	162	171	|B-IUPAC
,	171	172	|O
were	173	177	|O
developed	178	187	|O
.	187	188	|O
Silylation	189	199	|O
of	200	202	|O
1	203	204	|B-MODIFIER
-	204	205	|I-MODIFIER
substituted	205	216	|I-MODIFIER
xanthines	217	226	|B-IUPAC
followed	227	235	|O
by	236	238	|O
alkylation	239	249	|O
at	250	252	|O
the	253	256	|O
7	257	258	|O
-	258	259	|O
position	259	267	|O
provides	268	276	|O
a	277	278	|O
facile	279	285	|O
route	286	291	|O
to	292	294	|O
paraxanthine	295	307	|O
analogs	308	315	|O
.	315	316	|O
Regioselective	317	331	|O
alkylation	332	342	|O
of	343	345	|O
tris	346	350	|B-IUPAC
(	350	351	|I-IUPAC
trimethylsilyl	351	365	|I-IUPAC
)	365	366	|I-IUPAC
-	366	367	|I-IUPAC
6	367	368	|I-IUPAC
-	368	369	|I-IUPAC
aminouracil	369	380	|I-IUPAC
provides	381	389	|O
3	390	391	|B-MODIFIER
-	391	392	|I-MODIFIER
substituted	392	403	|I-MODIFIER
6	404	405	|B-IUPAC
-	405	406	|I-IUPAC
aminouracils	406	418	|I-IUPAC
,	418	419	|O
which	420	425	|O
are	426	429	|O
converted	430	439	|O
to	440	442	|O
1,8	443	446	|B-MODIFIER
-	446	447	|I-MODIFIER
disubstituted	447	460	|I-MODIFIER
xanthines	461	470	|B-IUPAC
by	471	473	|O
standard	474	482	|O
procedures	483	493	|O
.	493	494	|O
The	495	498	|O
ring	499	503	|O
closure	504	511	|O
of	512	514	|O
3	515	516	|B-MODIFIER
-	516	517	|I-MODIFIER
substituted	517	528	|I-MODIFIER
5	529	530	|B-PARTIUPAC
-	530	531	|I-PARTIUPAC
cyclopentanecarboxamido	531	554	|I-PARTIUPAC
-	554	555	|I-PARTIUPAC
and	556	559	|O
5	560	561	|B-IUPAC
-	561	562	|I-IUPAC
(	562	563	|I-IUPAC
benzoylamino	563	575	|I-IUPAC
)	575	576	|I-IUPAC
-	576	577	|I-IUPAC
6	577	578	|I-IUPAC
-	578	579	|I-IUPAC
aminouracils	579	591	|I-IUPAC
requires	592	600	|O
drastic	601	608	|O
reaction	609	617	|O
conditions	618	628	|O
.	628	629	|O
Affinity	630	638	|O
for	639	642	|O
brain	643	648	|O
A1	649	651	|O
and	652	655	|O
A2	656	658	|O
adenosine	659	668	|O
receptors	669	678	|O
was	679	682	|O
determined	683	693	|O
in	694	696	|O
binding	697	704	|O
assays	705	711	|O
for	712	715	|O
these	716	721	|O
and	722	725	|O
other	726	731	|O
xanthines	732	741	|O
with	742	746	|O
substituents	747	759	|O
in	760	762	|O
1	763	764	|O
-	764	765	|O
,	765	766	|O
3	767	768	|O
-	768	769	|O
,	769	770	|O
7	771	772	|O
-	772	773	|O
,	773	774	|O
8	775	776	|O
-	776	777	|O
,	777	778	|O
and	779	782	|O
9	783	784	|O
-	784	785	|O
positions	785	794	|O
.	794	795	|O
Substitution	796	808	|O
at	809	811	|O
the	812	815	|O
1	816	817	|O
-	817	818	|O
position	818	826	|O
was	827	830	|O
necessary	831	840	|O
for	841	844	|O
high	845	849	|O
affinity	850	858	|O
at	859	861	|O
adenosine	862	871	|O
receptors	872	881	|O
.	881	882	|O
1,3	883	886	|B-MODIFIER
-	886	887	|I-MODIFIER
Disubstituted	887	900	|I-MODIFIER
xanthines	901	910	|B-IUPAC
generally	911	920	|O
had	921	924	|O
higher	925	931	|O
affinity	932	940	|O
than	941	945	|O
1,7	946	949	|B-MODIFIER
-	949	950	|I-MODIFIER
disubstituted	950	963	|I-MODIFIER
xanthines	964	973	|B-IUPAC
.	973	974	|O
1,8	975	978	|B-MODIFIER
-	978	979	|I-MODIFIER
Disubstituted	979	992	|I-MODIFIER
xanthines	993	1002	|B-IUPAC
had	1003	1006	|O
high	1007	1011	|O
affinity	1012	1020	|O
for	1021	1024	|O
adenosine	1025	1034	|O
receptors	1035	1044	|O
;	1044	1045	|O
some	1046	1050	|O
were	1051	1055	|O
highly	1056	1062	|O
selective	1063	1072	|O
for	1073	1076	|O
A1	1077	1079	|O
receptors	1080	1089	|O
.	1089	1090	|O

### abstracts4118.txt
[	0	1	|O
1	1	2	|B-IUPAC
-	2	3	|I-IUPAC
N	3	4	|I-IUPAC
-	4	5	|I-IUPAC
methylisoleucine	5	21	|I-IUPAC
,	21	22	|I-IUPAC
8	22	23	|I-IUPAC
-	23	24	|I-IUPAC
threonine	24	33	|I-IUPAC
]	33	34	|O
-	34	35	|O
(	35	36	|O
I	36	37	|O
)	37	38	|O
,	38	39	|O
[	40	41	|O
1	41	42	|B-IUPAC
-	42	43	|I-IUPAC
dimethylglycine	43	58	|I-IUPAC
,	58	59	|I-IUPAC
8	59	60	|I-IUPAC
-	60	61	|I-IUPAC
threonine	61	70	|I-IUPAC
]	70	71	|O
-	71	72	|O
(	72	73	|O
II	73	75	|O
)	75	76	|O
,	76	77	|O
[	78	79	|O
1	79	80	|B-IUPAC
-	80	81	|I-IUPAC
guanidineacetic	81	96	|I-IUPAC
acid	97	101	|I-IUPAC
,	101	102	|I-IUPAC
8	102	103	|I-IUPAC
-	103	104	|I-IUPAC
threonine	104	113	|I-IUPAC
]	113	114	|O
-	114	115	|O
(	115	116	|O
III	116	119	|O
)	119	120	|O
,	120	121	|O
des	122	125	|B-IUPAC
-	125	126	|I-IUPAC
1	126	127	|I-IUPAC
-	127	128	|I-IUPAC
aspartic	128	136	|I-IUPAC
acid	137	141	|I-IUPAC
-	141	142	|I-IUPAC
[	142	143	|I-IUPAC
8	143	144	|I-IUPAC
-	144	145	|I-IUPAC
threonine	145	154	|I-IUPAC
]	154	155	|I-IUPAC
-	155	156	|O
(	156	157	|O
IV	157	159	|O
)	159	160	|O
,	160	161	|O
and	162	165	|O
[	166	167	|B-IUPAC
1	167	168	|I-IUPAC
-	168	169	|I-IUPAC
sarcosine	169	178	|I-IUPAC
,	178	179	|I-IUPAC
8	179	180	|I-IUPAC
-	180	181	|I-IUPAC
O	181	182	|I-IUPAC
-	182	183	|I-IUPAC
methylserine	183	195	|I-IUPAC
]	195	196	|I-IUPAC
angiotensin	196	207	|I-IUPAC
II	208	210	|I-IUPAC
(	211	212	|O
V	212	213	|O
)	213	214	|O
were	215	219	|O
synthesized	220	231	|O
by	232	234	|O
Merrifield	235	245	|O
's	245	247	|O
solid	248	253	|O
-	253	254	|O
phase	254	259	|O
procedure	260	269	|O
to	270	272	|O
study	273	278	|O
the	279	282	|O
effect	283	289	|O
of	290	292	|O
(	293	294	|O
a	294	295	|O
)	295	296	|O
substituents	297	309	|O
in	310	312	|O
position	313	321	|O
1	322	323	|O
on	324	326	|O
the	327	330	|O
antagonistic	331	343	|O
activity	344	352	|O
of	353	355	|O
[	356	357	|B-IUPAC
1	357	358	|I-IUPAC
-	358	359	|I-IUPAC
sarcosine	359	368	|I-IUPAC
,	368	369	|I-IUPAC
8	369	370	|I-IUPAC
-	370	371	|I-IUPAC
threonine	371	380	|I-IUPAC
]	380	381	|I-IUPAC
angiotensin	381	392	|I-IUPAC
II	393	395	|I-IUPAC
,	395	396	|O
and	397	400	|O
(	401	402	|O
b	402	403	|O
)	403	404	|O
a	405	406	|O
change	407	413	|O
in	414	416	|O
size	417	421	|O
and	422	425	|O
branching	426	435	|O
in	436	438	|O
position	439	447	|O
8	448	449	|O
of	450	452	|O
[	453	454	|B-IUPAC
1	454	455	|I-IUPAC
-	455	456	|I-IUPAC
sarcosine	456	465	|I-IUPAC
,	465	466	|I-IUPAC
-	466	467	|I-IUPAC
8	467	468	|I-IUPAC
-	468	469	|I-IUPAC
O	469	470	|I-IUPAC
-	470	471	|I-IUPAC
methylthreonine	471	486	|I-IUPAC
]	486	487	|I-IUPAC
angiotensin	487	498	|I-IUPAC
II	499	501	|I-IUPAC
.	501	502	|O
The	503	506	|O
analogues	507	516	|O
I	517	518	|O
-	518	519	|O
V	519	520	|O
caused	521	527	|O
an	528	530	|O
initial	531	538	|O
rise	539	543	|O
in	544	546	|O
blood	547	552	|O
pressure	553	561	|O
(	562	563	|O
30	563	565	|O
min	566	569	|O
of	570	572	|O
infusion	573	581	|O
,	581	582	|O
250	583	586	|O
ng	587	589	|O
/	589	590	|O
kg	590	592	|O
/	592	593	|O
min	593	596	|O
in	597	599	|O
vagotomized	600	611	|O
ganglion	612	620	|O
-	620	621	|O
blocked	621	628	|O
rats	629	633	|O
)	633	634	|O
of	635	637	|O
8.05	638	642	|O
,	642	643	|O
11.7	644	648	|O
,	648	649	|O
3.50	650	654	|O
,	654	655	|O
4.5	656	659	|O
,	659	660	|O
and	661	664	|O
11.16	665	670	|O
mmHg	671	675	|O
.	675	676	|O
The	677	680	|O
pA2	681	684	|O
values	685	691	|O
(	692	693	|O
rabbit	693	699	|O
aortic	700	706	|O
strips	707	713	|O
)	713	714	|O
obtained	715	723	|O
were	724	728	|O
7.68	729	733	|O
,	733	734	|O
7.53	735	739	|O
,	739	740	|O
7.23	741	745	|O
,	745	746	|O
7.53	747	751	|O
,	751	752	|O
and	753	756	|O
9.66	757	761	|O
,	761	762	|O
and	763	766	|O
the	767	770	|O
dose	771	775	|O
ratios	776	782	|O
(	783	784	|O
in	784	786	|O
vagotomized	787	798	|O
ganglion	799	807	|O
-	807	808	|O
blocked	808	815	|O
rats	816	820	|O
infused	821	828	|O
at	829	831	|O
250	832	835	|O
ng	836	838	|O
/	838	839	|O
kg	839	841	|O
/	841	842	|O
min	842	845	|O
)	845	846	|O
obtained	847	855	|O
were	856	860	|O
2.37	861	865	|O
,	865	866	|O
4.49	867	871	|O
,	871	872	|O
1.02	873	877	|O
,	877	878	|O
1.47	879	883	|O
,	883	884	|O
and	885	888	|O
24.04	889	894	|O
,	894	895	|O
respectively	896	908	|O
.	908	909	|O
The	910	913	|O
results	914	921	|O
obtained	922	930	|O
indicate	931	939	|O
that	940	944	|O
(	945	946	|O
a	946	947	|O
)	947	948	|O
the	949	952	|O
nature	953	959	|O
of	960	962	|O
the	963	966	|O
substituent	967	978	|O
in	979	981	|O
position	982	990	|O
1	991	992	|O
has	993	996	|O
an	997	999	|O
important	1000	1009	|O
influence	1010	1019	|O
on	1020	1022	|O
the	1023	1026	|O
biological	1027	1037	|O
activity	1038	1046	|O
of	1047	1049	|O
these	1050	1055	|O
peptides	1056	1064	|O
,	1064	1065	|O
and	1066	1069	|O
(	1070	1071	|O
b	1071	1072	|O
)	1072	1073	|O
the	1074	1077	|O
potency	1078	1085	|O
of	1086	1088	|O
antagonists	1089	1100	|O
I	1101	1102	|O
-	1102	1103	|O
IV	1103	1105	|O
(	1106	1107	|O
all	1107	1110	|O
less	1111	1115	|O
potent	1116	1122	|O
antagonists	1123	1134	|O
than	1135	1139	|O
[	1140	1141	|B-IUPAC
1	1141	1142	|I-IUPAC
-	1142	1143	|I-IUPAC
sarcosine	1143	1152	|I-IUPAC
,	1152	1153	|I-IUPAC
8	1153	1154	|I-IUPAC
-	1154	1155	|I-IUPAC
threonine	1155	1164	|I-IUPAC
]	1164	1165	|I-IUPAC
angiotensin	1165	1176	|I-IUPAC
II	1177	1179	|I-IUPAC
)	1179	1180	|O
is	1181	1183	|O
very	1184	1188	|O
much	1189	1193	|O
influenced	1194	1204	|O
by	1205	1207	|O
the	1208	1211	|O
length	1212	1218	|O
and	1219	1222	|O
branching	1223	1232	|O
of	1233	1235	|O
the	1236	1239	|O
side	1240	1244	|O
chain	1245	1250	|O
in	1251	1253	|O
position	1254	1262	|O
8	1263	1264	|O
.	1264	1265	|O
The	1266	1269	|O
in	1270	1272	|O
vivo	1273	1277	|O
antagonistic	1278	1290	|O
activity	1291	1299	|O
of	1300	1302	|O
[	1303	1304	|B-IUPAC
1	1304	1305	|I-IUPAC
-	1305	1306	|I-IUPAC
sarcosine	1306	1315	|I-IUPAC
,	1315	1316	|I-IUPAC
8	1316	1317	|I-IUPAC
-	1317	1318	|I-IUPAC
O	1318	1319	|I-IUPAC
-	1319	1320	|I-IUPAC
methylthreonine	1320	1335	|I-IUPAC
]	1335	1336	|I-IUPAC
angiotensin	1336	1347	|I-IUPAC
II	1348	1350	|I-IUPAC
is	1351	1353	|O
reduced	1354	1361	|O
considerably	1362	1374	|O
by	1375	1377	|O
shortening	1378	1388	|O
the	1389	1392	|O
chain	1393	1398	|O
length	1399	1405	|O
by	1406	1408	|O
one	1409	1412	|O
carbon	1413	1419	|O
atom	1420	1424	|O
as	1425	1427	|O
is	1428	1430	|O
in	1431	1433	|O
V	1434	1435	|O
.	1435	1436	|O

### abstracts3316.txt
In	0	2	|O
furtherance	3	14	|O
of	15	17	|O
our	18	21	|O
SAR	22	25	|O
study	26	31	|O
on	32	34	|O
the	35	38	|O
chemistry	39	48	|O
and	49	52	|O
antitumor	53	62	|O
activity	63	71	|O
of	72	74	|O
fused	75	80	|O
nitrogen	81	89	|O
heteroaromatic	90	104	|O
compounds	105	114	|O
,	114	115	|O
a	116	117	|O
series	118	124	|O
of	125	127	|O
linear	128	134	|O
,	134	135	|O
methyl	136	142	|B-IUPAC
-	142	143	|O
substituted	143	154	|B-MODIFIER
derivatives	155	166	|B-MODIFIER
of	167	169	|O
5H	170	172	|B-PARTIUPAC
-	172	173	|I-PARTIUPAC
and	174	177	|O
6H	178	180	|B-IUPAC
-	180	181	|I-IUPAC
indolo	181	187	|I-IUPAC
[	187	188	|I-IUPAC
2,3	188	191	|I-IUPAC
-	191	192	|I-IUPAC
b	192	193	|I-IUPAC
]	193	194	|I-IUPAC
quinolines	194	204	|I-IUPAC
were	205	209	|O
synthesized	210	221	|O
according	222	231	|O
to	232	234	|O
the	235	238	|O
modified	239	247	|O
Graebe	248	254	|O
-	254	255	|O
Ullmann	255	262	|O
reaction	263	271	|O
.	271	272	|O
To	273	275	|O
establish	276	285	|O
the	286	289	|O
relationship	290	302	|O
between	303	310	|O
the	311	314	|O
physicochemical	315	330	|O
and	331	334	|O
biological	335	345	|O
activities	346	356	|O
of	357	359	|O
indolo	360	366	|B-IUPAC
[	366	367	|I-IUPAC
2,3	367	370	|I-IUPAC
-	370	371	|I-IUPAC
b	371	372	|I-IUPAC
]	372	373	|I-IUPAC
quinolines	373	383	|I-IUPAC
,	383	384	|O
their	385	390	|O
lipophilic	391	401	|O
properties	402	412	|O
,	412	413	|O
cytotoxic	414	423	|O
and	424	427	|O
antimicrobial	428	441	|O
activity	442	450	|O
,	450	451	|O
and	452	455	|O
ability	456	463	|O
to	464	466	|O
induce	467	473	|O
topoisomerase	474	487	|O
II	488	490	|O
dependent	491	500	|O
pSP65	501	506	|O
DNA	507	510	|O
cleavage	511	519	|O
in	520	522	|O
vitro	523	528	|O
were	529	533	|O
investigated	534	546	|O
.	546	547	|O
We	548	550	|O
found	551	556	|O
that	557	561	|O
the	562	565	|O
antimicrobial	566	579	|O
and	580	583	|O
cytotoxic	584	593	|O
activity	594	602	|O
of	603	605	|O
indolo	606	612	|B-IUPAC
[	612	613	|I-IUPAC
2,3	613	616	|I-IUPAC
-	616	617	|I-IUPAC
b	617	618	|I-IUPAC
]	618	619	|I-IUPAC
quinolines	619	629	|I-IUPAC
was	630	633	|O
strongly	634	642	|O
influenced	643	653	|O
by	654	656	|O
the	657	660	|O
position	661	669	|O
,	669	670	|O
and	671	674	|O
the	675	678	|O
number	679	685	|O
of	686	688	|O
methyl	689	695	|B-IUPAC
substituents	696	708	|B-MODIFIER
and	709	712	|O
the	713	716	|O
presence	717	725	|O
of	726	728	|O
methyl	729	735	|B-IUPAC
group	736	741	|B-MODIFIER
at	742	744	|O
pyridine	745	753	|O
nitrogen	754	762	|O
was	763	766	|O
essential	767	776	|O
for	777	780	|O
the	781	784	|O
cytotoxicity	785	797	|O
of	798	800	|O
these	801	806	|O
compounds	807	816	|O
.	816	817	|O
All	818	821	|O
indolo	822	828	|B-IUPAC
[	828	829	|I-IUPAC
2,3	829	832	|I-IUPAC
-	832	833	|I-IUPAC
b	833	834	|I-IUPAC
]	834	835	|I-IUPAC
quinolines	835	845	|I-IUPAC
belonging	846	855	|O
to	856	858	|O
the	859	862	|O
5H	863	865	|O
series	866	872	|O
,	872	873	|O
i.e.	874	878	|O
,	878	879	|O
bearing	880	887	|O
a	888	889	|O
methyl	890	896	|B-IUPAC
group	897	902	|B-MODIFIER
on	903	905	|O
the	906	909	|O
pyridine	910	918	|O
nitrogen	919	927	|O
,	927	928	|O
showed	929	935	|O
significant	936	947	|O
activity	948	956	|O
against	957	964	|O
procaryotic	965	976	|O
and	977	980	|O
eucaryotic	981	991	|O
organisms	992	1001	|O
.	1001	1002	|O
They	1003	1007	|O
inhibited	1008	1017	|O
the	1018	1021	|O
growth	1022	1028	|O
of	1029	1031	|O
Gram	1032	1036	|O
-	1036	1037	|O
positive	1037	1045	|O
bacteria	1046	1054	|O
and	1055	1058	|O
pathogenic	1059	1069	|O
fungi	1070	1075	|O
at	1076	1078	|O
MIC	1079	1082	|O
range	1083	1088	|O
3	1089	1090	|O
x	1091	1092	|O
10	1093	1095	|O
(	1095	1096	|O
-	1096	1097	|O
2	1097	1098	|O
)	1098	1099	|O
to	1100	1102	|O
2.5	1103	1106	|O
x	1107	1108	|O
10	1109	1111	|O
(	1111	1112	|O
-	1112	1113	|O
1	1113	1114	|O
)	1114	1115	|O
mumol	1116	1121	|O
/	1121	1122	|O
mL	1122	1124	|O
,	1124	1125	|O
displayed	1126	1135	|O
cytotoxicity	1136	1148	|O
against	1149	1156	|O
KB	1157	1159	|O
cells	1160	1165	|O
ID50	1166	1170	|O
in	1171	1173	|O
the	1174	1177	|O
range	1178	1183	|O
2	1184	1185	|O
x	1186	1187	|O
10	1188	1190	|O
(	1190	1191	|O
-	1191	1192	|O
3	1192	1193	|O
)	1193	1194	|O
to	1195	1197	|O
9	1198	1199	|O
x	1200	1201	|O
10	1202	1204	|O
(	1204	1205	|O
-	1205	1206	|O
3	1206	1207	|O
)	1207	1208	|O
mumol	1209	1214	|O
/	1214	1215	|O
mL	1215	1217	|O
,	1217	1218	|O
and	1219	1222	|O
stimulated	1223	1233	|O
the	1234	1237	|O
formation	1238	1247	|O
of	1248	1250	|O
calf	1251	1255	|O
thymus	1256	1262	|O
topoisomerase	1263	1276	|O
II	1277	1279	|O
mediated	1280	1288	|O
DNA	1289	1292	|O
cleavage	1293	1301	|O
at	1302	1304	|O
concentration	1305	1318	|O
between	1319	1326	|O
0.4	1327	1330	|O
and	1331	1334	|O
10	1335	1337	|O
microM	1338	1344	|O
.	1344	1345	|O
None	1346	1350	|O
of	1351	1353	|O
the	1354	1357	|O
indolo	1358	1364	|B-IUPAC
[	1364	1365	|I-IUPAC
2,3	1365	1368	|I-IUPAC
-	1368	1369	|I-IUPAC
b	1369	1370	|I-IUPAC
]	1370	1371	|I-IUPAC
quinolines	1371	1381	|I-IUPAC
belonging	1382	1391	|O
to	1392	1394	|O
the	1395	1398	|O
6H	1399	1401	|O
series	1402	1408	|O
,	1408	1409	|O
i.e.	1410	1414	|O
,	1414	1415	|O
lacking	1416	1423	|O
a	1424	1425	|O
methyl	1426	1432	|B-IUPAC
group	1433	1438	|B-MODIFIER
on	1439	1441	|O
the	1442	1445	|O
pyridine	1446	1454	|O
nitrogen	1455	1463	|O
,	1463	1464	|O
was	1465	1468	|O
active	1469	1475	|O
in	1476	1478	|O
analogous	1479	1488	|O
tests	1489	1494	|O
.	1494	1495	|O
Of	1496	1498	|O
the	1499	1502	|O
investigated	1503	1515	|O
compounds	1516	1525	|O
,	1525	1526	|O
the	1527	1530	|O
most	1531	1535	|O
active	1536	1542	|O
was	1543	1546	|O
2,5,9,11	1547	1555	|B-IUPAC
-	1555	1556	|I-IUPAC
tetramethyl	1556	1567	|I-IUPAC
-	1567	1568	|I-IUPAC
5H	1568	1570	|I-IUPAC
-	1570	1571	|I-IUPAC
indolo	1571	1577	|I-IUPAC
[	1577	1578	|I-IUPAC
2,3	1578	1581	|I-IUPAC
-	1581	1582	|I-IUPAC
b	1582	1583	|I-IUPAC
]	1583	1584	|I-IUPAC
quinoline	1584	1593	|I-IUPAC
,	1593	1594	|O
a	1595	1596	|O
compound	1597	1605	|O
bearing	1606	1613	|O
the	1614	1617	|O
highest	1618	1625	|O
number	1626	1632	|O
of	1633	1635	|O
symmetrically	1636	1649	|O
distributed	1650	1661	|O
methyl	1662	1668	|B-IUPAC
groups	1669	1675	|B-MODIFIER
.	1675	1676	|O
The	1677	1680	|O
interaction	1681	1692	|O
of	1693	1695	|O
indolo	1696	1702	|B-IUPAC
[	1702	1703	|I-IUPAC
2,3	1703	1706	|I-IUPAC
-	1706	1707	|I-IUPAC
b	1707	1708	|I-IUPAC
]	1708	1709	|I-IUPAC
quinolines	1709	1719	|I-IUPAC
with	1720	1724	|O
DNA	1725	1728	|O
was	1729	1732	|O
studied	1733	1740	|O
by	1741	1743	|O
measuring	1744	1753	|O
the	1754	1757	|O
increase	1758	1766	|O
of	1767	1769	|O
calf	1770	1774	|O
thymus	1775	1781	|O
DNA	1782	1785	|O
denaturating	1786	1798	|O
temperature	1799	1810	|O
(	1811	1812	|O
Tm	1812	1814	|O
)	1814	1815	|O
.	1815	1816	|O
The	1817	1820	|O
delta	1821	1826	|O
Tm	1827	1829	|O
values	1830	1836	|O
for	1837	1840	|O
the	1841	1844	|O
5H	1845	1847	|O
series	1848	1854	|O
were	1855	1859	|O
found	1860	1865	|O
to	1866	1868	|O
be	1869	1871	|O
about	1872	1877	|O
10	1878	1880	|O
times	1881	1886	|O
as	1887	1889	|O
high	1890	1894	|O
as	1895	1897	|O
those	1898	1903	|O
for	1904	1907	|O
the	1908	1911	|O
6H	1912	1914	|O
compounds	1915	1924	|O
.	1924	1925	|O
Indolo	1926	1932	|B-IUPAC
[	1932	1933	|I-IUPAC
2,3	1933	1936	|I-IUPAC
-	1936	1937	|I-IUPAC
b	1937	1938	|I-IUPAC
]	1938	1939	|I-IUPAC
quinolines	1939	1949	|I-IUPAC
with	1950	1954	|O
the	1955	1958	|O
highest	1959	1966	|O
number	1967	1973	|O
of	1974	1976	|O
methyl	1977	1983	|B-IUPAC
groups	1984	1990	|B-MODIFIER
had	1991	1994	|O
the	1995	1998	|O
greatest	1999	2007	|O
contribution	2008	2020	|O
to	2021	2023	|O
the	2024	2027	|O
increase	2028	2036	|O
in	2037	2039	|O
the	2040	2043	|O
Tm	2044	2046	|O
of	2047	2049	|O
calf	2050	2054	|O
thymus	2055	2061	|O
DNA	2062	2065	|O
.	2065	2066	|O
The	2067	2070	|O
values	2071	2077	|O
of	2078	2080	|O
delta	2081	2086	|O
Tm	2087	2089	|O
reached	2090	2097	|O
19	2098	2100	|O
degrees	2101	2108	|O
C	2109	2110	|O
and	2111	2114	|O
1.6	2115	2118	|O
degrees	2119	2126	|O
C	2127	2128	|O
for	2129	2132	|O
the	2133	2136	|O
most	2137	2141	|O
substituted	2142	2153	|O
compounds	2154	2163	|O
of	2164	2166	|O
both	2167	2171	|O
series	2172	2178	|O
.	2178	2179	|O

### abstracts1169.txt
The	0	3	|O
dedifferentiation	4	21	|O
agent	22	27	|O
"	28	29	|O
reversine	29	38	|O
"	38	39	|O
[	40	41	|O
2	41	42	|B-IUPAC
-	42	43	|I-IUPAC
(	43	44	|I-IUPAC
4	44	45	|I-IUPAC
-	45	46	|I-IUPAC
morpholinoanilino	46	63	|I-IUPAC
)	63	64	|I-IUPAC
-	64	65	|I-IUPAC
N	65	66	|I-IUPAC
(	66	67	|I-IUPAC
6	67	68	|I-IUPAC
)	68	69	|I-IUPAC
-	69	70	|I-IUPAC
cyclohexyladenine	70	87	|I-IUPAC
2	88	89	|I-IUPAC
]	89	90	|O
was	91	94	|O
found	95	100	|O
to	101	103	|O
be	104	106	|O
a	107	108	|O
moderately	109	119	|O
potent	120	126	|O
antagonist	127	137	|O
for	138	141	|O
the	142	145	|O
human	146	151	|O
A	152	153	|O
(	153	154	|O
3	154	155	|O
)	155	156	|O
adenosine	157	166	|O
receptor	167	175	|O
(	176	177	|O
AR	177	179	|O
)	179	180	|O
with	181	185	|O
a	186	187	|O
K	188	189	|O
(	189	190	|O
i	190	191	|O
)	191	192	|O
value	193	198	|O
of	199	201	|O
0.66	202	206	|O
microM	207	213	|O
.	213	214	|O
This	215	219	|O
result	220	226	|O
prompted	227	235	|O
an	236	238	|O
exploration	239	250	|O
of	251	253	|O
the	254	257	|O
structure	258	267	|O
-	267	268	|O
activity	268	276	|O
relationship	277	289	|O
of	290	292	|O
related	293	300	|O
derivatives	301	312	|O
,	312	313	|O
synthesized	314	325	|O
via	326	329	|O
sequential	330	340	|O
substitution	341	353	|O
of	354	356	|O
6	357	358	|B-IUPAC
-	358	359	|I-IUPAC
chloro	359	365	|I-IUPAC
-	365	366	|I-IUPAC
2	366	367	|I-IUPAC
-	367	368	|I-IUPAC
fluoropurine	368	380	|I-IUPAC
with	381	385	|O
selected	386	394	|O
nucleophiles	395	407	|O
.	407	408	|O
Optimization	409	421	|O
of	422	424	|O
substituents	425	437	|O
at	438	440	|O
these	441	446	|O
two	447	450	|O
positions	451	460	|O
identified	461	471	|O
2	472	473	|B-IUPAC
-	473	474	|I-IUPAC
(	474	475	|I-IUPAC
phenylamino	475	486	|I-IUPAC
)	486	487	|I-IUPAC
-	487	488	|I-IUPAC
N	488	489	|I-IUPAC
(	489	490	|I-IUPAC
6	490	491	|I-IUPAC
)	491	492	|I-IUPAC
-	492	493	|I-IUPAC
cyclohexyladenine	493	510	|I-IUPAC
(	511	512	|O
12	512	514	|O
)	514	515	|O
,	515	516	|O
2	517	518	|B-IUPAC
-	518	519	|I-IUPAC
(	519	520	|I-IUPAC
phenylamino	520	531	|I-IUPAC
)	531	532	|I-IUPAC
-	532	533	|I-IUPAC
N	533	534	|I-IUPAC
(	534	535	|I-IUPAC
6	535	536	|I-IUPAC
)	536	537	|I-IUPAC
-	537	538	|I-IUPAC
cycloheptyladenine	538	556	|I-IUPAC
(	557	558	|O
19	558	560	|O
)	560	561	|O
,	561	562	|O
and	563	566	|O
2	567	568	|B-IUPAC
-	568	569	|I-IUPAC
phenylamino	569	580	|I-IUPAC
-	580	581	|I-IUPAC
N	581	582	|I-IUPAC
(	582	583	|I-IUPAC
6	583	584	|I-IUPAC
)	584	585	|I-IUPAC
-	585	586	|I-IUPAC
endo	586	590	|I-IUPAC
-	590	591	|I-IUPAC
norbornyladenine	591	607	|I-IUPAC
(	608	609	|O
21	609	611	|O
)	611	612	|O
as	613	615	|O
potent	616	622	|O
A	623	624	|O
(	624	625	|O
3	625	626	|O
)	626	627	|O
AR	628	630	|O
ligands	631	638	|O
with	639	643	|O
K	644	645	|O
(	645	646	|O
i	646	647	|O
)	647	648	|O
values	649	655	|O
of	656	658	|O
51	659	661	|O
,	661	662	|O
42	663	665	|O
,	665	666	|O
and	667	670	|O
37	671	673	|O
nM	674	676	|O
,	676	677	|O
respectively	678	690	|O
,	690	691	|O
with	692	696	|O
30-200	697	703	|O
-	703	704	|O
fold	704	708	|O
selectivity	709	720	|O
in	721	723	|O
comparison	724	734	|O
to	735	737	|O
A	738	739	|O
(	739	740	|O
1	740	741	|O
)	741	742	|O
and	743	746	|O
A	747	748	|O
(	748	749	|O
2A	749	751	|O
)	751	752	|O
ARs	753	756	|O
.	756	757	|O
The	758	761	|O
most	762	766	|O
selective	767	776	|O
A	777	778	|O
(	778	779	|O
3	779	780	|O
)	780	781	|O
AR	782	784	|O
antagonist	785	795	|O
(	796	797	|O
&	797	798	|O
gt	798	800	|O
;	800	801	|O
200	801	804	|O
-	804	805	|O
fold	805	809	|O
)	809	810	|O
was	811	814	|O
2	815	816	|B-IUPAC
-	816	817	|I-IUPAC
(	817	818	|I-IUPAC
phenyloxy	818	827	|I-IUPAC
)	827	828	|I-IUPAC
-	828	829	|I-IUPAC
N	829	830	|I-IUPAC
(	830	831	|I-IUPAC
6	831	832	|I-IUPAC
)	832	833	|I-IUPAC
-	833	834	|I-IUPAC
cyclohexyladenine	834	851	|I-IUPAC
(	852	853	|O
22	853	855	|O
)	855	856	|O
.	856	857	|O
9	858	859	|O
-	859	860	|O
Methylation	860	871	|O
of	872	874	|O
12	875	877	|O
,	877	878	|O
but	879	882	|O
not	883	886	|O
19	887	889	|O
,	889	890	|O
was	891	894	|O
well	895	899	|O
-	899	900	|O
tolerated	900	909	|O
in	910	912	|O
A	913	914	|O
(	914	915	|O
3	915	916	|O
)	916	917	|O
AR	918	920	|O
binding	921	928	|O
.	928	929	|O
Extension	930	939	|O
of	940	942	|O
the	943	946	|O
2	947	948	|B-IUPAC
-	948	949	|I-IUPAC
phenylamino	949	960	|I-IUPAC
group	961	966	|B-MODIFIER
to	967	969	|O
2	970	971	|B-PARTIUPAC
-	971	972	|I-PARTIUPAC
benzyl	972	978	|I-PARTIUPAC
-	978	979	|I-PARTIUPAC
and	980	983	|O
2	984	985	|B-IUPAC
-	985	986	|I-IUPAC
(	986	987	|I-IUPAC
2	987	988	|I-IUPAC
-	988	989	|I-IUPAC
phenylethylamino	989	1005	|I-IUPAC
)	1005	1006	|I-IUPAC
reduced	1007	1014	|O
affinity	1015	1023	|O
.	1023	1024	|O
In	1025	1027	|O
the	1028	1031	|O
series	1032	1038	|O
of	1039	1041	|O
2	1042	1043	|B-IUPAC
-	1043	1044	|I-IUPAC
(	1044	1045	|I-IUPAC
phenylamino	1045	1056	|I-IUPAC
)	1056	1057	|I-IUPAC
,	1057	1058	|O
2	1059	1060	|B-IUPAC
-	1060	1061	|I-IUPAC
(	1061	1062	|I-IUPAC
phenyloxy	1062	1071	|I-IUPAC
)	1071	1072	|I-IUPAC
,	1072	1073	|O
and	1074	1077	|O
2	1078	1079	|B-IUPAC
-	1079	1080	|I-IUPAC
(	1080	1081	|I-IUPAC
phenylthio	1081	1091	|I-IUPAC
)	1091	1092	|I-IUPAC
substitutions	1093	1106	|B-MODIFIER
,	1106	1107	|O
the	1108	1111	|O
order	1112	1117	|O
of	1118	1120	|O
affinity	1121	1129	|O
at	1130	1132	|O
the	1133	1136	|O
A	1137	1138	|O
(	1138	1139	|O
3	1139	1140	|O
)	1140	1141	|O
AR	1142	1144	|O
was	1145	1148	|O
oxy	1149	1152	|O
&	1153	1154	|O
gt	1154	1156	|O
;	1156	1157	|O
or	1158	1160	|O
=	1161	1162	|O
amino	1163	1168	|O
&	1169	1170	|O
gt	1170	1172	|O
;	1172	1173	|O
thio	1174	1178	|O
.	1178	1179	|O
Selected	1180	1188	|O
derivatives	1189	1200	|O
,	1200	1201	|O
including	1202	1211	|O
reversine	1212	1221	|O
(	1222	1223	|O
K	1223	1224	|O
(	1224	1225	|O
B	1225	1226	|O
)	1226	1227	|O
value	1228	1233	|O
of	1234	1236	|O
466	1237	1240	|O
nM	1241	1243	|O
via	1244	1247	|O
Schild	1248	1254	|O
analysis	1255	1263	|O
)	1263	1264	|O
,	1264	1265	|O
competitively	1266	1279	|O
antagonized	1280	1291	|O
the	1292	1295	|O
functional	1296	1306	|O
effects	1307	1314	|O
of	1315	1317	|O
a	1318	1319	|O
selective	1320	1329	|O
A	1330	1331	|O
(	1331	1332	|O
3	1332	1333	|O
)	1333	1334	|O
AR	1335	1337	|O
agonist	1338	1345	|O
,	1345	1346	|O
i.e.	1347	1351	|O
,	1351	1352	|O
inhibition	1353	1363	|O
of	1364	1366	|O
forskolin	1367	1376	|O
-	1376	1377	|O
stimulated	1377	1387	|O
cAMP	1388	1392	|O
production	1393	1403	|O
in	1404	1406	|O
stably	1407	1413	|O
transfected	1414	1425	|O
Chinese	1426	1433	|O
hamster	1434	1441	|O
ovary	1442	1447	|O
(	1448	1449	|O
CHO	1449	1452	|O
)	1452	1453	|O
cells	1454	1459	|O
.	1459	1460	|O
These	1461	1466	|O
results	1467	1474	|O
are	1475	1478	|O
in	1479	1481	|O
agreement	1482	1491	|O
with	1492	1496	|O
other	1497	1502	|O
studies	1503	1510	|O
suggesting	1511	1521	|O
the	1522	1525	|O
presence	1526	1534	|O
of	1535	1537	|O
a	1538	1539	|O
lipophilic	1540	1550	|O
pocket	1551	1557	|O
in	1558	1560	|O
the	1561	1564	|O
AR	1565	1567	|O
binding	1568	1575	|O
site	1576	1580	|O
that	1581	1585	|O
is	1586	1588	|O
filled	1589	1595	|O
by	1596	1598	|O
moderately	1599	1609	|O
sized	1610	1615	|O
cycloalkyl	1616	1626	|O
rings	1627	1632	|O
at	1633	1635	|O
the	1636	1639	|O
N	1640	1641	|O
(	1641	1642	|O
6	1642	1643	|O
)	1643	1644	|O
position	1645	1653	|O
of	1654	1656	|O
both	1657	1661	|O
adenine	1662	1669	|O
and	1670	1673	|O
adenosine	1674	1683	|O
derivatives	1684	1695	|O
.	1695	1696	|O
Thus	1697	1701	|O
,	1701	1702	|O
the	1703	1706	|O
compound	1707	1715	|O
series	1716	1722	|O
reported	1723	1731	|O
herein	1732	1738	|O
comprise	1739	1747	|O
an	1748	1750	|O
important	1751	1760	|O
new	1761	1764	|O
series	1765	1771	|O
of	1772	1774	|O
selective	1775	1784	|O
A	1785	1786	|O
(	1786	1787	|O
3	1787	1788	|O
)	1788	1789	|O
AR	1790	1792	|O
antagonists	1793	1804	|O
.	1804	1805	|O
We	1806	1808	|O
were	1809	1813	|O
unable	1814	1820	|O
to	1821	1823	|O
reproduce	1824	1833	|O
the	1834	1837	|O
dedifferentiation	1838	1855	|O
effect	1856	1862	|O
of	1863	1865	|O
reversine	1866	1875	|O
,	1875	1876	|O
previously	1877	1887	|O
reported	1888	1896	|O
,	1896	1897	|O
or	1898	1900	|O
to	1901	1903	|O
demonstrate	1904	1915	|O
any	1916	1919	|O
connection	1920	1930	|O
between	1931	1938	|O
A	1939	1940	|O
(	1940	1941	|O
3	1941	1942	|O
)	1942	1943	|O
AR	1944	1946	|O
antagonist	1947	1957	|O
effects	1958	1965	|O
and	1966	1969	|O
dedifferentiation	1970	1987	|O
.	1987	1988	|O

### abstracts2289.txt
In	0	2	|O
order	3	8	|O
to	9	11	|O
investigate	12	23	|O
the	24	27	|O
structural	28	38	|O
requirements	39	51	|O
for	52	55	|O
gastroprotective	56	72	|O
activity	73	81	|O
in	82	84	|O
6	85	86	|B-IUPAC
-	86	87	|I-IUPAC
[	87	88	|I-IUPAC
[	88	89	|I-IUPAC
1	89	90	|I-IUPAC
(	90	91	|I-IUPAC
S	91	92	|I-IUPAC
)	92	93	|I-IUPAC
-	93	94	|I-IUPAC
(	94	95	|I-IUPAC
3	95	96	|I-IUPAC
(	96	97	|I-IUPAC
S	97	98	|I-IUPAC
)	98	99	|I-IUPAC
,	99	100	|I-IUPAC
4	100	101	|I-IUPAC
-	101	102	|I-IUPAC
dihydro	102	109	|I-IUPAC
-	109	110	|I-IUPAC
8	110	111	|I-IUPAC
-	111	112	|I-IUPAC
hydroxy	113	120	|I-IUPAC
-	120	121	|I-IUPAC
1	121	122	|I-IUPAC
-	122	123	|I-IUPAC
oxo	123	126	|I-IUPAC
-	126	127	|I-IUPAC
1H	127	129	|I-IUPAC
-	129	130	|I-IUPAC
2	130	131	|I-IUPAC
-	131	132	|I-IUPAC
benzopyran	132	142	|I-IUPAC
-	142	143	|I-IUPAC
3	143	144	|I-IUPAC
-	144	145	|I-IUPAC
yl	145	147	|I-IUPAC
)	147	148	|I-IUPAC
-	148	149	|I-IUPAC
3	149	150	|I-IUPAC
-	150	151	|I-IUPAC
methylbutyl	151	162	|I-IUPAC
]	162	163	|I-IUPAC
amino	163	168	|I-IUPAC
]	168	169	|I-IUPAC
-	169	170	|I-IUPAC
4	170	171	|I-IUPAC
(	171	172	|I-IUPAC
S	172	173	|I-IUPAC
)	173	174	|I-IUPAC
,	174	175	|I-IUPAC
5	175	176	|I-IUPAC
(	176	177	|I-IUPAC
S	177	178	|I-IUPAC
)	178	179	|I-IUPAC
-	179	180	|I-IUPAC
dihydroxy	180	189	|I-IUPAC
6	190	191	|I-IUPAC
-	191	192	|I-IUPAC
oxo	192	195	|I-IUPAC
-	195	196	|I-IUPAC
3	196	197	|I-IUPAC
(	197	198	|I-IUPAC
S	198	199	|I-IUPAC
)	199	200	|I-IUPAC
-	200	201	|I-IUPAC
ammoniohexanoate	201	217	|I-IUPAC
[	218	219	|O
AI	219	221	|O
-	221	222	|O
77	222	224	|O
-	224	225	|O
B	225	226	|O
,	226	227	|O
1	228	229	|O
]	229	230	|O
,	230	231	|O
a	232	233	|O
product	234	241	|O
of	242	244	|O
Bacillus	245	253	|O
pumilus	254	261	|O
AI	262	264	|O
-	264	265	|O
77	265	267	|O
,	267	268	|O
nine	269	273	|O
derivatives	274	285	|O
were	286	290	|O
prepared	291	299	|O
and	300	303	|O
then	304	308	|O
tested	309	315	|O
for	316	319	|O
protective	320	330	|O
activity	331	339	|O
against	340	347	|O
stress	348	354	|O
-	354	355	|O
induced	355	362	|O
ulcers	363	369	|O
in	370	372	|O
rats	373	377	|O
.	377	378	|O
Neither	379	386	|O
the	387	390	|O
chromophore	391	402	|O
,	402	403	|O
[	404	405	|B-IUPAC
1	405	406	|I-IUPAC
-	406	407	|I-IUPAC
(	407	408	|I-IUPAC
3,4	408	411	|I-IUPAC
-	411	412	|I-IUPAC
dihydro	412	419	|I-IUPAC
-	419	420	|I-IUPAC
8	420	421	|I-IUPAC
-	421	422	|I-IUPAC
hydroxy	422	429	|I-IUPAC
-	429	430	|I-IUPAC
1	430	431	|I-IUPAC
-	431	432	|I-IUPAC
oxo	432	435	|I-IUPAC
-	435	436	|I-IUPAC
1H	436	438	|I-IUPAC
-	438	439	|I-IUPAC
2	439	440	|I-IUPAC
-	440	441	|I-IUPAC
benzopyran	441	451	|I-IUPAC
-	451	452	|I-IUPAC
3	452	453	|I-IUPAC
-	453	454	|I-IUPAC
yl	454	456	|I-IUPAC
)	456	457	|I-IUPAC
-	457	458	|I-IUPAC
3	458	459	|I-IUPAC
-	459	460	|I-IUPAC
methylbutyl	460	471	|I-IUPAC
]	471	472	|I-IUPAC
ammonium	472	480	|I-IUPAC
chloride	481	489	|I-IUPAC
(	490	491	|O
2	491	492	|O
)	492	493	|O
,	493	494	|O
nor	495	498	|O
the	499	502	|O
side	503	507	|O
-	507	508	|O
chain	508	513	|O
moiety	514	520	|O
,	520	521	|O
4	522	523	|B-IUPAC
-	523	524	|I-IUPAC
amino	524	529	|I-IUPAC
-	529	530	|I-IUPAC
2,3	530	533	|I-IUPAC
-	533	534	|I-IUPAC
dihydroxyhexanedioic	534	554	|I-IUPAC
acid	555	559	|I-IUPAC
(	560	561	|O
4	561	562	|O
)	562	563	|O
,	563	564	|O
as	565	567	|O
separate	568	576	|O
fragments	577	586	|O
alone	587	592	|O
showed	593	599	|O
any	600	603	|O
significant	604	615	|O
activity	616	624	|O
.	624	625	|O
Hydrolysis	626	636	|O
of	637	639	|O
the	640	643	|O
lactone	644	651	|O
ring	652	656	|O
of	657	659	|O
the	660	663	|O
1H	664	666	|B-IUPAC
-	666	667	|I-IUPAC
2	667	668	|I-IUPAC
-	668	669	|I-IUPAC
benzopyran	669	679	|I-IUPAC
-	679	680	|I-IUPAC
1	680	681	|I-IUPAC
-	681	682	|I-IUPAC
one	682	685	|I-IUPAC
skeleton	686	694	|B-MODIFIER
,	694	695	|O
to	696	698	|O
give	699	703	|O
6	704	705	|B-IUPAC
-	705	706	|I-IUPAC
[	706	707	|I-IUPAC
[	707	708	|I-IUPAC
1	708	709	|I-IUPAC
-	709	710	|I-IUPAC
(	710	711	|I-IUPAC
2	711	712	|I-IUPAC
-	712	713	|I-IUPAC
carboxy	713	720	|I-IUPAC
-	720	721	|I-IUPAC
3	721	722	|I-IUPAC
-	722	723	|I-IUPAC
hydroxyphenyl	723	736	|I-IUPAC
)	736	737	|I-IUPAC
-	737	738	|I-IUPAC
2	738	739	|I-IUPAC
-	739	740	|I-IUPAC
hydroxy	740	747	|I-IUPAC
-	747	748	|I-IUPAC
5	748	749	|I-IUPAC
-	749	750	|I-IUPAC
methylhex	750	759	|I-IUPAC
-	759	760	|I-IUPAC
3	760	761	|I-IUPAC
-	761	762	|I-IUPAC
yl	762	764	|I-IUPAC
]	764	765	|I-IUPAC
amino	765	770	|I-IUPAC
]	770	771	|I-IUPAC
-	771	772	|I-IUPAC
4	772	773	|I-IUPAC
,	773	774	|I-IUPAC
5	775	776	|I-IUPAC
-	776	777	|I-IUPAC
dihydroxy	777	786	|I-IUPAC
-	786	787	|I-IUPAC
6	787	788	|I-IUPAC
-	788	789	|I-IUPAC
oxo	789	792	|I-IUPAC
-	792	793	|I-IUPAC
3	793	794	|I-IUPAC
-	794	795	|I-IUPAC
ammoniohexanoate	795	811	|I-IUPAC
(	812	813	|O
5	813	814	|O
)	814	815	|O
,	815	816	|O
led	817	820	|O
to	821	823	|O
a	824	825	|O
considerable	826	838	|O
decrease	839	847	|O
in	848	850	|O
activity	851	859	|O
.	859	860	|O
The	861	864	|O
formation	865	874	|O
of	875	877	|O
a	878	879	|O
gamma	880	885	|O
-	885	886	|O
lactone	886	893	|O
ring	894	898	|O
in	899	901	|O
the	902	905	|O
side	906	910	|O
chain	911	916	|O
,	916	917	|O
4	918	919	|B-IUPAC
-	919	920	|I-IUPAC
[	920	921	|I-IUPAC
1	921	922	|I-IUPAC
-	922	923	|I-IUPAC
hydroxy	923	930	|I-IUPAC
-	930	931	|I-IUPAC
2	931	932	|I-IUPAC
-	932	933	|I-IUPAC
[	933	934	|I-IUPAC
[	934	935	|I-IUPAC
1	935	936	|I-IUPAC
-	936	937	|I-IUPAC
(	937	938	|I-IUPAC
3,4	938	941	|I-IUPAC
-	941	942	|I-IUPAC
dihydro	942	949	|I-IUPAC
-	949	950	|I-IUPAC
8	950	951	|I-IUPAC
-	951	952	|I-IUPAC
hydroxy	952	959	|I-IUPAC
-	959	960	|I-IUPAC
1	960	961	|I-IUPAC
-	961	962	|I-IUPAC
oxo	962	965	|I-IUPAC
-	965	966	|I-IUPAC
1H	966	968	|I-IUPAC
-	968	969	|I-IUPAC
2	969	970	|I-IUPAC
-	970	971	|I-IUPAC
benzopyran	971	981	|I-IUPAC
-	981	982	|I-IUPAC
3	982	983	|I-IUPAC
-	983	984	|I-IUPAC
yl	984	986	|I-IUPAC
)	986	987	|I-IUPAC
-	988	989	|I-IUPAC
3	989	990	|I-IUPAC
-	990	991	|I-IUPAC
methylbutyl	991	1002	|I-IUPAC
]	1002	1003	|I-IUPAC
-	1003	1004	|I-IUPAC
amino	1004	1009	|I-IUPAC
]	1009	1010	|I-IUPAC
-	1010	1011	|I-IUPAC
2	1011	1012	|I-IUPAC
-	1012	1013	|I-IUPAC
oxoethyl	1013	1021	|I-IUPAC
]	1021	1022	|I-IUPAC
butan	1022	1027	|I-IUPAC
-	1027	1028	|I-IUPAC
4	1028	1029	|I-IUPAC
-	1029	1030	|I-IUPAC
olid	1030	1034	|I-IUPAC
-	1034	1035	|I-IUPAC
3	1035	1036	|I-IUPAC
-	1036	1037	|I-IUPAC
yl	1037	1039	|I-IUPAC
]	1039	1040	|I-IUPAC
ammonium	1040	1048	|I-IUPAC
chloride	1049	1057	|I-IUPAC
(	1058	1059	|O
6	1059	1060	|O
)	1060	1061	|O
,	1061	1062	|O
resulted	1063	1071	|O
in	1072	1074	|O
a	1075	1076	|O
small	1077	1082	|O
decrease	1083	1091	|O
in	1092	1094	|O
activity	1095	1103	|O
.	1103	1104	|O
Selective	1105	1114	|O
acetylation	1115	1126	|O
at	1127	1129	|O
the	1130	1133	|O
primary	1134	1141	|O
amine	1142	1147	|O
position	1148	1156	|O
of	1157	1159	|O
6	1160	1161	|O
,	1161	1162	|O
to	1163	1165	|O
give	1166	1170	|O
4	1171	1172	|B-IUPAC
-	1172	1173	|I-IUPAC
[	1173	1174	|I-IUPAC
1	1174	1175	|I-IUPAC
-	1175	1176	|I-IUPAC
hydroxy	1176	1183	|I-IUPAC
-	1183	1184	|I-IUPAC
2	1184	1185	|I-IUPAC
-	1185	1186	|I-IUPAC
[	1187	1188	|I-IUPAC
[	1188	1189	|I-IUPAC
1	1189	1190	|I-IUPAC
-	1190	1191	|I-IUPAC
(	1191	1192	|I-IUPAC
3,4	1192	1195	|I-IUPAC
-	1195	1196	|I-IUPAC
dihydro	1196	1203	|I-IUPAC
-	1203	1204	|I-IUPAC
8	1204	1205	|I-IUPAC
-	1205	1206	|I-IUPAC
hydroxy	1207	1214	|I-IUPAC
-	1214	1215	|I-IUPAC
1	1215	1216	|I-IUPAC
-	1216	1217	|I-IUPAC
oxo	1217	1220	|I-IUPAC
-	1220	1221	|I-IUPAC
1H	1221	1223	|I-IUPAC
-	1223	1224	|I-IUPAC
2	1224	1225	|I-IUPAC
-	1225	1226	|I-IUPAC
benzopyran	1226	1236	|I-IUPAC
-	1236	1237	|I-IUPAC
3	1237	1238	|I-IUPAC
-	1238	1239	|I-IUPAC
yl	1239	1241	|I-IUPAC
)	1241	1242	|I-IUPAC
-	1242	1243	|I-IUPAC
3	1243	1244	|I-IUPAC
-	1244	1245	|I-IUPAC
methylbutyl	1245	1256	|I-IUPAC
]	1256	1257	|I-IUPAC
amino	1257	1262	|I-IUPAC
]	1262	1263	|I-IUPAC
-	1263	1264	|I-IUPAC
2	1264	1265	|I-IUPAC
-	1265	1266	|I-IUPAC
oxoethyl	1266	1274	|I-IUPAC
]	1274	1275	|I-IUPAC
-	1275	1276	|I-IUPAC
3	1276	1277	|I-IUPAC
-	1277	1278	|I-IUPAC
(	1279	1280	|I-IUPAC
acetylamino	1280	1291	|I-IUPAC
)	1291	1292	|I-IUPAC
butan	1292	1297	|I-IUPAC
-	1297	1298	|I-IUPAC
4	1298	1299	|I-IUPAC
-	1299	1300	|I-IUPAC
olide	1300	1305	|I-IUPAC
(	1306	1307	|O
7	1307	1308	|O
)	1308	1309	|O
,	1309	1310	|O
led	1311	1314	|O
to	1315	1317	|O
a	1318	1319	|O
considerable	1320	1332	|O
decrease	1333	1341	|O
in	1342	1344	|O
activity	1345	1353	|O
.	1353	1354	|O
Both	1355	1359	|O
di	1360	1362	|O
-	1362	1363	|O
and	1364	1367	|O
triacetylated	1368	1381	|O
derivatives	1382	1393	|O
of	1394	1396	|O
6	1397	1398	|B-IUPAC
,	1398	1399	|I-IUPAC
4	1400	1401	|I-IUPAC
-	1401	1402	|I-IUPAC
[	1402	1403	|I-IUPAC
1	1403	1404	|I-IUPAC
-	1404	1405	|I-IUPAC
acetoxy	1405	1412	|I-IUPAC
-	1412	1413	|I-IUPAC
2	1413	1414	|I-IUPAC
-	1415	1416	|I-IUPAC
[	1416	1417	|I-IUPAC
[	1417	1418	|I-IUPAC
1	1418	1419	|I-IUPAC
-	1419	1420	|I-IUPAC
(	1420	1421	|I-IUPAC
3,4	1421	1424	|I-IUPAC
-	1424	1425	|I-IUPAC
dihydro	1425	1432	|I-IUPAC
-	1432	1433	|I-IUPAC
8	1433	1434	|I-IUPAC
-	1434	1435	|I-IUPAC
hydroxy	1435	1442	|I-IUPAC
-	1442	1443	|I-IUPAC
1	1443	1444	|I-IUPAC
-	1444	1445	|I-IUPAC
oxo	1445	1448	|I-IUPAC
-	1448	1449	|I-IUPAC
1H	1449	1451	|I-IUPAC
-	1451	1452	|I-IUPAC
2	1452	1453	|I-IUPAC
-	1453	1454	|I-IUPAC
benzopyran	1454	1464	|I-IUPAC
-	1464	1465	|I-IUPAC
3	1465	1466	|I-IUPAC
-	1466	1467	|I-IUPAC
yl	1467	1469	|I-IUPAC
)	1469	1470	|I-IUPAC
-	1470	1471	|I-IUPAC
3	1471	1472	|I-IUPAC
-	1472	1473	|I-IUPAC
methylbutyl	1473	1484	|I-IUPAC
]	1484	1485	|I-IUPAC
amino	1486	1491	|I-IUPAC
]	1491	1492	|I-IUPAC
-	1492	1493	|I-IUPAC
2	1493	1494	|I-IUPAC
-	1494	1495	|I-IUPAC
oxoethyl	1495	1503	|I-IUPAC
]	1503	1504	|I-IUPAC
-	1504	1505	|I-IUPAC
3	1505	1506	|I-IUPAC
-	1506	1507	|I-IUPAC
(	1507	1508	|I-IUPAC
acetylamino	1508	1519	|I-IUPAC
)	1519	1520	|I-IUPAC
butan	1520	1525	|I-IUPAC
-	1525	1526	|I-IUPAC
4	1526	1527	|I-IUPAC
-	1527	1528	|I-IUPAC
olide	1528	1533	|I-IUPAC
(	1534	1535	|O
8	1535	1536	|O
)	1536	1537	|O
and	1538	1541	|O
4	1542	1543	|B-IUPAC
-	1543	1544	|I-IUPAC
[	1544	1545	|I-IUPAC
1	1545	1546	|I-IUPAC
-	1546	1547	|I-IUPAC
acetoxy	1547	1554	|I-IUPAC
-	1554	1555	|I-IUPAC
2	1555	1556	|I-IUPAC
-	1556	1557	|I-IUPAC
[	1558	1559	|I-IUPAC
[	1559	1560	|I-IUPAC
1	1560	1561	|I-IUPAC
-	1561	1562	|I-IUPAC
(	1562	1563	|I-IUPAC
3,4	1563	1566	|I-IUPAC
-	1566	1567	|I-IUPAC
dihydro	1568	1575	|I-IUPAC
-	1575	1576	|I-IUPAC
8	1576	1577	|I-IUPAC
-	1577	1578	|I-IUPAC
acetoxy	1578	1585	|I-IUPAC
-	1585	1586	|I-IUPAC
1	1586	1587	|I-IUPAC
-	1587	1588	|I-IUPAC
oxo	1588	1591	|I-IUPAC
-	1591	1592	|I-IUPAC
1H	1592	1594	|I-IUPAC
-	1594	1595	|I-IUPAC
2	1595	1596	|I-IUPAC
-	1596	1597	|I-IUPAC
benzopyran	1597	1607	|I-IUPAC
-	1607	1608	|I-IUPAC
3	1608	1609	|I-IUPAC
-	1609	1610	|I-IUPAC
yl	1610	1612	|I-IUPAC
)	1612	1613	|I-IUPAC
-	1613	1614	|I-IUPAC
3	1614	1615	|I-IUPAC
-	1615	1616	|I-IUPAC
methylbutyl	1616	1627	|I-IUPAC
]	1627	1628	|I-IUPAC
amino	1628	1633	|I-IUPAC
]	1633	1634	|I-IUPAC
-	1634	1635	|I-IUPAC
2	1635	1636	|I-IUPAC
-	1636	1637	|I-IUPAC
oxoethyl	1638	1646	|I-IUPAC
]	1646	1647	|I-IUPAC
-	1647	1648	|I-IUPAC
3	1648	1649	|I-IUPAC
-	1649	1650	|I-IUPAC
(	1650	1651	|I-IUPAC
acetylamino	1651	1662	|I-IUPAC
)	1662	1663	|I-IUPAC
butan	1663	1668	|I-IUPAC
-	1668	1669	|I-IUPAC
4	1669	1670	|I-IUPAC
-	1670	1671	|I-IUPAC
olide	1671	1676	|I-IUPAC
(	1677	1678	|O
9	1678	1679	|O
)	1679	1680	|O
,	1680	1681	|O
were	1682	1686	|O
inactive	1687	1695	|O
.	1695	1696	|O
Selective	1697	1706	|O
methylation	1707	1718	|O
of	1719	1721	|O
the	1722	1725	|O
phenolic	1726	1734	|B-MODIFIER
hydroxyl	1735	1743	|B-IUPAC
group	1744	1749	|B-MODIFIER
of	1750	1752	|O
to	1753	1755	|O
give	1756	1760	|O
1	1761	1762	|B-IUPAC
,	1762	1763	|I-IUPAC
6	1764	1765	|I-IUPAC
-	1765	1766	|I-IUPAC
[	1766	1767	|I-IUPAC
[	1767	1768	|I-IUPAC
1	1768	1769	|I-IUPAC
-	1769	1770	|I-IUPAC
(	1770	1771	|I-IUPAC
3,4	1771	1774	|I-IUPAC
-	1774	1775	|I-IUPAC
dihydro	1775	1782	|I-IUPAC
-	1782	1783	|I-IUPAC
8	1783	1784	|I-IUPAC
-	1784	1785	|I-IUPAC
methoxy	1785	1792	|I-IUPAC
-	1792	1793	|I-IUPAC
1	1793	1794	|I-IUPAC
-	1794	1795	|I-IUPAC
oxo	1795	1798	|I-IUPAC
-	1798	1799	|I-IUPAC
1H	1799	1801	|I-IUPAC
-	1801	1802	|I-IUPAC
2	1802	1803	|I-IUPAC
-	1803	1804	|I-IUPAC
benzopyran	1804	1814	|I-IUPAC
-	1814	1815	|I-IUPAC
3	1815	1816	|I-IUPAC
-	1816	1817	|I-IUPAC
yl	1817	1819	|I-IUPAC
)	1819	1820	|I-IUPAC
-	1821	1822	|I-IUPAC
3	1822	1823	|I-IUPAC
-	1823	1824	|I-IUPAC
methylbutyl	1824	1835	|I-IUPAC
]	1835	1836	|I-IUPAC
amino	1836	1841	|I-IUPAC
]	1841	1842	|I-IUPAC
-	1842	1843	|I-IUPAC
4,5	1843	1846	|I-IUPAC
-	1846	1847	|I-IUPAC
dihydroxy	1847	1856	|I-IUPAC
-	1856	1857	|I-IUPAC
6	1857	1858	|I-IUPAC
-	1858	1859	|I-IUPAC
oxo	1859	1862	|I-IUPAC
-	1862	1863	|I-IUPAC
3	1863	1864	|I-IUPAC
-	1864	1865	|I-IUPAC
ammoniohexanoate	1865	1881	|I-IUPAC
(	1882	1883	|O
15	1883	1885	|O
)	1885	1886	|O
,	1886	1887	|O
resulted	1888	1896	|O
in	1897	1899	|O
a	1900	1901	|O
small	1902	1907	|O
decrease	1908	1916	|O
in	1917	1919	|O
activity	1920	1928	|O
.	1928	1929	|O
On	1930	1932	|O
the	1933	1936	|O
other	1937	1942	|O
hand	1943	1947	|O
,	1947	1948	|O
conversion	1949	1959	|O
of	1960	1962	|O
the	1963	1966	|O
carboxyl	1967	1975	|B-IUPAC
group	1976	1981	|B-MODIFIER
of	1982	1984	|O
the	1985	1988	|O
side	1989	1993	|O
chain	1994	1999	|O
to	2000	2002	|O
an	2003	2005	|O
amide	2006	2011	|O
,	2011	2012	|O
to	2013	2015	|O
give	2016	2020	|O
[	2021	2022	|B-IUPAC
6	2022	2023	|I-IUPAC
-	2023	2024	|I-IUPAC
[	2024	2025	|I-IUPAC
[	2025	2026	|I-IUPAC
1	2026	2027	|I-IUPAC
-	2027	2028	|I-IUPAC
(	2028	2029	|I-IUPAC
3,4	2029	2032	|I-IUPAC
-	2032	2033	|I-IUPAC
dihydro	2033	2040	|I-IUPAC
-	2040	2041	|I-IUPAC
8	2041	2042	|I-IUPAC
-	2042	2043	|I-IUPAC
hydroxy	2043	2050	|I-IUPAC
-	2050	2051	|I-IUPAC
1	2051	2052	|I-IUPAC
-	2052	2053	|I-IUPAC
oxo	2053	2056	|I-IUPAC
-	2056	2057	|I-IUPAC
1H	2057	2059	|I-IUPAC
-	2059	2060	|I-IUPAC
2	2060	2061	|I-IUPAC
-	2061	2062	|I-IUPAC
benzopyran	2062	2072	|I-IUPAC
-	2072	2073	|I-IUPAC
3	2073	2074	|I-IUPAC
-	2074	2075	|I-IUPAC
yl	2075	2077	|I-IUPAC
)	2077	2078	|I-IUPAC
-	2078	2079	|I-IUPAC
3	2080	2081	|I-IUPAC
-	2081	2082	|I-IUPAC
methylbutyl	2082	2093	|I-IUPAC
]	2093	2094	|I-IUPAC
amino	2094	2099	|I-IUPAC
]	2099	2100	|I-IUPAC
-	2100	2101	|I-IUPAC
4,5	2101	2104	|I-IUPAC
-	2104	2105	|I-IUPAC
dihydroxy	2105	2114	|I-IUPAC
-	2114	2115	|I-IUPAC
6	2115	2116	|I-IUPAC
-	2116	2117	|I-IUPAC
oxo	2117	2120	|I-IUPAC
-	2120	2121	|I-IUPAC
3	2121	2122	|I-IUPAC
-	2122	2123	|I-IUPAC
hexanamido	2123	2133	|I-IUPAC
]	2133	2134	|I-IUPAC
ammonium	2134	2142	|I-IUPAC
chloride	2143	2151	|I-IUPAC
(	2152	2153	|O
10	2153	2155	|O
)	2155	2156	|O
,	2156	2157	|O
caused	2158	2164	|O
a	2165	2166	|O
considerable	2167	2179	|O
increase	2180	2188	|O
in	2189	2191	|O
both	2192	2196	|O
activity	2197	2205	|O
and	2206	2209	|O
toxicity	2210	2218	|O
.	2218	2219	|O
The	2220	2223	|O
findings	2224	2232	|O
showed	2233	2239	|O
that	2240	2244	|O
modifications	2245	2258	|O
at	2259	2261	|O
the	2262	2265	|O
position	2266	2274	|O
of	2275	2277	|O
the	2278	2281	|O
amino	2282	2287	|O
acid	2288	2292	|O
moiety	2293	2299	|O
of	2300	2302	|O
1	2303	2304	|O
significantly	2305	2318	|O
influenced	2319	2329	|O
the	2330	2333	|O
activity	2334	2342	|O
and	2343	2346	|O
that	2347	2351	|O
the	2352	2355	|O
1H	2356	2358	|B-IUPAC
-	2358	2359	|I-IUPAC
2	2359	2360	|I-IUPAC
-	2360	2361	|I-IUPAC
benzopyran	2361	2371	|I-IUPAC
-	2371	2372	|I-IUPAC
1	2372	2373	|I-IUPAC
-	2373	2374	|I-IUPAC
one	2374	2377	|I-IUPAC
skeleton	2378	2386	|B-MODIFIER
was	2387	2390	|O
also	2391	2395	|O
required	2396	2404	|O
for	2405	2408	|O
activity	2409	2417	|O
to	2418	2420	|O
occur	2421	2426	|O
.	2426	2427	|O

### abstracts7.txt
The	0	3	|O
binding	4	11	|O
of	12	14	|O
selective	15	24	|O
muscarinic	25	35	|O
receptor	36	44	|O
antagonists	45	56	|O
to	57	59	|O
regions	60	67	|O
of	68	70	|O
rat	71	74	|O
brain	75	80	|O
was	81	84	|O
examined	85	93	|O
through	94	101	|O
quantitative	102	114	|O
autoradiographic	115	131	|O
techniques	132	142	|O
.	142	143	|O
5,11	144	148	|B-IUPAC
-	148	149	|I-IUPAC
Dihydro	149	156	|I-IUPAC
-	156	157	|I-IUPAC
11	157	159	|I-IUPAC
-	159	160	|I-IUPAC
[	160	161	|I-IUPAC
(	161	162	|I-IUPAC
4	162	163	|I-IUPAC
-	163	164	|I-IUPAC
methyl	164	170	|I-IUPAC
-	170	171	|I-IUPAC
1	171	172	|I-IUPAC
-	172	173	|I-IUPAC
piperazinyl	173	184	|I-IUPAC
)	184	185	|I-IUPAC
acetyl	185	191	|I-IUPAC
]	191	192	|I-IUPAC
-	192	193	|I-IUPAC
6H	193	195	|I-IUPAC
-	195	196	|I-IUPAC
pyrido	197	203	|I-IUPAC
[	203	204	|I-IUPAC
2,3	204	207	|I-IUPAC
-	207	208	|I-IUPAC
b	208	209	|I-IUPAC
]	209	210	|I-IUPAC
[	210	211	|I-IUPAC
1,4	211	214	|I-IUPAC
]	214	215	|I-IUPAC
benzodiazepin	215	228	|I-IUPAC
-	228	229	|I-IUPAC
6	229	230	|I-IUPAC
-	230	231	|I-IUPAC
one	231	234	|I-IUPAC
[	235	236	|O
pirenzepine	236	247	|O
(	248	249	|O
compound	249	257	|O
I	258	259	|O
)	259	260	|O
]	260	261	|O
and	262	265	|O
11	266	268	|B-IUPAC
-	268	269	|I-IUPAC
[	269	270	|I-IUPAC
[	270	271	|I-IUPAC
2	271	272	|I-IUPAC
-	272	273	|I-IUPAC
[	273	274	|I-IUPAC
(	274	275	|I-IUPAC
diethylamino	275	287	|I-IUPAC
)	287	288	|I-IUPAC
methyl	288	294	|I-IUPAC
]	294	295	|I-IUPAC
-	295	296	|I-IUPAC
1	296	297	|I-IUPAC
-	297	298	|I-IUPAC
piperidinyl	298	309	|I-IUPAC
]	309	310	|I-IUPAC
acetyl	310	316	|I-IUPAC
]	316	317	|I-IUPAC
-	317	318	|I-IUPAC
5,11	318	322	|I-IUPAC
-	322	323	|I-IUPAC
dihydro	323	330	|I-IUPAC
-	330	331	|I-IUPAC
6H	332	334	|I-IUPAC
-	334	335	|I-IUPAC
pyrido	335	341	|I-IUPAC
[	341	342	|I-IUPAC
2,3	342	345	|I-IUPAC
-	345	346	|I-IUPAC
b	346	347	|I-IUPAC
]	347	348	|I-IUPAC
[	348	349	|I-IUPAC
1,4	349	352	|I-IUPAC
]	352	353	|I-IUPAC
benzodiazepin	353	366	|I-IUPAC
-	366	367	|I-IUPAC
6	367	368	|I-IUPAC
-	368	369	|I-IUPAC
one	369	372	|I-IUPAC
[	373	374	|O
AF	374	376	|O
-	376	377	|O
DX	377	379	|O
116	380	383	|O
(	384	385	|O
compound	385	393	|O
II	394	396	|O
)	396	397	|O
]	397	398	|O
were	399	403	|O
chosen	404	410	|O
on	411	413	|O
the	414	417	|O
basis	418	423	|O
of	424	426	|O
their	427	432	|O
selectivity	433	444	|O
for	445	448	|O
M1	449	451	|O
and	452	455	|O
M2	456	458	|O
muscarinic	459	469	|O
receptors	470	479	|O
,	479	480	|O
respectively	481	493	|O
,	493	494	|O
and	495	498	|O
similarities	499	511	|O
in	512	514	|O
chemical	515	523	|O
structure	524	533	|O
.	533	534	|O
Pirenzepine	535	546	|O
displayed	547	556	|O
a	557	558	|O
higher	559	565	|O
potency	566	573	|O
than	574	578	|O
II	579	581	|O
for	582	585	|O
inhibition	586	596	|O
of	597	599	|O
[	600	601	|B-IUPAC
3H	601	603	|I-IUPAC
]	603	604	|I-IUPAC
-	604	605	|I-IUPAC
l	605	606	|I-IUPAC
-	606	607	|I-IUPAC
quinuclidinyl	607	620	|I-IUPAC
benzilate	621	630	|I-IUPAC
(	631	632	|O
[	632	633	|O
3H	633	635	|O
]	635	636	|O
-	636	637	|O
l	637	638	|O
-	638	639	|O
QNB	639	642	|O
)	642	643	|O
binding	644	651	|O
to	652	654	|O
rat	655	658	|O
brain	659	664	|O
sections	665	673	|O
.	673	674	|O
Scatchard	675	684	|O
analyses	685	693	|O
of	694	696	|O
binding	697	704	|O
to	705	707	|O
brain	708	713	|O
sections	714	722	|O
revealed	723	731	|O
heterogeneous	732	745	|O
binding	746	753	|O
profiles	754	762	|O
for	763	766	|O
both	767	771	|O
antagonists	772	783	|O
,	783	784	|O
suggesting	785	795	|O
the	796	799	|O
presence	800	808	|O
of	809	811	|O
multiple	812	820	|O
receptor	821	829	|O
binding	830	837	|O
sites	838	843	|O
.	843	844	|O
Quantitative	845	857	|O
autoradiographic	858	874	|O
techniques	875	885	|O
were	886	890	|O
utilized	891	899	|O
in	900	902	|O
regional	903	911	|O
analyses	912	920	|O
of	921	923	|O
antagonist	924	934	|O
binding	935	942	|O
.	942	943	|O
Pirenzepine	944	955	|O
displayed	956	965	|O
the	966	969	|O
highest	970	977	|O
affinity	978	986	|O
for	987	990	|O
hippocampal	991	1002	|O
,	1002	1003	|O
striatal	1004	1012	|O
,	1012	1013	|O
and	1014	1017	|O
amygdaloid	1018	1028	|O
muscarinic	1029	1039	|O
receptors	1040	1049	|O
(	1050	1051	|O
IC50	1051	1055	|O
values	1056	1062	|O
less	1063	1067	|O
than	1068	1072	|O
0.4	1073	1076	|O
microM	1077	1083	|O
)	1083	1084	|O
,	1084	1085	|O
with	1086	1090	|O
a	1091	1092	|O
slightly	1093	1101	|O
lower	1102	1107	|O
affinity	1108	1116	|O
for	1117	1120	|O
cortical	1121	1129	|O
receptors	1130	1139	|O
(	1140	1141	|O
IC50	1141	1145	|O
values	1146	1152	|O
between	1153	1160	|O
0.4	1161	1164	|O
and	1165	1168	|O
0.8	1169	1172	|O
microM	1173	1179	|O
)	1179	1180	|O
.	1180	1181	|O
Pirenzepine	1182	1193	|O
displayed	1194	1203	|O
the	1204	1207	|O
lowest	1208	1214	|O
affinity	1215	1223	|O
for	1224	1227	|O
thalamic	1228	1236	|O
and	1237	1240	|O
brainstem	1241	1250	|O
regions	1251	1258	|O
with	1259	1263	|O
IC50	1264	1268	|O
values	1269	1275	|O
generally	1276	1285	|O
greater	1286	1293	|O
than	1294	1298	|O
1.0	1299	1302	|O
microM	1303	1309	|O
.	1309	1310	|O
In	1311	1313	|O
contrast	1314	1322	|O
,	1322	1323	|O
II	1324	1326	|O
bound	1327	1332	|O
with	1333	1337	|O
higher	1338	1344	|O
affinity	1345	1353	|O
to	1354	1356	|O
muscarinic	1357	1367	|O
receptors	1368	1377	|O
in	1378	1380	|O
brainstem	1381	1390	|O
,	1390	1391	|O
cerebellar	1392	1402	|O
,	1402	1403	|O
and	1404	1407	|O
hypothalamic	1408	1420	|O
nuclei	1421	1427	|O
(	1428	1429	|O
IC50	1429	1433	|O
values	1434	1440	|O
less	1441	1445	|O
than	1446	1450	|O
0.5	1451	1454	|O
microM	1455	1461	|O
)	1461	1462	|O
than	1463	1467	|O
to	1468	1470	|O
receptors	1471	1480	|O
in	1481	1483	|O
thalamic	1484	1492	|O
nuclei	1493	1499	|O
(	1500	1501	|O
IC50	1501	1505	|O
values	1506	1512	|O
between	1513	1520	|O
0.5	1521	1524	|O
and	1525	1528	|O
2.0	1529	1532	|O
microM	1533	1539	|O
)	1539	1540	|O
.	1540	1541	|O
Binding	1542	1549	|O
sites	1550	1555	|O
with	1556	1560	|O
the	1561	1564	|O
lowest	1565	1571	|O
affinity	1572	1580	|O
for	1581	1584	|O
II	1585	1587	|O
were	1588	1592	|O
found	1593	1598	|O
in	1599	1601	|O
cortical	1602	1610	|O
,	1610	1611	|O
striatal	1612	1620	|O
,	1620	1621	|O
and	1622	1625	|O
hippocampal	1626	1637	|O
regions	1638	1645	|O
(	1646	1647	|O
IC50	1647	1651	|O
values	1652	1658	|O
greater	1659	1666	|O
than	1667	1671	|O
2.0	1672	1675	|O
microM	1676	1682	|O
)	1682	1683	|O
.	1683	1684	|O
The	1685	1688	|O
binding	1689	1696	|O
profiles	1697	1705	|O
of	1706	1708	|O
the	1709	1712	|O
two	1713	1716	|O
selective	1717	1726	|O
muscarinic	1727	1737	|O
antagonists	1738	1749	|O
reveal	1750	1756	|O
the	1757	1760	|O
complexity	1761	1771	|O
and	1772	1775	|O
diversity	1776	1785	|O
of	1786	1788	|O
muscarinic	1789	1799	|O
receptor	1800	1808	|O
subtypes	1809	1817	|O
throughout	1818	1828	|O
the	1829	1832	|O
brain	1833	1838	|O
.	1838	1839	|O
The	1840	1843	|O
data	1844	1848	|O
provide	1849	1856	|O
a	1857	1858	|O
basis	1859	1864	|O
for	1865	1868	|O
identifying	1869	1880	|O
muscarinic	1881	1891	|O
receptor	1892	1900	|O
subtypes	1901	1909	|O
(	1910	1911	|O
as	1911	1913	|O
defined	1914	1921	|O
through	1922	1929	|O
cloning	1930	1937	|O
procedures	1938	1948	|O
)	1948	1949	|O
with	1950	1954	|O
selective	1955	1964	|O
ligands	1965	1972	|O
.	1972	1973	|O
Minimum	1974	1981	|O
-	1981	1982	|O
energy	1982	1988	|O
conformations	1989	2002	|O
of	2003	2005	|O
pirenzepine	2006	2017	|O
and	2018	2021	|O
II	2022	2024	|O
were	2025	2029	|O
calculated	2030	2040	|O
by	2041	2043	|O
using	2044	2049	|O
the	2050	2053	|O
program	2054	2061	|O
MacroModel	2062	2072	|O
(	2073	2074	|O
version	2074	2081	|O
2.0	2082	2085	|O
)	2085	2086	|O
.	2086	2087	|O
Pirenzepine	2088	2099	|O
displayed	2100	2109	|O
three	2110	2115	|O
energy	2116	2122	|O
minima	2123	2129	|O
,	2129	2130	|O
differing	2131	2140	|O
in	2141	2143	|O
the	2144	2147	|O
relative	2148	2156	|O
position	2157	2165	|O
of	2166	2168	|O
the	2169	2172	|O
piperazine	2173	2183	|O
ring	2184	2188	|O
with	2189	2193	|O
respect	2194	2201	|O
to	2202	2204	|O
the	2205	2208	|O
tricyclic	2209	2218	|O
system	2219	2225	|O
.	2225	2226	|O
In	2227	2229	|O
contrast	2230	2238	|O
,	2238	2239	|O
the	2240	2243	|O
(	2244	2245	|B-IUPAC
diethylamino	2245	2257	|I-IUPAC
)	2257	2258	|I-IUPAC
methyl	2258	2264	|I-IUPAC
substituent	2265	2276	|B-MODIFIER
on	2277	2279	|O
the	2280	2283	|O
piperidine	2284	2294	|O
ring	2295	2299	|O
conferred	2300	2309	|O
a	2310	2311	|O
much	2312	2316	|O
larger	2317	2323	|O
set	2324	2327	|O
of	2328	2330	|O
minimum	2331	2338	|O
-	2338	2339	|O
energy	2339	2345	|O
conformations	2346	2359	|O
on	2360	2362	|O
II	2363	2365	|O
.	2365	2366	|O
It	2367	2369	|O
is	2370	2372	|O
suggested	2373	2382	|O
that	2383	2387	|O
the	2388	2391	|O
greater	2392	2399	|O
conformational	2400	2414	|O
flexibility	2415	2426	|O
of	2427	2429	|O
the	2430	2433	|O
side	2434	2438	|O
chain	2439	2444	|O
allows	2445	2451	|O
II	2452	2454	|O
to	2455	2457	|O
achieve	2458	2465	|O
a	2466	2467	|O
conformation	2468	2480	|O
inaccessible	2481	2493	|O
to	2494	2496	|O
pirenzepine	2497	2508	|O
,	2508	2509	|O
which	2510	2515	|O
allows	2516	2522	|O
it	2523	2525	|O
to	2526	2528	|O
bind	2529	2533	|O
preferentially	2534	2548	|O
to	2549	2551	|O
M2	2552	2554	|O
receptors	2555	2564	|O
.	2564	2565	|O

### abstracts3301.txt
2	0	1	|O
-	1	2	|O
[	2	3	|O
5	3	4	|O
-	4	5	|O
(	5	6	|O
4	6	7	|O
-	7	8	|O
Amidinophenyl	8	21	|O
)	21	22	|O
-	22	23	|O
furan	23	28	|O
-	28	29	|O
2	29	30	|O
-	30	31	|O
yl	31	33	|O
]	33	34	|O
-	34	35	|O
5,6,7,8	35	42	|O
-	42	43	|O
tetrahydro	43	53	|O
-	53	54	|O
imidazo	54	61	|O
[	61	62	|O
1,2	62	65	|O
-	65	66	|O
a	66	67	|O
]	67	68	|O
pyridine	68	76	|O
-	76	77	|O
6	77	78	|O
-	78	79	|O
carboxamidine	79	92	|O
acetate	93	100	|O
salt	101	105	|O
(	106	107	|O
7	107	108	|O
)	108	109	|O
was	110	113	|O
synthesized	114	125	|O
from	126	130	|O
2	131	132	|B-IUPAC
-	132	133	|I-IUPAC
[	133	134	|I-IUPAC
5	134	135	|I-IUPAC
-	135	136	|I-IUPAC
(	136	137	|I-IUPAC
4	137	138	|I-IUPAC
-	138	139	|I-IUPAC
cyanophenyl	139	150	|I-IUPAC
)	150	151	|I-IUPAC
-	151	152	|I-IUPAC
furan	152	157	|I-IUPAC
-	157	158	|I-IUPAC
2	158	159	|I-IUPAC
-	159	160	|I-IUPAC
yl	160	162	|I-IUPAC
]	162	163	|I-IUPAC
-	163	164	|I-IUPAC
imidazo	164	171	|I-IUPAC
[	171	172	|I-IUPAC
1,2	172	175	|I-IUPAC
-	175	176	|I-IUPAC
a	176	177	|I-IUPAC
]	177	178	|I-IUPAC
pyridine	178	186	|I-IUPAC
-	186	187	|I-IUPAC
6	187	188	|I-IUPAC
-	188	189	|I-IUPAC
carbonitrile	189	201	|I-IUPAC
(	202	203	|O
4a	203	205	|O
)	205	206	|O
,	206	207	|O
through	208	215	|O
the	216	219	|O
bis	220	223	|B-IUPAC
-	223	224	|I-IUPAC
O	224	225	|I-IUPAC
-	225	226	|I-IUPAC
acetoxyamidoxime	226	242	|I-IUPAC
followed	243	251	|O
by	252	254	|O
hydrogenation	255	268	|O
in	269	271	|O
glacial	272	279	|O
acetic	280	286	|O
acid	287	291	|O
.	291	292	|O
Compound	293	301	|O
4a	302	304	|O
was	305	308	|O
obtained	309	317	|O
in	318	320	|O
four	321	325	|O
steps	326	331	|O
starting	332	340	|O
with	341	345	|O
two	346	349	|O
successive	350	360	|O
brominations	361	373	|O
of	374	376	|O
2	377	378	|B-IUPAC
-	378	379	|I-IUPAC
acetylfuran	379	390	|I-IUPAC
first	391	396	|O
with	397	401	|O
N	402	403	|B-IUPAC
-	403	404	|I-IUPAC
bromosuccinimide	404	420	|I-IUPAC
,	420	421	|O
and	422	425	|O
second	426	432	|O
with	433	437	|O
bromine	438	445	|O
to	446	448	|O
form	449	453	|O
alpha	454	459	|B-IUPAC
-	459	460	|I-IUPAC
bromo	460	465	|I-IUPAC
-	465	466	|I-IUPAC
2	466	467	|I-IUPAC
-	467	468	|I-IUPAC
acetyl	468	474	|I-IUPAC
-	474	475	|I-IUPAC
5	475	476	|I-IUPAC
-	476	477	|I-IUPAC
bromofuran	477	487	|I-IUPAC
(	488	489	|O
2	489	490	|O
)	490	491	|O
in	492	494	|O
a	495	496	|O
moderate	497	505	|O
yield	506	511	|O
.	511	512	|O
The	513	516	|O
product	517	524	|O
(	525	526	|O
3a	526	528	|O
)	528	529	|O
,	529	530	|O
of	531	533	|O
the	534	537	|O
condensation	538	550	|O
reaction	551	559	|O
between	560	567	|O
6	568	569	|B-IUPAC
-	569	570	|I-IUPAC
amino	570	575	|I-IUPAC
-	575	576	|I-IUPAC
nicotinonitrile	576	591	|I-IUPAC
and	592	595	|O
2	596	597	|O
,	597	598	|O
undergoes	599	608	|O
Suzuki	609	615	|O
coupling	616	624	|O
with	625	629	|O
4	630	631	|B-IUPAC
-	631	632	|I-IUPAC
cyanophenylboronic	632	650	|I-IUPAC
acid	651	655	|I-IUPAC
to	656	658	|O
furnish	659	666	|O
4a	667	669	|O
in	670	672	|O
good	673	677	|O
yield	678	683	|O
.	683	684	|O
Acetate	685	692	|O
salt	693	697	|O
of	698	700	|O
2	701	702	|B-IUPAC
-	702	703	|I-IUPAC
[	703	704	|I-IUPAC
5	704	705	|I-IUPAC
-	705	706	|I-IUPAC
(	706	707	|I-IUPAC
4	707	708	|I-IUPAC
-	708	709	|I-IUPAC
amidinophenyl	709	722	|I-IUPAC
)	722	723	|I-IUPAC
-	723	724	|I-IUPAC
furan	724	729	|I-IUPAC
-	729	730	|I-IUPAC
2	730	731	|I-IUPAC
-	731	732	|I-IUPAC
yl	732	734	|I-IUPAC
]	734	735	|I-IUPAC
-	735	736	|I-IUPAC
imidazo	736	743	|I-IUPAC
[	743	744	|I-IUPAC
1,2	744	747	|I-IUPAC
-	747	748	|I-IUPAC
a	748	749	|I-IUPAC
]	749	750	|I-IUPAC
pyridine	750	758	|I-IUPAC
-	758	759	|I-IUPAC
6	759	760	|I-IUPAC
-	760	761	|I-IUPAC
carboxamidine	761	774	|I-IUPAC
(	775	776	|O
8a	776	778	|O
)	778	779	|O
was	780	783	|O
obtained	784	792	|O
from	793	797	|O
4a	798	800	|O
,	800	801	|O
through	802	809	|O
the	810	813	|O
bis	814	817	|B-IUPAC
-	817	818	|I-IUPAC
O	818	819	|I-IUPAC
-	819	820	|I-IUPAC
acetoxyamidoxime	820	836	|I-IUPAC
followed	837	845	|O
by	846	848	|O
hydrogenation	849	862	|O
in	863	865	|O
a	866	867	|O
mixture	868	875	|O
of	876	878	|O
ethanol	879	886	|O
/	886	887	|O
ethyl	887	892	|O
acetate	893	900	|O
.	900	901	|O
N	902	903	|B-IUPAC
-	903	904	|I-IUPAC
Methoxy	904	911	|I-IUPAC
-	911	912	|I-IUPAC
2	912	913	|I-IUPAC
-	913	914	|I-IUPAC
(	914	915	|I-IUPAC
5	915	916	|I-IUPAC
-	916	917	|I-IUPAC
[	917	918	|I-IUPAC
4	918	919	|I-IUPAC
-	919	920	|I-IUPAC
(	920	921	|I-IUPAC
N	921	922	|I-IUPAC
-	922	923	|I-IUPAC
methoxyamidino	923	937	|I-IUPAC
)	937	938	|I-IUPAC
-	938	939	|I-IUPAC
phenyl	939	945	|I-IUPAC
]	945	946	|I-IUPAC
-	946	947	|I-IUPAC
furan	947	952	|I-IUPAC
-	952	953	|I-IUPAC
2	953	954	|I-IUPAC
-	954	955	|I-IUPAC
yl	955	957	|I-IUPAC
)	957	958	|I-IUPAC
-	958	959	|I-IUPAC
imidazo	959	966	|I-IUPAC
[	966	967	|I-IUPAC
1,2	967	970	|I-IUPAC
-	970	971	|I-IUPAC
a	971	972	|I-IUPAC
]	972	973	|I-IUPAC
pyridine	973	981	|I-IUPAC
-	981	982	|I-IUPAC
6	982	983	|I-IUPAC
-	983	984	|I-IUPAC
carboxamidine	984	997	|I-IUPAC
(	998	999	|O
6	999	1000	|O
)	1000	1001	|O
was	1002	1005	|O
prepared	1006	1014	|O
via	1015	1018	|O
methylation	1019	1030	|O
of	1031	1033	|O
the	1034	1037	|O
respective	1038	1048	|O
diamidoxime	1049	1060	|O
5a	1061	1063	|O
with	1064	1068	|O
dimethyl	1069	1077	|O
sulfate	1078	1085	|O
.	1085	1086	|O
By	1087	1089	|O
these	1090	1095	|O
approaches	1096	1106	|O
eight	1107	1112	|O
new	1113	1116	|O
diamidines	1117	1127	|O
and	1128	1131	|O
four	1132	1136	|O
potential	1137	1146	|O
prodrugs	1147	1155	|O
were	1156	1160	|O
prepared	1161	1169	|O
.	1169	1170	|O
All	1171	1174	|O
of	1175	1177	|O
the	1178	1181	|O
diamidines	1182	1192	|O
showed	1193	1199	|O
strong	1200	1206	|O
DNA	1207	1210	|O
affinities	1211	1221	|O
as	1222	1224	|O
judged	1225	1231	|O
by	1232	1234	|O
high	1235	1239	|O
DeltaT	1240	1246	|O
(	1246	1247	|O
m	1247	1248	|O
)	1248	1249	|O
values	1250	1256	|O
.	1256	1257	|O
Six	1258	1261	|O
of	1262	1264	|O
the	1265	1268	|O
eight	1269	1274	|O
diamidines	1275	1285	|O
gave	1286	1290	|O
in	1291	1293	|O
vitro	1294	1299	|O
IC	1300	1302	|O
(	1302	1303	|O
50	1303	1305	|O
)	1305	1306	|O
values	1307	1313	|O
of	1314	1316	|O
63	1317	1319	|O
nM	1320	1322	|O
or	1323	1325	|O
less	1326	1330	|O
vs	1331	1333	|O
T	1334	1335	|O
.	1335	1336	|O
b	1337	1338	|O
.	1338	1339	|O
rhodesiense	1340	1351	|O
with	1352	1356	|O
two	1357	1360	|O
exhibiting	1361	1371	|O
values	1372	1378	|O
of	1379	1381	|O
6	1382	1383	|O
nM	1384	1386	|O
and	1387	1390	|O
1	1391	1392	|O
nM	1393	1395	|O
.	1395	1396	|O
Also	1397	1401	|O
,	1401	1402	|O
six	1403	1406	|O
of	1407	1409	|O
the	1410	1413	|O
eight	1414	1419	|O
diamidines	1420	1430	|O
gave	1431	1435	|O
in	1436	1438	|O
vitro	1439	1444	|O
IC	1445	1447	|O
(	1447	1448	|O
50	1448	1450	|O
)	1450	1451	|O
values	1452	1458	|O
of	1459	1461	|O
88	1462	1464	|O
nM	1465	1467	|O
or	1468	1470	|O
less	1471	1475	|O
vs	1476	1478	|O
P	1479	1480	|O
.	1480	1481	|O
falciparum	1482	1492	|O
with	1493	1497	|O
two	1498	1501	|O
exhibiting	1502	1512	|O
values	1513	1519	|O
of	1520	1522	|O
14	1523	1525	|O
nM	1526	1528	|O
.	1528	1529	|O
Excellent	1530	1539	|O
in	1540	1542	|O
vivo	1543	1547	|O
activity	1548	1556	|O
in	1557	1559	|O
the	1560	1563	|O
trypanosomal	1564	1576	|O
STIB900	1577	1584	|O
mouse	1585	1590	|O
model	1591	1596	|O
was	1597	1600	|O
found	1601	1606	|O
for	1607	1610	|O
five	1611	1615	|O
of	1616	1618	|O
the	1619	1622	|O
diamidines	1623	1633	|O
on	1634	1636	|O
ip	1637	1639	|O
dosage	1640	1646	|O
;	1646	1647	|O
these	1648	1653	|O
compounds	1654	1663	|O
gave	1664	1668	|O
4/4	1669	1672	|O
cures	1673	1678	|O
in	1679	1681	|O
this	1682	1686	|O
model	1687	1692	|O
.	1692	1693	|O
The	1694	1697	|O
oral	1698	1702	|O
activity	1703	1711	|O
of	1712	1714	|O
the	1715	1718	|O
prodrugs	1719	1727	|O
was	1728	1731	|O
modest	1732	1738	|O
with	1739	1743	|O
only	1744	1748	|O
one	1749	1752	|O
showing	1753	1760	|O
2/4	1761	1764	|O
cures	1765	1770	|O
in	1771	1773	|O
the	1774	1777	|O
same	1778	1782	|O
mouse	1783	1788	|O
model	1789	1794	|O
.	1794	1795	|O

### abstracts3553.txt
Condensation	0	12	|O
of	13	15	|O
cyanothioacetamide	16	34	|O
(	35	36	|O
4	36	37	|O
)	37	38	|O
with	39	43	|O
ethyl	44	49	|B-IUPAC
alpha	50	55	|I-IUPAC
-	55	56	|I-IUPAC
(	56	57	|I-IUPAC
ethoxymethylene	57	72	|I-IUPAC
)	72	73	|I-IUPAC
acetoacetate	73	85	|I-IUPAC
(	86	87	|O
5b	87	89	|O
)	89	90	|O
,	90	91	|O
ethyl	92	97	|B-IUPAC
4	98	99	|I-IUPAC
-	99	100	|I-IUPAC
ethoxy	100	106	|I-IUPAC
-	106	107	|I-IUPAC
2	107	108	|I-IUPAC
-	108	109	|I-IUPAC
(	109	110	|I-IUPAC
ethoxymethylene	110	125	|I-IUPAC
)	125	126	|I-IUPAC
-	126	127	|I-IUPAC
3	127	128	|I-IUPAC
-	128	129	|I-IUPAC
oxobutanoate	129	141	|I-IUPAC
(	142	143	|O
5c	143	145	|O
)	145	146	|O
,	146	147	|O
ethyl	148	153	|B-IUPAC
2	154	155	|I-IUPAC
-	155	156	|I-IUPAC
(	156	157	|I-IUPAC
ethoxymethylene	157	172	|I-IUPAC
)	172	173	|I-IUPAC
-	173	174	|I-IUPAC
3	174	175	|I-IUPAC
-	175	176	|I-IUPAC
oxo	176	179	|I-IUPAC
-	179	180	|I-IUPAC
4	180	181	|I-IUPAC
-	181	182	|I-IUPAC
phenylpropanoate	182	198	|I-IUPAC
(	199	200	|O
5d	200	202	|O
)	202	203	|O
afforded	204	212	|O
exclusively	213	224	|O
the	225	228	|O
corresponding	229	242	|O
6	243	244	|O
-	244	245	|O
substituted	245	256	|O
pyridines	257	266	|O
(	267	268	|O
6b	268	270	|O
-	270	271	|O
d	271	272	|O
)	272	273	|O
.	273	274	|O
Cyclization	275	286	|O
of	287	289	|O
4	290	291	|O
with	292	296	|O
3	297	298	|B-IUPAC
-	298	299	|I-IUPAC
carbethoxybutane	299	315	|I-IUPAC
-	315	316	|I-IUPAC
2,4	316	319	|I-IUPAC
-	319	320	|I-IUPAC
dione	320	325	|I-IUPAC
(	326	327	|O
5e	327	329	|O
)	329	330	|O
gave	331	335	|O
3	336	337	|B-IUPAC
-	337	338	|I-IUPAC
cyano	338	343	|I-IUPAC
-	343	344	|I-IUPAC
5	344	345	|I-IUPAC
-	345	346	|I-IUPAC
(	346	347	|I-IUPAC
ethoxycarbonyl	347	361	|I-IUPAC
)	361	362	|I-IUPAC
-	362	363	|I-IUPAC
4,6	363	366	|I-IUPAC
-	366	367	|I-IUPAC
dimethylpyridine	367	383	|I-IUPAC
-	383	384	|I-IUPAC
2	384	385	|I-IUPAC
(	385	386	|I-IUPAC
1H	386	388	|I-IUPAC
)	388	389	|I-IUPAC
-	389	390	|I-IUPAC
thione	390	396	|I-IUPAC
(	397	398	|O
6e	398	400	|O
)	400	401	|O
,	401	402	|O
whereas	403	410	|O
reaction	411	419	|O
of	420	422	|O
4	423	424	|O
with	425	429	|O
3	430	431	|B-IUPAC
-	431	432	|I-IUPAC
carbethoxy	432	442	|I-IUPAC
-	442	443	|I-IUPAC
1	443	444	|I-IUPAC
-	444	445	|I-IUPAC
phenylpropane	445	458	|I-IUPAC
-	458	459	|I-IUPAC
1,3	459	462	|I-IUPAC
-	462	463	|I-IUPAC
dione	463	468	|I-IUPAC
(	469	470	|O
5f	470	472	|O
)	472	473	|O
yielded	474	481	|O
two	482	485	|O
products	486	494	|O
,	494	495	|O
3	496	497	|B-IUPAC
-	497	498	|I-IUPAC
cyano	498	503	|I-IUPAC
-	503	504	|I-IUPAC
5	504	505	|I-IUPAC
-	505	506	|I-IUPAC
(	506	507	|I-IUPAC
ethoxycarbonyl	507	521	|I-IUPAC
)	521	522	|I-IUPAC
-	522	523	|I-IUPAC
4	523	524	|I-IUPAC
-	524	525	|I-IUPAC
methyl	525	531	|I-IUPAC
-	531	532	|I-IUPAC
6	532	533	|I-IUPAC
-	533	534	|I-IUPAC
phenylpyridine	534	548	|I-IUPAC
-	548	549	|I-IUPAC
2	549	550	|I-IUPAC
(	550	551	|I-IUPAC
1H	551	553	|I-IUPAC
)	553	554	|I-IUPAC
-	554	555	|I-IUPAC
thione	555	561	|I-IUPAC
(	562	563	|O
6f	563	565	|O
)	565	566	|O
and	567	570	|O
the	571	574	|O
6	575	576	|B-IUPAC
-	576	577	|I-IUPAC
methyl	577	583	|I-IUPAC
-	583	584	|I-IUPAC
4	584	585	|I-IUPAC
-	585	586	|I-IUPAC
phenyl	586	592	|I-IUPAC
isomer	593	599	|B-MODIFIER
6g	600	602	|O
.	602	603	|O
The	604	607	|O
structural	608	618	|O
assignments	619	630	|O
for	631	634	|O
6f	635	637	|O
and	638	641	|O
6g	642	644	|O
are	645	648	|O
made	649	653	|O
on	654	656	|O
the	657	660	|O
basis	661	666	|O
of	667	669	|O
1H	670	672	|O
and	673	676	|O
13C	677	680	|O
NMR	681	684	|O
spectral	685	693	|O
analyses	694	702	|O
of	703	705	|O
the	706	709	|O
2	710	711	|B-IUPAC
-	711	712	|I-IUPAC
(	712	713	|I-IUPAC
methylthio	713	723	|I-IUPAC
)	723	724	|I-IUPAC
nicotinates	724	735	|I-IUPAC
(	736	737	|O
7f	737	739	|O
,	739	740	|O
g	740	741	|O
)	741	742	|O
prepared	743	751	|O
from	752	756	|O
6f	757	759	|O
and	760	763	|O
6g	764	766	|O
by	767	769	|O
treatment	770	779	|O
with	780	784	|O
MeI	785	788	|O
/	788	789	|O
K2CO3	789	794	|O
.	794	795	|O
Nicotinates	796	807	|O
7b	808	810	|O
,	810	811	|O
d	811	812	|O
-	812	813	|O
g	813	814	|O
were	815	819	|O
converted	820	829	|O
into	830	834	|O
their	835	840	|O
corresponding	841	854	|O
2,4	855	858	|B-IUPAC
-	858	859	|I-IUPAC
diaminopyrido	859	872	|I-IUPAC
[	872	873	|I-IUPAC
2,3	873	876	|I-IUPAC
-	876	877	|I-IUPAC
d	877	878	|I-IUPAC
]	878	879	|I-IUPAC
pyrimidines	879	890	|I-IUPAC
12b	891	894	|O
,	894	895	|O
d	895	896	|O
-	896	897	|O
g	897	898	|O
in	899	901	|O
five	902	906	|O
steps	907	912	|O
,	912	913	|O
via	914	917	|O
reduction	918	927	|O
,	927	928	|O
protection	929	939	|O
,	939	940	|O
oxidation	941	950	|O
,	950	951	|O
condensation	952	964	|O
with	965	969	|O
guanidine	970	979	|O
,	979	980	|O
and	981	984	|O
deprotection	985	997	|O
.	997	998	|O
The	999	1002	|O
7	1003	1004	|B-MODIFIER
-	1004	1005	|I-MODIFIER
mono	1005	1009	|I-MODIFIER
-	1009	1010	|I-MODIFIER
and	1011	1014	|O
5,7	1015	1018	|B-MODIFIER
-	1018	1019	|I-MODIFIER
disubstituted	1019	1032	|I-MODIFIER
-	1032	1033	|O
5	1033	1034	|B-IUPAC
-	1034	1035	|I-IUPAC
deazaaminopterins	1035	1052	|I-IUPAC
(	1053	1054	|O
1b	1054	1056	|O
,	1056	1057	|O
d	1057	1058	|O
-	1058	1059	|O
g	1059	1060	|O
)	1060	1061	|O
were	1062	1066	|O
prepared	1067	1075	|O
from	1076	1080	|O
the	1081	1084	|O
respective	1085	1095	|O
pyrido	1096	1102	|B-IUPAC
[	1102	1103	|I-IUPAC
2,3	1103	1106	|I-IUPAC
-	1106	1107	|I-IUPAC
d	1107	1108	|I-IUPAC
]	1108	1109	|I-IUPAC
pyrimidines	1109	1120	|I-IUPAC
12b	1121	1124	|O
,	1124	1125	|O
d	1125	1126	|O
-	1126	1127	|O
g	1127	1128	|O
.	1128	1129	|O
Preliminary	1130	1141	|O
biological	1142	1152	|O
studies	1153	1160	|O
showed	1161	1167	|O
that	1168	1172	|O
7	1173	1174	|B-IUPAC
-	1174	1175	|I-IUPAC
methyl	1175	1181	|I-IUPAC
and	1182	1185	|O
5,7	1186	1189	|B-IUPAC
-	1189	1190	|I-IUPAC
dimethyl	1190	1198	|I-IUPAC
analogues	1199	1208	|B-MODIFIER
(	1209	1210	|O
1b	1210	1212	|O
and	1213	1216	|O
1e	1217	1219	|O
)	1219	1220	|O
were	1221	1225	|O
less	1226	1230	|O
active	1231	1237	|O
than	1238	1242	|O
methotrexate	1243	1255	|O
against	1256	1263	|O
human	1264	1269	|O
leukemic	1270	1278	|O
HL	1279	1281	|O
-	1281	1282	|O
60	1282	1284	|O
and	1285	1288	|O
murine	1289	1295	|O
L	1296	1297	|O
-	1297	1298	|O
1210	1298	1302	|O
cells	1303	1308	|O
in	1309	1311	|O
tissue	1312	1318	|O
culture	1319	1326	|O
.	1326	1327	|O
Compound	1328	1336	|O
1e	1337	1339	|O
produced	1340	1348	|O
an	1349	1351	|O
ILS	1352	1355	|O
of	1356	1358	|O
71%	1359	1362	|O
at	1363	1365	|O
100	1366	1369	|O
mg	1370	1372	|O
/	1372	1373	|O
kg	1373	1375	|O
per	1376	1379	|O
day	1380	1383	|O
X	1384	1385	|O
5	1386	1387	|O
(	1388	1389	|O
ip	1389	1391	|O
)	1391	1392	|O
in	1393	1395	|O
BDF	1396	1399	|O
mice	1400	1404	|O
inoculated	1405	1415	|O
ip	1416	1418	|O
with	1419	1423	|O
10	1424	1426	|O
(	1426	1427	|O
6	1427	1428	|O
)	1428	1429	|O
L	1430	1431	|O
-	1431	1432	|O
1210	1432	1436	|O
cells	1437	1442	|O
.	1442	1443	|O

### abstracts3004.txt
In	0	2	|O
a	3	4	|O
sequence	5	13	|O
of	14	16	|O
reactions	17	26	|O
,	26	27	|O
methyl	28	34	|O
mesopyropheophorbide	35	55	|O
a	56	57	|O
,	57	58	|O
mesochlorin	59	70	|B-IUPAC
e	71	72	|I-IUPAC
(	72	73	|I-IUPAC
6	73	74	|I-IUPAC
)	74	75	|I-IUPAC
trimethyl	76	85	|I-IUPAC
ester	86	91	|I-IUPAC
,	91	92	|O
mesochlorin	93	104	|B-IUPAC
p	105	106	|I-IUPAC
(	106	107	|I-IUPAC
6	107	108	|I-IUPAC
)	108	109	|I-IUPAC
trimethyl	110	119	|I-IUPAC
ester	120	125	|I-IUPAC
,	125	126	|O
mesopurpurin	127	139	|B-IUPAC
-	139	140	|I-IUPAC
18	140	142	|I-IUPAC
-	142	143	|I-IUPAC
N	143	144	|I-IUPAC
-	144	145	|I-IUPAC
hexylimide	145	155	|I-IUPAC
methyl	156	162	|I-IUPAC
ester	163	168	|I-IUPAC
,	168	169	|O
and	170	173	|O
mesopurpurin	174	186	|B-IUPAC
-	186	187	|I-IUPAC
18	187	189	|I-IUPAC
-	189	190	|I-IUPAC
N	190	191	|I-IUPAC
-	191	192	|I-IUPAC
3,5	192	195	|I-IUPAC
-	195	196	|I-IUPAC
bis	196	199	|I-IUPAC
(	199	200	|I-IUPAC
trifluoromethyl	200	215	|I-IUPAC
)	215	216	|I-IUPAC
benzylimide	216	227	|I-IUPAC
methyl	228	234	|I-IUPAC
ester	235	240	|I-IUPAC
were	241	245	|O
synthesized	246	257	|O
from	258	262	|O
chlorophyll	263	274	|O
-	274	275	|O
a	275	276	|O
.	276	277	|O
These	278	283	|O
chlorins	284	292	|O
on	293	295	|O
reacting	296	304	|O
with	305	309	|O
osmium	310	316	|O
tetraoxide	317	327	|O
produced	328	336	|O
the	337	340	|O
corresponding	341	354	|O
vic	355	358	|O
-	358	359	|O
dihydroxybacteriochlorins	359	384	|O
.	384	385	|O
The	386	389	|O
8	390	391	|B-IUPAC
-	391	392	|I-IUPAC
vinylchlorins	392	405	|I-IUPAC
obtained	406	414	|O
by	415	417	|O
refluxing	418	427	|O
the	428	431	|O
related	432	439	|O
vic	440	443	|O
-	443	444	|O
dihydroxybacteriochlorins	444	469	|O
in	470	472	|O
o	473	474	|B-IUPAC
-	474	475	|I-IUPAC
dichlorobenzene	475	490	|I-IUPAC
were	491	495	|O
individually	496	508	|O
treated	509	516	|O
with	517	521	|O
dimethylacetylenedicarboxylate	522	552	|B-IUPAC
(	553	554	|O
DMAD	554	558	|O
)	558	559	|O
under	560	565	|O
Diels	566	571	|O
-	571	572	|O
Alder	572	577	|O
reaction	578	586	|O
conditions	587	597	|O
.	597	598	|O
The	599	602	|O
intermediate	603	615	|O
adducts	616	623	|O
on	624	626	|O
1,8	627	630	|B-IUPAC
-	630	631	|I-IUPAC
diazabicyclo	631	643	|I-IUPAC
[	643	644	|I-IUPAC
5.4.0	644	649	|I-IUPAC
]	649	650	|I-IUPAC
undec	650	655	|I-IUPAC
-	655	656	|I-IUPAC
7	656	657	|I-IUPAC
-	657	658	|I-IUPAC
ene	658	661	|I-IUPAC
(	662	663	|O
DBU	663	666	|O
)	666	667	|O
treatment	668	677	|O
rearranged	678	688	|O
to	689	691	|O
the	692	695	|O
corresponding	696	709	|O
stable	710	716	|O
benzobacteriochlorins	717	738	|O
,	738	739	|O
exhibiting	740	750	|O
the	751	754	|O
longest	755	762	|O
wavelength	763	773	|O
absorption	774	784	|O
in	785	787	|O
the	788	791	|O
range	792	797	|O
of	798	800	|O
737	801	804	|O
to	805	807	|O
805	808	811	|O
nm	812	814	|O
.	814	815	|O
In	816	818	|O
preliminary	819	830	|O
in	831	833	|O
vitro	834	839	|O
(	840	841	|O
RIF	841	844	|O
tumor	845	850	|O
cells	851	856	|O
)	856	857	|O
and	858	861	|O
in	862	864	|O
vivo	865	869	|O
screening	870	879	|O
(	880	881	|O
C3H	881	884	|O
/	884	885	|O
HeJ	885	888	|O
mice	889	893	|O
bearing	894	901	|O
RIF	902	905	|O
tumors	906	912	|O
)	912	913	|O
,	913	914	|O
some	915	919	|O
of	920	922	|O
these	923	928	|O
compounds	929	938	|O
were	939	943	|O
found	944	949	|O
to	950	952	|O
be	953	955	|O
quite	956	961	|O
effective	962	971	|O
.	971	972	|O
Under	973	978	|O
similar	979	986	|O
treatment	987	996	|O
conditions	997	1007	|O
(	1008	1009	|O
drug	1009	1013	|O
dose	1014	1018	|O
:	1018	1019	|O
5.0	1020	1023	|O
micromol	1024	1032	|O
/	1032	1033	|O
kg	1033	1035	|O
;	1035	1036	|O
light	1037	1042	|O
dose	1043	1047	|O
:	1047	1048	|O
135	1049	1052	|O
J	1053	1054	|O
/	1054	1055	|O
cm	1055	1057	|O
(	1057	1058	|O
2	1058	1059	|O
)	1059	1060	|O
,	1060	1061	|O
tumors	1062	1068	|O
were	1069	1073	|O
exposed	1074	1081	|O
to	1082	1084	|O
light	1085	1090	|O
for	1091	1094	|O
30	1095	1097	|O
min	1098	1101	|O
at	1102	1104	|O
24	1105	1107	|O
h	1108	1109	|O
postinjection	1110	1123	|O
)	1123	1124	|O
,	1124	1125	|O
the	1126	1129	|O
benzobacteriochlorins	1130	1151	|O
containing	1152	1162	|O
N	1163	1164	|O
-	1164	1165	|O
substituted	1165	1176	|O
-	1176	1177	|O
imide	1177	1182	|O
ring	1183	1187	|O
system	1188	1194	|O
produced	1195	1203	|O
enhanced	1204	1212	|O
photosensitizing	1213	1229	|O
efficacy	1230	1238	|O
with	1239	1243	|O
limited	1244	1251	|O
skin	1252	1256	|O
phototoxicity	1257	1270	|O
.	1270	1271	|O
These	1272	1277	|O
compounds	1278	1287	|O
were	1288	1292	|O
also	1293	1297	|O
found	1298	1303	|O
to	1304	1306	|O
bind	1307	1311	|O
to	1312	1314	|O
site	1315	1319	|O
II	1320	1322	|O
of	1323	1325	|O
human	1326	1331	|O
serum	1332	1337	|O
albumin	1338	1345	|O
(	1346	1347	|O
HSA	1347	1350	|O
)	1350	1351	|O
.	1351	1352	|O
However	1353	1360	|O
,	1360	1361	|O
no	1362	1364	|O
correlation	1365	1376	|O
between	1377	1384	|O
the	1385	1388	|O
binding	1389	1396	|O
constant	1397	1405	|O
values	1406	1412	|O
and	1413	1416	|O
photosensitizing	1417	1433	|O
efficacy	1434	1442	|O
was	1443	1446	|O
observed	1447	1455	|O
.	1455	1456	|O
A	1457	1458	|O
competitive	1459	1470	|O
intracellular	1471	1484	|O
localization	1485	1497	|O
study	1498	1503	|O
of	1504	1506	|O
these	1507	1512	|O
novel	1513	1518	|O
structures	1519	1529	|O
with	1530	1534	|O
Rhodamine	1535	1544	|O
-	1544	1545	|O
123	1545	1548	|O
(	1549	1550	|O
a	1550	1551	|O
mitochondrial	1552	1565	|O
probe	1566	1571	|O
)	1571	1572	|O
indicated	1573	1582	|O
their	1583	1588	|O
preferential	1589	1601	|O
localization	1602	1614	|O
in	1615	1617	|O
mitochondria	1618	1630	|O
,	1630	1631	|O
without	1632	1639	|O
producing	1640	1649	|O
any	1650	1653	|O
specific	1654	1662	|O
displacement	1663	1675	|O
of	1676	1678	|O
(	1679	1680	|O
3	1680	1681	|O
)	1681	1682	|O
H	1682	1683	|O
-	1683	1684	|O
PK11195	1684	1691	|O
(	1692	1693	|O
PBR	1693	1696	|O
probe	1697	1702	|O
,	1702	1703	|O
(	1704	1705	|B-MODIFIER
3	1705	1706	|I-MODIFIER
)	1706	1707	|I-MODIFIER
H	1707	1708	|I-MODIFIER
-	1708	1709	|I-MODIFIER
labeled	1709	1716	|I-MODIFIER
1	1717	1718	|B-IUPAC
-	1718	1719	|I-IUPAC
(	1719	1720	|I-IUPAC
2	1720	1721	|I-IUPAC
-	1721	1722	|I-IUPAC
chlorophenyl	1722	1734	|I-IUPAC
)	1734	1735	|I-IUPAC
-	1735	1736	|I-IUPAC
N	1736	1737	|I-IUPAC
-	1737	1738	|I-IUPAC
methyl	1738	1744	|I-IUPAC
-	1744	1745	|I-IUPAC
N	1745	1746	|I-IUPAC
-	1746	1747	|I-IUPAC
(	1747	1748	|I-IUPAC
1	1748	1749	|I-IUPAC
-	1749	1750	|I-IUPAC
methylpropyl	1750	1762	|I-IUPAC
)	1762	1763	|I-IUPAC
-	1763	1764	|I-IUPAC
3	1764	1765	|I-IUPAC
-	1765	1766	|I-IUPAC
isoquinoline	1766	1778	|I-IUPAC
carboxamide	1779	1790	|I-IUPAC
)	1790	1791	|O
.	1791	1792	|O
These	1793	1798	|O
results	1799	1806	|O
suggest	1807	1814	|O
that	1815	1819	|O
the	1820	1823	|O
mitochondrial	1824	1837	|O
peripheral	1838	1848	|O
benzodiazepine	1849	1863	|O
receptor	1864	1872	|O
(	1873	1874	|O
PBR	1874	1877	|O
)	1877	1878	|O
is	1879	1881	|O
not	1882	1885	|O
the	1886	1889	|O
cellular	1890	1898	|O
binding	1899	1906	|O
site	1907	1911	|O
for	1912	1915	|O
this	1916	1920	|O
class	1921	1926	|O
of	1927	1929	|O
compounds	1930	1939	|O
.	1939	1940	|O

### abstracts868.txt
7	0	1	|B-MODIFIER
-	1	2	|I-MODIFIER
substituted	2	13	|I-MODIFIER
3	14	15	|B-IUPAC
-	15	16	|I-IUPAC
(	16	17	|I-IUPAC
2,6	17	20	|I-IUPAC
-	20	21	|I-IUPAC
dichlorophenyl	21	35	|I-IUPAC
)	35	36	|I-IUPAC
-	36	37	|I-IUPAC
1,6	37	40	|I-IUPAC
-	40	41	|I-IUPAC
naphthyridin	41	53	|I-IUPAC
-	53	54	|I-IUPAC
2	54	55	|I-IUPAC
(	55	56	|I-IUPAC
1H	56	58	|I-IUPAC
)	58	59	|I-IUPAC
-	59	60	|I-IUPAC
ones	60	64	|I-IUPAC
are	65	68	|O
potent	69	75	|O
inhibitors	76	86	|O
of	87	89	|O
protein	90	97	|O
tyrosine	98	106	|O
kinases	107	114	|O
,	114	115	|O
with	116	120	|O
some	121	125	|O
selectivity	126	137	|O
for	138	141	|O
c	142	143	|O
-	143	144	|O
Src	144	147	|O
.	147	148	|O
The	149	152	|O
compounds	153	162	|O
were	163	167	|O
prepared	168	176	|O
by	177	179	|O
condensing	180	190	|O
4	191	192	|B-IUPAC
,	192	193	|I-IUPAC
6	194	195	|I-IUPAC
-	195	196	|I-IUPAC
diaminonicotinaldehyde	196	218	|I-IUPAC
with	219	223	|O
2,6	224	227	|B-IUPAC
-	227	228	|I-IUPAC
dichlorophenylacetonitrile	228	254	|I-IUPAC
and	255	258	|O
selectively	259	270	|O
converting	271	281	|O
the	282	285	|O
2	286	287	|O
-	287	288	|O
and	289	292	|O
7	293	294	|O
-	294	295	|O
amino	295	300	|O
groups	301	307	|O
of	308	310	|O
the	311	314	|O
product	315	322	|O
to	323	325	|O
hydroxy	326	333	|O
and	334	337	|O
fluoro	338	344	|O
groups	345	351	|O
,	351	352	|O
respectively	353	365	|O
,	365	366	|O
by	367	369	|O
prolonged	370	379	|O
diazotization	380	393	|O
in	394	396	|O
50%	397	400	|O
aqueous	401	408	|O
fluoboric	409	418	|O
acid	419	423	|O
.	423	424	|O
N	425	426	|O
-	426	427	|O
Methylation	427	438	|O
,	438	439	|O
followed	440	448	|O
by	449	451	|O
treatment	452	461	|O
with	462	466	|O
aliphatic	467	476	|O
diamines	477	485	|O
,	485	486	|O
aromatic	487	495	|O
amines	496	502	|O
,	502	503	|O
or	504	506	|O
their	507	512	|O
derived	513	520	|O
lithium	521	528	|O
anions	529	535	|O
,	535	536	|O
gave	537	541	|O
the	542	545	|O
desired	546	553	|O
compounds	554	563	|O
.	563	564	|O
Selected	565	573	|O
isomeric	574	582	|O
1	583	584	|B-IUPAC
,	584	585	|I-IUPAC
8	586	587	|I-IUPAC
-	587	588	|I-IUPAC
naphthyridin	588	600	|I-IUPAC
-	600	601	|I-IUPAC
2	601	602	|I-IUPAC
(	602	603	|I-IUPAC
1H	603	605	|I-IUPAC
)	605	606	|I-IUPAC
-	606	607	|I-IUPAC
ones	607	611	|I-IUPAC
were	612	616	|O
also	617	621	|O
prepared	622	630	|O
in	631	633	|O
order	634	639	|O
to	640	642	|O
evaluate	643	651	|O
the	652	655	|O
relative	656	664	|O
contributions	665	678	|O
of	679	681	|O
both	682	686	|O
ring	687	691	|O
A	692	693	|O
aza	694	697	|O
atoms	698	703	|O
of	704	706	|O
the	707	710	|O
related	711	718	|O
pyrido	719	725	|B-IUPAC
[	725	726	|I-IUPAC
2,3	726	729	|I-IUPAC
-	729	730	|I-IUPAC
d	730	731	|I-IUPAC
]	731	732	|I-IUPAC
pyrimidin	732	741	|I-IUPAC
-	741	742	|I-IUPAC
7	742	743	|I-IUPAC
(	743	744	|I-IUPAC
8H	744	746	|I-IUPAC
)	746	747	|I-IUPAC
-	747	748	|I-IUPAC
ones	748	752	|I-IUPAC
to	753	755	|O
the	756	759	|O
inhibitory	760	770	|O
activity	771	779	|O
.	779	780	|O
The	781	784	|O
compounds	785	794	|O
were	795	799	|O
evaluated	800	809	|O
for	810	813	|O
their	814	819	|O
ability	820	827	|O
to	828	830	|O
prevent	831	838	|O
phosphorylation	839	854	|O
of	855	857	|O
a	858	859	|O
model	860	865	|O
substrate	866	875	|O
by	876	878	|O
c	879	880	|O
-	880	881	|O
Src	881	884	|O
,	884	885	|O
FGF	886	889	|O
-	889	890	|O
1	890	891	|O
receptor	892	900	|O
,	900	901	|O
and	902	905	|O
PDGF	906	910	|O
-	910	911	|O
beta	911	915	|O
receptor	916	924	|O
enzymes	925	932	|O
.	932	933	|O
Overall	934	941	|O
,	941	942	|O
there	943	948	|O
was	949	952	|O
a	953	954	|O
high	955	959	|O
degree	960	966	|O
of	967	969	|O
correlation	970	981	|O
of	982	984	|O
the	985	988	|O
activities	989	999	|O
against	1000	1007	|O
the	1008	1011	|O
different	1012	1021	|O
kinases	1022	1029	|O
,	1029	1030	|O
with	1031	1035	|O
c	1036	1037	|O
-	1037	1038	|O
Src	1038	1041	|O
being	1042	1047	|O
generally	1048	1057	|O
the	1058	1061	|O
most	1062	1066	|O
sensitive	1067	1076	|O
to	1077	1079	|O
structural	1080	1090	|O
changes	1091	1098	|O
.	1098	1099	|O
1	1100	1101	|B-IUPAC
,	1101	1102	|I-IUPAC
6	1103	1104	|I-IUPAC
-	1104	1105	|I-IUPAC
Naphthyridin	1105	1117	|I-IUPAC
-	1117	1118	|I-IUPAC
2	1118	1119	|I-IUPAC
(	1119	1120	|I-IUPAC
1H	1120	1122	|I-IUPAC
)	1122	1123	|I-IUPAC
-	1123	1124	|I-IUPAC
one	1124	1127	|I-IUPAC
analogues	1128	1137	|B-MODIFIER
bearing	1138	1145	|O
basic	1146	1151	|O
aliphatic	1152	1161	|O
side	1162	1166	|O
chains	1167	1173	|O
[	1174	1175	|O
7	1175	1176	|O
-	1176	1177	|O
NH	1177	1179	|O
(	1179	1180	|O
CH	1180	1182	|O
(	1182	1183	|O
2	1183	1184	|O
)	1184	1185	|O
)	1185	1186	|O
(	1186	1187	|O
n	1187	1188	|O
)	1188	1189	|O
(	1189	1190	|O
)	1190	1191	|O
NRR	1191	1194	|O
,	1194	1195	|O
7	1196	1197	|O
-	1197	1198	|O
NHPhO	1198	1203	|O
(	1203	1204	|O
CH	1204	1206	|O
(	1206	1207	|O
2	1207	1208	|O
)	1208	1209	|O
)	1209	1210	|O
(	1210	1211	|O
n	1211	1212	|O
)	1212	1213	|O
(	1213	1214	|O
)	1214	1215	|O
NRR	1215	1218	|O
,	1218	1219	|O
or	1220	1222	|O
7	1223	1224	|O
-	1224	1225	|O
NHPhN	1225	1230	|O
(	1230	1231	|O
CH	1231	1233	|O
(	1233	1234	|O
2	1234	1235	|O
)	1235	1236	|O
)	1236	1237	|O
(	1237	1238	|O
4	1238	1239	|O
)	1239	1240	|O
NMe	1240	1243	|O
]	1243	1244	|O
were	1245	1249	|O
the	1250	1253	|O
most	1254	1258	|O
potent	1259	1265	|O
against	1266	1273	|O
c	1274	1275	|O
-	1275	1276	|O
Src	1276	1279	|O
(	1280	1281	|O
IC	1281	1283	|O
(	1283	1284	|O
50	1284	1286	|O
)	1286	1287	|O
s	1287	1288	|O
of	1289	1291	|O
10-80	1292	1297	|O
nM	1298	1300	|O
)	1300	1301	|O
,	1301	1302	|O
showing	1303	1310	|O
good	1311	1315	|O
selectivity	1316	1327	|O
with	1328	1332	|O
respect	1333	1340	|O
to	1341	1343	|O
PDGFR	1344	1349	|O
(	1350	1351	|O
10-300	1351	1357	|O
-	1357	1358	|O
fold	1358	1362	|O
)	1362	1363	|O
but	1364	1367	|O
less	1368	1372	|O
with	1373	1377	|O
respect	1378	1385	|O
to	1386	1388	|O
FGFR	1389	1393	|O
.	1393	1394	|O
The	1395	1398	|O
1	1399	1400	|B-IUPAC
,	1400	1401	|I-IUPAC
6	1402	1403	|I-IUPAC
-	1403	1404	|I-IUPAC
naphthyridin	1404	1416	|I-IUPAC
-	1416	1417	|I-IUPAC
2	1417	1418	|I-IUPAC
(	1418	1419	|I-IUPAC
1H	1419	1421	|I-IUPAC
)	1421	1422	|I-IUPAC
-	1422	1423	|I-IUPAC
ones	1423	1427	|I-IUPAC
showed	1428	1434	|O
broadly	1435	1442	|O
similar	1443	1450	|O
activity	1451	1459	|O
to	1460	1462	|O
the	1463	1466	|O
analogous	1467	1476	|B-MODIFIER
pyrido	1477	1483	|B-IUPAC
[	1483	1484	|I-IUPAC
2,3	1484	1487	|I-IUPAC
-	1487	1488	|I-IUPAC
d	1488	1489	|I-IUPAC
]	1489	1490	|I-IUPAC
pyrimidin	1490	1499	|I-IUPAC
-	1499	1500	|I-IUPAC
7	1500	1501	|I-IUPAC
(	1501	1502	|I-IUPAC
8H	1502	1504	|I-IUPAC
)	1504	1505	|I-IUPAC
-	1505	1506	|I-IUPAC
ones	1506	1510	|I-IUPAC
,	1510	1511	|O
whereas	1512	1519	|O
the	1520	1523	|O
1	1524	1525	|B-IUPAC
,	1525	1526	|I-IUPAC
8	1527	1528	|I-IUPAC
-	1528	1529	|I-IUPAC
naphthyridin	1529	1541	|I-IUPAC
-	1541	1542	|I-IUPAC
2	1542	1543	|I-IUPAC
(	1543	1544	|I-IUPAC
1H	1544	1546	|I-IUPAC
)	1546	1547	|I-IUPAC
-	1547	1548	|I-IUPAC
ones	1548	1552	|I-IUPAC
were	1553	1557	|O
at	1558	1560	|O
least	1561	1566	|O
10	1567	1569	|O
(	1569	1570	|O
3	1570	1571	|O
)	1571	1572	|O
-	1572	1573	|O
fold	1573	1577	|O
less	1578	1582	|O
potent	1583	1589	|O
.	1589	1590	|O
These	1591	1596	|O
results	1597	1604	|O
,	1604	1605	|O
indicating	1606	1616	|O
that	1617	1621	|O
the	1622	1625	|O
3	1626	1627	|O
-	1627	1628	|O
aza	1628	1631	|O
atom	1632	1636	|O
in	1637	1639	|O
the	1640	1643	|O
pyrido	1644	1650	|B-IUPAC
[	1650	1651	|I-IUPAC
2	1651	1652	|I-IUPAC
,	1652	1653	|I-IUPAC
3	1654	1655	|I-IUPAC
-	1655	1656	|I-IUPAC
d	1656	1657	|I-IUPAC
]	1657	1658	|I-IUPAC
pyrimidin	1658	1667	|I-IUPAC
-	1667	1668	|I-IUPAC
7	1668	1669	|I-IUPAC
(	1669	1670	|I-IUPAC
8H	1670	1672	|I-IUPAC
)	1672	1673	|I-IUPAC
-	1673	1674	|I-IUPAC
ones	1674	1678	|I-IUPAC
is	1679	1681	|O
mandatory	1682	1691	|O
,	1691	1692	|O
whereas	1693	1700	|O
the	1701	1704	|O
1	1705	1706	|O
-	1706	1707	|O
aza	1707	1710	|O
atom	1711	1715	|O
is	1716	1718	|O
not	1719	1722	|O
,	1722	1723	|O
support	1724	1731	|O
the	1732	1735	|O
published	1736	1745	|O
binding	1746	1753	|O
model	1754	1759	|O
for	1760	1763	|O
these	1764	1769	|O
compounds	1770	1779	|O
to	1780	1782	|O
c	1783	1784	|O
-	1784	1785	|O
Src	1785	1788	|O
(	1789	1790	|O
J	1790	1791	|O
.	1791	1792	|O
Med.	1793	1797	|O
Chem.	1798	1803	|O
1998	1804	1808	|O
,	1808	1809	|O
41	1810	1812	|O
,	1812	1813	|O
1752	1814	1818	|O
)	1818	1819	|O
,	1819	1820	|O
where	1821	1826	|O
the	1827	1830	|O
3	1831	1832	|O
-	1832	1833	|O
aza	1833	1836	|O
and	1837	1840	|O
2	1841	1842	|O
-	1842	1843	|O
NH	1843	1845	|O
atoms	1846	1851	|O
form	1852	1856	|O
a	1857	1858	|O
bidentate	1859	1868	|O
H	1869	1870	|O
-	1870	1871	|O
bond	1871	1875	|O
donor	1876	1881	|O
-	1881	1882	|O
acceptor	1882	1890	|O
motif	1891	1896	|O
that	1897	1901	|O
interacts	1902	1911	|O
with	1912	1916	|O
Met341	1917	1923	|O
and	1924	1927	|O
the	1928	1931	|O
1	1932	1933	|O
-	1933	1934	|O
aza	1934	1937	|O
atom	1938	1942	|O
is	1943	1945	|O
not	1946	1949	|O
involved	1950	1958	|O
in	1959	1961	|O
specific	1962	1970	|O
binding	1971	1978	|O
interactions	1979	1991	|O
.	1991	1992	|O

### abstracts1986.txt
beta	0	4	|O
-	4	5	|O
(	5	6	|O
1	6	7	|O
-	7	8	|O
Chloro	8	14	|O
-	14	15	|O
2	15	16	|O
-	16	17	|O
naphthyl	17	25	|O
)	25	26	|O
alanine	26	33	|O
and	34	37	|O
beta	38	42	|B-IUPAC
-	42	43	|I-IUPAC
(	43	44	|I-IUPAC
1	44	45	|I-IUPAC
-	45	46	|I-IUPAC
bromo	46	51	|I-IUPAC
-	51	52	|I-IUPAC
2	52	53	|I-IUPAC
-	53	54	|I-IUPAC
naphthyl	54	62	|I-IUPAC
)	62	63	|I-IUPAC
alanine	64	71	|I-IUPAC
were	72	76	|O
synthesized	77	88	|O
by	89	91	|O
ammonolysis	92	103	|O
of	104	106	|O
the	107	110	|O
corresponding	111	124	|O
alpha	125	130	|B-IUPAC
,	130	131	|I-IUPAC
1	132	133	|I-IUPAC
-	133	134	|I-IUPAC
dihalo	134	140	|I-IUPAC
-	140	141	|I-IUPAC
2	141	142	|I-IUPAC
-	142	143	|I-IUPAC
naphthalenepropanoic	143	163	|I-IUPAC
acids	164	169	|I-IUPAC
derived	170	177	|O
from	178	182	|O
1	183	184	|B-IUPAC
-	184	185	|I-IUPAC
nitro	185	190	|I-IUPAC
-	190	191	|I-IUPAC
2	191	192	|I-IUPAC
-	192	193	|I-IUPAC
naphthylamine	193	206	|I-IUPAC
by	207	209	|O
diazotization	210	223	|O
and	224	227	|O
condensation	228	240	|O
with	241	245	|O
acrylic	246	253	|O
acid	254	258	|O
in	259	261	|O
the	262	265	|O
presence	266	274	|O
of	275	277	|O
cuprous	278	285	|O
halides	286	293	|O
.	293	294	|O
The	295	298	|O
two	299	302	|O
analogs	303	310	|O
as	311	313	|O
well	314	318	|O
as	319	321	|O
the	322	325	|O
previously	326	336	|O
reported	337	345	|O
beta	346	350	|B-IUPAC
-	350	351	|I-IUPAC
(	351	352	|I-IUPAC
2	352	353	|I-IUPAC
-	353	354	|I-IUPAC
naphthyl	354	362	|I-IUPAC
)	362	363	|I-IUPAC
alanine	363	370	|I-IUPAC
and	371	374	|O
beta	375	379	|B-IUPAC
-	379	380	|I-IUPAC
(	380	381	|I-IUPAC
1	381	382	|I-IUPAC
-	382	383	|I-IUPAC
naphthyl	383	391	|I-IUPAC
)	391	392	|I-IUPAC
alanine	392	399	|I-IUPAC
were	400	404	|O
studied	405	412	|O
as	413	415	|O
growth	416	422	|O
inhibitors	423	433	|O
of	434	436	|O
Escherichia	437	448	|O
coli	449	453	|O
9723	454	458	|O
,	458	459	|O
Leuconostoc	460	471	|O
dextranicum	472	483	|O
8086	484	488	|O
,	488	489	|O
and	490	493	|O
Lactobacillus	494	507	|O
plantarum	508	517	|O
8014	518	522	|O
.	522	523	|O
In	524	526	|O
general	527	534	|O
,	534	535	|O
the	536	539	|O
chloro	540	546	|O
and	547	550	|O
bromo	551	556	|O
analogs	557	564	|O
were	565	569	|O
more	570	574	|O
effective	575	584	|O
than	585	589	|O
the	590	593	|O
unsubstituted	594	607	|O
naphthylalanines	608	624	|O
as	625	627	|O
growth	628	634	|O
inhibitors	635	645	|O
of	646	648	|O
the	649	652	|O
three	653	658	|O
microorganisms	659	673	|O
studied	674	681	|O
.	681	682	|O

### abstracts753.txt
Several	0	7	|O
6	8	9	|B-IUPAC
-	9	10	|I-IUPAC
benzyl	10	16	|I-IUPAC
analogs	17	24	|B-MODIFIER
of	25	27	|O
1	28	29	|B-IUPAC
-	29	30	|I-IUPAC
[	30	31	|I-IUPAC
(	31	32	|I-IUPAC
2	32	33	|I-IUPAC
-	33	34	|I-IUPAC
hydroxyethoxy	34	47	|I-IUPAC
)	47	48	|I-IUPAC
methyl	48	54	|I-IUPAC
]	54	55	|I-IUPAC
-	55	56	|I-IUPAC
6	56	57	|I-IUPAC
-	57	58	|I-IUPAC
(	58	59	|I-IUPAC
phenylthio	59	69	|I-IUPAC
)	69	70	|I-IUPAC
thymine	70	77	|I-IUPAC
(	78	79	|O
1	79	80	|O
;	80	81	|O
HEPT	82	86	|O
)	86	87	|O
were	88	92	|O
synthesized	93	104	|O
and	105	108	|O
evaluated	109	118	|O
for	119	122	|O
their	123	128	|O
anti	129	133	|O
-	133	134	|O
HIV	134	137	|O
-	137	138	|O
1	138	139	|O
activity	140	148	|O
.	148	149	|O
LDA	150	153	|O
(	154	155	|O
lithium	155	162	|O
diisopropylamide	163	179	|O
)	179	180	|O
lithiation	181	191	|O
of	192	194	|O
5	195	196	|B-IUPAC
-	196	197	|I-IUPAC
ethyluracil	197	208	|I-IUPAC
derivatives	209	220	|B-MODIFIER
7	221	222	|O
and	223	226	|O
8	227	228	|O
and	229	232	|O
subsequent	233	243	|O
reaction	244	252	|O
with	253	257	|O
an	258	260	|O
aryl	261	265	|O
aldehyde	266	274	|O
gave	275	279	|O
6	280	281	|B-IUPAC
-	281	282	|I-IUPAC
(	282	283	|I-IUPAC
arylhydroxymethyl	283	300	|I-IUPAC
)	300	301	|I-IUPAC
-	301	302	|I-IUPAC
5	302	303	|I-IUPAC
-	303	304	|I-IUPAC
ethyluracil	304	315	|I-IUPAC
derivatives	316	327	|B-MODIFIER
9-12	328	332	|O
.	332	333	|O
6	334	335	|B-IUPAC
-	335	336	|I-IUPAC
(	336	337	|I-IUPAC
Arylhydroxymethyl	337	354	|I-IUPAC
)	354	355	|I-IUPAC
-	355	356	|I-IUPAC
5	356	357	|I-IUPAC
-	357	358	|I-IUPAC
isopropyluracil	358	373	|I-IUPAC
derivatives	374	385	|B-MODIFIER
15-18	386	391	|O
were	392	396	|O
prepared	397	405	|O
from	406	410	|O
the	411	414	|O
5	415	416	|B-IUPAC
-	416	417	|I-IUPAC
isopropyl	417	426	|I-IUPAC
-	426	427	|I-IUPAC
2	427	428	|I-IUPAC
-	428	429	|I-IUPAC
thiouracil	429	439	|I-IUPAC
derivatives	440	451	|B-MODIFIER
13	452	454	|O
and	455	458	|O
14	459	461	|O
by	462	464	|O
the	465	468	|O
above	469	474	|O
procedure	475	484	|O
following	485	494	|O
oxidative	495	504	|O
hydrolysis	505	515	|O
of	516	518	|O
the	519	522	|O
thione	523	529	|O
.	529	530	|O
Preparation	531	542	|O
of	543	545	|O
the	546	549	|O
target	550	556	|O
5	557	558	|B-IUPAC
-	558	559	|I-IUPAC
alkyl	559	564	|I-IUPAC
-	564	565	|I-IUPAC
1	565	566	|I-IUPAC
-	566	567	|I-IUPAC
(	567	568	|I-IUPAC
alkoxymethyl	568	580	|I-IUPAC
)	580	581	|I-IUPAC
-	581	582	|I-IUPAC
6	582	583	|I-IUPAC
-	583	584	|I-IUPAC
benzyluracil	584	596	|I-IUPAC
derivatives	597	608	|B-MODIFIER
27-34	609	614	|O
was	615	618	|O
carried	619	626	|O
out	627	630	|O
by	631	633	|O
acetylation	634	645	|O
of	646	648	|O
9-14	649	653	|O
followed	654	662	|O
by	663	665	|O
Pd	666	668	|O
-	668	669	|O
catalyzed	669	678	|O
hydrogenolysis	679	693	|O
.	693	694	|O
The	695	698	|O
1	699	700	|B-PARTIUPAC
-	700	701	|I-PARTIUPAC
butyl	701	706	|I-PARTIUPAC
-	706	707	|I-PARTIUPAC
(	708	709	|O
37	709	711	|O
and	712	715	|O
39	716	718	|O
)	718	719	|O
and	720	723	|O
1	724	725	|B-PARTIUPAC
-	725	726	|I-PARTIUPAC
(	726	727	|I-PARTIUPAC
2	727	728	|I-PARTIUPAC
-	728	729	|I-PARTIUPAC
methoxyl	729	737	|I-PARTIUPAC
)	737	738	|I-PARTIUPAC
-	738	739	|I-PARTIUPAC
(	740	741	|O
38	741	743	|O
and	744	747	|O
40	748	750	|O
)	750	751	|O
5	752	753	|B-IUPAC
-	753	754	|I-IUPAC
alkyl	754	759	|I-IUPAC
-	759	760	|I-IUPAC
6	760	761	|I-IUPAC
-	761	762	|I-IUPAC
benzyluracils	762	775	|I-IUPAC
were	776	780	|O
synthesized	781	792	|O
by	793	795	|O
1	796	797	|O
-	797	798	|O
alkylation	798	808	|O
of	809	811	|O
the	812	815	|O
3	816	817	|B-IUPAC
-	817	818	|I-IUPAC
phenacyl	818	826	|I-IUPAC
derivatives	827	838	|B-MODIFIER
35	839	841	|O
and	842	845	|O
36	846	848	|O
with	849	853	|O
alkyl	854	859	|O
halides	860	867	|O
followed	868	876	|O
by	877	879	|O
deprotection	880	892	|O
of	893	895	|O
the	896	899	|O
3	900	901	|B-IUPAC
-	901	902	|I-IUPAC
phenacyl	902	910	|I-IUPAC
group	911	916	|B-MODIFIER
.	916	917	|O
Compounds	918	927	|O
synthesized	928	939	|O
in	940	942	|O
this	943	947	|O
study	948	953	|O
inhibited	954	963	|O
HIV	964	967	|O
-	967	968	|O
1	968	969	|O
replication	970	981	|O
in	982	984	|O
MT	985	987	|O
-	987	988	|O
4	988	989	|O
cells	990	995	|O
in	996	998	|O
the	999	1002	|O
submicromolar	1003	1016	|O
to	1017	1019	|O
namomolar	1020	1029	|O
concentration	1030	1043	|O
range	1044	1049	|O
.	1049	1050	|O
From	1051	1055	|O
this	1056	1060	|O
series	1061	1067	|O
of	1068	1070	|O
compounds	1071	1080	|O
,	1080	1081	|O
6	1082	1083	|B-IUPAC
-	1083	1084	|I-IUPAC
benzyl	1084	1090	|I-IUPAC
-	1090	1091	|I-IUPAC
1	1091	1092	|I-IUPAC
-	1092	1093	|I-IUPAC
(	1093	1094	|I-IUPAC
ethoxymethyl	1094	1106	|I-IUPAC
)	1106	1107	|I-IUPAC
-	1107	1108	|I-IUPAC
5	1108	1109	|I-IUPAC
-	1109	1110	|I-IUPAC
isopropyluracil	1110	1125	|I-IUPAC
(	1126	1127	|O
33	1127	1129	|O
)	1129	1130	|O
was	1131	1134	|O
selected	1135	1143	|O
for	1144	1147	|O
clinical	1148	1156	|O
evaluation	1157	1167	|O
.	1167	1168	|O

### abstracts33.txt
The	0	3	|O
novel	4	9	|O
semirigid	10	19	|O
derivatives	20	31	|O
(	32	33	|B-IUPAC
+	33	34	|I-IUPAC
)	34	35	|I-IUPAC
-	35	36	|I-IUPAC
cis	36	39	|I-IUPAC
-	39	40	|I-IUPAC
1	40	41	|I-IUPAC
-	41	42	|I-IUPAC
[	42	43	|I-IUPAC
2	43	44	|I-IUPAC
-	44	45	|I-IUPAC
phenyl	45	51	|I-IUPAC
-	51	52	|I-IUPAC
2	52	53	|I-IUPAC
-	53	54	|I-IUPAC
bicyclo	54	61	|I-IUPAC
[	61	62	|I-IUPAC
3.1.0	62	67	|I-IUPAC
]	67	68	|I-IUPAC
hexyl	68	73	|I-IUPAC
]	73	74	|I-IUPAC
piperidine	74	84	|I-IUPAC
[	85	86	|O
(	86	87	|O
+	87	88	|O
)	88	89	|O
-	89	90	|O
8	90	91	|O
]	91	92	|O
,	92	93	|O
its	94	97	|O
enantiomer	98	108	|O
(	109	110	|B-PARTIUPAC
-	110	111	|I-PARTIUPAC
)	111	112	|I-PARTIUPAC
-	112	113	|I-PARTIUPAC
8	113	114	|I-PARTIUPAC
,	114	115	|O
and	116	119	|O
(	120	121	|B-IUPAC
+	121	122	|I-IUPAC
-	122	123	|I-IUPAC
)	123	124	|I-IUPAC
-	124	125	|I-IUPAC
trans	125	130	|I-IUPAC
-	130	131	|I-IUPAC
1	131	132	|I-IUPAC
-	132	133	|I-IUPAC
[	133	134	|I-IUPAC
2	134	135	|I-IUPAC
-	135	136	|I-IUPAC
phenyl	136	142	|I-IUPAC
-	142	143	|I-IUPAC
2	143	144	|I-IUPAC
-	144	145	|I-IUPAC
bicyclo	145	152	|I-IUPAC
[	152	153	|I-IUPAC
3.1.0	153	158	|I-IUPAC
]	158	159	|I-IUPAC
hexyl	159	164	|I-IUPAC
]	164	165	|I-IUPAC
piperidine	165	175	|I-IUPAC
[	176	177	|O
(	177	178	|O
+	178	179	|O
/	179	180	|O
-	180	181	|O
)	181	182	|O
-	182	183	|O
9	183	184	|O
]	184	185	|O
were	186	190	|O
synthesized	191	202	|O
as	203	205	|O
probes	206	212	|O
to	213	215	|O
investigate	216	227	|O
the	228	231	|O
mode	232	236	|O
of	237	239	|O
interaction	240	251	|O
of	252	254	|O
phencyclidine	255	268	|O
(	269	270	|O
PCP	270	273	|O
)	273	274	|O
with	275	279	|O
its	280	283	|O
binding	284	291	|O
site	292	296	|O
on	297	299	|O
the	300	303	|O
N	304	305	|B-IUPAC
-	305	306	|I-IUPAC
methyl	306	312	|I-IUPAC
-	312	313	|I-IUPAC
D	313	314	|I-IUPAC
-	314	315	|I-IUPAC
aspartate	315	324	|I-IUPAC
receptor	325	333	|O
complex	334	341	|O
.	341	342	|O
Each	343	347	|O
target	348	354	|O
compound	355	363	|O
was	364	367	|O
obtained	368	376	|O
in	377	379	|O
five	380	384	|O
steps	385	390	|O
starting	391	399	|O
from	400	404	|O
cyclopent	405	414	|B-IUPAC
-	414	415	|I-IUPAC
2	415	416	|I-IUPAC
-	416	417	|I-IUPAC
enone	417	422	|I-IUPAC
.	422	423	|O
(	424	425	|O
+	425	426	|O
)	426	427	|O
-	427	428	|O
and	429	432	|O
(	433	434	|O
-	434	435	|O
)	435	436	|O
-	436	437	|O
8	437	438	|O
were	439	443	|O
obtained	444	452	|O
in	453	455	|O
greater	456	463	|O
than	464	468	|O
98%	469	472	|O
optical	473	480	|O
purity	481	487	|O
through	488	495	|O
three	496	501	|O
recrystallizations	502	520	|O
from	521	525	|O
ethanol	526	533	|O
of	534	536	|O
the	537	540	|O
(	541	542	|B-PARTIUPAC
S	542	543	|I-PARTIUPAC
)	543	544	|I-PARTIUPAC
-	544	545	|I-PARTIUPAC
(	545	546	|I-PARTIUPAC
+	546	547	|I-PARTIUPAC
)	547	548	|I-PARTIUPAC
-	548	549	|I-PARTIUPAC
and	550	553	|O
(	554	555	|B-IUPAC
R	555	556	|I-IUPAC
)	556	557	|I-IUPAC
-	557	558	|I-IUPAC
(	558	559	|I-IUPAC
-	559	560	|I-IUPAC
)	560	561	|I-IUPAC
-	561	562	|I-IUPAC
mandelate	562	571	|I-IUPAC
salts	572	577	|I-IUPAC
of	578	580	|O
intermediate	581	593	|O
(	594	595	|B-IUPAC
+	595	596	|I-IUPAC
-	596	597	|I-IUPAC
)	597	598	|I-IUPAC
-	598	599	|I-IUPAC
cis	599	602	|I-IUPAC
-	602	603	|I-IUPAC
2	603	604	|I-IUPAC
-	604	605	|I-IUPAC
phenyl	605	611	|I-IUPAC
-	611	612	|I-IUPAC
2	612	613	|I-IUPAC
-	613	614	|I-IUPAC
bicyclo	614	621	|I-IUPAC
[	621	622	|I-IUPAC
3.1.0	622	627	|I-IUPAC
]	627	628	|I-IUPAC
hexylamine	628	638	|I-IUPAC
(	639	640	|O
[	640	641	|O
(	641	642	|O
+	642	643	|O
/	643	644	|O
-	644	645	|O
)	645	646	|O
-	646	647	|O
16	647	649	|O
]	649	650	|O
.	650	651	|O
Crystallization	652	667	|O
of	668	670	|O
the	671	674	|O
(	675	676	|B-IUPAC
R	676	677	|I-IUPAC
)	677	678	|I-IUPAC
-	678	679	|I-IUPAC
(	679	680	|I-IUPAC
-	680	681	|I-IUPAC
)	681	682	|I-IUPAC
-	682	683	|I-IUPAC
mandelate	683	692	|I-IUPAC
salt	693	697	|I-IUPAC
afforded	698	706	|O
(	707	708	|O
1R	708	710	|O
,	710	711	|O
2R	711	713	|O
,	713	714	|O
5S	714	716	|O
)	716	717	|O
-	717	718	|O
(	718	719	|O
-	719	720	|O
)	720	721	|O
-	721	722	|O
16	722	724	|O
,	724	725	|O
whereas	726	733	|O
the	734	737	|O
(	738	739	|B-IUPAC
S	739	740	|I-IUPAC
)	740	741	|I-IUPAC
-	741	742	|I-IUPAC
(	742	743	|I-IUPAC
+	743	744	|I-IUPAC
)	744	745	|I-IUPAC
-	745	746	|I-IUPAC
mandelate	746	755	|I-IUPAC
salt	756	760	|I-IUPAC
afforded	761	769	|O
(	770	771	|O
1S	771	773	|O
,	773	774	|O
2S	774	776	|O
,	776	777	|O
5R	777	779	|O
)	779	780	|O
-	780	781	|O
(	781	782	|O
+	782	783	|O
)	783	784	|O
-	784	785	|O
16	785	787	|O
;	787	788	|O
the	789	792	|O
absolute	793	801	|O
configuration	802	815	|O
was	816	819	|O
determined	820	830	|O
by	831	833	|O
single	834	840	|O
-	840	841	|O
crystal	841	848	|O
X	849	850	|O
-	850	851	|O
ray	851	854	|O
analysis	855	863	|O
of	864	866	|O
(	867	868	|B-IUPAC
-	868	869	|I-IUPAC
)	869	870	|I-IUPAC
-	870	871	|I-IUPAC
16	871	873	|I-IUPAC
.	873	874	|I-IUPAC
(	874	875	|I-IUPAC
R	875	876	|I-IUPAC
)	876	877	|I-IUPAC
-	877	878	|I-IUPAC
(	878	879	|I-IUPAC
-	879	880	|I-IUPAC
)	880	881	|I-IUPAC
-	881	882	|I-IUPAC
mandelate	882	891	|I-IUPAC
.	891	892	|O
Single	893	899	|O
-	899	900	|O
crystal	900	907	|O
X	908	909	|O
-	909	910	|O
ray	910	913	|O
analysis	914	922	|O
of	923	925	|O
(	926	927	|B-IUPAC
+	927	928	|I-IUPAC
/	928	929	|I-IUPAC
-	929	930	|I-IUPAC
)	930	931	|I-IUPAC
-	931	932	|I-IUPAC
9	932	933	|I-IUPAC
-	933	934	|I-IUPAC
picrate	934	941	|I-IUPAC
confirmed	942	951	|O
its	952	955	|O
trans	956	961	|O
configuration	962	975	|O
and	976	979	|O
provided	980	988	|O
conformational	989	1003	|O
data	1004	1008	|O
.	1008	1009	|O
(	1010	1011	|O
+	1011	1012	|O
)	1012	1013	|O
-	1013	1014	|O
and	1015	1018	|O
(	1019	1020	|O
-	1020	1021	|O
)	1021	1022	|O
-	1022	1023	|O
8	1023	1024	|O
and	1025	1028	|O
(	1029	1030	|O
+	1030	1031	|O
/	1031	1032	|O
-	1032	1033	|O
)	1033	1034	|O
-	1034	1035	|O
9	1035	1036	|O
were	1037	1041	|O
examined	1042	1050	|O
for	1051	1054	|O
their	1055	1060	|O
ability	1061	1068	|O
to	1069	1071	|O
interact	1072	1080	|O
with	1081	1085	|O
PCP	1086	1089	|O
and	1090	1093	|O
sigma	1094	1099	|O
binding	1100	1107	|O
sites	1108	1113	|O
in	1114	1116	|O
vitro	1117	1122	|O
using	1123	1128	|O
[	1129	1130	|O
3H	1130	1132	|O
]	1132	1133	|O
TCP	1133	1136	|O
and	1137	1140	|O
[	1141	1142	|O
3H	1142	1144	|O
]	1144	1145	|O
pentazocine	1145	1156	|O
as	1157	1159	|O
radioligands	1160	1172	|O
.	1172	1173	|O
The	1174	1177	|O
binding	1178	1185	|O
was	1186	1189	|O
compared	1190	1198	|O
with	1199	1203	|O
that	1204	1208	|O
of	1209	1211	|O
PCP	1212	1215	|O
and	1216	1219	|O
contrasted	1220	1230	|O
with	1231	1235	|O
the	1236	1239	|O
rigid	1240	1245	|O
symmetrical	1246	1257	|O
phencyclidine	1258	1271	|O
derivatives	1272	1283	|O
cis	1284	1287	|B-PARTIUPAC
-	1287	1288	|I-PARTIUPAC
and	1289	1292	|O
trans	1293	1298	|B-IUPAC
-	1298	1299	|I-IUPAC
1	1299	1300	|I-IUPAC
-	1300	1301	|I-IUPAC
[	1301	1302	|I-IUPAC
3	1302	1303	|I-IUPAC
-	1303	1304	|I-IUPAC
phenyl	1304	1310	|I-IUPAC
-	1310	1311	|I-IUPAC
3	1311	1312	|I-IUPAC
-	1312	1313	|I-IUPAC
bicyclo	1313	1320	|I-IUPAC
[	1320	1321	|I-IUPAC
3.1.0	1321	1326	|I-IUPAC
]	1326	1327	|I-IUPAC
hexyl	1327	1332	|I-IUPAC
]	1332	1333	|I-IUPAC
piperidines	1333	1344	|I-IUPAC
(	1345	1346	|O
6	1346	1347	|O
and	1348	1351	|O
7	1352	1353	|O
)	1353	1354	|O
.	1354	1355	|O
The	1356	1359	|O
results	1360	1367	|O
of	1368	1370	|O
the	1371	1374	|O
study	1375	1380	|O
indicated	1381	1390	|O
that	1391	1395	|O
the	1396	1399	|O
conformations	1400	1413	|O
of	1414	1416	|O
PCP	1417	1420	|O
represented	1421	1432	|O
by	1433	1435	|O
6-9	1436	1439	|O
are	1440	1443	|O
not	1444	1447	|O
optimal	1448	1455	|O
for	1456	1459	|O
potent	1460	1466	|O
interaction	1467	1478	|O
at	1479	1481	|O
either	1482	1488	|O
of	1489	1491	|O
these	1492	1497	|O
sites	1498	1503	|O
.	1503	1504	|O
Affinities	1505	1515	|O
ranged	1516	1522	|O
from	1523	1527	|O
582	1528	1531	|O
nM	1532	1534	|O
[	1535	1536	|O
(	1536	1537	|O
+	1537	1538	|O
/	1538	1539	|O
-	1539	1540	|O
)	1540	1541	|O
-	1541	1542	|O
9	1542	1543	|O
]	1543	1544	|O
to	1545	1547	|O
29,000	1548	1554	|O
nM	1555	1557	|O
[	1558	1559	|O
(	1559	1560	|O
+	1560	1561	|O
)	1561	1562	|O
-	1562	1563	|O
8	1563	1564	|O
]	1564	1565	|O
at	1566	1568	|O
PCP	1569	1572	|O
binding	1573	1580	|O
sites	1581	1586	|O
and	1587	1590	|O
from	1591	1595	|O
1130	1596	1600	|O
nM	1601	1603	|O
[	1604	1605	|O
(	1605	1606	|O
-	1606	1607	|O
)	1607	1608	|O
-	1608	1609	|O
8	1609	1610	|O
]	1610	1611	|O
to	1612	1614	|O
16,300	1615	1621	|O
nM	1622	1624	|O
(	1625	1626	|O
7	1626	1627	|O
)	1627	1628	|O
at	1629	1631	|O
sigma	1632	1637	|O
sites	1638	1643	|O
.	1643	1644	|O
In	1645	1647	|O
this	1648	1652	|O
assay	1653	1658	|O
,	1658	1659	|O
PCP	1660	1663	|O
exhibited	1664	1673	|O
affinities	1674	1684	|O
of	1685	1687	|O
64.5	1688	1692	|O
nM	1693	1695	|O
at	1696	1698	|O
PCP	1699	1702	|O
and	1703	1706	|O
1090	1707	1711	|O
nM	1712	1714	|O
at	1715	1717	|O
sigma	1718	1723	|O
sites	1724	1729	|O
.	1729	1730	|O
Qualitative	1731	1742	|O
correlation	1743	1754	|O
between	1755	1762	|O
the	1763	1766	|O
sigma	1767	1772	|O
and	1773	1776	|O
PCP	1777	1780	|O
binding	1781	1788	|O
data	1789	1793	|O
suggests	1794	1802	|O
some	1803	1807	|O
similarities	1808	1820	|O
between	1821	1828	|O
these	1829	1834	|O
binding	1835	1842	|O
sites	1843	1848	|O
.	1848	1849	|O
An	1850	1852	|O
axial	1853	1858	|O
phenyl	1859	1865	|B-MODIFIER
and	1866	1869	|O
equatorial	1870	1880	|B-MODIFIER
piperidine	1881	1891	|B-IUPAC
ring	1892	1896	|B-MODIFIER
with	1897	1901	|O
the	1902	1905	|O
nitrogen	1906	1914	|O
lone	1915	1919	|O
pair	1920	1924	|O
of	1925	1927	|O
electrons	1928	1937	|O
antiperiplanar	1938	1952	|O
to	1953	1955	|O
the	1956	1959	|O
phenyl	1960	1966	|B-IUPAC
ring	1967	1971	|B-MODIFIER
has	1972	1975	|O
been	1976	1980	|O
postulated	1981	1991	|O
as	1992	1994	|O
the	1995	1998	|O
receptor	1999	2007	|O
-	2007	2008	|O
active	2008	2014	|O
conformation	2015	2027	|O
of	2028	2030	|O
PCP	2031	2034	|O
-	2034	2035	|O
like	2035	2039	|O
ligands	2040	2047	|O
at	2048	2050	|O
the	2051	2054	|O
PCP	2055	2058	|O
binding	2059	2066	|O
site	2067	2071	|O
.	2071	2072	|O
Comparison	2073	2083	|O
of	2084	2086	|O
the	2087	2090	|O
binding	2091	2098	|O
data	2099	2103	|O
of	2104	2106	|O
7-9	2107	2110	|O
with	2111	2115	|O
that	2116	2120	|O
of	2121	2123	|O
the	2124	2127	|O
previously	2128	2138	|O
described	2139	2148	|O
methylcyclohexyl	2149	2165	|O
-	2165	2166	|O
PCP	2166	2169	|O
derivatives	2170	2181	|O
allowed	2182	2189	|O
its	2190	2193	|O
rationalization	2194	2209	|O
in	2210	2212	|O
terms	2213	2218	|O
of	2219	2221	|O
this	2222	2226	|O
model	2227	2232	|O
.	2232	2233	|O
It	2234	2236	|O
is	2237	2239	|O
likely	2240	2246	|O
that	2247	2251	|O
the	2252	2255	|O
lowered	2256	2263	|O
affinity	2264	2272	|O
in	2273	2275	|O
this	2276	2280	|O
bicyclo	2281	2288	|B-IUPAC
[	2288	2289	|I-IUPAC
3.1.0	2289	2294	|I-IUPAC
]	2294	2295	|I-IUPAC
hexane	2295	2301	|I-IUPAC
series	2302	2308	|B-MODIFIER
is	2309	2311	|O
a	2312	2313	|O
consequence	2314	2325	|O
of	2326	2328	|O
nonoptimal	2329	2339	|O
geometry	2340	2348	|O
(	2349	2350	|O
pseudoequatorial	2350	2366	|O
phenyl	2367	2373	|O
or	2374	2376	|O
pseudoboat	2377	2387	|O
)	2387	2388	|O
for	2389	2392	|O
binding	2393	2400	|O
as	2401	2403	|O
opposed	2404	2411	|O
to	2412	2414	|O
the	2415	2418	|O
presence	2419	2427	|O
of	2428	2430	|O
steric	2431	2437	|O
bulk	2438	2442	|O
which	2443	2448	|O
proved	2449	2455	|O
deleterious	2456	2467	|O
in	2468	2470	|O
the	2471	2474	|O
methylcyclohexyl	2475	2491	|O
-	2491	2492	|O
PCP	2492	2495	|O
derivatives	2496	2507	|O
.	2507	2508	|O

### abstracts3028.txt
N10	0	3	|B-IUPAC
-	3	4	|I-IUPAC
Propargylfolic	4	18	|I-IUPAC
acid	19	23	|I-IUPAC
(	24	25	|O
2	25	26	|O
)	26	27	|O
,	27	28	|O
which	29	34	|O
is	35	37	|O
the	38	41	|O
closest	42	49	|O
pteridine	50	59	|O
analogue	60	68	|O
of	69	71	|O
the	72	75	|O
thymidylate	76	87	|O
synthase	88	96	|O
inhibitor	97	106	|O
N10	107	110	|B-IUPAC
-	110	111	|I-IUPAC
propargyl	111	120	|I-IUPAC
-	120	121	|I-IUPAC
5,8	121	124	|I-IUPAC
-	124	125	|I-IUPAC
dideazafolic	125	137	|I-IUPAC
acid	138	142	|I-IUPAC
(	143	144	|O
PDDF	144	148	|O
)	148	149	|O
,	149	150	|O
was	151	154	|O
synthesized	155	166	|O
starting	167	175	|O
from	176	180	|O
diethyl	181	188	|B-IUPAC
[	189	190	|I-IUPAC
p	190	191	|I-IUPAC
-	191	192	|I-IUPAC
(	192	193	|I-IUPAC
N	193	194	|I-IUPAC
-	194	195	|I-IUPAC
propargylamino	195	209	|I-IUPAC
)	209	210	|I-IUPAC
benzoyl	210	217	|I-IUPAC
]	217	218	|I-IUPAC
-	218	219	|I-IUPAC
L	219	220	|I-IUPAC
-	220	221	|I-IUPAC
glutamate	221	230	|I-IUPAC
(	231	232	|O
5	232	233	|O
)	233	234	|O
and	235	238	|O
N	239	240	|B-IUPAC
-	240	241	|I-IUPAC
(	241	242	|I-IUPAC
3	242	243	|I-IUPAC
-	243	244	|I-IUPAC
bromo	244	249	|I-IUPAC
-	249	250	|I-IUPAC
2	250	251	|I-IUPAC
-	251	252	|I-IUPAC
oxopropyl	252	261	|I-IUPAC
)	261	262	|I-IUPAC
phthalimide	262	273	|I-IUPAC
(	274	275	|O
8	275	276	|O
)	276	277	|O
.	277	278	|O
The	279	282	|O
7,8	283	286	|B-IUPAC
-	286	287	|I-IUPAC
dihydro	287	294	|I-IUPAC
derivative	295	305	|B-MODIFIER
of	306	308	|O
propargylfolic	309	323	|O
acid	324	328	|O
served	329	335	|O
as	336	338	|O
a	339	340	|O
synthetic	341	350	|O
substrate	351	360	|O
of	361	363	|O
Lactobacillus	364	377	|O
casei	378	383	|O
dihydrofolate	384	397	|O
reductase	398	407	|O
.	407	408	|O
Propargylfolic	409	423	|O
acid	424	428	|O
and	429	432	|O
its	433	436	|O
reduced	437	444	|O
derivatives	445	456	|O
were	457	461	|O
weak	462	466	|O
inhibitors	467	477	|O
of	478	480	|O
L	481	482	|O
.	482	483	|O
casei	484	489	|O
thymidylate	490	501	|O
synthase	502	510	|O
compared	511	519	|O
to	520	522	|O
PDDF	523	527	|O
.	527	528	|O
All	529	532	|O
derivatives	533	544	|O
of	545	547	|O
propargylfolate	548	563	|O
were	564	568	|O
active	569	575	|O
against	576	583	|O
the	584	587	|O
growth	588	594	|O
of	595	597	|O
Streptococcus	598	611	|O
faecium	612	619	|O
,	619	620	|O
but	621	624	|O
with	625	629	|O
the	630	633	|O
exception	634	643	|O
of	644	646	|O
7,8	647	650	|B-IUPAC
-	650	651	|I-IUPAC
dihydropropargylfolic	651	672	|I-IUPAC
acid	673	677	|I-IUPAC
,	677	678	|O
all	679	682	|O
were	683	687	|O
inactive	688	696	|O
against	697	704	|O
L	705	706	|O
.	706	707	|O
casei	708	713	|O
.	713	714	|O
Although	715	723	|O
less	724	728	|O
potent	729	735	|O
than	736	740	|O
PDDF	741	745	|O
,	745	746	|O
marked	747	753	|O
inhibition	754	764	|O
of	765	767	|O
thymidylate	768	779	|O
synthase	780	788	|O
by	789	791	|O
2	792	793	|O
was	794	797	|O
observed	798	806	|O
in	807	809	|O
permeabilized	810	823	|O
L1210	824	829	|O
cells	830	835	|O
.	835	836	|O

### abstracts1175.txt
Xanthine	0	8	|O
derivatives	9	20	|O
with	21	25	|O
several	26	33	|O
functional	34	44	|O
groups	45	51	|O
at	52	54	|O
the	55	58	|O
1	59	60	|O
-	60	61	|O
or	62	64	|O
7	65	66	|O
-	66	67	|O
position	67	75	|O
were	76	80	|O
synthesized	81	92	|O
,	92	93	|O
and	94	97	|O
their	98	103	|O
pharmacological	104	119	|O
activities	120	130	|O
in	131	133	|O
guinea	134	140	|O
pigs	141	145	|O
were	146	150	|O
studied	151	158	|O
.	158	159	|O
In	160	162	|O
general	163	170	|O
,	170	171	|O
the	172	175	|O
in	176	178	|O
vitro	179	184	|O
tracheal	185	193	|O
relaxant	194	202	|O
action	203	209	|O
and	210	213	|O
positive	214	222	|O
chronotropic	223	235	|O
action	236	242	|O
of	243	245	|O
3	246	247	|B-IUPAC
-	247	248	|I-IUPAC
propylxanthines	248	263	|I-IUPAC
were	264	268	|O
increased	269	278	|O
by	279	281	|O
substitutions	282	295	|O
with	296	300	|O
nonpolar	301	309	|O
functional	310	320	|O
groups	321	327	|O
at	328	330	|O
the	331	334	|O
1	335	336	|O
-	336	337	|O
position	337	345	|O
,	345	346	|O
but	347	350	|O
decreased	351	360	|O
by	361	363	|O
any	364	367	|O
substitution	368	380	|O
at	381	383	|O
the	384	387	|O
7	388	389	|O
-	389	390	|O
position	390	398	|O
.	398	399	|O
On	400	402	|O
the	403	406	|O
other	407	412	|O
hand	413	417	|O
,	417	418	|O
because	419	426	|O
positive	427	435	|O
chronotropic	436	448	|O
actions	449	456	|O
of	457	459	|O
substituents	460	472	|B-MODIFIER
with	473	477	|O
allyl	478	483	|B-IUPAC
,	483	484	|O
aminoalkyl	485	495	|B-IUPAC
,	495	496	|O
alkoxyalkyl	497	508	|B-IUPAC
,	508	509	|O
and	510	513	|O
normal	514	520	|O
alkyl	521	526	|B-IUPAC
groups	527	533	|B-MODIFIER
were	534	538	|O
much	539	543	|O
less	544	548	|O
than	549	553	|O
tracheal	554	562	|O
muscle	563	569	|O
became	570	576	|O
very	577	581	|O
high	582	586	|O
with	587	591	|O
substitutions	592	605	|B-MODIFIER
of	606	608	|O
3'	609	611	|B-IUPAC
-	611	612	|I-IUPAC
butenyl	612	619	|I-IUPAC
,	619	620	|O
(	621	622	|B-IUPAC
dimethylamino	622	635	|I-IUPAC
)	635	636	|I-IUPAC
ethyl	636	641	|I-IUPAC
,	641	642	|O
2'	643	645	|B-IUPAC
-	645	646	|I-IUPAC
ethoxyethyl	646	657	|I-IUPAC
,	657	658	|O
3'	659	661	|B-IUPAC
-	661	662	|I-IUPAC
methoxypropyl	662	675	|I-IUPAC
,	675	676	|O
and	677	680	|O
n	681	682	|B-IUPAC
-	682	683	|I-IUPAC
propyl	683	689	|I-IUPAC
groups	690	696	|B-MODIFIER
at	697	699	|O
the	700	703	|O
1	704	705	|O
-	705	706	|O
position	706	714	|O
and	715	718	|O
of	719	721	|O
2'	722	724	|B-IUPAC
-	724	725	|I-IUPAC
ethoxyethyl	725	736	|I-IUPAC
,	736	737	|O
2'	738	740	|B-IUPAC
-	740	741	|I-IUPAC
oxopropyl	741	750	|I-IUPAC
,	750	751	|O
and	752	755	|O
n	756	757	|B-IUPAC
-	757	758	|I-IUPAC
propyl	758	764	|I-IUPAC
groups	765	771	|B-MODIFIER
at	772	774	|O
the	775	778	|O
7	779	780	|O
-	780	781	|O
position	781	789	|O
,	789	790	|O
compared	791	799	|O
with	800	804	|O
theophylline	805	817	|O
and	818	821	|O
the	822	825	|O
corresponding	826	839	|O
unsubstituted	840	853	|O
xanthines	854	863	|O
,	863	864	|O
3	865	866	|B-IUPAC
-	866	867	|I-IUPAC
propylxanthine	867	881	|I-IUPAC
and	882	885	|O
1	886	887	|B-IUPAC
-	887	888	|I-IUPAC
methyl	888	894	|I-IUPAC
-	894	895	|I-IUPAC
3	895	896	|I-IUPAC
-	896	897	|I-IUPAC
propylxanthine	897	911	|I-IUPAC
.	911	912	|O
When	913	917	|O
compounds	918	927	|O
were	928	932	|O
intraduodenally	933	948	|O
administered	949	961	|O
to	962	964	|O
the	965	968	|O
guinea	969	975	|O
pig	976	979	|O
,	979	980	|O
1	981	982	|B-PARTIUPAC
-	982	983	|I-PARTIUPAC
(	983	984	|I-PARTIUPAC
2'	984	986	|I-PARTIUPAC
-	986	987	|I-PARTIUPAC
ethoxyethyl	987	998	|I-PARTIUPAC
)	998	999	|I-PARTIUPAC
-	999	1000	|I-PARTIUPAC
,	1000	1001	|O
1	1002	1003	|B-PARTIUPAC
-	1003	1004	|I-PARTIUPAC
(	1004	1005	|I-PARTIUPAC
3'	1005	1007	|I-PARTIUPAC
-	1007	1008	|I-PARTIUPAC
methoxypropyl	1008	1021	|I-PARTIUPAC
)	1021	1022	|I-PARTIUPAC
-	1022	1023	|I-PARTIUPAC
,	1023	1024	|O
1	1025	1026	|B-PARTIUPAC
-	1026	1027	|I-PARTIUPAC
(	1027	1028	|I-PARTIUPAC
3'	1028	1030	|I-PARTIUPAC
-	1030	1031	|I-PARTIUPAC
butenyl	1031	1038	|I-PARTIUPAC
)	1038	1039	|I-PARTIUPAC
-	1039	1040	|I-PARTIUPAC
,	1040	1041	|O
and	1042	1045	|O
1	1046	1047	|B-IUPAC
-	1047	1048	|I-IUPAC
[	1048	1049	|I-IUPAC
(	1049	1050	|I-IUPAC
dimethylamino	1050	1063	|I-IUPAC
)	1063	1064	|I-IUPAC
-	1064	1065	|I-IUPAC
ethyl	1065	1070	|I-IUPAC
]	1070	1071	|I-IUPAC
-	1071	1072	|I-IUPAC
3	1072	1073	|I-IUPAC
-	1073	1074	|I-IUPAC
propylxanthines	1074	1089	|I-IUPAC
,	1089	1090	|O
1	1091	1092	|B-IUPAC
-	1092	1093	|I-IUPAC
methyl	1093	1099	|I-IUPAC
-	1099	1100	|I-IUPAC
7	1100	1101	|I-IUPAC
-	1101	1102	|I-IUPAC
(	1102	1103	|I-IUPAC
2'	1103	1105	|I-IUPAC
-	1105	1106	|I-IUPAC
oxopropyl	1106	1115	|I-IUPAC
)	1115	1116	|I-IUPAC
-	1116	1117	|I-IUPAC
3	1117	1118	|I-IUPAC
-	1118	1119	|I-IUPAC
propylxanthine	1119	1133	|I-IUPAC
,	1133	1134	|O
and	1135	1138	|O
denbufylline	1139	1151	|O
(	1152	1153	|O
1,3	1153	1156	|B-IUPAC
-	1156	1157	|I-IUPAC
di	1157	1159	|I-IUPAC
-	1159	1160	|I-IUPAC
n	1160	1161	|I-IUPAC
-	1161	1162	|I-IUPAC
butyl	1162	1167	|I-IUPAC
-	1167	1168	|I-IUPAC
7	1168	1169	|I-IUPAC
-	1169	1170	|I-IUPAC
(	1170	1171	|I-IUPAC
2'	1171	1173	|I-IUPAC
-	1173	1174	|I-IUPAC
oxopropyl	1174	1183	|I-IUPAC
)	1183	1184	|I-IUPAC
xanthine	1184	1192	|I-IUPAC
)	1192	1193	|O
effectively	1194	1205	|O
inhibited	1206	1215	|O
the	1216	1219	|O
acetylcholine	1220	1233	|O
-	1233	1234	|O
induced	1234	1241	|O
bronchospasm	1242	1254	|O
without	1255	1262	|O
heart	1263	1268	|O
stimulation	1269	1280	|O
or	1281	1283	|O
central	1284	1291	|O
nervous	1292	1299	|O
system	1300	1306	|O
-	1306	1307	|O
stimulation	1307	1318	|O
at	1319	1321	|O
the	1322	1325	|O
effective	1326	1335	|O
dosage	1336	1342	|O
range	1343	1348	|O
.	1348	1349	|O
Particularly	1350	1362	|O
,	1362	1363	|O
the	1364	1367	|O
bronchodilatory	1368	1383	|O
effect	1384	1390	|O
of	1391	1393	|O
1	1394	1395	|B-IUPAC
-	1395	1396	|I-IUPAC
(	1396	1397	|I-IUPAC
2'	1397	1399	|I-IUPAC
-	1399	1400	|I-IUPAC
ethoxyethyl	1400	1411	|I-IUPAC
)	1411	1412	|I-IUPAC
-	1412	1413	|I-IUPAC
3	1413	1414	|I-IUPAC
-	1414	1415	|I-IUPAC
propylxanthine	1415	1429	|I-IUPAC
was	1430	1433	|O
much	1434	1438	|O
stronger	1439	1447	|O
and	1448	1451	|O
more	1452	1456	|O
continuous	1457	1467	|O
than	1468	1472	|O
those	1473	1478	|O
of	1479	1481	|O
theophylline	1482	1494	|O
and	1495	1498	|O
pentoxifylline	1499	1513	|O
.	1513	1514	|O
On	1515	1517	|O
the	1518	1521	|O
other	1522	1527	|O
hand	1528	1532	|O
,	1532	1533	|O
there	1534	1539	|O
were	1540	1544	|O
certain	1545	1552	|O
relationships	1553	1566	|O
among	1567	1572	|O
the	1573	1576	|O
in	1577	1579	|O
vitro	1580	1585	|O
tracheal	1586	1594	|O
relaxant	1595	1603	|O
activities	1604	1614	|O
of	1615	1617	|O
these	1618	1623	|O
compounds	1624	1633	|O
,	1633	1634	|O
their	1635	1640	|O
affinities	1641	1651	|O
for	1652	1655	|O
adenosine	1656	1665	|O
(	1666	1667	|O
A1	1667	1669	|O
)	1669	1670	|O
receptors	1671	1680	|O
in	1681	1683	|O
the	1684	1687	|O
brain	1688	1693	|O
membrane	1694	1702	|O
,	1702	1703	|O
and	1704	1707	|O
their	1708	1713	|O
inhibition	1714	1724	|O
of	1725	1727	|O
cyclic	1728	1734	|O
AMP	1735	1738	|O
-	1738	1739	|O
phosphodiesterase	1739	1756	|O
(	1757	1758	|O
PDE	1758	1761	|O
)	1761	1762	|O
in	1763	1765	|O
the	1766	1769	|O
tracheal	1770	1778	|O
muscle	1779	1785	|O
.	1785	1786	|O
The	1787	1790	|O
affinity	1791	1799	|O
for	1800	1803	|O
A2	1804	1806	|O
receptors	1807	1816	|O
of	1817	1819	|O
these	1820	1825	|O
compounds	1826	1835	|O
was	1836	1839	|O
very	1840	1844	|O
low	1845	1848	|O
or	1849	1851	|O
negligible	1852	1862	|O
.	1862	1863	|O
This	1864	1868	|O
suggests	1869	1877	|O
that	1878	1882	|O
both	1883	1887	|O
the	1888	1891	|O
action	1892	1898	|O
on	1899	1901	|O
A1	1902	1904	|O
receptors	1905	1914	|O
or	1915	1917	|O
interaction	1918	1929	|O
with	1930	1934	|O
adenosine	1935	1944	|O
and	1945	1948	|O
the	1949	1952	|O
cyclic	1953	1959	|O
AMP	1960	1963	|O
-	1963	1964	|O
PDE	1964	1967	|O
inhibitory	1968	1978	|O
activity	1979	1987	|O
contribute	1988	1998	|O
to	1999	2001	|O
the	2002	2005	|O
bronchodilator	2006	2020	|O
action	2021	2027	|O
of	2028	2030	|O
1	2031	2032	|O
-	2032	2033	|O
and	2034	2037	|O
7	2038	2039	|O
-	2039	2040	|O
substituted	2040	2051	|O
xanthines	2052	2061	|O
.	2061	2062	|O
This	2063	2067	|O
study	2068	2073	|O
indicates	2074	2083	|O
that	2084	2088	|O
the	2089	2092	|O
substitutions	2093	2106	|O
with	2107	2111	|O
none	2112	2116	|O
or	2117	2119	|O
low	2120	2123	|O
polar	2124	2129	|O
functional	2130	2140	|O
groups	2141	2147	|O
at	2148	2150	|O
the	2151	2154	|O
1	2155	2156	|O
-	2156	2157	|O
position	2157	2165	|O
could	2166	2171	|O
improve	2172	2179	|O
the	2180	2183	|O
selectivity	2184	2195	|O
and	2196	2199	|O
duration	2200	2208	|O
of	2209	2211	|O
the	2212	2215	|O
bronchodilator	2216	2230	|O
effects	2231	2238	|O
of	2239	2241	|O
xanthines	2242	2251	|O
.	2251	2252	|O

### abstracts3485.txt
The	0	3	|O
synthesis	4	13	|O
of	14	16	|O
5,11	17	21	|B-IUPAC
-	21	22	|I-IUPAC
methenyltetrahydrohomofolate	22	50	|I-IUPAC
was	51	54	|O
accomplished	55	67	|O
by	68	70	|O
treatment	71	80	|O
of	81	83	|O
tetrahydrohomofolate	84	104	|O
(	105	106	|O
H4homofolate	106	118	|O
)	118	119	|O
with	120	124	|O
triethyl	125	133	|O
orthoformate	134	146	|O
in	147	149	|O
glacial	150	157	|O
acetic	158	164	|O
acid	165	169	|O
.	169	170	|O
This	171	175	|O
compound	176	184	|O
is	185	187	|O
a	188	189	|O
homofolate	190	200	|O
analogue	201	209	|O
of	210	212	|O
5,10	213	217	|B-IUPAC
-	217	218	|I-IUPAC
methenyltetrahydrofolate	218	242	|I-IUPAC
which	243	248	|O
serves	249	255	|O
as	256	258	|O
one	259	262	|O
precursor	263	272	|O
to	273	275	|O
the	276	279	|O
10	280	282	|O
-	282	283	|O
formyl	283	289	|O
one	290	293	|O
-	293	294	|O
carbon	294	300	|O
donor	301	306	|O
for	307	310	|O
the	311	314	|O
first	315	320	|O
transformylation	321	337	|O
in	338	340	|O
de	341	343	|O
novo	344	348	|O
purine	349	355	|O
biosynthesis	356	368	|O
,	368	369	|O
namely	370	376	|O
,	376	377	|O
the	378	381	|O
conversion	382	392	|O
of	393	395	|O
glycinamide	396	407	|O
ribonucleotide	408	422	|O
(	423	424	|O
GAR	424	427	|O
)	427	428	|O
to	429	431	|O
N	432	433	|B-IUPAC
-	433	434	|I-IUPAC
formylglycinamide	434	451	|I-IUPAC
ribonucleotide	452	466	|I-IUPAC
(	467	468	|O
FGAR	468	472	|O
)	472	473	|O
,	473	474	|O
catalyzed	475	484	|O
by	485	487	|O
the	488	491	|O
enzyme	492	498	|O
glycinamide	499	510	|O
ribonucleotide	511	525	|O
transformylase	526	540	|O
(	541	542	|O
EC	542	544	|O
2.1.2.2	545	552	|O
)	552	553	|O
.	553	554	|O
The	555	558	|O
analogue	559	567	|O
proved	568	574	|O
to	575	577	|O
retard	578	584	|O
the	585	588	|O
rate	589	593	|O
of	594	596	|O
formation	597	606	|O
of	607	609	|O
formylglycinamide	610	627	|O
ribonucleotide	628	642	|O
apparently	643	653	|O
by	654	656	|O
inhibiting	657	667	|O
the	668	671	|O
rate	672	676	|O
of	677	679	|O
synthesis	680	689	|O
of	690	692	|O
10	693	695	|B-IUPAC
-	695	696	|I-IUPAC
formyltetrahydrofolate	696	718	|I-IUPAC
,	718	719	|O
the	720	723	|O
actual	724	730	|O
cofactor	731	739	|O
for	740	743	|O
the	744	747	|O
transformylase	748	762	|O
enzyme	763	769	|O
,	769	770	|O
from	771	775	|O
5,10	776	780	|B-IUPAC
-	780	781	|I-IUPAC
methenyltetrahydrofolate	781	805	|I-IUPAC
.	805	806	|O
Its	807	810	|O
inhibition	811	821	|O
of	822	824	|O
the	825	828	|O
enzyme	829	835	|O
,	835	836	|O
5,10	837	841	|B-IUPAC
-	841	842	|I-IUPAC
methenyltetrahydrofolate	842	866	|I-IUPAC
cyclohydrolase	867	881	|O
(	882	883	|O
EC	883	885	|O
3.5.4.9	886	893	|O
)	893	894	|O
,	894	895	|O
was	896	899	|O
competitive	900	911	|O
against	912	919	|O
(	920	921	|B-IUPAC
+	921	922	|I-IUPAC
)	922	923	|I-IUPAC
-	923	924	|I-IUPAC
L	924	925	|I-IUPAC
-	925	926	|I-IUPAC
5,10	926	930	|I-IUPAC
-	930	931	|I-IUPAC
methenyltetrahydrofolate	931	955	|I-IUPAC
,	955	956	|O
with	957	961	|O
a	962	963	|O
Ki	964	966	|O
=	967	968	|O
41	969	971	|O
micro	972	977	|O
M	978	979	|O
.	979	980	|O
This	981	985	|O
derivative	986	996	|O
of	997	999	|O
homofolate	1000	1010	|O
may	1011	1014	|O
be	1015	1017	|O
responsible	1018	1029	|O
for	1030	1033	|O
its	1034	1037	|O
inhibition	1038	1048	|O
of	1049	1051	|O
purine	1052	1058	|O
biosynthesis	1059	1071	|O
in	1072	1074	|O
Sarcoma	1075	1082	|O
180	1083	1086	|O
cells	1087	1092	|O
.	1092	1093	|O

### abstracts4497.txt
The	0	3	|O
anticonvulsant	4	18	|O
activity	19	27	|O
of	28	30	|O
diphenylhydantoin	31	48	|O
(	49	50	|O
DPH	50	53	|O
or	54	56	|O
phenytoin	57	66	|O
)	66	67	|O
is	68	70	|O
consistent	71	81	|O
with	82	86	|O
its	87	90	|O
actions	91	98	|O
on	99	101	|O
the	102	105	|O
neuronal	106	114	|O
voltage	115	122	|O
-	122	123	|O
dependent	123	132	|O
sodium	133	139	|O
channel	140	147	|O
.	147	148	|O
To	149	151	|O
further	152	159	|O
elucidate	160	169	|O
the	170	173	|O
binding	174	181	|O
requirements	182	194	|O
for	195	198	|O
this	199	203	|O
site	204	208	|O
,	208	209	|O
we	210	212	|O
synthesized	213	224	|O
several	225	232	|O
hydantoin	233	242	|O
analogs	243	250	|O
and	251	254	|O
evaluated	255	264	|O
these	265	270	|O
in	271	273	|O
in	274	276	|O
vitro	277	282	|O
sodium	283	289	|O
channel	290	297	|O
-	297	298	|O
binding	298	305	|O
and	306	309	|O
/	309	310	|O
or	310	312	|O
in	313	315	|O
vivo	316	320	|O
whole	321	326	|O
animal	327	333	|O
anticonvulsant	334	348	|O
assays	349	355	|O
.	355	356	|O
5	357	358	|B-IUPAC
-	358	359	|I-IUPAC
Pentyl	359	365	|I-IUPAC
-	365	366	|I-IUPAC
5	366	367	|I-IUPAC
-	367	368	|I-IUPAC
phenylhydantoin	368	383	|I-IUPAC
(	384	385	|O
8	385	386	|O
)	386	387	|O
,	387	388	|O
the	389	392	|O
most	393	397	|O
potent	398	404	|O
binder	405	411	|O
to	412	414	|O
the	415	418	|O
sodium	419	425	|O
channel	426	433	|O
in	434	436	|O
this	437	441	|O
study	442	447	|O
,	447	448	|O
had	449	452	|O
the	453	456	|O
same	457	461	|O
affinity	462	470	|O
as	471	473	|O
DPH	474	477	|O
(	478	479	|O
IC50	479	483	|O
=	484	485	|O
40	486	488	|O
microM	489	495	|O
)	495	496	|O
,	496	497	|O
revealing	498	507	|O
that	508	512	|O
one	513	516	|O
phenyl	517	523	|O
ring	524	528	|O
is	529	531	|O
sufficient	532	542	|O
for	543	546	|O
good	547	551	|O
interactions	552	564	|O
.	564	565	|O
Since	566	571	|O
our	572	575	|O
previous	576	584	|O
studies	585	592	|O
with	593	597	|O
monophenyl	598	608	|B-IUPAC
-	608	609	|O
substituted	609	620	|B-MODIFIER
bicyclic	621	629	|B-MODIFIER
2,4	630	633	|B-IUPAC
-	633	634	|I-IUPAC
oxazolidinediones	634	651	|I-IUPAC
suggested	652	661	|O
that	662	666	|O
N3	667	669	|O
-	669	670	|O
alkylation	670	680	|O
and	681	684	|O
the	685	688	|O
conformational	689	703	|O
constraint	704	714	|O
of	715	717	|O
a	718	719	|O
5	720	721	|O
-	721	722	|O
alkyl	722	727	|O
substituent	728	739	|O
over	740	744	|O
one	745	748	|O
face	749	753	|O
of	754	756	|O
the	757	760	|O
oxazolidinedione	761	777	|O
ring	778	782	|O
improved	783	791	|O
activity	792	800	|O
,	800	801	|O
we	802	804	|O
synthesized	805	816	|O
two	817	820	|O
examples	821	829	|O
of	830	832	|O
analogous	833	842	|O
bicyclic	843	851	|O
hydantoins	852	862	|O
.	862	863	|O
However	864	871	|O
,	871	872	|O
the	873	876	|O
bicyclic	877	885	|O
hydantoins	886	896	|O
were	897	901	|O
much	902	906	|O
less	907	911	|O
potent	912	918	|O
binders	919	926	|O
to	927	929	|O
the	930	933	|O
neuronal	934	942	|O
voltage	943	950	|O
-	950	951	|O
dependent	951	960	|O
sodium	961	967	|O
channel	968	975	|O
than	976	980	|O
their	981	986	|O
monocyclic	987	997	|O
counterparts	998	1010	|O
.	1010	1011	|O
The	1012	1015	|O
binding	1016	1023	|O
activity	1024	1032	|O
for	1033	1036	|O
the	1037	1040	|O
more	1041	1045	|O
potent	1046	1052	|O
bicyclic	1053	1061	|O
hydantoin	1062	1071	|O
,	1071	1072	|O
1,8	1073	1076	|B-IUPAC
-	1076	1077	|I-IUPAC
diaza	1077	1082	|I-IUPAC
-	1082	1083	|I-IUPAC
9,10	1083	1087	|I-IUPAC
-	1087	1088	|I-IUPAC
dioxo	1088	1093	|I-IUPAC
-	1093	1094	|I-IUPAC
7	1094	1095	|I-IUPAC
-	1095	1096	|I-IUPAC
phenylbicyclo	1096	1109	|I-IUPAC
[	1109	1110	|I-IUPAC
5.2.1	1110	1115	|I-IUPAC
]	1115	1116	|I-IUPAC
decane	1116	1122	|I-IUPAC
(	1123	1124	|O
4	1124	1125	|O
)	1125	1126	|O
(	1127	1128	|O
IC50	1128	1132	|O
=	1133	1134	|O
427	1135	1138	|O
microM	1139	1145	|O
)	1145	1146	|O
,	1146	1147	|O
was	1148	1151	|O
comparable	1152	1162	|O
to	1163	1165	|O
that	1166	1170	|O
of	1171	1173	|O
the	1174	1177	|O
ring	1178	1182	|O
-	1182	1183	|O
opened	1183	1189	|O
,	1189	1190	|O
N3	1191	1193	|O
-	1193	1194	|O
methylated	1194	1204	|O
monocyclic	1205	1215	|O
hydantoin	1216	1225	|O
model	1226	1231	|O
,	1231	1232	|O
5	1233	1234	|B-IUPAC
-	1234	1235	|I-IUPAC
butyl	1235	1240	|I-IUPAC
-	1240	1241	|I-IUPAC
3	1241	1242	|I-IUPAC
-	1242	1243	|I-IUPAC
methyl	1243	1249	|I-IUPAC
-	1249	1250	|I-IUPAC
5	1250	1251	|I-IUPAC
-	1251	1252	|I-IUPAC
phenylhydantoin	1252	1267	|I-IUPAC
(	1268	1269	|O
9	1269	1270	|O
)	1270	1271	|O
(	1272	1273	|O
IC50	1273	1277	|O
=	1278	1279	|O
285	1280	1283	|O
microM	1284	1290	|O
)	1290	1291	|O
,	1291	1292	|O
and	1293	1296	|O
these	1297	1302	|O
were	1303	1307	|O
8-11	1308	1312	|O
times	1313	1318	|O
less	1319	1323	|O
potent	1324	1330	|O
than	1331	1335	|O
the	1336	1339	|O
monocyclic	1340	1350	|O
model	1351	1356	|O
8	1357	1358	|O
,	1358	1359	|O
which	1360	1365	|O
contains	1366	1374	|O
a	1375	1376	|O
free	1377	1381	|O
imide	1382	1387	|O
NH	1388	1390	|O
.	1390	1391	|O
Furthermore	1392	1403	|O
,	1403	1404	|O
5	1405	1406	|B-IUPAC
-	1406	1407	|I-IUPAC
butyl	1407	1412	|I-IUPAC
-	1412	1413	|I-IUPAC
5	1413	1414	|I-IUPAC
-	1414	1415	|I-IUPAC
phenylhydantoin	1415	1430	|I-IUPAC
(	1431	1432	|O
7	1432	1433	|O
;	1433	1434	|O
IC50	1435	1439	|O
=	1440	1441	|O
103	1442	1445	|O
microM	1446	1452	|O
)	1452	1453	|O
was	1454	1457	|O
less	1458	1462	|O
potent	1463	1469	|O
than	1470	1474	|O
8	1475	1476	|O
,	1476	1477	|O
suggesting	1478	1488	|O
that	1489	1493	|O
increased	1494	1503	|O
log	1504	1507	|O
P	1508	1509	|O
may	1510	1513	|O
enhance	1514	1521	|O
binding	1522	1529	|O
.	1529	1530	|O
Thus	1531	1535	|O
,	1535	1536	|O
unlike	1537	1543	|O
2,4	1544	1547	|B-IUPAC
-	1547	1548	|I-IUPAC
oxazolidinediones	1548	1565	|I-IUPAC
,	1565	1566	|O
N3	1567	1569	|O
-	1569	1570	|O
alkylation	1570	1580	|O
of	1581	1583	|O
hydantoins	1584	1594	|O
dramatically	1595	1607	|O
decreases	1608	1617	|O
sodium	1618	1624	|O
channel	1625	1632	|O
-	1632	1633	|O
binding	1633	1640	|O
activity	1641	1649	|O
.	1649	1650	|O
Bicyclic	1651	1659	|O
hydantoin	1660	1669	|O
4	1670	1671	|O
was	1672	1675	|O
nevertheless	1676	1688	|O
a	1689	1690	|O
good	1691	1695	|O
anti	1696	1700	|O
-	1700	1701	|O
MES	1701	1704	|O
anticonvulsant	1705	1719	|O
in	1720	1722	|O
mice	1723	1727	|O
(	1728	1729	|O
ED50	1729	1733	|O
=	1734	1735	|O
86	1736	1738	|O
mg	1739	1741	|O
/	1741	1742	|O
kg	1742	1744	|O
)	1744	1745	|O
,	1745	1746	|O
although	1747	1755	|O
this	1756	1760	|O
activity	1761	1769	|O
likely	1770	1776	|O
results	1777	1784	|O
from	1785	1789	|O
mechanisms	1790	1800	|O
other	1801	1806	|O
than	1807	1811	|O
interactions	1812	1824	|O
at	1825	1827	|O
the	1828	1831	|O
neuronal	1832	1840	|O
voltage	1841	1848	|O
-	1848	1849	|O
dependent	1849	1858	|O
sodium	1859	1865	|O
channel	1866	1873	|O
.	1873	1874	|O
Compound	1875	1883	|O
4	1884	1885	|O
was	1886	1889	|O
also	1890	1894	|O
relatively	1895	1905	|O
neurotoxic	1906	1916	|O
(	1917	1918	|O
TD50	1918	1922	|O
=	1923	1924	|O
124	1925	1928	|O
mg	1929	1931	|O
/	1931	1932	|O
kg	1932	1934	|O
)	1934	1935	|O
.	1935	1936	|O
These	1937	1942	|O
results	1943	1950	|O
suggest	1951	1958	|O
that	1959	1963	|O
the	1964	1967	|O
binding	1968	1975	|O
of	1976	1978	|O
hydantoins	1979	1989	|O
to	1990	1992	|O
the	1993	1996	|O
sodium	1997	2003	|O
channel	2004	2011	|O
may	2012	2015	|O
be	2016	2018	|O
enhanced	2019	2027	|O
by	2028	2030	|O
(	2031	2032	|O
a	2032	2033	|O
)	2033	2034	|O
a	2035	2036	|O
free	2037	2041	|O
imide	2042	2047	|O
NH	2048	2050	|O
group	2051	2056	|O
and	2057	2060	|O
(	2061	2062	|O
b	2062	2063	|O
)	2063	2064	|O
an	2065	2067	|O
increased	2068	2077	|O
log	2078	2081	|O
P	2082	2083	|O
.	2083	2084	|O
Furthermore	2085	2096	|O
,	2096	2097	|O
2,4	2098	2101	|B-IUPAC
-	2101	2102	|I-IUPAC
oxazolidinediones	2102	2119	|I-IUPAC
and	2120	2123	|O
hydantoins	2124	2134	|O
must	2135	2139	|O
either	2140	2146	|O
orient	2147	2153	|O
differently	2154	2165	|O
in	2166	2168	|O
the	2169	2172	|O
same	2173	2177	|O
binding	2178	2185	|O
site	2186	2190	|O
or	2191	2193	|O
interact	2194	2202	|O
with	2203	2207	|O
different	2208	2217	|O
sites	2218	2223	|O
on	2224	2226	|O
the	2227	2230	|O
neuronal	2231	2239	|O
voltage	2240	2247	|O
-	2247	2248	|O
dependent	2248	2257	|O
sodium	2258	2264	|O
channel	2265	2272	|O
.	2272	2273	|O

### abstracts628.txt
Evidence	0	8	|O
incicating	9	19	|O
that	20	24	|O
effective	25	34	|O
in	35	37	|O
vivo	38	42	|O
inhibition	43	53	|O
of	54	56	|O
hypoxanthine	57	69	|O
-	69	70	|O
guanine	70	77	|O
phosphoribosyltransferase	78	103	|O
(	104	105	|O
HGPRT	105	110	|O
,	110	111	|O
EC	112	114	|O
2.4.2.8	115	122	|O
)	122	123	|O
should	124	130	|O
produce	131	138	|O
antiprotozoal	139	152	|O
activity	153	161	|O
without	162	169	|O
significant	170	181	|O
toxic	182	187	|O
effects	188	195	|O
on	196	198	|O
mammalian	199	208	|O
hosts	209	214	|O
prompted	215	223	|O
syntheses	224	233	|O
of	234	236	|O
1	237	238	|O
-	238	239	|O
substituted	239	250	|O
hypoxanthines	251	264	|O
bearing	265	272	|O
functionalized	273	287	|O
side	288	292	|O
chains	293	299	|O
whose	300	305	|O
groupings	306	315	|O
might	316	321	|O
interact	322	330	|O
with	331	335	|O
appropriate	336	347	|O
groupings	348	357	|O
of	358	360	|O
HGPRT	361	366	|O
to	367	369	|O
form	370	374	|O
covalent	375	383	|O
bonds	384	389	|O
or	390	392	|O
strong	393	399	|O
hydrophobic	400	411	|O
bonds	412	417	|O
.	417	418	|O
3	419	420	|B-IUPAC
-	420	421	|I-IUPAC
(	421	422	|I-IUPAC
Fluorosulfonyl	422	436	|I-IUPAC
)	436	437	|I-IUPAC
benzoyl	437	444	|I-IUPAC
,	444	445	|O
4	446	447	|B-IUPAC
-	447	448	|I-IUPAC
(	448	449	|I-IUPAC
fluorosulfonyl	449	463	|I-IUPAC
)	463	464	|I-IUPAC
benzoyl	464	471	|I-IUPAC
,	471	472	|O
4	473	474	|B-IUPAC
-	474	475	|I-IUPAC
chlorobenzoyl	475	488	|I-IUPAC
,	488	489	|O
and	490	493	|O
bromacetyl	494	504	|B-IUPAC
derivatives	505	516	|B-MODIFIER
of	517	519	|O
two	520	523	|O
parent	524	530	|O
amines	531	537	|O
,	537	538	|O
1	539	540	|B-IUPAC
-	540	541	|I-IUPAC
(	541	542	|I-IUPAC
2	542	543	|I-IUPAC
-	543	544	|I-IUPAC
aminoethyl	544	554	|I-IUPAC
)	554	555	|I-IUPAC
-	555	556	|I-IUPAC
hypoxanthine	556	568	|I-IUPAC
and	569	572	|O
1	573	574	|B-IUPAC
-	574	575	|I-IUPAC
(	575	576	|I-IUPAC
4	576	577	|I-IUPAC
-	577	578	|I-IUPAC
aminobenzyl	578	589	|I-IUPAC
)	589	590	|I-IUPAC
hypoxanthine	590	602	|I-IUPAC
,	602	603	|O
were	604	608	|O
synthesized	609	620	|O
for	621	624	|O
evaluation	625	635	|O
in	636	638	|O
this	639	643	|O
connection	644	654	|O
.	654	655	|O
None	656	660	|O
of	661	663	|O
these	664	669	|O
compounds	670	679	|O
extended	680	688	|O
the	689	692	|O
life	693	697	|O
span	698	702	|O
of	703	705	|O
Plasmodium	706	716	|O
berghei	717	724	|O
infected	725	733	|O
mice	734	738	|O
or	739	741	|O
showed	742	748	|O
significant	749	760	|O
in	761	763	|O
vitro	764	769	|O
inhibition	770	780	|O
of	781	783	|O
HGPRT	784	789	|O
from	790	794	|O
H	795	796	|O
.	796	797	|O
Ep	797	799	|O
.	799	800	|O
-	800	801	|O
2	801	802	|O
cells	803	808	|O
,	808	809	|O
but	810	813	|O
1	814	815	|B-IUPAC
-	815	816	|I-IUPAC
[	816	817	|I-IUPAC
2	817	818	|I-IUPAC
-	818	819	|I-IUPAC
(	819	820	|I-IUPAC
bromoacetamido	820	834	|I-IUPAC
)	834	835	|I-IUPAC
ethyl	835	840	|I-IUPAC
]	840	841	|I-IUPAC
hypoxanthine	841	853	|I-IUPAC
displayed	854	863	|O
in	864	866	|O
vivo	867	871	|O
activity	872	880	|O
against	881	888	|O
Trypanosoma	889	900	|O
rhodesiense	901	912	|O
.	912	913	|O

### abstracts3973.txt
Glucuronic	0	10	|O
acid	11	15	|O
linked	16	22	|O
prodrugs	23	31	|O
of	32	34	|O
O	35	36	|B-IUPAC
(	36	37	|I-IUPAC
6	37	38	|I-IUPAC
)	38	39	|I-IUPAC
-	39	40	|I-IUPAC
benzylguanine	40	53	|I-IUPAC
and	54	57	|O
O	58	59	|B-IUPAC
(	59	60	|I-IUPAC
6	60	61	|I-IUPAC
)	61	62	|I-IUPAC
-	62	63	|I-IUPAC
benzyl	63	69	|I-IUPAC
-	69	70	|I-IUPAC
2'	70	72	|I-IUPAC
-	72	73	|I-IUPAC
deoxyguanosine	73	87	|I-IUPAC
were	88	92	|O
synthesized	93	104	|O
.	104	105	|O
The	106	109	|O
prodrugs	110	118	|O
were	119	123	|O
found	124	129	|O
to	130	132	|O
be	133	135	|O
quite	136	141	|O
stable	142	148	|O
at	149	151	|O
physiological	152	165	|O
pH	166	168	|O
and	169	172	|O
were	173	177	|O
more	178	182	|O
than	183	187	|O
200	188	191	|O
-	191	192	|O
fold	192	196	|O
less	197	201	|O
active	202	208	|O
as	209	211	|O
inactivators	212	224	|O
of	225	227	|O
O	228	229	|B-IUPAC
(	229	230	|I-IUPAC
6	230	231	|I-IUPAC
)	231	232	|I-IUPAC
-	232	233	|I-IUPAC
alkylguanine	233	245	|I-IUPAC
-	245	246	|O
DNA	246	249	|O
alkyltransferase	250	266	|O
(	267	268	|O
alkyltransferase	268	284	|O
)	284	285	|O
than	286	290	|O
either	291	297	|O
O	298	299	|B-IUPAC
(	299	300	|I-IUPAC
6	300	301	|I-IUPAC
)	301	302	|I-IUPAC
-	302	303	|I-IUPAC
benzylguanine	303	316	|I-IUPAC
or	317	319	|O
O	320	321	|B-IUPAC
(	321	322	|I-IUPAC
6	322	323	|I-IUPAC
)	323	324	|I-IUPAC
-	324	325	|I-IUPAC
benzyl	325	331	|I-IUPAC
-	331	332	|I-IUPAC
2'	332	334	|I-IUPAC
-	334	335	|I-IUPAC
deoxyguanosine	335	349	|I-IUPAC
.	349	350	|O
Beta	351	355	|O
-	355	356	|O
glucuronidase	356	369	|O
from	370	374	|O
both	375	379	|O
Escherichia	380	391	|O
coli	392	396	|O
and	397	400	|O
bovine	401	407	|O
liver	408	413	|O
cleaved	414	421	|O
the	422	425	|O
prodrugs	426	434	|O
efficiently	435	446	|O
to	447	449	|O
release	450	457	|O
O	458	459	|B-IUPAC
(	459	460	|I-IUPAC
6	460	461	|I-IUPAC
)	461	462	|I-IUPAC
-	462	463	|I-IUPAC
benzylguanine	463	476	|I-IUPAC
and	477	480	|O
O	481	482	|B-IUPAC
(	482	483	|I-IUPAC
6	483	484	|I-IUPAC
)	484	485	|I-IUPAC
-	485	486	|I-IUPAC
benzyl	486	492	|I-IUPAC
-	492	493	|I-IUPAC
2'	493	495	|I-IUPAC
-	495	496	|I-IUPAC
deoxyguanosine	496	510	|I-IUPAC
,	510	511	|O
respectively	512	524	|O
.	524	525	|O
In	526	528	|O
combination	529	540	|O
with	541	545	|O
1,3	546	549	|B-IUPAC
-	549	550	|I-IUPAC
bis	550	553	|I-IUPAC
(	553	554	|I-IUPAC
2	554	555	|I-IUPAC
-	555	556	|I-IUPAC
chloroethyl	556	567	|I-IUPAC
)	567	568	|I-IUPAC
-	568	569	|I-IUPAC
1	569	570	|I-IUPAC
-	570	571	|I-IUPAC
nitrosourea	571	582	|I-IUPAC
(	583	584	|O
BCNU	584	588	|O
)	588	589	|O
,	589	590	|O
the	591	594	|O
prodrugs	595	603	|O
were	604	608	|O
not	609	612	|O
effective	613	622	|O
adjuvants	623	632	|O
for	633	636	|O
HT29	637	641	|O
cell	642	646	|O
killing	647	654	|O
.	654	655	|O
However	656	663	|O
,	663	664	|O
as	665	667	|O
expected	668	676	|O
,	676	677	|O
incubation	678	688	|O
of	689	691	|O
these	692	697	|O
prodrugs	698	706	|O
with	707	711	|O
beta	712	716	|O
-	716	717	|O
glucuronidase	717	730	|O
in	731	733	|O
the	734	737	|O
culture	738	745	|O
medium	746	752	|O
led	753	756	|O
to	757	759	|O
much	760	764	|O
more	765	769	|O
efficient	770	779	|O
cell	780	784	|O
killing	785	792	|O
by	793	795	|O
BCNU	796	800	|O
as	801	803	|O
a	804	805	|O
result	806	812	|O
of	813	815	|O
the	816	819	|O
liberation	820	830	|O
of	831	833	|O
the	834	837	|O
more	838	842	|O
potent	843	849	|O
inactivators	850	862	|O
,	862	863	|O
O	864	865	|B-IUPAC
(	865	866	|I-IUPAC
6	866	867	|I-IUPAC
)	867	868	|I-IUPAC
-	868	869	|I-IUPAC
benzylguanine	869	882	|I-IUPAC
and	883	886	|O
O	887	888	|B-IUPAC
(	888	889	|I-IUPAC
6	889	890	|I-IUPAC
)	890	891	|I-IUPAC
-	891	892	|I-IUPAC
benzyl	892	898	|I-IUPAC
-	898	899	|I-IUPAC
2'	899	901	|I-IUPAC
-	901	902	|I-IUPAC
deoxyguanosine	902	916	|I-IUPAC
.	916	917	|O
These	918	923	|O
prodrugs	924	932	|O
may	933	936	|O
be	937	939	|O
useful	940	946	|O
for	947	950	|O
prodrug	951	958	|O
monotherapy	959	970	|O
of	971	973	|O
necrotic	974	982	|O
tumors	983	989	|O
that	990	994	|O
liberate	995	1003	|O
beta	1004	1008	|O
-	1008	1009	|O
glucuronidase	1009	1022	|O
or	1023	1025	|O
for	1026	1029	|O
antibody	1030	1038	|O
-	1038	1039	|O
directed	1039	1047	|O
enzyme	1048	1054	|O
prodrug	1055	1062	|O
therapy	1063	1070	|O
with	1071	1075	|O
antibodies	1076	1086	|O
that	1087	1091	|O
can	1092	1095	|O
deliver	1096	1103	|O
beta	1104	1108	|O
-	1108	1109	|O
glucuronidase	1109	1122	|O
to	1123	1125	|O
target	1126	1132	|O
tumor	1133	1138	|O
cells	1139	1144	|O
.	1144	1145	|O

### abstracts108.txt
5,5	0	3	|B-IUPAC
-	3	4	|I-IUPAC
Bis	4	7	|I-IUPAC
(	7	8	|I-IUPAC
hydroxymethyl	8	21	|I-IUPAC
)	21	22	|I-IUPAC
tetrahydro	22	32	|I-IUPAC
-	32	33	|I-IUPAC
2	33	34	|I-IUPAC
-	34	35	|I-IUPAC
furanone	35	43	|I-IUPAC
and	44	47	|O
its	48	51	|O
isomer	52	58	|O
4,4	59	62	|B-IUPAC
-	62	63	|I-IUPAC
bis	63	66	|I-IUPAC
(	66	67	|I-IUPAC
hydroxymethyl	67	80	|I-IUPAC
)	80	81	|I-IUPAC
tetrahydro	81	91	|I-IUPAC
-	91	92	|I-IUPAC
2	92	93	|I-IUPAC
-	93	94	|I-IUPAC
furanone	94	102	|I-IUPAC
were	103	107	|O
investigated	108	120	|O
as	121	123	|O
possible	124	132	|O
templates	133	142	|O
for	143	146	|O
the	147	150	|O
construction	151	163	|O
of	164	166	|O
conformationally	167	183	|O
constrained	184	195	|O
analogues	196	205	|O
of	206	208	|O
the	209	212	|O
biologically	213	225	|O
important	226	235	|O
second	236	242	|O
messenger	243	252	|O
,	252	253	|O
diacylglycerol	254	268	|O
(	269	270	|O
DAG	270	273	|O
)	273	274	|O
.	274	275	|O
The	276	279	|O
former	280	286	|O
lactone	287	294	|O
contains	295	303	|O
embedded	304	312	|O
within	313	319	|O
its	320	323	|O
structure	324	333	|O
an	334	336	|O
exact	337	342	|O
glycerol	343	351	|O
moiety	352	358	|O
,	358	359	|O
while	360	365	|O
in	366	368	|O
the	369	372	|O
latter	373	379	|O
the	380	383	|O
ring	384	388	|O
oxygen	389	395	|O
has	396	399	|O
been	400	404	|O
transposed	405	415	|O
to	416	418	|O
the	419	422	|O
other	423	428	|O
side	429	433	|O
of	434	436	|O
the	437	440	|O
carbonyl	441	449	|O
group	450	455	|O
.	455	456	|O
All	457	460	|O
target	461	467	|O
compounds	468	477	|O
were	478	482	|O
synthesized	483	494	|O
as	495	497	|O
racemates	498	507	|O
from	508	512	|O
1,3	513	516	|B-IUPAC
-	516	517	|I-IUPAC
dihydroxy	517	526	|I-IUPAC
-	526	527	|I-IUPAC
2	527	528	|I-IUPAC
-	528	529	|I-IUPAC
propanone	529	538	|I-IUPAC
.	538	539	|O
The	540	543	|O
5,5	544	547	|B-IUPAC
-	547	548	|I-IUPAC
bis	548	551	|I-IUPAC
(	551	552	|I-IUPAC
hydroxymethyl	552	565	|I-IUPAC
)	565	566	|I-IUPAC
tetrahydro	566	576	|I-IUPAC
-	576	577	|I-IUPAC
2	577	578	|I-IUPAC
-	578	579	|I-IUPAC
furanone	579	587	|I-IUPAC
proved	588	594	|O
to	595	597	|O
be	598	600	|O
the	601	604	|O
better	605	611	|O
template	612	620	|O
for	621	624	|O
the	625	628	|O
construction	629	641	|O
of	642	644	|O
DAG	645	648	|O
surrogates	649	659	|O
that	660	664	|O
were	665	669	|O
demonstrated	670	682	|O
to	683	685	|O
have	686	690	|O
high	691	695	|O
binding	696	703	|O
affinities	704	714	|O
for	715	718	|O
the	719	722	|O
biological	723	733	|O
target	734	740	|O
,	740	741	|O
protein	742	749	|O
kinase	750	756	|O
C	757	758	|O
(	759	760	|O
PK	760	762	|O
-	762	763	|O
C	763	764	|O
)	764	765	|O
.	765	766	|O
The	767	770	|O
simplest	771	779	|O
target	780	786	|O
compounds	787	796	|O
derived	797	804	|O
from	805	809	|O
this	810	814	|O
template	815	823	|O
(	824	825	|O
3e	825	827	|O
and	828	831	|O
3f	832	834	|O
)	834	835	|O
have	836	840	|O
one	841	844	|O
of	845	847	|O
the	848	851	|O
hydroxyl	852	860	|B-IUPAC
moieties	861	869	|B-MODIFIER
functionalized	870	884	|O
either	885	891	|O
as	892	894	|O
a	895	896	|O
myristate	897	906	|O
or	907	909	|O
as	910	912	|O
an	913	915	|O
oleate	916	922	|O
ester	923	928	|O
.	928	929	|O
The	930	933	|O
simplest	934	942	|O
target	943	949	|O
compound	950	958	|O
(	959	960	|O
9c	960	962	|O
)	962	963	|O
derived	964	971	|O
from	972	976	|O
the	977	980	|O
ineffective	981	992	|O
4,4	993	996	|B-IUPAC
-	996	997	|I-IUPAC
bis	997	1000	|I-IUPAC
-	1000	1001	|I-IUPAC
(	1001	1002	|I-IUPAC
hydroxymethyl	1002	1015	|I-IUPAC
)	1015	1016	|I-IUPAC
tetrahydro	1016	1026	|I-IUPAC
-	1026	1027	|I-IUPAC
2	1027	1028	|I-IUPAC
-	1028	1029	|I-IUPAC
furanone	1029	1037	|I-IUPAC
template	1038	1046	|O
was	1047	1050	|O
investigated	1051	1063	|O
only	1064	1068	|O
with	1069	1073	|O
a	1074	1075	|O
myristoyl	1076	1085	|O
acyl	1086	1090	|O
chain	1091	1096	|O
.	1096	1097	|O
Reducing	1098	1106	|O
the	1107	1110	|O
long	1111	1115	|O
acyl	1116	1120	|O
chain	1121	1126	|O
to	1127	1129	|O
an	1130	1132	|O
acetyl	1133	1139	|O
moiety	1140	1146	|O
and	1147	1150	|O
attaching	1151	1160	|O
a	1161	1162	|O
compensating	1163	1175	|O
lipophilic	1176	1186	|O
chain	1187	1192	|O
to	1193	1195	|O
the	1196	1199	|O
lactone	1200	1207	|O
ring	1208	1212	|O
as	1213	1215	|O
an	1216	1218	|O
alpha	1219	1224	|B-IUPAC
-	1224	1225	|I-IUPAC
alkylidene	1225	1235	|I-IUPAC
moiety	1236	1242	|B-MODIFIER
produced	1243	1251	|O
compounds	1252	1261	|O
10e	1262	1265	|O
and	1266	1269	|O
10f	1270	1273	|O
(	1274	1275	|O
Z	1275	1276	|O
-	1276	1277	|O
isomers	1277	1284	|O
)	1284	1285	|O
and	1286	1289	|O
11e	1290	1293	|O
and	1294	1297	|O
11f	1298	1301	|O
(	1302	1303	|O
E	1303	1304	|O
-	1304	1305	|O
isomers	1305	1312	|O
)	1312	1313	|O
,	1313	1314	|O
which	1315	1320	|O
were	1321	1325	|O
constructed	1326	1337	|O
on	1338	1340	|O
the	1341	1344	|O
more	1345	1349	|O
effective	1350	1359	|O
5,5	1360	1363	|B-IUPAC
-	1363	1364	|I-IUPAC
bis	1364	1367	|I-IUPAC
(	1367	1368	|I-IUPAC
hydroxymethyl	1368	1381	|I-IUPAC
)	1381	1382	|I-IUPAC
tetrahydro	1382	1392	|I-IUPAC
-	1392	1393	|I-IUPAC
2	1393	1394	|I-IUPAC
-	1394	1395	|I-IUPAC
furanone	1395	1403	|I-IUPAC
template	1404	1412	|O
.	1412	1413	|O
Targets	1414	1421	|O
14c	1422	1425	|O
(	1426	1427	|O
Z	1427	1428	|O
-	1428	1429	|O
isomer	1429	1435	|O
)	1435	1436	|O
and	1437	1440	|O
15c	1441	1444	|O
(	1445	1446	|O
E	1446	1447	|O
-	1447	1448	|O
isomer	1448	1454	|O
)	1454	1455	|O
were	1456	1460	|O
derived	1461	1468	|O
,	1468	1469	|O
in	1470	1472	|O
turn	1473	1477	|O
,	1477	1478	|O
from	1479	1483	|O
4,4	1484	1487	|B-IUPAC
-	1487	1488	|I-IUPAC
bis	1488	1491	|I-IUPAC
(	1491	1492	|I-IUPAC
hydroxymethyl	1492	1505	|I-IUPAC
)	1505	1506	|I-IUPAC
tetrahydro	1506	1516	|I-IUPAC
-	1516	1517	|I-IUPAC
2	1517	1518	|I-IUPAC
-	1518	1519	|I-IUPAC
furanone	1519	1527	|I-IUPAC
.	1527	1528	|O
The	1529	1532	|O
affinities	1533	1543	|O
of	1544	1546	|O
these	1547	1552	|O
ligands	1553	1560	|O
for	1561	1564	|O
PK	1565	1567	|O
-	1567	1568	|O
C	1568	1569	|O
were	1570	1574	|O
assessed	1575	1583	|O
in	1584	1586	|O
terms	1587	1592	|O
of	1593	1595	|O
their	1596	1601	|O
ability	1602	1609	|O
to	1610	1612	|O
displace	1613	1621	|O
bound	1622	1627	|O
[	1628	1629	|B-IUPAC
3H	1629	1631	|I-IUPAC
-	1631	1632	|I-IUPAC
20	1632	1634	|I-IUPAC
]	1634	1635	|I-IUPAC
phorbol	1635	1642	|I-IUPAC
12,13	1643	1648	|I-IUPAC
-	1648	1649	|I-IUPAC
dibutyrate	1649	1659	|I-IUPAC
(	1660	1661	|O
PDBU	1661	1665	|O
)	1665	1666	|O
from	1667	1671	|O
the	1672	1675	|O
single	1676	1682	|O
isozyme	1683	1690	|O
PK	1691	1693	|O
-	1693	1694	|O
C	1694	1695	|O
alpha	1696	1701	|O
.	1701	1702	|O
The	1703	1706	|O
biological	1707	1717	|O
data	1718	1722	|O
support	1723	1730	|O
the	1731	1734	|O
hypothesis	1735	1745	|O
that	1746	1750	|O
the	1751	1754	|O
increase	1755	1763	|O
in	1764	1766	|O
binding	1767	1774	|O
affinity	1775	1783	|O
for	1784	1787	|O
PK	1788	1790	|O
-	1790	1791	|O
C	1791	1792	|O
shown	1793	1798	|O
by	1799	1801	|O
some	1802	1806	|O
of	1807	1809	|O
these	1810	1815	|O
constrained	1816	1827	|O
DAG	1828	1831	|O
mimetics	1832	1840	|O
appears	1841	1848	|O
to	1849	1851	|O
be	1852	1854	|O
entropic	1855	1863	|O
in	1864	1866	|O
nature	1867	1873	|O
.	1873	1874	|O
Two	1875	1878	|O
of	1879	1881	|O
the	1882	1885	|O
designed	1886	1894	|O
ligands	1895	1902	|O
(	1903	1904	|O
10e	1904	1907	|O
and	1908	1911	|O
10f	1912	1915	|O
)	1915	1916	|O
showed	1917	1923	|O
the	1924	1927	|O
highest	1928	1935	|O
affinities	1936	1946	|O
(	1947	1948	|O
34	1948	1950	|O
and	1951	1954	|O
24	1955	1957	|O
nM	1958	1960	|O
,	1960	1961	|O
respectively	1962	1974	|O
)	1974	1975	|O
reported	1976	1984	|O
so	1985	1987	|O
far	1988	1991	|O
for	1992	1995	|O
a	1996	1997	|O
DAG	1998	2001	|O
analogue	2002	2010	|O
.	2010	2011	|O
Assuming	2012	2020	|O
that	2021	2025	|O
the	2026	2029	|O
interaction	2030	2041	|O
between	2042	2049	|O
these	2050	2055	|O
racemic	2056	2063	|O
compounds	2064	2073	|O
and	2074	2077	|O
PK	2078	2080	|O
-	2080	2081	|O
C	2081	2082	|O
is	2083	2085	|O
stereospecific	2086	2100	|O
,	2100	2101	|O
the	2102	2105	|O
potency	2106	2113	|O
of	2114	2116	|O
the	2117	2120	|O
active	2121	2127	|O
enantiomer	2128	2138	|O
is	2139	2141	|O
anticipated	2142	2153	|O
to	2154	2156	|O
double	2157	2163	|O
.	2163	2164	|O

### abstracts1538.txt
In	0	2	|O
this	3	7	|O
study	8	13	|O
,	13	14	|O
13	15	17	|O
heteroarotinoids	18	34	|O
were	35	39	|O
synthesized	40	51	|O
.	51	52	|O
The	53	56	|O
key	57	60	|O
step	61	65	|O
in	66	68	|O
each	69	73	|O
preparation	74	85	|O
was	86	89	|O
the	90	93	|O
condensation	94	106	|O
of	107	109	|O
the	110	113	|O
appropriate	114	125	|O
chroman	126	133	|B-IUPAC
-	133	134	|O
,	134	135	|O
thiochroman	136	147	|B-IUPAC
-	147	148	|I-IUPAC
,	148	149	|O
or	150	152	|O
benzothienyl	153	165	|B-IUPAC
-	165	166	|I-IUPAC
substituted	166	177	|B-MODIFIER
phosphorus	178	188	|B-IUPAC
ylide	189	194	|I-IUPAC
,	194	195	|O
obtained	196	204	|O
from	205	209	|O
the	210	213	|O
independent	214	225	|O
synthesis	226	235	|O
of	236	238	|O
the	239	242	|O
corresponding	243	256	|O
phosphonium	257	268	|O
salts	269	274	|O
,	274	275	|O
with	276	280	|O
selected	281	289	|O
polyene	290	297	|B-IUPAC
-	297	298	|O
substituted	298	309	|B-MODIFIER
aldehyde	310	318	|B-IUPAC
esters	319	325	|I-IUPAC
.	325	326	|O
Nine	327	331	|O
of	332	334	|O
these	335	340	|O
heterocycles	341	353	|O
contained	354	363	|O
a	364	365	|O
thiochroman	366	377	|O
group	378	383	|O
,	383	384	|O
two	385	388	|O
had	389	392	|O
a	393	394	|O
chroman	395	402	|O
group	403	408	|O
,	408	409	|O
and	410	413	|O
two	414	417	|O
others	418	424	|O
had	425	428	|O
a	429	430	|O
benzothienyl	431	443	|O
system	444	450	|O
.	450	451	|O
Screening	452	461	|O
of	462	464	|O
the	465	468	|O
compounds	469	478	|O
was	479	482	|O
with	483	487	|O
one	488	491	|O
of	492	494	|O
two	495	498	|O
assays	499	505	|O
.	505	506	|O
One	507	510	|O
assay	511	516	|O
measured	517	525	|O
the	526	529	|O
ability	530	537	|O
of	538	540	|O
a	541	542	|O
retinoid	543	551	|O
to	552	554	|O
inhibit	555	562	|O
the	563	566	|O
phorbol	567	574	|O
ester	575	580	|O
induced	581	588	|O
increase	589	597	|O
of	598	600	|O
mouse	601	606	|O
epidermal	607	616	|O
ornithine	617	626	|O
decarboxylase	627	640	|O
(	641	642	|O
ODC	642	645	|O
)	645	646	|O
activity	647	655	|O
.	655	656	|O
The	657	660	|O
other	661	666	|O
assay	667	672	|O
measured	673	681	|O
retinoid	682	690	|O
-	690	691	|O
induced	691	698	|O
differentiation	699	714	|O
of	715	717	|O
the	718	721	|O
human	722	727	|O
myoloid	728	735	|O
leukemia	736	744	|O
cell	745	749	|O
line	750	754	|O
HL	755	757	|O
-	757	758	|O
60	758	760	|O
.	760	761	|O
In	762	764	|O
the	765	768	|O
ODC	769	772	|O
assay	773	778	|O
,	778	779	|O
all	780	783	|O
thirteen	784	792	|O
compounds	793	802	|O
were	803	807	|O
screened	808	816	|O
.	816	817	|O
The	818	821	|O
most	822	826	|O
active	827	833	|O
heteroarotinoids	834	850	|O
were	851	855	|O
ester	856	861	|O
10	862	864	|O
[	865	866	|O
methyl	866	872	|B-IUPAC
(	873	874	|I-IUPAC
E	874	875	|I-IUPAC
)	875	876	|I-IUPAC
-	876	877	|I-IUPAC
4	877	878	|I-IUPAC
-	878	879	|I-IUPAC
[	879	880	|I-IUPAC
2	880	881	|I-IUPAC
-	881	882	|I-IUPAC
(	882	883	|I-IUPAC
2,2,4,4	883	890	|I-IUPAC
-	890	891	|I-IUPAC
tetramethylthiochroman	891	913	|I-IUPAC
-	913	914	|I-IUPAC
6	914	915	|I-IUPAC
-	915	916	|I-IUPAC
yl	916	918	|I-IUPAC
)	918	919	|I-IUPAC
-	919	920	|I-IUPAC
1	920	921	|I-IUPAC
-	921	922	|I-IUPAC
propenyl	923	931	|I-IUPAC
]	931	932	|I-IUPAC
benzoate	932	940	|I-IUPAC
]	940	941	|O
and	942	945	|O
acid	946	950	|O
11	951	953	|O
[	954	955	|O
(	955	956	|B-IUPAC
E	956	957	|I-IUPAC
)	957	958	|I-IUPAC
-	958	959	|I-IUPAC
4	959	960	|I-IUPAC
-	960	961	|I-IUPAC
[	961	962	|I-IUPAC
2	962	963	|I-IUPAC
-	963	964	|I-IUPAC
(	964	965	|I-IUPAC
2,2,4,4	965	972	|I-IUPAC
-	972	973	|I-IUPAC
tetramethyl	973	984	|I-IUPAC
-	984	985	|I-IUPAC
3,4	985	988	|I-IUPAC
-	988	989	|I-IUPAC
dihydro	990	997	|I-IUPAC
-	997	998	|I-IUPAC
2H	998	1000	|I-IUPAC
-	1000	1001	|I-IUPAC
1	1001	1002	|I-IUPAC
-	1002	1003	|I-IUPAC
benzothiopyran	1004	1018	|I-IUPAC
-	1018	1019	|I-IUPAC
6	1019	1020	|I-IUPAC
-	1020	1021	|I-IUPAC
yl	1021	1023	|I-IUPAC
)	1023	1024	|I-IUPAC
-	1024	1025	|I-IUPAC
1	1025	1026	|I-IUPAC
-	1026	1027	|I-IUPAC
propenyl	1027	1035	|I-IUPAC
]	1035	1036	|I-IUPAC
benzoic	1036	1043	|I-IUPAC
acid	1044	1048	|I-IUPAC
]	1048	1049	|O
.	1049	1050	|O
Both	1051	1055	|O
of	1056	1058	|O
these	1059	1064	|O
retinoids	1065	1074	|O
had	1075	1078	|O
ID50	1079	1083	|O
values	1084	1090	|O
(	1091	1092	|O
dose	1092	1096	|O
required	1097	1105	|O
for	1106	1109	|O
half	1110	1114	|O
-	1114	1115	|O
maximal	1115	1122	|O
inhibition	1123	1133	|O
of	1134	1136	|O
phorbol	1137	1144	|O
ester	1145	1150	|O
induced	1151	1158	|O
ODC	1159	1162	|O
activity	1163	1171	|O
)	1171	1172	|O
of	1173	1175	|O
about	1176	1181	|O
0.3	1182	1185	|O
nmol	1186	1190	|O
.	1190	1191	|O
In	1192	1194	|O
comparison	1195	1205	|O
,	1205	1206	|O
the	1207	1210	|O
ID50	1211	1215	|O
value	1216	1221	|O
for	1222	1225	|O
trans	1226	1231	|O
-	1231	1232	|O
retinoic	1232	1240	|O
acid	1241	1245	|O
(	1246	1247	|O
1	1247	1248	|O
)	1248	1249	|O
was	1250	1253	|O
0.12	1254	1258	|O
nmol	1259	1263	|O
while	1264	1269	|O
the	1270	1273	|O
ID50	1274	1278	|O
values	1279	1285	|O
for	1286	1289	|O
acids	1290	1295	|O
7	1296	1297	|O
and	1298	1301	|O
9	1302	1303	|O
,	1303	1304	|O
namely	1305	1311	|O
(	1312	1313	|B-IUPAC
2Z	1313	1315	|I-IUPAC
,	1315	1316	|I-IUPAC
4E	1316	1318	|I-IUPAC
,	1318	1319	|I-IUPAC
6E	1319	1321	|I-IUPAC
)	1321	1322	|I-IUPAC
-	1322	1323	|I-IUPAC
3,7	1323	1326	|I-IUPAC
-	1326	1327	|I-IUPAC
dimethyl	1327	1335	|I-IUPAC
-	1335	1336	|I-IUPAC
7	1336	1337	|I-IUPAC
-	1337	1338	|I-IUPAC
(	1338	1339	|I-IUPAC
4,4	1339	1342	|I-IUPAC
-	1342	1343	|I-IUPAC
dimethyl	1343	1351	|I-IUPAC
-	1351	1352	|I-IUPAC
thiochroman	1352	1363	|I-IUPAC
-	1364	1365	|I-IUPAC
6	1365	1366	|I-IUPAC
-	1366	1367	|I-IUPAC
yl	1367	1369	|I-IUPAC
)	1369	1370	|I-IUPAC
-	1370	1371	|I-IUPAC
2,4,6	1371	1376	|I-IUPAC
-	1376	1377	|I-IUPAC
heptatrienoic	1377	1390	|I-IUPAC
acid	1391	1395	|I-IUPAC
and	1396	1399	|O
(	1400	1401	|B-IUPAC
2E	1401	1403	|I-IUPAC
,	1403	1404	|I-IUPAC
4E	1404	1406	|I-IUPAC
,	1406	1407	|I-IUPAC
6E	1407	1409	|I-IUPAC
)	1409	1410	|I-IUPAC
-	1410	1411	|I-IUPAC
3,7	1411	1414	|I-IUPAC
-	1414	1415	|I-IUPAC
dimethyl	1415	1423	|I-IUPAC
-	1423	1424	|I-IUPAC
7	1424	1425	|I-IUPAC
-	1425	1426	|I-IUPAC
(	1426	1427	|I-IUPAC
2,2,4,4	1427	1434	|I-IUPAC
-	1434	1435	|I-IUPAC
tetramethylthiochroman	1435	1457	|I-IUPAC
-	1458	1459	|I-IUPAC
6	1459	1460	|I-IUPAC
-	1460	1461	|I-IUPAC
yl	1461	1463	|I-IUPAC
)	1463	1464	|I-IUPAC
-	1464	1465	|I-IUPAC
2,4,6	1465	1470	|I-IUPAC
-	1470	1471	|I-IUPAC
heptatrienoic	1472	1485	|I-IUPAC
acid	1486	1490	|I-IUPAC
,	1490	1491	|O
respectively	1492	1504	|O
,	1504	1505	|O
were	1506	1510	|O
about	1511	1516	|O
3.5	1517	1520	|O
nmol	1521	1525	|O
.	1525	1526	|O
Heteroarotinoids	1527	1543	|O
8	1544	1545	|O
and	1546	1549	|O
12-17	1550	1555	|O
had	1556	1559	|O
ID50	1560	1564	|O
values	1565	1571	|O
of	1572	1574	|O
35	1575	1577	|O
nmol	1578	1582	|O
or	1583	1585	|O
greater	1586	1593	|O
.	1593	1594	|O
With	1595	1599	|O
a	1600	1601	|O
thiochroman	1602	1613	|O
unit	1614	1618	|O
,	1618	1619	|O
the	1620	1623	|O
most	1624	1628	|O
active	1629	1635	|O
acids	1636	1641	|O
in	1642	1644	|O
decreasing	1645	1655	|O
order	1656	1661	|O
of	1662	1664	|O
activity	1665	1673	|O
in	1674	1676	|O
the	1677	1680	|O
ODC	1681	1684	|O
assay	1685	1690	|O
were	1691	1695	|O
7	1696	1697	|O
greater	1698	1705	|O
than	1706	1710	|O
9	1711	1712	|O
greater	1713	1720	|O
than	1721	1725	|O
8	1726	1727	|O
.	1727	1728	|O
Thus	1729	1733	|O
,	1733	1734	|O
simple	1735	1741	|O
replacement	1742	1753	|O
of	1754	1756	|O
the	1757	1760	|O
terminal	1761	1769	|O
propenyl	1770	1778	|B-IUPAC
system	1779	1785	|B-MODIFIER
[	1786	1787	|O
C	1787	1788	|O
(	1788	1789	|O
16,17,18	1789	1797	|O
)	1797	1798	|O
]	1798	1799	|O
in	1800	1802	|O
7	1803	1804	|O
with	1805	1809	|O
a	1810	1811	|O
cyclopropyl	1812	1823	|B-IUPAC
group	1824	1829	|B-MODIFIER
produced	1830	1838	|O
acid	1839	1843	|O
8	1844	1845	|O
[	1846	1847	|O
(	1847	1848	|B-IUPAC
2E	1848	1850	|I-IUPAC
,	1850	1851	|I-IUPAC
4E	1851	1853	|I-IUPAC
,	1853	1854	|I-IUPAC
6E	1854	1856	|I-IUPAC
)	1856	1857	|I-IUPAC
-	1857	1858	|I-IUPAC
7	1858	1859	|I-IUPAC
-	1859	1860	|I-IUPAC
methyl	1860	1866	|I-IUPAC
-	1866	1867	|I-IUPAC
7	1867	1868	|I-IUPAC
-	1868	1869	|I-IUPAC
(	1869	1870	|I-IUPAC
4,4	1870	1873	|I-IUPAC
-	1873	1874	|I-IUPAC
dimethylthiochroman	1874	1893	|I-IUPAC
-	1893	1894	|I-IUPAC
6	1894	1895	|I-IUPAC
-	1895	1896	|I-IUPAC
yl	1896	1898	|I-IUPAC
)	1898	1899	|I-IUPAC
-	1899	1900	|I-IUPAC
2,3	1901	1904	|I-IUPAC
-	1904	1905	|I-IUPAC
methylene	1905	1914	|I-IUPAC
-	1914	1915	|I-IUPAC
4,6	1915	1918	|I-IUPAC
-	1918	1919	|I-IUPAC
heptadienoic	1919	1931	|I-IUPAC
acid	1932	1936	|I-IUPAC
with	1937	1941	|O
markedly	1942	1950	|O
reduced	1951	1958	|O
activity	1959	1967	|O
.	1967	1968	|O
With	1969	1973	|O
a	1974	1975	|O
benzoic	1976	1983	|O
acid	1984	1988	|O
group	1989	1994	|O
as	1995	1997	|O
part	1998	2002	|O
of	2003	2005	|O
the	2006	2009	|O
structure	2010	2019	|O
attached	2020	2028	|O
to	2029	2031	|O
the	2032	2035	|O
thiochroman	2036	2047	|O
unit	2048	2052	|O
,	2052	2053	|O
the	2054	2057	|O
ODC	2058	2061	|O
activity	2062	2070	|O
was	2071	2074	|O
enhanced	2075	2083	|O
as	2084	2086	|O
shown	2087	2092	|O
in	2093	2095	|O
10	2096	2098	|O
and	2099	2102	|O
11	2103	2105	|O
.	2105	2106	|O
The	2107	2110	|O
combination	2111	2122	|O
of	2123	2125	|O
the	2126	2129	|O
2,2,4,4	2130	2137	|B-IUPAC
-	2137	2138	|I-IUPAC
tetramethylthiochroman	2138	2160	|I-IUPAC
group	2161	2166	|B-MODIFIER
and	2167	2170	|O
the	2171	2174	|O
benzoic	2175	2182	|O
acid	2183	2187	|O
(	2188	2189	|O
or	2189	2191	|O
ester	2192	2197	|O
)	2197	2198	|O
terminal	2199	2207	|O
group	2208	2213	|O
seemed	2214	2220	|O
to	2221	2223	|O
enhance	2224	2231	|O
the	2232	2235	|O
biological	2236	2246	|O
action	2247	2253	|O
which	2254	2259	|O
resembles	2260	2269	|O
that	2270	2274	|O
found	2275	2280	|O
with	2281	2285	|O
(	2286	2287	|B-IUPAC
E	2287	2288	|I-IUPAC
)	2288	2289	|I-IUPAC
-	2289	2290	|I-IUPAC
4	2290	2291	|I-IUPAC
-	2291	2292	|I-IUPAC
[	2292	2293	|I-IUPAC
2	2293	2294	|I-IUPAC
-	2294	2295	|I-IUPAC
(	2295	2296	|I-IUPAC
5,6,7,8	2296	2303	|I-IUPAC
-	2303	2304	|I-IUPAC
tetrahydro	2304	2314	|I-IUPAC
-	2314	2315	|I-IUPAC
5,5,8,8	2315	2322	|I-IUPAC
-	2322	2323	|I-IUPAC
tetramethyl	2323	2334	|I-IUPAC
-	2334	2335	|I-IUPAC
2	2335	2336	|I-IUPAC
-	2336	2337	|I-IUPAC
naphthalenyl	2337	2349	|I-IUPAC
)	2349	2350	|I-IUPAC
-	2350	2351	|I-IUPAC
1	2352	2353	|I-IUPAC
-	2353	2354	|I-IUPAC
propenyl	2354	2362	|I-IUPAC
]	2362	2363	|I-IUPAC
benzoic	2363	2370	|I-IUPAC
acid	2371	2375	|I-IUPAC
(	2376	2377	|O
TTNPB	2377	2382	|O
,	2382	2383	|O
6b	2384	2386	|O
)	2386	2387	|O
,	2387	2388	|O
a	2389	2390	|O
well	2391	2395	|O
-	2395	2396	|O
known	2396	2401	|O
model	2402	2407	|O
system	2408	2414	|O
.	2414	2415	|O
(	2415	2416	|O
ABSTRACT	2416	2424	|O
TRUNCATED	2425	2434	|O
AT	2435	2437	|O
400	2438	2441	|O
WORDS	2442	2447	|O
)	2447	2448	|O

### abstracts590.txt
To	0	2	|O
develop	3	10	|O
a	11	12	|O
novel	13	18	|O
cerebroprotective	19	36	|O
agent	37	42	|O
with	43	47	|O
central	48	55	|O
nervous	56	63	|O
system	64	70	|O
(	71	72	|O
CNS	72	75	|O
)	75	76	|O
stimulating	77	88	|O
activity	89	97	|O
,	97	98	|O
a	99	100	|O
series	101	107	|B-MODIFIER
of	108	110	|O
1	111	112	|B-IUPAC
-	112	113	|I-IUPAC
amino	113	118	|I-IUPAC
-	118	119	|I-IUPAC
7	119	120	|I-IUPAC
-	120	121	|I-IUPAC
hydroxyindan	121	133	|I-IUPAC
derivatives	134	145	|B-MODIFIER
was	146	149	|O
synthesized	150	161	|O
,	161	162	|O
and	163	166	|O
their	167	172	|O
effects	173	180	|O
on	181	183	|O
the	184	187	|O
survival	188	196	|O
time	197	201	|O
of	202	204	|O
mice	205	209	|O
under	210	215	|O
hypoxic	216	223	|O
conditions	224	234	|O
were	235	239	|O
tested	240	246	|O
.	246	247	|O
CNS	248	251	|O
-	251	252	|O
stimulating	252	263	|O
activity	264	272	|O
was	273	276	|O
also	277	281	|O
evaluated	282	291	|O
by	292	294	|O
examining	295	304	|O
the	305	308	|O
promotional	309	320	|O
effect	321	327	|O
on	328	330	|O
the	331	334	|O
recovery	335	343	|O
from	344	348	|O
cerebral	349	357	|O
concussion	358	368	|O
induced	369	376	|O
coma	377	381	|O
in	382	384	|O
mice	385	389	|O
.	389	390	|O
Several	391	398	|O
compounds	399	408	|O
prolonged	409	418	|O
the	419	422	|O
survival	423	431	|O
time	432	436	|O
of	437	439	|O
mice	440	444	|O
in	445	447	|O
hypoxic	448	455	|O
conditions	456	466	|O
at	467	469	|O
a	470	471	|O
dose	472	476	|O
of	477	479	|O
30	480	482	|O
mg	483	485	|O
/	485	486	|O
kg	486	488	|O
(	489	490	|O
sc	490	492	|O
or	493	495	|O
ip	496	498	|O
)	498	499	|O
and	500	503	|O
100	504	507	|O
mg	508	510	|O
/	510	511	|O
kg	511	513	|O
(	514	515	|O
po	515	517	|O
)	517	518	|O
.	518	519	|O
They	520	524	|O
also	525	529	|O
exhibited	530	539	|O
the	540	543	|O
promotional	544	555	|O
effects	556	563	|O
on	564	566	|O
recovery	567	575	|O
from	576	580	|O
coma	581	585	|O
at	586	588	|O
a	589	590	|O
dose	591	595	|O
of	596	598	|O
100	599	602	|O
mg	603	605	|O
/	605	606	|O
kg	606	608	|O
po	609	611	|O
.	611	612	|O
The	613	616	|O
three	617	622	|O
most	623	627	|O
potent	628	634	|O
compounds	635	644	|O
in	645	647	|O
both	648	652	|O
tests	653	658	|O
,	658	659	|O
1	660	661	|B-IUPAC
-	661	662	|I-IUPAC
amino	662	667	|I-IUPAC
-	667	668	|I-IUPAC
7	668	669	|I-IUPAC
-	669	670	|I-IUPAC
hydroxy	670	677	|I-IUPAC
-	677	678	|I-IUPAC
6	678	679	|I-IUPAC
-	679	680	|I-IUPAC
(	680	681	|I-IUPAC
1	681	682	|I-IUPAC
-	682	683	|I-IUPAC
methylpropyl	683	695	|I-IUPAC
)	695	696	|I-IUPAC
indan	696	701	|I-IUPAC
,	701	702	|O
1	703	704	|B-IUPAC
-	704	705	|I-IUPAC
amino	705	710	|I-IUPAC
-	710	711	|I-IUPAC
7	711	712	|I-IUPAC
-	712	713	|I-IUPAC
hydroxy	713	720	|I-IUPAC
-	720	721	|I-IUPAC
4	721	722	|I-IUPAC
,	722	723	|I-IUPAC
6	724	725	|I-IUPAC
-	725	726	|I-IUPAC
dimethyl	726	734	|I-IUPAC
-	734	735	|I-IUPAC
2	735	736	|I-IUPAC
-	736	737	|I-IUPAC
phenylindan	737	748	|I-IUPAC
,	748	749	|O
and	750	753	|O
1	754	755	|B-IUPAC
-	755	756	|I-IUPAC
amino	756	761	|I-IUPAC
-	761	762	|I-IUPAC
7	762	763	|I-IUPAC
-	763	764	|I-IUPAC
hydroxy	764	771	|I-IUPAC
-	771	772	|I-IUPAC
2,2,4,6	772	779	|I-IUPAC
-	779	780	|I-IUPAC
tetramethylindan	780	796	|I-IUPAC
were	797	801	|O
selected	802	810	|O
for	811	814	|O
further	815	822	|O
investigations	823	837	|O
.	837	838	|O
Structure	839	848	|O
-	848	849	|O
activity	849	857	|O
relationships	858	871	|O
were	872	876	|O
also	877	881	|O
discussed	882	891	|O
.	891	892	|O

### abstracts622.txt
Prazosin	0	8	|O
-	8	9	|O
related	9	16	|O
quinazolines	17	29	|O
4-20	30	34	|O
were	35	39	|O
synthesized	40	51	|O
,	51	52	|O
and	53	56	|O
their	57	62	|O
biological	63	73	|O
profiles	74	82	|O
at	83	85	|O
alpha1	86	92	|O
-	92	93	|O
adrenoreceptor	93	107	|O
subtypes	108	116	|O
were	117	121	|O
assessed	122	130	|O
by	131	133	|O
functional	134	144	|O
experiments	145	156	|O
in	157	159	|O
isolated	160	168	|O
rat	169	172	|O
vas	173	176	|O
deferens	177	185	|O
(	186	187	|O
alpha1A	187	194	|O
)	194	195	|O
,	195	196	|O
spleen	197	203	|O
(	204	205	|O
alpha1B	205	212	|O
)	212	213	|O
,	213	214	|O
and	215	218	|O
aorta	219	224	|O
(	225	226	|O
alpha1D	226	233	|O
)	233	234	|O
and	235	238	|O
by	239	241	|O
binding	242	249	|O
assays	250	256	|O
in	257	259	|O
CHO	260	263	|O
cells	264	269	|O
expressing	270	280	|O
human	281	286	|O
cloned	287	293	|O
alpha1	294	300	|O
-	300	301	|O
adrenoreceptor	301	315	|O
subtypes	316	324	|O
.	324	325	|O
The	326	329	|O
replacement	330	341	|O
of	342	344	|O
piperazine	345	355	|O
and	356	359	|O
furan	360	365	|O
units	366	371	|O
of	372	374	|O
prazosin	375	383	|O
(	384	385	|O
1	385	386	|O
)	386	387	|O
by	388	390	|O
1	391	392	|B-IUPAC
,	392	393	|I-IUPAC
6	394	395	|I-IUPAC
-	395	396	|I-IUPAC
hexanediamine	396	409	|I-IUPAC
and	410	413	|O
phenyl	414	420	|B-IUPAC
moieties	421	429	|B-MODIFIER
,	429	430	|O
respectively	431	443	|O
,	443	444	|O
affording	445	454	|O
3-20	455	459	|O
,	459	460	|O
markedly	461	469	|O
affected	470	478	|O
both	479	483	|O
affinity	484	492	|O
and	493	496	|O
selectivity	497	508	|O
for	509	512	|O
alpha1	513	519	|O
-	519	520	|O
adrenoreceptor	520	534	|O
subtypes	535	543	|O
in	544	546	|O
functional	547	557	|O
experiments	558	569	|O
.	569	570	|O
Cystazosin	571	581	|O
(	582	583	|O
3	583	584	|O
)	584	585	|O
,	585	586	|O
bearing	587	594	|O
a	595	596	|O
cystamine	597	606	|O
moiety	607	613	|O
,	613	614	|O
was	615	618	|O
a	619	620	|O
selective	621	630	|O
alpha1D	631	638	|O
-	638	639	|O
adrenoreceptor	639	653	|O
antagonist	654	664	|O
being	665	670	|O
1	671	672	|O
order	673	678	|O
of	679	681	|O
magnitude	682	691	|O
more	692	696	|O
potent	697	703	|O
at	704	706	|O
alpha1D	707	714	|O
-	714	715	|O
adrenoreceptors	715	730	|O
(	731	732	|O
pA2	732	735	|O
,	735	736	|O
8.54	737	741	|O
+	742	743	|O
/	743	744	|O
-	744	745	|O
0.02	746	750	|O
)	750	751	|O
than	752	756	|O
at	757	759	|O
the	760	763	|O
alpha1A	764	771	|O
-	771	772	|O
(	773	774	|O
pA2	774	777	|O
,	777	778	|O
7.53	779	783	|O
+	784	785	|O
/	785	786	|O
-	786	787	|O
0.01	788	792	|O
)	792	793	|O
and	794	797	|O
alpha1B	798	805	|O
-	805	806	|O
subtypes	806	814	|O
(	815	816	|O
pA2	816	819	|O
,	819	820	|O
7.49	821	825	|O
+	826	827	|O
/	827	828	|O
-	828	829	|O
0	830	831	|O
.	831	832	|O
01	833	835	|O
)	835	836	|O
.	836	837	|O
The	838	841	|O
insertion	842	851	|O
of	852	854	|O
substituents	855	867	|O
on	868	870	|O
the	871	874	|O
furan	875	880	|O
ring	881	885	|O
of	886	888	|O
3	889	890	|O
,	890	891	|O
as	892	894	|O
in	895	897	|O
compounds	898	907	|O
4	908	909	|O
and	910	913	|O
5	914	915	|O
,	915	916	|O
did	917	920	|O
not	921	924	|O
improve	925	932	|O
the	933	936	|O
selectivity	937	948	|O
profile	949	956	|O
.	956	957	|O
The	958	961	|O
simultaneous	962	974	|O
replacement	975	986	|O
of	987	989	|O
both	990	994	|O
piperazine	995	1005	|O
and	1006	1009	|O
furan	1010	1015	|O
rings	1016	1021	|O
of	1022	1024	|O
1	1025	1026	|O
gave	1027	1031	|O
8	1032	1033	|O
which	1034	1039	|O
resulted	1040	1048	|O
in	1049	1051	|O
a	1052	1053	|O
potent	1054	1060	|O
,	1060	1061	|O
selective	1062	1071	|O
alpha1B	1072	1079	|O
-	1079	1080	|O
adrenoreceptor	1080	1094	|O
antagonist	1095	1105	|O
(	1106	1107	|O
85	1107	1109	|O
-	1109	1110	|O
and	1111	1114	|O
15	1115	1117	|O
-	1117	1118	|O
fold	1118	1122	|O
more	1123	1127	|O
potent	1128	1134	|O
than	1135	1139	|O
at	1140	1142	|O
alpha1A	1143	1150	|O
-	1150	1151	|O
and	1152	1155	|O
alpha1D	1156	1163	|O
-	1163	1164	|O
subtypes	1164	1172	|O
,	1172	1173	|O
respectively	1174	1186	|O
)	1186	1187	|O
.	1187	1188	|O
The	1189	1192	|O
insertion	1193	1202	|O
of	1203	1205	|O
substituents	1206	1218	|O
on	1219	1221	|O
the	1222	1225	|O
benzene	1226	1233	|O
ring	1234	1238	|O
of	1239	1241	|O
8	1242	1243	|O
affected	1244	1252	|O
,	1252	1253	|O
according	1254	1263	|O
to	1264	1266	|O
the	1267	1270	|O
type	1271	1275	|O
and	1276	1279	|O
the	1280	1283	|O
position	1284	1292	|O
of	1293	1295	|O
the	1296	1299	|O
substituent	1300	1311	|O
,	1311	1312	|O
affinity	1313	1321	|O
and	1322	1325	|O
selectivity	1326	1337	|O
for	1338	1341	|O
alpha1	1342	1348	|O
-	1348	1349	|O
adrenoreceptors	1349	1364	|O
.	1364	1365	|O
Consequently	1366	1378	|O
,	1378	1379	|O
the	1380	1383	|O
insertion	1384	1393	|O
of	1394	1396	|O
appropriate	1397	1408	|O
substituents	1409	1421	|O
in	1422	1424	|O
the	1425	1428	|O
phenyl	1429	1435	|O
ring	1436	1440	|O
of	1441	1443	|O
8	1444	1445	|O
may	1446	1449	|O
represent	1450	1459	|O
the	1460	1463	|O
basis	1464	1469	|O
of	1470	1472	|O
designing	1473	1482	|O
new	1483	1486	|O
selective	1487	1496	|O
ligands	1497	1504	|O
for	1505	1508	|O
alpha1	1509	1515	|O
-	1515	1516	|O
adrenoreceptor	1516	1530	|O
subtypes	1531	1539	|O
.	1539	1540	|O
Interestingly	1541	1554	|O
,	1554	1555	|O
the	1556	1559	|O
finding	1560	1567	|O
that	1568	1572	|O
polyamines	1573	1583	|O
11	1584	1586	|O
,	1586	1587	|O
16	1588	1590	|O
,	1590	1591	|O
and	1592	1595	|O
20	1596	1598	|O
,	1598	1599	|O
bearing	1600	1607	|O
a	1608	1609	|O
1,6	1610	1613	|B-IUPAC
-	1613	1614	|I-IUPAC
hexanediamine	1614	1627	|I-IUPAC
moiety	1628	1634	|B-MODIFIER
,	1634	1635	|O
retained	1636	1644	|O
high	1645	1649	|O
affinity	1650	1658	|O
for	1659	1662	|O
alpha1	1663	1669	|O
-	1669	1670	|O
adrenoreceptor	1670	1684	|O
subtypes	1685	1693	|O
suggests	1694	1702	|O
that	1703	1707	|O
the	1708	1711	|O
substituent	1712	1723	|O
did	1724	1727	|O
not	1728	1731	|O
give	1732	1736	|O
rise	1737	1741	|O
to	1742	1744	|O
negative	1745	1753	|O
interactions	1754	1766	|O
with	1767	1771	|O
the	1772	1775	|O
receptor	1776	1784	|O
.	1784	1785	|O
Finally	1786	1793	|O
,	1793	1794	|O
binding	1795	1802	|O
assays	1803	1809	|O
performed	1810	1819	|O
with	1820	1824	|O
selected	1825	1833	|O
quinazolines	1834	1846	|O
(	1847	1848	|O
2	1848	1849	|O
,	1849	1850	|O
3	1851	1852	|O
,	1852	1853	|O
and	1854	1857	|O
14	1858	1860	|O
)	1860	1861	|O
produced	1862	1870	|O
affinity	1871	1879	|O
results	1880	1887	|O
,	1887	1888	|O
which	1889	1894	|O
were	1895	1899	|O
not	1900	1903	|O
in	1904	1906	|O
agreement	1907	1916	|O
with	1917	1921	|O
the	1922	1925	|O
selectivity	1926	1937	|O
profiles	1938	1946	|O
obtained	1947	1955	|O
from	1956	1960	|O
functional	1961	1971	|O
experiments	1972	1983	|O
.	1983	1984	|O
This	1985	1989	|O
rather	1990	1996	|O
surprising	1997	2007	|O
and	2008	2011	|O
unexpected	2012	2022	|O
finding	2023	2030	|O
may	2031	2034	|O
be	2035	2037	|O
explained	2038	2047	|O
by	2048	2050	|O
considering	2051	2062	|O
neutral	2063	2070	|O
and	2071	2074	|O
negative	2075	2083	|O
antagonism	2084	2094	|O
.	2094	2095	|O

### abstracts4301.txt
New	0	3	|O
nucleoside	4	14	|O
analogues	15	24	|O
14-17	25	30	|O
based	31	36	|O
on	37	39	|O
a	40	41	|O
methylenecyclopropane	42	63	|O
structure	64	73	|O
were	74	78	|O
synthesized	79	90	|O
and	91	94	|O
evaluated	95	104	|O
for	105	108	|O
antiviral	109	118	|O
activity	119	127	|O
.	127	128	|O
Reaction	129	137	|O
of	138	140	|O
2,3	141	144	|B-IUPAC
-	144	145	|I-IUPAC
dibromopropene	145	159	|I-IUPAC
(	160	161	|O
19	161	163	|O
)	163	164	|O
with	165	169	|O
adenine	170	177	|O
(	178	179	|O
18	179	181	|O
)	181	182	|O
led	183	186	|O
to	187	189	|O
bromoalkene	190	201	|O
20	202	204	|O
,	204	205	|O
which	206	211	|O
was	212	215	|O
benzoylated	216	227	|O
to	228	230	|O
give	231	235	|O
N6	236	238	|B-IUPAC
,	238	239	|I-IUPAC
N6	239	241	|I-IUPAC
-	241	242	|I-IUPAC
dibenzoyl	242	251	|I-IUPAC
derivative	252	262	|B-MODIFIER
23	263	265	|O
.	265	266	|O
Attempts	267	275	|O
to	276	278	|O
convert	279	286	|O
20	287	289	|O
or	290	292	|O
23	293	295	|O
to	296	298	|O
bromocyclopropanes	299	317	|O
21	318	320	|O
and	321	324	|O
22	325	327	|O
by	328	330	|O
reaction	331	339	|O
with	340	344	|O
ethyl	345	350	|O
diazoacetate	351	363	|O
catalyzed	364	373	|O
by	374	376	|O
Rh2	377	380	|O
(	380	381	|O
OAc	381	384	|O
)	384	385	|O
4	385	386	|O
were	387	391	|O
futile	392	398	|O
.	398	399	|O
By	400	402	|O
contrast	403	411	|O
,	411	412	|O
2,3	413	416	|B-IUPAC
-	416	417	|I-IUPAC
dibromopropene	417	431	|I-IUPAC
(	432	433	|O
19	433	435	|O
)	435	436	|O
afforded	437	445	|O
smoothly	446	454	|O
(	455	456	|B-IUPAC
E	456	457	|I-IUPAC
)	457	458	|I-IUPAC
-	458	459	|I-IUPAC
and	460	463	|O
(	464	465	|B-IUPAC
Z	465	466	|I-IUPAC
)	466	467	|I-IUPAC
-	467	468	|I-IUPAC
dibromocyclopropane	468	487	|I-IUPAC
carboxylic	488	498	|I-IUPAC
esters	499	505	|I-IUPAC
24	506	508	|O
+	509	510	|O
25	511	513	|O
.	513	514	|O
Alkylation	515	525	|O
of	526	528	|O
adenine	529	536	|O
(	537	538	|O
18	538	540	|O
)	540	541	|O
with	542	546	|O
24	547	549	|O
+	550	551	|O
25	552	554	|O
gave	555	559	|O
(	560	561	|O
E	561	562	|O
)	562	563	|O
-	563	564	|O
and	565	568	|O
(	569	570	|O
Z	570	571	|O
)	571	572	|O
-	572	573	|O
bromo	573	578	|O
derivatives	579	590	|O
21	591	593	|O
+	594	595	|O
22	596	598	|O
.	598	599	|O
Base	600	604	|O
-	604	605	|O
catalyzed	605	614	|O
elimination	615	626	|O
of	627	629	|O
HBr	630	633	|O
resulted	634	642	|O
in	643	645	|O
the	646	649	|O
formation	650	659	|O
of	660	662	|O
(	663	664	|B-PARTIUPAC
Z	664	665	|I-PARTIUPAC
)	665	666	|I-PARTIUPAC
-	666	667	|I-PARTIUPAC
and	668	671	|O
(	672	673	|B-IUPAC
E	673	674	|I-IUPAC
)	674	675	|I-IUPAC
-	675	676	|I-IUPAC
methylenecyclopropanecarboxylic	676	707	|I-IUPAC
esters	708	714	|I-IUPAC
26	715	717	|O
+	718	719	|O
27	720	722	|O
.	722	723	|O
More	724	728	|O
convenient	729	739	|O
one	740	743	|O
-	743	744	|O
pot	744	747	|O
alkylation	748	758	|O
-	758	759	|O
elimination	759	770	|O
of	771	773	|O
adenine	774	781	|O
(	782	783	|O
18	783	785	|O
)	785	786	|O
or	787	789	|O
2	790	791	|B-IUPAC
-	791	792	|I-IUPAC
amino	792	797	|I-IUPAC
-	797	798	|I-IUPAC
6	798	799	|I-IUPAC
-	799	800	|I-IUPAC
chloropurine	800	812	|I-IUPAC
(	813	814	|O
30	814	816	|O
)	816	817	|O
with	818	822	|O
24	823	825	|O
+	826	827	|O
25	828	830	|O
afforded	831	839	|O
(	840	841	|B-PARTIUPAC
Z	841	842	|I-PARTIUPAC
)	842	843	|I-PARTIUPAC
-	843	844	|I-PARTIUPAC
and	845	848	|O
(	849	850	|B-IUPAC
E	850	851	|I-IUPAC
)	851	852	|I-IUPAC
-	852	853	|I-IUPAC
methylenecyclopropane	853	874	|I-IUPAC
derivatives	875	886	|B-MODIFIER
26	887	889	|O
+	890	891	|O
27	892	894	|O
and	895	898	|O
31	899	901	|O
+	902	903	|O
32	904	906	|O
.	906	907	|O
The	908	911	|O
Z	912	913	|O
-	913	914	|O
isomers	914	921	|O
were	922	926	|O
always	927	933	|O
predominant	934	945	|O
in	946	948	|O
these	949	954	|O
mixtures	955	963	|O
(	964	965	|O
Z	965	966	|O
/	966	967	|O
E	967	968	|O
approximately	969	982	|O
2/1	983	986	|O
)	986	987	|O
.	987	988	|O
Reduction	989	998	|O
of	999	1001	|O
26	1002	1004	|O
+	1005	1006	|O
27	1007	1009	|O
and	1010	1013	|O
31	1014	1016	|O
+	1017	1018	|O
32	1019	1021	|O
with	1022	1026	|O
DIBALH	1027	1033	|O
afforded	1034	1042	|O
(	1043	1044	|B-PARTIUPAC
Z	1044	1045	|I-PARTIUPAC
)	1045	1046	|I-PARTIUPAC
-	1046	1047	|I-PARTIUPAC
and	1048	1051	|O
(	1052	1053	|B-IUPAC
E	1053	1054	|I-IUPAC
)	1054	1055	|I-IUPAC
-	1055	1056	|I-IUPAC
methylenecyclopropane	1056	1077	|I-IUPAC
alcohols	1078	1086	|I-IUPAC
14	1087	1089	|O
+	1090	1091	|O
16	1092	1094	|O
and	1095	1098	|O
33	1099	1101	|O
+	1102	1103	|O
34	1104	1106	|O
.	1106	1107	|O
The	1108	1111	|O
latter	1112	1118	|O
were	1119	1123	|O
resolved	1124	1132	|O
directly	1133	1141	|O
by	1142	1144	|O
chromatography	1145	1159	|O
.	1159	1160	|O
Compounds	1161	1170	|O
14	1171	1173	|O
+	1174	1175	|O
16	1176	1178	|O
were	1179	1183	|O
converted	1184	1193	|O
to	1194	1196	|O
N6	1197	1199	|B-IUPAC
-	1199	1200	|I-IUPAC
(	1200	1201	|I-IUPAC
dimethylamino	1201	1214	|I-IUPAC
)	1214	1215	|I-IUPAC
methylene	1215	1224	|I-IUPAC
derivatives	1225	1236	|B-MODIFIER
28	1237	1239	|O
and	1240	1243	|O
29	1244	1246	|O
which	1247	1252	|O
were	1253	1257	|O
separated	1258	1267	|O
and	1268	1271	|O
deprotected	1272	1283	|O
to	1284	1286	|O
give	1287	1291	|O
14	1292	1294	|O
and	1295	1298	|O
16	1299	1301	|O
.	1301	1302	|O
Reaction	1303	1311	|O
of	1312	1314	|O
33	1315	1317	|O
and	1318	1321	|O
34	1322	1324	|O
with	1325	1329	|O
HCO2H	1330	1335	|O
led	1336	1339	|O
to	1340	1342	|O
guanine	1343	1350	|O
analogues	1351	1360	|O
15	1361	1363	|O
and	1364	1367	|O
17	1368	1370	|O
.	1370	1371	|O
The	1372	1375	|O
1H	1376	1378	|O
NMR	1379	1382	|O
spectra	1383	1390	|O
of	1391	1393	|O
the	1394	1397	|O
Z	1398	1399	|O
-	1399	1400	|O
analogues	1400	1409	|O
14	1410	1412	|O
and	1413	1416	|O
15	1417	1419	|O
are	1420	1423	|O
consistent	1424	1434	|O
with	1435	1439	|O
an	1440	1442	|O
anti	1443	1447	|O
-	1447	1448	|O
like	1448	1452	|O
conformation	1453	1465	|O
of	1466	1468	|O
the	1469	1472	|O
nucleobases	1473	1484	|O
.	1484	1485	|O
By	1486	1488	|O
contrast	1489	1497	|O
,	1497	1498	|O
1H	1499	1501	|O
NMR	1502	1505	|O
and	1506	1509	|O
IR	1510	1512	|O
spectra	1513	1520	|O
of	1521	1523	|O
bromo	1524	1529	|O
ester	1530	1535	|O
21	1536	1538	|O
are	1539	1542	|O
indicative	1543	1553	|O
of	1554	1556	|O
syn	1557	1560	|O
-	1560	1561	|O
conformation	1561	1573	|O
of	1574	1576	|O
adenine	1577	1584	|O
.	1584	1585	|O
Several	1586	1593	|O
Z	1594	1595	|B-IUPAC
-	1595	1596	|I-IUPAC
(	1596	1597	|I-IUPAC
hydroxymethyl	1597	1610	|I-IUPAC
)	1610	1611	|I-IUPAC
methylenecyclopropanes	1611	1633	|I-IUPAC
exhibited	1634	1643	|O
in	1644	1646	|O
vitro	1647	1652	|O
antiviral	1653	1662	|O
activity	1663	1671	|O
in	1672	1674	|O
micromolar	1675	1685	|O
or	1686	1688	|O
submicromolar	1689	1702	|O
range	1703	1708	|O
against	1709	1716	|O
human	1717	1722	|O
and	1723	1726	|O
murine	1727	1733	|O
cytomegalovirus	1734	1749	|O
(	1750	1751	|O
HCMV	1751	1755	|O
and	1756	1759	|O
MCMV	1760	1764	|O
)	1764	1765	|O
,	1765	1766	|O
Epstein	1767	1774	|O
-	1774	1775	|O
Barr	1775	1779	|O
virus	1780	1785	|O
(	1786	1787	|O
EBV	1787	1790	|O
)	1790	1791	|O
,	1791	1792	|O
human	1793	1798	|O
herpes	1799	1805	|O
virus	1806	1811	|O
6	1812	1813	|O
(	1814	1815	|O
HHV	1815	1818	|O
-	1818	1819	|O
6	1819	1820	|O
)	1820	1821	|O
,	1821	1822	|O
varicella	1823	1832	|O
zoster	1833	1839	|O
virus	1840	1845	|O
(	1846	1847	|O
VZV	1847	1850	|O
)	1850	1851	|O
,	1851	1852	|O
and	1853	1856	|O
hepatitis	1857	1866	|O
B	1867	1868	|O
virus	1869	1874	|O
(	1875	1876	|O
HBV	1876	1879	|O
)	1879	1880	|O
.	1880	1881	|O
Analogues	1882	1891	|O
14	1892	1894	|O
,	1894	1895	|O
15	1896	1898	|O
,	1898	1899	|O
and	1900	1903	|O
33	1904	1906	|O
were	1907	1911	|O
the	1912	1915	|O
most	1916	1920	|O
effective	1921	1930	|O
agents	1931	1937	|O
against	1938	1945	|O
HCMV	1946	1950	|O
(	1951	1952	|O
IC50	1952	1956	|O
1-2.1	1957	1962	|O
,	1962	1963	|O
0.04-2.1	1964	1972	|O
,	1972	1973	|O
and	1974	1977	|O
0.8-5.6	1978	1985	|O
microM	1986	1992	|O
)	1992	1993	|O
,	1993	1994	|O
MCMV	1995	1999	|O
(	2000	2001	|O
IC50	2001	2005	|O
2.1	2006	2009	|O
,	2009	2010	|O
0.3	2011	2014	|O
,	2014	2015	|O
and	2016	2019	|O
0.3	2020	2023	|O
microM	2024	2030	|O
)	2030	2031	|O
and	2032	2035	|O
EBV	2036	2039	|O
in	2040	2042	|O
H	2043	2044	|O
-	2044	2045	|O
1	2045	2046	|O
(	2047	2048	|O
IC50	2048	2052	|O
0.2	2053	2056	|O
,	2056	2057	|O
0.3	2058	2061	|O
,	2061	2062	|O
and	2063	2066	|O
0.7	2067	2070	|O
microM	2071	2077	|O
)	2077	2078	|O
and	2079	2082	|O
Daudi	2083	2088	|O
cells	2089	2094	|O
(	2095	2096	|O
IC50	2096	2100	|O
3.2	2101	2104	|O
,	2104	2105	|O
5.6	2106	2109	|O
,	2109	2110	|O
and	2111	2114	|O
1.2	2115	2118	|O
microM	2119	2125	|O
)	2125	2126	|O
.	2126	2127	|O
Adenine	2128	2135	|O
analogue	2136	2144	|O
14	2145	2147	|O
was	2148	2151	|O
active	2152	2158	|O
against	2159	2166	|O
HBV	2167	2170	|O
(	2171	2172	|O
IC50	2172	2176	|O
2	2177	2178	|O
microM	2179	2185	|O
)	2185	2186	|O
,	2186	2187	|O
VZV	2188	2191	|O
(	2192	2193	|O
IC50	2193	2197	|O
2.5	2198	2201	|O
microM	2202	2208	|O
)	2208	2209	|O
,	2209	2210	|O
and	2211	2214	|O
HHV	2215	2218	|O
-	2218	2219	|O
6	2219	2220	|O
(	2221	2222	|O
IC50	2222	2226	|O
14	2227	2229	|O
microM	2230	2236	|O
)	2236	2237	|O
.	2237	2238	|O
Synadenol	2239	2248	|O
(	2249	2250	|O
14	2250	2252	|O
)	2252	2253	|O
and	2254	2257	|O
the	2258	2261	|O
E	2262	2263	|O
-	2263	2264	|O
isomer	2264	2270	|O
(	2271	2272	|O
16	2272	2274	|O
)	2274	2275	|O
were	2276	2280	|O
substrates	2281	2291	|O
of	2292	2294	|O
moderate	2295	2303	|O
efficiency	2304	2314	|O
for	2315	2318	|O
adenosine	2319	2328	|O
deaminase	2329	2338	|O
from	2339	2343	|O
calf	2344	2348	|O
intestine	2349	2358	|O
.	2358	2359	|O
The	2360	2363	|O
E	2364	2365	|O
-	2365	2366	|O
isomer	2366	2372	|O
16	2373	2375	|O
was	2376	2379	|O
more	2380	2384	|O
reactive	2385	2393	|O
than	2394	2398	|O
Z	2399	2400	|O
-	2400	2401	|O
isomer	2401	2407	|O
14	2408	2410	|O
.	2410	2411	|O
The	2412	2415	|O
deamination	2416	2427	|O
of	2428	2430	|O
14	2431	2433	|O
effectively	2434	2445	|O
stopped	2446	2453	|O
at	2454	2456	|O
50%	2457	2460	|O
conversion	2461	2471	|O
.	2471	2472	|O
Synadenol	2473	2482	|O
(	2483	2484	|O
14	2484	2486	|O
)	2486	2487	|O
was	2488	2491	|O
also	2492	2496	|O
deaminated	2497	2507	|O
by	2508	2510	|O
AMP	2511	2514	|O
deaminase	2515	2524	|O
from	2525	2529	|O
aspergillus	2530	2541	|O
sp	2542	2544	|O
.	2544	2545	|O

### abstracts439.txt
We	0	2	|O
have	3	7	|O
previously	8	18	|O
reported	19	27	|O
that	28	32	|O
a	33	34	|O
series	35	41	|O
of	42	44	|O
4	45	46	|B-IUPAC
-	46	47	|I-IUPAC
[	47	48	|I-IUPAC
4	48	49	|I-IUPAC
-	49	50	|I-IUPAC
(	50	51	|I-IUPAC
N	51	52	|I-IUPAC
-	52	53	|I-IUPAC
substituted	53	64	|I-IUPAC
(	65	66	|I-IUPAC
thio	66	70	|I-IUPAC
)	70	71	|I-IUPAC
carbamoyl	71	80	|I-IUPAC
)	80	81	|I-IUPAC
-	81	82	|I-IUPAC
1	82	83	|I-IUPAC
-	83	84	|I-IUPAC
piperazinyl	84	95	|I-IUPAC
]	95	96	|I-IUPAC
-	96	97	|I-IUPAC
6,7	97	100	|I-IUPAC
-	100	101	|I-IUPAC
dimethoxyquinazoline	101	121	|I-IUPAC
derivatives	122	133	|B-MODIFIER
were	134	138	|O
potent	139	145	|O
and	146	149	|O
selective	150	159	|O
inhibitors	160	170	|O
of	171	173	|O
platelet	174	182	|O
-	182	183	|O
derived	183	190	|O
growth	191	197	|O
factor	198	204	|O
receptor	205	213	|O
(	214	215	|O
PDGFR	215	220	|O
)	220	221	|O
phosphorylation	222	237	|O
and	238	241	|O
demonstrated	242	254	|O
several	255	262	|O
biological	263	273	|O
effects	274	281	|O
such	282	286	|O
as	287	289	|O
suppression	290	301	|O
of	302	304	|O
neointima	305	314	|O
formation	315	324	|O
following	325	334	|O
balloon	335	342	|O
injury	343	349	|O
in	350	352	|O
rat	353	356	|O
carotid	357	364	|O
artery	365	371	|O
by	372	374	|O
oral	375	379	|O
administration	380	394	|O
.	394	395	|O
Here	396	400	|O
,	400	401	|O
we	402	404	|O
investigated	405	417	|O
structure	418	427	|O
-	427	428	|O
activity	428	436	|O
relationships	437	450	|O
of	451	453	|O
the	454	457	|O
6,7	458	461	|B-IUPAC
-	461	462	|I-IUPAC
dimethoxyquinazolinyl	462	483	|I-IUPAC
moiety	484	490	|B-MODIFIER
.	490	491	|O
In	492	494	|O
regard	495	501	|O
to	502	504	|O
6,7	505	508	|B-IUPAC
-	508	509	|I-IUPAC
dimethoxy	509	518	|I-IUPAC
groups	519	525	|B-MODIFIER
,	525	526	|O
ethoxy	527	533	|O
analogues	534	543	|O
showed	544	550	|O
potent	551	557	|O
activity	558	566	|O
(	567	568	|O
IC	568	570	|O
(	570	571	|O
50	571	573	|O
)	573	574	|O
of	575	577	|O
16b	578	581	|O
is	582	584	|O
0.04	585	589	|O
microM	590	596	|O
;	596	597	|O
IC	598	600	|O
(	600	601	|O
50	601	603	|O
)	603	604	|O
of	605	607	|O
17a	608	611	|O
is	612	614	|O
0.01	615	619	|O
microM	620	626	|O
)	626	627	|O
and	628	631	|O
further	632	639	|O
extension	640	649	|O
of	650	652	|O
the	653	656	|O
alkyl	657	662	|O
group	663	668	|O
reduced	669	676	|O
activity	677	685	|O
.	685	686	|O
Interestingly	687	700	|O
,	700	701	|O
methoxyethoxy	702	715	|O
(	716	717	|O
IC	717	719	|O
(	719	720	|O
50	720	722	|O
)	722	723	|O
of	724	726	|O
16j	727	730	|O
is	731	733	|O
0.02	734	738	|O
microM	739	745	|O
;	745	746	|O
IC	747	749	|O
(	749	750	|O
50	750	752	|O
)	752	753	|O
of	754	756	|O
17h	757	760	|O
is	761	763	|O
0.01	764	768	|O
microM	769	775	|O
)	775	776	|O
and	777	780	|O
ethoxyethoxy	781	793	|O
(	794	795	|O
IC	795	797	|O
(	797	798	|O
50	798	800	|O
)	800	801	|O
of	802	804	|O
17j	805	808	|O
is	809	811	|O
0.02	812	816	|O
micro	817	822	|O
M	823	824	|O
)	824	825	|O
analogues	826	835	|O
showed	836	842	|O
the	843	846	|O
most	847	851	|O
potent	852	858	|O
activity	859	867	|O
,	867	868	|O
suggesting	869	879	|O
that	880	884	|O
the	885	888	|O
inserted	889	897	|O
oxygen	898	904	|O
atom	905	909	|O
significantly	910	923	|O
interacts	924	933	|O
with	934	938	|O
beta	939	943	|O
-	943	944	|O
PDGFR	944	949	|O
.	949	950	|O
Among	951	956	|O
tricyclic	957	966	|O
quinazoline	967	978	|O
derivatives	979	990	|O
,	990	991	|O
the	992	995	|O
2	996	997	|B-IUPAC
-	997	998	|I-IUPAC
oxoimidazo	998	1008	|I-IUPAC
[	1008	1009	|I-IUPAC
4,5	1009	1012	|I-IUPAC
-	1012	1013	|I-IUPAC
e	1013	1014	|I-IUPAC
]	1014	1015	|I-IUPAC
quinazoline	1015	1026	|I-IUPAC
derivative	1027	1037	|B-MODIFIER
21a	1038	1041	|O
showed	1042	1048	|O
potent	1049	1055	|O
activity	1056	1064	|O
(	1065	1066	|O
IC	1066	1068	|O
(	1068	1069	|O
50	1069	1071	|O
)	1071	1072	|O
=	1073	1074	|O
0.10	1075	1079	|O
microM	1080	1086	|O
)	1086	1087	|O
.	1087	1088	|O
Regarding	1089	1098	|O
replacements	1099	1111	|O
of	1112	1114	|O
quinazoline	1115	1126	|O
by	1127	1129	|O
other	1130	1135	|O
heterocyclic	1136	1148	|O
rings	1149	1154	|O
,	1154	1155	|O
pyrazolo	1156	1164	|B-IUPAC
[	1164	1165	|I-IUPAC
3,4	1165	1168	|I-IUPAC
-	1168	1169	|I-IUPAC
d	1169	1170	|I-IUPAC
]	1170	1171	|I-IUPAC
pyrimidine	1171	1181	|I-IUPAC
(	1182	1183	|O
39a	1183	1186	|O
,	1186	1187	|O
IC	1188	1190	|O
(	1190	1191	|O
50	1191	1193	|O
)	1193	1194	|O
=	1195	1196	|O
0.17	1197	1201	|O
microM	1202	1208	|O
)	1208	1209	|O
and	1210	1213	|O
quinoline	1214	1223	|O
(	1224	1225	|O
IC	1225	1227	|O
(	1227	1228	|O
50	1228	1230	|O
)	1230	1231	|O
of	1232	1234	|O
40a	1235	1238	|O
is	1239	1241	|O
0.18	1242	1246	|O
microM	1247	1253	|O
;	1253	1254	|O
IC	1255	1257	|O
(	1257	1258	|O
50	1258	1260	|O
)	1260	1261	|O
of	1262	1264	|O
40b	1265	1268	|O
is	1269	1271	|O
0.09	1272	1276	|O
microM	1277	1283	|O
)	1283	1284	|O
derivatives	1285	1296	|O
showed	1297	1303	|O
potent	1304	1310	|O
activity	1311	1319	|O
.	1319	1320	|O
Isoquinoline	1321	1333	|O
and	1334	1337	|O
some	1338	1342	|O
pyridopyrimidine	1343	1359	|O
derivatives	1360	1371	|O
were	1372	1376	|O
completely	1377	1387	|O
inactive	1388	1396	|O
;	1396	1397	|O
therefore	1398	1407	|O
,	1407	1408	|O
1	1409	1410	|B-IUPAC
-	1410	1411	|I-IUPAC
aza	1411	1414	|I-IUPAC
has	1415	1418	|O
an	1419	1421	|O
important	1422	1431	|O
role	1432	1436	|O
.	1436	1437	|O
Also	1438	1442	|O
7	1443	1444	|B-IUPAC
-	1444	1445	|I-IUPAC
aza	1445	1448	|I-IUPAC
and	1449	1452	|O
8	1453	1454	|B-IUPAC
-	1454	1455	|I-IUPAC
aza	1455	1458	|I-IUPAC
substitution	1459	1471	|B-MODIFIER
on	1472	1474	|O
the	1475	1478	|O
parent	1479	1485	|O
quinazoline	1486	1497	|O
ring	1498	1502	|O
has	1503	1506	|O
a	1507	1508	|O
detrimental	1509	1520	|O
effect	1521	1527	|O
on	1528	1530	|O
the	1531	1534	|O
interaction	1535	1546	|O
with	1547	1551	|O
beta	1552	1556	|O
-	1556	1557	|O
PDGFR	1557	1562	|O
.	1562	1563	|O
We	1564	1566	|O
also	1567	1571	|O
demonstrated	1572	1584	|O
that	1585	1589	|O
the	1590	1593	|O
substituents	1594	1606	|O
on	1607	1609	|O
the	1610	1613	|O
quinazoline	1614	1625	|O
ring	1626	1630	|O
possess	1631	1638	|O
major	1639	1644	|O
consequences	1645	1657	|O
for	1658	1661	|O
metabolic	1662	1671	|O
polymorphism	1672	1684	|O
.	1684	1685	|O
Although	1686	1694	|O
there	1695	1700	|O
existed	1701	1708	|O
extensive	1709	1718	|O
metabolizers	1719	1731	|O
and	1732	1735	|O
poor	1736	1740	|O
metabolizers	1741	1753	|O
in	1754	1756	|O
Sprague	1757	1764	|O
-	1764	1765	|O
Dawley	1765	1771	|O
rats	1772	1776	|O
administrated	1777	1790	|O
6,7	1791	1794	|B-IUPAC
-	1794	1795	|I-IUPAC
dimethoxyquinazoline	1795	1815	|I-IUPAC
derivatives	1816	1827	|B-MODIFIER
(	1828	1829	|O
1b	1829	1831	|O
and	1832	1835	|O
1c	1836	1838	|O
)	1838	1839	|O
,	1839	1840	|O
6	1841	1842	|B-IUPAC
-	1842	1843	|I-IUPAC
(	1843	1844	|I-IUPAC
2	1844	1845	|I-IUPAC
-	1845	1846	|I-IUPAC
methoxy	1846	1853	|I-IUPAC
)	1853	1854	|I-IUPAC
ethoxy	1854	1860	|I-IUPAC
-	1860	1861	|I-IUPAC
7	1861	1862	|I-IUPAC
-	1862	1863	|I-IUPAC
methoxyquinazoline	1863	1881	|I-IUPAC
analogue	1882	1890	|B-MODIFIER
16k	1891	1894	|O
showed	1895	1901	|O
no	1902	1904	|O
metabolic	1905	1914	|O
polymorphism	1915	1927	|O
.	1927	1928	|O

### abstracts1213.txt
The	0	3	|O
structure	4	13	|O
-	13	14	|O
activity	14	22	|O
relationships	23	36	|O
of	37	39	|O
two	40	43	|O
series	44	50	|O
of	51	53	|O
novel	54	59	|O
retinoids	60	69	|O
(	70	71	|O
2	71	72	|B-IUPAC
-	72	73	|I-IUPAC
pyrazinylcarboxamidobenzoates	73	102	|I-IUPAC
and	103	106	|O
beta	107	111	|B-IUPAC
-	111	112	|I-IUPAC
ionylideneacetamidobenzoates	112	140	|I-IUPAC
)	140	141	|O
have	142	146	|O
been	147	151	|O
investigated	152	164	|O
by	165	167	|O
evaluating	168	178	|O
their	179	184	|O
ability	185	192	|O
to	193	195	|O
induce	196	202	|O
differentiation	203	218	|O
in	219	221	|O
both	222	226	|O
human	227	232	|O
promyelocytic	233	246	|O
leukemia	247	255	|O
(	256	257	|O
HL60	257	261	|O
)	261	262	|O
cells	263	268	|O
and	269	272	|O
mouse	273	278	|O
embryonal	279	288	|O
carcinoma	289	298	|O
(	299	300	|O
P19	300	303	|O
)	303	304	|O
cells	305	310	|O
.	310	311	|O
The	312	315	|O
most	316	320	|O
active	321	327	|O
compound	328	336	|O
(	337	338	|O
ED50	338	342	|O
=	343	344	|O
8.3	345	348	|O
x	349	350	|O
10	351	353	|O
(	353	354	|O
-	354	355	|O
9	355	356	|O
)	356	357	|O
M	358	359	|O
)	359	360	|O
of	361	363	|O
the	364	367	|O
2	368	369	|B-IUPAC
-	369	370	|I-IUPAC
pyrazinylcarboxamidobenzoates	370	399	|I-IUPAC
is	400	402	|O
4	403	404	|B-IUPAC
-	404	405	|I-IUPAC
[	405	406	|I-IUPAC
2	406	407	|I-IUPAC
-	407	408	|I-IUPAC
(	408	409	|I-IUPAC
5,6,7,8	409	416	|I-IUPAC
-	416	417	|I-IUPAC
tetrahydro	417	427	|I-IUPAC
-	427	428	|I-IUPAC
5,5,8	428	433	|I-IUPAC
,	433	434	|I-IUPAC
8	435	436	|I-IUPAC
-	436	437	|I-IUPAC
tetramethylquinoxalyl	437	458	|I-IUPAC
)	458	459	|I-IUPAC
carboxamido	459	470	|I-IUPAC
]	470	471	|I-IUPAC
benzoic	471	478	|I-IUPAC
acid	479	483	|I-IUPAC
(	484	485	|O
9u	485	487	|O
)	487	488	|O
,	488	489	|O
while	490	495	|O
the	496	499	|O
most	500	504	|O
active	505	511	|O
analogue	512	520	|O
of	521	523	|O
the	524	527	|O
beta	528	532	|O
-	532	533	|O
ionylideneacetamidobenzoates	533	561	|O
is	562	564	|O
4	565	566	|B-IUPAC
-	566	567	|I-IUPAC
[	567	568	|I-IUPAC
3	568	569	|I-IUPAC
-	569	570	|I-IUPAC
methyl	570	576	|I-IUPAC
-	576	577	|I-IUPAC
5	577	578	|I-IUPAC
-	578	579	|I-IUPAC
(	579	580	|I-IUPAC
2'	580	582	|I-IUPAC
,	582	583	|I-IUPAC
6'	583	585	|I-IUPAC
,	585	586	|I-IUPAC
6'	586	588	|I-IUPAC
-	588	589	|I-IUPAC
trimethyl	589	598	|I-IUPAC
-	598	599	|I-IUPAC
1'	599	601	|I-IUPAC
-	601	602	|I-IUPAC
cyclohexen	602	612	|I-IUPAC
-	612	613	|I-IUPAC
1'	613	615	|I-IUPAC
-	615	616	|I-IUPAC
yl	616	618	|I-IUPAC
)	618	619	|I-IUPAC
-	619	620	|I-IUPAC
(	620	621	|I-IUPAC
2E	621	623	|I-IUPAC
,	623	624	|I-IUPAC
4E	625	627	|I-IUPAC
)	627	628	|I-IUPAC
-	628	629	|I-IUPAC
pentadienamido	629	643	|I-IUPAC
]	643	644	|I-IUPAC
benzoic	644	651	|I-IUPAC
acid	652	656	|I-IUPAC
(	657	658	|O
10a	658	661	|O
,	661	662	|O
ED50	663	667	|O
=	668	669	|O
3.2	670	673	|O
x	674	675	|O
10	676	678	|O
(	678	679	|O
-	679	680	|O
8	680	681	|O
)	681	682	|O
M	683	684	|O
)	684	685	|O
.	685	686	|O
Our	687	690	|O
studies	691	698	|O
identify	699	707	|O
an	708	710	|O
absolute	711	719	|O
requirement	720	731	|O
for	732	735	|O
the	736	739	|O
carboxylic	740	750	|O
acid	751	755	|O
moiety	756	762	|O
on	763	765	|O
the	766	769	|O
aromatic	770	778	|O
ring	779	783	|O
to	784	786	|O
be	787	789	|O
para	790	794	|O
relative	795	803	|O
to	804	806	|O
the	807	810	|O
amide	811	816	|O
linkage	817	824	|O
for	825	828	|O
activity	829	837	|O
.	837	838	|O
Benzoate	839	847	|O
substitutions	848	861	|O
in	862	864	|O
the	865	868	|O
ortho	869	874	|O
position	875	883	|O
relative	884	892	|O
to	893	895	|O
the	896	899	|O
terminal	900	908	|O
carboxylate	909	920	|O
(	921	922	|O
9d	922	924	|O
,	924	925	|O
k	925	926	|O
,	926	927	|O
r	927	928	|O
)	928	929	|O
are	930	933	|O
well	934	938	|O
-	938	939	|O
tolerated	939	948	|O
;	948	949	|O
however	950	957	|O
,	957	958	|O
a	959	960	|O
methoxy	961	968	|O
substituent	969	980	|O
meta	981	985	|O
relative	986	994	|O
to	995	997	|O
the	998	1001	|O
terminal	1002	1010	|O
carboxylate	1011	1022	|O
gives	1023	1028	|O
rise	1029	1033	|O
to	1034	1036	|O
only	1037	1041	|O
weakly	1042	1048	|O
active	1049	1055	|O
analogues	1056	1065	|O
(	1066	1067	|O
9x	1067	1069	|O
)	1069	1070	|O
.	1070	1071	|O
Conformational	1072	1086	|O
studies	1087	1094	|O
(	1095	1096	|O
NMR	1096	1099	|O
,	1099	1100	|O
X	1101	1102	|O
-	1102	1103	|O
ray	1103	1106	|O
crystallography	1107	1122	|O
)	1122	1123	|O
of	1124	1126	|O
the	1127	1130	|O
2	1131	1132	|B-IUPAC
-	1132	1133	|I-IUPAC
pyrazinylcarboxamidobenzoates	1133	1162	|I-IUPAC
indicate	1163	1171	|O
that	1172	1176	|O
the	1177	1180	|O
preferred	1181	1190	|O
conformation	1191	1203	|O
exhibits	1204	1212	|O
a	1213	1214	|O
trans	1215	1220	|O
-	1220	1221	|O
amide	1221	1226	|O
bond	1227	1231	|O
and	1232	1235	|O
an	1236	1238	|O
internal	1239	1247	|O
hydrogen	1248	1256	|O
bond	1257	1261	|O
between	1262	1269	|O
the	1270	1273	|O
quinoxaline	1274	1285	|O
N1	1286	1288	|O
and	1289	1292	|O
HN	1293	1295	|O
amide	1296	1301	|O
which	1302	1307	|O
locks	1308	1313	|O
the	1314	1317	|O
torsional	1318	1327	|O
angle	1328	1333	|O
between	1334	1341	|O
C2	1342	1344	|O
and	1345	1348	|O
CO	1349	1351	|O
in	1352	1354	|O
the	1355	1358	|O
s	1359	1360	|O
-	1360	1361	|O
trans	1361	1366	|O
conformation	1367	1379	|O
.	1379	1380	|O
N	1381	1382	|O
-	1382	1383	|O
Methylation	1383	1394	|O
(	1395	1396	|O
9y	1396	1398	|O
)	1398	1399	|O
results	1400	1407	|O
in	1408	1410	|O
loss	1411	1415	|O
of	1416	1418	|O
activity	1419	1427	|O
.	1427	1428	|O
Studies	1429	1436	|O
indicate	1437	1445	|O
that	1446	1450	|O
there	1451	1456	|O
is	1457	1459	|O
now	1460	1463	|O
a	1464	1465	|O
cis	1466	1469	|O
-	1469	1470	|O
amide	1470	1475	|O
bond	1476	1480	|O
present	1481	1488	|O
which	1489	1494	|O
redirects	1495	1504	|O
the	1505	1508	|O
carboxylate	1509	1520	|O
toward	1521	1527	|O
the	1528	1531	|O
pharmacophoric	1532	1546	|O
gem	1547	1550	|O
-	1550	1551	|O
dimethyl	1551	1559	|O
groups	1560	1566	|O
.	1566	1567	|O
The	1568	1571	|O
distance	1572	1580	|O
between	1581	1588	|O
the	1589	1592	|O
gem	1593	1596	|O
-	1596	1597	|O
dimethyl	1597	1605	|O
group	1606	1611	|O
and	1612	1615	|O
the	1616	1619	|O
terminal	1620	1628	|O
carboxylate	1629	1640	|O
appears	1641	1648	|O
to	1649	1651	|O
be	1652	1654	|O
too	1655	1658	|O
short	1659	1664	|O
to	1665	1667	|O
activate	1668	1676	|O
the	1677	1680	|O
retinoid	1681	1689	|O
receptor	1690	1698	|O
.	1698	1699	|O
N	1700	1701	|O
-	1701	1702	|O
Methylation	1702	1713	|O
in	1714	1716	|O
the	1717	1720	|O
beta	1721	1725	|B-IUPAC
-	1725	1726	|I-IUPAC
ionylideneacetamidobenzoate	1726	1753	|I-IUPAC
series	1754	1760	|B-MODIFIER
(	1761	1762	|O
10c	1762	1765	|O
)	1765	1766	|O
also	1767	1771	|O
results	1772	1779	|O
in	1780	1782	|O
the	1783	1786	|O
formation	1787	1796	|O
of	1797	1799	|O
a	1800	1801	|O
cis	1802	1805	|O
-	1805	1806	|O
amide	1806	1811	|O
bond	1812	1816	|O
and	1817	1820	|O
loss	1821	1825	|O
of	1826	1828	|O
activity	1829	1837	|O
.	1837	1838	|O

### abstracts3049.txt
Examination	0	11	|O
of	12	14	|O
the	15	18	|O
PTP1B	19	24	|O
inhibitory	25	35	|O
potency	36	43	|O
of	44	46	|O
an	47	49	|O
extensive	50	59	|O
series	60	66	|O
of	67	69	|O
phosphotyrosyl	70	84	|B-IUPAC
(	85	86	|O
pTyr	86	90	|O
)	90	91	|O
mimetics	92	100	|B-MODIFIER
(	101	102	|O
Xxx	102	105	|O
)	105	106	|O
expressed	107	116	|O
in	117	119	|O
the	120	123	|O
EGFr	124	128	|O
-	128	129	|O
derived	129	136	|O
hexapeptide	137	148	|O
platform	149	157	|O
Ac	158	160	|O
-	160	161	|O
Asp	161	164	|O
-	164	165	|O
Ala	165	168	|O
-	168	169	|O
Asp	169	172	|O
-	172	173	|O
Xxx	173	176	|O
-	176	177	|O
Leu	177	180	|O
-	180	181	|O
amide	181	186	|O
previously	187	197	|O
led	198	201	|O
to	202	204	|O
the	205	208	|O
finding	209	216	|O
of	217	219	|O
high	220	224	|O
inhibitory	225	235	|O
potency	236	243	|O
when	244	248	|O
Xxx	249	252	|O
=	253	254	|O
4	255	256	|B-IUPAC
-	256	257	|I-IUPAC
(	257	258	|I-IUPAC
phosphonodifluoromethyl	258	281	|I-IUPAC
)	281	282	|I-IUPAC
phenylalanyl	282	294	|I-IUPAC
(	295	296	|O
F2Pmp	296	301	|O
)	301	302	|O
(	303	304	|O
K	304	305	|O
(	305	306	|O
i	306	307	|O
)	307	308	|O
=	309	310	|O
0.2	311	314	|O
microM	315	321	|O
)	321	322	|O
and	323	326	|O
when	327	331	|O
Xxx	332	335	|O
=	336	337	|O
3	338	339	|B-IUPAC
-	339	340	|I-IUPAC
carboxy	340	347	|I-IUPAC
-	347	348	|I-IUPAC
4	348	349	|I-IUPAC
-	349	350	|I-IUPAC
carboxymethyloxyphenylalanyl	350	378	|I-IUPAC
(	379	380	|O
K	380	381	|O
(	381	382	|O
i	382	383	|O
)	383	384	|O
=	385	386	|O
3.6	387	390	|O
microM	391	397	|O
)	397	398	|O
.	398	399	|O
In	400	402	|O
the	403	406	|O
first	407	412	|O
instance	413	421	|O
,	421	422	|O
further	423	430	|O
work	431	435	|O
led	436	439	|O
from	440	444	|O
the	445	448	|O
F2Pmp	449	454	|O
-	454	455	|O
containing	455	465	|O
peptide	466	473	|O
to	474	476	|O
monomeric	477	486	|O
inhibitor	487	496	|O
,	496	497	|O
6	498	499	|B-IUPAC
-	499	500	|I-IUPAC
(	500	501	|I-IUPAC
phosphonodifluoromethyl	501	524	|I-IUPAC
)	524	525	|I-IUPAC
-	525	526	|I-IUPAC
2	526	527	|I-IUPAC
-	527	528	|I-IUPAC
naphthoic	528	537	|I-IUPAC
acid	538	542	|I-IUPAC
(	543	544	|O
K	544	545	|O
(	545	546	|O
i	546	547	|O
)	547	548	|O
=	549	550	|O
22	551	553	|O
microM	554	560	|O
)	560	561	|O
,	561	562	|O
and	563	566	|O
to	567	569	|O
the	570	573	|O
pseudo	574	580	|O
-	580	581	|O
dipeptide	581	590	|O
mimetic	591	598	|O
,	598	599	|O
N	600	601	|B-IUPAC
-	601	602	|I-IUPAC
[	602	603	|I-IUPAC
6	603	604	|I-IUPAC
-	604	605	|I-IUPAC
(	605	606	|I-IUPAC
phosphonodifluoromethyl	606	629	|I-IUPAC
)	629	630	|I-IUPAC
-	630	631	|I-IUPAC
2	631	632	|I-IUPAC
-	632	633	|I-IUPAC
naphthoyl	633	642	|I-IUPAC
]	642	643	|I-IUPAC
-	643	644	|I-IUPAC
glutamic	644	652	|I-IUPAC
acid	653	657	|I-IUPAC
(	658	659	|O
K	659	660	|O
(	660	661	|O
i	661	662	|O
)	662	663	|O
=	664	665	|O
12	666	668	|O
microM	669	675	|O
)	675	676	|O
.	676	677	|O
In	678	680	|O
the	681	684	|O
current	685	692	|O
study	693	698	|O
,	698	699	|O
a	700	701	|O
similar	702	709	|O
approach	710	718	|O
was	719	722	|O
applied	723	730	|O
to	731	733	|O
the	734	737	|O
3	738	739	|B-IUPAC
-	739	740	|I-IUPAC
carboxy	740	747	|I-IUPAC
-	747	748	|I-IUPAC
4	748	749	|I-IUPAC
-	749	750	|I-IUPAC
carboxymethyloxyphenylalanyl	750	778	|I-IUPAC
-	778	779	|O
containing	779	789	|O
peptide	790	797	|O
,	797	798	|O
which	799	804	|O
led	805	808	|O
to	809	811	|O
the	812	815	|O
preparation	816	827	|O
of	828	830	|O
monomeric	831	840	|O
5	841	842	|B-IUPAC
-	842	843	|I-IUPAC
carboxy	843	850	|I-IUPAC
-	850	851	|I-IUPAC
6	851	852	|I-IUPAC
-	852	853	|I-IUPAC
carboxymethyloxy	853	869	|I-IUPAC
-	869	870	|I-IUPAC
2	870	871	|I-IUPAC
-	871	872	|I-IUPAC
naphthoic	872	881	|I-IUPAC
acid	882	886	|I-IUPAC
(	887	888	|O
K	888	889	|O
(	889	890	|O
i	890	891	|O
)	891	892	|O
=	893	894	|O
900	895	898	|O
microM	899	905	|O
)	905	906	|O
.	906	907	|O
However	908	915	|O
,	915	916	|O
contrary	917	925	|O
to	926	928	|O
expectations	929	941	|O
based	942	947	|O
on	948	950	|O
the	951	954	|O
aforementioned	955	969	|O
F2Pmp	970	975	|O
work	976	980	|O
,	980	981	|O
incorporation	982	995	|O
of	996	998	|O
this	999	1003	|O
putative	1004	1012	|O
pTyr	1013	1017	|O
mimetic	1018	1025	|O
into	1026	1030	|O
the	1031	1034	|O
pseudo	1035	1041	|O
-	1041	1042	|O
dipeptide	1042	1051	|O
,	1051	1052	|O
N	1053	1054	|B-IUPAC
-	1054	1055	|I-IUPAC
[	1055	1056	|I-IUPAC
5	1056	1057	|I-IUPAC
-	1057	1058	|I-IUPAC
carboxy	1058	1065	|I-IUPAC
-	1065	1066	|I-IUPAC
6	1066	1067	|I-IUPAC
-	1067	1068	|I-IUPAC
carboxymethyloxy	1068	1084	|I-IUPAC
-	1084	1085	|I-IUPAC
2	1085	1086	|I-IUPAC
-	1086	1087	|I-IUPAC
naphthoyl	1087	1096	|I-IUPAC
]	1096	1097	|I-IUPAC
-	1097	1098	|I-IUPAC
glutamic	1098	1106	|I-IUPAC
acid	1107	1111	|I-IUPAC
,	1111	1112	|O
resulted	1113	1121	|O
in	1122	1124	|O
a	1125	1126	|O
substantial	1127	1138	|O
loss	1139	1143	|O
of	1144	1146	|O
binding	1147	1154	|O
affinity	1155	1163	|O
.	1163	1164	|O
A	1165	1166	|O
reevaluation	1167	1179	|O
of	1180	1182	|O
binding	1183	1190	|O
orientation	1191	1202	|O
for	1203	1206	|O
5	1207	1208	|B-IUPAC
-	1208	1209	|I-IUPAC
carboxy	1209	1216	|I-IUPAC
-	1216	1217	|I-IUPAC
6	1217	1218	|I-IUPAC
-	1218	1219	|I-IUPAC
carboxymethyloxy	1219	1235	|I-IUPAC
-	1235	1236	|I-IUPAC
2	1236	1237	|I-IUPAC
-	1237	1238	|I-IUPAC
naphthoic	1238	1247	|I-IUPAC
acid	1248	1252	|I-IUPAC
was	1253	1256	|O
therefore	1257	1266	|O
undertaken	1267	1277	|O
,	1277	1278	|O
which	1279	1284	|O
indicated	1285	1294	|O
a	1295	1296	|O
180	1297	1300	|O
degrees	1301	1308	|O
reversal	1309	1317	|O
of	1318	1320	|O
the	1321	1324	|O
binding	1325	1332	|O
orientation	1333	1344	|O
within	1345	1351	|O
the	1352	1355	|O
PTP1B	1356	1361	|O
catalytic	1362	1371	|O
site	1372	1376	|O
.	1376	1377	|O
In	1378	1380	|O
the	1381	1384	|O
new	1385	1388	|O
orientation	1389	1400	|O
,	1400	1401	|O
the	1402	1405	|O
naphthyl	1406	1414	|B-IUPAC
2	1415	1416	|I-IUPAC
-	1416	1417	|I-IUPAC
carboxyl	1417	1425	|I-IUPAC
group	1426	1431	|B-MODIFIER
,	1431	1432	|O
and	1433	1436	|O
not	1437	1440	|O
the	1441	1444	|O
o	1445	1446	|B-IUPAC
-	1446	1447	|I-IUPAC
carboxy	1447	1454	|I-IUPAC
carboxymethyloxy	1455	1471	|I-IUPAC
groups	1472	1478	|B-MODIFIER
,	1478	1479	|O
mimics	1480	1486	|O
a	1487	1488	|O
phosphoryl	1489	1499	|O
group	1500	1505	|O
.	1505	1506	|O
Indeed	1507	1513	|O
,	1513	1514	|O
when	1515	1519	|O
5	1520	1521	|B-IUPAC
-	1521	1522	|I-IUPAC
carboxy	1522	1529	|I-IUPAC
-	1529	1530	|I-IUPAC
2	1530	1531	|I-IUPAC
-	1531	1532	|I-IUPAC
naphthoic	1532	1541	|I-IUPAC
acid	1542	1546	|I-IUPAC
itself	1547	1553	|O
was	1554	1557	|O
examined	1558	1566	|O
at	1567	1569	|O
neutral	1570	1577	|O
pH	1578	1580	|O
for	1581	1584	|O
inhibitory	1585	1595	|O
potency	1596	1603	|O
,	1603	1604	|O
it	1605	1607	|O
was	1608	1611	|O
found	1612	1617	|O
to	1618	1620	|O
have	1621	1625	|O
K	1626	1627	|O
(	1627	1628	|O
i	1628	1629	|O
)	1629	1630	|O
=	1631	1632	|O
31	1633	1635	|O
+	1636	1637	|O
/	1637	1638	|O
-	1638	1639	|O
7	1640	1641	|O
microM	1642	1648	|O
,	1648	1649	|O
which	1650	1655	|O
is	1656	1658	|O
lower	1659	1664	|O
than	1665	1669	|O
parent	1670	1676	|O
5	1677	1678	|B-IUPAC
-	1678	1679	|I-IUPAC
carboxy	1679	1686	|I-IUPAC
-	1686	1687	|I-IUPAC
6	1687	1688	|I-IUPAC
-	1688	1689	|I-IUPAC
carboxymethyloxy	1689	1705	|I-IUPAC
-	1705	1706	|I-IUPAC
2	1706	1707	|I-IUPAC
-	1707	1708	|I-IUPAC
naphthoic	1708	1717	|I-IUPAC
acid	1718	1722	|I-IUPAC
.	1722	1723	|O
In	1724	1726	|O
this	1727	1731	|O
fashion	1732	1739	|O
,	1739	1740	|O
5	1741	1742	|B-IUPAC
-	1742	1743	|I-IUPAC
carboxy	1743	1750	|I-IUPAC
-	1750	1751	|I-IUPAC
2	1751	1752	|I-IUPAC
-	1752	1753	|I-IUPAC
naphthoic	1753	1762	|I-IUPAC
acid	1763	1767	|I-IUPAC
(	1768	1769	|O
or	1769	1771	|O
more	1772	1776	|O
appropriately	1777	1790	|O
,	1790	1791	|O
6	1792	1793	|B-IUPAC
-	1793	1794	|I-IUPAC
carboxy	1794	1801	|I-IUPAC
-	1801	1802	|I-IUPAC
1	1802	1803	|I-IUPAC
-	1803	1804	|I-IUPAC
naphthoic	1804	1813	|I-IUPAC
acid	1814	1818	|I-IUPAC
)	1818	1819	|O
has	1820	1823	|O
been	1824	1828	|O
identified	1829	1839	|O
as	1840	1842	|O
a	1843	1844	|O
novel	1845	1850	|O
PTP1B	1851	1856	|O
binding	1857	1864	|O
motif	1865	1870	|O
.	1870	1871	|O

### abstracts2709.txt
Novel	0	5	|O
derivatives	6	17	|O
of	18	20	|O
benzo	21	26	|B-IUPAC
[	26	27	|I-IUPAC
b	27	28	|I-IUPAC
]	28	29	|I-IUPAC
thieno	29	35	|I-IUPAC
[	35	36	|I-IUPAC
2,3	36	39	|I-IUPAC
-	39	40	|I-IUPAC
c	40	41	|I-IUPAC
]	41	42	|I-IUPAC
quinolones	42	52	|I-IUPAC
3a	53	55	|O
-	55	56	|O
j	56	57	|O
were	58	62	|O
synthesized	63	74	|O
in	75	77	|O
a	78	79	|O
multistep	80	89	|O
synthesis	90	99	|O
starting	100	108	|O
from	109	113	|O
substituted	114	125	|B-MODIFIER
benzo	126	131	|B-IUPAC
[	131	132	|I-IUPAC
b	132	133	|I-IUPAC
]	133	134	|I-IUPAC
thiophene	134	143	|I-IUPAC
-	143	144	|I-IUPAC
2	144	145	|I-IUPAC
-	145	146	|I-IUPAC
carbonyl	146	154	|I-IUPAC
chlorides	155	164	|I-IUPAC
,	164	165	|O
to	166	168	|O
their	169	174	|O
corresponding	175	188	|O
benzo	189	194	|B-IUPAC
[	194	195	|I-IUPAC
b	195	196	|I-IUPAC
]	196	197	|I-IUPAC
thiophene	197	206	|I-IUPAC
-	206	207	|I-IUPAC
2	207	208	|I-IUPAC
-	208	209	|I-IUPAC
carboxamides	209	221	|I-IUPAC
,	221	222	|O
which	223	228	|O
were	229	233	|O
photochemically	234	249	|O
dehydrohalogenated	250	268	|O
to	269	271	|O
their	272	277	|O
corresponding	278	291	|O
substituted	292	303	|O
benzo	304	309	|B-IUPAC
[	309	310	|I-IUPAC
b	310	311	|I-IUPAC
]	311	312	|I-IUPAC
thieno	312	318	|I-IUPAC
[	318	319	|I-IUPAC
2,3	319	322	|I-IUPAC
-	322	323	|I-IUPAC
c	323	324	|I-IUPAC
]	324	325	|I-IUPAC
quinolones	325	335	|I-IUPAC
.	335	336	|O
Compound	337	345	|O
4	346	347	|O
was	348	351	|O
prepared	352	360	|O
from	361	365	|O
3i	366	368	|O
by	369	371	|O
alkylation	372	382	|O
with	383	387	|O
3	388	389	|B-IUPAC
-	389	390	|I-IUPAC
dimethylaminopropyl	390	409	|I-IUPAC
chloride	410	418	|I-IUPAC
in	419	421	|O
the	422	425	|O
presence	426	434	|O
of	435	437	|O
NaH	438	441	|O
.	441	442	|O
Compounds	443	452	|O
7a	453	455	|O
,	455	456	|O
b	456	457	|O
were	458	462	|O
prepared	463	471	|O
from	472	476	|O
3g	477	479	|O
in	480	482	|O
the	483	486	|O
multistep	487	496	|O
synthesis	497	506	|O
from	507	511	|O
compounds	512	521	|O
5	522	523	|O
and	524	527	|O
6	528	529	|O
.	529	530	|O
Compounds	531	540	|O
3b	541	543	|O
,	543	544	|O
3c	545	547	|O
-	547	548	|O
f	548	549	|O
,	549	550	|O
3h	551	553	|O
,	553	554	|O
7a	555	557	|O
,	557	558	|O
and	559	562	|O
7b	563	565	|O
were	566	570	|O
found	571	576	|O
to	577	579	|O
exert	580	585	|O
cytostatic	586	596	|O
activity	597	605	|O
against	606	613	|O
malignant	614	623	|O
cell	624	628	|O
lines	629	634	|O
:	634	635	|O
pancreatic	636	646	|O
carcinoma	647	656	|O
(	657	658	|O
MiaPaCa2	658	666	|O
)	666	667	|O
,	667	668	|O
breast	669	675	|O
carcinoma	676	685	|O
(	686	687	|O
MCF7	687	691	|O
)	691	692	|O
,	692	693	|O
cervical	694	702	|O
carcinoma	703	712	|O
(	713	714	|O
HeLa	714	718	|O
)	718	719	|O
,	719	720	|O
laryngeal	721	730	|O
carcinoma	731	740	|O
(	741	742	|O
Hep2	742	746	|O
)	746	747	|O
,	747	748	|O
colon	749	754	|O
carcinoma	755	764	|O
(	765	766	|O
CaCo	766	770	|O
-	770	771	|O
2	771	772	|O
)	772	773	|O
,	773	774	|O
melanoma	775	783	|O
(	784	785	|O
HBL	785	788	|O
)	788	789	|O
,	789	790	|O
human	791	796	|O
fibroblast	797	807	|O
cell	808	812	|O
lines	813	818	|O
(	819	820	|O
WI	820	822	|O
-	822	823	|O
38	823	825	|O
)	825	826	|O
.	826	827	|O
The	828	831	|O
compounds	832	841	|O
that	842	846	|O
bear	847	851	|O
a	852	853	|O
3	854	855	|B-IUPAC
-	855	856	|I-IUPAC
dimethylaminopropyl	856	875	|I-IUPAC
substituent	876	887	|B-MODIFIER
on	888	890	|O
the	891	894	|O
quinolone	895	904	|O
nitrogen	905	913	|O
(	914	915	|O
3b	915	917	|O
,	917	918	|O
3c	919	921	|O
-	921	922	|O
f	922	923	|O
,	923	924	|O
3h	925	927	|O
)	927	928	|O
showed	929	935	|O
higher	936	942	|O
antitumor	943	952	|O
activity	953	961	|O
than	962	966	|O
compounds	967	976	|O
bearing	977	984	|O
the	985	988	|O
same	989	993	|O
substituent	994	1005	|O
on	1006	1008	|O
the	1009	1012	|O
amidic	1013	1019	|O
nitrogen	1020	1028	|O
(	1029	1030	|O
7a	1030	1032	|O
and	1033	1036	|O
7b	1037	1039	|O
)	1039	1040	|O
.	1040	1041	|O
The	1042	1045	|O
compound	1046	1054	|O
3h	1055	1057	|O
,	1057	1058	|O
which	1059	1064	|O
has	1065	1068	|O
a	1069	1070	|O
3	1071	1072	|B-IUPAC
-	1072	1073	|I-IUPAC
dimethylaminopropyl	1073	1092	|I-IUPAC
substituent	1093	1104	|B-MODIFIER
on	1105	1107	|O
the	1108	1111	|O
quinolone	1112	1121	|O
nitrogen	1122	1130	|O
and	1131	1134	|O
a	1135	1136	|O
methoxycarbonyl	1137	1152	|B-IUPAC
substituent	1153	1164	|B-MODIFIER
at	1165	1167	|O
position	1168	1176	|O
9	1177	1178	|O
,	1178	1179	|O
had	1180	1183	|O
marked	1184	1190	|O
antitumor	1191	1200	|O
activity	1201	1209	|O
.	1209	1210	|O
Because	1211	1218	|O
of	1219	1221	|O
strong	1222	1228	|O
cytotoxic	1229	1238	|O
effect	1239	1245	|O
of	1246	1248	|O
compound	1249	1257	|O
4	1258	1259	|O
on	1260	1262	|O
melanoma	1263	1271	|O
cells	1272	1277	|O
(	1278	1279	|O
HBL	1279	1282	|O
,	1282	1283	|O
ME	1284	1286	|O
67.3	1287	1291	|O
,	1291	1292	|O
and	1293	1296	|O
ME	1297	1299	|O
67.1	1300	1304	|O
)	1304	1305	|O
,	1305	1306	|O
a	1307	1308	|O
potential	1309	1318	|O
mechanism	1319	1328	|O
of	1329	1331	|O
action	1332	1338	|O
was	1339	1342	|O
examined	1343	1351	|O
.	1351	1352	|O
Analysis	1353	1361	|O
of	1362	1364	|O
DNA	1365	1368	|O
and	1369	1372	|O
Annexin	1373	1380	|O
-	1380	1381	|O
V	1381	1382	|O
-	1382	1383	|O
FLUOS	1383	1388	|O
staining	1389	1397	|O
indicated	1398	1407	|O
that	1408	1412	|O
compound	1413	1421	|O
4	1422	1423	|O
causes	1424	1430	|O
cell	1431	1435	|O
death	1436	1441	|O
by	1442	1444	|O
apoptosis	1445	1454	|O
.	1454	1455	|O

### abstracts3641.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
aza	12	15	|B-IUPAC
-	15	16	|I-IUPAC
5	16	17	|I-IUPAC
[	17	18	|I-IUPAC
H	18	19	|I-IUPAC
]	19	20	|I-IUPAC
-	20	21	|I-IUPAC
phenanthridin	21	34	|I-IUPAC
-	34	35	|I-IUPAC
6	35	36	|I-IUPAC
-	36	37	|I-IUPAC
ones	37	41	|I-IUPAC
were	42	46	|O
synthesized	47	58	|O
and	59	62	|O
evaluated	63	72	|O
as	73	75	|O
inhibitors	76	86	|O
of	87	89	|O
poly	90	94	|O
ADP	95	98	|O
-	98	99	|O
ribose	99	105	|O
polymerase	106	116	|O
-	116	117	|O
1	117	118	|O
(	119	120	|O
PARP	120	124	|O
-	124	125	|O
1	125	126	|O
)	126	127	|O
.	127	128	|O
Inhibitory	129	139	|O
potency	140	147	|O
of	148	150	|O
the	151	154	|O
unsubstituted	155	168	|B-MODIFIER
aza	169	172	|B-IUPAC
-	172	173	|I-IUPAC
5	173	174	|I-IUPAC
[	174	175	|I-IUPAC
H	175	176	|I-IUPAC
]	176	177	|I-IUPAC
-	177	178	|I-IUPAC
phenanthridin	178	191	|I-IUPAC
-	191	192	|I-IUPAC
6	192	193	|I-IUPAC
-	193	194	|I-IUPAC
ones	194	198	|I-IUPAC
(	199	200	|O
i.e.	200	204	|O
,	204	205	|O
benzonaphthyridones	206	225	|O
)	225	226	|O
was	227	230	|O
dependent	231	240	|O
on	241	243	|O
the	244	247	|O
position	248	256	|O
of	257	259	|O
the	260	263	|O
nitrogen	264	272	|O
atom	273	277	|O
within	278	284	|O
the	285	288	|O
core	289	293	|O
structure	294	303	|O
.	303	304	|O
The	305	308	|O
A	309	310	|O
ring	311	315	|O
nitrogen	316	324	|O
analogues	325	334	|O
(	335	336	|O
7	336	337	|B-PARTIUPAC
-	337	338	|I-PARTIUPAC
,	338	339	|O
8	340	341	|B-PARTIUPAC
-	341	342	|I-PARTIUPAC
,	342	343	|O
and	344	347	|O
10	348	350	|B-IUPAC
-	350	351	|I-IUPAC
aza	351	354	|I-IUPAC
-	354	355	|I-IUPAC
5	355	356	|I-IUPAC
[	356	357	|I-IUPAC
H	357	358	|I-IUPAC
]	358	359	|I-IUPAC
-	359	360	|I-IUPAC
phenanthridin	360	373	|I-IUPAC
-	373	374	|I-IUPAC
6	374	375	|I-IUPAC
-	375	376	|I-IUPAC
ones	376	380	|I-IUPAC
)	380	381	|O
were	382	386	|O
an	387	389	|O
order	390	395	|O
of	396	398	|O
magnitude	399	408	|O
less	409	413	|O
potent	414	420	|O
than	421	425	|O
C	426	427	|O
ring	428	432	|O
nitrogen	433	441	|O
analogues	442	451	|O
(	452	453	|O
1	453	454	|B-PARTIUPAC
-	454	455	|I-PARTIUPAC
,	455	456	|O
2	457	458	|B-PARTIUPAC
-	458	459	|I-PARTIUPAC
,	459	460	|O
3	461	462	|B-PARTIUPAC
-	462	463	|I-PARTIUPAC
,	463	464	|O
and	465	468	|O
4	469	470	|B-IUPAC
-	470	471	|I-IUPAC
aza	471	474	|I-IUPAC
-	474	475	|I-IUPAC
5	475	476	|I-IUPAC
[	476	477	|I-IUPAC
H	477	478	|I-IUPAC
]	478	479	|I-IUPAC
-	479	480	|I-IUPAC
phenanthridin	480	493	|I-IUPAC
-	493	494	|I-IUPAC
6	494	495	|I-IUPAC
-	495	496	|I-IUPAC
ones	496	500	|I-IUPAC
)	500	501	|O
.	501	502	|O
Preliminary	503	514	|O
stroke	515	521	|O
results	522	529	|O
from	530	534	|O
1	535	536	|B-PARTIUPAC
-	536	537	|I-PARTIUPAC
and	538	541	|O
2	542	543	|B-IUPAC
-	543	544	|I-IUPAC
aza	544	547	|I-IUPAC
-	547	548	|I-IUPAC
5	548	549	|I-IUPAC
[	549	550	|I-IUPAC
H	550	551	|I-IUPAC
]	551	552	|I-IUPAC
-	552	553	|I-IUPAC
phenanthridin	553	566	|I-IUPAC
-	566	567	|I-IUPAC
6	567	568	|I-IUPAC
-	568	569	|I-IUPAC
one	569	572	|I-IUPAC
prompted	573	581	|O
structure	582	591	|O
-	591	592	|O
activity	592	600	|O
relationships	601	614	|O
to	615	617	|O
be	618	620	|O
established	621	632	|O
for	633	636	|O
several	637	644	|O
2	645	646	|B-MODIFIER
-	646	647	|I-MODIFIER
and	648	651	|O
3	652	653	|B-MODIFIER
-	653	654	|I-MODIFIER
substituted	654	665	|I-MODIFIER
1	666	667	|B-IUPAC
-	667	668	|I-IUPAC
aza	668	671	|I-IUPAC
-	671	672	|I-IUPAC
5	672	673	|I-IUPAC
[	673	674	|I-IUPAC
H	674	675	|I-IUPAC
]	675	676	|I-IUPAC
-	676	677	|I-IUPAC
phenanthridin	677	690	|I-IUPAC
-	690	691	|I-IUPAC
6	691	692	|I-IUPAC
-	692	693	|I-IUPAC
ones	693	697	|I-IUPAC
.	697	698	|O
The	699	702	|O
2	703	704	|B-MODIFIER
-	704	705	|I-MODIFIER
substituted	705	716	|I-MODIFIER
1	717	718	|B-IUPAC
-	718	719	|I-IUPAC
aza	719	722	|I-IUPAC
-	722	723	|I-IUPAC
5	723	724	|I-IUPAC
[	724	725	|I-IUPAC
H	725	726	|I-IUPAC
]	726	727	|I-IUPAC
-	727	728	|I-IUPAC
phenanthridin	728	741	|I-IUPAC
-	741	742	|I-IUPAC
6	742	743	|I-IUPAC
-	743	744	|I-IUPAC
ones	744	748	|I-IUPAC
were	749	753	|O
designed	754	762	|O
to	763	765	|O
improve	766	773	|O
the	774	777	|O
solubility	778	788	|O
and	789	792	|O
pharmacokinetic	793	808	|O
profiles	809	817	|O
for	818	821	|O
this	822	826	|O
series	827	833	|O
of	834	836	|O
PARP	837	841	|O
-	841	842	|O
1	842	843	|O
inhibitors	844	854	|O
.	854	855	|O
Most	856	860	|O
importantly	861	872	|O
,	872	873	|O
three	874	879	|O
compounds	880	889	|O
from	890	894	|O
this	895	899	|O
series	900	906	|O
demonstrated	907	919	|O
statistically	920	933	|O
significant	934	945	|O
protective	946	956	|O
effects	957	964	|O
in	965	967	|O
rat	968	971	|O
models	972	978	|O
of	979	981	|O
stroke	982	988	|O
and	989	992	|O
heart	993	998	|O
ischemia	999	1007	|O
.	1007	1008	|O

### abstracts1407.txt
Following	0	9	|O
the	10	13	|O
discovery	14	23	|O
of	24	26	|O
moderately	27	37	|O
potent	38	44	|O
antagonist	45	55	|O
activity	56	64	|O
platelet	65	73	|O
-	73	74	|O
activating	74	84	|O
factor	85	91	|O
(	92	93	|O
PAF	93	96	|O
)	96	97	|O
in	98	100	|O
2	101	102	|B-IUPAC
-	102	103	|I-IUPAC
methyl	103	109	|I-IUPAC
-	109	110	|I-IUPAC
1	110	111	|I-IUPAC
-	111	112	|I-IUPAC
phenylimidazo	112	125	|I-IUPAC
[	125	126	|I-IUPAC
4,5	126	129	|I-IUPAC
-	129	130	|I-IUPAC
c	130	131	|I-IUPAC
]	131	132	|I-IUPAC
pyridine	132	140	|I-IUPAC
(	141	142	|O
2	142	143	|O
)	143	144	|O
(	145	146	|O
IC50	146	150	|O
=	151	152	|O
840	153	156	|O
nM	157	159	|O
)	159	160	|O
,	160	161	|O
19	162	164	|O
derivatives	165	176	|O
(	177	178	|O
3-21	178	182	|O
)	182	183	|O
were	184	188	|O
prepared	189	197	|O
which	198	203	|O
incorporated	204	216	|O
various	217	224	|O
lipophilic	225	235	|O
groups	236	242	|O
attached	243	251	|O
to	252	254	|O
the	255	258	|O
phenyl	259	265	|O
4	266	267	|O
-	267	268	|O
position	268	276	|O
.	276	277	|O
Structure	278	287	|O
-	287	288	|O
activity	288	296	|O
relationships	297	310	|O
were	311	315	|O
evaluated	316	325	|O
where	326	331	|O
PAF	332	335	|O
antagonist	336	346	|O
activity	347	355	|O
was	356	359	|O
measured	360	368	|O
in	369	371	|O
vitro	372	377	|O
by	378	380	|O
determining	381	392	|O
the	393	396	|O
concentration	397	410	|O
of	411	413	|O
compound	414	422	|O
(	423	424	|O
IC50	424	428	|O
)	428	429	|O
required	430	438	|O
to	439	441	|O
inhibit	442	449	|O
the	450	453	|O
PAF	454	457	|O
-	457	458	|O
induced	458	465	|O
aggregation	466	477	|O
of	478	480	|O
rabbit	481	487	|O
washed	488	494	|O
platelets	495	504	|O
and	505	508	|O
in	509	511	|O
vivo	512	516	|O
by	517	519	|O
determining	520	531	|O
the	532	535	|O
oral	536	540	|O
dose	541	545	|O
(	546	547	|O
ED50	547	551	|O
)	551	552	|O
which	553	558	|O
protected	559	568	|O
mice	569	573	|O
from	574	578	|O
a	579	580	|O
lethal	581	587	|O
injection	588	597	|O
of	598	600	|O
PAF	601	604	|O
.	604	605	|O
[	606	607	|B-IUPAC
1,5	607	610	|I-IUPAC
]	610	611	|I-IUPAC
Benzodiazepines	611	626	|I-IUPAC
,	626	627	|O
e.g.	628	632	|O
,	632	633	|O
14	634	636	|O
(	637	638	|O
2,3	638	641	|B-IUPAC
-	641	642	|I-IUPAC
dihydro	642	649	|I-IUPAC
-	649	650	|I-IUPAC
1	650	651	|I-IUPAC
-	651	652	|I-IUPAC
methyl	652	658	|I-IUPAC
-	658	659	|I-IUPAC
4	659	660	|I-IUPAC
-	660	661	|I-IUPAC
[	661	662	|I-IUPAC
4	662	663	|I-IUPAC
-	663	664	|I-IUPAC
(	664	665	|I-IUPAC
2	665	666	|I-IUPAC
-	666	667	|I-IUPAC
methylimidazo	667	680	|I-IUPAC
[	680	681	|I-IUPAC
4,5	681	684	|I-IUPAC
-	684	685	|I-IUPAC
c	685	686	|I-IUPAC
]	686	687	|I-IUPAC
pyrid	688	693	|I-IUPAC
-	693	694	|I-IUPAC
1	694	695	|I-IUPAC
-	695	696	|I-IUPAC
yl	696	698	|I-IUPAC
)	698	699	|I-IUPAC
phenyl	699	705	|I-IUPAC
]	705	706	|I-IUPAC
-	706	707	|I-IUPAC
1H	707	709	|I-IUPAC
-	709	710	|I-IUPAC
[	710	711	|I-IUPAC
1,5	711	714	|I-IUPAC
]	714	715	|I-IUPAC
benzodiazepin	715	728	|I-IUPAC
-	728	729	|I-IUPAC
2	729	730	|I-IUPAC
-	730	731	|I-IUPAC
one	731	734	|I-IUPAC
)	734	735	|O
(	736	737	|O
IC50	737	741	|O
=	742	743	|O
4.9	744	747	|O
nM	748	750	|O
,	750	751	|O
Ed50	752	756	|O
=	757	758	|O
0.03	759	763	|O
mg	764	766	|O
/	766	767	|O
kg	767	769	|O
po	770	772	|O
)	772	773	|O
,	773	774	|O
were	775	779	|O
found	780	785	|O
to	786	788	|O
possess	789	796	|O
equivalent	797	807	|O
or	808	810	|O
superior	811	819	|O
potency	820	827	|O
to	828	830	|O
the	831	834	|O
1,4	835	838	|B-IUPAC
-	838	839	|I-IUPAC
dihydropyridine	839	854	|I-IUPAC
PAF	855	858	|O
antagonist	859	869	|O
UK	870	872	|O
-	872	873	|O
74,505	873	879	|O
(	880	881	|O
1,4	881	884	|B-IUPAC
-	884	885	|I-IUPAC
(	885	886	|I-IUPAC
2	886	887	|I-IUPAC
-	887	888	|I-IUPAC
chlorophenyl	888	900	|I-IUPAC
)	900	901	|I-IUPAC
-	901	902	|I-IUPAC
1,4	902	905	|I-IUPAC
-	905	906	|I-IUPAC
dihydro	906	913	|I-IUPAC
-	913	914	|I-IUPAC
3	914	915	|I-IUPAC
-	915	916	|I-IUPAC
(	916	917	|I-IUPAC
ethoxycarbonyl	917	931	|I-IUPAC
)	931	932	|I-IUPAC
-	932	933	|I-IUPAC
6	933	934	|I-IUPAC
-	934	935	|I-IUPAC
methyl	935	941	|I-IUPAC
-	941	942	|I-IUPAC
2	942	943	|I-IUPAC
-	943	944	|I-IUPAC
[	945	946	|I-IUPAC
4	946	947	|I-IUPAC
-	947	948	|I-IUPAC
(	948	949	|I-IUPAC
2	949	950	|I-IUPAC
-	950	951	|I-IUPAC
methylimidazo	951	964	|I-IUPAC
[	964	965	|I-IUPAC
4,5	965	968	|I-IUPAC
-	968	969	|I-IUPAC
c	969	970	|I-IUPAC
]	970	971	|I-IUPAC
pyrid	971	976	|I-IUPAC
-	976	977	|I-IUPAC
1	977	978	|I-IUPAC
-	978	979	|I-IUPAC
yl	979	981	|I-IUPAC
)	981	982	|I-IUPAC
phenyl	982	988	|I-IUPAC
]	988	989	|I-IUPAC
-	989	990	|I-IUPAC
5	990	991	|I-IUPAC
-	991	992	|I-IUPAC
[	992	993	|I-IUPAC
N	993	994	|I-IUPAC
-	994	995	|I-IUPAC
(	995	996	|I-IUPAC
2	996	997	|I-IUPAC
-	997	998	|I-IUPAC
pyridyl	998	1005	|I-IUPAC
)	1005	1006	|I-IUPAC
carbamoyl	1007	1016	|I-IUPAC
]	1016	1017	|I-IUPAC
pyridine	1017	1025	|I-IUPAC
)	1025	1026	|O
in	1027	1029	|O
vitro	1030	1035	|O
and	1036	1039	|O
in	1040	1042	|O
vivo	1043	1047	|O
.	1047	1048	|O
Furthermore	1049	1060	|O
,	1060	1061	|O
a	1062	1063	|O
potent	1064	1070	|O
benzazepine	1071	1082	|O
,	1082	1083	|O
21	1084	1086	|O
(	1087	1088	|O
7,8	1088	1091	|B-IUPAC
-	1091	1092	|I-IUPAC
dichloro	1092	1100	|I-IUPAC
-	1100	1101	|I-IUPAC
1	1101	1102	|I-IUPAC
-	1102	1103	|I-IUPAC
methyl	1103	1109	|I-IUPAC
-	1109	1110	|I-IUPAC
4	1110	1111	|I-IUPAC
-	1111	1112	|I-IUPAC
[	1112	1113	|I-IUPAC
4	1113	1114	|I-IUPAC
-	1114	1115	|I-IUPAC
(	1115	1116	|I-IUPAC
methylimidazo	1116	1129	|I-IUPAC
[	1129	1130	|I-IUPAC
4,5	1130	1133	|I-IUPAC
-	1133	1134	|I-IUPAC
c	1134	1135	|I-IUPAC
]	1135	1136	|I-IUPAC
pyrid	1136	1141	|I-IUPAC
-	1141	1142	|I-IUPAC
1	1142	1143	|I-IUPAC
-	1143	1144	|I-IUPAC
yl	1144	1146	|I-IUPAC
)	1146	1147	|I-IUPAC
phenyl	1148	1154	|I-IUPAC
]	1154	1155	|I-IUPAC
-	1155	1156	|I-IUPAC
2,3,4,5	1156	1163	|I-IUPAC
-	1163	1164	|I-IUPAC
tetrahydro	1164	1174	|I-IUPAC
-	1174	1175	|I-IUPAC
1H	1175	1177	|I-IUPAC
-	1177	1178	|I-IUPAC
1	1178	1179	|I-IUPAC
-	1179	1180	|I-IUPAC
benzazepin	1180	1190	|I-IUPAC
-	1190	1191	|I-IUPAC
2	1191	1192	|I-IUPAC
-	1192	1193	|I-IUPAC
one	1193	1196	|I-IUPAC
)	1196	1197	|O
(	1198	1199	|O
IC50	1199	1203	|O
=	1204	1205	|O
0.5	1206	1209	|O
nM	1210	1212	|O
,	1212	1213	|O
ED50	1214	1218	|O
=	1219	1220	|O
0.03	1221	1225	|O
mg	1226	1228	|O
/	1228	1229	|O
kg	1229	1231	|O
po	1232	1234	|O
)	1234	1235	|O
,	1235	1236	|O
was	1237	1240	|O
discovered	1241	1251	|O
.	1251	1252	|O
These	1253	1258	|O
investigations	1259	1273	|O
prompted	1274	1282	|O
the	1283	1286	|O
synthesis	1287	1296	|O
and	1297	1300	|O
evaluation	1301	1311	|O
of	1312	1314	|O
additional	1315	1325	|O
diazepine	1326	1335	|O
derivatives	1336	1347	|O
,	1347	1348	|O
which	1349	1354	|O
are	1355	1358	|O
described	1359	1368	|O
in	1369	1371	|O
the	1372	1375	|O
following	1376	1385	|O
paper	1386	1391	|O
.	1391	1392	|O
The	1393	1396	|O
relationship	1397	1409	|O
between	1410	1417	|O
the	1418	1421	|O
key	1422	1425	|O
PAF	1426	1429	|O
antagonist	1430	1440	|O
pharmacophores	1441	1455	|O
of	1456	1458	|O
2	1459	1460	|B-IUPAC
-	1460	1461	|I-IUPAC
methyl	1461	1467	|I-IUPAC
-	1467	1468	|I-IUPAC
1	1468	1469	|I-IUPAC
-	1469	1470	|I-IUPAC
phenylimidazo	1470	1483	|I-IUPAC
[	1483	1484	|I-IUPAC
4,5	1484	1487	|I-IUPAC
-	1487	1488	|I-IUPAC
c	1488	1489	|I-IUPAC
]	1489	1490	|I-IUPAC
pyridine	1490	1498	|I-IUPAC
,	1498	1499	|O
a	1500	1501	|O
triazolothienodiazepine	1502	1525	|O
(	1526	1527	|O
WEB2170	1527	1534	|O
)	1534	1535	|O
,	1535	1536	|O
and	1537	1540	|O
a	1541	1542	|O
pyrrolothiazolidine	1543	1562	|O
(	1563	1564	|O
RP	1564	1566	|O
-	1566	1567	|O
52,770	1567	1573	|O
)	1573	1574	|O
is	1575	1577	|O
discussed	1578	1587	|O
.	1587	1588	|O

### abstracts787.txt
Various	0	7	|O
substituted	8	19	|O
isoquinoline	20	32	|B-IUPAC
-	32	33	|I-IUPAC
1	33	34	|I-IUPAC
-	34	35	|I-IUPAC
carboxaldehyde	35	49	|I-IUPAC
thiosemicarbazones	50	68	|I-IUPAC
(	69	70	|O
12	70	72	|O
compounds	73	82	|O
)	82	83	|O
have	84	88	|O
been	89	93	|O
synthesized	94	105	|O
and	106	109	|O
evaluated	110	119	|O
for	120	123	|O
antineoplastic	124	138	|O
activity	139	147	|O
in	148	150	|O
mice	151	155	|O
bearing	156	163	|O
the	164	167	|O
L1210	168	173	|O
leukemia	174	182	|O
.	182	183	|O
Condensation	184	196	|O
of	197	199	|O
4	200	201	|B-IUPAC
-	201	202	|I-IUPAC
bromo	202	207	|I-IUPAC
-	207	208	|I-IUPAC
1	208	209	|I-IUPAC
-	209	210	|I-IUPAC
methylisoquinoline	210	228	|I-IUPAC
(	229	230	|O
4	230	231	|O
)	231	232	|O
with	233	237	|O
ammonium	238	246	|O
hydroxide	247	256	|O
,	256	257	|O
methylamine	258	269	|O
,	269	270	|O
ethylamine	271	281	|O
,	281	282	|O
and	283	286	|O
N	287	288	|B-IUPAC
-	288	289	|I-IUPAC
acetylethylenediamine	289	310	|I-IUPAC
gave	311	315	|O
the	316	319	|O
corresponding	320	333	|O
4	334	335	|B-IUPAC
-	335	336	|I-IUPAC
amino	336	341	|I-IUPAC
,	341	342	|O
4	343	344	|B-IUPAC
-	344	345	|I-IUPAC
methylamino	345	356	|I-IUPAC
,	356	357	|O
4	358	359	|B-IUPAC
-	359	360	|I-IUPAC
ethylamino	360	370	|I-IUPAC
,	370	371	|O
and	372	375	|O
4	376	377	|B-IUPAC
-	377	378	|I-IUPAC
N	378	379	|I-IUPAC
-	379	380	|I-IUPAC
(	380	381	|I-IUPAC
acetylethyl	381	392	|I-IUPAC
)	392	393	|I-IUPAC
amino	393	398	|I-IUPAC
derivatives	399	410	|B-MODIFIER
,	410	411	|O
which	412	417	|O
were	418	422	|O
then	423	427	|O
converted	428	437	|O
to	438	440	|O
amides	441	447	|O
and	448	451	|O
subsequently	452	464	|O
oxidized	465	473	|O
to	474	476	|O
aldehydes	477	486	|O
followed	487	495	|O
by	496	498	|O
condensation	499	511	|O
with	512	516	|O
thiosemicarbazide	517	534	|O
to	535	537	|O
yield	538	543	|O
thiosemicarbazones	544	562	|O
8a	563	565	|O
-	565	566	|O
c	566	567	|O
,	567	568	|O
9a	569	571	|O
-	571	572	|O
c	572	573	|O
,	573	574	|O
and	575	578	|O
16	579	581	|O
.	581	582	|O
Nitration	583	592	|O
of	593	595	|O
4	596	597	|O
,	597	598	|O
followed	599	607	|O
by	608	610	|O
oxidation	611	620	|O
with	621	625	|O
selenium	626	634	|O
dioxide	635	642	|O
,	642	643	|O
produced	644	652	|O
aldehyde	653	661	|O
18	662	664	|O
,	664	665	|O
which	666	671	|O
was	672	675	|O
then	676	680	|O
converted	681	690	|O
to	691	693	|O
the	694	697	|O
cyclic	698	704	|O
ethylene	705	713	|O
acetal	714	720	|O
19	721	723	|O
.	723	724	|O
Condensation	725	737	|O
of	738	740	|O
19	741	743	|O
with	744	748	|O
morpholine	749	759	|O
followed	760	768	|O
by	769	771	|O
catalytic	772	781	|O
reduction	782	791	|O
of	792	794	|O
the	795	798	|O
nitro	799	804	|O
group	805	810	|O
and	811	814	|O
treatment	815	824	|O
with	825	829	|O
thiosemicarbazide	830	847	|O
afforded	848	856	|O
5	857	858	|B-IUPAC
-	858	859	|I-IUPAC
amino	859	864	|I-IUPAC
-	864	865	|I-IUPAC
4	865	866	|I-IUPAC
-	866	867	|I-IUPAC
morpholinoisoquinoline	867	889	|I-IUPAC
-	889	890	|I-IUPAC
1	890	891	|I-IUPAC
-	891	892	|I-IUPAC
carboxaldehyde	892	906	|I-IUPAC
thiosemicarbazone	907	924	|I-IUPAC
(	925	926	|O
22	926	928	|O
)	928	929	|O
.	929	930	|O
N	931	932	|O
-	932	933	|O
Oxidation	933	942	|O
of	943	945	|O
1,5	946	949	|B-IUPAC
-	949	950	|I-IUPAC
dimethylisoquinoline	950	970	|I-IUPAC
,	970	971	|O
followed	972	980	|O
by	981	983	|O
rearrangement	984	997	|O
with	998	1002	|O
acetic	1003	1009	|O
anhydride	1010	1019	|O
,	1019	1020	|O
gave	1021	1025	|O
,	1025	1026	|O
after	1027	1032	|O
acid	1033	1037	|O
hydrolysis	1038	1048	|O
,	1048	1049	|O
1,5	1050	1053	|B-IUPAC
-	1053	1054	|I-IUPAC
dimethyl	1054	1062	|I-IUPAC
-	1062	1063	|I-IUPAC
4	1063	1064	|I-IUPAC
-	1064	1065	|I-IUPAC
hydroxyisoquinoline	1065	1084	|I-IUPAC
,	1084	1085	|O
which	1086	1091	|O
was	1092	1095	|O
converted	1096	1105	|O
to	1106	1108	|O
its	1109	1112	|O
acetate	1113	1120	|O
and	1121	1124	|O
then	1125	1129	|O
oxidized	1130	1138	|O
to	1139	1141	|O
yield	1142	1147	|O
4	1148	1149	|B-IUPAC
-	1149	1150	|I-IUPAC
acetoxy	1150	1157	|I-IUPAC
-	1157	1158	|I-IUPAC
5	1158	1159	|I-IUPAC
-	1159	1160	|I-IUPAC
methylisoquinoline	1160	1178	|I-IUPAC
-	1178	1179	|I-IUPAC
1	1179	1180	|I-IUPAC
-	1180	1181	|I-IUPAC
carboxaldehyde	1181	1195	|I-IUPAC
(	1196	1197	|O
32	1197	1199	|O
)	1199	1200	|O
.	1200	1201	|O
Sulfonation	1202	1213	|O
of	1214	1216	|O
1,4	1217	1220	|B-IUPAC
-	1220	1221	|I-IUPAC
dimethylisoquinoline	1221	1241	|I-IUPAC
,	1241	1242	|O
followed	1243	1251	|O
by	1252	1254	|O
reaction	1255	1263	|O
with	1264	1268	|O
potassium	1269	1278	|O
hydroxide	1279	1288	|O
,	1288	1289	|O
acetylation	1290	1301	|O
,	1301	1302	|O
and	1303	1306	|O
oxidation	1307	1316	|O
,	1316	1317	|O
gave	1318	1322	|O
5	1323	1324	|B-IUPAC
-	1324	1325	|I-IUPAC
acetoxy	1325	1332	|I-IUPAC
-	1332	1333	|I-IUPAC
4	1333	1334	|I-IUPAC
-	1334	1335	|I-IUPAC
methylisoquinoline	1335	1353	|I-IUPAC
-	1353	1354	|I-IUPAC
1	1354	1355	|I-IUPAC
-	1355	1356	|I-IUPAC
carboxaldehyde	1356	1370	|I-IUPAC
(	1371	1372	|O
40	1372	1374	|O
)	1374	1375	|O
.	1375	1376	|O
Condensation	1377	1389	|O
of	1390	1392	|O
compounds	1393	1402	|O
32	1403	1405	|O
and	1406	1409	|O
39	1410	1412	|O
with	1413	1417	|O
thiosemicarbazide	1418	1435	|O
afforded	1436	1444	|O
the	1445	1448	|O
respective	1449	1459	|O
4	1460	1461	|B-PARTIUPAC
-	1461	1462	|I-PARTIUPAC
and	1463	1466	|O
5	1467	1468	|B-PARTIUPAC
-	1468	1469	|I-PARTIUPAC
acetoxy	1469	1476	|I-PARTIUPAC
(	1476	1477	|I-PARTIUPAC
5	1477	1478	|I-PARTIUPAC
-	1478	1479	|I-PARTIUPAC
and	1480	1483	|O
4	1484	1485	|B-PARTIUPAC
-	1485	1486	|I-PARTIUPAC
methyl	1486	1492	|I-PARTIUPAC
)	1492	1493	|I-PARTIUPAC
thiosemicarbazones	1493	1511	|I-PARTIUPAC
33	1512	1514	|O
and	1515	1518	|O
40	1519	1521	|O
,	1521	1522	|O
which	1523	1528	|O
were	1529	1533	|O
then	1534	1538	|O
converted	1539	1548	|O
to	1549	1551	|O
their	1552	1557	|O
respective	1558	1568	|O
4	1569	1570	|O
-	1570	1571	|O
and	1572	1575	|O
5	1576	1577	|O
-	1577	1578	|O
hydroxy	1578	1585	|O
derivatives	1586	1597	|O
34	1598	1600	|O
and	1601	1604	|O
41	1605	1607	|O
by	1608	1610	|O
acid	1611	1615	|O
hydrolysis	1616	1626	|O
.	1626	1627	|O
The	1628	1631	|O
most	1632	1636	|O
active	1637	1643	|O
compounds	1644	1653	|O
synthesized	1654	1665	|O
were	1666	1670	|O
4	1671	1672	|B-IUPAC
-	1672	1673	|I-IUPAC
aminoisoquinoline	1673	1690	|I-IUPAC
-	1690	1691	|I-IUPAC
1	1691	1692	|I-IUPAC
-	1692	1693	|I-IUPAC
carboxaldehyde	1693	1707	|I-IUPAC
thiosemicarbazone	1708	1725	|I-IUPAC
(	1726	1727	|O
9a	1727	1729	|O
)	1729	1730	|O
and	1731	1734	|O
4	1735	1736	|B-IUPAC
-	1736	1737	|I-IUPAC
(	1737	1738	|I-IUPAC
methylamino	1738	1749	|I-IUPAC
)	1749	1750	|I-IUPAC
isoquinoline	1750	1762	|I-IUPAC
-	1762	1763	|I-IUPAC
1	1763	1764	|I-IUPAC
-	1764	1765	|I-IUPAC
carboxaldehyde	1765	1779	|I-IUPAC
thiosemicarbazone	1780	1797	|I-IUPAC
(	1798	1799	|O
9b	1799	1801	|O
)	1801	1802	|O
,	1802	1803	|O
which	1804	1809	|O
both	1810	1814	|O
produced	1815	1823	|O
optimum	1824	1831	|O
%	1832	1833	|O
T	1834	1835	|O
/	1835	1836	|O
C	1836	1837	|O
values	1838	1844	|O
of	1845	1847	|O
177	1848	1851	|O
against	1852	1859	|O
the	1860	1863	|O
L1210	1864	1869	|O
leukemia	1870	1878	|O
in	1879	1881	|O
mice	1882	1886	|O
when	1887	1891	|O
used	1892	1896	|O
at	1897	1899	|O
a	1900	1901	|O
daily	1902	1907	|O
dosage	1908	1914	|O
of	1915	1917	|O
40	1918	1920	|O
mg	1921	1923	|O
/	1923	1924	|O
kg	1924	1926	|O
for	1927	1930	|O
6	1931	1932	|O
consecutive	1933	1944	|O
days	1945	1949	|O
.	1949	1950	|O
Furthermore	1951	1962	|O
,	1962	1963	|O
when	1964	1968	|O
9a	1969	1971	|O
was	1972	1975	|O
given	1976	1981	|O
twice	1982	1987	|O
daily	1988	1993	|O
at	1994	1996	|O
a	1997	1998	|O
dosage	1999	2005	|O
of	2006	2008	|O
40	2009	2011	|O
mg	2012	2014	|O
/	2014	2015	|O
kg	2015	2017	|O
for	2018	2021	|O
6	2022	2023	|O
consecutive	2024	2035	|O
days	2036	2040	|O
,	2040	2041	|O
a	2042	2043	|O
T	2044	2045	|O
/	2045	2046	|O
C	2046	2047	|O
value	2048	2053	|O
of	2054	2056	|O
165	2057	2060	|O
was	2061	2064	|O
obtained	2065	2073	|O
and	2074	2077	|O
60%	2078	2081	|O
of	2082	2084	|O
the	2085	2088	|O
mice	2089	2093	|O
were	2094	2098	|O
60	2099	2101	|O
-	2101	2102	|O
day	2102	2105	|O
long	2106	2110	|O
-	2110	2111	|O
term	2111	2115	|O
survivors	2116	2125	|O
.	2125	2126	|O

### abstracts3687.txt
An	0	2	|O
enzymatically	3	16	|O
activated	17	26	|O
liposome	27	35	|O
-	35	36	|O
based	36	41	|O
drug	42	46	|O
-	46	47	|O
delivery	47	55	|O
concept	56	63	|O
involving	64	73	|O
masked	74	80	|O
antitumor	81	90	|O
ether	91	96	|O
lipids	97	103	|O
(	104	105	|O
AELs	105	109	|O
)	109	110	|O
has	111	114	|O
been	115	119	|O
investigated	120	132	|O
.	132	133	|O
This	134	138	|O
concept	139	146	|O
takes	147	152	|O
advantage	153	162	|O
of	163	165	|O
the	166	169	|O
cytotoxic	170	179	|O
properties	180	190	|O
of	191	193	|O
AEL	194	197	|O
drugs	198	203	|O
as	204	206	|O
well	207	211	|O
as	212	214	|O
the	215	218	|O
membrane	219	227	|O
permeability	228	240	|O
enhancing	241	250	|O
properties	251	261	|O
of	262	264	|O
these	265	270	|O
molecules	271	280	|O
,	280	281	|O
which	282	287	|O
can	288	291	|O
lead	292	296	|O
to	297	299	|O
enhanced	300	308	|O
drug	309	313	|O
diffusion	314	323	|O
into	324	328	|O
cells	329	334	|O
.	334	335	|O
Three	336	341	|O
prodrugs	342	350	|O
of	351	353	|O
AELs	354	358	|O
(	359	360	|O
proAELs	360	367	|O
)	367	368	|O
have	369	373	|O
been	374	378	|O
synthesized	379	390	|O
and	391	394	|O
four	395	399	|O
liposome	400	408	|O
systems	409	416	|O
,	416	417	|O
consisting	418	428	|O
of	429	431	|O
these	432	437	|O
proAELs	438	445	|O
,	445	446	|O
were	447	451	|O
investigated	452	464	|O
for	465	468	|O
enzymatic	469	478	|O
degradation	479	490	|O
by	491	493	|O
secretory	494	503	|O
phospholipase	504	517	|O
A	518	519	|O
(	519	520	|O
2	520	521	|O
)	521	522	|O
(	523	524	|O
sPLA	524	528	|O
(	528	529	|O
2	529	530	|O
)	530	531	|O
)	531	532	|O
,	532	533	|O
resulting	534	543	|O
in	544	546	|O
the	547	550	|O
release	551	558	|O
of	559	561	|O
AELs	562	566	|O
.	566	567	|O
The	568	571	|O
three	572	577	|O
synthesized	578	589	|O
proAELs	590	597	|O
were	598	602	|O
(	603	604	|B-IUPAC
R	604	605	|I-IUPAC
)	605	606	|I-IUPAC
-	606	607	|I-IUPAC
1	607	608	|I-IUPAC
-	608	609	|I-IUPAC
O	609	610	|I-IUPAC
-	610	611	|I-IUPAC
hexadecyl	611	620	|I-IUPAC
-	620	621	|I-IUPAC
2	621	622	|I-IUPAC
-	622	623	|I-IUPAC
palmitoyl	623	632	|I-IUPAC
-	632	633	|I-IUPAC
sn	633	635	|I-IUPAC
-	635	636	|I-IUPAC
glycero	636	643	|I-IUPAC
-	643	644	|I-IUPAC
3	644	645	|I-IUPAC
-	645	646	|I-IUPAC
phosphocholine	646	660	|I-IUPAC
(	661	662	|O
1	662	663	|O
-	663	664	|O
O	664	665	|O
-	665	666	|O
DPPC	666	670	|O
)	670	671	|O
,	671	672	|O
(	673	674	|B-IUPAC
R	674	675	|I-IUPAC
)	675	676	|I-IUPAC
-	676	677	|I-IUPAC
1	677	678	|I-IUPAC
-	678	679	|I-IUPAC
O	679	680	|I-IUPAC
-	680	681	|I-IUPAC
hexadecyl	681	690	|I-IUPAC
-	690	691	|I-IUPAC
2	691	692	|I-IUPAC
-	692	693	|I-IUPAC
palmitoyl	693	702	|I-IUPAC
-	702	703	|I-IUPAC
sn	703	705	|I-IUPAC
-	705	706	|I-IUPAC
glycero	706	713	|I-IUPAC
-	713	714	|I-IUPAC
3	714	715	|I-IUPAC
-	715	716	|I-IUPAC
phosphoethanolamine	716	735	|I-IUPAC
poly	736	740	|I-IUPAC
(	740	741	|I-IUPAC
ethylene	741	749	|I-IUPAC
glycol	750	756	|I-IUPAC
)	756	757	|I-IUPAC
(	757	758	|O
350	758	761	|O
)	761	762	|O
(	763	764	|O
1	764	765	|O
-	765	766	|O
O	766	767	|O
-	767	768	|O
DPPE	768	772	|O
-	772	773	|O
PEG	773	776	|O
(	776	777	|O
350	777	780	|O
)	780	781	|O
)	781	782	|O
,	782	783	|O
and	784	787	|O
1	788	789	|O
-	789	790	|O
O	790	791	|O
-	791	792	|O
DPPE	792	796	|O
-	796	797	|O
PEG	797	800	|O
(	800	801	|O
2000	801	805	|O
)	805	806	|O
of	807	809	|O
which	810	815	|O
1	816	817	|O
-	817	818	|O
O	818	819	|O
-	819	820	|O
DPPC	820	824	|O
was	825	828	|O
the	829	832	|O
main	833	837	|O
liposome	838	846	|O
component	847	856	|O
.	856	857	|O
All	858	861	|O
three	862	867	|O
phospholipids	868	881	|O
were	882	886	|O
synthesized	887	898	|O
from	899	903	|O
the	904	907	|O
versatile	908	917	|O
starting	918	926	|O
material	927	935	|O
(	936	937	|B-IUPAC
R	937	938	|I-IUPAC
)	938	939	|I-IUPAC
-	939	940	|I-IUPAC
O	940	941	|I-IUPAC
-	941	942	|I-IUPAC
benzyl	942	948	|I-IUPAC
glycidol	949	957	|I-IUPAC
.	957	958	|O
A	959	960	|O
phosphorylation	961	976	|O
method	977	983	|O
,	983	984	|O
employing	985	994	|O
methyl	995	1001	|O
dichlorophosphate	1002	1019	|O
,	1019	1020	|O
was	1021	1024	|O
developed	1025	1034	|O
and	1035	1038	|O
applied	1039	1046	|O
in	1047	1049	|O
the	1050	1053	|O
synthesis	1054	1063	|O
of	1064	1066	|O
two	1067	1070	|O
analogues	1071	1080	|O
of	1081	1083	|O
(	1084	1085	|B-IUPAC
R	1085	1086	|I-IUPAC
)	1086	1087	|I-IUPAC
-	1087	1088	|I-IUPAC
1	1088	1089	|I-IUPAC
-	1089	1090	|I-IUPAC
O	1090	1091	|I-IUPAC
-	1091	1092	|I-IUPAC
hexadecyl	1092	1101	|I-IUPAC
-	1101	1102	|I-IUPAC
2	1102	1103	|I-IUPAC
-	1103	1104	|I-IUPAC
palmitoyl	1104	1113	|I-IUPAC
-	1113	1114	|I-IUPAC
sn	1114	1116	|I-IUPAC
-	1116	1117	|I-IUPAC
glycero	1117	1124	|I-IUPAC
-	1124	1125	|I-IUPAC
3	1125	1126	|I-IUPAC
-	1126	1127	|I-IUPAC
phosphoethanolamine	1127	1146	|I-IUPAC
poly	1147	1151	|I-IUPAC
(	1151	1152	|I-IUPAC
ethylene	1152	1160	|I-IUPAC
glycol	1161	1167	|I-IUPAC
)	1167	1168	|I-IUPAC
.	1168	1169	|O
Differential	1170	1182	|O
scanning	1183	1191	|O
calorimetry	1192	1203	|O
has	1204	1207	|O
been	1208	1212	|O
used	1213	1217	|O
to	1218	1220	|O
investigate	1221	1232	|O
the	1233	1236	|O
phase	1237	1242	|O
behavior	1243	1251	|O
of	1252	1254	|O
the	1255	1258	|O
lipid	1259	1264	|O
bilayers	1265	1273	|O
.	1273	1274	|O
A	1275	1276	|O
release	1277	1284	|O
study	1285	1290	|O
,	1290	1291	|O
employing	1292	1301	|O
calcein	1302	1309	|O
encapsulated	1310	1322	|O
in	1323	1325	|O
non	1326	1329	|O
-	1329	1330	|O
hydrolyzable	1330	1342	|O
1,2	1343	1346	|B-IUPAC
-	1346	1347	|I-IUPAC
bis	1347	1350	|I-IUPAC
-	1350	1351	|I-IUPAC
O	1351	1352	|I-IUPAC
-	1352	1353	|I-IUPAC
octadecyl	1353	1362	|I-IUPAC
-	1362	1363	|I-IUPAC
sn	1363	1365	|I-IUPAC
-	1365	1366	|I-IUPAC
glycero	1366	1373	|I-IUPAC
-	1373	1374	|I-IUPAC
3	1374	1375	|I-IUPAC
-	1375	1376	|I-IUPAC
phosphocholine	1376	1390	|I-IUPAC
(	1391	1392	|O
D	1392	1393	|O
-	1393	1394	|O
O	1394	1395	|O
-	1395	1396	|O
SPC	1396	1399	|O
)	1399	1400	|O
liposomes	1401	1410	|O
,	1410	1411	|O
showed	1412	1418	|O
that	1419	1423	|O
proAELs	1424	1431	|O
,	1431	1432	|O
activated	1433	1442	|O
by	1443	1445	|O
sPLA	1446	1450	|O
(	1450	1451	|O
2	1451	1452	|O
)	1452	1453	|O
,	1453	1454	|O
perturb	1455	1462	|O
membranes	1463	1472	|O
because	1473	1480	|O
of	1481	1483	|O
the	1484	1487	|O
detergent	1488	1497	|O
-	1497	1498	|O
like	1498	1502	|O
properties	1503	1513	|O
of	1514	1516	|O
the	1517	1520	|O
released	1521	1529	|O
hydrolysis	1530	1540	|O
products	1541	1549	|O
.	1549	1550	|O
A	1551	1552	|O
hemolysis	1553	1562	|O
investigation	1563	1576	|O
was	1577	1580	|O
conducted	1581	1590	|O
on	1591	1593	|O
human	1594	1599	|O
red	1600	1603	|O
blood	1604	1609	|O
cells	1610	1615	|O
,	1615	1616	|O
and	1617	1620	|O
the	1621	1624	|O
results	1625	1632	|O
demonstrate	1633	1644	|O
that	1645	1649	|O
proAEL	1650	1656	|O
liposomes	1657	1666	|O
display	1667	1674	|O
a	1675	1676	|O
very	1677	1681	|O
low	1682	1685	|O
hemotoxicity	1686	1698	|O
,	1698	1699	|O
which	1700	1705	|O
has	1706	1709	|O
been	1710	1714	|O
a	1715	1716	|O
major	1717	1722	|O
obstacle	1723	1731	|O
for	1732	1735	|O
using	1736	1741	|O
AELs	1742	1746	|O
in	1747	1749	|O
cancer	1750	1756	|O
therapy	1757	1764	|O
.	1764	1765	|O
The	1766	1769	|O
results	1770	1777	|O
suggest	1778	1785	|O
a	1786	1787	|O
possible	1788	1796	|O
way	1797	1800	|O
of	1801	1803	|O
combining	1804	1813	|O
a	1814	1815	|O
drug	1816	1820	|O
-	1820	1821	|O
delivery	1821	1829	|O
and	1830	1833	|O
prodrug	1834	1841	|O
concept	1842	1849	|O
in	1850	1852	|O
a	1853	1854	|O
single	1855	1861	|O
liposome	1862	1870	|O
system	1871	1877	|O
.	1877	1878	|O
Our	1879	1882	|O
investigation	1883	1896	|O
of	1897	1899	|O
the	1900	1903	|O
permeability	1904	1916	|O
-	1916	1917	|O
enhancing	1917	1926	|O
properties	1927	1937	|O
of	1938	1940	|O
the	1941	1944	|O
AEL	1945	1948	|O
molecules	1949	1958	|O
imply	1959	1964	|O
that	1965	1969	|O
by	1970	1972	|O
encapsulating	1973	1986	|O
conventional	1987	1999	|O
chemotherapeutic	2000	2016	|O
drugs	2017	2022	|O
,	2022	2023	|O
such	2024	2028	|O
as	2029	2031	|O
doxorubicin	2032	2043	|O
,	2043	2044	|O
in	2045	2047	|O
liposomes	2048	2057	|O
consisting	2058	2068	|O
of	2069	2071	|O
proAELs	2072	2079	|O
,	2079	2080	|O
an	2081	2083	|O
increased	2084	2093	|O
effect	2094	2100	|O
of	2101	2103	|O
the	2104	2107	|O
encapsulated	2108	2120	|O
drug	2121	2125	|O
might	2126	2131	|O
be	2132	2134	|O
achievable	2135	2145	|O
due	2146	2149	|O
to	2150	2152	|O
an	2153	2155	|O
enhanced	2156	2164	|O
transmembrane	2165	2178	|O
drug	2179	2183	|O
diffusion	2184	2193	|O
.	2193	2194	|O

### abstracts1081.txt
As	0	2	|O
a	3	4	|O
continuation	5	17	|O
of	18	20	|O
our	21	24	|O
earlier	25	32	|O
study	33	38	|O
(	39	40	|O
J	40	41	|O
.	41	42	|O
Med.	43	47	|O
Chem.	48	53	|O
1992	54	58	|O
,	58	59	|O
35	60	62	|O
,	62	63	|O
4334-4343	64	73	|O
)	73	74	|O
we	75	77	|O
conformationally	78	94	|O
restricted	95	105	|O
the	106	109	|O
sigma	110	115	|O
-	115	116	|O
receptor	116	124	|O
ligand	125	131	|O
2	132	133	|B-IUPAC
-	133	134	|I-IUPAC
(	134	135	|I-IUPAC
1	135	136	|I-IUPAC
-	136	137	|I-IUPAC
pyrrolidinyl	137	149	|I-IUPAC
)	149	150	|I-IUPAC
-	150	151	|I-IUPAC
N	151	152	|I-IUPAC
-	152	153	|I-IUPAC
[	153	154	|I-IUPAC
2	154	155	|I-IUPAC
-	155	156	|I-IUPAC
(	156	157	|I-IUPAC
3,4	157	160	|I-IUPAC
-	160	161	|I-IUPAC
dichlorophenyl	161	175	|I-IUPAC
)	175	176	|I-IUPAC
ethyl	176	181	|I-IUPAC
]	181	182	|I-IUPAC
-	182	183	|I-IUPAC
N	183	184	|I-IUPAC
-	184	185	|I-IUPAC
methylethylamine	185	201	|I-IUPAC
(	202	203	|O
1	203	204	|O
)	204	205	|O
by	206	208	|O
incorporating	209	222	|O
it	223	225	|O
into	226	230	|O
a	231	232	|O
series	233	239	|O
of	240	242	|O
homologous	243	253	|O
piperazines	254	265	|O
3-9	266	269	|O
and	270	273	|O
homopiperazines	274	289	|O
10	290	292	|O
and	293	296	|O
11	297	299	|O
,	299	300	|O
diazabicyclononanes	301	320	|O
and	321	324	|O
decanes	325	332	|O
,	332	333	|O
bridgehead	334	344	|O
bicyclooctanes	345	359	|O
and	360	363	|O
nonanes	364	371	|O
as	372	374	|O
well	375	379	|O
as	380	382	|O
other	383	388	|O
miscellaneous	389	402	|O
compounds	403	412	|O
.	412	413	|O
sigma	414	419	|O
-	419	420	|O
Receptor	420	428	|O
binding	429	436	|O
affinities	437	447	|O
were	448	452	|O
obtained	453	461	|O
using	462	467	|O
[	468	469	|B-IUPAC
3H	469	471	|I-IUPAC
]	471	472	|I-IUPAC
(	472	473	|I-IUPAC
+	473	474	|I-IUPAC
)	474	475	|I-IUPAC
-	475	476	|I-IUPAC
pentazocine	476	487	|I-IUPAC
in	488	490	|O
guinea	491	497	|O
pig	498	501	|O
brain	502	507	|O
membrane	508	516	|O
sigma	517	522	|O
1	523	524	|O
sites	525	530	|O
.	530	531	|O
The	532	535	|O
studies	536	543	|O
suggest	544	551	|O
that	552	556	|O
the	557	560	|O
nitrogen	561	569	|O
lone	570	574	|O
pair	575	579	|O
orientation	580	591	|O
found	592	597	|O
in	598	600	|O
the	601	604	|O
piperazines	605	616	|O
affords	617	624	|O
the	625	628	|O
strongest	629	638	|O
binding	639	646	|O
interaction	647	658	|O
.	658	659	|O
Other	660	665	|O
nitrogen	666	674	|O
lone	675	679	|O
pair	680	684	|O
orientations	685	697	|O
or	698	700	|O
compounds	701	710	|O
representing	711	723	|O
unlikely	724	732	|O
staggered	733	742	|O
conformations	743	756	|O
of	757	759	|O
1	760	761	|O
[	762	763	|O
as	764	766	|O
in	767	769	|O
4	770	771	|B-IUPAC
-	771	772	|I-IUPAC
[	772	773	|I-IUPAC
2	773	774	|I-IUPAC
-	774	775	|I-IUPAC
(	775	776	|I-IUPAC
3,4	776	779	|I-IUPAC
-	779	780	|I-IUPAC
dichlorophenyl	780	794	|I-IUPAC
)	794	795	|I-IUPAC
ethyl	795	800	|I-IUPAC
]	800	801	|I-IUPAC
-	801	802	|I-IUPAC
1,4	802	805	|I-IUPAC
-	805	806	|I-IUPAC
diazabicyclo	806	818	|I-IUPAC
[	818	819	|I-IUPAC
3.2.2	819	824	|I-IUPAC
]	824	825	|I-IUPAC
nonane	825	831	|I-IUPAC
(	832	833	|O
16	833	835	|O
)	835	836	|O
]	836	837	|O
show	838	842	|O
very	843	847	|O
weak	848	852	|O
sigma	853	858	|O
interaction	859	870	|O
.	870	871	|O
Comparison	872	882	|O
of	883	885	|O
the	886	889	|O
binding	890	897	|O
data	898	902	|O
of	903	905	|O
different	906	915	|O
N	916	917	|O
-	917	918	|O
substituted	918	929	|O
homologues	930	940	|O
of	941	943	|O
1	944	945	|O
with	946	950	|O
those	951	956	|O
of	957	959	|O
the	960	963	|O
1	964	965	|B-IUPAC
-	965	966	|I-IUPAC
[	966	967	|I-IUPAC
2	967	968	|I-IUPAC
-	968	969	|I-IUPAC
(	969	970	|I-IUPAC
3,4	970	973	|I-IUPAC
-	973	974	|I-IUPAC
dichlorophenyl	974	988	|I-IUPAC
)	988	989	|I-IUPAC
ethyl	989	994	|I-IUPAC
]	994	995	|I-IUPAC
-	995	996	|I-IUPAC
4	996	997	|I-IUPAC
-	997	998	|I-IUPAC
alkylpiperazines	998	1014	|I-IUPAC
suggests	1015	1023	|O
that	1024	1028	|O
the	1029	1032	|O
two	1033	1036	|O
nitrogen	1037	1045	|O
atoms	1046	1051	|O
of	1052	1054	|O
1	1055	1056	|O
are	1057	1060	|O
working	1061	1068	|O
in	1069	1071	|O
opposition	1072	1082	|O
to	1083	1085	|O
one	1086	1089	|O
another	1090	1097	|O
in	1098	1100	|O
terms	1101	1106	|O
of	1107	1109	|O
their	1110	1115	|O
sensitivity	1116	1127	|O
to	1128	1130	|O
steric	1131	1137	|O
bulk	1138	1142	|O
.	1142	1143	|O
The	1144	1147	|O
high	1148	1152	|O
binding	1153	1160	|O
affinity	1161	1169	|O
of	1170	1172	|O
the	1173	1176	|O
1,4	1177	1180	|B-IUPAC
-	1180	1181	|I-IUPAC
diazabicyclo	1181	1193	|I-IUPAC
[	1193	1194	|O
4.3.0	1194	1199	|O
]	1199	1200	|O
nonanes	1200	1207	|B-IUPAC
12	1208	1210	|O
suggests	1211	1219	|O
that	1220	1224	|O
these	1225	1230	|O
may	1231	1234	|O
approximate	1235	1246	|O
the	1247	1250	|O
methyl	1251	1257	|O
and	1258	1261	|O
pyrrolidine	1262	1273	|O
ring	1274	1278	|O
conformations	1279	1292	|O
found	1293	1298	|O
in	1299	1301	|O
1	1302	1303	|O
when	1304	1308	|O
it	1309	1311	|O
is	1312	1314	|O
bound	1315	1320	|O
to	1321	1323	|O
the	1324	1327	|O
sigma	1328	1333	|O
receptor	1334	1342	|O
.	1342	1343	|O
Compound	1344	1352	|O
12	1353	1355	|O
exhibited	1356	1365	|O
a	1366	1367	|O
4	1368	1369	|O
-	1369	1370	|O
fold	1370	1374	|O
enantioselectivity	1375	1393	|O
favoring	1394	1402	|O
(	1403	1404	|O
+	1404	1405	|O
)	1405	1406	|O
-	1406	1407	|O
12	1407	1409	|O
.	1409	1410	|O
The	1411	1414	|O
synthesis	1415	1424	|O
of	1425	1427	|O
6,7	1428	1431	|B-IUPAC
-	1431	1432	|I-IUPAC
dichloro	1432	1440	|I-IUPAC
-	1440	1441	|I-IUPAC
2	1441	1442	|I-IUPAC
-	1442	1443	|I-IUPAC
[	1443	1444	|I-IUPAC
[	1444	1445	|I-IUPAC
2	1445	1446	|I-IUPAC
-	1446	1447	|I-IUPAC
(	1447	1448	|I-IUPAC
1	1448	1449	|I-IUPAC
-	1449	1450	|I-IUPAC
pyrrolidinyl	1450	1462	|I-IUPAC
)	1462	1463	|I-IUPAC
ethyl	1463	1468	|I-IUPAC
]	1468	1469	|I-IUPAC
amino	1469	1474	|I-IUPAC
]	1474	1475	|I-IUPAC
tetralin	1475	1483	|I-IUPAC
(	1484	1485	|O
19	1485	1487	|O
)	1487	1488	|O
and	1489	1492	|O
its	1493	1496	|O
desmethyl	1497	1506	|B-IUPAC
derivative	1507	1517	|I-IUPAC
20	1518	1520	|O
permitted	1521	1530	|O
constraint	1531	1541	|O
of	1542	1544	|O
the	1545	1548	|O
3,4	1549	1552	|B-IUPAC
-	1552	1553	|I-IUPAC
dichlorophenyl	1553	1567	|I-IUPAC
and	1568	1571	|O
N	1572	1573	|B-IUPAC
-	1573	1574	|I-IUPAC
methyl	1574	1580	|I-IUPAC
moieties	1581	1589	|B-MODIFIER
of	1590	1592	|O
1	1593	1594	|O
into	1595	1599	|O
a	1600	1601	|O
gauche	1602	1608	|O
orientation	1609	1620	|O
.	1620	1621	|O
The	1622	1625	|O
binding	1626	1633	|O
data	1634	1638	|O
suggests	1639	1647	|O
that	1648	1652	|O
this	1653	1657	|O
conformation	1658	1670	|O
in	1671	1673	|O
1	1674	1675	|O
favors	1676	1682	|O
strong	1683	1689	|O
binding	1690	1697	|O
interaction	1698	1709	|O
at	1710	1712	|O
sigma	1713	1718	|O
-	1718	1719	|O
receptors	1719	1728	|O
.	1728	1729	|O
sigma	1730	1735	|O
-	1735	1736	|O
Receptor	1736	1744	|O
Ki	1745	1747	|O
's	1747	1749	|O
ranged	1750	1756	|O
from	1757	1761	|O
0.55	1762	1766	|O
nM	1767	1769	|O
for	1770	1773	|O
1	1774	1775	|B-IUPAC
-	1775	1776	|I-IUPAC
[	1776	1777	|I-IUPAC
2	1777	1778	|I-IUPAC
-	1778	1779	|I-IUPAC
(	1779	1780	|I-IUPAC
3,4	1780	1783	|I-IUPAC
-	1783	1784	|I-IUPAC
dichlorophenyl	1784	1798	|I-IUPAC
)	1798	1799	|I-IUPAC
ethyl	1799	1804	|I-IUPAC
]	1804	1805	|I-IUPAC
-	1805	1806	|I-IUPAC
4	1806	1807	|I-IUPAC
-	1807	1808	|I-IUPAC
n	1808	1809	|I-IUPAC
-	1809	1810	|I-IUPAC
butylpiperazine	1810	1825	|I-IUPAC
(	1826	1827	|O
7	1827	1828	|O
)	1828	1829	|O
to	1830	1832	|O
654	1833	1836	|O
nM	1837	1839	|O
for	1840	1843	|O
16	1844	1846	|O
.	1846	1847	|O
Overall	1848	1855	|O
comparison	1856	1866	|O
of	1867	1869	|O
the	1870	1873	|O
results	1874	1881	|O
indicate	1882	1890	|O
that	1891	1895	|O
1	1896	1897	|O
is	1898	1900	|O
subject	1901	1908	|O
to	1909	1911	|O
considerable	1912	1924	|O
conformational	1925	1939	|O
freedom	1940	1947	|O
and	1948	1951	|O
suggests	1952	1960	|O
that	1961	1965	|O
the	1966	1969	|O
sigma	1970	1975	|O
receptor	1976	1984	|O
is	1985	1987	|O
not	1988	1991	|O
subject	1992	1999	|O
to	2000	2002	|O
rigid	2003	2008	|O
stereochemical	2009	2023	|O
restraints	2024	2034	|O
with	2035	2039	|O
1	2040	2041	|O
.	2041	2042	|O
These	2043	2048	|O
results	2049	2056	|O
add	2057	2060	|O
to	2061	2063	|O
our	2064	2067	|O
earlier	2068	2075	|O
study	2076	2081	|O
where	2082	2087	|O
we	2088	2090	|O
restrained	2091	2101	|O
1	2102	2103	|O
using	2104	2109	|O
simple	2110	2116	|O
monocyclic	2117	2127	|O
heterocycles	2128	2140	|O
.	2140	2141	|O

### abstracts2459.txt
A	0	1	|O
number	2	8	|O
of	9	11	|O
7	12	13	|B-MODIFIER
-	13	14	|I-MODIFIER
substituted	14	25	|I-MODIFIER
4	26	27	|B-IUPAC
-	27	28	|I-IUPAC
aminopyrrolo	28	40	|I-IUPAC
[	40	41	|I-IUPAC
2,3	41	44	|I-IUPAC
-	44	45	|I-IUPAC
d	45	46	|I-IUPAC
]	46	47	|I-IUPAC
pyrimidine	47	57	|I-IUPAC
-	57	58	|I-IUPAC
5	58	59	|I-IUPAC
-	59	60	|I-IUPAC
carbonitrile	60	72	|I-IUPAC
,	72	73	|O
-	74	75	|B-IUPAC
5	75	76	|I-IUPAC
-	76	77	|I-IUPAC
carboxamide	77	88	|I-IUPAC
,	88	89	|O
and	90	93	|O
-	94	95	|B-IUPAC
5	95	96	|I-IUPAC
-	96	97	|I-IUPAC
thiocarboxamide	97	112	|I-IUPAC
derivatives	113	124	|B-MODIFIER
related	125	132	|O
to	133	135	|O
the	136	139	|O
nucleoside	140	150	|O
antibiotics	151	162	|O
toyocamycin	163	174	|O
and	175	178	|O
sangivamycin	179	191	|O
were	192	196	|O
prepared	197	205	|O
and	206	209	|O
tested	210	216	|O
for	217	220	|O
their	221	226	|O
activity	227	235	|O
against	236	243	|O
human	244	249	|O
cytomegalovirus	250	265	|O
(	266	267	|O
HCMV	267	271	|O
)	271	272	|O
and	273	276	|O
herpes	277	283	|O
simplex	284	291	|O
virus	292	297	|O
type	298	302	|O
-	302	303	|O
1	303	304	|O
(	305	306	|O
HSV	306	309	|O
-	309	310	|O
1	310	311	|O
)	311	312	|O
.	312	313	|O
Treatment	314	323	|O
of	324	326	|O
2	327	328	|B-IUPAC
-	328	329	|I-IUPAC
amino	329	334	|I-IUPAC
-	334	335	|I-IUPAC
5	335	336	|I-IUPAC
-	336	337	|I-IUPAC
bromo	337	342	|I-IUPAC
-	342	343	|I-IUPAC
3,4	343	346	|I-IUPAC
-	346	347	|I-IUPAC
dicyanopyrrole	347	361	|I-IUPAC
(	362	363	|O
1	363	364	|O
)	364	365	|O
with	366	370	|O
triethyl	371	379	|O
orthoformate	380	392	|O
followed	393	401	|O
by	402	404	|O
alkylation	405	415	|O
via	416	419	|O
the	420	423	|O
sodium	424	430	|O
salt	431	435	|O
method	436	442	|O
with	443	447	|O
a	448	449	|O
variety	450	457	|O
of	458	460	|O
alkylating	461	471	|O
agents	472	478	|O
furnished	479	488	|O
the	489	492	|O
corresponding	493	506	|O
1	507	508	|O
-	508	509	|O
substituted	509	520	|O
pyrroles	521	529	|O
2a	530	532	|O
-	532	533	|O
k	533	534	|O
.	534	535	|O
Ring	536	540	|O
annulation	541	551	|O
was	552	555	|O
achieved	556	564	|O
with	565	569	|O
methanolic	570	580	|O
ammonia	581	588	|O
affording	589	598	|O
the	599	602	|O
7	603	604	|B-MODIFIER
-	604	605	|I-MODIFIER
substituted	605	616	|I-MODIFIER
4	617	618	|B-IUPAC
-	618	619	|I-IUPAC
amino	619	624	|I-IUPAC
-	624	625	|I-IUPAC
6	625	626	|I-IUPAC
-	626	627	|I-IUPAC
bromopyrrolo+	627	640	|I-IUPAC
+	640	641	|I-IUPAC
-	641	642	|I-IUPAC
[	642	643	|I-IUPAC
2,3	643	646	|I-IUPAC
-	646	647	|I-IUPAC
d	647	648	|I-IUPAC
]	648	649	|I-IUPAC
pyrimidine	649	659	|I-IUPAC
-	659	660	|I-IUPAC
5	660	661	|I-IUPAC
-	661	662	|I-IUPAC
carbonitrile	662	674	|I-IUPAC
derivatives	675	686	|B-MODIFIER
3a	687	689	|O
-	689	690	|O
k	690	691	|O
.	691	692	|O
Debromination	693	706	|O
of	707	709	|O
3a	710	712	|O
-	712	713	|O
k	713	714	|O
,	714	715	|O
via	716	719	|O
catalytic	720	729	|O
hydrogenation	730	743	|O
,	743	744	|O
gave	745	749	|O
the	750	753	|O
corresponding	754	767	|O
7	768	769	|B-MODIFIER
-	769	770	|I-MODIFIER
substituted	770	781	|I-MODIFIER
4	782	783	|B-IUPAC
-	783	784	|I-IUPAC
aminopyrrolo	784	796	|I-IUPAC
[	796	797	|I-IUPAC
2,3	797	800	|I-IUPAC
-	800	801	|I-IUPAC
d	801	802	|I-IUPAC
]	802	803	|I-IUPAC
pyrimidine	803	813	|I-IUPAC
-	813	814	|I-IUPAC
5	814	815	|I-IUPAC
-	815	816	|I-IUPAC
carbonitrile	816	828	|I-IUPAC
analogs	829	836	|B-MODIFIER
4a	837	839	|O
-	839	840	|O
j	840	841	|O
,	841	842	|O
l	842	843	|O
.	843	844	|O
A	845	846	|O
selective	847	856	|O
reduction	857	866	|O
of	867	869	|O
4	870	871	|B-IUPAC
-	871	872	|I-IUPAC
amino	872	877	|I-IUPAC
-	877	878	|I-IUPAC
6	878	879	|I-IUPAC
-	879	880	|I-IUPAC
bromo	880	885	|I-IUPAC
-	885	886	|I-IUPAC
7	886	887	|I-IUPAC
-	887	888	|I-IUPAC
allylpyrrolo	888	900	|I-IUPAC
[	900	901	|I-IUPAC
2,3	901	904	|I-IUPAC
-	904	905	|I-IUPAC
d	905	906	|I-IUPAC
]	906	907	|I-IUPAC
-	907	908	|I-IUPAC
pyrimidine	908	918	|I-IUPAC
-	918	919	|I-IUPAC
5	919	920	|I-IUPAC
-	920	921	|I-IUPAC
carbon	921	927	|I-IUPAC
ril	928	931	|I-IUPAC
e	932	933	|I-IUPAC
(	934	935	|O
3k	935	937	|O
)	937	938	|O
in	939	941	|O
zinc	942	946	|O
and	947	950	|O
acetic	951	957	|O
acid	958	962	|O
furnished	963	972	|O
4	973	974	|B-IUPAC
-	974	975	|I-IUPAC
amino	975	980	|I-IUPAC
-	980	981	|I-IUPAC
7	981	982	|I-IUPAC
-	982	983	|I-IUPAC
allylpyrrolo	983	995	|I-IUPAC
-	995	996	|I-IUPAC
[	996	997	|I-IUPAC
2,3	997	1000	|I-IUPAC
-	1000	1001	|I-IUPAC
d	1001	1002	|I-IUPAC
]	1002	1003	|I-IUPAC
pyrimidine	1003	1013	|I-IUPAC
-	1013	1014	|I-IUPAC
5	1014	1015	|I-IUPAC
-	1015	1016	|I-IUPAC
carbonitrile	1016	1028	|I-IUPAC
(	1029	1030	|O
4k	1030	1032	|O
)	1032	1033	|O
.	1033	1034	|O
Conventional	1035	1047	|O
functional	1048	1058	|O
group	1059	1064	|O
transformations	1065	1080	|O
involving	1081	1090	|O
the	1091	1094	|O
5	1095	1096	|B-IUPAC
-	1096	1097	|I-IUPAC
cyano	1097	1102	|I-IUPAC
group	1103	1108	|B-MODIFIER
of	1109	1111	|O
4	1112	1113	|O
furnished	1114	1123	|O
the	1124	1127	|O
5	1128	1129	|B-IUPAC
-	1129	1130	|I-IUPAC
carboxamide	1130	1141	|I-IUPAC
derivatives	1142	1153	|B-MODIFIER
5a	1154	1156	|O
-	1156	1157	|O
1	1157	1158	|O
and	1159	1162	|O
the	1163	1166	|O
5	1167	1168	|B-IUPAC
-	1168	1169	|I-IUPAC
thio	1169	1173	|I-IUPAC
-	1173	1174	|I-IUPAC
amide	1174	1179	|I-IUPAC
analogs	1180	1187	|B-MODIFIER
6a	1188	1190	|O
-	1190	1191	|O
l	1191	1192	|O
.	1192	1193	|O
A	1194	1195	|O
similar	1196	1203	|O
transformation	1204	1218	|O
of	1219	1221	|O
the	1222	1225	|O
aglycone	1226	1234	|O
of	1235	1237	|O
toyocamycin	1238	1249	|O
(	1250	1251	|O
4m	1251	1253	|O
)	1253	1254	|O
furnished	1255	1264	|O
the	1265	1268	|O
corresponding	1269	1282	|O
aglycone	1283	1291	|O
of	1292	1294	|O
thiosangivamycin	1295	1311	|O
(	1312	1313	|O
6m	1313	1315	|O
)	1315	1316	|O
.	1316	1317	|O
Several	1318	1325	|O
of	1326	1328	|O
the	1329	1332	|O
new	1333	1336	|O
compounds	1337	1346	|O
(	1347	1348	|O
4-6	1348	1351	|O
a	1351	1352	|O
-	1352	1353	|O
ej	1353	1355	|O
-	1355	1356	|O
l	1356	1357	|O
)	1357	1358	|O
were	1359	1363	|O
evaluated	1364	1373	|O
for	1374	1377	|O
their	1378	1383	|O
ability	1384	1391	|O
to	1392	1394	|O
inhibit	1395	1402	|O
the	1403	1406	|O
growth	1407	1413	|O
of	1414	1416	|O
L1210	1417	1422	|O
murine	1423	1429	|O
leukemic	1430	1438	|O
cells	1439	1444	|O
.	1444	1445	|O
Whereas	1446	1453	|O
a	1454	1455	|O
number	1456	1462	|O
of	1463	1465	|O
the	1466	1469	|O
carboxamide	1470	1481	|O
(	1482	1483	|O
5	1483	1484	|O
)	1484	1485	|O
and	1486	1489	|O
thioamide	1490	1499	|O
(	1500	1501	|O
6	1501	1502	|O
)	1502	1503	|O
derivatives	1504	1515	|O
had	1516	1519	|O
modest	1520	1526	|O
activity	1527	1535	|O
,	1535	1536	|O
the	1537	1540	|O
corresponding	1541	1554	|O
nitrile	1555	1562	|B-IUPAC
analogs	1563	1570	|B-MODIFIER
(	1571	1572	|O
4	1572	1573	|O
)	1573	1574	|O
were	1575	1579	|O
all	1580	1583	|O
inactive	1584	1592	|O
.	1592	1593	|O
All	1594	1597	|O
compounds	1598	1607	|O
were	1608	1612	|O
tested	1613	1619	|O
for	1620	1623	|O
activity	1624	1632	|O
against	1633	1640	|O
HCMV	1641	1645	|O
and	1646	1649	|O
HSV	1650	1653	|O
-	1653	1654	|O
1	1654	1655	|O
.	1655	1656	|O
The	1657	1660	|O
non	1661	1664	|O
-	1664	1665	|O
nucleoside	1665	1675	|O
nitrile	1676	1683	|O
analogs	1684	1691	|O
4a	1692	1694	|O
-	1694	1695	|O
m	1695	1696	|O
and	1697	1700	|O
carboxamide	1701	1712	|B-IUPAC
derivatives	1713	1724	|B-MODIFIER
5a	1725	1727	|O
-	1727	1728	|O
l	1728	1729	|O
were	1730	1734	|O
,	1734	1735	|O
with	1736	1740	|O
a	1741	1742	|O
few	1743	1746	|O
exceptions	1747	1757	|O
,	1757	1758	|O
essentially	1759	1770	|O
inactive	1771	1779	|O
against	1780	1787	|O
HCMV	1788	1792	|O
and	1793	1796	|O
HSV	1797	1800	|O
-	1800	1801	|O
1	1801	1802	|O
and	1803	1806	|O
relatively	1807	1817	|O
nontoxic	1818	1826	|O
.	1826	1827	|O
In	1828	1830	|O
direct	1831	1837	|O
contrast	1838	1846	|O
,	1846	1847	|O
nearly	1848	1854	|O
all	1855	1858	|O
of	1859	1861	|O
the	1862	1865	|O
thioamide	1866	1875	|B-IUPAC
derivates	1876	1885	|B-MODIFIER
6a	1886	1888	|O
-	1888	1889	|O
1	1889	1890	|O
,	1890	1891	|O
including	1892	1901	|O
the	1902	1905	|O
aglycone	1906	1914	|O
of	1915	1917	|O
thiosangivamycin	1918	1934	|O
(	1935	1936	|O
6m	1936	1938	|O
)	1938	1939	|O
,	1939	1940	|O
were	1941	1945	|O
good	1946	1950	|O
inhibitors	1951	1961	|O
of	1962	1964	|O
HCMV	1965	1969	|O
and	1970	1973	|O
HSV	1974	1977	|O
-	1977	1978	|O
1	1978	1979	|O
.	1979	1980	|O
Most	1981	1985	|O
were	1986	1990	|O
noncytotoxic	1991	2003	|O
in	2004	2006	|O
their	2007	2012	|O
antiviral	2013	2022	|O
concentration	2023	2036	|O
range	2037	2042	|O
.	2042	2043	|O
Cytotoxicity	2044	2056	|O
which	2057	2062	|O
was	2063	2066	|O
observed	2067	2075	|O
appeared	2076	2084	|O
to	2085	2087	|O
be	2088	2090	|O
a	2091	2092	|O
consequence	2093	2104	|O
of	2105	2107	|O
DNA	2108	2111	|O
synthesis	2112	2121	|O
inhibition	2122	2132	|O
.	2132	2133	|O
Several	2134	2141	|O
of	2142	2144	|O
these	2145	2150	|O
compounds	2151	2160	|O
,	2160	2161	|O
such	2162	2166	|O
as	2167	2169	|O
6b	2170	2172	|O
,	2172	2173	|O
e	2173	2174	|O
,	2174	2175	|O
were	2176	2180	|O
particularly	2181	2193	|O
interesting	2194	2205	|O
inhibitors	2206	2216	|O
of	2217	2219	|O
HCMV	2220	2224	|O
with	2225	2229	|O
IC	2230	2232	|O
(	2232	2233	|O
50	2233	2235	|O
)	2235	2236	|O
's	2236	2238	|O
ranging	2239	2246	|O
from	2247	2251	|O
0.1	2252	2255	|O
to	2256	2258	|O
1.3	2259	2262	|O
muM	2263	2266	|O
.	2266	2267	|O
The	2268	2271	|O
antiviral	2272	2281	|O
activity	2282	2290	|O
of	2291	2293	|O
both	2294	2298	|O
compounds	2299	2308	|O
was	2309	2312	|O
well	2313	2317	|O
separated	2318	2327	|O
from	2328	2332	|O
cytotoxicity	2333	2345	|O
in	2346	2348	|O
KB	2349	2351	|O
,	2351	2352	|O
HFF	2353	2356	|O
,	2356	2357	|O
and	2358	2361	|O
L1210	2362	2367	|O
cells	2368	2373	|O
.	2373	2374	|O

### abstracts3663.txt
The	0	3	|O
antitumor	4	13	|O
activity	14	22	|O
of	23	25	|O
various	26	33	|O
platinum	34	42	|O
(	42	43	|O
II	43	45	|O
)	45	46	|O
complexes	47	56	|O
of	57	59	|O
1,2	60	63	|B-IUPAC
-	63	64	|I-IUPAC
cyclohexanediamine	64	82	|I-IUPAC
and	83	86	|O
2	87	88	|B-IUPAC
-	88	89	|I-IUPAC
(	89	90	|I-IUPAC
aminomethyl	90	101	|I-IUPAC
)	101	102	|I-IUPAC
cyclohexylamine	102	117	|I-IUPAC
isomers	118	125	|O
against	126	133	|O
leukemia	134	142	|O
P388	143	147	|O
was	148	151	|O
evaluated	152	161	|O
by	162	164	|O
means	165	170	|O
of	171	173	|O
the	174	177	|O
platinum	178	186	|O
analogue	187	195	|O
study	196	201	|O
protocol	202	210	|O
recommended	211	222	|O
by	223	225	|O
the	226	229	|O
National	230	238	|O
Cancer	239	245	|O
Institute	246	255	|O
.	255	256	|O
For	257	260	|O
the	261	264	|O
former	265	271	|O
complexes	272	281	|O
,	281	282	|O
trans	283	288	|O
isomers	289	296	|O
are	297	300	|O
more	301	305	|O
efficacious	306	317	|O
than	318	322	|O
the	323	326	|O
corresponding	327	340	|O
cis	341	344	|O
isomers	345	352	|O
.	352	353	|O
For	354	357	|O
the	358	361	|O
latter	362	368	|O
complexes	369	378	|O
,	378	379	|O
cis	380	383	|O
isomers	384	391	|O
seem	392	396	|O
to	397	399	|O
be	400	402	|O
somewhat	403	411	|O
more	412	416	|O
active	417	423	|O
than	424	428	|O
trans	429	434	|O
isomers	435	442	|O
.	442	443	|O
2	444	445	|B-IUPAC
-	445	446	|I-IUPAC
(	446	447	|I-IUPAC
Aminomethyl	447	458	|I-IUPAC
)	458	459	|I-IUPAC
cyclohexylamine	459	474	|I-IUPAC
platinum	475	483	|I-IUPAC
complexes	484	493	|B-MODIFIER
exhibited	494	503	|O
higher	504	510	|O
activity	511	519	|O
than	520	524	|O
1,2	525	528	|B-IUPAC
-	528	529	|I-IUPAC
cyclohexanediamine	529	547	|I-IUPAC
complexes	548	557	|B-MODIFIER
in	558	560	|O
this	561	565	|O
tumor	566	571	|O
system	572	578	|O
.	578	579	|O
These	580	585	|O
findings	586	594	|O
encouraged	595	605	|O
us	606	608	|O
to	609	611	|O
determine	612	621	|O
the	622	625	|O
structural	626	636	|O
differences	637	648	|O
between	649	656	|O
1,2	657	660	|B-IUPAC
-	660	661	|I-IUPAC
cyclohexanediamine	661	679	|I-IUPAC
and	680	683	|O
2	684	685	|B-IUPAC
-	685	686	|I-IUPAC
(	686	687	|I-IUPAC
aminomethyl	687	698	|I-IUPAC
)	698	699	|I-IUPAC
cyclohexylamine	699	714	|I-IUPAC
complexes	715	724	|B-MODIFIER
.	724	725	|O
Their	726	731	|O
structures	732	742	|O
of	743	745	|O
platinum	746	754	|O
complexes	755	764	|O
were	765	769	|O
elucidated	770	780	|O
from	781	785	|O
circular	786	794	|O
dichroism	795	804	|O
and	805	808	|O
13C	809	812	|O
NMR	813	816	|O
spectral	817	825	|O
analyses	826	834	|O
,	834	835	|O
and	836	839	|O
it	840	842	|O
has	843	846	|O
been	847	851	|O
concluded	852	861	|O
that	862	866	|O
the	867	870	|O
cyclohexane	871	882	|O
ring	883	887	|O
of	888	890	|O
cis	891	894	|B-IUPAC
-	894	895	|I-IUPAC
1,2	895	898	|I-IUPAC
-	898	899	|I-IUPAC
cyclohexanediamine	899	917	|I-IUPAC
is	918	920	|O
nearly	921	927	|O
perpendicular	928	941	|O
to	942	944	|O
the	945	948	|O
chelate	949	956	|O
ring	957	961	|O
,	961	962	|O
while	963	968	|O
both	969	973	|O
rings	974	979	|O
of	980	982	|O
trans	983	988	|B-IUPAC
-	988	989	|I-IUPAC
1,2	989	992	|I-IUPAC
-	992	993	|I-IUPAC
cyclohexanediamine	993	1011	|I-IUPAC
and	1012	1015	|O
trans	1016	1021	|B-IUPAC
-	1021	1022	|I-IUPAC
2	1022	1023	|I-IUPAC
-	1023	1024	|I-IUPAC
(	1024	1025	|I-IUPAC
aminomethyl	1025	1036	|I-IUPAC
)	1036	1037	|I-IUPAC
cyclohexylamine	1037	1052	|I-IUPAC
complexes	1053	1062	|B-MODIFIER
lie	1063	1066	|O
in	1067	1069	|O
a	1070	1071	|O
common	1072	1078	|O
plane	1079	1084	|O
.	1084	1085	|O
The	1086	1089	|O
structure	1090	1099	|O
of	1100	1102	|O
cis	1103	1106	|B-IUPAC
-	1106	1107	|I-IUPAC
2	1107	1108	|I-IUPAC
-	1108	1109	|I-IUPAC
(	1109	1110	|I-IUPAC
aminomethyl	1110	1121	|I-IUPAC
)	1121	1122	|I-IUPAC
cyclohexylamine	1122	1137	|I-IUPAC
complexes	1138	1147	|B-MODIFIER
is	1148	1150	|O
flexible	1151	1159	|O
,	1159	1160	|O
and	1161	1164	|O
the	1165	1168	|O
cyclohexane	1169	1180	|O
ring	1181	1185	|O
is	1186	1188	|O
not	1189	1192	|O
perpendicular	1193	1206	|O
to	1207	1209	|O
the	1210	1213	|O
chelate	1214	1221	|O
ring	1222	1226	|O
.	1226	1227	|O
The	1228	1231	|O
coplanarity	1232	1243	|O
of	1244	1246	|O
trans	1247	1252	|O
isomers	1253	1260	|O
and	1261	1264	|O
the	1265	1268	|O
flexibility	1269	1280	|O
of	1281	1283	|O
cis	1284	1287	|B-IUPAC
-	1287	1288	|I-IUPAC
2	1288	1289	|I-IUPAC
-	1289	1290	|I-IUPAC
(	1290	1291	|I-IUPAC
aminomethyl	1291	1302	|I-IUPAC
)	1302	1303	|I-IUPAC
cyclohexylamine	1303	1318	|I-IUPAC
complexes	1319	1328	|B-MODIFIER
allow	1329	1334	|O
them	1335	1339	|O
easy	1340	1344	|O
approach	1345	1353	|O
to	1354	1356	|O
the	1357	1360	|O
target	1361	1367	|O
DNA	1368	1371	|O
.	1371	1372	|O
However	1373	1380	|O
,	1380	1381	|O
the	1382	1385	|O
perpendicular	1386	1399	|O
ring	1400	1404	|O
of	1405	1407	|O
cis	1408	1411	|B-IUPAC
-	1411	1412	|I-IUPAC
1,2	1412	1415	|I-IUPAC
-	1415	1416	|I-IUPAC
cyclohexanediamine	1416	1434	|I-IUPAC
complexes	1435	1444	|B-MODIFIER
would	1445	1450	|O
prevent	1451	1458	|O
their	1459	1464	|O
interactions	1465	1477	|O
with	1478	1482	|O
dna	1483	1486	|O
molecules	1487	1496	|O
due	1497	1500	|O
to	1501	1503	|O
the	1504	1507	|O
steric	1508	1514	|O
hindrance	1515	1524	|O
.	1524	1525	|O

### abstracts4043.txt
Two	0	3	|O
novel	4	9	|O
classical	10	19	|O
antifolates	20	31	|O
N	32	33	|B-IUPAC
-	33	34	|I-IUPAC
{	34	35	|I-IUPAC
4	35	36	|I-IUPAC
-	36	37	|I-IUPAC
[	37	38	|I-IUPAC
(	38	39	|I-IUPAC
2,4	39	42	|I-IUPAC
-	42	43	|I-IUPAC
diamino	43	50	|I-IUPAC
-	50	51	|I-IUPAC
5	51	52	|I-IUPAC
-	52	53	|I-IUPAC
methyl	53	59	|I-IUPAC
-	59	60	|I-IUPAC
4,7	60	63	|I-IUPAC
-	63	64	|I-IUPAC
dihydro	64	71	|I-IUPAC
-	71	72	|I-IUPAC
3H	72	74	|I-IUPAC
-	74	75	|I-IUPAC
pyrrolo	75	82	|I-IUPAC
[	82	83	|I-IUPAC
2,3	83	86	|I-IUPAC
-	86	87	|I-IUPAC
d	87	88	|I-IUPAC
]	88	89	|I-IUPAC
pyrimidin	89	98	|I-IUPAC
-	98	99	|I-IUPAC
6	99	100	|I-IUPAC
-	100	101	|I-IUPAC
yl	101	103	|I-IUPAC
)	103	104	|I-IUPAC
thio	104	108	|I-IUPAC
]	108	109	|I-IUPAC
benzoyl	109	116	|I-IUPAC
}	116	117	|I-IUPAC
-	117	118	|I-IUPAC
L	118	119	|I-IUPAC
-	119	120	|I-IUPAC
glutamic	120	128	|I-IUPAC
acid	129	133	|I-IUPAC
3	134	135	|O
and	136	139	|O
N	140	141	|B-IUPAC
-	141	142	|I-IUPAC
{	142	143	|I-IUPAC
4	143	144	|I-IUPAC
-	144	145	|I-IUPAC
[	145	146	|I-IUPAC
(	146	147	|I-IUPAC
2	147	148	|I-IUPAC
-	148	149	|I-IUPAC
amino	149	154	|I-IUPAC
-	154	155	|I-IUPAC
4	155	156	|I-IUPAC
-	156	157	|I-IUPAC
oxo	157	160	|I-IUPAC
-	160	161	|I-IUPAC
5	161	162	|I-IUPAC
-	162	163	|I-IUPAC
methyl	163	169	|I-IUPAC
-	169	170	|I-IUPAC
4,7	170	173	|I-IUPAC
-	173	174	|I-IUPAC
dihydro	174	181	|I-IUPAC
-	181	182	|I-IUPAC
3H	182	184	|I-IUPAC
-	184	185	|I-IUPAC
pyrrolo	185	192	|I-IUPAC
[	192	193	|I-IUPAC
2,3	193	196	|I-IUPAC
-	196	197	|I-IUPAC
d	197	198	|I-IUPAC
]	198	199	|I-IUPAC
pyrimidin	199	208	|I-IUPAC
-	208	209	|I-IUPAC
6	209	210	|I-IUPAC
-	210	211	|I-IUPAC
yl	211	213	|I-IUPAC
)	213	214	|I-IUPAC
thio	214	218	|I-IUPAC
]	218	219	|I-IUPAC
benzoyl	219	226	|I-IUPAC
}	226	227	|I-IUPAC
-	227	228	|I-IUPAC
L	228	229	|I-IUPAC
-	229	230	|I-IUPAC
glutamic	230	238	|I-IUPAC
acid	239	243	|I-IUPAC
4	244	245	|O
were	246	250	|O
designed	251	259	|O
,	259	260	|O
synthesized	261	272	|O
,	272	273	|O
and	274	277	|O
evaluated	278	287	|O
as	288	290	|O
antitumor	291	300	|O
agents	301	307	|O
.	307	308	|O
Compounds	309	318	|O
3	319	320	|O
and	321	324	|O
4	325	326	|O
were	327	331	|O
obtained	332	340	|O
from	341	345	|O
2,4	346	349	|B-IUPAC
-	349	350	|I-IUPAC
diamino	350	357	|I-IUPAC
-	357	358	|I-IUPAC
5	358	359	|I-IUPAC
-	359	360	|I-IUPAC
methylpyrrolo	360	373	|I-IUPAC
[	373	374	|I-IUPAC
2,3	374	377	|I-IUPAC
-	377	378	|I-IUPAC
d	378	379	|I-IUPAC
]	379	380	|I-IUPAC
pyrimidine	380	390	|I-IUPAC
7	391	392	|O
and	393	396	|O
2	397	398	|B-IUPAC
-	398	399	|I-IUPAC
amino	399	404	|I-IUPAC
-	404	405	|I-IUPAC
4	405	406	|I-IUPAC
-	406	407	|I-IUPAC
oxo	407	410	|I-IUPAC
-	410	411	|I-IUPAC
5	411	412	|I-IUPAC
-	412	413	|I-IUPAC
methylpyrrolo	413	426	|I-IUPAC
[	426	427	|I-IUPAC
2,3	427	430	|I-IUPAC
-	430	431	|I-IUPAC
d	431	432	|I-IUPAC
]	432	433	|I-IUPAC
pyrimidine	433	443	|I-IUPAC
12	444	446	|O
,	446	447	|O
respectively	448	460	|O
,	460	461	|O
in	462	464	|O
a	465	466	|O
concise	467	474	|O
three	475	480	|O
-	480	481	|O
step	481	485	|O
sequence	486	494	|O
.	494	495	|O
Compound	496	504	|O
3	505	506	|O
is	507	509	|O
the	510	513	|O
first	514	519	|O
example	520	527	|O
,	527	528	|O
to	529	531	|O
our	532	535	|O
knowledge	536	545	|O
,	545	546	|O
of	547	549	|O
a	550	551	|O
2,4	552	555	|O
-	555	556	|O
diamino	556	563	|O
classical	564	573	|O
antifolate	574	584	|O
that	585	589	|O
has	590	593	|O
potent	594	600	|O
inhibitory	601	611	|O
activity	612	620	|O
against	621	628	|O
both	629	633	|O
human	634	639	|O
dihydrofolate	640	653	|O
reductase	654	663	|O
(	664	665	|O
DHFR	665	669	|O
)	669	670	|O
and	671	674	|O
human	675	680	|O
thymidylate	681	692	|O
synthase	693	701	|O
(	702	703	|O
TS	703	705	|O
)	705	706	|O
.	706	707	|O
Compound	708	716	|O
4	717	718	|O
was	719	722	|O
a	723	724	|O
dual	725	729	|O
DHFR	730	734	|O
-	734	735	|O
TS	735	737	|O
inhibitor	738	747	|O
against	748	755	|O
the	756	759	|O
bifunctional	760	772	|O
enzyme	773	779	|O
derived	780	787	|O
from	788	792	|O
Toxoplasma	793	803	|O
gondii	804	810	|O
(	811	812	|O
tg	812	814	|O
)	814	815	|O
.	815	816	|O
Further	817	824	|O
evaluation	825	835	|O
of	836	838	|O
the	839	842	|O
mechanism	843	852	|O
of	853	855	|O
action	856	862	|O
of	863	865	|O
3	866	867	|O
implicated	868	878	|O
DHFR	879	883	|O
as	884	886	|O
its	887	890	|O
primary	891	898	|O
intracellular	899	912	|O
target	913	919	|O
.	919	920	|O
Both	921	925	|O
3	926	927	|O
and	928	931	|O
4	932	933	|O
were	934	938	|O
folylpolyglutamate	939	957	|O
synthetase	958	968	|O
(	969	970	|O
FPGS	970	974	|O
)	974	975	|O
substrates	976	986	|O
.	986	987	|O
Compound	988	996	|O
3	997	998	|O
also	999	1003	|O
inhibited	1004	1013	|O
the	1014	1017	|O
growth	1018	1024	|O
of	1025	1027	|O
several	1028	1035	|O
human	1036	1041	|O
tumor	1042	1047	|O
cell	1048	1052	|O
lines	1053	1058	|O
in	1059	1061	|O
culture	1062	1069	|O
with	1070	1074	|O
GI50	1075	1079	|O
&	1080	1081	|O
lt	1081	1083	|O
;	1083	1084	|O
10	1085	1087	|O
(	1087	1088	|O
-	1088	1089	|O
8	1089	1090	|O
)	1090	1091	|O
M	1092	1093	|O
.	1093	1094	|O
This	1095	1099	|O
study	1100	1105	|O
shows	1106	1111	|O
that	1112	1116	|O
the	1117	1120	|O
pyrrolo	1121	1128	|B-IUPAC
[	1128	1129	|I-IUPAC
2,3	1129	1132	|I-IUPAC
-	1132	1133	|I-IUPAC
d	1133	1134	|I-IUPAC
]	1134	1135	|I-IUPAC
pyrimidine	1135	1145	|I-IUPAC
scaffold	1146	1154	|B-MODIFIER
is	1155	1157	|O
conducive	1158	1167	|O
to	1168	1170	|O
dual	1171	1175	|O
DHFR	1176	1180	|O
-	1180	1181	|O
TS	1181	1183	|O
and	1184	1187	|O
tumor	1188	1193	|O
inhibitory	1194	1204	|O
activity	1205	1213	|O
,	1213	1214	|O
and	1215	1218	|O
the	1219	1222	|O
potency	1223	1230	|O
is	1231	1233	|O
determined	1234	1244	|O
by	1245	1247	|O
the	1248	1251	|O
4	1252	1253	|O
-	1253	1254	|O
position	1254	1262	|O
substituent	1263	1274	|O
.	1274	1275	|O

### abstracts614.txt
A	0	1	|O
diverse	2	9	|O
range	10	15	|O
of	16	18	|O
chromen	19	26	|B-IUPAC
-	26	27	|I-IUPAC
2	27	28	|I-IUPAC
-	28	29	|I-IUPAC
one	29	32	|I-IUPAC
,	32	33	|O
chromen	34	41	|B-IUPAC
-	41	42	|I-IUPAC
4	42	43	|I-IUPAC
-	43	44	|I-IUPAC
one	44	47	|I-IUPAC
and	48	51	|O
pyrimidoisoquinolin	52	71	|B-IUPAC
-	71	72	|I-IUPAC
4	72	73	|I-IUPAC
-	73	74	|I-IUPAC
one	74	77	|I-IUPAC
derivatives	78	89	|B-MODIFIER
was	90	93	|O
synthesized	94	105	|O
and	106	109	|O
evaluated	110	119	|O
for	120	123	|O
inhibitory	124	134	|O
activity	135	143	|O
against	144	151	|O
the	152	155	|O
DNA	156	159	|O
repair	160	166	|O
enzyme	167	173	|O
DNA	174	177	|O
-	177	178	|O
dependent	178	187	|O
protein	188	195	|O
kinase	196	202	|O
(	203	204	|O
DNA	204	207	|O
-	207	208	|O
PK	208	210	|O
)	210	211	|O
,	211	212	|O
with	213	217	|O
a	218	219	|O
view	220	224	|O
to	225	227	|O
elucidating	228	239	|O
structure	240	249	|O
-	249	250	|O
activity	250	258	|O
relationships	259	272	|O
for	273	276	|O
potency	277	284	|O
and	285	288	|O
kinase	289	295	|O
selectivity	296	307	|O
.	307	308	|O
DNA	309	312	|O
-	312	313	|O
PK	313	315	|O
inhibitory	316	326	|O
activity	327	335	|O
varied	336	342	|O
widely	343	349	|O
over	350	354	|O
the	355	358	|O
series	359	365	|O
of	366	368	|O
compounds	369	378	|O
evaluated	379	388	|O
(	389	390	|O
IC	390	392	|O
(	392	393	|O
50	393	395	|O
)	395	396	|O
values	397	403	|O
ranged	404	410	|O
from	411	415	|O
0.19	416	420	|O
to	421	423	|O
&	424	425	|O
gt	425	427	|O
;	427	428	|O
10	428	430	|O
microM	431	437	|O
)	437	438	|O
,	438	439	|O
with	440	444	|O
excellent	445	454	|O
activity	455	463	|O
being	464	469	|O
observed	470	478	|O
for	479	482	|O
the	483	486	|O
7,8	487	490	|B-IUPAC
-	490	491	|I-IUPAC
benzochromen	491	503	|I-IUPAC
-	503	504	|I-IUPAC
4	504	505	|I-IUPAC
-	505	506	|I-IUPAC
one	506	509	|I-IUPAC
and	510	513	|O
pyrimido	514	522	|B-IUPAC
[	522	523	|I-IUPAC
2,1	523	526	|I-IUPAC
-	526	527	|I-IUPAC
a	527	528	|I-IUPAC
]	528	529	|I-IUPAC
isoquinolin	529	540	|I-IUPAC
-	540	541	|I-IUPAC
4	541	542	|I-IUPAC
-	542	543	|I-IUPAC
one	543	546	|I-IUPAC
templates	547	556	|O
.	556	557	|O
By	558	560	|O
contrast	561	569	|O
,	569	570	|O
inhibitors	571	581	|O
based	582	587	|O
on	588	590	|O
the	591	594	|O
benzochromen	595	607	|B-IUPAC
-	607	608	|I-IUPAC
2	608	609	|I-IUPAC
-	609	610	|I-IUPAC
one	610	613	|I-IUPAC
(	614	615	|O
coumarin	615	623	|O
)	623	624	|O
or	625	627	|O
2	628	629	|B-IUPAC
-	629	630	|I-IUPAC
aryl	630	634	|I-IUPAC
-	634	635	|I-IUPAC
7,8	635	638	|I-IUPAC
-	638	639	|I-IUPAC
benzochromen	639	651	|I-IUPAC
-	651	652	|I-IUPAC
4	652	653	|I-IUPAC
-	653	654	|I-IUPAC
one	654	657	|I-IUPAC
(	658	659	|O
flavone	659	666	|O
)	666	667	|O
scaffolds	668	677	|B-MODIFIER
were	678	682	|O
less	683	687	|O
potent	688	694	|O
.	694	695	|O
Crucially	696	705	|O
,	705	706	|O
these	707	712	|O
studies	713	720	|O
revealed	721	729	|O
a	730	731	|O
very	732	736	|O
constrained	737	748	|O
structure	749	758	|O
-	758	759	|O
activity	759	767	|O
relationship	768	780	|O
at	781	783	|O
the	784	787	|O
2	788	789	|O
-	789	790	|O
position	790	798	|O
of	799	801	|O
the	802	805	|O
benzopyranone	806	819	|O
and	820	823	|O
pyrimido	824	832	|B-IUPAC
[	832	833	|I-IUPAC
2,1	833	836	|I-IUPAC
-	836	837	|I-IUPAC
a	837	838	|I-IUPAC
]	838	839	|I-IUPAC
isoquinolin	839	850	|I-IUPAC
-	850	851	|I-IUPAC
4	851	852	|I-IUPAC
-	852	853	|I-IUPAC
one	853	856	|I-IUPAC
pharmacophore	857	870	|B-MODIFIER
,	870	871	|O
with	872	876	|O
only	877	881	|O
a	882	883	|O
2	884	885	|B-IUPAC
-	885	886	|I-IUPAC
morpholino	886	896	|I-IUPAC
or	897	899	|O
2	900	901	|B-IUPAC
-	901	902	|I-IUPAC
(	902	903	|I-IUPAC
2'	903	905	|I-IUPAC
-	905	906	|I-IUPAC
methylmorpholino	906	922	|I-IUPAC
)	922	923	|I-IUPAC
group	924	929	|B-MODIFIER
being	930	935	|O
tolerated	936	945	|O
at	946	948	|O
this	949	953	|O
position	954	962	|O
.	962	963	|O
More	964	968	|O
detailed	969	977	|O
biological	978	988	|O
studies	989	996	|O
conducted	997	1006	|O
with	1007	1011	|O
the	1012	1015	|O
most	1016	1020	|O
potent	1021	1027	|O
inhibitor	1028	1037	|O
NU7163	1038	1044	|O
(	1045	1046	|O
48	1046	1048	|O
;	1048	1049	|O
IC	1050	1052	|O
(	1052	1053	|O
50	1053	1055	|O
)	1055	1056	|O
=	1057	1058	|O
0.19	1059	1063	|O
microM	1064	1070	|O
)	1070	1071	|O
demonstrated	1072	1084	|O
ATP	1085	1088	|O
-	1088	1089	|O
competitive	1089	1100	|O
DNA	1101	1104	|O
-	1104	1105	|O
PK	1105	1107	|O
inhibition	1108	1118	|O
,	1118	1119	|O
with	1120	1124	|O
a	1125	1126	|O
K	1127	1128	|O
(	1128	1129	|O
i	1129	1130	|O
)	1130	1131	|O
value	1132	1137	|O
of	1138	1140	|O
24	1141	1143	|O
nM	1144	1146	|O
,	1146	1147	|O
and	1148	1151	|O
48	1152	1154	|O
exhibited	1155	1164	|O
selectivity	1165	1176	|O
for	1177	1180	|O
DNA	1181	1184	|O
-	1184	1185	|O
PK	1185	1187	|O
compared	1188	1196	|O
with	1197	1201	|O
the	1202	1205	|O
related	1206	1213	|O
enzymes	1214	1221	|O
ATM	1222	1225	|O
,	1225	1226	|O
ATR	1227	1230	|O
,	1230	1231	|O
mTOR	1232	1236	|O
,	1236	1237	|O
and	1238	1241	|O
PI	1242	1244	|O
3	1245	1246	|O
-	1246	1247	|O
K	1247	1248	|O
(	1249	1250	|O
p110alpha	1250	1259	|O
)	1259	1260	|O
.	1260	1261	|O
Compound	1262	1270	|O
48	1271	1273	|O
sensitized	1274	1284	|O
the	1285	1288	|O
HeLa	1289	1293	|O
human	1294	1299	|O
tumor	1300	1305	|O
cell	1306	1310	|O
line	1311	1315	|O
to	1316	1318	|O
the	1319	1322	|O
cytotoxic	1323	1332	|O
effects	1333	1340	|O
of	1341	1343	|O
ionizing	1344	1352	|O
radiation	1353	1362	|O
in	1363	1365	|O
vitro	1366	1371	|O
,	1371	1372	|O
a	1373	1374	|O
dose	1375	1379	|O
modification	1380	1392	|O
factor	1393	1399	|O
of	1400	1402	|O
2.3	1403	1406	|O
at	1407	1409	|O
10%	1410	1413	|O
survival	1414	1422	|O
being	1423	1428	|O
observed	1429	1437	|O
with	1438	1442	|O
an	1443	1445	|O
inhibitor	1446	1455	|O
concentration	1456	1469	|O
of	1470	1472	|O
5	1473	1474	|O
microM	1475	1481	|O
.	1481	1482	|O
This	1483	1487	|O
study	1488	1493	|O
identified	1494	1504	|O
these	1505	1510	|O
structural	1511	1521	|O
classes	1522	1529	|O
as	1530	1532	|O
novel	1533	1538	|O
DNA	1539	1542	|O
-	1542	1543	|O
PK	1543	1545	|O
inhibitors	1546	1556	|O
and	1557	1560	|O
delineated	1561	1571	|O
initial	1572	1579	|O
structure	1580	1589	|O
-	1589	1590	|O
activity	1590	1598	|O
relationships	1599	1612	|O
against	1613	1620	|O
DNA	1621	1624	|O
-	1624	1625	|O
PK	1625	1627	|O
.	1627	1628	|O

### abstracts4469.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
analogues	12	21	|O
and	22	25	|O
homologues	26	36	|O
of	37	39	|O
N1	40	42	|B-IUPAC
,	42	43	|I-IUPAC
N12	43	46	|I-IUPAC
-	46	47	|I-IUPAC
diethylspermine	47	62	|I-IUPAC
(	63	64	|O
DESPM	64	69	|O
)	69	70	|O
was	71	74	|O
synthesized	75	86	|O
,	86	87	|O
and	88	91	|O
their	92	97	|O
biological	98	108	|O
properties	109	119	|O
were	120	124	|O
evaluated	125	134	|O
.	134	135	|O
These	136	141	|O
tetraamines	142	153	|O
include	154	161	|O
a	162	163	|O
simple	164	170	|O
linear	171	177	|O
analogue	178	186	|O
of	187	189	|O
DESPM	190	195	|O
,	195	196	|O
N1	197	199	|B-IUPAC
,	199	200	|I-IUPAC
N12	200	203	|I-IUPAC
-	203	204	|I-IUPAC
bis	204	207	|I-IUPAC
(	207	208	|I-IUPAC
2,2,2	208	213	|I-IUPAC
-	213	214	|I-IUPAC
trifluoroethyl	214	228	|I-IUPAC
)	228	229	|I-IUPAC
spermine	229	237	|I-IUPAC
(	238	239	|O
FDESPM	239	245	|O
)	245	246	|O
,	246	247	|O
the	248	251	|O
cyclic	252	258	|O
analogues	259	268	|O
of	269	271	|O
DESPM	272	277	|O
,	277	278	|O
N	279	280	|B-IUPAC
,	280	281	|I-IUPAC
N'	281	283	|I-IUPAC
-	283	284	|I-IUPAC
bis	284	287	|I-IUPAC
(	287	288	|I-IUPAC
4	288	289	|I-IUPAC
-	289	290	|I-IUPAC
piperidinylmethyl	290	307	|I-IUPAC
)	307	308	|I-IUPAC
-	308	309	|I-IUPAC
1,4	309	312	|I-IUPAC
-	312	313	|I-IUPAC
diaminobutane	313	326	|I-IUPAC
[	327	328	|O
PIP	328	331	|O
(	331	332	|O
4,4,4	332	337	|O
)	337	338	|O
]	338	339	|O
and	340	343	|O
N	344	345	|B-IUPAC
,	345	346	|I-IUPAC
N'	346	348	|I-IUPAC
-	348	349	|I-IUPAC
bis	349	352	|I-IUPAC
[	352	353	|I-IUPAC
2	353	354	|I-IUPAC
-	354	355	|I-IUPAC
(	355	356	|I-IUPAC
4	356	357	|I-IUPAC
-	357	358	|I-IUPAC
piperidinyl	358	369	|I-IUPAC
)	369	370	|I-IUPAC
ethyl	370	375	|I-IUPAC
]	375	376	|I-IUPAC
-	376	377	|I-IUPAC
1,4	377	380	|I-IUPAC
-	380	381	|I-IUPAC
diaminobutane	381	394	|I-IUPAC
[	395	396	|O
PIP	396	399	|O
(	399	400	|O
5,4,5	400	405	|O
)	405	406	|O
]	406	407	|O
,	407	408	|O
and	409	412	|O
their	413	418	|O
aromatic	419	427	|O
counterparts	428	440	|O
,	440	441	|O
N	442	443	|B-IUPAC
,	443	444	|I-IUPAC
N'	444	446	|I-IUPAC
-	446	447	|I-IUPAC
bis	447	450	|I-IUPAC
-	450	451	|I-IUPAC
(	451	452	|I-IUPAC
4	452	453	|I-IUPAC
-	453	454	|I-IUPAC
pyridylmethyl	454	467	|I-IUPAC
)	467	468	|I-IUPAC
-	468	469	|I-IUPAC
1,4	469	472	|I-IUPAC
-	472	473	|I-IUPAC
diaminobutane	473	486	|I-IUPAC
[	487	488	|O
PYR	488	491	|O
(	491	492	|O
4,4,4	492	497	|O
)	497	498	|O
]	498	499	|O
and	500	503	|O
N	504	505	|B-IUPAC
,	505	506	|I-IUPAC
N'	506	508	|I-IUPAC
-	508	509	|I-IUPAC
bis	509	512	|I-IUPAC
[	512	513	|I-IUPAC
2	513	514	|I-IUPAC
-	514	515	|I-IUPAC
(	515	516	|I-IUPAC
4	516	517	|I-IUPAC
-	517	518	|I-IUPAC
pyridyl	518	525	|I-IUPAC
)	525	526	|I-IUPAC
ethyl	526	531	|I-IUPAC
]	531	532	|I-IUPAC
-	532	533	|I-IUPAC
1,4	533	536	|I-IUPAC
-	536	537	|I-IUPAC
diaminobutane	537	550	|I-IUPAC
[	551	552	|O
PYR	552	555	|O
(	555	556	|O
5,4,5	556	561	|O
)	561	562	|O
]	562	563	|O
.	563	564	|O
The	565	568	|O
analogues	569	578	|O
FDESPM	579	585	|O
,	585	586	|O
PIP	587	590	|O
(	590	591	|O
4,4,4	591	596	|O
)	596	597	|O
,	597	598	|O
and	599	602	|O
PYR	603	606	|O
(	606	607	|O
4,4,4	607	612	|O
)	612	613	|O
have	614	618	|O
distances	619	628	|O
between	629	636	|O
their	637	642	|O
nitrogen	643	651	|O
atoms	652	657	|O
almost	658	664	|O
identical	665	674	|O
to	675	677	|O
those	678	683	|O
of	684	686	|O
DESPM	687	692	|O
.	692	693	|O
The	694	697	|O
longer	698	704	|O
analogues	705	714	|O
PIP	715	718	|O
(	718	719	|O
5,4,5	719	724	|O
)	724	725	|O
and	726	729	|O
PYR	730	733	|O
(	733	734	|O
5,4,5	734	739	|O
)	739	740	|O
are	741	744	|O
very	745	749	|O
similar	750	757	|O
in	758	760	|O
the	761	764	|O
spacing	765	772	|O
of	773	775	|O
their	776	781	|O
amino	782	787	|O
groups	788	794	|O
.	794	795	|O
However	796	803	|O
,	803	804	|O
the	805	808	|O
pKa	809	812	|O
of	813	815	|O
the	816	819	|O
nitrogens	820	829	|O
in	830	832	|O
the	833	836	|O
groups	837	843	|O
differ	844	850	|O
;	850	851	|O
thus	852	856	|O
,	856	857	|O
the	858	861	|O
extent	862	868	|O
of	869	871	|O
protonation	872	883	|O
and	884	887	|O
the	888	891	|O
charge	892	898	|O
characteristics	899	914	|O
among	915	920	|O
the	921	924	|O
members	925	932	|O
of	933	935	|O
the	936	939	|O
groups	940	946	|O
differ	947	953	|O
.	953	954	|O
A	955	956	|O
comparison	957	967	|O
of	968	970	|O
the	971	974	|O
biological	975	985	|O
properties	986	996	|O
of	997	999	|O
these	1000	1005	|O
compounds	1006	1015	|O
clearly	1016	1023	|O
demonstrates	1024	1036	|O
that	1037	1041	|O
the	1042	1045	|O
tetraamines	1046	1057	|O
must	1058	1062	|O
be	1063	1065	|O
charged	1066	1073	|O
to	1074	1076	|O
be	1077	1079	|O
"	1080	1081	|O
recognized	1081	1091	|O
"	1091	1092	|O
by	1093	1095	|O
the	1096	1099	|O
cell	1100	1104	|O
.	1104	1105	|O
Analogues	1106	1115	|O
with	1116	1120	|O
low	1121	1124	|O
nitrogen	1125	1133	|O
pKa	1134	1137	|O
's	1137	1139	|O
such	1140	1144	|O
that	1145	1149	|O
the	1150	1153	|O
nitrogens	1154	1163	|O
are	1164	1167	|O
poorly	1168	1174	|O
protonated	1175	1185	|O
at	1186	1188	|O
physiological	1189	1202	|O
pH	1203	1205	|O
do	1206	1208	|O
not	1209	1212	|O
compete	1213	1220	|O
well	1221	1225	|O
with	1226	1230	|O
spermidine	1231	1241	|O
for	1242	1245	|O
uptake	1246	1252	|O
and	1253	1256	|O
,	1256	1257	|O
as	1258	1260	|O
expected	1261	1269	|O
,	1269	1270	|O
have	1271	1275	|O
high	1276	1280	|O
96	1281	1283	|O
h	1284	1285	|O
IC50	1286	1290	|O
values	1291	1297	|O
and	1298	1301	|O
have	1302	1306	|O
little	1307	1313	|O
effect	1314	1320	|O
on	1321	1323	|O
S	1324	1325	|B-IUPAC
-	1325	1326	|I-IUPAC
adenosylmethionine	1326	1344	|I-IUPAC
decarboxylase	1345	1358	|O
,	1358	1359	|O
ornithine	1360	1369	|O
decarboxylase	1370	1383	|O
,	1383	1384	|O
and	1385	1388	|O
spermidine	1389	1399	|O
/	1399	1400	|O
spermine	1400	1408	|O
N1	1409	1411	|O
-	1411	1412	|O
acetyltransferase	1412	1429	|O
activities	1430	1440	|O
and	1441	1444	|O
on	1445	1447	|O
intracellular	1448	1461	|O
polyamine	1462	1471	|O
pools	1472	1477	|O
.	1477	1478	|O

### abstracts4539.txt
WB	0	2	|O
4101	3	7	|O
(	8	9	|O
1	9	10	|O
)	10	11	|O
-	11	12	|O
related	12	19	|O
benzodioxanes	20	33	|O
were	34	38	|O
synthesized	39	50	|O
by	51	53	|O
replacing	54	63	|O
the	64	67	|O
ethylene	68	76	|O
chain	77	82	|O
separating	83	93	|O
the	94	97	|O
amine	98	103	|O
and	104	107	|O
the	108	111	|O
phenoxy	112	119	|O
units	120	125	|O
of	126	128	|O
1	129	130	|O
with	131	135	|O
a	136	137	|O
cyclopentanol	138	151	|B-IUPAC
moiety	152	158	|I-IUPAC
,	158	159	|O
a	160	161	|O
feature	162	169	|O
of	170	172	|O
6	173	174	|B-IUPAC
,	174	175	|I-IUPAC
7	176	177	|I-IUPAC
-	177	178	|I-IUPAC
dihydro	178	185	|I-IUPAC
-	185	186	|I-IUPAC
5	186	187	|I-IUPAC
-	187	188	|I-IUPAC
[	188	189	|I-IUPAC
[	189	190	|I-IUPAC
(	190	191	|I-IUPAC
cis	191	194	|I-IUPAC
-	194	195	|I-IUPAC
2	195	196	|I-IUPAC
-	196	197	|I-IUPAC
hydroxy	197	204	|I-IUPAC
-	204	205	|I-IUPAC
trans	205	210	|I-IUPAC
-	210	211	|I-IUPAC
3	211	212	|I-IUPAC
-	212	213	|I-IUPAC
phenoxycyclopentyl	213	231	|I-IUPAC
)	231	232	|I-IUPAC
amino	232	237	|I-IUPAC
]	237	238	|I-IUPAC
meth	238	242	|I-IUPAC
yl	243	245	|I-IUPAC
]	245	246	|I-IUPAC
-	247	248	|I-IUPAC
2	248	249	|I-IUPAC
-	249	250	|I-IUPAC
methylbenzo	250	261	|I-IUPAC
[	261	262	|I-IUPAC
b	262	263	|I-IUPAC
]	263	264	|I-IUPAC
thiophen	264	272	|I-IUPAC
-	272	273	|I-IUPAC
4	273	274	|I-IUPAC
(	274	275	|I-IUPAC
5H	275	277	|I-IUPAC
)	277	278	|I-IUPAC
-	278	279	|I-IUPAC
one	279	282	|I-IUPAC
that	283	287	|O
was	288	291	|O
reported	292	300	|O
to	301	303	|O
display	304	311	|O
an	312	314	|O
intriguing	315	325	|O
selectivity	326	337	|O
profile	338	345	|O
at	346	348	|O
alpha	349	354	|O
(	354	355	|O
1	355	356	|O
)	356	357	|O
-	357	358	|O
adrenoreceptors	358	373	|O
.	373	374	|O
This	375	379	|O
synthesis	380	389	|O
strategy	390	398	|O
led	399	402	|O
to	403	405	|O
4	406	407	|O
out	408	411	|O
of	412	414	|O
16	415	417	|O
possible	418	426	|O
stereoisomers	427	440	|O
,	440	441	|O
which	442	447	|O
were	448	452	|O
isolated	453	461	|O
in	462	464	|O
the	465	468	|O
case	469	473	|O
of	474	476	|O
(	477	478	|O
-	478	479	|O
)	479	480	|O
-	480	481	|O
3	481	482	|O
,	482	483	|O
(	484	485	|O
+	485	486	|O
)	486	487	|O
-	487	488	|O
3	488	489	|O
,	489	490	|O
(	491	492	|O
-	492	493	|O
)	493	494	|O
-	494	495	|O
4	495	496	|O
,	496	497	|O
and	498	501	|O
(	502	503	|O
+	503	504	|O
)	504	505	|O
-	505	506	|O
4	506	507	|O
and	508	511	|O
whose	512	517	|O
absolute	518	526	|O
configuration	527	540	|O
was	541	544	|O
assigned	545	553	|O
using	554	559	|O
a	560	561	|O
chiral	562	568	|O
building	569	577	|O
block	578	583	|O
for	584	587	|O
the	588	591	|O
synthesis	592	601	|O
of	602	604	|O
(	605	606	|O
-	606	607	|O
)	607	608	|O
-	608	609	|O
3	609	610	|O
starting	611	619	|O
from	620	624	|O
(	625	626	|B-IUPAC
+	626	627	|I-IUPAC
)	627	628	|I-IUPAC
-	628	629	|I-IUPAC
(	629	630	|I-IUPAC
2R	630	632	|I-IUPAC
)	632	633	|I-IUPAC
-	633	634	|I-IUPAC
2	634	635	|I-IUPAC
,	635	636	|I-IUPAC
3	637	638	|I-IUPAC
-	638	639	|I-IUPAC
dihydro	639	646	|I-IUPAC
-	646	647	|I-IUPAC
1,4	647	650	|I-IUPAC
-	650	651	|I-IUPAC
benzodioxine	651	663	|I-IUPAC
-	663	664	|I-IUPAC
2	664	665	|I-IUPAC
-	665	666	|I-IUPAC
carboxylic	666	676	|I-IUPAC
acid	677	681	|I-IUPAC
(	682	683	|O
(	683	684	|O
+	684	685	|O
)	685	686	|O
-	686	687	|O
9	687	688	|O
)	688	689	|O
and	690	693	|O
(	694	695	|B-IUPAC
1S	695	697	|I-IUPAC
,	697	698	|I-IUPAC
2S	698	700	|I-IUPAC
,	700	701	|I-IUPAC
5S	702	704	|I-IUPAC
)	704	705	|I-IUPAC
-	705	706	|I-IUPAC
2	706	707	|I-IUPAC
-	707	708	|I-IUPAC
amino	708	713	|I-IUPAC
-	713	714	|I-IUPAC
5	714	715	|I-IUPAC
-	715	716	|I-IUPAC
phenoxycyclopentan	716	734	|I-IUPAC
-	734	735	|I-IUPAC
1	735	736	|I-IUPAC
-	736	737	|I-IUPAC
ol	737	739	|I-IUPAC
(	740	741	|O
(	741	742	|O
+	742	743	|O
)	743	744	|O
-	744	745	|O
10	745	747	|O
)	747	748	|O
.	748	749	|O
The	750	753	|O
aim	754	757	|O
of	758	760	|O
this	761	765	|O
project	766	773	|O
was	774	777	|O
to	778	780	|O
further	781	788	|O
investigate	789	800	|O
whether	801	808	|O
it	809	811	|O
is	812	814	|O
possible	815	823	|O
to	824	826	|O
differentiate	827	840	|O
between	841	848	|O
these	849	854	|O
compounds	855	864	|O
with	865	869	|O
respect	870	877	|O
to	878	880	|O
their	881	886	|O
affinity	887	895	|O
for	896	899	|O
alpha	900	905	|O
(	905	906	|O
1	906	907	|O
)	907	908	|O
-	908	909	|O
adrenoreceptor	909	923	|O
subtypes	924	932	|O
and	933	936	|O
the	937	940	|O
affinity	941	949	|O
for	950	953	|O
5	954	955	|O
-	955	956	|O
HT	956	958	|O
(	958	959	|O
1A	959	961	|O
)	961	962	|O
receptors	963	972	|O
,	972	973	|O
as	974	976	|O
1	977	978	|O
binds	979	984	|O
with	985	989	|O
high	990	994	|O
affinity	995	1003	|O
at	1004	1006	|O
both	1007	1011	|O
receptor	1012	1020	|O
systems	1021	1028	|O
.	1028	1029	|O
The	1030	1033	|O
biological	1034	1044	|O
profiles	1045	1053	|O
of	1054	1056	|O
reported	1057	1065	|O
compounds	1066	1075	|O
at	1076	1078	|O
alpha	1079	1084	|O
(	1084	1085	|O
1	1085	1086	|O
)	1086	1087	|O
-	1087	1088	|O
adrenoreceptor	1088	1102	|O
subtypes	1103	1111	|O
were	1112	1116	|O
assessed	1117	1125	|O
by	1126	1128	|O
functional	1129	1139	|O
experiments	1140	1151	|O
in	1152	1154	|O
isolated	1155	1163	|O
rat	1164	1167	|O
vas	1168	1171	|O
deferens	1172	1180	|O
(	1181	1182	|O
alpha	1182	1187	|O
(	1187	1188	|O
1A	1188	1190	|O
)	1190	1191	|O
)	1191	1192	|O
,	1192	1193	|O
spleen	1194	1200	|O
(	1201	1202	|O
alpha	1202	1207	|O
(	1207	1208	|O
1B	1208	1210	|O
)	1210	1211	|O
)	1211	1212	|O
,	1212	1213	|O
and	1214	1217	|O
aorta	1218	1223	|O
(	1224	1225	|O
alpha	1225	1230	|O
(	1230	1231	|O
1D	1231	1233	|O
)	1233	1234	|O
)	1234	1235	|O
and	1236	1239	|O
by	1240	1242	|O
binding	1243	1250	|O
assays	1251	1257	|O
in	1258	1260	|O
CHO	1261	1264	|O
and	1265	1268	|O
HeLa	1269	1273	|O
cells	1274	1279	|O
membranes	1280	1289	|O
expressing	1290	1300	|O
the	1301	1304	|O
human	1305	1310	|O
cloned	1311	1317	|O
alpha	1318	1323	|O
(	1323	1324	|O
1	1324	1325	|O
)	1325	1326	|O
-	1326	1327	|O
adrenoreceptor	1327	1341	|O
subtypes	1342	1350	|O
and	1351	1354	|O
5	1355	1356	|O
-	1356	1357	|O
HT	1357	1359	|O
(	1359	1360	|O
1A	1360	1362	|O
)	1362	1363	|O
receptors	1364	1373	|O
,	1373	1374	|O
respectively	1375	1387	|O
.	1387	1388	|O
Furthermore	1389	1400	|O
,	1400	1401	|O
the	1402	1405	|O
functional	1406	1416	|O
activity	1417	1425	|O
of	1426	1428	|O
(	1429	1430	|O
-	1430	1431	|O
)	1431	1432	|O
-	1432	1433	|O
3	1433	1434	|O
,	1434	1435	|O
(	1436	1437	|O
+	1437	1438	|O
)	1438	1439	|O
-	1439	1440	|O
3	1440	1441	|O
,	1441	1442	|O
(	1443	1444	|O
-	1444	1445	|O
)	1445	1446	|O
-	1446	1447	|O
4	1447	1448	|O
,	1448	1449	|O
and	1450	1453	|O
(	1454	1455	|O
+	1455	1456	|O
)	1456	1457	|O
-	1457	1458	|O
4	1458	1459	|O
toward	1460	1466	|O
5	1467	1468	|O
-	1468	1469	|O
HT	1469	1471	|O
(	1471	1472	|O
1A	1472	1474	|O
)	1474	1475	|O
receptors	1476	1485	|O
was	1486	1489	|O
evaluated	1490	1499	|O
by	1500	1502	|O
determining	1503	1514	|O
the	1515	1518	|O
induced	1519	1526	|O
stimulation	1527	1538	|O
of	1539	1541	|O
[	1542	1543	|O
(	1543	1544	|O
35	1544	1546	|O
)	1546	1547	|O
S	1547	1548	|O
]	1548	1549	|O
GTPgammaS	1549	1558	|O
binding	1559	1566	|O
in	1567	1569	|O
cell	1570	1574	|O
membranes	1575	1584	|O
from	1585	1589	|O
HeLa	1590	1594	|O
cells	1595	1600	|O
transfected	1601	1612	|O
with	1613	1617	|O
human	1618	1623	|O
cloned	1624	1630	|O
5	1631	1632	|O
-	1632	1633	|O
HT	1633	1635	|O
(	1635	1636	|O
1A	1636	1638	|O
)	1638	1639	|O
receptors	1640	1649	|O
.	1649	1650	|O
The	1651	1654	|O
configuration	1655	1668	|O
of	1669	1671	|O
the	1672	1675	|O
cyclopentane	1676	1688	|O
unit	1689	1693	|O
determined	1694	1704	|O
the	1705	1708	|O
affinity	1709	1717	|O
profile	1718	1725	|O
:	1725	1726	|O
a	1727	1728	|O
1R	1729	1731	|O
configuration	1732	1745	|O
,	1745	1746	|O
as	1747	1749	|O
in	1750	1752	|O
(	1753	1754	|O
+	1754	1755	|O
)	1755	1756	|O
-	1756	1757	|O
3	1757	1758	|O
and	1759	1762	|O
(	1763	1764	|O
-	1764	1765	|O
)	1765	1766	|O
-	1766	1767	|O
4	1767	1768	|O
,	1768	1769	|O
conferred	1770	1779	|O
higher	1780	1786	|O
affinity	1787	1795	|O
at	1796	1798	|O
alpha	1799	1804	|O
(	1804	1805	|O
1	1805	1806	|O
)	1806	1807	|O
-	1807	1808	|O
adrenoreceptors	1808	1823	|O
,	1823	1824	|O
whereas	1825	1832	|O
a	1833	1834	|O
1S	1835	1837	|O
configuration	1838	1851	|O
,	1851	1852	|O
as	1853	1855	|O
in	1856	1858	|O
(	1859	1860	|O
-	1860	1861	|O
)	1861	1862	|O
-	1862	1863	|O
3	1863	1864	|O
and	1865	1868	|O
(	1869	1870	|O
+	1870	1871	|O
)	1871	1872	|O
-	1872	1873	|O
4	1873	1874	|O
,	1874	1875	|O
produced	1876	1884	|O
higher	1885	1891	|O
affinity	1892	1900	|O
for	1901	1904	|O
5	1905	1906	|O
-	1906	1907	|O
HT	1907	1909	|O
(	1909	1910	|O
1A	1910	1912	|O
)	1912	1913	|O
receptors	1914	1923	|O
.	1923	1924	|O
For	1925	1928	|O
the	1929	1932	|O
enantiomers	1933	1944	|O
(	1945	1946	|O
+	1946	1947	|O
)	1947	1948	|O
-	1948	1949	|O
4	1949	1950	|O
and	1951	1954	|O
(	1955	1956	|O
-	1956	1957	|O
)	1957	1958	|O
-	1958	1959	|O
4	1959	1960	|O
also	1961	1965	|O
a	1966	1967	|O
remarkable	1968	1978	|O
selectivity	1979	1990	|O
was	1991	1994	|O
achieved	1995	2003	|O
.	2003	2004	|O
Functionally	2005	2017	|O
,	2017	2018	|O
the	2019	2022	|O
stereoisomers	2023	2036	|O
displayed	2037	2046	|O
a	2047	2048	|O
similar	2049	2056	|O
alpha	2057	2062	|O
(	2062	2063	|O
1	2063	2064	|O
)	2064	2065	|O
-	2065	2066	|O
selectivity	2066	2077	|O
profile	2078	2085	|O
,	2085	2086	|O
that	2087	2091	|O
is	2092	2094	|O
alpha	2095	2100	|O
(	2100	2101	|O
1D	2101	2103	|O
)	2103	2104	|O
&	2105	2106	|O
gt	2106	2108	|O
;	2108	2109	|O
alpha	2110	2115	|O
(	2115	2116	|O
1B	2116	2118	|O
)	2118	2119	|O
&	2120	2121	|O
gt	2121	2123	|O
;	2123	2124	|O
alpha	2125	2130	|O
(	2130	2131	|O
1A	2131	2133	|O
)	2133	2134	|O
,	2134	2135	|O
which	2136	2141	|O
is	2142	2144	|O
different	2145	2154	|O
from	2155	2159	|O
that	2160	2164	|O
exhibited	2165	2174	|O
by	2175	2177	|O
the	2178	2181	|O
reference	2182	2191	|O
compound	2192	2200	|O
1	2201	2202	|O
.	2202	2203	|O
The	2204	2207	|O
epimers	2208	2215	|O
(	2216	2217	|O
-	2217	2218	|O
)	2218	2219	|O
-	2219	2220	|O
3	2220	2221	|O
and	2222	2225	|O
(	2226	2227	|O
+	2227	2228	|O
)	2228	2229	|O
-	2229	2230	|O
4	2230	2231	|O
proved	2232	2238	|O
to	2239	2241	|O
be	2242	2244	|O
agonists	2245	2253	|O
at	2254	2256	|O
the	2257	2260	|O
5	2261	2262	|O
-	2262	2263	|O
HT	2263	2265	|O
(	2265	2266	|O
1A	2266	2268	|O
)	2268	2269	|O
receptors	2270	2279	|O
,	2279	2280	|O
with	2281	2285	|O
a	2286	2287	|O
potency	2288	2295	|O
comparable	2296	2306	|O
to	2307	2309	|O
that	2310	2314	|O
of	2315	2317	|O
5	2318	2319	|B-IUPAC
-	2319	2320	|I-IUPAC
hydroxytryptamine	2320	2337	|I-IUPAC
.	2337	2338	|O

### abstracts4747.txt
The	0	3	|O
development	4	15	|O
of	16	18	|O
99mTc	19	24	|O
-	24	25	|O
labeled	25	32	|O
fatty	33	38	|O
acid	39	43	|O
analogues	44	53	|O
metabolized	54	65	|O
by	66	68	|O
beta	69	73	|O
-	73	74	|O
oxidation	74	83	|O
in	84	86	|O
the	87	90	|O
myocardium	91	101	|O
constitutes	102	113	|O
an	114	116	|O
unsolved	117	125	|O
challenge	126	135	|O
.	135	136	|O
On	137	139	|O
the	140	143	|O
basis	144	149	|O
of	150	152	|O
our	153	156	|O
recent	157	163	|O
findings	164	172	|O
that	173	177	|O
[	178	179	|B-IUPAC
188Re	179	184	|I-IUPAC
]	184	185	|I-IUPAC
tricarbonyl	185	196	|I-IUPAC
(	196	197	|I-IUPAC
cyclopentadienylcarbonate	197	222	|I-IUPAC
)	222	223	|I-IUPAC
rhenium	223	230	|I-IUPAC
(	231	232	|O
[	232	233	|O
188Re	233	238	|O
]	238	239	|O
CpTR	239	243	|O
-	243	244	|O
COOH	244	248	|O
)	248	249	|O
was	250	253	|O
recognized	254	264	|O
as	265	267	|O
an	268	270	|O
aromatic	271	279	|O
compound	280	288	|O
and	289	292	|O
was	293	296	|O
metabolized	297	308	|O
as	309	311	|O
such	312	316	|O
in	317	319	|O
the	320	323	|O
body	324	328	|O
,	328	329	|O
[	330	331	|O
99mTc	331	336	|O
]	336	337	|O
cyclopentadienyltricarbonyltechnetium	337	374	|O
(	375	376	|O
[	376	377	|O
99mTc	377	382	|O
]	382	383	|O
CpTT	383	387	|O
)	387	388	|O
was	389	392	|O
conjugated	393	403	|O
at	404	406	|O
the	407	410	|O
omega	411	416	|O
-	416	417	|O
position	417	425	|O
of	426	428	|O
pentadecanoic	429	442	|O
acid	443	447	|O
to	448	450	|O
prepare	451	458	|O
[	459	460	|O
99mTc	460	465	|O
]	465	466	|O
CpTT	466	470	|O
-	470	471	|O
PA	471	473	|O
.	473	474	|O
When	475	479	|O
injected	480	488	|O
into	489	493	|O
rats	494	498	|O
,	498	499	|O
[	500	501	|O
99mTc	501	506	|O
]	506	507	|O
CpTT	507	511	|O
-	511	512	|O
PA	512	514	|O
exhibited	515	524	|O
the	525	528	|O
maximum	529	536	|O
myocardial	537	547	|O
accumulation	548	560	|O
and	561	564	|O
heart	565	570	|O
-	570	571	|O
to	571	573	|O
-	573	574	|O
blood	574	579	|O
ratio	580	585	|O
of	586	588	|O
3.85	589	593	|O
%	594	595	|O
ID	595	597	|O
/	597	598	|O
g	598	599	|O
at	600	602	|O
1	603	604	|O
min	605	608	|O
and	609	612	|O
4.60	613	617	|O
at	618	620	|O
10	621	623	|O
min	624	627	|O
postinjection	628	641	|O
,	641	642	|O
respectively	643	655	|O
.	655	656	|O
The	657	660	|O
metabolic	661	670	|O
study	671	676	|O
using	677	682	|O
isolated	683	691	|O
Langendorff	692	703	|O
perfused	704	712	|O
rat	713	716	|O
hearts	717	723	|O
demonstrated	724	736	|O
that	737	741	|O
approximately	742	755	|O
67%	756	759	|O
of	760	762	|O
perfused	763	771	|O
[	772	773	|O
99mTc	773	778	|O
]	778	779	|O
CpTT	779	783	|O
-	783	784	|O
PA	784	786	|O
was	787	790	|O
incorporated	791	803	|O
and	804	807	|O
[	808	809	|O
99mTc	809	814	|O
]	814	815	|O
CpTT	815	819	|O
-	819	820	|O
propionic	820	829	|O
acid	830	834	|O
,	834	835	|O
the	836	839	|O
metabolite	840	850	|O
after	851	856	|O
six	857	860	|O
cycles	861	867	|O
of	868	870	|O
beta	871	875	|O
-	875	876	|O
oxidation	876	885	|O
of	886	888	|O
[	889	890	|O
99mTc	890	895	|O
]	895	896	|O
CpTT	896	900	|O
-	900	901	|O
PA	901	903	|O
,	903	904	|O
was	905	908	|O
detected	909	917	|O
as	918	920	|O
the	921	924	|O
major	925	930	|O
radiometabolite	931	946	|O
in	947	949	|O
the	950	953	|O
perfusate	954	963	|O
and	964	967	|O
myocardium	968	978	|O
.	978	979	|O
These	980	985	|O
findings	986	994	|O
indicate	995	1003	|O
that	1004	1008	|O
[	1009	1010	|O
99mTc	1010	1015	|O
]	1015	1016	|O
CpTT	1016	1020	|O
-	1020	1021	|O
PA	1021	1023	|O
was	1024	1027	|O
recognized	1028	1038	|O
,	1038	1039	|O
transported	1040	1051	|O
,	1051	1052	|O
and	1053	1056	|O
metabolized	1057	1068	|O
as	1069	1071	|O
a	1072	1073	|O
long	1074	1078	|O
chain	1079	1084	|O
fatty	1085	1090	|O
acid	1091	1095	|O
analogue	1096	1104	|O
for	1105	1108	|O
energy	1109	1115	|O
production	1116	1126	|O
in	1127	1129	|O
the	1130	1133	|O
myocardium	1134	1144	|O
.	1144	1145	|O

### abstracts4644.txt
This	0	4	|O
paper	5	10	|O
outlines	11	19	|O
the	20	23	|O
synthesis	24	33	|O
of	34	36	|O
selected	37	45	|O
acid	46	50	|O
mimics	51	57	|O
of	58	60	|O
the	61	64	|O
non	65	68	|O
-	68	69	|O
peptide	69	76	|O
CCK	77	80	|O
-	80	81	|O
B	81	82	|O
selective	83	92	|O
antagonist	93	103	|O
CI	104	106	|O
-	106	107	|O
988	107	110	|O
,	110	111	|O
1	112	113	|O
.	113	114	|O
CCK	115	118	|O
-	118	119	|O
B	119	120	|O
and	121	124	|O
CCK	125	128	|O
-	128	129	|O
A	129	130	|O
binding	131	138	|O
affinities	139	149	|O
of	150	152	|O
these	153	158	|O
analogues	159	168	|O
are	169	172	|O
described	173	182	|O
and	183	186	|O
their	187	192	|O
CCK	193	196	|O
-	196	197	|O
B	197	198	|O
affinity	199	207	|O
and	208	211	|O
selectivity	212	223	|O
rationalized	224	236	|O
by	237	239	|O
consideration	240	253	|O
of	254	256	|O
the	257	260	|O
pK	261	263	|O
(	263	264	|O
a	264	265	|O
)	265	266	|O
values	267	273	|O
,	273	274	|O
charge	275	281	|O
distribution	282	294	|O
,	294	295	|O
and	296	299	|O
geometry	300	308	|O
of	309	311	|O
the	312	315	|O
respective	316	326	|O
acid	327	331	|O
mimics	332	338	|O
.	338	339	|O
Several	340	347	|O
of	348	350	|O
the	351	354	|O
compounds	355	364	|O
have	365	369	|O
CCK	370	373	|O
-	373	374	|O
B	374	375	|O
binding	376	383	|O
affinities	384	394	|O
similar	395	402	|O
to	403	405	|O
the	406	409	|O
parent	410	416	|O
carboxylic	417	427	|O
acid	428	432	|O
1	433	434	|O
(	435	436	|O
CCK	436	439	|O
-	439	440	|O
B	440	441	|O
,	441	442	|O
IC50	443	447	|O
=	448	449	|O
1.7	450	453	|O
nM	454	456	|O
;	456	457	|O
pK	458	460	|O
(	460	461	|O
a	461	462	|O
)	462	463	|O
=	464	465	|O
5.6	466	469	|O
)	469	470	|O
and	471	474	|O
span	475	479	|O
a	480	481	|O
pK	482	484	|O
(	484	485	|O
a	485	486	|O
)	486	487	|O
range	488	493	|O
of	494	496	|O
less	497	501	|O
than	502	506	|O
1	507	508	|O
(	509	510	|O
sulfonic	510	518	|O
acid	519	523	|O
27	524	526	|O
)	526	527	|O
to	528	530	|O
greater	531	538	|O
than	539	543	|O
9.5	544	547	|O
(	548	549	|O
5	549	550	|B-IUPAC
-	550	551	|I-IUPAC
thio	551	555	|I-IUPAC
-	555	556	|I-IUPAC
1,2,4	556	561	|I-IUPAC
-	561	562	|I-IUPAC
triazole	562	570	|I-IUPAC
24	571	573	|O
)	573	574	|O
.	574	575	|O
Among	576	581	|O
the	582	585	|O
more	586	590	|O
active	591	597	|O
compounds	598	607	|O
synthesized	608	619	|O
are	620	623	|O
tricyclo	624	632	|B-IUPAC
[	632	633	|I-IUPAC
3.3.1.1	633	640	|I-IUPAC
(	640	641	|I-IUPAC
3,7	641	644	|I-IUPAC
)	644	645	|I-IUPAC
]	645	646	|I-IUPAC
dec	646	649	|I-IUPAC
-	649	650	|I-IUPAC
2	650	651	|I-IUPAC
-	651	652	|I-IUPAC
yl	652	654	|I-IUPAC
[	655	656	|I-IUPAC
R	656	657	|I-IUPAC
-	657	658	|I-IUPAC
(	658	659	|I-IUPAC
R	659	660	|I-IUPAC
*	660	661	|I-IUPAC
,	661	662	|I-IUPAC
R	662	663	|I-IUPAC
*	663	664	|I-IUPAC
)	664	665	|I-IUPAC
]	665	666	|I-IUPAC
-	666	667	|I-IUPAC
[	667	668	|I-IUPAC
2	668	669	|I-IUPAC
-	669	670	|I-IUPAC
[	670	671	|I-IUPAC
[	671	672	|I-IUPAC
2	672	673	|I-IUPAC
-	673	674	|I-IUPAC
[	674	675	|I-IUPAC
[	675	676	|I-IUPAC
(	676	677	|I-IUPAC
3	677	678	|I-IUPAC
-	678	679	|I-IUPAC
hydroxy	679	686	|I-IUPAC
-	686	687	|I-IUPAC
5	687	688	|I-IUPAC
-	688	689	|I-IUPAC
isoxazolyl	689	699	|I-IUPAC
)	699	700	|I-IUPAC
acetyl	700	706	|I-IUPAC
]	706	707	|I-IUPAC
-	707	708	|I-IUPAC
amino	708	713	|I-IUPAC
]	713	714	|I-IUPAC
-	714	715	|I-IUPAC
2	715	716	|I-IUPAC
-	716	717	|I-IUPAC
phenylethyl	718	729	|I-IUPAC
]	729	730	|I-IUPAC
amino	730	735	|I-IUPAC
]	735	736	|I-IUPAC
-	736	737	|I-IUPAC
1	737	738	|I-IUPAC
-	738	739	|I-IUPAC
(	739	740	|I-IUPAC
1H	740	742	|I-IUPAC
-	742	743	|I-IUPAC
indol	743	748	|I-IUPAC
-	748	749	|I-IUPAC
3	749	750	|I-IUPAC
-	750	751	|I-IUPAC
ylmethyl	751	759	|I-IUPAC
)	759	760	|I-IUPAC
-	760	761	|I-IUPAC
1	761	762	|I-IUPAC
-	762	763	|I-IUPAC
methyl	763	769	|I-IUPAC
-	769	770	|I-IUPAC
2	770	771	|I-IUPAC
-	771	772	|I-IUPAC
oxoethyl+	772	781	|I-IUPAC
+	782	783	|I-IUPAC
+	783	784	|I-IUPAC
]	784	785	|I-IUPAC
carbamate	785	794	|I-IUPAC
(	795	796	|O
15	796	798	|O
)	798	799	|O
,	799	800	|O
tricyclo	801	809	|B-IUPAC
[	809	810	|I-IUPAC
3.3.1.1	810	817	|I-IUPAC
(	817	818	|I-IUPAC
3,7	818	821	|I-IUPAC
)	821	822	|I-IUPAC
]	822	823	|I-IUPAC
dec	823	826	|I-IUPAC
-	826	827	|I-IUPAC
2	827	828	|I-IUPAC
-	828	829	|I-IUPAC
yl	829	831	|I-IUPAC
[	832	833	|I-IUPAC
R	833	834	|I-IUPAC
-	834	835	|I-IUPAC
(	835	836	|I-IUPAC
R	836	837	|I-IUPAC
*	837	838	|I-IUPAC
,	838	839	|I-IUPAC
R	839	840	|I-IUPAC
*	840	841	|I-IUPAC
)	841	842	|I-IUPAC
]	842	843	|I-IUPAC
-	843	844	|I-IUPAC
[	844	845	|I-IUPAC
1	845	846	|I-IUPAC
-	846	847	|I-IUPAC
(	847	848	|I-IUPAC
1H	848	850	|I-IUPAC
-	850	851	|I-IUPAC
indol	851	856	|I-IUPAC
-	856	857	|I-IUPAC
3	857	858	|I-IUPAC
-	858	859	|I-IUPAC
ylmethyl	859	867	|I-IUPAC
)	867	868	|I-IUPAC
-	868	869	|I-IUPAC
1	869	870	|I-IUPAC
-	870	871	|I-IUPAC
methyl	871	877	|I-IUPAC
-	877	878	|I-IUPAC
2	878	879	|I-IUPAC
-	879	880	|I-IUPAC
oxo	880	883	|I-IUPAC
-	883	884	|I-IUPAC
2	884	885	|I-IUPAC
-	885	886	|I-IUPAC
[	886	887	|I-IUPAC
[	887	888	|I-IUPAC
2	888	889	|I-IUPAC
-	889	890	|I-IUPAC
[	890	891	|I-IUPAC
(	891	892	|I-IUPAC
1	892	893	|I-IUPAC
-	893	894	|I-IUPAC
oxo	894	897	|I-IUPAC
-	897	898	|I-IUPAC
3	899	900	|I-IUPAC
-	900	901	|I-IUPAC
sulfopropyl	901	912	|I-IUPAC
)	912	913	|I-IUPAC
amino	913	918	|I-IUPAC
]	918	919	|I-IUPAC
-	919	920	|I-IUPAC
2	920	921	|I-IUPAC
-	921	922	|I-IUPAC
phenylethyl	922	933	|I-IUPAC
]	933	934	|I-IUPAC
amino	934	939	|I-IUPAC
]	939	940	|I-IUPAC
-	940	941	|I-IUPAC
ethyl	941	946	|I-IUPAC
]	946	947	|I-IUPAC
carbamate	947	956	|I-IUPAC
,	956	957	|O
monosodium	958	968	|O
salt	969	973	|O
(	974	975	|O
27	975	977	|O
)	977	978	|O
,	978	979	|O
and	980	983	|O
tricyclo	984	992	|B-IUPAC
[	992	993	|I-IUPAC
3.3.1.1	993	1000	|I-IUPAC
(	1000	1001	|I-IUPAC
3,7	1001	1004	|I-IUPAC
)	1004	1005	|I-IUPAC
]	1005	1006	|I-IUPAC
dec	1006	1009	|I-IUPAC
-	1009	1010	|I-IUPAC
2	1010	1011	|I-IUPAC
-	1011	1012	|I-IUPAC
yl	1012	1014	|I-IUPAC
[	1015	1016	|I-IUPAC
R	1016	1017	|I-IUPAC
-	1017	1018	|I-IUPAC
(	1018	1019	|I-IUPAC
R	1019	1020	|I-IUPAC
*	1020	1021	|I-IUPAC
,	1021	1022	|I-IUPAC
R	1022	1023	|I-IUPAC
*	1023	1024	|I-IUPAC
)	1024	1025	|I-IUPAC
]	1025	1026	|I-IUPAC
-	1026	1027	|I-IUPAC
[	1027	1028	|I-IUPAC
1	1028	1029	|I-IUPAC
-	1029	1030	|I-IUPAC
(	1030	1031	|I-IUPAC
1H	1031	1033	|I-IUPAC
-	1033	1034	|I-IUPAC
indol	1034	1039	|I-IUPAC
-	1039	1040	|I-IUPAC
3	1040	1041	|I-IUPAC
-	1041	1042	|I-IUPAC
ylmethyl	1042	1050	|I-IUPAC
)	1050	1051	|I-IUPAC
-	1051	1052	|I-IUPAC
1	1052	1053	|I-IUPAC
-	1053	1054	|I-IUPAC
methyl	1055	1061	|I-IUPAC
-	1061	1062	|I-IUPAC
2	1062	1063	|I-IUPAC
-	1063	1064	|I-IUPAC
oxo	1064	1067	|I-IUPAC
-	1067	1068	|I-IUPAC
2	1068	1069	|I-IUPAC
-	1069	1070	|I-IUPAC
[	1070	1071	|I-IUPAC
[	1071	1072	|I-IUPAC
2	1072	1073	|I-IUPAC
-	1073	1074	|I-IUPAC
[	1074	1075	|I-IUPAC
[	1075	1076	|I-IUPAC
(	1076	1077	|I-IUPAC
1H	1077	1079	|I-IUPAC
-	1079	1080	|I-IUPAC
1,2,4	1080	1085	|I-IUPAC
-	1085	1086	|I-IUPAC
triazol	1086	1093	|I-IUPAC
-	1093	1094	|I-IUPAC
5	1094	1095	|I-IUPAC
-	1095	1096	|I-IUPAC
ylsulfinyl	1096	1106	|I-IUPAC
)	1106	1107	|I-IUPAC
acetyl	1107	1113	|I-IUPAC
]	1113	1114	|I-IUPAC
a	1114	1115	|I-IUPAC
mino	1116	1120	|I-IUPAC
]	1120	1121	|I-IUPAC
-	1121	1122	|I-IUPAC
2	1122	1123	|I-IUPAC
-	1123	1124	|I-IUPAC
phenylethyl	1124	1135	|I-IUPAC
]	1135	1136	|I-IUPAC
amino	1136	1141	|I-IUPAC
]	1141	1142	|I-IUPAC
ethyl	1142	1147	|I-IUPAC
]	1147	1148	|I-IUPAC
carbamic	1148	1156	|I-IUPAC
acid	1157	1161	|I-IUPAC
(	1162	1163	|O
34	1163	1165	|O
)	1165	1166	|O
which	1167	1172	|O
have	1173	1177	|O
CCK	1178	1181	|O
-	1181	1182	|O
B	1182	1183	|O
binding	1184	1191	|O
affinities	1192	1202	|O
of	1203	1205	|O
IC50	1206	1210	|O
=	1211	1212	|O
2.6	1213	1216	|O
,	1216	1217	|O
1.3	1218	1221	|O
,	1221	1222	|O
and	1223	1226	|O
1.7	1227	1230	|O
nM	1231	1233	|O
,	1233	1234	|O
CCK	1235	1238	|O
-	1238	1239	|O
A	1239	1240	|O
/	1240	1241	|O
-	1241	1242	|O
B	1242	1243	|O
ratios	1244	1250	|O
of	1251	1253	|O
650	1254	1257	|O
,	1257	1258	|O
780	1259	1262	|O
,	1262	1263	|O
and	1264	1267	|O
550	1268	1271	|O
and	1272	1275	|O
pK	1276	1278	|O
(	1278	1279	|O
a	1279	1280	|O
)	1280	1281	|O
values	1282	1288	|O
of	1289	1291	|O
6.5	1292	1295	|O
,	1295	1296	|O
less	1297	1301	|O
than	1302	1306	|O
1	1307	1308	|O
,	1308	1309	|O
and	1310	1313	|O
7.0	1314	1317	|O
,	1317	1318	|O
respectively	1319	1331	|O
.	1331	1332	|O

### abstracts1063.txt
Synthesis	0	9	|O
and	10	13	|O
antitetrabenazine	14	31	|O
activity	32	40	|O
of	41	43	|O
4	44	45	|B-IUPAC
-	45	46	|I-IUPAC
[	46	47	|I-IUPAC
2	47	48	|I-IUPAC
-	48	49	|I-IUPAC
(	49	50	|I-IUPAC
arylmethyl	50	60	|I-IUPAC
)	60	61	|I-IUPAC
phenyl	61	67	|I-IUPAC
]	67	68	|I-IUPAC
piperidines	68	79	|I-IUPAC
and	80	83	|O
4	84	85	|B-IUPAC
-	85	86	|I-IUPAC
(	86	87	|I-IUPAC
benzyloxy	87	96	|I-IUPAC
)	96	97	|I-IUPAC
-	97	98	|I-IUPAC
4	98	99	|I-IUPAC
-	99	100	|I-IUPAC
phenylpiperidines	100	117	|I-IUPAC
,	117	118	|O
prepared	119	127	|O
as	128	130	|O
simplified	131	141	|O
and	142	145	|O
possibly	146	154	|O
more	155	159	|O
readily	160	167	|O
synthesized	168	179	|O
analogues	180	189	|O
of	190	192	|O
3	193	194	|B-IUPAC
-	194	195	|I-IUPAC
phenylspiro	195	206	|I-IUPAC
[	206	207	|I-IUPAC
isobenzofuran	207	220	|I-IUPAC
-	220	221	|I-IUPAC
1	221	222	|I-IUPAC
(	223	224	|I-IUPAC
3H	224	226	|I-IUPAC
)	226	227	|I-IUPAC
,	227	228	|I-IUPAC
4'	228	230	|I-IUPAC
-	230	231	|I-IUPAC
piperidine	231	241	|I-IUPAC
]	241	242	|I-IUPAC
,	242	243	|O
are	244	247	|O
reported	248	256	|O
.	256	257	|O
Several	258	265	|O
4	266	267	|B-IUPAC
-	267	268	|I-IUPAC
[	268	269	|I-IUPAC
2	269	270	|I-IUPAC
-	270	271	|I-IUPAC
(	271	272	|I-IUPAC
arylmethyl	272	282	|I-IUPAC
)	282	283	|I-IUPAC
phenyl	283	289	|I-IUPAC
]	289	290	|I-IUPAC
piperidines	290	301	|I-IUPAC
display	302	309	|O
antitetrabenazine	310	327	|O
activity	328	336	|O
comparable	337	347	|O
to	348	350	|O
imipramine	351	361	|O
or	362	364	|O
amitriptyline	365	378	|O
but	379	382	|O
are	383	386	|O
two	387	390	|O
-	390	391	|O
to	392	394	|O
fourfold	395	403	|O
less	404	408	|O
active	409	415	|O
than	416	420	|O
analogous	421	430	|O
3	431	432	|B-IUPAC
-	432	433	|I-IUPAC
arylspiro	433	442	|I-IUPAC
[	442	443	|I-IUPAC
isobenzofuran	443	456	|I-IUPAC
-	456	457	|I-IUPAC
1	457	458	|I-IUPAC
(	458	459	|I-IUPAC
3H	459	461	|I-IUPAC
)	461	462	|I-IUPAC
,	462	463	|I-IUPAC
4'	463	465	|I-IUPAC
-	465	466	|I-IUPAC
piperidines	466	477	|I-IUPAC
]	477	478	|I-IUPAC
.	478	479	|O
Structure	480	489	|O
-	489	490	|O
-	490	491	|O
activity	491	499	|O
relationships	500	513	|O
for	514	517	|O
4	518	519	|B-IUPAC
-	519	520	|I-IUPAC
[	520	521	|I-IUPAC
2p	521	523	|I-IUPAC
(	523	524	|I-IUPAC
arylmethyl	524	534	|I-IUPAC
)	534	535	|I-IUPAC
phenyl	535	541	|I-IUPAC
]	541	542	|I-IUPAC
piperidines	542	553	|I-IUPAC
are	554	557	|O
generally	558	567	|O
similar	568	575	|O
to	576	578	|O
the	579	582	|O
profile	583	590	|O
established	591	602	|O
for	603	606	|O
3	607	608	|B-IUPAC
-	608	609	|I-IUPAC
arylspiro	609	618	|I-IUPAC
[	618	619	|I-IUPAC
isobenzofuran	619	632	|I-IUPAC
-	632	633	|I-IUPAC
1	633	634	|I-IUPAC
(	634	635	|I-IUPAC
3H	635	637	|I-IUPAC
)	637	638	|I-IUPAC
,	638	639	|I-IUPAC
4'	639	641	|I-IUPAC
-	641	642	|I-IUPAC
piperidines	642	653	|I-IUPAC
]	653	654	|I-IUPAC
.	654	655	|O
Significant	656	667	|O
antitetrabenazine	668	685	|O
activity	686	694	|O
is	695	697	|O
associated	698	708	|O
only	709	713	|O
with	714	718	|O
derivatives	719	730	|O
where	731	736	|O
the	737	740	|O
arylmethyl	741	751	|O
group	752	757	|O
is	758	760	|O
ortho	761	766	|O
to	767	769	|O
the	770	773	|O
piperidine	774	784	|O
ring	785	789	|O
.	789	790	|O
4	791	792	|B-IUPAC
-	792	793	|I-IUPAC
(	793	794	|I-IUPAC
Benzyloxy	794	803	|I-IUPAC
)	803	804	|I-IUPAC
-	804	805	|I-IUPAC
4	805	806	|I-IUPAC
-	806	807	|I-IUPAC
phenylpiperidines	807	824	|I-IUPAC
and	825	828	|O
4	829	830	|B-IUPAC
-	830	831	|I-IUPAC
[	831	832	|I-IUPAC
2	832	833	|I-IUPAC
-	833	834	|I-IUPAC
(	834	835	|I-IUPAC
arylmethyl	835	845	|I-IUPAC
)	845	846	|I-IUPAC
phenyl	846	852	|I-IUPAC
]	852	853	|I-IUPAC
-	853	854	|I-IUPAC
4	854	855	|I-IUPAC
-	855	856	|I-IUPAC
piperidinols	856	868	|I-IUPAC
and	869	872	|O
the	873	876	|O
corresponding	877	890	|O
methyl	891	897	|O
ethers	898	904	|O
and	905	908	|O
esters	909	915	|O
display	916	923	|O
weak	924	928	|O
to	929	931	|O
modest	932	938	|O
antitetrabenazine	939	956	|O
activity	957	965	|O
.	965	966	|O
4	967	968	|B-IUPAC
-	968	969	|I-IUPAC
[	969	970	|I-IUPAC
2	970	971	|I-IUPAC
-	971	972	|I-IUPAC
(	972	973	|I-IUPAC
Arylmethyl	973	983	|I-IUPAC
)	983	984	|I-IUPAC
phenyl	984	990	|I-IUPAC
]	990	991	|I-IUPAC
-	991	992	|I-IUPAC
1,2,3,6	992	999	|I-IUPAC
-	999	1000	|I-IUPAC
tetrahydropyridine	1000	1018	|I-IUPAC
derivatives	1019	1030	|B-MODIFIER
,	1030	1031	|O
at	1032	1034	|O
best	1035	1039	|O
,	1039	1040	|O
exhibit	1041	1048	|O
modest	1049	1055	|O
antitetrabenazine	1056	1073	|O
activity	1074	1082	|O
,	1082	1083	|O
with	1084	1088	|O
the	1089	1092	|O
exception	1093	1102	|O
of	1103	1105	|O
4	1106	1107	|B-IUPAC
-	1107	1108	|I-IUPAC
[	1108	1109	|I-IUPAC
2	1109	1110	|I-IUPAC
-	1110	1111	|I-IUPAC
(	1111	1112	|I-IUPAC
phenylmethyl	1112	1124	|I-IUPAC
)	1124	1125	|I-IUPAC
phenyl	1125	1131	|I-IUPAC
]	1131	1132	|I-IUPAC
-	1132	1133	|I-IUPAC
1,2,3,6	1133	1140	|I-IUPAC
-	1140	1141	|I-IUPAC
tetrahydropyridine	1141	1159	|I-IUPAC
which	1160	1165	|O
is	1166	1168	|O
approximately	1169	1182	|O
equipotent	1183	1193	|O
with	1194	1198	|O
amitriptyline	1199	1212	|O
.	1212	1213	|O
The	1214	1217	|O
results	1218	1225	|O
of	1226	1228	|O
these	1229	1234	|O
investigations	1235	1249	|O
allow	1250	1255	|O
certain	1256	1263	|O
speculations	1264	1276	|O
to	1277	1279	|O
be	1280	1282	|O
made	1283	1287	|O
with	1288	1292	|O
respect	1293	1300	|O
to	1301	1303	|O
the	1304	1307	|O
role	1308	1312	|O
of	1313	1315	|O
the	1316	1319	|O
furan	1320	1325	|O
ring	1326	1330	|O
in	1331	1333	|O
the	1334	1337	|O
3	1338	1339	|B-IUPAC
-	1339	1340	|I-IUPAC
arylspiro	1340	1349	|I-IUPAC
[	1349	1350	|I-IUPAC
isobenzofuran	1350	1363	|I-IUPAC
-	1363	1364	|I-IUPAC
1	1364	1365	|I-IUPAC
(	1365	1366	|I-IUPAC
3H	1366	1368	|I-IUPAC
)	1368	1369	|I-IUPAC
,	1369	1370	|I-IUPAC
4'	1370	1372	|I-IUPAC
-	1372	1373	|I-IUPAC
piperidines	1373	1384	|I-IUPAC
]	1384	1385	|I-IUPAC
and	1386	1389	|O
antitetrabenazine	1390	1407	|O
activity	1408	1416	|O
.	1416	1417	|O

### abstracts4401.txt
The	0	3	|O
adenosine	4	13	|O
antagonist	14	24	|O
9	25	26	|B-IUPAC
-	26	27	|I-IUPAC
chloro	27	33	|I-IUPAC
-	33	34	|I-IUPAC
2	34	35	|I-IUPAC
-	35	36	|I-IUPAC
(	36	37	|I-IUPAC
2	37	38	|I-IUPAC
-	38	39	|I-IUPAC
furanyl	39	46	|I-IUPAC
)	46	47	|I-IUPAC
[	47	48	|I-IUPAC
1,2,4	48	53	|I-IUPAC
]	53	54	|I-IUPAC
triazolo	54	62	|I-IUPAC
[	62	63	|I-IUPAC
1	63	64	|I-IUPAC
,	64	65	|I-IUPAC
5	66	67	|I-IUPAC
-	67	68	|I-IUPAC
c	68	69	|I-IUPAC
]	69	70	|I-IUPAC
quinazolin	70	80	|I-IUPAC
-	80	81	|I-IUPAC
5	81	82	|I-IUPAC
-	82	83	|I-IUPAC
amine	83	88	|I-IUPAC
(	89	90	|O
CGS	90	93	|O
15943	94	99	|O
)	99	100	|O
binds	101	106	|O
nonselectively	107	121	|O
to	122	124	|O
human	125	130	|O
A1	131	133	|O
,	133	134	|O
A2A	135	138	|O
,	138	139	|O
and	140	143	|O
A3	144	146	|O
receptors	147	156	|O
with	157	161	|O
high	162	166	|O
affinity	167	175	|O
.	175	176	|O
Acylated	177	185	|O
derivatives	186	197	|O
and	198	201	|O
one	202	205	|O
alkyl	206	211	|O
derivative	212	222	|O
of	223	225	|O
the	226	229	|O
5	230	231	|O
-	231	232	|O
amino	232	237	|O
group	238	243	|O
and	244	247	|O
other	248	253	|O
modifications	254	267	|O
were	268	272	|O
prepared	273	281	|O
in	282	284	|O
an	285	287	|O
effort	288	294	|O
to	295	297	|O
enhance	298	305	|O
A2B	306	309	|O
or	310	312	|O
A3	313	315	|O
subtype	316	323	|O
potency	324	331	|O
.	331	332	|O
In	333	335	|O
general	336	343	|O
,	343	344	|O
distal	345	351	|O
modifications	352	365	|O
of	366	368	|O
the	369	372	|O
N5	373	375	|O
-	375	376	|O
substituent	376	387	|O
were	388	392	|O
highly	393	399	|O
modulatory	400	410	|O
to	411	413	|O
potency	414	421	|O
and	422	425	|O
selectivity	426	437	|O
at	438	440	|O
adenosine	441	450	|O
receptors	451	460	|O
,	460	461	|O
as	462	464	|O
determined	465	475	|O
in	476	478	|O
radioligand	479	490	|O
binding	491	498	|O
assays	499	505	|O
at	506	508	|O
rat	509	512	|O
brain	513	518	|O
A1	519	521	|O
and	522	525	|O
A2A	526	529	|O
receptors	530	539	|O
and	540	543	|O
at	544	546	|O
recombinant	547	558	|O
human	559	564	|O
A3	565	567	|O
receptors	568	577	|O
.	577	578	|O
In	579	581	|O
Chinese	582	589	|O
hamster	590	597	|O
ovary	598	603	|O
cells	604	609	|O
stably	610	616	|O
transfected	617	628	|O
with	629	633	|O
human	634	639	|O
A2B	640	643	|O
receptor	644	652	|O
cDNA	653	657	|O
,	657	658	|O
inhibition	659	669	|O
of	670	672	|O
agonist	673	680	|O
-	680	681	|O
induced	681	688	|O
cyclic	689	695	|O
AMP	696	699	|O
production	700	710	|O
was	711	714	|O
measured	715	723	|O
.	723	724	|O
An	725	727	|O
N5	728	730	|B-IUPAC
-	730	731	|I-IUPAC
(	731	732	|I-IUPAC
2	732	733	|I-IUPAC
-	733	734	|I-IUPAC
iodophenyl	734	744	|I-IUPAC
)	744	745	|I-IUPAC
acetyl	745	751	|I-IUPAC
derivative	752	762	|B-MODIFIER
was	763	766	|O
highly	767	773	|O
selective	774	783	|O
for	784	787	|O
A2A	788	791	|O
receptors	792	801	|O
.	801	802	|O
An	803	805	|O
(	806	807	|B-IUPAC
R	807	808	|I-IUPAC
)	808	809	|I-IUPAC
-	809	810	|I-IUPAC
N5	810	812	|I-IUPAC
-	812	813	|I-IUPAC
alpha	813	818	|I-IUPAC
-	818	819	|I-IUPAC
methyl	819	825	|I-IUPAC
(	825	826	|I-IUPAC
phenylacetyl	826	838	|I-IUPAC
)	838	839	|I-IUPAC
derivative	840	850	|B-MODIFIER
was	851	854	|O
the	855	858	|O
most	859	863	|O
potent	864	870	|O
derivative	871	881	|O
at	882	884	|O
A3	885	887	|O
receptors	888	897	|O
,	897	898	|O
with	899	903	|O
a	904	905	|O
Ki	906	908	|O
value	909	914	|O
of	915	917	|O
0.36	918	922	|O
nM	923	925	|O
.	925	926	|O
A	927	928	|O
bulky	929	934	|O
N5	935	937	|B-IUPAC
-	937	938	|I-IUPAC
diphenylacetyl	938	952	|I-IUPAC
derivative	953	963	|B-MODIFIER
,	963	964	|O
13	965	967	|O
,	967	968	|O
displayed	969	978	|O
a	979	980	|O
Ki	981	983	|O
value	984	989	|O
of	990	992	|O
0	993	994	|O
.	994	995	|O
59	996	998	|O
nM	999	1001	|O
at	1002	1004	|O
human	1005	1010	|O
A3	1011	1013	|O
receptors	1014	1023	|O
and	1024	1027	|O
was	1028	1031	|O
moderately	1032	1042	|O
selective	1043	1052	|O
for	1053	1056	|O
that	1057	1061	|O
subtype	1062	1069	|O
.	1069	1070	|O
Thus	1071	1075	|O
,	1075	1076	|O
a	1077	1078	|O
large	1079	1084	|O
,	1084	1085	|O
nondiscriminating	1086	1103	|O
hydrophobic	1104	1115	|O
region	1116	1122	|O
occurs	1123	1129	|O
in	1130	1132	|O
the	1133	1136	|O
A3	1137	1139	|O
receptor	1140	1148	|O
in	1149	1151	|O
proximity	1152	1161	|O
to	1162	1164	|O
the	1165	1168	|O
N5	1169	1171	|O
-	1171	1172	|O
substituent	1172	1183	|O
.	1183	1184	|O
A	1185	1186	|O
series	1187	1193	|O
of	1194	1196	|O
straight	1197	1205	|O
-	1205	1206	|O
chain	1206	1211	|O
N5	1212	1214	|B-IUPAC
-	1214	1215	|I-IUPAC
aminoalkylacyl	1215	1229	|I-IUPAC
derivatives	1230	1241	|B-MODIFIER
demonstrated	1242	1254	|O
that	1255	1259	|O
for	1260	1263	|O
A2B	1264	1267	|O
receptors	1268	1277	|O
the	1278	1281	|O
optimal	1282	1289	|O
chain	1290	1295	|O
length	1296	1302	|O
occurs	1303	1309	|O
with	1310	1314	|O
three	1315	1320	|O
methylene	1321	1330	|O
groups	1331	1337	|O
,	1337	1338	|O
i.e.	1339	1343	|O
,	1343	1344	|O
the	1345	1348	|O
N5	1349	1351	|B-IUPAC
-	1351	1352	|I-IUPAC
gamma	1352	1357	|I-IUPAC
-	1357	1358	|I-IUPAC
aminobutyryl	1358	1370	|I-IUPAC
derivative	1371	1381	|B-MODIFIER
27	1382	1384	|O
which	1385	1390	|O
had	1391	1394	|O
a	1395	1396	|O
pA2	1397	1400	|O
value	1401	1406	|O
of	1407	1409	|O
8.0	1410	1413	|O
but	1414	1417	|O
was	1418	1421	|O
not	1422	1425	|O
selective	1426	1435	|O
for	1436	1439	|O
A2B	1440	1443	|O
receptors	1444	1453	|O
.	1453	1454	|O
At	1455	1457	|O
A1	1458	1460	|O
,	1460	1461	|O
A2A	1462	1465	|O
,	1465	1466	|O
and	1467	1470	|O
A3	1471	1473	|O
receptors	1474	1483	|O
however	1484	1491	|O
the	1492	1495	|O
optimum	1496	1503	|O
occurs	1504	1510	|O
with	1511	1515	|O
four	1516	1520	|O
methylene	1521	1530	|O
groups	1531	1537	|O
.	1537	1538	|O
An	1539	1541	|O
N5	1542	1544	|B-IUPAC
-	1544	1545	|I-IUPAC
pivaloyl	1545	1553	|I-IUPAC
derivative	1554	1564	|B-MODIFIER
,	1564	1565	|O
which	1566	1571	|O
was	1572	1575	|O
less	1576	1580	|O
potent	1581	1587	|O
than	1588	1592	|O
27	1593	1595	|O
at	1596	1598	|O
A1	1599	1601	|O
,	1601	1602	|O
A2A	1603	1606	|O
,	1606	1607	|O
and	1608	1611	|O
A3	1612	1614	|O
receptors	1615	1624	|O
,	1624	1625	|O
retained	1626	1634	|O
moderate	1635	1643	|O
potency	1644	1651	|O
at	1652	1654	|O
A2B	1655	1658	|O
receptors	1659	1668	|O
.	1668	1669	|O
A	1670	1671	|O
molecular	1672	1681	|O
model	1682	1687	|O
of	1688	1690	|O
the	1691	1694	|O
27	1695	1697	|O
-	1697	1698	|O
A2B	1698	1701	|O
receptor	1702	1710	|O
complex	1711	1718	|O
based	1719	1724	|O
on	1725	1727	|O
the	1728	1731	|O
structure	1732	1741	|O
of	1742	1744	|O
rhodopsin	1745	1754	|O
utilizing	1755	1764	|O
a	1765	1766	|O
"	1767	1768	|O
cross	1768	1773	|O
-	1773	1774	|O
docking	1774	1781	|O
"	1781	1782	|O
procedure	1783	1792	|O
was	1793	1796	|O
developed	1797	1806	|O
in	1807	1809	|O
order	1810	1815	|O
to	1816	1818	|O
visualize	1819	1828	|O
the	1829	1832	|O
environment	1833	1844	|O
of	1845	1847	|O
the	1848	1851	|O
ligand	1852	1858	|O
binding	1859	1866	|O
site	1867	1871	|O
.	1871	1872	|O

### abstracts3803.txt
By	0	2	|O
the	3	6	|O
use	7	10	|O
of	11	13	|O
space	14	19	|O
-	19	20	|O
filling	20	27	|O
models	28	34	|O
,	34	35	|O
a	36	37	|O
novel	38	43	|O
compound	44	52	|O
,	52	53	|O
6	54	55	|B-IUPAC
-	55	56	|I-IUPAC
carbamylmethyl	56	70	|I-IUPAC
-	70	71	|I-IUPAC
8	71	72	|I-IUPAC
-	72	73	|I-IUPAC
methyl	73	79	|I-IUPAC
-	79	80	|I-IUPAC
7	80	81	|I-IUPAC
(	81	82	|I-IUPAC
5	82	83	|I-IUPAC
)	83	84	|I-IUPAC
H	84	85	|I-IUPAC
-	85	86	|I-IUPAC
cyclopenta	86	96	|I-IUPAC
[	96	97	|I-IUPAC
f	97	98	|I-IUPAC
]	98	99	|I-IUPAC
isoquinolin	99	110	|I-IUPAC
-	110	111	|I-IUPAC
3	111	112	|I-IUPAC
-	112	113	|I-IUPAC
(	113	114	|I-IUPAC
2H	114	116	|I-IUPAC
)	116	117	|I-IUPAC
-	117	118	|I-IUPAC
one	118	121	|I-IUPAC
was	122	125	|O
devised	126	133	|O
which	134	139	|O
would	140	145	|O
be	146	148	|O
expected	149	157	|O
to	158	160	|O
hydrogen	161	169	|O
bond	170	174	|O
specifically	175	187	|O
to	188	190	|O
GC	191	193	|O
pairs	194	199	|O
in	200	202	|O
the	203	206	|O
major	207	212	|O
groove	213	219	|O
of	220	222	|O
the	223	226	|O
double	227	233	|O
helix	234	239	|O
such	240	244	|O
that	245	249	|O
(	250	251	|O
i	251	252	|O
)	252	253	|O
the	254	257	|O
amino	258	263	|B-IUPAC
group	264	269	|B-MODIFIER
of	270	272	|O
the	273	276	|O
cytosine	277	285	|O
molecule	286	294	|O
donates	295	302	|O
a	303	304	|O
hydrogen	305	313	|O
bond	314	318	|O
to	319	321	|O
the	322	325	|O
C	326	327	|O
-	327	328	|O
3	328	329	|O
carbonyl	330	338	|O
of	339	341	|O
the	342	345	|O
isoquinoline	346	358	|O
moiety	359	365	|O
and	366	369	|O
(	370	371	|O
ii	371	373	|O
)	373	374	|O
the	375	378	|O
amide	379	384	|O
proton	385	391	|O
of	392	394	|O
the	395	398	|O
side	399	403	|O
chain	404	409	|O
donates	410	417	|O
a	418	419	|O
hydrogen	420	428	|O
bond	429	433	|O
to	434	436	|O
the	437	440	|O
N	441	442	|O
-	442	443	|O
7	443	444	|O
of	445	447	|O
guanine	448	455	|O
.	455	456	|O
3	457	458	|B-IUPAC
-	458	459	|I-IUPAC
Ethoxy	459	465	|I-IUPAC
-	465	466	|I-IUPAC
8	466	467	|I-IUPAC
-	467	468	|I-IUPAC
methyl	468	474	|I-IUPAC
-	474	475	|I-IUPAC
7	475	476	|I-IUPAC
(	476	477	|I-IUPAC
5	477	478	|I-IUPAC
)	478	479	|I-IUPAC
H	479	480	|I-IUPAC
-	480	481	|I-IUPAC
cyclopenta	481	491	|I-IUPAC
[	491	492	|I-IUPAC
f	492	493	|I-IUPAC
]	493	494	|I-IUPAC
isoquinoline	494	506	|I-IUPAC
(	507	508	|O
4	508	509	|O
)	509	510	|O
which	511	516	|O
constitutes	517	528	|O
the	529	532	|O
basic	533	538	|O
ring	539	543	|O
system	544	550	|O
of	551	553	|O
1	554	555	|O
was	556	559	|O
synthesized	560	571	|O
in	572	574	|O
a	575	576	|O
multistep	577	586	|O
procedure	587	596	|O
starting	597	605	|O
from	606	610	|O
m	611	612	|B-IUPAC
-	612	613	|I-IUPAC
methyl	613	619	|I-IUPAC
-	619	620	|I-IUPAC
N	620	621	|I-IUPAC
-	621	622	|I-IUPAC
acetylbenzylamine	622	639	|I-IUPAC
(	640	641	|O
5	641	642	|O
)	642	643	|O
.	643	644	|O
Friedel	645	652	|O
-	652	653	|O
Crafts	653	659	|O
reaction	660	668	|O
of	669	671	|O
5	672	673	|O
led	674	677	|O
to	678	680	|O
2,4	681	684	|B-IUPAC
-	684	685	|I-IUPAC
bis	685	688	|I-IUPAC
(	688	689	|I-IUPAC
chloromethyl	689	701	|I-IUPAC
)	701	702	|I-IUPAC
-	702	703	|I-IUPAC
5	703	704	|I-IUPAC
-	704	705	|I-IUPAC
methyl	705	711	|I-IUPAC
-	711	712	|I-IUPAC
N	712	713	|I-IUPAC
-	713	714	|I-IUPAC
acetylbenzylamine	714	731	|I-IUPAC
(	732	733	|O
6	733	734	|O
)	734	735	|O
which	736	741	|O
on	742	744	|O
treatment	745	754	|O
with	755	759	|O
KCN	760	763	|O
,	763	764	|O
hydrolysis	765	775	|O
of	776	778	|O
the	779	782	|O
resultant	783	792	|O
nitrile	793	800	|O
,	800	801	|O
and	802	805	|O
subsequent	806	816	|O
esterification	817	831	|O
afforded	832	840	|O
6	841	842	|B-IUPAC
-	842	843	|I-IUPAC
carbethoxymethyl	843	859	|I-IUPAC
-	859	860	|I-IUPAC
7	860	861	|I-IUPAC
-	861	862	|I-IUPAC
methyl	862	868	|I-IUPAC
-	868	869	|I-IUPAC
1,2,3,4	869	876	|I-IUPAC
-	876	877	|I-IUPAC
tetrahydroisoquinolin	877	898	|I-IUPAC
-	898	899	|I-IUPAC
3	899	900	|I-IUPAC
-	900	901	|I-IUPAC
one	901	904	|I-IUPAC
(	905	906	|O
9	906	907	|O
)	907	908	|O
.	908	909	|O
Treatment	910	919	|O
of	920	922	|O
9	923	924	|O
with	925	929	|O
triethyloxonium	930	945	|O
fluoborate	946	956	|O
followed	957	965	|O
by	966	968	|O
dehydrogenation	969	984	|O
of	985	987	|O
the	988	991	|O
product	992	999	|O
gave	1000	1004	|O
6	1005	1006	|B-IUPAC
-	1006	1007	|I-IUPAC
carbethoxy	1007	1017	|I-IUPAC
-	1017	1018	|I-IUPAC
methyl	1018	1024	|I-IUPAC
-	1024	1025	|I-IUPAC
3	1025	1026	|I-IUPAC
-	1026	1027	|I-IUPAC
ethoxy	1027	1033	|I-IUPAC
-	1033	1034	|I-IUPAC
7	1034	1035	|I-IUPAC
-	1035	1036	|I-IUPAC
methylisoquinoline	1036	1054	|I-IUPAC
(	1055	1056	|O
14	1056	1058	|O
)	1058	1059	|O
.	1059	1060	|O
Chain	1061	1066	|O
extension	1067	1076	|O
of	1077	1079	|O
14	1080	1082	|O
followed	1083	1091	|O
by	1092	1094	|O
cyclization	1095	1106	|O
led	1107	1110	|O
to	1111	1113	|O
3	1114	1115	|B-IUPAC
-	1115	1116	|I-IUPAC
ethoxy	1116	1122	|I-IUPAC
-	1122	1123	|I-IUPAC
8	1123	1124	|I-IUPAC
-	1124	1125	|I-IUPAC
methyl	1125	1131	|I-IUPAC
-	1131	1132	|I-IUPAC
5,6	1132	1135	|I-IUPAC
-	1135	1136	|I-IUPAC
dihydro	1136	1143	|I-IUPAC
-	1143	1144	|I-IUPAC
7H	1144	1146	|I-IUPAC
-	1146	1147	|I-IUPAC
cyclopenta	1147	1157	|I-IUPAC
[	1157	1158	|I-IUPAC
f	1158	1159	|I-IUPAC
]	1159	1160	|I-IUPAC
isoquinolin	1160	1171	|I-IUPAC
-	1171	1172	|I-IUPAC
5	1172	1173	|I-IUPAC
-	1173	1174	|I-IUPAC
one	1174	1177	|I-IUPAC
(	1178	1179	|O
19	1179	1181	|O
)	1181	1182	|O
which	1183	1188	|O
on	1189	1191	|O
reduction	1192	1201	|O
and	1202	1205	|O
subsequent	1206	1216	|O
dehydration	1217	1228	|O
yielded	1229	1236	|O
3	1237	1238	|B-IUPAC
-	1238	1239	|I-IUPAC
ethoxy	1239	1245	|I-IUPAC
-	1245	1246	|I-IUPAC
8	1246	1247	|I-IUPAC
-	1247	1248	|I-IUPAC
methyl	1248	1254	|I-IUPAC
-	1254	1255	|I-IUPAC
7	1255	1256	|I-IUPAC
(	1256	1257	|I-IUPAC
5	1257	1258	|I-IUPAC
)	1258	1259	|I-IUPAC
H	1259	1260	|I-IUPAC
-	1260	1261	|I-IUPAC
cyclopenta	1261	1271	|I-IUPAC
[	1271	1272	|I-IUPAC
f	1272	1273	|I-IUPAC
]	1273	1274	|I-IUPAC
isoquinoline	1274	1286	|I-IUPAC
(	1287	1288	|O
4	1288	1289	|O
)	1289	1290	|O
.	1290	1291	|O

### abstracts295.txt
Reaction	0	8	|O
of	9	11	|O
hydroxyl	12	20	|O
-	20	21	|O
protected	21	30	|O
derivatives	31	42	|O
of	43	45	|O
hydroxyalkoxyamines	46	65	|O
(	66	67	|O
3a	67	69	|O
,	69	70	|O
b	70	71	|O
,	71	72	|O
c	72	73	|O
)	73	74	|O
with	75	79	|O
either	80	86	|O
4,6	87	90	|B-IUPAC
-	90	91	|I-IUPAC
dichloro	91	99	|I-IUPAC
-	99	100	|I-IUPAC
2,5	100	103	|I-IUPAC
-	103	104	|I-IUPAC
diformamidopyrimidine	104	125	|I-IUPAC
(	126	127	|O
5	127	128	|O
)	128	129	|O
or	130	132	|O
4,6	133	136	|B-IUPAC
-	136	137	|I-IUPAC
dichloro	137	145	|I-IUPAC
-	145	146	|I-IUPAC
5	146	147	|I-IUPAC
-	147	148	|I-IUPAC
formamidopyrimidine	148	167	|I-IUPAC
(	168	169	|O
31	169	171	|O
)	171	172	|O
and	173	176	|O
subsequent	177	187	|O
cyclization	188	199	|O
of	200	202	|O
the	203	206	|O
resultant	207	216	|O
6	217	218	|B-IUPAC
-	218	219	|I-IUPAC
(	219	220	|I-IUPAC
alkoxyamino	220	231	|I-IUPAC
)	231	232	|I-IUPAC
pyrimidines	232	243	|I-IUPAC
(	244	245	|O
6	245	246	|O
,	246	247	|O
17	248	250	|O
,	250	251	|O
32	252	254	|O
,	254	255	|O
35	256	258	|O
)	258	259	|O
by	260	262	|O
heating	263	270	|O
with	271	275	|O
diethoxymethyl	276	290	|O
acetate	291	298	|O
afforded	299	307	|O
9	308	309	|B-IUPAC
-	309	310	|I-IUPAC
alkoxy	310	316	|I-IUPAC
-	316	317	|I-IUPAC
6	317	318	|I-IUPAC
-	318	319	|I-IUPAC
chloropurines	319	332	|I-IUPAC
(	333	334	|O
7	334	335	|O
,	335	336	|O
18	337	339	|O
,	339	340	|O
33	341	343	|O
,	343	344	|O
36	345	347	|O
)	347	348	|O
,	348	349	|O
which	350	355	|O
were	356	360	|O
converted	361	370	|O
subsequently	371	383	|O
to	384	386	|O
9	387	388	|B-PARTIUPAC
-	388	389	|I-PARTIUPAC
(	389	390	|I-PARTIUPAC
3	390	391	|I-PARTIUPAC
-	391	392	|I-PARTIUPAC
hydroxypropoxy	392	406	|I-PARTIUPAC
)	406	407	|I-PARTIUPAC
-	407	408	|I-PARTIUPAC
and	409	412	|O
9	413	414	|B-IUPAC
-	414	415	|I-IUPAC
[	415	416	|I-IUPAC
3	416	417	|I-IUPAC
-	417	418	|I-IUPAC
hydroxy	418	425	|I-IUPAC
-	425	426	|I-IUPAC
2	426	427	|I-IUPAC
-	427	428	|I-IUPAC
(	428	429	|I-IUPAC
hydroxymethyl	429	442	|I-IUPAC
)	442	443	|I-IUPAC
propoxy	443	450	|I-IUPAC
]	450	451	|I-IUPAC
derivatives	452	463	|B-MODIFIER
of	464	466	|O
guanine	467	474	|O
,	474	475	|O
2	476	477	|B-IUPAC
-	477	478	|I-IUPAC
amino	478	483	|I-IUPAC
-	483	484	|I-IUPAC
6	484	485	|I-IUPAC
-	485	486	|I-IUPAC
chloropurine	486	498	|I-IUPAC
,	498	499	|O
2	500	501	|B-IUPAC
-	501	502	|I-IUPAC
amino	502	507	|I-IUPAC
-	507	508	|I-IUPAC
6	508	509	|I-IUPAC
-	509	510	|I-IUPAC
alkoxypurines	510	523	|I-IUPAC
,	523	524	|O
2	525	526	|B-IUPAC
-	526	527	|I-IUPAC
aminopurine	527	538	|I-IUPAC
,	538	539	|O
2,6	540	543	|B-IUPAC
-	543	544	|I-IUPAC
diaminopurine	544	557	|I-IUPAC
,	557	558	|O
adenine	559	566	|O
,	566	567	|O
hypoxanthine	568	580	|O
,	580	581	|O
and	582	585	|O
6	586	587	|B-IUPAC
-	587	588	|I-IUPAC
methoxypurine	588	601	|I-IUPAC
(	602	603	|O
8	603	604	|O
,	604	605	|O
12	606	608	|O
,	608	609	|O
13	610	612	|O
,	612	613	|O
19-21	614	619	|O
,	619	620	|O
23-26	621	626	|O
,	626	627	|O
34	628	630	|O
,	630	631	|O
37-39	632	637	|O
)	637	638	|O
.	638	639	|O
Carboxylic	640	650	|O
acid	651	655	|O
esters	656	662	|O
(	663	664	|O
9-11	664	668	|O
,	668	669	|O
14-16	670	675	|O
,	675	676	|O
27-29	677	682	|O
)	682	683	|O
and	684	687	|O
a	688	689	|O
cyclic	690	696	|O
phosphate	697	706	|O
derivative	707	717	|O
(	718	719	|O
22	719	721	|O
)	721	722	|O
of	723	725	|O
the	726	729	|O
9	730	731	|B-IUPAC
-	731	732	|I-IUPAC
(	732	733	|I-IUPAC
hydroxyalkoxy	733	746	|I-IUPAC
)	746	747	|I-IUPAC
guanines	747	755	|I-IUPAC
(	756	757	|O
8	757	758	|O
,	758	759	|O
21	760	762	|O
)	762	763	|O
and	764	767	|O
2	768	769	|B-IUPAC
-	769	770	|I-IUPAC
amino	770	775	|I-IUPAC
-	775	776	|I-IUPAC
9	776	777	|I-IUPAC
-	777	778	|I-IUPAC
(	778	779	|I-IUPAC
hydroxyalkoxy	779	792	|I-IUPAC
)	792	793	|I-IUPAC
purines	793	800	|I-IUPAC
(	801	802	|O
13	802	804	|O
,	804	805	|O
26	806	808	|O
)	808	809	|O
were	810	814	|O
also	815	819	|O
prepared	820	828	|O
.	828	829	|O
The	830	833	|O
guanine	834	841	|O
derivatives	842	853	|O
(	854	855	|O
8	855	856	|O
,	856	857	|O
21	858	860	|O
)	860	861	|O
showed	862	868	|O
potent	869	875	|O
and	876	879	|O
selective	880	889	|O
activity	890	898	|O
against	899	906	|O
herpes	907	913	|O
simplex	914	921	|O
virus	922	927	|O
types	928	933	|O
1	934	935	|O
and	936	939	|O
2	940	941	|O
and	942	945	|O
varicella	946	955	|O
zoster	956	962	|O
virus	963	968	|O
in	969	971	|O
cell	972	976	|O
cultures	977	985	|O
and	986	989	|O
8	990	991	|O
is	992	994	|O
more	995	999	|O
active	1000	1006	|O
than	1007	1011	|O
acyclovir	1012	1021	|O
.	1021	1022	|O
Although	1023	1031	|O
without	1032	1039	|O
significant	1040	1051	|O
antiviral	1052	1061	|O
activity	1062	1070	|O
in	1071	1073	|O
cell	1074	1078	|O
cultures	1079	1087	|O
,	1087	1088	|O
the	1089	1092	|O
2	1093	1094	|B-IUPAC
-	1094	1095	|I-IUPAC
aminopurines	1095	1107	|I-IUPAC
(	1108	1109	|O
13	1109	1111	|O
,	1111	1112	|O
14-16	1113	1118	|O
,	1118	1119	|O
26-29	1120	1125	|O
)	1125	1126	|O
and	1127	1130	|O
2	1131	1132	|B-IUPAC
-	1132	1133	|I-IUPAC
amino	1133	1138	|I-IUPAC
-	1138	1139	|I-IUPAC
6	1139	1140	|I-IUPAC
-	1140	1141	|I-IUPAC
alkoxypurines	1141	1154	|I-IUPAC
(	1155	1156	|O
12	1156	1158	|O
,	1158	1159	|O
23-25	1160	1165	|O
)	1165	1166	|O
are	1167	1170	|O
well	1171	1175	|O
absorbed	1176	1184	|O
after	1185	1190	|O
oral	1191	1195	|O
administration	1196	1210	|O
to	1211	1213	|O
mice	1214	1218	|O
and	1219	1222	|O
are	1223	1226	|O
converted	1227	1236	|O
efficiently	1237	1248	|O
to	1249	1251	|O
the	1252	1255	|O
antiviral	1256	1265	|O
guanine	1266	1273	|O
derivatives	1274	1285	|O
(	1286	1287	|O
8	1287	1288	|O
,	1288	1289	|O
21	1290	1292	|O
)	1292	1293	|O
in	1294	1296	|O
vivo	1297	1301	|O
.	1301	1302	|O

### abstracts2598.txt
Variation	0	9	|O
of	10	12	|O
the	13	16	|O
bridge	17	23	|O
linking	24	31	|O
the	32	35	|O
heterocyclic	36	48	|O
ring	49	53	|O
and	54	57	|O
p	58	59	|B-IUPAC
-	59	60	|I-IUPAC
aminobenzoyl	60	72	|I-IUPAC
-	72	73	|I-IUPAC
L	73	74	|I-IUPAC
-	74	75	|I-IUPAC
glutamate	75	84	|I-IUPAC
portions	85	93	|B-MODIFIER
of	94	96	|O
our	97	100	|O
previously	101	111	|O
described	112	121	|O
classical	122	131	|O
2,4	132	135	|B-IUPAC
-	135	136	|I-IUPAC
diaminofuro	136	147	|I-IUPAC
[	147	148	|I-IUPAC
2,3	148	151	|I-IUPAC
-	151	152	|I-IUPAC
d	152	153	|I-IUPAC
]	153	154	|I-IUPAC
pyrimidines	154	165	|I-IUPAC
1	166	167	|O
and	168	171	|O
2	172	173	|O
are	174	177	|O
reported	178	186	|O
as	187	189	|O
inhibitors	190	200	|O
of	201	203	|O
dihydrofolate	204	217	|O
reductase	218	227	|O
(	228	229	|O
DHFR	229	233	|O
)	233	234	|O
and	235	238	|O
thymidylate	239	250	|O
synthase	251	259	|O
(	260	261	|O
TS	261	263	|O
)	263	264	|O
and	265	268	|O
as	269	271	|O
antitumor	272	281	|O
agents	282	288	|O
.	288	289	|O
Specifically	290	302	|O
-	303	304	|O
CH2CH2	304	310	|O
-	310	311	|O
and	312	315	|O
-	316	317	|O
CH2NHCH2	317	325	|O
-	325	326	|O
bridged	327	334	|O
analogues	335	344	|O
,	344	345	|O
N	346	347	|B-IUPAC
-	347	348	|I-IUPAC
[	348	349	|I-IUPAC
4	349	350	|I-IUPAC
-	350	351	|I-IUPAC
[	351	352	|I-IUPAC
2	352	353	|I-IUPAC
-	353	354	|I-IUPAC
(	354	355	|I-IUPAC
2,4	355	358	|I-IUPAC
-	358	359	|I-IUPAC
diaminofuro	359	370	|I-IUPAC
[	370	371	|I-IUPAC
2,3	371	374	|I-IUPAC
-	374	375	|I-IUPAC
d	375	376	|I-IUPAC
]	376	377	|I-IUPAC
pyrimidin	377	386	|I-IUPAC
-	386	387	|I-IUPAC
5	387	388	|I-IUPAC
-	388	389	|I-IUPAC
yl	389	391	|I-IUPAC
)	391	392	|I-IUPAC
ethyl	393	398	|I-IUPAC
]	398	399	|I-IUPAC
benzoyl	399	406	|I-IUPAC
]	406	407	|I-IUPAC
-	407	408	|I-IUPAC
L	408	409	|I-IUPAC
-	409	410	|I-IUPAC
glutamic	410	418	|I-IUPAC
acid	419	423	|I-IUPAC
(	424	425	|O
3	425	426	|O
)	426	427	|O
and	428	431	|O
N	432	433	|B-IUPAC
-	433	434	|I-IUPAC
[	434	435	|I-IUPAC
4	435	436	|I-IUPAC
-	436	437	|I-IUPAC
[	437	438	|I-IUPAC
[	438	439	|I-IUPAC
N	439	440	|I-IUPAC
-	440	441	|I-IUPAC
[	441	442	|I-IUPAC
(	442	443	|I-IUPAC
2,4	443	446	|I-IUPAC
-	446	447	|I-IUPAC
diaminofuro	447	458	|I-IUPAC
[	458	459	|I-IUPAC
2,3	459	462	|I-IUPAC
-	462	463	|I-IUPAC
d	463	464	|I-IUPAC
]	464	465	|I-IUPAC
pyrimidin	465	474	|I-IUPAC
-	474	475	|I-IUPAC
5	475	476	|I-IUPAC
-	476	477	|I-IUPAC
yl	477	479	|I-IUPAC
)	479	480	|I-IUPAC
methyl	481	487	|I-IUPAC
]	487	488	|I-IUPAC
amino	488	493	|I-IUPAC
]	493	494	|I-IUPAC
methyl	494	500	|I-IUPAC
]	500	501	|I-IUPAC
benzoyl	501	508	|I-IUPAC
]	508	509	|I-IUPAC
-	509	510	|I-IUPAC
L	510	511	|I-IUPAC
-	511	512	|I-IUPAC
glutamic	512	520	|I-IUPAC
acid	521	525	|I-IUPAC
(	526	527	|O
4	527	528	|O
)	528	529	|O
,	529	530	|O
respectively	531	543	|O
,	543	544	|O
were	545	549	|O
synthesized	550	561	|O
.	561	562	|O
Compound	563	571	|O
3	572	573	|O
was	574	577	|O
obtained	578	586	|O
via	587	590	|O
a	591	592	|O
Wittig	593	599	|O
reaction	600	608	|O
of	609	611	|O
the	612	615	|O
tributylphosphonium	616	635	|O
salt	636	640	|O
of	641	643	|O
2,4	644	647	|B-IUPAC
-	647	648	|I-IUPAC
diamino	648	655	|I-IUPAC
-	655	656	|I-IUPAC
5	656	657	|I-IUPAC
-	657	658	|I-IUPAC
(	658	659	|I-IUPAC
chloromethyl	659	671	|I-IUPAC
)	671	672	|I-IUPAC
furo	672	676	|I-IUPAC
[	676	677	|I-IUPAC
2,3	677	680	|I-IUPAC
-	680	681	|I-IUPAC
d	681	682	|I-IUPAC
]	682	683	|I-IUPAC
pyrimidine	683	693	|I-IUPAC
(	694	695	|O
5	695	696	|O
)	696	697	|O
and	698	701	|O
methyl	702	708	|B-IUPAC
4	709	710	|I-IUPAC
-	710	711	|I-IUPAC
formylbenzoate	711	725	|I-IUPAC
(	726	727	|O
6	727	728	|O
)	728	729	|O
followed	730	738	|O
by	739	741	|O
reduction	742	751	|O
and	752	755	|O
coupling	756	764	|O
with	765	769	|O
the	770	773	|O
diethyl	774	781	|O
ester	782	787	|O
of	788	790	|O
L	791	792	|B-IUPAC
-	792	793	|I-IUPAC
glutamic	793	801	|I-IUPAC
acid	802	806	|I-IUPAC
.	806	807	|O
Compound	808	816	|O
4	817	818	|O
was	819	822	|O
synthesized	823	834	|O
by	835	837	|O
the	838	841	|O
nucleophilic	842	854	|O
displacement	855	867	|O
of	868	870	|O
5	871	872	|O
with	873	877	|O
diethyl	878	885	|B-IUPAC
N	886	887	|I-IUPAC
-	887	888	|I-IUPAC
[	888	889	|I-IUPAC
4	889	890	|I-IUPAC
-	890	891	|I-IUPAC
(	891	892	|I-IUPAC
aminomethyl	892	903	|I-IUPAC
)	903	904	|I-IUPAC
benzoyl	904	911	|I-IUPAC
]	911	912	|I-IUPAC
-	912	913	|I-IUPAC
L	913	914	|I-IUPAC
-	914	915	|I-IUPAC
glutamate	915	924	|I-IUPAC
(	925	926	|O
15	926	928	|O
)	928	929	|O
and	930	933	|O
saponification	934	948	|O
.	948	949	|O
Both	950	954	|O
analogues	955	964	|O
were	965	969	|O
evaluated	970	979	|O
in	980	982	|O
vitro	983	988	|O
as	989	991	|O
inhibitors	992	1002	|O
of	1003	1005	|O
DHFRs	1006	1011	|O
from	1012	1016	|O
(	1017	1018	|O
recombinant	1018	1029	|O
)	1029	1030	|O
human	1031	1036	|O
,	1036	1037	|O
human	1038	1043	|O
CCRF	1044	1048	|O
-	1048	1049	|O
CEM	1049	1052	|O
cells	1053	1058	|O
,	1058	1059	|O
and	1060	1063	|O
Lactobacillus	1064	1077	|O
casei	1078	1083	|O
.	1083	1084	|O
Compound	1085	1093	|O
3	1094	1095	|O
showed	1096	1102	|O
moderate	1103	1111	|O
activity	1112	1120	|O
(	1121	1122	|O
IC50	1122	1126	|O
10	1127	1129	|O
(	1129	1130	|O
-	1130	1131	|O
6	1131	1132	|O
)	1132	1133	|O
-	1133	1134	|O
10	1134	1136	|O
(	1136	1137	|O
-	1137	1138	|O
7	1138	1139	|O
)	1139	1140	|O
M	1141	1142	|O
)	1142	1143	|O
.	1143	1144	|O
Compound	1145	1153	|O
4	1154	1155	|O
was	1156	1159	|O
essentially	1160	1171	|O
inactive	1172	1180	|O
(	1181	1182	|O
IC50	1182	1186	|O
10	1187	1189	|O
(	1189	1190	|O
-	1190	1191	|O
5	1191	1192	|O
)	1192	1193	|O
M	1194	1195	|O
,	1195	1196	|O
CCRF	1197	1201	|O
-	1201	1202	|O
CEM	1202	1205	|O
)	1205	1206	|O
.	1206	1207	|O
The	1208	1211	|O
compounds	1212	1221	|O
were	1222	1226	|O
also	1227	1231	|O
evaluated	1232	1241	|O
against	1242	1249	|O
TS	1250	1252	|O
from	1253	1257	|O
(	1258	1259	|O
recombinant	1259	1270	|O
)	1270	1271	|O
human	1272	1277	|O
and	1278	1281	|O
L	1282	1283	|O
.	1283	1284	|O
casei	1285	1290	|O
and	1291	1294	|O
were	1295	1299	|O
of	1300	1302	|O
low	1303	1306	|O
activity	1307	1315	|O
(	1316	1317	|O
IC50	1317	1321	|O
10	1322	1324	|O
(	1324	1325	|O
-	1325	1326	|O
5	1326	1327	|O
)	1327	1328	|O
M	1329	1330	|O
)	1330	1331	|O
.	1331	1332	|O
The	1333	1336	|O
three	1337	1342	|O
-	1342	1343	|O
atom	1343	1347	|O
-	1347	1348	|O
bridged	1348	1355	|O
analogue	1356	1364	|O
4	1365	1366	|O
was	1367	1370	|O
somewhat	1371	1379	|O
more	1380	1384	|O
inhibitory	1385	1395	|O
to	1396	1398	|O
human	1399	1404	|O
TS	1405	1407	|O
than	1408	1412	|O
methotrexate	1413	1425	|O
(	1426	1427	|O
MTX	1427	1430	|O
)	1430	1431	|O
.	1431	1432	|O
Compound	1433	1441	|O
3	1442	1443	|O
inhibited	1444	1453	|O
the	1454	1457	|O
growth	1458	1464	|O
of	1465	1467	|O
tumor	1468	1473	|O
cells	1474	1479	|O
in	1480	1482	|O
culture	1483	1490	|O
(	1491	1492	|O
IC50	1492	1496	|O
10	1497	1499	|O
(	1499	1500	|O
-	1500	1501	|O
7	1501	1502	|O
)	1502	1503	|O
M	1504	1505	|O
)	1505	1506	|O
while	1507	1512	|O
4	1513	1514	|O
showed	1515	1521	|O
a	1522	1523	|O
low	1524	1527	|O
level	1528	1533	|O
of	1534	1536	|O
growth	1537	1543	|O
inhibitory	1544	1554	|O
activity	1555	1563	|O
.	1563	1564	|O
The	1565	1568	|O
inhibition	1569	1579	|O
of	1580	1582	|O
the	1583	1586	|O
growth	1587	1593	|O
of	1594	1596	|O
leukemia	1597	1605	|O
CCRF	1606	1610	|O
-	1610	1611	|O
CEM	1611	1614	|O
cells	1615	1620	|O
by	1621	1623	|O
both	1624	1628	|O
compounds	1629	1638	|O
parallels	1639	1648	|O
their	1649	1654	|O
inhibition	1655	1665	|O
of	1666	1668	|O
CCRF	1669	1673	|O
-	1673	1674	|O
CEM	1674	1677	|O
DHFR	1678	1682	|O
.	1682	1683	|O
Analogue	1684	1692	|O
3	1693	1694	|O
was	1695	1698	|O
a	1699	1700	|O
good	1701	1705	|O
substrate	1706	1715	|O
for	1716	1719	|O
human	1720	1725	|O
folylpolyglutamate	1726	1744	|O
synthetase	1745	1755	|O
(	1756	1757	|O
FPGS	1757	1761	|O
)	1761	1762	|O
derived	1763	1770	|O
from	1771	1775	|O
CCRF	1776	1780	|O
-	1780	1781	|O
CEM	1781	1784	|O
cells	1785	1790	|O
(	1791	1792	|O
Km	1792	1794	|O
8.5	1795	1798	|O
microM	1799	1805	|O
)	1805	1806	|O
.	1806	1807	|O
Further	1808	1815	|O
evaluation	1816	1826	|O
of	1827	1829	|O
the	1830	1833	|O
growth	1834	1840	|O
inhibitory	1841	1851	|O
activity	1852	1860	|O
of	1861	1863	|O
3	1864	1865	|O
against	1866	1873	|O
the	1874	1877	|O
MTX	1878	1881	|O
-	1881	1882	|O
resistant	1882	1891	|O
subline	1892	1899	|O
of	1900	1902	|O
CCRF	1903	1907	|O
-	1907	1908	|O
CEM	1908	1911	|O
cells	1912	1917	|O
(	1918	1919	|O
R30dm	1919	1924	|O
)	1924	1925	|O
with	1926	1930	|O
decreased	1931	1940	|O
FPGS	1941	1945	|O
indicated	1946	1955	|O
that	1956	1960	|O
poly	1961	1965	|O
-	1965	1966	|O
gamma	1966	1971	|O
-	1971	1972	|O
glutamylation	1972	1985	|O
was	1986	1989	|O
important	1990	1999	|O
for	2000	2003	|O
its	2004	2007	|O
action	2008	2014	|O
.	2014	2015	|O
Protection	2016	2026	|O
studies	2027	2034	|O
with	2035	2039	|O
3	2040	2041	|O
in	2042	2044	|O
the	2045	2048	|O
FaDu	2049	2053	|O
squamous	2054	2062	|O
cell	2063	2067	|O
carcinoma	2068	2077	|O
cell	2078	2082	|O
line	2083	2087	|O
indicated	2088	2097	|O
that	2098	2102	|O
inhibition	2103	2113	|O
was	2114	2117	|O
completely	2118	2128	|O
reversed	2129	2137	|O
by	2138	2140	|O
leucovorin	2141	2151	|O
[	2152	2153	|O
(	2153	2154	|O
6R	2154	2156	|B-IUPAC
,	2156	2157	|I-IUPAC
S	2157	2158	|I-IUPAC
-	2158	2159	|I-IUPAC
5	2159	2160	|I-IUPAC
-	2160	2161	|I-IUPAC
formyltetrahydrofolate	2161	2183	|I-IUPAC
]	2183	2184	|O
or	2185	2187	|O
by	2188	2190	|O
a	2191	2192	|O
combination	2193	2204	|O
of	2205	2207	|O
thymidine	2208	2217	|O
and	2218	2221	|O
hypoxanthine	2222	2234	|O
,	2234	2235	|O
suggesting	2236	2246	|O
an	2247	2249	|O
antifolate	2250	2260	|O
effect	2261	2267	|O
directed	2268	2276	|O
at	2277	2279	|O
DHFR	2280	2284	|O
.	2284	2285	|O

### abstracts2318.txt
Various	0	7	|O
6	8	9	|B-PARTIUPAC
-	9	10	|I-PARTIUPAC
[	10	11	|I-PARTIUPAC
[	11	12	|I-PARTIUPAC
(	12	13	|I-PARTIUPAC
aryl	13	17	|I-PARTIUPAC
and	18	21	|O
aralkyl	22	29	|B-PARTIUPAC
)	29	30	|I-PARTIUPAC
amino	30	35	|I-PARTIUPAC
]	35	36	|I-PARTIUPAC
methyl	36	42	|I-PARTIUPAC
]	42	43	|I-PARTIUPAC
-	43	44	|I-PARTIUPAC
2,4	44	47	|I-PARTIUPAC
-	47	48	|I-PARTIUPAC
pteridinediamines	48	65	|I-PARTIUPAC
and	66	69	|O
their	70	75	|O
8	76	77	|B-IUPAC
-	77	78	|I-IUPAC
oxides	78	84	|I-IUPAC
have	85	89	|O
been	90	94	|O
synthesized	95	106	|O
for	107	110	|O
antimalarial	111	123	|O
evaluation	124	134	|O
.	134	135	|O
Condensation	136	148	|O
of	149	151	|O
3	152	153	|B-IUPAC
-	153	154	|I-IUPAC
amino	154	159	|I-IUPAC
-	159	160	|I-IUPAC
6	160	161	|I-IUPAC
-	161	162	|I-IUPAC
(	162	163	|I-IUPAC
bromomethyl	163	174	|I-IUPAC
)	174	175	|I-IUPAC
-	175	176	|I-IUPAC
2	176	177	|I-IUPAC
-	177	178	|I-IUPAC
pyrazinecarbonitrile	178	198	|I-IUPAC
4	199	200	|I-IUPAC
-	200	201	|I-IUPAC
oxide	201	206	|I-IUPAC
(	207	208	|O
V	208	209	|O
)	209	210	|O
with	211	215	|O
the	216	219	|O
appropriately	220	233	|O
substituted	234	245	|O
amine	246	251	|O
afforded	252	260	|O
a	261	262	|O
series	263	269	|O
of	270	272	|O
3	273	274	|B-PARTIUPAC
-	274	275	|I-PARTIUPAC
amino	275	280	|I-PARTIUPAC
-	280	281	|I-PARTIUPAC
6	281	282	|I-PARTIUPAC
-	282	283	|I-PARTIUPAC
[	283	284	|I-PARTIUPAC
[	284	285	|I-PARTIUPAC
(	285	286	|I-PARTIUPAC
aryl	286	290	|I-PARTIUPAC
and	291	294	|O
aralkyl	295	302	|B-PARTIUPAC
)	302	303	|I-PARTIUPAC
amino	303	308	|I-PARTIUPAC
]	308	309	|I-PARTIUPAC
methyl	309	315	|I-PARTIUPAC
]	315	316	|I-PARTIUPAC
-	316	317	|I-PARTIUPAC
2	317	318	|I-PARTIUPAC
-	318	319	|I-PARTIUPAC
pyrazinecarbonitrile	319	339	|I-PARTIUPAC
4	340	341	|I-PARTIUPAC
-	341	342	|I-PARTIUPAC
oxides	342	348	|I-PARTIUPAC
VI	349	351	|O
.	351	352	|O
Deoxygenation	353	366	|O
gave	367	371	|O
the	372	375	|O
corresponding	376	389	|O
pyrazines	390	399	|O
VII	400	403	|O
.	403	404	|O
Cyclization	405	416	|O
of	417	419	|O
VI	420	422	|O
and	423	426	|O
VII	427	430	|O
with	431	435	|O
guanidine	436	445	|O
then	446	450	|O
produced	451	459	|O
the	460	463	|O
desired	464	471	|O
6	472	473	|B-IUPAC
-	473	474	|I-IUPAC
(	474	475	|I-IUPAC
aminomethyl	475	486	|I-IUPAC
)	486	487	|I-IUPAC
-	487	488	|I-IUPAC
2,4	488	491	|I-IUPAC
-	491	492	|I-IUPAC
pteridinediamine	492	508	|I-IUPAC
N	509	510	|I-IUPAC
-	510	511	|I-IUPAC
oxides	511	517	|I-IUPAC
VIII	518	522	|O
and	523	526	|O
teridinediamines	527	543	|O
IX	544	546	|O
,	546	547	|O
respectively	548	560	|O
.	560	561	|O
Formylation	562	573	|O
of	574	576	|O
6	577	578	|B-IUPAC
-	578	579	|I-IUPAC
[	579	580	|I-IUPAC
[	580	581	|I-IUPAC
(	581	582	|I-IUPAC
3,4	582	585	|I-IUPAC
-	585	586	|I-IUPAC
dichlorophenyl	586	600	|I-IUPAC
)	600	601	|I-IUPAC
amino	601	606	|I-IUPAC
]	606	607	|I-IUPAC
methyl	607	613	|I-IUPAC
]	613	614	|I-IUPAC
-	614	615	|I-IUPAC
2,4	615	618	|I-IUPAC
-	618	619	|I-IUPAC
pteridinediamine	619	635	|I-IUPAC
gave	636	640	|O
N	641	642	|B-IUPAC
-	642	643	|I-IUPAC
[	643	644	|I-IUPAC
(	644	645	|I-IUPAC
2,4	645	648	|I-IUPAC
-	648	649	|I-IUPAC
diamino	649	656	|I-IUPAC
-	656	657	|I-IUPAC
6	657	658	|I-IUPAC
-	658	659	|I-IUPAC
pteridinyl	659	669	|I-IUPAC
)	669	670	|I-IUPAC
-	670	671	|I-IUPAC
methyl	671	677	|I-IUPAC
]	677	678	|I-IUPAC
-	678	679	|I-IUPAC
N	679	680	|I-IUPAC
-	680	681	|I-IUPAC
(	681	682	|I-IUPAC
3,4	682	685	|I-IUPAC
-	685	686	|I-IUPAC
dichlorophenyl	686	700	|I-IUPAC
)	700	701	|I-IUPAC
formamide	701	710	|I-IUPAC
.	710	711	|O
The	712	715	|O
N	716	717	|B-IUPAC
-	717	718	|I-IUPAC
oxides	718	724	|I-IUPAC
VIII	725	729	|O
did	730	733	|O
not	734	737	|O
exhibit	738	745	|O
significant	746	757	|O
activity	758	766	|O
against	767	774	|O
Plasmodium	775	785	|O
berghei	786	793	|O
infections	794	804	|O
in	805	807	|O
mice	808	812	|O
.	812	813	|O
Activity	814	822	|O
among	823	828	|O
the	829	832	|O
2,4	833	836	|B-IUPAC
-	836	837	|I-IUPAC
pteridinediamines	837	854	|I-IUPAC
IX	855	857	|O
was	858	861	|O
generally	862	871	|O
poor	872	876	|O
with	877	881	|O
the	882	885	|O
exception	886	895	|O
of	896	898	|O
the	899	902	|O
3,4,5	903	908	|B-IUPAC
-	908	909	|I-IUPAC
trimethoxyphenyl	909	925	|I-IUPAC
and	926	929	|O
1	930	931	|B-IUPAC
-	931	932	|I-IUPAC
naphthalenyl	932	944	|I-IUPAC
analogues	945	954	|B-MODIFIER
which	955	960	|O
showed	961	967	|O
strong	968	974	|O
suppressive	975	986	|O
activity	987	995	|O
at	996	998	|O
doses	999	1004	|O
ranging	1005	1012	|O
from	1013	1017	|O
80	1018	1020	|O
to	1021	1023	|O
640	1024	1027	|O
mg	1028	1030	|O
/	1030	1031	|O
kg	1031	1033	|O
.	1033	1034	|O
Furthermore	1035	1046	|O
,	1046	1047	|O
several	1048	1055	|O
of	1056	1058	|O
the	1059	1062	|O
2,4	1063	1066	|B-IUPAC
-	1066	1067	|I-IUPAC
pteridinediamines	1067	1084	|I-IUPAC
exhibited	1085	1094	|O
potent	1095	1101	|O
prophylactic	1102	1114	|O
activity	1115	1123	|O
against	1124	1131	|O
Plasmodium	1132	1142	|O
gallinaceum	1143	1154	|O
infections	1155	1165	|O
in	1166	1168	|O
the	1169	1172	|O
chick	1173	1178	|O
and	1179	1182	|O
also	1183	1187	|O
showed	1188	1194	|O
strong	1195	1201	|O
antibacterial	1202	1215	|O
action	1216	1222	|O
against	1223	1230	|O
Streptococcus	1231	1244	|O
faecalis	1245	1253	|O
and	1254	1257	|O
Staphylococcus	1258	1272	|O
aureus	1273	1279	|O
.	1279	1280	|O

### abstracts2362.txt
The	0	3	|O
aim	4	7	|O
of	8	10	|O
this	11	15	|O
work	16	20	|O
was	21	24	|O
to	25	27	|O
improve	28	35	|O
the	36	39	|O
oral	40	44	|O
bioavailability	45	60	|O
of	61	63	|O
a	64	65	|O
recently	66	74	|O
discovered	75	85	|O
,	85	86	|O
novel	87	92	|O
structural	93	103	|O
class	104	109	|O
of	110	112	|O
5	113	114	|O
-	114	115	|O
HT1A	115	119	|O
receptor	120	128	|O
agonists	129	137	|O
:	137	138	|O
aryl	139	143	|B-IUPAC
-	143	144	|I-IUPAC
{	144	145	|I-IUPAC
[	145	146	|I-IUPAC
4	146	147	|I-IUPAC
-	147	148	|I-IUPAC
(	148	149	|I-IUPAC
6	149	150	|I-IUPAC
-	150	151	|I-IUPAC
R	151	152	|I-IUPAC
-	152	153	|I-IUPAC
pyridin	153	160	|I-IUPAC
-	160	161	|I-IUPAC
2	161	162	|I-IUPAC
-	162	163	|I-IUPAC
ylmethyl	163	171	|I-IUPAC
)	171	172	|I-IUPAC
-	172	173	|I-IUPAC
amino	173	178	|I-IUPAC
]	178	179	|I-IUPAC
-	179	180	|I-IUPAC
methyl	180	186	|I-IUPAC
}	186	187	|I-IUPAC
-	187	188	|I-IUPAC
piperidin	188	197	|I-IUPAC
-	197	198	|I-IUPAC
1	198	199	|I-IUPAC
-	200	201	|I-IUPAC
yl	201	203	|I-IUPAC
-	203	204	|I-IUPAC
metha	204	209	|I-IUPAC
none	210	214	|I-IUPAC
.	214	215	|O
Incorporation	216	229	|O
of	230	232	|O
a	233	234	|O
fluorine	235	243	|O
atom	244	248	|O
in	249	251	|O
the	252	255	|O
beta	256	260	|O
-	260	261	|O
position	261	269	|O
to	270	272	|O
the	273	276	|O
amino	277	282	|O
function	283	291	|O
in	292	294	|O
the	295	298	|O
side	299	303	|O
chain	304	309	|O
led	310	313	|O
to	314	316	|O
analogues	317	326	|O
that	327	331	|O
exhibited	332	341	|O
,	341	342	|O
in	343	345	|O
general	346	353	|O
,	353	354	|O
enhanced	355	363	|O
and	364	367	|O
long	368	372	|O
-	372	373	|O
lasting	373	380	|O
5	381	382	|O
-	382	383	|O
HT1A	383	387	|O
agonist	388	395	|O
activity	396	404	|O
in	405	407	|O
rats	408	412	|O
after	413	418	|O
oral	419	423	|O
administration	424	438	|O
.	438	439	|O
Location	440	448	|O
of	449	451	|O
the	452	455	|O
fluorine	456	464	|O
atom	465	469	|O
at	470	472	|O
the	473	476	|O
C	477	478	|O
-	478	479	|O
4	479	480	|O
position	481	489	|O
of	490	492	|O
the	493	496	|O
piperidine	497	507	|O
ring	508	512	|O
was	513	516	|O
the	517	520	|O
most	521	525	|O
favorable	526	535	|O
,	535	536	|O
and	537	540	|O
among	541	546	|O
the	547	550	|O
various	551	558	|O
substituents	559	571	|O
tested	572	578	|O
,	578	579	|O
the	580	583	|O
ability	584	591	|O
of	592	594	|O
the	595	598	|O
fluorine	599	607	|O
was	608	611	|O
unique	612	618	|O
in	619	621	|O
improving	622	631	|O
the	632	635	|O
oral	636	640	|O
activity	641	649	|O
of	650	652	|O
this	653	657	|O
family	658	664	|O
of	665	667	|O
ligands	668	675	|O
.	675	676	|O
Thus	677	681	|O
,	681	682	|O
the	683	686	|O
derivatives	687	698	|O
39	699	701	|O
,	701	702	|O
46	703	705	|O
,	705	706	|O
and	707	710	|O
61	711	713	|O
bound	714	719	|O
with	720	724	|O
higher	725	731	|O
affinity	732	740	|O
and	741	744	|O
selectivity	745	756	|O
to	757	759	|O
5	760	761	|O
-	761	762	|O
HT1A	762	766	|O
receptors	767	776	|O
(	777	778	|O
versus	778	784	|O
dopaminergic	785	797	|O
D2	798	800	|O
and	801	804	|O
adrenergic	805	815	|O
alpha1	816	822	|O
receptors	823	832	|O
)	832	833	|O
and	834	837	|O
displayed	838	847	|O
more	848	852	|O
potent	853	859	|O
5	860	861	|O
-	861	862	|O
HT1A	862	866	|O
agonist	867	874	|O
activity	875	883	|O
in	884	886	|O
vitro	887	892	|O
and	893	896	|O
in	897	899	|O
vivo	900	904	|O
than	905	909	|O
their	910	915	|O
C	916	917	|O
-	917	918	|O
4	918	919	|O
desfluoro	920	929	|O
analogues	930	939	|O
.	939	940	|O
To	941	943	|O
examine	944	951	|O
the	952	955	|O
relationship	956	968	|O
between	969	976	|O
the	977	980	|O
conformation	981	993	|O
of	994	996	|O
the	997	1000	|O
pharmacophore	1001	1014	|O
and	1015	1018	|O
the	1019	1022	|O
level	1023	1028	|O
of	1029	1031	|O
agonistic	1032	1041	|O
activity	1042	1050	|O
of	1051	1053	|O
this	1054	1058	|O
type	1059	1063	|O
of	1064	1066	|O
ligand	1067	1073	|O
,	1073	1074	|O
we	1075	1077	|O
synthesized	1078	1089	|O
a	1090	1091	|O
series	1092	1098	|O
of	1099	1101	|O
3	1102	1103	|B-IUPAC
-	1103	1104	|I-IUPAC
chloro	1104	1110	|I-IUPAC
-	1110	1111	|I-IUPAC
4	1111	1112	|I-IUPAC
-	1112	1113	|I-IUPAC
fluorophenyl	1113	1125	|I-IUPAC
-	1125	1126	|I-IUPAC
(	1126	1127	|I-IUPAC
4	1127	1128	|I-IUPAC
-	1128	1129	|I-IUPAC
fluoro	1129	1135	|I-IUPAC
-	1135	1136	|I-IUPAC
4	1136	1137	|I-IUPAC
{	1137	1138	|I-IUPAC
[	1138	1139	|I-IUPAC
(	1139	1140	|I-IUPAC
5	1140	1141	|I-IUPAC
-	1141	1142	|I-IUPAC
(	1142	1143	|I-IUPAC
H	1143	1144	|I-IUPAC
or	1145	1147	|I-IUPAC
CH3	1148	1151	|I-IUPAC
)	1151	1152	|I-IUPAC
-	1152	1153	|I-IUPAC
6	1153	1154	|I-IUPAC
-	1154	1155	|I-IUPAC
R	1155	1156	|I-IUPAC
-	1156	1157	|I-IUPAC
pyridin	1157	1164	|I-IUPAC
-	1164	1165	|I-IUPAC
2	1165	1166	|I-IUPAC
-	1166	1167	|I-IUPAC
ylmethyl	1167	1175	|I-IUPAC
)	1175	1176	|I-IUPAC
-	1176	1177	|I-IUPAC
amino	1177	1182	|I-IUPAC
]	1182	1183	|I-IUPAC
-	1183	1184	|I-IUPAC
methyl	1184	1190	|I-IUPAC
}	1190	1191	|I-IUPAC
-	1191	1192	|I-IUPAC
piperidin	1192	1201	|I-IUPAC
-	1201	1202	|I-IUPAC
1	1202	1203	|I-IUPAC
-	1203	1204	|I-IUPAC
yl	1204	1206	|I-IUPAC
-	1206	1207	|I-IUPAC
+	1207	1208	|I-IUPAC
+	1209	1210	|I-IUPAC
+	1210	1211	|I-IUPAC
methanone	1211	1220	|I-IUPAC
derivatives	1221	1232	|B-MODIFIER
and	1233	1236	|O
found	1237	1242	|O
that	1243	1247	|O
the	1248	1251	|O
combination	1252	1263	|O
of	1264	1266	|O
a	1267	1268	|O
5	1269	1270	|B-IUPAC
-	1270	1271	|I-IUPAC
methyl	1271	1277	|I-IUPAC
and	1278	1281	|O
a	1282	1283	|O
6	1284	1285	|B-IUPAC
-	1285	1286	|I-IUPAC
methylamino	1286	1297	|I-IUPAC
substituent	1298	1309	|B-MODIFIER
on	1310	1312	|O
the	1313	1316	|O
pyridine	1317	1325	|O
ring	1326	1330	|O
synergistically	1331	1346	|O
affected	1347	1355	|O
their	1356	1361	|O
5	1362	1363	|O
-	1363	1364	|O
HT1A	1364	1368	|O
agonist	1369	1376	|O
properties	1377	1387	|O
.	1387	1388	|O
Thus	1389	1393	|O
,	1393	1394	|O
the	1395	1398	|O
3	1399	1400	|B-IUPAC
-	1400	1401	|I-IUPAC
chloro	1401	1407	|I-IUPAC
-	1407	1408	|I-IUPAC
4	1408	1409	|I-IUPAC
-	1409	1410	|I-IUPAC
fluorophenyl	1410	1422	|I-IUPAC
-	1422	1423	|I-IUPAC
(	1423	1424	|I-IUPAC
4	1424	1425	|I-IUPAC
-	1425	1426	|I-IUPAC
fluoro	1426	1432	|I-IUPAC
-	1432	1433	|I-IUPAC
4	1433	1434	|I-IUPAC
{	1434	1435	|I-IUPAC
[	1435	1436	|I-IUPAC
(	1436	1437	|I-IUPAC
5	1437	1438	|I-IUPAC
-	1438	1439	|I-IUPAC
methyl	1439	1445	|I-IUPAC
-	1445	1446	|I-IUPAC
6	1446	1447	|I-IUPAC
-	1447	1448	|I-IUPAC
methylamino	1448	1459	|I-IUPAC
-	1459	1460	|I-IUPAC
pyridin	1460	1467	|I-IUPAC
-	1467	1468	|I-IUPAC
2	1469	1470	|I-IUPAC
-	1470	1471	|I-IUPAC
ylmethyl	1471	1479	|I-IUPAC
)	1479	1480	|I-IUPAC
-	1480	1481	|I-IUPAC
amino	1481	1486	|I-IUPAC
]	1486	1487	|I-IUPAC
-	1487	1488	|I-IUPAC
methyl	1488	1494	|I-IUPAC
}	1494	1495	|I-IUPAC
-	1495	1496	|I-IUPAC
piperidin	1496	1505	|I-IUPAC
-	1505	1506	|I-IUPAC
1	1506	1507	|I-IUPAC
-	1507	1508	|I-IUPAC
yl	1508	1510	|I-IUPAC
-	1510	1511	|I-IUPAC
methanone	1511	1520	|I-IUPAC
40	1521	1523	|O
behaved	1524	1531	|O
as	1532	1534	|O
a	1535	1536	|O
more	1537	1541	|O
potent	1542	1548	|O
5	1549	1550	|O
-	1550	1551	|O
HT1A	1551	1555	|O
receptor	1556	1564	|O
agonist	1565	1572	|O
in	1573	1575	|O
vitro	1576	1581	|O
and	1582	1585	|O
in	1586	1588	|O
vivo	1589	1593	|O
than	1594	1598	|O
its	1599	1602	|O
5	1603	1604	|O
-	1604	1605	|O
unsubstituted	1605	1618	|O
analogue	1619	1627	|O
38	1628	1630	|O
.	1630	1631	|O
The	1632	1635	|O
antidepressant	1636	1650	|O
potential	1651	1660	|O
of	1661	1663	|O
the	1664	1667	|O
lead	1668	1672	|O
compounds	1673	1682	|O
40	1683	1685	|O
,	1685	1686	|O
45	1687	1689	|O
,	1689	1690	|O
and	1691	1694	|O
54	1695	1697	|O
was	1698	1701	|O
examined	1702	1710	|O
by	1711	1713	|O
means	1714	1719	|O
of	1720	1722	|O
the	1723	1726	|O
forced	1727	1733	|O
swimming	1734	1742	|O
test	1743	1747	|O
(	1748	1749	|O
FST	1749	1752	|O
)	1752	1753	|O
in	1754	1756	|O
rats	1757	1761	|O
.	1761	1762	|O
The	1763	1766	|O
results	1767	1774	|O
indicated	1775	1784	|O
that	1785	1789	|O
,	1789	1790	|O
after	1791	1796	|O
a	1797	1798	|O
single	1799	1805	|O
oral	1806	1810	|O
administration	1811	1825	|O
,	1825	1826	|O
these	1827	1832	|O
compounds	1833	1842	|O
inhibited	1843	1852	|O
immobility	1853	1863	|O
in	1864	1866	|O
the	1867	1870	|O
FST	1871	1874	|O
more	1875	1879	|O
potently	1880	1888	|O
and	1889	1892	|O
more	1893	1897	|O
extensively	1898	1909	|O
than	1910	1914	|O
the	1915	1918	|O
clinically	1919	1929	|O
used	1930	1934	|O
antidepressant	1935	1949	|O
imipramine	1950	1960	|O
.	1960	1961	|O
Thus	1962	1966	|O
,	1966	1967	|O
40	1968	1970	|O
,	1970	1971	|O
45	1972	1974	|O
,	1974	1975	|O
and	1976	1979	|O
54	1980	1982	|O
are	1983	1986	|O
potent	1987	1993	|O
,	1993	1994	|O
orally	1995	2001	|O
active	2002	2008	|O
5	2009	2010	|O
-	2010	2011	|O
HT1A	2011	2015	|O
receptor	2016	2024	|O
agonists	2025	2033	|O
with	2034	2038	|O
marked	2039	2045	|O
antidepressant	2046	2060	|O
potential	2061	2070	|O
.	2070	2071	|O

### abstracts3130.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
4	12	13	|B-MODIFIER
-	13	14	|I-MODIFIER
substituted	14	25	|I-MODIFIER
2	26	27	|B-IUPAC
-	27	28	|I-IUPAC
formylpyridine	28	42	|I-IUPAC
thiosemicarbazones	43	61	|I-IUPAC
has	62	65	|O
been	66	70	|O
synthesized	71	82	|O
which	83	88	|O
contain	89	96	|O
a	97	98	|O
tertiary	99	107	|O
N	108	109	|O
at	110	112	|O
the	113	116	|O
4	117	118	|O
position	119	127	|O
.	127	128	|O
These	129	134	|O
materials	135	144	|O
were	145	149	|O
obtained	150	158	|O
by	159	161	|O
reacting	162	170	|O
4	171	172	|B-IUPAC
-	172	173	|I-IUPAC
nitro	173	178	|I-IUPAC
-	178	179	|I-IUPAC
2	179	180	|I-IUPAC
-	180	181	|I-IUPAC
picoline	181	189	|I-IUPAC
N	190	191	|I-IUPAC
-	191	192	|I-IUPAC
oxide	192	197	|I-IUPAC
,	197	198	|O
either	199	205	|O
directly	206	214	|O
or	215	217	|O
after	218	223	|O
conversion	224	234	|O
to	235	237	|O
the	238	241	|O
corresponding	242	255	|O
4	256	257	|B-IUPAC
-	257	258	|I-IUPAC
chloro	258	264	|I-IUPAC
derivative	265	275	|B-MODIFIER
,	275	276	|O
with	277	281	|O
a	282	283	|O
variety	284	291	|O
of	292	294	|O
secondary	295	304	|O
amines	305	311	|O
.	311	312	|O
Rearrangement	313	326	|O
of	327	329	|O
the	330	333	|O
4	334	335	|B-MODIFIER
-	335	336	|I-MODIFIER
substituted	336	347	|I-MODIFIER
2	348	349	|B-IUPAC
-	349	350	|I-IUPAC
picoline	350	358	|I-IUPAC
N	359	360	|I-IUPAC
-	360	361	|I-IUPAC
oxides	361	367	|I-IUPAC
with	368	372	|O
Ac2O	373	377	|O
yielded	378	385	|O
respective	386	396	|O
methyl	397	403	|O
acetates	404	412	|O
,	412	413	|O
which	414	419	|O
upon	420	424	|O
acid	425	429	|O
hydrolysis	430	440	|O
,	440	441	|O
MnO2	442	446	|O
oxidation	447	456	|O
,	456	457	|O
and	458	461	|O
reaction	462	470	|O
with	471	475	|O
thiosemicarbazide	476	493	|O
resulted	494	502	|O
in	503	505	|O
the	506	509	|O
desired	510	517	|O
compounds	518	527	|O
.	527	528	|O
An	529	531	|O
alternate	532	541	|O
procedure	542	551	|O
which	552	557	|O
consisted	558	567	|O
of	568	570	|O
reacting	571	579	|O
4	580	581	|B-IUPAC
-	581	582	|I-IUPAC
chloro	582	588	|I-IUPAC
-	588	589	|I-IUPAC
2	589	590	|I-IUPAC
-	590	591	|I-IUPAC
formylpyridine	591	605	|I-IUPAC
ethylene	606	614	|I-IUPAC
acetal	615	621	|I-IUPAC
with	622	626	|O
various	627	634	|O
amines	635	641	|O
,	641	642	|O
followed	643	651	|O
by	652	654	|O
hydrolysis	655	665	|O
and	666	669	|O
reaction	670	678	|O
with	679	683	|O
thiosemicarbazide	684	701	|O
,	701	702	|O
was	703	706	|O
also	707	711	|O
employed	712	720	|O
.	720	721	|O
Introduction	722	734	|O
of	735	737	|O
an	738	740	|O
alkyl	741	746	|O
group	747	752	|O
at	753	755	|O
the	756	759	|O
3	760	761	|O
position	762	770	|O
of	771	773	|O
the	774	777	|O
pyridine	778	786	|O
ring	787	791	|O
of	792	794	|O
4	795	796	|B-IUPAC
-	796	797	|I-IUPAC
morpholino	797	807	|I-IUPAC
-	807	808	|I-IUPAC
2	808	809	|I-IUPAC
-	809	810	|I-IUPAC
formylpyridine	810	824	|I-IUPAC
thiosemicarbazone	825	842	|I-IUPAC
was	843	846	|O
achieved	847	855	|O
by	856	858	|O
utilizing	859	868	|O
2,3	869	872	|B-IUPAC
-	872	873	|I-IUPAC
dimethyl	873	881	|I-IUPAC
-	881	882	|I-IUPAC
4	882	883	|I-IUPAC
-	883	884	|I-IUPAC
nitropyridine	884	897	|I-IUPAC
N	898	899	|I-IUPAC
-	899	900	|I-IUPAC
oxide	900	905	|I-IUPAC
;	905	906	|O
this	907	911	|O
material	912	920	|O
was	921	924	|O
converted	925	934	|O
to	935	937	|O
the	938	941	|O
corresponding	942	955	|O
4	956	957	|B-IUPAC
-	957	958	|I-IUPAC
chloro	958	964	|I-IUPAC
derivative	965	975	|B-MODIFIER
which	976	981	|O
was	982	985	|O
then	986	990	|O
subjected	991	1000	|O
to	1001	1003	|O
nucleophilic	1004	1016	|O
substitution	1017	1029	|O
.	1029	1030	|O
4	1031	1032	|B-IUPAC
-	1032	1033	|I-IUPAC
Morpholino	1033	1043	|I-IUPAC
-	1043	1044	|I-IUPAC
2	1044	1045	|I-IUPAC
-	1045	1046	|I-IUPAC
formylpyridine	1046	1060	|I-IUPAC
thiosemicarbazone	1061	1078	|I-IUPAC
was	1079	1082	|O
the	1083	1086	|O
most	1087	1091	|O
active	1092	1098	|O
antineoplastic	1099	1113	|O
agent	1114	1119	|O
of	1120	1122	|O
this	1123	1127	|O
series	1128	1134	|O
in	1135	1137	|O
mice	1138	1142	|O
bearing	1143	1150	|O
Sarcoma	1151	1158	|O
180	1159	1162	|O
ascites	1163	1170	|O
cells	1171	1176	|O
and	1177	1180	|O
was	1181	1184	|O
significantly	1185	1198	|O
superior	1200	1208	|O
to	1209	1211	|O
5	1212	1213	|B-IUPAC
-	1213	1214	|I-IUPAC
hydroxy	1214	1221	|I-IUPAC
-	1221	1222	|I-IUPAC
2	1222	1223	|I-IUPAC
-	1223	1224	|I-IUPAC
formylpyridine	1224	1238	|I-IUPAC
thiosemicarbazone	1239	1256	|I-IUPAC
in	1257	1259	|O
this	1260	1264	|O
test	1265	1269	|O
system	1270	1276	|O
.	1276	1277	|O

### abstracts4919.txt
Syntheses	0	9	|O
and	10	13	|O
biological	14	24	|O
activities	25	35	|O
of	36	38	|O
26	39	41	|O
N4	42	44	|B-MODIFIER
-	44	45	|I-MODIFIER
substituted	45	56	|I-MODIFIER
4	57	58	|B-IUPAC
-	58	59	|I-IUPAC
aminopyrazolo	59	72	|I-IUPAC
[	72	73	|I-IUPAC
3,4	73	76	|I-IUPAC
-	76	77	|I-IUPAC
d	77	78	|I-IUPAC
]	78	79	|I-IUPAC
pyrimidines	79	90	|I-IUPAC
as	91	93	|O
analogs	94	101	|O
of	102	104	|O
naturally	105	114	|O
occurring	115	124	|O
modified	125	133	|O
nucleic	134	141	|O
acid	142	146	|O
bases	147	152	|O
,	152	153	|O
N	154	155	|B-IUPAC
-	155	156	|I-IUPAC
(	156	157	|I-IUPAC
purin	157	162	|I-IUPAC
-	162	163	|I-IUPAC
6	163	164	|I-IUPAC
-	164	165	|I-IUPAC
ylcarbamoyl	165	176	|I-IUPAC
)	176	177	|I-IUPAC
-	177	178	|I-IUPAC
L	178	179	|I-IUPAC
-	179	180	|I-IUPAC
threonine	180	189	|I-IUPAC
and	190	193	|O
N6	194	196	|B-IUPAC
-	196	197	|I-IUPAC
(	197	198	|I-IUPAC
delta2	198	204	|I-IUPAC
-	204	205	|I-IUPAC
isopentenyl	205	216	|I-IUPAC
)	216	217	|I-IUPAC
adenine	217	224	|I-IUPAC
,	224	225	|O
are	226	229	|O
described	230	239	|O
.	239	240	|O
4	241	242	|B-IUPAC
-	242	243	|I-IUPAC
Aminopyrazolo	243	256	|I-IUPAC
[	256	257	|I-IUPAC
3,4	257	260	|I-IUPAC
-	260	261	|I-IUPAC
d	261	262	|I-IUPAC
]	262	263	|I-IUPAC
pyrimidine	263	273	|I-IUPAC
was	274	277	|O
converted	278	287	|O
into	288	292	|O
the	293	296	|O
desired	297	304	|O
intermediate	305	317	|O
,	317	318	|O
ethyl	319	324	|B-IUPAC
pyrazolo	325	333	|I-IUPAC
[	333	334	|I-IUPAC
3,4	334	337	|I-IUPAC
-	337	338	|I-IUPAC
d	338	339	|I-IUPAC
]	339	340	|I-IUPAC
pyrimidine	340	350	|I-IUPAC
-	350	351	|I-IUPAC
4	351	352	|I-IUPAC
-	352	353	|I-IUPAC
carbamate	353	362	|I-IUPAC
(	363	364	|O
2	364	365	|O
)	365	366	|O
.	366	367	|O
4	368	369	|B-IUPAC
-	369	370	|I-IUPAC
Ureidopyrazolo	370	384	|I-IUPAC
[	384	385	|I-IUPAC
3,4	385	388	|I-IUPAC
-	388	389	|I-IUPAC
d	389	390	|I-IUPAC
]	390	391	|I-IUPAC
pyrimidines	391	402	|I-IUPAC
(	403	404	|O
6-26	404	408	|O
)	408	409	|O
were	410	414	|O
prepared	415	423	|O
by	424	426	|O
displacement	427	439	|O
of	440	442	|O
the	443	446	|O
ethoxy	447	453	|O
group	454	459	|O
of	460	462	|O
the	463	466	|O
carbamate	467	476	|O
2	477	478	|O
by	479	481	|O
amino	482	487	|O
acids	488	493	|O
and	494	497	|O
a	498	499	|O
variety	500	507	|O
of	508	510	|O
amines	511	517	|O
and	518	521	|O
by	522	524	|O
a	525	526	|O
reaction	527	535	|O
of	536	538	|O
4	539	540	|B-IUPAC
-	540	541	|I-IUPAC
aminopyrazolo	541	554	|I-IUPAC
[	554	555	|I-IUPAC
3,4	555	558	|I-IUPAC
-	558	559	|I-IUPAC
d	559	560	|I-IUPAC
]	560	561	|I-IUPAC
pyrimidine	561	571	|I-IUPAC
(	572	573	|O
1	573	574	|O
)	574	575	|O
with	576	580	|O
isocyanates	581	592	|O
.	592	593	|O
N4	594	596	|B-IUPAC
-	596	597	|I-IUPAC
Alkylaminopyrazolo	597	615	|I-IUPAC
[	615	616	|I-IUPAC
3,4	616	619	|I-IUPAC
-	619	620	|I-IUPAC
d	620	621	|I-IUPAC
]	621	622	|I-IUPAC
pyrimidines	622	633	|I-IUPAC
were	634	638	|O
generally	639	648	|O
prepared	649	657	|O
by	658	660	|O
displacement	661	673	|O
of	674	676	|O
the	677	680	|O
chlorine	681	689	|O
from	690	694	|O
4	695	696	|B-IUPAC
-	696	697	|I-IUPAC
chloropyrazolo	697	711	|I-IUPAC
[	711	712	|I-IUPAC
3,4	712	715	|I-IUPAC
-	715	716	|I-IUPAC
d	716	717	|I-IUPAC
]	717	718	|I-IUPAC
pyrimidine	718	728	|I-IUPAC
with	729	733	|O
various	734	741	|O
amines	742	748	|O
.	748	749	|O
Several	750	757	|O
analogs	758	765	|O
exhibited	766	775	|O
moderate	776	784	|O
to	785	787	|O
very	788	792	|O
good	793	797	|O
growth	798	804	|O
inhibitory	805	815	|O
activities	816	826	|O
against	827	834	|O
cultured	835	843	|O
L1210	844	849	|O
leukemia	850	858	|O
and	859	862	|O
6410	863	867	|O
human	868	873	|O
leukemic	874	882	|O
myeloblasts	883	894	|O
.	894	895	|O

### abstracts1174.txt
In	0	2	|O
pursuit	3	10	|O
of	11	13	|O
radiolabeled	14	26	|O
monoclonal	27	37	|O
antibodies	38	48	|O
(	49	50	|O
mAbs	50	54	|O
)	54	55	|O
with	56	60	|O
rapid	61	66	|O
urinary	67	74	|O
excretion	75	84	|O
of	85	87	|O
radioactivity	88	101	|O
from	102	106	|O
nontarget	107	116	|O
tissues	117	124	|O
,	124	125	|O
radioiodinated	126	140	|O
mAbs	141	145	|O
releasing	146	155	|O
a	156	157	|O
m	158	159	|B-IUPAC
-	159	160	|I-IUPAC
iodohippuric	160	172	|I-IUPAC
acid	173	177	|I-IUPAC
from	178	182	|O
the	183	186	|O
mAbs	187	191	|O
in	192	194	|O
nontarget	195	204	|O
tissues	205	212	|O
were	213	217	|O
designed	218	226	|O
.	226	227	|O
A	228	229	|O
novel	230	235	|O
reagent	236	243	|O
,	243	244	|O
maleimidoethyl	245	259	|B-IUPAC
3	260	261	|I-IUPAC
-	261	262	|I-IUPAC
(	262	263	|I-IUPAC
tri	263	266	|I-IUPAC
-	266	267	|I-IUPAC
n	267	268	|I-IUPAC
-	268	269	|I-IUPAC
butylstannyl	269	281	|I-IUPAC
)	281	282	|I-IUPAC
hippurate	282	291	|I-IUPAC
(	292	293	|O
MIH	293	296	|O
)	296	297	|O
,	297	298	|O
was	299	302	|O
synthesized	303	314	|O
by	315	317	|O
reacting	318	326	|O
N	327	328	|B-IUPAC
-	328	329	|I-IUPAC
(	329	330	|I-IUPAC
hydroxyethyl	330	342	|I-IUPAC
)	342	343	|I-IUPAC
maleimide	343	352	|I-IUPAC
with	353	357	|O
N	358	359	|B-IUPAC
-	359	360	|I-IUPAC
Boc	360	363	|I-IUPAC
-	363	364	|I-IUPAC
glycine	364	371	|I-IUPAC
before	372	378	|O
coupling	379	387	|O
with	388	392	|O
N	393	394	|B-IUPAC
-	394	395	|I-IUPAC
succinimidyl	395	407	|I-IUPAC
3	408	409	|I-IUPAC
-	409	410	|I-IUPAC
(	410	411	|I-IUPAC
tri	411	414	|I-IUPAC
-	414	415	|I-IUPAC
n	415	416	|I-IUPAC
-	416	417	|I-IUPAC
butylstannyl	417	429	|I-IUPAC
)	429	430	|I-IUPAC
benzoate	430	438	|I-IUPAC
(	439	440	|O
ATE	440	443	|O
)	443	444	|O
.	444	445	|O
MIH	446	449	|O
possessed	450	459	|O
a	460	461	|O
maleimide	462	471	|O
group	472	477	|O
for	478	481	|O
mAb	482	485	|O
conjugation	486	497	|O
and	498	501	|O
a	502	503	|O
butylstannyl	504	516	|O
moiety	517	523	|O
for	524	527	|O
high	528	532	|O
-	532	533	|O
yield	533	538	|O
and	539	542	|O
site	543	547	|O
-	547	548	|O
specific	548	556	|O
radioiodination	557	572	|O
,	572	573	|O
and	574	577	|O
the	578	581	|O
two	582	585	|O
functional	586	596	|O
groups	597	603	|O
were	604	608	|O
linked	609	615	|O
via	616	619	|O
an	620	622	|O
ester	623	628	|O
bond	629	633	|O
to	634	636	|O
release	637	644	|O
m	645	646	|B-IUPAC
-	646	647	|I-IUPAC
iodohippuric	647	659	|I-IUPAC
acid	660	664	|I-IUPAC
.	664	665	|O
To	666	668	|O
investigate	669	680	|O
the	681	684	|O
fate	685	689	|O
of	690	692	|O
radiolabels	693	704	|O
after	705	710	|O
lysosomal	711	720	|O
proteolysis	721	732	|O
,	732	733	|O
hepatic	734	741	|O
parenchymal	742	753	|O
cells	754	759	|O
were	760	764	|O
used	765	769	|O
as	770	772	|O
a	773	774	|O
model	775	780	|O
nontarget	781	790	|O
tissue	791	797	|O
and	798	801	|O
131I	802	806	|O
-	806	807	|O
labeled	807	814	|O
MIH	815	818	|O
was	819	822	|O
conjugated	823	833	|O
with	834	838	|O
galactosyl	839	849	|O
-	849	850	|O
neoglycoalbumin	850	865	|O
(	866	867	|O
NGA	867	870	|O
)	870	871	|O
.	871	872	|O
Further	873	880	|O
conjugation	881	892	|O
of	893	895	|O
[	896	897	|O
131I	897	901	|O
]	901	902	|O
MIH	902	905	|O
with	906	910	|O
a	911	912	|O
mAb	913	916	|O
against	917	924	|O
osteogenic	925	935	|O
sarcoma	936	943	|O
(	944	945	|O
OST7	945	949	|O
)	949	950	|O
after	951	956	|O
reduction	957	966	|O
of	967	969	|O
its	970	973	|O
disulfide	974	983	|O
bonds	984	989	|O
was	990	993	|O
followed	994	1002	|O
up	1003	1005	|O
.	1005	1006	|O
In	1007	1009	|O
murine	1010	1016	|O
biodistribution	1017	1032	|O
studies	1033	1040	|O
,	1040	1041	|O
[	1042	1043	|O
131I	1043	1047	|O
]	1047	1048	|O
MIH	1048	1051	|O
-	1051	1052	|O
NGA	1052	1055	|O
exhibited	1056	1065	|O
rapid	1066	1071	|O
accumulation	1072	1084	|O
in	1085	1087	|O
the	1088	1091	|O
liver	1092	1097	|O
followed	1098	1106	|O
by	1107	1109	|O
radioactivity	1110	1123	|O
elimination	1124	1135	|O
from	1136	1140	|O
the	1141	1144	|O
liver	1145	1150	|O
at	1151	1153	|O
a	1154	1155	|O
rate	1156	1160	|O
that	1161	1165	|O
was	1166	1169	|O
identical	1170	1179	|O
to	1180	1182	|O
and	1183	1186	|O
faster	1187	1193	|O
than	1194	1198	|O
those	1199	1204	|O
of	1205	1207	|O
131I	1208	1212	|O
-	1212	1213	|O
labeled	1213	1220	|O
NGA	1221	1224	|O
via	1225	1228	|O
direct	1229	1235	|O
iodination	1236	1246	|O
(	1247	1248	|O
[	1248	1249	|O
131I	1249	1253	|O
]	1253	1254	|O
NGA	1254	1257	|O
)	1257	1258	|O
and	1259	1262	|O
[	1263	1264	|O
131I	1264	1268	|O
]	1268	1269	|O
ATE	1269	1272	|O
-	1272	1273	|O
labeled	1273	1280	|O
NGA	1281	1284	|O
,	1284	1285	|O
respectively	1286	1298	|O
.	1298	1299	|O
While	1300	1305	|O
[	1306	1307	|O
131I	1307	1311	|O
]	1311	1312	|O
NGA	1312	1315	|O
indicated	1316	1325	|O
high	1326	1330	|O
radioactivity	1331	1344	|O
levels	1345	1351	|O
in	1352	1354	|O
the	1355	1358	|O
murine	1359	1365	|O
neck	1366	1370	|O
,	1370	1371	|O
stomach	1372	1379	|O
,	1379	1380	|O
and	1381	1384	|O
blood	1385	1390	|O
,	1390	1391	|O
such	1392	1396	|O
increases	1397	1406	|O
in	1407	1409	|O
the	1410	1413	|O
radioactivity	1414	1427	|O
count	1428	1433	|O
were	1434	1438	|O
not	1439	1442	|O
detectable	1443	1453	|O
by	1454	1456	|O
the	1457	1460	|O
administration	1461	1475	|O
of	1476	1478	|O
either	1479	1485	|O
[	1486	1487	|O
131I	1487	1491	|O
]	1491	1492	|O
MIH	1492	1495	|O
-	1495	1496	|O
NGA	1496	1499	|O
or	1500	1502	|O
[	1503	1504	|O
131I	1504	1508	|O
]	1508	1509	|O
ATE	1509	1512	|O
-	1512	1513	|O
NGA	1513	1516	|O
.	1516	1517	|O
At	1518	1520	|O
6	1521	1522	|O
h	1523	1524	|O
postinjection	1525	1538	|O
of	1539	1541	|O
[	1542	1543	|O
131I	1543	1547	|O
]	1547	1548	|O
MIH	1548	1551	|O
-	1551	1552	|O
NGA	1552	1555	|O
,	1555	1556	|O
80%	1557	1560	|O
of	1561	1563	|O
the	1564	1567	|O
injected	1568	1576	|O
radioactivity	1577	1590	|O
was	1591	1594	|O
recovered	1595	1604	|O
in	1605	1607	|O
the	1608	1611	|O
urine	1612	1617	|O
.	1617	1618	|O
Analyses	1619	1627	|O
of	1628	1630	|O
urine	1631	1636	|O
samples	1637	1644	|O
indicated	1645	1654	|O
that	1655	1659	|O
m	1660	1661	|O
-	1661	1662	|O
iodohippuric	1662	1674	|O
acid	1675	1679	|O
was	1680	1683	|O
the	1684	1687	|O
sole	1688	1692	|O
radiolabeled	1693	1705	|O
metabolite	1706	1716	|O
.	1716	1717	|O
In	1718	1720	|O
biodistribution	1721	1736	|O
studies	1737	1744	|O
using	1745	1750	|O
[	1751	1752	|O
131I	1752	1756	|O
]	1756	1757	|O
-	1757	1758	|O
MIH	1758	1761	|O
-	1761	1762	|O
OST7	1762	1766	|O
and	1767	1770	|O
[	1771	1772	|O
131I	1772	1776	|O
]	1776	1777	|O
ATE	1777	1780	|O
-	1780	1781	|O
OST7	1781	1785	|O
,	1785	1786	|O
while	1787	1792	|O
both	1793	1797	|O
131I	1798	1802	|O
-	1802	1803	|O
labeled	1803	1810	|O
OST7s	1811	1816	|O
registered	1817	1827	|O
almost	1828	1834	|O
identical	1835	1844	|O
radioactivity	1845	1858	|O
levels	1859	1865	|O
in	1866	1868	|O
the	1869	1872	|O
blood	1873	1878	|O
up	1879	1881	|O
to	1882	1884	|O
6	1885	1886	|O
h	1887	1888	|O
postinjection	1889	1902	|O
,	1902	1903	|O
the	1904	1907	|O
former	1908	1914	|O
demonstrated	1915	1927	|O
a	1928	1929	|O
lower	1930	1935	|O
radioactivity	1936	1949	|O
level	1950	1955	|O
than	1956	1960	|O
[	1961	1962	|O
131I	1962	1966	|O
]	1966	1967	|O
ATE	1967	1970	|O
-	1970	1971	|O
OST7	1971	1975	|O
in	1976	1978	|O
nontarget	1979	1988	|O
tissues	1989	1996	|O
throughout	1997	2007	|O
the	2008	2011	|O
experiment	2012	2022	|O
.	2022	2023	|O
Such	2024	2028	|O
chemical	2029	2037	|O
and	2038	2041	|O
biological	2042	2052	|O
characteristics	2053	2068	|O
of	2069	2071	|O
MIH	2072	2075	|O
would	2076	2081	|O
enable	2082	2088	|O
high	2089	2093	|O
target	2094	2100	|O
/	2100	2101	|O
nontarget	2101	2110	|O
ratios	2111	2117	|O
in	2118	2120	|O
diagnostic	2121	2131	|O
and	2132	2135	|O
therapeutic	2136	2147	|O
nuclear	2148	2155	|O
medicine	2156	2164	|O
using	2165	2170	|O
mAbs	2171	2175	|O
and	2176	2179	|O
other	2180	2185	|O
polypeptides	2186	2198	|O
.	2198	2199	|O

### abstracts101.txt
In	0	2	|O
order	3	8	|O
to	9	11	|O
assess	12	18	|O
steric	19	25	|O
,	25	26	|O
lipophilic	27	37	|O
,	37	38	|O
and	39	42	|O
electronic	43	53	|O
influences	54	64	|O
on	65	67	|O
opioid	68	74	|O
binding	75	82	|O
affinity	83	91	|O
,	91	92	|O
analogs	93	100	|O
of	101	103	|O
the	104	107	|O
delta	108	113	|O
receptor	114	122	|O
selective	123	132	|O
peptide	133	140	|O
deltorphin	141	151	|O
I	152	153	|O
(	154	155	|O
Tyr	155	158	|O
-	158	159	|O
D	159	160	|O
-	160	161	|O
Ala	161	164	|O
-	164	165	|O
Phe	165	168	|O
-	168	169	|O
Asp	169	172	|O
-	172	173	|O
Val	173	176	|O
-	176	177	|O
Val	177	180	|O
-	180	181	|O
GlyNH2	181	187	|O
)	187	188	|O
were	189	193	|O
prepared	194	202	|O
in	203	205	|O
which	206	211	|O
the	212	215	|O
residue	216	223	|O
3	224	225	|O
phenylalanine	226	239	|O
was	240	243	|O
replaced	244	252	|O
with	253	257	|O
lipophilic	258	268	|O
fluoro	269	275	|B-IUPAC
-	275	276	|O
and	277	280	|O
methyl	281	287	|B-IUPAC
-	287	288	|O
substituted	288	299	|B-MODIFIER
phenylalanines	300	314	|B-IUPAC
or	315	317	|O
with	318	322	|O
the	323	326	|O
heterocyclic	327	339	|O
aromatic	340	348	|O
amino	349	354	|O
acids	355	360	|O
3	361	362	|B-IUPAC
-	362	363	|I-IUPAC
(	363	364	|I-IUPAC
4	364	365	|I-IUPAC
-	365	366	|I-IUPAC
thiazolyl	366	375	|I-IUPAC
)	375	376	|I-IUPAC
alanine	376	383	|I-IUPAC
,	383	384	|O
3	385	386	|B-IUPAC
-	386	387	|I-IUPAC
(	387	388	|I-IUPAC
2	388	389	|I-IUPAC
-	389	390	|I-IUPAC
pyridyl	390	397	|I-IUPAC
)	397	398	|I-IUPAC
alanine	398	405	|I-IUPAC
,	405	406	|O
3	407	408	|B-IUPAC
-	408	409	|I-IUPAC
(	409	410	|I-IUPAC
3	410	411	|I-IUPAC
-	411	412	|I-IUPAC
pyridyl	412	419	|I-IUPAC
)	419	420	|I-IUPAC
alanine	420	427	|I-IUPAC
,	427	428	|O
histidine	429	438	|O
,	438	439	|O
and	440	443	|O
3	444	445	|B-IUPAC
-	445	446	|I-IUPAC
(	446	447	|I-IUPAC
4	447	448	|I-IUPAC
-	448	449	|I-IUPAC
thiazolyl	449	458	|I-IUPAC
)	458	459	|I-IUPAC
alanine	459	466	|I-IUPAC
.	466	467	|O
mu	468	470	|O
binding	471	478	|O
was	479	482	|O
variable	483	491	|O
,	491	492	|O
with	493	497	|O
KiS	498	501	|O
in	502	504	|O
excess	505	511	|O
of	512	514	|O
10,000	515	521	|O
nM	522	524	|O
for	525	528	|O
most	529	533	|O
analogs	534	541	|O
,	541	542	|O
and	543	546	|O
all	547	550	|O
of	551	553	|O
the	554	557	|O
analogs	558	565	|O
bound	566	571	|O
poorly	572	578	|O
to	579	581	|O
k	582	583	|O
receptors	584	593	|O
.	593	594	|O
Among	595	600	|O
the	601	604	|O
phenyl	605	611	|O
ring	612	616	|O
-	616	617	|O
substituted	617	628	|O
analogs	629	636	|O
,	636	637	|O
those	638	643	|O
containing	644	654	|O
the	655	658	|O
smaller	659	666	|O
and	667	670	|O
electron	671	679	|O
-	679	680	|O
withdrawing	680	691	|O
halogens	692	700	|O
were	701	705	|O
favored	706	713	|O
over	714	718	|O
those	719	724	|O
with	725	729	|O
larger	730	736	|O
,	736	737	|O
electron	738	746	|O
-	746	747	|O
releasing	747	756	|O
methyl	757	763	|O
groups	764	770	|O
,	770	771	|O
although	772	780	|O
delta	781	786	|O
opioid	787	793	|O
binding	794	801	|O
affinity	802	810	|O
was	811	814	|O
reduced	815	822	|O
in	823	825	|O
all	826	829	|O
cases	830	835	|O
.	835	836	|O
The	837	840	|O
m	841	842	|O
-	842	843	|O
fluorophenylalanine	843	862	|O
analog	863	869	|O
demonstrated	870	882	|O
the	883	886	|O
best	887	891	|O
delta	892	897	|O
binding	898	905	|O
of	906	908	|O
the	909	912	|O
group	913	918	|O
,	918	919	|O
with	920	924	|O
a	925	926	|O
Ki	927	929	|O
of	930	932	|O
4.79	933	937	|O
nM	938	940	|O
.	940	941	|O
Within	942	948	|O
the	949	952	|O
group	953	958	|O
of	959	961	|O
heterocyclic	962	974	|O
analogs	975	982	|O
,	982	983	|O
3	984	985	|B-IUPAC
-	985	986	|I-IUPAC
(	986	987	|I-IUPAC
2	987	988	|I-IUPAC
-	988	989	|I-IUPAC
thienyl	989	996	|I-IUPAC
)	996	997	|I-IUPAC
alanine	997	1004	|I-IUPAC
proved	1005	1011	|O
to	1012	1014	|O
be	1015	1017	|O
the	1018	1021	|O
best	1022	1026	|O
modification	1027	1039	|O
,	1039	1040	|O
displaying	1041	1051	|O
a	1052	1053	|O
delta	1054	1059	|O
receptor	1060	1068	|O
Ki	1069	1071	|O
of	1072	1074	|O
1.38	1075	1079	|O
nM	1080	1082	|O
,	1082	1083	|O
while	1084	1089	|O
the	1090	1093	|O
polar	1094	1099	|O
histidine	1100	1109	|O
analog	1110	1116	|O
suffered	1117	1125	|O
the	1126	1129	|O
greatest	1130	1138	|O
loss	1139	1143	|O
in	1144	1146	|O
delta	1147	1152	|O
binding	1153	1160	|O
(	1161	1162	|O
Ki	1162	1164	|O
=	1165	1166	|O
317	1167	1170	|O
)	1170	1171	|O
.	1171	1172	|O
Compounds	1173	1182	|O
containing	1183	1193	|O
pyridylalanine	1194	1208	|O
and	1209	1212	|O
thiazolylalanine	1213	1229	|O
were	1230	1234	|O
intermediate	1235	1247	|O
in	1248	1250	|O
binding	1251	1258	|O
affinity	1259	1267	|O
,	1267	1268	|O
with	1269	1273	|O
delta	1274	1279	|O
KiS	1280	1283	|O
ranging	1284	1291	|O
from	1292	1296	|O
39.5	1297	1301	|O
to	1302	1304	|O
62.4	1305	1309	|O
nM	1310	1312	|O
.	1312	1313	|O
The	1314	1317	|O
major	1318	1323	|O
factor	1324	1330	|O
influencing	1331	1342	|O
the	1343	1346	|O
opioid	1347	1353	|O
binding	1354	1361	|O
of	1362	1364	|O
the	1365	1368	|O
similar	1369	1376	|O
-	1376	1377	|O
sized	1377	1382	|O
heterocyclic	1383	1395	|O
compounds	1396	1405	|O
was	1406	1409	|O
relative	1410	1418	|O
lipophilicity	1419	1432	|O
,	1432	1433	|O
which	1434	1439	|O
outweighed	1440	1450	|O
electronic	1451	1461	|O
character	1462	1471	|O
.	1471	1472	|O

### abstracts4396.txt
Six	0	3	|O
new	4	7	|O
B	8	9	|O
-	9	10	|O
ring	10	14	|O
analogues	15	24	|O
of	25	27	|O
the	28	31	|O
nonpolyglutamatable	32	51	|O
antifolate	52	62	|O
Nalpha	63	69	|B-IUPAC
-	69	70	|I-IUPAC
(	70	71	|I-IUPAC
4	71	72	|I-IUPAC
-	72	73	|I-IUPAC
amino	73	78	|I-IUPAC
-	78	79	|I-IUPAC
4	79	80	|I-IUPAC
-	80	81	|I-IUPAC
deoxypteroyl	81	93	|I-IUPAC
)	93	94	|I-IUPAC
-	94	95	|I-IUPAC
Ndelta	95	101	|I-IUPAC
-	101	102	|I-IUPAC
hemiphthaloy	102	114	|I-IUPAC
l	115	116	|I-IUPAC
-	116	117	|I-IUPAC
L	117	118	|I-IUPAC
-	118	119	|I-IUPAC
ornithine	119	128	|I-IUPAC
(	129	130	|O
PT523	130	135	|O
,	135	136	|O
3	137	138	|O
)	138	139	|O
were	140	144	|O
synthesized	145	156	|O
with	157	161	|O
a	162	163	|O
view	164	168	|O
to	169	171	|O
determining	172	183	|O
the	184	187	|O
effect	188	194	|O
of	195	197	|O
modifications	198	211	|O
at	212	214	|O
the	215	218	|O
5	219	220	|O
-	220	221	|O
and	222	225	|O
/	225	226	|O
or	226	228	|O
8	229	230	|O
-	230	231	|O
position	231	239	|O
on	240	242	|O
dihydrofolate	243	256	|O
reductase	257	266	|O
(	267	268	|O
DHFR	268	272	|O
)	272	273	|O
binding	274	281	|O
and	282	285	|O
tumor	286	291	|O
cell	292	296	|O
growth	297	303	|O
inhibition	304	314	|O
.	314	315	|O
The	316	319	|O
5	320	321	|B-PARTIUPAC
-	321	322	|I-PARTIUPAC
and	323	326	|O
8	327	328	|B-IUPAC
-	328	329	|I-IUPAC
deaza	329	334	|I-IUPAC
analogues	335	344	|B-MODIFIER
were	345	349	|O
prepared	350	358	|O
from	359	363	|O
methyl	364	370	|B-IUPAC
2	371	372	|I-IUPAC
-	372	373	|I-IUPAC
L	373	374	|I-IUPAC
-	374	375	|I-IUPAC
amino	375	380	|I-IUPAC
-	380	381	|I-IUPAC
5	381	382	|I-IUPAC
-	382	383	|I-IUPAC
phthalimidopentanoate	383	404	|I-IUPAC
and	405	408	|O
4	409	410	|B-PARTIUPAC
-	410	411	|I-PARTIUPAC
amino	411	416	|I-PARTIUPAC
-	416	417	|I-PARTIUPAC
4	417	418	|I-PARTIUPAC
-	418	419	|I-PARTIUPAC
deoxy	419	424	|I-PARTIUPAC
-	424	425	|I-PARTIUPAC
N10	425	428	|I-PARTIUPAC
-	428	429	|I-PARTIUPAC
formyl	429	435	|I-PARTIUPAC
-	435	436	|I-PARTIUPAC
5	436	437	|I-PARTIUPAC
-	437	438	|I-PARTIUPAC
deaza	438	443	|I-PARTIUPAC
-	443	444	|I-PARTIUPAC
and	445	448	|O
-	449	450	|B-PARTIUPAC
8	450	451	|I-PARTIUPAC
-	451	452	|I-PARTIUPAC
deazapteroic	452	464	|I-PARTIUPAC
acid	465	469	|I-PARTIUPAC
,	469	470	|O
respectively	471	483	|O
.	483	484	|O
The	485	488	|O
5,8	489	492	|B-IUPAC
-	492	493	|I-IUPAC
dideaza	493	500	|I-IUPAC
analogues	501	510	|B-MODIFIER
were	511	515	|O
prepared	516	524	|O
from	525	529	|O
methyl	530	536	|B-IUPAC
2	537	538	|I-IUPAC
-	538	539	|I-IUPAC
L	539	540	|I-IUPAC
-	540	541	|I-IUPAC
[	541	542	|I-IUPAC
(	542	543	|I-IUPAC
4	543	544	|I-IUPAC
-	544	545	|I-IUPAC
aminobenzoyl	545	557	|I-IUPAC
)	557	558	|I-IUPAC
amino	558	563	|I-IUPAC
]	563	564	|I-IUPAC
-	564	565	|I-IUPAC
5	565	566	|I-IUPAC
-	566	567	|I-IUPAC
phthalimidopentanoate	567	588	|I-IUPAC
and	589	592	|O
2	593	594	|B-IUPAC
,	594	595	|I-IUPAC
4	596	597	|I-IUPAC
-	597	598	|I-IUPAC
diaminoquinazoline	598	616	|I-IUPAC
-	616	617	|I-IUPAC
6	617	618	|I-IUPAC
-	618	619	|I-IUPAC
carbonitriles	619	632	|I-IUPAC
.	632	633	|O
The	634	637	|O
Ki	638	640	|O
for	641	644	|O
inhibition	645	655	|O
of	656	658	|O
human	659	664	|O
DHFR	665	669	|O
by	670	672	|O
the	673	676	|O
5	677	678	|B-IUPAC
-	678	679	|I-IUPAC
deaza	679	684	|I-IUPAC
and	685	688	|O
5	689	690	|B-IUPAC
-	690	691	|I-IUPAC
methyl	691	697	|I-IUPAC
-	697	698	|I-IUPAC
5	698	699	|I-IUPAC
-	699	700	|I-IUPAC
deaza	700	705	|I-IUPAC
analogues	706	715	|B-MODIFIER
was	716	719	|O
about	720	725	|O
the	726	729	|O
same	730	734	|O
as	735	737	|O
that	738	742	|O
of	743	745	|O
3	746	747	|O
(	748	749	|O
0.35	749	753	|O
pM	754	756	|O
)	756	757	|O
,	757	758	|O
11	759	761	|O
-	761	762	|O
fold	762	766	|O
lower	767	772	|O
than	773	777	|O
that	778	782	|O
of	783	785	|O
aminopterin	786	797	|O
(	798	799	|O
AMT	799	802	|O
,	802	803	|O
1	804	805	|O
)	805	806	|O
,	806	807	|O
and	808	811	|O
15	812	814	|O
-	814	815	|O
fold	815	819	|O
lower	820	825	|O
than	826	830	|O
that	831	835	|O
of	836	838	|O
methotrexate	839	851	|O
(	852	853	|O
MTX	853	856	|O
,	856	857	|O
2	858	859	|O
)	859	860	|O
.	860	861	|O
However	862	869	|O
the	870	873	|O
Ki	874	876	|O
of	877	879	|O
the	880	883	|O
8	884	885	|B-IUPAC
-	885	886	|I-IUPAC
deaza	886	891	|I-IUPAC
analogue	892	900	|B-MODIFIER
was	901	904	|O
27	905	907	|O
-	907	908	|O
fold	908	912	|O
lower	913	918	|O
than	919	923	|O
that	924	928	|O
of	929	931	|O
1	932	933	|O
,	933	934	|O
and	935	938	|O
that	939	943	|O
of	944	946	|O
the	947	950	|O
5,8	951	954	|B-IUPAC
-	954	955	|I-IUPAC
dideaza	955	962	|I-IUPAC
,	962	963	|O
5	964	965	|B-IUPAC
-	965	966	|I-IUPAC
methyl	966	972	|I-IUPAC
-	972	973	|I-IUPAC
5,8	973	976	|I-IUPAC
-	976	977	|I-IUPAC
dideaza	977	984	|I-IUPAC
,	984	985	|O
and	986	989	|O
5	990	991	|B-IUPAC
-	991	992	|I-IUPAC
chloro	992	998	|I-IUPAC
-	998	999	|I-IUPAC
5,8	999	1002	|I-IUPAC
-	1002	1003	|I-IUPAC
dideaza	1003	1010	|I-IUPAC
analogues	1011	1020	|B-MODIFIER
was	1021	1024	|O
approximately	1025	1038	|O
50	1039	1041	|O
-	1041	1042	|O
fold	1042	1046	|O
lower	1047	1052	|O
.	1052	1053	|O
This	1054	1058	|O
trend	1059	1064	|O
was	1065	1068	|O
consistent	1069	1079	|O
with	1080	1084	|O
the	1085	1088	|O
published	1089	1098	|O
literature	1099	1109	|O
on	1110	1112	|O
the	1113	1116	|O
corresponding	1117	1130	|O
DHFR	1131	1135	|O
inhibitors	1136	1146	|O
with	1147	1151	|O
a	1152	1153	|O
glutamate	1154	1163	|O
side	1164	1168	|O
chain	1169	1174	|O
.	1174	1175	|O
In	1176	1178	|O
colony	1179	1185	|O
formation	1186	1195	|O
assays	1196	1202	|O
against	1203	1210	|O
the	1211	1214	|O
human	1215	1220	|O
head	1221	1225	|O
and	1226	1229	|O
neck	1230	1234	|O
squamous	1235	1243	|O
carcinoma	1244	1253	|O
cell	1254	1258	|O
line	1259	1263	|O
SCC25	1264	1269	|O
after	1270	1275	|O
72	1276	1278	|O
h	1279	1280	|O
of	1281	1283	|O
treatment	1284	1293	|O
,	1293	1294	|O
the	1295	1298	|O
5	1299	1300	|B-PARTIUPAC
-	1300	1301	|I-PARTIUPAC
and	1302	1305	|O
8	1306	1307	|B-IUPAC
-	1307	1308	|I-IUPAC
deaza	1308	1313	|I-IUPAC
analogues	1314	1323	|B-MODIFIER
were	1324	1328	|O
approximately	1329	1342	|O
as	1343	1345	|O
potent	1346	1352	|O
as	1353	1355	|O
3	1356	1357	|O
,	1357	1358	|O
whereas	1359	1366	|O
the	1367	1370	|O
5,8	1371	1374	|B-IUPAC
-	1374	1375	|I-IUPAC
dideaza	1375	1382	|I-IUPAC
analogue	1383	1391	|B-MODIFIER
was	1392	1395	|O
3	1396	1397	|O
times	1398	1403	|O
more	1404	1408	|O
potent	1409	1415	|O
.	1415	1416	|O
5	1417	1418	|B-IUPAC
-	1418	1419	|I-IUPAC
Methyl	1419	1425	|I-IUPAC
and	1426	1429	|O
5	1430	1431	|B-IUPAC
-	1431	1432	|I-IUPAC
chloro	1432	1438	|I-IUPAC
substitution	1439	1451	|B-MODIFIER
was	1452	1455	|O
also	1456	1460	|O
favorable	1461	1470	|O
,	1470	1471	|O
with	1472	1476	|O
the	1477	1480	|O
5	1481	1482	|B-IUPAC
-	1482	1483	|I-IUPAC
methyl	1483	1489	|I-IUPAC
-	1489	1490	|I-IUPAC
5	1490	1491	|I-IUPAC
-	1491	1492	|I-IUPAC
deaza	1492	1497	|I-IUPAC
analogue	1498	1506	|B-MODIFIER
being	1507	1512	|O
2	1513	1514	|O
.	1514	1515	|O
5	1516	1517	|O
-	1517	1518	|O
fold	1518	1522	|O
more	1523	1527	|O
potent	1528	1534	|O
than	1535	1539	|O
the	1540	1543	|O
5	1544	1545	|B-IUPAC
-	1545	1546	|I-IUPAC
deaza	1546	1551	|I-IUPAC
analogue	1552	1560	|B-MODIFIER
.	1560	1561	|O
However	1562	1569	|O
the	1570	1573	|O
effect	1574	1580	|O
of	1581	1583	|O
5	1584	1585	|B-IUPAC
-	1585	1586	|I-IUPAC
methyl	1586	1592	|I-IUPAC
substitution	1593	1605	|B-MODIFIER
was	1606	1609	|O
less	1610	1614	|O
pronounced	1615	1625	|O
in	1626	1628	|O
the	1629	1632	|O
5,8	1633	1636	|B-IUPAC
-	1636	1637	|I-IUPAC
dideaza	1637	1644	|I-IUPAC
analogues	1645	1654	|B-MODIFIER
than	1655	1659	|O
in	1660	1662	|O
the	1663	1666	|O
5	1667	1668	|B-IUPAC
-	1668	1669	|I-IUPAC
deaza	1669	1674	|I-IUPAC
analogues	1675	1684	|B-MODIFIER
.	1684	1685	|O
The	1686	1689	|O
5	1690	1691	|B-IUPAC
-	1691	1692	|I-IUPAC
chloro	1692	1698	|I-IUPAC
-	1698	1699	|I-IUPAC
5,8	1699	1702	|I-IUPAC
-	1702	1703	|I-IUPAC
dideaza	1703	1710	|I-IUPAC
analogue	1711	1719	|B-MODIFIER
of	1720	1722	|O
3	1723	1724	|O
was	1725	1728	|O
the	1729	1732	|O
most	1733	1737	|O
active	1738	1744	|O
member	1745	1751	|O
of	1752	1754	|O
the	1755	1758	|O
series	1759	1765	|O
,	1765	1766	|O
with	1767	1771	|O
an	1772	1774	|O
IC50	1775	1779	|O
=	1780	1781	|O
0.33	1782	1786	|O
nM	1787	1789	|O
versus	1790	1796	|O
1.8	1797	1800	|O
nM	1801	1803	|O
for	1804	1807	|O
3	1808	1809	|O
and	1810	1813	|O
15	1814	1816	|O
nM	1817	1819	|O
for	1820	1823	|O
MTX	1824	1827	|O
.	1827	1828	|O
The	1829	1832	|O
5	1833	1834	|B-IUPAC
-	1834	1835	|I-IUPAC
methyl	1835	1841	|I-IUPAC
-	1841	1842	|I-IUPAC
5	1842	1843	|I-IUPAC
-	1843	1844	|I-IUPAC
deaza	1844	1849	|I-IUPAC
analogue	1850	1858	|B-MODIFIER
of	1859	1861	|O
3	1862	1863	|O
was	1864	1867	|O
also	1868	1872	|O
tested	1873	1879	|O
at	1880	1882	|O
the	1883	1886	|O
National	1887	1895	|O
Cancer	1896	1902	|O
Institute	1903	1912	|O
against	1913	1920	|O
a	1921	1922	|O
panel	1923	1928	|O
of	1929	1931	|O
50	1932	1934	|O
human	1935	1940	|O
tumor	1941	1946	|O
cell	1947	1951	|O
lines	1952	1957	|O
in	1958	1960	|O
culture	1961	1968	|O
and	1969	1972	|O
was	1973	1976	|O
consistently	1977	1989	|O
more	1990	1994	|O
potent	1995	2001	|O
than	2002	2006	|O
3	2007	2008	|O
,	2008	2009	|O
with	2010	2014	|O
IC50	2015	2019	|O
values	2020	2026	|O
in	2027	2029	|O
the	2030	2033	|O
low	2034	2037	|O
-	2037	2038	|O
nanomolar	2038	2047	|O
to	2048	2050	|O
subnanomolar	2051	2063	|O
range	2064	2069	|O
against	2070	2077	|O
most	2078	2082	|O
of	2083	2085	|O
the	2086	2089	|O
tumors	2090	2096	|O
.	2096	2097	|O
Leukemia	2098	2106	|O
and	2107	2110	|O
colorectal	2111	2121	|O
carcinoma	2122	2131	|O
cell	2132	2136	|O
lines	2137	2142	|O
were	2143	2147	|O
generally	2148	2157	|O
most	2158	2162	|O
sensitive	2163	2172	|O
,	2172	2173	|O
though	2174	2180	|O
good	2181	2185	|O
activity	2186	2194	|O
was	2195	2198	|O
also	2199	2203	|O
observed	2204	2212	|O
against	2213	2220	|O
CNS	2221	2224	|O
tumors	2225	2231	|O
and	2232	2235	|O
carcinomas	2236	2246	|O
of	2247	2249	|O
the	2250	2253	|O
breast	2254	2260	|O
and	2261	2264	|O
prostate	2265	2273	|O
.	2273	2274	|O
The	2275	2278	|O
results	2279	2286	|O
of	2287	2289	|O
this	2290	2294	|O
study	2295	2300	|O
demonstrate	2301	2312	|O
that	2313	2317	|O
B	2318	2319	|O
-	2319	2320	|O
ring	2320	2324	|O
analogues	2325	2334	|O
of	2335	2337	|O
3	2338	2339	|O
inhibit	2340	2347	|O
DHFR	2348	2352	|O
activity	2353	2361	|O
and	2362	2365	|O
tumor	2366	2371	|O
cell	2372	2376	|O
colony	2377	2383	|O
formation	2384	2393	|O
as	2394	2396	|O
well	2397	2401	|O
as	2402	2404	|O
,	2404	2405	|O
or	2406	2408	|O
better	2409	2415	|O
than	2416	2420	|O
,	2420	2421	|O
the	2422	2425	|O
parent	2426	2432	|O
compound	2433	2441	|O
.	2441	2442	|O
In	2443	2445	|O
view	2446	2450	|O
of	2451	2453	|O
the	2454	2457	|O
fact	2458	2462	|O
that	2463	2467	|O
3	2468	2469	|O
and	2470	2473	|O
its	2474	2477	|O
B	2478	2479	|O
-	2479	2480	|O
ring	2480	2484	|O
analogues	2485	2494	|O
cannot	2495	2501	|O
form	2502	2506	|O
polyglutamates	2507	2521	|O
,	2521	2522	|O
their	2523	2528	|O
high	2529	2533	|O
cytotoxicity	2534	2546	|O
relative	2547	2555	|O
to	2556	2558	|O
the	2559	2562	|O
corresponding	2563	2576	|O
B	2577	2578	|O
-	2578	2579	|O
ring	2579	2583	|O
analogues	2584	2593	|O
of	2594	2596	|O
AMT	2597	2600	|O
is	2601	2603	|O
noteworthy	2604	2614	|O
.	2614	2615	|O

### abstracts3708.txt
[	0	1	|O
1	1	2	|O
-	2	3	|O
Beta	3	7	|O
-	7	8	|O
mercapto	8	16	|O
-	16	17	|O
beta	17	21	|O
,	21	22	|O
beta	22	26	|O
-	26	27	|O
pentamethylenepropionic	27	50	|O
acid	51	55	|O
]	55	56	|O
oxytocin	56	64	|O
was	65	68	|O
prepared	69	77	|O
from	78	82	|O
beta	83	87	|O
-	87	88	|O
Mpa	88	91	|O
(	91	92	|O
beta	92	96	|O
-	96	97	|O
(	97	98	|O
CH2	98	101	|O
)	101	102	|O
5	102	103	|O
)	103	104	|O
(	104	105	|O
Bzl	105	108	|O
)	108	109	|O
-	109	110	|O
Tyr	110	113	|O
(	113	114	|O
Bzl	114	117	|O
)	117	118	|O
-	118	119	|O
Ile	119	122	|O
-	122	123	|O
Gln	123	126	|O
-	126	127	|O
Asn	127	130	|O
-	130	131	|O
Cys	131	134	|O
(	134	135	|O
Bzl	135	138	|O
)	138	139	|O
-	139	140	|O
Pro	140	143	|O
-	143	144	|O
Leu	144	147	|O
-	147	148	|O
Gly	148	151	|O
-	151	152	|O
NH2	152	155	|O
by	156	158	|O
removal	159	166	|O
of	167	169	|O
the	170	173	|O
Bzl	174	177	|O
-	177	178	|O
protecting	178	188	|O
groups	189	195	|O
with	196	200	|O
Na	201	203	|O
-	203	204	|O
NH3	204	207	|O
followed	208	216	|O
by	217	219	|O
cyclization	220	231	|O
of	232	234	|O
the	235	238	|O
resulting	239	248	|O
disulfhydryl	249	261	|O
compound	262	270	|O
with	271	275	|O
K3Fe	276	280	|O
(	280	281	|O
CN	281	283	|O
)	283	284	|O
6	284	285	|O
.	285	286	|O
The	286	289	|O
analog	290	296	|O
was	297	300	|O
purified	301	309	|O
by	310	312	|O
desalting	313	322	|O
on	323	325	|O
Sephadex	326	334	|O
G	335	336	|O
-	336	337	|O
15	337	339	|O
in	340	342	|O
50%	343	346	|O
HOAc	347	351	|O
and	352	355	|O
gel	356	359	|O
filtration	360	370	|O
on	371	373	|O
Sephadex	374	382	|O
G	383	384	|O
-	384	385	|O
25	385	387	|O
and	388	391	|O
LH	392	394	|O
-	394	395	|O
20	395	397	|O
.	397	398	|O
The	399	402	|O
protected	403	412	|O
intermediate	413	425	|O
above	426	431	|O
was	432	435	|O
synthesized	436	447	|O
from	448	452	|O
Z	453	454	|O
-	454	455	|O
Cys	455	458	|O
(	458	459	|O
Bzl	459	462	|O
)	462	463	|O
-	463	464	|O
Pro	464	467	|O
-	467	468	|O
Leu	468	471	|O
-	471	472	|O
Gly	472	475	|O
-	475	476	|O
NH2	476	479	|O
by	480	482	|O
the	483	486	|O
stepwose	487	495	|O
p	496	497	|O
-	497	498	|O
nitrophenyl	498	509	|O
ester	510	515	|O
method	516	522	|O
using	523	528	|O
Nalpha	529	535	|O
-	535	536	|O
Boc	536	539	|O
protection	540	550	|O
at	551	553	|O
the	554	557	|O
penta	558	563	|O
-	563	564	|O
,	564	565	|O
hexa	566	570	|O
-	570	571	|O
,	571	572	|O
and	573	576	|O
octapeptide	577	588	|O
stages	589	595	|O
.	595	596	|O
The	597	600	|O
analog	601	607	|O
was	608	611	|O
found	612	617	|O
to	618	620	|O
be	621	623	|O
a	624	625	|O
potent	626	632	|O
inhibitor	633	642	|O
of	643	645	|O
the	646	649	|O
oxytocic	650	658	|O
and	659	662	|O
avian	663	668	|O
vasodepressor	669	682	|O
effects	683	690	|O
of	691	693	|O
oxytocin	694	702	|O
(	703	704	|O
pA2	704	707	|O
values	708	714	|O
of	715	717	|O
7.43	718	722	|O
and	723	726	|O
8.30	727	731	|O
,	731	732	|O
respectively	733	745	|O
)	745	746	|O
but	747	750	|O
was	751	754	|O
only	755	759	|O
a	760	761	|O
weak	762	766	|O
inhibitor	767	776	|O
of	777	779	|O
the	780	783	|O
rat	784	787	|O
pressor	788	795	|O
effect	796	802	|O
of	803	805	|O
8	806	807	|B-IUPAC
-	807	808	|I-IUPAC
lysine	808	814	|I-IUPAC
-	814	815	|I-IUPAC
vasopressin	815	826	|I-IUPAC
.	826	827	|O
The	828	831	|O
rat	832	835	|O
antipressor	836	847	|O
potency	848	855	|O
of	856	858	|O
[	859	860	|B-IUPAC
1	860	861	|I-IUPAC
-	861	862	|I-IUPAC
deaminopenicillamine	862	882	|I-IUPAC
]	882	883	|I-IUPAC
oxytocin	883	891	|I-IUPAC
was	892	895	|O
also	896	900	|O
determined	901	911	|O
in	912	914	|O
this	915	919	|O
study	920	925	|O
:	925	926	|O
pA2	927	930	|O
=	931	932	|O
6.27	933	937	|O
.	937	938	|O
Of	939	941	|O
the	942	945	|O
alkyl	946	951	|O
-	951	952	|O
substituted	952	963	|O
1	964	965	|O
-	965	966	|O
position	966	974	|O
analogs	975	982	|O
of	983	985	|O
oxytocin	986	994	|O
studied	995	1002	|O
so	1003	1005	|O
far	1006	1009	|O
,	1009	1010	|O
[	1011	1012	|B-IUPAC
1	1012	1013	|I-IUPAC
-	1013	1014	|I-IUPAC
beta	1014	1018	|I-IUPAC
-	1018	1019	|I-IUPAC
mercapto	1019	1027	|I-IUPAC
-	1027	1028	|I-IUPAC
beta	1028	1032	|I-IUPAC
,	1032	1033	|I-IUPAC
beta	1033	1037	|I-IUPAC
-	1037	1038	|I-IUPAC
pentamethylenepropionic	1038	1061	|I-IUPAC
acid	1062	1066	|I-IUPAC
]	1066	1067	|I-IUPAC
oxytocin	1067	1075	|I-IUPAC
is	1076	1078	|O
the	1079	1082	|O
most	1083	1087	|O
potent	1088	1094	|O
antioxytocic	1095	1107	|O
agent	1108	1113	|O
.	1113	1114	|O

### abstracts75.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
thieno	12	18	|B-IUPAC
[	18	19	|I-IUPAC
1,3	19	22	|I-IUPAC
]	22	23	|I-IUPAC
oxazin	23	29	|I-IUPAC
-	29	30	|I-IUPAC
4	30	31	|I-IUPAC
-	31	32	|I-IUPAC
ones	32	36	|I-IUPAC
and	37	40	|O
thieno	41	47	|B-IUPAC
[	47	48	|I-IUPAC
1,3	48	51	|I-IUPAC
]	51	52	|I-IUPAC
thiazin	52	59	|I-IUPAC
-	59	60	|I-IUPAC
4	60	61	|I-IUPAC
-	61	62	|I-IUPAC
ones	62	66	|I-IUPAC
were	67	71	|O
synthesized	72	83	|O
and	84	87	|O
investigated	88	100	|O
as	101	103	|O
inhibitors	104	114	|O
of	115	117	|O
the	118	121	|O
alpha	122	127	|O
/	127	128	|O
beta	128	132	|O
hydrolases	133	143	|O
cholesterol	144	155	|O
esterase	156	164	|O
(	165	166	|O
CEase	166	171	|O
)	171	172	|O
and	173	176	|O
acetylcholinesterase	177	197	|O
(	198	199	|O
AChE	199	203	|O
)	203	204	|O
.	204	205	|O
The	206	209	|O
introduction	210	222	|O
of	223	225	|O
a	226	227	|O
cycloaliphatic	228	242	|O
five	243	247	|O
-	247	248	|O
or	249	251	|O
six	252	255	|O
-	255	256	|O
membered	256	264	|O
ring	265	269	|O
fused	270	275	|O
at	276	278	|O
the	279	282	|O
thiophene	283	292	|O
was	293	296	|O
favorable	297	306	|O
for	307	310	|O
CEase	311	316	|O
inhibition	317	327	|O
.	327	328	|O
Such	329	333	|O
compounds	334	343	|O
were	344	348	|O
analyzed	349	357	|O
as	358	360	|O
true	361	365	|O
alternate	366	375	|O
substrate	376	385	|O
inhibitors	386	396	|O
.	396	397	|O
6,7	398	401	|B-IUPAC
-	401	402	|I-IUPAC
Dihydro	402	409	|I-IUPAC
-	409	410	|I-IUPAC
2	410	411	|I-IUPAC
-	411	412	|I-IUPAC
(	412	413	|I-IUPAC
dimethylamino	413	426	|I-IUPAC
)	426	427	|I-IUPAC
-	427	428	|I-IUPAC
4H	428	430	|I-IUPAC
,	430	431	|I-IUPAC
5H	431	433	|I-IUPAC
-	433	434	|I-IUPAC
cyclopenta	434	444	|I-IUPAC
[	444	445	|I-IUPAC
4,5	445	448	|I-IUPAC
]	448	449	|I-IUPAC
thieno	449	455	|I-IUPAC
[	455	456	|I-IUPAC
2,3	456	459	|I-IUPAC
-	459	460	|I-IUPAC
d	460	461	|I-IUPAC
]	461	462	|I-IUPAC
[	462	463	|I-IUPAC
1,3	463	466	|I-IUPAC
]	466	467	|I-IUPAC
oxazin	467	473	|I-IUPAC
-	473	474	|I-IUPAC
4	474	475	|I-IUPAC
-	475	476	|I-IUPAC
one	476	479	|I-IUPAC
(	480	481	|O
33	481	483	|O
)	483	484	|O
exhibited	485	494	|O
a	495	496	|O
K	497	498	|O
(	498	499	|O
i	499	500	|O
)	500	501	|O
value	502	507	|O
of	508	510	|O
630	511	514	|O
nM	515	517	|O
and	518	521	|O
excelled	522	530	|O
in	531	533	|O
its	534	537	|O
low	538	541	|O
susceptibility	542	556	|O
to	557	559	|O
CEase	560	565	|O
-	565	566	|O
catalyzed	566	575	|O
degradation	576	587	|O
.	587	588	|O
Compound	589	597	|O
33	598	600	|O
and	601	604	|O
its	605	608	|O
analogues	609	618	|O
did	619	622	|O
not	623	626	|O
inhibit	627	634	|O
AChE	635	639	|O
.	639	640	|O
The	641	644	|O
introduction	645	657	|O
of	658	660	|O
a	661	662	|O
tetrahydropyrido	663	679	|O
ring	680	684	|O
with	685	689	|O
bulky	690	695	|O
hydrophobic	696	707	|O
substituents	708	720	|O
at	721	723	|O
the	724	727	|O
basic	728	733	|O
nitrogen	734	742	|O
provided	743	751	|O
inhibitors	752	762	|O
of	763	765	|O
AChE	766	770	|O
which	771	776	|O
were	777	781	|O
completely	782	792	|O
inactive	793	801	|O
toward	802	808	|O
CEase	809	814	|O
.	814	815	|O
7	816	817	|B-IUPAC
-	817	818	|I-IUPAC
Benzyl	818	824	|I-IUPAC
-	824	825	|I-IUPAC
5,6,7,8	825	832	|I-IUPAC
-	832	833	|I-IUPAC
tetrahydro	833	843	|I-IUPAC
-	843	844	|I-IUPAC
2	844	845	|I-IUPAC
-	845	846	|I-IUPAC
(	846	847	|I-IUPAC
N	847	848	|I-IUPAC
-	848	849	|I-IUPAC
3,4	849	852	|I-IUPAC
-	852	853	|I-IUPAC
dimethoxybenzyl	853	868	|I-IUPAC
-	868	869	|I-IUPAC
N	869	870	|I-IUPAC
-	870	871	|I-IUPAC
methylamino	871	882	|I-IUPAC
)	882	883	|I-IUPAC
-	883	884	|I-IUPAC
4H	884	886	|I-IUPAC
-	886	887	|I-IUPAC
pyrido	887	893	|I-IUPAC
[	893	894	|I-IUPAC
4'	894	896	|I-IUPAC
,	896	897	|I-IUPAC
3'	897	899	|I-IUPAC
:	899	900	|I-IUPAC
4,5	900	903	|I-IUPAC
]	903	904	|I-IUPAC
thieno	904	910	|I-IUPAC
[	910	911	|I-IUPAC
2,3	911	914	|I-IUPAC
-	914	915	|I-IUPAC
d	915	916	|I-IUPAC
]	916	917	|I-IUPAC
[	917	918	|I-IUPAC
1,3	918	921	|I-IUPAC
]	921	922	|I-IUPAC
oxazin	922	928	|I-IUPAC
-	928	929	|I-IUPAC
4	929	930	|I-IUPAC
-	930	931	|I-IUPAC
one	931	934	|I-IUPAC
(	935	936	|O
21	936	938	|O
)	938	939	|O
had	940	943	|O
the	944	947	|O
IC	948	950	|O
(	950	951	|O
50	951	953	|O
)	953	954	|O
value	955	960	|O
of	961	963	|O
330	964	967	|O
nM	968	970	|O
for	971	974	|O
AChE	975	979	|O
inhibition	980	990	|O
.	990	991	|O
A	992	993	|O
residual	994	1002	|O
enzymatic	1003	1012	|O
activity	1013	1021	|O
at	1022	1024	|O
an	1025	1027	|O
infinite	1028	1036	|O
inhibitor	1037	1046	|O
concentration	1047	1060	|O
and	1061	1064	|O
thus	1065	1069	|O
a	1070	1071	|O
catalytically	1072	1085	|O
active	1086	1092	|O
ternary	1093	1100	|O
enzyme	1101	1107	|O
-	1107	1108	|O
substrate	1108	1117	|O
-	1117	1118	|O
inhibitor	1118	1127	|O
complex	1128	1135	|O
was	1136	1139	|O
concluded	1140	1149	|O
.	1149	1150	|O
To	1151	1153	|O
specify	1154	1161	|O
kinetic	1162	1169	|O
parameters	1170	1180	|O
of	1181	1183	|O
inhibition	1184	1194	|O
,	1194	1195	|O
a	1196	1197	|O
new	1198	1201	|O
method	1202	1208	|O
was	1209	1212	|O
derived	1213	1220	|O
to	1221	1223	|O
characterize	1224	1236	|O
selected	1237	1245	|O
thieno	1246	1252	|B-IUPAC
[	1252	1253	|I-IUPAC
1,3	1253	1256	|I-IUPAC
]	1256	1257	|I-IUPAC
oxazin	1257	1263	|I-IUPAC
-	1263	1264	|I-IUPAC
4	1264	1265	|I-IUPAC
-	1265	1266	|I-IUPAC
ones	1266	1270	|I-IUPAC
as	1271	1273	|O
hyperbolic	1274	1284	|O
mixed	1285	1290	|O
-	1290	1291	|O
type	1291	1295	|O
inhibitors	1296	1306	|O
of	1307	1309	|O
AChE	1310	1314	|O
.	1314	1315	|O

### abstracts3482.txt
Series	0	6	|O
of	7	9	|O
3	10	11	|B-MODIFIER
-	11	12	|I-MODIFIER
substituted	12	23	|I-MODIFIER
-	23	24	|O
9,10	24	28	|B-IUPAC
-	28	29	|I-IUPAC
dimethoxy	29	38	|I-IUPAC
-	38	39	|I-IUPAC
3,4,6,7	39	46	|I-IUPAC
-	46	47	|I-IUPAC
tetrahydro	47	57	|I-IUPAC
-	57	58	|I-IUPAC
2H	58	60	|I-IUPAC
-	60	61	|I-IUPAC
pyrimido	61	69	|I-IUPAC
[	70	71	|I-IUPAC
6,1	71	74	|I-IUPAC
-	74	75	|I-IUPAC
a	75	76	|I-IUPAC
]	76	77	|I-IUPAC
isoquinoline	77	89	|I-IUPAC
-	89	90	|I-IUPAC
2,4	90	93	|I-IUPAC
-	93	94	|I-IUPAC
diones	94	100	|I-IUPAC
and	101	104	|O
2	105	106	|B-MODIFIER
-	106	107	|I-MODIFIER
substituted	107	118	|I-MODIFIER
-	118	119	|O
9,10	119	123	|B-IUPAC
-	123	124	|I-IUPAC
dimethoxy	124	133	|I-IUPAC
-	133	134	|I-IUPAC
6,7	134	137	|I-IUPAC
-	137	138	|I-IUPAC
dihydro	138	145	|I-IUPAC
-	145	146	|I-IUPAC
4H	146	148	|I-IUPAC
-	148	149	|I-IUPAC
pyrimido	149	157	|I-IUPAC
[	158	159	|I-IUPAC
6,1	159	162	|I-IUPAC
-	162	163	|I-IUPAC
a	163	164	|I-IUPAC
]	164	165	|I-IUPAC
isoquinolin	165	176	|I-IUPAC
-	176	177	|I-IUPAC
4	177	178	|I-IUPAC
-	178	179	|I-IUPAC
ones	179	183	|I-IUPAC
were	184	188	|O
synthesized	189	200	|O
and	201	204	|O
tested	205	211	|O
for	212	215	|O
blood	216	221	|O
pressure	222	230	|O
lowering	231	239	|O
properties	240	250	|O
in	251	253	|O
anesthetized	254	266	|O
normotensive	267	279	|O
cats	280	284	|O
and	285	288	|O
conscious	289	298	|O
spontaneously	299	312	|O
hypertensive	313	325	|O
rats	326	330	|O
.	330	331	|O
Several	332	339	|O
compounds	340	349	|O
in	350	352	|O
the	353	356	|O
2	357	358	|B-IUPAC
-	358	359	|I-IUPAC
(	359	360	|I-IUPAC
arylamino	360	369	|I-IUPAC
)	369	370	|I-IUPAC
-	370	371	|I-IUPAC
9,10	371	375	|I-IUPAC
-	375	376	|I-IUPAC
dimethoxy	376	385	|I-IUPAC
-	385	386	|I-IUPAC
6,7	386	389	|I-IUPAC
-	389	390	|I-IUPAC
dihydro	390	397	|I-IUPAC
-	397	398	|I-IUPAC
4H	398	400	|I-IUPAC
-	400	401	|I-IUPAC
pyrimido	401	409	|I-IUPAC
[	410	411	|I-IUPAC
6,1	411	414	|I-IUPAC
-	414	415	|I-IUPAC
a	415	416	|I-IUPAC
]	416	417	|I-IUPAC
isoquinolin	417	428	|I-IUPAC
-	428	429	|I-IUPAC
4	429	430	|I-IUPAC
-	430	431	|I-IUPAC
one	431	434	|I-IUPAC
series	435	441	|B-MODIFIER
display	442	449	|O
a	450	451	|O
high	452	456	|O
order	457	462	|O
of	463	465	|O
activity	466	474	|O
.	474	475	|O
The	476	479	|O
most	480	484	|O
active	485	491	|O
compounds	492	501	|O
are	502	505	|O
the	506	509	|O
alkyl	510	515	|O
derivatives	516	527	|O
of	528	530	|O
the	531	534	|O
2	535	536	|B-IUPAC
-	536	537	|I-IUPAC
mesitylamino	537	549	|I-IUPAC
/	549	550	|O
2	550	551	|B-IUPAC
-	551	552	|I-IUPAC
mesitylimino	552	564	|I-IUPAC
tautomeric	565	575	|B-MODIFIER
forms	576	581	|I-MODIFIER
.	581	582	|O
The	583	586	|O
2	587	588	|B-IUPAC
-	588	589	|I-IUPAC
(	589	590	|I-IUPAC
mesitylimino	590	602	|I-IUPAC
)	602	603	|I-IUPAC
-	603	604	|I-IUPAC
3	604	605	|I-IUPAC
-	605	606	|I-IUPAC
methyl	606	612	|I-IUPAC
analogue	613	621	|B-MODIFIER
trequinsin	622	632	|O
is	633	635	|O
a	636	637	|O
potent	638	644	|O
antihypertensive	645	661	|O
agent	662	667	|O
and	668	671	|O
displays	672	680	|O
a	681	682	|O
hemodynamic	683	694	|O
profile	695	702	|O
characteristic	703	717	|O
of	718	720	|O
an	721	723	|O
arteriolar	724	734	|O
dilator	735	742	|O
.	742	743	|O
It	744	746	|O
is	747	749	|O
also	750	754	|O
a	755	756	|O
potent	757	763	|O
inhibitor	764	773	|O
of	774	776	|O
both	777	781	|O
cAMP	782	786	|O
phosphodiesterase	787	804	|O
and	805	808	|O
platelet	809	817	|O
aggregation	818	829	|O
.	829	830	|O

### abstracts4816.txt
Cyclic	0	6	|O
depsipeptide	7	19	|O
cyclo	20	25	|O
-	25	26	|O
[	26	27	|O
D	27	28	|O
-	28	29	|O
Hmp	29	32	|O
(	32	33	|O
1	33	34	|O
)	34	35	|O
-	35	36	|O
L	36	37	|O
-	37	38	|O
MeVal	38	43	|O
(	43	44	|O
2	44	45	|O
)	45	46	|O
-	46	47	|O
L	47	48	|O
-	48	49	|O
Phe	49	52	|O
(	52	53	|O
3	53	54	|O
)	54	55	|O
-	55	56	|O
L	56	57	|O
-	57	58	|O
MePhe	58	63	|O
(	63	64	|O
4	64	65	|O
)	65	66	|O
-	66	67	|O
L	67	68	|O
-	68	69	|O
Pro	69	72	|O
(	72	73	|O
5	73	74	|O
)	74	75	|O
-	75	76	|O
L	76	77	|O
-	77	78	|O
aIle+	78	83	|O
+	84	85	|O
+	85	86	|O
(	86	87	|O
6	87	88	|O
)	88	89	|O
-	89	90	|O
L	90	91	|O
-	91	92	|O
MeVal	92	97	|O
(	97	98	|O
7	98	99	|O
)	99	100	|O
-	100	101	|O
L	101	102	|O
-	102	103	|O
Leu	103	106	|O
(	106	107	|O
8	107	108	|O
)	108	109	|O
-	109	110	|O
L	110	111	|O
-	111	112	|O
betaHOMeVal	112	123	|O
(	123	124	|O
9	124	125	|O
)	125	126	|O
]	126	127	|O
,	127	128	|O
the	129	132	|O
antifungal	133	143	|O
antibiotic	144	154	|O
aureobasidin	155	167	|O
A	168	169	|O
(	170	171	|O
AbA	171	174	|O
)	174	175	|O
,	175	176	|O
was	177	180	|O
reported	181	189	|O
to	190	192	|O
interfere	193	202	|O
with	203	207	|O
ATP	208	211	|O
-	211	212	|O
binding	212	219	|O
cassette	220	228	|O
(	229	230	|O
ABC	230	233	|O
)	233	234	|O
transporters	235	247	|O
in	248	250	|O
yeast	251	256	|O
and	257	260	|O
mammalian	261	270	|O
cells	271	276	|O
,	276	277	|O
particularly	278	290	|O
the	291	294	|O
MDR1	295	299	|O
P	300	301	|O
-	301	302	|O
glycoprotein	302	314	|O
(	315	316	|O
Pgp	316	319	|O
)	319	320	|O
,	320	321	|O
a	322	323	|O
transmembrane	324	337	|O
phospholipid	338	350	|O
flippase	351	359	|O
or	360	362	|O
"	363	364	|O
hydrophobic	364	375	|O
vacuum	376	382	|O
cleaner	383	390	|O
"	390	391	|O
that	392	396	|O
mediates	397	405	|O
multidrug	406	415	|O
resistance	416	426	|O
(	427	428	|O
MDR	428	431	|O
)	431	432	|O
of	433	435	|O
cancer	436	442	|O
cells	443	448	|O
.	448	449	|O
In	450	452	|O
a	453	454	|O
standardized	455	467	|O
assay	468	473	|O
that	474	478	|O
measures	479	487	|O
Pgp	488	491	|O
function	492	500	|O
by	501	503	|O
the	504	507	|O
Pgp	508	511	|O
-	511	512	|O
mediated	512	520	|O
efflux	521	527	|O
of	528	530	|O
the	531	534	|O
calcein	535	542	|O
-	542	543	|O
AM	543	545	|O
Pgp	546	549	|O
substrate	550	559	|O
and	560	563	|O
uses	564	568	|O
human	569	574	|O
lymphoblastoid	575	589	|O
MDR	590	593	|O
-	593	594	|O
CEM	594	597	|O
(	598	599	|O
VBL	599	602	|O
(	602	603	|O
100	603	606	|O
)	606	607	|O
)	607	608	|O
cells	609	614	|O
as	615	617	|O
highly	618	624	|O
resistant	625	634	|O
Pgp	635	638	|O
-	638	639	|O
expressing	639	649	|O
cells	650	655	|O
and	656	659	|O
the	660	663	|O
cyclic	664	670	|O
undecapeptide	671	684	|O
cyclosporin	685	696	|O
A	697	698	|O
(	699	700	|O
CsA	700	703	|O
)	703	704	|O
as	705	707	|O
a	708	709	|O
reference	710	719	|O
MDR	720	723	|O
-	723	724	|O
reversing	724	733	|O
agent	734	739	|O
(	740	741	|O
IC	741	743	|O
(	743	744	|O
50	744	746	|O
)	746	747	|O
of	748	750	|O
3.4	751	754	|O
microM	755	761	|O
)	761	762	|O
,	762	763	|O
AbA	764	767	|O
was	768	771	|O
found	772	777	|O
to	778	780	|O
be	781	783	|O
a	784	785	|O
more	786	790	|O
active	791	797	|O
Pgp	798	801	|O
inhibitor	802	811	|O
(	812	813	|O
IC	813	815	|O
(	815	816	|O
50	816	818	|O
)	818	819	|O
of	820	822	|O
2.3	823	826	|O
microM	827	833	|O
)	833	834	|O
.	834	835	|O
Out	836	839	|O
of	840	842	|O
seven	843	848	|O
natural	849	856	|O
analogues	857	866	|O
and	867	870	|O
18	871	873	|O
chemical	874	882	|O
derivatives	883	894	|O
of	895	897	|O
AbA	898	901	|O
,	901	902	|O
several	903	910	|O
were	911	915	|O
shown	916	921	|O
to	922	924	|O
display	925	932	|O
even	933	937	|O
more	938	942	|O
potent	943	949	|O
Pgp	950	953	|O
-	953	954	|O
inhibitory	954	964	|O
activity	965	973	|O
.	973	974	|O
The	975	978	|O
Pgp	979	982	|O
-	982	983	|O
inhibitory	983	993	|O
activity	994	1002	|O
was	1003	1006	|O
increased	1007	1016	|O
about	1017	1022	|O
2	1023	1024	|O
-	1024	1025	|O
fold	1025	1029	|O
by	1030	1032	|O
some	1033	1037	|O
minor	1038	1043	|O
modifications	1044	1057	|O
such	1058	1062	|O
as	1063	1065	|O
those	1066	1071	|O
found	1072	1077	|O
in	1078	1080	|O
the	1081	1084	|O
naturally	1085	1094	|O
occurring	1095	1104	|O
aureobasidins	1105	1118	|O
AbB	1119	1122	|O
(	1123	1124	|O
[	1124	1125	|O
D	1125	1126	|O
-	1126	1127	|O
Hiv	1127	1130	|O
(	1130	1131	|O
1	1131	1132	|O
)	1132	1133	|O
]	1133	1134	|O
-	1134	1135	|O
AbA	1135	1138	|O
)	1138	1139	|O
,	1139	1140	|O
AbC	1141	1144	|O
(	1145	1146	|O
[	1146	1147	|O
Val	1147	1150	|O
(	1150	1151	|O
6	1151	1152	|O
)	1152	1153	|O
]	1153	1154	|O
-	1154	1155	|O
AbA	1155	1158	|O
)	1158	1159	|O
,	1159	1160	|O
and	1161	1164	|O
AbD	1165	1168	|O
[	1169	1170	|O
gammaHOMeVal	1170	1182	|O
(	1182	1183	|O
9	1183	1184	|O
)	1184	1185	|O
]	1185	1186	|O
-	1186	1187	|O
AbA	1187	1190	|O
)	1190	1191	|O
.	1191	1192	|O
The	1193	1196	|O
replacement	1197	1208	|O
of	1209	1211	|O
the	1212	1215	|O
[	1216	1217	|O
Phe	1217	1220	|O
(	1220	1221	|O
3	1221	1222	|O
)	1222	1223	|O
-	1223	1224	|O
MePhe	1224	1229	|O
(	1229	1230	|O
4	1230	1231	|O
)	1231	1232	|O
-	1232	1233	|O
Pro	1233	1236	|O
(	1236	1237	|O
5	1237	1238	|O
)	1238	1239	|O
]	1239	1240	|O
tripeptide	1241	1251	|O
by	1252	1254	|O
an	1255	1257	|O
8	1258	1259	|B-IUPAC
-	1259	1260	|I-IUPAC
aminocaprylic	1260	1273	|I-IUPAC
acid	1274	1278	|I-IUPAC
or	1279	1281	|O
the	1282	1285	|O
N	1286	1287	|O
(	1287	1288	|O
7	1288	1289	|O
)	1289	1290	|O
(	1290	1291	|O
)	1291	1292	|O
-	1292	1293	|O
desmethylation	1293	1307	|O
of	1308	1310	|O
MeVal	1311	1316	|O
(	1316	1317	|O
7	1317	1318	|O
)	1318	1319	|O
led	1320	1323	|O
to	1324	1326	|O
only	1327	1331	|O
a	1332	1333	|O
3.3	1334	1337	|O
-	1337	1338	|O
fold	1338	1342	|O
decreased	1343	1352	|O
capacity	1353	1361	|O
to	1362	1364	|O
inhibit	1365	1372	|O
Pgp	1373	1376	|O
function	1377	1385	|O
,	1385	1386	|O
suggesting	1387	1397	|O
that	1398	1402	|O
the	1403	1406	|O
Pgp	1407	1410	|O
inhibitory	1411	1421	|O
potential	1422	1431	|O
of	1432	1434	|O
aureobasidins	1435	1448	|O
,	1448	1449	|O
though	1450	1456	|O
favored	1457	1464	|O
by	1465	1467	|O
the	1468	1471	|O
establishment	1472	1485	|O
of	1486	1488	|O
an	1489	1491	|O
antiparallel	1492	1504	|O
beta	1505	1509	|O
-	1509	1510	|O
sheet	1510	1515	|O
between	1516	1523	|O
the	1524	1527	|O
[	1528	1529	|O
D	1529	1530	|O
-	1530	1531	|O
Hmp	1531	1534	|O
(	1534	1535	|O
1	1535	1536	|O
)	1536	1537	|O
-	1537	1538	|O
L	1538	1539	|O
-	1539	1540	|O
MeVal	1540	1545	|O
(	1545	1546	|O
2	1546	1547	|O
)	1547	1548	|O
-	1548	1549	|O
L	1549	1550	|O
-	1550	1551	|O
Phe	1551	1554	|O
(	1554	1555	|O
3	1555	1556	|O
)	1556	1557	|O
]	1557	1558	|O
and	1559	1562	|O
[	1563	1564	|O
L	1564	1565	|O
-	1565	1566	|O
aIle	1566	1570	|O
(	1570	1571	|O
6	1571	1572	|O
)	1572	1573	|O
-	1573	1574	|O
L	1574	1575	|O
-	1575	1576	|O
MeVal	1576	1581	|O
(	1581	1582	|O
7	1582	1583	|O
)	1583	1584	|O
-	1584	1585	|O
L	1585	1586	|O
-	1586	1587	|O
Leu	1587	1590	|O
(	1590	1591	|O
8	1591	1592	|O
)	1592	1593	|O
-	1593	1594	|O
]	1594	1595	|O
tripeptides	1596	1607	|O
,	1607	1608	|O
does	1609	1613	|O
not	1614	1617	|O
critically	1618	1628	|O
depend	1629	1635	|O
on	1636	1638	|O
the	1639	1642	|O
occurrence	1643	1653	|O
of	1654	1656	|O
the	1657	1660	|O
[	1661	1662	|O
L	1662	1663	|O
-	1663	1664	|O
Phe	1664	1667	|O
(	1667	1668	|O
3	1668	1669	|O
)	1669	1670	|O
-	1670	1671	|O
L	1671	1672	|O
-	1672	1673	|O
MePhe	1673	1678	|O
(	1678	1679	|O
4	1679	1680	|O
)	1680	1681	|O
-	1681	1682	|O
L	1682	1683	|O
-	1683	1684	|O
Pro	1684	1687	|O
(	1687	1688	|O
5	1688	1689	|O
)	1689	1690	|O
-	1690	1691	|O
L	1691	1692	|O
-	1692	1693	|O
aIle	1693	1697	|O
(	1697	1698	|O
6	1698	1699	|O
)	1699	1700	|O
]	1700	1701	|O
type	1702	1706	|O
II	1707	1709	|O
'	1709	1710	|O
beta	1711	1715	|O
-	1715	1716	|O
turn	1716	1720	|O
secondary	1721	1730	|O
structure	1731	1740	|O
.	1740	1741	|O
In	1742	1744	|O
contrast	1745	1753	|O
,	1753	1754	|O
the	1755	1758	|O
most	1759	1763	|O
potent	1764	1770	|O
Pgp	1771	1774	|O
inhibitors	1775	1785	|O
were	1786	1790	|O
found	1791	1796	|O
among	1797	1802	|O
AbA	1803	1806	|O
analogues	1807	1816	|O
with	1817	1821	|O
[	1822	1823	|O
betaHO	1823	1829	|O
-	1829	1830	|O
MeVal	1830	1835	|O
(	1835	1836	|O
9	1836	1837	|O
)	1837	1838	|O
]	1838	1839	|O
residue	1840	1847	|O
alterations	1848	1859	|O
,	1859	1860	|O
with	1861	1865	|O
some	1866	1870	|O
data	1871	1875	|O
suggesting	1876	1886	|O
a	1887	1888	|O
negative	1889	1897	|O
impact	1898	1904	|O
of	1905	1907	|O
the	1908	1911	|O
[	1912	1913	|O
L	1913	1914	|O
-	1914	1915	|O
Leu	1915	1918	|O
(	1918	1919	|O
8	1919	1920	|O
)	1920	1921	|O
-	1921	1922	|O
L	1922	1923	|O
-	1923	1924	|O
betaHOMeVal	1924	1935	|O
(	1935	1936	|O
9	1936	1937	|O
)	1937	1938	|O
-	1938	1939	|O
D	1939	1940	|O
-	1940	1941	|O
Hmp	1941	1944	|O
(	1944	1945	|O
1	1945	1946	|O
)	1946	1947	|O
]	1947	1948	|O
gamma	1949	1954	|O
-	1954	1955	|O
turn	1955	1959	|O
secondary	1960	1969	|O
structure	1970	1979	|O
on	1980	1982	|O
Pgp	1983	1986	|O
inhibitory	1987	1997	|O
potential	1998	2007	|O
.	2007	2008	|O
The	2009	2012	|O
[	2013	2014	|O
2,3	2014	2017	|O
-	2017	2018	|O
dehydro	2018	2025	|O
-	2025	2026	|O
MeVal	2026	2031	|O
(	2031	2032	|O
9	2032	2033	|O
)	2033	2034	|O
]	2034	2035	|O
-	2035	2036	|O
AbA	2036	2039	|O
was	2040	2043	|O
the	2044	2047	|O
most	2048	2052	|O
potent	2053	2059	|O
Pgp	2060	2063	|O
inhibitory	2064	2074	|O
aureobasidin	2075	2087	|O
,	2087	2088	|O
being	2089	2094	|O
13	2095	2097	|O
-	2097	2098	|O
fold	2098	2102	|O
more	2103	2107	|O
potent	2108	2114	|O
than	2115	2119	|O
AbA	2120	2123	|O
and	2124	2127	|O
19	2128	2130	|O
-	2130	2131	|O
fold	2131	2135	|O
more	2136	2140	|O
potent	2141	2147	|O
(	2148	2149	|O
on	2149	2151	|O
a	2152	2153	|O
molar	2154	2159	|O
basis	2160	2165	|O
)	2165	2166	|O
than	2167	2171	|O
CsA	2172	2175	|O
.	2175	2176	|O
Finally	2177	2184	|O
,	2184	2185	|O
there	2186	2191	|O
was	2192	2195	|O
no	2196	2198	|O
correlation	2199	2210	|O
between	2211	2218	|O
the	2219	2222	|O
SAR	2223	2226	|O
for	2227	2230	|O
the	2231	2234	|O
human	2235	2240	|O
MDR1	2241	2245	|O
Pgp	2246	2249	|O
inhibition	2250	2260	|O
and	2261	2264	|O
the	2265	2268	|O
SAR	2269	2272	|O
for	2273	2276	|O
Saccharomyces	2277	2290	|O
cerevisiae	2291	2301	|O
antifungal	2302	2312	|O
activity	2313	2321	|O
,	2321	2322	|O
which	2323	2328	|O
is	2329	2331	|O
mediated	2332	2340	|O
by	2341	2343	|O
an	2344	2346	|O
inositol	2347	2355	|O
phosphoceramide	2356	2371	|O
synthase	2372	2380	|O
activity	2381	2389	|O
.	2389	2390	|O

### abstracts4760.txt
5	0	1	|O
-	1	2	|O
(	2	3	|O
4	3	4	|O
-	4	5	|O
Piperidyl	5	14	|O
)	14	15	|O
isoxazol	15	23	|O
-	23	24	|O
3	24	25	|O
-	25	26	|O
ol	26	28	|O
(	29	30	|O
4	30	31	|O
-	31	32	|O
PIOL	32	36	|O
,	36	37	|O
10	38	40	|O
)	40	41	|O
,	41	42	|O
a	43	44	|O
structural	45	55	|O
analog	56	62	|O
of	63	65	|O
4	66	67	|B-IUPAC
-	67	68	|I-IUPAC
aminobutanoic	68	81	|I-IUPAC
acid	82	86	|I-IUPAC
(	87	88	|O
GABA	88	92	|O
,	92	93	|O
1	94	95	|O
)	95	96	|O
and	97	100	|O
the	101	104	|O
GABAA	105	110	|O
agonist	111	118	|O
4,5,6,7	119	126	|B-IUPAC
-	126	127	|I-IUPAC
tetrahydroisoxazolo	127	146	|I-IUPAC
[	146	147	|I-IUPAC
5,4	147	150	|I-IUPAC
-	150	151	|I-IUPAC
c	151	152	|I-IUPAC
]	152	153	|I-IUPAC
pyridin	153	160	|I-IUPAC
-	160	161	|I-IUPAC
3	161	162	|I-IUPAC
-	162	163	|I-IUPAC
ol	163	165	|I-IUPAC
(	166	167	|O
THIP	167	171	|O
,	171	172	|O
5	173	174	|O
)	174	175	|O
,	175	176	|O
is	177	179	|O
a	180	181	|O
low	182	185	|O
-	185	186	|O
efficacy	186	194	|O
partial	195	202	|O
GABAA	203	208	|O
agonist	209	216	|O
.	216	217	|O
A	218	219	|O
number	220	226	|O
of	227	229	|O
compounds	230	239	|O
bioisosterically	240	256	|O
derived	257	264	|O
from	265	269	|O
10	270	272	|O
,	272	273	|O
including	274	283	|O
5	284	285	|B-IUPAC
-	285	286	|I-IUPAC
(	286	287	|I-IUPAC
4	287	288	|I-IUPAC
-	288	289	|I-IUPAC
piperidyl	289	298	|I-IUPAC
)	298	299	|I-IUPAC
isothiazol	299	309	|I-IUPAC
-	309	310	|I-IUPAC
3	310	311	|I-IUPAC
-	311	312	|I-IUPAC
ol	312	314	|I-IUPAC
(	315	316	|O
11	316	318	|O
)	318	319	|O
,	319	320	|O
3	321	322	|B-IUPAC
-	322	323	|I-IUPAC
(	323	324	|I-IUPAC
4	324	325	|I-IUPAC
-	325	326	|I-IUPAC
piperidyl	326	335	|I-IUPAC
)	335	336	|I-IUPAC
isoxazol	336	344	|I-IUPAC
-	344	345	|I-IUPAC
5	345	346	|I-IUPAC
-	346	347	|I-IUPAC
ol	347	349	|I-IUPAC
(	350	351	|O
12	351	353	|O
)	353	354	|O
,	354	355	|O
5	356	357	|B-IUPAC
-	357	358	|I-IUPAC
(	358	359	|I-IUPAC
1,2,3,6	359	366	|I-IUPAC
-	366	367	|I-IUPAC
tetrahydropyrid	367	382	|I-IUPAC
-	382	383	|I-IUPAC
4	383	384	|I-IUPAC
-	384	385	|I-IUPAC
yl	385	387	|I-IUPAC
)	387	388	|I-IUPAC
isoxazol	388	396	|I-IUPAC
-	396	397	|I-IUPAC
3	397	398	|I-IUPAC
-	398	399	|I-IUPAC
ol	399	401	|I-IUPAC
(	402	403	|O
13	403	405	|O
)	405	406	|O
,	406	407	|O
and	408	411	|O
5	412	413	|B-IUPAC
-	413	414	|I-IUPAC
(	414	415	|I-IUPAC
1,2,3,6	415	422	|I-IUPAC
-	422	423	|I-IUPAC
tetrahydropyrid	423	438	|I-IUPAC
-	438	439	|I-IUPAC
4	439	440	|I-IUPAC
-	440	441	|I-IUPAC
yl	441	443	|I-IUPAC
)	443	444	|I-IUPAC
isothiazol	444	454	|I-IUPAC
-	454	455	|I-IUPAC
3	455	456	|I-IUPAC
-	456	457	|I-IUPAC
ol	457	459	|I-IUPAC
(	460	461	|O
14	461	463	|O
)	463	464	|O
,	464	465	|O
were	466	470	|O
synthesized	471	482	|O
and	483	486	|O
tested	487	493	|O
as	494	496	|O
GABAA	497	502	|O
receptor	503	511	|O
ligands	512	519	|O
.	519	520	|O
Whereas	521	528	|O
none	529	533	|O
of	534	536	|O
these	537	542	|O
compounds	543	552	|O
significantly	553	566	|O
affected	567	575	|O
GABAB	576	581	|O
receptor	582	590	|O
binding	591	598	|O
or	599	601	|O
GABA	602	606	|O
uptake	607	613	|O
,	613	614	|O
they	615	619	|O
showed	620	626	|O
affinities	627	637	|O
for	638	641	|O
GABAA	642	647	|O
receptor	648	656	|O
sites	657	662	|O
in	663	665	|O
the	666	669	|O
low	670	673	|O
-	673	674	|O
micromolar	674	684	|O
range	685	690	|O
.	690	691	|O
Using	692	697	|O
cultured	698	706	|O
cerebral	707	715	|O
cortical	716	724	|O
neurons	725	732	|O
and	733	736	|O
whole	737	742	|O
-	742	743	|O
cell	743	747	|O
patch	748	753	|O
-	753	754	|O
clamp	754	759	|O
techniques	760	770	|O
,	770	771	|O
the	772	775	|O
efficacies	776	786	|O
of	787	789	|O
these	790	795	|O
compounds	796	805	|O
relative	806	814	|O
to	815	817	|O
that	818	822	|O
of	823	825	|O
the	826	829	|O
full	830	834	|O
GABAA	835	840	|O
agonist	841	848	|O
,	848	849	|O
isoguvacine	850	861	|O
(	862	863	|O
8	863	864	|O
)	864	865	|O
(	866	867	|O
20	867	869	|O
microM	870	876	|O
)	876	877	|O
,	877	878	|O
were	879	883	|O
determined	884	894	|O
.	894	895	|O
The	896	899	|O
relative	900	908	|O
efficacy	909	917	|O
of	918	920	|O
11	921	923	|O
,	923	924	|O
which	925	930	|O
has	931	934	|O
a	935	936	|O
higher	937	943	|O
receptor	944	952	|O
affinity	953	961	|O
(	962	963	|O
IC50	963	967	|O
=	968	969	|O
1.3	970	973	|O
+	974	975	|O
/	975	976	|O
-	976	977	|O
0.3	978	981	|O
microM	982	988	|O
)	988	989	|O
than	990	994	|O
10	995	997	|O
(	998	999	|O
IC50	999	1003	|O
=	1004	1005	|O
9.3	1006	1009	|O
+	1010	1011	|O
/	1011	1012	|O
-	1012	1013	|O
2.6	1014	1017	|O
microM	1018	1024	|O
)	1024	1025	|O
,	1025	1026	|O
was	1027	1030	|O
comparable	1031	1041	|O
with	1042	1046	|O
that	1047	1051	|O
of	1052	1054	|O
10	1055	1057	|O
(	1058	1059	|O
30-35%	1059	1065	|O
)	1065	1066	|O
.	1066	1067	|O
The	1068	1071	|O
tetrahydropyridine	1072	1090	|O
analog	1091	1097	|O
of	1098	1100	|O
10	1101	1103	|O
,	1103	1104	|O
compound	1105	1113	|O
13	1114	1116	|O
,	1116	1117	|O
showed	1118	1124	|O
a	1125	1126	|O
markedly	1127	1135	|O
lower	1136	1141	|O
receptor	1142	1150	|O
affinity	1151	1159	|O
(	1160	1161	|O
IC50	1161	1165	|O
=	1166	1167	|O
32	1168	1170	|O
+	1171	1172	|O
/	1172	1173	|O
-	1173	1174	|O
10	1175	1177	|O
microM	1178	1184	|O
)	1184	1185	|O
and	1186	1189	|O
apparently	1190	1200	|O
a	1201	1202	|O
lower	1203	1208	|O
relative	1209	1217	|O
efficacy	1218	1226	|O
than	1227	1231	|O
10	1232	1234	|O
.	1234	1235	|O
The	1236	1239	|O
corresponding	1240	1253	|O
unsaturated	1254	1265	|O
analog	1266	1272	|O
of	1273	1275	|O
11	1276	1278	|O
,	1278	1279	|O
compound	1280	1288	|O
14	1289	1291	|O
,	1291	1292	|O
showed	1293	1299	|O
a	1300	1301	|O
slightly	1302	1310	|O
weaker	1311	1317	|O
receptor	1318	1326	|O
affinity	1327	1335	|O
(	1336	1337	|O
IC50	1337	1341	|O
=	1342	1343	|O
4.0	1344	1347	|O
+	1348	1349	|O
/	1349	1350	|O
-	1350	1351	|O
2.0	1352	1355	|O
microM	1356	1362	|O
)	1362	1363	|O
but	1364	1367	|O
a	1368	1369	|O
significantly	1370	1383	|O
higher	1384	1390	|O
relative	1391	1399	|O
efficacy	1400	1408	|O
(	1409	1410	|O
50-55%	1410	1416	|O
)	1416	1417	|O
than	1418	1422	|O
11	1423	1425	|O
.	1425	1426	|O
The	1427	1430	|O
5	1431	1432	|O
-	1432	1433	|O
isoxazolol	1433	1443	|O
isomer	1444	1450	|O
of	1451	1453	|O
10	1454	1456	|O
,	1456	1457	|O
compound	1458	1466	|O
12	1467	1469	|O
,	1469	1470	|O
showed	1471	1477	|O
a	1478	1479	|O
reduced	1480	1487	|O
receptor	1488	1496	|O
affinity	1497	1505	|O
(	1506	1507	|O
IC50	1507	1511	|O
=	1512	1513	|O
26	1514	1516	|O
+	1517	1518	|O
/	1518	1519	|O
-	1519	1520	|O
7	1521	1522	|O
microM	1523	1529	|O
)	1529	1530	|O
and	1531	1534	|O
a	1535	1536	|O
very	1537	1541	|O
low	1542	1545	|O
relative	1546	1554	|O
efficacy	1555	1563	|O
.	1563	1564	|O
Substitution	1565	1577	|O
of	1578	1580	|O
propanoic	1581	1590	|O
or	1591	1593	|O
propenoic	1594	1603	|O
acid	1604	1608	|O
moieties	1609	1617	|O
for	1618	1621	|O
the	1622	1625	|O
acidic	1626	1632	|O
heterocyclic	1633	1645	|O
units	1646	1651	|O
of	1652	1654	|O
these	1655	1660	|O
compounds	1661	1670	|O
gave	1671	1675	|O
the	1676	1679	|O
monocyclic	1680	1690	|O
amino	1691	1696	|O
acids	1697	1702	|O
15-18	1703	1708	|O
,	1708	1709	|O
which	1710	1715	|O
have	1716	1720	|O
very	1721	1725	|O
little	1726	1732	|O
or	1733	1735	|O
no	1736	1738	|O
affinity	1739	1747	|O
for	1748	1751	|O
GABAA	1752	1757	|O
receptor	1758	1766	|O
sites	1767	1772	|O
.	1772	1773	|O

### abstracts3469.txt
Continuing	0	10	|O
studies	11	18	|O
on	19	21	|O
the	22	25	|O
chemical	26	34	|O
modification	35	47	|O
of	48	50	|O
the	51	54	|O
previously	55	65	|O
reported	66	74	|O
novel	75	80	|O
tripeptide	81	91	|O
SP	92	94	|O
antagonist	95	105	|O
,	105	106	|O
N	107	108	|B-IUPAC
alpha	109	114	|I-IUPAC
-	114	115	|I-IUPAC
[	115	116	|I-IUPAC
N	116	117	|I-IUPAC
alpha	118	123	|I-IUPAC
-	123	124	|I-IUPAC
[	124	125	|I-IUPAC
N	125	126	|I-IUPAC
alpha	127	132	|I-IUPAC
-	132	133	|I-IUPAC
(	134	135	|I-IUPAC
tert	135	139	|I-IUPAC
-	139	140	|I-IUPAC
butyloxycarbonyl	140	156	|I-IUPAC
)	156	157	|I-IUPAC
glutaminyl	157	167	|I-IUPAC
]	167	168	|I-IUPAC
-	168	169	|I-IUPAC
N1	169	171	|I-IUPAC
-	171	172	|I-IUPAC
formyl	172	178	|I-IUPAC
-	178	179	|I-IUPAC
D	179	180	|I-IUPAC
-	180	181	|I-IUPAC
tryptophyl	181	191	|I-IUPAC
]	191	192	|I-IUPAC
phenylalanine	192	205	|I-IUPAC
benzyl	206	212	|I-IUPAC
ester	213	218	|I-IUPAC
[	219	220	|O
Boc	220	223	|O
-	223	224	|O
Gln	224	227	|O
-	227	228	|O
D	228	229	|O
-	229	230	|O
Trp	230	233	|O
-	233	234	|O
(	234	235	|O
CHO	235	238	|O
)	238	239	|O
-	239	240	|O
Phe	240	243	|O
-	243	244	|O
OBzl	244	248	|O
(	249	250	|O
1	250	251	|O
)	251	252	|O
]	252	253	|O
,	253	254	|O
are	255	258	|O
described	259	268	|O
herein	269	275	|O
.	275	276	|O
We	277	279	|O
initially	280	289	|O
investigated	290	302	|O
the	303	306	|O
stability	307	316	|O
of	317	319	|O
1	320	321	|O
in	322	324	|O
guinea	325	331	|O
pig	332	335	|O
plasma	336	342	|O
and	343	346	|O
liver	347	352	|O
homogenate	353	363	|O
to	364	366	|O
elucidate	367	376	|O
the	377	380	|O
most	381	385	|O
labile	386	392	|O
part	393	397	|O
in	398	400	|O
the	401	404	|O
structure	405	414	|O
.	414	415	|O
It	416	418	|O
was	419	422	|O
consequently	423	435	|O
revealed	436	444	|O
that	445	449	|O
the	450	453	|O
benzyl	454	460	|O
ester	461	466	|O
part	467	471	|O
was	472	475	|O
easily	476	482	|O
hydrolyzed	483	493	|O
to	494	496	|O
produce	497	504	|O
the	505	508	|O
inactive	509	517	|O
acid	518	522	|O
analog	523	529	|O
.	529	530	|O
Thus	531	535	|O
we	536	538	|O
searched	539	547	|O
for	548	551	|O
a	552	553	|O
benzyl	554	560	|O
ester	561	566	|O
surrogate	567	576	|O
that	577	581	|O
would	582	587	|O
be	588	590	|O
more	591	595	|O
resistant	596	605	|O
to	606	608	|O
hydrolytic	609	619	|O
enzymes	620	627	|O
.	627	628	|O
This	629	633	|O
approach	634	642	|O
found	643	648	|O
an	649	651	|O
isosteric	652	661	|O
amide	662	667	|O
structure	668	677	|O
,	677	678	|O
N	679	680	|B-IUPAC
-	680	681	|I-IUPAC
methyl	681	687	|I-IUPAC
-	687	688	|I-IUPAC
N	688	689	|I-IUPAC
-	689	690	|I-IUPAC
(	690	691	|I-IUPAC
phenylmethyl	691	703	|I-IUPAC
)	703	704	|I-IUPAC
amide	704	709	|I-IUPAC
,	709	710	|O
suitable	711	719	|O
in	720	722	|O
terms	723	728	|O
of	729	731	|O
potency	732	739	|O
and	740	743	|O
stability	744	753	|O
.	753	754	|O
Subsequent	755	765	|O
modification	766	778	|O
of	779	781	|O
the	782	785	|O
amino	786	791	|O
terminal	792	800	|O
into	801	805	|O
N	806	807	|B-IUPAC
alpha	808	813	|I-IUPAC
-	813	814	|I-IUPAC
acetyl	814	820	|I-IUPAC
-	820	821	|I-IUPAC
L	821	822	|I-IUPAC
-	822	823	|I-IUPAC
threonine	823	832	|I-IUPAC
led	833	836	|O
to	837	839	|O
the	840	843	|O
most	844	848	|O
potent	849	855	|O
compound	856	864	|O
,	864	865	|O
N	866	867	|B-IUPAC
alpha	868	873	|I-IUPAC
-	873	874	|I-IUPAC
[	874	875	|I-IUPAC
N	875	876	|I-IUPAC
alpha	877	882	|I-IUPAC
-	882	883	|I-IUPAC
(	883	884	|I-IUPAC
N	884	885	|I-IUPAC
alpha	886	891	|I-IUPAC
-	891	892	|I-IUPAC
acetyl	892	898	|I-IUPAC
-	898	899	|I-IUPAC
L	899	900	|I-IUPAC
-	900	901	|I-IUPAC
threonyl	901	909	|I-IUPAC
)	909	910	|I-IUPAC
-	910	911	|I-IUPAC
N1	911	913	|I-IUPAC
-	913	914	|I-IUPAC
formyl	914	920	|I-IUPAC
-	920	921	|I-IUPAC
D	921	922	|I-IUPAC
-	922	923	|I-IUPAC
tryptophyl	923	933	|I-IUPAC
]	933	934	|I-IUPAC
-	934	935	|I-IUPAC
N	935	936	|I-IUPAC
-	936	937	|I-IUPAC
methyl	938	944	|I-IUPAC
-	944	945	|I-IUPAC
N	945	946	|I-IUPAC
-	946	947	|I-IUPAC
(	947	948	|I-IUPAC
phenylmethyl	948	960	|I-IUPAC
)	960	961	|I-IUPAC
-	961	962	|I-IUPAC
L	962	963	|I-IUPAC
-	963	964	|I-IUPAC
phenylalaninamide	964	981	|I-IUPAC
[	982	983	|O
Ac	983	985	|O
-	985	986	|O
Thr	986	989	|O
-	989	990	|O
D	990	991	|O
-	991	992	|O
Trp	992	995	|O
(	995	996	|O
CHO	996	999	|O
)	999	1000	|O
-	1000	1001	|O
Phe	1001	1004	|O
-	1004	1005	|O
NMeBzl	1005	1011	|O
(	1012	1013	|O
5a	1013	1015	|O
,	1015	1016	|O
FR113680	1017	1025	|O
)	1025	1026	|O
]	1026	1027	|O
.	1027	1028	|O
This	1029	1033	|O
compound	1034	1042	|O
5a	1043	1045	|O
potently	1046	1054	|O
blocked	1055	1062	|O
3H	1063	1065	|O
-	1065	1066	|O
SP	1066	1068	|O
binding	1069	1076	|O
to	1077	1079	|O
guinea	1080	1086	|O
pig	1087	1090	|O
lung	1091	1095	|O
membranes	1096	1105	|O
with	1106	1110	|O
IC50	1111	1115	|O
of	1116	1118	|O
(	1119	1120	|O
5.8	1120	1123	|O
+	1124	1125	|O
/	1125	1126	|O
-	1126	1127	|O
0.78	1128	1132	|O
)	1132	1133	|O
x	1134	1135	|O
10	1136	1138	|O
(	1138	1139	|O
-	1139	1140	|O
9	1140	1141	|O
)	1141	1142	|O
M	1143	1144	|O
.	1144	1145	|O
In	1146	1148	|O
vitro	1149	1154	|O
,	1154	1155	|O
5a	1156	1158	|O
inhibited	1159	1168	|O
SP	1169	1171	|O
-	1171	1172	|O
induced	1172	1179	|O
contraction	1180	1191	|O
of	1192	1194	|O
isolated	1195	1203	|O
guinea	1204	1210	|O
pig	1211	1214	|O
trachea	1215	1222	|O
strips	1223	1229	|O
with	1230	1234	|O
IC50	1235	1239	|O
of	1240	1242	|O
2.3	1243	1246	|O
x	1247	1248	|O
10	1249	1251	|O
(	1251	1252	|O
-	1252	1253	|O
6	1253	1254	|O
)	1254	1255	|O
M	1256	1257	|O
and	1258	1261	|O
caused	1262	1268	|O
no	1269	1271	|O
contraction	1272	1283	|O
when	1284	1288	|O
used	1289	1293	|O
alone	1294	1299	|O
in	1300	1302	|O
this	1303	1307	|O
preparation	1308	1319	|O
up	1320	1322	|O
to	1323	1325	|O
3.2	1326	1329	|O
x	1330	1331	|O
10	1332	1334	|O
(	1334	1335	|O
-	1335	1336	|O
5	1336	1337	|O
)	1337	1338	|O
M	1339	1340	|O
.	1340	1341	|O
In	1342	1344	|O
addition	1345	1353	|O
5a	1354	1356	|O
exhibited	1357	1366	|O
no	1367	1369	|O
effect	1370	1376	|O
on	1377	1379	|O
the	1380	1383	|O
contraction	1384	1395	|O
induced	1396	1403	|O
by	1404	1406	|O
histamine	1407	1416	|O
or	1417	1419	|O
acetylcholine	1420	1433	|O
.	1433	1434	|O
Intriguingly	1435	1447	|O
,	1447	1448	|O
it	1449	1451	|O
was	1452	1455	|O
demonstrated	1456	1468	|O
in	1469	1471	|O
vivo	1472	1476	|O
that	1477	1481	|O
5a	1482	1484	|O
suppressed	1485	1495	|O
the	1496	1499	|O
SP	1500	1502	|O
-	1502	1503	|O
induced	1503	1510	|O
bronchoconstriction	1511	1530	|O
and	1531	1534	|O
airway	1535	1541	|O
edema	1542	1547	|O
in	1548	1550	|O
guinea	1551	1557	|O
pigs	1558	1562	|O
with	1563	1567	|O
ED50	1568	1572	|O
of	1573	1575	|O
0.42	1576	1580	|O
mg	1581	1583	|O
/	1583	1584	|O
kg	1584	1586	|O
and	1587	1590	|O
0.66	1591	1595	|O
mg	1596	1598	|O
/	1598	1599	|O
kg	1599	1601	|O
,	1601	1602	|O
respectively	1603	1615	|O
,	1615	1616	|O
when	1617	1621	|O
administered	1622	1634	|O
intravenously	1635	1648	|O
.	1648	1649	|O

### abstracts1409.txt
Piperidine	0	10	|O
and	11	14	|O
cyclohexyl	15	25	|O
ring	26	30	|O
homologues	31	41	|O
of	42	44	|O
the	45	48	|O
high	49	53	|O
-	53	54	|O
affinity	54	62	|O
dopamine	63	71	|O
(	72	73	|O
DA	73	75	|O
)	75	76	|O
uptake	77	83	|O
inhibitor	84	93	|O
1	94	95	|B-IUPAC
-	95	96	|I-IUPAC
[	96	97	|I-IUPAC
1	97	98	|I-IUPAC
-	98	99	|I-IUPAC
(	99	100	|I-IUPAC
2	100	101	|I-IUPAC
-	101	102	|I-IUPAC
benzo	102	107	|I-IUPAC
[	107	108	|I-IUPAC
b	108	109	|I-IUPAC
]	109	110	|I-IUPAC
thienyl	110	117	|I-IUPAC
)	117	118	|I-IUPAC
cyclohexyl	118	128	|I-IUPAC
]	128	129	|I-IUPAC
piperidine	129	139	|I-IUPAC
(	140	141	|O
BTCP	141	145	|O
,	145	146	|O
3	147	148	|O
)	148	149	|O
were	150	154	|O
each	155	159	|O
prepared	160	168	|O
in	169	171	|O
four	172	176	|O
steps	177	182	|O
from	183	187	|O
the	188	191	|O
appropriate	192	203	|O
cycloalkanones	204	218	|O
.	218	219	|O
These	220	225	|O
compounds	226	235	|O
were	236	240	|O
tested	241	247	|O
for	248	251	|O
their	252	257	|O
ability	258	265	|O
to	266	268	|O
displace	269	277	|O
[	278	279	|O
3H	279	281	|O
]	281	282	|O
BTCP	282	286	|O
and	287	290	|O
[	291	292	|O
3H	292	294	|O
]	294	295	|O
cocaine	295	302	|O
and	303	306	|O
to	307	309	|O
inhibit	310	317	|O
[	318	319	|O
3H	319	321	|O
]	321	322	|O
DA	322	324	|O
uptake	325	331	|O
in	332	334	|O
rat	335	338	|O
striatal	339	347	|O
homogenates	348	359	|O
.	359	360	|O
The	361	364	|O
ratios	365	371	|O
IC50	372	376	|O
(	376	377	|O
[	377	378	|O
3H	378	380	|O
]	380	381	|O
cocaine	381	388	|O
)	388	389	|O
/	389	390	|O
IC50	390	394	|O
(	394	395	|O
[	395	396	|O
3H	396	398	|O
]	398	399	|O
BTCP	399	403	|O
)	403	404	|O
ranged	405	411	|O
from	412	416	|O
62	417	419	|O
for	420	423	|O
BTCP	424	428	|O
to	429	431	|O
1.5	432	435	|O
for	436	439	|O
1	440	441	|B-IUPAC
-	441	442	|I-IUPAC
[	442	443	|I-IUPAC
2	443	444	|I-IUPAC
-	444	445	|I-IUPAC
(	445	446	|I-IUPAC
benzo	446	451	|I-IUPAC
[	451	452	|I-IUPAC
b	452	453	|I-IUPAC
]	453	454	|I-IUPAC
thienyl	454	461	|I-IUPAC
)	461	462	|I-IUPAC
-	462	463	|I-IUPAC
cyclopentylamine	463	479	|I-IUPAC
(	480	481	|O
17	481	483	|O
)	483	484	|O
;	484	485	|O
cocaine	486	493	|O
gave	494	498	|O
a	499	500	|O
ratio	501	506	|O
of	507	509	|O
0.6	510	513	|O
.	513	514	|O
This	515	519	|O
indicates	520	529	|O
that	530	534	|O
BTCP	535	539	|O
is	540	542	|O
the	543	546	|O
most	547	551	|O
selective	552	561	|O
of	562	564	|O
all	565	568	|O
the	569	572	|O
compounds	573	582	|O
tested	583	589	|O
for	590	593	|O
sites	594	599	|O
labeled	600	607	|O
by	608	610	|O
[	611	612	|O
3H	612	614	|O
]	614	615	|O
BTCP	615	619	|O
whereas	620	627	|O
cocaine	628	635	|O
is	636	638	|O
most	639	643	|O
selective	644	653	|O
for	654	657	|O
sites	658	663	|O
labeled	664	671	|O
by	672	674	|O
[	675	676	|O
3H	676	678	|O
]	678	679	|O
cocaine	679	686	|O
.	686	687	|O
The	688	691	|O
wide	692	696	|O
differences	697	708	|O
in	709	711	|O
the	712	715	|O
relative	716	724	|O
abilities	725	734	|O
of	735	737	|O
these	738	743	|O
compounds	744	753	|O
to	754	756	|O
displace	757	765	|O
[	766	767	|O
3H	767	769	|O
]	769	770	|O
BTCP	770	774	|O
and	775	778	|O
[	779	780	|O
3H	780	782	|O
]	782	783	|O
cocaine	783	790	|O
suggests	791	799	|O
that	800	804	|O
these	805	810	|O
two	811	814	|O
radioligands	815	827	|O
are	828	831	|O
labeling	832	840	|O
different	841	850	|O
sites	851	856	|O
on	857	859	|O
the	860	863	|O
transporter	864	875	|O
.	875	876	|O
In	877	879	|O
general	880	887	|O
,	887	888	|O
the	889	892	|O
compounds	893	902	|O
structurally	903	915	|O
related	916	923	|O
to	924	926	|O
BTCP	927	931	|O
exhibited	932	941	|O
greater	942	949	|O
selectivity	950	961	|O
for	962	965	|O
sites	966	971	|O
labeled	972	979	|O
by	980	982	|O
[	983	984	|O
3H	984	986	|O
]	986	987	|O
BTCP	987	991	|O
.	991	992	|O
However	993	1000	|O
,	1000	1001	|O
several	1002	1009	|O
of	1010	1012	|O
the	1013	1016	|O
BTCP	1017	1021	|O
-	1021	1022	|O
related	1022	1029	|O
derivatives	1030	1041	|O
showed	1042	1048	|O
greater	1049	1056	|O
(	1057	1058	|O
compared	1058	1066	|O
with	1067	1071	|O
BTCP	1072	1076	|O
and	1077	1080	|O
cocaine	1081	1088	|O
)	1088	1089	|O
ability	1090	1097	|O
to	1098	1100	|O
displace	1101	1109	|O
[	1110	1111	|O
3H	1111	1113	|O
]	1113	1114	|O
cocaine	1114	1121	|O
.	1121	1122	|O
Most	1123	1127	|O
notably	1128	1135	|O
,	1135	1136	|O
1	1137	1138	|B-IUPAC
-	1138	1139	|I-IUPAC
[	1139	1140	|I-IUPAC
1	1140	1141	|I-IUPAC
-	1141	1142	|I-IUPAC
(	1142	1143	|I-IUPAC
2	1143	1144	|I-IUPAC
-	1144	1145	|I-IUPAC
benzo	1145	1150	|I-IUPAC
[	1150	1151	|I-IUPAC
b	1151	1152	|I-IUPAC
]	1152	1153	|I-IUPAC
thienyl	1153	1160	|I-IUPAC
)	1160	1161	|I-IUPAC
cyclohexyl	1161	1171	|I-IUPAC
]	1171	1172	|I-IUPAC
pyrrolidine	1172	1183	|I-IUPAC
(	1184	1185	|O
7	1185	1186	|O
)	1186	1187	|O
exhibited	1188	1197	|O
a	1198	1199	|O
3.4	1200	1203	|O
-	1203	1204	|O
fold	1204	1208	|O
greater	1209	1216	|O
affinity	1217	1225	|O
for	1226	1229	|O
these	1230	1235	|O
sites	1236	1241	|O
compared	1242	1250	|O
with	1251	1255	|O
BTCP	1256	1260	|O
and	1261	1264	|O
a	1265	1266	|O
9	1267	1268	|O
-	1268	1269	|O
fold	1269	1273	|O
greater	1274	1281	|O
affinity	1282	1290	|O
at	1291	1293	|O
these	1294	1299	|O
sites	1300	1305	|O
than	1306	1310	|O
cocaine	1311	1318	|O
.	1318	1319	|O
Most	1320	1324	|O
of	1325	1327	|O
the	1328	1331	|O
BTCP	1332	1336	|O
homologues	1337	1347	|O
displayed	1348	1357	|O
greater	1358	1365	|O
ability	1366	1373	|O
to	1374	1376	|O
inhibit	1377	1384	|O
[	1385	1386	|O
3H	1386	1388	|O
]	1388	1389	|O
DA	1389	1391	|O
uptake	1392	1398	|O
in	1399	1401	|O
rat	1402	1405	|O
forebrain	1406	1415	|O
synaptosomes	1416	1428	|O
than	1429	1433	|O
cocaine	1434	1441	|O
.	1441	1442	|O
BTCP	1443	1447	|O
and	1448	1451	|O
7	1452	1453	|O
were	1454	1458	|O
the	1459	1462	|O
most	1463	1467	|O
potent	1468	1474	|O
of	1475	1477	|O
all	1478	1481	|O
the	1482	1485	|O
compounds	1486	1495	|O
tested	1496	1502	|O
in	1503	1505	|O
terms	1506	1511	|O
of	1512	1514	|O
their	1515	1520	|O
ability	1521	1528	|O
to	1529	1531	|O
inhibit	1532	1539	|O
uptake	1540	1546	|O
of	1547	1549	|O
[	1550	1551	|O
3H	1551	1553	|O
]	1553	1554	|O
DA	1554	1556	|O
.	1556	1557	|O
IC50	1558	1562	|O
ratios	1563	1569	|O
for	1570	1573	|O
[	1574	1575	|O
3H	1575	1577	|O
]	1577	1578	|O
cocaine	1578	1585	|O
binding	1586	1593	|O
/	1593	1594	|O
[	1594	1595	|O
3H	1595	1597	|O
]	1597	1598	|O
DA	1598	1600	|O
uptake	1601	1607	|O
ranged	1608	1614	|O
from	1615	1619	|O
0.47	1620	1624	|O
for	1625	1628	|O
1	1629	1630	|B-IUPAC
-	1630	1631	|I-IUPAC
[	1631	1632	|I-IUPAC
1	1632	1633	|I-IUPAC
-	1633	1634	|I-IUPAC
(	1634	1635	|I-IUPAC
2	1635	1636	|I-IUPAC
-	1636	1637	|I-IUPAC
benzo	1637	1642	|I-IUPAC
[	1642	1643	|I-IUPAC
b	1643	1644	|I-IUPAC
]	1644	1645	|I-IUPAC
thienyl	1645	1652	|I-IUPAC
)	1652	1653	|I-IUPAC
cyclopentyl	1653	1664	|I-IUPAC
]	1664	1665	|I-IUPAC
homopiperidine	1665	1679	|I-IUPAC
(	1680	1681	|O
11	1681	1683	|O
)	1683	1684	|O
to	1685	1687	|O
8.8	1688	1691	|O
for	1692	1695	|O
1	1696	1697	|B-IUPAC
-	1697	1698	|I-IUPAC
(	1698	1699	|I-IUPAC
2	1699	1700	|I-IUPAC
-	1700	1701	|I-IUPAC
benzo	1701	1706	|I-IUPAC
[	1706	1707	|I-IUPAC
b	1707	1708	|I-IUPAC
]	1708	1709	|I-IUPAC
thienyl	1709	1716	|I-IUPAC
)	1716	1717	|I-IUPAC
cyclohexylamine	1717	1732	|I-IUPAC
(	1733	1734	|O
4	1734	1735	|O
)	1735	1736	|O
.	1736	1737	|O
The	1738	1741	|O
importance	1742	1752	|O
of	1753	1755	|O
this	1756	1760	|O
ratio	1761	1766	|O
remains	1767	1774	|O
unclear	1775	1782	|O
in	1783	1785	|O
terms	1786	1791	|O
of	1792	1794	|O
identification	1795	1809	|O
of	1810	1812	|O
potential	1813	1822	|O
cocaine	1823	1830	|O
antagonists	1831	1842	|O
.	1842	1843	|O
As	1844	1846	|O
for	1847	1850	|O
BTCP	1851	1855	|O
,	1855	1856	|O
all	1857	1860	|O
of	1861	1863	|O
the	1864	1867	|O
compounds	1868	1877	|O
tested	1878	1884	|O
showed	1885	1891	|O
Ki	1892	1894	|O
values	1895	1901	|O
&	1902	1903	|O
gt	1903	1905	|O
;	1905	1906	|O
10,000	1907	1913	|O
nM	1914	1916	|O
for	1917	1920	|O
displacement	1921	1933	|O
of	1934	1936	|O
[	1937	1938	|O
3H	1938	1940	|O
]	1940	1941	|O
TCP	1941	1944	|O
from	1945	1949	|O
rat	1950	1953	|O
brain	1954	1959	|O
homogenates	1960	1971	|O
.	1971	1972	|O
These	1973	1978	|O
compounds	1979	1988	|O
were	1989	1993	|O
able	1994	1998	|O
to	1999	2001	|O
displace	2002	2010	|O
the	2011	2014	|O
highly	2015	2021	|O
selective	2022	2031	|O
sigma	2032	2037	|O
receptor	2038	2046	|O
probe	2047	2052	|O
[	2053	2054	|B-IUPAC
3H	2054	2056	|I-IUPAC
]	2056	2057	|I-IUPAC
-	2057	2058	|I-IUPAC
(	2058	2059	|I-IUPAC
+	2059	2060	|I-IUPAC
)	2060	2061	|I-IUPAC
-	2061	2062	|I-IUPAC
pentazocine	2062	2073	|I-IUPAC
from	2074	2078	|O
guinea	2079	2085	|O
pig	2086	2089	|O
brain	2090	2095	|O
homogenates	2096	2107	|O
with	2108	2112	|O
Ki	2113	2115	|O
values	2116	2122	|O
ranging	2123	2130	|O
from	2131	2135	|O
125	2136	2139	|O
to	2140	2142	|O
9170	2143	2147	|O
nM	2148	2150	|O
.	2150	2151	|O
The	2152	2155	|O
significance	2156	2168	|O
of	2169	2171	|O
their	2172	2177	|O
sigma	2178	2183	|O
-	2183	2184	|O
binding	2184	2191	|O
activity	2192	2200	|O
in	2201	2203	|O
light	2204	2209	|O
of	2210	2212	|O
their	2213	2218	|O
dopaminergic	2219	2231	|O
properties	2232	2242	|O
is	2243	2245	|O
unclear	2246	2253	|O
.	2253	2254	|O
The	2255	2258	|O
diverse	2259	2266	|O
binding	2267	2274	|O
properties	2275	2285	|O
of	2286	2288	|O
these	2289	2294	|O
compounds	2295	2304	|O
at	2305	2307	|O
the	2308	2311	|O
DA	2312	2314	|O
-	2314	2315	|O
uptake	2315	2321	|O
site	2322	2326	|O
and	2327	2330	|O
their	2331	2336	|O
spectrum	2337	2345	|O
of	2346	2348	|O
inhibitory	2349	2359	|O
activities	2360	2370	|O
for	2371	2374	|O
[	2375	2376	|O
3H	2376	2378	|O
]	2378	2379	|O
DA	2379	2381	|O
uptake	2382	2388	|O
identifies	2389	2399	|O
them	2400	2404	|O
as	2405	2407	|O
a	2408	2409	|O
useful	2410	2416	|O
base	2417	2421	|O
for	2422	2425	|O
the	2426	2429	|O
development	2430	2441	|O
of	2442	2444	|O
subtype	2445	2452	|O
selective	2453	2462	|O
probes	2463	2469	|O
at	2470	2472	|O
this	2473	2477	|O
site	2478	2482	|O
.	2482	2483	|O
These	2484	2489	|O
compounds	2490	2499	|O
will	2500	2504	|O
allow	2505	2510	|O
further	2511	2518	|O
study	2519	2524	|O
of	2525	2527	|O
the	2528	2531	|O
structure	2532	2541	|O
and	2542	2545	|O
function	2546	2554	|O
of	2555	2557	|O
the	2558	2561	|O
"	2562	2563	|O
cocaine	2563	2570	|O
"	2570	2571	|O
receptor	2572	2580	|O
as	2581	2583	|O
well	2584	2588	|O
as	2589	2591	|O
the	2592	2595	|O
development	2596	2607	|O
of	2608	2610	|O
potential	2611	2620	|O
cocaine	2621	2628	|O
antagonists	2629	2640	|O
.	2640	2641	|O

### abstracts1621.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
new	12	15	|O
enantiomerically	16	32	|O
pure	33	37	|O
3	38	39	|B-IUPAC
-	39	40	|I-IUPAC
amino	40	45	|I-IUPAC
-	45	46	|I-IUPAC
3,4	46	49	|I-IUPAC
-	49	50	|I-IUPAC
dihydro	50	57	|I-IUPAC
-	57	58	|I-IUPAC
2H	58	60	|I-IUPAC
-	60	61	|I-IUPAC
1	61	62	|I-IUPAC
-	62	63	|I-IUPAC
benzopyrans	63	74	|I-IUPAC
(	75	76	|O
3	76	77	|B-IUPAC
-	77	78	|I-IUPAC
aminochromans	78	91	|I-IUPAC
)	91	92	|O
has	93	96	|O
been	97	101	|O
synthesized	102	113	|O
from	114	118	|O
(	119	120	|B-PARTIUPAC
R	120	121	|I-PARTIUPAC
)	121	122	|I-PARTIUPAC
-	122	123	|I-PARTIUPAC
and	124	127	|O
(	128	129	|B-IUPAC
S	129	130	|I-IUPAC
)	130	131	|I-IUPAC
-	131	132	|I-IUPAC
5	132	133	|I-IUPAC
-	133	134	|I-IUPAC
methoxy	134	141	|I-IUPAC
-	141	142	|I-IUPAC
3	142	143	|I-IUPAC
-	143	144	|I-IUPAC
amino	144	149	|I-IUPAC
-	149	150	|I-IUPAC
3,4	150	153	|I-IUPAC
-	153	154	|I-IUPAC
dihydro	154	161	|I-IUPAC
-	161	162	|I-IUPAC
2H	162	164	|I-IUPAC
-	164	165	|I-IUPAC
1	165	166	|I-IUPAC
-	166	167	|I-IUPAC
benzopyran	167	177	|I-IUPAC
.	177	178	|O
The	179	182	|O
absolute	183	191	|O
configuration	192	205	|O
of	206	208	|O
the	209	212	|O
respective	213	223	|O
(	224	225	|O
R	225	226	|O
)	226	227	|O
-	227	228	|O
and	229	232	|O
(	233	234	|O
S	234	235	|O
)	235	236	|O
-	236	237	|O
enantiomers	237	248	|O
was	249	252	|O
deduced	253	260	|O
from	261	265	|O
X	266	267	|O
-	267	268	|O
ray	268	271	|O
crystallography	272	287	|O
of	288	290	|O
(	291	292	|B-IUPAC
R	292	293	|I-IUPAC
)	293	294	|I-IUPAC
-	294	295	|I-IUPAC
3	295	296	|I-IUPAC
-	296	297	|I-IUPAC
(	297	298	|I-IUPAC
N	298	299	|I-IUPAC
-	299	300	|I-IUPAC
isopropylamino	300	314	|I-IUPAC
)	314	315	|I-IUPAC
-	315	316	|I-IUPAC
5	316	317	|I-IUPAC
-	317	318	|I-IUPAC
methoxy	318	325	|I-IUPAC
-	325	326	|I-IUPAC
3,4	326	329	|I-IUPAC
-	329	330	|I-IUPAC
dihydro	330	337	|I-IUPAC
-	337	338	|I-IUPAC
2H	338	340	|I-IUPAC
-	340	341	|I-IUPAC
1	341	342	|I-IUPAC
-	342	343	|I-IUPAC
benzopyran	343	353	|I-IUPAC
,	353	354	|O
(	355	356	|O
R	356	357	|O
)	357	358	|O
-	358	359	|O
9a	359	361	|O
.	361	362	|O
Various	363	370	|O
5	371	372	|O
-	372	373	|O
substituents	373	385	|O
were	386	390	|O
introduced	391	401	|O
via	402	405	|O
palladium	406	415	|O
-	415	416	|O
catalyzed	416	425	|O
carbonylation	426	439	|O
of	440	442	|O
N	443	444	|B-MODIFIER
-	444	445	|I-MODIFIER
substituted	445	456	|I-MODIFIER
3	457	458	|B-IUPAC
-	458	459	|I-IUPAC
amino	459	464	|I-IUPAC
-	464	465	|I-IUPAC
5	465	466	|I-IUPAC
-	466	467	|I-IUPAC
trifluoromethanesulfonyloxy	467	494	|I-IUPAC
-	494	495	|I-IUPAC
3,4	495	498	|I-IUPAC
-	498	499	|I-IUPAC
dihydro	499	506	|I-IUPAC
-	506	507	|I-IUPAC
2H	507	509	|I-IUPAC
-	509	510	|I-IUPAC
1	510	511	|I-IUPAC
-	511	512	|I-IUPAC
benzopyran	512	522	|I-IUPAC
.	522	523	|O
The	524	527	|O
effect	528	534	|O
of	535	537	|O
N	538	539	|O
-	539	540	|O
and	541	544	|O
5	545	546	|O
-	546	547	|O
substitution	547	559	|O
on	560	562	|O
affinity	563	571	|O
for	572	575	|O
the	576	579	|O
5	580	581	|O
-	581	582	|O
HT1A	582	586	|O
receptor	587	595	|O
was	596	599	|O
evaluated	600	609	|O
in	610	612	|O
competition	613	624	|O
experiments	625	636	|O
using	637	642	|O
rat	643	646	|O
hippocampal	647	658	|O
membranes	659	668	|O
and	669	672	|O
[	673	674	|O
3H	674	676	|O
]	676	677	|O
8	677	678	|O
-	678	679	|O
OH	679	681	|O
-	681	682	|O
DPAT	682	686	|O
as	687	689	|O
radioligand	690	701	|O
.	701	702	|O
Selected	703	711	|O
compounds	712	721	|O
were	722	726	|O
also	727	731	|O
tested	732	738	|O
for	739	742	|O
their	743	748	|O
affinity	749	757	|O
to	758	760	|O
the	761	764	|O
D1	765	767	|O
(	768	769	|O
rat	769	772	|O
striatum	773	781	|O
)	781	782	|O
,	782	783	|O
D2	784	786	|O
(	787	788	|O
rat	788	791	|O
striatum	792	800	|O
)	800	801	|O
,	801	802	|O
D2A	803	806	|O
(	807	808	|O
human	808	813	|O
cloned	814	820	|O
)	820	821	|O
,	821	822	|O
and	823	826	|O
5	827	828	|O
-	828	829	|O
HT2A	829	833	|O
(	834	835	|O
rat	835	838	|O
cortex	839	845	|O
)	845	846	|O
receptors	847	856	|O
.	856	857	|O
The	858	861	|O
intrinsic	862	871	|O
activity	872	880	|O
of	881	883	|O
the	884	887	|O
compounds	888	897	|O
was	898	901	|O
evaluated	902	911	|O
by	912	914	|O
measuring	915	924	|O
their	925	930	|O
effect	931	937	|O
on	938	940	|O
VIP	941	944	|O
-	944	945	|O
stimulated	945	955	|O
cAMP	956	960	|O
production	961	971	|O
in	972	974	|O
GH4ZD10	975	982	|O
cells	983	988	|O
stably	989	995	|O
transfected	996	1007	|O
with	1008	1012	|O
the	1013	1016	|O
5	1017	1018	|O
-	1018	1019	|O
HT1A	1019	1023	|O
receptor	1024	1032	|O
.	1032	1033	|O
High	1034	1038	|O
-	1038	1039	|O
affinity	1039	1047	|O
compounds	1048	1057	|O
with	1058	1062	|O
high	1063	1067	|O
selectivity	1068	1079	|O
for	1080	1083	|O
the	1084	1087	|O
5	1088	1089	|O
-	1089	1090	|O
HT1A	1090	1094	|O
receptor	1095	1103	|O
were	1104	1108	|O
found	1109	1114	|O
among	1115	1120	|O
structures	1121	1131	|O
substituted	1132	1143	|O
with	1144	1148	|O
carboxylate	1149	1160	|O
esters	1161	1167	|O
,	1167	1168	|O
amides	1169	1175	|O
,	1175	1176	|O
and	1177	1180	|O
ketones	1181	1188	|O
in	1189	1191	|O
the	1192	1195	|O
5	1196	1197	|O
-	1197	1198	|O
position	1198	1206	|O
.	1206	1207	|O
Primary	1208	1215	|O
and	1216	1219	|O
secondary	1220	1229	|O
amines	1230	1236	|O
bound	1237	1242	|O
with	1243	1247	|O
lower	1248	1253	|O
affinity	1254	1262	|O
than	1263	1267	|O
tertiary	1268	1276	|O
amines	1277	1283	|O
.	1283	1284	|O
Larger	1285	1291	|O
substituents	1292	1304	|O
were	1305	1309	|O
well	1310	1314	|O
-	1314	1315	|O
tolerated	1315	1324	|O
by	1325	1327	|O
the	1328	1331	|O
receptor	1332	1340	|O
,	1340	1341	|O
but	1342	1345	|O
the	1346	1349	|O
smaller	1350	1357	|O
N	1358	1359	|B-IUPAC
-	1359	1360	|I-IUPAC
ethyl	1360	1365	|I-IUPAC
-	1365	1366	|I-IUPAC
N	1366	1367	|I-IUPAC
-	1367	1368	|I-IUPAC
isopropyl	1368	1377	|I-IUPAC
bound	1378	1383	|B-MODIFIER
with	1384	1388	|O
lower	1389	1394	|O
affinity	1395	1403	|O
.	1403	1404	|O
Generally	1405	1414	|O
,	1414	1415	|O
the	1416	1419	|O
(	1420	1421	|O
R	1421	1422	|O
)	1422	1423	|O
-	1423	1424	|O
enantiomers	1424	1435	|O
displayed	1436	1445	|O
higher	1446	1452	|O
affinity	1453	1461	|O
for	1462	1465	|O
the	1466	1469	|O
5	1470	1471	|O
-	1471	1472	|O
HT1A	1472	1476	|O
receptor	1477	1485	|O
than	1486	1490	|O
the	1491	1494	|O
corresponding	1495	1508	|O
(	1509	1510	|O
S	1510	1511	|O
)	1511	1512	|O
-	1512	1513	|O
enantiomers	1513	1524	|O
.	1524	1525	|O
In	1526	1528	|O
the	1529	1532	|O
present	1533	1540	|O
series	1541	1547	|O
of	1548	1550	|O
compounds	1551	1560	|O
,	1560	1561	|O
both	1562	1566	|O
full	1567	1571	|O
and	1572	1575	|O
partial	1576	1583	|O
agonists	1584	1592	|O
were	1593	1597	|O
found	1598	1603	|O
.	1603	1604	|O

### abstracts2853.txt
3	0	1	|B-IUPAC
-	1	2	|I-IUPAC
Ethylaminomethyl	2	18	|I-IUPAC
-	18	19	|I-IUPAC
2	19	20	|I-IUPAC
-	20	21	|I-IUPAC
methyl	21	27	|I-IUPAC
-	27	28	|I-IUPAC
4	28	29	|I-IUPAC
(	29	30	|I-IUPAC
1H	30	32	|I-IUPAC
)	32	33	|I-IUPAC
-	33	34	|I-IUPAC
quinolone	34	43	|I-IUPAC
(	44	45	|O
1a	45	47	|O
)	47	48	|O
and	49	52	|O
its	53	56	|O
6	57	58	|O
-	58	59	|O
CH3	59	62	|O
,	62	63	|O
6	64	65	|O
-	65	66	|O
OCH3	66	70	|O
,	70	71	|O
and	72	75	|O
7	76	77	|O
-	77	78	|O
Cl	78	80	|O
derivatives	81	92	|O
were	93	97	|O
prepared	98	106	|O
by	107	109	|O
means	110	115	|O
of	116	118	|O
the	119	122	|O
Mannich	123	130	|O
reaction	131	139	|O
.	139	140	|O
Conversion	141	151	|O
to	152	154	|O
the	155	158	|O
4	159	160	|B-IUPAC
-	160	161	|I-IUPAC
chloro	161	167	|I-IUPAC
derivatives	168	179	|B-MODIFIER
and	180	183	|O
condensation	184	196	|O
with	197	201	|O
3	202	203	|B-IUPAC
-	203	204	|I-IUPAC
chloroaniline	204	217	|I-IUPAC
gave	218	222	|O
the	223	226	|O
corresponding	227	240	|O
4	241	242	|B-IUPAC
-	242	243	|I-IUPAC
(	243	244	|I-IUPAC
3	244	245	|I-IUPAC
-	245	246	|I-IUPAC
chloroanilino	246	259	|I-IUPAC
)	259	260	|I-IUPAC
derivatives	261	272	|B-MODIFIER
.	272	273	|O
Cyclization	274	285	|O
of	286	288	|O
4	289	290	|B-IUPAC
-	290	291	|I-IUPAC
(	291	292	|I-IUPAC
3	292	293	|I-IUPAC
-	293	294	|I-IUPAC
chloroanilino	294	307	|I-IUPAC
)	307	308	|I-IUPAC
-	308	309	|I-IUPAC
2,6	309	312	|I-IUPAC
-	312	313	|I-IUPAC
dimethyl	313	321	|I-IUPAC
-	321	322	|I-IUPAC
3	322	323	|I-IUPAC
-	323	324	|I-IUPAC
ethyl	324	329	|I-IUPAC
-	329	330	|I-IUPAC
aminomethylquinoline	330	350	|I-IUPAC
(	351	352	|O
3a	352	354	|O
)	354	355	|O
and	356	359	|O
its	360	363	|O
6	364	365	|O
-	365	366	|O
OCH3	366	370	|O
derivative	371	381	|O
with	382	386	|O
paraformaldehyde	387	403	|O
gave	404	408	|O
1	409	410	|B-IUPAC
-	410	411	|I-IUPAC
(	411	412	|I-IUPAC
3	412	413	|I-IUPAC
-	413	414	|I-IUPAC
chlorophenyl	414	426	|I-IUPAC
)	426	427	|I-IUPAC
-	427	428	|I-IUPAC
3,9	428	431	|I-IUPAC
-	431	432	|I-IUPAC
dimethyl	432	440	|I-IUPAC
-	440	441	|I-IUPAC
3	441	442	|I-IUPAC
-	442	443	|I-IUPAC
ethyltetrahydropyrimido	443	466	|I-IUPAC
[	466	467	|I-IUPAC
5,4	467	470	|I-IUPAC
-	470	471	|I-IUPAC
c	471	472	|I-IUPAC
]	472	473	|I-IUPAC
quinoline	473	482	|I-IUPAC
(	483	484	|O
4a	484	486	|O
)	486	487	|O
and	488	491	|O
the	492	495	|O
9	496	497	|O
-	497	498	|O
OCH3	498	502	|O
derivative	503	513	|O
4b	514	516	|O
.	516	517	|O
Treatment	518	527	|O
of	528	530	|O
4b	531	533	|O
with	534	538	|O
benzaldehyde	539	551	|B-IUPAC
gave	552	556	|O
1	557	558	|B-IUPAC
-	558	559	|I-IUPAC
(	559	560	|I-IUPAC
3	560	561	|I-IUPAC
-	561	562	|I-IUPAC
chlorophenyl	562	574	|I-IUPAC
)	574	575	|I-IUPAC
-	575	576	|I-IUPAC
3	576	577	|I-IUPAC
-	577	578	|I-IUPAC
ethyl	578	583	|I-IUPAC
-	583	584	|I-IUPAC
9	584	585	|I-IUPAC
-	585	586	|I-IUPAC
methoxy	586	593	|I-IUPAC
-	593	594	|I-IUPAC
5	594	595	|I-IUPAC
-	595	596	|I-IUPAC
styryltetrahydropyrimido	596	620	|I-IUPAC
[	620	621	|I-IUPAC
5,4	621	624	|I-IUPAC
-	624	625	|I-IUPAC
c	625	626	|I-IUPAC
]	626	627	|I-IUPAC
quinoline	627	636	|I-IUPAC
(	637	638	|O
5	638	639	|O
)	639	640	|O
.	640	641	|O
3	642	643	|B-IUPAC
-	643	644	|I-IUPAC
Benzylaminomethyl	644	661	|I-IUPAC
-	661	662	|I-IUPAC
6	662	663	|I-IUPAC
-	663	664	|I-IUPAC
methoxy	664	671	|I-IUPAC
-	671	672	|I-IUPAC
2	672	673	|I-IUPAC
-	673	674	|I-IUPAC
methyl	674	680	|I-IUPAC
-	680	681	|I-IUPAC
4	681	682	|I-IUPAC
(	682	683	|I-IUPAC
1H	683	685	|I-IUPAC
)	685	686	|I-IUPAC
-	686	687	|I-IUPAC
quinolone	687	696	|I-IUPAC
(	697	698	|O
1e	698	700	|O
)	700	701	|O
and	702	705	|O
3,3	706	709	|B-IUPAC
'	709	710	|I-IUPAC
-	710	711	|I-IUPAC
(	711	712	|I-IUPAC
1,3	712	715	|I-IUPAC
-	715	716	|I-IUPAC
benzyliminodimethylene	716	738	|I-IUPAC
)	738	739	|I-IUPAC
di	739	741	|I-IUPAC
[	741	742	|I-IUPAC
2	742	743	|I-IUPAC
-	743	744	|I-IUPAC
methyl	744	750	|I-IUPAC
-	750	751	|I-IUPAC
4	751	752	|I-IUPAC
(	752	753	|I-IUPAC
1H	753	755	|I-IUPAC
)	755	756	|I-IUPAC
-	756	757	|I-IUPAC
quinolone	757	766	|I-IUPAC
]	766	767	|I-IUPAC
(	768	769	|O
6b	769	771	|O
)	771	772	|O
were	773	777	|O
also	778	782	|O
synthesized	783	794	|O
.	794	795	|O
The	796	799	|O
compounds	800	809	|O
were	810	814	|O
inactive	815	823	|O
as	824	826	|O
antimalarials	827	840	|O
.	840	841	|O

### abstracts4917.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
1,1	12	15	|B-IUPAC
-	15	16	|I-IUPAC
dichloro	16	24	|I-IUPAC
-	24	25	|I-IUPAC
2,2,3	25	30	|I-IUPAC
-	30	31	|I-IUPAC
triarylcyclopropanes	31	51	|I-IUPAC
(	52	53	|O
DTACs	53	58	|O
)	58	59	|O
was	60	63	|O
synthesized	64	75	|O
and	76	79	|O
evaluated	80	89	|O
as	90	92	|O
pure	93	97	|O
antiestrogens	98	111	|O
.	111	112	|O
Addition	113	121	|O
of	122	124	|O
4	125	126	|B-PARTIUPAC
-	126	127	|I-PARTIUPAC
methoxy	127	134	|I-PARTIUPAC
-	134	135	|I-PARTIUPAC
or	136	138	|O
4	139	140	|B-IUPAC
-	140	141	|I-IUPAC
(	141	142	|I-IUPAC
benzyloxy	142	151	|I-IUPAC
)	151	152	|I-IUPAC
phenyl	152	158	|I-IUPAC
Grignard	159	167	|O
reagents	168	176	|O
to	177	179	|O
p	180	181	|B-IUPAC
-	181	182	|I-IUPAC
methoxy	182	189	|I-IUPAC
,	189	190	|O
p	191	192	|B-IUPAC
-	192	193	|I-IUPAC
benzyloxy	193	202	|I-IUPAC
,	202	203	|O
or	204	206	|O
unsubstituted	207	220	|O
deoxybenzoins	221	234	|O
,	234	235	|O
followed	236	244	|O
by	245	247	|O
dehydration	248	259	|O
of	260	262	|O
the	263	266	|O
resulting	267	276	|O
carbinols	277	286	|O
produced	287	295	|O
a	296	297	|O
mixture	298	305	|O
of	306	308	|O
E	309	310	|O
and	311	314	|O
Z	315	316	|O
olefins	317	324	|O
,	324	325	|O
which	326	331	|O
were	332	336	|O
reacted	337	344	|O
with	345	349	|O
dichlorocarbene	350	365	|O
to	366	368	|O
give	369	373	|O
O	374	375	|O
-	375	376	|O
protected	376	385	|O
DTACs	386	391	|O
.	391	392	|O
The	393	396	|O
E	397	398	|O
and	399	402	|O
Z	403	404	|O
isomers	405	412	|O
were	413	417	|O
separated	418	427	|O
by	428	430	|O
fractional	431	441	|O
crystallization	442	457	|O
and	458	461	|O
the	462	465	|O
central	466	473	|O
or	474	476	|O
geminal	477	484	|O
phenyl	485	491	|O
ring	492	496	|O
was	497	500	|O
deprotected	501	512	|O
to	513	515	|O
provide	516	523	|O
phenolic	524	532	|O
DTACs	533	538	|O
.	538	539	|O
Alkylation	540	550	|O
with	551	555	|O
(	556	557	|B-IUPAC
N	557	558	|I-IUPAC
,	558	559	|I-IUPAC
N	559	560	|I-IUPAC
-	560	561	|I-IUPAC
dimethylamino	561	574	|I-IUPAC
)	574	575	|I-IUPAC
ethyl	575	580	|I-IUPAC
chloride	581	589	|I-IUPAC
yielded	590	597	|O
basic	598	603	|O
cyclopropanes	604	617	|O
.	617	618	|O
Two	619	622	|O
chlorodiarylindenes	623	642	|O
were	643	647	|O
isolated	648	656	|O
as	657	659	|O
thermolysis	660	671	|O
products	672	680	|O
of	681	683	|O
the	684	687	|O
DTACs	688	693	|O
,	693	694	|O
and	695	698	|O
one	699	702	|O
was	703	706	|O
converted	707	716	|O
to	717	719	|O
a	720	721	|O
phenol	722	728	|O
by	729	731	|O
hydrogenolysis	732	746	|O
.	746	747	|O
All	748	751	|O
DTACs	752	757	|O
and	758	761	|O
indenes	762	769	|O
were	770	774	|O
competitive	775	786	|O
inhibitors	787	797	|O
of	798	800	|O
[	801	802	|O
3H	802	804	|O
]	804	805	|O
estradiol	805	814	|O
binding	815	822	|O
in	823	825	|O
the	826	829	|O
immature	830	838	|O
rat	839	842	|O
uterine	843	850	|O
cytosol	851	858	|O
receptor	859	867	|O
assay	868	873	|O
,	873	874	|O
with	875	879	|O
relative	880	888	|O
binding	889	896	|O
affinities	897	907	|O
of	908	910	|O
0.1-3.6%	911	919	|O
of	920	922	|O
estradiol	923	932	|O
.	932	933	|O
None	934	938	|O
of	939	941	|O
the	942	945	|O
new	946	949	|O
compounds	950	959	|O
were	960	964	|O
estrogenic	965	975	|O
in	976	978	|O
the	979	982	|O
3	983	984	|O
-	984	985	|O
day	985	988	|O
immature	989	997	|O
mouse	998	1003	|O
uterotrophic	1004	1016	|O
assay	1017	1022	|O
at	1023	1025	|O
doses	1026	1031	|O
up	1032	1034	|O
to	1035	1037	|O
750	1038	1041	|O
micrograms	1042	1052	|O
.	1052	1053	|O
In	1054	1056	|O
the	1057	1060	|O
3	1061	1062	|O
-	1062	1063	|O
day	1063	1066	|O
immature	1067	1075	|O
mouse	1076	1081	|O
antiuterotrophic	1082	1098	|O
assay	1099	1104	|O
,	1104	1105	|O
five	1106	1110	|O
DTACs	1111	1116	|O
with	1117	1121	|O
either	1122	1128	|O
a	1129	1130	|O
methoxy	1131	1138	|B-IUPAC
(	1139	1140	|O
5a	1140	1142	|O
)	1142	1143	|O
,	1143	1144	|O
benzyloxy	1145	1154	|B-IUPAC
(	1155	1156	|O
4d	1156	1158	|O
,	1158	1159	|O
5c	1160	1162	|O
)	1162	1163	|O
,	1163	1164	|O
or	1165	1167	|O
(	1168	1169	|B-IUPAC
dimethylamino	1169	1182	|I-IUPAC
)	1182	1183	|I-IUPAC
ethoxy	1183	1189	|I-IUPAC
(	1190	1191	|O
7a	1191	1193	|O
,	1193	1194	|O
7b	1195	1197	|O
)	1197	1198	|O
central	1199	1206	|O
ring	1207	1211	|O
side	1212	1216	|O
chain	1217	1222	|O
produced	1223	1231	|O
significant	1232	1243	|O
decreases	1244	1253	|O
in	1254	1256	|O
uterine	1257	1264	|O
weight	1265	1271	|O
at	1272	1274	|O
doses	1275	1280	|O
up	1281	1283	|O
to	1284	1286	|O
750	1287	1290	|O
micrograms	1291	1301	|O
.	1301	1302	|O
One	1303	1306	|O
compound	1307	1315	|O
,	1315	1316	|O
(	1317	1318	|B-IUPAC
Z	1318	1319	|I-IUPAC
)	1319	1320	|I-IUPAC
-	1320	1321	|I-IUPAC
1,1	1321	1324	|I-IUPAC
-	1324	1325	|I-IUPAC
dichloro	1325	1333	|I-IUPAC
-	1333	1334	|I-IUPAC
2	1334	1335	|I-IUPAC
-	1335	1336	|I-IUPAC
[	1336	1337	|I-IUPAC
4	1337	1338	|I-IUPAC
-	1338	1339	|I-IUPAC
[	1339	1340	|I-IUPAC
2	1340	1341	|I-IUPAC
-	1341	1342	|I-IUPAC
(	1342	1343	|I-IUPAC
dimethylamino	1343	1356	|I-IUPAC
)	1356	1357	|I-IUPAC
ethoxy	1357	1363	|I-IUPAC
]	1363	1364	|I-IUPAC
-	1364	1365	|I-IUPAC
phenyl	1365	1371	|I-IUPAC
]	1371	1372	|I-IUPAC
-	1372	1373	|I-IUPAC
2	1373	1374	|I-IUPAC
-	1374	1375	|I-IUPAC
(	1375	1376	|I-IUPAC
4	1376	1377	|I-IUPAC
-	1377	1378	|I-IUPAC
methoxyphenyl	1379	1392	|I-IUPAC
)	1392	1393	|I-IUPAC
-	1393	1394	|I-IUPAC
3	1394	1395	|I-IUPAC
-	1395	1396	|I-IUPAC
phenylcyclopropane	1396	1414	|I-IUPAC
(	1415	1416	|O
7b	1416	1418	|O
)	1418	1419	|O
,	1419	1420	|O
elicited	1421	1429	|O
a	1430	1431	|O
dose	1432	1436	|O
-	1436	1437	|O
dependent	1437	1446	|O
decrease	1447	1455	|O
in	1456	1458	|O
vivo	1459	1463	|O
comparable	1464	1474	|O
to	1475	1477	|O
MER	1478	1481	|O
25	1482	1484	|O
.	1484	1485	|O
These	1486	1491	|O
same	1492	1496	|O
five	1497	1501	|O
compounds	1502	1511	|O
,	1511	1512	|O
as	1513	1515	|O
well	1516	1520	|O
as	1521	1523	|O
the	1524	1527	|O
lead	1528	1532	|O
compound	1533	1541	|O
Analog	1542	1548	|O
II	1549	1551	|O
,	1551	1552	|O
were	1553	1557	|O
active	1558	1564	|O
in	1565	1567	|O
vitro	1568	1573	|O
against	1574	1581	|O
the	1582	1585	|O
estrogen	1586	1594	|O
-	1594	1595	|O
dependent	1595	1604	|O
MCF	1605	1608	|O
-	1608	1609	|O
7	1609	1610	|O
human	1611	1616	|O
breast	1617	1623	|O
tumor	1624	1629	|O
cell	1630	1634	|O
line	1635	1639	|O
in	1640	1642	|O
a	1643	1644	|O
dose	1645	1649	|O
-	1649	1650	|O
dependent	1650	1659	|O
fashion	1660	1667	|O
.	1667	1668	|O

### abstracts1503.txt
To	0	2	|O
develop	3	10	|O
potential	11	20	|O
antitumor	21	30	|O
agents	31	37	|O
directed	38	46	|O
toward	47	53	|O
HER2	54	58	|O
/	58	59	|O
ErbB2	59	64	|O
overexpression	65	79	|O
in	80	82	|O
cancer	83	89	|O
,	89	90	|O
we	91	93	|O
have	94	98	|O
designed	99	107	|O
inhibitors	108	118	|O
of	119	121	|O
the	122	125	|O
recognition	126	137	|O
between	138	145	|O
the	146	149	|O
phosphotyrosine	150	165	|O
of	166	168	|O
the	169	172	|O
receptor	173	181	|O
and	182	185	|O
the	186	189	|O
SH2	190	193	|O
domain	194	200	|O
of	201	203	|O
the	204	207	|O
adaptor	208	215	|O
protein	216	223	|O
Grb2	224	228	|O
.	228	229	|O
In	230	232	|O
the	233	236	|O
first	237	242	|O
part	243	247	|O
of	248	250	|O
the	251	254	|O
paper	255	260	|O
,	260	261	|O
we	262	264	|O
report	265	271	|O
the	272	275	|O
synthesis	276	285	|O
of	286	288	|O
mimetics	289	297	|O
of	298	300	|O
the	301	304	|O
constrained	305	316	|O
(	317	318	|O
alpha	318	323	|O
-	323	324	|O
Me	324	326	|O
)	326	327	|O
phosphotyrosine	327	342	|O
residue	343	350	|O
such	351	355	|O
as	356	358	|O
(	359	360	|B-MODIFIER
alpha	360	365	|I-MODIFIER
-	365	366	|I-MODIFIER
Me	366	368	|I-MODIFIER
)	368	369	|I-MODIFIER
-	369	370	|O
4	370	371	|B-IUPAC
-	371	372	|I-IUPAC
phosphonomethylphenylalanine	372	400	|I-IUPAC
(	401	402	|O
-	402	403	|O
CH2PO3H2	403	411	|O
)	411	412	|O
,	412	413	|O
(	414	415	|B-MODIFIER
alpha	415	420	|I-MODIFIER
-	420	421	|I-MODIFIER
Me	421	423	|I-MODIFIER
)	423	424	|I-MODIFIER
4	425	426	|B-IUPAC
-	426	427	|I-IUPAC
phosphonodifluoromethylphenylalanine	427	463	|I-IUPAC
(	464	465	|O
-	465	466	|O
CF2PO3H2	466	474	|O
)	474	475	|O
,	475	476	|O
and	477	480	|O
(	481	482	|B-MODIFIER
alpha	482	487	|I-MODIFIER
-	487	488	|I-MODIFIER
Me	488	490	|I-MODIFIER
)	490	491	|I-MODIFIER
-	491	492	|O
4	492	493	|B-IUPAC
-	493	494	|I-IUPAC
phosphonophenylalanine	494	516	|I-IUPAC
(	517	518	|O
-	518	519	|O
PO3H2	519	524	|O
)	524	525	|O
.	525	526	|O
The	527	530	|O
incorporation	531	544	|O
of	545	547	|O
these	548	553	|O
residues	554	562	|O
in	563	565	|O
the	566	569	|O
mAZ	570	573	|O
-	573	574	|O
pTyr	574	578	|O
-	578	579	|O
Xaa	579	582	|O
-	582	583	|O
Asn	583	586	|O
-	586	587	|O
NH2	587	590	|O
series	591	597	|O
provided	598	606	|O
compounds	607	616	|O
with	617	621	|O
very	622	626	|O
high	627	631	|O
affinity	632	640	|O
for	641	644	|O
the	645	648	|O
Grb2	649	653	|O
SH2	654	657	|O
domain	658	664	|O
,	664	665	|O
in	666	668	|O
the	669	672	|O
10	673	675	|O
(	675	676	|O
-	676	677	|O
8	677	678	|O
)	678	679	|O
-	679	680	|O
10	680	682	|O
(	682	683	|O
-	683	684	|O
9	684	685	|O
)	685	686	|O
range	687	692	|O
of	693	695	|O
Kd	696	698	|O
values	699	705	|O
.	705	706	|O
These	707	712	|O
compounds	713	722	|O
behave	723	729	|O
as	730	732	|O
potent	733	739	|O
antagonists	740	751	|O
of	752	754	|O
the	755	758	|O
Grb2	759	763	|O
-	763	764	|O
Shc	764	767	|O
interaction	768	779	|O
.	779	780	|O
Our	781	784	|O
results	785	792	|O
highlight	793	802	|O
the	803	806	|O
importance	807	817	|O
of	818	820	|O
the	821	824	|O
doubly	825	831	|O
negative	832	840	|O
charge	841	847	|O
borne	848	853	|O
by	854	856	|O
the	857	860	|O
pY	861	863	|O
+	864	865	|O
1	866	867	|O
amino	868	873	|O
acid	874	878	|O
in	879	881	|O
accordance	882	892	|O
with	893	897	|O
the	898	901	|O
interactions	902	914	|O
observed	915	923	|O
in	924	926	|O
the	927	930	|O
complex	931	938	|O
crystallized	939	951	|O
between	952	959	|O
mAZ	960	963	|O
-	963	964	|O
pTyr	964	968	|O
-	968	969	|O
(	969	970	|O
alphaMe	970	977	|O
)	977	978	|O
pTyr	978	982	|O
-	982	983	|O
Asn	983	986	|O
-	986	987	|O
NH2	987	990	|O
and	991	994	|O
the	995	998	|O
Grb2	999	1003	|O
SH2	1004	1007	|O
domain	1008	1014	|O
.	1014	1015	|O
mAZ	1016	1019	|O
-	1019	1020	|O
pTyr	1020	1024	|O
-	1024	1025	|O
(	1025	1026	|O
alphaMe	1026	1033	|O
)	1033	1034	|O
pTyr	1034	1038	|O
-	1038	1039	|O
Asn	1039	1042	|O
-	1042	1043	|O
NH2	1043	1046	|O
was	1047	1050	|O
derivatized	1051	1062	|O
as	1063	1065	|O
the	1066	1069	|O
S	1070	1071	|B-IUPAC
-	1071	1072	|I-IUPAC
acetyl	1072	1078	|I-IUPAC
thioester	1079	1088	|I-IUPAC
(	1089	1090	|O
SATE	1090	1094	|O
)	1094	1095	|O
of	1096	1098	|O
the	1099	1102	|O
phosphotyrosine	1103	1118	|O
residues	1119	1127	|O
,	1127	1128	|O
and	1129	1132	|O
its	1133	1136	|O
surrogates	1137	1147	|O
provided	1148	1156	|O
prodrugs	1157	1165	|O
with	1166	1170	|O
very	1171	1175	|O
potent	1176	1182	|O
antiproliferative	1183	1200	|O
activity	1201	1209	|O
on	1210	1212	|O
cells	1213	1218	|O
overexpressing	1219	1233	|O
HER2	1234	1238	|O
/	1238	1239	|O
ErbB2	1239	1244	|O
,	1244	1245	|O
with	1246	1250	|O
ED50	1251	1255	|O
values	1256	1262	|O
amounting	1263	1272	|O
to	1273	1275	|O
0.1	1276	1279	|O
microM	1280	1286	|O
.	1286	1287	|O
Finally	1288	1295	|O
a	1296	1297	|O
new	1298	1301	|O
prodrug	1302	1309	|O
is	1310	1312	|O
put	1313	1316	|O
forth	1317	1322	|O
under	1323	1328	|O
the	1329	1332	|O
form	1333	1337	|O
of	1338	1340	|O
a	1341	1342	|O
monobenzyl	1343	1353	|O
ester	1354	1359	|O
of	1360	1362	|O
phosphate	1363	1372	|O
group	1373	1378	|O
that	1379	1383	|O
is	1384	1386	|O
as	1387	1389	|O
active	1390	1396	|O
as	1397	1399	|O
and	1400	1403	|O
much	1404	1408	|O
easier	1409	1415	|O
to	1416	1418	|O
synthesize	1419	1429	|O
than	1430	1434	|O
SATE	1435	1439	|O
prodrugs	1440	1448	|O
.	1448	1449	|O
These	1450	1455	|O
compounds	1456	1465	|O
show	1466	1470	|O
promising	1471	1480	|O
activity	1481	1489	|O
for	1490	1493	|O
further	1494	1501	|O
testing	1502	1509	|O
on	1510	1512	|O
in	1513	1515	|O
vivo	1516	1520	|O
models	1521	1527	|O
.	1527	1528	|O

### abstracts2248.txt
Analogs	0	7	|O
of	8	10	|O
CVFM	11	15	|O
(	16	17	|O
a	17	18	|O
known	19	24	|O
nonsubstrate	25	37	|O
farnesyltransferase	38	57	|O
(	58	59	|O
FT	59	61	|O
)	61	62	|O
inhibitor	63	72	|O
derived	73	80	|O
from	81	85	|O
a	86	87	|O
CA1A2X	88	94	|O
sequence	95	103	|O
where	104	109	|O
C	110	111	|O
is	112	114	|O
cysteine	115	123	|O
,	123	124	|O
A	125	126	|O
is	127	129	|O
an	130	132	|O
aliphatic	133	142	|O
residue	143	150	|O
,	150	151	|O
and	152	155	|O
X	156	157	|O
is	158	160	|O
any	161	164	|O
residue	165	172	|O
)	172	173	|O
were	174	178	|O
prepared	179	187	|O
where	188	193	|O
phenylalanine	194	207	|O
was	208	211	|O
replaced	212	220	|O
by	221	223	|O
(	224	225	|B-IUPAC
Z	225	226	|I-IUPAC
)	226	227	|I-IUPAC
-	227	228	|I-IUPAC
dehydrophenylalanine	228	248	|I-IUPAC
,	248	249	|O
2	250	251	|B-IUPAC
-	251	252	|I-IUPAC
aminoindan	252	262	|I-IUPAC
-	262	263	|I-IUPAC
2	263	264	|I-IUPAC
-	264	265	|I-IUPAC
carboxylate	265	276	|I-IUPAC
,	276	277	|O
1,2,3,4	278	285	|B-IUPAC
-	285	286	|I-IUPAC
tetrahydroisoquinoline	286	308	|I-IUPAC
-	308	309	|I-IUPAC
3	309	310	|I-IUPAC
-	310	311	|I-IUPAC
carboxylate	311	322	|I-IUPAC
(	323	324	|O
Tic	324	327	|O
)	327	328	|O
,	328	329	|O
and	330	333	|O
indoline	334	342	|B-IUPAC
-	342	343	|I-IUPAC
2	343	344	|I-IUPAC
-	344	345	|I-IUPAC
carboxylate	345	356	|I-IUPAC
.	356	357	|O
The	358	361	|O
greatest	362	370	|O
improvement	371	382	|O
in	383	385	|O
FT	386	388	|O
inhibitory	389	399	|O
potency	400	407	|O
was	408	411	|O
observed	412	420	|O
for	421	424	|O
the	425	428	|O
Tic	429	432	|O
derivative	433	443	|O
(	444	445	|O
IC50	445	449	|O
=	450	451	|O
1	452	453	|O
nM	454	456	|O
)	456	457	|O
;	457	458	|O
however	459	466	|O
,	466	467	|O
this	468	472	|O
compound	473	481	|O
was	482	485	|O
ineffective	486	497	|O
in	498	500	|O
blocking	501	509	|O
oncogenic	510	519	|O
Ras	520	523	|O
-	523	524	|O
induced	524	531	|O
transformation	532	546	|O
of	547	549	|O
NIH	550	553	|O
-	553	554	|O
3T3	554	557	|O
fibroblast	558	568	|O
cells	569	574	|O
.	574	575	|O
A	576	577	|O
compound	578	586	|O
was	587	590	|O
prepared	591	599	|O
in	600	602	|O
which	603	608	|O
both	609	613	|O
the	614	617	|O
Cys	618	621	|O
-	621	622	|O
Val	622	625	|O
methyleneamine	626	640	|O
isostere	641	649	|O
and	650	653	|O
the	654	657	|O
Tic	658	661	|O
replacement	662	673	|O
were	674	678	|O
incorporated	679	691	|O
.	691	692	|O
This	693	697	|O
derivative	698	708	|O
inhibited	709	718	|O
FT	719	721	|O
with	722	726	|O
an	727	729	|O
IC50	730	734	|O
of	735	737	|O
0.6	738	741	|O
nM	742	744	|O
and	745	748	|O
inhibited	749	758	|O
anchorage	759	768	|O
-	768	769	|O
independent	769	780	|O
growth	781	787	|O
of	788	790	|O
stably	791	797	|O
transformed	798	809	|O
NIH	810	813	|O
-	813	814	|O
3T3	814	817	|O
fibroblast	818	828	|O
cells	829	834	|O
by	835	837	|O
50%	838	841	|O
at	842	844	|O
5	845	846	|O
microM	847	853	|O
.	853	854	|O
Replacing	855	864	|O
the	865	868	|O
A1	869	871	|O
side	872	876	|O
chain	877	882	|O
of	883	885	|O
this	886	890	|O
derivative	891	901	|O
with	902	906	|O
a	907	908	|O
tert	909	913	|B-IUPAC
-	913	914	|I-IUPAC
butyl	914	919	|I-IUPAC
group	920	925	|B-MODIFIER
and	926	929	|O
replacing	930	939	|O
the	940	943	|O
X	944	945	|O
position	946	954	|O
with	955	959	|O
glutamine	960	969	|O
led	970	973	|O
to	974	976	|O
a	977	978	|O
derivative	979	989	|O
with	990	994	|O
an	995	997	|O
IC50	998	1002	|O
of	1003	1005	|O
2.8	1006	1009	|O
nM	1010	1012	|O
and	1013	1016	|O
an	1017	1019	|O
EC50	1020	1024	|O
of	1025	1027	|O
0.19	1028	1032	|O
microM	1033	1039	|O
,	1039	1040	|O
a	1041	1042	|O
26	1043	1045	|O
-	1045	1046	|O
fold	1046	1050	|O
improvement	1051	1062	|O
over	1063	1067	|O
(	1068	1069	|B-IUPAC
S	1069	1070	|I-IUPAC
*	1070	1071	|I-IUPAC
,	1071	1072	|I-IUPAC
R	1072	1073	|I-IUPAC
*	1073	1074	|I-IUPAC
)	1074	1075	|I-IUPAC
-	1075	1076	|I-IUPAC
N	1076	1077	|I-IUPAC
-	1077	1078	|I-IUPAC
[	1078	1079	|I-IUPAC
[	1079	1080	|I-IUPAC
2	1080	1081	|I-IUPAC
-	1081	1082	|I-IUPAC
[	1082	1083	|I-IUPAC
N	1083	1084	|I-IUPAC
-	1084	1085	|I-IUPAC
(	1085	1086	|I-IUPAC
2	1086	1087	|I-IUPAC
-	1087	1088	|I-IUPAC
amino	1088	1093	|I-IUPAC
-	1093	1094	|I-IUPAC
3	1094	1095	|I-IUPAC
-	1095	1096	|I-IUPAC
mercaptopropyl	1096	1110	|I-IUPAC
)	1110	1111	|I-IUPAC
-	1111	1112	|I-IUPAC
L	1112	1113	|I-IUPAC
-	1113	1114	|I-IUPAC
valyl	1114	1119	|I-IUPAC
]	1119	1120	|I-IUPAC
-	1120	1121	|I-IUPAC
1,2,3,4	1121	1128	|I-IUPAC
-	1128	1129	|I-IUPAC
tetrahydro	1130	1140	|I-IUPAC
-	1140	1141	|I-IUPAC
3	1141	1142	|I-IUPAC
-	1142	1143	|I-IUPAC
isoquinolinyl	1143	1156	|I-IUPAC
]	1156	1157	|I-IUPAC
carbonyl	1157	1165	|I-IUPAC
]	1165	1166	|I-IUPAC
-	1166	1167	|I-IUPAC
L	1167	1168	|I-IUPAC
-	1168	1169	|I-IUPAC
methionine	1169	1179	|I-IUPAC
.	1179	1180	|O
This	1181	1185	|O
derivative	1186	1196	|O
,	1196	1197	|O
(	1198	1199	|B-IUPAC
S	1199	1200	|I-IUPAC
*	1200	1201	|I-IUPAC
,	1201	1202	|I-IUPAC
R	1202	1203	|I-IUPAC
*	1203	1204	|I-IUPAC
)	1204	1205	|I-IUPAC
-	1205	1206	|I-IUPAC
N	1206	1207	|I-IUPAC
-	1207	1208	|I-IUPAC
[	1208	1209	|I-IUPAC
[	1209	1210	|I-IUPAC
2	1210	1211	|I-IUPAC
-	1211	1212	|I-IUPAC
[	1212	1213	|I-IUPAC
N	1213	1214	|I-IUPAC
-	1214	1215	|I-IUPAC
(	1215	1216	|I-IUPAC
2	1216	1217	|I-IUPAC
-	1217	1218	|I-IUPAC
amino	1218	1223	|I-IUPAC
-	1223	1224	|I-IUPAC
3	1224	1225	|I-IUPAC
-	1225	1226	|I-IUPAC
mercaptopropyl	1226	1240	|I-IUPAC
)	1240	1241	|I-IUPAC
-	1241	1242	|I-IUPAC
L	1242	1243	|I-IUPAC
-	1243	1244	|I-IUPAC
tert	1244	1248	|I-IUPAC
-	1248	1249	|I-IUPAC
leucyl	1249	1255	|I-IUPAC
]	1255	1256	|I-IUPAC
-	1256	1257	|I-IUPAC
1,2,3,4	1257	1264	|I-IUPAC
-	1265	1266	|I-IUPAC
tetrahydro	1267	1277	|I-IUPAC
-	1277	1278	|I-IUPAC
3	1278	1279	|I-IUPAC
-	1279	1280	|I-IUPAC
isoquinolinyl	1280	1293	|I-IUPAC
]	1293	1294	|I-IUPAC
-	1294	1295	|I-IUPAC
carbonyl	1295	1303	|I-IUPAC
]	1303	1304	|I-IUPAC
-	1304	1305	|I-IUPAC
L	1305	1306	|I-IUPAC
-	1306	1307	|I-IUPAC
glutamine	1307	1316	|I-IUPAC
,	1316	1317	|O
was	1318	1321	|O
evaluated	1322	1331	|O
in	1332	1334	|O
vivo	1335	1339	|O
along	1340	1345	|O
with	1346	1350	|O
(	1351	1352	|B-IUPAC
S	1352	1353	|I-IUPAC
*	1353	1354	|I-IUPAC
,	1354	1355	|I-IUPAC
R	1355	1356	|I-IUPAC
*	1356	1357	|I-IUPAC
)	1357	1358	|I-IUPAC
-	1358	1359	|I-IUPAC
N	1359	1360	|I-IUPAC
-	1360	1361	|I-IUPAC
[	1361	1362	|I-IUPAC
[	1362	1363	|I-IUPAC
2	1363	1364	|I-IUPAC
-	1364	1365	|I-IUPAC
[	1365	1366	|I-IUPAC
N	1366	1367	|I-IUPAC
-	1367	1368	|I-IUPAC
(	1368	1369	|I-IUPAC
2	1369	1370	|I-IUPAC
-	1370	1371	|I-IUPAC
amino	1371	1376	|I-IUPAC
-	1376	1377	|I-IUPAC
3	1377	1378	|I-IUPAC
-	1378	1379	|I-IUPAC
mercaptopropyl	1380	1394	|I-IUPAC
)	1394	1395	|I-IUPAC
-	1395	1396	|I-IUPAC
L	1396	1397	|I-IUPAC
-	1397	1398	|I-IUPAC
tert	1398	1402	|I-IUPAC
-	1402	1403	|I-IUPAC
leucyl	1403	1409	|I-IUPAC
]	1409	1410	|I-IUPAC
-	1410	1411	|I-IUPAC
1,2,3,4	1411	1418	|I-IUPAC
-	1418	1419	|I-IUPAC
tetrahydro	1419	1429	|I-IUPAC
-	1429	1430	|I-IUPAC
3	1430	1431	|I-IUPAC
-	1431	1432	|I-IUPAC
isoquinolinyl	1433	1446	|I-IUPAC
]	1446	1447	|I-IUPAC
carbonyl	1447	1455	|I-IUPAC
]	1455	1456	|I-IUPAC
-	1456	1457	|I-IUPAC
L	1457	1458	|I-IUPAC
-	1458	1459	|I-IUPAC
methionine	1459	1469	|I-IUPAC
methyl	1470	1476	|I-IUPAC
ester	1477	1482	|I-IUPAC
for	1483	1486	|O
antitumor	1487	1496	|O
activity	1497	1505	|O
in	1506	1508	|O
an	1509	1511	|O
athymic	1512	1519	|O
mouse	1520	1525	|O
model	1526	1531	|O
implanted	1532	1541	|O
ip	1542	1544	|O
with	1545	1549	|O
H	1550	1551	|O
-	1551	1552	|O
ras	1552	1555	|O
-	1555	1556	|O
transformed	1556	1567	|O
rat	1568	1571	|O
-	1571	1572	|O
1	1572	1573	|O
tumor	1574	1579	|O
cells	1580	1585	|O
.	1585	1586	|O
When	1587	1591	|O
administered	1592	1604	|O
by	1605	1607	|O
injection	1608	1617	|O
twice	1618	1623	|O
a	1624	1625	|O
day	1626	1629	|O
at	1630	1632	|O
45	1633	1635	|O
mg	1636	1638	|O
/	1638	1639	|O
kg	1639	1641	|O
for	1642	1645	|O
11	1646	1648	|O
consecutive	1649	1660	|O
days	1661	1665	|O
,	1665	1666	|O
both	1667	1671	|O
compounds	1672	1681	|O
showed	1682	1688	|O
prolonged	1689	1698	|O
survival	1699	1707	|O
time	1708	1712	|O
(	1713	1714	|O
T	1714	1715	|O
/	1715	1716	|O
C	1716	1717	|O
=	1718	1719	|O
142-145%	1720	1728	|O
)	1728	1729	|O
,	1729	1730	|O
thus	1731	1735	|O
demonstrating	1736	1749	|O
efficacy	1750	1758	|O
against	1759	1766	|O
ras	1767	1770	|O
oncogene	1771	1779	|O
-	1779	1780	|O
containing	1780	1790	|O
tumors	1791	1797	|O
in	1798	1800	|O
vivo	1801	1805	|O
.	1805	1806	|O

### abstracts1157.txt
Substituted	0	11	|B-MODIFIER
9H	12	14	|B-IUPAC
-	14	15	|I-IUPAC
pyrido	15	21	|I-IUPAC
[	21	22	|I-IUPAC
3,4	22	25	|I-IUPAC
-	25	26	|I-IUPAC
b	26	27	|I-IUPAC
]	27	28	|I-IUPAC
indoles	28	35	|I-IUPAC
(	36	37	|O
beta	37	41	|O
-	41	42	|O
carbolines	42	52	|O
)	52	53	|O
,	53	54	|O
identified	55	65	|O
in	66	68	|O
our	69	72	|O
laboratory	73	83	|O
as	84	86	|O
potential	87	96	|O
pharmacophores	97	111	|O
for	112	115	|O
designing	116	125	|O
macrofilaricidal	126	142	|O
agents	143	149	|O
,	149	150	|O
have	151	155	|O
been	156	160	|O
explored	161	169	|O
further	170	177	|O
for	178	181	|O
identifying	182	193	|O
the	194	197	|O
pharmacophore	198	211	|O
responsible	212	223	|O
for	224	227	|O
the	228	231	|O
high	232	236	|O
order	237	242	|O
of	243	245	|O
adulticidal	246	257	|O
activity	258	266	|O
.	266	267	|O
This	268	272	|O
has	273	276	|O
led	277	280	|O
to	281	283	|O
syntheses	284	293	|O
and	294	297	|O
macrofilaricidal	298	314	|O
evaluations	315	326	|O
of	327	329	|O
a	330	331	|O
number	332	338	|O
of	339	341	|O
1	342	343	|B-IUPAC
-	343	344	|I-IUPAC
aryl	344	348	|I-IUPAC
-	348	349	|I-IUPAC
9H	349	351	|I-IUPAC
-	351	352	|I-IUPAC
pyrido	352	358	|I-IUPAC
[	358	359	|I-IUPAC
3,4	359	362	|I-IUPAC
-	362	363	|I-IUPAC
b	363	364	|I-IUPAC
]	364	365	|I-IUPAC
indole	365	371	|I-IUPAC
-	371	372	|I-IUPAC
3	372	373	|I-IUPAC
-	373	374	|I-IUPAC
carboxylate	374	385	|I-IUPAC
derivatives	386	397	|B-MODIFIER
(	398	399	|O
3-7	399	402	|O
)	402	403	|O
.	403	404	|O
The	405	408	|O
macrofilaricidal	409	425	|O
activity	426	434	|O
was	435	438	|O
initially	439	448	|O
evaluated	449	458	|O
in	459	461	|O
vivo	462	466	|O
against	467	474	|O
Acanthoeilonema	475	490	|O
viteae	491	497	|O
.	497	498	|O
Among	499	504	|O
all	505	508	|O
the	509	512	|O
synthesized	513	524	|O
compounds	525	534	|O
,	534	535	|O
only	536	540	|O
12	541	543	|O
compounds	544	553	|O
,	553	554	|O
namely	555	561	|O
3a	562	564	|O
,	564	565	|O
3c	566	568	|O
,	568	569	|O
3d	570	572	|O
,	572	573	|O
3f	574	576	|O
,	576	577	|O
4c	578	580	|O
,	580	581	|O
4d	582	584	|O
,	584	585	|O
4f	586	588	|O
,	588	589	|O
5a	590	592	|O
,	592	593	|O
6f	594	596	|O
,	596	597	|O
6h	598	600	|O
,	600	601	|O
6i	602	604	|O
,	604	605	|O
and	606	609	|O
7h	610	612	|O
,	612	613	|O
have	614	618	|O
exhibited	619	628	|O
either	629	635	|O
&	636	637	|O
gt	637	639	|O
;	639	640	|O
90%	640	643	|O
micro	644	649	|O
-	649	650	|O
or	651	653	|O
macrofilaricidal	654	670	|O
activity	671	679	|O
or	680	682	|O
sterlization	683	695	|O
of	696	698	|O
female	699	705	|O
worms	706	711	|O
.	711	712	|O
These	713	718	|O
compounds	719	728	|O
have	729	733	|O
also	734	738	|O
been	739	743	|O
screened	744	752	|O
against	753	760	|O
Litomosoides	761	773	|O
carinii	774	781	|O
,	781	782	|O
and	783	786	|O
of	787	789	|O
these	790	795	|O
only	796	800	|O
3f	801	803	|O
and	804	807	|O
5a	808	810	|O
have	811	815	|O
also	816	820	|O
been	821	825	|O
found	826	831	|O
to	832	834	|O
be	835	837	|O
active	838	844	|O
.	844	845	|O
Finally	846	853	|O
these	854	859	|O
two	860	863	|O
compounds	864	873	|O
have	874	878	|O
been	879	883	|O
evaluated	884	893	|O
against	894	901	|O
Brugia	902	908	|O
malayi	909	915	|O
.	915	916	|O
The	917	920	|O
structure	921	930	|O
-	930	931	|O
activity	931	939	|O
relationship	940	952	|O
(	953	954	|O
SAR	954	957	|O
)	957	958	|O
associated	959	969	|O
with	970	974	|O
position	975	983	|O
1	984	985	|O
and	986	989	|O
3	990	991	|O
substituents	992	1004	|O
in	1005	1007	|O
beta	1008	1012	|O
-	1012	1013	|O
carbolines	1013	1023	|O
has	1024	1027	|O
been	1028	1032	|O
discussed	1033	1042	|O
.	1042	1043	|O
It	1044	1046	|O
has	1047	1050	|O
been	1051	1055	|O
observed	1056	1064	|O
that	1065	1069	|O
the	1070	1073	|O
presence	1074	1082	|O
of	1083	1085	|O
a	1086	1087	|O
carbomethoxy	1088	1100	|O
at	1101	1103	|O
position	1104	1112	|O
3	1113	1114	|O
and	1115	1118	|O
an	1119	1121	|O
aryl	1122	1126	|O
substituent	1127	1138	|O
at	1139	1141	|O
position	1142	1150	|O
1	1151	1152	|O
in	1153	1155	|O
beta	1156	1160	|O
-	1160	1161	|O
carbolines	1161	1171	|O
effectively	1172	1183	|O
enhances	1184	1192	|O
antifilarial	1193	1205	|O
activity	1206	1214	|O
particularly	1215	1227	|O
against	1228	1235	|O
A	1236	1237	|O
.	1237	1238	|O
viteae	1239	1245	|O
.	1245	1246	|O
Among	1247	1252	|O
the	1253	1256	|O
various	1257	1264	|O
compounds	1265	1274	|O
screened	1275	1283	|O
,	1283	1284	|O
methyl	1285	1291	|B-IUPAC
1	1292	1293	|I-IUPAC
-	1293	1294	|I-IUPAC
(	1294	1295	|I-IUPAC
4	1295	1296	|I-IUPAC
-	1296	1297	|I-IUPAC
methylphenyl	1297	1309	|I-IUPAC
)	1309	1310	|I-IUPAC
-	1310	1311	|I-IUPAC
9H	1311	1313	|I-IUPAC
-	1313	1314	|I-IUPAC
pyrido	1314	1320	|I-IUPAC
[	1320	1321	|I-IUPAC
3,4	1321	1324	|I-IUPAC
-	1324	1325	|I-IUPAC
b	1325	1326	|I-IUPAC
]	1326	1327	|I-IUPAC
indole	1327	1333	|I-IUPAC
-	1333	1334	|I-IUPAC
3	1334	1335	|I-IUPAC
-	1335	1336	|I-IUPAC
carboxylate	1336	1347	|I-IUPAC
(	1348	1349	|O
4c	1349	1351	|O
)	1351	1352	|O
has	1353	1356	|O
shown	1357	1362	|O
the	1363	1366	|O
highest	1367	1374	|O
adulticidal	1375	1386	|O
activity	1387	1395	|O
and	1396	1399	|O
methyl	1400	1406	|B-IUPAC
1	1407	1408	|I-IUPAC
-	1408	1409	|I-IUPAC
(	1409	1410	|I-IUPAC
4	1410	1411	|I-IUPAC
-	1411	1412	|I-IUPAC
chlorophenyl	1412	1424	|I-IUPAC
)	1424	1425	|I-IUPAC
-	1425	1426	|I-IUPAC
1,2,3,4	1426	1433	|I-IUPAC
-	1433	1434	|I-IUPAC
tetrahydro	1434	1444	|I-IUPAC
-	1444	1445	|I-IUPAC
9H	1445	1447	|I-IUPAC
-	1447	1448	|I-IUPAC
pyrido	1448	1454	|I-IUPAC
[	1454	1455	|I-IUPAC
3	1455	1456	|I-IUPAC
,	1456	1457	|I-IUPAC
4	1458	1459	|I-IUPAC
-	1459	1460	|I-IUPAC
b	1460	1461	|I-IUPAC
]	1461	1462	|I-IUPAC
indole	1462	1468	|I-IUPAC
-	1468	1469	|I-IUPAC
3	1469	1470	|I-IUPAC
-	1470	1471	|I-IUPAC
carboxylate	1471	1482	|I-IUPAC
(	1483	1484	|O
3a	1484	1486	|O
)	1486	1487	|O
has	1488	1491	|O
shown	1492	1497	|O
the	1498	1501	|O
highest	1502	1509	|O
microfilaricidal	1510	1526	|O
action	1527	1533	|O
against	1534	1541	|O
A	1542	1543	|O
.	1543	1544	|O
viteae	1545	1551	|O
at	1552	1554	|O
50	1555	1557	|O
mg	1558	1560	|O
/	1560	1561	|O
kg	1561	1563	|O
x	1564	1565	|O
5	1566	1567	|O
days	1568	1572	|O
(	1573	1574	|O
ip	1574	1576	|O
)	1576	1577	|O
.	1577	1578	|O
Another	1579	1586	|O
derivative	1587	1597	|O
of	1598	1600	|O
this	1601	1605	|O
compound	1606	1614	|O
,	1614	1615	|O
namely	1616	1622	|O
1	1623	1624	|B-IUPAC
-	1624	1625	|I-IUPAC
(	1625	1626	|I-IUPAC
4	1626	1627	|I-IUPAC
-	1627	1628	|I-IUPAC
chlorophenyl	1628	1640	|I-IUPAC
)	1640	1641	|I-IUPAC
-	1641	1642	|I-IUPAC
3	1642	1643	|I-IUPAC
-	1643	1644	|I-IUPAC
(	1644	1645	|I-IUPAC
hydroxymethyl	1645	1658	|I-IUPAC
)	1658	1659	|I-IUPAC
-	1659	1660	|I-IUPAC
9H	1660	1662	|I-IUPAC
-	1662	1663	|I-IUPAC
pyrido	1663	1669	|I-IUPAC
[	1669	1670	|I-IUPAC
3,4	1670	1673	|I-IUPAC
-	1673	1674	|I-IUPAC
b	1674	1675	|I-IUPAC
]	1675	1676	|I-IUPAC
indole	1676	1682	|I-IUPAC
(	1683	1684	|O
5a	1684	1686	|O
)	1686	1687	|O
,	1687	1688	|O
exhibited	1689	1698	|O
the	1699	1702	|O
highest	1703	1710	|O
activity	1711	1719	|O
against	1720	1727	|O
L	1728	1729	|O
.	1729	1730	|O
carinii	1731	1738	|O
at	1739	1741	|O
30	1742	1744	|O
mg	1745	1747	|O
/	1747	1748	|O
kg	1748	1750	|O
x	1751	1752	|O
5	1753	1754	|O
days	1755	1759	|O
(	1760	1761	|O
ip	1761	1763	|O
)	1763	1764	|O
and	1765	1768	|O
against	1769	1776	|O
B	1777	1778	|O
.	1778	1779	|O
malayiat	1780	1788	|O
50	1789	1791	|O
mg	1792	1794	|O
/	1794	1795	|O
kg	1795	1797	|O
x	1798	1799	|O
5	1800	1801	|O
days	1802	1806	|O
(	1807	1808	|O
ip	1808	1810	|O
)	1810	1811	|O
or	1812	1814	|O
at	1815	1817	|O
200	1818	1821	|O
mg	1822	1824	|O
/	1824	1825	|O
kg	1825	1827	|O
x	1828	1829	|O
5	1830	1831	|O
days	1832	1836	|O
(	1837	1838	|O
po	1838	1840	|O
)	1840	1841	|O
.	1841	1842	|O

### abstracts3494.txt
Certain	0	7	|O
novel	8	13	|O
1	14	15	|B-IUPAC
-	15	16	|I-IUPAC
phenyl	16	22	|I-IUPAC
-	22	23	|I-IUPAC
3	23	24	|I-IUPAC
-	24	25	|I-IUPAC
amino	25	30	|I-IUPAC
-	30	31	|I-IUPAC
1,2,3,4	31	38	|I-IUPAC
-	38	39	|I-IUPAC
tetrahydronaphthalenes	39	61	|I-IUPAC
(	62	63	|O
1	63	64	|B-IUPAC
-	64	65	|I-IUPAC
phenyl	65	71	|I-IUPAC
-	71	72	|I-IUPAC
3	72	73	|I-IUPAC
-	73	74	|I-IUPAC
aminotetralins	74	88	|I-IUPAC
,	88	89	|O
PATs	90	94	|O
)	94	95	|O
produced	96	104	|O
stimulation	105	116	|O
(	117	118	|O
ca.	118	121	|O
30%	122	125	|O
above	126	131	|O
basal	132	137	|O
levels	138	144	|O
)	144	145	|O
of	146	148	|O
tyrosine	149	157	|O
hydroxylase	158	169	|O
(	170	171	|O
TH	171	173	|O
)	173	174	|O
activity	175	183	|O
at	184	186	|O
0.1	187	190	|O
microM	191	197	|O
concentrations	198	212	|O
in	213	215	|O
rodent	216	222	|O
brain	223	228	|O
tissue	229	235	|O
.	235	236	|O
This	237	241	|O
effect	242	248	|O
on	249	251	|O
TH	252	254	|O
was	255	258	|O
blocked	259	266	|O
by	267	269	|O
the	270	273	|O
putative	274	282	|O
sigma	283	288	|O
-	288	289	|O
receptor	289	297	|O
antagonist	298	308	|O
BMY	309	312	|O
-	312	313	|O
14802	313	318	|O
,	318	319	|O
suggesting	320	330	|O
involvement	331	342	|O
of	343	345	|O
a	346	347	|O
novel	348	353	|O
neuromodulatory	354	369	|O
sigma	370	375	|O
-	375	376	|O
like	376	380	|O
receptor	381	389	|O
.	389	390	|O
Within	391	397	|O
the	398	401	|O
new	402	405	|O
phenylaminotetralin	406	425	|O
series	426	432	|O
,	432	433	|O
a	434	435	|O
correlation	436	447	|O
was	448	451	|O
found	452	457	|O
between	458	465	|O
the	466	469	|O
ability	470	477	|O
to	478	480	|O
stimulate	481	490	|O
TH	491	493	|O
and	494	497	|O
the	498	501	|O
potency	502	509	|O
to	510	512	|O
compete	513	520	|O
for	521	524	|O
binding	525	532	|O
sites	533	538	|O
labeled	539	546	|O
by	547	549	|O
(	550	551	|B-IUPAC
+	551	552	|I-IUPAC
/	552	553	|I-IUPAC
-	553	554	|I-IUPAC
)	554	555	|I-IUPAC
-	555	556	|I-IUPAC
[	556	557	|I-IUPAC
3H	557	559	|I-IUPAC
]	559	560	|I-IUPAC
1	560	561	|I-IUPAC
-	561	562	|I-IUPAC
phenyl	562	568	|I-IUPAC
-	568	569	|I-IUPAC
3	569	570	|I-IUPAC
-	570	571	|I-IUPAC
(	571	572	|I-IUPAC
N	572	573	|I-IUPAC
,	573	574	|I-IUPAC
N	574	575	|I-IUPAC
-	575	576	|I-IUPAC
dimethylamino	576	589	|I-IUPAC
)	589	590	|I-IUPAC
-	590	591	|I-IUPAC
6	591	592	|I-IUPAC
-	592	593	|I-IUPAC
chloro	593	599	|I-IUPAC
-	599	600	|I-IUPAC
7	600	601	|I-IUPAC
-	601	602	|I-IUPAC
hydroxy	602	609	|I-IUPAC
-	609	610	|I-IUPAC
1,2,3,4	610	617	|I-IUPAC
-	617	618	|I-IUPAC
tetrahydronaphthalene	619	640	|I-IUPAC
(	641	642	|O
[	642	643	|O
3H	643	645	|O
]	645	646	|O
(	646	647	|O
+	647	648	|O
/	648	649	|O
-	649	650	|O
)	650	651	|O
-	651	652	|O
4	652	653	|O
)	653	654	|O
.	654	655	|O
trans	656	661	|O
-	661	662	|O
Catechol	662	670	|O
analogs	671	678	|O
had	679	682	|O
low	683	686	|O
affinity	687	695	|O
for	696	699	|O
[	700	701	|O
3H	701	703	|O
]	703	704	|O
4	704	705	|O
sites	706	711	|O
,	711	712	|O
and	713	716	|O
although	717	725	|O
they	726	730	|O
inhibited	731	740	|O
TH	741	743	|O
activity	744	752	|O
,	752	753	|O
this	754	758	|O
effect	759	765	|O
was	766	769	|O
not	770	773	|O
blocked	774	781	|O
by	782	784	|O
known	785	790	|O
sigma	791	796	|O
or	797	799	|O
dopamine	800	808	|O
antagonists	809	820	|O
.	820	821	|O
Analogs	822	829	|O
with	830	834	|O
dihydroxy	835	844	|B-IUPAC
substituents	845	857	|B-MODIFIER
(	858	859	|O
catechols	859	868	|O
)	868	869	|O
,	869	870	|O
as	871	873	|O
well	874	878	|O
as	879	881	|O
nitrogen	882	890	|O
substituents	891	903	|O
larger	904	910	|O
than	911	915	|O
methyl	916	922	|O
,	922	923	|O
had	924	927	|O
little	928	934	|O
affinity	935	943	|O
for	944	947	|O
[	948	949	|O
3H	949	951	|O
]	951	952	|O
4	952	953	|O
binding	954	961	|O
sites	962	967	|O
and	968	971	|O
did	972	975	|O
not	976	979	|O
significantly	980	993	|O
affect	994	1000	|O
TH	1001	1003	|O
activity	1004	1012	|O
.	1012	1013	|O
The	1014	1017	|O
pharmacology	1018	1030	|O
of	1031	1033	|O
the	1034	1037	|O
[	1038	1039	|O
3H	1039	1041	|O
]	1041	1042	|O
4	1042	1043	|O
binding	1044	1051	|O
site	1052	1056	|O
is	1057	1059	|O
unique	1060	1066	|O
from	1067	1071	|O
that	1072	1076	|O
of	1077	1079	|O
any	1080	1083	|O
known	1084	1089	|O
sigma	1090	1095	|O
or	1096	1098	|O
dopamine	1099	1107	|O
receptor	1108	1116	|O
,	1116	1117	|O
thus	1118	1122	|O
the	1123	1126	|O
effects	1127	1134	|O
appear	1135	1141	|O
to	1142	1144	|O
be	1145	1147	|O
mediated	1148	1156	|O
by	1157	1159	|O
a	1160	1161	|O
previously	1162	1172	|O
uncharacterized	1173	1188	|O
binding	1189	1196	|O
site	1197	1201	|O
/	1201	1202	|O
receptor	1202	1210	|O
.	1210	1211	|O
The	1212	1215	|O
site	1216	1220	|O
has	1221	1224	|O
stereoselectivity	1225	1242	|O
for	1243	1246	|O
the	1247	1250	|O
(	1251	1252	|O
1R	1252	1254	|O
,	1254	1255	|O
3S	1255	1257	|O
)	1257	1258	|O
-	1258	1259	|O
(	1259	1260	|O
-	1260	1261	|O
)	1261	1262	|O
-	1262	1263	|O
isomer	1263	1269	|O
of	1270	1272	|O
1	1273	1274	|B-IUPAC
-	1274	1275	|I-IUPAC
phenyl	1275	1281	|I-IUPAC
-	1281	1282	|I-IUPAC
3	1282	1283	|I-IUPAC
-	1283	1284	|I-IUPAC
(	1284	1285	|I-IUPAC
N	1285	1286	|I-IUPAC
,	1286	1287	|I-IUPAC
N	1287	1288	|I-IUPAC
-	1288	1289	|I-IUPAC
dimethylamino	1289	1302	|I-IUPAC
)	1302	1303	|I-IUPAC
-	1303	1304	|I-IUPAC
1,2,3,4	1304	1311	|I-IUPAC
-	1311	1312	|I-IUPAC
tetrahydronaphthalene	1312	1333	|I-IUPAC
;	1333	1334	|O
this	1335	1339	|O
isomer	1340	1346	|O
is	1347	1349	|O
also	1350	1354	|O
more	1355	1359	|O
active	1360	1366	|O
at	1367	1369	|O
stimulating	1370	1381	|O
TH	1382	1384	|O
.	1384	1385	|O
Thus	1386	1390	|O
,	1390	1391	|O
certain	1392	1399	|O
1	1400	1401	|B-IUPAC
-	1401	1402	|I-IUPAC
phenyl	1402	1408	|I-IUPAC
-	1408	1409	|I-IUPAC
3	1409	1410	|I-IUPAC
-	1410	1411	|I-IUPAC
amino	1411	1416	|I-IUPAC
-	1416	1417	|I-IUPAC
1,2,3,4	1417	1424	|I-IUPAC
-	1424	1425	|I-IUPAC
tetrahydronaphthalenes	1425	1447	|I-IUPAC
appear	1448	1454	|O
to	1455	1457	|O
be	1458	1460	|O
selective	1461	1470	|O
probes	1471	1477	|O
of	1478	1480	|O
a	1481	1482	|O
novel	1483	1488	|O
receptor	1489	1497	|O
type	1498	1502	|O
that	1503	1507	|O
mediates	1508	1516	|O
sigma	1517	1522	|O
-	1522	1523	|O
like	1523	1527	|O
neuromodulatory	1528	1543	|O
activity	1544	1552	|O
and	1553	1556	|O
may	1557	1560	|O
have	1561	1565	|O
pharmacotherapeutic	1566	1585	|O
utility	1586	1593	|O
in	1594	1596	|O
conditions	1597	1607	|O
in	1608	1610	|O
which	1611	1616	|O
modulation	1617	1627	|O
of	1628	1630	|O
dopamine	1631	1639	|O
function	1640	1648	|O
is	1649	1651	|O
important	1652	1661	|O
.	1661	1662	|O

### abstracts4859.txt
Various	0	7	|O
4	8	9	|B-MODIFIER
-	9	10	|I-MODIFIER
substituted	10	21	|I-MODIFIER
3	22	23	|B-PARTIUPAC
-	23	24	|I-PARTIUPAC
alkylamino	24	34	|I-PARTIUPAC
-	34	35	|I-PARTIUPAC
,	35	36	|O
3	37	38	|B-PARTIUPAC
-	38	39	|I-PARTIUPAC
alkoxy	39	45	|I-PARTIUPAC
-	45	46	|I-PARTIUPAC
,	46	47	|O
3	48	49	|B-PARTIUPAC
-	49	50	|I-PARTIUPAC
alkylthio	50	59	|I-PARTIUPAC
-	59	60	|I-PARTIUPAC
,	60	61	|O
and	62	65	|O
3	66	67	|B-IUPAC
-	67	68	|I-IUPAC
alkyl	68	73	|I-IUPAC
-	73	74	|I-IUPAC
5	74	75	|I-IUPAC
-	75	76	|I-IUPAC
sulfamoylbenzoic	76	92	|I-IUPAC
acids	93	98	|I-IUPAC
related	99	106	|O
to	107	109	|O
known	110	115	|O
aminobenzoic	116	128	|O
acid	129	133	|O
diuretics	134	143	|O
were	144	148	|O
synthesized	149	160	|O
and	161	164	|O
screened	165	173	|O
for	174	177	|O
their	178	183	|O
diuretic	184	192	|O
properties	193	203	|O
in	204	206	|O
dogs	207	211	|O
.	211	212	|O
The	213	216	|O
tabulated	217	226	|O
results	227	234	|O
from	235	239	|O
a	240	241	|O
3	242	243	|O
-	243	244	|O
hr	244	246	|O
test	247	251	|O
period	252	258	|O
revealed	259	267	|O
that	268	272	|O
generally	273	282	|O
the	283	286	|O
diuretic	287	295	|O
profile	296	303	|O
and	304	307	|O
potency	308	315	|O
could	316	321	|O
be	322	324	|O
retained	325	333	|O
when	334	338	|O
3	339	340	|B-IUPAC
-	340	341	|I-IUPAC
alkoxy	341	347	|I-IUPAC
,	347	348	|O
3	349	350	|B-IUPAC
-	350	351	|I-IUPAC
alkylthio	351	360	|I-IUPAC
,	360	361	|O
and	362	365	|O
3	366	367	|B-IUPAC
-	367	368	|I-IUPAC
phenethyl	368	377	|I-IUPAC
were	378	382	|O
substituted	383	394	|O
for	395	398	|O
the	399	402	|O
3	403	404	|B-IUPAC
-	404	405	|I-IUPAC
alkylamino	405	415	|I-IUPAC
moiety	416	422	|B-MODIFIER
.	422	423	|O
The	424	427	|O
high	428	432	|O
potency	433	440	|O
of	441	443	|O
several	444	451	|O
3	452	453	|B-PARTIUPAC
-	453	454	|I-PARTIUPAC
alkoxy	454	460	|I-PARTIUPAC
-	460	461	|I-PARTIUPAC
,	461	462	|O
3	463	464	|B-PARTIUPAC
-	464	465	|I-PARTIUPAC
alkylthio	465	474	|I-PARTIUPAC
-	474	475	|I-PARTIUPAC
,	475	476	|O
and	477	480	|O
3	481	482	|B-IUPAC
-	482	483	|I-IUPAC
phenethyl	483	492	|I-IUPAC
-	492	493	|I-IUPAC
4	493	494	|I-IUPAC
-	494	495	|I-IUPAC
benzoyl	495	502	|I-IUPAC
-	502	503	|I-IUPAC
5	503	504	|I-IUPAC
-	504	505	|I-IUPAC
sulfamoylbenzoic	505	521	|I-IUPAC
acids	522	527	|I-IUPAC
confirmed	528	537	|O
previous	538	546	|O
suggestions	547	558	|O
that	559	563	|O
the	564	567	|O
apparent	568	576	|O
diuretic	577	585	|O
effect	586	592	|O
of	593	595	|O
4	596	597	|B-PARTIUPAC
-	597	598	|I-PARTIUPAC
and	599	602	|O
5	603	604	|B-IUPAC
-	604	605	|I-IUPAC
alkylamino	605	615	|I-IUPAC
-	615	616	|I-IUPAC
6	616	617	|I-IUPAC
-	617	618	|I-IUPAC
carboxy	618	625	|I-IUPAC
-	625	626	|I-IUPAC
3	626	627	|I-IUPAC
-	627	628	|I-IUPAC
phenyl	628	634	|I-IUPAC
-	634	635	|I-IUPAC
1,2	635	638	|I-IUPAC
-	638	639	|I-IUPAC
benzisothiazole	639	654	|I-IUPAC
1,1	655	658	|I-IUPAC
-	658	659	|I-IUPAC
dioxides	659	667	|I-IUPAC
originates	668	678	|O
from	679	683	|O
the	684	687	|O
corresponding	688	701	|O
4	702	703	|B-IUPAC
-	703	704	|I-IUPAC
benzoyl	704	711	|I-IUPAC
-	711	712	|I-IUPAC
5	712	713	|I-IUPAC
-	713	714	|I-IUPAC
sulfamoylbenzoic	714	730	|I-IUPAC
acid	731	735	|I-IUPAC
derivatives	736	747	|B-MODIFIER
due	748	751	|O
to	752	754	|O
an	755	757	|O
existing	758	766	|O
equilibrium	767	778	|O
in	779	781	|O
plasma	782	788	|O
.	788	789	|O
4	790	791	|B-IUPAC
-	791	792	|I-IUPAC
Benzoyl	792	799	|I-IUPAC
-	799	800	|I-IUPAC
5	800	801	|I-IUPAC
-	801	802	|I-IUPAC
sulfamoyl	802	811	|I-IUPAC
-	811	812	|I-IUPAC
3	812	813	|I-IUPAC
-	813	814	|I-IUPAC
(	814	815	|I-IUPAC
3	815	816	|I-IUPAC
-	816	817	|I-IUPAC
thenyloxy	817	826	|I-IUPAC
)	826	827	|I-IUPAC
benzoic	828	835	|I-IUPAC
acid	836	840	|I-IUPAC
(	841	842	|O
118	842	845	|O
)	845	846	|O
is	847	849	|O
among	850	855	|O
the	856	859	|O
most	860	864	|O
potent	865	871	|O
benzoic	872	879	|O
acid	880	884	|O
diuretics	885	894	|O
hitherto	895	903	|O
synthesized	904	915	|O
and	916	919	|O
shows	920	925	|O
significant	926	937	|O
diuretic	938	946	|O
activity	947	955	|O
in	956	958	|O
dogs	959	963	|O
at	964	966	|O
1	967	968	|O
mug	969	972	|O
/	972	973	|O
kg	973	975	|O
.	975	976	|O
The	977	980	|O
results	981	988	|O
obtained	989	997	|O
with	998	1002	|O
different	1003	1012	|O
3	1013	1014	|B-MODIFIER
-	1014	1015	|I-MODIFIER
substituted	1015	1026	|I-MODIFIER
4	1027	1028	|B-IUPAC
-	1028	1029	|I-IUPAC
phenyl	1029	1035	|I-IUPAC
-	1035	1036	|I-IUPAC
5	1036	1037	|I-IUPAC
-	1037	1038	|I-IUPAC
sulfamoylbenzoic	1038	1054	|I-IUPAC
acids	1055	1060	|I-IUPAC
supported	1061	1070	|O
the	1071	1074	|O
earlier	1075	1082	|O
concept	1083	1090	|O
regarding	1091	1100	|O
the	1101	1104	|O
steric	1105	1111	|O
influence	1112	1121	|O
of	1122	1124	|O
the	1125	1128	|O
4	1129	1130	|O
-	1130	1131	|O
substituent	1131	1142	|O
on	1143	1145	|O
the	1146	1149	|O
diuretic	1150	1158	|O
potency	1159	1166	|O
of	1167	1169	|O
sulfamoylbenzoic	1170	1186	|O
acid	1187	1191	|O
diuretics	1192	1201	|O
.	1201	1202	|O

### abstracts334.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
1	12	13	|B-MODIFIER
-	13	14	|I-MODIFIER
substituted	14	25	|I-MODIFIER
2,4	26	29	|B-IUPAC
-	29	30	|I-IUPAC
dinitroimidazole	30	46	|I-IUPAC
analogues	47	56	|B-MODIFIER
have	57	61	|O
been	62	66	|O
synthesized	67	78	|O
and	79	82	|O
tested	83	89	|O
for	90	93	|O
their	94	99	|O
radiosensitizing	100	116	|O
ability	117	124	|O
for	125	128	|O
selectively	129	140	|O
sensitizing	141	152	|O
hypoxic	153	160	|O
mammalian	161	170	|O
cells	171	176	|O
to	177	179	|O
the	180	183	|O
lethal	184	190	|O
effect	191	197	|O
of	198	200	|O
radiation	201	210	|O
.	210	211	|O
The	212	215	|O
reaction	216	224	|O
of	225	227	|O
2,4	228	231	|B-IUPAC
-	231	232	|I-IUPAC
(	232	233	|I-IUPAC
5	233	234	|I-IUPAC
)	234	235	|I-IUPAC
-	235	236	|I-IUPAC
dinitroimidazole	236	252	|I-IUPAC
(	253	254	|O
1	254	255	|O
)	255	256	|O
with	257	261	|O
a	262	263	|O
variety	264	271	|O
of	272	274	|O
oxiranes	275	283	|O
upon	284	288	|O
heating	289	296	|O
in	297	299	|O
absolute	300	308	|O
ethanol	309	316	|O
yielded	317	324	|O
the	325	328	|O
expected	329	337	|O
1	338	339	|B-MODIFIER
-	339	340	|I-MODIFIER
substituted	340	351	|I-MODIFIER
2,4	352	355	|B-IUPAC
-	355	356	|I-IUPAC
dinitroimidazoles	356	373	|I-IUPAC
(	374	375	|O
2	375	376	|O
)	376	377	|O
and	378	381	|O
also	382	386	|O
resulted	387	395	|O
in	396	398	|O
the	399	402	|O
formation	403	412	|O
of	413	415	|O
a	416	417	|O
novel	418	423	|O
class	424	429	|O
of	430	432	|O
isomeric	433	441	|B-MODIFIER
nitroimidazo	442	454	|B-IUPAC
[	454	455	|I-IUPAC
2,1	455	458	|I-IUPAC
-	458	459	|I-IUPAC
b	459	460	|I-IUPAC
]	460	461	|I-IUPAC
oxazoles	461	469	|I-IUPAC
3	470	471	|O
and	472	475	|O
4	476	477	|O
)	477	478	|O
by	479	481	|O
intramolecular	482	496	|O
cyclization	497	508	|O
.	508	509	|O
The	510	513	|O
results	514	521	|O
of	522	524	|O
radiosensitizing	525	541	|O
activity	542	550	|O
of	551	553	|O
these	554	559	|O
agents	560	566	|O
against	567	574	|O
hypoxic	575	582	|O
Chinese	583	590	|O
hamster	591	598	|O
cells	599	604	|O
(	605	606	|O
V	606	607	|O
-	607	608	|O
79	608	610	|O
)	610	611	|O
indicated	612	621	|O
that	622	626	|O
2,4	627	630	|B-IUPAC
-	630	631	|I-IUPAC
dinitroimidazoles	631	648	|I-IUPAC
were	649	653	|O
better	654	660	|O
sensitizers	661	672	|O
than	673	677	|O
the	678	681	|O
nitroimidazo	682	694	|B-IUPAC
[	694	695	|I-IUPAC
2,1	695	698	|I-IUPAC
-	698	699	|I-IUPAC
b	699	700	|I-IUPAC
]	700	701	|I-IUPAC
oxazoles	701	709	|I-IUPAC
,	709	710	|O
suggesting	711	721	|O
the	722	725	|O
necessity	726	735	|O
of	736	738	|O
the	739	742	|O
2	743	744	|B-IUPAC
-	744	745	|I-IUPAC
nitro	745	750	|I-IUPAC
function	751	759	|B-MODIFIER
in	760	762	|O
the	763	766	|O
molecule	767	775	|O
.	775	776	|O
The	777	780	|O
1	781	782	|B-IUPAC
-	782	783	|I-IUPAC
(	783	784	|I-IUPAC
2	784	785	|I-IUPAC
-	785	786	|I-IUPAC
hydroxy	786	793	|I-IUPAC
-	793	794	|I-IUPAC
3	794	795	|I-IUPAC
-	795	796	|I-IUPAC
methoxypropyl	796	809	|I-IUPAC
)	809	810	|I-IUPAC
-	810	811	|I-IUPAC
2,4	811	814	|I-IUPAC
-	814	815	|I-IUPAC
dinitroimidazole	815	831	|I-IUPAC
(	832	833	|O
2d	833	835	|O
)	835	836	|O
was	837	840	|O
found	841	846	|O
to	847	849	|O
be	850	852	|O
the	853	856	|O
most	857	861	|O
effective	862	871	|O
radiosensitizer	872	887	|O
of	888	890	|O
this	891	895	|O
series	896	902	|O
.	902	903	|O

### abstracts4435.txt
Several	0	7	|O
8	8	9	|B-MODIFIER
-	9	10	|I-MODIFIER
substituted	10	21	|I-MODIFIER
O6	22	24	|B-IUPAC
-	24	25	|I-IUPAC
benzylguanines	25	39	|I-IUPAC
,	39	40	|O
2	41	42	|B-MODIFIER
-	42	43	|I-MODIFIER
and	44	47	|O
/	47	48	|O
or	48	50	|O
8	51	52	|B-MODIFIER
-	52	53	|I-MODIFIER
substituted	53	64	|I-MODIFIER
6	65	66	|B-IUPAC
-	66	67	|I-IUPAC
(	67	68	|I-IUPAC
benzyloxy	68	77	|I-IUPAC
)	77	78	|I-IUPAC
purines	78	85	|I-IUPAC
,	85	86	|O
substituted	87	98	|B-MODIFIER
6	99	100	|B-IUPAC
(	100	101	|I-IUPAC
4	101	102	|I-IUPAC
)	102	103	|I-IUPAC
-	103	104	|I-IUPAC
(	104	105	|I-IUPAC
benzyloxy	105	114	|I-IUPAC
)	114	115	|I-IUPAC
pyrimidines	115	126	|I-IUPAC
,	126	127	|O
and	128	131	|O
a	132	133	|O
6	134	135	|B-IUPAC
-	135	136	|I-IUPAC
(	136	137	|I-IUPAC
benzyloxy	137	146	|I-IUPAC
)	146	147	|I-IUPAC
-	147	148	|I-IUPAC
s	148	149	|I-IUPAC
-	149	150	|I-IUPAC
triazine	150	158	|I-IUPAC
were	159	163	|O
tested	164	170	|O
for	171	174	|O
their	175	180	|O
ability	181	188	|O
to	189	191	|O
inactivate	192	202	|O
the	203	206	|O
human	207	212	|O
DNA	213	216	|O
repair	217	223	|O
protein	224	231	|O
,	231	232	|O
O6	233	235	|B-IUPAC
-	235	236	|I-IUPAC
alkylguanine	236	248	|I-IUPAC
-	248	249	|O
DNA	249	252	|O
alkyltransferase	253	269	|O
(	270	271	|O
AGT	271	274	|O
,	274	275	|O
alkyltransferase	276	292	|O
)	292	293	|O
.	293	294	|O
Two	295	298	|O
types	299	304	|O
of	305	307	|O
compounds	308	317	|O
were	318	322	|O
identified	323	333	|O
as	334	336	|O
being	337	342	|O
significantly	343	356	|O
more	357	361	|O
effective	362	371	|O
than	372	376	|O
O6	377	379	|B-IUPAC
-	379	380	|I-IUPAC
benzylguanine	380	393	|I-IUPAC
(	394	395	|O
the	395	398	|O
prototype	399	408	|O
low	409	412	|O
molecular	413	422	|O
weight	423	429	|O
inactivator	430	441	|O
)	441	442	|O
at	443	445	|O
inactivating	446	458	|O
AGT	459	462	|O
in	463	465	|O
human	466	471	|O
HT29	472	476	|O
colon	477	482	|O
tumor	483	488	|O
cell	489	493	|O
extracts	494	502	|O
.	502	503	|O
These	504	509	|O
were	510	514	|O
8	515	516	|B-MODIFIER
-	516	517	|I-MODIFIER
substituted	517	528	|I-MODIFIER
O6	529	531	|B-IUPAC
-	531	532	|I-IUPAC
benzylguanines	532	546	|I-IUPAC
bearing	547	554	|O
electron	555	563	|O
-	563	564	|O
withdrawing	564	575	|O
groups	576	582	|O
at	583	585	|O
the	586	589	|O
8	590	591	|O
-	591	592	|O
position	592	600	|O
(	601	602	|O
e.g.	602	606	|O
8	607	608	|B-IUPAC
-	608	609	|I-IUPAC
aza	609	612	|I-IUPAC
-	612	613	|I-IUPAC
O6	613	615	|I-IUPAC
-	615	616	|I-IUPAC
benzylguanine	616	629	|I-IUPAC
and	630	633	|O
O6	634	636	|B-IUPAC
-	636	637	|I-IUPAC
benzyl	637	643	|I-IUPAC
-	643	644	|I-IUPAC
8	644	645	|I-IUPAC
-	645	646	|I-IUPAC
bromoguanine	646	658	|I-IUPAC
)	658	659	|O
and	660	663	|O
5	664	665	|B-MODIFIER
-	665	666	|I-MODIFIER
substituted	666	677	|I-MODIFIER
2,4	678	681	|B-IUPAC
-	681	682	|I-IUPAC
diamino	682	689	|I-IUPAC
-	689	690	|I-IUPAC
6	690	691	|I-IUPAC
-	691	692	|I-IUPAC
(	692	693	|I-IUPAC
benzyloxy	693	702	|I-IUPAC
)	702	703	|I-IUPAC
pyrimidines	703	714	|I-IUPAC
bearing	715	722	|O
electron	723	731	|O
-	731	732	|O
withdrawing	732	743	|O
groups	744	750	|O
at	751	753	|O
the	754	757	|O
5	758	759	|O
-	759	760	|O
position	760	768	|O
(	769	770	|O
e.g.	770	774	|O
2,4	775	778	|B-PARTIUPAC
-	778	779	|I-PARTIUPAC
diamino	779	786	|I-PARTIUPAC
-	786	787	|I-PARTIUPAC
6	787	788	|I-PARTIUPAC
-	788	789	|I-PARTIUPAC
(	789	790	|I-PARTIUPAC
benzyloxy	790	799	|I-PARTIUPAC
)	799	800	|I-PARTIUPAC
-	800	801	|I-PARTIUPAC
5	801	802	|I-PARTIUPAC
-	802	803	|I-PARTIUPAC
nitroso	803	810	|I-PARTIUPAC
-	810	811	|I-PARTIUPAC
and	812	815	|O
2,4	816	819	|B-IUPAC
-	819	820	|I-IUPAC
diamino	820	827	|I-IUPAC
-	827	828	|I-IUPAC
6	828	829	|I-IUPAC
-	829	830	|I-IUPAC
(	830	831	|I-IUPAC
benzyloxy	831	840	|I-IUPAC
)	840	841	|I-IUPAC
-	841	842	|I-IUPAC
5	842	843	|I-IUPAC
-	843	844	|I-IUPAC
nitropyrimidine	844	859	|I-IUPAC
)	859	860	|O
.	860	861	|O
The	862	865	|O
latter	866	872	|O
derivatives	873	884	|O
were	885	889	|O
also	890	894	|O
more	895	899	|O
effective	900	909	|O
than	910	914	|O
O6	915	917	|B-IUPAC
-	917	918	|I-IUPAC
benzylguanine	918	931	|I-IUPAC
at	932	934	|O
inactivating	935	947	|O
AGT	948	951	|O
in	952	954	|O
intact	955	961	|O
HT29	962	966	|O
colon	967	972	|O
tumor	973	978	|O
cells	979	984	|O
.	984	985	|O
Provided	986	994	|O
these	995	1000	|O
types	1001	1006	|O
of	1007	1009	|O
purines	1010	1017	|O
and	1018	1021	|O
pyrimidines	1022	1033	|O
do	1034	1036	|O
not	1037	1040	|O
exhibit	1041	1048	|O
undesirable	1049	1060	|O
toxicity	1061	1069	|O
,	1069	1070	|O
they	1071	1075	|O
may	1076	1079	|O
be	1080	1082	|O
superior	1083	1091	|O
to	1092	1094	|O
O6	1095	1097	|B-IUPAC
-	1097	1098	|I-IUPAC
benzylguanine	1098	1111	|I-IUPAC
as	1112	1114	|O
chemotherapeutic	1115	1131	|O
adjuvants	1132	1141	|O
for	1142	1145	|O
enhancing	1146	1155	|O
the	1156	1159	|O
effectiveness	1160	1173	|O
of	1174	1176	|O
antitumor	1177	1186	|O
drugs	1187	1192	|O
for	1193	1196	|O
which	1197	1202	|O
the	1203	1206	|O
mechanism	1207	1216	|O
of	1217	1219	|O
action	1220	1226	|O
involves	1227	1235	|O
modification	1236	1248	|O
of	1249	1251	|O
the	1252	1255	|O
O6	1256	1258	|O
-	1258	1259	|O
position	1259	1267	|O
of	1268	1270	|O
DNA	1271	1274	|O
guanine	1275	1282	|O
residues	1283	1291	|O
.	1291	1292	|O

### abstracts4562.txt
Structure	0	9	|O
-	9	10	|O
activity	10	18	|O
relationships	19	32	|O
for	33	36	|O
inhibition	37	47	|O
of	48	50	|O
DNA	51	54	|O
-	54	55	|O
dependent	55	64	|O
protein	65	72	|O
kinase	73	79	|O
(	80	81	|O
DNA	81	84	|O
-	84	85	|O
PK	85	87	|O
)	87	88	|O
have	89	93	|O
been	94	98	|O
defined	99	106	|O
for	107	110	|O
substituted	111	122	|B-MODIFIER
chromen	123	130	|B-IUPAC
-	130	131	|I-IUPAC
4	131	132	|I-IUPAC
-	132	133	|I-IUPAC
ones	133	137	|I-IUPAC
.	137	138	|O
For	139	142	|O
the	143	146	|O
2	147	148	|B-IUPAC
-	148	149	|I-IUPAC
amino	149	154	|I-IUPAC
-	154	155	|O
substituted	155	166	|B-MODIFIER
benzo	167	172	|B-IUPAC
[	172	173	|I-IUPAC
h	173	174	|I-IUPAC
]	174	175	|I-IUPAC
chromen	175	182	|I-IUPAC
-	182	183	|I-IUPAC
4	183	184	|I-IUPAC
-	184	185	|I-IUPAC
ones	185	189	|I-IUPAC
,	189	190	|O
a	191	192	|O
morpholine	193	203	|O
substituent	204	215	|O
at	216	218	|O
this	219	223	|O
position	224	232	|O
was	233	236	|O
essential	237	246	|O
for	247	250	|O
activity	251	259	|O
.	259	260	|O
Small	261	266	|O
libraries	267	276	|O
of	277	279	|O
6	280	281	|B-PARTIUPAC
-	281	282	|I-PARTIUPAC
and	283	286	|O
7	287	288	|B-IUPAC
-	288	289	|I-IUPAC
alkoxy	289	295	|I-IUPAC
-	295	296	|O
substituted	296	307	|B-MODIFIER
chromen	308	315	|B-IUPAC
-	315	316	|I-IUPAC
4	316	317	|I-IUPAC
-	317	318	|I-IUPAC
ones	318	322	|I-IUPAC
showed	323	329	|O
that	330	334	|O
a	335	336	|O
number	337	343	|O
of	344	346	|O
7	347	348	|B-IUPAC
-	348	349	|I-IUPAC
alkoxy	349	355	|I-IUPAC
-	355	356	|O
substituted	356	367	|B-MODIFIER
chromenones	368	379	|B-IUPAC
displayed	380	389	|O
improved	390	398	|O
activity	399	407	|O
.	407	408	|O
Focused	409	416	|O
libraries	417	426	|O
incorporating	427	440	|O
6	441	442	|B-PARTIUPAC
-	442	443	|I-PARTIUPAC
,	443	444	|O
7	445	446	|B-PARTIUPAC
-	446	447	|I-PARTIUPAC
,	447	448	|O
and	449	452	|O
8	453	454	|B-IUPAC
-	454	455	|I-IUPAC
aryl	455	459	|I-IUPAC
and	460	463	|O
heteroaryl	464	474	|B-IUPAC
substituents	475	487	|B-MODIFIER
were	488	492	|O
prepared	493	501	|O
.	501	502	|O
In	503	505	|O
these	506	511	|O
cases	512	517	|O
,	517	518	|O
6	519	520	|O
-	520	521	|O
and	522	525	|O
7	526	527	|O
-	527	528	|O
substitution	528	540	|O
was	541	544	|O
disfavored	545	555	|O
,	555	556	|O
whereas	557	564	|O
8	565	566	|O
-	566	567	|O
substitution	567	579	|O
was	580	583	|O
largely	584	591	|O
tolerated	592	601	|O
.	601	602	|O
Surprisingly	603	615	|O
,	615	616	|O
two	617	620	|O
compounds	621	630	|O
,	630	631	|O
2	632	633	|B-IUPAC
-	633	634	|I-IUPAC
N	634	635	|I-IUPAC
-	635	636	|I-IUPAC
morpholino	636	646	|I-IUPAC
-	646	647	|I-IUPAC
8	647	648	|I-IUPAC
-	648	649	|I-IUPAC
dibenzofuranyl	649	663	|I-IUPAC
-	663	664	|I-IUPAC
chromen	664	671	|I-IUPAC
-	671	672	|I-IUPAC
4	672	673	|I-IUPAC
-	673	674	|I-IUPAC
one	674	677	|I-IUPAC
(	678	679	|O
NU7427	679	685	|O
,	685	686	|O
32	687	689	|O
{	689	690	|O
38	690	692	|O
}	692	693	|O
)	693	694	|O
and	695	698	|O
the	699	702	|O
2	703	704	|B-IUPAC
-	704	705	|I-IUPAC
N	705	706	|I-IUPAC
-	706	707	|I-IUPAC
morpholino	707	717	|I-IUPAC
-	717	718	|I-IUPAC
8	718	719	|I-IUPAC
-	719	720	|I-IUPAC
dibenzothiophenyl	720	737	|I-IUPAC
-	737	738	|I-IUPAC
chromen	738	745	|I-IUPAC
-	745	746	|I-IUPAC
4	746	747	|I-IUPAC
-	747	748	|I-IUPAC
one	748	751	|I-IUPAC
(	752	753	|O
NU7441	753	759	|O
,	759	760	|O
32	761	763	|O
{	763	764	|O
26	764	766	|O
}	766	767	|O
)	767	768	|O
were	769	773	|O
excellent	774	783	|O
inhibitors	784	794	|O
(	795	796	|O
IC50	796	800	|O
vs	801	803	|O
DNA	804	807	|O
-	807	808	|O
PK	808	810	|O
=	811	812	|O
40	813	815	|O
and	816	819	|O
13	820	822	|O
nM	823	825	|O
,	825	826	|O
respectively	827	839	|O
)	839	840	|O
.	840	841	|O
The	842	845	|O
ring	846	850	|B-MODIFIER
-	850	851	|I-MODIFIER
saturated	851	860	|I-MODIFIER
analogue	861	869	|I-MODIFIER
2	870	871	|B-IUPAC
-	871	872	|I-IUPAC
N	872	873	|I-IUPAC
-	873	874	|I-IUPAC
morpholino	874	884	|I-IUPAC
-	884	885	|I-IUPAC
8	885	886	|I-IUPAC
-	886	887	|I-IUPAC
(	887	888	|I-IUPAC
6'	888	890	|I-IUPAC
,	890	891	|I-IUPAC
7'	891	893	|I-IUPAC
,	893	894	|I-IUPAC
8'	894	896	|I-IUPAC
,	896	897	|I-IUPAC
9'	897	899	|I-IUPAC
-	899	900	|I-IUPAC
tetrahydrodibenzothiophene	900	926	|I-IUPAC
)	926	927	|I-IUPAC
chromen	927	934	|I-IUPAC
-	934	935	|I-IUPAC
4	935	936	|I-IUPAC
-	936	937	|I-IUPAC
one	937	940	|I-IUPAC
,	940	941	|O
36	942	944	|O
,	944	945	|O
retained	946	954	|O
potent	955	961	|O
activity	962	970	|O
(	971	972	|O
IC50	972	976	|O
vs	977	979	|O
DNA	980	983	|O
-	983	984	|O
PK	984	986	|O
=	987	988	|O
23	989	991	|O
nM	992	994	|O
)	994	995	|O
.	995	996	|O
The	997	1000	|O
dibenzothiophene	1001	1017	|O
32	1018	1020	|O
{	1020	1021	|O
38	1021	1023	|O
}	1023	1024	|O
sensitized	1025	1035	|O
HeLa	1036	1040	|O
cells	1041	1046	|O
to	1047	1049	|O
ionizing	1050	1058	|O
radiation	1059	1068	|O
in	1069	1071	|O
vitro	1072	1077	|O
,	1077	1078	|O
with	1079	1083	|O
dose	1084	1088	|O
modification	1089	1101	|O
factors	1102	1109	|O
of	1110	1112	|O
2.5	1113	1116	|O
at	1117	1119	|O
10%	1120	1123	|O
survival	1124	1132	|O
being	1133	1138	|O
observed	1139	1147	|O
at	1148	1150	|O
0.5	1151	1154	|O
microM	1155	1161	|O
.	1161	1162	|O
The	1163	1166	|O
cytotoxicity	1167	1179	|O
of	1180	1182	|O
the	1183	1186	|O
topoisomerase	1187	1200	|O
II	1201	1203	|O
inhibitor	1204	1213	|O
etoposide	1214	1223	|O
was	1224	1227	|O
also	1228	1232	|O
potentiated	1233	1244	|O
.	1244	1245	|O

### abstracts760.txt
4,5,6,7	0	7	|B-IUPAC
-	7	8	|I-IUPAC
Tetrahydro	8	18	|I-IUPAC
-	18	19	|I-IUPAC
5	19	20	|I-IUPAC
-	20	21	|I-IUPAC
methylimidazo	21	34	|I-IUPAC
[	34	35	|I-IUPAC
4,5,1	35	40	|I-IUPAC
-	40	41	|I-IUPAC
jk	41	43	|I-IUPAC
]	43	44	|I-IUPAC
[	44	45	|I-IUPAC
1,4	45	48	|I-IUPAC
]	48	49	|I-IUPAC
benzodiazepin	49	62	|I-IUPAC
-	62	63	|I-IUPAC
2	63	64	|I-IUPAC
(	65	66	|I-IUPAC
1H	66	68	|I-IUPAC
)	68	69	|I-IUPAC
-	69	70	|I-IUPAC
ones	70	74	|I-IUPAC
(	75	76	|O
TIBO	76	80	|O
)	80	81	|O
,	81	82	|O
1	83	84	|O
,	84	85	|O
have	86	90	|O
been	91	95	|O
shown	96	101	|O
to	102	104	|O
significantly	105	118	|O
inhibit	119	126	|O
HIV	127	130	|O
-	130	131	|O
1	131	132	|O
replication	133	144	|O
in	145	147	|O
vitro	148	153	|O
by	154	156	|O
interfering	157	168	|O
with	169	173	|O
the	174	177	|O
virus	178	183	|O
's	183	185	|O
reverse	186	193	|O
transcriptase	194	207	|O
enzyme	208	214	|O
.	214	215	|O
They	216	220	|O
have	221	225	|O
also	226	230	|O
demonstrated	231	243	|O
potential	244	253	|O
clinical	254	262	|O
efficacy	263	271	|O
in	272	274	|O
combating	275	284	|O
HIV	285	288	|O
-	288	289	|O
1	289	290	|O
,	290	291	|O
on	292	294	|O
the	295	298	|O
basis	299	304	|O
of	305	307	|O
a	308	309	|O
preliminary	310	321	|O
study	322	327	|O
.	327	328	|O
Our	329	332	|O
prior	333	338	|O
publications	339	351	|O
have	352	356	|O
discussed	357	366	|O
the	367	370	|O
discovery	371	380	|O
of	381	383	|O
this	384	388	|O
series	389	395	|O
of	396	398	|O
compounds	399	408	|O
and	409	412	|O
reported	413	421	|O
some	422	426	|O
preliminary	427	438	|O
chemical	439	447	|O
and	448	451	|O
biological	452	462	|O
studies	463	470	|O
around	471	477	|O
N	478	479	|O
-	479	480	|O
6	480	481	|O
substitutions	482	495	|O
and	496	499	|O
5	500	501	|O
-	501	502	|O
membered	502	510	|O
ring	511	515	|O
variations	516	526	|O
of	527	529	|O
1	530	531	|O
.	531	532	|O
This	533	537	|O
manuscript	538	548	|O
describes	549	558	|O
our	559	562	|O
synthetic	563	572	|O
endeavors	573	582	|O
around	583	589	|O
4	590	591	|O
,	591	592	|O
5	593	594	|O
,	594	595	|O
and	596	599	|O
7	600	601	|O
mono	602	606	|O
-	606	607	|O
and	608	611	|O
disubstitutions	612	627	|O
of	628	630	|O
1	631	632	|O
and	633	636	|O
discusses	637	646	|O
related	647	654	|O
HIV	655	658	|O
-	658	659	|O
1	659	660	|O
inhibitory	661	671	|O
structure	672	681	|O
-	681	682	|O
activity	682	690	|O
relationships	691	704	|O
.	704	705	|O
On	706	708	|O
the	709	712	|O
basis	713	718	|O
of	719	721	|O
inhibition	722	732	|O
of	733	735	|O
HIV	736	739	|O
-	739	740	|O
1'	740	742	|O
s	742	743	|O
cytopathic	744	754	|O
effects	755	762	|O
in	763	765	|O
MT	766	768	|O
-	768	769	|O
4	769	770	|O
cells	771	776	|O
,	776	777	|O
we	778	780	|O
found	781	786	|O
that	787	791	|O
5	792	793	|O
-	793	794	|O
mono	794	798	|O
-	798	799	|O
Me	799	801	|O
-	801	802	|O
substituted	802	813	|O
analogues	814	823	|O
,	823	824	|O
the	825	828	|O
original	829	837	|O
substitution	838	850	|O
in	851	853	|O
the	854	857	|O
early	858	863	|O
lead	864	868	|O
compounds	869	878	|O
,	878	879	|O
and	880	883	|O
7	884	885	|O
-	885	886	|O
mono	886	890	|O
-	890	891	|O
Me	891	893	|O
-	893	894	|O
substituted	894	905	|O
analogues	906	915	|O
of	916	918	|O
1	919	920	|O
were	921	925	|O
comparable	926	936	|O
as	937	939	|O
being	940	945	|O
consistently	946	958	|O
the	959	962	|O
most	963	967	|O
active	968	974	|O
compounds	975	984	|O
.	984	985	|O
Although	986	994	|O
generally	995	1004	|O
less	1005	1009	|O
active	1010	1016	|O
,	1016	1017	|O
the	1018	1021	|O
4,5,7	1022	1027	|O
-	1027	1028	|O
unsubstituted	1028	1041	|O
,	1041	1042	|O
4	1043	1044	|O
-	1044	1045	|O
mono	1045	1049	|O
-	1049	1050	|O
substituted	1050	1061	|O
,	1061	1062	|O
cis	1063	1066	|O
-	1066	1067	|O
and	1068	1071	|O
trans	1072	1077	|O
-	1077	1078	|O
5,7	1078	1081	|O
-	1081	1082	|O
di	1082	1084	|O
-	1084	1085	|O
Me	1085	1087	|O
-	1087	1088	|O
substituted	1088	1099	|O
,	1099	1100	|O
and	1101	1104	|O
cis	1105	1108	|O
-	1108	1109	|O
4,5	1109	1112	|O
-	1112	1113	|O
di	1113	1115	|O
-	1115	1116	|O
Me	1116	1118	|O
-	1118	1119	|O
substituted	1119	1130	|O
analogues	1131	1140	|O
of	1141	1143	|O
1	1144	1145	|O
also	1146	1150	|O
exhibited	1151	1160	|O
some	1161	1165	|O
significant	1166	1177	|O
desired	1178	1185	|O
activity	1186	1194	|O
.	1194	1195	|O
The	1196	1199	|O
remaining	1200	1209	|O
trans	1210	1215	|O
-	1215	1216	|O
4,5	1216	1219	|O
-	1219	1220	|O
di	1220	1222	|O
-	1222	1223	|O
Me	1223	1225	|O
-	1225	1226	|O
substituted	1226	1237	|O
,	1237	1238	|O
cis	1239	1242	|O
-	1242	1243	|O
and	1244	1247	|O
trans	1248	1253	|O
-	1253	1254	|O
4,7	1254	1257	|O
-	1257	1258	|O
di	1258	1260	|O
-	1260	1261	|O
Me	1261	1263	|O
-	1263	1264	|O
substituted	1264	1275	|O
,	1275	1276	|O
and	1277	1280	|O
all	1281	1284	|O
4,5	1285	1288	|O
-	1288	1289	|O
,	1289	1290	|O
5,6	1291	1294	|O
-	1294	1295	|O
,	1295	1296	|O
6,7	1297	1300	|O
-	1300	1301	|O
,	1301	1302	|O
and	1303	1306	|O
7,8	1307	1310	|O
-	1310	1311	|O
fused	1311	1316	|O
disubstituted	1317	1330	|O
analogues	1331	1340	|O
of	1341	1343	|O
1	1344	1345	|O
possessed	1346	1355	|O
no	1356	1358	|O
noticeable	1359	1369	|O
desired	1370	1377	|O
activity	1378	1386	|O
.	1386	1387	|O

### abstracts3062.txt
From	0	4	|O
the	5	8	|O
reaction	9	17	|O
of	18	20	|O
silylated	21	30	|B-MODIFIER
4	31	32	|B-IUPAC
-	32	33	|I-IUPAC
(	33	34	|I-IUPAC
3,3	34	37	|I-IUPAC
-	37	38	|I-IUPAC
dimethyl	38	46	|I-IUPAC
-	46	47	|I-IUPAC
1	47	48	|I-IUPAC
-	48	49	|I-IUPAC
triazeno	49	57	|I-IUPAC
)	57	58	|I-IUPAC
imidazole	58	67	|I-IUPAC
-	67	68	|I-IUPAC
5	68	69	|I-IUPAC
-	69	70	|I-IUPAC
carboxamide	70	81	|I-IUPAC
(	82	83	|O
DTIC	83	87	|O
,	87	88	|O
5	89	90	|O
)	90	91	|O
and	92	95	|O
3	96	97	|B-IUPAC
-	97	98	|I-IUPAC
(	98	99	|I-IUPAC
3,3	99	102	|I-IUPAC
-	102	103	|I-IUPAC
dimethyl	103	111	|I-IUPAC
-	111	112	|I-IUPAC
1	112	113	|I-IUPAC
-	113	114	|I-IUPAC
triazeno	114	122	|I-IUPAC
)	122	123	|I-IUPAC
pyrazole	123	131	|I-IUPAC
-	131	132	|I-IUPAC
4	132	133	|I-IUPAC
-	133	134	|I-IUPAC
carboxamide	134	145	|I-IUPAC
(	146	147	|O
DTPC	147	151	|O
,	151	152	|O
9	153	154	|O
)	154	155	|O
with	156	160	|O
2	161	162	|B-IUPAC
-	162	163	|I-IUPAC
chlorotetrahydrofuran	163	184	|I-IUPAC
,	184	185	|O
we	186	188	|O
have	189	193	|O
isolated	194	202	|O
in	203	205	|O
both	206	210	|O
cases	211	216	|O
a	217	218	|O
single	219	225	|O
tetrahydrofuran	226	241	|B-IUPAC
-	241	242	|I-IUPAC
2	242	243	|I-IUPAC
-	243	244	|I-IUPAC
yl	244	246	|I-IUPAC
derivative	247	257	|B-MODIFIER
.	257	258	|O
However	259	266	|O
,	266	267	|O
when	268	272	|O
silylated	273	282	|O
DTPC	283	287	|O
was	288	291	|O
reacted	292	299	|O
with	300	304	|O
2	305	306	|B-IUPAC
-	306	307	|I-IUPAC
chlorotetrahydropyran	307	328	|I-IUPAC
,	328	329	|O
two	330	333	|O
tetrahydropyran	334	349	|B-IUPAC
-	349	350	|I-IUPAC
2	350	351	|I-IUPAC
-	351	352	|I-IUPAC
yl	352	354	|I-IUPAC
compounds	355	364	|B-MODIFIER
were	365	369	|O
obtained	370	378	|O
,	378	379	|O
and	380	383	|O
these	384	389	|O
were	390	394	|O
shown	395	400	|O
to	401	403	|O
be	404	406	|O
positional	407	417	|O
isomers	418	425	|O
on	426	428	|O
the	429	432	|O
basis	433	438	|O
of	439	441	|O
1H	442	444	|O
NMR	445	448	|O
and	449	452	|O
UV	453	455	|O
data	456	460	|O
.	460	461	|O
These	462	467	|O
furanyl	468	475	|B-IUPAC
and	476	479	|O
pyranyl	480	487	|B-IUPAC
derivatives	488	499	|B-MODIFIER
were	500	504	|O
tested	505	511	|O
for	512	515	|O
antileukemic	516	528	|O
activity	529	537	|O
(	538	539	|O
L	539	540	|O
-	540	541	|O
1210	541	545	|O
,	545	546	|O
in	547	549	|O
vivo	550	554	|O
)	554	555	|O
and	556	559	|O
the	560	563	|O
results	564	571	|O
were	572	576	|O
compared	577	585	|O
with	586	590	|O
the	591	594	|O
results	595	602	|O
obtained	603	611	|O
for	612	615	|O
the	616	619	|O
corresponding	620	633	|O
ribosyl	634	641	|B-IUPAC
derivatives	642	653	|B-MODIFIER
of	654	656	|O
DTIC	657	661	|O
and	662	665	|O
DTPC	666	670	|O
.	670	671	|O

### abstracts3836.txt
Syntheses	0	9	|O
of	10	12	|O
the	13	16	|O
trans	17	22	|B-IUPAC
-	22	23	|I-IUPAC
dihydrodiol	23	34	|I-IUPAC
derivatives	35	46	|B-MODIFIER
implicated	47	57	|O
as	58	60	|O
the	61	64	|O
proximate	65	74	|O
carcinogenic	75	87	|O
metabolites	88	99	|O
of	100	102	|O
the	103	106	|O
polycyclic	107	117	|O
hydrocarbons	118	130	|O
cholanthrene	131	143	|O
,	143	144	|O
6	145	146	|B-IUPAC
-	146	147	|I-IUPAC
methylcholanthrene	147	165	|I-IUPAC
,	165	166	|O
benz	167	171	|B-IUPAC
[	171	172	|I-IUPAC
a	172	173	|I-IUPAC
]	173	174	|I-IUPAC
anthracene	174	184	|I-IUPAC
,	184	185	|O
and	186	189	|O
7	190	191	|B-PARTIUPAC
-	191	192	|I-PARTIUPAC
and	193	196	|O
12	197	199	|B-IUPAC
-	199	200	|I-IUPAC
methylbenz	200	210	|I-IUPAC
[	210	211	|I-IUPAC
a	211	212	|I-IUPAC
]	212	213	|I-IUPAC
anthracene	213	223	|I-IUPAC
are	224	227	|O
described	228	237	|O
.	237	238	|O
These	239	244	|O
compounds	245	254	|O
are	255	258	|O
useful	259	265	|O
models	266	272	|O
for	273	276	|O
research	277	285	|O
to	286	288	|O
determine	289	298	|O
the	299	302	|O
molecular	303	312	|O
basis	313	318	|O
of	319	321	|O
the	322	325	|O
strong	326	332	|O
enhancement	333	344	|O
of	345	347	|O
carcinogenicity	348	363	|O
consequent	364	374	|O
upon	375	379	|O
methyl	380	386	|B-IUPAC
substitution	387	399	|B-MODIFIER
in	400	402	|O
nonbenzo	403	411	|O
bay	412	415	|O
molecular	416	425	|O
sites	426	431	|O
and	432	435	|O
meso	436	440	|O
regions	441	448	|O
of	449	451	|O
polycyclic	452	462	|O
hydrocarbons	463	475	|O
.	475	476	|O
Synthesis	477	486	|O
of	487	489	|O
the	490	493	|O
bay	494	497	|O
region	498	504	|O
anti	505	509	|O
-	509	510	|O
diol	510	514	|O
epoxide	515	522	|O
derivative	523	533	|O
of	534	536	|O
cholanthrene	537	549	|O
,	549	550	|O
its	551	554	|O
putative	555	563	|O
ultimate	564	572	|O
carcinogenic	573	585	|O
metabolite	586	596	|O
,	596	597	|O
is	598	600	|O
also	601	605	|O
described	606	615	|O
.	615	616	|O
Tumorigenicity	617	631	|O
assays	632	638	|O
indicate	639	647	|O
that	648	652	|O
the	653	656	|O
9,10	657	661	|B-IUPAC
-	661	662	|I-IUPAC
dihydrodiol	662	673	|I-IUPAC
derivatives	674	685	|B-MODIFIER
of	686	688	|O
cholanthrene	689	701	|O
and	702	705	|O
its	706	709	|O
3	710	711	|B-PARTIUPAC
-	711	712	|I-PARTIUPAC
and	713	716	|O
6	717	718	|B-IUPAC
-	718	719	|I-IUPAC
methyl	719	725	|I-IUPAC
derivatives	726	737	|B-MODIFIER
are	738	741	|O
all	742	745	|O
potent	746	752	|O
tumor	753	758	|O
initiators	759	769	|O
on	770	772	|O
mouse	773	778	|O
skin	779	783	|O
.	783	784	|O
The	785	788	|O
most	789	793	|O
active	794	800	|O
member	801	807	|O
of	808	810	|O
the	811	814	|O
series	815	821	|O
is	822	824	|O
the	825	828	|O
dihydrodiol	829	840	|B-IUPAC
derivative	841	851	|B-MODIFIER
of	852	854	|O
6	855	856	|B-IUPAC
-	856	857	|I-IUPAC
methylcholanthrene	857	875	|I-IUPAC
,	875	876	|O
which	877	882	|O
contains	883	891	|O
a	892	893	|O
bay	894	897	|O
region	898	904	|O
methyl	905	911	|B-IUPAC
group	912	917	|B-MODIFIER
.	917	918	|O
The	919	922	|O
ability	923	930	|O
of	931	933	|O
the	934	937	|O
dihydrodiols	938	950	|O
3a	951	953	|O
-	953	954	|O
c	954	955	|O
and	956	959	|O
the	960	963	|O
trans	964	969	|B-IUPAC
-	969	970	|I-IUPAC
3,4	970	973	|I-IUPAC
-	973	974	|I-IUPAC
dihydrodiol	974	985	|I-IUPAC
of	986	988	|O
7,12	989	993	|B-IUPAC
-	993	994	|I-IUPAC
dimethylbenz	994	1006	|I-IUPAC
[	1006	1007	|I-IUPAC
a	1007	1008	|I-IUPAC
]	1008	1009	|I-IUPAC
anthracene	1009	1019	|I-IUPAC
(	1020	1021	|O
3d	1021	1023	|O
)	1023	1024	|O
to	1025	1027	|O
induce	1028	1034	|O
chromosomal	1035	1046	|O
aberrations	1047	1058	|O
in	1059	1061	|O
rat	1062	1065	|O
bone	1066	1070	|O
marrow	1071	1077	|O
cells	1078	1083	|O
was	1084	1087	|O
also	1088	1092	|O
examined	1093	1101	|O
.	1101	1102	|O
The	1103	1106	|O
observed	1107	1115	|O
order	1116	1121	|O
of	1122	1124	|O
activity	1125	1133	|O
was	1134	1137	|O
3d	1138	1140	|O
greater	1141	1148	|O
than	1149	1153	|O
3c	1154	1156	|O
greater	1157	1164	|O
than	1165	1169	|O
3b	1170	1172	|O
greater	1173	1180	|O
than	1181	1185	|O
3a	1186	1188	|O
.	1188	1189	|O
These	1190	1195	|O
findings	1196	1204	|O
are	1205	1208	|O
consistent	1209	1219	|O
with	1220	1224	|O
the	1225	1228	|O
hypothesis	1229	1239	|O
that	1240	1244	|O
the	1245	1248	|O
diol	1249	1253	|O
epoxide	1254	1261	|O
metabolites	1262	1273	|O
of	1274	1276	|O
these	1277	1282	|O
dihydrodiols	1283	1295	|O
are	1296	1299	|O
the	1300	1303	|O
active	1304	1310	|O
carcinogenic	1311	1323	|O
forms	1324	1329	|O
of	1330	1332	|O
the	1333	1336	|O
parent	1337	1343	|O
hydrocarbons	1344	1356	|O
.	1356	1357	|O

### abstracts3.txt
The	0	3	|O
syntheses	4	13	|O
of	14	16	|O
(	17	18	|B-IUPAC
RS	18	20	|I-IUPAC
)	20	21	|I-IUPAC
-	21	22	|I-IUPAC
alpha	22	27	|I-IUPAC
-	27	28	|I-IUPAC
amino	28	33	|I-IUPAC
-	33	34	|I-IUPAC
3	34	35	|I-IUPAC
-	35	36	|I-IUPAC
hydroxy	36	43	|I-IUPAC
-	43	44	|I-IUPAC
5	44	45	|I-IUPAC
-	45	46	|I-IUPAC
tert	46	50	|I-IUPAC
-	50	51	|I-IUPAC
butyl	51	56	|I-IUPAC
-	56	57	|I-IUPAC
4	57	58	|I-IUPAC
-	58	59	|I-IUPAC
isoxazolepropionic	59	77	|I-IUPAC
acid	78	82	|I-IUPAC
(	83	84	|O
9	84	85	|O
,	85	86	|O
ATPA	87	91	|O
)	91	92	|O
,	92	93	|O
(	94	95	|B-IUPAC
alpha	95	100	|I-IUPAC
-	100	101	|I-IUPAC
RS	101	103	|I-IUPAC
,	103	104	|I-IUPAC
beta	105	109	|I-IUPAC
-	109	110	|I-IUPAC
RS	110	112	|I-IUPAC
)	112	113	|I-IUPAC
-	113	114	|I-IUPAC
alpha	114	119	|I-IUPAC
-	119	120	|I-IUPAC
amino	120	125	|I-IUPAC
-	125	126	|I-IUPAC
beta	126	130	|I-IUPAC
-	130	131	|I-IUPAC
methyl	131	137	|I-IUPAC
-	137	138	|I-IUPAC
3	138	139	|I-IUPAC
-	139	140	|I-IUPAC
hydroxy	140	147	|I-IUPAC
-	147	148	|I-IUPAC
5	148	149	|I-IUPAC
-	149	150	|I-IUPAC
isoxazolepropionic	150	168	|I-IUPAC
acid	169	173	|I-IUPAC
(	174	175	|O
8	175	176	|O
)	176	177	|O
,	177	178	|O
(	179	180	|B-IUPAC
RS	180	182	|I-IUPAC
)	182	183	|I-IUPAC
-	183	184	|I-IUPAC
alpha	184	189	|I-IUPAC
-	189	190	|I-IUPAC
amino	190	195	|I-IUPAC
-	195	196	|I-IUPAC
3	196	197	|I-IUPAC
-	197	198	|I-IUPAC
hydroxy	198	205	|I-IUPAC
-	205	206	|I-IUPAC
5	206	207	|I-IUPAC
-	207	208	|I-IUPAC
isoxazolebutyric	208	224	|I-IUPAC
acid	225	229	|I-IUPAC
(	230	231	|O
15a	231	234	|O
)	234	235	|O
,	235	236	|O
and	237	240	|O
(	241	242	|B-IUPAC
RS	242	244	|I-IUPAC
)	244	245	|I-IUPAC
-	245	246	|I-IUPAC
alpha	246	251	|I-IUPAC
-	251	252	|I-IUPAC
amino	252	257	|I-IUPAC
-	257	258	|I-IUPAC
3	258	259	|I-IUPAC
-	259	260	|I-IUPAC
hydroxy	260	267	|I-IUPAC
-	267	268	|I-IUPAC
5	268	269	|I-IUPAC
-	269	270	|I-IUPAC
isoxazolevaleric	270	286	|I-IUPAC
acid	287	291	|I-IUPAC
(	292	293	|O
15b	293	296	|O
)	296	297	|O
are	298	301	|O
described	302	311	|O
.	311	312	|O
The	313	316	|O
compounds	317	326	|O
were	327	331	|O
tested	332	338	|O
in	339	341	|O
vitro	342	347	|O
together	348	356	|O
with	357	361	|O
(	362	363	|B-IUPAC
RS	363	365	|I-IUPAC
)	365	366	|I-IUPAC
-	366	367	|I-IUPAC
alpha	367	372	|I-IUPAC
-	372	373	|I-IUPAC
amino	373	378	|I-IUPAC
-	378	379	|I-IUPAC
3	379	380	|I-IUPAC
-	380	381	|I-IUPAC
hydroxy	381	388	|I-IUPAC
-	388	389	|I-IUPAC
5	389	390	|I-IUPAC
-	390	391	|I-IUPAC
(	391	392	|I-IUPAC
bromomethyl	392	403	|I-IUPAC
)	403	404	|I-IUPAC
-	404	405	|I-IUPAC
4	405	406	|I-IUPAC
-	406	407	|I-IUPAC
isoxazolepropionic	407	425	|I-IUPAC
acid	426	430	|I-IUPAC
(	431	432	|O
ABPA	432	436	|O
)	436	437	|O
as	438	440	|O
inhibitors	441	451	|O
of	452	454	|O
the	455	458	|O
binding	459	466	|O
of	467	469	|O
radioactive	470	481	|O
-	481	482	|O
labeled	482	489	|O
(	490	491	|B-IUPAC
RS	491	493	|I-IUPAC
)	493	494	|I-IUPAC
-	494	495	|I-IUPAC
alpha	495	500	|I-IUPAC
-	500	501	|I-IUPAC
amino	501	506	|I-IUPAC
-	506	507	|I-IUPAC
3	507	508	|I-IUPAC
-	508	509	|I-IUPAC
hydroxy	509	516	|I-IUPAC
-	516	517	|I-IUPAC
5	517	518	|I-IUPAC
-	518	519	|I-IUPAC
methyl	519	525	|I-IUPAC
-	525	526	|I-IUPAC
4	526	527	|I-IUPAC
-	527	528	|I-IUPAC
isoxazolepropionic	528	546	|I-IUPAC
acid	547	551	|I-IUPAC
(	552	553	|O
AMPA	553	557	|O
)	557	558	|O
to	559	561	|O
rat	562	565	|O
brain	566	571	|O
synaptic	572	580	|O
membranes	581	590	|O
.	590	591	|O
These	592	597	|O
data	598	602	|O
were	603	607	|O
compared	608	616	|O
with	617	621	|O
the	622	625	|O
earlier	626	633	|O
reported	634	642	|O
effects	643	650	|O
of	651	653	|O
the	654	657	|O
compounds	658	667	|O
on	668	670	|O
single	671	677	|O
neurons	678	685	|O
in	686	688	|O
the	689	692	|O
feline	693	699	|O
spinal	700	706	|O
cord	707	711	|O
obtained	712	720	|O
by	721	723	|O
microelectrophoretic	724	744	|O
techniques	745	755	|O
.	755	756	|O
The	757	760	|O
three	761	766	|O
compounds	767	776	|O
AMPA	777	781	|O
,	781	782	|O
ATPA	783	787	|O
,	787	788	|O
and	789	792	|O
ABPA	793	797	|O
are	798	801	|O
agonists	802	810	|O
at	811	813	|O
the	814	817	|O
class	818	823	|O
of	824	826	|O
receptors	827	836	|O
assumed	837	844	|O
to	845	847	|O
represent	848	857	|O
a	858	859	|O
subtype	860	867	|O
of	868	870	|O
physiological	871	884	|O
(	885	886	|B-IUPAC
S	886	887	|I-IUPAC
)	887	888	|I-IUPAC
-	888	889	|I-IUPAC
glutamic	889	897	|I-IUPAC
acid	898	902	|I-IUPAC
(	903	904	|O
Glu	904	907	|O
)	907	908	|O
receptors	909	918	|O
.	918	919	|O
Inhibition	920	930	|O
of	931	933	|O
[	934	935	|O
3H	935	937	|O
]	937	938	|O
AMPA	938	942	|O
binding	943	950	|O
by	951	953	|O
ATPA	954	958	|O
was	959	962	|O
1	963	964	|O
order	965	970	|O
of	971	973	|O
magnitude	974	983	|O
weaker	984	990	|O
than	991	995	|O
that	996	1000	|O
of	1001	1003	|O
AMPA	1004	1008	|O
,	1008	1009	|O
in	1010	1012	|O
agreement	1013	1022	|O
with	1023	1027	|O
the	1028	1031	|O
relative	1032	1040	|O
potency	1041	1048	|O
of	1049	1051	|O
these	1052	1057	|O
compounds	1058	1067	|O
in	1068	1070	|O
vivo	1071	1075	|O
.	1075	1076	|O
ABPA	1077	1081	|O
proved	1082	1088	|O
to	1089	1091	|O
be	1092	1094	|O
equipotent	1095	1105	|O
with	1106	1110	|O
AMPA	1111	1115	|O
both	1116	1120	|O
as	1121	1123	|O
an	1124	1126	|O
inhibitor	1127	1136	|O
of	1137	1139	|O
AMPA	1140	1144	|O
binding	1145	1152	|O
and	1153	1156	|O
as	1157	1159	|O
a	1160	1161	|O
neuronal	1162	1170	|O
excitant	1171	1179	|O
.	1179	1180	|O
The	1181	1184	|O
compounds	1185	1194	|O
8	1195	1196	|O
,	1196	1197	|O
15a	1198	1201	|O
,	1201	1202	|O
and	1203	1206	|O
15b	1207	1210	|O
have	1211	1215	|O
no	1216	1218	|O
effect	1219	1225	|O
as	1226	1228	|O
inhibitors	1229	1239	|O
of	1240	1242	|O
AMPA	1243	1247	|O
binding	1248	1255	|O
,	1255	1256	|O
in	1257	1259	|O
agreement	1260	1269	|O
with	1270	1274	|O
in	1275	1277	|O
vivo	1278	1282	|O
studies	1283	1290	|O
that	1291	1295	|O
have	1296	1300	|O
shown	1301	1306	|O
that	1307	1311	|O
8	1312	1313	|O
does	1314	1318	|O
not	1319	1322	|O
affect	1323	1329	|O
the	1330	1333	|O
firing	1334	1340	|O
of	1341	1343	|O
central	1344	1351	|O
neurons	1352	1359	|O
whereas	1360	1367	|O
15a	1368	1371	|O
and	1372	1375	|O
15b	1376	1379	|O
are	1380	1383	|O
antagonists	1384	1395	|O
at	1396	1398	|O
NMDA	1399	1403	|O
receptors	1404	1413	|O
,	1413	1414	|O
a	1415	1416	|O
subpopulation	1417	1430	|O
of	1431	1433	|O
excitatory	1434	1444	|O
receptors	1445	1454	|O
not	1455	1458	|O
affected	1459	1467	|O
by	1468	1470	|O
AMPA	1471	1475	|O
.	1475	1476	|O
Molecular	1477	1486	|O
mechanical	1487	1497	|O
calculations	1498	1510	|O
on	1511	1513	|O
AMPA	1514	1518	|O
,	1518	1519	|O
ATPA	1520	1524	|O
,	1524	1525	|O
and	1526	1529	|O
ABPA	1530	1534	|O
using	1535	1540	|O
the	1541	1544	|O
program	1545	1552	|O
MM2	1553	1556	|O
showed	1557	1563	|O
that	1564	1568	|O
conformations	1569	1582	|O
of	1583	1585	|O
AMPA	1586	1590	|O
,	1590	1591	|O
ABPA	1592	1596	|O
,	1596	1597	|O
and	1598	1601	|O
especially	1602	1612	|O
ATPA	1613	1617	|O
by	1618	1620	|O
rotation	1621	1629	|O
of	1630	1632	|O
the	1633	1636	|O
amino	1637	1642	|O
acid	1643	1647	|O
side	1648	1652	|O
chain	1653	1658	|O
have	1659	1663	|O
energy	1664	1670	|O
barriers	1671	1679	|O
.	1679	1680	|O
A	1681	1682	|O
possible	1683	1691	|O
receptor	1692	1700	|O
-	1700	1701	|O
active	1701	1707	|O
conformation	1708	1720	|O
is	1721	1723	|O
suggested	1724	1733	|O
.	1733	1734	|O

### abstracts3728.txt
A	0	1	|O
number	2	8	|O
of	9	11	|O
3	12	13	|B-PARTIUPAC
-	13	14	|I-PARTIUPAC
bromo	14	19	|I-PARTIUPAC
-	19	20	|I-PARTIUPAC
,	20	21	|O
3	22	23	|B-PARTIUPAC
-	23	24	|I-PARTIUPAC
nitro	24	29	|I-PARTIUPAC
-	29	30	|I-PARTIUPAC
,	30	31	|O
and	32	35	|O
3	36	37	|B-IUPAC
-	37	38	|I-IUPAC
ethoxycarbonyl	38	52	|I-IUPAC
-	52	53	|I-IUPAC
5,7	53	56	|I-IUPAC
-	56	57	|I-IUPAC
dialkylpyrazolo	57	72	|I-IUPAC
[	72	73	|I-IUPAC
1,5	73	76	|I-IUPAC
-	76	77	|I-IUPAC
a	77	78	|I-IUPAC
]	78	79	|I-IUPAC
pyrimidines	79	90	|I-IUPAC
were	91	95	|O
synthesized	96	107	|O
and	108	111	|O
screened	112	120	|O
as	121	123	|O
in	124	126	|O
vitro	127	132	|O
cAMP	133	137	|O
phosphodiesterase	138	155	|O
inhibitors	156	166	|O
.	166	167	|O
The	168	171	|O
condensation	172	184	|O
of	185	187	|O
3	188	189	|B-IUPAC
-	189	190	|I-IUPAC
aminopyrazole	190	203	|I-IUPAC
with	204	208	|O
symmetrical	209	220	|O
beta	221	225	|O
-	225	226	|O
diketones	226	235	|O
(	236	237	|O
acetylacetone	237	250	|O
,	250	251	|O
heptane	252	259	|B-IUPAC
-	259	260	|I-IUPAC
3,5	260	263	|I-IUPAC
-	263	264	|I-IUPAC
dione	264	269	|I-IUPAC
,	269	270	|O
etc	271	274	|O
.	274	275	|O
)	275	276	|O
afforded	277	285	|O
symmetrical	286	297	|O
dialkylpyrazolo	298	313	|B-IUPAC
[	313	314	|I-IUPAC
1,5	314	317	|I-IUPAC
-	317	318	|I-IUPAC
a	318	319	|I-IUPAC
]	319	320	|I-IUPAC
pyrimidines	320	331	|I-IUPAC
(	332	333	|O
5	333	334	|O
)	334	335	|O
.	335	336	|O
The	337	340	|O
reaction	341	349	|O
of	350	352	|O
3	353	354	|B-IUPAC
-	354	355	|I-IUPAC
aminopyrazole	355	368	|I-IUPAC
with	369	373	|O
unsymmetrical	374	387	|O
beta	388	392	|O
-	392	393	|O
diketones	393	402	|O
(	403	404	|O
hexane	404	410	|B-IUPAC
-	410	411	|I-IUPAC
2,4	411	414	|I-IUPAC
-	414	415	|I-IUPAC
dione	415	420	|I-IUPAC
,	420	421	|O
heptane	422	429	|B-IUPAC
-	429	430	|I-IUPAC
3,5	430	433	|I-IUPAC
-	433	434	|I-IUPAC
dione	434	439	|I-IUPAC
,	439	440	|O
etc	441	444	|O
.	444	445	|O
)	445	446	|O
gave	447	451	|O
a	452	453	|O
mixture	454	461	|O
of	462	464	|O
5	465	466	|B-IUPAC
-	466	467	|I-IUPAC
methyl	467	473	|I-IUPAC
-	473	474	|I-IUPAC
7	474	475	|I-IUPAC
-	475	476	|I-IUPAC
alkylpyrazolo	476	489	|I-IUPAC
[	489	490	|I-IUPAC
1,5	490	493	|I-IUPAC
-	493	494	|I-IUPAC
a	494	495	|I-IUPAC
]	495	496	|I-IUPAC
pyrimidine	496	506	|I-IUPAC
(	507	508	|O
3	508	509	|O
)	509	510	|O
and	511	514	|O
5	515	516	|B-IUPAC
-	516	517	|I-IUPAC
alkyl	517	522	|I-IUPAC
-	522	523	|I-IUPAC
7	523	524	|I-IUPAC
-	524	525	|I-IUPAC
methylpyrazolo	525	539	|I-IUPAC
[	539	540	|I-IUPAC
1,5	540	543	|I-IUPAC
-	543	544	|I-IUPAC
a	544	545	|I-IUPAC
]	545	546	|I-IUPAC
pyrimidines	546	557	|I-IUPAC
(	558	559	|O
4	559	560	|O
)	560	561	|O
.	561	562	|O
The	563	566	|O
technique	567	576	|O
for	577	580	|O
the	581	584	|O
separation	585	595	|O
of	596	598	|O
3	599	600	|O
from	601	605	|O
4	606	607	|O
is	608	610	|O
described	611	620	|O
.	620	621	|O
The	622	625	|O
inhibition	626	636	|O
constants	637	646	|O
,	646	647	|O
alpha	648	653	|O
(	654	655	|O
the	655	658	|O
ratio	659	664	|O
of	665	667	|O
the	668	671	|O
molar	672	677	|O
I50	678	681	|O
of	682	684	|O
theophylline	685	697	|O
to	698	700	|O
the	701	704	|O
molar	705	710	|O
I50	711	714	|O
of	715	717	|O
the	718	721	|O
test	722	726	|O
compounds	727	736	|O
)	736	737	|O
,	737	738	|O
were	739	743	|O
subjected	744	753	|O
to	754	756	|O
a	757	758	|O
Hansch	759	765	|O
correlation	766	777	|O
analysis	778	786	|O
.	786	787	|O
The	788	791	|O
results	792	799	|O
indicated	800	809	|O
that	810	814	|O
PDE	815	818	|O
isolated	819	827	|O
from	828	832	|O
beef	833	837	|O
heart	838	843	|O
tissue	844	850	|O
was	851	854	|O
most	855	859	|O
sensitive	860	869	|O
to	870	872	|O
changes	873	880	|O
in	881	883	|O
the	884	887	|O
length	888	894	|O
of	895	897	|O
the	898	901	|O
alkyl	902	907	|O
group	908	913	|O
in	914	916	|O
the	917	920	|O
5	921	922	|O
position	923	931	|O
of	932	934	|O
the	935	938	|O
pyrazolo	939	947	|B-IUPAC
[	947	948	|I-IUPAC
1,5	948	951	|I-IUPAC
-	951	952	|I-IUPAC
a	952	953	|I-IUPAC
]	953	954	|I-IUPAC
pyrimidine	954	964	|I-IUPAC
ring	965	969	|B-MODIFIER
,	969	970	|O
whereas	971	978	|O
the	979	982	|O
PDE	983	986	|O
isolated	987	995	|O
from	996	1000	|O
rabbit	1001	1007	|O
lung	1008	1012	|O
tissue	1013	1019	|O
was	1020	1023	|O
more	1024	1028	|O
sensitive	1029	1038	|O
to	1039	1041	|O
changes	1042	1049	|O
in	1050	1052	|O
the	1053	1056	|O
length	1057	1063	|O
of	1064	1066	|O
the	1067	1070	|O
7	1071	1072	|O
-	1072	1073	|O
alkyl	1073	1078	|O
group	1079	1084	|O
.	1084	1085	|O
Experimentally	1086	1100	|O
and	1101	1104	|O
theoretically	1105	1118	|O
,	1118	1119	|O
the	1120	1123	|O
n	1124	1125	|B-IUPAC
-	1125	1126	|I-IUPAC
propyl	1126	1132	|I-IUPAC
group	1133	1138	|B-MODIFIER
was	1139	1142	|O
found	1143	1148	|O
to	1149	1151	|O
approximate	1152	1163	|O
the	1164	1167	|O
ideal	1168	1173	|O
size	1174	1178	|O
for	1179	1182	|O
the	1183	1186	|O
alkyl	1187	1192	|O
group	1193	1198	|O
in	1199	1201	|O
both	1202	1206	|O
the	1207	1210	|O
5	1211	1212	|O
and	1213	1216	|O
7	1217	1218	|O
positions	1219	1228	|O
;	1228	1229	|O
5,7	1229	1232	|B-IUPAC
-	1232	1233	|I-IUPAC
di	1233	1235	|I-IUPAC
-	1235	1236	|I-IUPAC
n	1236	1237	|I-IUPAC
-	1237	1238	|I-IUPAC
propyl	1238	1244	|I-IUPAC
-	1244	1245	|I-IUPAC
3	1245	1246	|I-IUPAC
-	1246	1247	|I-IUPAC
ethoxycarbonylpyrazolo	1247	1269	|I-IUPAC
[	1269	1270	|I-IUPAC
1,5	1270	1273	|I-IUPAC
-	1273	1274	|I-IUPAC
a	1274	1275	|I-IUPAC
]	1275	1276	|I-IUPAC
pyrimidine	1276	1286	|I-IUPAC
(	1287	1288	|O
5e	1288	1290	|O
)	1290	1291	|O
was	1292	1295	|O
the	1296	1299	|O
most	1300	1304	|O
potent	1305	1311	|O
inhibitor	1312	1321	|O
of	1322	1324	|O
both	1325	1329	|O
lung	1330	1334	|O
and	1335	1338	|O
heart	1339	1344	|O
PDE	1345	1348	|O
.	1348	1349	|O

### abstracts970.txt
In	0	2	|O
order	3	8	|O
to	9	11	|O
improve	12	19	|O
the	20	23	|O
oral	24	28	|O
bioavailability	29	44	|O
(	45	46	|O
BA	46	48	|O
)	48	49	|O
of	50	52	|O
2	53	54	|B-IUPAC
-	54	55	|I-IUPAC
butyl	55	60	|I-IUPAC
-	60	61	|I-IUPAC
1	61	62	|I-IUPAC
-	62	63	|I-IUPAC
[	63	64	|I-IUPAC
[	64	65	|I-IUPAC
2'	65	67	|I-IUPAC
-	67	68	|I-IUPAC
(	68	69	|I-IUPAC
1H	69	71	|I-IUPAC
-	71	72	|I-IUPAC
tetrazol	72	80	|I-IUPAC
-	80	81	|I-IUPAC
5	81	82	|I-IUPAC
-	82	83	|I-IUPAC
yl	83	85	|I-IUPAC
)	85	86	|I-IUPAC
biphenyl	86	94	|I-IUPAC
-	94	95	|I-IUPAC
4	95	96	|I-IUPAC
-	96	97	|I-IUPAC
yl	97	99	|I-IUPAC
]	99	100	|I-IUPAC
methyl	100	106	|I-IUPAC
]	106	107	|I-IUPAC
-	107	108	|I-IUPAC
1H	108	110	|I-IUPAC
-	110	111	|I-IUPAC
benzimid	111	119	|I-IUPAC
azole	120	125	|I-IUPAC
-	126	127	|I-IUPAC
7	128	129	|I-IUPAC
-	129	130	|I-IUPAC
carboxylic	130	140	|I-IUPAC
acid	141	145	|I-IUPAC
(	146	147	|O
3	147	148	|O
:	148	149	|O
CV	150	152	|O
-	152	153	|O
11194	153	158	|O
)	158	159	|O
and	160	163	|O
2	164	165	|B-IUPAC
-	165	166	|I-IUPAC
ethoxy	166	172	|I-IUPAC
-	172	173	|I-IUPAC
1	173	174	|I-IUPAC
-	174	175	|I-IUPAC
[	175	176	|I-IUPAC
[	176	177	|I-IUPAC
2'	177	179	|I-IUPAC
-	179	180	|I-IUPAC
(	180	181	|I-IUPAC
1H	181	183	|I-IUPAC
-	183	184	|I-IUPAC
tetrazol	184	192	|I-IUPAC
-	192	193	|I-IUPAC
5	193	194	|I-IUPAC
-	194	195	|I-IUPAC
yl	195	197	|I-IUPAC
)	197	198	|I-IUPAC
biphenyl	198	206	|I-IUPAC
-	206	207	|I-IUPAC
4	207	208	|I-IUPAC
-	208	209	|I-IUPAC
yl	210	212	|I-IUPAC
]	212	213	|I-IUPAC
methyl	213	219	|I-IUPAC
]	219	220	|I-IUPAC
-	220	221	|I-IUPAC
1H	221	223	|I-IUPAC
-	223	224	|I-IUPAC
benzimidazole	224	237	|I-IUPAC
-	237	238	|I-IUPAC
7	238	239	|I-IUPAC
-	239	240	|I-IUPAC
carboxylic	240	250	|I-IUPAC
acid	251	255	|I-IUPAC
(	256	257	|O
4	257	258	|O
:	258	259	|O
CV	260	262	|O
-	262	263	|O
11974	263	268	|O
)	268	269	|O
,	269	270	|O
novel	271	276	|O
angiotensin	277	288	|O
II	289	291	|O
(	292	293	|O
AII	293	296	|O
)	296	297	|O
receptor	298	306	|O
antagonists	307	318	|O
,	318	319	|O
chemical	320	328	|O
modification	329	341	|O
to	342	344	|O
yield	345	350	|O
prodrugs	351	359	|O
has	360	363	|O
been	364	368	|O
examined	369	377	|O
.	377	378	|O
After	379	384	|O
selective	385	394	|O
tritylation	395	406	|O
of	407	409	|O
the	410	413	|O
tetrazole	414	423	|O
rings	424	429	|O
in	430	432	|O
3	433	434	|O
and	435	438	|O
4	439	440	|O
,	440	441	|O
treatment	442	451	|O
of	452	454	|O
N	455	456	|B-MODIFIER
-	456	457	|I-MODIFIER
tritylated	457	467	|I-MODIFIER
benzimidazole	468	481	|B-IUPAC
-	481	482	|I-IUPAC
7	482	483	|I-IUPAC
-	483	484	|I-IUPAC
carboxylic	484	494	|I-IUPAC
acids	495	500	|I-IUPAC
(	501	502	|O
6	502	503	|O
,	503	504	|O
7	505	506	|O
)	506	507	|O
with	508	512	|O
a	513	514	|O
variety	515	522	|O
of	523	525	|O
alkyl	526	531	|O
halides	532	539	|O
,	539	540	|O
followed	541	549	|O
by	550	552	|O
deprotection	553	565	|O
with	566	570	|O
hydrochloric	571	583	|O
acid	584	588	|O
,	588	589	|O
afforded	590	598	|O
esters	599	605	|O
of	606	608	|O
3	609	610	|O
and	611	614	|O
4	615	616	|O
.	616	617	|O
Mainly	618	624	|O
1	625	626	|B-IUPAC
-	626	627	|I-IUPAC
(	627	628	|I-IUPAC
acyloxy	628	635	|I-IUPAC
)	635	636	|I-IUPAC
alkyl	636	641	|I-IUPAC
esters	642	648	|I-IUPAC
and	649	652	|O
1	653	654	|B-IUPAC
-	654	655	|I-IUPAC
[	655	656	|I-IUPAC
(	656	657	|I-IUPAC
alkoxycarbonyl	657	671	|I-IUPAC
)	671	672	|I-IUPAC
oxy	672	675	|I-IUPAC
]	675	676	|I-IUPAC
alkyl	676	681	|I-IUPAC
esters	682	688	|I-IUPAC
,	688	689	|O
double	690	696	|O
ester	697	702	|O
derivatives	703	714	|O
,	714	715	|O
were	716	720	|O
synthesized	721	732	|O
.	732	733	|O
Their	734	739	|O
inhibitory	740	750	|O
effect	751	757	|O
on	758	760	|O
AII	761	764	|O
-	764	765	|O
induced	765	772	|O
pressor	773	780	|O
response	781	789	|O
in	790	792	|O
rats	793	797	|O
and	798	801	|O
oral	802	806	|O
BA	807	809	|O
were	810	814	|O
investigated	815	827	|O
.	827	828	|O
(	829	830	|B-PARTIUPAC
Pivaloyloxy	830	841	|I-PARTIUPAC
)	841	842	|I-PARTIUPAC
methyl	842	848	|I-PARTIUPAC
and	849	852	|O
(	853	854	|B-IUPAC
+	854	855	|I-IUPAC
/	855	856	|I-IUPAC
-	856	857	|I-IUPAC
)	857	858	|I-IUPAC
-	858	859	|I-IUPAC
1	859	860	|I-IUPAC
-	860	861	|I-IUPAC
[	861	862	|I-IUPAC
[	862	863	|I-IUPAC
(	863	864	|I-IUPAC
cyclohexyloxy	864	877	|I-IUPAC
)	877	878	|I-IUPAC
-	878	879	|I-IUPAC
carbonyl	879	887	|I-IUPAC
]	887	888	|I-IUPAC
oxy	888	891	|I-IUPAC
]	891	892	|I-IUPAC
ethyl	892	897	|I-IUPAC
esters	898	904	|I-IUPAC
of	905	907	|O
3	908	909	|O
and	910	913	|O
4	914	915	|O
showed	916	922	|O
marked	923	929	|O
increases	930	939	|O
in	940	942	|O
oral	943	947	|O
bioavailability	948	963	|O
which	964	969	|O
significantly	970	983	|O
potentiated	984	995	|O
the	996	999	|O
inhibitory	1000	1010	|O
effect	1011	1017	|O
of	1018	1020	|O
the	1021	1024	|O
parent	1025	1031	|O
compounds	1032	1041	|O
on	1042	1044	|O
AII	1045	1048	|O
-	1048	1049	|O
induced	1049	1056	|O
pressor	1057	1064	|O
response	1065	1073	|O
.	1073	1074	|O
Among	1075	1080	|O
them	1081	1085	|O
,	1085	1086	|O
(	1087	1088	|B-IUPAC
+	1088	1089	|I-IUPAC
/	1089	1090	|I-IUPAC
-	1090	1091	|I-IUPAC
)	1091	1092	|I-IUPAC
-	1092	1093	|I-IUPAC
1	1093	1094	|I-IUPAC
-	1094	1095	|I-IUPAC
[	1095	1096	|I-IUPAC
[	1096	1097	|I-IUPAC
(	1097	1098	|I-IUPAC
cyclohexyloxy	1098	1111	|I-IUPAC
)	1111	1112	|I-IUPAC
carbonyl	1112	1120	|I-IUPAC
]	1120	1121	|I-IUPAC
oxy	1121	1124	|I-IUPAC
]	1124	1125	|I-IUPAC
ethyl	1125	1130	|I-IUPAC
2	1131	1132	|I-IUPAC
-	1132	1133	|I-IUPAC
ethoxy	1134	1140	|I-IUPAC
-	1140	1141	|I-IUPAC
1	1141	1142	|I-IUPAC
-	1142	1143	|I-IUPAC
[	1143	1144	|I-IUPAC
[	1144	1145	|I-IUPAC
2'	1145	1147	|I-IUPAC
-	1147	1148	|I-IUPAC
(	1148	1149	|I-IUPAC
1H	1149	1151	|I-IUPAC
-	1151	1152	|I-IUPAC
tetrazol	1152	1160	|I-IUPAC
-	1160	1161	|I-IUPAC
5	1161	1162	|I-IUPAC
-	1162	1163	|I-IUPAC
yl	1163	1165	|I-IUPAC
)	1165	1166	|I-IUPAC
biphenyl	1166	1174	|I-IUPAC
-	1174	1175	|I-IUPAC
4	1175	1176	|I-IUPAC
-	1176	1177	|I-IUPAC
yl	1177	1179	|I-IUPAC
]	1179	1180	|I-IUPAC
methyl	1180	1186	|I-IUPAC
]	1186	1187	|I-IUPAC
-	1187	1188	|I-IUPAC
1H	1188	1190	|I-IUPAC
-	1190	1191	|I-IUPAC
benzimida	1191	1200	|I-IUPAC
zole	1201	1205	|I-IUPAC
-	1205	1206	|I-IUPAC
7	1207	1208	|I-IUPAC
-	1208	1209	|I-IUPAC
carboxylate	1209	1220	|I-IUPAC
(	1221	1222	|O
10s	1222	1225	|O
,	1225	1226	|O
TCV	1227	1230	|O
-	1230	1231	|O
116	1231	1234	|O
)	1234	1235	|O
was	1236	1239	|O
selected	1240	1248	|O
as	1249	1251	|O
a	1252	1253	|O
candidate	1254	1263	|O
for	1264	1267	|O
clinical	1268	1276	|O
evaluation	1277	1287	|O
.	1287	1288	|O

### abstracts3110.txt
In	0	2	|O
this	3	7	|O
report	8	14	|O
,	14	15	|O
we	16	18	|O
describe	19	27	|O
structure	28	37	|O
-	37	38	|O
activity	38	46	|O
studies	47	54	|O
of	55	57	|O
the	58	61	|O
bicyclic	62	70	|O
oxytocin	71	79	|O
antagonist	80	90	|O
[	91	92	|O
Mpa1	92	96	|O
,	96	97	|O
cyclo	97	102	|O
(	102	103	|O
Glu4	103	107	|O
,	107	108	|O
Lys8	108	112	|O
)	112	113	|O
]	113	114	|O
oxytocin	114	122	|O
.	122	123	|O
The	124	127	|O
monocylic	128	137	|O
analogue	138	146	|O
[	147	148	|O
dPen1	148	153	|O
,	153	154	|O
(	155	156	|O
Glu4	156	160	|O
,	160	161	|O
Lys8	161	165	|O
)	165	166	|O
]	166	167	|O
oxytocin	167	175	|O
was	176	179	|O
a	180	181	|O
weak	182	186	|O
oxytocin	187	195	|O
antagonist	196	206	|O
with	207	211	|O
a	212	213	|O
pA2	214	217	|O
value	218	223	|O
of	224	226	|O
5.8	227	230	|O
in	231	233	|O
the	234	237	|O
uterotonic	238	248	|O
assay	249	254	|O
.	254	255	|O
Bicyclization	256	269	|O
of	270	272	|O
this	273	277	|O
analogue	278	286	|O
yielded	287	294	|O
[	295	296	|O
dPen1	296	301	|O
,	301	302	|O
cyclo	302	307	|O
(	307	308	|O
Glu4	308	312	|O
,	312	313	|O
Lys8	313	317	|O
)	317	318	|O
]	318	319	|O
oxytocin	319	327	|O
,	327	328	|O
a	329	330	|O
potent	331	337	|O
antagonist	338	348	|O
of	349	351	|O
oxytocin	352	360	|O
in	361	363	|O
the	364	367	|O
uterotonic	368	378	|O
assay	379	384	|O
(	385	386	|O
pA2	386	389	|O
8.74	390	394	|O
)	394	395	|O
with	396	400	|O
a	401	402	|O
potency	403	410	|O
3	411	412	|O
times	413	418	|O
greater	419	426	|O
than	427	431	|O
that	432	436	|O
of	437	439	|O
[	440	441	|O
Mpa1	441	445	|O
,	445	446	|O
cyclo	446	451	|O
(	451	452	|O
Glu4	452	456	|O
,	456	457	|O
Lys8	457	461	|O
)	461	462	|O
]	462	463	|O
oxytocin	463	471	|O
.	471	472	|O
[	473	474	|O
dPen1	474	479	|O
,	479	480	|O
cyclo	480	485	|O
(	485	486	|O
Glu4	486	490	|O
,	490	491	|O
Lys8	491	495	|O
)	495	496	|O
]	496	497	|O
oxytocin	497	505	|O
also	506	510	|O
was	511	514	|O
a	515	516	|O
weak	517	521	|O
antagonist	522	532	|O
in	533	535	|O
the	536	539	|O
pressor	540	547	|O
assay	548	553	|O
with	554	558	|O
a	559	560	|O
pA2	561	564	|O
of	565	567	|O
6.3	568	571	|O
.	571	572	|O
To	573	575	|O
establish	576	585	|O
if	586	588	|O
the	589	592	|O
potent	593	599	|O
antagonistic	600	612	|O
effects	613	620	|O
of	621	623	|O
these	624	629	|O
bicyclic	630	638	|O
compounds	639	648	|O
was	649	652	|O
because	653	660	|O
of	661	663	|O
the	664	667	|O
lactam	668	674	|O
ring	675	679	|O
or	680	682	|O
merely	683	689	|O
the	690	693	|O
result	694	700	|O
of	701	703	|O
obtaining	704	713	|O
an	714	716	|O
optimal	717	724	|O
degree	725	731	|O
of	732	734	|O
lipophilicity	735	748	|O
of	749	751	|O
the	752	755	|O
side	756	760	|O
chains	761	767	|O
in	768	770	|O
positions	771	780	|O
4	781	782	|O
and	783	786	|O
8	787	788	|O
,	788	789	|O
we	790	792	|O
synthesized	793	804	|O
a	805	806	|O
series	807	813	|O
of	814	816	|O
analogues	817	826	|O
containing	827	837	|O
neutral	838	845	|O
and	846	849	|O
/	849	850	|O
or	850	852	|O
charged	853	860	|O
groups	861	867	|O
on	868	870	|O
these	871	876	|O
side	877	881	|O
chains	882	888	|O
.	888	889	|O
Monocyclic	890	900	|O
derivatives	901	912	|O
of	913	915	|O
[	916	917	|O
Mpa1	917	921	|O
,	921	922	|O
Gln4	922	926	|O
,	926	927	|O
Lys	927	930	|O
(	930	931	|O
CHO	931	934	|O
)	934	935	|O
8	935	936	|O
]	936	937	|O
oxytocin	937	945	|O
were	946	950	|O
moderate	951	959	|O
to	960	962	|O
weak	963	967	|O
agonists	968	976	|O
of	977	979	|O
oxytocin	980	988	|O
all	989	992	|O
following	993	1002	|O
classical	1003	1012	|O
structure	1013	1022	|O
-	1022	1023	|O
activity	1023	1031	|O
profiles	1032	1040	|O
of	1041	1043	|O
oxytocin	1044	1052	|O
.	1052	1053	|O
The	1054	1057	|O
monocyclic	1058	1068	|O
derivatives	1069	1080	|O
of	1081	1083	|O
[	1084	1085	|O
dPen1	1085	1090	|O
,	1090	1091	|O
Gln4	1091	1095	|O
,	1095	1096	|O
Lys	1096	1099	|O
(	1099	1100	|O
CHO	1100	1103	|O
)	1103	1104	|O
8	1104	1105	|O
]	1105	1106	|O
oxytocin	1106	1114	|O
were	1115	1119	|O
antagonists	1120	1131	|O
of	1132	1134	|O
oxytocin	1135	1143	|O
which	1144	1149	|O
was	1150	1153	|O
attributed	1154	1164	|O
to	1165	1167	|O
the	1168	1171	|O
dPen1	1172	1177	|O
substitution	1178	1190	|O
.	1190	1191	|O
However	1192	1199	|O
,	1199	1200	|O
the	1201	1204	|O
potency	1205	1212	|O
of	1213	1215	|O
all	1216	1219	|O
of	1220	1222	|O
these	1223	1228	|O
latter	1229	1235	|O
derivatives	1236	1247	|O
was	1248	1251	|O
at	1252	1254	|O
least	1255	1260	|O
1	1261	1262	|O
order	1263	1268	|O
of	1269	1271	|O
magnitude	1272	1281	|O
less	1282	1286	|O
than	1287	1291	|O
[	1292	1293	|O
dPen1	1293	1298	|O
,	1298	1299	|O
cyclo	1299	1304	|O
(	1304	1305	|O
Glu4	1305	1309	|O
,	1309	1310	|O
Lys8	1310	1314	|O
)	1314	1315	|O
]	1315	1316	|O
oxytocin	1316	1324	|O
.	1324	1325	|O
These	1326	1331	|O
results	1332	1339	|O
suggest	1340	1347	|O
that	1348	1352	|O
the	1353	1356	|O
potent	1357	1363	|O
antagonistic	1364	1376	|O
properties	1377	1387	|O
of	1388	1390	|O
the	1391	1394	|O
bicyclic	1395	1403	|O
analogues	1404	1413	|O
[	1414	1415	|O
Mpa1	1415	1419	|O
,	1419	1420	|O
cyclo	1420	1425	|O
(	1425	1426	|O
Glu4	1426	1430	|O
,	1430	1431	|O
Lys8	1431	1435	|O
)	1435	1436	|O
]	1436	1437	|O
oxytocin	1437	1445	|O
and	1446	1449	|O
[	1450	1451	|O
dPen1	1451	1456	|O
,	1456	1457	|O
cyclo	1457	1462	|O
(	1462	1463	|O
Glu4	1463	1467	|O
,	1467	1468	|O
Lys8	1468	1472	|O
)	1472	1473	|O
]	1473	1474	|O
oxytocin	1474	1482	|O
can	1483	1486	|O
be	1487	1489	|O
attributed	1490	1500	|O
to	1501	1503	|O
the	1504	1507	|O
effect	1508	1514	|O
of	1515	1517	|O
the	1518	1521	|O
lactam	1522	1528	|O
bridge	1529	1535	|O
on	1536	1538	|O
the	1539	1542	|O
conformational	1543	1557	|O
flexibility	1558	1569	|O
and	1570	1573	|O
topographical	1574	1587	|O
properties	1588	1598	|O
of	1599	1601	|O
the	1602	1605	|O
analogues	1606	1615	|O
,	1615	1616	|O
rendering	1617	1626	|O
them	1627	1631	|O
more	1632	1636	|O
favorable	1637	1646	|O
for	1647	1650	|O
binding	1651	1658	|O
to	1659	1661	|O
the	1662	1665	|O
receptor	1666	1674	|O
in	1675	1677	|O
such	1678	1682	|O
a	1683	1684	|O
manner	1685	1691	|O
as	1692	1694	|O
to	1695	1697	|O
prevent	1698	1705	|O
transduction	1706	1718	|O
of	1719	1721	|O
a	1722	1723	|O
biological	1724	1734	|O
response	1735	1743	|O
.	1743	1744	|O

### abstracts1730.txt
A	0	1	|O
series	2	8	|B-MODIFIER
of	9	11	|O
4	12	13	|B-IUPAC
-	13	14	|I-IUPAC
methyl	14	20	|I-IUPAC
-	20	21	|I-IUPAC
3	21	22	|I-IUPAC
-	22	23	|I-IUPAC
(	23	24	|I-IUPAC
arylthio	24	32	|I-IUPAC
)	32	33	|I-IUPAC
furoxans	33	41	|I-IUPAC
were	42	46	|O
synthesized	47	58	|O
by	59	61	|O
oxidation	62	71	|O
of	72	74	|O
1	75	76	|B-IUPAC
-	76	77	|I-IUPAC
(	77	78	|I-IUPAC
arylthio	78	86	|I-IUPAC
)	86	87	|I-IUPAC
-	87	88	|I-IUPAC
2	88	89	|I-IUPAC
-	89	90	|I-IUPAC
methylglyoxymes	90	105	|I-IUPAC
with	106	110	|O
dinitrogen	111	121	|O
tetroxide	122	131	|O
.	131	132	|O
Reduction	133	142	|O
with	143	147	|O
trimethyl	148	157	|O
phosphite	158	167	|O
of	168	170	|O
the	171	174	|O
furoxan	175	182	|O
derivatives	183	194	|O
afforded	195	203	|O
the	204	207	|O
corresponding	208	221	|O
furazans	222	230	|O
,	230	231	|O
while	232	237	|O
oxidation	238	247	|O
with	248	252	|O
an	253	255	|O
equimolar	256	265	|O
amount	266	272	|O
of	273	275	|O
30%	276	279	|O
hydrogen	280	288	|O
peroxide	289	297	|O
in	298	300	|O
acetic	301	307	|O
acid	308	312	|O
or	313	315	|O
with	316	320	|O
an	321	323	|O
excess	324	330	|O
of	331	333	|O
81%	334	337	|O
hydrogen	338	346	|O
peroxide	347	355	|O
in	356	358	|O
trifluoroacetic	359	374	|O
acid	375	379	|O
afforded	380	388	|O
the	389	392	|O
corresponding	393	406	|O
arylsulfinyl	407	419	|B-IUPAC
and	420	423	|O
arylsulfonyl	424	436	|B-IUPAC
analogues	437	446	|B-MODIFIER
,	446	447	|O
respectively	448	460	|O
.	460	461	|O
All	462	465	|O
the	466	469	|O
furoxan	470	477	|O
and	478	481	|O
furazan	482	489	|O
derivatives	490	501	|O
showed	502	508	|O
activity	509	517	|O
as	518	520	|O
inhibitors	521	531	|O
of	532	534	|O
platelet	535	543	|O
aggregation	544	555	|O
.	555	556	|O
4	557	558	|B-IUPAC
-	558	559	|I-IUPAC
Methyl	559	565	|I-IUPAC
-	565	566	|I-IUPAC
3	566	567	|I-IUPAC
-	567	568	|I-IUPAC
(	568	569	|I-IUPAC
arylsulfonyl	569	581	|I-IUPAC
)	581	582	|I-IUPAC
furoxans	582	590	|I-IUPAC
were	591	595	|O
the	596	599	|O
most	600	604	|O
potent	605	611	|O
derivatives	612	623	|O
of	624	626	|O
the	627	630	|O
series	631	637	|O
.	637	638	|O
4	639	640	|B-IUPAC
-	640	641	|I-IUPAC
Methyl	641	647	|I-IUPAC
-	647	648	|I-IUPAC
3	648	649	|I-IUPAC
-	649	650	|I-IUPAC
(	650	651	|I-IUPAC
phenylsulfonyl	651	665	|I-IUPAC
)	665	666	|I-IUPAC
furoxan	666	673	|I-IUPAC
(	674	675	|O
10a	675	678	|O
)	678	679	|O
,	679	680	|O
one	681	684	|O
of	685	687	|O
the	688	691	|O
most	692	696	|O
active	697	703	|O
derivatives	704	715	|O
,	715	716	|O
inhibits	717	725	|O
the	726	729	|O
AA	730	732	|O
-	732	733	|O
induced	733	740	|O
increase	741	749	|O
of	750	752	|O
cytosolic	753	762	|O
free	763	767	|O
Ca2+	768	772	|O
and	773	776	|O
production	777	787	|O
of	788	790	|O
malondialdehyde	791	806	|O
.	806	807	|O
A	808	809	|O
primary	810	817	|O
action	818	824	|O
of	825	827	|O
the	828	831	|O
compound	832	840	|O
on	841	843	|O
cyclooxygenase	844	858	|O
is	859	861	|O
excluded	862	870	|O
,	870	871	|O
as	872	874	|O
a	875	876	|O
stable	877	883	|O
epoxymethano	884	896	|O
analogue	897	905	|O
of	906	908	|O
prostaglandin	909	922	|O
H2	923	925	|O
does	926	930	|O
not	931	934	|O
reverse	935	942	|O
the	943	946	|O
inhibitory	947	957	|O
effect	958	964	|O
of	965	967	|O
10a	968	971	|O
.	971	972	|O
This	973	977	|O
compound	978	986	|O
produces	987	995	|O
a	996	997	|O
significant	998	1009	|O
increase	1010	1018	|O
in	1019	1021	|O
cGMP	1022	1026	|O
which	1027	1032	|O
is	1033	1035	|O
likely	1036	1042	|O
to	1043	1045	|O
cause	1046	1051	|O
inhibition	1052	1062	|O
at	1063	1065	|O
an	1066	1068	|O
early	1069	1074	|O
stage	1075	1080	|O
of	1081	1083	|O
the	1084	1087	|O
platelet	1088	1096	|O
activation	1097	1107	|O
pathway	1108	1115	|O
.	1115	1116	|O

### abstracts2599.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
aldehydo	12	20	|O
sugars	21	27	|O
was	28	31	|O
subjected	32	41	|O
to	42	44	|O
condensation	45	57	|O
reactions	58	67	|O
with	68	72	|O
active	73	79	|O
methylene	80	89	|O
compounds	90	99	|O
.	99	100	|O
Acetylacetone	101	114	|O
was	115	118	|O
condensed	119	128	|O
with	129	133	|O
2,4	134	137	|B-IUPAC
-	137	138	|I-IUPAC
O	138	139	|I-IUPAC
-	139	140	|I-IUPAC
benzylidene	140	151	|I-IUPAC
-	151	152	|I-IUPAC
3,5	152	155	|I-IUPAC
-	155	156	|I-IUPAC
O	156	157	|I-IUPAC
-	157	158	|I-IUPAC
dibenzoyl	158	167	|I-IUPAC
-	167	168	|I-IUPAC
D	168	169	|I-IUPAC
-	169	170	|I-IUPAC
ribose	170	176	|I-IUPAC
(	177	178	|O
1	178	179	|O
)	179	180	|O
,	180	181	|O
2,4	182	185	|B-IUPAC
:	185	186	|I-IUPAC
3,5	186	189	|I-IUPAC
-	189	190	|I-IUPAC
O	190	191	|I-IUPAC
-	191	192	|I-IUPAC
dibenzylidene	192	205	|I-IUPAC
-	205	206	|I-IUPAC
D	206	207	|I-IUPAC
-	207	208	|I-IUPAC
ribose	208	214	|I-IUPAC
(	215	216	|O
6	216	217	|O
)	217	218	|O
,	218	219	|O
2,3,4,5	220	227	|B-IUPAC
-	227	228	|I-IUPAC
tetraacetyl	228	239	|I-IUPAC
-	239	240	|I-IUPAC
D	240	241	|I-IUPAC
-	241	242	|I-IUPAC
ribose	242	248	|I-IUPAC
(	249	250	|O
7	250	251	|O
)	251	252	|O
,	252	253	|O
and	254	257	|O
2,3,4,5,6	258	267	|B-IUPAC
-	267	268	|I-IUPAC
pentaacetyl	268	279	|I-IUPAC
-	279	280	|I-IUPAC
D	280	281	|I-IUPAC
-	281	282	|I-IUPAC
glucose	282	289	|I-IUPAC
(	290	291	|O
9	291	292	|O
)	292	293	|O
to	294	296	|O
yield	297	302	|O
3	303	304	|B-IUPAC
-	304	305	|I-IUPAC
ylidene	305	312	|I-IUPAC
-	312	313	|I-IUPAC
2,4	313	316	|I-IUPAC
-	316	317	|I-IUPAC
pentanedione	317	329	|I-IUPAC
derivatives	330	341	|B-MODIFIER
2	342	343	|O
,	343	344	|O
11	345	347	|O
,	347	348	|O
12	349	351	|O
,	351	352	|O
and	353	356	|O
13	357	359	|O
,	359	360	|O
respectively	361	373	|O
.	373	374	|O
Sugar	375	380	|O
derivatives	381	392	|O
1	393	394	|O
and	395	398	|O
6	399	400	|O
were	401	405	|O
also	406	410	|O
condensed	411	420	|O
with	421	425	|O
benzoylacetone	426	440	|O
to	441	443	|O
give	444	448	|O
14	449	451	|O
and	452	455	|O
18	456	458	|O
,	458	459	|O
with	460	464	|O
acetoacetanilide	465	481	|O
to	482	484	|O
give	485	489	|O
16	490	492	|O
and	493	496	|O
19	497	499	|O
,	499	500	|O
with	501	505	|O
malononitrile	506	519	|O
to	520	522	|O
give	523	527	|O
17	528	530	|O
and	531	534	|O
20	535	537	|O
,	537	538	|O
and	539	542	|O
with	543	547	|O
alpha	548	553	|B-IUPAC
-	553	554	|I-IUPAC
(	554	555	|I-IUPAC
gamma	555	560	|I-IUPAC
-	560	561	|I-IUPAC
butyrolactonylidene	561	580	|I-IUPAC
)	580	581	|I-IUPAC
triphenylphosphorane	581	601	|I-IUPAC
to	602	604	|O
give	605	609	|O
21	610	612	|O
and	613	616	|O
22	617	619	|O
,	619	620	|O
respectively	621	633	|O
.	633	634	|O
Condensation	635	647	|O
of	648	650	|O
1	651	652	|O
with	653	657	|O
dibenzoylmethane	658	674	|B-IUPAC
gave	675	679	|O
15	680	682	|O
.	682	683	|O
The	684	687	|O
double	688	694	|O
bond	695	699	|O
in	700	702	|O
compounds	703	712	|O
2	713	714	|O
and	715	718	|O
11	719	721	|O
was	722	725	|O
saturated	726	735	|O
by	736	738	|O
hydrogenation	739	752	|O
to	753	755	|O
give	756	760	|O
23	761	763	|O
and	764	767	|O
24	768	770	|O
.	770	771	|O
All	772	775	|O
alpha	776	781	|O
,	781	782	|O
beta	783	787	|O
-	787	788	|O
unsaturated	788	799	|O
carbonyl	800	808	|O
compounds	809	818	|O
obtained	819	827	|O
exhibited	828	837	|O
antiviral	838	847	|O
activity	848	856	|O
and	857	860	|O
cytotoxicity	861	873	|O
.	873	874	|O
Compound	875	883	|O
11	884	886	|O
was	887	890	|O
found	891	896	|O
to	897	899	|O
have	900	904	|O
the	905	908	|O
most	909	913	|O
significant	914	925	|O
and	926	929	|O
selective	930	939	|O
antiviral	940	949	|O
activity	950	958	|O
against	959	966	|O
herpes	967	973	|O
simplex	974	981	|O
virus	982	987	|O
.	987	988	|O

### abstracts3602.txt
New	0	3	|O
boron	4	9	|O
-	9	10	|O
containing	10	20	|O
polyamine	21	30	|O
have	31	35	|O
been	36	40	|O
synthesized	41	52	|O
:	52	53	|O
(	54	55	|B-IUPAC
aminoalkylamine	55	70	|I-IUPAC
)	70	71	|I-IUPAC
-	71	72	|I-IUPAC
N	72	73	|I-IUPAC
-	73	74	|I-IUPAC
(	74	75	|I-IUPAC
aminoalkyl	75	85	|I-IUPAC
)	85	86	|I-IUPAC
azanonaborane	86	99	|I-IUPAC
(	99	100	|O
11	100	102	|O
)	102	103	|O
derivatives	104	115	|B-MODIFIER
[	116	117	|O
H	117	118	|O
(	118	119	|O
2	119	120	|O
)	120	121	|O
N	121	122	|O
(	122	123	|O
CH	123	125	|O
(	125	126	|O
2	126	127	|O
)	127	128	|O
)	128	129	|O
(	129	130	|O
n	130	131	|O
)	131	132	|O
H	132	133	|O
(	133	134	|O
2	134	135	|O
)	135	136	|O
NB	136	138	|O
(	138	139	|O
8	139	140	|O
)	140	141	|O
H	141	142	|O
(	142	143	|O
11	143	145	|O
)	145	146	|O
NH	146	148	|O
(	148	149	|O
CH	149	151	|O
(	151	152	|O
2	152	153	|O
)	153	154	|O
)	154	155	|O
(	155	156	|O
n	156	157	|O
)	157	158	|O
NH	158	160	|O
(	160	161	|O
2	161	162	|O
)	162	163	|O
]	163	164	|O
,	164	165	|O
where	166	171	|O
n	172	173	|O
=	174	175	|O
4-6	176	179	|O
and	180	183	|O
12	184	186	|O
,	186	187	|O
and	188	191	|O
[	192	193	|O
H	193	194	|O
(	194	195	|O
2	195	196	|O
)	196	197	|O
N	197	198	|O
(	198	199	|O
CH	199	201	|O
(	201	202	|O
2	202	203	|O
)	203	204	|O
)	204	205	|O
(	205	206	|O
3	206	207	|O
)	207	208	|O
H	208	209	|O
(	209	210	|O
2	210	211	|O
)	211	212	|O
NB	212	214	|O
(	214	215	|O
8	215	216	|O
)	216	217	|O
H	217	218	|O
(	218	219	|O
11	219	221	|O
)	221	222	|O
NH	222	224	|O
(	224	225	|O
CH	225	227	|O
(	227	228	|O
2	228	229	|O
)	229	230	|O
)	230	231	|O
(	231	232	|O
4	232	233	|O
)	233	234	|O
NH	234	236	|O
(	236	237	|O
2	237	238	|O
)	238	239	|O
]	239	240	|O
.	240	241	|O
(	242	243	|B-IUPAC
4	243	244	|I-IUPAC
-	244	245	|I-IUPAC
Aminobutylamine	245	260	|I-IUPAC
)	260	261	|I-IUPAC
-	261	262	|I-IUPAC
N	262	263	|I-IUPAC
-	263	264	|I-IUPAC
(	264	265	|I-IUPAC
4	265	266	|I-IUPAC
-	266	267	|I-IUPAC
aminobutyl	267	277	|I-IUPAC
)	277	278	|I-IUPAC
azanonaborane	278	291	|I-IUPAC
and	292	295	|O
(	296	297	|B-IUPAC
3	297	298	|I-IUPAC
-	298	299	|I-IUPAC
aminopropylamine	299	315	|I-IUPAC
)	315	316	|I-IUPAC
-	316	317	|I-IUPAC
N	317	318	|I-IUPAC
-	318	319	|I-IUPAC
(	319	320	|I-IUPAC
4	320	321	|I-IUPAC
-	321	322	|I-IUPAC
aminobutyl	322	332	|I-IUPAC
)	332	333	|I-IUPAC
azanonaborane	333	346	|I-IUPAC
were	347	351	|O
less	352	356	|O
toxic	357	362	|O
in	363	365	|O
vitro	366	371	|O
(	372	373	|O
LD	373	375	|O
(	375	376	|O
50	376	378	|O
)	378	379	|O
of	380	382	|O
approximately	383	396	|O
700	397	400	|O
and	401	404	|O
approximately	405	418	|O
1100	419	423	|O
microM	424	430	|O
,	430	431	|O
respectively	432	444	|O
)	444	445	|O
than	446	450	|O
spermine	451	459	|O
,	459	460	|O
while	461	466	|O
(	467	468	|B-IUPAC
4	468	469	|I-IUPAC
-	469	470	|I-IUPAC
aminobutylamine	470	485	|I-IUPAC
)	485	486	|I-IUPAC
-	486	487	|I-IUPAC
N	487	488	|I-IUPAC
-	488	489	|I-IUPAC
isopropylazanonaborane	489	511	|I-IUPAC
with	512	516	|O
its	517	520	|O
hydrophobic	521	532	|O
isopropyl	533	542	|B-IUPAC
group	543	548	|B-MODIFIER
and	549	552	|O
those	553	558	|O
with	559	563	|O
n	564	565	|O
=	566	567	|O
5	568	569	|O
,	569	570	|O
6	571	572	|O
,	572	573	|O
and	574	577	|O
12	578	580	|O
were	581	585	|O
already	586	593	|O
toxic	594	599	|O
under	600	605	|O
similar	606	613	|O
conditions	614	624	|O
(	625	626	|O
LD	626	628	|O
(	628	629	|O
50	629	631	|O
)	631	632	|O
&	633	634	|O
lt	634	636	|O
;	636	637	|O
&	637	638	|O
lt	638	640	|O
;	640	641	|O
500	642	645	|O
microM	646	652	|O
)	652	653	|O
.	653	654	|O
These	655	660	|O
compounds	661	670	|O
may	671	674	|O
be	675	677	|O
useful	678	684	|O
as	685	687	|O
delivery	688	696	|O
agents	697	703	|O
for	704	707	|O
boron	708	713	|O
neutron	714	721	|O
capture	722	729	|O
therapy	730	737	|O
.	737	738	|O

### abstracts2103.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
squalestatins	12	25	|O
modified	26	34	|O
at	35	37	|O
the	38	41	|O
C3	42	44	|O
-	44	45	|O
position	45	53	|O
with	54	58	|O
a	59	60	|O
heterocyclic	61	73	|O
functionality	74	87	|O
was	88	91	|O
prepared	92	100	|O
and	101	104	|O
evaluated	105	114	|O
in	115	117	|O
vitro	118	123	|O
as	124	126	|O
inhibitors	127	137	|O
of	138	140	|O
squalene	141	149	|O
synthase	150	158	|O
(	159	160	|O
SQS	160	163	|O
)	163	164	|O
.	164	165	|O
Structure	166	175	|O
-	175	176	|O
activity	176	184	|O
relationships	185	198	|O
for	199	202	|O
compounds	203	212	|O
with	213	217	|O
the	218	221	|O
4,6	222	225	|B-IUPAC
-	225	226	|I-IUPAC
dimethyloctenoate	226	243	|I-IUPAC
at	244	246	|O
C6	247	249	|O
(	249	250	|O
S1	250	252	|O
analogues	253	262	|O
)	262	263	|O
were	264	268	|O
different	269	278	|O
from	279	283	|O
those	284	289	|O
for	290	293	|O
analogues	294	303	|O
lacking	304	311	|O
the	312	315	|O
C6	316	318	|O
ester	319	324	|O
(	325	326	|O
H1	326	328	|O
analogues	329	338	|O
)	338	339	|O
,	339	340	|O
with	341	345	|O
a	346	347	|O
greater	348	355	|O
dependence	356	366	|O
on	367	369	|O
the	370	373	|O
nature	374	380	|O
of	381	383	|O
the	384	387	|O
C3	388	390	|O
-	390	391	|O
substituent	391	402	|O
for	403	406	|O
the	407	410	|O
H1	411	413	|O
series	414	420	|O
.	420	421	|O
Potent	422	428	|O
SQS	429	432	|O
inhibitory	433	443	|O
activity	444	452	|O
equivalent	453	463	|O
to	464	466	|O
that	467	471	|O
of	472	474	|O
H1	475	477	|O
is	478	480	|O
retained	481	489	|O
by	490	492	|O
a	493	494	|O
C3	495	497	|B-IUPAC
-	497	498	|I-IUPAC
(	498	499	|I-IUPAC
tetrazol	499	507	|I-IUPAC
-	507	508	|I-IUPAC
5	508	509	|I-IUPAC
-	509	510	|I-IUPAC
yl	510	512	|I-IUPAC
)	512	513	|I-IUPAC
analogue	514	522	|B-MODIFIER
,	522	523	|O
i.e.	524	528	|O
,	528	529	|O
a	530	531	|O
carboxylic	532	542	|O
acid	543	547	|O
mimetic	548	555	|O
.	555	556	|O
The	557	560	|O
C3	561	563	|B-IUPAC
-	563	564	|I-IUPAC
methyl	564	570	|I-IUPAC
ester	571	576	|I-IUPAC
derivative	577	587	|B-MODIFIER
is	588	590	|O
10	591	593	|O
-	593	594	|O
fold	594	598	|O
less	599	603	|O
active	604	610	|O
than	611	615	|O
H1	616	618	|O
,	618	619	|O
and	620	623	|O
SQS	624	627	|O
inhibitory	628	638	|O
activity	639	647	|O
similar	648	655	|O
to	656	658	|O
that	659	663	|O
of	664	666	|O
the	667	670	|O
methyl	671	677	|O
ester	678	683	|O
was	684	687	|O
retained	688	696	|O
only	697	701	|O
in	702	704	|O
those	705	710	|O
C3	711	713	|O
-	713	714	|O
heterocycle	714	725	|O
-	725	726	|O
substituted	726	737	|O
H1	738	740	|O
analogues	741	750	|O
for	751	754	|O
which	755	760	|O
electrostatic	761	774	|O
potential	775	784	|O
maps	785	789	|O
of	790	792	|O
the	793	796	|O
C3	797	799	|O
-	799	800	|O
substituent	800	811	|O
were	812	816	|O
closely	817	824	|O
similar	825	832	|O
to	833	835	|O
that	836	840	|O
of	841	843	|O
a	844	845	|O
methyl	846	852	|O
ester	853	858	|O
.	858	859	|O

### abstracts658.txt
The	0	3	|O
present	4	11	|O
work	12	16	|O
explored	17	25	|O
3	26	27	|B-IUPAC
-	27	28	|I-IUPAC
alkylamino	28	38	|I-IUPAC
-	38	39	|I-IUPAC
4H	39	41	|I-IUPAC
-	41	42	|I-IUPAC
1,2,4	42	47	|I-IUPAC
-	47	48	|I-IUPAC
benzothiadiazine	48	64	|I-IUPAC
1,1	65	68	|I-IUPAC
-	68	69	|I-IUPAC
dioxides	69	77	|I-IUPAC
diversely	78	87	|O
substituted	88	99	|O
in	100	102	|O
the	103	106	|O
7	107	108	|O
-	108	109	|O
position	109	117	|O
.	117	118	|O
Those	119	124	|O
compounds	125	134	|O
,	134	135	|O
structurally	136	148	|O
related	149	156	|O
to	157	159	|O
previously	160	170	|O
described	171	180	|O
potassium	181	190	|O
channel	191	198	|O
openers	199	206	|O
such	207	211	|O
as	212	214	|O
the	215	218	|O
benzothiadiazine	219	235	|O
dioxide	236	243	|O
BPDZ	244	248	|O
73	249	251	|O
,	251	252	|O
were	253	257	|O
tested	258	264	|O
as	265	267	|O
putative	268	276	|O
K	277	278	|O
(	278	279	|O
ATP	279	282	|O
)	282	283	|O
channel	284	291	|O
activators	292	302	|O
on	303	305	|O
the	306	309	|O
pancreatic	310	320	|O
endocrine	321	330	|O
tissue	331	337	|O
and	338	341	|O
on	342	344	|O
the	345	348	|O
vascular	349	357	|O
smooth	358	364	|O
muscle	365	371	|O
tissue	372	378	|O
.	378	379	|O
The	380	383	|O
nature	384	390	|O
of	391	393	|O
the	394	397	|O
substituent	398	409	|O
introduced	410	420	|O
in	421	423	|O
the	424	427	|O
7	428	429	|O
-	429	430	|O
position	430	438	|O
as	439	441	|O
well	442	446	|O
as	447	449	|O
the	450	453	|O
nature	454	460	|O
of	461	463	|O
the	464	467	|O
alkylamino	468	478	|O
side	479	483	|O
chain	484	489	|O
in	490	492	|O
the	493	496	|O
3	497	498	|O
-	498	499	|O
position	499	507	|O
strongly	508	516	|O
affected	517	525	|O
both	526	530	|O
potency	531	538	|O
and	539	542	|O
tissue	543	549	|O
selectivity	550	561	|O
of	562	564	|O
4H	565	567	|B-IUPAC
-	567	568	|I-IUPAC
1,2,4	568	573	|I-IUPAC
-	573	574	|I-IUPAC
benzothiadiazine	574	590	|I-IUPAC
1,1	591	594	|I-IUPAC
-	594	595	|I-IUPAC
dioxides	595	603	|I-IUPAC
.	603	604	|O
Thus	605	609	|O
,	609	610	|O
compounds	611	620	|O
bearing	621	628	|O
in	629	631	|O
the	632	635	|O
7	636	637	|O
-	637	638	|O
position	638	646	|O
a	647	648	|O
methyl	649	655	|O
or	656	658	|O
a	659	660	|O
methoxy	661	668	|O
group	669	674	|O
or	675	677	|O
devoid	678	684	|O
of	685	687	|O
a	688	689	|O
substituent	690	701	|O
in	702	704	|O
this	705	709	|O
position	710	718	|O
,	718	719	|O
and	720	723	|O
bearing	724	731	|O
an	732	734	|O
ethyl	735	740	|O
,	740	741	|O
an	742	744	|O
isopropyl	745	754	|O
,	754	755	|O
or	756	758	|O
a	759	760	|O
cyclobutylamino	761	776	|O
group	777	782	|O
in	783	785	|O
the	786	789	|O
3	790	791	|O
-	791	792	|O
position	792	800	|O
were	801	805	|O
found	806	811	|O
to	812	814	|O
be	815	817	|O
potent	818	824	|O
and	825	828	|O
selective	829	838	|O
inhibitors	839	849	|O
of	850	852	|O
insulin	853	860	|O
release	861	868	|O
from	869	873	|O
rat	874	877	|O
pancreatic	878	888	|O
B	889	890	|O
-	890	891	|O
cells	891	896	|O
(	897	898	|O
i.e.	898	902	|O
10a	903	906	|O
,	906	907	|O
10b	908	911	|O
,	911	912	|O
12b	913	916	|O
,	916	917	|O
12d	918	921	|O
,	921	922	|O
22c	923	926	|O
)	926	927	|O
.	927	928	|O
In	929	931	|O
contrast	932	940	|O
,	940	941	|O
3	942	943	|B-PARTIUPAC
-	943	944	|I-PARTIUPAC
alkylamino	944	954	|I-PARTIUPAC
-	954	955	|I-PARTIUPAC
7	955	956	|I-PARTIUPAC
-	956	957	|I-PARTIUPAC
trifluoromethyl	957	972	|I-PARTIUPAC
-	972	973	|I-PARTIUPAC
(	974	975	|O
20a	975	978	|O
-	978	979	|O
c	979	980	|O
)	980	981	|O
and	982	985	|O
3	986	987	|B-IUPAC
-	987	988	|I-IUPAC
alkylamino	988	998	|I-IUPAC
-	998	999	|I-IUPAC
7	999	1000	|I-IUPAC
-	1000	1001	|I-IUPAC
pentyl	1001	1007	|I-IUPAC
-	1007	1008	|I-IUPAC
4H	1008	1010	|I-IUPAC
-	1010	1011	|I-IUPAC
1,2,4	1011	1016	|I-IUPAC
-	1016	1017	|I-IUPAC
benzothiadiazine	1017	1033	|I-IUPAC
1,1	1034	1037	|I-IUPAC
-	1037	1038	|I-IUPAC
dioxides	1038	1046	|I-IUPAC
(	1047	1048	|O
11a	1048	1051	|O
,	1051	1052	|O
b	1052	1053	|O
)	1053	1054	|O
expressed	1055	1064	|O
a	1065	1066	|O
marked	1067	1073	|O
myorelaxant	1074	1085	|O
activity	1086	1094	|O
on	1095	1097	|O
rat	1098	1101	|O
aorta	1102	1107	|O
ring	1108	1112	|O
.	1112	1113	|O
Among	1114	1119	|O
the	1120	1123	|O
latter	1124	1130	|O
compounds	1131	1140	|O
,	1140	1141	|O
the	1142	1145	|O
3	1146	1147	|B-IUPAC
-	1147	1148	|I-IUPAC
alkylamino	1148	1158	|I-IUPAC
-	1158	1159	|I-IUPAC
7	1159	1160	|I-IUPAC
-	1160	1161	|I-IUPAC
pentyl	1161	1167	|I-IUPAC
derivative	1168	1178	|B-MODIFIER
(	1179	1180	|O
11a	1180	1183	|O
)	1183	1184	|O
showed	1185	1191	|O
a	1192	1193	|O
clear	1194	1199	|O
selectivity	1200	1211	|O
for	1212	1215	|O
the	1216	1219	|O
vascular	1220	1228	|O
smooth	1229	1235	|O
muscle	1236	1242	|O
tissue	1243	1249	|O
.	1249	1250	|O
The	1251	1254	|O
present	1255	1262	|O
work	1263	1267	|O
gives	1268	1273	|O
new	1274	1277	|O
insights	1278	1286	|O
into	1287	1291	|O
the	1292	1295	|O
role	1296	1300	|O
of	1301	1303	|O
the	1304	1307	|O
substituent	1308	1319	|O
in	1320	1322	|O
both	1323	1327	|O
the	1328	1331	|O
7	1332	1333	|O
-	1333	1334	|O
and	1335	1338	|O
the	1339	1342	|O
3	1343	1344	|O
-	1344	1345	|O
position	1345	1353	|O
for	1354	1357	|O
the	1358	1361	|O
design	1362	1368	|O
of	1369	1371	|O
4H	1372	1374	|B-IUPAC
-	1374	1375	|I-IUPAC
1,2,4	1375	1380	|I-IUPAC
-	1380	1381	|I-IUPAC
benzothiadiazine	1381	1397	|I-IUPAC
1,1	1398	1401	|I-IUPAC
-	1401	1402	|I-IUPAC
dioxide	1402	1409	|I-IUPAC
potassium	1410	1419	|O
channel	1420	1427	|O
openers	1428	1435	|O
exhibiting	1436	1446	|O
different	1447	1456	|O
tissue	1457	1463	|O
selectivity	1464	1475	|O
profiles	1476	1484	|O
.	1484	1485	|O

### abstracts3079.txt
In	0	2	|O
order	3	8	|O
to	9	11	|O
study	12	17	|O
the	18	21	|O
structure	22	31	|O
-	31	32	|O
activity	32	40	|O
relationships	41	54	|O
of	55	57	|O
L	58	59	|B-IUPAC
-	59	60	|I-IUPAC
oxathiolanyl	60	72	|I-IUPAC
nucleosides	73	84	|B-MODIFIER
as	85	87	|O
potential	88	97	|O
anti	98	102	|O
-	102	103	|O
HIV	103	106	|O
agents	107	113	|O
,	113	114	|O
a	115	116	|O
series	117	123	|O
of	124	126	|O
enantiomerically	127	143	|O
pure	144	148	|O
L	149	150	|B-IUPAC
-	150	151	|I-IUPAC
oxathiolanyl	151	163	|I-IUPAC
pyrimidine	164	174	|I-IUPAC
and	175	178	|O
purine	179	185	|O
nucleosides	186	197	|O
were	198	202	|O
synthesized	203	214	|O
and	215	218	|O
evaluated	219	228	|O
for	229	232	|O
anti	233	237	|O
-	237	238	|O
HIV	238	241	|O
-	241	242	|O
1	242	243	|O
activity	244	252	|O
in	253	255	|O
human	256	261	|O
peripheral	262	272	|O
blood	273	278	|O
mononuclear	279	290	|O
(	291	292	|O
PBM	292	295	|O
)	295	296	|O
cells	297	302	|O
.	302	303	|O
The	304	307	|O
key	308	311	|O
intermediate	312	324	|O
8	325	326	|O
was	327	330	|O
synthesized	331	342	|O
starting	343	351	|O
from	352	356	|O
L	357	358	|O
-	358	359	|O
gulose	359	365	|O
via	366	369	|O
1,6	370	373	|B-IUPAC
-	373	374	|I-IUPAC
thioanhydro	374	385	|I-IUPAC
-	385	386	|I-IUPAC
L	386	387	|I-IUPAC
-	387	388	|I-IUPAC
gulopyranose	388	400	|I-IUPAC
.	400	401	|O
The	402	405	|O
acetate	406	413	|O
8	414	415	|O
was	416	419	|O
condensed	420	429	|O
with	430	434	|O
thymine	435	442	|O
,	442	443	|O
5	444	445	|B-MODIFIER
-	445	446	|I-MODIFIER
substituted	446	457	|I-MODIFIER
uracils	458	465	|B-IUPAC
and	466	469	|O
cytosines	470	479	|B-IUPAC
,	479	480	|O
6	481	482	|B-IUPAC
-	482	483	|I-IUPAC
chloropurine	483	495	|I-IUPAC
,	495	496	|O
and	497	500	|O
6	501	502	|B-IUPAC
-	502	503	|I-IUPAC
chloro	503	509	|I-IUPAC
-	509	510	|I-IUPAC
2	510	511	|I-IUPAC
-	511	512	|I-IUPAC
fluoropurine	512	524	|I-IUPAC
to	525	527	|O
give	528	532	|O
pyrimidine	533	543	|O
and	544	547	|O
purine	548	554	|O
nucleosides	555	566	|O
.	566	567	|O
Upon	568	572	|O
evaluation	573	583	|O
of	584	586	|O
these	587	592	|O
final	593	598	|O
nucleosides	599	610	|O
,	610	611	|O
the	612	615	|O
5	616	617	|B-IUPAC
-	617	618	|I-IUPAC
fluorocytosine	618	632	|I-IUPAC
derivative	633	643	|B-MODIFIER
51	644	646	|O
was	647	650	|O
found	651	656	|O
to	657	659	|O
be	660	662	|O
the	663	666	|O
most	667	671	|O
potent	672	678	|O
compound	679	687	|O
among	688	693	|O
those	694	699	|O
tested	700	706	|O
.	706	707	|O
In	708	710	|O
the	711	714	|O
case	715	719	|O
of	720	722	|O
5	723	724	|B-MODIFIER
-	724	725	|I-MODIFIER
substituted	725	736	|I-MODIFIER
cytosine	737	745	|B-IUPAC
analogues	746	755	|B-MODIFIER
,	755	756	|O
the	757	760	|O
antiviral	761	770	|O
potency	771	778	|O
was	779	782	|O
found	783	788	|O
to	789	791	|O
be	792	794	|O
in	795	797	|O
the	798	801	|O
following	802	811	|O
decreasing	812	822	|O
order	823	828	|O
:	828	829	|O
cytosine	830	838	|O
(	839	840	|O
beta	840	844	|O
-	844	845	|O
isomer	845	851	|O
)	851	852	|O
&	853	854	|O
gt	854	856	|O
;	856	857	|O
5	858	859	|B-IUPAC
-	859	860	|I-IUPAC
iodocytosine	860	872	|I-IUPAC
(	873	874	|O
beta	874	878	|O
-	878	879	|O
isomer	879	885	|O
)	885	886	|O
&	887	888	|O
gt	888	890	|O
;	890	891	|O
5	892	893	|B-IUPAC
-	893	894	|I-IUPAC
fluorocytosine	894	908	|I-IUPAC
(	909	910	|O
alpha	910	915	|O
-	915	916	|O
isomer	916	922	|O
)	922	923	|O
&	924	925	|O
gt	925	927	|O
;	927	928	|O
5	929	930	|B-IUPAC
-	930	931	|I-IUPAC
methylcytosine	931	945	|I-IUPAC
(	946	947	|O
alpha	947	952	|O
-	952	953	|O
isomer	953	959	|O
)	959	960	|O
&	961	962	|O
gt	962	964	|O
;	964	965	|O
5	966	967	|B-IUPAC
-	967	968	|I-IUPAC
methylcytosine	968	982	|I-IUPAC
(	983	984	|O
beta	984	988	|O
-	988	989	|O
isomer	989	995	|O
)	995	996	|O
&	997	998	|O
gt	998	1000	|O
;	1000	1001	|O
5	1002	1003	|B-IUPAC
-	1003	1004	|I-IUPAC
bromocytosine	1004	1017	|I-IUPAC
(	1018	1019	|O
beta	1019	1023	|O
-	1023	1024	|O
isomer	1024	1030	|O
)	1030	1031	|O
&	1032	1033	|O
gt	1033	1035	|O
;	1035	1036	|O
5	1037	1038	|B-IUPAC
-	1038	1039	|I-IUPAC
chlorocytosine	1039	1053	|I-IUPAC
(	1054	1055	|O
beta	1055	1059	|O
-	1059	1060	|O
isomer	1060	1066	|O
)	1066	1067	|O
.	1067	1068	|O
Among	1069	1074	|O
the	1075	1078	|O
thymine	1079	1086	|O
,	1086	1087	|O
uracil	1088	1094	|O
,	1094	1095	|O
and	1096	1099	|O
5	1100	1101	|B-MODIFIER
-	1101	1102	|I-MODIFIER
substituted	1102	1113	|I-MODIFIER
uracil	1114	1120	|B-IUPAC
derivatives	1121	1132	|B-MODIFIER
,	1132	1133	|O
thymine	1134	1141	|O
(	1142	1143	|O
alpha	1143	1148	|O
-	1148	1149	|O
isomer	1149	1155	|O
)	1155	1156	|O
and	1157	1160	|O
uracil	1161	1167	|O
(	1168	1169	|O
beta	1169	1173	|O
-	1173	1174	|O
isomer	1174	1180	|O
)	1180	1181	|O
derivatives	1182	1193	|O
exhibited	1194	1203	|O
moderate	1204	1212	|O
anti	1213	1217	|O
-	1217	1218	|O
HIV	1218	1221	|O
activity	1222	1230	|O
.	1230	1231	|O
In	1232	1234	|O
the	1235	1238	|O
purine	1239	1245	|O
series	1246	1252	|O
,	1252	1253	|O
the	1254	1257	|O
antiviral	1258	1267	|O
potency	1268	1275	|O
is	1276	1278	|O
found	1279	1284	|O
to	1285	1287	|O
be	1288	1290	|O
in	1291	1293	|O
the	1294	1297	|O
following	1298	1307	|O
decreasing	1308	1318	|O
order	1319	1324	|O
:	1324	1325	|O
adenine	1326	1333	|O
(	1334	1335	|O
beta	1335	1339	|O
-	1339	1340	|O
isomer	1340	1346	|O
)	1346	1347	|O
&	1348	1349	|O
gt	1349	1351	|O
;	1351	1352	|O
6	1353	1354	|B-IUPAC
-	1354	1355	|I-IUPAC
chloropurine	1355	1367	|I-IUPAC
(	1368	1369	|O
beta	1369	1373	|O
-	1373	1374	|O
isomer	1374	1380	|O
)	1380	1381	|O
&	1382	1383	|O
gt	1383	1385	|O
;	1385	1386	|O
6	1387	1388	|B-IUPAC
-	1388	1389	|I-IUPAC
chloropurine	1389	1401	|I-IUPAC
(	1402	1403	|O
alpha	1403	1408	|O
-	1408	1409	|O
isomer	1409	1415	|O
)	1415	1416	|O
&	1417	1418	|O
gt	1418	1420	|O
;	1420	1421	|O
2	1422	1423	|O
-	1423	1424	|O
NH2	1424	1427	|O
-	1427	1428	|O
6	1428	1429	|O
-	1429	1430	|O
Cl	1430	1432	|O
-	1432	1433	|O
purine	1433	1439	|O
(	1440	1441	|O
beta	1441	1445	|O
-	1445	1446	|O
isomer	1446	1452	|O
)	1452	1453	|O
&	1454	1455	|O
gt	1455	1457	|O
;	1457	1458	|O
guanine	1459	1466	|O
(	1467	1468	|O
beta	1468	1472	|O
-	1472	1473	|O
isomer	1473	1479	|O
)	1479	1480	|O
&	1481	1482	|O
gt	1482	1484	|O
;	1484	1485	|O
N6	1486	1488	|B-IUPAC
-	1488	1489	|I-IUPAC
methyladenine	1489	1502	|I-IUPAC
(	1503	1504	|O
alpha	1504	1509	|O
-	1509	1510	|O
isomer	1510	1516	|O
)	1516	1517	|O
&	1518	1519	|O
gt	1519	1521	|O
;	1521	1522	|O
N6	1523	1525	|B-IUPAC
-	1525	1526	|I-IUPAC
methyladenine	1526	1539	|I-IUPAC
(	1540	1541	|O
beta	1541	1545	|O
-	1545	1546	|O
isomer	1546	1552	|O
)	1552	1553	|O
.	1553	1554	|O
The	1555	1558	|O
cytotoxicity	1559	1571	|O
was	1572	1575	|O
also	1576	1580	|O
determined	1581	1591	|O
in	1592	1594	|O
human	1595	1600	|O
PBM	1601	1604	|O
cells	1605	1610	|O
as	1611	1613	|O
well	1614	1618	|O
as	1619	1621	|O
Vero	1622	1626	|O
cells	1627	1632	|O
.	1632	1633	|O
None	1634	1638	|O
of	1639	1641	|O
the	1642	1645	|O
synthesized	1646	1657	|O
nucleosides	1658	1669	|O
was	1670	1673	|O
toxic	1674	1679	|O
up	1680	1682	|O
to	1683	1685	|O
100	1686	1689	|O
microM	1690	1696	|O
in	1697	1699	|O
PBM	1700	1703	|O
cells	1704	1709	|O
.	1709	1710	|O

### abstracts2266.txt
The	0	3	|O
3	4	5	|B-IUPAC
-	5	6	|I-IUPAC
isoxazolol	6	16	|I-IUPAC
amino	17	22	|I-IUPAC
acid	23	27	|I-IUPAC
(	28	29	|B-IUPAC
RS	29	31	|I-IUPAC
)	31	32	|I-IUPAC
-	32	33	|I-IUPAC
2	33	34	|I-IUPAC
-	34	35	|I-IUPAC
amino	35	40	|I-IUPAC
-	40	41	|I-IUPAC
3	41	42	|I-IUPAC
-	42	43	|I-IUPAC
(	43	44	|I-IUPAC
3	44	45	|I-IUPAC
-	45	46	|I-IUPAC
hydroxy	46	53	|I-IUPAC
-	53	54	|I-IUPAC
5	54	55	|I-IUPAC
-	55	56	|I-IUPAC
methylisoxazol	56	70	|I-IUPAC
-	70	71	|I-IUPAC
4	71	72	|I-IUPAC
-	72	73	|I-IUPAC
yl	73	75	|I-IUPAC
)	75	76	|I-IUPAC
propionic	76	85	|I-IUPAC
acid	86	90	|I-IUPAC
(	91	92	|O
AMPA	92	96	|O
,	96	97	|O
2	98	99	|O
)	99	100	|O
and	101	104	|O
the	105	108	|O
isomeric	109	117	|O
compound	118	126	|O
(	127	128	|B-IUPAC
RS	128	130	|I-IUPAC
)	130	131	|I-IUPAC
-	131	132	|I-IUPAC
2	132	133	|I-IUPAC
-	133	134	|I-IUPAC
amino	134	139	|I-IUPAC
-	139	140	|I-IUPAC
3	140	141	|I-IUPAC
-	141	142	|I-IUPAC
(	142	143	|I-IUPAC
3	143	144	|I-IUPAC
-	144	145	|I-IUPAC
hydroxy	145	152	|I-IUPAC
-	152	153	|I-IUPAC
4	153	154	|I-IUPAC
-	154	155	|I-IUPAC
methylisoxazol	155	169	|I-IUPAC
-	169	170	|I-IUPAC
5	170	171	|I-IUPAC
-	171	172	|I-IUPAC
yl	172	174	|I-IUPAC
)	174	175	|I-IUPAC
propionic	175	184	|I-IUPAC
acid	185	189	|I-IUPAC
(	190	191	|O
4	191	192	|B-IUPAC
-	192	193	|I-IUPAC
methylhomoibotenic	193	211	|I-IUPAC
acid	212	216	|I-IUPAC
,	216	217	|O
4a	218	220	|O
)	220	221	|O
are	222	225	|O
potent	226	232	|O
agonists	233	241	|O
at	242	244	|O
the	245	248	|O
AMPA	249	253	|O
subtype	254	261	|O
of	262	264	|O
central	265	272	|O
excitatory	273	283	|O
amino	284	289	|O
acid	290	294	|O
receptors	295	304	|O
.	304	305	|O
Using	306	311	|O
4a	312	314	|O
as	315	317	|O
a	318	319	|O
lead	320	324	|O
structure	325	334	|O
,	334	335	|O
the	336	339	|O
amino	340	345	|O
acids	346	351	|O
4c	352	354	|O
-	354	355	|O
e	355	356	|O
,	356	357	|O
in	358	360	|O
which	361	366	|O
the	367	370	|O
4	371	372	|B-IUPAC
-	372	373	|I-IUPAC
methyl	373	379	|I-IUPAC
group	380	385	|B-MODIFIER
of	386	388	|O
4a	389	391	|O
is	392	394	|O
replaced	395	403	|O
by	404	406	|O
substituents	407	419	|O
of	420	422	|O
different	423	432	|O
size	433	437	|O
and	438	441	|O
polarity	442	450	|O
,	450	451	|O
were	452	456	|O
synthesized	457	468	|O
.	468	469	|O
Attempts	470	478	|O
to	479	481	|O
synthesize	482	492	|O
4	493	494	|B-IUPAC
-	494	495	|I-IUPAC
(	495	496	|I-IUPAC
bromomethyl	496	507	|I-IUPAC
)	507	508	|I-IUPAC
homoibotenic	508	520	|I-IUPAC
acid	521	525	|I-IUPAC
(	526	527	|O
4f	527	529	|O
)	529	530	|O
,	530	531	|O
a	532	533	|O
potential	534	543	|O
receptor	544	552	|O
alkylating	553	563	|O
agent	564	569	|O
,	569	570	|O
were	571	575	|O
unsuccessful	576	588	|O
.	588	589	|O
4	590	591	|B-IUPAC
-	591	592	|I-IUPAC
Butylhomoibotenic	592	609	|I-IUPAC
acid	610	614	|I-IUPAC
(	615	616	|O
4c	616	618	|O
)	618	619	|O
and	620	623	|O
4	624	625	|B-IUPAC
-	625	626	|I-IUPAC
(	626	627	|I-IUPAC
2	627	628	|I-IUPAC
-	628	629	|I-IUPAC
hydroxyethyl	629	641	|I-IUPAC
)	641	642	|I-IUPAC
homoibotenic	642	654	|I-IUPAC
acid	655	659	|I-IUPAC
(	660	661	|O
4e	661	663	|O
)	663	664	|O
were	665	669	|O
equipotent	670	680	|O
as	681	683	|O
inhibitors	684	694	|O
of	695	697	|O
[	698	699	|O
3H	699	701	|O
]	701	702	|O
AMPA	702	706	|O
binding	707	714	|O
(	715	716	|O
IC50	716	720	|O
=	721	722	|O
2	723	724	|O
microM	725	731	|O
)	731	732	|O
and	733	736	|O
showed	737	743	|O
similar	744	751	|O
excitatory	752	762	|O
activity	763	771	|O
in	772	774	|O
the	775	778	|O
rat	779	782	|O
cortical	783	791	|O
slice	792	797	|O
preparation	798	809	|O
.	809	810	|O
4d	811	813	|O
did	814	817	|O
not	818	821	|O
show	822	826	|O
significant	827	838	|O
affinity	839	847	|O
for	848	851	|O
AMPA	852	856	|O
receptor	857	865	|O
sites	866	871	|O
,	871	872	|O
but	873	876	|O
turned	877	883	|O
out	884	887	|O
to	888	890	|O
be	891	893	|O
a	894	895	|O
weak	896	900	|O
N	901	902	|B-IUPAC
-	902	903	|I-IUPAC
methyl	903	909	|I-IUPAC
-	909	910	|I-IUPAC
D	910	911	|I-IUPAC
-	911	912	|I-IUPAC
aspartic	912	920	|I-IUPAC
acid	921	925	|I-IUPAC
(	926	927	|O
NMDA	927	931	|O
)	931	932	|O
receptor	933	941	|O
antagonist	942	952	|O
.	952	953	|O
However	954	961	|O
,	961	962	|O
like	963	967	|O
4c	968	970	|O
,	970	971	|O
e	971	972	|O
,	972	973	|O
4d	974	976	|O
did	977	980	|O
not	981	984	|O
significantly	985	998	|O
affect	999	1005	|O
the	1006	1009	|O
binding	1010	1017	|O
of	1018	1020	|O
the	1021	1024	|O
competitive	1025	1036	|O
NMDA	1037	1041	|O
antagonist	1042	1052	|O
,	1052	1053	|O
[	1054	1055	|O
3H	1055	1057	|O
]	1057	1058	|O
CPP	1058	1061	|O
,	1061	1062	|O
or	1063	1065	|O
the	1066	1069	|O
noncompetitive	1070	1084	|O
NMDA	1085	1089	|O
antagonist	1090	1100	|O
,	1100	1101	|O
[	1102	1103	|O
3H	1103	1105	|O
]	1105	1106	|O
MK	1106	1108	|O
-	1108	1109	|O
801	1109	1112	|O
.	1112	1113	|O
None	1114	1118	|O
of	1119	1121	|O
the	1122	1125	|O
amino	1126	1131	|O
acids	1132	1137	|O
4c	1138	1140	|O
-	1140	1141	|O
e	1141	1142	|O
showed	1143	1149	|O
detectable	1150	1160	|O
affinity	1161	1169	|O
for	1170	1173	|O
[	1174	1175	|O
3H	1175	1177	|O
]	1177	1178	|O
kainic	1178	1184	|O
acid	1185	1189	|O
binding	1190	1197	|O
sites	1198	1203	|O
.	1203	1204	|O
Like	1205	1209	|O
the	1210	1213	|O
parent	1214	1220	|O
compound	1221	1229	|O
4a	1230	1232	|O
(	1233	1234	|O
IC50	1234	1238	|O
=	1239	1240	|O
0.18	1241	1245	|O
microM	1246	1252	|O
)	1252	1253	|O
,	1253	1254	|O
4c	1255	1257	|O
(	1258	1259	|O
IC50	1259	1263	|O
=	1264	1265	|O
0.18	1266	1270	|O
microM	1271	1277	|O
)	1277	1278	|O
,	1278	1279	|O
4e	1280	1282	|O
(	1283	1284	|O
IC50	1284	1288	|O
=	1289	1290	|O
0.14	1291	1295	|O
microM	1296	1302	|O
)	1302	1303	|O
,	1303	1304	|O
and	1305	1308	|O
in	1309	1311	|O
particular	1312	1322	|O
4d	1323	1325	|O
(	1326	1327	|O
IC50	1327	1331	|O
=	1332	1333	|O
0.02	1334	1338	|O
microM	1339	1345	|O
)	1345	1346	|O
were	1347	1351	|O
effective	1352	1361	|O
inhibitors	1362	1372	|O
of	1373	1375	|O
calcium	1376	1383	|O
chloride	1384	1392	|O
-	1392	1393	|O
dependent	1393	1402	|O
[	1403	1404	|O
3H	1404	1406	|O
]	1406	1407	|O
glutamic	1407	1415	|O
acid	1416	1420	|O
binding	1421	1428	|O
,	1428	1429	|O
whereas	1430	1437	|O
AMPA	1438	1442	|O
is	1443	1445	|O
inactive	1446	1454	|O
(	1455	1456	|O
IC50	1456	1460	|O
greater	1461	1468	|O
than	1469	1473	|O
100	1474	1477	|O
microM	1478	1484	|O
)	1484	1485	|O
in	1486	1488	|O
this	1489	1493	|O
binding	1494	1501	|O
assay	1502	1507	|O
.	1507	1508	|O
Thus	1509	1513	|O
,	1513	1514	|O
4d	1515	1517	|O
is	1518	1520	|O
an	1521	1523	|O
effective	1524	1533	|O
and	1534	1537	|O
highly	1538	1544	|O
selective	1545	1554	|O
inhibitor	1555	1564	|O
of	1565	1567	|O
calcium	1568	1575	|O
chloride	1576	1584	|O
-	1584	1585	|O
dependent	1585	1594	|O
[	1595	1596	|O
3H	1596	1598	|O
]	1598	1599	|O
glutamic	1599	1607	|O
acid	1608	1612	|O
binding	1613	1620	|O
and	1621	1624	|O
may	1625	1628	|O
be	1629	1631	|O
a	1632	1633	|O
useful	1634	1640	|O
tool	1641	1645	|O
for	1646	1649	|O
studies	1650	1657	|O
of	1658	1660	|O
the	1661	1664	|O
physiological	1665	1678	|O
relevance	1679	1688	|O
and	1689	1692	|O
pharmacological	1693	1708	|O
importance	1709	1719	|O
of	1720	1722	|O
this	1723	1727	|O
binding	1728	1735	|O
affinity	1736	1744	|O
.	1744	1745	|O

### abstracts664.txt
New	0	3	|O
water	4	9	|O
-	9	10	|O
soluble	10	17	|O
bis	18	21	|B-IUPAC
(	21	22	|I-IUPAC
2	22	23	|I-IUPAC
-	23	24	|I-IUPAC
phenylazopyridine	24	41	|I-IUPAC
)	41	42	|I-IUPAC
ruthenium	42	51	|I-IUPAC
(	51	52	|I-IUPAC
II	52	54	|I-IUPAC
)	54	55	|I-IUPAC
complexes	56	65	|B-MODIFIER
,	65	66	|O
all	67	70	|O
derivatives	71	82	|O
of	83	85	|O
the	86	89	|O
highly	90	96	|O
cytotoxic	97	106	|O
alpha	107	112	|O
-	112	113	|O
[	113	114	|O
Ru	114	116	|O
(	116	117	|O
azpy	117	121	|O
)	121	122	|O
(	122	123	|O
2	123	124	|O
)	124	125	|O
Cl	125	127	|O
(	127	128	|O
2	128	129	|O
)	129	130	|O
]	130	131	|O
(	132	133	|O
alpha	133	138	|O
denoting	139	147	|O
the	148	151	|O
coordinating	152	164	|O
pairs	165	170	|O
Cl	171	173	|O
,	173	174	|O
N	175	176	|O
(	176	177	|O
py	177	179	|O
)	179	180	|O
,	180	181	|O
and	182	185	|O
N	186	187	|O
(	187	188	|O
azo	188	191	|O
)	191	192	|O
as	193	195	|O
cis	196	199	|O
,	199	200	|O
trans	201	206	|O
,	206	207	|O
cis	208	211	|O
,	211	212	|O
respectively	213	225	|O
)	225	226	|O
have	227	231	|O
been	232	236	|O
developed	237	246	|O
.	246	247	|O
The	248	251	|O
compounds	252	261	|O
1,1	262	265	|B-IUPAC
-	265	266	|I-IUPAC
cyclobutanedicarboxylatobis	266	293	|I-IUPAC
(	293	294	|I-IUPAC
2	294	295	|I-IUPAC
-	295	296	|I-IUPAC
phenylazopyridine	296	313	|I-IUPAC
)	313	314	|I-IUPAC
ruthenium	314	323	|I-IUPAC
(	323	324	|I-IUPAC
II	324	326	|I-IUPAC
)	326	327	|I-IUPAC
,	327	328	|O
alpha	329	334	|O
-	334	335	|O
[	335	336	|O
Ru	336	338	|O
(	338	339	|O
azpy	339	343	|O
)	343	344	|O
(	344	345	|O
2	345	346	|O
)	346	347	|O
(	347	348	|O
cbdca	348	353	|O
-	353	354	|O
O	354	355	|O
,	355	356	|O
O'	356	358	|O
)	358	359	|O
]	359	360	|O
(	361	362	|O
1	362	363	|O
)	363	364	|O
,	364	365	|O
oxalatobis	366	376	|B-IUPAC
(	376	377	|I-IUPAC
2	377	378	|I-IUPAC
-	378	379	|I-IUPAC
phenylazopyridine	379	396	|I-IUPAC
)	396	397	|I-IUPAC
ruthenium	397	406	|I-IUPAC
(	406	407	|I-IUPAC
II	407	409	|I-IUPAC
)	409	410	|I-IUPAC
,	410	411	|O
alpha	412	417	|O
-	417	418	|O
[	418	419	|O
Ru	419	421	|O
(	421	422	|O
azpy	422	426	|O
)	426	427	|O
(	427	428	|O
2	428	429	|O
)	429	430	|O
(	430	431	|O
ox	431	433	|O
)	433	434	|O
]	434	435	|O
(	436	437	|O
2	437	438	|O
)	438	439	|O
,	439	440	|O
and	441	444	|O
malonatobis	445	456	|B-IUPAC
(	456	457	|I-IUPAC
2	457	458	|I-IUPAC
-	458	459	|I-IUPAC
phenylazopyridine	459	476	|I-IUPAC
)	476	477	|I-IUPAC
ruthenium	477	486	|I-IUPAC
(	486	487	|I-IUPAC
II	487	489	|I-IUPAC
)	489	490	|I-IUPAC
,	490	491	|O
alpha	492	497	|O
-	497	498	|O
[	498	499	|O
Ru	499	501	|O
(	501	502	|O
azpy	502	506	|O
)	506	507	|O
(	507	508	|O
2	508	509	|O
)	509	510	|O
(	510	511	|O
mal	511	514	|O
)	514	515	|O
]	515	516	|O
(	517	518	|O
3	518	519	|O
)	519	520	|O
,	520	521	|O
have	522	526	|O
been	527	531	|O
synthesized	532	543	|O
and	544	547	|O
fully	548	553	|O
characterized	554	567	|O
.	567	568	|O
X	569	570	|O
-	570	571	|O
ray	571	574	|O
analyses	575	583	|O
of	584	586	|O
1	587	588	|O
and	589	592	|O
2	593	594	|O
are	595	598	|O
reported	599	607	|O
,	607	608	|O
and	609	612	|O
compound	613	621	|O
1	622	623	|O
is	624	626	|O
the	627	630	|O
first	631	636	|O
example	637	644	|O
in	645	647	|O
which	648	653	|O
the	654	657	|O
cbdca	658	663	|O
ligand	664	670	|O
is	671	673	|O
coordinated	674	685	|O
to	686	688	|O
a	689	690	|O
ruthenium	691	700	|O
center	701	707	|O
.	707	708	|O
The	709	712	|O
cytotoxicity	713	725	|O
of	726	728	|O
this	729	733	|O
series	734	740	|O
of	741	743	|O
water	744	749	|O
-	749	750	|O
soluble	750	757	|O
bis	758	761	|B-IUPAC
(	761	762	|I-IUPAC
2	762	763	|I-IUPAC
-	763	764	|I-IUPAC
phenylazopyridine	764	781	|I-IUPAC
)	781	782	|I-IUPAC
complexes	783	792	|B-MODIFIER
has	793	796	|O
been	797	801	|O
determined	802	812	|O
in	813	815	|O
A2780	816	821	|O
human	822	827	|O
ovarian	828	835	|O
carcinoma	836	845	|O
and	846	849	|O
A2780cisR	850	859	|O
,	859	860	|O
the	861	864	|O
corresponding	865	878	|O
cisplatin	879	888	|O
-	888	889	|O
resistant	889	898	|O
cell	899	903	|O
line	904	908	|O
.	908	909	|O
For	910	913	|O
comparison	914	924	|O
reasons	925	932	|O
,	932	933	|O
the	934	937	|O
cytotoxicity	938	950	|O
of	951	953	|O
the	954	957	|O
complexes	958	967	|O
alpha	968	973	|O
-	973	974	|O
[	974	975	|O
Ru	975	977	|O
(	977	978	|O
azpy	978	982	|O
)	982	983	|O
(	983	984	|O
2	984	985	|O
)	985	986	|O
Cl	986	988	|O
(	988	989	|O
2	989	990	|O
)	990	991	|O
]	991	992	|O
,	992	993	|O
alpha	994	999	|O
-	999	1000	|O
[	1000	1001	|O
Ru	1001	1003	|O
(	1003	1004	|O
azpy	1004	1008	|O
)	1008	1009	|O
(	1009	1010	|O
2	1010	1011	|O
)	1011	1012	|O
(	1012	1013	|O
NO	1013	1015	|O
(	1015	1016	|O
3	1016	1017	|O
)	1017	1018	|O
)	1018	1019	|O
(	1019	1020	|O
2	1020	1021	|O
)	1021	1022	|O
]	1022	1023	|O
,	1023	1024	|O
beta	1025	1029	|O
-	1029	1030	|O
[	1030	1031	|O
Ru	1031	1033	|O
(	1033	1034	|O
azpy	1034	1038	|O
)	1038	1039	|O
(	1039	1040	|O
2	1040	1041	|O
)	1041	1042	|O
Cl	1042	1044	|O
(	1044	1045	|O
2	1045	1046	|O
)	1046	1047	|O
]	1047	1048	|O
(	1049	1050	|O
beta	1050	1054	|O
indicating	1055	1065	|O
the	1066	1069	|O
coordinating	1070	1082	|O
pairs	1083	1088	|O
Cl	1089	1091	|O
,	1091	1092	|O
N	1093	1094	|O
(	1094	1095	|O
py	1095	1097	|O
)	1097	1098	|O
,	1098	1099	|O
and	1100	1103	|O
N	1104	1105	|O
(	1105	1106	|O
azo	1106	1109	|O
)	1109	1110	|O
as	1111	1113	|O
cis	1114	1117	|O
,	1117	1118	|O
cis	1119	1122	|O
,	1122	1123	|O
cis	1124	1127	|O
,	1127	1128	|O
respectively	1129	1141	|O
)	1141	1142	|O
,	1142	1143	|O
and	1144	1147	|O
beta	1148	1152	|O
-	1152	1153	|O
[	1153	1154	|O
Ru	1154	1156	|O
(	1156	1157	|O
azpy	1157	1161	|O
)	1161	1162	|O
(	1162	1163	|O
2	1163	1164	|O
)	1164	1165	|O
(	1165	1166	|O
NO	1166	1168	|O
(	1168	1169	|O
3	1169	1170	|O
)	1170	1171	|O
)	1171	1172	|O
(	1172	1173	|O
2	1173	1174	|O
)	1174	1175	|O
]	1175	1176	|O
have	1177	1181	|O
been	1182	1186	|O
determined	1187	1197	|O
in	1198	1200	|O
this	1201	1205	|O
cell	1206	1210	|O
line	1211	1215	|O
.	1215	1216	|O
All	1217	1220	|O
the	1221	1224	|O
bis	1225	1228	|B-IUPAC
(	1228	1229	|I-IUPAC
2	1229	1230	|I-IUPAC
-	1230	1231	|I-IUPAC
phenylazopyridine	1231	1248	|I-IUPAC
)	1248	1249	|I-IUPAC
ruthenium	1249	1258	|I-IUPAC
(	1258	1259	|I-IUPAC
II	1259	1261	|I-IUPAC
)	1261	1262	|I-IUPAC
compounds	1263	1272	|B-MODIFIER
display	1273	1280	|O
a	1281	1282	|O
promising	1283	1292	|O
cytotoxicity	1293	1305	|O
in	1306	1308	|O
the	1309	1312	|O
A2780	1313	1318	|O
cell	1319	1323	|O
line	1324	1328	|O
(	1329	1330	|O
IC	1330	1332	|O
(	1332	1333	|O
50	1333	1335	|O
)	1335	1336	|O
=	1337	1338	|O
0.9-10	1339	1345	|O
microM	1346	1352	|O
)	1352	1353	|O
,	1353	1354	|O
with	1355	1359	|O
an	1360	1362	|O
activity	1363	1371	|O
comparable	1372	1382	|O
to	1383	1385	|O
that	1386	1390	|O
of	1391	1393	|O
cisplatin	1394	1403	|O
and	1404	1407	|O
even	1408	1412	|O
higher	1413	1419	|O
than	1420	1424	|O
the	1425	1428	|O
activity	1429	1437	|O
of	1438	1440	|O
carboplatin	1441	1452	|O
.	1452	1453	|O
Interestingly	1454	1467	|O
,	1467	1468	|O
the	1469	1472	|O
IC	1473	1475	|O
(	1475	1476	|O
50	1476	1478	|O
)	1478	1479	|O
values	1480	1486	|O
of	1487	1489	|O
this	1490	1494	|O
series	1495	1501	|O
of	1502	1504	|O
ruthenium	1505	1514	|O
compounds	1515	1524	|O
(	1525	1526	|O
except	1526	1532	|O
the	1533	1536	|O
beta	1537	1541	|O
isomeric	1542	1550	|O
compounds	1551	1560	|O
)	1560	1561	|O
are	1562	1565	|O
similar	1566	1573	|O
in	1574	1576	|O
the	1577	1580	|O
cisplatin	1581	1590	|O
-	1590	1591	|O
resistant	1591	1600	|O
A2780cisR	1601	1610	|O
cell	1611	1615	|O
line	1616	1620	|O
compared	1621	1629	|O
to	1630	1632	|O
the	1633	1636	|O
normal	1637	1643	|O
cell	1644	1648	|O
line	1649	1653	|O
A2780	1654	1659	|O
,	1659	1660	|O
suggesting	1661	1671	|O
that	1672	1676	|O
the	1677	1680	|O
activity	1681	1689	|O
of	1690	1692	|O
these	1693	1698	|O
compounds	1699	1708	|O
might	1709	1714	|O
not	1715	1718	|O
be	1719	1721	|O
influenced	1722	1732	|O
by	1733	1735	|O
the	1736	1739	|O
multifactorial	1740	1754	|O
resistance	1755	1765	|O
mechanism	1766	1775	|O
that	1776	1780	|O
affect	1781	1787	|O
platinum	1788	1796	|O
anticancer	1797	1807	|O
agents	1808	1814	|O
.	1814	1815	|O

### abstracts915.txt
Water	0	5	|O
-	5	6	|O
soluble	6	13	|O
prodrugs	14	22	|O
of	23	25	|O
potent	26	32	|O
,	32	33	|O
A	34	35	|O
(	35	36	|O
2A	36	38	|O
)	38	39	|O
-	39	40	|O
selective	40	49	|O
adenosine	50	59	|O
receptor	60	68	|O
(	69	70	|O
AR	70	72	|O
)	72	73	|O
antagonists	74	85	|O
were	86	90	|O
prepared	91	99	|O
.	99	100	|O
8	101	102	|B-IUPAC
-	102	103	|I-IUPAC
(	103	104	|I-IUPAC
m	104	105	|I-IUPAC
-	105	106	|I-IUPAC
Bromostyryl	106	117	|I-IUPAC
)	117	118	|I-IUPAC
-	118	119	|I-IUPAC
3	119	120	|I-IUPAC
,	120	121	|I-IUPAC
7	122	123	|I-IUPAC
-	123	124	|I-IUPAC
dimethyl	124	132	|I-IUPAC
-	132	133	|I-IUPAC
1	133	134	|I-IUPAC
-	134	135	|I-IUPAC
propargylxanthine	135	152	|I-IUPAC
(	153	154	|O
BS	154	156	|O
-	156	157	|O
DMPX	157	161	|O
,	161	162	|O
11	163	165	|O
)	165	166	|O
and	167	170	|O
the	171	174	|O
analogous	175	184	|B-MODIFIER
8	185	186	|B-IUPAC
-	186	187	|I-IUPAC
(	187	188	|I-IUPAC
m	188	189	|I-IUPAC
-	189	190	|I-IUPAC
methoxystyryl	190	203	|I-IUPAC
)	203	204	|I-IUPAC
xanthine	204	212	|I-IUPAC
derivative	213	223	|B-MODIFIER
(	224	225	|O
MS	225	227	|O
-	227	228	|O
DMPX	228	232	|O
,	232	233	|O
5b	234	236	|O
)	236	237	|O
were	238	242	|O
used	243	247	|O
as	248	250	|O
starting	251	259	|O
points	260	266	|O
.	266	267	|O
It	268	270	|O
was	271	274	|O
found	275	280	|O
that	281	285	|O
polar	286	291	|O
functional	292	302	|O
groups	303	309	|O
suitable	310	318	|O
for	319	322	|O
the	323	326	|O
attachment	327	337	|O
of	338	340	|O
a	341	342	|O
prodrug	343	350	|O
moiety	351	357	|O
were	358	362	|O
tolerated	363	372	|O
on	373	375	|O
the	376	379	|O
styryl	380	386	|O
ring	387	391	|O
and	392	395	|O
even	396	400	|O
better	401	407	|O
on	408	410	|O
the	411	414	|O
3	415	416	|O
-	416	417	|O
substituent	417	428	|O
.	428	429	|O
8	430	431	|B-IUPAC
-	431	432	|I-IUPAC
(	432	433	|I-IUPAC
m	433	434	|I-IUPAC
-	434	435	|I-IUPAC
Hydroxystyryl	435	448	|I-IUPAC
)	448	449	|I-IUPAC
-	449	450	|I-IUPAC
DMPX	450	454	|I-IUPAC
(	455	456	|O
7	456	457	|O
)	457	458	|O
and	459	462	|O
3	463	464	|B-IUPAC
-	464	465	|I-IUPAC
(	465	466	|I-IUPAC
3	466	467	|I-IUPAC
-	467	468	|I-IUPAC
hydroxypropyl	468	481	|I-IUPAC
)	481	482	|I-IUPAC
-	482	483	|I-IUPAC
8	483	484	|I-IUPAC
-	484	485	|I-IUPAC
(	485	486	|I-IUPAC
m	486	487	|I-IUPAC
-	487	488	|I-IUPAC
methoxystyryl	488	501	|I-IUPAC
)	501	502	|I-IUPAC
-	502	503	|I-IUPAC
1	503	504	|I-IUPAC
-	504	505	|I-IUPAC
propargylxanthine	505	522	|I-IUPAC
(	523	524	|O
5e	524	526	|O
,	526	527	|O
MSX	528	531	|O
-	531	532	|O
2	532	533	|O
)	533	534	|O
were	535	539	|O
the	540	543	|O
most	544	548	|O
potent	549	555	|O
and	556	559	|O
A	560	561	|O
(	561	562	|O
2A	562	564	|O
)	564	565	|O
-	565	566	|O
selective	566	575	|O
compounds	576	585	|O
and	586	589	|O
were	590	594	|O
selected	595	603	|O
for	604	607	|O
prodrug	608	615	|O
formation	616	625	|O
.	625	626	|O
For	627	630	|O
the	631	634	|O
preparation	635	646	|O
of	647	649	|O
5e	650	652	|O
a	653	654	|O
new	655	658	|O
ring	659	663	|O
-	663	664	|O
closure	664	671	|O
method	672	678	|O
was	679	682	|O
applied	683	690	|O
.	690	691	|O
Treatment	692	701	|O
of	702	704	|O
6	705	706	|B-IUPAC
-	706	707	|I-IUPAC
amino	707	712	|I-IUPAC
-	712	713	|I-IUPAC
1	713	714	|I-IUPAC
-	714	715	|I-IUPAC
(	715	716	|I-IUPAC
3	716	717	|I-IUPAC
-	717	718	|I-IUPAC
hydroxypropyl	718	731	|I-IUPAC
)	731	732	|I-IUPAC
-	732	733	|I-IUPAC
5	733	734	|I-IUPAC
-	734	735	|I-IUPAC
(	735	736	|I-IUPAC
m	736	737	|I-IUPAC
-	737	738	|I-IUPAC
methoxycinnamoylamino	738	759	|I-IUPAC
)	759	760	|I-IUPAC
-	760	761	|I-IUPAC
3	761	762	|I-IUPAC
-	762	763	|I-IUPAC
propa	763	768	|I-IUPAC
rgylur	769	775	|I-IUPAC
acil	776	780	|I-IUPAC
with	781	785	|O
hexamethyldisilazane	786	806	|O
at	807	809	|O
high	810	814	|O
temperature	815	826	|O
resulted	827	835	|O
in	836	838	|O
higher	839	845	|O
yields	846	852	|O
of	853	855	|O
the	856	859	|O
target	860	866	|O
xanthine	867	875	|O
than	876	880	|O
the	881	884	|O
standard	885	893	|O
ring	894	898	|O
-	898	899	|O
closure	899	906	|O
procedure	907	916	|O
using	917	922	|O
sodium	923	929	|O
hydroxide	930	939	|O
.	939	940	|O
Phosphate	941	950	|O
prodrugs	951	959	|O
were	960	964	|O
prepared	965	973	|O
by	974	976	|O
classical	977	986	|O
phosphorylation	987	1002	|O
using	1003	1008	|O
phosphorus	1009	1019	|O
oxychloride	1020	1031	|O
and	1032	1035	|O
alternatively	1036	1049	|O
by	1050	1052	|O
using	1053	1058	|O
a	1059	1060	|O
phosphoramidite	1061	1076	|O
method	1077	1083	|O
.	1083	1084	|O
Phosphates	1085	1095	|O
of	1096	1098	|O
the	1099	1102	|O
aliphatic	1103	1112	|O
alcohol	1113	1120	|O
5e	1121	1123	|O
could	1124	1129	|O
be	1130	1132	|O
obtained	1133	1141	|O
by	1142	1144	|O
both	1145	1149	|O
methods	1150	1157	|O
in	1158	1160	|O
similar	1161	1168	|O
yields	1169	1175	|O
.	1175	1176	|O
The	1177	1180	|O
phenolic	1181	1189	|O
compound	1190	1198	|O
7	1199	1200	|O
,	1200	1201	|O
however	1202	1209	|O
,	1209	1210	|O
could	1211	1216	|O
be	1217	1219	|O
phosphorylated	1220	1234	|O
only	1235	1239	|O
by	1240	1242	|O
using	1243	1248	|O
the	1249	1252	|O
phosphoramidite	1253	1268	|O
method	1269	1275	|O
.	1275	1276	|O
The	1277	1280	|O
disodium	1281	1289	|O
salts	1290	1295	|O
of	1296	1298	|O
the	1299	1302	|O
phosphate	1303	1312	|O
prodrugs	1313	1321	|O
exhibited	1322	1331	|O
high	1332	1336	|O
water	1337	1342	|O
solubility	1343	1353	|O
(	1354	1355	|B-IUPAC
8	1355	1356	|I-IUPAC
-	1356	1357	|I-IUPAC
(	1357	1358	|I-IUPAC
m	1358	1359	|I-IUPAC
-	1359	1360	|I-IUPAC
methoxystyryl	1360	1373	|I-IUPAC
)	1373	1374	|I-IUPAC
-	1374	1375	|I-IUPAC
7	1375	1376	|I-IUPAC
-	1376	1377	|I-IUPAC
methyl	1377	1383	|I-IUPAC
-	1383	1384	|I-IUPAC
3	1384	1385	|I-IUPAC
-	1385	1386	|I-IUPAC
[	1386	1387	|I-IUPAC
3	1387	1388	|I-IUPAC
-	1388	1389	|I-IUPAC
O	1389	1390	|I-IUPAC
-	1390	1391	|I-IUPAC
phosphatylpropyl	1391	1407	|I-IUPAC
]	1407	1408	|I-IUPAC
-	1408	1409	|I-IUPAC
1	1409	1410	|I-IUPAC
-	1410	1411	|I-IUPAC
propargylxan	1412	1424	|I-IUPAC
thine	1425	1430	|I-IUPAC
disodium	1431	1439	|I-IUPAC
salt	1440	1444	|I-IUPAC
,	1444	1445	|O
9b	1446	1448	|O
:	1448	1449	|O
17	1450	1452	|O
mM	1453	1455	|O
,	1455	1456	|O
9	1457	1458	|O
mg	1459	1461	|O
/	1461	1462	|O
mL	1462	1464	|O
)	1464	1465	|O
.	1465	1466	|O
Prodrug	1467	1474	|O
9b	1475	1477	|O
was	1478	1481	|O
found	1482	1487	|O
to	1488	1490	|O
be	1491	1493	|O
stable	1494	1500	|O
in	1501	1503	|O
aqueous	1504	1511	|O
solution	1512	1520	|O
(	1521	1522	|O
pH	1522	1524	|O
7	1525	1526	|O
)	1526	1527	|O
but	1528	1531	|O
readily	1532	1539	|O
cleaved	1540	1547	|O
by	1548	1550	|O
phosphatases	1551	1563	|O
to	1564	1566	|O
liberate	1567	1575	|O
5e	1576	1578	|O
(	1579	1580	|O
MSX	1580	1583	|O
-	1583	1584	|O
2	1584	1585	|O
)	1585	1586	|O
.	1586	1587	|O
Compound	1588	1596	|O
5e	1597	1599	|O
showed	1600	1606	|O
high	1607	1611	|O
affinity	1612	1620	|O
for	1621	1624	|O
rat	1625	1628	|O
A	1629	1630	|O
(	1630	1631	|O
2A	1631	1633	|O
)	1633	1634	|O
AR	1635	1637	|O
(	1638	1639	|O
K	1639	1640	|O
(	1640	1641	|O
i	1641	1642	|O
)	1642	1643	|O
=	1644	1645	|O
8	1646	1647	|O
nM	1648	1650	|O
)	1650	1651	|O
,	1651	1652	|O
human	1653	1658	|O
recombinant	1659	1670	|O
A	1671	1672	|O
(	1672	1673	|O
2A	1673	1675	|O
)	1675	1676	|O
AR	1677	1679	|O
(	1680	1681	|O
K	1681	1682	|O
(	1682	1683	|O
i	1683	1684	|O
)	1684	1685	|O
=	1686	1687	|O
5	1688	1689	|O
nM	1690	1692	|O
)	1692	1693	|O
,	1693	1694	|O
and	1695	1698	|O
human	1699	1704	|O
native	1705	1711	|O
A	1712	1713	|O
(	1713	1714	|O
2A	1714	1716	|O
)	1716	1717	|O
AR	1718	1720	|O
(	1721	1722	|O
K	1722	1723	|O
(	1723	1724	|O
i	1724	1725	|O
)	1725	1726	|O
=	1727	1728	|O
15	1729	1731	|O
nM	1732	1734	|O
)	1734	1735	|O
and	1736	1739	|O
was	1740	1743	|O
highly	1744	1750	|O
selective	1751	1760	|O
versus	1761	1767	|O
rat	1768	1771	|O
A	1772	1773	|O
(	1773	1774	|O
1	1774	1775	|O
)	1775	1776	|O
AR	1777	1779	|O
(	1780	1781	|O
110	1781	1784	|O
-	1784	1785	|O
fold	1785	1789	|O
)	1789	1790	|O
,	1790	1791	|O
human	1792	1797	|O
recombinant	1798	1809	|O
A	1810	1811	|O
(	1811	1812	|O
2A	1812	1814	|O
)	1814	1815	|O
AR	1816	1818	|O
(	1819	1820	|O
500	1820	1823	|O
-	1823	1824	|O
fold	1824	1828	|O
)	1828	1829	|O
,	1829	1830	|O
human	1831	1836	|O
A	1837	1838	|O
(	1838	1839	|O
2B	1839	1841	|O
)	1841	1842	|O
AR	1843	1845	|O
(	1846	1847	|O
&	1847	1848	|O
gt	1848	1850	|O
;	1850	1851	|O
2000	1851	1855	|O
-	1855	1856	|O
fold	1856	1860	|O
)	1860	1861	|O
,	1861	1862	|O
and	1863	1866	|O
human	1867	1872	|O
A	1873	1874	|O
(	1874	1875	|O
3	1875	1876	|O
)	1876	1877	|O
AR	1878	1880	|O
(	1881	1882	|O
&	1882	1883	|O
gt	1883	1885	|O
;	1885	1886	|O
2000	1886	1890	|O
-	1890	1891	|O
fold	1891	1895	|O
)	1895	1896	|O
.	1896	1897	|O

### abstracts2092.txt
The	0	3	|O
adenosine	4	13	|O
antagonist	14	24	|O
9	25	26	|B-IUPAC
-	26	27	|I-IUPAC
chloro	27	33	|I-IUPAC
-	33	34	|I-IUPAC
2	34	35	|I-IUPAC
-	35	36	|I-IUPAC
(	36	37	|I-IUPAC
2	37	38	|I-IUPAC
-	38	39	|I-IUPAC
furanyl	39	46	|I-IUPAC
)	46	47	|I-IUPAC
[	47	48	|I-IUPAC
1,2,4	48	53	|I-IUPAC
]	53	54	|I-IUPAC
triazolo	54	62	|I-IUPAC
[	62	63	|I-IUPAC
1,5	63	66	|I-IUPAC
-	66	67	|I-IUPAC
c	67	68	|I-IUPAC
]	68	69	|I-IUPAC
quinazolin	69	79	|I-IUPAC
-	79	80	|I-IUPAC
5	80	81	|I-IUPAC
-	81	82	|I-IUPAC
amine	82	87	|I-IUPAC
(	88	89	|O
CGS15943	89	97	|O
)	97	98	|O
binds	99	104	|O
to	105	107	|O
human	108	113	|O
A3	114	116	|O
receptors	117	126	|O
with	127	131	|O
high	132	136	|O
affinity	137	145	|O
(	146	147	|O
Ki	147	149	|O
=	150	151	|O
14	152	154	|O
nM	155	157	|O
)	157	158	|O
,	158	159	|O
while	160	165	|O
it	166	168	|O
lacks	169	174	|O
affinity	175	183	|O
at	184	186	|O
rat	187	190	|O
A3	191	193	|O
receptors	194	203	|O
.	203	204	|O
Acylated	205	213	|O
derivatives	214	225	|O
of	226	228	|O
the	229	232	|O
5	233	234	|B-IUPAC
-	234	235	|I-IUPAC
amino	235	240	|I-IUPAC
group	241	246	|B-MODIFIER
and	247	250	|O
other	251	256	|O
modifications	257	270	|O
were	271	275	|O
prepared	276	284	|O
in	285	287	|O
an	288	290	|O
effort	291	297	|O
to	298	300	|O
provide	301	308	|O
A3	309	311	|O
subtype	312	319	|O
selectivity	320	331	|O
.	331	332	|O
Affinity	333	341	|O
was	342	345	|O
determined	346	356	|O
in	357	359	|O
radioligand	360	371	|O
binding	372	379	|O
assays	380	386	|O
at	387	389	|O
rat	390	393	|O
brain	394	399	|O
A1	400	402	|O
and	403	406	|O
A2A	407	410	|O
receptors	411	420	|O
using	421	426	|O
[	427	428	|O
3H	428	430	|O
]	430	431	|O
-	431	432	|O
(	432	433	|O
R	433	434	|O
)	434	435	|O
-	435	436	|O
PIA	436	439	|O
(	440	441	|O
[	441	442	|B-IUPAC
3H	442	444	|I-IUPAC
]	444	445	|I-IUPAC
-	445	446	|I-IUPAC
(	446	447	|I-IUPAC
R	447	448	|I-IUPAC
)	448	449	|I-IUPAC
-	449	450	|I-IUPAC
N6	450	452	|I-IUPAC
-	452	453	|I-IUPAC
(	453	454	|I-IUPAC
phenylisopropyl	454	469	|I-IUPAC
)	469	470	|I-IUPAC
-	470	471	|I-IUPAC
adenosine	471	480	|I-IUPAC
)	480	481	|O
and	482	485	|O
[	486	487	|O
3H	487	489	|O
]	489	490	|O
CGS	490	493	|O
21680	494	499	|O
(	500	501	|O
[	501	502	|B-IUPAC
3H	502	504	|I-IUPAC
]	504	505	|I-IUPAC
-	505	506	|I-IUPAC
2	506	507	|I-IUPAC
-	507	508	|I-IUPAC
[	508	509	|I-IUPAC
[	509	510	|I-IUPAC
4	510	511	|I-IUPAC
-	511	512	|I-IUPAC
(	512	513	|I-IUPAC
2	513	514	|I-IUPAC
-	514	515	|I-IUPAC
carboxy	515	522	|I-IUPAC
ethyl	523	528	|I-IUPAC
)	528	529	|I-IUPAC
phenyl	529	535	|I-IUPAC
]	535	536	|I-IUPAC
ethylaminol	536	547	|I-IUPAC
]	547	548	|I-IUPAC
-	548	549	|I-IUPAC
5'	549	551	|I-IUPAC
-	551	552	|I-IUPAC
(	552	553	|I-IUPAC
N	553	554	|I-IUPAC
-	554	555	|I-IUPAC
ethyl	556	561	|I-IUPAC
-	561	562	|I-IUPAC
carbamoyl	563	572	|I-IUPAC
)	572	573	|I-IUPAC
adenosine	573	582	|I-IUPAC
)	582	583	|O
,	583	584	|O
respectively	585	597	|O
.	597	598	|O
Affinity	599	607	|O
was	608	611	|O
determined	612	622	|O
at	623	625	|O
cloned	626	632	|O
human	633	638	|O
A3	639	641	|O
receptors	642	651	|O
using	652	657	|O
[	658	659	|O
125I	659	663	|O
]	663	664	|O
AB	664	666	|O
-	666	667	|O
MECA	667	671	|O
(	672	673	|O
N6	673	675	|B-IUPAC
-	675	676	|I-IUPAC
(	676	677	|I-IUPAC
4	677	678	|I-IUPAC
-	678	679	|I-IUPAC
amino	679	684	|I-IUPAC
-	684	685	|I-IUPAC
3	685	686	|I-IUPAC
-	686	687	|I-IUPAC
iodobenzyl	687	697	|I-IUPAC
)	697	698	|I-IUPAC
-	698	699	|I-IUPAC
5'	699	701	|I-IUPAC
-	701	702	|I-IUPAC
(	702	703	|I-IUPAC
N	703	704	|I-IUPAC
-	704	705	|I-IUPAC
methylcarbamoyl	705	720	|I-IUPAC
)	720	721	|I-IUPAC
adenosine	721	730	|I-IUPAC
)	730	731	|O
.	731	732	|O
A	733	734	|O
series	735	741	|O
of	742	744	|O
straight	745	753	|O
chain	754	759	|O
alkyl	760	765	|O
amides	766	772	|O
demonstrated	773	785	|O
that	786	790	|O
the	791	794	|O
optimal	795	802	|O
chain	803	808	|O
length	809	815	|O
occurs	816	822	|O
with	823	827	|O
the	828	831	|O
5	832	833	|B-IUPAC
-	833	834	|I-IUPAC
N	834	835	|I-IUPAC
-	835	836	|I-IUPAC
propionyl	836	845	|I-IUPAC
derivative	846	856	|B-MODIFIER
,	856	857	|O
3	858	859	|O
,	859	860	|O
which	861	866	|O
had	867	870	|O
a	871	872	|O
Ki	873	875	|O
value	876	881	|O
of	882	884	|O
7.7	885	888	|O
nM	889	891	|O
at	892	894	|O
human	895	900	|O
A3	901	903	|O
receptors	904	913	|O
,	913	914	|O
and	915	918	|O
was	919	922	|O
40	923	925	|O
-	925	926	|O
and	927	930	|O
14	931	933	|O
-	933	934	|O
fold	934	938	|O
selective	939	948	|O
vs	949	951	|O
rat	952	955	|O
A1	956	958	|O
and	959	962	|O
A2A	963	966	|O
receptors	967	976	|O
,	976	977	|O
respectively	978	990	|O
.	990	991	|O
The	992	995	|O
5	996	997	|B-IUPAC
-	997	998	|I-IUPAC
N	998	999	|I-IUPAC
-	999	1000	|I-IUPAC
benzoyl	1000	1007	|I-IUPAC
derivative	1008	1018	|B-MODIFIER
,	1018	1019	|O
10	1020	1022	|O
,	1022	1023	|O
displayed	1024	1033	|O
Ki	1034	1036	|O
values	1037	1043	|O
of	1044	1046	|O
680	1047	1050	|O
and	1051	1054	|O
273	1055	1058	|O
nM	1059	1061	|O
at	1062	1064	|O
rat	1065	1068	|O
A1	1069	1071	|O
and	1072	1075	|O
A2A	1076	1079	|O
receptors	1080	1089	|O
,	1089	1090	|O
respectively	1091	1103	|O
,	1103	1104	|O
and	1105	1108	|O
3.0	1109	1112	|O
nM	1113	1115	|O
at	1116	1118	|O
human	1119	1124	|O
A3	1125	1127	|O
receptors	1128	1137	|O
.	1137	1138	|O
A	1139	1140	|O
5	1141	1142	|B-IUPAC
-	1142	1143	|I-IUPAC
N	1143	1144	|I-IUPAC
-	1144	1145	|I-IUPAC
phenylacetyl	1145	1157	|I-IUPAC
derivative	1158	1168	|B-MODIFIER
,	1168	1169	|O
12	1170	1172	|O
,	1172	1173	|O
was	1174	1177	|O
470	1178	1181	|O
-	1181	1182	|O
fold	1182	1186	|O
selective	1187	1196	|O
for	1197	1200	|O
human	1201	1206	|O
A3	1207	1209	|O
vs	1210	1212	|O
rat	1213	1216	|O
A1	1217	1219	|O
receptors	1220	1229	|O
with	1230	1234	|O
a	1235	1236	|O
Ki	1237	1239	|O
value	1240	1245	|O
of	1246	1248	|O
0.65	1249	1253	|O
nM	1254	1256	|O
.	1256	1257	|O
A	1258	1259	|O
conjugate	1260	1269	|O
of	1270	1272	|O
Boc	1273	1276	|O
-	1276	1277	|O
gamma	1277	1282	|O
-	1282	1283	|O
aminobutyric	1283	1295	|O
acid	1296	1300	|O
was	1301	1304	|O
also	1305	1309	|O
prepared	1310	1318	|O
but	1319	1322	|O
was	1323	1326	|O
nonselective	1327	1339	|O
.	1339	1340	|O
Conversion	1341	1351	|O
of	1352	1354	|O
the	1355	1358	|O
5	1359	1360	|B-IUPAC
-	1360	1361	|I-IUPAC
amino	1361	1366	|I-IUPAC
group	1367	1372	|B-MODIFIER
of	1373	1375	|O
CGS15943	1376	1384	|O
to	1385	1387	|O
an	1388	1390	|O
oxo	1391	1394	|O
function	1395	1403	|O
resulted	1404	1412	|O
in	1413	1415	|O
lower	1416	1421	|O
affinity	1422	1430	|O
but	1431	1434	|O
15	1435	1437	|O
-	1437	1438	|O
fold	1438	1442	|O
selectivity	1443	1454	|O
for	1455	1458	|O
human	1459	1464	|O
A3	1465	1467	|O
receptors	1468	1477	|O
.	1477	1478	|O

### abstracts2718.txt
Treatment	0	9	|O
of	10	12	|O
the	13	16	|O
5'	17	19	|B-IUPAC
-	19	20	|I-IUPAC
carboxaldehyde	20	34	|I-IUPAC
derived	35	42	|O
by	43	45	|O
Moffatt	46	53	|O
oxidation	54	63	|O
of	64	66	|O
6	67	68	|B-IUPAC
-	68	69	|I-IUPAC
N	69	70	|I-IUPAC
-	70	71	|I-IUPAC
benzoyl	71	78	|I-IUPAC
-	78	79	|I-IUPAC
2'	79	81	|I-IUPAC
,	81	82	|I-IUPAC
3'	82	84	|I-IUPAC
-	84	85	|I-IUPAC
O	85	86	|I-IUPAC
-	86	87	|I-IUPAC
isopropylideneadenosine	87	110	|I-IUPAC
(	111	112	|O
1	112	113	|O
)	113	114	|O
with	115	119	|O
the	120	123	|O
"	124	125	|O
(	125	126	|B-IUPAC
bromofluoromethylene	126	146	|I-IUPAC
)	146	147	|I-IUPAC
triphenylphosphorane	147	167	|I-IUPAC
"	167	168	|O
reagent	169	176	|O
and	177	180	|O
deprotection	181	193	|O
gave	194	198	|O
9	199	200	|B-IUPAC
-	200	201	|I-IUPAC
(	201	202	|I-IUPAC
6	202	203	|I-IUPAC
-	203	204	|I-IUPAC
bromo	204	209	|I-IUPAC
-	209	210	|I-IUPAC
5	210	211	|I-IUPAC
,	211	212	|I-IUPAC
6	213	214	|I-IUPAC
-	214	215	|I-IUPAC
dideoxy	215	222	|I-IUPAC
-	222	223	|I-IUPAC
6	223	224	|I-IUPAC
-	224	225	|I-IUPAC
fluoro	225	231	|I-IUPAC
-	231	232	|I-IUPAC
beta	232	236	|I-IUPAC
-	236	237	|I-IUPAC
d	237	238	|I-IUPAC
-	238	239	|I-IUPAC
ribo	239	243	|I-IUPAC
-	243	244	|I-IUPAC
hex	244	247	|I-IUPAC
-	247	248	|I-IUPAC
5	248	249	|I-IUPAC
-	249	250	|I-IUPAC
enofuranosyl	250	262	|I-IUPAC
)	262	263	|I-IUPAC
adenine	263	270	|I-IUPAC
(	271	272	|O
4	272	273	|O
)	273	274	|O
.	274	275	|O
Parallel	276	284	|O
treatment	285	294	|O
with	295	299	|O
a	300	301	|O
"	302	303	|O
dibromomethylene	303	319	|O
Wittig	320	326	|O
reagent	327	334	|O
"	334	335	|O
and	336	339	|O
deprotection	340	352	|O
gave	353	357	|O
9	358	359	|B-IUPAC
-	359	360	|I-IUPAC
(	360	361	|I-IUPAC
6,6	361	364	|I-IUPAC
-	364	365	|I-IUPAC
dibromo	365	372	|I-IUPAC
-	372	373	|I-IUPAC
5	373	374	|I-IUPAC
,	374	375	|I-IUPAC
6	376	377	|I-IUPAC
-	377	378	|I-IUPAC
dideoxy	378	385	|I-IUPAC
-	385	386	|I-IUPAC
beta	386	390	|I-IUPAC
-	390	391	|I-IUPAC
d	391	392	|I-IUPAC
-	392	393	|I-IUPAC
ribo	393	397	|I-IUPAC
-	397	398	|I-IUPAC
hex	398	401	|I-IUPAC
-	401	402	|I-IUPAC
5	402	403	|I-IUPAC
-	403	404	|I-IUPAC
enofuranosyl	404	416	|I-IUPAC
)	416	417	|I-IUPAC
adenine	417	424	|I-IUPAC
(	425	426	|O
7	426	427	|O
)	427	428	|O
,	428	429	|O
which	430	435	|O
also	436	440	|O
was	441	444	|O
prepared	445	453	|O
by	454	456	|O
successive	457	467	|O
bromination	468	479	|O
and	480	483	|O
dehydrobromination	484	502	|O
of	503	505	|O
the	506	509	|O
6'	510	512	|B-IUPAC
-	512	513	|I-IUPAC
bromohomovinyl	513	527	|I-IUPAC
nucleoside	528	538	|I-IUPAC
8	539	540	|O
.	540	541	|O
Bromination	542	553	|O
-	553	554	|O
dehydrobromination	554	572	|O
of	573	575	|O
the	576	579	|O
5'	580	582	|B-IUPAC
-	582	583	|I-IUPAC
bromohomovinyl	583	597	|I-IUPAC
analogue	598	606	|B-MODIFIER
11	607	609	|O
and	610	613	|O
deprotection	614	626	|O
gave	627	631	|O
(	632	633	|B-IUPAC
E	633	634	|I-IUPAC
)	634	635	|I-IUPAC
-	635	636	|I-IUPAC
9	636	637	|I-IUPAC
-	637	638	|I-IUPAC
(	638	639	|I-IUPAC
5	639	640	|I-IUPAC
,	640	641	|I-IUPAC
6	642	643	|I-IUPAC
-	643	644	|I-IUPAC
dibromo	644	651	|I-IUPAC
-	651	652	|I-IUPAC
5,6	652	655	|I-IUPAC
-	655	656	|I-IUPAC
dideoxy	656	663	|I-IUPAC
-	663	664	|I-IUPAC
beta	664	668	|I-IUPAC
-	668	669	|I-IUPAC
d	669	670	|I-IUPAC
-	670	671	|I-IUPAC
ribo	671	675	|I-IUPAC
-	675	676	|I-IUPAC
hex	676	679	|I-IUPAC
-	679	680	|I-IUPAC
5	680	681	|I-IUPAC
-	681	682	|I-IUPAC
enofuranosyl	682	694	|I-IUPAC
)	694	695	|I-IUPAC
adenine	695	702	|I-IUPAC
(	703	704	|O
15	704	706	|O
)	706	707	|O
.	707	708	|O
Compounds	709	718	|O
4	719	720	|O
,	720	721	|O
7	722	723	|O
,	723	724	|O
and	725	728	|O
15	729	731	|O
were	732	736	|O
designed	737	745	|O
as	746	748	|O
putative	749	757	|O
substrates	758	768	|O
of	769	771	|O
the	772	775	|O
"	776	777	|O
hydrolytic	777	787	|O
activity	788	796	|O
"	796	797	|O
of	798	800	|O
S	801	802	|B-IUPAC
-	802	803	|I-IUPAC
adenosyl	803	811	|I-IUPAC
-	811	812	|I-IUPAC
l	812	813	|I-IUPAC
-	813	814	|I-IUPAC
homocysteine	814	826	|I-IUPAC
(	827	828	|O
AdoHcy	828	834	|O
)	834	835	|O
hydrolase	836	845	|O
.	845	846	|O
Enzyme	847	853	|O
-	853	854	|O
mediated	854	862	|O
addition	863	871	|O
of	872	874	|O
water	875	880	|O
across	881	887	|O
the	888	891	|O
5,6	892	895	|O
-	895	896	|O
double	896	902	|O
bond	903	907	|O
could	908	913	|O
generate	914	922	|O
electrophilic	923	936	|O
acyl	937	941	|O
halide	942	948	|O
or	949	951	|O
alpha	952	957	|B-IUPAC
-	957	958	|I-IUPAC
halo	958	962	|I-IUPAC
ketone	963	969	|I-IUPAC
species	970	977	|O
that	978	982	|O
could	983	988	|O
undergo	989	996	|O
nucleophilic	997	1009	|O
attack	1010	1016	|O
by	1017	1019	|O
proximal	1020	1028	|O
groups	1029	1035	|O
on	1036	1038	|O
the	1039	1042	|O
enzyme	1043	1049	|O
.	1049	1050	|O
Such	1051	1055	|O
type	1056	1060	|O
II	1061	1063	|O
(	1064	1065	|O
covalent	1065	1073	|O
)	1073	1074	|O
mechanism	1075	1084	|O
-	1084	1085	|O
based	1085	1090	|O
inactivation	1091	1103	|O
is	1104	1106	|O
supported	1107	1116	|O
by	1117	1119	|O
protein	1120	1127	|O
labeling	1128	1136	|O
with	1137	1141	|O
8	1142	1143	|O
-	1143	1144	|O
[	1144	1145	|O
3H	1145	1147	|O
]	1147	1148	|O
-	1148	1149	|O
4	1149	1150	|O
and	1151	1154	|O
concomitant	1155	1166	|O
release	1167	1174	|O
of	1175	1177	|O
bromide	1178	1185	|O
and	1186	1189	|O
fluoride	1190	1198	|O
ions	1199	1203	|O
.	1203	1204	|O
Incubation	1205	1215	|O
of	1216	1218	|O
AdoHcy	1219	1225	|O
hydrolase	1226	1235	|O
with	1236	1240	|O
7	1241	1242	|O
or	1243	1245	|O
15	1246	1248	|O
resulted	1249	1257	|O
in	1258	1260	|O
irreversible	1261	1273	|O
inactivation	1274	1286	|O
and	1287	1290	|O
release	1291	1298	|O
of	1299	1301	|O
bromide	1302	1309	|O
ion	1310	1313	|O
.	1313	1314	|O
In	1315	1317	|O
contrast	1318	1326	|O
with	1327	1331	|O
type	1332	1336	|O
I	1337	1338	|O
mechanism	1339	1348	|O
-	1348	1349	|O
based	1349	1354	|O
inactivation	1355	1367	|O
,	1367	1368	|O
reduction	1369	1378	|O
of	1379	1381	|O
enzyme	1382	1388	|O
-	1388	1389	|O
bound	1389	1394	|O
NAD+	1395	1399	|O
to	1400	1402	|O
NADH	1403	1407	|O
was	1408	1411	|O
not	1412	1415	|O
observed	1416	1424	|O
.	1424	1425	|O
Compounds	1426	1435	|O
4	1436	1437	|O
,	1437	1438	|O
7	1439	1440	|O
,	1440	1441	|O
and	1442	1445	|O
15	1446	1448	|O
were	1449	1453	|O
not	1454	1457	|O
inhibitory	1458	1468	|O
to	1469	1471	|O
a	1472	1473	|O
variety	1474	1481	|O
of	1482	1484	|O
viruses	1485	1492	|O
in	1493	1495	|O
cell	1496	1500	|O
culture	1501	1508	|O
,	1508	1509	|O
and	1510	1513	|O
weak	1514	1518	|O
cytotoxicity	1519	1531	|O
was	1532	1535	|O
observed	1536	1544	|O
only	1545	1549	|O
for	1550	1553	|O
CEM	1554	1557	|O
cells	1558	1563	|O
.	1563	1564	|O

### abstracts4864.txt
New	0	3	|O
1	4	5	|B-IUPAC
-	5	6	|I-IUPAC
benzhydryl	6	16	|I-IUPAC
-	16	17	|I-IUPAC
3	17	18	|I-IUPAC
-	18	19	|I-IUPAC
phenylurea	19	29	|I-IUPAC
derivatives	30	41	|B-MODIFIER
and	42	45	|O
their	46	51	|O
1	52	53	|B-IUPAC
-	53	54	|I-IUPAC
benzhydryl	54	64	|I-IUPAC
-	64	65	|I-IUPAC
3	65	66	|I-IUPAC
-	66	67	|I-IUPAC
phenylthiourea	67	81	|I-IUPAC
isosteres	82	91	|B-MODIFIER
were	92	96	|O
synthesized	97	108	|O
and	109	112	|O
evaluated	113	122	|O
for	123	126	|O
their	127	132	|O
human	133	138	|O
CB1	139	142	|O
and	143	146	|O
CB2	147	150	|O
cannabinoid	151	162	|O
receptor	163	171	|O
affinity	172	180	|O
.	180	181	|O
These	182	187	|O
compounds	188	197	|O
proved	198	204	|O
to	205	207	|O
be	208	210	|O
selective	211	220	|O
CB1	221	224	|O
cannabinoid	225	236	|O
receptor	237	245	|O
ligands	246	253	|O
,	253	254	|O
acting	255	261	|O
as	262	264	|O
inverse	265	272	|O
agonists	273	281	|O
in	282	284	|O
a	285	286	|O
[	287	288	|O
35S	288	291	|O
]	291	292	|O
-	292	293	|O
GTPgammaS	293	302	|O
assay	303	308	|O
.	308	309	|O
The	310	313	|O
affinity	314	322	|O
of	323	325	|O
3,5,5	326	331	|B-IUPAC
'	331	332	|I-IUPAC
-	332	333	|I-IUPAC
triphenylimidazolidine	333	355	|I-IUPAC
-	355	356	|I-IUPAC
2,4	356	359	|I-IUPAC
-	359	360	|I-IUPAC
dione	360	365	|I-IUPAC
and	366	369	|O
3,5,5	370	375	|B-IUPAC
'	375	376	|I-IUPAC
-	376	377	|I-IUPAC
triphenyl	377	386	|I-IUPAC
-	386	387	|I-IUPAC
2	387	388	|I-IUPAC
-	388	389	|I-IUPAC
thioxoimidazolidin	389	407	|I-IUPAC
-	407	408	|I-IUPAC
4	408	409	|I-IUPAC
-	409	410	|I-IUPAC
one	410	413	|I-IUPAC
derivatives	414	425	|B-MODIFIER
,	425	426	|O
possessing	427	437	|O
the	438	441	|O
1	442	443	|B-IUPAC
-	443	444	|I-IUPAC
benzhydryl	444	454	|I-IUPAC
-	454	455	|I-IUPAC
3	455	456	|I-IUPAC
-	456	457	|I-IUPAC
phenylurea	457	467	|I-IUPAC
and	468	471	|O
1	472	473	|B-IUPAC
-	473	474	|I-IUPAC
benzhydryl	474	484	|I-IUPAC
-	484	485	|I-IUPAC
3	485	486	|I-IUPAC
-	486	487	|I-IUPAC
phenylthiourea	487	501	|I-IUPAC
moiety	502	508	|B-MODIFIER
,	508	509	|O
respectively	510	522	|O
,	522	523	|O
was	524	527	|O
also	528	532	|O
evaluated	533	542	|O
.	542	543	|O
In	544	546	|O
conclusion	547	557	|O
,	557	558	|O
the	559	562	|O
1	563	564	|B-IUPAC
-	564	565	|I-IUPAC
benzhydryl	565	575	|I-IUPAC
-	575	576	|I-IUPAC
3	576	577	|I-IUPAC
-	577	578	|I-IUPAC
phenylurea	578	588	|I-IUPAC
scaffold	589	597	|B-MODIFIER
seems	598	603	|O
to	604	606	|O
be	607	609	|O
a	610	611	|O
new	612	615	|O
interesting	616	627	|O
template	628	636	|O
of	637	639	|O
CB1	640	643	|O
cannabinoid	644	655	|O
receptor	656	664	|O
inverse	665	672	|O
agonists	673	681	|O
.	681	682	|O

### abstracts3479.txt
2	0	1	|O
-	1	2	|O
(	2	3	|O
4	3	4	|O
-	4	5	|O
Chloro	5	11	|O
-	11	12	|O
3	12	13	|O
-	13	14	|O
hydroxyphenyl	14	27	|O
)	27	28	|O
ethylamine	28	38	|O
(	39	40	|O
4	40	41	|O
)	41	42	|O
and	43	46	|O
some	47	51	|O
derivatives	52	63	|O
were	64	68	|O
synthesized	69	80	|O
as	81	83	|O
dopamine	84	92	|O
(	93	94	|O
DA	94	96	|O
)	96	97	|O
receptor	98	106	|O
ligands	107	114	|O
.	114	115	|O
Amine	116	121	|O
4	122	123	|O
retains	124	131	|O
the	132	135	|O
dopaminergic	136	148	|O
pharmacophore	149	162	|O
2	163	164	|B-IUPAC
-	164	165	|I-IUPAC
(	165	166	|I-IUPAC
3	166	167	|I-IUPAC
-	167	168	|I-IUPAC
hydroxyphenyl	168	181	|I-IUPAC
)	181	182	|I-IUPAC
-	182	183	|I-IUPAC
ethylamine	183	193	|I-IUPAC
,	193	194	|O
and	195	198	|O
the	199	202	|O
chlorine	203	211	|O
atom	212	216	|O
replaces	217	225	|O
the	226	229	|O
"	230	231	|O
para	231	235	|O
"	235	236	|O
hydroxyl	237	245	|B-IUPAC
group	246	251	|B-MODIFIER
of	252	254	|O
DA	255	257	|O
.	257	258	|O
The	259	262	|O
derivatives	263	274	|O
18a	275	278	|O
-	278	279	|O
e	279	280	|O
were	281	285	|O
obtained	286	294	|O
by	295	297	|O
introducing	298	309	|O
on	310	312	|O
the	313	316	|O
nitrogen	317	325	|O
of	326	328	|O
amine	329	334	|O
4	335	336	|O
the	337	340	|O
n	341	342	|B-IUPAC
-	342	343	|I-IUPAC
propyl	343	349	|I-IUPAC
and	350	353	|O
2	354	355	|B-IUPAC
-	355	356	|I-IUPAC
phenylethyl	356	367	|I-IUPAC
or	368	370	|O
3	371	372	|B-IUPAC
-	372	373	|I-IUPAC
phenylpropyl	373	385	|I-IUPAC
groups	386	392	|B-MODIFIER
which	393	398	|O
can	399	402	|O
be	403	405	|O
accommodated	406	418	|O
by	419	421	|O
the	422	425	|O
D	426	427	|O
-	427	428	|O
2	428	429	|O
receptor	430	438	|O
lipophilic	439	449	|O
sites	450	455	|O
3C	456	458	|O
and	459	462	|O
pi	463	465	|O
3	466	467	|O
,	467	468	|O
respectively	469	481	|O
.	481	482	|O
The	483	486	|O
affinity	487	495	|O
and	496	499	|O
selectivity	500	511	|O
of	512	514	|O
these	515	520	|O
compounds	521	530	|O
for	531	534	|O
D	535	536	|O
-	536	537	|O
1	537	538	|O
and	539	542	|O
D	543	544	|O
-	544	545	|O
2	545	546	|O
subtypes	547	555	|O
was	556	559	|O
determined	560	570	|O
in	571	573	|O
radioligand	574	585	|O
competition	586	597	|O
assays	598	604	|O
for	605	608	|O
the	609	612	|O
DA	613	615	|O
receptors	616	625	|O
of	626	628	|O
rat	629	632	|O
striatum	633	641	|O
membranes	642	651	|O
using	652	657	|O
[	658	659	|O
3H	659	661	|O
]	661	662	|O
SCH	662	665	|O
23390	666	671	|O
(	672	673	|O
D	673	674	|O
-	674	675	|O
1	675	676	|O
selective	677	686	|O
)	686	687	|O
and	688	691	|O
[	692	693	|O
3H	693	695	|O
]	695	696	|O
spiperone	696	705	|O
(	706	707	|O
D	707	708	|O
-	708	709	|O
2	709	710	|O
selective	711	720	|O
)	720	721	|O
as	722	724	|O
radioligands	725	737	|O
.	737	738	|O
The	739	742	|O
amine	743	748	|O
4	749	750	|O
shows	751	756	|O
about	757	762	|O
7	763	764	|O
-	764	765	|O
fold	765	769	|O
lower	770	775	|O
affinity	776	784	|O
than	785	789	|O
DA	790	792	|O
for	793	796	|O
both	797	801	|O
sites	802	807	|O
and	808	811	|O
is	812	814	|O
not	815	818	|O
able	819	823	|O
to	824	826	|O
discriminate	827	839	|O
between	840	847	|O
the	848	851	|O
two	852	855	|O
subtypes	856	864	|O
of	865	867	|O
DA	868	870	|O
receptors	871	880	|O
.	880	881	|O
The	882	885	|O
introduction	886	898	|O
of	899	901	|O
two	902	905	|O
n	906	907	|B-IUPAC
-	907	908	|I-IUPAC
propyl	908	914	|I-IUPAC
groups	915	921	|B-MODIFIER
(	922	923	|O
18a	923	926	|O
)	926	927	|O
on	928	930	|O
the	931	934	|O
nitrogen	935	943	|O
atom	944	948	|O
reduces	949	956	|O
by	957	959	|O
one	960	963	|O
-	963	964	|O
half	964	968	|O
and	969	972	|O
doubles	973	980	|O
the	981	984	|O
affinity	985	993	|O
for	994	997	|O
D	998	999	|O
-	999	1000	|O
1	1000	1001	|O
and	1002	1005	|O
D	1006	1007	|O
-	1007	1008	|O
2	1008	1009	|O
binding	1010	1017	|O
sites	1018	1023	|O
,	1023	1024	|O
respectively	1025	1037	|O
.	1037	1038	|O
The	1039	1042	|O
substitution	1043	1055	|O
of	1056	1058	|O
an	1059	1061	|O
n	1062	1063	|B-IUPAC
-	1063	1064	|I-IUPAC
propyl	1064	1070	|I-IUPAC
group	1071	1076	|B-MODIFIER
with	1077	1081	|O
different	1082	1091	|O
alkylphenyl	1092	1103	|O
groups	1104	1110	|O
,	1110	1111	|O
to	1112	1114	|O
give	1115	1119	|O
compounds	1120	1129	|O
18b	1130	1133	|O
-	1133	1134	|O
e	1134	1135	|O
,	1135	1136	|O
increases	1137	1146	|O
the	1147	1150	|O
affinity	1151	1159	|O
for	1160	1163	|O
the	1164	1167	|O
D	1168	1169	|O
-	1169	1170	|O
2	1170	1171	|O
subtype	1172	1179	|O
from	1180	1184	|O
19	1185	1187	|O
-	1187	1188	|O
fold	1188	1192	|O
to	1193	1195	|O
36	1196	1198	|O
-	1198	1199	|O
fold	1199	1203	|O
.	1203	1204	|O
These	1205	1210	|O
compounds	1211	1220	|O
have	1221	1225	|O
the	1226	1229	|O
same	1230	1234	|O
affinity	1235	1243	|O
at	1244	1246	|O
the	1247	1250	|O
D	1251	1252	|O
-	1252	1253	|O
2	1253	1254	|O
site	1255	1259	|O
as	1260	1262	|O
the	1263	1266	|O
DA	1267	1269	|O
agonist	1270	1277	|O
N	1278	1279	|B-IUPAC
-	1279	1280	|I-IUPAC
n	1280	1281	|I-IUPAC
-	1281	1282	|I-IUPAC
propyl	1282	1288	|I-IUPAC
-	1288	1289	|I-IUPAC
N	1289	1290	|I-IUPAC
-	1290	1291	|I-IUPAC
(	1291	1292	|I-IUPAC
2	1292	1293	|I-IUPAC
-	1293	1294	|I-IUPAC
phenylethyl	1294	1305	|I-IUPAC
)	1305	1306	|I-IUPAC
-	1306	1307	|I-IUPAC
2	1307	1308	|I-IUPAC
-	1308	1309	|I-IUPAC
(	1309	1310	|I-IUPAC
3	1310	1311	|I-IUPAC
-	1311	1312	|I-IUPAC
hydroxyphenyl	1312	1325	|I-IUPAC
)	1325	1326	|I-IUPAC
-	1326	1327	|I-IUPAC
ethylamine	1327	1337	|I-IUPAC
(	1338	1339	|O
2a	1339	1341	|O
)	1341	1342	|O
and	1343	1346	|O
are	1347	1350	|O
about	1351	1356	|O
20	1357	1359	|O
times	1360	1365	|O
more	1366	1370	|O
selective	1371	1380	|O
than	1381	1385	|O
DA	1386	1388	|O
for	1389	1392	|O
this	1393	1397	|O
binding	1398	1405	|O
site	1406	1410	|O
.	1410	1411	|O
In	1412	1414	|O
the	1415	1418	|O
assay	1419	1424	|O
for	1425	1428	|O
D	1429	1430	|O
-	1430	1431	|O
2	1431	1432	|O
receptor	1433	1441	|O
mediated	1442	1450	|O
inhibition	1451	1461	|O
of	1462	1464	|O
adenylate	1465	1474	|O
cyclase	1475	1482	|O
activity	1483	1491	|O
,	1491	1492	|O
all	1493	1496	|O
the	1497	1500	|O
tested	1501	1507	|O
compounds	1508	1517	|O
behaved	1518	1525	|O
as	1526	1528	|O
D	1529	1530	|O
-	1530	1531	|O
2	1531	1532	|O
agonists	1533	1541	|O
;	1541	1542	|O
N	1543	1544	|B-PARTIUPAC
-	1544	1545	|I-PARTIUPAC
n	1545	1546	|I-PARTIUPAC
-	1546	1547	|I-PARTIUPAC
propyl	1547	1553	|I-PARTIUPAC
-	1553	1554	|I-PARTIUPAC
N	1554	1555	|I-PARTIUPAC
-	1555	1556	|I-PARTIUPAC
[	1556	1557	|I-PARTIUPAC
2	1557	1558	|I-PARTIUPAC
(	1558	1559	|I-PARTIUPAC
4	1559	1560	|I-PARTIUPAC
-	1560	1561	|I-PARTIUPAC
hydroxyphenyl	1561	1574	|I-PARTIUPAC
)	1574	1575	|I-PARTIUPAC
ethyl	1575	1580	|I-PARTIUPAC
]	1580	1581	|I-PARTIUPAC
-	1581	1582	|I-PARTIUPAC
(	1583	1584	|O
18d	1584	1587	|O
)	1587	1588	|O
and	1589	1592	|O
N	1593	1594	|B-IUPAC
-	1594	1595	|I-IUPAC
n	1595	1596	|I-IUPAC
-	1596	1597	|I-IUPAC
propyl	1597	1603	|I-IUPAC
-	1603	1604	|I-IUPAC
N	1604	1605	|I-IUPAC
-	1605	1606	|I-IUPAC
(	1606	1607	|I-IUPAC
2	1607	1608	|I-IUPAC
-	1608	1609	|I-IUPAC
phenyl	1609	1615	|I-IUPAC
-	1615	1616	|I-IUPAC
ethyl	1616	1621	|I-IUPAC
)	1621	1622	|I-IUPAC
-	1622	1623	|I-IUPAC
2	1623	1624	|I-IUPAC
-	1624	1625	|I-IUPAC
(	1625	1626	|I-IUPAC
4	1626	1627	|I-IUPAC
-	1627	1628	|I-IUPAC
chloro	1628	1634	|I-IUPAC
-	1634	1635	|I-IUPAC
3	1635	1636	|I-IUPAC
-	1636	1637	|I-IUPAC
hydroxyphenyl	1637	1650	|I-IUPAC
)	1650	1651	|I-IUPAC
ethylamine	1651	1661	|I-IUPAC
(	1662	1663	|O
18b	1663	1666	|O
)	1666	1667	|O
were	1668	1672	|O
more	1673	1677	|O
effective	1678	1687	|O
than	1688	1692	|O
DA	1693	1695	|O
or	1696	1698	|O
2a	1699	1701	|O
.	1701	1702	|O
On	1703	1705	|O
the	1706	1709	|O
other	1710	1715	|O
hand	1716	1720	|O
,	1720	1721	|O
all	1722	1725	|O
compounds	1726	1735	|O
were	1736	1740	|O
less	1741	1745	|O
effective	1746	1755	|O
than	1756	1760	|O
DA	1761	1763	|O
in	1764	1766	|O
stimulation	1767	1778	|O
of	1779	1781	|O
adenylate	1782	1791	|O
cyclase	1792	1799	|O
activity	1800	1808	|O
in	1809	1811	|O
rat	1812	1815	|O
striatal	1816	1824	|O
homogenates	1825	1836	|O
,	1836	1837	|O
a	1838	1839	|O
kind	1840	1844	|O
of	1845	1847	|O
effect	1848	1854	|O
which	1855	1860	|O
is	1861	1863	|O
mediated	1864	1872	|O
by	1873	1875	|O
the	1876	1879	|O
D	1880	1881	|O
-	1881	1882	|O
1	1882	1883	|O
subtype	1884	1891	|O
of	1892	1894	|O
DA	1895	1897	|O
receptors	1898	1907	|O
.	1907	1908	|O
These	1909	1914	|O
results	1915	1922	|O
suggest	1923	1930	|O
that	1931	1935	|O
the	1936	1939	|O
nitrogen	1940	1948	|O
substitution	1949	1961	|O
enhances	1962	1970	|O
the	1971	1974	|O
affinity	1975	1983	|O
and	1984	1987	|O
selectivity	1988	1999	|O
for	2000	2003	|O
the	2004	2007	|O
D	2008	2009	|O
-	2009	2010	|O
2	2010	2011	|O
receptor	2012	2020	|O
.	2020	2021	|O
In	2022	2024	|O
the	2025	2028	|O
adenylate	2029	2038	|O
cyclase	2039	2046	|O
assay	2047	2052	|O
,	2052	2053	|O
the	2054	2057	|O
compounds	2058	2067	|O
behave	2068	2074	|O
as	2075	2077	|O
potent	2078	2084	|O
D	2085	2086	|O
-	2086	2087	|O
2	2087	2088	|O
agonists	2089	2097	|O
.	2097	2098	|O

### abstracts3573.txt
The	0	3	|O
nuclear	4	11	|O
enzyme	12	18	|O
poly	19	23	|O
(	23	24	|O
ADP	24	27	|O
-	27	28	|O
ribose	28	34	|O
)	34	35	|O
polymerase	36	46	|O
(	47	48	|O
PARP	48	52	|O
)	52	53	|O
facilitates	54	65	|O
the	66	69	|O
repair	70	76	|O
of	77	79	|O
DNA	80	83	|O
strand	84	90	|O
breaks	91	97	|O
and	98	101	|O
is	102	104	|O
implicated	105	115	|O
in	116	118	|O
the	119	122	|O
resistance	123	133	|O
of	134	136	|O
cancer	137	143	|O
cells	144	149	|O
to	150	152	|O
certain	153	160	|O
DNA	161	164	|O
-	164	165	|O
damaging	165	173	|O
agents	174	180	|O
.	180	181	|O
Inhibitors	182	192	|O
of	193	195	|O
PARP	196	200	|O
have	201	205	|O
clinical	206	214	|O
potential	215	224	|O
as	225	227	|O
resistance	228	238	|O
-	238	239	|O
modifying	239	248	|O
agents	249	255	|O
capable	256	263	|O
of	264	266	|O
potentiating	267	279	|O
radiotherapy	280	292	|O
and	293	296	|O
the	297	300	|O
cytotoxicity	301	313	|O
of	314	316	|O
some	317	321	|O
forms	322	327	|O
of	328	330	|O
cancer	331	337	|O
chemotherapy	338	350	|O
.	350	351	|O
The	352	355	|O
preclinical	356	367	|O
development	368	379	|O
of	380	382	|O
2	383	384	|B-IUPAC
-	384	385	|I-IUPAC
aryl	385	389	|I-IUPAC
-	389	390	|I-IUPAC
1H	390	392	|I-IUPAC
-	392	393	|I-IUPAC
benzimidazole	393	406	|I-IUPAC
-	406	407	|I-IUPAC
4	407	408	|I-IUPAC
-	408	409	|I-IUPAC
carboxamides	409	421	|I-IUPAC
as	422	424	|O
resistance	425	435	|O
-	435	436	|O
modifying	436	445	|O
agents	446	452	|O
in	453	455	|O
cancer	456	462	|O
chemotherapy	463	475	|O
is	476	478	|O
described	479	488	|O
.	488	489	|O
1H	490	492	|B-IUPAC
-	492	493	|I-IUPAC
Benzimidazole	493	506	|I-IUPAC
-	506	507	|I-IUPAC
4	507	508	|I-IUPAC
-	508	509	|I-IUPAC
carboxamides	509	521	|I-IUPAC
,	521	522	|O
particularly	523	535	|O
2	536	537	|B-IUPAC
-	537	538	|I-IUPAC
aryl	538	542	|I-IUPAC
derivatives	543	554	|B-MODIFIER
,	554	555	|O
are	556	559	|O
identified	560	570	|O
as	571	573	|O
a	574	575	|O
class	576	581	|O
of	582	584	|O
potent	585	591	|O
PARP	592	596	|O
inhibitors	597	607	|O
.	607	608	|O
Derivatives	609	620	|O
of	621	623	|O
2	624	625	|B-IUPAC
-	625	626	|I-IUPAC
phenyl	626	632	|I-IUPAC
-	632	633	|I-IUPAC
1H	633	635	|I-IUPAC
-	635	636	|I-IUPAC
benzimidazole	636	649	|I-IUPAC
-	649	650	|I-IUPAC
4	650	651	|I-IUPAC
-	651	652	|I-IUPAC
carboxamide	652	663	|I-IUPAC
(	664	665	|O
23	665	667	|O
,	667	668	|O
K	669	670	|O
(	670	671	|O
i	671	672	|O
)	672	673	|O
=	674	675	|O
15	676	678	|O
nM	679	681	|O
)	681	682	|O
,	682	683	|O
in	684	686	|O
which	687	692	|O
the	693	696	|O
phenyl	697	703	|O
ring	704	708	|O
contains	709	717	|O
substituents	718	730	|O
,	730	731	|O
have	732	736	|O
been	737	741	|O
synthesized	742	753	|O
.	753	754	|O
Many	755	759	|O
of	760	762	|O
these	763	768	|O
derivatives	769	780	|O
exhibit	781	788	|O
K	789	790	|O
(	790	791	|O
i	791	792	|O
)	792	793	|O
values	794	800	|O
for	801	804	|O
PARP	805	809	|O
inhibition	810	820	|O
&	821	822	|O
lt	822	824	|O
;	824	825	|O
10	826	828	|O
nM	829	831	|O
,	831	832	|O
with	833	837	|O
2	838	839	|B-IUPAC
-	839	840	|I-IUPAC
(	840	841	|I-IUPAC
4	841	842	|I-IUPAC
-	842	843	|I-IUPAC
hydroxymethylphenyl	843	862	|I-IUPAC
)	862	863	|I-IUPAC
-	863	864	|I-IUPAC
1H	864	866	|I-IUPAC
-	866	867	|I-IUPAC
benzimidazole	867	880	|I-IUPAC
-	880	881	|I-IUPAC
4	881	882	|I-IUPAC
-	882	883	|I-IUPAC
carboxamide	883	894	|I-IUPAC
(	895	896	|O
78	896	898	|O
,	898	899	|O
K	900	901	|O
(	901	902	|O
i	902	903	|O
)	903	904	|O
=	905	906	|O
1.6	907	910	|O
nM	911	913	|O
)	913	914	|O
being	915	920	|O
one	921	924	|O
of	925	927	|O
the	928	931	|O
most	932	936	|O
potent	937	943	|O
.	943	944	|O
Insight	945	952	|O
into	953	957	|O
structure	958	967	|O
-	967	968	|O
activity	968	976	|O
relationships	977	990	|O
(	991	992	|O
SAR	992	995	|O
)	995	996	|O
for	997	1000	|O
2	1001	1002	|B-IUPAC
-	1002	1003	|I-IUPAC
aryl	1003	1007	|I-IUPAC
-	1007	1008	|I-IUPAC
1H	1008	1010	|I-IUPAC
-	1010	1011	|I-IUPAC
benzimidazole	1011	1024	|I-IUPAC
-	1024	1025	|I-IUPAC
4	1025	1026	|I-IUPAC
-	1026	1027	|I-IUPAC
carboxamides	1027	1039	|I-IUPAC
has	1040	1043	|O
been	1044	1048	|O
enhanced	1049	1057	|O
by	1058	1060	|O
studying	1061	1069	|O
the	1070	1073	|O
complex	1074	1081	|O
formed	1082	1088	|O
between	1089	1096	|O
2	1097	1098	|B-IUPAC
-	1098	1099	|I-IUPAC
(	1099	1100	|I-IUPAC
3	1100	1101	|I-IUPAC
-	1101	1102	|I-IUPAC
methoxyphenyl	1102	1115	|I-IUPAC
)	1115	1116	|I-IUPAC
-	1116	1117	|I-IUPAC
1H	1117	1119	|I-IUPAC
-	1119	1120	|I-IUPAC
benzimidazole	1120	1133	|I-IUPAC
-	1133	1134	|I-IUPAC
4	1134	1135	|I-IUPAC
-	1135	1136	|I-IUPAC
carboxamide	1136	1147	|I-IUPAC
(	1148	1149	|O
44	1149	1151	|O
,	1151	1152	|O
K	1153	1154	|O
(	1154	1155	|O
i	1155	1156	|O
)	1156	1157	|O
=	1158	1159	|O
6	1160	1161	|O
nM	1162	1164	|O
)	1164	1165	|O
and	1166	1169	|O
the	1170	1173	|O
catalytic	1174	1183	|O
domain	1184	1190	|O
of	1191	1193	|O
chicken	1194	1201	|O
PARP	1202	1206	|O
.	1206	1207	|O
Important	1208	1217	|O
hydrogen	1218	1226	|O
-	1226	1227	|O
bonding	1227	1234	|O
and	1235	1238	|O
hydrophobic	1239	1250	|O
interactions	1251	1263	|O
with	1264	1268	|O
the	1269	1272	|O
protein	1273	1280	|O
have	1281	1285	|O
been	1286	1290	|O
identified	1291	1301	|O
for	1302	1305	|O
this	1306	1310	|O
inhibitor	1311	1320	|O
.	1320	1321	|O
2	1322	1323	|B-IUPAC
-	1323	1324	|I-IUPAC
(	1324	1325	|I-IUPAC
4	1325	1326	|I-IUPAC
-	1326	1327	|I-IUPAC
Hydroxyphenyl	1327	1340	|I-IUPAC
)	1340	1341	|I-IUPAC
-	1341	1342	|I-IUPAC
1H	1342	1344	|I-IUPAC
-	1344	1345	|I-IUPAC
benzimidazole	1345	1358	|I-IUPAC
-	1358	1359	|I-IUPAC
4	1359	1360	|I-IUPAC
-	1360	1361	|I-IUPAC
carboxamide	1361	1372	|I-IUPAC
(	1373	1374	|O
45	1374	1376	|O
,	1376	1377	|O
K	1378	1379	|O
(	1379	1380	|O
i	1380	1381	|O
)	1381	1382	|O
=	1383	1384	|O
6	1385	1386	|O
nM	1387	1389	|O
)	1389	1390	|O
potentiates	1391	1402	|O
the	1403	1406	|O
cytotoxicity	1407	1419	|O
of	1420	1422	|O
both	1423	1427	|O
temozolomide	1428	1440	|O
and	1441	1444	|O
topotecan	1445	1454	|O
against	1455	1462	|O
A2780	1463	1468	|O
cells	1469	1474	|O
in	1475	1477	|O
vitro	1478	1483	|O
(	1484	1485	|O
by	1485	1487	|O
2.8	1488	1491	|O
-	1491	1492	|O
and	1493	1496	|O
2.9	1497	1500	|O
-	1500	1501	|O
fold	1501	1505	|O
,	1505	1506	|O
respectively	1507	1519	|O
)	1519	1520	|O
.	1520	1521	|O

### abstracts4913.txt
The	0	3	|O
synthesis	4	13	|O
and	14	17	|O
biological	18	28	|O
evaluation	29	39	|O
of	40	42	|O
new	43	46	|O
histamine	47	56	|O
H3	57	59	|O
receptor	60	68	|O
antagonists	69	80	|O
with	81	85	|O
an	86	88	|O
iodinated	89	98	|O
aryl	99	103	|O
partial	104	111	|O
structure	112	121	|O
are	122	125	|O
described	126	135	|O
as	136	138	|O
part	139	143	|O
of	144	146	|O
an	147	149	|O
extensive	150	159	|O
research	160	168	|O
program	169	176	|O
to	177	179	|O
find	180	184	|O
model	185	190	|O
compounds	191	200	|O
for	201	204	|O
the	205	208	|O
development	209	220	|O
of	221	223	|O
a	224	225	|O
new	226	229	|O
radioligand	230	241	|O
with	242	246	|O
high	247	251	|O
H3	252	254	|O
receptor	255	263	|O
affinity	264	272	|O
and	273	276	|O
specific	277	285	|O
activity	286	294	|O
.	294	295	|O
All	296	299	|O
compounds	300	309	|O
were	310	314	|O
tested	315	321	|O
for	322	325	|O
their	326	331	|O
H3	332	334	|O
receptor	335	343	|O
antagonist	344	354	|O
activity	355	363	|O
in	364	366	|O
a	367	368	|O
[	369	370	|O
3H	370	372	|O
]	372	373	|O
-	373	374	|O
histamine	374	383	|O
-	383	384	|O
release	384	391	|O
assay	392	397	|O
with	398	402	|O
synaptosomes	403	415	|O
from	416	420	|O
rat	421	424	|O
cerebral	425	433	|O
cortex	434	440	|O
.	440	441	|O
The	442	445	|O
new	446	449	|O
leads	450	455	|O
with	456	460	|O
potent	461	467	|O
H3	468	470	|O
receptor	471	479	|O
antagonist	480	490	|O
activity	491	499	|O
belong	500	506	|O
to	507	509	|O
a	510	511	|O
series	512	518	|O
of	519	521	|O
derivatives	522	533	|O
of	534	536	|O
3	537	538	|B-IUPAC
-	538	539	|I-IUPAC
(	539	540	|I-IUPAC
1H	540	542	|I-IUPAC
-	542	543	|I-IUPAC
imidazol	543	551	|I-IUPAC
-	551	552	|I-IUPAC
4	552	553	|I-IUPAC
-	553	554	|I-IUPAC
yl	554	556	|I-IUPAC
)	556	557	|I-IUPAC
propanol	557	565	|I-IUPAC
with	566	570	|O
carbamate	571	580	|O
(	581	582	|O
4-7	582	585	|O
)	585	586	|O
,	586	587	|O
ester	588	593	|O
(	594	595	|O
8-16	595	599	|O
)	599	600	|O
,	600	601	|O
and	602	605	|O
ether	606	611	|O
(	612	613	|O
17-22	613	618	|O
)	618	619	|O
as	620	622	|O
functional	623	633	|O
groups	634	640	|O
.	640	641	|O
Structure	642	651	|O
-	651	652	|O
activity	652	660	|O
relationships	661	674	|O
are	675	678	|O
discussed	679	688	|O
.	688	689	|O
The	690	693	|O
most	694	698	|O
active	699	705	|O
compound	706	714	|O
in	715	717	|O
the	718	721	|O
functional	722	732	|O
test	733	737	|O
(	738	739	|O
-	739	740	|O
log	740	743	|O
Ki	744	746	|O
=	747	748	|O
8.3	749	752	|O
)	752	753	|O
and	754	757	|O
in	758	760	|O
binding	761	768	|O
studies	769	776	|O
with	777	781	|O
[	782	783	|B-IUPAC
3H	783	785	|I-IUPAC
]	785	786	|I-IUPAC
-	786	787	|I-IUPAC
(	787	788	|I-IUPAC
R	788	789	|I-IUPAC
)	789	790	|I-IUPAC
-	790	791	|I-IUPAC
alpha	791	796	|I-IUPAC
-	796	797	|I-IUPAC
methylhistamine	797	812	|I-IUPAC
on	813	815	|O
rat	816	819	|O
cerebral	820	828	|O
cortex	829	835	|O
(	836	837	|O
-	837	838	|O
log	838	841	|O
Ki	842	844	|O
=	845	846	|O
9.0	847	850	|O
)	850	851	|O
in	852	854	|O
vitro	855	860	|O
was	861	864	|O
3	865	866	|B-IUPAC
-	866	867	|I-IUPAC
(	867	868	|I-IUPAC
1H	868	870	|I-IUPAC
-	870	871	|I-IUPAC
imidazol	871	879	|I-IUPAC
-	879	880	|I-IUPAC
4	880	881	|I-IUPAC
-	881	882	|I-IUPAC
yl	882	884	|I-IUPAC
)	884	885	|I-IUPAC
propyl	885	891	|I-IUPAC
(	892	893	|I-IUPAC
4	893	894	|I-IUPAC
-	894	895	|I-IUPAC
iodophenyl	895	905	|I-IUPAC
)	905	906	|I-IUPAC
methyl	906	912	|I-IUPAC
ether	913	918	|I-IUPAC
(	919	920	|O
iodoproxyfan	920	932	|O
,	932	933	|O
19	934	936	|O
)	936	937	|O
exhibiting	938	948	|O
no	949	951	|O
central	952	959	|O
H3	960	962	|O
receptor	963	971	|O
antagonist	972	982	|O
activity	983	991	|O
in	992	994	|O
vivo	995	999	|O
.	999	1000	|O
The	1001	1004	|O
potency	1005	1012	|O
of	1013	1015	|O
iodoproxyfan	1016	1028	|O
is	1029	1031	|O
more	1032	1036	|O
than	1037	1041	|O
300	1042	1045	|O
times	1046	1051	|O
lower	1052	1057	|O
at	1058	1060	|O
H1	1061	1063	|O
,	1063	1064	|O
H2	1065	1067	|O
,	1067	1068	|O
alpha1	1069	1075	|O
,	1075	1076	|O
alpha2	1077	1083	|O
,	1083	1084	|O
beta1	1085	1090	|O
,	1090	1091	|O
5	1092	1093	|O
-	1093	1094	|O
HT2A	1094	1098	|O
,	1098	1099	|O
5	1100	1101	|O
-	1101	1102	|O
HT3	1102	1105	|O
,	1105	1106	|O
and	1107	1110	|O
M3	1111	1113	|O
receptors	1114	1123	|O
than	1124	1128	|O
at	1129	1131	|O
histamine	1132	1141	|O
H3	1142	1144	|O
receptors	1145	1154	|O
.	1154	1155	|O
Because	1156	1163	|O
of	1164	1166	|O
the	1167	1170	|O
high	1171	1175	|O
potency	1176	1183	|O
and	1184	1187	|O
selectivity	1188	1199	|O
of	1200	1202	|O
19	1203	1205	|O
,	1205	1206	|O
this	1207	1211	|O
compound	1212	1220	|O
has	1221	1224	|O
also	1225	1229	|O
been	1230	1234	|O
prepared	1235	1243	|O
in	1244	1246	|O
the	1247	1250	|O
[	1251	1252	|O
125I	1252	1256	|O
]	1256	1257	|O
-	1257	1258	|O
iodinated	1258	1267	|O
form	1268	1272	|O
by	1273	1275	|O
a	1276	1277	|O
nucleophilic	1278	1290	|O
halogen	1291	1298	|O
exchange	1299	1307	|O
reaction	1308	1316	|O
using	1317	1322	|O
the	1323	1326	|O
corresponding	1327	1340	|O
bromo	1341	1346	|O
derivative	1347	1357	|O
22	1358	1360	|O
as	1361	1363	|O
a	1364	1365	|O
precursor	1366	1375	|O
.	1375	1376	|O
The	1377	1380	|O
newly	1381	1386	|O
prepared	1387	1395	|O
[	1396	1397	|O
125I	1397	1401	|O
]	1401	1402	|O
iodoproxyfan	1402	1414	|O
(	1415	1416	|O
23	1416	1418	|O
)	1418	1419	|O
possesses	1420	1429	|O
advantageous	1430	1442	|O
pharmacological	1443	1458	|O
properties	1459	1469	|O
and	1470	1473	|O
fulfills	1474	1482	|O
all	1483	1486	|O
criteria	1487	1495	|O
of	1496	1498	|O
a	1499	1500	|O
useful	1501	1507	|O
radioligand	1508	1519	|O
.	1519	1520	|O

### abstracts2702.txt
Thrombin	0	8	|O
is	9	11	|O
a	12	13	|O
serine	14	20	|O
protease	21	29	|O
responsible	30	41	|O
for	42	45	|O
blood	46	51	|O
coagulation	52	63	|O
.	63	64	|O
Since	65	70	|O
thrombin	71	79	|O
inhibitors	80	90	|O
appear	91	97	|O
to	98	100	|O
be	101	103	|O
effective	104	113	|O
in	114	116	|O
the	117	120	|O
treatment	121	130	|O
and	131	134	|O
prevention	135	145	|O
of	146	148	|O
thrombotic	149	159	|O
and	160	163	|O
embolic	164	171	|O
disorders	172	181	|O
,	181	182	|O
considerable	183	195	|O
attention	196	205	|O
has	206	209	|O
been	210	214	|O
focused	215	222	|O
on	223	225	|O
the	226	229	|O
structure	230	239	|O
and	240	243	|O
interactions	244	256	|O
of	257	259	|O
this	260	264	|O
enzyme	265	271	|O
.	271	272	|O
In	273	275	|O
this	276	280	|O
work	281	285	|O
,	285	286	|O
to	287	289	|O
evaluate	290	298	|O
the	299	302	|O
relative	303	311	|O
free	312	316	|O
energies	317	325	|O
of	326	328	|O
hydration	329	338	|O
and	339	342	|O
binding	343	350	|O
to	351	353	|O
thrombin	354	362	|O
for	363	366	|O
some	367	371	|O
benzamidine	372	383	|O
derivatives	384	395	|O
,	395	396	|O
we	397	399	|O
used	400	404	|O
the	405	408	|O
finite	409	415	|O
difference	416	426	|O
thermodynamic	427	440	|O
integration	441	452	|O
(	453	454	|O
FDTI	454	458	|O
)	458	459	|O
algorithm	460	469	|O
within	470	476	|O
the	477	480	|O
Discover	481	489	|O
program	490	497	|O
of	498	500	|O
MSI	501	504	|O
.	504	505	|O
By	506	508	|O
this	509	513	|O
method	514	520	|O
,	520	521	|O
two	522	525	|O
possible	526	534	|O
orders	535	541	|O
of	542	544	|O
hydration	545	554	|O
for	555	558	|O
the	559	562	|O
candidates	563	573	|O
were	574	578	|O
obtained	579	587	|O
:	587	588	|O
p	589	590	|B-IUPAC
-	590	591	|I-IUPAC
amidinophenylpyruvate	591	612	|I-IUPAC
&	613	614	|O
gt	614	616	|O
;	616	617	|O
p	618	619	|B-IUPAC
-	619	620	|I-IUPAC
(	620	621	|I-IUPAC
2	621	622	|I-IUPAC
-	622	623	|I-IUPAC
oxo	623	626	|I-IUPAC
-	626	627	|I-IUPAC
1	627	628	|I-IUPAC
-	628	629	|I-IUPAC
propyl	629	635	|I-IUPAC
)	635	636	|I-IUPAC
benzamidine	636	647	|I-IUPAC
&	648	649	|O
gt	649	651	|O
;	651	652	|O
p	653	654	|B-IUPAC
-	654	655	|I-IUPAC
methylbenzamidine	655	672	|I-IUPAC
&	673	674	|O
gt	674	676	|O
;	676	677	|O
p	678	679	|B-IUPAC
-	679	680	|I-IUPAC
ethylbenzamidine	680	696	|I-IUPAC
&	697	698	|O
gt	698	700	|O
;	700	701	|O
p	702	703	|B-IUPAC
-	703	704	|I-IUPAC
(	704	705	|I-IUPAC
1	705	706	|I-IUPAC
-	706	707	|I-IUPAC
propyl	707	713	|I-IUPAC
)	713	714	|I-IUPAC
benzamidine	714	725	|I-IUPAC
&	726	727	|O
gt	727	729	|O
;	729	730	|O
benzamidine	731	742	|B-IUPAC
and	743	746	|O
p	747	748	|B-IUPAC
-	748	749	|I-IUPAC
amidinophenylpyruvate	749	770	|I-IUPAC
&	771	772	|O
gt	772	774	|O
;	774	775	|O
p	776	777	|B-IUPAC
-	777	778	|I-IUPAC
(	778	779	|I-IUPAC
2	779	780	|I-IUPAC
-	780	781	|I-IUPAC
oxo	781	784	|I-IUPAC
-	784	785	|I-IUPAC
1	785	786	|I-IUPAC
-	786	787	|I-IUPAC
propyl	787	793	|I-IUPAC
)	793	794	|I-IUPAC
benzamidine	794	805	|I-IUPAC
&	806	807	|O
gt	807	809	|O
;	809	810	|O
p	811	812	|B-IUPAC
-	812	813	|I-IUPAC
methylbenzamidine	813	830	|I-IUPAC
&	831	832	|O
gt	832	834	|O
;	834	835	|O
p	836	837	|B-IUPAC
-	837	838	|I-IUPAC
ethylbenzamidine	838	854	|I-IUPAC
&	855	856	|O
gt	856	858	|O
;	858	859	|O
benzamidine	860	871	|B-IUPAC
&	872	873	|O
gt	873	875	|O
;	875	876	|O
p	877	878	|B-IUPAC
-	878	879	|I-IUPAC
(	879	880	|I-IUPAC
1	880	881	|I-IUPAC
-	881	882	|I-IUPAC
propyl	882	888	|I-IUPAC
)	888	889	|I-IUPAC
benzamidine	889	900	|I-IUPAC
.	900	901	|O
We	902	904	|O
also	905	909	|O
obtained	910	918	|O
the	919	922	|O
following	923	932	|O
order	933	938	|O
for	939	942	|O
thrombin	943	951	|O
binding	952	959	|O
:	959	960	|O
p	961	962	|B-IUPAC
-	962	963	|I-IUPAC
(	963	964	|I-IUPAC
2	964	965	|I-IUPAC
-	965	966	|I-IUPAC
oxo	966	969	|I-IUPAC
-	969	970	|I-IUPAC
1	970	971	|I-IUPAC
-	971	972	|I-IUPAC
propyl	972	978	|I-IUPAC
)	978	979	|I-IUPAC
benzamidine	979	990	|I-IUPAC
&	991	992	|O
gt	992	994	|O
;	994	995	|O
p	996	997	|B-IUPAC
-	997	998	|I-IUPAC
ethylbenzamidine	998	1014	|I-IUPAC
&	1015	1016	|O
gt	1016	1018	|O
;	1018	1019	|O
p	1020	1021	|B-IUPAC
-	1021	1022	|I-IUPAC
(	1022	1023	|I-IUPAC
1	1023	1024	|I-IUPAC
-	1024	1025	|I-IUPAC
propyl	1025	1031	|I-IUPAC
)	1031	1032	|I-IUPAC
benzamidine	1032	1043	|I-IUPAC
&	1044	1045	|O
gt	1045	1047	|O
;	1047	1048	|O
p	1049	1050	|B-IUPAC
-	1050	1051	|I-IUPAC
methylbenzamidine	1051	1068	|I-IUPAC
&	1069	1070	|O
gt	1070	1072	|O
;	1072	1073	|O
benzamidine	1074	1085	|B-IUPAC
&	1086	1087	|O
gt	1087	1089	|O
;	1089	1090	|O
p	1091	1092	|B-IUPAC
-	1092	1093	|I-IUPAC
amidinophenylpyruvate	1093	1114	|I-IUPAC
.	1114	1115	|O

### abstracts2832.txt
In	0	2	|O
this	3	7	|O
paper	8	13	|O
,	13	14	|O
we	15	17	|O
describe	18	26	|O
the	27	30	|O
synthesis	31	40	|O
of	41	43	|O
a	44	45	|O
series	46	52	|O
of	53	55	|O
novel	56	61	|O
substituted	62	73	|B-MODIFIER
4	74	75	|B-IUPAC
-	75	76	|I-IUPAC
aryl	76	80	|I-IUPAC
-	80	81	|I-IUPAC
6,7	81	84	|I-IUPAC
-	84	85	|I-IUPAC
methylenedioxyphthalazin	85	109	|I-IUPAC
-	109	110	|I-IUPAC
1	110	111	|I-IUPAC
(	111	112	|I-IUPAC
2H	112	114	|I-IUPAC
)	114	115	|I-IUPAC
-	115	116	|I-IUPAC
ones	116	120	|I-IUPAC
.	120	121	|O
The	122	125	|O
anticonvulsant	126	140	|O
activity	141	149	|O
of	150	152	|O
these	153	158	|O
compounds	159	168	|O
against	169	176	|O
audiogenic	177	187	|O
seizures	188	196	|O
was	197	200	|O
evaluated	201	210	|O
in	211	213	|O
DBA	214	217	|O
/	217	218	|O
2	218	219	|O
mice	220	224	|O
after	225	230	|O
intraperitoneal	231	246	|O
(	247	248	|O
ip	248	250	|O
)	250	251	|O
injection	252	261	|O
.	261	262	|O
Most	263	267	|O
of	268	270	|O
these	271	276	|O
derivatives	277	288	|O
are	289	292	|O
more	293	297	|O
active	298	304	|O
than	305	309	|O
1	310	311	|B-IUPAC
-	311	312	|I-IUPAC
(	312	313	|I-IUPAC
4	313	314	|I-IUPAC
-	314	315	|I-IUPAC
aminophenyl	315	326	|I-IUPAC
)	326	327	|I-IUPAC
-	327	328	|I-IUPAC
4	328	329	|I-IUPAC
-	329	330	|I-IUPAC
methyl	330	336	|I-IUPAC
-	336	337	|I-IUPAC
7,8	337	340	|I-IUPAC
-	340	341	|I-IUPAC
methylenedioxy	341	355	|I-IUPAC
-	355	356	|I-IUPAC
5H	356	358	|I-IUPAC
-	358	359	|I-IUPAC
2,3	359	362	|I-IUPAC
-	362	363	|I-IUPAC
benzodiazepine	363	377	|I-IUPAC
(	378	379	|O
1	379	380	|O
,	380	381	|O
GYKI	382	386	|O
52466	387	392	|O
)	392	393	|O
,	393	394	|O
a	395	396	|O
well	397	401	|O
-	401	402	|O
known	402	407	|O
noncompetitive	408	422	|O
AMPA	423	427	|O
receptor	428	436	|O
antagonist	437	447	|O
.	447	448	|O
As	449	451	|O
deduced	452	459	|O
by	460	462	|O
the	463	466	|O
rotarod	467	474	|O
test	475	479	|O
,	479	480	|O
all	481	484	|O
the	485	488	|O
compounds	489	498	|O
exhibit	499	506	|O
a	507	508	|O
toxicity	509	517	|O
lower	518	523	|O
than	524	528	|O
that	529	533	|O
of	534	536	|O
1	537	538	|O
.	538	539	|O
Within	540	546	|O
the	547	550	|O
series	551	557	|O
of	558	560	|O
derivatives	561	572	|O
submitted	573	582	|O
to	583	585	|O
investigation	586	599	|O
,	599	600	|O
4	601	602	|B-IUPAC
-	602	603	|I-IUPAC
(	603	604	|I-IUPAC
4	604	605	|I-IUPAC
-	605	606	|I-IUPAC
aminophenyl	606	617	|I-IUPAC
)	617	618	|I-IUPAC
-	618	619	|I-IUPAC
2	619	620	|I-IUPAC
-	620	621	|I-IUPAC
butylcarbamoyl	621	635	|I-IUPAC
-	635	636	|I-IUPAC
6,7	636	639	|I-IUPAC
-	639	640	|I-IUPAC
methylenedioxyphthalazin	640	664	|I-IUPAC
-	665	666	|I-IUPAC
1	666	667	|I-IUPAC
(	667	668	|I-IUPAC
2H	668	670	|I-IUPAC
)	670	671	|I-IUPAC
-	671	672	|I-IUPAC
one	672	675	|I-IUPAC
(	676	677	|O
21	677	679	|O
)	679	680	|O
proved	681	687	|O
to	688	690	|O
be	691	693	|O
the	694	697	|O
most	698	702	|O
active	703	709	|O
compound	710	718	|O
and	719	722	|O
is	723	725	|O
11	726	728	|O
-	728	729	|O
fold	729	733	|O
more	734	738	|O
potent	739	745	|O
than	746	750	|O
1	751	752	|O
(	753	754	|O
i.e.	754	758	|O
,	758	759	|O
ED50	760	764	|O
3.25	765	769	|O
micromol	770	778	|O
/	778	779	|O
kg	779	781	|O
for	782	785	|O
21	786	788	|O
versus	789	795	|O
ED50	796	800	|O
35.8	801	805	|O
micromol	806	814	|O
/	814	815	|O
kg	815	817	|O
for	818	821	|O
1	822	823	|O
)	823	824	|O
.	824	825	|O
When	826	830	|O
compared	831	839	|O
to	840	842	|O
1	843	844	|O
,	844	845	|O
compound	846	854	|O
21	855	857	|O
as	858	860	|O
well	861	865	|O
as	866	868	|O
its	869	872	|O
analogue	873	881	|O
4	882	883	|B-IUPAC
-	883	884	|I-IUPAC
(	884	885	|I-IUPAC
4	885	886	|I-IUPAC
-	886	887	|I-IUPAC
aminophenyl	887	898	|I-IUPAC
)	898	899	|I-IUPAC
-	899	900	|I-IUPAC
6,7	900	903	|I-IUPAC
-	903	904	|I-IUPAC
methylenedioxyphthalazin	904	928	|I-IUPAC
-	928	929	|I-IUPAC
1	929	930	|I-IUPAC
(	930	931	|I-IUPAC
2H	931	933	|I-IUPAC
)	933	934	|I-IUPAC
-	934	935	|I-IUPAC
one	935	938	|I-IUPAC
(	939	940	|O
16	940	942	|O
)	942	943	|O
show	944	948	|O
a	949	950	|O
longer	951	957	|O
lasting	958	965	|O
anticonvulsant	966	980	|O
activity	981	989	|O
.	989	990	|O
Compound	991	999	|O
21	1000	1002	|O
also	1003	1007	|O
effectively	1008	1019	|O
suppresses	1020	1030	|O
seizures	1031	1039	|O
induced	1040	1047	|O
in	1048	1050	|O
Swiss	1051	1056	|O
mice	1057	1061	|O
by	1062	1064	|O
maximal	1065	1072	|O
electroshock	1073	1085	|O
(	1086	1087	|O
MES	1087	1090	|O
)	1090	1091	|O
and	1092	1095	|O
pentylenetetrazole	1096	1114	|O
(	1115	1116	|O
PTZ	1116	1119	|O
)	1119	1120	|O
.	1120	1121	|O
Furthermore	1122	1133	|O
,	1133	1134	|O
it	1135	1137	|O
antagonizes	1138	1149	|O
in	1150	1152	|O
vivo	1153	1157	|O
seizures	1158	1166	|O
induced	1167	1174	|O
by	1175	1177	|O
2	1178	1179	|B-IUPAC
-	1179	1180	|I-IUPAC
amino	1180	1185	|I-IUPAC
-	1185	1186	|I-IUPAC
3	1186	1187	|I-IUPAC
-	1187	1188	|I-IUPAC
(	1188	1189	|I-IUPAC
3	1189	1190	|I-IUPAC
-	1190	1191	|I-IUPAC
hydroxy	1191	1198	|I-IUPAC
-	1198	1199	|I-IUPAC
5	1199	1200	|I-IUPAC
-	1200	1201	|I-IUPAC
methylisoxazol	1201	1215	|I-IUPAC
-	1215	1216	|I-IUPAC
4	1216	1217	|I-IUPAC
-	1217	1218	|I-IUPAC
yl	1218	1220	|I-IUPAC
)	1220	1221	|I-IUPAC
propionic	1221	1230	|I-IUPAC
acid	1231	1235	|I-IUPAC
(	1236	1237	|O
AMPA	1237	1241	|O
)	1241	1242	|O
,	1242	1243	|O
2	1244	1245	|B-IUPAC
-	1245	1246	|I-IUPAC
amino	1246	1251	|I-IUPAC
-	1251	1252	|I-IUPAC
3	1252	1253	|I-IUPAC
-	1253	1254	|I-IUPAC
(	1254	1255	|I-IUPAC
3	1255	1256	|I-IUPAC
-	1256	1257	|I-IUPAC
hydroxy	1257	1264	|I-IUPAC
-	1264	1265	|I-IUPAC
5	1265	1266	|I-IUPAC
-	1266	1267	|I-IUPAC
tert	1267	1271	|I-IUPAC
-	1271	1272	|I-IUPAC
butyl	1272	1277	|I-IUPAC
-	1277	1278	|I-IUPAC
isoxazol	1278	1286	|I-IUPAC
-	1286	1287	|I-IUPAC
4	1287	1288	|I-IUPAC
-	1288	1289	|I-IUPAC
yl	1289	1291	|I-IUPAC
)	1291	1292	|I-IUPAC
propionic	1292	1301	|I-IUPAC
acid	1302	1306	|I-IUPAC
(	1307	1308	|O
ATPA	1308	1312	|O
)	1312	1313	|O
,	1313	1314	|O
and	1315	1318	|O
kainate	1319	1326	|O
(	1327	1328	|O
KA	1328	1330	|O
)	1330	1331	|O
,	1331	1332	|O
and	1333	1336	|O
its	1337	1340	|O
anticonvulsant	1341	1355	|O
activity	1356	1364	|O
is	1365	1367	|O
reversed	1368	1376	|O
by	1377	1379	|O
pretreatment	1380	1392	|O
with	1393	1397	|O
aniracetam	1398	1408	|O
.	1408	1409	|O
Using	1410	1415	|O
the	1416	1419	|O
patch	1420	1425	|O
-	1425	1426	|O
clamp	1426	1431	|O
technique	1432	1441	|O
,	1441	1442	|O
the	1443	1446	|O
capability	1447	1457	|O
of	1458	1460	|O
derivatives	1461	1472	|O
16	1473	1475	|O
and	1476	1479	|O
21	1480	1482	|O
to	1483	1485	|O
antagonize	1486	1496	|O
KA	1497	1499	|O
-	1499	1500	|O
evoked	1500	1506	|O
currents	1507	1515	|O
in	1516	1518	|O
primary	1519	1526	|O
cultures	1527	1535	|O
of	1536	1538	|O
granule	1539	1546	|O
neurons	1547	1554	|O
was	1555	1558	|O
tested	1559	1565	|O
.	1565	1566	|O
They	1567	1571	|O
behaved	1572	1579	|O
as	1580	1582	|O
antagonists	1583	1594	|O
,	1594	1595	|O
but	1596	1599	|O
they	1600	1604	|O
proved	1605	1611	|O
to	1612	1614	|O
be	1615	1617	|O
less	1618	1622	|O
effective	1623	1632	|O
than	1633	1637	|O
1	1638	1639	|O
and	1640	1643	|O
1	1644	1645	|B-IUPAC
-	1645	1646	|I-IUPAC
(	1646	1647	|I-IUPAC
4	1647	1648	|I-IUPAC
-	1648	1649	|I-IUPAC
aminophenyl	1649	1660	|I-IUPAC
)	1660	1661	|I-IUPAC
-	1661	1662	|I-IUPAC
3,4	1662	1665	|I-IUPAC
-	1665	1666	|I-IUPAC
dihydro	1666	1673	|I-IUPAC
-	1673	1674	|I-IUPAC
4	1674	1675	|I-IUPAC
-	1675	1676	|I-IUPAC
methyl	1676	1682	|I-IUPAC
-	1682	1683	|I-IUPAC
3	1683	1684	|I-IUPAC
-	1684	1685	|I-IUPAC
N	1685	1686	|I-IUPAC
-	1686	1687	|I-IUPAC
methylcarbamoyl	1687	1702	|I-IUPAC
-	1702	1703	|I-IUPAC
7,8	1703	1706	|I-IUPAC
-	1706	1707	|I-IUPAC
met	1707	1710	|I-IUPAC
hylenedioxy	1711	1722	|I-IUPAC
-	1722	1723	|I-IUPAC
5H	1723	1725	|I-IUPAC
-	1725	1726	|I-IUPAC
2,3	1726	1729	|I-IUPAC
-	1729	1730	|I-IUPAC
benzodiazepine	1730	1744	|I-IUPAC
(	1745	1746	|O
2	1746	1747	|O
,	1747	1748	|O
GYKI	1749	1753	|O
53655	1754	1759	|O
)	1759	1760	|O
to	1761	1763	|O
reduce	1764	1770	|O
the	1771	1774	|O
KA	1775	1777	|O
-	1777	1778	|O
evoked	1778	1784	|O
currents	1785	1793	|O
.	1793	1794	|O

### abstracts4177.txt
The	0	3	|O
synthesis	4	13	|O
of	14	16	|O
ethyl	17	22	|B-IUPAC
or	23	25	|O
methyl	26	32	|B-IUPAC
4	33	34	|B-MODIFIER
-	34	35	|I-MODIFIER
substituted	35	46	|I-MODIFIER
or	47	49	|O
unsubstituted	50	63	|B-MODIFIER
2	64	65	|B-IUPAC
-	65	66	|I-IUPAC
(	66	67	|I-IUPAC
dimethylamino	67	80	|I-IUPAC
)	80	81	|I-IUPAC
-	81	82	|I-IUPAC
5	82	83	|I-IUPAC
-	83	84	|I-IUPAC
pyrimidinecarboxylates	84	106	|I-IUPAC
10-20	107	112	|O
,	112	113	|O
which	114	119	|O
is	120	122	|O
mainly	123	129	|O
carried	130	137	|O
out	138	141	|O
by	142	144	|O
reaction	145	153	|O
of	154	156	|O
ethyl	157	162	|B-IUPAC
or	163	165	|O
methyl	166	172	|B-IUPAC
2	173	174	|I-IUPAC
-	174	175	|I-IUPAC
[	175	176	|I-IUPAC
(	176	177	|I-IUPAC
dimethylamino	177	190	|I-IUPAC
)	190	191	|I-IUPAC
methylene	191	200	|I-IUPAC
]	200	201	|I-IUPAC
-	201	202	|I-IUPAC
3	202	203	|I-IUPAC
-	203	204	|I-IUPAC
oxoalkanoates	204	217	|I-IUPAC
with	218	222	|O
1,1	223	226	|B-IUPAC
-	226	227	|I-IUPAC
dimethylguanidine	227	244	|I-IUPAC
,	244	245	|O
is	246	248	|O
described	249	258	|O
.	258	259	|O
The	260	263	|O
above	264	269	|O
esters	270	276	|O
were	277	281	|O
hydrolyzed	282	292	|O
to	293	295	|O
the	296	299	|O
relative	300	308	|O
carboxylic	309	319	|O
acids	320	325	|O
21-30	326	331	|O
,	331	332	|O
which	333	338	|O
were	339	343	|O
decarboxylated	344	358	|O
to	359	361	|O
the	362	365	|O
corresponding	366	379	|O
2,4	380	383	|B-MODIFIER
-	383	384	|I-MODIFIER
disubstituted	384	397	|I-MODIFIER
pyrimidines	398	409	|B-IUPAC
31-40	410	415	|O
.	415	416	|O
All	417	420	|O
the	421	424	|O
new	425	428	|O
synthesized	429	440	|O
pyrimidines	441	452	|O
were	453	457	|O
evaluated	458	467	|O
in	468	470	|O
spontaneously	471	484	|O
beating	485	492	|O
and	493	496	|O
electrically	497	509	|O
driven	510	516	|O
atria	517	522	|O
from	523	527	|O
reserpine	528	537	|O
-	537	538	|O
treated	538	545	|O
guinea	546	552	|O
pigs	553	557	|O
.	557	558	|O
Their	559	564	|O
effects	565	572	|O
were	573	577	|O
compared	578	586	|O
to	587	589	|O
those	590	595	|O
induced	596	603	|O
by	604	606	|O
milrinone	607	616	|O
in	617	619	|O
both	620	624	|O
atria	625	630	|O
preparations	631	643	|O
.	643	644	|O
Compound	645	653	|O
28	654	656	|O
(	657	658	|O
4	658	659	|B-IUPAC
-	659	660	|I-IUPAC
benzyl	660	666	|I-IUPAC
-	666	667	|I-IUPAC
2	667	668	|I-IUPAC
-	668	669	|I-IUPAC
(	669	670	|I-IUPAC
dimethylamino	670	683	|I-IUPAC
)	683	684	|I-IUPAC
-	684	685	|I-IUPAC
5	685	686	|I-IUPAC
-	686	687	|I-IUPAC
pyrimidinecarboxylic	687	707	|I-IUPAC
acid	708	712	|I-IUPAC
)	712	713	|O
was	714	717	|O
the	718	721	|O
most	722	726	|O
effective	727	736	|O
positive	737	745	|O
inotropic	746	755	|O
agent	756	761	|O
,	761	762	|O
while	763	768	|O
the	769	772	|O
corresponding	773	786	|O
methyl	787	793	|O
ester	794	799	|O
17	800	802	|O
reduced	803	810	|O
both	811	815	|O
the	816	819	|O
contractile	820	831	|O
force	832	837	|O
and	838	841	|O
the	842	845	|O
frequency	846	855	|O
of	856	858	|O
guinea	859	865	|O
pig	866	869	|O
atria	870	875	|O
.	875	876	|O
An	877	879	|O
antagonism	880	890	|O
toward	891	897	|O
the	898	901	|O
negative	902	910	|O
influence	911	920	|O
exerted	921	928	|O
by	929	931	|O
endogenous	932	942	|O
adenosine	943	952	|O
on	953	955	|O
the	956	959	|O
heart	960	965	|O
seems	966	971	|O
to	972	974	|O
be	975	977	|O
involved	978	986	|O
in	987	989	|O
the	990	993	|O
contractile	994	1005	|O
activity	1006	1014	|O
of	1015	1017	|O
compound	1018	1026	|O
28	1027	1029	|O
.	1029	1030	|O
By	1031	1033	|O
contrast	1034	1042	|O
,	1042	1043	|O
compound	1044	1052	|O
17	1053	1055	|O
might	1056	1061	|O
be	1062	1064	|O
partial	1065	1072	|O
agonist	1073	1080	|O
at	1081	1083	|O
the	1084	1087	|O
purinergic	1088	1098	|O
inhibitory	1099	1109	|O
(	1110	1111	|O
A1	1111	1113	|O
)	1113	1114	|O
receptor	1115	1123	|O
.	1123	1124	|O
X	1125	1126	|O
-	1126	1127	|O
ray	1127	1130	|O
analysis	1131	1139	|O
carried	1140	1147	|O
out	1148	1151	|O
on	1152	1154	|O
17	1155	1157	|O
and	1158	1161	|O
28	1162	1164	|O
and	1165	1168	|O
molecular	1169	1178	|O
modeling	1179	1187	|O
investigations	1188	1202	|O
extended	1203	1211	|O
also	1212	1216	|O
to	1217	1219	|O
related	1220	1227	|O
derivatives	1228	1239	|O
allowed	1240	1247	|O
a	1248	1249	|O
possible	1250	1258	|O
rationalization	1259	1274	|O
between	1275	1282	|O
structure	1283	1292	|O
and	1293	1296	|O
inotropic	1297	1306	|O
activity	1307	1315	|O
for	1316	1319	|O
this	1320	1324	|O
series	1325	1331	|O
of	1332	1334	|O
compounds	1335	1344	|O
.	1344	1345	|O

### abstracts2122.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
(	12	13	|B-IUPAC
beta	13	17	|I-IUPAC
-	17	18	|I-IUPAC
aminoethyl	18	28	|I-IUPAC
)	28	29	|I-IUPAC
indolones	29	38	|I-IUPAC
and	39	42	|O
related	43	50	|O
compounds	51	60	|O
was	61	64	|O
synthesized	65	76	|O
and	77	80	|O
evaluated	81	90	|O
in	91	93	|O
vitro	94	99	|O
as	100	102	|O
peripheral	103	113	|O
prejunctional	114	127	|O
dopaminergic	128	140	|O
agonists	141	149	|O
in	150	152	|O
the	153	156	|O
field	157	162	|O
-	162	163	|O
stimulated	163	173	|O
isolated	174	182	|O
perfused	183	191	|O
rabbit	192	198	|O
ear	199	202	|O
artery	203	209	|O
.	209	210	|O
4	211	212	|B-IUPAC
-	212	213	|I-IUPAC
[	213	214	|I-IUPAC
2	214	215	|I-IUPAC
-	215	216	|I-IUPAC
(	216	217	|I-IUPAC
Di	217	219	|I-IUPAC
-	219	220	|I-IUPAC
n	220	221	|I-IUPAC
-	221	222	|I-IUPAC
propylamino	222	233	|I-IUPAC
)	233	234	|I-IUPAC
ethyl	234	239	|I-IUPAC
]	239	240	|I-IUPAC
-	240	241	|I-IUPAC
7	241	242	|I-IUPAC
-	242	243	|I-IUPAC
hydroxy	243	250	|I-IUPAC
-	250	251	|I-IUPAC
2	251	252	|I-IUPAC
(	252	253	|I-IUPAC
3H	253	255	|I-IUPAC
)	255	256	|I-IUPAC
-	256	257	|I-IUPAC
indolone	257	265	|I-IUPAC
was	266	269	|O
the	270	273	|O
most	274	278	|O
potent	279	285	|O
compound	286	294	|O
(	295	296	|O
ED50	296	300	|O
=	301	302	|O
2	303	304	|O
+	305	306	|O
/	306	307	|O
-	307	308	|O
0.3	309	312	|O
nM	313	315	|O
)	315	316	|O
tested	317	323	|O
,	323	324	|O
while	325	330	|O
the	331	334	|O
related	335	342	|O
secondary	343	352	|O
amine	353	358	|O
24	359	361	|O
and	362	365	|O
the	366	369	|O
des	370	373	|O
-	373	374	|O
OH	374	376	|O
derivatives	377	388	|O
28	389	391	|O
and	392	395	|O
34	396	398	|O
were	399	403	|O
only	404	408	|O
slightly	409	417	|O
less	418	422	|O
potent	423	429	|O
.	429	430	|O
4	431	432	|B-IUPAC
-	432	433	|I-IUPAC
Methoxybenzeneethanamine	433	457	|I-IUPAC
and	458	461	|O
2	462	463	|B-IUPAC
-	463	464	|I-IUPAC
methyl	464	470	|I-IUPAC
-	470	471	|I-IUPAC
3	471	472	|I-IUPAC
-	472	473	|I-IUPAC
nitrophenylacetic	473	490	|I-IUPAC
acid	491	495	|I-IUPAC
were	496	500	|O
employed	501	509	|O
as	510	512	|O
starting	513	521	|O
materials	522	531	|O
for	532	535	|O
for	536	539	|O
the	540	543	|O
synthesis	544	553	|O
of	554	556	|O
the	557	560	|O
4	561	562	|B-IUPAC
-	562	563	|I-IUPAC
(	563	564	|I-IUPAC
beta	564	568	|I-IUPAC
-	568	569	|I-IUPAC
aminoethyl	569	579	|I-IUPAC
)	579	580	|I-IUPAC
indolones	580	589	|I-IUPAC
.	589	590	|O
The	591	594	|O
ring	595	599	|O
-	599	600	|O
opened	600	606	|O
3	607	608	|B-IUPAC
-	608	609	|I-IUPAC
acylamino	609	618	|I-IUPAC
analogues	619	628	|B-MODIFIER
46	629	631	|O
and	632	635	|O
47	636	638	|O
were	639	643	|O
prepared	644	652	|O
via	653	656	|O
nitration	657	666	|O
of	667	669	|O
the	670	673	|O
phenethylamine	674	688	|O
43	689	691	|O
derived	692	699	|O
from	700	704	|O
4	705	706	|B-IUPAC
-	706	707	|I-IUPAC
methoxyphenylacetic	707	726	|I-IUPAC
acid	727	731	|I-IUPAC
.	731	732	|O
The	733	736	|O
inactive	737	745	|O
isomeric	746	754	|O
indolones	755	764	|O
38	765	767	|O
,	767	768	|O
39	769	771	|O
,	771	772	|O
and	773	776	|O
41	777	779	|O
were	780	784	|O
derived	785	792	|O
from	793	797	|O
4	798	799	|B-IUPAC
-	799	800	|I-IUPAC
nitrobenzeneethanamine	800	822	|I-IUPAC
and	823	826	|O
from	827	831	|O
indolone	832	840	|B-IUPAC
-	840	841	|I-IUPAC
6	841	842	|I-IUPAC
-	842	843	|I-IUPAC
acetic	843	849	|I-IUPAC
acid	850	854	|I-IUPAC
.	854	855	|O

### abstracts3287.txt
Synthesis	0	9	|O
of	10	12	|O
2	13	14	|B-IUPAC
-	14	15	|I-IUPAC
[	15	16	|I-IUPAC
bis	16	19	|I-IUPAC
(	19	20	|I-IUPAC
2	20	21	|I-IUPAC
-	21	22	|I-IUPAC
chloroethyl	22	33	|I-IUPAC
)	33	34	|I-IUPAC
amino	34	39	|I-IUPAC
]	39	40	|I-IUPAC
-	40	41	|I-IUPAC
3,4	41	44	|I-IUPAC
-	44	45	|I-IUPAC
dihydro	45	52	|I-IUPAC
-	52	53	|I-IUPAC
2H	53	55	|I-IUPAC
-	55	56	|I-IUPAC
1,3,2	56	61	|I-IUPAC
-	61	62	|I-IUPAC
benzoxazaphosphorin	62	81	|I-IUPAC
2	82	83	|I-IUPAC
-	83	84	|I-IUPAC
oxide	84	89	|I-IUPAC
(	90	91	|O
2	91	92	|O
)	92	93	|O
,	93	94	|O
which	95	100	|O
is	101	103	|O
a	104	105	|O
benzo	106	111	|O
annulated	112	121	|O
analog	122	128	|O
of	129	131	|O
cyclophosphamide	132	148	|O
[	149	150	|O
2	150	151	|B-IUPAC
-	151	152	|I-IUPAC
bis	152	155	|I-IUPAC
(	155	156	|I-IUPAC
2	156	157	|I-IUPAC
-	157	158	|I-IUPAC
chloroethyl	158	169	|I-IUPAC
)	169	170	|I-IUPAC
aminotetrahydro	170	185	|I-IUPAC
-	185	186	|I-IUPAC
2H	186	188	|I-IUPAC
-	188	189	|I-IUPAC
1,3,2	189	194	|I-IUPAC
-	194	195	|I-IUPAC
oxazaphosphorin	195	210	|I-IUPAC
2	211	212	|I-IUPAC
-	212	213	|I-IUPAC
oxide	213	218	|I-IUPAC
(	219	220	|O
1	220	221	|O
)	221	222	|O
]	222	223	|O
,	223	224	|O
was	225	228	|O
carried	229	236	|O
out	237	240	|O
in	241	243	|O
order	244	249	|O
to	250	252	|O
test	253	257	|O
for	258	261	|O
possible	262	270	|O
increased	271	280	|O
antitumor	281	290	|O
activity	291	299	|O
relative	300	308	|O
to	309	311	|O
1	312	313	|O
due	314	317	|O
to	318	320	|O
the	321	324	|O
presence	325	333	|O
of	334	336	|O
an	337	339	|O
oxidatively	340	351	|O
reactive	352	360	|O
C	361	362	|O
-	362	363	|O
4	363	364	|O
benzylic	365	373	|O
site	374	378	|O
in	379	381	|O
2	382	383	|O
.	383	384	|O
A	385	386	|O
structural	387	397	|O
isomer	398	404	|O
of	405	407	|O
2	408	409	|B-IUPAC
,	409	410	|I-IUPAC
2	411	412	|I-IUPAC
-	412	413	|I-IUPAC
[	413	414	|I-IUPAC
bis	414	417	|I-IUPAC
(	417	418	|I-IUPAC
2	418	419	|I-IUPAC
-	419	420	|I-IUPAC
chloroethyl	420	431	|I-IUPAC
)	431	432	|I-IUPAC
amino	432	437	|I-IUPAC
]	437	438	|I-IUPAC
-	438	439	|I-IUPAC
1,4	439	442	|I-IUPAC
-	442	443	|I-IUPAC
dihydro	443	450	|I-IUPAC
-	450	451	|I-IUPAC
2H	451	453	|I-IUPAC
-	453	454	|I-IUPAC
3,1,2	454	459	|I-IUPAC
-	459	460	|I-IUPAC
benzoxazaphosphorin	460	479	|I-IUPAC
2	480	481	|I-IUPAC
-	481	482	|I-IUPAC
oxide	482	487	|I-IUPAC
(	488	489	|O
3	489	490	|O
)	490	491	|O
,	491	492	|O
and	493	496	|O
cognate	497	504	|O
systems	505	512	|O
2	513	514	|B-IUPAC
-	514	515	|I-IUPAC
[	515	516	|I-IUPAC
bis	516	519	|I-IUPAC
(	519	520	|I-IUPAC
2	520	521	|I-IUPAC
-	521	522	|I-IUPAC
chloroethyl	522	533	|I-IUPAC
)	533	534	|I-IUPAC
amino	534	539	|I-IUPAC
]	539	540	|I-IUPAC
-	540	541	|I-IUPAC
1,2,3,4	541	548	|I-IUPAC
-	548	549	|I-IUPAC
tetrahydro	549	559	|I-IUPAC
-	559	560	|I-IUPAC
1,3,2	560	565	|I-IUPAC
-	565	566	|I-IUPAC
benzodiazaphosphorin	566	586	|I-IUPAC
2	587	588	|I-IUPAC
-	588	589	|I-IUPAC
oxide	589	594	|I-IUPAC
(	595	596	|O
4	596	597	|O
)	597	598	|O
and	599	602	|O
2	603	604	|B-IUPAC
-	604	605	|I-IUPAC
[	605	606	|I-IUPAC
bis	606	609	|I-IUPAC
(	609	610	|I-IUPAC
2	610	611	|I-IUPAC
-	611	612	|I-IUPAC
chloroethyl	612	623	|I-IUPAC
)	623	624	|I-IUPAC
amino	624	629	|I-IUPAC
]	629	630	|I-IUPAC
-	630	631	|I-IUPAC
4H	631	633	|I-IUPAC
-	633	634	|I-IUPAC
1,3,2	634	639	|I-IUPAC
-	639	640	|I-IUPAC
benzodioxaphosphorin	640	660	|I-IUPAC
2	661	662	|I-IUPAC
-	662	663	|I-IUPAC
oxide	663	668	|I-IUPAC
(	669	670	|O
5	670	671	|O
)	671	672	|O
were	673	677	|O
also	678	682	|O
prepared	683	691	|O
for	692	695	|O
comparative	696	707	|O
purposes	708	716	|O
.	716	717	|O
In	718	720	|O
vivo	721	725	|O
antitumor	726	735	|O
evaluation	736	746	|O
in	747	749	|O
mice	750	754	|O
against	755	762	|O
L1210	763	768	|O
lymphoid	769	777	|O
leukemia	778	786	|O
indicated	787	796	|O
no	797	799	|O
significant	800	811	|O
activity	812	820	|O
for	821	824	|O
compound	825	833	|O
2	834	835	|O
.	835	836	|O
Compounds	837	846	|O
3	847	848	|O
and	849	852	|O
4	853	854	|O
were	855	859	|O
likewise	860	868	|O
found	869	874	|O
to	875	877	|O
be	878	880	|O
inactive	881	889	|O
and	890	893	|O
only	894	898	|O
marginal	899	907	|O
activity	908	916	|O
was	917	920	|O
exhibited	921	930	|O
by	931	933	|O
5	934	935	|O
.	935	936	|O

### abstracts2950.txt
Replacement	0	11	|O
of	12	14	|O
the	15	18	|O
polar	19	24	|O
head	25	29	|O
of	30	32	|O
our	33	36	|O
previous	37	45	|O
series	46	52	|O
of	53	55	|O
1	56	57	|B-IUPAC
-	57	58	|I-IUPAC
acyl	58	62	|I-IUPAC
-	62	63	|I-IUPAC
4	63	64	|I-IUPAC
-	64	65	|I-IUPAC
[	65	66	|I-IUPAC
(	66	67	|I-IUPAC
2	67	68	|I-IUPAC
-	68	69	|I-IUPAC
methyl	69	75	|I-IUPAC
-	75	76	|I-IUPAC
3	76	77	|I-IUPAC
-	77	78	|I-IUPAC
pyridyl	78	85	|I-IUPAC
)	85	86	|I-IUPAC
-	86	87	|I-IUPAC
cyanomethyl	87	98	|I-IUPAC
]	98	99	|I-IUPAC
piperazines	99	110	|I-IUPAC
with	111	115	|O
a	116	117	|O
2	118	119	|B-IUPAC
-	119	120	|I-IUPAC
methylimidazo	120	133	|I-IUPAC
[	133	134	|I-IUPAC
4,5	134	137	|I-IUPAC
-	137	138	|I-IUPAC
c	138	139	|I-IUPAC
]	139	140	|I-IUPAC
pyridine	140	148	|I-IUPAC
group	149	154	|B-MODIFIER
has	155	158	|O
led	159	162	|O
to	163	165	|O
the	166	169	|O
identification	170	184	|O
of	185	187	|O
a	188	189	|O
new	190	193	|O
series	194	200	|O
of	201	203	|O
1	204	205	|B-IUPAC
-	205	206	|I-IUPAC
[	206	207	|I-IUPAC
(	207	208	|I-IUPAC
1	208	209	|I-IUPAC
-	209	210	|I-IUPAC
acyl	210	214	|I-IUPAC
-	214	215	|I-IUPAC
4	215	216	|I-IUPAC
-	216	217	|I-IUPAC
piperidyl	218	227	|I-IUPAC
)	227	228	|I-IUPAC
methyl	228	234	|I-IUPAC
]	234	235	|I-IUPAC
-	235	236	|I-IUPAC
1H	236	238	|I-IUPAC
-	238	239	|I-IUPAC
2	239	240	|I-IUPAC
-	240	241	|I-IUPAC
methylimidazo	241	254	|I-IUPAC
[	254	255	|I-IUPAC
4,5	255	258	|I-IUPAC
-	258	259	|I-IUPAC
c	259	260	|I-IUPAC
]	260	261	|I-IUPAC
pyridine	261	269	|I-IUPAC
derivatives	270	281	|B-MODIFIER
as	282	284	|O
potent	285	291	|O
,	291	292	|O
orally	293	299	|O
active	300	306	|O
platelet	307	315	|O
-	315	316	|O
activating	316	326	|O
factor	327	333	|O
(	334	335	|O
PAF	335	338	|O
)	338	339	|O
antagonists	340	351	|O
.	351	352	|O
On	353	355	|O
the	356	359	|O
basis	360	365	|O
of	366	368	|O
the	369	372	|O
general	373	380	|O
structure	381	390	|O
-	390	391	|O
-	391	392	|O
activity	392	400	|O
relationship	401	413	|O
trends	414	420	|O
found	421	426	|O
for	427	430	|O
the	431	434	|O
acyl	435	439	|B-IUPAC
substituent	440	451	|B-MODIFIER
in	452	454	|O
our	455	458	|O
earlier	459	466	|O
series	467	473	|O
,	473	474	|O
five	475	479	|O
groups	480	486	|O
of	487	489	|O
compounds	490	499	|O
were	500	504	|O
tested	505	511	|O
,	511	512	|O
diaryl	513	519	|B-PARTIUPAC
-	519	520	|I-PARTIUPAC
or	521	523	|O
alkylarylpropanoyl	524	542	|B-IUPAC
derivatives	543	554	|B-MODIFIER
,	554	555	|O
their	556	561	|O
3	562	563	|B-IUPAC
-	563	564	|I-IUPAC
hydroxy	564	571	|I-IUPAC
-	571	572	|O
substituted	572	583	|B-MODIFIER
analogues	584	593	|I-MODIFIER
,	593	594	|O
and	595	598	|O
urea	599	603	|O
,	603	604	|O
carbamate	605	614	|O
and	615	618	|O
amino	619	624	|O
acid	625	629	|O
derivatives	630	641	|O
.	641	642	|O
The	643	646	|O
optimal	647	654	|O
compound	655	663	|O
19	664	666	|O
UR	667	669	|O
-	669	670	|O
12670	670	675	|O
)	675	676	|O
,	676	677	|O
bearing	678	685	|O
the	686	689	|O
3,3	690	693	|B-IUPAC
-	693	694	|I-IUPAC
diphenylpropanoyl	694	711	|I-IUPAC
moiety	712	718	|B-MODIFIER
,	718	719	|O
exhibited	720	729	|O
very	730	734	|O
high	735	739	|O
in	740	742	|O
vitro	743	748	|O
and	749	752	|O
in	753	755	|O
vivo	756	760	|O
potency	761	768	|O
IC50	769	773	|O
=	774	775	|O
0.0076	776	782	|O
microM	783	789	|O
for	790	793	|O
the	794	797	|O
in	798	800	|O
vitro	801	806	|O
PAF	807	810	|O
-	810	811	|O
induced	811	818	|O
platelet	819	827	|O
aggregation	828	839	|O
assay	840	845	|O
,	845	846	|O
ID50	847	851	|O
=	852	853	|O
0.0086	854	860	|O
mg	861	863	|O
/	863	864	|O
kg	864	866	|O
for	867	870	|O
the	871	874	|O
in	875	877	|O
vivo	878	882	|O
PAF	883	886	|O
-	886	887	|O
induced	887	894	|O
hypotension	895	906	|O
test	907	911	|O
in	912	914	|O
normotensive	915	927	|O
rats	928	932	|O
,	932	933	|O
and	934	937	|O
ID50	938	942	|O
=	943	944	|O
0.092	945	950	|O
mg	951	953	|O
/	953	954	|O
kg	954	956	|O
po	957	959	|O
and	960	963	|O
0.0008	964	970	|O
mg	971	973	|O
/	973	974	|O
kg	974	976	|O
i	977	978	|O
.	978	979	|O
v	979	980	|O
.	980	981	|O
for	982	985	|O
the	986	989	|O
PAF	990	993	|O
-	993	994	|O
induced	994	1001	|O
mortality	1002	1011	|O
test	1012	1016	|O
in	1017	1019	|O
mice	1020	1024	|O
)	1024	1025	|O
.	1025	1026	|O
Compound	1027	1035	|O
19	1036	1038	|O
also	1039	1043	|O
showed	1044	1050	|O
long	1051	1055	|O
duration	1056	1064	|O
of	1065	1067	|O
activity	1068	1076	|O
.	1076	1077	|O
It	1078	1080	|O
gave	1081	1085	|O
100%	1086	1090	|O
protection	1091	1101	|O
against	1102	1109	|O
PAF	1110	1113	|O
-	1113	1114	|O
induced	1114	1121	|O
mortality	1122	1131	|O
in	1132	1134	|O
mice	1135	1139	|O
7	1140	1141	|O
h	1142	1143	|O
after	1144	1149	|O
i	1150	1151	|O
.	1151	1152	|O
v	1152	1153	|O
.	1153	1154	|O
administration	1155	1169	|O
of	1170	1172	|O
a	1173	1174	|O
single	1175	1181	|O
dose	1182	1186	|O
of	1187	1189	|O
1	1190	1191	|O
mg	1192	1194	|O
/	1194	1195	|O
kg	1195	1197	|O
and	1198	1201	|O
also	1202	1206	|O
provided	1207	1215	|O
100%	1216	1220	|O
inhibition	1221	1231	|O
of	1232	1234	|O
PAF	1235	1238	|O
-	1238	1239	|O
induced	1239	1246	|O
aggregation	1247	1258	|O
in	1259	1261	|O
dog	1262	1265	|O
whole	1266	1271	|O
blood	1272	1277	|O
6	1278	1279	|O
h	1280	1281	|O
after	1282	1287	|O
i	1288	1289	|O
.	1289	1290	|O
v	1290	1291	|O
.	1291	1292	|O
administration	1293	1307	|O
of	1308	1310	|O
the	1311	1314	|O
same	1315	1319	|O
dose	1320	1324	|O
.	1324	1325	|O
The	1326	1329	|O
lead	1330	1334	|O
structure	1335	1344	|O
19	1345	1347	|O
has	1348	1351	|O
been	1352	1356	|O
selected	1357	1365	|O
for	1366	1369	|O
in	1370	1372	|O
-	1372	1373	|O
depth	1373	1378	|O
pharmacological	1379	1394	|O
evaluation	1395	1405	|O
.	1405	1406	|O

### abstracts219.txt
On	0	2	|O
the	3	6	|O
basis	7	12	|O
of	13	15	|O
the	16	19	|O
SAR	20	23	|O
of	24	26	|O
a	27	28	|O
series	29	35	|O
of	36	38	|O
known	39	44	|O
gamma	45	50	|O
-	50	51	|O
aminobutyric	51	63	|O
acid	64	68	|O
(	69	70	|O
GABA	70	74	|O
)	74	75	|O
uptake	76	82	|O
inhibitors	83	93	|O
,	93	94	|O
including	95	104	|O
4	105	106	|O
(	107	108	|O
SKF	108	111	|O
89976	112	117	|O
)	117	118	|O
,	118	119	|O
new	120	123	|O
tricyclic	124	133	|O
analogues	134	143	|O
have	144	148	|O
been	149	153	|O
prepared	154	162	|O
.	162	163	|O
These	164	169	|O
novel	170	175	|O
compounds	176	185	|O
are	186	189	|O
derivatives	190	201	|O
of	202	204	|O
nipecotic	205	214	|O
acid	215	219	|O
,	219	220	|O
guvacine	221	229	|O
,	229	230	|O
and	231	234	|O
homo	235	239	|B-IUPAC
-	239	240	|I-IUPAC
beta	240	244	|I-IUPAC
-	244	245	|I-IUPAC
proline	245	252	|I-IUPAC
,	252	253	|O
substituted	254	265	|O
at	266	268	|O
the	269	272	|O
nitrogen	273	281	|O
of	282	284	|O
these	285	290	|O
amino	291	296	|O
acids	297	302	|O
by	303	305	|O
various	306	313	|O
lipophilic	314	324	|O
moieties	325	333	|O
such	334	338	|O
as	339	341	|O
(	342	343	|B-IUPAC
10,11	343	348	|I-IUPAC
-	348	349	|I-IUPAC
dihydro	349	356	|I-IUPAC
-	356	357	|I-IUPAC
5H	357	359	|I-IUPAC
-	359	360	|I-IUPAC
dibenz	360	366	|I-IUPAC
[	366	367	|I-IUPAC
b	367	368	|I-IUPAC
,	368	369	|I-IUPAC
f	369	370	|I-IUPAC
]	370	371	|I-IUPAC
azepin	371	377	|I-IUPAC
-	377	378	|I-IUPAC
5	378	379	|I-IUPAC
-	379	380	|I-IUPAC
yl	380	382	|I-IUPAC
)	382	383	|I-IUPAC
alkoxyalkyl	383	394	|I-IUPAC
or	395	397	|O
(	398	399	|B-IUPAC
10,11	399	404	|I-IUPAC
-	404	405	|I-IUPAC
dihydro	405	412	|I-IUPAC
-	412	413	|I-IUPAC
5H	413	415	|I-IUPAC
-	415	416	|I-IUPAC
dibenzo	416	423	|I-IUPAC
[	423	424	|I-IUPAC
a	424	425	|I-IUPAC
,	425	426	|I-IUPAC
d	426	427	|I-IUPAC
]	427	428	|I-IUPAC
cyclohepten	428	439	|I-IUPAC
-	439	440	|I-IUPAC
5	440	441	|I-IUPAC
-	441	442	|I-IUPAC
ylidene	442	449	|I-IUPAC
)	449	450	|I-IUPAC
alkoxyalkyl	450	461	|I-IUPAC
.	461	462	|O
The	463	466	|O
in	467	469	|O
vitro	470	475	|O
values	476	482	|O
for	483	486	|O
inhibition	487	497	|O
of	498	500	|O
[	501	502	|O
(	502	503	|O
3	503	504	|O
)	504	505	|O
H	505	506	|O
]	506	507	|O
-	507	508	|O
GABA	508	512	|O
uptake	513	519	|O
in	520	522	|O
rat	523	526	|O
synaptosomes	527	539	|O
was	540	543	|O
determined	544	554	|O
for	555	558	|O
each	559	563	|O
compound	564	572	|O
in	573	575	|O
this	576	580	|O
new	581	584	|O
series	585	591	|O
,	591	592	|O
and	593	596	|O
it	597	599	|O
was	600	603	|O
found	604	609	|O
that	610	614	|O
several	615	622	|O
of	623	625	|O
the	626	629	|O
novel	630	635	|O
compounds	636	645	|O
showed	646	652	|O
a	653	654	|O
high	655	659	|O
potency	660	667	|O
comparable	668	678	|O
with	679	683	|O
that	684	688	|O
of	689	691	|O
the	692	695	|O
reference	696	705	|O
compounds	706	715	|O
4	716	717	|O
,	717	718	|O
5	719	720	|O
(	721	722	|O
tiagabine	722	731	|O
)	731	732	|O
,	732	733	|O
and	734	737	|O
6	738	739	|O
(	740	741	|O
CI	741	743	|O
-	743	744	|O
966	744	747	|O
)	747	748	|O
.	748	749	|O
Several	750	757	|O
of	758	760	|O
the	761	764	|O
novel	765	770	|O
compounds	771	780	|O
were	781	785	|O
also	786	790	|O
evaluated	791	800	|O
for	801	804	|O
their	805	810	|O
ability	811	818	|O
in	819	821	|O
vivo	822	826	|O
to	827	829	|O
inhibit	830	837	|O
clonic	838	844	|O
seizures	845	853	|O
induced	854	861	|O
by	862	864	|O
a	865	866	|O
15	867	869	|O
mg	870	872	|O
/	872	873	|O
kg	873	875	|O
(	876	877	|O
ip	877	879	|O
)	879	880	|O
dose	881	885	|O
of	886	888	|O
methyl	889	895	|B-IUPAC
6,7	896	899	|I-IUPAC
-	899	900	|I-IUPAC
dimethoxy	900	909	|I-IUPAC
-	909	910	|I-IUPAC
4	910	911	|I-IUPAC
-	911	912	|I-IUPAC
ethyl	912	917	|I-IUPAC
-	917	918	|I-IUPAC
beta	918	922	|I-IUPAC
-	922	923	|I-IUPAC
carboline	923	932	|I-IUPAC
-	932	933	|I-IUPAC
3	933	934	|I-IUPAC
-	934	935	|I-IUPAC
carboxylate	935	946	|I-IUPAC
(	947	948	|O
DMCM	948	952	|O
)	952	953	|O
.	953	954	|O
One	955	958	|O
compound	959	967	|O
,	967	968	|O
(	969	970	|B-IUPAC
R	970	971	|I-IUPAC
)	971	972	|I-IUPAC
-	972	973	|I-IUPAC
1	973	974	|I-IUPAC
-	974	975	|I-IUPAC
(	975	976	|I-IUPAC
2	976	977	|I-IUPAC
-	977	978	|I-IUPAC
(	978	979	|I-IUPAC
2	979	980	|I-IUPAC
-	980	981	|I-IUPAC
(	981	982	|I-IUPAC
10,11	982	987	|I-IUPAC
-	987	988	|I-IUPAC
dihydro	988	995	|I-IUPAC
-	995	996	|I-IUPAC
5H	996	998	|I-IUPAC
-	998	999	|I-IUPAC
dibenz	999	1005	|I-IUPAC
[	1005	1006	|I-IUPAC
b	1006	1007	|I-IUPAC
,	1007	1008	|I-IUPAC
f	1008	1009	|I-IUPAC
]	1009	1010	|I-IUPAC
azepin	1010	1016	|I-IUPAC
-	1016	1017	|I-IUPAC
5	1017	1018	|I-IUPAC
-	1018	1019	|I-IUPAC
yl	1019	1021	|I-IUPAC
)	1021	1022	|I-IUPAC
ethoxy	1022	1028	|I-IUPAC
)	1028	1029	|I-IUPAC
ethyl	1029	1034	|I-IUPAC
)	1034	1035	|I-IUPAC
-	1035	1036	|I-IUPAC
3	1036	1037	|I-IUPAC
-	1037	1038	|I-IUPAC
piperidinecarboxylic	1038	1058	|I-IUPAC
acid	1059	1063	|I-IUPAC
(	1064	1065	|O
23	1065	1067	|O
)	1067	1068	|O
,	1068	1069	|O
was	1070	1073	|O
selected	1074	1082	|O
for	1083	1086	|O
further	1087	1094	|O
biological	1095	1105	|O
investigations	1106	1120	|O
and	1121	1124	|O
showed	1125	1131	|O
a	1132	1133	|O
protective	1134	1144	|O
index	1145	1150	|O
comparable	1151	1161	|O
to	1162	1164	|O
or	1165	1167	|O
slightly	1168	1176	|O
better	1177	1183	|O
than	1184	1188	|O
that	1189	1193	|O
of	1194	1196	|O
the	1197	1200	|O
recently	1201	1209	|O
launched	1210	1218	|O
anticonvulsant	1219	1233	|O
product	1234	1241	|O
5	1242	1243	|O
(	1244	1245	|O
(	1245	1246	|B-IUPAC
R	1246	1247	|I-IUPAC
)	1247	1248	|I-IUPAC
-	1248	1249	|I-IUPAC
1	1249	1250	|I-IUPAC
-	1250	1251	|I-IUPAC
(	1251	1252	|I-IUPAC
4,4	1252	1255	|I-IUPAC
-	1255	1256	|I-IUPAC
bis	1256	1259	|I-IUPAC
(	1259	1260	|I-IUPAC
3	1260	1261	|I-IUPAC
-	1261	1262	|I-IUPAC
methyl	1262	1268	|I-IUPAC
-	1268	1269	|I-IUPAC
2	1269	1270	|I-IUPAC
-	1270	1271	|I-IUPAC
thienyl	1271	1278	|I-IUPAC
)	1278	1279	|I-IUPAC
-	1279	1280	|I-IUPAC
3	1280	1281	|I-IUPAC
-	1281	1282	|I-IUPAC
butenyl	1282	1289	|I-IUPAC
)	1289	1290	|I-IUPAC
-	1290	1291	|I-IUPAC
3	1291	1292	|I-IUPAC
-	1292	1293	|I-IUPAC
piperidinecarboxylic	1293	1313	|I-IUPAC
acid	1314	1318	|I-IUPAC
)	1318	1319	|O
.	1319	1320	|O

### abstracts4446.txt
In	0	2	|O
order	3	8	|O
to	9	11	|O
study	12	17	|O
the	18	21	|O
structure	22	31	|O
-	31	32	|O
activity	32	40	|O
relationships	41	54	|O
of	55	57	|O
L	58	59	|B-PARTIUPAC
-	59	60	|I-PARTIUPAC
(	60	61	|I-PARTIUPAC
2S	61	63	|I-PARTIUPAC
,	63	64	|I-PARTIUPAC
4S	64	66	|I-PARTIUPAC
)	66	67	|I-PARTIUPAC
-	67	68	|I-PARTIUPAC
and	69	72	|O
L	73	74	|B-IUPAC
-	74	75	|I-IUPAC
(	75	76	|I-IUPAC
2S	76	78	|I-IUPAC
,	78	79	|I-IUPAC
4R	79	81	|I-IUPAC
)	81	82	|I-IUPAC
-	82	83	|I-IUPAC
dioxolanyl	83	93	|I-IUPAC
nucleoside	94	104	|I-IUPAC
as	105	107	|O
potential	108	117	|O
anti	118	122	|O
-	122	123	|O
HIV	123	126	|O
agents	127	133	|O
,	133	134	|O
various	135	142	|O
enantiomerically	143	159	|O
pure	160	164	|O
L	165	166	|B-PARTIUPAC
-	166	167	|I-PARTIUPAC
(	167	168	|I-PARTIUPAC
2S	168	170	|I-PARTIUPAC
,	170	171	|I-PARTIUPAC
4S	171	173	|I-PARTIUPAC
)	173	174	|I-PARTIUPAC
-	174	175	|I-PARTIUPAC
and	176	179	|O
(	180	181	|B-IUPAC
2S	181	183	|I-IUPAC
,	183	184	|I-IUPAC
4R	184	186	|I-IUPAC
)	186	187	|I-IUPAC
-	187	188	|I-IUPAC
dioxolanylpyrimidine	188	208	|I-IUPAC
and	209	212	|O
-	213	214	|B-PARTIUPAC
purine	214	220	|I-PARTIUPAC
nucleosides	221	232	|I-PARTIUPAC
have	233	237	|O
been	238	242	|O
synthesized	243	254	|O
and	255	258	|O
evaluated	259	268	|O
against	269	276	|O
HIV	277	280	|O
-	280	281	|O
1	281	282	|O
in	283	285	|O
human	286	291	|O
peripheral	292	302	|O
blood	303	308	|O
mononuclear	309	320	|O
(	321	322	|O
PBM	322	325	|O
)	325	326	|O
cells	327	332	|O
.	332	333	|O
The	334	337	|O
enantiomerically	338	354	|O
pure	355	359	|O
key	360	363	|O
intermediate	364	376	|O
8	377	378	|O
has	379	382	|O
been	383	387	|O
synthesized	388	399	|O
in	400	402	|O
six	403	406	|O
steps	407	412	|O
from	413	417	|O
1,6	418	421	|B-IUPAC
-	421	422	|I-IUPAC
anhydro	422	429	|I-IUPAC
-	429	430	|I-IUPAC
beta	430	434	|I-IUPAC
-	434	435	|I-IUPAC
L	435	436	|I-IUPAC
-	436	437	|I-IUPAC
gulose	437	443	|I-IUPAC
(	444	445	|O
2	445	446	|O
)	446	447	|O
,	447	448	|O
and	449	452	|O
compound	453	461	|O
8	462	463	|O
was	464	467	|O
condensed	468	477	|O
with	478	482	|O
5	483	484	|B-MODIFIER
-	484	485	|I-MODIFIER
substituted	485	496	|I-MODIFIER
pyrimidines	497	508	|B-IUPAC
,	508	509	|O
6	510	511	|B-IUPAC
-	511	512	|I-IUPAC
chloropurine	512	524	|I-IUPAC
,	524	525	|O
and	526	529	|O
2,6	530	533	|B-MODIFIER
-	533	534	|I-MODIFIER
disubstituted	534	547	|I-MODIFIER
purine	548	554	|B-IUPAC
to	555	557	|O
obtain	558	564	|O
various	565	572	|O
dioxolanylpyrimidine	573	593	|B-IUPAC
and	594	597	|O
-	598	599	|B-PARTIUPAC
purine	599	605	|I-PARTIUPAC
nucleosides	606	617	|I-PARTIUPAC
,	617	618	|O
respectively	619	631	|O
.	631	632	|O
Among	633	638	|O
the	639	642	|O
compound	643	651	|O
synthesized	652	663	|O
,	663	664	|O
5	665	666	|B-IUPAC
-	666	667	|I-IUPAC
fluorocytosine	667	681	|I-IUPAC
derivative	682	692	|B-MODIFIER
29	693	695	|O
was	696	699	|O
found	700	705	|O
to	706	708	|O
exhibit	709	716	|O
the	717	720	|O
most	721	725	|O
potent	726	732	|O
anti	733	737	|O
-	737	738	|O
HIV	738	741	|O
activity	742	750	|O
(	751	752	|O
EC50	752	756	|O
=	757	758	|O
0.0012	759	765	|O
microM	766	772	|O
)	772	773	|O
although	774	782	|O
it	783	785	|O
was	786	789	|O
toxic	790	795	|O
(	796	797	|O
IC50	797	801	|O
=	802	803	|O
10.0	804	808	|O
microM	809	815	|O
)	815	816	|O
.	816	817	|O
The	818	821	|O
order	822	827	|O
of	828	830	|O
anti	831	835	|O
-	835	836	|O
HIV	836	839	|O
potency	840	847	|O
of	848	850	|O
pyrimidine	851	861	|O
analogues	862	871	|O
was	872	875	|O
as	876	878	|O
follows	879	886	|O
:	886	887	|O
5	888	889	|B-IUPAC
-	889	890	|I-IUPAC
fluorocytosine	890	904	|I-IUPAC
(	905	906	|O
beta	906	910	|O
-	910	911	|O
isomer	911	917	|O
)	917	918	|O
&	919	920	|O
gt	920	922	|O
;	922	923	|O
cytosine	924	932	|O
(	933	934	|O
beta	934	938	|O
-	938	939	|O
isomer	939	945	|O
)	945	946	|O
&	947	948	|O
gt	948	950	|O
;	950	951	|O
5	952	953	|B-IUPAC
-	953	954	|I-IUPAC
fluorocytosine	954	968	|I-IUPAC
(	969	970	|O
alpha	970	975	|O
-	975	976	|O
isomer	976	982	|O
)	982	983	|O
&	984	985	|O
gt	985	987	|O
;	987	988	|O
5	989	990	|B-IUPAC
-	990	991	|I-IUPAC
iodocytosine	991	1003	|I-IUPAC
(	1004	1005	|O
beta	1005	1009	|O
-	1009	1010	|O
isomer	1010	1016	|O
)	1016	1017	|O
&	1018	1019	|O
gt	1019	1021	|O
;	1021	1022	|O
cytosine	1023	1031	|O
(	1032	1033	|O
alpha	1033	1038	|O
-	1038	1039	|O
isomer	1039	1045	|O
)	1045	1046	|O
&	1047	1048	|O
gt	1048	1050	|O
;	1050	1051	|O
5	1052	1053	|B-IUPAC
-	1053	1054	|I-IUPAC
bromocytosine	1054	1067	|I-IUPAC
(	1068	1069	|O
beta	1069	1073	|O
-	1073	1074	|O
isomer	1074	1080	|O
)	1080	1081	|O
&	1082	1083	|O
gt	1083	1085	|O
;	1085	1086	|O
thymine	1087	1094	|O
(	1095	1096	|O
beta	1096	1100	|O
-	1100	1101	|O
isomer	1101	1107	|O
)	1107	1108	|O
&	1109	1110	|O
gt	1110	1112	|O
;	1112	1113	|O
5	1114	1115	|B-IUPAC
-	1115	1116	|I-IUPAC
methylcytosine	1116	1130	|I-IUPAC
(	1131	1132	|O
alpha	1132	1137	|O
-	1137	1138	|O
isomer	1138	1144	|O
)	1144	1145	|O
&	1146	1147	|O
gt	1147	1149	|O
;	1149	1150	|O
5	1151	1152	|B-IUPAC
-	1152	1153	|I-IUPAC
iodocytosine	1153	1165	|I-IUPAC
(	1166	1167	|O
alpha	1167	1172	|O
-	1172	1173	|O
isomer	1173	1179	|O
)	1179	1180	|O
&	1181	1182	|O
gt	1182	1184	|O
;	1184	1185	|O
5	1186	1187	|B-IUPAC
-	1187	1188	|I-IUPAC
chlorocytosine	1188	1202	|I-IUPAC
(	1203	1204	|O
beta	1204	1208	|O
-	1208	1209	|O
isomer	1209	1215	|O
)	1215	1216	|O
.	1216	1217	|O
The	1218	1221	|O
anti	1222	1226	|O
-	1226	1227	|O
HIV	1227	1230	|O
potency	1231	1238	|O
of	1239	1241	|O
purine	1242	1248	|O
analogues	1249	1258	|O
was	1259	1262	|O
found	1263	1268	|O
to	1269	1271	|O
be	1272	1274	|O
in	1275	1277	|O
the	1278	1281	|O
following	1282	1291	|O
decreasing	1292	1302	|O
order	1303	1308	|O
:	1308	1309	|O
2,6	1310	1313	|B-IUPAC
-	1313	1314	|I-IUPAC
diaminopurine	1314	1327	|I-IUPAC
(	1328	1329	|O
beta	1329	1333	|O
-	1333	1334	|O
isomer	1334	1340	|O
)	1340	1341	|O
&	1342	1343	|O
gt	1343	1345	|O
;	1345	1346	|O
2	1347	1348	|B-IUPAC
-	1348	1349	|I-IUPAC
chloroadenine	1349	1362	|I-IUPAC
(	1363	1364	|O
alpha	1364	1369	|O
-	1369	1370	|O
isomer	1370	1376	|O
)	1376	1377	|O
&	1378	1379	|O
gt	1379	1381	|O
;	1381	1382	|O
2	1383	1384	|B-IUPAC
-	1384	1385	|I-IUPAC
fluoroadenine	1385	1398	|I-IUPAC
(	1399	1400	|O
beta	1400	1404	|O
-	1404	1405	|O
isomer	1405	1411	|O
)	1411	1412	|O
&	1413	1414	|O
gt	1414	1416	|O
;	1416	1417	|O
adenine	1418	1425	|O
(	1426	1427	|O
beta	1427	1431	|O
-	1431	1432	|O
isomer	1432	1438	|O
)	1438	1439	|O
&	1440	1441	|O
gt	1441	1443	|O
;	1443	1444	|O
2	1445	1446	|B-IUPAC
-	1446	1447	|I-IUPAC
amino	1447	1452	|I-IUPAC
-	1452	1453	|I-IUPAC
6	1453	1454	|I-IUPAC
-	1454	1455	|I-IUPAC
chloropurine	1455	1467	|I-IUPAC
(	1468	1469	|O
alpha	1469	1474	|O
-	1474	1475	|O
isomer	1475	1481	|O
)	1481	1482	|O
&	1483	1484	|O
gt	1484	1486	|O
;	1486	1487	|O
2	1488	1489	|B-IUPAC
-	1489	1490	|I-IUPAC
amino	1490	1495	|I-IUPAC
-	1495	1496	|I-IUPAC
6	1496	1497	|I-IUPAC
-	1497	1498	|I-IUPAC
chloropurine	1498	1510	|I-IUPAC
(	1511	1512	|O
beta	1512	1516	|O
-	1516	1517	|O
isomer	1517	1523	|O
)	1523	1524	|O
&	1525	1526	|O
gt	1526	1528	|O
;	1528	1529	|O
guanine	1530	1537	|O
(	1538	1539	|O
beta	1539	1543	|O
-	1543	1544	|O
isomer	1544	1550	|O
)	1550	1551	|O
&	1552	1553	|O
gt	1553	1555	|O
;	1555	1556	|O
2	1557	1558	|B-IUPAC
-	1558	1559	|I-IUPAC
fluoroadenine	1559	1572	|I-IUPAC
(	1573	1574	|O
alpha	1574	1579	|O
-	1579	1580	|O
isomer	1580	1586	|O
)	1586	1587	|O
&	1588	1589	|O
gt	1589	1591	|O
;	1591	1592	|O
adenine	1593	1600	|O
(	1601	1602	|O
alpha	1602	1607	|O
-	1607	1608	|O
isomer	1608	1614	|O
)	1614	1615	|O
&	1616	1617	|O
gt	1617	1619	|O
;	1619	1620	|O
2,6	1621	1624	|B-IUPAC
-	1624	1625	|I-IUPAC
diaminopurine	1625	1638	|I-IUPAC
(	1639	1640	|O
alpha	1640	1645	|O
-	1645	1646	|O
isomer	1646	1652	|O
)	1652	1653	|O
&	1654	1655	|O
gt	1655	1657	|O
;	1657	1658	|O
N6	1659	1661	|B-IUPAC
-	1661	1662	|I-IUPAC
methyladenine	1662	1675	|I-IUPAC
(	1676	1677	|O
beta	1677	1681	|O
-	1681	1682	|O
isomer	1682	1688	|O
)	1688	1689	|O
.	1689	1690	|O
It	1691	1693	|O
is	1694	1696	|O
interesting	1697	1708	|O
to	1709	1711	|O
note	1712	1716	|O
that	1717	1721	|O
the	1722	1725	|O
alpha	1726	1731	|B-IUPAC
-	1731	1732	|I-IUPAC
5	1732	1733	|I-IUPAC
-	1733	1734	|I-IUPAC
fluorocytosine	1734	1748	|I-IUPAC
analogue	1749	1757	|B-MODIFIER
exhibited	1758	1767	|O
an	1768	1770	|O
excellent	1771	1780	|O
anti	1781	1785	|O
-	1785	1786	|O
HIV	1786	1789	|O
activity	1790	1798	|O
(	1799	1800	|O
EC50	1800	1804	|O
=	1805	1806	|O
0.063	1807	1812	|O
microM	1813	1819	|O
)	1819	1820	|O
without	1821	1828	|O
cytotoxicity	1829	1841	|O
up	1842	1844	|O
to	1845	1847	|O
100	1848	1851	|O
microM	1852	1858	|O
in	1859	1861	|O
PBM	1862	1865	|O
cell	1866	1870	|O
.	1870	1871	|O

### abstracts1703.txt
As	0	2	|O
shown	3	8	|O
by	9	11	|O
structure	12	21	|O
-	21	22	|O
activity	22	30	|O
relationship	31	43	|O
studies	44	51	|O
in	52	54	|O
8	55	56	|B-IUPAC
-	56	57	|I-IUPAC
(	57	58	|I-IUPAC
substituted	58	69	|I-IUPAC
-	69	70	|I-IUPAC
amino	70	75	|I-IUPAC
)	75	76	|I-IUPAC
-	76	77	|I-IUPAC
4	77	78	|I-IUPAC
-	78	79	|I-IUPAC
aryl	79	83	|I-IUPAC
-	83	84	|I-IUPAC
2	84	85	|I-IUPAC
-	85	86	|I-IUPAC
methyl	86	92	|I-IUPAC
-	92	93	|I-IUPAC
1,2,3,4	93	100	|I-IUPAC
-	100	101	|I-IUPAC
tetrahydroisoquinolines	101	124	|I-IUPAC
,	124	125	|O
the	126	129	|O
most	130	134	|O
important	135	144	|O
structural	145	155	|O
requirement	156	167	|O
for	168	171	|O
a	172	173	|O
marked	174	180	|O
antidepressant	181	195	|O
action	196	202	|O
is	203	205	|O
the	206	209	|O
presence	210	218	|O
of	219	221	|O
an	222	224	|O
ureido	225	231	|B-IUPAC
,	231	232	|O
(	233	234	|B-IUPAC
alkoxycarbonyl	234	248	|I-IUPAC
)	248	249	|I-IUPAC
amino	249	254	|I-IUPAC
,	254	255	|O
or	256	258	|O
[	259	260	|B-IUPAC
(	260	261	|I-IUPAC
alkylamino	261	271	|I-IUPAC
)	271	272	|I-IUPAC
acyl	272	276	|I-IUPAC
]	276	277	|I-IUPAC
amino	277	282	|I-IUPAC
group	283	288	|B-MODIFIER
attached	289	297	|O
to	298	300	|O
the	301	304	|O
isoquinoline	305	317	|O
skeleton	318	326	|O
in	327	329	|O
position	330	338	|O
8	339	340	|O
.	340	341	|O
In	342	344	|O
one	345	348	|O
of	349	351	|O
the	352	355	|O
biological	356	366	|O
tests	367	372	|O
a	373	374	|O
significant	375	386	|O
difference	387	397	|O
was	398	401	|O
found	402	407	|O
between	408	415	|O
8	416	417	|B-IUPAC
-	417	418	|I-IUPAC
amino	418	423	|I-IUPAC
-	423	424	|I-IUPAC
4	424	425	|I-IUPAC
-	425	426	|I-IUPAC
phenyl	426	432	|I-IUPAC
-	432	433	|I-IUPAC
2	433	434	|I-IUPAC
-	434	435	|I-IUPAC
methyl	435	441	|I-IUPAC
-	441	442	|I-IUPAC
1,2,3,4	442	449	|I-IUPAC
-	449	450	|I-IUPAC
tetrahydroisoquinoline	450	472	|I-IUPAC
(	473	474	|O
nomifensine	474	485	|O
)	485	486	|O
and	487	490	|O
the	491	494	|O
new	495	498	|O
compounds	499	508	|O
synthesized	509	520	|O
.	520	521	|O
Nearly	522	528	|O
all	529	532	|O
compounds	533	542	|O
substituted	543	554	|O
in	555	557	|O
the	558	561	|O
amino	562	567	|O
group	568	573	|O
either	574	580	|O
decrease	581	589	|O
the	590	593	|O
spontaneous	594	605	|O
motility	606	614	|O
in	615	617	|O
mice	618	622	|O
or	623	625	|O
exert	626	631	|O
no	632	634	|O
effect	635	641	|O
on	642	644	|O
it	645	647	|O
.	647	648	|O
Two	649	652	|O
syntheses	653	662	|O
have	663	667	|O
been	668	672	|O
elaborated	673	683	|O
for	684	687	|O
the	688	691	|O
preparation	692	703	|O
of	704	706	|O
the	707	710	|O
compounds	711	720	|O
represented	721	732	|O
by	733	735	|O
the	736	739	|O
general	740	747	|O
formulas	748	756	|O
II	757	759	|O
-	759	760	|O
V	760	761	|O
where	762	767	|O
R1	768	770	|O
=	771	772	|O
hydrogen	773	781	|O
,	781	782	|O
halogen	783	790	|O
,	790	791	|O
or	792	794	|O
methyl	795	801	|B-IUPAC
;	801	802	|O
Y	803	804	|O
=	805	806	|O
CONHR	807	812	|O
,	812	813	|O
OCOR	814	818	|O
,	818	819	|O
or	820	822	|O
CO	823	825	|O
(	825	826	|O
CH2	826	829	|O
)	829	830	|O
nNHR	830	834	|O
,	834	835	|O
in	836	838	|O
which	839	844	|O
R	845	846	|O
=	847	848	|O
alkyl	849	854	|O
or	855	857	|O
aralkyl	858	865	|O
or	866	868	|O
NHR	869	872	|O
=	873	874	|O
cyclic	875	881	|O
amine	882	887	|O
and	888	891	|O
n	892	893	|O
=	894	895	|O
1-2	896	899	|O
.	899	900	|O
The	901	904	|O
syntheses	905	914	|O
start	915	920	|O
either	921	927	|O
from	928	932	|O
the	933	936	|O
corresponding	937	950	|O
8	951	952	|B-IUPAC
-	952	953	|I-IUPAC
amino	953	958	|I-IUPAC
-	958	959	|I-IUPAC
4	959	960	|I-IUPAC
-	960	961	|I-IUPAC
aryl	961	965	|I-IUPAC
-	965	966	|I-IUPAC
2	966	967	|I-IUPAC
-	967	968	|I-IUPAC
methyl	968	974	|I-IUPAC
-	974	975	|I-IUPAC
1,2,3,4	975	982	|I-IUPAC
-	982	983	|I-IUPAC
tetrahydroisoquinolines	983	1006	|I-IUPAC
or	1007	1009	|O
from	1010	1014	|O
the	1015	1018	|O
corresponding	1019	1032	|O
noncyclized	1033	1044	|O
amino	1045	1050	|O
alcohols	1051	1059	|O
.	1059	1060	|O
Of	1061	1063	|O
the	1064	1067	|O
compounds	1068	1077	|O
,	1077	1078	|O
4	1079	1080	|B-IUPAC
-	1080	1081	|I-IUPAC
(	1081	1082	|I-IUPAC
p	1082	1083	|I-IUPAC
-	1083	1084	|I-IUPAC
chlorophenyl	1084	1096	|I-IUPAC
)	1096	1097	|I-IUPAC
-	1097	1098	|I-IUPAC
8	1098	1099	|I-IUPAC
-	1099	1100	|I-IUPAC
[	1100	1101	|I-IUPAC
(	1101	1102	|I-IUPAC
ethoxy	1102	1108	|I-IUPAC
-	1108	1109	|I-IUPAC
carbonyl	1109	1117	|I-IUPAC
)	1117	1118	|I-IUPAC
amino	1118	1123	|I-IUPAC
]	1123	1124	|I-IUPAC
-	1124	1125	|I-IUPAC
2	1125	1126	|I-IUPAC
-	1126	1127	|I-IUPAC
methyl	1127	1133	|I-IUPAC
-	1133	1134	|I-IUPAC
1,2,3,4	1134	1141	|I-IUPAC
-	1141	1142	|I-IUPAC
tetrahydroisoquinoline	1143	1165	|I-IUPAC
was	1166	1169	|O
found	1170	1175	|O
to	1176	1178	|O
possess	1179	1186	|O
the	1187	1190	|O
highest	1191	1198	|O
activity	1199	1207	|O
.	1207	1208	|O

### abstracts1887.txt
As	0	2	|O
part	3	7	|O
of	8	10	|O
an	11	13	|O
effort	14	20	|O
to	21	23	|O
develop	24	31	|O
a	32	33	|O
new	34	37	|O
class	38	43	|O
of	44	46	|O
subtype	47	54	|O
selective	55	64	|O
nicotine	65	73	|O
agonists	74	82	|O
,	82	83	|O
we	84	86	|O
have	87	91	|O
synthesized	92	103	|O
and	104	107	|O
tested	108	114	|O
a	115	116	|O
group	117	122	|O
of	123	125	|O
12	126	128	|O
hydroxylated	129	141	|O
2	142	143	|B-PARTIUPAC
-	143	144	|I-PARTIUPAC
(	144	145	|I-PARTIUPAC
2	145	146	|I-PARTIUPAC
-	146	147	|I-PARTIUPAC
piperidyl	147	156	|I-PARTIUPAC
)	156	157	|I-PARTIUPAC
-	157	158	|I-PARTIUPAC
and	159	162	|O
2	163	164	|B-IUPAC
-	164	165	|I-IUPAC
(	165	166	|I-IUPAC
2	166	167	|I-IUPAC
-	167	168	|I-IUPAC
pyrrolidyl	168	178	|I-IUPAC
)	178	179	|I-IUPAC
chromans	179	187	|I-IUPAC
.	187	188	|O
In	189	191	|O
rat	192	195	|O
brain	196	201	|O
membranes	202	211	|O
,	211	212	|O
all	213	216	|O
12	217	219	|O
compounds	220	229	|O
displayed	230	239	|O
poor	240	244	|O
affinity	245	253	|O
for	254	257	|O
[	258	259	|O
(	259	260	|O
125	260	263	|O
)	263	264	|O
I	264	265	|O
]	265	266	|O
-	266	267	|O
alpha	267	272	|O
-	272	273	|O
bunagarotoxin	273	286	|O
binding	287	294	|O
sites	295	300	|O
.	300	301	|O
In	302	304	|O
contrast	305	313	|O
,	313	314	|O
three	315	320	|O
compounds	321	330	|O
,	330	331	|O
17c	332	335	|O
,	335	336	|O
24	337	339	|O
,	339	340	|O
and	341	344	|O
26	345	347	|O
,	347	348	|O
displayed	349	358	|O
moderate	359	367	|O
to	368	370	|O
high	371	375	|O
affinity	376	384	|O
for	385	388	|O
[	389	390	|O
(	390	391	|O
3	391	392	|O
)	392	393	|O
H	393	394	|O
]	394	395	|O
cytisine	395	403	|O
binding	404	411	|O
sites	412	417	|O
,	417	418	|O
while	419	424	|O
three	425	430	|O
(	431	432	|O
17b	432	435	|O
,	435	436	|O
18b	437	440	|O
,	440	441	|O
c	441	442	|O
)	442	443	|O
and	444	447	|O
six	448	451	|O
(	452	453	|O
17a	453	456	|O
,	456	457	|O
d	457	458	|O
,	458	459	|O
e	459	460	|O
and	461	464	|O
18a	465	468	|O
,	468	469	|O
d	469	470	|O
,	470	471	|O
e	471	472	|O
)	472	473	|O
compounds	474	483	|O
showed	484	490	|O
weak	491	495	|O
and	496	499	|O
poor	500	504	|O
affinity	505	513	|O
,	513	514	|O
respectively	515	527	|O
,	527	528	|O
for	529	532	|O
these	533	538	|O
same	539	543	|O
sites	544	549	|O
.	549	550	|O
In	551	553	|O
subsequent	554	564	|O
studies	565	572	|O
,	572	573	|O
compounds	574	583	|O
17a	584	587	|O
and	588	591	|O
17c	592	595	|O
were	596	600	|O
found	601	606	|O
to	607	609	|O
stimulate	610	619	|O
the	620	623	|O
efflux	624	630	|O
of	631	633	|O
(	634	635	|O
86	635	637	|O
)	637	638	|O
Rb	638	640	|O
(	640	641	|O
+	641	642	|O
)	642	643	|O
from	644	648	|O
rat	649	652	|O
cortical	653	661	|O
synaptosomes	662	674	|O
,	674	675	|O
an	676	678	|O
indication	679	689	|O
of	690	692	|O
agonist	693	700	|O
activity	701	709	|O
.	709	710	|O
Further	711	718	|O
,	718	719	|O
both	720	724	|O
17c	725	728	|O
and	729	732	|O
26	733	735	|O
displayed	736	745	|O
high	746	750	|O
intrinsic	751	760	|O
activity	761	769	|O
in	770	772	|O
stimulating	773	784	|O
the	785	788	|O
release	789	796	|O
of	797	799	|O
[	800	801	|O
(	801	802	|O
3	802	803	|O
)	803	804	|O
H	804	805	|O
]	805	806	|O
dopamine	806	814	|O
from	815	819	|O
striatal	820	828	|O
synaptosomes	829	841	|O
;	841	842	|O
however	843	850	|O
,	850	851	|O
only	852	856	|O
17c	857	860	|O
was	861	864	|O
effective	865	874	|O
at	875	877	|O
stimulating	878	889	|O
the	890	893	|O
release	894	901	|O
of	902	904	|O
[	905	906	|O
(	906	907	|O
3	907	908	|O
)	908	909	|O
H	909	910	|O
]	910	911	|O
acetylcholine	911	924	|O
from	925	929	|O
cortical	930	938	|O
synaptosomes	939	951	|O
,	951	952	|O
suggesting	953	963	|O
differential	964	976	|O
selectivity	977	988	|O
.	988	989	|O
In	990	992	|O
cloned	993	999	|O
human	1000	1005	|O
nicotinic	1006	1015	|O
acetylcholine	1016	1029	|O
receptors	1030	1039	|O
(	1040	1041	|O
nAChR	1041	1046	|O
)	1046	1047	|O
expressed	1048	1057	|O
in	1058	1060	|O
Xenopus	1061	1068	|O
oocytes	1069	1076	|O
,	1076	1077	|O
both	1078	1082	|O
17c	1083	1086	|O
and	1087	1090	|O
26	1091	1093	|O
activated	1094	1103	|O
alpha7	1104	1110	|O
and	1111	1114	|O
alpha3beta2	1115	1126	|O
receptor	1127	1135	|O
subtypes	1136	1144	|O
in	1145	1147	|O
a	1148	1149	|O
dose	1150	1154	|O
-	1154	1155	|O
dependent	1155	1164	|O
manner	1165	1171	|O
,	1171	1172	|O
but	1173	1176	|O
26	1177	1179	|O
was	1180	1183	|O
clearly	1184	1191	|O
the	1192	1195	|O
more	1196	1200	|O
potent	1201	1207	|O
agonist	1208	1215	|O
.	1215	1216	|O
Last	1217	1221	|O
,	1221	1222	|O
neither	1223	1230	|O
compound	1231	1239	|O
displayed	1240	1249	|O
dose	1250	1254	|O
-	1254	1255	|O
dependent	1255	1264	|O
activation	1265	1275	|O
of	1276	1278	|O
alpha4beta2	1279	1290	|O
nAChRs	1291	1297	|O
.	1297	1298	|O
We	1299	1301	|O
conclude	1302	1310	|O
that	1311	1315	|O
2	1316	1317	|B-IUPAC
-	1317	1318	|I-IUPAC
(	1318	1319	|I-IUPAC
2	1319	1320	|I-IUPAC
-	1320	1321	|I-IUPAC
azacyclic	1321	1330	|I-IUPAC
)	1330	1331	|I-IUPAC
chromans	1331	1339	|I-IUPAC
appear	1340	1346	|O
to	1347	1349	|O
be	1350	1352	|O
a	1353	1354	|O
promising	1355	1364	|O
new	1365	1368	|O
class	1369	1374	|O
of	1375	1377	|O
nicotine	1378	1386	|O
agonists	1387	1395	|O
.	1395	1396	|O

### abstracts540.txt
In	0	2	|O
this	3	7	|O
paper	8	13	|O
,	13	14	|O
it	15	17	|O
is	18	20	|O
hypothesized	21	33	|O
that	34	38	|O
the	39	42	|O
distinction	43	54	|O
between	55	62	|O
certain	63	70	|O
active	71	77	|O
and	78	81	|O
inactive	82	90	|O
cannabinoids	91	103	|O
is	104	106	|O
that	107	111	|O
the	112	115	|O
inactive	116	124	|O
analogs	125	132	|O
possess	133	140	|O
extra	141	146	|O
volume	147	153	|O
associated	154	164	|O
with	165	169	|O
their	170	175	|O
carbocyclic	176	187	|O
rings	188	193	|O
that	194	198	|O
may	199	202	|O
be	203	205	|O
responsible	206	217	|O
for	218	221	|O
an	222	224	|O
unfavorable	225	236	|O
interaction	237	248	|O
at	249	251	|O
the	252	255	|O
cannabinoid	256	267	|O
receptor	268	276	|O
.	276	277	|O
Using	278	283	|O
the	284	287	|O
active	288	294	|O
analog	295	301	|O
approach	302	310	|O
,	310	311	|O
a	312	313	|O
model	314	319	|O
is	320	322	|O
developed	323	332	|O
of	333	335	|O
a	336	337	|O
region	338	344	|O
of	345	347	|O
steric	348	354	|O
interference	355	367	|O
at	368	370	|O
this	371	375	|O
receptor	376	384	|O
using	385	390	|O
the	391	394	|O
active	395	401	|O
cannabinoids	402	414	|O
(	415	416	|B-IUPAC
-	416	417	|I-IUPAC
)	417	418	|I-IUPAC
-	418	419	|I-IUPAC
trans	419	424	|I-IUPAC
-	424	425	|I-IUPAC
delta	425	430	|I-IUPAC
9	431	432	|I-IUPAC
-	432	433	|I-IUPAC
tetrahydrocannabinol	433	453	|I-IUPAC
,	453	454	|O
(	455	456	|B-IUPAC
-	456	457	|I-IUPAC
)	457	458	|I-IUPAC
-	458	459	|I-IUPAC
trans	459	464	|I-IUPAC
-	464	465	|I-IUPAC
delta	465	470	|I-IUPAC
8	471	472	|I-IUPAC
-	472	473	|I-IUPAC
tetrahydrocannabinol	473	493	|I-IUPAC
,	493	494	|O
(	495	496	|B-IUPAC
-	496	497	|I-IUPAC
)	497	498	|I-IUPAC
-	498	499	|I-IUPAC
11	499	501	|I-IUPAC
-	501	502	|I-IUPAC
hydroxy	502	509	|I-IUPAC
-	509	510	|I-IUPAC
beta	510	514	|I-IUPAC
-	514	515	|I-IUPAC
hexahydrocannabinol	515	534	|I-IUPAC
,	534	535	|O
and	536	539	|O
a	540	541	|O
(	542	543	|B-IUPAC
-	543	544	|I-IUPAC
)	544	545	|I-IUPAC
-	545	546	|I-IUPAC
trans	546	551	|I-IUPAC
-	551	552	|I-IUPAC
11	552	554	|I-IUPAC
-	554	555	|I-IUPAC
hydroxy	555	562	|I-IUPAC
-	562	563	|I-IUPAC
delta	563	568	|I-IUPAC
8	569	570	|I-IUPAC
-	570	571	|I-IUPAC
tetrahydrocannabinol	571	591	|I-IUPAC
dimethylheptyl	592	606	|I-IUPAC
derivative	607	617	|B-MODIFIER
and	618	621	|O
the	622	625	|O
inactive	626	634	|O
cannabinoids	635	647	|O
(	648	649	|B-IUPAC
9S	649	651	|I-IUPAC
,	651	652	|I-IUPAC
6aR	652	655	|I-IUPAC
)	655	656	|I-IUPAC
-	656	657	|I-IUPAC
trans	657	662	|I-IUPAC
-	662	663	|I-IUPAC
delta	663	668	|I-IUPAC
10,10	669	674	|I-IUPAC
a	674	675	|I-IUPAC
-	675	676	|I-IUPAC
tetrahydrocannabinol	676	696	|I-IUPAC
and	697	700	|O
a	701	702	|O
(	703	704	|B-IUPAC
+	704	705	|I-IUPAC
)	705	706	|I-IUPAC
-	706	707	|I-IUPAC
trans	707	712	|I-IUPAC
-	712	713	|I-IUPAC
11	713	715	|I-IUPAC
-	715	716	|I-IUPAC
hydroxy	716	723	|I-IUPAC
-	723	724	|I-IUPAC
delta	724	729	|I-IUPAC
8	730	731	|I-IUPAC
-	731	732	|I-IUPAC
tetrahydrocannabinol	732	752	|I-IUPAC
dimethylheptyl	753	767	|I-IUPAC
derivative	768	778	|B-MODIFIER
.	778	779	|O
Each	780	784	|O
of	785	787	|O
these	788	793	|O
molecules	794	803	|O
satisfy	804	811	|O
the	812	815	|O
cannabinoid	816	827	|O
pharmacophoric	828	842	|O
requirements	843	855	|O
,	855	856	|O
i.e.	857	861	|O
,	861	862	|O
a	863	864	|O
phenolic	865	873	|O
oxygen	874	880	|O
at	881	883	|O
C1	884	886	|O
and	887	890	|O
a	891	892	|O
side	893	897	|O
chain	898	903	|O
of	904	906	|O
acceptable	907	917	|O
length	918	924	|O
at	925	927	|O
C3	928	930	|O
.	930	931	|O
Accessible	932	942	|O
conformers	943	953	|O
of	954	956	|O
each	957	961	|O
molecule	962	970	|O
were	971	975	|O
identified	976	986	|O
by	987	989	|O
using	990	995	|O
the	996	999	|O
method	1000	1006	|O
of	1007	1009	|O
molecular	1010	1019	|O
mechanics	1020	1029	|O
as	1030	1032	|O
encoded	1033	1040	|O
in	1041	1043	|O
the	1044	1047	|O
MMP2	1048	1052	|O
(	1052	1053	|O
85	1053	1055	|O
)	1055	1056	|O
program	1057	1064	|O
.	1064	1065	|O
The	1066	1069	|O
MAP	1070	1073	|O
facility	1074	1082	|O
within	1083	1089	|O
the	1090	1093	|O
Chem	1094	1098	|O
-	1098	1099	|O
X	1099	1100	|O
molecular	1101	1110	|O
modeling	1111	1119	|O
program	1120	1127	|O
was	1128	1131	|O
then	1132	1136	|O
used	1137	1141	|O
to	1142	1144	|O
calculate	1145	1154	|O
the	1155	1158	|O
region	1159	1165	|O
of	1166	1168	|O
steric	1169	1175	|O
interference	1176	1188	|O
(	1189	1190	|O
termed	1190	1196	|O
the	1197	1200	|O
receptor	1201	1209	|O
essential	1210	1219	|O
volume	1220	1226	|O
,	1226	1227	|O
REV	1228	1231	|O
)	1231	1232	|O
from	1233	1237	|O
these	1238	1243	|O
accessible	1244	1254	|O
conformers	1255	1265	|O
.	1265	1266	|O
The	1267	1270	|O
calculations	1271	1283	|O
revealed	1284	1292	|O
an	1293	1295	|O
REV	1296	1299	|O
region	1300	1306	|O
located	1307	1314	|O
near	1315	1319	|O
the	1320	1323	|O
top	1324	1327	|O
of	1328	1330	|O
the	1331	1334	|O
carbocyclic	1335	1346	|O
ring	1347	1351	|O
in	1352	1354	|O
the	1355	1358	|O
bottom	1359	1365	|O
face	1366	1370	|O
of	1371	1373	|O
the	1374	1377	|O
molecule	1378	1386	|O
.	1386	1387	|O
In	1388	1390	|O
order	1391	1396	|O
to	1397	1399	|O
explore	1400	1407	|O
the	1408	1411	|O
use	1412	1415	|O
of	1416	1418	|O
this	1419	1423	|O
REV	1424	1427	|O
to	1428	1430	|O
account	1431	1438	|O
for	1439	1442	|O
the	1443	1446	|O
activities	1447	1457	|O
of	1458	1460	|O
other	1461	1466	|O
cannabinoids	1467	1479	|O
,	1479	1480	|O
the	1481	1484	|O
minimally	1485	1494	|O
active	1495	1501	|O
classical	1502	1511	|O
cannabinoid	1512	1523	|O
(	1524	1525	|B-IUPAC
-	1525	1526	|I-IUPAC
)	1526	1527	|I-IUPAC
-	1527	1528	|I-IUPAC
11	1528	1530	|I-IUPAC
-	1530	1531	|I-IUPAC
hydroxy	1531	1538	|I-IUPAC
-	1538	1539	|I-IUPAC
alpha	1539	1544	|I-IUPAC
-	1544	1545	|I-IUPAC
hexahydrocannabinol	1545	1564	|I-IUPAC
,	1564	1565	|O
an	1566	1568	|O
active	1569	1575	|O
benzofuran	1576	1586	|O
cannabinoid	1587	1598	|O
,	1598	1599	|O
and	1600	1603	|O
the	1604	1607	|O
active	1608	1614	|O
nonclassical	1615	1627	|O
cannabinoid	1628	1639	|O
CP	1640	1642	|O
-	1642	1643	|O
47,497	1643	1649	|O
were	1650	1654	|O
then	1655	1659	|O
studied	1660	1667	|O
.	1667	1668	|O
In	1669	1671	|O
each	1672	1676	|O
case	1677	1681	|O
,	1681	1682	|O
the	1683	1686	|O
activity	1687	1695	|O
or	1696	1698	|O
minimal	1699	1706	|O
activity	1707	1715	|O
of	1716	1718	|O
each	1719	1723	|O
compound	1724	1732	|O
can	1733	1736	|O
be	1737	1739	|O
explained	1740	1749	|O
on	1750	1752	|O
the	1753	1756	|O
basis	1757	1762	|O
of	1763	1765	|O
the	1766	1769	|O
ability	1770	1777	|O
of	1778	1780	|O
one	1781	1784	|O
or	1785	1787	|O
more	1788	1792	|O
accessible	1793	1803	|O
conformer	1804	1813	|O
of	1814	1816	|O
each	1817	1821	|O
molecule	1822	1830	|O
to	1831	1833	|O
clear	1834	1839	|O
the	1840	1843	|O
REV	1844	1847	|O
calculated	1848	1858	|O
here	1859	1863	|O
.	1863	1864	|O
The	1865	1868	|O
results	1869	1876	|O
of	1877	1879	|O
this	1880	1884	|O
study	1885	1890	|O
provide	1891	1898	|O
an	1899	1901	|O
explanation	1902	1913	|O
at	1914	1916	|O
the	1917	1920	|O
molecular	1921	1930	|O
level	1931	1936	|O
for	1937	1940	|O
observed	1941	1949	|O
activity	1950	1958	|O
differences	1959	1970	|O
between	1971	1978	|O
cannabinoids	1979	1991	|O
that	1992	1996	|O
exhibit	1997	2004	|O
shape	2005	2010	|O
differences	2011	2022	|O
associated	2023	2033	|O
with	2034	2038	|O
their	2039	2044	|O
carbocyclic	2045	2056	|O
rings	2057	2062	|O
.	2062	2063	|O

### abstracts2075.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
functionalized	12	26	|O
congeners	27	36	|O
of	37	39	|O
1,3	40	43	|B-IUPAC
-	43	44	|I-IUPAC
dialkylxanthines	44	60	|I-IUPAC
has	61	64	|O
been	65	69	|O
prepared	70	78	|O
as	79	81	|O
adenosine	82	91	|O
receptor	92	100	|O
antagonists	101	112	|O
.	112	113	|O
On	114	116	|O
the	117	120	|O
basis	121	126	|O
of	127	129	|O
the	130	133	|O
high	134	138	|O
potency	139	146	|O
of	147	149	|O
8	150	151	|B-IUPAC
-	151	152	|I-IUPAC
(	152	153	|I-IUPAC
p	153	154	|I-IUPAC
-	154	155	|I-IUPAC
hydroxyphenyl	155	168	|I-IUPAC
)	168	169	|I-IUPAC
-	169	170	|I-IUPAC
1,3	170	173	|I-IUPAC
-	173	174	|I-IUPAC
dialkylxanthines	174	190	|I-IUPAC
,	190	191	|O
the	192	195	|O
parent	196	202	|O
compounds	203	212	|O
were	213	217	|O
8	218	219	|B-IUPAC
-	219	220	|I-IUPAC
[	220	221	|I-IUPAC
4	221	222	|I-IUPAC
-	222	223	|I-IUPAC
[	223	224	|I-IUPAC
(	224	225	|I-IUPAC
carboxymethyl	225	238	|I-IUPAC
)	238	239	|I-IUPAC
oxy	239	242	|I-IUPAC
]	242	243	|I-IUPAC
phenyl	243	249	|I-IUPAC
]	249	250	|I-IUPAC
derivatives	251	262	|B-MODIFIER
of	263	265	|O
theophylline	266	278	|O
and	279	282	|O
1,3	283	286	|B-IUPAC
-	286	287	|I-IUPAC
dipropylxanthine	287	303	|I-IUPAC
.	303	304	|O
A	305	306	|O
series	307	313	|O
of	314	316	|O
analogues	317	326	|O
including	327	336	|O
esters	337	343	|O
of	344	346	|O
ethanol	347	354	|O
and	355	358	|O
N	359	360	|B-IUPAC
-	360	361	|I-IUPAC
hydroxysuccinimide	361	379	|I-IUPAC
,	379	380	|O
amides	381	387	|O
,	387	388	|O
a	389	390	|O
hydrazide	391	400	|O
,	400	401	|O
an	402	404	|O
acylurea	405	413	|O
,	413	414	|O
and	415	418	|O
anilides	419	427	|O
were	428	432	|O
prepared	433	441	|O
.	441	442	|O
The	443	446	|O
potency	447	454	|O
in	455	457	|O
blocking	458	466	|O
A1	467	469	|O
-	469	470	|O
adenosine	470	479	|O
receptors	480	489	|O
(	490	491	|O
inhibition	491	501	|O
of	502	504	|O
binding	505	512	|O
of	513	515	|O
N6	516	518	|B-IUPAC
-	518	519	|I-IUPAC
[	519	520	|I-IUPAC
3H	520	522	|I-IUPAC
]	522	523	|I-IUPAC
cyclohexyladenosine	523	542	|I-IUPAC
to	543	545	|O
brain	546	551	|O
membranes	552	561	|O
)	561	562	|O
and	563	566	|O
A2	567	569	|O
-	569	570	|O
adenosine	570	579	|O
receptors	580	589	|O
(	590	591	|O
inhibition	591	601	|O
of	602	604	|O
2	605	606	|B-IUPAC
-	606	607	|I-IUPAC
chloroadenosine	607	622	|I-IUPAC
-	622	623	|O
elicited	623	631	|O
accumulations	632	645	|O
of	646	648	|O
cyclic	649	655	|O
AMP	656	659	|O
in	660	662	|O
brain	663	668	|O
slices	669	675	|O
)	675	676	|O
was	677	680	|O
markedly	681	689	|O
affected	690	698	|O
by	699	701	|O
structural	702	712	|O
changes	713	720	|O
distal	721	727	|O
to	728	730	|O
the	731	734	|O
primary	735	742	|O
pharmacophore	743	756	|O
(	757	758	|O
8	758	759	|B-IUPAC
-	759	760	|I-IUPAC
phenyl	760	766	|I-IUPAC
-	766	767	|I-IUPAC
1,3	767	770	|I-IUPAC
-	770	771	|I-IUPAC
dialkylxanthine	771	786	|I-IUPAC
)	786	787	|O
.	787	788	|O
Potencies	789	798	|O
in	799	801	|O
the	802	805	|O
dipropyl	806	814	|B-IUPAC
series	815	821	|B-MODIFIER
at	822	824	|O
the	825	828	|O
A1	829	831	|O
receptor	832	840	|O
ranged	841	847	|O
from	848	852	|O
Ki	853	855	|O
values	856	862	|O
of	863	865	|O
1.2	866	869	|O
nM	870	872	|O
for	873	876	|O
a	877	878	|O
congener	879	887	|O
with	888	892	|O
a	893	894	|O
terminal	895	903	|O
amidoethyleneamine	904	922	|B-IUPAC
moiety	923	929	|B-MODIFIER
to	930	932	|O
a	933	934	|O
Ki	935	937	|O
value	938	943	|O
of	944	946	|O
58	947	949	|O
nM	950	952	|O
for	953	956	|O
the	957	960	|O
parent	961	967	|O
carboxylic	968	978	|O
acid	979	983	|O
to	984	986	|O
a	987	988	|O
Ki	989	991	|O
of	992	994	|O
96	995	997	|O
nM	998	1000	|O
for	1001	1004	|O
the	1005	1008	|O
bulky	1009	1014	|O
ureido	1015	1021	|O
congener	1022	1030	|O
.	1030	1031	|O
Certain	1032	1039	|O
congeners	1040	1049	|O
were	1050	1054	|O
up	1055	1057	|O
to	1058	1060	|O
145	1061	1064	|O
-	1064	1065	|O
fold	1065	1069	|O
more	1070	1074	|O
active	1075	1081	|O
at	1082	1084	|O
A1	1085	1087	|O
receptors	1088	1097	|O
than	1098	1102	|O
at	1103	1105	|O
A2	1106	1108	|O
receptors	1109	1118	|O
.	1118	1119	|O
Various	1120	1127	|O
derivatives	1128	1139	|O
of	1140	1142	|O
the	1143	1146	|O
congeners	1147	1156	|O
should	1157	1163	|O
be	1164	1166	|O
useful	1167	1173	|O
as	1174	1176	|O
receptor	1177	1185	|O
probes	1186	1192	|O
and	1193	1196	|O
for	1197	1200	|O
radioiodination	1201	1216	|O
,	1216	1217	|O
avidin	1218	1224	|O
binding	1225	1232	|O
,	1232	1233	|O
and	1234	1237	|O
preparation	1238	1249	|O
of	1250	1252	|O
affinity	1253	1261	|O
columns	1262	1269	|O
.	1269	1270	|O

### abstracts1532.txt
In	0	2	|O
general	3	10	|O
,	10	11	|O
3alpha	12	18	|B-IUPAC
-	18	19	|I-IUPAC
(	19	20	|I-IUPAC
diphenylmethoxy	20	35	|I-IUPAC
)	35	36	|I-IUPAC
tropane	36	43	|I-IUPAC
(	44	45	|O
benztropine	45	56	|O
)	56	57	|O
-	57	58	|O
based	58	63	|O
dopamine	64	72	|O
uptake	73	79	|O
inhibitors	80	90	|O
do	91	93	|O
not	94	97	|O
demonstrate	98	109	|O
cocaine	110	117	|O
-	117	118	|O
like	118	122	|O
pharmacological	123	138	|O
activity	139	147	|O
in	148	150	|O
models	151	157	|O
of	158	160	|O
psychostimulant	161	176	|O
abuse	177	182	|O
and	183	186	|O
have	187	191	|O
been	192	196	|O
proposed	197	205	|O
as	206	208	|O
potential	209	218	|O
medications	219	230	|O
for	231	234	|O
the	235	238	|O
treatment	239	248	|O
of	249	251	|O
cocaine	252	259	|O
addiction	260	269	|O
.	269	270	|O
However	271	278	|O
,	278	279	|O
several	280	287	|O
(	288	289	|B-IUPAC
S	289	290	|I-IUPAC
)	290	291	|I-IUPAC
-	291	292	|I-IUPAC
2	292	293	|I-IUPAC
-	293	294	|I-IUPAC
carboalkoxy	294	305	|I-IUPAC
-	305	306	|I-IUPAC
substituted	306	317	|I-IUPAC
-	317	318	|I-IUPAC
3alpha	318	324	|I-IUPAC
-	324	325	|I-IUPAC
[	325	326	|I-IUPAC
bis	326	329	|I-IUPAC
(	329	330	|I-IUPAC
4	330	331	|I-IUPAC
-	331	332	|I-IUPAC
fluorophenyl	332	344	|I-IUPAC
)	344	345	|I-IUPAC
methoxy	345	352	|I-IUPAC
]	352	353	|I-IUPAC
tropane	353	360	|I-IUPAC
analogues	361	370	|B-MODIFIER
were	371	375	|O
discovered	376	386	|O
to	387	389	|O
stimulate	390	399	|O
locomotor	400	409	|O
activity	410	418	|O
and	419	422	|O
substitute	423	433	|O
in	434	436	|O
subjects	437	445	|O
trained	446	453	|O
to	454	456	|O
discriminate	457	469	|O
cocaine	470	477	|O
,	477	478	|O
suggesting	479	489	|O
a	490	491	|O
role	492	496	|O
of	497	499	|O
the	500	503	|O
2	504	505	|O
-	505	506	|O
position	506	514	|O
substituent	515	526	|O
in	527	529	|O
mediating	530	539	|O
these	540	545	|O
cocaine	546	553	|O
-	553	554	|O
like	554	558	|O
actions	559	566	|O
.	566	567	|O
Herein	568	574	|O
,	574	575	|O
we	576	578	|O
describe	579	587	|O
the	588	591	|O
synthesis	592	601	|O
of	602	604	|O
a	605	606	|O
series	607	613	|O
of	614	616	|O
novel	617	622	|O
N	623	624	|B-MODIFIER
-	624	625	|I-MODIFIER
and	626	629	|O
2	630	631	|B-MODIFIER
-	631	632	|I-MODIFIER
substituted	632	643	|I-MODIFIER
-	643	644	|O
3alpha	644	650	|B-PARTIUPAC
-	650	651	|I-PARTIUPAC
[	651	652	|I-PARTIUPAC
bis	652	655	|I-PARTIUPAC
(	655	656	|I-PARTIUPAC
4	656	657	|I-PARTIUPAC
-	657	658	|I-PARTIUPAC
fluoro	658	664	|I-PARTIUPAC
-	664	665	|I-PARTIUPAC
or	666	668	|O
4	669	670	|B-IUPAC
-	670	671	|I-IUPAC
chlorophenyl	671	683	|I-IUPAC
)	683	684	|I-IUPAC
methoxy	684	691	|I-IUPAC
]	691	692	|I-IUPAC
tropane	692	699	|I-IUPAC
analogues	700	709	|B-MODIFIER
.	709	710	|O
Most	711	715	|O
of	716	718	|O
these	719	724	|O
analogues	725	734	|O
demonstrated	735	747	|O
high	748	752	|O
affinity	753	761	|O
binding	762	769	|O
to	770	772	|O
the	773	776	|O
dopamine	777	785	|O
transporter	786	797	|O
(	798	799	|O
DAT	799	802	|O
;	802	803	|O
K	804	805	|O
(	805	806	|O
i	806	807	|O
)	807	808	|O
=	809	810	|O
1.8-40	811	817	|O
nM	818	820	|O
)	820	821	|O
,	821	822	|O
and	823	826	|O
selectivity	827	838	|O
over	839	843	|O
the	844	847	|O
other	848	853	|O
monoamine	854	863	|O
transporters	864	876	|O
and	877	880	|O
muscarinic	881	891	|O
M	892	893	|O
(	893	894	|O
1	894	895	|O
)	895	896	|O
receptors	897	906	|O
.	906	907	|O
When	908	912	|O
the	913	916	|O
(	917	918	|B-IUPAC
S	918	919	|I-IUPAC
)	919	920	|I-IUPAC
-	920	921	|I-IUPAC
2	921	922	|I-IUPAC
-	922	923	|I-IUPAC
carboalkoxy	923	934	|I-IUPAC
substituent	935	946	|B-MODIFIER
was	947	950	|O
replaced	951	959	|O
with	960	964	|O
(	965	966	|B-IUPAC
S	966	967	|I-IUPAC
)	967	968	|I-IUPAC
-	968	969	|I-IUPAC
2	969	970	|I-IUPAC
-	970	971	|I-IUPAC
ethenyl	971	978	|I-IUPAC
,	978	979	|O
the	980	983	|O
resulting	984	993	|O
analogue	994	1002	|O
11	1003	1005	|O
demonstrated	1006	1018	|O
the	1019	1022	|O
highest	1023	1030	|O
DAT	1031	1034	|O
binding	1035	1042	|O
affinity	1043	1051	|O
in	1052	1054	|O
the	1055	1058	|O
series	1059	1065	|O
(	1066	1067	|O
K	1067	1068	|O
(	1068	1069	|O
i	1069	1070	|O
)	1070	1071	|O
=	1072	1073	|O
1.81	1074	1078	|O
nM	1079	1081	|O
)	1081	1082	|O
with	1083	1087	|O
DAT	1088	1091	|O
selectivity	1092	1103	|O
over	1104	1108	|O
serotonin	1109	1118	|O
transporters	1119	1131	|O
(	1132	1133	|O
SERT	1133	1137	|O
;	1137	1138	|O
989	1139	1142	|O
-	1142	1143	|O
fold	1143	1147	|O
)	1147	1148	|O
,	1148	1149	|O
norepinephrine	1150	1164	|O
transporters	1165	1177	|O
(	1178	1179	|O
NET	1179	1182	|O
;	1182	1183	|O
261	1184	1187	|O
-	1187	1188	|O
fold	1188	1192	|O
)	1192	1193	|O
and	1194	1197	|O
muscarinic	1198	1208	|O
receptors	1209	1218	|O
(	1219	1220	|O
90	1220	1222	|O
-	1222	1223	|O
fold	1223	1227	|O
)	1227	1228	|O
.	1228	1229	|O
When	1230	1234	|O
the	1235	1238	|O
4'	1239	1241	|O
-	1241	1242	|O
F	1242	1243	|O
groups	1244	1250	|O
of	1251	1253	|O
compounds	1254	1263	|O
5	1264	1265	|O
(	1266	1267	|O
K	1267	1268	|O
(	1268	1269	|O
i	1269	1270	|O
)	1270	1271	|O
=	1272	1273	|O
2.94	1274	1278	|O
nM	1279	1281	|O
)	1281	1282	|O
and	1283	1286	|O
8	1287	1288	|O
(	1289	1290	|O
K	1290	1291	|O
(	1291	1292	|O
i	1292	1293	|O
)	1293	1294	|O
=	1295	1296	|O
6.87	1297	1301	|O
nM	1302	1304	|O
)	1304	1305	|O
were	1306	1310	|O
replaced	1311	1319	|O
with	1320	1324	|O
4'	1325	1327	|O
-	1327	1328	|O
Cl	1328	1330	|O
in	1331	1333	|O
the	1334	1337	|O
(	1338	1339	|B-IUPAC
S	1339	1340	|I-IUPAC
)	1340	1341	|I-IUPAC
-	1341	1342	|I-IUPAC
2	1342	1343	|I-IUPAC
-	1343	1344	|I-IUPAC
carboalkoxy	1344	1355	|I-IUPAC
series	1356	1362	|B-MODIFIER
,	1362	1363	|O
DAT	1364	1367	|O
binding	1368	1375	|O
affinities	1376	1386	|O
were	1387	1391	|O
slightly	1392	1400	|O
reduced	1401	1408	|O
(	1409	1410	|O
K	1410	1411	|O
(	1411	1412	|O
i	1412	1413	|O
)	1413	1414	|O
=	1415	1416	|O
12.6	1417	1421	|O
and	1422	1425	|O
14.6	1426	1430	|O
nM	1431	1433	|O
for	1434	1437	|O
6	1438	1439	|O
and	1440	1443	|O
7	1444	1445	|O
,	1445	1446	|O
respectively	1447	1459	|O
)	1459	1460	|O
,	1460	1461	|O
yet	1462	1465	|O
inhibition	1466	1476	|O
of	1477	1479	|O
dopamine	1480	1488	|O
uptake	1489	1495	|O
potency	1496	1503	|O
remained	1504	1512	|O
comparably	1513	1523	|O
high	1524	1528	|O
(	1529	1530	|O
IC	1530	1532	|O
(	1532	1533	|O
50	1533	1535	|O
)	1535	1536	|O
range	1537	1542	|O
=	1543	1544	|O
1.5-2.5	1545	1552	|O
nM	1553	1555	|O
)	1555	1556	|O
.	1556	1557	|O
Interestingly	1558	1571	|O
,	1571	1572	|O
the	1573	1576	|O
4'	1577	1579	|O
-	1579	1580	|O
Cl	1580	1582	|O
analogue	1583	1591	|O
(	1592	1593	|O
+	1593	1594	|O
/	1594	1595	|O
-	1595	1596	|O
)	1596	1597	|O
-	1597	1598	|O
6	1598	1599	|O
substituted	1600	1611	|O
less	1612	1616	|O
in	1617	1619	|O
rats	1620	1624	|O
trained	1625	1632	|O
to	1633	1635	|O
discriminate	1636	1648	|O
cocaine	1649	1656	|O
than	1657	1661	|O
the	1662	1665	|O
4'	1666	1668	|O
-	1668	1669	|O
F	1669	1670	|O
analogue	1671	1679	|O
(	1680	1681	|O
+	1681	1682	|O
/	1682	1683	|O
-	1683	1684	|O
)	1684	1685	|O
-	1685	1686	|O
5	1686	1687	|O
.	1687	1688	|O
These	1689	1694	|O
studies	1695	1702	|O
demonstrate	1703	1714	|O
that	1715	1719	|O
manipulation	1720	1732	|O
of	1733	1735	|O
the	1736	1739	|O
2	1740	1741	|B-MODIFIER
-	1741	1742	|I-MODIFIER
,	1742	1743	|O
N	1744	1745	|B-MODIFIER
-	1745	1746	|I-MODIFIER
,	1746	1747	|O
and	1748	1751	|O
3	1752	1753	|B-MODIFIER
-	1753	1754	|I-MODIFIER
position	1754	1762	|I-MODIFIER
substituents	1763	1775	|I-MODIFIER
in	1776	1778	|O
the	1779	1782	|O
3alpha	1783	1789	|B-IUPAC
-	1789	1790	|I-IUPAC
(	1790	1791	|I-IUPAC
diphenylmethoxy	1791	1806	|I-IUPAC
)	1806	1807	|I-IUPAC
tropane	1807	1814	|I-IUPAC
class	1815	1820	|B-MODIFIER
of	1821	1823	|O
dopamine	1824	1832	|O
uptake	1833	1839	|O
inhibitors	1840	1850	|O
can	1851	1854	|O
result	1855	1861	|O
in	1862	1864	|O
ligands	1865	1872	|O
with	1873	1877	|O
high	1878	1882	|O
affinity	1883	1891	|O
and	1892	1895	|O
selectivity	1896	1907	|O
for	1908	1911	|O
the	1912	1915	|O
DAT	1916	1919	|O
,	1919	1920	|O
and	1921	1924	|O
distinctive	1925	1936	|O
in	1937	1939	|O
vivo	1940	1944	|O
pharmacological	1945	1960	|O
profiles	1961	1969	|O
that	1970	1974	|O
cannot	1975	1981	|O
be	1982	1984	|O
predicted	1985	1994	|O
by	1995	1997	|O
their	1998	2003	|O
effects	2004	2011	|O
in	2012	2014	|O
vitro	2015	2020	|O
.	2020	2021	|O

### abstracts4883.txt
The	0	3	|O
nonapeptide	4	15	|O
[	16	17	|O
des	17	20	|O
-	20	21	|O
Asp1	21	25	|O
]	25	26	|O
angiotensin	26	37	|O
I	38	39	|O
(	40	41	|O
IV	41	43	|O
)	43	44	|O
,	44	45	|O
synthesized	46	57	|O
by	58	60	|O
Merrifield	61	71	|O
's	71	73	|O
solid	74	79	|O
-	79	80	|O
phase	80	85	|O
procedure	86	95	|O
,	95	96	|O
was	97	100	|O
tested	101	107	|O
as	108	110	|O
a	111	112	|O
possible	113	121	|O
substrate	122	131	|O
for	132	135	|O
the	136	139	|O
converting	140	150	|O
enzymes	151	158	|O
from	159	163	|O
porcine	164	171	|O
lung	172	176	|O
and	177	180	|O
plasma	181	187	|O
.	187	188	|O
IV	189	191	|O
,	191	192	|O
[	193	194	|O
des	194	197	|O
-	197	198	|O
Asp1	198	202	|O
]	202	203	|O
angiotensin	203	214	|O
II	215	217	|O
(	218	219	|O
III	219	222	|O
)	222	223	|O
,	223	224	|O
[	225	226	|O
des	226	229	|O
-	229	230	|O
(	230	231	|O
Asp1	231	235	|O
,	235	236	|O
Arg2	236	240	|O
)	240	241	|O
]	241	242	|O
angiotensin	242	253	|O
II	254	256	|O
(	257	258	|O
V	258	259	|O
)	259	260	|O
,	260	261	|O
[	262	263	|O
des	263	266	|O
-	266	267	|O
(	267	268	|O
Asp1	268	272	|O
,	272	273	|O
Arg2	273	277	|O
,	277	278	|O
Val3	278	282	|O
)	282	283	|O
]	283	284	|O
angiotensin	284	295	|O
II	296	298	|O
(	299	300	|O
VI	300	302	|O
)	302	303	|O
,	303	304	|O
[	305	306	|O
Sar1	306	310	|O
,	310	311	|O
Ile8	311	315	|O
]	315	316	|O
angiotensin	316	327	|O
II	328	330	|O
(	331	332	|O
VII	332	335	|O
)	335	336	|O
,	336	337	|O
and	338	341	|O
[	342	343	|O
des	343	346	|O
-	346	347	|O
Asp1	347	351	|O
,	351	352	|O
Ile8	352	356	|O
]	356	357	|O
angiotensin	357	368	|O
II	369	371	|O
(	372	373	|O
VIII	373	377	|O
)	377	378	|O
possessed	379	388	|O
0.5	389	392	|O
,	392	393	|O
20	394	396	|O
,	396	397	|O
2	398	399	|O
,	399	400	|O
0	401	402	|O
less	403	407	|O
than	408	412	|O
0.1	413	416	|O
,	416	417	|O
and	418	421	|O
less	422	426	|O
than	427	431	|O
0.01%	432	437	|O
of	438	440	|O
the	441	444	|O
inotropic	445	454	|O
activity	455	463	|O
(	464	465	|O
rabbit	465	471	|O
atria	472	477	|O
)	477	478	|O
,	478	479	|O
1	480	481	|O
,	481	482	|O
15	483	485	|O
,	485	486	|O
5	487	488	|O
,	488	489	|O
0	490	491	|O
,	491	492	|O
3	493	494	|O
,	494	495	|O
and	496	499	|O
0%	500	502	|O
secretory	503	512	|O
activity	513	521	|O
of	522	524	|O
the	525	528	|O
cat	529	532	|O
adrenal	533	540	|O
medulla	541	548	|O
,	548	549	|O
and	550	553	|O
0.0	554	557	|O
,	557	558	|O
150	559	562	|O
,	562	563	|O
0.5	564	567	|O
,	567	568	|O
3	569	570	|O
,	570	571	|O
and	572	575	|O
10%	576	579	|O
of	580	582	|O
the	583	586	|O
adrenal	587	594	|O
steroidogenic	595	608	|O
activity	609	617	|O
of	618	620	|O
angiotensin	621	632	|O
II	633	635	|O
,	635	636	|O
respectively	637	649	|O
.	649	650	|O
When	651	655	|O
tested	656	662	|O
for	663	666	|O
their	667	672	|O
antagonistic	673	685	|O
activity	686	694	|O
in	695	697	|O
the	698	701	|O
above	702	707	|O
tissues	708	715	|O
,	715	716	|O
only	717	721	|O
VII	722	725	|O
and	726	729	|O
VIII	730	734	|O
were	735	739	|O
found	740	745	|O
to	746	748	|O
inhibit	749	756	|O
responses	757	766	|O
to	767	769	|O
angiotensin	770	781	|O
II	782	784	|O
.	784	785	|O
The	786	789	|O
pA2	790	793	|O
values	794	800	|O
for	801	804	|O
VII	805	808	|O
and	809	812	|O
VIII	813	817	|O
were	818	822	|O
8.31	823	827	|O
and	828	831	|O
10.0	832	836	|O
in	837	839	|O
the	840	843	|O
adrenal	844	851	|O
cortex	852	858	|O
and	859	862	|O
9.31	863	867	|O
and	868	871	|O
9.16	872	876	|O
in	877	879	|O
the	880	883	|O
adrenal	884	891	|O
medulla	892	899	|O
,	899	900	|O
respectively	901	913	|O
.	913	914	|O
All	915	918	|O
these	919	924	|O
peptides	925	933	|O
were	934	938	|O
also	939	943	|O
tested	944	950	|O
as	951	953	|O
product	954	961	|O
inhibitors	962	972	|O
for	973	976	|O
the	977	980	|O
plasma	981	987	|O
and	988	991	|O
lung	992	996	|O
converting	997	1007	|O
enzymes	1008	1015	|O
.	1015	1016	|O
With	1017	1021	|O
the	1022	1025	|O
plasma	1026	1032	|O
enzyme	1033	1039	|O
,	1039	1040	|O
the	1041	1044	|O
ID50	1045	1049	|O
values	1050	1056	|O
were	1057	1061	|O
II	1062	1064	|O
,	1064	1065	|O
1.6	1066	1069	|O
X	1070	1071	|O
10	1072	1074	|O
(	1074	1075	|O
-	1075	1076	|O
4	1076	1077	|O
)	1077	1078	|O
M	1079	1080	|O
;	1080	1081	|O
III	1082	1085	|O
,	1085	1086	|O
5	1087	1088	|O
X	1089	1090	|O
10	1091	1093	|O
(	1093	1094	|O
-	1094	1095	|O
5	1095	1096	|O
)	1096	1097	|O
M	1098	1099	|O
;	1099	1100	|O
V	1101	1102	|O
,	1102	1103	|O
1.2	1104	1107	|O
X	1108	1109	|O
10	1110	1112	|O
(	1112	1113	|O
-	1113	1114	|O
4	1114	1115	|O
)	1115	1116	|O
M	1117	1118	|O
;	1118	1119	|O
VI	1120	1122	|O
5	1123	1124	|O
X	1125	1126	|O
10	1127	1129	|O
(	1129	1130	|O
-	1130	1131	|O
4	1131	1132	|O
)	1132	1133	|O
M	1134	1135	|O
;	1135	1136	|O
VII	1137	1140	|O
5	1141	1142	|O
X	1143	1144	|O
10	1145	1147	|O
(	1147	1148	|O
-	1148	1149	|O
5	1149	1150	|O
)	1150	1151	|O
M	1152	1153	|O
;	1153	1154	|O
VIII	1155	1159	|O
,	1159	1160	|O
5	1161	1162	|O
X	1163	1164	|O
10	1165	1167	|O
(	1167	1168	|O
-	1168	1169	|O
4	1169	1170	|O
)	1170	1171	|O
M	1172	1173	|O
.	1173	1174	|O
Thus	1175	1179	|O
,	1179	1180	|O
IV	1181	1183	|O
is	1184	1186	|O
a	1187	1188	|O
good	1189	1193	|O
substrate	1194	1203	|O
for	1204	1207	|O
converting	1208	1218	|O
enzymes	1219	1226	|O
from	1227	1231	|O
lung	1232	1236	|O
and	1237	1240	|O
plasma	1241	1247	|O
while	1248	1253	|O
all	1254	1257	|O
other	1258	1263	|O
compounds	1264	1273	|O
were	1274	1278	|O
inhibitors	1279	1289	|O
of	1290	1292	|O
these	1293	1298	|O
enzymes	1299	1306	|O
.	1306	1307	|O
The	1308	1311	|O
most	1312	1316	|O
potent	1317	1323	|O
inhibitors	1324	1334	|O
of	1335	1337	|O
converting	1338	1348	|O
enzyme	1349	1355	|O
were	1356	1360	|O
III	1361	1364	|O
followed	1365	1373	|O
by	1374	1376	|O
VII	1377	1380	|O
and	1381	1384	|O
VIII	1385	1389	|O
.	1389	1390	|O
With	1391	1395	|O
the	1396	1399	|O
exception	1400	1409	|O
of	1410	1412	|O
II	1413	1415	|O
and	1416	1419	|O
III	1420	1423	|O
,	1423	1424	|O
all	1425	1428	|O
the	1429	1432	|O
other	1433	1438	|O
analogs	1439	1446	|O
had	1447	1450	|O
very	1451	1455	|O
low	1456	1459	|O
intrinsic	1460	1469	|O
activities	1470	1480	|O
,	1480	1481	|O
per	1482	1485	|O
se	1486	1488	|O
.	1488	1489	|O
These	1490	1495	|O
results	1496	1503	|O
suggest	1504	1511	|O
(	1512	1513	|O
a	1513	1514	|O
)	1514	1515	|O
an	1516	1518	|O
alternate	1519	1528	|O
pathway	1529	1536	|O
for	1537	1540	|O
the	1541	1544	|O
formation	1545	1554	|O
of	1555	1557	|O
heptapeptide	1558	1570	|O
III	1571	1574	|O
,	1574	1575	|O
viz	1576	1579	|O
.	1579	1580	|O
,	1580	1581	|O
by	1582	1584	|O
the	1585	1588	|O
action	1589	1595	|O
of	1596	1598	|O
converting	1599	1609	|O
enzyme	1610	1616	|O
on	1617	1619	|O
the	1620	1623	|O
nonapeptide	1624	1635	|O
IV	1636	1638	|O
,	1638	1639	|O
and	1640	1643	|O
(	1644	1645	|O
b	1645	1646	|O
)	1646	1647	|O
that	1648	1652	|O
III	1653	1656	|O
may	1657	1660	|O
also	1661	1665	|O
be	1666	1668	|O
acting	1669	1675	|O
as	1676	1678	|O
inhibitor	1679	1688	|O
of	1689	1691	|O
the	1692	1695	|O
converting	1696	1706	|O
enzyme	1707	1713	|O
by	1714	1716	|O
the	1717	1720	|O
feedback	1721	1729	|O
mechanism	1730	1739	|O
.	1739	1740	|O

### abstracts4052.txt
The	0	3	|O
sugar	4	9	|O
moiety	10	16	|O
of	17	19	|O
nucleosides	20	31	|O
in	32	34	|O
solution	35	43	|O
is	44	46	|O
known	47	52	|O
to	53	55	|O
exist	56	61	|O
in	62	64	|O
a	65	66	|O
rapid	67	72	|O
dynamic	73	80	|O
equilibrium	81	92	|O
between	93	100	|O
extreme	101	108	|O
Northern	109	117	|O
and	118	121	|O
Southern	122	130	|O
conformations	131	144	|O
as	145	147	|O
defined	148	155	|O
in	156	158	|O
the	159	162	|O
pseudorotational	163	179	|O
cycle	180	185	|O
.	185	186	|O
In	187	189	|O
the	190	193	|O
present	194	201	|O
work	202	206	|O
,	206	207	|O
we	208	210	|O
describe	211	219	|O
how	220	223	|O
the	224	227	|O
bicyclo	228	235	|B-IUPAC
[	235	236	|I-IUPAC
3.1.0	236	241	|I-IUPAC
]	241	242	|I-IUPAC
hexane	242	248	|I-IUPAC
template	249	257	|O
fixes	258	263	|O
the	264	267	|O
ring	268	272	|O
pucker	273	279	|O
of	280	282	|O
2'	283	285	|B-IUPAC
-	285	286	|I-IUPAC
deoxy	286	291	|I-IUPAC
-	291	292	|I-IUPAC
methanocarba	292	304	|I-IUPAC
-	304	305	|I-IUPAC
nucleosides	305	316	|I-IUPAC
1-5	317	320	|O
and	321	324	|O
12	325	327	|O
to	328	330	|O
values	331	337	|O
corresponding	338	351	|O
to	352	354	|O
either	355	361	|O
one	362	365	|O
of	366	368	|O
these	369	374	|O
two	375	378	|O
extreme	379	386	|O
conformations	387	400	|O
that	401	405	|O
are	406	409	|O
typical	410	417	|O
of	418	420	|O
nucleosides	421	432	|O
.	432	433	|O
The	434	437	|O
syntheses	438	447	|O
of	448	450	|O
the	451	454	|O
fixed	455	460	|O
Northern	461	469	|O
conformers	470	480	|O
1-5	481	484	|O
were	485	489	|O
performed	490	499	|O
by	500	502	|O
Mitsunobu	503	512	|O
coupling	513	521	|O
of	522	524	|O
the	525	528	|O
heterocyclic	529	541	|O
bases	542	547	|O
with	548	552	|O
the	553	556	|O
chiral	557	563	|O
carbocyclic	564	575	|O
alcohol	576	583	|O
6	584	585	|O
[	586	587	|O
(	587	588	|B-IUPAC
1R	588	590	|I-IUPAC
,	590	591	|I-IUPAC
2S	591	593	|I-IUPAC
,	593	594	|I-IUPAC
4R	594	596	|I-IUPAC
,	596	597	|I-IUPAC
5S	597	599	|I-IUPAC
)	599	600	|I-IUPAC
-	600	601	|I-IUPAC
1	601	602	|I-IUPAC
-	602	603	|I-IUPAC
[	603	604	|I-IUPAC
(	604	605	|I-IUPAC
benzyloxy	605	614	|I-IUPAC
)	614	615	|I-IUPAC
methyl	615	621	|I-IUPAC
]	621	622	|I-IUPAC
-	622	623	|I-IUPAC
2	623	624	|I-IUPAC
-	624	625	|I-IUPAC
(	625	626	|I-IUPAC
tert	626	630	|I-IUPAC
-	630	631	|I-IUPAC
butyloxy	631	639	|I-IUPAC
)	639	640	|I-IUPAC
-	640	641	|I-IUPAC
4	641	642	|I-IUPAC
-	642	643	|I-IUPAC
hydrox	643	649	|I-IUPAC
ybicyclo	650	658	|I-IUPAC
[	658	659	|I-IUPAC
3.1.0	659	664	|I-IUPAC
]	664	665	|I-IUPAC
hexane	665	671	|I-IUPAC
]	671	672	|O
,	672	673	|O
while	674	679	|O
the	680	683	|O
synthesis	684	693	|O
of	694	696	|O
the	697	700	|O
Southern	701	709	|O
conformer	710	719	|O
,	719	720	|O
(	721	722	|O
S	722	723	|O
)	723	724	|O
-	724	725	|O
methanocarba	725	737	|O
-	737	738	|O
T	738	739	|O
(	740	741	|O
12	741	743	|O
)	743	744	|O
,	744	745	|O
was	746	749	|O
reported	750	758	|O
earlier	759	766	|O
.	766	767	|O
Carbocyclic	768	779	|O
thymidine	780	789	|O
(	790	791	|O
carba	791	796	|O
-	796	797	|O
T	797	798	|O
,	798	799	|O
13	800	802	|O
)	802	803	|O
was	804	807	|O
used	808	812	|O
as	813	815	|O
a	816	817	|O
reference	818	827	|O
,	827	828	|O
flexible	829	837	|O
carbocyclic	838	849	|O
nucleoside	850	860	|O
.	860	861	|O
Antiviral	862	871	|O
evaluation	872	882	|O
of	883	885	|O
these	886	891	|O
compounds	892	901	|O
revealed	902	910	|O
a	911	912	|O
very	913	917	|O
potent	918	924	|O
antiherpetic	925	937	|O
activity	938	946	|O
associated	947	957	|O
with	958	962	|O
the	963	966	|O
Northern	967	975	|O
thymidine	976	985	|O
analogue	986	994	|O
2	995	996	|O
,	996	997	|O
which	998	1003	|O
was	1004	1007	|O
more	1008	1012	|O
powerful	1013	1021	|O
than	1022	1026	|O
the	1027	1030	|O
reference	1031	1040	|O
standard	1041	1049	|O
acyclovir	1050	1059	|O
against	1060	1067	|O
both	1068	1072	|O
HSV	1073	1076	|O
-	1076	1077	|O
1	1077	1078	|O
and	1079	1082	|O
HSV	1083	1086	|O
-	1086	1087	|O
2	1087	1088	|O
.	1088	1089	|O
(	1090	1091	|O
N	1091	1092	|O
)	1092	1093	|O
-	1093	1094	|O
Methanocarba	1094	1106	|O
-	1106	1107	|O
T	1107	1108	|O
(	1109	1110	|O
2	1110	1111	|O
)	1111	1112	|O
was	1113	1116	|O
further	1117	1124	|O
evaluated	1125	1134	|O
as	1135	1137	|O
a	1138	1139	|O
component	1140	1149	|O
of	1150	1152	|O
a	1153	1154	|O
short	1155	1160	|O
oligodeoxynucleotide	1161	1181	|O
(	1182	1183	|O
ODN	1183	1186	|O
)	1186	1187	|O
phosphorothioate	1188	1204	|O
(	1205	1206	|O
5'	1206	1208	|O
-	1208	1209	|O
CTTCATTTTTTCTTC	1209	1224	|O
-	1224	1225	|O
3'	1225	1227	|O
)	1227	1228	|O
where	1229	1234	|O
all	1235	1238	|O
thymidines	1239	1249	|O
were	1250	1254	|O
replaced	1255	1263	|O
by	1264	1266	|O
2	1267	1268	|O
.	1268	1269	|O
The	1270	1273	|O
expected	1274	1282	|O
thermodynamic	1283	1296	|O
stability	1297	1306	|O
resulting	1307	1316	|O
from	1317	1321	|O
the	1322	1325	|O
preorganization	1326	1341	|O
of	1342	1344	|O
the	1345	1348	|O
pseudosugar	1349	1360	|O
rings	1361	1366	|O
into	1367	1371	|O
a	1372	1373	|O
Northern	1374	1382	|O
conformation	1383	1395	|O
,	1395	1396	|O
typical	1397	1404	|O
of	1405	1407	|O
A	1408	1409	|O
-	1409	1410	|O
DNA	1410	1413	|O
,	1413	1414	|O
was	1415	1418	|O
evident	1419	1426	|O
by	1427	1429	|O
the	1430	1433	|O
increase	1434	1442	|O
in	1443	1445	|O
Tm	1446	1448	|O
of	1449	1451	|O
the	1452	1455	|O
corresponding	1456	1469	|O
DNA	1470	1473	|O
/	1473	1474	|O
RNA	1474	1477	|O
heteroduplex	1478	1490	|O
.	1490	1491	|O
However	1492	1499	|O
,	1499	1500	|O
the	1501	1504	|O
rigid	1505	1510	|O
A	1511	1512	|O
-	1512	1513	|O
tract	1513	1518	|O
ODN	1519	1522	|O
caused	1523	1529	|O
loss	1530	1534	|O
of	1535	1537	|O
RNase	1538	1543	|O
H	1544	1545	|O
recruitment	1546	1557	|O
.	1557	1558	|O
A	1559	1560	|O
detailed	1561	1569	|O
conformational	1570	1584	|O
analysis	1585	1593	|O
of	1594	1596	|O
(	1597	1598	|O
N	1598	1599	|O
)	1599	1600	|O
-	1600	1601	|O
methanocarba	1601	1613	|O
-	1613	1614	|O
T	1614	1615	|O
(	1616	1617	|O
2	1617	1618	|O
)	1618	1619	|O
and	1620	1623	|O
(	1624	1625	|O
S	1625	1626	|O
)	1626	1627	|O
-	1627	1628	|O
methanocarba	1628	1640	|O
-	1640	1641	|O
T	1641	1642	|O
(	1643	1644	|O
12	1644	1646	|O
)	1646	1647	|O
,	1647	1648	|O
as	1649	1651	|O
representative	1652	1666	|O
examples	1667	1675	|O
of	1676	1678	|O
conformationally	1679	1695	|O
rigid	1696	1701	|O
pseudorotational	1702	1718	|O
antipodes	1719	1728	|O
,	1728	1729	|O
revealed	1730	1738	|O
that	1739	1743	|O
in	1744	1746	|O
addition	1747	1755	|O
to	1756	1758	|O
their	1759	1764	|O
different	1765	1774	|O
forms	1775	1780	|O
of	1781	1783	|O
ring	1784	1788	|O
pucker	1789	1795	|O
,	1795	1796	|O
(	1797	1798	|O
S	1798	1799	|O
)	1799	1800	|O
-	1800	1801	|O
methanocarba	1801	1813	|O
-	1813	1814	|O
T	1814	1815	|O
appears	1816	1823	|O
to	1824	1826	|O
be	1827	1829	|O
a	1830	1831	|O
rather	1832	1838	|O
stiff	1839	1844	|O
molecule	1845	1853	|O
with	1854	1858	|O
fewer	1859	1864	|O
low	1865	1868	|O
-	1868	1869	|O
energy	1869	1875	|O
conformational	1876	1890	|O
states	1891	1897	|O
available	1898	1907	|O
compared	1908	1916	|O
to	1917	1919	|O
(	1920	1921	|O
N	1921	1922	|O
)	1922	1923	|O
-	1923	1924	|O
methanocarba	1924	1936	|O
-	1936	1937	|O
T	1937	1938	|O
.	1938	1939	|O
The	1940	1943	|O
syn	1944	1947	|O
/	1947	1948	|O
anti	1948	1952	|O
-	1952	1953	|O
energy	1953	1959	|O
barrier	1960	1967	|O
for	1968	1971	|O
these	1972	1977	|O
nucleoside	1978	1988	|O
analogues	1989	1998	|O
is	1999	2001	|O
5-6	2002	2005	|O
kcal	2006	2010	|O
/	2010	2011	|O
mol	2011	2014	|O
higher	2015	2021	|O
than	2022	2026	|O
for	2027	2030	|O
common	2031	2037	|O
nucleosides	2038	2049	|O
.	2049	2050	|O

### abstracts2960.txt
31P	0	3	|O
NMR	4	7	|O
spectroscopy	8	20	|O
was	21	24	|O
used	25	29	|O
to	30	32	|O
study	33	38	|O
the	39	42	|O
products	43	51	|O
of	52	54	|O
the	55	58	|O
decomposition	59	72	|O
of	73	75	|O
the	76	79	|O
antitumor	80	89	|O
drug	90	94	|O
ifosfamide	95	105	|O
(	106	107	|O
IF	107	109	|O
,	109	110	|O
1d	111	113	|O
)	113	114	|O
and	115	118	|O
its	119	122	|O
N	123	124	|B-IUPAC
-	124	125	|I-IUPAC
dechloroethylated	125	142	|I-IUPAC
metabolites	143	154	|B-MODIFIER
,	154	155	|O
namely	156	162	|O
,	162	163	|O
2,3	164	167	|B-IUPAC
-	167	168	|I-IUPAC
didechloroethylIF	168	185	|I-IUPAC
(	186	187	|O
1a	187	189	|O
)	189	190	|O
and	191	194	|O
2	195	196	|B-PARTIUPAC
-	196	197	|I-PARTIUPAC
(	198	199	|O
1b	199	201	|O
)	201	202	|O
and	203	206	|O
3	207	208	|B-IUPAC
-	208	209	|I-IUPAC
dechloroethylIF	209	224	|I-IUPAC
(	225	226	|O
1c	226	228	|O
)	228	229	|O
,	229	230	|O
in	231	233	|O
buffered	234	242	|O
solutions	243	252	|O
at	253	255	|O
acidic	256	262	|O
pH	263	265	|O
.	265	266	|O
The	267	270	|O
first	271	276	|O
stage	277	282	|O
of	283	285	|O
acid	286	290	|O
hydrolysis	291	301	|O
of	302	304	|O
these	305	310	|O
four	311	315	|O
oxazaphosphorines	316	333	|O
is	334	336	|O
a	337	338	|O
P	339	340	|O
-	340	341	|O
N	341	342	|O
bond	343	347	|O
cleavage	348	356	|O
of	357	359	|O
the	360	363	|O
six	364	367	|O
-	367	368	|O
membered	368	376	|O
ring	377	381	|O
leading	382	389	|O
to	390	392	|O
the	393	396	|O
phosphoramidic	397	411	|O
acid	412	416	|O
monoesters	417	427	|O
(	428	429	|O
2a	429	431	|O
-	431	432	|O
d	432	433	|O
)	433	434	|O
of	435	437	|O
type	438	442	|O
R'	443	445	|O
HN	445	447	|O
(	447	448	|O
CH	448	450	|O
(	450	451	|O
2	451	452	|O
)	452	453	|O
)	453	454	|O
(	454	455	|O
3	455	456	|O
)	456	457	|O
OP	457	459	|O
(	459	460	|O
O	460	461	|O
)	461	462	|O
(	462	463	|O
OH	463	465	|O
)	465	466	|O
NHR	466	469	|O
,	469	470	|O
with	471	475	|O
R	476	477	|O
and	478	481	|O
/	481	482	|O
or	482	484	|O
R'	485	487	|O
=	488	489	|O
H	490	491	|O
or	492	494	|O
(	495	496	|O
CH	496	498	|O
(	498	499	|O
2	499	500	|O
)	500	501	|O
)	501	502	|O
(	502	503	|O
2	503	504	|O
)	504	505	|O
Cl	505	507	|O
.	507	508	|O
The	509	512	|O
electron	513	521	|O
-	521	522	|O
withdrawing	522	533	|O
chloroethyl	534	545	|B-IUPAC
group	546	551	|B-MODIFIER
at	552	554	|O
the	555	558	|O
endocyclic	559	569	|O
and	570	573	|O
/	573	574	|O
or	574	576	|O
exocyclic	577	586	|O
nitrogens	587	596	|O
counteracts	597	608	|O
the	609	612	|O
endocyclic	613	623	|O
P	624	625	|O
-	625	626	|O
N	626	627	|O
bond	628	632	|O
hydrolysis	633	643	|O
.	643	644	|O
This	645	649	|O
effect	650	656	|O
is	657	659	|O
even	660	664	|O
more	665	669	|O
marked	670	676	|O
when	677	681	|O
the	682	685	|O
N	686	687	|B-IUPAC
-	687	688	|I-IUPAC
chloroethyl	688	699	|I-IUPAC
group	700	705	|B-MODIFIER
is	706	708	|O
in	709	711	|O
the	712	715	|O
exocyclic	716	725	|O
position	726	734	|O
since	735	740	|O
the	741	744	|O
order	745	750	|O
of	751	753	|O
stability	754	763	|O
is	764	766	|O
1d	767	769	|O
&	770	771	|O
gt	771	773	|O
;	773	774	|O
1c	775	777	|O
&	778	779	|O
gt	779	781	|O
;	781	782	|O
1b	783	785	|O
&	786	787	|O
gt	787	789	|O
;	789	790	|O
1a	791	793	|O
.	793	794	|O
In	795	797	|O
the	798	801	|O
second	802	808	|O
stage	809	814	|O
of	815	817	|O
hydrolysis	818	828	|O
,	828	829	|O
the	830	833	|O
remaining	834	843	|O
P	844	845	|O
-	845	846	|O
N	846	847	|O
bond	848	852	|O
is	853	855	|O
cleaved	856	863	|O
together	864	872	|O
with	873	877	|O
an	878	880	|O
intramolecular	881	895	|O
attack	896	902	|O
at	903	905	|O
the	906	909	|O
phosphorus	910	920	|O
atom	921	925	|O
by	926	928	|O
the	929	932	|O
non	933	936	|O
-	936	937	|O
P	937	938	|O
-	938	939	|O
linked	939	945	|O
nitrogen	946	954	|O
of	955	957	|O
the	958	961	|O
compounds	962	971	|O
2a	972	974	|O
-	974	975	|O
d	975	976	|O
.	976	977	|O
This	978	982	|O
leads	983	988	|O
to	989	991	|O
the	992	995	|O
formation	996	1005	|O
of	1006	1008	|O
a	1009	1010	|O
2	1011	1012	|B-IUPAC
-	1012	1013	|I-IUPAC
hydroxyoxazaphosphorine	1013	1036	|I-IUPAC
ring	1037	1041	|O
with	1042	1046	|O
R	1047	1048	|O
=	1049	1050	|O
H	1051	1052	|O
(	1053	1054	|O
3a	1054	1056	|O
coming	1057	1063	|O
from	1064	1068	|O
compounds	1069	1078	|O
2a	1079	1081	|O
,	1081	1082	|O
c	1082	1083	|O
)	1083	1084	|O
or	1085	1087	|O
(	1088	1089	|O
CH	1089	1091	|O
(	1091	1092	|O
2	1092	1093	|O
)	1093	1094	|O
)	1094	1095	|O
(	1095	1096	|O
2	1096	1097	|O
)	1097	1098	|O
Cl	1098	1100	|O
(	1101	1102	|O
3b	1102	1104	|O
coming	1105	1111	|O
from	1112	1116	|O
compounds	1117	1126	|O
2b	1127	1129	|O
,	1129	1130	|O
d	1130	1131	|O
)	1131	1132	|O
and	1133	1136	|O
to	1137	1139	|O
the	1140	1143	|O
release	1144	1151	|O
of	1152	1154	|O
ammonia	1155	1162	|O
or	1163	1165	|O
chloroethylamine	1166	1182	|O
.	1182	1183	|O
The	1184	1187	|O
third	1188	1193	|O
step	1194	1198	|O
is	1199	1201	|O
the	1202	1205	|O
P	1206	1207	|O
-	1207	1208	|O
N	1208	1209	|O
ring	1210	1214	|O
opening	1215	1222	|O
of	1223	1225	|O
the	1226	1229	|O
oxazaphosphorines	1230	1247	|O
3a	1248	1250	|O
,	1250	1251	|O
b	1251	1252	|O
leading	1253	1260	|O
to	1261	1263	|O
the	1264	1267	|O
phosphoric	1268	1278	|O
acid	1279	1283	|O
monoesters	1284	1294	|O
,	1294	1295	|O
H	1296	1297	|O
(	1297	1298	|O
2	1298	1299	|O
)	1299	1300	|O
N	1300	1301	|O
(	1301	1302	|O
CH	1302	1304	|O
(	1304	1305	|O
2	1305	1306	|O
)	1306	1307	|O
)	1307	1308	|O
(	1308	1309	|O
3	1309	1310	|O
)	1310	1311	|O
OP	1311	1313	|O
(	1313	1314	|O
O	1314	1315	|O
)	1315	1316	|O
(	1316	1317	|O
OH	1317	1319	|O
)	1319	1320	|O
(	1320	1321	|O
2	1321	1322	|O
)	1322	1323	|O
(	1324	1325	|O
4a	1325	1327	|O
)	1327	1328	|O
and	1329	1332	|O
Cl	1333	1335	|O
(	1335	1336	|O
CH	1336	1338	|O
(	1338	1339	|O
2	1339	1340	|O
)	1340	1341	|O
)	1341	1342	|O
(	1342	1343	|O
2	1343	1344	|O
)	1344	1345	|O
HN	1345	1347	|O
(	1347	1348	|O
CH	1348	1350	|O
(	1350	1351	|O
2	1351	1352	|O
)	1352	1353	|O
)	1353	1354	|O
(	1354	1355	|O
3	1355	1356	|O
)	1356	1357	|O
OP	1357	1359	|O
(	1359	1360	|O
O	1360	1361	|O
)	1361	1362	|O
(	1362	1363	|O
OH	1363	1365	|O
)	1365	1366	|O
(	1366	1367	|O
2	1367	1368	|O
)	1368	1369	|O
(	1370	1371	|O
4b	1371	1373	|O
-	1373	1374	|O
1	1374	1375	|O
)	1375	1376	|O
,	1376	1377	|O
respectively	1378	1390	|O
.	1390	1391	|O
For	1392	1395	|O
the	1396	1399	|O
latter	1400	1406	|O
compound	1407	1415	|O
,	1415	1416	|O
the	1417	1420	|O
chloroethyl	1421	1432	|O
group	1433	1438	|O
is	1439	1441	|O
partially	1442	1451	|O
(	1452	1453	|O
at	1453	1455	|O
pH	1456	1458	|O
5.5	1459	1462	|O
)	1462	1463	|O
or	1464	1466	|O
totally	1467	1474	|O
(	1475	1476	|O
at	1476	1478	|O
pH	1479	1481	|O
7.0	1482	1485	|O
)	1485	1486	|O
cyclized	1487	1495	|O
into	1496	1500	|O
aziridine	1501	1510	|O
(	1511	1512	|O
4b	1512	1514	|O
-	1514	1515	|O
2	1515	1516	|O
)	1516	1517	|O
,	1517	1518	|O
which	1519	1524	|O
is	1525	1527	|O
then	1528	1532	|O
progressively	1533	1546	|O
hydrolyzed	1547	1557	|O
into	1558	1562	|O
an	1563	1565	|O
N	1566	1567	|B-IUPAC
-	1567	1568	|I-IUPAC
hydroxyethyl	1568	1580	|I-IUPAC
group	1581	1586	|B-MODIFIER
(	1587	1588	|O
4b	1588	1590	|O
-	1590	1591	|O
3	1591	1592	|O
)	1592	1593	|O
.	1593	1594	|O
Compounds	1595	1604	|O
3a	1605	1607	|O
,	1607	1608	|O
b	1608	1609	|O
are	1610	1613	|O
transient	1614	1623	|O
intermediates	1624	1637	|O
,	1637	1638	|O
which	1639	1644	|O
in	1645	1647	|O
strongly	1648	1656	|O
acidic	1657	1663	|O
medium	1664	1670	|O
are	1671	1674	|O
not	1675	1678	|O
observed	1679	1687	|O
with	1688	1692	|O
(	1693	1694	|O
31	1694	1696	|O
)	1696	1697	|O
P	1697	1698	|O
NMR	1699	1702	|O
.	1702	1703	|O
In	1704	1706	|O
this	1707	1711	|O
case	1712	1716	|O
,	1716	1717	|O
cleavage	1718	1726	|O
of	1727	1729	|O
the	1730	1733	|O
P	1734	1735	|O
-	1735	1736	|O
N	1736	1737	|O
bond	1738	1742	|O
of	1743	1745	|O
the	1746	1749	|O
type	1750	1754	|O
2	1755	1756	|O
phosphoramidic	1757	1771	|O
acid	1772	1776	|O
monoesters	1777	1787	|O
leads	1788	1793	|O
directly	1794	1802	|O
to	1803	1805	|O
the	1806	1809	|O
type	1810	1814	|O
4	1815	1816	|O
phosphoric	1817	1827	|O
acid	1828	1832	|O
monoesters	1833	1843	|O
.	1843	1844	|O
The	1845	1848	|O
phosphate	1849	1858	|O
anion	1859	1864	|O
,	1864	1865	|O
derived	1866	1873	|O
from	1874	1878	|O
P	1879	1880	|O
-	1880	1881	|O
O	1881	1882	|O
bond	1883	1887	|O
cleavage	1888	1896	|O
of	1897	1899	|O
these	1900	1905	|O
latter	1906	1912	|O
compounds	1913	1922	|O
,	1922	1923	|O
is	1924	1926	|O
only	1927	1931	|O
observed	1932	1940	|O
at	1941	1943	|O
low	1944	1947	|O
levels	1948	1954	|O
after	1955	1960	|O
a	1961	1962	|O
long	1963	1967	|O
period	1968	1974	|O
of	1975	1977	|O
hydrolysis	1978	1988	|O
.	1988	1989	|O
Compounds	1990	1999	|O
1a	2000	2002	|O
-	2002	2003	|O
c	2003	2004	|O
and	2005	2008	|O
some	2009	2013	|O
of	2014	2016	|O
their	2017	2022	|O
hydrolytic	2023	2033	|O
degradation	2034	2045	|O
products	2046	2054	|O
(	2055	2056	|O
4b	2056	2058	|O
-	2058	2059	|O
1	2059	2060	|O
,	2060	2061	|O
4b	2062	2064	|O
-	2064	2065	|O
2	2065	2066	|O
,	2066	2067	|O
diphosphoric	2068	2080	|O
diester	2081	2088	|O
[	2089	2090	|O
Cl	2090	2092	|O
(	2092	2093	|O
CH	2093	2095	|O
(	2095	2096	|O
2	2096	2097	|O
)	2097	2098	|O
)	2098	2099	|O
(	2099	2100	|O
2	2100	2101	|O
)	2101	2102	|O
NH	2102	2104	|O
(	2104	2105	|O
CH	2105	2107	|O
(	2107	2108	|O
2	2108	2109	|O
)	2109	2110	|O
)	2110	2111	|O
(	2111	2112	|O
3	2112	2113	|O
)	2113	2114	|O
OP	2114	2116	|O
(	2116	2117	|O
O	2117	2118	|O
)	2118	2119	|O
(	2119	2120	|O
OH	2120	2122	|O
)	2122	2123	|O
]	2123	2124	|O
(	2124	2125	|O
2	2125	2126	|O
)	2126	2127	|O
O	2127	2128	|O
(	2129	2130	|O
5	2130	2131	|O
)	2131	2132	|O
,	2132	2133	|O
and	2134	2137	|O
chloroethylamine	2138	2154	|O
)	2154	2155	|O
did	2156	2159	|O
not	2160	2163	|O
exhibit	2164	2171	|O
,	2171	2172	|O
as	2173	2175	|O
expected	2176	2184	|O
,	2184	2185	|O
any	2186	2189	|O
antitumor	2190	2199	|O
efficacy	2200	2208	|O
in	2209	2211	|O
vivo	2212	2216	|O
against	2217	2224	|O
P388	2225	2229	|O
leukemia	2230	2238	|O
.	2238	2239	|O
(	2240	2241	|O
31	2241	2243	|O
)	2243	2244	|O
P	2244	2245	|O
NMR	2246	2249	|O
determination	2250	2263	|O
of	2264	2266	|O
the	2267	2270	|O
N	2271	2272	|O
-	2272	2273	|O
dechloroethylated	2273	2290	|O
metabolites	2291	2302	|O
of	2303	2305	|O
IF	2306	2308	|O
or	2309	2311	|O
its	2312	2315	|O
structural	2316	2326	|O
isomer	2327	2333	|O
,	2333	2334	|O
cyclophosphamide	2335	2351	|O
(	2352	2353	|O
CP	2353	2355	|O
)	2355	2356	|O
,	2356	2357	|O
and	2358	2361	|O
their	2362	2367	|O
degradation	2368	2379	|O
compounds	2380	2389	|O
could	2390	2395	|O
provide	2396	2403	|O
an	2404	2406	|O
indirect	2407	2415	|O
and	2416	2419	|O
accurate	2420	2428	|O
estimation	2429	2439	|O
of	2440	2442	|O
chloroacetaldehyde	2443	2461	|O
amounts	2462	2469	|O
formed	2470	2476	|O
from	2477	2481	|O
CP	2482	2484	|O
or	2485	2487	|O
IF	2488	2490	|O
.	2490	2491	|O

### abstracts2245.txt
The	0	3	|O
high	4	8	|O
antiradiation	9	22	|O
activity	23	31	|O
and	32	35	|O
low	36	39	|O
toxicity	40	48	|O
of	49	51	|O
sodium	52	58	|B-IUPAC
3	59	60	|I-IUPAC
-	60	61	|I-IUPAC
amino	61	66	|I-IUPAC
-	66	67	|I-IUPAC
2	67	68	|I-IUPAC
-	68	69	|I-IUPAC
hydroxypropyl	69	82	|I-IUPAC
hydrogen	83	91	|I-IUPAC
phosphorothioate	92	108	|I-IUPAC
(	109	110	|O
1	110	111	|O
)	111	112	|O
suggested	113	122	|O
the	123	126	|O
introduction	127	139	|O
of	140	142	|O
hydroxyl	143	151	|B-IUPAC
groups	152	158	|B-MODIFIER
into	159	163	|O
other	164	169	|O
types	170	175	|O
of	176	178	|O
radioprotective	179	194	|O
phosphorothioates	195	212	|O
.	212	213	|O
A	214	215	|O
number	216	222	|O
of	223	225	|O
such	226	230	|O
compounds	231	240	|O
were	241	245	|O
synthesized	246	257	|O
,	257	258	|O
including	259	268	|O
S	269	270	|B-IUPAC
-	270	271	|I-IUPAC
3	271	272	|I-IUPAC
-	272	273	|I-IUPAC
(	273	274	|I-IUPAC
3	274	275	|I-IUPAC
-	275	276	|I-IUPAC
aminopropylamino	276	292	|I-IUPAC
)	292	293	|I-IUPAC
-	293	294	|I-IUPAC
2	294	295	|I-IUPAC
-	295	296	|I-IUPAC
hydroxypropyl	296	309	|I-IUPAC
dihydrogen	310	320	|I-IUPAC
phosphorothioate	321	337	|I-IUPAC
(	338	339	|O
11	339	341	|O
,	341	342	|O
n	343	344	|O
equals	345	351	|O
3	352	353	|O
)	353	354	|O
,	354	355	|O
S	356	357	|B-IUPAC
-	357	358	|I-IUPAC
2	358	359	|I-IUPAC
-	359	360	|I-IUPAC
(	360	361	|I-IUPAC
3	361	362	|I-IUPAC
-	362	363	|I-IUPAC
amino	363	368	|I-IUPAC
-	368	369	|I-IUPAC
2	369	370	|I-IUPAC
-	370	371	|I-IUPAC
hydroxypropylamino	371	389	|I-IUPAC
)	389	390	|I-IUPAC
ethyl	390	395	|I-IUPAC
dihydrogen	396	406	|I-IUPAC
phosphorothioate	407	423	|I-IUPAC
(	424	425	|O
20	425	427	|O
)	427	428	|O
and	429	432	|O
its	433	436	|O
propyl	437	443	|B-IUPAC
homolog	444	451	|B-MODIFIER
26	452	454	|O
,	454	455	|O
N	456	457	|B-IUPAC
,	457	458	|I-IUPAC
N'	458	460	|I-IUPAC
-	460	461	|I-IUPAC
(	461	462	|I-IUPAC
2	462	463	|I-IUPAC
-	463	464	|I-IUPAC
hydroxytrimethylene	464	483	|I-IUPAC
)	483	484	|I-IUPAC
bis	484	487	|I-IUPAC
(	487	488	|I-IUPAC
S	488	489	|I-IUPAC
-	489	490	|I-IUPAC
2	490	491	|I-IUPAC
-	491	492	|I-IUPAC
aminoethyl	492	502	|I-IUPAC
dihydrogen	503	513	|I-IUPAC
phosphorothioate	514	530	|I-IUPAC
)	530	531	|I-IUPAC
(	532	533	|O
40	533	535	|O
)	535	536	|O
,	536	537	|O
S	538	539	|B-IUPAC
-	539	540	|I-IUPAC
2	540	541	|I-IUPAC
-	541	542	|I-IUPAC
[	542	543	|I-IUPAC
3	543	544	|I-IUPAC
-	544	545	|I-IUPAC
(	545	546	|I-IUPAC
2	546	547	|I-IUPAC
-	547	548	|I-IUPAC
hydroxyethylamino	548	565	|I-IUPAC
)	565	566	|I-IUPAC
propylaminoi1ethyl	566	584	|I-IUPAC
dihydrogen	585	595	|I-IUPAC
phosphorothioate	596	612	|I-IUPAC
(	613	614	|O
44	614	616	|O
)	616	617	|O
,	617	618	|O
and	619	622	|O
sodium	623	629	|B-IUPAC
S	630	631	|I-IUPAC
-	631	632	|I-IUPAC
2	632	633	|I-IUPAC
-	633	634	|I-IUPAC
amino	634	639	|I-IUPAC
-	639	640	|I-IUPAC
2	640	641	|I-IUPAC
-	641	642	|I-IUPAC
(	642	643	|I-IUPAC
hydroxymethyl	643	656	|I-IUPAC
)	656	657	|I-IUPAC
-	657	658	|I-IUPAC
3	658	659	|I-IUPAC
-	659	660	|I-IUPAC
hydroxypropyl	660	673	|I-IUPAC
hydrogen	674	682	|I-IUPAC
phosphorothioate	683	699	|I-IUPAC
(	700	701	|O
49	701	703	|O
)	703	704	|O
.	704	705	|O
Compounds	706	715	|O
11	716	718	|O
(	719	720	|O
n	720	721	|O
equals	722	728	|O
3	729	730	|O
)	730	731	|O
,	731	732	|O
20	733	735	|O
,	735	736	|O
26	737	739	|O
,	739	740	|O
and	741	744	|O
49	745	747	|O
were	748	752	|O
highly	753	759	|O
protective	760	770	|O
when	771	775	|O
administered	776	788	|O
intraperitoneally	789	806	|O
but	807	810	|O
were	811	815	|O
generally	816	825	|O
ineffective	826	837	|O
when	838	842	|O
given	843	848	|O
perorally	849	858	|O
,	858	859	|O
as	860	862	|O
were	863	867	|O
the	868	871	|O
other	872	877	|O
hydroxylated	878	890	|O
phosphorothioates	891	908	|O
prepared	909	917	|O
.	917	918	|O
The	919	922	|O
introduction	923	935	|O
of	936	938	|O
hydroxyl	939	947	|B-IUPAC
groups	948	954	|B-MODIFIER
significantly	955	968	|O
enhanced	969	977	|O
the	978	981	|O
radioprotective	982	997	|O
properties	998	1008	|O
of	1009	1011	|O
nonhydroxylated	1012	1027	|O
parent	1028	1034	|O
compounds	1035	1044	|O
,	1044	1045	|O
however	1046	1053	|O
,	1053	1054	|O
only	1055	1059	|O
in	1060	1062	|O
the	1063	1066	|O
case	1067	1071	|O
of	1072	1074	|O
intraperitoneally	1075	1092	|O
administered	1093	1105	|O
.	1105	1106	|O

### abstracts252.txt
We	0	2	|O
have	3	7	|O
designed	8	16	|O
and	17	20	|O
synthesized	21	32	|O
16	33	35	|O
new	36	39	|O
olean	40	45	|B-PARTIUPAC
-	45	46	|I-PARTIUPAC
and	47	50	|O
urs	51	54	|B-IUPAC
-	54	55	|I-IUPAC
1	55	56	|I-IUPAC
-	56	57	|I-IUPAC
en	57	59	|I-IUPAC
-	59	60	|I-IUPAC
3	60	61	|I-IUPAC
-	61	62	|I-IUPAC
one	62	65	|I-IUPAC
triterpenoids	66	79	|I-IUPAC
with	80	84	|O
various	85	92	|O
modified	93	101	|O
rings	102	107	|O
C	108	109	|O
as	110	112	|O
potential	113	122	|O
antiinflammatory	123	139	|O
and	140	143	|O
cancer	144	150	|O
chemopreventive	151	166	|O
agents	167	173	|O
and	174	177	|O
evaluated	178	187	|O
their	188	193	|O
inhibitory	194	204	|O
activities	205	215	|O
against	216	223	|O
production	224	234	|O
of	235	237	|O
nitric	238	244	|O
oxide	245	250	|O
induced	251	258	|O
by	259	261	|O
interferon	262	272	|O
-	272	273	|O
gamma	273	278	|O
in	279	281	|O
mouse	282	287	|O
macrophages	288	299	|O
.	299	300	|O
This	301	305	|O
investigation	306	319	|O
revealed	320	328	|O
that	329	333	|O
9	334	335	|B-IUPAC
(	335	336	|I-IUPAC
11	336	338	|I-IUPAC
)	338	339	|I-IUPAC
-	339	340	|I-IUPAC
en	340	342	|I-IUPAC
-	342	343	|I-IUPAC
12	343	345	|I-IUPAC
-	345	346	|I-IUPAC
one	346	349	|I-IUPAC
and	350	353	|O
12	354	356	|B-IUPAC
-	356	357	|I-IUPAC
en	357	359	|I-IUPAC
-	359	360	|I-IUPAC
11	360	362	|I-IUPAC
-	362	363	|I-IUPAC
one	363	366	|I-IUPAC
functionalities	367	382	|O
in	383	385	|O
ring	386	390	|O
C	391	392	|O
increase	393	401	|O
the	402	405	|O
potency	406	413	|O
by	414	416	|O
about	417	422	|O
2-10	423	427	|O
times	428	433	|O
compared	434	442	|O
with	443	447	|O
the	448	451	|O
original	452	460	|O
12	461	463	|B-IUPAC
-	463	464	|I-IUPAC
ene	464	467	|I-IUPAC
.	467	468	|O
Subsequently	469	481	|O
,	481	482	|O
we	483	485	|O
have	486	490	|O
designed	491	499	|O
and	500	503	|O
synthesized	504	515	|O
novel	516	521	|O
olean	522	527	|B-PARTIUPAC
-	527	528	|I-PARTIUPAC
and	529	532	|O
urs	533	536	|B-IUPAC
-	536	537	|I-IUPAC
1	537	538	|I-IUPAC
-	538	539	|I-IUPAC
en	539	541	|I-IUPAC
-	541	542	|I-IUPAC
3	542	543	|I-IUPAC
-	543	544	|I-IUPAC
one	544	547	|I-IUPAC
derivatives	548	559	|B-MODIFIER
with	560	564	|O
nitrile	565	572	|B-IUPAC
and	573	576	|O
carboxyl	577	585	|B-IUPAC
groups	586	592	|B-MODIFIER
at	593	595	|O
C	596	597	|O
-	597	598	|O
2	598	599	|O
in	600	602	|O
ring	603	607	|O
A	608	609	|O
and	610	613	|O
with	614	618	|O
9	619	620	|B-IUPAC
(	620	621	|I-IUPAC
11	621	623	|I-IUPAC
)	623	624	|I-IUPAC
-	624	625	|I-IUPAC
en	625	627	|I-IUPAC
-	627	628	|I-IUPAC
12	628	630	|I-IUPAC
-	630	631	|I-IUPAC
one	631	634	|I-IUPAC
and	635	638	|O
12	639	641	|B-IUPAC
-	641	642	|I-IUPAC
en	642	644	|I-IUPAC
-	644	645	|I-IUPAC
11	645	647	|I-IUPAC
-	647	648	|I-IUPAC
one	648	651	|I-IUPAC
functionalities	652	667	|B-MODIFIER
in	668	670	|O
ring	671	675	|O
C	676	677	|O
.	677	678	|O
Among	679	684	|O
them	685	689	|O
,	689	690	|O
we	691	693	|O
have	694	698	|O
found	699	704	|O
that	705	709	|O
methyl	710	716	|B-IUPAC
2	717	718	|I-IUPAC
-	718	719	|I-IUPAC
cyano	719	724	|I-IUPAC
-	724	725	|I-IUPAC
3	725	726	|I-IUPAC
,	726	727	|I-IUPAC
12	728	730	|I-IUPAC
-	730	731	|I-IUPAC
dioxooleana	731	742	|I-IUPAC
-	742	743	|I-IUPAC
1,9	743	746	|I-IUPAC
(	746	747	|I-IUPAC
11	747	749	|I-IUPAC
)	749	750	|I-IUPAC
-	750	751	|I-IUPAC
dien	751	755	|I-IUPAC
-	755	756	|I-IUPAC
28	756	758	|I-IUPAC
-	758	759	|I-IUPAC
oate	759	763	|I-IUPAC
(	764	765	|O
25	765	767	|O
)	767	768	|O
,	768	769	|O
2	770	771	|B-IUPAC
-	771	772	|I-IUPAC
cyano	772	777	|I-IUPAC
-	777	778	|I-IUPAC
3,12	778	782	|I-IUPAC
-	782	783	|I-IUPAC
dioxooleana	783	794	|I-IUPAC
-	794	795	|I-IUPAC
1,9	795	798	|I-IUPAC
(	798	799	|I-IUPAC
11	799	801	|I-IUPAC
)	801	802	|I-IUPAC
-	802	803	|I-IUPAC
dien	803	807	|I-IUPAC
-	807	808	|I-IUPAC
28	808	810	|I-IUPAC
-	810	811	|I-IUPAC
oic	811	814	|I-IUPAC
acid	815	819	|I-IUPAC
(	820	821	|O
CDDO	821	825	|O
)	825	826	|O
(	827	828	|O
26	828	830	|O
)	830	831	|O
,	831	832	|O
and	833	836	|O
methyl	837	843	|B-IUPAC
2	844	845	|I-IUPAC
-	845	846	|I-IUPAC
carboxy	846	853	|I-IUPAC
-	853	854	|I-IUPAC
3,12	854	858	|I-IUPAC
-	858	859	|I-IUPAC
dioxooleana	859	870	|I-IUPAC
-	870	871	|I-IUPAC
1,9	871	874	|I-IUPAC
(	874	875	|I-IUPAC
11	875	877	|I-IUPAC
)	877	878	|I-IUPAC
-	878	879	|I-IUPAC
dien	879	883	|I-IUPAC
-	883	884	|I-IUPAC
28	884	886	|I-IUPAC
-	886	887	|I-IUPAC
oate	887	891	|I-IUPAC
(	892	893	|O
29	893	895	|O
)	895	896	|O
have	897	901	|O
extremely	902	911	|O
high	912	916	|O
potency	917	924	|O
(	925	926	|O
IC	926	928	|O
(	928	929	|O
50	929	931	|O
)	931	932	|O
=	933	934	|O
0.1	935	938	|O
nM	939	941	|O
level	942	947	|O
)	947	948	|O
.	948	949	|O
Their	950	955	|O
potency	956	963	|O
is	964	966	|O
similar	967	974	|O
to	975	977	|O
that	978	982	|O
of	983	985	|O
dexamethasone	986	999	|O
although	1000	1008	|O
they	1009	1013	|O
do	1014	1016	|O
not	1017	1020	|O
act	1021	1024	|O
through	1025	1032	|O
the	1033	1036	|O
glucocorticoid	1037	1051	|O
receptor	1052	1060	|O
.	1060	1061	|O
Overall	1062	1069	|O
,	1069	1070	|O
the	1071	1074	|O
combination	1075	1086	|O
of	1087	1089	|O
modified	1090	1098	|O
rings	1099	1104	|O
A	1105	1106	|O
and	1107	1110	|O
C	1111	1112	|O
increases	1113	1122	|O
the	1123	1126	|O
potency	1127	1134	|O
by	1135	1137	|O
about	1138	1143	|O
10	1144	1146	|O
000	1147	1150	|O
times	1151	1156	|O
compared	1157	1165	|O
with	1166	1170	|O
the	1171	1174	|O
lead	1175	1179	|O
compound	1180	1188	|O
,	1188	1189	|O
3	1190	1191	|B-IUPAC
-	1191	1192	|I-IUPAC
oxooleana	1192	1201	|I-IUPAC
-	1201	1202	|I-IUPAC
1,12	1202	1206	|I-IUPAC
-	1206	1207	|I-IUPAC
dien	1207	1211	|I-IUPAC
-	1211	1212	|I-IUPAC
28	1212	1214	|I-IUPAC
-	1214	1215	|I-IUPAC
oic	1215	1218	|I-IUPAC
acid	1219	1223	|I-IUPAC
(	1224	1225	|O
8	1225	1226	|O
)	1226	1227	|O
(	1228	1229	|O
IC	1229	1231	|O
(	1231	1232	|O
50	1232	1234	|O
)	1234	1235	|O
=	1236	1237	|O
1	1238	1239	|O
microM	1240	1246	|O
level	1247	1252	|O
)	1252	1253	|O
.	1253	1254	|O
The	1255	1258	|O
selected	1259	1267	|O
oleanane	1268	1276	|O
triterpenoid	1277	1289	|O
,	1289	1290	|O
CDDO	1291	1295	|O
(	1296	1297	|O
26	1297	1299	|O
)	1299	1300	|O
,	1300	1301	|O
was	1302	1305	|O
found	1306	1311	|O
to	1312	1314	|O
be	1315	1317	|O
a	1318	1319	|O
potent	1320	1326	|O
,	1326	1327	|O
multifunctional	1328	1343	|O
agent	1344	1349	|O
in	1350	1352	|O
various	1353	1360	|O
in	1361	1363	|O
vitro	1364	1369	|O
assays	1370	1376	|O
and	1377	1380	|O
to	1381	1383	|O
show	1384	1388	|O
antiinflammatory	1389	1405	|O
activity	1406	1414	|O
against	1415	1422	|O
thioglycollate	1423	1437	|O
-	1437	1438	|O
interferon	1438	1448	|O
-	1448	1449	|O
gamma	1449	1454	|O
-	1454	1455	|O
induced	1455	1462	|O
mouse	1463	1468	|O
peritonitis	1469	1480	|O
.	1480	1481	|O

### abstracts122.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
new	12	15	|O
N	16	17	|B-IUPAC
-	17	18	|I-IUPAC
(	18	19	|I-IUPAC
pyridin	19	26	|I-IUPAC
-	26	27	|I-IUPAC
4	27	28	|I-IUPAC
-	28	29	|I-IUPAC
yl	29	31	|I-IUPAC
)	31	32	|I-IUPAC
-	32	33	|I-IUPAC
(	33	34	|I-IUPAC
indol	34	39	|I-IUPAC
-	39	40	|I-IUPAC
3	40	41	|I-IUPAC
-	41	42	|I-IUPAC
yl	42	44	|I-IUPAC
)	44	45	|I-IUPAC
alkylamides	45	56	|I-IUPAC
44-84	57	62	|O
has	63	66	|O
been	67	71	|O
prepared	72	80	|O
in	81	83	|O
the	84	87	|O
search	88	94	|O
of	95	97	|O
novel	98	103	|O
antiallergic	104	116	|O
compounds	117	126	|O
.	126	127	|O
Synthesis	128	137	|O
of	138	140	|O
the	141	144	|O
desired	145	152	|O
ethyl	153	158	|B-IUPAC
(	159	160	|I-IUPAC
2	160	161	|I-IUPAC
-	161	162	|I-IUPAC
methyindol	162	172	|I-IUPAC
-	172	173	|I-IUPAC
3	173	174	|I-IUPAC
-	174	175	|I-IUPAC
yl	175	177	|I-IUPAC
)	177	178	|I-IUPAC
acetates	178	186	|I-IUPAC
1-4	187	190	|O
was	191	194	|O
achieved	195	203	|O
by	204	206	|O
indolization	207	219	|O
under	220	225	|O
Fischer	226	233	|O
conditions	234	244	|O
;	244	245	|O
Japp	246	250	|O
-	250	251	|O
Klingemann	251	261	|O
method	262	268	|O
followed	269	277	|O
by	278	280	|O
2	281	282	|O
-	282	283	|O
decarboxylation	283	298	|O
afforded	299	307	|O
the	308	311	|O
ethyl	312	317	|B-IUPAC
(	318	319	|I-IUPAC
indol	319	324	|I-IUPAC
-	324	325	|I-IUPAC
3	325	326	|I-IUPAC
-	326	327	|I-IUPAC
yl	327	329	|I-IUPAC
)	329	330	|I-IUPAC
alkanoates	330	340	|I-IUPAC
17-25	341	346	|O
.	346	347	|O
Amidification	348	361	|O
was	362	365	|O
successfully	366	378	|O
carried	379	386	|O
out	387	390	|O
by	391	393	|O
condensation	394	406	|O
of	407	409	|O
the	410	413	|O
corresponding	414	427	|O
acids	428	433	|O
or	434	436	|O
their	437	442	|O
N	443	444	|B-IUPAC
-	444	445	|I-IUPAC
aryl	445	449	|I-IUPAC
(	449	450	|I-IUPAC
methyl	450	456	|I-IUPAC
)	456	457	|I-IUPAC
derivatives	458	469	|B-MODIFIER
with	470	474	|O
4	475	476	|B-IUPAC
-	476	477	|I-IUPAC
aminopyridine	477	490	|I-IUPAC
promoted	491	499	|O
by	500	502	|O
2	503	504	|B-IUPAC
-	504	505	|I-IUPAC
chloro	505	511	|I-IUPAC
-	511	512	|I-IUPAC
1	512	513	|I-IUPAC
-	513	514	|I-IUPAC
methylpyridinium	514	530	|I-IUPAC
iodide	531	537	|I-IUPAC
.	537	538	|O
Efforts	539	546	|O
to	547	549	|O
improve	550	557	|O
the	558	561	|O
antiallergic	562	574	|O
potency	575	582	|O
of	583	585	|O
the	586	589	|O
title	590	595	|O
series	596	602	|O
by	603	605	|O
variation	606	615	|O
of	616	618	|O
the	619	622	|O
indole	623	629	|O
substituents	630	642	|O
(	643	644	|O
R1	644	646	|O
,	646	647	|O
R2	648	650	|O
,	650	651	|O
R	652	653	|O
)	653	654	|O
and	655	658	|O
the	659	662	|O
length	663	669	|O
of	670	672	|O
the	673	676	|O
alkanoic	677	685	|O
chain	686	691	|O
(	692	693	|O
n	693	694	|O
=	695	696	|O
1	697	698	|O
,	698	699	|O
2	700	701	|O
,	701	702	|O
3	703	704	|O
)	704	705	|O
led	706	709	|O
to	710	712	|O
the	713	716	|O
selection	717	726	|O
of	727	729	|O
N	730	731	|B-IUPAC
-	731	732	|I-IUPAC
(	732	733	|I-IUPAC
pyridin	733	740	|I-IUPAC
-	740	741	|I-IUPAC
4	741	742	|I-IUPAC
-	742	743	|I-IUPAC
yl	743	745	|I-IUPAC
)	745	746	|I-IUPAC
-	746	747	|I-IUPAC
[	747	748	|I-IUPAC
1	748	749	|I-IUPAC
-	749	750	|I-IUPAC
(	750	751	|I-IUPAC
4	751	752	|I-IUPAC
-	752	753	|I-IUPAC
fluorobenzyl	753	765	|I-IUPAC
)	765	766	|I-IUPAC
indol	766	771	|I-IUPAC
-	771	772	|I-IUPAC
3	772	773	|I-IUPAC
-	773	774	|I-IUPAC
yl	774	776	|I-IUPAC
]	776	777	|I-IUPAC
acetamide	777	786	|I-IUPAC
45	787	789	|O
,	789	790	|O
out	791	794	|O
of	795	797	|O
41	798	800	|O
compounds	801	810	|O
.	810	811	|O
This	811	815	|O
amide	816	821	|O
was	822	825	|O
406	826	829	|O
-	829	830	|O
fold	830	834	|O
more	835	839	|O
potent	840	846	|O
than	847	851	|O
astemizole	852	862	|O
in	863	865	|O
the	866	869	|O
ovalbumin	870	879	|O
-	879	880	|O
induced	880	887	|O
histamine	888	897	|O
release	898	905	|O
assay	906	911	|O
,	911	912	|O
using	913	918	|O
guinea	919	925	|O
pig	926	929	|O
peritoneal	930	940	|O
mast	941	945	|O
cells	946	951	|O
,	951	952	|O
with	953	957	|O
an	958	960	|O
IC50	961	965	|O
=	966	967	|O
0.016	968	973	|O
microM	974	980	|O
.	980	981	|O
Its	982	985	|O
inhibitory	986	996	|O
activity	997	1005	|O
in	1006	1008	|O
IL	1009	1011	|O
-	1011	1012	|O
4	1012	1013	|O
production	1014	1024	|O
test	1025	1029	|O
from	1030	1034	|O
Th	1035	1037	|O
-	1037	1038	|O
2	1038	1039	|O
cells	1040	1045	|O
was	1046	1049	|O
identical	1050	1059	|O
to	1060	1062	|O
that	1063	1067	|O
of	1068	1070	|O
the	1071	1074	|O
reference	1075	1084	|O
histamine	1085	1094	|O
antagonist	1095	1105	|O
(	1106	1107	|O
IC50	1107	1111	|O
=	1112	1113	|O
8.0	1114	1117	|O
microM	1118	1124	|O
)	1124	1125	|O
and	1126	1129	|O
twice	1130	1135	|O
higher	1136	1142	|O
in	1143	1145	|O
IL	1146	1148	|O
-	1148	1149	|O
5	1149	1150	|O
assay	1151	1156	|O
:	1156	1157	|O
IC50	1158	1162	|O
=	1163	1164	|O
1.5	1165	1168	|O
and	1169	1172	|O
3.3	1173	1176	|O
microM	1177	1183	|O
,	1183	1184	|O
respectively	1185	1197	|O
.	1197	1198	|O
In	1199	1201	|O
vivo	1202	1206	|O
antiallergic	1207	1219	|O
activity	1220	1228	|O
evaluation	1229	1239	|O
confirmed	1240	1249	|O
efficiency	1250	1260	|O
of	1261	1263	|O
45	1264	1266	|O
in	1267	1269	|O
sensitized	1270	1280	|O
guinea	1281	1287	|O
pig	1288	1291	|O
late	1292	1296	|O
phase	1297	1302	|O
eosinophilia	1303	1315	|O
inhibition	1316	1326	|O
,	1326	1327	|O
after	1328	1333	|O
parenteral	1334	1344	|O
and	1345	1348	|O
oral	1349	1353	|O
administration	1354	1368	|O
at	1369	1371	|O
5	1372	1373	|O
and	1374	1377	|O
30	1378	1380	|O
mg	1381	1383	|O
/	1383	1384	|O
kg	1384	1386	|O
,	1386	1387	|O
respectively	1388	1400	|O
.	1400	1401	|O
Its	1402	1405	|O
efficiency	1406	1416	|O
in	1417	1419	|O
inhibition	1420	1430	|O
of	1431	1433	|O
microvascular	1434	1447	|O
permeability	1448	1460	|O
was	1461	1464	|O
assessed	1465	1473	|O
in	1474	1476	|O
two	1477	1480	|O
rhinitis	1481	1489	|O
models	1490	1496	|O
;	1496	1497	|O
ovalbumin	1498	1507	|O
and	1508	1511	|O
capsaicin	1512	1521	|O
-	1521	1522	|O
induced	1522	1529	|O
rhinorrhea	1530	1540	|O
could	1541	1546	|O
be	1547	1549	|O
prevented	1550	1559	|O
after	1560	1565	|O
topical	1566	1573	|O
application	1574	1585	|O
of	1586	1588	|O
submicromolar	1589	1602	|O
concentrations	1603	1617	|O
of	1618	1620	|O
45	1621	1623	|O
(	1624	1625	|O
IC50	1625	1629	|O
=	1630	1631	|O
0.25	1632	1636	|O
and	1637	1640	|O
0.30	1641	1645	|O
microM	1646	1652	|O
)	1652	1653	|O
;	1653	1654	|O
and	1655	1658	|O
it	1659	1661	|O
also	1662	1666	|O
exerted	1667	1674	|O
significant	1675	1686	|O
inhibitory	1687	1697	|O
effect	1698	1704	|O
in	1705	1707	|O
the	1708	1711	|O
first	1712	1717	|O
test	1718	1722	|O
after	1723	1728	|O
iv	1729	1731	|O
and	1732	1735	|O
oral	1736	1740	|O
administration	1741	1755	|O
,	1755	1756	|O
with	1757	1761	|O
ID50	1762	1766	|O
=	1767	1768	|O
0.005	1769	1774	|O
and	1775	1778	|O
0.46	1779	1783	|O
mg	1784	1786	|O
/	1786	1787	|O
kg	1787	1789	|O
.	1789	1790	|O

### abstracts4102.txt
5	0	1	|O
-	1	2	|O
Alkyl	2	7	|O
-	7	8	|O
and	9	12	|O
5	13	14	|B-IUPAC
-	14	15	|I-IUPAC
arylalkyl	15	24	|I-IUPAC
-	24	25	|I-IUPAC
3	25	26	|I-IUPAC
-	26	27	|I-IUPAC
methylenedihydrofuran	27	48	|I-IUPAC
-	48	49	|I-IUPAC
2	49	50	|I-IUPAC
-	50	51	|I-IUPAC
ones	51	55	|I-IUPAC
13a	56	59	|O
-	59	60	|O
e	60	61	|O
,	61	62	|O
3	63	64	|B-IUPAC
-	64	65	|I-IUPAC
alkylidenedihydrofuran	65	87	|I-IUPAC
-	87	88	|I-IUPAC
2	88	89	|I-IUPAC
-	89	90	|I-IUPAC
ones	90	94	|I-IUPAC
18a	95	98	|O
-	98	99	|O
c	99	100	|O
,	100	101	|O
and	102	105	|O
3	106	107	|B-IUPAC
-	107	108	|I-IUPAC
methylenepyrrolidin	108	127	|I-IUPAC
-	127	128	|I-IUPAC
2	128	129	|I-IUPAC
-	129	130	|I-IUPAC
ones	130	134	|I-IUPAC
16a	135	138	|O
-	138	139	|O
e	139	140	|O
were	141	145	|O
synthesized	146	157	|O
utilizing	158	167	|O
ethyl	168	173	|B-IUPAC
2	174	175	|I-IUPAC
-	175	176	|I-IUPAC
diethoxyphosphoryl	176	194	|I-IUPAC
-	194	195	|I-IUPAC
4	195	196	|I-IUPAC
-	196	197	|I-IUPAC
nitroalkanoates	197	212	|I-IUPAC
9a	213	215	|O
-	215	216	|O
e	216	217	|O
as	218	220	|O
common	221	227	|O
intermediates	228	241	|O
.	241	242	|O
All	243	246	|O
obtained	247	255	|O
compounds	256	265	|O
were	266	270	|O
tested	271	277	|O
against	278	285	|O
L	286	287	|O
-	287	288	|O
1210	288	292	|O
,	292	293	|O
HL	294	296	|O
-	296	297	|O
60	297	299	|O
,	299	300	|O
and	301	304	|O
NALM	305	309	|O
-	309	310	|O
6	310	311	|O
leukemia	312	320	|O
cells	321	326	|O
.	326	327	|O
The	328	331	|O
highest	332	339	|O
cytotoxic	340	349	|O
activity	350	358	|O
was	359	362	|O
observed	363	371	|O
for	372	375	|O
3	376	377	|B-IUPAC
-	377	378	|I-IUPAC
methylenefuranones	378	396	|I-IUPAC
13d	397	400	|O
,	400	401	|O
e	401	402	|O
bearing	403	410	|O
benzyl	411	417	|B-IUPAC
or	418	420	|O
3,4	421	424	|B-IUPAC
-	424	425	|I-IUPAC
dimethoxyphenylmethyl	425	446	|I-IUPAC
substituents	447	459	|B-MODIFIER
at	460	462	|O
position	463	471	|O
5	472	473	|O
,	473	474	|O
with	475	479	|O
IC	480	482	|O
(	482	483	|O
50	483	485	|O
)	485	486	|O
values	487	493	|O
of	494	496	|O
5.4	497	500	|O
and	501	504	|O
6.0	505	508	|O
microM	509	515	|O
,	515	516	|O
respectively	517	529	|O
.	529	530	|O
Contrary	531	539	|O
to	540	542	|O
the	543	546	|O
literature	547	557	|O
reports	558	565	|O
,	565	566	|O
no	567	569	|O
enhancement	570	581	|O
in	582	584	|O
activity	585	593	|O
due	594	597	|O
to	598	600	|O
the	601	604	|O
presence	605	613	|O
of	614	616	|O
a	617	618	|O
hydroxy	619	626	|O
group	627	632	|O
was	633	636	|O
found	637	642	|O
when	643	647	|O
the	648	651	|O
cytotoxicity	652	664	|O
of	665	667	|O
furanones	668	677	|O
13a	678	681	|O
,	681	682	|O
b	682	683	|O
,	683	684	|O
d	684	685	|O
and	686	689	|O
5	690	691	|B-IUPAC
-	691	692	|I-IUPAC
(	692	693	|I-IUPAC
1'	693	695	|I-IUPAC
-	695	696	|I-IUPAC
hydroxyalkyl	696	708	|I-IUPAC
)	708	709	|I-IUPAC
-	709	710	|I-IUPAC
3	710	711	|I-IUPAC
-	711	712	|I-IUPAC
methylenedihydrofuran	712	733	|I-IUPAC
-	733	734	|I-IUPAC
2	734	735	|I-IUPAC
-	735	736	|I-IUPAC
ones	736	740	|I-IUPAC
6a	741	743	|O
,	743	744	|O
b	744	745	|O
,	745	746	|O
d	746	747	|O
was	748	751	|O
compared	752	760	|O
.	760	761	|O
The	762	765	|O
anticancer	766	776	|O
activity	777	785	|O
of	786	788	|O
pyrrolidinones	789	803	|O
16a	804	807	|O
-	807	808	|O
e	808	809	|O
and	810	813	|O
3	814	815	|B-IUPAC
-	815	816	|I-IUPAC
alkylidenefuranones	816	835	|I-IUPAC
18a	836	839	|O
-	839	840	|O
c	840	841	|O
was	842	845	|O
much	846	850	|O
weaker	851	857	|O
than	858	862	|O
that	863	867	|O
of	868	870	|O
furanones	871	880	|O
13a	881	884	|O
-	884	885	|O
e	885	886	|O
.	886	887	|O

### abstracts408.txt
Several	0	7	|O
derivatives	8	19	|O
of	20	22	|O
4,5	23	26	|B-MODIFIER
-	26	27	|I-MODIFIER
disubstituted	27	40	|I-MODIFIER
imidazole	41	50	|B-IUPAC
,	50	51	|O
2,4,5	52	57	|B-MODIFIER
-	57	58	|I-MODIFIER
trisubstituted	58	72	|I-MODIFIER
pyrimidine	73	83	|B-IUPAC
,	83	84	|O
2	85	86	|B-MODIFIER
-	86	87	|I-MODIFIER
substituted	87	98	|I-MODIFIER
purine	99	105	|B-IUPAC
,	105	106	|O
thiazolo	107	115	|B-IUPAC
[	115	116	|I-IUPAC
3,2	116	119	|I-IUPAC
-	119	120	|I-IUPAC
alpha	120	125	|I-IUPAC
]	125	126	|I-IUPAC
purine	126	132	|I-IUPAC
,	132	133	|O
[	134	135	|B-IUPAC
1,3	135	138	|I-IUPAC
]	138	139	|I-IUPAC
thiazino	139	147	|I-IUPAC
[	147	148	|I-IUPAC
3,2	148	151	|I-IUPAC
-	151	152	|I-IUPAC
alpha	152	157	|I-IUPAC
]	157	158	|I-IUPAC
purine	158	164	|I-IUPAC
,	164	165	|O
thiazolo	166	174	|B-IUPAC
[	174	175	|I-IUPAC
2,3	175	178	|I-IUPAC
-	178	179	|I-IUPAC
i	179	180	|I-IUPAC
]	180	181	|I-IUPAC
purine	181	187	|I-IUPAC
,	187	188	|O
[	189	190	|B-IUPAC
1,3	190	193	|I-IUPAC
]	193	194	|I-IUPAC
thiazino	194	202	|I-IUPAC
-	202	203	|I-IUPAC
[	203	204	|I-IUPAC
2,3	204	207	|I-IUPAC
-	207	208	|I-IUPAC
i	208	209	|I-IUPAC
]	209	210	|I-IUPAC
purine	210	216	|I-IUPAC
,	216	217	|O
and	218	221	|O
6	222	223	|B-MODIFIER
-	223	224	|I-MODIFIER
substituted	224	235	|I-MODIFIER
pyrazolo	236	244	|B-IUPAC
[	244	245	|I-IUPAC
3,4	245	248	|I-IUPAC
-	248	249	|I-IUPAC
d	249	250	|I-IUPAC
]	250	251	|I-IUPAC
pyrimidine	251	261	|I-IUPAC
were	262	266	|O
synthesized	267	278	|O
and	279	282	|O
tested	283	289	|O
as	290	292	|O
inhibitors	293	303	|O
of	304	306	|O
the	307	310	|O
xanthine	311	319	|O
oxidase	320	327	|O
enzyme	328	334	|O
.	334	335	|O
Of	336	338	|O
those	339	344	|O
,	344	345	|O
some	346	350	|O
4	351	352	|B-IUPAC
-	352	353	|I-IUPAC
(	353	354	|I-IUPAC
acylamino	354	363	|I-IUPAC
)	363	364	|I-IUPAC
-	364	365	|I-IUPAC
5	365	366	|I-IUPAC
-	366	367	|I-IUPAC
carbamoylimidazoles	367	386	|I-IUPAC
and	387	390	|O
2	391	392	|B-IUPAC
-	392	393	|I-IUPAC
thioalkyl	393	402	|I-IUPAC
-	402	403	|O
substituted	403	414	|B-MODIFIER
purines	415	422	|B-IUPAC
exhibited	423	432	|O
very	433	437	|O
good	438	442	|O
inhibitory	443	453	|O
activity	454	462	|O
,	462	463	|O
being	464	469	|O
at	470	472	|O
least	473	478	|O
500	479	482	|O
times	483	488	|O
more	489	493	|O
effective	494	503	|O
than	504	508	|O
allopurinol	509	520	|O
.	520	521	|O
The	522	525	|O
ineffectiveness	526	541	|O
of	542	544	|O
6	545	546	|B-IUPAC
-	546	547	|I-IUPAC
n	547	548	|I-IUPAC
-	548	549	|I-IUPAC
alkylpyrazolo	549	562	|I-IUPAC
[	562	563	|I-IUPAC
3,4	563	566	|I-IUPAC
-	566	567	|I-IUPAC
d	567	568	|I-IUPAC
]	568	569	|I-IUPAC
pyrimidines	569	580	|I-IUPAC
is	581	583	|O
imputable	584	593	|O
to	594	596	|O
the	597	600	|O
alkyl	601	606	|O
chain	607	612	|O
which	613	618	|O
could	619	624	|O
hinder	625	631	|O
the	632	635	|O
coordination	636	648	|O
with	649	653	|O
molybdenum	654	664	|O
according	665	674	|O
to	675	677	|O
the	678	681	|O
known	682	687	|O
mechanism	688	697	|O
for	698	701	|O
the	702	705	|O
binding	706	713	|O
of	714	716	|O
the	717	720	|O
inhibitor	721	730	|O
allopurinol	731	742	|O
;	742	743	|O
the	744	747	|O
effectiveness	748	761	|O
of	762	764	|O
imidazole	765	774	|O
derivatives	775	786	|O
,	786	787	|O
by	788	790	|O
contrast	791	799	|O
with	800	804	|O
the	805	808	|O
ineffectiveness	809	824	|O
of	825	827	|O
4,5	828	831	|B-IUPAC
-	831	832	|I-IUPAC
diamino	832	839	|I-IUPAC
-	839	840	|I-IUPAC
2	840	841	|I-IUPAC
-	841	842	|I-IUPAC
(	842	843	|I-IUPAC
thioalkyl	843	852	|I-IUPAC
)	852	853	|I-IUPAC
-	853	854	|I-IUPAC
6	854	855	|I-IUPAC
-	855	856	|I-IUPAC
hydroxypyrimidines	856	874	|I-IUPAC
,	874	875	|O
indicates	876	885	|O
the	886	889	|O
relative	890	898	|O
importance	899	909	|O
of	910	912	|O
the	913	916	|O
five	917	921	|O
-	921	922	|O
membered	922	930	|O
ring	931	935	|O
in	936	938	|O
the	939	942	|O
interaction	943	954	|O
with	955	959	|O
the	960	963	|O
enzyme	964	970	|O
.	970	971	|O
Moreover	972	980	|O
,	980	981	|O
the	982	985	|O
marked	986	992	|O
effectiveness	993	1006	|O
of	1007	1009	|O
the	1010	1013	|O
angularly	1014	1023	|O
-	1023	1024	|O
cyclized	1024	1032	|O
[	1033	1034	|B-IUPAC
1,3	1034	1037	|I-IUPAC
]	1037	1038	|I-IUPAC
thiazino	1038	1046	|I-IUPAC
[	1046	1047	|I-IUPAC
2,3	1047	1050	|I-IUPAC
-	1050	1051	|I-IUPAC
i	1051	1052	|I-IUPAC
]	1052	1053	|I-IUPAC
purinones	1053	1062	|I-IUPAC
,	1062	1063	|O
which	1064	1069	|O
constitute	1070	1080	|O
an	1081	1083	|O
interesting	1084	1095	|O
new	1096	1099	|O
class	1100	1105	|O
of	1106	1108	|O
inhibitors	1109	1119	|O
,	1119	1120	|O
together	1121	1129	|O
with	1130	1134	|O
the	1135	1138	|O
weak	1139	1143	|O
activity	1144	1152	|O
of	1153	1155	|O
linearly	1156	1164	|O
-	1164	1165	|O
cyclized	1165	1173	|O
derivatives	1174	1185	|O
,	1185	1186	|O
allowed	1187	1194	|O
us	1195	1197	|O
to	1198	1200	|O
characterize	1201	1213	|O
more	1214	1218	|O
precisely	1219	1228	|O
the	1229	1232	|O
lipophilic	1233	1243	|O
region	1244	1250	|O
of	1251	1253	|O
the	1254	1257	|O
enzyme	1258	1264	|O
facing	1265	1271	|O
the	1272	1275	|O
N	1276	1277	|O
(	1277	1278	|O
1	1278	1279	|O
)	1279	1280	|O
-	1280	1281	|O
C	1281	1282	|O
(	1282	1283	|O
2	1283	1284	|O
)	1284	1285	|O
positions	1286	1295	|O
of	1296	1298	|O
the	1299	1302	|O
substrate	1303	1312	|O
hypoxanthine	1313	1325	|O
.	1325	1326	|O

### abstracts1105.txt
A	0	1	|O
synthesis	2	11	|O
scheme	12	18	|O
for	19	22	|O
3'	23	25	|B-IUPAC
-	25	26	|I-IUPAC
C	26	27	|I-IUPAC
-	27	28	|I-IUPAC
methyl	28	34	|I-IUPAC
-	34	35	|I-IUPAC
2'	35	37	|I-IUPAC
-	37	38	|I-IUPAC
deoxynucleosides	38	54	|I-IUPAC
and	55	58	|O
3'	59	61	|B-IUPAC
-	61	62	|I-IUPAC
C	62	63	|I-IUPAC
-	63	64	|I-IUPAC
methylidene	64	75	|I-IUPAC
-	75	76	|I-IUPAC
2'	76	78	|I-IUPAC
,	78	79	|I-IUPAC
3'	79	81	|I-IUPAC
-	81	82	|I-IUPAC
dideoxy	82	89	|I-IUPAC
-	89	90	|I-IUPAC
5	90	91	|I-IUPAC
-	91	92	|I-IUPAC
methyluridine	92	105	|I-IUPAC
has	106	109	|O
been	110	114	|O
proposed	115	123	|O
with	124	128	|O
2	129	130	|B-IUPAC
-	130	131	|I-IUPAC
deoxyribose	131	142	|I-IUPAC
as	143	145	|O
the	146	149	|O
starting	150	158	|O
material	159	167	|O
.	167	168	|O
Methyl	169	175	|O
5	176	177	|B-IUPAC
-	177	178	|I-IUPAC
O	178	179	|I-IUPAC
-	179	180	|I-IUPAC
benzoyl	180	187	|I-IUPAC
-	187	188	|I-IUPAC
2	188	189	|I-IUPAC
-	189	190	|I-IUPAC
deoxyribofuranose	190	207	|I-IUPAC
was	208	211	|O
oxidized	212	220	|O
and	221	224	|O
the	225	228	|O
mixture	229	236	|O
of	237	239	|O
the	240	243	|O
3'	244	246	|B-IUPAC
-	246	247	|I-IUPAC
keto	247	251	|I-IUPAC
derivatives	252	263	|B-MODIFIER
was	264	267	|O
separated	268	277	|O
into	278	282	|O
the	283	286	|O
alpha	287	292	|O
-	292	293	|O
and	294	297	|O
beta	298	302	|O
-	302	303	|O
anomers	303	310	|O
.	310	311	|O
The	312	315	|O
beta	316	320	|O
-	320	321	|O
keto	321	325	|O
derivative	326	336	|O
was	337	340	|O
converted	341	350	|O
by	351	353	|O
reaction	354	362	|O
with	363	367	|O
MeMgBr	368	374	|O
,	374	375	|O
and	376	379	|O
after	380	385	|O
reaction	386	394	|O
with	395	399	|O
thymine	400	407	|O
and	408	411	|O
subsequent	412	422	|O
deprotection	423	435	|O
1	436	437	|B-IUPAC
-	437	438	|I-IUPAC
(	438	439	|I-IUPAC
3'	439	441	|I-IUPAC
-	441	442	|I-IUPAC
C	442	443	|I-IUPAC
-	443	444	|I-IUPAC
methyl	444	450	|I-IUPAC
-	450	451	|I-IUPAC
2'	451	453	|I-IUPAC
-	453	454	|I-IUPAC
alpha	454	459	|I-IUPAC
-	459	460	|I-IUPAC
deoxy	460	465	|I-IUPAC
-	465	466	|I-IUPAC
alpha	466	471	|I-IUPAC
-	471	472	|I-IUPAC
D	472	473	|I-IUPAC
-	473	474	|I-IUPAC
threo	474	479	|I-IUPAC
-	479	480	|I-IUPAC
pentofuranosyl	480	494	|I-IUPAC
)	494	495	|I-IUPAC
thymine	495	502	|I-IUPAC
and	503	506	|O
its	507	510	|O
beta	511	515	|O
-	515	516	|O
anomer	516	522	|O
were	523	527	|O
obtained	528	536	|O
.	536	537	|O
The	538	541	|O
same	542	546	|O
reactions	547	556	|O
with	557	561	|O
the	562	565	|O
alpha	566	571	|O
-	571	572	|O
keto	572	576	|O
sugar	577	582	|O
gave	583	587	|O
1	588	589	|B-IUPAC
-	589	590	|I-IUPAC
(	590	591	|I-IUPAC
3'	591	593	|I-IUPAC
-	593	594	|I-IUPAC
C	594	595	|I-IUPAC
-	595	596	|I-IUPAC
methyl	596	602	|I-IUPAC
-	602	603	|I-IUPAC
2'	603	605	|I-IUPAC
-	605	606	|I-IUPAC
deoxy	606	611	|I-IUPAC
-	611	612	|I-IUPAC
alpha	612	617	|I-IUPAC
-	617	618	|I-IUPAC
D	618	619	|I-IUPAC
-	619	620	|I-IUPAC
erythro	620	627	|I-IUPAC
-	627	628	|I-IUPAC
pentofuranosyl	628	642	|I-IUPAC
)	642	643	|I-IUPAC
thymine	643	650	|I-IUPAC
and	651	654	|O
its	655	658	|O
beta	659	663	|O
-	663	664	|O
anomer	664	670	|O
.	670	671	|O
1	672	673	|B-IUPAC
-	673	674	|I-IUPAC
(	674	675	|I-IUPAC
5	675	676	|I-IUPAC
-	676	677	|I-IUPAC
O	677	678	|I-IUPAC
-	678	679	|I-IUPAC
Benzoyl	679	686	|I-IUPAC
-	686	687	|I-IUPAC
3'	687	689	|I-IUPAC
-	689	690	|I-IUPAC
C	690	691	|I-IUPAC
-	691	692	|I-IUPAC
methyl	692	698	|I-IUPAC
-	698	699	|I-IUPAC
2'	699	701	|I-IUPAC
-	701	702	|I-IUPAC
deoxy	702	707	|I-IUPAC
-	707	708	|I-IUPAC
alpha	708	713	|I-IUPAC
-	713	714	|I-IUPAC
D	714	715	|I-IUPAC
-	715	716	|I-IUPAC
threo	716	721	|I-IUPAC
-	721	722	|I-IUPAC
pentofuranosyl	722	736	|I-IUPAC
)	736	737	|I-IUPAC
thymine	737	744	|I-IUPAC
was	745	748	|O
converted	749	758	|O
to	759	761	|O
a	762	763	|O
mixture	764	771	|O
of	772	774	|O
3'	775	777	|B-IUPAC
-	777	778	|I-IUPAC
C	778	779	|I-IUPAC
-	779	780	|I-IUPAC
methylidene	780	791	|I-IUPAC
-	791	792	|I-IUPAC
2'	792	794	|I-IUPAC
,	794	795	|I-IUPAC
3'	795	797	|I-IUPAC
-	797	798	|I-IUPAC
dideoxy	798	805	|I-IUPAC
-	805	806	|I-IUPAC
5	806	807	|I-IUPAC
-	807	808	|I-IUPAC
methyluridine	808	821	|I-IUPAC
and	822	825	|O
3'	826	828	|B-IUPAC
-	828	829	|I-IUPAC
C	829	830	|I-IUPAC
-	830	831	|I-IUPAC
methyl	831	837	|I-IUPAC
-	837	838	|I-IUPAC
2'	838	840	|I-IUPAC
,	840	841	|I-IUPAC
3'	841	843	|I-IUPAC
-	843	844	|I-IUPAC
dideoxy	844	851	|I-IUPAC
-	851	852	|I-IUPAC
2'	852	854	|I-IUPAC
,	854	855	|I-IUPAC
3'	855	857	|I-IUPAC
-	857	858	|I-IUPAC
didehydro	858	867	|I-IUPAC
-	867	868	|I-IUPAC
5	868	869	|I-IUPAC
-	869	870	|I-IUPAC
methyluridine	870	883	|I-IUPAC
,	883	884	|O
which	885	890	|O
were	891	895	|O
separated	896	905	|O
.	905	906	|O
The	907	910	|O
stereoselectivity	911	928	|O
of	929	931	|O
the	932	935	|O
Grignard	936	944	|O
reagent	945	952	|O
's	952	954	|O
attachment	955	965	|O
to	966	968	|O
2	969	970	|B-IUPAC
-	970	971	|I-IUPAC
deoxyfuranose	971	984	|I-IUPAC
3	985	986	|I-IUPAC
-	986	987	|I-IUPAC
ulosides	987	995	|I-IUPAC
has	996	999	|O
been	1000	1004	|O
ruled	1005	1010	|O
by	1011	1013	|O
the	1014	1017	|O
substitute	1018	1028	|O
configuration	1029	1042	|O
at	1043	1045	|O
Cl	1046	1048	|O
.	1048	1049	|O
Also	1050	1054	|O
,	1054	1055	|O
the	1056	1059	|O
effect	1060	1066	|O
of	1067	1069	|O
the	1070	1073	|O
hydroxyl	1074	1082	|B-IUPAC
or	1083	1085	|O
OBz	1086	1089	|O
group	1090	1095	|O
configuration	1096	1109	|O
at	1110	1112	|O
C3	1113	1115	|O
on	1116	1118	|O
the	1119	1122	|O
condensation	1123	1135	|O
stereoselectivity	1136	1153	|O
of	1154	1156	|O
3	1157	1158	|B-IUPAC
-	1158	1159	|I-IUPAC
C	1159	1160	|I-IUPAC
-	1160	1161	|I-IUPAC
methyl	1161	1167	|I-IUPAC
-	1167	1168	|I-IUPAC
2	1168	1169	|I-IUPAC
-	1169	1170	|I-IUPAC
deoxyfuranosides	1170	1186	|I-IUPAC
with	1187	1191	|O
silylated	1192	1201	|O
thymine	1202	1209	|O
has	1210	1213	|O
been	1214	1218	|O
studied	1219	1226	|O
.	1226	1227	|O
The	1228	1231	|O
structure	1232	1241	|O
of	1242	1244	|O
the	1245	1248	|O
obtained	1249	1257	|O
compounds	1258	1267	|O
was	1268	1271	|O
proved	1272	1278	|O
by	1279	1281	|O
1H	1282	1284	|O
NMR	1285	1288	|O
UV	1289	1291	|O
,	1291	1292	|O
13C	1293	1296	|O
NMR	1297	1300	|O
,	1300	1301	|O
and	1302	1305	|O
CD	1306	1308	|O
spectroscopy	1309	1321	|O
,	1321	1322	|O
as	1323	1325	|O
well	1326	1330	|O
as	1331	1333	|O
elemental	1334	1343	|O
(	1344	1345	|O
C	1345	1346	|O
,	1346	1347	|O
H	1348	1349	|O
,	1349	1350	|O
N	1351	1352	|O
)	1352	1353	|O
analysis	1354	1362	|O
.	1362	1363	|O
The	1364	1367	|O
C2	1368	1370	|O
'	1370	1371	|O
-	1371	1372	|O
endo	1372	1376	|O
-	1376	1377	|O
C1	1377	1379	|O
'	1379	1380	|O
-	1380	1381	|O
exo	1381	1384	|O
conformation	1385	1397	|O
,	1397	1398	|O
the	1399	1402	|O
anti	1403	1407	|O
conformation	1408	1420	|O
of	1421	1423	|O
thymine	1424	1431	|O
in	1432	1434	|O
relation	1435	1443	|O
to	1444	1446	|O
the	1447	1450	|O
glycosidic	1451	1461	|O
bond	1462	1466	|O
,	1466	1467	|O
and	1468	1471	|O
the	1472	1475	|O
gauche+	1476	1483	|O
conformation	1483	1495	|O
in	1496	1498	|O
relation	1499	1507	|O
to	1508	1510	|O
the	1511	1514	|O
C4	1515	1517	|O
'	1517	1518	|O
-	1518	1519	|O
C5	1519	1521	|O
'	1521	1522	|O
bond	1523	1527	|O
are	1528	1531	|O
characteristic	1532	1546	|O
for	1547	1550	|O
the	1551	1554	|O
3'	1555	1557	|B-IUPAC
-	1557	1558	|I-IUPAC
C	1558	1559	|I-IUPAC
-	1559	1560	|I-IUPAC
methyl	1560	1566	|I-IUPAC
-	1566	1567	|I-IUPAC
2'	1567	1569	|I-IUPAC
-	1569	1570	|I-IUPAC
deoxythymidine	1570	1584	|I-IUPAC
structure	1585	1594	|O
in	1595	1597	|O
the	1598	1601	|O
crystals	1602	1610	|O
.	1610	1611	|O
3'	1612	1614	|B-IUPAC
-	1614	1615	|I-IUPAC
C	1615	1616	|I-IUPAC
-	1616	1617	|I-IUPAC
Methyl	1617	1623	|I-IUPAC
-	1623	1624	|I-IUPAC
2'	1624	1626	|I-IUPAC
-	1626	1627	|I-IUPAC
deoxythymidine	1627	1641	|I-IUPAC
5'	1642	1644	|I-IUPAC
-	1644	1645	|I-IUPAC
triphosphate	1645	1657	|I-IUPAC
was	1658	1661	|O
synthesized	1662	1673	|O
and	1674	1677	|O
proved	1678	1684	|O
to	1685	1687	|O
be	1688	1690	|O
a	1691	1692	|O
competitive	1693	1704	|O
inhibitor	1705	1714	|O
,	1714	1715	|O
with	1716	1720	|O
respect	1721	1728	|O
to	1729	1731	|O
dTTP	1732	1736	|O
,	1736	1737	|O
of	1738	1740	|O
a	1741	1742	|O
number	1743	1749	|O
of	1750	1752	|O
DNA	1753	1756	|O
polymerases	1757	1768	|O
,	1768	1769	|O
including	1770	1779	|O
the	1780	1783	|O
reverse	1784	1791	|O
transcriptases	1792	1806	|O
of	1807	1809	|O
human	1810	1815	|O
immunodeficiency	1816	1832	|O
virus	1833	1838	|O
type	1839	1843	|O
1	1844	1845	|O
(	1846	1847	|O
HIV	1847	1850	|O
-	1850	1851	|O
1	1851	1852	|O
)	1852	1853	|O
and	1854	1857	|O
avian	1858	1863	|O
myeloblastosis	1864	1878	|O
virus	1879	1884	|O
(	1885	1886	|O
AMV	1886	1889	|O
)	1889	1890	|O
.	1890	1891	|O
None	1892	1896	|O
of	1897	1899	|O
the	1900	1903	|O
DNA	1904	1907	|O
polymerases	1908	1919	|O
examined	1920	1928	|O
were	1929	1933	|O
able	1934	1938	|O
to	1939	1941	|O
incorporate	1942	1953	|O
this	1954	1958	|O
compound	1959	1967	|O
into	1968	1972	|O
the	1973	1976	|O
growing	1977	1984	|O
DNA	1985	1988	|O
chain	1989	1994	|O
.	1994	1995	|O
In	1996	1998	|O
contrast	1999	2007	|O
,	2007	2008	|O
3'	2009	2011	|B-IUPAC
-	2011	2012	|I-IUPAC
C	2012	2013	|I-IUPAC
-	2013	2014	|I-IUPAC
methylidene	2014	2025	|I-IUPAC
-	2025	2026	|I-IUPAC
2'	2026	2028	|I-IUPAC
,	2028	2029	|I-IUPAC
3'	2029	2031	|I-IUPAC
-	2031	2032	|I-IUPAC
dideoxy	2032	2039	|I-IUPAC
-	2039	2040	|I-IUPAC
5	2040	2041	|I-IUPAC
-	2041	2042	|I-IUPAC
methyluridine	2042	2055	|I-IUPAC
5'	2056	2058	|I-IUPAC
-	2058	2059	|I-IUPAC
triphosphate	2059	2071	|I-IUPAC
was	2072	2075	|O
found	2076	2081	|O
to	2082	2084	|O
be	2085	2087	|O
incorporated	2088	2100	|O
at	2101	2103	|O
the	2104	2107	|O
3'	2108	2110	|O
-	2110	2111	|O
end	2111	2114	|O
of	2115	2117	|O
the	2118	2121	|O
DNA	2122	2125	|O
chain	2126	2131	|O
by	2132	2134	|O
HIV	2135	2138	|O
-	2138	2139	|O
1	2139	2140	|O
reverse	2141	2148	|O
transcriptase	2149	2162	|O
,	2162	2163	|O
albeit	2164	2170	|O
with	2171	2175	|O
very	2176	2180	|O
low	2181	2184	|O
efficiency	2185	2195	|O
.	2195	2196	|O
3'	2197	2199	|B-IUPAC
-	2199	2200	|I-IUPAC
C	2200	2201	|I-IUPAC
-	2201	2202	|I-IUPAC
Methyl	2202	2208	|I-IUPAC
-	2208	2209	|I-IUPAC
2'	2209	2211	|I-IUPAC
-	2211	2212	|I-IUPAC
deoxy	2212	2217	|I-IUPAC
-	2217	2218	|I-IUPAC
5	2218	2219	|I-IUPAC
-	2219	2220	|I-IUPAC
methyluridine	2220	2233	|I-IUPAC
did	2234	2237	|O
not	2238	2241	|O
suppress	2242	2250	|O
HIV	2251	2254	|O
-	2254	2255	|O
1	2255	2256	|O
replication	2257	2268	|O
in	2269	2271	|O
MT	2272	2274	|O
-	2274	2275	|O
4	2275	2276	|O
cells	2277	2282	|O
at	2283	2285	|O
500	2286	2289	|O
microM	2290	2296	|O
while	2297	2302	|O
its	2303	2306	|O
5'	2307	2309	|B-IUPAC
-	2309	2310	|I-IUPAC
phosphite	2310	2319	|I-IUPAC
derivative	2320	2330	|B-MODIFIER
exhibited	2331	2340	|O
modest	2341	2347	|O
anti	2348	2352	|O
-	2352	2353	|O
HIV	2353	2356	|O
-	2356	2357	|O
1	2357	2358	|O
activity	2359	2367	|O
.	2367	2368	|O

### abstracts3249.txt
Treatment	0	9	|O
of	10	12	|O
3'	13	15	|B-IUPAC
,	15	16	|I-IUPAC
5'	16	18	|I-IUPAC
-	18	19	|I-IUPAC
di	19	21	|I-IUPAC
-	21	22	|I-IUPAC
O	22	23	|I-IUPAC
-	23	24	|I-IUPAC
acetyl	24	30	|I-IUPAC
-	30	31	|I-IUPAC
(	31	32	|I-IUPAC
E	32	33	|I-IUPAC
)	33	34	|I-IUPAC
-	34	35	|I-IUPAC
5	35	36	|I-IUPAC
-	36	37	|I-IUPAC
(	37	38	|I-IUPAC
2	38	39	|I-IUPAC
-	39	40	|I-IUPAC
bromovinyl	40	50	|I-IUPAC
)	50	51	|I-IUPAC
-	51	52	|I-IUPAC
2'	52	54	|I-IUPAC
-	54	55	|I-IUPAC
deoxyuridine	55	67	|I-IUPAC
(	68	69	|O
2	69	70	|O
)	70	71	|O
with	72	76	|O
p	77	78	|B-IUPAC
-	78	79	|I-IUPAC
chlorophenyl	79	91	|I-IUPAC
phosphorodichloridate	92	113	|I-IUPAC
and	114	117	|O
1,2,4	118	123	|B-IUPAC
-	123	124	|I-IUPAC
triazole	124	132	|I-IUPAC
gave	133	137	|O
1	138	139	|B-IUPAC
-	139	140	|I-IUPAC
(	140	141	|I-IUPAC
3,5	141	144	|I-IUPAC
-	144	145	|I-IUPAC
di	145	147	|I-IUPAC
-	147	148	|I-IUPAC
O	148	149	|I-IUPAC
-	149	150	|I-IUPAC
acetyl	150	156	|I-IUPAC
-	156	157	|I-IUPAC
2	157	158	|I-IUPAC
-	158	159	|I-IUPAC
deoxy	159	164	|I-IUPAC
-	164	165	|I-IUPAC
beta	165	169	|I-IUPAC
-	169	170	|I-IUPAC
D	170	171	|I-IUPAC
-	171	172	|I-IUPAC
erythro	172	179	|I-IUPAC
-	179	180	|I-IUPAC
pentofuranosyl	180	194	|I-IUPAC
)	194	195	|I-IUPAC
-	195	196	|I-IUPAC
(	196	197	|I-IUPAC
E	197	198	|I-IUPAC
)	198	199	|I-IUPAC
-	199	200	|I-IUPAC
5	200	201	|I-IUPAC
-	201	202	|I-IUPAC
(	202	203	|I-IUPAC
2	203	204	|I-IUPAC
-	204	205	|I-IUPAC
br	205	207	|I-IUPAC
o	208	209	|I-IUPAC
movinyl	210	217	|I-IUPAC
)	217	218	|I-IUPAC
-	218	219	|I-IUPAC
4	220	221	|I-IUPAC
-	221	222	|I-IUPAC
(	222	223	|I-IUPAC
1,2,4	223	228	|I-IUPAC
-	228	229	|I-IUPAC
triazol	229	236	|I-IUPAC
-	236	237	|I-IUPAC
1	237	238	|I-IUPAC
-	238	239	|I-IUPAC
yl	239	241	|I-IUPAC
)	241	242	|I-IUPAC
pyrimidin	242	251	|I-IUPAC
-	251	252	|I-IUPAC
2	252	253	|I-IUPAC
(	253	254	|I-IUPAC
1H	254	256	|I-IUPAC
)	256	257	|I-IUPAC
-	257	258	|I-IUPAC
one	258	261	|I-IUPAC
(	262	263	|O
3	263	264	|O
)	264	265	|O
.	265	266	|O
Reaction	267	275	|O
of	276	278	|O
3	279	280	|O
with	281	285	|O
ammonia	286	293	|O
gave	294	298	|O
(	299	300	|B-IUPAC
E	300	301	|I-IUPAC
)	301	302	|I-IUPAC
-	302	303	|I-IUPAC
5	303	304	|I-IUPAC
-	304	305	|I-IUPAC
(	305	306	|I-IUPAC
2	306	307	|I-IUPAC
-	307	308	|I-IUPAC
bromovinyl	308	318	|I-IUPAC
)	318	319	|I-IUPAC
-	319	320	|I-IUPAC
2'	320	322	|I-IUPAC
-	322	323	|I-IUPAC
deoxycytidine	323	336	|I-IUPAC
(	337	338	|O
1	338	339	|O
)	339	340	|O
,	340	341	|O
the	342	345	|O
overall	346	353	|O
yield	354	359	|O
from	360	364	|O
2	365	366	|O
being	367	372	|O
60%	373	376	|O
.	376	377	|O
A	378	379	|O
similar	380	387	|O
4	388	389	|B-IUPAC
-	389	390	|I-IUPAC
(	390	391	|I-IUPAC
1,2,4	391	396	|I-IUPAC
-	396	397	|I-IUPAC
triazol	397	404	|I-IUPAC
-	404	405	|I-IUPAC
1	405	406	|I-IUPAC
-	406	407	|I-IUPAC
yl	407	409	|I-IUPAC
)	409	410	|I-IUPAC
derivative	411	421	|B-MODIFIER
(	422	423	|O
4	423	424	|O
)	424	425	|O
was	426	429	|O
obtained	430	438	|O
from	439	443	|O
3'	444	446	|B-IUPAC
,	446	447	|I-IUPAC
5'	447	449	|I-IUPAC
-	449	450	|I-IUPAC
di	450	452	|I-IUPAC
-	452	453	|I-IUPAC
O	453	454	|I-IUPAC
-	454	455	|I-IUPAC
acetyl	455	461	|I-IUPAC
-	461	462	|I-IUPAC
thymidine	462	471	|I-IUPAC
by	472	474	|O
the	475	478	|O
use	479	482	|O
of	483	485	|O
phosphoryl	486	496	|O
chloride	497	505	|O
as	506	508	|O
the	509	512	|O
condensing	513	523	|O
agent	524	529	|O
.	529	530	|O
Treatment	531	540	|O
of	541	543	|O
thymidine	544	553	|O
with	554	558	|O
trimethylsilyl	559	573	|O
chloride	574	582	|O
and	583	586	|O
then	587	591	|O
with	592	596	|O
phosphoryl	597	607	|O
chloride	608	616	|O
and	617	620	|O
1,2,4	621	626	|B-IUPAC
-	626	627	|I-IUPAC
triazole	627	635	|I-IUPAC
gave	636	640	|O
upon	641	645	|O
workup	646	652	|O
1	653	654	|B-IUPAC
-	654	655	|I-IUPAC
(	655	656	|I-IUPAC
2	656	657	|I-IUPAC
-	657	658	|I-IUPAC
deoxy	658	663	|I-IUPAC
-	663	664	|I-IUPAC
beta	664	668	|I-IUPAC
-	668	669	|I-IUPAC
D	669	670	|I-IUPAC
-	670	671	|I-IUPAC
erythro	671	678	|I-IUPAC
-	678	679	|I-IUPAC
pentofuranosyl	679	693	|I-IUPAC
)	693	694	|I-IUPAC
-	694	695	|I-IUPAC
5	695	696	|I-IUPAC
-	696	697	|I-IUPAC
methyl	697	703	|I-IUPAC
-	703	704	|I-IUPAC
4	704	705	|I-IUPAC
(	705	706	|I-IUPAC
1,2,4	706	711	|I-IUPAC
-	711	712	|I-IUPAC
triazol	712	719	|I-IUPAC
-	720	721	|I-IUPAC
1	721	722	|I-IUPAC
-	722	723	|I-IUPAC
yl	723	725	|I-IUPAC
)	725	726	|I-IUPAC
pyrimidin	727	736	|I-IUPAC
-	736	737	|I-IUPAC
2	737	738	|I-IUPAC
(	738	739	|I-IUPAC
1H	739	741	|I-IUPAC
)	741	742	|I-IUPAC
-	742	743	|I-IUPAC
one	743	746	|I-IUPAC
(	747	748	|O
5	748	749	|O
)	749	750	|O
.	750	751	|O
(	752	753	|B-IUPAC
E	753	754	|I-IUPAC
)	754	755	|I-IUPAC
-	755	756	|I-IUPAC
5	756	757	|I-IUPAC
-	757	758	|I-IUPAC
(	758	759	|I-IUPAC
2	759	760	|I-IUPAC
-	760	761	|I-IUPAC
Bromovinyl	761	771	|I-IUPAC
)	771	772	|I-IUPAC
-	772	773	|I-IUPAC
2'	773	775	|I-IUPAC
-	775	776	|I-IUPAC
deoxyuridine	776	788	|I-IUPAC
(	789	790	|O
BVDU	790	794	|O
)	794	795	|O
when	796	800	|O
similarly	801	810	|O
treated	811	818	|O
gave	819	823	|O
the	824	827	|O
corresponding	828	841	|O
(	842	843	|B-IUPAC
E	843	844	|I-IUPAC
)	844	845	|I-IUPAC
-	845	846	|I-IUPAC
5	846	847	|I-IUPAC
-	847	848	|I-IUPAC
(	848	849	|I-IUPAC
2	849	850	|I-IUPAC
-	850	851	|I-IUPAC
bromovinyl	851	861	|I-IUPAC
)	861	862	|I-IUPAC
compound	863	871	|B-MODIFIER
7	872	873	|O
.	873	874	|O
A	875	876	|O
minor	877	882	|O
product	883	890	|O
formed	891	897	|O
in	898	900	|O
both	901	905	|O
cases	906	911	|O
was	912	915	|O
a	916	917	|O
4	918	919	|B-IUPAC
-	919	920	|I-IUPAC
(	920	921	|I-IUPAC
1,2,4	921	926	|I-IUPAC
-	926	927	|I-IUPAC
triazol	927	934	|I-IUPAC
-	934	935	|I-IUPAC
1	935	936	|I-IUPAC
-	936	937	|I-IUPAC
yl	937	939	|I-IUPAC
)	939	940	|I-IUPAC
derivative	941	951	|B-MODIFIER
in	952	954	|O
which	955	960	|O
the	961	964	|O
nucleoside	965	975	|O
5'	976	978	|B-IUPAC
-	978	979	|I-IUPAC
hydroxyl	979	987	|I-IUPAC
group	988	993	|B-MODIFIER
had	994	997	|O
been	998	1002	|O
replaced	1003	1011	|O
by	1012	1014	|O
chlorine	1015	1023	|O
(	1024	1025	|O
6	1025	1026	|O
and	1027	1030	|O
8	1031	1032	|O
)	1032	1033	|O
.	1033	1034	|O
Whereas	1035	1042	|O
compounds	1043	1052	|O
4-6	1053	1056	|O
and	1057	1060	|O
8	1061	1062	|O
did	1063	1066	|O
not	1067	1070	|O
exhibit	1071	1078	|O
a	1079	1080	|O
selective	1081	1090	|O
antiviral	1091	1100	|O
effect	1101	1107	|O
,	1107	1108	|O
compounds	1109	1118	|O
1-3	1119	1122	|O
and	1123	1126	|O
7	1127	1128	|O
proved	1129	1135	|O
almost	1136	1142	|O
as	1143	1145	|O
active	1146	1152	|O
as	1153	1155	|O
the	1156	1159	|O
reference	1160	1169	|O
compound	1170	1178	|O
BVDU	1179	1183	|O
.	1183	1184	|O
In	1185	1187	|O
particular	1188	1198	|O
,	1198	1199	|O
compound	1200	1208	|O
7	1209	1210	|O
,	1210	1211	|O
the	1212	1215	|O
4	1216	1217	|B-IUPAC
-	1217	1218	|I-IUPAC
triazolyl	1218	1227	|I-IUPAC
derivative	1228	1238	|B-MODIFIER
of	1239	1241	|O
BVDU	1242	1246	|O
,	1246	1247	|O
would	1248	1253	|O
seem	1254	1258	|O
worth	1259	1264	|O
pursuing	1265	1273	|O
for	1274	1277	|O
its	1278	1281	|O
potential	1282	1291	|O
as	1292	1294	|O
an	1295	1297	|O
inhibitor	1298	1307	|O
of	1308	1310	|O
herpes	1311	1317	|O
simplex	1318	1325	|O
virus	1326	1331	|O
type	1332	1336	|O
1	1337	1338	|O
and	1339	1342	|O
varicella	1343	1352	|O
-	1352	1353	|O
zoster	1353	1359	|O
virus	1360	1365	|O
.	1365	1366	|O

### abstracts1595.txt
Certain	0	7	|O
derivatives	8	19	|O
containing	20	30	|O
the	31	34	|O
1,2	35	38	|B-IUPAC
-	38	39	|I-IUPAC
dihydropyrido	39	52	|I-IUPAC
[	52	53	|I-IUPAC
3,4	53	56	|I-IUPAC
-	56	57	|I-IUPAC
b	57	58	|I-IUPAC
]	58	59	|I-IUPAC
pyrazine	59	67	|I-IUPAC
(	68	69	|O
1	69	70	|B-IUPAC
-	70	71	|I-IUPAC
deaza	71	76	|I-IUPAC
-	76	77	|I-IUPAC
7,8	77	80	|I-IUPAC
-	80	81	|I-IUPAC
dihydropteridine	81	97	|I-IUPAC
)	97	98	|O
ring	99	103	|B-MODIFIER
system	104	110	|I-MODIFIER
are	111	114	|O
active	115	121	|O
against	122	129	|O
experimental	130	142	|O
neoplasms	143	152	|O
in	153	155	|O
mice	156	160	|O
.	160	161	|O
The	162	165	|O
mechanism	166	175	|O
of	176	178	|O
action	179	185	|O
of	186	188	|O
these	189	194	|O
agents	195	201	|O
has	202	205	|O
been	206	210	|O
attributed	211	221	|O
to	222	224	|O
the	225	228	|O
accumulation	229	241	|O
of	242	244	|O
cells	245	250	|O
at	251	253	|O
mitosis	254	261	|O
.	261	262	|O
Identification	263	277	|O
of	278	280	|O
the	281	284	|O
structural	285	295	|O
features	296	304	|O
that	305	309	|O
are	310	313	|O
necessary	314	323	|O
for	324	327	|O
activity	328	336	|O
was	337	340	|O
accomplished	341	353	|O
by	354	356	|O
evaluation	357	367	|O
of	368	370	|O
modified	371	379	|O
1	380	381	|B-IUPAC
-	381	382	|I-IUPAC
deazapteridines	382	397	|I-IUPAC
and	398	401	|O
ring	402	406	|O
and	407	410	|O
ring	411	415	|O
-	415	416	|O
opened	416	422	|O
analogues	423	432	|O
.	432	433	|O
Relative	434	442	|O
to	443	445	|O
ethyl	446	451	|B-IUPAC
4	452	453	|I-IUPAC
-	453	454	|I-IUPAC
amino	454	459	|I-IUPAC
-	459	460	|I-IUPAC
1	460	461	|I-IUPAC
-	461	462	|I-IUPAC
deaza	462	467	|I-IUPAC
-	467	468	|I-IUPAC
7,8	468	471	|I-IUPAC
-	471	472	|I-IUPAC
dihydro	472	479	|I-IUPAC
-	479	480	|I-IUPAC
6	480	481	|I-IUPAC
-	481	482	|I-IUPAC
[	482	483	|I-IUPAC
(	483	484	|I-IUPAC
N	484	485	|I-IUPAC
-	485	486	|I-IUPAC
methylanilino	486	499	|I-IUPAC
)	499	500	|I-IUPAC
methyl	500	506	|I-IUPAC
]	506	507	|I-IUPAC
pteridine	507	516	|I-IUPAC
-	516	517	|I-IUPAC
2	517	518	|I-IUPAC
-	518	519	|I-IUPAC
carbamate	519	528	|I-IUPAC
(	529	530	|O
11	530	532	|O
)	532	533	|O
and	534	537	|O
the	538	541	|O
corresponding	542	555	|O
6	556	557	|B-IUPAC
-	557	558	|I-IUPAC
phenyl	558	564	|I-IUPAC
compound	565	573	|B-MODIFIER
(	574	575	|O
12	575	577	|O
)	577	578	|O
,	578	579	|O
no	580	582	|O
antitumor	583	592	|O
activity	593	601	|O
was	602	605	|O
observed	606	614	|O
with	615	619	|O
7,8	620	623	|B-IUPAC
-	623	624	|I-IUPAC
dihydropteridines	624	641	|I-IUPAC
,	641	642	|O
3	643	644	|B-IUPAC
-	644	645	|I-IUPAC
deaza	645	650	|I-IUPAC
-	650	651	|I-IUPAC
7,8	651	654	|I-IUPAC
-	654	655	|I-IUPAC
dihydropteridines	655	672	|I-IUPAC
,	672	673	|O
and	674	677	|O
the	678	681	|O
corresponding	682	695	|O
heteroaromatic	696	710	|O
compounds	711	720	|O
.	720	721	|O
Also	722	726	|O
,	726	727	|O
activity	728	736	|O
was	737	740	|O
diminished	741	751	|O
or	752	754	|O
destroyed	755	764	|O
when	765	769	|O
1	770	771	|B-IUPAC
-	771	772	|I-IUPAC
deaza	772	777	|I-IUPAC
-	777	778	|I-IUPAC
7,8	778	781	|I-IUPAC
-	781	782	|I-IUPAC
dihydropteridines	782	799	|I-IUPAC
were	800	804	|O
oxidized	805	813	|O
to	814	816	|O
1	817	818	|B-IUPAC
-	818	819	|I-IUPAC
deazapteridines	819	834	|I-IUPAC
or	835	837	|O
reduced	838	845	|O
to	846	848	|O
1	849	850	|B-IUPAC
-	850	851	|I-IUPAC
deaza	851	856	|I-IUPAC
-	856	857	|I-IUPAC
5,6,7,8	857	864	|I-IUPAC
-	864	865	|I-IUPAC
tetrahydropteridines	865	885	|I-IUPAC
.	885	886	|O
In	887	889	|O
addition	890	898	|O
,	898	899	|O
replacement	900	911	|O
of	912	914	|O
the	915	918	|O
4	919	920	|B-IUPAC
-	920	921	|I-IUPAC
amino	921	926	|I-IUPAC
group	927	932	|B-MODIFIER
with	933	937	|O
other	938	943	|O
substituents	944	956	|O
destroyed	957	966	|O
activity	967	975	|O
.	975	976	|O
The	977	980	|O
presence	981	989	|O
of	990	992	|O
a	993	994	|O
6	995	996	|O
-	996	997	|O
substituent	997	1008	|O
containing	1009	1019	|O
an	1020	1022	|O
aryl	1023	1027	|O
group	1028	1033	|O
appeared	1034	1042	|O
to	1043	1045	|O
be	1046	1048	|O
necessary	1049	1058	|O
for	1059	1062	|O
activity	1063	1071	|O
,	1071	1072	|O
which	1073	1078	|O
was	1079	1082	|O
increased	1083	1092	|O
when	1093	1097	|O
a	1098	1099	|O
methyl	1100	1106	|B-IUPAC
group	1107	1112	|I-IUPAC
was	1113	1116	|O
substituted	1117	1128	|B-MODIFIER
at	1129	1131	|O
the	1132	1135	|O
7	1136	1137	|O
-	1137	1138	|O
position	1138	1146	|O
.	1146	1147	|O

### abstracts625.txt
2	0	1	|O
-	1	2	|O
(	2	3	|O
Aminomethyl	3	14	|O
)	14	15	|O
-	15	16	|O
4	16	17	|O
-	17	18	|O
aminobutyric	18	30	|O
acid	31	35	|O
(	36	37	|O
isoornithine	37	49	|O
)	49	50	|O
,	50	51	|O
3	52	53	|B-IUPAC
-	53	54	|I-IUPAC
methylisoornithine	54	72	|I-IUPAC
,	72	73	|O
and	74	77	|O
2,3	78	81	|B-IUPAC
-	81	82	|I-IUPAC
dimethylisoornithine	82	102	|I-IUPAC
were	103	107	|O
not	108	111	|O
decarboxylated	112	126	|O
by	127	129	|O
liver	130	135	|O
ornithine	136	145	|O
decarboxylase	146	159	|O
(	160	161	|O
ODC	161	164	|O
,	164	165	|O
EC	166	168	|O
4.1.1.17	169	177	|O
)	177	178	|O
of	179	181	|O
thioacetamide	182	195	|O
-	195	196	|O
treated	196	203	|O
rats	204	208	|O
but	209	212	|O
were	213	217	|O
good	218	222	|O
competitive	223	234	|O
inhibitors	235	245	|O
of	246	248	|O
the	249	252	|O
enzyme	253	259	|O
(	260	261	|O
Ki	261	263	|O
ranged	264	270	|O
from	271	275	|O
0.72	276	280	|O
to	281	283	|O
1.79	284	288	|O
mM	289	291	|O
)	291	292	|O
.	292	293	|O
When	294	298	|O
assayed	299	306	|O
in	307	309	|O
vivo	310	314	|O
in	315	317	|O
the	318	321	|O
treated	322	329	|O
rats	330	334	|O
,	334	335	|O
the	336	339	|O
above	340	345	|O
mentioned	346	355	|O
isoornithines	356	369	|O
were	370	374	|O
also	375	379	|O
found	380	385	|O
to	386	388	|O
inhibit	389	396	|O
liver	397	402	|O
ODC	403	406	|O
when	407	411	|O
administered	412	424	|O
1	425	426	|O
h	427	428	|O
before	429	435	|O
sacrifice	436	445	|O
.	445	446	|O
When	447	451	|O
the	452	455	|O
methylputrescines	456	473	|O
formally	474	482	|O
derived	483	490	|O
from	491	495	|O
the	496	499	|O
decarboxylation	500	515	|O
of	516	518	|O
several	519	526	|O
isoornithines	527	540	|O
were	541	545	|O
assayed	546	553	|O
on	554	556	|O
rat	557	560	|O
liver	561	566	|O
ODC	567	570	|O
,	570	571	|O
it	572	574	|O
was	575	578	|O
found	579	584	|O
that	585	589	|O
only	590	594	|O
2,3	595	598	|B-IUPAC
-	598	599	|I-IUPAC
dimethylputrescine	599	617	|I-IUPAC
decreased	618	627	|O
the	628	631	|O
enzymatic	632	641	|O
activity	642	650	|O
.	650	651	|O
When	652	656	|O
assayed	657	664	|O
in	665	667	|O
vivo	668	672	|O
,	672	673	|O
it	674	676	|O
was	677	680	|O
found	681	686	|O
to	687	689	|O
decrease	690	698	|O
ODC	699	702	|O
activity	703	711	|O
by	712	714	|O
60%	715	718	|O
,	718	719	|O
when	720	724	|O
the	725	728	|O
latter	729	735	|O
was	736	739	|O
measured	740	748	|O
1	749	750	|O
h	751	752	|O
after	753	758	|O
administration	759	773	|O
.	773	774	|O
The	775	778	|O
effect	779	785	|O
was	786	789	|O
reverted	790	798	|O
4	799	800	|O
h	801	802	|O
after	803	808	|O
administration	809	823	|O
of	824	826	|O
the	827	830	|O
drug	831	835	|O
.	835	836	|O
Isoornithines	837	850	|O
were	851	855	|O
not	856	859	|O
taken	860	865	|O
up	866	868	|O
by	869	871	|O
H	872	873	|O
-	873	874	|O
35	874	876	|O
hepatoma	877	885	|O
cells	886	891	|O
;	891	892	|O
hence	893	898	|O
they	899	903	|O
did	904	907	|O
not	908	911	|O
affect	912	918	|O
their	919	924	|O
ODC	925	928	|O
activity	929	937	|O
.	937	938	|O
2,3	939	942	|B-IUPAC
-	942	943	|I-IUPAC
Dimethylputrescine	943	961	|I-IUPAC
however	962	969	|O
,	969	970	|O
was	971	974	|O
transported	975	986	|O
into	987	991	|O
the	992	995	|O
cells	996	1001	|O
and	1002	1005	|O
significantly	1006	1019	|O
decreased	1020	1029	|O
its	1030	1033	|O
ODC	1034	1037	|O
activity	1038	1046	|O
.	1046	1047	|O

### abstracts2371.txt
Eleven	0	6	|O
new	7	10	|O
12	11	13	|B-IUPAC
-	13	14	|I-IUPAC
amino	14	19	|I-IUPAC
-	19	20	|I-IUPAC
6,7,10,11	20	29	|I-IUPAC
-	29	30	|I-IUPAC
tetrahydro	30	40	|I-IUPAC
-	40	41	|I-IUPAC
7	41	42	|I-IUPAC
,	42	43	|I-IUPAC
11	44	46	|I-IUPAC
-	46	47	|I-IUPAC
methanocycloocta	47	63	|I-IUPAC
[	63	64	|I-IUPAC
b	64	65	|I-IUPAC
]	65	66	|I-IUPAC
quinoline	66	75	|I-IUPAC
derivatives	76	87	|B-MODIFIER
[	88	89	|O
tacrine	89	96	|O
(	97	98	|O
THA	98	101	|O
)	101	102	|O
-	102	103	|O
huperzine	103	112	|O
A	113	114	|O
hybrids	115	122	|O
,	122	123	|O
rac	124	127	|O
-	127	128	|O
21-31	128	133	|O
]	133	134	|O
have	135	139	|O
been	140	144	|O
synthesized	145	156	|O
as	157	159	|O
racemic	160	167	|O
mixtures	168	176	|O
and	177	180	|O
tested	181	187	|O
as	188	190	|O
acetylcholinesterase	191	211	|O
(	212	213	|O
AChE	213	217	|O
)	217	218	|O
inhibitors	219	229	|O
.	229	230	|O
For	231	234	|O
derivatives	235	246	|O
unsubstituted	247	260	|O
at	261	263	|O
the	264	267	|O
benzene	268	275	|O
ring	276	280	|O
,	280	281	|O
the	282	285	|O
highest	286	293	|O
activity	294	302	|O
was	303	306	|O
obtained	307	315	|O
for	316	319	|O
the	320	323	|O
9	324	325	|B-IUPAC
-	325	326	|I-IUPAC
ethyl	326	331	|I-IUPAC
derivative	332	342	|B-MODIFIER
rac	343	346	|O
-	346	347	|O
20	347	349	|O
,	349	350	|O
previously	351	361	|O
prepared	362	370	|O
by	371	373	|O
our	374	377	|O
group	378	383	|O
.	383	384	|O
More	385	389	|O
bulky	390	395	|O
substituents	396	408	|O
at	409	411	|O
position	412	420	|O
9	421	422	|O
led	423	426	|O
to	427	429	|O
less	430	434	|O
active	435	441	|O
compounds	442	451	|O
,	451	452	|O
although	453	461	|O
some	462	466	|O
of	467	469	|O
them	470	474	|O
[	475	476	|O
9	476	477	|B-IUPAC
-	477	478	|I-IUPAC
isopropyl	478	487	|I-IUPAC
(	488	489	|O
rac	489	492	|O
-	492	493	|O
22	493	495	|O
)	495	496	|O
,	496	497	|O
9	498	499	|B-IUPAC
-	499	500	|I-IUPAC
allyl	500	505	|I-IUPAC
(	506	507	|O
rac	507	510	|O
-	510	511	|O
23	511	513	|O
)	513	514	|O
,	514	515	|O
and	516	519	|O
9	520	521	|B-IUPAC
-	521	522	|I-IUPAC
phenyl	522	528	|I-IUPAC
(	529	530	|O
rac	530	533	|O
-	533	534	|O
26	534	536	|O
)	536	537	|O
]	537	538	|O
show	539	543	|O
activities	544	554	|O
similar	555	562	|O
to	563	565	|O
that	566	570	|O
of	571	573	|O
THA	574	577	|O
.	577	578	|O
Substitution	579	591	|O
at	592	594	|O
position	595	603	|O
1	604	605	|O
or	606	608	|O
3	609	610	|O
with	611	615	|O
methyl	616	622	|O
or	623	625	|O
fluorine	626	634	|O
atoms	635	640	|O
always	641	647	|O
led	648	651	|O
to	652	654	|O
more	655	659	|O
active	660	666	|O
compounds	667	676	|O
.	676	677	|O
Among	678	683	|O
them	684	688	|O
,	688	689	|O
the	690	693	|O
highest	694	701	|O
activity	702	710	|O
was	711	714	|O
observed	715	723	|O
for	724	727	|O
the	728	731	|O
3	732	733	|B-IUPAC
-	733	734	|I-IUPAC
fluoro	734	740	|I-IUPAC
-	740	741	|I-IUPAC
9	741	742	|I-IUPAC
-	742	743	|I-IUPAC
methyl	743	749	|I-IUPAC
derivative	750	760	|B-MODIFIER
rac	761	764	|O
-	764	765	|O
28	765	767	|O
[	768	769	|O
about	769	774	|O
15	775	777	|O
-	777	778	|O
fold	778	782	|O
more	783	787	|O
active	788	794	|O
than	795	799	|O
THA	800	803	|O
and	804	807	|O
about	808	813	|O
9	814	815	|O
-	815	816	|O
fold	816	820	|O
more	821	825	|O
active	826	832	|O
than	833	837	|O
(	838	839	|O
-	839	840	|O
)	840	841	|O
-	841	842	|O
huperzine	842	851	|O
A	852	853	|O
]	853	854	|O
.	854	855	|O
The	856	859	|O
activity	860	868	|O
of	869	871	|O
some	872	876	|O
THA	877	880	|O
-	880	881	|O
huperzine	881	890	|O
A	891	892	|O
hybrids	893	900	|O
(	901	902	|O
rac	902	905	|O
-	905	906	|O
19	906	908	|O
,	908	909	|O
rac	910	913	|O
-	913	914	|O
20	914	916	|O
,	916	917	|O
rac	918	921	|O
-	921	922	|O
28	922	924	|O
,	924	925	|O
and	926	929	|O
rac	930	933	|O
-	933	934	|O
30	934	936	|O
)	936	937	|O
,	937	938	|O
which	939	944	|O
were	945	949	|O
separated	950	959	|O
into	960	964	|O
their	965	970	|O
enantiomers	971	982	|O
by	983	985	|O
chiral	986	992	|O
medium	993	999	|O
-	999	1000	|O
pressure	1000	1008	|O
liquid	1009	1015	|O
chromatography	1016	1030	|O
(	1031	1032	|O
chiral	1032	1038	|O
MPLC	1039	1043	|O
)	1043	1044	|O
,	1044	1045	|O
using	1046	1051	|O
microcrystalline	1052	1068	|O
cellulose	1069	1078	|O
triacetate	1079	1089	|O
as	1090	1092	|O
the	1093	1096	|O
chiral	1097	1103	|O
stationary	1104	1114	|O
phase	1115	1120	|O
,	1120	1121	|O
showed	1122	1128	|O
the	1129	1132	|O
eutomer	1133	1140	|O
to	1141	1143	|O
be	1144	1146	|O
always	1147	1153	|O
the	1154	1157	|O
levorotatory	1158	1170	|O
enantiomer	1171	1181	|O
,	1181	1182	|O
their	1183	1188	|O
activity	1189	1197	|O
being	1198	1203	|O
roughly	1204	1211	|O
double	1212	1218	|O
that	1219	1223	|O
of	1224	1226	|O
the	1227	1230	|O
corresponding	1231	1244	|O
racemic	1245	1252	|O
mixture	1253	1260	|O
,	1260	1261	|O
the	1262	1265	|O
distomer	1266	1274	|O
being	1275	1280	|O
much	1281	1285	|O
less	1286	1290	|O
active	1291	1297	|O
.	1297	1298	|O
Also	1299	1303	|O
,	1303	1304	|O
the	1305	1308	|O
activity	1309	1317	|O
of	1318	1320	|O
some	1321	1325	|O
of	1326	1328	|O
these	1329	1334	|O
compounds	1335	1344	|O
inhibiting	1345	1355	|O
butyrylcholinesterase	1356	1377	|B-IUPAC
(	1378	1379	|O
BChE	1379	1383	|O
)	1383	1384	|O
was	1385	1388	|O
tested	1389	1395	|O
.	1395	1396	|O
Most	1397	1401	|O
of	1402	1404	|O
them	1405	1409	|O
[	1410	1411	|O
rac	1411	1414	|O
-	1414	1415	|O
27-31	1415	1420	|O
,	1420	1421	|O
(	1422	1423	|O
-	1423	1424	|O
)	1424	1425	|O
-	1425	1426	|O
28	1426	1428	|O
,	1428	1429	|O
and	1430	1433	|O
(	1434	1435	|O
-	1435	1436	|O
)	1436	1437	|O
-	1437	1438	|O
30	1438	1440	|O
]	1440	1441	|O
,	1441	1442	|O
which	1443	1448	|O
are	1449	1452	|O
more	1453	1457	|O
active	1458	1464	|O
than	1465	1469	|O
(	1470	1471	|O
-	1471	1472	|O
)	1472	1473	|O
-	1473	1474	|O
huperzine	1474	1483	|O
A	1484	1485	|O
as	1486	1488	|O
AChE	1489	1493	|O
inhibitors	1494	1504	|O
,	1504	1505	|O
turned	1506	1512	|O
out	1513	1516	|O
to	1517	1519	|O
be	1520	1522	|O
quite	1523	1528	|O
selective	1529	1538	|O
for	1539	1542	|O
AChE	1543	1547	|O
,	1547	1548	|O
although	1549	1557	|O
not	1558	1561	|O
so	1562	1564	|O
selective	1565	1574	|O
as	1575	1577	|O
(	1578	1579	|O
-	1579	1580	|O
)	1580	1581	|O
-	1581	1582	|O
huperzine	1582	1591	|O
A	1592	1593	|O
.	1593	1594	|O
Most	1595	1599	|O
of	1600	1602	|O
the	1603	1606	|O
tested	1607	1613	|O
compounds	1614	1623	|O
19-31	1624	1629	|O
proved	1630	1636	|O
to	1637	1639	|O
be	1640	1642	|O
much	1643	1647	|O
more	1648	1652	|O
active	1653	1659	|O
than	1660	1664	|O
THA	1665	1668	|O
in	1669	1671	|O
reversing	1672	1681	|O
the	1682	1685	|O
neuromuscular	1686	1699	|O
blockade	1700	1708	|O
induced	1709	1716	|O
by	1717	1719	|O
d	1720	1721	|O
-	1721	1722	|O
tubocurarine	1722	1734	|O
.	1734	1735	|O
Molecular	1736	1745	|O
modeling	1746	1754	|O
of	1755	1757	|O
the	1758	1761	|O
interaction	1762	1773	|O
of	1774	1776	|O
these	1777	1782	|O
compounds	1783	1792	|O
with	1793	1797	|O
AChE	1798	1802	|O
from	1803	1807	|O
Torpedo	1808	1815	|O
californica	1816	1827	|O
showed	1828	1834	|O
them	1835	1839	|O
to	1840	1842	|O
interact	1843	1851	|O
as	1852	1854	|O
truly	1855	1860	|O
THA	1861	1864	|O
-	1864	1865	|O
huperzine	1865	1874	|O
A	1875	1876	|O
hybrids	1877	1884	|O
:	1884	1885	|O
the	1886	1889	|O
4	1890	1891	|B-IUPAC
-	1891	1892	|I-IUPAC
aminoquinoline	1892	1906	|I-IUPAC
subunit	1907	1914	|B-MODIFIER
of	1915	1917	|O
(	1918	1919	|O
-	1919	1920	|O
)	1920	1921	|O
-	1921	1922	|O
19	1922	1924	|O
occupies	1925	1933	|O
the	1934	1937	|O
same	1938	1942	|O
position	1943	1951	|O
of	1952	1954	|O
the	1955	1958	|O
corresponding	1959	1972	|O
subunit	1973	1980	|O
in	1981	1983	|O
THA	1984	1987	|O
,	1987	1988	|O
while	1989	1994	|O
its	1995	1998	|O
bicyclo	1999	2006	|O
[	2006	2007	|O
3.3.1	2007	2012	|O
]	2012	2013	|O
nonadiene	2013	2022	|O
substructure	2023	2035	|O
roughly	2036	2043	|O
occupies	2044	2052	|O
the	2053	2056	|O
same	2057	2061	|O
position	2062	2070	|O
of	2071	2073	|O
the	2074	2077	|O
corresponding	2078	2091	|O
substructure	2092	2104	|O
in	2105	2107	|O
(	2108	2109	|O
-	2109	2110	|O
)	2110	2111	|O
-	2111	2112	|O
huperzine	2112	2121	|O
A	2122	2123	|O
,	2123	2124	|O
in	2125	2127	|O
agreement	2128	2137	|O
with	2138	2142	|O
the	2143	2146	|O
absolute	2147	2155	|O
configurations	2156	2170	|O
of	2171	2173	|O
(	2174	2175	|O
-	2175	2176	|O
)	2176	2177	|O
-	2177	2178	|O
19	2178	2180	|O
and	2181	2184	|O
(	2185	2186	|O
-	2186	2187	|O
)	2187	2188	|O
-	2188	2189	|O
huperzine	2189	2198	|O
A	2199	2200	|O
.	2200	2201	|O

### abstracts1565.txt
The	0	3	|O
linear	4	10	|O
octadentate	11	22	|O
ligand	23	29	|O
3,4,3	30	35	|O
-	35	36	|O
LIHOPO	36	42	|O
,	42	43	|O
which	44	49	|O
contains	50	58	|O
four	59	63	|O
1	64	65	|B-IUPAC
-	65	66	|I-IUPAC
hydroxy	66	73	|I-IUPAC
-	73	74	|I-IUPAC
2	74	75	|I-IUPAC
(	75	76	|I-IUPAC
1H	76	78	|I-IUPAC
)	78	79	|I-IUPAC
-	79	80	|I-IUPAC
pyridinone	80	90	|I-IUPAC
(	91	92	|O
1,2	92	95	|O
-	95	96	|O
HOPO	96	100	|O
)	100	101	|O
groups	102	108	|O
,	108	109	|O
is	110	112	|O
the	113	116	|O
most	117	121	|O
effective	122	131	|O
agent	132	137	|O
for	138	141	|O
in	142	144	|O
vivo	145	149	|O
chelation	150	159	|O
of	160	162	|O
Pu	163	165	|O
(	165	166	|O
IV	166	168	|O
)	168	169	|O
yet	170	173	|O
prepared	174	182	|O
.	182	183	|O
However	184	191	|O
,	191	192	|O
its	193	196	|O
clinical	197	205	|O
potential	206	215	|O
is	216	218	|O
limited	219	226	|O
by	227	229	|O
acute	230	235	|O
toxicity	236	244	|O
of	245	247	|O
the	248	251	|O
free	252	256	|O
ligand	257	263	|O
(	264	265	|O
but	265	268	|O
not	269	272	|O
Fe3+	273	277	|O
complex	278	285	|O
)	285	286	|O
at	287	289	|O
high	290	294	|O
dosage	295	301	|O
.	301	302	|O
The	303	306	|O
high	307	311	|O
acidity	312	319	|O
of	320	322	|O
HOPO	323	327	|O
ligands	328	335	|O
and	336	339	|O
the	340	343	|O
much	344	348	|O
lower	349	354	|O
acidity	355	362	|O
of	363	365	|O
catechol	366	374	|O
(	375	376	|O
CAM	376	379	|O
)	379	380	|O
ligands	381	388	|O
suggested	389	398	|O
that	399	403	|O
mixed	404	409	|O
octadentate	410	421	|O
(	422	423	|O
CAM	423	426	|O
-	426	427	|O
HOPO	427	431	|O
)	431	432	|O
ligands	433	440	|O
containing	441	451	|O
one	452	455	|O
or	456	458	|O
two	459	462	|O
1,2	463	466	|O
-	466	467	|O
HOPO	467	471	|O
and	472	475	|O
three	476	481	|O
(	482	483	|O
or	483	485	|O
two	486	489	|O
)	489	490	|O
catechol	491	499	|O
(	500	501	|O
CAM	501	504	|O
)	504	505	|O
groups	506	512	|O
might	513	518	|O
be	519	521	|O
as	522	524	|O
effective	525	534	|O
for	535	538	|O
Pu	539	541	|O
removal	542	549	|O
[	550	551	|O
fully	551	556	|O
eight	557	562	|O
-	562	563	|O
coordinated	563	574	|O
Pu	575	577	|O
(	577	578	|O
IV	578	580	|O
)	580	581	|O
complexes	582	591	|O
formed	592	598	|O
at	599	601	|O
pH	602	604	|O
&	605	606	|O
gt	606	608	|O
;	608	609	|O
or	610	612	|O
=	613	614	|O
6	615	616	|O
]	616	617	|O
and	618	621	|O
less	622	626	|O
toxic	627	632	|O
than	633	637	|O
3,4,3	638	643	|O
-	643	644	|O
LIHOPO	644	650	|O
.	650	651	|O
Treatment	652	661	|O
of	662	664	|O
spermine	665	673	|O
with	674	678	|O
3	679	680	|B-IUPAC
-	680	681	|I-IUPAC
(	681	682	|I-IUPAC
2,3	682	685	|I-IUPAC
-	685	686	|I-IUPAC
dimethoxybenzoyl	686	702	|I-IUPAC
)	702	703	|I-IUPAC
thiazol	703	710	|I-IUPAC
-	710	711	|I-IUPAC
idine	711	716	|I-IUPAC
-	716	717	|I-IUPAC
2	717	718	|I-IUPAC
-	718	719	|I-IUPAC
thione	719	725	|I-IUPAC
(	726	727	|O
1	727	728	|O
)	728	729	|O
(	730	731	|O
molar	731	736	|O
ratio	737	742	|O
2	743	744	|O
:	744	745	|O
1	745	746	|O
)	746	747	|O
gave	748	752	|O
1,14	753	757	|B-IUPAC
-	757	758	|I-IUPAC
bis	758	761	|I-IUPAC
(	761	762	|I-IUPAC
2,3	762	765	|I-IUPAC
-	765	766	|I-IUPAC
dimethoxybenzoyl	766	782	|I-IUPAC
)	782	783	|I-IUPAC
-	783	784	|I-IUPAC
1,5,10,14	784	793	|I-IUPAC
-	793	794	|I-IUPAC
tetraazatetradecane	794	813	|I-IUPAC
(	814	815	|O
2	815	816	|O
,	816	817	|O
DiCAM	818	823	|O
-	823	824	|O
spermine	824	832	|O
)	832	833	|O
in	834	836	|O
80%	837	840	|O
yield	841	846	|O
.	846	847	|O
Addition	848	856	|O
of	857	859	|O
2	860	861	|O
to	862	864	|O
a	865	866	|O
2	867	868	|O
-	868	869	|O
fold	869	873	|O
excess	874	880	|O
of	881	883	|O
the	884	887	|O
reaction	888	896	|O
product	897	904	|O
of	905	907	|O
1	908	909	|B-IUPAC
-	909	910	|I-IUPAC
hydroxy	910	917	|I-IUPAC
-	917	918	|I-IUPAC
2	918	919	|I-IUPAC
-	919	920	|I-IUPAC
pyridone	920	928	|I-IUPAC
-	928	929	|I-IUPAC
6	929	930	|I-IUPAC
-	930	931	|I-IUPAC
carboxylic	931	941	|I-IUPAC
acid	942	946	|I-IUPAC
(	947	948	|O
HOPO	948	952	|O
-	952	953	|O
C	953	954	|O
)	954	955	|O
and	956	959	|O
1,1	960	963	|B-IUPAC
'	963	964	|I-IUPAC
-	964	965	|I-IUPAC
carbonyldiimidazole	965	984	|I-IUPAC
(	985	986	|O
CDI	986	989	|O
)	989	990	|O
in	991	993	|O
N	994	995	|B-IUPAC
,	995	996	|I-IUPAC
N	996	997	|I-IUPAC
-	997	998	|I-IUPAC
dimethylformamide	998	1015	|I-IUPAC
(	1016	1017	|O
DMF	1017	1020	|O
)	1020	1021	|O
and	1022	1025	|O
deprotection	1026	1038	|O
with	1039	1043	|O
BBr3	1044	1048	|O
gave	1049	1053	|O
1,14	1054	1058	|B-IUPAC
-	1058	1059	|I-IUPAC
bis	1059	1062	|I-IUPAC
(	1062	1063	|I-IUPAC
2,3	1063	1066	|I-IUPAC
-	1066	1067	|I-IUPAC
dihydroxybenzoyl	1067	1083	|I-IUPAC
)	1083	1084	|I-IUPAC
-	1084	1085	|I-IUPAC
5,10	1085	1089	|I-IUPAC
-	1089	1090	|I-IUPAC
bis	1090	1093	|I-IUPAC
(	1093	1094	|I-IUPAC
1	1094	1095	|I-IUPAC
-	1095	1096	|I-IUPAC
hydroxy	1096	1103	|I-IUPAC
-	1103	1104	|I-IUPAC
2	1104	1105	|I-IUPAC
-	1105	1106	|I-IUPAC
pyridon	1106	1113	|I-IUPAC
-	1113	1114	|I-IUPAC
6	1114	1115	|I-IUPAC
-	1115	1116	|I-IUPAC
oyl	1116	1119	|I-IUPAC
)	1119	1120	|I-IUPAC
-	1121	1122	|I-IUPAC
1,5,10,14	1122	1131	|I-IUPAC
-	1131	1132	|I-IUPAC
tetraaza	1132	1140	|I-IUPAC
-	1140	1141	|I-IUPAC
tetradecane	1141	1152	|I-IUPAC
[	1153	1154	|O
3	1154	1155	|O
,	1155	1156	|O
3,4,3	1157	1162	|O
-	1162	1163	|O
LI	1163	1165	|O
(	1165	1166	|O
diCAM	1166	1171	|O
-	1171	1172	|O
diHOPO	1172	1178	|O
)	1178	1179	|O
]	1179	1180	|O
in	1181	1183	|O
5%	1184	1186	|O
yield	1187	1192	|O
.	1192	1193	|O
Addition	1194	1202	|O
of	1203	1205	|O
2	1206	1207	|O
to	1208	1210	|O
an	1211	1213	|O
equimolar	1214	1223	|O
amount	1224	1230	|O
of	1231	1233	|O
the	1234	1237	|O
reaction	1238	1246	|O
product	1247	1254	|O
of	1255	1257	|O
HOPO	1258	1262	|O
-	1262	1263	|O
C	1263	1264	|O
and	1265	1268	|O
CDI	1269	1272	|O
in	1273	1275	|O
N	1276	1277	|B-IUPAC
,	1277	1278	|I-IUPAC
N	1278	1279	|I-IUPAC
-	1279	1280	|I-IUPAC
dimethylacetamide	1280	1297	|I-IUPAC
(	1298	1299	|O
DMAA	1299	1303	|O
)	1303	1304	|O
,	1304	1305	|O
purification	1306	1318	|O
of	1319	1321	|O
the	1322	1325	|O
hexadentate	1326	1337	|O
intermediate	1338	1350	|O
,	1350	1351	|O
subsequent	1352	1362	|O
treatment	1363	1372	|O
with	1373	1377	|O
an	1378	1380	|O
equimolar	1381	1390	|O
amount	1391	1397	|O
of	1398	1400	|O
2,3	1401	1404	|B-IUPAC
-	1404	1405	|I-IUPAC
dimethoxybenzoyl	1405	1421	|I-IUPAC
chloride	1422	1430	|I-IUPAC
(	1431	1432	|O
DMB	1432	1435	|O
)	1435	1436	|O
,	1436	1437	|O
and	1438	1441	|O
deprotection	1442	1454	|O
with	1455	1459	|O
BBr3	1460	1464	|O
gave	1465	1469	|O
1,5,14	1470	1476	|B-IUPAC
-	1476	1477	|I-IUPAC
tris	1477	1481	|I-IUPAC
(	1481	1482	|I-IUPAC
2,3	1482	1485	|I-IUPAC
-	1485	1486	|I-IUPAC
dihydroxybenzoyl	1486	1502	|I-IUPAC
)	1502	1503	|I-IUPAC
-	1503	1504	|I-IUPAC
10	1504	1506	|I-IUPAC
-	1506	1507	|I-IUPAC
(	1507	1508	|I-IUPAC
1	1508	1509	|I-IUPAC
-	1509	1510	|I-IUPAC
hydroxy	1510	1517	|I-IUPAC
-	1517	1518	|I-IUPAC
2	1518	1519	|I-IUPAC
-	1519	1520	|I-IUPAC
pyridon	1520	1527	|I-IUPAC
-	1527	1528	|I-IUPAC
6	1528	1529	|I-IUPAC
-	1529	1530	|I-IUPAC
oyl	1530	1533	|I-IUPAC
)	1533	1534	|I-IUPAC
-	1534	1535	|I-IUPAC
1	1535	1536	|I-IUPAC
,	1537	1538	|I-IUPAC
5,10,14	1538	1545	|I-IUPAC
-	1545	1546	|I-IUPAC
tetraazatetradecane	1547	1566	|I-IUPAC
[	1567	1568	|O
4	1568	1569	|O
,	1569	1570	|O
3,4,3	1571	1576	|O
-	1576	1577	|O
LI	1577	1579	|O
(	1579	1580	|O
triCAM	1580	1586	|O
-	1586	1587	|O
HOPO	1587	1591	|O
)	1591	1592	|O
]	1592	1593	|O
in	1594	1596	|O
5%	1597	1599	|O
yield	1600	1605	|O
.	1605	1606	|O
Ligands	1607	1614	|O
were	1615	1619	|O
administered	1620	1632	|O
to	1633	1635	|O
mice	1636	1640	|O
[	1641	1642	|O
30	1642	1644	|O
mumol	1645	1650	|O
kg	1651	1653	|O
-	1653	1654	|O
1	1654	1655	|O
ip	1656	1658	|O
at	1659	1661	|O
1	1662	1663	|O
h	1664	1665	|O
or	1666	1668	|O
orally	1669	1675	|O
at	1676	1678	|O
3	1679	1680	|O
min	1681	1684	|O
after	1685	1690	|O
iv	1691	1693	|O
injection	1694	1703	|O
of	1704	1706	|O
plutonium	1707	1716	|O
(	1716	1717	|O
IV	1717	1719	|O
)	1719	1720	|O
-	1720	1721	|O
238	1721	1724	|O
citrate	1725	1732	|O
,	1732	1733	|O
kill	1734	1738	|O
at	1739	1741	|O
24	1742	1744	|O
h	1745	1746	|O
]	1746	1747	|O
.	1747	1748	|O
Plutonium	1749	1758	|O
excretion	1759	1768	|O
after	1769	1774	|O
injection	1775	1784	|O
of	1785	1787	|O
either	1788	1794	|O
CAM	1795	1798	|O
-	1798	1799	|O
HOPO	1799	1803	|O
ligand	1804	1810	|O
was	1811	1814	|O
700%	1815	1819	|O
of	1820	1822	|O
that	1823	1827	|O
for	1828	1831	|O
24	1832	1834	|O
-	1834	1835	|O
h	1835	1836	|O
Pu	1837	1839	|O
-	1839	1840	|O
injected	1840	1848	|O
controls	1849	1857	|O
,	1857	1858	|O
140%	1859	1863	|O
of	1864	1866	|O
that	1867	1871	|O
for	1872	1875	|O
mice	1876	1880	|O
given	1881	1886	|O
the	1887	1890	|O
tetracatecholate	1891	1907	|O
analogue	1908	1916	|O
3,4,3	1917	1922	|O
-	1922	1923	|O
LICAM	1923	1928	|O
(	1929	1930	|O
significantly	1930	1943	|O
more	1944	1948	|O
,	1948	1949	|O
p	1950	1951	|O
&	1952	1953	|O
lt	1953	1955	|O
;	1955	1956	|O
0.01	1957	1961	|O
)	1961	1962	|O
,	1962	1963	|O
but	1964	1967	|O
only	1968	1972	|O
80%	1973	1976	|O
of	1977	1979	|O
that	1980	1984	|O
promoted	1985	1993	|O
by	1994	1996	|O
3,4,3	1997	2002	|O
-	2002	2003	|O
LIHOPO	2003	2009	|O
(	2010	2011	|O
significantly	2011	2024	|O
less	2025	2029	|O
)	2029	2030	|O
.	2030	2031	|O
Orally	2032	2038	|O
administered	2039	2051	|O
3,4,3	2052	2057	|O
-	2057	2058	|O
LI	2058	2060	|O
-	2060	2061	|O
(	2061	2062	|O
diCAM	2062	2067	|O
-	2067	2068	|O
diHOPO	2068	2074	|O
)	2074	2075	|O
promoted	2076	2084	|O
significantly	2085	2098	|O
more	2099	2103	|O
Pu	2104	2106	|O
excretion	2107	2116	|O
than	2117	2121	|O
an	2122	2124	|O
equimolar	2125	2134	|O
amount	2135	2141	|O
of	2142	2144	|O
CaNa3DTPA	2145	2154	|O
.	2154	2155	|O
Potency	2156	2163	|O
of	2164	2166	|O
the	2167	2170	|O
CAM	2171	2174	|O
-	2174	2175	|O
HOPO	2175	2179	|O
ligands	2180	2187	|O
for	2188	2191	|O
in	2192	2194	|O
vivo	2195	2199	|O
chelation	2200	2209	|O
of	2210	2212	|O
Pu	2213	2215	|O
(	2215	2216	|O
IV	2216	2218	|O
)	2218	2219	|O
resembled	2220	2229	|O
that	2230	2234	|O
of	2235	2237	|O
structurally	2238	2250	|O
hexadentate	2251	2262	|B-IUPAC
tris	2263	2267	|I-IUPAC
-	2267	2268	|I-IUPAC
(	2268	2269	|I-IUPAC
hydroxypyridinonate	2269	2288	|I-IUPAC
)	2288	2289	|I-IUPAC
and	2290	2293	|O
tris	2294	2298	|B-IUPAC
(	2298	2299	|I-IUPAC
sulfocatecholate	2299	2315	|I-IUPAC
)	2315	2316	|I-IUPAC
ligands	2317	2324	|O
and	2325	2328	|O
functionally	2329	2341	|O
hexadentate	2342	2353	|O
tetrakis	2354	2362	|B-IUPAC
-	2362	2363	|I-IUPAC
(	2363	2364	|I-IUPAC
sulfocatecholate	2364	2380	|I-IUPAC
)	2380	2381	|I-IUPAC
and	2382	2385	|O
tetrakis	2386	2394	|B-IUPAC
(	2394	2395	|I-IUPAC
carboxycatecholate	2395	2413	|I-IUPAC
)	2413	2414	|I-IUPAC
ligands	2415	2422	|O
.	2422	2423	|O
The	2424	2427	|O
Pu	2428	2430	|O
complexes	2431	2440	|O
of	2441	2443	|O
the	2444	2447	|O
CAM	2448	2451	|O
-	2451	2452	|O
HOPO	2452	2456	|O
ligands	2457	2464	|O
are	2465	2468	|O
to	2469	2471	|O
some	2472	2476	|O
degree	2477	2483	|O
unstable	2484	2492	|O
at	2493	2495	|O
pH	2496	2498	|O
&	2499	2500	|O
lt	2500	2502	|O
;	2502	2503	|O
7.4	2504	2507	|O
,	2507	2508	|O
as	2509	2511	|O
judged	2512	2518	|O
by	2519	2521	|O
Pu	2522	2524	|O
residues	2525	2533	|O
in	2534	2536	|O
kidneys	2537	2544	|O
in	2545	2547	|O
excess	2548	2554	|O
of	2555	2557	|O
24	2558	2560	|O
-	2560	2561	|O
h	2561	2562	|O
Pu	2563	2565	|O
-	2565	2566	|O
injected	2566	2574	|O
controls	2575	2583	|O
.	2583	2584	|O
Synthetic	2585	2594	|O
yields	2595	2601	|O
were	2602	2606	|O
insufficient	2607	2619	|O
for	2620	2623	|O
chemical	2624	2632	|O
investigations	2633	2647	|O
or	2648	2650	|O
evaluation	2651	2661	|O
of	2662	2664	|O
acute	2665	2670	|O
toxicity	2671	2679	|O
.	2679	2680	|O
(	2680	2681	|O
ABSTRACT	2681	2689	|O
TRUNCATED	2690	2699	|O
AT	2700	2702	|O
400	2703	2706	|O
WORDS	2707	2712	|O
)	2712	2713	|O

### abstracts2516.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
2,6	12	15	|B-PARTIUPAC
-	15	16	|I-PARTIUPAC
and	17	20	|O
2,4	21	24	|B-IUPAC
-	24	25	|I-IUPAC
dihydroxyphenyl	25	40	|I-IUPAC
alkyl	41	46	|I-IUPAC
ketones	47	54	|I-IUPAC
has	55	58	|O
been	59	63	|O
investigated	64	76	|O
as	77	79	|O
inhibitors	80	90	|O
of	91	93	|O
hepatic	94	101	|O
microsomal	102	112	|O
aniline	113	120	|O
hydroxylase	121	132	|O
and	133	136	|O
aminopyrine	137	148	|O
demethylase	149	160	|O
activities	161	171	|O
.	171	172	|O
Structural	173	183	|O
alterations	184	195	|O
in	196	198	|O
both	199	203	|O
series	204	210	|O
did	211	214	|O
little	215	221	|O
to	222	224	|O
enhance	225	232	|O
the	233	236	|O
inhibitory	237	247	|O
activity	248	256	|O
of	257	259	|O
the	260	263	|O
parent	264	270	|O
compounds	271	280	|O
2,6	281	284	|B-IUPAC
-	284	285	|I-IUPAC
dihydroxyacetophenone	285	306	|I-IUPAC
(	307	308	|O
3	308	309	|O
)	309	310	|O
and	311	314	|O
2,4	315	318	|B-IUPAC
-	318	319	|I-IUPAC
dihydroxyacetophenone	319	340	|I-IUPAC
(	341	342	|O
27	342	344	|O
)	344	345	|O
.	345	346	|O
In	347	349	|O
the	350	353	|O
2,6	354	357	|O
series	358	364	|O
activity	365	373	|O
against	374	381	|O
both	382	386	|O
microsomal	387	397	|O
systems	398	405	|O
varied	406	412	|O
only	413	417	|O
over	418	422	|O
a	423	424	|O
relatively	425	435	|O
narrow	436	442	|O
range	443	448	|O
,	448	449	|O
6	450	451	|B-IUPAC
-	451	452	|I-IUPAC
allyloxy	452	460	|I-IUPAC
-	460	461	|I-IUPAC
2	461	462	|I-IUPAC
-	462	463	|I-IUPAC
hydroxyacetophenone	463	482	|I-IUPAC
(	483	484	|O
19	484	486	|O
)	486	487	|O
being	488	493	|O
the	494	497	|O
most	498	502	|O
potent	503	509	|O
inhibitor	510	519	|O
.	519	520	|O
In	521	523	|O
the	524	527	|O
2,4	528	531	|O
series	532	538	|O
,	538	539	|O
activity	540	548	|O
against	549	556	|O
aniline	557	564	|O
hydroxylase	565	576	|O
was	577	580	|O
poor	581	585	|O
or	586	588	|O
absent	589	595	|O
in	596	598	|O
most	599	603	|O
cases	604	609	|O
.	609	610	|O
tthe	611	615	|O
most	616	620	|O
potent	621	627	|O
inhibitor	628	637	|O
was	638	641	|O
5	642	643	|B-IUPAC
-	643	644	|I-IUPAC
ethyl	644	649	|I-IUPAC
-	649	650	|I-IUPAC
2,4	650	653	|I-IUPAC
-	653	654	|I-IUPAC
dihydroxyacetophenone	654	675	|I-IUPAC
(	676	677	|O
31	677	679	|O
)	679	680	|O
.	680	681	|O
In	682	684	|O
contrast	685	693	|O
,	693	694	|O
high	695	699	|O
activity	700	708	|O
against	709	716	|O
aminopyrine	717	728	|O
demethylase	729	740	|O
was	741	744	|O
frequently	745	755	|O
displayed	756	765	|O
in	766	768	|O
this	769	773	|O
series	774	780	|O
,	780	781	|O
3,5	782	785	|B-IUPAC
-	785	786	|I-IUPAC
dibromo	786	793	|I-IUPAC
-	793	794	|I-IUPAC
2,4	794	797	|I-IUPAC
-	797	798	|I-IUPAC
dihydroxypropiophenone	798	820	|I-IUPAC
(	821	822	|O
36	822	824	|O
)	824	825	|O
showing	826	833	|O
greatest	834	842	|O
inhibitory	843	853	|O
potency	854	861	|O
.	861	862	|O
The	863	866	|O
effects	867	874	|O
of	875	877	|O
some	878	882	|O
compounds	883	892	|O
on	893	895	|O
hexobarbital	896	908	|O
sleeping	909	917	|O
times	918	923	|O
and	924	927	|O
zoxazolamine	928	940	|O
paralysis	941	950	|O
times	951	956	|O
in	957	959	|O
mice	960	964	|O
were	965	969	|O
also	970	974	|O
examined	975	983	|O
.	983	984	|O

### abstracts2180.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
aporphine	12	21	|O
nitrogen	22	30	|O
mustards	31	39	|O
and	40	43	|O
their	44	49	|O
congeners	50	59	|O
(	60	61	|O
1b	61	63	|O
-	63	64	|O
g	64	65	|O
)	65	66	|O
has	67	70	|O
been	71	75	|O
prepared	76	84	|O
.	84	85	|O
N	86	87	|B-IUPAC
-	87	88	|I-IUPAC
[	88	89	|I-IUPAC
[	89	90	|I-IUPAC
Bis	90	93	|I-IUPAC
(	93	94	|I-IUPAC
2	94	95	|I-IUPAC
-	95	96	|I-IUPAC
chloroethyl	96	107	|I-IUPAC
)	107	108	|I-IUPAC
-	108	109	|I-IUPAC
amino	109	114	|I-IUPAC
]	114	115	|I-IUPAC
-	115	116	|I-IUPAC
2,11	116	120	|I-IUPAC
-	120	121	|I-IUPAC
dihyroxy	121	129	|I-IUPAC
-	129	130	|I-IUPAC
10	130	132	|I-IUPAC
-	132	133	|I-IUPAC
methoxynoraporphine	133	152	|I-IUPAC
(	153	154	|O
1b	154	156	|O
)	156	157	|O
and	158	161	|O
its	162	165	|O
mono	166	170	|O
-	170	171	|O
and	172	175	|O
diacetyl	176	184	|O
ester	185	190	|O
derivatives	191	202	|O
(	203	204	|O
1c	204	206	|O
-	206	207	|O
d	207	208	|O
)	208	209	|O
were	210	214	|O
prepared	215	223	|O
from	224	228	|O
N	229	230	|B-IUPAC
-	230	231	|I-IUPAC
(	231	232	|I-IUPAC
chloroacetyl	232	244	|I-IUPAC
)	244	245	|I-IUPAC
-	245	246	|I-IUPAC
2,11	246	250	|I-IUPAC
-	250	251	|I-IUPAC
diacetoxy	251	260	|I-IUPAC
-	260	261	|I-IUPAC
10	261	263	|I-IUPAC
-	263	264	|I-IUPAC
methoxynoraporphine	264	283	|I-IUPAC
(	284	285	|O
2	285	286	|O
)	286	287	|O
.	287	288	|O
Reaction	289	297	|O
of	298	300	|O
2	301	302	|O
with	303	307	|O
diethanolamine	308	322	|O
under	323	328	|O
various	329	336	|O
conditions	337	347	|O
and	348	351	|O
different	352	361	|O
solvents	362	370	|O
resulted	371	379	|O
in	380	382	|O
the	383	386	|O
corresponding	387	400	|O
N	401	402	|B-IUPAC
-	402	403	|I-IUPAC
[	403	404	|I-IUPAC
[	404	405	|I-IUPAC
bis	405	408	|I-IUPAC
(	408	409	|I-IUPAC
2	409	410	|I-IUPAC
-	410	411	|I-IUPAC
hydroxyethyl	411	423	|I-IUPAC
)	423	424	|I-IUPAC
amino	424	429	|I-IUPAC
]	429	430	|I-IUPAC
acetyl	430	436	|I-IUPAC
]	436	437	|I-IUPAC
precursors	438	448	|O
,	448	449	|O
which	450	455	|O
were	456	460	|O
subsequently	461	473	|O
treated	474	481	|O
with	482	486	|O
SOCl2	487	492	|O
to	493	495	|O
yield	496	501	|O
the	502	505	|O
target	506	512	|O
compounds	513	522	|O
.	522	523	|O
N	524	525	|B-IUPAC
-	525	526	|I-IUPAC
(	526	527	|I-IUPAC
2	527	528	|I-IUPAC
-	528	529	|I-IUPAC
Choroethyl	529	539	|I-IUPAC
)	539	540	|I-IUPAC
norapocodeine	540	553	|I-IUPAC
(	554	555	|O
1e	555	557	|O
)	557	558	|O
was	559	562	|O
obtained	563	571	|O
from	572	576	|O
the	577	580	|O
chlorination	581	593	|O
of	594	596	|O
N	597	598	|B-IUPAC
-	598	599	|I-IUPAC
(	599	600	|I-IUPAC
2	600	601	|I-IUPAC
-	601	602	|I-IUPAC
hydroxyethyl	602	614	|I-IUPAC
)	614	615	|I-IUPAC
norapocodeine	615	628	|I-IUPAC
(	629	630	|O
9	630	631	|O
)	631	632	|O
with	633	637	|O
SOCl2	638	643	|O
.	643	644	|O
Prolonging	645	655	|O
such	656	660	|O
treatment	661	670	|O
was	671	674	|O
found	675	680	|O
to	681	683	|O
result	684	690	|O
in	691	693	|O
the	694	697	|O
formation	698	707	|O
of	708	710	|O
N	711	712	|B-IUPAC
-	712	713	|I-IUPAC
[	713	714	|I-IUPAC
2	714	715	|I-IUPAC
-	715	716	|I-IUPAC
(	716	717	|I-IUPAC
chloroethoxy	717	729	|I-IUPAC
)	729	730	|I-IUPAC
ethyl	730	735	|I-IUPAC
]	735	736	|I-IUPAC
norapocodeine	736	749	|I-IUPAC
(	750	751	|O
1f	751	753	|O
)	753	754	|O
at	755	757	|O
the	758	761	|O
expense	762	769	|O
of	770	772	|O
1e	773	775	|O
.	775	776	|O
N	777	778	|B-IUPAC
-	778	779	|I-IUPAC
[	779	780	|I-IUPAC
[	780	781	|I-IUPAC
[	781	782	|I-IUPAC
N'	782	784	|I-IUPAC
-	784	785	|I-IUPAC
(	785	786	|I-IUPAC
2	786	787	|I-IUPAC
-	787	788	|I-IUPAC
Chloroethyl	788	799	|I-IUPAC
)	799	800	|I-IUPAC
carbamyl	800	808	|I-IUPAC
]	808	809	|I-IUPAC
oxy	809	812	|I-IUPAC
]	812	813	|I-IUPAC
ethyl	813	818	|I-IUPAC
]	818	819	|I-IUPAC
norapocodeine	819	832	|I-IUPAC
(	833	834	|O
1g	834	836	|O
)	836	837	|O
and	838	841	|O
its	842	845	|O
11	846	848	|B-IUPAC
-	848	849	|I-IUPAC
(	849	850	|I-IUPAC
2	850	851	|I-IUPAC
-	851	852	|I-IUPAC
chloroethyl	852	863	|I-IUPAC
)	863	864	|I-IUPAC
carbamyl	864	872	|I-IUPAC
derivative	873	883	|B-MODIFIER
(	884	885	|O
1h	885	887	|O
)	887	888	|O
were	889	893	|O
also	894	898	|O
prepared	899	907	|O
.	907	908	|O
All	909	912	|O
the	913	916	|O
double	917	923	|O
-	923	924	|O
armed	924	929	|O
aporphine	930	939	|O
amide	940	945	|O
nitrogen	946	954	|O
mustards	955	963	|O
(	964	965	|O
ab	965	967	|O
-	967	968	|O
d	968	969	|O
)	969	970	|O
were	971	975	|O
found	976	981	|O
to	982	984	|O
have	985	989	|O
antitumor	990	999	|O
activity	1000	1008	|O
.	1008	1009	|O
The	1010	1013	|O
single	1014	1020	|O
-	1020	1021	|O
armed	1021	1026	|O
aporphine	1027	1036	|O
nitrogen	1037	1045	|O
mustard	1046	1053	|O
(	1054	1055	|O
1e	1055	1057	|O
)	1057	1058	|O
was	1059	1062	|O
also	1063	1067	|O
active	1068	1074	|O
in	1075	1077	|O
P388	1078	1082	|O
but	1083	1086	|O
the	1087	1090	|O
activity	1091	1099	|O
was	1100	1103	|O
less	1104	1108	|O
than	1109	1113	|O
that	1114	1118	|O
observed	1119	1127	|O
with	1128	1132	|O
1b	1133	1135	|O
-	1135	1136	|O
d	1136	1137	|O
.	1137	1138	|O
The	1139	1142	|O
lead	1143	1147	|O
compound	1148	1156	|O
1a	1157	1159	|O
was	1160	1163	|O
inactive	1164	1172	|O
in	1173	1175	|O
the	1176	1179	|O
LE1210	1180	1186	|O
and	1187	1190	|O
P388	1191	1195	|O
systems	1196	1203	|O
at	1204	1206	|O
the	1207	1210	|O
doses	1211	1216	|O
tested	1217	1223	|O
.	1223	1224	|O
Similarly	1225	1234	|O
,	1234	1235	|O
the	1236	1239	|O
two	1240	1243	|O
aporphine	1244	1253	|O
mustard	1254	1261	|O
congeners	1262	1271	|O
(	1272	1273	|O
1f	1273	1275	|O
,	1275	1276	|O
g	1276	1277	|O
)	1277	1278	|O
were	1279	1283	|O
also	1284	1288	|O
inactive	1289	1297	|O
in	1298	1300	|O
the	1301	1304	|O
P388	1305	1309	|O
system	1310	1316	|O
.	1316	1317	|O
All	1318	1321	|O
the	1322	1325	|O
activity	1326	1334	|O
was	1335	1338	|O
observed	1339	1347	|O
in	1348	1350	|O
the	1351	1354	|O
intraperitoneally	1355	1372	|O
innoculated	1373	1384	|O
tumor	1385	1390	|O
systems	1391	1398	|O
.	1398	1399	|O

### abstracts4007.txt
7	0	1	|B-IUPAC
-	1	2	|I-IUPAC
(	2	3	|I-IUPAC
Aminosulfonyl	3	16	|I-IUPAC
)	16	17	|I-IUPAC
-	17	18	|I-IUPAC
1,2,3,4	18	25	|I-IUPAC
-	25	26	|I-IUPAC
tetrahydroisoquinoline	26	48	|I-IUPAC
(	49	50	|O
SK	50	52	|O
&	52	53	|O
amp	53	56	|O
;	56	57	|O
F	57	58	|O
29661	59	64	|O
,	64	65	|O
1	66	67	|O
)	67	68	|O
is	69	71	|O
a	72	73	|O
potent	74	80	|O
inhibitor	81	90	|O
of	91	93	|O
the	94	97	|O
enzyme	98	104	|O
phenylethanolamine	105	123	|O
N	124	125	|O
-	125	126	|O
methyltransferase	126	143	|O
(	144	145	|O
PNMT	145	149	|O
,	149	150	|O
EC	151	153	|O
2.1.1.28	154	162	|O
)	162	163	|O
.	163	164	|O
In	165	167	|O
contrast	168	176	|O
to	177	179	|O
other	180	185	|O
inhibitors	186	196	|O
of	197	199	|O
PNMT	200	204	|O
,	204	205	|O
it	206	208	|O
is	209	211	|O
also	212	216	|O
highly	217	223	|O
selective	224	233	|O
toward	234	240	|O
PNMT	241	245	|O
in	246	248	|O
comparison	249	259	|O
with	260	264	|O
its	265	268	|O
affinity	269	277	|O
toward	278	284	|O
the	285	288	|O
alpha	289	294	|O
2	295	296	|O
-	296	297	|O
adrenoceptor	297	309	|O
(	310	311	|O
PNMT	311	315	|O
Ki	316	318	|O
=	319	320	|O
0.55	321	325	|O
microM	326	332	|O
,	332	333	|O
alpha	334	339	|O
2	340	341	|O
Ki	342	344	|O
=	345	346	|O
100	347	350	|O
microM	351	357	|O
,	357	358	|O
selectivity	359	370	|O
[	371	372	|O
alpha	372	377	|O
2	378	379	|O
Ki	380	382	|O
/	382	383	|O
PNMT	383	387	|O
Ki	388	390	|O
]	390	391	|O
=	392	393	|O
180	394	397	|O
)	397	398	|O
.	398	399	|O
A	400	401	|O
diverse	402	409	|O
set	410	413	|O
of	414	416	|O
compounds	417	426	|O
was	427	430	|O
synthesized	431	442	|O
and	443	446	|O
evaluated	447	456	|O
to	457	459	|O
probe	460	465	|O
the	466	469	|O
role	470	474	|O
of	475	477	|O
the	478	481	|O
acidic	482	488	|O
hydrogen	489	497	|O
of	498	500	|O
the	501	504	|O
aminosulfonyl	505	518	|B-IUPAC
group	519	524	|B-MODIFIER
of	525	527	|O
1	528	529	|O
in	530	532	|O
imparting	533	542	|O
this	543	547	|O
selectivity	548	559	|O
.	559	560	|O
Compounds	561	570	|O
were	571	575	|O
designed	576	584	|O
to	585	587	|O
investigate	588	599	|O
the	600	603	|O
effect	604	610	|O
on	611	613	|O
selectivity	614	625	|O
of	626	628	|O
the	629	632	|O
acidity	633	640	|O
of	641	643	|O
the	644	647	|O
NH	648	650	|O
group	651	656	|O
[	657	658	|O
the	658	661	|O
7	662	663	|B-IUPAC
-	663	664	|I-IUPAC
N	664	665	|I-IUPAC
-	665	666	|I-IUPAC
methyl	666	672	|I-IUPAC
(	673	674	|O
compound	674	682	|O
5	683	684	|O
)	684	685	|O
and	686	689	|O
7	690	691	|B-IUPAC
-	691	692	|I-IUPAC
N	692	693	|I-IUPAC
-	693	694	|I-IUPAC
(	694	695	|I-IUPAC
p	695	696	|I-IUPAC
-	696	697	|I-IUPAC
chlorophenyl	697	709	|I-IUPAC
)	709	710	|I-IUPAC
(	711	712	|O
compound	712	720	|O
4	721	722	|O
)	722	723	|O
derivatives	724	735	|B-MODIFIER
of	736	738	|O
1	739	740	|O
]	740	741	|O
,	741	742	|O
the	743	746	|O
relative	747	755	|O
spatial	756	763	|O
position	764	772	|O
of	773	775	|O
the	776	779	|O
acidic	780	786	|O
hydrogen	787	795	|B-IUPAC
[	796	797	|I-IUPAC
7	797	798	|I-IUPAC
-	798	799	|I-IUPAC
(	799	800	|I-IUPAC
N	800	801	|I-IUPAC
-	801	802	|I-IUPAC
(	802	803	|I-IUPAC
methylsulfonyl	803	817	|I-IUPAC
)	817	818	|I-IUPAC
amino	818	823	|I-IUPAC
)	823	824	|I-IUPAC
-	824	825	|I-IUPAC
1,2,3,4	825	832	|I-IUPAC
-	832	833	|I-IUPAC
tetrahydroisoquinoline	833	855	|I-IUPAC
(	856	857	|O
6	857	858	|O
)	858	859	|O
and	860	863	|O
7	864	865	|B-IUPAC
-	865	866	|I-IUPAC
(	866	867	|I-IUPAC
(	867	868	|I-IUPAC
N	868	869	|I-IUPAC
-	869	870	|I-IUPAC
(	870	871	|I-IUPAC
methylsulfonyl	871	885	|I-IUPAC
)	885	886	|I-IUPAC
amino	886	891	|I-IUPAC
)	891	892	|I-IUPAC
methyl	892	898	|I-IUPAC
)	898	899	|I-IUPAC
-	899	900	|I-IUPAC
1,2,3,4	900	907	|I-IUPAC
-	907	908	|I-IUPAC
tetrahydroisoquinoline	908	930	|I-IUPAC
(	931	932	|O
8	932	933	|O
)	933	934	|O
]	934	935	|O
,	935	936	|O
or	937	939	|O
the	940	943	|O
effect	944	950	|O
of	951	953	|O
the	954	957	|O
substitution	958	970	|O
of	971	973	|O
an	974	976	|O
acidic	977	983	|O
phenolic	984	992	|O
group	993	998	|O
for	999	1002	|O
the	1003	1006	|O
aminosulfonyl	1007	1020	|B-IUPAC
moiety	1021	1027	|B-MODIFIER
[	1028	1029	|B-IUPAC
1	1029	1030	|I-IUPAC
-	1030	1031	|I-IUPAC
(	1031	1032	|I-IUPAC
aminomethyl	1032	1043	|I-IUPAC
)	1043	1044	|I-IUPAC
-	1044	1045	|I-IUPAC
6	1045	1046	|I-IUPAC
-	1046	1047	|I-IUPAC
hydroxynaphthalene	1047	1065	|I-IUPAC
(	1066	1067	|O
23	1067	1069	|O
)	1069	1070	|O
and	1071	1074	|O
8	1075	1076	|B-IUPAC
-	1076	1077	|I-IUPAC
hydroxy	1077	1084	|I-IUPAC
-	1084	1085	|I-IUPAC
1,2,3,4	1085	1092	|I-IUPAC
-	1092	1093	|I-IUPAC
tetrahydrobenz	1093	1107	|I-IUPAC
[	1107	1108	|I-IUPAC
h	1108	1109	|I-IUPAC
]	1109	1110	|I-IUPAC
isoquinoline	1110	1122	|I-IUPAC
(	1123	1124	|O
9	1124	1125	|O
)	1125	1126	|O
]	1126	1127	|O
.	1127	1128	|O
All	1129	1132	|O
of	1133	1135	|O
the	1136	1139	|O
compounds	1140	1149	|O
studied	1150	1157	|O
displayed	1158	1167	|O
lower	1168	1173	|O
affinity	1174	1182	|O
for	1183	1186	|O
PNMT	1187	1191	|O
than	1192	1196	|O
1	1197	1198	|O
,	1198	1199	|O
and	1200	1203	|O
nine	1204	1208	|O
of	1209	1211	|O
the	1212	1215	|O
eleven	1216	1222	|O
compounds	1223	1232	|O
studied	1233	1240	|O
showed	1241	1247	|O
increased	1248	1257	|O
,	1257	1258	|O
rather	1259	1265	|O
than	1266	1270	|O
the	1271	1274	|O
desired	1275	1282	|O
decreased	1283	1292	|O
,	1292	1293	|O
affinity	1294	1302	|O
for	1303	1306	|O
the	1307	1310	|O
alpha	1311	1316	|O
2	1317	1318	|O
-	1318	1319	|O
adrenoceptor	1319	1331	|O
.	1331	1332	|O
Specifically	1333	1345	|O
,	1345	1346	|O
compound	1347	1355	|O
4	1356	1357	|O
,	1357	1358	|O
in	1359	1361	|O
which	1362	1367	|O
the	1368	1371	|O
aminosulfonyl	1372	1385	|O
NH	1386	1388	|O
group	1389	1394	|O
is	1395	1397	|O
more	1398	1402	|O
acidic	1403	1409	|O
than	1410	1414	|O
that	1415	1419	|O
in	1420	1422	|O
1	1423	1424	|O
,	1424	1425	|O
showed	1426	1432	|O
greatly	1433	1440	|O
reduced	1441	1448	|O
selectivity	1449	1460	|O
on	1461	1463	|O
account	1464	1471	|O
of	1472	1474	|O
increased	1475	1484	|O
alpha	1485	1490	|O
2	1491	1492	|O
-	1492	1493	|O
adrenoceptor	1493	1505	|O
affinity	1506	1514	|O
as	1515	1517	|O
compared	1518	1526	|O
to	1527	1529	|O
1	1530	1531	|O
(	1532	1533	|O
PNMT	1533	1537	|O
Ki	1538	1540	|O
=	1541	1542	|O
2.6	1543	1546	|O
microM	1547	1553	|O
,	1553	1554	|O
alpha	1555	1560	|O
2	1561	1562	|O
Ki	1563	1565	|O
=	1566	1567	|O
6.3	1568	1571	|O
microM	1572	1578	|O
,	1578	1579	|O
selectivity	1580	1591	|O
=	1592	1593	|O
2.4	1594	1597	|O
)	1597	1598	|O
.	1598	1599	|O
Compound	1600	1608	|O
8	1609	1610	|O
,	1610	1611	|O
in	1612	1614	|O
which	1615	1620	|O
the	1621	1624	|O
acidic	1625	1631	|O
NH	1632	1634	|O
group	1635	1640	|O
is	1641	1643	|O
in	1644	1646	|O
the	1647	1650	|O
same	1651	1655	|O
region	1656	1662	|O
of	1663	1665	|O
space	1666	1671	|O
as	1672	1674	|O
that	1675	1679	|O
in	1680	1682	|O
1	1683	1684	|O
,	1684	1685	|O
although	1686	1694	|O
the	1695	1698	|O
aminosulfonyl	1699	1712	|B-IUPAC
group	1713	1718	|B-MODIFIER
is	1719	1721	|O
reversed	1722	1730	|O
with	1731	1735	|O
respect	1736	1743	|O
to	1744	1746	|O
the	1747	1750	|O
aromatic	1751	1759	|O
ring	1760	1764	|O
,	1764	1765	|O
showed	1766	1772	|O
poor	1773	1777	|O
PNMT	1778	1782	|O
affinity	1783	1791	|O
and	1792	1795	|O
modest	1796	1802	|O
alpha	1803	1808	|O
2	1809	1810	|O
-	1810	1811	|O
adrenoceptor	1811	1823	|O
affinity	1824	1832	|O
(	1833	1834	|O
PNMT	1834	1838	|O
Ki	1839	1841	|O
=	1842	1843	|O
330	1844	1847	|O
microM	1848	1854	|O
,	1854	1855	|O
alpha	1856	1861	|O
2	1862	1863	|O
Ki	1864	1866	|O
=	1867	1868	|O
18	1869	1871	|O
microM	1872	1878	|O
,	1878	1879	|O
selectivity	1880	1891	|O
=	1892	1893	|O
0.055	1894	1899	|O
)	1899	1900	|O
.	1900	1901	|O
Compound	1902	1910	|O
9	1911	1912	|O
,	1912	1913	|O
in	1914	1916	|O
which	1917	1922	|O
a	1923	1924	|O
phenolic	1925	1933	|O
group	1934	1939	|O
is	1940	1942	|O
in	1943	1945	|O
the	1946	1949	|O
same	1950	1954	|O
region	1955	1961	|O
of	1962	1964	|O
space	1965	1970	|O
as	1971	1973	|O
the	1974	1977	|O
acidic	1978	1984	|O
NH	1985	1987	|O
of	1988	1990	|O
1	1991	1992	|O
,	1992	1993	|O
exhibited	1994	2003	|O
the	2004	2007	|O
best	2008	2012	|O
alpha	2013	2018	|O
2	2019	2020	|O
-	2020	2021	|O
adrenoceptor	2021	2033	|O
affinity	2034	2042	|O
of	2043	2045	|O
any	2046	2049	|O
of	2050	2052	|O
the	2053	2056	|O
compounds	2057	2066	|O
studied	2067	2074	|O
(	2075	2076	|O
PNMT	2076	2080	|O
Ki	2081	2083	|O
=	2084	2085	|O
0.98	2086	2090	|O
microM	2091	2097	|O
,	2097	2098	|O
alpha	2099	2104	|O
2	2105	2106	|O
Ki	2107	2109	|O
=	2110	2111	|O
0.078	2112	2117	|O
microM	2118	2124	|O
,	2124	2125	|O
selectivity	2126	2137	|O
=	2138	2139	|O
0.080	2140	2145	|O
)	2145	2146	|O
.	2146	2147	|O
Results	2148	2155	|O
from	2156	2160	|O
this	2161	2165	|O
study	2166	2171	|O
suggest	2172	2179	|O
that	2180	2184	|O
the	2185	2188	|O
selectivity	2189	2200	|O
of	2201	2203	|O
1	2204	2205	|O
is	2206	2208	|O
not	2209	2212	|O
solely	2213	2219	|O
due	2220	2223	|O
to	2224	2226	|O
the	2227	2230	|O
presence	2231	2239	|O
of	2240	2242	|O
an	2243	2245	|O
acidic	2246	2252	|O
hydrogen	2253	2261	|O
on	2262	2264	|O
the	2265	2268	|O
7	2269	2270	|B-IUPAC
-	2270	2271	|I-IUPAC
aminosulfonyl	2271	2284	|I-IUPAC
group	2285	2290	|B-MODIFIER
of	2291	2293	|O
1	2294	2295	|O
but	2296	2299	|O
is	2300	2302	|O
likely	2303	2309	|O
also	2310	2314	|O
dependent	2315	2324	|O
on	2325	2327	|O
some	2328	2332	|O
other	2333	2338	|O
property	2339	2347	|O
(	2348	2349	|O
e.g.	2349	2353	|O
electron	2354	2362	|O
-	2362	2363	|O
withdrawing	2363	2374	|O
character	2375	2384	|O
)	2384	2385	|O
of	2386	2388	|O
the	2389	2392	|O
aminosulfonyl	2393	2406	|B-IUPAC
group	2407	2412	|B-MODIFIER
.	2412	2413	|O

### abstracts386.txt
Synthetic	0	9	|O
routes	10	16	|O
to	17	19	|O
a	20	21	|O
series	22	28	|O
of	29	31	|O
mono	32	36	|B-PARTIUPAC
-	36	37	|I-PARTIUPAC
and	38	41	|O
difluorinated	42	55	|B-IUPAC
2	56	57	|I-IUPAC
-	57	58	|I-IUPAC
(	58	59	|I-IUPAC
4	59	60	|I-IUPAC
-	60	61	|I-IUPAC
amino	61	66	|I-IUPAC
-	66	67	|I-IUPAC
3	67	68	|I-IUPAC
-	68	69	|O
substituted	69	80	|B-MODIFIER
-	80	81	|O
phenyl	81	87	|B-IUPAC
)	87	88	|I-IUPAC
benzothiazoles	88	102	|I-IUPAC
have	103	107	|O
been	108	112	|O
devised	113	120	|O
.	120	121	|O
Whereas	122	129	|O
mixtures	130	138	|O
of	139	141	|O
regioisomeric	142	155	|O
5	156	157	|B-PARTIUPAC
-	157	158	|I-PARTIUPAC
and	159	162	|O
7	163	164	|B-IUPAC
-	164	165	|I-IUPAC
fluoro	165	171	|I-IUPAC
-	171	172	|I-IUPAC
benzothiazoles	172	186	|I-IUPAC
were	187	191	|O
formed	192	198	|O
from	199	203	|O
the	204	207	|O
established	208	219	|O
Jacobsen	220	228	|O
cyclization	229	240	|O
of	241	243	|O
precursor	244	253	|O
3	254	255	|B-IUPAC
-	255	256	|I-IUPAC
fluoro	256	262	|I-IUPAC
-	262	263	|I-IUPAC
thiobenzanilides	263	279	|I-IUPAC
,	279	280	|O
two	281	284	|O
modifications	285	298	|O
to	299	301	|O
this	302	306	|O
general	307	314	|O
process	315	322	|O
have	323	327	|O
allowed	328	335	|O
the	336	339	|O
synthesis	340	349	|O
of	350	352	|O
pure	353	357	|O
samples	358	365	|O
of	366	368	|O
these	369	374	|O
target	375	381	|O
compounds	382	391	|O
.	391	392	|O
Fluorinated	393	404	|O
2	405	406	|B-IUPAC
-	406	407	|I-IUPAC
(	407	408	|I-IUPAC
4	408	409	|I-IUPAC
-	409	410	|I-IUPAC
aminophenyl	410	421	|I-IUPAC
)	421	422	|I-IUPAC
benzothiazoles	422	436	|I-IUPAC
were	437	441	|O
potently	442	450	|O
cytotoxic	451	460	|O
(	461	462	|O
GI	462	464	|O
(	464	465	|O
50	465	467	|O
)	467	468	|O
&	469	470	|O
lt	470	472	|O
;	472	473	|O
1	474	475	|O
nM	476	478	|O
)	478	479	|O
in	480	482	|O
vitro	483	488	|O
in	489	491	|O
sensitive	492	501	|O
human	502	507	|O
breast	508	514	|O
MCF	515	518	|O
-	518	519	|O
7	519	520	|O
(	521	522	|O
ER+	522	525	|O
)	525	526	|O
and	527	530	|O
MDA	531	534	|O
468	535	538	|O
(	539	540	|O
ER	540	542	|O
-	542	543	|O
)	543	544	|O
cell	545	549	|O
lines	550	555	|O
but	556	559	|O
inactive	560	568	|O
(	569	570	|O
GI	570	572	|O
(	572	573	|O
50	573	575	|O
)	575	576	|O
&	577	578	|O
gt	578	580	|O
;	580	581	|O
10	582	584	|O
microM	585	591	|O
)	591	592	|O
against	593	600	|O
PC	601	603	|O
3	604	605	|O
prostate	606	614	|O
,	614	615	|O
nonmalignant	616	628	|O
HBL	629	632	|O
100	633	636	|O
breast	637	643	|O
,	643	644	|O
and	645	648	|O
HCT	649	652	|O
116	653	656	|O
colon	657	662	|O
cells	663	668	|O
.	668	669	|O
The	670	673	|O
biphasic	674	682	|O
dose	683	687	|O
-	687	688	|O
response	688	696	|O
relationship	697	709	|O
characteristically	710	728	|O
shown	729	734	|O
by	735	737	|O
the	738	741	|O
benzothiazole	742	755	|O
series	756	762	|O
against	763	770	|O
sensitive	771	780	|O
cell	781	785	|O
lines	786	791	|O
was	792	795	|O
exhibited	796	805	|O
by	806	808	|O
the	809	812	|O
4	813	814	|B-PARTIUPAC
-	814	815	|I-PARTIUPAC
and	816	819	|O
6	820	821	|B-IUPAC
-	821	822	|I-IUPAC
fluoro	822	828	|I-IUPAC
-	828	829	|I-IUPAC
benzothiazoles	829	843	|I-IUPAC
(	844	845	|O
10b	845	848	|O
,	848	849	|O
d	849	850	|O
)	850	851	|O
but	852	855	|O
not	856	859	|O
by	860	862	|O
the	863	866	|O
5	867	868	|B-PARTIUPAC
-	868	869	|I-PARTIUPAC
and	870	873	|O
7	874	875	|B-IUPAC
-	875	876	|I-IUPAC
fluoro	876	882	|I-IUPAC
-	882	883	|I-IUPAC
benzothiazoles	883	897	|I-IUPAC
(	898	899	|O
10h	899	902	|O
,	902	903	|O
i	903	904	|O
)	904	905	|O
.	905	906	|O
The	907	910	|O
most	911	915	|O
potent	916	922	|O
broad	923	928	|O
spectrum	929	937	|O
agent	938	943	|O
in	944	946	|O
the	947	950	|O
NCI	951	954	|O
cell	955	959	|O
panel	960	965	|O
was	966	969	|O
2	970	971	|B-IUPAC
-	971	972	|I-IUPAC
(	972	973	|I-IUPAC
4	973	974	|I-IUPAC
-	974	975	|I-IUPAC
amino	975	980	|I-IUPAC
-	980	981	|I-IUPAC
3	981	982	|I-IUPAC
-	982	983	|I-IUPAC
methylphenyl	983	995	|I-IUPAC
)	995	996	|I-IUPAC
-	996	997	|I-IUPAC
5	997	998	|I-IUPAC
-	998	999	|I-IUPAC
fluorobenzothiazole	999	1018	|I-IUPAC
(	1019	1020	|O
10h	1020	1023	|O
)	1023	1024	|O
which	1025	1030	|O
,	1030	1031	|O
unlike	1032	1038	|O
the	1039	1042	|O
6	1043	1044	|B-IUPAC
-	1044	1045	|I-IUPAC
fluoro	1045	1051	|I-IUPAC
isomer	1052	1058	|B-MODIFIER
(	1059	1060	|O
10d	1060	1063	|O
)	1063	1064	|O
,	1064	1065	|O
produces	1066	1074	|O
no	1075	1077	|O
exportable	1078	1088	|O
metabolites	1089	1100	|O
in	1101	1103	|O
the	1104	1107	|O
presence	1108	1116	|O
of	1117	1119	|O
sensitive	1120	1129	|O
MCF	1130	1133	|O
-	1133	1134	|O
7	1134	1135	|O
cells	1136	1141	|O
.	1141	1142	|O
Induction	1143	1152	|O
of	1153	1155	|O
cytochrome	1156	1166	|O
P450	1167	1171	|O
CYP1A1	1172	1178	|O
,	1178	1179	|O
a	1180	1181	|O
crucial	1182	1189	|O
event	1190	1195	|O
in	1196	1198	|O
determining	1199	1210	|O
the	1211	1214	|O
antitumor	1215	1224	|O
specificity	1225	1236	|O
of	1237	1239	|O
this	1240	1244	|O
series	1245	1251	|O
of	1252	1254	|O
benzothiazoles	1255	1269	|O
,	1269	1270	|O
was	1271	1274	|O
not	1275	1278	|O
compromised	1279	1290	|O
.	1290	1291	|O
10h	1292	1295	|O
is	1296	1298	|O
currently	1299	1308	|O
the	1309	1312	|O
focus	1313	1318	|O
of	1319	1321	|O
pharmaceutical	1322	1336	|O
and	1337	1340	|O
preclinical	1341	1352	|O
development	1353	1364	|O
.	1364	1365	|O

### abstracts2937.txt
With	0	4	|O
a	5	6	|O
novel	7	12	|O
assay	13	18	|O
using	19	24	|O
isolated	25	33	|O
ferret	34	40	|O
detrusor	41	49	|O
to	50	52	|O
estimate	53	61	|O
beta	62	66	|O
(	66	67	|O
3	67	68	|O
)	68	69	|O
-	69	70	|O
adrenoceptor	70	82	|O
agonistic	83	92	|O
activity	93	101	|O
,	101	102	|O
we	103	105	|O
found	106	111	|O
that	112	116	|O
a	117	118	|O
series	119	125	|O
of	126	128	|O
glycine	129	136	|O
derivatives	137	148	|O
of	149	151	|O
ritodrine	152	161	|O
,	161	162	|O
a	163	164	|O
beta	165	169	|O
(	169	170	|O
2	170	171	|O
)	171	172	|O
-	172	173	|O
adrenoceptor	173	185	|O
agonist	186	193	|O
,	193	194	|O
are	195	198	|O
potent	199	205	|O
beta	206	210	|O
(	210	211	|O
3	211	212	|O
)	212	213	|O
-	213	214	|O
adrenoceptor	214	226	|O
agonists	227	235	|O
,	235	236	|O
with	237	241	|O
excellent	242	251	|O
selectivity	252	263	|O
versus	264	270	|O
beta	271	275	|O
(	275	276	|O
1	276	277	|O
)	277	278	|O
and	279	282	|O
beta	283	287	|O
(	287	288	|O
2	288	289	|O
)	289	290	|O
subtypes	291	299	|O
.	299	300	|O
Substitution	301	313	|O
of	314	316	|O
halogens	317	325	|O
in	326	328	|O
the	329	332	|O
phenyl	333	339	|B-IUPAC
ring	340	344	|B-MODIFIER
increased	345	354	|O
potency	355	362	|O
and	363	366	|O
selectivity	367	378	|O
for	379	382	|O
the	383	386	|O
beta	387	391	|O
(	391	392	|O
3	392	393	|O
)	393	394	|O
-	394	395	|O
adrenoceptor	395	407	|O
,	407	408	|O
and	409	412	|O
this	413	417	|O
was	418	421	|O
dependent	422	431	|O
upon	432	436	|O
the	437	440	|O
position	441	449	|O
of	450	452	|O
the	453	456	|O
halogens	457	465	|O
.	465	466	|O
The	467	470	|O
chlorine	471	479	|O
-	479	480	|O
substituted	480	491	|O
derivatives	492	503	|O
3f	504	506	|O
-	506	507	|O
i	507	508	|O
exhibited	509	518	|O
potent	519	525	|O
beta	526	530	|O
(	530	531	|O
3	531	532	|O
)	532	533	|O
-	533	534	|O
adrenoceptor	534	546	|O
-	546	547	|O
mediated	547	555	|O
relaxation	556	566	|O
of	567	569	|O
ferret	570	576	|O
detrusor	577	585	|O
(	586	587	|O
EC	587	589	|O
(	589	590	|O
50	590	592	|O
)	592	593	|O
=	594	595	|O
0.93	596	600	|O
,	600	601	|O
11	602	604	|O
,	604	605	|O
14	606	608	|O
,	608	609	|O
and	610	613	|O
160	614	617	|O
nM	618	620	|O
)	620	621	|O
and	622	625	|O
higher	626	632	|O
potency	633	640	|O
at	641	643	|O
beta	644	648	|O
(	648	649	|O
3	649	650	|O
)	650	651	|O
-	651	652	|O
adrenoceptors	652	665	|O
than	666	670	|O
at	671	673	|O
beta	674	678	|O
(	678	679	|O
1	679	680	|O
)	680	681	|O
or	682	684	|O
beta	685	689	|O
(	689	690	|O
2	690	691	|O
)	691	692	|O
.	692	693	|O
The	694	697	|O
intravenous	698	709	|O
administration	710	724	|O
of	725	727	|O
3h	728	730	|O
significantly	731	744	|O
reduced	745	752	|O
the	753	756	|O
urinary	757	764	|O
bladder	765	772	|O
pressure	773	781	|O
in	782	784	|O
anesthetized	785	797	|O
male	798	802	|O
rats	803	807	|O
(	808	809	|O
ED	809	811	|O
(	811	812	|O
50	812	814	|O
)	814	815	|O
=	816	817	|O
48	818	820	|O
microg	821	827	|O
/	827	828	|O
kg	828	830	|O
)	830	831	|O
without	832	839	|O
cardiovascular	840	854	|O
side	855	859	|O
effects	860	867	|O
.	867	868	|O
This	869	873	|O
article	874	881	|O
is	882	884	|O
the	885	888	|O
first	889	894	|O
report	895	901	|O
of	902	904	|O
structure	905	914	|O
-	914	915	|O
activity	915	923	|O
relationships	924	937	|O
(	938	939	|O
SAR	939	942	|O
)	942	943	|O
concerning	944	954	|O
beta	955	959	|O
(	959	960	|O
3	960	961	|O
)	961	962	|O
-	962	963	|O
adrenoceptor	963	975	|O
agonists	976	984	|O
as	985	987	|O
agents	988	994	|O
for	995	998	|O
the	999	1002	|O
treatment	1003	1012	|O
of	1013	1015	|O
urinary	1016	1023	|O
frequency	1024	1033	|O
and	1034	1037	|O
incontinence	1038	1050	|O
.	1050	1051	|O

### abstracts256.txt
Sugar	0	5	|O
-	5	6	|O
modified	6	14	|O
analogs	15	22	|O
of	23	25	|O
4	26	27	|B-IUPAC
-	27	28	|I-IUPAC
amino	28	33	|I-IUPAC
-	33	34	|I-IUPAC
1	34	35	|I-IUPAC
-	35	36	|I-IUPAC
(	36	37	|I-IUPAC
beta	37	41	|I-IUPAC
-	41	42	|I-IUPAC
D	42	43	|I-IUPAC
-	43	44	|I-IUPAC
ribofuranosyl	44	57	|I-IUPAC
)	57	58	|I-IUPAC
pyrrolo	58	65	|I-IUPAC
[	65	66	|I-IUPAC
2,3	66	69	|I-IUPAC
-	69	70	|I-IUPAC
d	70	71	|I-IUPAC
]	71	72	|I-IUPAC
pyridazin	72	81	|I-IUPAC
-	81	82	|I-IUPAC
7	82	83	|I-IUPAC
-	83	84	|I-IUPAC
one	84	87	|I-IUPAC
(	88	89	|O
1	89	90	|O
)	90	91	|O
and	92	95	|O
4	96	97	|B-IUPAC
-	97	98	|I-IUPAC
amino	98	103	|I-IUPAC
-	103	104	|I-IUPAC
3	104	105	|I-IUPAC
-	105	106	|I-IUPAC
bromo	106	111	|I-IUPAC
-	111	112	|I-IUPAC
1	112	113	|I-IUPAC
-	113	114	|I-IUPAC
(	114	115	|I-IUPAC
beta	115	119	|I-IUPAC
-	119	120	|I-IUPAC
D	120	121	|I-IUPAC
-	121	122	|I-IUPAC
ribofuranosyl	122	135	|I-IUPAC
)	135	136	|I-IUPAC
pyrrolo	136	143	|I-IUPAC
[	143	144	|I-IUPAC
2,3	144	147	|I-IUPAC
-	147	148	|I-IUPAC
d	148	149	|I-IUPAC
]	149	150	|I-IUPAC
pyridazin	150	159	|I-IUPAC
-	159	160	|I-IUPAC
7	160	161	|I-IUPAC
-	161	162	|I-IUPAC
one	163	166	|I-IUPAC
(	167	168	|O
3	168	169	|O
)	169	170	|O
were	171	175	|O
prepared	176	184	|O
in	185	187	|O
an	188	190	|O
effort	191	197	|O
to	198	200	|O
obtain	201	207	|O
selective	208	217	|O
antiviral	218	227	|O
agents	228	234	|O
.	234	235	|O
Treatment	236	245	|O
of	246	248	|O
ethyl	249	254	|B-IUPAC
3	255	256	|I-IUPAC
-	256	257	|I-IUPAC
cyano	257	262	|I-IUPAC
-	262	263	|I-IUPAC
1	263	264	|I-IUPAC
-	264	265	|I-IUPAC
(	265	266	|I-IUPAC
2,3,5	266	271	|I-IUPAC
-	271	272	|I-IUPAC
tri	272	275	|I-IUPAC
-	275	276	|I-IUPAC
O	276	277	|I-IUPAC
-	277	278	|I-IUPAC
benzyl	278	284	|I-IUPAC
-	284	285	|I-IUPAC
1	285	286	|I-IUPAC
-	286	287	|I-IUPAC
beta	287	291	|I-IUPAC
-	291	292	|I-IUPAC
D	292	293	|I-IUPAC
-	293	294	|I-IUPAC
arabinofuranosyl	294	310	|I-IUPAC
)	310	311	|I-IUPAC
pyrrole	311	318	|I-IUPAC
-	318	319	|I-IUPAC
2	319	320	|I-IUPAC
-	320	321	|I-IUPAC
carboxylate	322	333	|I-IUPAC
(	334	335	|O
6	335	336	|O
)	336	337	|O
with	338	342	|O
hydrazine	343	352	|O
afforded	353	361	|O
4	362	363	|B-IUPAC
-	363	364	|I-IUPAC
amino	364	369	|I-IUPAC
-	369	370	|I-IUPAC
1	370	371	|I-IUPAC
-	371	372	|I-IUPAC
(	372	373	|I-IUPAC
2,3,5	373	378	|I-IUPAC
-	378	379	|I-IUPAC
tri	379	382	|I-IUPAC
-	382	383	|I-IUPAC
O	383	384	|I-IUPAC
-	384	385	|I-IUPAC
benzyl	385	391	|I-IUPAC
-	391	392	|I-IUPAC
1	392	393	|I-IUPAC
-	393	394	|I-IUPAC
beta	394	398	|I-IUPAC
-	398	399	|I-IUPAC
D	399	400	|I-IUPAC
-	400	401	|I-IUPAC
arabinofuranosyl	402	418	|I-IUPAC
)	418	419	|I-IUPAC
pyrrolo	419	426	|I-IUPAC
[	426	427	|I-IUPAC
2,3	427	430	|I-IUPAC
-	430	431	|I-IUPAC
d	431	432	|I-IUPAC
]	432	433	|I-IUPAC
pyridazin	433	442	|I-IUPAC
-	442	443	|I-IUPAC
7	443	444	|I-IUPAC
-	444	445	|I-IUPAC
one	445	448	|I-IUPAC
(	449	450	|O
7	450	451	|O
)	451	452	|O
.	452	453	|O
Treatment	454	463	|O
of	464	466	|O
7	467	468	|O
with	469	473	|O
bromine	474	481	|O
afforded	482	490	|O
4	491	492	|B-IUPAC
-	492	493	|I-IUPAC
amino	493	498	|I-IUPAC
-	498	499	|I-IUPAC
3	499	500	|I-IUPAC
-	500	501	|I-IUPAC
bromo	501	506	|I-IUPAC
-	506	507	|I-IUPAC
1	507	508	|I-IUPAC
-	508	509	|I-IUPAC
(	509	510	|I-IUPAC
2,3,5	510	515	|I-IUPAC
-	515	516	|I-IUPAC
tri	516	519	|I-IUPAC
-	519	520	|I-IUPAC
O	520	521	|I-IUPAC
-	521	522	|I-IUPAC
benzyl	522	528	|I-IUPAC
-	528	529	|I-IUPAC
beta	529	533	|I-IUPAC
-	533	534	|I-IUPAC
D	534	535	|I-IUPAC
-	535	536	|I-IUPAC
arabinofuranosyl	536	552	|I-IUPAC
)	552	553	|I-IUPAC
pyrrolo	554	561	|I-IUPAC
[	561	562	|I-IUPAC
2,3	562	565	|I-IUPAC
-	565	566	|I-IUPAC
d	566	567	|I-IUPAC
]	567	568	|I-IUPAC
pyridazin	568	577	|I-IUPAC
-	577	578	|I-IUPAC
7	578	579	|I-IUPAC
-	579	580	|I-IUPAC
one	580	583	|I-IUPAC
hydrobromide	584	596	|I-IUPAC
(	597	598	|O
9	598	599	|O
)	599	600	|O
.	600	601	|O
The	602	605	|O
benzyl	606	612	|B-IUPAC
ether	613	618	|I-IUPAC
functions	619	628	|B-MODIFIER
of	629	631	|O
7	632	633	|O
and	634	637	|O
9	638	639	|O
were	640	644	|O
removed	645	652	|O
with	653	657	|O
boron	658	663	|O
trichloride	664	675	|O
to	676	678	|O
afford	679	685	|O
4	686	687	|B-IUPAC
-	687	688	|I-IUPAC
amino	688	693	|I-IUPAC
-	693	694	|I-IUPAC
1	694	695	|I-IUPAC
-	695	696	|I-IUPAC
(	696	697	|I-IUPAC
beta	697	701	|I-IUPAC
-	701	702	|I-IUPAC
D	702	703	|I-IUPAC
-	703	704	|I-IUPAC
arabinofuranosyl	704	720	|I-IUPAC
)	720	721	|I-IUPAC
pyrrolo	721	728	|I-IUPAC
[	728	729	|I-IUPAC
2,3	729	732	|I-IUPAC
-	732	733	|I-IUPAC
d	733	734	|I-IUPAC
]	734	735	|I-IUPAC
pyridazin	735	744	|I-IUPAC
-	744	745	|I-IUPAC
7	745	746	|I-IUPAC
-	746	747	|I-IUPAC
one	747	750	|I-IUPAC
(	751	752	|O
8	752	753	|O
)	753	754	|O
and	755	758	|O
its	759	762	|O
3	763	764	|O
-	764	765	|O
bromo	765	770	|O
analog	771	777	|O
10	778	780	|O
.	780	781	|O
4	782	783	|B-IUPAC
-	783	784	|I-IUPAC
Amino	784	789	|I-IUPAC
-	789	790	|I-IUPAC
1	790	791	|I-IUPAC
-	791	792	|I-IUPAC
(	792	793	|I-IUPAC
2	793	794	|I-IUPAC
-	794	795	|I-IUPAC
deoxy	795	800	|I-IUPAC
-	800	801	|I-IUPAC
beta	801	805	|I-IUPAC
-	805	806	|I-IUPAC
D	806	807	|I-IUPAC
-	807	808	|I-IUPAC
erythro	808	815	|I-IUPAC
-	815	816	|I-IUPAC
pentofuranosyl	816	830	|I-IUPAC
)	830	831	|I-IUPAC
pyrrolo	831	838	|I-IUPAC
[	838	839	|I-IUPAC
2,3	839	842	|I-IUPAC
-	842	843	|I-IUPAC
d	843	844	|I-IUPAC
]	844	845	|I-IUPAC
pyrida	845	851	|I-IUPAC
zin	852	855	|I-IUPAC
-	855	856	|I-IUPAC
7	856	857	|I-IUPAC
-	857	858	|I-IUPAC
one	859	862	|I-IUPAC
(	863	864	|O
13	864	866	|O
)	866	867	|O
was	868	871	|O
prepared	872	880	|O
by	881	883	|O
the	884	887	|O
sodium	888	894	|O
salt	895	899	|O
condensation	900	912	|O
of	913	915	|O
ethyl	916	921	|B-IUPAC
3	922	923	|I-IUPAC
-	923	924	|I-IUPAC
cyanopyrrole	924	936	|I-IUPAC
-	936	937	|I-IUPAC
2	937	938	|I-IUPAC
-	938	939	|I-IUPAC
carboxylate	939	950	|I-IUPAC
(	951	952	|O
5	952	953	|O
)	953	954	|O
with	955	959	|O
2	960	961	|B-IUPAC
-	961	962	|I-IUPAC
deoxy	962	967	|I-IUPAC
-	967	968	|I-IUPAC
3,5	968	971	|I-IUPAC
-	971	972	|I-IUPAC
di	972	974	|I-IUPAC
-	974	975	|I-IUPAC
O	975	976	|I-IUPAC
-	976	977	|I-IUPAC
p	977	978	|I-IUPAC
-	978	979	|I-IUPAC
toluoyl	979	986	|I-IUPAC
-	986	987	|I-IUPAC
alpha	987	992	|I-IUPAC
-	992	993	|I-IUPAC
D	993	994	|I-IUPAC
-	994	995	|I-IUPAC
erythro	995	1002	|I-IUPAC
-	1002	1003	|I-IUPAC
pentofuranosyl	1003	1017	|I-IUPAC
chloride	1018	1026	|I-IUPAC
(	1027	1028	|O
11	1028	1030	|O
)	1030	1031	|O
followed	1032	1040	|O
by	1041	1043	|O
ring	1044	1048	|O
annulation	1049	1059	|O
with	1060	1064	|O
hydrazine	1065	1074	|O
.	1074	1075	|O
Deprotection	1076	1088	|O
of	1089	1091	|O
ethyl	1092	1097	|B-IUPAC
3	1098	1099	|I-IUPAC
-	1099	1100	|I-IUPAC
cyano	1100	1105	|I-IUPAC
-	1105	1106	|I-IUPAC
1	1106	1107	|I-IUPAC
-	1107	1108	|I-IUPAC
(	1108	1109	|I-IUPAC
2	1109	1110	|I-IUPAC
-	1110	1111	|I-IUPAC
deoxy	1111	1116	|I-IUPAC
-	1116	1117	|I-IUPAC
3,5	1117	1120	|I-IUPAC
-	1120	1121	|I-IUPAC
di	1121	1123	|I-IUPAC
-	1123	1124	|I-IUPAC
O	1124	1125	|I-IUPAC
-	1125	1126	|I-IUPAC
p	1126	1127	|I-IUPAC
-	1127	1128	|I-IUPAC
toluoyl	1128	1135	|I-IUPAC
-	1135	1136	|I-IUPAC
beta	1136	1140	|I-IUPAC
-	1140	1141	|I-IUPAC
D	1141	1142	|I-IUPAC
-	1142	1143	|I-IUPAC
erythro	1143	1150	|I-IUPAC
-	1150	1151	|I-IUPAC
pentofuranosyl	1151	1165	|I-IUPAC
)	1165	1166	|I-IUPAC
pyrr	1166	1170	|I-IUPAC
ole	1171	1174	|I-IUPAC
-	1174	1175	|I-IUPAC
2	1176	1177	|I-IUPAC
-	1177	1178	|I-IUPAC
carboxylate	1178	1189	|I-IUPAC
(	1190	1191	|O
12	1191	1193	|O
)	1193	1194	|O
using	1195	1200	|O
sodium	1201	1207	|O
ethoxide	1208	1216	|O
furnished	1217	1226	|O
ethyl	1227	1232	|B-IUPAC
1	1233	1234	|I-IUPAC
-	1234	1235	|I-IUPAC
(	1235	1236	|I-IUPAC
2	1236	1237	|I-IUPAC
-	1237	1238	|I-IUPAC
deoxy	1238	1243	|I-IUPAC
-	1243	1244	|I-IUPAC
beta	1244	1248	|I-IUPAC
-	1248	1249	|I-IUPAC
D	1249	1250	|I-IUPAC
-	1250	1251	|I-IUPAC
erythro	1251	1258	|I-IUPAC
-	1258	1259	|I-IUPAC
pentofuranosyl	1259	1273	|I-IUPAC
)	1273	1274	|I-IUPAC
-	1274	1275	|I-IUPAC
3	1275	1276	|I-IUPAC
-	1276	1277	|I-IUPAC
cyanopyrrole	1277	1289	|I-IUPAC
-	1289	1290	|I-IUPAC
2	1290	1291	|I-IUPAC
-	1291	1292	|I-IUPAC
carboxy	1292	1299	|I-IUPAC
late	1300	1304	|I-IUPAC
(	1305	1306	|O
14	1306	1308	|O
)	1308	1309	|O
which	1310	1315	|O
served	1316	1322	|O
as	1323	1325	|O
the	1326	1329	|O
starting	1330	1338	|O
material	1339	1347	|O
for	1348	1351	|O
the	1352	1355	|O
preparation	1356	1367	|O
of	1368	1370	|O
4	1371	1372	|B-IUPAC
-	1372	1373	|I-IUPAC
amino	1373	1378	|I-IUPAC
-	1378	1379	|I-IUPAC
1	1379	1380	|I-IUPAC
-	1380	1381	|I-IUPAC
(	1381	1382	|I-IUPAC
2,3	1382	1385	|I-IUPAC
-	1385	1386	|I-IUPAC
dideoxy	1386	1393	|I-IUPAC
-	1393	1394	|I-IUPAC
beta	1394	1398	|I-IUPAC
-	1398	1399	|I-IUPAC
D	1399	1400	|I-IUPAC
-	1400	1401	|I-IUPAC
glycero	1401	1408	|I-IUPAC
-	1408	1409	|I-IUPAC
pentofuranosyl	1409	1423	|I-IUPAC
)	1423	1424	|I-IUPAC
pyrrolo	1424	1431	|I-IUPAC
[	1431	1432	|I-IUPAC
2,3	1432	1435	|I-IUPAC
-	1435	1436	|I-IUPAC
d	1436	1437	|I-IUPAC
]	1437	1438	|I-IUPAC
pyridazin	1439	1448	|I-IUPAC
-	1448	1449	|I-IUPAC
7	1449	1450	|I-IUPAC
-	1450	1451	|I-IUPAC
one	1451	1454	|I-IUPAC
(	1455	1456	|O
20	1456	1458	|O
)	1458	1459	|O
.	1459	1460	|O
Selective	1461	1470	|O
protection	1471	1481	|O
of	1482	1484	|O
the	1485	1488	|O
5'	1489	1491	|B-IUPAC
-	1491	1492	|I-IUPAC
hydroxyl	1492	1500	|I-IUPAC
group	1501	1506	|B-MODIFIER
of	1507	1509	|O
14	1510	1512	|O
with	1513	1517	|O
tert	1518	1522	|B-IUPAC
-	1522	1523	|I-IUPAC
butyldimethylsilyl	1523	1541	|I-IUPAC
chloride	1542	1550	|I-IUPAC
followed	1551	1559	|O
by	1560	1562	|O
a	1563	1564	|O
Barton	1565	1571	|O
type	1572	1576	|O
deoxygenation	1577	1590	|O
sequence	1591	1599	|O
of	1600	1602	|O
the	1603	1606	|O
3'	1607	1609	|B-IUPAC
-	1609	1610	|I-IUPAC
hydroxyl	1610	1618	|I-IUPAC
groups	1619	1625	|B-MODIFIER
afforded	1626	1634	|O
ethyl	1635	1640	|B-IUPAC
3	1641	1642	|I-IUPAC
-	1642	1643	|I-IUPAC
cyano	1643	1648	|I-IUPAC
-	1648	1649	|I-IUPAC
1	1649	1650	|I-IUPAC
-	1650	1651	|I-IUPAC
[	1651	1652	|I-IUPAC
2,3	1652	1655	|I-IUPAC
-	1655	1656	|I-IUPAC
dideoxy	1656	1663	|I-IUPAC
-	1663	1664	|I-IUPAC
5	1664	1665	|I-IUPAC
-	1665	1666	|I-IUPAC
O	1666	1667	|I-IUPAC
-	1667	1668	|I-IUPAC
tert	1668	1672	|I-IUPAC
-	1672	1673	|I-IUPAC
butyldimethylsilyl	1673	1691	|I-IUPAC
)	1691	1692	|I-IUPAC
-	1692	1693	|I-IUPAC
beta	1693	1697	|I-IUPAC
-	1697	1698	|I-IUPAC
D	1698	1699	|I-IUPAC
-	1699	1700	|I-IUPAC
glycero	1700	1707	|I-IUPAC
-	1707	1708	|I-IUPAC
pentofuranosyl	1709	1723	|I-IUPAC
]	1723	1724	|I-IUPAC
pyrrole	1724	1731	|I-IUPAC
-	1731	1732	|I-IUPAC
2	1732	1733	|I-IUPAC
-	1733	1734	|I-IUPAC
carboxylate	1734	1745	|I-IUPAC
(	1746	1747	|O
18	1747	1749	|O
)	1749	1750	|O
.	1750	1751	|O
Deprotection	1752	1764	|O
of	1765	1767	|O
18	1768	1770	|O
with	1771	1775	|O
tetra	1776	1781	|B-IUPAC
-	1781	1782	|I-IUPAC
n	1782	1783	|I-IUPAC
-	1783	1784	|I-IUPAC
butylammonium	1784	1797	|I-IUPAC
fluoride	1798	1806	|I-IUPAC
and	1807	1810	|O
ring	1811	1815	|O
annulation	1816	1826	|O
with	1827	1831	|O
hydrazine	1832	1841	|O
afforded	1842	1850	|O
20	1851	1853	|O
.	1853	1854	|O
The	1855	1858	|O
acyclic	1859	1866	|B-MODIFIER
analog	1867	1873	|I-MODIFIER
4	1874	1875	|B-IUPAC
-	1875	1876	|I-IUPAC
amino	1876	1881	|I-IUPAC
-	1881	1882	|I-IUPAC
1	1882	1883	|I-IUPAC
-	1883	1884	|I-IUPAC
[	1884	1885	|I-IUPAC
(	1885	1886	|I-IUPAC
1,3	1886	1889	|I-IUPAC
-	1889	1890	|I-IUPAC
dihydroxy	1890	1899	|I-IUPAC
-	1899	1900	|I-IUPAC
2	1900	1901	|I-IUPAC
-	1901	1902	|I-IUPAC
propoxy	1902	1909	|I-IUPAC
)	1909	1910	|I-IUPAC
methyl	1910	1916	|I-IUPAC
]	1916	1917	|I-IUPAC
pyrrolo	1917	1924	|I-IUPAC
[	1924	1925	|I-IUPAC
2,3	1925	1928	|I-IUPAC
-	1928	1929	|I-IUPAC
d	1929	1930	|I-IUPAC
]	1930	1931	|I-IUPAC
pyridazin	1931	1940	|I-IUPAC
-	1941	1942	|I-IUPAC
7	1942	1943	|I-IUPAC
-	1943	1944	|I-IUPAC
one	1944	1947	|I-IUPAC
(	1948	1949	|O
24	1949	1951	|O
)	1951	1952	|O
was	1953	1956	|O
prepared	1957	1965	|O
via	1966	1969	|O
the	1970	1973	|O
sodium	1974	1980	|O
salt	1981	1985	|O
glycosylation	1986	1999	|O
of	2000	2002	|O
5	2003	2004	|O
with	2005	2009	|O
(	2010	2011	|B-IUPAC
1,3	2011	2014	|I-IUPAC
-	2014	2015	|I-IUPAC
dihydroxy	2015	2024	|I-IUPAC
-	2024	2025	|I-IUPAC
2	2025	2026	|I-IUPAC
-	2026	2027	|I-IUPAC
propoxy	2027	2034	|I-IUPAC
)	2034	2035	|I-IUPAC
methyl	2035	2041	|I-IUPAC
bromide	2042	2049	|I-IUPAC
(	2050	2051	|O
22	2051	2053	|O
)	2053	2054	|O
followed	2055	2063	|O
by	2064	2066	|O
a	2067	2068	|O
ring	2069	2073	|O
annulation	2074	2084	|O
with	2085	2089	|O
hydrazine	2090	2099	|O
.	2099	2100	|O
N	2101	2102	|B-IUPAC
-	2102	2103	|I-IUPAC
Bromosuccinimide	2103	2119	|I-IUPAC
treatment	2120	2129	|O
of	2130	2132	|O
13	2133	2135	|O
,	2135	2136	|O
20	2137	2139	|O
,	2139	2140	|O
and	2141	2144	|O
25	2145	2147	|O
afforded	2148	2156	|O
the	2157	2160	|O
3	2161	2162	|B-IUPAC
-	2162	2163	|I-IUPAC
bromo	2163	2168	|I-IUPAC
derivatives	2169	2180	|B-MODIFIER
15	2181	2183	|O
,	2183	2184	|O
21	2185	2187	|O
,	2187	2188	|O
and	2189	2192	|O
25	2193	2195	|O
.	2195	2196	|O
Evaluation	2197	2207	|O
of	2208	2210	|O
these	2211	2216	|O
compounds	2217	2226	|O
in	2227	2229	|O
L1210	2230	2235	|O
,	2235	2236	|O
HFF	2237	2240	|O
,	2240	2241	|O
and	2242	2245	|O
KB	2246	2248	|O
cells	2249	2254	|O
showed	2255	2261	|O
that	2262	2266	|O
the	2267	2270	|O
sugar	2271	2276	|O
-	2276	2277	|O
modified	2277	2285	|O
analogs	2286	2293	|O
all	2294	2297	|O
were	2298	2302	|O
less	2303	2307	|O
cytotoxic	2308	2317	|O
than	2318	2322	|O
their	2323	2328	|O
corresponding	2329	2342	|O
ribonucleoside	2343	2357	|O
analogs	2358	2365	|O
.	2365	2366	|O
The	2367	2370	|O
compounds	2371	2380	|O
also	2381	2385	|O
were	2386	2390	|O
less	2391	2395	|O
active	2396	2402	|O
against	2403	2410	|O
human	2411	2416	|O
cytomegalovirus	2417	2432	|O
(	2433	2434	|O
HCMV	2434	2438	|O
)	2438	2439	|O
and	2440	2443	|O
herpes	2444	2450	|O
simplex	2451	2458	|O
virus	2459	2464	|O
type	2465	2469	|O
1	2470	2471	|O
(	2472	2473	|O
HSV	2473	2476	|O
-	2476	2477	|O
1	2477	2478	|O
)	2478	2479	|O
.	2479	2480	|O
The	2481	2484	|O
3	2485	2486	|O
-	2486	2487	|O
bromo	2487	2492	|O
derivatives	2493	2504	|O
were	2505	2509	|O
much	2510	2514	|O
more	2515	2519	|O
active	2520	2526	|O
than	2527	2531	|O
the	2532	2535	|O
3	2536	2537	|O
-	2537	2538	|O
unsubstituted	2538	2551	|O
analogs	2552	2559	|O
in	2560	2562	|O
both	2563	2567	|O
the	2568	2571	|O
cytotoxicity	2572	2584	|O
,	2584	2585	|O
and	2586	2589	|O
antiviral	2590	2599	|O
assays	2600	2606	|O
.	2606	2607	|O
However	2608	2615	|O
,	2615	2616	|O
there	2617	2622	|O
was	2623	2626	|O
only	2627	2631	|O
modest	2632	2638	|O
separation	2639	2649	|O
between	2650	2657	|O
activity	2658	2666	|O
against	2667	2674	|O
HCMV	2675	2679	|O
and	2680	2683	|O
cytotoxicity	2684	2696	|O
and	2697	2700	|O
there	2701	2706	|O
was	2707	2710	|O
virtually	2711	2720	|O
no	2721	2723	|O
selectivity	2724	2735	|O
for	2736	2739	|O
activity	2740	2748	|O
against	2749	2756	|O
HSV	2757	2760	|O
-	2760	2761	|O
1	2761	2762	|O
.	2762	2763	|O

### abstracts4671.txt
The	0	3	|O
conformationally	4	20	|O
restricted	21	31	|O
linear	32	38	|O
tricyclic	39	48	|O
analogs	49	56	|O
of	57	59	|O
5	60	61	|B-PARTIUPAC
-	61	62	|I-PARTIUPAC
and	63	66	|O
8	67	68	|B-IUPAC
-	68	69	|I-IUPAC
hydroxy	69	76	|I-IUPAC
-	76	77	|I-IUPAC
2	77	78	|I-IUPAC
-	78	79	|I-IUPAC
(	79	80	|I-IUPAC
di	80	82	|I-IUPAC
-	82	83	|I-IUPAC
n	83	84	|I-IUPAC
-	84	85	|I-IUPAC
propylamino	85	96	|I-IUPAC
)	96	97	|I-IUPAC
-	97	98	|I-IUPAC
tetralins	98	107	|I-IUPAC
were	108	112	|O
investigated	113	125	|O
for	126	129	|O
their	130	135	|O
serotonergic	136	148	|O
and	149	152	|O
dopaminergic	153	165	|O
properties	166	176	|O
.	176	177	|O
These	178	183	|O
cis	184	187	|O
and	188	191	|O
trans	192	197	|O
analogs	198	205	|O
of	206	208	|O
2,3,3	209	214	|B-IUPAC
a	214	215	|I-IUPAC
,	215	216	|I-IUPAC
4,9,9	216	221	|I-IUPAC
a	221	222	|I-IUPAC
-	222	223	|I-IUPAC
hexahydro	223	232	|I-IUPAC
-	232	233	|I-IUPAC
1H	233	235	|I-IUPAC
-	235	236	|I-IUPAC
benz	236	240	|I-IUPAC
[	240	241	|I-IUPAC
f	241	242	|I-IUPAC
]	242	243	|I-IUPAC
indole	243	249	|I-IUPAC
(	250	251	|O
3	251	252	|O
)	252	253	|O
,	253	254	|O
where	255	260	|O
a	261	262	|O
five	263	267	|O
-	267	268	|O
membered	268	276	|O
ring	277	281	|O
is	282	284	|O
fused	285	290	|O
between	291	298	|O
the	299	302	|O
nitrogen	303	311	|O
and	312	315	|O
C	316	317	|O
-	317	318	|O
3	318	319	|O
carbon	320	326	|O
of	327	329	|O
2	330	331	|B-IUPAC
-	331	332	|I-IUPAC
aminotetralin	332	345	|I-IUPAC
,	345	346	|O
were	347	351	|O
synthesized	352	363	|O
from	364	368	|O
5	369	370	|B-PARTIUPAC
-	370	371	|I-PARTIUPAC
methoxy	371	378	|I-PARTIUPAC
-	378	379	|I-PARTIUPAC
and	380	383	|O
8	384	385	|B-IUPAC
-	385	386	|I-IUPAC
methoxytetralones	386	403	|I-IUPAC
.	403	404	|O
The	405	408	|O
enantiomers	409	420	|O
of	421	423	|O
trans	424	429	|B-IUPAC
-	429	430	|I-IUPAC
5	430	431	|I-IUPAC
-	431	432	|I-IUPAC
methoxy	432	439	|I-IUPAC
-	439	440	|I-IUPAC
N	440	441	|I-IUPAC
-	441	442	|I-IUPAC
n	442	443	|I-IUPAC
-	443	444	|I-IUPAC
propyl	444	450	|I-IUPAC
and	451	454	|O
-	455	456	|B-PARTIUPAC
N	456	457	|I-PARTIUPAC
-	457	458	|I-PARTIUPAC
allyl	458	463	|I-PARTIUPAC
analogs	464	471	|B-MODIFIER
were	472	476	|O
obtained	477	485	|O
via	486	489	|O
fractional	490	500	|O
recrystallization	501	518	|O
of	519	521	|O
their	522	527	|O
di	528	530	|B-IUPAC
-	530	531	|I-IUPAC
p	531	532	|I-IUPAC
-	532	533	|I-IUPAC
toluoyl	533	540	|I-IUPAC
-	540	541	|I-IUPAC
L	541	542	|I-IUPAC
(	543	544	|O
or	544	546	|O
D	547	548	|B-PARTIUPAC
)	548	549	|O
tartaric	550	558	|B-IUPAC
acid	559	563	|I-IUPAC
salts	564	569	|I-IUPAC
.	569	570	|O
All	571	574	|O
analogs	575	582	|O
were	583	587	|O
evaluated	588	597	|O
in	598	600	|O
the	601	604	|O
in	605	607	|O
vitro	608	613	|O
5	614	615	|O
-	615	616	|O
HT1A	616	620	|O
and	621	624	|O
D2	625	627	|O
binding	628	635	|O
assays	636	642	|O
and	643	646	|O
selected	647	655	|O
analogs	656	663	|O
were	664	668	|O
investigated	669	681	|O
further	682	689	|O
in	690	692	|O
biochemical	693	704	|O
and	705	708	|O
behavioral	709	719	|O
tests	720	725	|O
.	725	726	|O
In	727	729	|O
the	730	733	|O
5	734	735	|O
-	735	736	|O
substituted	736	747	|O
series	748	754	|O
(	755	756	|O
R1	756	758	|O
in	759	761	|O
3	762	763	|O
)	763	764	|O
,	764	765	|O
the	766	769	|O
trans	770	775	|O
isomers	776	783	|O
were	784	788	|O
found	789	794	|O
to	795	797	|O
possess	798	805	|O
higher	806	812	|O
levels	813	819	|O
of	820	822	|O
pharmacological	823	838	|O
activity	839	847	|O
then	848	852	|O
the	853	856	|O
corresponding	857	870	|O
cis	871	874	|O
isomers	875	882	|O
.	882	883	|O
The	884	887	|O
trans	888	893	|B-IUPAC
-	893	894	|I-IUPAC
5	894	895	|I-IUPAC
-	895	896	|I-IUPAC
methoxy	896	903	|I-IUPAC
analogs	904	911	|B-MODIFIER
showed	912	918	|O
selective	919	928	|O
5	929	930	|O
-	930	931	|O
HT1A	931	935	|O
receptor	936	944	|O
activity	945	953	|O
in	954	956	|O
vitro	957	962	|O
but	963	966	|O
displayed	967	976	|O
mixed	977	982	|O
5	983	984	|O
-	984	985	|O
HT1A	985	989	|O
and	990	993	|O
D2	994	996	|O
agonist	997	1004	|O
properties	1005	1015	|O
in	1016	1018	|O
vivo	1019	1023	|O
.	1023	1024	|O
The	1025	1028	|O
corresponding	1029	1042	|O
trans	1043	1048	|B-IUPAC
-	1048	1049	|I-IUPAC
5	1049	1050	|I-IUPAC
-	1050	1051	|I-IUPAC
hydroxy	1051	1058	|I-IUPAC
analogs	1059	1066	|B-MODIFIER
were	1067	1071	|O
found	1072	1077	|O
to	1078	1080	|O
be	1081	1083	|O
potent	1084	1090	|O
D2	1091	1093	|O
agonists	1094	1102	|O
with	1103	1107	|O
full	1108	1112	|O
intrinsic	1113	1122	|O
activity	1123	1131	|O
.	1131	1132	|O
An	1133	1135	|O
examination	1136	1147	|O
of	1148	1150	|O
nitrogen	1151	1159	|O
substitution	1160	1172	|O
(	1173	1174	|O
R2	1174	1176	|O
in	1177	1179	|O
3	1180	1181	|O
)	1181	1182	|O
revealed	1183	1191	|O
that	1192	1196	|O
analogs	1197	1204	|O
with	1205	1209	|O
either	1210	1216	|O
an	1217	1219	|O
allyl	1220	1225	|O
or	1226	1228	|O
an	1229	1231	|O
n	1232	1233	|B-IUPAC
-	1233	1234	|I-IUPAC
propyl	1234	1240	|I-IUPAC
group	1241	1246	|B-MODIFIER
displayed	1247	1256	|O
equipotent	1257	1267	|O
activities	1268	1278	|O
.	1278	1279	|O
Substitution	1280	1292	|O
with	1293	1297	|O
a	1298	1299	|O
cyclopropylmethyl	1300	1317	|O
or	1318	1320	|O
benzyl	1321	1327	|O
group	1328	1333	|O
resulted	1334	1342	|O
in	1343	1345	|O
reduced	1346	1353	|O
activity	1354	1362	|O
.	1362	1363	|O
Among	1364	1369	|O
the	1370	1373	|O
resolved	1374	1382	|O
analogs	1383	1390	|O
tested	1391	1397	|O
,	1397	1398	|O
the	1399	1402	|O
activity	1403	1411	|O
was	1412	1415	|O
found	1416	1421	|O
to	1422	1424	|O
reside	1425	1431	|O
exclusively	1432	1443	|O
in	1444	1446	|O
the	1447	1450	|O
(	1451	1452	|O
3aS	1452	1455	|O
)	1455	1456	|O
-	1456	1457	|O
(	1457	1458	|O
-	1458	1459	|O
)	1459	1460	|O
-	1460	1461	|O
enantiomers	1461	1472	|O
.	1472	1473	|O
In	1474	1476	|O
the	1477	1480	|O
8	1481	1482	|O
-	1482	1483	|O
substituted	1483	1494	|O
series	1495	1501	|O
(	1502	1503	|O
R1	1503	1505	|O
in	1506	1508	|O
3	1509	1510	|O
)	1510	1511	|O
,	1511	1512	|O
only	1513	1517	|O
8	1518	1519	|B-IUPAC
-	1519	1520	|I-IUPAC
methoxy	1520	1527	|I-IUPAC
-	1527	1528	|I-IUPAC
N	1528	1529	|I-IUPAC
-	1529	1530	|I-IUPAC
allyl	1530	1535	|I-IUPAC
analogs	1536	1543	|B-MODIFIER
were	1544	1548	|O
synthesized	1549	1560	|O
and	1561	1564	|O
evaluated	1565	1574	|O
.	1574	1575	|O
In	1576	1578	|O
this	1579	1583	|O
case	1584	1588	|O
,	1588	1589	|O
both	1590	1594	|O
cis	1595	1598	|O
and	1599	1602	|O
trans	1603	1608	|O
isomers	1609	1616	|O
showed	1617	1623	|O
equally	1624	1631	|O
weak	1632	1636	|O
in	1637	1639	|O
vitro	1640	1645	|O
5	1646	1647	|O
-	1647	1648	|O
HT1A	1648	1652	|O
receptor	1653	1661	|O
agonist	1662	1669	|O
activity	1670	1678	|O
devoid	1679	1685	|O
of	1686	1688	|O
dopaminergic	1689	1701	|O
effects	1702	1709	|O
.	1709	1710	|O
The	1711	1714	|O
presence	1715	1723	|O
of	1724	1726	|O
an	1727	1729	|O
additional	1730	1740	|O
methyl	1741	1747	|O
group	1748	1753	|O
at	1754	1756	|O
the	1757	1760	|O
C	1761	1762	|O
-	1762	1763	|O
2	1763	1764	|O
position	1765	1773	|O
(	1774	1775	|O
R3	1775	1777	|O
in	1778	1780	|O
3	1781	1782	|O
)	1782	1783	|O
of	1784	1786	|O
the	1787	1790	|O
cis	1791	1794	|B-IUPAC
-	1794	1795	|I-IUPAC
(	1795	1796	|I-IUPAC
+	1796	1797	|I-IUPAC
/	1797	1798	|I-IUPAC
-	1798	1799	|I-IUPAC
)	1799	1800	|I-IUPAC
-	1800	1801	|I-IUPAC
8	1801	1802	|I-IUPAC
-	1802	1803	|I-IUPAC
methoxy	1803	1810	|I-IUPAC
-	1810	1811	|I-IUPAC
N	1811	1812	|I-IUPAC
-	1812	1813	|I-IUPAC
n	1813	1814	|I-IUPAC
-	1814	1815	|I-IUPAC
propyl	1815	1821	|I-IUPAC
analog	1822	1828	|B-MODIFIER
resulted	1829	1837	|O
in	1838	1840	|O
enhancement	1841	1852	|O
of	1853	1855	|O
in	1856	1858	|O
vitro	1859	1864	|O
5	1865	1866	|O
-	1866	1867	|O
HT1A	1867	1871	|O
receptor	1872	1880	|O
binding	1881	1888	|O
affinity	1889	1897	|O
,	1897	1898	|O
with	1899	1903	|O
the	1904	1907	|O
(	1908	1909	|O
2	1909	1910	|O
beta	1911	1915	|O
,	1915	1916	|O
3a	1916	1918	|O
alpha	1919	1924	|O
,	1924	1925	|O
9a	1925	1927	|O
alpha	1928	1933	|O
)	1933	1934	|O
-	1934	1935	|O
(	1935	1936	|O
+	1936	1937	|O
/	1937	1938	|O
-	1938	1939	|O
)	1939	1940	|O
-	1940	1941	|O
isomer	1941	1947	|O
displaying	1948	1958	|O
potency	1959	1966	|O
35	1967	1969	|O
times	1970	1975	|O
greater	1976	1983	|O
than	1984	1988	|O
the	1989	1992	|O
(	1993	1994	|O
2	1994	1995	|O
alpha	1996	2001	|O
,	2001	2002	|O
3a	2002	2004	|O
alpha	2005	2010	|O
,	2010	2011	|O
9a	2011	2013	|O
alpha	2014	2019	|O
)	2019	2020	|O
-	2020	2021	|O
(	2021	2022	|O
+	2022	2023	|O
/	2023	2024	|O
-	2024	2025	|O
)	2025	2026	|O
-	2026	2027	|O
isomer	2027	2033	|O
.	2033	2034	|O

### abstracts1053.txt
N	0	1	|B-IUPAC
-	1	2	|I-IUPAC
Acetyl	2	8	|I-IUPAC
-	8	9	|I-IUPAC
2,6	9	12	|I-IUPAC
-	12	13	|I-IUPAC
dimethyl	13	21	|I-IUPAC
-	21	22	|I-IUPAC
p	22	23	|I-IUPAC
-	23	24	|I-IUPAC
benzoquinone	24	36	|I-IUPAC
imine	37	42	|I-IUPAC
and	43	46	|O
N	47	48	|B-IUPAC
-	48	49	|I-IUPAC
acetyl	49	55	|I-IUPAC
-	55	56	|I-IUPAC
3,5	56	59	|I-IUPAC
-	59	60	|I-IUPAC
dimethyl	60	68	|I-IUPAC
-	68	69	|I-IUPAC
p	69	70	|I-IUPAC
-	70	71	|I-IUPAC
benzoquinone	71	83	|I-IUPAC
imine	84	89	|I-IUPAC
were	90	94	|O
prepared	95	103	|O
from	104	108	|O
2,6	109	112	|B-IUPAC
-	112	113	|I-IUPAC
dimethylacetaminophen	113	134	|I-IUPAC
and	135	138	|O
3,5	139	142	|B-IUPAC
-	142	143	|I-IUPAC
dimethylacetaminophen	143	164	|I-IUPAC
by	165	167	|O
oxidation	168	177	|O
with	178	182	|O
lead	183	187	|O
tetraacetate	188	200	|O
.	200	201	|O
Reaction	202	210	|O
of	211	213	|O
N	214	215	|B-IUPAC
-	215	216	|I-IUPAC
acetyl	216	222	|I-IUPAC
-	222	223	|I-IUPAC
2,6	223	226	|I-IUPAC
-	226	227	|I-IUPAC
dimethyl	227	235	|I-IUPAC
-	235	236	|I-IUPAC
p	236	237	|I-IUPAC
-	237	238	|I-IUPAC
benzoquinone	238	250	|I-IUPAC
imine	251	256	|I-IUPAC
with	257	261	|O
hydrochloric	262	274	|O
acid	275	279	|O
gave	280	284	|O
3'	285	287	|B-IUPAC
-	287	288	|I-IUPAC
chloro	288	294	|I-IUPAC
-	294	295	|I-IUPAC
2'	295	297	|I-IUPAC
,	297	298	|I-IUPAC
6'	298	300	|I-IUPAC
-	300	301	|I-IUPAC
dimethyl	301	309	|I-IUPAC
-	309	310	|I-IUPAC
4'	310	312	|I-IUPAC
-	312	313	|I-IUPAC
hydroxyacetanilide	313	331	|I-IUPAC
,	331	332	|O
whereas	333	340	|O
ethanethiol	341	352	|O
,	352	353	|O
aniline	354	361	|O
,	361	362	|O
and	363	366	|O
ethanol	367	374	|O
gave	375	379	|O
tetrahedral	380	391	|O
adducts	392	399	|O
resulting	400	409	|O
from	410	414	|O
addition	415	423	|O
to	424	426	|O
the	427	430	|O
imine	431	436	|O
carbon	437	443	|O
.	443	444	|O
Water	445	450	|O
gave	451	455	|O
2,6	456	459	|B-IUPAC
-	459	460	|I-IUPAC
dimethyl	460	468	|I-IUPAC
-	468	469	|I-IUPAC
p	469	470	|I-IUPAC
-	470	471	|I-IUPAC
benzoquinone	471	483	|I-IUPAC
.	483	484	|O
With	485	489	|O
N	490	491	|B-IUPAC
-	491	492	|I-IUPAC
acetyl	492	498	|I-IUPAC
-	498	499	|I-IUPAC
3,5	499	502	|I-IUPAC
-	502	503	|I-IUPAC
dimethyl	503	511	|I-IUPAC
-	511	512	|I-IUPAC
p	512	513	|I-IUPAC
-	513	514	|I-IUPAC
benzoquinone	514	526	|I-IUPAC
imine	527	532	|I-IUPAC
,	532	533	|O
water	534	539	|O
and	540	543	|O
aniline	544	551	|O
gave	552	556	|O
substitution	557	569	|O
on	570	572	|O
the	573	576	|O
imine	577	582	|O
carbon	583	589	|O
,	589	590	|O
yielding	591	599	|O
2,6	600	603	|B-IUPAC
-	603	604	|I-IUPAC
dimethyl	604	612	|I-IUPAC
-	612	613	|I-IUPAC
p	613	614	|I-IUPAC
-	614	615	|I-IUPAC
benzoquinone	615	627	|I-IUPAC
and	628	631	|O
3,5	632	635	|B-IUPAC
-	635	636	|I-IUPAC
dimethyl	636	644	|I-IUPAC
-	644	645	|I-IUPAC
N	645	646	|I-IUPAC
-	646	647	|I-IUPAC
phenyl	647	653	|I-IUPAC
-	653	654	|I-IUPAC
p	654	655	|I-IUPAC
-	655	656	|I-IUPAC
benzoquinone	656	668	|I-IUPAC
imine	669	674	|I-IUPAC
,	674	675	|O
respectively	676	688	|O
.	688	689	|O
Ethanethiol	690	701	|O
gave	702	706	|O
3'	707	709	|B-IUPAC
.5	709	711	|I-IUPAC
'	711	712	|I-IUPAC
-	712	713	|I-IUPAC
dimethyl	713	721	|I-IUPAC
-	721	722	|I-IUPAC
2'	722	724	|I-IUPAC
-	724	725	|I-IUPAC
(	725	726	|I-IUPAC
ethylthio	726	735	|I-IUPAC
)	735	736	|I-IUPAC
-	736	737	|I-IUPAC
4'	737	739	|I-IUPAC
-	739	740	|I-IUPAC
hydroxyacetanilide	740	758	|I-IUPAC
.	758	759	|O
The	760	763	|O
toxicity	764	772	|O
of	773	775	|O
2,6	776	779	|B-IUPAC
-	779	780	|I-IUPAC
dimethylacetaminophen	780	801	|I-IUPAC
and	802	805	|O
3,5	806	809	|B-IUPAC
-	809	810	|I-IUPAC
dimethylacetaminophen	810	831	|I-IUPAC
was	832	835	|O
examined	836	844	|O
histologically	845	859	|O
in	860	862	|O
mice	863	867	|O
and	868	871	|O
rats	872	876	|O
.	876	877	|O
3,5	878	881	|B-IUPAC
-	881	882	|I-IUPAC
Dimethylacetaminophen	882	903	|I-IUPAC
was	904	907	|O
slightly	908	916	|O
more	917	921	|O
nephrotoxic	922	933	|O
but	934	937	|O
showed	938	944	|O
a	945	946	|O
similar	947	954	|O
hepatotoxicity	955	969	|O
to	970	972	|O
acetaminophen	973	986	|O
.	986	987	|O
2,6	988	991	|B-IUPAC
-	991	992	|I-IUPAC
Dimethylacetaminophen	992	1013	|I-IUPAC
,	1013	1014	|O
like	1015	1019	|O
N	1020	1021	|B-IUPAC
-	1021	1022	|I-IUPAC
methylacetaminophen	1022	1041	|I-IUPAC
,	1041	1042	|O
showed	1043	1049	|O
very	1050	1054	|O
little	1055	1061	|O
tissue	1062	1068	|O
damage	1069	1075	|O
.	1075	1076	|O

### abstracts4433.txt
The	0	3	|O
in	4	6	|O
vitro	7	12	|O
pharmacological	13	28	|O
properties	29	39	|O
and	40	43	|O
conformational	44	58	|O
features	59	67	|O
of	68	70	|O
analogs	71	78	|O
of	79	81	|O
the	82	85	|O
delta	86	91	|O
opioid	92	98	|O
receptor	99	107	|O
selective	108	117	|O
tetrapeptide	118	130	|O
Tyr	131	134	|O
-	134	135	|O
c	135	136	|O
[	136	137	|O
D	137	138	|O
-	138	139	|O
Cys	139	142	|O
-	142	143	|O
Phe	143	146	|O
-	146	147	|O
D	147	148	|O
-	148	149	|O
Pen	149	152	|O
]	152	153	|O
OH	153	155	|O
(	156	157	|O
JOM	157	160	|O
-	160	161	|O
13	161	163	|O
)	163	164	|O
in	165	167	|O
which	168	173	|O
the	174	177	|O
Phe3	178	182	|O
residue	183	190	|O
was	191	194	|O
replaced	195	203	|O
by	204	206	|O
each	207	211	|O
of	212	214	|O
the	215	218	|O
four	219	223	|O
stereoisomers	224	237	|O
of	238	240	|O
beta	241	245	|B-IUPAC
-	245	246	|I-IUPAC
methylphenylalanine	246	265	|I-IUPAC
(	266	267	|O
beta	267	271	|O
-	271	272	|O
MePhe	272	277	|O
)	277	278	|O
were	279	283	|O
investigated	284	296	|O
.	296	297	|O
Both	298	302	|O
analogs	303	310	|O
in	311	313	|O
which	314	319	|O
the	320	323	|O
alpha	324	329	|O
carbon	330	336	|O
of	337	339	|O
the	340	343	|O
Phe3	344	348	|O
replacement	349	360	|O
has	361	364	|O
L	365	366	|O
-	366	367	|O
stereochemistry	367	382	|O
display	383	390	|O
high	391	395	|O
affinity	396	404	|O
for	405	408	|O
delta	409	414	|O
receptors	415	424	|O
with	425	429	|O
the	430	433	|O
(	434	435	|O
2S	435	437	|O
,	437	438	|O
3S	438	440	|O
)	440	441	|O
-	441	442	|O
MePhe3	442	448	|O
analog	449	455	|O
exhibiting	456	466	|O
approximately	467	480	|O
8	481	482	|O
-	482	483	|O
fold	483	487	|O
higher	488	494	|O
affinity	495	503	|O
than	504	508	|O
the	509	512	|O
(	513	514	|O
2S	514	516	|O
,	516	517	|O
3R	517	519	|O
)	519	520	|O
-	520	521	|O
MePhe3	521	527	|O
diastereomer	528	540	|O
.	540	541	|O
Surprisingly	542	554	|O
,	554	555	|O
one	556	559	|O
analog	560	566	|O
with	567	571	|O
D	572	573	|O
-	573	574	|O
stereochemistry	574	589	|O
in	590	592	|O
residue	593	600	|O
3	601	602	|O
,	602	603	|O
the	604	607	|O
(	608	609	|O
2R	609	611	|O
,	611	612	|O
3R	612	614	|O
)	614	615	|O
-	615	616	|O
MePhe3	616	622	|O
analog	623	629	|O
,	629	630	|O
also	631	635	|O
displays	636	644	|O
high	645	649	|O
affinity	650	658	|O
for	659	662	|O
the	663	666	|O
delta	667	672	|O
receptor	673	681	|O
and	682	685	|O
is	686	688	|O
extraordinarily	689	704	|O
selective	705	714	|O
for	715	718	|O
this	719	723	|O
receptor	724	732	|O
.	732	733	|O
All	734	737	|O
analogs	738	745	|O
were	746	750	|O
agonists	751	759	|O
in	760	762	|O
the	763	766	|O
mouse	767	772	|O
vas	773	776	|O
deferens	777	785	|O
(	786	787	|O
MVD	787	790	|O
)	790	791	|O
and	792	795	|O
guinea	796	802	|O
pig	803	806	|O
ileum	807	812	|O
(	813	814	|O
GPI	814	817	|O
)	817	818	|O
smooth	819	825	|O
muscle	826	832	|O
bioassays	833	842	|O
,	842	843	|O
displaying	844	854	|O
MVD	855	858	|O
and	859	862	|O
GPI	863	866	|O
potencies	867	876	|O
consistent	877	887	|O
with	888	892	|O
their	893	898	|O
delta	899	904	|O
and	905	908	|O
mu	909	911	|O
opioid	912	918	|O
receptor	919	927	|O
affinities	928	938	|O
,	938	939	|O
respectively	940	952	|O
.	952	953	|O
The	954	957	|O
use	958	961	|O
of	962	964	|O
beta	965	969	|O
-	969	970	|O
MePhe	970	975	|O
as	976	978	|O
a	979	980	|O
replacement	981	992	|O
for	993	996	|O
Phe3	997	1001	|O
was	1002	1005	|O
based	1006	1011	|O
upon	1012	1016	|O
the	1017	1020	|O
desire	1021	1027	|O
to	1028	1030	|O
reduce	1031	1037	|O
the	1038	1041	|O
conformational	1042	1056	|O
flexibility	1057	1068	|O
of	1069	1071	|O
the	1072	1075	|O
Phe3	1076	1080	|O
side	1081	1085	|O
chain	1086	1091	|O
by	1092	1094	|O
imposing	1095	1103	|O
a	1104	1105	|O
steric	1106	1112	|O
rotational	1113	1123	|O
constraint	1124	1134	|O
in	1135	1137	|O
the	1138	1141	|O
form	1142	1146	|O
of	1147	1149	|O
the	1150	1153	|O
beta	1154	1158	|O
-	1158	1159	|O
methyl	1159	1165	|O
substituent	1166	1177	|O
and	1178	1181	|O
to	1182	1184	|O
thus	1185	1189	|O
deduce	1190	1196	|O
the	1197	1200	|O
residue	1201	1208	|O
3	1209	1210	|O
side	1211	1215	|O
chain	1216	1221	|O
orientation	1222	1233	|O
in	1234	1236	|O
the	1237	1240	|O
delta	1241	1246	|O
receptor	1247	1255	|O
-	1255	1256	|O
bound	1256	1261	|O
conformation	1262	1274	|O
from	1275	1279	|O
the	1280	1283	|O
correlation	1284	1295	|O
between	1296	1303	|O
delta	1304	1309	|O
receptor	1310	1318	|O
binding	1319	1326	|O
affinities	1327	1337	|O
and	1338	1341	|O
conformational	1342	1356	|O
preferences	1357	1368	|O
.	1368	1369	|O
Molecular	1370	1379	|O
mechanics	1380	1389	|O
computations	1390	1402	|O
revealed	1403	1411	|O
,	1411	1412	|O
however	1413	1420	|O
,	1420	1421	|O
that	1422	1426	|O
the	1427	1430	|O
conformational	1431	1445	|O
constraints	1446	1457	|O
imposed	1458	1465	|O
by	1466	1468	|O
the	1469	1472	|O
beta	1473	1477	|O
-	1477	1478	|O
methyl	1478	1484	|O
group	1485	1490	|O
in	1491	1493	|O
the	1494	1497	|O
(	1498	1499	|O
2S	1499	1501	|O
,	1501	1502	|O
3S	1502	1504	|O
)	1504	1505	|O
-	1505	1506	|O
MePhe3	1506	1512	|O
and	1513	1516	|O
(	1517	1518	|O
2S	1518	1520	|O
,	1520	1521	|O
3R	1521	1523	|O
)	1523	1524	|O
-	1524	1525	|O
MePhe3	1525	1531	|O
analogs	1532	1539	|O
were	1540	1544	|O
too	1545	1548	|O
modest	1549	1555	|O
to	1556	1558	|O
allow	1559	1564	|O
unequivocal	1565	1576	|O
determination	1577	1590	|O
of	1591	1593	|O
delta	1594	1599	|O
receptor	1600	1608	|O
-	1608	1609	|O
bound	1609	1614	|O
residue	1615	1622	|O
3	1623	1624	|O
side	1625	1629	|O
chain	1630	1635	|O
conformation	1636	1648	|O
.	1648	1649	|O
However	1650	1657	|O
,	1657	1658	|O
analysis	1659	1667	|O
of	1668	1670	|O
the	1671	1674	|O
high	1675	1679	|O
-	1679	1680	|O
affinity	1680	1688	|O
(	1689	1690	|O
2R	1690	1692	|O
,	1692	1693	|O
3R	1693	1695	|O
)	1695	1696	|O
-	1696	1697	|O
MePhe3	1697	1703	|O
analog	1704	1710	|O
revealed	1711	1719	|O
a	1720	1721	|O
strong	1722	1728	|O
preference	1729	1739	|O
for	1740	1743	|O
a	1744	1745	|O
single	1746	1752	|O
side	1753	1757	|O
chain	1758	1763	|O
conformer	1764	1773	|O
(	1774	1775	|O
chi	1775	1778	|O
1	1779	1780	|O
approximately	1781	1794	|O
60	1795	1797	|O
degrees	1798	1805	|O
)	1805	1806	|O
.	1806	1807	|O
Low	1808	1811	|O
-	1811	1812	|O
energy	1812	1818	|O
conformers	1819	1829	|O
of	1830	1832	|O
this	1833	1837	|O
analog	1838	1844	|O
could	1845	1850	|O
only	1851	1855	|O
be	1856	1858	|O
effectively	1859	1870	|O
superimposed	1871	1883	|O
with	1884	1888	|O
low	1889	1892	|O
-	1892	1893	|O
energy	1893	1899	|O
conformers	1900	1910	|O
of	1911	1913	|O
the	1914	1917	|O
parent	1918	1924	|O
peptide	1925	1932	|O
in	1933	1935	|O
which	1936	1941	|O
the	1942	1945	|O
Phe3	1946	1950	|O
side	1951	1955	|O
chain	1956	1961	|O
conformation	1962	1974	|O
was	1975	1978	|O
limited	1979	1986	|O
to	1987	1989	|O
chi	1990	1993	|O
1	1994	1995	|O
approximately	1996	2009	|O
-	2010	2011	|O
60	2011	2013	|O
degrees	2014	2021	|O
.	2021	2022	|O
This	2023	2027	|O
observation	2028	2039	|O
eliminates	2040	2050	|O
the	2051	2054	|O
last	2055	2059	|O
remaining	2060	2069	|O
uncertainty	2070	2081	|O
regarding	2082	2091	|O
conformational	2092	2106	|O
features	2107	2115	|O
of	2116	2118	|O
the	2119	2122	|O
pharmacophore	2123	2136	|O
elements	2137	2145	|O
in	2146	2148	|O
the	2149	2152	|O
delta	2153	2158	|O
receptor	2159	2167	|O
-	2167	2168	|O
bound	2168	2173	|O
state	2174	2179	|O
,	2179	2180	|O
allowing	2181	2189	|O
the	2190	2193	|O
proposal	2194	2202	|O
of	2203	2205	|O
a	2206	2207	|O
complete	2208	2216	|O
model	2217	2222	|O
.	2222	2223	|O

### abstracts325.txt
Aromatic	0	8	|O
carboxylic	9	19	|O
esters	20	26	|O
of	27	29	|O
1	30	31	|B-IUPAC
-	31	32	|I-IUPAC
methyl	32	38	|I-IUPAC
-	38	39	|I-IUPAC
4	39	40	|I-IUPAC
-	40	41	|I-IUPAC
piperidinol	41	52	|I-IUPAC
were	53	57	|O
prepared	58	66	|O
and	67	70	|O
evaluated	71	80	|O
for	81	84	|O
analgesic	85	94	|O
activity	95	103	|O
.	103	104	|O
In	105	107	|O
addition	108	116	|O
,	116	117	|O
aralkyl	118	125	|B-IUPAC
,	125	126	|O
alkyl	127	132	|B-IUPAC
,	132	133	|O
and	134	137	|O
cycloalkyl	138	148	|B-IUPAC
carboxylates	149	161	|B-IUPAC
of	162	164	|O
the	165	168	|O
4	169	170	|B-IUPAC
-	170	171	|I-IUPAC
piperidinol	171	182	|I-IUPAC
system	183	189	|B-MODIFIER
and	190	193	|O
3,4	194	197	|B-IUPAC
-	197	198	|I-IUPAC
dimethoxybenzoates	198	216	|I-IUPAC
of	217	219	|O
isomeric	220	228	|O
piperidinols	229	241	|O
(	242	243	|O
24-26	243	248	|O
)	248	249	|O
were	250	254	|O
synthesized	255	266	|O
.	266	267	|O
The	268	271	|O
3,4	272	275	|B-IUPAC
-	275	276	|I-IUPAC
dimethoxybenzoate	276	293	|I-IUPAC
23	294	296	|O
was	297	300	|O
nearly	301	307	|O
twice	308	313	|O
as	314	316	|O
active	317	323	|O
as	324	326	|O
codeine	327	334	|O
in	335	337	|O
the	338	341	|O
mouse	342	347	|O
hot	348	351	|O
-	351	352	|O
plate	352	357	|O
assay	358	363	|O
.	363	364	|O
In	365	367	|O
monkeys	368	375	|O
,	375	376	|O
23	377	379	|O
showed	380	386	|O
no	387	389	|O
morphine	390	398	|O
-	398	399	|O
like	399	403	|O
physical	404	412	|O
dependence	413	423	|O
liability	424	433	|O
,	433	434	|O
cis	435	438	|B-PARTIUPAC
-	438	439	|I-PARTIUPAC
and	440	443	|O
trans	444	449	|B-IUPAC
-	449	450	|I-IUPAC
1,3	450	453	|I-IUPAC
-	453	454	|I-IUPAC
dimethyl	454	462	|I-IUPAC
-	462	463	|I-IUPAC
4	463	464	|I-IUPAC
-	464	465	|I-IUPAC
piperidinol	465	476	|I-IUPAC
esters	477	483	|I-IUPAC
24	484	486	|O
and	487	490	|O
25	491	493	|O
showed	494	500	|O
no	501	503	|O
binding	504	511	|O
to	512	514	|O
the	515	518	|O
opiate	519	525	|O
receptor	526	534	|O
in	535	537	|O
rat	538	541	|O
brain	542	547	|O
homogenates	548	559	|O
.	559	560	|O
The	561	564	|O
3	565	566	|O
-	566	567	|O
and	568	571	|O
4	572	573	|O
-	573	574	|O
monosubstituted	574	589	|O
and	590	593	|O
the	594	597	|O
3,4	598	601	|O
-	601	602	|O
disubstituted	602	615	|O
benzoate	616	624	|O
esters	625	631	|O
were	632	636	|O
examined	637	645	|O
for	646	649	|O
qualitative	650	661	|O
structure	662	671	|O
-	671	672	|O
activity	672	680	|O
relationships	681	694	|O
with	695	699	|O
respect	700	707	|O
to	708	710	|O
parameters	711	721	|O
Esc	722	725	|O
and	726	729	|O
pi	730	732	|O
.	732	733	|O
Various	734	741	|O
structural	742	752	|O
features	753	761	|O
of	762	764	|O
this	765	769	|O
series	770	776	|O
of	777	779	|O
compounds	780	789	|O
that	790	794	|O
may	795	798	|O
have	799	803	|O
an	804	806	|O
affinity	807	815	|O
for	816	819	|O
receptor	820	828	|O
binding	829	836	|O
sites	837	842	|O
are	843	846	|O
discussed	847	856	|O
.	856	857	|O

### abstracts93.txt
Convenient	0	10	|O
and	11	14	|O
efficient	15	24	|O
methods	25	32	|O
were	33	37	|O
developed	38	47	|O
for	48	51	|O
preparing	52	61	|O
1	62	63	|B-IUPAC
-	63	64	|I-IUPAC
(	64	65	|I-IUPAC
tetrahydro	65	75	|I-IUPAC
-	75	76	|I-IUPAC
2	76	77	|I-IUPAC
-	77	78	|I-IUPAC
furanyl	78	85	|I-IUPAC
)	85	86	|I-IUPAC
-	86	87	|I-IUPAC
5	87	88	|I-IUPAC
-	88	89	|I-IUPAC
fluorouracil	89	101	|I-IUPAC
(	102	103	|O
Thf	103	106	|O
-	106	107	|O
FU	107	109	|O
,	109	110	|O
3	111	112	|O
)	112	113	|O
[	114	115	|O
trade	115	120	|O
name	121	125	|O
,	125	126	|O
Futraful	127	135	|O
(	136	137	|O
Ftorafur	137	145	|O
)	145	146	|O
or	147	149	|O
FT	150	152	|O
-	152	153	|O
207	153	156	|O
]	156	157	|O
,	157	158	|O
which	159	164	|O
is	165	167	|O
used	168	172	|O
clinically	173	183	|O
as	184	186	|O
an	187	189	|O
antitumor	190	199	|O
agent	200	205	|O
,	205	206	|O
and	207	210	|O
1,3	211	214	|B-IUPAC
-	214	215	|I-IUPAC
bis	215	218	|I-IUPAC
(	218	219	|I-IUPAC
tetrahydro	219	229	|I-IUPAC
-	229	230	|I-IUPAC
2	230	231	|I-IUPAC
-	231	232	|I-IUPAC
furanyl	232	239	|I-IUPAC
)	239	240	|I-IUPAC
-	240	241	|I-IUPAC
5	241	242	|I-IUPAC
-	242	243	|I-IUPAC
fluorouracil	243	255	|I-IUPAC
(	256	257	|O
Thf2	257	261	|O
-	261	262	|O
FU	262	264	|O
,	264	265	|O
4	266	267	|O
)	267	268	|O
.	268	269	|O
For	270	273	|O
the	274	277	|O
syntheses	278	287	|O
,	287	288	|O
2,4	289	292	|B-IUPAC
-	292	293	|I-IUPAC
bis	293	296	|I-IUPAC
(	296	297	|I-IUPAC
trimethylsily	297	310	|I-IUPAC
)	310	311	|I-IUPAC
-	311	312	|I-IUPAC
5	312	313	|I-IUPAC
-	313	314	|I-IUPAC
fluorouracil	314	326	|I-IUPAC
(	327	328	|O
Me3Si	328	333	|O
-	333	334	|O
FU	334	336	|O
,	336	337	|O
1	338	339	|O
)	339	340	|O
and	341	344	|O
2	345	346	|B-IUPAC
-	346	347	|I-IUPAC
acetoxytetrahydrofuran	347	369	|I-IUPAC
(	370	371	|O
Thf	371	374	|O
-	374	375	|O
OAc	375	378	|O
,	378	379	|O
2	380	381	|O
)	381	382	|O
were	383	387	|O
condensed	388	397	|O
in	398	400	|O
the	401	404	|O
presence	405	413	|O
of	414	416	|O
Friedel	417	424	|O
-	424	425	|O
Crafts	425	431	|O
catalysts	432	441	|O
,	441	442	|O
such	443	447	|O
as	448	450	|O
SnCl4	451	456	|O
and	457	460	|O
BF3	461	464	|O
-	464	465	|O
Et2O	465	469	|O
in	470	472	|O
dichloromethane	473	488	|O
,	488	489	|O
or	490	492	|O
in	493	495	|O
the	496	499	|O
presence	500	508	|O
of	509	511	|O
NaI	512	515	|O
in	516	518	|O
acetonitrile	519	531	|O
to	532	534	|O
give	535	539	|O
Thf	540	543	|O
-	543	544	|O
Fu	544	546	|O
or	547	549	|O
Thf2	550	554	|O
-	554	555	|O
FU	555	557	|O
depending	558	567	|O
on	568	570	|O
the	571	574	|O
reaction	575	583	|O
conditions	584	594	|O
and	595	598	|O
workup	599	605	|O
procedure	606	615	|O
.	615	616	|O
A	617	618	|O
trace	619	624	|O
of	625	627	|O
3	628	629	|B-IUPAC
-	629	630	|I-IUPAC
(	630	631	|I-IUPAC
tetrahydro	631	641	|I-IUPAC
-	641	642	|I-IUPAC
2	642	643	|I-IUPAC
-	643	644	|I-IUPAC
furanyl	644	651	|I-IUPAC
)	651	652	|I-IUPAC
-	652	653	|I-IUPAC
5	653	654	|I-IUPAC
-	654	655	|I-IUPAC
fluorouracil	655	667	|I-IUPAC
(	668	669	|O
3	669	670	|O
-	670	671	|O
Thf	671	674	|O
-	674	675	|O
FU	675	677	|O
,	677	678	|O
5	679	680	|O
)	680	681	|O
was	682	685	|O
formed	686	692	|O
in	693	695	|O
these	696	701	|O
reactions	702	711	|O
.	711	712	|O
Thf2	713	717	|O
-	717	718	|O
FU	718	720	|O
was	721	724	|O
easily	725	731	|O
hydrolyzed	732	742	|O
to	743	745	|O
Thf	746	749	|O
-	749	750	|O
FU	750	752	|O
.	752	753	|O
2	754	755	|B-IUPAC
-	755	756	|I-IUPAC
Methoxytetrahydrofuran	756	778	|I-IUPAC
can	779	782	|O
be	783	785	|O
used	786	790	|O
instead	791	798	|O
of	799	801	|O
Thf	802	805	|O
-	805	806	|O
OAc	806	809	|O
for	810	813	|O
preparation	814	825	|O
of	826	828	|O
Thf	829	832	|O
-	832	833	|O
FU	833	835	|O
under	836	841	|O
similar	842	849	|O
conditions	850	860	|O
.	860	861	|O
The	862	865	|O
optimal	866	873	|O
ratios	874	880	|O
of	881	883	|O
Me3Si	884	889	|O
-	889	890	|O
FU	890	892	|O
,	892	893	|O
Thf	894	897	|O
-	897	898	|O
OAc	898	901	|O
,	901	902	|O
and	903	906	|O
SnCl4	907	912	|O
or	913	915	|O
NaI	916	919	|O
for	920	923	|O
preparation	924	935	|O
of	936	938	|O
Thf	939	942	|O
-	942	943	|O
FU	943	945	|O
and	946	949	|O
Thf2	950	954	|O
-	954	955	|O
FU	955	957	|O
were	958	962	|O
determined	963	973	|O
.	973	974	|O
In	975	977	|O
all	978	981	|O
cases	982	987	|O
,	987	988	|O
2-2.5	989	994	|O
equiv	995	1000	|O
of	1001	1003	|O
Thf	1004	1007	|O
-	1007	1008	|O
OAc	1008	1011	|O
with	1012	1016	|O
respect	1017	1024	|O
to	1025	1027	|O
Me3Si	1028	1033	|O
-	1033	1034	|O
FU	1034	1036	|O
gave	1037	1041	|O
the	1042	1045	|O
best	1046	1050	|O
results	1051	1058	|O
.	1058	1059	|O
The	1060	1063	|O
yields	1064	1070	|O
of	1071	1073	|O
Thf	1074	1077	|O
-	1077	1078	|O
FU	1078	1080	|O
and	1081	1084	|O
more	1085	1089	|O
especially	1090	1100	|O
of	1101	1103	|O
Thf2	1104	1108	|O
-	1108	1109	|O
FU	1109	1111	|O
were	1112	1116	|O
greatly	1117	1124	|O
dependent	1125	1134	|O
on	1135	1137	|O
the	1138	1141	|O
relative	1142	1150	|O
amount	1151	1157	|O
of	1158	1160	|O
SnCl4	1161	1166	|O
,	1166	1167	|O
and	1168	1171	|O
0.01-0.1	1172	1180	|O
equiv	1181	1186	|O
of	1187	1189	|O
the	1190	1193	|O
catalyst	1194	1202	|O
with	1203	1207	|O
respect	1208	1215	|O
to	1216	1218	|O
Me3Si	1219	1224	|O
-	1224	1225	|O
FU	1225	1227	|O
gave	1228	1232	|O
the	1233	1236	|O
best	1237	1241	|O
results	1242	1249	|O
.	1249	1250	|O
Thf2	1251	1255	|O
-	1255	1256	|O
FU	1256	1258	|O
was	1259	1262	|O
found	1263	1268	|O
to	1269	1271	|O
be	1272	1274	|O
effective	1275	1284	|O
against	1285	1292	|O
murine	1293	1299	|O
solid	1300	1305	|O
tumors	1306	1312	|O
and	1313	1316	|O
it	1317	1319	|O
was	1320	1323	|O
less	1324	1328	|O
toxic	1329	1334	|O
than	1335	1339	|O
Thf	1340	1343	|O
-	1343	1344	|O
FU	1344	1346	|O
when	1347	1351	|O
given	1352	1357	|O
orally	1358	1364	|O
.	1364	1365	|O
The	1366	1369	|O
antitumor	1370	1379	|O
activity	1380	1388	|O
of	1389	1391	|O
3	1392	1393	|O
-	1393	1394	|O
Thf	1394	1397	|O
-	1397	1398	|O
FU	1398	1400	|O
is	1401	1403	|O
also	1404	1408	|O
reported	1409	1417	|O
.	1417	1418	|O

### abstracts893.txt
Previous	0	8	|O
findings	9	17	|O
suggesting	18	28	|O
that	29	33	|O
5,10	34	38	|B-IUPAC
-	38	39	|I-IUPAC
dialkyl	39	46	|I-IUPAC
-	46	47	|O
substituted	47	58	|B-MODIFIER
derivatives	59	70	|I-MODIFIER
of	71	73	|O
5,10	74	78	|B-IUPAC
-	78	79	|I-IUPAC
dideazaaminopterin	79	97	|I-IUPAC
warranted	98	107	|O
study	108	113	|O
as	114	116	|O
potential	117	126	|O
antifolates	127	138	|O
prompted	139	147	|O
synthesis	148	157	|O
of	158	160	|O
10	161	163	|B-IUPAC
-	163	164	|I-IUPAC
ethyl	164	169	|I-IUPAC
-	169	170	|I-IUPAC
5	170	171	|I-IUPAC
-	171	172	|I-IUPAC
methyl	172	178	|I-IUPAC
-	178	179	|I-IUPAC
5,10	179	183	|I-IUPAC
-	183	184	|I-IUPAC
dideazaaminopterin	185	203	|I-IUPAC
(	204	205	|O
12a	205	208	|O
)	208	209	|O
.	209	210	|O
The	211	214	|O
key	215	218	|O
step	219	223	|O
in	224	226	|O
the	227	230	|O
synthetic	231	240	|O
route	241	246	|O
to	247	249	|O
12a	250	253	|O
was	254	257	|O
Wittig	258	264	|O
condensation	265	277	|O
of	278	280	|O
the	281	284	|O
tributylphosphorane	285	304	|O
derived	305	312	|O
from	313	317	|O
6	318	319	|B-IUPAC
-	319	320	|I-IUPAC
(	320	321	|I-IUPAC
bromomethyl	321	332	|I-IUPAC
)	332	333	|I-IUPAC
-	333	334	|I-IUPAC
2,4	334	337	|I-IUPAC
-	337	338	|I-IUPAC
diamino	338	345	|I-IUPAC
-	345	346	|I-IUPAC
5	346	347	|I-IUPAC
-	347	348	|I-IUPAC
methylpyrido	348	360	|I-IUPAC
[	360	361	|I-IUPAC
2,3	361	364	|I-IUPAC
-	364	365	|I-IUPAC
d	365	366	|I-IUPAC
]	366	367	|I-IUPAC
pyrimidine	367	377	|I-IUPAC
(	378	379	|O
7a	379	381	|O
)	381	382	|O
with	383	387	|O
methyl	388	394	|B-IUPAC
4	395	396	|I-IUPAC
-	396	397	|I-IUPAC
propionylbenzoate	397	414	|I-IUPAC
.	414	415	|O
Reaction	416	424	|O
conditions	425	435	|O
for	436	439	|O
the	440	443	|O
Wittig	444	450	|O
condensation	451	463	|O
were	464	468	|O
developed	469	478	|O
using	479	484	|O
the	485	488	|O
tributylphosphorane	489	508	|O
prepared	509	517	|O
from	518	522	|O
6	523	524	|B-IUPAC
-	524	525	|I-IUPAC
(	525	526	|I-IUPAC
bromomethyl	526	537	|I-IUPAC
)	537	538	|I-IUPAC
-	538	539	|I-IUPAC
2,4	539	542	|I-IUPAC
-	542	543	|I-IUPAC
pteridinediamine	543	559	|I-IUPAC
(	560	561	|O
7b	561	563	|O
)	563	564	|O
as	565	567	|O
a	568	569	|O
model	570	575	|O
.	575	576	|O
Each	577	581	|O
of	582	584	|O
the	585	588	|O
respective	589	599	|O
Wittig	600	606	|O
products	607	615	|O
8a	616	618	|O
and	619	622	|O
8b	623	625	|O
was	626	629	|O
obtained	630	638	|O
in	639	641	|O
75-80%	642	648	|O
yield	649	654	|O
.	654	655	|O
Hydrogenation	656	669	|O
of	670	672	|O
8a	673	675	|O
and	676	679	|O
8b	680	682	|O
at	683	685	|O
their	686	691	|O
9,10	692	696	|O
-	696	697	|O
double	697	703	|O
bond	704	708	|O
afforded	709	717	|O
4	718	719	|B-IUPAC
-	719	720	|I-IUPAC
amino	720	725	|I-IUPAC
-	725	726	|I-IUPAC
4	726	727	|I-IUPAC
-	727	728	|I-IUPAC
deoxy	728	733	|I-IUPAC
-	733	734	|I-IUPAC
10	734	736	|I-IUPAC
-	736	737	|I-IUPAC
ethyl	737	742	|I-IUPAC
-	742	743	|I-IUPAC
5	743	744	|I-IUPAC
-	744	745	|I-IUPAC
methyl	745	751	|I-IUPAC
-	751	752	|I-IUPAC
5,10	752	756	|I-IUPAC
-	756	757	|I-IUPAC
dideazapteroic	757	771	|I-IUPAC
acid	772	776	|I-IUPAC
methyl	777	783	|I-IUPAC
ester	784	789	|I-IUPAC
(	790	791	|O
9a	791	793	|O
)	793	794	|O
and	795	798	|O
4	799	800	|B-IUPAC
-	800	801	|I-IUPAC
amino	801	806	|I-IUPAC
-	806	807	|I-IUPAC
4	807	808	|I-IUPAC
-	808	809	|I-IUPAC
deoxy	809	814	|I-IUPAC
-	814	815	|I-IUPAC
10	815	817	|I-IUPAC
-	817	818	|I-IUPAC
ethyl	818	823	|I-IUPAC
-	823	824	|I-IUPAC
10	824	826	|I-IUPAC
-	826	827	|I-IUPAC
deazapteroic	827	839	|I-IUPAC
acid	840	844	|I-IUPAC
methyl	845	851	|I-IUPAC
ester	852	857	|I-IUPAC
(	858	859	|O
9b	859	861	|O
)	861	862	|O
.	862	863	|O
This	864	868	|O
route	869	874	|O
to	875	877	|O
9b	878	880	|O
intersects	881	891	|O
reported	892	900	|O
synthetic	901	910	|O
approaches	911	921	|O
leading	922	929	|O
to	930	932	|O
10	933	935	|B-IUPAC
-	935	936	|I-IUPAC
ethyl	936	941	|I-IUPAC
-	941	942	|I-IUPAC
10	942	944	|I-IUPAC
-	944	945	|I-IUPAC
deazaaminopterin	945	961	|I-IUPAC
(	962	963	|O
10	963	965	|O
-	965	966	|O
EDAM	966	970	|O
,	970	971	|O
edatrexate	972	982	|O
)	982	983	|O
,	983	984	|O
an	985	987	|O
agent	988	993	|O
now	994	997	|O
in	998	1000	|O
advanced	1001	1009	|O
clinical	1010	1018	|O
trials	1019	1025	|O
.	1025	1026	|O
Thus	1027	1031	|O
the	1032	1035	|O
Wittig	1036	1042	|O
approach	1043	1051	|O
affords	1052	1059	|O
an	1060	1062	|O
alternative	1063	1074	|O
synthetic	1075	1084	|O
route	1085	1090	|O
to	1091	1093	|O
10	1094	1096	|O
-	1096	1097	|O
EDAM	1097	1101	|O
.	1101	1102	|O
Remaining	1103	1112	|O
steps	1113	1118	|O
were	1119	1123	|O
ester	1124	1129	|O
hydrolysis	1130	1140	|O
of	1141	1143	|O
9a	1144	1146	|O
,	1146	1147	|O
b	1147	1148	|O
to	1149	1151	|O
give	1152	1156	|O
carboxylic	1157	1167	|O
acids	1168	1173	|O
10a	1174	1177	|O
,	1177	1178	|O
b	1178	1179	|O
followed	1180	1188	|O
by	1189	1191	|O
standard	1192	1200	|O
peptide	1201	1208	|O
coupling	1209	1217	|O
with	1218	1222	|O
diethyl	1223	1230	|O
L	1231	1232	|O
-	1232	1233	|O
glutamate	1233	1242	|O
to	1243	1245	|O
produce	1246	1253	|O
diethyl	1254	1261	|O
esters	1262	1268	|O
11a	1269	1272	|O
,	1272	1273	|O
b	1273	1274	|O
,	1274	1275	|O
which	1276	1281	|O
on	1282	1284	|O
hydrolysis	1285	1295	|O
gave	1296	1300	|O
12a	1301	1304	|O
and	1305	1308	|O
10	1309	1311	|O
-	1311	1312	|O
EDAM	1312	1316	|O
(	1317	1318	|O
12b	1318	1321	|O
)	1321	1322	|O
,	1322	1323	|O
respectively	1324	1336	|O
.	1336	1337	|O
The	1338	1341	|O
relative	1342	1350	|O
influx	1351	1357	|O
of	1358	1360	|O
12a	1361	1364	|O
was	1365	1368	|O
enhanced	1369	1377	|O
about	1378	1383	|O
3.2	1384	1387	|O
-	1387	1388	|O
fold	1388	1392	|O
over	1393	1397	|O
MTX	1398	1401	|O
,	1401	1402	|O
but	1403	1406	|O
as	1407	1409	|O
an	1410	1412	|O
inhibitor	1413	1422	|O
of	1423	1425	|O
dihydrofolate	1426	1439	|O
reductase	1440	1449	|O
(	1450	1451	|O
DHFR	1451	1455	|O
)	1455	1456	|O
from	1457	1461	|O
L1210	1462	1467	|O
cells	1468	1473	|O
and	1474	1477	|O
in	1478	1480	|O
the	1481	1484	|O
inhibition	1485	1495	|O
of	1496	1498	|O
L1210	1499	1504	|O
cell	1505	1509	|O
growth	1510	1516	|O
in	1517	1519	|O
vitro	1520	1525	|O
,	1525	1526	|O
this	1527	1531	|O
compound	1532	1540	|O
was	1541	1544	|O
approximately	1545	1558	|O
20	1559	1561	|O
-	1561	1562	|O
fold	1562	1566	|O
less	1567	1571	|O
effective	1572	1581	|O
than	1582	1586	|O
MTX	1587	1590	|O
(	1591	1592	|O
DHFR	1592	1596	|O
inhibition	1597	1607	|O
,	1607	1608	|O
Ki	1609	1611	|O
=	1612	1613	|O
4.82	1614	1618	|O
+	1619	1620	|O
/	1620	1621	|O
-	1621	1622	|O
0.60	1623	1627	|O
pM	1628	1630	|O
for	1631	1634	|O
MTX	1635	1638	|O
,	1638	1639	|O
100	1640	1643	|O
pM	1644	1646	|O
for	1647	1650	|O
12a	1651	1654	|O
;	1654	1655	|O
cell	1656	1660	|O
growth	1661	1667	|O
,	1667	1668	|O
IC50	1669	1673	|O
=	1674	1675	|O
3.4	1676	1679	|O
+	1680	1681	|O
/	1681	1682	|O
-	1682	1683	|O
1.0	1684	1687	|O
nM	1688	1690	|O
for	1691	1694	|O
MTX	1695	1698	|O
,	1698	1699	|O
65	1700	1702	|O
+	1703	1704	|O
/	1704	1705	|O
-	1705	1706	|O
18	1707	1709	|O
nM	1710	1712	|O
for	1713	1716	|O
12a	1717	1720	|O
)	1720	1721	|O
.	1721	1722	|O

### abstracts663.txt
The	0	3	|O
lead	4	8	|O
compound	9	17	|O
of	18	20	|O
a	21	22	|O
new	23	26	|O
series	27	33	|O
of	34	36	|O
3	37	38	|B-IUPAC
-	38	39	|I-IUPAC
pyridyl	39	46	|I-IUPAC
ethers	47	53	|I-IUPAC
,	53	54	|O
the	55	58	|O
azetidine	59	68	|O
derivative	69	79	|O
A	80	81	|O
-	81	82	|O
85380	82	87	|O
(	88	89	|O
3	89	90	|B-IUPAC
-	90	91	|I-IUPAC
[	91	92	|I-IUPAC
(	92	93	|I-IUPAC
S	93	94	|I-IUPAC
)	94	95	|I-IUPAC
-	95	96	|I-IUPAC
2	96	97	|I-IUPAC
-	97	98	|I-IUPAC
azetidinylmethoxy	98	115	|I-IUPAC
]	115	116	|I-IUPAC
pyridine	116	124	|I-IUPAC
)	124	125	|O
,	125	126	|O
is	127	129	|O
a	130	131	|O
potent	132	138	|O
and	139	142	|O
selective	143	152	|O
ligand	153	159	|O
for	160	163	|O
the	164	167	|O
human	168	173	|O
alpha4beta2	174	185	|O
nicotinic	186	195	|O
acetylcholine	196	209	|O
receptor	210	218	|O
(	219	220	|O
nAChR	220	225	|O
)	225	226	|O
subtype	227	234	|O
.	234	235	|O
In	236	238	|O
vitro	239	244	|O
,	244	245	|O
the	246	249	|O
fluoro	250	256	|O
derivative	257	267	|O
of	268	270	|O
A	271	272	|O
-	272	273	|O
85380	273	278	|O
(	279	280	|O
2	280	281	|B-IUPAC
-	281	282	|I-IUPAC
fluoro	282	288	|I-IUPAC
-	288	289	|I-IUPAC
3	289	290	|I-IUPAC
-	290	291	|I-IUPAC
[	291	292	|I-IUPAC
(	292	293	|I-IUPAC
S	293	294	|I-IUPAC
)	294	295	|I-IUPAC
-	295	296	|I-IUPAC
2	296	297	|I-IUPAC
-	297	298	|I-IUPAC
azetidinylmethoxy	298	315	|I-IUPAC
]	315	316	|I-IUPAC
pyridine	316	324	|I-IUPAC
or	325	327	|O
F	328	329	|O
-	329	330	|O
A	330	331	|O
-	331	332	|O
85380	332	337	|O
)	337	338	|O
competitively	339	352	|O
displaced	353	362	|O
[	363	364	|O
3H	364	366	|O
]	366	367	|O
cytisine	367	375	|O
or	376	378	|O
[	379	380	|O
3H	380	382	|O
]	382	383	|O
epibatidine	383	394	|O
with	395	399	|O
Ki	400	402	|O
values	403	409	|O
of	410	412	|O
48	413	415	|O
and	416	419	|O
46	420	422	|O
pM	423	425	|O
,	425	426	|O
respectively	427	439	|O
.	439	440	|O
F	441	442	|O
-	442	443	|O
A	443	444	|O
-	444	445	|O
85380	445	450	|O
has	451	454	|O
been	455	459	|O
labeled	460	467	|O
with	468	472	|O
the	473	476	|O
positron	477	485	|O
emitter	486	493	|O
fluorine	494	502	|O
-	502	503	|O
18	503	505	|O
(	506	507	|O
t1/2	507	511	|O
(	512	513	|O
half	513	517	|O
-	517	518	|O
life	518	522	|O
)	522	523	|O
=	524	525	|O
110	526	529	|O
min	530	533	|O
)	533	534	|O
by	535	537	|O
no	538	540	|O
-	540	541	|O
carrier	541	548	|O
-	548	549	|O
added	549	554	|O
nucleophilic	555	567	|O
aromatic	568	576	|O
substitution	577	589	|O
by	590	592	|O
K	593	594	|O
[	594	595	|O
18F	595	598	|O
]	598	599	|O
F	599	600	|O
-	600	601	|O
K222	601	605	|O
complex	606	613	|O
with	614	618	|O
(	619	620	|B-IUPAC
3	620	621	|I-IUPAC
-	621	622	|I-IUPAC
[	622	623	|I-IUPAC
2	623	624	|I-IUPAC
(	624	625	|I-IUPAC
S	625	626	|I-IUPAC
)	626	627	|I-IUPAC
-	627	628	|I-IUPAC
N	628	629	|I-IUPAC
-	629	630	|I-IUPAC
(	630	631	|I-IUPAC
tert	631	635	|I-IUPAC
-	635	636	|I-IUPAC
butoxycarbonyl	636	650	|I-IUPAC
)	650	651	|I-IUPAC
-	651	652	|I-IUPAC
2	652	653	|I-IUPAC
-	653	654	|I-IUPAC
azetidinylmethoxy	654	671	|I-IUPAC
]	671	672	|I-IUPAC
pyridin	672	679	|I-IUPAC
-	679	680	|I-IUPAC
2	680	681	|I-IUPAC
-	681	682	|I-IUPAC
yl	682	684	|I-IUPAC
)	684	685	|I-IUPAC
tri	686	689	|I-IUPAC
methylammonium	690	704	|I-IUPAC
trifluoromethanesulfonate	705	730	|I-IUPAC
as	731	733	|O
a	734	735	|O
highly	736	742	|O
efficient	743	752	|O
labeling	753	761	|O
precursor	762	771	|O
,	771	772	|O
followed	773	781	|O
by	782	784	|O
TFA	785	788	|O
removal	789	796	|O
of	797	799	|O
the	800	803	|O
Boc	804	807	|O
protective	808	818	|O
group	819	824	|O
.	824	825	|O
The	826	829	|O
total	830	835	|O
synthesis	836	845	|O
time	846	850	|O
was	851	854	|O
50-53	855	860	|O
min	861	864	|O
from	865	869	|O
the	870	873	|O
end	874	877	|O
of	878	880	|O
cyclotron	881	890	|O
fluorine	891	899	|O
-	899	900	|O
18	900	902	|O
production	903	913	|O
(	914	915	|O
EOB	915	918	|O
)	918	919	|O
.	919	920	|O
Radiochemical	921	934	|O
yields	935	941	|O
,	941	942	|O
with	943	947	|O
respect	948	955	|O
to	956	958	|O
initial	959	966	|O
[	967	968	|O
18F	968	971	|O
]	971	972	|O
fluoride	972	980	|O
ion	981	984	|O
radioactivity	985	998	|O
,	998	999	|O
were	1000	1004	|O
68-72%	1005	1011	|O
(	1012	1013	|O
decay	1013	1018	|O
-	1018	1019	|O
corrected	1019	1028	|O
)	1028	1029	|O
and	1030	1033	|O
49-52%	1034	1040	|O
(	1041	1042	|O
non	1042	1045	|O
-	1045	1046	|O
decay	1046	1051	|O
-	1051	1052	|O
corrected	1052	1061	|O
)	1061	1062	|O
,	1062	1063	|O
and	1064	1067	|O
the	1068	1071	|O
specific	1072	1080	|O
radioactivities	1081	1096	|O
at	1097	1099	|O
EOB	1100	1103	|O
were	1104	1108	|O
4-7	1109	1112	|O
Ci	1113	1115	|O
/	1115	1116	|O
micromol	1116	1124	|O
(	1125	1126	|O
148-259	1126	1133	|O
GBq	1134	1137	|O
/	1137	1138	|O
micromol	1138	1146	|O
)	1146	1147	|O
.	1147	1148	|O
In	1149	1151	|O
vivo	1152	1156	|O
characterization	1157	1173	|O
of	1174	1176	|O
[	1177	1178	|O
18F	1178	1181	|O
]	1181	1182	|O
F	1182	1183	|O
-	1183	1184	|O
A	1184	1185	|O
-	1185	1186	|O
85380	1186	1191	|O
showed	1192	1198	|O
promising	1199	1208	|O
properties	1209	1219	|O
for	1220	1223	|O
PET	1224	1227	|O
imaging	1228	1235	|O
of	1236	1238	|O
central	1239	1246	|O
nAChRs	1247	1253	|O
.	1253	1254	|O
This	1255	1259	|O
compound	1260	1268	|O
does	1269	1273	|O
not	1274	1277	|O
bind	1278	1282	|O
in	1283	1285	|O
vivo	1286	1290	|O
to	1291	1293	|O
alpha7	1294	1300	|O
nicotinic	1301	1310	|O
or	1311	1313	|O
5HT3	1314	1318	|O
receptors	1319	1328	|O
.	1328	1329	|O
Moreover	1330	1338	|O
,	1338	1339	|O
its	1340	1343	|O
cerebral	1344	1352	|O
uptake	1353	1359	|O
can	1360	1363	|O
be	1364	1366	|O
modulated	1367	1376	|O
by	1377	1379	|O
the	1380	1383	|O
synaptic	1384	1392	|O
concentration	1393	1406	|O
of	1407	1409	|O
the	1410	1413	|O
endogenous	1414	1424	|O
ligand	1425	1431	|O
acetylcholine	1432	1445	|O
.	1445	1446	|O
The	1447	1450	|O
preliminary	1451	1462	|O
PET	1463	1466	|O
experiments	1467	1478	|O
in	1479	1481	|O
baboons	1482	1489	|O
with	1490	1494	|O
[	1495	1496	|O
18F	1496	1499	|O
]	1499	1500	|O
F	1500	1501	|O
-	1501	1502	|O
A	1502	1503	|O
-	1503	1504	|O
85380	1504	1509	|O
show	1510	1514	|O
an	1515	1517	|O
accumulation	1518	1530	|O
of	1531	1533	|O
the	1534	1537	|O
radiotracer	1538	1549	|O
in	1550	1552	|O
the	1553	1556	|O
brain	1557	1562	|O
within	1563	1569	|O
60	1570	1572	|O
min	1573	1576	|O
.	1576	1577	|O
In	1578	1580	|O
the	1581	1584	|O
thalamus	1585	1593	|O
,	1593	1594	|O
a	1595	1596	|O
nAChR	1597	1602	|O
-	1602	1603	|O
rich	1603	1607	|O
area	1608	1612	|O
,	1612	1613	|O
uptake	1614	1620	|O
of	1621	1623	|O
radioactivity	1624	1637	|O
reached	1638	1645	|O
a	1646	1647	|O
maximum	1648	1655	|O
at	1656	1658	|O
60	1659	1661	|O
min	1662	1665	|O
(	1666	1667	|O
4%	1667	1669	|O
I	1670	1671	|O
.	1671	1672	|O
D	1672	1673	|O
.	1673	1674	|O
/	1674	1675	|O
100	1675	1678	|O
mL	1679	1681	|O
of	1682	1684	|O
tissue	1685	1691	|O
)	1691	1692	|O
.	1692	1693	|O
[	1694	1695	|O
18F	1695	1698	|O
]	1698	1699	|O
F	1699	1700	|O
-	1700	1701	|O
A	1701	1702	|O
-	1702	1703	|O
85380	1703	1708	|O
appears	1709	1716	|O
to	1717	1719	|O
be	1720	1722	|O
a	1723	1724	|O
suitable	1725	1733	|O
radioligand	1734	1745	|O
for	1746	1749	|O
brain	1750	1755	|O
imaging	1756	1763	|O
nAChRs	1764	1770	|O
with	1771	1775	|O
PET	1776	1779	|O
.	1779	1780	|O

### abstracts3625.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
28	12	14	|O
new	15	18	|O
pyrrolo	19	26	|B-IUPAC
[	26	27	|I-IUPAC
2,3	27	30	|I-IUPAC
-	30	31	|I-IUPAC
d	31	32	|I-IUPAC
]	32	33	|I-IUPAC
pyrimidine	33	43	|I-IUPAC
-	43	44	|I-IUPAC
4	44	45	|I-IUPAC
-	45	46	|I-IUPAC
amines	46	52	|I-IUPAC
,	52	53	|O
pyrimido	54	62	|B-IUPAC
[	62	63	|I-IUPAC
4	63	64	|I-IUPAC
,	64	65	|I-IUPAC
5	66	67	|I-IUPAC
-	67	68	|I-IUPAC
b	68	69	|I-IUPAC
]	69	70	|I-IUPAC
indole	70	76	|I-IUPAC
-	76	77	|I-IUPAC
4	77	78	|I-IUPAC
-	78	79	|I-IUPAC
amines	79	85	|I-IUPAC
,	85	86	|O
and	87	90	|O
tetrahydropyrimido	91	109	|B-IUPAC
[	109	110	|I-IUPAC
4,5	110	113	|I-IUPAC
-	113	114	|I-IUPAC
b	114	115	|I-IUPAC
]	115	116	|I-IUPAC
indole	116	122	|I-IUPAC
-	122	123	|I-IUPAC
4	123	124	|I-IUPAC
-	124	125	|I-IUPAC
amines	125	131	|I-IUPAC
was	132	135	|O
synthesized	136	147	|O
and	148	151	|O
their	152	157	|O
adenosine	158	167	|O
receptor	168	176	|O
affinity	177	185	|O
determined	186	196	|O
in	197	199	|O
radioligand	200	211	|O
binding	212	219	|O
assays	220	226	|O
at	227	229	|O
rat	230	233	|O
A	234	235	|O
(	235	236	|O
1	236	237	|O
)	237	238	|O
and	239	242	|O
A	243	244	|O
(	244	245	|O
2A	245	247	|O
)	247	248	|O
adenosine	249	258	|O
receptors	259	268	|O
(	269	270	|O
ARs	270	273	|O
)	273	274	|O
.	274	275	|O
Selected	276	284	|O
compounds	285	294	|O
were	295	299	|O
additionally	300	312	|O
investigated	313	325	|O
in	326	328	|O
binding	329	336	|O
assays	337	343	|O
at	344	346	|O
recombinant	347	358	|O
A	359	360	|O
(	360	361	|O
3	361	362	|O
)	362	363	|O
ARs	364	367	|O
.	367	368	|O
The	369	372	|O
2	373	374	|B-IUPAC
-	374	375	|I-IUPAC
phenyl	375	381	|I-IUPAC
residue	382	389	|B-MODIFIER
in	390	392	|O
(	393	394	|B-IUPAC
R	394	395	|I-IUPAC
)	395	396	|I-IUPAC
-	396	397	|I-IUPAC
7	397	398	|I-IUPAC
-	398	399	|I-IUPAC
(	399	400	|I-IUPAC
1	400	401	|I-IUPAC
-	401	402	|I-IUPAC
methylbenzyl	402	414	|I-IUPAC
)	414	415	|I-IUPAC
-	415	416	|I-IUPAC
2	416	417	|I-IUPAC
-	417	418	|I-IUPAC
phenylpyrrolo	418	431	|I-IUPAC
[	431	432	|I-IUPAC
2,3	432	435	|I-IUPAC
-	435	436	|I-IUPAC
d	436	437	|I-IUPAC
]	437	438	|I-IUPAC
pyrimidine	438	448	|I-IUPAC
-	448	449	|I-IUPAC
4	449	450	|I-IUPAC
-	450	451	|I-IUPAC
amine	451	456	|I-IUPAC
(	457	458	|O
ADPEP	458	463	|O
,	463	464	|O
1	465	466	|O
)	466	467	|O
and	468	471	|O
in	472	474	|O
the	475	478	|O
corresponding	479	492	|O
pyrimido	493	501	|B-IUPAC
[	501	502	|I-IUPAC
4,5	502	505	|I-IUPAC
-	505	506	|I-IUPAC
b	506	507	|I-IUPAC
]	507	508	|I-IUPAC
indole	508	514	|I-IUPAC
(	515	516	|O
APEPI	516	521	|O
,	521	522	|O
3	523	524	|O
)	524	525	|O
could	526	531	|O
be	532	534	|O
bioisosterically	535	551	|O
replaced	552	560	|O
by	561	563	|O
heterocyclic	564	576	|O
rings	577	582	|O
,	582	583	|O
such	584	588	|O
as	589	591	|O
2	592	593	|B-IUPAC
-	593	594	|I-IUPAC
thienyl	594	601	|I-IUPAC
and	602	605	|O
4	606	607	|B-IUPAC
-	607	608	|I-IUPAC
pyridyl	608	615	|I-IUPAC
.	615	616	|O
The	617	620	|O
resulting	621	630	|O
compounds	631	640	|O
retained	641	649	|O
high	650	654	|O
affinity	655	663	|O
and	664	667	|O
selectivity	668	679	|O
for	680	683	|O
A	684	685	|O
(	685	686	|O
1	686	687	|O
)	687	688	|O
ARs	689	692	|O
.	692	693	|O
Judging	694	701	|O
from	702	706	|O
the	707	710	|O
investigation	711	724	|O
of	725	727	|O
selected	728	736	|O
compounds	737	746	|O
,	746	747	|O
it	748	750	|O
appears	751	758	|O
that	759	763	|O
they	764	768	|O
are	769	772	|O
also	773	777	|O
potent	778	784	|O
at	785	787	|O
human	788	793	|O
A	794	795	|O
(	795	796	|O
1	796	797	|O
)	797	798	|O
ARs	799	802	|O
and	803	806	|O
selective	807	816	|O
not	817	820	|O
only	821	825	|O
versus	826	832	|O
A	833	834	|O
(	834	835	|O
2A	835	837	|O
)	837	838	|O
ARs	839	842	|O
but	843	846	|O
also	847	851	|O
highly	852	858	|O
selective	859	868	|O
versus	869	875	|O
A	876	877	|O
(	877	878	|O
2B	878	880	|O
)	880	881	|O
and	882	885	|O
A	886	887	|O
(	887	888	|O
3	888	889	|O
)	889	890	|O
ARs	891	894	|O
.	894	895	|O
The	896	899	|O
p	900	901	|B-IUPAC
-	901	902	|I-IUPAC
pyridyl	902	909	|I-IUPAC
-	909	910	|O
substituted	910	921	|B-MODIFIER
derivatives	922	933	|B-MODIFIER
11	934	936	|O
and	937	940	|O
27	941	943	|O
(	944	945	|O
APPPI	945	950	|O
)	950	951	|O
may	952	955	|O
be	956	958	|O
interesting	959	970	|O
pharmacological	971	986	|O
tools	987	992	|O
due	993	996	|O
to	997	999	|O
their	1000	1005	|O
fluorescent	1006	1017	|O
properties	1018	1028	|O
.	1028	1029	|O
Pyrrolo	1030	1037	|B-IUPAC
[	1037	1038	|I-IUPAC
2,3	1038	1041	|I-IUPAC
-	1041	1042	|I-IUPAC
d	1042	1043	|I-IUPAC
]	1043	1044	|I-IUPAC
pyrimidine	1044	1054	|I-IUPAC
-	1054	1055	|I-IUPAC
4	1055	1056	|I-IUPAC
-	1056	1057	|I-IUPAC
amine	1057	1062	|I-IUPAC
derivatives	1063	1074	|B-MODIFIER
which	1075	1080	|O
were	1081	1085	|O
simultaneously	1086	1100	|O
substituted	1101	1112	|O
at	1113	1115	|O
N7	1116	1118	|O
and	1119	1122	|O
N	1123	1124	|O
(	1124	1125	|O
4	1125	1126	|O
)	1126	1127	|O
,	1127	1128	|O
combining	1129	1138	|O
the	1139	1142	|O
substitution	1143	1155	|O
pattern	1156	1163	|O
of	1164	1166	|O
ADPEP	1167	1172	|O
(	1173	1174	|O
1	1174	1175	|O
)	1175	1176	|O
and	1177	1180	|O
DPEAP	1181	1186	|O
(	1187	1188	|O
2	1188	1189	|O
)	1189	1190	|O
,	1190	1191	|O
showed	1192	1198	|O
very	1199	1203	|O
low	1204	1207	|O
affinity	1208	1216	|O
for	1217	1220	|O
A	1221	1222	|O
(	1222	1223	|O
1	1223	1224	|O
)	1224	1225	|O
ARs	1226	1229	|O
.	1229	1230	|O
This	1231	1235	|O
finding	1236	1243	|O
supports	1244	1252	|O
our	1253	1256	|O
previously	1257	1267	|O
published	1268	1277	|O
hypothesis	1278	1288	|O
of	1289	1291	|O
different	1292	1301	|O
binding	1302	1309	|O
modes	1310	1315	|O
for	1316	1319	|O
pyrrolopyrimidines	1320	1338	|O
,	1338	1339	|O
such	1340	1344	|O
as	1345	1347	|O
ADPEP	1348	1353	|O
(	1354	1355	|O
1	1355	1356	|O
)	1356	1357	|O
and	1358	1361	|O
DPEAP	1362	1367	|O
(	1368	1369	|O
2	1369	1370	|O
)	1370	1371	|O
.	1371	1372	|O
DPEAP	1373	1378	|O
(	1379	1380	|O
2	1380	1381	|O
)	1381	1382	|O
,	1382	1383	|O
a	1384	1385	|O
pyrrolo	1386	1393	|B-IUPAC
[	1393	1394	|I-IUPAC
2,3	1394	1397	|I-IUPAC
-	1397	1398	|I-IUPAC
d	1398	1399	|I-IUPAC
]	1399	1400	|I-IUPAC
pyrimidine	1400	1410	|I-IUPAC
-	1410	1411	|I-IUPAC
4	1411	1412	|I-IUPAC
-	1412	1413	|I-IUPAC
amine	1413	1418	|I-IUPAC
substituted	1419	1430	|O
at	1431	1433	|O
the	1434	1437	|O
amino	1438	1443	|O
group	1444	1449	|O
(	1450	1451	|O
N	1451	1452	|O
(	1452	1453	|O
4	1453	1454	|O
)	1454	1455	|O
)	1455	1456	|O
,	1456	1457	|O
was	1458	1461	|O
found	1462	1467	|O
to	1468	1470	|O
exhibit	1471	1478	|O
high	1479	1483	|O
affinity	1484	1492	|O
for	1493	1496	|O
human	1497	1502	|O
A	1503	1504	|O
(	1504	1505	|O
3	1505	1506	|O
)	1506	1507	|O
ARs	1508	1511	|O
(	1512	1513	|O
K	1513	1514	|O
(	1514	1515	|O
i	1515	1516	|O
)	1516	1517	|O
=	1518	1519	|O
28	1520	1522	|O
nM	1523	1525	|O
)	1525	1526	|O
,	1526	1527	|O
whereas	1528	1535	|O
N	1536	1537	|O
(	1537	1538	|O
4	1538	1539	|O
)	1539	1540	|O
-	1540	1541	|O
unsubstituted	1541	1554	|O
analogues	1555	1564	|O
were	1565	1569	|O
inactive	1570	1578	|O
.	1578	1579	|O
DPEAP	1580	1585	|O
(	1586	1587	|O
2	1587	1588	|O
)	1588	1589	|O
and	1590	1593	|O
related	1594	1601	|O
compounds	1602	1611	|O
provide	1612	1619	|O
new	1620	1623	|O
leads	1624	1629	|O
for	1630	1633	|O
the	1634	1637	|O
development	1638	1649	|O
of	1650	1652	|O
antagonists	1653	1664	|O
for	1665	1668	|O
the	1669	1672	|O
human	1673	1678	|O
A	1679	1680	|O
(	1680	1681	|O
3	1681	1682	|O
)	1682	1683	|O
AR	1684	1686	|O
.	1686	1687	|O

### abstracts2228.txt
N	0	1	|B-PARTIUPAC
-	1	2	|I-PARTIUPAC
(	2	3	|I-PARTIUPAC
omega	3	8	|I-PARTIUPAC
-	8	9	|I-PARTIUPAC
Aminoalkyl	9	19	|I-PARTIUPAC
)	19	20	|I-PARTIUPAC
-	20	21	|I-PARTIUPAC
2,2,5,5	21	28	|I-PARTIUPAC
-	28	29	|I-PARTIUPAC
tetramethyl	29	40	|I-PARTIUPAC
-	40	41	|I-PARTIUPAC
3	41	42	|I-PARTIUPAC
-	42	43	|I-PARTIUPAC
pyrroline	43	52	|I-PARTIUPAC
-	52	53	|I-PARTIUPAC
or	54	56	|O
-	57	58	|B-PARTIUPAC
pyrrolidine	58	69	|I-PARTIUPAC
-	69	70	|I-PARTIUPAC
3	70	71	|I-PARTIUPAC
-	71	72	|I-PARTIUPAC
carboxamides	72	84	|I-PARTIUPAC
were	85	89	|O
acylated	90	98	|O
on	99	101	|O
the	102	105	|O
primary	106	113	|O
amino	114	119	|O
group	120	125	|O
of	126	128	|O
the	129	132	|O
side	133	137	|O
chain	138	143	|O
by	144	146	|O
means	147	152	|O
of	153	155	|O
reactive	156	164	|O
acid	165	169	|O
derivatives	170	181	|O
(	182	183	|O
acid	183	187	|O
chlorides	188	197	|O
,	197	198	|O
activated	199	208	|O
esters	209	215	|O
,	215	216	|O
phthalic	217	225	|O
anhydrides	226	236	|O
,	236	237	|O
phthalimide	238	249	|O
,	249	250	|O
2	251	252	|B-IUPAC
-	252	253	|I-IUPAC
alkyl	253	258	|I-IUPAC
-	258	259	|I-IUPAC
4H	259	261	|I-IUPAC
-	261	262	|I-IUPAC
3,1	262	265	|I-IUPAC
-	265	266	|I-IUPAC
benzoxazin	266	276	|I-IUPAC
-	276	277	|I-IUPAC
4	277	278	|I-IUPAC
-	278	279	|I-IUPAC
ones	279	283	|I-IUPAC
)	283	284	|O
or	285	287	|O
they	288	292	|O
were	293	297	|O
alkylated	298	307	|O
by	308	310	|O
forming	311	318	|O
the	319	322	|O
Schiff	323	329	|O
bases	330	335	|O
and	336	339	|O
subsequent	340	350	|O
sodium	351	357	|O
borohydride	358	369	|O
reduction	370	379	|O
.	379	380	|O
Other	381	386	|O
tetramethyl	387	398	|B-IUPAC
-	398	399	|I-IUPAC
3	399	400	|I-IUPAC
-	400	401	|I-IUPAC
pyrrolinecarboxamide	401	421	|I-IUPAC
compounds	422	431	|B-MODIFIER
were	432	436	|O
synthesized	437	448	|O
by	449	451	|O
acylating	452	461	|O
the	462	465	|O
aminoalkyl	466	476	|B-IUPAC
compounds	477	486	|B-MODIFIER
with	487	491	|O
2,2,6,6	492	499	|B-IUPAC
-	499	500	|I-IUPAC
tetramethyl	500	511	|I-IUPAC
-	511	512	|I-IUPAC
3,5	512	515	|I-IUPAC
-	515	516	|I-IUPAC
dibromo	516	523	|I-IUPAC
-	523	524	|I-IUPAC
4	524	525	|I-IUPAC
-	525	526	|I-IUPAC
piperidinone	526	538	|I-IUPAC
in	539	541	|O
a	542	543	|O
reaction	544	552	|O
involving	553	562	|O
Favorskii	563	572	|O
rearrangement	573	586	|O
.	586	587	|O
Saturation	588	598	|O
of	599	601	|O
the	602	605	|O
double	606	612	|O
bond	613	617	|O
of	618	620	|O
some	621	625	|O
pyrroline	626	635	|B-IUPAC
derivatives	636	647	|B-MODIFIER
furnished	648	657	|O
the	658	661	|O
pyrrolidinecarboxamides	662	685	|O
.	685	686	|O
The	687	690	|O
new	691	694	|O
compounds	695	704	|O
of	705	707	|O
each	708	712	|O
type	713	717	|O
were	718	722	|O
active	723	729	|O
against	730	737	|O
aconitine	738	747	|O
-	747	748	|O
induced	748	755	|O
arrhythmia	756	766	|O
and	767	770	|O
several	771	778	|O
of	779	781	|O
them	782	786	|O
had	787	790	|O
higher	791	797	|O
activity	798	806	|O
and	807	810	|O
better	811	817	|O
chemotherapeutic	818	834	|O
index	835	840	|O
than	841	845	|O
quinidine	846	855	|O
.	855	856	|O
A	857	858	|O
few	859	862	|O
selected	863	871	|O
examples	872	880	|O
from	881	885	|O
each	886	890	|O
type	891	895	|O
of	896	898	|O
the	899	902	|O
active	903	909	|O
new	910	913	|O
compounds	914	923	|O
showed	924	930	|O
strong	931	937	|O
activity	938	946	|O
against	947	954	|O
ouabain	955	962	|O
-	962	963	|O
induced	963	970	|O
arrhythmia	971	981	|O
;	981	982	|O
for	983	986	|O
comparison	987	997	|O
known	998	1003	|O
drugs	1004	1009	|O
such	1010	1014	|O
as	1015	1017	|O
lidocaine	1018	1027	|O
,	1027	1028	|O
mexiletine	1029	1039	|O
,	1039	1040	|O
and	1041	1044	|O
tocainide	1045	1054	|O
were	1055	1059	|O
selected	1060	1068	|O
.	1068	1069	|O
The	1070	1073	|O
most	1074	1078	|O
potent	1079	1085	|O
compounds	1086	1095	|O
were	1096	1100	|O
oxidized	1101	1109	|O
to	1110	1112	|O
the	1113	1116	|O
paramagnetic	1117	1129	|O
nitroxides	1130	1140	|O
and	1141	1144	|O
the	1145	1148	|O
latter	1149	1155	|O
were	1156	1160	|O
reduced	1161	1168	|O
to	1169	1171	|O
the	1172	1175	|O
N	1176	1177	|B-IUPAC
-	1177	1178	|I-IUPAC
hydroxy	1178	1185	|I-IUPAC
derivatives	1186	1197	|B-MODIFIER
;	1197	1198	|O
these	1199	1204	|O
products	1205	1213	|O
had	1214	1217	|O
no	1218	1220	|O
or	1221	1223	|O
only	1224	1228	|O
decreased	1229	1238	|O
antiarrhythmic	1239	1253	|O
effect	1254	1260	|O
.	1260	1261	|O

### abstracts750.txt
New	0	3	|O
1H	4	6	|B-IUPAC
,	6	7	|I-IUPAC
3H	7	9	|I-IUPAC
-	9	10	|I-IUPAC
pyrimido	10	18	|I-IUPAC
[	18	19	|I-IUPAC
2,1	19	22	|I-IUPAC
-	22	23	|I-IUPAC
f	23	24	|I-IUPAC
]	24	25	|I-IUPAC
purine	25	31	|I-IUPAC
-	31	32	|I-IUPAC
2,4	32	35	|I-IUPAC
-	35	36	|I-IUPAC
dione	36	41	|I-IUPAC
derivatives	42	53	|B-MODIFIER
of	54	56	|O
arylpiperazine	57	71	|O
(	72	73	|O
11-22	73	78	|O
)	78	79	|O
were	80	84	|O
prepared	85	93	|O
and	94	97	|O
evaluated	98	107	|O
in	108	110	|O
vitro	111	116	|O
for	117	120	|O
their	121	126	|O
affinity	127	135	|O
for	136	139	|O
5	140	141	|O
-	141	142	|O
HT	142	144	|O
(	144	145	|O
1A	145	147	|O
)	147	148	|O
,	148	149	|O
5	150	151	|O
-	151	152	|O
HT	152	154	|O
(	154	155	|O
2A	155	157	|O
)	157	158	|O
,	158	159	|O
alpha	160	165	|O
(	165	166	|O
1	166	167	|O
)	167	168	|O
,	168	169	|O
and	170	173	|O
D	174	175	|O
(	175	176	|O
2	176	177	|O
)	177	178	|O
receptors	179	188	|O
.	188	189	|O
The	190	193	|O
tested	194	200	|O
compounds	201	210	|O
showed	211	217	|O
high	218	222	|O
affinity	223	231	|O
for	232	235	|O
5	236	237	|O
-	237	238	|O
HT	238	240	|O
(	240	241	|O
1A	241	243	|O
)	243	244	|O
and	245	248	|O
alpha	249	254	|O
(	254	255	|O
1	255	256	|O
)	256	257	|O
receptors	258	267	|O
(	268	269	|O
K	269	270	|O
(	270	271	|O
i	271	272	|O
)	272	273	|O
=	274	275	|O
1.1-87	276	282	|O
and	283	286	|O
10-62	287	292	|O
nM	293	295	|O
,	295	296	|O
respectively	297	309	|O
)	309	310	|O
and	311	314	|O
moderate	315	323	|O
to	324	326	|O
low	327	330	|O
affinity	331	339	|O
for	340	343	|O
5	344	345	|O
-	345	346	|O
HT	346	348	|O
(	348	349	|O
2A	349	351	|O
)	351	352	|O
(	353	354	|O
K	354	355	|O
(	355	356	|O
i	356	357	|O
)	357	358	|O
=	359	360	|O
56-881	361	367	|O
nM	368	370	|O
)	370	371	|O
and	372	375	|O
D	376	377	|O
(	377	378	|O
2	378	379	|O
)	379	380	|O
receptors	381	390	|O
(	391	392	|O
K	392	393	|O
(	393	394	|O
i	394	395	|O
)	395	396	|O
=	397	398	|O
94-1245	399	406	|O
nM	407	409	|O
)	409	410	|O
.	410	411	|O
Compounds	412	421	|O
14	422	424	|O
,	424	425	|O
15	426	428	|O
,	428	429	|O
18	430	432	|O
,	432	433	|O
19	434	436	|O
,	436	437	|O
and	438	441	|O
21	442	444	|O
,	444	445	|O
mostly	446	452	|O
3'	453	455	|B-IUPAC
-	455	456	|I-IUPAC
chlorophenylpiperazine	456	478	|I-IUPAC
derivatives	479	490	|B-MODIFIER
,	490	491	|O
can	492	495	|O
be	496	498	|O
classified	499	509	|O
as	510	512	|O
mixed	513	518	|O
5	519	520	|O
-	520	521	|O
HT	521	523	|O
(	523	524	|O
1A	524	526	|O
)	526	527	|O
/	527	528	|O
5	528	529	|O
-	529	530	|O
HT	530	532	|O
(	532	533	|O
2A	533	535	|O
)	535	536	|O
/	536	537	|O
alpha	537	542	|O
(	542	543	|O
1	543	544	|O
)	544	545	|O
ligands	546	553	|O
.	553	554	|O
Compound	555	563	|O
13	564	566	|O
,	566	567	|O
which	568	573	|O
showed	574	580	|O
the	581	584	|O
highest	585	592	|O
5	593	594	|O
-	594	595	|O
HT	595	597	|O
(	597	598	|O
1A	598	600	|O
)	600	601	|O
receptor	602	610	|O
affinity	611	619	|O
(	620	621	|O
K	621	622	|O
(	622	623	|O
i	623	624	|O
)	624	625	|O
=	626	627	|O
1.1	628	631	|O
nM	632	634	|O
)	634	635	|O
,	635	636	|O
was	637	640	|O
50	641	643	|O
-	643	644	|O
fold	644	648	|O
selective	649	658	|O
in	659	661	|O
relation	662	670	|O
to	671	673	|O
alpha	674	679	|O
(	679	680	|O
1	680	681	|O
)	681	682	|O
adrenoceptors	683	696	|O
and	697	700	|O
at	701	703	|O
least	704	709	|O
250	710	713	|O
-	713	714	|O
fold	714	718	|O
over	719	723	|O
5	724	725	|O
-	725	726	|O
HT	726	728	|O
(	728	729	|O
2A	729	731	|O
)	731	732	|O
and	733	736	|O
D	737	738	|O
(	738	739	|O
2	739	740	|O
)	740	741	|O
sites	742	747	|O
.	747	748	|O
On	749	751	|O
the	752	755	|O
basis	756	761	|O
of	762	764	|O
in	765	767	|O
vivo	768	772	|O
functional	773	783	|O
tests	784	789	|O
,	789	790	|O
8	791	792	|B-IUPAC
-	792	793	|I-IUPAC
phenylpiperazinoethylamino	793	819	|I-IUPAC
(	820	821	|O
11	821	823	|O
)	823	824	|O
,	824	825	|O
8	826	827	|B-IUPAC
-	827	828	|I-IUPAC
(	828	829	|I-IUPAC
2'	829	831	|I-IUPAC
-	831	832	|I-IUPAC
methoxyphenylpiperazino	832	855	|I-IUPAC
)	855	856	|I-IUPAC
ethylamino	856	866	|I-IUPAC
(	867	868	|O
13	868	870	|O
)	870	871	|O
,	871	872	|O
and	873	876	|O
8	877	878	|B-IUPAC
-	878	879	|I-IUPAC
phenylpiperazinopropylamino	879	906	|I-IUPAC
(	907	908	|O
14	908	910	|O
)	910	911	|O
derivatives	912	923	|B-MODIFIER
of	924	926	|O
1,3	927	930	|B-IUPAC
-	930	931	|I-IUPAC
dimethyl	931	939	|I-IUPAC
-	939	940	|I-IUPAC
1H	940	942	|I-IUPAC
,	942	943	|I-IUPAC
3H	943	945	|I-IUPAC
-	945	946	|I-IUPAC
pyrimido	946	954	|I-IUPAC
[	954	955	|I-IUPAC
2,1	955	958	|I-IUPAC
-	958	959	|I-IUPAC
f	959	960	|I-IUPAC
]	960	961	|I-IUPAC
purine	961	967	|I-IUPAC
-	967	968	|I-IUPAC
2,4	968	971	|I-IUPAC
-	971	972	|I-IUPAC
dione	972	977	|I-IUPAC
were	978	982	|O
identified	983	993	|O
as	994	996	|O
potent	997	1003	|O
pre	1004	1007	|O
-	1007	1008	|O
and	1009	1012	|O
postsynaptic	1013	1025	|O
5	1026	1027	|O
-	1027	1028	|O
HT	1028	1030	|O
(	1030	1031	|O
1A	1031	1033	|O
)	1033	1034	|O
receptor	1035	1043	|O
antagonists	1044	1055	|O
.	1055	1056	|O
1,3	1057	1060	|B-IUPAC
-	1060	1061	|I-IUPAC
Dimethyl	1061	1069	|I-IUPAC
-	1069	1070	|I-IUPAC
7	1070	1071	|I-IUPAC
-	1071	1072	|I-IUPAC
bromo	1072	1077	|I-IUPAC
-	1077	1078	|I-IUPAC
8	1078	1079	|I-IUPAC
-	1079	1080	|I-IUPAC
(	1080	1081	|I-IUPAC
phenylpiperazinopropylamino	1081	1108	|I-IUPAC
)	1108	1109	|I-IUPAC
-	1109	1110	|I-IUPAC
1H	1110	1112	|I-IUPAC
,	1112	1113	|I-IUPAC
3H	1113	1115	|I-IUPAC
-	1115	1116	|I-IUPAC
pyrimido	1116	1124	|I-IUPAC
[	1124	1125	|I-IUPAC
2,1	1125	1128	|I-IUPAC
-	1128	1129	|I-IUPAC
f	1129	1130	|I-IUPAC
]	1130	1131	|I-IUPAC
purine	1131	1137	|I-IUPAC
-	1137	1138	|I-IUPAC
2,4	1138	1141	|I-IUPAC
-	1141	1142	|I-IUPAC
dione	1142	1147	|I-IUPAC
(	1148	1149	|O
20	1149	1151	|O
)	1151	1152	|O
behaved	1153	1160	|O
like	1161	1165	|O
an	1166	1168	|O
agonist	1169	1176	|O
of	1177	1179	|O
presynaptic	1180	1191	|O
and	1192	1195	|O
as	1196	1198	|O
a	1199	1200	|O
partial	1201	1208	|O
agonist	1209	1216	|O
of	1217	1219	|O
postsynaptic	1220	1232	|O
5	1233	1234	|O
-	1234	1235	|O
HT	1235	1237	|O
(	1237	1238	|O
1A	1238	1240	|O
)	1240	1241	|O
receptors	1242	1251	|O
and	1252	1255	|O
resembled	1256	1265	|O
ipsapirone	1266	1276	|O
in	1277	1279	|O
terms	1280	1285	|O
of	1286	1288	|O
functional	1289	1299	|O
intrinsic	1300	1309	|O
activity	1310	1318	|O
.	1318	1319	|O
It	1320	1322	|O
revealed	1323	1331	|O
marked	1332	1338	|O
anxiolytic	1339	1349	|O
-	1349	1350	|O
like	1350	1354	|O
activity	1355	1363	|O
in	1364	1366	|O
the	1367	1370	|O
Vogel	1371	1376	|O
test	1377	1381	|O
in	1382	1384	|O
rats	1385	1389	|O
,	1389	1390	|O
comparable	1391	1401	|O
to	1402	1404	|O
that	1405	1409	|O
of	1410	1412	|O
the	1413	1416	|O
reference	1417	1426	|O
drug	1427	1431	|O
diazepam	1432	1440	|O
,	1440	1441	|O
and	1442	1445	|O
exhibited	1446	1455	|O
antidepressant	1456	1470	|O
-	1470	1471	|O
like	1471	1475	|O
activity	1476	1484	|O
in	1485	1487	|O
the	1488	1491	|O
Porsolt	1492	1499	|O
test	1500	1504	|O
in	1505	1507	|O
rats	1508	1512	|O
.	1512	1513	|O
The	1514	1517	|O
sedative	1518	1526	|O
effect	1527	1533	|O
of	1534	1536	|O
20	1537	1539	|O
,	1539	1540	|O
evaluated	1541	1550	|O
in	1551	1553	|O
the	1554	1557	|O
open	1558	1562	|O
field	1563	1568	|O
test	1569	1573	|O
in	1574	1576	|O
rats	1577	1581	|O
,	1581	1582	|O
appeared	1583	1591	|O
at	1592	1594	|O
doses	1595	1600	|O
twice	1601	1606	|O
as	1607	1609	|O
high	1610	1614	|O
as	1615	1617	|O
those	1618	1623	|O
inducing	1624	1632	|O
a	1633	1634	|O
minimal	1635	1642	|O
anxiolytic	1643	1653	|O
-	1653	1654	|O
like	1654	1658	|O
effect	1659	1665	|O
and	1666	1669	|O
was	1670	1673	|O
similar	1674	1681	|O
to	1682	1684	|O
the	1685	1688	|O
effects	1689	1696	|O
of	1697	1699	|O
diazepam	1700	1708	|O
.	1708	1709	|O

### abstracts2749.txt
N	0	1	|B-IUPAC
-	1	2	|I-IUPAC
Methyl	2	8	|I-IUPAC
-	8	9	|I-IUPAC
N	9	10	|I-IUPAC
-	10	11	|I-IUPAC
phenethylphenylacetamide	11	35	|I-IUPAC
has	36	39	|O
been	40	44	|O
reported	45	53	|O
to	54	56	|O
be	57	59	|O
a	60	61	|O
key	62	65	|O
binding	66	73	|O
domain	74	80	|O
to	81	83	|O
LTB4	84	88	|O
receptors	89	98	|O
.	98	99	|O
Here	100	104	|O
we	105	107	|O
describe	108	116	|O
the	117	120	|O
synthesis	121	130	|O
and	131	134	|O
structure	135	144	|O
-	144	145	|O
activity	145	153	|O
relationship	154	166	|O
(	167	168	|O
SAR	168	171	|O
)	171	172	|O
studies	173	180	|O
of	181	183	|O
two	184	187	|O
new	188	191	|O
series	192	198	|O
of	199	201	|O
LTB4	202	206	|O
receptor	207	215	|O
antagonists	216	227	|O
in	228	230	|O
which	231	236	|O
the	237	240	|O
phenyl	241	247	|O
ring	248	252	|O
of	253	255	|O
this	256	260	|O
receptor	261	269	|O
binding	270	277	|O
domain	278	284	|O
is	285	287	|O
replaced	288	296	|O
with	297	301	|O
indole	302	308	|O
and	309	312	|O
naphthalene	313	324	|O
,	324	325	|O
respectively	326	338	|O
.	338	339	|O
Results	340	347	|O
of	348	350	|O
these	351	356	|O
studies	357	364	|O
indicate	365	373	|O
that	374	378	|O
,	378	379	|O
in	380	382	|O
addition	383	391	|O
to	392	394	|O
the	395	398	|O
2	399	400	|B-IUPAC
-	400	401	|I-IUPAC
[	401	402	|I-IUPAC
methyl	402	408	|I-IUPAC
(	408	409	|I-IUPAC
2	409	410	|I-IUPAC
-	410	411	|I-IUPAC
phenethyl	411	420	|I-IUPAC
)	420	421	|I-IUPAC
amino	421	426	|I-IUPAC
]	426	427	|I-IUPAC
-	427	428	|I-IUPAC
2	428	429	|I-IUPAC
-	429	430	|I-IUPAC
oxoethyl	430	438	|I-IUPAC
moiety	439	445	|B-MODIFIER
,	445	446	|O
the	447	450	|O
presence	451	459	|O
of	460	462	|O
an	463	465	|O
acid	466	470	|O
group	471	476	|O
and	477	480	|O
a	481	482	|O
lipophilic	483	493	|O
side	494	498	|O
chain	499	504	|O
,	504	505	|O
as	506	508	|O
well	509	513	|O
as	514	516	|O
the	517	520	|O
spatial	521	528	|O
relationship	529	541	|O
of	542	544	|O
these	545	550	|O
three	551	556	|O
functions	557	566	|O
,	566	567	|O
is	568	570	|O
crucial	571	578	|O
for	579	582	|O
high	583	587	|O
binding	588	595	|O
affinity	596	604	|O
with	605	609	|O
LTB4	610	614	|O
receptors	615	624	|O
.	624	625	|O
Our	626	629	|O
SAR	630	633	|O
studies	634	641	|O
also	642	646	|O
reveal	647	653	|O
that	654	658	|O
an	659	661	|O
arenecarboxylic	662	677	|O
acid	678	682	|O
,	682	683	|O
or	684	686	|O
an	687	689	|O
enoic	690	695	|O
acid	696	700	|O
in	701	703	|O
which	704	709	|O
the	710	713	|O
carboxyl	714	722	|B-IUPAC
group	723	728	|B-MODIFIER
is	729	731	|O
conjugated	732	742	|O
with	743	747	|O
the	748	751	|O
central	752	759	|O
ring	760	764	|O
,	764	765	|O
is	766	768	|O
the	769	772	|O
preferred	773	782	|O
polar	783	788	|O
group	789	794	|O
.	794	795	|O
The	796	799	|O
lipophilic	800	810	|O
side	811	815	|O
chain	816	821	|O
of	822	824	|O
the	825	828	|O
naphthyl	829	837	|B-IUPAC
series	838	844	|B-MODIFIER
was	845	848	|O
found	849	854	|O
to	855	857	|O
tolerate	858	866	|O
minor	867	872	|O
variations	873	883	|O
,	883	884	|O
ranging	885	892	|O
from	893	897	|O
a	898	899	|O
phenylmethoxy	900	913	|B-IUPAC
group	914	919	|B-MODIFIER
to	920	922	|O
phenyl	923	929	|B-IUPAC
and	930	933	|O
alkyloxy	934	942	|B-IUPAC
groups	943	949	|B-MODIFIER
.	949	950	|O
The	951	954	|O
most	955	959	|O
active	960	966	|O
compounds	967	976	|O
are	977	980	|O
2	981	982	|B-IUPAC
-	982	983	|I-IUPAC
ethyl	983	988	|I-IUPAC
-	988	989	|I-IUPAC
3	989	990	|I-IUPAC
-	990	991	|I-IUPAC
[	991	992	|I-IUPAC
1	992	993	|I-IUPAC
-	993	994	|I-IUPAC
[	994	995	|I-IUPAC
2	995	996	|I-IUPAC
-	996	997	|I-IUPAC
[	997	998	|I-IUPAC
methyl	998	1004	|I-IUPAC
(	1004	1005	|I-IUPAC
2	1005	1006	|I-IUPAC
-	1006	1007	|I-IUPAC
phenethyl	1007	1016	|I-IUPAC
)	1016	1017	|I-IUPAC
amino	1018	1023	|I-IUPAC
]	1023	1024	|I-IUPAC
-	1024	1025	|I-IUPAC
2	1025	1026	|I-IUPAC
-	1026	1027	|I-IUPAC
oxoethyl	1027	1035	|I-IUPAC
]	1035	1036	|I-IUPAC
-	1036	1037	|I-IUPAC
5	1037	1038	|I-IUPAC
-	1038	1039	|I-IUPAC
(	1039	1040	|I-IUPAC
phenylmethoxy	1040	1053	|I-IUPAC
)	1053	1054	|I-IUPAC
indol	1054	1059	|I-IUPAC
-	1059	1060	|I-IUPAC
3	1060	1061	|I-IUPAC
-	1061	1062	|I-IUPAC
yl	1062	1064	|I-IUPAC
]	1064	1065	|I-IUPAC
propenoic+	1065	1075	|I-IUPAC
+	1076	1077	|I-IUPAC
+	1077	1078	|I-IUPAC
acid	1079	1083	|I-IUPAC
(	1084	1085	|O
4g	1085	1087	|O
)	1087	1088	|O
of	1089	1091	|O
the	1092	1095	|O
indolyl	1096	1103	|O
series	1104	1110	|O
and	1111	1114	|O
4	1115	1116	|B-IUPAC
-	1116	1117	|I-IUPAC
[	1117	1118	|I-IUPAC
2	1118	1119	|I-IUPAC
-	1119	1120	|I-IUPAC
[	1120	1121	|I-IUPAC
methyl	1121	1127	|I-IUPAC
(	1127	1128	|I-IUPAC
2	1128	1129	|I-IUPAC
-	1129	1130	|I-IUPAC
phenethyl	1130	1139	|I-IUPAC
)	1139	1140	|I-IUPAC
amino	1140	1145	|I-IUPAC
]	1145	1146	|I-IUPAC
-	1146	1147	|I-IUPAC
2	1147	1148	|I-IUPAC
-	1148	1149	|I-IUPAC
oxoethyl	1149	1157	|I-IUPAC
]	1157	1158	|I-IUPAC
-	1158	1159	|I-IUPAC
8	1159	1160	|I-IUPAC
-	1160	1161	|I-IUPAC
(	1161	1162	|I-IUPAC
phenylmethoxy	1162	1175	|I-IUPAC
)	1176	1177	|I-IUPAC
-	1177	1178	|I-IUPAC
2	1178	1179	|I-IUPAC
-	1179	1180	|I-IUPAC
naphthalenecarboxylic	1180	1201	|I-IUPAC
acid	1202	1206	|I-IUPAC
(	1207	1208	|O
2a	1208	1210	|O
)	1210	1211	|O
or	1212	1214	|O
the	1215	1218	|O
naphthyl	1219	1227	|B-IUPAC
series	1228	1234	|B-MODIFIER
,	1234	1235	|O
with	1236	1240	|O
IC50	1241	1245	|O
of	1246	1248	|O
8	1249	1250	|O
and	1251	1254	|O
4.7	1255	1258	|O
nM	1259	1261	|O
respectively	1262	1274	|O
,	1274	1275	|O
in	1276	1278	|O
the	1279	1282	|O
receptor	1283	1291	|O
binding	1292	1299	|O
assay	1300	1305	|O
using	1306	1311	|O
intact	1312	1318	|O
human	1319	1324	|O
neutrophils	1325	1336	|O
.	1336	1337	|O

### abstracts4226.txt
5	0	1	|B-IUPAC
-	1	2	|I-IUPAC
Deaza	2	7	|I-IUPAC
-	7	8	|I-IUPAC
10	8	10	|I-IUPAC
-	10	11	|I-IUPAC
propargylfolic	11	25	|I-IUPAC
acid	26	30	|I-IUPAC
(	31	32	|O
4	32	33	|O
)	33	34	|O
,	34	35	|O
an	36	38	|O
analogue	39	47	|O
of	48	50	|O
the	51	54	|O
thymidylate	55	66	|O
synthase	67	75	|O
(	76	77	|O
TS	77	79	|O
)	79	80	|O
inhibitor	81	90	|O
10	91	93	|B-IUPAC
-	93	94	|I-IUPAC
propargyl	94	103	|I-IUPAC
-	103	104	|I-IUPAC
5,8	104	107	|I-IUPAC
-	107	108	|I-IUPAC
dideazafolic	108	120	|I-IUPAC
acid	121	125	|I-IUPAC
(	126	127	|O
PDDF	127	131	|O
,	131	132	|O
1	133	134	|O
)	134	135	|O
,	135	136	|O
was	137	140	|O
prepared	141	149	|O
via	150	153	|O
alkylation	154	164	|O
of	165	167	|O
diethyl	168	175	|B-IUPAC
N	176	177	|I-IUPAC
-	177	178	|I-IUPAC
[	178	179	|I-IUPAC
4	179	180	|I-IUPAC
-	180	181	|I-IUPAC
(	181	182	|I-IUPAC
propargylamino	182	196	|I-IUPAC
)	196	197	|I-IUPAC
benzoyl	197	204	|I-IUPAC
]	204	205	|I-IUPAC
-	205	206	|I-IUPAC
L	206	207	|I-IUPAC
-	207	208	|I-IUPAC
glutamate	208	217	|I-IUPAC
(	218	219	|O
7	219	220	|O
)	220	221	|O
by	222	224	|O
2	225	226	|B-IUPAC
-	226	227	|I-IUPAC
amino	227	232	|I-IUPAC
-	232	233	|I-IUPAC
6	233	234	|I-IUPAC
-	234	235	|I-IUPAC
(	235	236	|I-IUPAC
bromomethyl	236	247	|I-IUPAC
)	247	248	|I-IUPAC
-	248	249	|I-IUPAC
4	249	250	|I-IUPAC
(	250	251	|I-IUPAC
3H	251	253	|I-IUPAC
)	253	254	|I-IUPAC
-	254	255	|I-IUPAC
pyrido	255	261	|I-IUPAC
[	261	262	|I-IUPAC
2,3	262	265	|I-IUPAC
-	265	266	|I-IUPAC
d	266	267	|I-IUPAC
]	267	268	|I-IUPAC
pyrimidinone	268	280	|I-IUPAC
(	281	282	|O
15	282	284	|O
)	284	285	|O
.	285	286	|O
Bromomethyl	287	298	|O
intermediate	299	311	|O
15	312	314	|O
was	315	318	|O
prepared	319	327	|O
from	328	332	|O
the	333	336	|O
corresponding	337	350	|O
hydroxymethyl	351	364	|B-IUPAC
precursor	365	374	|B-MODIFIER
14	375	377	|O
by	378	380	|O
treatment	381	390	|O
with	391	395	|O
48%	396	399	|O
HBr	400	403	|O
.	403	404	|O
Hydroxymethyl	405	418	|O
compound	419	427	|O
14	428	430	|O
was	431	434	|O
obtained	435	443	|O
by	444	446	|O
deamination	447	458	|O
of	459	461	|O
reported	462	470	|O
2,4	471	474	|B-IUPAC
-	474	475	|I-IUPAC
diaminopyrido	475	488	|I-IUPAC
[	488	489	|I-IUPAC
2,3	489	492	|I-IUPAC
-	492	493	|I-IUPAC
d	493	494	|I-IUPAC
]	494	495	|I-IUPAC
pyrimidine	495	505	|I-IUPAC
-	505	506	|I-IUPAC
6	506	507	|I-IUPAC
-	507	508	|I-IUPAC
methanol	508	516	|I-IUPAC
(	517	518	|O
12a	518	521	|O
)	521	522	|O
in	523	525	|O
refluxing	526	535	|O
1	536	537	|O
N	538	539	|O
NaOH	540	544	|O
.	544	545	|O
Both	546	550	|O
12a	551	554	|O
and	555	558	|O
its	559	562	|O
5	563	564	|B-IUPAC
-	564	565	|I-IUPAC
methyl	565	571	|I-IUPAC
-	571	572	|O
substituted	572	583	|B-MODIFIER
analogue	584	592	|B-MODIFIER
12b	593	596	|O
were	597	601	|O
converted	602	611	|O
to	612	614	|O
versatile	615	624	|O
6	625	626	|B-IUPAC
-	626	627	|I-IUPAC
bromomethyl	627	638	|I-IUPAC
intermediates	639	652	|B-MODIFIER
13a	653	656	|O
and	657	660	|O
13b	661	664	|O
from	665	669	|O
which	670	675	|O
important	676	685	|O
antifolates	686	697	|O
may	698	701	|O
be	702	704	|O
readily	705	712	|O
derived	713	720	|O
.	720	721	|O
Alkylation	722	732	|O
of	733	735	|O
7	736	737	|O
by	738	740	|O
13a	741	744	|O
,	744	745	|O
b	745	746	|O
led	747	750	|O
to	751	753	|O
10	754	756	|B-IUPAC
-	756	757	|I-IUPAC
propargyl	757	766	|I-IUPAC
-	766	767	|I-IUPAC
5	767	768	|I-IUPAC
-	768	769	|I-IUPAC
deazaaminopterin	769	785	|I-IUPAC
(	786	787	|O
5	787	788	|O
)	788	789	|O
and	790	793	|O
5	794	795	|B-IUPAC
-	795	796	|I-IUPAC
methyl	796	802	|I-IUPAC
-	802	803	|I-IUPAC
10	803	805	|I-IUPAC
-	805	806	|I-IUPAC
propargyl	806	815	|I-IUPAC
-	815	816	|I-IUPAC
5	816	817	|I-IUPAC
-	817	818	|I-IUPAC
deazaaminopterin	818	834	|I-IUPAC
(	835	836	|O
6	836	837	|O
)	837	838	|O
.	838	839	|O
As	840	842	|O
an	843	845	|O
inhibitor	846	855	|O
of	856	858	|O
TS	859	861	|O
from	862	866	|O
H35F	867	871	|O
/	871	872	|O
F	872	873	|O
cells	874	879	|O
,	879	880	|O
4	881	882	|O
gave	883	887	|O
an	888	890	|O
IC50	891	895	|O
value	896	901	|O
showing	902	909	|O
it	910	912	|O
to	913	915	|O
be	916	918	|O
approximately	919	932	|O
6	933	934	|O
-	934	935	|O
fold	935	939	|O
less	940	944	|O
inhibitory	945	955	|O
than	956	960	|O
PDDF	961	965	|O
(	966	967	|O
90	967	969	|O
nM	970	972	|O
for	973	976	|O
4	977	978	|O
vs	979	981	|O
14	982	984	|O
nM	985	987	|O
for	988	991	|O
PDDF	992	996	|O
)	996	997	|O
.	997	998	|O
In	999	1001	|O
in	1002	1004	|O
vitro	1005	1010	|O
studies	1011	1018	|O
,	1018	1019	|O
IC50	1020	1024	|O
(	1025	1026	|O
microM	1026	1032	|O
)	1032	1033	|O
values	1034	1040	|O
obtained	1041	1049	|O
for	1050	1053	|O
4	1054	1055	|O
vs	1056	1058	|O
L1210	1059	1064	|O
and	1065	1068	|O
S180	1069	1073	|O
of	1074	1076	|O
1.50	1077	1081	|O
and	1082	1085	|O
2.35	1086	1090	|O
,	1090	1091	|O
respectively	1092	1104	|O
,	1104	1105	|O
were	1106	1110	|O
similar	1111	1118	|O
to	1119	1121	|O
those	1122	1127	|O
obtained	1128	1136	|O
for	1137	1140	|O
PDDF	1141	1145	|O
(	1146	1147	|O
2.61	1147	1151	|O
and	1152	1155	|O
1.97	1156	1160	|O
)	1160	1161	|O
.	1161	1162	|O
Against	1163	1170	|O
HL60	1171	1175	|O
cells	1176	1181	|O
,	1181	1182	|O
4	1183	1184	|O
was	1185	1188	|O
about	1189	1194	|O
7	1195	1196	|O
-	1196	1197	|O
fold	1197	1201	|O
more	1202	1206	|O
cytotoxic	1207	1216	|O
than	1217	1221	|O
PDDF	1222	1226	|O
(	1227	1228	|O
IC50	1228	1232	|O
values	1233	1239	|O
0.72	1240	1244	|O
and	1245	1248	|O
5.29	1249	1253	|O
microM	1254	1260	|O
)	1260	1261	|O
.	1261	1262	|O
Inclusion	1263	1272	|O
of	1273	1275	|O
thymidine	1276	1285	|O
did	1286	1289	|O
not	1290	1293	|O
establish	1294	1303	|O
TS	1304	1306	|O
as	1307	1309	|O
the	1310	1313	|O
site	1314	1318	|O
of	1319	1321	|O
cytotoxic	1322	1331	|O
action	1332	1338	|O
for	1339	1342	|O
either	1343	1349	|O
4	1350	1351	|O
or	1352	1354	|O
PDDF	1355	1359	|O
in	1360	1362	|O
the	1363	1366	|O
cell	1367	1371	|O
lines	1372	1377	|O
used	1378	1382	|O
.	1382	1383	|O
In	1384	1386	|O
in	1387	1389	|O
vivo	1390	1394	|O
tests	1395	1400	|O
against	1401	1408	|O
L1210	1409	1414	|O
in	1415	1417	|O
mice	1418	1422	|O
,	1422	1423	|O
4	1424	1425	|O
failed	1426	1432	|O
to	1433	1435	|O
show	1436	1440	|O
therapeutic	1441	1452	|O
effect	1453	1459	|O
.	1459	1460	|O
The	1461	1464	|O
2,4	1465	1468	|B-IUPAC
-	1468	1469	|I-IUPAC
diamino	1469	1476	|I-IUPAC
compounds	1477	1486	|B-MODIFIER
5	1487	1488	|O
and	1489	1492	|O
6	1493	1494	|O
were	1495	1499	|O
as	1500	1502	|O
potent	1503	1509	|O
inhibitors	1510	1520	|O
of	1521	1523	|O
DHFR	1524	1528	|O
from	1529	1533	|O
L1210	1534	1539	|O
cells	1540	1545	|O
as	1546	1548	|O
MTX	1549	1552	|O
and	1553	1556	|O
7	1557	1558	|O
-	1558	1559	|O
and	1560	1563	|O
35	1564	1566	|O
-	1566	1567	|O
fold	1567	1571	|O
,	1571	1572	|O
respectively	1573	1585	|O
,	1585	1586	|O
more	1587	1591	|O
inhibitory	1592	1602	|O
than	1603	1607	|O
MTX	1608	1611	|O
toward	1612	1618	|O
L1210	1619	1624	|O
cell	1625	1629	|O
growth	1630	1636	|O
.	1636	1637	|O
In	1638	1640	|O
mediated	1641	1649	|O
influx	1650	1656	|O
into	1657	1661	|O
L1210	1662	1667	|O
cells	1668	1673	|O
,	1673	1674	|O
5	1675	1676	|O
and	1677	1680	|O
6	1681	1682	|O
were	1683	1687	|O
transported	1688	1699	|O
2.7	1700	1703	|O
-	1703	1704	|O
and	1705	1708	|O
8.5	1709	1712	|O
-	1712	1713	|O
fold	1713	1717	|O
,	1717	1718	|O
respectively	1719	1731	|O
,	1731	1732	|O
more	1733	1737	|O
readily	1738	1745	|O
than	1746	1750	|O
MTX	1751	1754	|O
.	1754	1755	|O
Against	1756	1763	|O
the	1764	1767	|O
EO771	1768	1773	|O
mammary	1774	1781	|O
adenocarcinoma	1782	1796	|O
in	1797	1799	|O
mice	1800	1804	|O
,	1804	1805	|O
6	1806	1807	|O
produced	1808	1816	|O
greater	1817	1824	|O
antitumor	1825	1834	|O
effect	1835	1841	|O
than	1842	1846	|O
MTX	1847	1850	|O
.	1850	1851	|O
A	1852	1853	|O
dose	1854	1858	|O
of	1859	1861	|O
36	1862	1864	|O
mg	1865	1867	|O
/	1867	1868	|O
kg	1868	1870	|O
per	1871	1874	|O
day	1875	1878	|O
for	1879	1882	|O
5	1883	1884	|O
days	1885	1889	|O
caused	1890	1896	|O
no	1897	1899	|O
toxic	1900	1905	|O
deaths	1906	1912	|O
while	1913	1918	|O
the	1919	1922	|O
average	1923	1930	|O
tumor	1931	1936	|O
volume	1937	1943	|O
among	1944	1949	|O
10	1950	1952	|O
mice	1953	1957	|O
was	1958	1961	|O
reduced	1962	1969	|O
to	1970	1972	|O
8-9%	1973	1977	|O
of	1978	1980	|O
that	1981	1985	|O
of	1986	1988	|O
the	1989	1992	|O
control	1993	2000	|O
,	2000	2001	|O
and	2002	2005	|O
20%	2006	2009	|O
of	2010	2012	|O
the	2013	2016	|O
test	2017	2021	|O
animals	2022	2029	|O
were	2030	2034	|O
rendered	2035	2043	|O
tumor	2044	2049	|O
free	2050	2054	|O
.	2054	2055	|O

### abstracts1858.txt
1	0	1	|B-IUPAC
-	1	2	|I-IUPAC
[	2	3	|I-IUPAC
(	3	4	|I-IUPAC
6	4	5	|I-IUPAC
-	5	6	|I-IUPAC
Chloro	6	12	|I-IUPAC
-	12	13	|I-IUPAC
3	13	14	|I-IUPAC
-	14	15	|I-IUPAC
pyridinyl	15	24	|I-IUPAC
)	24	25	|I-IUPAC
methyl	25	31	|I-IUPAC
]	31	32	|I-IUPAC
-	32	33	|I-IUPAC
2	33	34	|I-IUPAC
-	34	35	|I-IUPAC
imidazolidine	35	48	|I-IUPAC
(	49	50	|O
1	50	51	|O
)	51	52	|O
,	52	53	|O
the	54	57	|O
N	58	59	|B-IUPAC
-	59	60	|I-IUPAC
desnitro	60	68	|I-IUPAC
metabolite	69	79	|B-MODIFIER
of	80	82	|O
the	83	86	|O
major	87	92	|O
insecticide	93	104	|O
imidacloprid	105	117	|O
,	117	118	|O
is	119	121	|O
known	122	127	|O
to	128	130	|O
have	131	135	|O
similar	136	143	|O
potency	144	151	|O
to	152	154	|O
that	155	159	|O
of	160	162	|O
(	163	164	|B-IUPAC
-	164	165	|I-IUPAC
)	165	166	|I-IUPAC
-	166	167	|I-IUPAC
nicotine	167	175	|I-IUPAC
as	176	178	|O
an	179	181	|O
inhibitor	182	191	|O
of	192	194	|O
[	195	196	|B-IUPAC
3H	196	198	|I-IUPAC
]	198	199	|I-IUPAC
(	199	200	|I-IUPAC
-	200	201	|I-IUPAC
)	201	202	|I-IUPAC
-	202	203	|I-IUPAC
nicotine	203	211	|I-IUPAC
binding	212	219	|O
at	220	222	|O
the	223	226	|O
rat	227	230	|O
recombinant	231	242	|O
alpha4beta2	243	254	|O
neuronal	255	263	|O
nicotinic	264	273	|O
acetylcholine	274	287	|O
receptor	288	296	|O
(	297	298	|O
nAChR	298	303	|O
)	303	304	|O
;	304	305	|O
IC50	306	310	|O
values	311	317	|O
in	318	320	|O
the	321	324	|O
present	325	332	|O
study	333	338	|O
are	339	342	|O
3.8	343	346	|O
nM	347	349	|O
for	350	353	|O
(	354	355	|B-IUPAC
-	355	356	|I-IUPAC
)	356	357	|I-IUPAC
-	357	358	|I-IUPAC
nicotine	358	366	|I-IUPAC
,	366	367	|O
6.0	368	371	|O
nM	372	374	|O
for	375	378	|O
1	379	380	|O
,	380	381	|O
and	382	385	|O
155	386	389	|O
nM	390	392	|O
for	393	396	|O
imidacloprid	397	409	|O
.	409	410	|O
Synthesis	411	420	|O
of	421	423	|O
new	424	427	|O
analogues	428	437	|O
of	438	440	|O
1	441	442	|O
,	442	443	|O
modified	444	452	|O
only	453	457	|O
in	458	460	|O
the	461	464	|O
heterocyclic	465	477	|O
moiety	478	484	|O
(	485	486	|O
five	486	490	|O
-	490	491	|O
,	491	492	|O
six	493	496	|O
-	496	497	|O
,	497	498	|O
or	499	501	|O
seven	502	507	|O
-	507	508	|O
membered	508	516	|O
rings	517	522	|O
with	523	527	|O
NH	528	530	|O
,	530	531	|O
S	532	533	|O
,	533	534	|O
O	535	536	|O
,	536	537	|O
and	538	541	|O
CH2	542	545	|O
substituents	546	558	|O
)	558	559	|O
,	559	560	|O
gave	561	565	|O
compounds	566	575	|O
varying	576	583	|O
from	584	588	|O
4	589	590	|O
-	590	591	|O
fold	591	595	|O
higher	596	602	|O
potency	603	610	|O
(	611	612	|B-IUPAC
2	612	613	|I-IUPAC
-	613	614	|I-IUPAC
iminothiazole	614	627	|I-IUPAC
analogue	628	636	|O
10	637	639	|O
)	639	640	|O
to	641	643	|O
&	644	645	|O
gt	645	647	|O
;	647	648	|O
6000	648	652	|O
-	652	653	|O
fold	653	657	|O
less	658	662	|O
active	663	669	|O
than	670	674	|O
(	675	676	|B-IUPAC
-	676	677	|I-IUPAC
)	677	678	|I-IUPAC
-	678	679	|I-IUPAC
nicotine	679	687	|I-IUPAC
.	687	688	|O
Other	689	694	|O
potent	695	701	|O
N	702	703	|B-IUPAC
-	703	704	|I-IUPAC
[	704	705	|I-IUPAC
(	705	706	|I-IUPAC
6	706	707	|I-IUPAC
-	707	708	|I-IUPAC
chloro	708	714	|I-IUPAC
-	714	715	|I-IUPAC
3	715	716	|I-IUPAC
-	716	717	|I-IUPAC
pyridinyl	717	726	|I-IUPAC
)	726	727	|I-IUPAC
methyl	727	733	|I-IUPAC
]	733	734	|I-IUPAC
compounds	735	744	|B-MODIFIER
are	745	748	|O
those	749	754	|O
in	755	757	|O
which	758	763	|O
the	764	767	|O
heterocyclic	768	780	|O
imine	781	786	|O
is	787	789	|O
replaced	790	798	|O
with	799	803	|O
pyrrolidine	804	815	|O
(	816	817	|O
19	817	819	|O
)	819	820	|O
(	821	822	|O
IC50	822	826	|O
9	827	828	|O
nM	829	831	|O
)	831	832	|O
or	833	835	|O
trimethylammonium	836	853	|O
(	854	855	|O
22	855	857	|O
)	857	858	|O
(	859	860	|O
IC50	860	864	|O
18	865	867	|O
nM	868	870	|O
)	870	871	|O
.	871	872	|O
A	873	874	|O
novel	875	880	|O
conversion	881	891	|O
of	892	894	|O
(	895	896	|B-IUPAC
-	896	897	|I-IUPAC
)	897	898	|I-IUPAC
-	898	899	|I-IUPAC
nicotine	899	907	|I-IUPAC
to	908	910	|O
its	911	914	|O
6	915	916	|B-IUPAC
-	916	917	|I-IUPAC
chloro	917	923	|I-IUPAC
analogue	924	932	|B-MODIFIER
increased	933	942	|O
the	943	946	|O
potency	947	954	|O
2	955	956	|O
-	956	957	|O
fold	957	961	|O
.	961	962	|O
These	963	968	|O
6	969	970	|B-IUPAC
-	970	971	|I-IUPAC
chloro	971	977	|I-IUPAC
-	977	978	|I-IUPAC
3	978	979	|I-IUPAC
-	979	980	|I-IUPAC
pyridinyl	980	989	|I-IUPAC
compounds	990	999	|B-MODIFIER
are	1000	1003	|O
of	1004	1006	|O
interest	1007	1015	|O
as	1016	1018	|O
novel	1019	1024	|O
nAChR	1025	1030	|O
probes	1031	1037	|O
and	1038	1041	|O
potential	1042	1051	|O
metabolites	1052	1063	|O
of	1064	1066	|O
candidate	1067	1076	|O
insecticides	1077	1089	|O
.	1089	1090	|O

### abstracts4897.txt
Two	0	3	|O
complete	4	12	|O
and	13	16	|O
two	17	20	|O
partial	21	28	|O
structure	29	38	|O
-	38	39	|O
activity	39	47	|O
relationship	48	60	|O
scans	61	66	|O
of	67	69	|O
the	70	73	|O
active	74	80	|O
fragment	81	89	|O
of	90	92	|O
human	93	98	|O
growth	99	105	|O
hormone	106	113	|O
-	113	114	|O
releasing	114	123	|O
hormone	124	131	|O
,	131	132	|O
[	133	134	|O
Nle27	134	139	|O
]	139	140	|O
-	140	141	|O
hGHRH	141	146	|O
(	146	147	|O
1-29	147	151	|O
)	151	152	|O
-	152	153	|O
NH2	153	156	|O
,	156	157	|O
have	158	162	|O
identified	163	173	|O
potent	174	180	|O
agonists	181	189	|O
in	190	192	|O
vitro	193	198	|O
.	198	199	|O
Single	200	206	|O
-	206	207	|O
point	207	212	|O
replacement	213	224	|O
of	225	227	|O
each	228	232	|O
amino	233	238	|O
acid	239	243	|O
by	244	246	|O
alanine	247	254	|O
led	255	258	|O
to	259	261	|O
the	262	265	|O
identification	266	280	|O
of	281	283	|O
[	284	285	|O
Ala8	285	289	|O
]	289	290	|O
-	290	291	|O
,	291	292	|O
[	293	294	|O
Ala9	294	298	|O
]	298	299	|O
-	299	300	|O
,	300	301	|O
[	302	303	|O
Ala15	303	308	|O
]	308	309	|O
-	309	310	|O
(	311	312	|O
Felix	312	317	|O
et	318	320	|O
al.	321	324	|O
Peptides	325	333	|O
1986	334	338	|O
1986	339	343	|O
,	343	344	|O
481	345	348	|O
)	348	349	|O
,	349	350	|O
[	351	352	|O
Ala22	352	357	|O
]	357	358	|O
-	358	359	|O
,	359	360	|O
and	361	364	|O
[	365	366	|O
Ala28	366	371	|O
,	371	372	|O
Nle27	373	378	|O
]	378	379	|O
-	379	380	|O
hGHRH	380	385	|O
(	385	386	|O
1-29	386	390	|O
)	390	391	|O
-	391	392	|O
NH2	392	395	|O
as	396	398	|O
being	399	404	|O
2-6	405	408	|O
times	409	414	|O
more	415	419	|O
potent	420	426	|O
than	427	431	|O
hGHRH	432	437	|O
(	437	438	|O
1-40	438	442	|O
)	442	443	|O
-	443	444	|O
OH	444	446	|O
(	447	448	|O
standard	448	456	|O
)	456	457	|O
in	458	460	|O
vitro	461	466	|O
.	466	467	|O
Nearly	468	474	|O
complete	475	483	|O
loss	484	488	|O
of	489	491	|O
potency	492	499	|O
was	500	503	|O
seen	504	508	|O
for	509	512	|O
[	513	514	|O
Ala1	514	518	|O
]	518	519	|O
,	519	520	|O
[	521	522	|O
Ala3	522	526	|O
]	526	527	|O
,	527	528	|O
[	529	530	|O
Ala5	530	534	|O
]	534	535	|O
,	535	536	|O
[	537	538	|O
Ala6	538	542	|O
]	542	543	|O
,	543	544	|O
[	545	546	|O
Ala10	546	551	|O
]	551	552	|O
,	552	553	|O
[	554	555	|O
Ala11	555	560	|O
]	560	561	|O
,	561	562	|O
[	563	564	|O
Ala13	564	569	|O
]	569	570	|O
,	570	571	|O
[	572	573	|O
Ala14	573	578	|O
]	578	579	|O
,	579	580	|O
and	581	584	|O
[	585	586	|O
Ala23	586	591	|O
]	591	592	|O
,	592	593	|O
whereas	594	601	|O
[	602	603	|O
Ala16	603	608	|O
]	608	609	|O
,	609	610	|O
[	611	612	|O
Ala18	612	617	|O
]	617	618	|O
,	618	619	|O
[	620	621	|O
Ala24	621	626	|O
]	626	627	|O
,	627	628	|O
[	629	630	|O
Ala25	630	635	|O
]	635	636	|O
,	636	637	|O
[	638	639	|O
Ala26	639	644	|O
]	644	645	|O
,	645	646	|O
and	647	650	|O
[	651	652	|O
Ala29	652	657	|O
]	657	658	|O
yielded	659	666	|O
equipotent	667	677	|O
analogues	678	687	|O
and	688	691	|O
[	692	693	|O
Ala7	693	697	|O
]	697	698	|O
,	698	699	|O
[	700	701	|O
Ala12	701	706	|O
]	706	707	|O
,	707	708	|O
[	709	710	|O
Ala17	710	715	|O
]	715	716	|O
,	716	717	|O
[	718	719	|O
Ala20	719	724	|O
]	724	725	|O
,	725	726	|O
[	727	728	|O
Ala21	728	733	|O
]	733	734	|O
,	734	735	|O
and	736	739	|O
[	740	741	|O
Ala27	741	746	|O
]	746	747	|O
gave	748	752	|O
weak	753	757	|O
agonists	758	766	|O
with	767	771	|O
potencies	772	781	|O
15-40%	782	788	|O
that	789	793	|O
of	794	796	|O
the	797	800	|O
standard	801	809	|O
.	809	810	|O
The	811	814	|O
multiple	815	823	|O
-	823	824	|O
alanine	824	831	|O
-	831	832	|O
substituted	832	843	|O
peptides	844	852	|O
[	853	854	|O
MeTyr1	854	860	|O
,	860	861	|O
Ala15	861	866	|O
,	866	867	|O
22	867	869	|O
,	869	870	|O
Nle27	870	875	|O
]	875	876	|O
-	876	877	|O
hGHRH	877	882	|O
(	882	883	|O
1-29	883	887	|O
)	887	888	|O
-	888	889	|O
NH2	889	892	|O
(	893	894	|O
29	894	896	|O
)	896	897	|O
and	898	901	|O
[	902	903	|O
MeTyr1	903	909	|O
,	909	910	|O
Ala8	910	914	|O
,	914	915	|O
9,15,22,28	915	925	|O
,	925	926	|O
Nle	926	929	|O
27	930	932	|O
]	932	933	|O
-	933	934	|O
hGHRH	934	939	|O
(	939	940	|O
1-29	940	944	|O
)	944	945	|O
-	945	946	|O
NH2	946	949	|O
(	950	951	|O
30	951	953	|O
)	953	954	|O
released	955	963	|O
growth	964	970	|O
hormone	971	978	|O
26	979	981	|O
and	982	985	|O
11	986	988	|O
times	989	994	|O
,	994	995	|O
respectively	996	1008	|O
,	1008	1009	|O
more	1010	1014	|O
effectively	1015	1026	|O
than	1027	1031	|O
the	1032	1035	|O
standard	1036	1044	|O
in	1045	1047	|O
vitro	1048	1053	|O
.	1053	1054	|O
Individual	1055	1065	|O
substitution	1066	1078	|O
of	1079	1081	|O
the	1082	1085	|O
nine	1086	1090	|O
most	1091	1095	|O
potent	1096	1102	|O
peptides	1103	1111	|O
identified	1112	1122	|O
from	1123	1127	|O
the	1128	1131	|O
Ala	1132	1135	|O
series	1136	1142	|O
with	1143	1147	|O
the	1148	1151	|O
helix	1152	1157	|O
promoter	1158	1166	|O
alpha	1167	1172	|B-IUPAC
-	1172	1173	|I-IUPAC
aminoisobutyric	1173	1188	|I-IUPAC
acid	1189	1193	|I-IUPAC
(	1194	1195	|O
Aib	1195	1198	|O
)	1198	1199	|O
produced	1200	1208	|O
similar	1209	1216	|O
results	1217	1224	|O
,	1224	1225	|O
except	1226	1232	|O
for	1233	1236	|O
[	1237	1238	|O
Aib8	1238	1242	|O
]	1242	1243	|O
(	1244	1245	|O
doubling	1245	1253	|O
vs	1254	1256	|O
[	1257	1258	|O
Ala8	1258	1262	|O
]	1262	1263	|O
)	1263	1264	|O
,	1264	1265	|O
[	1266	1267	|O
Aib9	1267	1271	|O
]	1271	1272	|O
(	1273	1274	|O
having	1274	1280	|O
vs	1281	1283	|O
[	1284	1285	|O
Ala9	1285	1289	|O
]	1289	1290	|O
)	1290	1291	|O
,	1291	1292	|O
and	1293	1296	|O
[	1297	1298	|O
Aib15	1298	1303	|O
]	1303	1304	|O
(	1305	1306	|O
10	1306	1308	|O
-	1308	1309	|O
fold	1309	1313	|O
decrease	1314	1322	|O
vs	1323	1325	|O
[	1326	1327	|O
Ala15	1327	1332	|O
]	1332	1333	|O
)	1333	1334	|O
.	1334	1335	|O
A	1336	1337	|O
series	1338	1344	|O
of	1345	1347	|O
cyclic	1348	1354	|O
analogues	1355	1364	|O
was	1365	1368	|O
synthesized	1369	1380	|O
having	1381	1387	|O
the	1388	1391	|O
general	1392	1399	|O
formula	1400	1407	|O
cyclo	1408	1413	|O
(	1413	1414	|O
25-29	1414	1419	|O
)	1419	1420	|O
[	1420	1421	|O
MeTyr1	1421	1427	|O
,	1427	1428	|O
-	1428	1429	|O
Ala15	1429	1434	|O
,	1434	1435	|O
Xaa25	1435	1440	|O
,	1440	1441	|O
Nle27	1441	1446	|O
,	1446	1447	|O
Yaa29+	1447	1453	|O
+	1454	1455	|O
+	1455	1456	|O
]	1456	1457	|O
-	1457	1458	|O
GHRH	1458	1462	|O
(	1462	1463	|O
1-29	1463	1467	|O
)	1467	1468	|O
-	1468	1469	|O
NH2	1469	1472	|O
,	1472	1473	|O
where	1474	1479	|O
Xaa	1480	1483	|O
and	1484	1487	|O
Yaa	1488	1491	|O
represent	1492	1501	|O
the	1502	1505	|O
bridgehead	1506	1516	|O
residues	1517	1525	|O
of	1526	1528	|O
a	1529	1530	|O
side	1531	1535	|O
-	1535	1536	|O
chain	1536	1541	|O
cystine	1542	1549	|O
or	1550	1552	|O
[	1553	1554	|O
i	1554	1555	|O
-	1555	1556	|O
(	1556	1557	|O
i	1557	1558	|O
+	1559	1560	|O
4	1561	1562	|O
)	1562	1563	|O
]	1563	1564	|O
lactam	1565	1571	|O
ring	1572	1576	|O
.	1576	1577	|O
The	1578	1581	|O
ring	1582	1586	|O
size	1587	1591	|O
,	1591	1592	|O
bridgehead	1593	1603	|O
amino	1604	1609	|O
acid	1610	1614	|O
chirality	1615	1624	|O
,	1624	1625	|O
and	1626	1629	|O
side	1630	1634	|O
-	1634	1635	|O
chain	1635	1640	|O
amide	1641	1646	|O
bond	1647	1651	|O
location	1652	1660	|O
were	1661	1665	|O
varied	1666	1672	|O
in	1673	1675	|O
this	1676	1680	|O
partial	1681	1688	|O
series	1689	1695	|O
in	1696	1698	|O
an	1699	1701	|O
attempt	1702	1709	|O
to	1710	1712	|O
maximize	1713	1721	|O
potency	1722	1729	|O
.	1729	1730	|O
Application	1731	1742	|O
of	1743	1745	|O
lactam	1746	1752	|O
constraints	1753	1764	|O
in	1765	1767	|O
the	1768	1771	|O
C	1772	1773	|O
-	1773	1774	|O
terminus	1774	1782	|O
of	1783	1785	|O
GHRH	1786	1790	|O
(	1790	1791	|O
1-29	1791	1795	|O
)	1795	1796	|O
-	1796	1797	|O
NH2	1797	1800	|O
identified	1801	1811	|O
cyclo	1812	1817	|O
(	1817	1818	|O
25-29	1818	1823	|O
)	1823	1824	|O
[	1824	1825	|O
MeTyr1	1825	1831	|O
,	1831	1832	|O
Ala15	1832	1837	|O
,	1837	1838	|O
DAsp25	1838	1844	|O
,	1844	1845	|O
Nle27	1845	1850	|O
,	1850	1851	|O
Orn29+	1851	1857	|O
+	1858	1859	|O
+	1859	1860	|O
]	1860	1861	|O
-	1861	1862	|O
hGHRH	1862	1867	|O
(	1867	1868	|O
1-29	1868	1872	|O
)	1872	1873	|O
-	1873	1874	|O
NH2	1874	1877	|O
(	1878	1879	|O
46	1879	1881	|O
)	1881	1882	|O
as	1883	1885	|O
containing	1886	1896	|O
the	1897	1900	|O
optimum	1901	1908	|O
bridging	1909	1917	|O
element	1918	1925	|O
(	1926	1927	|O
19	1927	1929	|O
-	1929	1930	|O
membered	1930	1938	|O
ring	1939	1943	|O
)	1943	1944	|O
in	1945	1947	|O
this	1948	1952	|O
region	1953	1959	|O
of	1960	1962	|O
the	1963	1966	|O
molecule	1967	1975	|O
.	1975	1976	|O
This	1977	1981	|O
analogue	1982	1990	|O
(	1991	1992	|O
46	1992	1994	|O
)	1994	1995	|O
was	1996	1999	|O
17	2000	2002	|O
times	2003	2008	|O
more	2009	2013	|O
potent	2014	2020	|O
than	2021	2025	|O
the	2026	2029	|O
standard	2030	2038	|O
.	2038	2039	|O
Equally	2040	2047	|O
effective	2048	2057	|O
was	2058	2061	|O
an	2062	2064	|O
[	2065	2066	|O
i	2066	2067	|O
-	2067	2068	|O
(	2068	2069	|O
i	2069	2070	|O
+	2071	2072	|O
3	2073	2074	|O
)	2074	2075	|O
]	2075	2076	|O
constraint	2077	2087	|O
yielding	2088	2096	|O
the	2097	2100	|O
18	2101	2103	|O
-	2103	2104	|O
membered	2104	2112	|O
ring	2113	2117	|O
cyclo	2118	2123	|O
(	2123	2124	|O
25-28	2124	2129	|O
)	2129	2130	|O
[	2130	2131	|O
MeTyr1	2131	2137	|O
,	2137	2138	|O
Ala15	2138	2143	|O
,	2143	2144	|O
Glu25	2144	2149	|O
,	2149	2150	|O
Nle	2150	2153	|O
,	2153	2154	|O
27Lys28	2154	2161	|O
]	2161	2162	|O
-	2162	2163	|O
hGHRH	2164	2169	|O
-	2169	2170	|O
(	2170	2171	|O
1-29	2171	2175	|O
)	2175	2176	|O
-	2176	2177	|O
NH2	2177	2180	|O
(	2181	2182	|O
51	2182	2184	|O
)	2184	2185	|O
which	2186	2191	|O
was	2192	2195	|O
14	2196	2198	|O
times	2199	2204	|O
more	2205	2209	|O
potent	2210	2216	|O
than	2217	2221	|O
the	2222	2225	|O
standard	2226	2234	|O
.	2234	2235	|O
A	2236	2237	|O
complete	2238	2246	|O
[	2247	2248	|O
i	2248	2249	|O
-	2249	2250	|O
(	2250	2251	|O
i	2251	2252	|O
+	2253	2254	|O
3	2255	2256	|O
)	2256	2257	|O
]	2257	2258	|O
scan	2259	2263	|O
of	2264	2266	|O
cyclo	2267	2272	|O
(	2272	2273	|O
i	2273	2274	|O
,	2274	2275	|O
i	2275	2276	|O
+	2277	2278	|O
3	2279	2280	|O
)	2280	2281	|O
[	2281	2282	|O
MeTyr1	2282	2288	|O
,	2288	2289	|O
Ala15	2289	2294	|O
,	2294	2295	|O
Glui	2295	2299	|O
,	2299	2300	|O
Lys	2300	2303	|O
(	2303	2304	|O
i	2304	2305	|O
+	2306	2307	|O
3	2308	2309	|O
)	2309	2310	|O
,	2310	2311	|O
Nle27	2311	2316	|O
]	2316	2317	|O
-	2317	2318	|O
hGHRH	2318	2323	|O
(	2323	2324	|O
1-29	2324	2328	|O
)	2328	2329	|O
-	2329	2330	|O
NH2	2330	2333	|O
was	2334	2337	|O
then	2338	2342	|O
produced	2343	2351	|O
in	2352	2354	|O
order	2355	2360	|O
to	2361	2363	|O
test	2364	2368	|O
the	2369	2372	|O
effects	2373	2380	|O
of	2381	2383	|O
a	2384	2385	|O
Glu	2386	2389	|O
-	2389	2390	|O
to	2390	2392	|O
-	2392	2393	|O
Lys	2393	2396	|O
lactam	2397	2403	|O
bridge	2404	2410	|O
at	2411	2413	|O
all	2414	2417	|O
points	2418	2424	|O
in	2425	2427	|O
the	2428	2431	|O
peptide	2432	2439	|O
.	2439	2440	|O
Of	2441	2443	|O
the	2444	2447	|O
26	2448	2450	|O
analogues	2451	2460	|O
in	2461	2463	|O
the	2464	2467	|O
series	2468	2474	|O
,	2474	2475	|O
11	2476	2478	|O
had	2479	2482	|O
diminished	2483	2493	|O
potencies	2494	2503	|O
of	2504	2506	|O
less	2507	2511	|O
than	2512	2516	|O
10%	2517	2520	|O
that	2521	2525	|O
of	2526	2528	|O
the	2529	2532	|O
agonist	2533	2540	|O
standard	2541	2549	|O
,	2549	2550	|O
4	2551	2552	|O
were	2553	2557	|O
weak	2558	2562	|O
agonists	2563	2571	|O
(	2572	2573	|O
15-40%	2573	2579	|O
relative	2580	2588	|O
potency	2589	2596	|O
)	2596	2597	|O
,	2597	2598	|O
and	2599	2602	|O
4	2603	2604	|O
analogues	2605	2614	|O
were	2615	2619	|O
equipotent	2620	2630	|O
to	2631	2633	|O
the	2634	2637	|O
standard	2638	2646	|O
.	2646	2647	|O
The	2648	2651	|O
7	2652	2653	|O
most	2654	2658	|O
potent	2659	2665	|O
analogues	2666	2675	|O
ranged	2676	2682	|O
in	2683	2685	|O
potency	2686	2693	|O
from	2694	2698	|O
3	2699	2700	|O
to	2701	2703	|O
14	2704	2706	|O
times	2707	2712	|O
greater	2713	2720	|O
than	2721	2725	|O
that	2726	2730	|O
of	2731	2733	|O
the	2734	2737	|O
standard	2738	2746	|O
and	2747	2750	|O
contained	2751	2760	|O
the	2761	2764	|O
[	2765	2766	|O
i	2766	2767	|O
-	2767	2768	|O
(	2768	2769	|O
i	2769	2770	|O
+	2771	2772	|O
3	2773	2774	|O
)	2774	2775	|O
]	2775	2776	|O
cycles	2777	2783	|O
between	2784	2791	|O
residues	2792	2800	|O
4-7	2801	2804	|O
,	2804	2805	|O
5-8	2806	2809	|O
,	2809	2810	|O
9-12	2811	2815	|O
,	2815	2816	|O
16-19	2817	2822	|O
,	2822	2823	|O
21-24	2824	2829	|O
,	2829	2830	|O
22-25	2831	2836	|O
,	2836	2837	|O
and	2838	2841	|O
25-28	2842	2847	|O
.	2847	2848	|O
The	2849	2852	|O
combined	2853	2861	|O
results	2862	2869	|O
from	2870	2874	|O
these	2875	2880	|O
systematic	2881	2891	|O
studies	2892	2899	|O
allowed	2900	2907	|O
for	2908	2911	|O
an	2912	2914	|O
analysis	2915	2923	|O
of	2924	2926	|O
structural	2927	2937	|O
features	2938	2946	|O
in	2947	2949	|O
the	2950	2953	|O
native	2954	2960	|O
peptide	2961	2968	|O
that	2969	2973	|O
are	2974	2977	|O
important	2978	2987	|O
for	2988	2991	|O
receptor	2992	3000	|O
activation	3001	3011	|O
.	3011	3012	|O
Reinforcement	3013	3026	|O
of	3027	3029	|O
the	3030	3033	|O
characteristics	3034	3049	|O
of	3050	3052	|O
amphiphilicity	3053	3067	|O
,	3067	3068	|O
helicity	3069	3077	|O
,	3077	3078	|O
and	3079	3082	|O
peptide	3083	3090	|O
dipolar	3091	3098	|O
effects	3099	3106	|O
,	3106	3107	|O
using	3108	3113	|O
recognized	3114	3124	|O
medicinal	3125	3134	|O
chemistry	3135	3144	|O
approaches	3145	3155	|O
including	3156	3165	|O
introduction	3166	3178	|O
of	3179	3181	|O
conformational	3182	3196	|O
constraints	3197	3208	|O
,	3208	3209	|O
has	3210	3213	|O
resulted	3214	3222	|O
in	3223	3225	|O
several	3226	3233	|O
potent	3234	3240	|O
GHRH	3241	3245	|O
analogues	3246	3255	|O
.	3255	3256	|O

### abstracts3157.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
unsaturated	12	23	|O
analogues	24	33	|O
of	34	36	|O
nucleosides	37	48	|O
were	49	53	|O
prepared	54	62	|O
and	63	66	|O
their	67	72	|O
cytotoxic	73	82	|O
,	82	83	|O
antitumor	84	93	|O
,	93	94	|O
and	95	98	|O
antiviral	99	108	|O
activities	109	119	|O
were	120	124	|O
investigated	125	137	|O
.	137	138	|O
Alkylation	139	149	|O
of	150	152	|O
cytosine	153	161	|O
with	162	166	|O
(	167	168	|B-IUPAC
E	168	169	|I-IUPAC
)	169	170	|I-IUPAC
-	170	171	|I-IUPAC
1,4	171	174	|I-IUPAC
-	174	175	|I-IUPAC
dichloro	175	183	|I-IUPAC
-	183	184	|I-IUPAC
2	184	185	|I-IUPAC
-	185	186	|I-IUPAC
butene	186	192	|I-IUPAC
gave	193	197	|O
chloro	198	204	|O
derivative	205	215	|O
2f	216	218	|O
,	218	219	|O
which	220	225	|O
was	226	229	|O
hydrolyzed	230	240	|O
to	241	243	|O
alcohol	244	251	|O
2h	252	254	|O
.	254	255	|O
Cytosine	256	264	|O
,	264	265	|O
adenine	266	273	|O
,	273	274	|O
2	275	276	|B-IUPAC
-	276	277	|I-IUPAC
amino	277	282	|I-IUPAC
-	282	283	|I-IUPAC
6	283	284	|I-IUPAC
-	284	285	|I-IUPAC
chloropurine	285	297	|I-IUPAC
,	297	298	|O
thymine	299	306	|O
,	306	307	|O
and	308	311	|O
(	312	313	|B-IUPAC
Z	313	314	|I-IUPAC
)	314	315	|I-IUPAC
-	315	316	|I-IUPAC
1,4	316	319	|I-IUPAC
-	319	320	|I-IUPAC
chloro	320	326	|I-IUPAC
-	326	327	|I-IUPAC
2	327	328	|I-IUPAC
-	328	329	|I-IUPAC
butene	329	335	|I-IUPAC
gave	336	340	|O
compounds	341	350	|O
4c	351	353	|O
-	353	354	|O
f	354	355	|O
,	355	356	|O
which	357	362	|O
,	362	363	|O
after	364	369	|O
hydrolysis	370	380	|O
,	380	381	|O
afforded	382	390	|O
alcohols	391	399	|O
4a	400	402	|O
,	402	403	|O
4b	404	406	|O
,	406	407	|O
4g	408	410	|O
,	410	411	|O
and	412	415	|O
4h	416	418	|O
.	418	419	|O
Alkenes	420	427	|O
4d	428	430	|O
and	431	434	|O
4e	435	437	|O
were	438	442	|O
cyclized	443	451	|O
to	452	454	|O
heterocycles	455	467	|O
12	468	470	|O
and	471	474	|O
13	475	477	|O
.	477	478	|O
Alkylation	479	489	|O
of	490	492	|O
2,6	493	496	|B-IUPAC
-	496	497	|I-IUPAC
diaminopurine	497	510	|I-IUPAC
with	511	515	|O
1,4	516	519	|B-IUPAC
-	519	520	|I-IUPAC
dichloro	520	528	|I-IUPAC
-	528	529	|I-IUPAC
2	529	530	|I-IUPAC
-	530	531	|I-IUPAC
butyne	531	537	|I-IUPAC
led	538	541	|O
to	542	544	|O
chloro	545	551	|B-IUPAC
derivative	552	562	|B-MODIFIER
6a	563	565	|O
,	565	566	|O
which	567	572	|O
was	573	576	|O
hydrolyzed	577	587	|O
to	588	590	|O
alcohol	591	598	|O
6b	599	601	|O
.	601	602	|O
Allenic	603	610	|O
isomerization	611	624	|O
of	625	627	|O
6b	628	630	|O
gave	631	635	|O
compound	636	644	|O
5c	645	647	|O
.	647	648	|O
Chloro	649	655	|B-IUPAC
derivatives	656	667	|B-MODIFIER
2e	668	670	|O
-	670	671	|O
g	671	672	|O
,	672	673	|O
4c	674	676	|O
-	676	677	|O
f	677	678	|O
,	678	679	|O
5d	680	682	|O
,	682	683	|O
and	684	687	|O
6c	688	690	|O
-	690	691	|O
e	691	692	|O
as	693	695	|O
well	696	700	|O
as	701	703	|O
pyrimidine	704	714	|O
oxacyclopentenes	715	731	|O
9c	732	734	|O
and	735	738	|O
9d	739	741	|O
are	742	745	|O
slow	746	750	|O
-	750	751	|O
acting	751	757	|O
inhibitors	758	768	|O
of	769	771	|O
murine	772	778	|O
leukemia	779	787	|O
L1210	788	793	|O
of	794	796	|O
IC50	797	801	|O
10-100	802	808	|O
microM	809	815	|O
.	815	816	|O
The	817	820	|O
most	821	825	|O
active	826	832	|O
were	833	837	|O
analogues	838	847	|O
4c	848	850	|O
,	850	851	|O
4d	852	854	|O
,	854	855	|O
4e	856	858	|O
,	858	859	|O
and	860	863	|O
6e	864	866	|O
(	867	868	|O
IC50	868	872	|O
10-20	873	878	|O
microM	879	885	|O
)	885	886	|O
.	886	887	|O
The	888	891	|O
corresponding	892	905	|O
hydroxy	906	913	|B-IUPAC
derivatives	914	925	|B-MODIFIER
were	926	930	|O
less	931	935	|O
active	936	942	|O
of	943	945	|O
inactive	946	954	|O
.	954	955	|O
Inhibition	956	966	|O
of	967	969	|O
macromolecular	970	984	|O
synthesis	985	994	|O
with	995	999	|O
compounds	1000	1009	|O
4c	1010	1012	|O
,	1012	1013	|O
4d	1014	1016	|O
,	1016	1017	|O
6e	1018	1020	|O
,	1020	1021	|O
9c	1022	1024	|O
,	1024	1025	|O
and	1026	1029	|O
9d	1030	1032	|O
follows	1033	1040	|O
the	1041	1044	|O
order	1045	1050	|O
:	1050	1051	|O
DNA	1052	1055	|O
greater	1056	1063	|O
than	1064	1068	|O
RNA	1069	1072	|O
greater	1073	1080	|O
than	1081	1085	|O
or	1086	1088	|O
equal	1089	1094	|O
to	1095	1097	|O
protein	1098	1105	|O
.	1105	1106	|O
Cytotoxic	1107	1116	|O
effects	1117	1124	|O
of	1125	1127	|O
4c	1128	1130	|O
,	1130	1131	|O
6e	1132	1134	|O
,	1134	1135	|O
and	1136	1139	|O
9d	1140	1142	|O
are	1143	1146	|O
not	1147	1150	|O
reversed	1151	1159	|O
with	1160	1164	|O
any	1165	1168	|O
of	1169	1171	|O
the	1172	1175	|O
four	1176	1180	|O
basic	1181	1186	|O
ribonucleosides	1187	1202	|O
or	1203	1205	|O
2'	1206	1208	|B-IUPAC
-	1208	1209	|I-IUPAC
deoxyribonucleosides	1209	1229	|I-IUPAC
.	1229	1230	|O
Inhibitory	1231	1241	|O
activity	1242	1250	|O
of	1251	1253	|O
cytosine	1254	1262	|O
derivative	1263	1273	|O
9c	1274	1276	|O
is	1277	1279	|O
reversed	1280	1288	|O
with	1289	1293	|O
uridine	1294	1301	|O
and	1302	1305	|O
2'	1306	1308	|B-IUPAC
-	1308	1309	|I-IUPAC
deoxyuridine	1309	1321	|I-IUPAC
but	1322	1325	|O
not	1326	1329	|O
with	1330	1334	|O
the	1335	1338	|O
corresponding	1339	1352	|O
cytosine	1353	1361	|O
nucleosides	1362	1373	|O
.	1373	1374	|O
Zone	1375	1379	|O
assays	1380	1386	|O
in	1387	1389	|O
several	1390	1397	|O
tumor	1398	1403	|O
cell	1404	1408	|O
lines	1409	1414	|O
show	1415	1419	|O
that	1420	1424	|O
active	1425	1431	|O
compounds	1432	1441	|O
are	1442	1445	|O
cytotoxic	1446	1455	|O
agents	1456	1462	|O
with	1463	1467	|O
little	1468	1474	|O
selectivity	1475	1486	|O
for	1487	1490	|O
tumor	1491	1496	|O
cells	1497	1502	|O
.	1502	1503	|O
Analogue	1504	1512	|O
6c	1513	1515	|O
showed	1516	1522	|O
16.7%	1523	1528	|O
ILS	1529	1532	|O
in	1533	1535	|O
leukemia	1536	1544	|O
P388	1545	1549	|O
/	1549	1550	|O
o	1550	1551	|O
implanted	1552	1561	|O
ip	1562	1564	|O
in	1565	1567	|O
mice	1568	1572	|O
at	1573	1575	|O
510	1576	1579	|O
and	1580	1583	|O
1020	1584	1588	|O
mg	1589	1591	|O
/	1591	1592	|O
kg	1592	1594	|O
,	1594	1595	|O
respectively	1596	1608	|O
.	1608	1609	|O
Cytallene	1610	1619	|O
(	1620	1621	|O
5b	1621	1623	|O
)	1623	1624	|O
and	1625	1628	|O
6'	1629	1631	|B-IUPAC
beta	1631	1635	|I-IUPAC
-	1635	1636	|I-IUPAC
hydroxyaristeromycin	1636	1656	|I-IUPAC
(	1657	1658	|O
10	1658	1660	|O
)	1660	1661	|O
exhibited	1662	1671	|O
significant	1672	1683	|O
activity	1684	1692	|O
against	1693	1700	|O
Friend	1701	1707	|O
and	1708	1711	|O
Rauscher	1712	1720	|O
murine	1721	1727	|O
leukemia	1728	1736	|O
viruses	1737	1744	|O
.	1744	1745	|O
The	1746	1749	|O
rest	1750	1754	|O
of	1755	1757	|O
the	1758	1761	|O
hydroxy	1762	1769	|O
derivatives	1770	1781	|O
,	1781	1782	|O
with	1783	1787	|O
the	1788	1791	|O
exception	1792	1801	|O
of	1802	1804	|O
4a	1805	1807	|O
,	1807	1808	|O
were	1809	1813	|O
moderately	1814	1824	|O
effective	1825	1834	|O
or	1835	1837	|O
inactive	1838	1846	|O
as	1847	1849	|O
antiviral	1850	1859	|O
agents	1860	1866	|O
.	1866	1867	|O
None	1868	1872	|O
of	1873	1875	|O
the	1876	1879	|O
chloro	1880	1886	|O
derivatives	1887	1898	|O
or	1899	1901	|O
oxacyclopentenes	1902	1918	|O
exhibited	1919	1928	|O
an	1929	1931	|O
antiviral	1932	1941	|O
effect	1942	1948	|O
at	1949	1951	|O
noncytotoxic	1952	1964	|O
concentrations	1965	1979	|O
.	1979	1980	|O
Z	1981	1982	|O
-	1982	1983	|O
Olefin	1983	1989	|O
4b	1990	1992	|O
and	1993	1996	|O
2	1997	1998	|B-IUPAC
-	1998	1999	|I-IUPAC
aminoadenallene	1999	2014	|I-IUPAC
(	2015	2016	|O
5c	2016	2018	|O
)	2018	2019	|O
are	2020	2023	|O
substrates	2024	2034	|O
for	2035	2038	|O
adenosine	2039	2048	|O
deaminase	2049	2058	|O
.	2058	2059	|O

### abstracts2465.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
bis	12	15	|O
(	15	16	|O
hydroxymethyl	16	29	|O
)	29	30	|O
-	30	31	|O
substituted	31	42	|O
heterocycles	43	55	|O
were	56	60	|O
synthesized	61	72	|O
and	73	76	|O
converted	77	86	|O
to	87	89	|O
the	90	93	|O
corresponding	94	107	|O
bis	108	111	|B-IUPAC
(	111	112	|I-IUPAC
methylcarbamate	112	127	|I-IUPAC
)	127	128	|I-IUPAC
derivatives	129	140	|B-MODIFIER
.	140	141	|O
The	142	145	|O
heterocyclic	146	158	|O
systems	159	166	|O
studied	167	174	|O
were	175	179	|O
based	180	185	|O
on	186	188	|O
2	189	190	|B-IUPAC
-	190	191	|I-IUPAC
phenyl	191	197	|I-IUPAC
-	197	198	|I-IUPAC
3	198	199	|I-IUPAC
-	199	200	|I-IUPAC
methylfuran	200	211	|I-IUPAC
(	212	213	|O
2-4	213	216	|O
)	216	217	|O
,	217	218	|O
1	219	220	|B-IUPAC
-	220	221	|I-IUPAC
phenylpyrazole	221	235	|I-IUPAC
(	236	237	|O
5-7	237	240	|O
)	240	241	|O
,	241	242	|O
1	243	244	|B-IUPAC
-	244	245	|I-IUPAC
phenyl	245	251	|I-IUPAC
-	251	252	|I-IUPAC
5	252	253	|I-IUPAC
-	253	254	|I-IUPAC
methylpyrazole	254	268	|I-IUPAC
(	269	270	|O
9-11	270	274	|O
)	274	275	|O
,	275	276	|O
1	277	278	|B-IUPAC
-	278	279	|I-IUPAC
phenyl	279	285	|I-IUPAC
-	285	286	|I-IUPAC
5	286	287	|I-IUPAC
-	287	288	|I-IUPAC
methylthiophene	288	303	|I-IUPAC
(	304	305	|O
13	305	307	|O
)	307	308	|O
,	308	309	|O
1	310	311	|B-IUPAC
-	311	312	|I-IUPAC
phenyl	312	318	|I-IUPAC
-	318	319	|I-IUPAC
1,2,3	319	324	|I-IUPAC
-	324	325	|I-IUPAC
triazole	325	333	|I-IUPAC
(	334	335	|O
14	335	337	|O
)	337	338	|O
,	338	339	|O
3	340	341	|B-IUPAC
-	341	342	|I-IUPAC
phenylisoxazole	342	357	|I-IUPAC
(	358	359	|O
15	359	361	|O
)	361	362	|O
,	362	363	|O
3	364	365	|B-IUPAC
-	365	366	|I-IUPAC
phenylisothiazole	366	383	|I-IUPAC
(	384	385	|O
16	385	387	|O
)	387	388	|O
,	388	389	|O
2	390	391	|B-IUPAC
-	391	392	|I-IUPAC
phenylthiazole	392	406	|I-IUPAC
(	407	408	|O
17	408	410	|O
)	410	411	|O
,	411	412	|O
and	413	416	|O
2	417	418	|B-IUPAC
-	418	419	|I-IUPAC
phenyloxazole	419	432	|I-IUPAC
(	433	434	|O
18	434	436	|O
)	436	437	|O
.	437	438	|O
None	439	443	|O
of	444	446	|O
the	447	450	|O
bis	451	454	|O
(	454	455	|O
carbamates	455	465	|O
)	465	466	|O
prepared	467	475	|O
was	476	479	|O
active	480	486	|O
against	487	494	|O
murine	495	501	|O
P388	502	506	|O
lymphocytic	507	518	|O
leukemia	519	527	|O
.	527	528	|O
Pyrrole	529	536	|B-IUPAC
bis	537	540	|I-IUPAC
(	540	541	|I-IUPAC
carbamates	541	551	|I-IUPAC
)	551	552	|I-IUPAC
20	553	555	|O
and	556	559	|O
21	560	562	|O
,	562	563	|O
which	564	569	|O
exhibited	570	579	|O
antileukemic	580	592	|O
activity	593	601	|O
,	601	602	|O
also	603	607	|O
showed	608	614	|O
reactivity	615	625	|O
toward	626	632	|O
4	633	634	|B-IUPAC
-	634	635	|I-IUPAC
(	635	636	|I-IUPAC
p	636	637	|I-IUPAC
-	637	638	|I-IUPAC
nitrobenzyl	638	649	|I-IUPAC
)	649	650	|I-IUPAC
pyridine	650	658	|I-IUPAC
while	659	664	|O
the	665	668	|O
inactive	669	677	|O
bis	678	681	|B-IUPAC
(	681	682	|I-IUPAC
carbamates	682	692	|I-IUPAC
)	692	693	|I-IUPAC
were	694	698	|O
unreactive	699	709	|O
in	710	712	|O
the	713	716	|O
4	717	718	|B-IUPAC
-	718	719	|I-IUPAC
(	719	720	|I-IUPAC
p	720	721	|I-IUPAC
-	721	722	|I-IUPAC
nitrobenzyl	722	733	|I-IUPAC
)	733	734	|I-IUPAC
pyridine	734	742	|I-IUPAC
assay	743	748	|O
.	748	749	|O

### abstracts1514.txt
Urokinase	0	9	|O
-	9	10	|O
type	10	14	|O
plasminogen	15	26	|O
activator	27	36	|O
(	37	38	|O
uPA	38	41	|O
)	41	42	|O
,	42	43	|O
a	44	45	|O
trypsin	46	53	|O
-	53	54	|O
like	54	58	|O
serine	59	65	|O
protease	66	74	|O
,	74	75	|O
has	76	79	|O
been	80	84	|O
implicated	85	95	|O
in	96	98	|O
large	99	104	|O
number	105	111	|O
of	112	114	|O
malignancies	115	127	|O
,	127	128	|O
tumor	129	134	|O
cell	135	139	|O
invasion	140	148	|O
,	148	149	|O
angiogenesis	150	162	|O
and	163	166	|O
metastasis	167	177	|O
;	177	178	|O
hence	179	184	|O
,	184	185	|O
the	186	189	|O
potent	190	196	|O
and	197	200	|O
selective	201	210	|O
inhibitors	211	221	|O
of	222	224	|O
uPA	225	228	|O
may	229	232	|O
therefore	233	242	|O
be	243	245	|O
therapeutically	246	261	|O
useful	262	268	|O
drugs	269	274	|O
for	275	278	|O
treatment	279	288	|O
of	289	291	|O
various	292	299	|O
forms	300	305	|O
of	306	308	|O
cancer	309	315	|O
.	315	316	|O
A	317	318	|O
three	319	324	|O
-	324	325	|O
dimensional	325	336	|O
quantitative	337	349	|O
structure	350	359	|O
-	359	360	|O
activity	360	368	|O
relationship	369	381	|O
(	382	383	|O
3D	383	385	|O
QSAR	386	390	|O
)	390	391	|O
study	392	397	|O
was	398	401	|O
performed	402	411	|O
on	412	414	|O
five	415	419	|O
different	420	429	|O
chemical	430	438	|O
series	439	445	|O
reported	446	454	|O
as	455	457	|O
selective	458	467	|O
uPA	468	471	|O
inhibitors	472	482	|O
employing	483	492	|O
comparative	493	504	|O
molecular	505	514	|O
field	515	520	|O
analysis	521	529	|O
(	530	531	|O
CoMFA	531	536	|O
)	536	537	|O
/	537	538	|O
comparative	538	549	|O
molecular	550	559	|O
similarity	560	570	|O
indices	571	578	|O
analysis	579	587	|O
(	588	589	|O
CoMSIA	589	595	|O
)	595	596	|O
techniques	597	607	|O
to	608	610	|O
investigate	611	622	|O
the	623	626	|O
structural	627	637	|O
requirements	638	650	|O
for	651	654	|O
substrates	655	665	|O
and	666	669	|O
derive	670	676	|O
a	677	678	|O
predictive	679	689	|O
model	690	695	|O
that	696	700	|O
may	701	704	|O
be	705	707	|O
used	708	712	|O
for	713	716	|O
the	717	720	|O
design	721	727	|O
of	728	730	|O
novel	731	736	|O
uPA	737	740	|O
inhibitors	741	751	|O
.	751	752	|O
ClogP	753	758	|O
has	759	762	|O
been	763	767	|O
used	768	772	|O
as	773	775	|O
an	776	778	|O
additional	779	789	|O
descriptor	790	800	|O
in	801	803	|O
the	804	807	|O
CoMFA	808	813	|O
analysis	814	822	|O
to	823	825	|O
study	826	831	|O
the	832	835	|O
effects	836	843	|O
of	844	846	|O
lipophilic	847	857	|O
parameters	858	868	|O
on	869	871	|O
activity	872	880	|O
.	880	881	|O
Inclusion	882	891	|O
of	892	894	|O
ClogP	895	900	|O
did	901	904	|O
not	905	908	|O
improve	909	916	|O
the	917	920	|O
models	921	927	|O
significantly	928	941	|O
and	942	945	|O
exhibited	946	955	|O
comparable	956	966	|O
correlation	967	978	|O
coefficients	979	991	|O
with	992	996	|O
CoMFA	997	1002	|O
steric	1003	1009	|O
and	1010	1013	|O
electrostatic	1014	1027	|O
models	1028	1034	|O
.	1034	1035	|O
3D	1036	1038	|O
QSAR	1039	1043	|O
models	1044	1050	|O
were	1051	1055	|O
derived	1056	1063	|O
for	1064	1067	|O
2	1068	1069	|B-IUPAC
-	1069	1070	|I-IUPAC
pyridinylguanidines	1070	1089	|I-IUPAC
(	1090	1091	|O
training	1091	1099	|O
set	1100	1103	|O
N	1104	1105	|O
=	1106	1107	|O
25	1108	1110	|O
,	1110	1111	|O
test	1112	1116	|O
set	1117	1120	|O
N	1121	1122	|O
=	1123	1124	|O
8	1125	1126	|O
)	1126	1127	|O
,	1127	1128	|O
4	1129	1130	|B-IUPAC
-	1130	1131	|I-IUPAC
aminoarylguanidines	1131	1150	|I-IUPAC
and	1151	1154	|O
4	1155	1156	|B-IUPAC
-	1156	1157	|I-IUPAC
aminoarylbenzamidines	1157	1178	|I-IUPAC
(	1179	1180	|O
training	1180	1188	|O
set	1189	1192	|O
N	1193	1194	|O
=	1195	1196	|O
29	1197	1199	|O
,	1199	1200	|O
test	1201	1205	|O
set	1206	1209	|O
N	1210	1211	|O
=	1212	1213	|O
8	1214	1215	|O
)	1215	1216	|O
,	1216	1217	|O
thiophene	1218	1227	|B-IUPAC
-	1227	1228	|I-IUPAC
2	1228	1229	|I-IUPAC
-	1229	1230	|I-IUPAC
carboxamindines	1230	1245	|I-IUPAC
(	1246	1247	|O
training	1247	1255	|O
set	1256	1259	|O
N	1260	1261	|O
=	1262	1263	|O
64	1264	1266	|O
,	1266	1267	|O
test	1268	1272	|O
set	1273	1276	|O
N	1277	1278	|O
=	1279	1280	|O
19	1281	1283	|O
)	1283	1284	|O
,	1284	1285	|O
2	1286	1287	|B-IUPAC
-	1287	1288	|I-IUPAC
naphthamidines	1288	1302	|I-IUPAC
(	1303	1304	|O
training	1304	1312	|O
set	1313	1316	|O
N	1317	1318	|O
=	1319	1320	|O
32	1321	1323	|O
,	1323	1324	|O
test	1325	1329	|O
set	1330	1333	|O
N	1334	1335	|O
=	1336	1337	|O
8	1338	1339	|O
)	1339	1340	|O
,	1340	1341	|O
and	1342	1345	|O
1	1346	1347	|B-IUPAC
-	1347	1348	|I-IUPAC
isoquinolinylguanidines	1348	1371	|I-IUPAC
(	1372	1373	|O
training	1373	1381	|O
set	1382	1385	|O
N	1386	1387	|O
=	1388	1389	|O
29	1390	1392	|O
,	1392	1393	|O
test	1394	1398	|O
set	1399	1402	|O
N	1403	1404	|O
=	1405	1406	|O
7	1407	1408	|O
)	1408	1409	|O
.	1409	1410	|O
The	1411	1414	|O
CoMFA	1415	1420	|O
models	1421	1427	|O
with	1428	1432	|O
steric	1433	1439	|O
and	1440	1443	|O
electrostatic	1444	1457	|O
fields	1458	1464	|O
exhibited	1465	1474	|O
r	1475	1476	|O
(	1476	1477	|O
2	1477	1478	|O
)	1478	1479	|O
(	1479	1480	|O
cv	1480	1482	|O
)	1482	1483	|O
0.452-0.722	1484	1495	|O
,	1495	1496	|O
r	1497	1498	|O
(	1498	1499	|O
2	1499	1500	|O
)	1500	1501	|O
(	1501	1502	|O
ncv	1502	1505	|O
)	1505	1506	|O
0.812-0.986	1507	1518	|O
,	1518	1519	|O
r	1520	1521	|O
(	1521	1522	|O
2	1522	1523	|O
)	1523	1524	|O
(	1524	1525	|O
pred	1525	1529	|O
)	1529	1530	|O
0.597-0.870	1531	1542	|O
,	1542	1543	|O
whereas	1544	1551	|O
CoMFA	1552	1557	|O
ClogP	1558	1563	|O
models	1564	1570	|O
showed	1571	1577	|O
r	1578	1579	|O
(	1579	1580	|O
2	1580	1581	|O
)	1581	1582	|O
(	1582	1583	|O
cv	1583	1585	|O
)	1585	1586	|O
0.420-0.707	1587	1598	|O
,	1598	1599	|O
r	1600	1601	|O
(	1601	1602	|O
2	1602	1603	|O
)	1603	1604	|O
(	1604	1605	|O
ncv	1605	1608	|O
)	1608	1609	|O
0.849-0.957	1610	1621	|O
,	1621	1622	|O
r	1623	1624	|O
(	1624	1625	|O
2	1625	1626	|O
)	1626	1627	|O
(	1627	1628	|O
pred	1628	1632	|O
)	1632	1633	|O
0.600-0.870	1634	1645	|O
.	1645	1646	|O
The	1647	1650	|O
CoMSIA	1651	1657	|O
models	1658	1664	|O
displayed	1665	1674	|O
r	1675	1676	|O
(	1676	1677	|O
2	1677	1678	|O
)	1678	1679	|O
(	1679	1680	|O
cv	1680	1682	|O
)	1682	1683	|O
0.663-0.729	1684	1695	|O
,	1695	1696	|O
r	1697	1698	|O
(	1698	1699	|O
2	1699	1700	|O
)	1700	1701	|O
(	1701	1702	|O
ncv	1702	1705	|O
)	1705	1706	|O
0.909-0.998	1707	1718	|O
,	1718	1719	|O
r	1720	1721	|O
(	1721	1722	|O
2	1722	1723	|O
)	1723	1724	|O
(	1724	1725	|O
pred	1725	1729	|O
)	1729	1730	|O
0.554-0.855	1731	1742	|O
.	1742	1743	|O
3D	1744	1746	|O
contour	1747	1754	|O
maps	1755	1759	|O
generated	1760	1769	|O
from	1770	1774	|O
these	1775	1780	|O
models	1781	1787	|O
were	1788	1792	|O
analyzed	1793	1801	|O
individually	1802	1814	|O
,	1814	1815	|O
which	1816	1821	|O
provides	1822	1830	|O
the	1831	1834	|O
regions	1835	1842	|O
in	1843	1845	|O
space	1846	1851	|O
where	1852	1857	|O
interactive	1858	1869	|O
fields	1870	1876	|O
may	1877	1880	|O
influence	1881	1890	|O
the	1891	1894	|O
activity	1895	1903	|O
.	1903	1904	|O
The	1905	1908	|O
superimposition	1909	1924	|O
of	1925	1927	|O
contour	1928	1935	|O
maps	1936	1940	|O
on	1941	1943	|O
the	1944	1947	|O
active	1948	1954	|O
site	1955	1959	|O
of	1960	1962	|O
serine	1963	1969	|O
proteases	1970	1979	|O
additionally	1980	1992	|O
helps	1993	1998	|O
in	1999	2001	|O
understanding	2002	2015	|O
the	2016	2019	|O
structural	2020	2030	|O
requirements	2031	2043	|O
of	2044	2046	|O
these	2047	2052	|O
inhibitors	2053	2063	|O
.	2063	2064	|O
Further	2065	2072	|O
,	2072	2073	|O
the	2074	2077	|O
predictive	2078	2088	|O
ability	2089	2096	|O
of	2097	2099	|O
3D	2100	2102	|O
QSAR	2103	2107	|O
models	2108	2114	|O
was	2115	2118	|O
affirmed	2119	2127	|O
by	2128	2130	|O
predicting	2131	2141	|O
the	2142	2145	|O
activity	2146	2154	|O
of	2155	2157	|O
novel	2158	2163	|O
2	2164	2165	|B-IUPAC
-	2165	2166	|I-IUPAC
naphthamidines	2166	2180	|I-IUPAC
.	2180	2181	|O
3D	2182	2184	|O
QSAR	2185	2189	|O
models	2190	2196	|O
developed	2197	2206	|O
may	2207	2210	|O
be	2211	2213	|O
used	2214	2218	|O
in	2219	2221	|O
designing	2222	2231	|O
and	2232	2235	|O
predicting	2236	2246	|O
the	2247	2250	|O
uPA	2251	2254	|O
inhibitory	2255	2265	|O
activity	2266	2274	|O
of	2275	2277	|O
novel	2278	2283	|O
molecules	2284	2293	|O
.	2293	2294	|O

### abstracts4493.txt
A	0	1	|O
new	2	5	|O
class	6	11	|O
of	12	14	|O
5	15	16	|B-IUPAC
-	16	17	|I-IUPAC
(	17	18	|I-IUPAC
1	18	19	|I-IUPAC
-	19	20	|I-IUPAC
cyanamido	20	29	|I-IUPAC
-	29	30	|I-IUPAC
2	30	31	|I-IUPAC
-	31	32	|I-IUPAC
haloethyl	32	41	|I-IUPAC
)	41	42	|I-IUPAC
-	42	43	|I-IUPAC
2'	43	45	|I-IUPAC
-	45	46	|I-IUPAC
deoxyuridines	46	59	|I-IUPAC
(	60	61	|O
4-6	61	64	|O
)	64	65	|O
and	66	69	|O
arabinouridines	70	85	|O
(	86	87	|O
7	87	88	|O
,	88	89	|O
8	90	91	|O
)	91	92	|O
were	93	97	|O
synthesized	98	109	|O
by	110	112	|O
the	113	116	|O
regiospecific	117	130	|O
addition	131	139	|O
of	140	142	|O
halogenocyanamides	143	161	|O
(	162	163	|O
X	163	164	|O
-	164	165	|O
NHCN	165	169	|O
)	169	170	|O
to	171	173	|O
the	174	177	|O
5	178	179	|B-IUPAC
-	179	180	|I-IUPAC
vinyl	180	185	|I-IUPAC
substituent	186	197	|B-MODIFIER
of	198	200	|O
the	201	204	|O
respective	205	215	|O
5	216	217	|B-IUPAC
-	217	218	|I-IUPAC
vinyl	218	223	|I-IUPAC
-	223	224	|I-IUPAC
2'	224	226	|I-IUPAC
-	226	227	|I-IUPAC
deoxyuridine	227	239	|I-IUPAC
(	240	241	|O
2	241	242	|O
)	242	243	|O
and	244	247	|O
2'	248	250	|B-IUPAC
-	250	251	|I-IUPAC
arabinouridine	251	265	|I-IUPAC
(	266	267	|O
3	267	268	|O
)	268	269	|O
.	269	270	|O
Reaction	271	279	|O
of	280	282	|O
2	283	284	|O
with	285	289	|O
sodium	290	296	|O
azide	297	302	|O
,	302	303	|O
ceric	304	309	|O
ammonium	310	318	|O
nitrate	319	326	|O
,	326	327	|O
and	328	331	|O
acetonitrile	332	344	|O
-	344	345	|O
methanol	345	353	|O
or	354	356	|O
water	357	362	|O
afforded	363	371	|O
the	372	375	|O
5	376	377	|B-PARTIUPAC
-	377	378	|I-PARTIUPAC
(	378	379	|I-PARTIUPAC
1	379	380	|I-PARTIUPAC
-	380	381	|I-PARTIUPAC
hydroxy	381	388	|I-PARTIUPAC
-	388	389	|I-PARTIUPAC
2	389	390	|I-PARTIUPAC
-	390	391	|I-PARTIUPAC
azidoethyl	391	401	|I-PARTIUPAC
)	401	402	|I-PARTIUPAC
-	402	403	|I-PARTIUPAC
(	403	404	|O
10	404	406	|O
)	406	407	|O
and	408	411	|O
5	412	413	|B-IUPAC
-	413	414	|I-IUPAC
(	414	415	|I-IUPAC
1	415	416	|I-IUPAC
-	416	417	|I-IUPAC
methoxy	417	424	|I-IUPAC
-	424	425	|I-IUPAC
2	425	426	|I-IUPAC
-	426	427	|I-IUPAC
azidoethyl	427	437	|I-IUPAC
)	437	438	|I-IUPAC
-	438	439	|I-IUPAC
2'	439	441	|I-IUPAC
-	441	442	|I-IUPAC
deoxyuridines	442	455	|I-IUPAC
(	456	457	|O
11	457	459	|O
)	459	460	|O
.	460	461	|O
In	462	464	|O
vitro	465	470	|O
antiviral	471	480	|O
activities	481	491	|O
against	492	499	|O
HSV	500	503	|O
-	503	504	|O
1	504	505	|O
-	505	506	|O
TK	506	508	|O
(	508	509	|O
+	509	510	|O
)	510	511	|O
(	512	513	|O
KOS	513	516	|O
and	517	520	|O
E	521	522	|O
-	522	523	|O
377	523	526	|O
)	526	527	|O
,	527	528	|O
HSV	529	532	|O
-	532	533	|O
1	533	534	|O
-	534	535	|O
TK	535	537	|O
(	537	538	|O
-	538	539	|O
)	539	540	|O
,	540	541	|O
HSV	542	545	|O
-	545	546	|O
2	546	547	|O
,	547	548	|O
VZV	549	552	|O
,	552	553	|O
HCMV	554	558	|O
,	558	559	|O
and	560	563	|O
DHBV	564	568	|O
were	569	573	|O
determined	574	584	|O
.	584	585	|O
Of	586	588	|O
the	589	592	|O
newly	593	598	|O
synthesized	599	610	|O
compounds	611	620	|O
,	620	621	|O
5	622	623	|B-IUPAC
-	623	624	|I-IUPAC
(	624	625	|I-IUPAC
1	625	626	|I-IUPAC
-	626	627	|I-IUPAC
cyanamido	627	636	|I-IUPAC
-	636	637	|I-IUPAC
2	637	638	|I-IUPAC
-	638	639	|I-IUPAC
iodoethyl	639	648	|I-IUPAC
)	648	649	|I-IUPAC
-	649	650	|I-IUPAC
2'	650	652	|I-IUPAC
-	652	653	|I-IUPAC
deoxyuridine	653	665	|I-IUPAC
(	666	667	|O
6	667	668	|O
)	668	669	|O
exhibited	670	679	|O
the	680	683	|O
most	684	688	|O
potent	689	695	|O
anti	696	700	|O
-	700	701	|O
HSV	701	704	|O
-	704	705	|O
1	705	706	|O
activity	707	715	|O
,	715	716	|O
which	717	722	|O
was	723	726	|O
equipotent	727	737	|O
to	738	740	|O
acyclovir	741	750	|O
and	751	754	|O
superior	755	763	|O
to	764	766	|O
5	767	768	|B-IUPAC
-	768	769	|I-IUPAC
ethyl	769	774	|I-IUPAC
-	774	775	|I-IUPAC
2'	775	777	|I-IUPAC
-	777	778	|I-IUPAC
deoxyuridine	778	790	|I-IUPAC
(	791	792	|O
EDU	792	795	|O
)	795	796	|O
.	796	797	|O
In	798	800	|O
addition	801	809	|O
,	809	810	|O
it	811	813	|O
was	814	817	|O
significantly	818	831	|O
inhibitory	832	842	|O
for	843	846	|O
thymidine	847	856	|O
kinase	857	863	|O
deficient	864	873	|O
strain	874	880	|O
of	881	883	|O
HSV	884	887	|O
-	887	888	|O
1	888	889	|O
(	890	891	|O
EC	891	893	|O
(	893	894	|O
50	894	896	|O
)	896	897	|O
=	898	899	|O
2.3-15.3	900	908	|O
microM	909	915	|O
)	915	916	|O
.	916	917	|O
The	918	921	|O
5	922	923	|B-IUPAC
-	923	924	|I-IUPAC
(	924	925	|I-IUPAC
1	925	926	|I-IUPAC
-	926	927	|I-IUPAC
cyanamido	927	936	|I-IUPAC
-	936	937	|I-IUPAC
2	937	938	|I-IUPAC
-	938	939	|I-IUPAC
haloethyl	939	948	|I-IUPAC
)	948	949	|I-IUPAC
-	949	950	|I-IUPAC
2'	950	952	|I-IUPAC
-	952	953	|I-IUPAC
deoxyuridines	953	966	|I-IUPAC
(	967	968	|O
4-6	968	971	|O
)	971	972	|O
all	973	976	|O
were	977	981	|O
approximately	982	995	|O
equipotent	996	1006	|O
against	1007	1014	|O
HSV	1015	1018	|O
-	1018	1019	|O
2	1019	1020	|O
and	1021	1024	|O
were	1025	1029	|O
approximately	1030	1043	|O
1.5	1044	1047	|O
-	1047	1048	|O
and	1049	1052	|O
15	1053	1055	|O
-	1055	1056	|O
fold	1056	1060	|O
less	1061	1065	|O
inhibitory	1066	1076	|O
for	1077	1080	|O
HSV	1081	1084	|O
-	1084	1085	|O
2	1085	1086	|O
than	1087	1091	|O
EDU	1092	1095	|O
and	1096	1099	|O
acyclovir	1100	1109	|O
,	1109	1110	|O
respectively	1111	1123	|O
.	1123	1124	|O
Compounds	1125	1134	|O
4-6	1135	1138	|O
were	1139	1143	|O
all	1144	1147	|O
inactive	1148	1156	|O
against	1157	1164	|O
HCMV	1165	1169	|O
but	1170	1173	|O
exhibited	1174	1183	|O
appreciable	1184	1195	|O
antiviral	1196	1205	|O
activity	1206	1214	|O
against	1215	1222	|O
VZV	1223	1226	|O
.	1226	1227	|O
Their	1228	1233	|O
anti	1234	1238	|O
-	1238	1239	|O
VZV	1239	1242	|O
activity	1243	1251	|O
was	1252	1255	|O
similar	1256	1263	|O
or	1264	1266	|O
higher	1267	1273	|O
to	1274	1276	|O
that	1277	1281	|O
of	1282	1284	|O
EDU	1285	1288	|O
and	1289	1292	|O
approximately	1293	1306	|O
5-12	1307	1311	|O
-	1311	1312	|O
fold	1312	1316	|O
lower	1317	1322	|O
than	1323	1327	|O
that	1328	1332	|O
of	1333	1335	|O
acyclovir	1336	1345	|O
.	1345	1346	|O
The	1347	1350	|O
5	1351	1352	|B-IUPAC
-	1352	1353	|I-IUPAC
(	1353	1354	|I-IUPAC
1	1354	1355	|I-IUPAC
-	1355	1356	|I-IUPAC
cyanamido	1356	1365	|I-IUPAC
-	1365	1366	|I-IUPAC
2	1366	1367	|I-IUPAC
-	1367	1368	|I-IUPAC
haloethyl	1368	1377	|I-IUPAC
)	1377	1378	|I-IUPAC
-	1378	1379	|I-IUPAC
(	1379	1380	|I-IUPAC
7,8	1380	1383	|I-IUPAC
)	1383	1384	|I-IUPAC
analogues	1385	1394	|B-MODIFIER
of	1395	1397	|O
arabinouridine	1398	1412	|O
were	1413	1417	|O
moderately	1418	1428	|O
inhibitory	1429	1439	|O
for	1440	1443	|O
VZV	1444	1447	|O
and	1448	1451	|O
HSV	1452	1455	|O
-	1455	1456	|O
1	1456	1457	|O
(	1458	1459	|O
strain	1459	1465	|O
KOS	1466	1469	|O
)	1469	1470	|O
,	1470	1471	|O
whereas	1472	1479	|O
compounds	1480	1489	|O
10	1490	1492	|O
and	1493	1496	|O
11	1497	1499	|O
were	1500	1504	|O
inactive	1505	1513	|O
against	1514	1521	|O
herpes	1522	1528	|O
viruses	1529	1536	|O
.	1536	1537	|O
Compounds	1538	1547	|O
5	1548	1549	|O
and	1550	1553	|O
6	1554	1555	|O
also	1556	1560	|O
demonstrated	1561	1573	|O
modest	1574	1580	|O
anti	1581	1585	|O
-	1585	1586	|O
hepatitis	1586	1595	|O
B	1596	1597	|O
virus	1598	1603	|O
activity	1604	1612	|O
against	1613	1620	|O
DHBV	1621	1625	|O
(	1626	1627	|O
EC	1627	1629	|O
(	1629	1630	|O
50	1630	1632	|O
)	1632	1633	|O
=	1634	1635	|O
19.9-23.6	1636	1645	|O
microM	1646	1652	|O
)	1652	1653	|O
.	1653	1654	|O
Interestingly	1655	1668	|O
,	1668	1669	|O
the	1670	1673	|O
related	1674	1681	|O
5	1682	1683	|B-IUPAC
-	1683	1684	|I-IUPAC
(	1684	1685	|I-IUPAC
1	1685	1686	|I-IUPAC
-	1686	1687	|I-IUPAC
azido	1687	1692	|I-IUPAC
-	1692	1693	|I-IUPAC
2	1693	1694	|I-IUPAC
-	1694	1695	|I-IUPAC
bromoethyl	1695	1705	|I-IUPAC
)	1705	1706	|I-IUPAC
-	1706	1707	|I-IUPAC
2'	1707	1709	|I-IUPAC
-	1709	1710	|I-IUPAC
deoxyuridine	1710	1722	|I-IUPAC
(	1723	1724	|O
1n	1724	1726	|O
)	1726	1727	|O
analogue	1728	1736	|O
proved	1737	1743	|O
to	1744	1746	|O
be	1747	1749	|O
markedly	1750	1758	|O
inhibitory	1759	1769	|O
to	1770	1772	|O
DHBV	1773	1777	|O
replication	1778	1789	|O
(	1790	1791	|O
EC	1791	1793	|O
(	1793	1794	|O
50	1794	1796	|O
)	1796	1797	|O
=	1798	1799	|O
2.6-6.6	1800	1807	|O
microM	1808	1814	|O
)	1814	1815	|O
.	1815	1816	|O
All	1817	1820	|O
compounds	1821	1830	|O
investigated	1831	1843	|O
exhibited	1844	1853	|O
low	1854	1857	|O
host	1858	1862	|O
cell	1863	1867	|O
toxicity	1868	1876	|O
to	1877	1879	|O
several	1880	1887	|O
stationary	1888	1898	|O
and	1899	1902	|O
proliferating	1903	1916	|O
host	1917	1921	|O
cell	1922	1926	|O
lines	1927	1932	|O
as	1933	1935	|O
well	1936	1940	|O
as	1941	1943	|O
mitogen	1944	1951	|O
-	1951	1952	|O
stimulated	1952	1962	|O
proliferating	1963	1976	|O
human	1977	1982	|O
T	1983	1984	|O
lymphocytes	1985	1996	|O
.	1996	1997	|O

### abstracts335.txt
Four	0	4	|O
isomers	5	12	|O
of	13	15	|O
[	16	17	|B-IUPAC
(	17	18	|I-IUPAC
4	18	19	|I-IUPAC
-	19	20	|I-IUPAC
fluoro	20	26	|I-IUPAC
-	26	27	|I-IUPAC
5	27	28	|I-IUPAC
-	28	29	|I-IUPAC
methyl	29	35	|I-IUPAC
-	35	36	|I-IUPAC
tetrahydrofuran	36	51	|I-IUPAC
-	51	52	|I-IUPAC
2	52	53	|I-IUPAC
-	53	54	|I-IUPAC
yl	54	56	|I-IUPAC
)	56	57	|I-IUPAC
methyl	57	63	|I-IUPAC
]	63	64	|I-IUPAC
trimethylammonium	64	81	|I-IUPAC
iodide	82	88	|I-IUPAC
(	89	90	|I-IUPAC
4	90	91	|I-IUPAC
-	91	92	|I-IUPAC
deoxy	92	97	|I-IUPAC
-	97	98	|I-IUPAC
4	98	99	|I-IUPAC
-	99	100	|I-IUPAC
fluoro	100	106	|I-IUPAC
-	106	107	|I-IUPAC
muscarines	107	117	|I-IUPAC
)	117	118	|I-IUPAC
were	119	123	|O
prepared	124	132	|O
in	133	135	|O
enantiomerically	136	152	|O
and	153	156	|O
diastereomerically	157	175	|O
pure	176	180	|O
form	181	185	|O
from	186	190	|O
(	191	192	|B-IUPAC
S	192	193	|I-IUPAC
)	193	194	|I-IUPAC
-	194	195	|I-IUPAC
(	195	196	|I-IUPAC
-	196	197	|I-IUPAC
)	197	198	|I-IUPAC
-	198	199	|I-IUPAC
methyl	199	205	|I-IUPAC
4	206	207	|I-IUPAC
-	207	208	|I-IUPAC
methylphenyl	208	220	|I-IUPAC
sulfoxide	221	230	|I-IUPAC
,	230	231	|O
ethyl	232	237	|O
fluoroacetate	238	251	|O
,	251	252	|O
and	253	256	|O
allyl	257	262	|O
bromide	263	270	|O
.	270	271	|O
Their	272	277	|O
absolute	278	286	|O
configurations	287	301	|O
were	302	306	|O
assigned	307	315	|O
by	316	318	|O
1H	319	321	|O
NMR	322	325	|O
analyses	326	334	|O
.	334	335	|O
The	336	339	|O
four	340	344	|O
optically	345	354	|O
pure	355	359	|O
compounds	360	369	|O
were	370	374	|O
tested	375	381	|O
in	382	384	|O
vitro	385	390	|O
on	391	393	|O
guinea	394	400	|O
pig	401	404	|O
and	405	408	|O
their	409	414	|O
muscarinic	415	425	|O
potency	426	433	|O
was	434	437	|O
evaluated	438	447	|O
at	448	450	|O
M3	451	453	|O
(	454	455	|O
ileum	455	460	|O
and	461	464	|O
bladder	465	472	|O
)	472	473	|O
and	474	477	|O
M2	478	480	|O
(	481	482	|O
heart	482	487	|O
)	487	488	|O
muscarinic	489	499	|O
receptor	500	508	|O
subtypes	509	517	|O
.	517	518	|O
Compound	519	527	|O
1a	528	530	|O
,	530	531	|O
the	532	535	|O
most	536	540	|O
potent	541	547	|O
isomer	548	554	|O
of	555	557	|O
the	558	561	|O
series	562	568	|O
,	568	569	|O
was	570	573	|O
also	574	578	|O
tested	579	585	|O
in	586	588	|O
vivo	589	593	|O
on	594	596	|O
pithed	597	603	|O
rat	604	607	|O
and	608	611	|O
its	612	615	|O
muscarinic	616	626	|O
activity	627	635	|O
at	636	638	|O
the	639	642	|O
M1	643	645	|O
receptor	646	654	|O
subtype	655	662	|O
was	663	666	|O
compared	667	675	|O
with	676	680	|O
that	681	685	|O
of	686	688	|O
muscarine	689	698	|O
.	698	699	|O
Moreover	700	708	|O
,	708	709	|O
affinity	710	718	|O
and	719	722	|O
relative	723	731	|O
efficacy	732	740	|O
were	741	745	|O
calculated	746	756	|O
in	757	759	|O
vitro	760	765	|O
for	766	769	|O
this	770	774	|O
compound	775	783	|O
at	784	786	|O
M2	787	789	|O
(	790	791	|O
heart	791	796	|O
force	797	802	|O
and	803	806	|O
rate	807	811	|O
)	811	812	|O
and	813	816	|O
M3	817	819	|O
(	820	821	|O
ileum	821	826	|O
and	827	830	|O
bladder	831	838	|O
)	838	839	|O
receptors	840	849	|O
in	850	852	|O
order	853	858	|O
to	859	861	|O
investigate	862	873	|O
muscarinic	874	884	|O
receptor	885	893	|O
heterogeneity	894	907	|O
.	907	908	|O
The	909	912	|O
4	913	914	|B-IUPAC
-	914	915	|I-IUPAC
deoxy	915	920	|I-IUPAC
-	920	921	|I-IUPAC
4	921	922	|I-IUPAC
-	922	923	|I-IUPAC
fluoromuscarines	923	939	|I-IUPAC
display	940	947	|O
a	948	949	|O
similar	950	957	|O
trend	958	963	|O
of	964	966	|O
potency	967	974	|O
as	975	977	|O
the	978	981	|O
corresponding	982	995	|O
muscarines	996	1006	|O
and	1007	1010	|O
compound	1011	1019	|O
1a	1020	1022	|O
shows	1023	1028	|O
differences	1029	1040	|O
in	1041	1043	|O
the	1044	1047	|O
affinity	1048	1056	|O
constants	1057	1066	|O
among	1067	1072	|O
the	1073	1076	|O
studied	1077	1084	|O
tissues	1085	1092	|O
.	1092	1093	|O
Replacement	1094	1105	|O
of	1106	1108	|O
a	1109	1110	|O
hydroxyl	1111	1119	|B-IUPAC
group	1120	1125	|B-MODIFIER
for	1126	1129	|O
a	1130	1131	|O
fluorine	1132	1140	|O
atom	1141	1145	|O
in	1146	1148	|O
the	1149	1152	|O
4	1153	1154	|O
position	1155	1163	|O
of	1164	1166	|O
muscarine	1167	1176	|O
produces	1177	1185	|O
1	1186	1187	|O
order	1188	1193	|O
of	1194	1196	|O
magnitude	1197	1206	|O
increase	1207	1215	|O
in	1216	1218	|O
affinity	1219	1227	|O
for	1228	1231	|O
cardiac	1232	1239	|O
M2	1240	1242	|O
muscarinic	1243	1253	|O
receptors	1254	1263	|O
controlling	1264	1275	|O
rate	1276	1280	|O
,	1280	1281	|O
while	1282	1287	|O
the	1288	1291	|O
affinity	1292	1300	|O
at	1301	1303	|O
cardiac	1304	1311	|O
M2	1312	1314	|O
muscarinic	1315	1325	|O
receptors	1326	1335	|O
controlling	1336	1347	|O
force	1348	1353	|O
is	1354	1356	|O
unchanged	1357	1366	|O
,	1366	1367	|O
opening	1368	1375	|O
the	1376	1379	|O
possibility	1380	1391	|O
of	1392	1394	|O
a	1395	1396	|O
further	1397	1404	|O
classification	1405	1419	|O
of	1420	1422	|O
cardiac	1423	1430	|O
muscarinic	1431	1441	|O
receptors	1442	1451	|O
.	1451	1452	|O

### abstracts4329.txt
N5	0	2	|B-IUPAC
-	2	3	|I-IUPAC
Acetyl	3	9	|I-IUPAC
-	9	10	|I-IUPAC
N5	10	12	|I-IUPAC
-	12	13	|I-IUPAC
hydroxy	13	20	|I-IUPAC
-	20	21	|I-IUPAC
L	21	22	|I-IUPAC
-	22	23	|I-IUPAC
ornithine	23	32	|I-IUPAC
(	33	34	|O
1	34	35	|O
)	35	36	|O
,	36	37	|O
the	38	41	|O
key	42	45	|O
constituent	46	57	|O
of	58	60	|O
several	61	68	|O
microbial	69	78	|O
siderophores	79	91	|O
,	91	92	|O
has	93	96	|O
been	97	101	|O
synthesized	102	113	|O
in	114	116	|O
23%	117	120	|O
yield	121	126	|O
overall	127	134	|O
from	135	139	|O
N	140	141	|O
-	141	142	|O
Cbz	142	145	|O
-	145	146	|O
L	146	147	|O
-	147	148	|O
glutamic	148	156	|O
acid	157	161	|O
1	162	163	|B-IUPAC
-	163	164	|I-IUPAC
tert	164	168	|I-IUPAC
-	168	169	|I-IUPAC
butyl	169	174	|I-IUPAC
ester	175	180	|I-IUPAC
(	181	182	|O
6	182	183	|O
)	183	184	|O
derived	185	192	|O
from	193	197	|O
L	198	199	|B-IUPAC
-	199	200	|I-IUPAC
glutamic	200	208	|I-IUPAC
acid	209	213	|I-IUPAC
.	213	214	|O
Reduction	215	224	|O
of	225	227	|O
6	228	229	|O
to	230	232	|O
7	233	234	|O
and	235	238	|O
treatment	239	248	|O
with	249	253	|O
N	254	255	|B-IUPAC
-	255	256	|I-IUPAC
[	256	257	|I-IUPAC
(	257	258	|I-IUPAC
trichloroethoxy	258	273	|I-IUPAC
)	273	274	|I-IUPAC
carbonyl	274	282	|I-IUPAC
]	282	283	|I-IUPAC
-	283	284	|I-IUPAC
O	284	285	|I-IUPAC
-	285	286	|I-IUPAC
benzylhydroxylamine	286	305	|I-IUPAC
(	306	307	|O
8	307	308	|O
)	308	309	|O
,	309	310	|O
and	311	314	|O
diethyl	315	322	|B-IUPAC
azodicarboxylate	323	339	|I-IUPAC
and	340	343	|O
triphenylphosphine	344	362	|O
followed	363	371	|O
by	372	374	|O
deprotection	375	387	|O
produced	388	396	|O
the	397	400	|O
protected	401	410	|O
N5	411	413	|B-IUPAC
-	413	414	|I-IUPAC
acetyl	414	420	|I-IUPAC
-	420	421	|I-IUPAC
N5	421	423	|I-IUPAC
-	423	424	|I-IUPAC
hydroxy	424	431	|I-IUPAC
-	431	432	|I-IUPAC
L	432	433	|I-IUPAC
-	433	434	|I-IUPAC
ornithine	434	443	|I-IUPAC
derivatives	444	455	|B-MODIFIER
11	456	458	|O
and	459	462	|O
12	463	465	|O
in	466	468	|O
large	469	474	|O
quantities	475	485	|O
(	486	487	|O
10-20	487	492	|O
g	493	494	|O
)	494	495	|O
.	495	496	|O
Following	497	506	|O
alpha	507	512	|B-IUPAC
-	512	513	|I-IUPAC
amino	513	518	|I-IUPAC
and	519	522	|O
alpha	523	528	|B-IUPAC
-	528	529	|I-IUPAC
carboxyl	529	537	|I-IUPAC
deprotections	538	551	|B-MODIFIER
of	552	554	|O
11	555	557	|O
and	558	561	|O
12	562	564	|O
,	564	565	|O
EEDQ	566	570	|O
[	571	572	|O
2	572	573	|B-IUPAC
-	573	574	|I-IUPAC
ethoxy	574	580	|I-IUPAC
-	580	581	|I-IUPAC
N	581	582	|I-IUPAC
-	582	583	|I-IUPAC
(	583	584	|I-IUPAC
ethoxycarbonyl	584	598	|I-IUPAC
)	598	599	|I-IUPAC
-	599	600	|I-IUPAC
1,2	600	603	|I-IUPAC
-	603	604	|I-IUPAC
dihydroquinoline	604	620	|I-IUPAC
]	620	621	|O
mediated	622	630	|O
peptide	631	638	|O
coupling	639	647	|O
and	648	651	|O
final	652	657	|O
deprotection	658	670	|O
provided	671	679	|O
amino	680	685	|O
acid	686	690	|O
1	691	692	|O
and	693	696	|O
six	697	700	|O
albomycin	701	710	|O
-	710	711	|O
like	711	715	|O
peptides	716	724	|O
(	725	726	|O
20	726	728	|O
,	728	729	|O
23	730	732	|O
,	732	733	|O
25	734	736	|O
,	736	737	|O
28	738	740	|O
,	740	741	|O
35	742	744	|O
,	744	745	|O
and	746	749	|O
36	750	752	|O
)	752	753	|O
.	753	754	|O
The	755	758	|O
growth	759	765	|O
-	765	766	|O
promoting	766	775	|O
ability	776	783	|O
of	784	786	|O
each	787	791	|O
was	792	795	|O
evaluated	796	805	|O
with	806	810	|O
the	811	814	|O
siderophore	815	826	|O
biosynthesis	827	839	|O
mutant	840	846	|O
Shigella	847	855	|O
flexneri	856	864	|O
SA240	865	870	|O
(	871	872	|O
SA	872	874	|O
100	875	878	|O
iucD	879	883	|O
:	883	884	|O
Tn5	884	887	|O
)	887	888	|O
.	888	889	|O
These	890	895	|O
results	896	903	|O
indicate	904	912	|O
that	913	917	|O
substantial	918	929	|O
modification	930	942	|O
of	943	945	|O
the	946	949	|O
framework	950	959	|O
of	960	962	|O
peptide	963	970	|O
-	970	971	|O
based	971	976	|O
siderophores	977	989	|O
can	990	993	|O
be	994	996	|O
tolerated	997	1006	|O
by	1007	1009	|O
microbial	1010	1019	|O
iron	1020	1024	|O
-	1024	1025	|O
transport	1025	1034	|O
systems	1035	1042	|O
.	1042	1043	|O

### abstracts4092.txt
4	0	1	|B-IUPAC
-	1	2	|I-IUPAC
(	2	3	|I-IUPAC
Phenylethynyl	3	16	|I-IUPAC
)	16	17	|I-IUPAC
-	17	18	|I-IUPAC
6	18	19	|I-IUPAC
-	19	20	|I-IUPAC
phenyl	20	26	|I-IUPAC
-	26	27	|I-IUPAC
1,4	27	30	|I-IUPAC
-	30	31	|I-IUPAC
dihydropyridine	31	46	|I-IUPAC
derivatives	47	58	|B-MODIFIER
are	59	62	|O
selective	63	72	|O
antagonists	73	84	|O
at	85	87	|O
human	88	93	|O
A3	94	96	|O
adenosine	97	106	|O
receptors	107	116	|O
,	116	117	|O
with	118	122	|O
Ki	123	125	|O
values	126	132	|O
in	133	135	|O
a	136	137	|O
radioligand	138	149	|O
binding	150	157	|O
assay	158	163	|O
vs	164	166	|O
[	167	168	|O
125I	168	172	|O
]	172	173	|O
AB	173	175	|O
-	175	176	|O
MECA	176	180	|O
(	181	182	|O
N6	182	184	|B-IUPAC
-	184	185	|I-IUPAC
(	185	186	|I-IUPAC
4	186	187	|I-IUPAC
-	187	188	|I-IUPAC
amino	188	193	|I-IUPAC
-	193	194	|I-IUPAC
3	194	195	|I-IUPAC
-	195	196	|I-IUPAC
iodobenzyl	196	206	|I-IUPAC
)	206	207	|I-IUPAC
-	207	208	|I-IUPAC
5'	208	210	|I-IUPAC
-	210	211	|I-IUPAC
(	211	212	|I-IUPAC
N	212	213	|I-IUPAC
-	213	214	|I-IUPAC
methylcarbamoyl	214	229	|I-IUPAC
)	229	230	|I-IUPAC
adenosine	230	239	|I-IUPAC
)	239	240	|O
in	241	243	|O
the	244	247	|O
submicromolar	248	261	|O
range	262	267	|O
.	267	268	|O
In	269	271	|O
this	272	276	|O
study	277	282	|O
,	282	283	|O
structure	284	293	|O
-	293	294	|O
activity	294	302	|O
relationships	303	316	|O
at	317	319	|O
various	320	327	|O
positions	328	337	|O
of	338	340	|O
the	341	344	|O
dihydropyridine	345	360	|O
ring	361	365	|O
(	366	367	|O
the	367	370	|O
3	371	372	|B-PARTIUPAC
-	372	373	|I-PARTIUPAC
and	374	377	|O
5	378	379	|B-IUPAC
-	379	380	|I-IUPAC
acyl	380	384	|I-IUPAC
substituents	385	397	|B-MODIFIER
,	397	398	|O
the	399	402	|O
4	403	404	|B-IUPAC
-	404	405	|I-IUPAC
aryl	405	409	|I-IUPAC
substituent	410	421	|B-MODIFIER
,	421	422	|O
and	423	426	|O
1	427	428	|B-IUPAC
-	428	429	|I-IUPAC
methyl	429	435	|I-IUPAC
group	436	441	|B-MODIFIER
)	441	442	|O
were	443	447	|O
probed	448	454	|O
synthetically	455	468	|O
.	468	469	|O
Using	470	475	|O
the	476	479	|O
combined	480	488	|O
protection	489	499	|O
of	500	502	|O
the	503	506	|O
1	507	508	|B-IUPAC
-	508	509	|I-IUPAC
ethoxymethyl	509	521	|I-IUPAC
and	522	525	|O
the	526	529	|O
5	530	531	|B-IUPAC
-	531	532	|I-IUPAC
[	532	533	|I-IUPAC
2	533	534	|I-IUPAC
-	534	535	|I-IUPAC
(	535	536	|I-IUPAC
trimethylsilyl	536	550	|I-IUPAC
)	550	551	|I-IUPAC
ethyl	551	556	|I-IUPAC
]	556	557	|I-IUPAC
ester	558	563	|I-IUPAC
groups	564	570	|B-MODIFIER
,	570	571	|O
a	572	573	|O
free	574	578	|O
carboxylic	579	589	|O
acid	590	594	|O
was	595	598	|O
formed	599	605	|O
at	606	608	|O
the	609	612	|O
5	613	614	|O
-	614	615	|O
position	615	623	|O
allowing	624	632	|O
various	633	640	|O
substitutions	641	654	|O
.	654	655	|O
Selectivity	656	667	|O
of	668	670	|O
the	671	674	|O
new	675	678	|O
analogues	679	688	|O
for	689	692	|O
cloned	693	699	|O
human	700	705	|O
A3	706	708	|O
adenosine	709	718	|O
receptors	719	728	|O
was	729	732	|O
determined	733	743	|O
vs	744	746	|O
radioligand	747	758	|O
binding	759	766	|O
at	767	769	|O
rat	770	773	|O
brain	774	779	|O
A1	780	782	|O
and	783	786	|O
A2A	787	790	|O
receptors	791	800	|O
.	800	801	|O
Structure	802	811	|O
-	811	812	|O
activity	812	820	|O
analysis	821	829	|O
at	830	832	|O
adenosine	833	842	|O
receptors	843	852	|O
indicated	853	862	|O
that	863	867	|O
pyridyl	868	875	|O
,	875	876	|O
furyl	877	882	|O
,	882	883	|O
benzofuryl	884	894	|O
,	894	895	|O
and	896	899	|O
thienyl	900	907	|O
groups	908	914	|O
at	915	917	|O
the	918	921	|O
4	922	923	|O
-	923	924	|O
position	924	932	|O
resulted	933	941	|O
in	942	944	|O
,	944	945	|O
at	946	948	|O
most	949	953	|O
,	953	954	|O
only	955	959	|O
moderate	960	968	|O
selectivity	969	980	|O
for	981	984	|O
A3	985	987	|O
adenosine	988	997	|O
receptors	998	1007	|O
.	1007	1008	|O
Ring	1009	1013	|O
substitution	1014	1026	|O
(	1027	1028	|O
e.g.	1028	1032	|O
,	1032	1033	|O
4	1034	1035	|B-IUPAC
-	1035	1036	|I-IUPAC
nitro	1036	1041	|I-IUPAC
)	1041	1042	|O
of	1043	1045	|O
the	1046	1049	|O
4	1050	1051	|B-IUPAC
-	1051	1052	|I-IUPAC
phenylethylnyl	1052	1066	|I-IUPAC
group	1067	1072	|B-MODIFIER
did	1073	1076	|O
not	1077	1080	|O
provide	1081	1088	|O
enhanced	1089	1097	|O
selectivity	1098	1109	|O
,	1109	1110	|O
as	1111	1113	|O
it	1114	1116	|O
did	1117	1120	|O
for	1121	1124	|O
the	1125	1128	|O
4	1129	1130	|B-IUPAC
-	1130	1131	|I-IUPAC
styryl	1131	1137	|I-IUPAC
-	1137	1138	|O
substituted	1138	1149	|B-MODIFIER
dihydropyridines	1150	1166	|B-IUPAC
.	1166	1167	|O
At	1168	1170	|O
the	1171	1174	|O
3	1175	1176	|O
-	1176	1177	|O
position	1177	1185	|O
of	1186	1188	|O
the	1189	1192	|O
dihydropyridine	1193	1208	|O
ring	1209	1213	|O
,	1213	1214	|O
esters	1215	1221	|O
were	1222	1226	|O
much	1227	1231	|O
more	1232	1236	|O
selective	1237	1246	|O
for	1247	1250	|O
A3	1251	1253	|O
receptors	1254	1263	|O
than	1264	1268	|O
closely	1269	1276	|O
related	1277	1284	|O
thioester	1285	1294	|O
,	1294	1295	|O
amide	1296	1301	|O
,	1301	1302	|O
and	1303	1306	|O
ketone	1307	1313	|O
derivatives	1314	1325	|O
.	1325	1326	|O
A	1327	1328	|O
cyclic	1329	1335	|O
3	1336	1337	|O
-	1337	1338	|O
keto	1338	1342	|O
derivative	1343	1353	|O
was	1354	1357	|O
5	1358	1359	|O
-	1359	1360	|O
fold	1360	1364	|O
more	1365	1369	|O
potent	1370	1376	|O
at	1377	1379	|O
A3	1380	1382	|O
receptors	1383	1392	|O
than	1393	1397	|O
a	1398	1399	|O
related	1400	1407	|O
open	1408	1412	|O
-	1412	1413	|O
ring	1413	1417	|O
analogue	1418	1426	|O
.	1426	1427	|O
At	1428	1430	|O
the	1431	1434	|O
5	1435	1436	|O
-	1436	1437	|O
position	1437	1445	|O
,	1445	1446	|O
a	1447	1448	|O
homologous	1449	1459	|O
series	1460	1466	|O
of	1467	1469	|O
phenylalkyl	1470	1481	|O
esters	1482	1488	|O
and	1489	1492	|O
a	1493	1494	|O
series	1495	1501	|O
of	1502	1504	|O
substituted	1505	1516	|B-MODIFIER
benzyl	1517	1523	|B-IUPAC
esters	1524	1530	|I-IUPAC
were	1531	1535	|O
prepared	1536	1544	|O
and	1545	1548	|O
tested	1549	1555	|O
.	1555	1556	|O
(	1557	1558	|B-PARTIUPAC
Trifluoromethyl	1558	1573	|I-PARTIUPAC
)	1573	1574	|I-PARTIUPAC
-	1574	1575	|I-PARTIUPAC
,	1575	1576	|O
nitro	1577	1582	|B-PARTIUPAC
-	1582	1583	|I-PARTIUPAC
,	1583	1584	|O
and	1585	1588	|O
other	1589	1594	|O
benzyl	1595	1601	|O
esters	1602	1608	|O
substituted	1609	1620	|O
with	1621	1625	|O
electron	1626	1634	|O
-	1634	1635	|O
withdrawing	1635	1646	|O
groups	1647	1653	|O
were	1654	1658	|O
specific	1659	1667	|O
for	1668	1671	|O
A3	1672	1674	|O
receptors	1675	1684	|O
with	1685	1689	|O
nanomolar	1690	1699	|O
Ki	1700	1702	|O
values	1703	1709	|O
and	1710	1713	|O
selectivity	1714	1725	|O
as	1726	1728	|O
high	1729	1733	|O
as	1734	1736	|O
37000	1737	1742	|O
-	1742	1743	|O
fold	1743	1747	|O
.	1747	1748	|O
A	1749	1750	|O
functionalized	1751	1765	|O
congener	1766	1774	|O
bearing	1775	1782	|O
an	1783	1785	|O
[	1786	1787	|B-IUPAC
(	1787	1788	|I-IUPAC
aminoethyl	1788	1798	|I-IUPAC
)	1798	1799	|I-IUPAC
amino	1799	1804	|I-IUPAC
]	1804	1805	|I-IUPAC
carbonyl	1805	1813	|I-IUPAC
group	1814	1819	|B-MODIFIER
was	1820	1823	|O
also	1824	1828	|O
prepared	1829	1837	|O
as	1838	1840	|O
an	1841	1843	|O
intermediate	1844	1856	|O
in	1857	1859	|O
the	1860	1863	|O
synthesis	1864	1873	|O
of	1874	1876	|O
biologically	1877	1889	|O
active	1890	1896	|O
conjugates	1897	1907	|O
.	1907	1908	|O

### abstracts808.txt
The	0	3	|O
synthesis	4	13	|O
and	14	17	|O
biological	18	28	|O
evaluation	29	39	|O
of	40	42	|O
N	43	44	|B-IUPAC
-	44	45	|I-IUPAC
[	45	46	|I-IUPAC
4	46	47	|I-IUPAC
-	47	48	|I-IUPAC
[	48	49	|I-IUPAC
[	49	50	|I-IUPAC
3	50	51	|I-IUPAC
-	51	52	|I-IUPAC
(	52	53	|I-IUPAC
2,4	53	56	|I-IUPAC
-	56	57	|I-IUPAC
diamino	57	64	|I-IUPAC
-	64	65	|I-IUPAC
1,6	65	68	|I-IUPAC
-	68	69	|I-IUPAC
dihydro	69	76	|I-IUPAC
-	76	77	|I-IUPAC
6	77	78	|I-IUPAC
-	78	79	|I-IUPAC
oxo	79	82	|I-IUPAC
-	82	83	|I-IUPAC
5	83	84	|I-IUPAC
-	84	85	|I-IUPAC
pyrimidinyl	85	96	|I-IUPAC
)	96	97	|I-IUPAC
propyl	97	103	|I-IUPAC
]	103	104	|I-IUPAC
amino	104	109	|I-IUPAC
]	109	110	|I-IUPAC
-	110	111	|I-IUPAC
benzoyl	112	119	|I-IUPAC
]	119	120	|I-IUPAC
-	120	121	|I-IUPAC
L	121	122	|I-IUPAC
-	122	123	|I-IUPAC
glutamic	123	131	|I-IUPAC
acid	132	136	|I-IUPAC
(	137	138	|O
1	138	139	|O
)	139	140	|O
(	141	142	|O
5	142	143	|O
-	143	144	|O
DACTHF	144	150	|O
,	150	151	|O
543U76	152	158	|O
)	158	159	|O
,	159	160	|O
an	161	163	|O
acyclic	164	171	|O
analogue	172	180	|O
of	181	183	|O
5,6,7,8	184	191	|B-IUPAC
-	191	192	|I-IUPAC
tetrahydrofolic	192	207	|I-IUPAC
acid	208	212	|I-IUPAC
(	213	214	|O
THFA	214	218	|O
)	218	219	|O
,	219	220	|O
are	221	224	|O
described	225	234	|O
.	234	235	|O
The	236	239	|O
key	240	243	|O
intermediate	244	256	|O
,	256	257	|O
hemiaminal	258	268	|O
8	269	270	|O
,	270	271	|O
was	272	275	|O
prepared	276	284	|O
in	285	287	|O
four	288	292	|O
stages	293	299	|O
from	300	304	|O
3	305	306	|B-IUPAC
-	306	307	|I-IUPAC
chloropropionaldehyde	307	328	|I-IUPAC
diethyl	329	336	|I-IUPAC
acetal	337	343	|I-IUPAC
.	343	344	|O
Reaction	345	353	|O
of	354	356	|O
8	357	358	|O
with	359	363	|O
dimethyl	364	372	|B-IUPAC
N	373	374	|I-IUPAC
-	374	375	|I-IUPAC
(	375	376	|I-IUPAC
4	376	377	|I-IUPAC
-	377	378	|I-IUPAC
aminobenzoyl	378	390	|I-IUPAC
)	390	391	|I-IUPAC
-	391	392	|I-IUPAC
L	392	393	|I-IUPAC
-	393	394	|I-IUPAC
glutamate	394	403	|I-IUPAC
gave	404	408	|O
the	409	412	|O
2,4	413	416	|B-IUPAC
-	416	417	|I-IUPAC
bis	417	420	|I-IUPAC
(	420	421	|I-IUPAC
acetylamino	421	432	|I-IUPAC
)	432	433	|I-IUPAC
derivative	434	444	|B-MODIFIER
11	445	447	|O
,	447	448	|O
which	449	454	|O
was	455	458	|O
hydrolyzed	459	469	|O
with	470	474	|O
1	475	476	|O
N	477	478	|O
sodium	479	485	|O
hydroxide	486	495	|O
to	496	498	|O
give	499	503	|O
1	504	505	|O
;	505	506	|O
the	507	510	|O
glycine	511	518	|O
analogue	519	527	|O
16	528	530	|O
was	531	534	|O
prepared	535	543	|O
in	544	546	|O
a	547	548	|O
similar	549	556	|O
manner	557	563	|O
.	563	564	|O
The	565	568	|O
N	569	570	|O
-	570	571	|O
methyl	571	577	|O
analogue	578	586	|O
2	587	588	|O
and	589	592	|O
N	593	594	|O
-	594	595	|O
formyl	595	601	|O
analogue	602	610	|O
3	611	612	|O
were	613	617	|O
prepared	618	626	|O
from	627	631	|O
11	632	634	|O
and	635	638	|O
1	639	640	|O
,	640	641	|O
respectively	642	654	|O
.	654	655	|O
Compounds	656	665	|O
1-3	666	669	|O
inhibited	670	679	|O
growth	680	686	|O
of	687	689	|O
Detroit	690	697	|O
98	698	700	|O
and	701	704	|O
L	705	706	|O
cells	707	712	|O
in	713	715	|O
cell	716	720	|O
culture	721	728	|O
,	728	729	|O
with	730	734	|O
IC50s	735	740	|O
ranging	741	748	|O
from	749	753	|O
2	754	755	|O
to	756	758	|O
0.018	759	764	|O
microM	765	771	|O
.	771	772	|O
Cell	773	777	|O
culture	778	785	|O
toxicity	786	794	|O
reversal	795	803	|O
studies	804	811	|O
and	812	815	|O
enzyme	816	822	|O
inhibition	823	833	|O
tests	834	839	|O
showed	840	846	|O
that	847	851	|O
1	852	853	|O
was	854	857	|O
cytotoxic	858	867	|O
but	868	871	|O
not	872	875	|O
by	876	878	|O
the	879	882	|O
mechanism	883	892	|O
of	893	895	|O
the	896	899	|O
dihydrofolate	900	913	|O
reductase	914	923	|O
inhibitor	924	933	|O
aminopterin	934	945	|O
.	945	946	|O
Compound	947	955	|O
1	956	957	|O
and	958	961	|O
its	962	965	|O
polyglutamylated	966	982	|O
homologues	983	993	|O
inhibited	994	1003	|O
glycinamide	1004	1015	|O
ribonucleotide	1016	1030	|O
transformylase	1031	1045	|O
(	1046	1047	|O
GAR	1047	1050	|O
-	1050	1051	|O
TFase	1051	1056	|O
)	1056	1057	|O
and	1058	1061	|O
aminoimidazole	1062	1076	|O
ribonucleotide	1077	1091	|O
transformylase	1092	1106	|O
(	1107	1108	|O
AICAR	1108	1113	|O
-	1113	1114	|O
TFase	1114	1119	|O
)	1119	1120	|O
,	1120	1121	|O
the	1122	1125	|O
folate	1126	1132	|O
-	1132	1133	|O
dependent	1133	1142	|O
enzymes	1143	1150	|O
in	1151	1153	|O
de	1154	1156	|O
novo	1157	1161	|O
purine	1162	1168	|O
biosynthesis	1169	1181	|O
;	1181	1182	|O
and	1183	1186	|O
1	1187	1188	|O
was	1189	1192	|O
an	1193	1195	|O
effective	1196	1205	|O
substrate	1206	1215	|O
for	1216	1219	|O
mammalian	1220	1229	|O
folyl	1230	1235	|O
-	1235	1236	|O
polyglutamate	1236	1249	|O
synthetase	1250	1260	|O
.	1260	1261	|O
The	1262	1265	|O
compound	1266	1274	|O
inhibited	1275	1284	|O
(	1285	1286	|O
IC50	1286	1290	|O
=	1291	1292	|O
20	1293	1295	|O
nM	1296	1298	|O
)	1298	1299	|O
the	1300	1303	|O
conversion	1304	1314	|O
of	1315	1317	|O
[	1318	1319	|O
14C	1319	1322	|O
]	1322	1323	|O
formate	1323	1330	|O
to	1331	1333	|O
[	1334	1335	|B-IUPAC
14C	1335	1338	|I-IUPAC
]	1338	1339	|I-IUPAC
-	1339	1340	|I-IUPAC
formylglycinamide	1340	1357	|I-IUPAC
ribonucleotide	1358	1372	|I-IUPAC
by	1373	1375	|O
MOLT	1376	1380	|O
-	1380	1381	|O
4	1381	1382	|O
cells	1383	1388	|O
in	1389	1391	|O
culture	1392	1399	|O
.	1399	1400	|O
These	1401	1406	|O
data	1407	1411	|O
suggest	1412	1419	|O
that	1420	1424	|O
the	1425	1428	|O
site	1429	1433	|O
of	1434	1436	|O
action	1437	1443	|O
of	1444	1446	|O
1	1447	1448	|O
is	1449	1451	|O
inhibition	1452	1462	|O
of	1463	1465	|O
purine	1466	1472	|O
de	1473	1475	|O
novo	1476	1480	|O
biosynthesis	1481	1493	|O
.	1493	1494	|O
Moderate	1495	1503	|O
activity	1504	1512	|O
was	1513	1516	|O
observed	1517	1525	|O
against	1526	1533	|O
P388	1534	1538	|O
leukemia	1539	1547	|O
in	1548	1550	|O
vivo	1551	1555	|O
.	1555	1556	|O

### abstracts4113.txt
Crystal	0	7	|O
structure	8	17	|O
determinations	18	32	|O
have	33	37	|O
been	38	42	|O
carried	43	50	|O
out	51	54	|O
for	55	58	|O
the	59	62	|O
following	63	72	|O
seven	73	78	|O
thyrotropin	79	90	|O
releasing	91	100	|O
hormone	101	108	|O
analogues	109	118	|O
:	118	119	|O
I	120	121	|O
,	121	122	|O
(	123	124	|B-IUPAC
3R	124	126	|I-IUPAC
,	126	127	|I-IUPAC
6R	127	129	|I-IUPAC
)	129	130	|I-IUPAC
-	130	131	|I-IUPAC
6	131	132	|I-IUPAC
-	132	133	|I-IUPAC
methyl	133	139	|I-IUPAC
-	139	140	|I-IUPAC
5	140	141	|I-IUPAC
-	141	142	|I-IUPAC
oxothiomorpholin	142	158	|I-IUPAC
-	158	159	|I-IUPAC
3	159	160	|I-IUPAC
-	160	161	|I-IUPAC
ylcarbonyl	161	171	|I-IUPAC
-	171	172	|I-IUPAC
L	172	173	|I-IUPAC
-	173	174	|I-IUPAC
histidinyl	175	185	|I-IUPAC
-	185	186	|I-IUPAC
L	186	187	|I-IUPAC
-	187	188	|I-IUPAC
proline	188	195	|I-IUPAC
amide	196	201	|I-IUPAC
;	201	202	|O
II	203	205	|O
,	205	206	|O
(	207	208	|B-IUPAC
3R	208	210	|I-IUPAC
,	210	211	|I-IUPAC
6S	211	213	|I-IUPAC
)	213	214	|I-IUPAC
-	214	215	|I-IUPAC
6	215	216	|I-IUPAC
-	216	217	|I-IUPAC
methyl	217	223	|I-IUPAC
-	223	224	|I-IUPAC
5	224	225	|I-IUPAC
-	225	226	|I-IUPAC
oxothiomorpholin	226	242	|I-IUPAC
-	242	243	|I-IUPAC
3	243	244	|I-IUPAC
-	244	245	|I-IUPAC
ylcarbonyl	245	255	|I-IUPAC
-	255	256	|I-IUPAC
L	256	257	|I-IUPAC
-	257	258	|I-IUPAC
histid	258	264	|I-IUPAC
inyl	265	269	|I-IUPAC
-	269	270	|I-IUPAC
L	270	271	|I-IUPAC
-	271	272	|I-IUPAC
proline	272	279	|I-IUPAC
amide	280	285	|I-IUPAC
;	285	286	|O
III	287	290	|O
,	290	291	|O
(	292	293	|B-IUPAC
4R	293	295	|I-IUPAC
)	295	296	|I-IUPAC
-	296	297	|I-IUPAC
2	297	298	|I-IUPAC
-	298	299	|I-IUPAC
oxothiazolidin	299	313	|I-IUPAC
-	313	314	|I-IUPAC
4	314	315	|I-IUPAC
-	315	316	|I-IUPAC
ylcarbonyl	316	326	|I-IUPAC
-	326	327	|I-IUPAC
D	327	328	|I-IUPAC
-	328	329	|I-IUPAC
histidinyl	329	339	|I-IUPAC
-	339	340	|I-IUPAC
L	340	341	|I-IUPAC
-	341	342	|I-IUPAC
prol	342	346	|I-IUPAC
ine	347	350	|I-IUPAC
amide	351	356	|I-IUPAC
;	356	357	|O
IV	358	360	|O
,	360	361	|O
5	362	363	|B-IUPAC
-	363	364	|I-IUPAC
ethylorotyl	364	375	|I-IUPAC
-	375	376	|I-IUPAC
L	376	377	|I-IUPAC
-	377	378	|I-IUPAC
histidinyl	378	388	|I-IUPAC
-	388	389	|I-IUPAC
L	389	390	|I-IUPAC
-	390	391	|I-IUPAC
proline	391	398	|I-IUPAC
amide	399	404	|I-IUPAC
;	404	405	|O
V	406	407	|O
,	407	408	|O
5	409	410	|B-IUPAC
-	410	411	|I-IUPAC
n	411	412	|I-IUPAC
-	412	413	|I-IUPAC
propylorotyl	413	425	|I-IUPAC
-	425	426	|I-IUPAC
L	426	427	|I-IUPAC
-	427	428	|I-IUPAC
histidinyl	428	438	|I-IUPAC
-	438	439	|I-IUPAC
L	439	440	|I-IUPAC
-	440	441	|I-IUPAC
proline	441	448	|I-IUPAC
amide	449	454	|I-IUPAC
;	454	455	|O
VI	456	458	|O
,	458	459	|O
5	460	461	|B-IUPAC
-	461	462	|I-IUPAC
bromoorotyl	462	473	|I-IUPAC
-	473	474	|I-IUPAC
L	474	475	|I-IUPAC
-	475	476	|I-IUPAC
histidinyl	476	486	|I-IUPAC
-	486	487	|I-IUPAC
L	487	488	|I-IUPAC
-	488	489	|I-IUPAC
proline	489	496	|I-IUPAC
amide	497	502	|I-IUPAC
;	502	503	|O
and	504	507	|O
VII	508	511	|O
,	511	512	|O
Phe2	513	517	|O
-	517	518	|O
TRH	518	521	|O
.	521	522	|O
A	523	524	|O
surprising	525	535	|O
degree	536	542	|O
of	543	545	|O
conformational	546	560	|O
similarity	561	571	|O
has	572	575	|O
been	576	580	|O
observed	581	589	|O
for	590	593	|O
the	594	597	|O
peptide	598	605	|O
backbone	606	614	|O
.	614	615	|O
All	616	619	|O
peptide	620	627	|O
bonds	628	633	|O
are	634	637	|O
found	638	643	|O
to	644	646	|O
be	647	649	|O
trans	650	655	|O
.	655	656	|O
A	657	658	|O
composite	659	668	|O
hydrogen	669	677	|O
-	677	678	|O
bonding	678	685	|O
environment	686	697	|O
has	698	701	|O
been	702	706	|O
constructed	707	718	|O
for	719	722	|O
the	723	726	|O
TRH	727	730	|O
analogue	731	739	|O
system	740	746	|O
and	747	750	|O
examined	751	759	|O
for	760	763	|O
its	764	767	|O
inference	768	777	|O
with	778	782	|O
respect	783	790	|O
to	791	793	|O
receptor	794	802	|O
binding	803	810	|O
.	810	811	|O
A	812	813	|O
comparison	814	824	|O
of	825	827	|O
the	828	831	|O
conformations	832	845	|O
of	846	848	|O
these	849	854	|O
analogues	855	864	|O
with	865	869	|O
those	870	875	|O
displayed	876	885	|O
by	886	888	|O
Leu5	889	893	|O
-	893	894	|O
enkephalin	894	904	|O
has	905	908	|O
also	909	913	|O
been	914	918	|O
made	919	923	|O
,	923	924	|O
and	925	928	|O
unexpected	929	939	|O
similarities	940	952	|O
have	953	957	|O
been	958	962	|O
revealed	963	971	|O
.	971	972	|O

### abstracts585.txt
We	0	2	|O
prepared	3	11	|O
six	12	15	|O
pairs	16	21	|O
of	22	24	|O
alpha	25	30	|B-IUPAC
-	30	31	|I-IUPAC
heteroaromatic	31	45	|I-IUPAC
aldoximes	46	55	|I-IUPAC
,	55	56	|O
RC	57	59	|O
(	59	60	|O
=	60	61	|O
NOH	62	65	|O
)	65	66	|O
H	66	67	|O
,	67	68	|O
and	69	72	|O
thiohydroximates	73	89	|O
,	89	90	|O
RC	91	93	|O
(	93	94	|O
=	94	95	|O
NOH	96	99	|O
)	99	100	|O
S	100	101	|O
-	101	102	|O
(	102	103	|O
CH2	103	106	|O
)	106	107	|O
2N	107	109	|O
(	109	110	|O
C2H5	110	114	|O
)	114	115	|O
2	115	116	|O
,	116	117	|O
where	118	123	|O
R	124	125	|O
represents	126	136	|O
various	137	144	|O
oxadiazole	145	155	|O
and	156	159	|O
thiadiazole	160	171	|O
rings	172	177	|O
.	177	178	|O
Each	179	183	|O
compound	184	192	|O
was	193	196	|O
characterized	197	210	|O
with	211	215	|O
respect	216	223	|O
to	224	226	|O
the	227	230	|O
following	231	240	|O
:	240	241	|O
structure	242	251	|O
,	251	252	|O
(	253	254	|B-IUPAC
hydroxyimino	254	266	|I-IUPAC
)	266	267	|I-IUPAC
methyl	267	273	|I-IUPAC
acid	274	278	|I-IUPAC
dissociation	279	291	|O
constant	292	300	|O
,	300	301	|O
nucleophilicity	302	317	|O
toward	318	324	|O
trigonal	325	333	|O
carbon	334	340	|O
and	341	344	|O
tetrahedral	345	356	|O
phosphorus	357	367	|O
,	367	368	|O
octanol	369	376	|O
-	376	377	|O
buffer	377	383	|O
partition	384	393	|O
coefficient	394	405	|O
,	405	406	|O
reversible	407	417	|O
inhibition	418	428	|O
of	429	431	|O
eel	432	435	|O
acetylcholinesterase	436	456	|O
(	457	458	|O
AChE	458	462	|O
)	462	463	|O
,	463	464	|O
and	465	468	|O
in	469	471	|O
vitro	472	477	|O
reactivation	478	490	|O
of	491	493	|O
AChE	494	498	|O
inhibited	499	508	|O
by	509	511	|O
ethyl	512	517	|O
p	518	519	|O
-	519	520	|O
nitrophenyl	520	531	|O
methylphosphonate	532	549	|O
.	549	550	|O
Eight	551	556	|O
of	557	559	|O
the	560	563	|O
twelve	564	570	|O
compounds	571	580	|O
significantly	581	594	|O
reactivate	595	605	|O
ethyl	606	611	|O
methylphosphonyl	612	628	|O
-	628	629	|O
AChE	629	633	|O
,	633	634	|O
but	635	638	|O
inherent	639	647	|O
reactivities	648	660	|O
are	661	664	|O
moderate	665	673	|O
to	674	676	|O
low	677	680	|O
:	680	681	|O
the	682	685	|O
most	686	690	|O
potent	691	697	|O
nonquaternary	698	711	|O
reactivator	712	723	|O
,	723	724	|O
3	725	726	|B-IUPAC
-	726	727	|I-IUPAC
phenyl	727	733	|I-IUPAC
-	733	734	|I-IUPAC
5	734	735	|I-IUPAC
-	735	736	|I-IUPAC
[	736	737	|I-IUPAC
(	737	738	|I-IUPAC
hydroxyimino	738	750	|I-IUPAC
)	750	751	|I-IUPAC
methyl	751	757	|I-IUPAC
]	757	758	|I-IUPAC
-	758	759	|I-IUPAC
1,2,4	759	764	|I-IUPAC
-	764	765	|I-IUPAC
oxadiazole	765	775	|I-IUPAC
,	775	776	|O
is	777	779	|O
17	780	782	|O
times	783	788	|O
less	789	793	|O
reactive	794	802	|O
than	803	807	|O
the	808	811	|O
well	812	816	|O
-	816	817	|O
known	817	822	|O
reactivator	823	834	|O
2	835	836	|B-IUPAC
-	836	837	|I-IUPAC
[	837	838	|I-IUPAC
(	838	839	|I-IUPAC
hydroxyimino	839	851	|I-IUPAC
)	851	852	|I-IUPAC
methyl	852	858	|I-IUPAC
]	858	859	|I-IUPAC
-	859	860	|I-IUPAC
1	860	861	|I-IUPAC
-	861	862	|I-IUPAC
methylpyridinium	862	878	|I-IUPAC
iodide	879	885	|I-IUPAC
(	886	887	|O
2	887	888	|O
-	888	889	|O
PAM	889	892	|O
)	892	893	|O
.	893	894	|O
One	895	898	|O
of	899	901	|O
the	902	905	|O
nonquaternary	906	919	|O
compounds	920	929	|O
,	929	930	|O
3	931	932	|B-IUPAC
-	932	933	|I-IUPAC
phenyl	933	939	|I-IUPAC
-	939	940	|I-IUPAC
1,2,4	940	945	|I-IUPAC
-	945	946	|I-IUPAC
oxadiazole	946	956	|I-IUPAC
-	956	957	|I-IUPAC
5	957	958	|I-IUPAC
-	958	959	|I-IUPAC
thiohydroximic	959	973	|I-IUPAC
acid	974	978	|I-IUPAC
2	979	980	|I-IUPAC
-	980	981	|I-IUPAC
(	981	982	|I-IUPAC
diethylamino	982	994	|I-IUPAC
)	994	995	|I-IUPAC
ethyl	995	1000	|I-IUPAC
S	1001	1002	|I-IUPAC
-	1002	1003	|I-IUPAC
ester	1003	1008	|I-IUPAC
,	1008	1009	|O
is	1010	1012	|O
a	1013	1014	|O
powerful	1015	1023	|O
reversible	1024	1034	|O
inhibitor	1035	1044	|O
of	1045	1047	|O
AChE	1048	1052	|O
(	1053	1054	|O
I50	1054	1057	|O
=	1058	1059	|O
7.5	1060	1063	|O
microM	1064	1070	|O
)	1070	1071	|O
.	1071	1072	|O
The	1073	1076	|O
observed	1077	1085	|O
relationships	1086	1099	|O
between	1100	1107	|O
nonquaternary	1108	1121	|O
compound	1122	1130	|O
structure	1131	1140	|O
,	1140	1141	|O
reactivation	1142	1154	|O
potency	1155	1162	|O
,	1162	1163	|O
and	1164	1167	|O
anti	1168	1172	|O
-	1172	1173	|O
AChE	1173	1177	|O
activity	1178	1186	|O
reveal	1187	1193	|O
important	1194	1203	|O
molecular	1204	1213	|O
requirements	1214	1226	|O
for	1227	1230	|O
high	1231	1235	|O
reactivity	1236	1246	|O
toward	1247	1253	|O
phosphonylated	1254	1268	|O
AChE	1269	1273	|O
.	1273	1274	|O

### abstracts1563.txt
The	0	3	|O
structural	4	14	|O
basis	15	20	|O
of	21	23	|O
protein	24	31	|O
kinase	32	38	|O
C	39	40	|O
(	41	42	|O
PKC	42	45	|O
)	45	46	|O
binding	47	54	|O
to	55	57	|O
several	58	65	|O
classes	66	73	|O
of	74	76	|O
high	77	81	|O
-	81	82	|O
affinity	82	90	|O
ligands	91	98	|O
has	99	102	|O
been	103	107	|O
investigated	108	120	|O
through	121	128	|O
complementary	129	142	|O
computational	143	156	|O
and	157	160	|O
experimental	161	173	|O
methods	174	181	|O
.	181	182	|O
Employing	183	192	|O
a	193	194	|O
recently	195	203	|O
developed	204	213	|O
q	214	215	|O
-	215	216	|O
jumping	216	223	|O
molecular	224	233	|O
dynamics	234	242	|O
(	243	244	|O
MD	244	246	|O
)	246	247	|O
simulation	248	258	|O
method	259	265	|O
,	265	266	|O
which	267	272	|O
allows	273	279	|O
us	280	282	|O
to	283	285	|O
consider	286	294	|O
the	295	298	|O
flexibility	299	310	|O
of	311	313	|O
both	314	318	|O
the	319	322	|O
ligands	323	330	|O
and	331	334	|O
the	335	338	|O
receptor	339	347	|O
in	348	350	|O
docking	351	358	|O
studies	359	366	|O
,	366	367	|O
we	368	370	|O
predicted	371	380	|O
the	381	384	|O
binding	385	392	|O
models	393	399	|O
of	400	402	|O
phorbol	403	410	|B-IUPAC
-	410	411	|I-IUPAC
13	411	413	|I-IUPAC
-	413	414	|I-IUPAC
acetate	414	421	|I-IUPAC
,	421	422	|O
phorbol	423	430	|B-IUPAC
-	430	431	|I-IUPAC
12,13	431	436	|I-IUPAC
-	436	437	|I-IUPAC
dibutyrate	437	447	|I-IUPAC
(	448	449	|O
PDBu	449	453	|O
)	453	454	|O
,	454	455	|O
indolactam	456	466	|O
V	467	468	|O
(	469	470	|O
ILV	470	473	|O
)	473	474	|O
,	474	475	|O
ingenol	476	483	|B-IUPAC
-	483	484	|I-IUPAC
3	484	485	|I-IUPAC
-	485	486	|I-IUPAC
benzoate	486	494	|I-IUPAC
,	494	495	|O
and	496	499	|O
thymeleatoxin	500	513	|O
to	514	516	|O
PKC	517	520	|O
.	520	521	|O
The	522	525	|O
"	526	527	|O
predicted	527	536	|O
"	536	537	|O
binding	538	545	|O
model	546	551	|O
for	552	555	|O
phorbol	556	563	|B-IUPAC
-	563	564	|I-IUPAC
13	564	566	|I-IUPAC
-	566	567	|I-IUPAC
acetate	567	574	|I-IUPAC
is	575	577	|O
virtually	578	587	|O
identical	588	597	|O
to	598	600	|O
the	601	604	|O
experimentally	605	619	|O
determined	620	630	|O
binding	631	638	|O
model	639	644	|O
for	645	648	|O
this	649	653	|O
ligand	654	660	|O
.	660	661	|O
The	662	665	|O
predicted	666	675	|O
binding	676	683	|O
model	684	689	|O
for	690	693	|O
PDBU	694	698	|O
is	699	701	|O
the	702	705	|O
same	706	710	|O
as	711	713	|O
that	714	718	|O
for	719	722	|O
phorbol	723	730	|B-IUPAC
-	730	731	|I-IUPAC
13	731	733	|I-IUPAC
-	733	734	|I-IUPAC
acetate	734	741	|I-IUPAC
in	742	744	|O
terms	745	750	|O
of	751	753	|O
the	754	757	|O
hydrogen	758	766	|O
-	766	767	|O
bonding	767	774	|O
network	775	782	|O
and	783	786	|O
hydrophobic	787	798	|O
contacts	799	807	|O
.	807	808	|O
The	809	812	|O
predicted	813	822	|O
binding	823	830	|O
model	831	836	|O
for	837	840	|O
ILV	841	844	|O
is	845	847	|O
the	848	851	|O
same	852	856	|O
as	857	859	|O
that	860	864	|O
obtained	865	873	|O
in	874	876	|O
a	877	878	|O
previous	879	887	|O
docking	888	895	|O
study	896	901	|O
using	902	907	|O
a	908	909	|O
Monte	910	915	|O
Carlo	916	921	|O
method	922	928	|O
and	929	932	|O
is	933	935	|O
consistent	936	946	|O
with	947	951	|O
the	952	955	|O
structure	956	965	|O
-	965	966	|O
activity	966	974	|O
relationships	975	988	|O
for	989	992	|O
this	993	997	|O
class	998	1003	|O
of	1004	1006	|O
ligands	1007	1014	|O
.	1014	1015	|O
Together	1016	1024	|O
with	1025	1029	|O
the	1030	1033	|O
X	1034	1035	|O
-	1035	1036	|O
ray	1036	1039	|O
structure	1040	1049	|O
of	1050	1052	|O
phorbol	1053	1060	|B-IUPAC
-	1060	1061	|I-IUPAC
13	1061	1063	|I-IUPAC
-	1063	1064	|I-IUPAC
acetate	1064	1071	|I-IUPAC
in	1072	1074	|O
complex	1075	1082	|O
with	1083	1087	|O
PKCdelta	1088	1096	|O
C1b	1097	1100	|O
,	1100	1101	|O
the	1102	1105	|O
predicted	1106	1115	|O
binding	1116	1123	|O
models	1124	1130	|O
of	1131	1133	|O
PDBu	1134	1138	|O
,	1138	1139	|O
ILV	1140	1143	|O
,	1143	1144	|O
ingenol	1145	1152	|B-IUPAC
-	1152	1153	|I-IUPAC
3	1153	1154	|I-IUPAC
-	1154	1155	|I-IUPAC
benzoate	1155	1163	|I-IUPAC
,	1163	1164	|O
and	1165	1168	|O
thymeleatoxin	1169	1182	|O
in	1183	1185	|O
complex	1186	1193	|O
with	1194	1198	|O
PKC	1199	1202	|O
showed	1203	1209	|O
that	1210	1214	|O
the	1215	1218	|O
binding	1219	1226	|O
of	1227	1229	|O
these	1230	1235	|O
ligands	1236	1243	|O
to	1244	1246	|O
PKC	1247	1250	|O
is	1251	1253	|O
governed	1254	1262	|O
by	1263	1265	|O
a	1266	1267	|O
combination	1268	1279	|O
of	1280	1282	|O
several	1283	1290	|O
highly	1291	1297	|O
specific	1298	1306	|O
and	1307	1310	|O
optimal	1311	1318	|O
hydrogen	1319	1327	|O
bonds	1328	1333	|O
and	1334	1337	|O
hydrophobic	1338	1349	|O
contacts	1350	1358	|O
.	1358	1359	|O
However	1360	1367	|O
,	1367	1368	|O
the	1369	1372	|O
hydrogen	1373	1381	|O
-	1381	1382	|O
bonding	1382	1389	|O
network	1390	1397	|O
for	1398	1401	|O
each	1402	1406	|O
class	1407	1412	|O
of	1413	1415	|O
ligand	1416	1422	|O
is	1423	1425	|O
somewhat	1426	1434	|O
different	1435	1444	|O
and	1445	1448	|O
the	1449	1452	|O
number	1453	1459	|O
of	1460	1462	|O
hydrogen	1463	1471	|O
bonds	1472	1477	|O
formed	1478	1484	|O
between	1485	1492	|O
PKC	1493	1496	|O
and	1497	1500	|O
these	1501	1506	|O
ligands	1507	1514	|O
has	1515	1518	|O
no	1519	1521	|O
correlation	1522	1533	|O
with	1534	1538	|O
their	1539	1544	|O
binding	1545	1552	|O
affinities	1553	1563	|O
.	1563	1564	|O
To	1565	1567	|O
provide	1568	1575	|O
a	1576	1577	|O
direct	1578	1584	|O
and	1585	1588	|O
quantitative	1589	1601	|O
assessment	1602	1612	|O
of	1613	1615	|O
the	1616	1619	|O
contributions	1620	1633	|O
of	1634	1636	|O
several	1637	1644	|O
conserved	1645	1654	|O
residues	1655	1663	|O
around	1664	1670	|O
the	1671	1674	|O
binding	1675	1682	|O
site	1683	1687	|O
to	1688	1690	|O
PKC	1691	1694	|O
-	1694	1695	|O
ligand	1695	1701	|O
binding	1702	1709	|O
,	1709	1710	|O
we	1711	1713	|O
have	1714	1718	|O
made	1719	1723	|O
11	1724	1726	|O
mutations	1727	1736	|O
and	1737	1740	|O
measured	1741	1749	|O
the	1750	1753	|O
binding	1754	1761	|O
affinities	1762	1772	|O
of	1773	1775	|O
the	1776	1779	|O
high	1780	1784	|O
-	1784	1785	|O
affinity	1785	1793	|O
PKC	1794	1797	|O
ligands	1798	1805	|O
to	1806	1808	|O
these	1809	1814	|O
mutants	1815	1822	|O
.	1822	1823	|O
The	1824	1827	|O
results	1828	1835	|O
obtained	1836	1844	|O
through	1845	1852	|O
site	1853	1857	|O
-	1857	1858	|O
directed	1858	1866	|O
mutagenic	1867	1876	|O
analysis	1877	1885	|O
support	1886	1893	|O
our	1894	1897	|O
predicted	1898	1907	|O
binding	1908	1915	|O
models	1916	1922	|O
for	1923	1926	|O
these	1927	1932	|O
ligands	1933	1940	|O
and	1941	1944	|O
provide	1945	1952	|O
new	1953	1956	|O
insights	1957	1965	|O
into	1966	1970	|O
PKC	1971	1974	|O
-	1974	1975	|O
ligand	1975	1981	|O
binding	1982	1989	|O
.	1989	1990	|O
Although	1991	1999	|O
all	2000	2003	|O
the	2004	2007	|O
ligands	2008	2015	|O
have	2016	2020	|O
high	2021	2025	|O
affinity	2026	2034	|O
for	2035	2038	|O
the	2039	2042	|O
wild	2043	2047	|O
-	2047	2048	|O
type	2048	2052	|O
PKCdelta	2053	2061	|O
C1b	2062	2065	|O
,	2065	2066	|O
our	2067	2070	|O
site	2071	2075	|O
-	2075	2076	|O
directed	2076	2084	|O
mutagenic	2085	2094	|O
results	2095	2102	|O
showed	2103	2109	|O
that	2110	2114	|O
ILV	2115	2118	|O
is	2119	2121	|O
the	2122	2125	|O
ligand	2126	2132	|O
most	2133	2137	|O
sensitive	2138	2147	|O
to	2148	2150	|O
structural	2151	2161	|O
perturbations	2162	2175	|O
of	2176	2178	|O
the	2179	2182	|O
binding	2183	2190	|O
site	2191	2195	|O
while	2196	2201	|O
ingenol	2202	2209	|B-IUPAC
-	2209	2210	|I-IUPAC
3	2210	2211	|I-IUPAC
-	2211	2212	|I-IUPAC
benzoate	2212	2220	|I-IUPAC
is	2221	2223	|O
the	2224	2227	|O
least	2228	2233	|O
sensitive	2234	2243	|O
among	2244	2249	|O
the	2250	2253	|O
four	2254	2258	|O
classes	2259	2266	|O
of	2267	2269	|O
ligands	2270	2277	|O
examined	2278	2286	|O
here	2287	2291	|O
.	2291	2292	|O
Finally	2293	2300	|O
,	2300	2301	|O
we	2302	2304	|O
have	2305	2309	|O
employed	2310	2318	|O
conventional	2319	2331	|O
MD	2332	2334	|O
simulations	2335	2346	|O
to	2347	2349	|O
investigate	2350	2361	|O
the	2362	2365	|O
structural	2366	2376	|O
perturbations	2377	2390	|O
caused	2391	2397	|O
by	2398	2400	|O
each	2401	2405	|O
mutation	2406	2414	|O
to	2415	2417	|O
further	2418	2425	|O
examine	2426	2433	|O
the	2434	2437	|O
role	2438	2442	|O
played	2443	2449	|O
by	2450	2452	|O
each	2453	2457	|O
individual	2458	2468	|O
residue	2469	2476	|O
in	2477	2479	|O
PKC	2480	2483	|O
-	2483	2484	|O
ligand	2484	2490	|O
binding	2491	2498	|O
.	2498	2499	|O
MD	2500	2502	|O
simulations	2503	2514	|O
revealed	2515	2523	|O
that	2524	2528	|O
several	2529	2536	|O
mutations	2537	2546	|O
,	2546	2547	|O
including	2548	2557	|O
Pro11	2558	2563	|O
-	2564	2565	|O
-	2565	2566	|O
&	2566	2567	|O
gt	2567	2569	|O
;	2569	2570	|O
Gly	2571	2574	|O
,	2574	2575	|O
Leu21	2576	2581	|O
-	2582	2583	|O
-	2583	2584	|O
&	2584	2585	|O
gt	2585	2587	|O
;	2587	2588	|O
Gly	2589	2592	|O
,	2592	2593	|O
Leu24	2594	2599	|O
-	2600	2601	|O
-	2601	2602	|O
&	2602	2603	|O
gt	2603	2605	|O
;	2605	2606	|O
Gly	2607	2610	|O
,	2610	2611	|O
and	2612	2615	|O
Gln27	2616	2621	|O
-	2622	2623	|O
-	2623	2624	|O
&	2624	2625	|O
gt	2625	2627	|O
;	2627	2628	|O
Gly	2629	2632	|O
,	2632	2633	|O
cause	2634	2639	|O
a	2640	2641	|O
rather	2642	2648	|O
large	2649	2654	|O
conformational	2655	2669	|O
alteration	2670	2680	|O
to	2681	2683	|O
the	2684	2687	|O
PKC	2688	2691	|O
binding	2692	2699	|O
site	2700	2704	|O
and	2705	2708	|O
,	2708	2709	|O
in	2710	2712	|O
some	2713	2717	|O
cases	2718	2723	|O
,	2723	2724	|O
to	2725	2727	|O
the	2728	2731	|O
overall	2732	2739	|O
structure	2740	2749	|O
of	2750	2752	|O
the	2753	2756	|O
protein	2757	2764	|O
.	2764	2765	|O
The	2766	2769	|O
complete	2770	2778	|O
abolishment	2779	2790	|O
or	2791	2793	|O
the	2794	2797	|O
significant	2798	2809	|O
reduction	2810	2819	|O
in	2820	2822	|O
PKC	2823	2826	|O
-	2826	2827	|O
ligand	2827	2833	|O
binding	2834	2841	|O
observed	2842	2850	|O
for	2851	2854	|O
these	2855	2860	|O
mutants	2861	2868	|O
thus	2869	2873	|O
reflects	2874	2882	|O
the	2883	2886	|O
loss	2887	2891	|O
of	2892	2894	|O
certain	2895	2902	|O
direct	2903	2909	|O
contacts	2910	2918	|O
between	2919	2926	|O
the	2927	2930	|O
side	2931	2935	|O
chain	2936	2941	|O
of	2942	2944	|O
the	2945	2948	|O
mutated	2949	2956	|O
residue	2957	2964	|O
in	2965	2967	|O
PKC	2968	2971	|O
and	2972	2975	|O
ligands	2976	2983	|O
as	2984	2986	|O
well	2987	2991	|O
as	2992	2994	|O
the	2995	2998	|O
large	2999	3004	|O
conformational	3005	3019	|O
alteration	3020	3030	|O
to	3031	3033	|O
the	3034	3037	|O
binding	3038	3045	|O
site	3046	3050	|O
caused	3051	3057	|O
by	3058	3060	|O
the	3061	3064	|O
mutation	3065	3073	|O
.	3073	3074	|O

### abstracts169.txt
Five	0	4	|O
new	5	8	|O
analogues	9	18	|O
(	19	20	|O
1c	20	22	|O
-	22	23	|O
g	23	24	|O
)	24	25	|O
of	26	28	|O
the	29	32	|O
antifolate	33	43	|O
N10	44	47	|B-IUPAC
-	47	48	|I-IUPAC
propargyl	48	57	|I-IUPAC
-	57	58	|I-IUPAC
5,8	58	61	|I-IUPAC
-	61	62	|I-IUPAC
dideazafolic	62	74	|I-IUPAC
acid	75	79	|I-IUPAC
(	80	81	|O
1a	81	83	|O
)	83	84	|O
are	85	88	|O
described	89	98	|O
in	99	101	|O
which	102	107	|O
the	108	111	|O
benzoyl	112	119	|B-IUPAC
-	119	120	|I-IUPAC
L	120	121	|I-IUPAC
-	121	122	|I-IUPAC
glutamate	122	131	|I-IUPAC
moiety	132	138	|B-MODIFIER
was	139	142	|O
replaced	143	151	|O
by	152	154	|O
benzoic	155	162	|O
acid	163	167	|O
(	168	169	|O
desglutamyl	169	180	|B-IUPAC
-	180	181	|I-IUPAC
N10	181	184	|I-IUPAC
-	184	185	|I-IUPAC
propargyl	185	194	|I-IUPAC
-	194	195	|I-IUPAC
5,8	195	198	|I-IUPAC
-	198	199	|I-IUPAC
dideazafolic	199	211	|I-IUPAC
acid	212	216	|I-IUPAC
)	216	217	|O
,	217	218	|O
benzoyl	219	226	|B-IUPAC
-	226	227	|I-IUPAC
L	227	228	|I-IUPAC
-	228	229	|I-IUPAC
aspartate	229	238	|I-IUPAC
,	238	239	|O
4	240	241	|B-IUPAC
-	241	242	|I-IUPAC
phenylbutyrate	242	256	|I-IUPAC
,	256	257	|O
benzoylglycine	258	272	|O
,	272	273	|O
and	274	277	|O
benzoyl	278	285	|B-IUPAC
-	285	286	|I-IUPAC
L	286	287	|I-IUPAC
-	287	288	|I-IUPAC
alanine	288	295	|I-IUPAC
.	295	296	|O
The	297	300	|O
esters	301	307	|O
of	308	310	|O
the	311	314	|O
appropriate	315	326	|O
4	327	328	|B-IUPAC
-	328	329	|I-IUPAC
aminophenyl	329	340	|I-IUPAC
(	341	342	|O
benzoyl	342	349	|B-PARTIUPAC
)	349	350	|O
starting	351	359	|O
materials	360	369	|O
were	370	374	|O
sequentially	375	387	|O
alkylated	388	397	|O
upon	398	402	|O
nitrogen	403	411	|O
,	411	412	|O
first	413	418	|O
with	419	423	|O
a	424	425	|O
propargyl	426	435	|O
halide	436	442	|O
and	443	446	|O
then	447	451	|O
with	452	456	|O
2	457	458	|B-IUPAC
-	458	459	|I-IUPAC
amino	459	464	|I-IUPAC
-	464	465	|I-IUPAC
6	465	466	|I-IUPAC
-	466	467	|I-IUPAC
(	467	468	|I-IUPAC
bromomethyl	468	479	|I-IUPAC
)	479	480	|I-IUPAC
-	480	481	|I-IUPAC
4	481	482	|I-IUPAC
-	482	483	|I-IUPAC
hydroxyquinazoline	483	501	|I-IUPAC
hydrobromide	502	514	|I-IUPAC
.	514	515	|O
Saponification	516	530	|O
of	531	533	|O
the	534	537	|O
antifolate	538	548	|O
esters	549	555	|O
so	556	558	|O
produced	559	567	|O
gave	568	572	|O
the	573	576	|O
desired	577	584	|O
analogues	585	594	|O
.	594	595	|O
The	596	599	|O
new	600	603	|O
derivatives	604	615	|O
(	616	617	|O
1c	617	619	|O
-	619	620	|O
g	620	621	|O
)	621	622	|O
and	623	626	|O
also	627	631	|O
the	632	635	|O
known	636	641	|O
diethyl	642	649	|O
ester	650	655	|O
of	656	658	|O
1a	659	661	|O
(	662	663	|O
1b	663	665	|O
)	665	666	|O
were	667	671	|O
tested	672	678	|O
for	679	682	|O
their	683	688	|O
inhibition	689	699	|O
of	700	702	|O
purified	703	711	|O
L1210	712	717	|O
thymidylate	718	729	|O
synthase	730	738	|O
(	739	740	|O
TS	740	742	|O
)	742	743	|O
and	744	747	|O
for	748	751	|O
their	752	757	|O
inhibition	758	768	|O
of	769	771	|O
the	772	775	|O
growth	776	782	|O
of	783	785	|O
L1210	786	791	|O
cells	792	797	|O
in	798	800	|O
culture	801	808	|O
.	808	809	|O
The	810	813	|O
TS	814	816	|O
inhibition	817	827	|O
of	828	830	|O
the	831	834	|O
analogues	835	844	|O
1b	845	847	|O
-	847	848	|O
g	848	849	|O
was	850	853	|O
estimated	854	863	|O
by	864	866	|O
calculating	867	878	|O
the	879	882	|O
inverse	883	890	|O
relative	891	899	|O
potency	900	907	|O
,	907	908	|O
defined	909	916	|O
as	917	919	|O
the	920	923	|O
ratio	924	929	|O
IC50	930	934	|O
(	934	935	|O
compound	935	943	|O
)	943	944	|O
/	944	945	|O
IC50	945	949	|O
(	949	950	|O
1a	950	952	|O
)	952	953	|O
.	953	954	|O
The	955	958	|O
results	959	966	|O
obtained	967	975	|O
were	976	980	|O
as	981	983	|O
follows	984	991	|O
:	991	992	|O
greater	993	1000	|O
than	1001	1005	|O
62	1006	1008	|O
,	1008	1009	|O
84	1010	1012	|O
,	1012	1013	|O
9	1014	1015	|O
,	1015	1016	|O
333	1017	1020	|O
,	1020	1021	|O
21	1022	1024	|O
,	1024	1025	|O
and	1026	1029	|O
5	1030	1031	|O
,	1031	1032	|O
respectively	1033	1045	|O
.	1045	1046	|O
All	1047	1050	|O
were	1051	1055	|O
thus	1056	1060	|O
less	1061	1065	|O
inhibitory	1066	1076	|O
than	1077	1081	|O
1a	1082	1084	|O
.	1084	1085	|O
None	1086	1090	|O
of	1091	1093	|O
the	1094	1097	|O
compounds	1098	1107	|O
improved	1108	1116	|O
upon	1117	1121	|O
1a	1122	1124	|O
in	1125	1127	|O
inhibiting	1128	1138	|O
the	1139	1142	|O
growth	1143	1149	|O
of	1150	1152	|O
L1210	1153	1158	|O
cells	1159	1164	|O
in	1165	1167	|O
culture	1168	1175	|O
.	1175	1176	|O

### abstracts1961.txt
The	0	3	|O
syntheses	4	13	|O
of	14	16	|O
N	17	18	|B-IUPAC
,	18	19	|I-IUPAC
N	19	20	|I-IUPAC
-	20	21	|I-IUPAC
dimethyl	21	29	|I-IUPAC
-	29	30	|I-IUPAC
6,7,8,9	30	37	|I-IUPAC
-	37	38	|I-IUPAC
tetrahydro	38	48	|I-IUPAC
-	48	49	|I-IUPAC
3H	49	51	|I-IUPAC
,	51	52	|I-IUPAC
10H	52	55	|I-IUPAC
-	55	56	|I-IUPAC
pyrrolo	56	63	|I-IUPAC
[	63	64	|I-IUPAC
3,2	64	67	|I-IUPAC
-	67	68	|I-IUPAC
a	68	69	|I-IUPAC
]	69	70	|I-IUPAC
carbazol	71	79	|I-IUPAC
-	79	80	|I-IUPAC
7	80	81	|I-IUPAC
-	81	82	|I-IUPAC
amine	82	87	|I-IUPAC
(	88	89	|O
8	89	90	|O
)	90	91	|O
,	91	92	|O
N	93	94	|B-IUPAC
,	94	95	|I-IUPAC
N	95	96	|I-IUPAC
-	96	97	|I-IUPAC
dimethyl	97	105	|I-IUPAC
-	105	106	|I-IUPAC
7,8,9,10	106	114	|I-IUPAC
-	114	115	|I-IUPAC
tetrahydro	115	125	|I-IUPAC
-	125	126	|I-IUPAC
11H	126	129	|I-IUPAC
-	129	130	|I-IUPAC
pyrido	130	136	|I-IUPAC
[	136	137	|I-IUPAC
3,2	137	140	|I-IUPAC
-	140	141	|I-IUPAC
a	141	142	|I-IUPAC
]	142	143	|I-IUPAC
carbazol	144	152	|I-IUPAC
-	152	153	|I-IUPAC
8	153	154	|I-IUPAC
-	154	155	|I-IUPAC
amine	155	160	|I-IUPAC
(	161	162	|O
9a	162	164	|O
)	164	165	|O
,	165	166	|O
and	167	170	|O
the	171	174	|O
N	175	176	|B-IUPAC
,	176	177	|I-IUPAC
N	177	178	|I-IUPAC
,	178	179	|I-IUPAC
11	179	181	|I-IUPAC
-	181	182	|I-IUPAC
trimethyl	182	191	|I-IUPAC
analogue	192	200	|B-MODIFIER
(	201	202	|O
9b	202	204	|O
)	204	205	|O
are	206	209	|O
described	210	219	|O
.	219	220	|O
The	221	224	|O
in	225	227	|O
vitro	228	233	|O
inotropic	234	243	|O
activity	244	252	|O
of	253	255	|O
these	256	261	|O
compounds	262	271	|O
,	271	272	|O
as	273	275	|O
well	276	280	|O
as	281	283	|O
the	284	287	|O
known	288	293	|O
cardiotonics	294	306	|O
amrinone	307	315	|O
and	316	319	|O
7	320	321	|B-IUPAC
-	321	322	|I-IUPAC
hydroxycyclindole	322	339	|I-IUPAC
(	340	341	|O
7	341	342	|O
)	342	343	|O
,	343	344	|O
was	345	348	|O
investigated	349	361	|O
.	361	362	|O
Compound	363	371	|O
8	372	373	|O
,	373	374	|O
a	375	376	|O
pyrrolo	377	384	|O
analogue	385	393	|O
of	394	396	|O
7	397	398	|O
,	398	399	|O
was	400	403	|O
devoid	404	410	|O
of	411	413	|O
inotropic	414	423	|O
activity	424	432	|O
,	432	433	|O
while	434	439	|O
the	440	443	|O
pyrido	444	450	|B-IUPAC
analogues	451	460	|B-MODIFIER
9	461	462	|O
were	463	467	|O
equiactive	468	478	|O
to	479	481	|O
7	482	483	|O
and	484	487	|O
amrinone	488	496	|O
.	496	497	|O
These	498	503	|O
results	504	511	|O
suggest	512	519	|O
that	520	524	|O
the	525	528	|O
hydroxyl	529	537	|O
group	538	543	|O
of	544	546	|O
7	547	548	|O
functions	549	558	|O
as	559	561	|O
an	562	564	|O
H	565	566	|O
-	566	567	|O
bond	567	571	|O
acceptor	572	580	|O
,	580	581	|O
rather	582	588	|O
than	589	593	|O
a	594	595	|O
donor	596	601	|O
,	601	602	|O
and	603	606	|O
that	607	611	|O
on	612	614	|O
interaction	615	626	|O
of	627	629	|O
7	630	631	|O
,	631	632	|O
and	633	636	|O
the	637	640	|O
pyrido	641	647	|O
analogues	648	657	|O
9	658	659	|O
,	659	660	|O
with	661	665	|O
a	666	667	|O
common	668	674	|O
receptor	675	683	|O
,	683	684	|O
an	685	687	|O
orbital	688	695	|O
occupied	696	704	|O
by	705	707	|O
one	708	711	|O
of	712	714	|O
the	715	718	|O
oxygen	719	725	|O
lone	726	730	|O
pair	731	735	|O
electrons	736	745	|O
of	746	748	|O
7	749	750	|O
must	751	755	|O
assume	756	762	|O
the	763	766	|O
same	767	771	|O
orientation	772	783	|O
as	784	786	|O
the	787	790	|O
orbital	791	798	|O
occupied	799	807	|O
by	808	810	|O
the	811	814	|O
pyridine	815	823	|O
nitrogen	824	832	|O
lone	833	837	|O
pair	838	842	|O
.	842	843	|O

### abstracts1583.txt
Study	0	5	|O
of	6	8	|O
P2	9	11	|O
-	11	12	|O
purinoceptor	12	24	|O
subtypes	25	33	|O
has	34	37	|O
been	38	42	|O
difficult	43	52	|O
due	53	56	|O
to	57	59	|O
the	60	63	|O
lack	64	68	|O
of	69	71	|O
potent	72	78	|O
and	79	82	|O
selective	83	92	|O
ligands	93	100	|O
.	100	101	|O
With	102	106	|O
the	107	110	|O
goal	111	115	|O
of	116	118	|O
developing	119	129	|O
high	130	134	|O
affinity	135	143	|O
P2	144	146	|O
-	146	147	|O
purinoceptor	147	159	|O
-	159	160	|O
selective	160	169	|O
agonist	170	177	|O
,	177	178	|O
we	179	181	|O
have	182	186	|O
synthesized	187	198	|O
a	199	200	|O
series	201	207	|O
of	208	210	|O
analogues	211	220	|O
of	221	223	|O
adenine	224	231	|O
nucleotides	232	243	|O
modified	244	252	|O
on	253	255	|O
the	256	259	|O
purine	260	266	|O
ring	267	271	|O
as	272	274	|O
chain	275	280	|O
-	280	281	|O
extended	281	289	|O
2	290	291	|O
-	291	292	|O
thioethers	292	302	|O
or	303	305	|O
as	306	308	|O
N6	309	311	|B-IUPAC
-	311	312	|I-IUPAC
methyl	312	318	|I-IUPAC
-	318	319	|O
substituted	319	330	|B-MODIFIER
compounds	331	340	|O
.	340	341	|O
Chemical	342	350	|O
functionality	351	364	|O
incorporated	365	377	|O
in	378	380	|O
the	381	384	|O
thioether	385	394	|O
moiety	395	401	|O
included	402	410	|O
cyanoalkyl	411	421	|O
,	421	422	|O
nitroaromatic	423	436	|O
,	436	437	|O
amino	438	443	|B-IUPAC
,	443	444	|O
thiol	445	450	|B-IUPAC
,	450	451	|O
cycloalkyl	452	462	|O
,	462	463	|O
n	464	465	|O
-	465	466	|O
alkyl	466	471	|O
,	471	472	|O
and	473	476	|O
olefinic	477	485	|O
groups	486	492	|O
.	492	493	|O
Apparent	494	502	|O
affinity	503	511	|O
of	512	514	|O
the	515	518	|O
compounds	519	528	|O
for	529	532	|O
P2Y	533	536	|O
-	536	537	|O
purinoceptors	537	550	|O
was	551	554	|O
established	555	566	|O
by	567	569	|O
measurement	570	581	|O
of	582	584	|O
P2Y	585	588	|O
-	588	589	|O
purinoceptor	589	601	|O
-	601	602	|O
promoted	602	610	|O
phospholipase	611	624	|O
C	625	626	|O
activity	627	635	|O
in	636	638	|O
turkey	639	645	|O
erythrocyte	646	657	|O
membranes	658	667	|O
and	668	671	|O
relaxation	672	682	|O
of	683	685	|O
carbachol	686	695	|O
-	695	696	|O
contracted	696	706	|O
smooth	707	713	|O
muscle	714	720	|O
in	721	723	|O
three	724	729	|O
different	730	739	|O
preparations	740	752	|O
(	753	754	|O
guinea	754	760	|O
pig	761	764	|O
taenia	765	771	|O
coli	772	776	|O
,	776	777	|O
rabbit	778	784	|O
aorta	785	790	|O
,	790	791	|O
and	792	795	|O
rabbit	796	802	|O
mesenteric	803	813	|O
artery	814	820	|O
)	820	821	|O
.	821	822	|O
Activity	823	831	|O
at	832	834	|O
P2X	835	838	|O
-	838	839	|O
purinoceptors	839	852	|O
was	853	856	|O
established	857	868	|O
by	869	871	|O
measurement	872	883	|O
of	884	886	|O
contraction	887	898	|O
of	899	901	|O
rabbit	902	908	|O
saphenous	909	918	|O
artery	919	925	|O
and	926	929	|O
of	930	932	|O
the	933	936	|O
guinea	937	943	|O
pig	944	947	|O
vas	948	951	|O
deferens	952	960	|O
and	961	964	|O
urinary	965	972	|O
bladder	973	980	|O
.	980	981	|O
All	982	985	|O
11	986	988	|O
of	989	991	|O
the	992	995	|O
2	996	997	|O
-	997	998	|O
thioethers	998	1008	|O
of	1009	1011	|O
ATP	1012	1015	|O
stimulated	1016	1026	|O
the	1027	1030	|O
production	1031	1041	|O
of	1042	1044	|O
inositol	1045	1053	|O
phosphates	1054	1064	|O
with	1065	1069	|O
K0	1070	1072	|O
.5	1072	1074	|O
values	1075	1081	|O
of	1082	1084	|O
1.5-770	1085	1092	|O
nM	1093	1095	|O
,	1095	1096	|O
with	1097	1101	|O
an	1102	1104	|O
(	1105	1106	|O
aminophenyl	1106	1117	|O
)	1117	1118	|O
ethyl	1118	1123	|O
derivative	1124	1134	|O
being	1135	1140	|O
most	1141	1145	|O
potent	1146	1152	|O
.	1152	1153	|O
Two	1154	1157	|O
adenosine	1158	1167	|O
diphosphate	1168	1179	|O
analogues	1180	1189	|O
were	1190	1194	|O
equipotent	1195	1205	|O
to	1206	1208	|O
the	1209	1212	|O
corresponding	1213	1226	|O
ATP	1227	1230	|O
analogues	1231	1240	|O
.	1240	1241	|O
Adenosine	1242	1251	|O
monophosphate	1252	1265	|O
analogues	1266	1275	|O
were	1276	1280	|O
full	1281	1285	|O
agonists	1286	1294	|O
,	1294	1295	|O
although	1296	1304	|O
generally	1305	1314	|O
4	1315	1316	|O
orders	1317	1323	|O
of	1324	1326	|O
magnitude	1327	1336	|O
less	1337	1341	|O
potent	1342	1348	|O
.	1348	1349	|O
ATP	1350	1353	|O
2	1354	1355	|O
-	1355	1356	|O
thioethers	1356	1366	|O
displayed	1367	1376	|O
pD2	1377	1380	|O
values	1381	1387	|O
in	1388	1390	|O
the	1391	1394	|O
range	1395	1400	|O
of	1401	1403	|O
6-8	1404	1407	|O
in	1408	1410	|O
smooth	1411	1417	|O
muscle	1418	1424	|O
assay	1425	1430	|O
systems	1431	1438	|O
for	1439	1442	|O
activity	1443	1451	|O
at	1452	1454	|O
P2Y	1455	1458	|O
-	1458	1459	|O
receptors	1459	1468	|O
.	1468	1469	|O
There	1470	1475	|O
was	1476	1479	|O
a	1480	1481	|O
significant	1482	1493	|O
correlation	1494	1505	|O
for	1506	1509	|O
the	1510	1513	|O
2	1514	1515	|O
-	1515	1516	|O
thioether	1516	1525	|O
compounds	1526	1535	|O
between	1536	1543	|O
the	1544	1547	|O
pK0	1548	1551	|O
.5	1551	1553	|O
values	1554	1560	|O
for	1561	1564	|O
inositol	1565	1573	|O
phosphate	1574	1583	|O
production	1584	1594	|O
and	1595	1598	|O
the	1599	1602	|O
pD2	1603	1606	|O
values	1607	1613	|O
for	1614	1617	|O
relaxation	1618	1628	|O
mediated	1629	1637	|O
via	1638	1641	|O
the	1642	1645	|O
P2Y	1646	1649	|O
-	1649	1650	|O
purinoceptors	1650	1663	|O
in	1664	1666	|O
the	1667	1670	|O
guinea	1671	1677	|O
pig	1678	1681	|O
taenia	1682	1688	|O
coli	1689	1693	|O
,	1693	1694	|O
but	1695	1698	|O
not	1699	1702	|O
for	1703	1706	|O
the	1707	1710	|O
vascular	1711	1719	|O
P2Y	1720	1723	|O
-	1723	1724	|O
receptors	1724	1733	|O
or	1734	1736	|O
for	1737	1740	|O
the	1741	1744	|O
P2X	1745	1748	|O
-	1748	1749	|O
receptors	1749	1758	|O
.	1758	1759	|O
At	1760	1762	|O
P2X	1763	1766	|O
-	1766	1767	|O
receptors	1767	1776	|O
,	1776	1777	|O
no	1778	1780	|O
activity	1781	1789	|O
was	1790	1793	|O
observed	1794	1802	|O
in	1803	1805	|O
the	1806	1809	|O
rabbit	1810	1816	|O
saphenous	1817	1826	|O
artery	1827	1833	|O
,	1833	1834	|O
but	1835	1838	|O
variable	1839	1847	|O
degrees	1848	1855	|O
of	1856	1858	|O
activity	1859	1867	|O
were	1868	1872	|O
observed	1873	1881	|O
in	1882	1884	|O
the	1885	1888	|O
guinea	1889	1895	|O
pig	1896	1899	|O
vas	1900	1903	|O
deferens	1904	1912	|O
and	1913	1916	|O
bladder	1917	1924	|O
depending	1925	1934	|O
on	1935	1937	|O
distal	1938	1944	|O
substituents	1945	1957	|O
of	1958	1960	|O
the	1961	1964	|O
thioether	1965	1974	|O
moiety	1975	1981	|O
.	1981	1982	|O
N6	1983	1985	|O
-	1985	1986	|O
Methyl	1986	1992	|O
-	1992	1993	|O
ATP	1993	1996	|O
was	1997	2000	|O
inactive	2001	2009	|O
at	2010	2012	|O
P2X	2013	2016	|O
-	2016	2017	|O
receptors	2017	2026	|O
,	2026	2027	|O
and	2028	2031	|O
approximately	2032	2045	|O
equipotent	2046	2056	|O
to	2057	2059	|O
ATP	2060	2063	|O
at	2064	2066	|O
taenia	2067	2073	|O
coil	2074	2078	|O
P2Y	2079	2082	|O
-	2082	2083	|O
receptors	2083	2092	|O
.	2092	2093	|O
This	2094	2098	|O
suggested	2099	2108	|O
that	2109	2113	|O
hybrid	2114	2120	|O
N6	2121	2123	|B-IUPAC
-	2123	2124	|I-IUPAC
methyl	2124	2130	|I-IUPAC
and	2131	2134	|O
2	2135	2136	|B-IUPAC
-	2136	2137	|I-IUPAC
thioether	2137	2146	|I-IUPAC
ATP	2147	2150	|I-IUPAC
derivatives	2151	2162	|B-MODIFIER
might	2163	2168	|O
be	2169	2171	|O
potent	2172	2178	|O
and	2179	2182	|O
selective	2183	2192	|O
for	2193	2196	|O
certain	2197	2204	|O
P2Y	2205	2208	|O
-	2208	2209	|O
receptors	2209	2218	|O
,	2218	2219	|O
as	2220	2222	|O
was	2223	2226	|O
shown	2227	2232	|O
for	2233	2236	|O
one	2237	2240	|O
such	2241	2245	|O
derivative	2246	2256	|O
,	2256	2257	|O
N6	2258	2260	|B-IUPAC
-	2260	2261	|I-IUPAC
methyl	2261	2267	|I-IUPAC
-	2267	2268	|I-IUPAC
2	2268	2269	|I-IUPAC
-	2269	2270	|I-IUPAC
(	2270	2271	|I-IUPAC
5	2271	2272	|I-IUPAC
-	2272	2273	|I-IUPAC
hexenylthio	2273	2284	|I-IUPAC
)	2284	2285	|I-IUPAC
-	2285	2286	|I-IUPAC
ATP	2286	2289	|I-IUPAC
.	2289	2290	|O

### abstracts613.txt
1,3,5	0	5	|B-MODIFIER
-	5	6	|I-MODIFIER
Substituted	6	17	|I-MODIFIER
indoles	18	25	|O
and	26	29	|O
indazoles	30	39	|O
have	40	44	|O
been	45	49	|O
studied	50	57	|O
as	58	60	|O
receptor	61	69	|O
antagonists	70	81	|O
of	82	84	|O
the	85	88	|O
peptidoleukotrienes	89	108	|O
.	108	109	|O
The	110	113	|O
best	114	118	|O
of	119	121	|O
these	122	127	|O
compounds	128	137	|O
generally	138	147	|O
had	148	151	|O
a	152	153	|O
methyl	154	160	|O
group	161	166	|O
at	167	169	|O
the	170	173	|O
N1	174	176	|O
position	177	185	|O
,	185	186	|O
a	187	188	|O
[	189	190	|B-IUPAC
(	190	191	|I-IUPAC
cyclopentyloxy	191	205	|I-IUPAC
)	205	206	|I-IUPAC
carbonyl	206	214	|I-IUPAC
]	214	215	|I-IUPAC
amino	215	220	|I-IUPAC
or	221	223	|O
2	224	225	|B-IUPAC
-	225	226	|I-IUPAC
cyclopentylacetamido	226	246	|I-IUPAC
or	247	249	|O
N'	250	252	|B-IUPAC
-	252	253	|I-IUPAC
cyclopentylureido	253	270	|I-IUPAC
group	271	276	|B-MODIFIER
at	277	279	|O
the	280	283	|O
C	284	285	|O
-	285	286	|O
5	286	287	|O
position	288	296	|O
,	296	297	|O
and	298	301	|O
an	302	304	|O
arylsulfonyl	305	317	|O
amide	318	323	|O
group	324	329	|O
as	330	332	|O
part	333	337	|O
of	338	340	|O
the	341	344	|O
acidic	345	351	|O
chain	352	357	|O
at	358	360	|O
the	361	364	|O
C	365	366	|O
-	366	367	|O
3	367	368	|O
position	369	377	|O
of	378	380	|O
the	381	384	|O
ring	385	389	|O
.	389	390	|O
Such	391	395	|O
compounds	396	405	|O
had	406	409	|O
in	410	412	|O
vitro	413	418	|O
dissociation	419	431	|O
constants	432	441	|O
(	442	443	|O
KB	443	445	|O
)	445	446	|O
in	447	449	|O
the	450	453	|O
range	454	459	|O
10	460	462	|O
(	462	463	|O
-	463	464	|O
9	464	465	|O
)	465	466	|O
-	467	468	|O
10	469	471	|O
(	471	472	|O
-	472	473	|O
11	473	475	|O
)	475	476	|O
M	477	478	|O
on	479	481	|O
guinea	482	488	|O
pig	489	492	|O
trachea	493	500	|O
against	501	508	|O
LTE4	509	513	|O
as	514	516	|O
agonist	517	524	|O
and	525	528	|O
inhibition	529	539	|O
constants	540	549	|O
(	550	551	|O
Ki	551	553	|O
)	553	554	|O
less	555	559	|O
than	560	564	|O
or	565	567	|O
equal	568	573	|O
to	574	576	|O
10	577	579	|O
(	579	580	|O
-	580	581	|O
9	581	582	|O
)	582	583	|O
M	584	585	|O
on	586	588	|O
guinea	589	595	|O
pig	596	599	|O
parenchymal	600	611	|O
membranes	612	621	|O
against	622	629	|O
[	630	631	|O
3H	631	633	|O
]	633	634	|O
LTD4	634	638	|O
.	638	639	|O
A	640	641	|O
number	642	648	|O
of	649	651	|O
compounds	652	661	|O
were	662	666	|O
orally	667	673	|O
effective	674	683	|O
at	684	686	|O
doses	687	692	|O
less	693	697	|O
than	698	702	|O
or	703	705	|O
equal	706	711	|O
to	712	714	|O
1	715	716	|O
mg	717	719	|O
/	719	720	|O
kg	720	722	|O
in	723	725	|O
blocking	726	734	|O
LTD4	735	739	|O
-	739	740	|O
induced	740	747	|O
"	748	749	|O
dyspnea	749	756	|O
"	756	757	|O
in	758	760	|O
guinea	761	767	|O
pigs	768	772	|O
.	772	773	|O
Compound	774	782	|O
45	783	785	|O
[	786	787	|B-IUPAC
N	787	788	|I-IUPAC
-	788	789	|I-IUPAC
[	789	790	|I-IUPAC
4	790	791	|I-IUPAC
-	791	792	|I-IUPAC
[	792	793	|I-IUPAC
[	793	794	|I-IUPAC
5	794	795	|I-IUPAC
-	795	796	|I-IUPAC
[	796	797	|I-IUPAC
[	797	798	|I-IUPAC
(	798	799	|I-IUPAC
cyclopentyloxy	799	813	|I-IUPAC
)	813	814	|I-IUPAC
carbonyl	814	822	|I-IUPAC
]	822	823	|I-IUPAC
-	823	824	|I-IUPAC
amino	824	829	|I-IUPAC
]	829	830	|I-IUPAC
-	830	831	|I-IUPAC
1	831	832	|I-IUPAC
-	832	833	|I-IUPAC
methylindol	833	844	|I-IUPAC
-	844	845	|I-IUPAC
3	845	846	|I-IUPAC
-	846	847	|I-IUPAC
yl	848	850	|I-IUPAC
]	850	851	|I-IUPAC
methyl	851	857	|I-IUPAC
]	857	858	|I-IUPAC
-	858	859	|I-IUPAC
3	859	860	|I-IUPAC
-	860	861	|I-IUPAC
methoxybenzoyl	861	875	|I-IUPAC
]	875	876	|I-IUPAC
-	876	877	|I-IUPAC
2	877	878	|I-IUPAC
-	878	879	|I-IUPAC
methylbenzenesulfonamide	879	903	|I-IUPAC
,	903	904	|O
ICI	905	908	|O
204,219	909	916	|O
;	916	917	|O
pKB	918	921	|O
=	922	923	|O
9.67	924	928	|O
+	929	930	|O
/	930	931	|O
-	931	932	|O
0.13	933	937	|O
,	937	938	|O
Ki	939	941	|O
=	942	943	|O
0.3	944	947	|O
+	948	949	|O
/	949	950	|O
-	950	951	|O
0.03	952	956	|O
nM	957	959	|O
,	959	960	|O
po	961	963	|O
ED50	964	968	|O
=	969	970	|O
0.3	971	974	|O
mg	975	977	|O
/	977	978	|O
kg	978	980	|O
]	980	981	|O
is	982	984	|O
currently	985	994	|O
under	995	1000	|O
clinical	1001	1009	|O
investigation	1010	1023	|O
for	1024	1027	|O
asthma	1028	1034	|O
.	1034	1035	|O
In	1036	1038	|O
the	1039	1042	|O
indole	1043	1049	|O
series	1050	1056	|O
,	1056	1057	|O
certain	1058	1065	|O
alkylsulfonyl	1066	1079	|O
amides	1080	1086	|O
possessing	1087	1097	|O
a	1098	1099	|O
3	1100	1101	|B-IUPAC
-	1101	1102	|I-IUPAC
cyanobenzyl	1102	1113	|I-IUPAC
substituent	1114	1125	|B-MODIFIER
at	1126	1128	|O
the	1129	1132	|O
N	1133	1134	|O
-	1134	1135	|O
1	1135	1136	|O
position	1137	1145	|O
(	1146	1147	|O
60	1147	1149	|O
,	1149	1150	|O
61	1151	1153	|O
)	1153	1154	|O
were	1155	1159	|O
produced	1160	1168	|O
that	1169	1173	|O
had	1174	1177	|O
KB	1178	1180	|O
less	1181	1185	|O
than	1186	1190	|O
or	1191	1193	|O
equal	1194	1199	|O
to	1200	1202	|O
10	1203	1205	|O
(	1205	1206	|O
-	1206	1207	|O
9	1207	1208	|O
)	1208	1209	|O
M	1210	1211	|O
on	1212	1214	|O
guinea	1215	1221	|O
pig	1222	1225	|O
trachea	1226	1233	|O
.	1233	1234	|O

### abstracts4306.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
substituted	12	23	|B-MODIFIER
dibenzo	24	31	|B-IUPAC
[	31	32	|I-IUPAC
1,4	32	35	|I-IUPAC
]	35	36	|I-IUPAC
dioxin	36	42	|I-IUPAC
-	42	43	|I-IUPAC
1	43	44	|I-IUPAC
-	44	45	|I-IUPAC
carboxamides	45	57	|I-IUPAC
has	58	61	|O
been	62	66	|O
synthesized	67	78	|O
and	79	82	|O
evaluated	83	92	|O
for	93	96	|O
in	97	99	|O
vitro	100	105	|O
and	106	109	|O
in	110	112	|O
vivo	113	117	|O
antitumor	118	127	|O
activity	128	136	|O
.	136	137	|O
The	138	141	|O
required	142	150	|O
substituted	151	162	|B-MODIFIER
dibenzo	163	170	|B-IUPAC
[	170	171	|I-IUPAC
1,4	171	174	|I-IUPAC
]	174	175	|I-IUPAC
dioxin	175	181	|I-IUPAC
-	181	182	|I-IUPAC
1	182	183	|I-IUPAC
-	183	184	|I-IUPAC
carboxylic	184	194	|I-IUPAC
acids	195	200	|I-IUPAC
were	201	205	|O
prepared	206	214	|O
by	215	217	|O
a	218	219	|O
variety	220	227	|O
of	228	230	|O
methods	231	238	|O
.	238	239	|O
No	240	242	|O
regiospecific	243	256	|O
syntheses	257	266	|O
were	267	271	|O
available	272	281	|O
for	282	285	|O
many	286	290	|O
of	291	293	|O
these	294	299	|O
,	299	300	|O
and	301	304	|O
separation	305	315	|O
of	316	318	|O
the	319	322	|O
mixtures	323	331	|O
of	332	334	|O
regioisomers	335	347	|O
obtained	348	356	|O
was	357	360	|O
sometimes	361	370	|O
difficult	371	380	|O
.	380	381	|O
The	382	385	|O
dibenzo	386	393	|B-IUPAC
[	393	394	|I-IUPAC
1,4	394	397	|I-IUPAC
]	397	398	|I-IUPAC
dioxin	398	404	|I-IUPAC
-	404	405	|I-IUPAC
1	405	406	|I-IUPAC
-	406	407	|I-IUPAC
carboxamides	407	419	|I-IUPAC
are	420	423	|O
active	424	430	|O
against	431	438	|O
wild	439	443	|O
-	443	444	|O
type	444	448	|O
P388	449	453	|O
leukemia	454	462	|O
in	463	465	|O
vitro	466	471	|O
and	472	475	|O
in	476	478	|O
vivo	479	483	|O
,	483	484	|O
with	485	489	|O
structure	490	499	|O
-	499	500	|O
activity	500	508	|O
relationships	509	522	|O
resembling	523	533	|O
those	534	539	|O
for	540	543	|O
both	544	548	|O
the	549	552	|O
acridine	553	561	|B-IUPAC
-	561	562	|I-IUPAC
4	562	563	|I-IUPAC
-	563	564	|I-IUPAC
carboxamide	564	575	|I-IUPAC
and	576	579	|O
phenazine	580	589	|B-IUPAC
-	589	590	|I-IUPAC
1	590	591	|I-IUPAC
-	591	592	|I-IUPAC
carboxamide	592	603	|I-IUPAC
series	604	610	|B-MODIFIER
of	611	613	|O
DNA	614	617	|O
-	617	618	|O
intercalating	618	631	|O
antitumor	632	641	|O
agents	642	648	|O
.	648	649	|O
In	650	652	|O
all	653	656	|O
three	657	662	|O
series	663	669	|O
,	669	670	|O
substituents	671	683	|O
placed	684	690	|O
peri	691	695	|O
to	696	698	|O
the	699	702	|O
carboxamide	703	714	|O
sidechain	715	724	|O
(	725	726	|O
the	726	729	|O
5	730	731	|O
-	731	732	|O
position	732	740	|O
in	741	743	|O
the	744	747	|O
acridines	748	757	|O
,	757	758	|O
and	759	762	|O
the	763	766	|O
9	767	768	|O
-	768	769	|O
position	769	777	|O
in	778	780	|O
the	781	784	|O
phenazines	785	795	|O
and	796	799	|O
dibenzo	800	807	|B-IUPAC
[	807	808	|I-IUPAC
1,4	808	811	|I-IUPAC
]	811	812	|I-IUPAC
dioxins	812	819	|I-IUPAC
)	819	820	|O
enhance	821	828	|O
activity	829	837	|O
and	838	841	|O
potency	842	849	|O
.	849	850	|O
The	851	854	|O
9	855	856	|B-IUPAC
-	856	857	|I-IUPAC
chlorodibenzodioxin	857	876	|I-IUPAC
-	876	877	|I-IUPAC
1	877	878	|I-IUPAC
-	878	879	|I-IUPAC
carboxamide	879	890	|I-IUPAC
was	891	894	|O
also	895	899	|O
curative	900	908	|O
against	909	916	|O
the	917	920	|O
remotely	921	929	|O
sited	930	935	|O
Lewis	936	941	|O
lung	942	946	|O
carcinoma	947	956	|O
.	956	957	|O
Several	958	965	|O
of	966	968	|O
the	969	972	|O
compounds	973	982	|O
showed	983	989	|O
much	990	994	|O
lower	995	1000	|O
levels	1001	1007	|O
of	1008	1010	|O
cross	1011	1016	|O
-	1016	1017	|O
resistance	1017	1027	|O
to	1028	1030	|O
the	1031	1034	|O
P388	1035	1039	|O
/	1039	1040	|O
AMSA	1040	1044	|O
line	1045	1049	|O
than	1050	1054	|O
classical	1055	1064	|O
DNA	1065	1068	|O
-	1068	1069	|O
intercalating	1069	1082	|O
agents	1083	1089	|O
,	1089	1090	|O
which	1091	1096	|O
suggests	1097	1105	|O
that	1106	1110	|O
their	1111	1116	|O
primary	1117	1124	|O
mechanism	1125	1134	|O
of	1135	1137	|O
action	1138	1144	|O
may	1145	1148	|O
not	1149	1152	|O
be	1153	1155	|O
via	1156	1159	|O
interference	1160	1172	|O
with	1173	1177	|O
topoisomerase	1178	1191	|O
II	1192	1194	|O
alpha	1195	1200	|O
.	1200	1201	|O
This	1202	1206	|O
is	1207	1209	|O
of	1210	1212	|O
interest	1213	1221	|O
with	1222	1226	|O
regard	1227	1233	|O
to	1234	1236	|O
the	1237	1240	|O
development	1241	1252	|O
of	1253	1255	|O
drugs	1256	1261	|O
to	1262	1264	|O
combat	1265	1271	|O
resistance	1272	1282	|O
mechanisms	1283	1293	|O
which	1294	1299	|O
arise	1300	1305	|O
by	1306	1308	|O
the	1309	1312	|O
expression	1313	1323	|O
of	1324	1326	|O
the	1327	1330	|O
topo	1331	1335	|O
II	1336	1338	|O
beta	1339	1343	|O
isozyme	1344	1351	|O
.	1351	1352	|O

### abstracts16.txt
Octreotide	0	10	|O
,	10	11	|O
an	12	14	|O
analogue	15	23	|O
of	24	26	|O
the	27	30	|O
hormone	31	38	|O
somatostatin	39	51	|O
,	51	52	|O
has	53	56	|O
applications	57	69	|O
as	70	72	|O
a	73	74	|O
therapeutic	75	86	|O
and	87	90	|O
imaging	91	98	|O
agent	99	104	|O
for	105	108	|O
somatostatin	109	121	|O
-	121	122	|O
positive	122	130	|O
tumors	131	137	|O
.	137	138	|O
We	139	141	|O
have	142	146	|O
developed	147	156	|O
a	157	158	|O
generally	159	168	|O
applicable	169	179	|O
,	179	180	|O
convenient	181	191	|O
stepwise	192	200	|O
solid	201	206	|O
-	206	207	|O
phase	207	212	|O
synthetic	213	222	|O
protocol	223	231	|O
for	232	235	|O
octreotide	236	246	|O
(	247	248	|O
D	248	249	|O
-	249	250	|O
Phe	250	253	|O
-	253	254	|O
Cys	254	257	|O
-	257	258	|O
Phe	258	261	|O
-	261	262	|O
D	262	263	|O
-	263	264	|O
Trp	264	267	|O
-	267	268	|O
Lys	268	271	|O
-	271	272	|O
Thr	272	275	|O
-	275	276	|O
Cys	276	279	|O
-	279	280	|O
threoninol	280	290	|O
)	290	291	|O
.	291	292	|O
[	293	294	|O
Cys	294	297	|O
(	297	298	|O
Acm	298	301	|O
)	301	302	|O
2	302	303	|O
,	303	304	|O
D	304	305	|O
-	305	306	|O
Trp	306	309	|O
(	309	310	|O
Boc	310	313	|O
)	313	314	|O
4	314	315	|O
,	315	316	|O
Lys	316	319	|O
(	319	320	|O
Boc	320	323	|O
)	323	324	|O
5	324	325	|O
,	325	326	|O
Thr	326	329	|O
(	329	330	|O
tBu	330	333	|O
)	333	334	|O
6	334	335	|O
,	335	336	|O
Cys	336	339	|O
(	339	340	|O
Acm	340	343	|O
)	343	344	|O
7	344	345	|O
,	345	346	|O
des	347	350	|B-IUPAC
(	350	351	|I-IUPAC
threoninol	351	361	|I-IUPAC
)	361	362	|I-IUPAC
]	362	363	|I-IUPAC
-	363	364	|I-IUPAC
octreotide	364	374	|I-IUPAC
was	375	378	|O
assembled	379	388	|O
by	389	391	|O
Fmoc	392	396	|O
solid	397	402	|O
-	402	403	|O
phase	403	408	|O
synthesis	409	418	|O
and	419	422	|O
the	423	426	|O
intramolecular	427	441	|O
disulfide	442	451	|O
bond	452	456	|O
formed	457	463	|O
by	464	466	|O
treatment	467	476	|O
of	477	479	|O
the	480	483	|O
resin	484	489	|O
-	489	490	|O
bound	490	495	|O
peptide	496	503	|O
with	504	508	|O
thallium	509	517	|O
trifluoroacetate	518	534	|O
[	535	536	|O
Tl	536	538	|O
(	538	539	|O
Tfa	539	542	|O
)	542	543	|O
3	543	544	|O
]	544	545	|O
.	545	546	|O
Side	547	551	|O
-	551	552	|O
chain	552	557	|O
protection	558	568	|O
of	569	571	|O
Trp	572	575	|O
by	576	578	|O
the	579	582	|O
Boc	583	586	|O
group	587	592	|O
was	593	596	|O
found	597	602	|O
to	603	605	|O
preserve	606	614	|O
Trp	615	618	|O
integrity	619	628	|O
during	629	635	|O
Tl	636	638	|O
(	638	639	|O
Tfa	639	642	|O
)	642	643	|O
3	643	644	|O
treatment	645	654	|O
.	654	655	|O
The	656	659	|O
protected	660	669	|O
peptide	670	677	|O
was	678	681	|O
cleaved	682	689	|O
from	690	694	|O
the	695	698	|O
resin	699	704	|O
by	705	707	|O
aminolysis	708	718	|O
with	719	723	|O
threoninol	724	734	|O
and	735	738	|O
purified	739	747	|O
by	748	750	|O
semipreparative	751	766	|O
RP	767	769	|O
-	769	770	|O
HPLC	770	774	|O
.	774	775	|O
Isolated	776	784	|O
[	785	786	|O
D	786	787	|O
-	787	788	|O
Trp	788	791	|O
(	791	792	|O
Boc	792	795	|O
)	795	796	|O
4	796	797	|O
,	797	798	|O
Lys	798	801	|O
(	801	802	|O
Boc	802	805	|O
)	805	806	|O
5	806	807	|O
,	807	808	|O
Thr	808	811	|O
(	811	812	|O
tBu	812	815	|O
)	815	816	|O
6	816	817	|O
]	817	818	|O
octreotide	818	828	|O
had	829	832	|O
the	833	836	|O
correct	837	844	|O
molecular	845	854	|O
mass	855	859	|O
(	860	861	|O
[	861	862	|O
M+	862	864	|O
H	864	865	|O
]	865	866	|O
+	866	867	|O
=	868	869	|O
1275	870	874	|O
Da	875	877	|O
)	877	878	|O
and	879	882	|O
sequence	883	891	|O
and	892	895	|O
was	896	899	|O
obtained	900	908	|O
in	909	911	|O
14%	912	915	|O
yield	916	921	|O
at	922	924	|O
&	925	926	|O
gt	926	928	|O
;	928	929	|O
98%	930	933	|O
purity	934	940	|O
.	940	941	|O
[	942	943	|O
D	943	944	|O
-	944	945	|O
Trp	945	948	|O
(	948	949	|O
Boc	949	952	|O
)	952	953	|O
4	953	954	|O
,	954	955	|O
Lys	955	958	|O
(	958	959	|O
Boc	959	962	|O
)	962	963	|O
5	963	964	|O
,	964	965	|O
Thr	965	968	|O
(	968	969	|O
tBu	969	972	|O
)	972	973	|O
6	973	974	|O
]	974	975	|O
octreotide	975	985	|O
was	986	989	|O
utilized	990	998	|O
for	999	1002	|O
the	1003	1006	|O
solution	1007	1015	|O
-	1015	1016	|O
phase	1016	1021	|O
synthesis	1022	1031	|O
of	1032	1034	|O
CPTA	1035	1039	|O
-	1039	1040	|O
D	1040	1041	|O
-	1041	1042	|O
Phe1	1042	1046	|O
-	1046	1047	|O
octreotide	1047	1057	|O
,	1057	1058	|O
where	1059	1064	|O
CPTA	1065	1069	|O
is	1070	1072	|O
4	1073	1074	|B-IUPAC
-	1074	1075	|I-IUPAC
[	1075	1076	|I-IUPAC
(	1076	1077	|I-IUPAC
1,4,8,11	1077	1085	|I-IUPAC
-	1085	1086	|I-IUPAC
tetraazacyclotetradec	1086	1107	|I-IUPAC
-	1107	1108	|I-IUPAC
1	1108	1109	|I-IUPAC
-	1109	1110	|I-IUPAC
yl	1110	1112	|I-IUPAC
)	1112	1113	|I-IUPAC
methyl	1113	1119	|I-IUPAC
]	1119	1120	|I-IUPAC
benzoic	1120	1127	|I-IUPAC
acid	1128	1132	|I-IUPAC
.	1132	1133	|O
Cyclic	1134	1140	|O
dianhydride	1141	1152	|O
of	1153	1155	|O
diethylenetriaminepentaacetic	1156	1185	|O
acid	1186	1190	|O
(	1191	1192	|O
DTPA	1192	1196	|O
)	1196	1197	|O
was	1198	1201	|O
coupled	1202	1209	|O
to	1210	1212	|O
a	1213	1214	|O
portion	1215	1222	|O
of	1223	1225	|O
the	1226	1229	|O
protected	1230	1239	|O
peptide	1240	1247	|O
-	1247	1248	|O
resin	1248	1253	|O
following	1254	1263	|O
disulfide	1264	1273	|O
bond	1274	1278	|O
formation	1279	1288	|O
.	1288	1289	|O
The	1290	1293	|O
DTPA	1294	1298	|O
-	1298	1299	|O
conjugated	1299	1309	|O
,	1309	1310	|O
side	1311	1315	|O
-	1315	1316	|O
chain	1316	1321	|O
-	1321	1322	|O
protected	1322	1331	|O
peptide	1332	1339	|O
was	1340	1343	|O
cleaved	1344	1351	|O
from	1352	1356	|O
the	1357	1360	|O
resin	1361	1366	|O
by	1367	1369	|O
aminolysis	1370	1380	|O
with	1381	1385	|O
threoninol	1386	1396	|O
,	1396	1397	|O
side	1398	1402	|O
-	1402	1403	|O
chain	1403	1408	|O
deprotected	1409	1420	|O
with	1421	1425	|O
trifluoroacetic	1426	1441	|O
acid	1442	1446	|O
,	1446	1447	|O
and	1448	1451	|O
purified	1452	1460	|O
by	1461	1463	|O
semipreparative	1464	1479	|O
RP	1480	1482	|O
-	1482	1483	|O
HPLC	1483	1487	|O
.	1487	1488	|O
The	1489	1492	|O
isolated	1493	1501	|O
DTPA	1502	1506	|O
-	1506	1507	|O
D	1507	1508	|O
-	1508	1509	|O
Phe1	1509	1513	|O
-	1513	1514	|O
octreotide	1514	1524	|O
had	1525	1528	|O
the	1529	1532	|O
correct	1533	1540	|O
molecular	1541	1550	|O
mass	1551	1555	|O
(	1556	1557	|O
[	1557	1558	|O
M+	1558	1560	|O
H	1560	1561	|O
]	1561	1562	|O
+	1562	1563	|O
=	1564	1565	|O
1395	1566	1570	|O
Da	1571	1573	|O
)	1573	1574	|O
and	1575	1578	|O
was	1579	1582	|O
obtained	1583	1591	|O
in	1592	1594	|O
5%	1595	1597	|O
yield	1598	1603	|O
at	1604	1606	|O
&	1607	1608	|O
gt	1608	1610	|O
;	1610	1611	|O
90%	1612	1615	|O
purity	1616	1622	|O
.	1622	1623	|O
The	1624	1627	|O
efficiency	1628	1638	|O
of	1639	1641	|O
aminolysis	1642	1652	|O
was	1653	1656	|O
partially	1657	1666	|O
dependent	1667	1676	|O
upon	1677	1681	|O
the	1682	1685	|O
linkage	1686	1693	|O
between	1694	1701	|O
4	1702	1703	|B-IUPAC
-	1703	1704	|I-IUPAC
(	1704	1705	|I-IUPAC
hydroxymethyl	1705	1718	|I-IUPAC
)	1718	1719	|I-IUPAC
phenoxy	1719	1726	|I-IUPAC
(	1727	1728	|O
HMP	1728	1731	|O
)	1731	1732	|O
handles	1733	1740	|B-MODIFIER
and	1741	1744	|O
the	1745	1748	|O
resin	1749	1754	|O
and	1755	1758	|O
/	1758	1759	|O
or	1759	1761	|O
resin	1762	1767	|O
particle	1768	1776	|O
size	1777	1781	|O
.	1781	1782	|O
The	1783	1786	|O
somatostatin	1787	1799	|O
receptor	1800	1808	|O
binding	1809	1816	|O
affinities	1817	1827	|O
of	1828	1830	|O
synthetic	1831	1840	|O
DTPA	1841	1845	|O
-	1845	1846	|O
D	1846	1847	|O
-	1847	1848	|O
Phe1	1848	1852	|O
-	1852	1853	|O
octreotide	1853	1863	|O
and	1864	1867	|O
CPTA	1868	1872	|O
-	1872	1873	|O
D	1873	1874	|O
-	1874	1875	|O
Phe1	1875	1879	|O
-	1879	1880	|O
octreotide	1880	1890	|O
to	1891	1893	|O
AtT	1894	1897	|O
-	1897	1898	|O
20	1898	1900	|O
mouse	1901	1906	|O
pituitary	1907	1916	|O
carcinoma	1917	1926	|O
cell	1927	1931	|O
membranes	1932	1941	|O
were	1942	1946	|O
examined	1947	1955	|O
by	1956	1958	|O
labeling	1959	1967	|O
with	1968	1972	|O
111In	1973	1978	|O
and	1979	1982	|O
64Cu	1983	1987	|O
,	1987	1988	|O
respectively	1989	2001	|O
,	2001	2002	|O
and	2003	2006	|O
performing	2007	2017	|O
Scatchard	2018	2027	|O
analyses	2028	2036	|O
.	2036	2037	|O
The	2038	2041	|O
dissociation	2042	2054	|O
constant	2055	2063	|O
(	2064	2065	|O
Kd	2065	2067	|O
)	2067	2068	|O
for	2069	2072	|O
our	2073	2076	|O
synthetic	2077	2086	|O
[	2087	2088	|O
111In	2088	2093	|O
]	2093	2094	|O
DTPA	2094	2098	|O
-	2098	2099	|O
D	2099	2100	|O
-	2100	2101	|O
Phe1	2101	2105	|O
-	2105	2106	|O
octreotide	2106	2116	|O
was	2117	2120	|O
4.31	2121	2125	|O
nM	2126	2128	|O
,	2128	2129	|O
which	2130	2135	|O
is	2136	2138	|O
comparable	2139	2149	|O
to	2150	2152	|O
a	2153	2154	|O
Kd	2155	2157	|O
=	2158	2159	|O
5.57	2160	2164	|O
nM	2165	2167	|O
obtained	2168	2176	|O
with	2177	2181	|O
commercially	2182	2194	|O
available	2195	2204	|O
DTPA	2205	2209	|O
-	2209	2210	|O
D	2210	2211	|O
-	2211	2212	|O
Phe1	2212	2216	|O
-	2216	2217	|O
octreotide	2217	2227	|O
.	2227	2228	|O
The	2229	2232	|O
Kd	2233	2235	|O
for	2236	2239	|O
[	2240	2241	|O
64Cu	2241	2245	|O
]	2245	2246	|O
CPTA	2246	2250	|O
-	2250	2251	|O
D	2251	2252	|O
-	2252	2253	|O
Phe1	2253	2257	|O
-	2257	2258	|O
octreotide	2258	2268	|O
was	2269	2272	|O
78.5	2273	2277	|O
pM	2278	2280	|O
.	2280	2281	|O
On	2282	2284	|O
the	2285	2288	|O
basis	2289	2294	|O
of	2295	2297	|O
the	2298	2301	|O
criteria	2302	2310	|O
of	2311	2313	|O
molecular	2314	2323	|O
mass	2324	2328	|O
,	2328	2329	|O
RP	2330	2332	|O
-	2332	2333	|O
HPLC	2333	2337	|O
elution	2338	2345	|O
time	2346	2350	|O
,	2350	2351	|O
sequence	2352	2360	|O
analysis	2361	2369	|O
,	2369	2370	|O
and	2371	2374	|O
somatostatin	2375	2387	|O
receptor	2388	2396	|O
binding	2397	2404	|O
affinity	2405	2413	|O
,	2413	2414	|O
our	2415	2418	|O
synthetic	2419	2428	|O
octreotide	2429	2439	|O
is	2440	2442	|O
identical	2443	2452	|O
to	2453	2455	|O
commercially	2456	2468	|O
available	2469	2478	|O
octreotide	2479	2489	|O
.	2489	2490	|O
The	2491	2494	|O
aminolysis	2495	2505	|O
protocol	2506	2514	|O
used	2515	2519	|O
here	2520	2524	|O
has	2525	2528	|O
distinct	2529	2537	|O
advantages	2538	2548	|O
over	2549	2553	|O
either	2554	2560	|O
reductive	2561	2570	|O
cleavage	2571	2579	|O
or	2580	2582	|O
preformed	2583	2592	|O
linker	2593	2599	|O
methods	2600	2607	|O
described	2608	2617	|O
previously	2618	2628	|O
for	2629	2632	|O
the	2633	2636	|O
preparation	2637	2648	|O
of	2649	2651	|O
octreotide	2652	2662	|O
.	2662	2663	|O

### abstracts3219.txt
The	0	3	|O
antimicrobial	4	17	|O
and	18	21	|O
cytotoxic	22	31	|O
properties	32	42	|O
of	43	45	|O
a	46	47	|O
series	48	54	|O
of	55	57	|O
9,10	58	62	|B-IUPAC
-	62	63	|I-IUPAC
dihydrophenanthrenes	63	83	|I-IUPAC
structurally	84	96	|O
related	97	104	|O
to	105	107	|O
juncusol	108	116	|O
(	117	118	|O
1a	118	120	|O
)	120	121	|O
,	121	122	|O
a	123	124	|O
postulated	125	135	|O
phytoalexin	136	147	|O
with	148	152	|O
confirmed	153	162	|O
cytotoxic	163	172	|O
properties	173	183	|O
,	183	184	|O
are	185	188	|O
detailed	189	197	|O
.	197	198	|O
Two	199	202	|O
simple	203	209	|O
9,10	210	214	|B-IUPAC
-	214	215	|I-IUPAC
dihydrophenanthrenes	215	235	|I-IUPAC
,	235	236	|O
2,7	237	240	|B-IUPAC
-	240	241	|I-IUPAC
dihydroxy	241	250	|I-IUPAC
-	250	251	|I-IUPAC
3,8	251	254	|I-IUPAC
-	254	255	|I-IUPAC
dimethyl	255	263	|I-IUPAC
-	263	264	|I-IUPAC
9,10	264	268	|I-IUPAC
-	268	269	|I-IUPAC
dihydrophenanthrene	269	288	|I-IUPAC
(	289	290	|O
2h	290	292	|O
,	292	293	|O
desvinyljuncusol	294	310	|O
)	310	311	|O
and	312	315	|O
2	316	317	|B-IUPAC
-	317	318	|I-IUPAC
hydroxy	318	325	|I-IUPAC
-	325	326	|I-IUPAC
3	326	327	|I-IUPAC
-	327	328	|I-IUPAC
methyl	328	334	|I-IUPAC
-	334	335	|I-IUPAC
9,10	335	339	|I-IUPAC
-	339	340	|I-IUPAC
dihydrophenanthrene	340	359	|I-IUPAC
(	360	361	|O
3h	361	363	|O
)	363	364	|O
,	364	365	|O
were	366	370	|O
found	371	376	|O
to	377	379	|O
possess	380	387	|O
in	388	390	|O
vitro	391	396	|O
antimicrobial	397	410	|O
activity	411	419	|O
comparable	420	430	|O
with	431	435	|O
that	436	440	|O
of	441	443	|O
the	444	447	|O
natural	448	455	|O
product	456	463	|O
.	463	464	|O
Two	465	468	|O
9,10	469	473	|B-IUPAC
-	473	474	|I-IUPAC
dihydrophenanthrenes	474	494	|I-IUPAC
substituted	495	506	|O
with	507	511	|O
quaternary	512	522	|O
ammonium	523	531	|O
salts	532	537	|O
,	537	538	|O
2d	539	541	|O
and	542	545	|O
3d	546	548	|O
,	548	549	|O
each	550	554	|O
containing	555	565	|O
a	566	567	|O
reactive	568	576	|O
benzylic	577	585	|B-MODIFIER
dimethyl	586	594	|B-IUPAC
[	594	595	|I-IUPAC
(	595	596	|I-IUPAC
phenylthio	596	606	|I-IUPAC
)	606	607	|I-IUPAC
methyl	607	613	|I-IUPAC
]	613	614	|I-IUPAC
ammonio	614	621	|I-IUPAC
group	622	627	|B-MODIFIER
,	627	628	|O
were	629	633	|O
found	634	639	|O
to	640	642	|O
be	643	645	|O
10-20	646	651	|O
times	652	657	|O
more	658	662	|O
potent	663	669	|O
than	670	674	|O
juncusol	675	683	|O
(	684	685	|O
1a	685	687	|O
)	687	688	|O
.	688	689	|O
Confirmed	690	699	|O
in	700	702	|O
vitro	703	708	|O
cytotoxic	709	718	|O
activity	719	727	|O
that	728	732	|O
parallels	733	742	|O
antimicrobial	743	756	|O
activity	757	765	|O
was	766	769	|O
found	770	775	|O
for	776	779	|O
juncusol	780	788	|O
(	789	790	|O
1a	790	792	|O
)	792	793	|O
,	793	794	|O
desvinyljuncusol	795	811	|O
(	812	813	|O
2h	813	815	|O
)	815	816	|O
,	816	817	|O
2	818	819	|B-IUPAC
-	819	820	|I-IUPAC
hydroxy	820	827	|I-IUPAC
-	827	828	|I-IUPAC
3	828	829	|I-IUPAC
-	829	830	|I-IUPAC
methyl	830	836	|I-IUPAC
-	836	837	|I-IUPAC
9,10	837	841	|I-IUPAC
-	841	842	|I-IUPAC
dihydrophenanthrene	842	861	|I-IUPAC
(	862	863	|O
3h	863	865	|O
)	865	866	|O
,	866	867	|O
and	868	871	|O
the	872	875	|O
quaternary	876	886	|B-MODIFIER
dimethyl	887	895	|B-IUPAC
[	895	896	|I-IUPAC
(	896	897	|I-IUPAC
phenylthio	897	907	|I-IUPAC
)	907	908	|I-IUPAC
methyl	908	914	|I-IUPAC
]	914	915	|I-IUPAC
ammonium	915	923	|I-IUPAC
salts	924	929	|B-MODIFIER
2d	930	932	|O
and	933	936	|O
3d	937	939	|O
in	940	942	|O
a	943	944	|O
human	945	950	|O
lymphoblastic	951	964	|O
leukemia	965	973	|O
cell	974	978	|O
culture	979	986	|O
(	987	988	|O
CCRF	988	992	|O
-	992	993	|O
CEM	993	996	|O
,	996	997	|O
IC50	998	1002	|O
=	1003	1004	|O
nt	1005	1007	|O
,	1007	1008	|O
9.3	1009	1012	|O
,	1012	1013	|O
nt	1014	1016	|O
,	1016	1017	|O
0.9	1018	1021	|O
and	1022	1025	|O
1.4	1026	1029	|O
microgram	1030	1039	|O
/	1039	1040	|O
mL	1040	1042	|O
,	1042	1043	|O
respectively	1044	1056	|O
)	1056	1057	|O
,	1057	1058	|O
B	1059	1060	|O
-	1060	1061	|O
16	1061	1063	|O
mouse	1064	1069	|O
melanoma	1070	1078	|O
cell	1079	1083	|O
culture	1084	1091	|O
(	1092	1093	|O
IC50	1093	1097	|O
=	1098	1099	|O
12.5	1100	1104	|O
,	1104	1105	|O
17.5	1106	1110	|O
,	1110	1111	|O
27.7	1112	1116	|O
,	1116	1117	|O
0.3	1118	1121	|O
,	1121	1122	|O
and	1123	1126	|O
0.5	1127	1130	|O
microgram	1131	1140	|O
/	1140	1141	|O
mL	1141	1143	|O
,	1143	1144	|O
respectively	1145	1157	|O
)	1157	1158	|O
,	1158	1159	|O
and	1160	1163	|O
L	1164	1165	|O
-	1165	1166	|O
1210	1166	1170	|O
mouse	1171	1176	|O
lymphocytic	1177	1188	|O
leukemia	1189	1197	|O
cell	1198	1202	|O
culture	1203	1210	|O
(	1211	1212	|O
IC50	1212	1216	|O
=	1217	1218	|O
13.8	1219	1223	|O
,	1223	1224	|O
10.2	1225	1229	|O
,	1229	1230	|O
24.5	1231	1235	|O
,	1235	1236	|O
1.3	1237	1240	|O
,	1240	1241	|O
and	1242	1245	|O
3.7	1246	1249	|O
micrograms	1250	1260	|O
/	1260	1261	|O
mL	1261	1263	|O
,	1263	1264	|O
respectively	1265	1277	|O
)	1277	1278	|O
.	1278	1279	|O
The	1280	1283	|O
comparable	1284	1294	|O
potency	1295	1302	|O
and	1303	1306	|O
spectrum	1307	1315	|O
of	1316	1318	|O
activity	1319	1327	|O
of	1328	1330	|O
juncusol	1331	1339	|O
(	1340	1341	|O
1a	1341	1343	|O
)	1343	1344	|O
,	1344	1345	|O
desvinyljuncusol	1346	1362	|O
(	1363	1364	|O
2h	1364	1366	|O
)	1366	1367	|O
,	1367	1368	|O
and	1369	1372	|O
2	1373	1374	|B-IUPAC
-	1374	1375	|I-IUPAC
hydroxy	1375	1382	|I-IUPAC
-	1382	1383	|I-IUPAC
3	1383	1384	|I-IUPAC
-	1384	1385	|I-IUPAC
methyl	1385	1391	|I-IUPAC
-	1391	1392	|I-IUPAC
9,10	1392	1396	|I-IUPAC
-	1396	1397	|I-IUPAC
dihydrophenanthrene	1397	1416	|I-IUPAC
(	1417	1418	|O
3h	1418	1420	|O
)	1420	1421	|O
suggest	1422	1429	|O
that	1430	1434	|O
the	1435	1438	|O
agents	1439	1445	|O
are	1446	1449	|O
acting	1450	1456	|O
as	1457	1459	|O
simple	1460	1466	|O
phenols	1467	1474	|O
in	1475	1477	|O
exerting	1478	1486	|O
their	1487	1492	|O
antimicrobial	1493	1506	|O
and	1507	1510	|O
cytotoxic	1511	1520	|O
effects	1521	1528	|O
.	1528	1529	|O

### abstracts1142.txt
A	0	1	|O
number	2	8	|O
of	9	11	|O
17	12	14	|B-PARTIUPAC
beta	15	19	|I-PARTIUPAC
-	19	20	|I-PARTIUPAC
(	20	21	|I-PARTIUPAC
N	21	22	|I-PARTIUPAC
-	22	23	|I-PARTIUPAC
alkyl	23	28	|I-PARTIUPAC
/	28	29	|I-PARTIUPAC
arylformamido	29	42	|I-PARTIUPAC
)	42	43	|I-PARTIUPAC
-	43	44	|I-PARTIUPAC
and	45	48	|O
17	49	51	|B-PARTIUPAC
beta	52	56	|I-PARTIUPAC
-	56	57	|I-PARTIUPAC
[	57	58	|I-PARTIUPAC
(	58	59	|I-PARTIUPAC
N	59	60	|I-PARTIUPAC
-	60	61	|I-PARTIUPAC
alkyl	61	66	|I-PARTIUPAC
/	66	67	|I-PARTIUPAC
aryl	67	71	|I-PARTIUPAC
)	71	72	|I-PARTIUPAC
alkyl	72	77	|I-PARTIUPAC
/	77	78	|I-PARTIUPAC
arylamido	78	87	|I-PARTIUPAC
]	87	88	|I-PARTIUPAC
-	88	89	|I-PARTIUPAC
3	89	90	|I-PARTIUPAC
-	90	91	|I-PARTIUPAC
oxo	91	94	|I-PARTIUPAC
-	94	95	|I-PARTIUPAC
4	95	96	|I-PARTIUPAC
-	96	97	|I-PARTIUPAC
aza	97	100	|I-PARTIUPAC
-	100	101	|I-PARTIUPAC
5	101	102	|I-PARTIUPAC
alpha	103	108	|I-PARTIUPAC
-	108	109	|O
steroids	109	117	|B-MODIFIER
were	118	122	|O
prepared	123	131	|O
from	132	136	|O
17	137	139	|B-IUPAC
beta	140	144	|I-IUPAC
-	144	145	|I-IUPAC
hydroxy	145	152	|I-IUPAC
-	152	153	|I-IUPAC
4	153	154	|I-IUPAC
-	154	155	|I-IUPAC
azasteroids	155	166	|I-IUPAC
and	167	170	|O
evaluated	171	180	|O
as	181	183	|O
inhibitors	184	194	|O
of	195	197	|O
human	198	203	|O
5	204	205	|O
alpha	206	211	|O
-	211	212	|O
reductase	212	221	|O
and	222	225	|O
antagonists	226	237	|O
of	238	240	|O
the	241	244	|O
androgen	245	253	|O
receptor	254	262	|O
.	262	263	|O
Jones	264	269	|O
'	269	270	|O
oxidation	271	280	|O
of	281	283	|O
17	284	286	|B-PARTIUPAC
beta	287	291	|I-PARTIUPAC
-	291	292	|I-PARTIUPAC
hydroxy	292	299	|I-PARTIUPAC
compounds	300	309	|B-MODIFIER
gave	310	314	|O
the	315	318	|O
17	319	321	|B-IUPAC
-	321	322	|I-IUPAC
keto	322	326	|I-IUPAC
-	326	327	|I-IUPAC
4	327	328	|I-IUPAC
-	328	329	|I-IUPAC
azasteroids	329	340	|I-IUPAC
,	340	341	|O
which	342	347	|O
were	348	352	|O
treated	353	360	|O
with	361	365	|O
amines	366	372	|O
and	373	376	|O
NaBH	377	381	|O
(	381	382	|O
OAc	382	385	|O
)	385	386	|O
3	386	387	|O
/	387	388	|O
NaBH3CN	388	395	|O
to	396	398	|O
give	399	403	|O
17	404	406	|B-IUPAC
beta	407	411	|I-IUPAC
-	411	412	|I-IUPAC
(	412	413	|I-IUPAC
N	413	414	|I-IUPAC
-	414	415	|I-IUPAC
alkyl	415	420	|I-IUPAC
/	420	421	|I-IUPAC
arylamino	421	430	|I-IUPAC
)	430	431	|I-IUPAC
-	431	432	|I-IUPAC
4	432	433	|I-IUPAC
-	433	434	|I-IUPAC
azasteroids	434	445	|I-IUPAC
10-27	446	451	|O
.	451	452	|O
Alternatively	453	466	|O
,	466	467	|O
the	468	471	|O
above	472	477	|O
-	477	478	|O
indicated	478	487	|O
compounds	488	497	|O
were	498	502	|O
prepared	503	511	|O
from	512	516	|O
amines	517	523	|O
and	524	527	|O
17	528	530	|B-IUPAC
-	530	531	|I-IUPAC
keto	531	535	|I-IUPAC
-	535	536	|I-IUPAC
4	536	537	|I-IUPAC
-	537	538	|I-IUPAC
azasteroids	538	549	|I-IUPAC
to	550	552	|O
form	553	557	|O
imines	558	564	|O
,	564	565	|O
which	566	571	|O
were	572	576	|O
then	577	581	|O
reduced	582	589	|O
with	590	594	|O
NaBH4	595	600	|O
.	600	601	|O
Formylation	602	613	|O
of	614	616	|O
amines	617	623	|O
10-27	624	629	|O
gave	630	634	|O
17	635	637	|B-IUPAC
beta	638	642	|I-IUPAC
-	642	643	|I-IUPAC
(	643	644	|I-IUPAC
N	644	645	|I-IUPAC
-	645	646	|I-IUPAC
alkylformamides	646	661	|I-IUPAC
)	661	662	|I-IUPAC
28-41	663	668	|O
;	668	669	|O
however	670	677	|O
,	677	678	|O
acylation	679	688	|O
afforded	689	697	|O
17	698	700	|B-IUPAC
beta	701	705	|I-IUPAC
-	705	706	|I-IUPAC
[	706	707	|I-IUPAC
(	707	708	|I-IUPAC
N	708	709	|I-IUPAC
-	709	710	|I-IUPAC
alkyl	710	715	|I-IUPAC
/	715	716	|I-IUPAC
aryl	716	720	|I-IUPAC
)	720	721	|I-IUPAC
alkyl	721	726	|I-IUPAC
/	726	727	|I-IUPAC
arylamides	727	737	|I-IUPAC
]	737	738	|I-IUPAC
42-53	739	744	|O
.	744	745	|O
In	746	748	|O
comparison	749	759	|O
to	760	762	|O
N	763	764	|B-IUPAC
,	764	765	|I-IUPAC
N	765	766	|I-IUPAC
-	766	767	|I-IUPAC
diethyl	767	774	|I-IUPAC
-	774	775	|I-IUPAC
4	775	776	|I-IUPAC
-	776	777	|I-IUPAC
methyl	777	783	|I-IUPAC
-	783	784	|I-IUPAC
3	784	785	|I-IUPAC
-	785	786	|I-IUPAC
oxo	786	789	|I-IUPAC
-	789	790	|I-IUPAC
4	790	791	|I-IUPAC
-	791	792	|I-IUPAC
aza	792	795	|I-IUPAC
-	795	796	|I-IUPAC
5	796	797	|I-IUPAC
alpha	798	803	|I-IUPAC
-	803	804	|I-IUPAC
androstane	804	814	|I-IUPAC
-	814	815	|I-IUPAC
17	815	817	|I-IUPAC
beta	818	822	|I-IUPAC
-	822	823	|I-IUPAC
carboxamide	823	834	|I-IUPAC
(	835	836	|O
4	836	837	|O
-	837	838	|O
MA	838	840	|O
;	840	841	|O
IC50	842	846	|O
=	847	848	|O
4.15	849	853	|O
nM	854	856	|O
)	856	857	|O
,	857	858	|O
17	859	861	|B-IUPAC
beta	862	866	|I-IUPAC
-	866	867	|I-IUPAC
(	867	868	|I-IUPAC
N	868	869	|I-IUPAC
-	869	870	|I-IUPAC
alkylformamido	870	884	|I-IUPAC
)	884	885	|I-IUPAC
-	885	886	|I-IUPAC
4	886	887	|I-IUPAC
-	887	888	|I-IUPAC
azasteroids	888	899	|I-IUPAC
were	900	904	|O
potent	905	911	|O
inhibitors	912	922	|O
of	923	925	|O
human	926	931	|O
type	932	936	|O
I	937	938	|O
5	939	940	|O
alpha	941	946	|O
-	946	947	|O
reductase	947	956	|O
,	956	957	|O
IC50	958	962	|O
values	963	969	|O
of	970	972	|O
compounds	973	982	|O
29	983	985	|O
,	985	986	|O
30	987	989	|O
,	989	990	|O
36	991	993	|O
,	993	994	|O
and	995	998	|O
37	999	1001	|O
being	1002	1007	|O
measured	1008	1016	|O
as	1017	1019	|O
3.05	1020	1024	|O
,	1024	1025	|O
0.91	1026	1030	|O
,	1030	1031	|O
2.19	1032	1036	|O
,	1036	1037	|O
and	1038	1041	|O
2.35	1042	1046	|O
nM	1047	1049	|O
,	1049	1050	|O
respectively	1051	1063	|O
.	1063	1064	|O
The	1065	1068	|O
structure	1069	1078	|O
-	1078	1079	|O
activity	1079	1087	|O
relationships	1088	1101	|O
suggest	1102	1109	|O
that	1110	1114	|O
the	1115	1118	|O
type	1119	1123	|O
I	1124	1125	|O
enzyme	1126	1132	|O
has	1133	1136	|O
preference	1137	1147	|O
for	1148	1151	|O
N	1152	1153	|O
-	1153	1154	|O
substituted	1154	1165	|O
straight	1166	1174	|O
alkyl	1175	1180	|O
side	1181	1185	|O
chains	1186	1192	|O
of	1193	1195	|O
four	1196	1200	|O
to	1201	1203	|O
five	1204	1208	|O
carbon	1209	1215	|O
atoms	1216	1221	|O
.	1221	1222	|O
On	1223	1225	|O
the	1226	1229	|O
other	1230	1235	|O
hand	1236	1240	|O
,	1240	1241	|O
formamides	1242	1252	|O
32	1253	1255	|O
(	1256	1257	|O
N	1257	1258	|B-IUPAC
-	1258	1259	|I-IUPAC
heptyl	1259	1265	|I-IUPAC
)	1265	1266	|O
and	1267	1270	|O
33	1271	1273	|O
(	1274	1275	|O
N	1275	1276	|B-IUPAC
-	1276	1277	|I-IUPAC
octyl	1277	1282	|I-IUPAC
)	1282	1283	|O
,	1283	1284	|O
in	1285	1287	|O
addition	1288	1296	|O
to	1297	1299	|O
inhibiting	1300	1310	|O
the	1311	1314	|O
type	1315	1319	|O
I	1320	1321	|O
enzyme	1322	1328	|O
(	1329	1330	|O
IC50s	1330	1335	|O
=	1336	1337	|O
9.57	1338	1342	|O
and	1343	1346	|O
16.9	1347	1351	|O
nM	1352	1354	|O
,	1354	1355	|O
respectively	1356	1368	|O
)	1368	1369	|O
,	1369	1370	|O
showed	1371	1377	|O
also	1378	1382	|O
strong	1383	1389	|O
inhibitory	1390	1400	|O
activity	1401	1409	|O
(	1410	1411	|O
IC50s	1411	1416	|O
=	1417	1418	|O
14.0	1419	1423	|O
and	1424	1427	|O
18.4	1428	1432	|O
nM	1433	1435	|O
,	1435	1436	|O
respectively	1437	1449	|O
)	1449	1450	|O
for	1451	1454	|O
human	1455	1460	|O
type	1461	1465	|O
II	1466	1468	|O
5	1469	1470	|O
alpha	1471	1476	|O
-	1476	1477	|O
reductase	1477	1486	|O
,	1486	1487	|O
in	1488	1490	|O
comparison	1491	1501	|O
to	1502	1504	|O
N	1505	1506	|B-IUPAC
-	1506	1507	|I-IUPAC
(	1507	1508	|I-IUPAC
1'	1508	1510	|I-IUPAC
,	1510	1511	|I-IUPAC
1'	1511	1513	|I-IUPAC
-	1513	1514	|I-IUPAC
dimethylethyl	1514	1527	|I-IUPAC
)	1527	1528	|I-IUPAC
-	1528	1529	|I-IUPAC
3	1529	1530	|I-IUPAC
-	1530	1531	|I-IUPAC
oxo	1531	1534	|I-IUPAC
-	1534	1535	|I-IUPAC
4	1535	1536	|I-IUPAC
-	1536	1537	|I-IUPAC
aza	1537	1540	|I-IUPAC
-	1540	1541	|I-IUPAC
5	1541	1542	|I-IUPAC
alpha	1543	1548	|I-IUPAC
-	1548	1549	|I-IUPAC
androst	1549	1556	|I-IUPAC
-	1556	1557	|I-IUPAC
1	1557	1558	|I-IUPAC
-	1558	1559	|I-IUPAC
ene	1559	1562	|I-IUPAC
-	1562	1563	|I-IUPAC
17	1563	1565	|I-IUPAC
beta	1566	1570	|I-IUPAC
-	1570	1571	|I-IUPAC
carboxamide	1571	1582	|I-IUPAC
(	1583	1584	|O
MK	1584	1586	|O
-	1586	1587	|O
906	1587	1590	|O
;	1590	1591	|O
IC50	1592	1596	|O
=	1597	1598	|O
4.53	1599	1603	|O
nM	1604	1606	|O
)	1606	1607	|O
.	1607	1608	|O
Other	1609	1614	|O
compounds	1615	1624	|O
in	1625	1627	|O
this	1628	1632	|O
series	1633	1639	|O
showed	1640	1646	|O
moderate	1647	1655	|O
activities	1656	1666	|O
(	1667	1668	|O
IC50	1668	1672	|O
&	1673	1674	|O
gt	1674	1676	|O
;	1676	1677	|O
100	1678	1681	|O
nM	1682	1684	|O
)	1684	1685	|O
on	1686	1688	|O
the	1689	1692	|O
type	1693	1697	|O
II	1698	1700	|O
enzyme	1701	1707	|O
.	1707	1708	|O
17	1709	1711	|B-IUPAC
beta	1712	1716	|I-IUPAC
-	1716	1717	|I-IUPAC
[	1717	1718	|I-IUPAC
(	1718	1719	|I-IUPAC
N	1719	1720	|I-IUPAC
-	1720	1721	|I-IUPAC
Alkyl	1721	1726	|I-IUPAC
/	1726	1727	|I-IUPAC
aryl	1727	1731	|I-IUPAC
)	1731	1732	|I-IUPAC
alkyl	1732	1737	|I-IUPAC
/	1737	1738	|I-IUPAC
arylamides	1738	1748	|I-IUPAC
]	1748	1749	|I-IUPAC
45	1750	1752	|O
,	1752	1753	|O
46	1754	1756	|O
,	1756	1757	|O
48	1758	1760	|O
,	1760	1761	|O
and	1762	1765	|O
51	1766	1768	|O
exhibited	1769	1778	|O
highly	1779	1785	|O
potent	1786	1792	|O
inhibitory	1793	1803	|O
activity	1804	1812	|O
for	1813	1816	|O
human	1817	1822	|O
type	1823	1827	|O
I	1828	1829	|O
5	1830	1831	|O
alpha	1832	1837	|O
-	1837	1838	|O
reductase	1838	1847	|O
with	1848	1852	|O
IC50s	1853	1858	|O
of	1859	1861	|O
1.77	1862	1866	|O
,	1866	1867	|O
2.42	1868	1872	|O
,	1872	1873	|O
2.93	1874	1878	|O
,	1878	1879	|O
and	1880	1883	|O
5.44	1884	1888	|O
nM	1889	1891	|O
,	1891	1892	|O
respectively	1893	1905	|O
,	1905	1906	|O
while	1907	1912	|O
moderate	1913	1921	|O
to	1922	1924	|O
no	1925	1927	|O
effect	1928	1934	|O
was	1935	1938	|O
observed	1939	1947	|O
on	1948	1950	|O
the	1951	1954	|O
type	1955	1959	|O
II	1960	1962	|O
enzyme	1963	1969	|O
(	1970	1971	|O
100	1971	1974	|O
&	1975	1976	|O
lt	1976	1978	|O
;	1978	1979	|O
IC50s	1980	1985	|O
&	1986	1987	|O
lt	1987	1989	|O
;	1989	1990	|O
1000	1991	1995	|O
nM	1996	1998	|O
)	1998	1999	|O
,	1999	2000	|O
except	2001	2007	|O
for	2008	2011	|O
compound	2012	2020	|O
48	2021	2023	|O
(	2024	2025	|O
IC50	2025	2029	|O
=	2030	2031	|O
3.75	2032	2036	|O
nM	2037	2039	|O
)	2039	2040	|O
.	2040	2041	|O
In	2042	2044	|O
another	2045	2052	|O
substitution	2053	2065	|O
pattern	2066	2073	|O
,	2073	2074	|O
N	2075	2076	|B-IUPAC
-	2076	2077	|I-IUPAC
aryl	2077	2081	|I-IUPAC
/	2081	2082	|O
alkylamides	2082	2093	|B-IUPAC
were	2094	2098	|O
studied	2099	2106	|O
;	2106	2107	|O
an	2108	2110	|O
electron	2111	2119	|O
-	2119	2120	|O
donating	2120	2128	|O
group	2129	2134	|O
increased	2135	2144	|O
the	2145	2148	|O
potency	2149	2156	|O
of	2157	2159	|O
compound	2160	2168	|O
51	2169	2171	|O
,	2171	2172	|O
whereas	2173	2180	|O
an	2181	2183	|O
electron	2184	2192	|O
-	2192	2193	|O
withdrawing	2193	2204	|O
group	2205	2210	|O
decreased	2211	2220	|O
the	2221	2224	|O
potency	2225	2232	|O
of	2233	2235	|O
compounds	2236	2245	|O
52	2246	2248	|O
and	2249	2252	|O
53	2253	2255	|O
compared	2256	2264	|O
to	2265	2267	|O
parent	2268	2274	|O
compound	2275	2283	|O
50	2284	2286	|O
.	2286	2287	|O
In	2288	2290	|O
addition	2291	2299	|O
to	2300	2302	|O
their	2303	2308	|O
5	2309	2310	|O
alpha	2311	2316	|O
-	2316	2317	|O
reductase	2317	2326	|O
activities	2327	2337	|O
,	2337	2338	|O
17	2339	2341	|B-IUPAC
beta	2342	2346	|I-IUPAC
-	2346	2347	|I-IUPAC
(	2347	2348	|I-IUPAC
N	2348	2349	|I-IUPAC
-	2349	2350	|I-IUPAC
alkylformamides	2350	2365	|I-IUPAC
)	2365	2366	|I-IUPAC
were	2367	2371	|O
also	2372	2376	|O
studied	2377	2384	|O
for	2385	2388	|O
their	2389	2394	|O
inhibitory	2395	2405	|O
activities	2406	2416	|O
on	2417	2419	|O
dihydrotestosterone	2420	2439	|O
(	2440	2441	|O
DHT	2441	2444	|O
)	2444	2445	|O
-	2445	2446	|O
stimulated	2446	2456	|O
proliferation	2457	2470	|O
of	2471	2473	|O
androgen	2474	2482	|O
-	2482	2483	|O
sensitive	2483	2492	|O
Shionogi	2493	2501	|O
mouse	2502	2507	|O
mammary	2508	2515	|O
carcinoma	2516	2525	|O
cells	2526	2531	|O
(	2532	2533	|O
clone	2533	2538	|O
SEM	2539	2542	|O
-	2542	2543	|O
107	2543	2546	|O
)	2546	2547	|O
.	2547	2548	|O
(	2548	2549	|O
ABSTRACT	2549	2557	|O
TRUNCATED	2558	2567	|O
AT	2568	2570	|O
400	2571	2574	|O
WORDS	2575	2580	|O
)	2580	2581	|O

### abstracts2802.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
analogues	12	21	|O
of	22	24	|O
the	25	28	|O
conformationally	29	45	|O
restricted	46	56	|O
delta	57	62	|O
opioid	63	69	|O
receptor	70	78	|O
selective	79	88	|O
tetrapeptide	89	101	|O
Tyr	102	105	|O
-	105	106	|O
c	106	107	|O
[	107	108	|O
D	108	109	|O
-	109	110	|O
Cys	110	113	|O
-	113	114	|O
Phe	114	117	|O
-	117	118	|O
D	118	119	|O
-	119	120	|O
Pen	120	123	|O
]	123	124	|O
OH	124	126	|O
(	127	128	|O
JOM	128	131	|O
13	132	134	|O
)	134	135	|O
was	136	139	|O
prepared	140	148	|O
in	149	151	|O
which	152	157	|O
the	158	161	|O
conformationally	162	178	|O
labile	179	185	|O
Tyr	186	189	|O
residue	190	197	|O
was	198	201	|O
replaced	202	210	|O
with	211	215	|O
several	216	223	|O
less	224	228	|O
flexible	229	237	|O
tyrosine	238	246	|O
analogues	247	256	|O
.	256	257	|O
Among	258	263	|O
these	264	269	|O
tyrosine	270	278	|O
analogues	279	288	|O
were	289	293	|O
the	294	297	|O
bicyclic	298	306	|O
structures	307	317	|O
1,2,3,4	318	325	|B-IUPAC
-	325	326	|I-IUPAC
tetrahydro	326	336	|I-IUPAC
-	336	337	|I-IUPAC
7	337	338	|I-IUPAC
-	338	339	|I-IUPAC
hydroxyisoquinoline	339	358	|I-IUPAC
-	358	359	|I-IUPAC
3	359	360	|I-IUPAC
-	360	361	|I-IUPAC
carboxylic	361	371	|I-IUPAC
acid	372	376	|I-IUPAC
(	377	378	|O
HO	378	380	|O
-	380	381	|O
Tic	381	384	|O
)	384	385	|O
,	385	386	|O
2	387	388	|B-IUPAC
-	388	389	|I-IUPAC
amino	389	394	|I-IUPAC
-	394	395	|I-IUPAC
6	395	396	|I-IUPAC
-	396	397	|I-IUPAC
hydroxytetralin	397	412	|I-IUPAC
-	412	413	|I-IUPAC
2	413	414	|I-IUPAC
-	414	415	|I-IUPAC
carboxylic	415	425	|I-IUPAC
acid	426	430	|I-IUPAC
(	431	432	|O
Hat	432	435	|O
)	435	436	|O
,	436	437	|O
and	438	441	|O
2	442	443	|B-IUPAC
-	443	444	|I-IUPAC
amino	444	449	|I-IUPAC
-	449	450	|I-IUPAC
5	450	451	|I-IUPAC
-	451	452	|I-IUPAC
hydroxyindan	452	464	|I-IUPAC
-	464	465	|I-IUPAC
2	465	466	|I-IUPAC
-	466	467	|I-IUPAC
carboxylic	467	477	|I-IUPAC
acid	478	482	|I-IUPAC
(	483	484	|O
Hai	484	487	|O
)	487	488	|O
in	489	491	|O
which	492	497	|O
rotations	498	507	|O
about	508	513	|O
the	514	517	|O
C	518	519	|O
alpha	520	525	|O
-	525	526	|O
C	526	527	|O
beta	528	532	|O
and	533	536	|O
C	537	538	|O
beta	539	543	|O
-	543	544	|O
C	544	545	|O
gamma	546	551	|O
bonds	552	557	|O
are	558	561	|O
restricted	562	572	|O
due	573	576	|O
to	577	579	|O
cyclization	580	591	|O
of	592	594	|O
the	595	598	|O
side	599	603	|O
chain	604	609	|O
to	610	612	|O
the	613	616	|O
backbone	617	625	|O
.	625	626	|O
Also	627	631	|O
examined	632	640	|O
were	641	645	|O
analogues	646	655	|O
in	656	658	|O
which	659	664	|O
tyrosine	665	673	|O
was	674	677	|O
replaced	678	686	|O
with	687	691	|O
either	692	698	|O
trans	699	704	|B-IUPAC
-	704	705	|I-IUPAC
3	705	706	|I-IUPAC
-	706	707	|I-IUPAC
(	707	708	|I-IUPAC
4'	708	710	|I-IUPAC
-	710	711	|I-IUPAC
hydroxyphenyl	711	724	|I-IUPAC
)	724	725	|I-IUPAC
proline	725	732	|I-IUPAC
(	733	734	|O
t	734	735	|O
-	735	736	|O
Hpp	736	739	|O
)	739	740	|O
or	741	743	|O
cis	744	747	|B-IUPAC
-	747	748	|I-IUPAC
3	748	749	|I-IUPAC
-	749	750	|I-IUPAC
(	750	751	|I-IUPAC
4'	751	753	|I-IUPAC
-	753	754	|I-IUPAC
hydroxyphenyl	754	767	|I-IUPAC
)	767	768	|I-IUPAC
proline	768	775	|I-IUPAC
(	776	777	|O
c	777	778	|O
-	778	779	|O
Hpp	779	782	|O
)	782	783	|O
,	783	784	|O
residues	785	793	|O
in	794	796	|O
which	797	802	|O
rotations	803	812	|O
about	813	818	|O
C	819	820	|O
alpha	821	826	|O
-	826	827	|O
C	827	828	|O
beta	829	833	|O
,	833	834	|O
but	835	838	|O
not	839	842	|O
C	843	844	|O
beta	845	849	|O
-	849	850	|O
C	850	851	|O
gamma	852	857	|O
,	857	858	|O
are	859	862	|O
restricted	863	873	|O
.	873	874	|O
Both	875	879	|O
the	880	883	|O
t	884	885	|O
-	885	886	|O
Hpp1	886	890	|O
and	891	894	|O
c	895	896	|O
-	896	897	|O
Hpp1	897	901	|O
analogues	902	911	|O
displayed	912	921	|O
delta	922	927	|O
receptor	928	936	|O
binding	937	944	|O
affinity	945	953	|O
similar	954	961	|O
to	962	964	|O
the	965	968	|O
parent	969	975	|O
Tyr1	976	980	|O
-	980	981	|O
containing	981	991	|O
peptide	992	999	|O
,	999	1000	|O
while	1001	1006	|O
the	1007	1010	|O
D	1011	1012	|O
-	1012	1013	|O
Hat1	1013	1017	|O
,	1017	1018	|O
L	1019	1020	|O
-	1020	1021	|O
Hat1	1021	1025	|O
,	1025	1026	|O
and	1027	1030	|O
L	1031	1032	|O
-	1032	1033	|O
Hai1	1033	1037	|O
analogues	1038	1047	|O
exhibited	1048	1057	|O
somewhat	1058	1066	|O
lower	1067	1072	|O
affinity	1073	1081	|O
.	1081	1082	|O
The	1083	1086	|O
results	1087	1094	|O
observed	1095	1103	|O
for	1104	1107	|O
the	1108	1111	|O
t	1112	1113	|O
-	1113	1114	|O
Hpp1	1114	1118	|O
and	1119	1122	|O
c	1123	1124	|O
-	1124	1125	|O
Hpp1	1125	1129	|O
analogues	1130	1139	|O
are	1140	1143	|O
particularly	1144	1156	|O
significant	1157	1168	|O
since	1169	1174	|O
these	1175	1180	|O
two	1181	1184	|O
residues	1185	1193	|O
have	1194	1198	|O
little	1199	1205	|O
accessible	1206	1216	|O
conformational	1217	1231	|O
space	1232	1237	|O
in	1238	1240	|O
common	1241	1247	|O
.	1247	1248	|O
Since	1249	1254	|O
the	1255	1258	|O
binding	1259	1266	|O
conformation	1267	1279	|O
of	1280	1282	|O
residue	1283	1290	|O
1	1291	1292	|O
must	1293	1297	|O
be	1298	1300	|O
included	1301	1309	|O
in	1310	1312	|O
this	1313	1317	|O
limited	1318	1325	|O
conformational	1326	1340	|O
intersection	1341	1353	|O
,	1353	1354	|O
its	1355	1358	|O
elucidation	1359	1370	|O
is	1371	1373	|O
facilitated	1374	1385	|O
.	1385	1386	|O
Bioassay	1387	1395	|O
results	1396	1403	|O
from	1404	1408	|O
guinea	1409	1415	|O
pig	1416	1419	|O
ileum	1420	1425	|O
and	1426	1429	|O
mouse	1430	1435	|O
vas	1436	1439	|O
deferens	1440	1448	|O
preparations	1449	1461	|O
are	1462	1465	|O
in	1466	1468	|O
general	1469	1476	|O
agreement	1477	1486	|O
with	1487	1491	|O
the	1492	1495	|O
binding	1496	1503	|O
results	1504	1511	|O
;	1511	1512	|O
however	1513	1520	|O
some	1521	1525	|O
potency	1526	1533	|O
discrepancies	1534	1547	|O
are	1548	1551	|O
observed	1552	1560	|O
.	1560	1561	|O
These	1562	1567	|O
discrepancies	1568	1581	|O
may	1582	1585	|O
reflect	1586	1593	|O
different	1594	1603	|O
selectivities	1604	1617	|O
among	1618	1623	|O
delta	1624	1629	|O
receptor	1630	1638	|O
subtypes	1639	1647	|O
for	1648	1651	|O
the	1652	1655	|O
analogues	1656	1665	|O
or	1666	1668	|O
may	1669	1672	|O
represent	1673	1682	|O
differing	1683	1692	|O
efficacies	1693	1703	|O
among	1704	1709	|O
these	1710	1715	|O
conformationally	1716	1732	|O
restricted	1733	1743	|O
peptides	1744	1752	|O
.	1752	1753	|O
The	1754	1757	|O
conformational	1758	1772	|O
properties	1773	1783	|O
of	1784	1786	|O
the	1787	1790	|O
parent	1791	1797	|O
tetrapeptide	1798	1810	|O
and	1811	1814	|O
the	1815	1818	|O
residue	1819	1826	|O
1	1827	1828	|O
-	1828	1829	|O
modified	1829	1837	|O
analogues	1838	1847	|O
were	1848	1852	|O
studied	1853	1860	|O
by	1861	1863	|O
molecular	1864	1873	|O
mechanics	1874	1883	|O
computations	1884	1896	|O
.	1896	1897	|O
All	1898	1901	|O
these	1902	1907	|O
peptides	1908	1916	|O
share	1917	1922	|O
a	1923	1924	|O
common	1925	1931	|O
rigid	1932	1937	|O
tripeptide	1938	1948	|O
cycle	1949	1954	|O
with	1955	1959	|O
a	1960	1961	|O
single	1962	1968	|O
energetically	1969	1982	|O
preferred	1983	1992	|O
backbone	1993	2001	|O
conformation	2002	2014	|O
and	2015	2018	|O
three	2019	2024	|O
different	2025	2034	|O
conformers	2035	2045	|O
of	2046	2048	|O
the	2049	2052	|O
D	2053	2054	|O
-	2054	2055	|O
Cys	2055	2058	|O
,	2058	2059	|O
D	2060	2061	|O
-	2061	2062	|O
Pen	2062	2065	|O
disulfide	2066	2075	|O
bridge	2076	2082	|O
,	2082	2083	|O
two	2084	2087	|O
of	2088	2090	|O
which	2091	2096	|O
are	2097	2100	|O
observed	2101	2109	|O
in	2110	2112	|O
the	2113	2116	|O
solid	2117	2122	|O
state	2123	2128	|O
and	2129	2132	|O
in	2133	2135	|O
aqueous	2136	2143	|O
solution	2144	2152	|O
,	2152	2153	|O
as	2154	2156	|O
previously	2157	2167	|O
determined	2168	2178	|O
from	2179	2183	|O
X	2184	2185	|O
-	2185	2186	|O
ray	2186	2189	|O
crystallography	2190	2205	|O
and	2206	2209	|O
1H	2210	2212	|O
NMR	2213	2216	|O
spectroscopy	2217	2229	|O
data	2230	2234	|O
(	2235	2236	|O
Lomize	2236	2242	|O
,	2242	2243	|O
A	2244	2245	|O
;	2245	2246	|O
et	2247	2249	|O
al.	2250	2253	|O
J	2254	2255	|O
.	2255	2256	|O
Am.	2257	2260	|O
Chem.	2261	2266	|O
Soc	2267	2270	|O
.	2270	2271	|O
1994	2272	2276	|O
,	2276	2277	|O
116	2278	2281	|O
,	2281	2282	|O
429-436	2283	2290	|O
)	2290	2291	|O
.	2291	2292	|O
All	2293	2296	|O
the	2297	2300	|O
peptides	2301	2309	|O
have	2310	2314	|O
similar	2315	2322	|O
sets	2323	2327	|O
of	2328	2330	|O
low	2331	2334	|O
-	2334	2335	|O
energy	2335	2341	|O
conformations	2342	2355	|O
of	2356	2358	|O
their	2359	2364	|O
common	2365	2371	|O
flexible	2372	2380	|O
elements	2381	2389	|O
,	2389	2390	|O
the	2391	2394	|O
Phe3	2395	2399	|O
side	2400	2404	|O
chain	2405	2410	|O
and	2411	2414	|O
the	2415	2418	|O
peptide	2419	2426	|O
group	2427	2432	|O
between	2433	2440	|O
the	2441	2444	|O
first	2445	2450	|O
residue	2451	2458	|O
and	2459	2462	|O
the	2463	2466	|O
rigid	2467	2472	|O
tripeptide	2473	2483	|O
cycle	2484	2489	|O
.	2489	2490	|O
However	2491	2498	|O
,	2498	2499	|O
possible	2500	2508	|O
conformations	2509	2522	|O
of	2523	2525	|O
the	2526	2529	|O
first	2530	2535	|O
residue	2536	2543	|O
differ	2544	2550	|O
and	2551	2554	|O
depend	2555	2561	|O
on	2562	2564	|O
the	2565	2568	|O
covalent	2569	2577	|O
constraints	2578	2589	|O
incorporated	2590	2602	|O
into	2603	2607	|O
the	2608	2611	|O
side	2612	2616	|O
chain	2617	2622	|O
.	2622	2623	|O
(	2623	2624	|O
ABSTRACT	2624	2632	|O
TRUNCATED	2633	2642	|O
AT	2643	2645	|O
400	2646	2649	|O
WORDS	2650	2655	|O
)	2655	2656	|O

### abstracts1023.txt
The	0	3	|O
synthesis	4	13	|O
and	14	17	|O
sigma	18	23	|O
receptor	24	32	|O
affinity	33	41	|O
of	42	44	|O
a	45	46	|O
series	47	53	|O
of	54	56	|O
conformationally	57	73	|O
restricted	74	84	|O
derivatives	85	96	|O
of	97	99	|O
2	100	101	|B-IUPAC
-	101	102	|I-IUPAC
(	102	103	|I-IUPAC
1	103	104	|I-IUPAC
-	104	105	|I-IUPAC
pyrrolidinyl	105	117	|I-IUPAC
)	117	118	|I-IUPAC
-	118	119	|I-IUPAC
N	119	120	|I-IUPAC
-	120	121	|I-IUPAC
[	121	122	|I-IUPAC
2	122	123	|I-IUPAC
-	123	124	|I-IUPAC
(	124	125	|I-IUPAC
3,4	125	128	|I-IUPAC
-	128	129	|I-IUPAC
dichlorophenyl	129	143	|I-IUPAC
)	143	144	|I-IUPAC
ethyl	144	149	|I-IUPAC
]	149	150	|I-IUPAC
-	150	151	|I-IUPAC
N	151	152	|I-IUPAC
-	152	153	|I-IUPAC
methylethylenedi	153	169	|I-IUPAC
amine	170	175	|I-IUPAC
(	176	177	|O
1	177	178	|O
)	178	179	|O
is	180	182	|O
described	183	192	|O
.	192	193	|O
The	194	197	|O
pyrrolidinyl	198	210	|B-IUPAC
(	211	212	|O
or	212	214	|O
N	215	216	|B-IUPAC
,	216	217	|I-IUPAC
N	217	218	|I-IUPAC
-	218	219	|I-IUPAC
dialkyl	219	226	|I-IUPAC
)	226	227	|I-IUPAC
,	227	228	|I-IUPAC
ethylenediamine	228	243	|I-IUPAC
,	243	244	|O
N	244	245	|B-IUPAC
-	245	246	|I-IUPAC
alkyl	246	251	|I-IUPAC
,	251	252	|O
and	253	256	|O
phenylethyl	257	268	|B-IUPAC
portions	269	277	|B-MODIFIER
of	278	280	|O
this	281	285	|O
sigma	286	291	|O
receptor	292	300	|O
pharmacophore	301	314	|O
were	315	319	|O
restricted	320	330	|O
by	331	333	|O
its	334	337	|O
incorporation	338	351	|O
into	352	356	|O
1,2	357	360	|B-IUPAC
-	360	361	|I-IUPAC
cyclohexanediamine	361	379	|I-IUPAC
-	379	380	|O
,	380	381	|O
pyrrolidine	382	393	|B-IUPAC
-	393	394	|O
,	394	395	|O
piperidine	396	406	|B-PARTIUPAC
-	406	407	|O
,	407	408	|O
homopiperidine	409	423	|B-PARTIUPAC
-	423	424	|O
,	424	425	|O
and	426	429	|O
tetrahydroisoquinoline	430	452	|B-IUPAC
-	452	453	|O
containing	453	463	|B-MODIFIER
ligands	464	471	|I-MODIFIER
.	471	472	|O
The	473	476	|O
sigma	477	482	|O
receptor	483	491	|O
binding	492	499	|O
affinities	500	510	|O
of	511	513	|O
these	514	519	|O
compounds	520	529	|O
were	530	534	|O
determined	535	545	|O
using	546	551	|O
[	552	553	|B-IUPAC
3H	553	555	|I-IUPAC
]	555	556	|I-IUPAC
(	556	557	|I-IUPAC
+	557	558	|I-IUPAC
)	558	559	|I-IUPAC
-	559	560	|I-IUPAC
pentazocine	560	571	|I-IUPAC
in	572	574	|O
guinea	575	581	|O
pig	582	585	|O
brain	586	591	|O
homogenates	592	603	|O
.	603	604	|O
The	605	608	|O
synthesis	609	618	|O
of	619	621	|O
all	622	625	|O
but	626	629	|O
one	630	633	|O
class	634	639	|O
was	640	643	|O
achieved	644	652	|O
by	653	655	|O
acylation	656	665	|O
and	666	669	|O
alane	670	675	|O
reduction	676	685	|O
of	686	688	|O
the	689	692	|O
appropriate	693	704	|O
diamine	705	712	|O
precursors	713	723	|O
whose	724	729	|O
synthesis	730	739	|O
is	740	742	|O
also	743	747	|O
reported	748	756	|O
.	756	757	|O
sigma	758	763	|O
receptor	764	772	|O
affinities	773	783	|O
ranged	784	790	|O
from	791	795	|O
1.34	796	800	|O
nM	801	803	|O
for	804	807	|O
6,7	808	811	|B-IUPAC
-	811	812	|I-IUPAC
dichloro	812	820	|I-IUPAC
-	820	821	|I-IUPAC
2	821	822	|I-IUPAC
-	822	823	|I-IUPAC
[	823	824	|I-IUPAC
2	824	825	|I-IUPAC
-	825	826	|I-IUPAC
(	826	827	|I-IUPAC
1	827	828	|I-IUPAC
-	828	829	|I-IUPAC
pyrrolidinyl	829	841	|I-IUPAC
)	841	842	|I-IUPAC
ethyl	842	847	|I-IUPAC
]	847	848	|I-IUPAC
tetrahydroisoquinoline	848	870	|I-IUPAC
(	871	872	|O
12	872	874	|O
)	874	875	|O
to	876	878	|O
455	879	882	|O
nM	883	885	|O
for	886	889	|O
(	890	891	|B-IUPAC
1R	891	893	|I-IUPAC
,	893	894	|I-IUPAC
2R	894	896	|I-IUPAC
)	896	897	|I-IUPAC
-	897	898	|I-IUPAC
trans	898	903	|I-IUPAC
-	903	904	|I-IUPAC
N	904	905	|I-IUPAC
-	905	906	|I-IUPAC
[	906	907	|I-IUPAC
2	907	908	|I-IUPAC
-	908	909	|I-IUPAC
(	909	910	|I-IUPAC
3,4	910	913	|I-IUPAC
-	913	914	|I-IUPAC
dichlorophenyl	914	928	|I-IUPAC
)	928	929	|I-IUPAC
ethyl	929	934	|I-IUPAC
]	934	935	|I-IUPAC
-	935	936	|I-IUPAC
N	936	937	|I-IUPAC
-	937	938	|I-IUPAC
methyl	938	944	|I-IUPAC
-	944	945	|I-IUPAC
2	945	946	|I-IUPAC
-	946	947	|I-IUPAC
(	948	949	|I-IUPAC
1	949	950	|I-IUPAC
-	950	951	|I-IUPAC
pyrrolidinyl	951	963	|I-IUPAC
)	963	964	|I-IUPAC
cyclohexylamine	964	979	|I-IUPAC
[	980	981	|O
(	981	982	|O
-	982	983	|O
)	983	984	|O
-	984	985	|O
4	985	986	|O
]	986	987	|O
.	987	988	|O
In	989	991	|O
this	992	996	|O
displacement	997	1009	|O
assay	1010	1015	|O
,	1015	1016	|O
(	1017	1018	|B-IUPAC
+	1018	1019	|I-IUPAC
)	1019	1020	|I-IUPAC
-	1020	1021	|I-IUPAC
pentazocine	1021	1032	|I-IUPAC
exhibited	1033	1042	|O
a	1043	1044	|O
Ki	1045	1047	|O
of	1048	1050	|O
3.1	1051	1054	|O
nM	1055	1057	|O
while	1058	1063	|O
DTG	1064	1067	|O
and	1068	1071	|O
haloperidol	1072	1083	|O
showed	1084	1090	|O
Ki	1091	1093	|O
values	1094	1100	|O
of	1101	1103	|O
27.7	1104	1108	|O
and	1109	1112	|O
3.7	1113	1116	|O
nM	1117	1119	|O
,	1119	1120	|O
respectively	1121	1133	|O
.	1133	1134	|O
The	1135	1138	|O
conformationally	1139	1155	|O
free	1156	1160	|O
parent	1161	1167	|O
compound	1168	1176	|O
1	1177	1178	|O
exhibited	1179	1188	|O
a	1189	1190	|O
Ki	1191	1193	|O
value	1194	1199	|O
of	1200	1202	|O
2.1	1203	1206	|O
nM	1207	1209	|O
.	1209	1210	|O
Comparison	1211	1221	|O
of	1222	1224	|O
both	1225	1229	|O
the	1230	1233	|O
sigma	1234	1239	|O
receptor	1240	1248	|O
affinities	1249	1259	|O
and	1260	1263	|O
nitrogen	1264	1272	|O
atom	1273	1277	|O
geometry	1278	1286	|O
of	1287	1289	|O
the	1290	1293	|O
compounds	1294	1303	|O
revealed	1304	1312	|O
that	1313	1317	|O
a	1318	1319	|O
gauche	1320	1326	|O
relation	1327	1335	|O
of	1336	1338	|O
the	1339	1342	|O
nitrogen	1343	1351	|O
atoms	1352	1357	|O
of	1358	1360	|O
cis	1361	1364	|B-IUPAC
-	1364	1365	|I-IUPAC
1,2	1365	1368	|I-IUPAC
-	1368	1369	|I-IUPAC
cyclohexanediamines	1369	1388	|I-IUPAC
is	1389	1391	|O
not	1392	1395	|O
imperative	1396	1406	|O
for	1407	1410	|O
high	1411	1415	|O
affinity	1416	1424	|O
as	1425	1427	|O
we	1428	1430	|O
had	1431	1434	|O
previously	1435	1445	|O
thought	1446	1453	|O
.	1453	1454	|O
It	1455	1457	|O
is	1458	1460	|O
highly	1461	1467	|O
likely	1468	1474	|O
that	1475	1479	|O
nitrogen	1480	1488	|O
lone	1489	1493	|O
pair	1494	1498	|O
orientations	1499	1511	|O
and	1512	1515	|O
steric	1516	1522	|O
factors	1523	1530	|O
on	1531	1533	|O
the	1534	1537	|O
aliphatic	1538	1547	|O
portions	1548	1556	|O
of	1557	1559	|O
these	1560	1565	|O
ligands	1566	1573	|O
play	1574	1578	|O
a	1579	1580	|O
major	1581	1586	|O
role	1587	1591	|O
in	1592	1594	|O
the	1595	1598	|O
sigma	1599	1604	|O
receptor	1605	1613	|O
binding	1614	1621	|O
of	1622	1624	|O
this	1625	1629	|O
pharmacophore	1630	1643	|O
.	1643	1644	|O

### abstracts3449.txt
The	0	3	|O
design	4	10	|O
of	11	13	|O
analogues	14	23	|O
of	24	26	|O
7,8	27	30	|B-IUPAC
-	30	31	|I-IUPAC
dihydroretinoic	31	46	|I-IUPAC
acid	47	51	|I-IUPAC
(	52	53	|O
7,8	53	56	|O
-	56	57	|O
dihydro	57	64	|O
-	64	65	|O
RA	65	67	|O
)	67	68	|O
was	69	72	|O
based	73	78	|O
on	79	81	|O
reported	82	90	|O
biological	91	101	|O
activities	102	112	|O
of	113	115	|O
this	116	120	|O
retinoid	121	129	|O
and	130	133	|O
its	134	137	|O
dihydro	138	145	|O
-	145	146	|O
TMMP	146	150	|O
(	150	151	|O
1	151	152	|O
)	152	153	|O
analogue	154	162	|O
and	163	166	|O
on	167	169	|O
structural	170	180	|O
hypotheses	181	191	|O
.	191	192	|O
7	193	194	|B-IUPAC
-	194	195	|I-IUPAC
Oxa	195	198	|I-IUPAC
-	198	199	|I-IUPAC
7,8	199	202	|I-IUPAC
-	202	203	|I-IUPAC
dihydroretinoids	203	219	|I-IUPAC
(	220	221	|O
5	221	222	|O
,	222	223	|O
6	224	225	|O
)	225	226	|O
were	227	231	|O
prepared	232	240	|O
by	241	243	|O
O	244	245	|O
-	245	246	|O
alkylation	246	256	|O
of	257	259	|O
phenoxides	260	270	|O
by	271	273	|O
methyl	274	280	|B-IUPAC
8	281	282	|I-IUPAC
-	282	283	|I-IUPAC
bromo	283	288	|I-IUPAC
-	288	289	|I-IUPAC
3,7	289	292	|I-IUPAC
-	292	293	|I-IUPAC
dimethyl	293	301	|I-IUPAC
-	301	302	|I-IUPAC
2,4,6	302	307	|I-IUPAC
-	307	308	|I-IUPAC
octatrienoate	308	321	|I-IUPAC
.	321	322	|O
In	323	325	|O
some	326	330	|O
cases	331	336	|O
,	336	337	|O
C	338	339	|O
-	339	340	|O
alkylation	340	350	|O
also	351	355	|O
occurred	356	364	|O
.	364	365	|O
7	366	367	|B-IUPAC
-	367	368	|I-IUPAC
Aza	368	371	|I-IUPAC
-	371	372	|I-IUPAC
8	372	373	|I-IUPAC
-	373	374	|I-IUPAC
oxo	374	377	|I-IUPAC
-	377	378	|I-IUPAC
7,8	378	381	|I-IUPAC
-	381	382	|I-IUPAC
dihydroretinoids	382	398	|I-IUPAC
(	399	400	|O
12	400	402	|O
,	402	403	|O
13	404	406	|O
)	406	407	|O
were	408	412	|O
synthesized	413	424	|O
from	425	429	|O
benzeneamines	430	443	|O
and	444	447	|O
the	448	451	|O
acyl	452	456	|B-IUPAC
cyano	457	462	|I-IUPAC
or	463	465	|O
bromo	466	471	|B-IUPAC
derivative	472	482	|B-MODIFIER
of	483	485	|O
the	486	489	|O
monomethyl	490	500	|O
ester	501	506	|O
of	507	509	|O
3,7	510	513	|B-IUPAC
-	513	514	|I-IUPAC
dimethyl	514	522	|I-IUPAC
-	522	523	|I-IUPAC
2,4,6	523	528	|I-IUPAC
-	528	529	|I-IUPAC
octatriene	529	539	|I-IUPAC
-	539	540	|I-IUPAC
1,8	540	543	|I-IUPAC
-	543	544	|I-IUPAC
dioic	544	549	|I-IUPAC
acid	550	554	|I-IUPAC
.	554	555	|O
These	556	561	|O
monomethyl	562	572	|O
ester	573	578	|O
precursors	579	589	|O
were	590	594	|O
synthesized	595	606	|O
from	607	611	|O
the	612	615	|O
known	616	621	|O
analogous	622	631	|O
aldehyde	632	640	|O
via	641	644	|O
an	645	647	|O
O	648	649	|B-IUPAC
-	649	650	|I-IUPAC
trimethylsilyl	650	664	|I-IUPAC
cyanohydrin	665	676	|I-IUPAC
.	676	677	|O
7	678	679	|B-IUPAC
-	679	680	|I-IUPAC
(	680	681	|I-IUPAC
2,3,5	681	686	|I-IUPAC
-	686	687	|I-IUPAC
Trimethylphenoxy	687	703	|I-IUPAC
)	703	704	|I-IUPAC
-	704	705	|I-IUPAC
3,5	705	708	|I-IUPAC
-	708	709	|I-IUPAC
dimethyl	709	717	|I-IUPAC
-	717	718	|I-IUPAC
2,4,6	718	723	|I-IUPAC
-	723	724	|I-IUPAC
octatrienoic	724	736	|I-IUPAC
acid	737	741	|I-IUPAC
(	742	743	|O
6b	743	745	|O
)	745	746	|O
was	747	750	|O
the	751	754	|O
most	755	759	|O
active	760	766	|O
of	767	769	|O
the	770	773	|O
7	774	775	|O
-	775	776	|O
oxa	776	779	|O
-	779	780	|O
7,8	780	783	|O
-	783	784	|O
dihydro	784	791	|O
-	791	792	|O
RAs	792	795	|O
in	796	798	|O
inhibiting	799	809	|O
DMBA	810	814	|O
-	814	815	|O
initiated	815	824	|O
and	825	828	|O
TPA	829	832	|O
-	832	833	|O
promoted	833	841	|O
mouse	842	847	|O
-	847	848	|O
skin	848	852	|O
papillomas	853	863	|O
.	863	864	|O
The	865	868	|O
ED	869	871	|O
(	871	872	|O
50	872	874	|O
)	874	875	|O
was	876	879	|O
about	880	885	|O
4	886	887	|O
-	887	888	|O
fold	888	892	|O
that	893	897	|O
of	898	900	|O
etretinate	901	911	|O
.	911	912	|O
Two	913	916	|O
additional	917	927	|O
7	928	929	|O
-	929	930	|O
oxa	930	933	|O
-	933	934	|O
7,8	934	937	|O
-	937	938	|O
dihydro	938	945	|O
-	945	946	|O
RAs	946	949	|O
exhibited	950	959	|O
modest	960	966	|O
activity	967	975	|O
in	976	978	|O
the	979	982	|O
papilloma	983	992	|O
assay	993	998	|O
.	998	999	|O
Some	1000	1004	|O
of	1005	1007	|O
the	1008	1011	|O
7	1012	1013	|O
-	1013	1014	|O
oxa	1014	1017	|O
-	1017	1018	|O
7,8	1018	1021	|O
-	1021	1022	|O
dihydro	1022	1029	|O
-	1029	1030	|O
RAs	1030	1033	|O
bind	1034	1038	|O
to	1039	1041	|O
CRABP	1042	1047	|O
and	1048	1051	|O
RARalpha	1052	1060	|O
.	1060	1061	|O

### abstracts4314.txt
Anthelmintic	0	12	|O
efficacies	13	23	|O
of	24	26	|O
a	27	28	|O
series	29	35	|O
of	36	38	|O
6	39	40	|B-MODIFIER
-	40	41	|I-MODIFIER
substituted	41	52	|I-MODIFIER
methyl	53	59	|B-IUPAC
imidazo	60	67	|I-IUPAC
[	67	68	|I-IUPAC
1,2	68	71	|I-IUPAC
-	71	72	|I-IUPAC
alpha	72	77	|I-IUPAC
]	77	78	|I-IUPAC
pyridine	78	86	|I-IUPAC
-	86	87	|I-IUPAC
2	87	88	|I-IUPAC
-	88	89	|I-IUPAC
carbamates	89	99	|I-IUPAC
were	100	104	|O
compared	105	113	|O
to	114	116	|O
similarly	117	126	|O
substituted	127	138	|B-MODIFIER
benzimidazole	139	152	|B-IUPAC
-	152	153	|I-IUPAC
2	153	154	|I-IUPAC
-	154	155	|I-IUPAC
carbamates	155	165	|I-IUPAC
.	165	166	|O
With	167	171	|O
only	172	176	|O
one	177	180	|O
exception	181	190	|O
,	190	191	|O
methyl	192	198	|B-IUPAC
6	199	200	|I-IUPAC
-	200	201	|I-IUPAC
benzoylimidazo	201	215	|I-IUPAC
[	215	216	|I-IUPAC
1,2	216	219	|I-IUPAC
-	219	220	|I-IUPAC
alpha	220	225	|I-IUPAC
]	225	226	|I-IUPAC
pyridine	226	234	|I-IUPAC
-	234	235	|I-IUPAC
2	235	236	|I-IUPAC
-	236	237	|I-IUPAC
carbamate	237	246	|I-IUPAC
,	246	247	|O
both	248	252	|O
classes	253	260	|O
of	261	263	|O
compounds	264	273	|O
exhibited	274	283	|O
similar	284	291	|O
activity	292	300	|O
vs.	301	304	|O
Nematospiroides	305	320	|O
dubius	321	327	|O
in	328	330	|O
mice	331	335	|O
.	335	336	|O
Preliminary	337	348	|O
screening	349	358	|O
indicated	359	368	|O
methyl	369	375	|B-IUPAC
6	376	377	|I-IUPAC
-	377	378	|I-IUPAC
(	378	379	|I-IUPAC
1,2,2	379	384	|I-IUPAC
-	384	385	|I-IUPAC
trichloroethenyl	385	401	|I-IUPAC
)	401	402	|I-IUPAC
imidazo	402	409	|I-IUPAC
[	409	410	|I-IUPAC
1,2	410	413	|I-IUPAC
-	413	414	|I-IUPAC
alpha	414	419	|I-IUPAC
]	419	420	|I-IUPAC
pyridine	420	428	|I-IUPAC
-	428	429	|I-IUPAC
2	429	430	|I-IUPAC
-	430	431	|I-IUPAC
carbamate	431	440	|I-IUPAC
to	441	443	|O
be	444	446	|O
the	447	450	|O
most	451	455	|O
potent	456	462	|O
derivative	463	473	|O
in	474	476	|O
the	477	480	|O
series	481	487	|O
.	487	488	|O
However	489	496	|O
,	496	497	|O
evaluation	498	508	|O
in	509	511	|O
sheep	512	517	|O
indicated	518	527	|O
that	528	532	|O
its	533	536	|O
anthelmintic	537	549	|O
spectrum	550	558	|O
was	559	562	|O
inferior	563	571	|O
to	572	574	|O
methyl	575	581	|B-IUPAC
6	582	583	|I-IUPAC
-	583	584	|I-IUPAC
(	584	585	|I-IUPAC
phenylsulfinyl	585	599	|I-IUPAC
)	599	600	|I-IUPAC
imidazo	600	607	|I-IUPAC
[	607	608	|I-IUPAC
1,2	608	611	|I-IUPAC
-	611	612	|I-IUPAC
alpha	612	617	|I-IUPAC
]	617	618	|I-IUPAC
pyridine	618	626	|I-IUPAC
-	626	627	|I-IUPAC
2	627	628	|I-IUPAC
-	628	629	|I-IUPAC
carbamate	629	638	|I-IUPAC
.	638	639	|O

### abstracts2023.txt
Methods	0	7	|O
have	8	12	|O
been	13	17	|O
developed	18	27	|O
for	28	31	|O
the	32	35	|O
preparation	36	47	|O
of	48	50	|O
2	51	52	|B-IUPAC
-	52	53	|I-IUPAC
(	53	54	|I-IUPAC
2	54	55	|I-IUPAC
(	55	56	|I-IUPAC
RS	56	58	|I-IUPAC
)	58	59	|I-IUPAC
-	59	60	|I-IUPAC
aminopropyl	60	71	|I-IUPAC
)	71	72	|I-IUPAC
-	72	73	|I-IUPAC
5	73	74	|I-IUPAC
-	74	75	|I-IUPAC
iodothiophenes	75	89	|I-IUPAC
.	89	90	|O
The	91	94	|O
syntheses	95	104	|O
and	105	108	|O
physical	109	117	|O
properties	118	128	|O
of	129	131	|O
2	132	133	|B-IUPAC
-	133	134	|I-IUPAC
(	134	135	|I-IUPAC
2	135	136	|I-IUPAC
(	136	137	|I-IUPAC
RS	137	139	|I-IUPAC
)	139	140	|I-IUPAC
-	140	141	|I-IUPAC
aminopropyl	141	152	|I-IUPAC
)	152	153	|I-IUPAC
-	153	154	|I-IUPAC
5	154	155	|I-IUPAC
-	155	156	|I-IUPAC
iodothiophene	156	169	|I-IUPAC
and	170	173	|O
N	174	175	|B-IUPAC
-	175	176	|I-IUPAC
isopropyl	176	185	|I-IUPAC
-	185	186	|I-IUPAC
2	186	187	|I-IUPAC
-	187	188	|I-IUPAC
(	188	189	|I-IUPAC
2	189	190	|I-IUPAC
(	190	191	|I-IUPAC
RS	191	193	|I-IUPAC
)	193	194	|I-IUPAC
-	194	195	|I-IUPAC
aminopropyl	195	206	|I-IUPAC
)	206	207	|I-IUPAC
-	207	208	|I-IUPAC
5	208	209	|I-IUPAC
-	209	210	|I-IUPAC
iodothiophene	210	223	|I-IUPAC
are	224	227	|O
described	228	237	|O
.	237	238	|O
The	239	242	|O
radioiodinated	243	257	|O
agents	258	264	|O
are	265	268	|O
of	269	271	|O
interest	272	280	|O
because	281	288	|O
of	289	291	|O
the	292	295	|O
high	296	300	|O
expected	301	309	|O
uptake	310	316	|O
and	317	320	|O
prolonged	321	330	|O
brain	331	336	|O
retention	337	346	|O
that	347	351	|O
may	352	355	|O
result	356	362	|O
from	363	367	|O
binding	368	375	|O
to	376	378	|O
high	379	383	|O
-	383	384	|O
capacity	384	392	|O
,	392	393	|O
relatively	394	404	|O
nonspecific	405	416	|O
amine	417	422	|O
binding	423	430	|O
sites	431	436	|O
.	436	437	|O
Radioiodine	438	449	|O
was	450	453	|O
introduced	454	464	|O
into	465	469	|O
the	470	473	|O
5	474	475	|O
-	475	476	|O
position	476	484	|O
of	485	487	|O
2	488	489	|B-IUPAC
-	489	490	|I-IUPAC
(	490	491	|I-IUPAC
2	491	492	|I-IUPAC
(	492	493	|I-IUPAC
RS	493	495	|I-IUPAC
)	495	496	|I-IUPAC
-	496	497	|I-IUPAC
aminopropyl	497	508	|I-IUPAC
)	508	509	|I-IUPAC
-	509	510	|I-IUPAC
5	510	511	|I-IUPAC
-	511	512	|I-IUPAC
iodothiophene	512	525	|I-IUPAC
and	526	529	|O
N	530	531	|B-IUPAC
-	531	532	|I-IUPAC
isopropyl	532	541	|I-IUPAC
-	541	542	|I-IUPAC
2	542	543	|I-IUPAC
-	543	544	|I-IUPAC
(	544	545	|I-IUPAC
2	545	546	|I-IUPAC
(	546	547	|I-IUPAC
RS	547	549	|I-IUPAC
)	549	550	|I-IUPAC
-	550	551	|I-IUPAC
aminopropyl	551	562	|I-IUPAC
)	562	563	|I-IUPAC
-	563	564	|I-IUPAC
5	564	565	|I-IUPAC
-	565	566	|I-IUPAC
iodothiophene	566	579	|I-IUPAC
by	580	582	|O
radioiodination	583	598	|O
of	599	601	|O
the	602	605	|O
corresponding	606	619	|O
5	620	621	|B-IUPAC
-	621	622	|I-IUPAC
boronic	622	629	|I-IUPAC
acid	630	634	|I-IUPAC
or	635	637	|O
5	638	639	|B-IUPAC
-	639	640	|I-IUPAC
(	640	641	|I-IUPAC
trimethylstannyl	641	657	|I-IUPAC
)	657	658	|I-IUPAC
derivatives	659	670	|B-MODIFIER
.	670	671	|O
Tissue	672	678	|O
distribution	679	691	|O
studies	692	699	|O
in	700	702	|O
rats	703	707	|O
with	708	712	|O
2	713	714	|B-IUPAC
-	714	715	|I-IUPAC
(	715	716	|I-IUPAC
2	716	717	|I-IUPAC
(	717	718	|I-IUPAC
RS	718	720	|I-IUPAC
)	720	721	|I-IUPAC
-	721	722	|I-IUPAC
aminopropyl	722	733	|I-IUPAC
)	733	734	|I-IUPAC
-	734	735	|I-IUPAC
5	735	736	|I-IUPAC
-	736	737	|I-IUPAC
[	737	738	|I-IUPAC
125I	738	742	|I-IUPAC
]	742	743	|I-IUPAC
iodothiophene	743	756	|I-IUPAC
showed	757	763	|O
high	764	768	|O
brain	769	774	|O
uptake	775	781	|O
(	782	783	|O
5	783	784	|O
min	785	788	|O
,	788	789	|O
2.77%	790	795	|O
dose	796	800	|O
/	800	801	|O
g	801	802	|O
;	802	803	|O
30	804	806	|O
min	807	810	|O
,	810	811	|O
2.51%	812	817	|O
dose	818	822	|O
/	822	823	|O
g	823	824	|O
)	824	825	|O
and	826	829	|O
good	830	834	|O
brain	835	840	|O
/	840	841	|O
blood	841	846	|O
(	847	848	|O
B	848	849	|O
/	849	850	|O
B	850	851	|O
)	851	852	|O
ratios	853	859	|O
(	860	861	|O
5	861	862	|O
min	863	866	|O
,	866	867	|O
6/1	868	871	|O
;	871	872	|O
30	873	875	|O
min	876	879	|O
3.8/1	880	885	|O
.	885	886	|O
A	887	888	|O
comparison	889	899	|O
of	900	902	|O
the	903	906	|O
brain	907	912	|O
uptake	913	919	|O
of	920	922	|O
the	923	926	|O
N	927	928	|B-IUPAC
-	928	929	|I-IUPAC
isopropyl	929	938	|I-IUPAC
derivative	939	949	|B-MODIFIER
with	950	954	|O
the	955	958	|O
2	959	960	|B-IUPAC
(	960	961	|I-IUPAC
RS	961	963	|I-IUPAC
)	963	964	|I-IUPAC
-	964	965	|I-IUPAC
aminopropyl	965	976	|I-IUPAC
analogue	977	985	|B-MODIFIER
demonstrated	986	998	|O
higher	999	1005	|O
initial	1006	1013	|O
brain	1014	1019	|O
uptake	1020	1026	|O
and	1027	1030	|O
brain	1031	1036	|O
to	1037	1039	|O
blood	1040	1045	|O
ratios	1046	1052	|O
(	1053	1054	|O
5	1054	1055	|O
min	1056	1059	|O
,	1059	1060	|O
3.2%	1061	1065	|O
dose	1066	1070	|O
/	1070	1071	|O
g	1071	1072	|O
;	1072	1073	|O
10.3/1	1074	1080	|O
)	1080	1081	|O
but	1082	1085	|O
more	1086	1090	|O
rapid	1091	1096	|O
washout	1097	1104	|O
(	1105	1106	|O
30	1106	1108	|O
min	1109	1112	|O
,	1112	1113	|O
1.37%	1114	1119	|O
dose	1120	1124	|O
;	1124	1125	|O
2.8/1	1126	1131	|O
)	1131	1132	|O
.	1132	1133	|O
These	1134	1139	|O
data	1140	1144	|O
suggest	1145	1152	|O
that	1153	1157	|O
radiolabeled	1158	1170	|O
2	1171	1172	|B-IUPAC
-	1172	1173	|I-IUPAC
(	1173	1174	|I-IUPAC
2	1174	1175	|I-IUPAC
(	1175	1176	|I-IUPAC
RS	1176	1178	|I-IUPAC
)	1178	1179	|I-IUPAC
-	1179	1180	|I-IUPAC
aminopropyl	1180	1191	|I-IUPAC
)	1191	1192	|I-IUPAC
-	1192	1193	|I-IUPAC
5	1193	1194	|I-IUPAC
-	1194	1195	|I-IUPAC
iodothiophenes	1195	1209	|I-IUPAC
are	1210	1213	|O
potentially	1214	1225	|O
useful	1226	1232	|O
agents	1233	1239	|O
for	1240	1243	|O
cerebral	1244	1252	|O
perfusion	1253	1262	|O
imaging	1263	1270	|O
by	1271	1273	|O
single	1274	1280	|O
-	1280	1281	|O
photon	1281	1287	|O
-	1287	1288	|O
emission	1288	1296	|O
computerized	1297	1309	|O
tomography	1310	1320	|O
(	1321	1322	|O
SPECT	1322	1327	|O
)	1327	1328	|O
.	1328	1329	|O

### abstracts2975.txt
N	0	1	|O
-	1	2	|O
Substituted	2	13	|O
analogues	14	23	|O
of	24	26	|O
trans	27	32	|B-PARTIUPAC
-	32	33	|I-PARTIUPAC
7	33	34	|I-PARTIUPAC
-	34	35	|I-PARTIUPAC
and	36	39	|O
trans	40	45	|B-IUPAC
-	45	46	|I-IUPAC
9	46	47	|I-IUPAC
-	47	48	|I-IUPAC
hydroxy	48	55	|I-IUPAC
-	55	56	|I-IUPAC
1,2,3,4,4	56	65	|I-IUPAC
a	65	66	|I-IUPAC
,	66	67	|I-IUPAC
5,6,10	67	73	|I-IUPAC
b	73	74	|I-IUPAC
-	74	75	|I-IUPAC
octahydrobenzo	75	89	|I-IUPAC
[	89	90	|I-IUPAC
f	90	91	|I-IUPAC
]	91	92	|I-IUPAC
quinoline	92	101	|I-IUPAC
(	102	103	|O
trans	103	108	|O
-	108	109	|O
7	109	110	|O
-	110	111	|O
and	112	115	|O
trans	116	121	|O
-	121	122	|O
9	122	123	|O
-	123	124	|O
OH	124	126	|O
-	126	127	|O
OHBQ	127	131	|O
)	131	132	|O
were	133	137	|O
tested	138	144	|O
for	145	148	|O
dopamine	149	157	|O
(	158	159	|O
DA	159	161	|O
)	161	162	|O
D2	163	165	|O
receptor	166	174	|O
affinity	175	183	|O
by	184	186	|O
using	187	192	|O
in	193	195	|O
vitro	196	201	|O
[	202	203	|O
3H	203	205	|O
]	205	206	|O
spiperone	206	215	|O
and	216	219	|O
in	220	222	|O
vivo	223	227	|O
5,6	228	231	|O
-	231	232	|O
di	232	234	|O
-	234	235	|O
n	235	236	|O
-	236	237	|O
Pr	237	239	|O
-	239	240	|O
ADTN	240	244	|O
binding	245	252	|O
assays	253	259	|O
.	259	260	|O
Potencies	261	270	|O
at	271	273	|O
central	274	281	|O
pre	282	285	|O
-	285	286	|O
(	287	288	|O
auto	288	292	|O
-	292	293	|O
)	293	294	|O
and	295	298	|O
postsynaptic	299	311	|O
DA	312	314	|O
receptors	315	324	|O
were	325	329	|O
determined	330	340	|O
by	341	343	|O
a	344	345	|O
biochemical	346	357	|O
and	358	361	|O
a	362	363	|O
behavioral	364	374	|O
method	375	381	|O
,	381	382	|O
respectively	383	395	|O
.	395	396	|O
Corresponding	397	410	|O
data	411	415	|O
were	416	420	|O
included	421	429	|O
for	430	433	|O
analogous	434	443	|O
,	443	444	|O
resolved	445	453	|O
3	454	455	|B-IUPAC
-	455	456	|I-IUPAC
(	456	457	|I-IUPAC
3	457	458	|I-IUPAC
-	458	459	|I-IUPAC
hydroxyphenyl	459	472	|I-IUPAC
)	472	473	|I-IUPAC
piperidines	473	484	|I-IUPAC
and	485	488	|O
a	489	490	|O
few	491	494	|O
other	495	500	|O
substituted	501	512	|O
,	512	513	|O
racemic	514	521	|B-MODIFIER
3	522	523	|B-IUPAC
-	523	524	|I-IUPAC
phenylpiperidines	524	541	|I-IUPAC
.	541	542	|O
Beside	543	549	|O
the	550	553	|O
central	554	561	|O
dopaminergic	562	574	|O
effects	575	582	|O
of	583	585	|O
these	586	591	|O
compounds	592	601	|O
,	601	602	|O
previously	603	613	|O
reported	614	622	|O
sigma	623	628	|O
receptor	629	637	|O
affinity	638	646	|O
data	647	651	|O
[	652	653	|O
[	653	654	|B-IUPAC
3H	654	656	|I-IUPAC
]	656	657	|I-IUPAC
-	657	658	|I-IUPAC
(	658	659	|I-IUPAC
+	659	660	|I-IUPAC
)	660	661	|I-IUPAC
-	661	662	|I-IUPAC
3	662	663	|I-IUPAC
-	663	664	|I-IUPAC
(	664	665	|I-IUPAC
3	665	666	|I-IUPAC
-	666	667	|I-IUPAC
hydroxyphenyl	667	680	|I-IUPAC
)	680	681	|I-IUPAC
-	681	682	|I-IUPAC
N	682	683	|I-IUPAC
-	683	684	|I-IUPAC
n	684	685	|I-IUPAC
-	685	686	|I-IUPAC
propylpiperidine	686	702	|I-IUPAC
;	702	703	|O
[	704	705	|O
3H	705	707	|O
]	707	708	|O
-	708	709	|O
(	709	710	|O
+	710	711	|O
)	711	712	|O
-	712	713	|O
3	713	714	|O
-	714	715	|O
PPP	715	718	|O
]	718	719	|O
were	720	724	|O
also	725	729	|O
taken	730	735	|O
into	736	740	|O
account	741	748	|O
for	749	752	|O
a	753	754	|O
comparison	755	765	|O
of	766	768	|O
the	769	772	|O
structure	773	782	|O
-	782	783	|O
activity	783	791	|O
/	791	792	|O
affinity	792	800	|O
relationships	801	814	|O
of	815	817	|O
these	818	823	|O
compounds	824	833	|O
at	834	836	|O
these	837	842	|O
two	843	846	|O
receptor	847	855	|O
types	856	861	|O
.	861	862	|O
Larger	863	869	|O
N	870	871	|O
-	871	872	|O
substituents	872	884	|O
in	885	887	|O
both	888	892	|O
phenylpiperidines	893	910	|O
and	911	914	|O
OHBQs	915	920	|O
increase	921	929	|O
both	930	934	|O
pre	935	938	|O
-	938	939	|O
and	940	943	|O
postsynaptic	944	956	|O
dopaminergic	957	969	|O
activity	970	978	|O
.	978	979	|O
An	980	982	|O
n	983	984	|B-IUPAC
-	984	985	|I-IUPAC
propyl	985	991	|I-IUPAC
group	992	997	|B-MODIFIER
gives	998	1003	|O
high	1004	1008	|O
dopaminergic	1009	1021	|O
efficacy	1022	1030	|O
at	1031	1033	|O
both	1034	1038	|O
receptor	1039	1047	|O
sites	1048	1053	|O
(	1054	1055	|O
pre	1055	1058	|O
-	1058	1059	|O
and	1060	1063	|O
postsynaptic	1064	1076	|O
)	1076	1077	|O
in	1078	1080	|O
all	1081	1084	|O
series	1085	1091	|O
.	1091	1092	|O
However	1093	1100	|O
,	1100	1101	|O
even	1102	1106	|O
higher	1107	1113	|O
dopaminergic	1114	1126	|O
potency	1127	1134	|O
is	1135	1137	|O
observed	1138	1146	|O
for	1147	1150	|O
trans	1151	1156	|O
-	1156	1157	|O
7	1157	1158	|O
-	1158	1159	|O
OH	1159	1161	|O
-	1161	1162	|O
OHBQs	1162	1167	|O
and	1168	1171	|O
(	1172	1173	|B-IUPAC
S	1173	1174	|I-IUPAC
)	1174	1175	|I-IUPAC
-	1175	1176	|I-IUPAC
3	1176	1177	|I-IUPAC
-	1177	1178	|I-IUPAC
(	1178	1179	|I-IUPAC
3	1179	1180	|I-IUPAC
-	1180	1181	|I-IUPAC
hydroxyphenyl	1181	1194	|I-IUPAC
)	1194	1195	|I-IUPAC
piperidines	1195	1206	|I-IUPAC
with	1207	1211	|O
N	1212	1213	|O
-	1213	1214	|O
substituents	1214	1226	|O
larger	1227	1233	|O
than	1234	1238	|O
n	1239	1240	|B-IUPAC
-	1240	1241	|I-IUPAC
propyl	1241	1247	|I-IUPAC
.	1247	1248	|O
In	1249	1251	|O
contrast	1252	1260	|O
,	1260	1261	|O
trans	1262	1267	|O
-	1267	1268	|O
4	1268	1269	|O
-	1269	1270	|O
n	1270	1271	|O
-	1271	1272	|O
Bu	1272	1274	|O
-	1274	1275	|O
9	1275	1276	|O
-	1276	1277	|O
OH	1277	1279	|O
-	1279	1280	|O
OHBQ	1280	1284	|O
is	1285	1287	|O
inactive	1288	1296	|O
,	1296	1297	|O
and	1298	1301	|O
(	1302	1303	|B-IUPAC
R	1303	1304	|I-IUPAC
)	1304	1305	|I-IUPAC
-	1305	1306	|I-IUPAC
3	1306	1307	|I-IUPAC
-	1307	1308	|I-IUPAC
(	1308	1309	|I-IUPAC
3	1309	1310	|I-IUPAC
-	1310	1311	|I-IUPAC
hydroxyphenyl	1311	1324	|I-IUPAC
)	1324	1325	|I-IUPAC
-	1325	1326	|I-IUPAC
N	1326	1327	|I-IUPAC
-	1327	1328	|I-IUPAC
n	1328	1329	|I-IUPAC
-	1329	1330	|I-IUPAC
butylpiperidine	1330	1345	|I-IUPAC
is	1346	1348	|O
less	1349	1353	|O
active	1354	1360	|O
at	1361	1363	|O
central	1364	1371	|O
DA	1372	1374	|O
receptors	1375	1384	|O
than	1385	1389	|O
its	1390	1393	|O
corresponding	1394	1407	|O
n	1408	1409	|B-IUPAC
-	1409	1410	|I-IUPAC
propyl	1410	1416	|I-IUPAC
analogue	1417	1425	|B-MODIFIER
.	1425	1426	|O
This	1427	1431	|O
implies	1432	1439	|O
interesting	1440	1451	|O
differences	1452	1463	|O
in	1464	1466	|O
N	1467	1468	|O
-	1468	1469	|O
substituent	1469	1480	|O
sensitivity	1481	1492	|O
for	1493	1496	|O
the	1497	1500	|O
different	1501	1510	|O
classes	1511	1518	|O
of	1519	1521	|O
compounds	1522	1531	|O
with	1532	1536	|O
respect	1537	1544	|O
to	1545	1547	|O
the	1548	1551	|O
direction	1552	1561	|O
of	1562	1564	|O
their	1565	1570	|O
respective	1571	1581	|O
N	1582	1583	|O
-	1583	1584	|O
substituents	1584	1596	|O
at	1597	1599	|O
the	1600	1603	|O
drug	1604	1608	|O
-	1608	1609	|O
receptor	1609	1617	|O
interaction	1618	1629	|O
.	1629	1630	|O
The	1631	1634	|O
stereochemical	1635	1649	|O
and	1650	1653	|O
steric	1654	1660	|O
demands	1661	1668	|O
for	1669	1672	|O
sigma	1673	1678	|O
receptor	1679	1687	|O
affinity	1688	1696	|O
are	1697	1700	|O
much	1701	1705	|O
less	1706	1710	|O
stringent	1711	1720	|O
.	1720	1721	|O
The	1722	1725	|O
general	1726	1733	|O
trend	1734	1739	|O
is	1740	1742	|O
that	1743	1747	|O
,	1747	1748	|O
up	1749	1751	|O
to	1752	1754	|O
a	1755	1756	|O
certain	1757	1764	|O
size	1765	1769	|O
,	1769	1770	|O
the	1771	1774	|O
more	1775	1779	|O
lipophilic	1780	1790	|O
the	1791	1794	|O
N	1795	1796	|O
-	1796	1797	|O
substituent	1797	1808	|O
,	1808	1809	|O
the	1810	1813	|O
higher	1814	1820	|O
the	1821	1824	|O
affinity	1825	1833	|O
for	1834	1837	|O
sigma	1838	1843	|O
receptor	1844	1852	|O
sites	1853	1858	|O
.	1858	1859	|O

### abstracts1528.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
N	12	13	|B-IUPAC
-	13	14	|I-IUPAC
[	14	15	|I-IUPAC
4	15	16	|I-IUPAC
-	16	17	|I-IUPAC
(	17	18	|I-IUPAC
3	18	19	|I-IUPAC
-	19	20	|I-IUPAC
pyridinyl	20	29	|I-IUPAC
)	29	30	|I-IUPAC
butyl	30	35	|I-IUPAC
]	35	36	|I-IUPAC
3	37	38	|B-MODIFIER
-	38	39	|I-MODIFIER
substituted	39	50	|I-MODIFIER
propenyl	51	59	|B-IUPAC
carboxamide	60	71	|I-IUPAC
derivatives	72	83	|B-MODIFIER
bearing	84	91	|O
an	92	94	|O
unsaturated	95	106	|O
bicyclic	107	115	|O
moiety	116	122	|O
in	123	125	|O
the	126	129	|O
3	130	131	|O
-	131	132	|O
position	132	140	|O
was	141	144	|O
prepared	145	153	|O
and	154	157	|O
evaluated	158	167	|O
for	168	171	|O
PAF	172	175	|O
(	176	177	|O
platelet	177	185	|O
activating	186	196	|O
factor	197	203	|O
)	203	204	|O
antagonist	205	215	|O
activity	216	224	|O
.	224	225	|O
These	226	231	|O
compounds	232	241	|O
represent	242	251	|O
conformationally	252	268	|O
constrained	269	280	|O
direct	281	287	|O
analogues	288	297	|O
of	298	300	|O
the	301	304	|O
corresponding	305	318	|O
potent	319	325	|O
5	326	327	|B-IUPAC
-	327	328	|I-IUPAC
aryl	328	332	|I-IUPAC
-	332	333	|I-IUPAC
pentadienecarboxamides	333	355	|I-IUPAC
(	356	357	|O
5	357	358	|O
)	358	359	|O
.	359	360	|O
Most	361	365	|O
of	366	368	|O
the	369	372	|O
new	373	376	|O
compounds	377	386	|O
were	387	391	|O
active	392	398	|O
in	399	401	|O
a	402	403	|O
PAF	404	407	|O
-	407	408	|O
binding	408	415	|O
assay	416	421	|O
employing	422	431	|O
whole	432	437	|O
,	437	438	|O
washed	439	445	|O
dog	446	449	|O
platelets	450	459	|O
as	460	462	|O
the	463	466	|O
receptor	467	475	|O
source	476	482	|O
and	483	486	|O
inhibited	487	496	|O
PAF	497	500	|O
-	500	501	|O
induced	501	508	|O
bronchoconstriction	509	528	|O
in	529	531	|O
guinea	532	538	|O
pigs	539	543	|O
after	544	549	|O
intravenous	550	561	|O
administration	562	576	|O
.	576	577	|O
However	578	585	|O
,	585	586	|O
oral	587	591	|O
activity	592	600	|O
in	601	603	|O
the	604	607	|O
PAF	608	611	|O
-	611	612	|O
induced	612	619	|O
bronchoconstriction	620	639	|O
model	640	645	|O
was	646	649	|O
highly	650	656	|O
sensitive	657	666	|O
to	667	669	|O
the	670	673	|O
nature	674	680	|O
and	681	684	|O
substitution	685	697	|O
of	698	700	|O
the	701	704	|O
bicyclic	705	713	|O
ring	714	718	|O
system	719	725	|O
.	725	726	|O
The	727	730	|O
most	731	735	|O
interesting	736	747	|O
compounds	748	757	|O
included	758	766	|O
[	767	768	|B-IUPAC
R	768	769	|I-IUPAC
-	769	770	|I-IUPAC
(	770	771	|I-IUPAC
E	771	772	|I-IUPAC
)	772	773	|I-IUPAC
]	773	774	|I-IUPAC
-	774	775	|I-IUPAC
(	775	776	|I-IUPAC
1	776	777	|I-IUPAC
-	777	778	|I-IUPAC
butyl	778	783	|I-IUPAC
-	783	784	|I-IUPAC
6	784	785	|I-IUPAC
-	785	786	|I-IUPAC
methoxy	786	793	|I-IUPAC
-	793	794	|I-IUPAC
2	794	795	|I-IUPAC
-	795	796	|I-IUPAC
naphthyl	796	804	|I-IUPAC
)	804	805	|I-IUPAC
-	805	806	|I-IUPAC
N	806	807	|I-IUPAC
-	807	808	|I-IUPAC
[	808	809	|I-IUPAC
1	809	810	|I-IUPAC
-	810	811	|I-IUPAC
methyl	811	817	|I-IUPAC
-	817	818	|I-IUPAC
4	818	819	|I-IUPAC
-	819	820	|I-IUPAC
(	820	821	|I-IUPAC
3	821	822	|I-IUPAC
-	822	823	|I-IUPAC
pyridinyl	824	833	|I-IUPAC
)	833	834	|I-IUPAC
butyl	834	839	|I-IUPAC
]	839	840	|I-IUPAC
-	840	841	|I-IUPAC
2	841	842	|I-IUPAC
-	842	843	|I-IUPAC
propenamide	843	854	|I-IUPAC
(	855	856	|O
4b	856	858	|O
)	858	859	|O
,	859	860	|O
[	861	862	|B-IUPAC
R	862	863	|I-IUPAC
-	863	864	|I-IUPAC
(	864	865	|I-IUPAC
E	865	866	|I-IUPAC
)	866	867	|I-IUPAC
]	867	868	|I-IUPAC
-	868	869	|I-IUPAC
(	869	870	|I-IUPAC
3	870	871	|I-IUPAC
-	871	872	|I-IUPAC
butyl	872	877	|I-IUPAC
-	877	878	|I-IUPAC
6	878	879	|I-IUPAC
-	879	880	|I-IUPAC
methoxy	880	887	|I-IUPAC
-	887	888	|I-IUPAC
2	888	889	|I-IUPAC
-	889	890	|I-IUPAC
benzo	891	896	|I-IUPAC
[	896	897	|I-IUPAC
b	897	898	|I-IUPAC
]	898	899	|I-IUPAC
thiophene	899	908	|I-IUPAC
-	908	909	|I-IUPAC
yl	909	911	|I-IUPAC
)	911	912	|I-IUPAC
-	912	913	|I-IUPAC
N	913	914	|I-IUPAC
-	914	915	|I-IUPAC
[	915	916	|I-IUPAC
1	916	917	|I-IUPAC
-	917	918	|I-IUPAC
methyl	918	924	|I-IUPAC
-	924	925	|I-IUPAC
4	925	926	|I-IUPAC
-	926	927	|I-IUPAC
(	927	928	|I-IUPAC
3	928	929	|I-IUPAC
-	929	930	|I-IUPAC
pyridinyl	930	939	|I-IUPAC
)	939	940	|I-IUPAC
butyl	940	945	|I-IUPAC
]	945	946	|I-IUPAC
-	946	947	|I-IUPAC
2	947	948	|I-IUPAC
-	948	949	|I-IUPAC
propenamide	949	960	|I-IUPAC
(	961	962	|O
4k	962	964	|O
)	964	965	|O
,	965	966	|O
and	967	970	|O
[	971	972	|B-IUPAC
R	972	973	|I-IUPAC
-	973	974	|I-IUPAC
(	974	975	|I-IUPAC
E	975	976	|I-IUPAC
)	976	977	|I-IUPAC
]	977	978	|I-IUPAC
-	978	979	|I-IUPAC
(	979	980	|I-IUPAC
3	980	981	|I-IUPAC
-	981	982	|I-IUPAC
butyl	982	987	|I-IUPAC
-	987	988	|I-IUPAC
6	988	989	|I-IUPAC
-	989	990	|I-IUPAC
methoxy	990	997	|I-IUPAC
-	997	998	|I-IUPAC
1	998	999	|I-IUPAC
-	999	1000	|I-IUPAC
methyl	1000	1006	|I-IUPAC
-	1006	1007	|I-IUPAC
2	1007	1008	|I-IUPAC
-	1008	1009	|I-IUPAC
indoly	1009	1015	|I-IUPAC
)	1015	1016	|I-IUPAC
-	1016	1017	|I-IUPAC
N	1017	1018	|I-IUPAC
-	1018	1019	|I-IUPAC
[	1019	1020	|I-IUPAC
1	1020	1021	|I-IUPAC
-	1021	1022	|I-IUPAC
ethyl	1022	1027	|I-IUPAC
-	1027	1028	|I-IUPAC
4	1028	1029	|I-IUPAC
-	1029	1030	|I-IUPAC
(	1031	1032	|I-IUPAC
3	1032	1033	|I-IUPAC
-	1033	1034	|I-IUPAC
pyridinyl	1034	1043	|I-IUPAC
)	1043	1044	|I-IUPAC
butyl	1044	1049	|I-IUPAC
]	1049	1050	|I-IUPAC
-	1050	1051	|I-IUPAC
2	1051	1052	|I-IUPAC
-	1052	1053	|I-IUPAC
propenamide	1053	1064	|I-IUPAC
(	1065	1066	|O
4l	1066	1068	|O
)	1068	1069	|O
which	1070	1075	|O
inhibited	1076	1085	|O
PAF	1086	1089	|O
-	1089	1090	|O
induced	1090	1097	|O
broncho	1098	1105	|O
-	1105	1106	|O
constriction	1106	1118	|O
in	1119	1121	|O
guinea	1122	1128	|O
pigs	1129	1133	|O
with	1134	1138	|O
IC50s	1139	1144	|O
of	1145	1147	|O
3.0-5.4	1148	1155	|O
mg	1156	1158	|O
/	1158	1159	|O
kg	1159	1161	|O
,	1161	1162	|O
when	1163	1167	|O
the	1168	1171	|O
animals	1172	1179	|O
were	1180	1184	|O
challenged	1185	1195	|O
2	1196	1197	|O
h	1198	1199	|O
after	1200	1205	|O
drug	1206	1210	|O
treatment	1211	1220	|O
.	1220	1221	|O
They	1222	1226	|O
were	1227	1231	|O
also	1232	1236	|O
highly	1237	1243	|O
effective	1244	1253	|O
6	1254	1255	|O
h	1256	1257	|O
after	1258	1263	|O
a	1264	1265	|O
50	1266	1268	|O
mg	1269	1271	|O
/	1271	1272	|O
kg	1272	1274	|O
oral	1275	1279	|O
dose	1280	1284	|O
.	1284	1285	|O
This	1286	1290	|O
study	1291	1296	|O
supports	1297	1305	|O
the	1306	1309	|O
notion	1310	1316	|O
that	1317	1321	|O
the	1322	1325	|O
key	1326	1329	|O
remote	1330	1336	|O
aromatic	1337	1345	|O
ring	1346	1350	|O
present	1351	1358	|O
in	1359	1361	|O
the	1362	1365	|O
5	1366	1367	|B-IUPAC
-	1367	1368	|I-IUPAC
arylpentadienecarboxamides	1368	1394	|I-IUPAC
(	1395	1396	|O
5	1396	1397	|O
)	1397	1398	|O
is	1399	1401	|O
preferentially	1402	1416	|O
coplanar	1417	1425	|O
with	1426	1430	|O
the	1431	1434	|O
diene	1435	1440	|O
system	1441	1447	|O
for	1448	1451	|O
good	1452	1456	|O
PAF	1457	1460	|O
antagonist	1461	1471	|O
activity	1472	1480	|O
.	1480	1481	|O

### abstracts2786.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
secondary	12	21	|O
and	22	25	|O
tertiary	26	34	|O
N	35	36	|O
-	36	37	|O
alkyl	37	42	|O
derivatives	43	54	|O
of	55	57	|O
(	58	59	|B-IUPAC
R	59	60	|I-IUPAC
)	60	61	|I-IUPAC
-	61	62	|I-IUPAC
2	62	63	|I-IUPAC
-	63	64	|I-IUPAC
amino	64	69	|I-IUPAC
-	69	70	|I-IUPAC
5	70	71	|I-IUPAC
-	71	72	|I-IUPAC
fluorotetralin	72	86	|I-IUPAC
have	87	91	|O
been	92	96	|O
prepared	97	105	|O
.	105	106	|O
The	107	110	|O
affinities	111	121	|O
of	122	124	|O
the	125	128	|O
compounds	129	138	|O
for	139	142	|O
[	143	144	|O
3H	144	146	|O
]	146	147	|O
raclopride	147	157	|O
-	157	158	|O
labeled	158	165	|O
cloned	166	172	|O
human	173	178	|O
dopamine	179	187	|O
(	188	189	|O
DA	189	191	|O
)	191	192	|O
D2	193	195	|O
and	196	199	|O
D3	200	202	|O
receptors	203	212	|O
as	213	215	|O
well	216	220	|O
as	221	223	|O
[	224	225	|O
3H	225	227	|O
]	227	228	|O
-	228	229	|O
8	229	230	|O
-	230	231	|O
OH	231	233	|O
-	233	234	|O
DPAT	234	238	|O
-	238	239	|O
labeled	239	246	|O
rat	247	250	|O
hippocampal	251	262	|O
5	263	264	|O
-	264	265	|O
HT1A	265	269	|O
receptors	270	279	|O
were	280	284	|O
determined	285	295	|O
.	295	296	|O
In	297	299	|O
order	300	305	|O
to	306	308	|O
selectively	309	320	|O
determine	321	330	|O
affinities	331	341	|O
for	342	345	|O
the	346	349	|O
high	350	354	|O
-	354	355	|O
affinity	355	363	|O
agonist	364	371	|O
binding	372	379	|O
site	380	384	|O
at	385	387	|O
DA	388	390	|O
D2	391	393	|O
receptors	394	403	|O
,	403	404	|O
the	405	408	|O
agonist	409	416	|O
[	417	418	|O
3H	418	420	|O
]	420	421	|O
quinpirole	421	431	|O
was	432	435	|O
used	436	440	|O
.	440	441	|O
The	442	445	|O
intrinsic	446	455	|O
activities	456	466	|O
of	467	469	|O
the	470	473	|O
compounds	474	483	|O
at	484	486	|O
DA	487	489	|O
D2	490	492	|O
and	493	496	|O
D3	497	499	|O
receptors	500	509	|O
were	510	514	|O
evaluated	515	524	|O
in	525	527	|O
a	528	529	|O
[	530	531	|O
35S	531	534	|O
]	534	535	|O
GTP	535	538	|O
gamma	539	544	|O
S	545	546	|O
binding	547	554	|O
assay	555	560	|O
.	560	561	|O
The	562	565	|O
novel	566	571	|O
compounds	572	581	|O
were	582	586	|O
characterized	587	600	|O
as	601	603	|O
dopaminergic	604	616	|O
antagonists	617	628	|O
or	629	631	|O
inverse	632	639	|O
agonists	640	648	|O
.	648	649	|O
The	650	653	|O
antagonist	654	664	|O
(	665	666	|B-IUPAC
R	666	667	|I-IUPAC
)	667	668	|I-IUPAC
-	668	669	|I-IUPAC
2	669	670	|I-IUPAC
-	670	671	|I-IUPAC
(	671	672	|I-IUPAC
butylpropylamino	672	688	|I-IUPAC
)	688	689	|I-IUPAC
-	689	690	|I-IUPAC
5	690	691	|I-IUPAC
-	691	692	|I-IUPAC
fluorotetralin	692	706	|I-IUPAC
(	707	708	|O
16	708	710	|O
)	710	711	|O
bound	712	717	|O
with	718	722	|O
high	723	727	|O
affinity	728	736	|O
(	737	738	|O
Ki	738	740	|O
=	741	742	|O
4.4	743	746	|O
nM	747	749	|O
)	749	750	|O
to	751	753	|O
the	754	757	|O
DA	758	760	|O
D3	761	763	|O
receptor	764	772	|O
and	773	776	|O
was	777	780	|O
the	781	784	|O
most	785	789	|O
D3	790	792	|O
-	792	793	|O
selective	793	802	|O
compound	803	811	|O
(	812	813	|O
10	813	815	|O
-	815	816	|O
fold	816	820	|O
)	820	821	|O
.	821	822	|O
(	823	824	|B-IUPAC
R	824	825	|I-IUPAC
)	825	826	|I-IUPAC
-	826	827	|I-IUPAC
2	827	828	|I-IUPAC
-	828	829	|I-IUPAC
[	829	830	|I-IUPAC
[	830	831	|I-IUPAC
4	831	832	|I-IUPAC
-	832	833	|I-IUPAC
(	833	834	|I-IUPAC
8	834	835	|I-IUPAC
-	835	836	|I-IUPAC
Aza	836	839	|I-IUPAC
-	839	840	|I-IUPAC
7	840	841	|I-IUPAC
,	841	842	|I-IUPAC
9	843	844	|I-IUPAC
-	844	845	|I-IUPAC
dioxospiro	845	855	|I-IUPAC
[	855	856	|I-IUPAC
4.5	856	859	|I-IUPAC
]	859	860	|I-IUPAC
decan	860	865	|I-IUPAC
-	865	866	|I-IUPAC
8	866	867	|I-IUPAC
-	867	868	|I-IUPAC
yl	868	870	|I-IUPAC
)	870	871	|I-IUPAC
butyl	871	876	|I-IUPAC
]	876	877	|I-IUPAC
propylamino	877	888	|I-IUPAC
]	888	889	|I-IUPAC
-	889	890	|I-IUPAC
5	890	891	|I-IUPAC
-	891	892	|I-IUPAC
fluorote	892	900	|I-IUPAC
tralin	901	907	|I-IUPAC
(	908	909	|O
18	909	911	|O
)	911	912	|O
bound	913	918	|O
with	919	923	|O
very	924	928	|O
high	929	933	|O
affinity	934	942	|O
to	943	945	|O
both	946	950	|O
DA	951	953	|O
D3	954	956	|O
and	957	960	|O
5	961	962	|O
-	962	963	|O
HT1A	963	967	|O
receptors	968	977	|O
(	978	979	|O
Ki	979	981	|O
=	982	983	|O
0.2	984	987	|O
nM	988	990	|O
)	990	991	|O
and	992	995	|O
was	996	999	|O
also	1000	1004	|O
characterized	1005	1018	|O
as	1019	1021	|O
a	1022	1023	|O
dopaminergic	1024	1036	|O
antagonist	1037	1047	|O
.	1047	1048	|O
(	1049	1050	|B-IUPAC
R	1050	1051	|I-IUPAC
)	1051	1052	|I-IUPAC
-	1052	1053	|I-IUPAC
2	1053	1054	|I-IUPAC
-	1054	1055	|I-IUPAC
(	1055	1056	|I-IUPAC
Benzylpropylamino	1056	1073	|I-IUPAC
)	1073	1074	|I-IUPAC
-	1074	1075	|I-IUPAC
5	1075	1076	|I-IUPAC
-	1076	1077	|I-IUPAC
fluorotetralin	1077	1091	|I-IUPAC
(	1092	1093	|O
10	1093	1095	|O
)	1095	1096	|O
behaved	1097	1104	|O
as	1105	1107	|O
an	1108	1110	|O
inverse	1111	1118	|O
agonist	1119	1126	|O
at	1127	1129	|O
both	1130	1134	|O
DA	1135	1137	|O
D2	1138	1140	|O
and	1141	1144	|O
D3	1145	1147	|O
receptors	1148	1157	|O
.	1157	1158	|O
It	1159	1161	|O
decreased	1162	1171	|O
the	1172	1175	|O
basal	1176	1181	|O
[	1182	1183	|O
35S	1183	1186	|O
]	1186	1187	|O
GTP	1187	1190	|O
gamma	1191	1196	|O
S	1197	1198	|O
binding	1199	1206	|O
and	1207	1210	|O
potently	1211	1219	|O
inhibited	1220	1229	|O
the	1230	1233	|O
DA	1234	1236	|O
-	1236	1237	|O
stimulated	1237	1247	|O
[	1248	1249	|O
35S	1249	1252	|O
]	1252	1253	|O
GTP	1253	1256	|O
gamma	1257	1262	|O
S	1263	1264	|O
binding	1265	1272	|O
.	1272	1273	|O
It	1274	1276	|O
is	1277	1279	|O
apparent	1280	1288	|O
that	1289	1293	|O
the	1294	1297	|O
intrinsic	1298	1307	|O
activity	1308	1316	|O
of	1317	1319	|O
a	1320	1321	|O
2	1322	1323	|B-IUPAC
-	1323	1324	|I-IUPAC
aminotetralin	1324	1337	|I-IUPAC
derivative	1338	1348	|B-MODIFIER
may	1349	1352	|O
be	1353	1355	|O
modified	1356	1364	|O
by	1365	1367	|O
varying	1368	1375	|O
the	1376	1379	|O
N	1380	1381	|B-IUPAC
-	1381	1382	|I-IUPAC
alkyl	1382	1387	|I-IUPAC
substituents	1388	1400	|B-MODIFIER
.	1400	1401	|O

### abstracts976.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
dialkyl	12	19	|B-MODIFIER
N	20	21	|B-IUPAC
,	21	22	|I-IUPAC
N'	22	24	|I-IUPAC
-	24	25	|I-IUPAC
(	25	26	|I-IUPAC
m	26	27	|I-IUPAC
-	27	28	|I-IUPAC
phenylene	28	37	|I-IUPAC
)	37	38	|I-IUPAC
dioxamates	38	48	|I-IUPAC
was	49	52	|O
synthesized	53	64	|O
by	65	67	|O
treatment	68	77	|O
of	78	80	|O
the	81	84	|O
requisite	85	94	|O
m	95	96	|B-IUPAC
-	96	97	|I-IUPAC
phenylenediamines	97	114	|I-IUPAC
with	115	119	|O
an	120	122	|O
alkyloxalyl	123	134	|O
chloride	135	143	|O
in	144	146	|O
the	147	150	|O
presence	151	159	|O
of	160	162	|O
triethylamine	163	176	|O
.	176	177	|O
Hydrolysis	178	188	|O
with	189	193	|O
sodium	194	200	|O
hydroxide	201	210	|O
solution	211	219	|O
gave	220	224	|O
the	225	228	|O
corresponding	229	242	|O
N	243	244	|B-IUPAC
,	244	245	|I-IUPAC
N'	245	247	|I-IUPAC
-	247	248	|I-IUPAC
(	248	249	|I-IUPAC
m	249	250	|I-IUPAC
-	250	251	|I-IUPAC
phenylene	251	260	|I-IUPAC
)	260	261	|I-IUPAC
dioxamic	261	269	|I-IUPAC
acids	270	275	|I-IUPAC
.	275	276	|O
Several	277	284	|O
N	285	286	|B-IUPAC
,	286	287	|I-IUPAC
N'	287	289	|I-IUPAC
-	289	290	|I-IUPAC
(	290	291	|I-IUPAC
p	291	292	|I-IUPAC
-	292	293	|I-IUPAC
phenylene	293	302	|I-IUPAC
)	302	303	|I-IUPAC
dioxamic	303	311	|I-IUPAC
acids	312	317	|I-IUPAC
were	318	322	|O
synthesized	323	334	|O
also	335	339	|O
in	340	342	|O
the	343	346	|O
same	347	351	|O
manner	352	358	|O
starting	359	367	|O
with	368	372	|O
the	373	376	|O
requisite	377	386	|O
p	387	388	|B-IUPAC
-	388	389	|I-IUPAC
phenylenediamines	389	406	|I-IUPAC
.	406	407	|O
These	408	413	|O
compounds	414	423	|O
were	424	428	|O
tested	429	435	|O
in	436	438	|O
the	439	442	|O
rat	443	446	|O
passive	447	454	|O
cutaneous	455	464	|O
anaphylaxis	465	476	|O
(	477	478	|O
PCA	478	481	|O
)	481	482	|O
assay	483	488	|O
.	488	489	|O
When	490	494	|O
tested	495	501	|O
iv	502	504	|O
,	504	505	|O
activity	506	514	|O
was	515	518	|O
found	519	524	|O
in	525	527	|O
the	528	531	|O
N	532	533	|B-IUPAC
,	533	534	|I-IUPAC
N'	534	536	|I-IUPAC
-	536	537	|I-IUPAC
(	537	538	|I-IUPAC
m	538	539	|I-IUPAC
-	539	540	|I-IUPAC
phenylene	540	549	|I-IUPAC
)	549	550	|I-IUPAC
dioxamic	551	559	|I-IUPAC
acids	560	565	|I-IUPAC
up	566	568	|O
to	569	571	|O
2500	572	576	|O
times	577	582	|O
that	583	587	|O
shown	588	593	|O
by	594	596	|O
disodium	597	605	|O
cromoglycate	606	618	|O
[	619	620	|O
50%	620	623	|O
inhibition	624	634	|O
at	635	637	|O
0.001	638	643	|O
mg	644	646	|O
/	646	647	|O
kg	647	649	|O
for	650	653	|O
N	654	655	|B-IUPAC
,	655	656	|I-IUPAC
N'	656	658	|I-IUPAC
-	658	659	|I-IUPAC
(	659	660	|I-IUPAC
2	660	661	|I-IUPAC
-	661	662	|I-IUPAC
chloro	662	668	|I-IUPAC
-	668	669	|I-IUPAC
5	669	670	|I-IUPAC
-	670	671	|I-IUPAC
cyano	671	676	|I-IUPAC
-	676	677	|I-IUPAC
m	677	678	|I-IUPAC
-	678	679	|I-IUPAC
phenylene	679	688	|I-IUPAC
)	688	689	|I-IUPAC
dioxamic	689	697	|I-IUPAC
acid	698	702	|I-IUPAC
(	703	704	|O
compound	704	712	|O
61	713	715	|O
)	715	716	|O
]	716	717	|O
.	717	718	|O
Oral	719	723	|O
activity	724	732	|O
was	733	736	|O
seen	737	741	|O
in	742	744	|O
this	745	749	|O
series	750	756	|O
of	757	759	|O
compounds	760	769	|O
with	770	774	|O
duration	775	783	|O
of	784	786	|O
activity	787	795	|O
up	796	798	|O
to	799	801	|O
120	802	805	|O
min	806	809	|O
.	809	810	|O
Oral	811	815	|O
activity	816	824	|O
was	825	828	|O
detected	829	837	|O
in	838	840	|O
diethyl	841	848	|B-IUPAC
N	849	850	|I-IUPAC
,	850	851	|I-IUPAC
N'	851	853	|I-IUPAC
-	853	854	|I-IUPAC
(	854	855	|I-IUPAC
2	855	856	|I-IUPAC
-	856	857	|I-IUPAC
chloro	857	863	|I-IUPAC
-	863	864	|I-IUPAC
5	864	865	|I-IUPAC
-	865	866	|I-IUPAC
cyano	866	871	|I-IUPAC
-	871	872	|I-IUPAC
m	872	873	|I-IUPAC
-	873	874	|I-IUPAC
phenylene	874	883	|I-IUPAC
)	883	884	|I-IUPAC
dioxamate	884	893	|I-IUPAC
(	894	895	|O
compound	895	903	|O
38	904	906	|O
)	906	907	|O
at	908	910	|O
levels	911	917	|O
of	918	920	|O
drug	921	925	|O
as	926	928	|O
low	929	932	|O
as	933	935	|O
0.1	936	939	|O
mg	940	942	|O
/	942	943	|O
kg	943	945	|O
.	945	946	|O

### abstracts4019.txt
Tumor	0	5	|O
cell	6	10	|O
migration	11	20	|O
and	21	24	|O
metastasis	25	35	|O
in	36	38	|O
cancer	39	45	|O
are	46	49	|O
facilitated	50	61	|O
by	62	64	|O
interaction	65	76	|O
of	77	79	|O
the	80	83	|O
serine	84	90	|O
protease	91	99	|O
urokinase	100	109	|O
type	110	114	|O
plasminogen	115	126	|O
activator	127	136	|O
(	137	138	|O
uPA	138	141	|O
)	141	142	|O
with	143	147	|O
its	148	151	|O
receptor	152	160	|O
uPAR	161	165	|O
(	166	167	|O
CD	167	169	|O
87	170	172	|O
)	172	173	|O
.	173	174	|O
Overexpression	175	189	|O
of	190	192	|O
uPA	193	196	|O
and	197	200	|O
uPAR	201	205	|O
in	206	208	|O
cancer	209	215	|O
tissues	216	223	|O
is	224	226	|O
associated	227	237	|O
with	238	242	|O
a	243	244	|O
high	245	249	|O
incidence	250	259	|O
of	260	262	|O
disease	263	270	|O
recurrence	271	281	|O
and	282	285	|O
early	286	291	|O
death	292	297	|O
.	297	298	|O
In	299	301	|O
agreement	302	311	|O
with	312	316	|O
these	317	322	|O
findings	323	331	|O
,	331	332	|O
disruption	333	343	|O
of	344	346	|O
the	347	350	|O
protein	351	358	|O
-	358	359	|O
protein	359	366	|O
interaction	367	378	|O
between	379	386	|O
uPAR	387	391	|O
present	392	399	|O
on	400	402	|O
tumor	403	408	|O
cells	409	414	|O
and	415	418	|O
its	419	422	|O
ligand	423	429	|O
uPA	430	433	|O
evolved	434	441	|O
as	442	444	|O
an	445	447	|O
attractive	448	458	|O
intervention	459	471	|O
strategy	472	480	|O
to	481	483	|O
impair	484	490	|O
tumor	491	496	|O
growth	497	503	|O
and	504	507	|O
metastasis	508	518	|O
.	518	519	|O
For	520	523	|O
this	524	528	|O
,	528	529	|O
the	530	533	|O
uPAR	534	538	|O
antagonist	539	549	|O
cyclo	550	555	|O
[	555	556	|O
19,31	556	561	|O
]	561	562	|O
[	562	563	|O
D	563	564	|O
-	564	565	|O
Cys	565	568	|O
(	568	569	|O
19	569	571	|O
)	571	572	|O
]	572	573	|O
-	573	574	|O
uPA	574	577	|O
(	577	578	|O
19	578	580	|O
)	580	581	|O
(	581	582	|O
-	582	583	|O
)	583	584	|O
(	584	585	|O
31	585	587	|O
)	587	588	|O
was	589	592	|O
optimized	593	602	|O
to	603	605	|O
efficiently	606	617	|O
interrupt	618	627	|O
binding	628	635	|O
of	636	638	|O
uPA	639	642	|O
to	643	645	|O
cellular	646	654	|O
uPAR	655	659	|O
.	659	660	|O
First	661	666	|O
,	666	667	|O
the	668	671	|O
disulfide	672	681	|O
bridge	682	688	|O
of	689	691	|O
this	692	696	|O
lead	697	701	|O
compound	702	710	|O
was	711	714	|O
shifted	715	722	|O
and	723	726	|O
then	727	731	|O
the	732	735	|O
modified	736	744	|O
peptide	745	752	|O
was	753	756	|O
shortened	757	766	|O
from	767	771	|O
the	772	775	|O
amino	776	781	|O
and	782	785	|O
carboxy	786	793	|O
terminus	794	802	|O
to	803	805	|O
generate	806	814	|O
cyclo	815	820	|O
[	820	821	|O
21,29	821	826	|O
]	826	827	|O
[	827	828	|O
Cys	828	831	|O
(	831	832	|O
21,29	832	837	|O
)	837	838	|O
]	838	839	|O
-	839	840	|O
uPA	840	843	|O
(	843	844	|O
21	844	846	|O
)	846	847	|O
(	847	848	|O
-	848	849	|O
)	849	850	|O
(	850	851	|O
30	851	853	|O
)	853	854	|O
.	854	855	|O
Next	856	860	|O
,	860	861	|O
cyclo	862	867	|O
[	867	868	|O
21,29	868	873	|O
]	873	874	|O
[	874	875	|O
D	875	876	|O
-	876	877	|O
Cys	877	880	|O
(	880	881	|O
21	881	883	|O
)	883	884	|O
Cys	884	887	|O
(	887	888	|O
29	888	890	|O
)	890	891	|O
]	891	892	|O
-	892	893	|O
uPA	893	896	|O
(	896	897	|O
21	897	899	|O
)	899	900	|O
(	900	901	|O
-	901	902	|O
)	902	903	|O
(	903	904	|O
30	904	906	|O
)	906	907	|O
was	908	911	|O
yielded	912	919	|O
by	920	922	|O
changing	923	931	|O
the	932	935	|O
chirality	936	945	|O
of	946	948	|O
Cys	949	952	|O
(	952	953	|O
21	953	955	|O
)	955	956	|O
to	957	959	|O
D	960	961	|O
-	961	962	|O
Cys	962	965	|O
(	965	966	|O
21	966	968	|O
)	968	969	|O
.	969	970	|O
For	971	974	|O
analysis	975	983	|O
of	984	986	|O
uPAR	987	991	|O
binding	992	999	|O
activity	1000	1008	|O
,	1008	1009	|O
we	1010	1012	|O
employed	1013	1021	|O
competitive	1022	1033	|O
flow	1034	1038	|O
cytofluorometric	1039	1055	|O
receptor	1056	1064	|O
binding	1065	1072	|O
assays	1073	1079	|O
,	1079	1080	|O
using	1081	1086	|O
FITC	1087	1091	|O
-	1091	1092	|O
uPA	1092	1095	|O
as	1096	1098	|O
the	1099	1102	|O
ligand	1103	1109	|O
and	1110	1113	|O
U937	1114	1118	|O
promyeloid	1119	1129	|O
leukemia	1130	1138	|O
cells	1139	1144	|O
as	1145	1147	|O
the	1148	1151	|O
cellular	1152	1160	|O
source	1161	1167	|O
of	1168	1170	|O
uPAR	1171	1175	|O
.	1175	1176	|O
As	1177	1179	|O
demonstrated	1180	1192	|O
for	1193	1196	|O
cyclo	1197	1202	|O
[	1202	1203	|O
21,29	1203	1208	|O
]	1208	1209	|O
[	1209	1210	|O
D	1210	1211	|O
-	1211	1212	|O
Cys	1212	1215	|O
(	1215	1216	|O
21	1216	1218	|O
)	1218	1219	|O
Cys	1219	1222	|O
(	1222	1223	|O
29	1223	1225	|O
)	1225	1226	|O
]	1226	1227	|O
-	1227	1228	|O
uPA	1228	1231	|O
(	1231	1232	|O
21	1232	1234	|O
)	1234	1235	|O
(	1235	1236	|O
-	1236	1237	|O
)	1237	1238	|O
(	1238	1239	|O
30	1239	1241	|O
)	1241	1242	|O
,	1242	1243	|O
the	1244	1247	|O
achieved	1248	1256	|O
peptide	1257	1264	|O
modifications	1265	1278	|O
maintained	1279	1289	|O
receptor	1290	1298	|O
binding	1299	1306	|O
activity	1307	1315	|O
(	1316	1317	|O
IC	1317	1319	|O
(	1319	1320	|O
50	1320	1322	|O
)	1322	1323	|O
=	1324	1325	|O
0.04	1326	1330	|O
microM	1331	1337	|O
)	1337	1338	|O
,	1338	1339	|O
which	1340	1345	|O
is	1346	1348	|O
close	1349	1354	|O
in	1355	1357	|O
order	1358	1363	|O
to	1364	1366	|O
that	1367	1371	|O
of	1372	1374	|O
the	1375	1378	|O
parent	1379	1385	|O
protein	1386	1393	|O
ligand	1394	1400	|O
,	1400	1401	|O
uPA	1402	1405	|O
(	1406	1407	|O
IC	1407	1409	|O
(	1409	1410	|O
50	1410	1412	|O
)	1412	1413	|O
=	1414	1415	|O
0.01	1416	1420	|O
microM	1421	1427	|O
)	1427	1428	|O
.	1428	1429	|O
A	1430	1431	|O
detailed	1432	1440	|O
NMR	1441	1444	|O
analysis	1445	1453	|O
with	1454	1458	|O
restrained	1459	1469	|O
and	1470	1473	|O
free	1474	1478	|O
molecular	1479	1488	|O
dynamics	1489	1497	|O
calculations	1498	1510	|O
in	1511	1513	|O
explicit	1514	1522	|O
H	1523	1524	|O
(	1524	1525	|O
2	1525	1526	|O
)	1526	1527	|O
O	1527	1528	|O
exhibits	1529	1537	|O
a	1538	1539	|O
well	1540	1544	|O
-	1544	1545	|O
defined	1545	1552	|O
structure	1553	1562	|O
with	1563	1567	|O
characteristic	1568	1582	|O
features	1583	1591	|O
such	1592	1596	|O
as	1597	1599	|O
an	1600	1602	|O
omega	1603	1608	|O
-	1608	1609	|O
loop	1609	1613	|O
with	1614	1618	|O
two	1619	1622	|O
betaI	1623	1628	|O
-	1628	1629	|O
turns	1629	1634	|O
about	1635	1640	|O
Lys	1641	1644	|O
(	1644	1645	|O
3	1645	1646	|O
)	1646	1647	|O
,	1647	1648	|O
Tyr	1649	1652	|O
(	1652	1653	|O
4	1653	1654	|O
)	1654	1655	|O
,	1655	1656	|O
Ser	1657	1660	|O
(	1660	1661	|O
6	1661	1662	|O
)	1662	1663	|O
,	1663	1664	|O
and	1665	1668	|O
Asn	1669	1672	|O
(	1672	1673	|O
7	1673	1674	|O
)	1674	1675	|O
.	1675	1676	|O
Hydrophobic	1677	1688	|O
clustering	1689	1699	|O
of	1700	1702	|O
the	1703	1706	|O
side	1707	1711	|O
chains	1712	1718	|O
of	1719	1721	|O
Tyr	1722	1725	|O
(	1725	1726	|O
4	1726	1727	|O
)	1727	1728	|O
,	1728	1729	|O
Phe	1730	1733	|O
(	1733	1734	|O
5	1734	1735	|O
)	1735	1736	|O
,	1736	1737	|O
Ile	1738	1741	|O
(	1741	1742	|O
8	1742	1743	|O
)	1743	1744	|O
,	1744	1745	|O
and	1746	1749	|O
Trp	1750	1753	|O
(	1753	1754	|O
10	1754	1756	|O
)	1756	1757	|O
is	1758	1760	|O
observed	1761	1769	|O
.	1769	1770	|O
Side	1771	1775	|O
chain	1776	1781	|O
mobility	1782	1790	|O
is	1791	1793	|O
analyzed	1794	1802	|O
with	1803	1807	|O
time	1808	1812	|O
-	1812	1813	|O
dependent	1813	1822	|O
distance	1823	1831	|O
restraints	1832	1842	|O
.	1842	1843	|O
The	1844	1847	|O
NMR	1848	1851	|O
structure	1852	1861	|O
of	1862	1864	|O
cyclo	1865	1870	|O
[	1870	1871	|O
21,29	1871	1876	|O
]	1876	1877	|O
[	1877	1878	|O
D	1878	1879	|O
-	1879	1880	|O
Cys	1880	1883	|O
(	1883	1884	|O
21	1884	1886	|O
)	1886	1887	|O
Cys	1887	1890	|O
(	1890	1891	|O
29	1891	1893	|O
)	1893	1894	|O
]	1894	1895	|O
-	1895	1896	|O
uPA	1896	1899	|O
(	1899	1900	|O
21	1900	1902	|O
)	1902	1903	|O
(	1903	1904	|O
-	1904	1905	|O
)	1905	1906	|O
(	1906	1907	|O
30	1907	1909	|O
)	1909	1910	|O
is	1911	1913	|O
very	1914	1918	|O
similar	1919	1926	|O
to	1927	1929	|O
the	1930	1933	|O
previously	1934	1944	|O
reported	1945	1953	|O
structure	1954	1963	|O
of	1964	1966	|O
the	1967	1970	|O
amino	1971	1976	|O
terminal	1977	1985	|O
fragment	1986	1994	|O
of	1995	1997	|O
uPA	1998	2001	|O
.	2001	2002	|O
Systematic	2003	2013	|O
point	2014	2019	|O
mutations	2020	2029	|O
led	2030	2033	|O
to	2034	2036	|O
cyclo	2037	2042	|O
[	2042	2043	|O
21,29	2043	2048	|O
]	2048	2049	|O
[	2049	2050	|O
D	2050	2051	|O
-	2051	2052	|O
Cys	2052	2055	|O
(	2055	2056	|O
21	2056	2058	|O
)	2058	2059	|O
Nle	2059	2062	|O
(	2062	2063	|O
23	2063	2065	|O
)	2065	2066	|O
Cys	2066	2069	|O
(	2069	2070	|O
29	2070	2072	|O
)	2072	2073	|O
]	2073	2074	|O
-	2074	2075	|O
uPA	2075	2078	|O
(	2078	2079	|O
21	2079	2081	|O
)	2081	2082	|O
(	2082	2083	|O
-	2083	2084	|O
)	2084	2085	|O
(	2085	2086	|O
30	2086	2088	|O
)	2088	2089	|O
,	2089	2090	|O
which	2091	2096	|O
still	2097	2102	|O
binds	2103	2108	|O
to	2109	2111	|O
uPAR	2112	2116	|O
but	2117	2120	|O
is	2121	2123	|O
resistant	2124	2133	|O
to	2134	2136	|O
proteolytic	2137	2148	|O
cleavage	2149	2157	|O
,	2157	2158	|O
e.g.	2159	2163	|O
,	2163	2164	|O
by	2165	2167	|O
the	2168	2171	|O
tumor	2172	2177	|O
-	2177	2178	|O
associated	2178	2188	|O
serine	2189	2195	|O
proteases	2196	2205	|O
uPA	2206	2209	|O
and	2210	2213	|O
plasmin	2214	2221	|O
,	2221	2222	|O
and	2223	2226	|O
is	2227	2229	|O
stable	2230	2236	|O
in	2237	2239	|O
blood	2240	2245	|O
serum	2246	2251	|O
or	2252	2254	|O
plasma	2255	2261	|O
.	2261	2262	|O
In	2263	2265	|O
conclusion	2266	2276	|O
,	2276	2277	|O
small	2278	2283	|O
cyclic	2284	2290	|O
peptides	2291	2299	|O
were	2300	2304	|O
created	2305	2312	|O
,	2312	2313	|O
which	2314	2319	|O
mimic	2320	2325	|O
the	2326	2329	|O
structure	2330	2339	|O
and	2340	2343	|O
activity	2344	2352	|O
of	2353	2355	|O
the	2356	2359	|O
binding	2360	2367	|O
epitope	2368	2375	|O
of	2376	2378	|O
uPA	2379	2382	|O
to	2383	2385	|O
uPAR	2386	2390	|O
and	2391	2394	|O
which	2395	2400	|O
may	2401	2404	|O
serve	2405	2410	|O
as	2411	2413	|O
novel	2414	2419	|O
therapeutic	2420	2431	|O
agents	2432	2438	|O
in	2439	2441	|O
cancer	2442	2448	|O
metastasis	2449	2459	|O
.	2459	2460	|O

### abstracts73.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
imidazo	12	19	|B-IUPAC
[	19	20	|I-IUPAC
4,5	20	23	|I-IUPAC
-	23	24	|I-IUPAC
d	24	25	|I-IUPAC
]	25	26	|I-IUPAC
isothiazole	26	37	|I-IUPAC
nucleosides	38	49	|B-MODIFIER
related	50	57	|O
to	58	60	|O
the	61	64	|O
antibiotic	65	75	|O
nebularine	76	86	|O
and	87	90	|O
the	91	94	|O
highly	95	101	|O
cytotoxic	102	111	|O
6	112	113	|B-IUPAC
-	113	114	|I-IUPAC
methyl	114	120	|I-IUPAC
-	120	121	|I-IUPAC
9	121	122	|I-IUPAC
-	122	123	|I-IUPAC
beta	123	127	|I-IUPAC
-	127	128	|I-IUPAC
D	128	129	|I-IUPAC
-	129	130	|I-IUPAC
ribofuranosylpurine	130	149	|I-IUPAC
have	150	154	|O
been	155	159	|O
synthesized	160	171	|O
from	172	176	|O
the	177	180	|O
corresponding	181	194	|O
heterocycles	195	207	|O
.	207	208	|O
The	209	212	|O
sodium	213	219	|O
salt	220	224	|O
glycosylation	225	238	|O
of	239	241	|O
the	242	245	|O
imidazo	246	253	|B-IUPAC
[	253	254	|I-IUPAC
4,5	254	257	|I-IUPAC
-	257	258	|I-IUPAC
d	258	259	|I-IUPAC
]	259	260	|I-IUPAC
isothiazoles	260	272	|I-IUPAC
proceeded	273	282	|O
smoothly	283	291	|O
,	291	292	|O
giving	293	299	|O
mixtures	300	308	|O
of	309	311	|O
N	312	313	|O
-	313	314	|O
4	314	315	|O
and	316	319	|O
N	320	321	|O
-	321	322	|O
6	322	323	|O
regioisomers	324	336	|O
in	337	339	|O
generally	340	349	|O
good	350	354	|O
yields	355	361	|O
.	361	362	|O
The	363	366	|O
protected	367	376	|O
derivatives	377	388	|O
were	389	393	|O
deblocked	394	403	|O
using	404	409	|O
standard	410	418	|O
conditions	419	429	|O
to	430	432	|O
afford	433	439	|O
the	440	443	|O
desired	444	451	|O
imidazo	452	459	|B-IUPAC
[	459	460	|I-IUPAC
4,5	460	463	|I-IUPAC
-	463	464	|I-IUPAC
d	464	465	|I-IUPAC
]	465	466	|I-IUPAC
-	466	467	|I-IUPAC
isothiazole	467	478	|I-IUPAC
nucleosides	479	490	|B-MODIFIER
,	490	491	|O
usually	492	499	|O
as	500	502	|O
crystalline	503	514	|O
solids	515	521	|O
.	521	522	|O
None	523	527	|O
of	528	530	|O
the	531	534	|O
new	535	538	|O
nucleosides	539	550	|O
or	551	553	|O
heterocycles	554	566	|O
displayed	567	576	|O
selective	577	586	|O
activity	587	595	|O
against	596	603	|O
human	604	609	|O
cytomegalovirus	610	625	|O
(	626	627	|O
HCMV	627	631	|O
)	631	632	|O
or	633	635	|O
herpes	636	642	|O
simplex	643	650	|O
virus	651	656	|O
type	657	661	|O
1	662	663	|O
(	664	665	|O
HSV	665	668	|O
-	668	669	|O
1	669	670	|O
)	670	671	|O
.	671	672	|O
The	673	676	|O
N	677	678	|B-MODIFIER
-	678	679	|I-MODIFIER
6	679	680	|I-MODIFIER
glycosylated	681	693	|I-MODIFIER
imidazo	694	701	|B-IUPAC
[	701	702	|I-IUPAC
4,5	702	705	|I-IUPAC
-	705	706	|I-IUPAC
d	706	707	|I-IUPAC
]	707	708	|I-IUPAC
isothiazoles	708	720	|I-IUPAC
were	721	725	|O
completely	726	736	|O
inactive	737	745	|O
up	746	748	|O
to	749	751	|O
the	752	755	|O
highest	756	763	|O
concentration	764	777	|O
tested	778	784	|O
.	784	785	|O
The	786	789	|O
N	790	791	|B-MODIFIER
-	791	792	|I-MODIFIER
6	792	793	|I-MODIFIER
glycosylated	794	806	|I-MODIFIER
imidazo	807	814	|B-IUPAC
[	814	815	|I-IUPAC
4,5	815	818	|I-IUPAC
-	818	819	|I-IUPAC
d	819	820	|I-IUPAC
]	820	821	|I-IUPAC
isothiazoles	821	833	|I-IUPAC
also	834	838	|O
were	839	843	|O
inactive	844	852	|O
in	853	855	|O
antiproliferative	856	873	|O
and	874	877	|O
cytotoxicity	878	890	|O
assays	891	897	|O
,	897	898	|O
except	899	905	|O
for	906	909	|O
3	910	911	|B-IUPAC
-	911	912	|I-IUPAC
methyl	912	918	|I-IUPAC
-	918	919	|I-IUPAC
6	919	920	|I-IUPAC
-	920	921	|I-IUPAC
beta	921	925	|I-IUPAC
-	925	926	|I-IUPAC
D	926	927	|I-IUPAC
-	927	928	|I-IUPAC
ribofuranosylimidazo	928	948	|I-IUPAC
[	948	949	|I-IUPAC
4,5	949	952	|I-IUPAC
-	952	953	|I-IUPAC
d	953	954	|I-IUPAC
]	954	955	|I-IUPAC
isothiazole	955	966	|I-IUPAC
(	967	968	|O
15a	968	971	|O
)	971	972	|O
and	973	976	|O
5	977	978	|B-IUPAC
-	978	979	|I-IUPAC
(	979	980	|I-IUPAC
benzylthio	980	990	|I-IUPAC
)	990	991	|I-IUPAC
-	991	992	|I-IUPAC
6	992	993	|I-IUPAC
-	993	994	|I-IUPAC
(	994	995	|I-IUPAC
2	995	996	|I-IUPAC
-	996	997	|I-IUPAC
deoxy	997	1002	|I-IUPAC
-	1002	1003	|I-IUPAC
beta	1003	1007	|I-IUPAC
-	1007	1008	|I-IUPAC
D	1008	1009	|I-IUPAC
-	1009	1010	|I-IUPAC
ribofuranosyl	1010	1023	|I-IUPAC
)	1023	1024	|I-IUPAC
imidazo	1024	1031	|I-IUPAC
[	1031	1032	|I-IUPAC
4,5	1032	1035	|I-IUPAC
-	1035	1036	|I-IUPAC
d	1036	1037	|I-IUPAC
]	1037	1038	|I-IUPAC
isothiaz	1038	1046	|I-IUPAC
ole	1047	1050	|I-IUPAC
(	1051	1052	|O
5e	1052	1054	|O
)	1054	1055	|O
,	1055	1056	|O
which	1057	1062	|O
showed	1063	1069	|O
moderate	1070	1078	|O
inhibition	1079	1089	|O
of	1090	1092	|O
L1210	1093	1098	|O
cell	1099	1103	|O
growth	1104	1110	|O
.	1110	1111	|O
However	1112	1119	|O
,	1119	1120	|O
the	1121	1124	|O
heterocycles	1125	1137	|O
and	1138	1141	|O
several	1142	1149	|O
of	1150	1152	|O
the	1153	1156	|O
N	1157	1158	|O
-	1158	1159	|O
4	1159	1160	|O
glycosylated	1161	1173	|O
derivatives	1174	1185	|O
were	1186	1190	|O
toxic	1191	1196	|O
to	1197	1199	|O
HFF	1200	1203	|O
,	1203	1204	|O
KB	1205	1207	|O
and	1208	1211	|O
L1210	1212	1217	|O
cells	1218	1223	|O
;	1223	1224	|O
compounds	1225	1234	|O
with	1235	1239	|O
5	1240	1241	|B-IUPAC
-	1241	1242	|I-IUPAC
benzylthio	1242	1252	|I-IUPAC
substituents	1253	1265	|B-MODIFIER
were	1266	1270	|O
the	1271	1274	|O
most	1275	1279	|O
cytotoxic	1280	1289	|O
agents	1290	1296	|O
in	1297	1299	|O
this	1300	1304	|O
series	1305	1311	|O
.	1311	1312	|O

### abstracts1415.txt
In	0	2	|O
order	3	8	|O
to	9	11	|O
obtain	12	18	|O
agents	19	25	|O
with	26	30	|O
therapeutic	31	42	|O
indices	43	50	|O
superior	51	59	|O
to	60	62	|O
those	63	68	|O
of	69	71	|O
AZT	72	75	|O
,	75	76	|O
FLT	77	80	|O
,	80	81	|O
or	82	84	|O
D4T	85	88	|O
,	88	89	|O
several	90	97	|O
analogues	98	107	|O
of	108	110	|O
anti	111	115	|O
-	115	116	|O
HIV	116	119	|O
-	119	120	|O
1	120	121	|O
nucleosides	122	133	|O
were	134	138	|O
synthesized	139	150	|O
.	150	151	|O
These	152	157	|O
include	158	165	|O
2'	166	168	|B-IUPAC
,	168	169	|I-IUPAC
3'	169	171	|I-IUPAC
-	171	172	|I-IUPAC
dideoxy	172	179	|I-IUPAC
-	179	180	|I-IUPAC
2'	180	182	|I-IUPAC
,	182	183	|I-IUPAC
3'	183	185	|I-IUPAC
-	186	187	|I-IUPAC
difluoro	187	195	|I-IUPAC
-	195	196	|I-IUPAC
5	196	197	|I-IUPAC
-	197	198	|I-IUPAC
methyluridine	198	211	|I-IUPAC
(	212	213	|O
13	213	215	|O
)	215	216	|O
,	216	217	|O
its	218	221	|O
arabino	222	229	|O
analogue	230	238	|O
19	239	241	|O
,	241	242	|O
arabino	243	250	|B-IUPAC
-	250	251	|I-IUPAC
5	251	252	|I-IUPAC
-	252	253	|I-IUPAC
methylcytosine	253	267	|I-IUPAC
analogue	268	276	|O
21	277	279	|O
,	279	280	|O
3'	281	283	|B-IUPAC
-	283	284	|I-IUPAC
deoxy	284	289	|I-IUPAC
-	289	290	|I-IUPAC
2'	290	292	|I-IUPAC
,	292	293	|I-IUPAC
3'	293	295	|I-IUPAC
-	295	296	|I-IUPAC
didehydro	296	305	|I-IUPAC
-	305	306	|I-IUPAC
2'	306	308	|I-IUPAC
-	309	310	|I-IUPAC
fluorothymidine	310	325	|I-IUPAC
(	326	327	|O
25	327	329	|O
)	329	330	|O
,	330	331	|O
3'	332	334	|B-IUPAC
-	334	335	|I-IUPAC
azido	335	340	|I-IUPAC
-	340	341	|I-IUPAC
2'	341	343	|I-IUPAC
,	343	344	|I-IUPAC
3'	344	346	|I-IUPAC
-	346	347	|I-IUPAC
dideoxy	347	354	|I-IUPAC
-	354	355	|I-IUPAC
2'	355	357	|I-IUPAC
-	357	358	|I-IUPAC
fluoro	358	364	|I-IUPAC
-	364	365	|I-IUPAC
5	365	366	|I-IUPAC
-	366	367	|I-IUPAC
methyluridine	367	380	|I-IUPAC
(	381	382	|O
29	382	384	|O
)	384	385	|O
,	385	386	|O
2'	387	389	|B-IUPAC
-	389	390	|I-IUPAC
azido	390	395	|I-IUPAC
-	395	396	|I-IUPAC
3'	396	398	|I-IUPAC
-	398	399	|I-IUPAC
fluoro	399	405	|I-IUPAC
-	405	406	|I-IUPAC
2'	406	408	|I-IUPAC
,	408	409	|I-IUPAC
3'	409	411	|I-IUPAC
-	411	412	|I-IUPAC
dideoxy	412	419	|I-IUPAC
-	419	420	|I-IUPAC
5	420	421	|I-IUPAC
-	421	422	|I-IUPAC
methyluridine	422	435	|I-IUPAC
(	436	437	|O
31	437	439	|O
)	439	440	|O
,	440	441	|O
and	442	445	|O
2'	446	448	|B-IUPAC
3'	448	450	|I-IUPAC
-	450	451	|I-IUPAC
dideoxy	451	458	|I-IUPAC
-	458	459	|I-IUPAC
2'	459	461	|I-IUPAC
-	462	463	|I-IUPAC
fluoro	463	469	|I-IUPAC
-	469	470	|I-IUPAC
5	470	471	|I-IUPAC
-	471	472	|I-IUPAC
methyluridine	472	485	|I-IUPAC
(	486	487	|O
37	487	489	|O
)	489	490	|O
.	490	491	|O
These	492	497	|O
new	498	501	|O
nucleosides	502	513	|O
were	514	518	|O
screened	519	527	|O
for	528	531	|O
their	532	537	|O
activity	538	546	|O
against	547	554	|O
HIV	555	558	|O
and	559	562	|O
feline	563	569	|O
TLV	570	573	|O
in	574	576	|O
vitro	577	582	|O
.	582	583	|O
None	584	588	|O
of	589	591	|O
the	592	595	|O
compounds	596	605	|O
showed	606	612	|O
significant	613	624	|O
activity	625	633	|O
.	633	634	|O
It	635	637	|O
is	638	640	|O
interesting	641	652	|O
to	653	655	|O
note	656	660	|O
that	661	665	|O
such	666	670	|O
a	671	672	|O
small	673	678	|O
modification	679	691	|O
in	692	694	|O
the	695	698	|O
sugar	699	704	|O
moiety	705	711	|O
of	712	714	|O
active	715	721	|O
anti	722	726	|O
-	726	727	|O
HIV	727	730	|O
nucleosides	731	742	|O
(	743	744	|O
i.e.	744	748	|O
,	748	749	|O
displacement	750	762	|O
of	763	765	|O
hydrogen	766	774	|O
by	775	777	|O
fluorine	778	786	|O
)	786	787	|O
almost	788	794	|O
completely	795	805	|O
inactivate	806	816	|O
the	817	820	|O
agents	821	827	|O
.	827	828	|O

### abstracts3750.txt
In	0	2	|O
this	3	7	|O
study	8	13	|O
we	14	16	|O
designed	17	25	|O
,	25	26	|O
prepared	27	35	|O
,	35	36	|O
and	37	40	|O
analyzed	41	49	|O
a	50	51	|O
water	52	57	|O
-	57	58	|O
soluble	58	65	|O
,	65	66	|O
long	67	71	|O
-	71	72	|O
acting	72	78	|O
insulin	79	86	|O
derivative	87	97	|O
whose	98	103	|O
protracted	104	114	|O
action	115	121	|O
in	122	124	|O
vivo	125	129	|O
is	130	132	|O
based	133	138	|O
on	139	141	|O
a	142	143	|O
new	144	147	|O
principle	148	157	|O
rather	158	164	|O
than	165	169	|O
on	170	172	|O
slower	173	179	|O
absorption	180	190	|O
rates	191	196	|O
of	197	199	|O
suspended	200	209	|O
insulin	210	217	|O
formulations	218	230	|O
.	230	231	|O
To	232	234	|O
this	235	239	|O
end	240	243	|O
,	243	244	|O
we	245	247	|O
have	248	252	|O
prepared	253	261	|O
(	262	263	|O
9	263	264	|O
-	264	265	|O
fluorenylmethoxycarbonyl	265	289	|O
-	289	290	|O
SO	290	292	|O
(	292	293	|O
3	293	294	|O
)	294	295	|O
H	295	296	|O
)	296	297	|O
(	297	298	|O
3	298	299	|O
)	299	300	|O
-	300	301	|O
insulin	301	308	|O
(	309	310	|O
(	310	311	|O
FMS	311	314	|O
)	314	315	|O
(	315	316	|O
3	316	317	|O
)	317	318	|O
-	318	319	|O
insulin	319	326	|O
)	326	327	|O
,	327	328	|O
a	329	330	|O
derivative	331	341	|O
having	342	348	|O
three	349	354	|O
9	355	356	|O
-	356	357	|O
fluorenylmethoxycarbonyl	357	381	|O
-	381	382	|O
SO	382	384	|O
(	384	385	|O
3	385	386	|O
)	386	387	|O
H	387	388	|O
(	389	390	|O
FMS	390	393	|O
)	393	394	|O
moieties	395	403	|O
covalently	404	414	|O
linked	415	421	|O
to	422	424	|O
the	425	428	|O
three	429	434	|O
amino	435	440	|O
side	441	445	|O
chains	446	452	|O
of	453	455	|O
insulin	456	463	|O
.	463	464	|O
(	465	466	|O
FMS	466	469	|O
)	469	470	|O
(	470	471	|O
3	471	472	|O
)	472	473	|O
-	473	474	|O
insulin	474	481	|O
is	482	484	|O
soluble	485	492	|O
in	493	495	|O
aqueous	496	503	|O
buffers	504	511	|O
at	512	514	|O
neutral	515	522	|O
pH	523	525	|O
,	525	526	|O
at	527	529	|O
a	530	531	|O
concentration	532	545	|O
range	546	551	|O
of	552	554	|O
0.15-0.60	555	564	|O
mM	565	567	|O
,	567	568	|O
and	569	572	|O
has	573	576	|O
about	577	582	|O
1%	583	585	|O
of	586	588	|O
both	589	593	|O
the	594	597	|O
biological	598	608	|O
potency	609	616	|O
and	617	620	|O
the	621	624	|O
receptor	625	633	|O
-	633	634	|O
binding	634	641	|O
affinity	642	650	|O
of	651	653	|O
the	654	657	|O
native	658	664	|O
hormone	665	672	|O
.	672	673	|O
Upon	674	678	|O
incubation	679	689	|O
at	690	692	|O
pH	693	695	|O
7.4	696	699	|O
and	700	703	|O
37	704	706	|O
degrees	707	714	|O
C	715	716	|O
,	716	717	|O
it	718	720	|O
undergoes	721	730	|O
a	731	732	|O
slow	733	737	|O
hydrolysis	738	748	|O
with	749	753	|O
linear	754	760	|O
regeneration	761	773	|O
of	774	776	|O
insulin	777	784	|O
possessing	785	795	|O
full	796	800	|O
biological	801	811	|O
potency	812	819	|O
.	819	820	|O
A	821	822	|O
single	823	829	|O
subcutaneous	830	842	|O
administration	843	857	|O
of	858	860	|O
(	861	862	|O
FMS	862	865	|O
)	865	866	|O
(	866	867	|O
3	867	868	|O
)	868	869	|O
-	869	870	|O
insulin	870	877	|O
to	878	880	|O
streptozocin	881	893	|O
-	893	894	|O
treated	894	901	|O
rats	902	906	|O
lowered	907	914	|O
circulating	915	926	|O
glucose	927	934	|O
levels	935	941	|O
for	942	945	|O
a	946	947	|O
prolonged	948	957	|O
period	958	964	|O
(	965	966	|O
t	966	967	|O
(	967	968	|O
1/2	968	971	|O
)	971	972	|O
=	973	974	|O
30	975	977	|O
h	978	979	|O
)	979	980	|O
.	980	981	|O
Similarly	982	991	|O
,	991	992	|O
intraperitoneal	993	1008	|O
administration	1009	1023	|O
of	1024	1026	|O
(	1027	1028	|O
FMS	1028	1031	|O
)	1031	1032	|O
(	1032	1033	|O
3	1033	1034	|O
)	1034	1035	|O
-	1035	1036	|O
insulin	1036	1043	|O
to	1044	1046	|O
healthy	1047	1054	|O
rats	1055	1059	|O
had	1060	1063	|O
a	1064	1065	|O
prolonged	1066	1075	|O
glucose	1076	1083	|O
-	1083	1084	|O
lowering	1084	1092	|O
effect	1093	1099	|O
.	1099	1100	|O
In	1101	1103	|O
this	1104	1108	|O
experimental	1109	1121	|O
system	1122	1128	|O
,	1128	1129	|O
recovery	1130	1138	|O
from	1139	1143	|O
hypoglycemia	1144	1156	|O
proceeded	1157	1166	|O
with	1167	1171	|O
a	1172	1173	|O
t	1174	1175	|O
(	1175	1176	|O
1/2	1176	1179	|O
)	1179	1180	|O
value	1181	1186	|O
of	1187	1189	|O
14	1190	1192	|O
+	1193	1194	|O
/	1194	1195	|O
-	1195	1196	|O
1	1197	1198	|O
h	1199	1200	|O
,	1200	1201	|O
as	1202	1204	|O
compared	1205	1213	|O
with	1214	1218	|O
t	1219	1220	|O
(	1220	1221	|O
1/2	1221	1224	|O
)	1224	1225	|O
=	1226	1227	|O
8.0	1228	1231	|O
+	1232	1233	|O
/	1233	1234	|O
-	1234	1235	|O
1	1236	1237	|O
h	1238	1239	|O
for	1240	1243	|O
native	1244	1250	|O
insulin	1251	1258	|O
and	1259	1262	|O
t	1263	1264	|O
(	1264	1265	|O
1/2	1265	1268	|O
)	1268	1269	|O
=	1270	1271	|O
10.0	1272	1276	|O
+	1277	1278	|O
/	1278	1279	|O
-	1279	1280	|O
1	1281	1282	|O
h	1283	1284	|O
for	1285	1288	|O
NPH	1289	1292	|O
-	1292	1293	|O
insulin	1293	1300	|O
.	1300	1301	|O
(	1302	1303	|O
FMS	1303	1306	|O
)	1306	1307	|O
(	1307	1308	|O
3	1308	1309	|O
)	1309	1310	|O
-	1310	1311	|O
insulin	1311	1318	|O
is	1319	1321	|O
more	1322	1326	|O
resistant	1327	1336	|O
to	1337	1339	|O
proteolysis	1340	1351	|O
and	1352	1355	|O
appears	1356	1363	|O
to	1364	1366	|O
be	1367	1369	|O
nonimmunogenic	1370	1384	|O
.	1384	1385	|O
On	1386	1388	|O
the	1389	1392	|O
whole	1393	1398	|O
,	1398	1399	|O
(	1400	1401	|O
FMS	1401	1404	|O
)	1404	1405	|O
(	1405	1406	|O
3	1406	1407	|O
)	1407	1408	|O
(	1408	1409	|O
-	1409	1410	|O
)	1410	1411	|O
insulin	1411	1418	|O
represents	1419	1429	|O
a	1430	1431	|O
prototype	1432	1441	|O
version	1442	1449	|O
of	1450	1452	|O
a	1453	1454	|O
water	1455	1460	|O
-	1460	1461	|O
soluble	1461	1468	|O
,	1468	1469	|O
long	1470	1474	|O
-	1474	1475	|O
acting	1475	1481	|O
preparation	1482	1493	|O
of	1494	1496	|O
insulin	1497	1504	|O
.	1504	1505	|O
It	1506	1508	|O
is	1509	1511	|O
nearly	1512	1518	|O
inactive	1519	1527	|O
at	1528	1530	|O
the	1531	1534	|O
time	1535	1539	|O
of	1540	1542	|O
administration	1543	1557	|O
,	1557	1558	|O
and	1559	1562	|O
therefore	1563	1572	|O
can	1573	1576	|O
be	1577	1579	|O
administered	1580	1592	|O
,	1592	1593	|O
at	1594	1596	|O
high	1597	1601	|O
dose	1602	1606	|O
,	1606	1607	|O
with	1608	1612	|O
no	1613	1615	|O
concern	1616	1623	|O
for	1624	1627	|O
hypoglycemia	1628	1640	|O
.	1640	1641	|O
Because	1642	1649	|O
of	1650	1652	|O
its	1653	1656	|O
decreased	1657	1666	|O
receptor	1667	1675	|O
-	1675	1676	|O
binding	1676	1683	|O
affinity	1684	1692	|O
,	1692	1693	|O
(	1694	1695	|O
FMS	1695	1698	|O
)	1698	1699	|O
(	1699	1700	|O
3	1700	1701	|O
)	1701	1702	|O
-	1702	1703	|O
insulin	1703	1710	|O
evades	1711	1717	|O
receptor	1718	1726	|O
-	1726	1727	|O
mediated	1727	1735	|O
endocytosis	1736	1747	|O
and	1748	1751	|O
degradation	1752	1763	|O
and	1764	1767	|O
,	1767	1768	|O
hence	1769	1774	|O
,	1774	1775	|O
persists	1776	1784	|O
for	1785	1788	|O
a	1789	1790	|O
long	1791	1795	|O
period	1796	1802	|O
in	1803	1805	|O
the	1806	1809	|O
circulation	1810	1821	|O
.	1821	1822	|O
The	1823	1826	|O
insulin	1827	1834	|O
constituent	1835	1846	|O
of	1847	1849	|O
the	1850	1853	|O
(	1854	1855	|O
FMS	1855	1858	|O
)	1858	1859	|O
(	1859	1860	|O
3	1860	1861	|O
)	1861	1862	|O
-	1862	1863	|O
insulin	1863	1870	|O
conjugate	1871	1880	|O
undergoes	1881	1890	|O
a	1891	1892	|O
slow	1893	1897	|O
,	1897	1898	|O
spontaneous	1899	1910	|O
activation	1911	1921	|O
in	1922	1924	|O
the	1925	1928	|O
circulatory	1929	1940	|O
system	1941	1947	|O
,	1947	1948	|O
manifesting	1949	1960	|O
a	1961	1962	|O
prolonged	1963	1972	|O
glucose	1973	1980	|O
-	1980	1981	|O
lowering	1981	1989	|O
action	1990	1996	|O
in	1997	1999	|O
vivo	2000	2004	|O
.	2004	2005	|O
According	2006	2015	|O
to	2016	2018	|O
the	2019	2022	|O
data	2023	2027	|O
presented	2028	2037	|O
here	2038	2042	|O
,	2042	2043	|O
(	2044	2045	|O
FMS	2045	2048	|O
)	2048	2049	|O
(	2049	2050	|O
3	2050	2051	|O
)	2051	2052	|O
-	2052	2053	|O
insulin	2053	2060	|O
represents	2061	2071	|O
a	2072	2073	|O
typical	2074	2081	|O
prodrug	2082	2089	|O
:	2089	2090	|O
a	2091	2092	|O
compound	2093	2101	|O
which	2102	2107	|O
by	2108	2110	|O
itself	2111	2117	|O
shows	2118	2123	|O
only	2124	2128	|O
marginal	2129	2137	|O
activity	2138	2146	|O
but	2147	2150	|O
over	2151	2155	|O
time	2156	2160	|O
it	2161	2163	|O
is	2164	2166	|O
chemically	2167	2177	|O
hydrolyzed	2178	2188	|O
to	2189	2191	|O
the	2192	2195	|O
fully	2196	2201	|O
active	2202	2208	|O
hormone	2209	2216	|O
.	2216	2217	|O

### abstracts4556.txt
As	0	2	|O
part	3	7	|O
of	8	10	|O
our	11	14	|O
investigation	15	28	|O
into	29	33	|O
the	34	37	|O
structure	38	47	|O
-	47	48	|O
activity	48	56	|O
relationship	57	69	|O
of	70	72	|O
a	73	74	|O
novel	75	80	|O
class	81	86	|O
of	87	89	|O
aromatase	90	99	|O
inhibitors	100	110	|O
,	110	111	|O
C	112	113	|O
(	113	114	|O
19	114	116	|O
)	116	117	|O
steroids	118	126	|O
having	127	133	|O
no	134	136	|O
oxygen	137	143	|O
function	144	152	|O
at	153	155	|O
C	156	157	|O
-	157	158	|O
3	158	159	|O
,	159	160	|O
we	161	163	|O
tested	164	170	|O
aromatase	171	180	|O
inhibition	181	191	|O
activity	192	200	|O
of	201	203	|O
polar	204	209	|O
diol	210	214	|O
compounds	215	224	|O
4,19	225	229	|B-IUPAC
-	229	230	|I-IUPAC
dihydroxyandrost	230	246	|I-IUPAC
-	246	247	|I-IUPAC
5	247	248	|I-IUPAC
-	248	249	|I-IUPAC
en	249	251	|I-IUPAC
-	251	252	|I-IUPAC
17	252	254	|I-IUPAC
-	254	255	|I-IUPAC
ones	255	259	|I-IUPAC
(	260	261	|O
25	261	263	|O
and	264	267	|O
27	268	270	|O
)	270	271	|O
and	272	275	|O
6,19	276	280	|B-IUPAC
-	280	281	|I-IUPAC
dihydroxyandrost	281	297	|I-IUPAC
-	297	298	|I-IUPAC
4	298	299	|I-IUPAC
-	299	300	|I-IUPAC
en	300	302	|I-IUPAC
-	302	303	|I-IUPAC
17	303	305	|I-IUPAC
-	305	306	|I-IUPAC
ones	306	310	|I-IUPAC
(	311	312	|O
36	312	314	|O
and	315	318	|O
37	319	321	|O
)	321	322	|O
.	322	323	|O
4alpha	324	330	|B-IUPAC
,	330	331	|I-IUPAC
19	331	333	|I-IUPAC
-	333	334	|I-IUPAC
Diol	334	338	|I-IUPAC
25	339	341	|O
was	342	345	|O
synthesized	346	357	|O
from	358	362	|O
tert	363	367	|B-IUPAC
-	367	368	|I-IUPAC
butyldimethylsilyoxyandrost	368	395	|I-IUPAC
-	395	396	|I-IUPAC
4	396	397	|I-IUPAC
-	397	398	|I-IUPAC
ene	398	401	|I-IUPAC
steroid	402	409	|B-MODIFIER
(	410	411	|O
9	411	412	|O
)	412	413	|O
through	414	421	|O
its	422	425	|O
OsO	426	429	|O
(	429	430	|O
4	430	431	|O
)	431	432	|O
oxidation	433	442	|O
,	442	443	|O
giving	444	450	|O
the	451	454	|O
4alpha	455	461	|B-IUPAC
,	461	462	|I-IUPAC
5alpha	462	468	|I-IUPAC
-	468	469	|I-IUPAC
dihydroxy	469	478	|I-IUPAC
derivative	479	489	|B-MODIFIER
12	490	492	|O
,	492	493	|O
as	494	496	|O
a	497	498	|O
key	499	502	|O
reaction	503	511	|O
.	511	512	|O
Acetylation	513	524	|O
of	525	527	|O
5beta	528	533	|B-IUPAC
,	533	534	|I-IUPAC
6alpha	534	540	|I-IUPAC
-	540	541	|I-IUPAC
dihydroxy	541	550	|I-IUPAC
-	550	551	|I-IUPAC
19	551	553	|I-IUPAC
-	553	554	|I-IUPAC
acetate	554	561	|I-IUPAC
30	562	564	|O
and	565	568	|O
its	569	572	|O
5alpha	573	579	|B-IUPAC
,	579	580	|I-IUPAC
6beta	580	585	|I-IUPAC
-	585	586	|I-IUPAC
analogue	586	594	|I-IUPAC
31	595	597	|O
followed	598	606	|O
by	607	609	|O
dehydration	610	621	|O
with	622	626	|O
SOCl	627	631	|O
(	631	632	|O
2	632	633	|O
)	633	634	|O
and	635	638	|O
alkaline	639	647	|O
hydroxysis	648	658	|O
gave	659	663	|O
6alpha	664	670	|O
,	670	671	|O
19	671	673	|O
-	673	674	|O
diol	674	678	|O
36	679	681	|O
and	682	685	|O
its	686	689	|O
6beta	690	695	|O
-	695	696	|O
isomer	696	702	|O
37	703	705	|O
,	705	706	|O
respectively	707	719	|O
.	719	720	|O
The	721	724	|O
stereochemistry	725	740	|O
of	741	743	|O
a	744	745	|O
hydroxy	746	753	|O
group	754	759	|O
at	760	762	|O
C	763	764	|O
-	764	765	|O
4	765	766	|O
of	767	769	|O
compound	770	778	|O
25	779	781	|O
and	782	785	|O
that	786	790	|O
at	791	793	|O
C	794	795	|O
-	795	796	|O
6	796	797	|O
of	798	800	|O
compounds	801	810	|O
36	811	813	|O
and	814	817	|O
37	818	820	|O
were	821	825	|O
determined	826	836	|O
on	837	839	|O
the	840	843	|O
basis	844	849	|O
of	850	852	|O
(	853	854	|O
1	854	855	|O
)	855	856	|O
H	856	857	|O
NMR	858	861	|O
spectroscopy	862	874	|O
in	875	877	|O
each	878	882	|O
case	883	887	|O
.	887	888	|O
4beta	889	894	|B-IUPAC
,	894	895	|I-IUPAC
19	895	897	|I-IUPAC
-	897	898	|I-IUPAC
Diol	898	902	|I-IUPAC
27	903	905	|O
,	905	906	|O
previously	907	917	|O
synthesized	918	929	|O
,	929	930	|O
was	931	934	|O
identified	935	945	|O
as	946	948	|O
an	949	951	|O
extremely	952	961	|O
powerful	962	970	|O
competitive	971	982	|O
inhibitor	983	992	|O
of	993	995	|O
aromatase	996	1005	|O
(	1006	1007	|O
K	1007	1008	|O
(	1008	1009	|O
i	1009	1010	|O
)	1010	1011	|O
=	1012	1013	|O
3.4	1014	1017	|O
nM	1018	1020	|O
)	1020	1021	|O
.	1021	1022	|O
In	1023	1025	|O
contrast	1026	1034	|O
,	1034	1035	|O
its	1036	1039	|O
4alpha	1040	1046	|B-IUPAC
,	1046	1047	|I-IUPAC
19	1047	1049	|I-IUPAC
-	1049	1050	|I-IUPAC
dihydroxy	1050	1059	|I-IUPAC
isomer	1060	1066	|B-MODIFIER
25	1067	1069	|O
and	1070	1073	|O
other	1074	1079	|O
series	1080	1086	|O
of	1087	1089	|O
diol	1090	1094	|O
compounds	1095	1104	|O
,	1104	1105	|O
6,19	1106	1110	|B-IUPAC
-	1110	1111	|I-IUPAC
dihydroxy	1111	1120	|I-IUPAC
-	1120	1121	|I-IUPAC
4	1121	1122	|I-IUPAC
-	1122	1123	|I-IUPAC
en	1123	1125	|I-IUPAC
-	1125	1126	|I-IUPAC
17	1126	1128	|I-IUPAC
-	1128	1129	|I-IUPAC
one	1129	1132	|I-IUPAC
steroids	1133	1141	|B-MODIFIER
,	1141	1142	|O
were	1143	1147	|O
moderate	1148	1156	|O
to	1157	1159	|O
poor	1160	1164	|O
competitive	1165	1176	|O
inhibitors	1177	1187	|O
(	1188	1189	|O
K	1189	1190	|O
(	1190	1191	|O
i	1191	1192	|O
)	1192	1193	|O
=	1194	1195	|O
110-800	1196	1203	|O
nM	1204	1206	|O
)	1206	1207	|O
.	1207	1208	|O
Through	1209	1216	|O
this	1217	1221	|O
series	1222	1228	|O
of	1229	1231	|O
analyses	1232	1240	|O
,	1240	1241	|O
it	1242	1244	|O
was	1245	1248	|O
concluded	1249	1258	|O
that	1259	1263	|O
hydrophilic	1264	1275	|O
interaction	1276	1287	|O
of	1288	1290	|O
a	1291	1292	|O
4beta	1293	1298	|B-IUPAC
,	1298	1299	|I-IUPAC
19	1299	1301	|I-IUPAC
-	1301	1302	|I-IUPAC
diol	1302	1306	|I-IUPAC
function	1307	1315	|B-MODIFIER
with	1316	1320	|O
the	1321	1324	|O
active	1325	1331	|O
site	1332	1336	|O
of	1337	1339	|O
aromatase	1340	1349	|O
plays	1350	1355	|O
a	1356	1357	|O
critical	1358	1366	|O
role	1367	1371	|O
in	1372	1374	|O
the	1375	1378	|O
tight	1379	1384	|O
binding	1385	1392	|O
of	1393	1395	|O
3	1396	1397	|B-IUPAC
-	1397	1398	|I-IUPAC
deoxy	1398	1403	|I-IUPAC
-	1403	1404	|I-IUPAC
5	1404	1405	|I-IUPAC
-	1405	1406	|I-IUPAC
ene	1406	1409	|I-IUPAC
steroids	1410	1418	|B-MODIFIER
.	1418	1419	|O

### abstracts2857.txt
6	0	1	|O
-	1	2	|O
[	2	3	|O
5	3	4	|O
-	4	5	|O
(	5	6	|O
4	6	7	|O
-	7	8	|O
Amidinophenyl	8	21	|O
)	21	22	|O
furan	22	27	|O
-	27	28	|O
2	28	29	|O
-	29	30	|O
yl	30	32	|O
]	32	33	|O
nicotinamidine	33	47	|O
(	48	49	|O
8a	49	51	|O
)	51	52	|O
was	53	56	|O
synthesized	57	68	|O
from	69	73	|O
6	74	75	|B-IUPAC
-	75	76	|I-IUPAC
[	76	77	|I-IUPAC
5	77	78	|I-IUPAC
-	78	79	|I-IUPAC
(	79	80	|I-IUPAC
4	80	81	|I-IUPAC
-	81	82	|I-IUPAC
cyanophenyl	82	93	|I-IUPAC
)	93	94	|I-IUPAC
furan	94	99	|I-IUPAC
-	99	100	|I-IUPAC
2	100	101	|I-IUPAC
-	101	102	|I-IUPAC
yl	102	104	|I-IUPAC
]	104	105	|I-IUPAC
nicotinonitrile	105	120	|I-IUPAC
(	121	122	|O
4a	122	124	|O
)	124	125	|O
,	125	126	|O
through	127	134	|O
the	135	138	|O
bis	139	142	|B-IUPAC
-	142	143	|I-IUPAC
O	143	144	|I-IUPAC
-	144	145	|I-IUPAC
acetoxyamidoxime	145	161	|I-IUPAC
followed	162	170	|O
by	171	173	|O
hydrogenation	174	187	|O
.	187	188	|O
Compound	189	197	|O
4a	198	200	|O
was	201	204	|O
prepared	205	213	|O
via	214	217	|O
selective	218	227	|O
bromination	228	239	|O
of	240	242	|O
6	243	244	|B-IUPAC
-	244	245	|I-IUPAC
(	245	246	|I-IUPAC
furan	246	251	|I-IUPAC
-	251	252	|I-IUPAC
2	252	253	|I-IUPAC
-	253	254	|I-IUPAC
yl	254	256	|I-IUPAC
)	256	257	|I-IUPAC
nicotinonitrile	257	272	|I-IUPAC
(	273	274	|O
2a	274	276	|O
)	276	277	|O
with	278	282	|O
N	283	284	|B-IUPAC
-	284	285	|I-IUPAC
bromosuccinimide	285	301	|I-IUPAC
,	301	302	|O
followed	303	311	|O
by	312	314	|O
Suzuki	315	321	|O
coupling	322	330	|O
with	331	335	|O
4	336	337	|B-IUPAC
-	337	338	|I-IUPAC
cyanophenylboronic	338	356	|I-IUPAC
acid	357	361	|I-IUPAC
.	361	362	|O
In	363	365	|O
a	366	367	|O
similar	368	375	|O
way	376	379	|O
,	379	380	|O
diamidines	381	391	|O
8b	392	394	|O
and	395	398	|O
8c	399	401	|O
were	402	406	|O
prepared	407	415	|O
from	416	420	|O
the	421	424	|O
dicyano	425	432	|B-IUPAC
derivatives	433	444	|B-MODIFIER
4c	445	447	|O
and	448	451	|O
4d	452	454	|O
,	454	455	|O
respectively	456	468	|O
.	468	469	|O
N	470	471	|B-IUPAC
-	471	472	|I-IUPAC
Methoxy	472	479	|I-IUPAC
-	479	480	|I-IUPAC
6	480	481	|I-IUPAC
-	481	482	|I-IUPAC
[	482	483	|I-IUPAC
5	483	484	|I-IUPAC
-	484	485	|I-IUPAC
[	485	486	|I-IUPAC
4	486	487	|I-IUPAC
-	487	488	|I-IUPAC
(	488	489	|I-IUPAC
N	489	490	|I-IUPAC
-	490	491	|I-IUPAC
methoxyamidino	491	505	|I-IUPAC
)	505	506	|I-IUPAC
phenyl	506	512	|I-IUPAC
]	512	513	|I-IUPAC
-	513	514	|I-IUPAC
furan	514	519	|I-IUPAC
-	519	520	|I-IUPAC
2	520	521	|I-IUPAC
-	521	522	|I-IUPAC
yl	522	524	|I-IUPAC
]	524	525	|I-IUPAC
-	525	526	|I-IUPAC
nicotinamidine	526	540	|I-IUPAC
(	541	542	|O
6a	542	544	|O
)	544	545	|O
was	546	549	|O
prepared	550	558	|O
via	559	562	|O
methylation	563	574	|O
of	575	577	|O
the	578	581	|O
respective	582	592	|O
diamidoxime	593	604	|O
5a	605	607	|O
with	608	612	|O
dimethylsulfate	613	628	|O
.	628	629	|O
Prodrugs	630	638	|O
6b	639	641	|O
and	642	645	|O
6c	646	648	|O
were	649	653	|O
also	654	658	|O
prepared	659	667	|O
by	668	670	|O
methylation	671	682	|O
of	683	685	|O
the	686	689	|O
respective	690	700	|O
diamidoximes	701	713	|O
5b	714	716	|O
and	717	720	|O
5d	721	723	|O
.	723	724	|O
The	725	728	|O
symmetrical	729	740	|O
diamidines	741	751	|O
14a	752	755	|O
,	755	756	|O
b	756	757	|O
were	758	762	|O
synthesized	763	774	|O
through	775	782	|O
the	783	786	|O
corresponding	787	800	|O
bis	801	804	|B-IUPAC
-	804	805	|I-IUPAC
O	805	806	|I-IUPAC
-	806	807	|I-IUPAC
acetoxyamidoxime	807	823	|I-IUPAC
followed	824	832	|O
by	833	835	|O
hydrogenation	836	849	|O
.	849	850	|O
The	851	854	|O
key	855	858	|O
compounds	859	868	|O
11a	869	872	|O
,	872	873	|O
b	873	874	|O
were	875	879	|O
conveniently	880	892	|O
obtained	893	901	|O
by	902	904	|O
Stille	905	911	|O
coupling	912	920	|O
between	921	928	|O
2,5	929	932	|B-IUPAC
-	932	933	|I-IUPAC
bis	933	936	|I-IUPAC
(	936	937	|I-IUPAC
tri	937	940	|I-IUPAC
-	940	941	|I-IUPAC
n	941	942	|I-IUPAC
-	942	943	|I-IUPAC
butylstannyl	943	955	|I-IUPAC
)	955	956	|I-IUPAC
furan	956	961	|I-IUPAC
and	962	965	|O
the	966	969	|O
corresponding	970	983	|O
heteroaryl	984	994	|O
halides	995	1002	|O
.	1002	1003	|O
These	1004	1009	|O
compounds	1010	1019	|O
have	1020	1024	|O
been	1025	1029	|O
evaluated	1030	1039	|O
in	1040	1042	|O
vitro	1043	1048	|O
for	1049	1052	|O
activity	1053	1061	|O
against	1062	1069	|O
Trypanosoma	1070	1081	|O
b	1082	1083	|O
.	1083	1084	|O
rhodesiense	1084	1095	|O
(	1096	1097	|O
T	1097	1098	|O
.	1098	1099	|O
b	1100	1101	|O
.	1101	1102	|O
r	1103	1104	|O
.	1104	1105	|O
)	1105	1106	|O
and	1107	1110	|O
P	1111	1112	|O
.	1112	1113	|O
falciparum	1114	1124	|O
(	1125	1126	|O
P	1126	1127	|O
.	1127	1128	|O
f	1129	1130	|O
.	1130	1131	|O
)	1131	1132	|O
.	1132	1133	|O
The	1134	1137	|O
diamidines	1138	1148	|O
8a	1149	1151	|O
,	1151	1152	|O
8c	1153	1155	|O
,	1155	1156	|O
and	1157	1160	|O
14b	1161	1164	|O
gave	1165	1169	|O
IC	1170	1172	|O
(	1172	1173	|O
50	1173	1175	|O
)	1175	1176	|O
values	1177	1183	|O
versus	1184	1190	|O
T	1191	1192	|O
.	1192	1193	|O
b	1194	1195	|O
.	1195	1196	|O
r	1197	1198	|O
.	1198	1199	|O
of	1200	1202	|O
less	1203	1207	|O
than	1208	1212	|O
10	1213	1215	|O
nM	1216	1218	|O
.	1218	1219	|O
Against	1220	1227	|O
P	1228	1229	|O
.	1229	1230	|O
f	1231	1232	|O
.	1232	1233	|O
8a	1234	1236	|O
,	1236	1237	|O
8b	1238	1240	|O
,	1240	1241	|O
and	1242	1245	|O
14b	1246	1249	|O
exhibited	1250	1259	|O
IC	1260	1262	|O
(	1262	1263	|O
50	1263	1265	|O
)	1265	1266	|O
values	1267	1273	|O
less	1274	1278	|O
than	1279	1283	|O
10	1284	1286	|O
nM	1287	1289	|O
.	1289	1290	|O
In	1291	1293	|O
an	1294	1296	|O
in	1297	1299	|O
vivo	1300	1304	|O
mouse	1305	1310	|O
model	1311	1316	|O
for	1317	1320	|O
T	1321	1322	|O
.	1322	1323	|O
b	1324	1325	|O
.	1325	1326	|O
r	1327	1328	|O
.	1328	1329	|O
four	1330	1334	|O
compounds	1335	1344	|O
6a	1345	1347	|O
,	1347	1348	|O
6c	1349	1351	|O
,	1351	1352	|O
6d	1353	1355	|O
,	1355	1356	|O
and	1357	1360	|O
8a	1361	1363	|O
were	1364	1368	|O
curative	1369	1377	|O
.	1377	1378	|O
Compound	1379	1387	|O
6a	1388	1390	|O
produced	1391	1399	|O
cures	1400	1405	|O
at	1406	1408	|O
an	1409	1411	|O
oral	1412	1416	|O
dosage	1417	1423	|O
of	1424	1426	|O
5	1427	1428	|O
mg	1429	1431	|O
/	1431	1432	|O
kg	1432	1434	|O
.	1434	1435	|O

### abstracts69.txt
8,9	0	3	|O
-	3	4	|O
Dioxo	4	9	|O
-	9	10	|O
6	10	11	|O
-	11	12	|O
phenyl	12	18	|O
-	18	19	|O
1	19	20	|O
-	20	21	|O
aza	21	24	|O
-	24	25	|O
7	25	26	|O
-	26	27	|O
oxabicyclo	27	37	|O
[	37	38	|O
4.2.1	38	43	|O
]	43	44	|O
nonane	44	50	|O
(	51	52	|O
1	52	53	|O
)	53	54	|O
and	55	58	|O
9,10	59	63	|B-IUPAC
-	63	64	|I-IUPAC
dioxo	64	69	|I-IUPAC
-	69	70	|I-IUPAC
7	70	71	|I-IUPAC
-	71	72	|I-IUPAC
phenyl	72	78	|I-IUPAC
-	78	79	|I-IUPAC
1	79	80	|I-IUPAC
-	80	81	|I-IUPAC
aza	81	84	|I-IUPAC
-	84	85	|I-IUPAC
8	85	86	|I-IUPAC
-	86	87	|I-IUPAC
oxabicyclo	87	97	|I-IUPAC
[	97	98	|I-IUPAC
5.2.1	98	103	|I-IUPAC
]	103	104	|I-IUPAC
decane	104	110	|I-IUPAC
(	111	112	|O
2	112	113	|O
)	113	114	|O
,	114	115	|O
examples	116	124	|O
of	125	127	|O
anti	128	132	|O
-	132	133	|O
Bredt	133	138	|O
bicyclic	139	147	|O
2,4	148	151	|B-IUPAC
-	151	152	|I-IUPAC
oxazolidinediones	152	169	|I-IUPAC
,	169	170	|O
were	171	175	|O
investigated	176	188	|O
as	189	191	|O
anticonvulsants	192	207	|O
in	208	210	|O
mice	211	215	|O
.	215	216	|O
Compound	217	225	|O
2	226	227	|O
was	228	231	|O
the	232	235	|O
more	236	240	|O
potent	241	247	|O
(	248	249	|O
anti	249	253	|O
-	253	254	|O
MES	254	257	|O
ED50	258	262	|O
=	263	264	|O
66	265	267	|O
mg	268	270	|O
/	270	271	|O
kg	271	273	|O
)	273	274	|O
,	274	275	|O
and	276	279	|O
its	280	283	|O
in	284	286	|O
vivo	287	291	|O
anti	292	296	|O
-	296	297	|O
MES	297	300	|O
effect	301	307	|O
was	308	311	|O
consistent	312	322	|O
with	323	327	|O
its	328	331	|O
in	332	334	|O
vitro	335	340	|O
potency	341	348	|O
of	349	351	|O
binding	352	359	|O
to	360	362	|O
the	363	366	|O
voltage	367	374	|O
-	374	375	|O
sensitive	375	384	|O
sodium	385	391	|O
channel	392	399	|O
(	400	401	|O
IC50	401	405	|O
=	406	407	|O
160	408	411	|O
microM	412	418	|O
for	419	422	|O
the	423	426	|O
inhibition	427	437	|O
of	438	440	|O
binding	441	448	|O
of	449	451	|O
[	452	453	|O
3H	453	455	|O
]	455	456	|O
BTX	456	459	|O
-	459	460	|O
B	460	461	|O
)	461	462	|O
,	462	463	|O
suggesting	464	474	|O
that	475	479	|O
2	480	481	|O
may	482	485	|O
be	486	488	|O
a	489	490	|O
new	491	494	|O
class	495	500	|O
I	501	502	|O
anticonvulsant	503	517	|O
.	517	518	|O
Several	519	526	|O
partial	527	534	|O
structures	535	545	|O
of	546	548	|O
2	549	550	|O
,	550	551	|O
either	552	558	|O
monocyclic	559	569	|O
lactams	570	577	|O
or	578	580	|O
monocyclic	581	591	|O
2,4	592	595	|B-IUPAC
-	595	596	|I-IUPAC
oxazolidinediones	596	613	|I-IUPAC
,	613	614	|O
were	615	619	|O
also	620	624	|O
evaluated	625	634	|O
in	635	637	|O
these	638	643	|O
assays	644	650	|O
,	650	651	|O
but	652	655	|O
no	656	658	|O
correlation	659	670	|O
was	671	674	|O
observed	675	683	|O
between	684	691	|O
sodium	692	698	|O
channel	699	706	|O
binding	707	714	|O
and	715	718	|O
anti	719	723	|O
-	723	724	|O
MES	724	727	|O
effects	728	735	|O
.	735	736	|O
A	737	738	|O
significant	739	750	|O
finding	751	758	|O
was	759	762	|O
that	763	767	|O
monocyclic	768	778	|O
5	779	780	|B-IUPAC
-	780	781	|I-IUPAC
alkyl	781	786	|I-IUPAC
-	786	787	|I-IUPAC
5	787	788	|I-IUPAC
-	788	789	|I-IUPAC
phenyl	789	795	|I-IUPAC
-	795	796	|I-IUPAC
2,4	796	799	|I-IUPAC
-	799	800	|I-IUPAC
oxazolidinediones	800	817	|I-IUPAC
provided	818	826	|O
relatively	827	837	|O
potent	838	844	|O
,	844	845	|O
nontoxic	846	854	|O
,	854	855	|O
broad	856	861	|O
-	861	862	|O
spectrum	862	870	|O
anticonvulsants	871	886	|O
.	886	887	|O

### abstracts1077.txt
The	0	3	|O
peripheral	4	14	|O
benzodiazepine	15	29	|O
receptor	30	38	|O
(	39	40	|O
PBR	40	43	|O
)	43	44	|O
is	45	47	|O
widely	48	54	|O
expressed	55	64	|O
in	65	67	|O
peripheral	68	78	|O
tissues	79	86	|O
,	86	87	|O
blood	88	93	|O
cells	94	99	|O
,	99	100	|O
and	101	104	|O
in	105	107	|O
glia	108	112	|O
cells	113	118	|O
in	119	121	|O
the	122	125	|O
brain	126	131	|O
.	131	132	|O
We	133	135	|O
have	136	140	|O
previously	141	151	|O
developed	152	161	|O
two	162	165	|O
positron	166	174	|O
emission	175	183	|O
tomography	184	194	|O
(	195	196	|O
PET	196	199	|O
)	199	200	|O
ligands	201	208	|O
,	208	209	|O
N	210	211	|B-IUPAC
-	211	212	|I-IUPAC
(	212	213	|I-IUPAC
2	213	214	|I-IUPAC
-	214	215	|I-IUPAC
[	215	216	|I-IUPAC
(	216	217	|I-IUPAC
11	217	219	|I-IUPAC
)	219	220	|I-IUPAC
C	220	221	|I-IUPAC
]	221	222	|I-IUPAC
,	222	223	|I-IUPAC
5	223	224	|I-IUPAC
-	224	225	|I-IUPAC
dimethoxybenzyl	225	240	|I-IUPAC
)	240	241	|I-IUPAC
-	241	242	|I-IUPAC
N	242	243	|I-IUPAC
-	243	244	|I-IUPAC
(	244	245	|I-IUPAC
5	245	246	|I-IUPAC
-	246	247	|I-IUPAC
fluoro	247	253	|I-IUPAC
-	253	254	|I-IUPAC
2	254	255	|I-IUPAC
-	255	256	|I-IUPAC
phenoxyphenyl	256	269	|I-IUPAC
)	269	270	|I-IUPAC
acetamide	270	279	|I-IUPAC
(	280	281	|O
[	281	282	|O
(	282	283	|O
11	283	285	|O
)	285	286	|O
C	286	287	|O
]	287	288	|O
2	288	289	|O
)	289	290	|O
and	291	294	|O
its	295	298	|O
[	299	300	|B-IUPAC
(	300	301	|I-IUPAC
18	301	303	|I-IUPAC
)	303	304	|I-IUPAC
F	304	305	|I-IUPAC
]	305	306	|I-IUPAC
fluoroethyl	306	317	|I-IUPAC
analogue	318	326	|B-MODIFIER
(	327	328	|O
[	328	329	|O
(	329	330	|O
18	330	332	|O
)	332	333	|O
F	333	334	|O
]	334	335	|O
6	335	336	|O
)	336	337	|O
,	337	338	|O
for	339	342	|O
the	343	346	|O
current	347	354	|O
investigation	355	368	|O
of	369	371	|O
PBR	372	375	|O
in	376	378	|O
the	379	382	|O
human	383	388	|O
brain	389	394	|O
.	394	395	|O
The	396	399	|O
aim	400	403	|O
of	404	406	|O
this	407	411	|O
study	412	417	|O
was	418	421	|O
to	422	424	|O
label	425	430	|O
the	431	434	|O
potent	435	441	|O
PBR	442	445	|O
agonist	446	453	|O
N	454	455	|B-IUPAC
-	455	456	|I-IUPAC
(	456	457	|I-IUPAC
4	457	458	|I-IUPAC
-	458	459	|I-IUPAC
chloro	459	465	|I-IUPAC
-	465	466	|I-IUPAC
2	466	467	|I-IUPAC
-	467	468	|I-IUPAC
phenoxyphenyl	468	481	|I-IUPAC
)	481	482	|I-IUPAC
-	482	483	|I-IUPAC
N	483	484	|I-IUPAC
-	484	485	|I-IUPAC
(	485	486	|I-IUPAC
isopropoxybenzyl	486	502	|I-IUPAC
)	502	503	|I-IUPAC
acetamide	503	512	|I-IUPAC
(	513	514	|O
3	514	515	|O
)	515	516	|O
and	517	520	|O
its	521	524	|O
ethyl	525	530	|B-IUPAC
(	531	532	|O
7	532	533	|O
)	533	534	|O
and	535	538	|O
methyl	539	545	|B-IUPAC
(	546	547	|O
8	547	548	|O
)	548	549	|O
homologues	550	560	|B-MODIFIER
with	561	565	|O
(	566	567	|O
11	567	569	|O
)	569	570	|O
C	570	571	|O
and	572	575	|O
to	576	578	|O
evaluate	579	587	|O
them	588	592	|O
as	593	595	|O
PET	596	599	|O
ligands	600	607	|O
for	608	611	|O
PBR	612	615	|O
with	616	620	|O
mice	621	625	|O
,	625	626	|O
rats	627	631	|O
,	631	632	|O
and	633	636	|O
monkeys	637	644	|O
.	644	645	|O
Ligands	646	653	|O
[	654	655	|O
(	655	656	|O
11	656	658	|O
)	658	659	|O
C	659	660	|O
]	660	661	|O
3	661	662	|O
,	662	663	|O
[	664	665	|O
(	665	666	|O
11	666	668	|O
)	668	669	|O
C	669	670	|O
]	670	671	|O
7	671	672	|O
,	672	673	|O
and	674	677	|O
[	678	679	|O
(	679	680	|O
11	680	682	|O
)	682	683	|O
C	683	684	|O
]	684	685	|O
8	685	686	|O
were	687	691	|O
synthesized	692	703	|O
by	704	706	|O
alkylation	707	717	|O
of	718	720	|O
phenol	721	727	|O
precursor	728	737	|O
9	738	739	|O
with	740	744	|O
2	745	746	|B-IUPAC
-	746	747	|I-IUPAC
[	747	748	|I-IUPAC
2	748	749	|I-IUPAC
-	749	750	|I-IUPAC
(	750	751	|I-IUPAC
11	751	753	|I-IUPAC
)	753	754	|I-IUPAC
C	754	755	|I-IUPAC
]	755	756	|I-IUPAC
iodopropane	756	767	|I-IUPAC
(	768	769	|O
[	769	770	|O
(	770	771	|O
11	771	773	|O
)	773	774	|O
C	774	775	|O
]	775	776	|O
10	776	778	|O
)	778	779	|O
,	779	780	|O
[	781	782	|B-IUPAC
1	782	783	|I-IUPAC
-	783	784	|I-IUPAC
(	784	785	|I-IUPAC
11	785	787	|I-IUPAC
)	787	788	|I-IUPAC
C	788	789	|I-IUPAC
]	789	790	|I-IUPAC
iodoethane	790	800	|I-IUPAC
(	801	802	|O
[	802	803	|O
(	803	804	|O
11	804	806	|O
)	806	807	|O
C	807	808	|O
]	808	809	|O
11	809	811	|O
)	811	812	|O
,	812	813	|O
and	814	817	|O
[	818	819	|B-IUPAC
(	819	820	|I-IUPAC
11	820	822	|I-IUPAC
)	822	823	|I-IUPAC
C	823	824	|I-IUPAC
]	824	825	|I-IUPAC
iodomethane	825	836	|I-IUPAC
(	837	838	|O
[	838	839	|O
(	839	840	|O
11	840	842	|O
)	842	843	|O
C	843	844	|O
]	844	845	|O
12	845	847	|O
)	847	848	|O
,	848	849	|O
respectively	850	862	|O
.	862	863	|O
The	864	867	|O
alkylating	868	878	|O
agent	879	884	|O
[	885	886	|O
(	886	887	|O
11	887	889	|O
)	889	890	|O
C	890	891	|O
]	891	892	|O
10	892	894	|O
or	895	897	|O
[	898	899	|O
(	899	900	|O
11	900	902	|O
)	902	903	|O
C	903	904	|O
]	904	905	|O
11	905	907	|O
was	908	911	|O
prepared	912	920	|O
by	921	923	|O
reacting	924	932	|O
CH	933	935	|O
(	935	936	|O
3	936	937	|O
)	937	938	|O
MgBr	938	942	|O
with	943	947	|O
[	948	949	|O
(	949	950	|O
11	950	952	|O
)	952	953	|O
C	953	954	|O
]	954	955	|O
CO	955	957	|O
(	957	958	|O
2	958	959	|O
)	959	960	|O
,	960	961	|O
followed	962	970	|O
by	971	973	|O
reduction	974	983	|O
with	984	988	|O
LiAlH	989	994	|O
(	994	995	|O
4	995	996	|O
)	996	997	|O
and	998	1001	|O
iodination	1002	1012	|O
with	1013	1017	|O
HI	1018	1020	|O
.	1020	1021	|O
In	1022	1024	|O
vitro	1025	1030	|O
quantitative	1031	1043	|O
autoradiography	1044	1059	|O
determined	1060	1070	|O
that	1071	1075	|O
3	1076	1077	|O
,	1077	1078	|O
7	1079	1080	|O
,	1080	1081	|O
and	1082	1085	|O
8	1086	1087	|O
had	1088	1091	|O
potent	1092	1098	|O
binding	1099	1106	|O
affinities	1107	1117	|O
(	1118	1119	|O
K	1119	1120	|O
(	1120	1121	|O
i	1121	1122	|O
)	1122	1123	|O
=	1124	1125	|O
0.07-0.19	1126	1135	|O
nM	1136	1138	|O
)	1138	1139	|O
for	1140	1143	|O
PBR	1144	1147	|O
in	1148	1150	|O
the	1151	1154	|O
rat	1155	1158	|O
brain	1159	1164	|O
.	1164	1165	|O
These	1166	1171	|O
[	1172	1173	|O
(	1173	1174	|O
11	1174	1176	|O
)	1176	1177	|O
C	1177	1178	|O
]	1178	1179	|O
ligands	1179	1186	|O
could	1187	1192	|O
pass	1193	1197	|O
across	1198	1204	|O
the	1205	1208	|O
blood	1209	1214	|O
-	1214	1215	|O
brain	1215	1220	|O
barrier	1221	1228	|O
and	1229	1232	|O
enter	1233	1238	|O
the	1239	1242	|O
rat	1243	1246	|O
brain	1247	1252	|O
(	1253	1254	|O
0.17-0.32%	1254	1264	|O
of	1265	1267	|O
injected	1268	1276	|O
dose	1277	1281	|O
per	1282	1285	|O
gram	1286	1290	|O
wet	1291	1294	|O
tissue	1295	1301	|O
)	1301	1302	|O
.	1302	1303	|O
Ex	1304	1306	|O
vivo	1307	1311	|O
autoradiography	1312	1327	|O
showed	1328	1334	|O
that	1335	1339	|O
the	1340	1343	|O
[	1344	1345	|O
(	1345	1346	|O
11	1346	1348	|O
)	1348	1349	|O
C	1349	1350	|O
]	1350	1351	|O
ligands	1351	1358	|O
preferably	1359	1369	|O
distributed	1370	1381	|O
in	1382	1384	|O
the	1385	1388	|O
olfactory	1389	1398	|O
bulb	1399	1403	|O
and	1404	1407	|O
cerebellum	1408	1418	|O
,	1418	1419	|O
two	1420	1423	|O
regions	1424	1431	|O
with	1432	1436	|O
richer	1437	1443	|O
PBR	1444	1447	|O
density	1448	1455	|O
in	1456	1458	|O
the	1459	1462	|O
rat	1463	1466	|O
brain	1467	1472	|O
.	1472	1473	|O
The	1474	1477	|O
co	1478	1480	|O
-	1480	1481	|O
injection	1481	1490	|O
of	1491	1493	|O
PBR	1494	1497	|O
-	1497	1498	|O
selective	1498	1507	|O
2	1508	1509	|O
reduced	1510	1517	|O
the	1518	1521	|O
[	1522	1523	|O
(	1523	1524	|O
11	1524	1526	|O
)	1526	1527	|O
C	1527	1528	|O
]	1528	1529	|O
ligand	1529	1535	|O
binding	1536	1543	|O
in	1544	1546	|O
the	1547	1550	|O
two	1551	1554	|O
regions	1555	1562	|O
,	1562	1563	|O
suggesting	1564	1574	|O
that	1575	1579	|O
binding	1580	1587	|O
in	1588	1590	|O
the	1591	1594	|O
rat	1595	1598	|O
brain	1599	1604	|O
was	1605	1608	|O
specific	1609	1617	|O
to	1618	1620	|O
PBR	1621	1624	|O
.	1624	1625	|O
PET	1626	1629	|O
study	1630	1635	|O
determined	1636	1646	|O
that	1647	1651	|O
the	1652	1655	|O
[	1656	1657	|O
(	1657	1658	|O
11	1658	1660	|O
)	1660	1661	|O
C	1661	1662	|O
]	1662	1663	|O
ligands	1663	1670	|O
preferably	1671	1681	|O
accumulate	1682	1692	|O
in	1693	1695	|O
the	1696	1699	|O
occipital	1700	1709	|O
cortex	1710	1716	|O
of	1717	1719	|O
the	1720	1723	|O
monkey	1724	1730	|O
brain	1731	1736	|O
,	1736	1737	|O
a	1738	1739	|O
region	1740	1746	|O
with	1747	1751	|O
a	1752	1753	|O
high	1754	1758	|O
density	1759	1766	|O
of	1767	1769	|O
PBR	1770	1773	|O
in	1774	1776	|O
the	1777	1780	|O
primate	1781	1788	|O
brain	1789	1794	|O
.	1794	1795	|O
Moreover	1796	1804	|O
,	1804	1805	|O
in	1806	1808	|O
vivo	1809	1813	|O
binding	1814	1821	|O
of	1822	1824	|O
the	1825	1828	|O
methyl	1829	1835	|O
homologue	1836	1845	|O
[	1846	1847	|O
(	1847	1848	|O
11	1848	1850	|O
)	1850	1851	|O
C	1851	1852	|O
]	1852	1853	|O
8	1853	1854	|O
in	1855	1857	|O
the	1858	1861	|O
monkey	1862	1868	|O
brain	1869	1874	|O
could	1875	1880	|O
be	1881	1883	|O
inhibited	1884	1893	|O
by	1894	1896	|O
PBR	1897	1900	|O
-	1900	1901	|O
selective	1901	1910	|O
2	1911	1912	|O
or	1913	1915	|O
1	1916	1917	|O
,	1917	1918	|O
indicating	1919	1929	|O
that	1930	1934	|O
some	1935	1939	|O
of	1940	1942	|O
the	1943	1946	|O
[	1947	1948	|O
(	1948	1949	|O
11	1949	1951	|O
)	1951	1952	|O
C	1952	1953	|O
]	1953	1954	|O
8	1954	1955	|O
binding	1956	1963	|O
was	1964	1967	|O
due	1968	1971	|O
to	1972	1974	|O
PBR	1975	1978	|O
.	1978	1979	|O
Metabolite	1980	1990	|O
analysis	1991	1999	|O
demonstrated	2000	2012	|O
that	2013	2017	|O
these	2018	2023	|O
[	2024	2025	|O
(	2025	2026	|O
11	2026	2028	|O
)	2028	2029	|O
C	2029	2030	|O
]	2030	2031	|O
ligands	2031	2038	|O
were	2039	2043	|O
metabolized	2044	2055	|O
by	2056	2058	|O
debenzylation	2059	2072	|O
to	2073	2075	|O
polar	2076	2081	|O
products	2082	2090	|O
mainly	2091	2097	|O
in	2098	2100	|O
the	2101	2104	|O
plasma	2105	2111	|O
.	2111	2112	|O

### abstracts4648.txt
Vasotocin	0	9	|O
(	10	11	|O
AVT	11	14	|O
)	14	15	|O
analogues	16	25	|O
with	26	30	|O
tyrosine	31	39	|O
or	40	42	|O
phenylalanine	43	56	|O
in	57	59	|O
position	60	68	|O
9	69	70	|O
,	70	71	|O
i.e.	72	76	|O
,	76	77	|O
[	78	79	|O
9	79	80	|B-IUPAC
-	80	81	|I-IUPAC
tyrosine	81	89	|I-IUPAC
]	89	90	|O
AVT	90	93	|O
,	93	94	|O
[	95	96	|O
2	96	97	|B-IUPAC
-	97	98	|I-IUPAC
phenylalanine	98	111	|I-IUPAC
,	111	112	|I-IUPAC
-	112	113	|I-IUPAC
9	113	114	|I-IUPAC
-	114	115	|I-IUPAC
tyrosine	115	123	|I-IUPAC
]	123	124	|O
AVT	124	127	|O
,	127	128	|O
and	129	132	|O
1	133	134	|B-IUPAC
-	134	135	|I-IUPAC
desamino	135	143	|I-IUPAC
[	143	144	|I-IUPAC
9	144	145	|I-IUPAC
-	145	146	|I-IUPAC
(	146	147	|I-IUPAC
p	147	148	|I-IUPAC
-	148	149	|I-IUPAC
aminophenylalanine	149	167	|I-IUPAC
)	167	168	|I-IUPAC
]	168	169	|I-IUPAC
AVT	169	172	|O
,	172	173	|O
were	174	178	|O
synthesized	179	190	|O
by	191	193	|O
the	194	197	|O
solid	198	203	|O
-	203	204	|O
phase	204	209	|O
method	210	216	|O
.	216	217	|O
These	218	223	|O
compounds	224	233	|O
showed	234	240	|O
a	241	242	|O
high	243	247	|O
biological	248	258	|O
activity	259	267	|O
in	268	270	|O
the	271	274	|O
hydroosmotic	275	287	|O
toad	288	292	|O
bladder	293	300	|O
assay	301	306	|O
.	306	307	|O
Using	308	313	|O
the	314	317	|O
chemically	318	328	|O
reactive	329	337	|O
functional	338	348	|O
groups	349	355	|O
on	356	358	|O
tyrosine	359	367	|O
and	368	371	|O
p	372	373	|O
-	373	374	|O
aminophenylalanine	374	392	|O
in	393	395	|O
position	396	404	|O
9	405	406	|O
,	406	407	|O
we	408	410	|O
prepared	411	419	|O
iodinated	420	429	|O
,	429	430	|O
photoreactive	431	444	|O
,	444	445	|O
and	446	449	|O
affinity	450	458	|O
ligands	459	466	|O
,	466	467	|O
i.e.	468	472	|O
,	472	473	|O
[	474	475	|O
2	475	476	|B-IUPAC
-	476	477	|I-IUPAC
phenylalanine	477	490	|I-IUPAC
,	490	491	|I-IUPAC
9	491	492	|I-IUPAC
-	492	493	|I-IUPAC
(	493	494	|I-IUPAC
iodotyrosine	494	506	|I-IUPAC
)	506	507	|I-IUPAC
]	507	508	|O
AVT	508	511	|O
,	511	512	|O
1	513	514	|B-IUPAC
-	514	515	|I-IUPAC
desamino	515	523	|I-IUPAC
[	523	524	|I-IUPAC
9	524	525	|I-IUPAC
-	525	526	|I-IUPAC
(	526	527	|I-IUPAC
p	527	528	|I-IUPAC
-	528	529	|I-IUPAC
azidophenylalanine	529	547	|I-IUPAC
)	547	548	|I-IUPAC
]	548	549	|I-IUPAC
AVT	549	552	|O
,	552	553	|O
and	554	557	|O
1	558	559	|B-IUPAC
-	559	560	|I-IUPAC
desamino	560	568	|I-IUPAC
[	568	569	|I-IUPAC
9	569	570	|I-IUPAC
-	570	571	|I-IUPAC
(	571	572	|I-IUPAC
biotinylphenylalanine	572	593	|I-IUPAC
)	593	594	|I-IUPAC
]	594	595	|I-IUPAC
AVT	595	598	|O
,	598	599	|O
respectively	600	612	|O
.	612	613	|O
Half	614	618	|O
-	618	619	|O
maximal	619	626	|O
hydroosmotic	627	639	|O
responses	640	649	|O
(	650	651	|O
ED	651	653	|O
-	653	654	|O
50	654	656	|O
values	657	663	|O
)	663	664	|O
were	665	669	|O
obtained	670	678	|O
with	679	683	|O
2.5	684	687	|O
X	688	689	|O
10	690	692	|O
(	692	693	|O
-	693	694	|O
9	694	695	|O
)	695	696	|O
M	697	698	|O
for	699	702	|O
the	703	706	|O
iodinated	707	716	|O
analogue	717	725	|O
,	725	726	|O
with	727	731	|O
0.9	732	735	|O
X	736	737	|O
10	738	740	|O
(	740	741	|O
-	741	742	|O
10	742	744	|O
)	744	745	|O
M	746	747	|O
for	748	751	|O
the	752	755	|O
photoaffinity	756	769	|O
analogue	770	778	|O
,	778	779	|O
and	780	783	|O
with	784	788	|O
1.2	789	792	|O
X	793	794	|O
10	795	797	|O
(	797	798	|O
-	798	799	|O
8	799	800	|O
)	800	801	|O
M	802	803	|O
for	804	807	|O
the	808	811	|O
biotinyl	812	820	|O
analogue	821	829	|O
.	829	830	|O
The	831	834	|O
hydroosmotic	835	847	|O
activity	848	856	|O
of	857	859	|O
the	860	863	|O
biotinyl	864	872	|O
analogue	873	881	|O
was	882	885	|O
reversed	886	894	|O
following	895	904	|O
addition	905	913	|O
of	914	916	|O
avidin	917	923	|O
,	923	924	|O
whereas	925	932	|O
the	933	936	|O
photoaffinity	937	950	|O
analogue	951	959	|O
induced	960	967	|O
a	968	969	|O
persistent	970	980	|O
response	981	989	|O
following	990	999	|O
UV	1000	1002	|O
irradiation	1003	1014	|O
that	1015	1019	|O
was	1020	1023	|O
not	1024	1027	|O
reversed	1028	1036	|O
upon	1037	1041	|O
repeated	1042	1050	|O
and	1051	1054	|O
prolonged	1055	1064	|O
periods	1065	1072	|O
of	1073	1075	|O
washout	1076	1083	|O
.	1083	1084	|O
These	1085	1090	|O
analogues	1091	1100	|O
of	1101	1103	|O
vasotocin	1104	1113	|O
are	1114	1117	|O
the	1118	1121	|O
most	1122	1126	|O
potent	1127	1133	|O
that	1134	1138	|O
have	1139	1143	|O
been	1144	1148	|O
synthesized	1149	1160	|O
to	1161	1163	|O
date	1164	1168	|O
,	1168	1169	|O
and	1170	1173	|O
they	1174	1178	|O
should	1179	1185	|O
serve	1186	1191	|O
as	1192	1194	|O
useful	1195	1201	|O
probes	1202	1208	|O
in	1209	1211	|O
the	1212	1215	|O
isolation	1216	1225	|O
and	1226	1229	|O
characterization	1230	1246	|O
of	1247	1249	|O
vasotocin	1250	1259	|O
receptors	1260	1269	|O
in	1270	1272	|O
toad	1273	1277	|O
bladders	1278	1286	|O
and	1287	1290	|O
tissues	1291	1298	|O
from	1299	1303	|O
other	1304	1309	|O
species	1310	1317	|O
that	1318	1322	|O
use	1323	1326	|O
vasotocin	1327	1336	|O
as	1337	1339	|O
an	1340	1342	|O
antidiuretic	1343	1355	|O
/	1355	1356	|O
pressor	1356	1363	|O
principle	1364	1373	|O
.	1373	1374	|O
The	1375	1378	|O
photoaffinity	1379	1392	|O
and	1393	1396	|O
biotinyl	1397	1405	|O
analogues	1406	1415	|O
had	1416	1419	|O
a	1420	1421	|O
rat	1422	1425	|O
antidiuretic	1426	1438	|O
activity	1439	1447	|O
of	1448	1450	|O
66	1451	1453	|O
and	1454	1457	|O
40	1458	1460	|O
units	1461	1466	|O
/	1466	1467	|O
mg	1467	1469	|O
,	1469	1470	|O
respectively	1471	1483	|O
.	1483	1484	|O
These	1485	1490	|O
compounds	1491	1500	|O
are	1501	1504	|O
,	1504	1505	|O
therefore	1506	1515	|O
,	1515	1516	|O
also	1517	1521	|O
suitable	1522	1530	|O
for	1531	1534	|O
the	1535	1538	|O
isolation	1539	1548	|O
of	1549	1551	|O
V	1552	1553	|O
-	1553	1554	|O
2	1554	1555	|O
vasopressin	1556	1567	|O
receptors	1568	1577	|O
from	1578	1582	|O
mammalian	1583	1592	|O
tissues	1593	1600	|O
.	1600	1601	|O

### abstracts352.txt
trans	0	5	|O
-	5	6	|O
2	6	7	|O
-	7	8	|O
Carboxy	8	15	|O
-	15	16	|O
5,7	16	19	|O
-	19	20	|O
dichloro	20	28	|O
-	28	29	|O
4	29	30	|O
-	30	31	|O
amidotetrahydroquinolines	31	56	|O
,	56	57	|O
evolved	58	65	|O
from	66	70	|O
the	71	74	|O
lead	75	79	|O
5,7	80	83	|B-IUPAC
-	83	84	|I-IUPAC
dichlorokynurenic	84	101	|I-IUPAC
acid	102	106	|I-IUPAC
,	106	107	|O
have	108	112	|O
been	113	117	|O
synthesized	118	129	|O
and	130	133	|O
tested	134	140	|O
for	141	144	|O
in	145	147	|O
vitro	148	153	|O
antagonist	154	164	|O
activity	165	173	|O
at	174	176	|O
the	177	180	|O
glycine	181	188	|O
site	189	193	|O
on	194	196	|O
the	197	200	|O
N	201	202	|B-IUPAC
-	202	203	|I-IUPAC
methyl	203	209	|I-IUPAC
-	209	210	|I-IUPAC
D	210	211	|I-IUPAC
-	211	212	|I-IUPAC
aspartate	212	221	|I-IUPAC
(	222	223	|O
NMDA	223	227	|O
)	227	228	|O
receptor	229	237	|O
.	237	238	|O
Optimization	239	251	|O
of	252	254	|O
the	255	258	|O
4	259	260	|O
-	260	261	|O
substituent	261	272	|O
has	273	276	|O
provided	277	285	|O
antagonists	286	297	|O
having	298	304	|O
nanomolar	305	314	|O
affinity	315	323	|O
,	323	324	|O
including	325	334	|O
the	335	338	|O
urea	339	343	|O
trans	344	349	|B-IUPAC
-	349	350	|I-IUPAC
2	350	351	|I-IUPAC
-	351	352	|I-IUPAC
carboxy	352	359	|I-IUPAC
-	359	360	|I-IUPAC
5,7	360	363	|I-IUPAC
-	363	364	|I-IUPAC
dichloro	364	372	|I-IUPAC
-	372	373	|I-IUPAC
4	373	374	|I-IUPAC
[	374	375	|I-IUPAC
[	375	376	|I-IUPAC
(	376	377	|I-IUPAC
phenylamino	377	388	|I-IUPAC
)	388	389	|I-IUPAC
carbonyl	389	397	|I-IUPAC
]	397	398	|I-IUPAC
amino	398	403	|I-IUPAC
]	403	404	|I-IUPAC
-	404	405	|I-IUPAC
1,2,3	405	410	|I-IUPAC
,	410	411	|I-IUPAC
4	412	413	|I-IUPAC
-	413	414	|I-IUPAC
tetrahydroquinoline	414	433	|I-IUPAC
(	434	435	|O
35	435	437	|O
;	437	438	|O
IC50	439	443	|O
=	444	445	|O
7.4	446	449	|O
nM	450	452	|O
vs	453	455	|O
[	456	457	|O
3H	457	459	|O
]	459	460	|O
glycine	460	467	|O
binding	468	475	|O
;	475	476	|O
Kb	477	479	|O
=	480	481	|O
130	482	485	|O
nM	486	488	|O
for	489	492	|O
block	493	498	|O
of	499	501	|O
NMDA	502	506	|O
responses	507	516	|O
in	517	519	|O
the	520	523	|O
rat	524	527	|O
cortical	528	536	|O
slice	537	542	|O
)	542	543	|O
,	543	544	|O
which	545	550	|O
is	551	553	|O
one	554	557	|O
of	558	560	|O
the	561	564	|O
most	565	569	|O
potent	570	576	|O
NMDA	577	581	|O
antagonists	582	593	|O
yet	594	597	|O
found	598	603	|O
.	603	604	|O
The	605	608	|O
absolute	609	617	|O
stereochemical	618	632	|O
requirements	633	645	|O
for	646	649	|O
binding	650	657	|O
were	658	662	|O
found	663	668	|O
to	669	671	|O
be	672	674	|O
2S	675	677	|O
,	677	678	|O
4R	678	680	|O
,	680	681	|O
showing	682	689	|O
that	690	694	|O
,	694	695	|O
in	696	698	|O
common	699	705	|O
with	706	710	|O
other	711	716	|O
glycine	717	724	|O
-	724	725	|O
site	725	729	|O
NMDA	730	734	|O
receptor	735	743	|O
ligands	744	751	|O
,	751	752	|O
the	753	756	|O
unnatural	757	766	|O
configuration	767	780	|O
at	781	783	|O
the	784	787	|O
alpha	788	793	|O
-	793	794	|O
amino	794	799	|O
acid	800	804	|O
center	805	811	|O
is	812	814	|O
required	815	823	|O
.	823	824	|O
The	825	828	|O
preferred	829	838	|O
conformation	839	851	|O
of	852	854	|O
the	855	858	|O
trans	859	864	|B-MODIFIER
-	864	865	|I-MODIFIER
2,4	865	868	|I-MODIFIER
-	868	869	|I-MODIFIER
disubstituted	869	882	|I-MODIFIER
tetrahydroquinoline	883	902	|B-IUPAC
system	903	909	|O
,	909	910	|O
as	911	913	|O
shown	914	919	|O
by	920	922	|O
X	923	924	|O
-	924	925	|O
ray	925	928	|O
crystallography	929	944	|O
and	945	948	|O
1H	949	951	|O
NMR	952	955	|O
studies	956	963	|O
,	963	964	|O
places	965	971	|O
the	972	975	|O
2	976	977	|O
-	977	978	|O
carboxyl	978	986	|O
pseudoequatorial	987	1003	|O
and	1004	1007	|O
the	1008	1011	|O
4	1012	1013	|O
-	1013	1014	|O
substituent	1014	1025	|O
pseudoaxial	1026	1037	|O
.	1037	1038	|O
Modifications	1039	1052	|O
of	1053	1055	|O
the	1056	1059	|O
4	1060	1061	|O
-	1061	1062	|O
amide	1062	1067	|O
show	1068	1072	|O
that	1073	1077	|O
bulky	1078	1083	|O
substituents	1084	1096	|O
are	1097	1100	|O
tolerated	1101	1110	|O
and	1111	1114	|O
reveal	1115	1121	|O
the	1122	1125	|O
critical	1126	1134	|O
importance	1135	1145	|O
for	1146	1149	|O
activity	1150	1158	|O
of	1159	1161	|O
correct	1162	1169	|O
positioning	1170	1181	|O
of	1182	1184	|O
the	1185	1188	|O
carbonyl	1189	1197	|O
group	1198	1203	|O
.	1203	1204	|O
The	1205	1208	|O
high	1209	1213	|O
affinity	1214	1222	|O
of	1223	1225	|O
trans	1226	1231	|B-IUPAC
-	1231	1232	|I-IUPAC
2	1232	1233	|I-IUPAC
-	1233	1234	|I-IUPAC
carboxy	1234	1241	|I-IUPAC
-	1241	1242	|I-IUPAC
5,7	1242	1245	|I-IUPAC
-	1245	1246	|I-IUPAC
dichloro	1246	1254	|I-IUPAC
-	1254	1255	|I-IUPAC
4	1255	1256	|I-IUPAC
-	1256	1257	|I-IUPAC
[	1257	1258	|I-IUPAC
1	1258	1259	|I-IUPAC
-	1259	1260	|I-IUPAC
(	1260	1261	|I-IUPAC
3	1261	1262	|I-IUPAC
-	1262	1263	|I-IUPAC
phenyl	1263	1269	|I-IUPAC
-	1269	1270	|I-IUPAC
2	1270	1271	|I-IUPAC
-	1271	1272	|I-IUPAC
oxoimidazolidinyl	1272	1289	|I-IUPAC
)	1289	1290	|I-IUPAC
]	1290	1291	|I-IUPAC
-	1291	1292	|I-IUPAC
1,2,3,4	1293	1300	|I-IUPAC
-	1300	1301	|I-IUPAC
tetrahydroquinoline	1301	1320	|I-IUPAC
(	1321	1322	|O
55	1322	1324	|O
;	1324	1325	|O
IC50	1326	1330	|O
=	1331	1332	|O
6	1333	1334	|O
nM	1335	1337	|O
)	1337	1338	|O
suggests	1339	1347	|O
that	1348	1352	|O
the	1353	1356	|O
Z	1357	1358	|O
,	1358	1359	|O
Z	1359	1360	|O
conformer	1361	1370	|O
of	1371	1373	|O
the	1374	1377	|O
phenyl	1378	1384	|O
urea	1385	1389	|O
moiety	1390	1396	|O
in	1397	1399	|O
35	1400	1402	|O
is	1403	1405	|O
recognized	1406	1416	|O
by	1417	1419	|O
the	1420	1423	|O
receptor	1424	1432	|O
.	1432	1433	|O
Molecular	1434	1443	|O
modeling	1444	1452	|O
studies	1453	1460	|O
show	1461	1465	|O
that	1466	1470	|O
the	1471	1474	|O
4	1475	1476	|O
-	1476	1477	|O
carbonyl	1477	1485	|O
groups	1486	1492	|O
of	1493	1495	|O
the	1496	1499	|O
kynurenic	1500	1509	|O
acids	1510	1515	|O
,	1515	1516	|O
the	1517	1520	|O
tetrahydroquinolines	1521	1541	|O
,	1541	1542	|O
and	1543	1546	|O
related	1547	1554	|O
antagonists	1555	1566	|O
based	1567	1572	|O
on	1573	1575	|O
N	1576	1577	|B-IUPAC
-	1577	1578	|I-IUPAC
(	1578	1579	|I-IUPAC
chlorophenyl	1579	1591	|I-IUPAC
)	1591	1592	|I-IUPAC
glycine	1592	1599	|I-IUPAC
,	1599	1600	|O
can	1601	1604	|O
interact	1605	1613	|O
with	1614	1618	|O
a	1619	1620	|O
single	1621	1627	|O
putative	1628	1636	|O
H	1637	1638	|O
-	1638	1639	|O
bond	1639	1643	|O
donor	1644	1649	|O
on	1650	1652	|O
the	1653	1656	|O
receptor	1657	1665	|O
.	1665	1666	|O
The	1667	1670	|O
results	1671	1678	|O
allow	1679	1684	|O
the	1685	1688	|O
establishment	1689	1702	|O
of	1703	1705	|O
a	1706	1707	|O
three	1708	1713	|O
-	1713	1714	|O
dimensional	1714	1725	|O
pharmacophore	1726	1739	|O
of	1740	1742	|O
the	1743	1746	|O
glycine	1747	1754	|O
receptor	1755	1763	|O
antagonist	1764	1774	|O
site	1775	1779	|O
,	1779	1780	|O
incorporating	1781	1794	|O
a	1795	1796	|O
newly	1797	1802	|O
defined	1803	1810	|O
bulk	1811	1815	|O
tolerance	1816	1825	|O
/	1825	1826	|O
hydrophobic	1826	1837	|O
region	1838	1844	|O
.	1844	1845	|O

### abstracts124.txt
The	0	3	|O
synthesis	4	13	|O
and	14	17	|O
sigma	18	23	|O
1	24	25	|O
and	26	29	|O
sigma	30	35	|O
2	36	37	|O
binding	38	45	|O
properties	46	56	|O
of	57	59	|O
several	60	67	|O
(	68	69	|B-PARTIUPAC
+	69	70	|I-PARTIUPAC
)	70	71	|I-PARTIUPAC
-	71	72	|I-PARTIUPAC
and	73	76	|O
(	77	78	|B-PARTIUPAC
-	78	79	|I-PARTIUPAC
)	79	80	|I-PARTIUPAC
-	80	81	|I-PARTIUPAC
2	81	82	|I-PARTIUPAC
-	82	83	|I-PARTIUPAC
benzyl	83	89	|I-PARTIUPAC
-	89	90	|I-PARTIUPAC
and	91	94	|O
2	95	96	|B-IUPAC
-	96	97	|I-IUPAC
dimethylallyl	97	110	|I-IUPAC
-	110	111	|I-IUPAC
2'	111	113	|I-IUPAC
-	113	114	|I-IUPAC
substituted	114	125	|I-IUPAC
-	125	126	|I-IUPAC
5,9	126	129	|I-IUPAC
alpha	130	135	|I-IUPAC
-	135	136	|I-IUPAC
dimethyl	136	144	|I-IUPAC
-	144	145	|I-IUPAC
6,7	145	148	|I-IUPAC
-	148	149	|I-IUPAC
benzomorphans	149	162	|I-IUPAC
(	163	164	|O
3	164	165	|O
and	166	169	|O
4	170	171	|O
)	171	172	|O
are	173	176	|O
presented	177	186	|O
.	186	187	|O
In	188	190	|O
agreement	191	200	|O
with	201	205	|O
previously	206	216	|O
reported	217	225	|O
binding	226	233	|O
data	234	238	|O
for	239	242	|O
2	243	244	|B-MODIFIER
-	244	245	|I-MODIFIER
substituted	245	256	|I-MODIFIER
5,9	257	260	|B-IUPAC
alpha	261	266	|I-IUPAC
-	266	267	|I-IUPAC
dimethyl	267	275	|I-IUPAC
-	275	276	|I-IUPAC
2'	276	278	|I-IUPAC
-	278	279	|I-IUPAC
hydroxy	279	286	|I-IUPAC
-	286	287	|I-IUPAC
6,7	287	290	|I-IUPAC
-	290	291	|I-IUPAC
benzomorphans	291	304	|I-IUPAC
(	305	306	|O
N	306	307	|B-MODIFIER
-	307	308	|I-MODIFIER
substituted	308	319	|I-MODIFIER
-	319	320	|O
N	320	321	|B-IUPAC
-	321	322	|I-IUPAC
normetazocine	322	335	|I-IUPAC
)	335	336	|O
,	336	337	|O
all	338	341	|O
(	342	343	|O
1S	343	345	|O
,	345	346	|O
5S	346	348	|O
,	348	349	|O
9S	349	351	|O
)	351	352	|O
-	352	353	|O
(	353	354	|O
+	354	355	|O
)	355	356	|O
-	356	357	|O
isomers	357	364	|O
showed	365	371	|O
higher	372	378	|O
affinity	379	387	|O
for	388	391	|O
the	392	395	|O
sigma	396	401	|O
1	402	403	|O
site	404	408	|O
than	409	413	|O
the	414	417	|O
corresponding	418	431	|O
(	432	433	|O
1R	433	435	|O
,	435	436	|O
5R	436	438	|O
,	438	439	|O
9R	439	441	|O
)	441	442	|O
-	442	443	|O
(	443	444	|O
-	444	445	|O
)	445	446	|O
-	446	447	|O
isomers	447	454	|O
.	454	455	|O
Replacement	456	467	|O
of	468	470	|O
the	471	474	|O
2'	475	477	|B-IUPAC
-	477	478	|I-IUPAC
hydroxy	478	485	|I-IUPAC
group	486	491	|B-MODIFIER
of	492	494	|O
(	495	496	|B-IUPAC
+	496	497	|I-IUPAC
)	497	498	|I-IUPAC
-	498	499	|I-IUPAC
2	499	500	|I-IUPAC
-	500	501	|I-IUPAC
benzyl	501	507	|I-IUPAC
-	507	508	|I-IUPAC
5,9	508	511	|I-IUPAC
alpha	512	517	|I-IUPAC
-	517	518	|I-IUPAC
dimethyl	518	526	|I-IUPAC
-	526	527	|I-IUPAC
2'	527	529	|I-IUPAC
-	529	530	|I-IUPAC
hydroxy	530	537	|I-IUPAC
-	537	538	|I-IUPAC
6,7	538	541	|I-IUPAC
-	541	542	|I-IUPAC
benzomorphan	542	554	|I-IUPAC
[	555	556	|O
(	556	557	|O
+	557	558	|O
)	558	559	|O
-	559	560	|O
1f	560	562	|O
]	562	563	|O
with	564	568	|O
a	569	570	|O
2'	571	573	|O
-	573	574	|O
NH2	574	577	|O
and	578	581	|O
2'	582	584	|O
-	584	585	|O
N	585	586	|O
(	586	587	|O
CH3	587	590	|O
)	590	591	|O
2	591	592	|O
[	593	594	|O
(	594	595	|O
+	595	596	|O
)	596	597	|O
-	597	598	|O
3b	598	600	|O
and	601	604	|O
(	605	606	|O
+	606	607	|O
)	607	608	|O
-	608	609	|O
3c	609	611	|O
,	611	612	|O
respectively	613	625	|O
]	625	626	|O
had	627	630	|O
only	631	635	|O
a	636	637	|O
small	638	643	|O
effect	644	650	|O
on	651	653	|O
the	654	657	|O
sigma	658	663	|O
1	664	665	|O
Ki	666	668	|O
values	669	675	|O
.	675	676	|O
Changing	677	685	|O
the	686	689	|O
2'	690	692	|B-IUPAC
-	692	693	|I-IUPAC
hydroxy	693	700	|I-IUPAC
group	701	706	|B-MODIFIER
of	707	709	|O
(	710	711	|O
+	711	712	|O
)	712	713	|O
-	713	714	|O
1f	714	716	|O
to	717	719	|O
an	720	722	|O
H	723	724	|O
,	724	725	|O
F	726	727	|O
,	727	728	|O
Cl	729	731	|O
,	731	732	|O
Br	733	735	|O
,	735	736	|O
I	737	738	|O
,	738	739	|O
NHAc	740	744	|O
,	744	745	|O
or	746	748	|O
NHSO2CH3	749	757	|O
resulted	758	766	|O
in	767	769	|O
a	770	771	|O
5	772	773	|O
-	773	774	|O
fold	774	778	|O
or	779	781	|O
greater	782	789	|O
loss	790	794	|O
in	795	797	|O
potency	798	805	|O
.	805	806	|O
In	807	809	|O
contrast	810	818	|O
,	818	819	|O
replacement	820	831	|O
of	832	834	|O
the	835	838	|O
2'	839	841	|B-IUPAC
-	841	842	|I-IUPAC
hydroxy	842	849	|I-IUPAC
group	850	855	|B-MODIFIER
of	856	858	|O
(	859	860	|B-IUPAC
+	860	861	|I-IUPAC
)	861	862	|I-IUPAC
-	862	863	|I-IUPAC
2	863	864	|I-IUPAC
-	864	865	|I-IUPAC
(	865	866	|I-IUPAC
dimethylallyl	866	879	|I-IUPAC
)	879	880	|I-IUPAC
-	880	881	|I-IUPAC
5,9	881	884	|I-IUPAC
alpha	885	890	|I-IUPAC
-	890	891	|I-IUPAC
dimethyl	891	899	|I-IUPAC
-	899	900	|I-IUPAC
2'	900	902	|I-IUPAC
-	902	903	|I-IUPAC
hydroxy	903	910	|I-IUPAC
-	910	911	|I-IUPAC
6,7	911	914	|I-IUPAC
-	914	915	|I-IUPAC
benzomorphan	915	927	|I-IUPAC
[	928	929	|O
(	929	930	|O
+	930	931	|O
)	931	932	|O
-	932	933	|O
1b	933	935	|O
,	935	936	|O
(	937	938	|B-IUPAC
+	938	939	|I-IUPAC
)	939	940	|I-IUPAC
-	940	941	|I-IUPAC
pentazocine	941	952	|I-IUPAC
]	952	953	|O
with	954	958	|O
a	959	960	|O
2'	961	963	|O
-	963	964	|O
H	964	965	|O
or	966	968	|O
2'	969	971	|O
-	971	972	|O
F	972	973	|O
group	974	979	|O
resulted	980	988	|O
in	989	991	|O
a	992	993	|O
2	994	995	|O
-	995	996	|O
fold	996	1000	|O
increase	1001	1009	|O
in	1010	1012	|O
potency	1013	1020	|O
.	1020	1021	|O
Conversion	1022	1032	|O
of	1033	1035	|O
(	1036	1037	|O
+	1037	1038	|O
)	1038	1039	|O
-	1039	1040	|O
1f	1040	1042	|O
to	1043	1045	|O
its	1046	1049	|O
2'	1050	1052	|B-IUPAC
-	1052	1053	|I-IUPAC
desoxy	1053	1059	|I-IUPAC
analogue	1060	1068	|B-MODIFIER
(	1069	1070	|O
+	1070	1071	|O
)	1071	1072	|O
-	1072	1073	|O
2d	1073	1075	|O
resulted	1076	1084	|O
in	1085	1087	|O
a	1088	1089	|O
27.5	1090	1094	|O
-	1094	1095	|O
fold	1095	1099	|O
loss	1100	1104	|O
in	1105	1107	|O
affinity	1108	1116	|O
.	1116	1117	|O
This	1118	1122	|O
suggests	1123	1131	|O
that	1132	1136	|O
(	1137	1138	|O
+	1138	1139	|O
)	1139	1140	|O
-	1140	1141	|O
1f	1141	1143	|O
and	1144	1147	|O
other	1148	1153	|O
N	1154	1155	|O
-	1155	1156	|O
substituted	1156	1167	|O
benzomorphan	1168	1180	|O
analogues	1181	1190	|O
may	1191	1194	|O
be	1195	1197	|O
binding	1198	1205	|O
to	1206	1208	|O
single	1209	1215	|O
sigma	1216	1221	|O
1	1222	1223	|O
receptors	1224	1233	|O
in	1234	1236	|O
a	1237	1238	|O
different	1239	1248	|O
way	1249	1252	|O
or	1253	1255	|O
to	1256	1258	|O
different	1259	1268	|O
sigma	1269	1274	|O
1	1275	1276	|O
receptors	1277	1286	|O
.	1286	1287	|O
(	1288	1289	|B-IUPAC
-	1289	1290	|I-IUPAC
)	1290	1291	|I-IUPAC
-	1291	1292	|I-IUPAC
Pentazocine	1292	1303	|I-IUPAC
[	1304	1305	|O
(	1305	1306	|O
-	1306	1307	|O
)	1307	1308	|O
-	1308	1309	|O
1b	1309	1311	|O
]	1311	1312	|O
and	1313	1316	|O
its	1317	1320	|O
2'	1321	1323	|B-IUPAC
-	1323	1324	|I-IUPAC
fluoro	1324	1330	|I-IUPAC
analogue	1331	1339	|B-MODIFIER
,	1339	1340	|O
(	1341	1342	|B-IUPAC
-	1342	1343	|I-IUPAC
)	1343	1344	|I-IUPAC
-	1344	1345	|I-IUPAC
2	1345	1346	|I-IUPAC
-	1346	1347	|I-IUPAC
(	1347	1348	|I-IUPAC
dimethylallyl	1348	1361	|I-IUPAC
)	1361	1362	|I-IUPAC
-	1362	1363	|I-IUPAC
5,9	1363	1366	|I-IUPAC
alpha	1367	1372	|I-IUPAC
-	1372	1373	|I-IUPAC
dimethyl	1373	1381	|I-IUPAC
-	1381	1382	|I-IUPAC
2'	1382	1384	|I-IUPAC
-	1384	1385	|I-IUPAC
fluoro	1385	1391	|I-IUPAC
-	1391	1392	|I-IUPAC
6,7	1392	1395	|I-IUPAC
-	1395	1396	|I-IUPAC
benzomorphan	1396	1408	|I-IUPAC
[	1409	1410	|O
(	1410	1411	|O
-	1411	1412	|O
)	1412	1413	|O
-	1413	1414	|O
4a	1414	1416	|O
]	1416	1417	|O
showed	1418	1424	|O
the	1425	1428	|O
highest	1429	1436	|O
potency	1437	1444	|O
for	1445	1448	|O
the	1449	1452	|O
sigma	1453	1458	|O
2	1459	1460	|O
binding	1461	1468	|O
site	1469	1473	|O
.	1473	1474	|O

### abstracts34.txt
The	0	3	|O
synthesis	4	13	|O
and	14	17	|O
biological	18	28	|O
activities	29	39	|O
of	40	42	|O
14	43	45	|O
6	46	47	|B-MODIFIER
-	47	48	|I-MODIFIER
substituted	48	59	|I-MODIFIER
2,4	60	63	|B-IUPAC
-	63	64	|I-IUPAC
diaminoquinazolines	64	83	|I-IUPAC
are	84	87	|O
reported	88	96	|O
.	96	97	|O
These	98	103	|O
compounds	104	113	|O
were	114	118	|O
designed	119	127	|O
to	128	130	|O
improve	131	138	|O
the	139	142	|O
cell	143	147	|O
penetration	148	159	|O
of	160	162	|O
a	163	164	|O
previously	165	175	|O
reported	176	184	|O
series	185	191	|O
of	192	194	|O
2,4	195	198	|B-IUPAC
-	198	199	|I-IUPAC
diamino	199	206	|I-IUPAC
-	206	207	|I-IUPAC
6	207	208	|I-IUPAC
-	208	209	|O
substituted	209	220	|B-MODIFIER
-	220	221	|O
pyrido	221	227	|B-IUPAC
[	227	228	|I-IUPAC
2,3	228	231	|I-IUPAC
-	231	232	|I-IUPAC
d	232	233	|I-IUPAC
]	233	234	|I-IUPAC
pyrimidines	234	245	|I-IUPAC
which	246	251	|O
had	252	255	|O
shown	256	261	|O
significant	262	273	|O
potency	274	281	|O
and	282	285	|O
remarkable	286	296	|O
selectivity	297	308	|O
for	309	312	|O
Toxoplasma	313	323	|O
gondii	324	330	|O
dihydrofolate	331	344	|O
reductase	345	354	|O
(	355	356	|O
DHFR	356	360	|O
)	360	361	|O
,	361	362	|O
but	363	366	|O
had	367	370	|O
much	371	375	|O
lower	376	381	|O
inhibitory	382	392	|O
effects	393	400	|O
on	401	403	|O
the	404	407	|O
growth	408	414	|O
of	415	417	|O
T	418	419	|O
.	419	420	|O
gondii	421	427	|O
cells	428	433	|O
in	434	436	|O
culture	437	444	|O
.	444	445	|O
The	446	449	|O
target	450	456	|O
N9	457	459	|O
-	459	460	|O
H	460	461	|O
analogues	462	471	|O
were	472	476	|O
obtained	477	485	|O
via	486	489	|O
regiospecific	490	503	|O
reductive	504	513	|O
amination	514	523	|O
of	524	526	|O
the	527	530	|O
appropriate	531	542	|O
benzaldehydes	543	556	|O
with	557	561	|O
2,4,6	562	567	|B-IUPAC
-	567	568	|I-IUPAC
triaminoquinazoline	568	587	|I-IUPAC
,	587	588	|O
which	589	594	|O
,	594	595	|O
in	596	598	|O
turn	599	603	|O
,	603	604	|O
was	605	608	|O
synthesized	609	620	|O
from	621	625	|O
2,4	626	629	|B-IUPAC
-	629	630	|I-IUPAC
diamino	630	637	|I-IUPAC
-	637	638	|I-IUPAC
6	638	639	|I-IUPAC
-	639	640	|I-IUPAC
nitroquinazoline	640	656	|I-IUPAC
.	656	657	|O
The	658	661	|O
N9	662	664	|O
-	664	665	|O
CH3	665	668	|O
analogues	669	678	|O
were	679	683	|O
synthesized	684	695	|O
via	696	699	|O
a	700	701	|O
regiospecific	702	715	|O
reductive	716	725	|O
methylation	726	737	|O
of	738	740	|O
the	741	744	|O
corresponding	745	758	|O
N9	759	761	|O
-	761	762	|O
H	762	763	|O
precursors	764	774	|O
.	774	775	|O
The	776	779	|O
compounds	780	789	|O
were	790	794	|O
evaluated	795	804	|O
as	805	807	|O
inhibitors	808	818	|O
of	819	821	|O
DHFR	822	826	|O
from	827	831	|O
human	832	837	|O
,	837	838	|O
Pneumocystis	839	851	|O
carinii	852	859	|O
,	859	860	|O
T	861	862	|O
.	862	863	|O
gondii	864	870	|O
,	870	871	|O
rat	872	875	|O
liver	876	881	|O
,	881	882	|O
Lactobacillus	883	896	|O
casei	897	902	|O
,	902	903	|O
and	904	907	|O
Escherichia	908	919	|O
coli	920	924	|O
,	924	925	|O
and	926	929	|O
selected	930	938	|O
analogues	939	948	|O
were	949	953	|O
evaluated	954	963	|O
as	964	966	|O
inhibitors	967	977	|O
of	978	980	|O
the	981	984	|O
growth	985	991	|O
of	992	994	|O
tumor	995	1000	|O
cells	1001	1006	|O
in	1007	1009	|O
culture	1010	1017	|O
.	1017	1018	|O
These	1019	1024	|O
analogues	1025	1034	|O
displayed	1035	1044	|O
potent	1045	1051	|O
T	1052	1053	|O
.	1053	1054	|O
gondii	1055	1061	|O
DHFR	1062	1066	|O
inhibition	1067	1077	|O
as	1078	1080	|O
well	1081	1085	|O
as	1086	1088	|O
inhibition	1089	1099	|O
of	1100	1102	|O
the	1103	1106	|O
growth	1107	1113	|O
of	1114	1116	|O
T	1117	1118	|O
.	1118	1119	|O
gondii	1120	1126	|O
cells	1127	1132	|O
in	1133	1135	|O
culture	1136	1143	|O
.	1143	1144	|O
Further	1145	1152	|O
,	1152	1153	|O
selected	1154	1162	|O
analogues	1163	1172	|O
were	1173	1177	|O
potent	1178	1184	|O
inhibitors	1185	1195	|O
of	1196	1198	|O
the	1199	1202	|O
growth	1203	1209	|O
of	1210	1212	|O
tumor	1213	1218	|O
cells	1219	1224	|O
in	1225	1227	|O
culture	1228	1235	|O
in	1236	1238	|O
the	1239	1242	|O
in	1243	1245	|O
vitro	1246	1251	|O
screening	1252	1261	|O
program	1262	1269	|O
of	1270	1272	|O
the	1273	1276	|O
National	1277	1285	|O
Cancer	1286	1292	|O
Institute	1293	1302	|O
with	1303	1307	|O
GI50s	1308	1313	|O
in	1314	1316	|O
the	1317	1320	|O
nanomolar	1321	1330	|O
and	1331	1334	|O
subnanomolar	1335	1347	|O
range	1348	1353	|O
.	1353	1354	|O
Crystallographic	1355	1371	|O
data	1372	1376	|O
for	1377	1380	|O
the	1381	1384	|O
ternary	1385	1392	|O
complex	1393	1400	|O
of	1401	1403	|O
hDHFR	1404	1409	|O
-	1409	1410	|O
NADPH	1410	1415	|O
and	1416	1419	|O
2,4	1420	1423	|B-IUPAC
-	1423	1424	|I-IUPAC
diamino	1424	1431	|I-IUPAC
-	1431	1432	|I-IUPAC
6	1432	1433	|I-IUPAC
-	1433	1434	|I-IUPAC
[	1434	1435	|I-IUPAC
N	1435	1436	|I-IUPAC
-	1436	1437	|I-IUPAC
(	1437	1438	|I-IUPAC
2'	1438	1440	|I-IUPAC
,	1440	1441	|I-IUPAC
5'	1442	1444	|I-IUPAC
-	1444	1445	|I-IUPAC
dimethoxybenzyl	1445	1460	|I-IUPAC
)	1460	1461	|I-IUPAC
-	1461	1462	|I-IUPAC
N	1462	1463	|I-IUPAC
-	1463	1464	|I-IUPAC
methylamino	1464	1475	|I-IUPAC
]	1475	1476	|I-IUPAC
pyrido	1476	1482	|I-IUPAC
[	1482	1483	|I-IUPAC
2,3	1483	1486	|I-IUPAC
-	1486	1487	|I-IUPAC
d	1487	1488	|I-IUPAC
]	1488	1489	|I-IUPAC
pyrimidine	1489	1499	|I-IUPAC
,	1499	1500	|O
1c	1501	1503	|O
,	1503	1504	|O
reveal	1505	1511	|O
the	1512	1515	|O
first	1516	1521	|O
structural	1522	1532	|O
details	1533	1540	|O
for	1541	1544	|O
a	1545	1546	|O
reversed	1547	1555	|O
N9	1556	1558	|O
-	1558	1559	|O
C10	1559	1562	|O
folate	1563	1569	|O
bridge	1570	1576	|O
geometry	1577	1585	|O
as	1586	1588	|O
well	1589	1593	|O
as	1594	1596	|O
the	1597	1600	|O
first	1601	1606	|O
conformational	1607	1621	|O
details	1622	1629	|O
of	1630	1632	|O
a	1633	1634	|O
hybrid	1635	1641	|O
piritrexim	1642	1652	|O
-	1652	1653	|O
trimetrexate	1653	1665	|O
analogue	1666	1674	|O
.	1674	1675	|O

### abstracts2441.txt
A	0	1	|O
novel	2	7	|O
series	8	14	|O
of	15	17	|O
10	18	20	|B-IUPAC
-	20	21	|I-IUPAC
benzylidene	21	32	|I-IUPAC
-	32	33	|I-IUPAC
9	33	34	|I-IUPAC
(	34	35	|I-IUPAC
10H	35	38	|I-IUPAC
)	38	39	|I-IUPAC
-	39	40	|I-IUPAC
anthracenones	40	53	|I-IUPAC
and	54	57	|O
10	58	60	|B-IUPAC
-	60	61	|I-IUPAC
(	61	62	|I-IUPAC
phenylmethyl	62	74	|I-IUPAC
)	74	75	|I-IUPAC
-	75	76	|I-IUPAC
9	76	77	|I-IUPAC
(	77	78	|I-IUPAC
10H	78	81	|I-IUPAC
)	81	82	|I-IUPAC
-	82	83	|I-IUPAC
anthracenones	83	96	|I-IUPAC
were	97	101	|O
synthesized	102	113	|O
and	114	117	|O
evaluated	118	127	|O
for	128	131	|O
antiproliferative	132	149	|O
activity	150	158	|O
in	159	161	|O
an	162	164	|O
assay	165	170	|O
based	171	176	|O
on	177	179	|O
K562	180	184	|O
leukemia	185	193	|O
cells	194	199	|O
.	199	200	|O
The	201	204	|O
3	205	206	|B-IUPAC
-	206	207	|I-IUPAC
hydroxy	207	214	|I-IUPAC
-	214	215	|I-IUPAC
4	215	216	|I-IUPAC
-	216	217	|I-IUPAC
methoxybenzylidene	217	235	|I-IUPAC
analogue	236	244	|B-MODIFIER
9h	245	247	|O
was	248	251	|O
found	252	257	|O
to	258	260	|O
be	261	263	|O
the	264	267	|O
most	268	272	|O
active	273	279	|O
compound	280	288	|O
(	289	290	|O
IC	290	292	|O
(	292	293	|O
50	293	295	|O
)	295	296	|O
K562	297	301	|O
:	301	302	|O
20	303	305	|O
nM	306	308	|O
)	308	309	|O
.	309	310	|O
Structure	311	320	|O
-	320	321	|O
activity	321	329	|O
relationships	330	343	|O
are	344	347	|O
also	348	352	|O
considered	353	363	|O
.	363	364	|O
The	365	368	|O
highly	369	375	|O
active	376	382	|O
compound	383	391	|O
9h	392	394	|O
and	395	398	|O
the	399	402	|O
2,4	403	406	|B-IUPAC
-	406	407	|I-IUPAC
dimethoxy	407	416	|I-IUPAC
-	416	417	|I-IUPAC
3	417	418	|I-IUPAC
-	418	419	|I-IUPAC
hydroxybenzylidene	419	437	|I-IUPAC
analogue	438	446	|B-MODIFIER
9l	447	449	|O
were	450	454	|O
tested	455	461	|O
against	462	469	|O
five	470	474	|O
tumor	475	480	|O
cell	481	485	|O
lines	486	491	|O
using	492	497	|O
the	498	501	|O
XTT	502	505	|O
assay	506	511	|O
,	511	512	|O
including	513	522	|O
multidrug	523	532	|O
resistant	533	542	|O
phenotypes	543	553	|O
.	553	554	|O
Induction	555	564	|O
of	565	567	|O
cell	568	572	|O
death	573	578	|O
in	579	581	|O
a	582	583	|O
variety	584	591	|O
of	592	594	|O
tumor	595	600	|O
cell	601	605	|O
lines	606	611	|O
was	612	615	|O
determined	616	626	|O
in	627	629	|O
a	630	631	|O
monolayer	632	641	|O
assay	642	647	|O
using	648	653	|O
propidium	654	663	|O
iodide	664	670	|O
.	670	671	|O
Noteworthy	672	682	|O
,	682	683	|O
all	684	687	|O
compounds	688	697	|O
within	698	704	|O
the	705	708	|O
series	709	715	|O
induced	716	723	|O
elongations	724	735	|O
in	736	738	|O
K562	739	743	|O
cells	744	749	|O
similar	750	757	|O
to	758	760	|O
vinblastine	761	772	|O
-	772	773	|O
treated	773	780	|O
cells	781	786	|O
.	786	787	|O
The	788	791	|O
effect	792	798	|O
of	799	801	|O
the	802	805	|O
lead	806	810	|O
compound	811	819	|O
9h	820	822	|O
on	823	825	|O
K562	826	830	|O
cell	831	835	|O
growth	836	842	|O
was	843	846	|O
associated	847	857	|O
with	858	862	|O
cell	863	867	|O
cycle	868	873	|O
arrest	874	880	|O
in	881	883	|O
G2	884	886	|O
/	886	887	|O
M	887	888	|O
.	888	889	|O
Concentrations	890	904	|O
for	905	908	|O
50%	909	912	|O
KB	913	915	|O
/	915	916	|O
HeLa	916	920	|O
cells	921	926	|O
arrested	927	935	|O
in	936	938	|O
G2	939	941	|O
/	941	942	|O
M	942	943	|O
after	944	949	|O
treatment	950	959	|O
with	960	964	|O
9h	965	967	|O
and	968	971	|O
9l	972	974	|O
were	975	979	|O
determined	980	990	|O
and	991	994	|O
found	995	1000	|O
to	1001	1003	|O
be	1004	1006	|O
in	1007	1009	|O
the	1010	1013	|O
range	1014	1019	|O
of	1020	1022	|O
0.2	1023	1026	|O
microM	1027	1033	|O
.	1033	1034	|O
Additionally	1035	1047	|O
,	1047	1048	|O
we	1049	1051	|O
monitored	1052	1061	|O
the	1062	1065	|O
dose	1066	1070	|O
dependent	1071	1080	|O
caspase	1081	1088	|O
-	1088	1089	|O
3	1089	1090	|O
-	1090	1091	|O
like	1091	1095	|O
protease	1096	1104	|O
activity	1105	1113	|O
in	1114	1116	|O
K562	1117	1121	|O
cells	1122	1127	|O
and	1128	1131	|O
MCF	1132	1135	|O
-	1135	1136	|O
7	1136	1137	|O
/	1137	1138	|O
Casp	1138	1142	|O
-	1142	1143	|O
3	1143	1144	|O
cells	1145	1150	|O
treated	1151	1158	|O
with	1159	1163	|O
9h	1164	1166	|O
,	1166	1167	|O
indicating	1168	1178	|O
induction	1179	1188	|O
of	1189	1191	|O
apoptosis	1192	1201	|O
.	1201	1202	|O
Western	1203	1210	|O
blotting	1211	1219	|O
analysis	1220	1228	|O
demonstrated	1229	1241	|O
that	1242	1246	|O
9h	1247	1249	|O
caused	1250	1256	|O
a	1257	1258	|O
shift	1259	1264	|O
in	1265	1267	|O
tubulin	1268	1275	|O
concentration	1276	1289	|O
from	1290	1294	|O
the	1295	1298	|O
polymerized	1299	1310	|O
state	1311	1316	|O
found	1317	1322	|O
in	1323	1325	|O
the	1326	1329	|O
cell	1330	1334	|O
pellet	1335	1341	|O
to	1342	1344	|O
the	1345	1348	|O
unpolymerized	1349	1362	|O
state	1363	1368	|O
found	1369	1374	|O
in	1375	1377	|O
the	1378	1381	|O
cell	1382	1386	|O
supernatant	1387	1398	|O
.	1398	1399	|O
Seven	1400	1405	|O
compounds	1406	1415	|O
strongly	1416	1424	|O
inhibited	1425	1434	|O
tubulin	1435	1442	|O
polymerization	1443	1457	|O
with	1458	1462	|O
activities	1463	1473	|O
higher	1474	1480	|O
or	1481	1483	|O
comparable	1484	1494	|O
to	1495	1497	|O
those	1498	1503	|O
of	1504	1506	|O
the	1507	1510	|O
reference	1511	1520	|O
compounds	1521	1530	|O
such	1531	1535	|O
as	1536	1538	|O
colchicine	1539	1549	|O
,	1549	1550	|O
podophyllotoxin	1551	1566	|O
,	1566	1567	|O
and	1568	1571	|O
nocodazole	1572	1582	|O
.	1582	1583	|O
In	1584	1586	|O
general	1587	1594	|O
,	1594	1595	|O
the	1596	1599	|O
antiproliferative	1600	1617	|O
activity	1618	1626	|O
correlated	1627	1637	|O
with	1638	1642	|O
inhibition	1643	1653	|O
of	1654	1656	|O
tubulin	1657	1664	|O
polymerization	1665	1679	|O
.	1679	1680	|O
The	1681	1684	|O
most	1685	1689	|O
active	1690	1696	|O
compounds	1697	1706	|O
strongly	1707	1715	|O
displaced	1716	1725	|O
[	1726	1727	|O
(	1727	1728	|O
3	1728	1729	|O
)	1729	1730	|O
H	1730	1731	|O
]	1731	1732	|O
colchicine	1732	1742	|O
from	1743	1747	|O
its	1748	1751	|O
binding	1752	1759	|O
site	1760	1764	|O
in	1765	1767	|O
the	1768	1771	|O
tubulin	1772	1779	|O
,	1779	1780	|O
yielding	1781	1789	|O
IC	1790	1792	|O
(	1792	1793	|O
50	1793	1795	|O
)	1795	1796	|O
values	1797	1803	|O
3	1804	1805	|O
-	1805	1806	|O
to	1807	1809	|O
4	1810	1811	|O
-	1811	1812	|O
fold	1812	1816	|O
lower	1817	1822	|O
than	1823	1827	|O
that	1828	1832	|O
of	1833	1835	|O
colchicine	1836	1846	|O
.	1846	1847	|O
The	1848	1851	|O
novel	1852	1857	|O
benzylidene	1858	1869	|B-IUPAC
-	1869	1870	|I-IUPAC
9	1870	1871	|I-IUPAC
(	1871	1872	|I-IUPAC
10H	1872	1875	|I-IUPAC
)	1875	1876	|I-IUPAC
-	1876	1877	|I-IUPAC
anthracenones	1877	1890	|I-IUPAC
described	1891	1900	|O
in	1901	1903	|O
the	1904	1907	|O
present	1908	1915	|O
study	1916	1921	|O
constitute	1922	1932	|O
an	1933	1935	|O
interesting	1936	1947	|O
group	1948	1953	|O
of	1954	1956	|O
highly	1957	1963	|O
active	1964	1970	|O
and	1971	1974	|O
easily	1975	1981	|O
accessible	1982	1992	|O
antimitotic	1993	2004	|O
agents	2005	2011	|O
that	2012	2016	|O
inhibit	2017	2024	|O
tubulin	2025	2032	|O
polymerization	2033	2047	|O
.	2047	2048	|O

### abstracts4001.txt
The	0	3	|O
synthesis	4	13	|O
,	13	14	|O
physical	15	23	|O
properties	24	34	|O
,	34	35	|O
antitumor	36	45	|O
activity	46	54	|O
,	54	55	|O
structure	56	65	|O
-	65	66	|O
activity	66	74	|O
relationships	75	88	|O
,	88	89	|O
and	90	93	|O
nephrotoxicity	94	108	|O
of	109	111	|O
a	112	113	|O
series	114	120	|O
of	121	123	|O
[	124	125	|O
2	125	126	|B-MODIFIER
-	126	127	|I-MODIFIER
substituted	127	138	|I-MODIFIER
-	138	139	|O
4,5	139	142	|B-IUPAC
-	142	143	|I-IUPAC
bis	143	146	|I-IUPAC
(	146	147	|I-IUPAC
aminomethyl	147	158	|I-IUPAC
)	158	159	|I-IUPAC
-	159	160	|I-IUPAC
1,3	160	163	|I-IUPAC
-	163	164	|I-IUPAC
dioxolane	164	173	|I-IUPAC
]	173	174	|I-IUPAC
platinum	174	182	|I-IUPAC
(	182	183	|I-IUPAC
II	183	185	|I-IUPAC
)	185	186	|I-IUPAC
complexes	187	196	|B-MODIFIER
are	197	200	|O
described	201	210	|O
.	210	211	|O
The	212	215	|O
42	216	218	|O
platinum	219	227	|O
(	227	228	|O
II	228	230	|O
)	230	231	|O
complexes	232	241	|O
having	242	248	|O
a	249	250	|O
seven	251	256	|O
-	256	257	|O
membered	257	265	|O
ring	266	270	|O
structure	271	280	|O
in	281	283	|O
this	284	288	|O
series	289	295	|O
have	296	300	|O
been	301	305	|O
prepared	306	314	|O
and	315	318	|O
characterized	319	332	|O
by	333	335	|O
1H	336	338	|O
NMR	339	342	|O
,	342	343	|O
13C	344	347	|O
NMR	348	351	|O
,	351	352	|O
IR	353	355	|O
,	355	356	|O
FAB	357	360	|O
-	360	361	|O
MS	361	363	|O
,	363	364	|O
and	365	368	|O
elemental	369	378	|O
analysis	379	387	|O
.	387	388	|O
All	389	392	|O
members	393	400	|O
of	401	403	|O
the	404	407	|O
series	408	414	|O
were	415	419	|O
designed	420	428	|O
to	429	431	|O
have	432	436	|O
a	437	438	|O
1,3	439	442	|O
-	442	443	|O
dioxolane	443	452	|O
ring	453	457	|O
moiety	458	464	|O
in	465	467	|O
their	468	473	|O
carrier	474	481	|O
ligands	482	489	|O
to	490	492	|O
increase	493	501	|O
water	502	507	|O
solubility	508	518	|O
.	518	519	|O
The	520	523	|O
solubility	524	534	|O
of	535	537	|O
platinum	538	546	|O
complexes	547	556	|O
was	557	560	|O
related	561	568	|O
to	569	571	|O
the	572	575	|O
nature	576	582	|O
of	583	585	|O
leaving	586	593	|O
ligands	594	601	|O
and	602	605	|O
2	606	607	|O
-	607	608	|O
substituents	608	620	|O
in	621	623	|O
the	624	627	|O
4,5	628	631	|B-IUPAC
-	631	632	|I-IUPAC
bis	632	635	|I-IUPAC
(	635	636	|I-IUPAC
aminomethyl	636	647	|I-IUPAC
)	647	648	|I-IUPAC
-	648	649	|I-IUPAC
1,3	649	652	|I-IUPAC
-	652	653	|I-IUPAC
dioxolane	653	662	|I-IUPAC
carrier	663	670	|O
ligands	671	678	|O
.	678	679	|O
In	680	682	|O
general	683	690	|O
,	690	691	|O
compounds	692	701	|O
having	702	708	|O
two	709	712	|O
different	713	722	|O
R1	723	725	|O
and	726	729	|O
R2	730	732	|O
substituents	733	745	|O
in	746	748	|O
the	749	752	|O
4,5	753	756	|B-IUPAC
-	756	757	|I-IUPAC
bis	757	760	|I-IUPAC
(	760	761	|I-IUPAC
aminomethyl	761	772	|I-IUPAC
)	772	773	|I-IUPAC
-	773	774	|I-IUPAC
1,3	774	777	|I-IUPAC
-	777	778	|I-IUPAC
dioxolane	778	787	|I-IUPAC
moiety	788	794	|B-MODIFIER
were	795	799	|O
more	800	804	|O
water	805	810	|O
-	810	811	|O
soluble	811	818	|O
than	819	823	|O
those	824	829	|O
having	830	836	|O
the	837	840	|O
same	841	845	|O
substituents	846	858	|O
.	858	859	|O
Most	860	864	|O
members	865	872	|O
of	873	875	|O
this	876	880	|O
series	881	887	|O
showed	888	894	|O
the	895	898	|O
excellent	899	908	|O
antitumor	909	918	|O
activity	919	927	|O
against	928	935	|O
murine	936	942	|O
L1210	943	948	|O
leukemia	949	957	|O
cells	958	963	|O
transplanted	964	976	|O
in	977	979	|O
mice	980	984	|O
and	985	988	|O
were	989	993	|O
superior	994	1002	|O
to	1003	1005	|O
cisplatin	1006	1015	|O
and	1016	1019	|O
carboplatin	1020	1031	|O
.	1031	1032	|O
The	1033	1036	|O
(	1037	1038	|O
4R	1038	1040	|O
,	1040	1041	|O
5R	1041	1043	|O
)	1043	1044	|O
-	1044	1045	|O
stereoisomer	1045	1057	|O
1a	1058	1060	|O
-	1060	1061	|O
h	1061	1062	|O
exhibited	1063	1072	|O
the	1073	1076	|O
higher	1077	1083	|O
antitumor	1084	1093	|O
activity	1094	1102	|O
than	1103	1107	|O
the	1108	1111	|O
corresponding	1112	1125	|O
(	1126	1127	|O
4S	1127	1129	|O
,	1129	1130	|O
5S	1130	1132	|O
)	1132	1133	|O
-	1133	1134	|O
stereoisomer	1134	1146	|O
2a	1147	1149	|O
-	1149	1150	|O
h	1150	1151	|O
in	1152	1154	|O
the	1155	1158	|O
(	1159	1160	|B-IUPAC
1,1	1160	1163	|I-IUPAC
-	1163	1164	|I-IUPAC
cyclobutanedicarboxylato	1164	1188	|I-IUPAC
)	1188	1189	|I-IUPAC
platinum	1189	1197	|I-IUPAC
(	1197	1198	|I-IUPAC
II	1198	1200	|I-IUPAC
)	1200	1201	|I-IUPAC
complexes	1202	1211	|B-MODIFIER
.	1211	1212	|O
The	1213	1216	|O
(	1217	1218	|B-IUPAC
glycolato	1218	1227	|I-IUPAC
)	1227	1228	|I-IUPAC
-	1228	1229	|I-IUPAC
platinum	1229	1237	|I-IUPAC
(	1237	1238	|I-IUPAC
II	1238	1240	|I-IUPAC
)	1240	1241	|I-IUPAC
complexes	1242	1251	|B-MODIFIER
were	1252	1256	|O
highly	1257	1263	|O
cytotoxic	1264	1273	|O
toward	1274	1280	|O
four	1281	1285	|O
human	1286	1291	|O
stomach	1292	1299	|O
cancer	1300	1306	|O
cell	1307	1311	|O
lines	1312	1317	|O
,	1317	1318	|O
SNU	1319	1322	|O
-	1322	1323	|O
1	1323	1324	|O
,	1324	1325	|O
SNU	1326	1329	|O
-	1329	1330	|O
5	1330	1331	|O
,	1331	1332	|O
SNU	1333	1336	|O
-	1336	1337	|O
16	1337	1339	|O
,	1339	1340	|O
and	1341	1344	|O
NCI	1345	1348	|O
-	1348	1349	|O
N87	1349	1352	|O
,	1352	1353	|O
and	1354	1357	|O
among	1358	1363	|O
them	1364	1368	|O
,	1368	1369	|O
complexes	1370	1379	|O
3d	1380	1382	|O
-	1382	1383	|O
g	1383	1384	|O
were	1385	1389	|O
even	1390	1394	|O
more	1395	1399	|O
cytotoxic	1400	1409	|O
than	1410	1414	|O
cisplatin	1415	1424	|O
.	1424	1425	|O
The	1426	1429	|O
(	1430	1431	|O
malonato	1431	1439	|O
)	1439	1440	|O
platinum	1440	1448	|O
(	1448	1449	|O
II	1449	1451	|O
)	1451	1452	|O
complex	1453	1460	|O
1m	1461	1463	|O
and	1464	1467	|O
the	1468	1471	|O
(	1472	1473	|O
glycolato	1473	1482	|O
)	1482	1483	|O
platinum	1483	1491	|O
(	1491	1492	|O
II	1492	1494	|O
)	1494	1495	|O
complexes	1496	1505	|O
3d	1506	1508	|O
-	1508	1509	|O
g	1509	1510	|O
were	1511	1515	|O
selected	1516	1524	|O
for	1525	1528	|O
further	1529	1536	|O
studies	1537	1544	|O
based	1545	1550	|O
on	1551	1553	|O
the	1554	1557	|O
greater	1558	1565	|O
in	1566	1568	|O
vivo	1569	1573	|O
and	1574	1577	|O
in	1578	1580	|O
vitro	1581	1586	|O
antitumor	1587	1596	|O
activity	1597	1605	|O
and	1606	1609	|O
desirable	1610	1619	|O
physical	1620	1628	|O
properties	1629	1639	|O
.	1639	1640	|O
The	1641	1644	|O
complexes	1645	1654	|O
3e	1655	1657	|O
-	1657	1658	|O
g	1658	1659	|O
were	1660	1664	|O
almost	1665	1671	|O
equally	1672	1679	|O
cytotoxic	1680	1689	|O
to	1690	1692	|O
cisplatin	1693	1702	|O
toward	1703	1709	|O
human	1710	1715	|O
stomach	1716	1723	|O
cancer	1724	1730	|O
cell	1731	1735	|O
lines	1736	1741	|O
,	1741	1742	|O
KATO	1743	1747	|O
-	1747	1748	|O
III	1748	1751	|O
and	1752	1755	|O
MKN	1756	1759	|O
-	1759	1760	|O
45	1760	1762	|O
,	1762	1763	|O
and	1764	1767	|O
a	1768	1769	|O
human	1770	1775	|O
non	1776	1779	|O
-	1779	1780	|O
small	1780	1785	|O
cell	1786	1790	|O
lung	1791	1795	|O
cancer	1796	1802	|O
cell	1803	1807	|O
line	1808	1812	|O
,	1812	1813	|O
PC14	1814	1818	|O
.	1818	1819	|O
In	1820	1822	|O
contrast	1823	1831	|O
with	1832	1836	|O
cisplatin	1837	1846	|O
and	1847	1850	|O
carboplatin	1851	1862	|O
,	1862	1863	|O
five	1864	1868	|O
complexes	1869	1878	|O
selected	1879	1887	|O
significantly	1888	1901	|O
increased	1902	1911	|O
in	1912	1914	|O
life	1915	1919	|O
span	1920	1924	|O
in	1925	1927	|O
mice	1928	1932	|O
transplanted	1933	1945	|O
with	1946	1950	|O
cisplatin	1951	1960	|O
-	1960	1961	|O
resistant	1961	1970	|O
L1210	1971	1976	|O
cells	1977	1982	|O
.	1982	1983	|O
Nephrotoxicity	1984	1998	|O
studies	1999	2006	|O
in	2007	2009	|O
ICR	2010	2013	|O
mice	2014	2018	|O
indicated	2019	2028	|O
that	2029	2033	|O
serum	2034	2039	|O
BUN	2040	2043	|O
and	2044	2047	|O
creatinine	2048	2058	|O
levels	2059	2065	|O
were	2066	2070	|O
not	2071	2074	|O
elevated	2075	2083	|O
when	2084	2088	|O
five	2089	2093	|O
complexes	2094	2103	|O
were	2104	2108	|O
given	2109	2114	|O
at	2115	2117	|O
a	2118	2119	|O
dose	2120	2124	|O
equal	2125	2130	|O
to	2131	2133	|O
1.5	2134	2137	|O
times	2138	2143	|O
the	2144	2147	|O
optimal	2148	2155	|O
dose	2156	2160	|O
determined	2161	2171	|O
in	2172	2174	|O
the	2175	2178	|O
in	2179	2181	|O
vivo	2182	2186	|O
L1210	2187	2192	|O
screening	2193	2202	|O
system	2203	2209	|O
.	2209	2210	|O

### abstracts2339.txt
5	0	1	|O
-	1	2	|O
(	2	3	|O
2	3	4	|O
-	4	5	|O
Acylethynyl	5	16	|O
)	16	17	|O
-	17	18	|O
2,4	18	21	|O
-	21	22	|O
dimethoxypyrimidines	22	42	|O
(	43	44	|O
3-6	44	47	|O
)	47	48	|O
were	49	53	|O
synthesized	54	65	|O
in	66	68	|O
excellent	69	78	|O
yields	79	85	|O
from	86	90	|O
2,4	91	94	|B-IUPAC
-	94	95	|I-IUPAC
dimethoxy	95	104	|I-IUPAC
-	104	105	|I-IUPAC
5	105	106	|I-IUPAC
-	106	107	|I-IUPAC
[	107	108	|I-IUPAC
2	108	109	|I-IUPAC
-	109	110	|I-IUPAC
(	110	111	|I-IUPAC
trimethylsilyl	111	125	|I-IUPAC
)	125	126	|I-IUPAC
ethynyl	126	133	|I-IUPAC
]	133	134	|I-IUPAC
pyrimidine	134	144	|I-IUPAC
(	145	146	|O
2	146	147	|O
)	147	148	|O
by	149	151	|O
treatment	152	161	|O
with	162	166	|O
acid	167	171	|O
chlorides	172	181	|O
in	182	184	|O
the	185	188	|O
presence	189	197	|O
of	198	200	|O
anhydrous	201	210	|O
aluminum	211	219	|O
chloride	220	228	|O
.	228	229	|O
Compounds	230	239	|O
3-6	240	243	|O
were	244	248	|O
deblocked	249	258	|O
with	259	263	|O
chlorotrimethylsilane	264	285	|B-IUPAC
and	286	289	|O
sodium	290	296	|O
iodide	297	303	|O
in	304	306	|O
acetonitrile	307	319	|O
to	320	322	|O
the	323	326	|O
corresponding	327	340	|O
5	341	342	|B-IUPAC
-	342	343	|I-IUPAC
[	343	344	|I-IUPAC
(	344	345	|I-IUPAC
2	345	346	|I-IUPAC
-	346	347	|I-IUPAC
acyl	347	351	|I-IUPAC
-	351	352	|I-IUPAC
1	352	353	|I-IUPAC
-	353	354	|I-IUPAC
iodo	354	358	|I-IUPAC
)	358	359	|I-IUPAC
vinyl	359	364	|I-IUPAC
]	364	365	|I-IUPAC
uracils	365	372	|I-IUPAC
(	373	374	|O
7-10	374	378	|O
)	378	379	|O
,	379	380	|O
which	381	386	|O
on	387	389	|O
treatment	390	399	|O
with	400	404	|O
potassium	405	414	|O
hydroxide	415	424	|O
in	425	427	|O
dioxane	428	435	|O
yielded	436	443	|O
the	444	447	|O
corresponding	448	461	|O
5	462	463	|B-IUPAC
-	463	464	|I-IUPAC
(	464	465	|I-IUPAC
2	465	466	|I-IUPAC
-	466	467	|I-IUPAC
acylethynyl	467	478	|I-IUPAC
)	478	479	|I-IUPAC
uracils	479	486	|I-IUPAC
(	487	488	|O
11-14	488	493	|O
)	493	494	|O
.	494	495	|O
The	496	499	|O
5	500	501	|B-IUPAC
-	501	502	|I-IUPAC
(	502	503	|I-IUPAC
2	503	504	|I-IUPAC
-	504	505	|I-IUPAC
acylethynyl	505	516	|I-IUPAC
)	516	517	|I-IUPAC
uracils	517	524	|I-IUPAC
were	525	529	|O
found	530	535	|O
to	536	538	|O
be	539	541	|O
active	542	548	|O
against	549	556	|O
Ehrlich	557	564	|O
ascites	565	572	|O
carcinoma	573	582	|O
(	583	584	|O
EAC	584	587	|O
)	587	588	|O
cells	589	594	|O
in	595	597	|O
vivo	598	602	|O
,	602	603	|O
the	604	607	|O
most	608	612	|O
active	613	619	|O
compounds	620	629	|O
being	630	635	|O
5	636	637	|B-IUPAC
-	637	638	|I-IUPAC
(	638	639	|I-IUPAC
2	639	640	|I-IUPAC
-	640	641	|I-IUPAC
benzoylethynyl	641	655	|I-IUPAC
)	655	656	|I-IUPAC
uracil	656	662	|I-IUPAC
(	663	664	|O
11	664	666	|O
)	666	667	|O
and	668	671	|O
5	672	673	|B-IUPAC
-	673	674	|I-IUPAC
(	674	675	|I-IUPAC
2	675	676	|I-IUPAC
-	676	677	|I-IUPAC
p	677	678	|I-IUPAC
-	678	679	|I-IUPAC
toluoylethynyl	679	693	|I-IUPAC
)	693	694	|I-IUPAC
uracil	694	700	|I-IUPAC
(	701	702	|O
12	702	704	|O
)	704	705	|O
.	705	706	|O
The	707	710	|O
T	711	712	|O
/	712	713	|O
C	713	714	|O
values	715	721	|O
of	722	724	|O
281	725	728	|O
and	729	732	|O
300	733	736	|O
were	737	741	|O
obtained	742	750	|O
for	751	754	|O
compounds	755	764	|O
11	765	767	|O
and	768	771	|O
12	772	774	|O
,	774	775	|O
respectively	776	788	|O
,	788	789	|O
in	790	792	|O
the	793	796	|O
case	797	801	|O
of	802	804	|O
mice	805	809	|O
bearing	810	817	|O
EAC	818	821	|O
cells	822	827	|O
.	827	828	|O
The	829	832	|O
5	833	834	|B-IUPAC
-	834	835	|I-IUPAC
(	835	836	|I-IUPAC
2	836	837	|I-IUPAC
-	837	838	|I-IUPAC
acylethynyl	838	849	|I-IUPAC
)	849	850	|I-IUPAC
uracils	850	857	|I-IUPAC
have	858	862	|O
also	863	867	|O
shown	868	873	|O
in	874	876	|O
vitro	877	882	|O
activity	883	891	|O
against	892	899	|O
CCRF	900	904	|O
-	904	905	|O
CEM	905	908	|O
and	909	912	|O
L1210/0	913	920	|O
tumor	921	926	|O
cell	927	931	|O
lines	932	937	|O
.	937	938	|O
The	939	942	|O
lead	943	947	|O
compound	948	956	|O
5	957	958	|B-IUPAC
-	958	959	|I-IUPAC
(	959	960	|I-IUPAC
2	960	961	|I-IUPAC
-	961	962	|I-IUPAC
p	962	963	|I-IUPAC
-	963	964	|I-IUPAC
toluoylethynyl	964	978	|I-IUPAC
)	978	979	|I-IUPAC
uracil	979	985	|I-IUPAC
effectively	986	997	|O
inhibited	998	1007	|O
thymidylate	1008	1019	|O
synthetase	1020	1030	|O
.	1030	1031	|O

### abstracts4280.txt
Chemical	0	8	|O
and	9	12	|O
biological	13	23	|O
similarities	24	36	|O
of	37	39	|O
plutonium	40	49	|O
(	49	50	|O
IV	50	52	|O
)	52	53	|O
and	54	57	|O
iron	58	62	|O
(	62	63	|O
III	63	66	|O
)	66	67	|O
suggested	68	77	|O
that	78	82	|O
octadentate	83	94	|O
ligands	95	102	|O
containing	103	113	|O
hydroxamate	114	125	|O
or	126	128	|O
catecholate	129	140	|O
functional	141	151	|O
groups	152	158	|O
,	158	159	|O
which	160	165	|O
are	166	169	|O
found	170	175	|O
in	176	178	|O
microbial	179	188	|O
iron	189	193	|O
chelating	194	203	|O
agents	204	210	|O
(	211	212	|O
siderophores	212	224	|O
)	224	225	|O
,	225	226	|O
would	227	232	|O
be	233	235	|O
effective	236	245	|O
and	246	249	|O
relatively	250	260	|O
selective	261	270	|O
complexing	271	281	|O
agents	282	288	|O
for	289	292	|O
actinide	293	301	|O
(	301	302	|O
IV	302	304	|O
)	304	305	|O
ions	306	310	|O
.	310	311	|O
However	312	319	|O
,	319	320	|O
their	321	326	|O
usefulness	327	337	|O
for	338	341	|O
in	342	344	|O
vivo	345	349	|O
chelation	350	359	|O
of	360	362	|O
actinide	363	371	|O
(	371	372	|O
IV	372	374	|O
)	374	375	|O
is	376	378	|O
limited	379	386	|O
,	386	387	|O
because	388	395	|O
catechol	396	404	|O
and	405	408	|O
hydroxamate	409	420	|O
are	421	424	|O
such	425	429	|O
weak	430	434	|O
acids	435	440	|O
that	441	445	|O
the	446	449	|O
potential	450	459	|O
for	460	463	|O
octadentate	464	475	|O
binding	476	483	|O
of	484	486	|O
actinide	487	495	|O
(	495	496	|O
IV	496	498	|O
)	498	499	|O
cannot	500	506	|O
be	507	509	|O
achieved	510	518	|O
at	519	521	|O
physiological	522	535	|O
pH	536	538	|O
.	538	539	|O
The	540	543	|O
structurally	544	556	|O
similar	557	564	|O
monoprotic	565	575	|O
and	576	579	|O
more	580	584	|O
acidic	585	591	|O
1	592	593	|B-IUPAC
-	593	594	|I-IUPAC
hydroxy	594	601	|I-IUPAC
-	601	602	|I-IUPAC
2	602	603	|I-IUPAC
(	603	604	|I-IUPAC
1H	604	606	|I-IUPAC
)	606	607	|I-IUPAC
-	607	608	|I-IUPAC
pyridinone	608	618	|I-IUPAC
(	619	620	|O
1,2	620	623	|O
-	623	624	|O
HOPO	624	628	|O
)	628	629	|O
group	630	635	|O
was	636	639	|O
,	639	640	|O
therefore	641	650	|O
,	650	651	|O
incorporated	652	664	|O
into	665	669	|O
multidentate	670	682	|O
ligands	683	690	|O
.	690	691	|O
Treatment	692	701	|O
of	702	704	|O
1,2	705	708	|B-IUPAC
-	708	709	|I-IUPAC
dihydro	709	716	|I-IUPAC
-	716	717	|I-IUPAC
1	717	718	|I-IUPAC
-	718	719	|I-IUPAC
hydroxy	719	726	|I-IUPAC
-	726	727	|I-IUPAC
2	727	728	|I-IUPAC
-	728	729	|I-IUPAC
oxopyridine	729	740	|I-IUPAC
-	740	741	|I-IUPAC
6	741	742	|I-IUPAC
-	742	743	|I-IUPAC
carboxylic	743	753	|I-IUPAC
acid	754	758	|I-IUPAC
(	759	760	|O
5	760	761	|O
)	761	762	|O
with	763	767	|O
phosgene	768	776	|O
in	777	779	|O
THF	780	783	|O
solution	784	792	|O
gives	793	798	|O
the	799	802	|O
active	803	809	|O
ester	810	815	|O
poly	816	820	|B-IUPAC
[	820	821	|I-IUPAC
1,2	821	824	|I-IUPAC
-	824	825	|I-IUPAC
dihydro	825	832	|I-IUPAC
-	832	833	|I-IUPAC
1,2	833	836	|I-IUPAC
-	836	837	|I-IUPAC
dioxopyridine	837	850	|I-IUPAC
-	850	851	|I-IUPAC
6	851	852	|I-IUPAC
-	852	853	|I-IUPAC
carboxylate	853	864	|I-IUPAC
]	864	865	|I-IUPAC
,	865	866	|O
which	867	872	|O
upon	873	877	|O
treatment	878	887	|O
with	888	892	|O
excess	893	899	|O
anhydrous	900	909	|O
dimethylamine	910	923	|O
gave	924	928	|O
a	929	930	|O
60%	931	934	|O
yield	935	940	|O
of	941	943	|O
N	944	945	|B-IUPAC
,	945	946	|I-IUPAC
N	946	947	|I-IUPAC
-	947	948	|I-IUPAC
dimethyl	948	956	|I-IUPAC
-	956	957	|I-IUPAC
1,2	957	960	|I-IUPAC
-	960	961	|I-IUPAC
dihydro	961	968	|I-IUPAC
-	968	969	|I-IUPAC
1	969	970	|I-IUPAC
-	970	971	|I-IUPAC
hydroxy	971	978	|I-IUPAC
-	978	979	|I-IUPAC
2	979	980	|I-IUPAC
-	980	981	|I-IUPAC
oxopyridine	981	992	|I-IUPAC
-	992	993	|I-IUPAC
6	993	994	|I-IUPAC
-	994	995	|I-IUPAC
carboxamide	995	1006	|I-IUPAC
(	1007	1008	|O
6	1008	1009	|O
)	1009	1010	|O
.	1010	1011	|O
A	1012	1013	|O
similarly	1014	1023	|O
reactive	1024	1032	|O
intermediate	1033	1045	|O
was	1046	1049	|O
prepared	1050	1058	|O
from	1059	1063	|O
5	1064	1065	|O
and	1066	1069	|O
an	1070	1072	|O
equimolar	1073	1082	|O
amount	1083	1089	|O
of	1090	1092	|O
phosgene	1093	1101	|O
in	1102	1104	|O
N	1105	1106	|B-IUPAC
,	1106	1107	|I-IUPAC
N	1107	1108	|I-IUPAC
-	1108	1109	|I-IUPAC
dimethylacetamide	1109	1126	|I-IUPAC
.	1126	1127	|O
Combined	1128	1136	|O
in	1137	1139	|O
situ	1140	1144	|O
with	1145	1149	|O
1,3	1150	1153	|B-IUPAC
-	1153	1154	|I-IUPAC
propanediamine	1154	1168	|I-IUPAC
,	1168	1169	|O
benzylamine	1170	1181	|O
,	1181	1182	|O
spermine	1183	1191	|O
,	1191	1192	|O
spermidine	1193	1203	|O
,	1203	1204	|O
1,3,5	1205	1210	|B-IUPAC
-	1210	1211	|I-IUPAC
tris	1211	1215	|I-IUPAC
(	1215	1216	|I-IUPAC
aminomethyl	1216	1227	|I-IUPAC
)	1227	1228	|I-IUPAC
benzene	1228	1235	|I-IUPAC
,	1235	1236	|O
or	1237	1239	|O
desferrioxamine	1240	1255	|O
B	1256	1257	|O
and	1258	1261	|O
excess	1262	1268	|O
triethylamine	1269	1282	|O
,	1282	1283	|O
the	1284	1287	|O
latter	1288	1294	|O
intermediate	1295	1307	|O
gave	1308	1312	|O
the	1313	1316	|O
corresponding	1317	1330	|O
amides	1331	1337	|O
in	1338	1340	|O
isolated	1341	1349	|O
yields	1350	1356	|O
ranging	1357	1364	|O
from	1365	1369	|O
16%	1370	1373	|O
to	1374	1376	|O
60%	1377	1380	|O
.	1380	1381	|O
The	1382	1385	|O
free	1386	1390	|O
ligands	1391	1398	|O
,	1398	1399	|O
their	1400	1405	|O
Zn	1406	1408	|O
(	1408	1409	|O
II	1409	1411	|O
)	1411	1412	|O
complexes	1413	1422	|O
,	1422	1423	|O
and	1424	1427	|O
the	1428	1431	|O
ferric	1432	1438	|O
complex	1439	1446	|O
of	1447	1449	|O
3,4,3	1450	1455	|O
-	1455	1456	|O
LIHOPO	1456	1462	|O
were	1463	1467	|O
administered	1468	1480	|O
to	1481	1483	|O
mice	1484	1488	|O
[	1489	1490	|O
30	1490	1492	|O
mumol	1493	1498	|O
/	1498	1499	|O
kg	1499	1501	|O
intraperitoneally	1502	1519	|O
1	1520	1521	|O
h	1522	1523	|O
after	1524	1529	|O
Pu	1530	1532	|O
(	1532	1533	|O
IV	1533	1535	|O
)	1535	1536	|O
-	1536	1537	|O
238	1537	1540	|O
citrate	1541	1548	|O
,	1548	1549	|O
kill	1550	1554	|O
at	1555	1557	|O
24	1558	1560	|O
h	1561	1562	|O
]	1562	1563	|O
.	1563	1564	|O
Net	1565	1568	|O
Pu	1569	1571	|O
removal	1572	1579	|O
[	1580	1581	|O
Pu	1581	1583	|O
excretion	1584	1593	|O
(	1594	1595	|O
treated	1595	1602	|O
)	1602	1603	|O
-	1603	1604	|O
PU	1604	1606	|O
excretion	1607	1616	|O
(	1617	1618	|O
control	1618	1625	|O
)	1625	1626	|O
]	1626	1627	|O
,	1627	1628	|O
expressed	1629	1638	|O
as	1639	1641	|O
percent	1642	1649	|O
of	1650	1652	|O
injected	1653	1661	|O
Pu	1662	1664	|O
,	1664	1665	|O
was	1666	1669	|O
as	1670	1672	|O
follows	1673	1680	|O
:	1680	1681	|O
Na	1682	1684	|O
salts	1685	1690	|O
and	1691	1694	|O
Zn	1695	1697	|O
(	1697	1698	|O
II	1698	1700	|O
)	1700	1701	|O
complexes	1702	1711	|O
,	1711	1712	|O
respectively	1713	1725	|O
,	1725	1726	|O
of	1727	1729	|O
3	1730	1731	|O
-	1731	1732	|O
LIHOPO	1732	1738	|O
(	1739	1740	|O
54	1740	1742	|O
,	1742	1743	|O
56	1744	1746	|O
)	1746	1747	|O
,	1747	1748	|O
3,4	1749	1752	|O
-	1752	1753	|O
LIHOPO	1753	1759	|O
(	1760	1761	|O
58	1761	1763	|O
,	1763	1764	|O
60	1765	1767	|O
)	1767	1768	|O
,	1768	1769	|O
3,4,3	1770	1775	|O
-	1775	1776	|O
LIHOPO	1776	1782	|O
(	1783	1784	|O
73	1784	1786	|O
,	1786	1787	|O
76	1788	1790	|O
)	1790	1791	|O
;	1791	1792	|O
Na	1793	1795	|O
salts	1796	1801	|O
of	1802	1804	|O
MEHOPO	1805	1811	|O
(	1812	1813	|O
46	1813	1815	|O
)	1815	1816	|O
,	1816	1817	|O
DFO	1818	1821	|O
-	1821	1822	|O
HOPO	1822	1826	|O
(	1827	1828	|O
78	1828	1830	|O
)	1830	1831	|O
;	1831	1832	|O
Fe	1833	1835	|O
(	1835	1836	|O
III	1836	1839	|O
)	1839	1840	|O
complex	1841	1848	|O
of	1849	1851	|O
3,4,3	1852	1857	|O
-	1857	1858	|O
LIHOPO	1858	1864	|O
(	1865	1866	|O
79	1866	1868	|O
)	1868	1869	|O
.	1869	1870	|O
DFO	1871	1874	|O
-	1874	1875	|O
HOPO	1875	1879	|O
and	1880	1883	|O
3,4,3	1884	1889	|O
-	1889	1890	|O
LIHOPO	1890	1896	|O
and	1897	1900	|O
its	1901	1904	|O
Zn	1905	1907	|O
(	1907	1908	|O
II	1908	1910	|O
)	1910	1911	|O
and	1912	1915	|O
Fe	1916	1918	|O
(	1918	1919	|O
III	1919	1922	|O
)	1922	1923	|O
complexes	1924	1933	|O
promoted	1934	1942	|O
significantly	1943	1956	|O
more	1957	1961	|O
Pu	1962	1964	|O
excretion	1965	1974	|O
than	1975	1979	|O
CaNa3	1980	1985	|O
-	1985	1986	|O
DTPA	1986	1990	|O
(	1991	1992	|O
61%	1992	1995	|O
of	1996	1998	|O
injected	1999	2007	|O
Pu	2008	2010	|O
)	2010	2011	|O
.	2011	2012	|O
Preliminary	2013	2024	|O
findings	2025	2033	|O
on	2034	2036	|O
the	2037	2040	|O
acute	2041	2046	|O
toxicity	2047	2055	|O
of	2056	2058	|O
the	2059	2062	|O
poly	2063	2067	|O
(	2067	2068	|O
HOPO	2068	2072	|O
)	2072	2073	|O
ligands	2074	2081	|O
and	2082	2085	|O
HOPO	2086	2090	|O
monomers	2091	2099	|O
are	2100	2103	|O
presented	2104	2113	|O
in	2114	2116	|O
an	2117	2119	|O
appendix	2120	2128	|O
.	2128	2129	|O
The	2130	2133	|O
biological	2134	2144	|O
data	2145	2149	|O
indicate	2150	2158	|O
strongly	2159	2167	|O
that	2168	2172	|O
the	2173	2176	|O
aqueous	2177	2184	|O
solubility	2185	2195	|O
and	2196	2199	|O
relatively	2200	2210	|O
high	2211	2215	|O
acidity	2216	2223	|O
of	2224	2226	|O
the	2227	2230	|O
octadentate	2231	2242	|O
HOPO	2243	2247	|O
ligands	2248	2255	|O
,	2255	2256	|O
3,4,3	2257	2262	|O
-	2262	2263	|O
LIHOPO	2263	2269	|O
and	2270	2273	|O
DFO	2274	2277	|O
-	2277	2278	|O
HOPO	2278	2282	|O
allow	2283	2288	|O
them	2289	2293	|O
to	2294	2296	|O
form	2297	2301	|O
complete	2302	2310	|O
eight	2311	2316	|O
-	2316	2317	|O
coordinate	2317	2327	|O
complexes	2328	2337	|O
with	2338	2342	|O
Pu	2343	2345	|O
(	2345	2346	|O
IV	2346	2348	|O
)	2348	2349	|O
ion	2350	2353	|O
.	2353	2354	|O

### abstracts3935.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
N	12	13	|O
-	13	14	|O
substituted	14	25	|O
imidazolines	26	38	|O
and	39	42	|O
ethylenediamines	43	59	|O
were	60	64	|O
synthesized	65	76	|O
and	77	80	|O
examined	81	89	|O
for	90	93	|O
their	94	99	|O
activity	100	108	|O
in	109	111	|O
alpha	112	117	|O
-	117	118	|O
and	119	122	|O
beta	123	127	|O
-	127	128	|O
adrenergic	128	138	|O
systems	139	146	|O
.	146	147	|O
The	148	151	|O
length	152	158	|O
of	159	161	|O
the	162	165	|O
intermediate	166	178	|O
side	179	183	|O
chain	184	189	|O
between	190	197	|O
the	198	201	|O
catechol	202	210	|O
and	211	214	|O
imidazoline	215	226	|O
ring	227	231	|O
or	232	234	|O
the	235	238	|O
amine	239	244	|O
of	245	247	|O
the	248	251	|O
ethylenediamine	252	267	|O
segment	268	275	|O
was	276	279	|O
shown	280	285	|O
to	286	288	|O
affect	289	295	|O
the	296	299	|O
adrenergic	300	310	|O
activity	311	319	|O
.	319	320	|O
N	321	322	|B-IUPAC
-	322	323	|I-IUPAC
[	323	324	|I-IUPAC
2	324	325	|I-IUPAC
-	325	326	|I-IUPAC
(	326	327	|I-IUPAC
3,4	327	330	|I-IUPAC
-	330	331	|I-IUPAC
Dihydroxyphenyl	331	346	|I-IUPAC
)	346	347	|I-IUPAC
ethyl	347	352	|I-IUPAC
]	352	353	|I-IUPAC
imidazoline	353	364	|I-IUPAC
hydrochloride	365	378	|I-IUPAC
(	379	380	|O
2	380	381	|O
)	381	382	|O
and	383	386	|O
N	387	388	|B-IUPAC
-	388	389	|I-IUPAC
[	389	390	|I-IUPAC
2	390	391	|I-IUPAC
-	391	392	|I-IUPAC
(	392	393	|I-IUPAC
3,4	393	396	|I-IUPAC
-	396	397	|I-IUPAC
dihydroxyphenyl	397	412	|I-IUPAC
)	412	413	|I-IUPAC
ethyl	413	418	|I-IUPAC
]	418	419	|I-IUPAC
ethylenediamine	419	434	|I-IUPAC
dihydrochloride	435	450	|I-IUPAC
(	451	452	|O
4	452	453	|O
)	453	454	|O
,	454	455	|O
both	456	460	|O
with	461	465	|O
two	466	469	|O
methylene	470	479	|O
groups	480	486	|O
between	487	494	|O
the	495	498	|O
catechol	499	507	|O
and	508	511	|O
amine	512	517	|O
segment	518	525	|O
,	525	526	|O
were	527	531	|O
found	532	537	|O
to	538	540	|O
be	541	543	|O
somewhat	544	552	|O
selective	553	562	|O
for	563	566	|O
alpha	567	572	|O
2	573	574	|O
-	574	575	|O
adrenergic	575	585	|O
receptors	586	595	|O
while	596	601	|O
1	602	603	|B-IUPAC
-	603	604	|I-IUPAC
(	604	605	|I-IUPAC
3,4	605	608	|I-IUPAC
-	608	609	|I-IUPAC
dihydroxybenzyl	609	624	|I-IUPAC
)	624	625	|I-IUPAC
imidazoline	625	636	|I-IUPAC
hydrochloride	637	650	|I-IUPAC
(	651	652	|O
1	652	653	|O
)	653	654	|O
and	655	658	|O
N	659	660	|B-IUPAC
-	660	661	|I-IUPAC
2	661	662	|I-IUPAC
-	662	663	|I-IUPAC
(	663	664	|I-IUPAC
3,4	664	667	|I-IUPAC
-	667	668	|I-IUPAC
dihydroxybenzyl	668	683	|I-IUPAC
)	683	684	|I-IUPAC
ethylenediamine	684	699	|I-IUPAC
dihydrochloride	700	715	|I-IUPAC
(	716	717	|O
3	717	718	|O
)	718	719	|O
,	719	720	|O
both	721	725	|O
with	726	730	|O
one	731	734	|O
methylene	735	744	|B-IUPAC
group	745	750	|B-MODIFIER
between	751	758	|O
the	759	762	|O
catechol	763	771	|O
and	772	775	|O
amine	776	781	|O
segment	782	789	|O
,	789	790	|O
were	791	795	|O
more	796	800	|O
selective	801	810	|O
for	811	814	|O
alpha1	815	821	|O
-	821	822	|O
adrenergic	822	832	|O
receptors	833	842	|O
in	843	845	|O
a	846	847	|O
pithed	848	854	|O
rat	855	858	|O
model	859	864	|O
.	864	865	|O
Of	866	868	|O
the	869	872	|O
four	873	877	|O
compounds	878	887	|O
examined	888	896	|O
,	896	897	|O
only	898	902	|O
compound	903	911	|O
2	912	913	|O
showed	914	920	|O
significant	921	932	|O
direct	933	939	|O
activity	940	948	|O
on	949	951	|O
beta1	952	957	|O
-	957	958	|O
and	959	962	|O
beta2	963	968	|O
-	968	969	|O
adrenergic	969	979	|O
receptors	980	989	|O
.	989	990	|O

### abstracts4206.txt
O	0	1	|O
(	1	2	|O
6	2	3	|O
)	3	4	|O
-	4	5	|O
Substituted	5	16	|O
guanine	17	24	|B-IUPAC
derivatives	25	36	|B-MODIFIER
are	37	40	|O
powerful	41	49	|O
agents	50	56	|O
used	57	61	|O
for	62	65	|O
tumor	66	71	|O
cell	72	76	|O
sensitization	77	90	|O
by	91	93	|O
inhibition	94	104	|O
of	105	107	|O
the	108	111	|O
DNA	112	115	|O
repair	116	122	|O
enzyme	123	129	|O
O	130	131	|O
(	131	132	|O
6	132	133	|O
)	133	134	|O
-	134	135	|O
methylguanine	135	148	|O
-	148	149	|O
DNA	149	152	|O
methyltransferase	153	170	|O
(	171	172	|O
MGMT	172	176	|O
)	176	177	|O
.	177	178	|O
To	179	181	|O
provide	182	189	|O
targeted	190	198	|O
accumulation	199	211	|O
of	212	214	|O
MGMT	215	219	|O
inhibitors	220	230	|O
in	231	233	|O
tumor	234	239	|O
tissue	240	246	|O
as	247	249	|O
well	250	254	|O
as	255	257	|O
tools	258	263	|O
for	264	267	|O
in	268	270	|O
vivo	271	275	|O
imaging	276	283	|O
,	283	284	|O
we	285	287	|O
synthesized	288	299	|O
iodinated	300	309	|O
C	310	311	|O
(	311	312	|O
8	312	313	|O
)	313	314	|O
-	314	315	|O
alkyl	315	320	|O
-	320	321	|O
linked	321	327	|O
glucose	328	335	|O
conjugates	336	346	|O
of	347	349	|O
2	350	351	|B-IUPAC
-	351	352	|I-IUPAC
amino	352	357	|I-IUPAC
-	357	358	|I-IUPAC
6	358	359	|I-IUPAC
-	359	360	|I-IUPAC
(	360	361	|I-IUPAC
5	361	362	|I-IUPAC
-	362	363	|I-IUPAC
iodothenyl	363	373	|I-IUPAC
)	373	374	|I-IUPAC
-	374	375	|I-IUPAC
9H	375	377	|I-IUPAC
-	377	378	|I-IUPAC
purine	378	384	|I-IUPAC
(	385	386	|O
O	386	387	|B-IUPAC
(	387	388	|I-IUPAC
6	388	389	|I-IUPAC
)	389	390	|I-IUPAC
-	390	391	|I-IUPAC
(	391	392	|I-IUPAC
5	392	393	|I-IUPAC
-	393	394	|I-IUPAC
iodothenyl	394	404	|I-IUPAC
)	404	405	|I-IUPAC
guanine	406	413	|I-IUPAC
,	413	414	|O
ITG	415	418	|O
)	418	419	|O
and	420	423	|O
2	424	425	|B-IUPAC
-	425	426	|I-IUPAC
amino	426	431	|I-IUPAC
-	431	432	|I-IUPAC
6	432	433	|I-IUPAC
-	433	434	|I-IUPAC
(	434	435	|I-IUPAC
3	435	436	|I-IUPAC
-	436	437	|I-IUPAC
iodobenzyloxy	437	450	|I-IUPAC
)	450	451	|I-IUPAC
-	451	452	|I-IUPAC
9H	452	454	|I-IUPAC
-	454	455	|I-IUPAC
purine	455	461	|I-IUPAC
(	462	463	|O
O	463	464	|B-IUPAC
(	464	465	|I-IUPAC
6	465	466	|I-IUPAC
)	466	467	|I-IUPAC
-	467	468	|I-IUPAC
(	468	469	|I-IUPAC
5	469	470	|I-IUPAC
-	470	471	|I-IUPAC
iodobenzyl	471	481	|I-IUPAC
)	481	482	|I-IUPAC
guanine	483	490	|I-IUPAC
,	490	491	|O
IBG	492	495	|O
)	495	496	|O
.	496	497	|O
These	498	503	|O
compounds	504	513	|O
have	514	518	|O
MGMT	519	523	|O
inhibitor	524	533	|O
constants	534	543	|O
(	544	545	|O
IC	545	547	|O
(	547	548	|O
50	548	550	|O
)	550	551	|O
values	552	558	|O
)	558	559	|O
of	560	562	|O
0.8	563	566	|O
and	567	570	|O
0.45	571	575	|O
microM	576	582	|O
for	583	586	|O
ITGG	587	591	|O
and	592	595	|O
IBGG	596	600	|O
,	600	601	|O
respectively	602	614	|O
,	614	615	|O
as	616	618	|O
determined	619	629	|O
in	630	632	|O
HeLa	633	637	|O
S3	638	640	|O
cells	641	646	|O
after	647	652	|O
2	653	654	|O
-	654	655	|O
h	655	656	|O
incubation	657	667	|O
with	668	672	|O
inhibitor	673	682	|O
.	682	683	|O
To	684	686	|O
substantiate	687	699	|O
that	700	704	|O
the	705	708	|O
(	709	710	|B-IUPAC
131	710	713	|I-IUPAC
)	713	714	|I-IUPAC
I	714	715	|I-IUPAC
-	715	716	|I-IUPAC
(	716	717	|I-IUPAC
hetero	717	723	|I-IUPAC
)	723	724	|I-IUPAC
arylmethylene	724	737	|I-IUPAC
group	738	743	|B-MODIFIER
at	744	746	|O
the	747	750	|O
O	751	752	|O
(	752	753	|O
6	753	754	|O
)	754	755	|O
-	755	756	|O
position	756	764	|O
of	765	767	|O
guanine	768	775	|O
is	776	778	|O
transferred	779	790	|O
to	791	793	|O
MGMT	794	798	|O
,	798	799	|O
both	800	804	|O
the	805	808	|O
glucose	809	816	|O
conjugated	817	827	|O
inhibitors	828	838	|O
ITGG	839	843	|O
and	844	847	|O
IBGG	848	852	|O
and	853	856	|O
the	857	860	|O
corresponding	861	874	|O
nonglucose	875	885	|O
conjugated	886	896	|O
compounds	897	906	|O
ITG	907	910	|O
and	911	914	|O
IBG	915	918	|O
were	919	923	|O
labeled	924	931	|O
with	932	936	|O
iodine	937	943	|O
-	943	944	|O
131	944	947	|O
.	947	948	|O
The	949	952	|O
radioiodinations	953	969	|O
of	970	972	|O
all	973	976	|O
compounds	977	986	|O
with	987	991	|O
[	992	993	|O
(	993	994	|O
131	994	997	|O
)	997	998	|O
I	998	999	|O
]	999	1000	|O
I	1000	1001	|O
(	1001	1002	|O
-	1002	1003	|O
)	1003	1004	|O
were	1005	1009	|O
performed	1010	1019	|O
with	1020	1024	|O
radiochemical	1025	1038	|O
yields	1039	1045	|O
of	1046	1048	|O
&	1049	1050	|O
gt	1050	1052	|O
;	1052	1053	|O
70%	1053	1056	|O
for	1057	1060	|O
the	1061	1064	|O
destannylation	1065	1079	|O
of	1080	1082	|O
the	1083	1086	|O
corresponding	1087	1100	|O
tri	1101	1104	|O
-	1104	1105	|O
n	1105	1106	|O
-	1106	1107	|O
butylstannylated	1107	1123	|O
precursors	1124	1134	|O
.	1134	1135	|O
The	1136	1139	|O
binding	1140	1147	|O
ability	1148	1155	|O
of	1156	1158	|O
[	1159	1160	|O
(	1160	1161	|O
131	1161	1164	|O
)	1164	1165	|O
I	1165	1166	|O
]	1166	1167	|O
ITGG	1167	1171	|O
,	1171	1172	|O
[	1173	1174	|O
(	1174	1175	|O
131	1175	1178	|O
)	1178	1179	|O
]	1179	1180	|O
IBGG	1180	1184	|O
,	1184	1185	|O
[	1186	1187	|O
(	1187	1188	|O
131	1188	1191	|O
)	1191	1192	|O
I	1192	1193	|O
]	1193	1194	|O
ITG	1194	1197	|O
,	1197	1198	|O
and	1199	1202	|O
[	1203	1204	|O
(	1204	1205	|O
131	1205	1208	|O
)	1208	1209	|O
I	1209	1210	|O
]	1210	1211	|O
IBG	1211	1214	|O
to	1215	1217	|O
purified	1218	1226	|O
MGMT	1227	1231	|O
was	1232	1235	|O
tested	1236	1242	|O
.	1242	1243	|O
All	1244	1247	|O
radioactive	1248	1259	|O
compounds	1260	1269	|O
were	1270	1274	|O
substrates	1275	1285	|O
for	1286	1289	|O
MGMT	1290	1294	|O
,	1294	1295	|O
as	1296	1298	|O
demonstrated	1299	1311	|O
using	1312	1317	|O
a	1318	1319	|O
competitive	1320	1331	|O
repair	1332	1338	|O
assay	1339	1344	|O
.	1344	1345	|O
The	1346	1349	|O
newly	1350	1355	|O
synthesized	1356	1367	|O
radioactive	1368	1379	|O
inhibitors	1380	1390	|O
were	1391	1395	|O
utilized	1396	1404	|O
to	1405	1407	|O
study	1408	1413	|O
ex	1414	1416	|O
vivo	1417	1421	|O
biodistribution	1422	1437	|O
in	1438	1440	|O
mice	1441	1445	|O
,	1445	1446	|O
and	1447	1450	|O
the	1451	1454	|O
tumor	1455	1460	|O
-	1460	1461	|O
to	1461	1463	|O
-	1463	1464	|O
blood	1464	1469	|O
ratio	1470	1475	|O
of	1476	1478	|O
tissue	1479	1485	|O
uptake	1486	1492	|O
of	1493	1495	|O
[	1496	1497	|O
(	1497	1498	|O
131	1498	1501	|O
)	1501	1502	|O
I	1502	1503	|O
]	1503	1504	|O
IBG	1504	1507	|O
and	1508	1511	|O
[	1512	1513	|O
(	1513	1514	|O
131	1514	1517	|O
)	1517	1518	|O
I	1518	1519	|O
]	1519	1520	|O
IBGG	1520	1524	|O
was	1525	1528	|O
determined	1529	1539	|O
to	1540	1542	|O
be	1543	1545	|O
0.24	1546	1550	|O
and	1551	1554	|O
0.76	1555	1559	|O
after	1560	1565	|O
0.5	1566	1569	|O
h	1570	1571	|O
,	1571	1572	|O
respectively	1573	1585	|O
.	1585	1586	|O

### abstracts4218.txt
4,5	0	3	|O
-	3	4	|O
Diphenyl	4	12	|O
-	12	13	|O
2	13	14	|O
-	14	15	|O
oxazolenonanoic	15	30	|O
acid	31	35	|O
(	36	37	|O
2	37	38	|O
)	38	39	|O
and	40	43	|O
2	44	45	|B-IUPAC
-	45	46	|I-IUPAC
[	46	47	|I-IUPAC
3	47	48	|I-IUPAC
-	48	49	|I-IUPAC
[	49	50	|I-IUPAC
2	50	51	|I-IUPAC
-	51	52	|I-IUPAC
(	52	53	|I-IUPAC
4,5	53	56	|I-IUPAC
-	56	57	|I-IUPAC
diphenyl	57	65	|I-IUPAC
-	65	66	|I-IUPAC
2	66	67	|I-IUPAC
-	67	68	|I-IUPAC
oxazolyl	68	76	|I-IUPAC
)	76	77	|I-IUPAC
ethyl	77	82	|I-IUPAC
]	82	83	|I-IUPAC
phenoxy	83	90	|I-IUPAC
]	90	91	|I-IUPAC
acetic	91	97	|I-IUPAC
acid	98	102	|I-IUPAC
(	103	104	|O
3	104	105	|O
)	105	106	|O
were	107	111	|O
previously	112	122	|O
identified	123	133	|O
as	134	136	|O
nonprostanoid	137	150	|O
prostacyclin	151	163	|O
(	164	165	|O
PGI2	165	169	|O
)	169	170	|O
mimetics	171	179	|O
that	180	184	|O
inhibit	185	192	|O
ADP	193	196	|O
-	196	197	|O
induced	197	204	|O
aggregation	205	216	|O
of	217	219	|O
human	220	225	|O
platelets	226	235	|O
in	236	238	|O
vitro	239	244	|O
.	244	245	|O
The	246	249	|O
effects	250	257	|O
on	258	260	|O
biological	261	271	|O
activity	272	280	|O
of	281	283	|O
substitution	284	296	|O
and	297	300	|O
structural	301	311	|O
modification	312	324	|O
of	325	327	|O
the	328	331	|O
4	332	333	|B-PARTIUPAC
-	333	334	|I-PARTIUPAC
and	335	338	|O
5	339	340	|B-IUPAC
-	340	341	|I-IUPAC
phenyl	341	347	|I-IUPAC
rings	348	353	|B-MODIFIER
of	354	356	|O
3	357	358	|O
was	359	362	|O
examined	363	371	|O
.	371	372	|O
Potency	373	380	|O
showed	381	387	|O
a	388	389	|O
marked	390	396	|O
sensitivity	397	408	|O
to	409	411	|O
the	412	415	|O
introduction	416	428	|O
of	429	431	|O
substituents	432	444	|O
to	445	447	|O
these	448	453	|O
aromatic	454	462	|O
rings	463	468	|O
and	469	472	|O
only	473	477	|O
the	478	481	|O
bis	482	485	|B-IUPAC
-	485	486	|I-IUPAC
4	486	487	|I-IUPAC
-	487	488	|I-IUPAC
methyl	488	494	|I-IUPAC
derivative	495	505	|B-MODIFIER
9j	506	508	|O
,	508	509	|O
IC50	510	514	|O
=	515	516	|O
0.34	517	521	|O
microM	522	528	|O
,	528	529	|O
demonstrated	530	542	|O
enhanced	543	551	|O
potency	552	559	|O
compared	560	568	|O
to	569	571	|O
the	572	575	|O
parent	576	582	|O
structure	583	592	|O
3	593	594	|O
,	594	595	|O
IC50	596	600	|O
=	601	602	|O
1.2	603	606	|O
microM	607	613	|O
.	613	614	|O
Substitution	615	627	|O
at	628	630	|O
the	631	634	|O
ortho	635	640	|O
or	641	643	|O
meta	644	648	|O
positions	649	658	|O
of	659	661	|O
the	662	665	|O
phenyl	666	672	|O
rings	673	678	|O
,	678	679	|O
replacement	680	691	|O
by	692	694	|O
thiopheneyl	695	706	|O
or	707	709	|O
cyclohexyl	710	720	|O
moieties	721	729	|O
,	729	730	|O
or	731	733	|O
constraining	734	746	|O
in	747	749	|O
a	750	751	|O
planar	752	758	|O
phenanthrene	759	771	|O
system	772	778	|O
resulted	779	787	|O
in	788	790	|O
compounds	791	800	|O
that	801	805	|O
were	806	810	|O
less	811	815	|O
effective	816	825	|O
inhibitors	826	836	|O
of	837	839	|O
ADP	840	843	|O
-	843	844	|O
induced	844	851	|O
platelet	852	860	|O
aggregation	861	872	|O
.	872	873	|O
In	874	876	|O
contrast	877	885	|O
,	885	886	|O
variation	887	896	|O
of	897	899	|O
the	900	903	|O
heterocycle	904	915	|O
moiety	916	922	|O
revealed	923	931	|O
a	932	933	|O
much	934	938	|O
less	939	943	|O
stringent	944	953	|O
SAR	954	957	|O
and	958	961	|O
many	962	966	|O
5	967	968	|O
-	968	969	|O
and	970	973	|O
6	974	975	|O
-	975	976	|O
membered	976	984	|O
heterocycles	985	997	|O
were	998	1002	|O
found	1003	1008	|O
to	1009	1011	|O
effectively	1012	1023	|O
substitute	1024	1034	|O
for	1035	1038	|O
the	1039	1042	|O
oxazole	1043	1050	|O
ring	1051	1055	|O
of	1056	1058	|O
2	1059	1060	|O
and	1061	1064	|O
3	1065	1066	|O
.	1066	1067	|O
The	1068	1071	|O
diphenylmethyl	1072	1086	|O
moiety	1087	1093	|O
functioned	1094	1104	|O
as	1105	1107	|O
an	1108	1110	|O
effective	1111	1120	|O
isostere	1121	1129	|O
for	1130	1133	|O
4,5	1134	1137	|O
-	1137	1138	|O
diphenylated	1138	1150	|O
heterocycles	1151	1163	|O
since	1164	1169	|O
13aad	1170	1175	|O
showed	1176	1182	|O
similar	1183	1190	|O
platelet	1191	1199	|O
inhibitory	1200	1210	|O
activity	1211	1219	|O
to	1220	1222	|O
3	1223	1224	|O
.	1224	1225	|O
With	1226	1230	|O
the	1231	1234	|O
exception	1235	1244	|O
of	1245	1247	|O
the	1248	1251	|O
3,4,5	1252	1257	|B-IUPAC
-	1257	1258	|I-IUPAC
triphenylpyrazole	1258	1275	|I-IUPAC
derivative	1276	1286	|B-MODIFIER
13g	1287	1290	|O
,	1290	1291	|O
compounds	1292	1301	|O
presenting	1302	1312	|O
the	1313	1316	|O
(	1317	1318	|B-IUPAC
m	1318	1319	|I-IUPAC
-	1319	1320	|I-IUPAC
ethylphenoxy	1320	1332	|I-IUPAC
)	1332	1333	|I-IUPAC
acetic	1333	1339	|I-IUPAC
acid	1340	1344	|I-IUPAC
side	1345	1349	|B-MODIFIER
chain	1350	1355	|I-MODIFIER
discovered	1356	1366	|O
with	1367	1371	|O
3	1372	1373	|O
demonstrated	1374	1386	|O
enhanced	1387	1395	|O
potency	1396	1403	|O
compared	1404	1412	|O
to	1413	1415	|O
the	1416	1419	|O
analogously	1420	1431	|O
substituted	1432	1443	|O
alkanoic	1444	1452	|O
acid	1453	1457	|O
derivative	1458	1468	|O
.	1468	1469	|O
The	1470	1473	|O
structure	1474	1483	|O
-	1483	1484	|O
activity	1484	1492	|O
findings	1493	1501	|O
led	1502	1505	|O
to	1506	1508	|O
a	1509	1510	|O
refinement	1511	1521	|O
of	1522	1524	|O
a	1525	1526	|O
model	1527	1532	|O
of	1533	1535	|O
the	1536	1539	|O
nonprostanoid	1540	1553	|O
PGI2	1554	1558	|O
mimetic	1559	1566	|O
pharmacophore	1567	1580	|O
.	1580	1581	|O

### abstracts4728.txt
5'	0	2	|B-IUPAC
-	2	3	|I-IUPAC
[	3	4	|I-IUPAC
4	4	5	|I-IUPAC
-	5	6	|I-IUPAC
(	6	7	|I-IUPAC
Pivaloyloxy	7	18	|I-IUPAC
)	18	19	|I-IUPAC
-	19	20	|I-IUPAC
1,3,2	20	25	|I-IUPAC
-	25	26	|I-IUPAC
dioxaphosphorinan	26	43	|I-IUPAC
-	43	44	|I-IUPAC
2	44	45	|I-IUPAC
-	45	46	|I-IUPAC
yl	46	48	|I-IUPAC
]	48	49	|I-IUPAC
-	49	50	|I-IUPAC
2'	50	52	|I-IUPAC
-	52	53	|I-IUPAC
deoxy	53	58	|I-IUPAC
-	58	59	|I-IUPAC
5	59	60	|I-IUPAC
-	61	62	|I-IUPAC
fluorouridine	62	75	|I-IUPAC
(	76	77	|O
1c	77	79	|O
)	79	80	|O
was	81	84	|O
designed	85	93	|O
as	94	96	|O
a	97	98	|O
potential	99	108	|O
membrane	109	117	|O
-	117	118	|O
permeable	118	127	|O
prodrug	128	135	|O
of	136	138	|O
2'	139	141	|B-IUPAC
-	141	142	|I-IUPAC
deoxy	142	147	|I-IUPAC
-	147	148	|I-IUPAC
5	148	149	|I-IUPAC
-	149	150	|I-IUPAC
fluorouridine	150	163	|I-IUPAC
5'	164	166	|I-IUPAC
-	166	167	|I-IUPAC
monophosphate	167	180	|I-IUPAC
(	181	182	|O
FdUMP	182	187	|O
)	187	188	|O
,	188	189	|O
a	190	191	|O
putative	192	200	|O
active	201	207	|O
metabolite	208	218	|O
of	219	221	|O
the	222	225	|O
antitumor	226	235	|O
drug	236	240	|O
5	241	242	|B-IUPAC
-	242	243	|I-IUPAC
fluorouracil	243	255	|I-IUPAC
(	256	257	|O
FU	257	259	|O
)	259	260	|O
.	260	261	|O
It	262	264	|O
was	265	268	|O
anticipated	269	280	|O
that	281	285	|O
1c	286	288	|O
would	289	294	|O
be	295	297	|O
hydrolyzed	298	308	|O
in	309	311	|O
vivo	312	316	|O
by	317	319	|O
carboxylate	320	331	|O
esterase	332	340	|O
(	341	342	|O
E	342	343	|O
.	343	344	|O
C	344	345	|O
.	345	346	|O
3.1.1.1	347	354	|O
)	354	355	|O
to	356	358	|O
the	359	362	|O
labile	363	369	|O
4	370	371	|B-IUPAC
-	371	372	|I-IUPAC
hydroxy	372	379	|I-IUPAC
analogue	380	388	|B-MODIFIER
2a	389	391	|O
,	391	392	|O
which	393	398	|O
should	399	405	|O
penetrate	406	415	|O
cells	416	421	|O
by	422	424	|O
passive	425	432	|O
diffusion	433	442	|O
and	443	446	|O
ring	447	451	|O
open	452	456	|O
to	457	459	|O
the	460	463	|O
aldehyde	464	472	|O
3a	473	475	|O
.	475	476	|O
Spontaneous	477	488	|O
elimination	489	500	|O
of	501	503	|O
acrolein	504	512	|O
from	513	517	|O
3a	518	520	|O
would	521	526	|O
then	527	531	|O
generate	532	540	|O
the	541	544	|O
free	545	549	|O
nucleotide	550	560	|O
,	560	561	|O
FdUMP	562	567	|O
.	567	568	|O
1c	569	571	|O
might	572	577	|O
also	578	582	|O
penetrate	583	592	|O
cells	593	598	|O
directly	599	607	|O
and	608	611	|O
undergo	612	619	|O
the	620	623	|O
same	624	628	|O
degradation	629	640	|O
sequence	641	649	|O
after	650	655	|O
hydrolysis	656	666	|O
by	667	669	|O
cellular	670	678	|O
esterases	679	688	|O
.	688	689	|O
1c	690	692	|O
was	693	696	|O
prepared	697	705	|O
by	706	708	|O
condensing	709	719	|O
2	720	721	|B-IUPAC
-	721	722	|I-IUPAC
hydroxy	722	729	|I-IUPAC
-	729	730	|I-IUPAC
2	730	731	|I-IUPAC
-	731	732	|I-IUPAC
oxo	732	735	|I-IUPAC
-	735	736	|I-IUPAC
4	736	737	|I-IUPAC
-	737	738	|I-IUPAC
(	738	739	|I-IUPAC
pivaloyloxy	739	750	|I-IUPAC
)	750	751	|I-IUPAC
-	751	752	|I-IUPAC
1,3,2	752	757	|I-IUPAC
-	757	758	|I-IUPAC
dioxaphosphorinane	758	776	|I-IUPAC
with	777	781	|O
2'	782	784	|B-IUPAC
-	784	785	|I-IUPAC
deoxy	785	790	|I-IUPAC
-	790	791	|I-IUPAC
5	791	792	|I-IUPAC
-	792	793	|I-IUPAC
fluorouridine	793	806	|I-IUPAC
(	807	808	|O
FUdR	808	812	|O
)	812	813	|O
in	814	816	|O
the	817	820	|O
presence	821	829	|O
of	830	832	|O
triphenylphosphine	833	851	|O
and	852	855	|O
diethyl	856	863	|O
azodicarboxylate	864	880	|O
.	880	881	|O
1c	882	884	|O
was	885	888	|O
moderately	889	899	|O
stable	900	906	|O
in	907	909	|O
aqueous	910	917	|O
buffers	918	925	|O
over	926	930	|O
the	931	934	|O
pH	935	937	|O
range	938	943	|O
1-7.4	944	949	|O
(	950	951	|O
T1/2	951	955	|O
&	956	957	|O
gt	957	959	|O
;	959	960	|O
30	961	963	|O
h	964	965	|O
)	965	966	|O
.	966	967	|O
In	968	970	|O
the	971	974	|O
presence	975	983	|O
of	984	986	|O
carboxylate	987	998	|O
esterase	999	1007	|O
,	1007	1008	|O
however	1009	1016	|O
,	1016	1017	|O
it	1018	1020	|O
was	1021	1024	|O
degraded	1025	1033	|O
,	1033	1034	|O
in	1035	1037	|O
a	1038	1039	|O
concentration	1040	1053	|O
-	1053	1054	|O
dependent	1054	1063	|O
manner	1064	1070	|O
,	1070	1071	|O
to	1072	1074	|O
FdUMP	1075	1080	|O
.	1080	1081	|O
No	1082	1084	|O
intermediates	1085	1098	|O
were	1099	1103	|O
detected	1104	1112	|O
in	1113	1115	|O
the	1116	1119	|O
incubation	1120	1130	|O
mixture	1131	1138	|O
.	1138	1139	|O
In	1140	1142	|O
mouse	1143	1148	|O
plasma	1149	1155	|O
,	1155	1156	|O
1c	1157	1159	|O
was	1160	1163	|O
degraded	1164	1172	|O
first	1173	1178	|O
to	1179	1181	|O
FdUMP	1182	1187	|O
and	1188	1191	|O
then	1192	1196	|O
to	1197	1199	|O
FUdR	1200	1204	|O
.	1204	1205	|O
The	1206	1209	|O
latter	1210	1216	|O
is	1217	1219	|O
presumably	1220	1230	|O
formed	1231	1237	|O
by	1238	1240	|O
dephosphorylation	1241	1258	|O
of	1259	1261	|O
FdUMP	1262	1267	|O
by	1268	1270	|O
plasma	1271	1277	|O
5'	1278	1280	|O
-	1280	1281	|O
nucleotidases	1281	1294	|O
or	1295	1297	|O
phosphatases	1298	1310	|O
.	1310	1311	|O
1c	1312	1314	|O
and	1315	1318	|O
FU	1319	1321	|O
inhibited	1322	1331	|O
the	1332	1335	|O
growth	1336	1342	|O
of	1343	1345	|O
Chinese	1346	1353	|O
hamster	1354	1361	|O
ovary	1362	1367	|O
(	1368	1369	|O
CHO	1369	1372	|O
)	1372	1373	|O
cells	1374	1379	|O
in	1380	1382	|O
culture	1383	1390	|O
at	1391	1393	|O
a	1394	1395	|O
concentration	1396	1409	|O
of	1410	1412	|O
5	1413	1414	|O
x	1415	1416	|O
10	1417	1419	|O
(	1419	1420	|O
-	1420	1421	|O
6	1421	1422	|O
)	1422	1423	|O
M	1424	1425	|O
.	1425	1426	|O
1c	1427	1429	|O
was	1430	1433	|O
equally	1434	1441	|O
potent	1442	1448	|O
against	1449	1456	|O
a	1457	1458	|O
CHO	1459	1462	|O
variant	1463	1470	|O
that	1471	1475	|O
was	1476	1479	|O
20	1480	1482	|O
-	1482	1483	|O
fold	1483	1487	|O
resistant	1488	1497	|O
to	1498	1500	|O
FU	1501	1503	|O
.	1503	1504	|O
Administered	1505	1517	|O
intraperitoneally	1518	1535	|O
for	1536	1539	|O
5	1540	1541	|O
consecutive	1542	1553	|O
days	1554	1558	|O
,	1558	1559	|O
1c	1560	1562	|O
was	1563	1566	|O
as	1567	1569	|O
effective	1570	1579	|O
as	1580	1582	|O
FU	1583	1585	|O
at	1586	1588	|O
prolonging	1589	1599	|O
the	1600	1603	|O
life	1604	1608	|O
span	1609	1613	|O
of	1614	1616	|O
mice	1617	1621	|O
bearing	1622	1629	|O
P	1630	1631	|O
-	1631	1632	|O
388	1632	1635	|O
leukemia	1636	1644	|O
.	1644	1645	|O
In	1646	1648	|O
the	1649	1652	|O
presence	1653	1661	|O
of	1662	1664	|O
2	1665	1666	|B-IUPAC
-	1666	1667	|I-IUPAC
mercaptoehtanesulfonic	1667	1689	|I-IUPAC
acid	1690	1694	|I-IUPAC
,	1694	1695	|O
an	1696	1698	|O
acrolein	1699	1707	|O
scavenger	1708	1717	|O
,	1717	1718	|O
1c	1719	1721	|O
was	1722	1725	|O
equally	1726	1733	|O
effective	1734	1743	|O
against	1744	1751	|O
a	1752	1753	|O
P	1754	1755	|O
-	1755	1756	|O
388	1756	1759	|O
mutant	1760	1766	|O
cell	1767	1771	|O
line	1772	1776	|O
that	1777	1781	|O
was	1782	1785	|O
resistant	1786	1795	|O
to	1796	1798	|O
FU	1799	1801	|O
.	1801	1802	|O
Collectively	1803	1815	|O
,	1815	1816	|O
these	1817	1822	|O
data	1823	1827	|O
suggest	1828	1835	|O
that	1836	1840	|O
1c	1841	1843	|O
acts	1844	1848	|O
as	1849	1851	|O
a	1852	1853	|O
membrane	1854	1862	|O
-	1862	1863	|O
permeable	1863	1872	|O
prodrug	1873	1880	|O
of	1881	1883	|O
FdUMP	1884	1889	|O
.	1889	1890	|O
This	1891	1895	|O
prodrug	1896	1903	|O
strategy	1904	1912	|O
may	1913	1916	|O
be	1917	1919	|O
generally	1920	1929	|O
useful	1930	1936	|O
for	1937	1940	|O
introducing	1941	1952	|O
dianionic	1953	1962	|O
phosphates	1963	1973	|O
and	1974	1977	|O
phosphonates	1978	1990	|O
into	1991	1995	|O
cells	1996	2001	|O
.	2001	2002	|O

### abstracts3381.txt
The	0	3	|O
hydrogen	4	12	|O
-	12	13	|O
bond	13	17	|O
-	17	18	|O
acceptor	18	26	|O
properties	27	37	|O
of	38	40	|O
the	41	44	|O
carbonyl	45	53	|B-IUPAC
moiety	54	60	|B-MODIFIER
in	61	63	|O
the	64	67	|O
17beta	68	74	|B-IUPAC
-	74	75	|I-IUPAC
acetyl	75	81	|I-IUPAC
group	82	87	|B-MODIFIER
on	88	90	|O
the	91	94	|O
D	95	96	|O
-	96	97	|O
ring	97	101	|O
of	102	104	|O
the	105	108	|O
anesthetic	109	119	|O
steroids	120	128	|O
(	129	130	|B-PARTIUPAC
3alpha	130	136	|I-PARTIUPAC
,	136	137	|I-PARTIUPAC
5alpha	137	143	|I-PARTIUPAC
)	143	144	|I-PARTIUPAC
-	144	145	|I-PARTIUPAC
and	146	149	|O
(	150	151	|B-IUPAC
3alpha	151	157	|I-IUPAC
,	157	158	|I-IUPAC
5beta	158	163	|I-IUPAC
)	163	164	|I-IUPAC
-	164	165	|I-IUPAC
3	165	166	|I-IUPAC
-	166	167	|I-IUPAC
hydroxypregan	167	180	|I-IUPAC
-	180	181	|I-IUPAC
20	181	183	|I-IUPAC
-	183	184	|I-IUPAC
one	184	187	|I-IUPAC
form	188	192	|O
an	193	195	|O
important	196	205	|O
part	206	210	|O
of	211	213	|O
the	214	217	|O
anesthetic	218	228	|O
steroid	229	236	|O
pharmacophore	237	250	|O
.	250	251	|O
13,24	252	257	|B-IUPAC
-	257	258	|I-IUPAC
Cyclo	258	263	|I-IUPAC
-	263	264	|I-IUPAC
18,21	264	269	|I-IUPAC
-	269	270	|I-IUPAC
dinorcholanes	270	283	|I-IUPAC
containing	284	294	|O
a	295	296	|O
ketone	297	303	|O
or	304	306	|O
conjugated	307	317	|O
ketone	318	324	|O
group	325	330	|O
at	331	333	|O
C	334	335	|O
-	335	336	|O
20	336	338	|O
,	338	339	|O
C	340	341	|O
-	341	342	|O
22	342	344	|O
,	344	345	|O
C	346	347	|O
-	347	348	|O
23	348	350	|O
,	350	351	|O
or	352	354	|O
C	355	356	|O
-	356	357	|O
24	357	359	|O
were	360	364	|O
prepared	365	373	|O
as	374	376	|O
conformationally	377	393	|O
constrained	394	405	|O
analogues	406	415	|O
of	416	418	|O
these	419	424	|O
anesthetic	425	435	|O
steroids	436	444	|O
and	445	448	|O
were	449	453	|O
used	454	458	|O
to	459	461	|O
probe	462	467	|O
for	468	471	|O
alternate	472	481	|O
locations	482	491	|O
for	492	495	|O
the	496	499	|O
D	500	501	|O
-	501	502	|O
ring	502	506	|O
hydrogen	507	515	|O
-	515	516	|O
bond	516	520	|O
-	520	521	|O
accepting	521	530	|O
carbonyl	531	539	|B-IUPAC
group	540	545	|B-MODIFIER
.	545	546	|O
The	547	550	|O
analogues	551	560	|O
were	561	565	|O
evaluated	566	575	|O
(	576	577	|O
1	577	578	|O
)	578	579	|O
.	579	580	|O
in	581	583	|O
[	584	585	|B-IUPAC
(	585	586	|I-IUPAC
35	586	588	|I-IUPAC
)	588	589	|I-IUPAC
S	589	590	|I-IUPAC
]	590	591	|I-IUPAC
-	591	592	|I-IUPAC
tert	592	596	|I-IUPAC
-	596	597	|I-IUPAC
butylbicyclophosphorothionate	597	626	|I-IUPAC
binding	627	634	|O
experiments	635	646	|O
,	646	647	|O
(	648	649	|O
2	649	650	|O
)	650	651	|O
.	651	652	|O
in	653	655	|O
electrophysiological	656	676	|O
experiments	677	688	|O
using	689	694	|O
rat	695	698	|O
alpha	699	704	|O
(	704	705	|O
1	705	706	|O
)	706	707	|O
beta	707	711	|O
(	711	712	|O
2	712	713	|O
)	713	714	|O
gamma	714	719	|O
(	719	720	|O
2L	720	722	|O
)	722	723	|O
GABA	724	728	|O
(	728	729	|O
A	729	730	|O
)	730	731	|O
receptors	732	741	|O
expressed	742	751	|O
in	752	754	|O
Xenopus	755	762	|O
laevis	763	769	|O
oocytes	770	777	|O
,	777	778	|O
and	779	782	|O
(	783	784	|O
3	784	785	|O
)	785	786	|O
.	786	787	|O
as	788	790	|O
tadpole	791	798	|O
anesthetics	799	810	|O
.	810	811	|O
In	812	814	|O
the	815	818	|O
binding	819	826	|O
assay	827	832	|O
,	832	833	|O
the	834	837	|O
relative	838	846	|O
order	847	852	|O
of	853	855	|O
potencies	856	865	|O
for	866	869	|O
the	870	873	|O
analogues	874	883	|O
in	884	886	|O
the	887	890	|O
5alpha	891	897	|O
-	897	898	|O
and	899	902	|O
5beta	903	908	|O
-	908	909	|O
series	909	915	|O
is	916	918	|O
identical	919	928	|O
.	928	929	|O
For	930	933	|O
the	934	937	|O
ketones	938	945	|O
,	945	946	|O
the	947	950	|O
order	951	956	|O
is	957	959	|O
24	960	962	|O
-	962	963	|O
one	963	966	|O
&	967	968	|O
gt	968	970	|O
;	970	971	|O
or	971	973	|O
=	973	974	|O
23	975	977	|O
-	977	978	|O
one	978	981	|O
&	982	983	|O
gt	983	985	|O
;	985	986	|O
20	987	989	|O
-	989	990	|O
one	990	993	|O
&	994	995	|O
gt	995	997	|O
;	997	998	|O
22	999	1001	|O
-	1001	1002	|O
one	1002	1005	|O
.	1005	1006	|O
Likewise	1007	1015	|O
,	1015	1016	|O
for	1017	1020	|O
the	1021	1024	|O
enones	1025	1031	|O
,	1031	1032	|O
the	1033	1036	|O
order	1037	1042	|O
is	1043	1045	|O
delta	1046	1051	|O
(	1051	1052	|O
22	1052	1054	|O
)	1054	1055	|O
-	1055	1056	|O
24	1056	1058	|O
-	1058	1059	|O
one	1059	1062	|O
&	1063	1064	|O
gt	1064	1066	|O
;	1066	1067	|O
delta	1068	1073	|O
(	1073	1074	|O
20	1074	1076	|O
(	1076	1077	|O
22	1077	1079	|O
)	1079	1080	|O
)	1080	1081	|O
-	1081	1082	|O
23	1082	1084	|O
-	1084	1085	|O
one	1085	1088	|O
&	1089	1090	|O
gt	1090	1092	|O
;	1092	1093	|O
delta	1094	1099	|O
(	1099	1100	|O
22	1100	1102	|O
)	1102	1103	|O
-	1103	1104	|O
20	1104	1106	|O
-	1106	1107	|O
one	1107	1110	|O
&	1111	1112	|O
gt	1112	1114	|O
;	1114	1115	|O
delta	1116	1121	|O
(	1121	1122	|O
23	1122	1124	|O
)	1124	1125	|O
-	1125	1126	|O
22	1126	1128	|O
-	1128	1129	|O
one	1129	1132	|O
.	1132	1133	|O
Similar	1134	1141	|O
relative	1142	1150	|O
orders	1151	1157	|O
of	1158	1160	|O
potencies	1161	1170	|O
are	1171	1174	|O
also	1175	1179	|O
found	1180	1185	|O
in	1186	1188	|O
the	1189	1192	|O
other	1193	1198	|O
two	1199	1202	|O
bioassays	1203	1212	|O
.	1212	1213	|O
The	1214	1217	|O
activities	1218	1228	|O
of	1229	1231	|O
the	1232	1235	|O
24	1236	1238	|O
-	1238	1239	|O
one	1239	1242	|O
and	1243	1246	|O
delta	1247	1252	|O
(	1252	1253	|O
22	1253	1255	|O
)	1255	1256	|O
-	1256	1257	|O
24	1257	1259	|O
-	1259	1260	|O
one	1260	1263	|O
compounds	1264	1273	|O
were	1274	1278	|O
expected	1279	1287	|O
to	1288	1290	|O
be	1291	1293	|O
very	1294	1298	|O
low	1299	1302	|O
,	1302	1303	|O
because	1304	1311	|O
the	1312	1315	|O
carbonyl	1316	1324	|B-IUPAC
group	1325	1330	|B-MODIFIER
in	1331	1333	|O
these	1334	1339	|O
compounds	1340	1349	|O
is	1350	1352	|O
located	1353	1360	|O
over	1361	1365	|O
the	1366	1369	|O
steroid	1370	1377	|O
C	1378	1379	|O
-	1379	1380	|O
ring	1380	1384	|O
and	1385	1388	|O
oriented	1389	1397	|O
toward	1398	1404	|O
C	1405	1406	|O
-	1406	1407	|O
8	1407	1408	|O
.	1408	1409	|O
Instead	1410	1417	|O
,	1417	1418	|O
these	1419	1424	|O
compounds	1425	1434	|O
have	1435	1439	|O
the	1440	1443	|O
highest	1444	1451	|O
activities	1452	1462	|O
in	1463	1465	|O
their	1466	1471	|O
respective	1472	1482	|O
series	1483	1489	|O
,	1489	1490	|O
with	1491	1495	|O
the	1496	1499	|O
delta	1500	1505	|O
(	1505	1506	|O
22	1506	1508	|O
)	1508	1509	|O
-	1509	1510	|O
24	1510	1512	|O
-	1512	1513	|O
one	1513	1516	|O
compounds	1517	1526	|O
having	1527	1533	|O
activities	1534	1544	|O
comparable	1545	1555	|O
to	1556	1558	|O
those	1559	1564	|O
of	1565	1567	|O
the	1568	1571	|O
reference	1572	1581	|O
anesthetic	1582	1592	|O
steroids	1593	1601	|O
.	1601	1602	|O
The	1603	1606	|O
electrophysiology	1607	1624	|O
results	1625	1632	|O
obtained	1633	1641	|O
with	1642	1646	|O
the	1647	1650	|O
24	1651	1653	|B-IUPAC
-	1653	1654	|I-IUPAC
oxo	1654	1657	|I-IUPAC
-	1657	1658	|I-IUPAC
cyclosteroids	1658	1671	|I-IUPAC
suggest	1672	1679	|O
that	1680	1684	|O
rat	1685	1688	|O
alpha	1689	1694	|O
(	1694	1695	|O
1	1695	1696	|O
)	1696	1697	|O
beta	1697	1701	|O
(	1701	1702	|O
2	1702	1703	|O
)	1703	1704	|O
gamma	1704	1709	|O
(	1709	1710	|O
2L	1710	1712	|O
)	1712	1713	|O
GABA	1714	1718	|O
(	1718	1719	|O
A	1719	1720	|O
)	1720	1721	|O
receptors	1722	1731	|O
contain	1732	1739	|O
more	1740	1744	|O
than	1745	1749	|O
one	1750	1753	|O
donor	1754	1759	|O
for	1760	1763	|O
the	1764	1767	|O
hydrogen	1768	1776	|O
-	1776	1777	|O
bond	1777	1781	|O
-	1781	1782	|O
acceptor	1782	1790	|O
group	1791	1796	|O
of	1797	1799	|O
anesthetic	1800	1810	|O
steroids	1811	1819	|O
.	1819	1820	|O
The	1821	1824	|O
family	1825	1831	|O
of	1832	1834	|O
cyclosteroids	1835	1848	|O
should	1849	1855	|O
be	1856	1858	|O
useful	1859	1865	|O
for	1866	1869	|O
future	1870	1876	|O
structure	1877	1886	|O
-	1886	1887	|O
activity	1887	1895	|O
relationship	1896	1908	|O
studies	1909	1916	|O
of	1917	1919	|O
steroid	1920	1927	|O
modulation	1928	1938	|O
of	1939	1941	|O
other	1942	1947	|O
GABA	1948	1952	|O
(	1952	1953	|O
A	1953	1954	|O
)	1954	1955	|O
receptor	1956	1964	|O
subtypes	1965	1973	|O
.	1973	1974	|O

### abstracts3405.txt
Syntheses	0	9	|O
of	10	12	|O
(	13	14	|B-IUPAC
E	14	15	|I-IUPAC
)	15	16	|I-IUPAC
-	16	17	|I-IUPAC
5	17	18	|I-IUPAC
-	18	19	|I-IUPAC
(	19	20	|I-IUPAC
3,3,3	20	25	|I-IUPAC
-	25	26	|I-IUPAC
trifluoro	26	35	|I-IUPAC
-	35	36	|I-IUPAC
1	36	37	|I-IUPAC
-	37	38	|I-IUPAC
propenyl	38	46	|I-IUPAC
)	46	47	|I-IUPAC
-	47	48	|I-IUPAC
2'	48	50	|I-IUPAC
-	50	51	|I-IUPAC
deoxyuridine	51	63	|I-IUPAC
(	64	65	|O
TFPe	65	69	|O
-	69	70	|O
dUrd	70	74	|O
)	74	75	|O
(	76	77	|O
1	77	78	|O
)	78	79	|O
,	79	80	|O
5	81	82	|B-IUPAC
-	82	83	|I-IUPAC
(	83	84	|I-IUPAC
3,3,3	84	89	|I-IUPAC
-	89	90	|I-IUPAC
trifluoro	90	99	|I-IUPAC
-	99	100	|I-IUPAC
1	100	101	|I-IUPAC
-	101	102	|I-IUPAC
propyl	102	108	|I-IUPAC
)	108	109	|I-IUPAC
-	109	110	|I-IUPAC
2'	110	112	|I-IUPAC
-	112	113	|I-IUPAC
deoxyuridine	113	125	|I-IUPAC
(	126	127	|O
11	127	129	|O
)	129	130	|O
,	130	131	|O
5	132	133	|B-IUPAC
-	133	134	|I-IUPAC
(	134	135	|I-IUPAC
3,3,3	135	140	|I-IUPAC
-	140	141	|I-IUPAC
trifluoro	141	150	|I-IUPAC
-	150	151	|I-IUPAC
1	151	152	|I-IUPAC
-	152	153	|I-IUPAC
methoxy	153	160	|I-IUPAC
-	160	161	|I-IUPAC
1	161	162	|I-IUPAC
-	162	163	|I-IUPAC
propyl	163	169	|I-IUPAC
)	169	170	|I-IUPAC
-	170	171	|I-IUPAC
2'	171	173	|I-IUPAC
-	173	174	|I-IUPAC
deoxyuridine	174	186	|I-IUPAC
(	187	188	|O
8	188	189	|O
)	189	190	|O
,	190	191	|O
and	192	195	|O
5	196	197	|B-IUPAC
-	197	198	|I-IUPAC
(	198	199	|I-IUPAC
3,3,3	199	204	|I-IUPAC
-	204	205	|I-IUPAC
trifluoro	205	214	|I-IUPAC
-	214	215	|I-IUPAC
1	215	216	|I-IUPAC
-	216	217	|I-IUPAC
hydroxy	217	224	|I-IUPAC
-	224	225	|I-IUPAC
1	225	226	|I-IUPAC
-	226	227	|I-IUPAC
propyl	227	233	|I-IUPAC
)	233	234	|I-IUPAC
-	234	235	|I-IUPAC
2'	235	237	|I-IUPAC
-	237	238	|I-IUPAC
deoxyuridine	238	250	|I-IUPAC
(	251	252	|O
10	252	254	|O
)	254	255	|O
from	256	260	|O
5	261	262	|B-IUPAC
-	262	263	|I-IUPAC
chloromercuri	263	276	|I-IUPAC
-	276	277	|I-IUPAC
2'	277	279	|I-IUPAC
-	279	280	|I-IUPAC
deoxyuridine	280	292	|I-IUPAC
are	293	296	|O
described	297	306	|O
.	306	307	|O
The	308	311	|O
antiviral	312	321	|O
activity	322	330	|O
of	331	333	|O
TFPe	334	338	|O
-	338	339	|O
dUrd	339	343	|O
was	344	347	|O
determined	348	358	|O
in	359	361	|O
cell	362	366	|O
culture	367	374	|O
against	375	382	|O
herpes	383	389	|O
simplex	390	397	|O
virus	398	403	|O
type	404	408	|O
1	409	410	|O
(	411	412	|O
HSV	412	415	|O
-	415	416	|O
1	416	417	|O
)	417	418	|O
,	418	419	|O
herpes	420	426	|O
simplex	427	434	|O
virus	435	440	|O
type	441	445	|O
2	446	447	|O
(	448	449	|O
HSV	449	452	|O
-	452	453	|O
2	453	454	|O
)	454	455	|O
,	455	456	|O
and	457	460	|O
vaccinia	461	469	|O
virus	470	475	|O
and	476	479	|O
compared	480	488	|O
concurrently	489	501	|O
with	502	506	|O
5	507	508	|B-IUPAC
-	508	509	|I-IUPAC
(	509	510	|I-IUPAC
1	510	511	|I-IUPAC
-	511	512	|I-IUPAC
propenyl	512	520	|I-IUPAC
)	520	521	|I-IUPAC
-	521	522	|I-IUPAC
2'	522	524	|I-IUPAC
-	524	525	|I-IUPAC
deoxyuridine	525	537	|I-IUPAC
,	537	538	|O
5	539	540	|B-IUPAC
-	540	541	|I-IUPAC
(	541	542	|I-IUPAC
2	542	543	|I-IUPAC
-	543	544	|I-IUPAC
bromovinyl	544	554	|I-IUPAC
)	554	555	|I-IUPAC
-	555	556	|I-IUPAC
2'	556	558	|I-IUPAC
-	558	559	|I-IUPAC
deoxyuridine	559	571	|I-IUPAC
,	571	572	|O
5	573	574	|B-IUPAC
-	574	575	|I-IUPAC
iodo	575	579	|I-IUPAC
-	579	580	|I-IUPAC
2'	580	582	|I-IUPAC
-	582	583	|I-IUPAC
deoxyuridine	583	595	|I-IUPAC
,	595	596	|O
and	597	600	|O
5	601	602	|B-IUPAC
-	602	603	|I-IUPAC
(	603	604	|I-IUPAC
trifluoromethyl	604	619	|I-IUPAC
)	619	620	|I-IUPAC
-	620	621	|I-IUPAC
2'	621	623	|I-IUPAC
-	623	624	|I-IUPAC
deoxyuridine	624	636	|I-IUPAC
.	636	637	|O
TFPe	638	642	|O
-	642	643	|O
dUrd	643	647	|O
demonstrated	648	660	|O
a	661	662	|O
potent	663	669	|O
and	670	673	|O
unusually	674	683	|O
selective	684	693	|O
activity	694	702	|O
against	703	710	|O
HSV	711	714	|O
-	714	715	|O
1	715	716	|O
,	716	717	|O
with	718	722	|O
a	723	724	|O
2	725	726	|O
-	726	727	|O
log	727	730	|O
reduction	731	740	|O
in	741	743	|O
virus	744	749	|O
yield	750	755	|O
at	756	758	|O
0.03	759	763	|O
micrograms	764	774	|O
/	774	775	|O
mL	775	777	|O
(	778	779	|O
0.09	779	783	|O
microM	784	790	|O
)	790	791	|O
;	791	792	|O
L	793	794	|O
-	794	795	|O
1210	795	799	|O
cell	800	804	|O
growth	805	811	|O
was	812	815	|O
inhibited	816	825	|O
by	826	828	|O
50%	829	832	|O
only	833	837	|O
at	838	840	|O
290	841	844	|O
micrograms	845	855	|O
/	855	856	|O
mL	856	858	|O
.	858	859	|O
Isopycnic	860	869	|O
centrifugation	870	884	|O
of	885	887	|O
32P	888	891	|O
-	891	892	|O
labeled	892	899	|O
DNA	900	903	|O
indicated	904	913	|O
that	914	918	|O
if	919	921	|O
0.5	922	925	|O
or	926	928	|O
2	929	930	|O
microM	931	937	|O
TFPe	938	942	|O
-	942	943	|O
dUrd	943	947	|O
was	948	951	|O
present	952	959	|O
for	960	963	|O
0-6	964	967	|O
h	968	969	|O
postinfection	970	983	|O
,	983	984	|O
viral	985	990	|O
DNA	991	994	|O
synthesis	995	1004	|O
was	1005	1008	|O
reduced	1009	1016	|O
by	1017	1019	|O
ca.	1020	1023	|O
50	1024	1026	|O
and	1027	1030	|O
85%	1031	1034	|O
,	1034	1035	|O
respectively	1036	1048	|O
;	1048	1049	|O
concomitantly	1050	1063	|O
,	1063	1064	|O
a	1065	1066	|O
new	1067	1070	|O
DNA	1071	1074	|O
band	1075	1079	|O
appeared	1080	1088	|O
at	1089	1091	|O
lower	1092	1097	|O
density	1098	1105	|O
than	1106	1110	|O
normal	1111	1117	|O
cellular	1118	1126	|O
or	1127	1129	|O
viral	1130	1135	|O
DNA	1136	1139	|O
.	1139	1140	|O

### abstracts1547.txt
This	0	4	|O
paper	5	10	|O
describes	11	20	|O
the	21	24	|O
synthesis	25	34	|O
and	35	38	|O
kappa	39	44	|O
and	45	48	|O
mu	49	51	|O
opioid	52	58	|O
receptor	59	67	|O
binding	68	75	|O
affinity	76	84	|O
of	85	87	|O
some	88	92	|O
conformationally	93	109	|O
restrained	110	120	|O
derivatives	121	132	|O
of	133	135	|O
the	136	139	|O
arylacetamide	140	153	|O
group	154	159	|O
in	160	162	|O
the	163	166	|O
selective	167	176	|O
kappa	177	182	|O
opioid	183	189	|O
receptor	190	198	|O
agonist	199	206	|O
(	207	208	|B-IUPAC
+	208	209	|I-IUPAC
/	209	210	|I-IUPAC
-	210	211	|I-IUPAC
)	211	212	|I-IUPAC
-	212	213	|I-IUPAC
trans	213	218	|I-IUPAC
-	218	219	|I-IUPAC
N	219	220	|I-IUPAC
-	220	221	|I-IUPAC
methyl	221	227	|I-IUPAC
-	227	228	|I-IUPAC
N	228	229	|I-IUPAC
-	229	230	|I-IUPAC
[	230	231	|I-IUPAC
2	231	232	|I-IUPAC
-	232	233	|I-IUPAC
(	233	234	|I-IUPAC
1	234	235	|I-IUPAC
-	235	236	|I-IUPAC
pyrrolidinyl	236	248	|I-IUPAC
)	248	249	|I-IUPAC
cyclohexyl	250	260	|I-IUPAC
]	260	261	|I-IUPAC
benzo	261	266	|I-IUPAC
[	267	268	|I-IUPAC
b	268	269	|I-IUPAC
]	269	270	|I-IUPAC
thiophene	270	279	|I-IUPAC
-	279	280	|I-IUPAC
4	280	281	|I-IUPAC
-	281	282	|I-IUPAC
acetamide	282	291	|I-IUPAC
monohydrochloride	292	309	|I-IUPAC
(	310	311	|O
1	311	312	|O
,	312	313	|O
PD117302	313	321	|O
)	321	322	|O
,	322	323	|O
which	324	329	|O
is	330	332	|O
an	333	335	|O
analogue	336	344	|O
of	345	347	|O
U	348	349	|O
-	349	350	|O
50	350	352	|O
,	352	353	|O
488	354	357	|O
.	357	358	|O
The	359	362	|O
methyl	363	369	|B-IUPAC
-	369	370	|O
substituted	370	381	|B-MODIFIER
derivatives	382	393	|B-MODIFIER
(	394	395	|B-IUPAC
+	395	396	|I-IUPAC
/	396	397	|I-IUPAC
-	397	398	|I-IUPAC
)	398	399	|I-IUPAC
-	399	400	|I-IUPAC
trans	400	405	|I-IUPAC
-	405	406	|I-IUPAC
N	406	407	|I-IUPAC
,	407	408	|I-IUPAC
alpha	409	414	|I-IUPAC
-	414	415	|I-IUPAC
dimethyl	415	423	|I-IUPAC
-	423	424	|I-IUPAC
N	424	425	|I-IUPAC
-	425	426	|I-IUPAC
[	426	427	|I-IUPAC
2	427	428	|I-IUPAC
-	428	429	|I-IUPAC
(	429	430	|I-IUPAC
1	430	431	|I-IUPAC
-	431	432	|I-IUPAC
pyrrolidinyl	432	444	|I-IUPAC
)	444	445	|I-IUPAC
cyclohexyl	445	455	|I-IUPAC
]	455	456	|I-IUPAC
benzo	456	461	|I-IUPAC
-	461	462	|I-IUPAC
[	462	463	|I-IUPAC
b	463	464	|I-IUPAC
]	464	465	|I-IUPAC
thiophene	466	475	|I-IUPAC
-	475	476	|I-IUPAC
4	476	477	|I-IUPAC
-	477	478	|I-IUPAC
acetamide	478	487	|I-IUPAC
monohydrochloride	488	505	|I-IUPAC
(	506	507	|O
6a	507	509	|O
,	509	510	|O
b	510	511	|O
)	511	512	|O
possess	513	520	|O
significantly	521	534	|O
weaker	535	541	|O
affinity	542	550	|O
than	551	555	|O
1	556	557	|O
for	558	561	|O
the	562	565	|O
kappa	566	571	|O
opioid	572	578	|O
receptor	579	587	|O
(	588	589	|O
Ki	589	591	|O
=	592	593	|O
172	594	597	|O
and	598	601	|O
3.7	602	605	|O
nM	606	608	|O
,	608	609	|O
respectively	610	622	|O
)	622	623	|O
.	623	624	|O
It	625	627	|O
is	628	630	|O
proposed	631	639	|O
that	640	644	|O
this	645	649	|O
is	650	652	|O
due	653	656	|O
to	657	659	|O
the	660	663	|O
conformational	664	678	|O
restriction	679	690	|O
imposed	691	698	|O
by	699	701	|O
the	702	705	|O
methyl	706	712	|B-IUPAC
group	713	718	|B-MODIFIER
of	719	721	|O
6	722	723	|O
.	723	724	|O
In	725	727	|O
order	728	733	|O
to	734	736	|O
test	737	741	|O
this	742	746	|O
proposal	747	755	|O
the	756	759	|O
acenaphthene	760	772	|O
derivative	773	783	|O
and	784	787	|O
the	788	791	|O
4,5	792	795	|B-IUPAC
-	795	796	|I-IUPAC
dihydro	796	803	|I-IUPAC
-	803	804	|I-IUPAC
3H	804	806	|I-IUPAC
-	806	807	|I-IUPAC
naphtho	807	814	|I-IUPAC
[	815	816	|I-IUPAC
1,8	816	819	|I-IUPAC
-	819	820	|I-IUPAC
bc	820	822	|I-IUPAC
]	822	823	|I-IUPAC
thiophene	823	832	|I-IUPAC
derivative	833	843	|B-MODIFIER
were	844	848	|O
prepared	849	857	|O
.	857	858	|O
The	859	862	|O
acenaphthene	863	875	|B-IUPAC
derivative	876	886	|B-MODIFIER
(	887	888	|B-IUPAC
+	888	889	|I-IUPAC
)	889	890	|I-IUPAC
-	890	891	|I-IUPAC
N	891	892	|I-IUPAC
-	892	893	|I-IUPAC
methyl	893	899	|I-IUPAC
-	899	900	|I-IUPAC
N	900	901	|I-IUPAC
-	901	902	|I-IUPAC
[	902	903	|I-IUPAC
7	903	904	|I-IUPAC
-	904	905	|I-IUPAC
(	905	906	|I-IUPAC
1	906	907	|I-IUPAC
-	907	908	|I-IUPAC
pyrrolidinyl	908	920	|I-IUPAC
)	920	921	|I-IUPAC
-	921	922	|I-IUPAC
1	922	923	|I-IUPAC
-	923	924	|I-IUPAC
oxaspiro	924	932	|I-IUPAC
[	933	934	|I-IUPAC
4.5	934	937	|I-IUPAC
]	937	938	|I-IUPAC
dec	938	941	|I-IUPAC
-	941	942	|I-IUPAC
8	942	943	|I-IUPAC
-	943	944	|I-IUPAC
yl	944	946	|I-IUPAC
]	946	947	|I-IUPAC
acenaphthenecarboxamide	947	970	|I-IUPAC
monohydrochloride	971	988	|I-IUPAC
(	989	990	|O
9	990	991	|O
)	991	992	|O
was	993	996	|O
found	997	1002	|O
to	1003	1005	|O
have	1006	1010	|O
high	1011	1015	|O
kappa	1016	1021	|O
opioid	1022	1028	|O
receptor	1029	1037	|O
affinity	1038	1046	|O
and	1047	1050	|O
selectivity	1051	1062	|O
(	1063	1064	|O
kappa	1064	1069	|O
Ki	1070	1072	|O
=	1073	1074	|O
0.37	1075	1079	|O
+	1080	1081	|O
/	1081	1082	|O
-	1082	1083	|O
0.05	1084	1088	|O
nM	1089	1091	|O
,	1091	1092	|O
mu	1093	1095	|O
/	1095	1096	|O
kappa	1096	1101	|O
=	1102	1103	|O
659	1104	1107	|O
,	1107	1108	|O
delta	1109	1114	|O
/	1114	1115	|O
kappa	1115	1120	|O
=	1121	1122	|O
1562	1123	1127	|O
)	1127	1128	|O
and	1129	1132	|O
is	1133	1135	|O
100	1136	1139	|O
times	1140	1145	|O
more	1146	1150	|O
potent	1151	1157	|O
than	1158	1162	|O
morphine	1163	1171	|O
as	1172	1174	|O
an	1175	1177	|O
analgesic	1178	1187	|O
in	1188	1190	|O
the	1191	1194	|O
rat	1195	1198	|O
paw	1199	1202	|O
pressure	1203	1211	|O
test	1212	1216	|O
for	1217	1220	|O
analgesia	1221	1230	|O
after	1231	1236	|O
intravenous	1237	1248	|O
administration	1249	1263	|O
(	1264	1265	|O
MPE50	1265	1270	|O
=	1271	1272	|O
0.014	1273	1278	|O
and	1279	1282	|O
1.4	1283	1286	|O
mg	1287	1289	|O
/	1289	1290	|O
kg	1290	1292	|O
,	1292	1293	|O
respectively	1294	1306	|O
)	1306	1307	|O
.	1307	1308	|O
The	1309	1312	|O
4,5	1313	1316	|B-IUPAC
-	1316	1317	|I-IUPAC
dihydro	1317	1324	|I-IUPAC
-	1324	1325	|I-IUPAC
3H	1325	1327	|I-IUPAC
-	1327	1328	|I-IUPAC
naphtho	1328	1335	|I-IUPAC
[	1335	1336	|I-IUPAC
1,8	1336	1339	|I-IUPAC
-	1339	1340	|I-IUPAC
bc	1340	1342	|I-IUPAC
]	1342	1343	|I-IUPAC
thiophene	1343	1352	|I-IUPAC
derivative	1353	1363	|B-MODIFIER
(	1364	1365	|B-IUPAC
-	1365	1366	|I-IUPAC
)	1366	1367	|I-IUPAC
-	1367	1368	|I-IUPAC
4,5	1368	1371	|I-IUPAC
-	1371	1372	|I-IUPAC
dihydro	1372	1379	|I-IUPAC
-	1379	1380	|I-IUPAC
N	1380	1381	|I-IUPAC
-	1381	1382	|I-IUPAC
methyl	1382	1388	|I-IUPAC
-	1388	1389	|I-IUPAC
N	1389	1390	|I-IUPAC
-	1390	1391	|I-IUPAC
[	1391	1392	|I-IUPAC
7	1392	1393	|I-IUPAC
-	1393	1394	|I-IUPAC
(	1394	1395	|I-IUPAC
1	1395	1396	|I-IUPAC
-	1396	1397	|I-IUPAC
pyrrolidinyl	1397	1409	|I-IUPAC
)	1409	1410	|I-IUPAC
-	1410	1411	|I-IUPAC
1	1411	1412	|I-IUPAC
-	1412	1413	|I-IUPAC
oxaspiro	1413	1421	|I-IUPAC
[	1422	1423	|I-IUPAC
4.5	1423	1426	|I-IUPAC
]	1426	1427	|I-IUPAC
dec	1427	1430	|I-IUPAC
-	1430	1431	|I-IUPAC
8	1431	1432	|I-IUPAC
-	1432	1433	|I-IUPAC
yl	1433	1435	|I-IUPAC
]	1435	1436	|I-IUPAC
-	1436	1437	|I-IUPAC
3H	1437	1439	|I-IUPAC
-	1439	1440	|I-IUPAC
naphthol	1440	1448	|I-IUPAC
[	1448	1449	|I-IUPAC
1,8	1449	1452	|I-IUPAC
-	1452	1453	|I-IUPAC
bc	1453	1455	|I-IUPAC
]	1455	1456	|I-IUPAC
thiophene	1456	1465	|I-IUPAC
-	1465	1466	|I-IUPAC
5	1466	1467	|I-IUPAC
-	1467	1468	|I-IUPAC
carboxamide	1468	1479	|I-IUPAC
p	1480	1481	|I-IUPAC
-	1481	1482	|I-IUPAC
toluenesulfonate	1482	1498	|I-IUPAC
(	1499	1500	|O
17	1500	1502	|O
)	1502	1503	|O
also	1504	1508	|O
has	1509	1512	|O
high	1513	1517	|O
kappa	1518	1523	|O
opioid	1524	1530	|O
receptor	1531	1539	|O
affinity	1540	1548	|O
and	1549	1552	|O
selectivity	1553	1564	|O
(	1565	1566	|O
kappa	1566	1571	|O
Ki	1572	1574	|O
=	1575	1576	|O
4.65	1577	1581	|O
nM	1582	1584	|O
,	1584	1585	|O
mu	1586	1588	|O
/	1588	1589	|O
kappa	1589	1594	|O
=	1595	1596	|O
109	1597	1600	|O
)	1600	1601	|O
.	1601	1602	|O

### abstracts1753.txt
4	0	1	|B-MODIFIER
-	1	2	|I-MODIFIER
N	2	3	|I-MODIFIER
-	3	4	|I-MODIFIER
Substituted	4	15	|B-MODIFIER
and	16	19	|O
-	20	21	|B-MODIFIER
unsubstituted	21	34	|I-MODIFIER
3	35	36	|B-PARTIUPAC
-	36	37	|I-PARTIUPAC
alkyl	37	42	|I-PARTIUPAC
-	42	43	|I-PARTIUPAC
and	44	47	|O
3	48	49	|B-IUPAC
-	49	50	|I-IUPAC
(	50	51	|I-IUPAC
alkylamino	51	61	|I-IUPAC
)	61	62	|I-IUPAC
-	62	63	|I-IUPAC
4H	63	65	|I-IUPAC
-	65	66	|I-IUPAC
pyrido	66	72	|I-IUPAC
[	72	73	|I-IUPAC
4,3	73	76	|I-IUPAC
-	76	77	|I-IUPAC
e	77	78	|I-IUPAC
]	78	79	|I-IUPAC
-	79	80	|I-IUPAC
1,2,4	80	85	|I-IUPAC
-	85	86	|I-IUPAC
thiadiazine	86	97	|I-IUPAC
1,1	98	101	|I-IUPAC
-	101	102	|I-IUPAC
dioxides	102	110	|I-IUPAC
were	111	115	|O
synthesized	116	127	|O
and	128	131	|O
tested	132	138	|O
vs	139	141	|O
diazoxide	142	151	|O
and	152	155	|O
selected	156	164	|O
3	165	166	|B-PARTIUPAC
-	166	167	|I-PARTIUPAC
alykl	167	172	|I-PARTIUPAC
-	172	173	|I-PARTIUPAC
and	174	177	|O
3	178	179	|B-IUPAC
-	179	180	|I-IUPAC
(	180	181	|I-IUPAC
alkylamino	181	191	|I-IUPAC
)	191	192	|I-IUPAC
-	192	193	|I-IUPAC
7	193	194	|I-IUPAC
-	194	195	|I-IUPAC
chloro	195	201	|I-IUPAC
-	201	202	|I-IUPAC
4H	202	204	|I-IUPAC
-	204	205	|I-IUPAC
1,2,4	205	210	|I-IUPAC
-	210	211	|I-IUPAC
benzothiadiazine	211	227	|I-IUPAC
1,1	228	231	|I-IUPAC
-	231	232	|I-IUPAC
dioxides	232	240	|I-IUPAC
as	241	243	|O
potassium	244	253	|O
channel	254	261	|O
openers	262	269	|O
on	270	272	|O
pancreatic	273	283	|O
and	284	287	|O
vascular	288	296	|O
tissues	297	304	|O
.	304	305	|O
Several	306	313	|O
4	314	315	|B-MODIFIER
-	315	316	|I-MODIFIER
N	316	317	|I-MODIFIER
-	317	318	|I-MODIFIER
unsubstituted	318	331	|I-MODIFIER
3	332	333	|B-IUPAC
-	333	334	|I-IUPAC
(	334	335	|I-IUPAC
alkylamino	335	345	|I-IUPAC
)	345	346	|I-IUPAC
pyridothiadiazines	346	364	|I-IUPAC
and	365	368	|O
some	369	373	|O
3	374	375	|B-IUPAC
-	375	376	|I-IUPAC
(	376	377	|I-IUPAC
alkylamino	377	387	|I-IUPAC
)	387	388	|I-IUPAC
-	388	389	|I-IUPAC
7	389	390	|I-IUPAC
-	390	391	|I-IUPAC
chlorobenzothiadiazines	391	414	|I-IUPAC
were	415	419	|O
found	420	425	|O
to	426	428	|O
be	429	431	|O
more	432	436	|O
potent	437	443	|O
than	444	448	|O
diazoxide	449	458	|O
for	459	462	|O
the	463	466	|O
inhibition	467	477	|O
of	478	480	|O
the	481	484	|O
insulin	485	492	|O
-	492	493	|O
releasing	493	502	|O
process	503	510	|O
.	510	511	|O
Moreover	512	520	|O
,	520	521	|O
the	522	525	|O
3	526	527	|B-IUPAC
-	527	528	|I-IUPAC
(	528	529	|I-IUPAC
alkylamino	529	539	|I-IUPAC
)	539	540	|I-IUPAC
pyridothiadiazines	540	558	|I-IUPAC
appeared	559	567	|O
to	568	570	|O
be	571	573	|O
more	574	578	|O
selective	579	588	|O
for	589	592	|O
the	593	596	|O
pancreatic	597	607	|O
than	608	612	|O
for	613	616	|O
the	617	620	|O
vascular	621	629	|O
tissue	630	636	|O
.	636	637	|O
By	638	640	|O
means	641	646	|O
of	647	649	|O
the	650	653	|O
pharmacological	654	669	|O
results	670	677	|O
obtained	678	686	|O
on	687	689	|O
pancreatic	690	700	|O
B	701	702	|O
-	702	703	|O
cells	703	708	|O
,	708	709	|O
structure	710	719	|O
-	719	720	|O
-	720	721	|O
activity	721	729	|O
relationships	730	743	|O
were	744	748	|O
deduced	749	756	|O
and	757	760	|O
a	761	762	|O
pharmacophoric	763	777	|O
model	778	783	|O
for	784	787	|O
the	788	791	|O
interaction	792	803	|O
of	804	806	|O
these	807	812	|O
drugs	813	818	|O
with	819	823	|O
their	824	829	|O
receptor	830	838	|O
site	839	843	|O
associated	844	854	|O
to	855	857	|O
the	858	861	|O
pancreatic	862	872	|O
K	873	874	|O
(	874	875	|O
ATP	875	878	|O
)	878	879	|O
channel	880	887	|O
was	888	891	|O
proposed	892	900	|O
.	900	901	|O
According	902	911	|O
to	912	914	|O
their	915	920	|O
selectivity	921	932	|O
for	933	936	|O
the	937	940	|O
B	941	942	|O
-	942	943	|O
cell	943	947	|O
(	948	949	|O
endocrine	949	958	|O
tissue	959	965	|O
)	965	966	|O
vs	967	969	|O
the	970	973	|O
vascular	974	982	|O
(	983	984	|O
smooth	984	990	|O
muscle	991	997	|O
tissue	998	1004	|O
)	1004	1005	|O
ionic	1006	1011	|O
channel	1012	1019	|O
,	1019	1020	|O
selected	1021	1029	|O
3	1030	1031	|B-IUPAC
-	1031	1032	|I-IUPAC
(	1032	1033	|I-IUPAC
alkylamino	1033	1043	|I-IUPAC
)	1043	1044	|I-IUPAC
-	1044	1045	|I-IUPAC
4H	1045	1047	|I-IUPAC
-	1047	1048	|I-IUPAC
pyrido	1048	1054	|I-IUPAC
[	1054	1055	|I-IUPAC
4,3	1055	1058	|I-IUPAC
-	1058	1059	|I-IUPAC
e	1059	1060	|I-IUPAC
]	1060	1061	|I-IUPAC
-	1061	1062	|I-IUPAC
1,2,4	1062	1067	|I-IUPAC
,	1067	1068	|I-IUPAC
-	1068	1069	|I-IUPAC
thiadiazine	1069	1080	|I-IUPAC
1,1	1081	1084	|I-IUPAC
-	1084	1085	|I-IUPAC
dioxides	1085	1093	|I-IUPAC
may	1094	1097	|O
serve	1098	1103	|O
as	1104	1106	|O
pharmacological	1107	1122	|O
tools	1123	1128	|O
in	1129	1131	|O
studying	1132	1140	|O
the	1141	1144	|O
K	1145	1146	|O
(	1146	1147	|O
ATP	1147	1150	|O
)	1150	1151	|O
channels	1152	1160	|O
(	1161	1162	|O
"	1162	1163	|O
pancreatic	1163	1173	|O
-	1173	1174	|O
like	1174	1178	|O
"	1178	1179	|O
K	1180	1181	|O
(	1181	1182	|O
ATP	1182	1185	|O
)	1185	1186	|O
channels	1187	1195	|O
)	1195	1196	|O
in	1197	1199	|O
other	1200	1205	|O
tissues	1206	1213	|O
.	1213	1214	|O

### abstracts2414.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
2,3	12	15	|B-IUPAC
-	15	16	|I-IUPAC
diaryl	16	22	|I-IUPAC
-	22	23	|I-IUPAC
1	23	24	|I-IUPAC
-	24	25	|I-IUPAC
benzopyran	25	35	|I-IUPAC
analogues	36	45	|B-MODIFIER
substituted	46	57	|B-MODIFIER
at	58	60	|O
position	61	69	|O
4	70	71	|O
of	72	74	|O
2	75	76	|B-IUPAC
-	76	77	|I-IUPAC
phenyl	77	83	|I-IUPAC
with	84	88	|O
a	89	90	|O
hydroxy	91	98	|B-IUPAC
or	99	101	|O
pyrrolidinoethoxy	102	119	|B-IUPAC
residue	120	127	|B-MODIFIER
were	128	132	|O
synthesized	133	144	|O
as	145	147	|O
models	148	154	|O
for	155	158	|O
(	159	160	|B-IUPAC
E	160	161	|I-IUPAC
)	161	162	|I-IUPAC
-	162	163	|I-IUPAC
triarylpropenones	163	180	|I-IUPAC
constrained	181	192	|O
in	193	195	|O
the	196	199	|O
s	200	201	|O
-	201	202	|O
trans	202	207	|O
conformation	208	220	|O
.	220	221	|O
The	222	225	|O
prototypes	226	236	|O
,	236	237	|O
belonging	238	247	|O
to	248	250	|O
five	251	255	|O
chemical	256	264	|O
series	265	271	|O
,	271	272	|O
were	273	277	|O
evaluated	278	287	|O
for	288	291	|O
their	292	297	|O
estrogen	298	306	|O
receptor	307	315	|O
affinity	316	324	|O
and	325	328	|O
for	329	332	|O
estrogen	333	341	|O
agonist	342	349	|O
-	349	350	|O
antagonist	350	360	|O
activities	361	371	|O
.	371	372	|O
The	373	376	|O
4H	377	379	|B-IUPAC
-	379	380	|I-IUPAC
1	380	381	|I-IUPAC
-	381	382	|I-IUPAC
benzopyran	382	392	|I-IUPAC
-	392	393	|I-IUPAC
4	393	394	|I-IUPAC
-	394	395	|I-IUPAC
one	395	398	|I-IUPAC
,	398	399	|O
the	400	403	|O
2,3	404	407	|B-IUPAC
-	407	408	|I-IUPAC
dihydro	408	415	|I-IUPAC
-	415	416	|I-IUPAC
4H	416	418	|I-IUPAC
-	418	419	|I-IUPAC
1	419	420	|I-IUPAC
-	420	421	|I-IUPAC
benzopyran	421	431	|I-IUPAC
-	431	432	|I-IUPAC
4	432	433	|I-IUPAC
-	433	434	|I-IUPAC
one	434	437	|I-IUPAC
,	437	438	|O
the	439	442	|O
4H	443	445	|B-IUPAC
-	445	446	|I-IUPAC
1	446	447	|I-IUPAC
-	447	448	|I-IUPAC
benzopyran	448	458	|I-IUPAC
,	458	459	|O
and	460	463	|O
the	464	467	|O
2,3	468	471	|B-IUPAC
-	471	472	|I-IUPAC
dihydro	472	479	|I-IUPAC
-	479	480	|I-IUPAC
1	480	481	|I-IUPAC
-	481	482	|I-IUPAC
benzopyran	482	492	|I-IUPAC
derivatives	493	504	|B-MODIFIER
were	505	509	|O
found	510	515	|O
to	516	518	|O
be	519	521	|O
inactive	522	530	|O
or	531	533	|O
only	534	538	|O
marginally	539	549	|O
activate	550	558	|O
as	559	561	|O
receptor	562	570	|O
ligands	571	578	|O
or	579	581	|O
estrogen	582	590	|O
agonists	591	599	|O
-	599	600	|O
antagonists	600	611	|O
.	611	612	|O
In	613	615	|O
the	616	619	|O
2H	620	622	|B-IUPAC
-	622	623	|I-IUPAC
1	623	624	|I-IUPAC
-	624	625	|I-IUPAC
benzopyran	625	635	|I-IUPAC
category	636	644	|O
the	645	648	|O
parent	649	655	|O
phenol	656	662	|O
was	663	666	|O
also	667	671	|O
inactive	672	680	|O
whereas	681	688	|O
the	689	692	|O
basic	693	698	|O
ethers	699	705	|O
16	706	708	|O
and	709	712	|O
26	713	715	|O
were	716	720	|O
modest	721	727	|O
receptor	728	736	|O
ligands	737	744	|O
while	745	750	|O
being	751	756	|O
quite	757	762	|O
active	763	769	|O
as	770	772	|O
antiestrogens	773	786	|O
.	786	787	|O
In	788	790	|O
a	791	792	|O
comparative	793	804	|O
study	805	810	|O
the	811	814	|O
benzopyran	815	825	|O
16	826	828	|O
was	829	832	|O
found	833	838	|O
to	839	841	|O
be	842	844	|O
more	845	849	|O
effective	850	859	|O
antiestrogen	860	872	|O
than	873	877	|O
tamoxifen	878	887	|O
while	888	893	|O
being	894	899	|O
as	900	902	|O
effective	903	912	|O
as	913	915	|O
LY	916	918	|O
-	918	919	|O
117018	919	925	|O
.	925	926	|O
The	927	930	|O
benzopyrans	931	942	|O
have	943	947	|O
thus	948	952	|O
emerged	953	960	|O
as	961	963	|O
a	964	965	|O
new	966	969	|O
class	970	975	|O
of	976	978	|O
potent	979	985	|O
antiestrogens	986	999	|O
.	999	1000	|O

### abstracts861.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
synthetic	12	21	|O
estrogens	22	31	|O
containing	32	42	|O
hydroxyalkyl	43	55	|O
side	56	60	|O
chains	61	67	|O
at	68	70	|O
the	71	74	|O
C	75	76	|O
-	76	77	|O
4	77	78	|O
position	79	87	|O
of	88	90	|O
the	91	94	|O
A	95	96	|O
ring	97	101	|O
were	102	106	|O
designed	107	115	|O
as	116	118	|O
metabolically	119	132	|O
stable	133	139	|O
analogs	140	147	|O
of	148	150	|O
4	151	152	|B-IUPAC
-	152	153	|I-IUPAC
hydroxyestradiol	153	169	|I-IUPAC
,	169	170	|O
a	171	172	|O
catechol	173	181	|O
estrogen	182	190	|O
.	190	191	|O
These	192	197	|O
synthetic	198	207	|O
steroids	208	216	|O
would	217	222	|O
facilitate	223	233	|O
investigations	234	248	|O
on	249	251	|O
the	252	255	|O
potential	256	265	|O
biological	266	276	|O
role	277	281	|O
of	282	284	|O
catechol	285	293	|O
estrogens	294	303	|O
and	304	307	|O
also	308	312	|O
enable	313	319	|O
further	320	327	|O
examination	328	339	|O
of	340	342	|O
the	343	346	|O
structural	347	357	|O
and	358	361	|O
electronic	362	372	|O
constraints	373	384	|O
on	385	387	|O
the	388	391	|O
A	392	393	|O
ring	394	398	|O
in	399	401	|O
the	402	405	|O
interaction	406	417	|O
of	418	420	|O
estrogens	421	430	|O
with	431	435	|O
the	436	439	|O
estrogen	440	448	|O
receptor	449	457	|O
.	457	458	|O
Catechol	459	467	|O
estrogens	468	477	|O
are	478	481	|O
implicated	482	492	|O
as	493	495	|O
possible	496	504	|O
causative	505	514	|O
agents	515	521	|O
in	522	524	|O
estrogen	525	533	|O
-	533	534	|O
induced	534	541	|O
tumorigenesis	542	555	|O
.	555	556	|O
4	557	558	|B-IUPAC
-	558	559	|I-IUPAC
Hydroxyestradiol	559	575	|I-IUPAC
has	576	579	|O
weaker	580	586	|O
affinity	587	595	|O
for	596	599	|O
the	600	603	|O
estrogen	604	612	|O
receptor	613	621	|O
and	622	625	|O
exhibits	626	634	|O
lower	635	640	|O
estrogenic	641	651	|O
activity	652	660	|O
in	661	663	|O
vivo	664	668	|O
;	668	669	|O
on	670	672	|O
the	673	676	|O
other	677	682	|O
hand	683	687	|O
,	687	688	|O
the	689	692	|O
catechol	693	701	|O
estrogens	702	711	|O
are	712	715	|O
prone	716	721	|O
to	722	724	|O
further	725	732	|O
oxidative	733	742	|O
metabolism	743	753	|O
and	754	757	|O
can	758	761	|O
form	762	766	|O
reactive	767	775	|O
intermediates	776	789	|O
.	789	790	|O
This	791	795	|O
report	796	802	|O
describes	803	812	|O
the	813	816	|O
synthesis	817	826	|O
and	827	830	|O
initial	831	838	|O
biochemical	839	850	|O
evaluation	851	861	|O
of	862	864	|O
4	865	866	|B-IUPAC
-	866	867	|I-IUPAC
(	867	868	|I-IUPAC
hydroxyalkyl	868	880	|I-IUPAC
)	880	881	|I-IUPAC
estrogens	881	890	|I-IUPAC
and	891	894	|O
4	895	896	|B-IUPAC
-	896	897	|I-IUPAC
(	897	898	|I-IUPAC
aminoalkyl	898	908	|I-IUPAC
)	908	909	|I-IUPAC
estradiols	909	919	|I-IUPAC
.	919	920	|O
The	921	924	|O
4	925	926	|B-IUPAC
-	926	927	|I-IUPAC
(	927	928	|I-IUPAC
hydroxyalkyl	928	940	|I-IUPAC
)	940	941	|I-IUPAC
estrogens	941	950	|I-IUPAC
were	951	955	|O
prepared	956	964	|O
by	965	967	|O
oxidative	968	977	|O
hydroboration	978	991	|O
of	992	994	|O
4	995	996	|B-IUPAC
-	996	997	|I-IUPAC
alkenylestradiols	997	1014	|I-IUPAC
.	1014	1015	|O
The	1016	1019	|O
alkenylestradiols	1020	1037	|O
were	1038	1042	|O
obtained	1043	1051	|O
via	1052	1055	|O
a	1056	1057	|O
Stille	1058	1064	|O
cross	1065	1070	|O
-	1070	1071	|O
coupling	1071	1079	|O
between	1080	1087	|O
a	1088	1089	|O
MOM	1090	1093	|O
-	1093	1094	|O
protected	1094	1103	|O
4	1104	1105	|B-IUPAC
-	1105	1106	|I-IUPAC
bromoestradiol	1106	1120	|I-IUPAC
and	1121	1124	|O
an	1125	1127	|O
alkenylstannane	1128	1143	|O
.	1143	1144	|O
The	1145	1148	|O
(	1149	1150	|B-IUPAC
4	1150	1151	|I-IUPAC
-	1151	1152	|I-IUPAC
aminoalkyl	1152	1162	|I-IUPAC
)	1162	1163	|I-IUPAC
estrogens	1163	1172	|I-IUPAC
were	1173	1177	|O
prepared	1178	1186	|O
from	1187	1191	|O
the	1192	1195	|O
hydroxyalkyl	1196	1208	|O
derivatives	1209	1220	|O
with	1221	1225	|O
phthalimide	1226	1237	|O
under	1238	1243	|O
Mitsunobu	1244	1253	|O
conditions	1254	1264	|O
.	1264	1265	|O
The	1266	1269	|O
substituted	1270	1281	|O
estradiols	1282	1292	|O
were	1293	1297	|O
evaluated	1298	1307	|O
for	1308	1311	|O
estrogen	1312	1320	|O
receptor	1321	1329	|O
binding	1330	1337	|O
activity	1338	1346	|O
in	1347	1349	|O
MCF	1350	1353	|O
-	1353	1354	|O
7	1354	1355	|O
human	1356	1361	|O
mammary	1362	1369	|O
carcinoma	1370	1379	|O
cells	1380	1385	|O
,	1385	1386	|O
and	1387	1390	|O
4	1391	1392	|B-IUPAC
-	1392	1393	|I-IUPAC
(	1393	1394	|I-IUPAC
hydroxymethyl	1394	1407	|I-IUPAC
)	1407	1408	|I-IUPAC
estradiol	1408	1417	|I-IUPAC
1	1418	1419	|O
exhibited	1420	1429	|O
the	1430	1433	|O
highest	1434	1441	|O
affinity	1442	1450	|O
with	1451	1455	|O
an	1456	1458	|O
apparent	1459	1467	|O
EC50	1468	1472	|O
value	1473	1478	|O
of	1479	1481	|O
364	1482	1485	|O
nM	1486	1488	|O
.	1488	1489	|O
The	1490	1493	|O
relative	1494	1502	|O
activities	1503	1513	|O
for	1514	1517	|O
mRNA	1518	1522	|O
induction	1523	1532	|O
of	1533	1535	|O
the	1536	1539	|O
pS2	1540	1543	|O
gene	1544	1548	|O
in	1549	1551	|O
MCF	1552	1555	|O
-	1555	1556	|O
7	1556	1557	|O
cell	1558	1562	|O
cultures	1563	1571	|O
by	1572	1574	|O
the	1575	1578	|O
4	1579	1580	|B-IUPAC
-	1580	1581	|I-IUPAC
(	1581	1582	|I-IUPAC
hydroxyalkyl	1582	1594	|I-IUPAC
)	1594	1595	|I-IUPAC
estrogens	1595	1604	|I-IUPAC
closely	1605	1612	|O
parallel	1613	1621	|O
the	1622	1625	|O
relative	1626	1634	|O
binding	1635	1642	|O
affinities	1643	1653	|O
.	1653	1654	|O
4	1655	1656	|B-IUPAC
-	1656	1657	|I-IUPAC
(	1657	1658	|I-IUPAC
Hydroxymethyl	1658	1671	|I-IUPAC
)	1671	1672	|I-IUPAC
estradiol	1672	1681	|I-IUPAC
1	1682	1683	|O
did	1684	1687	|O
not	1688	1691	|O
stimulate	1692	1701	|O
the	1702	1705	|O
growth	1706	1712	|O
of	1713	1715	|O
MCF	1716	1719	|O
-	1719	1720	|O
7	1720	1721	|O
cells	1722	1727	|O
at	1728	1730	|O
concentrations	1731	1745	|O
up	1746	1748	|O
to	1749	1751	|O
1	1752	1753	|O
microM	1754	1760	|O
.	1760	1761	|O
Thus	1762	1766	|O
,	1766	1767	|O
4	1768	1769	|B-IUPAC
-	1769	1770	|I-IUPAC
(	1770	1771	|I-IUPAC
hydroxymethyl	1771	1784	|I-IUPAC
)	1784	1785	|I-IUPAC
estradiol	1785	1794	|I-IUPAC
1	1795	1796	|O
exhibited	1797	1806	|O
similar	1807	1814	|O
estrogen	1815	1823	|O
receptor	1824	1832	|O
affinity	1833	1841	|O
as	1842	1844	|O
the	1845	1848	|O
catechol	1849	1857	|O
estrogen	1858	1866	|O
,	1866	1867	|O
4	1868	1869	|B-IUPAC
-	1869	1870	|I-IUPAC
hydroxyestradiol	1870	1886	|I-IUPAC
,	1886	1887	|O
and	1888	1891	|O
may	1892	1895	|O
prove	1896	1901	|O
useful	1902	1908	|O
in	1909	1911	|O
the	1912	1915	|O
examination	1916	1927	|O
of	1928	1930	|O
the	1931	1934	|O
biological	1935	1945	|O
effects	1946	1953	|O
of	1954	1956	|O
4	1957	1958	|B-IUPAC
-	1958	1959	|I-IUPAC
hydroxyestrogens	1959	1975	|I-IUPAC
.	1975	1976	|O

### abstracts2925.txt
A	0	1	|O
library	2	9	|O
of	10	12	|O
compounds	13	22	|O
were	23	27	|O
prepared	28	36	|O
by	37	39	|O
reacting	40	48	|O
2	49	50	|B-IUPAC
-	50	51	|I-IUPAC
(	51	52	|I-IUPAC
bromomethyl	52	63	|I-IUPAC
)	63	64	|I-IUPAC
-	64	65	|I-IUPAC
1	65	66	|I-IUPAC
,	66	67	|I-IUPAC
2	68	69	|I-IUPAC
-	69	70	|I-IUPAC
benzisothiazol	70	84	|I-IUPAC
-	84	85	|I-IUPAC
3	85	86	|I-IUPAC
(	86	87	|I-IUPAC
2H	87	89	|I-IUPAC
)	89	90	|I-IUPAC
-	90	91	|I-IUPAC
one	91	94	|I-IUPAC
1,1	95	98	|I-IUPAC
-	98	99	|I-IUPAC
dioxide	99	106	|I-IUPAC
(	107	108	|O
5	108	109	|O
)	109	110	|O
with	111	115	|O
commercially	116	128	|O
available	129	138	|O
carboxylic	139	149	|O
acids	150	155	|O
in	156	158	|O
the	159	162	|O
presence	163	171	|O
of	172	174	|O
potassium	175	184	|O
carbonate	185	194	|O
or	195	197	|O
a	198	199	|O
tertiary	200	208	|O
amine	209	214	|O
base	215	219	|O
.	219	220	|O
From	221	225	|O
this	226	230	|O
library	231	238	|O
,	238	239	|O
(	240	241	|B-IUPAC
1,1	241	244	|I-IUPAC
-	244	245	|I-IUPAC
dioxido	245	252	|I-IUPAC
-	252	253	|I-IUPAC
3	253	254	|I-IUPAC
-	254	255	|I-IUPAC
oxo	255	258	|I-IUPAC
-	258	259	|I-IUPAC
1	259	260	|I-IUPAC
,	260	261	|I-IUPAC
2	262	263	|I-IUPAC
-	263	264	|I-IUPAC
benzisothiazol	264	278	|I-IUPAC
-	278	279	|I-IUPAC
2	279	280	|I-IUPAC
(	280	281	|I-IUPAC
3H	281	283	|I-IUPAC
)	283	284	|I-IUPAC
-	284	285	|I-IUPAC
yl	285	287	|I-IUPAC
)	287	288	|I-IUPAC
methyl	288	294	|I-IUPAC
N	295	296	|I-IUPAC
-	296	297	|I-IUPAC
[	297	298	|I-IUPAC
(	298	299	|I-IUPAC
phenylmethoxy	299	312	|I-IUPAC
)	312	313	|I-IUPAC
carbonyl	313	321	|I-IUPAC
]	321	322	|I-IUPAC
-	322	323	|I-IUPAC
beta	323	327	|I-IUPAC
-	327	328	|I-IUPAC
alanate	328	335	|I-IUPAC
(	336	337	|O
7b	337	339	|O
)	339	340	|O
emerged	341	348	|O
as	349	351	|O
a	352	353	|O
potent	354	360	|O
inhibitor	361	370	|O
of	371	373	|O
human	374	379	|O
mast	380	384	|O
cell	385	389	|O
tryptase	390	398	|O
(	399	400	|O
IC50	400	404	|O
=	405	406	|O
0.85	407	411	|O
microM	412	418	|O
)	418	419	|O
.	419	420	|O
Extension	421	430	|O
of	431	433	|O
the	434	437	|O
side	438	442	|O
chain	443	448	|O
of	449	451	|O
7b	452	454	|O
by	455	457	|O
two	458	461	|O
carbons	462	469	|O
gave	470	474	|O
(	475	476	|B-IUPAC
1	476	477	|I-IUPAC
,	477	478	|I-IUPAC
1	479	480	|B-IUPAC
-	480	481	|I-IUPAC
dioxido	481	488	|I-IUPAC
-	488	489	|I-IUPAC
3	489	490	|I-IUPAC
-	490	491	|I-IUPAC
oxo	491	494	|I-IUPAC
-	494	495	|I-IUPAC
1,2	495	498	|I-IUPAC
-	498	499	|I-IUPAC
benzisothiazol	499	513	|I-IUPAC
-	513	514	|I-IUPAC
2	514	515	|I-IUPAC
(	515	516	|I-IUPAC
3H	516	518	|I-IUPAC
)	518	519	|I-IUPAC
-	519	520	|I-IUPAC
yl	520	522	|I-IUPAC
)	522	523	|I-IUPAC
methyl	523	529	|I-IUPAC
5	530	531	|I-IUPAC
-	531	532	|I-IUPAC
[	532	533	|I-IUPAC
[	533	534	|I-IUPAC
(	534	535	|I-IUPAC
phenylmethoxy	535	548	|I-IUPAC
)	548	549	|I-IUPAC
carbonyl	549	557	|I-IUPAC
]	557	558	|I-IUPAC
amino	558	563	|I-IUPAC
]	563	564	|I-IUPAC
pentanoate	564	574	|I-IUPAC
(	575	576	|O
7d	576	578	|O
)	578	579	|O
which	580	585	|O
was	586	589	|O
an	590	592	|O
8	593	594	|O
-	594	595	|O
fold	595	599	|O
more	600	604	|O
potent	605	611	|O
inhibitor	612	621	|O
(	622	623	|O
IC50	623	627	|O
=	628	629	|O
0.1	630	633	|O
microM	634	640	|O
)	640	641	|O
.	641	642	|O
Further	643	650	|O
modification	651	663	|O
of	664	666	|O
this	667	671	|O
series	672	678	|O
produced	679	687	|O
benzoic	688	695	|O
acid	696	700	|O
derivative	701	711	|O
(	712	713	|B-IUPAC
1	713	714	|I-IUPAC
,	714	715	|I-IUPAC
1	716	717	|I-IUPAC
-	717	718	|I-IUPAC
dioxido	718	725	|I-IUPAC
-	725	726	|I-IUPAC
3	726	727	|I-IUPAC
-	727	728	|I-IUPAC
oxo	728	731	|I-IUPAC
-	731	732	|I-IUPAC
1,2	732	735	|I-IUPAC
-	735	736	|I-IUPAC
benzisothiazol	736	750	|I-IUPAC
-	750	751	|I-IUPAC
2	751	752	|I-IUPAC
(	752	753	|I-IUPAC
3H	753	755	|I-IUPAC
)	755	756	|I-IUPAC
-	756	757	|I-IUPAC
yl	757	759	|I-IUPAC
)	759	760	|I-IUPAC
methyl	760	766	|I-IUPAC
4	767	768	|I-IUPAC
-	768	769	|I-IUPAC
[	769	770	|I-IUPAC
[	770	771	|I-IUPAC
(	771	772	|I-IUPAC
phenylmethoxy	772	785	|I-IUPAC
)	785	786	|I-IUPAC
carbonyl	786	794	|I-IUPAC
]	794	795	|I-IUPAC
amino	795	800	|I-IUPAC
]	800	801	|I-IUPAC
benzoate	801	809	|I-IUPAC
(	810	811	|O
7n	811	813	|O
)	813	814	|O
which	815	820	|O
is	821	823	|O
the	824	827	|O
most	828	832	|O
potent	833	839	|O
inhibitor	840	849	|O
identified	850	860	|O
in	861	863	|O
this	864	868	|O
series	869	875	|O
(	876	877	|O
IC50	877	881	|O
=	882	883	|O
0.064	884	889	|O
microM	890	896	|O
)	896	897	|O
.	897	898	|O
These	899	904	|O
compounds	905	914	|O
exhibit	915	922	|O
time	923	927	|O
-	927	928	|O
dependent	928	937	|O
inhibition	938	948	|O
consistent	949	959	|O
with	960	964	|O
mechanism	965	974	|O
-	974	975	|O
based	975	980	|O
inhibition	981	991	|O
.	991	992	|O
For	993	996	|O
7b	997	999	|O
,	999	1000	|O
the	1001	1004	|O
initial	1005	1012	|O
enzyme	1013	1019	|O
velocity	1020	1028	|O
is	1029	1031	|O
not	1032	1035	|O
a	1036	1037	|O
saturable	1038	1047	|O
function	1048	1056	|O
of	1057	1059	|O
the	1060	1063	|O
inhibitor	1064	1073	|O
concentration	1074	1087	|O
and	1088	1091	|O
the	1092	1095	|O
initial	1096	1103	|O
Ki	1104	1106	|O
could	1107	1112	|O
not	1113	1116	|O
be	1117	1119	|O
determined	1120	1130	|O
(	1131	1132	|O
Ki	1132	1134	|O
&	1135	1136	|O
gt	1136	1138	|O
;	1138	1139	|O
10	1140	1142	|O
microM	1143	1149	|O
)	1149	1150	|O
.	1150	1151	|O
The	1152	1155	|O
steady	1156	1162	|O
-	1162	1163	|O
state	1163	1168	|O
rate	1169	1173	|O
constant	1174	1182	|O
,	1182	1183	|O
Ki	1184	1186	|O
,	1186	1187	|O
was	1188	1191	|O
determined	1192	1202	|O
to	1203	1205	|O
be	1206	1208	|O
396	1209	1212	|O
nM	1213	1215	|O
.	1215	1216	|O
On	1217	1219	|O
the	1220	1223	|O
other	1224	1229	|O
hand	1230	1234	|O
,	1234	1235	|O
compounds	1236	1245	|O
7d	1246	1248	|O
and	1249	1252	|O
7n	1253	1255	|O
are	1256	1259	|O
time	1260	1264	|O
-	1264	1265	|O
dependent	1265	1274	|O
inhibitors	1275	1285	|O
with	1286	1290	|O
a	1291	1292	|O
saturable	1293	1302	|O
initial	1303	1310	|O
complex	1311	1318	|O
.	1318	1319	|O
From	1320	1324	|O
these	1325	1330	|O
studies	1331	1338	|O
,	1338	1339	|O
an	1340	1342	|O
initial	1343	1350	|O
rate	1351	1355	|O
constant	1356	1364	|O
,	1364	1365	|O
Ki	1366	1368	|O
,	1368	1369	|O
for	1370	1373	|O
7d	1374	1376	|O
and	1377	1380	|O
7n	1381	1383	|O
was	1384	1387	|O
found	1388	1393	|O
to	1394	1396	|O
be	1397	1399	|O
345	1400	1403	|O
and	1404	1407	|O
465	1408	1411	|O
nM	1412	1414	|O
,	1414	1415	|O
respectively	1416	1428	|O
.	1428	1429	|O
The	1430	1433	|O
steady	1434	1440	|O
-	1440	1441	|O
state	1441	1446	|O
inhibition	1447	1457	|O
constants	1458	1467	|O
,	1467	1468	|O
Ki	1469	1471	|O
,	1471	1472	|O
for	1473	1476	|O
7d	1477	1479	|O
and	1480	1483	|O
7n	1484	1486	|O
were	1487	1491	|O
calculated	1492	1502	|O
to	1503	1505	|O
be	1506	1508	|O
60	1509	1511	|O
and	1512	1515	|O
52	1516	1518	|O
nM	1519	1521	|O
,	1521	1522	|O
respectively	1523	1535	|O
.	1535	1536	|O
Compound	1537	1545	|O
7n	1546	1548	|O
is	1549	1551	|O
a	1552	1553	|O
13	1554	1556	|O
-	1556	1557	|O
fold	1557	1561	|O
more	1562	1566	|O
potent	1567	1573	|O
inhibitor	1574	1583	|O
than	1584	1588	|O
7b	1589	1591	|O
,	1591	1592	|O
and	1593	1596	|O
these	1597	1602	|O
kinetic	1603	1610	|O
studies	1611	1618	|O
indicate	1619	1627	|O
that	1628	1632	|O
the	1633	1636	|O
increase	1637	1645	|O
in	1646	1648	|O
inhibitory	1649	1659	|O
activity	1660	1668	|O
is	1669	1671	|O
due	1672	1675	|O
to	1676	1678	|O
an	1679	1681	|O
increase	1682	1690	|O
in	1691	1693	|O
initial	1694	1701	|O
affinity	1702	1710	|O
toward	1711	1717	|O
the	1718	1721	|O
enzyme	1722	1728	|O
and	1729	1732	|O
not	1733	1736	|O
an	1737	1739	|O
increase	1740	1748	|O
in	1749	1751	|O
chemical	1752	1760	|O
reactivity	1761	1771	|O
.	1771	1772	|O
These	1773	1778	|O
inhibitors	1779	1789	|O
generally	1790	1799	|O
show	1800	1804	|O
high	1805	1809	|O
selectivity	1810	1821	|O
for	1822	1825	|O
tryptase	1826	1834	|O
,	1834	1835	|O
being	1836	1841	|O
40	1842	1844	|O
-	1844	1845	|O
fold	1845	1849	|O
weaker	1850	1856	|O
inhibitors	1857	1867	|O
of	1868	1870	|O
elastase	1871	1879	|O
,	1879	1880	|O
being	1881	1886	|O
100	1887	1890	|O
-	1890	1891	|O
fold	1891	1895	|O
weaker	1896	1902	|O
against	1903	1910	|O
trypsin	1911	1918	|O
,	1918	1919	|O
and	1920	1923	|O
showing	1924	1931	|O
no	1932	1934	|O
inhibition	1935	1945	|O
against	1946	1953	|O
thrombin	1954	1962	|O
.	1962	1963	|O
These	1964	1969	|O
compounds	1970	1979	|O
are	1980	1983	|O
not	1984	1987	|O
inhibitors	1988	1998	|O
of	1999	2001	|O
thrombin	2002	2010	|O
,	2010	2011	|O
plasmin	2012	2019	|O
t	2020	2021	|O
-	2021	2022	|O
PA	2022	2024	|O
,	2024	2025	|O
urokinase	2026	2035	|O
,	2035	2036	|O
and	2037	2040	|O
factor	2041	2047	|O
Xa	2048	2050	|O
(	2051	2052	|O
IC50	2052	2056	|O
&	2057	2058	|O
gt	2058	2060	|O
;	2060	2061	|O
33	2062	2064	|O
microM	2065	2071	|O
)	2071	2072	|O
.	2072	2073	|O
In	2074	2076	|O
the	2077	2080	|O
delayed	2081	2088	|O
-	2088	2089	|O
type	2089	2093	|O
hypersensitivity	2094	2110	|O
(	2111	2112	|O
DTH	2112	2115	|O
)	2115	2116	|O
mouse	2117	2122	|O
model	2123	2128	|O
,	2128	2129	|O
a	2130	2131	|O
model	2132	2137	|O
of	2138	2140	|O
skin	2141	2145	|O
inflammation	2146	2158	|O
,	2158	2159	|O
a	2160	2161	|O
5%	2162	2164	|O
solution	2165	2173	|O
of	2174	2176	|O
7d	2177	2179	|O
reduced	2180	2187	|O
edema	2188	2193	|O
by	2194	2196	|O
69%	2197	2200	|O
compared	2201	2209	|O
to	2210	2212	|O
control	2213	2220	|O
animals	2221	2228	|O
.	2228	2229	|O

### abstracts2582.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
N	12	13	|B-IUPAC
-	13	14	|I-IUPAC
(	14	15	|I-IUPAC
arylalkyl	15	24	|I-IUPAC
)	24	25	|I-IUPAC
indol	25	30	|I-IUPAC
-	30	31	|I-IUPAC
3	31	32	|I-IUPAC
-	32	33	|I-IUPAC
ylglyoxylylamides	33	50	|I-IUPAC
(	51	52	|O
4-8	52	55	|O
)	55	56	|O
was	57	60	|O
synthesized	61	72	|O
as	73	75	|O
ligands	76	83	|O
of	84	86	|O
the	87	90	|O
benzodiazepine	91	105	|O
receptor	106	114	|O
(	115	116	|O
BzR	116	119	|O
)	119	120	|O
and	121	124	|O
tested	125	131	|O
for	132	135	|O
their	136	141	|O
ability	142	149	|O
to	150	152	|O
displace	153	161	|O
[	162	163	|O
(	163	164	|O
3	164	165	|O
)	165	166	|O
H	166	167	|O
]	167	168	|O
flumazenil	168	178	|O
from	179	183	|O
bovine	184	190	|O
brain	191	196	|O
membranes	197	206	|O
.	206	207	|O
The	208	211	|O
new	212	215	|O
compounds	216	225	|O
,	225	226	|O
bearing	227	234	|O
a	235	236	|O
branched	237	245	|O
(	246	247	|O
4	247	248	|O
)	248	249	|O
or	250	252	|O
a	253	254	|O
geometrically	255	268	|O
constrained	269	280	|O
benzyl	281	287	|B-IUPAC
/	287	288	|O
phenylethyl	288	299	|B-IUPAC
amide	300	305	|I-IUPAC
side	306	310	|B-MODIFIER
chain	311	316	|I-MODIFIER
(	317	318	|O
5-8	318	321	|O
)	321	322	|O
,	322	323	|O
represent	324	333	|O
the	334	337	|O
continuation	338	350	|O
of	351	353	|O
our	354	357	|O
research	358	366	|O
on	367	369	|O
N	370	371	|B-IUPAC
-	371	372	|I-IUPAC
benzylindol	372	383	|I-IUPAC
-	383	384	|I-IUPAC
3	384	385	|I-IUPAC
-	385	386	|I-IUPAC
ylglyoxylylamides	386	403	|I-IUPAC
1	404	405	|O
(	406	407	|O
Da	407	409	|O
Settimo	410	417	|O
et	418	420	|O
al.	421	424	|O
,	424	425	|O
1996	426	430	|O
)	430	431	|O
,	431	432	|O
N'	433	435	|B-IUPAC
-	435	436	|I-IUPAC
phenylindol	436	447	|I-IUPAC
-	447	448	|I-IUPAC
3	448	449	|I-IUPAC
-	449	450	|I-IUPAC
ylglyoxylohydrazides	450	470	|I-IUPAC
2	471	472	|O
(	473	474	|O
Da	474	476	|O
Settimo	477	484	|O
et	485	487	|O
al.	488	491	|O
,	491	492	|O
1998	493	497	|O
)	497	498	|O
,	498	499	|O
and	500	503	|O
N	504	505	|B-IUPAC
-	505	506	|I-IUPAC
(	506	507	|I-IUPAC
indol	507	512	|I-IUPAC
-	512	513	|I-IUPAC
3	513	514	|I-IUPAC
-	514	515	|I-IUPAC
ylglyoxylyl	515	526	|I-IUPAC
)	526	527	|I-IUPAC
alanine	527	534	|I-IUPAC
derivatives	535	546	|B-MODIFIER
3	547	548	|O
(	549	550	|O
Primofiore	550	560	|O
et	561	563	|O
al.	564	567	|O
,	567	568	|O
1989	569	573	|O
)	573	574	|O
.	574	575	|O
A	576	577	|O
few	578	581	|O
indoles	582	589	|O
belonging	590	599	|O
to	600	602	|O
the	603	606	|O
previously	607	617	|O
investigated	618	630	|O
benzylamides	631	643	|O
1	644	645	|O
and	646	649	|O
phenylhydrazides	650	666	|O
2	667	668	|O
were	669	673	|O
synthesized	674	685	|O
and	686	689	|O
tested	690	696	|O
to	697	699	|O
enrich	700	706	|O
the	707	710	|O
SARs	711	715	|O
in	716	718	|O
these	719	724	|O
two	725	728	|O
series	729	735	|O
.	735	736	|O
The	737	740	|O
affinities	741	751	|O
and	752	755	|O
the	756	759	|O
GABA	760	764	|O
ratios	765	771	|O
of	772	774	|O
selected	775	783	|O
compounds	784	793	|O
for	794	797	|O
clonal	798	804	|O
mammalian	805	814	|O
alpha	815	820	|O
(	820	821	|O
1	821	822	|O
)	822	823	|O
beta	823	827	|O
(	827	828	|O
2	828	829	|O
)	829	830	|O
gamma	830	835	|O
(	835	836	|O
2	836	837	|O
)	837	838	|O
,	838	839	|O
alpha	840	845	|O
(	845	846	|O
3	846	847	|O
)	847	848	|O
beta	848	852	|O
(	852	853	|O
2	853	854	|O
)	854	855	|O
gamma	855	860	|O
(	860	861	|O
2	861	862	|O
)	862	863	|O
,	863	864	|O
and	865	868	|O
alpha	869	874	|O
(	874	875	|O
5	875	876	|O
)	876	877	|O
beta	877	881	|O
(	881	882	|O
3	882	883	|O
)	883	884	|O
gamma	884	889	|O
(	889	890	|O
2	890	891	|O
)	891	892	|O
BzR	893	896	|O
subtypes	897	905	|O
were	906	910	|O
also	911	915	|O
determined	916	926	|O
.	926	927	|O
It	928	930	|O
was	931	934	|O
hypothesized	935	947	|O
that	948	952	|O
the	953	956	|O
reduced	957	964	|O
flexibility	965	976	|O
of	977	979	|O
indoles	980	987	|O
4-8	988	991	|O
would	992	997	|O
both	998	1002	|O
facilitate	1003	1013	|O
the	1014	1017	|O
mapping	1018	1025	|O
of	1026	1028	|O
the	1029	1032	|O
BzR	1033	1036	|O
binding	1037	1044	|O
cleft	1045	1050	|O
and	1051	1054	|O
increase	1055	1063	|O
the	1064	1067	|O
chances	1068	1075	|O
of	1076	1078	|O
conferring	1079	1089	|O
selectivity	1090	1101	|O
for	1102	1105	|O
the	1106	1109	|O
considered	1110	1120	|O
receptor	1121	1129	|O
subtypes	1130	1138	|O
.	1138	1139	|O
In	1140	1142	|O
the	1143	1146	|O
series	1147	1153	|O
of	1154	1156	|O
indoles	1157	1164	|O
4	1165	1166	|O
,	1166	1167	|O
the	1168	1171	|O
introduction	1172	1184	|O
of	1185	1187	|O
a	1188	1189	|O
methyl	1190	1196	|B-IUPAC
group	1197	1202	|B-MODIFIER
on	1203	1205	|O
the	1206	1209	|O
benzylic	1210	1218	|O
carbon	1219	1225	|O
with	1226	1230	|O
the	1231	1234	|O
R	1235	1236	|O
configuration	1237	1250	|O
improved	1251	1259	|O
affinity	1260	1268	|O
of	1269	1271	|O
the	1272	1275	|O
5	1276	1277	|O
-	1277	1278	|O
substituted	1278	1289	|O
(	1290	1291	|O
5	1291	1292	|O
-	1292	1293	|O
Cl	1293	1295	|O
and	1296	1299	|O
5	1300	1301	|O
-	1301	1302	|O
NO	1302	1304	|O
(	1304	1305	|O
2	1305	1306	|O
)	1306	1307	|O
)	1307	1308	|O
derivatives	1309	1320	|O
,	1320	1321	|O
whereas	1322	1329	|O
it	1330	1332	|O
was	1333	1336	|O
detrimental	1337	1348	|O
for	1349	1352	|O
their	1353	1358	|O
5	1359	1360	|O
-	1360	1361	|O
unsubtituted	1361	1373	|O
(	1374	1375	|O
5	1375	1376	|O
-	1376	1377	|O
H	1377	1378	|O
)	1378	1379	|O
counterparts	1380	1392	|O
.	1392	1393	|O
All	1394	1397	|O
S	1398	1399	|O
enantiomers	1400	1411	|O
were	1412	1416	|O
less	1417	1421	|O
potent	1422	1428	|O
than	1429	1433	|O
the	1434	1437	|O
R	1438	1439	|O
ones	1440	1444	|O
.	1444	1445	|O
Replacement	1446	1457	|O
of	1458	1460	|O
the	1461	1464	|O
methyl	1465	1471	|O
with	1472	1476	|O
hydrophilic	1477	1488	|O
substituents	1489	1501	|O
on	1502	1504	|O
the	1505	1508	|O
benzylic	1509	1517	|O
carbon	1518	1524	|O
lowered	1525	1532	|O
affinity	1533	1541	|O
.	1541	1542	|O
The	1543	1546	|O
isoindolinylamide	1547	1564	|B-IUPAC
side	1565	1569	|B-MODIFIER
chain	1570	1575	|I-MODIFIER
was	1576	1579	|O
tolerated	1580	1589	|O
if	1590	1592	|O
the	1593	1596	|O
5	1597	1598	|O
-	1598	1599	|O
position	1599	1607	|O
was	1608	1611	|O
unsubstituted	1612	1625	|O
(	1626	1627	|O
K	1627	1628	|O
(	1628	1629	|O
i	1629	1630	|O
)	1630	1631	|O
of	1632	1634	|O
5a	1635	1637	|O
=	1638	1639	|O
123	1640	1643	|O
nM	1644	1646	|O
)	1646	1647	|O
,	1647	1648	|O
otherwise	1649	1658	|O
affinity	1659	1667	|O
was	1668	1671	|O
abolished	1672	1681	|O
(	1682	1683	|O
5b	1683	1685	|O
,	1685	1686	|O
c	1687	1688	|O
)	1688	1689	|O
.	1689	1690	|O
All	1691	1694	|O
the	1695	1698	|O
2	1699	1700	|B-IUPAC
-	1700	1701	|I-IUPAC
indanylamides	1701	1714	|I-IUPAC
6	1715	1716	|O
and	1717	1720	|O
(	1721	1722	|B-IUPAC
S	1722	1723	|I-IUPAC
)	1723	1724	|I-IUPAC
-	1724	1725	|I-IUPAC
1	1725	1726	|I-IUPAC
-	1726	1727	|I-IUPAC
indanylamides	1727	1740	|I-IUPAC
8	1741	1742	|O
were	1743	1747	|O
devoid	1748	1754	|O
of	1755	1757	|O
any	1758	1761	|O
appreciable	1762	1773	|O
affinity	1774	1782	|O
.	1782	1783	|O
The	1784	1787	|O
5	1788	1789	|B-PARTIUPAC
-	1789	1790	|I-PARTIUPAC
Cl	1790	1792	|I-PARTIUPAC
and	1793	1796	|O
5	1797	1798	|B-IUPAC
-	1798	1799	|I-IUPAC
NO	1799	1801	|I-IUPAC
(	1801	1802	|I-IUPAC
2	1802	1803	|I-IUPAC
)	1803	1804	|I-IUPAC
(	1805	1806	|I-IUPAC
R	1806	1807	|I-IUPAC
)	1807	1808	|I-IUPAC
-	1808	1809	|I-IUPAC
1	1809	1810	|I-IUPAC
-	1810	1811	|I-IUPAC
indanylamides	1811	1824	|I-IUPAC
7b	1825	1827	|O
(	1828	1829	|O
K	1829	1830	|O
(	1830	1831	|O
i	1831	1832	|O
)	1832	1833	|O
80	1834	1836	|O
nM	1837	1839	|O
)	1839	1840	|O
and	1841	1844	|O
7c	1845	1847	|O
(	1848	1849	|O
K	1849	1850	|O
(	1850	1851	|O
i	1851	1852	|O
)	1852	1853	|O
28	1854	1856	|O
nM	1857	1859	|O
)	1859	1860	|O
were	1861	1865	|O
the	1866	1869	|O
most	1870	1874	|O
potent	1875	1881	|O
among	1882	1887	|O
the	1888	1891	|O
indoles	1892	1899	|O
5-8	1900	1903	|O
geometrically	1904	1917	|O
constrained	1918	1929	|O
about	1930	1935	|O
the	1936	1939	|O
side	1940	1944	|O
chain	1945	1950	|O
.	1950	1951	|O
The	1952	1955	|O
5	1956	1957	|B-IUPAC
-	1957	1958	|I-IUPAC
H	1958	1959	|I-IUPAC
(	1960	1961	|I-IUPAC
R	1961	1962	|I-IUPAC
)	1962	1963	|I-IUPAC
-	1963	1964	|I-IUPAC
1	1964	1965	|I-IUPAC
-	1965	1966	|I-IUPAC
indanylamide	1966	1978	|I-IUPAC
7a	1979	1981	|O
displayed	1982	1991	|O
a	1992	1993	|O
lower	1994	1999	|O
affinity	2000	2008	|O
(	2009	2010	|O
K	2010	2011	|O
(	2011	2012	|O
i	2012	2013	|O
)	2013	2014	|O
675	2015	2018	|O
nM	2019	2021	|O
)	2021	2022	|O
.	2022	2023	|O
The	2024	2027	|O
SARs	2028	2032	|O
developed	2033	2042	|O
from	2043	2047	|O
the	2048	2051	|O
new	2052	2055	|O
compounds	2056	2065	|O
,	2065	2066	|O
together	2067	2075	|O
with	2076	2080	|O
those	2081	2086	|O
collected	2087	2096	|O
from	2097	2101	|O
our	2102	2105	|O
previous	2106	2114	|O
studies	2115	2122	|O
,	2122	2123	|O
confirmed	2124	2133	|O
the	2134	2137	|O
hypothesis	2138	2148	|O
of	2149	2151	|O
different	2152	2161	|O
binding	2162	2169	|O
modes	2170	2175	|O
for	2176	2179	|O
5	2180	2181	|O
-	2181	2182	|O
substituted	2182	2193	|O
and	2194	2197	|O
5	2198	2199	|O
-	2199	2200	|O
unsubstituted	2200	2213	|O
indoles	2214	2221	|O
,	2221	2222	|O
suggesting	2223	2233	|O
that	2234	2238	|O
the	2239	2242	|O
shape	2243	2248	|O
of	2249	2251	|O
the	2252	2255	|O
lipophilic	2256	2266	|O
pocket	2267	2273	|O
L	2274	2275	|O
(	2275	2276	|O
1	2276	2277	|O
)	2277	2278	|O
(	2279	2280	|O
notation	2280	2288	|O
in	2289	2291	|O
accordance	2292	2302	|O
with	2303	2307	|O
Cook	2308	2312	|O
's	2312	2314	|O
BzR	2315	2318	|O
topological	2319	2330	|O
model	2331	2336	|O
)	2336	2337	|O
is	2338	2340	|O
asymmetric	2341	2351	|O
and	2352	2355	|O
highlighted	2356	2367	|O
the	2368	2371	|O
stereoelectronic	2372	2388	|O
and	2389	2392	|O
conformational	2393	2407	|O
properties	2408	2418	|O
of	2419	2421	|O
the	2422	2425	|O
amide	2426	2431	|O
side	2432	2436	|O
chain	2437	2442	|O
required	2443	2451	|O
for	2452	2455	|O
high	2456	2460	|O
potency	2461	2468	|O
.	2468	2469	|O
Several	2470	2477	|O
of	2478	2480	|O
the	2481	2484	|O
new	2485	2488	|O
indoles	2489	2496	|O
showed	2497	2503	|O
selectivity	2504	2515	|O
for	2516	2519	|O
the	2520	2523	|O
alpha	2524	2529	|O
(	2529	2530	|O
1	2530	2531	|O
)	2531	2532	|O
beta	2532	2536	|O
(	2536	2537	|O
2	2537	2538	|O
)	2538	2539	|O
gamma	2539	2544	|O
(	2544	2545	|O
2	2545	2546	|O
)	2546	2547	|O
subtype	2548	2555	|O
compared	2556	2564	|O
with	2565	2569	|O
the	2570	2573	|O
alpha	2574	2579	|O
(	2579	2580	|O
3	2580	2581	|O
)	2581	2582	|O
beta	2582	2586	|O
(	2586	2587	|O
2	2587	2588	|O
)	2588	2589	|O
gamma	2589	2594	|O
(	2594	2595	|O
2	2595	2596	|O
)	2596	2597	|O
and	2598	2601	|O
alpha	2602	2607	|O
(	2607	2608	|O
5	2608	2609	|O
)	2609	2610	|O
beta	2610	2614	|O
(	2614	2615	|O
3	2615	2616	|O
)	2616	2617	|O
gamma	2617	2622	|O
(	2622	2623	|O
2	2623	2624	|O
)	2624	2625	|O
subtypes	2626	2634	|O
(	2635	2636	|O
e.g.	2636	2640	|O
:	2640	2641	|O
4t	2642	2644	|O
and	2645	2648	|O
7c	2649	2651	|O
bind	2652	2656	|O
to	2657	2659	|O
these	2660	2665	|O
three	2666	2671	|O
BzR	2672	2675	|O
isoforms	2676	2684	|O
with	2685	2689	|O
K	2690	2691	|O
(	2691	2692	|O
i	2692	2693	|O
)	2693	2694	|O
values	2695	2701	|O
of	2702	2704	|O
14	2705	2707	|O
nM	2708	2710	|O
,	2710	2711	|O
283	2712	2715	|O
nM	2716	2718	|O
,	2718	2719	|O
239	2720	2723	|O
nM	2724	2726	|O
,	2726	2727	|O
and	2728	2731	|O
9	2732	2733	|O
nM	2734	2736	|O
,	2736	2737	|O
1960	2738	2742	|O
nM	2743	2745	|O
,	2745	2746	|O
95	2747	2749	|O
nM	2750	2752	|O
,	2752	2753	|O
respectively	2754	2766	|O
)	2766	2767	|O
.	2767	2768	|O
The	2769	2772	|O
GABA	2773	2777	|O
ratios	2778	2784	|O
close	2785	2790	|O
to	2791	2793	|O
unity	2794	2799	|O
exhibited	2800	2809	|O
by	2810	2812	|O
all	2813	2816	|O
the	2817	2820	|O
tested	2821	2827	|O
compounds	2828	2837	|O
on	2838	2840	|O
each	2841	2845	|O
BzR	2846	2849	|O
subtype	2850	2857	|O
were	2858	2862	|O
predictive	2863	2873	|O
of	2874	2876	|O
an	2877	2879	|O
efficacy	2880	2888	|O
profile	2889	2896	|O
typical	2897	2904	|O
of	2905	2907	|O
antagonists	2908	2919	|O
.	2919	2920	|O

### abstracts2135.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
new	12	15	|O
S	16	17	|B-IUPAC
-	17	18	|I-IUPAC
adenosyl	18	26	|I-IUPAC
-	26	27	|I-IUPAC
L	27	28	|I-IUPAC
-	28	29	|I-IUPAC
homocysteine	29	41	|I-IUPAC
(	42	43	|O
AdoHcy	43	49	|O
)	49	50	|O
analogues	51	60	|B-MODIFIER
with	61	65	|O
modifications	66	79	|O
to	80	82	|O
amino	83	88	|O
acid	89	93	|O
and	94	97	|O
nucleoside	98	108	|O
moieties	109	117	|O
was	118	121	|O
prepared	122	130	|O
via	131	134	|O
condensation	135	147	|O
of	148	150	|O
appropriate	151	162	|O
nucleoside	163	173	|O
precursors	174	184	|O
and	185	188	|O
suitably	189	197	|O
protected	198	207	|O
L	208	209	|O
-	209	210	|O
homocystine	210	221	|O
derivatives	222	233	|O
.	233	234	|O
The	235	238	|O
AdoHcy	239	245	|O
derivatives	246	257	|O
as	258	260	|O
well	261	265	|O
as	266	268	|O
the	269	272	|O
nucleoside	273	283	|O
precursors	284	294	|O
were	295	299	|O
evaluated	300	309	|O
for	310	313	|O
their	314	319	|O
antiviral	320	329	|O
activity	330	338	|O
.	338	339	|O
Some	340	344	|O
of	345	347	|O
the	348	351	|O
compounds	352	361	|O
,	361	362	|O
in	363	365	|O
particular	366	376	|O
S	377	378	|B-IUPAC
-	378	379	|I-IUPAC
tubercidinyl	379	391	|I-IUPAC
-	391	392	|I-IUPAC
L	392	393	|I-IUPAC
-	393	394	|I-IUPAC
homocysteine	394	406	|I-IUPAC
propyl	407	413	|I-IUPAC
ester	414	419	|I-IUPAC
(	420	421	|O
36	421	423	|O
)	423	424	|O
,	424	425	|O
N	426	427	|B-IUPAC
-	427	428	|I-IUPAC
(	428	429	|I-IUPAC
trifluoroacetyl	429	444	|I-IUPAC
)	444	445	|I-IUPAC
-	445	446	|I-IUPAC
S	446	447	|I-IUPAC
-	447	448	|I-IUPAC
tubercidinyl	448	460	|I-IUPAC
-	460	461	|I-IUPAC
L	461	462	|I-IUPAC
-	462	463	|I-IUPAC
homocysteine	463	475	|I-IUPAC
isopropyl	476	485	|I-IUPAC
ester	486	491	|I-IUPAC
(	492	493	|O
27	493	495	|O
)	495	496	|O
,	496	497	|O
S	498	499	|B-IUPAC
-	499	500	|I-IUPAC
3'	500	502	|I-IUPAC
-	502	503	|I-IUPAC
deoxytubercidinyl	503	520	|I-IUPAC
-	520	521	|I-IUPAC
L	521	522	|I-IUPAC
-	522	523	|I-IUPAC
homocysteine	523	535	|I-IUPAC
(	536	537	|O
58	537	539	|O
)	539	540	|O
,	540	541	|O
N	542	543	|B-IUPAC
-	543	544	|I-IUPAC
(	544	545	|I-IUPAC
trifluoracetyl	545	559	|I-IUPAC
)	559	560	|I-IUPAC
-	560	561	|I-IUPAC
S	561	562	|I-IUPAC
-	562	563	|I-IUPAC
tubercidinyl	563	575	|I-IUPAC
-	575	576	|I-IUPAC
L	576	577	|I-IUPAC
-	577	578	|I-IUPAC
homocysteine	578	590	|I-IUPAC
propyl	591	597	|I-IUPAC
ester	598	603	|I-IUPAC
(	604	605	|O
26	605	607	|O
)	607	608	|O
,	608	609	|O
and	610	613	|O
N	614	615	|B-IUPAC
-	615	616	|I-IUPAC
(	616	617	|I-IUPAC
methoxyacetyl	617	630	|I-IUPAC
)	630	631	|I-IUPAC
-	631	632	|I-IUPAC
S	632	633	|I-IUPAC
-	633	634	|I-IUPAC
tubercidinyl	634	646	|I-IUPAC
-	646	647	|I-IUPAC
L	647	648	|I-IUPAC
-	648	649	|I-IUPAC
homocysteine	649	661	|I-IUPAC
ethyl	662	667	|I-IUPAC
ester	668	673	|I-IUPAC
(	674	675	|O
31	675	677	|O
)	677	678	|O
showed	679	685	|O
potent	686	692	|O
and	693	696	|O
selective	697	706	|O
activity	707	715	|O
against	716	723	|O
HSV	724	727	|O
,	727	728	|O
VV	729	731	|O
,	731	732	|O
and	733	736	|O
VSV	737	740	|O
.	740	741	|O
It	742	744	|O
is	745	747	|O
likely	748	754	|O
that	755	759	|O
they	760	764	|O
exert	765	770	|O
their	771	776	|O
antiviral	777	786	|O
effect	787	793	|O
via	794	797	|O
selective	798	807	|O
inhibition	808	818	|O
of	819	821	|O
the	822	825	|O
methyltransferases	826	844	|O
which	845	850	|O
are	851	854	|O
required	855	863	|O
for	864	867	|O
the	868	871	|O
maturation	872	882	|O
of	883	885	|O
viral	886	891	|O
mRNAs	892	897	|O
.	897	898	|O

### abstracts2700.txt
As	0	2	|O
part	3	7	|O
of	8	10	|O
a	11	12	|O
search	13	19	|O
for	20	23	|O
dihydrofolate	24	37	|O
reductase	38	47	|O
(	48	49	|O
DHFR	49	53	|O
)	53	54	|O
inhibitors	55	65	|O
combining	66	75	|O
the	76	79	|O
high	80	84	|O
potency	85	92	|O
of	93	95	|O
piritrexim	96	106	|O
(	107	108	|O
PTX	108	111	|O
)	111	112	|O
with	113	117	|O
the	118	121	|O
high	122	126	|O
antiparasitic	127	140	|O
vs	141	143	|O
mammalian	144	153	|O
selectivity	154	165	|O
of	166	168	|O
trimethoprim	169	181	|O
(	182	183	|O
TMP	183	186	|O
)	186	187	|O
,	187	188	|O
the	189	192	|O
heretofore	193	203	|O
undescribed	204	215	|O
2,4	216	219	|B-PARTIUPAC
-	219	220	|I-PARTIUPAC
diamino	220	227	|I-PARTIUPAC
-	227	228	|I-PARTIUPAC
6	228	229	|I-PARTIUPAC
-	229	230	|I-PARTIUPAC
(	230	231	|I-PARTIUPAC
2'	231	233	|B-MODIFIER
,	233	234	|I-MODIFIER
5'	234	236	|I-MODIFIER
-	236	237	|I-MODIFIER
disubstituted	237	250	|I-MODIFIER
benzyl	251	257	|B-PARTIUPAC
)	257	258	|I-PARTIUPAC
pyrido	258	264	|I-PARTIUPAC
[	264	265	|I-PARTIUPAC
2,3	265	268	|I-PARTIUPAC
-	268	269	|I-PARTIUPAC
d	269	270	|I-PARTIUPAC
]	270	271	|I-PARTIUPAC
pyrimidines	271	282	|I-PARTIUPAC
6-14	283	287	|O
with	288	292	|O
O	293	294	|B-IUPAC
-	294	295	|I-IUPAC
(	295	296	|I-IUPAC
omega	296	301	|I-IUPAC
-	301	302	|I-IUPAC
carboxyalkyl	302	314	|I-IUPAC
)	314	315	|I-IUPAC
or	316	318	|O
omega	319	324	|B-IUPAC
-	324	325	|I-IUPAC
carboxy	325	332	|I-IUPAC
-	332	333	|I-IUPAC
1	333	334	|I-IUPAC
-	334	335	|I-IUPAC
alkynyl	335	342	|I-IUPAC
groups	343	349	|B-MODIFIER
on	350	352	|O
the	353	356	|O
benzyl	357	363	|B-IUPAC
moiety	364	370	|B-MODIFIER
were	371	375	|O
synthesized	376	387	|O
and	388	391	|O
tested	392	398	|O
against	399	406	|O
Pneumocystis	407	419	|O
carinii	420	427	|O
,	427	428	|O
Toxoplasma	429	439	|O
gondii	440	446	|O
,	446	447	|O
and	448	451	|O
Mycobacterium	452	465	|O
avium	466	471	|O
DHFR	472	476	|O
vs	477	479	|O
rat	480	483	|O
DHFR	484	488	|O
.	488	489	|O
Three	490	495	|O
N	496	497	|B-IUPAC
-	497	498	|I-IUPAC
(	498	499	|I-IUPAC
2,4	499	502	|I-IUPAC
-	502	503	|I-IUPAC
diaminopteridin	503	518	|I-IUPAC
-	518	519	|I-IUPAC
6	519	520	|I-IUPAC
-	520	521	|I-IUPAC
yl	521	523	|I-IUPAC
)	523	524	|I-IUPAC
methyl	524	530	|I-IUPAC
)	530	531	|I-IUPAC
-	531	532	|I-IUPAC
2'	532	534	|I-IUPAC
-	534	535	|I-IUPAC
(	535	536	|I-IUPAC
omega	536	541	|I-IUPAC
-	541	542	|I-IUPAC
carboxy	542	549	|I-IUPAC
-	549	550	|I-IUPAC
1	550	551	|I-IUPAC
-	551	552	|I-IUPAC
alkynyl	552	559	|I-IUPAC
)	559	560	|I-IUPAC
dibenz	560	566	|I-IUPAC
[	566	567	|I-IUPAC
b	567	568	|I-IUPAC
,	568	569	|I-IUPAC
f	569	570	|I-IUPAC
]	570	571	|I-IUPAC
azepines	571	579	|I-IUPAC
(	580	581	|O
19-21	581	586	|O
)	586	587	|O
were	588	592	|O
also	593	597	|O
synthesized	598	609	|O
and	610	613	|O
tested	614	620	|O
.	620	621	|O
The	622	625	|O
pyridopyrimidine	626	642	|O
with	643	647	|O
the	648	651	|O
best	652	656	|O
combination	657	668	|O
of	669	671	|O
potency	672	679	|O
and	680	683	|O
selectivity	684	695	|O
was	696	699	|O
2,4	700	703	|B-IUPAC
-	703	704	|I-IUPAC
diamino	704	711	|I-IUPAC
-	711	712	|I-IUPAC
5	712	713	|I-IUPAC
-	713	714	|I-IUPAC
methyl	714	720	|I-IUPAC
-	720	721	|I-IUPAC
6	721	722	|I-IUPAC
-	722	723	|I-IUPAC
[	723	724	|I-IUPAC
2'	724	726	|I-IUPAC
-	726	727	|I-IUPAC
(	727	728	|I-IUPAC
5	728	729	|I-IUPAC
-	729	730	|I-IUPAC
carboxy	730	737	|I-IUPAC
-	737	738	|I-IUPAC
1	738	739	|I-IUPAC
-	739	740	|I-IUPAC
butynyl	740	747	|I-IUPAC
)	747	748	|I-IUPAC
-	748	749	|I-IUPAC
5'	749	751	|I-IUPAC
-	751	752	|I-IUPAC
methoxy	752	759	|I-IUPAC
]	759	760	|I-IUPAC
benzyl	760	766	|I-IUPAC
]	766	767	|I-IUPAC
pyrimidine	767	777	|I-IUPAC
(	778	779	|O
13	779	781	|O
)	781	782	|O
,	782	783	|O
with	784	788	|O
an	789	791	|O
IC	792	794	|O
(	794	795	|O
50	795	797	|O
)	797	798	|O
value	799	804	|O
of	805	807	|O
0.65	808	812	|O
nM	813	815	|O
against	816	823	|O
P	824	825	|O
.	825	826	|O
carinii	827	834	|O
DHFR	835	839	|O
,	839	840	|O
0.57	841	845	|O
nM	846	848	|O
against	849	856	|O
M	857	858	|O
.	858	859	|O
avium	860	865	|O
DHFR	866	870	|O
,	870	871	|O
and	872	875	|O
55	876	878	|O
nM	879	881	|O
against	882	889	|O
rat	890	893	|O
DHFR	894	898	|O
.	898	899	|O
The	900	903	|O
potency	904	911	|O
of	912	914	|O
13	915	917	|O
against	918	925	|O
P	926	927	|O
.	927	928	|O
carinii	929	936	|O
DHFR	937	941	|O
was	942	945	|O
20	946	948	|O
-	948	949	|O
fold	949	953	|O
greater	954	961	|O
than	962	966	|O
that	967	971	|O
of	972	974	|O
PTX	975	978	|O
(	979	980	|O
IC	980	982	|O
(	982	983	|O
50	983	985	|O
)	985	986	|O
=	987	988	|O
13	989	991	|O
nM	992	994	|O
)	994	995	|O
,	995	996	|O
and	997	1000	|O
its	1001	1004	|O
selectivity	1005	1016	|O
index	1017	1022	|O
(	1023	1024	|O
SI	1024	1026	|O
)	1026	1027	|O
relative	1028	1036	|O
to	1037	1039	|O
rat	1040	1043	|O
DHFR	1044	1048	|O
was	1049	1052	|O
85	1053	1055	|O
,	1055	1056	|O
whereas	1057	1064	|O
PTX	1065	1068	|O
was	1069	1072	|O
nonselective	1073	1085	|O
.	1085	1086	|O
The	1087	1090	|O
activity	1091	1099	|O
of	1100	1102	|O
13	1103	1105	|O
against	1106	1113	|O
P	1114	1115	|O
.	1115	1116	|O
carinii	1117	1124	|O
DHFR	1125	1129	|O
was	1130	1133	|O
20	1134	1136	|O
000	1137	1140	|O
times	1141	1146	|O
greater	1147	1154	|O
than	1155	1159	|O
that	1160	1164	|O
of	1165	1167	|O
TMP	1168	1171	|O
,	1171	1172	|O
with	1173	1177	|O
an	1178	1180	|O
SI	1181	1183	|O
of	1184	1186	|O
96	1187	1189	|O
,	1189	1190	|O
whereas	1191	1198	|O
that	1199	1203	|O
of	1204	1206	|O
TMP	1207	1210	|O
was	1211	1214	|O
only	1215	1219	|O
14	1220	1222	|O
.	1222	1223	|O
However	1224	1231	|O
13	1232	1234	|O
was	1235	1238	|O
no	1239	1241	|O
more	1242	1246	|O
potent	1247	1253	|O
than	1254	1258	|O
PTX	1259	1262	|O
against	1263	1270	|O
M	1271	1272	|O
.	1272	1273	|O
avium	1274	1279	|O
DHFR	1280	1284	|O
,	1284	1285	|O
and	1286	1289	|O
its	1290	1293	|O
SI	1294	1296	|O
was	1297	1300	|O
no	1301	1303	|O
better	1304	1310	|O
than	1311	1315	|O
that	1316	1320	|O
of	1321	1323	|O
TMP	1324	1327	|O
.	1327	1328	|O
Molecular	1329	1338	|O
modeling	1339	1347	|O
dynamics	1348	1356	|O
studies	1357	1364	|O
using	1365	1370	|O
compounds	1371	1380	|O
10	1381	1383	|O
and	1384	1387	|O
13	1388	1390	|O
indicated	1391	1400	|O
a	1401	1402	|O
slight	1403	1409	|O
binding	1410	1417	|O
preference	1418	1428	|O
for	1429	1432	|O
the	1433	1436	|O
latter	1437	1443	|O
,	1443	1444	|O
in	1445	1447	|O
qualitative	1448	1459	|O
agreement	1460	1469	|O
with	1470	1474	|O
the	1475	1478	|O
IC	1479	1481	|O
(	1481	1482	|O
50	1482	1484	|O
)	1484	1485	|O
data	1486	1490	|O
.	1490	1491	|O
Among	1492	1497	|O
the	1498	1501	|O
pteridines	1502	1512	|O
,	1512	1513	|O
the	1514	1517	|O
most	1518	1522	|O
potent	1523	1529	|O
against	1530	1537	|O
P	1538	1539	|O
.	1539	1540	|O
carinii	1541	1548	|O
DHFR	1549	1553	|O
and	1554	1557	|O
M	1558	1559	|O
.	1559	1560	|O
avium	1561	1566	|O
DHFR	1567	1571	|O
was	1572	1575	|O
the	1576	1579	|O
2'	1580	1582	|B-IUPAC
-	1582	1583	|I-IUPAC
(	1583	1584	|I-IUPAC
5	1584	1585	|I-IUPAC
-	1585	1586	|I-IUPAC
carboxy	1586	1593	|I-IUPAC
-	1593	1594	|I-IUPAC
1	1594	1595	|I-IUPAC
-	1595	1596	|I-IUPAC
butynyl	1596	1603	|I-IUPAC
)	1603	1604	|I-IUPAC
dibenz	1604	1610	|I-IUPAC
[	1610	1611	|I-IUPAC
b	1611	1612	|I-IUPAC
,	1612	1613	|I-IUPAC
f	1613	1614	|I-IUPAC
]	1614	1615	|I-IUPAC
azepinyl	1615	1623	|I-IUPAC
derivative	1624	1634	|B-MODIFIER
20	1635	1637	|O
(	1638	1639	|O
IC	1639	1641	|O
(	1641	1642	|O
50	1642	1644	|O
)	1644	1645	|O
=	1646	1647	|O
2.9	1648	1651	|O
nM	1652	1654	|O
)	1654	1655	|O
,	1655	1656	|O
whereas	1657	1664	|O
the	1665	1668	|O
most	1669	1673	|O
selective	1674	1683	|O
was	1684	1687	|O
the	1688	1691	|O
2'	1692	1694	|B-IUPAC
-	1694	1695	|I-IUPAC
(	1695	1696	|I-IUPAC
5	1696	1697	|I-IUPAC
-	1697	1698	|I-IUPAC
carboxy	1698	1705	|I-IUPAC
-	1705	1706	|I-IUPAC
1	1706	1707	|I-IUPAC
-	1707	1708	|I-IUPAC
pentynyl	1708	1716	|I-IUPAC
)	1716	1717	|I-IUPAC
analogue	1718	1726	|B-MODIFIER
21	1727	1729	|O
,	1729	1730	|O
with	1731	1735	|O
SI	1736	1738	|O
values	1739	1745	|O
of	1746	1748	|O
&	1749	1750	|O
gt	1750	1752	|O
;	1752	1753	|O
100	1753	1756	|O
against	1757	1764	|O
both	1765	1769	|O
P	1770	1771	|O
.	1771	1772	|O
carinii	1773	1780	|O
and	1781	1784	|O
M	1785	1786	|O
.	1786	1787	|O
avium	1788	1793	|O
DHFR	1794	1798	|O
relative	1799	1807	|O
to	1808	1810	|O
rat	1811	1814	|O
DHFR	1815	1819	|O
.	1819	1820	|O
The	1821	1824	|O
final	1825	1830	|O
compound	1831	1839	|O
,	1839	1840	|O
2,4	1841	1844	|B-IUPAC
-	1844	1845	|I-IUPAC
diamino	1845	1852	|I-IUPAC
-	1852	1853	|I-IUPAC
5	1853	1854	|I-IUPAC
-	1854	1855	|I-IUPAC
[	1855	1856	|I-IUPAC
3'	1856	1858	|I-IUPAC
-	1858	1859	|I-IUPAC
(	1859	1860	|I-IUPAC
4	1860	1861	|I-IUPAC
-	1861	1862	|I-IUPAC
carboxy	1862	1869	|I-IUPAC
-	1869	1870	|I-IUPAC
1	1870	1871	|I-IUPAC
-	1871	1872	|I-IUPAC
butynyl	1872	1879	|I-IUPAC
)	1879	1880	|I-IUPAC
-	1880	1881	|I-IUPAC
4'	1881	1883	|I-IUPAC
-	1883	1884	|I-IUPAC
bromo	1884	1889	|I-IUPAC
-	1889	1890	|I-IUPAC
5'	1890	1892	|I-IUPAC
-	1892	1893	|I-IUPAC
methoxybenzyl	1893	1906	|I-IUPAC
]	1906	1907	|I-IUPAC
pyrimidine	1907	1917	|I-IUPAC
(	1918	1919	|O
22	1919	1921	|O
)	1921	1922	|O
,	1922	1923	|O
was	1924	1927	|O
both	1928	1932	|O
potent	1933	1939	|O
and	1940	1943	|O
selective	1944	1953	|O
against	1954	1961	|O
M	1962	1963	|O
.	1963	1964	|O
avium	1965	1970	|O
DHFR	1971	1975	|O
(	1976	1977	|O
IC	1977	1979	|O
(	1979	1980	|O
50	1980	1982	|O
)	1982	1983	|O
=	1984	1985	|O
0.47	1986	1990	|O
nM	1991	1993	|O
,	1993	1994	|O
SI	1995	1997	|O
=	1998	1999	|O
1300	2000	2004	|O
)	2004	2005	|O
but	2006	2009	|O
was	2010	2013	|O
not	2014	2017	|O
potent	2018	2024	|O
or	2025	2027	|O
selective	2028	2037	|O
against	2038	2045	|O
either	2046	2052	|O
P	2053	2054	|O
.	2054	2055	|O
carinii	2056	2063	|O
or	2064	2066	|O
T	2067	2068	|O
.	2068	2069	|O
gondii	2070	2076	|O
DHFR	2077	2081	|O
.	2081	2082	|O

### abstracts688.txt
6	0	1	|B-IUPAC
-	1	2	|I-IUPAC
Hydroxypyrimidines	2	20	|I-IUPAC
substituted	21	32	|B-MODIFIER
at	33	35	|O
positions	36	45	|O
2	46	47	|O
and	48	51	|O
4	52	53	|O
by	54	56	|O
hydrogen	57	65	|O
,	65	66	|O
methyl	67	73	|O
,	73	74	|O
amino	75	80	|O
,	80	81	|O
cyclopropylamino	82	98	|O
,	98	99	|O
dimethylamino	100	113	|O
,	113	114	|O
methylsulfanyl	115	129	|O
,	129	130	|O
or	131	133	|O
hydroxyl	134	142	|O
group	143	148	|O
afford	149	155	|O
by	156	158	|O
the	159	162	|O
reaction	163	171	|O
with	172	176	|O
diisopropyl	177	188	|B-IUPAC
2	189	190	|I-IUPAC
-	190	191	|I-IUPAC
(	191	192	|I-IUPAC
chloroethoxy	192	204	|I-IUPAC
)	204	205	|I-IUPAC
methylphosphonate	205	222	|I-IUPAC
in	223	225	|O
the	226	229	|O
presence	230	238	|O
of	239	241	|O
NaH	242	245	|O
,	245	246	|O
Cs	247	249	|O
(	249	250	|O
2	250	251	|O
)	251	252	|O
CO	252	254	|O
(	254	255	|O
3	255	256	|O
)	256	257	|O
,	257	258	|O
or	259	261	|O
DBU	262	265	|O
a	266	267	|O
mixture	268	275	|O
of	276	278	|O
N	279	280	|B-PARTIUPAC
(	280	281	|I-PARTIUPAC
1	281	282	|I-PARTIUPAC
)	282	283	|I-PARTIUPAC
-	283	284	|I-PARTIUPAC
and	285	288	|O
O	289	290	|B-IUPAC
(	290	291	|I-IUPAC
6	291	292	|I-IUPAC
)	292	293	|I-IUPAC
-	293	294	|I-IUPAC
[	294	295	|I-IUPAC
2	295	296	|I-IUPAC
-	296	297	|I-IUPAC
(	297	298	|I-IUPAC
diisopropylphosphorylmethoxy	298	326	|I-IUPAC
)	326	327	|I-IUPAC
ethyl	327	332	|I-IUPAC
]	332	333	|I-IUPAC
isomers	334	341	|B-MODIFIER
which	342	347	|O
were	348	352	|O
converted	353	362	|O
to	363	365	|O
the	366	369	|O
free	370	374	|O
phosphonic	375	385	|O
acids	386	391	|O
by	392	394	|O
treatment	395	404	|O
with	405	409	|O
bromotrimethylsilane	410	430	|O
followed	431	439	|O
by	440	442	|O
hydrolysis	443	453	|O
.	453	454	|O
Analogously	455	466	|O
,	466	467	|O
2,4	468	471	|B-IUPAC
-	471	472	|I-IUPAC
diamino	472	479	|I-IUPAC
-	479	480	|I-IUPAC
6	480	481	|I-IUPAC
-	481	482	|I-IUPAC
hydroxypyrimidine	482	499	|I-IUPAC
gave	500	504	|O
on	505	507	|O
reaction	508	516	|O
with	517	521	|O
[	522	523	|O
(	523	524	|B-PARTIUPAC
R	524	525	|I-PARTIUPAC
)	525	526	|I-PARTIUPAC
-	526	527	|I-PARTIUPAC
and	528	531	|O
(	532	533	|B-IUPAC
S	533	534	|I-IUPAC
)	534	535	|I-IUPAC
-	535	536	|I-IUPAC
2	536	537	|I-IUPAC
-	537	538	|I-IUPAC
(	538	539	|I-IUPAC
diisopropylphosphorylmethoxy	539	567	|I-IUPAC
)	567	568	|I-IUPAC
propyl	568	574	|I-IUPAC
]	574	575	|O
tosylate	576	584	|B-MODIFIER
,	584	585	|O
followed	586	594	|O
by	595	597	|O
deprotection	598	610	|O
,	610	611	|O
the	612	615	|O
enantiomeric	616	628	|O
6	629	630	|B-IUPAC
-	630	631	|I-IUPAC
[	631	632	|I-IUPAC
2	632	633	|I-IUPAC
-	633	634	|I-IUPAC
(	634	635	|I-IUPAC
phosphonomethoxy	635	651	|I-IUPAC
)	651	652	|I-IUPAC
propoxy	652	659	|I-IUPAC
]	659	660	|I-IUPAC
pyrimidines	660	671	|I-IUPAC
.	671	672	|O
2,4	673	676	|B-IUPAC
-	676	677	|I-IUPAC
Diamino	677	684	|I-IUPAC
-	684	685	|I-IUPAC
6	685	686	|I-IUPAC
-	686	687	|I-IUPAC
sulfanylpyrimidine	687	705	|I-IUPAC
gave	706	710	|O
,	710	711	|O
on	712	714	|O
treatment	715	724	|O
with	725	729	|O
diisopropyl	730	741	|B-IUPAC
2	742	743	|I-IUPAC
-	743	744	|I-IUPAC
(	744	745	|I-IUPAC
chloroethoxy	745	757	|I-IUPAC
)	757	758	|I-IUPAC
methylphosphonate	758	775	|I-IUPAC
in	776	778	|O
the	779	782	|O
presence	783	791	|O
of	792	794	|O
NaH	795	798	|O
and	799	802	|O
subsequent	803	813	|O
deprotection	814	826	|O
,	826	827	|O
2,4	828	831	|B-IUPAC
-	831	832	|I-IUPAC
diamino	832	839	|I-IUPAC
-	839	840	|I-IUPAC
6	840	841	|I-IUPAC
-	841	842	|I-IUPAC
[	842	843	|I-IUPAC
[	843	844	|I-IUPAC
2	844	845	|I-IUPAC
-	845	846	|I-IUPAC
(	846	847	|I-IUPAC
phosphonomethoxy	847	863	|I-IUPAC
)	863	864	|I-IUPAC
ethyl	864	869	|I-IUPAC
]	869	870	|I-IUPAC
sulfanyl	870	878	|I-IUPAC
]	878	879	|I-IUPAC
pyrimidine	879	889	|I-IUPAC
.	889	890	|O
2	891	892	|B-IUPAC
-	892	893	|I-IUPAC
Amino	893	898	|I-IUPAC
-	898	899	|I-IUPAC
4	899	900	|I-IUPAC
-	900	901	|I-IUPAC
hydroxy	901	908	|I-IUPAC
-	908	909	|I-IUPAC
6	909	910	|I-IUPAC
-	910	911	|I-IUPAC
[	911	912	|I-IUPAC
2	912	913	|I-IUPAC
-	913	914	|I-IUPAC
(	914	915	|I-IUPAC
phosphonomethoxy	915	931	|I-IUPAC
)	931	932	|I-IUPAC
ethyl	932	937	|I-IUPAC
]	937	938	|I-IUPAC
pyrimidine	938	948	|I-IUPAC
was	949	952	|O
obtained	953	961	|O
from	962	966	|O
the	967	970	|O
appropriate	971	982	|O
2	983	984	|B-IUPAC
-	984	985	|I-IUPAC
amino	985	990	|I-IUPAC
-	990	991	|I-IUPAC
4	991	992	|I-IUPAC
-	992	993	|I-IUPAC
chloropyrimidine	993	1009	|I-IUPAC
derivative	1010	1020	|B-MODIFIER
by	1021	1023	|O
alkaline	1024	1032	|O
hydrolysis	1033	1043	|O
and	1044	1047	|O
ester	1048	1053	|O
cleavage	1054	1062	|O
.	1062	1063	|O
Direct	1064	1070	|O
alkylation	1071	1081	|O
of	1082	1084	|O
2	1085	1086	|B-IUPAC
-	1086	1087	|I-IUPAC
amino	1087	1092	|I-IUPAC
-	1092	1093	|I-IUPAC
4,6	1093	1096	|I-IUPAC
-	1096	1097	|I-IUPAC
dihydroxypyrimidine	1097	1116	|I-IUPAC
afforded	1117	1125	|O
a	1126	1127	|O
mixture	1128	1135	|O
of	1136	1138	|O
2	1139	1140	|B-PARTIUPAC
-	1140	1141	|I-PARTIUPAC
amino	1141	1146	|I-PARTIUPAC
-	1146	1147	|I-PARTIUPAC
4,6	1147	1150	|I-PARTIUPAC
-	1150	1151	|I-PARTIUPAC
bis	1151	1154	|I-PARTIUPAC
[	1154	1155	|I-PARTIUPAC
2	1155	1156	|I-PARTIUPAC
-	1156	1157	|I-PARTIUPAC
(	1157	1158	|I-PARTIUPAC
phosphonomethoxy	1158	1174	|I-PARTIUPAC
)	1174	1175	|I-PARTIUPAC
ethyl	1175	1180	|I-PARTIUPAC
]	1180	1181	|I-PARTIUPAC
-	1181	1182	|I-PARTIUPAC
and	1183	1186	|O
2	1187	1188	|B-IUPAC
-	1188	1189	|I-IUPAC
amino	1189	1194	|I-IUPAC
-	1194	1195	|I-IUPAC
1,4	1195	1198	|I-IUPAC
-	1198	1199	|I-IUPAC
bis	1199	1202	|I-IUPAC
[	1202	1203	|I-IUPAC
2	1203	1204	|I-IUPAC
-	1204	1205	|I-IUPAC
(	1205	1206	|I-IUPAC
phosphonomethoxy	1206	1222	|I-IUPAC
)	1222	1223	|I-IUPAC
ethyl	1223	1228	|I-IUPAC
]	1228	1229	|I-IUPAC
pyrimidine	1229	1239	|I-IUPAC
.	1239	1240	|O
None	1241	1245	|O
of	1246	1248	|O
the	1249	1252	|O
N	1253	1254	|B-IUPAC
(	1254	1255	|I-IUPAC
1	1255	1256	|I-IUPAC
)	1256	1257	|I-IUPAC
-	1257	1258	|I-IUPAC
[	1258	1259	|I-IUPAC
2	1259	1260	|I-IUPAC
-	1260	1261	|I-IUPAC
(	1261	1262	|I-IUPAC
phosphonomethoxy	1262	1278	|I-IUPAC
)	1278	1279	|I-IUPAC
ethyl	1279	1284	|I-IUPAC
]	1284	1285	|I-IUPAC
isomers	1286	1293	|B-MODIFIER
exhibited	1294	1303	|O
any	1304	1307	|O
antiviral	1308	1317	|O
activity	1318	1326	|O
against	1327	1334	|O
DNA	1335	1338	|O
viruses	1339	1346	|O
or	1347	1349	|O
RNA	1350	1353	|O
viruses	1354	1361	|O
tested	1362	1368	|O
in	1369	1371	|O
vitro	1372	1377	|O
.	1377	1378	|O
On	1379	1381	|O
the	1382	1385	|O
contrary	1386	1394	|O
,	1394	1395	|O
the	1396	1399	|O
O	1400	1401	|O
(	1401	1402	|O
6	1402	1403	|O
)	1403	1404	|O
-	1404	1405	|O
isomers	1405	1412	|O
,	1412	1413	|O
namely	1414	1420	|O
the	1421	1424	|O
compounds	1425	1434	|O
derived	1435	1442	|O
from	1443	1447	|O
2,4	1448	1451	|B-PARTIUPAC
-	1451	1452	|I-PARTIUPAC
diamino	1452	1459	|I-PARTIUPAC
-	1459	1460	|I-PARTIUPAC
,	1460	1461	|O
2	1462	1463	|B-PARTIUPAC
-	1463	1464	|I-PARTIUPAC
amino	1464	1469	|I-PARTIUPAC
-	1469	1470	|I-PARTIUPAC
4	1470	1471	|I-PARTIUPAC
-	1471	1472	|I-PARTIUPAC
hydroxy	1472	1479	|I-PARTIUPAC
-	1479	1480	|I-PARTIUPAC
,	1480	1481	|O
or	1482	1484	|O
2	1485	1486	|B-IUPAC
-	1486	1487	|I-IUPAC
amino	1487	1492	|I-IUPAC
-	1492	1493	|I-IUPAC
4	1493	1494	|I-IUPAC
-	1494	1495	|I-IUPAC
[	1495	1496	|I-IUPAC
2	1496	1497	|I-IUPAC
-	1497	1498	|I-IUPAC
(	1498	1499	|I-IUPAC
phosphonomethoxy	1499	1515	|I-IUPAC
)	1515	1516	|I-IUPAC
ethoxy	1516	1522	|I-IUPAC
]	1522	1523	|I-IUPAC
-	1523	1524	|I-IUPAC
6	1524	1525	|I-IUPAC
-	1525	1526	|I-IUPAC
hydroxypyrimidine	1526	1543	|I-IUPAC
,	1543	1544	|O
inhibited	1545	1554	|O
the	1555	1558	|O
replication	1559	1570	|O
of	1571	1573	|O
herpes	1574	1580	|O
viruses	1581	1588	|O
[	1589	1590	|O
herpes	1590	1596	|O
simplex	1597	1604	|O
type	1605	1609	|O
1	1610	1611	|O
(	1612	1613	|O
HSV	1613	1616	|O
-	1616	1617	|O
1	1617	1618	|O
)	1618	1619	|O
and	1620	1623	|O
type	1624	1628	|O
2	1629	1630	|O
(	1631	1632	|O
HSV	1632	1635	|O
-	1635	1636	|O
2	1636	1637	|O
)	1637	1638	|O
,	1638	1639	|O
varicella	1640	1649	|O
-	1649	1650	|O
zoster	1650	1656	|O
virus	1657	1662	|O
(	1663	1664	|O
VZV	1664	1667	|O
)	1667	1668	|O
,	1668	1669	|O
and	1670	1673	|O
cytomegalovirus	1674	1689	|O
(	1690	1691	|O
CMV	1691	1694	|O
)	1694	1695	|O
]	1695	1696	|O
and	1697	1700	|O
retroviruses	1701	1713	|O
[	1714	1715	|O
Moloney	1715	1722	|O
sarcoma	1723	1730	|O
virus	1731	1736	|O
(	1737	1738	|O
MSV	1738	1741	|O
)	1741	1742	|O
and	1743	1746	|O
human	1747	1752	|O
immunodeficiency	1753	1769	|O
virus	1770	1775	|O
type	1776	1780	|O
1	1781	1782	|O
(	1783	1784	|O
HIV	1784	1787	|O
-	1787	1788	|O
1	1788	1789	|O
)	1789	1790	|O
and	1791	1794	|O
type	1795	1799	|O
2	1800	1801	|O
(	1802	1803	|O
HIV	1803	1806	|O
-	1806	1807	|O
2	1807	1808	|O
)	1808	1809	|O
]	1809	1810	|O
,	1810	1811	|O
their	1812	1817	|O
activity	1818	1826	|O
being	1827	1832	|O
most	1833	1837	|O
pronounced	1838	1848	|O
against	1849	1856	|O
the	1857	1860	|O
latter	1861	1867	|O
.	1867	1868	|O
The	1869	1872	|O
antiviral	1873	1882	|O
activity	1883	1891	|O
was	1892	1895	|O
lower	1896	1901	|O
if	1902	1904	|O
the	1905	1908	|O
oxygen	1909	1915	|O
at	1916	1918	|O
the	1919	1922	|O
position	1923	1931	|O
6	1932	1933	|O
was	1934	1937	|O
replaced	1938	1946	|O
by	1947	1949	|O
a	1950	1951	|O
sulfur	1952	1958	|O
atom	1959	1963	|O
,	1963	1964	|O
as	1965	1967	|O
in	1968	1970	|O
2,4	1971	1974	|B-IUPAC
-	1974	1975	|I-IUPAC
diamino	1975	1982	|I-IUPAC
-	1982	1983	|I-IUPAC
6	1983	1984	|I-IUPAC
-	1984	1985	|I-IUPAC
[	1985	1986	|I-IUPAC
2	1986	1987	|I-IUPAC
-	1987	1988	|I-IUPAC
(	1988	1989	|I-IUPAC
phosphonomethoxy	1989	2005	|I-IUPAC
)	2005	2006	|I-IUPAC
ethylsulfanyl	2006	2019	|I-IUPAC
]	2019	2020	|I-IUPAC
pyrimidine	2020	2030	|I-IUPAC
.	2030	2031	|O
In	2032	2034	|O
analogy	2035	2042	|O
to	2043	2045	|O
N	2046	2047	|B-IUPAC
(	2047	2048	|I-IUPAC
9	2048	2049	|I-IUPAC
)	2049	2050	|I-IUPAC
-	2050	2051	|I-IUPAC
[	2051	2052	|I-IUPAC
2	2052	2053	|I-IUPAC
-	2053	2054	|I-IUPAC
(	2054	2055	|I-IUPAC
phosphonomethoxy	2055	2071	|I-IUPAC
)	2071	2072	|I-IUPAC
propyl	2072	2078	|I-IUPAC
]	2078	2079	|I-IUPAC
-	2079	2080	|I-IUPAC
2,6	2080	2083	|I-IUPAC
-	2083	2084	|I-IUPAC
diaminopurine	2084	2097	|I-IUPAC
(	2098	2099	|O
PMPDAP	2099	2105	|O
)	2105	2106	|O
,	2106	2107	|O
solely	2108	2114	|O
the	2115	2118	|O
(	2119	2120	|B-IUPAC
R	2120	2121	|I-IUPAC
)	2121	2122	|I-IUPAC
-	2122	2123	|I-IUPAC
2,4	2123	2126	|I-IUPAC
-	2126	2127	|I-IUPAC
diamino	2127	2134	|I-IUPAC
-	2134	2135	|I-IUPAC
6	2135	2136	|I-IUPAC
-	2136	2137	|I-IUPAC
[	2137	2138	|I-IUPAC
2	2138	2139	|I-IUPAC
-	2139	2140	|I-IUPAC
(	2140	2141	|I-IUPAC
phosphonomethoxy	2141	2157	|I-IUPAC
)	2157	2158	|I-IUPAC
propoxy	2158	2165	|I-IUPAC
]	2165	2166	|I-IUPAC
pyrimidine	2166	2176	|I-IUPAC
exerted	2177	2184	|O
antiviral	2185	2194	|O
activity	2195	2203	|O
,	2203	2204	|O
whereas	2205	2212	|O
its	2213	2216	|O
(	2217	2218	|O
S	2218	2219	|O
)	2219	2220	|O
-	2220	2221	|O
enantiomer	2221	2231	|O
was	2232	2235	|O
essentially	2236	2247	|O
inactive	2248	2256	|O
.	2256	2257	|O

### abstracts402.txt
Twenty	0	6	|O
-	6	7	|O
six	7	10	|O
compounds	11	20	|O
derived	21	28	|O
from	29	33	|O
the	34	37	|O
5	38	39	|B-PARTIUPAC
-	39	40	|I-PARTIUPAC
deaza	40	45	|I-PARTIUPAC
-	45	46	|I-PARTIUPAC
and	47	50	|O
5,10	51	55	|B-IUPAC
-	55	56	|I-IUPAC
dideazaaminopterin	56	74	|I-IUPAC
series	75	81	|B-MODIFIER
of	82	84	|O
aminopterin	85	96	|O
analogues	97	106	|O
were	107	111	|O
evaluated	112	121	|O
for	122	125	|O
antiarthritic	126	139	|O
activity	140	148	|O
in	149	151	|O
the	152	155	|O
mouse	156	161	|O
type	162	166	|O
II	167	169	|O
collagen	170	178	|O
model	179	184	|O
.	184	185	|O
New	186	189	|O
compounds	190	199	|O
in	200	202	|O
the	203	206	|O
5	207	208	|B-IUPAC
-	208	209	|I-IUPAC
deaza	209	214	|I-IUPAC
series	215	221	|B-MODIFIER
were	222	226	|O
prepared	227	235	|O
by	236	238	|O
alkylation	239	249	|O
of	250	252	|O
an	253	255	|O
appropriate	256	267	|O
N	268	269	|B-MODIFIER
-	269	270	|I-MODIFIER
substituted	270	281	|I-MODIFIER
(	282	283	|B-IUPAC
4	283	284	|I-IUPAC
-	284	285	|I-IUPAC
aminobenzoyl	285	297	|I-IUPAC
)	297	298	|I-IUPAC
-	298	299	|I-IUPAC
L	299	300	|I-IUPAC
-	300	301	|I-IUPAC
glutamic	301	309	|I-IUPAC
acid	310	314	|I-IUPAC
dialkyl	315	322	|I-IUPAC
ester	323	328	|I-IUPAC
or	329	331	|O
N	332	333	|B-IUPAC
-	333	334	|I-IUPAC
(	334	335	|I-IUPAC
5	335	336	|I-IUPAC
-	336	337	|I-IUPAC
amino	337	342	|I-IUPAC
-	342	343	|I-IUPAC
2	343	344	|I-IUPAC
-	344	345	|I-IUPAC
thenoyl	345	352	|I-IUPAC
)	352	353	|I-IUPAC
-	353	354	|I-IUPAC
L	354	355	|I-IUPAC
-	355	356	|I-IUPAC
glutamate	356	365	|I-IUPAC
diester	366	373	|I-IUPAC
with	374	378	|O
a	379	380	|O
2,4	381	384	|B-IUPAC
-	384	385	|I-IUPAC
diamino	385	392	|I-IUPAC
-	392	393	|I-IUPAC
5	393	394	|I-IUPAC
-	394	395	|I-IUPAC
alkyl	395	400	|I-IUPAC
-	400	401	|I-IUPAC
6	401	402	|I-IUPAC
-	402	403	|I-IUPAC
(	403	404	|I-IUPAC
bromomethyl	404	415	|I-IUPAC
)	415	416	|I-IUPAC
-	416	417	|I-IUPAC
5	417	418	|I-IUPAC
-	418	419	|I-IUPAC
deazapteridine	419	433	|I-IUPAC
.	433	434	|O
The	435	438	|O
resultant	439	448	|O
5	449	450	|B-IUPAC
-	450	451	|I-IUPAC
deazaaminopterin	451	467	|I-IUPAC
diesters	468	476	|I-IUPAC
were	477	481	|O
saponified	482	492	|O
to	493	495	|O
provide	496	503	|O
the	504	507	|O
target	508	514	|O
5	515	516	|B-IUPAC
-	516	517	|I-IUPAC
deaza	517	522	|I-IUPAC
analogues	523	532	|B-MODIFIER
.	532	533	|O
5,10	534	538	|B-IUPAC
-	538	539	|I-IUPAC
Dideazaaminopterins	539	558	|I-IUPAC
were	559	563	|O
synthesized	564	575	|O
by	576	578	|O
similar	579	586	|O
alkylation	587	597	|O
of	598	600	|O
the	601	604	|O
carbanions	605	615	|O
of	616	618	|O
appropriate	619	630	|O
4	631	632	|B-PARTIUPAC
-	632	633	|I-PARTIUPAC
carboxyphenylacetic	633	652	|I-PARTIUPAC
,	652	653	|O
(	654	655	|B-PARTIUPAC
5	655	656	|I-PARTIUPAC
-	656	657	|I-PARTIUPAC
carboxy	657	664	|I-PARTIUPAC
-	664	665	|I-PARTIUPAC
2	665	666	|I-PARTIUPAC
-	666	667	|I-PARTIUPAC
thienyl	667	674	|I-PARTIUPAC
)	674	675	|I-PARTIUPAC
acetic	675	681	|I-PARTIUPAC
,	681	682	|O
or	683	685	|O
(	686	687	|B-IUPAC
5	687	688	|I-IUPAC
-	688	689	|I-IUPAC
carboxy	689	696	|I-IUPAC
-	696	697	|I-IUPAC
2	697	698	|I-IUPAC
-	698	699	|I-IUPAC
pyridyl	699	706	|I-IUPAC
)	706	707	|I-IUPAC
acetic	707	713	|I-IUPAC
acid	714	718	|I-IUPAC
dimethyl	719	727	|I-IUPAC
esters	728	734	|I-IUPAC
.	734	735	|O
The	736	739	|O
diesters	740	748	|O
of	749	751	|O
the	752	755	|O
2,4	756	759	|B-IUPAC
-	759	760	|I-IUPAC
diamino	760	767	|I-IUPAC
-	767	768	|I-IUPAC
4	768	769	|I-IUPAC
-	769	770	|I-IUPAC
deoxy	770	775	|I-IUPAC
-	775	776	|I-IUPAC
10	776	778	|I-IUPAC
-	778	779	|I-IUPAC
carboxy	779	786	|I-IUPAC
-	786	787	|I-IUPAC
5,10	787	791	|I-IUPAC
-	791	792	|I-IUPAC
dideazapteroic	792	806	|I-IUPAC
acid	807	811	|I-IUPAC
types	812	817	|O
so	818	820	|O
obtained	821	829	|O
were	830	834	|O
saponified	835	845	|O
and	846	849	|O
then	850	854	|O
readily	855	862	|O
decarboxylated	863	877	|O
by	878	880	|O
heating	881	888	|O
in	889	891	|O
Me2SO	892	897	|O
solution	898	906	|O
to	907	909	|O
provide	910	917	|O
the	918	921	|O
2,4	922	925	|B-IUPAC
-	925	926	|I-IUPAC
diamino	926	933	|I-IUPAC
-	933	934	|I-IUPAC
5,10	934	938	|I-IUPAC
-	938	939	|I-IUPAC
dideazapteroic	939	953	|I-IUPAC
acid	954	958	|I-IUPAC
-	958	959	|O
type	959	963	|O
intermediates	964	977	|O
.	977	978	|O
Peptide	979	986	|O
coupling	987	995	|O
with	996	1000	|O
diethyl	1001	1008	|O
L	1009	1010	|O
-	1010	1011	|O
glutamate	1011	1020	|O
followed	1021	1029	|O
by	1030	1032	|O
ester	1033	1038	|O
hydrolysis	1039	1049	|O
at	1050	1052	|O
room	1053	1057	|O
temperature	1058	1069	|O
afforded	1070	1078	|O
the	1079	1082	|O
new	1083	1086	|O
5,10	1087	1091	|B-IUPAC
-	1091	1092	|I-IUPAC
dideazaaminopterin	1092	1110	|I-IUPAC
analogues	1111	1120	|B-MODIFIER
.	1120	1121	|O
5	1122	1123	|B-IUPAC
-	1123	1124	|I-IUPAC
Deazaaminopterins	1124	1141	|I-IUPAC
bearing	1142	1149	|O
an	1150	1152	|O
alkyl	1153	1158	|O
substituent	1159	1170	|O
at	1171	1173	|O
the	1174	1177	|O
5	1178	1179	|O
-	1179	1180	|O
position	1180	1188	|O
were	1189	1193	|O
generally	1194	1203	|O
quite	1204	1209	|O
effective	1210	1219	|O
as	1220	1222	|O
antiinflammatory	1223	1239	|O
agents	1240	1246	|O
.	1246	1247	|O
Thus	1248	1252	|O
5	1253	1254	|B-IUPAC
-	1254	1255	|I-IUPAC
propyl	1255	1261	|I-IUPAC
-	1261	1262	|I-IUPAC
5	1262	1263	|I-IUPAC
-	1263	1264	|I-IUPAC
deazaaminopterin	1264	1280	|I-IUPAC
,	1280	1281	|O
5	1282	1283	|B-IUPAC
-	1283	1284	|I-IUPAC
methyl	1284	1290	|I-IUPAC
-	1290	1291	|I-IUPAC
10	1291	1293	|I-IUPAC
-	1293	1294	|I-IUPAC
propargyl	1294	1303	|I-IUPAC
-	1303	1304	|I-IUPAC
5	1304	1305	|I-IUPAC
-	1305	1306	|I-IUPAC
deazaaminopterin	1306	1322	|I-IUPAC
,	1322	1323	|O
5	1324	1325	|B-IUPAC
-	1325	1326	|I-IUPAC
methyl	1326	1332	|I-IUPAC
-	1332	1333	|I-IUPAC
10	1333	1335	|I-IUPAC
-	1335	1336	|I-IUPAC
allyl	1336	1341	|I-IUPAC
-	1341	1342	|I-IUPAC
5	1342	1343	|I-IUPAC
-	1343	1344	|I-IUPAC
deazaaminopterin	1344	1360	|I-IUPAC
,	1360	1361	|O
5	1362	1363	|B-IUPAC
-	1363	1364	|I-IUPAC
ethyl	1364	1369	|I-IUPAC
-	1369	1370	|I-IUPAC
5	1370	1371	|I-IUPAC
-	1371	1372	|I-IUPAC
deazamethotrexate	1372	1389	|I-IUPAC
,	1389	1390	|O
and	1391	1394	|O
2,5	1395	1398	|B-MODIFIER
-	1398	1399	|I-MODIFIER
disubstituted	1399	1412	|I-MODIFIER
thiophene	1413	1422	|B-IUPAC
analogue	1423	1431	|B-MODIFIER
of	1432	1434	|O
5	1435	1436	|B-IUPAC
-	1436	1437	|I-IUPAC
methyl	1437	1443	|I-IUPAC
-	1443	1444	|I-IUPAC
5	1444	1445	|I-IUPAC
-	1445	1446	|I-IUPAC
deazaaminopterin	1446	1462	|I-IUPAC
showed	1463	1469	|O
potencies	1470	1479	|O
greater	1480	1487	|O
than	1488	1492	|O
methotrexate	1493	1505	|O
by	1506	1508	|O
intraperitoneal	1509	1524	|O
or	1525	1527	|O
oral	1528	1532	|O
administration	1533	1547	|O
and	1548	1551	|O
were	1552	1556	|O
active	1557	1563	|O
over	1564	1568	|O
a	1569	1570	|O
considerably	1571	1583	|O
broader	1584	1591	|O
dose	1592	1596	|O
range	1597	1602	|O
.	1602	1603	|O
Useful	1604	1610	|O
activity	1611	1619	|O
in	1620	1622	|O
the	1623	1626	|O
5,10	1627	1631	|B-IUPAC
-	1631	1632	|I-IUPAC
dideaza	1632	1639	|I-IUPAC
series	1640	1646	|B-MODIFIER
was	1647	1650	|O
only	1651	1655	|O
observed	1656	1664	|O
for	1665	1668	|O
5,10	1669	1673	|B-IUPAC
-	1673	1674	|I-IUPAC
dideazaaminopterin	1674	1692	|I-IUPAC
and	1693	1696	|O
its	1697	1700	|O
10	1701	1703	|B-IUPAC
-	1703	1704	|I-IUPAC
methyl	1704	1710	|I-IUPAC
analogue	1711	1719	|B-MODIFIER
.	1719	1720	|O
Alkyl	1721	1726	|O
substitution	1727	1739	|O
at	1740	1742	|O
C	1743	1744	|O
-	1744	1745	|O
5	1745	1746	|O
or	1747	1749	|O
C	1750	1751	|O
-	1751	1752	|O
10	1752	1754	|O
was	1755	1758	|O
generally	1759	1768	|O
detrimental	1769	1780	|O
to	1781	1783	|O
antiinflammatory	1784	1800	|O
activity	1801	1809	|O
in	1810	1812	|O
this	1813	1817	|O
series	1818	1824	|O
.	1824	1825	|O

### abstracts3009.txt
The	0	3	|O
synthesis	4	13	|O
and	14	17	|O
pharmacological	18	33	|O
activities	34	44	|O
of	45	47	|O
the	48	51	|O
four	52	56	|O
stereoisomers	57	70	|O
of	71	73	|O
methyl	74	80	|B-IUPAC
tetrahydrofuran	81	96	|I-IUPAC
-	96	97	|I-IUPAC
2	97	98	|I-IUPAC
-	98	99	|I-IUPAC
ylmethyl	99	107	|I-IUPAC
2,6	108	111	|I-IUPAC
-	111	112	|I-IUPAC
dimethyl	112	120	|I-IUPAC
-	120	121	|I-IUPAC
4	121	122	|I-IUPAC
-	122	123	|I-IUPAC
(	123	124	|I-IUPAC
2'	124	126	|I-IUPAC
-	126	127	|I-IUPAC
nitrophenyl	127	138	|I-IUPAC
)	138	139	|I-IUPAC
-	139	140	|I-IUPAC
1,4	140	143	|I-IUPAC
-	143	144	|I-IUPAC
dihydropyridine	144	159	|I-IUPAC
-	159	160	|I-IUPAC
3,5	160	163	|I-IUPAC
-	163	164	|I-IUPAC
dicarboxylate	165	178	|I-IUPAC
(	178	179	|I-IUPAC
furnidipine	179	190	|I-IUPAC
)	190	191	|I-IUPAC
are	192	195	|O
reported	196	204	|O
.	204	205	|O
The	206	209	|O
four	210	214	|O
isomers	215	222	|O
were	223	227	|O
synthesized	228	239	|O
by	240	242	|O
a	243	244	|O
modified	245	253	|O
Hantzsch	254	262	|O
synthesis	263	272	|O
by	273	275	|O
reaction	276	284	|O
of	285	287	|O
(	288	289	|B-PARTIUPAC
-	289	290	|I-PARTIUPAC
)	290	291	|I-PARTIUPAC
-	291	292	|I-PARTIUPAC
or	293	295	|O
(	296	297	|B-IUPAC
+	297	298	|I-IUPAC
)	298	299	|I-IUPAC
-	299	300	|I-IUPAC
tetrahydrofuran	300	315	|I-IUPAC
-	315	316	|I-IUPAC
2	316	317	|I-IUPAC
-	317	318	|I-IUPAC
ylmethyl	318	326	|I-IUPAC
3	327	328	|I-IUPAC
-	328	329	|I-IUPAC
aminocrotonate	329	343	|I-IUPAC
and	344	347	|O
methyl	348	354	|B-IUPAC
2	355	356	|I-IUPAC
-	356	357	|I-IUPAC
[	357	358	|I-IUPAC
(	358	359	|I-IUPAC
2'	359	361	|I-IUPAC
-	361	362	|I-IUPAC
nitrophenyl	362	373	|I-IUPAC
)	373	374	|I-IUPAC
methylene	374	383	|I-IUPAC
]	383	384	|I-IUPAC
acetoacetate	384	396	|I-IUPAC
or	397	399	|O
,	399	400	|O
alternatively	401	414	|O
,	414	415	|O
by	416	418	|O
reaction	419	427	|O
of	428	430	|O
(	431	432	|B-PARTIUPAC
-	432	433	|I-PARTIUPAC
)	433	434	|I-PARTIUPAC
-	434	435	|I-PARTIUPAC
or	436	438	|O
(	439	440	|B-IUPAC
+	440	441	|I-IUPAC
)	441	442	|I-IUPAC
-	442	443	|I-IUPAC
tetrahydrofuran	443	458	|I-IUPAC
-	458	459	|I-IUPAC
2	459	460	|I-IUPAC
-	460	461	|I-IUPAC
ylmethyl	461	469	|I-IUPAC
2	470	471	|I-IUPAC
-	471	472	|I-IUPAC
[	472	473	|I-IUPAC
(	473	474	|I-IUPAC
2'	474	476	|I-IUPAC
-	476	477	|I-IUPAC
nitrophenyl	477	488	|I-IUPAC
)	488	489	|I-IUPAC
methylene	489	498	|I-IUPAC
]	498	499	|I-IUPAC
acetoacetate	499	511	|I-IUPAC
and	512	515	|O
methyl	516	522	|B-IUPAC
3	523	524	|I-IUPAC
-	524	525	|I-IUPAC
aminocrotonate	525	539	|I-IUPAC
.	539	540	|O
The	541	544	|O
1	545	546	|O
:	546	547	|O
1	547	548	|O
diastereomeric	549	563	|O
mixtures	564	572	|O
thus	573	577	|O
obtained	578	586	|O
were	587	591	|O
separated	592	601	|O
by	602	604	|O
chromatography	605	619	|O
,	619	620	|O
using	621	626	|O
poly	627	631	|O
(	631	632	|O
D	632	633	|O
-	633	634	|O
phenylglycine	634	647	|O
)	647	648	|O
as	649	651	|O
the	652	655	|O
chiral	656	662	|O
stationary	663	673	|O
phase	674	679	|O
.	679	680	|O
The	681	684	|O
enantiomeric	685	697	|O
purity	698	704	|O
of	705	707	|O
the	708	711	|O
stereoisomers	712	725	|O
was	726	729	|O
determined	730	740	|O
by	741	743	|O
a	744	745	|O
high	746	750	|O
-	750	751	|O
performance	751	762	|O
liquid	763	769	|O
chromatography	770	784	|O
-	784	785	|O
chiral	785	791	|O
stationary	792	802	|O
phase	803	808	|O
technique	809	818	|O
(	819	820	|O
HPLC	820	824	|O
-	824	825	|O
CSP	825	828	|O
)	828	829	|O
.	829	830	|O
Attempts	831	839	|O
to	840	842	|O
obtain	843	849	|O
crystals	850	858	|O
of	859	861	|O
a	862	863	|O
single	864	870	|O
stereoisomer	871	883	|O
failed	884	890	|O
in	891	893	|O
different	894	903	|O
solvents	904	912	|O
,	912	913	|O
while	914	919	|O
methanol	920	928	|O
crystallization	929	944	|O
of	945	947	|O
the	948	951	|O
product	952	959	|O
obtained	960	968	|O
from	969	973	|O
(	974	975	|B-IUPAC
+	975	976	|I-IUPAC
/	976	977	|I-IUPAC
-	977	978	|I-IUPAC
)	978	979	|I-IUPAC
-	979	980	|I-IUPAC
tetrahydrofuran	980	995	|I-IUPAC
-	995	996	|I-IUPAC
2	996	997	|I-IUPAC
-	997	998	|I-IUPAC
ylmethyl	998	1006	|I-IUPAC
2	1007	1008	|I-IUPAC
-	1008	1009	|I-IUPAC
[	1009	1010	|I-IUPAC
(	1010	1011	|I-IUPAC
2'	1011	1013	|I-IUPAC
-	1013	1014	|I-IUPAC
nitrophenyl	1014	1025	|I-IUPAC
)	1025	1026	|I-IUPAC
methylene	1026	1035	|I-IUPAC
]	1035	1036	|I-IUPAC
acetoacetate	1036	1048	|I-IUPAC
and	1049	1052	|O
methyl	1053	1059	|B-IUPAC
3	1060	1061	|I-IUPAC
-	1061	1062	|I-IUPAC
aminocrotonate	1062	1076	|I-IUPAC
yielded	1077	1084	|O
good	1085	1089	|O
-	1089	1090	|O
quality	1090	1097	|O
crystals	1098	1106	|O
of	1107	1109	|O
the	1110	1113	|O
most	1114	1118	|O
insoluble	1119	1128	|O
racemate	1129	1137	|O
which	1138	1143	|O
proved	1144	1150	|O
to	1151	1153	|O
be	1154	1156	|O
a	1157	1158	|O
mixture	1159	1166	|O
of	1167	1169	|O
the	1170	1173	|O
(	1174	1175	|O
SS	1175	1177	|O
)	1177	1178	|O
/	1178	1179	|O
(	1179	1180	|O
RR	1180	1182	|O
)	1182	1183	|O
enantiomers	1184	1195	|O
by	1196	1198	|O
X	1199	1200	|O
-	1200	1201	|O
ray	1201	1204	|O
crystallography	1205	1220	|O
.	1220	1221	|O
Conformational	1222	1236	|O
analysis	1237	1245	|O
of	1246	1248	|O
the	1249	1252	|O
stereoisomers	1253	1266	|O
,	1266	1267	|O
assuming	1268	1276	|O
rotation	1277	1285	|O
of	1286	1288	|O
the	1289	1292	|O
aryl	1293	1297	|O
substituent	1298	1309	|O
and	1310	1313	|O
ester	1314	1319	|O
groups	1320	1326	|O
,	1326	1327	|O
shows	1328	1333	|O
small	1334	1339	|O
energy	1340	1346	|O
differences	1347	1358	|O
(	1359	1360	|O
about	1360	1365	|O
4	1366	1367	|O
kcal	1368	1372	|O
.	1372	1373	|O
mol	1373	1376	|O
-	1376	1377	|O
1	1377	1378	|O
)	1378	1379	|O
between	1380	1387	|O
the	1388	1391	|O
most	1392	1396	|O
and	1397	1400	|O
the	1401	1404	|O
least	1405	1410	|O
favorable	1411	1420	|O
conformations	1421	1434	|O
.	1434	1435	|O
Binding	1436	1443	|O
studies	1444	1451	|O
were	1452	1456	|O
performed	1457	1466	|O
using	1467	1472	|O
[	1473	1474	|O
3H	1474	1476	|O
]	1476	1477	|O
isradipine	1477	1487	|O
as	1488	1490	|O
a	1491	1492	|O
reference	1493	1502	|O
ligand	1503	1509	|O
.	1509	1510	|O
The	1511	1514	|O
results	1515	1522	|O
showed	1523	1529	|O
stereospecificity	1530	1547	|O
of	1548	1550	|O
the	1551	1554	|O
furnidipine	1555	1566	|O
isomers	1567	1574	|O
in	1575	1577	|O
brain	1578	1583	|O
,	1583	1584	|O
ileum	1585	1590	|O
,	1590	1591	|O
and	1592	1595	|O
cardiac	1596	1603	|O
tissues	1604	1611	|O
,	1611	1612	|O
the	1613	1616	|O
(	1617	1618	|O
SS	1618	1620	|O
)	1620	1621	|O
-	1621	1622	|O
and	1623	1626	|O
(	1627	1628	|O
SR	1628	1630	|O
)	1630	1631	|O
-	1631	1632	|O
isomers	1632	1639	|O
clearly	1640	1647	|O
being	1648	1653	|O
more	1654	1658	|O
potent	1659	1665	|O
than	1666	1670	|O
their	1671	1676	|O
(	1677	1678	|O
RR	1678	1680	|O
)	1680	1681	|O
-	1681	1682	|O
and	1683	1686	|O
(	1687	1688	|O
RS	1688	1690	|O
)	1690	1691	|O
-	1691	1692	|O
enantiomers	1692	1703	|O
.	1703	1704	|O
The	1705	1708	|O
(	1709	1710	|O
SS	1710	1712	|O
)	1712	1713	|O
-	1713	1714	|O
and	1715	1718	|O
(	1719	1720	|O
SR	1720	1722	|O
)	1722	1723	|O
-	1723	1724	|O
isomers	1724	1731	|O
were	1732	1736	|O
also	1737	1741	|O
more	1742	1746	|O
selective	1747	1756	|O
on	1757	1759	|O
cerebral	1760	1768	|O
tissue	1769	1775	|O
when	1776	1780	|O
compared	1781	1789	|O
with	1790	1794	|O
ileal	1795	1800	|O
and	1801	1804	|O
cardiac	1805	1812	|O
preparations	1813	1825	|O
.	1825	1826	|O

### abstracts59.txt
Synthesis	0	9	|O
and	10	13	|O
biological	14	24	|O
activities	25	35	|O
of	36	38	|O
12	39	41	|O
analogs	42	49	|O
of	50	52	|O
N6	53	55	|B-IUPAC
-	55	56	|I-IUPAC
benzyladenosine	56	71	|I-IUPAC
are	72	75	|O
described	76	85	|O
.	85	86	|O
The	87	90	|O
compounds	91	100	|O
were	101	105	|O
prepared	106	114	|O
by	115	117	|O
two	118	121	|O
methods	122	129	|O
:	129	130	|O
(	131	132	|O
1	132	133	|O
)	133	134	|O
direct	135	141	|O
alkylation	142	152	|O
of	153	155	|O
adenosine	156	165	|O
with	166	170	|O
an	171	173	|O
appropriately	174	187	|O
substituted	188	199	|O
benzyl	200	206	|O
bromide	207	214	|O
to	215	217	|O
give	218	222	|O
the	223	226	|O
N1	227	229	|O
-	229	230	|O
substituted	230	241	|O
derivative	242	252	|O
which	253	258	|O
was	259	262	|O
then	263	267	|O
rearranged	268	278	|O
in	279	281	|O
base	282	286	|O
to	287	289	|O
give	290	294	|O
the	295	298	|O
N6	299	301	|O
-	301	302	|O
substituted	302	313	|O
compound	314	322	|O
,	322	323	|O
and	324	327	|O
(	328	329	|O
2	329	330	|O
)	330	331	|O
by	332	334	|O
nucleophilic	335	347	|O
displacement	348	360	|O
of	361	363	|O
chlorine	364	372	|O
in	373	375	|O
6	376	377	|B-IUPAC
-	377	378	|I-IUPAC
chloropurine	378	390	|I-IUPAC
ribonucleoside	391	405	|B-MODIFIER
,	405	406	|O
6	407	408	|B-IUPAC
-	408	409	|I-IUPAC
chloro	409	415	|I-IUPAC
-	415	416	|I-IUPAC
2	416	417	|I-IUPAC
-	417	418	|I-IUPAC
aminopurine	418	429	|I-IUPAC
ribonucleoside	430	444	|B-MODIFIER
,	444	445	|O
and	446	449	|O
6	450	451	|B-IUPAC
-	451	452	|I-IUPAC
chloro	452	458	|I-IUPAC
-	458	459	|I-IUPAC
2	459	460	|I-IUPAC
-	460	461	|I-IUPAC
aminopurine	461	472	|I-IUPAC
with	473	477	|O
an	478	480	|O
amine	481	486	|O
.	486	487	|O
These	488	493	|O
analogs	494	501	|O
were	502	506	|O
examined	507	515	|O
for	516	519	|O
their	520	525	|O
growth	526	532	|O
inhibitory	533	543	|O
effect	544	550	|O
in	551	553	|O
cultured	554	562	|O
leukemic	563	571	|O
cells	572	577	|O
and	578	581	|O
also	582	586	|O
for	587	590	|O
their	591	596	|O
effect	597	603	|O
on	604	606	|O
adenosine	607	616	|O
aminohydrolase	617	631	|O
activity	632	640	|O
.	640	641	|O
N6	642	644	|B-IUPAC
-	644	645	|I-IUPAC
p	645	646	|I-IUPAC
-	646	647	|I-IUPAC
Nitrobenzyladenosine	647	667	|I-IUPAC
and	668	671	|O
its	672	675	|O
2'	676	678	|O
-	678	679	|O
deoxy	679	684	|O
analog	685	691	|O
were	692	696	|O
competitive	697	708	|O
inhibitors	709	719	|O
(	720	721	|O
K1	721	723	|O
65	724	726	|O
,	726	727	|O
22	728	730	|O
MUM	731	734	|O
)	734	735	|O
.	735	736	|O
The	737	740	|O
2	741	742	|B-IUPAC
-	742	743	|I-IUPAC
amino	743	748	|I-IUPAC
-	748	749	|I-IUPAC
N6	749	751	|I-IUPAC
-	751	752	|I-IUPAC
p	752	753	|I-IUPAC
-	753	754	|I-IUPAC
nitrobenzyladenine	754	772	|I-IUPAC
and	773	776	|O
its	777	780	|O
ribonucleoside	781	795	|O
were	796	800	|O
found	801	806	|O
to	807	809	|O
be	810	812	|O
noncompetitive	813	827	|O
inhibitors	828	838	|O
of	839	841	|O
adenosine	842	851	|O
aminohydrolase	852	866	|O
.	866	867	|O
In	868	870	|O
cultured	871	879	|O
L1210	880	885	|O
leukemia	886	894	|O
,	894	895	|O
2	896	897	|B-IUPAC
-	897	898	|I-IUPAC
amino	898	903	|I-IUPAC
-	903	904	|I-IUPAC
6	904	905	|I-IUPAC
-	905	906	|I-IUPAC
p	906	907	|I-IUPAC
-	907	908	|I-IUPAC
nitrobenzylaminopurine	908	930	|I-IUPAC
and	931	934	|O
the	935	938	|O
corresponding	939	952	|O
ribonucleoside	953	967	|O
were	968	972	|O
better	973	979	|O
growth	980	986	|O
inhibitors	987	997	|O
than	998	1002	|O
N6	1003	1005	|B-IUPAC
-	1005	1006	|I-IUPAC
benzyladenosine	1006	1021	|I-IUPAC
,	1021	1022	|O
while	1023	1028	|O
N6	1029	1031	|B-IUPAC
-	1031	1032	|I-IUPAC
p	1032	1033	|I-IUPAC
-	1033	1034	|I-IUPAC
nitrobenzyladenosine	1034	1054	|I-IUPAC
,	1054	1055	|O
its	1056	1059	|O
2'	1060	1062	|O
-	1062	1063	|O
deoxy	1063	1068	|O
analog	1069	1075	|O
,	1075	1076	|O
and	1077	1080	|O
N6	1081	1083	|B-IUPAC
-	1083	1084	|I-IUPAC
p	1084	1085	|I-IUPAC
-	1085	1086	|I-IUPAC
fluorobenzyladenosine	1086	1107	|I-IUPAC
were	1108	1112	|O
as	1113	1115	|O
active	1116	1122	|O
as	1123	1125	|O
N6	1126	1128	|B-IUPAC
-	1128	1129	|I-IUPAC
benzyladenosine	1129	1144	|I-IUPAC
.	1144	1145	|O

### abstracts1030.txt
Numerous	0	8	|O
3	9	10	|B-MODIFIER
-	10	11	|I-MODIFIER
substituted	11	22	|I-MODIFIER
-	22	23	|O
6	23	24	|B-IUPAC
-	24	25	|I-IUPAC
(	25	26	|I-IUPAC
3	26	27	|I-IUPAC
-	27	28	|I-IUPAC
ethyl	28	33	|I-IUPAC
-	33	34	|I-IUPAC
4	34	35	|I-IUPAC
-	35	36	|I-IUPAC
methylanilino	36	49	|I-IUPAC
)	49	50	|I-IUPAC
uracils	50	57	|I-IUPAC
(	58	59	|O
EMAU	59	63	|O
)	63	64	|O
have	65	69	|O
been	70	74	|O
synthesized	75	86	|O
and	87	90	|O
screened	91	99	|O
for	100	103	|O
their	104	109	|O
capacity	110	118	|O
to	119	121	|O
inhibit	122	129	|O
the	130	133	|O
replication	134	145	|O
-	145	146	|O
specific	146	154	|O
bacterial	155	164	|O
DNA	165	168	|O
polymerase	169	179	|O
IIIC	180	184	|O
(	185	186	|O
pol	186	189	|O
IIIC	190	194	|O
)	194	195	|O
and	196	199	|O
the	200	203	|O
growth	204	210	|O
of	211	213	|O
Gram+	214	219	|O
bacteria	220	228	|O
in	229	231	|O
culture	232	239	|O
.	239	240	|O
Direct	241	247	|O
alkylation	248	258	|O
of	259	261	|O
2	262	263	|B-IUPAC
-	263	264	|I-IUPAC
methoxy	264	271	|I-IUPAC
-	271	272	|I-IUPAC
6	272	273	|I-IUPAC
-	273	274	|I-IUPAC
amino	274	279	|I-IUPAC
-	279	280	|I-IUPAC
4	280	281	|I-IUPAC
-	281	282	|I-IUPAC
pyrimidone	282	292	|I-IUPAC
produced	293	301	|O
the	302	305	|O
N3	306	308	|O
-	308	309	|O
substituted	309	320	|O
derivatives	321	332	|O
,	332	333	|O
which	334	339	|O
were	340	344	|O
separated	345	354	|O
from	355	359	|O
the	360	363	|O
byproduct	364	373	|O
4	374	375	|B-IUPAC
-	375	376	|I-IUPAC
alkoxy	376	382	|I-IUPAC
analogues	383	392	|B-MODIFIER
.	392	393	|O
The	394	397	|O
N3	398	400	|O
-	400	401	|O
substituted	401	412	|O
derivatives	413	424	|O
were	425	429	|O
heated	430	436	|O
with	437	441	|O
a	442	443	|O
mixture	444	451	|O
of	452	454	|O
3	455	456	|B-IUPAC
-	456	457	|I-IUPAC
ethyl	457	462	|I-IUPAC
-	462	463	|I-IUPAC
4	463	464	|I-IUPAC
-	464	465	|I-IUPAC
methylaniline	465	478	|I-IUPAC
and	479	482	|O
its	483	486	|O
hydrochloride	487	500	|O
to	501	503	|O
effect	504	510	|O
displacement	511	523	|O
of	524	526	|O
the	527	530	|O
6	531	532	|O
-	532	533	|O
amino	533	538	|O
group	539	544	|O
and	545	548	|O
simultaneous	549	561	|O
demethylation	562	575	|O
of	576	578	|O
the	579	582	|O
2	583	584	|B-IUPAC
-	584	585	|I-IUPAC
methoxy	585	592	|I-IUPAC
group	593	598	|B-MODIFIER
to	599	601	|O
yield	602	607	|O
target	608	614	|O
compounds	615	624	|O
in	625	627	|O
good	628	632	|O
yields	633	639	|O
.	639	640	|O
Certain	641	648	|O
intermediates	649	662	|O
,	662	663	|O
e.g.	664	668	|O
the	669	672	|O
3	673	674	|B-IUPAC
-	674	675	|I-IUPAC
(	675	676	|I-IUPAC
iodoalkyl	676	685	|I-IUPAC
)	685	686	|I-IUPAC
compounds	687	696	|B-MODIFIER
,	696	697	|O
were	698	702	|O
converted	703	712	|O
to	713	715	|O
a	716	717	|O
variety	718	725	|O
of	726	728	|O
(	729	730	|O
3	730	731	|B-MODIFIER
-	731	732	|I-MODIFIER
substituted	732	743	|I-MODIFIER
-	743	744	|O
alkyl	744	749	|B-IUPAC
)	749	750	|O
-	750	751	|O
EMAUs	751	756	|O
by	757	759	|O
displacement	760	772	|O
.	772	773	|O
Most	774	778	|O
compounds	779	788	|O
were	789	793	|O
potent	794	800	|O
competitive	801	812	|O
inhibitors	813	823	|O
of	824	826	|O
pol	827	830	|O
IIIC	831	835	|O
(	836	837	|O
K	837	838	|O
(	838	839	|O
i	839	840	|O
)	840	841	|O
s	841	842	|O
0.02-0.5	843	851	|O
microM	852	858	|O
)	858	859	|O
,	859	860	|O
and	861	864	|O
those	865	870	|O
with	871	875	|O
neutral	876	883	|O
,	883	884	|O
moderately	885	895	|O
polar	896	901	|O
3	902	903	|O
-	903	904	|O
substituents	904	916	|O
had	917	920	|O
potent	921	927	|O
antibacterial	928	941	|O
activity	942	950	|O
against	951	958	|O
Gram+	959	964	|O
organisms	965	974	|O
in	975	977	|O
culture	978	985	|O
(	986	987	|O
MICs	987	991	|O
0.125-10	992	1000	|O
microg	1001	1007	|O
/	1007	1008	|O
mL	1008	1010	|O
)	1010	1011	|O
.	1011	1012	|O
Several	1013	1020	|O
compounds	1021	1030	|O
protected	1031	1040	|O
mice	1041	1045	|O
from	1046	1050	|O
lethal	1051	1057	|O
intraperitoneal	1058	1073	|O
(	1074	1075	|O
ip	1075	1077	|O
)	1077	1078	|O
infections	1079	1089	|O
with	1090	1094	|O
S	1095	1096	|O
.	1096	1097	|O
aureus	1098	1104	|O
(	1105	1106	|O
Smith	1106	1111	|O
)	1111	1112	|O
when	1113	1117	|O
given	1118	1123	|O
by	1124	1126	|O
the	1127	1130	|O
ip	1131	1133	|O
route	1134	1139	|O
.	1139	1140	|O
A	1141	1142	|O
water	1143	1148	|O
soluble	1149	1156	|O
derivative	1157	1167	|O
,	1167	1168	|O
3	1169	1170	|B-IUPAC
-	1170	1171	|I-IUPAC
(	1171	1172	|I-IUPAC
4	1172	1173	|I-IUPAC
-	1173	1174	|I-IUPAC
morpholinylbutyl	1174	1190	|I-IUPAC
)	1190	1191	|I-IUPAC
-	1191	1192	|I-IUPAC
EMAU	1192	1196	|I-IUPAC
hydrochloride	1197	1210	|I-IUPAC
,	1210	1211	|O
given	1212	1217	|O
subcutaneously	1218	1232	|O
,	1232	1233	|O
prolonged	1234	1243	|O
the	1244	1247	|O
life	1248	1252	|O
of	1253	1255	|O
infected	1256	1264	|O
mice	1265	1269	|O
in	1270	1272	|O
a	1273	1274	|O
dose	1275	1279	|O
dependent	1280	1289	|O
manner	1290	1296	|O
.	1296	1297	|O

### abstracts215.txt
The	0	3	|O
synthesis	4	13	|O
and	14	17	|O
structure	18	27	|O
-	27	28	|O
activity	28	36	|O
relationship	37	49	|O
of	50	52	|O
a	53	54	|O
series	55	61	|O
of	62	64	|O
4	65	66	|B-IUPAC
-	66	67	|I-IUPAC
aryl	67	71	|I-IUPAC
-	71	72	|I-IUPAC
2	72	73	|I-IUPAC
-	73	74	|I-IUPAC
hydroxy	74	81	|I-IUPAC
-	81	82	|I-IUPAC
4	82	83	|I-IUPAC
-	83	84	|I-IUPAC
oxobut	84	90	|I-IUPAC
-	90	91	|I-IUPAC
2	91	92	|I-IUPAC
-	92	93	|I-IUPAC
enoic	93	98	|I-IUPAC
acids	99	104	|I-IUPAC
and	105	108	|O
esters	109	115	|B-PARTIUPAC
and	116	119	|O
2	120	121	|B-IUPAC
-	121	122	|I-IUPAC
amino	122	127	|I-IUPAC
-	127	128	|I-IUPAC
4	128	129	|I-IUPAC
-	129	130	|I-IUPAC
aryl	130	134	|I-IUPAC
-	134	135	|I-IUPAC
4	135	136	|I-IUPAC
-	136	137	|I-IUPAC
oxobut	137	143	|I-IUPAC
-	143	144	|I-IUPAC
2	144	145	|I-IUPAC
-	145	146	|I-IUPAC
enoic	146	151	|I-IUPAC
acids	152	157	|I-IUPAC
and	158	161	|O
esters	162	168	|B-PARTIUPAC
as	169	171	|O
potent	172	178	|O
inhibitors	179	189	|O
of	190	192	|O
kynurenine	193	203	|O
-	203	204	|O
3	204	205	|O
-	205	206	|O
hydroxylase	206	217	|O
are	218	221	|O
described	222	231	|O
.	231	232	|O
These	233	238	|O
compounds	239	248	|O
are	249	252	|O
the	253	256	|O
most	257	261	|O
potent	262	268	|O
inhibitors	269	279	|O
of	280	282	|O
the	283	286	|O
kynurenine	287	297	|O
-	297	298	|O
3	298	299	|O
-	299	300	|O
hydroxylase	300	311	|O
enzyme	312	318	|O
so	319	321	|O
far	322	325	|O
disclosed	326	335	|O
.	335	336	|O
Additionally	337	349	|O
methyl	350	356	|B-IUPAC
4	357	358	|I-IUPAC
-	358	359	|I-IUPAC
(	359	360	|I-IUPAC
3	360	361	|I-IUPAC
-	361	362	|I-IUPAC
chlorophenyl	362	374	|I-IUPAC
)	374	375	|I-IUPAC
-	375	376	|I-IUPAC
2	376	377	|I-IUPAC
-	377	378	|I-IUPAC
hydroxy	378	385	|I-IUPAC
-	385	386	|I-IUPAC
4	386	387	|I-IUPAC
-	387	388	|I-IUPAC
oxobut	388	394	|I-IUPAC
-	394	395	|I-IUPAC
2	395	396	|I-IUPAC
-	396	397	|I-IUPAC
enoate	397	403	|I-IUPAC
(	404	405	|O
2d	405	407	|O
)	407	408	|O
,	408	409	|O
4	410	411	|B-IUPAC
-	411	412	|I-IUPAC
(	412	413	|I-IUPAC
3	413	414	|I-IUPAC
-	414	415	|I-IUPAC
chlorophenyl	415	427	|I-IUPAC
)	427	428	|I-IUPAC
-	428	429	|I-IUPAC
2	429	430	|I-IUPAC
-	430	431	|I-IUPAC
hydroxy	431	438	|I-IUPAC
-	438	439	|I-IUPAC
4	439	440	|I-IUPAC
-	440	441	|I-IUPAC
oxobut	441	447	|I-IUPAC
-	447	448	|I-IUPAC
2	448	449	|I-IUPAC
-	449	450	|I-IUPAC
enoic	450	455	|I-IUPAC
acid	456	460	|I-IUPAC
(	461	462	|O
3d	462	464	|O
)	464	465	|O
,	465	466	|O
methyl	467	473	|B-IUPAC
4	474	475	|I-IUPAC
-	475	476	|I-IUPAC
(	476	477	|I-IUPAC
3	477	478	|I-IUPAC
-	478	479	|I-IUPAC
fluorophenyl	479	491	|I-IUPAC
)	491	492	|I-IUPAC
-	492	493	|I-IUPAC
2	493	494	|I-IUPAC
-	494	495	|I-IUPAC
hydroxy	495	502	|I-IUPAC
-	502	503	|I-IUPAC
4	503	504	|I-IUPAC
-	504	505	|I-IUPAC
oxobut	505	511	|I-IUPAC
-	511	512	|I-IUPAC
2	512	513	|I-IUPAC
-	513	514	|I-IUPAC
enoate	514	520	|I-IUPAC
(	521	522	|O
2f	522	524	|O
)	524	525	|O
,	525	526	|O
and	527	530	|O
4	531	532	|B-IUPAC
-	532	533	|I-IUPAC
(	533	534	|I-IUPAC
3	534	535	|I-IUPAC
-	535	536	|I-IUPAC
fluorophenyl	536	548	|I-IUPAC
)	548	549	|I-IUPAC
-	549	550	|I-IUPAC
2	550	551	|I-IUPAC
-	551	552	|I-IUPAC
hydroxy	552	559	|I-IUPAC
-	559	560	|I-IUPAC
4	560	561	|I-IUPAC
-	561	562	|I-IUPAC
oxobut	562	568	|I-IUPAC
-	568	569	|I-IUPAC
2	569	570	|I-IUPAC
-	570	571	|I-IUPAC
enoic	571	576	|I-IUPAC
acid	577	581	|I-IUPAC
(	582	583	|O
3f	583	585	|O
)	585	586	|O
prevent	587	594	|O
the	595	598	|O
increase	599	607	|O
in	608	610	|O
the	611	614	|O
interferon	615	625	|O
-	625	626	|O
gamma	626	631	|O
-	631	632	|O
induced	632	639	|O
synthesis	640	649	|O
of	650	652	|O
quinolinic	653	663	|O
acid	664	668	|O
in	669	671	|O
primary	672	679	|O
cultures	680	688	|O
of	689	691	|O
cultured	692	700	|O
human	701	706	|O
peripheral	707	717	|O
blood	718	723	|O
monocyte	724	732	|O
-	732	733	|O
derived	733	740	|O
macrophages	741	752	|O
.	752	753	|O

### abstracts4756.txt
The	0	3	|O
present	4	11	|O
work	12	16	|O
reports	17	24	|O
the	25	28	|O
synthesis	29	38	|O
of	39	41	|O
enantiomeric	42	54	|O
pairs	55	60	|O
of	61	63	|O
the	64	67	|O
trans	68	73	|B-IUPAC
-	73	74	|I-IUPAC
2	74	75	|I-IUPAC
-	75	76	|I-IUPAC
amino	76	81	|I-IUPAC
-	81	82	|I-IUPAC
6	82	83	|I-IUPAC
-	83	84	|I-IUPAC
hydroxy	84	91	|I-IUPAC
-	91	92	|I-IUPAC
1	92	93	|I-IUPAC
-	93	94	|I-IUPAC
phenyl	94	100	|I-IUPAC
-	100	101	|I-IUPAC
2,3	101	104	|I-IUPAC
-	104	105	|I-IUPAC
dihydro	105	112	|I-IUPAC
-	112	113	|I-IUPAC
1H	113	115	|I-IUPAC
-	115	116	|I-IUPAC
indene	116	122	|I-IUPAC
[	123	124	|O
(	124	125	|O
+	125	126	|O
)	126	127	|O
-	127	128	|O
14a	128	131	|O
,	131	132	|O
(	133	134	|O
-	134	135	|O
)	135	136	|O
-	136	137	|O
14a	137	140	|O
]	140	141	|O
and	142	145	|O
trans	146	151	|B-IUPAC
-	151	152	|I-IUPAC
2	152	153	|I-IUPAC
-	153	154	|I-IUPAC
amino	154	159	|I-IUPAC
-	159	160	|I-IUPAC
5	160	161	|I-IUPAC
-	161	162	|I-IUPAC
hydroxy	162	169	|I-IUPAC
-	169	170	|I-IUPAC
1	170	171	|I-IUPAC
-	171	172	|I-IUPAC
phenyl	172	178	|I-IUPAC
-	178	179	|I-IUPAC
2,3	179	182	|I-IUPAC
-	182	183	|I-IUPAC
dihydro	183	190	|I-IUPAC
-	190	191	|I-IUPAC
1	191	192	|I-IUPAC
H	193	194	|I-IUPAC
-	194	195	|I-IUPAC
indene	195	201	|I-IUPAC
[	202	203	|O
(	203	204	|O
+	204	205	|O
)	205	206	|O
-	206	207	|O
14b	207	210	|O
,	210	211	|O
(	212	213	|O
-	213	214	|O
)	214	215	|O
-	215	216	|O
14b	216	219	|O
]	219	220	|O
and	221	224	|O
their	225	230	|O
N	231	232	|B-IUPAC
,	232	233	|I-IUPAC
N	233	234	|I-IUPAC
-	234	235	|I-IUPAC
di	235	237	|I-IUPAC
-	237	238	|I-IUPAC
n	238	239	|I-IUPAC
-	239	240	|I-IUPAC
propyl	240	246	|I-IUPAC
[	247	248	|O
(	248	249	|O
+	249	250	|O
)	250	251	|O
-	251	252	|O
and	252	255	|O
(	256	257	|O
-	257	258	|O
)	258	259	|O
-	259	260	|O
15a	260	263	|O
,	263	264	|O
b	264	265	|O
]	265	266	|O
,	266	267	|O
N	268	269	|B-IUPAC
-	269	270	|I-IUPAC
methyl	270	276	|I-IUPAC
-	276	277	|I-IUPAC
N	277	278	|I-IUPAC
-	278	279	|I-IUPAC
allyl	279	284	|I-IUPAC
[	285	286	|O
(	286	287	|O
+	287	288	|O
)	288	289	|O
-	289	290	|O
and	290	293	|O
(	294	295	|O
-	295	296	|O
)	296	297	|O
-	297	298	|O
16a	298	301	|O
,	301	302	|O
b	302	303	|O
]	303	304	|O
,	304	305	|O
and	306	309	|O
N	310	311	|B-IUPAC
-	311	312	|I-IUPAC
methyl	312	318	|I-IUPAC
-	318	319	|I-IUPAC
N	319	320	|I-IUPAC
-	320	321	|I-IUPAC
n	321	322	|I-IUPAC
-	322	323	|I-IUPAC
propyl	323	329	|I-IUPAC
[	330	331	|O
(	331	332	|O
+	332	333	|O
)	333	334	|O
and	335	338	|O
(	339	340	|O
-	340	341	|O
)	341	342	|O
-	342	343	|O
17a	343	346	|O
,	346	347	|O
b	347	348	|O
]	348	349	|O
derivatives	350	361	|B-MODIFIER
obtained	362	370	|O
by	371	373	|O
a	374	375	|O
combination	376	387	|O
of	388	390	|O
stereospecific	391	405	|O
reactions	406	415	|O
and	416	419	|O
optical	420	427	|O
resolution	428	438	|O
.	438	439	|O
The	440	443	|O
new	444	447	|O
compounds	448	457	|O
were	458	462	|O
evaluated	463	472	|O
for	473	476	|O
their	477	482	|O
affinity	483	491	|O
at	492	494	|O
the	495	498	|O
dopamine	499	507	|O
D1	508	510	|O
and	511	514	|O
D2	515	517	|O
receptors	518	527	|O
.	527	528	|O
The	529	532	|O
amines	533	539	|O
(	540	541	|O
+	541	542	|O
)	542	543	|O
-	543	544	|O
and	545	548	|O
(	549	550	|O
-	550	551	|O
)	551	552	|O
-	552	553	|O
14a	553	556	|O
,	556	557	|O
incorporating	558	571	|O
the	572	575	|O
D1	576	578	|O
pharmacophore	579	592	|O
2	593	594	|B-IUPAC
-	594	595	|I-IUPAC
phenyl	595	601	|I-IUPAC
-	601	602	|I-IUPAC
2	602	603	|I-IUPAC
-	603	604	|I-IUPAC
(	604	605	|I-IUPAC
3	605	606	|I-IUPAC
-	606	607	|I-IUPAC
hydroxyphenyl	607	620	|I-IUPAC
)	620	621	|I-IUPAC
ethylamine	621	631	|I-IUPAC
in	632	634	|O
a	635	636	|O
trans	637	642	|O
extended	643	651	|O
conformation	652	664	|O
,	664	665	|O
and	666	669	|O
their	670	675	|O
derivatives	676	687	|O
displayed	688	697	|O
D1	698	700	|O
and	701	704	|O
D2	705	707	|O
affinity	708	716	|O
in	717	719	|O
the	720	723	|O
nanomolar	724	733	|O
range	734	739	|O
.	739	740	|O
On	741	743	|O
the	744	747	|O
other	748	753	|O
hand	754	758	|O
,	758	759	|O
the	760	763	|O
enantiomers	764	775	|O
(	776	777	|O
+	777	778	|O
)	778	779	|O
-	779	780	|O
and	781	784	|O
(	785	786	|O
-	786	787	|O
)	787	788	|O
-	788	789	|O
14b	789	792	|O
,	792	793	|O
(	794	795	|O
+	795	796	|O
)	796	797	|O
-	797	798	|O
and	799	802	|O
(	803	804	|O
-	804	805	|O
)	805	806	|O
-	806	807	|O
15b	807	810	|O
displayed	811	820	|O
high	821	825	|O
affinity	826	834	|O
and	835	838	|O
selectivity	839	850	|O
for	851	854	|O
the	855	858	|O
D1	859	861	|O
receptor	862	870	|O
.	870	871	|O
In	872	874	|O
a	875	876	|O
preliminary	877	888	|O
behavioral	889	899	|O
study	900	905	|O
on	906	908	|O
rats	909	913	|O
(	914	915	|O
+	915	916	|O
)	916	917	|O
-	917	918	|O
14b	918	921	|O
,	921	922	|O
and	923	926	|O
to	927	929	|O
a	930	931	|O
greater	932	939	|O
extent	940	946	|O
(	947	948	|O
+	948	949	|O
)	949	950	|O
-	950	951	|O
15b	951	954	|O
,	954	955	|O
promoted	956	964	|O
episodes	965	973	|O
of	974	976	|O
intense	977	984	|O
grooming	985	993	|O
,	993	994	|O
thus	995	999	|O
indicating	1000	1010	|O
that	1011	1015	|O
they	1016	1020	|O
act	1021	1024	|O
as	1025	1027	|O
central	1028	1035	|O
D1	1036	1038	|O
agonists	1039	1047	|O
.	1047	1048	|O
The	1049	1052	|O
trans	1053	1058	|B-IUPAC
-	1058	1059	|I-IUPAC
2	1059	1060	|I-IUPAC
-	1060	1061	|I-IUPAC
amino	1061	1066	|I-IUPAC
-	1066	1067	|I-IUPAC
5	1067	1068	|I-IUPAC
-	1068	1069	|I-IUPAC
hydroxy	1069	1076	|I-IUPAC
-	1076	1077	|I-IUPAC
1	1077	1078	|I-IUPAC
-	1078	1079	|I-IUPAC
phenyl	1079	1085	|I-IUPAC
-	1085	1086	|I-IUPAC
2,3	1086	1089	|I-IUPAC
-	1089	1090	|I-IUPAC
dihydro	1090	1097	|I-IUPAC
-	1097	1098	|I-IUPAC
1H	1098	1100	|I-IUPAC
-	1100	1101	|I-IUPAC
indenes	1101	1108	|I-IUPAC
(	1109	1110	|O
+	1110	1111	|O
)	1111	1112	|O
-	1112	1113	|O
14b	1113	1116	|O
and	1117	1120	|O
(	1121	1122	|O
+	1122	1123	|O
)	1123	1124	|O
-	1124	1125	|O
15b	1125	1128	|O
represent	1129	1138	|O
selective	1139	1148	|O
D1	1149	1151	|O
agonists	1152	1160	|O
lacking	1161	1168	|O
a	1169	1170	|O
catechol	1171	1179	|O
group	1180	1185	|O
,	1185	1186	|O
which	1187	1192	|O
should	1193	1199	|O
meet	1200	1204	|O
the	1205	1208	|O
prerequisites	1209	1222	|O
for	1223	1226	|O
a	1227	1228	|O
central	1229	1236	|O
nervous	1237	1244	|O
system	1245	1251	|O
penetration	1252	1263	|O
.	1263	1264	|O

### abstracts3225.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
4	12	13	|B-IUPAC
-	13	14	|I-IUPAC
phenylisoquinolone	14	32	|I-IUPAC
derivatives	33	44	|B-MODIFIER
were	45	49	|O
synthesized	50	61	|O
and	62	65	|O
evaluated	66	75	|O
for	76	79	|O
NK1	80	83	|O
(	84	85	|O
substance	85	94	|O
P	95	96	|O
)	96	97	|O
antagonist	98	108	|O
activity	109	117	|O
.	117	118	|O
Highly	119	125	|O
potent	126	132	|O
antagonists	133	144	|O
,	144	145	|O
4	146	147	|B-IUPAC
-	147	148	|I-IUPAC
phenyl	148	154	|I-IUPAC
-	154	155	|I-IUPAC
3	155	156	|I-IUPAC
-	156	157	|I-IUPAC
isoquinolone	157	169	|I-IUPAC
-	169	170	|I-IUPAC
N	170	171	|I-IUPAC
-	171	172	|I-IUPAC
benzylcarboxamides	172	190	|I-IUPAC
(	191	192	|O
11	192	194	|O
)	194	195	|O
,	195	196	|O
were	197	201	|O
discovered	202	212	|O
from	213	217	|O
the	218	221	|O
structure	222	231	|O
-	231	232	|O
activity	232	240	|O
relationship	241	253	|O
studies	254	261	|O
on	262	264	|O
the	265	268	|O
isoquinolone	269	281	|O
-	281	282	|O
urea	282	286	|O
lead	287	291	|O
1a	292	294	|O
.	294	295	|O
Optimization	296	308	|O
of	309	311	|O
the	312	315	|O
activity	316	324	|O
in	325	327	|O
this	328	332	|O
series	333	339	|O
resulted	340	348	|O
in	349	351	|O
the	352	355	|O
development	356	367	|O
of	368	370	|O
5	371	372	|B-IUPAC
-	372	373	|I-IUPAC
phenyl	373	379	|I-IUPAC
-	379	380	|I-IUPAC
6	380	381	|I-IUPAC
-	381	382	|I-IUPAC
pyrido	382	388	|I-IUPAC
[	388	389	|I-IUPAC
3,4	389	392	|I-IUPAC
-	392	393	|I-IUPAC
b	393	394	|I-IUPAC
]	394	395	|I-IUPAC
pyridine	395	403	|I-IUPAC
-	403	404	|I-IUPAC
N	404	405	|I-IUPAC
-	405	406	|I-IUPAC
benzylcarboxamides	406	424	|I-IUPAC
(	425	426	|O
30	426	428	|O
)	428	429	|O
which	430	435	|O
are	436	439	|O
highly	440	446	|O
potent	447	453	|O
orally	454	460	|O
active	461	467	|O
NK1	468	471	|O
antagonists	472	483	|O
.	483	484	|O
Among	485	490	|O
the	491	494	|O
compounds	495	504	|O
synthesized	505	516	|O
,	516	517	|O
N	518	519	|B-PARTIUPAC
-	519	520	|I-PARTIUPAC
[	520	521	|I-PARTIUPAC
3,5	521	524	|I-PARTIUPAC
-	524	525	|I-PARTIUPAC
bis	525	528	|I-PARTIUPAC
(	528	529	|I-PARTIUPAC
trifluoromethyl	529	544	|I-PARTIUPAC
)	544	545	|I-PARTIUPAC
benzyl	545	551	|I-PARTIUPAC
]	551	552	|I-PARTIUPAC
-	552	553	|I-PARTIUPAC
7,8	553	556	|I-PARTIUPAC
-	556	557	|I-PARTIUPAC
dihydro	557	564	|I-PARTIUPAC
-	564	565	|I-PARTIUPAC
N	565	566	|I-PARTIUPAC
,	566	567	|I-PARTIUPAC
7	567	568	|I-PARTIUPAC
-	568	569	|I-PARTIUPAC
dimethyl	569	577	|I-PARTIUPAC
-	577	578	|I-PARTIUPAC
8	578	579	|I-PARTIUPAC
-	579	580	|I-PARTIUPAC
oxo	580	583	|I-PARTIUPAC
-	583	584	|I-PARTIUPAC
5	584	585	|I-PARTIUPAC
-	585	586	|I-PARTIUPAC
(	587	588	|I-PARTIUPAC
substituted	588	599	|B-MODIFIER
phenyl	600	606	|B-IUPAC
)	606	607	|B-PARTIUPAC
-	607	608	|I-PARTIUPAC
6	608	609	|I-PARTIUPAC
-	609	610	|I-PARTIUPAC
pyrido	610	616	|I-PARTIUPAC
[	616	617	|I-PARTIUPAC
3,4	617	620	|I-PARTIUPAC
-	620	621	|I-PARTIUPAC
b	621	622	|I-PARTIUPAC
]	622	623	|I-PARTIUPAC
pyridinecarboxamides	623	643	|I-PARTIUPAC
(	644	645	|O
30a	645	648	|O
,	648	649	|O
f	649	650	|O
,	650	651	|O
g	651	652	|O
)	652	653	|O
showed	654	660	|O
excellent	661	670	|O
antagonist	671	681	|O
activities	682	692	|O
with	693	697	|O
IC50	698	702	|O
values	703	709	|O
(	710	711	|O
in	711	713	|O
vitro	714	719	|O
inhibition	720	730	|O
of	731	733	|O
[	734	735	|O
125I	735	739	|O
]	739	740	|O
-	740	741	|O
BH	741	743	|O
-	743	744	|O
SP	744	746	|O
binding	747	754	|O
in	755	757	|O
human	758	763	|O
IM	764	766	|O
-	766	767	|O
9	767	768	|O
cells	769	774	|O
)	774	775	|O
of	776	778	|O
0.21-0.34	779	788	|O
nM	789	791	|O
and	792	795	|O
ED50	796	800	|O
values	801	807	|O
(	808	809	|O
in	809	811	|O
vivo	812	816	|O
inhibition	817	827	|O
of	828	830	|O
capsaicin	831	840	|O
-	840	841	|O
induced	841	848	|O
plasma	849	855	|O
extravasation	856	869	|O
in	870	872	|O
guinea	873	879	|O
-	879	880	|O
pig	880	883	|O
trachea	884	891	|O
,	891	892	|O
iv	893	895	|O
)	895	896	|O
of	897	899	|O
0.017-0.030	900	911	|O
mg	912	914	|O
/	914	915	|O
kg	915	917	|O
.	917	918	|O
These	919	924	|O
compounds	925	934	|O
exhibited	935	944	|O
significantly	945	958	|O
potent	959	965	|O
activity	966	974	|O
upon	975	979	|O
oral	980	984	|O
administration	985	999	|O
with	1000	1004	|O
ED50	1005	1009	|O
values	1010	1016	|O
of	1017	1019	|O
0.068-0.17	1020	1030	|O
mg	1031	1033	|O
/	1033	1034	|O
kg	1034	1036	|O
.	1036	1037	|O
Conformational	1038	1052	|O
studies	1053	1060	|O
on	1061	1063	|O
30g	1064	1067	|O
indicated	1068	1077	|O
that	1078	1082	|O
the	1083	1086	|O
two	1087	1090	|O
stable	1091	1097	|O
conformers	1098	1108	|O
of	1109	1111	|O
30g	1112	1115	|O
are	1116	1119	|O
quite	1120	1125	|O
similar	1126	1133	|O
to	1134	1136	|O
those	1137	1142	|O
of	1143	1145	|O
CP	1146	1148	|O
-	1148	1149	|O
99,994	1149	1155	|O
.	1155	1156	|O

### abstracts3131.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
5	12	13	|B-IUPAC
-	13	14	|I-IUPAC
aryl	14	18	|I-IUPAC
-	18	19	|I-IUPAC
2,4	19	22	|I-IUPAC
-	22	23	|I-IUPAC
dihydro	23	30	|I-IUPAC
-	30	31	|I-IUPAC
3H	31	33	|I-IUPAC
-	33	34	|I-IUPAC
1,2,4	34	39	|I-IUPAC
-	39	40	|I-IUPAC
triazol	40	47	|I-IUPAC
-	47	48	|I-IUPAC
3	48	49	|I-IUPAC
-	49	50	|I-IUPAC
ones	50	54	|I-IUPAC
was	55	58	|O
evaluated	59	68	|O
for	69	72	|O
anticonvulsant	73	87	|O
activity	88	96	|O
.	96	97	|O
In	98	100	|O
general	101	108	|O
the	109	112	|O
members	113	120	|O
of	121	123	|O
this	124	128	|O
series	129	135	|O
were	136	140	|O
prepared	141	149	|O
by	150	152	|O
the	153	156	|O
alkaline	157	165	|O
cyclization	166	177	|O
of	178	180	|O
1	181	182	|B-IUPAC
-	182	183	|I-IUPAC
aroyl	183	188	|I-IUPAC
-	188	189	|I-IUPAC
4	189	190	|I-IUPAC
-	190	191	|I-IUPAC
alkylsemicarbazides	191	210	|I-IUPAC
.	210	211	|O
The	212	215	|O
resulting	216	225	|O
2	226	227	|B-MODIFIER
-	227	228	|I-MODIFIER
unsubstituted	228	241	|I-MODIFIER
3H	242	244	|B-IUPAC
-	244	245	|I-IUPAC
1,2,4	245	250	|I-IUPAC
-	250	251	|I-IUPAC
triazol	251	258	|I-IUPAC
-	258	259	|I-IUPAC
3	259	260	|I-IUPAC
-	260	261	|I-IUPAC
ones	261	265	|I-IUPAC
were	266	270	|O
then	271	275	|O
alkylated	276	285	|O
,	285	286	|O
yielding	287	295	|O
2,4	296	299	|B-IUPAC
-	299	300	|I-IUPAC
dialkyl	300	307	|I-IUPAC
-	307	308	|I-IUPAC
3H	308	310	|I-IUPAC
-	310	311	|I-IUPAC
1,2,4	311	316	|I-IUPAC
-	316	317	|I-IUPAC
triazol	317	324	|I-IUPAC
-	324	325	|I-IUPAC
3	325	326	|I-IUPAC
-	326	327	|I-IUPAC
ones	327	331	|I-IUPAC
.	331	332	|O
Approximately	333	346	|O
one	347	350	|O
-	350	351	|O
third	351	356	|O
of	357	359	|O
the	360	363	|O
compounds	364	373	|O
examined	374	382	|O
exhibited	383	392	|O
activity	393	401	|O
against	402	409	|O
both	410	414	|O
maximal	415	422	|O
electroshock	423	435	|O
-	435	436	|O
and	437	440	|O
pentylenetetrazole	441	459	|O
-	459	460	|O
induced	460	467	|O
seizures	468	476	|O
in	477	479	|O
mice	480	484	|O
.	484	485	|O
Receptor	486	494	|O
-	494	495	|O
binding	495	502	|O
studies	503	510	|O
suggest	511	518	|O
that	519	523	|O
this	524	528	|O
activity	529	537	|O
was	538	541	|O
not	542	545	|O
a	546	547	|O
consequence	548	559	|O
of	560	562	|O
activity	563	571	|O
at	572	574	|O
either	575	581	|O
benzodiazepine	582	596	|O
or	597	599	|O
NMDA	600	604	|O
-	604	605	|O
type	605	609	|O
glutamate	610	619	|O
receptors	620	629	|O
.	629	630	|O
From	631	635	|O
this	636	640	|O
series	641	647	|O
,	647	648	|O
compound	649	657	|O
45	658	660	|O
was	661	664	|O
selected	665	673	|O
for	674	677	|O
further	678	685	|O
evaluation	686	696	|O
where	697	702	|O
it	703	705	|O
was	706	709	|O
also	710	714	|O
found	715	720	|O
to	721	723	|O
be	724	726	|O
active	727	733	|O
against	734	741	|O
3	742	743	|B-IUPAC
-	743	744	|I-IUPAC
mercaptopropionic	744	761	|I-IUPAC
acid	762	766	|I-IUPAC
,	766	767	|O
bicuculline	768	779	|O
,	779	780	|O
and	781	784	|O
quinolinic	785	795	|O
acid	796	800	|O
induced	801	808	|O
seizures	809	817	|O
in	818	820	|O
mice	821	825	|O
.	825	826	|O
In	827	829	|O
addition	830	838	|O
,	838	839	|O
45	840	842	|O
also	843	847	|O
protected	848	857	|O
gerbils	858	865	|O
from	866	870	|O
hippocampal	871	882	|O
neuronal	883	891	|O
degeneration	892	904	|O
produced	905	913	|O
by	914	916	|O
either	917	923	|O
hypoxia	924	931	|O
or	932	934	|O
intrastriatal	935	948	|O
quinolinic	949	959	|O
acid	960	964	|O
injection	965	974	|O
.	974	975	|O

### abstracts3857.txt
In	0	2	|O
order	3	8	|O
to	9	11	|O
determine	12	21	|O
the	22	25	|O
active	26	32	|O
site	33	37	|O
binding	38	45	|O
orientation	46	57	|O
of	58	60	|O
norepinephrine	61	75	|O
,	75	76	|O
a	77	78	|O
series	79	85	|O
of	86	88	|O
conformationally	89	105	|O
defined	106	113	|O
analogues	114	123	|O
of	124	126	|O
the	127	130	|O
tyramines	131	140	|O
,	140	141	|O
in	142	144	|O
which	145	150	|O
the	151	154	|O
ethylamine	155	165	|O
side	166	170	|O
chain	171	176	|O
is	177	179	|O
held	180	184	|O
fixed	185	190	|O
by	191	193	|O
incorporation	194	207	|O
into	208	212	|O
a	213	214	|O
benzonorbornene	215	230	|O
skeleton	231	239	|O
,	239	240	|O
were	241	245	|O
prepared	246	254	|O
and	255	258	|O
evaluated	259	268	|O
for	269	272	|O
phenylethanolamine	273	291	|O
N	292	293	|O
-	293	294	|O
methyltransferase	294	311	|O
(	312	313	|O
PNMT	313	317	|O
)	317	318	|O
activity	319	327	|O
.	327	328	|O
While	329	334	|O
exo	335	338	|B-PARTIUPAC
-	338	339	|I-PARTIUPAC
2	339	340	|I-PARTIUPAC
-	340	341	|I-PARTIUPAC
amino	341	346	|I-PARTIUPAC
-	346	347	|I-PARTIUPAC
5	347	348	|I-PARTIUPAC
-	348	349	|I-PARTIUPAC
and	350	353	|O
exo	354	357	|B-IUPAC
-	357	358	|I-IUPAC
2	358	359	|I-IUPAC
-	359	360	|I-IUPAC
amino	360	365	|I-IUPAC
-	365	366	|I-IUPAC
8	366	367	|I-IUPAC
-	367	368	|I-IUPAC
hydroxybenzonorbornene	368	390	|I-IUPAC
(	391	392	|O
7	392	393	|O
and	394	397	|O
10	398	400	|O
,	400	401	|O
respectively	402	414	|O
)	414	415	|O
were	416	420	|O
prepared	421	429	|O
from	430	434	|O
5	435	436	|B-IUPAC
-	436	437	|I-IUPAC
methoxybenzonorbornadiene	437	462	|I-IUPAC
by	463	465	|O
azidomercuration	466	482	|O
/	482	483	|O
demercuration	483	496	|O
and	497	500	|O
reduction	501	510	|O
,	510	511	|O
it	512	514	|O
was	515	518	|O
necessary	519	528	|O
to	529	531	|O
employ	532	538	|O
both	539	543	|O
normal	544	550	|O
(	551	552	|O
inversion	552	561	|O
of	562	564	|O
configuration	565	578	|O
)	578	579	|O
and	580	583	|O
abnormal	584	592	|O
(	593	594	|O
retention	594	603	|O
of	604	606	|O
configuration	607	620	|O
)	620	621	|O
Mitsunobu	622	631	|O
reactions	632	641	|O
to	642	644	|O
prepare	645	652	|O
,	652	653	|O
stereoselectively	654	671	|O
,	671	672	|O
exo	673	676	|B-PARTIUPAC
-	676	677	|I-PARTIUPAC
2	677	678	|I-PARTIUPAC
-	678	679	|I-PARTIUPAC
amino	679	684	|I-PARTIUPAC
-	684	685	|I-PARTIUPAC
6	685	686	|I-PARTIUPAC
-	686	687	|I-PARTIUPAC
and	688	691	|O
exo	692	695	|B-IUPAC
-	695	696	|I-IUPAC
2	696	697	|I-IUPAC
-	697	698	|I-IUPAC
amino	698	703	|I-IUPAC
-	703	704	|I-IUPAC
7	704	705	|I-IUPAC
-	705	706	|I-IUPAC
hydroxybenzonorbornene	706	728	|I-IUPAC
(	729	730	|O
8	730	731	|O
and	732	735	|O
9	736	737	|O
,	737	738	|O
respectively	739	751	|O
)	751	752	|O
from	753	757	|O
6	758	759	|B-PARTIUPAC
-	759	760	|I-PARTIUPAC
and	761	764	|O
7	765	766	|B-IUPAC
-	766	767	|I-IUPAC
methoxybenzonorbornen	767	788	|I-IUPAC
-	788	789	|I-IUPAC
2	789	790	|I-IUPAC
-	790	791	|I-IUPAC
ol	791	793	|I-IUPAC
.	793	794	|O
None	795	799	|O
of	800	802	|O
the	803	806	|O
six	807	810	|O
analogues	811	820	|O
were	821	825	|O
substrates	826	836	|O
.	836	837	|O
However	838	845	|O
,	845	846	|O
exo	847	850	|B-IUPAC
-	850	851	|I-IUPAC
2	851	852	|I-IUPAC
-	852	853	|I-IUPAC
amino	853	858	|I-IUPAC
-	858	859	|I-IUPAC
6	859	860	|I-IUPAC
-	860	861	|I-IUPAC
hydroxybenzonorbornene	861	883	|I-IUPAC
(	884	885	|O
8	885	886	|O
)	886	887	|O
and	888	891	|O
anti	892	896	|B-IUPAC
-	896	897	|I-IUPAC
9	897	898	|I-IUPAC
-	898	899	|I-IUPAC
amino	899	904	|I-IUPAC
-	904	905	|I-IUPAC
6	905	906	|I-IUPAC
-	906	907	|I-IUPAC
hydroxybenzonorbornene	907	929	|I-IUPAC
(	930	931	|O
12	931	933	|O
)	933	934	|O
displayed	935	944	|O
significant	945	956	|O
activity	957	965	|O
as	966	968	|O
inhibitors	969	979	|O
toward	980	986	|O
PNMT	987	991	|O
.	991	992	|O
The	993	996	|O
greater	997	1004	|O
potency	1005	1012	|O
of	1013	1015	|O
8	1016	1017	|O
and	1018	1021	|O
12	1022	1024	|O
,	1024	1025	|O
as	1026	1028	|O
compared	1029	1037	|O
to	1038	1040	|O
the	1041	1044	|O
parent	1045	1051	|O
unsubstituted	1052	1065	|O
analogues	1066	1075	|O
exo	1076	1079	|B-PARTIUPAC
-	1079	1080	|I-PARTIUPAC
2	1080	1081	|I-PARTIUPAC
-	1081	1082	|I-PARTIUPAC
amino	1082	1087	|I-PARTIUPAC
-	1087	1088	|I-PARTIUPAC
and	1089	1092	|O
anti	1093	1097	|B-IUPAC
-	1097	1098	|I-IUPAC
9	1098	1099	|I-IUPAC
-	1099	1100	|I-IUPAC
amino	1100	1105	|I-IUPAC
-	1105	1106	|I-IUPAC
benzonorbornene	1106	1121	|I-IUPAC
(	1122	1123	|O
4	1123	1124	|O
and	1125	1128	|O
5	1129	1130	|O
,	1130	1131	|O
respectively	1132	1144	|O
)	1144	1145	|O
,	1145	1146	|O
indicates	1147	1156	|O
the	1157	1160	|O
presence	1161	1169	|O
of	1170	1172	|O
a	1173	1174	|O
spatially	1175	1184	|O
compact	1185	1192	|O
hydrophilic	1193	1204	|O
pocket	1205	1211	|O
within	1212	1218	|O
the	1219	1222	|O
aromatic	1223	1231	|O
ring	1232	1236	|O
binding	1237	1244	|O
region	1245	1251	|O
of	1252	1254	|O
the	1255	1258	|O
active	1259	1265	|O
site	1266	1270	|O
of	1271	1273	|O
the	1274	1277	|O
enzyme	1278	1284	|O
.	1284	1285	|O
Furthermore	1286	1297	|O
,	1297	1298	|O
the	1299	1302	|O
greater	1303	1310	|O
activity	1311	1319	|O
of	1320	1322	|O
12	1323	1325	|O
,	1325	1326	|O
relative	1327	1335	|O
to	1336	1338	|O
8	1339	1340	|O
,	1340	1341	|O
is	1342	1344	|O
consistent	1345	1355	|O
with	1356	1360	|O
an	1361	1363	|O
active	1364	1370	|O
site	1371	1375	|O
binding	1376	1383	|O
preference	1384	1394	|O
for	1395	1398	|O
molecules	1399	1408	|O
in	1409	1411	|O
which	1412	1417	|O
a	1418	1419	|O
more	1420	1424	|O
coplanar	1425	1433	|O
relationship	1434	1446	|O
exists	1447	1453	|O
between	1454	1461	|O
the	1462	1465	|O
aromatic	1466	1474	|O
ring	1475	1479	|O
and	1480	1483	|O
the	1484	1487	|O
amine	1488	1493	|O
nitrogen	1494	1502	|O
.	1502	1503	|O
From	1504	1508	|O
the	1509	1512	|O
findings	1513	1521	|O
of	1522	1524	|O
this	1525	1529	|O
study	1530	1535	|O
,	1535	1536	|O
it	1537	1539	|O
appears	1540	1547	|O
that	1548	1552	|O
norepinephrine	1553	1567	|O
has	1568	1571	|O
a	1572	1573	|O
different	1574	1583	|O
active	1584	1590	|O
site	1591	1595	|O
binding	1596	1603	|O
orientation	1604	1615	|O
than	1616	1620	|O
most	1621	1625	|O
known	1626	1631	|O
substrates	1632	1642	|O
and	1643	1646	|O
competitive	1647	1658	|O
inhibitors	1659	1669	|O
of	1670	1672	|O
PNMT	1673	1677	|O
.	1677	1678	|O

### abstracts853.txt
To	0	2	|O
provide	3	10	|O
potential	11	20	|O
new	21	24	|O
leads	25	30	|O
for	31	34	|O
the	35	38	|O
treatment	39	48	|O
of	49	51	|O
orthopoxvirus	52	65	|O
infections	66	76	|O
,	76	77	|O
the	78	81	|O
5	82	83	|O
-	83	84	|O
position	84	92	|O
of	93	95	|O
the	96	99	|O
pyrimidine	100	110	|O
nucleosides	111	122	|O
have	123	127	|O
been	128	132	|O
modified	133	141	|O
with	142	146	|O
a	147	148	|O
gem	149	152	|O
diether	153	160	|O
moiety	161	167	|O
to	168	170	|O
yield	171	176	|O
the	177	180	|O
following	181	190	|O
new	191	194	|O
nucleosides	195	206	|O
:	206	207	|O
5	208	209	|B-IUPAC
-	209	210	|I-IUPAC
(	210	211	|I-IUPAC
dimethoxymethyl	211	226	|I-IUPAC
)	226	227	|I-IUPAC
-	227	228	|I-IUPAC
2'	228	230	|I-IUPAC
-	230	231	|I-IUPAC
deoxyuridine	231	243	|I-IUPAC
(	244	245	|O
2b	245	247	|O
)	247	248	|O
,	248	249	|O
5	250	251	|B-IUPAC
-	251	252	|I-IUPAC
(	252	253	|I-IUPAC
diethoxymethyl	253	267	|I-IUPAC
)	267	268	|I-IUPAC
-	268	269	|I-IUPAC
2'	269	271	|I-IUPAC
-	271	272	|I-IUPAC
deoxyuridine	272	284	|I-IUPAC
(	285	286	|O
3b	286	288	|O
)	288	289	|O
,	289	290	|O
5	291	292	|B-IUPAC
-	292	293	|I-IUPAC
formyl	293	299	|I-IUPAC
-	299	300	|I-IUPAC
2'	300	302	|I-IUPAC
-	302	303	|I-IUPAC
deoxyuridine	303	315	|I-IUPAC
ethylene	316	324	|I-IUPAC
acetal	325	331	|I-IUPAC
(	332	333	|O
4b	333	335	|O
)	335	336	|O
,	336	337	|O
and	338	341	|O
5	342	343	|B-IUPAC
-	343	344	|I-IUPAC
formyl	344	350	|I-IUPAC
-	350	351	|I-IUPAC
2'	351	353	|I-IUPAC
-	353	354	|I-IUPAC
deoxyuridine	354	366	|I-IUPAC
propylene	367	376	|I-IUPAC
acetal	377	383	|I-IUPAC
(	384	385	|O
5b	385	387	|O
)	387	388	|O
.	388	389	|O
These	390	395	|O
were	396	400	|O
evaluated	401	410	|O
in	411	413	|O
human	414	419	|O
foreskin	420	428	|O
fibroblast	429	439	|O
cells	440	445	|O
challenged	446	456	|O
with	457	461	|O
the	462	465	|O
vaccinia	466	474	|O
virus	475	480	|O
or	481	483	|O
cowpox	484	490	|O
virus	491	496	|O
.	496	497	|O
Of	498	500	|O
the	501	504	|O
four	505	509	|O
gem	510	513	|O
diether	514	521	|O
nucleosides	522	533	|O
,	533	534	|O
only	535	539	|O
the	540	543	|O
dimethyl	544	552	|O
gem	553	556	|O
diether	557	564	|O
congener	565	573	|O
showed	574	580	|O
significant	581	592	|O
antiviral	593	602	|O
activity	603	611	|O
against	612	619	|O
both	620	624	|O
viruses	625	632	|O
.	632	633	|O
This	634	638	|O
antiviral	639	648	|O
activity	649	657	|O
did	658	661	|O
not	662	665	|O
appear	666	672	|O
to	673	675	|O
be	676	678	|O
related	679	686	|O
to	687	689	|O
the	690	693	|O
decomposition	694	707	|O
to	708	710	|O
the	711	714	|O
5	715	716	|B-IUPAC
-	716	717	|I-IUPAC
formyl	717	723	|I-IUPAC
-	723	724	|I-IUPAC
2'	724	726	|I-IUPAC
-	726	727	|I-IUPAC
deoxyuridine	727	739	|I-IUPAC
,	739	740	|O
which	741	746	|O
was	747	750	|O
itself	751	757	|O
devoid	758	764	|O
of	765	767	|O
anti	768	772	|O
-	772	773	|O
orthopoxvirus	773	786	|O
activity	787	795	|O
in	796	798	|O
these	799	804	|O
assays	805	811	|O
.	811	812	|O
Moreover	813	821	|O
,	821	822	|O
at	823	825	|O
the	826	829	|O
pH	830	832	|O
of	833	835	|O
the	836	839	|O
in	840	842	|O
vitro	843	848	|O
assays	849	855	|O
,	855	856	|O
2b	857	859	|O
was	860	863	|O
very	864	868	|O
stable	869	875	|O
with	876	880	|O
a	881	882	|O
decomposition	883	896	|O
(	897	898	|O
to	898	900	|O
aldehyde	901	909	|O
)	909	910	|O
half	911	915	|O
-	915	916	|O
life	916	920	|O
of	921	923	|O
&	924	925	|O
gt	925	927	|O
;	927	928	|O
15	928	930	|O
d	931	932	|O
.	932	933	|O
The	934	937	|O
anti	938	942	|O
-	942	943	|O
orthopoxvirus	943	956	|O
activity	957	965	|O
of	966	968	|O
pyrimidine	969	979	|O
may	980	983	|O
be	984	986	|O
favored	987	994	|O
by	995	997	|O
the	998	1001	|O
introduction	1002	1014	|O
of	1015	1017	|O
hydrophilic	1018	1029	|O
moieties	1030	1038	|O
to	1039	1041	|O
the	1042	1045	|O
5	1046	1047	|O
-	1047	1048	|O
position	1048	1056	|O
side	1057	1061	|O
chain	1062	1067	|O
.	1067	1068	|O

### abstracts2007.txt
New	0	3	|O
acylated	4	12	|O
bis	13	16	|B-IUPAC
-	16	17	|I-IUPAC
catecholates	17	29	|I-IUPAC
and	30	33	|O
1,3	34	37	|B-IUPAC
-	37	38	|I-IUPAC
benzoxazine	38	49	|I-IUPAC
-	49	50	|I-IUPAC
2,4	50	53	|I-IUPAC
-	53	54	|I-IUPAC
dione	54	59	|I-IUPAC
derivatives	60	71	|B-MODIFIER
based	72	77	|O
on	78	80	|O
secondary	81	90	|O
diamino	91	98	|O
acids	99	104	|O
(	105	106	|O
N	106	107	|B-IUPAC
-	107	108	|I-IUPAC
(	108	109	|I-IUPAC
aminoalkyl	109	119	|I-IUPAC
)	119	120	|I-IUPAC
glycines	120	128	|I-IUPAC
,	128	129	|O
N	130	131	|B-IUPAC
-	131	132	|I-IUPAC
aminopropyl	132	143	|I-IUPAC
-	143	144	|I-IUPAC
alanine	144	151	|I-IUPAC
,	151	152	|O
and	153	156	|O
N	157	158	|B-IUPAC
-	158	159	|I-IUPAC
aminopropyl	159	170	|I-IUPAC
-	170	171	|I-IUPAC
4	171	172	|I-IUPAC
-	172	173	|I-IUPAC
aminovaleric	173	185	|I-IUPAC
acid	186	190	|I-IUPAC
)	190	191	|O
,	191	192	|O
on	193	195	|O
N	196	197	|B-IUPAC
-	197	198	|I-IUPAC
(	198	199	|I-IUPAC
aminoalkyl	199	209	|I-IUPAC
)	209	210	|I-IUPAC
aminomethyl	210	221	|I-IUPAC
benzoic	222	229	|I-IUPAC
acids	230	235	|I-IUPAC
,	235	236	|O
on	237	239	|O
N	240	241	|B-IUPAC
-	241	242	|I-IUPAC
(	242	243	|I-IUPAC
aminoalkyl	243	253	|I-IUPAC
)	253	254	|I-IUPAC
aminomethyl	254	265	|I-IUPAC
phenoxyacetic	266	279	|I-IUPAC
acids	280	285	|I-IUPAC
,	285	286	|O
or	287	289	|O
on	290	292	|O
3,5	293	296	|B-IUPAC
-	296	297	|I-IUPAC
diaminobenzoic	297	311	|I-IUPAC
acid	312	316	|I-IUPAC
were	317	321	|O
synthesized	322	333	|O
as	334	336	|O
artificial	337	347	|O
siderophores	348	360	|O
.	360	361	|O
The	362	365	|O
corresponding	366	379	|O
diamino	380	387	|O
acids	388	393	|O
were	394	398	|O
obtained	399	407	|O
from	408	412	|O
the	413	416	|O
diamines	417	425	|O
and	426	429	|O
oxocarboxylic	430	443	|O
acids	444	449	|O
by	450	452	|O
catalytic	453	462	|O
hydrogenation	463	476	|O
.	476	477	|O
The	478	481	|O
acylated	482	490	|O
bis	491	494	|B-IUPAC
-	494	495	|I-IUPAC
catecholates	495	507	|I-IUPAC
and	508	511	|O
1,3	512	515	|B-IUPAC
-	515	516	|I-IUPAC
benzoxazine	516	527	|I-IUPAC
-	527	528	|I-IUPAC
2,4	528	531	|I-IUPAC
-	531	532	|I-IUPAC
diones	532	538	|I-IUPAC
were	539	543	|O
coupled	544	551	|O
with	552	556	|O
ampicillin	557	567	|O
or	568	570	|O
amoxicillin	571	582	|O
to	583	585	|O
new	586	589	|O
siderophore	590	601	|O
aminoacylpenicillin	602	621	|O
conjugates	622	632	|O
.	632	633	|O
These	634	639	|O
conjugates	640	650	|O
exhibited	651	660	|O
very	661	665	|O
strong	666	672	|O
antibacterial	673	686	|O
activity	687	695	|O
in	696	698	|O
vitro	699	704	|O
against	705	712	|O
Gram	713	717	|O
-	717	718	|O
negative	718	726	|O
bacterial	727	736	|O
pathogens	737	746	|O
including	747	756	|O
Pseudomonas	757	768	|O
aeruginosa	769	779	|O
,	779	780	|O
Stenotrophomonas	781	797	|O
maltophilia	798	809	|O
,	809	810	|O
Escherichia	811	822	|O
coli	823	827	|O
,	827	828	|O
Klebsiella	829	839	|O
pneumoniae	840	850	|O
,	850	851	|O
and	852	855	|O
Serratia	856	864	|O
marcescens	865	875	|O
.	875	876	|O
The	877	880	|O
ampicillin	881	891	|O
derivative	892	902	|O
7b	903	905	|O
(	906	907	|O
HKI	907	910	|O
9924154	911	918	|O
)	918	919	|O
and	920	923	|O
the	924	927	|O
corresponding	928	941	|O
amoxicillin	942	953	|O
derivative	954	964	|O
8	965	966	|O
(	967	968	|O
HKI	968	971	|O
9924155	972	979	|O
)	979	980	|O
represent	981	990	|O
the	991	994	|O
most	995	999	|O
active	1000	1006	|O
compounds	1007	1016	|O
.	1016	1017	|O
The	1018	1021	|O
conjugates	1022	1032	|O
can	1033	1036	|O
use	1037	1040	|O
bacterial	1041	1050	|O
iron	1051	1055	|O
siderophore	1056	1067	|O
uptake	1068	1074	|O
routes	1075	1081	|O
to	1082	1084	|O
penetrate	1085	1094	|O
the	1095	1098	|O
Gram	1099	1103	|O
-	1103	1104	|O
negative	1104	1112	|O
outer	1113	1118	|O
membrane	1119	1127	|O
permeability	1128	1140	|O
barrier	1141	1148	|O
.	1148	1149	|O
This	1150	1154	|O
was	1155	1158	|O
demonstrated	1159	1171	|O
by	1172	1174	|O
assays	1175	1181	|O
with	1182	1186	|O
mutants	1187	1194	|O
deficient	1195	1204	|O
in	1205	1207	|O
components	1208	1218	|O
of	1219	1221	|O
the	1222	1225	|O
iron	1226	1230	|O
transport	1231	1240	|O
systems	1241	1248	|O
.	1248	1249	|O
New	1250	1253	|O
siderophore	1254	1265	|O
penicillin	1266	1276	|O
V	1277	1278	|O
conjugates	1279	1289	|O
with	1290	1294	|O
the	1295	1298	|O
siderophore	1299	1310	|O
component	1311	1320	|O
attached	1321	1329	|O
to	1330	1332	|O
the	1333	1336	|O
phenyl	1337	1343	|O
ring	1344	1348	|O
of	1349	1351	|O
penicillin	1352	1362	|O
V	1363	1364	|O
are	1365	1368	|O
inactive	1369	1377	|O
against	1378	1385	|O
these	1386	1391	|O
Gram	1392	1396	|O
-	1396	1397	|O
negative	1397	1405	|O
bacteria	1406	1414	|O
.	1414	1415	|O

### abstracts4910.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
O'	12	14	|B-IUPAC
-	14	15	|I-IUPAC
(	15	16	|I-IUPAC
epoxyalkyl	16	26	|I-IUPAC
)	26	27	|I-IUPAC
tyrosines	27	36	|I-IUPAC
and	37	40	|O
a	41	42	|O
carboxy	43	50	|O
terminal	51	59	|O
(	60	61	|B-IUPAC
epoxyalkyl	61	71	|I-IUPAC
)	71	72	|I-IUPAC
tyrosine	72	80	|I-IUPAC
and	81	84	|O
-	85	86	|B-PARTIUPAC
phenylalanine	86	99	|I-PARTIUPAC
were	100	104	|O
synthesized	105	116	|O
as	117	119	|O
potential	120	129	|O
serine	130	136	|O
protease	137	145	|O
inhibitors	146	156	|O
.	156	157	|O
N	158	159	|B-IUPAC
-	159	160	|I-IUPAC
Acetyl	160	166	|I-IUPAC
derivatives	167	178	|B-MODIFIER
showed	179	185	|O
irreversible	186	198	|O
inactivation	199	211	|O
vis	212	215	|O
-	215	216	|O
a	216	217	|O
-	217	218	|O
vis	218	221	|O
subtilisin	222	232	|O
,	232	233	|O
while	234	239	|O
the	240	243	|O
N	244	245	|B-IUPAC
-	245	246	|I-IUPAC
benzoyl	246	253	|I-IUPAC
ones	254	258	|I-IUPAC
were	259	263	|O
specific	264	272	|O
toward	273	279	|O
chymotrypsin	280	292	|O
.	292	293	|O
The	294	297	|O
most	298	302	|O
potent	303	309	|O
inactivation	310	322	|O
of	323	325	|O
chymotrypsin	326	338	|O
was	339	342	|O
achieved	343	351	|O
by	352	354	|O
a	355	356	|O
O'	357	359	|B-IUPAC
-	359	360	|I-IUPAC
(	360	361	|I-IUPAC
3,4	361	364	|I-IUPAC
-	364	365	|I-IUPAC
epoxybutyl	365	375	|I-IUPAC
)	375	376	|I-IUPAC
-	376	377	|I-IUPAC
L	377	378	|I-IUPAC
-	378	379	|I-IUPAC
tyrosine	379	387	|I-IUPAC
derivative	388	398	|B-MODIFIER
.	398	399	|O
The	400	403	|O
inactivation	404	416	|O
was	417	420	|O
shown	421	426	|O
to	427	429	|O
be	430	432	|O
stereospecific	433	447	|O
since	448	453	|O
a	454	455	|O
D	456	457	|O
derivative	458	468	|O
led	469	472	|O
to	473	475	|O
no	476	478	|O
irreversible	479	491	|O
inactivation	492	504	|O
.	504	505	|O
Placement	506	515	|O
of	516	518	|O
the	519	522	|O
epoxyalkyl	523	533	|O
group	534	539	|O
at	540	542	|O
the	543	546	|O
carboxy	547	554	|O
terminus	555	563	|O
led	564	567	|O
to	568	570	|O
potent	571	577	|O
rapid	578	583	|O
inactivation	584	596	|O
.	596	597	|O
Under	598	603	|O
these	604	609	|O
conditions	610	620	|O
some	621	625	|O
of	626	628	|O
the	629	632	|O
activity	633	641	|O
was	642	645	|O
later	646	651	|O
recovered	652	661	|O
.	661	662	|O
The	663	666	|O
two	667	670	|O
classes	671	678	|O
of	679	681	|O
inactivators	682	694	|O
(	695	696	|O
O'	696	698	|B-IUPAC
-	698	699	|I-IUPAC
epoxyalkyl	699	709	|I-IUPAC
and	710	713	|O
carboxy	714	721	|B-IUPAC
-	721	722	|I-IUPAC
epoxyalkyl	722	732	|I-IUPAC
)	732	733	|O
appear	734	740	|O
to	741	743	|O
operate	744	751	|O
by	752	754	|O
different	755	764	|O
mechanisms	765	775	|O
.	775	776	|O
Most	777	781	|O
importantly	782	793	|O
,	793	794	|O
it	795	797	|O
was	798	801	|O
found	802	807	|O
that	808	812	|O
irreversible	813	825	|O
inactivation	826	838	|O
by	839	841	|O
O'	842	844	|B-IUPAC
-	844	845	|I-IUPAC
(	845	846	|I-IUPAC
epoxyalkyl	846	856	|I-IUPAC
)	856	857	|I-IUPAC
-	857	858	|I-IUPAC
L	858	859	|I-IUPAC
-	859	860	|I-IUPAC
tyrosine	860	868	|I-IUPAC
only	869	873	|O
resulted	874	882	|O
if	883	885	|O
the	886	889	|O
carboxy	890	897	|O
terminus	898	906	|O
was	907	910	|O
a	911	912	|O
substrate	913	922	|O
(	923	924	|O
i.e.	924	928	|O
a	929	930	|O
compound	931	939	|O
with	940	944	|O
free	945	949	|O
carboxy	950	957	|O
terminus	958	966	|O
did	967	970	|O
not	971	974	|O
lead	975	979	|O
to	980	982	|O
inactivation	983	995	|O
)	995	996	|O
.	996	997	|O
The	998	1001	|O
ultimate	1002	1010	|O
activity	1011	1019	|O
kinetic	1020	1027	|O
assay	1028	1033	|O
(	1034	1035	|O
Daniels	1035	1042	|O
,	1042	1043	|O
S	1044	1045	|O
.	1045	1046	|O
B	1047	1048	|O
.	1048	1049	|O
;	1049	1050	|O
et	1051	1053	|O
al.	1054	1057	|O
J	1058	1059	|O
.	1059	1060	|O
Biol.	1061	1066	|O
Chem.	1067	1072	|O
1983	1073	1077	|O
,	1077	1078	|O
258	1079	1082	|O
,	1082	1083	|O
15046-15053	1084	1095	|O
.	1095	1096	|O
)	1096	1097	|O
indicated	1098	1107	|O
that	1108	1112	|O
the	1113	1116	|O
epoxyalkyl	1117	1127	|O
group	1128	1133	|O
on	1134	1136	|O
the	1137	1140	|O
phenolic	1141	1149	|O
oxygen	1150	1156	|O
had	1157	1160	|O
an	1161	1163	|O
optimal	1164	1171	|O
length	1172	1178	|O
of	1179	1181	|O
four	1182	1186	|O
carbons	1187	1194	|O
with	1195	1199	|O
respect	1200	1207	|O
to	1208	1210	|O
the	1211	1214	|O
turnover	1215	1223	|O
ratio	1224	1229	|O
(	1230	1231	|O
the	1231	1234	|O
ratio	1235	1240	|O
of	1241	1243	|O
molecules	1244	1253	|O
undergoing	1254	1264	|O
turnover	1265	1273	|O
compared	1274	1282	|O
to	1283	1285	|O
those	1286	1291	|O
that	1292	1296	|O
inactivate	1297	1307	|O
the	1308	1311	|O
enzyme	1312	1318	|O
)	1318	1319	|O
for	1320	1323	|O
chymotrypsin	1324	1336	|O
.	1336	1337	|O
A	1338	1339	|O
different	1340	1349	|O
kinetic	1350	1357	|O
assay	1358	1363	|O
(	1364	1365	|O
Ashani	1365	1371	|O
,	1371	1372	|O
Y	1373	1374	|O
.	1374	1375	|O
;	1375	1376	|O
Wins	1377	1381	|O
,	1381	1382	|O
P	1383	1384	|O
.	1384	1385	|O
;	1385	1386	|O
Wilson	1387	1393	|O
,	1393	1394	|O
I	1395	1396	|O
.	1396	1397	|O
B	1398	1399	|O
.	1399	1400	|O
Biochim	1401	1408	|O
.	1408	1409	|O
Biophys	1410	1417	|O
.	1417	1418	|O
Acta	1419	1423	|O
1972	1424	1428	|O
,	1428	1429	|O
284	1430	1433	|O
,	1433	1434	|O
427-434	1435	1442	|O
.	1442	1443	|O
)	1443	1444	|O
demonstrated	1445	1457	|O
that	1458	1462	|O
substratelike	1463	1476	|O
turnover	1477	1485	|O
was	1486	1489	|O
proceeding	1490	1500	|O
at	1501	1503	|O
considerably	1504	1516	|O
slower	1517	1523	|O
rates	1524	1529	|O
than	1530	1534	|O
for	1535	1538	|O
the	1539	1542	|O
corresponding	1543	1556	|O
true	1557	1561	|O
substrates	1562	1572	|O
and	1573	1576	|O
with	1577	1581	|O
rate	1582	1586	|O
-	1586	1587	|O
limiting	1587	1595	|O
deacylation	1596	1607	|O
of	1608	1610	|O
the	1611	1614	|O
acyl	1615	1619	|O
-	1619	1620	|O
enzyme	1620	1626	|O
.	1626	1627	|O
Amino	1628	1633	|O
acid	1634	1638	|O
analysis	1639	1647	|O
subsequent	1648	1658	|O
to	1659	1661	|O
acid	1662	1666	|O
hydrolysis	1667	1677	|O
demonstrated	1678	1690	|O
that	1691	1695	|O
Met	1696	1699	|O
had	1700	1703	|O
been	1704	1708	|O
selectively	1709	1720	|O
alkylated	1721	1730	|O
by	1731	1733	|O
the	1734	1737	|O
O'	1738	1740	|B-IUPAC
-	1740	1741	|I-IUPAC
(	1741	1742	|I-IUPAC
epoxyalkyl	1742	1752	|I-IUPAC
)	1752	1753	|I-IUPAC
tyrosine	1753	1761	|I-IUPAC
derivative	1762	1772	|B-MODIFIER
.	1772	1773	|O
By	1774	1776	|O
contrast	1777	1785	|O
,	1785	1786	|O
alpha	1787	1792	|O
-	1792	1793	|O
chymotrypsin	1793	1805	|O
inactivated	1806	1817	|O
with	1818	1822	|O
N	1823	1824	|B-IUPAC
-	1824	1825	|I-IUPAC
benzoyl	1825	1832	|I-IUPAC
-	1832	1833	|I-IUPAC
L	1833	1834	|I-IUPAC
-	1834	1835	|I-IUPAC
Phe	1835	1838	|I-IUPAC
-	1838	1839	|I-IUPAC
2,3	1839	1842	|I-IUPAC
-	1842	1843	|I-IUPAC
epoxypropyl	1843	1854	|I-IUPAC
ester	1855	1860	|I-IUPAC
then	1861	1865	|O
subjected	1866	1875	|O
to	1876	1878	|O
amino	1879	1884	|O
acid	1885	1889	|O
analysis	1890	1898	|O
showed	1899	1905	|O
no	1906	1908	|O
change	1909	1915	|O
in	1916	1918	|O
the	1919	1922	|O
content	1923	1930	|O
of	1931	1933	|O
any	1934	1937	|O
amino	1938	1943	|O
acid	1944	1948	|O
that	1949	1953	|O
would	1954	1959	|O
serve	1960	1965	|O
as	1966	1968	|O
a	1969	1970	|O
potential	1971	1980	|O
nucleophile	1981	1992	|O
to	1993	1995	|O
the	1996	1999	|O
inhibitor	2000	2009	|O
.	2009	2010	|O
Yet	2011	2014	|O
,	2014	2015	|O
the	2016	2019	|O
L	2020	2021	|O
-	2021	2022	|O
Phe	2022	2025	|O
content	2026	2033	|O
increased	2034	2043	|O
,	2043	2044	|O
indicating	2045	2055	|O
that	2056	2060	|O
a	2061	2062	|O
covalent	2063	2071	|O
bond	2072	2076	|O
had	2077	2080	|O
been	2081	2085	|O
formed	2086	2092	|O
between	2093	2100	|O
the	2101	2104	|O
inhibitor	2105	2114	|O
and	2115	2118	|O
the	2119	2122	|O
enzyme	2123	2129	|O
.	2129	2130	|O
Either	2131	2137	|O
the	2138	2141	|O
bond	2142	2146	|O
between	2147	2154	|O
the	2155	2158	|O
inhibitor	2159	2168	|O
and	2169	2172	|O
the	2173	2176	|O
enzyme	2177	2183	|O
did	2184	2187	|O
not	2188	2191	|O
withstand	2192	2201	|O
the	2202	2205	|O
hydrolytic	2206	2216	|O
conditions	2217	2227	|O
and	2228	2231	|O
/	2231	2232	|O
or	2232	2234	|O
there	2235	2240	|O
was	2241	2244	|O
less	2245	2249	|O
than	2250	2254	|O
10%	2255	2258	|O
decrease	2259	2267	|O
in	2268	2270	|O
the	2271	2274	|O
amino	2275	2280	|O
acids	2281	2286	|O
with	2287	2291	|O
nucleophilic	2292	2304	|O
side	2305	2309	|O
chains	2310	2316	|O
upon	2317	2321	|O
inactivation	2322	2334	|O
.	2334	2335	|O
Finally	2336	2343	|O
,	2343	2344	|O
two	2345	2348	|O
tripeptides	2349	2360	|O
containing	2361	2371	|O
O'	2372	2374	|B-IUPAC
-	2374	2375	|I-IUPAC
(	2375	2376	|I-IUPAC
epoxyalkyl	2376	2386	|I-IUPAC
)	2386	2387	|I-IUPAC
-	2387	2388	|I-IUPAC
L	2388	2389	|I-IUPAC
-	2389	2390	|I-IUPAC
tryosines	2390	2399	|I-IUPAC
were	2400	2404	|O
synthesized	2405	2416	|O
[	2417	2418	|O
N	2418	2419	|B-IUPAC
-	2419	2420	|I-IUPAC
(	2420	2421	|I-IUPAC
tert	2421	2425	|I-IUPAC
-	2425	2426	|I-IUPAC
butoxycarbonyl	2426	2440	|I-IUPAC
)	2440	2441	|I-IUPAC
-	2441	2442	|I-IUPAC
L	2442	2443	|I-IUPAC
-	2443	2444	|I-IUPAC
alanyl	2444	2450	|I-IUPAC
-	2450	2451	|I-IUPAC
L	2451	2452	|I-IUPAC
-	2452	2453	|I-IUPAC
alanyl	2453	2459	|I-IUPAC
-	2459	2460	|I-IUPAC
O'	2460	2462	|I-IUPAC
-	2462	2463	|I-IUPAC
(	2463	2464	|I-IUPAC
2,3	2464	2467	|I-IUPAC
-	2467	2468	|I-IUPAC
epoxypropyl	2468	2479	|I-IUPAC
)	2479	2480	|I-IUPAC
-	2480	2481	|I-IUPAC
L	2481	2482	|I-IUPAC
-	2482	2483	|I-IUPAC
tyrosi	2483	2489	|I-IUPAC
ne	2490	2492	|I-IUPAC
ethyl	2493	2498	|I-IUPAC
ester	2499	2504	|I-IUPAC
and	2505	2508	|O
N	2509	2510	|B-IUPAC
-	2510	2511	|I-IUPAC
(	2511	2512	|I-IUPAC
trifluoroacetyl	2512	2527	|I-IUPAC
)	2527	2528	|I-IUPAC
-	2528	2529	|I-IUPAC
L	2529	2530	|I-IUPAC
-	2530	2531	|I-IUPAC
valyl	2531	2536	|I-IUPAC
-	2536	2537	|I-IUPAC
O'	2537	2539	|I-IUPAC
-	2539	2540	|I-IUPAC
(	2540	2541	|I-IUPAC
2,3	2541	2544	|I-IUPAC
-	2544	2545	|I-IUPAC
epoxypropyl	2545	2556	|I-IUPAC
)	2556	2557	|I-IUPAC
-	2557	2558	|I-IUPAC
L	2558	2559	|I-IUPAC
-	2559	2560	|I-IUPAC
tyrosyl	2560	2567	|I-IUPAC
-	2567	2568	|I-IUPAC
L	2568	2569	|I-IUPAC
-	2569	2570	|I-IUPAC
valine	2570	2576	|I-IUPAC
methyl	2577	2583	|I-IUPAC
ester	2584	2589	|I-IUPAC
]	2589	2590	|O
as	2591	2593	|O
potential	2594	2603	|O
elastase	2604	2612	|O
inhibitors	2613	2623	|O
and	2624	2627	|O
were	2628	2632	|O
found	2633	2638	|O
to	2639	2641	|O
reversibly	2642	2652	|O
and	2653	2656	|O
competitively	2657	2670	|O
inhibit	2671	2678	|O
porcine	2679	2686	|O
pancreatic	2687	2697	|O
elastase	2698	2706	|O
.	2706	2707	|O

### abstracts1868.txt
A	0	1	|O
series	2	8	|O
of	9	11	|O
erythro	12	19	|B-IUPAC
-	19	20	|I-IUPAC
1	20	21	|I-IUPAC
-	21	22	|I-IUPAC
(	22	23	|I-IUPAC
2	23	24	|I-IUPAC
-	24	25	|I-IUPAC
hydroxy	25	32	|I-IUPAC
-	32	33	|I-IUPAC
3	33	34	|I-IUPAC
-	34	35	|I-IUPAC
nonyl	35	40	|I-IUPAC
)	40	41	|I-IUPAC
azole	41	46	|I-IUPAC
derivatives	47	58	|B-MODIFIER
have	59	63	|O
been	64	68	|O
synthesized	69	80	|O
and	81	84	|O
evaluated	85	94	|O
for	95	98	|O
adenosine	99	108	|O
deaminase	109	118	|O
(	119	120	|O
ADA	120	123	|O
)	123	124	|O
inhibitory	125	135	|O
activity	136	144	|O
,	144	145	|O
in	146	148	|O
order	149	154	|O
to	155	157	|O
introduce	158	167	|O
simplifications	168	183	|O
in	184	186	|O
the	187	190	|O
ADA	191	194	|O
inhibitor	195	204	|O
erythro	205	212	|B-IUPAC
-	212	213	|I-IUPAC
9	213	214	|I-IUPAC
-	214	215	|I-IUPAC
(	215	216	|I-IUPAC
2	216	217	|I-IUPAC
-	217	218	|I-IUPAC
hydroxy	218	225	|I-IUPAC
-	225	226	|I-IUPAC
3	226	227	|I-IUPAC
-	227	228	|I-IUPAC
nonyl	228	233	|I-IUPAC
)	233	234	|I-IUPAC
adenine	234	241	|I-IUPAC
(	242	243	|O
EHNA	243	247	|O
,	247	248	|O
1a	249	251	|O
)	251	252	|O
.	252	253	|O
The	254	257	|O
synthesis	258	267	|O
of	268	270	|O
most	271	275	|O
of	276	278	|O
the	279	282	|O
reported	283	291	|O
compounds	292	301	|O
was	302	305	|O
achieved	306	314	|O
by	315	317	|O
reaction	318	326	|O
of	327	329	|O
2	330	331	|B-IUPAC
-	331	332	|I-IUPAC
bromo	332	337	|I-IUPAC
-	337	338	|I-IUPAC
3	338	339	|I-IUPAC
-	339	340	|I-IUPAC
nonanone	340	348	|I-IUPAC
with	349	353	|O
the	354	357	|O
suitable	358	366	|O
azole	367	372	|O
followed	373	381	|O
by	382	384	|O
reduction	385	394	|O
of	395	397	|O
the	398	401	|O
carbonyl	402	410	|B-IUPAC
group	411	416	|B-MODIFIER
to	417	419	|O
give	420	424	|O
a	425	426	|O
diastereoisomeric	427	444	|O
mixture	445	452	|O
of	453	455	|O
N	456	457	|B-MODIFIER
-	457	458	|I-MODIFIER
substituted	458	469	|I-MODIFIER
(	470	471	|B-IUPAC
2	471	472	|I-IUPAC
-	472	473	|I-IUPAC
hydroxy	473	480	|I-IUPAC
-	480	481	|I-IUPAC
3	481	482	|I-IUPAC
-	482	483	|I-IUPAC
nonyl	483	488	|I-IUPAC
)	488	489	|I-IUPAC
azoles	489	495	|I-IUPAC
.	495	496	|O
Separation	497	507	|O
of	508	510	|O
diastereoisomers	511	527	|O
was	528	531	|O
achieved	532	540	|O
by	541	543	|O
HPLC	544	548	|O
or	549	551	|O
by	552	554	|O
preparative	555	566	|O
TLC	567	570	|O
plates	571	577	|O
.	577	578	|O
The	579	582	|O
results	583	590	|O
of	591	593	|O
the	594	597	|O
enzymatic	598	607	|O
test	608	612	|O
indicate	613	621	|O
that	622	626	|O
the	627	630	|O
nitrogen	631	639	|O
in	640	642	|O
the	643	646	|O
3	647	648	|O
-	648	649	|O
position	649	657	|O
,	657	658	|O
and	659	662	|O
secondly	663	671	|O
,	671	672	|O
the	673	676	|O
nitrogen	677	685	|O
in	686	688	|O
the	689	692	|O
5	693	694	|O
-	694	695	|O
position	695	703	|O
are	704	707	|O
very	708	712	|O
important	713	722	|O
for	723	726	|O
the	727	730	|O
interaction	731	742	|O
of	743	745	|O
the	746	749	|O
azole	750	755	|O
ring	756	760	|O
with	761	765	|O
the	766	769	|O
inhibitory	770	780	|O
site	781	785	|O
on	786	788	|O
the	789	792	|O
enzyme	793	799	|O
.	799	800	|O
In	801	803	|O
fact	804	808	|O
,	808	809	|O
the	810	813	|O
pyrazole	814	822	|O
and	823	826	|O
the	827	830	|O
2	831	832	|B-MODIFIER
-	832	833	|I-MODIFIER
substituted	833	844	|I-MODIFIER
1,2,3	845	850	|B-IUPAC
-	850	851	|I-IUPAC
triazole	851	859	|I-IUPAC
derivatives	860	871	|B-MODIFIER
(	872	873	|O
10	873	875	|O
and	876	879	|O
15	880	882	|O
,	882	883	|O
respectively	884	896	|O
)	896	897	|O
are	898	901	|O
nearly	902	908	|O
inactive	909	917	|O
,	917	918	|O
whereas	919	926	|O
the	927	930	|O
erythro	931	938	|B-IUPAC
-	938	939	|I-IUPAC
1	939	940	|I-IUPAC
-	940	941	|I-IUPAC
(	941	942	|I-IUPAC
2	942	943	|I-IUPAC
-	943	944	|I-IUPAC
hydroxy	945	952	|I-IUPAC
-	952	953	|I-IUPAC
3	953	954	|I-IUPAC
-	954	955	|I-IUPAC
nonyl	955	960	|I-IUPAC
)	960	961	|I-IUPAC
-	961	962	|I-IUPAC
1,2,4	962	967	|I-IUPAC
-	967	968	|I-IUPAC
triazole	968	976	|I-IUPAC
(	977	978	|O
18e	978	981	|O
)	981	982	|O
was	983	986	|O
the	987	990	|O
most	991	995	|O
potent	996	1002	|O
ADA	1003	1006	|O
inhibitor	1007	1016	|O
in	1017	1019	|O
the	1020	1023	|O
series	1024	1030	|O
with	1031	1035	|O
Ki	1036	1038	|O
=	1039	1040	|O
0.3	1041	1044	|O
microM	1045	1051	|O
.	1051	1052	|O

